FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Hassan, HA
   Abdelmohsen, UR
   Aly, OM
   Desoukey, SY
   Mohamed, KM
   Kamel, MS
AF Hassan, Heba Ali
   Abdelmohsen, Usama Ramadan
   Aly, Omar M.
   Desoukey, Samar Y.
   Mohamed, Khaled M.
   Kamel, Mohamed S.
TI Potential of Ficus microcarpa metabolites against SARS-CoV-2 main
   protease supported by docking studies
SO NATURAL PRODUCT RESEARCH
LA English
DT Article; Early Access
DE COVID-19; Ficus microcarpa; metabolic profiling; molecular docking
ID CONSTITUENTS
AB COVID 19; an infectious disease; firstly identified in December 2019 in Wuhan, China and has since spread globally, resulting in an ongoing pandemic. Searching for protease inhibitors is a challenging task in controlling COVID 19. Genus Ficus is known to be a rich source of phenolic compounds. Metabolic profiling of leaves methanolic extract of Ficus microcarpa (Moraceae) revealed nine compounds (1-9) mainly phenolics. Docking studies concerning these compounds against SARS-CoV-2 main protease showed that quercetin 3,7-O-alpha-L-dirhamnoside (1) and rutin (3) possessed significant binding stability at the N3 binding site in different activity degrees, which is comparable with COVID-19 main protease inhibitor, darunavir. Our study suggests that compounds quercetin 3,7-O-alpha-L-dirhamnoside and rutin might be potential candidates for the development of therapies against SARS-CoV-2.
C1 [Hassan, Heba Ali; Abdelmohsen, Usama Ramadan; Kamel, Mohamed S.] Deraya Univ, Fac Pharm, Pharmacognosy Dept, New Minia City, Egypt.
   [Abdelmohsen, Usama Ramadan; Desoukey, Samar Y.; Kamel, Mohamed S.] Menia Univ, Fac Pharm, Pharmacognosy Dept, Al Minya, Egypt.
   [Aly, Omar M.] Menia Univ, Fac Pharm, Med Chem Dept, Al Minya, Egypt.
   [Mohamed, Khaled M.] Fayoum Univ, Pharmacognosy Dept, Fac Pharm, Al Fayyum, Egypt.
RP Hassan, HA (corresponding author), Deraya Univ, Fac Pharm, Pharmacognosy Dept, New Minia City, Egypt.
EM dr_heba_ah@yahoo.com
RI Desoukey, Samar/ABF-3565-2020
CR Abdelhameed RFA, 2020, MAR DRUGS, V18, DOI 10.3390/md18070354
   Ali M. S. S., 2011, INT P EC DEV RES, V5, pV2
   Alqasoumi SI, 2014, SAUDI PHARM J, V22, P460, DOI 10.1016/j.jsps.2013.12.010
   Ashok K, 2007, J BIOL SCI, V7
   Chiang YM, 2005, PHYTOCHEMISTRY, V66, P495, DOI 10.1016/j.phytochem.2004.12.026
   Elmaidomy AH, 2020, MOLECULES, V25, DOI 10.3390/molecules25143116
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Imran M, 2014, CHEM CENT J, V8, DOI 10.1186/1752-153X-8-12
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Mawa S, 2013, EVID-BASED COMPL ALT, V2013, P1, DOI DOI 10.1155/2013/974256
   Mohamed El-Sayed M., 2010, PHARMACOLOGYONLINE, V3, P317
   Nana F, 2012, J BRAZIL CHEM SOC, V23, P482, DOI 10.1590/S0103-50532012000300015
   Owis AI, 2020, RSC ADV, V10, P19570, DOI 10.1039/d0ra03582c
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Ramadan MA, 2009, NAT PROD RES, V23, P1218, DOI 10.1080/14786410902757899
   Riaz N, 2012, J ASIAN NAT PROD RES, V14, P1149, DOI 10.1080/10286020.2012.733702
   Taira T, 2005, BIOSCI BIOTECH BIOCH, V69, P811, DOI 10.1271/bbb.69.811
   Yi T, 2013, CHEM CENT J, V7, DOI 10.1186/1752-153X-7-115
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 20
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
DI 10.1080/14786419.2020.1839452
EA OCT 2020
PG 5
WC Chemistry, Applied; Chemistry, Medicinal
SC Chemistry; Pharmacology & Pharmacy
GA OM5NH
UT WOS:000586070800001
PM 33121282
DA 2021-01-01
ER

PT J
AU Akuamoa-Boateng, D
   Wegen, S
   Ferdinandus, J
   Marksteder, R
   Baues, C
   Marnitz, S
AF Akuamoa-Boateng, Dennis
   Wegen, Simone
   Ferdinandus, Justin
   Marksteder, Regina
   Baues, Christian
   Marnitz, Simone
TI Managing patient flows in radiation oncology during the COVID-19
   pandemic Reworking existing treatment designs to prevent infections at a
   German hot spot area University Hospital
SO STRAHLENTHERAPIE UND ONKOLOGIE
LA English
DT Article
DE COVID-19; SARS-CoV-2; Radiation oncology; Disease transmission;
   infectious; Radiation dose hypofractionation; Stereotactic radiosurgery
ID RADIOTHERAPY
AB Purpose The described work aimed to avoid cancellations of indispensable treatments by implementing active patient flow management practices and optimizing infrastructure utilization in the radiation oncology department of a large university hospital and regional COVID-19 treatment center close to the first German SARS-CoV-2 hotspot region Heinsberg in order to prevent nosocomial infections in patients and personnel during the pandemic.
   Patients and methods The study comprised year-to-date intervention analyses of in- and outpatient key procedures, machine occupancy, and no-show rates in calendar weeks 12 to 19 of 2019 and 2020 to evaluate effects of active patient flow management while monitoring nosocomial COVID-19 infections.
   Results Active patient flow management helped to maintain first-visit appointment compliance above 85.5%. A slight appointment reduction of 10.3% daily (p = 0.004) could still significantly increase downstream planning CT scheduling (p = 0.00001) and performance (p = 0.0001), resulting in an absolute 20.1% (p = 0.009) increment of CT performance while avoiding overbooking practices. Daily treatment start was significantly increased by an absolute value of 18.5% (p = 0.026). Hypofractionation and acceleration were significantly increased (p = 0.0043). Integrating strict testing guidelines, a distancing regimen for staff and patients, hygiene regulations, and precise appointment scheduling, no SARS-CoV-2 infection in 164 tested radiation oncology service inpatients was observed.
   Conclusion In times of reduced medical infrastructure capacities and resources, controlling infrastructural time per patient as well as optimizing facility utilization and personnel workload during treatment evaluation, planning, and irradiation can help to improve appointment compliance and quality management. Avoiding recurrent and preventable exposure to healthcare infrastructure has potential health benefits and might avert cross infections during the pandemic. Active patient flow management in high-risk COVID-19 regions can help Radiation Oncologists to continue and initiate treatments safely, instead of cancelling and deferring indicated therapies.
C1 [Akuamoa-Boateng, Dennis; Wegen, Simone; Baues, Christian; Marnitz, Simone] Univ Hosp Cologne, Ctr Integrated Oncol, Dept Radiat Oncol, Cologne, Germany.
   [Ferdinandus, Justin] Univ Hosp Essen, Dept Nucl Med, Essen, Germany.
   [Marksteder, Regina] Univ Hosp Cologne, Dept Hosp Pharm, Cologne, Germany.
RP Akuamoa-Boateng, D (corresponding author), Univ Hosp Cologne, Ctr Integrated Oncol, Dept Radiat Oncol, Cologne, Germany.
EM Dennis.Akuamoa-Boateng@uk-koeln.de
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR Chia PY, 2020, DETECTION AIR SURFAC, DOI DOI 10.1101/2020.03.29.20046557V2
   Dearnaley D, 2016, LANCET ONCOL, V17, P1047, DOI 10.1016/S1470-2045(16)30102-4
   Degro, 2020, STRAHL ZEIT COR EMPF
   Deutsches Arzteblatt, 2020, DTSCH ARZTEBLATT
   Docs Google, 2020, COVID 19 RT EM MAN R
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guckenberger M, 2020, STRAHLENTHER ONKOL, V196, P417, DOI 10.1007/s00066-020-01603-1
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Huang Y, 2014, Appl Clin Inform, V5, P836, DOI 10.4338/ACI-2014-04-RA-0026
   Huang YL, 2016, INT J HEALTH CARE Q, V29, P475, DOI 10.1108/IJHCQA-06-2015-0077
   Hubner N-O, 2020, EPIDEMIOL B, DOI [10.25646/6861, DOI 10.25646/6861]
   Jiang H Joanna, 2006, J Health Care Finance, V32, P39
   Kaplan-Lewis E, 2013, NO SHOW PRIMARY CARE, DOI [10.1177/2150131913498513?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed, DOI 10.1177/2150131913498513?URL_VER=Z39.88-2003&RFR_ID=0RI%3ARID%3ACROSSREF.ORG&RFR_DAT=CR_PUB++0PUBMED]
   Liu Y, 2020, NATURE, V582, P557, DOI 10.1038/s41586-020-2271-3
   Molfenter T, 2013, SUBST USE MISUSE, V48, P743, DOI 10.3109/10826084.2013.787098
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Parikh A, 2010, AM J MED, V123, P542, DOI 10.1016/j.amjmed.2009.11.022
   RKI, 2020, HINW TEST PAT INF NE
   RKI, 2020, COVID 19 FALLZ DEUTS
   RKI, 2020, EMPF RKI HYG NAHM RA
   Santarpia JL, 2020, TRANSMISSION POTENTI, DOI DOI 10.1101/2020.03.23.20039446V2
   The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, EP CHAR OUTBR 2019 N
   Troost EGC, 2020, RADIOTHER ONCOL, V147, P227, DOI 10.1016/j.radonc.2020.04.030
   Uniklinik Koln, 2020, JAHR QUAL
   von Lilienfeld-Toal M, 2020, CORONAVIRUS INFEKTIO
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, WHO COR DIS COVID 19
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yahalom J, 2020, BLOOD, V135, P1829, DOI 10.1182/blood.2020006028
NR 30
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0179-7158
EI 1439-099X
J9 STRAHLENTHER ONKOL
JI Strahlenther. Onkol.
PD DEC
PY 2020
VL 196
IS 12
SI SI
BP 1080
EP 1085
DI 10.1007/s00066-020-01698-6
EA OCT 2020
PG 6
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA PB8LZ
UT WOS:000584939600001
PM 33123776
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gupta, S
   Singh, V
   Varadwaj, PK
   Chakravartty, N
   Katta, AVSKM
   Lekkala, SP
   Thomas, G
   Narasimhan, S
   Reddy, AR
   Lachagari, VBR
AF Gupta, Saurabh
   Singh, Vishal
   Varadwaj, Pritish Kumar
   Chakravartty, Navajeet
   Katta, A. V. S. Krishna Mohan
   Lekkala, Sivarama Prasad
   Thomas, George
   Narasimhan, Srinivasan
   Reddy, Arjula R.
   Reddy Lachagari, V. B.
TI Secondary metabolites from spice and herbs as potential multitarget
   inhibitors of SARS-CoV-2 proteins
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Anupama; SARS-CoV-2; epicatechin; hesperidin; murrayanine; docking and
   simulation
ID SARS-CORONAVIRUS; INFECTION; PNEUMONIA
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for the current global pandemic that has caused a death toll of >1.12 million worldwide and number continues to climb in several countries. Currently, there are neither specific antiviral drugs nor vaccines for the treatment and prevention of COVID-19. We screened in silico, a group of natural spice and herbal secondary metabolites (SMs) for their inhibition efficacy against multiple target proteins of SARS-CoV-2 as well as the human angiotensin-converting enzyme 2 protein. Docking and simulation results indicated that epicatechin, embelin, hesperidin, cafestol, murrayanine and murrayaquinone-A have higher inhibition efficacy over at least one of the known antiviral drugs such as Hydroxychloroquine, Remdesivir and Ribavirin. Combination of these potentially effective SMs from their respective plant sources was analysed, and its absorption and acute oral toxicity were examined in Wistar rats and classified as category 5 as per the Globally Harmonized System. The identified SMs may be useful in the development of preventive nutraceuticals, food supplements and antiviral drugs.
   Communicated by Ramaswamy H. Sarma
C1 [Gupta, Saurabh; Chakravartty, Navajeet; Katta, A. V. S. Krishna Mohan; Lekkala, Sivarama Prasad; Reddy Lachagari, V. B.] AgriGenome Labs Pvt Ltd, IKP Knowledge Pk Genome Valley, Hyderabad 500101, Telangana, India.
   [Singh, Vishal; Varadwaj, Pritish Kumar] Indian Inst Informat Technol, Dept Appl Sci, Allahabad, Uttar Pradesh, India.
   [Thomas, George] AgriGenome Labs Pvt Ltd, Kakkanad, India.
   [Narasimhan, Srinivasan] Asthagiri Herbal Res Fdn, Chennai, Tamil Nadu, India.
   [Reddy, Arjula R.] Univ Hyderabad, Dept Plant Sci, Hyderabad, India.
RP Gupta, S; Lachagari, VBR (corresponding author), AgriGenome Labs Pvt Ltd, IKP Knowledge Pk Genome Valley, Hyderabad 500101, Telangana, India.
EM saurabh.g@aggenome.com; vb.reddy@aggenome.com
RI ; Gupta, Dr. Saurabh/F-9004-2017
OI Lekkala, Sivarama Prasad/0000-0002-4973-0659; Lachagari, V B
   Reddy/0000-0002-4708-7866; Varadwaj, Pritish/0000-0001-5706-2411; Gupta,
   Dr. Saurabh/0000-0002-1327-7389; Thomas, George/0000-0003-1914-5923
FU SciGenom Research Foundation (SGRF)
FX The authors would like to acknowledge SciGenom Research Foundation
   (SGRF) for providing financial support to execute this work.
CR Almeida MS, 2007, J VIROL, V81, P3151, DOI 10.1128/JVI.01939-06
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ang L, 2020, INTEGR MED RES, V9, DOI 10.1016/j.imr.2020.100407
   Angeletti S, 2020, J MED VIROL, V92, P584, DOI 10.1002/jmv.25719
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Benvenuto D, 2020, J INFECTION, V81, pE24, DOI 10.1016/j.jinf.2020.03.058
   Bianchi M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4389089
   Boriskin YS, 2008, CURR MED CHEM, V15, P997, DOI 10.2174/092986708784049658
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Chowdhury R, 2020, BIOPHYSICAL CHARACTE, DOI [10.1101/2020.03.30.015891, DOI 10.1101/2020.03.30.015891]
   Covey T.R., 1986, ANAL CHEM, V58, p1451A
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Dong SJ, 2020, J MED VIROL, V92, P1542, DOI 10.1002/jmv.25768
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Dutta K., 2020, BECLABUVIR CAN INHIB, DOI [10.20944/preprints202003.0395.v2, DOI 10.20944/PREPRINTS202003.0395.V2]
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta S, 2015, J BIOMOL STRUCT DYN, V33, P2421, DOI 10.1080/07391102.2015.1051114
   Gupta S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136630
   Hao W, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006474
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jaseela V. K., 2019, J AYURVEDA INTEGRATE, V4
   Jauregui AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062416
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Kang S., 2020, ACTA PHARM SINICA B
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36918-8
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Levantovsky Rachel, 2020, Nat Rev Immunol, V20, P350, DOI 10.1038/s41577-020-0315-4
   Littler DR, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101258
   Lokugamage KG, 2012, J VIROL, V86, P13598, DOI 10.1128/JVI.01958-12
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Man MQ, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/2676307
   Natsume M, 2003, FREE RADICAL BIO MED, V34, P840, DOI 10.1016/S0891-5849(02)01434-X
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Owusu M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099782
   Romano M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051267
   Sachan A., 2018, J MED PLANTS STUDIES, V6, P116
   Sakai Y, 2017, VIROLOGY, V510, P165, DOI 10.1016/j.virol.2017.07.019
   Sakakibara H, 2003, J AGR FOOD CHEM, V51, P571, DOI 10.1021/jf020926l
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shay J, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/181260
   Shen Z, 2019, J BIOL CHEM, V294, P13606, DOI 10.1074/jbc.RA119.009713
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Sutton G, 2004, STRUCTURE, V12, P341, DOI 10.1016/j.str.2004.01.016
   Velthuis AJWT, 2012, NUCLEIC ACIDS RES, V40, P1737, DOI 10.1093/nar/gkr893
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang M, 2005, EMERG INFECT DIS, V11, P1860, DOI 10.3201/eid1112.041293
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang X, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0169-8
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zachariah T. J., 2018, INDIAN SPICES, DOI DOI 10.1007/978-3-319-75016-3_10
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 64
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1837679
EA OCT 2020
PG 20
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OI0GE
UT WOS:000582964800001
PM 33107812
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Haniff, HS
   Tong, YQ
   Liu, XH
   Chen, JL
   Suresh, BM
   Andrews, RJ
   Peterson, JM
   O'Leary, CA
   Benhamou, RI
   Moss, WN
   Disney, MD
AF Haniff, Hafeez S.
   Tong, Yuquan
   Liu, Xiaohui
   Chen, Jonathan L.
   Suresh, Blessy M.
   Andrews, Ryan J.
   Peterson, Jake M.
   O'Leary, Collin A.
   Benhamou, Raphael, I
   Moss, Walter N.
   Disney, Matthew D.
TI Targeting the SARS-CoV-2 RNA Genome with Small Molecule Binders and
   Ribonuclease Targeting Chimera (RIBOTAC) Degraders
SO ACS CENTRAL SCIENCE
LA English
DT Article
ID SARS-CORONAVIRUS; INTERFERON ACTION; PROTEINS; COVID-19; ORIGIN
AB COVID-19 is a global pandemic, thus requiring multiple strategies to develop modalities against it. Herein, we designed multiple bioactive small molecules that target a functional structure within the SARS-CoV-2's RNA genome, the causative agent of COVID-19. An analysis to characterize the structure of the RNA genome provided a revised model of the SARS-CoV-2 frameshifting element, in particular its attenuator hairpin. By studying an RNA-focused small molecule collection, we identified a drug-like small molecule (C5) that avidly binds to the revised attenuator hairpin structure with a K-d of 11 nM. The compound stabilizes the hairpin's folded state and impairs frameshifting in cells. The ligand was further elaborated into a ribonuclease targeting chimera (RIBOTAC) to recruit a cellular ribonuclease to destroy the viral genome (C5-RIBOTAC) and into a covalent molecule (C5-Chem-CLIP) that validated direct target engagement and demonstrated its specificity for the viral RNA, as compared to highly expressed host mRNAs. The RIBOTAC lead optimization strategy improved the bioactivity of the compound at least 10-fold. Collectively, these studies demonstrate that the SARS-CoV-2 RNA genome should be considered druggable.
C1 [Haniff, Hafeez S.; Tong, Yuquan; Liu, Xiaohui; Chen, Jonathan L.; Suresh, Blessy M.; Benhamou, Raphael, I; Disney, Matthew D.] Scripps Res Inst, Dept Chem, Jupiter, FL 33458 USA.
   [Andrews, Ryan J.; Peterson, Jake M.; O'Leary, Collin A.; Moss, Walter N.] Iowa State Univ, Roy J Carver Dept Biophys Biochem & Mol Biol, Ames, IA 50011 USA.
RP Disney, MD (corresponding author), Scripps Res Inst, Dept Chem, Jupiter, FL 33458 USA.
EM disney@scripps.edu
OI Suresh, Blessy/0000-0003-0344-4777; Andrews, Ryan/0000-0003-0275-0019
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 CA249180, R35
   NS116846]; NIH/NIGMSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R00 GM112877, R01 GM133810]
FX This work was funded by the National Institutes of Health (R01 CA249180,
   and R35 NS116846 to M.D.D; as well as NIH/NIGMS Grants R00 GM112877 and
   R01 GM133810 to W.N.M). We thank Dr. Jessica Childs-Disney for
   assistance with writing and editing the manuscript and Prof. Jonathan D.
   Dinman at the University of Maryland College Park for providing the
   SARS-CoV-2, SARS-CoV, and ORF reporter plasmids used in these studies.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Andrews R. J., 2020, BIORXIV
   Blanco-Melo D., 2020, BIORXIV
   Cho CP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062283
   Costales M. G., 2017, RNA THERAPEUTICS, V27, DOI [10.1007/7355_2016_21, DOI 10.1007/7355_2016_21]
   Costales MG, 2020, P NATL ACAD SCI USA, V117, P2406, DOI 10.1073/pnas.1914286117
   Costales MG, 2019, CELL CHEM BIOL, V26, P1180, DOI 10.1016/j.chembiol.2019.04.008
   Costales MG, 2018, J AM CHEM SOC, V140, P6741, DOI 10.1021/jacs.8b01233
   Disney MD, 2019, J AM CHEM SOC, V141, P6776, DOI 10.1021/jacs.8b13419
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Graham RL, 2008, VIRUS RES, V133, P88, DOI 10.1016/j.virusres.2007.02.017
   Hafeez H., 2020, NAT CHEM, DOI [10.1038/s41557- 020-0514-4, DOI 10.1038/S41557-020-0514-4]
   Hermann T, 2016, WIRES RNA, V7, P726, DOI 10.1002/wrna.1373
   Hu HT, 2016, NUCLEIC ACIDS RES, V44, P256, DOI 10.1093/nar/gkv1307
   Ivanov D, 2020, TRANSPORT RES E-LOG, V136, DOI 10.1016/j.tre.2020.101922
   Kelly J. A., 2020, BIORXIV
   Lan T. C. T., 2020, BIORXIV
   Liu XH, 2020, J AM CHEM SOC, V142, P6970, DOI 10.1021/jacs.9b13159
   Ofori LO, 2014, J MED CHEM, V57, P723, DOI 10.1021/jm401438g
   Ottis P, 2017, ACS CHEM BIOL, V12, P892, DOI 10.1021/acschembio.6b01068
   Park SJ, 2011, J AM CHEM SOC, V133, P10094, DOI 10.1021/ja1098325
   Plant EP, 2010, J VIROL, V84, P4330, DOI 10.1128/JVI.02480-09
   Rangan R., 2020, BIORXIV
   Rzuczek SG, 2017, NAT CHEM BIOL, V13, P188, DOI [10.1038/NCHEMBIO.2251, 10.1038/nchembio.2251]
   Schroder I, 2020, ACS CHEM HEALTH SAFE, V27, P160, DOI 10.1021/acs.chas.0c00035
   Su MC, 2005, NUCLEIC ACIDS RES, V33, P4265, DOI 10.1093/nar/gki731
   Tan YJ, 2005, ANTIVIR RES, V65, P69, DOI 10.1016/j.antiviral.2004.10.001
   Tao YJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000943
   Velagapudi SP, 2019, BIOORG MED CHEM LETT, V29, P1532, DOI 10.1016/j.bmcl.2019.04.001
   Velagapudi SP, 2018, CELL CHEM BIOL, V25, P1086, DOI 10.1016/j.chembiol.2018.05.015
   Velagapudi SP, 2014, NAT CHEM BIOL, V10, P291, DOI [10.1038/NCHEMBIO.1452, 10.1038/nchembio.1452]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0
   Zhang G., 2020, BIORXIV
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
NR 39
TC 1
Z9 1
U1 3
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2374-7943
EI 2374-7951
J9 ACS CENTRAL SCI
JI ACS Central Sci.
PD OCT 28
PY 2020
VL 6
IS 10
BP 1713
EP 1721
DI 10.1021/acscentsci.0c00984
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA ON7ZL
UT WOS:000586913800010
PM 33140033
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Casalino, L
   Gaieb, Z
   Goldsmith, JA
   Hjorth, CK
   Dommer, AC
   Harbison, AM
   Fogarty, CA
   Barros, EP
   Taylor, BC
   McLellan, JS
   Fadda, E
   Amaro, RE
AF Casalino, Lorenzo
   Gaieb, Zied
   Goldsmith, Jory A.
   Hjorth, Christy K.
   Dommer, Abigail C.
   Harbison, Aoife M.
   Fogarty, Carl A.
   Barros, Emilia P.
   Taylor, Bryn C.
   McLellan, Jason S.
   Fadda, Elisa
   Amaro, Rommie E.
TI Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein
SO ACS CENTRAL SCIENCE
LA English
DT Article
ID MOLECULAR-DYNAMICS; DC-SIGN; FORCE-FIELD; CORONAVIRUS; NEUTRALIZATION;
   BILAYERS; ENTRY; CHAIN; GUI
AB The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in more than 28,000,000 infections and 900,000 deaths worldwide to date. Antibody development efforts mainly revolve around the extensively glycosylated SARS-CoV-2 spike (S) protein, which mediates host cell entry by binding to the angiotensin-converting enzyme 2 (ACE2). Similar to many other viral fusion proteins, the SARS-CoV-2 spike utilizes a glycan shield to thwart the host immune response. Here, we built a full-length model of the glycosylated SARS-CoV-2 S protein, both in the open and dosed states, augmenting the available structural and biological data. Multiple microsecond-long, all-atom molecular dynamics simulations were used to provide an atomistic perspective on the roles of glycans and on the protein structure and dynamics. We reveal an essential structural role of N-glycans at sites N165 and N234 in modulating the conformational dynamics of the spike's receptor binding domain (RBD), which is responsible for ACE2 recognition. This finding is corroborated by biolayer interferometry experiments, which show that deletion of these glycans through N165A and N234A mutations significantly reduces binding to ACE2 as a result of the RBD conformational shift toward the "down" state. Additionally, end-to-end accessibility analyses outline a complete overview of the vulnerabilities of the glycan shield of the SARS-CoV-2 S protein, which may be exploited in the therapeutic efforts targeting this molecular machine. Overall, this work presents hitherto unseen functional and structural insights into the SARS-CoV-2 S protein and its glycan coat, providing a strategy to control the conformational plasticity of the RBD that could be harnessed for vaccine development.
C1 [Casalino, Lorenzo; Gaieb, Zied; Dommer, Abigail C.; Barros, Emilia P.; Taylor, Bryn C.; Amaro, Rommie E.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.
   [Goldsmith, Jory A.; Hjorth, Christy K.; McLellan, Jason S.] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.
   [Harbison, Aoife M.; Fogarty, Carl A.; Fadda, Elisa] Maynooth Univ, Dept Chem, Dublin, Ireland.
   [Harbison, Aoife M.; Fogarty, Carl A.; Fadda, Elisa] Maynooth Univ, Hamilton Inst, Dublin, Ireland.
   [Taylor, Bryn C.; Amaro, Rommie E.] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA.
RP Amaro, RE (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.; Amaro, RE (corresponding author), Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA.
EM ramaro@ucsd.edu
OI Casalino, Lorenzo/0000-0003-3581-1148
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [GM132826, R01-AI127521]; NSF
   RAPIDNational Science Foundation (NSF) [MCB-2032054]; RCSA Research
   Corp.; Visible Molecular Cell Consortium fellowship; Irish Research
   CouncilIrish Research Council for Science, Engineering and Technology;
   UC San Diego Moore's Cancer Center 2020 SARS-COV-2 seed grant
FX This work was supported by NIH GM132826, NSF RAPID MCB-2032054, an award
   from the RCSA Research Corp., a UC San Diego Moore's Cancer Center 2020
   SARS-COV-2 seed grant, and the Irish Research Council. L.C. is funded by
   a dVisible Molecular Cell Consortium fellowship. This work was supported
   in part by NIH grant R01-AI127521 to J.S.M.
CR Altman MO, 2019, MBIO, V10, DOI 10.1128/mBio.00204-19
   Amaro RE, 2020, J CHEM INF MODEL, V60, P2653, DOI 10.1021/acs.jcim.0c00319
   [Anonymous], 2020, NY TIMES
   Apellaniz B, 2014, CHEM PHYS LIPIDS, V181, P40, DOI 10.1016/j.chemphyslip.2014.03.003
   Behrens AJ, 2017, CURR OPIN STRUC BIOL, V44, P125, DOI 10.1016/j.sbi.2017.03.008
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Berkowitz ML, 2009, BBA-BIOMEMBRANES, V1788, P86, DOI 10.1016/j.bbamem.2008.09.009
   Bonomelli C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023521
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Crispin M, 2018, ANNU REV BIOPHYS, V47, P499, DOI 10.1146/annurev-biophys-060414-034156
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Cunningham AL, 2007, NAT IMMUNOL, V8, P556, DOI 10.1038/ni0607-556
   Davidson AD, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00763-0
   Doores KJ, 2010, P NATL ACAD SCI USA, V107, P13800, DOI 10.1073/pnas.1006498107
   Ejemel M., 2020, BIORXIV, DOI [10.1101/2020.05.15.096719, DOI 10.1101/2020.05.15.096719V1]
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Ghysels A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13432-7
   Go EP, 2015, J VIROL, V89, P8245, DOI 10.1128/JVI.00628-15
   Goncalves AR, 2013, J VIROL, V87, P11504, DOI 10.1128/JVI.01893-13
   Grant O. C., 2020, BIORXIV, DOI [10.1101/2020.04.07.030445., DOI 10.1101/2020.04.07.030445V2]
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Guvench O, 2009, J CHEM THEORY COMPUT, V5, P2353, DOI 10.1021/ct900242e
   Harbison AM, 2019, GLYCOBIOLOGY, V29, P94, DOI 10.1093/glycob/cwy097
   Henderson R, 2020, NAT STRUCT MOL BIOL, V27, P925, DOI 10.1038/s41594-020-0479-4
   heng Z., 2020, EUROSURVEILLANCE, V25
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Huo J., 2020, CELL HOST MICROBE, DOI [10.1016/j.chom.2020.06.010, DOI 10.1016/J.CH0M.2020.06.010]
   Janosi L, 2010, J CHEM THEORY COMPUT, V6, P3267, DOI 10.1021/ct100381g
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Jo S, 2011, J COMPUT CHEM, V32, P3135, DOI 10.1002/jcc.21886
   Kirschner KN, 2008, J COMPUT CHEM, V29, P622, DOI 10.1002/jcc.20820
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   McGibbon RT, 2015, BIOPHYS J, V109, P1528, DOI 10.1016/j.bpj.2015.08.015
   Mckee M, 2020, NAT MED, V26, P640, DOI 10.1038/s41591-020-0863-y
   Ng S, 2019, NAT MED, V25, P962, DOI 10.1038/s41591-019-0463-x
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Park SJ, 2019, GLYCOBIOLOGY, V29, P320, DOI 10.1093/glycob/cwz003
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Raman R, 2016, CURR OPIN STRUC BIOL, V40, P153, DOI 10.1016/j.sbi.2016.10.003
   Rog T, 2006, BIOCHIMIE, V88, P449, DOI 10.1016/j.biochi.2005.10.005
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Saito H, 2018, J PHYS CONF SER, V1136, DOI 10.1088/1742-6596/1136/1/012022
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Seitz C., 2020, BIORXIV, DOI [10.1101/2020.08.12.248690., DOI 10.1101/2020.08.12.248690V1]
   Shahane G, 2019, J MOL MODEL, V25, DOI 10.1007/s00894-019-3964-0
   Shajahan Asif, 2020, Glycobiology, V30, P981, DOI 10.1093/glycob/cwaa042
   Shulla A, 2009, J BIOL CHEM, V284, P32725, DOI 10.1074/jbc.M109.043547
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stewart-Jones GBE, 2016, CELL, V165, P813, DOI 10.1016/j.cell.2016.04.010
   Tai WB, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104820
   Thorp EB, 2006, J VIROL, V80, P1280, DOI 10.1128/JVI.80.3.1280-1289.2006
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Urbanowicz RA, 2019, J VIROL, V93, DOI 10.1128/JVI.01403-18
   Venable RM, 2015, CHEM PHYS LIPIDS, V192, P60, DOI 10.1016/j.chemphyslip.2015.07.014
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Watanabe Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16567-0
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Watanabe Y, 2019, BBA-GEN SUBJECTS, V1863, P1480, DOI 10.1016/j.bbagen.2019.05.012
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu EL, 2014, J COMPUT CHEM, V35, P1997, DOI 10.1002/jcc.23702
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang ML, 2017, SCI REP-UK, V7, DOI 10.1038/srep43829
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhou T., 2020, BIORXIV, DOI [10.1101/2020.07.04.187989, DOI 10.1101/2020.07.04.187989V1]
   Zost SJ, 2020, NATURE, DOI 10.1038/s41586-020-2548-6
NR 79
TC 10
Z9 10
U1 2
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2374-7943
EI 2374-7951
J9 ACS CENTRAL SCI
JI ACS Central Sci.
PD OCT 28
PY 2020
VL 6
IS 10
BP 1722
EP 1734
DI 10.1021/acscentsci.0c01056
PG 13
WC Chemistry, Multidisciplinary
SC Chemistry
GA ON7ZL
UT WOS:000586913800011
PM 33140034
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kimmig, LM
   Wu, D
   Gold, M
   Pettit, NN
   Pitrak, D
   Mueller, J
   Husain, AN
   Mutlu, EA
   Mutlu, GM
AF Kimmig, Lucas M.
   Wu, David
   Gold, Matthew
   Pettit, Natasha N.
   Pitrak, David
   Mueller, Jeffrey
   Husain, Aliya N.
   Mutlu, Ece A.
   Mutlu, Gokhan M.
TI IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With
   Increased Secondary Infections
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; tocilizumab; cytokine release syndrome;
   immunosuppression
ID TOCILIZUMAB; RISK
AB Background: Anti-inflammatory therapies such as IL-6 inhibition have been proposed for COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory response in infectious diseases may impair a desired host response and pre-dispose to secondary infections.
   Methods: We retrospectively reviewed the medical record of critically ill COVID-19 patients during an 8-week span and compared the prevalence of secondary infection and outcomes in patients who did and did not receive tocilizumab. Additionally, we included representative histopathologic post-mortem findings from several COVID-19 cases that underwent autopsy at our institution.
   Results: One hundred eleven patients were identified, of which 54 had received tocilizumab while 57 had not. Receiving tocilizumab was associated with a higher risk of secondary bacterial (48.1 vs. 28.1%; p = 0.029 and fungal (5.6 vs. 0%; p = 0.112) infections. Consistent with higher number of infections, patients who received tocilizumab had higher mortality (35.2 vs. 19.3%; p = 0.020). Seven cases underwent autopsy. In three cases who received tocilizumab, there was evidence of pneumonia on pathology. Of the four cases that had not been given tocilizumab, two showed evidence of aspiration pneumonia and two exhibited diffuse alveolar damage.
   Conclusions: Experimental therapies are currently being applied to COVID-19 outside of clinical trials. Anti-inflammatory therapies such as anti-IL-6 therapy have the potential to impair viral clearance, pre-dispose to secondary infection, and cause harm. We seek to raise physician awareness of these issues and highlight the need to better understand the immune response in COVID-19.
C1 [Kimmig, Lucas M.; Wu, David; Gold, Matthew; Pettit, Natasha N.; Pitrak, David; Mutlu, Gokhan M.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Kimmig, Lucas M.; Wu, David; Mutlu, Gokhan M.] Univ Chicago, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA.
   [Pettit, Natasha N.; Pitrak, David] Univ Chicago, Sect Infect Dis, Chicago, IL 60637 USA.
   [Mueller, Jeffrey; Husain, Aliya N.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Mutlu, Ece A.] Rush Univ, Sect Gastroenterol & Hepatol, Chicago, IL 60612 USA.
RP Mutlu, GM (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.; Mutlu, GM (corresponding author), Univ Chicago, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA.
EM gmutlu@medicine.bsd.uchicago.edu
FU  [T32HL007605];  [K99HL145113];  [R01ES010524];  [W81XWH16-1-0711]
FX This work was supported by the following grants: T32HL007605 (LK),
   K99HL145113 (DW), and R01ES010524, and W81XWH16-1-0711 (GM).
CR Ali T, 2013, DRUG HEALTHC PATIENT, V5, P79, DOI 10.2147/DHPS.S28801
   Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Davis JS, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00035-19
   Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603
   Kimmig Lucas M, 2020, medRxiv, DOI 10.1101/2020.05.15.20103531
   KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0
   Lang VR, 2012, RHEUMATOLOGY, V51, P852, DOI 10.1093/rheumatology/ker223
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mansournia MA, 2018, AM J EPIDEMIOL, V187, P864, DOI 10.1093/aje/kwx299
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Morena V, 2020, EUR J INTERN MED, V76, P36, DOI 10.1016/j.ejim.2020.05.011
   Narazaki M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113528
   Pawar A, 2019, ANN RHEUM DIS, V78, P456, DOI 10.1136/annrheumdis-2018-214367
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Velazquez-Salinas L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01057
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 17
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD OCT 28
PY 2020
VL 7
AR 583897
DI 10.3389/fmed.2020.583897
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA OT2UG
UT WOS:000590706200001
PM 33195334
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kandeil, A
   Gomaa, MR
   El Taweel, A
   Mostafa, A
   Shehata, M
   Kayed, AE
   Kutkat, O
   Moatasim, Y
   Mahmoud, SH
   Kamel, MN
   Shama, NMA
   El Sayes, M
   El-Shesheny, R
   Yassien, MA
   Webby, RJ
   Kayali, G
   Ali, MA
AF Kandeil, Ahmed
   Gomaa, Mokhtar R.
   El Taweel, Ahmed
   Mostafa, Ahmed
   Shehata, Mahmoud
   Kayed, Ahmed E.
   Kutkat, Omnia
   Moatasim, Yassmin
   Mahmoud, Sara H.
   Kamel, Mina Nabil
   Shama, Noura M. Abo
   El Sayes, Mohamed
   El-Shesheny, Rabeh
   Yassien, Mahmoud A.
   Webby, Richard J.
   Kayali, Ghazi
   Ali, Mohamed A.
TI Common childhood vaccines do not elicit a cross-reactive antibody
   response against SARS-CoV-2
SO PLOS ONE
LA English
DT Article
ID NONSPECIFIC PROTECTION; TRAINED IMMUNITY; BCG VACCINATION; INFECTION
AB Anecdotal evidence showed a negative correlation between Bacille Calmette-Guerin (BCG) vaccination and incidence of COVID-19. Incidence of the disease in children is much lower than in adults. It is hypothesized that BCG and other childhood vaccinations may provide some protection against SARS-CoV-2 infection through trained or adaptive immune responses. Here, we tested whether BCG, Pneumococcal, Rotavirus, Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenzae, Hepatitis B, Meningococcal, Measles, Mumps, and Rubella vaccines provide cross-reactive neutralizing antibodies against SARS-CoV-2 in BALB/c mice. Results indicated that none of these vaccines provided antibodies capable of neutralizing SARS-CoV-2 up to seven weeks post vaccination. We conclude that if such vaccines have any role in COVID-19 immunity, this role is not antibody-mediated.
C1 [Kandeil, Ahmed; Gomaa, Mokhtar R.; El Taweel, Ahmed; Mostafa, Ahmed; Shehata, Mahmoud; Kayed, Ahmed E.; Kutkat, Omnia; Moatasim, Yassmin; Mahmoud, Sara H.; Kamel, Mina Nabil; Shama, Noura M. Abo; El Sayes, Mohamed; El-Shesheny, Rabeh; Ali, Mohamed A.] Natl Res Ctr, Ctr Sci Excellence Influenza Viruses, Giza, Egypt.
   [Yassien, Mahmoud A.] Egyptian Drug Author, Biol Sect, Cairo, Egypt.
   [Webby, Richard J.] St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Kayali, Ghazi] Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77004 USA.
   [Kayali, Ghazi] Human Link, Hazmieh, Baabda, Lebanon.
RP Ali, MA (corresponding author), Natl Res Ctr, Ctr Sci Excellence Influenza Viruses, Giza, Egypt.; Kayali, G (corresponding author), Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77004 USA.; Kayali, G (corresponding author), Human Link, Hazmieh, Baabda, Lebanon.
EM ghazi@human-link.org; mohamedahmedali2004@yahoo.com
RI Elsayed, Ahmed Moustafa Mohamed/S-7462-2016; Kandeil, Ahmed/B-3345-2016
OI Elsayed, Ahmed Moustafa Mohamed/0000-0002-2878-5714; Kandeil,
   Ahmed/0000-0003-3253-6961; Moatasim, Yassmin/0000-0003-2159-2511
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, US Department of Health and Human ServicesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID)NIH National Institute of Neurological Disorders &
   Stroke (NINDS) [HHSN272201400006C]
FX This research was funded by the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health, US Department of
   Health and Human Services (under contract HHSN272201400006C).
CR Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Baskar PV, 1998, CLIN EXP IMMUNOL, V111, P251
   Cortis D, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00202
   Covian C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00970
   COVID-19 National Incident Room Surveillance Team, 2020, Commun Dis Intell (2018), V44, DOI 10.33321/cdi.2020.44.52
   Dawson Patrick, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa799
   Escobar LE, 2020, P NATL ACAD SCI USA, V117, P17720, DOI 10.1073/pnas.2008410117
   Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189
   Kleinnijenhuis J, 2014, CLIN IMMUNOL, V155, P213, DOI 10.1016/j.clim.2014.10.005
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Klinger D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030378
   Liu Y, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01112-2020
   Lyu JL, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109842
   Madan M, 2020, PUBLIC HEALTH, V185, P91, DOI 10.1016/j.puhe.2020.05.042
   Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Pereira M, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01439-4
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Sidiq KR, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00120
   Weng CH, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001569
   World Health Organization, 2020, 182 WHO
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
NR 22
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 28
PY 2020
VL 15
IS 10
AR e0241471
DI 10.1371/journal.pone.0241471
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OP8XL
UT WOS:000588374000069
PM 33112930
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Oliveira, SC
   de Magalhaes, MTQ
   Homan, EJ
AF Oliveira, Sergio C.
   de Magalhaes, Mariana T. Q.
   Homan, E. Jane
TI Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and
   Identification of COVID-19 Vaccine Targets
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE severe acute respiratory syndrome coronavirus 2; Coronavirus Disease
   2019; epitopes; vaccine; T cells; B cells; nucleocapsid
ID ACUTE RESPIRATORY SYNDROME; RNA-BINDING DOMAIN; T-CELL;
   IMMUNE-RESPONSES; CORONAVIRUS; PEPTIDES; OUTBREAK; EPITOPES; CHIMERA;
   VIRUS
AB COVID-19 is a worldwide emergency; therefore, there is a critical need for foundational knowledge about B and T cell responses to SARS-CoV-2 essential for vaccine development. However, little information is available defining which determinants of SARS-CoV-2 other than the spike glycoprotein are recognized by the host immune system. In this study, we focus on the SARS-CoV-2 nucleocapsid protein as a suitable candidate target for vaccine formulations. Major B and T cell epitopes of the SARS-CoV-2 N protein are predicted and resulting sequences compared with the homolog immunological domains of other coronaviruses that infect human beings. The most dominant of B cell epitope is located between 176-206 amino acids in the SRGGSQASSRSSSRSRNSSRNSTPGSSRGTS sequence. Further, we identify sequences which are predicted to bind multiple common MHC I and MHC II alleles. Most notably there is a region of potential T cell cross-reactivity within the SARS-CoV-2 N protein position 102-110 amino acids that traverses multiple human alpha and betacoronaviruses. Vaccination strategies designed to target these conserved epitope regions could generate immune responses that are cross-reactive across human coronaviruses, with potential to protect or modulate disease. Finally, these predictions can facilitate effective vaccine design against this high priority virus.
C1 [Oliveira, Sergio C.; de Magalhaes, Mariana T. Q.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.
   [Oliveira, Sergio C.] Minist Ciencia & Tecnol MCT, Conselho Nacl Desenvolvimento Cient & Tecnol CNPq, Inst Nacl Ciencia & Tecnol Doencas Trop INCT DT, Salvador, BA, Brazil.
   [Homan, E. Jane] IoGenetics LLC, Madison, WI USA.
RP Oliveira, SC (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.; Oliveira, SC (corresponding author), Minist Ciencia & Tecnol MCT, Conselho Nacl Desenvolvimento Cient & Tecnol CNPq, Inst Nacl Ciencia & Tecnol Doencas Trop INCT DT, Salvador, BA, Brazil.
EM scozeus1@gmail.com
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [465229/2014-0, 401209/2020-2, 302660/2015-1]; Fundacao de Amparo
   a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP) [2017/24832-6]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [88887.506611/2020-00, 88887.504420/2020-00]; National Institute of
   Health (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 AI 116453]
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) grant #465229/2014-0,
   401209/2020-2 and 302660/2015-1 (to SO) and Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) grant #2017/24832-6 (to SO) and
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
   grant #88887.506611/2020-00 and 88887.504420/2020-00 and National
   Institute of Health (NIH) grant#R01 AI 116453 (to SO).
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Altmann DM, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6160
   Altschul SF, 2005, FEBS J, V272, P5101, DOI 10.1111/j.1742-4658.2005.04945.x
   Bremel RD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00538
   Bremel RD, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00541
   Bremel Robert D, 2010, Immunome Res, V6, P8, DOI 10.1186/1745-7580-6-8
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9
   Chang MS, 2004, BIOCHEM BIOPH RES CO, V314, P931, DOI 10.1016/j.bbrc.2003.12.195
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Chen IJ, 2013, BBA-PROTEINS PROTEOM, V1834, P1054, DOI 10.1016/j.bbapap.2013.03.003
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   Crooke SN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70864-8
   Dahlke C, 2020, DISTINCT EARLY IGA P, DOI [10.1101/2020.04.14.20059733, DOI 10.1101/2020.04.14.20059733]
   Dutta NK, 2020, J VIROL, V94, DOI 10.1128/JVI.00647-20
   Gao WT, 2003, LANCET, V362, P1895, DOI 10.1016/S0140-6736(03)14962-8
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Hoglund RA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00598
   Hoglund RA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194843
   Homan EJ, 2014, HUM VACC IMMUNOTHER, V10, P290, DOI 10.4161/hv.27139
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0358-6
   Huang QL, 2004, BIOCHEMISTRY-US, V43, P6059, DOI 10.1021/bi036155b
   JOHNSON NL, 1949, BIOMETRIKA, V36, P149, DOI 10.1093/biomet/36.1-2.149
   Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091
   Joshi Amit, 2020, Inform Med Unlocked, V19, P100338, DOI 10.1016/j.imu.2020.100338
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Kiyotani K, 2020, J HUM GENET, V65, P569, DOI 10.1038/s10038-020-0771-5
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   LEBERT NT, 2020, NATURE 0715, DOI DOI 10.1101/2020.05.26.115832
   Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871
   Mercurio I, 2020, CELL MOL LIFE SCI, DOI 10.1007/s00018-020-03580-1
   Morais SB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01762
   Mukherjee S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020290
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   Shen LJ, 2004, IMMUNITY, V21, P155, DOI 10.1016/j.immuni.2004.07.004
   Shi JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144475
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Specht CA, 2017, MBIO, V8, DOI 10.1128/mBio.01872-17
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Tilocca B, 2020, MICROBES INFECT, V22, P188, DOI 10.1016/j.micinf.2020.04.002
   Veit S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120718
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   Yang K, 2009, GENE THER, V16, P1353, DOI 10.1038/gt.2009.92
   Zeng WH, 2020, BIOCHEM BIOPH RES CO, V527, P618, DOI 10.1016/j.bbrc.2020.04.136
   Zhang T, 2020, CURR BIOL, V30, P1578, DOI 10.1016/j.cub.2020.03.063
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu Y, 2005, VIRUS GENES, V30, P93, DOI 10.1007/s11262-004-4586-9
   Zuwala K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117833
NR 61
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 28
PY 2020
VL 11
AR 587615
DI 10.3389/fimmu.2020.587615
PG 10
WC Immunology
SC Immunology
GA OP4AT
UT WOS:000588023700001
PM 33193414
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Huang, WC
   Zhou, SQ
   He, XD
   Chiem, K
   Mabrouk, MT
   Nissly, RH
   Bird, IM
   Strauss, M
   Sambhara, S
   Ortega, J
   Wohlfert, EA
   Martinez-Sobrido, L
   Kuchipudi, SV
   Davidson, BA
   Lovell, JF
AF Huang, Wei-Chiao
   Zhou, Shiqi
   He, Xuedan
   Chiem, Kevin
   Mabrouk, Moustafa T.
   Nissly, Ruth H.
   Bird, Ian M.
   Strauss, Mike
   Sambhara, Suryaprakash
   Ortega, Joaquin
   Wohlfert, Elizabeth A.
   Martinez-Sobrido, Luis
   Kuchipudi, Suresh, V
   Davidson, Bruce A.
   Lovell, Jonathan F.
TI SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by
   Particulate Vaccination
SO ADVANCED MATERIALS
LA English
DT Article
DE antigens; COVID&#8208; 19; liposomes; nanoparticles; SARS&#8208;
   CoV&#8208; 2; vaccines
ID SARS CORONAVIRUS; DENDRITIC CELLS; COMBINATION; VACCINES
AB The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is a candidate vaccine antigen that binds angiotensin-converting enzyme 2 (ACE2), leading to virus entry. Here, it is shown that rapid conversion of recombinant RBD into particulate form via admixing with liposomes containing cobalt-porphyrin-phospholipid (CoPoP) potently enhances the functional antibody response. Antigen binding via His-tag insertion into the CoPoP bilayer results in a serum-stable and conformationally intact display of the RBD on the liposome surface. Compared to other vaccine formulations, immunization using CoPoP liposomes admixed with recombinant RBD induces multiple orders of magnitude higher levels of antibody titers in mice that neutralize pseudovirus cell entry, block RBD interaction with ACE2, and inhibit live virus replication. Enhanced immunogenicity can be accounted for by greater RBD uptake into antigen-presenting cells in particulate form and improved immune cell infiltration in draining lymph nodes. QS-21 inclusion in the liposomes results in an enhanced antigen-specific polyfunctional T cell response. In mice, high dose immunization results in minimal local reactogenicity, is well-tolerated, and does not elevate serum cobalt levels. Taken together, these results confirm that particulate presentation strategies for the RBD immunogen should be considered for inducing strongly neutralizing antibody responses against SARS-CoV-2.
C1 [Huang, Wei-Chiao; Zhou, Shiqi; He, Xuedan; Mabrouk, Moustafa T.; Lovell, Jonathan F.] Univ Buffalo State Univ New York, Dept Biomed Engn, Buffalo, NY 14260 USA.
   [Chiem, Kevin; Martinez-Sobrido, Luis] Texas Biomed Res Inst, San Antonio, TX 78227 USA.
   [Nissly, Ruth H.; Bird, Ian M.; Kuchipudi, Suresh, V] Penn State Univ, Dept Vet & Biomed Sci, Anim Diagnost Lab, University Pk, PA 16802 USA.
   [Strauss, Mike; Ortega, Joaquin] McGill Univ Montreal, Dept Anat & Cell Biol, Montreal, PQ H3A 0C7, Canada.
   [Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, 1600 Clifton Rd, Atlanta, GA 30329 USA.
   [Wohlfert, Elizabeth A.] Univ Buffalo State Univ New York, Dept Microbiol & Immunol, Buffalo, NY 14203 USA.
   [Kuchipudi, Suresh, V] Penn State Univ, Ctr Infect Dis Dynam, Dept Vet & Biomed Sci, Anim Diagnost Lab, University Pk, PA 16802 USA.
   [Davidson, Bruce A.] Univ Buffalo State Univ New York, Dept Pathol & Anat Sci, Dept Anesthesiol, Buffalo, NY 14203 USA.
RP Lovell, JF (corresponding author), Univ Buffalo State Univ New York, Dept Biomed Engn, Buffalo, NY 14260 USA.
EM jflovell@buffalo.edu
OI Bird, Ian/0000-0003-3176-3054; strauss, mike/0000-0002-0986-2868
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01AI148557,
   R01CA247771]; Canadian Foundation for InnovationCanada Foundation for
   Innovation; Quebec Government; McGill University
FX The authors acknowledge assistance from Dr. Michael Farzan and Dr.
   Huihui Mu for providing the reagents and protocols to generate
   pseudovirus, as well as providing HEK293 cells expressing hACE2. This
   study was supported by the National Institutes of Health (R01AI148557
   and R01CA247771). The authors thank Kelly Sears and other staff members
   of the Facility for Electron Microscopy Research (FEMR) at McGill
   University. FEMR is supported by the Canadian Foundation for Innovation,
   Quebec Government and McGill University. All animal experiments were
   carried out in accordance to protocols approved by the University at
   Buffalo or the Pocono Rabbit Farm Institutional Animal Care and Use
   Committee.
CR Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090
   Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035
   Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768
   Edelson BT, 2010, J EXP MED, V207, P823, DOI 10.1084/jem.20091627
   Federizon J, 2020, VACCINE, V38, P942, DOI 10.1016/j.vaccine.2019.10.073
   Funk CD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00937
   Ginhoux F, 2009, J EXP MED, V206, P3115, DOI 10.1084/jem.20091756
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Honda-Okubo Y, 2012, VACCINE, V30, P5373, DOI 10.1016/j.vaccine.2012.06.021
   Huang WC, 2020, MALARIA J, V19, DOI 10.1186/s12936-020-03368-5
   Huang WC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0173-x
   Huang WC, 2018, NAT NANOTECHNOL, V13, P1174, DOI 10.1038/s41565-018-0271-3
   Kataoka M, 2009, VACCINE, V27, P1881, DOI 10.1016/j.vaccine.2009.01.095
   Liang F, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2094
   Mabrouk M, 2020, INT J PHARMACEUT, V587, DOI 10.1016/j.ijpharm.2020.119658
   Petersen E, 2020, LANCET INFECT DIS, V20, pE238, DOI 10.1016/S1473-3099(20)30484-9
   Poland GA, 2020, MAYO CLIN PROC, V95, P2172, DOI 10.1016/j.mayocp.2020.07.021
   Quinlan B. D., 2020, BIORXIV, DOI [10.1101/2020.04.10.036418, DOI 10.1101/2020.04.10.036418]
   Salazar E., 2020, J CLIN INVEST
   Sauer SW, 2001, ANN EMERG MED, V37, P635, DOI 10.1067/mem.2001.114315
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shao S, 2015, NAT CHEM, V7, P438, DOI [10.1038/NCHEM.2236, 10.1038/nchem.2236]
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Manh TPV, 2013, EUR J IMMUNOL, V43, P1706, DOI 10.1002/eji.201243106
   U. S. FDA, INV COVID 19 CONV PL
   Walls Alexandra C, 2020, bioRxiv, DOI 10.1101/2020.08.11.247395
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wherry EJ, 2004, J VIROL, V78, P5535, DOI 10.1128/JVI.78.11.5535-5545.2004
   Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46533-w
NR 34
TC 0
Z9 0
U1 3
U2 3
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD DEC
PY 2020
VL 32
IS 50
AR 2005637
DI 10.1002/adma.202005637
EA OCT 2020
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA PG7WN
UT WOS:000586001600001
PM 33111375
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Yang, L
   Pei, RJ
   Li, H
   Ma, XN
   Zhou, Y
   Zhu, FH
   He, PL
   Tang, W
   Zhang, YC
   Xiong, J
   Xiao, SQ
   Tong, XK
   Zhang, B
   Zuo, JP
AF Yang, Li
   Pei, Rong-juan
   Li, Heng
   Ma, Xin-na
   Zhou, Yu
   Zhu, Feng-hua
   He, Pei-lan
   Tang, Wei
   Zhang, Ye-cheng
   Xiong, Jin
   Xiao, Shu-qi
   Tong, Xian-kun
   Zhang, Bo
   Zuo, Jian-ping
TI Identification of SARS-CoV-2 entry inhibitors among already approved
   drugs
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; virus entry inhibitors; high throughput screening
   assay; approved drug library; histamine receptor antagonists; clemastine
ID RESPIRATORY SYNDROME CORONAVIRUS; TRIMEPRAZINE TARTRATE; VIRUS;
   REPLICATION; PNEUMONIA; INFECTION; COMPOUND; ABL
AB To discover effective drugs for COVID-19 treatment amongst already clinically approved drugs, we developed a high throughput screening assay for SARS-CoV-2 virus entry inhibitors using SARS2-S pseudotyped virus. An approved drug library of 1800 small molecular drugs was screened for SARS2 entry inhibitors and 15 active drugs were identified as specific SARS2-S pseudovirus entry inhibitors. Antiviral tests using native SARS-CoV-2 virus in Vero E6 cells confirmed that 7 of these drugs (clemastine, amiodarone, trimeprazine, bosutinib, toremifene, flupenthixol, and azelastine) significantly inhibited SARS2 replication, reducing supernatant viral RNA load with a promising level of activity. Three of the drugs were classified as histamine receptor antagonists with clemastine showing the strongest anti-SARS2 activity (EC50 = 0.95 +/- 0.83 mu M). Our work suggests that these 7 drugs could enter into further in vivo studies and clinical investigations for COVID-19 treatment.
C1 [Yang, Li; Li, Heng; Zhou, Yu; Zhu, Feng-hua; He, Pei-lan; Tang, Wei; Tong, Xian-kun; Zuo, Jian-ping] Chinese Acad Sci, Shanghai Inst Mat Med, Lab Immunopharmacol, Shanghai 201203, Peoples R China.
   [Pei, Rong-juan; Zhang, Ye-cheng; Xiong, Jin; Xiao, Shu-qi; Zhang, Bo] Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, Key Lab Special Pathogens & Biosafety, Wuhan 430071, Peoples R China.
   [Li, Heng; Zuo, Jian-ping] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Ma, Xin-na; Zuo, Jian-ping] Shanghai Univ Tradit Chinese Med, Lab Immunol & Virol, Shanghai 201203, Peoples R China.
RP Tong, XK; Zuo, JP (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Lab Immunopharmacol, Shanghai 201203, Peoples R China.; Zhang, B (corresponding author), Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, Key Lab Special Pathogens & Biosafety, Wuhan 430071, Peoples R China.; Zuo, JP (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Zuo, JP (corresponding author), Shanghai Univ Tradit Chinese Med, Lab Immunol & Virol, Shanghai 201203, Peoples R China.
EM xktong@simm.ac.cn; zhangbo@wh.iov.cn; jpzuo@simm.ac.cn
OI zhang, Yecheng/0000-0003-3662-7262
FU National Key Research and Development Program of China [2018YFC1200604]
FX This work was supported by the National Key Research and Development
   Program of China (2018YFC1200604). Experiments related to SARS-CoV-2
   were carried out at the National Biosafety Laboratory, Wuhan, Chinese
   Academy of Sciences. We are particularly grateful to Tao Du and Lun Wang
   from the Zhengdian Biosafety Level 3 Laboratory and the team running the
   laboratory for their work. The pNL4.3.Luc.R-.E- plasmid was kindly
   gifted by Dr Shi-bo Jiang and Dr Lu Lu from Fudan University.
CR Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Chen JG, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008156
   Chen S, 2005, ACTA PHARMACOL SIN, V26, P99, DOI 10.1111/j.1745-7254.2005.00010.x
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   Cong Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194868
   Coyne CB, 2006, CELL, V124, P119, DOI 10.1016/j.cell.2005.10.035
   Cuellar S, 2018, J ONCOL PHARM PRACT, V24, P433, DOI 10.1177/1078155217710553
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   France KG, 1999, EXP CLIN PSYCHOPHARM, V7, P502, DOI 10.1037/1064-1297.7.4.502
   Garcia M, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003500
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   HARLING DW, 1995, ANAESTHESIA, V50, P97, DOI 10.1111/j.1365-2044.1995.tb04550.x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Janakiram NB, 2008, ACTA PHARMACOL SIN, V29, P1, DOI 10.1111/j.1745-7254.2008.00742.x
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Johansen LM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005471
   KRISTIANSEN JE, 1991, PHARMACOL TOXICOL, V68, P399, DOI 10.1111/j.1600-0773.1991.tb01260.x
   Kritas SK, 2020, J BIOL REG HOMEOS AG, V34, P9, DOI 10.23812/20-Editorial-Kritas
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   LARGENT BL, 1987, MOL PHARMACOL, V32, P772
   Li H, 2020, ACTA PHARMACOL SIN, V41, P1133, DOI 10.1038/s41401-020-0438-y
   Reeves PM, 2011, J VIROL, V85, P21, DOI 10.1128/JVI.01814-10
   Salata C, 2018, NEW MICROBIOL, V41, P162
   Salata C, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv032
   Schafer A, 2018, ANTIVIR RES, V157, P47, DOI 10.1016/j.antiviral.2018.07.003
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shoemaker CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056265
   Stadler K, 2008, AM J RESP CELL MOL, V39, P142, DOI 10.1165/rcmb.2007-0217OC
   Tong XK, 2010, ACTA PHARMACOL SIN, V31, P585, DOI 10.1038/aps.2010.29
   Toth K, 2008, P NATL ACAD SCI USA, V105, P7293, DOI 10.1073/pnas.0800200105
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Wenzel JM, 2013, PHARMACOL BIOCHEM BE, V114, P90, DOI 10.1016/j.pbb.2013.08.014
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xu W, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02643
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang L, 2014, ACTA PHARMACOL SIN, V35, P410, DOI 10.1038/aps.2013.175
   Zhao GY, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-266
   Zhao YG, 2016, NATURE, V535, P169, DOI 10.1038/nature18615
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 46
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
DI 10.1038/s41401-020-00556-6
EA OCT 2020
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA OK8AC
UT WOS:000584865400002
PM 33116249
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yepes-Perez, AF
   Herrera-Calderon, O
   Quintero-Saumeth, J
AF Yepes-Perez, Andres F.
   Herrera-Calderon, Oscar
   Quintero-Saumeth, Jorge
TI Uncaria tomentosa (cat's claw): a promising herbal medicine against
   SARS-CoV-2/ACE-2 junction and SARS-CoV-2 spike protein based on
   molecular modeling
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; viral spike protein; ACE-2; cat&#8217; s claw; Uncaria
   tomentosa; molecular modeling; COVID-19
ID QUINOVIC ACID GLYCOSIDES; SCORING FUNCTION; WILLD. DC; DRUG;
   PERMEABILITY; TRITERPENES; BINDING; PREDICTION; ALGORITHM; DOCKING
AB COVID-19 is a novel severe acute respiratory syndrome coronavirus. Currently, there is no effective treatment and vaccines seem to be the solution in the future. Virtual screening of potential drugs against the S protein of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) has provided small molecular compounds with a high binding affinity. Unfortunately, most of these drugs do not attach with the binding interface of the receptor-binding domain (RBD)-angiotensin-converting enzyme-2 (ACE-2) complex in host cells. Molecular modeling was carried out to evaluate the potential antiviral properties of the components of the medicinal herb Uncaria tomentosa (cat's claw) focusing on the binding interface of the RBD-ACE-2 and the viral spike protein. The in silico approach starts with protein-ligand docking of 26 Cat's claw key components followed by molecular dynamics simulations and re-docked calculations. Finally, we carried out drug-likeness calculations for the most qualified cat's claw components. The structural bioinformatics approaches led to the identification of several bioactive compounds of U. tomentosa with potential therapeutic effect by dual strong interaction with interface of the RBD-ACE-2 and the ACE-2 binding site on SARS-CoV-2 RBD viral spike. In addition, in silico drug-likeness indices for these components were calculated and showed good predicted therapeutic profiles of these phytochemicals found in U. tomentosa (cat's claw). Our findings suggest the potential effectiveness of cat's claw as complementary and/or alternative medicine for COVID-19 treatment.
   Communicated by Ramaswamy H. Sarma
C1 [Yepes-Perez, Andres F.] Univ Antioquia UdeA, Chem Colombian Plants, Inst Chem, Fac Exact & Nat Sci, Medellin, Colombia.
   [Herrera-Calderon, Oscar] Univ Nacl Mayor San Marcos, Fac Pharm & Biochem, Acad Dept Pharmacol Bromatol & Toxicol, Lima, Peru.
   [Quintero-Saumeth, Jorge] Univ Pamplona, Fac Basic Sci, Pamplona, Colombia.
RP Yepes-Perez, AF (corresponding author), Univ Antioquia UdeA, Chem Colombian Plants, Inst Chem, Fac Exact & Nat Sci, Medellin, Colombia.; Herrera-Calderon, O (corresponding author), Univ Nacl Mayor San Marcos, Fac Pharm & Biochem, Acad Dept Pharmacol Bromatol & Toxicol, Lima, Peru.
EM andresf.yepes@udea.edu.co; oherreraca@unmsm.edu.pe
RI Herrera-Calderon, Oscar/L-5712-2017
OI Herrera-Calderon, Oscar/0000-0001-7264-0961; Yepes Perez, Andres
   Felipe/0000-0001-6975-5119; Quintero-Saumeth, Jorge/0000-0002-6544-9429
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Akram M, 2018, PHYTOTHER RES, V32, P811, DOI 10.1002/ptr.6024
   [Anonymous], 2020, COR DIS COVID 19 WEE
   Aquino R, 1997, PHYTOCHEMISTRY, V45, P1035, DOI 10.1016/S0031-9422(96)00716-9
   AQUINO R, 1990, J NAT PROD, V53, P559, DOI 10.1021/np50069a004
   ARAUJO LCC, 2018, SCI REP UK, V8, DOI DOI https://doi.org/10.1038/s41598-018-29044-y
   BATIHA GES, 2020, APPL SCI BASEL, V10, DOI DOI https://doi.org/10.3390/app10082668
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004
   Broccatelli F, 2016, MOL PHARMACEUT, V13, P4199, DOI 10.1021/acs.molpharmaceut.6b00836
   Caon T, 2014, FOOD CHEM TOXICOL, V66, P30, DOI 10.1016/j.fct.2014.01.013
   ChemAxon, 2016, CHEMAXON SOFTW SOL S
   Colmenarejo G, 2003, MED RES REV, V23, P275, DOI 10.1002/med.10039
   Penaloza EMC, 2015, QUIM NOVA, V38, P378, DOI 10.5935/0100-4042.20150007
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002
   Ertl P, 2000, J MED CHEM, V43, P3714, DOI 10.1021/jm000942e
   FORESMAN JB, 1992, J PHYS CHEM-US, V96, P135, DOI 10.1021/j100180a030
   Glendening ED, 2012, WIRES COMPUT MOL SCI, V2, P1, DOI 10.1002/wcms.51
   Gohlke H, 2000, J MOL BIOL, V295, P337, DOI 10.1006/jmbi.1999.3371
   Gonzales Gustavo F, 2010, Evid Based Complement Alternat Med, V7, P271, DOI 10.1093/ecam/nen042
   Pham-The H, 2018, CURR TOP MED CHEM, V18, P2209, DOI 10.2174/1568026619666181130140350
   HAMMA S, 2020, J MOL MODEL, V26, DOI DOI https://doi.org/10.1007/s00894-020-04408-2
   Han YX, 2020, ACS NANO, V14, P5143, DOI 10.1021/acsnano.0c02857
   Heinrich M., 2002, J ETHNOPHARMACOL, V82, DOI [https://doi.org/10.1016/s0378-8741, DOI 10.1016/S0378-8741(02)00173-3]
   Huang XQ, 2020, AGING-US, V12, P11263, DOI 10.18632/aging.103416
   Jamwal S, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118105
   Keplinger K, 1999, J ETHNOPHARMACOL, V64, P23, DOI 10.1016/S0378-8741(98)00096-8
   Kitajima M, 2000, TETRAHEDRON, V56, P547, DOI 10.1016/S0040-4020(99)01048-0
   Kramer B, 1999, PROTEINS, V37, P228, DOI 10.1002/(SICI)1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO;2-8
   Kuras M, 2009, J ETHNOPHARMACOL, V121, P140, DOI 10.1016/j.jep.2008.10.023
   KWON PS, 2020, CELL DISCOV, V6, DOI DOI https://doi.org/10.1038/s41421-020-00192-8
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Laus G, 1997, PHYTOCHEMISTRY, V45, P855, DOI 10.1016/S0031-9422(97)00061-7
   Lenzi RM, 2013, FOOD RES INT, V53, P767, DOI 10.1016/j.foodres.2013.02.042
   Li SR, 2020, EUR J CLIN MICROBIOL, V39, P1021, DOI 10.1007/s10096-020-03883-y
   Lima RS, 2013, NAT PROD COMMUN, V8, P1547
   Lipinski CA, 2012, ADV DRUG DELIVER REV, V64, P4, DOI 10.1016/j.addr.2012.09.019
   Lock O, 2016, NAT PROD COMMUN, V11, P315
   Montoro P, 2004, PHYTOCHEM ANALYSIS, V15, P55, DOI 10.1002/pca.740
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   NAVARRO M, 2019, ANTIOXIDANTS BASEL, V8, DOI DOI https://doi.org/10.3390/antiox8090339
   NAVARRO M, 2017, ANTIOXIDANTS, V6, DOI DOI https://doi.org/10.3390/antiox6030060
   Navarro-Hoyos M, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6010012
   Nishizawa M., 2010, J BIOPHYS CHEM, V01, DOI https://doi.org/10.4236/jbpc.2010.11003
   Ostrakhovich E. A., 1997, PHARM CHEM J, V31, DOI [https://doi.org/10.1007/BF02464127, DOI 10.1007/BF02464127]
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pavei C, 2012, J PHARMACEUT BIOMED, V62, P250, DOI 10.1016/j.jpba.2011.12.031
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Press B, 2008, CURR DRUG METAB, V9, P893, DOI 10.2174/138920008786485119
   Reis SRIN, 2008, INT IMMUNOPHARMACOL, V8, P468, DOI 10.1016/j.intimp.2007.11.010
   ROOTHAAN CCJ, 1951, REV MOD PHYS, V23, P69, DOI 10.1103/RevModPhys.23.69
   Sandoval M, 2000, FREE RADICAL BIO MED, V29, P71, DOI 10.1016/S0891-5849(00)00327-0
   SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112
   SINGH UC, 1984, J COMPUT CHEM, V5, P129, DOI 10.1002/jcc.540050204
   SNOW AD, 2019, SCI REP UK, V9, DOI DOI https://doi.org/10.1038/s41598-019-38645-0
   Terlizzi ME, 2016, ANTIVIR RES, V132, P154, DOI 10.1016/j.antiviral.2016.06.006
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   VERAREYES I, 2015, FRONT ENV SCI SWITZ, V3, DOI DOI https://doi.org/10.3389/fenvs.2015.00027
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wu J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01576
   Wu XM, 2019, NAT PROD REP, V36, P788, DOI 10.1039/c8np00041g
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhivkova ZD, 2015, CURR PHARM DESIGN, V21, P1817, DOI 10.2174/1381612821666150302113710
   2018, WHO TECH REP SER, V1010, P1
NR 67
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1837676
EA OCT 2020
PG 17
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OL8XW
UT WOS:000585616300001
PM 33118480
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Jeffs, E
   Lucas, N
   Walls, T
AF Jeffs, Emma
   Lucas, Nathanael
   Walls, Tony
TI CoVID-19: Parent and caregiver concerns about reopening New Zealand
   schools
SO JOURNAL OF PAEDIATRICS AND CHILD HEALTH
LA English
DT Article; Early Access
DE CoVID&#8208; 19; education; knowledge; paediatrics; schooling
ID INCLUDING COVID-19
AB Aim Children generally have a milder CoVID-19 disease course and better prognosis than adults. Many countries have closed schools as part of measures to limit transmission and this has had a considerable impact on children world-wide. This includes New Zealand (NZ), where rates of CoVID-19 have been very low. The aims of this study were to investigate parents' and caregivers' knowledge of CoVID-19 in children, to understand their levels of concern and to identify their most trusted sources of information.
   Methods Participants were recruited via NZ parenting support and interest groups on . Knowledge was assessed by way of a self-administered questionnaire during the 10 days prior to NZ schools reopening on 18 May 2020.
   Results Of the 1191 study participants, 721 (60%) expressed some level of worry (14.5% very or extremely worried) that their child would catch CoVID-19 at school. A high proportion (79%, 941) thought it likely or very likely that their child would catch CoVID-19 at school if there were to be widespread community transmission. Fear scores for CoVID-19 were generally high, and 828 (80%) of participants said they would vaccinate their child if a newly developed vaccine were available.
   Conclusions Parents and caregivers were generally fearful of their children acquiring CoVID-19 at school. This was despite messaging from multiple trusted sources that transmission in schools is unlikely, and the number of NZ CoVID-19 cases being extremely low. These findings have implications for policy development and public health messaging both in NZ and in countries with ongoing community transmission of CoVID-19.
C1 [Jeffs, Emma; Lucas, Nathanael; Walls, Tony] Univ Otago, Dept Paediat, Christchurch, New Zealand.
RP Walls, T (corresponding author), Univ Otago, Dept Paediat, Christchurch Mail Ctr, POB 4345, Christchurch 8140, New Zealand.
EM tony.walls@otago.ac.nz
OI Lucas, Nathanael/0000-0002-4376-3847
CR Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8
   Bi QF, 2020, LANCET INFECT DIS, V20, P911, DOI 10.1016/S1473-3099(20)30287-5
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Cluver L, 2020, LANCET, V395, pE64, DOI 10.1016/S0140-6736(20)30736-4
   Cui YX, 2020, J INFECT DIS, V221, P1775, DOI 10.1093/infdis/jiaa113
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   European Centre for Disease Prevention and Control, 2020, RAP RISK ASS PAED IN
   European Centre for Disease Prevention and Control, 2020, COVID 19 SIT UPD WOR
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Isaacs D, 2020, J PAEDIATR CHILD H, V56, P978, DOI 10.1111/jpc.14937
   Lee J, 2020, LANCET CHILD ADOLESC, V4, P421, DOI 10.1016/S2352-4642(20)30109-7
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Ministry of Health, 2020, COVID 19 HLTH DIS SY
   Ministry of health, 2020, COVID 19 CURR CAS
   Ministry of Social Development, 2016, SOC REP 2016 TE PUR
   Mizumoto K., 2020, AGE SPECIFICITY CASE, DOI [10.1101/2020.03.09.20033142, DOI 10.1101/2020.03.09.20033142]
   National Centre for Immunisation Research and Surveillance, 2020, COVID 19 SCH EXP NSW
   New Zealand Government, 2020, NZ COVID 19 AL LEV S
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   United Nations Educational Scientific and Cultural Organization, 2020, COVID 19 ED DISR RES
   Viner RM, 2020, LANCET CHILD ADOLESC, V4, P397, DOI 10.1016/S2352-4642(20)30095-X
   WHO, 2020, COR DIS COVID 19 PAN
   World Health Organization, 2020, 39 WHO
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
NR 25
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1034-4810
EI 1440-1754
J9 J PAEDIATR CHILD H
JI J. Paediatr. Child Health
DI 10.1111/jpc.15234
EA OCT 2020
PG 6
WC Pediatrics
SC Pediatrics
GA OM4LC
UT WOS:000585996900001
PM 33112012
OA Bronze
DA 2021-01-01
ER

PT J
AU Altuntas, F
   Ata, N
   Yigenoglu, TN
   Basci, S
   Dal, MS
   Korkmaz, S
   Namdaroglu, S
   Basturk, A
   Hacibekiroglu, T
   Dogu, MH
   Berber, I
   Dal, K
   Erkurt, MA
   Turgut, B
   Ulgu, MM
   Celik, O
   Akunal, A
   Birinci, S
AF Altuntas, Fevzi
   Ata, Naim
   Yigenoglu, Tugce Nur
   Basci, Semih
   Dal, Mehmet Sinan
   Korkmaz, Serdal
   Namdaroglu, Sinem
   Basturk, Abdulkadir
   Hacibekiroglu, Tuba
   Dogu, Mehmet Hilmi
   Berber, Ilhami
   Dal, Kursat
   Erkurt, Mehmet Ali
   Turgut, Burhan
   Ulgu, Mustafa Mahir
   Celik, Osman
   Akunal, Abdullah
   Birinci, Suayip
CA Turkish Minist Hlth
   Hematology Sci Working Grp
TI COVID-19 in hematopoietic cell transplant recipients
SO BONE MARROW TRANSPLANTATION
LA English
DT Article; Early Access
AB In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients.
C1 [Altuntas, Fevzi; Yigenoglu, Tugce Nur; Basci, Semih; Dal, Mehmet Sinan] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Dept Hematol, Ankara, Turkey.
   [Altuntas, Fevzi; Yigenoglu, Tugce Nur; Basci, Semih; Dal, Mehmet Sinan] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Bone Marrow Transplantat Ctr, Ankara, Turkey.
   [Altuntas, Fevzi] Yildirim Beyazit Univ, Dept Internal Med, Div Hematol, Ankara, Turkey.
   [Ata, Naim] Minist Hlth, Dept Strategy Dev, Ankara, Turkey.
   [Korkmaz, Serdal] Univ Hlth Sci, Kayseri Training & Res Hosp, Dept Hematol, Kayseri, Turkey.
   [Namdaroglu, Sinem] Univ Hlth Sci, Bozyaka Training & Res Hosp, Dept Hematol, Izmir, Turkey.
   [Basturk, Abdulkadir] Selcuk Univ, Sch Med, Dept Internal Med, Div Hematol, Konya, Turkey.
   [Hacibekiroglu, Tuba] Sakarya Univ, Sch Med, Dept Internal Med, Div Hematol, Sakarya, Turkey.
   [Dogu, Mehmet Hilmi] Istanbul Training & Res Hosp, Dept Hematol, Istanbul, Turkey.
   [Berber, Ilhami; Erkurt, Mehmet Ali] Inonu Univ, Sch Med, Dept Internal Med, Div Hematol, Malatya, Turkey.
   [Dal, Kursat] Kecioren Training & Res Hosp, Dept Internal Med, Ankara, Turkey.
   [Turgut, Burhan] Namik Kemal Univ, Sch Med, Dept Internal Med, Div Hematol, Tekirdag, Turkey.
   [Ulgu, Mustafa Mahir; Akunal, Abdullah] Minist Hlth, Gen Directorate Hlth Informat Syst, Ankara, Turkey.
   [Celik, Osman] Minist Hlth, Publ Hosp Gen Directorate, Ankara, Turkey.
   [Birinci, Suayip] Hlth, Ankara, Turkey.
RP Altuntas, F (corresponding author), Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Dept Hematol, Ankara, Turkey.; Altuntas, F (corresponding author), Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Bone Marrow Transplantat Ctr, Ankara, Turkey.; Altuntas, F (corresponding author), Yildirim Beyazit Univ, Dept Internal Med, Div Hematol, Ankara, Turkey.
EM dr.faltuntas@gmail.com
RI Hacibekiroglu, Tuba/ABH-2380-2020; Erkurt, Mehmet Ali/ABI-7232-2020
OI Erkurt, Mehmet Ali/0000-0002-3285-417X; celik,
   osman/0000-0003-2131-2866; ULGU, MUSTAFA MAHIR/0000-0003-0825-1851;
   BASTURK, ABDULKADIR/0000-0003-1864-0316
CR Basci S, 2020, J ONCOL PHARM PRACT, V26, P1676, DOI 10.1177/1078155220953198
   EBMT, 2020, COVID 19 BMT
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haroon A, 2020, MEDITERR J HEMATOL I, V12, DOI 10.4084/MJHID.2020.070
   Huang JF, 2020, AM J TRANSPLANT, V20, P1879, DOI 10.1111/ajt.15896
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Malard F, 2020, BONE MARROW TRANSPL, V55, P2180, DOI 10.1038/s41409-020-0931-4
   Vicent MG, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28514
   Yigenoglu TN, 2020, J MED VIROL, DOI 10.1002/jmv.26404
NR 9
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
DI 10.1038/s41409-020-01084-x
EA OCT 2020
PG 4
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA OK3ME
UT WOS:000584556900001
PM 33110186
OA Bronze
DA 2021-01-01
ER

PT J
AU Lunski, MJ
   Burton, J
   Tawagi, K
   Maslov, D
   Simenson, V
   Barr, D
   Yuan, H
   Johnson, D
   Matrana, M
   Cole, J
   Larned, Z
   Moore, B
AF Lunski, Michael J.
   Burton, Jeffrey
   Tawagi, Karine
   Maslov, Diana
   Simenson, Victoria
   Barr, Daniel, III
   Yuan, Helen
   Johnson, Daniel
   Matrana, Marc
   Cole, John
   Larned, Zoe
   Moore, Brian
TI Multivariate mortality analyses in COVID-19: Comparing patients with
   cancer and patients without cancer in Louisiana
SO CANCER
LA English
DT Article; Early Access
DE cancer; coronavirus; coronavirus disease 2019 (COVID&#8208; 19);
   mortality; outcomes; severe acute respiratory syndrome coronavirus 2
   (SARS&#8208; CoV&#8208; 2)
AB Background This is the largest and only multivariate study evaluating the difference in mortality from coronavirus disease 2019 (COVID-19) between patients with cancer and patients without cancer in the United States. The objective was to assess COVID-19 mortality rates in patients with cancer versus patients without cancer and uncover possible statistically significant characteristics contributing to mortality.
   Methods This retrospective study analyzed patients with cancer and patients without cancer who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from March 1 through April 30, 2020. This was a multicenter study in the state of Louisiana throughout the Ochsner Health System in both tertiary and nontertiary centers. Patients older than 18 years were eligible. Three hundred twelve patients with cancer were compared with 4833 patients without cancer.
   Results Mortality was found to be higher in the cancer group. Patients of advanced age with cancer had a significant increase in mortality (odds ratio [OR], 5.96; P < .001). Other significant risk factors for increased mortality were male sex (OR, 2.15), a history of chronic kidney disease (OR, 3.84), and obesity (OR, 1.30). In hospitalized patients with cancer, adverse vital signs on admission, decreased absolute lymphocyte counts, thrombocytopenia, elevated creatinine, lactic acidosis, and elevated procalcitonin all seemed to increase the risk of death. Among patients with cancer, active or progressive disease (P < .001) and recent therapy (OR, 2.34; 95% confidence interval, 1.08-5.08) were shown to increase mortality.
   Conclusions Patients with cancer have increased mortality in the setting of infection with SARS-CoV-2 in comparison with patients without cancer. Patients with cancer who are 65 years of age or older and those with certain comorbidities have the greatest risk of death. Recent cancer-directed therapy and disease status also seem to play roles in mortality.
   Lay Summary
   This is the largest study of patients with cancer versus patients without cancer to date and is the first multivariate analysis study comparing these 2 patient populations.
   This study confirms the hypothesis that patients with cancer are at increased risk for mortality and that there are multiple characteristics posing the potential to risk-stratify these patients in the setting of a future outbreak.
C1 [Lunski, Michael J.; Tawagi, Karine; Johnson, Daniel; Matrana, Marc; Cole, John; Larned, Zoe; Moore, Brian] Ochsner Canc Inst, New Orleans, LA USA.
   [Burton, Jeffrey; Maslov, Diana; Simenson, Victoria; Yuan, Helen] Ochsner Med Ctr, New Orleans, LA USA.
   [Barr, Daniel, III] Univ Queensland, Sch Med, Brisbane, Qld, Australia.
RP Lunski, MJ (corresponding author), Ochsner Canc Inst, Gayle & Tom Benson Canc Ctr, 1514 Jefferson Hwy, New Orleans, LA 70121 USA.
EM michael.lunski@ochsner.org
OI Lunski, Michael/0000-0003-0494-8213
CR American Cancer Society Cancer Statistics Center, LOU GLANC
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1131, DOI 10.1515/cclm-2020-0198
   Louisiana Department of Health, LOU COR COVID 19 INF
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686
   Worldometer, COVID 19 COR PAND CO
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 14
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
DI 10.1002/cncr.33243
EA OCT 2020
PG 9
WC Oncology
SC Oncology
GA OI4QV
UT WOS:000583266100001
PM 33112411
OA Bronze
DA 2021-01-01
ER

PT J
AU Abu-Saleh, AA
   Awad, IE
   Yadav, A
   Poirier, RA
AF Abu-Saleh, Abd Al-Aziz A.
   Awad, Ibrahim E.
   Yadav, Arpita
   Poirier, Raymond A.
TI Discovery of potent inhibitors for SARS-CoV-2's main protease by
   ligand-based/structure-based virtual screening, MD simulations, and
   binding energy calculations
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article
ID PARTICLE MESH EWALD; MOLECULAR-DYNAMICS; CORONAVIRUS; DOCKING; SARS;
   DESIGN
AB COVID-19 has caused lockdowns all over the world in early 2020, as a global pandemic. Both theoretical and experimental efforts are seeking to find an effective treatment to suppress the virus. In silico drug design can play a vital role in identifying promising drug candidates against COVID-19. Herein, we focused on the main protease of SARS-CoV-2 that has crucial biological functions in the virus. We performed a ligand-based virtual screening followed by a docking screening for testing approved drugs and bioactive compounds listed in the DrugBank and ChEMBL databases. The top 8 docking results were advanced to all-atom MD simulations to study the relative stability of the protein-ligand interactions. MD simulations support that the catalytic residue, His41, has a neutral side chain with a protonated delta position. An absolute binding energy (Delta G) of -42 kJ mol(-1) for the protein-ligand (Mpro-N3) complex has been calculated using the potential-of-mean-force (geometrical) approach. Furthermore, the relative binding energies were computed for the top docking results. Our results suggest several promising approved and bioactive inhibitors of SARS-CoV-2 Mpro as follows: a bioactive compound, ChEMBL275592, which has the best MM/GBSA binding energy; the second-best compound, montelukast, is an approved drug used in the treatment of asthma and allergic rhinitis; the third-best compound, ChEMBL288347, is a bioactive compound. Bromocriptine and saquinavir are other approved drugs that also demonstrate stability in the active site of Mpro, albeit their relative binding energies are low compared to the N3 inhibitor. This study provides useful insights into de novo protein design and novel inhibitor development, which could reduce the cost and time required for the discovery of a potent drug to combat SARS-CoV-2.
C1 [Abu-Saleh, Abd Al-Aziz A.; Awad, Ibrahim E.; Poirier, Raymond A.] Mem Univ, Chem Dept, St John, NF A1B 3X7, Canada.
   [Yadav, Arpita] Chhatrapati Shahu Ji Maharaj Univ, Dept Chem, Univ Inst Engn & Technol, Kanpur 208024, Uttar Pradesh, India.
RP Poirier, RA (corresponding author), Mem Univ, Chem Dept, St John, NF A1B 3X7, Canada.
EM rpoirier@mun.ca
OI Abu-Saleh, Abd Al-Aziz/0000-0002-3546-5161; E. Awad,
   Ibrahim/0000-0002-6487-0270
FU Natural Sciences and Engineering Council of Canada (NSERC)Natural
   Sciences and Engineering Research Council of Canada; Chen Graduate
   Scholarship; School of Graduate Studies of Memorial University of
   Newfoundland; Science and Engineering Research Board, New Delhi
   [EMR/2016/000769]; Shastri Indo Canadian Institute, New Delhi
FX We gratefully acknowledge Compute Canada for computer time. We are also
   immensely grateful to Shahidul M. Islam for his comments on an earlier
   version of the manuscript. R. A. P. is grateful to the Natural Sciences
   and Engineering Council of Canada (NSERC) for financial support. A. A.
   A. thanks Chen Graduate Scholarship and the School of Graduate Studies
   of Memorial University of Newfoundland for funding. A. Y. thanks Science
   and Engineering Research Board, New Delhi for research grant number
   EMR/2016/000769. A. Y. is also grateful to Shastri Indo Canadian
   Institute, New Delhi for Shastri Scholar Travel Subsidy Grant in the
   year 2016.
CR Aminpour M, 2019, MOLECULES, V24, DOI 10.3390/molecules24091693
   Anandakrishnan R, 2012, NUCLEIC ACIDS RES, V40, pW537, DOI 10.1093/nar/gks375
   [Anonymous], 2019, MAESTR SCHROD REL 11
   Banegas-Luna AJ, 2019, J CHEM INF MODEL, V59, P2805, DOI 10.1021/acs.jcim.9b00279
   Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Das G, 2020, RSC ADV, V10, P28243, DOI 10.1039/d0ra05434h
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fu HH, 2018, J CHEM INF MODEL, V58, P556, DOI 10.1021/acs.jcim.7b00695
   Fu HH, 2017, J CHEM THEORY COMPUT, V13, P5173, DOI 10.1021/acs.jctc.7b00791
   Gaulton A, 2017, NUCLEIC ACIDS RES, V45, pD945, DOI 10.1093/nar/gkw1074
   Genheden S, 2012, PROTEINS, V80, P1326, DOI 10.1002/prot.24029
   Goetz DH, 2007, BIOCHEMISTRY-US, V46, P8744, DOI 10.1021/bi0621415
   GREST GS, 1986, PHYS REV A, V33, P3628, DOI 10.1103/PhysRevA.33.3628
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gumbart JC, 2013, J CHEM THEORY COMPUT, V9, P794, DOI 10.1021/ct3008099
   Guterres H, 2020, J CHEM INF MODEL, V60, P2189, DOI 10.1021/acs.jcim.0c00057
   Halgren TA, 1999, J COMPUT CHEM, V20, P730, DOI 10.1002/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.0.CO;2-T
   Hatada R, 2020, J CHEM INF MODEL, V60, P3593, DOI 10.1021/acs.jcim.0c00283
   Havranek B., 2020, J BIOMOL STRUCT DYN, P1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jungheim LN, 1996, J MED CHEM, V39, P96, DOI 10.1021/jm950576c
   Kalaszi A, 2014, J CHEM INF MODEL, V54, P1036, DOI 10.1021/ci400620f
   Kotter A, 2019, J CHEM THEORY COMPUT, V15, P6403, DOI 10.1021/acs.jctc.9b00428
   Kumar Sumit, 2020, J Chem Inf Model, DOI 10.1021/acs.jcim.0c00326
   Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068
   Li CL, 2020, EUR J MED CHEM, V201, DOI 10.1016/j.ejmech.2020.112515
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Macalino SJY, 2015, ARCH PHARM RES, V38, P1686, DOI 10.1007/s12272-015-0640-5
   Ngo Son Tung, 2020, J Chem Inf Model, DOI 10.1021/acs.jcim.0c00491
   Njogu PM, 2016, ACS INFECT DIS, V2, P8, DOI 10.1021/acsinfecdis.5b00093
   NOSE S, 1984, MOL PHYS, V52, P255, DOI 10.1080/00268978400101201
   NOSE S, 1983, MOL PHYS, V50, P1055, DOI 10.1080/00268978300102851
   Nutho B, 2020, BIOCHEMISTRY-US, V59, P1769, DOI 10.1021/acs.biochem.0c00160
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Otto HH, 1997, CHEM REV, V97, P133, DOI 10.1021/cr950025u
   Owis AI, 2020, RSC ADV, V10, P19570, DOI 10.1039/d0ra03582c
   Panda PK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb8097
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Ribeiro J. V., 2016, SCI REP, V6, P1
   ROSENBERG SH, 1990, J MED CHEM, V33, P1582, DOI 10.1021/jm00168a009
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Ryunosuke Y., 2020, SCI REP, V10, P12493
   Salmaso V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00923
   Sang P, 2020, RSC ADV, V10, P15775, DOI 10.1039/d0ra01899f
   Scheurer M, 2018, BIOPHYS J, V114, P577, DOI 10.1016/j.bpj.2017.12.003
   Shaffer L, 2020, NAT MED, V26, P2, DOI 10.1038/s41591-019-0717-7
   Shawky E, 2020, RSC ADV, V10, P27961, DOI 10.1039/d0ra05126h
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Swiderek K, 2020, CHEM SCI, V11, P10626, DOI 10.1039/d0sc02823a
   Huynh T, 2020, J PHYS CHEM LETT, V11, P4413, DOI 10.1021/acs.jpclett.0c00994
   Tsuji M, 2020, FEBS OPEN BIO, V10, P995, DOI 10.1002/2211-5463.12875
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Vina A., 2010, J COMPUT CHEM, V31, P455, DOI DOI 10.1002/JCC.21334
   Wang EC, 2019, CHEM REV, V119, P9478, DOI 10.1021/acs.chemrev.9b00055
   Wang FH, 2017, J MED CHEM, V60, P3212, DOI 10.1021/acs.jmedchem.7b00103
   Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677
   Wang FH, 2016, J VIROL, V90, P1910, DOI 10.1128/JVI.02685-15
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wang Z, 2016, PHYS CHEM CHEM PHYS, V18, P12964, DOI 10.1039/c6cp01555g
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yu WB, 2012, J COMPUT CHEM, V33, P2451, DOI 10.1002/jcc.23067
   Zhao Q, 2008, J VIROL, V82, P8647, DOI 10.1128/JVI.00298-08
NR 66
TC 0
Z9 0
U1 8
U2 8
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
EI 1463-9084
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PD OCT 28
PY 2020
VL 22
IS 40
BP 23099
EP 23106
DI 10.1039/d0cp04326e
PG 8
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA OG0PG
UT WOS:000581596800025
PM 33025993
DA 2021-01-01
ER

PT J
AU Hurlburt, NK
   Seydoux, E
   Wan, YH
   Edara, VV
   Stuart, AB
   Feng, JL
   Suthar, MS
   McGuire, AT
   Stamatatos, L
   Pancera, M
AF Hurlburt, Nicholas K.
   Seydoux, Emilie
   Wan, Yu-Hsin
   Edara, Venkata Viswanadh
   Stuart, Andrew B.
   Feng, Junli
   Suthar, Mehul S.
   McGuire, Andrew T.
   Stamatatos, Leonidas
   Pancera, Marie
TI Structural basis for potent neutralization of SARS-CoV-2 and role of
   antibody affinity maturation
SO NATURE COMMUNICATIONS
LA English
DT Article
AB SARS-CoV-2 is a betacoronavirus virus responsible for the COVID-19 pandemic. Here, we determine the X-ray crystal structure of a potent neutralizing monoclonal antibody, CV30, isolated from a patient infected with SARS-CoV-2, in complex with the receptor binding domain. The structure reveals that CV30 binds to an epitope that overlaps with the human ACE2 receptor binding motif providing a structural basis for its neutralization. CV30 also induces shedding of the S1 subunit, indicating an additional mechanism of neutralization. A germline reversion of CV30 results in a substantial reduction in both binding affinity and neutralization potential indicating the minimal somatic mutation is needed for potently neutralizing antibodies against SARS-CoV-2. Currently there is neither a vaccine nor an effective treatment strategy available for COVID19. Here, Hurlburt et al. provide the crystal structure of a patient-derived monoclonal antibody neutralizing SARS-CoV-2 via shedding of the S1 subunit and competing for the receptor binding domain.
C1 [Hurlburt, Nicholas K.; Seydoux, Emilie; Wan, Yu-Hsin; Stuart, Andrew B.; Feng, Junli; McGuire, Andrew T.; Stamatatos, Leonidas; Pancera, Marie] Fred Hutchinson Canc Res Ctr, Vaccines & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Edara, Venkata Viswanadh; Suthar, Mehul S.] Emory Univ, Sch Med, Div Infect Dis, Dept Pediat,Emory Vaccine Ctr,Yerkes Natl Primate, Atlanta, GA USA.
   [McGuire, Andrew T.; Stamatatos, Leonidas] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Pancera, Marie] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Pancera, M (corresponding author), Fred Hutchinson Canc Res Ctr, Vaccines & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.; Pancera, M (corresponding author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM mpancera@fredhutch.org
OI Hurlburt, Nicholas/0000-0001-9891-916X
FU U.S. Department of Energy, Office of Biological and Environmental
   ResearchUnited States Department of Energy (DOE) [DE-AC02-06CH11357];
   Emory EVPHA Synergy Fund award; Center for Childhood Infections and
   Vaccines; Children's Healthcare of Atlanta; Woodruff Health Sciences
   Center; Emory School of Medicine
FX This work was supported by generous donations to Fred Hutch COVID-19
   Research Fund. We thank Dr. McLellan for providing the SARS-CoV-2 RBD
   plasmid. We thank the J. B. Pendleton Charitable Trust for its generous
   support of Formulatrix robotic instruments. Results shown in this report
   are derived from work performed at Argonne National Laboratory,
   Structural Biology Center (SBC), ID-19, at the Advanced Photon Source.
   SBC-CAT is operated by UChicago Argonne, LLC, for the U.S. Department of
   Energy, Office of Biological and Environmental Research under contract
   DE-AC02-06CH11357. The SARS-CoV-2 neutralization assay efforts were in
   part supported by the Emory EVPHA Synergy Fund award, Center for
   Childhood Infections and Vaccines, Children's Healthcare of Atlanta,
   COVID-Catalyst-I3 Funds from the Woodruff Health Sciences Center and
   Emory School of Medicine.
CR Adams PD, 2004, J SYNCHROTRON RADIAT, V11, P53, DOI 10.1107/S0909049503024130
   Barnes CO, 2020, CELL, V182, P828, DOI 10.1016/j.cell.2020.06.025
   Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Katzelnick LC, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006862
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1036
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Meuris L, 2014, NAT BIOTECHNOL, V32, P485, DOI 10.1038/nbt.2885
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Seydoux E, 2020, IMMUNITY, V53, P98, DOI 10.1016/j.immuni.2020.06.001
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Teplyakov A, 2016, MABS-AUSTIN, V8, P1045, DOI 10.1080/19420862.2016.1190060
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Wu YT, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30557-2
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yuan M, 2020, SCIENCE, V369, P1119, DOI 10.1126/science.abd2321
NR 29
TC 1
Z9 1
U1 2
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 27
PY 2020
VL 11
IS 1
AR 5413
DI 10.1038/s41467-020-19231-9
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OZ0JN
UT WOS:000594622700003
PM 33110068
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lubrano, C
   Matrone, GM
   Iaconis, G
   Santoro, F
AF Lubrano, Claudia
   Matrone, Giovanni Maria
   Iaconis, Gennaro
   Santoro, Francesca
TI New Frontiers for Selective Biosensing with Biomembrane-Based Organic
   Transistors
SO ACS NANO
LA English
DT Article
ID SUPPORTED LIPID-BILAYERS; THIN-FILM TRANSISTORS; ELECTROCHEMICAL
   TRANSISTORS; PROTEIN MOBILITY; CORONAVIRUS; SARS-COV-2; SPECIMENS
AB Biosensing plays vital roles in multiple fields, including healthcare monitoring, drug screening, disease diagnosis, and environmental pollution control. In recent years, transistor-based devices have been considered to be valid platforms for fast, low-cost sensing of diverse analytes. Without additional functionalization, however, these devices lack selectivity; several strategies have been developed for the direct immobilization of bioreceptors on the transistor surface to improve detection capabilities. In this scenario, organic transistors have gained attention for their abilities to be coupled to biological systems and to detect biomolecules. In this Perspective, we discuss recent developments in organic-transistor-based biosensors, highlighting how their coupling with artificial membranes provides a strategy to improve sensitivity and selectivity in biosensing applications. Looking at future applications, this class of biosensors represents a breakthrough starting point for implementing multimodal high-throughput screening platforms.
C1 [Lubrano, Claudia; Matrone, Giovanni Maria; Santoro, Francesca] Ist Italiano Tecnol, Tissue Elect, I-80125 Naples, Italy.
   [Lubrano, Claudia] Univ Napoli Federico II, Dipartimento Chim Mat & Prod Ind, I-80126 Naples, Italy.
   [Iaconis, Gennaro] Univ Cambridge, Dept Med, Cambridge CB2 1TN, England.
RP Santoro, F (corresponding author), Ist Italiano Tecnol, Tissue Elect, I-80125 Naples, Italy.
EM francesca.santoro@iit.it
OI Santoro, Francesca/0000-0001-7323-9504
CR Alberts B, 2002, MOL BIOL CELL
   Ball P, 2020, MRS BULL, V45, P609, DOI 10.1557/mrs.2020.206
   Bhalla N, 2016, ESSAYS BIOCHEM, V60, P1, DOI 10.1042/EBC20150001
   Biessmann L, 2018, ACS APPL MATER INTER, V10, P9865, DOI 10.1021/acsami.8b00446
   Bolles M, 2011, CURR OPIN VIROL, V1, P624, DOI 10.1016/j.coviro.2011.10.012
   Cavassin P, 2020, ADV MATER TECHNOL-US, V5, DOI 10.1002/admt.201900680
   Cheung KM, 2020, NANO LETT, V20, P5982, DOI 10.1021/acs.nanolett.0c01971
   Choi SE, 2016, BIOINTERPHASES, V11, DOI 10.1116/1.4945306
   Domingo E, 2000, VIROLOGY, V270, P251, DOI 10.1006/viro.2000.0320
   Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151
   Duffy S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000003
   Ferhan AR, 2019, NAT PROTOC, V14, P2091, DOI 10.1038/s41596-019-0174-2
   Funari R, 2020, BIOSENS BIOELECTRON, V169, DOI 10.1016/j.bios.2020.112578
   Garcia-Chame MA, 2020, BIOSENS BIOELECTRON, V159, DOI 10.1016/j.bios.2020.112129
   Golowasch J., 2013, ENCY COMPUTATIONAL N, P5
   Gong H, 2019, ACS NANO, V13, P3714, DOI 10.1021/acsnano.9b00911
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gualandi I, 2015, J MATER CHEM B, V3, P6753, DOI 10.1039/c5tb00916b
   Gualandi I, 2016, SCI REP-UK, V6, DOI 10.1038/srep35419
   Hammock ML, 2013, ACS NANO, V7, P3970, DOI 10.1021/nn305903q
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holmes E, 2020, ANDROLOGIA, V52, DOI 10.1111/and.13859
   Kawan M, 2020, MATER HORIZ, V7, P2348, DOI 10.1039/d0mh00548g
   Koenig BW, 1996, LANGMUIR, V12, P1343, DOI 10.1021/la950580r
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Le TH, 2017, POLYMERS-BASEL, V9, DOI 10.3390/polym9040150
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liao CZ, 2015, ADV MATER, V27, P676, DOI 10.1002/adma.201404378
   Lingler S, 1997, LANGMUIR, V13, P7085, DOI 10.1021/la970600k
   Liu HY, 2020, LANGMUIR, V36, P7325, DOI 10.1021/acs.langmuir.0c00804
   Liu HY, 2020, ANAL BIOANAL CHEM, V412, P6265, DOI 10.1007/s00216-020-02449-3
   Liu HY, 2018, LANGMUIR, V34, P1061, DOI 10.1021/acs.langmuir.7b02945
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luz R. A. S., 2013, NANOBIOELECTROCHEMIS
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Macchia E, 2020, ACS SENSORS, V5, P1822, DOI 10.1021/acssensors.0c00694
   Macchia E, 2020, MATER HORIZ, V7, P999, DOI 10.1039/c9mh01544b
   Mehrotra Parikha, 2016, J Oral Biol Craniofac Res, V6, P153, DOI 10.1016/j.jobcr.2015.12.002
   Morales-Narvaez E, 2020, BIOSENS BIOELECTRON, V163, DOI 10.1016/j.bios.2020.112274
   Moser M, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201807033
   Nakatsuka N, 2018, SCIENCE, V362, P319, DOI 10.1126/science.aao6750
   Nam HJ, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002997
   Nikoleli GP, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9091745
   Nikolka M, 2020, ACS APPL MATER INTER, V12, P40581, DOI 10.1021/acsami.0c10201
   Pappa AM, 2020, ACS NANO, V14, P12538, DOI 10.1021/acsnano.0c01330
   Parlak O, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2904
   Picca RA, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201904513
   Richards MJ, 2016, LANGMUIR, V32, P2963, DOI 10.1021/acs.langmuir.5b03415
   Richter RP, 2006, LANGMUIR, V22, P3497, DOI 10.1021/la052687c
   Rivnay J, 2018, NAT REV MATER, V3, DOI 10.1038/natrevmats.2017.86
   Saem S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61561-7
   Seo G, 2020, ACS NANO, V14, P5135, DOI 10.1021/acsnano.0c02823
   Shen HG, 2018, MATER HORIZ, V5, P240, DOI 10.1039/c7mh00887b
   Si B, 2018, MICROELECTRON ENG, V187, P58, DOI 10.1016/j.mee.2017.11.016
   Songa EA, 2016, TALANTA, V155, P289, DOI 10.1016/j.talanta.2016.04.046
   Stern E, 2007, NANO LETT, V7, P3405, DOI 10.1021/nl071792z
   Straus M. R., 2020, FDA APPROVED CALCIUM, DOI [10.1101/2020.07.21.214577, DOI 10.1101/2020.07.21.214577]
   Su H, 2019, ACS APPL MATER INTER, V11, P43799, DOI 10.1021/acsami.9b10303
   Tabaei SR, 2016, ACS APPL MATER INTER, V8, P11875, DOI 10.1021/acsami.6b02837
   Tybrandt K, 2014, SENSOR ACTUAT B-CHEM, V195, P651, DOI 10.1016/j.snb.2014.01.097
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang J, 2020, ADV MATER TECHNOL-US, V5, DOI 10.1002/admt.202000218
   Xi X, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201905361
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang QT, 2007, BIOSENS BIOELECTRON, V22, P3182, DOI 10.1016/j.bios.2007.02.015
   Zhang Y, 2016, ADV FUNCT MATER, V26, P7304, DOI 10.1002/adfm.201602123
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 69
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD OCT 27
PY 2020
VL 14
IS 10
BP 12271
EP 12280
DI 10.1021/acsnano.0c07053
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA ON6FD
UT WOS:000586793400004
PM 33052643
DA 2021-01-01
ER

PT J
AU Campos, RK
   Jin, J
   Rafael, GH
   Zhao, M
   Liao, L
   Simmons, G
   Chu, S
   Weaver, SC
   Chiu, W
   Cui, Y
AF Campos, Rafael K.
   Jin, Jing
   Rafael, Grace H.
   Zhao, Mervin
   Liao, Lei
   Simmons, Graham
   Chu, Steven
   Weaver, Scott C.
   Chiu, Wah
   Cui, Yi
TI Decontamination of SARS-CoV-2 and Other RNA Viruses from N95 Level
   Meltblown Polypropylene Fabric Using Heat under Different Humidities
SO ACS NANO
LA English
DT Article
DE COVID-19; SARS-CoV-2; coronavirus; humidity; N95; decontamination;
   aerosol
ID FACE MASKS; DRY HEAT; TRANSMISSION; PROTECTION; RESPIRATORS;
   PERFORMANCE; IMPACT; SPUTUM
AB In March of 2020, the World Health Organization declared a pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The pandemic led to a shortage of N95-grade filtering facepiece respirators (FFRs), especially surgical-grade N95 FFRs for protection of healthcare professionals against airborne transmission of SARS-CoV-2. We and others have previously reported promising decontamination methods that may be applied to the recycling and reuse of FFRs. In this study we tested disinfection of three viruses, including SARS-CoV-2, dried on a piece of meltblown fabric, the principal component responsible for filtering of fine particles in N95-level FFRs, under a range of temperatures (60-95 degrees C) at ambient or 100% relative humidity (RH) in conjunction with filtration efficiency testing. We found that heat treatments of 75 degrees C for 30 min or 85 degrees C for 20 min at 100% RH resulted in efficient decontamination from the fabric of SARS-CoV-2, human coronavirus NL63 (HCoV-NL63), and another enveloped RNA virus, chikungunya virus vaccine strain 181/25 (CHIKV-181/25), without lowering the meltblown fabrics filtration efficiency.
C1 [Campos, Rafael K.; Rafael, Grace H.; Weaver, Scott C.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77550 USA.
   [Jin, Jing; Simmons, Graham] Vitalant Res Inst, San Francisco, CA 94118 USA.
   [Jin, Jing; Chiu, Wah] SLAC Natl Accelerator Lab, Div CryoEM & Bioimaging SSRL, Menlo Pk, CA 94025 USA.
   [Zhao, Mervin; Liao, Lei] 4C Air Inc, Sunnyvale, CA 94089 USA.
   [Chu, Steven] Stanford Univ, Dept Phys, Stanford, CA 94305 USA.
   [Chu, Steven] Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.
   [Weaver, Scott C.] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77550 USA.
   [Chiu, Wah] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.
   [Cui, Yi] Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA.
   [Cui, Yi] SLAC Natl Accelerator Lab, Stanford Inst Mat & Energy Sci, Menlo Pk, CA 94305 USA.
RP Weaver, SC (corresponding author), Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77550 USA.; Chiu, W (corresponding author), SLAC Natl Accelerator Lab, Div CryoEM & Bioimaging SSRL, Menlo Pk, CA 94025 USA.; Weaver, SC (corresponding author), Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77550 USA.; Chiu, W (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.; Cui, Y (corresponding author), Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA.; Cui, Y (corresponding author), SLAC Natl Accelerator Lab, Stanford Inst Mat & Energy Sci, Menlo Pk, CA 94305 USA.
EM sweaver@utmb.edu; wahc@stanford.edu; yicui@stanford.edu
RI ; Simmons, Graham/G-3523-2012
OI Zhao, Mervin/0000-0002-7313-7150; Simmons, Graham/0000-0002-9615-7023
FU DOE Office of Science through the National Virtual Biotechnology
   Laboratory, a consortium of DOE national laboratories focused on
   response to COVID19United States Department of Energy (DOE); Coronavirus
   CARES Act; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R24 AI120942]
FX This research was funded by DOE Office of Science through the National
   Virtual Biotechnology Laboratory, a consortium of DOE national
   laboratories focused on response to COVID19, with funding provided by
   the Coronavirus CARES Act (to W.C.); NIH grant R24 AI120942 to S.C.W. We
   thank our colleagues, especially Nehad Saada and Dr. Sasha Azar, for
   their helpful suggestions.
CR Anderegg L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234851
   Balazy A, 2006, AM J INFECT CONTROL, V34, P51, DOI 10.1016/j.ajic.2005.08.018
   Bergman MS, 2012, AM J INFECT CONTROL, V40, P375, DOI 10.1016/j.ajic.2011.05.003
   Bishwal SC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37662-9
   Blanchard E. L., 2020, ENVELOPED VIRUS INAC, DOI [10.1101/2020.05.23.20111435v2, DOI 10.1101/2020.05.23.20111435V2]
   Bopp N. E., 2020, APPL BIOSAF
   Chan K, 2011, ADV OPTOELECTRON, V2011, DOI [10.1155/2011/734690, 10.1155/2011/196707]
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Fears AC, 2020, EMERG INFECT DIS, V26, P2168, DOI 10.3201/eid2609.201806
   Jayaweera M, 2020, ENVIRON RES, V188, DOI 10.1016/j.envres.2020.109819
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   KOTLAR HK, 1980, EUR J RESPIR DIS, V61, P233
   Lawrence RB, 2006, J OCCUP ENVIRON HYG, V3, P465, DOI 10.1080/15459620600829211
   Liao L, 2020, ACS NANO, V14, P6348, DOI 10.1021/acsnano.0c03597
   Lindsley WG, 2015, J OCCUP ENVIRON HYG, V12, P509, DOI 10.1080/15459624.2015.1018518
   Lindsley WG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015100
   McDevitt J, 2010, APPL ENVIRON MICROB, V76, P3943, DOI 10.1128/AEM.02674-09
   Pascoe MJ, 2020, J HOSP INFECT, V106, P10, DOI 10.1016/j.jhin.2020.07.008
   PASTORINO B, 2020, VIRUSES-BASEL, V12, DOI DOI 10.3390/V12070735
   PASTORINO B, 2020, VIRUSES-BASEL, V12, P21706, DOI DOI 10.3390/V12060624
   Petersen E, 2020, LANCET INFECT DIS, V20, pE238, DOI 10.1016/S1473-3099(20)30484-9
   Price A., 2020, IS FIT N95 FACIAL MA, DOI [10.1101/2020.04.14.20062810v1, DOI 10.1101/2020.04.14.20062810V1]
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rodriguez-Martinez CE, 2020, AM J INFECT CONTROL, V48, P1520, DOI 10.1016/j.ajic.2020.07.004
   Saini V, 2020, GUT PATHOG, V12, DOI 10.1186/s13099-020-00367-4
   Sauerbrei A, 2009, ARCH VIROL, V154, P115, DOI 10.1007/s00705-008-0264-x
   Tariq K, 2019, RESP MED, V150, P66, DOI 10.1016/j.rmed.2019.02.008
   Tellier R, 2006, EMERG INFECT DIS, V12, P1657, DOI 10.3201/eid1211.060426
   Viscusi DJ, 2011, J OCCUP ENVIRON HYG, V8, P426, DOI 10.1080/15459624.2011.585927
   Wilson NM, 2020, ANAESTHESIA, V75, P1086, DOI 10.1111/anae.15093
   Xiang Y, 2020, AM J INFECT CONTROL, V48, P880, DOI 10.1016/j.ajic.2020.05.026
   Zhang RY, 2020, P NATL ACAD SCI USA, V117, P14857, DOI 10.1073/pnas.2009637117
   Zhao M, 2020, NANO LETT, V20, P5544, DOI 10.1021/acs.nanolett.0c02211
   Zulauf KE, 2020, MBIO, V11, DOI 10.1128/mBio.00997-20
NR 34
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD OCT 27
PY 2020
VL 14
IS 10
BP 14017
EP 14025
DI 10.1021/acsnano.0c06565
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA ON6FD
UT WOS:000586793400148
PM 32955847
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ivanov, J
   Polshakov, D
   Kato-Weinstein, J
   Zhou, QQ
   Li, YZ
   Granet, R
   Garner, L
   Deng, Y
   Liu, C
   Albaiu, D
   Wilson, J
   Aultman, C
AF Ivanov, Julian
   Polshakov, Dmitrii
   Kato-Weinstein, Junko
   Zhou, Qiongqiong
   Li, Yingzhu
   Granet, Roger
   Garner, Linda
   Deng, Yi
   Liu, Cynthia
   Albaiu, Dana
   Wilson, Jeffrey
   Aultman, Christopher
TI Quantitative Structure-Activity Relationship Machine Learning Models and
   their Applications for Identifying Viral 3CLpro-and RdRp-Targeting
   Compounds as Potential Therapeutics for COVID-19 and Related Viral
   Infections
SO ACS OMEGA
LA English
DT Article
ID AUTOMATED STRUCTURE EVALUATION; BIOLOGICAL-ACTIVITY; DESIGN;
   IDENTIFICATION; DERIVATIVES; PREDICTION; INHIBITORS; CHEMISTRY;
   CONSTANTS; FEATURES
AB In response to the ongoing COVID-19 pandemic, there is a worldwide effort being made to identify potential anti-SARS-CoV-2 therapeutics. Here, we contribute to these efforts by building machine-learning predictive models to identify novel drug candidates for the viral targets 3 chymotrypsin-like protease (3CLpro) and RNA-dependent RNA polymerase (RdRp). Chemist-curated training sets of substances were assembled from CAS data collections and integrated with curated bioassay data. The best-performing classification models were applied to screen a set of FDA-approved drugs and CAS REGISTRY substances that are similar to, or associated with, antiviral agents. Numerous substances with potential activity against 3CLpro or RdRp were found, and some were validated by published bioassay studies and/or by their inclusion in upcoming or ongoing COVID-19 clinical trials. This study further supports that machine learning-based predictive models may be used to assist the drug discovery process for COVID-19 and other diseases.
C1 [Ivanov, Julian; Polshakov, Dmitrii; Kato-Weinstein, Junko; Zhou, Qiongqiong; Li, Yingzhu; Granet, Roger; Garner, Linda; Deng, Yi; Liu, Cynthia; Albaiu, Dana; Wilson, Jeffrey; Aultman, Christopher] CAS, Div Amer Chem Soc, Columbus, OH 43210 USA.
RP Ivanov, J (corresponding author), CAS, Div Amer Chem Soc, Columbus, OH 43210 USA.
EM jivanov@cas.org
OI Ivanov, Julian/0000-0002-3519-359X
CR Adams SP, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012282.pub2
   Agarwal K, 2018, J HEPATOL, V68, P672, DOI 10.1016/j.jhep.2017.11.039
   Amin SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1780946
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   BALABAN AT, 1982, CHEM PHYS LETT, V89, P399, DOI 10.1016/0009-2614(82)80009-2
   BALABAN AT, 1983, PURE APPL CHEM, V55, P199, DOI 10.1351/pac198855020199
   Beigelman L., 2019, Patent No. [W02019053696A1, 2019053696]
   Bell RM, 2007, SIGKDD EXPLOR NEWSL, V9, P75, DOI DOI 10.1145/1345448.1345465
   Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57
   Blondel M, 2013, MACH LEARN, V93, P31, DOI 10.1007/s10994-013-5367-2
   Bourliere M, 2017, NEW ENGL J MED, V376, P2134, DOI 10.1056/NEJMoa1613512
   Butler T., 2009, Patent No. [WO 2009132135, 2009132135, W02009132135A1]
   CARHART RE, 1985, J CHEM INF COMP SCI, V25, P64, DOI 10.1021/ci00046a002
   Chakravarti S., 2005, MC4PC ARTIFICIAL INT
   Chen W, 2016, 2016 IEEE INTERNATIONAL CONFERENCE ON REAL-TIME COMPUTING AND ROBOTICS (IEEE RCAR), P22, DOI 10.1109/RCAR.2016.7783995
   Clark T, 2001, RATIONAL APPROACHES TO DRUG DESIGN, P29
   Clark T., 2000, P BEILST WORKSH MAY
   CRAMER RD, 1988, QUANT STRUCT-ACT REL, V7, P18, DOI 10.1002/qsar.19880070105
   CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   DEBNATH AK, 1991, J MED CHEM, V34, P786, DOI 10.1021/jm00106a046
   Deng YH, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00539
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010
   Ferenci P, 2014, NEW ENGL J MED, V370, P1983, DOI 10.1056/NEJMoa1402338
   Flinn IW, 2019, AM J HEMATOL, V94, P1325, DOI 10.1002/ajh.25634
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gasteiger J, 1996, J CHEM INF COMP SCI, V36, P1030, DOI 10.1021/ci960343+
   Ghosh K., 2021, J MOL STRUCT, V1224
   Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   GUTMAN I, 1972, CHEM PHYS LETT, V17, P535, DOI 10.1016/0009-2614(72)85099-1
   HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035
   HANSCH C, 1962, NATURE, V194, P178, DOI 10.1038/194178b0
   HANSCH C, 1963, J AM CHEM SOC, V85, P2817, DOI 10.1021/ja00901a033
   HOPFINGER AJ, 1980, J AM CHEM SOC, V102, P7196, DOI 10.1021/ja00544a005
   HOSOYA H, 1971, B CHEM SOC JPN, V44, P2332, DOI 10.1246/bcsj.44.2332
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   IVANOV J, 1994, J CHEM INF COMP SCI, V34, P234, DOI 10.1021/ci00018a001
   KLOPMAN G, 1991, J COMPUT CHEM, V12, P1025, DOI 10.1002/jcc.540120815
   KLOPMAN G, 1984, J AM CHEM SOC, V106, P7315, DOI 10.1021/ja00336a004
   Kumar V, 2020, SAR QSAR ENVIRON RES, V31, P511, DOI 10.1080/1062936X.2020.1776388
   Kumar V, 2017, ANTIVIR RES, V141, P101, DOI 10.1016/j.antiviral.2017.02.007
   Lee AA, 2019, P NATL ACAD SCI USA, V116, P3373, DOI 10.1073/pnas.1810847116
   Li P, 2016, BIOORG MED CHEM LETT, V26, P3346, DOI 10.1016/j.bmcl.2016.05.036
   Lipkus AH, 2008, J ORG CHEM, V73, P4443, DOI 10.1021/jo8001276
   MEKENYAN O, 1986, ARZNEIMITTELFORSCH, V36-1, P176
   Mustapha IB, 2016, MOLECULES, V21, DOI 10.3390/molecules21080983
   Nguyen KT, 2009, CHEMMEDCHEM, V4, P1803, DOI 10.1002/cmdc.200900317
   Nie QD, 2018, CHEM BIOL DRUG DES, V92, P1750, DOI 10.1111/cbdd.13344
   NILAKANTAN R, 1987, J CHEM INF COMP SCI, V27, P82, DOI 10.1021/ci00054a008
   O'Connor SE, 1999, FUND CLIN PHARMACOL, V13, P145, DOI 10.1111/j.1472-8206.1999.tb00333.x
   Ogura K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47536-3
   Polshakov D, 2005, BIOCHEMISTRY-US, V44, P11241, DOI 10.1021/bi050859z
   Rahman MM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1794974
   RANDIC M, 1975, J AM CHEM SOC, V97, P6609, DOI 10.1021/ja00856a001
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Rothlin RP, 2020, DRUG DEVELOP RES, V81, P768, DOI 10.1002/ddr.21679
   Rust KY, 2012, THER DRUG MONIT, V34, P729, DOI 10.1097/FTD.0b013e31827318b8
   te Velthuis AJW, 2014, CELL MOL LIFE SCI, V71, P4403, DOI 10.1007/s00018-014-1695-z
   Teschner S, 2010, IMMUNOTHERAPY-UK, V2, P637, DOI 10.2217/IMT.10.52
   Tong H., 2015, JMLR W CP, V42, P69
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Vamathevan J, 2019, NAT REV DRUG DISCOV, V18, P463, DOI 10.1038/s41573-019-0024-5
   Wildman SA, 1999, J CHEM INF COMP SCI, V39, P868, DOI 10.1021/ci990307l
   Wu JJ, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0250-9
   Xiong R., 2020, BIORXIV, DOI [10.1101/2020.03.11.983056, DOI 10.1101/2020.03.11.983056]
   Yan AX, 2003, J CHEM INF COMP SCI, V43, P429, DOI 10.1021/ci025590u
   Zhang QY, 2009, J CHEM INF MODEL, V49, P1857, DOI 10.1021/ci900080f
   Zheng J., 2020, MULTIOMICS STUDY REV, DOI [10.1101/2020.05.07.20093286, DOI 10.1101/2020.05.07.20093286]
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 73
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470-1343
J9 ACS OMEGA
JI ACS Omega
PD OCT 27
PY 2020
VL 5
IS 42
BP 27344
EP 27358
DI 10.1021/acsomega.0c03682
PG 15
WC Chemistry, Multidisciplinary
SC Chemistry
GA ON6BP
UT WOS:000586784200042
PM 33134697
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sandhu, T
   Tieng, A
   Chilimuri, S
   Franchin, G
AF Sandhu, Tegveer
   Tieng, Arlene
   Chilimuri, Sridhar
   Franchin, Giovanni
TI A Case Control Study to Evaluate the Impact of Colchicine on Patients
   Admitted to the Hospital with Moderate to Severe COVID-19 Infection
SO CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY
LA English
DT Article
AB Background. Colchicine has been used in conditions such as periodic febrile illness, acute pericarditis, and gouty arthritis, all having a common hyperinflammatory response as seen in moderate to severe forms of coronavirus disease 2019 (COVID-19). This project was carried out during the rapid surge of cases in New York City, and the goal was to assess the efficacy of colchicine in treating patients with COVID-19. Methods. Patients admitted to two distinct pulmonary oriented floors of the BronxCare Hospital Center were compared. Patients on one floor were given colchicine in addition to standard of care, while control patients from another floor received only standard of care. Patients who had at least two separate timepoint measurements for at least two out of four serum inflammatory markers (C-reactive protein (CRP), D-dimer, ferritin, or lactate dehydrogenase (LDH)) were selected for the final comprehensive analysis. Results. An initial analysis performed on all patients, irrespective of the availability of two timepoint inflammatory markers, revealed a lower mortality (49.1% versus 72.9%, P=0.002), a lower percentage of intubations (52.8% versus 73.6%, P=0.006), and a higher discharge rate (50.9% versus 27.1%, P=0.002), in the patients who received colchicine. Patients in the final comprehensive analysis groups (34 in the colchicine group and 78 in the control group) had a similar prevalence of comorbid medical conditions, except for renal failure, which was higher in the control group (65.3% versus 35.2%, P=0.015). HTN (71.8% versus 52.9%, P=0.053) and DM (51.3% versus 32.4%, P=0.064) were also more prevalent in the control group, although the difference was not statistically significant. Patients who received colchicine had a lower mortality than the control group (47.1% versus 80.8%, P=0.0003), lower rate of intubations (47.1% versus 87.2%, P0.0001), and a higher discharge rate (52.9% versus 19.2%, P=0.0003). Patients in the colchicine group also showed a more significant decrease in inflammatory markers for D-dimer (P=0.037), CRP (P=0.014), and ferritin (P=0.012). Conclusions. Our study demonstrates that colchicine improved outcomes in patients with COVID-19 receiving standard of care therapy. Future randomized, placebo-controlled clinical trials to assess the potential benefit of colchicine in COVID-19 are warranted.
C1 [Sandhu, Tegveer; Tieng, Arlene; Chilimuri, Sridhar; Franchin, Giovanni] BronxCare Hlth Syst, Dept Internal Med, Bronx, NY 10457 USA.
RP Sandhu, T (corresponding author), BronxCare Hlth Syst, Dept Internal Med, Bronx, NY 10457 USA.
EM tsandhu@bronxleb.org; artieng@bronxleb.org; chilimuri@bronxleb.org;
   gfranchi@bronxleb.org
OI Chilimuri, Sridhar/0000-0001-9866-4785
CR Adapa Sreedhar, 2020, J Clin Med Res, V12, P352, DOI 10.14740/jocmr4200
   Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022
   Begbie M, 2000, THROMB HAEMOSTASIS, V84, P216
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Chilimuri S, 2020, WEST J EMERG MED, V21, P779, DOI 10.5811/westjem.2020.6.47919
   Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136
   Deftereos SG, 2020, HELL J CARDIOL, V61, P42, DOI 10.1016/j.hjc.2020.03.002
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Kewan Tariq, 2020, EClinicalMedicine, V24, P100418, DOI 10.1016/j.eclinm.2020.100418
   Leung YY, 2015, SEMIN ARTHRITIS RHEU, V45, P341, DOI 10.1016/j.semarthrit.2015.06.013
   Li Y, 2020, BRIT J HAEMATOL, V190, pE24, DOI 10.1111/bjh.16811
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Martinez GJ, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002128
   Montealegre-Gomez Giovanni, 2020, Reumatol Clin, DOI 10.1016/j.reuma.2020.05.001
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shukla Ashutosh M, 2020, Drugs Context, V9, DOI 10.7573/dic.2020-4-5
   Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388
   Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 27
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1712-9532
EI 1918-1493
J9 CAN J INFECT DIS MED
JI Can. J. Infect. Dis. Med. Microbiol.
PD OCT 27
PY 2020
VL 2020
AR 8865954
DI 10.1155/2020/8865954
PG 9
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA OT3OL
UT WOS:000590759600001
PM 33133323
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, X
   Li, JH
   Qi, W
   Zhou, XY
   Hu, YB
   Quan, H
   Wang, Z
AF Zhang, Xin
   Li, Jiehao
   Qi, Wen
   Zhou, Xuanyi
   Hu, Yingbai
   Quan, Hao
   Wang, Zhen
TI A Novel Human-Like Control Framework for Mobile Medical Service Robot
SO COMPLEXITY
LA English
DT Article
ID TRACKING CONTROL; EXOSKELETONS; SYSTEMS
AB Recently, as a highly infectious disease of novel coronavirus (COVID-19) has swept the globe, more and more patients need to be isolated in the rooms of the hospitals, so how to deliver the meals or drugs to these infectious patients is the urgent work. It is a reliable and effective method to transport medical supplies or meals to patients using robots, but how to teach the robot to the destination and to enter the door like a human is an exciting task. In this paper, a novel human-like control framework for the mobile medical service robot is considered, where a Kinect sensor is used to manage human activity recognition to generate a designed teaching trajectory. Meanwhile, the learning technique of dynamic movement primitives (DMP) with the Gaussian mixture model (GMM) is applied to transfer the skill from humans to robots. A neural-based model predictive tracking controller is implemented to follow the teaching trajectory. Finally, some demonstrations are carried out in a hospital room to illustrate the superiority and effectiveness of the developed framework.
C1 [Zhang, Xin] Soochow Univ, Suzhou 215000, Peoples R China.
   [Li, Jiehao; Qi, Wen; Zhou, Xuanyi; Quan, Hao; Wang, Zhen] Politecn Milan, Dept Elect Informat & Bioengn, I-20133 Milan, Italy.
   [Hu, Yingbai] Tech Univ Munich, Dept Informat, D-85748 Munich, Germany.
RP Qi, W (corresponding author), Politecn Milan, Dept Elect Informat & Bioengn, I-20133 Milan, Italy.
EM wen.qi@polimi.it
FU National Key Research and Development Program of China [2019YFC1511401];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [61103157]
FX This work was supported by the National Key Research and Development
   Program of China under Grant 2019YFC1511401 and the National Natural
   Science Foundation of China under Grant 61103157.
CR Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Cao ZR, 2020, INFORM SCIENCES, V515, P324, DOI 10.1016/j.ins.2019.12.032
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Deng M. D., 2018, IEEE T CYBERNETICS, V50, P112
   Gong J., 2014, MODEL PREDICTIVE CON
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He W, 2019, IEEE T CYBERNETICS, V49, P1524, DOI 10.1109/TCYB.2018.2808321
   He W, 2018, IEEE T NEUR NET LEAR, V29, P1174, DOI 10.1109/TNNLS.2017.2665581
   Hu YB, 2019, IEEE T IND ELECTRON, V66, P7788, DOI 10.1109/TIE.2018.2884240
   Hu YB, 2017, IEEE T SYST MAN CY-S, V47, P1169, DOI 10.1109/TSMC.2016.2560530
   Klamt T, 2019, IEEE ROBOT AUTOM MAG, V26, P59, DOI 10.1109/MRA.2019.2941248
   Klamt T, 2020, J FIELD ROBOT, V37, P889, DOI 10.1002/rob.21895
   Li JH, 2020, NEUROCOMPUTING, V410, P342, DOI 10.1016/j.neucom.2020.05.091
   Li JH, 2020, ASSEMBLY AUTOM, V40, P675, DOI 10.1108/AA-08-2019-0148
   Li Z, 2018, IEEE ACCESS, V6, DOI 10.1109/ACCESS.2018.2836221
   Li ZJ, 2020, IEEE T IND INFORM, V16, P2985, DOI 10.1109/TII.2019.2900121
   Li ZJ, 2019, IEEE T COGN DEV SYST, V11, P145, DOI 10.1109/TCDS.2019.2915408
   Li ZJ, 2019, IEEE T NEUR NET LEAR, V30, P3558, DOI 10.1109/TNNLS.2018.2872595
   Li ZJ, 2018, IEEE T IND ELECTRON, V65, P9614, DOI 10.1109/TIE.2018.2821649
   Li ZJ, 2018, IEEE T ROBOT, V34, P264, DOI 10.1109/TRO.2017.2765334
   Li ZJ, 2016, IEEE T CONTR SYST T, V24, P553, DOI 10.1109/TCST.2015.2454484
   Liu Z, 2020, AUTOMATICA, V111, DOI 10.1016/j.automatica.2019.108596
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Peng H, 2019, PEER PEER NETW APPL, V12, P1741, DOI 10.1007/s12083-019-00747-x
   Peng H, 2019, ENERGY, V175, P309, DOI 10.1016/j.energy.2019.03.088
   Qi W, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19173731
   Ren HR, 2020, IEEE T IND ELECTRON, V67, P4980, DOI 10.1109/TIE.2019.2928241
   Sandoval J, 2018, ROBOT AUTON SYST, V106, P95, DOI 10.1016/j.robot.2018.04.001
   Su H., 2020, P 2020 IEEE INT C RO
   Su H, 2020, SENSOR MATER, V32, P1223, DOI 10.18494/SAM.2020.2618
   Su H, 2020, ADV ROBOTICS, V34, P985, DOI 10.1080/01691864.2020.1713886
   Su H, 2019, IEEE ACCESS, V7, P124207, DOI 10.1109/ACCESS.2019.2937380
   Su H, 2019, IEEE ACCESS, V7, P122041, DOI 10.1109/ACCESS.2019.2936334
   Su H, 2019, IEEE ROBOT AUTOM LET, V4, P1447, DOI 10.1109/LRA.2019.2897145
   Su H, 2018, INT J ADV ROBOT SYST, V15, DOI 10.1177/1729881418814695
   Wei Q, 2020, IEEE-ASME T MECH, V25, P705, DOI 10.1109/TMECH.2019.2961567
   Wu XY, 2020, IEEE T IND ELECTRON, V67, P6629, DOI 10.1109/TIE.2019.2937036
   Wu XY, 2020, IEEE T CYBERNETICS, V50, P3740, DOI 10.1109/TCYB.2019.2933019
   Wu Z., 2019, IEEE T NEURAL NETWOR, V24, P699, DOI [10.1016/j.neunet.2011.03.018, DOI 10.1016/J.NEUNET.2011.03.018]
   Xiao B, 2019, IEEE T IND ELECTRON, V66, P9417, DOI 10.1109/TIE.2019.2893852
   Zhang LB, 2017, IEEE T IND ELECTRON, V64, P2236, DOI 10.1109/TIE.2016.2624260
   Zhang X, 2020, ELECTRONICS-SWITZ, V9, DOI 10.3390/electronics9020343
   Zhao XD, 2020, IEEE T FUZZY SYST, V28, P632, DOI 10.1109/TFUZZ.2019.2912138
NR 43
TC 0
Z9 0
U1 4
U2 4
PU WILEY-HINDAWI
PI LONDON
PA ADAM HOUSE, 3RD FL, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND
SN 1076-2787
EI 1099-0526
J9 COMPLEXITY
JI Complexity
PD OCT 27
PY 2020
VL 2020
AR 2905841
DI 10.1155/2020/2905841
PG 11
WC Mathematics, Interdisciplinary Applications; Multidisciplinary Sciences
SC Mathematics; Science & Technology - Other Topics
GA OT7HF
UT WOS:000591012100001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Akbari, M
   Morad, R
   Maaza, M
AF Akbari, Mahmood
   Morad, Razieh
   Maaza, Malik
TI First principle study of silver nanoparticle interactions with
   antimalarial drugs extracted from Artemisia annua plant
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Silver nanoparticle; Artemisia annua plant; Artemisinin; Artemether;
   Artesunate; Density functional theory; Molecular dynamics simulations;
   Drug delivery
ID DER-WAALS COMPLEXES; ANTIBACTERIAL; GOLD; ARTESUNATE; WATER; IONS; BOND
AB Silver nanoparticles have a great potential in a broad range of applications such as drug-delivery carriers because of their antiviral and antibacterial properties. In this study, the coating properties of silver nanoparticle (size range of 1.6 nm) with three common anti-malarial drugs, Artemisinin, Artemether, and Artesunate have been studied by using the quantum mechanical and classical atomistic molecular dynamics simulation in order to use as the drug delivery to treat malaria and COVID-19 diseases. The optimized structure, frequencies, charge distribution, and the electrostatic potential maps of the three drug molecules were simulated by using the density functional theory (DFT) at the B3LYP/6-311++g(d,p) level of theory. Then, molecular dynamics simulation was used to study the coating of AgNP with each of these drugs. The affinity of interaction was obtained as Artesunate > Artemether > Artemisinin which is in agreement with the DFT results on the adsorption of drugs on the Ag(111) slab.
C1 [Akbari, Mahmood; Morad, Razieh; Maaza, Malik] Univ South Africa UNISA, Coll Grad Studies, UNISA Africa Chair Nanosci & Nanotechnol, UNESCO, Pretoria, South Africa.
   [Akbari, Mahmood; Morad, Razieh; Maaza, Malik] Natl Res Fdn, iThemba LABS, Mat Res Div, Nanosci African Network NANOAFNET, ZA-7129 Somerset West, South Africa.
RP Akbari, M (corresponding author), Univ South Africa UNISA, Coll Grad Studies, UNISA Africa Chair Nanosci & Nanotechnol, UNESCO, Pretoria, South Africa.
EM makbari@tlabs.ac.za
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Aderibigbe BA, 2017, MOLECULES, V22, DOI 10.3390/molecules22081370
   Alexander JW, 2009, SURG INFECT, V10, P289, DOI 10.1089/sur.2008.9941
   Antusek A, 2003, J CHEM PHYS, V119, P7247, DOI 10.1063/1.1605936
   Bazban-Shotorbani S, 2017, J CONTROL RELEASE, V253, P46, DOI 10.1016/j.jconrel.2017.02.021
   Burdusel AC, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8090681
   Choi O, 2008, WATER RES, V42, P3066, DOI 10.1016/j.watres.2008.02.021
   Chowdhury NR, 2016, J COLLOID INTERF SCI, V482, P151, DOI 10.1016/j.jcis.2016.08.003
   Dalrymple DG, 2013, ARTEMISIA ANNUA ARTE
   Duffy PE, 2006, LANCET, V367, P2037, DOI 10.1016/S0140-6736(06)68900-9
   Efferth T, 2007, PLANTA MED, V73, P299, DOI 10.1055/s-2007-967138
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Feng QL, 2000, J BIOMED MATER RES, V52, P662, DOI 10.1002/1097-4636(20001215)52:4<662::AID-JBM10>3.0.CO;2-3
   Ferreira JFS, 2010, MOLECULES, V15, P3135, DOI 10.3390/molecules15053135
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   Galdiero S, 2011, MOLECULES, V16, P8894, DOI 10.3390/molecules16108894
   Geraldo DA, 2016, BIOINTERFACE RES APP, V6, P1263
   Giannozzi P, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/39/395502
   Gilmore K, 2020, ARTEMISIA ANN PLANT
   Granatier J, 2007, J PHYS CHEM A, V111, P13238, DOI 10.1021/jp0757098
   Grimme S, 2011, J COMPUT CHEM, V32, P1456, DOI 10.1002/jcc.21759
   Haq FU, 2020, PHYTOTHER RES, V34, P2423, DOI 10.1002/ptr.6733
   Henke P, 2016, ACS APPL MATER INTER, V8, P25127, DOI 10.1021/acsami.6b08234
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Ivanova N, 2018, NANOMEDICINES, DOI [10.5772/intechopen.80238, DOI 10.5772/INTECHOPEN.80238]
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   KHAN MMAA, 1991, PLANT SCI, V75, P161, DOI 10.1016/0168-9452(91)90230-6
   Kordzadeh A, 2019, J MOL GRAPH MODEL, V88, P11, DOI 10.1016/j.jmgm.2018.12.009
   Kyrychenko A, 2017, PHYS CHEM CHEM PHYS, V19, P8742, DOI 10.1039/c6cp05562a
   Mody VV, 2010, J PHARM BIOALLIED SC, V2, P282, DOI 10.4103/0975-7406.72127
   Morris D, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11080732
   Nedelcu IA, 2014, CURR ORG CHEM, V18, P173, DOI 10.2174/13852728113176660141
   Pakiari AH, 2007, J PHYS CHEM A, V111, P4391, DOI 10.1021/jp070306t
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0392-8
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Petrovska Biljana Bauer, 2012, Pharmacogn Rev, V6, P1, DOI 10.4103/0973-7847.95849
   Prusty K, 2018, MAT SCI ENG C-MATER, V85, P130, DOI 10.1016/j.msec.2017.11.028
   Rezaee P, 2020, 1 PRINCIPLE SIMULATI
   Sambasivam A, 2016, LANGMUIR, V32, P1214, DOI 10.1021/acs.langmuir.5b03689
   Sohraby F, 2020, NANO BIOMED ENG, V12, P90, DOI [10.5101/nbe.v12i1.p90-98, DOI 10.5101/NBE.V12I1.P90-98]
   Stojanoski N, 1999, DEV HLTH CULTURE VEL, P13
   Suputtamongkol Y, 2001, BRIT J CLIN PHARMACO, V52, P655, DOI 10.1046/j.1365-2125.2001.01458.x
   Tavaf Z, 2017, EUR J INTEGR MED, V12, P163, DOI 10.1016/j.eujim.2017.05.011
   Tehrani ZA, 2012, J PHYS CHEM A, V116, P4338, DOI 10.1021/jp2080226
   Vanommeslaeghe K, 2012, J CHEM INF MODEL, V52, P3144, DOI 10.1021/ci300363c
   Villeret B, 2018, ACS NANO, V12, P1188, DOI 10.1021/acsnano.7b06934
   Wang CM, 2015, MOL MED REP, V12, P1291, DOI 10.3892/mmr.2015.3500
   White NJ, 2008, SCIENCE, V320, P330, DOI 10.1126/science.1155165
   Wong HN, 2020, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00901
   Yousefpour A, 2018, J MOL MODEL, V24, DOI 10.1007/s00894-018-3617-8
NR 52
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
EI 1572-896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD OCT 27
PY 2020
VL 22
IS 11
AR 331
DI 10.1007/s11051-020-05058-4
PG 9
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA OP7ZD
UT WOS:000588306700002
PM 33132747
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lo, MK
   Albarino, CG
   Perry, JK
   Chang, S
   Tchesnokov, EP
   Guerrero, L
   Chakrabarti, A
   Shrivastava-Ranjan, P
   Chatterjee, P
   McMullan, LK
   Martin, R
   Jordan, R
   Gotte, M
   Montgomery, JM
   Nichol, ST
   Flint, M
   Porter, D
   Spiropoulou, CF
AF Lo, Michael K.
   Albarino, Cesar G.
   Perry, Jason K.
   Chang, Silvia
   Tchesnokov, Egor P.
   Guerrero, Lisa
   Chakrabarti, Ayan
   Shrivastava-Ranjan, Punya
   Chatterjee, Payel
   McMullan, Laura K.
   Martin, Ross
   Jordan, Robert
   Gotte, Matthias
   Montgomery, Joel M.
   Nichol, Stuart T.
   Flint, Mike
   Porter, Danielle
   Spiropoulou, Christina F.
TI Remdesivir targets a structurally analogous region of the Ebola virus
   and SARS-CoV-2 polymerases
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE remdesivir; Ebola; COVID-19; SARS-CoV-2; antiviral nucleotide analog
ID GS-5734
AB Remdesivir is a broad-spectrum antiviral nucleotide prodrug that has been clinically evaluated in Ebola virus patients and recently received emergency use authorization (EUA) for treatment of COVID-19. With approvals from the Federal Select Agent Program and the Centers for Disease Control and Prevention's Institutional Biosecurity Board, we characterized the resistance profile of remdesivir by serially passaging Ebola virus under remdesivir selection; we generated lineages with low-level reduced susceptibility to remdesivir after 35 passages. We found that a single amino acid substitution, F5485, in the Ebola virus polymerase conferred low-level reduced susceptibility to remdesivir. The F548 residue is highly conserved in filoviruses but should be subject to specific surveillance among novel filoviruses, in newly emerging variants in ongoing outbreaks, and also in Ebola virus patients undergoing remdesivir therapy. Homology modeling suggests that the Ebola virus polymerase F548 residue lies in the F-motif of the polymerase active site, a region that was previously identified as susceptible to resistance mutations in coronaviruses. Our data suggest that molecular surveillance of this region of the polymerase in remdesivir-treated COVID-19 patients is also warranted.
C1 [Lo, Michael K.; Albarino, Cesar G.; Guerrero, Lisa; Chakrabarti, Ayan; Shrivastava-Ranjan, Punya; Chatterjee, Payel; McMullan, Laura K.; Montgomery, Joel M.; Nichol, Stuart T.; Flint, Mike; Spiropoulou, Christina F.] US Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30329 USA.
   [Perry, Jason K.; Chang, Silvia; Martin, Ross; Jordan, Robert; Porter, Danielle] Gilead Sci Inc, Foster City, CA 94404 USA.
   [Tchesnokov, Egor P.; Gotte, Matthias] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2E1, Canada.
   [Tchesnokov, Egor P.; Gotte, Matthias] Univ Alberta, Li Ka Shing Inst Virol, Edmonton, AB T6G 2E1, Canada.
   [Jordan, Robert] Meissa Vaccines Inc, Res & Dev, San Francisco, CA 94080 USA.
RP Lo, MK; Spiropoulou, CF (corresponding author), US Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30329 USA.
EM mko2@cdc.gov; ccs8@cdc.gov
OI Lo, Michael/0000-0002-0409-7896; McMullan, Laura/0000-0003-2748-5151
FU CDC Emerging Infectious Disease core funds
FX Y We thank Tatyana Klimova for helpful comments and edits to the
   manuscript. This study was funded by CDC Emerging Infectious Disease
   core funds. The findings and conclusions in this report are those of the
   authors and do not necessarily represent the official position of the
   CDC.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Albarino CG, 2015, VIROLOGY, V484, P259, DOI 10.1016/j.virol.2015.06.013
   Alfson KJ, 2016, J VIROL, V90, P2345, DOI 10.1128/JVI.02701-15
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Gehring G, 2014, J ANTIMICROB CHEMOTH, V69, P2123, DOI 10.1093/jac/dku091
   Gilman MSA, 2019, CELL, V179, P193, DOI 10.1016/j.cell.2019.08.014
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8
   Jia HX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01945
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Jordan PC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006889
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Lo MK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9242
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Miler CR, 2016, PEERJ, V4, DOI 10.7717/peerj.1674
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Pan Junhua, 2020, Nature, V577, P275, DOI 10.1038/s41586-019-1759-1
   Patel JS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211093
   Pruijssers AJ, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107940
   Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316
   Schrodinger L., 2020, MACR PRIM REL 2020 2
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Tchesnokov EP, 2020, J BIOL CHEM, V295, P16156, DOI 10.1074/jbc.AC120.015720
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Tchesnokov EP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22328-3
   Towner JS, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000212
   US Food and Drug Administration, EM US AUTH EUA EM US
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   Welch SR, 2016, ANTIVIR RES, V136, P9, DOI 10.1016/j.antiviral.2016.10.007
   WHO, EB VIR DIS
   Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593
NR 37
TC 2
Z9 2
U1 1
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 27
PY 2020
VL 117
IS 43
BP 26946
EP 26954
DI 10.1073/pnas.2012294117
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OH6ZD
UT WOS:000582743300053
PM 33028676
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Kaptein, SJF
   Jacobs, S
   Langendries, L
   Seldeslachts, L
   ter Horst, S
   Liesenborghs, L
   Hens, B
   Vergote, V
   Heylen, E
   Barthelemy, K
   Maas, E
   De Keyzer, C
   Bervoets, L
   Rymenants, J
   Van Buyten, T
   Zhang, X
   Abdelnabi, R
   Pang, J
   Williams, R
   Thibaut, HJ
   Dallmeier, K
   Boudewijns, R
   Wouters, J
   Augustijns, P
   Verougstraete, N
   Cawthorne, C
   Breuer, J
   Solas, C
   Weynand, B
   Annaert, P
   Spriet, I
   Velde, GV
   Neyts, J
   Rocha-Pereira, J
   Delang, L
AF Kaptein, Suzanne J. F.
   Jacobs, Sofie
   Langendries, Lana
   Seldeslachts, Laura
   ter Horst, Sebastiaan
   Liesenborghs, Laurens
   Hens, Bart
   Vergote, Valentijn
   Heylen, Elisabeth
   Barthelemy, Karine
   Maas, Elke
   De Keyzer, Carolien
   Bervoets, Lindsey
   Rymenants, Jasper
   Van Buyten, Tina
   Zhang, Xin
   Abdelnabi, Rana
   Pang, Juanita
   Williams, Rachel
   Thibaut, Hendrik Jan
   Dallmeier, Kai
   Boudewijns, Robbert
   Wouters, Jens
   Augustijns, Patrick
   Verougstraete, Nick
   Cawthorne, Christopher
   Breuer, Judith
   Solas, Caroline
   Weynand, Birgit
   Annaert, Pieter
   Spriet, Isabel
   Vande Velde, Greetje
   Neyts, Johan
   Rocha-Pereira, Joana
   Delang, Leen
TI Favipiravir at high doses has potent antiviral activity in
   SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE antiviral therapy; SARS-CoV-2; preclinical model; favipiravir;
   hydroxychloroquine
ID RESPIRATORY SYNDROME CORONAVIRUS; FEVER VIRUS-INFECTION; COMPOUND;
   COVID-19; DISEASE; T-705
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the globe after its emergence in Wuhan in December 2019. With no specific therapeutic and prophylactic options available, the virus has infected millions of people of which more than half a million succumbed to the viral disease, COVID-19. The urgent need for an effective treatment together with a lack of small animal infection models has led to clinical trials using repurposed drugs without preclinical evidence of their in vivo efficacy. We established an infection model in Syrian hamsters to evaluate the efficacy of small molecules on both infection and transmission. Treatment of SARS-CoV-2-infected hamsters with a low dose of favipiravir or hydroxychloroquine with(out) azithromycin resulted in, respectively, a mild or no reduction in virus levels. However, high doses of favipiravir significantly reduced infectious virus titers in the lungs and markedly improved lung histopathology. Moreover, a high dose of favipiravir decreased virus transmission by direct contact, whereas hydroxychloroquine failed as prophylaxis. Pharmacokinetic modeling of hydroxychloroquine suggested that the total lung exposure to the drug did not cause the failure. Our data on hydroxychloroquine (together with previous reports in macaques and ferrets) thus provide no scientific basis for the use of this drug in COVID-19 patients. In contrast, the results with favipiravir demonstrate that an antiviral drug at nontoxic doses exhibits a marked protective effect against SARS-CoV-2 in a small animal model. Clinical studies are required to assess whether a similar antiviral effect is achievable in humans without toxic effects.
C1 [Kaptein, Suzanne J. F.; Jacobs, Sofie; Langendries, Lana; ter Horst, Sebastiaan; Liesenborghs, Laurens; Vergote, Valentijn; Heylen, Elisabeth; Maas, Elke; De Keyzer, Carolien; Bervoets, Lindsey; Rymenants, Jasper; Van Buyten, Tina; Zhang, Xin; Abdelnabi, Rana; Thibaut, Hendrik Jan; Dallmeier, Kai; Boudewijns, Robbert; Neyts, Johan; Rocha-Pereira, Joana; Delang, Leen] Katholieke Univ Leuven, Lab Virol & Chemotherapy, Dept Microbiol Immunol & Transplantat, Rega Inst Med Res, B-3000 Leuven, Belgium.
   [Seldeslachts, Laura; Vande Velde, Greetje] Katholieke Univ Leuven, Biomed MRI & Mol Small Anim Imaging Ctr, Dept Imaging & Pathol, B-3000 Leuven, Belgium.
   [Hens, Bart; Augustijns, Patrick; Annaert, Pieter] Katholieke Univ Leuven, Drug Delivery & Disposit, Dept Pharmaceut & Pharmacol Sci, B-3000 Leuven, Belgium.
   [Barthelemy, Karine] Aix Marseille Univ, Unite Virus Emergents, Inst Rech Dev IRD 190, Inst Natl Sante & Rech Med INSERM 1207, F-13005 Marseille, France.
   [Pang, Juanita; Williams, Rachel; Breuer, Judith] UCL, UCL Great Ormond St Inst Child Hlth, London WC1N 1EH, England.
   [Wouters, Jens] Katholieke Univ Leuven, Dept Imaging & Pathol, Mol Small Anim Imaging Ctr, B-3000 Leuven, Belgium.
   [Verougstraete, Nick] Ghent Univ Hosp, Dept Lab Med, B-9000 Ghent, Belgium.
   [Cawthorne, Christopher] Katholieke Univ Leuven, Dept Imaging & Pathol, Nucl Med & Mol Imaging, B-3000 Leuven, Belgium.
   [Solas, Caroline] Aix Marseille Univ, Assistance Publ Hop Marseille, Unite Virus Emergents,Lab Pharmacocinet & Toxicol, Inst Rech Dev IRD 190,Inst Natl Sante & Rech Med, F-13005 Marseille, France.
   [Weynand, Birgit] Katholieke Univ Leuven, Dept Imaging & Pathol, Translat Cell & Tissue Res, B-3000 Leuven, Belgium.
   [Spriet, Isabel] Univ Hosp Leuven, Pharm Dept, B-3000 Leuven, Belgium.
   [Spriet, Isabel] Univ Leuven, Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, B-3000 Leuven, Belgium.
   [Neyts, Johan] Global Virus Network, Baltimore, MD 21201 USA.
RP Kaptein, SJF; Neyts, J; Rocha-Pereira, J; Delang, L (corresponding author), Katholieke Univ Leuven, Lab Virol & Chemotherapy, Dept Microbiol Immunol & Transplantat, Rega Inst Med Res, B-3000 Leuven, Belgium.; Neyts, J (corresponding author), Global Virus Network, Baltimore, MD 21201 USA.
EM suzanne.kaptein@kuleuven.be; johan.neyts@kuleuven.be;
   joana.rochapereira@kuleuven.be; leen.delang@kuleuven.be
RI Kaptein, Suzanne JF/O-4714-2019; thibaut, Hendrik Jan/P-4267-2019;
   Seldeslachts, Laura/ABG-8034-2020; abdelnabi, rana/D-9526-2018; Vergote,
   Valentijn/F-5831-2018; NEYTS, Johan/U-8267-2017; ter Horst,
   Sebastiaan/I-7521-2018; Rocha-Pereira, Joana/H-7806-2018
OI Kaptein, Suzanne JF/0000-0002-7935-0219; thibaut, Hendrik
   Jan/0000-0001-5785-8276; Seldeslachts, Laura/0000-0002-9562-2923;
   abdelnabi, rana/0000-0001-9771-7312; Vergote,
   Valentijn/0000-0002-4436-3212; Breuer, Judith/0000-0001-8246-0534;
   Liesenborghs, Laurens/0000-0001-5616-8548; NEYTS,
   Johan/0000-0002-0033-7514; ter Horst, Sebastiaan/0000-0001-7981-6376;
   Rocha-Pereira, Joana/0000-0001-8299-3787; Jacobs,
   Sofie/0000-0001-8657-6841
FU European UnionEuropean Union (EU) [101003627]; Bill and Melinda Gates
   FoundationBill & Melinda Gates Foundation [INV-00636]; Stichting Antoine
   Faes; KU Leuven Internal Funds [C24/17/061]; James Black charitable
   foundation [559133]; FWOFWO [1001719N]; Fund for Scientific Research
   Flanders (FWO)FWO [1S21918N, G0G4820N]; KU Leuven internal project;
   Rosetrees studentshipRosetrees Trust [M876]; National Institute for
   Health Research University College London/University College London
   Hospitals Biomedical Research Centre; Covid-19-Fund KU
   Leuven/Universitair Ziekenhuis Leuven; Flemish Research Council (FWO)FWO
   [12R2119N]
FX We thank Eef Allegaert, Sabrina D'Haese, and Kathleen Van den Eynde for
   excellent technical assistance. We are grateful to Piet Maes for kindly
   providing the SARS-CoV-2 strain used in this study. We thank Molecubes
   and Bruker Belgium for their support with the implementation of the
   micro-CT installation, Jef Arnout and Annelies Sterckx (KU Leuven
   Faculty of Medicine, Biomedical Sciences Group Management) and Animalia
   and Biosafety Departments of KU Leuven for facilitating the studies.
   This project has received funding from the Covid-19-Fund KU
   Leuven/Universitair Ziekenhuis Leuven and the COVID-19 call of Fund for
   Scientific Research Flanders (FWO) (grant G0G4820N), the European
   Union's Horizon 2020 research and innovation program under Grant
   Agreement 101003627 (Swift COronavirus therapeutics REsponse project),
   funding from Bill and Melinda Gates Foundation under Grant Agreement
   INV-00636, and the Stichting Antoine Faes. G.V.V. acknowledges grant
   support from KU Leuven Internal Funds (grant C24/17/061). The deep
   sequencing was funded by the James Black charitable foundation (grant
   559133). C.C. was supported by the FWO (FWO grant 1001719N). S.J. is
   supported by a PhD fellowship of the Fund for Scientific Research
   Flanders (FWO grant 1S21918N). S.t.H. and L. Langendries are supported
   by a KU Leuven internal project. B.H. is a postdoctoral fellow of the
   Flemish Research Council (FWO grant 12R2119N). J.P. is funded by a
   Rosetrees studentship (grant M876). J.B. receives funding from the
   National Institute for Health Research University College
   London/University College London Hospitals Biomedical Research Centre.
CR Berghen N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53876-x
   Boudewijns R, 2020, STAT2 SIGNALING DOUB, DOI [DOI 10.1101/2020.04.23.056838, 10.1101/2020.04.23.056838]
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Cleary SJ, 2020, BRIT J PHARMACOL, V177, P4851, DOI 10.1111/bph.15143
   Dawes BE, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25780-3
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Delang L., 2020, MED TREATMENT OPTION
   Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003
   Driouich J.-S., 2020, BIORXIV, DOI DOI 10.1101/2020.07.07.191775
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Eloy P, 2020, CLIN PHARMACOL THER, V108, P188, DOI 10.1002/cpt.1877
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Gowen BB, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002614
   Irie K, 2020, CTS-CLIN TRANSL SCI, V13, P880, DOI 10.1111/cts.12827
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Julander JG, 2009, ANTIMICROB AGENTS CH, V53, P202, DOI 10.1128/AAC.01074-08
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111
   LI X, 2020, CLIN INFECT DIS, DOI DOI 10.1093/CID/CIAA325
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lumby Casper K, 2020, Clin Infect Dis, V71, pe191, DOI 10.1093/cid/ciaa023
   Madelain V, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01305-16, 10.1128/aac.01305-16]
   Maisonnasse P., 2020, HYDROXYCHLOROQUINE T, DOI [10.21203/RS.3.RS-27223/V1, DOI 10.21203/RS.3.RS-27223/V1, 10.21203/rs.3.rs-27223/v1]
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Okonechnikov K, 2016, BIOINFORMATICS, V32, P292, DOI 10.1093/bioinformatics/btv566
   Park SJ, 2020, MBIO, V11, DOI 10.1128/mBio.01114-20
   Pilkington V, 2020, J VIRUS ERAD, V6, P45
   Poelmans J, 2016, LAB INVEST, V96, P692, DOI 10.1038/labinvest.2016.45
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Roldan EQ, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104904
   Ruis C, 2018, NEW ENGL J MED, V379, P2173, DOI 10.1056/NEJMc1806941
   Scharton D, 2014, ANTIVIR RES, V104, P84, DOI 10.1016/j.antiviral.2014.01.016
   Shannon A, 2020, bioRxiv, DOI 10.1101/2020.05.15.098731
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Spiteri G, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.9.2000178
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x
   Nguyen THT, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005389
   Touret F., 2020, IN VITRO SCREENING F, DOI [10.1101/2020.04.03.023846., DOI 10.1101/2020.04.03.023846]
   Vande Velde G, 2016, DIS MODEL MECH, V9, P91, DOI 10.1242/dmm.020321
   Vandeghinste B, 2013, IEEE T NUCL SCI, V60, P3305, DOI 10.1109/TNS.2013.2275994
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang Y, 2020, BRIT J PHARMACOL, V177, P4995, DOI 10.1111/bph.15102
   Watson SJ, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0205
   Wei YM, 1995, CHIRALITY, V7, P598, DOI 10.1002/chir.530070807
   Weston S., 2020, BIORXIV, DOI [10.1101/2020.03.25.008482, DOI 10.1101/2020.03.25.008482]
   Wrapp D, 2020, CELL, V181, P1436, DOI 10.1016/j.cell.2020.05.047
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang B, 2020, PLOS ONE, V15, DOI [10.1371/journal.pone. 0235458, DOI 10.1371/JOURNAL.PONE.0235458]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 55
TC 0
Z9 0
U1 1
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 27
PY 2020
VL 117
IS 43
BP 26955
EP 26965
DI 10.1073/pnas.2014441117
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OH6ZD
UT WOS:000582743300054
PM 33037151
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Kolacz, J
   Dale, LP
   Nix, EJ
   Roath, OK
   Lewis, GF
   Porges, SW
AF Kolacz, Jacek
   Dale, Lourdes P.
   Nix, Evan J.
   Roath, Olivia K.
   Lewis, Gregory F.
   Porges, Stephen W.
TI Adversity History Predicts Self-Reported Autonomic Reactivity and Mental
   Health in US Residents During the COVID-19 Pandemic
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE coronavirus; COVID-19; autonomic nervous system; polyvagal theory; PTSD;
   depression; worry; trauma
ID HEART-RATE-VARIABILITY; POSTTRAUMATIC-STRESS-DISORDER; GENERALIZED
   ANXIETY DISORDER; PSYCHOMETRIC PROPERTIES; CHILDHOOD EXPERIENCES;
   EMOTION REGULATION; PTSD CHECKLIST; TRAUMA; MODEL; DEPRESSION
AB Background: The spread of the COVID-19 virus presents an unprecedented event that rapidly introduced widespread life threat, economic destabilization, and social isolation. The human nervous system is tuned to detect safety and danger, integrating body and brain responses via the autonomic nervous system. Shifts in brain-body states toward danger responses can compromise mental health. For those who have experienced prior potentially traumatic events, the autonomic threat response system may be sensitive to new dangers and these threat responses may mediate the association between prior adversity and current mental health.
   Method: The present study collected survey data from adult U.S. residents (n = 1,666; 68% female; Age M = 46.24, SD = 15.14) recruited through websites, mailing lists, social media, and demographically-targeted sampling collected between March and May 2020. Participants reported on their adversity history, subjective experiences of autonomic reactivity, PTSD and depression symptoms, and intensity of worry related to the COVID-19 pandemic using a combination of standardized questionnaires and questions developed for the study. Formal mediation testing was conducted using path analysis and structural equation modeling.
   Results: Respondents with prior adversities reported higher levels of destabilized autonomic reactivity, PTSD and depression symptoms, and worry related to COVID-19. Autonomic reactivity mediated the relation between adversity and all mental health variables (standardized indirect effect range for unadjusted models: 0.212-0.340; covariate-adjusted model: 0.183-0.301).
   Discussion: The data highlight the important role of autonomic regulation as an intervening variable in mediating the impact of adversity on mental health. Because of the important role that autonomic function plays in the expression of mental health vulnerability, brain-body oriented therapies that promote threat response reduction should be investigated as possible therapeutic targets.
C1 [Kolacz, Jacek; Nix, Evan J.; Roath, Olivia K.; Lewis, Gregory F.; Porges, Stephen W.] Indiana Univ, Kinsey Inst, Traumat Stress Res Consortium, Bloomington, IN 47405 USA.
   [Dale, Lourdes P.] Univ Florida, Coll Med Jacksonville, Dept Psychiat, Jacksonville, FL USA.
   [Lewis, Gregory F.] Indiana Univ, Intelligent Syst Engn, Bloomington, IN USA.
   [Porges, Stephen W.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27515 USA.
RP Kolacz, J (corresponding author), Indiana Univ, Kinsey Inst, Traumat Stress Res Consortium, Bloomington, IN 47405 USA.
EM jacekkolacz@gmail.com
FU Dillon Foundation; United States Association of Body Psychotherapy
FX Funding in support of this work was provided by the Dillon Foundation
   and the United States Association of Body Psychotherapy.
CR American Psychiatric Association, DIAGNOSTIC STAT MANU, V4th
   Austin MA, 2007, BRAIN COGNITION, V65, P69, DOI 10.1016/j.bandc.2006.05.007
   Baldwin JR, 2019, JAMA PSYCHIAT, V76, P584, DOI 10.1001/jamapsychiatry.2019.0097
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   Beauchaine T, 2001, DEV PSYCHOPATHOL, V13, P183, DOI 10.1017/S0954579401002012
   BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238
   Bernard C., 1865, INTRO ETUDE MED EXPT
   Boas TC, 2020, POLIT SCI RES METH, V8, P232, DOI 10.1017/psrm.2018.28
   Bollen KA, 2011, PSYCHOL METHODS, V16, P265, DOI 10.1037/a0024448
   Borelli JL, 2019, PSYCHOPHYSIOLOGY, V56, DOI 10.1111/psyp.13443
   Bottomley JM, 2020, COMPR PSYCHIAT, V98, DOI 10.1016/j.comppsych.2019.152156
   Cabrera A, 2018, INT J METH PSYCH RES, V27, DOI 10.1002/mpr.1596
   Cannon WB, 1929, PHYSIOL REV, V9, P399
   Carreno FR, 2017, NEUROTHERAPEUTICS, V14, P716, DOI 10.1007/s13311-017-0537-8
   Centers for Disease Control and Prevention (CDC), 2020, 1 TRAV REL CAS 2019
   Chalmers JA, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00080
   Chatel-Goldman J, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00095
   Chida Y, 2008, PSYCHOL BULL, V134, P829, DOI 10.1037/a0013342
   Cohen H, 1998, BIOL PSYCHIAT, V44, P1054, DOI 10.1016/S0006-3223(97)00475-7
   Dale LP, 2018, PSYCHOL TRAUMA-US, V10, P427, DOI 10.1037/tra0000342
   Dale LP, 2009, APPL PSYCHOPHYS BIOF, V34, P299, DOI 10.1007/s10484-009-9111-4
   Dale LP, 2020, ADVERSE TRAUMATIC EX
   Carvalho PMD, 2020, PSYCHIAT RES, V286, DOI 10.1016/j.psychres.2020.112902
   Del Giudice M, 2011, NEUROSCI BIOBEHAV R, V35, P1562, DOI 10.1016/j.neubiorev.2010.11.007
   Dieterich-Hartwell R, 2017, ART PSYCHOTHER, V54, P38, DOI 10.1016/j.aip.2017.02.010
   Ditto B, 2006, ANN BEHAV MED, V32, P227, DOI 10.1207/s15324796abm3203_9
   Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8
   Goldstein Michael R, 2016, Int J Yoga, V9, P20, DOI 10.4103/0973-6131.171718
   Gurel NZ, 2020, BRAIN STIMUL, V13, P47, DOI 10.1016/j.brs.2019.08.002
   Hastings PD, 2019, DEVELOPMENTAL SCI, V22, DOI 10.1111/desc.12725
   Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI 10.1080/03637750903310360
   Hess W. R., 1948, ORG AUTONOMIC NERVOU
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Holochwost Steven J, 2020, Dev Psychopathol, P1, DOI 10.1017/S0954579420000383
   Hooper LM, 2011, J LOSS TRAUMA, V16, P258, DOI 10.1080/15325024.2011.572035
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Janig W, 2008, INTEGRATIVE ACTION A, P633
   Kemp AH, 2010, BIOL PSYCHIAT, V67, P1067, DOI [10.1016/j.biopsych.2009.11.019, 10.1016/j.biopsych.2009.12.012]
   Kizakevich PN, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/12590
   Koenig J, 2016, CLIN PSYCHOL REV, V46, P136, DOI 10.1016/j.cpr.2016.04.013
   Kolacz J, 2018, BODY PERCEPTION QUES
   Kolacz J, 2019, DEV PSYCHOBIOL, V61, P796, DOI 10.1002/dev.21852
   Kolacz J, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00145
   Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C
   Lahey BB, 2009, AM PSYCHOL, V64, P241, DOI 10.1037/a0015309
   Langley J, 1921, AUTONOMIC NERVOUS 1
   Levine JC, 2016, J AFFECT DISORDERS, V205, P207, DOI 10.1016/j.jad.2016.07.019
   MACCALLUM RC, 1992, PSYCHOL BULL, V111, P490, DOI 10.1037/0033-2909.111.3.490
   MacKinnon DP, 2004, MULTIVAR BEHAV RES, V39, P99, DOI 10.1207/s15327906mbr3901_4
   MacKinnon DP, 2008, INTRO STAT MEDIATION, P479
   McGinty EE, 2020, JAMA-J AM MED ASSOC, V324, P93, DOI 10.1001/jama.2020.9740
   McLaughlin KA, 2015, P NATL ACAD SCI USA, V112, P5637, DOI 10.1073/pnas.1423363112
   Noble LJ, 2019, BRAIN STIMUL, V12, P9, DOI 10.1016/j.brs.2018.09.013
   Ormel J, 2013, NEUROSCI BIOBEHAV R, V37, P59, DOI 10.1016/j.neubiorev.2012.09.004
   Pole N, 2007, PSYCHOL BULL, V133, P725, DOI 10.1037/0033-2909.133.5.725
   Porges S., 1993, BODY PERCEPTION QUES
   Porges S. W., 2011, POLYVAGAL THEORY NEU
   Porges SW, 2007, BIOL PSYCHOL, V74, P116, DOI 10.1016/j.biopsycho.2006.06.009
   Porges SW, 2011, INFANT CHILD DEV, V20, P106, DOI 10.1002/icd.688
   PORGES SW, 1995, PSYCHOPHYSIOLOGY, V32, P301, DOI 10.1111/j.1469-8986.1995.tb01213.x
   Porges SW, 2001, INT J PSYCHOPHYSIOL, V42, P123, DOI 10.1016/S0167-8760(01)00162-3
   Porges SW, 2020, COVID 19 PANDEMIC IS
   Propper CB, 2013, DEV REV, V33, P151, DOI 10.1016/j.dr.2013.05.001
   R Core Team, 2019, R LANG ENV STAT COMP
   Reuben A, 2016, J CHILD PSYCHOL PSYC, V57, P1103, DOI 10.1111/jcpp.12621
   Rosseel Y, 2012, J STAT SOFTW, V48, P1, DOI 10.18637/jss.v048.i02
   Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117
   Ruxton GD, 2006, BEHAV ECOL, V17, P688, DOI 10.1093/beheco/ark016
   Schnurr P, 1999, BRIEF TRAUMA QUESTIO
   Shanahan Lilly, 2020, Psychol Med, P1, DOI 10.1017/S003329172000241X
   Solomon EP, 2005, J INTERPERS VIOLENCE, V20, P51, DOI 10.1177/0886260504268119
   Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737
   Steiger JH, 1998, STRUCT EQU MODELING, V5, P411, DOI 10.1080/10705519809540115
   Thayer JF, 1996, BIOL PSYCHIAT, V39, P255, DOI 10.1016/0006-3223(95)00136-0
   Thayer JF, 2000, J AFFECT DISORDERS, V61, P201, DOI 10.1016/S0165-0327(00)00338-4
   TUCKER LR, 1973, PSYCHOMETRIKA, V38, P1, DOI 10.1007/bf02291170
   van der Kolk BA, 2003, CHILD ADOL PSYCH CL, V12, P293, DOI 10.1016/S1056-4993(03)00003-8
   Van der Kolk BA, 2015, BODY KEEPS SCORE BRA, P466
   Walter SL, 2019, J BUS PSYCHOL, V34, P425, DOI 10.1007/s10869-018-9552-y
   Weathers F, 2013, LIFE EVENTS CHECKLIS
   Weathers F. W., 1991, PTSD CHECKLIST CIVIL
   White House, 2020, PROCL DECL NAT EM NO
   Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837
   Williamson JB, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01571
   World Health Organization, 2020, WHO VIRT PRESS C COV
NR 85
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD OCT 27
PY 2020
VL 11
AR 577728
DI 10.3389/fpsyt.2020.577728
PG 11
WC Psychiatry
SC Psychiatry
GA OO9SZ
UT WOS:000587715900001
PM 33192715
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, ZL
   Yang, L
AF Li, Zhonglin
   Yang, Ling
TI Underlying Mechanisms and Candidate Drugs for COVID-19 Based on the
   Connectivity Map Database
SO FRONTIERS IN GENETICS
LA English
DT Article
DE severe acute respiratory syndrome coronavirus 2; angiotensin-converting
   enzyme 2; underlying mechanisms; potential drugs; coronavirus disease
   2019
ID DISCOVERY; PNEUMONIA; PROTECTS; CELLS
AB Background The coronavirus disease 2019 (COVID-19) has become a worldwide public health crisis. At present, there are no effective antiviral drugs to treat COVID-19. Although some vaccines have been developed, late-stage clinical trials that allow licensure by regulatory agencies are still needed. Previous reports have indicated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV are highly homologous and both use angiotensin-converting enzyme 2 (ACE2) as the receptor to enter cells, and SARS-CoV infection reduces the ACE2 expression in the lung. Therefore, the analysis of genes co-expressed with ACE2 in the lung may uncover the underlying mechanism of COVID-19. Finally, we used the Connectivity map (Cmap) database to search for candidate drugs using transcriptome profiles of patients with COVID-19. Method Based on the differentially expressed genes (DEGs), indicated by the expression of RNAs isolated from bronchoalveolar lavage fluid (BALF) cells of patients with COVID-19, we performed functional enrichment analysis and hub gene cluster analysis. Furthermore, we identified genes co-expressed with ACE2 in healthy lung samples and analyzed the significant genes. Additionally, to identify several candidate drugs for the treatment of COVID-19, we queried Cmap using DEGs and genes co-expressed with ACE2. Results and Conclusion The up-regulated genes in the BALF cells of patients with COVID-19 are related to viral mRNA translation. The down-regulated genes are related to immune response functions. Genes positively correlated with ACE2 are related to immune defense and those negatively correlated are enriched in synaptic transmission functions. The results reflected prosperous viral proliferation and immune dysfunction in patients. Furthermore, ACE2 may not only mediate viral entrance, but also play an important role in immune defense. By using Cmap with transcriptome profiles of patients with COVID-19, we identified candidate drugs for the treatment of COVID-19, such as amantadine and acyclovir.
C1 [Li, Zhonglin; Yang, Ling] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Div Gastroenterol, Wuhan, Peoples R China.
RP Yang, L (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Div Gastroenterol, Wuhan, Peoples R China.
EM hepayang@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81974078, 81570530, 81370550]; Department of
   Science and Technology, Hubei Provincial People's GovernmentDepartment
   of Science & Technology (DOST), Philippines [2019ACA133]
FX This study was supported by the National Natural Science Foundation of
   China (Nos. 81974078, 81570530, 81370550 to LY) and Department of
   Science and Technology, Hubei Provincial People's Government (No.
   2019ACA133 to LY).
CR Abreu GEA, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109755
   Brenner SR, 2020, J MED VIROL, V92, P2341, DOI 10.1002/jmv.26030
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Delahaye-Duriez A, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1097-7
   Deng Y, 2019, NEUROSCI BULL, V35, P67, DOI 10.1007/s12264-018-0298-3
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Halary S, 2010, P NATL ACAD SCI USA, V107, P127, DOI 10.1073/pnas.0908978107
   Hassane DC, 2008, BLOOD, V111, P5654, DOI 10.1182/blood-2007-11-126003
   Hensel A, 2020, PLANTA MED, V86, P659, DOI 10.1055/a-1177-4396
   Hoang HD, 2018, J MOL BIOL, V430, P1965, DOI 10.1016/j.jmb.2018.04.040
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Klein N, 2013, CRIT CARE MED, V41, pE334, DOI 10.1097/CCM.0b013e31828a6688
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kunkel SD, 2011, CELL METAB, V13, P627, DOI 10.1016/j.cmet.2011.03.020
   Lammermann T, 2019, IMMUNOL REV, V289, P205, DOI 10.1111/imr.12752
   Li Z., 2020, RES SQUARE, DOI [10.21203/rs.2.24684/v1, DOI 10.21203/RS.2.24684/V1]
   Liu Q, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2017.21
   Luo D, 2019, ORTHOP SURG, V11, P1209, DOI 10.1111/os.12533
   Pang JS, 2019, ONCOL REP, V41, P2089, DOI 10.3892/or.2019.7014
   Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515
   Qu XYA, 2012, DRUG DISCOV TODAY, V17, P1289, DOI 10.1016/j.drudis.2012.07.017
   Rejdak K, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102163
   Richards EM, 2018, AM J RESP CRIT CARE, V198, P422, DOI 10.1164/rccm.201803-0569ED
   Scardoni Giovanni, 2014, F1000Res, V3, P139, DOI 10.12688/f1000research.4477.1
   Sirota M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001318
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tan WSD, 2018, CURR OPIN PHARMACOL, V40, P9, DOI 10.1016/j.coph.2017.12.002
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang J, 2020, ACE2 EXPRESSION COLO, DOI [10.1101/2020.02.05.20020545, DOI 10.1101/2020.02.05.20020545]
   Wei-jie Guan Z. N. Y. H., 2020, CLIN CHARACTERISTICS
   Wu Y Y, 2020, Zhonghua Gan Zang Bing Za Zhi, V28, P240, DOI 10.3760/cma.j.cn501113-20200224-00067
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yeh CT, 2012, AM J RESP CRIT CARE, V186, P1180, DOI 10.1164/rccm.201207-1180OC
   Zhang NR, 2020, J MED VIROL, V92, P408, DOI 10.1002/jmv.25674
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
NR 39
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD OCT 27
PY 2020
VL 11
AR 558557
DI 10.3389/fgene.2020.558557
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA OO9PC
UT WOS:000587704800001
PM 33193639
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kuckertz, JM
   Van Kirk, N
   Alperovitz, D
   Nota, JA
   Falkenstein, MJ
   Schreck, M
   Krompinger, JW
AF Kuckertz, Jennie M.
   Van Kirk, Nathaniel
   Alperovitz, David
   Nota, Jacob A.
   Falkenstein, Martha J.
   Schreck, Meghan
   Krompinger, Jason W.
TI Ahead of the Curve: Responses From Patients in Treatment for
   Obsessive-Compulsive Disorder to Coronavirus Disease 2019
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE obsessive compulsive disorder; anxiety; COVID-19; coronavirus;
   acceptance and commitment therapy; exposure and response prevention;
   resilience
ID PSYCHOLOGICAL PREDICTORS; QUESTIONNAIRE; DIMENSIONS
AB Alongside concern about the physical health impacts of the coronavirus disease 2019 (COVID-19) crisis, public health officials have also raised concerns about the potential for massive mental health impact. This has led many to wonder, how are individuals with obsessive-compulsive disorder (OCD), and especially those with contamination fears, doing in the era of COVID-19? We present data from eight patients in our residential treatment program for OCD who were admitted prior to any COVID-19 restrictions and continued in treatment at the facility during the pandemic. Much like the general population, our patients varied in the ways they were impacted by COVID-19, yet the majority experienced improvements in OCD symptoms despite the context. This is not to downplay the many ways in which our patients were personally affected by COVID-19. Rather our patients' relatively resilient responses mirror our program's treatment model, which emphasizes exposure and response prevention (ERP) within the complementary framework of acceptance and commitment therapy (ACT). The intention of this article is to challenge the notion that by definition this population will fare worse than the general public or that ERP cannot proceed effectively during this time. In contrast, we underscore that effective OCD treatment can and should continue in the era of COVID-19.
C1 [Kuckertz, Jennie M.; Van Kirk, Nathaniel; Alperovitz, David; Nota, Jacob A.; Falkenstein, Martha J.; Schreck, Meghan; Krompinger, Jason W.] McLean Hosp, Obsess Compuls Disorder Inst, 115 Mill St, Belmont, MA 02178 USA.
   [Kuckertz, Jennie M.; Van Kirk, Nathaniel; Alperovitz, David; Nota, Jacob A.; Falkenstein, Martha J.; Schreck, Meghan; Krompinger, Jason W.] Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA.
RP Kuckertz, JM (corresponding author), McLean Hosp, Obsess Compuls Disorder Inst, 115 Mill St, Belmont, MA 02178 USA.; Kuckertz, JM (corresponding author), Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA.
EM jkuckertz@mclean.harvard.edu
CR Abramowitz JS, 2010, PSYCHOL ASSESSMENT, V22, P180, DOI 10.1037/a0018260
   [Anonymous], 2020, GALLUP
   Anxiety and Depression Association of America, 2020, COR ANX HELPF EXP TI
   Blakey SM, 2017, J CLIN PSYCHOL MED S, V24, P270, DOI 10.1007/s10880-017-9514-y
   Blakey SM, 2015, COGNITIVE THER RES, V39, P816, DOI 10.1007/s10608-015-9701-9
   Callaway E, 2020, NATURE, V579, P482, DOI 10.1038/d41586-020-00758-2
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Crittendon J, 2006, J ANXIETY DISORD, V20, P1036, DOI 10.1016/j.janxdis.2005.11.006
   Delgado D, 2020, PSYCHOL REC, DOI 10.1007/s40732-020-00438-7
   ENDICOTT J, 1993, PSYCHOPHARMACOL BULL, V29, P321
   Fontenelle LF, 2020, DEPRESS ANXIETY, V37, P510, DOI 10.1002/da.23037
   GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   International OCD Foundation, 2020, COR COVID 19 RES OCD
   Ipsos MORI, 2020, COVID 19 MENT WELLB
   Krompinger J.W., 2020, BEHAV THERAPIST, V43, P166
   Liu NQ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112921
   Lu W, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112936
   Matsunaga H, 2010, PSYCHIAT RES, V180, P25, DOI 10.1016/j.psychres.2009.09.005
   Morse B., 2020, NBC 10 NEWS
   Muth C, 2016, EDUC PSYCHOL MEAS, V76, P64, DOI 10.1177/0013164415580432
   Pew Research Center, 2020, MOST AM SAY COR OUTB
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Pinheiro J., 2019, NLME LINEAR NONLINEA
   Pinto A, 2008, PSYCHIAT RES, V160, P83, DOI 10.1016/j.psychres.2007.07.010
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Rosman K., 2020, NY TIMES
   Rosmarin D. H., 2020, BLESSING ANXIETY DIS
   Steketee G, 2005, BEHAV RES THER, V43, P1527, DOI 10.1016/j.brat.2004.07.010
   Tan O, 2017, PSYCHIAT RES, V258, P166, DOI 10.1016/j.psychres.2016.04.088
   Twohig M., 2009, J COGNITIVE BEHAV, V16, P18, DOI DOI 10.1016/j.cbpra.2008.02.008
   Twohig MP, 2018, BEHAV RES THER, V108, P1, DOI 10.1016/j.brat.2018.06.005
   Wheaton MG, 2012, COGNITIVE THER RES, V36, P210, DOI 10.1007/s10608-011-9353-3
   Wickham H, 2016, GGPLOT2 CREATE ELEGA
   World Health Organization, 2020, WHO TIM COVID 19
   Yao H, 2020, LANCET PSYCHIAT, V7, pE21, DOI 10.1016/S2215-0366(20)30090-0
NR 37
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD OCT 27
PY 2020
VL 11
AR 572153
DI 10.3389/fpsyg.2020.572153
PG 7
WC Psychology, Multidisciplinary
SC Psychology
GA OO9JF
UT WOS:000587688900001
PM 33192865
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sen Gupta, PS
   Biswal, S
   Panda, SK
   Ray, AK
   Rana, MK
AF Sen Gupta, Parth Sarthi
   Biswal, Satyaranjan
   Panda, Saroj Kumar
   Ray, Abhik Kumar
   Rana, Malay Kumar
TI Binding mechanism and structural insights into the identified protein
   target of COVID-19 and importin-alpha with in-vitro effective drug
   ivermectin
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; molecular target; ivermectin; antiviral drug; molecular
   dynamics
ID REPLICATION; INHIBITOR
AB While an FDA approved drug Ivermectin was reported to dramatically reduce the cell line of SARS-CoV-2 by similar to 5000 folds within 48 h, the precise mechanism of action and the COVID-19 molecular target involved in interaction with this in-vitro effective drug are unknown yet. Among 12 different COVID-19 targets along with Importin-alpha studied here, the RNA dependent RNA polymerase (RdRp) with RNA and Helicase NCB site show the strongest affinity to Ivermectin amounting -10.4 kcal/mol and -9.6 kcal/mol, respectively, followed by Importin-alpha with -9.0 kcal/mol. Molecular dynamics of corresponding protein-drug complexes reveals that the drug bound state of RdRp with RNA has better structural stability than the Helicase NCB site and Importin-alpha, with MM/PBSA free energy of -187.3 kJ/mol, almost twice that of Helicase (-94.6 kJ/mol) and even lower than that of Importin-alpha (-156.7 kJ/mol). The selectivity of Ivermectin to RdRp is triggered by a cooperative interaction of RNA-RdRp by ternary complex formation. Identification of the target and its interaction profile with Ivermectin can lead to more powerful drug designs for COVID-19 and experimental exploration.
C1 [Sen Gupta, Parth Sarthi; Biswal, Satyaranjan; Panda, Saroj Kumar; Ray, Abhik Kumar; Rana, Malay Kumar] IISER, Dept Chem Sci, Berhampur 760010, Odisha, India.
RP Rana, MK (corresponding author), IISER, Dept Chem Sci, Berhampur 760010, Odisha, India.
EM mrana@iiserbpr.ac.in
OI Sen Gupta, Parth Sarthi/0000-0002-3083-3957
FU IISER Berhampur
FX P.S.S.G also sincerely acknowledges IISER Berhampur for providing him
   the Institute Postdoc Fellowship to carry out this work.
CR Atkinson SC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18742-8
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hess U, 1997, J NONVERBAL BEHAV, V21, P241, DOI 10.1023/A:1024952730333
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Khan Y, 2016, ADV FUNCT MATER, V26, P8764, DOI 10.1002/adfm.201603763
   King CR, 2020, J VIROL, V94, DOI [10.1128/JVI.00710-20, 10.1128/JVI.00710-20.]
   Kong Ren, 2020, Bioinformatics, V36, P5109, DOI 10.1093/bioinformatics/btaa645
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147
   Miyamoto Y, 2016, J BIOCHEM, V160, P69, DOI 10.1093/jb/mvw036
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Sen Gupta PS, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/01443615.2020.1789956, 10.1080/07391102.2020.1736158]
   Shechter S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17672-9
   Singh VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1748111
   Trott O., 2010, J COMPUTATIONAL CHEM, V31, pP455
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wagstaff KM, 2011, J BIOMOL SCREEN, V16, P192, DOI 10.1177/1087057110390360
   Wishart D. S., 2018, NUCL ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang SNY, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104760
   Zhang CX, 2020, J PROTEOME RES, V19, P1351, DOI 10.1021/acs.jproteome.0c00129
   Zhu N, 2020, NEW ENGL J MED, V382, P8, DOI DOI https://doi.org/10.1056/NEJMoa2001017
NR 35
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1839564
EA OCT 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA ON8YO
UT WOS:000586979100001
PM 33111618
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Boretti, A
AF Boretti, Alberto
TI Favipiravir use for SARS CoV-2 infection
SO PHARMACOLOGICAL REPORTS
LA English
DT Article
DE SARS CoV-2; Favipiravir; Human trials; Animal studies; Laboratory
   experiments
ID T-705 FAVIPIRAVIR
AB Introduction The pandemic of SARS CoV-2 has required urgent medical treatments for numerous patients. As no specific antiviral agents were available, different off-the-shelf alternatives have been explored. Objective Here, we review the rationale behind the use of Favipiravir, and report of the specific studies supporting this treatment being conducted. Methods Here we analyze the relevant literature to conclude about the present opportunities offered by this therapeutic agent. Results This antiviral drug approved influenza in Japan since 2014, has a demonstrated in vitro activity against SARS CoV-2 and is being investigated in several trials for SARS CoV-2. Signals of benefit were shown in a small trial for SARS CoV-2. However, in another small study, there was no advantage. Conclusions Further studies, statistically more significant, are urgently needed to understand the best opportunities offered by this treatment.
C1 [Boretti, Alberto] Prince Mohammad Bin Fahd Univ, POB 1664, Al Khobar 31952, Saudi Arabia.
RP Boretti, A (corresponding author), Prince Mohammad Bin Fahd Univ, POB 1664, Al Khobar 31952, Saudi Arabia.
EM deanshipofresearch@pmu.edu.sa
RI Boretti, Alberto/S-8109-2019
OI Boretti, Alberto/0000-0002-3374-0238
CR Baranovich T, 2013, J VIROL, V87, P3741, DOI 10.1128/JVI.02346-12
   Bendavid E, 2020, COVID 19 ANTIBODY SE, DOI [10.1101/2020.04.14.20062463v1.full.pdf, DOI 10.1101/2020.04.14.20062463V1]
   Boretti A, 2020, INTEGR J MED SCI, V7, P179, DOI [10.15342/ijms.7.179, DOI 10.15342/IJMS.7.179]
   Boretti A, 2020, INTEGR J MED SCI, V7, P174, DOI [10.15342/ijms.7.174, DOI 10.15342/IJMS.7.174]
   Boretti A., 2020, INT J MED SCI, V7, P172, DOI [10.15342/ijms.7.172, DOI 10.15342/IJMS.7.172]
   Boretti A, 2020, J GLOB ANTIMICROB RE, V22, P845, DOI 10.1016/j.jgar.2020.07.014
   Boretti A, 2020, HEALTH SERV RES MANA, V7, DOI 10.1177/2333392820932324
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Chen C, 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.2003743, DOI 10.1101/2020.03.17.2003743]
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Coomes EA, 2020, J ANTIMICROB CHEMOTH, V75, P2013, DOI 10.1093/jac/dkaa171
   Costanzo M, 2020, CURR MED CHEM, V27, P4536, DOI 10.2174/0929867327666200416131117
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Du YX, 2020, CLIN PHARMACOL THER, V108, P190, DOI 10.1002/cpt.1878
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Eloy P, 2020, CLIN PHARMACOL THER, V108, P188, DOI 10.1002/cpt.1877
   Ferguson N, 2020, IMPACT NONPHARMACEUT, DOI [10.25561/77482, DOI 10.25561/77482]
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Furuta Y, 2009, ANTIVIR RES, V82, P95, DOI 10.1016/j.antiviral.2009.02.198
   Jin ZN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068347
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Pilkington V, 2020, J VIRUS ERAD, V6, P45
   Piller C, 2020, SCIENCE
   Shiraki K, 2020, PHARMACOL THERAPEUT, V209, DOI 10.1016/j.pharmthera.2020.107512
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, J INFECT DIS, V221, P1688, DOI 10.1093/infdis/jiz656
   Yoon JJ, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.00766-18;e00766-18
NR 28
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1734-1140
EI 2299-5684
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD DEC
PY 2020
VL 72
IS 6
SI SI
BP 1542
EP 1552
DI 10.1007/s43440-020-00175-2
EA OCT 2020
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ3OU
UT WOS:000586568300001
PM 33108587
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Faico, KS
   Conte, DD
   Luna, LKD
   Carvalho, JMA
   Perosa, AHS
   Bellei, N
AF Faico-Filho, Klinger Soares
   Conte, Danielle Dias
   de Souza Luna, Luciano Kleber
   Almeida Carvalho, Joseane Mayara
   Sitta Perosa, Ana Helena
   Bellei, Nancy
TI No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in
   non-critical hospitalized patients with COVID-19
SO BRAZILIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article; Early Access
DE Viral load; SARS-CoV-2; Hydroxychloroquine; COVID-19
ID CHLOROQUINE
AB Background Some studies have shown that hydroxychloroquine (HCQ) is an effective drug in reducing the in vitro replication of SARS-CoV-2. However, the in vivo effect of HCQ still unclear. Objectives This study aims to evaluate viral load clearance in patients with COVID-19 who underwent HCQ treatment in comparison with a control group that did not receive the drug. Study design This prospective study comprised consecutive viral load measurements in patients with COVID-19 hospitalized with a moderate illness. Patients received 400 mg of HCQ every 12 h for 10 days according to the medical decision. Nasal swab samples were collected from patients during early, intermediary, and final clinical stage of COVID-19. Results A total of 155 samples were collected from 66 patients with COVID-19 (60% female), with a median age of 58 years. The viral load between studied groups, assumed as a semiquantitative measure of cycle threshold (Ct) values, presented no significant difference within the three consecutive measures (Delta Ct) (p 0.05). We also analyzed the Delta Ct viral load at different intervals of sample collection (Delta t < 7; 7-12; and > 12 days) without significant differences at any Delta Ct (p 0.05). Conclusion In this study, we did not observe any change in viral load reduction in vivo with the use of HCQ.
C1 [Faico-Filho, Klinger Soares; Conte, Danielle Dias; de Souza Luna, Luciano Kleber; Almeida Carvalho, Joseane Mayara; Bellei, Nancy] Univ Fed Sao Paulo, Dept Med, Lab Virol Clin, Discipline Infect Dis, Rua Pedro de Toledo 781, BR-04039032 Sao Paulo, SP, Brazil.
   [Sitta Perosa, Ana Helena] Univ Fed Sao Paulo, Hosp Sao Paulo, Sao Paulo, Brazil.
RP Faico, KS (corresponding author), Univ Fed Sao Paulo, Dept Med, Lab Virol Clin, Discipline Infect Dis, Rua Pedro de Toledo 781, BR-04039032 Sao Paulo, SP, Brazil.
EM klingerfaiko@hotmail.com
RI Faico-Filho, Klinger/ABE-7192-2020; de Souza Luna, Luciano
   Kleber/AAG-6418-2019; de Souza Luna, Luciano Kleber/L-1213-2013
OI Faico-Filho, Klinger/0000-0003-2071-0061; de Souza Luna, Luciano
   Kleber/0000-0002-3552-5507; de Souza Luna, Luciano
   Kleber/0000-0002-3552-5507
CR Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228
   [Anonymous], 2020, 51 WHO
   CDC, 2020, CDC 2019 NOV COR 201
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   TORJESEN I, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2263
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 18
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1517-8382
EI 1678-4405
J9 BRAZ J MICROBIOL
JI Braz. J. Microbiol.
DI 10.1007/s42770-020-00395-x
EA OCT 2020
PG 5
WC Microbiology
SC Microbiology
GA OK5GC
UT WOS:000584677800001
PM 33111169
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yang, RR
   Gui, X
   Zhang, YX
   Xiong, Y
   Gao, SC
   Ke, HN
AF Yang, Rongrong
   Gui, Xien
   Zhang, Yongxi
   Xiong, Yong
   Gao, Shicheng
   Ke, Hengning
TI Clinical characteristics of COVID-19 patients with HIV coinfection in
   Wuhan, China
SO EXPERT REVIEW OF RESPIRATORY MEDICINE
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; AIDS; viral shedding
ID VACCINATION
AB Background
   Information about the impact of HIV coinfection on clinical characteristics of COVID-19 patients remains limited.
   Methods
   Maximum body temperatures, fever duration, chest CT and viral shedding, lymphocyte counts, and titer of SARS-CoV-2 antibody were compared between COVID-19 patients with and without HIV infection in Zhongnan Hospital of Wuhan University from January 20th to February 14th, 2020.
   Results
   Compared with 53 COVID-19 patients without HIV infection, the patients with SARS-CoV-2 and HIV coinfection had higher maximum body temperatures (38.7 degrees C vs 37.6 degrees C, P = 0.044), longer duration of fever (8.7 +/- 4.5 vs 4.2 +/- 2.1 days, P = 0.038), longer time to have improvement of chest CT images (22 vs 15 days from the onset of illness, P = 0.011), lower level of SARS-CoV-2 IgG (5.11 +/- 32.33 vs 37.45 +/- 15.48 AU/ml, P = 0.042). However, no statistically significant difference of duration of SARS-CoV-2 shedding in the two groups was found (12.3 +/- 2.6 vs 13.4 +/- 2.4 days, , P = 0.813).
   Conclusion
   Lower level of CD4(+) T lymphocyte counts caused by HIV infection itself might be one of reasons for relatively weak ability to produce SARS-CoV-2 specific antibodies. The effects of anti-HIV drugs in prevention and treatment of COVID-19 appears to be limited.
C1 [Yang, Rongrong; Gui, Xien; Zhang, Yongxi; Xiong, Yong; Gao, Shicheng; Ke, Hengning] Wuhan Univ, Zhongnan Hosp, Dept Infect Dis, Wuhan 430071, Hubei, Peoples R China.
RP Gao, SC; Ke, HN (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Infect Dis, Wuhan 430071, Hubei, Peoples R China.
EM shichengg@126.com; 15729577635@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81572902]
FX This project was supported by National Natural Science Foundation of
   China (Grant No. 81572902).
CR [Anonymous], 2020, UPD COVI 19 1 SEPT
   Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chaiklang K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080409
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Costenaro P, 2020, REV MED VIROL, DOI 10.1002/rmv.2155
   de Vries-Sluijs TEMS, 2011, J INFECT DIS, V203, P984, DOI 10.1093/infdis/jiq137
   Guo W, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25568
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim UJ, 2016, ANTIVIR THER, V21, P455, DOI 10.3851/IMP3002
   Launay O, 2011, JAMA-J AM MED ASSOC, V305, P1432, DOI 10.1001/jama.2011.351
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lillie PJ, 2020, J INFECTION, V80, P600, DOI 10.1016/j.jinf.2020.02.020
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lyu P, 2019, Zhonghua Liu Xing Bing Xue Za Zhi, V40, P1191, DOI 10.3760/cma.j.issn.0254-6450.2019.10.004
   National Institute for Viral Disease Control and Prevention, 2020, SPEC PRIM PROB DET 2
   Psevdos G, 2010, AIDS PATIENT CARE ST, V24, P403, DOI 10.1089/apc.2009.0340
   Sayad B, 2012, HEPAT MON, V12, DOI 10.5812/hepatmon.6234
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Spina S, 2020, LANCET, V395, pE49, DOI 10.1016/S0140-6736(20)30493-1
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Zhao Juanjuan, 2020, Clin Infect Dis, V71, P2233, DOI 10.1093/cid/ciaa408
   Zhu F, 2020, J MED VIROL, V92, P529, DOI 10.1002/jmv.25732
NR 24
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1747-6348
EI 1747-6356
J9 EXPERT REV RESP MED
JI Expert Rev. Respir. Med.
DI 10.1080/17476348.2021.1836965
EA OCT 2020
PG 7
WC Respiratory System
SC Respiratory System
GA OJ3ZJ
UT WOS:000583903400001
PM 33074039
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Carothers, C
   Birrer, K
   Vo, M
AF Carothers, Chancey
   Birrer, Kara
   Vo, Mai
TI Acetylcysteine for the Treatment of Suspected Remdesivir-Associated
   Acute Liver Failure in COVID-19: A Case Series
SO PHARMACOTHERAPY
LA English
DT Article
DE adverse drug reactions; toxicology; COVID&#8208; 19; Remdesivir; acute
   liver failure; acetylcysteine; coronavirus; SARS&#8208; CoV&#8208; 2
ID N-ACETYLCYSTEINE
AB Remdesivir is a direct-acting nucleoside RNA polymerase inhibitor with activity against the novel severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) virus used in the treatment of coronavirus disease 2019 (COVID-19) pneumonia. Here, we present two cases of suspected remdesivir-associated acute liver failure (ALF) in which the liver failure improved after continuous infusion acetylcysteine and withdrawal of remdesivir. Both patients had significant increases in transaminases between day 3 and day 10 of remdesivir therapy accompanied by coagulopathy and encephalopathy. After initiation of continuous infusion acetylcysteine, the transaminases of both patients rapidly improved. Ultimately, one patient fully recovered while the other died of suspected septic shock. Due to its novel nature and only recent widespread use, there are very little data on the risk of ALF from remdesivir. Additionally, the data for the use of acetylcysteine to manage non-acetaminophen-induced ALF are limited. It is important to consider the risk of remdesivir-associated ALF when weighing the risk versus benefits of use, and acetylcysteine may have a role in its management.
C1 [Carothers, Chancey; Birrer, Kara] Orlando Reg Med Ctr Inc, Dept Pharm, 52 West Underwood St, Orlando, FL 32806 USA.
   [Vo, Mai] Orlando Reg Med Ctr Inc, Dept Crit Care Med, Orlando, FL USA.
RP Carothers, C (corresponding author), Orlando Reg Med Ctr Inc, Dept Pharm, 52 West Underwood St, Orlando, FL 32806 USA.
EM william.carothers@orlandohealth.com
CR Amiodarone, 2020, LEX DRUGS
   [Anonymous], 2012, LIVERTOX CLIN RES IN
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bhimraj A, INFECT DIS SOC AM GU
   Centers for Disease Control and Prevention, CAS US
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   COVID-19 Treatment Guidelines Panel, 2020, COR DIS 2019 COVID 1
   Darweesh SK, 2017, CLIN DRUG INVEST, V37, P473, DOI 10.1007/s40261-017-0505-4
   European Assoc Study Liver, 2017, J HEPATOL, V66, P1047, DOI 10.1016/j.jhep.2016.12.003
   Flamm SL, 2017, GASTROENTEROLOGY, V152, P644, DOI 10.1053/j.gastro.2016.12.026
   Gilead Sciences Inc, FACT SHEET HLTH CAR
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Lee WM, 2009, GASTROENTEROLOGY, V137, P856, DOI 10.1053/j.gastro.2009.06.006
   Lee WM, 2011, HEPATOLOGY
   Leegwater E, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa883/5864408, DOI 10.1093/CID/CIAA883/5864408]
   Mumtaz K, 2009, HEPATOL INT, V3, P563, DOI 10.1007/s12072-009-9151-0
   Nabi T, 2017, SAUDI J GASTROENTERO, V23, P169, DOI 10.4103/1319-3767.207711
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Remdesivir, 2020, LEX DRUGS
   Sales I, 2013, ANN HEPATOL, V12, P6, DOI 10.1016/S1665-2681(19)31379-1
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xu L, 2020, LIVER INT, V40, P998, DOI 10.1111/liv.14435
NR 23
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
EI 1875-9114
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD NOV
PY 2020
VL 40
IS 11
BP 1166
EP 1171
DI 10.1002/phar.2464
EA OCT 2020
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OT2ER
UT WOS:000583726200001
PM 33006138
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Fitzpatrick, O
   Carson, A
   Weisz, JR
AF Fitzpatrick, Olivia
   Carson, Amani
   Weisz, John R.
TI Using Mixed Methods to Identify the Primary Mental Health Problems and
   Needs of Children, Adolescents, and Their Caregivers during the
   Coronavirus (COVID-19) Pandemic
SO CHILD PSYCHIATRY & HUMAN DEVELOPMENT
LA English
DT Article; Early Access
DE Coronavirus disease 2019; Children; Adolescents; Families; Mental health
   intervention
ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; TRIPLE P
   ONLINE; PARTICIPATORY RESEARCH; DISRUPTIVE BEHAVIOR; DATA SATURATION;
   ANXIETY; INTERVENTION; COMMUNITY; PARENTS
AB Our understanding of child, adolescent, and caregiver mental health (MH) problems during the coronavirus pandemic, and which interventions are needed, may be advanced by consumer input. 133 general population caregivers reported top MH problems and needs for themselves and their children (M-age = 8.21; SD = 4.94), using standardized and idiographic measures. We applied linear regression models to quantitative data and thematic analysis to qualitative data. Caregivers' COVID-era depression and anxiety symptom means fell within the clinical range, as did their children's MH symptoms. Caregiver-reported child and adolescent symptoms were positively associated with number of children in the home. Caregiver and caregiver-reported child and adolescent symptoms were more pronounced in regions with more lenient COVID-19 restrictions. Among the kinds of help most urgently needed, MH services were ranked #1 for caregivers and adolescents, #2 for 6-12 year-olds, and #3 for 1-5 year-olds. Top problems identified for each age group highlight pressing pandemic-related intervention targets.
C1 [Fitzpatrick, Olivia; Weisz, John R.] Harvard Univ, Dept Psychol, 33 Kirkland St 1036, Cambridge, MA 02138 USA.
   [Carson, Amani] Harvard Med Sch, Cambridge, MA USA.
RP Fitzpatrick, O (corresponding author), Harvard Univ, Dept Psychol, 33 Kirkland St 1036, Cambridge, MA 02138 USA.
EM ofitzpatrick@g.harvard.edu
OI Fitzpatrick, Olivia/0000-0001-8868-6702
FU Harvard University
FX This study was supported by funding to John Weisz from Harvard
   University Seed Funds.
CR Ackerson J, 1998, J CONSULT CLIN PSYCH, V66, P685, DOI 10.1037/0022-006X.66.4.685
   Ali MM, 2019, J SCHOOL HEALTH, V89, P393, DOI 10.1111/josh.12753
   [Anonymous], IBM SPSS STAT WIND V
   Arnold T, 2020, COUNS PSYCHOL Q, DOI 10.1080/09515070.2020.1769026
   Athay MM, 2012, ADM POLICY MENT HLTH, V39, P30, DOI 10.1007/s10488-011-0385-5
   Baguley T, 2009, BRIT J PSYCHOL, V100, P603, DOI 10.1348/000712608X377117
   Baker S, 2017, BEHAV RES THER, V91, P78, DOI 10.1016/j.brat.2017.01.016
   Bigorra A, 2016, EUR CHILD ADOLES PSY, V25, P853, DOI 10.1007/s00787-015-0804-3
   Bikic A, 2017, NORD J PSYCHIAT, V71, P455, DOI 10.1080/08039488.2017.1328070
   Boden JM, 2008, J CHILD PSYCHOL PSYC, V49, P151, DOI 10.1111/j.1469-7610.2007.01830.x
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]
   Caldwell LL, 2004, J LEISURE RES, V36, P310
   Cassano M, 2006, J CLIN CHILD ADOLESC, V35, P583, DOI 10.1207/s15374424jccp3504_10
   Cernvall M, 2016, J CLIN PSYCHOL MED S, V23, P67, DOI 10.1007/s10880-015-9437-4
   Day JJ, 2018, BEHAV THER, V49, P1020, DOI 10.1016/j.beth.2018.03.002
   de Bruin EJ, 2015, SLEEP, V38, P1913, DOI 10.5665/sleep.5240
   Dijkstra-Kersten SMA, 2015, J EPIDEMIOL COMMUN H, V69, P660, DOI 10.1136/jech-2014-205088
   Ehrensaft MK, 2016, J PRIM PREV, V37, P527, DOI 10.1007/s10935-016-0448-1
   Enebrink P, 2012, BEHAV RES THER, V50, P240, DOI 10.1016/j.brat.2012.01.006
   Francis JJ, 2010, PSYCHOL HEALTH, V25, P1229, DOI 10.1080/08870440903194015
   Garcia C, 2012, HEALTH PROMOT PRACT, V13, P755, DOI 10.1177/1524839911404224
   Gerrits R, 2007, AUSTR E J ADV MENTAL, V6, P1446
   Ginossar T, 2010, J COMPUT-MEDIAT COMM, V15, P530, DOI 10.1111/j.1083-6101.2009.01513.x
   Gruber June, 2020, Am Psychol, DOI 10.1037/amp0000707
   Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903
   Hawke LD, 2020, CAN J PSYCHIAT, V65, P701, DOI 10.1177/0706743720940562
   HOLM S, 1979, SCAND J STAT, V6, P65
   Hughes J, 2016, PSI CHI J PSYCHOL RE, DOI [10.24839/b21.3.138, DOI 10.24839/B21.3.138]
   Israel B A, 2001, Educ Health (Abingdon), V14, P182
   Johnson AD, 2019, ACAD PEDIATR, V19, P18, DOI 10.1016/j.acap.2018.05.006
   Jones RB, 2018, JMIR MENT HEALTH, V5, DOI 10.2196/mental.8894
   Kauer SD, 2012, J MED INTERNET RES, V14, P15, DOI 10.2196/jmir.1858
   King CA, 2018, J COMMUNITY PSYCHOL, V46, P885, DOI 10.1002/jcop.21979
   Kroenke K, 2009, J AFFECT DISORDERS, V114, P163, DOI 10.1016/j.jad.2008.06.026
   Larsen TB, 2019, SCAND J EDUC RES, DOI 10.1080/00313831.2019.1659405
   Liang LL, 2020, PSYCHIAT QUART, V91, P841, DOI 10.1007/s11126-020-09744-3
   Lichtveld M, 2016, ENVIRON HEALTH-GLOB, V15, DOI 10.1186/s12940-016-0201-5
   Lim MH, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00604
   Loades ME, 2020, J AM ACAD CHILD PSY, V59, P1218, DOI 10.1016/j.jaac.2020.05.009
   Mance Gishawn A, 2010, Prog Community Health Partnersh, V4, P131, DOI 10.1353/cpr.0.0112
   March S, 2009, J PEDIATR PSYCHOL, V34, P474, DOI 10.1093/jpepsy/jsn099
   McGrath PJ, 2011, J AM ACAD CHILD PSY, V50, P1162, DOI 10.1016/j.jaac.2011.07.013
   McLaughlin KA, 2012, ARCH GEN PSYCHIAT, V69, P1151, DOI 10.1001/archgenpsychiatry.2011.2277
   Moreno C, 2020, LANCET PSYCHIAT, V7, P813, DOI 10.1016/S2215-0366(20)30307-2
   Morris J, 2016, ANXIETY STRESS COPIN, V29, P415, DOI 10.1080/10615806.2015.1058924
   Morse JM, 2015, QUAL HEALTH RES, V25, P587, DOI 10.1177/1049732315576699
   Motamedi M, 2016, PREV SCI, V17, P700, DOI 10.1007/s11121-016-0654-3
   Panchal N, 2020, IMPLICATIONS COVID 1
   Patrick SW, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-016824
   Rapee RM, 2006, J CONSULT CLIN PSYCH, V74, P436, DOI 10.1037/0022-006X.74.3.436
   Rhodes SD, 2010, AIDS EDUC PREV, V22, P173, DOI 10.1521/aeap.2010.22.3.173
   Sareen J, 2011, ARCH GEN PSYCHIAT, V68, P419, DOI 10.1001/archgenpsychiatry.2011.15
   Sourander A, 2016, JAMA PSYCHIAT, V73, P378, DOI 10.1001/jamapsychiatry.2015.3411
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   STANGER C, 1993, J CLIN CHILD PSYCHOL, V22, P107, DOI 10.1207/s15374424jccp2201_11
   Topooco N, 2019, J MED INTERNET RES, V21, DOI 10.2196/13393
   Van Vliet H, 2009, AUST NZ J PSYCHIAT, V43, P305, DOI 10.1080/00048670902721145
   Van Voorhees BW, 2009, J DEV BEHAV PEDIATR, V30, P23, DOI 10.1097/DBP.0b013e3181966c2a
   Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445
   Webster P, 2020, LANCET, V395, P1180, DOI 10.1016/S0140-6736(20)30818-7
   Weisz John R, 2020, J Clin Child Adolesc Psychol, V49, P737, DOI 10.1080/15374416.2018.1547973
   Weisz JR, 2011, J CONSULT CLIN PSYCH, V79, P369, DOI 10.1037/a0023307
   Werner-Seidler A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026502
   WHO, 2020, COR DIS COVID 19 PAN
   Wiersma JE, 2011, J CLIN PSYCHIAT, V72, P288, DOI 10.4088/JCP.09m05735blu
   YOGMAN M, 2018, PEDIATRICS, V142, P1
NR 66
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0009-398X
EI 1573-3327
J9 CHILD PSYCHIAT HUM D
JI Child Psychiat. Hum. Dev.
DI 10.1007/s10578-020-01089-z
EA OCT 2020
PG 12
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA OK4FM
UT WOS:000584608400001
PM 33108612
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hoiland, RL
   Fergusson, NA
   Mitra, AR
   Griesdale, DEG
   Devine, DV
   Stukas, S
   Cooper, J
   Thiara, S
   Foster, D
   Chen, LYC
   Lee, AYY
   Conway, EM
   Wellington, CL
   Sekhon, MS
AF Hoiland, Ryan L.
   Fergusson, Nicholas A.
   Mitra, Anish R.
   Griesdale, Donald E. G.
   Devine, Dana, V
   Stukas, Sophie
   Cooper, Jennifer
   Thiara, Sonny
   Foster, Denise
   Chen, Luke Y. C.
   Lee, Agnes Y. Y.
   Conway, Edward M.
   Wellington, Cheryl L.
   Sekhon, Mypinder S.
TI The association of ABO blood group with indices of disease severity and
   multiorgan dysfunction in COVID-19
SO BLOOD ADVANCES
LA English
DT Article
ID CORONAVIRUS; PNEUMONIA; PROTEIN
AB Studies on severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) suggest a protective effect of anti-A antibodies against viral cell entry that may hold relevance for SARS-CoV-2 infection. Therefore, we aimed to determine whether ABO blood groups are associated with different severities of COVID-19. We conducted a multicenter retrospective analysis and nested prospective observational substudy of critically ill patients with COVID-19. We collected data pertaining to age, sex, comorbidities, dates of symptom onset, hospital admission, intensive care unit (ICU) admission, mechanical ventilation, continuous renal replacement therapy (CRRT), standard laboratory parameters, and serum inflammatory cytokines. National (N = 398 671; P = .38) and provincial (n = 62 246; P = .60) ABO blood group distributions did not differ from our cohort (n = 95). A higher proportion of COVID-19 patients with blood group A or AB required mechanical ventilation (P = .02) and CRRT (P = .004) and had a longer ICU stay (P = .03) compared with patients with blood group O or B. Blood group A or AB also had an increased probability of requiring mechanical ventilation and CRRT after adjusting for age, sex, and presence of >= 1 comorbidity. Inflammatory cytokines did not differ between patients with blood group A or AB (n = 11) vs O or B (n = 14; P > .10 for all cytokines). Collectively, our data indicate that critically ill COVID-19 patients with blood group A or AB are at increased risk for requiring mechanical ventilation, CRRT, and prolonged ICU admission compared with patients with blood group O or B. Further work is needed to understand the underlying mechanisms.
C1 [Hoiland, Ryan L.; Griesdale, Donald E. G.] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC, Canada.
   [Hoiland, Ryan L.] Univ British Columbia Okanagan, Ctr Heart, Sch Hlth & Exercise Sci, Kelowna, BC, Canada.
   [Fergusson, Nicholas A.] Univ British Columbia, MD Undergrad Program, Vancouver, BC, Canada.
   [Fergusson, Nicholas A.; Griesdale, Donald E. G.] Vancouver Coastal Hlth, Med Qual & Safety, Vancouver, BC, Canada.
   [Mitra, Anish R.; Griesdale, Donald E. G.; Thiara, Sonny; Foster, Denise; Sekhon, Mypinder S.] Univ British Columbia, Dept Med, Div Crit Care Med, Vancouver, BC, Canada.
   [Griesdale, Donald E. G.] Vancouver Coastal Hlth Res Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC, Canada.
   [Devine, Dana, V; Stukas, Sophie; Cooper, Jennifer; Wellington, Cheryl L.] Univ British Columbia, Fac Med, Dept Pathol & Lab Med, Vancouver, BC, Canada.
   [Devine, Dana, V] Canadian Blood Serv, Ottawa, ON, Canada.
   [Devine, Dana, V; Conway, Edward M.] Univ British Columbia, Life Sci Inst, Ctr Blood Res, Vancouver, BC, Canada.
   [Chen, Luke Y. C.; Lee, Agnes Y. Y.; Conway, Edward M.] Univ British Columbia, Div Hematol, Dept Med, Vancouver, BC, Canada.
   [Wellington, Cheryl L.] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC, Canada.
   [Wellington, Cheryl L.] Univ British Columbia, Sch Biomed Engn, Vancouver, BC, Canada.
   [Wellington, Cheryl L.] Univ British Columbia, Int Collaborat Repair Discoveries ICORD, Vancouver, BC, Canada.
RP Sekhon, MS (corresponding author), Univ British Columbia, Fac Med, Dept Med, Div Crit Care Med, Room 2438,Jim Pattison Pavil,2nd Floor, Vancouver, BC V5Z 1M9, Canada.
EM dersekhon@gmail.com
RI Chen, Luke Yu Chung/I-6027-2019
OI Chen, Luke Yu Chung/0000-0002-9551-2951; Hoiland,
   Ryan/0000-0002-5657-0059; Griesdale, Donald/0000-0001-5985-8624
FU Vancouver General Hospital Foundation; Vancouver Coastal Health Research
   Institute Clinician Scientist Award; Michael Smith Foundation for Health
   Research Health Professional Investigator AwardMichael Smith Foundation
   for Health Research; Burroughs Wellcome Fund Innovation in Regulatory
   Science Award; Canada Research ChairNatural Resources CanadaCanadian
   Forest ServiceCanada Research Chairs; Canadian Institutes for Health
   ResearchCanadian Institutes of Health Research (CIHR); Heart and Stroke
   Foundation of CanadaHeart & Stroke Foundation of Canada; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; Weston Brain
   Institute; Cure Alzheimer Fund
FX This work was supported by the Vancouver General Hospital Foundation.
   M.S.S. is supported by the Vancouver Coastal Health Research Institute
   Clinician Scientist Award. D.E.G.G. is supported by a Michael Smith
   Foundation for Health Research Health Professional Investigator Award.
   D.V.D. is supported by a Burroughs Wellcome Fund Innovation in
   Regulatory Science Award. E.M.C. is supported by a Canada Research Chair
   and grants from the Canadian Institutes for Health Research and the
   Heart and Stroke Foundation of Canada. C.L.W. is supported by grants
   from the Canadian Institutes for Health Research, National Institutes of
   Health, Weston Brain Institute, and Cure Alzheimer Fund.
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheng YF, 2005, JAMA-J AM MED ASSOC, V293, P1450, DOI 10.1001/jama.293.12.1450-c
   Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
   Focosi D, 2020, BRIT J HAEMATOL, DOI 10.1111/bjh.16932
   Franchini Massimo, 2007, Thromb J, V5, P14
   Gerard C, 2020, BRIT J HAEMATOL, V190, pE93, DOI 10.1111/bjh.16884
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Guillon P, 2008, GLYCOBIOLOGY, V18, P1085, DOI 10.1093/glycob/cwn093
   Hoiland RL, 2020, BRIT J HAEMATOL, V190, pE150, DOI 10.1111/bjh.16961
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Latz CA, 2020, ANN HEMATOL, V99, P2113, DOI 10.1007/s00277-020-04169-1
   Li JY, 2020, BRIT J HAEMATOL, V190, P24, DOI 10.1111/bjh.16797
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Mitra AR, 2020, CAN MED ASSOC J, V192, pE694, DOI 10.1503/cmaj.200794
   Murray GP, 2020, J CLIN PATHOL, V73, P347, DOI 10.1136/jclinpath-2019-206182
   O'Donnell J, 2001, TRANSFUSION MED, V11, P343, DOI 10.1046/j.1365-3148.2001.00315.x
   Pan Daniel, 2020, EClinicalMedicine, V23, P100404, DOI 10.1016/j.eclinm.2020.100404
   Portelli B, 2020, FACT EXTRACTION AND VERIFICATION (FEVER), P47
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Randhawa AK, 2020, JAMA-J AM MED ASSOC, V323, P2334, DOI 10.1001/jama.2020.8097
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Stukas S, CRIT CARE EXPLOR
   Treibel TA, 2020, LANCET, V395, P1608, DOI 10.1016/S0140-6736(20)31100-4
   WHO, 2020, COR DIS COVID 19 SIT
   WHO, 2020, LAB TEST COR DIS COV
   Wilson DH, 2016, JALA-J LAB AUTOM, V21, P533, DOI 10.1177/2211068215589580
   Zhong M, 2015, ARTERIOSCL THROM VAS, V35, P1570, DOI 10.1161/ATVBAHA.115.305337
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zietz M, 2020, TESTING ASS BLOOD TY
NR 38
TC 1
Z9 1
U1 4
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 2473-9529
EI 2473-9537
J9 BLOOD ADV
JI Blood Adv.
PD OCT 27
PY 2020
VL 4
IS 20
BP 4981
EP 4989
DI 10.1182/bloodadvances.2020002623
PG 9
WC Hematology
SC Hematology
GA OH7TK
UT WOS:000582796200001
PM 33057633
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Osman, M
   Faridi, RM
   Sligl, W
   Shabani-Rad, MT
   Dharmani-Khan, P
   Parker, A
   Kalra, A
   Tripathi, MB
   Storek, J
   Tervaert, JWC
   Khan, FM
AF Osman, Mohammed
   Faridi, Rehan M.
   Sligl, Wendy
   Shabani-Rad, Meer-Taher
   Dharmani-Khan, Poonam
   Parker, Arabesque
   Kalra, Amit
   Tripathi, Minal Borkar
   Storek, Jan
   Tervaert, Jan Willem Cohen
   Khan, Faisal M.
TI Impaired natural killer cell counts and cytolytic activity in patients
   with severe COVID-19
SO BLOOD ADVANCES
LA English
DT Article
ID HSCORE
AB The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-driven coronavirus disease 2019 (COVID-19) has caused unprecedented human death and has seriously threatened the global economy. Early data suggest a surge in proinflammatory cytokines in patients with severe COVID-19, which has been associated with poor outcomes. We recently postulated that the inflammatory response in patients with severe COVID-19 disease is not inhibited by natural killer (NK) cells, resulting in a "cytokine storm." Here, we assessed the NK-cell functional activity and the associated cytokines and soluble mediators in hospitalized COVID-19 patients. Significantly impaired NK-cell counts and cytolytic activity were observed in COVID-19 patients when compared with healthy controls. Also, cytokines like interleukin 12 (IL12), IL15, and IL21 that are important for NK-cell activity were not detected systematically. Serum concentrations of soluble CD25 (sCD25)/soluble IL2 receptor alpha (sIL2-R alpha) were significantly elevated and were inversely correlated with the percentage of NK cells. Impaired NK-cell cytolytic activity together with other laboratory trends including elevated sCD25 were consistent with a hyperinflammatory state in keeping with macrophage-activation syndrome. Our findings suggest that impaired counts and cytolytic activity of NK cells are important characteristics of severe COVID-19 and can potentially facilitate strategies for immunomodulatory therapies.
C1 [Osman, Mohammed; Sligl, Wendy; Parker, Arabesque; Tervaert, Jan Willem Cohen] Univ Alberta, Dept Med, Edmonton, AB, Canada.
   [Faridi, Rehan M.; Shabani-Rad, Meer-Taher; Dharmani-Khan, Poonam; Kalra, Amit; Tripathi, Minal Borkar; Khan, Faisal M.] Univ Calgary, Dept Pathol & Lab Med, HMRB 320 Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
   [Faridi, Rehan M.; Shabani-Rad, Meer-Taher; Dharmani-Khan, Poonam; Khan, Faisal M.] Alberta Precis Labs, Calgary, AB, Canada.
   [Storek, Jan] Univ Calgary, Dept Med, Calgary, AB, Canada.
RP Khan, FM (corresponding author), Univ Calgary, Dept Pathol & Lab Med, HMRB 320 Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
EM fkhan@ucalgary.ca
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cifaldi L, 2015, ARTHRITIS RHEUMATOL, V67, P3037, DOI 10.1002/art.39295
   Corbett Kizzmekia S, 2020, Nature, V586, P567, DOI 10.1038/s41586-020-2622-0
   Daien CI, 2015, RHEUMATOLOGY, V54, P601, DOI 10.1093/rheumatology/keu363
   de Jager W, 2009, ARTHRITIS RHEUM-US, V60, P2782, DOI 10.1002/art.24750
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Foley B, 2011, BLOOD, V118, P2784, DOI 10.1182/blood-2011-04-347070
   Gao Z, 2019, CLIN IMMUNOL, V202, P18, DOI 10.1016/j.clim.2019.03.006
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grzybowski B, 2017, J PEDIATR NEUROSCI, V12, P55, DOI 10.4103/jpn.JPN_140_16
   Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lee J, 2009, BIOCHEM BIOPH RES CO, V386, P718, DOI 10.1016/j.bbrc.2009.06.120
   Leverenz DL, 2020, LANCET, V395, pE83, DOI 10.1016/S0140-6736(20)31057-6
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mao HW, 2010, J VIROL, V84, P4148, DOI 10.1128/JVI.02340-09
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Osman MS, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102561
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Plotkin SA, 2020, J INFECT DIS, V221, P113, DOI 10.1093/infdis/jiz447
   Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Villanueva J, 2005, ARTHRITIS RES THER, V7, pR30, DOI 10.1186/ar1453
   Wang W, DEFINITION RISKS CYT, DOI DOI 10.1101/2020.02.26.20026989V1
   Wilk AJ, 2020, NAT MED, V26, P1070, DOI 10.1038/s41591-020-0944-y
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   World Health Organization, COR DIS COVID 2019 S
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 33
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 2473-9529
EI 2473-9537
J9 BLOOD ADV
JI Blood Adv.
PD OCT 27
PY 2020
VL 4
IS 20
BP 5035
EP 5039
DI 10.1182/bloodadvances.2020002650
PG 5
WC Hematology
SC Hematology
GA OH7TK
UT WOS:000582796200007
PM 33075136
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Jensen, JD
   Stikeleather, RA
   Kowalik, TF
   Lynch, M
AF Jensen, Jeffrey D.
   Stikeleather, Ryan A.
   Kowalik, Timothy F.
   Lynch, Michael
TI Imposed mutational meltdown as an antiviral strategy
SO EVOLUTION
LA English
DT Article
DE Antivirals; lethal mutagenesis; mutational meltdown; population
   genetics; SARS&#8208; CoV&#8208; 2
ID SKEWED OFFSPRING DISTRIBUTIONS; LETHAL MUTAGENESIS; ERROR CATASTROPHE;
   RNA-POLYMERASE; OSELTAMIVIR RESISTANCE; BACKGROUND SELECTION; FIDELITY
   VARIANTS; MULLERS RATCHET; VIRUS; CORONAVIRUS
AB Following widespread infections of the most recent coronavirus known to infect humans, SARS-CoV-2, attention has turned to potential therapeutic options. With no drug or vaccine yet approved, one focal point of research is to evaluate the potential value of repurposing existing antiviral treatments, with the logical strategy being to identify at least a short-term intervention to prevent within-patient progression, while long-term vaccine strategies unfold. Here, we offer an evolutionary/population-genetic perspective on one approach that may overwhelm the capacity for pathogen defense (i.e., adaptation) - induced mutational meltdown - providing an overview of key concepts, review of previous theoretical and experimental work of relevance, and guidance for future research. Applied with appropriate care, including target specificity, induced mutational meltdown may provide a general, rapidly implemented approach for the within-patient eradication of a wide range of pathogens or other undesirable microorganisms.
C1 [Jensen, Jeffrey D.; Lynch, Michael] Arizona State Univ, Sch Life Sci, Tempe, AZ 85281 USA.
   [Jensen, Jeffrey D.] Arizona State Univ, Ctr Evolut & Med, Tempe, AZ 85281 USA.
   [Stikeleather, Ryan A.; Lynch, Michael] Arizona State Univ, Biodesign Ctr Mech Evolut, Tempe, AZ 85281 USA.
   [Kowalik, Timothy F.] Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA 01655 USA.
RP Jensen, JD (corresponding author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85281 USA.; Jensen, JD (corresponding author), Arizona State Univ, Ctr Evolut & Med, Tempe, AZ 85281 USA.
EM jeffrey.d.jensen@asu.edu; mlynch11@asu.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01-GM135899,
   R35-GM122566-01, P01AI129859]; US Department of Army MURI award
   [W911NF-14-1-0411]; US Department of DefenseUnited States Department of
   Defense [W81XWH-15-1-0317]
FX The authors thank Matt Dean, Jim Bull, and an anonymous reviewer for
   helpful comments and suggestions that improved the manuscript. This work
   was funded by National Institutes of Health grant R01-GM135899 to
   J.D.J., National Institutes of Health grant R35-GM122566-01 and US
   Department of Army MURI award W911NF-14-1-0411 to M.L., and subawards
   from the US Department of Defense award W81XWH-15-1-0317 and National
   Institutes of Health grant P01AI129859 to T.F.K.
CR Abdelnabi R, 2017, J VIROL, V91, DOI 10.1128/JVI.00487-17
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Airaksinen A, 2003, VIROLOGY, V311, P339, DOI 10.1016/S0042-6822(03)00144-2
   Anderson JP, 2004, ANNU REV MICROBIOL, V58, P183, DOI 10.1146/annurev.micro.58.030603.123649
   Arias A, 2014, ELIFE, V3, DOI 10.7554/eLife.03679
   Bachtrog D, 2004, EVOLUTION, V58, P1403
   Bank C, 2016, EVOLUTION, V70, P2470, DOI 10.1111/evo.13041
   Bank C, 2014, TRENDS GENET, V30, P540, DOI 10.1016/j.tig.2014.09.010
   Bank C, 2014, GENETICS, V196, P841, DOI 10.1534/genetics.113.156190
   Baranovich T, 2013, J VIROL, V87, P3741, DOI 10.1128/JVI.02346-12
   BARTON NH, 1995, GENETICS, V140, P821
   Beigel J. H., 2020, N ENGL J MED
   Bloom JD, 2010, SCIENCE, V328, P1272, DOI 10.1126/science.1187816
   Bull JJ, 2007, J VIROL, V81, P2930, DOI 10.1128/JVI.01624-06
   BURGER R, 1989, GENETICS, V121, P175
   Charlesworth B, 2013, J HERED, V104, P161, DOI 10.1093/jhered/ess136
   Coffey LL, 2011, P NATL ACAD SCI USA, V108, P16038, DOI 10.1073/pnas.1111650108
   Collins PJ, 2008, NATURE, V453, P1258, DOI 10.1038/nature06956
   Crotty S, 2000, NAT MED, V6, P1375
   Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598
   Crow James F., 1993, Oxford Surveys in Evolutionary Biology, V9, P3
   D'Abramo CM, 2004, J MOL BIOL, V337, P1, DOI 10.1016/j.jmb.2004.01.030
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Drake JW, 1999, P NATL ACAD SCI USA, V96, P13910, DOI 10.1073/pnas.96.24.13910
   Eckerle LD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000896
   EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322
   Elena SF, 2005, J VIROL, V79, P11555, DOI 10.1128/JVI.79.18.11555-11558.2005
   Eyre-Walker A, 2007, NAT REV GENET, V8, P610, DOI 10.1038/nrg2146
   Fabreti LG, 2019, B MATH BIOL, V81, P1031, DOI 10.1007/s11538-018-00550-4
   FELSENSTEIN J, 1974, GENETICS, V78, P737
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Fitzsimmons WJ, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006459
   Foll M, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004185
   Frank SA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001021
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   GABRIEL W, 1993, EVOLUTION, V47, P1744, DOI 10.1111/j.1558-5646.1993.tb01266.x
   Gago S, 2009, SCIENCE, V323, P1308, DOI 10.1126/science.1169202
   Goldhill DH, 2018, P NATL ACAD SCI USA, V115, P11613, DOI 10.1073/pnas.1811345115
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Gordo I, 2000, GENETICS, V156, P2137
   Goyal S, 2012, GENETICS, V191, P1309, DOI 10.1534/genetics.112.141291
   Graepel KW, 2019, J VIROL, V93, DOI 10.1128/JVI.00711-19
   Graepel KW, 2017, MBIO, V8, DOI 10.1128/mBio.01503-17
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   HAIGH J, 1978, THEOR POPUL BIOL, V14, P251, DOI 10.1016/0040-5809(78)90027-8
   Haldane JBS, 1937, AM NAT, V71, P337, DOI 10.1086/280722
   Haldane JBS, 1927, P CAMB PHILOS SOC, V23, P838, DOI 10.1017/S0305004100015644
   Herman R, 2020, POLAR BIOL, V43, P1947, DOI 10.1007/s00300-020-02759-3
   HILL WG, 1966, GENET RES, V8, P269, DOI 10.1017/S0016672300010156
   HUANG AS, 1973, ANNU REV MICROBIOL, V27, P101, DOI 10.1146/annurev.mi.27.100173.000533
   Hughes AL, 2009, VIROLOGY, V393, P127, DOI 10.1016/j.virol.2009.07.016
   Irwin KK, 2016, HEREDITY, V117, P393, DOI 10.1038/hdy.2016.58
   Ives JAL, 2002, ANTIVIR RES, V55, P307, DOI 10.1016/S0166-3542(02)00053-0
   Jensen JD, 2020, HEREDITY, V124, P619, DOI 10.1038/s41437-020-0314-z
   Johri P, 2020, GENETICS, V215, P173, DOI 10.1534/genetics.119.303002
   KIMURA M, 1967, GENET RES, V9, P23, DOI 10.1017/S0016672300010284
   KIMURA M, 1964, GENETICS, V49, P725
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lanford RE, 2001, J VIROL, V75, P8074, DOI 10.1128/JVI.75.17.8074-8081.2001
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Loeb LA, 1999, P NATL ACAD SCI USA, V96, P1492, DOI 10.1073/pnas.96.4.1492
   Lumby C. K., 2020, CLIN INFECT DIS
   Lynch M, 1999, EVOLUTION, V53, P645, DOI 10.1111/j.1558-5646.1999.tb05361.x
   LYNCH M, 1993, J HERED, V84, P339, DOI 10.1093/oxfordjournals.jhered.a111354
   Lynch M, 1995, EVOLUTION, V49, P1067, DOI 10.2307/2410432
   LYNCH M, 1990, EVOLUTION, V44, P1725, DOI [10.2307/2409502, 10.1111/j.1558-5646.1990.tb05244.x]
   Lynch M, 2008, GENETICS, V180, P933, DOI 10.1534/genetics.108.090456
   Lynch M, 2016, NAT REV GENET, V17, P704, DOI 10.1038/nrg.2016.104
   Lynch M, 2012, P NATL ACAD SCI USA, V109, P18851, DOI 10.1073/pnas.1216130109
   Lynch M, 2011, GENOME BIOL EVOL, V3, P1107, DOI 10.1093/gbe/evr066
   Lynch M, 2010, P NATL ACAD SCI USA, V107, P16577, DOI 10.1073/pnas.1010836107
   Matuszewski S, 2018, GENETICS, V208, P323, DOI 10.1534/genetics.117.300499
   Matuszewski S, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex004
   McVean GAT, 2000, GENETICS, V155, P929
   Meng T, 2014, J VIROL, V88, P5803, DOI 10.1128/JVI.00289-14
   Mitchison Denis A, 2012, Handb Exp Pharmacol, P87, DOI 10.1007/978-3-642-28951-4_6
   Miyashita S, 2010, J VIROL, V84, P1828, DOI 10.1128/JVI.01890-09
   Moscona A, 2005, NEW ENGL J MED, V353, P2633, DOI 10.1056/NEJMp058291
   Moscona A, 2009, NEW ENGL J MED, V360, P953, DOI 10.1056/NEJMp0900648
   MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8
   Nagata T., 2014, DIS MED PUB HLTH PRE, V9, P79
   Neher RA, 2013, ANNU REV ECOL EVOL S, V44, P195, DOI 10.1146/annurev-ecolsys-110512-135920
   Nowak M, 2000, VIRUS DYNAMICS MATH
   Ormond L, 2017, GENOME BIOL EVOL, V9, P1913, DOI 10.1093/gbe/evx138
   Penisson S, 2017, GENETICS, V205, P1305, DOI 10.1534/genetics.116.194597
   Persi E, 2018, P NATL ACAD SCI USA, V115, pE11101, DOI 10.1073/pnas.1807256115
   Pfeiffer JK, 2003, P NATL ACAD SCI USA, V100, P7289, DOI 10.1073/pnas.1232294100
   Poirier EZ, 2016, J VIROL, V90, P2446, DOI 10.1128/JVI.02921-15
   Poon A, 2000, EVOLUTION, V54, P1467, DOI 10.1111/j.0014-3820.2000.tb00693.x
   Renzette N, 2014, J VIROL, V88, P272, DOI 10.1128/JVI.01067-13
   Renzette N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003735
   Sackman AM, 2019, GENETICS, V211, P1019, DOI 10.1534/genetics.118.301684
   Sadeghipour S, 2013, VIRUS RES, V176, P265, DOI 10.1016/j.virusres.2013.06.019
   Sanjuan R, 2010, J VIROL, V84, P9733, DOI 10.1128/JVI.00694-10
   Santiago E, 2020, HEREDITY, V125, P169, DOI 10.1038/s41437-020-0337-5
   Sevajol M, 2014, VIRUS RES, V194, P90, DOI 10.1016/j.virusres.2014.10.008
   Severson WE, 2003, J VIROL, V77, P481, DOI 10.1128/JVI.77.1.481-488.2003
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Smee DF, 2013, FUTURE VIROL, V8, P1085, DOI 10.2217/fvl.13.98
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   STEPHAN W, 1993, GENET RES, V61, P225, DOI 10.1017/S0016672300031384
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   VONMAGNUS P, 1954, ADV VIRUS RES, V2, P59, DOI 10.1016/S0065-3527(08)60529-1
   WAGNER GP, 1990, EVOLUTION, V44, P715, DOI 10.1111/j.1558-5646.1990.tb05950.x
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weissman DB, 2010, GENETICS, V186, P1389, DOI 10.1534/genetics.110.123240
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wylie CS, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002609
   Zeyl C, 2001, EVOLUTION, V55, P909, DOI 10.1554/0014-3820(2001)055[0909:MMILYP]2.0.CO;2
   Zhang YZ, 2019, MOL BIOL EVOL, V36, P541, DOI 10.1093/molbev/msy231
   Zhao ZM, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-21
NR 114
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-3820
EI 1558-5646
J9 EVOLUTION
JI Evolution
PD DEC
PY 2020
VL 74
IS 12
BP 2549
EP 2559
DI 10.1111/evo.14107
EA OCT 2020
PG 11
WC Ecology; Evolutionary Biology; Genetics & Heredity
SC Environmental Sciences & Ecology; Evolutionary Biology; Genetics &
   Heredity
GA PH6PW
UT WOS:000583294200001
PM 33047822
DA 2021-01-01
ER

PT J
AU Lasky, JA
   Fuloria, J
   Morrison, ME
   Lanier, R
   Naderer, O
   Brundage, T
   Melemed, A
AF Lasky, Joseph A.
   Fuloria, Jyotsna
   Morrison, Marion E.
   Lanier, Randall
   Naderer, Odin
   Brundage, Tom
   Melemed, Allen
TI Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled,
   Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated
   with Severe COVID-19
SO ADVANCES IN THERAPY
LA English
DT Article; Early Access
DE Acute lung injury; COVID-19; Dociparstat; HMGB1; NETs; Neutrophil
   extracellular traps; P-selectin; Platelet factor 4
ID HEPARIN; HMGB1
AB Introduction The COVID-19 global pandemic caused by the novel coronavirus, SARS-CoV-2, and the consequent morbidity and mortality attributable to progressive hypoxemia and subsequent respiratory failure threaten to overrun hospital critical care units globally. New agents that address the hyperinflammatory "cytokine storm" and hypercoagulable pathology seen in these patients may be a promising approach to treat patients, minimize hospital stays, and ensure hospital wards and critical care units are able to operate effectively. Dociparstat sodium (DSTAT) is a glycosaminoglycan derivative of heparin with robust anti-inflammatory properties, with the potential to address underlying causes of coagulation disorders with substantially reduced risk of bleeding compared to commercially available heparin. Methods This study is a randomized, double-blind, placebo-controlled, phase 2/3 trial to determine the safety and efficacy of DSTAT added to standard of care in hospitalized adults with COVID-19 who require supplemental oxygen. Phase 2 will enroll 12 participants in each of two dose-escalating cohorts to confirm the safety of DSTAT in this population. Following review of the data, an additional 50 participants will be enrolled. Contingent upon positive results, phase 3 will enroll approximately 450 participants randomized to DSTAT or placebo. The primary endpoint is the proportion of participants who survive and do not require mechanical ventilation through day 28. Discussion Advances in standard of care, recent emergency use authorizations, and positive data with dexamethasone have likely contributed to an increasing proportion of patients who are surviving without the need for mechanical ventilation. Therefore, examining the time to improvement in the NIAID score will be essential to provide a measure of drug effect on recovery. Analysis of additional endpoints, including supportive biomarkers (e.g., IL-6, HMGB1, soluble-RAGE, D-dimer), will be performed to further define the effect of DSTAT in patients with COVID-19 infection.
C1 [Lasky, Joseph A.] Tulane Univ, Med Ctr, New Orleans, LA USA.
   [Fuloria, Jyotsna] Univ Med Ctr New Orleans, New Orleans, LA USA.
   [Morrison, Marion E.; Lanier, Randall; Naderer, Odin; Brundage, Tom; Melemed, Allen] Chimerix Inc, Durham, NC 27713 USA.
RP Morrison, ME (corresponding author), Chimerix Inc, Durham, NC 27713 USA.
EM mmorrison@chimerix.com
FU Chimerix, Inc.
FX Sponsorship for this study and the journal's Rapid Service and Open
   Access Fees were funded by Chimerix, Inc., located in Durham, NC, USA.
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Beigel JH, 2020, NEW ENGL J MED, V383, P994, DOI 10.1056/NEJMc2022236
   Chen LT, 2020, CELL MOL IMMUNOL, V17, P992, DOI 10.1038/s41423-020-0492-x
   Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300
   Griffin KL, 2014, AM J RESP CELL MOL, V50, P684, DOI 10.1165/rcmb.2013-0338RC
   Harrill AH, 2012, CLIN PHARMACOL THER, V92, P214, DOI 10.1038/clpt.2012.40
   Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Joglekar MV, 2012, THROMB HAEMOSTASIS, V107, P717, DOI 10.1160/TH11-11-0795
   Kim S, 2013, MOL MED, V19, P88, DOI 10.2119/molmed.2012.00306
   Kowalska MA, 2014, ARTERIOSCL THROM VAS, V34, P120, DOI 10.1161/ATVBAHA.113.302236
   Lauzier F, 2013, INTENS CARE MED, V39, P2135, DOI 10.1007/s00134-013-3044-3
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Manne BK, 2020, BLOOD, V136, P1317, DOI 10.1182/blood.2020007214
   Middleton EA, 2020, BLOOD, V136, P1169, DOI 10.1182/blood.2020007008
   Nativel B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076039
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Rao NV, 2010, AM J PHYSIOL-CELL PH, V299, pC97, DOI 10.1152/ajpcell.00009.2010
   Sharma L, 2014, J IMMUNOTOXICOL, V11, P260, DOI 10.3109/1547691X.2013.839587
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zheng S, 2017, AM J RESP CELL MOL, V56, P90, DOI 10.1165/rcmb.2016-0069OC
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 26
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
DI 10.1007/s12325-020-01539-z
EA OCT 2020
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OH7JF
UT WOS:000582769500002
PM 33108622
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Rahikainen, R
   Rijal, P
   Tan, TK
   Wu, HJ
   Andersson, AMC
   Barrett, JR
   Bowden, TA
   Draper, SJ
   Townsend, AR
   Howarth, M
AF Rahikainen, Rolle
   Rijal, Pramila
   Tan, Tiong Kit
   Wu, Hung-Jen
   Andersson, Anne-Marie C.
   Barrett, Jordan R.
   Bowden, Thomas A.
   Draper, Simon J.
   Townsend, Alain R.
   Howarth, Mark
TI Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous
   Amidation
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article; Early Access
DE bioconjugation; nanoparticle; nanotechnology; SpyTag; vaccines
ID ANTIBODY-RESPONSES; PROTEIN; VIRUS; INDUCTION; CHILDREN
AB Matching of symmetry at interfaces is a fundamental obstacle in molecular assembly. Virus-like particles (VLPs) are important vaccine platforms against pathogenic threats, including Covid-19. However, symmetry mismatch can prohibit vaccine nanoassembly. We established an approach for coupling VLPs to diverse antigen symmetries. SpyCatcher003 enabled efficient VLP conjugation and extreme thermal resilience. Many people had pre-existing antibodies to SpyTag:SpyCatcher but less to the 003 variants. We coupled the computer-designed VLP not only to monomers (SARS-CoV-2) but also to cyclic dimers (Newcastle disease, Lyme disease), trimers (influenza hemagglutinins), and tetramers (influenza neuraminidases). Even an antigen with dihedral symmetry could be displayed. For the global challenge of influenza, SpyTag-mediated display of trimer and tetramer antigens strongly induced neutralizing antibodies. SpyCatcher003 conjugation enables nanodisplay of diverse symmetries towards generation of potent vaccines.
C1 [Rahikainen, Rolle; Wu, Hung-Jen; Andersson, Anne-Marie C.; Howarth, Mark] Univ Oxford, Dept Biochem, South Parks Rd, Oxford OX1 3QU, England.
   [Rijal, Pramila; Tan, Tiong Kit; Townsend, Alain R.] Univ Oxford, Radcliffe Dept Med, MRC Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford OX3 9DS, England.
   [Andersson, Anne-Marie C.] InProTher Aps, Ole Maaloes Vej 3, DK-2200 Copenhagen, Denmark.
   [Barrett, Jordan R.; Draper, Simon J.] Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England.
   [Bowden, Thomas A.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
RP Howarth, M (corresponding author), Univ Oxford, Dept Biochem, South Parks Rd, Oxford OX1 3QU, England.; Townsend, AR (corresponding author), Univ Oxford, Radcliffe Dept Med, MRC Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford OX3 9DS, England.
EM alain.townsend@imm.ox.ac.uk; mark.howarth@bioch.ox.ac.uk
OI Barrett, Jordan/0000-0003-0746-1945; Bowden, Thomas/0000-0002-8066-8785;
   Rijal, Pramila/0000-0002-9214-9851; Tan, Tiong Kit/0000-0001-8746-8308;
   Draper, Simon/0000-0002-9415-1357; Townsend, Alain/0000-0002-3702-0107;
   Andersson, Anne-Marie/0000-0001-5455-4162; Howarth,
   Mark/0000-0001-8870-7147
FU Medical Research CouncilMedical Research Council UK (MRC) [MR/P001351/1,
   MR/L009528/1, MR/S007555/1]; European UnionEuropean Union (EU); Wellcome
   TrustWellcome Trust [106917/Z/15/Z]; Finnish Cultural FoundationFinnish
   Cultural Foundation; Foundations Post Doc Pool [00191229]; Chinese
   Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences
   (CIFMS) [2018-I2M-2-002]; Townsend-Jeantet Prize Charitable Trust
   [1011770]; EPA Cephalosporin Early Career Teaching and Research
   Fellowship; Wellcome Trust Centre for Human Genetics - Wellcome Centre
   grant [203141/Z/16Z]
FX R.R., A.C.A., J.R.B., S.J.D. and M.H. were funded by the Medical
   Research Council (MR/P001351/1). This UK funded award is part of the
   EDCTP2 programme supported by the European Union. S.J.D. is also a
   Lister Institute Research Prize Fellow, a Jenner Investigator and a
   Wellcome Trust Senior Fellow (106917/Z/15/Z). R.R. was supported by the
   Finnish Cultural Foundation and the Foundations Post Doc Pool with grant
   00191229. P.R. and A.R.T. were funded by the Chinese Academy of Medical
   Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS), China
   (grant number: 2018-I2M-2-002) and Townsend-Jeantet Prize Charitable
   Trust (Charity Number 1011770). T.K.T. was funded by the EPA
   Cephalosporin Early Career Teaching and Research Fellowship and
   Townsend-Jeantet Prize Charitable Trust (Charity Number 1011770). T.A.B.
   was funded by the Medical Research Council (MR/L009528/1 and
   MR/S007555/1), with theWellcome Trust Centre for Human Genetics
   supported by Wellcome Centre grant 203141/Z/16Z. At the University of
   Oxford we thank Angela Minassian for VAC063 clinical trial sample
   access, Niels Wicke for assistance with TEM, and David Staunton of the
   Department of Biochemistry Biophysical Suite for assistance with
   particle analysis.
CR Amelung S, 2011, CELL MICROBIOL, V13, P1200, DOI 10.1111/j.1462-5822.2011.01610.x
   Andersson AMC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40985-w
   Bowden TA, 2010, J VIROL, V84, P6208, DOI 10.1128/JVI.00317-10
   Brune KD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01432
   Brune KD, 2017, BIOCONJUGATE CHEM, V28, P1544, DOI 10.1021/acs.bioconjchem.7b00174
   Brune KD, 2016, SCI REP-UK, V6, DOI 10.1038/srep19234
   Bruun TUJ, 2018, ACS NANO, V12, P8855, DOI 10.1021/acsnano.8b02805
   Edmondson DG, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/cvi.00306-16, 10.1128/CVI.00306-16]
   Gomes AC, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5010006
   Goodsell DS, 2000, ANNU REV BIOPH BIOM, V29, P105, DOI 10.1146/annurev.biophys.29.1.105
   Green MR, 2006, ANN ONCOL, V17, P1263, DOI 10.1093/annonc/mdl104
   Hagen A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05162-z
   Hsia Y, 2016, NATURE, V535, P136, DOI 10.1038/nature18010
   Huiskonen JT, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20170203
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Kanekiyo M, 2019, NAT IMMUNOL, V20, P362, DOI 10.1038/s41590-018-0305-x
   Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202
   Keeble AH, 2020, CHEM SCI, V11, P7281, DOI 10.1039/d0sc01878c
   Keeble AH, 2019, P NATL ACAD SCI USA, V116, P26523, DOI 10.1073/pnas.1909653116
   Kim H, 2019, BIOTECHNOL BIOENG, V116, P2843, DOI 10.1002/bit.27129
   Krammer F, 2018, MBIO, V9, DOI 10.1128/mBio.02332-17
   Kumru OS, 2014, BIOLOGICALS, V42, P237, DOI 10.1016/j.biologicals.2014.05.007
   Lai JCC, 2010, J GEN VIROL, V91, P2322, DOI 10.1099/vir.0.019935-0
   Leneghan D. B., 2017, SCI REP, V7, P1
   Li MX, 2019, ACS PHOTONICS, V6, P1451, DOI 10.1021/acsphotonics.9b00090
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046
   Marini A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02931
   McLean HQ, 2015, J INFECT DIS, V211, P1529, DOI 10.1093/infdis/jiu647
   Mortensen R, 2016, SCI REP-UK, V6, DOI 10.1038/srep22030
   Powell TJ, 2012, J VIROL, V86, P13397, DOI 10.1128/JVI.01820-12
   Quan FS, 2012, VIROLOGY, V430, P127, DOI 10.1016/j.virol.2012.05.006
   Rijal P, 2020, J VIROL, V94, DOI 10.1128/JVI.01182-19
   Sharma J, 2020, ACS APPL MATER INTER, V12, P18211, DOI 10.1021/acsami.9b21776
   Smith AM, 2009, NAT NANOTECHNOL, V4, P56, DOI [10.1038/nnano.2008.360, 10.1038/NNANO.2008.360]
   Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8
   Tree JA, 2001, VACCINE, V19, P3444, DOI 10.1016/S0264-410X(01)00053-6
   Wang F, 2019, CHEM SCI, V10, P7755, DOI 10.1039/c9sc02576f
   Weiser JN, 2018, NAT REV MICROBIOL, V16, P354, DOI 10.1038/s41579-018-0001-8
   Yuan P, 2011, P NATL ACAD SCI USA, V108, P14920, DOI 10.1073/pnas.1111691108
   Zaiss AK, 2009, J CELL BIOCHEM, V108, P778, DOI 10.1002/jcb.22328
   Zhang QB, 2006, EUR J IMMUNOL, V36, P46, DOI 10.1002/eji.200535101
   Zhao MC, 2019, VACCINE, V37, P5491, DOI 10.1016/j.vaccine.2018.02.090
NR 43
TC 0
Z9 0
U1 3
U2 3
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
DI 10.1002/anie.202009663
EA OCT 2020
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA OH4DB
UT WOS:000582520000001
PM 32886840
OA Other Gold
DA 2021-01-01
ER

PT J
AU Zhao, CQ
   Qin, G
   Niu, JS
   Wang, Z
   Wang, CY
   Ren, JS
   Qu, XG
AF Zhao, Chuanqi
   Qin, Geng
   Niu, Jingsheng
   Wang, Zhao
   Wang, Chunyu
   Ren, Jinsong
   Qu, Xiaogang
TI Targeting RNA G-Quadruplex in SARS-CoV-2: A Promising Therapeutic Target
   for COVID-19?
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article; Early Access
DE drug discovery; inhibitors; G-quadruplex; RNA; viruses
ID DNA G-QUADRUPLEXES
AB The COVID-19 pandemic caused by SARS-CoV-2 has become a global threat. Understanding the underlying mechanisms and developing innovative treatments are extremely urgent. G-quadruplexes (G4s) are important noncanonical nucleic acid structures with distinct biofunctions. Four putative G4-forming sequences (PQSs) in the SARS-CoV-2 genome were studied. One of them (RG-1), which locates in the coding sequence region of SARS-CoV-2 nucleocapsid phosphoprotein (N), has been verified to form a stable RNA G4 structure in live cells. G4-specific compounds, such as PDP (pyridostatin derivative), can stabilize RG-1 G4 and significantly reduce the protein levels of SARS-CoV-2 N by inhibiting its translation both in vitro and in vivo. This result is the first evidence that PQSs in SARS-CoV-2 can form G4 structures in live cells, and that their biofunctions can be regulated by a G4-specific stabilizer. This finding will provide new insights into developing novel antiviral drugs against COVID-19.
C1 [Zhao, Chuanqi; Qin, Geng; Niu, Jingsheng; Wang, Zhao; Ren, Jinsong; Qu, Xiaogang] Chinese Acad Sci, Biol Chem Lab, Changchun Inst Appl Chem, Changchun 130022, Jilin, Peoples R China.
   [Zhao, Chuanqi; Qin, Geng; Niu, Jingsheng; Wang, Zhao; Ren, Jinsong; Qu, Xiaogang] Chinese Acad Sci, State Key Lab Rare Earth Resource Utilizat, Changchun Inst Appl Chem, Changchun 130022, Jilin, Peoples R China.
   [Niu, Jingsheng; Wang, Zhao; Ren, Jinsong; Qu, Xiaogang] Univ Sci & Technol China, Hefei 230026, Anhui, Peoples R China.
   [Wang, Chunyu] Jilin Univ, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.
RP Qu, XG (corresponding author), Chinese Acad Sci, Biol Chem Lab, Changchun Inst Appl Chem, Changchun 130022, Jilin, Peoples R China.; Qu, XG (corresponding author), Chinese Acad Sci, State Key Lab Rare Earth Resource Utilizat, Changchun Inst Appl Chem, Changchun 130022, Jilin, Peoples R China.; Qu, XG (corresponding author), Univ Sci & Technol China, Hefei 230026, Anhui, Peoples R China.
EM xqu@ciac.ac.cn
OI Zhao, Chuanqi/0000-0003-1211-3873; qin, geng/0000-0001-7589-4465
FU National Key R&D Program of China [2019YFA0709202]; Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [21533008, 91856205, 21820102009, 21871249, 21877105]; Key Program of
   Frontier of Sciences (CAS) [QYZDJ-SSW-SLH052]
FX Financial support was provided by the National Key R&D Program of China
   (2019YFA0709202), Natural Science Foundation of China (21533008,
   91856205, 21820102009, 21871249, 21877105), the Key Program of Frontier
   of Sciences (CAS QYZDJ-SSW-SLH052). The authors thank Prof. S. Wang
   (Wuhan University) for his help. The pCAG-Flag vector was a generous
   gift from Professor Peihui Wang (Cheeloo College of Medicine, Shandong
   University, Jinan).
CR Adrian M, 2012, METHODS, V57, P11, DOI 10.1016/j.ymeth.2012.05.003
   Artusi S, 2016, NUCLEIC ACIDS RES, V44, P10343, DOI 10.1093/nar/gkw968
   Bartas M, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01583
   Biffi G, 2014, NAT CHEM, V6, P75, DOI [10.1038/NCHEM.1805, 10.1038/nchem.1805]
   Binas O, 2020, CHEMBIOCHEM, V21, P1656, DOI 10.1002/cbic.201900696
   Callaway E, 2020, NATURE, V581, P363, DOI 10.1038/d41586-020-01092-3
   Cammas A, 2017, NUCLEIC ACIDS RES, V45, P1584, DOI 10.1093/nar/gkw1280
   Chambers VS, 2015, NAT BIOTECHNOL, V33, P877, DOI 10.1038/nbt.3295
   Chan C.-Y., 2020, ANGEW CHEM, V132, P5331
   Chan CY, 2020, ANGEW CHEM INT EDIT, V59, P5293, DOI [10.1002/anie.201914955, 10.1002/ange.201914955]
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Davis JT, 2004, ANGEW CHEM INT EDIT, V43, P668, DOI 10.1002/anie.200300589
   Davis JT., 2004, ANGEW CHEM, V116, P684
   del Villar-Guerra R, 2018, ANGEW CHEM, V130, P7289
   del Villar-Guerra R, 2018, ANGEW CHEM INT EDIT, V57, P7171, DOI 10.1002/anie.201709184
   Garant JM, 2018, BIOCHIMIE, V151, P115, DOI 10.1016/j.biochi.2018.06.002
   Hansel-Hertsch R, 2017, NAT REV MOL CELL BIO, V18, P279, DOI 10.1038/nrm.2017.3
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hognon C, 2020, J PHYS CHEM LETT, V11, P5661, DOI 10.1021/acs.jpclett.0c01097
   Horsburgh BC, 1996, CELL, V86, P949, DOI 10.1016/S0092-8674(00)80170-1
   Ji Danyang, 2020, Brief Bioinform, DOI 10.1093/bib/bbaa114
   Kikin O, 2006, NUCLEIC ACIDS RES, V34, pW676, DOI 10.1093/nar/gkl253
   Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q
   Kreig A, 2015, NUCLEIC ACIDS RES, V43, P7961, DOI 10.1093/nar/gkv749
   Kumari S, 2007, NAT CHEM BIOL, V3, P218, DOI 10.1038/nchembio864
   Maity A, 2020, NUCLEIC ACIDS RES, V48, P3315, DOI 10.1093/nar/gkaa008
   Mergny JL, 2003, OLIGONUCLEOTIDES, V13, P515, DOI 10.1089/154545703322860825
   Metifiot M, 2014, NUCLEIC ACIDS RES, V42, P12352, DOI 10.1093/nar/gku999
   Moye AL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8643
   Murat P, 2014, NAT CHEM BIOL, V10, P358, DOI [10.1038/NCHEMBIO.1479, 10.1038/nchembio.1479]
   Nakano S, 2014, CHEM REV, V114, P2733, DOI 10.1021/cr400113m
   Neidle S, 2017, NAT REV CHEM, V1, DOI 10.1038/s41570-017-0041
   Panera N, 2020, DRUGS, V80, P941, DOI 10.1007/s40265-020-01321-z
   Perrone R, 2014, J ANTIMICROB CHEMOTH, V69, P3248, DOI 10.1093/jac/dku280
   Phan AT, 2002, NUCLEIC ACIDS RES, V30, P4618, DOI 10.1093/nar/gkf597
   Piekna-Przybylska D, 2014, BIOCHEMISTRY-US, V53, P2581, DOI 10.1021/bi4016692
   Punnoose JA, 2017, J AM CHEM SOC, V139, P7476, DOI 10.1021/jacs.7b00607
   Qin HS, 2017, J AM CHEM SOC, V139, P16201, DOI 10.1021/jacs.7b07490
   Rhodes D, 2015, NUCLEIC ACIDS RES, V43, P8627, DOI 10.1093/nar/gkv862
   Ruggiero E, 2018, NUCLEIC ACIDS RES, V46, P3270, DOI 10.1093/nar/gky187
   SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097
   Shivalingam A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9178
   Song JW, 2016, TRANSLATION, V4, DOI 10.1080/21690731.2016.1244031
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   Tluckova K, 2013, BIOCHEMISTRY-US, V52, P7207, DOI 10.1021/bi400897g
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang SR, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501535
   Xu H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14432
   Xu SJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep24793
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 52
TC 0
Z9 0
U1 17
U2 17
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
DI 10.1002/anie.202011419
EA OCT 2020
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA OH4DC
UT WOS:000582520100001
PM 32939952
OA Bronze
DA 2021-01-01
ER

PT J
AU Pinney, SP
   Giustino, G
   Halperin, JL
   Mechanick, JI
   Neibart, E
   Olin, JW
   Rosenson, RS
   Fuster, V
AF Pinney, Sean P.
   Giustino, Gennaro
   Halperin, Jonathan L.
   Mechanick, Jeffrey, I
   Neibart, Eric
   Olin, Jeffrey W.
   Rosenson, Robert S.
   Fuster, Valentin
TI Coronavirus Historical Perspective, Disease Mechanisms, and Clinical
   Outcomes JACC Focus Seminar
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE cardiovascular disease; COVID-19; inflammation; SARS-CoV-2; thrombosis
ID ACUTE RESPIRATORY SYNDROME; DOUBLE-STRANDED-RNA; EPIDEMIOLOGY;
   SARS-COV-2; COVID-19; SEPSIS; CELLS
AB The emergence of a new coronavirus disease (coronavirus disease 2019 [COVID-19]) has raised global concerns regarding the health and safety of a vulnerable population. Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incites a profound inflammatory response leading to tissue injury and organ failure. COVID-19 is characterized by the bidirectional relationship between inflammation and thrombosis. The clinical syndrome is propelled by inflammation producing acute lung injury, large-vessel thrombosis, and in situ microthrombi that may contribute to organ failure. Myocardial injury is common, but true myocarditis is rare. Elderly patients, those with established cardiovascular disease, and mechanically ventilated patients face the highest mortality risk. Therapies for COVID-19 are evolving. The antiviral drug remdesivir, dexamethasone, transfusion of convalescent plasma, and use of antithrombotic therapy are promising. Most require additional prospective studies. Although most patients recover, those who survive severe illness may experience persistent physical and psychological disabilities. (C) 2020 by the American College of Cardiology Foundation.
C1 [Pinney, Sean P.; Giustino, Gennaro; Halperin, Jonathan L.; Mechanick, Jeffrey, I; Neibart, Eric; Olin, Jeffrey W.; Rosenson, Robert S.; Fuster, Valentin] Icahn Sch Med Mt Sinai, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA.
RP Pinney, SP (corresponding author), Univ Chicago, Med Cardiol, 5841 South Maryland Ave,Room A621,MC2016, Chicago, IL 60637 USA.
EM pinneys@medicine.bsd.uchicago.edu
RI Fuster, Valentin/H-4319-2015
OI Fuster, Valentin/0000-0002-9043-9986
CR Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   [Anonymous], COVID 19 TREATM GUID
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Baumann Kreuziger L, 2020, COVID 19 VTE ANTICOA
   Bedford T., 2020, CRYPTIC TRANSMISSION
   Beigel J. H., 2020, N ENGL J MED
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603
   Centers for Disease Control and Prevention, INF CLIN INV THER PA
   Centers for Disease Control and Prevention, WEEKL UPD SEL DEM GE
   Centers for Disease Control and Prevention, PROV DEATH COUNTS CO
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI DOI 10.1101/2020.03.22.20040758V3
   Cohen AT, 2016, NEW ENGL J MED, V375, P534, DOI 10.1056/NEJMoa1601747
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Dashti-Khavidaki S, 2020, PHARMACOTHERAPY, V40, P484, DOI 10.1002/phar.2397
   Day M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1375
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Dowd JB, 2020, P NATL ACAD SCI USA, V117, P9696, DOI 10.1073/pnas.2004911117
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Esmon CT, 2011, J THROMB HAEMOST, V9, P4
   Faure E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088716
   Fried JA, 2020, CIRCULATION, V141, P1930, DOI 10.1161/CIRCULATIONAHA.120.047164
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Gralinski LE, 2013, MBIO, V4, DOI 10.1128/mBio.00271-13
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2005, CHEST, V128, P2247, DOI 10.1378/chest.128.4.2247
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Kim IC, 2020, EUR HEART J, V41, P1859, DOI 10.1093/eurheartj/ehaa288
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lala A, 2020, J AM COLL CARDIOL, V76, P533, DOI 10.1016/j.jacc.2020.06.007
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li SSL, 2003, CIRCULATION, V108, P1798, DOI 10.1161/01.CIR.0000094737.21775.32
   Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Liu W, 2020, CHINA MED J
   Livingston E., 2020, JAMA
   Madjid M, 2020, JAMA CARDIOL
   Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Meyer P, 2020, EUR HEART J, V41, P1860, DOI 10.1093/eurheartj/ehaa306
   Moores LK, 2020, CHEST
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Oberfeld B, 2020, CELL, V181, P954, DOI 10.1016/j.cell.2020.04.013
   Paranjpe I, 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.04.19.20062117v2, DOI 10.1101/2020.04.19.20062117V2]
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Recovery Collaborative Group, 2020, N ENGL J MED
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Salmon A., 2020, ASIA TIMES
   Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103
   Senchenkova EY, 2019, HYPERTENSION, V73, P829, DOI 10.1161/HYPERTENSIONAHA.118.12286
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Spyropoulos AC, 2019, CLIN APPL THROMB-HEM, V25, DOI 10.1177/1076029619886022
   Steinberg BE, 2012, ANTIVIR RES, V93, P2, DOI 10.1016/j.antiviral.2011.10.019
   Steinberg KP, 2006, NEW ENGL J MED, V354, P1671
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
   Thomas O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116835
   Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Tremblay D, 2020, BLOOD, V136, P144, DOI 10.1182/blood.2020006941
   Walborn A, 2020, CLIN APPL THROMB-HEM, V25, P1
   Wang Q, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002070
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA SURG, V155, P1142, DOI 10.1001/jamasurg.2020.4132
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Zhai ZG, 2020, THROMB HAEMOSTASIS, V120, P937, DOI 10.1055/s-0040-1710019
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zulfiqar AA, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2010472
NR 96
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 27
PY 2020
VL 76
IS 17
BP 1999
EP 2010
DI 10.1016/j.jacc.2020.08.058
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OD0DX
UT WOS:000579526200011
PM 33092736
OA Green Published
DA 2021-01-01
ER

PT J
AU Mechanick, JI
   Rosenson, RS
   Pinney, SP
   Mancini, DM
   Narula, J
   Fuster, V
AF Mechanick, Jeffrey, I
   Rosenson, Robert S.
   Pinney, Sean P.
   Mancini, Donna M.
   Narula, Jagat
   Fuster, Valentin
TI Coronavirus and Cardiometabolic Syndrome JACC Focus Seminar
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE adiposity; angiotensin-converting enzyme 2; cardiometabolic;
   cardiovascular disease; chronic disease; COVID-19; diabetes;
   dysglycemia; dyslipidemia; hypertension; lifestyle; lipids; obesity;
   prevention; SARS-CoV-2; statin
ID EPICARDIAL ADIPOSE-TISSUE; CHRONIC DISEASE; CLINICAL ENDOCRINOLOGISTS;
   AMERICAN ASSOCIATION; COVID-19 INFECTION; UP-REGULATION; HYPERTENSION;
   CHINA; RISK; OUTCOMES
AB The coronavirus disease 2019 (COVID-19) pandemic exposes unexpected cardiovascular vulnerabilities and the need to improve cardiometabolic health. Four cardiometabolic drivers-abnormal adiposity, dysglycemia, dyslipidemia, and hypertension-are examined in the context of COVID-19. Specific recommendations are provided for lifestyle change, despite social distancing restrictions, and pharmacotherapy, particularly for those with diabetes. Inpatient recommendations emphasize diligent and exclusive use of insulin to avert hyperglycemia in the face of hypercytokinemia and potential islet cell injury. Continuation of statins is advised, but initiating statin therapy to treat COVID-19 is as yet unsubstantiated by the evidence. The central role of the renin-angiotensin system is discussed. Research, knowledge, and practice gaps are analyzed with the intent to motivate prompt action. An emerging model of COVID-related cardiometabolic syndrome encompassing events before, during the acute phase, and subsequently in the chronic phase is presented to guide preventive measures and improve overall cardiometabolic health so future viral pandemics confer less threat. (C) 2020 by the American College of Cardiology Foundation.
C1 [Mechanick, Jeffrey, I; Rosenson, Robert S.; Pinney, Sean P.; Mancini, Donna M.; Narula, Jagat; Fuster, Valentin] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, New York, NY 10029 USA.
RP Mechanick, JI (corresponding author), Icahn Sch Med Mt Sinai, 1 Gustave L Levy Pl,Box 1030, New York, NY 10029 USA.
EM Jeffrey.mechanick@mountsinai.org
RI Fuster, Valentin/H-4319-2015
OI Fuster, Valentin/0000-0002-9043-9986
CR Argenziano MG, 2020, CHARACTERIZATION CLI
   Badawi A, 2016, J PUBLIC HEALTH RES, V5, P130, DOI 10.4081/jphr.2016.733
   Bavishi C, 2020, JAMA CARDIOL
   Belser JA, 2013, VIROLOGY, V439, P42, DOI 10.1016/j.virol.2013.01.017
   Bhatraju PK, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-01935-1
   Bode Bruce, 2020, J Diabetes Sci Technol, V14, P813, DOI 10.1177/1932296820924469
   Caccialanza R, 2020, NUTRITION, V74, DOI 10.1016/j.nut.2020.110835
   Cadegiani FA, 2020, AM J PHYSIOL-ENDOC M, V318, pE587, DOI 10.1152/ajpendo.00136.2020
   Calfee CS, 2018, LANCET RESP MED, V6, P691, DOI 10.1016/S2213-2600(18)30177-2
   Carey RM, 2018, J AM COLL CARDIOL, V72, P1278, DOI 10.1016/j.jacc.2018.07.008
   Centers for Disease Control and Prevention, NAT CTR HLTH STAT OB
   Centers for Disease Control and Prevention, 2020 NAT DIAB STAT R
   Centers for Disease Control and Prevention, PROV DEATH COUNTS CO
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen PJ, 2020, J SPORT HEALTH SCI, V9, P103, DOI 10.1016/j.jshs.2020.02.001
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Colantonio LD, 2019, J AM COLL CARDIOL, V74, P2496, DOI 10.1016/j.jacc.2019.09.025
   Cummings MJ, 2020, EPIDEMIOLOGY CLIN CO
   Das UN, 2020, ARCH MED RES, V51, P282, DOI 10.1016/j.arcmed.2020.03.004
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Dutour A, 2010, J CLIN ENDOCR METAB, V95, P963, DOI 10.1210/jc.2009-1222
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   European Association for the Study of Obesity, SHAR AD OB
   Fernandez C, 2018, J INTERN MED, V284, P377, DOI 10.1111/joim.12783
   Fryar Cheryl D, 2017, NCHS Data Brief, P1
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESP J
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Handelsman Y, 2016, ENDOCR PRACT, V22, P753, DOI 10.4158/EP161292.PS
   Hemnes AR, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02638-2017
   Hennig BJW, 2007, GENES IMMUN, V8, P707, DOI 10.1038/sj.gene.6364444
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui KPY, 2015, ANTIVIR RES, V119, P1, DOI 10.1016/j.antiviral.2015.04.005
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Indexmundi, DIAB PREV POP AG 20
   Intensive Care National Audit and Research Centre, 2020, ICNARC REP COVID 19
   International Diabetes Federation, 2019, IDF DIABETES ATLAS
   Istituto Superiore Di Sanita, COR
   Jose RJ, 2020, OBESITY, V28, P1007, DOI 10.1002/oby.22835
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Lee YM, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0921-z
   Li B, 2020, EUR J PREV CARDIOL, V27, P1320, DOI 10.1177/2047487320925218
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415
   Lippi G, 2020, POL ARCH INTERN MED, V130, P304, DOI 10.20452/pamw.15272
   Liu BY, 2018, J AM COLL CARDIOL, V72, P2089, DOI 10.1016/j.jacc.2018.07.086
   Liu F, 2020, HIGHLY ACE2 EXPRESSI
   Liu M, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE016, DOI [10.3760/cma.j.issn.1001-0939.2020.03.014, 10.3760/cma.j.issn.1001-0939.2020.0016]
   Lu JP, 2017, LANCET, V390, P2549, DOI [10.1016/S0140-6736(17)32478-9, 10.1016/s0140-6736(17)32478-9]
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mechanick JI, 2020, J AM COLL CARDIOL, V75, P539, DOI 10.1016/j.jacc.2019.11.046
   Mechanick JI, 2020, J AM COLL CARDIOL, V75, P525, DOI 10.1016/j.jacc.2019.11.044
   Mechanick JI, 2017, ENDOCR PRACT, V23, P372, DOI 10.4158/EP161688.PS
   Mechanick JL, 2018, ENDOCR PRACT, V24, P995, DOI 10.4158/PS-2018-0139
   Mehrbod P, 2014, INT J MOL MED, V34, P61, DOI 10.3892/ijmm.2014.1761
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Mills KT, 2020, NAT REV NEPHROL, V16, P223, DOI 10.1038/s41581-019-0244-2
   Moser JAS, 2019, INFLUENZA OTHER RESP, V13, P3, DOI 10.1111/irv.12618
   Nambiar L, 2020, J AM COLL CARDIOL, V75, P2644, DOI 10.1016/j.jacc.2020.03.009
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Onder G, 2020, JAMA
   Pate VB, 2016, DIABETES, V65, P85, DOI 10.2337/db15-0399
   Paz Ocaranza Maria, 2020, Nat Rev Cardiol, V17, P116, DOI 10.1038/s41569-019-0244-8
   Peng TD, 2020, ZHONGHUA XIN XUE GUA, V48, pe004
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Philibert I, 2012, CAN J ANESTH, V59, P203, DOI 10.1007/s12630-011-9639-7
   Philips BJ, 2003, INTENS CARE MED, V29, P2204, DOI 10.1007/s00134-003-1961-2
   Rehman K, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0303-y
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Richard C, 2017, BMJ OPEN DIAB RES CA, V5, DOI 10.1136/bmjdrc-2016-000379
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ridker PM, 2013, EUR HEART J, V34, P1258, DOI 10.1093/eurheartj/eht022
   Rosenson RS, 2017, J AM COLL CARDIOL, V70, P1290, DOI 10.1016/j.jacc.2017.07.752
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Rundle AG, 2020, OBESITY, V28, P1008, DOI 10.1002/oby.22813
   Samanic CM, 2020, MMWR-MORBID MORTAL W, V69, P393, DOI 10.15585/mmwr.mm6914a1
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Singh AK, 2020, DIABETES METAB SYND, V14, P283, DOI 10.1016/j.dsx.2020.03.016
   Tate M., 2018, CONVERSATION
   The Centers for Disease Control and Prevention, PUBL HLTH IM LIB
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Tikoo K, 2015, BIOCHEM PHARMACOL, V93, P343, DOI 10.1016/j.bcp.2014.11.013
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Virani SS, 2020, CIRCULATION, V141, pE139, DOI 10.1161/CIR.0000000000000757
   Vuorio A, 2020, J Intern Med, V287, P2, DOI 10.1111/joim.12981
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wan Y, 2020, J VIROLOGY
   Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   Wang ZW, 2018, CIRCULATION, V137, P2344, DOI 10.1161/CIRCULATIONAHA.117.032380
   Whelton PK, 2018, J AM COLL CARDIOL, V71, P2275, DOI 10.1016/j.jacc.2018.03.016
   World Health Organization, 2020, OB OV
   World Health Organization, NONC DIS COUNTR PROF
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xie JF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.5619
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zheng QS, 2015, CELL PHYSIOL BIOCHEM, V37, P735, DOI 10.1159/000430391
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
   Zieber M, 2020, NURS PHILOS, V21, DOI 10.1111/nup.12296
   Zielinski C, 2019, LANCET GLOB HEALTH, V7, pE842, DOI 10.1016/S2214-109X(19)30206-2
   Zuin M, 2020, J INFECTION, V81, pE84, DOI 10.1016/j.jinf.2020.03.059
NR 111
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 27
PY 2020
VL 76
IS 17
BP 2024
EP 2035
DI 10.1016/j.jacc.2020.07.069
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OD0DX
UT WOS:000579526200013
PM 33092738
OA Green Published
DA 2021-01-01
ER

PT J
AU Liu, XL
   Drelich, A
   Li, W
   Chen, CH
   Sun, ZH
   Shi, M
   Adams, C
   Mellors, JW
   Tseng, CT
   Dimitrov, DS
AF Liu, Xianglei
   Drelich, Aleksandra
   Li, Wei
   Chen, Chuan
   Sun, Zehua
   Shi, Megan
   Adams, Cynthia
   Mellors, John W.
   Tseng, Chien-Te
   Dimitrov, Dimiter S.
TI Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2
   spike receptor binding domain Fc fusion protein in mice
SO VACCINE
LA English
DT Article
DE SARS-CoV-2; Subunit vaccine; Receptor-binding domain (RBD); Cell-cell
   fusion assay
ID VACCINES; TARGET; ACE2
AB The development of an effective vaccine against SARS-CoV-2 is urgently needed. We generated SARS-CoV-2 RBD-Fc fusion protein and evaluated its potency to elicit neutralizing antibody response in mice. RBD-Fc elicited a higher neutralizing antibodies titer than RBD as evaluated by a pseudovirus neutralization assay and a live virus based microneutralization assay. Furthermore, RBD-Fc immunized sera better inhibited cell-cell fusion, as evaluated by a quantitative cell-cell fusion assay. The cell-cell fusion assay results correlated well with the virus neutralization potency and could be used for high-throughput screening of large panels of anti-SARS-CoV-2 antibodies and vaccines without the requirement of live virus infection in BSL3 containment. Moreover, the anti-RBD sera did not enhance the pseudotyped SARS-CoV-2 infection of K562 cells. These results demonstrate that Fc fusion can significantly improve the humoral immune response to recombinant RBD immunogen, and suggest that RBD-Fc could serve as a useful component of effective vaccines against SARS-CoV-2. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Liu, Xianglei; Li, Wei; Chen, Chuan; Sun, Zehua; Shi, Megan; Adams, Cynthia; Mellors, John W.; Dimitrov, Dimiter S.] Univ Pittsburgh, Ctr Antibody Therapeut, Dept Med, Div Infect Dis,Med Sch, S843 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
   [Drelich, Aleksandra; Tseng, Chien-Te] Galveston Natl Lab, Dept Microbiol & Immunol, Ctr Biodef & Emerging Dis, 301 Univ Blvd, Galveston, TX 77550 USA.
   [Mellors, John W.; Dimitrov, Dimiter S.] Abound Bio, 1401 Forbes Ave, Pittsburgh, PA 15219 USA.
RP Liu, XL; Dimitrov, DS (corresponding author), Univ Pittsburgh, Ctr Antibody Therapeut, Dept Med, Div Infect Dis,Med Sch, S843 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM xil225@pitt.edu; mit666666@pitt.edu
FU University of Pittsburgh Medical Center
FX We would like to thank the members of the Center for Antibody
   Therapeutics Doncho Zhelev, Du-San Baek, Liyong Zhang, and Xiaojie Chu
   for their helpful discussions. This work was supported by the University
   of Pittsburgh Medical Center.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   CAFRUNY WA, 1986, VIRUS RES, V5, P357, DOI 10.1016/0168-1702(86)90029-8
   Chawla T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065231
   Dimitrov DS, 2003, CELL, V115, P652, DOI 10.1016/S0092-8674(03)00976-0
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Eroshenko N, 2020, NAT BIOTECHNOL, V38, P789, DOI 10.1038/s41587-020-0577-1
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Khurana S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000624
   Li W, 2020, CELL, V183, P429, DOI 10.1016/j.cell.2020.09.007
   Li Y, 2020, VIRUSES, V12
   Li Y, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2032057
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Poland GA, 2020, VACCINE, V38, P4219, DOI 10.1016/j.vaccine.2020.04.073
   Ravichandran S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3539
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Sun ZH, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2020.1778435
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z
   Taylor A, 2015, IMMUNOL REV, V268, P340, DOI 10.1111/imr.12367
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Wan Y., 2020, J VIROL, V94
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang J, 2020, J CLIN TRANSL SCI, P1, DOI [DOI 10.1017/CTS.2020.39, 10.1017/cts.2020.39]
   Yang J, 2020, NATURE
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zang JK, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-00199-1
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zhu XJ, 2013, J THORAC DIS, V5, pS142, DOI 10.3978/j.issn.2072-1439.2013.06.06
NR 29
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 27
PY 2020
VL 38
IS 46
BP 7205
EP 7212
DI 10.1016/j.vaccine.2020.09.058
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OD4ER
UT WOS:000579806100004
PM 33010978
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Dean, NE
   Piontti, APY
   Madewell, ZJ
   Cummings, DAT
   Hitchings, MDT
   Joshi, K
   Kahn, R
   Vespignani, A
   Halloran, ME
   Longini, IM
AF Dean, Natalie E.
   Piontti, Ana Pastore Y.
   Madewell, Zachary J.
   Cummings, Derek A. T.
   Hitchings, Matthew D. T.
   Joshi, Keya
   Kahn, Rebecca
   Vespignani, Alessandro
   Halloran, M. Elizabeth
   Longini, Ira M., Jr.
TI Ensemble forecast modeling for the design of COVID-19 vaccine efficacy
   trials
SO VACCINE
LA English
DT Article
DE Efficacy trial; Trial planning; Forecast model; Ensemble modeling
ID VIRUS
AB To rapidly evaluate the safety and efficacy of COVID-19 vaccine candidates, prioritizing vaccine trial sites in areas with high expected disease incidence can speed endpoint accrual and shorten trial duration. Mathematical and statistical forecast models can inform the process of site selection, integrating available data sources and facilitating comparisons across locations. We recommend the use of ensemble forecast modeling - combining projections from independent modeling groups - to guide investigators identifying suitable sites for COVID-19 vaccine efficacy trials. We describe an appropriate structure for this process, including minimum requirements, suggested output, and a user-friendly tool for displaying results. Importantly, we advise that this process be repeated regularly throughout the trial, to inform decisions about enrolling new participants at existing sites with waning incidence versus adding entirely new sites. These types of data-driven models can support the implementation of flexible efficacy trials tailored to the outbreak setting. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Dean, Natalie E.; Madewell, Zachary J.; Longini, Ira M., Jr.] Univ Florida, Dept Biostat, POB 117450, Gainesville, FL 32611 USA.
   [Cummings, Derek A. T.; Hitchings, Matthew D. T.] Univ Florida, Dept Biol, Gainesville, FL 32611 USA.
   [Joshi, Keya; Kahn, Rebecca] Harvard TH Chan Sch Publ Hlth, Ctr Communicable Dis Dynam, Dept Epidemiol, Boston, MA USA.
   [Piontti, Ana Pastore Y.; Vespignani, Alessandro] Northeastern Univ, Lab Modeling Biol & Sociotech Syst, Boston, MA 02115 USA.
   [Halloran, M. Elizabeth] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Halloran, M. Elizabeth] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
RP Dean, NE (corresponding author), Univ Florida, Dept Biostat, POB 117450, Gainesville, FL 32611 USA.
EM nataliedean@ufl.edu
RI Madewell, Zachary/AAM-4921-2020
OI Madewell, Zachary/0000-0002-5667-9660
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01-AI139761,
   R37-AI032042]
FX This work was supported by the National Institutes of Health
   R01-AI139761 (NED, MEH, IML, AV, APP, ZJM). R37-AI032042 (MEH).
CR Asher J, 2017, BIORXIV, DOI [10.1101/187591, DOI 10.1101/187591]
   Bellan SE, 2015, LANCET INFECT DIS, V15, P703, DOI 10.1016/S1473-3099(15)70139-8
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chang W, SHINY WEB APPL FRAME
   Chretien JP, 2015, ELIFE, V4, DOI 10.7554/eLife.09186
   Dean NE, 2020, NEW ENGL J MED, V382, P1366, DOI 10.1056/NEJMsb1905390
   Dean NE, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat0360
   Gsell PS, 2017, LANCET INFECT DIS, V17, P1276, DOI 10.1016/S1473-3099(17)30541-8
   Halloran ME, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0985-3
   Johansson MA, 2019, P NATL ACAD SCI USA, V116, P24268, DOI 10.1073/pnas.1909865116
   Lipsitch M, 2020, NAT MED, V26, P818, DOI 10.1038/s41591-020-0887-3
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Ray EL, 2020, ENSEMBLE FORECASTS C
   Ray EL, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1005910
   Reich NG, 2019, PLOS COMPUT BIOL, V15, DOI [10.1371/journal.pcbi.1007486, 10.1371/journal.pcbi.1007486.r001, 10.1371/journal.pcbi.1007486.r002, 10.1371/journal.pcbi.1007486.r003, 10.1371/journal.pcbi.1007486.r004]
   Vannice KS, 2019, VACCINE, V37, P863, DOI 10.1016/j.vaccine.2018.12.040
   Viboud C, 2018, EPIDEMICS-NETH, V22, P13, DOI 10.1016/j.epidem.2017.08.002
   World Health Organization, 2020, INT RAND TRIAL CAND
   Zhang Q, 2017, P NATL ACAD SCI USA, V114, pE4334, DOI 10.1073/pnas.1620161114
NR 19
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 27
PY 2020
VL 38
IS 46
BP 7213
EP 7216
DI 10.1016/j.vaccine.2020.09.031
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OD4ER
UT WOS:000579806100005
PM 33012602
OA Green Published
DA 2021-01-01
ER

PT J
AU Domenico, A
   Nicola, G
   Daniela, T
   Fulvio, C
   Nicola, A
   Orazio, N
AF Domenico, Alberga
   Nicola, Gambacorta
   Daniela, Trisciuzzi
   Fulvio, Ciriaco
   Nicola, Amoroso
   Orazio, Nicolotti
TI De Novo Drug Design of Targeted Chemical Libraries Based on Artificial
   Intelligence and Pair-Based Multiobjective Optimization
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID INHIBITORS; STRATEGIES; DISCOVERY; SPACE
AB Artificial intelligence and multiobjective optimization represent promising solutions to bridge chemical and biological landscapes by addressing the automated de novo design of compounds as a result of a humanlike creative process. In the present study, we conceived a novel pair-based multiobjective approach implemented in an adapted SMILES generative algorithm based on recurrent neural networks for the automated de novo design of new molecules whose overall features are optimized by finding the best trade-offs among relevant physicochemical properties (MW, logP, HBA, HBD) and additional similarity-based constraints biasing specific biological targets. In this respect, we carried out the de novo design of chemical libraries targeting neuraminidase, acetylcholinesterase, and the main protease of severe acute respiratory syndrome coronavirus 2. Several quality metrics were employed to assess drug-likeness, chemical feasibility, diversity content, and validity. Molecular docking was finally carried out to better evaluate the scoring and posing of the de novo generated molecules with respect to X-ray cognate ligands of the corresponding molecular counterparts. Our results indicate that artificial intelligence and multiobjective optimization allow us to capture the latent links joining chemical and biological aspects, thus providing easy-to-use options for customizable design strategies, which are especially effective for both lead generation and lead optimization. The algorithm is freely downloadable at https://github.com/alberdom88/moo-denovo and all of the data are available as Supporting Information.
C1 [Domenico, Alberga; Nicola, Gambacorta; Daniela, Trisciuzzi; Nicola, Amoroso; Orazio, Nicolotti] Univ Bari Aldo Moro, Dipartimento Farm Sci Farmaco, I-70126 Bari, Italy.
   [Daniela, Trisciuzzi] Mol Horizon Srl, I-06084 Bettona, Italy.
   [Fulvio, Ciriaco] Univ Bari Aldo Moro, Dipartimento Chim, I-70126 Bari, Italy.
RP Orazio, N (corresponding author), Univ Bari Aldo Moro, Dipartimento Farm Sci Farmaco, I-70126 Bari, Italy.
EM orazio.nicolotti@uniba.it
RI Nicolotti, Orazio/F-3209-2012; ciriaco, fulvio/L-3184-2017
OI Nicolotti, Orazio/0000-0001-6533-5539; ciriaco,
   fulvio/0000-0002-0695-6607
CR Alberga D, 2019, J CHEM INF MODEL, V59, P586, DOI 10.1021/acs.jcim.8b00698
   [Anonymous], 2019, SCHROD REL 2019 4 BI
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Benhenda M., 2017, ARXIVPHYSICS17080822
   Birks J., 2006, COCHRANE DATABASE SY, V363
   Brown N, 2019, J CHEM INF MODEL, V59, P1096, DOI 10.1021/acs.jcim.8b00839
   Cavalluzzi MM, 2017, EXPERT OPIN DRUG DIS, V12, P1087, DOI 10.1080/17460441.2017.1365056
   Chang Y.-C., 2020, POTENTIAL THERAPEUTI
   Chen HM, 2018, DRUG DISCOV TODAY, V23, P1241, DOI 10.1016/j.drudis.2018.01.039
   Cheung J, 2012, J MED CHEM, V55, P10282, DOI 10.1021/jm300871x
   Chung J., 2014, CORR, DOI DOI 10.1109/IJCNN.2015.7280624
   Conejo-Garcia A, 2011, J MED CHEM, V54, P2627, DOI 10.1021/jm101299d
   Deng J., 2020, ARXIVPHYSICS20040476
   Gomez-Bombarelli R, 2018, ACS CENTRAL SCI, V4, P268, DOI 10.1021/acscentsci.7b00572
   Grebner C, 2020, J MED CHEM, V63, P8809, DOI 10.1021/acs.jmedchem.9b02044
   Gupta A, 2018, MOL INFORM, V37, DOI 10.1002/minf.201700111
   Hann MM, 2004, CURR OPIN CHEM BIOL, V8, P255, DOI 10.1016/j.cbpa.2004.04.003
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Jin Z., 2020, BIORXIV
   John Harris C., 2020, COMB CHEM HIGH T SCR, V14, P521
   Kadurin A, 2017, MOL PHARMACEUT, V14, P3098, DOI 10.1021/acs.molpharmaceut.7b00346
   Kalgutkar Amit S, 2005, Expert Opin Drug Metab Toxicol, V1, P91, DOI 10.1517/17425255.1.1.91
   Kalgutkar AS, 2005, CURR DRUG METAB, V6, P161, DOI 10.2174/1389200054021799
   KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078
   Lai C.-C., 2020, INT J ANTIMICROB AGE, V55
   Landrum G., 2006, RDKIT OPEN SOURCE CH
   Li YB, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0287-6
   Lim J, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0286-7
   Lo YC, 2018, DRUG DISCOV TODAY, V23, P1538, DOI 10.1016/j.drudis.2018.05.010
   Macarron R, 2011, NAT REV DRUG DISCOV, V10, P188, DOI 10.1038/nrd3368
   Mangiatordi GF, 2017, EUR J MED CHEM, V139, P792, DOI 10.1016/j.ejmech.2017.07.037
   Medina-Franco JL, 2014, EXPERT OPIN DRUG DIS, V9, P151, DOI 10.1517/17460441.2014.872624
   Mendez D, 2019, NUCLEIC ACIDS RES, V47, pD930, DOI 10.1093/nar/gky1075
   Merk D, 2018, J MED CHEM, V61, P5442, DOI 10.1021/acs.jmedchem.8b00494
   Merk D, 2018, MOL INFORM, V37, DOI 10.1002/minf.201700153
   Mnih V, 2015, NATURE, V518, P529, DOI 10.1038/nature14236
   Montaruli M, 2019, MOLECULES, V24, DOI 10.3390/molecules24122233
   Moscona A, 2005, NEW ENGL J MED, V353, P1363, DOI 10.1056/NEJMra050740
   Nicolaou Christos A, 2013, Drug Discov Today Technol, V10, pe427, DOI 10.1016/j.ddtec.2013.02.001
   Nicolotti O, 2002, J MED CHEM, V45, P5069, DOI 10.1021/jm020919o
   Nicolotti O, 2011, EXPERT OPIN DRUG DIS, V6, P871, DOI 10.1517/17460441.2011.588696
   Nicolotti O, 2009, J CHEM INF MODEL, V49, P2290, DOI 10.1021/ci9002409
   Olivecrona M, 2017, J CHEMINFORMATICS, V9, DOI 10.1186/s13321-017-0235-x
   Patick AK, 1998, CLIN MICROBIOL REV, V11, P614, DOI 10.1128/CMR.11.4.614
   Pisani L, 2016, MOLECULES, V21, DOI 10.3390/molecules21030362
   Pogany P, 2019, J CHEM INF MODEL, V59, P1136, DOI 10.1021/acs.jcim.8b00626
   Polykovskiy D., 2019, ARXIVPHYSICS18111282
   Polykovskiy D, 2018, MOL PHARMACEUT, V15, P4398, DOI 10.1021/acs.molpharmaceut.8b00839
   Popova M, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aap7885
   Prykhodko O, 2019, J CHEMINFORMATICS, V11, DOI 10.1186/s13321-019-0397-9
   Putin E, 2018, J CHEM INF MODEL, V58, P1194, DOI 10.1021/acs.jcim.7b00690
   Reymond JL, 2010, MEDCHEMCOMM, V1, P30, DOI 10.1039/c0md00020e
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Sattarov B, 2019, J CHEM INF MODEL, V59, P1182, DOI 10.1021/acs.jcim.8b00751
   Schneider G, 2005, NAT REV DRUG DISCOV, V4, P649, DOI 10.1038/nrd1799
   Schneider G, 2019, ANGEW CHEM INT EDIT, V58, P10792, DOI 10.1002/anie.201814681
   Schneider P, 2020, NAT REV DRUG DISCOV, V19, P353, DOI 10.1038/s41573-019-0050-3
   Singh N., 2020, BRIEF BIOINFORM, P1
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Stahl N, 2019, J CHEM INF MODEL, V59, P3166, DOI 10.1021/acs.jcim.9b00325
   Stanciu GD, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010040
   Struble TJ, 2020, J MED CHEM, V63, P8667, DOI 10.1021/acs.jmedchem.9b02120
   Sutton R.S, 1998, REINFORCEMENT LEARNI
   Waring MJ, 2015, NAT REV DRUG DISCOV, V14, P475, DOI 10.1038/nrd4609
   Willett P, 1998, J CHEM INF COMP SCI, V38, P983, DOI 10.1021/ci9800211
   Xu XJ, 2008, J VIROL, V82, P10493, DOI 10.1128/JVI.00959-08
   Zhavoronkov A, 2019, NAT BIOTECHNOL, V37, P1038, DOI 10.1038/s41587-019-0224-x
   Zhou ZP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47148-x
NR 68
TC 0
Z9 0
U1 4
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9596
EI 1549-960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD OCT 26
PY 2020
VL 60
IS 10
BP 4582
EP 4593
DI 10.1021/acs.jcim.0c00517
PG 12
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA ON5BS
UT WOS:000586716900018
PM 32845150
DA 2021-01-01
ER

PT J
AU Amamuddy, OS
   Verkhivker, GM
   Bishop, OT
AF Amamuddy, Olivier Sheik
   Verkhivker, Gennady M.
   Bishop, Ozlem Tastan
TI Impact of Early Pandemic Stage Mutations on Molecular Dynamics of
   SARS-CoV-2 M-pro
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID CORONAVIRUS 3C-LIKE PROTEASE; SARS CORONAVIRUS; MAIN PROTEASE; DIMER
   INTERFACE; DIMERIZATION; COVID-19; DESIGN; VIRUS; MECHANISMS; INHIBITORS
AB A new coronavirus (SARS-CoV-2) is a global threat to world health and economy. Its dimeric main protease (M-pro), which is required for the proteolytic cleavage of viral precursor proteins, is a good candidate for drug development owing to its conservation and the absence of a human homolog. Improving our understanding of M-pro behavior can accelerate the discovery of effective therapies to reduce mortality. All-atom molecular dynamics (MD) simulations (100 ns) of 50 mutant M-pro dimers obtained from filtered sequences from the GISAID database were analyzed using root-mean-square deviation, root-mean-square fluctuation, R-g, averaged betweenness centrality, and geometry calculations. The results showed that SARS-CoV-2 M-pro essentially behaves in a similar manner to its SAR-CoV homolog. However, we report the following new findings from the variants: (1) Residues GLY15, VAL157, and PRO184 have mutated more than once in SARS CoV-2; (2) the D48E variant has lead to a novel "TSEEMLN"" loop at the binding pocket; (3) inactive apo M-pro does not show signs of dissociation in 100 ns MD; (4) a non-canonical pose for PHE140 widens the substrate binding surface; (5) dual allosteric pockets coinciding with various stabilizing and functional components of the substrate binding pocket were found to display correlated compaction dynamics; (6) high betweenness centrality values for residues 17 and 128 in all M-pro samples suggest their high importance in dimer stability-one such consequence has been observed for the M17I mutation whereby one of the N-fingers was highly unstable. (7) Independent coarse-grained Monte Carlo simulations suggest a relationship between the rigidity/mutability and enzymatic function. Our entire approach combining database preparation, variant retrieval, homology modeling, dynamic residue network (DRN), relevant conformation retrieval from 1-D kernel density estimates from reaction coordinates to other existing approaches of structural analysis, and data visualization within the coronaviral M-pro is also novel and is applicable to other coronaviral proteins.
C1 [Amamuddy, Olivier Sheik; Bishop, Ozlem Tastan] Rhodes Univ, Dept Microbiol & Biochem, Res Unit Bioinformat, ZA-6140 Grahamstown, South Africa.
   [Verkhivker, Gennady M.] Chapman Univ, Grad Program Computat & Data Sci, Schmid Coll Sci & Technol, Orange, CA 92866 USA.
   [Verkhivker, Gennady M.] Chapman Univ, Dept Biomed & Pharmaceut Sci, Sch Pharm, Irvine, CA 92618 USA.
   [Verkhivker, Gennady M.] Univ Calif San Diego, Dept Pharmacol, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.
RP Bishop, OT (corresponding author), Rhodes Univ, Dept Microbiol & Biochem, Res Unit Bioinformat, ZA-6140 Grahamstown, South Africa.
EM o.tastanbishop@ru.ac.za
RI Verkhivker, Gennady/V-9404-2018; Tastan Bishop, Ozlem/J-3084-2016
OI Verkhivker, Gennady/0000-0002-4507-4471; Sheik Amamuddy,
   Olivier/0000-0002-1781-1382; Tastan Bishop, Ozlem/0000-0001-6861-7849
FU National Institutes of Health Common FundUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [U24HG006941]
FX O.S.A. is funded as a postdoctoral fellow by H3ABioNet, which is
   supported by the National Institutes of Health Common Fund grant number
   U24HG006941. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript. The
   content of this publication is solely the responsibility of the authors
   and does not necessarily represent the official views of the funders.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abecasis AB, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-7
   Alamri MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1782768
   Alazmi M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1803965
   Aledo JC, 2019, PROTEIN SCI, V28, P1785, DOI 10.1002/pro.3698
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], 2019, DISC STUD VIS V19 1
   Bakan A, 2011, BIOINFORMATICS, V27, P1575, DOI 10.1093/bioinformatics/btr168
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Brown DK, 2017, GLOB HEART, V12, P121, DOI 10.1016/j.gheart.2017.01.006
   Brown DK, 2017, BIOINFORMATICS, V33, P2768, DOI 10.1093/bioinformatics/btx349
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Carter RW, 2012, THEOR BIOL MED MODEL, V9, DOI 10.1186/1742-4682-9-42
   Cava C, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040404
   Chen H, 2006, J BIOL CHEM, V281, P13894, DOI 10.1074/jbc.M510745200
   Chen S, 2005, J BIOL CHEM, V280, P164, DOI 10.1074/jbc.M408211200
   Chen S, 2008, J BIOL CHEM, V283, P554, DOI 10.1074/jbc.M705240200
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Cheng SC, 2010, BIOPHYS J, V98, P1327, DOI 10.1016/j.bpj.2009.12.4272
   Chookajorn T, 2020, P NATL ACAD SCI USA, V117, P12520, DOI 10.1073/pnas.2007076117
   Chou CY, 2004, BIOCHEMISTRY-US, V43, P14958, DOI 10.1021/bi0490237
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Ciemny MP, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030606
   Cock PJA, 2009, BIOINFORMATICS, V25, P1422, DOI 10.1093/bioinformatics/btp163
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Das S, 2020, J HUM BEHAV SOC ENVI, DOI 10.1080/10911359.2020.1781015
   Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381
   Duffy S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000003
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Faraggi E, 2019, ENTROPY-SWITZ, V21, DOI 10.3390/e21080764
   Fearon D., 2020, PANDDA ANAL GROUP DE
   Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Ghosh R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779818
   Goyal B, 2020, ACS COMB SCI, V22, P297, DOI 10.1021/acscombsci.0c00058
   Gysi D.M., 2004, ARXIV PREPRINT ARXIV
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Nguyen H, 2018, BIOINFORMATICS, V34, P1241, DOI 10.1093/bioinformatics/btx789
   Hatcher EL, 2017, NUCLEIC ACIDS RES, V45, pD482, DOI 10.1093/nar/gkw1065
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Helmy YA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041225
   Horowitz S, 2012, J BIOL CHEM, V287, P41576, DOI 10.1074/jbc.R112.418574
   Hu TC, 2009, VIROLOGY, V388, P324, DOI 10.1016/j.virol.2009.03.034
   Hu XP, 2020, FUTURE VIROL, V15, P359, DOI 10.2217/fvl-2020-0099
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Jubb HC, 2017, PROG BIOPHYS MOL BIO, V128, P3, DOI 10.1016/j.pbiomolbio.2016.10.002
   Jubb HC, 2017, J MOL BIOL, V429, P365, DOI 10.1016/j.jmb.2016.12.004
   Khelfaoui H, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1803967
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kmiecik S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113496
   Kmiecik S, 2016, CHEM REV, V116, P7898, DOI 10.1021/acs.chemrev.6b00163
   Kolinski A, 2004, ACTA BIOCHIM POL, V51, P349
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kozakov D, 2015, NAT PROTOC, V10, P733, DOI 10.1038/nprot.2015.043
   Kumar Sumit, 2020, J Chem Inf Model, DOI 10.1021/acs.jcim.0c00326
   Kurcinski M, 2019, BIOINFORMATICS, V35, P694, DOI 10.1093/bioinformatics/bty685
   Li CM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20918
   Li CM, 2010, J BIOL CHEM, V285, P28134, DOI 10.1074/jbc.M109.095851
   Liang YW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01022
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Mahmud S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1796808
   McGibbon RT, 2015, BIOPHYS J, V109, P1528, DOI 10.1016/j.bpj.2015.08.015
   McKinney W, 2010, P 9 PYTH SCI C, V9, P51, DOI DOI 10.1016/S0168-0102(02)00204-3
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Peele K.A., 2020, INF MED UNLOCKED, V19
   Penlder DL, 2018, J CHEM INF MODEL, V58, P383, DOI 10.1021/acs.jcim.7b00630
   Pfeiffer JK, 2005, PLOS PATHOG, V1, P102, DOI 10.1371/journal.ppat.0010011
   Pond SLK, 2009, CLIN INFECT DIS, V48, P1306, DOI 10.1086/598503
   Rambaut A., 2020, NAT MICROBIOL, P1
   Randhawa GS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232391
   RASSCHAERT D, 1990, J GEN VIROL, V71, P2599, DOI 10.1099/0022-1317-71-11-2599
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rice A.M., 2020, BIORXIV, DOI [10.1101/2020.05.11.088112., DOI 10.1101/2020.05.11.088112]
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Sali A., 2013, ROCKEFELLER U, V9, P779
   Schrodinger L., 2015, PYMOL MOL GRAPHICS S
   Scott DW, 2015, WILEY SER PROBAB ST, P125
   Sevajol M, 2014, VIRUS RES, V194, P90, DOI 10.1016/j.virusres.2014.10.008
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Shi JH, 2006, FEBS J, V273, P1035, DOI 10.1111/j.1742-4658.2006.05130.x
   Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200
   Shi JH, 2008, J VIROL, V82, P4620, DOI 10.1128/JVI.02680-07
   Smith R. H. B., 2019, BIORXIV
   Suarez Dimas, 2020, J Chem Inf Model, DOI 10.1021/acs.jcim.0c00575
   TALAL A, 2020, J MULTINATL FINANC M, P1, DOI DOI 10.1016/B978-0-08-102834-6.00001-X
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   van der Walt S, 2011, COMPUT SCI ENG, V13, P22, DOI 10.1109/MCSE.2011.37
   Van Lancker W, 2020, LANCET PUBLIC HEALTH, V5, pE243, DOI 10.1016/S2468-2667(20)30084-0
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vignuzzi M, 2005, VIRUS RES, V107, P173, DOI 10.1016/j.virusres.2004.11.007
   Virtanen P, 2020, NAT METHODS, V17, P261, DOI 10.1038/s41592-019-0686-2
   Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677
   Wang JF, 2020, AGR ECOSYST ENVIRON, V289, DOI 10.1016/j.agee.2019.106745
   Wei P, 2006, BIOCHEM BIOPH RES CO, V339, P865, DOI 10.1016/j.bbrc.2005.11.102
   Wensing AM, 2017, TOP ANTIVIR MED, V2017, P132
   Wensing Annemarie M, 2019, Top Antivir Med, V27, P111
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106012
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao Q, 2008, J VIROL, V82, P8647, DOI 10.1128/JVI.00298-08
   Zheng KW, 2007, PROTEINS, V66, P467, DOI 10.1002/prot.21160
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 116
TC 1
Z9 1
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9596
EI 1549-960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD OCT 26
PY 2020
VL 60
IS 10
BP 5080
EP 5102
DI 10.1021/acs.jcim.0c00634
PG 23
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA ON5BS
UT WOS:000586716900060
PM 32853525
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hsu, M
   Ahern, DK
   Suzuki, J
AF Hsu, Michael
   Ahern, David K.
   Suzuki, Joji
TI Digital Phenotyping to Enhance Substance Use Treatment During the
   COVID-19 Pandemic
SO JMIR MENTAL HEALTH
LA English
DT Article
DE digital phenotyping; digital psychiatry; addiction; psychiatry;
   coronavirus; COVID-19; digital health; treatment; drugs; substance use
   disorder
ID SMARTPHONE; ALCOHOL; ADDICTION; RELAPSE
AB Due to the COVID-19 pandemic, many clinical addiction treatment programs have been required to transition to telephonic or virtual visits. Novel solutions are needed to enhance substance use treatment during a time when many patients are disconnected from clinical care and social support. Digital phenotyping, which leverages the unique functionality of smartphone sensors (GPS, social behavior, and typing patterns), can buttress clinical treatment in a remote, scalable fashion. Specifically, digital phenotyping has the potential to improve relapse prediction and intervention, relapse detection, and overdose intervention. Digital phenotyping may enhance relapse prediction through coupling machine learning algorithms with the enormous amount of collected behavioral data. Activity-based analysis in real time can potentially be used to prevent relapse by warning substance users when they approach locational triggers such as bars or liquor stores. Wearable devices detect when a person has relapsed to substances through measuring physiological changes such as electrodermal activity and locomotion. Despite the initial promise of this approach, privacy, security, and barriers to access are important issues to address.
C1 [Hsu, Michael] Brigham & Womens Hosp, Dept Psychiat, 75 Francis St, Boston, MA 02115 USA.
   [Ahern, David K.] Brigham & Womens Hosp, Digital Behav Hlth & Informat Res Program, 75 Francis St, Boston, MA 02115 USA.
   [Suzuki, Joji] Brigham & Womens Hosp, Div Addict Psychiat, 75 Francis St, Boston, MA 02115 USA.
RP Hsu, M (corresponding author), Brigham & Womens Hosp, Dept Psychiat, 75 Francis St, Boston, MA 02115 USA.
EM mhsu7@partners.org
OI Ahern, David/0000-0002-4349-4130
FU NIH/NIDAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA) [K23DA042326]
FX This work was supported by an NIH/NIDA grant (K23DA042326).
CR Alexander GC, 2020, ANN INTERN MED, V173, P57, DOI 10.7326/M20-1141
   Alterman AI, 2000, DRUG ALCOHOL DEPEN, V59, P215, DOI 10.1016/S0376-8716(99)00124-6
   Andersson HW, 2019, ADDICT BEHAV, V90, P222, DOI 10.1016/j.addbeh.2018.11.008
   [Anonymous], APP EV MOD
   [Anonymous], 2020, LIF PROGR LOW INC CO
   [Anonymous], 2014, FREE CELL PHON MED R
   Barnett I, 2018, NEUROPSYCHOPHARMACOL, V43, P1660, DOI 10.1038/s41386-018-0030-z
   Carreiro S, 2016, J MED TOXICOL, V12, P255, DOI 10.1007/s13181-016-0557-5
   Carroll KM, 2008, AM J PSYCHIAT, V165, P881, DOI 10.1176/appi.ajp.2008.07111835
   Connor JP, 2007, SUBST USE MISUSE, V42, P2193, DOI 10.1080/10826080701658125
   Curtin J, 2019, CONTEXTUALIZED DAILY
   Dahne J, 2015, J SUBST ABUSE TREAT, V58, P95, DOI 10.1016/j.jsat.2015.06.017
   Epstein DH, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0234-6
   Faurholt-Jepsen M, 2015, BIPOLAR DISORD, V17, P715, DOI 10.1111/bdi.12332
   Grundy Q, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l920
   Gustafson DH, 2014, JAMA PSYCHIAT, V71, P566, DOI 10.1001/jamapsychiatry.2013.4642
   Henson P, 2019, LANCET DIGIT HEALTH, V1, pE52, DOI 10.1016/S2589-7500(19)30013-5
   Hesse BW, 2020, J APPALACH HLTH, V2, P6, DOI [10.13023/jah.0201.02, DOI 10.13023/JAH.0201.02]
   Hoffman J., 2020, NY TIMES
   Hsu M, 2020, TECHNOLOGY MENTAL HL, P107
   Jacobson NC, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0078-0
   Kiluk BD, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0420-1
   Mohr DC, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0251-5
   NANDAKUMAR R., 2019, SCI TRANSL MED, V11, P474
   Owens MD, 2014, ADDICT DISORD TREAT, V13, P179, DOI 10.1097/ADT.0000000000000039
   Parvaz MA, 2016, JAMA PSYCHIAT, V73, P1127, DOI 10.1001/jamapsychiatry.2016.2181
   Pasareanu AR, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1548-6
   PETROV KA, 2018, ADDICT BEHAV REP, V9
   Roberts ET, 2020, JAMA INTERN MED, V180, P1386, DOI 10.1001/jamainternmed.2020.2666
   Samuels Elizabeth A, 2020, J Addict Med, V14, pe8, DOI 10.1097/ADM.0000000000000685
   Selvam AP, 2016, SCI REP-UK, V6, DOI 10.1038/srep23111
   Silva MJ, 2020, AM J MANAG CARE, V26, pE202, DOI 10.37765/ajmc.2020.43386
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   White R., 2012, ELECT HLTH RECORDS B
   Yuksel R, 2016, CLIN INVEST MED, V39, pS147
NR 35
TC 0
Z9 0
U1 0
U2 0
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2368-7959
J9 JMIR MENT HEALTH
JI JMIR Ment. Health
PD OCT 26
PY 2020
VL 7
IS 10
AR e21814
DI 10.2196/21814
PG 6
WC Psychiatry
SC Psychiatry
GA OH2RK
UT WOS:000582416400001
PM 33031044
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Plante, JA
   Liu, Y
   Liu, JY
   Xia, HJ
   Johnson, BA
   Lokugamage, KG
   Zhang, XW
   Muruato, AE
   Zou, J
   Fontes-Garfias, CR
   Mirchandani, D
   Scharton, D
   Bilello, JP
   Ku, ZQ
   An, ZQ
   Kalveram, B
   Freiberg, AN
   Menachery, VD
   Xie, XP
   Plante, KS
   Weaver, SC
   Shi, PY
AF Plante, Jessica A.
   Liu, Yang
   Liu, Jianying
   Xia, Hongjie
   Johnson, Bryan A.
   Lokugamage, Kumari G.
   Zhang, Xianwen
   Muruato, Antonio E.
   Zou, Jing
   Fontes-Garfias, Camila R.
   Mirchandani, Divya
   Scharton, Dionna
   Bilello, John P.
   Ku, Zhiqiang
   An, Zhiqiang
   Kalveram, Birte
   Freiberg, Alexander N.
   Menachery, Vineet D.
   Xie, Xuping
   Plante, Kenneth S.
   Weaver, Scott C.
   Shi, Pei-Yong
TI Spike mutation D614G alters SARS-CoV-2 fitness
SO NATURE
LA English
DT Article; Early Access
ID CORONAVIRUS; INFECTION; PROTEIN
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein substitution D614G became dominant during the coronavirus disease 2019 (COVID-19) pandemic(1,2). However, the effect of this variant on viral spread and vaccine efficacy remains to be defined. Here we engineered the spike D614G substitution in the USA-WA1/2020 SARS-CoV-2 strain, and found that it enhances viral replication in human lung epithelial cells and primary human airway tissues by increasing the infectivity and stability of virions. Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs, supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission. Sera from hamsters infected with D614 virus exhibit modestly higher neutralization titres against G614 virus than against D614 virus, suggesting that the mutation is unlikely to reduce the ability of vaccines in clinical trials to protect against COVID-19, and that therapeutic antibodies should be tested against the circulating G614 virus. Together with clinical findings, our work underscores the importance of this variant in viral spread and its implications for vaccine efficacy and antibody therapy.
   The SARS-CoV-2 variant expressing spike(D641G) shows increased infectivity in human lung epithelial cells and in hamster and primary human upper airway tissues, but is more susceptible to neutralization by antibodies raised against SARS-CoV-2.
C1 [Plante, Jessica A.; Mirchandani, Divya; Scharton, Dionna; Plante, Kenneth S.; Weaver, Scott C.] Univ Texas Med Branch, World Reference Ctr Emerging Viruses & Arboviruse, Galveston, TX 77555 USA.
   [Plante, Jessica A.; Liu, Jianying; Johnson, Bryan A.; Muruato, Antonio E.; Mirchandani, Divya; Scharton, Dionna; Freiberg, Alexander N.; Menachery, Vineet D.; Plante, Kenneth S.; Weaver, Scott C.; Shi, Pei-Yong] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.
   [Plante, Jessica A.; Liu, Jianying; Lokugamage, Kumari G.; Muruato, Antonio E.; Mirchandani, Divya; Scharton, Dionna; Menachery, Vineet D.; Plante, Kenneth S.; Weaver, Scott C.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
   [Liu, Yang; Xia, Hongjie; Zhang, Xianwen; Zou, Jing; Fontes-Garfias, Camila R.; Xie, Xuping; Shi, Pei-Yong] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
   [Bilello, John P.] Gilead Sci, Foster City, CA USA.
   [Ku, Zhiqiang; An, Zhiqiang] Univ Texas Hlth Sci Ctr Houston, Texas Therapeut Inst, Brown Fdn Inst Mol Med, Houston, TX 77030 USA.
   [Kalveram, Birte; Freiberg, Alexander N.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Freiberg, Alexander N.; Weaver, Scott C.; Shi, Pei-Yong] Univ Texas Med Branch, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA.
   [Freiberg, Alexander N.; Weaver, Scott C.; Shi, Pei-Yong] Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX 77555 USA.
   [Weaver, Scott C.; Shi, Pei-Yong] Univ Texas Med Branch, Inst Translat Sci, Galveston, TX 77555 USA.
   [Weaver, Scott C.; Shi, Pei-Yong] Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA.
RP Plante, KS; Weaver, SC (corresponding author), Univ Texas Med Branch, World Reference Ctr Emerging Viruses & Arboviruse, Galveston, TX 77555 USA.; Plante, KS; Weaver, SC; Shi, PY (corresponding author), Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.; Plante, KS; Weaver, SC (corresponding author), Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.; Xie, XP; Shi, PY (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.; Weaver, SC; Shi, PY (corresponding author), Univ Texas Med Branch, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA.; Weaver, SC; Shi, PY (corresponding author), Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX 77555 USA.; Weaver, SC; Shi, PY (corresponding author), Univ Texas Med Branch, Inst Translat Sci, Galveston, TX 77555 USA.; Weaver, SC; Shi, PY (corresponding author), Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA.
EM xuxie@utmb.edu; ksplante@utmb.edu; sweaver@utmb.edu; peshi@utmb.edu
OI Xia, Hongjie/0000-0002-2520-7038
FU NIA of the NIH [AI153602, AG049042, R24AI120942]; NIAID of the NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [AI153602, AG049042, R24AI120942]; STARs Award by the
   University of Texas System; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [AI142759,
   AI134907, AI145617, UL1TR001439]; Sealy & Smith Foundation; Kleberg
   Foundation; John S. Dunn Foundation; Amon G. Carter Foundation; Gilson
   Longenbaugh Foundation; Summerfield Robert Foundation; Clinical and
   Translational Science Award NRSA (TL1) Training Core from NIH
   [TL1TR001440]; McLaughlin Fellowship at the University of Texas Medical
   Branch;  [NIH5UC7AI094660]
FX This research was supported by grants from NIA and NIAID of the NIH
   (AI153602 and AG049042 to V.D.M.; R24AI120942 (WRCEVA) to S.C.W.) and by
   STARs Award provided by the University of Texas System to V.D.M. X.X.
   was partially supported by NIH5UC7AI094660. P.-Y.S. was supported by NIH
   grants AI142759, AI134907, AI145617 and UL1TR001439, and awards from the
   Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn
   Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh
   Foundation, and the Summerfield Robert Foundation. A.E.M. is supported
   by a Clinical and Translational Science Award NRSA (TL1) Training Core
   (TL1TR001440) from NIH. J.L. and C.R.F.-G. were supported by the
   McLaughlin Fellowship at the University of Texas Medical Branch.
CR Andersen C, 2019, CATSEYES CREATE CATS
   Bai JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118286
   Bergren NA, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008102
   Carr IM, 2009, BIOINFORMATICS, V25, P3244, DOI 10.1093/bioinformatics/btp583
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Coffey LL, 2011, J VIROL, V85, P1025, DOI 10.1128/JVI.01918-10
   Cumming G, 2014, PSYCHOL SCI, V25, P7, DOI 10.1177/0956797613504966
   Daniloski Zharko, 2020, bioRxiv, DOI 10.1101/2020.06.14.151357
   Domingo P, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102887
   Fauver JR, 2020, CELL, V181, P990, DOI 10.1016/j.cell.2020.04.021
   Grubaugh ND, 2016, CELL HOST MICROBE, V19, P481, DOI 10.1016/j.chom.2016.03.002
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Hou Yixuan J, 2020, bioRxiv, DOI 10.1101/2020.09.28.317685
   Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042
   Jackson George R Jr, 2018, Appl In Vitro Toxicol, V4, P149, DOI 10.1089/aivt.2018.0004
   Jackson L. A, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2022483, DOI 10.1056/NEJM0A2022483, 10.1056/NEJMoa2022483.]
   Johnson B. A, 2020, FURIN CLEAVAGE SITE, DOI [10.1101/2020.08.26.268854, DOI 10.1101/2020.08.26.268854]
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lorenzo-Redondo Ramon, 2020, medRxiv, DOI 10.1101/2020.05.19.20107144
   Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4
   Muruato AE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17892-0
   Reznik G, 1978, CLIN ANATOMY EUROPEA
   Richard M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14626-0
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Wagner C, 2020, COMP VIRAL LOAD CLIN
   Wiser MJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126210
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Yurkovetskiy L, 2020, CELL, V183, P739, DOI 10.1016/j.cell.2020.09.032
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 35
TC 6
Z9 6
U1 11
U2 11
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
DI 10.1038/s41586-020-2895-3
EA OCT 2020
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OW1BX
UT WOS:000592632600001
PM 33106671
OA Other Gold
DA 2021-01-01
ER

PT J
AU Chowdhury, FR
   Hoque, A
   Chowdhury, FUH
   Amin, MR
   Rahim, A
   Rahman, MM
   Yasmin, R
   Amin, MR
   Miah, MT
   Kalam, MA
   Rahman, MS
AF Chowdhury, Fazle Rabbi
   Hoque, Ashraful
   Chowdhury, Forhad Uddin Hasan
   Amin, Md. Ruhul
   Rahim, Abdur
   Rahman, M. Mujibur
   Yasmin, Rubina
   Amin, Md. Robed
   Miah, Md. Titu
   Kalam, Md. Abul
   Rahman, Md. Sayedur
TI Convalescent plasma transfusion therapy in severe COVID-19 patients- a
   safety, efficacy and dose response study: A structured summary of a
   study protocol of a phase II randomized controlled trial
SO TRIALS
LA English
DT Letter
DE Convalescent plasma; severe COVID-19; Randomised controlled trial;
   SARS-CoV-2; BSMMU
AB Objectives: General: To assess the safety, efficacy and dose response of convalescent plasma (CP) transfusion in severe COVID-19 patientsSpecific:
   a. To identify the appropriate effective dose of CP therapy in severe patients
   b. To identify the efficacy of the therapy with their end point based on clinical improvement within seven days of treatment or until discharge whichever is later and in-hospital mortality
   c. To assess the clinical improvement after CP transfusion in severe COVID-19 patients
   d. To assess the laboratory improvement after CP transfusion in severe COVID-19 patients
   Trial Design: This is a multicentre, multi-arm phase II Randomised Controlled Trial.
   Participants: Age and sex matched COVID-19 positive (by RT-PCR) severe cases will be enrolled in this trial. Severe case is defined by the World Health Organization (W.H.O) clinical case definition. The inclusion criteria are
   1. Respiratory rate > 30 breaths/min; PLUS
   2. Severe respiratory distress; or SpO2 <= 88% on room air or PaO2/FiO2 <= 300 mm of Hg, PLUS
   3. Radiological (X-ray or CT scan) evidence of bilateral lung infiltrate, AND OR
   4. Systolic BP < 90 mm of Hg or diastolic BP <60 mm of Hg.AND/OR
   5. Criteria 1 to 4 AND or patient in ventilator support
   Patients' below18 years, pregnant and lactating women, previous history of allergic reaction to plasma, patients who have already received plasma from a different source will be excluded. Patients will be enrolled at Bangabandhu Sheikh Mujib Medical University (BSMMU) hospital, Dhaka medical college hospital (DMCH) and Mugda medical college hospital (MuMCH). Apheretic plasma will be collected at the transfusion medicine department of SHNIBPS hospital, ELISA antibody titre will be done at BSMMU and CMBT and neutralizing antibody titre will be checked in collaboration with the University of Oxford.Patients who have recovered from COVID-19 will be recruited as donors of CP. The recovery criteria are normality of body temperature for more than 3 days, resolution of respiratory symptoms, two consecutively negative results of sputum SARS-CoV-2 by RT-PCR assay (at least 24 hours apart) 22 to 35 days of post onset period, and neutralizing antibody titre >= 1:160.
   Intervention and comparator: This RCT consists of three arms, a. standard care, b. standard care and 200 ml CP and c. standard care and 400 ml CP. Patients will receive plasma as a single transfusion. Intervention arms will be compared to the standard care arm.
   Main outcomes: The primary outcome will be time to clinical improvement within seven days of treatment or until discharge whichever is later and in-hospital mortality. The secondary outcome would be improvement of laboratory parameters after therapy (neutrophil, lymphocyte ratio, CRP, serum ferritin, SGPT, SGOT, serum creatinine and radiology), length of hospital stay, length of ICU stay, reduction in proportion of deaths, requirement of ventilator and duration of oxygen and ventilator support.
   Randomisation: Randomization will be done by someone not associated with the care or assessment of the patients by means of a computer generated random number table using an allocation ratio of 1:1:1.
   Blinding (masking): This is an open level study; neither the physician nor the patients will be blinded. However, the primary and secondary outcome (oxygen saturations, PaO2/FiO2, BP, day specific laboratory tests) will be recorded using an objective automated method; the study staff will not be able to influence the recording of these data.
   Number to be randomised (sample size)No similar study has been performed previously. Therefore no data are available that could be used to generate a sample size calculation. This phase II study is required to provide some initial data on efficacy and safety that will allow design of a larger study. The trial will recruit 60 participants (20 in each arm).
   Trial Status: Protocol version 1.4 dated May 5, 2020 and amended version 1.5, dated June 16, 2020. First case was recruited on May 27, 2020. By August 10, 2020, the trial had recruited one-third (21 out of 60) of the participants. The recruitment is expected to finish by October 31, 2020.
   Full Protocol: The full protocol is attached as an additional file, accessible from the Trial's website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
C1 [Chowdhury, Fazle Rabbi; Rahman, Md. Sayedur] Bangabandhu Sheikh Mujib Med Univ BSMMU, Dept Internal Med, Dhaka, Bangladesh.
   [Hoque, Ashraful; Kalam, Md. Abul] Sheikh Hasina Natl Inst Burn & Plast Surg SHNIBPS, Dept Blood Transfus, Dhaka, Bangladesh.
   [Chowdhury, Forhad Uddin Hasan; Rahman, M. Mujibur; Amin, Md. Robed] Dhaka Med Coll, Dept Med, Dhaka, Bangladesh.
   [Amin, Md. Ruhul] Ctr Med Biotechnol, Dhaka, Bangladesh.
   [Rahim, Abdur] Kuwait Bangladesh Friendship Govt Hosp, Dhaka, Bangladesh.
   [Yasmin, Rubina; Miah, Md. Titu] Mugda Med Coll, Dept Med, Dhaka, Bangladesh.
   [Rahman, Md. Sayedur] Bangabandhu Sheikh Mujib Med Univ, Dept Pharmacol, Dhaka, Bangladesh.
RP Chowdhury, FR (corresponding author), Bangabandhu Sheikh Mujib Med Univ BSMMU, Dept Internal Med, Dhaka, Bangladesh.
EM rabbimedicine@bsmmu.edu.bd
FU BSMMU [2020/7231(01)]
FX The trial will be funded by BSMMU grant number, 2020/7231(01). The
   funding body has no influence in the design of the study and data
   collection, analysis and interpretation of data and in writing the
   manuscript.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 26
PY 2020
VL 21
IS 1
AR 883
DI 10.1186/s13063-020-04734-z
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OS3NQ
UT WOS:000590072400006
PM 33106167
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Darazam, IA
   Hatami, F
   Rabiei, MM
   Pourhoseingholi, MA
   Moradi, O
   Shokouhi, S
   Hajesmaeili, MR
   Shabani, M
   Irvani, SSN
AF Darazam, Ilad Alavi
   Hatami, Firouze
   Rabiei, Mohammad Mahdi
   Pourhoseingholi, Mohamad Amin
   Moradi, Omid
   Shokouhi, Shervin
   Hajesmaeili, Mohammad Reza
   Shabani, Minoosh
   Irvani, Seyed Sina Naghibi
TI An investigation into the beneficial effects of high-dose interferon
   beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic
   regimen) in moderate to severe COVID-19: A structured summary of a study
   protocol for a randomized controlled l trial
SO TRIALS
LA English
DT Letter
DE COVID-19; SARS-COV-2; Randomized controlled trial; lopinavir; ritonavir;
   Interferon-beta 1a
AB Objectives We will investigate the effectiveness of high dose Interferon Beta 1a, compared to low dose Interferon Beta 1a (the base therapeutic regimen) in COVID-19 Confirmed Cases (Either RT-PCR or CT Scan Confirmed) with moderate to severe disease
   Trial Design: This is a single center, open label, randomized, controlled, 2-arm parallel group (1:1 ratio), clinical trial.
   Participants: The eligibility criteria in this study is: age >= 18 years, oxygen saturation (SPO2) <= 93% or respiratory rate >= 24, at least one of the following manifestation: radiation contactless body temperature >= 37.8, Cough, shortness of breath, nasal congestion/ discharge, myalgia/arthralgia, diarrhea/vomiting, headache or fatigue on admission. The onset of the symptoms should be acute (<= 14 days). The exclusion criteria include refusal to participate, using drugs with potential interaction with lopinavir/ritonavir or interferon-beta 1a, blood ALT/AST levels > 5 times the upper limit of normal on laboratory results, pregnant or lactating women, history of alcohol or drug addiction in the past 5 years, the patients who be intubated less than one hours after admission to hospital.This study will be undertaken at the Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences.
   Intervention and Comparator: COVID- 19 confirmed patients (using the RT-PCR test or CT scan) will be randomly assigned to one of two groups. The intervention group (Arms1) will be treated with lopinavir / ritonavir (Kaletra) + high dose Interferon-beta 1a (Recigen) and the control group will be treated with lopinavir / ritonavir (Kaletra) + low dose Interferon-beta 1a (Recigen) (the base therapeutic regimen). Both groups will receive standard care consisting of the necessary oxygen support, non-invasive, or invasive mechanical ventilation.
   Main outcomes: Primary outcome: Time to clinical improvement is our primary outcome measure. This is an improvement of two points on a seven-category ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R&D. Geneva: World Health Organization) or discharge from the hospital, whichever comes first.Secondary outcomes: mortality from the date of randomization until the last day of the study which will be the day all of the patients have had at least one of the following outcomes: 1) Improvement of two points on a seven-category ordinal scale. 2) Discharge from the hospital 3) Death. Improvement of SPO2 during the hospitalization, duration of hospitalization from date of randomization until the date of hospital discharge or death, whichever comes first. The incidence of new mechanical ventilation uses from the date of randomization until the last day of the study and the duration of it will be extracted. Please note that we are trying to add further secondary outcomes and this section of the protocol is still evolving.
   Randomization: Eligible patients with confirmed SARS-Cov-2 infections will be randomly assigned in a 1:1 ratio to two therapeutic arms using permuted, block-randomization to balance the number of patients allocated to each group. The permuted block (three or six patients per block) randomization sequence will be generated, using Package 'randomizeR' in R software version 3.6.1. and placed in individual sealed and opaque envelopes by the statistician. The investigator will enroll the patients and only then open envelopes to assign patients to the different treatment groups. This method of allocation concealment will result in minimum selection and confounding biases.
   Blinding (Masking): The present research is open-label (no masking) of patients and health care professionals who are undertaking outcome assessment of the primary outcome - time to clinical improvement.
   Numbers to be randomised (sample size): Of the 100 patients randomised, 50 patients will be assigned to receive high dose Interferon beta-1a plus lopinavir/ritonavir (Kaletra), 50 patients will be assigned to receive low dose Interferon beta 1a plus lopinavir/ritonavir (Kaletra).
   Trial Status: Protocol version 1.2.1. Recruitment is finished, the start date of recruitment was on August 20(th) 2020, and the end date was on September 4(th) 2020. Last point of data collection will be the last day on which all of the 100 participants have had an outcome of clinical improvement or death, up to 14th days after hospitalization.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Darazam, Ilad Alavi; Hatami, Firouze; Rabiei, Mohammad Mahdi; Shokouhi, Shervin; Shabani, Minoosh; Irvani, Seyed Sina Naghibi] Shahid Beheshti Univ Med Sci, Infect Dis & Trop Med Res Ctr, Tehran, Iran.
   [Darazam, Ilad Alavi] Shahid Beheshti Univ Med Sci, Loghman Hakim Hosp, Dept Infect Dis, Tehran, Iran.
   [Pourhoseingholi, Mohamad Amin] Shahid Beheshti Univ Med Sci, Res Inst Gastroenterol & Liver Dis, Gastroenterol & Liver Dis Res Ctr, Tehran, Iran.
   [Moradi, Omid] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Clin Pharm, Tehran, Iran.
   [Hajesmaeili, Mohammad Reza] Shahid Beheshti Univ Med Sci, Loghman Hakim Hosp, Anesthesiol Res Ctr, Tehran, Iran.
RP Darazam, IA (corresponding author), Shahid Beheshti Univ Med Sci, Infect Dis & Trop Med Res Ctr, Tehran, Iran.; Darazam, IA (corresponding author), Shahid Beheshti Univ Med Sci, Loghman Hakim Hosp, Dept Infect Dis, Tehran, Iran.
EM ilad13@yahoo.com
FU Clinical Research Development Unit (CRDU) of Loghman Hakim Hospital,
   Shahid Beheshti University of Medical Sciences, Tehran, Iran
FX The authors would like to thank the Clinical Research Development Unit
   (CRDU) of Loghman Hakim Hospital, Shahid Beheshti University of Medical
   Sciences, Tehran, Iran for their support.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 26
PY 2020
VL 21
IS 1
AR 880
DI 10.1186/s13063-020-04812-2
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OS3NQ
UT WOS:000590072400003
PM 33106183
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Junqueira-Kipnis, AP
   dos Anjos, LRB
   Barbosa, LCD
   da Costa, AC
   Borges, KCM
   Cardoso, ADO
   Ribeiro, KM
   Rosa, SBA
   Souza, CD
   das Neves, RC
   Saraiva, G
   da Silva, SM
   da Silveira, EA
   Rabahi, MF
   Conte, MB
   Kipnis, A
AF Junqueira-Kipnis, Ana Paula
   Borges dos Anjos, Laura Raniere
   de Souza Barbosa, Lilia Cristina
   da Costa, Adeliane Castro
   Malheiros Borges, Kellen Christina
   Oliveira Cardoso, Amanda da Rocha
   Ribeiro, Kaio Mota
   Aparecida Rosa, Sarah Brena
   Souza, Carine de Castro
   das Neves, Rogerio Coutinho
   Saraiva, Guylherme
   da Silva, Sueli Meira
   da Silveira, Erika Aparecida
   Rabahi, Marcelo Fouad
   Conte, Marcus Barreto
   Kipnis, Andre
TI BCG revaccination of health workers in Brazil to improve innate immune
   responses against COVID-19: A structured summary of a study protocol for
   a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; BCG revaccination;
   health workers; innate immune response; NK; macrophages;
   cross-protection
AB Objectives: The BCG vaccine, widely used in Brazil in new-borns, induces adjuvant protection for several diseases, including childhood virus infections. BCG activates monocytes and innate memory NK cells which are crucial for the antiviral immune response. Therefore, strategies to prevent COVID-19 in health workers (HW) should be carried out to prevent them becoming unwell so that they can continue to work during the pandemic. The hypothesis is that BCG will improve the innate immune response and prevent symptomatic infection or COVID-19 severity.The primary objective is to verify the effectiveness and safety of the BCG vaccine to prevent or reduce incidence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the city of Goiania (Brazil) among HW previously vaccinated with BCG and also its severity and mortality during the pandemic of the disease.Secondary objectives are to estimate the incidence of COVID-19 among these professionals and the innate immune response elicited to BCG.
   Trial design: This a phase II trial for repositioning BCG as a preventive strategy against COVID-19.The trial is an open-label, parallel-group randomised clinical trial, comparing HW vaccinated with BCG and HW not vaccinated.
   Participants: The trial will recruit 800 HW of Goiania - Goias, Brazil to reach a total of 400 HW included after comorbidities questioning and laboratorial evaluation.
   Eligibility criteria: Any HW presenting BCG vaccination scar with direct contact with suspected COVID-19 patients for at least 8 hours per week, whether in hospital beds, ICU, or in transportation or admission (nurses, doctors, physiotherapists, nutritionists, receptionists, etc.) who have negative IgM and IgG COVID-19 test.Participants with any of the following characteristics will be excluded:-
   - Have had in the last fifteen days any signs or symptoms of virus infection, including COVID-19;
   - Have had fever in the last fifteen days;
   - Have been vaccinated fifteen days before the inclusion;
   - Have a history or confirmation of any immunosuppressive disease such as HIV, presented solid tumour in the last two years or autoimmune diseases;
   - Are under preventive medication with antibiotics, steroid anti-inflammatories, or chemotherapy;
   - Have less than 500 neutrophils per mL of blood;
   - Have previously been diagnosed with tuberculosis;
   - Are breastfeeding or pregnant;
   - Are younger than 18 years old;
   - Are participating as an investigator in this clinical trial.
   Intervention and comparator: HW will be randomized into the BCG vaccinated group or the BCG unvaccinated control group.
   The BCG vaccinated group will receive in the right arm, intradermally, a one off dose of 0.1 mL corresponding to approximately 2 x10(5) to 8 x10(5) CFU of live, freeze-dried, attenuated BCG Moscow 361-I, Bacillus Calmette Guerin vaccine (Serum Institute of India PVT. LTD.).
   The unvaccinated control group will not be vaccinated.
   The HW allocated in both groups will be followed up at specific times points until 180 days post inclusion.
   The vaccinated and control groups will be compared according to COVID-19 related outcomes.
   Main outcomesThe primary outcomes are the incidence coefficient of infection by SARS-CoV-2 determined by RT-PCR of naso-oropharyngeal swab specimen or rapid lateral flow IgG and IgM test, and presence of general COVID-19 symptoms, disease severity and admission to hospital during the 180 days of follow up.The secondary outcome is the innate immune response elicited 15-20 days after vaccination.
   Randomisation: The vaccine vial contains approximately 10 doses. In order to optimize the vaccine use, the randomisation was performed in blocks of 20 participants using the platform randomization.com [http://www.jerrydallal.com/random/permute.htm].The randomization was prepared before any HW inclusion. The results were printed and inserted in sealed envelopes that were numbered with BCG-001 to BCG-400. The printed results as well the envelopes had the same numbers. At the time of the randomisation, each participant that meets the inclusion criteria will receive a consecutive participant number [BCG-001-BCG-400]. The sealed envelope with the assigned number, blinded to the researchers, will be opened in front of the participant and the arm allocation will be known.
   Blinding (masking): There is no masking for the participants or for the healthcare providers.The study will be blinded to the laboratory researchers and to those who will be evaluating the outcomes and performing the statistical analyses. In this case, only the participant identification number will be available.
   Numbers to be randomised (sample size): Four hundred heath workers will be randomised in two groups. Two hundred participants will be vaccinated, and 200 participants will not be vaccinated.
   Trial Status: The protocol approved by the Brazilian Ethical Committee is the seventh version, number CAAE: 31783720.0.0000.5078. The trial has been recruiting since September 20(th), 2020. The clinical trial protocol was registered on August 5(th), 2020. It is estimated that recruitment will finish by March 2021.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Junqueira-Kipnis, Ana Paula; Borges dos Anjos, Laura Raniere; de Souza Barbosa, Lilia Cristina; Malheiros Borges, Kellen Christina; Ribeiro, Kaio Mota; Aparecida Rosa, Sarah Brena; Souza, Carine de Castro; das Neves, Rogerio Coutinho; da Silva, Sueli Meira; Kipnis, Andre] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil.
   [da Costa, Adeliane Castro] Fac Estacio Sa Goias FESGO, Goiania, Go, Brazil.
   [Oliveira Cardoso, Amanda da Rocha; Saraiva, Guylherme; da Silveira, Erika Aparecida; Rabahi, Marcelo Fouad] Univ Fed Goias, Fac Med, Goiania, Go, Brazil.
   [Conte, Marcus Barreto] UNIFASE Petropolis, Ctr Univ Arthur Sa Earp Neto, Rio De Janeiro, Brazil.
RP Junqueira-Kipnis, AP (corresponding author), Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil.
EM ana_kipnis@ufg.br
OI Junqueira Kipnis, Ana Paula/0000-0002-4200-6617
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/National
   Council for Scientific and Technological DevelopmentNational Council for
   Scientific and Technological Development (CNPq)
FX This trial is funded by Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico/National Council for Scientific and Technological
   Development. It received R$ 1,241,028.00 (approximately US $206,000.00)
   that provided equipment and the material costs for the project.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 26
PY 2020
VL 21
IS 1
AR 881
DI 10.1186/s13063-020-04822-0
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OS3NQ
UT WOS:000590072400004
PM 33106170
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ziaei, A
   Davoodian, P
   Dadvand, H
   Safa, O
   Hassanipour, S
   Omidi, M
   Masjedi, M
   Mahmoudikia, F
   Rafiee, B
   Fathalipour, M
AF Ziaei, Ava
   Davoodian, Parivash
   Dadvand, Habib
   Safa, Omid
   Hassanipour, Soheil
   Omidi, Mahmoud
   Masjedi, Moein
   Mahmoudikia, Fahime
   Rafiee, Bahareh
   Fathalipour, Mohammad
TI Evaluation of the efficacy and safety of Melatonin in moderately ill
   patients with COVID-19: A structured summary of a study protocol for a
   randomized controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; Protocol; Melatonin; Inflammatory
   responses; Clinical symptoms
AB Objectives: We will evaluate the efficacy and safety of Melatonin, compared to the standard therapeutic regimen on clinical symptoms and serum inflammatory parameters in patients with confirmed COVID-19, who are moderately ill.
   Trial design: This is a single-center, randomized, double-blind, placebo-controlled clinical trial with a parallel-group design conducted at Shahid Mohammadi Hospital, Bandar Abbas, Iran.
   Participants: All patients admitted to Severe Acute Respiratory Syndrome Departments of Shahid Mohammadi Hospital, Bandar Abbas, Iran will be screened for the following criteria.Inclusion criteria:
   1. Age >= 20 years
   2. Confirmed SARS-CoV-2 diagnosis (positive polymerase chain reaction).
   3. Moderate COVID-19 pneumonia (via computed tomography and or X-ray imaging), requiring hospitalization.
   4. Hospitalized <= 48 hours.
   5. Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm.
   Exclusion criteria:
   1. Underlying diseases, including chronic hypertension, diabetes mellitus, seizure, depression, chronic hepatitis, cirrhosis, and cholestatic liver diseases.
   2. Severe and critical COVID-19 pneumonia.
   3. Use of warfarin, corticosteroids, hormonal drugs, alcohol, other antiviral and investigational medicines, and illegal drugs (during the last 30 days).
   4. History of known allergy to Melatonin.
   5. Pregnancy and breastfeeding.
   Intervention and comparator: Intervention group: The standard treatment regimen for COVID-19, according to the Iranian Ministry of Health and Medical Education's protocol, along with Melatonin capsules at a dose of 50 mg daily for a period of seven days.Control group: The standard therapeutic regimen for COVID-19 along with Melatonin-like placebo capsules at a dose of one capsule daily for a period of seven days.Both Melatonin and placebo capsules were prepared at the Faculty of Pharmacy and Pharmaceutical Sciences, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
   Main outcomes: The primary outcomes are the recovery rate of clinical symptoms and oxygen saturation as well as improvement of serum inflammatory parameters, including C-reactive protein, tumor necrosis factor-alpha (TNF-?), interleukin-1 beta (IL-1 beta), and IL-6 within seven days of randomization.The secondary outcomes are the time to improve clinical and paraclinical features along with the incidence of serious adverse drug reactions within seven days of randomization.
   Randomization: Included patients will be allocated to one of the study arms using block randomization in a 1:1 ratio (each block consists of 10 patients). This randomization method ensures a balanced allocation between the arms during the study. A web-based system will generate random numbers for the allocation sequence and concealment of participants. Each number relates to one of the study arms.
   Blinding (masking): All study participants, clinicians, nurses, research coordinators, and those analyzing the data are blinded to the group assignment.
   Numbers to be randomized (sample size): A total of 60 patients randomized into two groups (30 in each group).
   Trial Status: The trial protocol is Version 1.0, August 14, 2020. Recruitment began August 22, 2020, and is anticipated to be completed by November 30, 2020.
   Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Ziaei, Ava; Davoodian, Parivash; Dadvand, Habib; Mahmoudikia, Fahime] Hormozgan Univ Med Sci, Hormozgan Hlth Inst, Infect & Trop Dis Res Ctr, Bandar Abbas, Iran.
   [Safa, Omid] Hormozgan Univ Med Sci, Fac Pharm, Dept Clin Pharm, Bandar Abbas, Iran.
   [Hassanipour, Soheil] Guilan Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Rasht, Iran.
   [Omidi, Mahmoud; Rafiee, Bahareh; Fathalipour, Mohammad] Hormozgan Univ Med Sci, Fac Pharm, Dept Pharmacol & Toxicol, Bandar Abbas, Iran.
   [Masjedi, Moein] Shiraz Univ Med Sci, Sch Pharm, Dept Pharmaceut, Shiraz, Iran.
   [Fathalipour, Mohammad] Hormozgan Univ Med Sci, Endocrinol & Metab Res Ctr, Bandar Abbas, Iran.
RP Fathalipour, M (corresponding author), Hormozgan Univ Med Sci, Fac Pharm, Dept Pharmacol & Toxicol, Bandar Abbas, Iran.; Fathalipour, M (corresponding author), Hormozgan Univ Med Sci, Endocrinol & Metab Res Ctr, Bandar Abbas, Iran.
EM M.fathalipour@hums.ac.ir
RI Hassanipour, Soheil/Y-7903-2019; Fathalipour, Mohammad/L-9204-2016
OI Fathalipour, Mohammad/0000-0002-4568-7024
FU Hormozgan University of Medical Sciences, Bandar Abbas, Iran [990191]
FX This trial has been supported by Hormozgan University of Medical
   Sciences, Bandar Abbas, Iran (grant no. 990191). The funders have no
   role in the trial design, the intervention procedures, collection,
   evaluation, and analysis of data.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 26
PY 2020
VL 21
IS 1
AR 882
DI 10.1186/s13063-020-04737-w
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OS3NQ
UT WOS:000590072400005
PM 33106171
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cun, YN
   Li, CY
   Shi, L
   Sun, M
   Dai, SY
   Sun, L
   Shi, L
   Yao, YF
AF Cun, Yina
   Li, Chuanyin
   Shi, Lei
   Sun, Ming
   Dai, Shuying
   Sun, Le
   Shi, Li
   Yao, Yufeng
TI COVID-19 coronavirus vaccine T cell epitope prediction analysis based on
   distributions of HLA class I loci (HLA-A, -B, -C) across global
   populations
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE SARS-CoV-2; Human Leukocyte Antigen (HLA); T cell epitopes; population
   coverage; vaccine
ID ACUTE RESPIRATORY SYNDROME; SYNDROME SARS CORONAVIRUS; SPIKE PROTEIN;
   RESPONSES; IDENTIFICATION; PNEUMONIA; OUTBREAK; WUHAN
AB T cell immunity, such as CD4 and/or CD8 T cell responses, plays a vital role in controlling the virus infection and pathological damage. Several studies have reported SARS-CoV-2 proteins could serve as ideal vaccine candidates against SARS-CoV-2 infection by activating the T cell responses. In the current study, based on the SARS-CoV-2 sequence and distribution of host human leukocyte antigen (HLA), we predicted the possible epitopes for the vaccine against SARS-CoV-2 infections. Firstly, the current study retrieved the SARS-CoV-2 S and N protein sequences from the NCBI Database. Then, using the Immune Epitope Database Analysis Resource, we predicted the CTL epitopes of the SARS-CoV-2 S and N proteins according to worldwide frequency distributions of HLA-A, -B, and -C alleles (>1%). Our results predicted 90 and 106 epitopes of N and S proteins, respectively. Epitope cluster analysis showed 16 and 34 respective clusters of SARS-CoV-2 N and S proteins, which covered 95.91% and 96.14% of the global population, respectively. After epitope conservancy analysis, 8 N protein epitopes and 6 S protein epitopes showed conservancy within two SARS-CoV-2 types. Of these 14 epitopes, 13 could cover SARS coronavirus and Bat SARS-like coronavirus. The remaining epitope (KWPWYIWLGF(1211-1220)) could cover MERS coronavirus. Finally, the 14-epitope combination could vaccinate 89.60% of all individuals worldwide. Our results propose single or combined CTL epitopes predicted in the current study as candidates for vaccines to effectively control SARS-CoV-2 infection and development.
C1 [Cun, Yina; Li, Chuanyin; Shi, Lei; Sun, Ming; Shi, Li; Yao, Yufeng] Chinese Acad Med Sci & Peking Union Med Coll, Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Yunnan Engn Res Ctr Vaccine Res & Dev Severe Infe, Inst Med Biol, Kunming, Yunnan, Peoples R China.
   [Dai, Shuying; Sun, Le] Kunming Med Univ, Sch Basic Med Sci, Kunming, Yunnan, Peoples R China.
RP Shi, L; Yao, YF (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming 650118, Yunnan, Peoples R China.
EM shili.imb@gmail.com; yufeng_yao@imbcams.com.cn
OI Shi, Li/0000-0001-9508-7863
FU Special Funds for high-level health talents of Yunnan Province
   [D-201669, L-201615]; Yunnan Provincial Science and Technology
   Department [2019HC0060]
FX This work was supported by grant from Special Funds for high-level
   health talents of Yunnan Province (D-201669 and L-201615) and the Yunnan
   Provincial Science and Technology Department (2019HC0060). The funders
   had no role in the design of the study, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Bezu L, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1511506
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Cheung Y K, 2008, Hong Kong Med J, V14 Suppl 4, P27
   Cheung YK, 2007, VACCINE, V25, P6070, DOI 10.1016/j.vaccine.2007.05.025
   Coleman CM, 2017, J VIROL
   Dhanda SK, 2018, IMMUNOLOGY, V155, P331, DOI 10.1111/imm.12984
   Fan YY, 2009, ARCH VIROL, V154, P1093, DOI 10.1007/s00705-009-0409-6
   GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403
   He YX, 2004, J IMMUNOL, V173, P4050, DOI 10.4049/jimmunol.173.6.4050
   HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Hung CF, 2008, EXPERT OPIN BIOL TH, V8, P421, DOI 10.1517/14712598.8.4.421 
   Ibrahim Hiba Siddig, 2020, Methods Mol Biol, V2131, P39, DOI 10.1007/978-1-0716-0389-5_4
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Liu J, 2010, J VIROL, V84, P11849, DOI 10.1128/JVI.01464-10
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20
   Peng H, 2006, VIROLOGY, V351, P466, DOI 10.1016/j.virol.2006.03.036
   Shi YL, 2004, J CLIN VIROL, V31, P66, DOI 10.1016/j.jcv.2004.05.006
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Tsao YP, 2006, BIOCHEM BIOPH RES CO, V344, P63, DOI 10.1016/j.bbrc.2006.03.152
   Wang BM, 2004, BLOOD, V104, P200, DOI 10.1182/blood-2003-11-4072
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YD, 2004, J VIROL, V78, P5612, DOI 10.1128/JVI.78.11.5612-5618.2004
   Zhou MH, 2006, J IMMUNOL, V177, P2138, DOI 10.4049/jimmunol.177.4.2138
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 31
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1823777
EA OCT 2020
PG 12
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA OQ0VU
UT WOS:000588511000001
PM 33175614
OA Bronze
DA 2021-01-01
ER

PT J
AU Francescangeli, F
   De Angelis, ML
   Baiocchi, M
   Rossi, R
   Biffoni, M
   Zeuner, A
AF Francescangeli, Federica
   De Angelis, Maria Laura
   Baiocchi, Marta
   Rossi, Rachele
   Biffoni, Mauro
   Zeuner, Ann
TI COVID-19-Induced Modifications in the Tumor Microenvironment: Do They
   Affect Cancer Reawakening and Metastatic Relapse?
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE coronavirus disease 2019; cancer; dormancy; relapse; inflammation;
   disseminated tumor cells; tumor microenvironment
ID CELLS; INFLAMMATION; IMMUNITY; INHIBITION; ACTIVATION; MORTALITY;
   VACCINE; ESCAPE; HEAD; IL-6
AB Severe coronavirus disease 2019 (COVID-19) causes an uncontrolled activation of the innate immune response, resulting in acute respiratory distress syndrome and systemic inflammation. The effects of COVID-19-induced inflammation on cancer cells and their microenvironment are yet to be elucidated. Here, we formulate the hypothesis that COVID-19-associated inflammation may generate a microenvironment favorable to tumor cell proliferation and particularly to the reawakening of dormant cancer cells (DCCs). DCCs often survive treatment of primary tumors and populate premetastatic niches in the lungs and other organs, retaining the potential for metastatic outgrowth. DCCs reawakening may be promoted by several events associated to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, including activation of neutrophils and monocytes/macrophages, lymphopenia and an uncontrolled production of pro-inflammatory cytokines. Among pro-inflammatory factors produced during COVID-19, neutrophil extracellular traps (NETs) released by activated neutrophils have been specifically shown to activate premetastatic cancer cells disseminated in the lungs, suggesting they may be involved in DCCs reawakening in COVID-19 patients. If confirmed by further studies, the links between COVID-19, DCCs reactivation and tumor relapse may support the use of specific anti-inflammatory and anti-metastatic therapies in patients with COVID-19 and an active or previous cancer.
C1 [Francescangeli, Federica; De Angelis, Maria Laura; Baiocchi, Marta; Rossi, Rachele; Biffoni, Mauro; Zeuner, Ann] Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy.
RP Zeuner, A (corresponding author), Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy.
EM a.zeuner@iss.it
OI Baiocchi, Marta/0000-0003-0976-0690
FU Italian Association for Cancer Research (AIRC)Associazione Italiana per
   la Ricerca sul Cancro (AIRC) [20744]
FX This work was supported by an Italian Association for Cancer Research
   (AIRC) Investigator Grant to AZ (AIRC IG 2017 Ref: 20744).
CR Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227
   Atsumi T, 2014, CANCER RES, V74, P8, DOI 10.1158/0008-5472.CAN-13-2322
   Au L, 2020, CELL, V183, P4, DOI 10.1016/j.cell.2020.09.005
   Balamurugan K, 2019, ONCOGENE, V38, P3765, DOI 10.1038/s41388-018-0516-5
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Bent R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082155
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Chan LC, 2019, J CLIN INVEST, V129, P3324, DOI 10.1172/JCI126022
   Chang TS, 2015, CLIN CANCER RES, V21, P201, DOI 10.1158/1078-0432.CCR-13-3274
   Chen ZY, 2020, NAT REV IMMUNOL, V20, P529, DOI 10.1038/s41577-020-0402-6
   Cools-Lartigue J, 2013, J CLIN INVEST, V123, P3446, DOI 10.1172/JCI67484
   COVIDsurg Collaborative, 2020, LANCET, V396, P27, DOI 10.1016/S0140-6736(20)31182-X
   De Cock JM, 2016, CANCER RES, V76, P6778, DOI 10.1158/0008-5472.CAN-16-0608
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Delpino MV, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00340
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   El Rayes T, 2015, P NATL ACAD SCI USA, V112, P16000, DOI 10.1073/pnas.1507294112
   Erickson JJ, 2015, J IMMUNOL, V195, P4319, DOI 10.4049/jimmunol.1403004
   Eyles J, 2010, J CLIN INVEST, V120, P2030, DOI 10.1172/JCI42002
   Feng Y, 2010, ONCOL REP, V23, P941, DOI 10.3892/or_00000718
   Finkel KA, 2016, NEOPLASIA, V18, P273, DOI 10.1016/j.neo.2016.03.004
   Fiorini E, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00166
   Fisher DT, 2014, SEMIN IMMUNOL, V26, P38, DOI 10.1016/j.smim.2014.01.008
   Franco R, 2020, J IMMUNOL, V205, P1198, DOI 10.4049/jimmunol.2000642
   Gallo Marianna, 2018, Oncotarget, V9, P17543, DOI 10.18632/oncotarget.24784
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Ghajar CM, 2015, NAT REV CANCER, V15, P238, DOI 10.1038/nrc3910
   Goddard ET, 2018, NAT CELL BIOL, V20, P1240, DOI 10.1038/s41556-018-0214-0
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Gross AC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99791
   Hiller JG, 2018, NAT REV CLIN ONCOL, V15, P205, DOI 10.1038/nrclinonc.2017.194
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang L, 2016, WIREL POWER TRANSF, V3, P53, DOI 10.1017/wpt.2016.2
   Itoh H, 2018, ONCOGENE, V37, P2903, DOI 10.1038/s41388-018-0160-0
   Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577-018-0066-7
   Kang SJ, 2019, IMMUNITY, V50, P1007, DOI 10.1016/j.immuni.2019.03.026
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lai SC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1442-2
   Leach J, 2019, MOL IMMUNOL, V110, P69, DOI 10.1016/j.molimm.2017.12.013
   Lee JW, 2019, NATURE, V567, P249, DOI 10.1038/s41586-019-1004-y
   Lee LYW, 2020, LANCET ONCOL, V21, P1309, DOI 10.1016/S1470-2045(20)30442-3
   Li S, 2012, CANCER RES, V72, P865, DOI 10.1158/0008-5472.CAN-11-1357
   Liao D, 2011, CANCER RES, V71, P5688, DOI 10.1158/0008-5472.CAN-11-1264
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Lu CW, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1247135
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025
   Mantovani A, 2018, IMMUNOL REV, V281, P57, DOI 10.1111/imr.12614
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Meyer F, 2010, CLIN CANCER RES, V16, P1008, DOI 10.1158/1078-0432.CCR-09-2014
   Middleton EA, 2020, BLOOD, V136, P1169, DOI 10.1182/blood.2020007008
   Murakami M, 2019, IMMUNITY, V50, P812, DOI 10.1016/j.immuni.2019.03.027
   Obradovic MMS, 2019, NATURE, V567, P540, DOI 10.1038/s41586-019-1019-4
   Phan TG, 2020, NAT REV CANCER, V20, P398, DOI 10.1038/s41568-020-0263-0
   Quail DF, 2017, NAT CELL BIOL, V19, P974, DOI 10.1038/ncb3578
   Radermecker Coraline, 2020, J Exp Med, V217, DOI 10.1084/jem.20201012
   Rapoport BL, 2020, MOLECULES, V25, DOI 10.3390/molecules25071618
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rivellese F, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102536
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Rodrigues CFD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29947-w
   Romero I, 2014, CANCER RES, V74, P1958, DOI 10.1158/0008-5472.CAN-13-2084
   Saini KS, 2020, EUR J CANCER, V139, P43, DOI 10.1016/j.ejca.2020.08.011
   Semesiuk N., 2013, Experimental Oncology, V35, P295
   Seyfried Thomas N., 2013, Critical Reviews in Oncogenesis, V18, P43
   Stebbing J, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012697
   Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180
   Takesue S, 2020, INT J ONCOL, V56, P596, DOI 10.3892/ijo.2019.4951
   Takimoto-Ohnishi E, 2019, J PHYSIOL SCI, V69, P581, DOI 10.1007/s12576-019-00679-4
   Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142
   Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001
   Thibaud S, 2020, BRIT J HAEMATOL, V190, pE73, DOI 10.1111/bjh.16863
   Tutuncuoglu B, 2020, CANCER DISCOV, V10, P916, DOI 10.1158/2159-8290.CD-20-0559
   Ungprasert P, 2015, RHEUMATOLOGY, V54, P736, DOI 10.1093/rheumatology/keu408
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Veras FP, 2020, J EXP MED, V217, DOI 10.1101/2020.06.08.20125823
   Wang TY, 2019, ONCOGENE, V38, P4932, DOI 10.1038/s41388-019-0763-0
   Wang YN, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122360
   Wang YH, 2018, MICROMACHINES-BASEL, V9, DOI 10.3390/mi9010019
   Wellenstein MD, 2019, NATURE, V572, P538, DOI 10.1038/s41586-019-1450-6
   Yan LB, 2013, CLIN CANCER RES, V19, P4706, DOI 10.1158/1078-0432.CCR-13-0011
   Yeleswaram S, 2020, CLIN IMMUNOL, V218, DOI 10.1016/j.clim.2020.108517
   Yu CH, 2016, CANCER LETT, V376, P268, DOI 10.1016/j.canlet.2016.04.006
   Zhang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1156-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00784-1
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 89
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD OCT 26
PY 2020
VL 10
AR 592891
DI 10.3389/fonc.2020.592891
PG 9
WC Oncology
SC Oncology
GA OO5AG
UT WOS:000587390600001
PM 33194755
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Istifli, ES
   Netz, PA
   Tepe, AS
   Husunet, MT
   Sarikurkcu, C
   Tepe, B
AF Istifli, Erman Salih
   Netz, Paulo A.
   Tepe, Arzuhan Sihoglu
   Husunet, Mehmet Tahir
   Sarikurkcu, Cengiz
   Tepe, Bektas
TI In silico analysis of the interactions of certain flavonoids with the
   receptor-binding domain of 2019 novel coronavirus and cellular proteases
   and their pharmacokinetic properties
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; flavonoid; molecular docking; molecular dynamics; MM; PBSA
ID PARTICLE MESH EWALD; CATHEPSIN-L; SARS CORONAVIRUS; SERINE-PROTEASE;
   SARS-COV-2; DYNAMICS; TMPRSS2; CELLS; HEART; ACE2
AB Coronavirus Disease 2019 (COVID-19) has infected more than thirty five million people worldwide and caused nearly 1 million deaths as of October 2020. The microorganism causing COVID-19 was named as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 or 2019-nCoV). The aim of this study was to investigate the interactions of twenty-three phytochemicals belonging to different flavonoid subgroups with the receptor binding domain (RBD) of the spike glycoprotein of 2019-nCoV, and cellular proteases [transmembrane serine protease 2 (TMPRSS2), cathepsin B and L (CatB/L)]. The compounds interacted more strongly with CatB and CatL than with the other proteins. Van der Waals and hydrogen bonds played an important role in the receptor-ligand interactions. As a result of RBCI (relative binding capacity index) analysis conducted to rank flavonoids in terms of their interactions with the target proteins, (-)-epicatechin gallate interacted strongly with all the proteins studied. The results obtained from molecular dynamics and molecular mechanics Poisson-Boltzmann surface area (MM/PBSA) methods also supported this data. According to Lipinski's rule of five, (-)-epicatechin gallate showed drug-likeness properties. Although this molecule is not capable of crossing the blood-brain barrier (BBB), it was concluded that (-)-epicatechin gallate can be evaluated as a candidate molecule in drug development studies against 2019-nCoV since it was not the substrate of P-gp (P-glycoprotein), did not inhibit any of the cytochrome Ps, and did not show AMES toxicity or hepatotoxicity on eukaryotic cells.
C1 [Istifli, Erman Salih; Husunet, Mehmet Tahir] Cukurova Univ, Fac Sci & Literature, Dept Biol, TR-01330 Adana, Turkey.
   [Netz, Paulo A.] Univ Fed Rio Grande do Sul, Inst Chem, Theoret Chem Grp, Porto Alegre, RS, Brazil.
   [Tepe, Arzuhan Sihoglu] Gaziantep Univ, Fac Sci & Literature, Dept Biol, Gaziantep, Turkey.
   [Sarikurkcu, Cengiz] Afyonkarahisar Hlth Sci Univ, Fac Pharm, Dept Analyt Chem, Afyon, Turkey.
   [Tepe, Bektas] Kilis 7 Aralik Univ, Dept Mol Biol & Genet, Fac Sci & Literature, Kilis, Turkey.
RP Istifli, ES (corresponding author), Cukurova Univ, Fac Sci & Literature, Dept Biol, TR-01330 Adana, Turkey.
EM ermansalih@gmail.com
RI TEPE, Bektas/N-2987-2013
OI TEPE, Bektas/0000-0001-8982-5188; Sarikurkcu,
   Cengiz/0000-0001-5094-2520; Istifli, Erman Salih/0000-0003-2189-0703;
   SIHOGLU TEPE, Arzuhan/0000-0001-8290-9880
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES [001]; Centro Nacional de Supercomputacao (CESUP),
   Universidade Federal do Rio Grande do Sul (UFRGS)
FX P. A. N. acknowledges financial support from CNPq and CAPES (Financial
   code 001), as well as the Centro Nacional de Supercomputacao (CESUP),
   Universidade Federal do Rio Grande do Sul (UFRGS) for providing HPC
   resources.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Anguiano L, 2017, CURR MED CHEM, V24, P3231, DOI 10.2174/0929867324666170414162841
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Bhowmik D., 2020, EVALUATION FLAVONOID, DOI [10.26434/chemrxiv.12071508.v1, DOI 10.26434/CHEMRXIV.12071508.V1]
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Carletti G, 2014, INT J BIOL SCI, V10, P1159, DOI 10.7150/ijbs.9672
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de Andrade J., 2020, DOES NOVEL CORONAVIR, DOI [10.26434/chemrxiv.12361238.v2, DOI 10.26434/CHEMRXIV.12361238.V2]
   Devika PT, 2008, CHEM-BIOL INTERACT, V172, P245, DOI 10.1016/j.cbi.2008.01.003
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI [10.1186/1756-0500-5-185, 10.1186/1756-0500-5-367]
   Greenspan PD, 2001, J MED CHEM, V44, P4524, DOI 10.1021/jm010206q
   Guex N, 2009, ELECTROPHORESIS, V30, pS162, DOI 10.1002/elps.200900140
   Hardegger LA, 2011, CHEMMEDCHEM, V6, P2048, DOI 10.1002/cmdc.201100353
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Homeyer N, 2012, MOL INFORM, V31, P114, DOI 10.1002/minf.201100135
   HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695
   Huang IC, 2006, J BIOL CHEM, V281, P3198, DOI 10.1074/jbc.M508381200
   Istifli ES, 2020, TURK J BIOL, V44, P242, DOI 10.3906/biy-2005-46
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lam T. T.-Y., 2020, BIORXIV, DOI [10.1101/2020.1102.1113.945485, DOI 10.1101/2020.1102.1113.945485]
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Luan JW, 2020, BIOCHEM BIOPH RES CO, V526, P165, DOI 10.1016/j.bbrc.2020.03.047
   Maiti S., 2020, EPIGALLOCATECHIN GAL, V2020040247, DOI 10.20944/preprints202004.0247.v1
   Majumdar ID, 2011, BIOCHEM BIOPH RES CO, V416, P397, DOI 10.1016/j.bbrc.2011.11.052
   Mandal SM, 2010, PLANT SIGNAL BEHAV, V5, P359, DOI 10.4161/psb.5.4.10871
   Manish M., 2020, STUDIES COMPUTATIONA, DOI [10.26434/chemrxiv.12024789.v2, DOI 10.26434/CHEMRXIV.12024789.V2]
   Middleton E, 2000, PHARMACOL REV, V52, P673
   Morris G M, 2008, MOL MODELING PROTEIN, P365, DOI DOI 10.1007/978-1-59745-177-2_19
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nasab RR, 2017, RES PHARM SCI, V12, P425, DOI 10.4103/1735-5362.213988
   NOSE S, 1984, J CHEM PHYS, V81, P511, DOI 10.1063/1.447334
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Omotuyi IO, 2020, J COMPUT CHEM, V41, P2158, DOI 10.1002/jcc.26383
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pedretti A, 2004, J COMPUT AID MOL DES, V18, P167, DOI 10.1023/B:JCAM.0000035186.90683.f2
   Peterson L., 2020, COVID 19 FLAVONOIDS
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Rahman N, 2020, MOLECULES, V25, DOI 10.3390/molecules25102271
   Remmert M, 2012, NAT METHODS, V9, P173, DOI [10.1038/NMETH.1818, 10.1038/nmeth.1818]
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   Sayed AM, 2020, RSC ADV, V10, P19790, DOI 10.1039/d0ra04199h
   Sharma S., 1996, 2 GROUP DISCRIMINATN
   Studer G, 2020, BIOINFORMATICS, V36, P1765, DOI 10.1093/bioinformatics/btz828
   Sudhan DR, 2015, PHARMACOL THERAPEUT, V155, P105, DOI 10.1016/j.pharmthera.2015.08.007
   Tallei T. E., 2020, POTENTIAL PLANT BIOA, DOI [10.20944/preprints202004.0102.v1, DOI 10.20944/PREPRINTS202004.0102.V2]
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang YJ, 2020, P NATL ACAD SCI USA, V117, P13967, DOI 10.1073/pnas.2008209117
   Wilson S, 2005, BIOCHEM J, V388, P967, DOI 10.1042/BJ20041066
   Wong M. C., 2020, BIORXIV, DOI [10.1101/2020.1102.1107.939207, DOI 10.1101/2020.1102.1107.939207]
   Woo H, 2020, J PHYS CHEM B, V124, P7128, DOI 10.1021/acs.jpcb.0c04553
   Worldometer, 2020, COVID 19 COR PAND
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zakaryan H, 2017, ARCH VIROL, V162, P2539, DOI 10.1007/s00705-017-3417-y
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044593
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 71
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1840444
EA OCT 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OK6ZY
UT WOS:000584797200001
PM 33111622
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Iradukunda, PG
   Pierre, G
   Muhozi, V
   Denhere, K
   Dzinamarira, T
AF Iradukunda, Patrick Gad
   Pierre, Gashema
   Muhozi, Valens
   Denhere, Knowledge
   Dzinamarira, Tafadzwa
TI Knowledge, Attitude, and Practice Towards COVID-19 Among People Living
   with HIV/AIDS in Kigali, Rwanda
SO JOURNAL OF COMMUNITY HEALTH
LA English
DT Article; Early Access
DE COVID-19; HIV; Knowledge; Attitude; Practice
ID ACUTE RESPIRATORY SYNDROME; OUTBREAK; DISEASE; HIV
AB As with other countries globally, Rwanda has faced a recent outbreak of the coronavirus disease 2019 (COVID-19) against a backdrop of an HIV epidemic. At present, there is no successful cure or vaccine for both COVID-19 and HIV. People with underlying conditions, including HIV, are at increased risk of severe COVID-19 manifestations. This underscores the need to enhance the knowledge, attitudes, and practice of people living with HIV (PLWH) to protect this population against COVID-19. An institution-based cross-sectional study was conducted from August 31 to September 18, 2020 among 376 participants who were selected by a simple random sampling technique. A pretested and structured self-administered questionnaire was used to collect data. Quality scores were calculated as a measure of the participants' knowledge, attitudes, and practice (KAP) levels. The student t-test was used to compare continuous variables between low (<65%) and high (>= 65%) KAP scores. The chi-square test was used to determine the association between KAP scores and categorical variables. All decisions on statistical tests were concluded at 5% level of significance. All statistical analysis was performed using STATA statistical package version 11.2 (STATA Corp., Texas, USA). Of the 376 participants, 363 (97%) obtained a high knowledge score, while more than a quarter of the participants (26%) had a poor attitude score, and the majority (90%) having a high practice score. There was no association between gender, age, place of residence, employment, or duration on ART and knowledge score. Employment status and duration on antiretroviral treatment (ART) were significantly associated with attitude scores (p = 0.004 and p = 0.013, respectively). Gender and duration on ART were significantly associated with practice scores (p = 0.02 and p = 0.012, respectively). There was a moderate positive correlation (r = 0.57) between knowledge and attitude scores, and knowledge and practice scores (r = 0.55). There was a strong positive correlation (r = 0.67) between attitude scores and practice scores. Health education programs tailored for PLWH and aimed at mobilizing and improving COVID-19-related knowledge, attitude, and practice should be prioritized in the Rwandan COVID-19 response.
C1 [Iradukunda, Patrick Gad; Dzinamarira, Tafadzwa] Mt Kenya Univ, Dept Publ Hlth, Kigali, Rwanda.
   [Pierre, Gashema; Muhozi, Valens] Univ Rwanda, Coll Med & Hlth Sci, Kigali, Rwanda.
   [Denhere, Knowledge] Univ Western Cape, Sch Publ Hlth, Bellville, South Africa.
   [Dzinamarira, Tafadzwa] Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Dept Publ Hlth Med, ZA-4001 Durban, South Africa.
RP Dzinamarira, T (corresponding author), Mt Kenya Univ, Dept Publ Hlth, Kigali, Rwanda.; Dzinamarira, T (corresponding author), Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Dept Publ Hlth Med, ZA-4001 Durban, South Africa.
EM anthonydzina@gmail.com
OI Dzinamarira, Tafadzwa/0000-0002-9929-5739; IRADUKUNDA, Patrick
   Gad/0000-0002-0236-7776
CR Akalu Y, 2020, INFECT DRUG RESIST, V13, P1949, DOI 10.2147/IDR.S258736
   Al-Hanawi MK, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00217
   ALdowyan N., 2017, INT ARCH MED, V10, DOI [10.3823/2524, DOI 10.3823/2524]
   [Anonymous], 2020, AFRICA SURVEYORS NEW
   Austrian K, 2020, COVID 19 RELATED KNO, DOI [10.2139/ssrn.3576785, DOI 10.2139/SSRN.3576785]
   Blendon RJ, 2004, CLIN INFECT DIS, V38, P925, DOI 10.1086/382355
   Carpio A.L.M., 2020, STATPEARLS
   CDC, 2020, COR COVID 19, DOI 10.1016/S0140-6736(20)30673-5
   Chang CC, 2013, IMMUNOL REV, V254, P114, DOI 10.1111/imr.12063
   Cooper TJ, 2020, HIV MED, V21, P567, DOI 10.1111/hiv.12911
   de Mendoza C, 2019, AIDS REV, V21, P170
   Erfani A, 2020, B WORLD HEALTH ORGAN, DOI [10.2471/BLT.20.256651, DOI 10.2471/BLT.20.256651]
   Estacio EV, 2019, J HEALTH PSYCHOL, V24, P1668, DOI 10.1177/1359105317695429
   GoR, 2020, OFF PRIM MIN ANN ENH
   Kebede Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233744
   Khalili M., 2020, EPIDEMIOLOGICAL CHAR, V2020, DOI [10.1101/2020.04.01.20050138., DOI 10.1101/2020.04.01.20050138, 10.1101/2020.04.01.20050138]
   Leung GM, 2003, J EPIDEMIOL COMMUN H, V57, P857, DOI 10.1136/jech.57.11.857
   McEachan R, 2016, ANN BEHAV MED, V50, P592, DOI 10.1007/s12160-016-9798-4
   Mirzaei H, 2020, AIDS BEHAV, DOI 10.1007/s10461-020-02983-2
   Moran KR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164541
   Mutesa L., 2020, STRATEGY FINDING PEO
   Nepal R., 2020, KNOWLEDGE ATTITUDE P, DOI [10.21203/rs.3.rs-26774/v1, DOI 10.21203/RS.3.RS-26774/V1]
   Nsanzimana S, 2019, PEDIATR INFECT DIS J, V38, P149, DOI 10.1097/INF.0000000000002101
   Ozma Mahdi Asghari, 2020, Infez Med, V28, P153
   Pierre G, 2020, AIDS BEHAV, V24, P3299, DOI 10.1007/s10461-020-02956-5
   RBC, 2020, UPD COVID 19
   Spanou C, 2009, PSYCHOL HEALTH, V24, P372
   Taghrir MH, 2020, ARCH IRAN MED, V23, P249, DOI [10.34172/aim.2020.06, 10.34172/aim.2020.06 Abstract View:]
   UNAIDS, 2019, FACTSH GLOB AIDS UPD
   Van den Broucke S, 2020, WHY HLTH PROMOTION M
   WHO, 2020, NOV COR COVID 19
   Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221
NR 32
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0094-5145
EI 1573-3610
J9 J COMMUN HEALTH
JI J. Community Health
DI 10.1007/s10900-020-00938-1
EA OCT 2020
PG 6
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA OJ4LO
UT WOS:000583935300001
PM 33106963
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Chen, L
   Liu, B
   Sun, P
   Wang, WJ
   Luo, SQ
   Zhang, WY
   Yang, YF
   Wang, ZH
   Lin, J
   Chen, PR
AF Chen, Long
   Liu, Bo
   Sun, Peng
   Wang, Wenjun
   Luo, Shiqiang
   Zhang, Wenyuan
   Yang, Yuanfan
   Wang, Zihao
   Lin, Jian
   Chen, Peng R.
TI Severe Acute Respiratory Syndrome Coronavirus-2 Spike Protein Nanogel as
   a Pro-Antigen Strategy with Enhanced Protective Immune Responses
SO SMALL
LA English
DT Article
DE coronavirus disease&#8208; 19; nanogel; receptor binding domain; severe
   acute respiratory syndrome coronavirus&#8208; 2; subunit vaccine
ID RECEPTOR-BINDING DOMAIN; VACCINE
AB Prevention and intervention methods are urgently needed to curb the global pandemic of coronavirus disease-19 caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Herein, a general pro-antigen strategy for subunit vaccine development based on the reversibly formulated receptor binding domain of SARS-CoV-2 spike protein (S-RBD) is reported. Since the poor lymph node targeting and uptake of S-RBD by antigen-presenting cells prevent effective immune responses, S-RBD protein is formulated into a reversible nanogel (S-RBD-NG), which serves as a pro-antigen with enhanced lymph node targeting and dendritic cell and macrophage accumulation. Synchronized release of S-RBD monomers from the internalized S-RBD-NG pro-antigen triggers more potent immune responses in vivo. In addition, by optimizing the adjuvant used, the potency of S-RBD-NG is further improved, which may provide a generally applicable, safer, and more effective strategy for subunit vaccine development against SARS-CoV-2 as well as other viruses.
C1 [Chen, Long; Zhang, Wenyuan; Yang, Yuanfan; Lin, Jian; Chen, Peng R.] Peking Univ, Minist Educ, Coll Chem & Mol Engn, Beijing Natl Lab Mol Sci,Key Lab Bioorgan Chem &, Beijing 100871, Peoples R China.
   [Liu, Bo; Sun, Peng; Luo, Shiqiang] Beijing Inst Biotechnol, Dept Microorganism Engn, Beijing 100071, Peoples R China.
   [Wang, Wenjun] Chinese Acad Sci, Univ Chinese Acad Sci, Coll Life Sci, Inst Biophys,Key Lab Infect & Immun, Beijing 100101, Peoples R China.
   [Luo, Shiqiang] Anhui Univ, Inst Phys Sci & Informat, Hefei 230601, Peoples R China.
   [Wang, Zihao] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China.
   [Chen, Peng R.] Peking Univ, Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China.
RP Lin, J; Chen, PR (corresponding author), Peking Univ, Minist Educ, Coll Chem & Mol Engn, Beijing Natl Lab Mol Sci,Key Lab Bioorgan Chem &, Beijing 100871, Peoples R China.; Chen, PR (corresponding author), Peking Univ, Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China.
EM linjian@pku.edu.cn; pengchen@pku.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31471299, 81522046, 21521003, 21432002];
   National Key Research and Development Program of China [2016YFA0501500];
   National Science and Technology Major Projects for "Major New Drugs
   Innovation and Development" [2018ZX09711003]
FX L.C. and B.L. contributed equally to this work. This research was
   supported by the National Natural Science Foundation of China (31471299,
   81522046, 21521003, and 21432002), National Key Research and Development
   Program of China (2016YFA0501500), and National Science and Technology
   Major Projects for "Major New Drugs Innovation and Development"
   (2018ZX09711003). Animal experiments were performed according to the
   guidelines of the IACUC of Peking University Health Science Center (No.
   LA2018033) and were approved by the Ethics Committee of Beijing
   Institute of Biotechnology (No. IACUCDWZX-2020-038) DC 2.4, RAW 264.7
   and HEK293T cells were obtained from the American Type Culture
   Collection (ATCC). COS7-hACE2 cells were purchased from VITALSTAR
   (Beijing, China).
CR Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Caproni E, 2012, J IMMUNOL, V188, P3088, DOI 10.4049/jimmunol.1101764
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Chen WH, 2017, J PHARM SCI-US, V106, P1961, DOI 10.1016/j.xphs.2017.04.037
   Chen WH, 2014, HUM VACC IMMUNOTHER, V10, P648, DOI 10.4161/hv.27464
   Chen YG, 2019, MICROB PATHOGENESIS, V130, P204, DOI 10.1016/j.micpath.2019.02.030
   Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035
   Du LY, 2009, VIROLOGY, V393, P144, DOI 10.1016/j.virol.2009.07.018
   Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Gomes AC, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5010006
   Hanson MC, 2017, METHODS MOL BIOL, V1494, P145, DOI 10.1007/978-1-4939-6445-1_10
   Hanson MC, 2015, J CLIN INVEST, V125, P2532, DOI 10.1172/JCI79915
   Hanson MC, 2015, VACCINE, V33, P861, DOI 10.1016/j.vaccine.2014.12.045
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI 10.1038/s41594-020-0469-6
   Irvine DJ, 2015, CHEM REV, V115, P11109, DOI 10.1021/acs.chemrev.5b00109
   Irvine DJ, 2013, NAT MATER, V12, P978, DOI [10.1038/NMAT3775, 10.1038/nmat3775]
   Jiang SB, 2012, EXPERT REV VACCINES, V11, P1405, DOI [10.1586/erv.12.126, 10.1586/ERV.12.126]
   Karch CP, 2016, BIOCHEM PHARMACOL, V120, P1, DOI 10.1016/j.bcp.2016.05.001
   Kishimoto TK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00230
   Kou LF, 2013, ASIAN J PHARM SCI, V8, P1, DOI 10.1016/j.ajps.2013.07.001
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Metcalfe SM, 2012, TRENDS MOL MED, V18, P72, DOI 10.1016/j.molmed.2011.11.002
   Muraoka D, 2019, J CLIN INVEST, V129, P1278, DOI 10.1172/JCI97642
   Riley RS, 2019, NAT REV DRUG DISCOV, V18, P175, DOI 10.1038/s41573-018-0006-z
   Smith DM, 2013, NAT REV IMMUNOL, V13, P592, DOI 10.1038/nri3488
   Taylor A, 2015, IMMUNOL REV, V268, P340, DOI 10.1111/imr.12367
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wei LX, 2020, ACS CENTRAL SCI, V6, P404, DOI 10.1021/acscentsci.9b01174
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Yoon HY, 2018, BIOMATERIALS, V178, P597, DOI 10.1016/j.biomaterials.2018.03.036
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 34
TC 0
Z9 0
U1 5
U2 5
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613-6810
EI 1613-6829
J9 SMALL
JI Small
PD NOV
PY 2020
VL 16
IS 46
AR 2004237
DI 10.1002/smll.202004237
EA OCT 2020
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA OZ9VZ
UT WOS:000583614400001
PM 33107685
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Nicol, M
   Cacoub, L
   Baudet, M
   Nahmani, Y
   Cacoub, P
   Cohen-Solal, A
   Henry, P
   Adle-Biassette, H
   Logeart, D
AF Nicol, Martin
   Cacoub, Lea
   Baudet, Mathilde
   Nahmani, Yoram
   Cacoub, Patrice
   Cohen-Solal, Alain
   Henry, Patrick
   Adle-Biassette, Homa
   Logeart, Damien
TI Delayed acute myocarditis and COVID-19-related multisystem inflammatory
   syndrome
SO ESC HEART FAILURE
LA English
DT Article; Early Access
DE Myocarditis; COVID-19; Pathological analysis
ID PATIENT
AB Precise descriptions of coronavirus disease 2019 (COVID-19)-related cardiac damage as well as underlying mechanisms are scarce. We describe clinical presentation and diagnostic workup of acute myocarditis in a patient who had developed COVID-19 syndrome 1 month earlier. A healthy 40-year-old man suffered from typical COVID-19 symptoms. Four weeks later, he was admitted because of fever and tonsillitis. Blood tests showed major inflammation. Thoracic computed tomography was normal, and RT-PCR for SARS-CoV-2 on nasopharyngeal swab was negative. Because of haemodynamic worsening with both an increase in cardiac troponin and B-type natriuretic peptide levels and normal electrocardiogram, acute myocarditis was suspected. Cardiac echographic examination showed left ventricular ejection fraction at 45%. Exhaustive diagnostic workup included RT-PCR and serologies for infectious agents and autoimmune blood tests as well as cardiac magnetic resonance imaging and endomyocardial biopsies. Cardiac magnetic resonance with T2 mapping sequences showed evidence of myocardial inflammation and focal lateral subepicardial late gadolinium enhancement. Pathological analysis exhibited interstitial oedema, small foci of necrosis, and infiltrates composed of plasmocytes, T-lymphocytes, and mainly CD163(+) macrophages. These findings led to the diagnosis of acute lympho-plasmo-histiocytic myocarditis. There was no evidence of viral RNA within myocardium. The only positive viral serology was for SARS-CoV-2. The patient and his cardiac function recovered in the next few days without use of anti-inflammatory or antiviral drugs. This case highlights that systemic inflammation associated with acute myocarditis can be delayed up to 1 month after initial SARS-CoV-2 infection and can be resolved spontaneously.
C1 [Nicol, Martin; Cacoub, Lea; Baudet, Mathilde; Nahmani, Yoram; Cohen-Solal, Alain; Henry, Patrick; Logeart, Damien] Lariboisiere Hosp, AP HP, Cardiol Dept, Paris, France.
   [Cacoub, Patrice] Hop La Pitie Salpetriere, AP HP, Internal Med Dept, Paris, France.
   [Adle-Biassette, Homa] Lariboisiere Hosp, AP HP, Pathol Lab, Paris, France.
   [Cohen-Solal, Alain; Henry, Patrick; Adle-Biassette, Homa; Logeart, Damien] Univ Paris, Paris, France.
RP Logeart, D (corresponding author), Hop Lariboisiere, Cardiol Dept, 2 Rue Ambroise Pare, F-75010 Paris, France.
EM damien.logeart@aphp.fr
CR Belhadjer Z, 2020, CIRCULATION, V142, P429, DOI 10.1161/CIRCULATIONAHA.120.048360
   Bonnet M, 2020, EUR HEART J, V41, P3863, DOI 10.1093/eurheartj/ehaa588
   Caforio ALP, 2013, EUR HEART J, V34, P2636, DOI 10.1093/eurheartj/eht210
   Doyen D, 2020, LANCET, V395, P1516, DOI 10.1016/S0140-6736(20)30912-0
   Ferreira VM, 2018, J AM COLL CARDIOL, V72, P3158, DOI 10.1016/j.jacc.2018.09.072
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Kim IC, 2020, EUR HEART J, V41, P1859, DOI 10.1093/eurheartj/ehaa288
   Luetkens JA, 2020, CIRC-CARDIOVASC IMAG, V13, DOI 10.1161/CIRCIMAGING.120.010897
   Peretto G, 2020, EUR HEART J, V41
   Sala S, 2020, EUR HEART J, V41, P1861, DOI 10.1093/eurheartj/ehaa286
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Zhou R, 2020, EUR HEART J, V41
NR 13
TC 0
Z9 0
U1 1
U2 1
PU WILEY PERIODICALS, INC
PI SAN FRANCISCO
PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA
SN 2055-5822
J9 ESC HEART FAIL
JI ESC Heart Fail.
DI 10.1002/ehf2.13047
EA OCT 2020
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OI9UB
UT WOS:000583613200001
PM 33107217
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Bruynseels, K
AF Bruynseels, Koen
TI Responsible innovation in synthetic biology in response to COVID-19: the
   role of data positionality
SO ETHICS AND INFORMATION TECHNOLOGY
LA English
DT Article; Early Access
DE Positionality; Synthetic biology; Responsible innovation; Data
   frictions; Knowledge commons; Pandemic; COVID-19
ID SOCIETY; SCIENCE
AB Synthetic biology, as an engineering approach to biological systems, has the potential to disruptively innovate the development of vaccines, therapeutics, and diagnostics. Data accessibility and differences in data-usage capabilities are important factors in shaping this innovation landscape. In this paper, the data that underpin synthetic biology responses to the COVID-19 pandemic are analyzed as positional information goods-goods whose value depends on exclusivity. The positionality of biological data impacts the ability to guide innovations toward societally preferred goals. From both an ethical and economic point of view, positionality can lead to suboptimal as well as beneficial situations. When aiming for responsible innovation (i.e. embedding societal deliberation in the innovation process), it is important to consider hurdles and facilitators in data access and use. Central governance and knowledge commons provide routes to mitigate the negative effects of data positionality.
C1 [Bruynseels, Koen] Delft Univ Technol, Technol Policy & Management, Dept Philosophy, Jaffalaan 5, NL-2628 BX Delft, Netherlands.
RP Bruynseels, K (corresponding author), Delft Univ Technol, Technol Policy & Management, Dept Philosophy, Jaffalaan 5, NL-2628 BX Delft, Netherlands.
EM K.R.C.Bruynseels@tudelft.nl
CR [Anonymous], 2020, BIOBRICKS TM PUBLIC
   [Anonymous], 2020, GENBANK SARS COV 2
   [Anonymous], 2019, SYNTH BIOL INV REP 2
   [Anonymous], 2020, WHY OP SCI IS CRIT C
   Bates J, 2018, J DOC, V74, P412, DOI 10.1108/JD-05-2017-0080
   Begley S, 2020, STAT NEWS
   Bogner A, 2018, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01884
   Bogner P, 2006, NATURE, V442, P981, DOI 10.1038/442981a
   Boyle James, 2008, PUBLIC DOMAIN ENCLOS
   Braun R, 2020, J RESPONSIBLE INNOV, V7, P680, DOI 10.1080/23299460.2020.1789387
   Broughton JP, 2020, NAT BIOTECHNOL, V38, P870, DOI 10.1038/s41587-020-0513-4
   Bruynseels K, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00031
   Burgelman JC, 2019, FRONT BIG DATA, V2, P43, DOI DOI 10.3389/FDATA.2019.00043
   Burget M, 2017, SCI ENG ETHICS, V23, P1, DOI 10.1007/s11948-016-9782-1
   Butler D, 2013, NATURE NEWS, DOI [10.1038/nature.2012.12108, DOI 10.1038/NATURE.2012.12108]
   CEPI, 2020, COAL EP PREP INN
   Chadwick Ruth, 2004, Res Publica, V10, P123, DOI 10.1023/B:RESP.0000034637.15364.11
   Cole P, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a020891
   Covid 19 Host Genetics Initiative, 2020, EUR J HUM GENET, V28, P715, DOI 10.1038/s41431-020-0636-6
   COVID-19 Genomics UK (COG-UK) consortiumcontact@cogconsortium.uk, 2020, Lancet Microbe, V1, pe99, DOI 10.1016/S2666-5247(20)30054-9
   Douglas Conor M W, 2013, Syst Synth Biol, V7, P139, DOI 10.1007/s11693-013-9119-1
   Edwards P. N., 2010, VAST MACHINE COMPUTE
   European Commission, 2014, ROM DECL RESP RES IN
   Frank R., 2011, DARWIN EC LIBERTY CO
   FRANK RH, 1985, AM ECON REV, V75, P101
   Freemont PS, 2019, EMERG TOP LIFE SCI, V3, P651, DOI 10.1042/ETLS20190040
   Gouglas D, 2018, LANCET GLOB HEALTH, V6, pE1386, DOI 10.1016/S2214-109X(18)30346-2
   GRCIDP, 2018, DAT SHAR W AFR EB PU
   Hardy BJ, 2008, NAT REV GENET, V9, pS19, DOI 10.1038/nrg2441
   Hirsch F., 1976, SOCIAL LIMITS GROWTH
   Holmes E, 2020, INITIAL GENOME RELEA
   Jensen AB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5022
   Kritikos M., 2020, 10 TECHNOLOGIES FIGH
   Ledford H, 2020, NATURE, V582, P172, DOI 10.1038/d41586-020-01524-0
   Leslie D, 2020, HARVARD DATA SCI REV, DOI [10.2139/ssrn.3652970, DOI 10.2139/SSRN.3652970]
   Levin Nadine, 2016, Bull Sci Technol Soc, V36, P128
   Lezaun J, 2015, SCI TECHNOL HUM VAL, V40, P3, DOI 10.1177/0162243914542349
   Liddicoat J, 2019, EUR J HUM GENET, V27, P997, DOI 10.1038/s41431-019-0368-7
   Macnaghten P, 2016, ESSAYS BIOCHEM, V60, P347, DOI 10.1042/EBC20160048
   Manders-Huits N, 2008, FUTURE OF IDENTITY IN THE INFORMATION SOCIETY, P77
   Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046
   National Health Commission of the People's Republic of China (NHC), 2020, TIM CHIN REL INF COV
   Olena A, 2020, SCIENTIST
   Owen R., 2013, RESPONSIBLE INNOVATI
   Owen R, 2012, SCI PUBL POLICY, V39, P751, DOI 10.1093/scipol/scs093
   Pagano U, 1999, POLITICS EC POWER, P116
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Piller C, 2020, SCIENCE, V368, P1167, DOI 10.1126/science.368.6496.1167
   Prainsack B, 2019, BIG DATA SOC, V6, DOI 10.1177/2053951719829773
   Quah D, 2003, CEPDP0563563 LOND SC
   Raimbault B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161522
   RDA COVID-19 Working Group, 2020, REC GUID DAT SHAR, DOI [10.15497/rda00052, DOI 10.15497/RDA00052]
   Sachsenmeier P, 2016, ENGINEERING, V2, P225, DOI 10.1016/J.ENG.2016.02.015
   Sedyaningsih ER, 2008, ANN ACAD MED SINGAP, V37, P482
   Shin MD, 2020, NAT NANOTECHNOL, V15, P646, DOI 10.1038/s41565-020-0737-y
   Silva HP, 2018, HEALTH RES POLICY SY, V16, DOI 10.1186/s12961-018-0362-5
   Stilgoe J, 2013, RES POLICY, V42, P1568, DOI 10.1016/j.respol.2013.05.008
   Strandburg KJ, 2017, KNOWLEDGE COMMONS FR
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Torrance AW, 2017, GOVERNING MED KNOWLE, P192
   UK Biobank, 2020, UK BIOB MAK HLTH DAT
   Urquiza-Garcia U, 2019, SYN BIOL, V4, DOI 10.1093/synbio/ysz016
   van den Hoven J, 2012, EUR PHYS J-SPEC TOP, V214, P153, DOI 10.1140/epjst/e2012-01691-2
   Vatiero M, 2009, QUADERNI DIPARTIMENT, V575
   Vaught J, 2020, BIOPRESERV BIOBANK, V18, P153, DOI 10.1089/bio.2020.29069.jjv
   Vinatzer BA, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00106
   von Schomberg R., 2012, TECHNIKFOLGEN ABSCHA, P39, DOI DOI 10.1007/978-3-531-93468-6_2
   Yozwiak NL, 2015, NATURE, V518, P477, DOI 10.1038/518477a
   Zhuang L, 2020, METAB ENG, V60, P37, DOI 10.1016/j.ymben.2020.03.009
   Zinnbauer D, 2018, INFORM WANTS BE EXPE, DOI [10.2139/ssrn.3125074, DOI 10.2139/SSRN.3125074]
NR 70
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-1957
EI 1572-8439
J9 ETHICS INF TECHNOL
JI Ethics Inf. Technol.
DI 10.1007/s10676-020-09565-9
EA OCT 2020
PG 9
WC Ethics; Information Science & Library Science; Philosophy
SC Social Sciences - Other Topics; Information Science & Library Science;
   Philosophy
GA OJ6DW
UT WOS:000584050500001
PM 33132748
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Malosh, RE
   Petrie, JG
   Callear, AP
   Monto, AS
   Martin, ET
AF Malosh, Ryan E.
   Petrie, Joshua G.
   Callear, Amy P.
   Monto, Arnold S.
   Martin, Emily T.
TI Home collection of nasal swabs for detection of influenza in the
   Household Influenza Vaccine Evaluation Study
SO INFLUENZA AND OTHER RESPIRATORY VIRUSES
LA English
DT Article; Early Access
DE acute respiratory illness; community&#8208; based; influenza;
   self&#8208; collected nasal swabs
ID SELF-COLLECTION; VIRUS-INFECTION; PCR; DESIGN; TOOL
AB Background Community-based studies of influenza and other respiratory viruses (eg, SARS-CoV-2) require laboratory confirmation of infection. During the current COVID-19 pandemic, social distancing guidelines require alternative data collection in order to protect both research staff and participants. Home-collected respiratory specimens are less resource-intensive, can be collected earlier after symptom onset, and provide a low-contact means of data collection. A prospective, multi-year, community-based cohort study is an ideal setting to examine the utility of home-collected specimens for identification of influenza.
   Methods We describe the feasibility and reliability of home-collected specimens for the detection of influenza. We collected data and specimens between October 2014 and June 2017 from the Household Influenza Vaccine Evaluation (HIVE) Study. Cohort participants were asked to collect a nasal swab at home upon onset of acute respiratory illness. Research staff also collected nose and throat swab specimens in the study clinic within 7 days of onset. We estimated agreement using Cohen's kappa and calculated sensitivity and specificity of home-collected compared to staff-collected specimens.
   Results We tested 336 paired staff- and home-collected respiratory specimens for influenza by RT-PCR; 150 staff-collected specimens were positive for influenza A/H3N2, 23 for influenza A/H1N1, 14 for influenza B/Victoria, and 31 for influenza B/Yamagata. We found moderate agreement between collection methods for influenza A/H3N2 (0.70) and B/Yamagata (0.69) and high agreement for influenza A/H1N1 (0.87) and B/Victoria (0.86). Sensitivity ranged from 78% to 86% for all influenza types and subtypes. Specificity was high for influenza A/H1N1 and both influenza B lineages with a range from 96% to 100%, and slightly lower for A/H3N2 infections (88%).
   Conclusions Collection of nasal swab specimens at home is both feasible and reliable for identification of influenza virus infections.
C1 [Malosh, Ryan E.; Petrie, Joshua G.; Callear, Amy P.; Monto, Arnold S.; Martin, Emily T.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 1415 Washingon Hts, Ann Arbor, MI 48109 USA.
RP Malosh, RE (corresponding author), Univ Michigan, Sch Publ Hlth, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM rmalosh@umich.edu
OI Petrie, Joshua/0000-0002-5696-965X; Monto, Arnold/0000-0003-3018-435X
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [U01 IP000474]; National Institute for Allergy and Infectious
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI097150]
FX The HIVE Study is supported by the Centers for Disease Control and
   Prevention (U01 IP000474) and the National Institute for Allergy and
   Infectious Diseases (R01 AI097150).
CR Akmatov MK, 2011, INT J INFECT DIS, V15, pE589, DOI 10.1016/j.ijid.2011.04.009
   Akmatov MK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048508
   Akmatov MK, 2011, INT J INFECT DIS, V15, pE799, DOI 10.1016/j.ijid.2011.07.005
   Campbell AP, 2013, J CLIN MICROBIOL, V51, P324, DOI 10.1128/JCM.02871-12
   Emery SL, 2004, EMERG INFECT DIS, V10, P311, DOI 10.3201/eid1002.030759
   Esposito S, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-85
   Fisher CE, 2019, J CLIN VIROL, V115, P43, DOI 10.1016/j.jcv.2019.04.001
   Flannery B, 2019, CLIN INFECT DIS, V68, P1798, DOI 10.1093/cid/ciy775
   Granados A, 2017, J MED VIROL, V89, P1295, DOI 10.1002/jmv.24753
   Ip DKM, 2012, J INFECT DIS, V205, P631, DOI 10.1093/infdis/jir803
   Jackson ML, 2017, NEW ENGL J MED, V377, P534, DOI [10.1056/NEJMoa1700153, 10.1056/nejmoa1700153]
   Klick B, 2014, EPIDEMIOL INFECT, V142, P744, DOI 10.1017/S0950268813001623
   Lambert SB, 2008, PEDIATRICS, V122, pE615, DOI 10.1542/peds.2008-0691
   Larios OE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021335
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046
   Shu B, 2011, J CLIN MICROBIOL, V49, P2614, DOI 10.1128/JCM.02636-10
   Smieja M, 2010, J CLIN MICROBIOL, V48, P3340, DOI 10.1128/JCM.02235-09
   Spencer S, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.00027-19
   Spencer S, 2016, J MED VIROL, V88, P719, DOI 10.1002/jmv.24373
   Spencer S, 2013, J CLIN MICROBIOL, V51, P3880, DOI 10.1128/JCM.01873-13
   Thompson MG, 2015, INFLUENZA OTHER RESP, V9, P155, DOI 10.1111/irv.12309
   Vargas CY, 2016, CLIN EPIDEMIOL, V8, P1, DOI 10.2147/CLEP.S95847
NR 23
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1750-2640
EI 1750-2659
J9 INFLUENZA OTHER RESP
JI Influenza Other Respir. Viruses
DI 10.1111/irv.12822
EA OCT 2020
PG 8
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA OJ1SR
UT WOS:000583748100001
PM 33107200
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Seow, J
   Graham, C
   Merrick, B
   Acors, S
   Pickering, S
   Steel, KJA
   Hemmings, O
   O'Byrne, A
   Kouphou, N
   Galao, RP
   Betancor, G
   Wilson, HD
   Signell, AW
   Winstone, H
   Kerridge, C
   Huettner, I
   Jimenez-Guardeno, JM
   Lista, MJ
   Temperton, N
   Snell, LB
   Bisnauthsing, K
   Moore, A
   Green, A
   Martinez, L
   Stokes, B
   Honey, J
   Izquierdo-Barras, A
   Arbane, G
   Patel, A
   Tan, MKI
   O'Connell, L
   O'Hara, G
   MacMahon, E
   Douthwaite, S
   Nebbia, G
   Batra, R
   Martinez-Nunez, R
   Shankar-Hari, M
   Edgeworth, JD
   Neil, SJD
   Malim, MH
   Doores, KJ
AF Seow, Jeffrey
   Graham, Carl
   Merrick, Blair
   Acors, Sam
   Pickering, Suzanne
   Steel, Kathryn J. A.
   Hemmings, Oliver
   O'Byrne, Aoife
   Kouphou, Neophytos
   Galao, Rui Pedro
   Betancor, Gilberto
   Wilson, Harry D.
   Signell, Adrian W.
   Winstone, Helena
   Kerridge, Claire
   Huettner, Isabella
   Jimenez-Guardeno, Jose M.
   Lista, Maria Jose
   Temperton, Nigel
   Snell, Luke B.
   Bisnauthsing, Karen
   Moore, Amelia
   Green, Adrian
   Martinez, Lauren
   Stokes, Brielle
   Honey, Johanna
   Izquierdo-Barras, Alba
   Arbane, Gill
   Patel, Amita
   Tan, Mark Kia Ik
   O'Connell, Lorcan
   O'Hara, Geraldine
   MacMahon, Eithne
   Douthwaite, Sam
   Nebbia, Gaia
   Batra, Rahul
   Martinez-Nunez, Rocio
   Shankar-Hari, Manu
   Edgeworth, Jonathan D.
   Neil, Stuart J. D.
   Malim, Michael H.
   Doores, Katie J.
TI Longitudinal observation and decline of neutralizing antibody responses
   in the three months following SARS-CoV-2 infection in humans
SO NATURE MICROBIOLOGY
LA English
DT Article
ID CORONAVIRUS
AB Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10-15 d after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how long antibody responses will be maintained or whether they will provide protection from reinfection. Using sequential serum samples collected up to 94 d post onset of symptoms (POS) from 65 individuals with real-time quantitative PCR-confirmed SARS-CoV-2 infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 8 d POS. We show that the kinetics of the neutralizing antibody response is typical of an acute viral infection, with declining neutralizing antibody titres observed after an initial peak, and that the magnitude of this peak is dependent on disease severity. Although some individuals with high peak infective dose (ID50 > 10,000) maintained neutralizing antibody titres >1,000 at >60 d POS, some with lower peak ID50 had neutralizing antibody titres approaching baseline within the follow-up period. A similar decline in neutralizing antibody titres was observed in a cohort of 31 seropositive healthcare workers. The present study has important implications when considering widespread serological testing and antibody protection against reinfection with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection.
   Neutralizing antibody responses of patients infected with SARS-CoV-2 peak at 3-4 weeks post onset of symptoms, then decline to low levels over the course of 3 months in some individuals.
C1 [Seow, Jeffrey; Graham, Carl; Acors, Sam; Pickering, Suzanne; Galao, Rui Pedro; Betancor, Gilberto; Wilson, Harry D.; Signell, Adrian W.; Winstone, Helena; Kerridge, Claire; Huettner, Isabella; Jimenez-Guardeno, Jose M.; Lista, Maria Jose; Martinez-Nunez, Rocio; Shankar-Hari, Manu; Edgeworth, Jonathan D.; Neil, Stuart J. D.; Malim, Michael H.; Doores, Katie J.] Kings Coll London, Sch Immunol & Microbial Sci, Dept Infect Dis, London, England.
   [Merrick, Blair; Snell, Luke B.; Bisnauthsing, Karen; Patel, Amita; Tan, Mark Kia Ik; O'Connell, Lorcan; O'Hara, Geraldine; MacMahon, Eithne; Douthwaite, Sam; Nebbia, Gaia; Batra, Rahul; Edgeworth, Jonathan D.] Guys & St Thomas NHS Fdn Trust, Dept Infect Dis, Ctr Clin Infect & Diagnost Res, London, England.
   [Steel, Kathryn J. A.; O'Byrne, Aoife] Kings Coll London, Sch Immunol & Microbial Sci, Dept Inflammat Biol, Ctr Inflammat Biol & Canc Immunol, London, England.
   [Hemmings, Oliver] Kings Coll London, Fac Life Sci & Med, Sch Immunol & Microbial Sci, Dept Immunobiol, London, England.
   [Temperton, Nigel] Univ Kent, Medway Sch Pharm, Viral Pseudotype Unit, Chatham, Kent, England.
   [Moore, Amelia; Green, Adrian; Martinez, Lauren; Stokes, Brielle; Honey, Johanna; Izquierdo-Barras, Alba] Guys & St Thomas NHS Fdn Trust, Guys & St Thomas R&D Dept, London, England.
   [Arbane, Gill; Shankar-Hari, Manu] Guys & St Thomas NHS Fdn Trust, Dept Intens Care Med, London, England.
RP Doores, KJ (corresponding author), Kings Coll London, Sch Immunol & Microbial Sci, Dept Infect Dis, London, England.
EM katie.doores@kcl.ac.uk
RI Temperton, Nigel/M-1164-2019; Shankar-Hari, Manu/Q-9056-2019; Snell,
   Luke Blagdon/ABD-7401-2020
OI Temperton, Nigel/0000-0002-7978-3815; Shankar-Hari,
   Manu/0000-0002-5338-2538; Snell, Luke Blagdon/0000-0002-6263-9497; Tan,
   Kia Ik Mark/0000-0002-7774-3836; Pickering, Suzanne/0000-0002-2747-9029;
   Wilson, Harry David/0000-0002-3185-1073; Acors, Sam/0000-0001-6428-7707;
   Betancor Quintana, Gilberto/0000-0003-0548-7690; Doores,
   Katie/0000-0002-5507-1725; O'Byrne, Aoife/0000-0001-8185-2501; Seow,
   Jeffrey/0000-0003-0722-8561; Merrick, Blair/0000-0002-6061-6064; Galao,
   Rui/0000-0003-3368-5053; Malim, Michael/0000-0002-7699-2064
FU King's Together Rapid COVID-19 Call awards; MRCMedical Research Council
   UK (MRC) [MC/PC/15068]; Huo Family Foundation; MRC-KCL [MR/N013700/1,
   MR/R015643/1]; Wellcome TrustWellcome Trust [106223/Z/14/Z,
   WT098049AIA]; Orchard Therapeutics [MR/R015643/1]; Medical Research
   CouncilMedical Research Council UK (MRC) [MR/S023747/1]; National
   Institute for Health ResearchNational Institute for Health Research
   (NIHR) [CS-2016-16-011]; Fondation Dormeur, Vaduz; NIAID Centers of
   Excellence for Influenza Research and Surveillance (CEIRS)
   [HHSN272201400008C]
FX King's Together Rapid COVID-19 Call awards were received by M.H.M.,
   K.J.D., S.J.D.N. and R.M.N. MRC Discovery award MC/PC/15068 was received
   by S.J.D.N., K.J.D. and M.H.M. J.S., S.P. and J.M.J.-G. received support
   from the Huo Family Foundation (M.H.M., S.J.D.N,. K.J.D., R.M.N., J.D.E.
   and M.S.-H.). A.W.S. and C.G. were supported by the MRC-KCL Doctoral
   Training Partnership in Biomedical Sciences (MR/N013700/1). G.B. and
   J.M.J.-G. were supported by the Wellcome Trust (grant no. 106223/Z/14/Z
   to M.H.M.). S.A. was supported by an MRC-KCL Doctoral Training
   Partnership in Biomedical Sciences industrial Collaborative Award in
   Science & Engineering (iCASE) in partnership with Orchard Therapeutics
   (MR/R015643/1). N.K. was supported by the Medical Research Council
   (MR/S023747/1 to M.H.M.). M.S.H. is supported by the National Institute
   for Health Research Clinician Scientist Award (CS-2016-16-011). The
   views expressed in this publication are those of the authors and not
   necessarily those of the NHS, the National Institute for Health Research
   or the Department of Health and Social Care. S.P., H.D.W. and S.J.D.N.
   were supported by a Wellcome Trust Senior Fellowship (WT098049AIA).
   Fondation Dormeur, Vaduz provided funding for equipment (to K.J.D.).
   Development of SARS-CoV-2 reagents (RBD expression plasmid) was
   partially supported by the NIAID Centers of Excellence for Influenza
   Research and Surveillance (CEIRS; contract no. HHSN272201400008C). We
   thank F. Krammer for provision of the RBD expression plasmid, P.
   Brouwer, M. van Gils and R. Sanders (University of Amsterdam) for the S
   glycoprotein construct; L. James, J. Luptak and L. Kiss (LMB) for the
   provision of purified N protein; and J. Voss and D. Huang for providing
   the HeLa-ACE-2 cells. We thank L. Mccoy (UCL) for the provision of the
   murine CR3009 monoclonal antibody. We thank W. James (University of
   Oxford) for advice on microneutralization assays. We thank all patients
   and staff at St Thomas' Hospital who participated in this study. We
   thank the COVID-19 core research team members, including O. Tijani, K.
   Brooks, M. Flanagan, R. Kaye, R. Williams, C. Blanco-Gil, H. Kerslake,
   A. Walters, R. Dakari, J. Squires, A. Stanton, S. Tripoli, A. Amon, I.
   Chow, O. Okolo and N. Lumlertgul.
CR Amanat F, 2020, NAT MED, DOI [10.1038/s41591-020-0913-5, DOI 10.1038/S41591-020-0913-5(2020)]
   Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092
   Beaudoin-Bussieres G, 2020, MBIO, V11, DOI 10.1128/mBio.02590-20
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Carter MJ, 2020, NAT MED, V26, P1701, DOI 10.1038/s41591-020-1054-6
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Choe PG, 2017, EMERG INFECT DIS, V23, P1079, DOI 10.3201/eid2307.170310
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Crawford Katharine H D, 2020, J Infect Dis, DOI 10.1093/infdis/jiaa618
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   Edridge AWD, 2020, NAT MED, V26, P1691, DOI 10.1038/s41591-020-1083-1
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Gorse GJ, 2020, J MED VIROL, V92, P512, DOI 10.1002/jmv.25715
   Grehan K, 2015, METHODSX, V2, P379, DOI 10.1016/j.mex.2015.09.003
   Isho B, 2020, SCI IMMUNOL, V5
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Iyer AS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0367
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Keech Cheryl, 2020, N Engl J Med, V383, P2320, DOI 10.1056/NEJMoa2026920
   Kellam P, 2020, J GEN VIROL, V101, P791, DOI 10.1099/jgv.0.001439
   Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6
   Lee N, 2006, J CLIN VIROL, V35, P179, DOI 10.1016/j.jcv.2005.07.005
   Lee W. T, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.07.10.20150557, DOI 10.1101/2020.07.10.20150557]
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Luchsinger LL, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.02005-20
   Mo HY, 2006, RESPIROLOGY, V11, P49, DOI 10.1111/j.1440-1843.2006.00783.x
   Moore JP, 2020, J VIROL, V94, DOI 10.1128/JVI.01083-20
   Muecksch Frauke, 2020, medRxiv, DOI 10.1101/2020.08.05.20169128
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Petersen E, 2020, LANCET INFECT DIS, V20, pE238, DOI 10.1016/S1473-3099(20)30484-9
   Pickering S, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008817
   Prevost Jeremie, 2020, Cell Rep Med, V1, P100126, DOI 10.1016/j.xcrm.2020.100126
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Robinson SA, 2020, ROUTL RES EDUC EQUAL, P1
   Rodda Lauren B, 2020, medRxiv, DOI 10.1101/2020.08.11.20171843
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Schmidt F, 2020, J EXP MED, V217, DOI 10.1084/jem.20201181
   Sekine T, 2020, CELL, V183, P158, DOI [10.10160.cell.2020.08.017, 10.1016/j.cell.2020.08.017]
   Seydoux E, 2020, IMMUNITY, V53, P98, DOI 10.1016/j.immuni.2020.06.001
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Sterlin D, 2020, IGA DOMINATES EARLY, DOI [10.1101/2020.06.10.20126532, DOI 10.1101/2020.06.10.20126532]
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Wajnberg A, 2020, SARS COV 2 INFECT IN, DOI [10.1101/2020.07.14.20151126, DOI 10.1101/2020.07.14.20151126]
   Wang Kai, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1143
   Wang M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016809
   Wu F, 2020, JAMA INTERN MED, V180, P1356, DOI 10.1001/jamainternmed.2020.4616
   Wu J, 2020, SARS COV 2 INFECT IN, DOI [10.1101/2020.07.21.20159178, DOI 10.1101/2020.07.21.20159178]
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
NR 54
TC 8
Z9 8
U1 4
U2 4
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2058-5276
J9 NAT MICROBIOL
JI NAT. MICROBIOL
PD DEC
PY 2020
VL 5
IS 12
BP 1598
EP +
DI 10.1038/s41564-020-00813-8
EA OCT 2020
PG 17
WC Microbiology
SC Microbiology
GA OT7ZT
UT WOS:000584007600002
PM 33106674
OA Bronze, Green Accepted
DA 2021-01-01
ER

PT J
AU Gurumurthy, CB
   Quadros, RM
   Richardson, GP
   Poluektova, LY
   Mansour, SL
   Ohtsuka, M
AF Gurumurthy, Channabasavaiah B.
   Quadros, Rolen M.
   Richardson, Guy P.
   Poluektova, Larisa Y.
   Mansour, Suzanne L.
   Ohtsuka, Masato
TI Genetically modified mouse models to help fight COVID-19
SO NATURE PROTOCOLS
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; BALB/C MICE; T-CELLS; SARS; INFECTION;
   PATHOGENESIS; SYSTEMS; ACE2; VIVO
AB The research community is in a race to understand the molecular mechanisms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to repurpose currently available antiviral drugs and to develop new therapies and vaccines against coronavirus disease 2019 (COVID-19). One major challenge in achieving these goals is the paucity of suitable preclinical animal models. Mice constitute similar to 70% of all the laboratory animal species used in biomedical research. Unfortunately, SARS-CoV-2 infects mice only if they have been genetically modified to express human ACE2. The inherent resistance of wild-type mice to SARS-CoV-2, combined with a wealth of genetic tools that are available only for modifying mice, offers a unique opportunity to create a versatile set of genetically engineered mouse models useful for COVID-19 research. We propose three broad categories of these models and more than two dozen designs that may be useful for SARS-CoV-2 research and for fighting COVID-19.
C1 [Gurumurthy, Channabasavaiah B.; Poluektova, Larisa Y.] Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Gurumurthy, Channabasavaiah B.; Quadros, Rolen M.] Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Mouse Genome Engn Core Facil, Omaha, NE 68198 USA.
   [Richardson, Guy P.] Univ Sussex, Sussex Neurosci, Brighton, E Sussex, England.
   [Mansour, Suzanne L.] Univ Utah, Dept Human Genet, Salt Lake City, UT USA.
   [Ohtsuka, Masato] Tokai Univ, Sch Med, Div Basic Med Sci & Mol Med, Dept Mol Life Sci, Isehara, Kanagawa, Japan.
   [Ohtsuka, Masato] Tokai Univ, Inst Med Sci, Isehara, Kanagawa, Japan.
RP Gurumurthy, CB (corresponding author), Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.; Gurumurthy, CB (corresponding author), Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Mouse Genome Engn Core Facil, Omaha, NE 68198 USA.; Ohtsuka, M (corresponding author), Tokai Univ, Sch Med, Div Basic Med Sci & Mol Med, Dept Mol Life Sci, Isehara, Kanagawa, Japan.; Ohtsuka, M (corresponding author), Tokai Univ, Inst Med Sci, Isehara, Kanagawa, Japan.
EM cgurumurthy@unmc.edu; masato@is.icc.u-tokai.ac.jp
RI ; Gurumurthy, CB/H-8268-2016
OI Ohtsuka, Masato/0000-0002-6952-4238; Poluektova,
   Larisa/0000-0001-7339-8732; Gurumurthy, CB/0000-0002-8022-4033
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R35HG010719, R21GM129559, R21AI143394,
   R21DA046831, R01DC011819, R01DC014470]; JSPSMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [16KK0189]
FX We thank H. Zeng, B. Tasic and T. Daigle (Allen Institute for Brain
   Science) for advice and discussions on the design of re-engineered
   alleles. We thank M. A. Montgomery and D. D. Meigs (University of
   Nebraska Medical Center) for professional editing. C.B.G. is funded by
   NIH grants R35HG010719, R21GM129559, R21AI143394 and R21DA046831. S.L.M.
   is funded by NIH grants R01DC011819 and R01DC014470. M.O. is funded by
   JSPS (16KK0189) for the Promotion of Joint International Research
   (Fostering Joint International Research).
CR Abe T, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107653
   Aida T, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0653-x
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Barnabei MS, 2010, PHYSIOL GENOMICS, V42A, P103, DOI 10.1152/physiolgenomics.00071.2010
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Couzin-Frankel J, 2020, SCIENCE
   Covid 19 Host Genetics Initiative, 2020, EUR J HUM GENET, V28, P715, DOI 10.1038/s41431-020-0636-6
   Dagur RS, 2019, BMC IMMUNOL, V20, DOI 10.1186/s12865-018-0279-3
   Daigle TL, 2018, CELL, V174, P465, DOI 10.1016/j.cell.2018.06.035
   Dash PK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10366-y
   Dinnon Kenneth H, 2020, bioRxiv, DOI 10.1101/2020.05.06.081497
   Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
   Gorantla S, 2012, TRENDS NEUROSCI, V35, P197, DOI 10.1016/j.tins.2011.12.006
   Gralinski LE, 2017, G3-GENES GENOM GENET, V7, P1653, DOI 10.1534/g3.117.041434
   Gralinski LE, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005504
   Gu HJ, 2020, SCIENCE, V369, P1603, DOI 10.1126/science.abc4730
   Gurumurthy C. B, 2016, GENOME EDITING, P65
   Gurumurthy CB, 2019, NAT PROTOC, V14, P2452, DOI 10.1038/s41596-019-0187-x
   Gurumurthy CB, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.029462
   Harms DW, 2014, CURR PROTOC HUM GENE, V83, P15
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Hikmet F, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20209610
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hou Y, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01673-z
   Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516
   Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207
   Jelinek M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20792-5
   Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027
   Koralnik IJ, 2020, ANN NEUROL, V88, P1, DOI 10.1002/ana.25807
   Leist Sarah R, 2020, Methods Mol Biol, V2099, P137, DOI 10.1007/978-1-0716-0211-9_12
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li YW, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104833
   Lindner Diana, 2020, JAMA Cardiol, V5, P1281, DOI 10.1001/jamacardio.2020.3551
   LoPresti M, 2020, AM J HUM GENET, V107, P381, DOI 10.1016/j.ajhg.2020.08.007
   Lore NI, 2020, MBIO, V11, DOI 10.1128/mBio.00097-20
   Luan JW, 2020, BIOCHEM BIOPH RES CO, V526, P165, DOI 10.1016/j.bbrc.2020.03.047
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Miura H, 2018, NAT PROTOC, V13, P195, DOI 10.1038/nprot.2017.153
   Miura H, 2015, SCI REP-UK, V5, DOI 10.1038/srep12799
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Ohtsuka M, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1400-x
   Parasa S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.11335
   Quadros RM, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1220-4
   Rathnasinghe R, 2020, COMP TRANSGENIC ADEN, DOI [10.1101/2020.07.06.190066v1, DOI 10.1101/2020.07.06.190066V1]
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Roberts A, 2005, J VIROL, V79, P5833, DOI 10.1128/JVI.79.9.5833-5838.2005
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Robles-Oteiza C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9783
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Saito Y, 2002, INT IMMUNOL, V14, P1113, DOI 10.1093/intimm/dxf087
   Shen B, 2013, CELL RES, V23, P720, DOI 10.1038/cr.2013.46
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Singh A, 2020, VIROL SIN, V35, P290, DOI 10.1007/s12250-020-00252-z
   Soldatov VO, 2020, RES RESULTS PHARM, V6, P1, DOI [10.3897/rrpharmacology.6.53633, DOI 10.3897/rrpharmacology.6.53633]
   Steppan J, 2020, HYPERTENS RES, V43, P1175, DOI 10.1038/s41440-020-0467-4
   Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010
   Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020
   Threadgill DW, 2011, ILAR J, V52, P24, DOI 10.1093/ilar.52.1.24
   Tseng CTK, 2007, J VIROL, V81, P1162, DOI 10.1128/JVI.01702-06
   VERONI MC, 1991, DIABETES, V40, P1480, DOI 10.2337/diabetes.40.11.1480
   Vyse TJ, 1996, J CLIN INVEST, V98, P1762, DOI 10.1172/JCI118975
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Yoshimi K, 2020, HUM GENET, DOI 10.1007/s00439-020-02198-4
   Yoshimi K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10431
   Yuan LZ, 2020, EMERG MICROBES INFEC, V9, P949, DOI 10.1080/22221751.2020.1764871
   Zhao WY, 2018, AM J HYPERTENS, V31, P108, DOI 10.1093/ajh/hpx144
NR 75
TC 0
Z9 0
U1 3
U2 3
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1754-2189
EI 1750-2799
J9 NAT PROTOC
JI Nat. Protoc.
PD DEC
PY 2020
VL 15
IS 12
BP 3777
EP 3787
DI 10.1038/s41596-020-00403-2
EA OCT 2020
PG 11
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OX4XT
UT WOS:000583953500003
PM 33106680
OA Bronze
DA 2021-01-01
ER

PT J
AU Hu, YL
   Tu, C
   Dong, JW
   Chen, WL
   Wang, XH
   Luo, D
   Shi, M
   Zhou, ML
   Song, YT
   Zhang, C
   Xiong, F
AF Hu, Yanglin
   Tu, Can
   Dong, Jun-Wu
   Chen, Wen-Li
   Wang, Xiao-Hui
   Luo, Dan
   Shi, Ming
   Zhou, Mengliang
   Song, Yuting
   Zhang, Chun
   Xiong, Fei
TI Bed-sided short-duration renal replacement therapy provide a possible
   option to treat non-critical coronavirus disease 2019 in maintenance
   hemodialysis patients in public health crisis
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article; Early Access
DE coronavirus disease 2019; hemodialysis patient; intervention; public
   crisis
ID COVID-19; INFECTION; INTENSITY; WUHAN; RISK
AB HD care may experience great stress with the coronavirus disease 2019 (COVID-19) pandemic. A modified HD modality named bed-sided short-duration renal replacement therapy (BSRRT) was used in noncritical maintenance HD (MHD) patients diagnosed with COVID-19 in Wuhan due to extreme situation. To determine the safety and efficacy as a substitution for intermittent HD (IHD), we conducted this study. We used the data of 88 noncritical COVID-19 MHD patients collected from 65 medical units at the hospitals in Wuhan, China, from January 1 to March 10, 2020. t-test, Wilcoxon rank sum test, and Fisher exact probability method were used to compare the baseline characteristics, treatment, and death. Log-rank test and Cox regression multivariate analysis was used to compare the survival of noncritical patients who were transferred to BSRRT modality versus those who were continued on the IHD. Univariate analysis showed the level of reported fatigue symptom at present, bilateral lung computed tomography infiltration and steroid treatment differed between the two groups. The outcome of death of the two groups did not show significant differences in univariate analysis (P = .0563). Multivariate Cox regression analysis dialysis showed modality of treatment after COVID-19 diagnosis was not a significant predictor of death (P = .1000). These data suggest that for noncritical COVID-19 MHD patients, the transfer from IHD to BSRRT does not have significant difference in the risk of death compared with IHD group. This finding suggests this modified modality could be an option for the substitution for IHD during the COVID-19 pandemic period.
C1 [Hu, Yanglin; Tu, Can; Xiong, Fei] Wuhan 1 Hosp, Dept Nephrol, Zhongshan Rd,215 Qiaokou Area, Wuhan 430022, Hubei, Peoples R China.
   [Tu, Can] Guangzhou Univ Chinese Med, Affiliated Coll Med 2, Guangzhou, Peoples R China.
   [Dong, Jun-Wu] Huazhong Univ Sci & Technol, Tongji Med Coll, Puai Hosp, Wuhan Hosp 4, Wuhan, Peoples R China.
   [Chen, Wen-Li] Huazhong Univ Sci & Technol, Tongji Med Coll, Cent Hosp Wuhan, Wuhan, Peoples R China.
   [Wang, Xiao-Hui] Wuhan 5 Hosp, Dept Nephrol, Wuhan, Peoples R China.
   [Luo, Dan] Wuhan Univ, Tongren Hosp, Wuhan Hosp 3, Dept Nephrol, Wuhan, Peoples R China.
   [Shi, Ming] Wuhan Univ, Renmin Hosp, Dept Nephrol, Wuhan, Peoples R China.
   [Zhou, Mengliang; Song, Yuting] Hubei Univ Tradit Chinese Med, Affiliated Med Coll 1, Wuhan, Peoples R China.
   [Zhang, Chun] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China.
RP Xiong, F (corresponding author), Wuhan 1 Hosp, Dept Nephrol, Zhongshan Rd,215 Qiaokou Area, Wuhan 430022, Hubei, Peoples R China.; Zhang, C (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Nephrol, 1277 Jie Fang Ave, Wuhan 430022, Hubei, Peoples R China.
EM yanglin_hu@aliyun.com; drzhangchun@hust.edu.cn; xiongf23@sina.com
OI hu, Yanglin/0000-0002-1130-3467
FU International (Regional) Cooperation and Exchange Project grant
   [81961138007]; National Key Research and Development Program grants
   [2020YFC0845800, 2020YFC0844700, 2018YFC1314000]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81700603, 81770711, 81974096]; Program for HUST Academic
   Frontier Youth Team grant [2017QYTD20]
FX International (Regional) Cooperation and Exchange Project grant,
   Grant/Award Number: 81961138007; National Key Research and Development
   Program grants, Grant/Award Numbers: 2020YFC0845800, 2020YFC0844700,
   2018YFC1314000; National Natural Science Foundation of China grants,
   Grant/Award Numbers: 81700603, 81770711, 81974096; Program for HUST
   Academic Frontier Youth Team grant, Grant/Award Number: 2017QYTD20
CR Alberici F, 2020, KIDNEY INT, V97, P1083, DOI 10.1016/j.kint.2020.04.002
   Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413
   Betjes MGH, 2013, NAT REV NEPHROL, V9, P255, DOI 10.1038/nrneph.2013.44
   Burgner A, 2020, CLIN J AM SOC NEPHRO, V15, P720, DOI 10.2215/CJN.03750320
   Centers for Disease Control and Prevention (CDC), 2020, INF CLIN INV THER PA
   Sanchez-Alvarez JE, 2020, NEFROLOGIA, V40, P272, DOI 10.1016/j.nefro.2020.04.002
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ikizler TA, 2020, AM J KIDNEY DIS, V76, P1, DOI [10.1053/j.ajkd.2020.03.008, 10.1053/j.ajkd.2020.05.006]
   Kikuchi K, 2020, THER APHER DIAL, V24, P361, DOI 10.1111/1744-9987.13531
   Kliger AS, 2020, CLIN J AM SOC NEPHRO, V15, P707, DOI 10.2215/CJN.03340320
   Kwan BCH, 2004, J AM SOC NEPHROL, V15, P1883, DOI 10.1097/01.ASN.0000131522.16404.1F
   Li JH, 2020, CLIN J AM SOC NEPHRO, V15, P717, DOI 10.2215/CJN.03420320
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Macedo E, 2016, AM J KIDNEY DIS, V68, P645, DOI 10.1053/j.ajkd.2016.03.427
   Otsubo S, 2020, THER APHER DIAL, DOI 10.1111/1744-9987.13566
   Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639
   Ronco C, 2002, EDTNA ERCA J, VSuppl 2, P7
   Vaziri ND, 2012, J RENAL NUTR, V22, P149, DOI 10.1053/j.jrn.2011.10.020
   Xiong F, 2020, J AM SOC NEPHROL, V31, P1387, DOI 10.1681/ASN.2020030354
NR 20
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-9979
EI 1744-9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
DI 10.1111/1744-9987.13590
EA OCT 2020
PG 11
WC Hematology; Urology & Nephrology
SC Hematology; Urology & Nephrology
GA OJ1OR
UT WOS:000583737500001
PM 33012089
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wu, J
   Hu, ZJ
   Wang, L
   Tan, YQ
   Hou, W
   Li, ZW
   Gao, TT
   Fan, JQ
   Guo, BJ
   Dai, HP
   Li, W
   Hao, J
   Jin, RH
   Hu, BY
AF Wu, Jun
   Hu, Zhongjie
   Wang, Liu
   Tan, Yuanqing
   Hou, Wei
   Li, Zhongwen
   Gao, Tingting
   Fan, Jiaqi
   Guo, Baojie
   Dai, Huaping
   Li, Wei
   Hao, Jie
   Jin, Ronghua
   Hu, Baoyang
TI First case of COVID-19 infused with hESC derived immunity- and
   matrix-regulatory cells
SO CELL PROLIFERATION
LA English
DT Letter
DE case report; cell therapy; COVID&#8208; 19; hESC; IMRCs
C1 [Wu, Jun; Wang, Liu; Tan, Yuanqing; Li, Zhongwen; Gao, Tingting; Fan, Jiaqi; Guo, Baojie; Li, Wei; Hao, Jie; Hu, Baoyang] Chinese Acad Sci, Inst Zool, Natl Stem Cell Resource Ctr, Beijing, Peoples R China.
   [Wu, Jun; Wang, Liu; Tan, Yuanqing; Li, Zhongwen; Gao, Tingting; Fan, Jiaqi; Guo, Baojie; Li, Wei; Hao, Jie; Hu, Baoyang] Chinese Acad Sci, Inst Stem Cell & Regenerat, Beijing 100101, Peoples R China.
   [Wu, Jun; Wang, Liu; Li, Zhongwen; Gao, Tingting; Guo, Baojie; Li, Wei; Hao, Jie; Jin, Ronghua; Hu, Baoyang] Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing, Peoples R China.
   [Hu, Zhongjie; Hou, Wei] Capital Med Univ, Beijing Youan Hosp, Beijing 100101, Peoples R China.
   [Wang, Liu; Gao, Tingting; Guo, Baojie; Li, Wei; Hu, Baoyang] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Dai, Huaping] Chinese Acad Med Sci, Inst Resp Med, Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China.
RP Hao, J; Hu, BY (corresponding author), Chinese Acad Sci, Inst Stem Cell & Regenerat, Beijing 100101, Peoples R China.; Jin, RH (corresponding author), Capital Med Univ, Beijing Youan Hosp, Beijing 100101, Peoples R China.; Hao, J (corresponding author), Chinese Acad Sci, Inst Zool, Dept Natl Stem Cell Resource Ctr, Beijing 100101, Peoples R China.
EM haojie@ioz.ac.cn; jin_eagle@sina.com; byhu@ioz.ac.cn
FU National Emergency Project of the Ministry of Science and Technology of
   China [2020YFC0843900, 2020YFC0841900]; Beijing Municipal Science &
   Technology CommissionBeijing Municipal Science & Technology Commission
   [Z181100003818005]; National Key Research and Development Program
   [2016YFA0101502]; Strategic Priority Research Program of the Chinese
   Academy of SciencesChinese Academy of Sciences [XDA16030701,
   XDA16040502]; International Partnership Program of Chinese Academy of
   Sciences [152111KYSB20160004]
FX This work was supported by National Emergency Project of the Ministry of
   Science and Technology of China (2020YFC0843900 and 2020YFC0841900),
   Beijing Municipal Science & Technology Commission (Z181100003818005),
   National Key Research and Development Program (2016YFA0101502), the
   Strategic Priority Research Program of the Chinese Academy of Sciences
   (XDA16030701, XDA16040502), and International Partnership Program of
   Chinese Academy of Sciences (152111KYSB20160004).
CR World Health Organization, 2020, PUBL HLTH EM INT DEC
   World Health Organization, 2020, PNEUM UNKN CAUS REP
   Wu J, 2020, CELL RES, V16, P1
NR 3
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7722
EI 1365-2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD DEC
PY 2020
VL 53
IS 12
SI SI
AR e12943
DI 10.1111/cpr.12943
EA OCT 2020
PG 3
WC Cell Biology
SC Cell Biology
GA PB0MV
UT WOS:000582497700001
PM 33107123
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Deganutti, G
   Prischi, F
   Reynolds, CA
AF Deganutti, Giuseppe
   Prischi, Filippo
   Reynolds, Christopher A.
TI Supervised molecular dynamics for exploring the druggability of the
   SARS-CoV-2 spike protein
SO JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; Drug repurposing; Spike protein; Molecular
   dynamics; Supervised molecular dynamics
ID RESPIRATORY SYNDROME CORONAVIRUS; ANGIOTENSIN-ALDOSTERONE SYSTEM;
   GPCR-LIGAND RECOGNITION; HOT-SPOTS; DOCKING; IDENTIFICATION; ACCURACY;
   RECEPTOR; SITE; ACE2
AB The recent outbreak of the respiratory syndrome-related coronavirus (SARS-CoV-2) is stimulating an unprecedented scientific campaign to alleviate the burden of the coronavirus disease (COVID-19). One line of research has focused on targeting SARS-CoV-2 proteins fundamental for its replication by repurposing drugs approved for other diseases. The first interaction between the virus and the host cell is mediated by the spike protein on the virus surface and the human angiotensin-converting enzyme (ACE2). Small molecules able to bind the receptor-binding domain (RBD) of the spike protein and disrupt the binding to ACE2 would offer an important tool for slowing, or even preventing, the infection. Here, we screened 2421 approved small molecules in silico and validated the docking outcomes through extensive molecular dynamics simulations. Out of six drugs characterized as putative RBD binders, the cephalosporin antibiotic cefsulodin was further assessed for its effect on the binding between the RBD and ACE2, suggesting that it is important to consider the dynamic formation of the heterodimer between RBD and ACE2 when judging any potential candidate.
C1 [Deganutti, Giuseppe; Reynolds, Christopher A.] Coventry Univ, Ctr Sport Exercise & Life Sci, Coventry CV1 5FB, W Midlands, England.
   [Prischi, Filippo] Univ Essex, Sch Life Sci, Wivenhoe Pk, Colchester CO4 3SQ, Essex, England.
RP Deganutti, G (corresponding author), Coventry Univ, Ctr Sport Exercise & Life Sci, Coventry CV1 5FB, W Midlands, England.
EM ad5288@coventry.ac.uk
RI Prischi, Filippo/I-4844-2019; Reynolds, Christopher/G-1036-2010
OI Prischi, Filippo/0000-0003-2107-938X; Reynolds,
   Christopher/0000-0001-9267-5141; Deganutti, Giuseppe/0000-0001-8780-2986
FU Leverhulme TrustLeverhulme Trust [RPG-2017-255]
FX CAR and GD received funding from Leverhulme Trust Grant No.
   RPG-2017-255.
CR ABRAHAM S, 1990, VIROLOGY, V176, P296, DOI 10.1016/0042-6822(90)90257-R
   Alexander SPH, 2020, BRIT J PHARMACOL, V177, P4942, DOI 10.1111/bph.15094
   Atanasio S, 2020, J COMPUT AID MOL DES, V34, P1181, DOI 10.1007/s10822-020-00338-6
   Brenke R, 2009, BIOINFORMATICS, V25, P621, DOI 10.1093/bioinformatics/btp036
   Bronson J, 2013, MARKET MARKET 2012, P471
   Brooke GN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72528-z
   CHANDEL V, 2020, J BIOMOL STRUCT 0824, DOI DOI 10.26434/chemrxiv.12292514.v1
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Choudhary S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01664
   CLAGHORN JL, 1979, J CLIN PSYCHIAT, V40, P107
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   Contini A., 2020, VIRTUAL SCREENING FD, DOI [10.26434/Chemrxiv.11847381.V1., DOI 10.26434/CHEMRXIV.11847381.V1, 10.26434/chemrxiv.11847381.v1]
   Cuzzolin A, 2016, J CHEM INF MODEL, V56, P687, DOI 10.1021/acs.jcim.5b00702
   Deganutti G, 2020, J CHEM INF MODEL, V60, P1804, DOI 10.1021/acs.jcim.9b01094
   Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Durdagi S., 2020, SCREENING CLIN APPRO, DOI [10.26434/chemrxiv.12032712.v2., DOI 10.26434/CHEMRXIV.12032712.V2]
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Forester TR, 1998, CHEM J COMPUT
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:6<490::AID-JCC1>3.3.CO;2-V
   Harvey MJ, 2009, J CHEM THEORY COMPUT, V5, P1632, DOI 10.1021/ct9000685
   Ho TY, 2006, ANTIVIR RES, V69, P70, DOI 10.1016/j.antiviral.2005.10.005
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Jimenez J, 2017, BIOINFORMATICS, V33, P3036, DOI 10.1093/bioinformatics/btx350
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Joshi S, 2020, FUTURE MED CHEM, V12, P1579, DOI 10.4155/fmc-2020-0147
   Kozakov D, 2015, NAT PROTOC, V10, P733, DOI 10.1038/nprot.2015.043
   Krautler V, 2001, J COMPUT CHEM, V22, P501, DOI 10.1002/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x
   Lundin A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004166
   Ma TKW, 2010, BRIT J PHARMACOL, V160, P1273, DOI 10.1111/j.1476-5381.2010.00750.x
   Mahdian S, 2020, J DIABETES METAB DIS, DOI 10.1007/s40200-020-00546-9
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Nichols SE, 2011, J CHEM INF MODEL, V51, P1439, DOI 10.1021/ci200117n
   NOMURA H, 1974, J MED CHEM, V17, P1312, DOI 10.1021/jm00258a017
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Olsson MHM, 2011, J CHEM THEORY COMPUT, V7, P525, DOI 10.1021/ct100578z
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Ruster C, 2006, J AM SOC NEPHROL, V17, P2985, DOI 10.1681/ASN.2006040356
   Sabbadin D, 2014, J CHEM INF MODEL, V54, P372, DOI [10.1021/ci4007t6b, 10.1021/ci400766b]
   Sabbadin D, 2014, J CHEM INF MODEL, V54, P169, DOI 10.1021/ci400532b
   Salmaso V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00923
   Sharanya CS, 2020, J BIOMOL STRUCT DYN, DOI [10.26434/chemrxiv.12324980.v1, DOI 10.26434/CHEMRXIV.12324980.V1]
   Sisk JM, 2018, J GEN VIROL, V99, P619, DOI 10.1099/jgv.0.001047
   Spinello A, 2020, J PHYS CHEM LETT, V11, P4785, DOI 10.1021/acs.jpclett.0c01148
   Tikellis Chris, 2012, Int J Pept, V2012, P256294, DOI 10.1155/2012/256294
   Tiwari V, 2020, DRUG DISCOV TODAY, V25, P1535, DOI 10.1016/j.drudis.2020.06.017
   Trezza A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70863-9
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Whisenant J, 2020, ACS MED CHEM LETT, V11, P1076, DOI 10.1021/acsmedchemlett.0c00233
   WRIGHT DB, 1986, DRUG INTEL CLIN PHAR, V20, P845
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xiu SY, 2020, J MED CHEM, V63, P12256, DOI 10.1021/acs.jmedchem.0c00502
   Xydakis MS, 2020, LANCET INFECT DIS, V20, P1015, DOI 10.1016/S1473-3099(20)30293-0
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
NR 76
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-654X
EI 1573-4951
J9 J COMPUT AID MOL DES
JI J. Comput.-Aided Mol. Des.
DI 10.1007/s10822-020-00356-4
EA OCT 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics; Computer Science,
   Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Computer Science
GA OH2TK
UT WOS:000582421800001
PM 33103220
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Selmi, R
   Hammoudeh, S
   Errami, Y
   Wohar, ME
AF Selmi, Refk
   Hammoudeh, Shawkat
   Errami, Youssef
   Wohar, Mark E.
TI Is COVID-19 Related Anxiety an Accelerator for Responsible and
   Sustainable Investing ? A Sentiment Analysis
SO APPLIED ECONOMICS
LA English
DT Article; Early Access
DE COVID-19; anxiety; environmental and social responsibilities; Sentiment
   analysis
ID LONG-RUN CAUSALITY; TIME-SERIES
AB The excessive volatility generated by the COVID-19 pandemic highlights that environmental and social issues are potential elements that businesses and governments must manage effectively and swiftly. This study seeks to test whether the rising anxiety over this pandemic has affected the attitudes and choices towards environmentally and socially responsible investing. To this end, we first use machine learning tools to examine tweets related to this unprecedented and wild shock. Second, we compare the impact of these sentiments on the stock performance of companies from the S&P500 that meet environmental and social sustainability criteria for three COVID-19 phases with varying levels of anxiety, which we label incubation, fever and the increasing risk of second wave pandemic (in the absence of vaccine). Our findings reveal that the increasing uncertainty and worries over COVID-19 and its consequences has not distracted investors' attention away from environmental and social issues, but companies with responsible strategies on environmental issues that specifically address climate responsibility are likely to be more responsive to sentiments at the current situation of emergency.
C1 [Selmi, Refk; Errami, Youssef] ESC Pau Business Sch, Pau, France.
   [Hammoudeh, Shawkat] Drexel Univ, Lebow Coll Business, Philadelphia, PA USA.
   [Wohar, Mark E.] Univ Econ, Inst Business Res, Ho Chi Minh, Vietnam.
   Univ Nebraska, Coll Business Adm, Sch Business & Econ, Omaha, NE 68182 USA.
RP Wohar, ME (corresponding author), Univ Nebraska, Coll Business Adm, Omaha, NE 68182 USA.
EM mwohar@mail.unomaha.edu
CR Breitung J, 2006, J ECONOMETRICS, V132, P363, DOI 10.1016/j.jeconom.2005.02.004
   Broock W.A., 1996, ECONOMET REV, V15, P197, DOI DOI 10.1080/07474939608800353
   Dufour JM, 2006, J ECONOMETRICS, V132, P337, DOI 10.1016/j.jeconom.2005.02.003
   Dufour JM, 1998, ECONOMETRICA, V66, P1099, DOI 10.2307/2999631
   Fahlenbrach R., W27106 NAT BUR EC RE
   Fernandez M, 2016, PROCEEDINGS OF THE 2016 ACM WEB SCIENCE CONFERENCE (WEBSCI'16), P85, DOI 10.1145/2908131.2908167
   Garel A., INVESTOR REWARDS ENV
   Hodson J., 2018, INTERDISCIPLINARY EN, V12, P17, DOI DOI 10.18848/2329-1621/CGP/V12I03/17-35
   Jost F., ENV SCI POLICY
   O'Brien K, 2015, SCIENCE, V350, P1170, DOI 10.1126/science.aad0267
   Porshnev A., SSRN ELECT J
   Scharl A, 2017, IEEE SYST J, V11, P762, DOI 10.1109/JSYST.2015.2466439
   Sluban B, 2015, COMPUTATIONAL SOC NE, V2, P1, DOI DOI 10.1186/S40649-015-0016-5
   Sluban B, 2014, 10TH INTERNATIONAL CONFERENCE ON SIGNAL-IMAGE TECHNOLOGY AND INTERNET-BASED SYSTEMS SITIS 2014, P376, DOI 10.1109/SITIS.2014.27
   Weichselbraun A, 2016, P ANN HICSS, P1040, DOI 10.1109/HICSS.2016.133
NR 15
TC 0
Z9 0
U1 10
U2 10
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0003-6846
EI 1466-4283
J9 APPL ECON
JI Appl. Econ.
DI 10.1080/00036846.2020.1834501
EA OCT 2020
PG 12
WC Economics
SC Business & Economics
GA OJ6OM
UT WOS:000584078100001
OA Bronze
DA 2021-01-01
ER

PT J
AU Haberman, RH
   Castillo, R
   Chen, A
   Yan, D
   Ramirez, D
   Sekar, V
   Lesser, R
   Solomon, G
   Neimann, AL
   Blank, RB
   Izmirly, P
   Webster, DE
   Ogdie, A
   Troxel, AB
   Adhikari, S
   Scher, JU
AF Haberman, Rebecca H.
   Castillo, Rochelle
   Chen, Alan
   Yan, Di
   Ramirez, Deborah
   Sekar, Vaish
   Lesser, Robert
   Solomon, Gary
   Neimann, Andrea L.
   Blank, Rebecca B.
   Izmirly, Peter
   Webster, Dan E.
   Ogdie, Alexis
   Troxel, Andrea B.
   Adhikari, Samrachana
   Scher, Jose U.
TI COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on
   the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs
   on Clinical Outcomes
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID RHEUMATOID-ARTHRITIS; RISK
AB Objective To characterize the hospitalization and death rates among patients with inflammatory arthritis (IA) affected by coronavirus disease 2019 (COVID-19) and to analyze the associations of comorbidities and immunomodulatory medications with infection outcomes.
   Methods Data on clinical and demographic features, maintenance treatment, disease course, and outcomes in individuals with IA (rheumatoid arthritis and spondyloarthritis) with symptomatic COVID-19 infection were prospectively assessed via web-based questionnaire followed by individual phone calls and electronic medical record review. Baseline characteristics and medication use were summarized for hospitalized and ambulatory patients, and outcomes with the different medication classes were compared using multivariable logistic regression.
   Results A total of 103 patients with IA were included in the study (80 with confirmed COVID-19 and 23 with high suspicion of COVID-19). Hospitalization was required in 26% of the participants, and 4% died. Patients who were hospitalized were significantly more likely to be older (P < 0.001) and have comorbid hypertension (P = 0.001) and chronic obstructive pulmonary disease (P = 0.02). IA patients taking oral glucocorticoids had an increased likelihood of being admitted for COVID-19 (P < 0.001), while those receiving maintenance anticytokine biologic therapies did not.
   Conclusion Among patients with underlying IA, COVID-19 outcomes were worse in those receiving glucocorticoids but not in patients receiving maintenance anticytokine therapy. Further work is needed to understand whether immunomodulatory therapies affect COVID-19 incidence.
C1 [Haberman, Rebecca H.; Castillo, Rochelle; Chen, Alan; Yan, Di; Ramirez, Deborah; Sekar, Vaish; Lesser, Robert; Solomon, Gary; Neimann, Andrea L.; Blank, Rebecca B.; Izmirly, Peter; Troxel, Andrea B.; Adhikari, Samrachana; Scher, Jose U.] NYU, Sch Med, New York, NY USA.
   [Haberman, Rebecca H.; Castillo, Rochelle; Chen, Alan; Yan, Di; Ramirez, Deborah; Lesser, Robert; Solomon, Gary; Neimann, Andrea L.; Blank, Rebecca B.; Izmirly, Peter; Troxel, Andrea B.; Adhikari, Samrachana; Scher, Jose U.] NYU Langone, Orthoped Hosp, New York, NY USA.
   [Webster, Dan E.] Sage Bionetworks, Seattle, WA USA.
   [Ogdie, Alexis] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Haberman, RH; Adhikari, S; Scher, JU (corresponding author), 333 East 38th St, New York, NY 10016 USA.
EM rebecca.haberman@nyulangone.org; samrachana.adhikari@nyulangone.org;
   jose.scher@nyulangone.org
OI Izmirly, Peter/0000-0001-5445-2182; Troxel, Andrea/0000-0002-1393-3075;
   Haberman, Rebecca/0000-0002-7119-8136; Adhikari,
   Samrachana/0000-0001-9954-5999
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases,
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [T32-AR-069515,
   R01-AR-074500-01A]; Bloomberg Philanthropies COVID-19 Response
   Initiative grant; Riley Family Foundation; Snyder Family Foundation
FX Supported in part by the National Institute of Arthritis and
   Musculoskeletal and Skin Diseases, NIH (grants T32-AR-069515 to Dr.
   Haberman and R01-AR-074500-01A to Dr. Scher), a Bloomberg Philanthropies
   COVID-19 Response Initiative grant, the Riley Family Foundation, and the
   Snyder Family Foundation.
CR Bechman K, 2019, RHEUMATOLOGY, V58, P1755, DOI 10.1093/rheumatology/kez087
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Cavalcanti AB, 2020, N ENGL J MED
   Centers for Disease Control and Prevention, 2020, SYMPT COR 2019 COVID
   D'Silva KM, 2020, ANN RHEUM DIS, V79, P1156, DOI [10.1136/annrheumdis-2020-217888, 10.1136/annrheumdis-2020-218196, 10.1136/annrheumdis-2020-218179, 10.1136/annrheumdis-2020-218431]
   Fauver JR, 2020, CELL, V181, P990, DOI 10.1016/j.cell.2020.04.021
   Fleming SB, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030023
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Koff WC, 2020, NEW ENGL J MED, V383, P804, DOI 10.1056/NEJMp2006761
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mathian A, 2020, ANN RHEUM DIS, V79, P837, DOI 10.1136/annrheumdis-2020-217566
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   NYC Health, 2020, COVID 19 DATA
   Ogdie A, 2015, ANN RHEUM DIS, V74, P326, DOI 10.1136/annrheumdis-2014-205675
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   R Core Team, 2018, R LANG ENV STAT COMP
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Solomon DH, 2010, ANN RHEUM DIS, V69, P1920, DOI 10.1136/ard.2009.122226
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang W, 2007, VIRUS RES, V128, P1, DOI 10.1016/j.virusres.2007.02.007
   WHO, 2020, PNEUM UNK CAUS CHIN
   Winthrop KL, 2017, NAT REV RHEUMATOL, V13, P234, DOI 10.1038/nrrheum.2017.23
   Yates F., 1934, J R STAT SOC S, V1, P217, DOI DOI 10.2307/2983604
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 36
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD DEC
PY 2020
VL 72
IS 12
BP 1981
EP 1989
DI 10.1002/art.41456
EA OCT 2020
PG 9
WC Rheumatology
SC Rheumatology
GA OW7OV
UT WOS:000582242300001
PM 32725762
OA Bronze
DA 2021-01-01
ER

PT J
AU Tau, N
   Yahav, D
   Shepshelovich, D
AF Tau, Noam
   Yahav, Dafna
   Shepshelovich, Daniel
TI Vaccine safety - is the SARS-CoV-2 vaccine any different?
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE Vaccine; VAERS; FDA; safety; COVID-19; SARS-CoV-2
AB Vaccines have changed modern medicine, and are a mainstay in reducing morbidity and mortality from infections. Our research group recently published a study in which we found that vaccines approved by the US Food and Drugs Administration were safe with few clinically important post-approval adverse effects. The current COVID-19 pandemic presents regulators with the unprecedented challenge of balancing a public demand for the rapid development and approval of a safe and effective SARS-CoV-2 vaccine without compromising the strict pre-marketing requirements used for previous vaccines. Here, we review the approval process and safety profiles of FDA approved vaccines and discuss some of the challenges currently facing the FDA regarding the SARS-CoV-2 vaccine approval.
C1 [Tau, Noam] Sheba Med Ctr, Dept Diagnost Imaging, Ramat Gan, Israel.
   [Tau, Noam; Yahav, Dafna; Shepshelovich, Daniel] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
   [Yahav, Dafna] Beilinson Med Ctr, Rabin Med Ctr, Infect Dis Unit, Petah Tiqwa, Israel.
   [Shepshelovich, Daniel] Tel Aviv Sourasky Med Ctr, Dept Internal Med 1, 6 Weitzman St, IL-6423906 Tel Aviv, Israel.
RP Shepshelovich, D (corresponding author), Tel Aviv Sourasky Med Ctr, Dept Internal Med 1, 6 Weitzman St, IL-6423906 Tel Aviv, Israel.
EM shepshelovich@yahoo.com
RI Tau, Noam/AAK-6164-2020
OI Tau, Noam/0000-0003-0849-1708
CR Alcendor DJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082442
   [Anonymous], 2020, AP NEWS         0528
   Armstrong GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/jama.281.1.61
   Bregu M, 2011, PHILOS T R SOC B, V366, P2841, DOI 10.1098/rstb.2011.0100
   Bremmer I, 2020, TIME
   Calderon-Larranaga A, 2020, AGEING RES REV, V63, DOI 10.1016/j.arr.2020.101149
   CDC, WITHDR ROT VACC REC
   CDC, 2020, CLIN IMM SAF ASS CIS
   Coleman J, 2020, COVID 19 NOW NO 3 CA
   Corman V, 2020, DIAGNOSTIC DETECTION
   COVID-19 Map, COVID 19 MAP
   Edwards K, 2019, PEDIATR INFECT DIS J, V38, P873, DOI 10.1097/INF.0000000000002398
   FDA Center for Biologics Evaluation and Research, 2020, DEV LIC VACC PREV CO
   Gardner L, 2020, LANCET INFECT DIS, V20, P1114, DOI 10.1016/S1473-3099(20)30522-3
   IFPMA, 2014, COMPL JOURN VACC
   JAMA, 2020, JAMA            0730
   Kaur SP, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198114
   McGovern ME, 2015, AM J EPIDEMIOL, V182, P791, DOI 10.1093/aje/kwv125
   National Institutes of Health (NIH), 2019, BUILD TRUST VACC
   NCBI, 2020, WUH SEAF MARK PNEUM
   Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6
   Oxford Law Faculty, 2020, LAUNCH REP CHILD PAR
   Phadke VK, 2020, JAMA-J AM MED ASSOC, V324, P1344, DOI 10.1001/jama.2020.14828
   Roush SW, 2007, JAMA-J AM MED ASSOC, V298, P2155, DOI 10.1001/jama.298.18.2155
   Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2
   Scherer LD, 2016, VACCINE, V34, P2424, DOI 10.1016/j.vaccine.2016.03.087
   Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035
   Shin MD, 2020, NAT NANOTECHNOL, V15, P646, DOI 10.1038/s41565-020-0737-y
   Tau N, 2020, ANN INTERN MED, V173, P445, DOI 10.7326/M20-2726
   Tau N, 2019, JAMA INTERN MED, V179, P1590, DOI 10.1001/jamainternmed.2019.3066
   Verstraeten T, 2016, HUM VACC IMMUNOTHER, V12, P187, DOI 10.1080/21645515.2015.1068486
   WHO, 2020, LANDSC COVID 19 CAND
NR 32
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1829414
EA OCT 2020
PG 4
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA PB4MS
UT WOS:000596297400001
PM 33270474
DA 2021-01-01
ER

PT J
AU Sticchi, L
   Taramasso, L
   Di Biagio, A
   Olobardi, D
   Icardi, G
   Bassetti, M
AF Sticchi, Laura
   Taramasso, Lucia
   Di Biagio, Antonio
   Olobardi, Dario
   Icardi, Giancarlo
   Bassetti, Matteo
TI Will vaccine hesitancy compromise our efforts to face the next
   SARS-CoV-2 epidemic wave?
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE Hesitancy; influenza; Streptococcus pneumoniae; vaccine; Italy
AB We have checked the vaccination history of 389 elderly patients (62.9% males, mean age of 78.5 + 8.4 years) hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Information regarding pneumococcal vaccination was available for 354 patients (91.0%): the overall vaccination coverage rate (VCR) was 19.8% (70/354), 11.3% received only 13-valent pneumococcal conjugate vaccine (PCV13), 3.4% were immunized with 23-valent pneumococcal polysaccharide vaccine (PPSV23), 5.1% received both vaccines. VCR among the elderly population in Liguria Region was 26.2% (118,581/453,082), among them 13.7% received PCV13, 12.4% were immunized with at least one dose of PPSV23. Regarding the 2019-2020 influenza season vaccination data were available for 46 patients: 59% of them were immunized. VCR in the elderly population was 51.7% (234,153/453,082).
C1 [Sticchi, Laura; Taramasso, Lucia; Di Biagio, Antonio; Icardi, Giancarlo; Bassetti, Matteo] Univ Genoa, Dept Hlth Sci Dissal, Via Pastore 1, I-16132 Genoa, Italy.
   [Sticchi, Laura; Olobardi, Dario; Icardi, Giancarlo; Bassetti, Matteo] IRCCS Policlin San Martino Hosp, Hyg Unit, Genoa, Italy.
   [Di Biagio, Antonio] IRCCS Policlin San Martino Hosp, Infect Dis Unit, Genoa, Italy.
RP Di Biagio, A (corresponding author), Univ Genoa, Dept Hlth Sci Dissal, Via Pastore 1, I-16132 Genoa, Italy.
EM adibiagioa@gmail.com
RI ; Di Biagio, Antonio/J-4901-2019
OI Taramasso, Lucia/0000-0002-6622-6358; Di Biagio,
   Antonio/0000-0003-1436-5089
CR Italian Ministry of Health, 2017, NAT IMM PREV PLAN 20
   Italian Ministry of Health, 2020, PREV CONTR INFL REC
   Martinelli D, 2010, AM J INFECT CONTROL, V38, pE8, DOI 10.1016/j.ajic.2009.09.019
   Richmond H, 2020, HUM VACC IMMUNOTHER, V16, P2219, DOI 10.1080/21645515.2020.1793713
NR 4
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1829413
EA OCT 2020
PG 2
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA OQ5DN
UT WOS:000588804000001
PM 33180669
OA Bronze
DA 2021-01-01
ER

PT J
AU Ogidigo, JO
   Iwuchukwu, EA
   Ibeji, CU
   Okpalefe, O
   Soliman, MES
AF Ogidigo, Joyce Oloaigbe
   Iwuchukwu, Emmanuel A.
   Ibeji, Collins U.
   Okpalefe, Okiemute
   Soliman, Mahmoud E. S.
TI Natural phyto, compounds as possible noncovalent inhibitors against
   SARS-CoV2 protease: computational approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; natural phytocompounds; MMGBA; molecular dynamics
   simulations
ID POLAR SURFACE-AREA; MOLECULAR-PROPERTIES; DYNAMICS; BINDING;
   BIOAVAILABILITY; PERMEABILITY; SOLUBILITY; DESIGN; DRUGS; MODEL
AB At present, there is no cure or vaccine for the devastating new highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has affected people globally. Herein, we identified potent phytocompounds from two antiviral plants Momordica charantia L. and Azadirachta indica used locally for the treatment of viral and parasitic infections. Structure-based virtual screening and molecular dynamics (MD) simulation have been employed to study their inhibitory potential against the main protease (M-pro) SARS-CoV-2. A total of 86 compounds from M. charantia L. and A. indica were identified. The top six phytocompounds; momordicine, deacetylnimninene, margolonone, momordiciode F2, nimbandiol, 17-hydroxyazadiradione were examined and when compared with three FDA reference drugs (remdesivir, hydroxychloroquine and ribavirin). The top six ranked compounds and FDA drugs were then subjected to MD simulation and pharmacokinetic studies. These phytocompounds showed strong and stable interactions with the active site amino acid residues of SARS-CoV-2 Mpro similar to the reference compound. Results obtained from this study showed that momordicine and momordiciode F2 exhibited good inhibition potential (best MMGBA-binding energies; -41.1 and -43.4 kcal/mol) against the M-pro of SARS-CoV-2 when compared with FDA reference anti-viral drugs (Ribavirin, remdesivir and hydroxychloroquine). Per-residue analysis, root mean square deviation and solvent-accessible surface area revealed that compounds interacted with key amino acid residues at the active site of the enzyme and showed good system stability. The results obtained in this study show that these phytocompounds could emerge as promising therapeutic inhibitors for the M-pro of SARS-CoV-2. However, urgent trials should be conducted to validate this outcome.
   Communicated by Ramaswamy H. Sarma
C1 [Ogidigo, Joyce Oloaigbe] Natl Biotechnol Dev Agcy, Bioresources Dev Ctr, Abuja, Nigeria.
   [Ogidigo, Joyce Oloaigbe] Natl Biotechnol Dev Agcy, Genet Genom & Bioinformat Dept, Abuja, Nigeria.
   [Ogidigo, Joyce Oloaigbe; Okpalefe, Okiemute] Univ Nigeria, Fac Biol Sci, Dept Biochem, Nsukka, Enugu, Nigeria.
   [Iwuchukwu, Emmanuel A.; Soliman, Mahmoud E. S.] Univ KwaZulu Natal, Sch Hlth Sci, Mol Biocomputat & Drug Design Lab, Durban, South Africa.
   [Ibeji, Collins U.] Univ KwaZulu Natal, Sch Hlth Sci, Catalysis & Peptide Res Unit, ZA-4041 Durban, South Africa.
   [Ibeji, Collins U.] Univ Nigeria, Fac Phys Sci, Dept Pure & Ind Chem, Nsukka 410001, Enugu State, Nigeria.
RP Ibeji, CU (corresponding author), Univ KwaZulu Natal, Sch Hlth Sci, Catalysis & Peptide Res Unit, ZA-4041 Durban, South Africa.; Ibeji, CU (corresponding author), Univ Nigeria, Fac Phys Sci, Dept Pure & Ind Chem, Nsukka 410001, Enugu State, Nigeria.
EM ugochukwu.ibeji@unn.edu.ng
CR Abad-Zapatero C, 2007, EXPERT OPIN DRUG DIS, V2, P469, DOI 10.1517/17460441.2.4.469
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   Bennion BJ, 2017, J PHYS CHEM B, V121, P5228, DOI 10.1021/acs.jpcb.7b02914
   Chapman KL, 2013, REGUL TOXICOL PHARM, V66, P88, DOI 10.1016/j.yrtph.2013.03.001
   Daga PR, 2018, MOL PHARMACEUT, V15, P831, DOI 10.1021/acs.molpharmaceut.7b00973
   Di L, 2006, DRUG DISCOV TODAY, V11, P446, DOI 10.1016/j.drudis.2006.03.004
   Doak BC, 2014, CHEM BIOL, V21, P1115, DOI 10.1016/j.chembiol.2014.08.013
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Emmanuel IA, 2019, MED HYPOTHESES, V130, DOI 10.1016/j.mehy.2019.109277
   Emmanuel IA, 2019, CHEM BIODIVERS, V16, DOI 10.1002/cbdv.201900085
   Ertl P, 2000, J MED CHEM, V43, P3714, DOI 10.1021/jm000942e
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Garcia-Fernandez R, 2016, PROTEIN EXPRES PURIF, V123, P42, DOI 10.1016/j.pep.2016.03.003
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Hopkins AL, 2014, NAT REV DRUG DISCOV, V13, P105, DOI 10.1038/nrd4163
   Husain A, 2016, SAUDI PHARM J, V24, P104, DOI 10.1016/j.jsps.2015.02.008
   Ibeji CU, 2020, MOL SIMULAT, V46, P62, DOI 10.1080/08927022.2019.1674850
   Johnson TW, 2018, J MED CHEM, V61, P6401, DOI 10.1021/acs.jmedchem.8b00077
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kholmurodov K, 2000, J COMPUT CHEM, V21, P1187, DOI 10.1002/1096-987X(200010)21:13<1187::AID-JCC7>3.0.CO;2-7
   Krishnan KA, 2002, IND ENG CHEM RES, V41, P5085, DOI 10.1021/ie0110181
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Liu JQ, 2009, MOLECULES, V14, P4804, DOI 10.3390/molecules14124804
   LLORACHPARES L, 2017, MAR DRUGS, V15, DOI DOI https://doi.org/10.3390/md15120366
   Lopez-Lopez E, 2019, EXPERT OPIN DRUG DIS, V14, P335, DOI 10.1080/17460441.2019.1581170
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Mohammad A.-N., 2016, P 9 INT C MOB COMP U
   Mukherjee PK, 2007, PHYTOTHER RES, V21, P1142, DOI 10.1002/ptr.2224
   Munsamy G, 2018, RSC ADV, V8, P21829, DOI 10.1039/c8ra04360d
   Olotu FA, 2019, APPL BIOCHEM BIOTECH, V187, P1061, DOI 10.1007/s12010-018-2863-7
   Omran Z, 2014, EUR BIOPHYS J BIOPHY, V43, P199, DOI 10.1007/s00249-014-0953-1
   Perez A, 2015, J CHEM THEORY COMPUT, V11, P4770, DOI 10.1021/acs.jctc.5b00662
   Pongthanapisith V, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/729081
   Prasanna S, 2009, CURR MED CHEM, V16, P21, DOI 10.2174/092986709787002817
   Read J. M., 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.23.20018549, DOI 10.1101/2020.01.23.20018549]
   Remko M, 2011, STRUCT CHEM, V22, P635, DOI 10.1007/s11224-011-9741-z
   Remko M, 2009, J MOL STRUC-THEOCHEM, V916, P76, DOI 10.1016/j.theochem.2009.09.011
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Seifert E., 2014, ORIGINPRO 9 1 SCI DA
   Shityakov Sergey, 2013, International Journal of Computational Biology and Drug Design, V6, P146, DOI 10.1504/IJCBDD.2013.052195
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   WANG JM, 2001, ABSTR PAP AM CHEM 1, V222
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhavoronkov A., 2020, POTENTIAL NONCOVALEN
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou ZG, 2004, PROTEINS, V57, P493, DOI 10.1002/prot.20223
   Zhou ZG, 2009, J COMPUT CHEM, V30, P2165, DOI 10.1002/jcc.21214
NR 54
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1837681
EA OCT 2020
PG 18
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OJ4BB
UT WOS:000583907900001
PM 33103616
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sainz-Amo, R
   Baena-Alvarez, B
   Parees, I
   Sanchez-Diez, G
   Perez-Torre, P
   Lopez-Sendon, JL
   Fanjul-Arbos, S
   Monreal, E
   Corral-Corral, I
   Garcia-Barragan, N
   Martinez-Castrillo, JC
   Fasano, A
   Alonso-Canovas, A
AF Sainz-Amo, R.
   Baena-Alvarez, B.
   Parees, I.
   Sanchez-Diez, G.
   Perez-Torre, P.
   Lopez-Sendon, J. L.
   Fanjul-Arbos, S.
   Monreal, E.
   Corral-Corral, I.
   Garcia-Barragan, N.
   Martinez-Castrillo, J. C.
   Fasano, A.
   Alonso-Canovas, A.
TI COVID-19 in Parkinson's disease: what holds the key?
SO JOURNAL OF NEUROLOGY
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; Parkinson; Institutionalization; Comorbidity;
   Prognosis
AB Introduction Parkinson's disease (PD) is more frequent in the elderly and increases the risk of respiratory infections. Previous data on PD and SARS-CoV-2 are scarce, suggesting a poor prognosis in advanced disease and second-line therapies. Methods A retrospective case-control study comparing patients with PD and COVID-19 and patients with PD without COVID-19 was conducted during the pandemic period in Spain (March 1st-July 31st 2020) in a tertiary university hospital. Results Thirty-nine (COVID-19 +) and 172 (COVID-19-) PD patients were included. Fifty-nine percent were males in both groups, with similar age (75.9 +/- 9.0 COVID-19 + , 73.9 +/- 10.0 COVID-19-), disease duration (8.9 +/- 6.2 COVID-19 + , 8.5 +/- 5.6 COVID-19-) and PD treatments. COVID-19 was mild in 10 (26%), required admission in 21 (54%) and caused death in 8 (21%) patients. Dementia was the only comorbidity more frequent in COVID-19 + patients (36% vs. 14%, p = 0.0013). However, in a multivariate analysis, institutionalization was the only variable associated with COVID-19 + (OR 17.0, 95% CI 5.0-60.0, p < 0.001). When considering severe COVID-19 (admission or death) vs. mild or absent COVID-19, institutionalization, neoplasm, dementia and a lower frequency of dopamine agonists were associated with severe COVID-19. In multivariate analysis, only institutionalization [OR 5.17, 95% CI 1.57-17, p = 0.004] and neoplasm [OR 8.0, 95%CI 1.27-49.8, p = 0.027] remained significantly associated. Conclusion In our experience, institutionalization and oncologic comorbidity, rather than PD-related variables, increased the risk of developing COVID-19, and impacted on its severity. These findings suggest that epidemiologic factors and frailty are key factors for COVID-19 morbidity/mortality in PD. Appropriate preventive strategies should be implemented in institutionalized patients to prevent infection and improve prognosis.
C1 [Sainz-Amo, R.; Baena-Alvarez, B.; Parees, I.; Sanchez-Diez, G.; Perez-Torre, P.; Lopez-Sendon, J. L.; Fanjul-Arbos, S.; Monreal, E.; Corral-Corral, I.; Garcia-Barragan, N.; Martinez-Castrillo, J. C.; Alonso-Canovas, A.] Hosp Univ Ramon y Cajal, Movement Disorders Unit, Neurol Dept, Carretera Colmenar Km 9-100, Madrid 28034, Spain.
   [Fasano, A.] Univ Toronto, Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Div Neurol,UHN, Toronto, ON, Canada.
   [Fasano, A.] Univ Toronto, Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Ctr, UHN, Toronto, ON, Canada.
   [Fasano, A.] Krembil Brain Inst, Toronto, ON, Canada.
RP Sainz-Amo, R (corresponding author), Hosp Univ Ramon y Cajal, Movement Disorders Unit, Neurol Dept, Carretera Colmenar Km 9-100, Madrid 28034, Spain.
EM raquelsainzamo@gmail.com
RI ; Martinez Castrillo, Juan Carlos/F-3119-2013
OI Sainz Amo, Raquel/0000-0002-2432-0039; Martinez Castrillo, Juan
   Carlos/0000-0001-7744-6850
CR [Anonymous], 2020, WORLD HLTH ORG CORON
   Antonini A, 2020, MOVEMENT DISORD, V35, P905, DOI 10.1002/mds.28104
   Centers for Disease Control and Prevention, 2020, CORONAVIRUS DIS 2019
   Cilia R, 2020, MOVEMENT DISORD, V35, P1287, DOI 10.1002/mds.28170
   Fasano Alfonso, 2020, Parkinsonism Relat Disord, V78, P134, DOI 10.1016/j.parkreldis.2020.08.012
   Fasano A, 2020, MOVEMENT DISORD, V35, P1089, DOI 10.1002/mds.28176
   Gosain R, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-00934-7
   Helmich RC, 2020, J PARKINSON DIS, V10, P351, DOI 10.3233/JPD-202038
   Hribar CA, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10050284
   Ministerio de Sanidad, 2020, SITUACION COVID 19 E
   Monteiro L, 2012, CLIN THER, V34, P1049, DOI 10.1016/j.clinthera.2012.03.001
   Nataf S, 2020, J MED VIROL, V92, P1743, DOI 10.1002/jmv.25826
   Postuma RB, 2015, MOVEMENT DISORD, V30, P1591, DOI 10.1002/mds.26424
   Prasad S, 2020, MOVEMENT DISORD, V35, P912, DOI 10.1002/mds.28088
   RADA AG, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1554
   Rejdak K, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102163
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zipprich HM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061643
NR 19
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
DI 10.1007/s00415-020-10272-0
EA OCT 2020
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA OI7UC
UT WOS:000583477800001
PM 33098468
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Saidipour, P
AF Saidipour, Panthea
TI The Precedent of Good Enough Therapy During Unprecedented Times
SO CLINICAL SOCIAL WORK JOURNAL
LA English
DT Article; Early Access
DE Coronavirus; COVID-19; Shared trauma; Good enough therapy; Holding
   environment; Self-disclosure
AB The unprecedented nature of the coronavirus pandemic and clinicians' own concerns for safety and stability amidst collective uncertainty have threatened to undermine our ability to trust what we already know about our clients and how to help them. Rather than search for a novel solution, I suggest that what we need during a shared crisis is to renew our trust in the existing ethos of good enough therapy, a metaphoric corollary to Winnicott's concept of good enough mothering, which presupposes the realities of imperfection and uncertainty along the continuum of growth. Using personal reflections, clinical vignettes from my psychotherapy practice, and drawing from modern attachment theory, contemporary relational psychoanalysis, and object relations theory, I posit in this article that clinical social workers already possess the framework, skills, and knowledge needed to deeply understand and meaningfully work with clients as they, and we, endure shared trauma. Through the clinical material, I examine opportunities to make use of clients' reactions, as well as my own, in order to deepen the therapeutic process. I discuss the necessity of holding the therapeutic frame with increased flexibility in light of my use of self-disclosure surrounding my COVID-19 diagnosis and recovery, and I assess the impact of this disclosure.
C1 [Saidipour, Panthea] Psychoanalyt Psychotherapy Study Ctr, MSW Interns, New York, NY 10011 USA.
   [Saidipour, Panthea] Psychoanalyt Psychotherapy Study Ctr, Clin Journeys Program, New York, NY 10011 USA.
   [Saidipour, Panthea] NYU, Silver Sch Social Work, New York, NY 10003 USA.
RP Saidipour, P (corresponding author), Psychoanalyt Psychotherapy Study Ctr, MSW Interns, New York, NY 10011 USA.; Saidipour, P (corresponding author), Psychoanalyt Psychotherapy Study Ctr, Clin Journeys Program, New York, NY 10011 USA.; Saidipour, P (corresponding author), NYU, Silver Sch Social Work, New York, NY 10003 USA.
EM panthea@pantheacounselingnyc.com
CR Aron L., 1996, M MINDS MUTUALITY PS
   CHESCHEIR MW, 1985, CLIN SOC WORK J, V13, P218, DOI 10.1007/BF00754648
   Freud S, 1935, COMMUNICATION   0502, P424
   Kuchuck S, 2015, NY TIMES
   Saakvitne KW, 2002, PSYCHOANAL DIALOGUES, V12, P443, DOI 10.1080/10481881209348678
   Schore JR, 2008, CLIN SOC WORK J, V36, P9, DOI 10.1007/s10615-007-0111-7
   Slochower J, 2017, INTRO CONT PSYCHOANA, P97
   Slochower J, 2013, CONTEMP PSYCHOANAL, V49, P606, DOI 10.1080/00107530.2013.10779266
   Tosone C., 2003, PSYCHOANALYTIC SOCIA, V10, P57, DOI DOI 10.1300/J032v10n01_06
   Tosone C, 2006, SMITH COLL STUD SOC, V76, P89, DOI 10.1300/J497v76n04_12
   Tosone C, 2012, CLIN SOC WORK J, V40, P231, DOI 10.1007/s10615-012-0395-0
   WINNICOTT DW, 1960, INT J PSYCHOANAL, V41, P585
NR 12
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0091-1674
EI 1573-3343
J9 CLIN SOC WORK J
JI Clin. Soc. Work J.
DI 10.1007/s10615-020-00776-7
EA OCT 2020
PG 8
WC Social Work
SC Social Work
GA OH1GE
UT WOS:000582319300001
PM 33132457
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Schulman, S
   Hu, Y
   Konstantinides, S
AF Schulman, Sam
   Hu, Yu
   Konstantinides, Stavros
TI Venous Thromboembolism in COVID-19
SO THROMBOSIS AND HAEMOSTASIS
LA English
DT Article; Early Access
DE COVID-19; D-dimer; risk assessment models; venous thromboembolism;
   prophylaxis; treatment
ID DEEP-VEIN THROMBOSIS; MEDICAL PATIENTS; RISK; INFECTION; PNEUMONIA;
   THERAPY; IMPACT
AB The coronavirus disease 2019 (COVID-19) is our latest pandemic, preceded by the H1N1 swine flu in 2009, which lasted approximately 19 months. One of the special characteristics of COVID-19 is the propensity to cause venous thromboembolism (VTE). Thromboinflammation seems to play a prominent role in the pathogenesis. We will here review some mechanisms in the pathogenesis and discuss some hematological biomarkers, and also whether they serve as useful risk factors for VTE. The role of general risk assessment models for medically ill patients specifically in COVID-19 is appraised. The type of prophylaxis and particularly whether standard or augmented doses of chemoprophylaxis should be used is reviewed based on available evidence. We are also comparing recommendations from 10 different guidance or position/consensus statements. Treatment recommendations for patients with COVID-19 and pulmonary embolism are discussed with current general treatment guidelines as reference. Specifics for patients with COVID-19 are pointed out and the potential role of thrombolytic treatment is explored.
C1 [Schulman, Sam] McMaster Univ, Thrombosis & Atherosclerosis Res Inst, Dept Med, Hamilton, ON, Canada.
   [Schulman, Sam] IM Sechenov First Moscow State Med Univ, Dept Obstet & Gynecol, Moscow, Russia.
   [Hu, Yu] Huazhong Univ Sci & Technol, Inst Hematol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China.
   [Konstantinides, Stavros] Univ Med Ctr Mainz, Ctr Thrombosis & Hemostasis, Mainz, Germany.
   [Konstantinides, Stavros] Democritus Univ Thrace, Dept Cardiol, Thrace, Greece.
RP Schulman, S (corresponding author), HHS Gen Hosp, Thrombosis Serv, Hamilton, ON L8L 2X2, Canada.
EM schulms@mcmaster.ca
CR Abdel-Wahab N, 2018, LUPUS, V27, P572, DOI 10.1177/0961203317731532
   Abou-Ismail MY, 2020, THROMB RES, V194, P101, DOI 10.1016/j.thromres.2020.06.029
   Al-Ani F, 2020, THROMB RES, V192, P152, DOI 10.1016/j.thromres.2020.05.039
   Al-Samkari H, 2020, RES PRACT THROMB S1, V4
   [Anonymous], 2020, COVID 19 VTE ANT FRE
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barbar S, 2010, J THROMB HAEMOST, V8, P2450, DOI 10.1111/j.1538-7836.2010.04044.x
   Barnes GD, 2020, J THROMB THROMBOLYS, V50, P72, DOI 10.1007/s11239-020-02138-z
   Bauersachs R, 2019, VASA, V48, P483, DOI 10.1024/0301-1526/a000815
   Bikdeli B, 2020, THROMB HAEMOSTASIS, V120, P1004, DOI 10.1055/s-0040-1713152
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Blondon M, 2018, THROMB HAEMOSTASIS, V118, P82, DOI 10.1160/TH17-06-0403
   Boscolo A, 2020, THROMB HAEMOSTASIS, V120, P1474, DOI 10.1055/s-0040-1714350
   Casini Alessandro, 2020, Swiss Med Wkly, V150, pw20247, DOI 10.4414/smw.2020.20247
   Cattaneo M, 2020, THROMB HAEMOSTASIS, V120, P1230, DOI 10.1055/s-0040-1712097
   Chaudhary R, 2020, THROMB HAEMOSTASIS, V120, P1594, DOI 10.1055/s-0040-1714217
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chopard P, 2006, J THROMB HAEMOST, V4, P915, DOI 10.1111/j.1538-7836.2006.01818.x
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Demelo-Rodriguez P, 2020, THROMB RES, V192, P23, DOI 10.1016/j.thromres.2020.05.018
   Di Minno A, 2020, SEMIN THROMB HEMOST, V46, P763, DOI 10.1055/s-0040-1715456
   Duan QL, 2012, INT J MED SCI, V9, P453, DOI 10.7150/ijms.4453
   European Society of Cardiology, 2020, ESC GUID DIAGN MAN C
   Fauvel C, 2020, EUR HEART J, V41, P3058, DOI 10.1093/eurheartj/ehaa500
   Frydman GH, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620943671
   Gao T, 2020, HIGHLY PATHOGENIC CO, DOI [10.1101/2020.03.29.20041962, DOI 10.1101/2020.03.29.20041962]
   Gibson C Michael, 2017, TH Open, V1, pe56, DOI 10.1055/s-0037-1603929
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin SE, 2020, THROMB HAEMOSTASIS, V120, P1524, DOI 10.1055/s-0040-1714369
   Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026
   Khider L, 2020, J Med Vasc, V45, P210, DOI 10.1016/j.jdmv.2020.04.008
   Kirchhof P, 2016, EUROPACE, V18, DOI 10.1093/europace/euw295
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Koch V, 2020, EUR HEART J-ACUTE CA, DOI 10.1177/2048872620907322
   Konstantinides SV, 2020, EUR HEART J, V41, P543, DOI 10.1093/eurheartj/ehz405
   Konstantinides SV, 2017, J AM COLL CARDIOL, V69, P1536, DOI 10.1016/j.jacc.2016.12.039
   Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1733, DOI 10.1002/jmv.25819
   Lax SF, 2020, ANN INTERN MED, V173, P350, DOI 10.7326/M20-2566
   Leisman DE, 2020, INTENS CARE MED, V46, P1105, DOI 10.1007/s00134-020-06059-6
   Levi M, 2004, CIRCULATION, V109, P2698, DOI 10.1161/01.CIR.0000131660.51520.9A
   Llau JV, 2020, REV ESP ANEST REANIM, V67, P391, DOI 10.1016/j.redar.2020.05.007
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Malato A, 2015, BLOOD TRANSFUS-ITALY, V13, P559, DOI 10.2450/2015.0277-14
   Marietta M, 2020, BLOOD TRANSFUS-ITALY, V18, P167, DOI 10.2450/2020.0083-20
   Mazzolai L, 2018, EUR HEART J, V39, P4208, DOI 10.1093/eurheartj/ehx003
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meyer G, 2014, NEW ENGL J MED, V370, P1402, DOI 10.1056/NEJMoa1302097
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Miesbach W, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620938149
   Minet C, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1003-9
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Pengo V, 2018, BLOOD, V132, P1365, DOI 10.1182/blood-2018-04-848333
   Pesavento R, 2020, J THROMB HAEMOST, V18, P2629, DOI 10.1111/jth.15022
   de Chambrun MP, 2020, J INTERN MED, DOI 10.1111/joim.13166
   Poggiali Erika, 2020, Eur J Case Rep Intern Med, V7, P001646, DOI 10.12890/2020_001646
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Roberts LN, 2020, BLOOD, V136, P1347, DOI 10.1182/blood.2020008086
   Rosenberg D, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001152
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Spyropoulos AC, 2020, J THROMB HAEMOST, V18, P1859, DOI 10.1111/jth.14929
   Stals MAM, 2020, RES PRACT THROMB S1, V4
   Steffel J, 2018, EUR HEART J, V39, P1330, DOI 10.1093/eurheartj/ehy136
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Testa S, 2020, J THROMB HAEMOST, V18, P1320, DOI 10.1111/jth.14871
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Tremblay D, 2020, BLOOD, V136, P144, DOI 10.1182/blood.2020006941
   Vaughan CJ, 2020, THROMB HAEMOSTASIS, V120, P1590, DOI 10.1055/s-0040-1714216
   Violi F, 2020, THROMB HAEMOSTASIS, V120, P949, DOI 10.1055/s-0040-1710317
   Vivas D., 2020, Revista Espanola de Cardiologia, V73, P749, DOI 10.1016/j.rec.2020.04.025
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Whyte CS, 2020, J THROMB HAEMOST, V18, P1548, DOI 10.1111/jth.14872
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Xiao M, 2020, ARTHRITIS RHEUMATOL, V72, P1998, DOI 10.1002/art.41425
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Zerwes S, 2020, CHIRURG, V91, P588, DOI 10.1007/s00104-020-01222-7
   Zhai ZG, 2020, THROMB HAEMOSTASIS, V120, P937, DOI 10.1055/s-0040-1710019
   Zhang L, 2020, CIRCULATION, V142, P114, DOI 10.1161/CIRCULATIONAHA.120.046702
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zondag W, 2011, J THROMB HAEMOST, V9, P1500, DOI 10.1111/j.1538-7836.2011.04388.x
NR 91
TC 1
Z9 1
U1 1
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0340-6245
EI 2567-689X
J9 THROMB HAEMOSTASIS
JI Thromb. Haemost.
DI 10.1055/s-0040-1718532
EA OCT 2020
PG 12
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA OG9EU
UT WOS:000582178900003
PM 33099284
OA Other Gold
DA 2021-01-01
ER

PT J
AU Huddart, R
   Whirl-Carrillo, M
   Altman, RB
   Klein, TE
AF Huddart, Rachel
   Whirl-Carrillo, Michelle
   Altman, Russ B.
   Klein, Teri E.
TI PharmGKB Tutorial for Pharmacogenomics of Drugs Potentially Used in the
   Context of COVID-19
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article; Early Access
AB Pharmacogenomics (PGx) is a key area of precision medicine, which is already being implemented in some health systems and may help guide clinicians toward effective therapies for individual patients. Over the last 2 decades, the Pharmacogenomics Knowledgebase (PharmGKB) has built a unique repository of PGx knowledge, including annotations of clinical guideline and regulator-approved drug labels in addition to evidence-based drug pathways and annotations of the scientific literature. All of this knowledge is freely accessible on the PharmGKB website. In the first of a series of PharmGKB tutorials, we introduce the PharmGKB coronavirus disease 2019 (COVID-19) portal and, using examples of drugs found in the portal, demonstrate some of the main features of PharmGKB. This paper is intended as a resource to help users become quickly acquainted with the wealth of information stored in PharmGKB.
C1 [Huddart, Rachel; Whirl-Carrillo, Michelle; Altman, Russ B.; Klein, Teri E.] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.
   [Altman, Russ B.] Stanford Univ, Dept Biomed Engn, Stanford, CA 94305 USA.
   [Altman, Russ B.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA.
   [Altman, Russ B.; Klein, Teri E.] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
RP Klein, TE (corresponding author), Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.; Klein, TE (corresponding author), Stanford Univ, Dept Med, Stanford, CA 94305 USA.
EM feedback@pharmgkb.org
FU National Institutes of Health (NIH)/National Human Genome Research
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Human Genome Research
   Institute (NHGRI) [NHGRI: U24 HG010615]
FX PharmGKB is supported by National Institutes of Health (NIH)/National
   Human Genome Research Institute (NHGRI: U24 HG010615).
CR Back D, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14358
   Hicks JK, 2017, CLIN PHARMACOL THER, V102, P37, DOI 10.1002/cpt.597
   Hicks JK, 2015, CLIN PHARMACOL THER, V98, P127, DOI 10.1002/cpt.147
   Lever Jake, 2020, Pac Symp Biocomput, V25, P611
   PharmGKB, 2020, CLIN ANN LEV EV
   PharmGKB, 2020, DRUG LAB INF LEG
   US Food and Drug Administration (FDA), 2020, FDA DRUG SHORT CURR
   Whirl-Carrillo M, 2012, CLIN PHARMACOL THER, V92, P414, DOI 10.1038/clpt.2012.96
NR 8
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
DI 10.1002/cpt.2067
EA OCT 2020
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OG5LG
UT WOS:000581924700001
PM 32978778
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Simpson, S
   Richardson, L
   Pietrabissa, G
   Castelnuovo, G
   Reid, C
AF Simpson, Susan
   Richardson, Lisa
   Pietrabissa, Giada
   Castelnuovo, Gianluca
   Reid, Corinne
TI Videotherapy and therapeutic alliance in the age of COVID-19
SO CLINICAL PSYCHOLOGY & PSYCHOTHERAPY
LA English
DT Article; Early Access
DE COVID&#8208; 19; telemental health; telepsychology; therapeutic
   alliance; videotherapy
ID FACE-TO-FACE; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIOR THERAPY;
   TELEMENTAL HEALTH; VIDEOCONFERENCING PSYCHOTHERAPY; PRACTICE GUIDELINES;
   PSYCHOLOGY; TELEPSYCHOLOGY; TELEHEALTH; AUSTRALIA
AB The arrival of the coronavirus (COVID-19) pandemic has confronted us with a global and unprecedented challenge of community-wide psychological distress alongside reduced access to therapeutic services in the traditional face-to-face format, due to the need to self-isolate. This previously unimagineable set of circumstances provides a unique opportunity, and indeed an imperative, for videotherapy to fulfil its potential in addressing mental health and well-being needs from a distance. Historically, the uptake of videotherapy has been hindered by psychotherapist expectations of inferior therapeutic alliance and outcomes, in spite of considerable research evidence to the contrary. Research suggests that videotherapy provides a powerful pathway for clients to experience enhanced opportunities for self-expression, connection and intimacy. This more neutral therapeutic 'space' provides clients with multifarious opportunities for self-awareness, creative experience and collaboration, with potentially a greater sense of agency over their own experience. This paper explores ways in which videotherapy can lead to a revitalisation of the concept of the therapeutic relationship, in order to meet the challenges associated with COVID-19. A number of specific considerations for videotherapy adaptations and etiquette in the midst of COVID-19 are described.
C1 [Simpson, Susan] St Johns Hosp, NHS Lothian, Howden West Rd, Livingston EH54 6PP, Scotland.
   [Simpson, Susan] Univ South Australia, Dept Justice & Soc, Adelaide, SA, Australia.
   [Richardson, Lisa] MHPHDS, North Metropolitan Hlth Serv, Perth, WA, Australia.
   [Pietrabissa, Giada; Castelnuovo, Gianluca] IRCCS Ist Auxol Italiano, Psychol Res Lab, Milan, Italy.
   [Pietrabissa, Giada; Castelnuovo, Gianluca] Univ Cattolica Sacro Cuore, Dept Psychol, Milan, Italy.
   [Reid, Corinne] Victoria Univ, Res, Melbourne, Vic, Australia.
RP Simpson, S (corresponding author), St Johns Hosp, NHS Lothian, Howden West Rd, Livingston EH54 6PP, Scotland.
EM susan.g.simpson@nhslothian.scot.nhs.uk
RI Simpson, Susan/F-3261-2013
OI Simpson, Susan/0000-0002-9625-0797; Castelnuovo,
   Gianluca/0000-0003-2633-9822; Pietrabissa, Giada/0000-0002-5911-5748
CR American Psychiatric Association (APA), 2016, WEB BAS TEL HLTH TOO
   Andersson G, 2016, ANNU REV CLIN PSYCHO, V12, P157, DOI 10.1146/annurev-clinpsy-021815-093006
   Andersson Gerhard, 2009, Cognitive Behaviour Therapy, V38, P196, DOI 10.1080/16506070903318960
   Anthony K., 2010, THERAPY ONLINE PRACT
   Austen S, 2006, J TELEMED TELECARE, V12, P146, DOI 10.1258/135763306776738594
   Backhaus A, 2012, PSYCHOL SERV, V9, P111, DOI 10.1037/a0027924
   Badawi A., 2016, J AUSTR TRADITIONAL, V22, P90
   Berwick DM, 2020, JAMA-J AM MED ASSOC, V323, P2125, DOI 10.1001/jama.2020.6949
   Bischoff RJ, 2004, CONTEMP FAM THER, V26, P179, DOI 10.1023/B:COFT.0000031242.83259.fa
   Bouchard S, 2004, TELEMED J E-HEALTH, V10, P13, DOI 10.1089/153056204773644535
   Bridges N A, 1999, J Psychother Pract Res, V8, P292
   Brown R., 2018, UNDERSTANDING BOUNDA
   Castelnuovo G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00559
   Chen QN, 2020, LANCET PSYCHIAT, V7, pE15, DOI 10.1016/S2215-0366(20)30078-X
   Day SX, 2002, J COUNS PSYCHOL, V49, P499, DOI 10.1037/0022-0167.49.4.499
   de la Torre I, 2017, JMIR MHEALTH UHEALTH, V5, DOI 10.2196/mhealth.8036
   Drum KB, 2014, PROF PSYCHOL-RES PR, V45, P309, DOI 10.1037/a0036127
   Dunn K., 2018, PSYCHOTHERAPY 2 0, P75
   Dunn K, 2012, COUNS PSYCHOTHER RES, V12, P316, DOI 10.1080/14733145.2012.669772
   Dunstan DA, 2012, RURAL REMOTE HEALTH, V12
   Elkin N., 2008, AM SEARCHES HLTH WEL, P1
   Fletcher-Tomenius L., 2009, COUNSELLING PSYCHOL, V24, P24
   Frissa S., 2020, OSF PREPRINTS, DOI [10.31219/osf.io/yq9kn, DOI 10.31219/OSF.IO/YQ9KN]
   Frueh C., 2007, BEHAV MODCATION, V31, P856, DOI DOI 10.1177/0145445507302125
   Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49
   Greenberg N, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1211
   Greene CJ, 2010, J CONSULT CLIN PSYCH, V78, P746, DOI 10.1037/a0020158
   Hailey D, 2008, CAN J PSYCHIAT, V53, P769, DOI 10.1177/070674370805301109
   Hale T, 2020, OXFORD COVID 19 GOVT
   Hermansson G., 1997, BRIT J GUID COUNS, V25, P133
   Hilty DM, 2013, TELEMED E-HEALTH, V19, P444, DOI 10.1089/tmj.2013.0075
   Himle JA, 2006, BEHAV RES THER, V44, P1821, DOI 10.1016/j.brat.2005.12.010
   Himle MB, 2012, BEHAV RES THER, V50, P565, DOI 10.1016/j.brat.2012.05.009
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Hong YR, 2020, JMIR PUBLIC HLTH SUR, V6, P168, DOI 10.2196/18961
   Horvath A. O., 2011, PSYCHOTHERAPY RELATI
   Joint Task Force Dev Telepsycholog, 2013, AM PSYCHOL, V68, P791, DOI 10.1037/a0035001
   Kilinc A, 2003, EUROPEAN J COUNSELLI, V6, P56, DOI DOI 10.5964/ejcop.v2i1.5
   Kim RJ, 2020, INT J FOOD SCI NUTR, DOI [10.1080/09637486.2020.1840533, 10.1109/EMR.2020.2990115]
   Knopf A., 2020, BROWN U CHILD ADOLES, V36, P7, DOI [10.1002/cbl.30463, DOI 10.1002/CBL.30463]
   Langarizadeh Mostafa, 2017, Acta Inform Med, V25, P240, DOI 10.5455/aim.2017.25.240-246
   Lazarus Arnold A, 1994, Ethics Behav, V4, P255, DOI 10.1207/s15327019eb0403_10
   Lazarus W., 2000, ONLINE CONTENT LOW I
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Lozano BE, 2015, BEHAV TELEHEALTH, P221, DOI 10.1007/978-3-319-08765-8_10
   Lustgarten Samuel D, 2020, Curr Opin Psychol, V36, P25, DOI 10.1016/j.copsyc.2020.03.012
   Luxton D., 2016, PRACTITIONERS GUIDE
   Maheu MM, 2012, PROF PSYCHOL-RES PR, V43, P613, DOI 10.1037/a0029458
   Manchanda M, 1998, J TELEMED TELECARE, V4, P53, DOI 10.1258/1357633981931452
   McCord CE, 2015, COUNS PSYCHOL Q, V28, P324, DOI 10.1080/09515070.2015.1053433
   Ministry of Education of the People's Republic of China, 2020, RESP EP PSYCH DEP BE
   Ministry of Education of the People's Republic of China, 2020, MENT HLTH SERV PLATF
   MITCHELL E, 2020, EUROPEAN J QUALITATI, V10, P121
   MORI Ipsos, 2020, COVID 19 MENT WELLB
   Morland LA, 2010, J CLIN PSYCHIAT, V71, P855, DOI 10.4088/JCP.09m05604blu
   Nelson EL, 2003, TELEMED J E-HEALTH, V9, P49, DOI 10.1089/153056203763317648
   Nelson EL, 2016, J CHILD ADOL PSYCHOP, V26, P212, DOI 10.1089/cap.2015.0021
   Nelson EL, 2006, COUNS PSYCHOTHER RES, V6, P191, DOI 10.1080/14733140600862303
   New Zealand Psychologists Board, 2012, PRACT TEL
   Perle JG, 2013, J CLIN PSYCHOL, V69, P100, DOI 10.1002/jclp.21912
   Perle JG, 2011, CLIN PSYCHOL REV, V31, P1247, DOI 10.1016/j.cpr.2011.08.003
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Pierce BS, 2020, PROF PSYCHOL-RES PR, V51, P184, DOI 10.1037/pro0000267
   Pietrabissa G, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.02201
   Quackenbush DM, 2012, J PSYCHIATR PRACT, V18, P451, DOI 10.1097/01.pra.0000422745.17990.be
   Rees CS, 2005, PROF PSYCHOL-RES PR, V36, P649, DOI 10.1037/0735-7028.36.6.649
   Reese RJ, 2016, COUNS PSYCHOTHER RES, V16, P256, DOI 10.1002/capr.12092
   Reynolds DJ, 2013, CYBERPSYCH BEH SOC N, V16, P370, DOI 10.1089/cyber.2012.0195
   Richards P, 2016, CLIN PSYCHOL, V22, P171
   Richardson L., 2012, THESIS
   Richardson LK, 2015, AUST PSYCHOL, V50, P307, DOI 10.1111/ap.12134
   Richardson LK, 2009, CLIN PSYCHOL-SCI PR, V16, P323, DOI 10.1111/j.1468-2850.2009.01170.x
   Robotham Dan, 2016, J Med Internet Res, V18, pe309
   Rochlen AB, 2004, J CLIN PSYCHOL, V60, P269, DOI 10.1002/jclp.10263
   Roser M., 2020, INTERNET
   Roy Hermione, 2008, Clin Child Psychol Psychiatry, V13, P95, DOI 10.1177/1359104507086344
   Sabatier F, 2009, GEOMORPHOLOGIE, P3
   Sabin JE, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0815-5
   Sales CP, 2018, J FORENSIC PSYCHI PS, V29, P387, DOI 10.1080/14789949.2017.1396487
   Sammons Morgan T, 2020, J Health Serv Psychol, P1, DOI 10.1007/s42843-020-00013-2
   Sander E. J., 2020, CONVERSATION
   Shore JH, 2018, TELEMED E-HEALTH, V24, P827, DOI 10.1089/tmj.2018.0237
   Silva M., 2020, EPIDEMIOL PSYCHIAT S, V29, pe7
   Simpson J, 2001, J TELEMED TELECARE, V7, P155, DOI 10.1258/1357633011936318
   Simpson S, 2005, CLIN PSYCHOL PSYCHOT, V12, P156, DOI 10.1002/cpp.436
   Simpson S, 2001, CLIN PSYCHOL PSYCHOT, V8, P130, DOI 10.1002/cpp.279
   Simpson S, 2003, J TELEMED TELECARE, V9, pS37, DOI 10.1258/135763303322196286
   Simpson S., 2016, USE TECHNOLOGY MENTA
   Simpson S., 2005, EATING DISORDERS NEW, P99
   Simpson S., 2010, USE TECHNOLOGY MENTA
   Simpson S., 2020, SCHEMA THERAPY B, V17, P14
   Simpson S, 2015, AUST PSYCHOL, V50, P285, DOI 10.1111/ap.12131
   Simpson S, 2014, AUST J RURAL HEALTH, V22, P306, DOI 10.1111/ajr.12103
   Simpson S, 2009, BRIT J GUID COUNS, V37, P271, DOI 10.1080/03069880902957007
   Simpson SG, 2014, AUST J RURAL HEALTH, V22, P280, DOI 10.1111/ajr.12149
   Simpson Susan G, 2011, Clin Pract Epidemiol Ment Health, V7, P38, DOI 10.2174/1745017901107010038
   Simpson SG, 2014, AUST PSYCHOL, V49, P193, DOI 10.1111/ap.12049
   Smith AC, 2020, J TELEMED TELECARE, V26, P309, DOI 10.1177/1357633X20916567
   Springer P, 2020, J MARITAL FAM THER, V46, P201, DOI 10.1111/jmft.12431
   Stubbings DR, 2015, AUST PSYCHOL, V50, P265, DOI 10.1111/ap.12111
   Stubbings DR, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2564
   Sucala M, 2012, J MED INTERNET RES, V14, P175, DOI 10.2196/jmir.2084
   Suler J, 2004, CYBERPSYCHOL BEHAV, V7, P321, DOI 10.1089/1094931041291295
   The Academy of Medical Sciences, 2020, SURV RES UND PEOPL M
   Thomas KC, 2009, PSYCHIAT SERV, V60, P1323, DOI 10.1176/ps.2009.60.10.1323
   Torous J, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/18848
   Totton N., 2006, DEMOCRACY THERAPY, V18
   Totton N., 2006, POLITICS PSYCHOTHERA
   Tuerk PW, 2010, J TRAUMA STRESS, V23, P116, DOI 10.1002/jts.20494
   Turvey C, 2013, TELEMED E-HEALTH, V19, P722, DOI 10.1089/tmj.2013.9989
   United Nations, 2020, POL BRIEF COVID 19 N
   Wagnild G, 2006, TELEMED J E-HEALTH, V12, P546, DOI 10.1089/tmj.2006.12.546
   Wampold BE, 2015, GREAT PSYCHOTHERAPY DEBATE: THE EVIDENCE FOR WHAT MAKES PSYCHOTHERAPY WORK, 2ND EDITION, P1
   Webster P, 2020, LANCET, V395, P1180, DOI 10.1016/S0140-6736(20)30818-7
   Weitz P., 2018, PSYCHOTHERAPY 2 0 PS
   Whaibeh Emile, 2020, Curr Treat Options Psychiatry, P1, DOI 10.1007/s40501-020-00210-2
   Whiteford H, 2016, HEALTH AFFAIR, V35, P1114, DOI 10.1377/hlthaff.2016.0082
   Wind TR, 2020, INTERNET INTERV, V20, DOI 10.1016/j.invent.2020.100317
   World Health Organization, 2020, WEEKL OP UPD COVID 1
   World Health Organization, 2019, WHO SPEC IN MENT HLT
   World Health Organization, 2020, MENT HLTH PSYCH CONS
   Wosik J, 2020, J AM MED INFORM ASSN, V27, P957, DOI 10.1093/jamia/ocaa067
   Yan Zheng, 2020, Hum Behav Emerg Technol, DOI 10.1002/hbe2.192
   Yellowlees P, 2010, TELEMED J E-HEALTH, V16, P1074, DOI 10.1089/tmj.2010.0148
   Zhou JY, 2020, AM J PSYCHIAT, V177, P574, DOI 10.1176/appi.ajp.2020.20030304
   Zur O., 2007, BOUNDARIES PSYCHOTHE
NR 126
TC 0
Z9 0
U1 8
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1063-3995
EI 1099-0879
J9 CLIN PSYCHOL PSYCHOT
JI Clin. Psychol. Psychother.
DI 10.1002/cpp.2521
EA OCT 2020
PG 13
WC Psychology, Clinical
SC Psychology
GA OG5KM
UT WOS:000581922700001
PM 33037682
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Wu, CR
   Zheng, MZ
   Yang, YY
   Gu, XX
   Yang, KY
   Li, MX
   Liu, Y
   Zhang, QZ
   Zhang, P
   Wang, YL
   Wang, QQ
   Xu, Y
   Zhou, YR
   Zhang, YH
   Chen, LX
   Li, H
AF Wu, Canrong
   Zheng, Mengzhu
   Yang, Yueying
   Gu, Xiaoxia
   Yang, Kaiyin
   Li, Mingxue
   Liu, Yang
   Zhang, Qingzhe
   Zhang, Peng
   Wang, Yali
   Wang, Qiqi
   Xu, Yang
   Zhou, Yirong
   Zhang, Yonghui
   Chen, Lixia
   Li, Hua
TI Furin: A Potential Therapeutic Target for COVID-19
SO ISCIENCE
LA English
DT Article
ID CORONAVIRUS SPIKE-PROTEIN; INFECTIOUS-BRONCHITIS VIRUS; INHIBITORS;
   CELL; DETERMINANTS; ACTIVATION; ENTRY
AB COVID-19 broke out in the end of December 2019 and is still spreading rapidly, which has been listed as an international concerning public health emergency. We found that the Spike protein of SARS-CoV-2 contains a furin cleavage site, which did not exist in any other betacoronavirus subtype B. Based on a series of analysis, we speculate that the presence of a redundant furin cut site in its Spike protein is responsible for SARS-CoV-2's stronger infectious nature than other coronaviruses, which leads to higher membrane fusion efficiency. Subsequently, a library of 4,000 compounds including approved drugs and natural products was screened against furin through structure-based virtual screening and then assayed for their inhibitory effects on furin activity. Among them, an anti-parasitic drug, diminazene, showed the highest inhibition effects on furin with an IC50 of 5.42 +/- 0.11 mu M, which might be used for the treatment of COVID-19.
C1 [Wu, Canrong; Zheng, Mengzhu; Gu, Xiaoxia; Yang, Kaiyin; Zhang, Qingzhe; Zhou, Yirong; Zhang, Yonghui; Li, Hua] Huazhong Univ Sci & Technol, Hubei Key Lab Nat Med Chem & Resource Evaluat, Sch Pharm, Tongji Rongcheng Ctr Biomed,Tongji Med Coll, Wuhan 430030, Peoples R China.
   [Yang, Yueying; Li, Mingxue; Liu, Yang; Zhang, Peng; Wang, Yali; Wang, Qiqi; Xu, Yang; Chen, Lixia; Li, Hua] Shenyang Pharmaceut Univ, Wuya Coll Innovat, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Peoples R China.
RP Zhou, YR; Zhang, YH; Li, H (corresponding author), Huazhong Univ Sci & Technol, Hubei Key Lab Nat Med Chem & Resource Evaluat, Sch Pharm, Tongji Rongcheng Ctr Biomed,Tongji Med Coll, Wuhan 430030, Peoples R China.; Chen, LX; Li, H (corresponding author), Shenyang Pharmaceut Univ, Wuya Coll Innovat, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Peoples R China.
EM zhouyirong@hust.edu.cn; zhangyh@mails.tjmu.edu.cn; syzyclx@163.com;
   li_hua@hust.edu.cn
FU National Mega-project for Innovative Drugs [2019ZX09721001-004-007];
   National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [U1803122, 81773637, 81773594,
   U1703111]; Fundamental Research Fund for the Central Universities (HUST
   COVID-19 Rapid Response Call) [2020kfyXGYJ037]; China Postdoctoral
   Science FoundationChina Postdoctoral Science Foundation [2020T130039ZX];
   Wuhan COVID-19 Emergency Research Fund [EX20C02]
FX We are very grateful to the Protein Data Bank, DTU Health Tech, ZINC
   database, and researchers for making data freely available. We
   acknowledge support fromNational Mega-project for Innovative Drugs
   (grant number 2019ZX09721001-004-007), National Natural Science
   Foundation of China (NSFC) (grant number U1803122, 81773637, 81773594,
   U1703111), the Fundamental Research Fund for the Central Universities
   (HUST COVID-19 Rapid Response Call, No. 2020kfyXGYJ037), fellowship of
   China Postdoctoral Science Foundation (grant number 2020T130039ZX), and
   Wuhan COVID-19 Emergency Research Fund (grant number EX20C02).
CR ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Dahms SO, 2018, BIOCHEMISTRY-US, V57, P925, DOI 10.1021/acs.biochem.7b01124
   Dahms SO, 2017, ACS CHEM BIOL, V12, P1211, DOI 10.1021/acschembio.6b01110
   Feliciangeli SF, 2006, J BIOL CHEM, V281, P16108, DOI 10.1074/jbc.M600760200
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   Kam YW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007870
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li X., 2020, CHINESE J BIOINFORMA, V18, P1, DOI [DOI 10.12113/202002001, 10.12113/202002001]
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Matsuyama S, 2018, J VIROL, V92, DOI 10.1128/JVI.00683-18
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Park JE, 2016, P NATL ACAD SCI USA, V113, P12262, DOI 10.1073/pnas.1608147113
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Simmons G, 2011, VIROLOGY, V413, P265, DOI 10.1016/j.virol.2011.02.020
   Tay FPL, 2012, VIROLOGY, V433, P421, DOI 10.1016/j.virol.2012.08.037
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yamada Y, 2009, J VIROL, V83, P8744, DOI 10.1128/JVI.00613-09
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhou H., 2020, BIORXIV, DOI [10.1101/2020.03.02.974139., DOI 10.1101/2020.03.02.974139]
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 31
TC 0
Z9 0
U1 0
U2 0
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2589-0042
J9 ISCIENCE
JI iScience
PD OCT 23
PY 2020
VL 23
IS 10
AR 101642
DI 10.1016/j.isci.2020.101642
PG 31
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OG6IQ
UT WOS:000581985500095
PM 33043282
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chamberlain, LR
   Hall, CL
   Andren, P
   Davies, EB
   Kilgariff, J
   Kouzoupi, N
   Murphy, T
   Hollis, C
AF Chamberlain, Liam R.
   Hall, Charlotte L.
   Andren, Per
   Davies, E. Bethan
   Kilgariff, Joseph
   Kouzoupi, Natalia
   Murphy, Tara
   Hollis, Chris
TI Therapist-Supported Online Interventions for Children and Young People
   With Tic Disorders: Lessons Learned From a Randomized Controlled Trial
   and Considerations for Future Practice
SO JMIR MENTAL HEALTH
LA English
DT Article
DE Tourette syndrome; tic disorders; internet-based cognitive behavioral
   therapy (iCBT); remote therapy; therapist support
ID BEHAVIOR-THERAPY
AB In recent years, research into internet-based cognitive behavioral therapy (iCBT) has suggested that therapist-guided digital interventions have greater engagement, adherence, and effectiveness than self-directed digital therapies. While research has focused on the effectiveness of, and adherence to, these interventions, less attention has been paid to their implementation in practice and what aspects of the therapist role support success. An understanding of the key factors related to the therapist role and intervention delivery is required if these iCBTs are to be applied in routine clinical care and outcomes optimized. In light of the coronavirus disease 2019 (COVID-19) pandemic, there is greater emphasis on allowing patients access to remote therapies. We report the experiences and reflections of 4 therapists and their 2 supervisors in delivering an online, therapist-supported intervention in a randomized controlled trial for children and young people with tic disorders (the Online Remote Behavioural Intervention for Tics [ORBIT] trial). Themes discussed include the importance of training, supervision, creating support documents/manuals, and record keeping. Alongside this are communication strategies used by therapists to encourage patient adherence and treatment effectiveness. These include rapport building, treatment personalization, and suggestions for overcoming non-engagement. These reflections offer important considerations for the delivery of iCBTs as well as implications associated with the implementation of these interventions in existing services and future research studies. We share thoughts on where iCBTs may sit in a stepped care model, how services may deal with comorbid conditions, and the potential role of iCBTs in collecting clinical data.
C1 [Chamberlain, Liam R.; Hall, Charlotte L.; Davies, E. Bethan; Hollis, Chris] Univ Nottingham, Inst Mental Hlth, NIHR MindTech Medtech Cooperat, Nottingham, England.
   [Andren, Per] Karolinska Inst, Ctr Psychiat Res, Dept Clin Neurosci, Stockholm, Sweden.
   [Andren, Per] Reg Stockholm, Stockholm Hlth Care Serv, Stockholm, Sweden.
   [Kilgariff, Joseph] Nottinghamshire Healthcare NHS Fdn Trust, Nottingham, England.
   [Kouzoupi, Natalia; Murphy, Tara] UCL, UCL Great Ormond St Inst Child Hlth, London, England.
   [Kouzoupi, Natalia; Murphy, Tara] Great Ormond St Hosp Children NHS Fdn Trust, London, England.
   [Hollis, Chris] Univ Nottingham Innovat Pk, Div Psychiat & Appl Psychol, Inst Mental Hlth, Triumph Rd, Nottingham NG7 2TU, England.
   [Hollis, Chris] NIHR Nottingham Biomed Res Ctr, Nottingham, England.
RP Hollis, C (corresponding author), Univ Nottingham Innovat Pk, Div Psychiat & Appl Psychol, Inst Mental Hlth, Triumph Rd, Nottingham NG7 2TU, England.
EM Chris.Hollis@nottingham.ac.uk
OI Chamberlain, Liam/0000-0002-0432-9415; Hollis,
   Chris/0000-0003-1083-6744; Hall, Charlotte/0000-0002-5412-6165
FU National Institute for Health Research Biomedical Research Centre at
   Great Ormond Street Hospital for Children NHS Foundation Trust and
   University College London; National Institute for Health Research (NIHR)
   Heath Technology Assessment (HTA)National Institute for Health Research
   (NIHR) [16/19/02]; NIHR Nottingham Biomedical Research Centre
FX We acknowledge the on-going support of Angela Summerfield. Additionally,
   we thank the wider ORBIT team including Sophie Bennett, Bev Brown, Sue
   Brown, Mike Craven, Amber Evans, Cris Glazebrook, Isobel Heyman, Rachael
   Hunter, Rebecca Jones, Kareem Khan, Louise Marston, David Mataix-Cols,
   Caitlin McKenzie, Elizabeth Murray, Charlotte Sanderson, and Eva
   Serlachius. We also thank members of the ORBIT trial Steering Committee:
   Professor Edmund Sonuga-Barke (Chair), Mrs Neelam Gurav, Dr Prathiba
   Chisabesan, Dr Kim Goldsmith, Dr David Manley and Dr Cara Verdellen. We
   also thank members of The ORBIT Data Safety and Monitoring Committee:
   Professor Stephen Scott (Chair), Dr Uttom Chowdhury, and Professor
   Richard Emsley. Authors EBD and CH acknowledge the support of NIHR
   MindTech MedTech Co-operative. TM acknowledges support from the National
   Institute for Health Research Biomedical Research Centre at Great Ormond
   Street Hospital for Children NHS Foundation Trust and University College
   London. This research was funded by the National Institute for Health
   Research (NIHR) Heath Technology Assessment (HTA) (Ref 16/19/02). The
   views expressed are those of the author(s) and not necessarily those of
   the NHS, the NIHR, or the Department of Health and social care. CH
   acknowledges the financial support of the NIHR Nottingham Biomedical
   Research Centre.
CR Andersson G, 2019, WORLD PSYCHIATRY, V18, P20, DOI 10.1002/wps.20610
   Andren P, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024685
   Collins LM, 2014, CLIN TRIALS, V11, P426, DOI 10.1177/1740774514536795
   Hall CC, 2019, BMJ SUPPORT PALLIAT, V9, P1, DOI 10.1136/bmjspcare-2018-001526
   Himle MB, 2012, BEHAV RES THER, V50, P565, DOI 10.1016/j.brat.2012.05.009
   Hollis C, 2018, LANCET PSYCHIAT, V5, P845, DOI 10.1016/S2215-0366(18)30296-7
   Hollis C, 2017, J CHILD PSYCHOL PSYC, V58, P474, DOI 10.1111/jcpp.12663
   Hollis C, 2016, HEALTH TECHNOL ASSES, V20, pI, DOI 10.3310/hta20040
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Khan K, 2020, TRIALS, V21, DOI 10.1186/s13063-019-3974-3
   Knowles SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084323
   LECKMAN JF, 1989, J AM ACAD CHILD PSY, V28, P566, DOI 10.1097/00004583-198907000-00015
   Ruzek JI, 2017, GLOB MENT HEALTH, V4, DOI 10.1017/gmh.2017.11
   Schneider LH, 2016, BEHAV COGN PSYCHOTH, V44, P625, DOI 10.1017/S1352465816000254
NR 14
TC 1
Z9 1
U1 0
U2 0
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2368-7959
J9 JMIR MENT HEALTH
JI JMIR Ment. Health
PD OCT 23
PY 2020
VL 7
IS 10
AR e19600
DI 10.2196/19600
PG 7
WC Psychiatry
SC Psychiatry
GA OH1GU
UT WOS:000582320900001
PM 33095180
OA DOAJ Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Rao, XR
   Wu, CY
   Wang, SH
   Tong, S
   Wang, G
   Wu, G
   Zhou, R
AF Rao, Xinrui
   Wu, Chuangyan
   Wang, Sihua
   Tong, Song
   Wang, Geng
   Wu, Gang
   Zhou, Rui
TI The importance of overweight in COVID-19 A retrospective analysis in a
   single center of Wuhan, China
SO MEDICINE
LA English
DT Article
DE body mass index; China; COVID-19; overweight; severe pneumonia
ID OBESITY
AB The aim of this study was to evaluate the association between overweight and severity, drug response, and clinical outcomes of novel coronavirus disease 2019 (COVID-19). In this retrospective cohort study, we reviewed medical records of 240 COVID-19 patients admitted to Union Hospital in Wuhan, China, between December 24, 2019, and March 25, 2020. Physical, clinical, laboratory, radiological characteristics, treatment, and outcome data were abstracted. Patients who were obese [body mass index (BMI) >= 28 kg/m(2)], underweight (BMI < 18.5 kg/m(2)), under 18 years old, pregnant, or still in hospital were excluded. Disease severity was classified as moderate or severe pneumonia based on the World Health Organization interim guidance. Overweight was defined as BMI >= 24 kg/m(2) and <28 kg/m(2). Patients were followed for discharge or death through April 10, 2020. We used logistic regression models to identify risk factors for severe disease, Cox proportional hazard models to explore associations between medications and patient outcomes (discharge or in-hospital death), and Kaplan-Meier survival curves and Cox regression models to evaluate risk factors for in-hospital death. One-half of patients (120, 50.0%) had severe pneumonia, while nearly one-half (114, 47.5%) were overweight. Among patients over 45 years old, overweight patients had significantly lower rates of fatigue, higher rates of headache, and higher median C-reactive protein levels. Patients under 45 years old had higher rates of cough and myalgia and higher proportions of increased alanine aminotransferase and lactic dehydrogenase, as well as more pulmonary lobes involved in the pneumonia revealed by chest computed tomography scans. Overweight patients were at higher risk of developing severe pneumonia. Although weight was not a risk factor for in-hospital death, overweight patients showed different responses to medications compared with normal weight patients. Intravenous interferon-alpha, intravenous glucocorticoids, and antifungal drugs were associated with reduced mortality in overweight patients. Intravenous immunoglobulin, oseltamivir, and ribavirin were associated with reduced mortality in normal weight patients. Overweight is a worldwide health problem. We found overweight to be related to the COVID-19 severity but not to in-hospital death. Clinicians should be aware that overweight COVID-19 patients require increased attention for different clinical features and treatment response.
C1 [Rao, Xinrui; Wu, Gang; Zhou, Rui] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, 1277 Jie Fang Ave, Wuhan 430022, Peoples R China.
   [Wu, Chuangyan; Wang, Sihua; Tong, Song] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Thorac Surg, Wuhan, Peoples R China.
   [Wang, Geng] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan, Peoples R China.
RP Zhou, R (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, 1277 Jie Fang Ave, Wuhan 430022, Peoples R China.
EM mimiruirui2@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81802287]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81802287 to R. Zhou).
CR Alijotas-Reig J, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102569
   Barba C, 2004, LANCET, V363, P157, DOI 10.1016/s0140-6736(03)15268-3
   Beigel J. H., 2020, N ENGL J MED
   Bluher M, 2019, NAT REV ENDOCRINOL, V15, P288, DOI 10.1038/s41574-019-0176-8
   Chen YJ, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7633-0
   Chobot A, 2018, DIABETES-METAB RES, V34, DOI 10.1002/dmrr.3042
   Chongqing Public Health Medical Center, 2020, COMP EFF SAF RIB PLU
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Fuhrman C, 2011, EPIDEMIOL INFECT, V139, P1202, DOI 10.1017/S0950268810002414
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Huttunen R, 2013, INT J OBESITY, V37, P333, DOI 10.1038/ijo.2012.62
   Jaacks LM, 2019, LANCET DIABETES ENDO, V7, P231, DOI 10.1016/S2213-8587(19)30026-9
   Lai ST, 2005, EUR J CLIN MICROBIOL, V24, P583, DOI 10.1007/s10096-005-0004-z
   Lee CMY, 2011, OBES REV, V12, pe454, DOI 10.1111/j.1467-789X.2010.00849.x
   Li Meng, 2020, Radiol Infect Dis, V7, P51, DOI 10.1016/j.jrid.2020.04.001
   Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415
   Louie JK, 2011, CLIN INFECT DIS, V52, P301, DOI 10.1093/cid/ciq152
   Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132
   National Institutes of Health, 2020, COR DIS 2019 COVID 1
   Oz HS, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101085
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Schetz M, 2019, INTENS CARE MED, V45, P757, DOI 10.1007/s00134-019-05594-1
   Sheridan PA, 2012, INT J OBESITY, V36, P1072, DOI 10.1038/ijo.2011.208
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   World Health Organization, 2020, WORLD HLTH STAT 2020
   World Health Organization, 2020, CLIN MAN COVID 19
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
   Zhang YF, 2020, LIVER INT, V40, P2095, DOI 10.1111/liv.14455
NR 34
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 23
PY 2020
VL 99
IS 43
DI 10.1097/MD.0000000000022766
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA OP6IA
UT WOS:000588186800061
PM 33120785
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Song, G
   Cheng, MQ
   Wei, XW
AF Song, Gao
   Cheng, Meng Qun
   Wei, Xian Wen
TI Analysis of the WHO ICTRP for novel coronavirus clinical trial
   registrations
SO MEDICINE
LA English
DT Article
DE high frequency drug research; novel coronavirus (COVID-19); registered
   clinical trials; SARS-CoV-2; vaccine; WHO ICTRP
ID RESPONSES; VACCINES; ANTIBODY; VIRUS; MICE
AB Up-to-date information on the current progress made in the research and development to control the global COVID-19 pandemic is important. The study aimed to analyze the clinical trial characteristics and vaccine development progress of the new Coronavirus Disease 2019 (COVID-19) registered with the World Health Organization International Clinical Trial Registry Platform (WHO ICTRP). A comprehensive search of COVID-19 clinical trials since the establishment of the ICTRP to June 11, 2020, was conducted to record and analyze relevant characteristics. Chi-Squared test was used to compare the statistical differences between different research types, interventions, and sources. A total of 3282 COVID-19 clinical trials in 17 clinical trial registration centers were registered with the WHO ICTRP. The main research sources for the present study were ClinicalTrials.gov and ChiCTR. There were significant differences in the parameters of study location (P = .000), number of participants (P = .000), study duration (P = .001), research stage (P = .000), randomization procedure (P = .000), and blinding method (P = .000) between the 2 registration sources. There were significant differences in all the parameters between different kinds of intervention methods. Hydroxychloroquine, plasma therapy, and Xiyanping injection were the high-frequency research drugs used. Ten different vaccine studies were registered under phases I-II. Amongst the studies researched, heterogeneity existed for various parameters. Differences in the type of study, interventions, and registration sources of the studies led to significant differences in certain parameters of the COVID-19 clinical trials. The statistics of high-frequency drugs and the progress of vaccine trials may provide an informative reference for the prevention and control of COVID-19.
C1 [Song, Gao] Puer Peoples Hosp, Dept Pharm, Puer, Yunnan, Peoples R China.
   [Cheng, Meng Qun] Puer Peoples Hosp, Dept Reprod Med, Puer, Yunnan, Peoples R China.
   [Wei, Xian Wen] Puer Peoples Hosp, Dept Neurol, Puer, Yunnan, Peoples R China.
RP Song, G (corresponding author), Puer Peoples Hosp Yunna, Dept Pharm, 44 Zhenxing Rd, Puer 665000, Peoples R China.
EM 387925693@qq.com
CR Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Alzoughool F, 2020, INT J RISK SAF MED, V31, P47, DOI 10.3233/JRS-201017
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Bothwell LE, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018320
   Chan JFW, 2016, J INFECTION, V72, P507, DOI 10.1016/j.jinf.2016.02.011
   Chen JB, 2020, J INFECTION, V80, P310, DOI 10.1016/j.jinf.2019.11.024
   Chen LL, 2020, J SHANGHAI UNIVERS T, V34, P1
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Chen YHJ, 2015, CLIN TRIALS, V12, P84, DOI 10.1177/1740774514552110
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Feizabadi Mansoureh, 2017, J Evid Based Med, V10, P91, DOI 10.1111/jebm.12248
   Huang MX, 2020, NATL SCI REV, V7, P1428, DOI 10.1093/nsr/nwaa113
   Leavy B, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0809-2
   Lin JT, 2007, ANTIVIR THER, V12, P1107
   Lupia T, 2020, J GLOB ANTIMICROB RE, V21, P22, DOI 10.1016/j.jgar.2020.02.021
   Magdalena Z, 2018, BMJ-BRIT MED J, pk2130
   Martin JE, 2008, VACCINE, V26, P6338, DOI 10.1016/j.vaccine.2008.09.026
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64
   Mehr a MR, 2020, LANCET
   Modjarrad K, 2016, VACCINE, V34, P2982, DOI 10.1016/j.vaccine.2016.03.104
   Okada M, 2005, VACCINE, V23, P2269, DOI 10.1016/j.vaccine.2005.01.036
   Robertson K, 2016, J NEUROVIROL, V22, P472, DOI 10.1007/s13365-015-0415-2
   Robinson MJ, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3203-0
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Simiao Ruozhen Yuan, 2018, BMJ OPEN, V8
   Smith JA, 2020, HEALTH PROMOT J AUST, V31, P158, DOI 10.1002/hpja.333
   Song G, 2020, J VIROL, P1, DOI [10.13242/j.cnki.bingduxuebao.00, DOI 10.13242/J.CNKI.BINGDUXUEBAO.00]
   Song Menghuan, 2016, J Evid Based Med, V9, P59, DOI 10.1111/jebm.12203
   Taichman DB, 2017, DTSCH ARZTEBL INT, V114, P401, DOI 10.3238/arztebl.2017.0401
   Verweij J, 2019, CANCER TREAT REV, V74, P15, DOI 10.1016/j.ctrv.2019.01.001
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu T, 2017, AMBIO, V46, P18, DOI 10.1007/s13280-016-0809-2
   Yingchun H, 2018, BIOMED RES INT, V2018, P1
   Zhang C, 2018, IEEE T POWER SYST, V33, P7042, DOI 10.1109/TPWRS.2018.2849384
   Zhang WB, 2020, J HAINAN MED COLL, V26, P1045
   Zhao HJ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013062
NR 38
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 23
PY 2020
VL 99
IS 43
DI 10.1097/MD.0000000000022840
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OP6IA
UT WOS:000588186800088
PM 33120812
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Meyer-Berg, H
   Yang, LZ
   de Lucas, MP
   Zambrano, A
   Hyde, SC
   Gill, DR
AF Meyer-Berg, Helena
   Zhou Yang, Lucia
   Pilar de Lucas, Maria
   Zambrano, Alberto
   Hyde, Stephen C.
   Gill, Deborah R.
TI Identification of AAV serotypes for lung gene therapy in human embryonic
   stem cell-derived lung organoids
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE human embryonic stem cells; stem cell-based tissue model; gene therapy;
   rAAV; AAV capsids; AAV serotypes; lung organoids; viral infection model;
   alveolar type II cells
ID TRANSDUCTION; EXPRESSION; VECTORS; MODEL
AB Gene therapy is being investigated for a range of serious lung diseases, such as cystic fibrosis and emphysema. Recombinant adeno-associated virus (rAAV) is a well-established, safe, viral vector for gene delivery with multiple naturally occurring and artificial serotypes available displaying alternate cell, tissue, and species-specific tropisms. Efficient AAV serotypes for the transduction of the conducting airways have been identified for several species; however, efficient serotypes for human lung parenchyma have not yet been identified. Here, we screened the ability of multiple AAV serotypes to transduce lung bud organoids (LBOs)-a model of human lung parenchyma generated from human embryonic stem cells. Microinjection of LBOs allowed us to model transduction from the luminal surface, similar to dosing via vector inhalation. We identified the naturally occurring rAAV2 and rAAV6 serotypes, along with synthetic rAAV6 variants, as having tropism for the human lung parenchyma. Positive staining of LBOs for surfactant proteins B and C confirmed distal lung identity and suggested the suitability of these vectors for the transduction of alveolar type II cells. Our findings establish LBOs as a new model for pulmonary gene therapy and stress the relevance of LBOs as a viral infection model of the lung parenchyma as relevant in SARS-CoV-2 research.
C1 [Meyer-Berg, Helena; Hyde, Stephen C.; Gill, Deborah R.] Univ Oxford, Nuffield Div Clin Lab Sci, Radcliffe Dept Med, Gene Med Res Grp, Oxford, England.
   [Zhou Yang, Lucia; Zambrano, Alberto] Inst Salud Carlos III, Dept Biotechnol Stem Cells & Organoids, Funct Unit Res Chron Dis, Madrid, Spain.
   [Pilar de Lucas, Maria] Inst Salud Carlos III, Dept Cellular Biol, Funct Unit Res Chron Dis, Madrid, Spain.
RP Gill, DR (corresponding author), Univ Oxford, Nuffield Div Clin Lab Sci, Radcliffe Dept Med, Gene Med Res Grp, Oxford, England.
EM deborah.gill@ndcls.ox.ac.uk
RI de Lucas, Maria Pilar/F-2272-2016; Zambrano, Alberto/A-1580-2013
OI de Lucas, Maria Pilar/0000-0001-9516-2157; Zambrano,
   Alberto/0000-0001-5677-2999; Meyer-Berg, Helena/0000-0001-6435-7584
FU Wellcome TrustWellcome Trust [110579/Z/15/Z]; MRCMedical Research
   Council UK (MRC)
FX The material of this study was funded by the Wellcome Trust
   (110579/Z/15/Z) and the MRC studentship of HMB.
CR Barnett RC, 2017, EXP BIOL MED, V242, P1345, DOI 10.1177/1535370217713000
   Bock C, 2011, CELL, V144, P439, DOI 10.1016/j.cell.2010.12.032
   Chen YW, 2017, NAT CELL BIOL, V19, P542, DOI 10.1038/ncb3510
   de Silva SR, 2015, GENE DELIVERY THERAP, P203
   Flotte TR, 2010, MOL THER, V18, P594, DOI 10.1038/mt.2009.230
   Haeger SM, 2016, AM J RESP CELL MOL, V55, P5, DOI 10.1165/rcmb.2016-0043TR
   Huang SXL, 2015, NAT PROTOC, V10, DOI 10.1038/nprot.2015.023
   Hyde SC, 2008, NAT BIOTECHNOL, V26, P549, DOI 10.1038/nbt1399
   Li CW, 2020, NAT REV GENET, V21, P255, DOI 10.1038/s41576-019-0205-4
   Limberis MP, 2009, MOL THER, V17, P294, DOI 10.1038/mt.2008.261
   Magro-Lopez E, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0943-9
   Magro-Lopez E, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120379
   Moss RB, 2007, HUM GENE THER, V18, P726, DOI 10.1089/hum.2007.022
   Nicholls JM, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-73
   Pillay S, 2016, NATURE, V530, P108, DOI 10.1038/nature16465
   Porotto M, 2019, MBIO, V10, DOI 10.1128/mBio.00723-19
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   van Lieshout LP, 2018, MOL THER-METH CLIN D, V9, P323, DOI 10.1016/j.omtm.2018.04.005
   Westergren-Thorsson G, 2017, INT J BIOCHEM CELL B, V83, P27, DOI 10.1016/j.biocel.2016.12.005
   Yan ZY, 2006, J BIOL CHEM, V281, P29684, DOI 10.1074/jbc.M604099200
NR 20
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD OCT 23
PY 2020
VL 11
IS 1
AR 448
DI 10.1186/s13287-020-01950-x
PG 6
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA OP3LO
UT WOS:000587983800001
PM 33097094
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wickremsinhe, ER
   Ji, QC
   Gleason, CR
   Anderson, M
   Booth, BP
AF Wickremsinhe, Enaksha R.
   Ji, Qin C.
   Gleason, Carol R.
   Anderson, Melanie
   Booth, Brian P.
TI Land O'Lakes Workshop on Microsampling: Enabling Broader Adoption
SO AAPS JOURNAL
LA English
DT Article
DE bridging study; capillary blood; correlation; finger prick;
   microsampling; patient-centric sampling
ID REGRESSION PROCEDURES; DRUG CONCENTRATIONS; VENOUS PLASMA; BLOOD;
   CAPILLARY; IMPLEMENTATION; PALIPERIDONE; RISPERIDONE; VALIDATION;
   OLANZAPINE
AB The microsampling workshop generated recommendations pertaining to blood sampling site (venous blood versus capillary blood), when to conduct a bridging study, statistical approaches to establish correlation/concordance and deciding on sample size, opportunities and challenges with patient-centric sampling, and how microsampling technology can enrich clinical drug development. Overall, the goal was to provide clarity and recommendations and enable the broader adoption of microsampling supporting patients' needs, convenience, and the transformation from clinic-centric to patient-centric drug development. The need and adoption of away-from-clinic sampling techniques has become critical to maintain patient safety during the current COVID-19 pandemic.
C1 [Wickremsinhe, Enaksha R.] Eli Lilly & Co, Indianapolis, IN 46285 USA.
   [Ji, Qin C.; Gleason, Carol R.] Bristol Myers Squibb Co, Princeton, NJ 08543 USA.
   [Anderson, Melanie] Merck & Co Inc, West Point, PA 19486 USA.
   [Booth, Brian P.] US FDA, CDER, Off Translat Sci, Off Clin Pharmacol, Silver Spring, MD USA.
RP Wickremsinhe, ER (corresponding author), Eli Lilly & Co, Indianapolis, IN 46285 USA.
EM enaksha@lilly.com
CR Bateman KP, 2020, BIOANALYSIS, V12, P971, DOI 10.4155/bio-2020-0075
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Boyd R, 2005, EMERG MED J, V22, P177, DOI 10.1136/emj.2003.011619
   Crawford ML, 2020, CLIN CHEM, V66, P821, DOI 10.1093/clinchem/hvaa082
   DILETTI E, 1992, INT J CLIN PHARM TH, V30, pS51
   Evans C, 2015, AAPS J, V17, P292, DOI 10.1208/s12248-014-9695-3
   Evans CA, 2010, BIOANALYSIS, V2, P1355, DOI 10.4155/BIO.10.101
   FDA, 2018, BIOAN METH VAL GUID
   Gleason CR, 2020, BIOANALYSIS, V12, P419, DOI 10.4155/bio-2020-0019
   ICH, 2016, ICH S3A TOX ASS SYST
   Instiaty I, 2013, ANTIMICROB AGENTS CH, V57, P2858, DOI 10.1128/AAC.02408-12
   Kothare PA, 2016, AAPS J, V18, P519, DOI 10.1208/s12248-015-9860-3
   Kuwa K, 2001, CLIN CHIM ACTA, V307, P187, DOI 10.1016/S0009-8981(01)00426-0
   Li CC, 2018, J CLIN PHARMACOL, V58, P294, DOI 10.1002/jcph.1021
   LINNET K, 1993, CLIN CHEM, V39, P424
   PASSING H, 1983, J CLIN CHEM CLIN BIO, V21, P709
   Patel SR, 2019, BIOANALYSIS, V11, P619, DOI 10.4155/bio-2019-0019
   Remmerie B, 2016, CLIN PHARM DRUG DEV, V5, P528, DOI 10.1002/cpdd.290
   Remmerie B, 2016, CLIN PHARM DRUG DEV, V5, P538, DOI 10.1002/cpdd.291
   Roadcap B, 2020, BIOANALYSIS, V12, P893, DOI 10.4155/bio-2020-0074
   Rocci ML, 2007, AAPS J, V9, pE336, DOI 10.1208/aapsj0903040
   Shah V P, 2000, Pharm Res, V17, P1551, DOI 10.1023/A:1007669411738
   Spooner N, 2019, BIOANALYSIS, V11, P1015, DOI 10.4155/bio-2019-0041
   Thway TM, 2009, J PHARMACEUT BIOMED, V49, P613, DOI 10.1016/j.jpba.2008.12.008
   Wilhelm AJ, 2013, THER DRUG MONIT, V35, P92, DOI 10.1097/FTD.0b013e31827d76ce
   Xing JM, 2020, BIOANALYSIS, V12, P919, DOI 10.4155/bio-2020-0063
NR 26
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1550-7416
J9 AAPS J
JI AAPS J.
PD OCT 23
PY 2020
VL 22
IS 6
AR 135
DI 10.1208/s12248-020-00524-2
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ON0JZ
UT WOS:000586400200001
PM 33098040
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Marbaniang, I
   Sangle, S
   Nimkar, S
   Zarekar, K
   Salvi, S
   Chavan, A
   Gupta, A
   Suryavanshi, N
   Mave, V
AF Marbaniang, Ivan
   Sangle, Shashikala
   Nimkar, Smita
   Zarekar, Kanta
   Salvi, Sonali
   Chavan, Amol
   Gupta, Amita
   Suryavanshi, Nishi
   Mave, Vidya
TI The burden of anxiety among people living with HIV during the COVID-19
   pandemic in Pune, India
SO BMC PUBLIC HEALTH
LA English
DT Article
DE India; COVID-19 pandemic; Poverty; GAD-7; Anxiety; Screening
ID DEPRESSIVE SYMPTOMS; MENTAL-HEALTH; ADHERENCE; CARE; DISORDER; ADULTS
AB Introduction Globally, India has the third largest population of people living with HIV (PLHIV) and the second highest number of COVID-19 cases. Anxiety is associated with antiretroviral therapy (ART) nonadherence. It is crucial to understand the burden of anxiety and its sources among Asian Indian PLHIV during the COVID pandemic, but data are limited. Methods During the first month of government mandated lockdown, we administered an anxiety assessment via telephone among PLHIV registered for care at a publicly funded antiretroviral therapy (ART) center in Pune, India. Generalized anxiety was defined as GAD-7 score >= 10. Sociodemographic and clinical variables were compared by anxiety status (GAD-7 score >= 10 vs GAD-7 score < 10). Qualitative responses to an open-ended question about causes of concern were evaluated using thematic analysis. Results Among 167 PLHIV, median age was 44 years (IQR 40-50); the majority were cisgender women (60%) and had a monthly family income < 200 USD (81%). Prior history of tuberculosis and other comorbidities were observed in 38 and 27%, respectively. Overall, prevalence of generalized anxiety was 25% (n = 41). PLHIV with GAD-7 score >= 10 had fewer remaining doses of ART than those with lower GAD-7 scores (p = 0.05). Thematic analysis indicated that concerns were both health related and unrelated, and stated temporally. Present concerns were often also projected as future concerns. Conclusions The burden of anxiety was high during COVID lockdown in our population of socioeconomically disadvantaged PLHIV in Pune and appeared to be influenced by concerns about ART availability. The burden of anxiety among PLHIV will likely increase with the worsening pandemic in India, as sources of anxiety are expected to persist. We recommend the regular use of short screening tools for anxiety to monitor and triage patients as an extension of current HIV services.
C1 [Marbaniang, Ivan; Nimkar, Smita; Zarekar, Kanta; Chavan, Amol; Gupta, Amita; Suryavanshi, Nishi; Mave, Vidya] Johns Hopkins Univ, Byramjee Jeejeebhoy Govt Med Coll, Clinical Res Site,Jai Prakash Narayan Rd, Pune 411001, Maharashtra, India.
   [Marbaniang, Ivan] McGill Univ, Dept Epidemiol, Purvis Hall,1020 Pine Ave, Montreal, PQ H3G 1A2, Canada.
   [Sangle, Shashikala; Salvi, Sonali] Byramjee Jeejeebhoy Govt Med Coll, Dept Gen Med, Pune, Maharashtra, India.
   [Gupta, Amita; Mave, Vidya] Johns Hopkins Univ, Dept Med & Infect Dis, Baltimore, MD USA.
RP Marbaniang, I (corresponding author), Johns Hopkins Univ, Byramjee Jeejeebhoy Govt Med Coll, Clinical Res Site,Jai Prakash Narayan Rd, Pune 411001, Maharashtra, India.; Marbaniang, I (corresponding author), McGill Univ, Dept Epidemiol, Purvis Hall,1020 Pine Ave, Montreal, PQ H3G 1A2, Canada.
EM ivan.marbaniang@mail.mcgill.ca
FU amfAR, The Foundation for AIDS Research; National Institute of Health's
   National Institute of Allergy and Infectious Diseases; Eunice Kennedy
   Shriver National Institute of Child Health and Human DevelopmentUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); National Cancer InstituteUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI); National
   Institute of Mental HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH); National Institute on Drug AbuseUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Drug Abuse (NIDA); National Heart, Lung,
   and Blood InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI); National Institute on Alcohol Abuse and
   AlcoholismUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse
   & Alcoholism (NIAAA); National Institute of Diabetes and Digestive and
   Kidney DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK); Fogarty International
   Centre, as part of the International Epidemiology Databases to Evaluate
   AIDS (IeDEA) [U01AI069907]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [UM1AI069465]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was supported through a grant from amfAR, The Foundation for AIDS
   Research with support from the National Institute of Health's National
   Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver
   National Institute of Child Health and Human Development, National
   Cancer Institute, National Institute of Mental Health, National
   Institute on Drug Abuse, the National Heart, Lung, and Blood Institute,
   the National Institute on Alcohol Abuse and Alcoholism, the National
   Institute of Diabetes and Digestive and Kidney Diseases, and the Fogarty
   International Centre, as part of the International Epidemiology
   Databases to Evaluate AIDS (IeDEA; U01AI069907) and the NIH-funded Johns
   Hopkins Baltimore-Washington-India Clinical Trials Unit for NIAID
   Networks [UM1AI069465]. The content and views expressed are those of the
   authors and does not necessarily represent the official views of any of
   the governments or institutions mentioned above.
CR Alemu H, 2012, AIDS CARE, V24, P866, DOI 10.1080/09540121.2011.648160
   Bagcchi S, 2014, LANCET PSYCHIAT, V1, P503, DOI 10.1016/S2215-0366(14)00096-0
   Bharali I, 2020, INDIAS POLICY RESPON
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]
   Chakraborty A, 2020, AIDS BEHAV, V24, P2130, DOI 10.1007/s10461-020-02779-4
   Choi EPH, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103740
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Gonzalez A, 2009, J HEALTH PSYCHOL, V14, P403, DOI 10.1177/1359105309102193
   Gonzalez-Sanguino C, 2020, BRAIN BEHAV IMMUN, V87, P172, DOI 10.1016/j.bbi.2020.05.040
   Gopalan HS, 2020, DIABETES METAB SYND, V14, P757, DOI 10.1016/j.dsx.2020.05.041
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   John Detrixhe, 2020, GOVT BAILOUTS ARE BE
   Joshi B, 2014, INDIAN J MED RES, V140, P84
   Joshi RK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216321
   Krumme AA, 2015, J EPIDEMIOL COMMUN H, V69, P284, DOI 10.1136/jech-2014-204494
   Li JF, 2020, WORLD PSYCHIATRY, V19, P249, DOI 10.1002/wps.20758
   Maharashtra State AIDS Control Society (2018-2019), 2018, HIV SENT SURV
   Maragakis L, CORONAVIRUS COVID 19
   Marbaniang I, 2019, DIABETES METAB SYND, V13, P1813, DOI 10.1016/j.dsx.2019.04.009
   Marconi VC, 2013, AIDS PATIENT CARE ST, V27, P657, DOI 10.1089/apc.2013.0263
   Mascarenhas A, INDIAN EXPRESS
   Mazza C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093165
   Naik A, 2020, INDIAS LOCKDOWN ENDS
   National AIDS Control Organization (NACO), IND HIV EST 2017 TEC
   National AIDS Control Programme Care Support and Treatment Services: National AIDS Control Organization, 2018, NAT AIDS CONTR PROGR
   National Center for Immunization and Repiratory Diseases (NCIRD) Division of Viral Diseases CDC, 2020, COR DIS 2019 COVID 1
   Ng E, 2014, WILEY BLACKWELL ENCY
   NJ Khaitan, INDIAS COVID 19 FINA
   Press Trust of India, 2020, IND PER CAP INC RIS
   Remien RH, 2019, AIDS, V33, P1411, DOI 10.1097/QAD.0000000000002227
   Rooks-Peck CR, 2018, HEALTH PSYCHOL, V37, P574, DOI 10.1037/hea0000606
   Rukmini S, 2020, COVID 19 RESPONSE DI
   Rutter LA, 2017, J PSYCHOPATHOL BEHAV, V39, P140, DOI 10.1007/s10862-016-9571-9
   Saddock BJ, 2017, KAPLAN SADOCKS COMPR, VI, P1731
   Sanchez-Paramo C, 2020, WORLD BANK BLOGS
   Schultz K., 2020, NY TIMES
   Spitzer R. L, GAD 7 MARATHI INDIA
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Wagner GJ, 2012, AIDS BEHAV, V16, P1862, DOI 10.1007/s10461-011-0051-7
   WHO Team Global Tuberculosis Programme, Q A TUB COVID 19
   Wykowski J, 2019, AIDS BEHAV, V23, P2059, DOI 10.1007/s10461-018-02390-8
NR 42
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD OCT 23
PY 2020
VL 20
IS 1
AR 1598
DI 10.1186/s12889-020-09656-8
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA ON0TF
UT WOS:000586424200005
PM 33097028
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Payen, D
   Cravat, M
   Maadadi, H
   Didelot, C
   Prosic, L
   Dupuis, C
   Losser, MR
   Bittencourt, MD
AF Payen, Didier
   Cravat, Maxime
   Maadadi, Hadil
   Didelot, Carole
   Prosic, Lydia
   Dupuis, Claire
   Losser, Marie-Reine
   De Carvalho Bittencourt, Marcelo
TI A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE SARS-CoV-2; immunity; monocyte HLA-DR; antigen-specific polyfunctional
   T-cells; intensive care unit
ID EXPRESSION; INFECTION; SEPSIS
AB Little is known about the time-dependent immune responses in severe COVID-19. Data of 15 consecutive patients were sequentially recorded from intensive care unit admission. Lymphocyte subsets and total monocyte and subsets counts were monitored as well as the expression of HLA-DR. For 5 patients, SARS-CoV-2-specific T-cell polyfunctionality was assessed against Spike and Nucleoprotein SARS-CoV-2 peptides. Non-specific inflammation markers were increased in all patients. Median monocyte HLA-DR expression was below the 8,000 AB/C threshold defining acquired immunodepression. A "V" trend curve for lymphopenia, monocyte numbers, and HLA-DR expression was observed with a nadir between days 11 and 14 after symptoms' onset. Intermediate CD14(++)CD16(+) monocytes increased early with a reduction in classic CD14(++)CD16(-) monocytes. Polyfunctional SARS-Cov-2-specific CD4 T-cells were present and functional, whereas virus-specific CD8 T-cells were less frequent and not efficient. We report a temporal variation of both innate and adaptive immunity in severe COVID-19 patients, helpful in guiding therapeutic decisions (e.g. anti-inflammatory vs. immunostimulatory ones). We describe a defect in virus-specific CD8 T-cells, a potential biomarker of clinical severity. These combined data also provide helpful knowledge for vaccine design.
C1 [Payen, Didier] Univ Paris 07, INSERM, UMR 1160, Paris, France.
   [Cravat, Maxime; De Carvalho Bittencourt, Marcelo] Univ Lorraine, CHRU Nancy, Lab Immunol, Nancy, France.
   [Maadadi, Hadil] Univ Lorraine, CHRU Nancy, Partement Anesthesie Reanimat Brabois Adulte, Nancy, France.
   [Didelot, Carole; Prosic, Lydia; De Carvalho Bittencourt, Marcelo] CHRU Nancy, Plateforme Cytometrie Flux Diagnost, Nancy, France.
   [Dupuis, Claire] CHU Clermont Ferrand, Serv Med Intens & Reanimat, Clermont Ferrand, France.
   [Losser, Marie-Reine] Univ Lorraine, INSERM, UMR 1116, Nancy, France.
   [De Carvalho Bittencourt, Marcelo] Univ Lorraine, CNRS, UMR 7365, IMoPA, Nancy, France.
RP Bittencourt, MD (corresponding author), Univ Lorraine, CHRU Nancy, Lab Immunol, Nancy, France.; Bittencourt, MD (corresponding author), CHRU Nancy, Plateforme Cytometrie Flux Diagnost, Nancy, France.; Bittencourt, MD (corresponding author), Univ Lorraine, CNRS, UMR 7365, IMoPA, Nancy, France.
EM marcelo.decarvalho@univ-lorraine.fr
RI De Carvalho Bittencourt, Marcelo/E-9316-2012
OI De Carvalho Bittencourt, Marcelo/0000-0002-2698-2458
CR Biller K, 2014, SHOCK, V42, P129, DOI 10.1097/SHK.0000000000000187
   Boyd A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128714
   BRAUN J, 2020, NATURE 0729, DOI DOI 10.1101/2020.04.17.20061440
   Burel JG, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.87499
   Calandra T, 2005, CRIT CARE MED, V33, P1538, DOI 10.1097/01.CCM.0000168253.91200.83
   Chen ATC, 2020, NEW ENGL J MED, V382, P1859, DOI 10.1056/NEJMc2005203
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Cox MA, 2013, VIROLOGY, V435, P157, DOI 10.1016/j.virol.2012.09.012
   Dekeyser M, 2017, KIDNEY INT REP, V2, P486, DOI 10.1016/j.ekir.2017.02.016
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Gouel-Cheron A, 2015, INTENS CARE MED, V41, P2229, DOI 10.1007/s00134-015-4045-1
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Ingraham NE, 2020, LANCET RESP MED, V8, P544, DOI 10.1016/S2213-2600(20)30226-5
   Lamoreaux L, 2012, CYTOM PART A, V81A, P362, DOI 10.1002/cyto.a.22042
   Larsen M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042403
   Li SH, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138070
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   Lukaszewicz AC, 2009, CRIT CARE MED, V37, P2746, DOI 10.1097/CCM.0b013e3181ab858a
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Oh HLJ, 2011, J VIROL, V85, P10464, DOI 10.1128/JVI.05039-11
   Ozanska A, 2020, SCAND J IMMUNOL, V92, DOI 10.1111/sji.12883
   Payen D, 2020, LONGITUDINAL STUDY I, DOI [10.1101/2020.06.16.20130914, DOI 10.1101/2020.06.16.20130914]
   Payen D, 2020, INTENS CARE MED, V46, P506, DOI 10.1007/s00134-019-05923-4
   Payen D, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4526-x
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Sampath P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01726
   Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Wang F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137799
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862
   Wong KL, 2012, IMMUNOL RES, V53, P41, DOI 10.1007/s12026-012-8297-3
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zeng Q., 2020, MORTALITY COVID 19 I, DOI [10.1101/2020.03.08.20031229, DOI 10.1101/2020.03.08.20031229]
   Zhang D, 2020, J LEUKOCYTE BIO 1011, DOI [10.1101/2020.03.24.20042655, DOI 10.1101/2020.03.24.20042655]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Ziegler-Heitbrock L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00423
NR 43
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 23
PY 2020
VL 11
AR 580250
DI 10.3389/fimmu.2020.580250
PG 12
WC Immunology
SC Immunology
GA ON9MW
UT WOS:000587016300001
PM 33178207
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, BS
   Chao, CW
   Tsybovsky, Y
   Abiona, OM
   Hutchinson, GB
   Moliva, JI
   Olia, AS
   Pegu, A
   Phung, E
   Stewart-Jones, G
   Verardi, R
   Wang, LS
   Wang, SS
   Werner, A
   Yang, ES
   Yap, C
   Zhou, TQ
   Mascola, JR
   Sullivan, NJ
   Graham, BS
   Corbett, KS
   Kwong, PD
AF Zhang, Baoshan
   Chao, Cara W.
   Tsybovsky, Yaroslav
   Abiona, Olubukola M.
   Hutchinson, Geoffrey B.
   Moliva, Juan, I
   Olia, Adam S.
   Pegu, Amarendra
   Phung, Emily
   Stewart-Jones, Guillaume
   Verardi, Raffaello
   Wang, Lingshu
   Wang, Shuishu
   Werner, Anne
   Yang, Eun Sung
   Yap, Christina
   Zhou, Tongqing
   Mascola, John R.
   Sullivan, Nancy J.
   Graham, Barney S.
   Corbett, Kizzmekia S.
   Kwong, Peter D.
TI A platform incorporating trimeric antigens into self-assembling
   nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit
   substantially higher neutralizing responses than spike alone
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PNEUMONIA REQUIRING HOSPITALIZATION; FUSION-GLYCOPROTEIN VACCINE;
   CRYO-EM STRUCTURE; PROTEIN; DESIGN; VIRUSES
AB Antigens displayed on self-assembling nanoparticles can stimulate strong immune responses and have been playing an increasingly prominent role in structure-based vaccines. However, the development of such immunogens is often complicated by inefficiencies in their production. To alleviate this issue, we developed a plug-and-play platform using the spontaneous isopeptide-bond formation of the SpyTag:SpyCatcher system to display trimeric antigens on self-assembling nanoparticles, including the 60-subunit Aquifex aeolicus lumazine synthase (LuS) and the 24-subunit Helicobacter pylori ferritin. LuS and ferritin coupled to SpyTag expressed well in a mammalian expression system when an N-linked glycan was added to the nanoparticle surface. The respiratory syncytial virus fusion (F) glycoprotein trimer-stabilized in the prefusion conformation and fused with SpyCatcher-could be efficiently conjugated to LuS-SpyTag or ferritin-SpyTag, enabling multivalent display of F trimers with prefusion antigenicity. Similarly, F-glycoprotein trimers from human parainfluenza virus-type 3 and spike-glycoprotein trimers from SARS-CoV-2 could be displayed on LuS nanoparticles with decent yield and antigenicity. Notably, murine vaccination with 0.08 mu g of SARS-CoV-2 spike-LuS nanoparticle elicited similar neutralizing responses as 2.0 mu g of spike, which was similar to 25-fold higher on a weight-per-weight basis. The versatile platform described here thus allows for multivalent plug-and-play presentation on self-assembling nanoparticles of trimeric viral antigens, with SARS-CoV-2 spike-LuS nanoparticles inducing particularly potent neutralizing responses.
C1 [Zhang, Baoshan; Chao, Cara W.; Abiona, Olubukola M.; Hutchinson, Geoffrey B.; Moliva, Juan, I; Olia, Adam S.; Pegu, Amarendra; Phung, Emily; Stewart-Jones, Guillaume; Verardi, Raffaello; Wang, Lingshu; Wang, Shuishu; Werner, Anne; Yang, Eun Sung; Yap, Christina; Zhou, Tongqing; Mascola, John R.; Sullivan, Nancy J.; Graham, Barney S.; Corbett, Kizzmekia S.; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Tsybovsky, Yaroslav] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Electron Microscopy Lab, Canc Res Technol Program, Frederick, MD USA.
   [Phung, Emily] George Washington Univ, Inst Biomed Sci, Washington, DC USA.
RP Kwong, PD (corresponding author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM pdkwong@nih.gov
FU Intramural Research Program of the Vaccine Research Center, National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health; Frederick National Laboratory for Cancer Research, NIH
   [HHSN261200800001E]; Undergraduate Scholarship Program, Office of
   Intramural Training and Education, Office of the Director, NIH
FX We thank T. Beaumont and H. Spits for antibody D25, A. Lanzavecchia for
   antibodies PIA174, PIA75 and MPE8, J. Stuckey for assistance with
   figures, and members of the Vaccine Research Center for discussions or
   comments on the manuscript. We thank members of the NIH NIAID VRC
   Translational Research Program for technical assistance with mouse
   experiments. Support for this work was provided by the Intramural
   Research Program of the Vaccine Research Center, National Institute of
   Allergy and Infectious Diseases, National Institutes of Health. This
   project has been funded in part with Federal funds from Frederick
   National Laboratory for Cancer Research, NIH, under Contract No.
   HHSN261200800001E (Y. Tsybovsky). K.S. Corbett is the recipient of a
   research fellowship that was partially funded by the Undergraduate
   Scholarship Program, Office of Intramural Training and Education, Office
   of the Director, NIH. The content of this publication does not
   necessarily reflect the views or policies of the Department of Health
   and Human Services, nor does mention of trade names, commercial
   products, or organizations imply endorsement by the U.S. Government.
CR Bottcher E, 2006, J VIROL, V80, P9896, DOI 10.1128/JVI.01118-06
   Brune KD, 2016, SCI REP-UK, V6, DOI 10.1038/srep19234
   Cavelti-Weder C, 2016, MOL THER, V24, P1003, DOI 10.1038/mt.2015.227
   Cho KJ, 2009, J MOL BIOL, V390, P83, DOI 10.1016/j.jmb.2009.04.078
   Corbett Kizzmekia S, 2020, Nature, V586, P567, DOI 10.1038/s41586-020-2622-0
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Corbett KS, 2019, MBIO, V10, DOI 10.1128/mBio.02810-18
   Cornuz J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002547
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Darricarrere N, 2018, J VIROL, V92, DOI 10.1128/JVI.01349-18
   Duan HY, 2018, IMMUNITY, V49, P301, DOI 10.1016/j.immuni.2018.07.005
   EFIMOV VP, 1994, J MOL BIOL, V242, P470, DOI 10.1006/jmbi.1994.1595
   Escolano A, 2019, NATURE, V570, P468, DOI 10.1038/s41586-019-1250-z
   Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030
   Govasli ML, 2019, VACCINE, V37, P6405, DOI 10.1016/j.vaccine.2019.09.004
   Graham BS, 2019, CURR OPIN IMMUNOL, V59, P57, DOI 10.1016/j.coi.2019.03.005
   He LL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12041
   Ingale J, 2014, J VIROL, V88, P14002, DOI 10.1128/JVI.02614-14
   Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245
   Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870
   Janitzek CM, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1574-1
   Jardine JG, 2016, SCIENCE, V351, P1458, DOI 10.1126/science.aad9195
   Joyce MG, 2016, NAT STRUCT MOL BIOL, V23, P811, DOI 10.1038/nsmb.3267
   Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202
   Lopez-Sagaseta J, 2016, COMPUT STRUCT BIOTEC, V14, P58, DOI 10.1016/j.csbj.2015.11.001
   Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046
   Marini A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02931
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   Morris CD, 2017, MBIO, V8, DOI 10.1128/mBio.00036-17
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pantophlet R, 2003, J VIROL, V77, P5889, DOI 10.1128/JVI.77.10.5889-5901.2003
   Reddington SC, 2015, CURR OPIN CHEM BIOL, V29, P94, DOI 10.1016/j.cbpa.2015.10.002
   Rey FA, 2018, CELL, V172, P1319, DOI 10.1016/j.cell.2018.02.054
   Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006
   Stewart-Jones GBE, 2018, P NATL ACAD SCI USA, V115, P12265, DOI 10.1073/pnas.1811980115
   Stewart-Jones GBE, 2016, CELL, V165, P813, DOI 10.1016/j.cell.2016.04.010
   Swanson KA, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba6466
   Tang G, 2007, J STRUCT BIOL, V157, P38, DOI 10.1016/j.jsb.2006.05.009
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Thrane S, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0181-1
   Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8
   Walls Alexandra C, 2020, bioRxiv, DOI 10.1101/2020.08.11.247395
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8712
   Wang WJ, 2019, NANOMED-NANOTECHNOL, V16, P69, DOI 10.1016/j.nano.2018.11.009
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zakeri B, 2012, P NATL ACAD SCI USA, V109, pE690, DOI 10.1073/pnas.1115485109
   Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435
   Zhou Tongqing, 2020, bioRxiv, DOI 10.1101/2020.06.22.166033
NR 52
TC 0
Z9 0
U1 5
U2 5
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 23
PY 2020
VL 10
IS 1
AR 18149
DI 10.1038/s41598-020-74949-2
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ON1QW
UT WOS:000586485700007
PM 33097791
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gao, W
   Chen, S
   Wang, K
   Chen, RZ
   Guo, Q
   Lu, JJ
   Wu, XD
   He, YN
   Yan, QY
   Wang, SY
   Wang, FL
   Jin, L
   Hua, J
   Li, Q
AF Gao, Wei
   Chen, Si
   Wang, Kun
   Chen, Rongzhang
   Guo, Qian
   Lu, Jingjing
   Wu, Xiaodong
   He, Yanan
   Yan, Qiaoyun
   Wang, Shengyun
   Wang, Feilong
   Jin, Li
   Hua, Jing
   Li, Qiang
TI Clinical features and efficacy of antiviral drug, Arbidol in 220
   nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in
   Wuhan: a retrospective case series
SO VIROLOGY JOURNAL
LA English
DT Article
DE Coronavirus disease; COVID-19; Arbidol; Efficacy; SARS-CoV-2
AB Objective We aimed to describe the features of 220 nonemergency (mild or common type) COVID-19 patients from a shelter hospital, as well as evaluate the efficiency of antiviral drug, Arbidol in their disease progressions. Methods Basic clinical characteristics were described and the efficacy of Arbidol was evaluated based on gender, age, maximum body temperature of the patients. Results Basically, males had a higher risk of fever and more onset symptoms than females. Arbidol could accelerate fever recovery and viral clearance in respiratory specimens, particularly in males. Arbidol also contributed to shorter hospital stay without obvious adverse reactions. Conclusions In the retrospective COVID-19 cohort, gender was one of the important factors affecting patient's conditions. Arbidol showed several beneficial effects in these patients, especially in males. This study brought more researches enlightenment in understanding the emerging infectious disease.
C1 [Gao, Wei; Chen, Si; Wang, Kun; Chen, Rongzhang; Guo, Qian; Lu, Jingjing; Wu, Xiaodong; He, Yanan; Yan, Qiaoyun; Wang, Feilong; Jin, Li; Hua, Jing; Li, Qiang] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Pulm & Crit Care Med, Shanghai 200123, Peoples R China.
   [Wang, Shengyun] Second Mil Med Univ, Changzheng Hosp, Dept Emergency & Crit Care Med, Shanghai 200082, Peoples R China.
RP Hua, J; Li, Q (corresponding author), Tongji Univ, Sch Med, Shanghai East Hosp, Dept Pulm & Crit Care Med, Shanghai 200123, Peoples R China.
EM erichua@163.com; 871242050@qq.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81870064]; "Gaoyuan" project of Pudong
   Health and Family Planning Commission [PWYgy2018-06]; National Key RD
   Program [2018YFC1313700]; Research Foundation of Shanghai Science and
   Technology Commission [18140904100]
FX This work was supported by National Natural Science Foundation of China
   (Grant Number: 81870064), "Gaoyuan" project of Pudong Health and Family
   Planning Commission (Grant Number: PWYgy2018-06), National Key R&D
   Program (Grant Number: 2018YFC1313700) from Qiang Li and the Research
   Foundation of Shanghai Science and Technology Commission (Grant Number:
   18140904100) from Shengyun Wang.
CR Boriskin YS, 2008, CURR MED CHEM, V15, P997, DOI 10.2174/092986708784049658
   Chen J, 2020, CHIN J INFECT DIS, V38, pE008, DOI [10.3760/cma.j.cn311365-20200210-00050, DOI 10.3760/CMA.J.CN311365-20200210-00050]
   Fedyakina I. T., 2005, Voprosy Virusologii, V50, P32
   Fink SL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27224-4
   GIAGULLI VA, 2020, ANDROLOGY US 0628, DOI DOI 10.1111/ANDR.12836
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hulseberg CE, 2019, J VIROL, V93, DOI [10.1128/jvi.02185-18, 10.1128/JVI.02185-18]
   Jacobs M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02378-2020
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   National Health Commission of the People's Republic of China, 2020, PNEUM DIAGN TREATM C
   [魏茹楠 Wei Runan], 2020, [中华临床感染病杂志, Chinese Journal of Clinical Infectious Diseases], V13, P9
NR 11
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD OCT 23
PY 2020
VL 17
IS 1
AR 162
DI 10.1186/s12985-020-01428-5
PG 9
WC Virology
SC Virology
GA ON4IQ
UT WOS:000586667100001
PM 33097047
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Carino, A
   Moraca, F
   Fiorillo, B
   Marchiano, S
   Sepe, V
   Biagioli, M
   Finamore, C
   Bozza, S
   Francisci, D
   Distrutti, E
   Catalanotti, B
   Zampella, A
   Fiorucci, S
AF Carino, Adriana
   Moraca, Federica
   Fiorillo, Bianca
   Marchiano, Silvia
   Sepe, Valentina
   Biagioli, Michele
   Finamore, Claudia
   Bozza, Silvia
   Francisci, Daniela
   Distrutti, Eleonora
   Catalanotti, Bruno
   Zampella, Angela
   Fiorucci, Stefano
TI Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and
   Semi-synthetic Steroidal Agents Acting on Functional Pockets on the
   Receptor Binding Domain
SO FRONTIERS IN CHEMISTRY
LA English
DT Article
DE SARS-CoV-2; COVID-19; virtual screening; nutraceuticals; drug
   repurposing and repositioning; bile acids; spike protein
ID BETULINIC ACID; TGR5 AGONIST; PROTEIN; ACTIVATION; SARS; SPIKE; FXR
AB The coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by the severe acute respiratory syndrome coronavirus (SARS)-CoV-2. In light of the urgent need to identify novel approaches to be used in the emergency phase, we have embarked on an exploratory campaign aimed at repurposing natural substances and clinically available drugs as potential anti-SARS-CoV2-2 agents by targeting viral proteins. Here we report on a strategy based on the virtual screening of druggable pockets located in the central beta-sheet core of the SARS-CoV-2 Spike's protein receptor binding domain (RBD). By combining an in silico approach and molecular in vitro testing we have been able to identify several triterpenoid/steroidal agents that inhibit interaction of the Spike RBD with the carboxypeptidase domain of the Angiotensin Converting Enzyme (ACE2). In detail, we provide evidence that potential binding sites exist in the RBD of the SARS CoV-2 Spike protein and that occupancy of these pockets reduces the ability of the RBD to bind to the ACE2 consensus in vitro. Naturally occurring and clinically available triterpenoids such as glycyrrhetinic and oleanolic acids, as well as primary and secondary bile acids and their amidated derivatives such as glyco-ursodeoxycholic acid and semi-synthetic derivatives such as obeticholic acid reduces the RBD/ACE2 binding. In aggregate, these results might help to define novel approaches to COVID-19 based on SARS-CoV-2 entry inhibitors.
C1 [Carino, Adriana; Marchiano, Silvia; Biagioli, Michele; Fiorucci, Stefano] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Moraca, Federica; Fiorillo, Bianca; Sepe, Valentina; Finamore, Claudia; Catalanotti, Bruno; Zampella, Angela] Univ Naples Federico II, Dept Pharm, Naples, Italy.
   [Moraca, Federica] Magna Graecia Univ Catanzaro, Net4Sci Srl, Campus Univ S Venuta, Catanzaro, Italy.
   [Bozza, Silvia; Francisci, Daniela] Univ Perugia, Dept Med, Microbiol Sect, Perugia, Italy.
   [Distrutti, Eleonora] Azienda Osped Perugia, SC Gastroenterol & Epatol, Perugia, Italy.
RP Catalanotti, B (corresponding author), Univ Naples Federico II, Dept Pharm, Naples, Italy.
EM bruno.catalanotti@unina.it
RI Sepe, Valentina/F-5994-2010; Catalanotti, Bruno/D-4025-2016
OI Catalanotti, Bruno/0000-0002-7532-6959
FU BAR Pharmaceuticals S.r.L.
FX This paper was supported by a research grant by BAR Pharmaceuticals
   S.r.L. to the Department of Pharmacy of the University of Napoli
   Federico II and to the Department of Surgical and Biomedical Sciences,
   University of Perugia. The authors declare the following competing
   financial interest(s): SF, AZ, and BC have filed an Italian patent
   application no.102020000011092 in the name of BAR Pharmaceuticals S.r.L.
   on the compounds described in this paper.
CR Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bertoni M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09654-8
   Biagioli M, 2017, J IMMUNOL, V199, P718, DOI 10.4049/jimmunol.1700183
   Carino A., 2020, HIJACKING SARS COV 2, DOI [10.1101/2020.06.10.144964, DOI 10.1101/2020.06.10.144964]
   Carino A, 2019, BBA-MOL CELL BIOL L, P1422, DOI 10.1016/j.bbalip.2019.07.006
   De Marino Simona, 2019, Handb Exp Pharmacol, V256, P137, DOI 10.1007/164_2019_237
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Distrutti E, 2015, J GASTROENTEROL, V50, P707, DOI 10.1007/s00535-015-1041-8
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Festa C, 2014, J MED CHEM, V57, P8477, DOI 10.1021/jm501273r
   Fiorucci Stefano, 2019, Handb Exp Pharmacol, V256, P3, DOI 10.1007/164_2019_238
   Fiorucci S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01853
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Genet C, 2010, J MED CHEM, V53, P178, DOI 10.1021/jm900872z
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Girvan M, 2002, P NATL ACAD SCI USA, V99, P7821, DOI 10.1073/pnas.122653799
   Glykos NM, 2006, J COMPUT CHEM, V27, P1765, DOI 10.1002/jcc.20482
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hong EH, 2015, BIOMOL THER, V23, P345, DOI 10.4062/biomolther.2015.019
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Khan A, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1779128, 10.1080/01634372.2020.1787575]
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Le Guilloux V, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-168
   Lee TS, 2018, J CHEM INF MODEL, V58, P2043, DOI 10.1021/acs.jcim.8b00462
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Lo SH, 2016, DRUG DES DEV THER, V10, P2669, DOI 10.2147/DDDT.S113197
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Maruyama T, 2002, BIOCHEM BIOPH RES CO, V298, P714, DOI 10.1016/S0006-291X(02)02550-0
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rezanka T., 2009, Anti-Infective Agents in Medicinal Chemistry, V8, P193
   Sato H, 2007, BIOCHEM BIOPH RES CO, V362, P793, DOI 10.1016/j.bbrc.2007.06.130
   Schmidtke P, 2010, NUCLEIC ACIDS RES, V38, pW582, DOI 10.1093/nar/gkq383
   Schrodinger, 2019, SCHROD REL 2019 1 MA
   Senathilake K., 2020, PREPRINTS, DOI [10.20944/preprints202003.0042.v1., DOI 10.20944/PREPRINTS202003.0042.V1, 10.20944/preprints202003.0042.v1]
   Sepe V, 2016, SCI REP-UK, V6, DOI 10.1038/srep19008
   Sepe V, 2015, FUTURE MED CHEM, V7, P1109, DOI [10.4155/FMC.15.54, 10.4155/fmc.15.54]
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   Utomo R. Y., 2020, REVEALING POTENCY CI, DOI [10.20944/preprints202003.0214.v1, DOI 10.20944/PREPRINTS202003.0214.V1, 10.20944/preprints202003.0214.v1.]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wang C, 2020, GASTROENTEROLOGY, V159, P1145, DOI 10.1053/j.gastro.2020.05.015
   Wang LY, 2017, BIOMED PHARMACOTHER, V95, P599, DOI 10.1016/j.biopha.2017.08.087
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang Y, 2018, EUR J MED CHEM, V143, P1723, DOI 10.1016/j.ejmech.2017.10.070
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 59
TC 0
Z9 0
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2646
J9 FRONT CHEM
JI Front. Chem.
PD OCT 23
PY 2020
VL 8
AR 572885
DI 10.3389/fchem.2020.572885
PG 15
WC Chemistry, Multidisciplinary
SC Chemistry
GA OM4JO
UT WOS:000585992700001
PM 33195060
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shen, M
   Liu, C
   Xu, R
   Ruan, ZJ
   Zhao, SY
   Zhang, HD
   Wang, W
   Huang, XH
   Yang, L
   Tang, Y
   Yang, T
   Jia, X
AF Shen, Min
   Liu, Chao
   Xu, Run
   Ruan, Zijing
   Zhao, Shiying
   Zhang, Huidong
   Wang, Wen
   Huang, Xinhe
   Yang, Li
   Tang, Yong
   Yang, Tai
   Jia, Xu
TI Predicting the Animal Susceptibility and Therapeutic Drugs to SARS-CoV-2
   Based on Spike Glycoprotein Combined With ACE2
SO FRONTIERS IN GENETICS
LA English
DT Article
DE SARS-CoV-2; angiotensin-converting enzyme 2 (ACE2); nelfinavir (NFV);
   binding affinity [K(b)]; cross-species transmission
ID PROTEASE INHIBITOR; NELFINAVIR; SARS; ANTAGONIST; FIDUXOSIN; RIBAVIRIN;
   TEGOBUVIR; RESPONSES
AB Recently, a few animals have been frequently reported to have been diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Whether they are SARS-CoV-2 intermediate hosts is worthy of great attention. The interaction of SARS-CoV-2 spike protein and its acceptor protein ACE2 is an important issue in determining viral host range and cross-species infection, while the binding capacity of Spike protein to ACE2 of different species is unknown. Here, we used the atomic structure model of SARS-CoV-2 and human ACE2 to assess the receptor utilization capacity of ACE2s from 10 kinds of animals. Results show that chimpanzees, domestic cats and cattles are more susceptible to infection by SARS-CoV-2. Cats in particular, such as pet cats and stray cats, interact very closely with humans, implying the necessity to carefully evaluate the risk of cats during the current COVID-19 pandemic. Furthermore, based on ACE2(cats)-SARS-CoV-2-RBD model, through high-throughput screening methods using a pool of 30,000 small molecules, eight compounds were selected for binding free energy calculations. All the eight compounds can effectively interfere with the binding of ACE2 and Spike protein, especially Nelfinavir, providing drug candidates for the treatment and prevention of SARS-CoV-2, suggesting further assessment of the anti-SARS-CoV-2 activity of these compounds in cell culture. Although we only reported the results of the simulation, and more laboratory and epidemiological investigation are required. Like cats are a risk factor, we can further detect SARS-CoV-2 according to the susceptibility of different animals, find the potential host of infection, and completely cut off the living space of the virus. Especially, cats could be a choice of animal model for screening antiviral drugs or vaccine candidates against SARS-CoV-2.
C1 [Shen, Min; Liu, Chao; Xu, Run; Zhao, Shiying; Yang, Li; Tang, Yong; Jia, Xu] Chengdu Med Coll, Noncoding RNA & Drug Discovery Key Lab Sichuan Pr, Chengdu, Peoples R China.
   [Ruan, Zijing; Huang, Xinhe] Southwest Jiaotong Univ, Sch Life Sci & Engn, Chengdu, Peoples R China.
   [Zhang, Huidong; Wang, Wen] Sichuan Univ, West China Sch Publ Hlth, Chengdu, Peoples R China.
   [Yang, Tai] Chengdu Med Coll, Sch Pharm, Chengdu, Peoples R China.
RP Jia, X (corresponding author), Chengdu Med Coll, Noncoding RNA & Drug Discovery Key Lab Sichuan Pr, Chengdu, Peoples R China.; Yang, T (corresponding author), Chengdu Med Coll, Sch Pharm, Chengdu, Peoples R China.
EM taiyang@cmc.edu.cn; jiaxu@cmc.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31870135, 31600116]; "1000 Talent Plan" of
   Sichuan Province [980, 1060]; Research Fund of Chengdu Medical College
   [CYZ18-03]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Nos. 31870135 and 31600116), the "1000 Talent Plan"
   of Sichuan Province (Nos. 980 and 1060), and the Research Fund of
   Chengdu Medical College (CYZ18-03).
CR Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4
   Brune ME, 2002, J PHARMACOL EXP THER, V300, P487, DOI 10.1124/jpet.300.2.487
   Chen H, 2020, SUSCEPTIBILITY FERRE, p20200330015347, DOI [10.1101/2020.03.30.015347, DOI 10.1101/2020.03.30.015347]
   Connelly M, 2020, HEADACHE, V60, P101, DOI 10.1111/head.13685
   Figgitt DP, 2000, DRUGS, V60, P481, DOI 10.2165/00003495-200060020-00016
   Gantt S, 2015, ADV VIROL, V2015, DOI 10.1155/2015/687162
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Hancock AA, 2002, J PHARMACOL EXP THER, V300, P478, DOI 10.1124/jpet.300.2.478
   Hsieh LE, 2010, ANTIVIR RES, V88, P25, DOI 10.1016/j.antiviral.2010.06.010
   Kalu NN, 2014, J VIROL, V88, P5455, DOI 10.1128/JVI.03790-13
   Kupferschmidt K., 2020, SCIENCE, V3, DOI [10.1126/science.abb1524, DOI 10.1126/SCIENCE.ABB1524]
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Le Poder S, 2011, ADV VIROL, V2011, DOI 10.1155/2011/609465
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mallalieu NL, 2014, CLIN THER, V36, P2047, DOI 10.1016/j.clinthera.2014.10.002
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   METRA M, 1995, J CARDIOVASC PHARM, V25, P732, DOI 10.1097/00005344-199505000-00008
   O'Brien SJ, 2006, BIOL CONSERV, V131, P255, DOI 10.1016/j.biocon.2006.05.001
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Shen M., 2020, SARS COV 2 INFECTION, V2020040116
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Villamil-Hernandez MT, 2014, EUR J PHARMACOL, V740, P512, DOI 10.1016/j.ejphar.2014.06.036
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang J, 2020, ACE2 EXPRESSION COLO, DOI [10.1101/2020.02.05.20020545, DOI 10.1101/2020.02.05.20020545]
   Wu C., 2020, PREPRINT, DOI [10.1101/2020.02.11.20022228v2, DOI 10.1101/2020.02.11.20022228V2]
   Wyles DL, 2014, HEPATOLOGY, V60, P56, DOI 10.1002/hep.27053
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Zeuzem S, 2012, HEPATOLOGY, V55, P749, DOI 10.1002/hep.24744
   Zhang Q., 2020, SARS COV 2 NEUTRALIZ, DOI [10.1101/2020.04.01.021196, DOI 10.1101/2020.04.01.021196]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 32
TC 1
Z9 1
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD OCT 23
PY 2020
VL 11
AR 575012
DI 10.3389/fgene.2020.575012
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA OM3QR
UT WOS:000585941500001
PM 33193684
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Velazquez-Salinas, L
   Zarate, S
   Eberl, S
   Gladue, DP
   Novella, I
   Borca, MV
AF Velazquez-Salinas, Lauro
   Zarate, Selene
   Eberl, Samantha
   Gladue, Douglas P.
   Novella, Isabel
   Borca, Manuel, V
TI Positive Selection of ORF1ab, ORF3a, and ORF8 Genes Drives the Early
   Evolutionary Trends of SARS-CoV-2 During the 2020 COVID-19 Pandemic
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE evolution; epistasis; positive selection; COVID-19; SARS-CoV2
ID NETWORK ANALYSIS; CORONAVIRUS; VIRUS; VIRULENCE; INFERENCE; MUTATION;
   MRBAYES
AB In this study, we analyzed full-length SARS-CoV-2 genomes from multiple countries to determine early trends in the evolutionary dynamics of the novel COVID-19 pandemic. Results indicated SARS-CoV-2 evolved early into at least three phylogenetic groups, characterized by positive selection at specific residues of the accessory proteins ORF3a and ORF8. Also, we are reporting potential relevant sites under positive selection at specific sites of non-structural proteins nsp6 and helicase. Our analysis of co-evolution showed evidence of epistatic interactions among sites in the genome that may be important in the generation of variants adapted to humans. These observations might impact not only public health but also suggest that more studies are needed to understand the genetic mechanisms that may affect the development of therapeutic and preventive tools, like antivirals and vaccines. Collectively, our results highlight the identification of ongoing selection even in a scenario of conserved sequences collected over the first 3 months of this pandemic.
C1 [Velazquez-Salinas, Lauro; Gladue, Douglas P.; Borca, Manuel, V] USDA ARS, Foreign Anim Dis Res Unit, Plum Isl Anim Dis Ctr, Greenport, NY 11944 USA.
   [Velazquez-Salinas, Lauro] Kansas State Univ, Coll Vet Med, Manhattan, KS 66506 USA.
   [Zarate, Selene] Univ Autonoma Ciudad Mexico, Ciencias Genom, Mexico City, DF, Mexico.
   [Eberl, Samantha] Cent Connecticut State Univ, Dept Psychol Sci, New Britain, CT 06050 USA.
RP Velazquez-Salinas, L (corresponding author), USDA ARS, Foreign Anim Dis Res Unit, Plum Isl Anim Dis Ctr, Greenport, NY 11944 USA.; Velazquez-Salinas, L (corresponding author), Kansas State Univ, Coll Vet Med, Manhattan, KS 66506 USA.
EM lauro.velazquez@usda.gov
FU USDA Research Service CRIS Project [8064-32000-060-00D]
FX This work was performed under USDA Research Service CRIS Project no.
   8064-32000-060-00D.
CR Alm E, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.32.2001410
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036
   Benvenuto D, 2020, J INFECTION, V81, pE24, DOI 10.1016/j.jinf.2020.03.058
   Chookajorn T, 2020, P NATL ACAD SCI USA, V117, P12520, DOI 10.1073/pnas.2007076117
   Cornman RS, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-154
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Cottam EM, 2014, AUTOPHAGY, V10, P1426, DOI 10.4161/auto.29309
   Delport W, 2010, BIOINFORMATICS, V26, P2455, DOI 10.1093/bioinformatics/btq429
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Fehr AR, 2015, J VIROL, V89, P1523, DOI 10.1128/JVI.02596-14
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Frost SDW, 2018, MOL BIOL EVOL, V35, P1348, DOI 10.1093/molbev/msy088
   HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694
   HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915
   HUDSON RR, 1992, GENETICS, V132, P583
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   Ibeh N, 2016, J VIROL, V90, P5475, DOI 10.1128/JVI.00322-16
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Mavian C, 2020, P NATL ACAD SCI USA, V117, P12522, DOI 10.1073/pnas.2007295117
   McBride R, 2012, VIRUSES-BASEL, V4, P2902, DOI 10.3390/v4112902
   Murrell B, 2013, MOL BIOL EVOL, V30, P1196, DOI 10.1093/molbev/mst030
   Murrell B, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002764
   Nascimento FF, 2017, NAT ECOL EVOL, V1, P1446, DOI 10.1038/s41559-017-0280-x
   Novella IS, 2004, J MOL BIOL, V342, P1415, DOI 10.1016/j.jmb.2004.08.003
   Park Matthew D, 2020, Nat Rev Immunol, V20, P408, DOI 10.1038/s41577-020-0360-z
   Phan MVT, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey035
   Pond SLK, 2008, MOL BIOL EVOL, V25, P1809, DOI 10.1093/molbev/msn123
   Pond SLK, 2006, BIOINFORMATICS, V22, P3096, DOI 10.1093/bioinformatics/btl474
   Pond SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105
   Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
   Poon AFY, 2007, PLOS COMPUT BIOL, V3, P2279, DOI 10.1371/journal.pcbi.0030231
   Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032
   Ren YJ, 2020, CELL MOL IMMUNOL, V17, P881, DOI 10.1038/s41423-020-0485-9
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Salemi M, 2004, J VIROL, V78, P1602, DOI 10.1128/JVI.78.3.1602-1603.2004
   Salmona M, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.07.032
   Sanchez-Pacheco SJ, 2020, P NATL ACAD SCI USA, V117, P12518, DOI 10.1073/pnas.2007062117
   Schliep K, 2017, METHODS ECOL EVOL, V8, P1212, DOI 10.1111/2041-210X.12760
   Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7
   Simmonds Peter, 2012, BMC Res Notes, V5, P50, DOI 10.1186/1756-0500-5-50
   Spielman Stephanie J, 2019, Methods Mol Biol, V1910, P427, DOI 10.1007/978-1-4939-9074-0_14
   Sun PF, 2020, J MED VIROL, V92, P612, DOI 10.1002/jmv.25735
   Velazquez-Salinas L, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01891
   vonHoldt BM, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501714
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   Weaver S, 2018, MOL BIOL EVOL, V35, P773, DOI 10.1093/molbev/msx335
   Wei TY, 2009, J GEN VIROL, V90, P1025, DOI 10.1099/vir.0.006858-0
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Yip CW, 2009, INFECT GENET EVOL, V9, P1185, DOI 10.1016/j.meegid.2009.09.015
   Yuen CK, 2020, EMERG MICROBES INFEC, V9, P1418, DOI 10.1080/22221751.2020.1780953
   Zhang Y., 2020, ORF8 PROTEIN SARS CO, DOI [10.1101/2020.05.24.111823, DOI 10.1101/2020.05.24.111823]
   Zhao ZM, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-21
   Zu HY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224569
NR 59
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD OCT 23
PY 2020
VL 11
AR 550674
DI 10.3389/fmicb.2020.550674
PG 13
WC Microbiology
SC Microbiology
GA OM4KF
UT WOS:000585994400001
PM 33193132
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tang, BF
   Zhu, JY
   Cong, Y
   Yang, WB
   Kong, CL
   Chen, WY
   Wang, YJ
   Zeng, Y
   Ji, JS
AF Tang, Bufu
   Zhu, Jinyu
   Cong, Ying
   Yang, Weibin
   Kong, Chunli
   Chen, Weiyue
   Wang, Yajie
   Zeng, Yong
   Ji, Jiansong
TI The Landscape of Coronavirus Disease 2019 (COVID-19) and Integrated
   Analysis SARS-CoV-2 Receptors and Potential Inhibitors in Lung
   Adenocarcinoma Patients
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE coronavirus disease 2019 (COVID-19); severe acute respiratory syndrome
   coronavirus 2 (SARS-CoV-2); lung adenocarcinoma (LUAD); immune
   infiltration; inflammation
ID OUTBREAK; CELL; PNEUMONIA; GENOMICS
AB The outbreak of novel coronavirus disease 2019 (COVID-19) has become the largest health threat worldwide, with more than 34.40 million positive cases and over 1.02 million deaths confirmed. In this study, we confirmed that significantly differentially expressed genes in COVID-19 patients were mainly involved in the regulation of immune and inflammation-related signaling pathways. It is worth noting that many infected COVID-19 patients have malignant tumors, and their prognosis is poor. To explore the susceptibility factors of cancer patients, we assessed the expression of ACE2, TMPRSS2, and the endocytic regulator AAK1 in lung adenocarcinoma (LUAD) patients and explored their effects on immune infiltration. We found that the expression of ACE2 and TMPRSS2 in LUAD patients was significantly increased, which may explain why LUAD patients are susceptible to SARS-CoV-2, and the patients with high-expression genes presented increased infiltration of immune cells such as B cells and CD4 T cells. In addition, we also identified miR-432-5p as a potential targeted molecule and bexarotene as a potential targeted drug of the three genes through bioinformatic analysis and further verified the anti-inflammatory effect of bexarotene, providing new ideas for the treatment of COVID-19.
C1 [Tang, Bufu; Zhu, Jinyu; Yang, Weibin; Kong, Chunli; Chen, Weiyue; Ji, Jiansong] Zhejiang Univ, Key Lab Imaging Diag & Minimally Invas Intervent, Lishui Hosp, Sch Med, Lishui, Peoples R China.
   [Tang, Bufu; Zhu, Jinyu] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Radiol, Hangzhou, Peoples R China.
   [Cong, Ying] Ctr Dis Control & Prevent, Dept Microbiol, Lishui, Peoples R China.
   [Yang, Weibin; Kong, Chunli; Chen, Weiyue; Wang, Yajie; Ji, Jiansong] Wenzhou Med Univ, Affiliated Hosp 5, Dept Radiol, Lishui, Peoples R China.
   [Zeng, Yong] Qingtian Cty Ctr Dis Control & Prevent, Lishui, Peoples R China.
RP Ji, JS (corresponding author), Zhejiang Univ, Key Lab Imaging Diag & Minimally Invas Intervent, Lishui Hosp, Sch Med, Lishui, Peoples R China.; Ji, JS (corresponding author), Wenzhou Med Univ, Affiliated Hosp 5, Dept Radiol, Lishui, Peoples R China.
EM lschrjjs@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81803778]; Key Research and Development
   Project of Zhejiang Province [2018C03024]; Public Welfare Research
   Program of Zhejiang Province [LQ20H160056, LGD19h160002]; Natural
   Science Foundation of Zhejiang ProvinceNatural Science Foundation of
   Zhejiang Province [LYQ20H280003]; Science and Technology Project of
   Lishui City [2020KJGG10]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81803778), The Key Research and Development Project of
   Zhejiang Province (No. 2018C03024), the Public Welfare Research Program
   of Zhejiang Province (Nos. LQ20H160056 and LGD19h160002), the Natural
   Science Foundation of Zhejiang Province (No. LYQ20H280003), and the
   Science and Technology Project of Lishui City (2020KJGG10 to YZ).
CR Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Berry I, 2020, CAN MED ASSOC J, V192, pE420, DOI 10.1503/cmaj.75262
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bourgonje AR, 2020, J PATHOL, V251, P228, DOI 10.1002/path.5471
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chai PW, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00883-5
   Chen L, 2016, ONCOTARGET, V7, P20041, DOI 10.18632/oncotarget.7884
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103
   Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kong Q, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01209-2
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Langfelder P, 2012, J STAT SOFTW, V46, P1
   Lee JS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd1554
   Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307
   Li Y, 2019, INT J MOL MED, V44, P1963, DOI 10.3892/ijmm.2019.4336
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu SC, 2017, SCI REP-UK, V7, DOI 10.1038/srep43205
   Longbottom ER, 2016, ANN SURG, V264, P370, DOI 10.1097/SLA.0000000000001484
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rivellese F, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102536
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547
   Shen DY, 2018, EXPERT REV ANTICANC, V18, P487, DOI 10.1080/14737140.2018.1449648
   Stahlmann R, 2020, DTSCH ARZTEBL INT, V117, P213, DOI 10.3238/arztebl.2020.0213
   Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   Talpur R, 2002, J AM ACAD DERMATOL, V47, P672, DOI 10.1067/mjd.2002.124607
   Tan MK, 2020, IMMUNOLOGY, V160, P261, DOI 10.1111/imm.13223
   Tobaiqy M, 2020, INFECT PREVENTION PR, V100061, DOI [10.1016/j.infpip.2020.100061, DOI 10.1016/J.INFPIP.2020.100061]
   TOZEREN A, 1990, J BIOMECH ENG-T ASME, V112, P311, DOI 10.1115/1.2891189
   Vaid S, 2020, J BONE JOINT SURG AM, V102, DOI 10.2106/JBJS.20.00715
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111
   Zhang Q, 2019, NANO LETT, V19, P2231, DOI 10.1021/acs.nanolett.8b04309
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
NR 47
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD OCT 23
PY 2020
VL 8
AR 577032
DI 10.3389/fcell.2020.577032
PG 13
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA OM3RF
UT WOS:000585943000001
PM 33195212
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dickinson, PJ
AF Dickinson, Peter J.
TI Coronavirus Infection of the Central Nervous System: Animal Models in
   the Time of COVID-19
SO FRONTIERS IN VETERINARY SCIENCE
LA English
DT Article
DE GS-441524; remdesivir; SARS-CoV-2; feline infectious peritonitis (FIP);
   treatment
ID RESPIRATORY SYNDROME CORONAVIRUS; FELINE-CORONAVIRUS; PERITONITIS VIRUS;
   MONOCLONAL-ANTIBODIES; CEREBROSPINAL-FLUID; PATHOGENESIS; RECEPTOR;
   BRAIN; CATS; GLYCOPROTEIN
AB Naturally occurring coronaviral infections have been studied for several decades in the context of companion and production animals, and central nervous system involvement is a common finding, particularly in cats with feline infectious peritonitis (FIP). These companion and production animal coronaviruses have many similarities to recent human pandemic-associated coronaviruses such as SARS-CoV, MERS-CoV, and SARS-CoV2 (COVID-19). Neurological involvement is being increasingly recognized as an important clinical presentation in human COVID-19 patients, often associated with para-infectious processes, and potentially with direct infection within the CNS. Recent breakthroughs in the treatment of coronaviral infections in cats, including neurological FIP, have utilized antiviral drugs similar to those currently in human COVID-19 clinical trials. Differences in specific coronavirus and host factors are reflected in major variations in incidence and mechanisms of CNS coronaviral infection and pathology between species; however, broad lessons relating to treatment of coronavirus infection present within the CNS may be informative across species.
C1 [Dickinson, Peter J.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA.
RP Dickinson, PJ (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA.
EM pjdickinson@ucdavis.edu
CR Addie D, 2009, J FELINE MED SURG, V11, P594, DOI 10.1016/j.jfms.2009.05.008
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Al-Harthi L, 2020, AIDS RES HUM RETROV, DOI [10.1089/AID.2020.0161, 10.1089/aid.2020.0161]
   Algahtani H, 2016, CASE REP NEUROL MED, DOI 10.1155/2016/3502683
   ANDRIES K, 1980, AM J VET RES, V41, P215
   Arabi YM, 2015, INFECTION, V43, P495, DOI 10.1007/s15010-015-0720-y
   Arbour N, 2000, J VIROL, V74, P8913, DOI 10.1128/JVI.74.19.8913-8921.2000
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Behzadi MA, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01327
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Benetka V, 2004, VET MICROBIOL, V99, P31, DOI 10.1016/j.vetmic.2003.07.010
   Bergmann CC, 2006, NAT REV MICROBIOL, V4, P121, DOI 10.1038/nrmicro1343
   Beyrouti R, 2020, J NEUROL NEUROSUR PS, V91, P889, DOI 10.1136/jnnp-2020-323586
   BURKS JS, 1980, SCIENCE, V209, P933, DOI 10.1126/science.7403860
   Cavanagh D., 1995, CORONAVIRIDAE, P73, DOI DOI 10.1007/978-1-4899-1531-3_5
   Chen DS, 1995, P NATL ACAD SCI USA, V92, P12095, DOI 10.1073/pnas.92.26.12095
   Chiocchetti R, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00514
   Cilia R, 2020, MOVEMENT DISORD, V35, P1287, DOI 10.1002/mds.28170
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   Conte C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020309
   Cook SE, 2020, BIORXIV PREPRINT, DOI [10.1101/2020.07.09.195016, DOI 10.1101/2020.07.09.195016]
   Damas J, 2020, P NATL ACAD SCI USA, V117, P22311, DOI 10.1073/pnas.2010146117
   Desforges M, 2014, VIRUS RES, V194, P145, DOI 10.1016/j.virusres.2014.09.011
   Dessau RB, 2001, ACTA NEUROPATHOL, V101, P601
   Dickinson PJ, 2020, J VET INTERN MED, V34, P1587, DOI 10.1111/jvim.15780
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Doki T, 2020, ARCH VIROL, V165, P1197, DOI 10.1007/s00705-020-04605-7
   Doki T, 2016, RES VET SCI, V104, P17, DOI 10.1016/j.rvsc.2015.11.005
   Dye C, 2007, J GEN VIROL, V88, P1753, DOI 10.1099/vir.0.82666-0
   FAZZINI E, 1992, MOVEMENT DISORD, V7, P153, DOI 10.1002/mds.870070210
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fischer Y, 2011, J VET INTERN MED, V25, P1270, DOI 10.1111/j.1939-1676.2011.00806.x
   Foley JE, 1998, J VET INTERN MED, V12, P415, DOI 10.1111/j.1939-1676.1998.tb02144.x
   Foley JE, 2003, J FELINE MED SURG, V5, P313, DOI 10.1016/S1098-612X(03)00048-2
   Foley JE, 2001, J VET INTERN MED, V15, P438, DOI 10.1892/0891-6640(2001)015&lt;0438:AROCII&gt;2.3.CO;2
   GALLAGHER TM, 1992, VIROLOGY, V191, P517, DOI 10.1016/0042-6822(92)90223-C
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Halfmann PJ, 2020, NEW ENGL J MED, V383, P592, DOI 10.1056/NEJMc2013400
   Hartmann K, 2008, VET IMMUNOL IMMUNOP, V123, P172, DOI 10.1016/j.vetimm.2008.01.026
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496
   Herrewegh AAPM, 1998, J VIROL, V72, P4508, DOI 10.1128/JVI.72.5.4508-4514.1998
   HOHDATSU T, 1991, VET MICROBIOL, V28, P13, DOI 10.1016/0378-1135(91)90096-X
   Hohdatsu T, 1998, ARCH VIROL, V143, P839, DOI 10.1007/s007050050336
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Hung ECW, 2003, CLIN CHEM, V49, P2108, DOI 10.1373/clinchem.2003.025437
   Jaimes JA, 2018, VIROLOGY, V517, P108, DOI 10.1016/j.virol.2017.12.027
   Kato V, 2020, ACTA NEUROL BELG, V120, P1051, DOI 10.1007/s13760-020-01412-4
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   KLINE KL, 1994, J AM ANIM HOSP ASSOC, V30, P111
   KORNEGAY JN, 1978, J AM ANIM HOSP ASSOC, V14, P580
   Kremer S, 2020, RADIOLOGY, V297, pE242, DOI [10.1148/radiol.2020202222, 10.1148/radiol.202020222]
   Kummrow M, 2005, CLIN DIAGN LAB IMMUN, V12, P1209, DOI 10.1128/CDLI.12.10.1209-1215.2005
   Lau KK, 2004, EMERG INFECT DIS, V10, P342, DOI 10.3201/eid1002.030638
   Li CC, 2019, DRUG DISCOV TODAY, V24, P726, DOI 10.1016/j.drudis.2019.01.018
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Li YY, 2016, INTERVIROLOGY, V59, P163, DOI 10.1159/000453066
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Marioni-Henry K, 2004, J VET INTERN MED, V18, P851, DOI 10.1892/0891-6640(2004)18&lt;851:PODOTS&gt;2.0.CO;2
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   MEYVISCH C, 1978, VET PATHOL, V15, P102, DOI 10.1177/030098587801500112
   Montalvan V, 2020, CLIN NEUROL NEUROSUR, V194, DOI 10.1016/j.clineuro.2020.105921
   Mora-Diaz JC, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00053
   Morfopoulou S, 2016, NEW ENGL J MED, V375, P497, DOI 10.1056/NEJMc1509458
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Murphy BG, 2018, VET MICROBIOL, V219, P226, DOI 10.1016/j.vetmic.2018.04.026
   MURRAY RS, 1992, ANN NEUROL, V31, P525, DOI 10.1002/ana.410310511
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Nilsson A, 2020, INFECT DIS-NOR, V52, P419, DOI 10.1080/23744235.2020.1729403
   Paniz-Mondolfi A, 2020, J MED VIROL, V92, P699, DOI 10.1002/jmv.25915
   Pardo Joe, 2020, Drugs Context, V9, DOI 10.7573/dic.2020-4-14
   Paterson Ross W, 2020, Brain, V143, P3104, DOI 10.1093/brain/awaa240
   Pedersen N C, 1984, Adv Exp Med Biol, V173, P365
   PEDERSEN NC, 1976, AM J VET RES, V37, P567
   PEDERSEN NC, 1980, AM J VET RES, V41, P868
   Pedersen NC, 2019, J FELINE MED SURG, V21, P271, DOI 10.1177/1098612X19825701
   Pedersen NC, 2018, J FELINE MED SURG, V20, P378, DOI 10.1177/1098612X17729626
   Pedersen NC, 2014, VET J, V201, P133, DOI 10.1016/j.tvjl.2014.04.016
   Pedersen NC, 2014, VET J, V201, P123, DOI 10.1016/j.tvjl.2014.04.017
   Pedersen NC, 2009, J FELINE MED SURG, V11, P225, DOI 10.1016/j.jfms.2008.09.008
   PERLMAN S, 1989, VIROLOGY, V170, P556, DOI 10.1016/0042-6822(89)90446-7
   Politi LS, 2020, JAMA NEUROL, V77, P1028, DOI 10.1001/jamaneurol.2020.2125
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   Ramakrishna C, 2004, J VIROL, V78, P7828, DOI 10.1128/JVI.78.14.7828-7832.2004
   Reichard RR, 2020, ACTA NEUROPATHOL, V140, P1, DOI 10.1007/s00401-020-02166-2
   Rissi DR, 2018, J VET DIAGN INVEST, V30, P392, DOI 10.1177/1040638718755833
   Roman GC, 2020, J NEUROL SCI, V414, DOI 10.1016/j.jns.2020.116884
   Rottier PJM, 2005, J VIROL, V79, P14122, DOI 10.1128/JVI.79.22.14122-14130.2005
   Schaumburg CS, 2008, FRONT BIOSCI-LANDMRK, V13, P4393, DOI 10.2741/3012
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Skinner D, 2019, VIRAL IMMUNOL, V32, P25, DOI 10.1089/vim.2018.0073
   Solomon IH, 2020, NEW ENGL J MED, V383, P989, DOI 10.1056/NEJMc2019373
   STEWART JN, 1992, VIROLOGY, V191, P502, DOI 10.1016/0042-6822(92)90220-J
   Szczepanski A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040328
   Takano T, 2013, ANTIVIR RES, V99, P100, DOI 10.1016/j.antiviral.2013.04.016
   TAMMER R, 1995, VET IMMUNOL IMMUNOP, V49, P177, DOI 10.1016/0165-2427(95)05459-J
   Tizard IR, 2020, VACCINE, V38, P5123, DOI 10.1016/j.vaccine.2020.06.026
   Toljan K, 2020, ACS CHEM NEUROSCI, V11, P1192, DOI 10.1021/acschemneuro.0c00174
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Tse LV, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00658
   von Weyhern CH, 2020, LANCET, V395, pE109, DOI 10.1016/S0140-6736(20)31282-4
   WANG FI, 1992, LAB INVEST, V66, P744
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   WEINER LP, 1973, ARCH NEUROL-CHICAGO, V28, P298, DOI 10.1001/archneur.1973.00490230034003
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94
   Xiang P, 2020, CHINAXIVT, VT202003, P15
   Xu J, 2005, CLIN INFECT DIS, V41, P1089, DOI 10.1086/444461
   Yan VC, 2020, ACS MED CHEM LETT, V11, P1361, DOI 10.1021/acsmedchemlett.0c00316
   Yeh EA, 2004, PEDIATRICS, V113, pE73, DOI 10.1542/peds.113.1.e73
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
   Zhou JH, 2003, J IMMUNOL, V170, P3331, DOI 10.4049/jimmunol.170.6.3331
   Zhou LY, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101642
   Zubair AS, 2020, JAMA NEUROL, V77, P1018, DOI 10.1001/jamaneurol.2020.2065
NR 119
TC 0
Z9 0
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2297-1769
J9 FRONT VET SCI
JI Front. Vet. Sci.
PD OCT 23
PY 2020
VL 7
AR 584673
DI 10.3389/fvets.2020.584673
PG 9
WC Veterinary Sciences
SC Veterinary Sciences
GA OM4PC
UT WOS:000586007800001
PM 33195610
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hussain, S
   Hussain, A
   Ho, J
   Sparagano, OAE
   Zia, UUR
AF Hussain, Sabir
   Hussain, Abrar
   Ho, Jeffery
   Sparagano, Olivier A. E.
   Zia, Ubaid-ur-Rehman
TI Economic and Social Impacts of COVID-19 on Animal Welfare and Dairy
   Husbandry in Central Punjab, Pakistan
SO FRONTIERS IN VETERINARY SCIENCE
LA English
DT Article
DE animal health; economic losses; milk production reduction; COVID-19;
   animal feeding shortage
ID DISEASE
AB Studies on the impact of the COVID-19 pandemic on animal welfare and dairy husbandry in low-income countries are limited. We conducted a survey between February and June 2020 to evaluate the economic impact and animal health problems upon the pandemic. Participants were lead veterinarians from 14 dairy farms with herd size between 100 and 500 in Lahore. These farms were major suppliers of milk and dairy products to central Punjab, Pakistan. During the pandemic, 10 of the 14 dairy farms relied on feed mill concentrates to provide feeds to their herds. Half of the farms reported feed shortage due to lockdowns. Six (43%) dairy farms have witnessed a 7.5% shortage of dry feed intake. In seven (50%) farms, the body condition score decreased by 0.24 point. The body score reduction was significantly associated with depleted feed intake (P = 0.005). The veterinarians of 10 (71%) farms failed to gain access to essential veterinary medications, hampering the treatment of sick animals. Due to feed shortage and drug unavailability, daily milk production reduced by two litters per cow in the herd of five (35%) farms. The reduced feed intake was significantly associated with the decrease in milk production (P = 0.003), while numerous downstream milk-processing facilities were out of service during the pandemic, significantly reducing the profit of six (43%) dairy farms. Finally, our study showed that the dairy farming industry and animal welfare were critically affected by three aspects: feed shortage, inaccessibility to essential veterinary drugs, and a reduced consumer demand for dairy products.
C1 [Hussain, Sabir; Hussain, Abrar; Zia, Ubaid-ur-Rehman] Univ Vet & Anim Sci, Dept Epidemiol & Publ Hlth, Lahore, Pakistan.
   [Hussain, Sabir; Ho, Jeffery; Sparagano, Olivier A. E.] City Univ Hong Kong, Jockey Club Coll Vet Med & Life Sci, Dept Infect Dis & Publ Hlth, Hong Kong, Peoples R China.
RP Hussain, S (corresponding author), Univ Vet & Anim Sci, Dept Epidemiol & Publ Hlth, Lahore, Pakistan.; Hussain, S (corresponding author), City Univ Hong Kong, Jockey Club Coll Vet Med & Life Sci, Dept Infect Dis & Publ Hlth, Hong Kong, Peoples R China.
EM sabir.hussain@uvas.edu.pk
OI Sparagano, Olivier/0000-0003-3141-310X; Ho, Jeffery/0000-0003-3357-2729;
   Hussain, Sabir/0000-0002-8573-1907
FU Department of Infectious Diseases and Public Health of the City
   University of Hong Kong [9380108]
FX Prof. Olivier Sparagano is a principal investigator of an internal
   research fund of the Department of Infectious Diseases and Public Health
   of the City University of Hong Kong (Project number 9380108).
CR Abiad A, 2020, ADB BRIEFS, DOI [10.22617/BRF200096, DOI 10.22617/BRF200096]
   Aitken MM, 2020, VET REC, V186, DOI 10.1136/vr.m1195
   Alagawany MM, 2020, FRONT VET SCI, V7, P570748, DOI 10.3389/fvets.2020.570748
   [Anonymous], 2020, CORONAVIRUS DIS COVI, P1
   Baldwin R, 2020, EC TIME COVID 19, P32
   Begum M, 2020, COVID 19 BANGLADESH, V2020, P2020040458, DOI 10.20944/preprints202004.0458.v1
   Bhatia Rajesh, 2020, Indian J Med Res, V151, P132, DOI 10.4103/ijmr.IJMR_623_20
   Bonilla-Aldana DK, 2020, ADV ANIM VET SCI, V8, P234, DOI DOI 10.17582/J0URNAL.AAVS/2020/8.3.234.237
   Boyden P, 2020, VET REC, V186, DOI 10.1136/vr.m1454
   Coronavirus The world economy at risk, 2020, OECD EC OUTL INT REP
   Dev SM, 2020, COVID 19 IMPACT INDI, P17
   Dhama K, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101830
   Dyal JW, 2020, MMWR-MORBID MORTAL W, V69, P557
   Emadi MH, 2020, FOOD SECURITY LAND U, P19, DOI [10.1007/978-3-030-36762-6_2, DOI 10.1007/978-3-030-36762-6_2]
   Forsido SF, 2020, COVID 19 PROBABLE IM, P38, DOI [10.13140/RG.2.2.29988.42888, DOI 10.13140/RG.2.2.29988.42888]
   Ghafar A, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00248
   Hafez HM, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00516
   Hashem NM, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.582528
   Hossain ST, 2020, J AGR SCI-SRI LANKA, V15, P116, DOI 10.4038/jas.v15i2.8794
   Lenzen M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235654
   Leroy EM, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100133
   McNamara T, 2020, VECTOR-BORNE ZOONOT, V20, P393, DOI 10.1089/vbz.2020.2650
   Mehrotra A, 2020, NEJM CATAL, V1, P1, DOI [DOI 10.1056/CAT.20.0091, 10.1056/CAT.20.0091]
   Mobasheri A, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00522
   Newman J, 2020, WALL STREET J
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   Poudel P. B., 2020, J BIOL TODAYS WORLD, V9, P221, DOI DOI 10.35248/2322-3308.20.09.221
   Salik KM, 2020, SUSTAIN DEV POLICY I
   Siche R, 2020, SCI AGROPEC, V11, P3, DOI 10.17268/sci.agropecu.2020.01.00
   Tiwari R, 2020, VET QUART, V40, P169, DOI 10.1080/01652176.2020.1766725
   Wang DM, 2020, J INFECTION, V80, pE25, DOI 10.1016/j.jinf.2020.03.008
   Weersink A, 2020, CAN J AGR ECON, V68, P195, DOI 10.1111/cjag.12240
   Yamin Mohammad, 2020, Int J Inf Technol, P1, DOI 10.1007/s41870-020-00466-0
NR 33
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2297-1769
J9 FRONT VET SCI
JI Front. Vet. Sci.
PD OCT 23
PY 2020
VL 7
AR 589971
DI 10.3389/fvets.2020.589971
PG 5
WC Veterinary Sciences
SC Veterinary Sciences
GA OM3HU
UT WOS:000585917600001
PM 33195626
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Karami, Z
   Knoop, BT
   Dofferhoff, ASM
   Blaauw, MJT
   Janssen, NA
   van Apeldoorn, M
   Kerckhoffs, APM
   van de Maat, JS
   Hoogerwerf, JJ
   ten Oever, J
AF Karami, Zara
   Knoop, Bram T.
   Dofferhoff, Anton S. M.
   Blaauw, Marc J. T.
   Janssen, Nico A.
   van Apeldoorn, Marjan
   Kerckhoffs, Angele P. M.
   van de Maat, Josephine S.
   Hoogerwerf, Jacobien J.
   ten Oever, Jaap
TI Few bacterial co-infections but frequent empiric antibiotic use in the
   early phase of hospitalized patients with COVID-19: results from a
   multicentre retrospective cohort study in The Netherlands
SO INFECTIOUS DISEASES
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; bacterial co-infections; pneumonia; antibiotic
   use; antimicrobial stewardship
ID COMMUNITY-ACQUIRED PNEUMONIA; STEWARDSHIP; VALIDATION; MANAGEMENT;
   INFLUENZA
AB Background
   Knowledge on bacterial co-infections in COVID-19 is crucial to use antibiotics appropriately. Therefore, we aimed to determine the incidence of bacterial co-infections, antibiotic use and application of antimicrobial stewardship principles in hospitalized patients with COVID-19.
   Methods
   We performed a retrospective observational study in four hospitals (1 university, 2 non-university teaching, 1 non-teaching hospital) in the Netherlands from March to May 2020 including consecutive patients with PCR-confirmed COVID-19. Data on first microbiological investigations obtained at the discretion of the physician and antibiotic use in the first week of hospital admission were collected.
   Results
   Twelve (1.2%) of the 925 patients included had a documented bacterial co-infection (75.0% pneumonia) within the first week. Microbiological testing was performed in 749 (81%) patients: sputum cultures in 105 (11.4%), blood cultures in 711 (76.9%), pneumococcal urinary antigen testing in 202 (21.8%), and Legionella urinary antigen testing in 199 (21.5%) patients, with clear variation between hospitals. On presentation 556 (60.1%; range 33.3-73.4%) patients received antibiotics for a median duration of 2 days (IQR 1-4). Intravenous to oral switch was performed in 41 of 413 (9.9%) patients who received intravenous treatment >48 h. Mean adherence to the local guideline on empiric antibiotic therapy on day 1 was on average 60.3% (range 45.3%-74.7%).
   Conclusions
   On presentation to the hospital bacterial co-infections are rare, while empiric antibiotic use is abundant. This implies that in patients with COVID-19 empiric antibiotic should be withheld. This has the potential to dramatically reduce the current overuse of antibiotics in the COVID-19 pandemic.
C1 [Karami, Zara; Knoop, Bram T.; Blaauw, Marc J. T.; Janssen, Nico A.; van de Maat, Josephine S.; Hoogerwerf, Jacobien J.; ten Oever, Jaap] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands.
   [Karami, Zara; Knoop, Bram T.; Blaauw, Marc J. T.; Janssen, Nico A.; van de Maat, Josephine S.; Hoogerwerf, Jacobien J.; ten Oever, Jaap] Radboud Ctr Infect Dis, Nijmegen, Netherlands.
   [Dofferhoff, Anton S. M.; Blaauw, Marc J. T.] Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands.
   [Blaauw, Marc J. T.] Bernhoven Univ, Uden, Netherlands.
   [van Apeldoorn, Marjan; Kerckhoffs, Angele P. M.] Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands.
RP ten Oever, J (corresponding author), Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands.
EM jaap.tenoever@radboudumc.nl
RI Janssen, Nico/R-5973-2017; Sepehri, Mohammad Mehdi/A-3030-2011
OI Janssen, Nico/0000-0002-9629-8627; Sepehri, Mohammad
   Mehdi/0000-0002-9920-7452
CR Berrevoets MAH, 2019, JAC ANTIMICROB RESIS, V1
   Capelastegul A, 2006, EUR RESPIR J, V27, P151, DOI 10.1183/09031936.06.00062505
   Clancy Cornelius J, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa524
   Dargere S, 2018, CLIN MICROBIOL INFEC, V24, P964, DOI 10.1016/j.cmi.2018.03.030
   Dofferhoff ASM, 2020, NED TIJDSCHR GENEES, V164
   Egilmezer E, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1995
   Fischer F, 2016, HEALTHCARE-BASEL, V4, DOI 10.3390/healthcare4030036
   Garcia-Vidal Carolina, 2021, Clin Microbiol Infect, V27, P83, DOI 10.1016/j.cmi.2020.07.041
   Ghazi IM, 2016, INFECT CONT HOSP EP, V37, P583, DOI 10.1017/ice.2016.17
   Hu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106051
   Hulscher MEJL, 2017, CLIN MICROBIOL INFEC, V23, P799, DOI 10.1016/j.cmi.2017.07.017
   Huttner BD, 2020, CLIN MICROBIOL INFEC, V26, P808, DOI 10.1016/j.cmi.2020.04.024
   Klein EY, 2016, INFLUENZA OTHER RESP, V10, P394, DOI 10.1111/irv.12398
   Langford Bradley J, 2020, Clin Microbiol Infect, V26, P1622, DOI 10.1016/j.cmi.2020.07.016
   Lansbury L, 2020, J INFECTION, V81, P266, DOI 10.1016/j.jinf.2020.05.046
   Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377
   Loens K, 2009, J CLIN MICROBIOL, V47, P21, DOI 10.1128/JCM.02037-08
   Molinos L, 2015, ANN AM THORAC SOC, V12, P1482, DOI 10.1513/AnnalsATS.201505-304OC
   National Institutes of Health, COVID 19 TREATM GUID
   Palacios G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008540
   Prokop M, 2020, RADIOLOGY, V296, pE97, DOI 10.1148/radiol.2020201473
   Rawson TM, 2020, J ANTIMICROB CHEMOTH, V75, P1681, DOI 10.1093/jac/dkaa194
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   Robsky KO, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05099-z
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Schouten JA, 2005, J ANTIMICROB CHEMOTH, V56, P575, DOI 10.1093/jac/dki275
   Seaton RA, 2020, J INFECTION, V81, P952, DOI 10.1016/j.jinf.2020.09.024
   Shiley KT, 2010, INFECT CONT HOSP EP, V31, P1177, DOI 10.1086/656596
   Sieswerda E, 2020, CLIN MICROBIOL INFEC, pS1198
   van Berkel M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03291-w
   Vaughn Valerie M, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1239
   Wiersinga WJ, 2018, NETH J MED, V76, P4
   Youngs J, 2020, J INFECTION, V81, pE55, DOI 10.1016/j.jinf.2020.06.056
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 34
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2374-4235
EI 2374-4243
J9 INFECT DIS-NOR
JI Infect. Dis.
DI 10.1080/23744235.2020.1839672
EA OCT 2020
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA OJ2WK
UT WOS:000583827000001
PM 33103530
OA Bronze
DA 2021-01-01
ER

PT J
AU Awad, IE
   Abu-Saleh, AA
   Sharma, S
   Yadav, A
   Poirier, RA
AF Awad, Ibrahim E.
   Abu-Saleh, Abd Al-Aziz A.
   Sharma, Sweta
   Yadav, Arpita
   Poirier, Raymond A.
TI High-throughput virtual screening of drug databanks for potential
   inhibitors of SARS-CoV-2 spike glycoprotein
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; potential inhibitors; binding energy; molecular
   dynamics; steered molecular dynamics; docking
ID MOLECULAR-FORCE FIELD; DYNAMICS; GEOMETRIES; DISCOVERY; PROTEIN; DESIGN
AB COVID-19, which is caused by a novel coronavirus known as SARS-CoV-2, has spread rapidly around the world, and it has infected more than 29 million individuals as recorded on 16 September 2020. Much effort has been made to stop the virus from spreading, and there are currently no approved pharmaceutical products to treat COVID-19. Here, we apply an in silico approach to investigate more than 3800 FDA approved drugs on the viral RBD S-1-ACE2 interface as a target. The compounds were investigated through flexible ligand docking, ADME property calculations and protein-ligand interaction maps. Molecular dynamics (MD) simulations were also performed on eleven compounds to study the stability and the interactions of the protein-ligand complexes. The MD simulations show that bagrosin, chidamide, ebastine, indacaterol, regorafenib, salazosulfadimidine, silodosin and tasosartan are relatively stable near the C terminal domain (CTD1) of the S-1 subunit of the viral S protein. The relative MMGBSA binding energies show that silodosin has the best binding to the target. The constant velocity steered molecular dynamics (SMD) simulations show that silodosin preferentially interacts with the RBD S-1 and has potential to act as an interfering compound between viral spike-host ACE2 interactions.
   Communicated by Ramaswamy H. Sarma
C1 [Awad, Ibrahim E.; Abu-Saleh, Abd Al-Aziz A.; Poirier, Raymond A.] Mem Univ Newfoundland, Dept Chem, St John, NF A1B 3X7, Canada.
   [Sharma, Sweta; Yadav, Arpita] Chhatrapati Shahu Ji Maharaj Univ, Univ Inst Engn & Technol, Dept Chem, Kanpur, Uttar Pradesh, India.
RP Awad, IE; Poirier, RA (corresponding author), Mem Univ Newfoundland, Dept Chem, St John, NF A1B 3X7, Canada.
EM iawad@mun.ca; rpoirier@mun.ca
OI yadav, arpita/0000-0001-9734-0068; E. Awad, Ibrahim/0000-0002-6487-0270
FU Natural Sciences and Engineering Council of Canada (NSERC)Natural
   Sciences and Engineering Research Council of Canada
FX The Natural Sciences and Engineering Council of Canada (NSERC).
CR Amin M, 2020, J PHYS CHEM LETT, V11, P4897, DOI 10.1021/acs.jpclett.0c01064
   AMINPOUR M, 2019, MOLECULES, V24, DOI DOI HTTPS://DOI.ORG/10.3390/MOLECULES24091693
   [Anonymous], 2019, CORONAVIRUS DIS
   [Anonymous], 2020, MAESTR
   [Anonymous], 2020, MOLINSPIRATION CHEMI
   Arunachalam D. K, 2020, SOCIAL SCI RES NETWO, DOI [10.2139/ssrn.3578294, DOI 10.2139/SSRN.3578294]
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   BABADAEI MMN, 2020, J BIOMOL STRUCT 0529, DOI DOI https://doi.org/10.1080/07391102.2020.1767211
   Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   CALLIGARI P, 2020, VIRUSES BASEL, V12, DOI DOI https://doi.org/10.3390/v12040445
   CAVASOTTO CN, 2020, MOL INFORM 0818, DOI DOI https://doi.org/10.1002/minf.202000115
   Celik I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1792993
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   DeLano W.L., 2002, PYMOL
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   GREST GS, 1986, PHYS REV A, V33, P3628, DOI 10.1103/PhysRevA.33.3628
   Halgren TA, 1996, J COMPUT CHEM, V17, P520, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<520::AID-JCC2>3.0.CO;2-W
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:6<490::AID-JCC1>3.3.CO;2-V
   Halgren TA, 1996, J COMPUT CHEM, V17, P616, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X
   Halgren TA, 1996, J COMPUT CHEM, V17, P553
   Halgren TA, 1996, J COMPUT CHEM, V17, P587, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<587::AID-JCC4>3.0.CO;2-Q
   Han YX, 2020, ACS NANO, V14, P5143, DOI 10.1021/acsnano.0c02857
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang C, 2020, LANCET, V395, P496, DOI 10.1016/S0140-6736(20)30252-X
   Izrailev S., 1999, STEERED MOL DYNAMICS, P39, DOI DOI 10.1007/978-3-642-58360-5_2
   KIRCHDOERFER RN, 2018, SCI REP UK, V8, DOI DOI https://doi.org/10.1038/s41598-018-34171-7
   Klauda JB, 2010, J PHYS CHEM B, V114, P7830, DOI 10.1021/jp101759q
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Macalino SJY, 2015, ARCH PHARM RES, V38, P1686, DOI 10.1007/s12272-015-0640-5
   Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Njogu PM, 2016, ACS INFECT DIS, V2, P8, DOI 10.1021/acsinfecdis.5b00093
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Panda PK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb8097
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Senathilake K., 2020, VIRTUAL SCREENING IN, DOI [10.20944/PREPRINTS202003.0042.V1, DOI 10.20944/PREPRINTS202003.0042.V1]
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Sun HY, 2018, PHYS CHEM CHEM PHYS, V20, P14450, DOI 10.1039/c7cp07623a
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   TREZZA A, 2020, SCI REP UK, V10, DOI DOI https://doi.org/10.1038/s41598-020-70863-9
   Trott O., 2009, J COMPUT CHEM, V31, pNA461
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   TUCKERMAN M, 1992, J CHEM PHYS, V97, P1990, DOI 10.1063/1.463137
   Ursu O, 2017, NUCLEIC ACIDS RES, V45, pD932, DOI 10.1093/nar/gkw993
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wei TZ, 2020, CHIN J INTEGR MED, V26, P663, DOI 10.1007/s11655-020-3427-6
   Whisenant J, 2020, ACS MED CHEM LETT, V11, P1076, DOI 10.1021/acsmedchemlett.0c00233
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
NR 53
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1835721
EA OCT 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OI9PI
UT WOS:000583600900001
PM 33103586
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Romani, S
   Gerard, A
   Fresse, A
   Viard, D
   Van-Obberghen, E
   Micallef, J
   Rocher, F
   Drici, MD
AF Romani, Serena
   Gerard, Alexandre
   Fresse, Audrey
   Viard, Delphine
   Van-Obberghen, Elise
   Micallef, Joelle
   Rocher, Fanny
   Drici, Milou-Daniel
CA French Pharmacovigilance Network
TI Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior
   and During COVID-19 Epidemic
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article; Early Access
ID AMERICAN-HEART-ASSOCIATION; INDUCED CARDIOMYOPATHY; SCIENTIFIC
   STATEMENT; QT INTERVAL; CHLOROQUINE; RISK; CARDIOLOGY
AB The recent empirical use of hydroxychloroquine (HCQ) in coronavirus disease 2019 (COVID-19) revived the interest in its cardiac toxicity, increasingly sidelined over time. We aimed to assess and compare the profile of cardiac adverse drug reactions (CADRs) associated with HCQ before and during COVID-19. We performed a retrospective comparative observational study using the French Pharmacovigilance network database between 1985 and May 2020 to assess all postmarketing CADRs associated with HCQ notified before COVID-19 in its approved indications for lupus and rheumatoid arthritis (preCOV), and those concerning its empirical use in COVID-19 (COV). Eighty-five CADR in preCOV were compared with 141 CADRs in COV. The most common CADR of preCOV were cardiomyopathies (42.4%) and conduction disorders (28.2%), both statistically more frequent than in COV (P < 0.001). COV notifications significantly highlighted repolarization and ventricular rhythm disorders (78.0%, P < 0.001) as well as sinus bradycardias (14.9%, P = 0.01) as compared with preCOV. Estimated incidence of CADR was significantly higher among patients exposed to off-label use of HCQ in COVID-19 (2.9%) than before COVID-19 in its approved indications (0.01%, P < 0.001). The use of HCQ in COVID-19 sheds a new light on the spectrum of its cardiac toxicity. This fosters the value of a closer monitoring of all patients treated with HCQ, regardless of its indication, and the importance of an update of its summary of product characteristics.
C1 [Romani, Serena; Gerard, Alexandre; Fresse, Audrey; Viard, Delphine; Van-Obberghen, Elise; Rocher, Fanny; Drici, Milou-Daniel] Univ Cote dAzur, Pasteur Hosp, Med Ctr, Pharmacovigilance,Dept Clin Pharmacol, Nice, France.
   [Micallef, Joelle] Aix Marseille Univ, AP HP, Dept Clin Pharmacol & Pharmacovigilance,INSERM, Pharmacovigilance,Inst Neurosci Syst,UMR 110, Marseille, France.
RP Drici, MD (corresponding author), Univ Cote dAzur, Pasteur Hosp, Med Ctr, Pharmacovigilance,Dept Clin Pharmacol, Nice, France.
EM pharmacovigilance@chu-nice.fr
CR American College of Cardiology, 2020, COVID 19 CLIN GUID C
   Bihan Kevin, 2020, Therapie, V75, P591, DOI 10.1016/j.therap.2020.02.022
   Bump P., 2020, RISE FALL TRUMPS OBS
   Capel RA, 2015, HEART RHYTHM, V12, P2186, DOI 10.1016/j.hrthm.2015.05.027
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   de Olano J, 2019, AM J EMERG MED, V37, DOI 10.1016/j.ajem.2019.158387
   Drew BJ, 2010, CIRCULATION, V121, P1047, DOI 10.1161/CIRCULATIONAHA.109.192704
   Drici MD, 2000, THERAPIE, V55, P185
   European Medicines Agency (EMA), 2020, COVID 19 REM RISK SE
   Fanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis-2019-215089
   Frustaci A, 2012, INT J CARDIOL, V157, P117, DOI 10.1016/j.ijcard.2012.03.112
   Funck-Brentano C, 2020, ARCH CARDIOVASC DIS, V113, P367, DOI 10.1016/j.acvd.2020.04.001
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Gerard A, 2020, THERAPIE, V75, P371, DOI 10.1016/j.therap.2020.05.002
   Grandvuillemin A, 2020, THERAPIE, V75, P385, DOI 10.1016/j.therap.2020.05.001
   HONERJAGER P, 1986, N-S ARCH PHARMACOL, V332, P184, DOI 10.1007/BF00511411
   HONERJAGER P, 1986, BASIC RES CARDIOL, V81, P33
   Kang I, 2003, CURR OPIN RHEUMATOL, V15, P528, DOI 10.1097/00002281-200309000-00002
   Karimi G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068938
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Melles RB, 2014, JAMA OPHTHALMOL, V132, P1453, DOI 10.1001/jamaophthalmol.2014.3459
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Miller LW, 2002, AM J TRANSPLANT, V2, P807, DOI 10.1034/j.1600-6143.2002.20902.x
   Nguyen LS, 2020, CIRCULATION, V142, P303, DOI 10.1161/CIRCULATIONAHA.120.048238
   OMS, 2020, WHO DIR GEN REM MED
   Rautaharju PM, 2009, J AM COLL CARDIOL, V53, P982, DOI 10.1016/j.jacc.2008.12.014
   Rautaharju PM, 2004, AM J CARDIOL, V93, P1017, DOI 10.1016/j.amjcard.2003.12.055
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Roden DM, 2006, ESC EDUC SER, P177
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Sanchez-Capula JA, 2001, J PHARMACOL EXP THER, V297, P437
   Sandhu VK, 2019, J RHEUMATOL, V46, P340, DOI 10.3899/jrheum.180639
   Saussine A, 2009, ANN DERMATOL VENER, V136, P530, DOI 10.1016/j.annder.2009.01.016
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Smith ER, 2005, J EMERG MED, V28, P437, DOI 10.1016/j.jemermed.2004.12.011
   Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis-2019-216655
   Sumpter MD, 2012, LUPUS, V21, P1594, DOI 10.1177/0961203312462757
   Tonnesmann E, 2013, IMMUNOPHARM IMMUNOT, V35, P434, DOI 10.3109/08923973.2013.780078
   Tselios K, 2018, LUPUS, V27, P591, DOI 10.1177/0961203317734922
   Tselios K, 2019, J RHEUMATOL, V46, P391, DOI 10.3899/jrheum.180124
   Vink AS, 2018, CIRCULATION, V138, P2345, DOI 10.1161/CIRCULATIONAHA.118.033943
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   World Health Organization (WHO), 2019, WHOCC ATC DDD HYDR
   Xu CY, 2020, QJM-INT J MED, V113, P569, DOI 10.1093/qjmed/hcaa153
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yogasundaram H, 2014, CAN J CARDIOL, V30, P1706, DOI 10.1016/j.cjca.2014.08.016
   Yue L., 2020, EFFECT HYDROXYCHLORO
NR 49
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
DI 10.1111/cts.12883
EA OCT 2020
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OH3GM
UT WOS:000582456700001
PM 32964653
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Milder, TY
   Stocker, SL
   Day, RO
   Greenfield, JR
AF Milder, Tamara Y.
   Stocker, Sophie L.
   Day, Richard O.
   Greenfield, Jerry R.
TI Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2
   Inhibitors, Particularly in People with Type 2 Diabetes and Chronic
   Kidney Disease
SO DRUG SAFETY
LA English
DT Article
ID CARDIOVASCULAR OUTCOMES; RENAL IMPAIRMENT; SGLT2 INHIBITOR;
   CO-TRANSPORTER-2 INHIBITORS; EMPAGLIFLOZIN; PHARMACOKINETICS;
   KETOACIDOSIS; EFFICACY; PHARMACODYNAMICS; CANAGLIFLOZIN
AB Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a major advance in the fields of diabetology, nephrology, and cardiology. The cardiovascular and renal benefits of SGLT2 inhibitors are likely largely independent of their glycaemic effects, and this understanding is central to the use of these agents in the high-risk population of people with type 2 diabetes and chronic kidney disease. There are a number of potential safety issues associated with the use of SGLT2 inhibitors. These include the rare but serious risks of diabetic ketoacidosis and necrotising fasciitis of the perineum. The data regarding a possibly increased risk of lower limb amputation and fracture with SGLT2 inhibitor therapy are conflicting. This article aims to explore the potential safety issues associated with the use of SGLT2 inhibitors, with a particular focus on the safety of these drugs in people with type 2 diabetes and chronic kidney disease. We discuss strategies that clinicians can implement to minimise the risk of adverse effects including diabetic ketoacidosis and volume depletion. Risk mitigation strategies with respect to SGLT2 inhibitor-associated diabetic ketoacidosis are of particular importance during the current coronavirus disease 2019 (COVID-19) pandemic.
C1 [Milder, Tamara Y.; Greenfield, Jerry R.] St Vincents Hosp, Dept Diabet & Endocrinol, Sydney, NSW, Australia.
   [Milder, Tamara Y.; Stocker, Sophie L.; Day, Richard O.] St Vincents Hosp, Dept Clin Pharmacol & Toxicol, Sydney, NSW, Australia.
   [Milder, Tamara Y.; Greenfield, Jerry R.] Garvan Inst Med Res, Diabet & Metab, Sydney, NSW, Australia.
   [Milder, Tamara Y.; Stocker, Sophie L.; Day, Richard O.; Greenfield, Jerry R.] Univ NSW, St Vincents Clin Sch, Sydney, NSW, Australia.
RP Greenfield, JR (corresponding author), St Vincents Hosp, Dept Diabet & Endocrinol, Sydney, NSW, Australia.; Greenfield, JR (corresponding author), Garvan Inst Med Res, Diabet & Metab, Sydney, NSW, Australia.; Greenfield, JR (corresponding author), Univ NSW, St Vincents Clin Sch, Sydney, NSW, Australia.
EM j.greenfield@garvan.org.au
CR AstraZeneca Pty Ltd, 2020, AUSTR PROD INF FORX
   Bakris GL, 2019, AM J KIDNEY DIS, V74, P573, DOI 10.1053/j.ajkd.2019.05.009
   Bersoff-Matcha SJ, 2019, ANN INTERN MED, V170, P764, DOI 10.7326/M19-0085
   Biesenbach G, 2003, DIABETIC MED, V20, P642, DOI 10.1046/j.1464-5491.2003.01025.x
   Bjornstad P, 2020, KIDNEY INT, V97, P31, DOI 10.1016/j.kint.2019.09.023
   Blau JE, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99123
   Boehringer Ingelheim Pty Limited, 2020, AUSTR PROD INF JARD
   Bonora BM, 2018, DIABETES OBES METAB, V20, P25, DOI 10.1111/dom.13012
   Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Branch M, 2019, J DIABETES COMPLICAT, V33, P468, DOI 10.1016/j.jdiacomp.2019.04.004
   Cahn A, 2020, DIABETES OBES METAB, V22, P1357, DOI 10.1111/dom.14041
   Cannon CP, 2020, CIRCULATION, V141, P407, DOI 10.1161/CIRCULATIONAHA.119.044359
   Cannon CP, 2018, AM HEART J, V206, P11, DOI 10.1016/j.ahj.2018.08.016
   Ceriello A, 2020, DIABETES CARE, V43, P1427, DOI 10.2337/dc20-0941
   Cheng L, 2019, DIABETES METAB, V45, P436, DOI 10.1016/j.diabet.2019.01.010
   Cherney DZ, 2020, NEPHROL DIAL TRANSPL, V35, P3, DOI 10.1093/ndt/gfz230
   Cherney DZI, 2014, CIRCULATION, V129, P587, DOI 10.1161/CIRCULATIONAHA.113.005081
   Cooper ME, 2019, AM J KIDNEY DIS, V74, P713, DOI 10.1053/j.ajkd.2019.03.432
   Cowie MR, 2020, NAT REV CARDIOL, V17, P761, DOI 10.1038/s41569-020-0406-8
   Dave CV, 2019, DIABETES OBES METAB, V21, P434, DOI 10.1111/dom.13531
   de Jong MA, 2019, CLIN J AM SOC NEPHRO, V14, P66, DOI 10.2215/CJN.04530418
   Devineni D, 2015, CLIN THER, V37, P610, DOI 10.1016/j.clinthera.2014.12.013
   Donnan JR, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022577
   Edmonston D, 2019, CLIN J AM SOC NEPHRO, V14, P7, DOI 10.2215/CJN.13801118
   European Society of Cardiology Press Office, 2020, DAPA CKD TRIAL MEETS
   Ferrannini E, 2020, DIABETES OBES METAB, V22, P99, DOI 10.1111/dom.13870
   Ferrannini E, 2017, CELL METAB, V26, P27, DOI 10.1016/j.cmet.2017.04.011
   Ferrannini E, 2016, DIABETES, V65, P1190, DOI 10.2337/db15-1356
   Ferrannini E, 2014, J CLIN INVEST, V124, P499, DOI 10.1172/JCI72227
   Fitchett D, 2019, DIABETES OBES METAB, V21, P34, DOI 10.1111/dom.13611
   Fralick M, 2020, DIABETES OBES METAB, V22, P755, DOI 10.1111/dom.13959
   Geerlings S, 2014, DIABETES RES CLIN PR, V103, P373, DOI 10.1016/j.diabres.2013.12.052
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Halden TAS, 2019, DIABETES CARE, V42, P1067, DOI 10.2337/dc19-0093
   Hamblin PS, 2019, J CLIN ENDOCR METAB, V104, P3077, DOI 10.1210/jc.2019-00139
   Handelsman Y, 2016, ENDOCR PRACT, V22, P753, DOI 10.4158/EP161292.PS
   Heerspink HJL, 2020, NEPHROL DIAL TRANSPL, V35, P274, DOI 10.1093/ndt/gfz290
   Heyman SN, 2017, DIABETES CARE, V40, pE40, DOI 10.2337/dc16-2200
   Hidayat K, 2019, OSTEOPOROSIS INT, V30, P1923, DOI 10.1007/s00198-019-04968-x
   Inzucchi SE, 2018, CIRCULATION, V138, P1904, DOI 10.1161/CIRCULATIONAHA.118.035759
   Inzucchi SE, 2018, DIABETES CARE, V41, pE4, DOI 10.2337/dc17-1551
   Isaacs M, 2017, INTERN MED J, V47, P701, DOI 10.1111/imj.13442
   Janssen Pharmaceuticals Inc., 2020, INV CAN TABL FULL PR
   Jardine MJ, 2020, J AM SOC NEPHROL, V31, P1128, DOI 10.1681/ASN.2019111168
   Kasichayanula S, 2013, BRIT J CLIN PHARMACO, V76, P432, DOI 10.1111/bcp.12056
   Kohan DE, 2014, KIDNEY INT, V85, P962, DOI 10.1038/ki.2013.356
   Kumbhani DJ, 2020, EVALUATION ERTUGLIFL
   Lega IC, 2019, DIABETES OBES METAB, V21, P2394, DOI 10.1111/dom.13820
   Li XY, 2019, DIABETES-METAB RES, V35, DOI 10.1002/dmrr.3170
   Liu JL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02733-w
   Gorriz JL, 2020, NEPHROL DIAL TRANSPL, V35, P13, DOI 10.1093/ndt/gfz237
   Lupsa BC, 2018, DIABETOLOGIA, V61, P2118, DOI 10.1007/s00125-018-4663-6
   Macha S, 2014, DIABETES OBES METAB, V16, P215, DOI 10.1111/dom.12182
   Matthews DR, 2019, DIABETOLOGIA, V62, P926, DOI 10.1007/s00125-019-4839-8
   Mayer GJ, 2019, KIDNEY INT, V96, P489, DOI 10.1016/j.kint.2019.02.033
   McGovern AP, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001238
   McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303
   Merck Sharp & Dohme (Australia) Pty Limited, 2019, AUSTR PROD INF STEGL
   Meyer EJ, 2018, DIABETES CARE, V41, pE47, DOI 10.2337/dc17-1721
   Milder TY, 2019, EUR J CLIN PHARMACOL, V75, P1481, DOI 10.1007/s00228-019-02732-y
   Monteiro-Soares M, 2019, DIABETOLOGIA, V62, P900, DOI 10.1007/s00125-019-4861-x
   Neal B, 2017, NEW ENGL J MED, V377, P644, DOI 10.1056/NEJMoa1611925
   Neuen BL, 2019, LANCET DIABETES ENDO, V7, P845, DOI 10.1016/S2213-8587(19)30256-6
   Neuen BL, 2020, NEPHROL DIAL TRANSPL, V35, P48, DOI 10.1093/ndt/gfz252
   Neuen BL, 2018, CIRCULATION, V138, P1537, DOI 10.1161/CIRCULATIONAHA.118.035901
   Neumiller JJ, 2019, CLIN J AM SOC NEPHRO, V14, P1667, DOI 10.2215/CJN.05340419
   Packer M, 2020, NEW ENGL J MED, V383, P1413, DOI 10.1056/NEJMoa2022190
   Perkovic V, 2019, NEW ENGL J MED, V380, P2295, DOI 10.1056/NEJMoa1811744
   Phadke G, 2020, AM J KIDNEY DIS, V76, P144, DOI 10.1053/j.ajkd.2020.01.015
   Polidori D, 2018, DIABETES OBES METAB, V20, P1321, DOI 10.1111/dom.13224
   Potier L, 2019, DIABETOLOGIA, V62, P939, DOI 10.1007/s00125-019-4835-z
   Rieg T, 2018, DIABETOLOGIA, V61, P2079, DOI 10.1007/s00125-018-4654-7
   Rodrigues CF, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010076
   Sahasrabudhe V, 2017, J CLIN PHARMACOL, V57, P1432, DOI 10.1002/jcph.955
   Saran R, 2020, AM J KIDNEY DIS, V75, pSVI, DOI 10.1053/j.ajkd.2019.09.003
   Sato Y, 2020, DIABETES OBES METAB, V22, P222, DOI 10.1111/dom.13890
   Toyama T, 2019, DIABETES OBES METAB, V21, P1237, DOI 10.1111/dom.13648
   Triantafylidis Laura K, 2019, J Pharm Pract, p897190019876499, DOI 10.1177/0897190019876499
   Tuttle KR, 2020, CLIN J AM SOC NEPHRO, V15, P285, DOI 10.2215/CJN.07730719
   U.S. Food and Drug Administration, 2018, FDA WARNS RAR OCC SE
   U.S. Food and Drug Administration (FDA), 2015, FDA DRUG SAF COMM FD
   Ueda P, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4365
   US Food and Drug Administration, 2016, FDA DRUG SAF COMM FD
   van Bommel EJM, 2020, KIDNEY INT, V97, P202, DOI 10.1016/j.kint.2019.09.013
   Vardeny O, 2019, JACC-HEART FAIL, V7, P169, DOI 10.1016/j.jchf.2018.11.013
   Vinke JSJ, 2019, CURR OPIN NEPHROL HY, V28, P321, DOI 10.1097/MNH.0000000000000505
   Wanner C, 2018, CIRCULATION, V137, P119, DOI 10.1161/CIRCULATIONAHA.117.028268
   Wanner C, 2016, NEW ENGL J MED, V375, P323, DOI [10.1056/NEJMoa1515920, 10.1056/NEJMc1611290]
   Watts NB, 2016, J CLIN ENDOCR METAB, V101, P156, DOI 10.1210/jc.2015-3167
   Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI 10.1056/NEJMoa1812389
   Zaccardi F, 2016, DIABETES OBES METAB, V18, P783, DOI 10.1111/dom.12670
   Zelniker TA, 2019, LANCET, V393, P31, DOI 10.1016/S0140-6736(18)32590-X
   Zinman B, 2015, NEW ENGL J MED, V373, P2117, DOI 10.1056/NEJMoa1504720
NR 93
TC 0
Z9 0
U1 1
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD DEC
PY 2020
VL 43
IS 12
BP 1211
EP 1221
DI 10.1007/s40264-020-01010-6
EA OCT 2020
PG 11
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA OW1DX
UT WOS:000582104000002
PM 33095409
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mayer, CS
   Huser, V
AF Mayer, Craig S.
   Huser, Vojtech
TI Computerized monitoring of COVID-19 trials, studies and registries in
   ClinicalTrials.gov registry
SO PEERJ
LA English
DT Article
DE COVID-19; Clinical trials; Data science
AB Clinical trial registries can provide important information about relevant studies for a given condition to other researchers and the public. We developed a computerized informatics based approach to provide an overview and analysis of COVID-19 studies registered on ClinicalTrials.gov registry. Using the perspective of analyzing active or completed COVID-19 studies, we identified 401 interventional clinical trials, 287 observational studies and 64 registries. We analyzed features of each study type separately such as location, design, interventions and update history. Our results show that the United States had the most COVID-19 interventional trials, France had the most COVID-19 observational studies and France and the United States tied for the most COVID-19 registries on ClinicalTrials.gov. The majority of studies in all three study types had a single study site. For update history "Study Status" is the most updated information and we found that studies located in Canada (2.70 updates per study) and the United States (1.76 updates per study) update their studies more often than studies in any other country. Using normalization and mapping techniques, we identified Hydroxychloroquine (92 studies) as the most common drug intervention, while convalescent plasma (20 studies) is the most common biological intervention. The primary purpose of most interventional trials is for treatment with 298 studies (74.3%). For COVID-19 registries we found the most common proposed follow-up time is 1 year (15 studies). Of specific importance and interest is COVID-19 vaccine trials, of which 12 were identified. Our informatics based approach allows for constant monitoring and updating as well as multiple applications to other conditions and interests.
C1 [Mayer, Craig S.; Huser, Vojtech] NIH, Lister Hill Natl Ctr Biomed Commun, NLM, Bldg 10, Bethesda, MD 20892 USA.
RP Mayer, CS (corresponding author), NIH, Lister Hill Natl Ctr Biomed Commun, NLM, Bldg 10, Bethesda, MD 20892 USA.
EM craig.mayer2@nih.gov
FU Intramural Research Program of the National Institutes of Health
   (NIH)/National Library of Medicine (NLM)/Lister Hill National Center for
   Biomedical Communications (LHNCBC)
FX This research was supported by the Intramural Research Program of the
   National Institutes of Health (NIH)/National Library of Medicine
   (NLM)/Lister Hill National Center for Biomedical Communications
   (LHNCBC). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR AACT Team, 2020, AGGR AN CLIN GOV AAA
   Cepeda MS, 2013, CLIN TRIALS, V10, P347, DOI 10.1177/1740774513475849
   Checcucci Enrico, 2020, Panminerva Med, DOI 10.23736/S0031-0808.20.03958-0
   CTG Team, 2020, CLIN GOV API HOM
   CTG Team, 2020, DEF
   Embi PJ, 2009, J AM MED INFORM ASSN, V16, P316, DOI 10.1197/jamia.M3005
   Fleminger J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193088
   Fragkou PC, 2020, CLIN MICROBIOL INFEC, V26, P988, DOI 10.1016/j.cmi.2020.05.019
   Huser V, 2013, J AM MED INFORM ASSN, V20, pE169, DOI 10.1136/amiajnl-2012-001501
   Moore JH, 2020, BIODATA MIN, V13, DOI 10.1186/s13040-020-00213-y
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Zarin DA, 2019, NEW ENGL J MED, V381, P1966, DOI 10.1056/NEJMsr1907644
NR 12
TC 0
Z9 0
U1 2
U2 2
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD OCT 23
PY 2020
VL 8
AR e10261
DI 10.7717/peerj.10261
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OH0AJ
UT WOS:000582235300006
PM 33150094
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rouphael, C
   D'Amico, G
   Ricci, K
   Cywinski, J
   Miranda, C
   Koval, C
   Duggal, A
   Quintini, C
   Menon, KVN
   Miller, C
   Esfeh, JM
AF Rouphael, Carol
   D'Amico, Giuseppe
   Ricci, Kristin
   Cywinski, Jacek
   Miranda, Cyndee
   Koval, Christine
   Duggal, Abhijit
   Quintini, Cristiano
   Menon, K. V. Narayanan
   Miller, Charles
   Modaresi Esfeh, Jamak
TI Successful orthotopic liver transplantation in a patient with a positive
   SARS-CoV2 test and acute liver failure secondary to acetaminophen
   overdose
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article; Early Access
DE clinical research; practice; drug toxicity; fulminant hepatic failure;
   infection and infectious agents &#8211; viral; infectious disease; liver
   transplantation; hepatology; plasmapheresis; plasma exchange
AB SARS-CoV2, first described in December 2019, was declared a pandemic by the World Health Organization in March 2020. Various surgical and medical societies promptly published guidelines, based on expert opinion, on managing patients with COVID-19, with a consensus to postpone elective surgeries and procedures. We describe the case of an orthotopic liver transplantation (OLT) in a young female who presented with acute liver failure secondary to acetaminophen toxicity to manage abdominal pain and in the setting of a positive SARS-CoV2 test. Despite a positive test, she had no respiratory symptoms at time of presentation. The positive test was thought to be residual viral load. The patient had a very favorable outcome, likely related to multiple factors including her young age, lack of respiratory COVID-19 manifestations and plasma exchange peri-operatively. We recommend a full work-up for OLT in COVID-19 patients with uncomplicated disease according to standard of care, with careful interpretation of COVID-19 testing in patients presenting with conditions requiring urgent or emergent surgery as well as repeat testing even a few days after initial testing, as this could alter management.
C1 [Rouphael, Carol; Menon, K. V. Narayanan; Modaresi Esfeh, Jamak] Cleveland Clin, Dept Gastroenterol & Hepatol, Digest Dis & Surg Inst, Cleveland, OH 44106 USA.
   [D'Amico, Giuseppe; Quintini, Cristiano; Miller, Charles] Cleveland Clin, Dept Gen Surg, Digest Dis & Surg Inst, Transplantat Ctr, Cleveland, OH 44106 USA.
   [Ricci, Kristin] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA.
   [Cywinski, Jacek] Cleveland Clin, Anesthesiol Inst, Dept Gen Anesthesiol, Cleveland, OH 44106 USA.
   [Miranda, Cyndee; Koval, Christine] Cleveland Clin, Dept Infect Dis, Cleveland, OH 44106 USA.
   [Duggal, Abhijit] Cleveland Clin, Dept Crit Care, Cleveland, OH 44106 USA.
RP Esfeh, JM (corresponding author), Cleveland Clin, Dept Gastroenterol & Hepatol, Digest Dis & Surg Inst, Cleveland, OH 44106 USA.
EM modarej@ccf.org
CR American College of Surgeons, COVID 19 REC MAN EL
   American Society of Transplant Surgeons, REENG ORG TRANSPL CO
   Cai QX, 2020, J HEPATOL, V73, P566, DOI 10.1016/j.jhep.2020.04.006
   COVIDsurg Collaborative, 2020, LANCET, V396, P27, DOI 10.1016/S0140-6736(20)31182-X
   Feng GZ, 2020, CASE STUD THERM ENG, V21, DOI 10.1016/j.csite.2020.100685
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han CQ, 2020, AM J GASTROENTEROL, V115, P916, DOI 10.14309/ajg.0000000000000664
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Keith P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2836-4
   Nahshon C, 2020, WORLD J SURG, V44, P2477, DOI 10.1007/s00268-020-05575-2
   World Health Organization, WHO COR DIS COVID 19
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
NR 13
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
DI 10.1111/ajt.16330
EA OCT 2020
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OG0YS
UT WOS:000581621400001
PM 33017864
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Masih, A
   Agnihotri, AK
   Srivastava, JK
   Pandey, N
   Bhat, HR
   Singh, UP
AF Masih, Anup
   Agnihotri, Amol K.
   Srivastava, Jitendra K.
   Pandey, Nidhi
   Bhat, Hans R.
   Singh, Udaya P.
TI Discovery of novel pyrazole derivatives as a potent anti-inflammatory
   agent in RAW264.7 cells via inhibition of NF-kappa B for possible
   benefit against SARS-CoV-2
SO JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
LA English
DT Article; Early Access
DE docking; inflammation; NF-kappa B; pyrazole; SARS-CoV-2
ID CYTOKINE STORM; COVID-19; DESIGN; ANTIBACTERIAL; INFLAMMATION; DOCKING;
   PATHWAY
AB Due to unavailability of a specific drug/vaccine to attenuate severe acute respiratory syndrome coronavirus 2, the current strategy to combat the infection has been largely dependent upon the use of anti-inflammatory drugs to control cytokines storm responsible for respiratory depression. Thus, in this study, we discovered novel pyrazole analogs as a potent nuclear factor kappa B (NF-kappa B) inhibitor. The compounds were assessed for NF-kappa B transcriptional inhibitory activity in RAW264.7 cells after stimulation with lipopolysaccharides (LPS), revealing Compound 6c as the most potent analog among the tested series. The effect of Compound 6c was further investigated on the levels of interleukin-1 beta, tumor necrosis factor-alpha, and interleukin-6 in LPS-stimulated RAW267.4 cells by enzyme immunoassay, where it causes a significant reduction in the level of these cytokines. In Western blot analysis, Compound 6c also causes the inhibition of inhibitor kappa B-alpha and NF-kappa B. It was found to be snugly fitted into the inner grove of the active site of NF-kappa B by forming H-bonds and a nonbonded interaction with Asn28 in a docking analysis.
C1 [Masih, Anup; Agnihotri, Amol K.; Srivastava, Jitendra K.; Singh, Udaya P.] Sam Higginbottom Univ Agr Technol & Sci, Dept Pharmaceut Sci, Drug Design & Discovery Lab, Allahabad 211007, Uttar Pradesh, India.
   [Pandey, Nidhi] Univ Rovira & Virgili, Dept Med & Hlth Sci, Tarragona, Spain.
   [Bhat, Hans R.] Dibrugarh Univ, Dept Pharmaceut Sci, Dibrugarh, Assam, India.
RP Singh, UP (corresponding author), Sam Higginbottom Univ Agr Technol & Sci, Dept Pharmaceut Sci, Drug Design & Discovery Lab, Allahabad 211007, Uttar Pradesh, India.
EM udaysingh98@gmail.com
CR Ansari A, 2017, NEW J CHEM, V41, P16, DOI 10.1039/c6nj03181a
   Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Dubey V, 2012, CHEM BIOL DRUG DES, V80, P598, DOI 10.1111/j.1747-0285.2012.01433.x
   Faria JV, 2017, BIOORGAN MED CHEM, V25, P5891, DOI 10.1016/j.bmc.2017.09.035
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Kerru N, 2020, MOLECULES, V25, DOI 10.3390/molecules25081909
   Khan MF, 2016, EUR J MED CHEM, V120, P170, DOI 10.1016/j.ejmech.2016.04.077
   Lawrence T, 2009, COLD SPRING HARB PER, V1, pa1651
   Li FY, 2012, INFLAMMATION, V35, P1669, DOI 10.1007/s10753-012-9483-0
   Li M, 2014, EUR J MED CHEM, V85, P311, DOI 10.1016/j.ejmech.2014.07.102
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Neumann M, 2007, FASEB J, V21, P2642, DOI 10.1096/fj.06-7615rev
   Newton K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006049
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Pippione AC, 2018, MEDCHEMCOMM, V9, P963, DOI 10.1039/c8md00068a
   Qiao L, 2019, HETEROCYCL COMMUN, V25, P66, DOI 10.1515/hc-2019-0012
   Rahman Arshad, 2011, Proc Am Thorac Soc, V8, P497, DOI 10.1513/pats.201101-009MW
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Sahu S, 2019, PHARMACOL REP, V71, P762, DOI 10.1016/j.pharep.2019.04.006
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Si WJ, 2019, NEW J CHEM, V43, P3000, DOI 10.1039/c8nj05150j
   Simmonds RE, 2008, RHEUMATOLOGY, V47, P584, DOI 10.1093/rheumatology/kem298
   Singh B, 2014, BIOORG MED CHEM LETT, V24, P3321, DOI 10.1016/j.bmcl.2014.05.103
   Singh UP, 2014, AIDS RES HUM RETROV, V30, pA206, DOI 10.1089/aid.2014.5446.abstract
   Singh UP, 2013, RSC ADV, V3, P17335, DOI 10.1039/c3ra41604f
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Srivastava JK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05934-5
   Srivastava JK, 2015, RSC ADV, V5, P88710, DOI 10.1039/c5ra09250g
   Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52
   Sun XJ, 2020, CYTOKINE GROWTH F R, V53, P38, DOI 10.1016/j.cytogfr.2020.04.002
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Vaninov Natalie, 2020, Nat Rev Immunol, V20, P277, DOI 10.1038/s41577-020-0305-6
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Wu YC, 2020, J CHIN MED ASSOC, V83, P217, DOI 10.1097/JCMA.0000000000000270
   Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Ying XZ, 2013, CELL IMMUNOL, V285, P49, DOI 10.1016/j.cellimm.2013.09.001
NR 42
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1095-6670
EI 1099-0461
J9 J BIOCHEM MOL TOXIC
JI J. Biochem. Mol. Toxicol.
AR e22656
DI 10.1002/jbt.22656
EA OCT 2020
PG 9
WC Biochemistry & Molecular Biology; Toxicology
SC Biochemistry & Molecular Biology; Toxicology
GA OF2XT
UT WOS:000581078000001
PM 33094891
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Marino, D
   Finotto, S
   Basso, U
   Galiano, A
   Bolshinsky, M
   Amato, O
   Marson, P
   Tison, T
   Colpo, A
   Zagonel, V
AF Marino, Dario
   Finotto, Silvia
   Basso, Umberto
   Galiano, Antonella
   Bolshinsky, Maital
   Amato, Ottavia
   Marson, Piero
   Tison, Tiziana
   Colpo, Anna
   Zagonel, Vittorina
TI To Transplant or Not to Transplant During the SARS-CoV-2 Pandemic? That
   Is the Question
SO ONCOLOGIST
LA English
DT Article; Early Access
ID CELLULAR THERAPY; COVID-19
AB The novel coronavirus disease 2019 has grown to be a global public health emergency. The rapid spread of the infection has raised many questions in the oncohematological scientific community regarding the appropriateness of high-dose chemotherapy with autologous stem cell transplantation (ASCT). We here report two cases of patients who received ASCT at our Institute during the epidemic in Italy, affected with Hodgkin lymphoma and germ cell tumor, respectively. The two patients underwent a nasopharyngeal swab for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on hospital admittance and during the period of bone marrow aplasia. They were attended to exclusively by dedicated health care staff who followed specifically implemented protocols for bedside nursing and care. They completed the procedure without unexpected side effect. Our experience demonstrates how ASCT can be performed safely if procedures are reorganized ad hoc to reduce the risk of SARS-CoV-2 infection.
C1 [Marino, Dario; Finotto, Silvia; Basso, Umberto; Galiano, Antonella; Bolshinsky, Maital; Amato, Ottavia; Zagonel, Vittorina] Ist Ric Cura Carattere Sci, Veneto Inst Oncol IOV, Med Oncol Unit 1, Dept Clin & Expt Oncol, Padua, Italy.
   [Marson, Piero; Tison, Tiziana; Colpo, Anna] Univ Hosp Padua, Dept Transfus Med, Padua, Italy.
RP Marino, D (corresponding author), IRCCS, IOV, Veneto Inst Oncol, Dept Clin & Expt Oncol,Med Oncol Unit 1, Padua, Italy.
EM dario.marino@iov.veneto.it
CR [Anonymous], 1997, J Clin Oncol, V15, P594
   Barrington SF, 2016, BLOOD, V127, P1531, DOI 10.1182/blood-2015-11-679407
   Dholaria B, 2020, BRIT J HAEMATOL, V189, P239, DOI 10.1111/bjh.16597
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kalra M, 2020, CANCER-AM CANCER SOC, V126, P1202, DOI 10.1002/cncr.32628
   Mahmoudjafari Z, 2020, BIOL BLOOD MARROW TR, V26, P1043, DOI 10.1016/j.bbmt.2020.04.005
   Sainati L, 2020, BRIT J HAEMATOL, V189, P640, DOI 10.1111/bjh.16699
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
NR 9
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
DI 10.1002/onco.13563
EA OCT 2020
PG 2
WC Oncology
SC Oncology
GA OF3SG
UT WOS:000581131400001
PM 33044758
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Dinnon, KH
   Leist, SR
   Schafer, A
   Edwards, CE
   Martinez, DR
   Montgomery, SA
   West, A
   Yount, BL
   Hou, YXJ
   Adams, LE
   Gully, KL
   Brown, AJ
   Huang, E
   Bryant, MD
   Choong, IC
   Glenn, JS
   Gralinski, LE
   Sheahan, TP
   Baric, RS
AF Dinnon, Kenneth H.
   Leist, Sarah R.
   Schafer, Alexandra
   Edwards, Caitlin E.
   Martinez, David R.
   Montgomery, Stephanie A.
   West, Ande
   Yount, Boyd L., Jr.
   Hou, Yixuan J.
   Adams, Lily E.
   Gully, Kendra L.
   Brown, Ariane J.
   Huang, Emily
   Bryant, Matthew D.
   Choong, Ingrid C.
   Glenn, Jeffrey S.
   Gralinski, Lisa E.
   Sheahan, Timothy P.
   Baric, Ralph S.
TI A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
SO NATURE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; LENGTH INFECTIOUS CDNA; RANDOMIZED PHASE 2B;
   REVERSE GENETICS; CORONAVIRUS; SARS; LAMBDA; IFN; TRANSMISSION;
   PROTECTION
AB Coronaviruses are prone to transmission to new host species, as recently demonstrated by the spread to humans of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic(1). Small animal models that recapitulate SARS-CoV-2 disease are needed urgently for rapid evaluation of medical countermeasures(2,3). SARS-CoV-2 cannot infect wild-type laboratory mice owing to inefficient interactions between the viral spike protein and the mouse orthologue of the human receptor, angiotensin-converting enzyme 2 (ACE2)4. Here we used reverse genetics(5) to remodel the interaction between SARS-CoV-2 spike protein and mouse ACE2 and designed mouse-adapted SARS-CoV-2 (SARS-CoV-2 MA), a recombinant virus that can use mouse ACE2 for entry into cells. SARS-CoV-2 MA was able to replicate in the upper and lower airways of both young adult and aged BALB/c mice. SARS-CoV-2 MA caused more severe disease in aged mice, and exhibited more clinically relevant phenotypes than those seen in Hfh4-ACE2 transgenic mice, which express human ACE2 under the control of the Hfh4 (also known as Foxj1) promoter. We demonstrate the utility of this model using vaccine-challenge studies in immune-competent mice with native expression of mouse ACE2. Finally, we show that the clinical candidate interferon-lambda 1a (IFN-lambda 1a) potently inhibits SARS-CoV-2 replication in primary human airway epithelial cells in vitro-both prophylactic and therapeutic administration of IFN-lambda 1a diminished SARS-CoV-2 replication in mice. In summary, the mouse-adapted SARS-CoV-2 MA model demonstrates age-related disease pathogenesis and supports the clinical use of pegylated IFN-lambda 1a as a treatment for human COVID-19(6).
C1 [Dinnon, Kenneth H.; Adams, Lily E.; Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA.
   [Leist, Sarah R.; Schafer, Alexandra; Edwards, Caitlin E.; Martinez, David R.; West, Ande; Yount, Boyd L., Jr.; Hou, Yixuan J.; Gully, Kendra L.; Brown, Ariane J.; Huang, Emily; Gralinski, Lisa E.; Sheahan, Timothy P.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.
   [Montgomery, Stephanie A.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA.
   [Bryant, Matthew D.; Choong, Ingrid C.] Eiger BioPharmaceut, Palo Alto, CA USA.
   [Glenn, Jeffrey S.] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
   [Glenn, Jeffrey S.] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA.
   [Glenn, Jeffrey S.] Palo Alto Vet Adm, Palo Alto, CA USA.
   [Baric, Ralph S.] Univ N Carolina, Rapidly Emerging Antiviral Drug Discovery Initiat, Chapel Hill, NC 27515 USA.
RP Baric, RS (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA.; Baric, RS (corresponding author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.; Baric, RS (corresponding author), Univ N Carolina, Rapidly Emerging Antiviral Drug Discovery Initiat, Chapel Hill, NC 27515 USA.
EM rbaric@email.unc.edu
RI Hou, Yixuan/P-6443-2019
OI Hou, Yixuan/0000-0002-8323-7243; Dinnon, Kenneth/0000-0002-8942-1551
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human Service award [1U19
   AI142759, 5R01AI132178]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HHSN272201700036I,
   DK065988]; North Carolina Policy Collaboratory at the University of
   North Carolina at Chapel Hill; North Carolina Coronavirus Relief Fund;
   NIH NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [T32 AI007419, T32 AI007151]; Burroughs
   Wellcome Fund Postdoctoral Enrichment Program AwardBurroughs Wellcome
   Fund; Cystic Fibrosis Foundation [BOUCHE15RO]; NCI Center Core Support
   Grant [5P30CA016086-41]
FX This project was funded in part by the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health, Department of Health
   and Human Service award: 1U19 AI142759 (Antiviral Drug Discovery and
   Development Center awarded to R.S.B.); 5R01AI132178 (partnership grant
   awarded to T.P.S. and R.S.B.) and an animal models contract from the NIH
   (HHSN272201700036I). This project was supported in part by the North
   Carolina Policy Collaboratory at the University of North Carolina at
   Chapel Hill with funding from the North Carolina Coronavirus Relief Fund
   established and appropriated by the North Carolina General Assembly.
   K.H.D. is funded by an NIH NIAID T32 AI007419. D.R.M. is funded by an
   NIH NIAID T32 AI007151 and a Burroughs Wellcome Fund Postdoctoral
   Enrichment Program Award. The Marsico Lung Institute Tissue Procurement
   and Cell Culture Core is supported by NIH grant DK065988 and Cystic
   Fibrosis Foundation grant BOUCHE15RO. Animal histopathology service was
   performed by D. Hilliard and L. Wang in the Animal Histopathology and
   Laboratory Medicine Core at the University of North Carolina, which is
   supported in part by an NCI Center Core Support Grant (5P30CA016086-41)
   to the UNC Lineberger Comprehensive Cancer Center.
CR Abdi K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03812-w
   Agnihothram S, 2018, J VIROL, V92, DOI [10.1128/JVI.00027-18, 10.1128/jvi.00027-18]
   Andreakos E, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012465
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Chan HLY, 2016, J HEPATOL, V64, P1011, DOI 10.1016/j.jhep.2015.12.018
   Corbett Kizzmekia S, 2020, Nature, V586, P567, DOI 10.1038/s41586-020-2622-0
   Davidson S, 2016, EMBO MOL MED, V8, P1099, DOI 10.15252/emmm.201606413
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Elazar M, 2017, CURR OPIN VIROL, V24, P55, DOI 10.1016/j.coviro.2017.04.004
   Felgenhauer U., 2020, J BIOL CHEM
   Fulcher M Leslie, 2005, Methods Mol Med, V107, P183
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042
   Humeniuk R, 2020, CTS-CLIN TRANSL SCI, V13, P896, DOI 10.1111/cts.12840
   Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI [10.1073/pnas.2009799117/-/DCSupplemental., 10.1073/pnas.2009799117]
   Israelow Benjamin, 2020, J Exp Med, V217, DOI 10.1084/jem.20201241
   Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li L, 2017, ANTIVIR RES, V140, P76, DOI 10.1016/j.antiviral.2017.01.012
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Menachery VD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131451
   Mordstein M, 2010, J VIROL, V84, P5670, DOI 10.1128/JVI.00272-10
   Muir AJ, 2014, J HEPATOL, V61, P1238, DOI 10.1016/j.jhep.2014.07.022
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Ostrowski LE, 2003, MOL THER, V8, P637, DOI 10.1016/S1525-0016(03)00221-1
   Roberts A, 2005, J VIROL, V79, P5833, DOI 10.1128/JVI.79.9.5833-5838.2005
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Rockx B, 2010, J INFECT DIS, V201, P946, DOI 10.1086/651022
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Sui JH, 2014, J VIROL, V88, P13769, DOI 10.1128/JVI.02232-14
   Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010
   Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Yu P., 2020, EXP MED, V3, P93
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zost SJ, 2020, NATURE, DOI 10.1038/s41586-020-2548-6
NR 48
TC 10
Z9 8
U1 13
U2 13
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD OCT 22
PY 2020
VL 586
IS 7830
BP 560
EP +
DI 10.1038/s41586-020-2708-8
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OE6NR
UT WOS:000580645800032
PM 32854108
OA Bronze
DA 2021-01-01
ER

PT J
AU Yang, JY
   Wang, W
   Chen, ZM
   Lu, SY
   Yang, FL
   Bi, ZF
   Bao, LL
   Mo, F
   Li, X
   Huang, Y
   Hong, WQ
   Yang, Y
   Zhao, Y
   Ye, F
   Lin, S
   Deng, W
   Chen, H
   Lei, H
   Zhang, ZQ
   Luo, M
   Gao, H
   Zheng, Y
   Gong, YQ
   Jiang, XH
   Xu, YF
   Lv, Q
   Li, D
   Wang, MN
   Li, FD
   Wang, SY
   Wang, GP
   Yu, P
   Qu, YJ
   Yang, L
   Deng, HX
   Tong, AP
   Li, J
   Wang, ZL
   Yang, JL
   Shen, GB
   Zhao, ZW
   Li, YH
   Luo, JW
   Liu, HQ
   Yu, WH
   Yang, ML
   Xu, JW
   Wang, JB
   Li, HY
   Wang, HX
   Kuang, DX
   Lin, PP
   Hu, ZT
   Guo, W
   Cheng, W
   He, YL
   Song, XR
   Chen, C
   Xue, ZH
   Yao, SH
   Chen, L
   Ma, XL
   Chen, SY
   Gou, ML
   Huang, WJ
   Wang, YC
   Fan, CF
   Tian, ZX
   Shi, M
   Wang, FS
   Dai, LZ
   Wu, M
   Li, G
   Wang, GY
   Peng, Y
   Qian, ZY
   Huang, CH
   Lau, JYN
   Yang, ZL
   Wei, YQ
   Cen, XB
   Peng, XZ
   Qin, C
   Zhang, K
   Lu, GW
   Wei, XW
AF Yang, Jingyun
   Wang, Wei
   Chen, Zimin
   Lu, Shuaiyao
   Yang, Fanli
   Bi, Zhenfei
   Bao, Linlin
   Mo, Fei
   Li, Xue
   Huang, Yong
   Hong, Weiqi
   Yang, Yun
   Zhao, Yuan
   Ye, Fei
   Lin, Sheng
   Deng, Wei
   Chen, Hua
   Lei, Hong
   Zhang, Ziqi
   Luo, Min
   Gao, Hong
   Zheng, Yue
   Gong, Yanqiu
   Jiang, Xiaohua
   Xu, Yanfeng
   Lv, Qi
   Li, Dan
   Wang, Manni
   Li, Fengdi
   Wang, Shunyi
   Wang, Guanpeng
   Yu, Pin
   Qu, Yajin
   Yang, Li
   Deng, Hongxin
   Tong, Aiping
   Li, Jiong
   Wang, Zhenling
   Yang, Jinliang
   Shen, Guobo
   Zhao, Zhiwei
   Li, Yuhua
   Luo, Jingwen
   Liu, Hongqi
   Yu, Wenhai
   Yang, Mengli
   Xu, Jingwen
   Wang, Junbin
   Li, Haiyan
   Wang, Haixuan
   Kuang, Dexuan
   Lin, Panpan
   Hu, Zhengtao
   Guo, Wei
   Cheng, Wei
   He, Yanlin
   Song, Xiangrong
   Chen, Chong
   Xue, Zhihong
   Yao, Shaohua
   Chen, Lu
   Ma, Xuelei
   Chen, Siyuan
   Gou, Maling
   Huang, Weijin
   Wang, Youchun
   Fan, Changfa
   Tian, Zhixin
   Shi, Ming
   Wang, Fu-Sheng
   Dai, Lunzhi
   Wu, Min
   Li, Gen
   Wang, Guangyu
   Peng, Yong
   Qian, Zhiyong
   Huang, Canhua
   Lau, Johnson Yiu-Nam
   Yang, Zhenglin
   Wei, Yuquan
   Cen, Xiaobo
   Peng, Xiaozhong
   Qin, Chuan
   Zhang, Kang
   Lu, Guangwen
   Wei, Xiawei
TI A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces
   protective immunity
SO NATURE
LA English
DT Article
ID RECEPTOR-BINDING DOMAIN; MERS-COV; CORONAVIRUS; SPIKE; NEUTRALIZATION;
   ANTIBODIES; MICE; RESPONSES; ALUMINUM; SUBUNIT
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a respiratory disease called coronavirus disease 2019 (COVID-19), the spread of which has led to a pandemic. An effective preventive vaccine against this virus is urgently needed. As an essential step during infection, SARS-CoV-2 uses the receptor-binding domain (RBD) of the spike protein to engage with the receptor angiotensin-converting enzyme 2 (ACE2) on host cells(1,2). Here we show that a recombinant vaccine that comprises residues 319-545 of the RBD of the spike protein induces a potent functional antibody response in immunized mice, rabbits and non-human primates (Macaca mulatta) as early as 7 or 14 days after the injection of a single vaccine dose. The sera from the immunized animals blocked the binding of the RBD to ACE2, which is expressed on the cell surface, and neutralized infection with a SARS-CoV-2 pseudovirus and live SARS-CoV-2 in vitro. Notably, vaccination also provided protection in non-human primates to an in vivo challenge with SARS-CoV-2. We found increased levels of RBD-specific antibodies in the sera of patients with COVID-19. We show that several immune pathways and CD4 T lymphocytes are involved in the induction of the vaccine antibody response. Our findings highlight the importance of the RBD domain in the design of SARS-CoV-2 vaccines and provide a rationale for the development of a protective vaccine through the induction of antibodies against the RBD domain.
C1 [Yang, Jingyun; Wang, Wei; Chen, Zimin; Yang, Fanli; Bi, Zhenfei; Mo, Fei; Li, Xue; Huang, Yong; Hong, Weiqi; Ye, Fei; Lin, Sheng; Chen, Hua; Lei, Hong; Zhang, Ziqi; Luo, Min; Zheng, Yue; Gong, Yanqiu; Jiang, Xiaohua; Li, Dan; Wang, Manni; Yang, Li; Deng, Hongxin; Tong, Aiping; Li, Jiong; Wang, Zhenling; Yang, Jinliang; Shen, Guobo; Zhao, Zhiwei; Luo, Jingwen; Lin, Panpan; Cheng, Wei; Song, Xiangrong; Chen, Chong; Xue, Zhihong; Yao, Shaohua; Chen, Lu; Ma, Xuelei; Chen, Siyuan; Gou, Maling; Dai, Lunzhi; Wu, Min; Peng, Yong; Qian, Zhiyong; Huang, Canhua; Wei, Yuquan; Cen, Xiaobo; Lu, Guangwen; Wei, Xiawei] Sichuan Univ, West China Hosp, Lab Aging Res & Canc Drug Target, State Key Lab Biotherapy & Canc Ctr,Natl Clin Res, Chengdu, Sichuan, Peoples R China.
   [Lu, Shuaiyao; Yang, Yun; Zhao, Yuan; Liu, Hongqi; Yu, Wenhai; Yang, Mengli; Xu, Jingwen; Wang, Junbin; Li, Haiyan; Wang, Haixuan; Kuang, Dexuan; Peng, Xiaozhong] Chinese Acad Med Sci, Inst Med Biol, Natl Kunming High Level Biosafety Primate Res Ctr, Yunnan, Peoples R China.
   [Lu, Shuaiyao; Yang, Yun; Zhao, Yuan; Liu, Hongqi; Yu, Wenhai; Yang, Mengli; Xu, Jingwen; Wang, Junbin; Li, Haiyan; Wang, Haixuan; Kuang, Dexuan; Peng, Xiaozhong] Peking Union Med Coll, Beijing, Peoples R China.
   [Bao, Linlin; Deng, Wei; Gao, Hong; Xu, Yanfeng; Lv, Qi; Li, Fengdi; Wang, Shunyi; Wang, Guanpeng; Yu, Pin; Qu, Yajin; Qin, Chuan] Chinese Acad Med Sci, Beijing Key Lab Anim Models Emerging & Remerging, Key Lab Human Dis Comparat Med, Chinese Minist Hlth,Inst Lab Anim Sci, Beijing, Peoples R China.
   [Bao, Linlin; Deng, Wei; Gao, Hong; Xu, Yanfeng; Lv, Qi; Li, Fengdi; Wang, Shunyi; Wang, Guanpeng; Yu, Pin; Qu, Yajin; Qin, Chuan] Peking Union Med Coll, Comparat Med Ctr, Beijing, Peoples R China.
   [Li, Yuhua; Huang, Weijin; Wang, Youchun; Fan, Changfa] Natl Inst Food & Drug Control NIFDC, Beijing, Peoples R China.
   [Hu, Zhengtao; Guo, Wei; He, Yanlin; Cen, Xiaobo] Sichuan Univ, Natl Chengdu Ctr Safety Evaluat Drugs, State Key Lab Biotherapy & Canc Ctr, West China Hosp,Collaborat Innovat Ctr Biotherapy, Chengdu, Sichuan, Peoples R China.
   [Tian, Zhixin] Tongji Univ, Sch Chem Sci & Engn, Shanghai Key Lab Chem Assessment & Sustainabil, Shanghai, Peoples R China.
   [Shi, Ming; Wang, Fu-Sheng] Fifth Med Ctr PLA Gen Hosp, Natl Clin Res Ctr Infect Dis, Treatment & Res Ctr Infect Dis, Beijing, Peoples R China.
   [Li, Gen; Zhang, Kang] Macau Univ Sci & Technol, Fac Med, Ctr Biomed & Innovat, Macau, Peoples R China.
   [Wang, Guangyu] Tsinghua Univ, Dept Comp Sci & Technol, Beijing, Peoples R China.
   [Lau, Johnson Yiu-Nam] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Peoples R China.
   [Yang, Zhenglin] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Sichuan, Peoples R China.
   [Yang, Zhenglin] Inst Lab Med, Chengdu, Sichuan, Peoples R China.
   [Peng, Xiaozhong] Chinese Acad Med Sci, Sch Basic Med, Peking Union Med Coll, State Key Lab Med Mol Biol, Beijing, Peoples R China.
   [Lu, Guangwen] Sichuan Univ, West China Hosp, Emergency Dept, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China.
RP Lu, GW; Wei, XW (corresponding author), Sichuan Univ, West China Hosp, Lab Aging Res & Canc Drug Target, State Key Lab Biotherapy & Canc Ctr,Natl Clin Res, Chengdu, Sichuan, Peoples R China.; Zhang, K (corresponding author), Macau Univ Sci & Technol, Fac Med, Ctr Biomed & Innovat, Macau, Peoples R China.; Lu, GW (corresponding author), Sichuan Univ, West China Hosp, Emergency Dept, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China.
EM kang.zhang@gmail.com; lugw@scu.edu.cn; xiaweiwei@scu.edu.cn
RI qin, chuan/ABG-4508-2020; Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697
FU National Key Research and Development Program of China [2016YFA0201402];
   National Natural Science Foundation Regional Innovation and Development
   [U19A2003]; National Major Scientific and Technological Special Project
   for 'Significant New Drugs Development' [2018ZX09733001]; Ministry of
   Science and Technology, National Health Commission, Ministry of
   Education of the People's Republic of China, Sichuan province; National
   Key Research and Development Project of China [2016YFD0500304]; Sichuan
   province [2020YFS0010]; West China Hospital Sichuan UniversitySichuan
   University [HX-2019-nCoV-004]; Macao Science and Technology Development
   Fund (FDCT)
FX We thank Z. Li, G. Wei, Q. Chen, H. Yan, X. Zhou, X. Wu, F. Fu, H. Yang
   and X. Wu for assisting with the maintenance of the mouse facility, the
   collection of sera, and providing cell culture, ELISA assays and other
   technical support. This work was supported by the National Key Research
   and Development Program of China (2016YFA0201402), National Natural
   Science Foundation Regional Innovation and Development (U19A2003), the
   National Major Scientific and Technological Special Project for
   `Significant New Drugs Development' (2018ZX09733001), the projects for
   the vaccine by the Ministry of Science and Technology, National Health
   Commission, Ministry of Education of the People's Republic of China,
   Sichuan province, National Key Research and Development Project of China
   (2016YFD0500304). The special research fund on COVID-19 of Sichuan
   province (2020YFS0010), the special research fund on COVID-19 of West
   China Hospital Sichuan University (HX-2019-nCoV-004) and Macao Science
   and Technology Development Fund (FDCT).
CR Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Contreras-Gomez A, 2014, BIOTECHNOL PROGR, V30, P1, DOI 10.1002/btpr.1842
   Cox MMJ, 2011, J INVERTEBR PATHOL, V107, pS31, DOI 10.1016/j.jip.2011.05.003
   Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Guo YJ, 2005, DNA CELL BIOL, V24, P510, DOI 10.1089/dna.2005.24.510
   Gupta M, 2001, J VIROL, V75, P4649, DOI 10.1128/JVI.75.10.4649-4654.2001
   He YX, 2006, J IMMUNOL, V176, P6085, DOI 10.4049/jimmunol.176.10.6085
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu MQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00535-2
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Luo M, 2017, CELL RES, V27, P586, DOI 10.1038/cr.2017.14
   MacLeod MKL, 2011, P NATL ACAD SCI USA, V108, P7914, DOI 10.1073/pnas.1104588108
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Stadlmann J, 2017, NATURE, V549, P538, DOI 10.1038/nature24015
   Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Wang QH, 2014, CELL HOST MICROBE, V16, P328, DOI 10.1016/j.chom.2014.08.009
   Wang Y, 2020, J AM SOC MASS SPECTR, V31, P651, DOI 10.1021/jasms.9b00089
   Wang Y, 2019, CHEM COMMUN, V55, P7934, DOI 10.1039/c9cc04114a
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiao KJ, 2019, J PROTEOME RES, V18, P2885, DOI 10.1021/acs.jproteome.9b00191
   Xiao YH, 2013, VACCINE, V31, P319, DOI 10.1016/j.vaccine.2012.11.007
   Yang WM, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20188486
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 35
TC 15
Z9 15
U1 43
U2 43
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD OCT 22
PY 2020
VL 586
IS 7830
BP 572
EP +
DI 10.1038/s41586-020-2599-8
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OE6NR
UT WOS:000580645800033
PM 32726802
OA Bronze
DA 2021-01-01
ER

PT J
AU van Doremalen, N
   Lambe, T
   Spencer, A
   Belij-Rammerstorfer, S
   Purushotham, JN
   Port, JR
   Avanzato, VA
   Bushmaker, T
   Flaxman, A
   Ulaszewska, M
   Feldmann, F
   Allen, ER
   Sharpe, H
   Schulz, J
   Holbrook, M
   Okumura, A
   Meade-White, K
   Perez-Perez, L
   Edwards, NJ
   Wright, D
   Bissett, C
   Gilbride, C
   Williamson, BN
   Rosenke, R
   Long, D
   Ishwarbhai, A
   Kailath, R
   Rose, L
   Morris, S
   Powers, C
   Lovaglio, J
   Hanley, PW
   Scott, D
   Saturday, G
   de Wit, E
   Gilbert, SC
   Munster, VJ
AF van Doremalen, Neeltje
   Lambe, Teresa
   Spencer, Alexandra
   Belij-Rammerstorfer, Sandra
   Purushotham, Jyothi N.
   Port, Julia R.
   Avanzato, Victoria A.
   Bushmaker, Trenton
   Flaxman, Amy
   Ulaszewska, Marta
   Feldmann, Friederike
   Allen, Elizabeth R.
   Sharpe, Hannah
   Schulz, Jonathan
   Holbrook, Myndi
   Okumura, Atsushi
   Meade-White, Kimberly
   Perez-Perez, Lizzette
   Edwards, Nick J.
   Wright, Daniel
   Bissett, Cameron
   Gilbride, Ciaran
   Williamson, Brandi N.
   Rosenke, Rebecca
   Long, Dan
   Ishwarbhai, Alka
   Kailath, Reshma
   Rose, Louisa
   Morris, Susan
   Powers, Claire
   Lovaglio, Jamie
   Hanley, Patrick W.
   Scott, Dana
   Saturday, Greg
   de Wit, Emmie
   Gilbert, Sarah C.
   Munster, Vincent J.
TI ChAdOx1nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
SO NATURE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; IMMUNIZATION; MICE
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019(1,2) and is responsible for the coronavirus disease 2019 (COVID-19) pandemic(3). Vaccines are an essential countermeasure and are urgently needed to control the pandemic(4). Here we show that the adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS-CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response. This response was predominantly mediated by type-1 T helper cells, as demonstrated by the profiling of the IgG subclass and the expression of cytokines. Vaccination with ChAdOx1 nCoV-19 (using either a prime-only or a prime-boost regimen) induced a balanced humoral and cellular immune response of type-1 and type-2 T helper cells in rhesus macaques. We observed a significantly reduced viral load in the bronchoalveolar lavage fluid and lower respiratory tract tissue of vaccinated rhesus macaques that were challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated SARS-CoV-2-infected animals. However, there was no difference in nasal shedding between vaccinated and control SARS-CoV-2-infected macaques. Notably, we found no evidence of immune-enhanced disease after viral challenge in vaccinated SARS-CoV-2-infected animals. The safety, immunogenicity and efficacy profiles of ChAdOx1 nCoV-19 against symptomatic PCR-positive COVID-19 disease will now be assessed in randomized controlled clinical trials in humans.
C1 [van Doremalen, Neeltje; Purushotham, Jyothi N.; Port, Julia R.; Avanzato, Victoria A.; Bushmaker, Trenton; Schulz, Jonathan; Holbrook, Myndi; Okumura, Atsushi; Meade-White, Kimberly; Perez-Perez, Lizzette; Williamson, Brandi N.; de Wit, Emmie; Munster, Vincent J.] NIAID, Virol Lab, NIH, Hamilton, MT 59840 USA.
   [Lambe, Teresa; Spencer, Alexandra; Belij-Rammerstorfer, Sandra; Purushotham, Jyothi N.; Flaxman, Amy; Ulaszewska, Marta; Allen, Elizabeth R.; Sharpe, Hannah; Edwards, Nick J.; Wright, Daniel; Bissett, Cameron; Gilbride, Ciaran; Ishwarbhai, Alka; Kailath, Reshma; Rose, Louisa; Morris, Susan; Powers, Claire; Gilbert, Sarah C.] Univ Oxford, Jenner Inst, Oxford, England.
   [Feldmann, Friederike; Rosenke, Rebecca; Long, Dan; Lovaglio, Jamie; Hanley, Patrick W.; Scott, Dana; Saturday, Greg] NIAID, Rocky Mt Vet Branch, Hamilton, MT USA.
RP Munster, VJ (corresponding author), NIAID, Virol Lab, NIH, Hamilton, MT 59840 USA.; Gilbert, SC (corresponding author), Univ Oxford, Jenner Inst, Oxford, England.
EM sarah.gilbert@ndm.ox.ac.uk; vincent.munster@nih.gov
RI ; Lambe, Teresa/E-5733-2016; Munster, Vincent/I-7607-2018
OI Port, Julia Rebecca/0000-0002-0489-6591; Lambe,
   Teresa/0000-0001-7711-897X; Bissett, Cameron/0000-0003-3345-663X; Van
   Doremalen, Neeltje/0000-0003-4368-6359; Allen,
   Elizabeth/0000-0002-6406-4834; Wright, Daniel/0000-0002-8114-1838;
   Munster, Vincent/0000-0002-2288-3196; Spencer,
   Alexandra/0000-0001-7958-6961; Sharpe, Hannah/0000-0002-1194-2429
FU Intramural Research Program of the National Institute of Allergy and
   Infectious Diseases (NIAID), National Institutes of Health (NIH)
   [1ZIAAI001179-01]; Department of Health and Social Care using UK Aid
   funding
FX We thank O. Abiona, B. Bailes, A. Carmody, K. Corbett, K. Cordova, J.
   Faris, H. Feldmann, S. Gerber, B. Graham, E. Haddock, R. Kissinger, M.
   Jones, M. Marsh, K. Menk, A. Mora, S. Seifert, L. Shupert, B. Smith, N.
   Thornburg, A. Weidow, M. Woods and K. C. Yinda for their assistance
   during this study. This work was supported by the Intramural Research
   Program of the National Institute of Allergy and Infectious Diseases
   (NIAID), National Institutes of Health (NIH) (1ZIAAI001179-01) and the
   Department of Health and Social Care using UK Aid funding managed by the
   NIHR.
CR Bewig B, 2000, BIOTECHNIQUES, V28, P870, DOI 10.2144/00285bm08
   Bliss CM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21630-4
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   van Doremalen N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba8399
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   WHO, 2020, 113 WHO
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 52
Z9 49
U1 15
U2 15
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD OCT 22
PY 2020
VL 586
IS 7830
BP 578
EP +
DI 10.1038/s41586-020-2608-y
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OE6NR
UT WOS:000580645800034
PM 32731258
OA Other Gold
DA 2021-01-01
ER

PT J
AU Mercado, NB
   Zahn, R
   Wegmann, F
   Loos, C
   Chandrashekar, A
   Yu, JY
   Liu, JY
   Peter, L
   McMahan, K
   Tostanoski, LH
   He, X
   Martinez, DR
   Rutten, L
   Bos, R
   van Manen, D
   Vellinga, J
   Custers, J
   Langedijk, JP
   Kwaks, T
   Bakkers, MJG
   Zuijdgeest, D
   Huber, SKR
   Atyeo, C
   Fischinger, S
   Burke, JS
   Feldman, J
   Hauser, BM
   Caradonna, TM
   Bondzie, EA
   Dagotto, G
   Gebre, MS
   Hoffman, E
   Jacob-Dolan, C
   Kirilova, M
   Li, ZF
   Lin, ZJ
   Mahrokhian, SH
   Maxfield, LF
   Nampanya, F
   Nityanandam, R
   Nkolola, JP
   Patel, S
   Ventura, JD
   Verrington, K
   Wan, HH
   Pessaint, L
   Van Ry, A
   Blade, K
   Strasbaugh, A
   Cabus, M
   Brown, R
   Cook, A
   Zouantchangadou, S
   Teow, E
   Andersen, H
   Lewis, MG
   Cai, YF
   Chen, B
   Schmidt, AG
   Reeves, RK
   Baric, RS
   Lauffenburger, DA
   Alter, G
   Stoffels, P
   Mammen, M
   Van Hoof, J
   Schuitemaker, H
   Barouch, DH
AF Mercado, Noe B.
   Zahn, Roland
   Wegmann, Frank
   Loos, Carolin
   Chandrashekar, Abishek
   Yu, Jingyou
   Liu, Jinyan
   Peter, Lauren
   McMahan, Katherine
   Tostanoski, Lisa H.
   He, Xuan
   Martinez, David R.
   Rutten, Lucy
   Bos, Rinke
   van Manen, Danielle
   Vellinga, Jort
   Custers, Jerome
   Langedijk, Johannes P.
   Kwaks, Ted
   Bakkers, Mark J. G.
   Zuijdgeest, David
   Huber, Sietske K. Rosendahl
   Atyeo, Caroline
   Fischinger, Stephanie
   Burke, John S.
   Feldman, Jared
   Hauser, Blake M.
   Caradonna, Timothy M.
   Bondzie, Esther A.
   Dagotto, Gabriel
   Gebre, Makda S.
   Hoffman, Emily
   Jacob-Dolan, Catherine
   Kirilova, Marinela
   Li, Zhenfeng
   Lin, Zijin
   Mahrokhian, Shant H.
   Maxfield, Lori F.
   Nampanya, Felix
   Nityanandam, Ramya
   Nkolola, Joseph P.
   Patel, Shivani
   Ventura, John D.
   Verrington, Kaylee
   Wan, Huahua
   Pessaint, Laurent
   Van Ry, Alex
   Blade, Kelvin
   Strasbaugh, Amanda
   Cabus, Mehtap
   Brown, Renita
   Cook, Anthony
   Zouantchangadou, Serge
   Teow, Elyse
   Andersen, Hanne
   Lewis, Mark G.
   Cai, Yongfei
   Chen, Bing
   Schmidt, Aaron G.
   Reeves, R. Keith
   Baric, Ralph S.
   Lauffenburger, Douglas A.
   Alter, Galit
   Stoffels, Paul
   Mammen, Mathai
   Van Hoof, Johan
   Schuitemaker, Hanneke
   Barouch, Dan H.
TI Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
SO NATURE
LA English
DT Article
ID LENGTH INFECTIOUS CDNA; REVERSE GENETICS; CORONAVIRUS; IMMUNOGENICITY;
   SPIKE; ANTIBODIES; PNEUMONIA; EFFICACY; IMMUNITY; CHINA
AB A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic(1-8). For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in non-human primates. Fifty-two rhesus macaques (Macaca mulatta) were immunized with Ad26 vectors that encoded S variants or sham control, and then challenged with SARS-CoV-2 by the intranasal and intratracheal routes(9,10). The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs after SARS-CoV-2 challenge. Titres of vaccine-elicited neutralizing antibodies correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in non-human primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.
C1 [Mercado, Noe B.; Chandrashekar, Abishek; Yu, Jingyou; Liu, Jinyan; Peter, Lauren; McMahan, Katherine; Tostanoski, Lisa H.; He, Xuan; Bondzie, Esther A.; Dagotto, Gabriel; Gebre, Makda S.; Hoffman, Emily; Jacob-Dolan, Catherine; Kirilova, Marinela; Li, Zhenfeng; Lin, Zijin; Mahrokhian, Shant H.; Maxfield, Lori F.; Nampanya, Felix; Nityanandam, Ramya; Nkolola, Joseph P.; Patel, Shivani; Ventura, John D.; Verrington, Kaylee; Wan, Huahua; Reeves, R. Keith; Barouch, Dan H.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA.
   [Zahn, Roland; Wegmann, Frank; Rutten, Lucy; Bos, Rinke; van Manen, Danielle; Vellinga, Jort; Custers, Jerome; Langedijk, Johannes P.; Kwaks, Ted; Bakkers, Mark J. G.; Zuijdgeest, David; Huber, Sietske K. Rosendahl; Stoffels, Paul; Mammen, Mathai; Van Hoof, Johan; Schuitemaker, Hanneke] Janssen Vaccines & Prevent BV, Leiden, Netherlands.
   [Loos, Carolin; Atyeo, Caroline; Fischinger, Stephanie; Burke, John S.; Feldman, Jared; Hauser, Blake M.; Caradonna, Timothy M.; Schmidt, Aaron G.; Alter, Galit; Barouch, Dan H.] MIT & Harvard, Ragon Inst MGH, Cambridge, MA 02139 USA.
   [Loos, Carolin; Lauffenburger, Douglas A.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Martinez, David R.; Baric, Ralph S.] Univ N Carolina, Chapel Hill, NC 27515 USA.
   [Atyeo, Caroline; Fischinger, Stephanie; Feldman, Jared; Hauser, Blake M.; Caradonna, Timothy M.; Dagotto, Gabriel; Gebre, Makda S.; Jacob-Dolan, Catherine; Schmidt, Aaron G.; Barouch, Dan H.] Harvard Med Sch, Boston, MA 02115 USA.
   [Pessaint, Laurent; Van Ry, Alex; Blade, Kelvin; Strasbaugh, Amanda; Cabus, Mehtap; Brown, Renita; Cook, Anthony; Zouantchangadou, Serge; Teow, Elyse; Andersen, Hanne; Lewis, Mark G.] Bioqual, Rockville, MD USA.
   [Cai, Yongfei; Chen, Bing] Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.
   [Chen, Bing; Schmidt, Aaron G.; Alter, Galit; Barouch, Dan H.] Massachusetts Consortium Pathogen Readiness, Boston, MA 02115 USA.
RP Barouch, DH (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA.; Barouch, DH (corresponding author), MIT & Harvard, Ragon Inst MGH, Cambridge, MA 02139 USA.; Barouch, DH (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Barouch, DH (corresponding author), Massachusetts Consortium Pathogen Readiness, Boston, MA 02115 USA.
EM dbarouch@bidmc.harvard.edu
RI Cai, Yongfei/ABI-7748-2020; Mercado, Noe/ABE-8247-2020; Chandrashekar,
   Abishek/P-2610-2019
OI Cai, Yongfei/0000-0002-3628-3802; Mercado, Noe/0000-0001-7769-7326;
   Chandrashekar, Abishek/0000-0001-7821-5552; Hauser,
   Blake/0000-0002-0100-1684; Jacob-Dolan, Catherine/0000-0001-6641-0342;
   Mahrokhian, Shant/0000-0003-4094-8739; Gebre, Makda/0000-0001-8520-2178;
   Tostanoski, Lisa/0000-0001-9255-5684; Caradonna,
   Timothy/0000-0001-7138-4441
FU Department of Health and Human Services Biomedical Advanced Research and
   Development Authority (BARDA) [HHS0100201700018C]; Janssen Vaccines
   Prevention BV; Ragon Institute of MGH, MIT, and Harvard; Mark and Lisa
   Schwartz Foundation; Massachusetts Consortium on Pathogen Readiness
   (MassCPR); National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [OD024917, AI129797, AI124377, AI128751, AI126603, AI007151, AI152296,
   AI146779, 272201700036I-0-759301900131-1, AI100625, AI110700, AI132178,
   AI149644, AI108197]; Burroughs Wellcome Fund Postdoctoral Enrichment
   Program AwardBurroughs Wellcome Fund
FX We thank S. Blokland, Y. Choi, K. de Boer, I. de los Rios Oakes, E. van
   der Helm, D. Spek, I. Swart, M. Koning, A. Brandjes, N. van Dijk, A. de
   Wilde, M. Navis, R. van Schie, J. Verhagen, R. Vogels, R. van der Vlugt,
   A. Roos Broekhuijsen, B. Bart, J. Velasco, B. Finneyfrock, C. Shaver, J.
   Yalley-Ogunro, D. Wesemann, N. Kordana, M. Lifton, E. Borducchi, M.
   Silva, A. Richardson and C. Caron for advice, assistance and reagents.
   This project was funded in part by the Department of Health and Human
   Services Biomedical Advanced Research and Development Authority (BARDA)
   under contract HHS0100201700018C. We also acknowledge support from
   Janssen Vaccines & Prevention BV, the Ragon Institute of MGH, MIT, and
   Harvard, Mark and Lisa Schwartz Foundation, Massachusetts Consortium on
   Pathogen Readiness (MassCPR), and the National Institutes of Health
   (OD024917, AI129797, AI124377, AI128751, AI126603 to D.H.B.; AI007151
   and AI152296 to D.R.M.; AI146779 to A.G.S.;
   272201700036I-0-759301900131-1, AI100625, AI110700, AI132178, AI149644,
   AI108197 to R.S.B.). We also acknowledge a Burroughs Wellcome Fund
   Postdoctoral Enrichment Program Award to D.R.M.
CR Abbink P, 2007, J VIROL, V81, P4654, DOI 10.1128/JVI.02696-06
   Abbink P, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4163
   Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157
   Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016
   Alharbi NK, 2017, VACCINE, V35, P3780, DOI 10.1016/j.vaccine.2017.05.032
   Baden LR, 2013, J INFECT DIS, V207, P240, DOI 10.1093/infdis/jis670
   Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/s0140-6736(18)31364-3, 10.1016/S0140-6736(18)31364-3]
   Barouch DH, 2015, SCIENCE, V349, P320, DOI 10.1126/science.aab3886
   Barouch DH, 2011, VACCINE, V29, P5203, DOI 10.1016/j.vaccine.2011.05.025
   Brown EP, 2017, J IMMUNOL METHODS, V443, P33, DOI 10.1016/j.jim.2017.01.010
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung AW, 2015, CELL, V163, P988, DOI 10.1016/j.cell.2015.10.027
   Cox F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202820
   Fischinger S, 2019, J IMMUNOL METHODS, V473, DOI 10.1016/j.jim.2019.07.002
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu LL, 2016, CELL, V167, P433, DOI 10.1016/j.cell.2016.08.072
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 33
TC 31
Z9 29
U1 10
U2 10
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD OCT 22
PY 2020
VL 586
IS 7830
BP 583
EP +
DI 10.1038/s41586-020-2607-z
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OE6NR
UT WOS:000580645800035
PM 32731257
OA Bronze
DA 2021-01-01
ER

PT J
AU Mulligan, MJ
   Lyke, KE
   Kitchin, N
   Absalon, J
   Gurtman, A
   Lockhart, S
   Neuzil, K
   Raabe, V
   Bailey, R
   Swanson, KA
   Li, P
   Koury, K
   Kalina, W
   Cooper, D
   Fontes-Garfias, C
   Shi, PY
   Tureci, O
   Tompkins, KR
   Walsh, EE
   Frenck, R
   Falsey, AR
   Dormitzer, PR
   Gruber, WC
   Sahin, U
   Jansen, KU
AF Mulligan, Mark J.
   Lyke, Kirsten E.
   Kitchin, Nicholas
   Absalon, Judith
   Gurtman, Alejandra
   Lockhart, Stephen
   Neuzil, Kathleen
   Raabe, Vanessa
   Bailey, Ruth
   Swanson, Kena A.
   Li, Ping
   Koury, Kenneth
   Kalina, Warren
   Cooper, David
   Fontes-Garfias, Camila
   Shi, Pei-Yong
   Tuereci, Oezlem
   Tompkins, Kristin R.
   Walsh, Edward E.
   Frenck, Robert
   Falsey, Ann R.
   Dormitzer, Philip R.
   Gruber, William C.
   Sahin, Ugur
   Jansen, Kathrin U.
TI Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
SO NATURE
LA English
DT Article
ID IMMUNOGENICITY; SAFETY; DOMAIN
AB In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(1), a pandemic. With rapidly accumulating numbers of cases and deaths reported globally(2), a vaccine is urgently needed. Here we report the available safety, tolerability and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose-escalation study (ClinicalTrials.gov identifier NCT04368728) among 45 healthy adults (18-55 years of age), who were randomized to receive 2 doses-separated by 21 days-of 10 mu g, 30 mu g or 100 mu g of BNT162b1. BNT162b1 is a lipid-nanoparticle-formulated, nucleoside-modified mRNA vaccine that encodes the trimerized receptor-binding domain (RBD) of the spike glycoprotein of SARS-CoV-2. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. A second vaccination with 100 mu g was not administered because of the increased reactogenicity and a lack of meaningfully increased immunogenicity after a single dose compared with the 30-mu g dose. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second dose. Geometric mean neutralizing titres reached 1.9-4.6-fold that of a panel of COVID-19 convalescent human sera, which were obtained at least 14 days after a positive SARS-CoV-2 PCR. These results support further evaluation of this mRNA vaccine candidate.
C1 [Mulligan, Mark J.; Raabe, Vanessa] NYU, Langone Vaccine Ctr, New York, NY USA.
   [Mulligan, Mark J.; Raabe, Vanessa] NYU, Grossman Sch Med, New York, NY USA.
   [Lyke, Kirsten E.; Neuzil, Kathleen] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.
   [Kitchin, Nicholas; Lockhart, Stephen; Bailey, Ruth] Pfizer Inc, Vaccine Res & Dev, Hurley, England.
   [Absalon, Judith; Gurtman, Alejandra; Swanson, Kena A.; Koury, Kenneth; Kalina, Warren; Cooper, David; Tompkins, Kristin R.; Dormitzer, Philip R.; Gruber, William C.; Jansen, Kathrin U.] Pfizer Inc, Vaccine Res & Dev, Pearl River, NY 10965 USA.
   [Li, Ping] Pfizer Inc, Vaccine Res & Dev, Collegeville, PA USA.
   [Fontes-Garfias, Camila; Shi, Pei-Yong] Univ Texas Med Branch, Galveston, TX 77555 USA.
   [Tuereci, Oezlem; Sahin, Ugur] BioNTech, Mainz, Germany.
   [Walsh, Edward E.; Falsey, Ann R.] Univ Rochester, 601 Elmwood Ave, Rochester, NY USA.
   [Walsh, Edward E.; Falsey, Ann R.] Rochester Gen Hosp, Rochester, NY 14621 USA.
   [Frenck, Robert] Cincinnati Childrens Hosp, Cincinnati, OH USA.
RP Absalon, J (corresponding author), Pfizer Inc, Vaccine Res & Dev, Pearl River, NY 10965 USA.
EM judith.absalon@pfizer.com
OI Raabe, Vanessa/0000-0003-2579-1104
FU NYU CTSA grant from the National Center for Advancing Translational
   Sciences, National Institutes of Health [UL1 TR001445]; BioNTech
FX We thank C. Monahan and D. Gantt for writing and editorial support; H.
   Ma, J. Trammel and K. Challagali for statistical analysis support in the
   generation of this manuscript; all of the participants who volunteered
   for this study; A. Kottkamp, R. Herati, R. Pellet Madan, M. Olson, M.
   Samanovic-Golden, E. Cohen, A. Cornelius, L. Frye, H. Youn, B. Fran, K.
   Ballani, N. Veling, J. Erb, M. Ali, L. Zhao, S. Rettig, H. Khan, H.
   Lambert, K. Hu, J. Hyde, M. McArthur, J. Ortiz, R. Rapaka, L. Wadsworth,
   G. Cummings, T. Robinson, N. Greenberg, L. Chrisley, W. Somrajit, J.
   Marron, C. Thomas, K. Brooks, L. Turek, P. Farley, S. Eddington, P.
   Komninou, M. Reymann, K. Strauss, B. Shrestha, S. Joshi, R. Barnes, R.
   Sukhavasi, M. Lee, A. Kwon, T. Sharp, E. Pierce, M. Criddle, A. Cline,
   S. Parker, M. Dickey, K. Buschle, A. Cawein, J. L. Perez, H. Seehra, D.
   Tresnan, R. Maroko, H. Smith, S. Tweedy, A. Jones, G. Adams, R. Malick,
   E. Worobetz, E. Weaver, L. Zhang, C. Devlin, D. Boyce, E. Harkins Tull,
   M. Boaz, M. Cruz, C. Rosenbaum, C. Miculka, A. Kuhn, F. Bates, P.
   Strecker, A. Kemmer-Bruck, and the Vaccines Clinical Assay Team and
   Vaccines Assay Development Team for their assistance during this study.
   Staffing services were supported in part by an NYU CTSA grant (UL1
   TR001445) from the National Center for Advancing Translational Sciences,
   National Institutes of Health. BioNTech is the sponsor of the study.
   Pfizer was responsible for the design, data collection, data analysis,
   data interpretation and writing of the report. The corresponding authors
   had full access to all of the data in the study and had final
   responsibility for the decision to submit the data for publication. All
   study data were available to all authors.
CR Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074
   Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3
   Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Coronavirus-Resources-Center, 2020, COVID 19 DASHB CTR S
   Foster GR, 2004, J IMMUNOL, V173, P1663, DOI 10.4049/jimmunol.173.3.1663
   Guthe S, 2004, J MOL BIOL, V337, P905, DOI 10.1016/j.jmb.2004.02.020
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Hopkins RJ, 2013, VACCINE, V31, P3051, DOI 10.1016/j.vaccine.2013.04.063
   Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200
   Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300
   Lai LL, 2015, JAMA-J AM MED ASSOC, V313, P1249, DOI 10.1001/jama.2015.1995
   Muruato AE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17892-0
   Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007
   Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436
   Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963
   Regules JA, 2017, NEW ENGL J MED, V376, P330, DOI 10.1056/NEJMoa1414216
   Sahin U, 2020, CONCURRENT HUMAN ANT, DOI [10.1101/2020.07.17.20140533, DOI 10.1101/2020.07.17.20140533]
   Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003
   Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278
   Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2
   Walsh Edward E, 2020, medRxiv, DOI 10.1101/2020.08.17.20176651
   World Health Organization, 2020, 154 WHO
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Zost SJ, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0998-x
NR 25
TC 32
Z9 30
U1 59
U2 59
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD OCT 22
PY 2020
VL 586
IS 7830
BP 589
EP +
DI 10.1038/s41586-020-2639-4
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OE6NR
UT WOS:000580645800036
PM 32785213
DA 2021-01-01
ER

PT J
AU Sahin, U
   Muik, A
   Derhovanessian, E
   Vogler, I
   Kranz, LM
   Vormehr, M
   Baum, A
   Pascal, K
   Quandt, J
   Maurus, D
   Brachtendorf, S
   Lorks, V
   Sikorski, J
   Hilker, R
   Becker, D
   Eller, AK
   Grutzner, J
   Boesler, C
   Rosenbaum, C
   Kuhnle, MC
   Luxemburger, U
   Kemmer-Bruck, A
   Langer, D
   Bexon, M
   Bolte, S
   Kariko, K
   Palanche, T
   Fischer, B
   Schultz, A
   Shi, PY
   Fontes-Garfias, C
   Perez, JL
   Swanson, KA
   Loschko, J
   Scully, IL
   Cutler, M
   Kalina, W
   Kyratsous, CA
   Cooper, D
   Dormitzer, PR
   Jansen, KU
   Tureci, O
AF Sahin, Ugur
   Muik, Alexander
   Derhovanessian, Evelyna
   Vogler, Isabel
   Kranz, Lena M.
   Vormehr, Mathias
   Baum, Alina
   Pascal, Kristen
   Quandt, Jasmin
   Maurus, Daniel
   Brachtendorf, Sebastian
   Loerks, Verena
   Sikorski, Julian
   Hilker, Rolf
   Becker, Dirk
   Eller, Ann-Kathrin
   Gruetzner, Jan
   Boesler, Carsten
   Rosenbaum, Corinna
   Kuehnle, Marie-Cristine
   Luxemburger, Ulrich
   Kemmer-Brueck, Alexandra
   Langer, David
   Bexon, Martin
   Bolte, Stefanie
   Kariko, Katalin
   Palanche, Tania
   Fischer, Boris
   Schultz, Armin
   Shi, Pei-Yong
   Fontes-Garfias, Camila
   Perez, John L.
   Swanson, Kena A.
   Loschko, Jakob
   Scully, Ingrid L.
   Cutler, Mark
   Kalina, Warren
   Kyratsous, Christos A.
   Cooper, David
   Dormitzer, Philip R.
   Jansen, Kathrin U.
   Tuereci, Oezlem
TI COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1T cell
   responses
SO NATURE
LA English
DT Article
ID RNA; CORONAVIRUS; CAPACITY; MICE
AB An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein(1). Here we present antibody and T cell responses after vaccination with BNT162b1 from a second, non-randomized open-label phase I/II trial in healthy adults, 18-55 years of age. Two doses of 1-50 mu g of BNT162b1 elicited robust CD4(+) and CD8(+) T cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those seen in serum from a cohort of individuals who had recovered from COVID-19. Geometric mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were 0.7-fold (1-mu g dose) to 3.5-fold (50-mu g dose) those of the recovered individuals. Immune sera broadly neutralized pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (T(H)1)-skewed T cell immune responses with RBD-specific CD8(+) and CD4(+) T cell expansion. Interferon-. was produced by a large fraction of RBD-specific CD8(+) and CD4(+) T cells. The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
C1 [Sahin, Ugur; Muik, Alexander; Derhovanessian, Evelyna; Vogler, Isabel; Kranz, Lena M.; Vormehr, Mathias; Quandt, Jasmin; Maurus, Daniel; Brachtendorf, Sebastian; Loerks, Verena; Sikorski, Julian; Hilker, Rolf; Becker, Dirk; Eller, Ann-Kathrin; Gruetzner, Jan; Boesler, Carsten; Rosenbaum, Corinna; Kuehnle, Marie-Cristine; Luxemburger, Ulrich; Kemmer-Brueck, Alexandra; Langer, David; Bolte, Stefanie; Kariko, Katalin; Palanche, Tania; Fischer, Boris; Tuereci, Oezlem] BioNTech, Mainz, Germany.
   [Sahin, Ugur] Univ Med Ctr Johannes Gutenberg, TRON gGmbH Translat Oncol, Mainz, Germany.
   [Baum, Alina; Pascal, Kristen; Kyratsous, Christos A.] Regeneron Pharmaceut, Tarrytown, NY USA.
   [Bexon, Martin] Bexon Clin Consulting, Montclair, NJ USA.
   [Schultz, Armin] CRS Clin Res Serv Mannheim GmbH, Mannheim, Germany.
   [Shi, Pei-Yong; Fontes-Garfias, Camila] Univ Texas Med Branch, Galveston, TX 77555 USA.
   [Perez, John L.; Swanson, Kena A.; Loschko, Jakob; Scully, Ingrid L.; Cutler, Mark; Kalina, Warren; Cooper, David; Dormitzer, Philip R.; Jansen, Kathrin U.] Pfizer, Pearl River, NY USA.
RP Sahin, U (corresponding author), BioNTech, Mainz, Germany.; Sahin, U (corresponding author), Univ Med Ctr Johannes Gutenberg, TRON gGmbH Translat Oncol, Mainz, Germany.
EM sahin@biontech.de
OI Hilker, Rolf/0000-0002-8576-7731; Vormehr, Mathias/0000-0001-7788-3380
CR Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074
   [Anonymous], COR DIS COVID 19 DAS
   Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Chong WP, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-82
   Destexhe E, 2013, J PHARMACOL TOX MET, V68, P367, DOI 10.1016/j.vascn.2013.04.003
   Doener F, 2019, VACCINE, V37, P1819, DOI 10.1016/j.vaccine.2019.02.024
   Gallais F., 2020, INTRAFAMILIAL EXPOSU, DOI [10.1101/2020.06.21.20132449v1, DOI 10.1101/2020.06.21.20132449V1]
   Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921
   Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024
   Kamphuis E, 2006, BLOOD, V108, P3253, DOI 10.1182/blood-2006-06-027599
   Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200
   Moodie Z, 2010, CANCER IMMUNOL IMMUN, V59, P1489, DOI 10.1007/s00262-010-0875-4
   Moodie Z, 2006, J IMMUNOL METHODS, V315, P121, DOI 10.1016/j.jim.2006.07.015
   Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4
   Muruato AE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17892-0
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Pardi N, 2019, MOL THER-NUCL ACIDS, V15, P36, DOI 10.1016/j.omtn.2019.03.003
   Pardi N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05482-0
   Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450
   Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428
   Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007
   Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963
   Sahin U, 2020, NATURE, V585, P107, DOI 10.1038/s41586-020-2537-9
   Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278
   Sainz B, 2004, VIROLOGY, V329, P11, DOI 10.1016/j.virol.2004.08.011
   Sette A, 2008, IMMUNITY, V28, P847, DOI 10.1016/j.immuni.2008.04.018
   Tai WB, 2016, VIROLOGY, V499, P375, DOI 10.1016/j.virol.2016.10.005
   Taylor DN, 2012, VACCINE, V30, P5761, DOI 10.1016/j.vaccine.2012.06.086
   Tsai MY, 2005, J LAB CLIN MED, V145, P323, DOI 10.1016/j.lab.2005.03.009
   U.S. Department of Health and Human Services, TOX GRAD SCAL HLTH A
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   von Niessen AGO, 2019, MOL THER, V27, P824, DOI 10.1016/j.ymthe.2018.12.011
   Walsh E. E., 2020, RNA BASED COVID 19 V, DOI [10.1101/2020.08.17.20176651v2, DOI 10.1101/2020.08.17.20176651V2]
   Xie X., 2020, CELL HOST MICROBE, V27
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Zhang L., 2020, BIORXIV, DOI [10.1101/2020.06.12.148726v1, DOI 10.1101/2020.06.12.148726V1]
NR 38
TC 5
Z9 5
U1 37
U2 37
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD OCT 22
PY 2020
VL 586
IS 7830
BP 594
EP +
DI 10.1038/s41586-020-2814-7
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OE6NR
UT WOS:000580645800037
PM 32998157
OA Other Gold
DA 2021-01-01
ER

PT J
AU Chouker, A
   Stahn, AC
AF Chouker, Alexander
   Stahn, Alexander C.
TI COVID-19-The largest isolation study in history: the value of shared
   learnings from spaceflight analogs
SO NPJ MICROGRAVITY
LA English
DT Article
ID REALITY EXPOSURE THERAPY; VIRTUAL ENVIRONMENTS; ANXIETY DISORDERS;
   STRESS; NEUROGENESIS; PSYCHOLOGY; EXERCISE
AB The world is currently experiencing the largest isolation experiment in history. In an attempt to slow down the spread of the COVID-19 pandemic numerous countries across the world have been shutting down economies, education, and public life. Governments have mandated strict regulations of quarantine and social distancing in an unprecedented manner. The effects of these measures on brain, behavior, neuro-humoral and immunological responses in humans are largely unknown. Life science research for space exploration has a long history in using high-fidelity spaceflight analogs to better understand the effect of prolonged isolation and confinement on genes, molecules, cells, neural circuits, and physiological systems to behavior. We here propose to leverage the extensive experience and data from these studies and build a bridge between spaceflight research and clinical settings to foster transdisciplinary approaches to characterize the neurobehavioral effects on the immune system and vice versa. These approaches are expected to develop innovative and efficient health screening tools, diagnostic systems, and treatments to mitigate health risks associated with isolation and confinement on Earth and during future exploratory spaceflight missions.
C1 [Chouker, Alexander] Hosp Ludwig Maximilians Univ, Dept Anesthesiol, Lab Translat Res Stress & Immun, Marchioninistr 15, D-81377 Munich, Germany.
   [Stahn, Alexander C.] Univ Penn, Perelman Sch Med, Dept Psychiat, Res Sect Behav Regulat & Hlth, 1016 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19004 USA.
RP Chouker, A (corresponding author), Hosp Ludwig Maximilians Univ, Dept Anesthesiol, Lab Translat Res Stress & Immun, Marchioninistr 15, D-81377 Munich, Germany.; Stahn, AC (corresponding author), Univ Penn, Perelman Sch Med, Dept Psychiat, Res Sect Behav Regulat & Hlth, 1016 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19004 USA.
EM achouker@med.uni-muenchen.de; astahn@pennmedicine.upenn.edu
FU German Space Agency (DLR) on behalf of the Federal Ministry of Economics
   and Technology/Energy (BMWi) [50WB1319, 50WB0919, 50WB1622, 50WB1931,
   50WB1915, 50WB1525]; European Space Agency (ESA, ELIPS program)
   [21183/07/NL/VJ]; European Space Agency (ESA, SciSpacE program)
   [21183/07/NL/VJ]; IBMP; DLRHelmholtz AssociationGerman Aerospace Centre
   (DLR); ESAEuropean Space Agency; NASANational Aeronautics & Space
   Administration (NASA)
FX The work was supported by the German Space Agency (DLR) on behalf of the
   Federal Ministry of Economics and Technology/Energy (BMWi) through
   grants 50WB1319, 50WB0919, 50WB1622, 50WB1931, 50WB1915, 50WB1525; and
   the European Space Agency (ESA, ELIPS and SciSpacE programs, Topical
   Team #21183/07/NL/VJ). We thank the Alfred Wegener Institute, Helmholtz
   Centre for Polar and Marine Research in Bremerhaven, Germany, and the
   French (IPEV) and Italian (PNRA) polar institutes for continuous
   logistical and technical support in conducting research in ICC. We also
   like to acknowledge the support from IBMP, DLR, ESA and NASA for their
   initiatives and research support in studies at the NEK and HERA space
   analogs. We thank Judith-Irina Buchheim, Hanns-Christian Gunga and David
   F. Dinges for the constructive discussions.
CR Ahn SJ, 2014, COMPUT HUM BEHAV, V39, P235, DOI 10.1016/j.chb.2014.07.025
   [Anonymous], 2020, NASA HUM RES ROADM
   [Anonymous], 2020, HYBRID TRAINING SENS
   Antonutto G, 2003, EUR J APPL PHYSIOL, V90, P283, DOI 10.1007/s00421-003-0884-5
   Bachevalier J, 2019, P NATL ACAD SCI USA, V116, P26210, DOI 10.1073/pnas.1902278116
   Banos RM, 2012, INTERACT COMPUT, V24, P131, DOI 10.1016/j.intcom.2012.04.002
   Brem C, 2020, LIFE SCI SPACE RES, V24, P83, DOI 10.1016/j.lssr.2019.09.004
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Brown FF, 2018, PHYSIOL BEHAV, V194, P191, DOI 10.1016/j.physbeh.2018.05.012
   Buchheim JI, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00085
   Cacioppo JT, 2018, LANCET, V391, P426, DOI 10.1016/S0140-6736(18)30142-9
   Cacioppo JT, 2011, ANN NY ACAD SCI, V1231, P17, DOI 10.1111/j.1749-6632.2011.06028.x
   Carl E, 2019, J ANXIETY DISORD, V61, P27, DOI 10.1016/j.janxdis.2018.08.003
   Carter JA, 2005, AVIAT SPACE ENVIR MD, V76, pB213
   Chouker A., 2020, STRESS CHALLENGES IM
   Cinini SM, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00045
   Cook F.A, 1900, 1 ANTARCTIC NIGHT 18
   Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750
   Diamond R, 2020, PSYCHOL PSYCHOTHER-T, DOI 10.1111/papt.12294
   Dietrich D, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9458
   Dixon ML, 2017, PSYCHOL BULL, V143, P1033, DOI 10.1037/bul0000096
   Eastwood JD, 2012, PERSPECT PSYCHOL SCI, V7, P482, DOI 10.1177/1745691612456044
   Fa MX, 2014, NEUROBIOL LEARN MEM, V112, P53, DOI 10.1016/j.nlm.2014.04.008
   Feuerecker M, 2019, ALLERGY, V74, P64, DOI 10.1111/all.13545
   Gao Z, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061986
   Gould E, 1997, J NEUROSCI, V17, P2492
   Gunga HC, 2009, RESP PHYSIOL NEUROBI, V169, pS63, DOI 10.1016/j.resp.2009.04.005
   Gustafson MP, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0231-8
   Guttmann L, 2019, FASEB J, V33
   Heeter C., 1992, PRESENCE TELEOPERATO, V1, DOI [DOI 10.1162/PRES.1992.1.2.262, 10.1162/pres.1992.1.2.262]
   Kamal A, 2014, NEUROSCIENCE, V256, P262, DOI 10.1016/j.neuroscience.2013.10.016
   Kehler DS, 2019, EXP GERONTOL, V124, DOI 10.1016/j.exger.2019.110643
   Krall SC, 2015, BRAIN STRUCT FUNCT, V220, P587, DOI 10.1007/s00429-014-0803-z
   Kunz HE, 2018, PHYSIOL BEHAV, V194, P56, DOI 10.1016/j.physbeh.2018.04.035
   Lennon Jack C, 2020, J Alzheimers Dis Rep, V4, P217, DOI 10.3233/ADR-200190
   Liu Y, 2015, I C VIRTUAL REALITY, P1, DOI 10.1109/ICVRV.2015.54
   Makedonas G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02407
   Mendt S, 2017, CHRONOBIOL INT, V34, P666, DOI 10.1080/07420528.2016.1224241
   Meyerbroker K, 2010, DEPRESS ANXIETY, V27, P933, DOI 10.1002/da.20734
   O'Connor DB, 2020, BRIT J PSYCHOL, V111, P603, DOI 10.1111/bjop.12468
   Opris D, 2012, DEPRESS ANXIETY, V29, P85, DOI 10.1002/da.20910
   Pagel JI, 2016, J APPL PHYSIOL, V120, P1449, DOI 10.1152/japplphysiol.00928.2015
   Palinkas LA, 2003, AM PSYCHOL, V58, P353, DOI 10.1037/0003-066X.58.5.353
   Palinkas LA, 2008, LANCET, V371, P153, DOI 10.1016/S0140-6736(07)61056-3
   Pi XQ, 2020, J CLIN PEDIATR DENT, V44, P1, DOI 10.17796/1053-4625-44.1.1
   Rittweger J, 1999, J Gravit Physiol, V6, pP133
   Schloesser RJ, 2010, MOL PSYCHIATR, V15, P1152, DOI 10.1038/mp.2010.34
   Serrano B, 2016, COMPUT HUM BEHAV, V55, P1, DOI 10.1016/j.chb.2015.08.007
   Smith B, 2020, PUBLIC HEALTH RES PR, V30, DOI 10.17061/phrp3022008
   Smith SM, 2014, J BONE MINER RES, V29, P1639, DOI 10.1002/jbmr.2185
   Stahn AC, 2019, NEW ENGL J MED, V381, P2273, DOI 10.1056/NEJMc1904905
   Stahn AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15560-w
   Stranahan AM, 2006, NAT NEUROSCI, V9, P526, DOI 10.1038/nn1668
   Stuster J, 2011, BOLD ENDEAVORS LESSO
   Tcore TM, 2020, TEMPERATURE MONITORI
   Ursin H, 1993, Adv Space Biol Med, V3, P23
   Vaernes R J, 1996, Adv Space Biol Med, V5, P7
   Valtchanov D, 2010, CYBERPSYCH BEH SOC N, V13, P503, DOI 10.1089/cyber.2009.0308
   van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558
   Vessel E. A., 2015, NASATM2015218576
   Voss MW, 2013, TRENDS COGN SCI, V17, P525, DOI 10.1016/j.tics.2013.08.001
   Wikenheiser AM, 2016, NAT REV NEUROSCI, V17, P513, DOI 10.1038/nrn.2016.56
   Yi BQ, 2015, SCI REP-UK, V5, DOI 10.1038/srep13367
   Yuan M, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00575
NR 64
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2373-8065
J9 NPJ MICROGRAVITY
JI NPJ Microgravity
PD OCT 22
PY 2020
VL 6
IS 1
DI 10.1038/s41526-020-00122-8
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OO4PM
UT WOS:000587362600001
PM 33110938
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Honore, PM
   Gutierrez, LB
   Kugener, L
   Redant, S
   Attou, R
   Gallerani, A
   De Bels, D
AF Honore, Patrick M.
   Barreto Gutierrez, Leonel
   Kugener, Luc
   Redant, Sebastien
   Attou, Rachid
   Gallerani, Andrea
   De Bels, David
TI SARS-CoV-2 infection as a risk factor for herpesviridae reactivation:
   consider the potential influence of corticosteroid therapy
SO CRITICAL CARE
LA English
DT Letter
C1 [Honore, Patrick M.; Barreto Gutierrez, Leonel; Kugener, Luc; Redant, Sebastien; Attou, Rachid; Gallerani, Andrea; De Bels, David] Brugmann Univ Hosp, Ctr Hosp Univ Brugmann, ICU Dept, Pl Gehuchtenpl 4,1020, B-1020 Brussels, Belgium.
RP Honore, PM (corresponding author), Brugmann Univ Hosp, Ctr Hosp Univ Brugmann, ICU Dept, Pl Gehuchtenpl 4,1020, B-1020 Brussels, Belgium.
EM Patrick.Honore@CHU-Brugmann.be
CR Le Balc'h P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03252-3
   Minderhoud T. C., 2018, Nederlands Tijdschrift voor Geneeskunde, V162, pD2215
   Osterman A, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4859-5
   Pines N, 2020, PEDIATR EMERG CARE, V36, pE735, DOI 10.1097/PEC.0000000000001519
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
NR 5
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1364-8535
EI 1466-609X
J9 CRIT CARE
JI Crit. Care
PD OCT 22
PY 2020
VL 24
IS 1
AR 623
DI 10.1186/s13054-020-03349-9
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA ON0BJ
UT WOS:000586377800002
PM 33092622
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dubey, A
   Dahiya, S
   Rouse, BT
   Sehrawat, S
AF Dubey, Abhishek
   Dahiya, Surbhi
   Rouse, Barry T.
   Sehrawat, Sharvan
TI Perspective: Reducing SARS-CoV2 Infectivity and Its Associated
   Immunopathology
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE inflammation; therapy; sdAb; immunoregulation; viruses
ID ANTIBODY-DEPENDENT ENHANCEMENT; REGULATORY T-CELLS; VIRUS-INFECTION;
   PATHOGEN RECOGNITION; SPIKE PROTEIN; DOMAIN; CORONAVIRUS; IMMUNITY;
   MACROPHAGES; DISEASE
AB COVID-19 has become difficult to contain in our interconnected world. In this article, we discuss some approaches that could reduce the consequences of COVID-19. We elaborate upon the utility of camelid single-domain antibodies (sdAbs), also referred to as nanobodies, which are naturally poised to neutralize viruses without enhancing its infectivity. Smaller sized sdAbs can be easily selected using microbes or the subcellular organelle display methods and can neutralize SARS-CoV2 infectivity. We also discuss issues related to their production using scalable platforms. The favorable outcome of the infection is evident in patients when the inflammatory response is adequately curtailed. Therefore, we discuss approaches to mitigate hyperinflammatory reactions initiated by SARS-CoV2 but orchestrated by immune mediators.
C1 [Dubey, Abhishek; Dahiya, Surbhi; Sehrawat, Sharvan] Indian Inst Sci Educ & Res Mohali, Dept Biol Sci, Mohali, India.
   [Rouse, Barry T.] Univ Tennessee, Coll Vet Med, Biomed & Diagnost Sci, Knoxville, TN USA.
RP Sehrawat, S (corresponding author), Indian Inst Sci Educ & Res Mohali, Dept Biol Sci, Mohali, India.
EM sharvan@iisermohali.ac.in
FU DBTDepartment of Biotechnology (DBT) India
   [BT/PR20283/BBE/117/258/2016]; IISERM
FX The work in the lab of SS is supported by Intramural funding from IISERM
   and the extramural grant from DBT (BT/PR20283/BBE/117/258/2016).
CR Arvin AM, 2020, NATURE, DOI 10.1038/s41586-020-2538-8
   Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309
   Biswas M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030424
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   Casanova JL, 2020, CELL, V181, P1194, DOI 10.1016/j.cell.2020.05.016
   Chames P, 2009, BRIT J PHARMACOL, V157, P220, DOI 10.1111/j.1476-5381.2009.00190.x
   Cheng PKC, 2004, LANCET, V363, P1699, DOI 10.1016/S0140-6736(04)16255-7
   Cho HJ, 2020, J INFECT PUBLIC HEAL, V13, P1678, DOI 10.1016/j.jiph.2020.05.001
   Chun J, 2010, CLIN NEUROPHARMACOL, V33, P91, DOI 10.1097/WNF.0b013e3181cbf825
   Crotta S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003773
   Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628
   Dasaraju PV, 1996, MED MICROBIOLOGY
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   Dohla M., 2020, SARS COV 2 ENV SAMPL, V49, P1, DOI [10.1101/2020.05.28.20114041, DOI 10.1101/2020.05.28.20114041]
   DROBYSKI WR, 1994, NEW ENGL J MED, V330, P1356, DOI 10.1056/NEJM199405123301905
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Duarte JN, 2016, J IMMUNOL, V197, P4838, DOI 10.4049/jimmunol.1600692
   Egloff C, 2020, J CLIN VIROL, V128
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Felsenstein S, 2020, CLIN IMMUNOL, V220, DOI 10.1016/j.clim.2020.108588
   Flipse J, 2016, SCI REP-UK, V6, DOI 10.1038/srep29201
   Flipse J, 2013, TRAFFIC, V14, P25, DOI 10.1111/tra.12012
   Franchimont D, 2002, J IMMUNOL, V168, P2212, DOI 10.4049/jimmunol.168.5.2212
   Franklin R., 2020, HOMOLOGOUS PROTEIN D, DOI [10.1101/2020.04.10.20053207, DOI 10.1101/2020.04.10.20053207]
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guillon P, 2008, GLYCOBIOLOGY, V18, P1085, DOI 10.1093/glycob/cwn093
   Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   Halstead SB, 2010, LANCET INFECT DIS, V10, P712, DOI 10.1016/S1473-3099(10)70166-3
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   Han WZ, 2020, J MED VIROL, V92, P461, DOI 10.1002/jmv.25711
   Harmsen MM, 2007, APPL MICROBIOL BIOT, V77, P13, DOI 10.1007/s00253-007-1142-2
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hohdatsu T, 1998, J VET MED SCI, V60, P49, DOI 10.1292/jvms.60.49
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huentelman MJ, 2004, HYPERTENSION, V44, P903, DOI 10.1161/01.HYP.0000146120.29648.36
   Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI 10.1038/s41594-020-0469-6
   Ingram JR, 2018, ANNU REV IMMUNOL, V36, P695, DOI 10.1146/annurev-immunol-042617-053327
   Kao RY, 2004, CHEM BIOL, V11, P1293, DOI 10.1016/j.chembiol.2004.07.013
   KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Kaur M, 2019, TOXICON, V172, P15, DOI 10.1016/j.toxicon.2019.10.240
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Koff WC, 2020, NEW ENGL J MED, V383, P804, DOI 10.1056/NEJMp2006761
   Konwarh R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01531
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kumar D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01521
   Laporte M, 2017, CURR OPIN VIROL, V24, P16, DOI 10.1016/j.coviro.2017.03.018
   Lee JS, 2020, NAT REV IMMUNOL, V20, P585, DOI 10.1038/s41577-020-00429-3
   Lee JS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd1554
   Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5
   Li JY, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.198074
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Mabry R, 2010, PROTEIN ENG DES SEL, V23, P115, DOI 10.1093/protein/gzp073
   Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871
   Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511
   Meckes DG, 2011, J VIROL, V85, P12844, DOI 10.1128/JVI.05853-11
   Metcalf TU, 2015, AGING CELL, V14, P421, DOI 10.1111/acel.12320
   Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08
   Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449
   Ng K., 2020, PREEXISTING NOVO HUM, V15, DOI [10.1101/2020.05.14.095414, DOI 10.1101/2020.05.14.095414]
   Nguyen VK, 1999, MOL IMMUNOL, V36, P515
   Nikolich-Zugich J, 2018, NAT IMMUNOL, V19, P10, DOI 10.1038/s41590-017-0006-x
   Oja A. E., 2020, DIVERGENT SARS COV 2, DOI 10.1101/2020.06.18.159202
   Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Poston JT, 2020, JAMA-J AM MED ASSOC, V323, P1839, DOI 10.1001/jama.2020.4914
   Rahimkhoei V, 2020, CELL BIOCHEM FUNCT, DOI 10.1002/cbf.3576
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802
   Rudensky AY, 2011, IMMUNOL REV, V241, P260, DOI 10.1111/j.1600-065X.2011.01018.x
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Saif LJ, 2004, DEV BIOLOGICALS, V119, P129
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Schoot TS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01333
   Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200
   Sehrawat S, 2008, J IMMUNOL, V180, P7636, DOI 10.4049/jimmunol.180.11.7636
   Sehrawat S, 2020, MICROBES INFECT, V22, P400, DOI 10.1016/j.micinf.2020.07.002
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Stadler K, 2008, AM J RESP CELL MOL, V39, P142, DOI 10.1165/rcmb.2007-0217OC
   Swee LK, 2013, P NATL ACAD SCI USA, V110, P1428, DOI 10.1073/pnas.1214994110
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   van der Heide Verena, 2020, Nat Rev Immunol, V20, P408, DOI 10.1038/s41577-020-0362-x
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Veiga-Parga T, 2013, IMMUNOL REV, V255, P182, DOI 10.1111/imr.12085
   Vu KB, 1997, MOL IMMUNOL, V34, P1121, DOI 10.1016/S0161-5890(97)00146-6
   Walter J. D, 2020, SYBODIES TARGETING S, DOI [10.1101/2020.04.16.045419, DOI 10.1101/2020.04.16.045419]
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   WHO, 2020, CLIN MAN SEV AC RESP
   Wong Lydia Su Yin, 2020, J Allergy Clin Immunol Pract, V8, P3251, DOI 10.1016/j.jaip.2020.08.026
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101
   Wu YL, 2020, CELL HOST MICROBE, V27, P891, DOI 10.1016/j.chom.2020.04.023
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang Y, 2020, J ALLERGY CLIN IMMUN, V146, P119, DOI 10.1016/j.jaci.2020.04.027
   Zhang GH, 1999, INFECT IMMUN, V67, P1353, DOI 10.1128/IAI.67.3.1353-1358.1999
NR 105
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 22
PY 2020
VL 11
AR 581076
DI 10.3389/fimmu.2020.581076
PG 9
WC Immunology
SC Immunology
GA OL4UX
UT WOS:000585338200001
PM 33193385
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sutanto, H
   Heijman, J
AF Sutanto, Henry
   Heijman, Jordi
TI Beta-Adrenergic Receptor Stimulation Modulates the Cellular
   Proarrhythmic Effects of Chloroquine and Azithromycin
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE arrhythmia; computational modeling; COVID-19; chloroquine; azithromycin;
   beta-adrenergic; electrophysiology-basic
ID IN-VITRO; HYDROXYCHLOROQUINE; COMBINATION; ELECTROPHYSIOLOGY; COVID-19;
   VARIABILITY; ARRHYTHMIA; INCREASE; DRUGS
AB The antimalarial drug, chloroquine (CQ), and antimicrobial drug, azithromycin (AZM), have received significant attention during the COVID-19 pandemic. Both drugs can alter cardiac electrophysiology and have been associated with drug-induced arrhythmias. Meanwhile, sympathetic activation is commonly observed during systemic inflammation and oxidative stress (e.g., in SARS-CoV-2 infection) and may influence the electrophysiological effects of CQ and AZM. Here, we investigated the effect of beta-adrenergic stimulation on proarrhythmic properties of CQ and AZM using detailed in silico models of ventricular electrophysiology. Concentration-dependent alterations in ion-channel function were incorporated into the Heijman canine and O'Hara-Rudy human ventricular cardiomyocyte models. Single and combined drug effects on action-potential (AP) properties were analyzed using a population of 1,000 models accommodating inter-individual variability. Sympathetic stimulation was simulated by increasing pacing rate and experimentally validated isoproterenol (ISO)-induced changes in ion-channel function. In the canine ventricular model at 1 Hz pacing, therapeutic doses of CQ and AZM (5 and 20 mu M, respectively) individually prolonged AP duration (APD) by 33 and 13%. Their combination produced synergistic APD prolongation (+161%) with incidence of proarrhythmic early afterdepolarizations in 53.5% of models. Increasing the pacing frequency to 2 Hz shortened APD and together with 1 mu M ISO counteracted the drug-induced APD prolongation. No afterdepolarizations occurred following increased rate and simulated application of ISO. Similarly, CQ and AZM individually prolonged APD by 43 and 29% in the human ventricular cardiomyocyte model, while their combination prolonged APD by 76% without causing early afterdepolarizations. Consistently, 1 mu M ISO at 2 Hz pacing counteracted the drug-induced APD prolongation. Increasing the I-Ca,I-L window current produced afterdepolarizations, which were exacerbated by ISO. In both models, reduced extracellular K+ reduced the repolarization reserve and increased drug effects. In conclusion, CQ- and AZM-induced proarrhythmia is promoted by conditions with reduced repolarization reserve. Sympathetic stimulation limits drug-induced APD prolongation, suggesting the potential importance of heart rate and autonomic status monitoring in particular conditions (e.g., COVID-19).
C1 [Sutanto, Henry; Heijman, Jordi] Maastricht Univ, Sch Cardiovasc Dis, Cardiovasc Res Inst Maastricht CARIM, Dept Cardiol, Maastricht, Netherlands.
RP Heijman, J (corresponding author), Maastricht Univ, Sch Cardiovasc Dis, Cardiovasc Res Inst Maastricht CARIM, Dept Cardiol, Maastricht, Netherlands.
EM jordi.heijman@maastrichtuniversity.nl
RI Sutanto, Henry/AAM-5694-2020
OI Sutanto, Henry/0000-0002-5730-2013
CR Adameova A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124200
   Anyukhovsky EP, 1996, CIRCULATION, V94, P1981, DOI 10.1161/01.CIR.94.8.1981
   Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Atkinson JG, 2020, INT J INFECT DIS, V99, P37, DOI 10.1016/j.ijid.2020.07.057
   Bartos DC, 2014, HEART RHYTHM, V11, P459, DOI 10.1016/j.hrthm.2013.11.021
   Bhatla A, 2020, HEART RHYTHM, V17, P1439, DOI 10.1016/j.hrthm.2020.06.016
   Boczek NJ, 2015, HEART RHYTHM, V12, P211, DOI 10.1016/j.hrthm.2014.09.051
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Britton OJ, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00597
   Buckley NA, 1996, HUM EXP TOXICOL, V15, P909, DOI 10.1177/096032719601501108
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Clerx M, 2016, PROG BIOPHYS MOL BIO, V120, P100, DOI 10.1016/j.pbiomolbio.2015.12.008
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Crumb WJ, 2016, J PHARMACOL TOX MET, V81, P251, DOI 10.1016/j.vascn.2016.03.009
   Dang SP, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.31
   Fossa AA, 2007, AM J TROP MED HYG, V77, P929, DOI 10.4269/ajtmh.2007.77.929
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809
   Gong JQX, 2020, J MOL CELL CARDIOL, V143, P96, DOI 10.1016/j.yjmcc.2020.04.009
   Heijman J, 2012, CIRC RES, V110, P211, DOI 10.1161/CIRCRESAHA.111.249482
   Heijman J, 2011, J MOL CELL CARDIOL, V50, P863, DOI 10.1016/j.yjmcc.2011.02.007
   Huang MX, 2020, J MOL CELL BIOL, V12, P322, DOI 10.1093/jmcb/mjaa014
   Jaeger A, 1997, Rev Prat, V47, P748
   Jankelson L, 2020, HEART RHYTHM, V17, P1472, DOI 10.1016/j.hrthm.2020.05.008
   Johnson DM, 2013, CIRC RES, V112, P246, DOI 10.1161/CIRCRESAHA.112.275735
   Lazzerini PE, 2020, CIRCULATION, V142, P7, DOI 10.1161/CIRCULATIONAHA.120.047293
   Li ZH, 2020, CLIN PHARMACOL THER, V107, P102, DOI 10.1002/cpt.1647
   Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   MICHAEL TAD, 1970, AM HEART J, V79, P831, DOI 10.1016/0002-8703(70)90371-6
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Monnerat G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13344
   Murphy KR, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01277
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   Nishiga M, 2020, NAT REV CARDIOL, V17, P543, DOI 10.1038/s41569-020-0413-9
   O'Hara T, 2012, AM J PHYSIOL-HEART C, V302, pH1023, DOI 10.1152/ajpheart.00785.2011
   O'Hara T, 2012, HEART RHYTHM, V9, P275, DOI 10.1016/j.hrthm.2011.09.066
   O'Hara T, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002061
   Qu YS, 2019, J PHARMACOL TOX MET, V99, DOI 10.1016/j.vascn.2019.05.105
   Ridder BJ, 2020, TOXICOL APPL PHARM, V394, DOI 10.1016/j.taap.2020.114961
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   Sanchez C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105897
   Sanchez-Alonso JL, 2016, CIRC RES, V119, P944, DOI 10.1161/CIRCRESAHA.116.308698
   Scheuer J, 1999, AM J CARDIOL, V83, p70H
   Shah A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01021
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Sobie EA, 2009, BIOPHYS J, V96, P1264, DOI 10.1016/j.bpj.2008.10.056
   SOFOLA OA, 1983, CLIN PHYSIOL, V3, P75, DOI 10.1111/j.1475-097X.1983.tb00701.x
   Sutanto H, 2020, J MOL CELL CARDIOL, V146, P69, DOI 10.1016/j.yjmcc.2020.07.007
   Sutanto H, 2020, PROG BIOPHYS MOL BIO, V157, P54, DOI 10.1016/j.pbiomolbio.2020.02.008
   Sutanto H, 2019, PHARMACOL RES, V148, DOI 10.1016/j.phrs.2019.104444
   Swaminathan PD, 2012, CIRC RES, V110, P1661, DOI 10.1161/CIRCRESAHA.111.243956
   Tomek J, 2017, AM J PHYSIOL-HEART C, V313, pH338, DOI 10.1152/ajpheart.00094.2017
   Uzelac I, 2020, HEART RHYTHM, V17, P1445, DOI 10.1016/j.hrthm.2020.05.030
   van den Broek MPH, 2020, NETH HEART J, V28, P406, DOI 10.1007/s12471-020-01429-7
   Varisco TJ, 2020, INT J INFECT DIS, V99, P373, DOI 10.1016/j.ijid.2020.07.071
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QL, 2018, CIRC-ARRHYTHMIA ELEC, V11, DOI 10.1161/CIRCEP.117.005682
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Weiss JN, 2010, HEART RHYTHM, V7, P1891, DOI 10.1016/j.hrthm.2010.09.017
NR 63
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD OCT 22
PY 2020
VL 11
AR 587709
DI 10.3389/fphys.2020.587709
PG 17
WC Physiology
SC Physiology
GA OL6VF
UT WOS:000585474200001
PM 33192602
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kharroubi, S
   Saleh, F
AF Kharroubi, Samer
   Saleh, Fatima
TI Are Lockdown Measures Effective Against COVID-19?
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE COVID-19; lockdown measures; Poisson regression model; modeling; Lebanon
AB As the Coronavirus Disease 2019 (COVID-19) pandemic progresses, countries around the world are increasingly implementing a range of responses that are intended to help prevent the transmission of this disease. In the absence of a COVID-19 vaccine, we assess the potential role of containment measures to suppress the virus transmission, thereby slowing down the growth rate of cases and rapidly reducing case incidence. The aim of this study is to show that country lockdown has a critical and significant impact on the pandemic. This is explored using real time incidence data in Lebanon. We analyze COVID-19 cases in Lebanon before and after lockdown measures have been implemented. The findings show that the nationwide lockdown was effective in reducing cases and has been successful in, so far, containing the virus. This study could be an evidence-based call to continue with the lockdown measures, based on real time incidence data. Further research is encouraged.
C1 [Kharroubi, Samer] Amer Univ Beirut, Fac Agr & Food Sci, Dept Nutr & Food Sci, Beirut, Lebanon.
   [Saleh, Fatima] Beirut Arab Univ, Fac Hlth Sci, Dept Med Lab Sci, Beirut, Lebanon.
RP Kharroubi, S (corresponding author), Amer Univ Beirut, Fac Agr & Food Sci, Dept Nutr & Food Sci, Beirut, Lebanon.
EM sk157@aub.edu.lb
CR Garvey MI, 2018, ANTIMICROB RESIST IN, V7, DOI 10.1186/s13756-018-0445-7
   Horton R, 2020, LANCET, V395, P935, DOI 10.1016/S0140-6736(20)30669-3
   Hwang SW, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-93
   Kwok KO, 2020, J INFECTION, V80, pE32, DOI 10.1016/j.jinf.2020.03.027
   Levy B, 2018, PEERJ, V6, DOI 10.7717/peerj.5888
   Ministry of Public Health, 2020, NOV COR 2019
   R Core Team, 2016, R LANG ENV STAT COMP
   Segun OE, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103474
   World Health Organization, 2020, COR DIS 2019
   Worldometer, 2020, COR CAS, DOI [10.1101/2020.01.23.20018549V2, DOI 10.1101/2020.01.23.20018549V2]
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zadoks RN, 2002, EPIDEMIOL INFECT, V129, P397, DOI 10.1017/S0950268802007483
NR 12
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD OCT 22
PY 2020
VL 8
AR 549692
DI 10.3389/fpubh.2020.549692
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OM8LY
UT WOS:000586270100001
PM 33194950
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Elzupir, AO
AF Elzupir, Amin O.
TI Caffeine and caffeine-containing pharmaceuticals as promising inhibitors
   for 3-chymotrypsin-like protease of SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Coronavirus SARS-CoV-2; COVID-19; 3-chymotrypsin-like protease;
   caffeine-containing pharmaceuticals; molecular dynamics
ID MOLECULAR-DYNAMICS; CORONAVIRUS; DYPHYLLINE; ACCURACY; SOFTWARE;
   COVID-19; EFFICACY; CHIMERA; SPEED
AB In December 2019, a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the outbreak of a pulmonary disease called COVID-19, which killed thousands of people worldwide. Therefore, the necessity to find out the potential therapeutic pharmaceuticals is imperious. This study investigates the inhibitory effect of SARS-CoV-2 3-chymotrypsin-like protease (3CL(pro)) using caffeine and caffeine-containing pharmaceuticals (3CPs) based on molecular dynamics simulations and free energy calculations by means of molecular mechanics-Poisson-Boltzmann surface area (MMPBSA) and molecular mechanics-generalized-Born surface area (MMGBSA). Of these 3CPs, seven drugs approved by the US-Food and Drug Administration have shown a good binding affinity to the catalytic residues of 3CL(pro) of His(41) and Cys(145): caffeine, theophylline, dyphylline, pentoxifylline, linagliptin, bromotheophylline and istradefylline. Their binding affinity score ranged from -4.9 to -8.6 kcal/mol. The molecular dynamic simulation in an aqueous solution of docked complexes demonstrated that the 3CPs conformations bound to the active sites of 3CL(pro) during 200 ns molecular dynamics simulations. The free energy of binding also confirms the stability of the 3CPs-3CL(pro) complexes. To our knowledge, this in silico study shows for the first time very inexpensive drugs available in large quantities that can be potential inhibitors against 3CL(pro). In particular, the repurposing of linagliptin, and caffeine are recommended for COVID-19 treatment after in vitro, in vivo and clinical trial validation.
   Communicated by Ramaswamy H. Sarma
C1 [Elzupir, Amin O.] Imam Mohammad Ibn Saud Islamic Univ IMSIU, Deanship Sci Res, Coll Sci, Riyadh, Saudi Arabia.
RP Elzupir, AO (corresponding author), Imam Mohammad Ibn Saud Islamic Univ IMSIU, Deanship Sci Res, Coll Sci, Riyadh, Saudi Arabia.
EM aminosman81@gmail.com
CR Ahmad S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1775129
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   ARANDA JV, 1977, J PEDIATR-US, V90, P467, DOI 10.1016/S0022-3476(77)80718-X
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Case D. A., 2006, AMBER 9
   Chang D, 2020, JAMA-J AM MED ASSOC, V323, P1092, DOI 10.1001/jama.2020.1623
   Chang YC, 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2., 10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   Charles MJ, 1997, J CHEM EDUC, V74, P1114
   Cooper A, 2004, J AM SOC NEPHROL, V15, P1877, DOI 10.1097/01.asn.0000131523.17045.56
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Deacon CF, 2010, EXPERT OPIN INV DRUG, V19, P133, DOI 10.1517/13543780903463862
   DELEEUW SW, 1980, P ROY SOC LOND A MAT, V373, P27, DOI 10.1098/rspa.1980.0135
   Duan YT, 2020, DRUG DISCOV TODAY, V25, P810, DOI 10.1016/j.drudis.2020.02.011
   Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381
   ELSAID Y, 1991, DRUG DEV IND PHARM, V17, P281, DOI 10.3109/03639049109043825
   Elzupir Amin O, 2020, J Mol Struct, V1222, P128878, DOI 10.1016/j.molstruc.2020.128878
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI [10.1186/1756-0500-5-185, 10.1186/1756-0500-5-367]
   FURUKAWA CT, 1983, J CLIN PHARMACOL, V23, P414, DOI 10.1002/j.1552-4604.1983.tb01784.x
   Hauser RA, 2003, NEUROLOGY, V61, P297, DOI 10.1212/01.WNL.0000081227.84197.0B
   Herten-Crabb A, 2020, LANCET, V395, P1018, DOI 10.1016/S0140-6736(20)30110-0
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   HOLBERT JM, 1955, J AM PHARM ASSOC, V44, P355, DOI 10.1002/jps.3030440614
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jilani TN, 2019, STATPEARLS
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   MUIR WW, 1987, VET CLIN N AM-EQUINE, V3, P37, DOI 10.1016/S0749-0739(17)30690-9
   Nair K. P., FOOD HUMAN RESPONSES, DOI [10.1007/978-3-030-35437-4_10, DOI 10.1007/978-3-030-35437-4_10]
   Ndikuryayo F, 2019, EUR J MED CHEM, V166, P22, DOI 10.1016/j.ejmech.2019.01.032
   Nelson MT, 1996, INT J SUPERCOMPUT AP, V10, P251, DOI 10.1177/109434209601000401
   Numata J, 2007, GENOME INFORM SER, V18, P192
   Petimar J, 2019, EUR J NEUROL, V26, P468, DOI 10.1111/ene.13840
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Risner CH, 2008, J CHROMATOGR SCI, V46, P892, DOI 10.1093/chromsci/46.10.892
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sabino-Silva R, 2020, CLIN ORAL INVEST, V24, P1619, DOI 10.1007/s00784-020-03248-x
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Sk MF, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768149
   Speer EM, 2017, PEDIATR RES, V81, P806, DOI 10.1038/pr.2017.6
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   US-Food & drug Administration, 2020, GS5734 US FOOD DRUG
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   World Health O, 2020, COR DIS 2019 COVID 1
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 58
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1835732
EA OCT 2020
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OI6LK
UT WOS:000583387400001
PM 33094705
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bsteh, G
   Bitschnau, C
   Hegen, H
   Auer, M
   Di Pauli, F
   Rommer, P
   Deisenhammer, F
   Berger, T
AF Bsteh, G.
   Bitschnau, C.
   Hegen, H.
   Auer, M.
   Di Pauli, F.
   Rommer, P.
   Deisenhammer, F.
   Berger, T.
TI Multiple sclerosis and COVID-19: how many are at risk?
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article; Early Access
DE comorbidities; COVID&#8208; 19; multiple sclerosis; risk; SARS&#8208;
   CoV&#8208; 2
ID PREVALENCE; REVISIONS; DISEASE; CANCER
AB Background and purpose The coronavirus disease 2019 (COVID-19) pandemic challenges neurologists in counseling multiple sclerosis (MS) patients with respect to their risk for and by severe acute respiratory syndrome coronavirus 2 and in guiding disease-modifying treatment (DMT). The objective was to determine the frequency and distribution of currently known risk factors for COVID-19 mortality in an MS population.
   Methods Multiple sclerosis patients with at least one complete case report between January 1, 2015 and December 31, 2019 from the Innsbruck MS database were cross-sectionally included. Frequencies of currently estimated COVID-19 mortality risk factors were analyzed, and the cumulative risk was calculated by a recently developed score. For every risk group, the proportions of patients under DMT and immunosuppressive treatment were determined.
   Results Of 1931 MS patients, 63.4% had low risk of COVID-19 mortality, 26% had mild risk, 8.8% had a moderate risk, whereas a combined 0.9% had high or very high risk of COVID-19 mortality. Of the patients at high or very high risk, only one patient received DMT and none had an immunosuppressive therapy.
   Conclusions In a population-based MS cohort, the proportion of patients at high risk of COVID-19 mortality is below 1%. Importantly, the vast majority of these MS patients did not receive any DMT.
C1 [Bsteh, G.; Rommer, P.; Berger, T.] Med Univ Vienna, Dept Neurol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Bitschnau, C.; Hegen, H.; Auer, M.; Di Pauli, F.; Deisenhammer, F.] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria.
RP Bsteh, G (corresponding author), Med Univ Vienna, Dept Neurol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM gabriel.bsteh@meduniwien.ac.at
CR Amor S, 2020, ANN NEUROL, V87, P794, DOI 10.1002/ana.25770
   [Anonymous], 2010, COVID 19 DEATH RATES
   Asamer EM, 2016, AUST J STAT, V45, P3, DOI 10.17713/ajs.v45i2.97
   Berger JR, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000761
   Bsteh G, 2017, J NEUROL SCI, V376, P71, DOI 10.1016/j.jns.2017.03.002
   Bsteh G, 2018, MULTIPLE SCLER, V127
   Bsteh G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158978
   Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X
   Grebenciucova E, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0800-8
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamer M, 2020, BRAIN BEHAV IMMUN, V87, P184, DOI 10.1016/j.bbi.2020.05.059
   Khurana SR, 2009, AM J PHYS MED REHAB, V88, P83, DOI 10.1097/PHM.0b013e318194f8b5
   Louapre C, 2020, JAMA NEUROL, V77, P1079, DOI 10.1001/jamaneurol.2020.2581
   Marrie RA, 2015, MULT SCLER J, V21, P318, DOI 10.1177/1352458514564485
   Marrie RA, 2015, MULT SCLER J, V21, P294, DOI 10.1177/1352458514564489
   Marrie RA, 2015, MULT SCLER J, V21, P263, DOI 10.1177/1352458514564491
   Minden SL, 2004, NEUROREHABILITATION, V19, P55
   Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.20703
   Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366
   Salhofer-Polanyi S, 2017, NEUROEPIDEMIOLOGY, V49, P40, DOI 10.1159/000479696
   Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2
   Tian JB, 2020, LANCET ONCOL, V21, P893, DOI 10.1016/S1470-2045(20)30309-0
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Bello-Chavolla OY, 2020, J CLIN ENDOCR METAB, V105, P2752, DOI 10.1210/clinem/dgaa346
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 25
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
DI 10.1111/ene.14555
EA OCT 2020
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OH0XF
UT WOS:000582295100001
PM 32978860
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Rut, W
   Groborz, K
   Zhang, LL
   Sun, XYY
   Zmudzinski, M
   Pawlik, B
   Wang, XY
   Jochmans, D
   Neyts, J
   Mlynarski, W
   Hilgenfeld, R
   Drag, M
AF Rut, Wioletta
   Groborz, Katarzyna
   Zhang, Linlin
   Sun, Xinyuanyuan
   Zmudzinski, Mikolaj
   Pawlik, Bartlomiej
   Wang, Xinyu
   Jochmans, Dirk
   Neyts, Johan
   Mlynarski, Wojciech
   Hilgenfeld, Rolf
   Drag, Marcin
TI SARS-CoV-2 M-pro inhibitors and activity-based probes for patient-sample
   imaging
SO NATURE CHEMICAL BIOLOGY
LA English
DT Article; Early Access
ID CORONAVIRUS; PROTEASE; SARS; DESIGN; OUTBREAK
AB In December 2019, the first cases of infection with a novel coronavirus, SARS-CoV-2, were diagnosed. Currently, there is no effective antiviral treatment for COVID-19. To address this emerging problem, we focused on the SARS-CoV-2 main protease that constitutes one of the most attractive antiviral drug targets. We have synthesized a combinatorial library of fluorogenic substrates with glutamine in the P1 position. We used it to determine the substrate preferences of the SARS-CoV and SARS-CoV-2 main proteases. On the basis of these findings, we designed and synthesized a potent SARS-CoV-2 inhibitor (Ac-Abu-dTyr-Leu-Gln-VS, half-maximal effective concentration of 3.7 mu M) and two activity-based probes, for one of which we determined the crystal structure of its complex with the SARS-CoV-2 M-pro. We visualized active SARS-CoV-2 M-pro in nasopharyngeal epithelial cells of patients suffering from COVID-19 infection. The results of our work provide a structural framework for the design of inhibitors as antiviral agents and/or diagnostic tests.
C1 [Rut, Wioletta; Groborz, Katarzyna; Zmudzinski, Mikolaj; Drag, Marcin] Wroclaw Univ Sci & Technol, Dept Chem Biol & Bioimaging, Wroclaw, Poland.
   [Zhang, Linlin; Sun, Xinyuanyuan; Hilgenfeld, Rolf] Univ Lubeck, Inst Mol Med, Lubeck, Germany.
   [Zhang, Linlin; Sun, Xinyuanyuan] Univ Lubeck, Inst Biochem, Ctr Struct & Cell Biol Med, Lubeck, Germany.
   [Zhang, Linlin; Sun, Xinyuanyuan; Hilgenfeld, Rolf] Univ Lubeck, German Ctr Infect Res DZIF, Hamburg Lubeck Borstel Riems Site, Lubeck, Germany.
   [Pawlik, Bartlomiej; Mlynarski, Wojciech] Med Univ Lodz, Dept Pediat Oncol & Hematol, Lodz, Poland.
   [Pawlik, Bartlomiej] Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland.
   [Wang, Xinyu; Jochmans, Dirk; Neyts, Johan] Katholieke Univ Leuven, Rega Inst, Dept Microbiol Immunol & Transplantat, Lab Virol & Chemotherapy, Leuven, Belgium.
   [Hilgenfeld, Rolf] Univ Lubeck, Ctr Brain Behav & Metab, Lubeck, Germany.
RP Rut, W; Drag, M (corresponding author), Wroclaw Univ Sci & Technol, Dept Chem Biol & Bioimaging, Wroclaw, Poland.
EM wioletta.rut@pwr.edu.pl; marcin.drag@pwr.edu.pl
RI ; NEYTS, Johan/U-8267-2017; Pawlik, Bartlomiej/H-7072-2018; JOCHMANS,
   DIRK/T-6223-2017
OI Mlynarski, Wojciech/0000-0003-2714-5851; NEYTS,
   Johan/0000-0002-0033-7514; Pawlik, Bartlomiej/0000-0002-8803-1033;
   JOCHMANS, DIRK/0000-0002-9265-6028
FU National Science Center in PolandNational Science Center, PolandNational
   Science Centre, Poland [TEAM/2017-4/32]; Foundation for Polish
   ScienceFoundation for Polish Science; European Union under the European
   Regional Development Fund; SCORE project of the European Union
   [101003627]; DZIF; Government of Schleswig-Holstein; Possehl Foundation
   (Lubeck); University of Lubeck; China Scholarship CouncilChina
   Scholarship Council [201806170087]; FIXNET project; European Union under
   the European Regional Development Fund [POIR.04.04.00-00-1603/18]
FX The Drag laboratory is supported by the National Science Center in
   Poland and the 'TEAM/2017-4/32' project, which is conducted within the
   TEAM program of the Foundation for Polish Science cofinanced by the
   European Union under the European Regional Development Fund. Work in the
   Hilgenfeld laboratory was supported by the SCORE project of the European
   Union (grant agreement no. 101003627), by DZIF and by the Government of
   Schleswig-Holstein through its Structure and Excellence Fund, as well as
   by a close partnership between the Possehl Foundation (Lubeck) and the
   University of Lubeck. Work in the Neyts laboratory was similarly
   supported by the SCORE project of the European Union (grant agreement
   no. 101003627). X.W. received funding of the China Scholarship Council
   (grant no. 201806170087). L.Z. is supported by a stipend from DZIF. W.R.
   is a beneficiary of a START scholarship from the Foundation for Polish
   Science. The Mlynarski laboratory (B.P. and W.M.) is supported by the
   FIXNET project, which is conducted within the TEAM-NET program of the
   Foundation for Polish Science cofinanced by the European Union under the
   European Regional Development Fund (no POIR.04.04.00-00-1603/18). We
   thank A. Piekarska (Medical University of Lodz, Poland) for an expert
   consultation in clinical assessments of patients with COVID-19.
CR Aleshin AE, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.388678
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Boudewijns R, 2020, STAT2 SIGNALING DOUB, DOI [DOI 10.1101/2020.04.23.056838, 10.1101/2020.04.23.056838]
   Chuck CP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027228
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693
   Evans PR, 2011, ACTA CRYSTALLOGR D, V67, P282, DOI 10.1107/S090744491003982X
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kasperkiewicz P, 2017, J AM CHEM SOC, V139, P10115, DOI 10.1021/jacs.7b04394
   Kasperkiewicz P, 2014, P NATL ACAD SCI USA, V111, P2518, DOI 10.1073/pnas.1318548111
   Krug M, 2012, J APPL CRYSTALLOGR, V45, P568, DOI 10.1107/S0021889812011715
   Lebedev AA, 2012, ACTA CRYSTALLOGR D, V68, P431, DOI 10.1107/S090744491200251X
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Maluch I, 2019, CHEM-ASIAN J, V14, P4103, DOI 10.1002/asia.201901152
   Maly DJ, 2002, J ORG CHEM, V67, P910, DOI 10.1021/jo016140o
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Poreba M, 2019, CELL DEATH DIFFER, V26, P2695, DOI 10.1038/s41418-019-0329-2
   Poreba M, 2018, CHEM SCI, V9, P2113, DOI 10.1039/c7sc04303a
   Poreba M, 2015, CHEM REV, V115, P12546, DOI 10.1021/acs.chemrev.5b00434
   Poreba M, 2014, CELL DEATH DIFFER, V21, P1482, DOI 10.1038/cdd.2014.64
   Rut W, 2018, J MED CHEM, V61, P5222, DOI 10.1021/acs.jmedchem.8b00026
   Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   World Health Organization, 2020, COR DIS COVID 2019 S
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu AD, 2015, VIRUS RES, V208, P56, DOI 10.1016/j.virusres.2015.05.018
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu LL, 2011, ANTIVIR RES, V92, P204, DOI 10.1016/j.antiviral.2011.08.001
NR 37
TC 0
Z9 0
U1 6
U2 6
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1552-4450
EI 1552-4469
J9 NAT CHEM BIOL
JI Nat. Chem. Biol.
DI 10.1038/s41589-020-00689-z
EA OCT 2020
PG 20
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OG0LZ
UT WOS:000581588300001
PM 33093684
OA Bronze
DA 2021-01-01
ER

PT J
AU Staehler, MD
   Battle, DJ
   Bergerot, CD
   Pal, SK
   Penson, DF
AF Staehler, Michael D.
   Battle, Dena J.
   Bergerot, Cristiane D.
   Pal, Sumanta Kumar
   Penson, David F.
TI COVID-19 and financial toxicity in patients with renal cell carcinoma
SO WORLD JOURNAL OF UROLOGY
LA English
DT Article; Early Access
DE Renal cell carcinoma; Health care survey; Frustration; Qualitative
   study; Financial toxicity; COST score
AB Purpose To ascertain renal cell carcinoma (RCC) financial toxicity on COVID-19 during the COVID-19 crisis as patients are struggling with therapeutic and financial implications. Methods An online survey was conducted from March 22 to March 25, 2020. It included baseline demographic, clinicopathologic, treatment-related information, anxiety levels related to COVID-19, questions related to financial concerns about COVID-19 as well as the validated 11-item COST measure. Results Five-hundred-and-thirty-nine patients (39%:58% male:female) from 14 countries responded. 23% of the patients did not feel in control of their financial situation but 8% reported being very satisfied with their finances. The median COST score was 21.5 (range 1-44). Metastatic patients who have not started systemic therapy had a COST score (19.8 range 2-41) versus patients on oral systemic therapy had a COST score (23.9 range 4-44). Patients in follow-up after surgery had a median COST score at 20.8 (range 1-40). A low COST scores correlated (p < 0.001) were female gender (r = 0.108), younger age (r = 0.210), urban living situation (r = 0.68), a lower educational level (r = 0.155), lower income (r = 0.165), higher anxiety about acquiring COVID-19 (r = 0.198), having metastatic disease (r = 0.073) and a higher distress score about cancer progression (r = 0.224). Conclusion Our data highlight severe financial impact of COVID-19. Acknowledging financial hardship and thorough counseling of cancer patients should be part of the conversation during the pandemic. Treatment and surveillance of RCC patients might have to be adjusted to contemplate financial and medical needs.
C1 [Staehler, Michael D.] Univ Munich, Ludwig Maximilians Univ, Dept Urol, Marchioninistr 15, D-81377 Munich, Germany.
   [Battle, Dena J.] Kidney Canc Res Alliance KCCure, Alexandria, VA USA.
   [Bergerot, Cristiane D.; Pal, Sumanta Kumar] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA.
   [Penson, David F.] Vanderbilt Univ, Med Ctr, Dept Urol, Nashville, TN USA.
RP Staehler, MD (corresponding author), Univ Munich, Ludwig Maximilians Univ, Dept Urol, Marchioninistr 15, D-81377 Munich, Germany.
EM michael.staehler@med.lmu-muenchen.de
RI Staehler, Michael/N-6463-2014
OI Staehler, Michael/0000-0002-4574-6522
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR Addario BJ, 2018, HEALTH EXPECT, V21, P57, DOI 10.1111/hex.12628
   Bergerot CD, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00011
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Costanzo M, 2020, CURR MED CHEM, V27, P4536, DOI 10.2174/0929867327666200416131117
   de Souza JA, 2017, CANCER-AM CANCER SOC, V123, P476, DOI 10.1002/cncr.30369
   de Souza JA, 2014, CANCER-AM CANCER SOC, V120, P3245, DOI 10.1002/cncr.28814
   Desai Aakash, 2020, EClinicalMedicine, V20, P100269, DOI 10.1016/j.eclinm.2020.100269
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Pagano MB, 2020, TRANSFUSION, V60, P908, DOI 10.1111/trf.15789
   Parmet WE, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2004211
   Pisu M, 2018, CANCER-AM CANCER SOC, V124, P4181, DOI 10.1002/cncr.31643
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   UNACD, COR SHOCK AN STOR GL
   Yang GL, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420912811
   Zheng ZY, 2019, CANCER-AM CANCER SOC, V125, P1737, DOI 10.1002/cncr.31913
NR 16
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0724-4983
EI 1433-8726
J9 WORLD J UROL
JI World J. Urol.
DI 10.1007/s00345-020-03476-6
EA OCT 2020
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA OG5TW
UT WOS:000581947100002
PM 33090258
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ghosh, R
   Chakraborty, A
   Biswas, A
   Chowdhuri, S
AF Ghosh, Rajesh
   Chakraborty, Ayon
   Biswas, Ashis
   Chowdhuri, Snehasis
TI Potential therapeutic use of corticosteroids as SARS CoV-2 main protease
   inhibitors: a computational study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS CoV-2 main protease; docking and molecular dynamics
   simulation; corticosteroids; dexamethasone
ID MOLECULAR-DYNAMICS; ANTIVIRAL AGENTS; CORONAVIRUS; DEXAMETHASONE;
   SARS-COV-2; VIRUS; INFLAMMATION; PROTEINASE; MECHANISMS; PREVENTION
AB The outbreak of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), represents a pandemic threat to global public health. To date, similar to 530,000 people died of this disease worldwide. Presently, researchers/clinicians are adopting the drug repurposing strategy to combat this disease. It has also been observed that some repurposed anti-viral drugs may serve as potent inhibitors of SARS CoV-2 Mpro, a key component of viral replication. Apart from these anti-viral drugs, recently dexamethasone (an important corticosteroid) is effectively used to treat COVID-19 patients. However, the mechanism behind the mode of its action is not so clear. Additionally, the effect of other well-known corticosteroids to control this disease by inhibiting the proteolytic activity of Mpro is ambiguous. In this study, we have adopted computational approaches to understand these aspects. Six well-known corticosteroids (cortisone, hydrocortisone, prednisolone, methylprednisolone, betamethasone and dexamethasone) and two repurposed drugs (darunavir and lopinavir) against COVID-19 were subjected for molecular docking studies. Two of them (betamethasone and dexamethasone) were selected by comparing their binding affinities with selected repurposed drugs toward Mpro. Betamethasone and dexamethasone interacted with both the catalytic residues of Mpro (His41 and Cys145). Molecular dynamics studies further revealed that these two Mpro-corticosteroid complexes are more stable, experience less conformational fluctuations and more compact than Mpro-darunavir/lopinavir complexes. These findings were additionally validated by MM-GBSA analysis. This study provides corroboration for execution of anti-COVID-19 activity of dexamethasone. Our study also emphasizes on the use of another important corticosteroid (betamethasone) as potential therapeutic agent for COVID-19 treatment.
C1 [Ghosh, Rajesh; Chakraborty, Ayon; Biswas, Ashis; Chowdhuri, Snehasis] Indian Inst Technol Bhubaneswar, Sch Basic Sci, Bhubaneswar, India.
RP Biswas, A; Chowdhuri, S (corresponding author), Indian Inst Technol Bhubaneswar, Sch Basic Sci, Arugul 752050, Odisha, India.
EM abiswas@iitbbs.ac.in; snehasis@iitbbs.ac.in
OI Chakraborty, Ayon/0000-0002-1155-7862
FU IIT Bhubaneswar
FX RG acknowledges IIT Bhubaneswar for providing fellowship. The authors
   thank IIT Delhi HPC facility for computational resources.
CR Abeyagunawardena AS, 2008, ARCH DIS CHILD, V93, P226, DOI 10.1136/adc.2007.116079
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Alberti C, 2011, J MED VIROL, V83, P1641, DOI 10.1002/jmv.22131
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Baby Krishnaprasad, 2020, Arch Med Res, DOI 10.1016/j.arcmed.2020.09.013
   Barnes PJ, 2006, BRIT J PHARMACOL, V148, P245, DOI 10.1038/sj.bjp.0706736
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bharadwaj S, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118080
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   Biovia D. S., 2017, DISCOVERY STUDIO MOD
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Cascella M, 2020, FEATURES EVALUATION
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chou KC, 2003, BIOCHEM BIOPH RES CO, V308, P148, DOI 10.1016/S0006-291X(03)01342-1
   Clement C, 2011, INVEST OPHTH VIS SCI, V52, P339, DOI 10.1167/iovs.10-5944
   Confalonieri Marco, 2010, Ther Adv Respir Dis, V4, P233, DOI 10.1177/1753465810376951
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   Dobson J, 2015, LANCET, V385, P1729, DOI 10.1016/S0140-6736(14)62449-1
   Emery VC, 2000, J INFECT DIS, V182, P1610, DOI 10.1086/317636
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Frisch M. J., 2013, GAUSSIAN 09 REVISION
   Gagyor I, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001869.pub9
   GHOSH R, 2020, J BIOMOL STRUCT 0620, DOI DOI https://doi.org/10.1080/07391102.2020.1779818
   GHOSH R, 2020, J BIOMOL STRUCT 0806, DOI DOI https://doi.org/10.1080/07391102.2020.1802347
   Gorla Uma Sankar, 2020, Comb Chem High Throughput Screen, DOI 10.2174/1386207323999200818162706
   Grum-Tokars V, 2008, VIRUS RES, V133, P63, DOI 10.1016/j.virusres.2007.02.015
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gurung AB, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117831
   Hage-Melim LID, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117963
   Hakmi M, 2020, BIOINFORMATION, V16, P301, DOI 10.6026/97320630016301
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hodos RA, 2016, WIRES SYST BIOL MED, V8, P186, DOI 10.1002/wsbm.1337
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Hsu MF, 2005, J BIOL CHEM, V280, P31257, DOI 10.1074/jbc.M502577200
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jimenez-Alberto A, 2020, COMPUT BIOL CHEM, V88, DOI 10.1016/j.compbiolchem.2020.107325
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi T, 2020, EUR REV MED PHARMACO, V24, P4529, DOI 10.26355/eurrev_202004_21036
   JOSHI T, 2020, MOL DIVERS 0629, DOI DOI https://doi.org/10.1007/s11030-020-10118-x
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   KILBOURNE ED, 1957, J EXP MED, V106, P863, DOI 10.1084/jem.106.6.863
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Kumar Y, 2020, J INFECT PUBLIC HEAL, V13, P1210, DOI 10.1016/j.jiph.2020.06.016
   Liu HX, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016620
   Lv ZT, 2015, HIV AIDS-RES PALLIAT, V7, P95, DOI 10.2147/HIV.S79956
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mazzini S, 2020, MOLECULES, V25, DOI 10.3390/molecules25163745
   Mercorelli B, 2018, TRENDS MICROBIOL, V26, P865, DOI 10.1016/j.tim.2018.04.004
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805
   Morris Garrett M, 2008, Curr Protoc Bioinformatics, VChapter 8, DOI 10.1002/0471250953.bi0814s24
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Odhar HA, 2020, BIOINFORMATION, V16, P236, DOI 10.6026/97320630016236
   Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090
   Osman EEA, 2020, ACS INFECT DIS, V6, P1548, DOI 10.1021/acsinfecdis.0c00224
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   SPOTO S, 2019, BMC INFECT DIS, V19, DOI DOI https://doi.org/10.1186/s12879-018-3606-7
   Sullivan F, 2016, JAMA-J AM MED ASSOC, V316, P874, DOI 10.1001/jama.2016.10160
   Tang EJ, 2014, INT J CARDIOL, V173, P133, DOI 10.1016/j.ijcard.2014.03.019
   Thaera GM, 2010, NEUROLOGIST, V16, P138, DOI 10.1097/NRL.0b013e3181d35775
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Turner MT, 2014, OTOL NEUROTOL, V35, P712, DOI 10.1097/MAO.0000000000000231
   WHEELER CE, 1961, J INVEST DERMATOL, V36, P89, DOI 10.1038/jid.1961.18
   Wright JJ, 2005, J HEART LUNG TRANSPL, V24, P343, DOI 10.1016/j.healun.2004.01.003
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue HQ, 2018, INT J BIOL SCI, V14, P1232, DOI 10.7150/ijbs.24612
   Yan L, 2003, FEBS LETT, V554, P257, DOI 10.1016/S0014-5793(03)01115-3
   Yim EK, 2006, INT J GYNECOL CANCER, V16, P2023, DOI 10.1111/j.1525-1438.2006.00726.x
   YODER MC, 1991, AM REV RESPIR DIS, V143, P1044, DOI 10.1164/ajrccm/143.5_Pt_1.1044
   Yu WC, 2004, THORAX, V59, P643, DOI 10.1136/thx.2003.017665
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 79
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1835728
EA OCT 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OF4CP
UT WOS:000581158300001
PM 33094701
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Mandour, YM
   Zlotos, DP
   Salem, MA
AF Mandour, Yasmine M.
   Zlotos, Darius P.
   Salem, M. Alaraby
TI A multi-stage virtual screening of FDA-approved drugs reveals potential
   inhibitors of SARS-CoV-2 main protease
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2 main protease; drug repurposing; virtual screening;
   pharmacophore; docking; MD simulations
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS-CORONAVIRUS; TRIFLUOROMETHYL
   KETONES; BIOLOGICAL EVALUATION; GENETIC ALGORITHM; BINDING; DESIGN;
   IDENTIFICATION; DISCOVERY; DYNAMICS
AB Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing global health emergency. Repurposing of approved pharmaceutical drugs for COVID-19 treatment represents an attractive approach to quickly identify promising drug candidates. SARS-CoV-2 main protease (M-pro) is responsible for the maturation of viral functional proteins making it a key antiviral target. Based on the recently revealed crystal structures of SARS-CoV-2 M-pro, we herein describe a multi-stage virtual screening protocol including pharmacophore screening, molecular docking and protein-ligand interaction fingerprints (PLIF) post-docking filtration for efficient enrichment of potent SARS-CoV-2 M-pro inhibitors. Potential hits, along with a cocrystallized control were further studied via molecular dynamics. A 150-ns production trajectory was followed by RMSD, free energy calculation, and H-bond analysis for each compound. The applied virtual screening protocol led to identification of five FDA-approved drugs with promising binding modes to key subsites of the substrate-binding pocket of SARS-CoV-2 M-pro. The identified compounds belong to different pharmaceutical classes, including several protease inhibitors, antineoplastic agents and a natural flavonoid. The drug candidates discovered in this study present a potential extension of the recently reported SARS-CoV-2 M-pro inhibitors that have been identified using other virtual screening protocols and may be repurposed for COVID-19 treatment.
C1 [Mandour, Yasmine M.; Zlotos, Darius P.] German Univ Cairo, Fac Pharm & Biotechnol, Pharmaceut Chem Dept, Cairo, Egypt.
   [Mandour, Yasmine M.] Univ Hertfordshire, Sch Life & Med Sci, Global Acad Fdn, Cairo, Egypt.
   [Salem, M. Alaraby] October Univ Modern Sci & Arts MSA, Fac Pharm, Dept Pharmaceut Chem, Giza, Egypt.
RP Mandour, YM (corresponding author), German Univ Cairo, Fac Pharm & Biotechnol, Pharmaceut Chem Dept, Cairo, Egypt.; Mandour, YM (corresponding author), Univ Hertfordshire, Sch Life & Med Sci, Global Acad Fdn, Cairo, Egypt.
EM yasminemandour@yahoo.com
OI Mandour, Yasmine/0000-0001-7104-3268
FU Westgrid; Compute/Calcul Canada
FX This research was enabled in part by support provided by Westgrid
   (www.westgrid.ca) and Compute/Calcul Canada
   (www.computecanada.ca).Access to Westgrid was provided through
   collaboration with Professor Alex Brown, University of Alberta. We also
   thank Dr. Ahmed Taha Ayoub for helpful discussions and useful insights
   on the MD part of the study.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   ANCY I, 2020, J BIOMOL STRUCT 0703, DOI DOI https://doi.org/10.1080/07391102.2020.1786459
   Anighoro A, 2016, J COMPUT AID MOL DES, V30, P447, DOI 10.1007/s10822-016-9918-z
   Anighoro A, 2016, J CHEM INF MODEL, V56, P580, DOI 10.1021/acs.jcim.5b00745
   [Anonymous], 2015, PYMOL MOL GRAPH SYST
   AOUIDATE A, 2020, J BIOMOL STRUCT 0617, DOI DOI https://doi.org/10.1080/07391102.2020.1779130
   ARUN KG, 2020, J BIOMOL STRUCT 0620, DOI DOI https://doi.org/10.1080/07391102.2020.1779819
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   BAILEY OT, 1949, J EXP MED, V90, P195, DOI 10.1084/jem.90.3.195
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Bartlam Mark, 2007, Journal of Structural and Functional Genomics, V8, P85, DOI 10.1007/s10969-007-9024-5
   BEGUE JP, 1991, TETRAHEDRON, V47, P3207, DOI 10.1016/S0040-4020(01)86391-2
   Case D. A., 2020, AMBER 12
   CHATTERJEE S, 2020, J BIOMOL STRUCT 0630, DOI DOI https://doi.org/10.1080/07391102.2020.1787228
   Chen LL, 2006, BIOORGAN MED CHEM, V14, P8295, DOI 10.1016/j.bmc.2006.09.014
   Chen ZM, 2020, WORLD J PEDIATR, V16, P240, DOI 10.1007/s12519-020-00345-5
   Da C, 2014, J CHEM INF MODEL, V54, P2555, DOI 10.1021/ci500319f
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   GELB MH, 1985, BIOCHEMISTRY-US, V24, P1813, DOI 10.1021/bi00329a001
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Homeyer N, 2012, MOL INFORM, V31, P114, DOI 10.1002/minf.201100135
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jacobs J, 2013, J MED CHEM, V56, P534, DOI 10.1021/jm301580n
   Jain RP, 2004, J MED CHEM, V47, P6113, DOI 10.1021/jm0494873
   Jenwitheesuk E, 2003, BIOORG MED CHEM LETT, V13, P3989, DOI 10.1016/j.bmcl.2003.08.066
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   KUMAR D, 2020, J BIOMOL STRUCT 0620, DOI DOI https://doi.org/10.1080/07391102.2020.1779131
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   LONCHARICH RJ, 1992, BIOPOLYMERS, V32, P523, DOI 10.1002/bip.360320508
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Molecular Operating Environment (MOE), 2019, MOL OP ENV MOE
   Mysinger MM, 2012, J MED CHEM, V55, P6582, DOI 10.1021/jm300687e
   Neudert G, 2011, J CHEM INF MODEL, V51, P2731, DOI 10.1021/ci200274q
   Payne S, 2017, VIRUSES: FROM UNDERSTANDING TO INVESTIGATION, P149, DOI 10.1016/B978-0-12-803109-4.00017-9
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Salem MA, 2015, PHYS CHEM CHEM PHYS, V17, P25563, DOI 10.1039/c5cp03875h
   Shao YM, 2008, BIOORGAN MED CHEM, V16, P4652, DOI 10.1016/j.bmc.2008.02.040
   Shie JJ, 2005, J MED CHEM, V48, P4469, DOI 10.1021/jm050184y
   Shimamoto Y, 2015, BIOORGAN MED CHEM, V23, P876, DOI 10.1016/j.bmc.2014.12.028
   Thanigaimalai P, 2013, EUR J MED CHEM, V68, P372, DOI 10.1016/j.ejmech.2013.07.037
   Thanigaimalai P, 2013, EUR J MED CHEM, V65, P436, DOI 10.1016/j.ejmech.2013.05.005
   Tomlinson SM, 2011, ANTIVIR RES, V89, P127, DOI 10.1016/j.antiviral.2010.12.006
   Turlington M, 2013, BIOORG MED CHEM LETT, V23, P6172, DOI 10.1016/j.bmcl.2013.08.112
   Turner P., 2005, XMGRACE VERSION 5 1
   Wang F. H., 2016, SCI REP UK, V6, DOI DOI https://doi.org/10.1038/srep22677
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wang JM, 2019, J CHEM INF MODEL, V59, P53, DOI 10.1021/acs.jcim.8b00537
   Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401
   World Health Organization, 2020, TIM WHOS RESP COVID
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yi L, 2004, J VIROL, V78, P11334, DOI 10.1128/JVI.78.20.11334-11339.2004
   Zhang HZ, 2006, J MED CHEM, V49, P1198, DOI 10.1021/jm0507678
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhu LL, 2011, ANTIVIR RES, V92, P204, DOI 10.1016/j.antiviral.2011.08.001
NR 67
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1837680
EA OCT 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OF4CZ
UT WOS:000581159300001
PM 33094680
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Collica-Cox, K
   Molina, L
AF Collica-Cox, Kimberly
   Molina, Louis
TI A Case Study of the Westchester County New York's Jail Response to
   COVID-19: Controlling COVID while Balancing Service Needs for the
   Incarcerated-A National Model for Jails
SO VICTIMS & OFFENDERS
LA English
DT Article; Early Access
DE COVID; county jails; pandemic; correctional; Covid-19; pandemic;
   alternatives to incarceration; early release mechanisms; prison reform
AB Controlling COVID rates, which initially soared within New York State, proved to be more challenging for correctional institutions, which were tasked with trying to protect a captive population. This article profiles the Westchester County Department of Correction (WCDOC), a county jail located 20 miles north of Manhattan; it is the second-largest jail in New York State. By employing a multitude of modalities, the WCDOC was able to lower their COVID-19 rates significantly, while simultaneously providing medical, mental health, drug treatment, and court-related services. By leveraging the use of technology and employing innovative policies for prisoners and staff, the WCDOC can serve as a model for other correctional institutions.
C1 [Collica-Cox, Kimberly] PACE Univ, Dyson Coll Arts & Sci, Criminal Justice & Secur, New York, NY 10038 USA.
   [Molina, Louis] WCDOC, Headquarters, Valhalla, NY USA.
RP Collica-Cox, K (corresponding author), PACE Univ, Dyson Coll Arts & Sci, Criminal Justice & Secur, New York, NY 10038 USA.
EM kcollicacox@pace.edu
OI Collica-Cox, Kimberly/0000-0002-6598-8000
CR AMA, 2020, ISS BRIEF REP INCR O
   Andrews DA, 2006, CRIME DELINQUENCY, V52, P7, DOI 10.1177/0011128705281756
   Andrews DA, 2012, INT J OFFENDER THER, V56, P113, DOI 10.1177/0306624X10395716
   Bronson J., 2017, 250612 NCJ BUR JUST
   Carissimo J., 2020, CBS NEWS
   CDC (Centers For Disease Control and Prevention), 2020, INT GUID MAN COR DIS
   Centers for Disease Control, 2020, COR DIS 2019
   Collica-Cox K., 2018, AM JAILS, V31
   Collica-Cox K, 2020, J CORRECT HEALTH CAR, V26, P138, DOI 10.1177/1078345820916475
   Coltin J., 2020, CITY STATE NEW  0404
   Ferre-Sadurni L, 2020, NY TIMES
   Higgins-Dunn N., 2020, CNBC NEWS       0522
   Jewkes Y., 2009, HOWARD J CRIMINAL JU, V48, P132, DOI [10.1111/j.1468-2311.2009.00559.x, DOI 10.1111/J.1468-2311.2009.00559.X]
   Jin B., 2020, POLITICO
   Joudrey PJ, 2019, ADDICT SCI CLIN PRAC, V14, DOI 10.1186/s13722-019-0145-5
   Kindy K., 2020, WASHINGTON POST
   King D. H., 2020, SHELTERFORCE    0511
   Lartey J., 2020, NEW YORK ROLLED BACK
   Lewis N., 2020, CAN COLL PROGRAMS PR
   Longley J., 2020, OVERDOSES SPIKE CORO
   Lungariello M., 2020, LOHUD
   Marroquin M., 2020, LOHUD
   McCarthy C., 2020, NEW YORK POST   0419
   McKinley J., 2020, NY TIMES
   Merkl T. A., 2020, NEW YORKS LATEST BAI
   New York State Division of Criminal Justice Services, 2013, CHILDR INC PAR NEW Y
   NYS (New York State), 2020, INF NOV COR
   Park K., 2020, STAT SAT LOOK COR VI
   Prison Policy Initiative, 2020, RESP COV 19 PAND
   Tampone K., 2020, SYRACUSE
   Tolan C., 2020, CNN
   Wagner P., 2020, 5 WAYS CRIMINAL JUST
   Weichselbaum S., 2020, CANT MAKE BAIL SIT J
   Westchester County New York Office of the District Attorney, 2020, 65 INM REL COUNT JAI
   Westchester Government, 2020, COUNT EX G LAT DECL
   Westervelt E., 2020, ADVOCATES INMATES RE
   WHO, 2020, TRANSM SARS COV 2 IM
   Widra E., 2020, FAILING GRADES STATE
   Williams T, 2020, NY TIMES
   Zeng Z., 2018, 251210 NCJ BUR JUST
NR 40
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1556-4886
EI 1556-4991
J9 VICTIMS OFFENDERS
JI Victims Offenders
DI 10.1080/15564886.2020.1820923
EA OCT 2020
PG 12
WC Criminology & Penology
SC Criminology & Penology
GA OD5LT
UT WOS:000579895900001
OA Bronze
DA 2021-01-01
ER

PT J
AU Baruah, C
   Devi, P
   Sharma, DK
AF Baruah, Chittaranjan
   Devi, Papari
   Sharma, Dhirendra K.
TI Sequence Analysis and Structure Prediction of SARS-CoV-2 Accessory
   Proteins 9b and ORF14: Evolutionary Analysis Indicates Close Relatedness
   to Bat Coronavirus
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS-CORONAVIRUS; COV; SENSITIVITY;
   GENERATION; VIRUS; GENES
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a single-stranded RNA genome that encodes 14 open reading frames (ORFs), eight of which encode accessory proteins that allow the virus to infect the host and promote virulence. The genome expresses around 29 structural and nonstructural protein products. The accessory proteins of SARS-CoV-2 are not essential for virus replication but do affect viral release, stability, and pathogenesis and finally contribute to virulence. This paper has attempted the structure prediction and functional analysis of two such accessory proteins, 9b and ORF14, in the absence of experimental structures. Sequence analysis, structure prediction, functional characterization, and evolutionary analysis based on the UniProtKB reviewed the amino acid sequences of SARS-CoV-2 9b (P0DTD2) and ORF14 (P0DTD3) proteins. Modeling has been presented with the introduction of hybrid comparative and ab initio modeling. QMEANDisCo 4.0.0 and ProQ3 for global and local (per residue) quality estimates verified the structures as high quality, which may be attributed to structure-based drug design targets. Tunnel analysis revealed the presence of 1-2 highly active tunneling sites, perhaps which will able to provide certain inputs for advanced structure-based drug design or to formulate potential vaccines in the absence of a complete experimental structure. The evolutionary analysis of both proteins of human SARS-CoV-2 indicates close relatedness to the bat coronavirus. The whole-genome phylogeny indicates that only the new bat coronavirus followed by pangolin coronaviruses has a close evolutionary relationship with the novel SARS-CoV-2.
C1 [Baruah, Chittaranjan] Darrang Coll, Bioinformat Lab DBT Star Coll, PG Dept Zool, Tezpur 784001, Assam, India.
   [Devi, Papari] TCRP Fdn, Gauhati 781006, India.
   [Sharma, Dhirendra K.] Univ Sci & Technol, Sch Biol Sci, Baridua 793101, Meghalaya, India.
RP Baruah, C (corresponding author), Darrang Coll, Bioinformat Lab DBT Star Coll, PG Dept Zool, Tezpur 784001, Assam, India.
EM chittaranjan_21@yahoo.co.in
OI BARUAH, CHITTARANJAN/0000-0001-7030-7567
FU DBT-Govt. of IndiaDepartment of Biotechnology (DBT) India
FX The authors are grateful to DBT-Govt. of India for supporting
   Bioinformatics Laboratory (under the DBT-Star College scheme) at the
   Post Graduate Department of Zoology, Darrang College, Tezpur, Assam. The
   authors are thankful to the Principal, Darrang College (Gauhati
   University), Tezpur (Assam), India, and Head of the Post Graduate
   Department of Zoology, Darrang College, and the University of Science
   and Technology, Meghalaya, India, for supporting the research laboratory
   facility.
CR Agnihothram S, 2014, MBIO, V5, DOI 10.1128/mBio.00047-14
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Baruah C., 2020, BIORXIV, DOI [10.1101/2020.05.23.104919, DOI 10.1101/2020.05.23.104919]
   Brezovsky J, 2016, ACS CATAL, V6, P7597, DOI 10.1021/acscatal.6b02081
   Brussow H, 2020, MICROB BIOTECHNOL, V13, P607, DOI 10.1111/1751-7915.13557
   Chang CK, 2016, MOL BIOSYST, V12, P59, DOI 10.1039/c5mb00582e
   Cui J, 2007, EMERG INFECT DIS, V13, P1526, DOI 10.3201/eid1310.070448
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Eswar N., 2006, CURRENT PROTOCOLS PR
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Felsenstein J., 2003, INFERRING PHYLOGENIE
   Finn RD, 2011, NUCLEIC ACIDS RES, V39, pW29, DOI 10.1093/nar/gkr367
   Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625
   Haas J, 2019, PROTEINS, V87, P1378, DOI 10.1002/prot.25815
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Halpin K, 2000, J GEN VIROL, V81, P1927, DOI 10.1099/0022-1317-81-8-1927
   Hu B, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0422-1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Johara MY, 2001, EMERG INFECT DIS, V7, P439
   JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275
   KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492
   Kong JQ, 2015, ACTA PHARM SIN B, V5, P487, DOI 10.1016/j.apsb.2015.05.002
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Laskowski RA, 2005, NUCLEIC ACIDS RES, V33, pW89, DOI 10.1093/nar/gki414
   Li WH, 2006, J VIROL, V80, P4211, DOI 10.1128/JVI.80.9.4211-4219.2006
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Liu DX, 2014, ANTIVIR RES, V109, P97, DOI 10.1016/j.antiviral.2014.06.013
   Lopes LR, 2020, BRAZ J MICROBIOL, DOI 10.1007/s42770-020-00321-1
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lu GW, 2012, PROTEIN CELL, V3, P803, DOI 10.1007/s13238-012-2811-1
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Meier C, 2006, STRUCTURE, V14, P1157, DOI 10.1016/j.str.2006.05.012
   Moshynskyy I, 2007, VIRUS RES, V127, P116, DOI 10.1016/j.virusres.2007.03.011
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   PEARSON WR, 1991, GENOMICS, V11, P635, DOI 10.1016/0888-7543(91)90071-L
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X
   Qiu MF, 2005, MICROBES INFECT, V7, P882, DOI 10.1016/j.micinf.2005.02.006
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Sehnal D, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-39
   Sharma K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019436
   Shi CS, 2014, J IMMUNOL, V193, P3080, DOI 10.4049/jimmunol.1303196
   Shukla A, 2015, VIRUS GENES, V50, P29, DOI 10.1007/s11262-014-1139-8
   Singh T, 2011, J CHEM INF MODEL, V51, P2515, DOI 10.1021/ci200193z
   Stourac J, 2019, NUCLEIC ACIDS RES, V47, pW414, DOI 10.1093/nar/gkz378
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Touati Rabeb, 2020, Genomics, V112, P4189, DOI 10.1016/j.ygeno.2020.07.003
   TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441
   Vijaykrishna D, 2007, J VIROL, V81, P4012, DOI 10.1128/JVI.02605-06
   von Brunn A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000459
   Wang LF, 2007, CURR TOP MICROBIOL, V315, P325
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Xu K, 2009, VIROLOGY, V388, P279, DOI 10.1016/j.virol.2009.03.032
   Yang HT, 2006, CURR PHARM DESIGN, V12, P4573, DOI 10.2174/138161206779010369
   Zhang LL, 2018, AUTOPHAGY, V14, P1665, DOI 10.1080/15548627.2018.1466014
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 64
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD OCT 21
PY 2020
VL 2020
AR 7234961
DI 10.1155/2020/7234961
PG 13
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA OU6KX
UT WOS:000591636500012
PM 33102591
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Patel, SS
   Kalma, J
   Bluman, EM
AF Patel, Shalin S.
   Kalma, Jeremy
   Bluman, Eric M.
TI Understanding COVID-19 Vaccines and Their Development
SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
LA English
DT Article
ID IMMUNE-RESPONSES; VIRUS-VACCINES; MOUTH-DISEASE; SEX; IMMUNIZATION;
   PROTECTION; ADJUVANTS; POLIO; MICE; FOOT
C1 [Patel, Shalin S.; Kalma, Jeremy; Bluman, Eric M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [Patel, Shalin S.; Bluman, Eric M.] Brigham & Womens Hosp, Dept Orthopaed Surg, 75 Francis St, Boston, MA 02115 USA.
   [Kalma, Jeremy] Beaumont Hosp, Dept Orthopaed Surg, Royal Oak, MI USA.
RP Bluman, EM (corresponding author), Brigham & Womens Hosp, Dept Orthopaed Surg, 75 Francis St, Boston, MA 02115 USA.
EM ebluman@bwh.harvard.edu
RI Bluman, Eric M./K-5849-2019
OI Bluman, Eric M./0000-0002-3848-1677
CR Ada Gordon L., 1993, P1309
   [Anonymous], 2020, GENETIC ENG BIOTECHN
   AP- NORC Center, EXP COVID 19 VACC
   Ax J, 2020, REUTERS IPSOS POLL
   Baggaley K, 2020, OXFORD U TIMELINE CO
   Bandyopadhyay AS, 2015, FUTURE MICROBIOL, V10, P791, DOI [10.2217/FMB.15.19, 10.2217/fmb.15.19]
   Barouch D, 2020, NBC NEWS
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   BROWN F, 1990, LANCET, V335, P587, DOI 10.1016/0140-6736(90)90360-H
   Liang ZC, 2020, J BONE JOINT SURG AM, V102, P745, DOI 10.2106/JBJS.20.00236
   CHANOCK RM, 1988, VACCINE, V6, P129, DOI 10.1016/S0264-410X(88)80014-8
   Chen WH, 2020, CURR TROP MED REP
   Collins PL, 2008, J VIROL, V82, P2040, DOI 10.1128/JVI.01625-07
   Delrue I, 2012, EXPERT REV VACCINES, V11, P695, DOI [10.1586/ERV.12.38, 10.1586/erv.12.38]
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Diehl MC, 2013, HUM VACC IMMUNOTHER, V9, P2246, DOI 10.4161/hv.24702
   Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007
   Frew C, ALTIMMUNE BECOMES 2
   Galanti M, 2020, J INFECT DIS, DOI 10.1093/infdis/jiaa392/5868459
   Ghosh Pallab, 2020, CORONAVIRUS SOME SCI
   Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326
   Goodson JL, 2015, INFECT DIS CLIN N AM, V29, P725, DOI 10.1016/j.idc.2015.08.001
   GORZIGLIA M, 1988, J VIROL, V62, P2978, DOI 10.1128/JVI.62.8.2978-2984.1988
   Graham B.S., 2013, FIELDS VIROL, V1, P374
   Gronevik E, 2005, J GENE MED, V7, P1246, DOI 10.1002/jgm.760
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamborsky J, 2015, EP PREV VACC PREV DI, P247
   Hamilton Health Sciences Corporation, 2020, CONVALESCENT PLASM H
   Hensyl WR., 1990, STEDMANS MED DICT
   Hirschmann MT, 2020, KNEE SURG SPORT TR A, V28, P1690, DOI 10.1007/s00167-020-06022-4
   Hobernik D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113605
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Humphreys IR, 2018, IMMUNOLOGY, V153, P1, DOI 10.1111/imm.12829
   Hussein IH, 2015, FRONT PUBLIC HEALTH, V3, DOI 10.3389/fpubh.2015.00269
   JAHRLING PB, 1984, J CLIN MICROBIOL, V19, P429, DOI 10.1128/JCM.19.3.429-431.1984
   Jiang SB, 2012, EXPERT REV VACCINES, V11, P1405, DOI [10.1586/erv.12.126, 10.1586/ERV.12.126]
   Keown A, 2020, VAXART PLANS PUSH CO
   KING AMQ, 1981, NATURE, V293, P479, DOI 10.1038/293479a0
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5
   Lei S, 2020, ECLINICALMEDICINE
   Li L, 2017, CURR ISSUES MOL BIOL, V22, P17, DOI 10.21775/cimb.022.017
   Li X, 2020, ASAIO J, V66, P475, DOI 10.1097/MAT.0000000000001172
   Liu A, 2020, CHINAS CANSINO BIOAD
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Luo Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22874-w
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2
   Mi BB, 2020, J BONE JOINT SURG AM, V102, P750, DOI 10.2106/JBJS.20.00390
   Moderna Inc, 2020, FORM 8 K US SEC EXCH
   NIEDRIG M, 1993, VACCINE, V11, P67, DOI 10.1016/0264-410X(93)90341-T
   Orenstein WA, 2015, PEDIATRICS, V135, P196, DOI 10.1542/peds.2014-3163
   Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243
   Patel R, 2020, MBIO, V11, DOI 10.1128/mBio.00722-20
   Patil PK, 2002, VACCINE, V20, P1163, DOI 10.1016/S0264-410X(01)00431-5
   Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111
   Rabaan Ali A, 2020, Infez Med, V28, P174
   Sayedahmed EE, 2018, VACCINE, V36, P6744, DOI 10.1016/j.vaccine.2018.09.031
   Schwartz Andrew M, 2020, JB JS Open Access, V5, pe0045, DOI 10.2106/JBJS.OA.20.00045
   Selby M, 2000, J BIOTECHNOL, V83, P147, DOI 10.1016/S0168-1656(00)00308-4
   Sharma PK, 2018, CANCER GENE THER, V25, DOI 10.1038/s41417-017-0002-1
   Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013
   Tollefsen S, 2002, VACCINE, V20, P3370, DOI 10.1016/S0264-410X(02)00289-X
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   U.S. Centers for Disease Control and Prevention, 2018, UND VACC WORK
   U.S. Senate Committee on Health  Education  Labor  and Pensions, 2020, COVID 19 SAF GETT BA
   University of Chicago, 2020, COVID 19 CONV PLASM
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wassilak SGF, 2014, J INFECT DIS, V210, pS5, DOI 10.1093/infdis/jiu456
   WHO, COR DIS COVID 19 PAN
   Wilson N, 2020, EMERG INFECT DIS, V26, P1339, DOI 10.3201/eid2606.200320
   World Health Organization, 2020, 63 WHO
   World Health Organization, 1979, GLOB ER SMALLP FIN R
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
NR 77
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0021-9355
EI 1535-1386
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg.-Am. Vol.
PD OCT 21
PY 2020
VL 102
IS 20
BP 1759
EP 1769
DI 10.2106/JBJS.20.01191
PG 11
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA OP1JK
UT WOS:000587836900009
PM 33086342
OA Bronze
DA 2021-01-01
ER

PT J
AU Zaki, AA
   Al-Karmalawy, AA
   El-Amier, YA
   Ashour, A
AF Zaki, Ahmed A.
   Al-Karmalawy, Ahmed A.
   El-Amier, Yasser A.
   Ashour, Ahmed
TI Molecular docking reveals the potential of Cleome amblyocarpa isolated
   compounds to inhibit COVID-19 virus main protease
SO NEW JOURNAL OF CHEMISTRY
LA English
DT Article
ID FLAVONOIDS
AB Nine flavonoids and one saponin were isolated from the aerial parts of Cleome amblyocarpa. Molecular docking of isolated compounds on COVID-19 virus main protease showed variable binding affinities with scores ranging from -8.63 to -6.08 compared to N3 inhibitor (-10.10) and binding modes better than N3 inhibitor in some of the isolated compounds. The descending order of the binding affinity of the tested drugs was as follows: N3 inhibitor (11, docked) > kaempferitrin (6) > isorhamnetin 3,7-O-alpha-L-dirhamnoside (3) > kaempferol 3-O-beta-glucoside-7-O-alpha-rhamnoside (2) > soysaponin I (1) > isorhamnetin 7-O-alpha-L-rhamnoside (10) > genistein-8-C-glucoside (8) > tamarixetin 7-O-beta-D-glucoside (4) > isoprunetin-7-glucoside (9) > genistin (5) > 5-O-methylgenistein (7). These results could be a good start for fast further examination of the isolated compoundsin vitroandin vivoeither alone or in combination for the treatment of the COVID-19 virus. Besides, this work gives an explanation of the SAR required for targeting the newly emerged SARS-CoV-2 protease and facilitates the future design and synthesis of new drugs targeting it as well.
C1 [Zaki, Ahmed A.; Ashour, Ahmed] Mansoura Univ, Fac Pharm, Dept Pharmacognosy, Mansoura 35516, Egypt.
   [Al-Karmalawy, Ahmed A.] Horus Univ Egypt, Fac Pharm, Dept Pharmaceut Med Chem, New Damietta 34518, Egypt.
   [El-Amier, Yasser A.] Mansoura Univ, Fac Sci, Bot Dept, Ecol, Mansoura 35516, Egypt.
   [Ashour, Ahmed] Horus Univ, Fac Pharm, Dept Pharmacognosy, New Damietta, Egypt.
RP Ashour, A (corresponding author), Mansoura Univ, Fac Pharm, Dept Pharmacognosy, Mansoura 35516, Egypt.; Ashour, A (corresponding author), Horus Univ, Fac Pharm, Dept Pharmacognosy, New Damietta, Egypt.
EM ahmedadelashour@yahoo.com
RI ; Ashour, Ahmed/M-5468-2018
OI Al-Karmalawy, Ahmed/0000-0002-8173-6073; Ashour,
   Ahmed/0000-0003-4081-0369
CR Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Bae EA, 2000, BIOL PHARM BULL, V23, P1122, DOI 10.1248/bpb.23.1122
   Bouriche H, 2010, ACTA HORTIC, V854, P15
   Bouriche H, 2003, PHARM BIOL, V41, P10, DOI 10.1076/phbi.41.1.10.14698
   Davis IW, 2009, J MOL BIOL, V385, P381, DOI 10.1016/j.jmb.2008.11.010
   Feng SX, 2012, FITOTERAPIA, V83, P161, DOI 10.1016/j.fitote.2011.10.007
   Friedman M, 2007, MOL NUTR FOOD RES, V51, P116, DOI 10.1002/mnfr.200600173
   GRAYERBARKMEIJER RJ, 1978, PHYTOCHEMISTRY, V17, P829, DOI 10.1016/S0031-9422(00)94255-9
   Iwashina Tsukasa, 2012, Bulletin of the National Museum of Nature and Science Series B-Botany, V38, P189
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kinfe HH, 2015, S AFR J BOT, V100, P75, DOI 10.1016/j.sajb.2015.05.014
   Mabberley D. J., 2017, MABBERLEYS PLANT BOO
   McConkey BJ, 2002, CURR SCI INDIA, V83, P845
   Navarra M, 2020, EUR J NUTR, V59, P885, DOI 10.1007/s00394-019-01948-z
   Ngwa W, 2020, MOLECULES, V25, DOI 10.3390/molecules25112707
   Oh JS, 2017, J NUTR SCI VITAMINOL, V63, P51, DOI 10.3177/jnsv.63.51
   Peterson L., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3599426, DOI 10.2139/SSRN.3599426]
   Rassouli E, 2014, J ESSENT OIL BEAR PL, V17, P158, DOI 10.1080/0972060X.2014.884784
   Shahin S, 2018, J ESSENT OIL BEAR PL, V21, P1235, DOI 10.1080/0972060X.2018.1512422
   Sharaf M, 1997, BIOCHEM SYST ECOL, V25, P161, DOI 10.1016/S0305-1978(96)00099-3
   Solanki L, 2015, ADV NUTR, V6, P64, DOI 10.3945/an.114.007500
   Sordon S, 2017, MOLECULES, V22, DOI 10.3390/molecules22010081
   Tan N., 1995, J FAC PHARNZ ISTARTB, V31, P29
   TSCHESCHE R, 1979, PHYTOCHEMISTRY, V18, P1248, DOI 10.1016/0031-9422(79)80157-0
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
   Zhang W, 2009, MOLECULES, V14, P2959, DOI 10.3390/molecules14082959
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1144-0546
EI 1369-9261
J9 NEW J CHEM
JI New J. Chem.
PD OCT 21
PY 2020
VL 44
IS 39
BP 16752
EP 16758
DI 10.1039/d0nj03611k
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA OD0WY
UT WOS:000579576200008
DA 2021-01-01
ER

PT J
AU Bouricha, E
   Hakmi, M
   Akachar, J
   Belyamani, L
   Ibrahimi, A
AF Bouricha, El Mehdi
   Hakmi, Mohammed
   Akachar, Jihane
   Belyamani, Lahcen
   Ibrahimi, Azeddine
TI In silicoanalysis of ACE2 orthologues to predict animal host range with
   high susceptibility to SARS-CoV-2
SO 3 BIOTECH
LA English
DT Article
DE ACE2 orthologues; COVID-19; SARS-CoV-2 susceptibility; Host range
ID CORONAVIRUS; SPIKE
AB SARS-CoV-2, which causes severe pneumonia epidemics, probably originated from Chinese horseshoe bats, but the intermediate and host range is still unknown. ACE2 is the entry receptor for SARS-CoV-2. The binding capacity of SARS-CoV-2 spike protein to ACE2 is the critical determinant of viral host range and cross-species infection. Here, we used anin silicoapproach to predict the potential animals range with high susceptibility to SARS-CoV-2 by modelling and studying the Spike-ACE2 interaction of 22 domestic and wild animals. Our results showed that all studied animals are potentially susceptible to SARS-CoV-2 infection with a slight difference in the binding affinity and stability of their ACE2-RBD complexes. Furthermore, we identified a specific substitution of tyrosine to histidine at position 41 in ACE2 that likely reduces the affinity to SARS-CoV-2 in horses and greater horseshoe bats. These results may help to provide important insights into SARS-CoV-2 host range which will make it possible to control the spread of the virus and identify animal models that could be used for screening antiviral drugs or vaccine candidates against SARS-CoV-2.
C1 [Bouricha, El Mehdi; Hakmi, Mohammed; Akachar, Jihane; Ibrahimi, Azeddine] Mohammed Vth Univ Rabat, Rabat Med & Pharm Sch, Med Biotechnol Lab MedBiotech, Rabat, Morocco.
   [Belyamani, Lahcen] Mohammed Vth Univ Rabat, Mil Hosp Mohammed V, Rabat Med & Pharm Sch, Emergency Dept, Rabat, Morocco.
RP Ibrahimi, A (corresponding author), Mohammed Vth Univ Rabat, Rabat Med & Pharm Sch, Med Biotechnol Lab MedBiotech, Rabat, Morocco.
EM a.ibrahimi@um5s.net
OI Ibrahimi, Azeddine/0000-0003-3226-3836
FU Moroccan Ministry of Higher Education and Scientific Research (COVID-19
   Program); Institute of Cancer Research
FX This work was carried out under National Funding from the Moroccan
   Ministry of Higher Education and Scientific Research (COVID-19 Program)
   to AI. This work was also supported by a grant to AI from Institute of
   Cancer Research and the PPR-1 program to AI.
CR Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Douam F, 2015, ANNU REV GENET, V49, P21, DOI 10.1146/annurev-genet-112414-054823
   Du LY, 2016, EXPERT REV VACCINES, V15, P1123, DOI 10.1586/14760584.2016.1167603
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Liu Y, 2020, BIORXIV, DOI [10.1101/2020.04.22.046565, 10.1101/2020.04.22.046565v3, DOI 10.1101/2020.04.22.046565]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Moreira IS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08321-2
   Peiris J. S. M., 2012, Medical microbiology: a guide to microbial infections: pathogenesis, immunity, laboratory investigation and control, P587
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Qiu Y, 2020, MICROBES INFECT, V22, P221, DOI 10.1016/j.micinf.2020.03.003
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Vangone A, 2015, ELIFE, V4, DOI 10.7554/eLife.07454
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 32
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-572X
EI 2190-5738
J9 3 BIOTECH
JI 3 Biotech
PD OCT 21
PY 2020
VL 10
IS 11
AR 483
DI 10.1007/s13205-020-02471-3
PG 8
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA OL1KX
UT WOS:000585101700003
PM 33101829
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gharebaghi, N
   Nejadrahim, R
   Mousavi, SJ
   Sadat-Ebrahimi, SR
   Hajizadeh, R
AF Gharebaghi, Naser
   Nejadrahim, Rahim
   Mousavi, Seyed Jalil
   Sadat-Ebrahimi, Seyyed-Reza
   Hajizadeh, Reza
TI The use of intravenous immunoglobulin gamma for the treatment of severe
   coronavirus disease 2019: a randomized placebo-controlled double-blind
   clinical trial
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Coronavirus disease 2019; COVID-19; SARS-CoV-2; Severe infection;
   Intravenous immunoglobulin
ID OUTCOMES
AB Background Coronavirus disease 2019 (COVID-19) has infected people in many countries worldwide. Discovering an effective treatment for this disease, particularly in severe cases, has become the subject of intense scientific investigation. Therefore, the objective of this study was to evaluate the efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 infection.
   Methods This study was conducted as a randomized placebo-controlled double-blind clinical trial. Fifty-nine patients with severe COVID-19 infection who did not respond to initial treatments were randomly assigned into two groups. One group received IVIg (human)-four vials daily for 3 days (in addition to initial treatment), while the other group received a placebo. Patients' demographic, clinical, and select laboratory test results, as well as the occurrence of in-hospital mortality, were recorded.
   Results Among total study subjects, 30 patients received IVIg and 29 patients received a placebo. Demographics, clinical characteristics, and laboratory tests were not statistically different (P > 0.05) between the two groups. The in-hospital mortality rate was significantly lower in the IVIg group compared to the control group (6 [20.0%] vs. 14 [48.3%], respectively; P = 0.022). Multivariate regression analysis demonstrated that administration of IVIg did indeed have a significant impact on mortality rate (aOR = 0.003 [95% CI: 0.001-0.815];P = 0.042).
   Conclusions Our study demonstrated that the administration of IVIg in patients with severe COVID-19 infection who did not respond to initial treatment could improve their clinical outcome and significantly reduce mortality rate. Further multicenter studies with larger sample sizes are nonetheless required to confirm the appropriateness of this medication as a standard treatment.
C1 [Gharebaghi, Naser; Nejadrahim, Rahim; Mousavi, Seyed Jalil] Urmia Univ Med Sci, Dept Infect Dis, Orumiyeh, Iran.
   [Sadat-Ebrahimi, Seyyed-Reza] Tabriz Univ Med Sci, Cardiovasc Res Ctr, Tabriz, Iran.
   [Hajizadeh, Reza] Urmia Univ Med Sci, Dept Cardiol, Orumiyeh, Iran.
RP Sadat-Ebrahimi, SR (corresponding author), Tabriz Univ Med Sci, Cardiovasc Res Ctr, Tabriz, Iran.; Hajizadeh, R (corresponding author), Urmia Univ Med Sci, Dept Cardiol, Orumiyeh, Iran.
EM sadat@tbzmed.ac.ir; hajizadeh.reza@gmail.com
RI Ebrahimi, Seyyed Reza Sadat/AAI-1482-2019
OI Ebrahimi, Seyyed Reza Sadat/0000-0002-6697-4372
FU Urmia University of Medical Sciences
FX This study was supported by the Urmia University of Medical Sciences.
CR [Anonymous], 2020, WORLD BANK COUNTR LE
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao W, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa102
   Cascella M, 2020, FEATURES EVALUATION
   Davey RT, 2019, LANCET RESP MED, V7, P951, DOI 10.1016/S2213-2600(19)30253-X
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Galeotti C, 2017, INT IMMUNOL, V29, P491, DOI 10.1093/intimm/dxx039
   Gao JJ, 2020, BIOSCI TRENDS, V14, P156, DOI 10.5582/bst.2020.03072
   Ghebreyesus WD-GTA, 2020, WHO DIRECTOR GEN OPE
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Henry BM, 2020, AM J EMERG MED, V38, P1722, DOI 10.1016/j.ajem.2020.05.073
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   IBM Corporation, 2013, IBM SPSS STAT WIND V
   Jalili M, 2020, ANN INTERN MED, pM20
   Khanna N, 2008, CLIN INFECT DIS, V46, P402, DOI 10.1086/525263
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Nikpouraghdam M, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104378
   Prohaska S, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0278-8
   Shao Z, 2020, CLIN EFFICACY INTRAV
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Wang JT, 2004, EMERG INFECT DIS, V10, P818, DOI 10.3201/eid1005.030640
   Xie Y, 2020, J INFECTION, V81, P340, DOI 10.1016/j.jinf.2020.03.044
   Zandman-Goddard G, 2013, AUTOIMMUNITY BENCH B
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 28
TC 1
Z9 1
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD OCT 21
PY 2020
VL 20
IS 1
AR 786
DI 10.1186/s12879-020-05507-4
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA OL1IY
UT WOS:000585096500002
PM 33087047
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Weiner, L
   Berna, F
   Nourry, N
   Severac, F
   Vidailhet, P
   Mengin, AC
AF Weiner, Luisa
   Berna, Fabrice
   Nourry, Nathalie
   Severac, Francois
   Vidailhet, Pierre
   Mengin, Amaury C.
TI Efficacy of an online cognitive behavioral therapy program developed for
   healthcare workers during the COVID-19 pandemic: the REduction of STress
   (REST) study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Randomized controlled trial; Protocol; Online CBT; Healthcare
   workers; Stress; Resilience; PTSD; Depression
ID PSYCHOMETRIC PROPERTIES; DEPRESSION; SARS; VALIDATION; BURNOUT; PHQ-9
AB Background: The acknowledgment of the mental health toll of the COVID-19 epidemic in healthcare workers has increased considerably as the disease evolved into a pandemic status. Indeed, high prevalence rates of depression, sleep disorders, and post-traumatic stress disorder (PTSD) have been reported in Chinese healthcare workers during the epidemic peak. Symptoms of psychological distress are expected to be long-lasting and have a systemic impact on healthcare systems, warranting the need for evidence-based psychological treatments aiming at relieving immediate stress and preventing the onset of psychological disorders in this population. In the current COVID-19 context, internet-based interventions have the potential to circumvent the pitfalls of face-to-face formats and provide the flexibility required to facilitate accessibility to healthcare workers. Online cognitive behavioral therapy (CBT) in particular has proved to be effective in treating and preventing a number of stress-related disorders in populations other than healthcare workers. The aim of our randomized controlled trial study protocol is to evaluate the efficacy of the 'My Health too' CBT program-a program we have developed for healthcare workers facing the pandemic-on immediate perceived stress and on the emergence of psychiatric disorders at 3- and 6-month follow-up compared to an active control group (i.e., bibliotherapy).
   Methods: Powered for superiority testing, this six-site open trial involves the random assignment of 120 healthcare workers with stress levels > 16 on the Perceived Stress Scale (PSS-10) to either the 7-session online CBT program or bibliotherapy. The primary outcome is the decrease of PSS-10 scores at 8 weeks. Secondary outcomes include depression, insomnia, and PTSD symptoms; self-reported resilience and rumination; and credibility and satisfaction. Assessments are scheduled at pretreatment, mid-treatment (at 4 weeks), end of active treatment (at 8 weeks), and at 3-month and 6-month follow-up.
   Discussion: This is the first study assessing the efficacy and the acceptability of a brief online CBT program specifically developed for healthcare workers. Given the potential short- and long-term consequences of the COVID-19 pandemic on healthcare workers' mental health, but also on healthcare systems, our findings can significantly impact clinical practice and management of the ongoing, and probably long-lasting, health crisis.
C1 [Weiner, Luisa; Berna, Fabrice; Vidailhet, Pierre; Mengin, Amaury C.] Hop Univ Strasbourg, Pole Psychiat Sante Mentale & Addictol, 1 Pl Hop, F-67000 Strasbourg, France.
   [Weiner, Luisa] Univ Strasbourg, Lab Psychol Cognit, 12 Rue Goethe, F-67000 Strasbourg, France.
   [Berna, Fabrice; Vidailhet, Pierre; Mengin, Amaury C.] INSERM U1114 Neuropsychol Cognit & Physiopathol S, Strasbourg, France.
   [Berna, Fabrice; Nourry, Nathalie; Vidailhet, Pierre] Univ Strasbourg, Fac Med, Strasbourg, France.
   [Nourry, Nathalie] Hop Univ Strasbourg, Serv Pathol Profess & Med Travail, Strasbourg, France.
   [Severac, Francois] Hop Univ Strasbourg, Dept Sante Publ, GMRC, Strasbourg, France.
   [Severac, Francois] Univ Strasbourg, Lab Biostat & Informat Med, iCUBE UMR 7357, Illkirch Graffenstaden, France.
   [Vidailhet, Pierre; Mengin, Amaury C.] Ctr Reg Psychotraumatisme Grand Est, Strasbourg, France.
RP Weiner, L (corresponding author), Hop Univ Strasbourg, Pole Psychiat Sante Mentale & Addictol, 1 Pl Hop, F-67000 Strasbourg, France.; Weiner, L (corresponding author), Univ Strasbourg, Lab Psychol Cognit, 12 Rue Goethe, F-67000 Strasbourg, France.
EM weiner.l@gmail.com
FU COVID-19 Programme Hospitalier de Recherche Clinique-Interregional
   (PHRC-I) Est; University Hospital of Strasbourg [7799]
FX Our study is funded by the COVID-19 Programme Hospitalier de Recherche
   Clinique-Interregional (PHRC-I) Est, planned by the Groupement
   Interregional de Recherche Clinique et d'Innovation Est (GIRCI Est). The
   funding body did not have any role in the design of the study and in
   writing the manuscript. The study was coordinated by the University
   Hospital of Strasbourg (PHRC-I-2020 - project no. 7799).
CR Amanullah S, 2017, ASIAN J PSYCHIATR, V26, P66, DOI 10.1016/j.ajp.2017.01.009
   Arroll B, 2010, ANN FAM MED, V8, P348, DOI 10.1370/afm.1139
   Attkisson C C, 1982, Eval Program Plann, V5, P233, DOI 10.1016/0149-7189(82)90074-X
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   Bellinghausen Lisa, 2009, Sante Publique, V21, P365
   Cao JY, 2020, PSYCHOTHER PSYCHOSOM, V89, P252, DOI 10.1159/000507453
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   Chen QN, 2020, LANCET PSYCHIAT, V7, pE15, DOI 10.1016/S2215-0366(20)30078-X
   Cheng P, 2019, SLEEP, V42
   Chew NWS, 2020, BRAIN BEHAV IMMUN, V88, P559, DOI 10.1016/j.bbi.2020.04.049
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Cropley M, 2012, STRESS HEALTH, V28, P23, DOI 10.1002/smi.1397
   Davies PDO, 2020, INT J TUBERC LUNG D, V24, P1, DOI 10.5588/ijtld.19.0325
   Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   Fagiolini A, 2020, J CLIN PSYCHIAT, V81, P3, DOI DOI 10.4088/JCP.20C0M13357
   Folkman S, 1984, STRESS APPRAISAL COP, P460
   Gartlehner G, 2013, INTERVENTIONS PREVEN
   Gavin B, 2020, Ir Med J, V113, P51
   Gilbert P, 2014, BRIT J CLIN PSYCHOL, V53, P1, DOI 10.1111/bjc.12045
   Hayes SC, 2006, BEHAV RES THER, V44, P1, DOI 10.1016/j.brat.2005.06.006
   Holmes EA, 2020, LANCET PSYCHIAT, P15
   Hu X, 2020, NURS HLTH SCI, P26
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Joyce S, 2018, J MED INTERNET RES, V20, DOI 10.2196/10326
   Joyce S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-017858
   Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06
   Kwek SK, 2006, J PSYCHOSOM RES, V60, P513, DOI 10.1016/j.jpsychores.2005.08.020
   Lancee WJ, 2008, PSYCHIAT SERV, V59, P91, DOI 10.1176/ps.2008.59.1.91
   Lesage FX, 2012, INT J OCCUP MED ENV, V25, P178, DOI 10.2478/S13382-012-0024-8
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Lu W, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112936
   Maben J, 2020, J CLIN NURS, V29, P2742, DOI 10.1111/jocn.15307
   Maunder RG, 2006, EMERG INFECT DIS, V12, P1924
   Maunder RG, 2009, GEN HOSP PSYCHIAT, V31, P316, DOI 10.1016/j.genhosppsych.2009.04.004
   Neff KD, 2013, J CLIN PSYCHOL, V69, P28, DOI 10.1002/jclp.21923
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Richards D, 2012, CLIN PSYCHOL REV, V32, P329, DOI 10.1016/j.cpr.2012.02.004
   Rose RD, 2013, BEHAV RES THER, V51, P106, DOI 10.1016/j.brat.2012.11.003
   Ruwaard J, 2013, CLIN PSYCHOL PSYCHOT, V20, P308, DOI 10.1002/cpp.1767
   Smoktunowicz E, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3401-9
   Ullah R, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.113020
   Vaishnavi S, 2007, PSYCHIAT RES, V152, P293, DOI 10.1016/j.psychres.2007.01.006
   Xiao H, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923549
   Zhang CX, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00306
   Zuromski KL, 2019, DEPRESS ANXIETY, V36, P790, DOI 10.1002/da.22942
NR 46
TC 0
Z9 0
U1 8
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 21
PY 2020
VL 21
IS 1
AR 870
DI 10.1186/s13063-020-04772-7
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OM2LW
UT WOS:000585859700003
PM 33087178
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Boldrini, T
   Lomoriello, AS
   Del Corno, F
   Lingiardi, V
   Salcuni, S
AF Boldrini, Tommaso
   Lomoriello, Arianna Schiano
   Del Corno, Franco
   Lingiardi, Vittorio
   Salcuni, Silvia
TI Psychotherapy During COVID-19: How the Clinical Practice of Italian
   Psychotherapists Changed During the Pandemic
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE telepsychotherapy; COVID-19; public health; remote psychotherapy;
   psychotherapy
ID COGNITIVE-BEHAVIORAL THERAPY; MENTAL-HEALTH; DEPRESSION;
   TELEPSYCHOTHERAPY; RISK
AB Aims: Italy was one of the first countries to be significantly affected by the coronavirus disease 2019 (COVID-19) pandemic, determining a unique scenario for Italian psychotherapists to consider changing the modality in which they deliver treatment. The present study aimed at studying which factors related to psychotherapists and their clinical practice had a major role in predicting two main outcomes: (1) the rate of interrupted treatments during lockdown and (2) psychotherapists' satisfaction with the telepsychotherapy modality.
   Methods: An online survey was administered to licensed psychotherapists (n = 306), who worked mainly as private practitioners, between April 5 and May 10, 2020 (i.e., the peak of the pandemic in Italy).
   Results: Psychotherapists reported that 42.1% (SD = 28.9) of their treatments had been interrupted, suggesting that Italy faced an important undersupply of psychotherapy during the lockdown. Using the Akaike information criterion (AIC) model selection, we identified three predictors of the rate of interrupted treatments: (1) psychotherapists' lack of experience with telepsychotherapy prior to the lockdown, (2) their theoretical orientation (with cognitive behavioral psychotherapists reporting a higher rate of interrupted treatments), and (3) patients' lack of privacy at home, as reported to the psychotherapists. Furthermore, we found four predictors of psychotherapists' satisfaction with the telepsychotherapy modality: (1) the rate of interrupted treatments, (2) psychotherapists' previous experience with telepsychotherapy, (3) their beliefs about the compatibility of telepsychotherapy with their theoretical orientation, and (4) their use of a video-conferencing modality, rather than telephone.
   Conclusion: The following recommendations can help policy makers, professional associations, and practitioners in promoting the continuity of psychotherapy treatments during the COVID-19 outbreak and in future emergencies: (i) disseminating training programs for practitioners on telepsychotherapy, (ii) supporting patients to pragmatically access a private space at home, (iii) encouraging practitioners to use video-conferencing (instead of telephone) to deliver remote therapy, and (iv) increasing the acceptance of telepsychotherapy among both clinicians and the general public.
C1 [Boldrini, Tommaso; Lomoriello, Arianna Schiano; Salcuni, Silvia] Univ Padua, Dept Dev Psychol & Socializat, Padua, Italy.
   [Lomoriello, Arianna Schiano] Denmark Tech Univ DTU, Dept Cognit Syst, Copenhagen, Denmark.
   [Del Corno, Franco] Assoc Res Clin Psychol ARP, Milan, Italy.
   [Lingiardi, Vittorio] Sapienza Univ Rome, Fac Med & Psychol, Dept Dynam & Clin Psychol, Rome, Italy.
RP Lomoriello, AS (corresponding author), Univ Padua, Dept Dev Psychol & Socializat, Padua, Italy.; Lomoriello, AS (corresponding author), Denmark Tech Univ DTU, Dept Cognit Syst, Copenhagen, Denmark.
EM arianna.schianolomoriello@unipd.it
OI Schiano Lomoriello, Arianna/0000-0003-4521-0450
CR AKAIKE H, 1973, BIOMETRIKA, V60, P255, DOI 10.2307/2334537
   Apolinario-Hagen J, 2017, JMIR MENT HEALTH, V4, DOI 10.2196/mental.6375
   Asmundson GJG, 2020, J ANXIETY DISORD, V74, DOI 10.1016/j.janxdis.2020.102271
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Boldrini T, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00429
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Catarino A, 2018, BJPSYCH OPEN, V4, P411, DOI 10.1192/bjo.2018.57
   Cipolletta S, 2018, CLIN PSYCHOL-UK, V22, P220, DOI 10.1111/cp.12117
   DeLuca JS, 2020, J PSYCHOTHER INTEGR, V30, P304, DOI 10.1037/int0000211
   Dennis CL, 2020, BRIT J PSYCHIAT, V216, P189, DOI 10.1192/bjp.2019.275
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   Egede LE, 2015, LANCET PSYCHIAT, V2, P693, DOI 10.1016/S2215-0366(15)00122-4
   Etzelmueller A, 2018, INTERNET INTERV, V12, P165, DOI 10.1016/j.invent.2018.01.003
   Fagioli F, 2015, COMPR PSYCHIAT, V60, P161, DOI 10.1016/j.comppsych.2014.06.007
   Fletcher TL, 2018, CURR PSYCHIAT REP, V20, DOI 10.1007/s11920-018-0922-y
   Fox J, 2019, R COMPANION APPL REG
   Gao JL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231924
   Gordon R. M., 2016, PSYCHOANALYSIS PSYCH, V2, P86
   Gordon Robert M, 2015, Psychodyn Psychiatry, V43, P585, DOI 10.1521/pdps.2015.43.4.585
   Hantsoo L, 2017, J WOMENS HEALTH, V26, P1106, DOI 10.1089/jwh.2016.6255
   Humer E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17134811
   Lomoriello AS, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01824
   Moreno C, 2020, LANCET PSYCHIAT, V7, P813, DOI 10.1016/S2215-0366(20)30307-2
   National Council of Psychologists (CNOP), 2017, DIG PSYCH PROF WEB B
   Norwood C, 2018, CLIN PSYCHOL PSYCHOT, V25, P797, DOI 10.1002/cpp.2315
   Perle JG, 2013, J CLIN PSYCHOL, V69, P100, DOI 10.1002/jclp.21912
   Pierce BS, 2020, PROF PSYCHOL-RES PR, V51, P184, DOI 10.1037/pro0000267
   Pierce BS, 2020, J CLIN PSYCHOL, V76, P1135, DOI 10.1002/jclp.22851
   Poletti B, 2020, COUNS PSYCHOL Q, DOI 10.1080/09515070.2020.1769557
   Probst T, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17113815
   Racine Nicole, 2020, Child Abuse Negl, V110, P104698, DOI 10.1016/j.chiabu.2020.104698
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Rossler W, 2011, SCHIZOPHR RES, V131, P18, DOI 10.1016/j.schres.2011.06.019
   Rogers H, 2017, TELEMED E-HEALTH, V23, P707, DOI 10.1089/tmj.2016.0248
   Schulze N, 2019, TELEMED E-HEALTH, V25, P926, DOI 10.1089/tmj.2018.0225
   Stoll J, 2020, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00993
   Swartz HA, 2020, AM J PSYCHOTHER, V73, P41, DOI 10.1176/appi.psychotherapy.20200015
   Van Daele T, 2020, J PSYCHOTHER INTEGR, V30, P160, DOI 10.1037/int0000218
   Varker T, 2019, PSYCHOL SERV, V16, P621, DOI 10.1037/ser0000239
   Wagenmakers EJ, 2004, PSYCHON B REV, V11, P192, DOI 10.3758/BF03206482
   Wierwille JL, 2016, PSYCHOL SERV, V13, P373, DOI 10.1037/ser0000106
   Wind TR, 2020, INTERNET INTERV, V20, DOI 10.1016/j.invent.2020.100317
   Zerwas SC, 2017, PSYCHOTHER PSYCHOSOM, V86, P47, DOI 10.1159/000449025
NR 43
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD OCT 21
PY 2020
VL 11
AR 591170
DI 10.3389/fpsyg.2020.591170
PG 9
WC Psychology, Multidisciplinary
SC Psychology
GA OK3BR
UT WOS:000584527900001
PM 33192932
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Secer, I
   Ulas, S
   Karaman-Ozlu, Z
AF Secer, Ismail
   Ulas, Sumeyye
   Karaman-Ozlu, Zeynep
TI The Effect of the Fear of COVID-19 on Healthcare Professionals'
   Psychological Adjustment Skills: Mediating Role of Experiential
   Avoidance and Psychological Resilience
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE fear of COVID-19; psychological adjustment; experiential avoidance;
   psychological resilience; healthcare professionals
ID STRESS SCALES DASS; CORONAVIRUS OUTBREAK; DEPRESSION; DISORDER; THERAPY
AB As the COVID-19 outbreak is rapidly spreading all over the world, it's secondary consequences will negatively affect both societies and individuals. The target group, expected to be exposed to the secondary negative consequences most intensely during the pandemic process and afterward, is undoubtedly the healthcare professionals. In this research, the impact of the fear that healthcare professionals in Turkey developed against the outbreak of COVID-19 on their psychological adjustment skills is examined, and in this context, the mediating role of experiential avoidance and psychological resilience is examined. In this context, an answer was sought for the question "Does experiential avoidance and psychological resilience have a mediating role in the impact of COVID-19 fear on psychological adjustment skills of healthcare professionals?" The research was carried out with a total of 370 healthcare professionals reached via online data collection method. Structural equation modeling was used in the data analysis process, and as a result, it was determined that the fear of COVID-19 had a negative effect on the psychological adjustment in healthcare professionals; however, psychological resilience was found to have a protective function that limits this effect, and experiential avoidance has a risk factor that aggravates this effect. Findings obtained from the research are discussed in the context of the literature.
C1 [Secer, Ismail] Ataturk Univ, Fac Educ Counseling & Guidance, Erzurum, Turkey.
   [Ulas, Sumeyye] Gumushane Univ, Sch Hlth, Gumushane, Turkey.
   [Karaman-Ozlu, Zeynep] Ataturk Univ, Fac Nursing, Erzurum, Turkey.
RP Secer, I (corresponding author), Ataturk Univ, Fac Educ Counseling & Guidance, Erzurum, Turkey.
EM ismail.secer@atauni.edu.tr
CR Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8
   Aydn E., 2020, AFR ED RES J, V8, P90, DOI [10.30918/AERJ.81.20.020, DOI 10.30918/AERJ.81.20.020]
   Banerjee D, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112966
   Berking M, 2009, BEHAV RES THER, V47, P663, DOI 10.1016/j.brat.2009.04.011
   Bond FW, 2006, J ORGAN BEHAV MANAGE, V26, P25, DOI 10.1300/J075v26n01_02
   Briggs ES, 2009, J ANXIETY DISORD, V23, P1037, DOI 10.1016/j.janxdis.2009.07.004
   Brooks S, 2020, BMJ MILITARY HEALTH, V166, P52, DOI 10.1136/jramc-2017-000876
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Brown TA, 1997, BEHAV RES THER, V35, P79, DOI 10.1016/S0005-7967(96)00068-X
   Cribb G, 2006, BEHAV CHANGE, V23, P165, DOI 10.1375/bech.23.3.165
   Dalrymple KL, 2007, BEHAV MODIF, V31, P543, DOI 10.1177/0145445507302037
   Deci EL, 2000, PSYCHOL INQ, V11, P227, DOI 10.1207/S15327965PLI1104_01
   Dogan T., 2015, J HAPPINESS WELL BEI, V3, P93
   Earvolino-Ramirez M, 2007, NURS FORUM, V42, P73, DOI 10.1111/j.1744-6198.2007.00070.x
   Eki H., 2018, MULTDMENSONAL EXPERE, P483
   Garcia R, 2017, LEARN MEMORY, V24, P462, DOI 10.1101/lm.044115.116
   Greenberg N, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1211
   Hayes S. C., 2012, ACCEPTANCE COMMITMEN
   Hayes SC, 1996, J CONSULT CLIN PSYCH, V64, P1152, DOI 10.1037/0022-006X.64.6.1152
   Kashdan TB, 2010, CLIN PSYCHOL REV, V30, P865, DOI 10.1016/j.cpr.2010.03.001
   LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U
   Luthans F, 2006, J ORGAN BEHAV, V27, P387, DOI 10.1002/job.373
   Machell KA, 2015, COGNITION EMOTION, V29, P351, DOI 10.1080/02699931.2014.911143
   Mahaffey BL, 2013, BEHAV COGN PSYCHOTH, V41, P52, DOI 10.1017/S1352465812000367
   Orcutt HK, 2005, J SOC CLIN PSYCHOL, V24, P1003, DOI 10.1521/jscp.2005.24.7.1003
   Ornell F, 2020, BRAZ J PSYCHIAT, V42, P232, DOI 10.1590/1516-4446-2020-0008
   Ottenbreit ND, 2004, BEHAV RES THER, V42, P293, DOI 10.1016/S0005-7967(03)00140-2
   Oz P. D. F., 2009, SAGLIK BILIMLERI FAK, V16, P82
   Park SC, 2020, PSYCHIAT INVEST, V17, P85, DOI 10.30773/pi.2020.0058
   Rawal A, 2010, BEHAV RES THER, V48, P851, DOI 10.1016/j.brat.2010.05.009
   Reardon S, 2015, NATURE, V519, P13, DOI 10.1038/519013a
   Rusch N, 2008, J BEHAV THER EXP PSY, V39, P497, DOI 10.1016/j.jbtep.2007.11.006
   Sahdra BK, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00189
   Santanello AW, 2007, COGNITIVE THER RES, V31, P319, DOI 10.1007/s10608-006-9000-6
   Satici B, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00294-0
   Schumacker R.E., 2004, BEGINNERS GUIDE STRU
   Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194
   Secer, 2015, PRACTICAL DATA ANAL
   Secer I, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00322-z
   Secer I, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.00557
   Shigemura J, 2020, PSYCHIAT CLIN NEUROS, V74, P281, DOI 10.1111/pcn.12988
   Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83
   Shultz JM, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0741-y
   Smith BW, 2008, INT J BEHAV MED, V15, P194, DOI 10.1080/10705500802222972
   Tabachnick B. G., 2013, USING MULTIVARIATE S
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   World Health Organization, 2020, 54 WHO
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
   Ylmaz o, 2017, FINANS EKONOMI SOSYA, V2, P78
NR 49
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD OCT 21
PY 2020
VL 11
AR 561536
DI 10.3389/fpsyg.2020.561536
PG 10
WC Psychology, Multidisciplinary
SC Psychology
GA OK2YH
UT WOS:000584518800001
PM 33192830
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Perrone, F
   Piccirillo, MC
   Ascierto, PA
   Salvarani, C
   Parrella, R
   Marata, AM
   Popoli, P
   Ferraris, L
   Marrocco-Trischitta, MM
   Ripamonti, D
   Binda, F
   Bonfanti, P
   Squillace, N
   Castelli, F
   Muiesan, ML
   Lichtner, M
   Calzetti, C
   Salerno, ND
   Atripaldi, L
   Cascella, M
   Costantini, M
   Dolci, G
   Facciolongo, NC
   Fraganza, F
   Massari, M
   Montesarchio, V
   Mussini, C
   Negri, EA
   Botti, G
   Cardone, C
   Gargiulo, P
   Gravina, A
   Schettino, C
   Arenare, L
   Chiodini, P
   Gallo, C
AF Perrone, Francesco
   Piccirillo, Maria Carmela
   Ascierto, Paolo Antonio
   Salvarani, Carlo
   Parrella, Roberto
   Marata, Anna Maria
   Popoli, Patrizia
   Ferraris, Laurenzia
   Marrocco-Trischitta, Massimiliano M.
   Ripamonti, Diego
   Binda, Francesca
   Bonfanti, Paolo
   Squillace, Nicola
   Castelli, Francesco
   Muiesan, Maria Lorenza
   Lichtner, Miriam
   Calzetti, Carlo
   Salerno, Nicola Duccio
   Atripaldi, Luigi
   Cascella, Marco
   Costantini, Massimo
   Dolci, Giovanni
   Facciolongo, Nicola Cosimo
   Fraganza, Fiorentino
   Massari, Marco
   Montesarchio, Vincenzo
   Mussini, Cristina
   Negri, Emanuele Alberto
   Botti, Gerardo
   Cardone, Claudia
   Gargiulo, Piera
   Gravina, Adriano
   Schettino, Clorinda
   Arenare, Laura
   Chiodini, Paolo
   Gallo, Ciro
CA TOCIVID 19 Investigators
TI Tocilizumab for patients with COVID-19 pneumonia. The single-arm
   TOCIVID-19 prospective trial
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE COVID-19; Pneumonia; Coronavirus; Tocilizumab; IL-6; Phase 2; Mortality;
   Safety
ID MULTICENTER
AB BackgroundTocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.MethodsA multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.ResultsIn the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6-24.0, P=0.52) and 22.4% (97.5% CI: 17.2-28.3, P<0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.ConclusionsTocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092).
C1 [Perrone, Francesco; Piccirillo, Maria Carmela; Botti, Gerardo; Cardone, Claudia; Gargiulo, Piera; Gravina, Adriano; Schettino, Clorinda; Arenare, Laura] Ist Nazl Tumori, IRCCS, Fdn G Pascale, Clin Trial Unit, Naples, Italy.
   [Ascierto, Paolo Antonio] Ist Nazl Tumori, IRCCS, Fdn G Pascale, Melanoma Canc Immunotherapy & Dev Therapeut Unit, Naples, Italy.
   [Salvarani, Carlo; Dolci, Giovanni] Univ Modena & Reggio Emilia, Rheumathol, Modena, Italy.
   [Salvarani, Carlo; Dolci, Giovanni] Azienda USL IRCCS Reggio Emilia, Modena, Italy.
   [Parrella, Roberto; Atripaldi, Luigi; Fraganza, Fiorentino; Montesarchio, Vincenzo] AORN Osped Colli, Cotugno Hosp, Naples, Italy.
   [Marata, Anna Maria] Emilia Romagna Hlth Directorate, Bologna, Italy.
   [Popoli, Patrizia] Ist Super Sanita, Ctr Drug Res & Evaluat, Rome, Italy.
   [Ferraris, Laurenzia; Marrocco-Trischitta, Massimiliano M.] IRCCS Policlin San Donato, Hosp Hlth Direct, Infect Dis Unit, Milano Milano, Italy.
   [Ripamonti, Diego; Binda, Francesca] ASST Papa Giovanni XXIII, Infect Dis Unit, Bergamo, Italy.
   [Bonfanti, Paolo; Squillace, Nicola] ASST Monza, Infect Dis Unit, Milan, Italy.
   [Bonfanti, Paolo; Squillace, Nicola] Univ Milano Bicocca, Milan, Italy.
   [Castelli, Francesco; Muiesan, Maria Lorenza] Univ Brescia, Brescia, Italy.
   [Castelli, Francesco; Muiesan, Maria Lorenza] ASST Spedali Civili, Brescia, Italy.
   [Lichtner, Miriam] Sapienza Univ Rome, Santa Maria Goretti Hosp, Latina, Italy.
   [Calzetti, Carlo] Infect Dis & Hepatol Unit AOU, Parma, Italy.
   [Salerno, Nicola Duccio] AOUI, UOC Malattie Infett & Tropicali, Verona, Italy.
   [Cascella, Marco] Ist Nazl Tumori, IRCCS, Fdn G Pascale, Anesthesia & Resuscitat Unit, Naples, Italy.
   [Costantini, Massimo; Facciolongo, Nicola Cosimo; Massari, Marco; Negri, Emanuele Alberto] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy.
   [Mussini, Cristina] Univ Modena & Reggio Emilia, Modena, Italy.
   [Chiodini, Paolo; Gallo, Ciro] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Prevent Med, Caserta, Italy.
RP Perrone, F (corresponding author), Ist Nazl Tumori, IRCCS, Fdn G Pascale, Clin Trial Unit, Naples, Italy.
EM f.perrone@istitutotumori.na.it
OI urru, silvana anna maria/0000-0001-6213-1290; Roman-Pognuz,
   Erik/0000-0002-0859-3424
CR Addis A, 2020, ANN INTERN MED, V173, P654, DOI 10.7326/M20-3775
   Agresti A, 2000, AM STAT, V54, P280, DOI 10.2307/2685779
   Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   Albertini Laetitia, 2021, Eur J Hosp Pharm, V28, P22, DOI 10.1136/ejhpharm-2020-002414
   Angus DC, 2020, JAMA-J AM MED ASSOC, V323, P1895, DOI 10.1001/jama.2020.4984
   Antwi-Amoabeng D, 2020, J MED VIROL, V92, P2516, DOI 10.1002/jmv.26038
   Berlin David A, 2020, N Engl J Med, V383, P2451, DOI 10.1056/NEJMcp2009575
   Biran N, 2020, LANCET RHEUMATOL, V2, pE603, DOI 10.1016/S2665-9913(20)30277-0
   Capra R, 2020, EUR J INTERN MED, V76, P31, DOI 10.1016/j.ejim.2020.05.009
   Chiodini Paolo, 2020, Contemp Clin Trials Commun, V20, P100665, DOI 10.1016/j.conctc.2020.100665
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   Desai Aakash, 2020, EClinicalMedicine, V23, P100403, DOI 10.1016/j.eclinm.2020.100403
   Giacobbe DR, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13319
   Giorgi Rossi P, 2020, SURVIVAL HOSP COVID, DOI [10.1101/2020.05.15.20103119, DOI 10.1101/2020.05.15.20103119]
   Goodman JL, 2020, JAMA-J AM MED ASSOC, V323, P1899, DOI 10.1001/jama.2020.6434
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jordan Stanley C, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa812
   Klopfenstein T, 2020, MED MALADIES INFECT, V50, P397, DOI 10.1016/j.medmal.2020.05.001
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Mushtaq MZ, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106926
   Okoh AK, 2020, J MED VIROL, DOI 10.1002/jmv.26471
   Petrak RM, 2020, CTS-CLIN TRANSL SCI, DOI [10.1101/2020.06.05.20122622, DOI 10.1101/2020.06.05.20122622]
   Piano S, 2020, LIVER INT, V40, P2394, DOI 10.1111/liv.14565
   Piccirillo MC, 2020, CONTEMP CLIN TRIALS, V98, DOI 10.1016/j.cct.2020.106165
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rojas-Marte G, 2020, QJM-INT J MED, V113, P546, DOI 10.1093/qjmed/hcaa206
   Herrero FS, 2020, J INTERN MED, DOI 10.1111/joim.13145
   Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529
   Scott LJ, 2017, DRUGS, V77, P1029, DOI 10.1007/s40265-017-0752-y
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhao J, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03224-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 36
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD OCT 21
PY 2020
VL 18
IS 1
AR 405
DI 10.1186/s12967-020-02573-9
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OL2JN
UT WOS:000585167700005
PM 33087150
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Swargiary, A
   Mahmud, S
   Abu Saleh, M
AF Swargiary, Ananta
   Mahmud, Shafi
   Abu Saleh, Md.
TI Screening of phytochemicals as potent inhibitor of 3-chymotrypsin and
   papain-like proteases of SARS-CoV2: an in silico approach to combat
   COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Phytocompounds; 3CLpro; PLpro; SARS-CoV2; docking
ID SCORING FUNCTION; AMENTOFLAVONE; DERIVATIVES
AB COVID-19 and its causative organism SARS-CoV2 that emerged from Wuhan city, China have paralyzed the world. With no clinically approved drugs, the global health system is struggling to find an effective treatment measure. At this crucial juncture, screening of plant-derived compounds may be an effective strategy to combat COVID-19. The present study investigated the binding affinity of phytocompounds with 3-Chymotrypsin-like (3CLpro) and Papain-like proteases (PLpro) of SARS-CoV2 using in-silico techniques. A total of 32 anti-protease phytocompounds were investigated for the binding affinity to the proteins. Docking was performed in Autodock Vina. Pharmacophore descriptors of best ligands were studied using LigandScout. Molecular dynamics (MD) simulation of apo-protein and ligand-bound complexes was carried out in YASARA software. The druglikeness properties of phytocompounds were studied using ADMETlab. Out of 32 phytochemicals, amentoflavone and gallocatechin gallate showed the best binding affinity to 3CLpro (-9.4 kcal/mol) and PLpro (-8.8 kcal/mol). Phytochemicals such as savinin, theaflavin-3,3-digallate, and kazinol-A also showed strong affinity. MD simulation revealed ligand-induced conformational changes in the protein with decreased surface area and higher stability. The RMSD/F of proteins and ligands showed stability of the protein suggesting the effective binding of the ligand in both the proteins. Both amentoflavone and gallocatechin gallate possess promising druglikeness property. The present study thus suggests that Amentoflavone and Gallocatechin gallate may be potential inhibitors of 3CLpro and PLpro proteins and effective drug candidates for SARS-CoV2. However, the findings of in silico study need to be supported by in vivo studies to establish the exact mode of action.
   Communicated by Ramaswamy H. Sarma
C1 [Swargiary, Ananta] Bodoland Univ, Dept Zool, Kokrajhar, Assam, India.
   [Mahmud, Shafi; Abu Saleh, Md.] Rajshahi Univ, Genet Engn & Biotechnol, Bioinformat Div, Microbiol Lab, Rajshahi, Bangladesh.
RP Swargiary, A (corresponding author), Bodoland Univ, Dept Zool, Kokrajhar, Assam, India.
EM ananbuzoo101@gmail.com
OI Mahmud, shafi/0000-0003-1604-8626; Swargiary, Ananta/0000-0001-9594-3666
CR Banerjee T, 2002, MOL CELL BIOCHEM, V238, P105, DOI 10.1023/A:1019963222510
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chen CN, 2005, EVID-BASED COMPL ALT, V2, P209, DOI 10.1093/ecam/neh081
   Chojnacka K, 2020, J FUNCT FOODS, V73, DOI 10.1016/j.jff.2020.104146
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dickson CJ, 2014, J CHEM THEORY COMPUT, V10, P865, DOI 10.1021/ct4010307
   DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1
   Dong J, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0270-2
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249
   GHOSH R, 2020, J BIOMOL STRUCT 0620, DOI DOI https://doi.org/10.1080/07391102.2020.1779818
   GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104
   Gogoi A, 2019, POLYHEDRON, V168, P113, DOI 10.1016/j.poly.2019.04.043
   Guan LF, 2019, MEDCHEMCOMM, V10, P148, DOI 10.1039/c8md00472b
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Hawas UW, 2019, NAT PROD RES, V33, P3364, DOI 10.1080/14786419.2018.1477153
   Islam MJ, 2019, COMPUT BIOL CHEM, V80, P31, DOI 10.1016/j.compbiolchem.2019.03.004
   Jayadevappa M. K., 2020, J HERBMED PHARM, V9, DOI [https://doi.org/10.34172/jhp.2020.46, DOI 10.34172/JHP.2020.46]
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   KHAN MA, 2020, J BIOMOL STRUCT 0721, DOI DOI https://doi.org/10.1080/07391102.2020.1796813
   Kim DW, 2014, J ENZYM INHIB MED CH, V29, P59, DOI 10.3109/14756366.2012.753591
   Krieger E., 2003, YASARA YET ANOTHER S
   Krieger E, 2006, J MOL GRAPH MODEL, V25, P481, DOI 10.1016/j.jmgm.2006.02.009
   Krieger E, 2015, J COMPUT CHEM, V36, P996, DOI 10.1002/jcc.23899
   Laskar M. A., 2020, RESEARCHSQUARE, DOI [10.21203/rs.3.rs-33294/v1, DOI 10.21203/RS.3.RS-3]
   Lee JS, 2013, PHYTOTHER RES, V27, P713, DOI 10.1002/ptr.4778
   Lee J, 2009, PLANTA MED, V75, P268, DOI 10.1055/s-0028-1088395
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Liu HY, 2020, BRIT J NUTR, V124, P1013, DOI 10.1017/S0007114520002263
   MAHMUD S, 2020, J BIOMOL STRUCT 0723, DOI DOI https://doi.org/10.1080/07391102.2020.1796808
   Mahmud S, 2020, J BIOMOL STRUCT DYN, V38, P4221, DOI 10.1080/07391102.2019.1680440
   Mishra A., 2020, RESEARCHSQUARE, DOI [10.21203/rs.3.rs-22839/v2, DOI 10.21203/RS.3.RS-22839/V2]
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   MUCHTARIDI M, 2017, PHARMACEUTICALS, V10, DOI DOI https://doi.org/10.3390/ph10040081
   Nutan, 2013, INDIAN J MED RES, V137, P540
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Okebe J, 2014, PEDIATR INFECT DIS J, V33, P522, DOI 10.1097/INF.0000000000000306
   Omolo CA, 2020, EUR J PHARMACOL, V883, DOI 10.1016/j.ejphar.2020.173348
   Pan WL, 2005, BIOORGAN MED CHEM, V13, P5819, DOI 10.1016/j.bmc.2005.05.071
   PANDEY P, 2020, J BIOMOL STRUCT 0722, DOI DOI https://doi.org/10.1080/07391102.2020.1796811
   Park JH, 2012, ORTHOPEDICS, V35, pe1104, DOI DOI https://doi.org/10.1248/bpb.b12-00623
   Park JY, 2017, J ENZYM INHIB MED CH, V32, P504, DOI 10.1080/14756366.2016.1265519
   Park JY, 2016, J ENZYM INHIB MED CH, V31, P23, DOI 10.3109/14756366.2014.1003215
   Park JY, 2013, BIOORGAN MED CHEM, V21, P3730, DOI 10.1016/j.bmc.2013.04.026
   Razzaghi-Asl N, 2018, J MOL GRAPH MODEL, V83, P138, DOI 10.1016/j.jmgm.2018.05.010
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Ryu YB, 2010, BIOORG MED CHEM LETT, V20, P1873, DOI 10.1016/j.bmcl.2010.01.152
   Shin DH, 2006, J NEUROCHEM, V96, P561, DOI 10.1111/j.1471-4159.2005.03582.x
   Song YH, 2014, BIOL PHARM BULL, V37, P1021, DOI 10.1248/bpb.b14-00026
   Strodel B, 2020, HIGH THROUGHPUT VIRT, DOI [10.20944/preprints202004.0161.v1, DOI 10.20944/PREPRINTS202004.0161.V1]
   Sun C. M., 1995, J TRADITIONAL CHINES, V6
   Swargiary Ananta, 2020, Anticancer Agents Med Chem, DOI 10.2174/1871520620666200719000449
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Thi THN, 2012, BIOTECHNOL LETT, V34, P831, DOI 10.1007/s10529-011-0845-8
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   VARDHAN S, 2020, COMPUT BIOL MED, V124, DOI DOI https://doi.org/10.1016/j.compbiomed.2020.103936
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Zhou H, 2020, BRIT J PHARMACOL, V177, P3147, DOI 10.1111/bph.15092
   Zhou JW, 2019, FASEB J, V33, P14575, DOI 10.1096/fj.201901624RR
NR 66
TC 1
Z9 1
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1835729
EA OCT 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OG8SU
UT WOS:000582147500001
PM 33089730
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Fernandez-Capitan, C
   Barba, R
   Diaz-Pedroche, MD
   Siguenza, P
   Demelo-Rodriguez, P
   Siniscalchi, C
   Pedrajas, JM
   Farfan-Sedano, AI
   Olivera, PE
   Gomez-Cuervo, C
   Llamas, P
   Villares, P
   Sanchez, O
   Lopez-Reyes, R
   Catella, J
   Bikdeli, B
   Weinberg, I
   Tafur, AJ
   Jimenez, D
   Monreal, M
AF Fernandez-Capitan, Carmen
   Barba, Raquel
   Diaz-Pedroche, Maria del Carmen
   Siguenza, Patricia
   Demelo-Rodriguez, Pablo
   Siniscalchi, Carmine
   Pedrajas, Jose Maria
   Farfan-Sedano, Ana I.
   Olivera, Pavel Eduardo
   Gomez-Cuervo, Covadonga
   Llamas, Pilar
   Villares, Paula
   Sanchez, Olivier
   Lopez-Reyes, Raquel
   Catella, Judith
   Bikdeli, Behnood
   Weinberg, Ido
   Tafur, Alfonso J.
   Jimenez, David
   Monreal, Manuel
CA RIETE Investigators
TI Presenting Characteristics, Treatment Patterns, and Outcomes among
   Patients with Venous Thromboembolism during Hospitalization for COVID-19
SO SEMINARS IN THROMBOSIS AND HEMOSTASIS
LA English
DT Article; Early Access
DE COVID-19; venous thromboembolism; hospitalization; outcomes
ID PULMONARY-EMBOLISM; COMPLICATIONS; MANAGEMENT
AB Venous thromboembolism (VTE) is common in patients with coronavirus disease-2019 (COVID-19). However, limited data exist on patient characteristics, treatments, and outcomes. To describe the clinical characteristics, treatment patterns, and short-term outcomes of patients diagnosed with VTE during hospitalization for COVID-19. This is a prospective multinational study of patients with incident VTE during the course of hospitalization for COVID-19. Data were obtained from the Registro Informatizado de la Enfermedad TromboEmbolica (RIETE) registry. All-cause mortality, VTE recurrences, and major bleeding during the first 10 days were separately investigated for patients in hospital wards versus those in intensive care units (ICUs). As of May 03, 2020, a total number of 455 patients were diagnosed with VTE (83% pulmonary embolism, 17% isolated deep vein thrombosis) during their hospital stay; 71% were male, the median age was 65 (interquartile range, 55-74) years. Most patients (68%) were hospitalized in medical wards, and 145 in ICUs. Three hundred and seventeen (88%; 95% confidence interval [CI]: 84-91%) patients were receiving thromboprophylaxis at the time of VTE diagnosis. Most patients (88%) received therapeutic low-molecular-weight heparin, and 15 (3.6%) received reperfusion therapies. Among 420 patients with complete 10-day follow-up, 51 (12%; 95% CI: 9.3-15%) died, no patient recurred, and 12 (2.9%; 95% CI: 1.6-4.8%) experienced major bleeding. The 10-day mortality rate was 9.1% (95% CI: 6.1-13%) among patients in hospital wards and 19% (95% CI: 13-26%) among those in ICUs. This study provides characteristics and early outcomes of patients diagnosed with acute VTE during hospitalization for COVID-19. Additional studies are needed to identify the optimal strategies to prevent VTE and to mitigate adverse outcomes associated.
C1 [Fernandez-Capitan, Carmen] Hosp Univ La Paz, Dept Internal Med, Madrid, Spain.
   [Barba, Raquel] Hosp Rey Juan Carlos, Dept Internal Med, Madrid, Spain.
   [Diaz-Pedroche, Maria del Carmen; Gomez-Cuervo, Covadonga] Hosp Univ 12 Octubre, Dept Internal Med, Madrid, Spain.
   [Siguenza, Patricia] Hosp Badalona Germans Trias & Pujol, Dept Internal Med, Barcelona, Spain.
   [Demelo-Rodriguez, Pablo] Hosp Gen Univ Gregorio Maranon, Dept Internal Med, Madrid, Spain.
   [Siniscalchi, Carmine] Parma Univ Hosp, Dept Internal & Emergency Med, Angiol Unit, Parma, Italy.
   [Pedrajas, Jose Maria] Hosp Clin San Carlos, Dept Internal Med, Madrid, Spain.
   [Farfan-Sedano, Ana I.] Hosp Univ Fuenlabrada, Dept Internal Med, Madrid, Spain.
   [Olivera, Pavel Eduardo] Hosp Univ Sagrat Cor, Dept Hematol, Barcelona, Spain.
   [Llamas, Pilar] Hosp Univ Fdn Jimenez Diaz, Dept Hematol, Madrid, Spain.
   [Villares, Paula] Hosp Madrid Norte Sanchinarro Madrid, Dept Internal Med, Madrid, Spain.
   [Sanchez, Olivier] Hop Europeen Georges Pompidou, Dept Pneumonol, Paris, France.
   [Lopez-Reyes, Raquel] Hosp Univ & Politecn La Fe, Dept Pneumonol, Valencia, Spain.
   [Catella, Judith] Hop Edouard Herriot, Dept Internal Med, Lyon, France.
   [Bikdeli, Behnood] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, Dept Cardiol, Boston, MA 02115 USA.
   [Bikdeli, Behnood] Yale YNHH Ctr Outcomes Res & Evaluat, Dept Cardiol, New Haven, CT USA.
   [Bikdeli, Behnood] Cardiovasc Res Fdn, Dept Cardiol, New York, NY USA.
   [Weinberg, Ido] Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA.
   [Tafur, Alfonso J.] Evanston NorthShore Univ Hlth Syst, Dept Med & Vasc Med, Evanston, IL USA.
   [Jimenez, David] Hosp Ramon y Cajal IRYCIS, Resp Dept, Madrid, Spain.
   [Jimenez, David] Univ Alcala IRYCIS, Med Dept, Madrid, Spain.
   [Jimenez, David; Monreal, Manuel] CIBER Enfermedades Resp CIBERES, Madrid, Spain.
   [Monreal, Manuel] Hosp Badalona Germans Trias & Pujol, Dept Internal Med, Barcelona, Spain.
   [Monreal, Manuel] Univ Catolica Murcia, Catedra Enfermedad Tromboembol, Murcia, Spain.
RP Monreal, M (corresponding author), Hosp Badalona Germans Trias & Pujol, Dept Internal Med, Badalona, Spain.; Monreal, M (corresponding author), Univ Catolica Murcia, Barcelona 08916, Spain.
EM manuel.monreal@uab.cat
FU Sanofi SpainSanofi-Aventis
FX This study was supported by Sanofi Spain with an unrestricted
   educational grant. The funders had no role in the design, conduct, or
   analyses, or the decision to submit this study.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Bikdeli B, 2018, THROMB HAEMOSTASIS, V118, P214, DOI 10.1160/TH17-07-0511
   Cattaneo M, 2020, THROMB HAEMOSTASIS, V120, P1230, DOI 10.1055/s-0040-1712097
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Jimenez D, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4416
   Jimenez D, 2016, J AM COLL CARDIOL, V67, P162, DOI 10.1016/j.jacc.2015.10.060
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Laporte S, 2008, CIRCULATION, V117, P1711, DOI 10.1161/CIRCULATIONAHA.107.726232
   Lax SF, 2020, ANN INTERN MED, V173, P350, DOI 10.7326/M20-2566
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Thachil J, 2020, SEMIN THROMB HEMOST, V46, P777, DOI 10.1055/s-0040-1712155
   Trujillo-Santos J, 2008, THROMB HAEMOSTASIS, V100, P435, DOI 10.1160/TH08-02-0125
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 30
TC 1
Z9 1
U1 3
U2 3
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0094-6176
EI 1098-9064
J9 SEMIN THROMB HEMOST
JI Semin. Thromb. Hemost.
DI 10.1055/s-0040-1718402
EA OCT 2020
PG 11
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA OG3WR
UT WOS:000581819200001
PM 33086403
DA 2021-01-01
ER

PT J
AU Rosenbaum, JE
   Jennings, J
   Ellen, JM
   Borkovic, LM
   Scott, JA
   Wylie, C
   Rompalo, A
AF Rosenbaum, Janet E.
   Jennings, Jacky
   Ellen, Jonathan M.
   Borkovic, Laurel M.
   Scott, Jo-Ann
   Wylie, Charleen
   Rompalo, Anne
TI Giving syphilis and gonorrhea to friends: using in-person friendship
   networks to find additional cases of gonorrhea and syphilis
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Gonorrhea; Syphilis; Partner notification; Contact tracing; Bisexuality;
   Sexual orientation; Labeling; Self-concept
ID PARTNER NOTIFICATION; MEN; SEX
AB Background Syphilis and gonorrhea reached an all-time high in 2018. The resurgence of syphilis and gonorrhea requires innovative methods of sexual contact tracing that encourage disclosure of same-sex sexual contacts that might otherwise be suppressed. Over 75% of Grindr mobile phone application users report seeking "friendship," so this study asked people diagnosed with syphilis and gonorrhea to identify their friends. Methods Patients at the two Baltimore sexually transmitted infection (STI) clinics and the Baltimore City Health Department were asked 12 questions to elicit members of their friendship networks before eliciting sexual networks. The study included 353 index cases and 172 friendship contacts, yielding a friendship network of 331 non-isolates (n = 331) and sexual-only network of 140 non-isolates. The data were plotted and analyzed using exponential family random graph analysis. Results Eliciting respondents' in-person social contacts yielded 12 syphilis cases and 6 gonorrhea cases in addition to the 16 syphilis cases and 4 gonorrhea cases that would have been found with sexual contacts alone. Syphilis is clustered within sexual (odds ratio = 2.2, 95% confidence interval (1.36, 3.66)) and social contacts (OR = 1.31, 95% CI (1.02, 1.68)). Gonorrhea is clustered within reported social (OR = 1.56, 95% CI (1.22, 2.00)) but not sexual contacts (OR = 0.98, 95% CI (0.62, 1.53)). Conclusions Eliciting friendship networks of people diagnosed with syphilis and gonorrhea may find members of their sexual networks, drug use networks, or people of similar STI risk. Friendship networks include more diagnosed cases of syphilis and gonorrhea than sexual networks alone, especially among populations with many non-disclosing men who have sex with men (MSM) and women who have sex with women (WSW). Future research should evaluate whether this friendship network method of contact tracing can be implemented by adapting automated mobile phone COVID-19 contact tracing protocols, if these COVID-19 contact tracing methods are able to maintain anonymity and public trust.
C1 [Rosenbaum, Janet E.] SUNY Downstate Hlth Sci Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 450 Clarkson Ave, Brooklyn, NY 11203 USA.
   [Jennings, Jacky; Ellen, Jonathan M.] Johns Hopkins Med Inst, Dept Pediat, Baltimore, MD 21205 USA.
   [Borkovic, Laurel M.; Scott, Jo-Ann; Wylie, Charleen; Rompalo, Anne] Johns Hopkins Med Inst, Dept Infect Dis, Baltimore, MD 21205 USA.
RP Rosenbaum, JE (corresponding author), SUNY Downstate Hlth Sci Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 450 Clarkson Ave, Brooklyn, NY 11203 USA.
EM janet.rosenbaum@downstate.edu
RI Rosenbaum, Janet/Y-6915-2018
OI Rosenbaum, Janet/0000-0001-9796-513X
FU STD/HIV Prevention Training center [5R30PS000259-04]; Johns Hopkins STD
   Center training grant [T32-AI050056]; National Institute for Child
   Health and DevelopmentUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [1R01HD33982]
FX This work was supported by STD/HIV Prevention Training center
   (5R30PS000259-04), Johns Hopkins STD Center training grant
   (T32-AI050056), and the National Institute for Child Health and
   Development (1R01HD33982). The funding agency had no input in the design
   of the study and collection, analysis, interpretation of data, writing
   the manuscript, or approving the final manuscript.
CR [Anonymous], 2006, TOG WE CAN NAT PLAN
   [Anonymous], 2020, EXP NOT FREQ ASK QUE
   [Anonymous], 2017, CDC CALL ACT LETS WO
   Bolding G, 2007, AIDS BEHAV, V11, P522, DOI 10.1007/s10461-007-9224-9
   Centers for Disease Control and Prevention, 2019, SEX TRANSM DIS SURV
   Christakis NA, 2013, STAT MED, V32, P556, DOI 10.1002/sim.5408
   Cope AB, 2019, PUBLIC HEALTH REP, V134, P11, DOI 10.1177/0033354918813549
   Csardi G., 2006, INTERJOURNAL COMPLEX, V1695
   Friedman SR, 2018, CURR HIV-AIDS REP, V15, P283, DOI 10.1007/s11904-018-0403-2
   Goodreau SM, 2007, SOC NETWORKS, V29, P231, DOI 10.1016/j.socnet.2006.08.001
   Grov C, 2014, J SEX RES, V51, P390, DOI 10.1080/00224499.2013.871626
   Harling G, 2019, JAIDS-J ACQ IMM DEF, V82, pS244, DOI 10.1097/QAI.0000000000002203
   Hochberg CH, 2015, SEX TRANSM DIS, V42, P533, DOI 10.1097/OLQ.0000000000000335
   Huang E, 2016, AIDS EDUC PREV, V28, P341, DOI 10.1521/aeap.2016.28.4.341
   Hunter D. R., 2008, J STAT SOFTW, V24, P1, DOI DOI 10.18637/jss.v024.i03
   Hunter P, 2014, PUBLIC HEALTH REP, V129, P43, DOI 10.1177/00333549141291S107
   Kakietek J, 2011, AIDS EDUC PREV, V23, P118, DOI 10.1521/aeap.2011.23.2.118
   Kim AA, 2001, J ACQ IMMUN DEF SYND, V28, P89
   Landovitz RJ, 2013, J URBAN HEALTH, V90, P729, DOI 10.1007/s11524-012-9766-7
   Levine DK, 2005, SEX TRANSM DIS, V32, P139, DOI 10.1097/01.olq.0000149783.67826.4d
   Liau A, 2006, SEX TRANSM DIS, V33, P576, DOI 10.1097/01.olq.0000204710.35332.c5
   Neale J, 2016, HEALTH SOC CARE COMM, V24, P557, DOI 10.1111/hsc.12215
   Paudyal P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124310
   Pellowski J, 2016, J HEALTH COMMUN, V21, P629, DOI 10.1080/10810730.2015.1128020
   Peterman TA, 2018, SEX TRANSM DIS, V45, pE7, DOI [10.1097/OLQ.0000000000000737, 10.1097/olq.0000000000000737]
   Philip Susan S, 2018, Sex Transm Dis, V45, pS63, DOI [10.1097/olq.0000000000000779, 10.1097/OLQ.0000000000000779]
   SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127
   Stephens SC, 2014, SEX TRANSM DIS, V41, P333, DOI 10.1097/OLQ.0000000000000116
   Thomas DR, 2016, SEX TRANSM INFECT, V92, P359, DOI 10.1136/sextrans-2015-052323
   Tongsinoot L, 2017, 2017 19TH IEEE INTERNATIONAL CONFERENCE ON HIGH PERFORMANCE COMPUTING AND COMMUNICATIONS (HPCC) / 2017 15TH IEEE INTERNATIONAL CONFERENCE ON SMART CITY (SMARTCITY) / 2017 3RD IEEE INTERNATIONAL CONFERENCE ON DATA SCIENCE AND SYSTEMS (DSS), P123, DOI 10.1109/HPCC-SmartCity-DSS.2017.16
   Ugeagu CC, 2014, SEX TRANSM DIS, V41, P631, DOI [10.1097/OLQ.0000000000000181, DOI 10.1097/OLQ.0000000000000181]
   Wilson E, 2019, SEX TRANSM INFECT, V95, P569, DOI 10.1136/sextrans-2019-053992
   Zenilman JM, 1999, SEX TRANSM DIS, V26, P75, DOI 10.1097/00007435-199902000-00002
NR 33
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD OCT 21
PY 2020
VL 20
IS 1
AR 1526
DI 10.1186/s12889-020-09589-2
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OD4ME
UT WOS:000579825700001
PM 33081743
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Casucci, G
   Acanfora, D
   Incalzi, RA
AF Casucci, Gerardo
   Acanfora, Domenico
   Incalzi, Raffaele Antonelli
TI The Cross-Talk between Age, Hypertension and Inflammation in COVID-19
   Patients: Therapeutic Targets
SO DRUGS & AGING
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME; ACE2; EXPRESSION
AB This paper presents a brief overview of the complex interaction between age, hypertension, the renin-angiotensin-aldosterone system (RAAS), inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. Coronavirus disease 2019 (COVID-19) is more frequent and more severe in comorbid elderly patients, especially those with hypertension, diabetes, obesity, or cardiovascular diseases. There are concerns regarding the use of RAAS inhibitors in patients with COVID-19. Some physicians have considered the need for interrupting RAAS inhibition in order to reduce the possibility of SARS-CoV2 entering lung cells after binding to angiotensin-converting enzyme 2 (ACE2) receptors. We offer a different point of view in relation to the need for continuing to use RAAS inhibitors in patients with COVID-19. We focused our article on elderly patients because of the distinctive imbalance between the immune response, which is depressed, and the exacerbated inflammatory response, 'inflammaging', which makes the geriatric patient an appropriate candidate for therapeutic strategies aimed at modulating the inflammatory response. Indeed, COVID-19 is an inflammatory storm that starts and worsens during the course of the disease. During the COVID-19 pandemic, various therapeutic approaches have been tested, including antiviral drugs, interferon, anti-interleukins, hydroxychloroquine, anti-inflammatories, immunoglobulins from recovered patients, and heparins. Some of these therapeutic approaches did not prove to be beneficial, or even induced serious complications. Based on current evidence, in the early stages of the disease modulation of the inflammatory response through the inhibition of neprilysin and modulation of the RAAS could affect the course and outcome of COVID-19.
C1 [Casucci, Gerardo; Acanfora, Domenico] San Francesco Hosp, Unit Internal Med, Viale Europa 21, I-82037 Telese Terme, BN, Italy.
   [Incalzi, Raffaele Antonelli] Policlin Univ Campus Biomed Roma, Unit Geriatr, Via Alvaro Portillo 21, I-00128 Rome, Italy.
RP Acanfora, D (corresponding author), San Francesco Hosp, Unit Internal Med, Viale Europa 21, I-82037 Telese Terme, BN, Italy.
EM domenico.acanfora29@gmail.com
CR Acanfora D, 2020, EUR HEART J-CARD PHA, V6, P135, DOI 10.1093/ehjcvp/pvaa028
   Acanfora D, 2020, CLIN DRUG INVEST, V40, P493, DOI 10.1007/s40261-020-00908-4
   Amat-Santos IJ, 2020, J AM COLL CARDIOL, V76, P268, DOI 10.1016/j.jacc.2020.05.040
   [Anonymous], 2019, I SUPERIORE SANITA C
   Bourgonje AR, 2020, J PATHOL, V251, P228, DOI 10.1002/path.5471
   Braga FAV, 2019, NAT MED, V25, P1153, DOI 10.1038/s41591-019-0468-5
   Brook CE, 2020, ELIFE, V9, DOI 10.7554/eLife.48401
   Burrell LM, 2005, EUR HEART J, V26, P369, DOI 10.1093/eurheartj/ehi114
   Chen Y, 2020, LANCET INFECT DIS, V20, P515, DOI 10.1016/S1473-3099(20)30235-8
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   de Abajo FJ, 2020, LANCET, V395, P1705, DOI 10.1016/S0140-6736(20)31030-8
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Franceschi C, 2018, NAT REV ENDOCRINOL, V14, P576, DOI 10.1038/s41574-018-0059-4
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   GUO LM, 2019, FRONT MICROBIOL, V10, DOI DOI 10.3389/FMICB.2019.00001
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Han SX, 2010, TOXICOL APPL PHARM, V245, P100, DOI 10.1016/j.taap.2010.02.009
   He X, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011152
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kreutz R, 2020, CARDIOVASC RES, V116, P1688, DOI 10.1093/cvr/cvaa097
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuba K, 2006, CURR OPIN PHARMACOL, V6, P271, DOI 10.1016/j.coph.2006.03.001
   Li JY, 2020, MICROBES INFECT, V22, P80, DOI 10.1016/j.micinf.2020.02.002
   Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624
   Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005
   Liang WH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00562-2020
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Marshall RP, 2003, CURR PHARM DESIGN, V9, P715, DOI 10.2174/1381612033455431
   Matsushita K, 2020, RELATIONSHIP COVID 1, DOI [10.1101/2020.04.05.20054155, DOI 10.1101/2020.04.05.20054155]
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta N, 2020, JAMA CARDIOL, V5, P1020, DOI 10.1001/jamacardio.2020.1855
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Mou H, 2013, J VIROL, V13, P1277
   Paizis G, 2005, GUT, V54, P1790, DOI 10.1136/gut.2004.062398
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Sama IE, 2020, EUR HEART J, V41, P1810, DOI 10.1093/eurheartj/ehaa373
   Sanchis-Gomar F, 2020, MAYO CLIN PROC, V95, P1222, DOI 10.1016/j.mayocp.2020.03.026
   Sharma A, 2020, MAYO CLIN PROC, V95, P2040, DOI 10.1016/j.mayocp.2020.06.046
   The New York Times Coronavirus Map, NY TIMES
   Tikellis C, 2003, HYPERTENSION, V41, P392, DOI 10.1161/01.HYP.0000060689.38912.CB
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wu C, 2020, JAMA INTERN MED, V180, P1031
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu YT, 2020, VIROL SIN, V35, P256, DOI 10.1007/s12250-020-00205-6
   Xu Y, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.90558
   Yagil Y, 2003, HYPERTENSION, V41, P871, DOI 10.1161/01.HYP.0000063886.71596.C8
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42994-1
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhao Y, 2020, BIORXIV, DOI [10.1101/2020.01.26.9199857523209, DOI 10.1101/2020.01.26.9199857523209]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 59
TC 0
Z9 0
U1 4
U2 4
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PD NOV
PY 2020
VL 37
IS 11
BP 779
EP 785
DI 10.1007/s40266-020-00808-4
EA OCT 2020
PG 7
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA OM7AP
UT WOS:000580726800001
PM 33084001
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gyebi, GA
   Adegunloye, AP
   Ibrahim, IM
   Ogunyemi, OM
   Afolabi, SO
   Ogunro, OB
AF Gyebi, Gideon A.
   Adegunloye, Adegbenro P.
   Ibrahim, Ibrahim M.
   Ogunyemi, Oludare M.
   Afolabi, Saheed O.
   Ogunro, Olalekan B.
TI Prevention of SARS-CoV-2 cell entry: insight from in silico interaction
   of drug-like alkaloids with spike glycoprotein, human ACE2, and TMPRSS2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; ACE2; TMPRSS2; spike glycoprotein; alkaloid
ID ANGIOTENSIN-CONVERTING ENZYME-2; HUMAN CORONAVIRUSES 229E; ANTIVIRAL
   ACTIVITY; RECEPTOR; INHIBITOR; BINDING; SERINE; CHARMM; DOMAIN
AB COVID-19 is a respiratory disease caused by SARS-CoV-2, an enveloped positive sense RNA virus. The SARS-CoV-2 spike glycoprotein, human angiotensin-converting enzyme 2 (ACE2) and human transmembrane protease serine 2 (TMPRSS2) are essential for the host cell-mediated viral entry. Targeting these proteins represent viable options to stop the first stage of infection and transmission. Hence, 97 alkaloids from African medicinal plants with reported antiviral activity were evaluated for this purpose via in silico studies. These alkaloids were docked for their interactions with SARS-CoV-2 spike glycoprotein, ACE2, and TMPRSS2. Top 20 alkaloids with highest binding affinities were further screened for their interactions with spike glycoprotein of SARS-CoV and MERS-CoV, and with ACE2-SARS-CoV-2 receptor-binding domain complex (ACE2-RBD). The energy profiling, molecular dynamics simulation (MDS), binding free energy base on Molecular Mechanics/Generalized Born Surface Area (MMGBSA), clustering of MDS trajectories, and virtual physicochemical and pharmacokinetic screening of the best docked alkaloids were performed. Results revealed that more than 15 alkaloids interacted better than the reference compounds. 10-Hydroxyusambarensine and Cryptospirolepine were docked in a similar binding pattern to the S1-specificy pocket of TMPRSS2 as camostat (reference inhibitor). The strong binding affinities, stability of the alkaloid-protein complexes and amino acid interactions displayed by cryptospirolepine, 10-hydroxyusambarensine, and cryptoquindoline with important binding hotspots of the proteins suggest these alkaloids have the potential of altering the capacity of SARS-CoV-2 membrane mediated host cell entry. Further in vitro and in vivo evaluation of these "drug-like" alkaloids as potential inhibitors of coronavirus cell entry is proposed.
   Communicated by Ramaswamy H. Sarma
C1 [Gyebi, Gideon A.; Ogunyemi, Oludare M.] Salem Univ, Dept Biol Sci, Lokoja, Nigeria.
   [Adegunloye, Adegbenro P.] Univ Ilorin, Fac Life Sci, Dept Biochem, Ilorin, Nigeria.
   [Ibrahim, Ibrahim M.] Cairo Univ, Fac Sci, Dept Biophys, Giza, Egypt.
   [Afolabi, Saheed O.] Univ Ilorin, Fac Basic Med Sci, Dept Pharmacol & Therapeut, Ilorin, Nigeria.
   [Ogunro, Olalekan B.] KolaDaisi Univ, Dept Biol Sci, Ibadan, Nigeria.
RP Gyebi, GA (corresponding author), Salem Univ, Dept Biol Sci, Lokoja, Nigeria.
EM gideonagyebi@gmail.com
OI Gyebi, Gideon/0000-0002-1945-1739; Ogunyemi, Oludare/0000-0002-9956-3860
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Adeoye AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1765876
   Al-Tawfiq JA, 2014, TRENDS MICROBIOL, V22, P573, DOI 10.1016/j.tim.2014.08.001
   Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   Bolles M, 2011, CURR OPIN VIROL, V1, P624, DOI 10.1016/j.coviro.2011.10.012
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Cabeca TK, 2013, INFLUENZA OTHER RESP, V7, P1040, DOI 10.1111/irv.12101
   Case D., 2020, AMBER
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Dhama K, 2018, CURR DRUG METAB, V19, P236, DOI 10.2174/1389200219666180129145252
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Gaunt ER, 2010, J CLIN MICROBIOL, V48, P2940, DOI 10.1128/JCM.00636-10
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gyebi A. G., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/7391102.2021764868, DOI 10.1080/7391102.2021764868]
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772110
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kudi AC, 1999, J ETHNOPHARMACOL, V68, P289, DOI 10.1016/S0378-8741(99)00049-5
   Kyrieleis OJP, 2007, FEBS J, V274, P2148, DOI 10.1111/j.1742-4658.2007.05756.x
   Lee J, 2016, J CHEM THEORY COMPUT, V12, P405, DOI 10.1021/acs.jctc.5b00935
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li NN, 2008, P NATL ACAD SCI USA, V105, P4796, DOI 10.1073/pnas.0712051105
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lobo-Galo N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764393
   Lu RJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038638
   Meyer JJM, 1997, J ETHNOPHARMACOL, V56, P165, DOI 10.1016/S0378-8741(97)01514-6
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   OGBOLE OO, 2018, VIROL J, V15, DOI DOI https://doi.org/10.1186/s12985-018-1022-7
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Sanchez-Linares I, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S14-S13
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Simmons G, 2013, ANTIVIR RES, V100, P605, DOI 10.1016/j.antiviral.2013.09.028
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Tong Tommy R., 2009, Infectious Disorders - Drug Targets, V9, P223
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tubiana T, 2018, J CHEM INF MODEL, V58, P2178, DOI 10.1021/acs.jcim.8b00512
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walsh EE, 2013, J INFECT DIS, V208, P1634, DOI 10.1093/infdis/jit393
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   WHO, 2020, REP WHO CHIN JOINT M
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yuan YC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14657
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 67
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1835726
EA OCT 2020
PG 25
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OF3YG
UT WOS:000581147000001
PM 33089728
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Shiohara, T
   Mizukawa, Y
AF Shiohara, T.
   Mizukawa, Y.
TI Comment on 'Drug reaction with eosinophilia and systemic symptoms
   syndrome in a patient with COVID-19': involvement of herpesvirus
   reactivations and adverse drug reactions in diverse cutaneous
   manifestations and overall disease severity of COVID-19
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Letter; Early Access
C1 [Shiohara, T.; Mizukawa, Y.] Kyorin Univ, Sch Med, Dept Dermatol, Tokyo, Japan.
RP Shiohara, T (corresponding author), Kyorin Univ, Sch Med, Dept Dermatol, Tokyo, Japan.
EM tpshio@ks.kyorin-u.ac.jp
OI Mizukawa, Yoshiko/0000-0002-9035-1298
CR Ehsani AH, 2020, J EUR ACAD DERMATOL, V34, pE436, DOI 10.1111/jdv.16579
   Hayakawa J, 2020, J EUR ACAD DERMATOL, DOI 10.1111/jdv.16878
   Herman A, 2020, J EUR ACAD DERMATOL, DOI 10.1111/jdv.16838
   Labe P, 2020, J EUR ACAD DERMATOL, V34, pE539, DOI 10.1111/jdv.16666
   Mizukawa Y, 2019, J AM ACAD DERMATOL, V80, P670, DOI 10.1016/j.jaad.2018.08.052
   Ramirez E, 2020, SUSPECTED SERIOUS AD, DOI [10.20944/preprints202008.0283.v1, DOI 10.20944/PREPRINTS202008.0283.V1]
   Rodriguez-Jimenez P, 2020, J EUR ACAD DERMATOL, V34, pE459, DOI 10.1111/jdv.16618
   Shiohara T, 2019, ALLERGOL INT, V68, P301, DOI 10.1016/j.alit.2019.03.006
   Takahashi R, 2009, J IMMUNOL, V182, P8071, DOI 10.4049/jimmunol.0804002
   Xu R, 2020, BRIT J DERMATOL, V183, P1145, DOI 10.1111/bjd.19484
NR 10
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
EI 1468-3083
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
DI 10.1111/jdv.16959
EA OCT 2020
PG 2
WC Dermatology
SC Dermatology
GA OE3VV
UT WOS:000580463100001
PM 32970885
OA Bronze, Green Accepted
DA 2021-01-01
ER

PT J
AU Detoc, M
   Bruel, S
   Frappe, P
   Tardy, B
   Botelho-Nevers, E
   Gagneux-Brunon, A
AF Detoc, Maelle
   Bruel, Sebastien
   Frappe, Paul
   Tardy, Bernard
   Botelho-Nevers, Elisabeth
   Gagneux-Brunon, Amandine
TI Intention to participate in a COVID-19 vaccine clinical trial and to get
   vaccinated against COVID-19 in France during the pandemic
SO VACCINE
LA English
DT Article
DE COVID-19; Vaccine; Vaccine hesitancy; Pandemics; SARS-CoV-2
ID HESITANCY
AB Introduction: The world is facing the COVID-19 pandemic. The development of a vaccine is challenging. We aimed to determine the proportion of people who intend to get vaccinated against COVID-19 in France or to participate in a vaccine clinical trial.
   Methods: We conducted an anonymous on-line survey from the 26th of March to the 20th of April 2020. Primary endpoints were the intention to get vaccinated against COVID-19 if a vaccine was available or participate in a vaccine clinical trial.
   Results: Three thousand two hundred and fifty nine individuals answered the survey; women accounted for 67.4% of the respondents. According to their statements, 2.512 participants (77.6%, 95% CI 76.2-79%) will certainly or probably agree to get vaccinated against COVID-19. Older age, male gender, fear about COVID-19, being a healthcare worker and individual perceived risk were associated with COVID-19 vaccine acceptance. Vaccine hesitancy was associated with a decrease in COVID-19 vaccine acceptance. One thousand and five hundred and fifty respondents (47.6% 95% CI 45.9-49.3%) will certainly or probably agree to participate in a COVID-19 vaccine clinical trial. Older age, male gender, being a healthcare worker and individual perceived risk were associated with potential acceptance to participate in a COVID-19 vaccine clinical trial. Vaccine hesitancy was associated with refusal for participation in a COVID-19 vaccine clinical trial.
   Conclusions: Nearly 75% and 48% of the survey respondents were respectively likely to accept vaccination or participation in a clinical trial against COVID-19. Vaccine hesitancy will be the major barrier to COVID-19 vaccine uptake. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Detoc, Maelle; Bruel, Sebastien; Frappe, Paul; Tardy, Bernard; Botelho-Nevers, Elisabeth; Gagneux-Brunon, Amandine] Univ Hosp St Etienne, Ctr Invest Clin INSERM 1408, St Etienne, France.
   [Bruel, Sebastien; Frappe, Paul] Univ Lyon, Univ Jean Monnet, Fac Med Jacques Lisfranc, Dept Gen Practice, St Etienne, France.
   [Botelho-Nevers, Elisabeth; Gagneux-Brunon, Amandine] Univ Lyon, Univ Jean Monnet, Grp Immunite Muqueuses & Agents Pathogenes, St Etienne, France.
   [Bruel, Sebastien; Frappe, Paul; Botelho-Nevers, Elisabeth; Gagneux-Brunon, Amandine] Univ Lyon, PRESAGE Inst, St Etienne, France.
RP Gagneux-Brunon, A (corresponding author), Univ Hosp St Etienne, Ctr Invest Clin INSERM 1408, St Etienne, France.; Gagneux-Brunon, A (corresponding author), Univ Lyon, Univ Jean Monnet, Grp Immunite Muqueuses & Agents Pathogenes, St Etienne, France.; Gagneux-Brunon, A (corresponding author), Univ Lyon, PRESAGE Inst, St Etienne, France.
EM amandine.gagneux-brunon@chu-st-etienne.fr
OI Bruel, Sebastien/0000-0001-7413-5248
CR Agrinier N, 2017, CLIN MICROBIOL INFEC, V23, P311, DOI 10.1016/j.cmi.2016.08.019
   Ahmed N, 2018, VACCINE, V36, P7556, DOI 10.1016/j.vaccine.2018.10.049
   [Anonymous], PROJ RECH
   Chirico F, 2020, INFECT CONT HOSP EP, V41, P1117, DOI 10.1017/ice.2020.148
   Cobb EM, 2014, CTS-CLIN TRANSL SCI, V7, P145, DOI 10.1111/cts.12142
   COVID-19 Map, COVID 19 MAP
   Determann D, 2016, VACCINE, V34, P803, DOI 10.1016/j.vaccine.2015.12.035
   Detoc M, 2019, VACCINE, V37, P6633, DOI 10.1016/j.vaccine.2019.09.048
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Guthmann JP, 2012, VACCINE, V30, P995, DOI 10.1016/j.vaccine.2011.12.011
   John TJ, 2000, EUR J EPIDEMIOL, V16, P601, DOI 10.1023/A:1007626510002
   Killian M, 2016, EUR J CLIN MICROBIOL, V35, P1837, DOI 10.1007/s10096-016-2735-4
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Maltezou Helena C, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa888
   Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6
   Rey Dominique, 2018, Euro Surveill, V23, DOI 10.2807/1560-7917.ES.2018.23.17.17-00816
   Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Torreele E, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3209
   Trujillo KL, CONVERSATION
   Wilson R, 2020, VACCINE, V38, P1144, DOI 10.1016/j.vaccine.2019.11.018
   World Health Organization: WHO, IMPR VACC DEM ADDR H
NR 23
TC 0
Z9 0
U1 8
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 21
PY 2020
VL 38
IS 45
BP 7002
EP 7006
DI 10.1016/j.vaccine.2020.09.041
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OD4DW
UT WOS:000579804000008
PM 32988688
OA Green Published
DA 2021-01-01
ER

PT J
AU Wang, KL
   Wong, ELY
   Ho, KF
   Cheung, AWL
   Chan, EYY
   Yeoh, EK
   Wong, SYS
AF Wang, Kailu
   Wong, Eliza Lai Yi
   Ho, Kin Fai
   Cheung, Annie Wai Ling
   Chan, Emily Ying Yang
   Yeoh, Eng Kiong
   Wong, Samuel Yeung Shan
TI Intention of nurses to accept coronavirus disease 2019 vaccination and
   change of intention to accept seasonal influenza vaccination during the
   coronavirus disease 2019 pandemic: A cross-sectional survey
SO VACCINE
LA English
DT Article
DE Vaccination; Vaccine acceptance; Coronavirus disease 2019; Influenza
   vaccines; Nurses
ID HEALTH-CARE WORKERS; HESITANCY; ADULTS
AB Background: Maintaining health of healthcare workers with vaccination is a major component of pandemic preparedness and acceptance of vaccinations is essential to its success. This study aimed to examine impact of the coronavirus disease 2019 (COVID-19) pandemic on change of influenza vaccination acceptance and identify factors associated with acceptance of potential COVID-19 vaccination.
   Method: A cross-sectional self-administered anonymous questionnaire survey was conducted among nurses in Hong Kong, China during 26 February and 31 March 2020. Their previous acceptance of influenza vaccination and intentions to accept influenza and COVID-19 vaccination were collected. Their relationship with work-related and other factors were examined using multiple multinomial logistic regressions.
   Results: Responses from 806 participants were retrieved. More nurses changed from vaccination refusal to hesitancy or acceptance than those changed from acceptance to vaccination hesitancy or refusal (15.5% vs 6.8% among all participants, P < 0.001). 40.0% participants intended to accept COVID-19 vaccination, and those in private sector (OR: 1.67, 95%CI: 1.11-2.51), with chronic conditions (OR: 1.83, 95%CI: 1.22-2.77), encountering with suspected or confirmed COVID-19 patients (OR: 1.63, 95%CI: 1.14-2.33), accepted influenza vaccination in 2019 (OR: 2.03, 95%CI: 1.47-2.81) had higher intentions to accept it. Reasons for refusal and hesitation for COVID-19 vaccination included "suspicion on efficacy, effectiveness and safety", "believing it unnecessary", and "no time to take it".
   Conclusion: With a low level of COVID-19 acceptance intentions and high proportion of hesitation in both influenza and COVID-19 vaccination, evidence-based planning are needed to improve the uptake of both vaccinations in advance of their implementation. Future studies are needed to explore reasons of change of influenza vaccination acceptance, look for actual behaviour patterns of COVID-19 vaccination acceptance and examine effectiveness of promotion strategies. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Wang, Kailu; Wong, Eliza Lai Yi; Cheung, Annie Wai Ling; Yeoh, Eng Kiong] Chinese Univ Hong Kong, Fac Med, Ctr Hlth Syst & Policy Res, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China.
   [Ho, Kin Fai; Chan, Emily Ying Yang; Wong, Samuel Yeung Shan] Chinese Univ Hong Kong, Fac Med, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China.
   [Wang, Kailu; Wong, Eliza Lai Yi; Ho, Kin Fai; Cheung, Annie Wai Ling; Chan, Emily Ying Yang; Yeoh, Eng Kiong; Wong, Samuel Yeung Shan] Prince Wales Hosp, Sch Publ Hlth Bldg, Sha Tin, Hong Kong, Peoples R China.
RP Wong, ELY (corresponding author), Prince Wales Hosp, Sha Tin, Room 418,4-F Sch Publ Hlth Bldg, Hong Kong, Peoples R China.
EM lywong@cuhk.edu.hk
RI Wong, Eliza Lai-Yi/ABI-2092-2020
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   Blank PR, 2009, J INFECTION, V58, P446, DOI 10.1016/j.jinf.2009.04.001
   Bridges CB, 2000, JAMA-J AM MED ASSOC, V284, P1655, DOI 10.1001/jama.284.13.1655
   Caille-Brillet AL, 2013, EUROSURVEILLANCE, V18, P13, DOI 10.2807/1560-7917.ES2013.18.45.20628
   Centre for Health Protection, 2020, LAT SIT CAS COVID 19
   Centre for Health Protection, SEAS INFL VACC PNEUM
   Centre for Health Protection, SUMM STAT VACC PRACT
   Cheung EC, 2020, HONG KONG 3 WAVE INF
   Chor JSY, 2011, VACCINE, V29, P7364, DOI 10.1016/j.vaccine.2011.07.079
   Chor JSY, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3391
   Department of Health, 2016, SUMM CHAR REG NURS E
   Ding Q, 2020, J MED VIROL, V92, P1549, DOI 10.1002/jmv.25781
   Gao J, 2020, DEVELOPMENTAL SCI, V23, DOI 10.1111/desc.12975
   Gaygisiz U, 2010, VACCINE, V29, P329, DOI 10.1016/j.vaccine.2010.10.030
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Helmy YA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041225
   Hong Kong SAR Government, 2020, PAM YOUD NETH E HOSP
   Hughes MM, 2020, CLIN INFECT DIS, V70, P2496, DOI 10.1093/cid/ciz676
   Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040
   Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177
   Kim TH, 2011, SCAND J INFECT DIS, V43, P683, DOI 10.3109/00365548.2011.582247
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Liao Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023786
   Lin CJ, 2010, VACCINE, V28, P7706, DOI 10.1016/j.vaccine.2010.07.009
   Liu H, 2020, AGING DIS, V11, P668, DOI 10.14336/AD.2020.0502
   Nuno M, 2007, J R SOC INTERFACE, V4, P505, DOI 10.1098/rsif.2006.0186
   Prematunge C, 2012, VACCINE, V30, P4733, DOI 10.1016/j.vaccine.2012.05.018
   Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013
   Schoeb V, 2016, CHINA PERSPECT, P51
   Siu FL Z., 2020, S MORNING CHINA POST
   Tam DKP, 2008, INFECT CONT HOSP EP, V29, P256, DOI 10.1086/527507
   To KW, 2010, AM J INFECT CONTROL, V38, P623, DOI 10.1016/j.ajic.2010.05.015
   Verger P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041837
   Whibley A, 2020, ACTA PAEDIATR, V109, P1706, DOI 10.1111/apa.15285
   Wong SYS, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-316
   World Health Organization, 2020, WHATS NEED NOW PROT
   Wu SS, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-636
   Yeung MPS, 2016, J PUBLIC HEALTH-UK, V38, P746, DOI 10.1093/pubmed/fdv194
   Zarocostas J., 2009, BMJ
NR 39
TC 0
Z9 0
U1 11
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 21
PY 2020
VL 38
IS 45
BP 7049
EP 7056
DI 10.1016/j.vaccine.2020.09.021
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OD4DW
UT WOS:000579804000014
PM 32980199
DA 2021-01-01
ER

PT J
AU Chandir, S
   Siddiqi, DA
   Mehmood, M
   Setayesh, H
   Siddique, M
   Mirza, A
   Soundardjee, R
   Dharma, VK
   Shah, MT
   Abdullah, S
   Akhter, MA
   Khan, AA
   Khan, AJ
AF Chandir, Subhash
   Siddiqi, Danya Arif
   Mehmood, Mariam
   Setayesh, Hamidreza
   Siddique, Muhammad
   Mirza, Amna
   Soundardjee, Riswana
   Dharma, Vijay Kumar
   Shah, Mubarak Taighoon
   Abdullah, Sara
   Akhter, Mohammed Adil
   Khan, Anokhi Ali
   Khan, Aamir Javed
TI Impact of COVID-19 pandemic response on uptake of routine immunizations
   in Sindh, Pakistan: An analysis of provincial electronic immunization
   registry data
SO VACCINE
LA English
DT Article
DE Immunization coverage; COVID-19; Electronic Immunization Registry;
   Predictors of immunization; mHealth
ID EBOLA OUTBREAK; WEST-AFRICA; MEASLES; DETERMINANTS
AB Background: COVID-19 pandemic has affected routine immunization globally. Impact will likely be higher in low and middle-income countries with limited healthcare resources and fragile health systems. We quantified the impact, spatial heterogeneity, and determinants for childhood immunizations of 48 million population affected in the Sindh province of Pakistan.
   Methods: We extracted individual immunization records from real-time provincial Electronic Immunization Registry from September 23, 2019, to July 11, 2020. Comparing baseline (6 months preceding the lockdown) and the COVID-19 lockdown period, we analyzed the impact on daily immunization coverage rate for each antigen by geographical area. We used multivariable logistic regression to explore the predictors associated with immunizations during the lockdown.
   Results: There was a 52.5% decline in the daily average total number of vaccinations administered during lockdown compared to baseline. The highest decline was seen for Bacille Calmette Guerin (BCG) (40.6% (958/2360) immunization at fixed sites. Around 8438 children/day were missing immunization during the lockdown. Enrollments declined furthest in rural districts, urban sub-districts with large slums, and polio-endemic super high-risk sub-districts. Pentavalent-3 (penta-3) immunization rates were higher in infants born in hospitals (RR: 1.09; 95% CI: 1.04-1.15) and those with mothers having higher education (RR: 1.19-1.50; 95% CI: 1.13-1.65). Likelihood of penta-3 immunization was reduced by 5% for each week of delayed enrollment into the immunization program.
   Conclusion: One out of every two children in Sindh province has missed their routine vaccinations during the provincial COVID-19 lockdown. The pool of un-immunized children is expanding during lockdown, leaving them susceptible to vaccine-preventable diseases. There is a need for tailored interventions to promote immunization visits and safe service delivery. Higher maternal education, facility-based births, and early enrollment into the immunization program continue to show a positive association with immunization uptake, even during a challenging lockdown. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Chandir, Subhash; Siddiqi, Danya Arif; Khan, Aamir Javed] IRD Global, 15 Beach Rd 02-01, Singapore 189677, Singapore.
   [Chandir, Subhash; Khan, Aamir Javed] Harvard Med Sch, Dept Global Hlth & Social Med, 641 Huntington Ave, Boston, MA 02115 USA.
   [Mehmood, Mariam; Siddique, Muhammad; Mirza, Amna; Dharma, Vijay Kumar; Shah, Mubarak Taighoon; Abdullah, Sara; Akhter, Mohammed Adil; Khan, Anokhi Ali] IRD Pakistan, 4th Floor Woodcraft Bldg, Karachi 75190, Pakistan.
   [Setayesh, Hamidreza; Soundardjee, Riswana] Gavi Vaccine Alliance, Chemin Pommier 40, CH-1218 Le Grand Saconnex, Switzerland.
   [Dharma, Vijay Kumar; Akhter, Mohammed Adil] Indus Hlth Network, Global Hlth Directorate, 5th Floor Woodcraft Bldg, Karachi 75190, Pakistan.
RP Chandir, S (corresponding author), IRD Global, 15 Beach Rd 02-01, Singapore 189677, Singapore.
EM subhash.chandir@ird.global
OI Setayesh, Hamidreza/0000-0003-1691-0298
CR Abbas K, 2020, LANCET GLOB HEALTH, V8, pE1264, DOI [10.1016/52214-109X(20)30308-9, 10.1016/S2214-109X(20)30308-9]
   Acharya P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202742
   [Anonymous], 2017, PROF URB PER URB SLU
   [Anonymous], 2020, DAWN NEWS
   Bolkan Hakon Angell, 2014, PLoS Curr, V6, DOI 10.1371/currents.outbreaks.0307d588df619f9c9447f8ead5b72b2d
   Buechner MM, 2020, FORBES
   Bureau of Statistics Government of Sindh, 2020, SINDH GLANC
   Carter ED, 2019, VACCINE, V37, P5242, DOI 10.1016/j.vaccine.2019.07.063
   CDC, 2020, OP CONS IMM SERV COV
   Chandir S, 2018, ZINDAGI MEHFOOZ SAFE, V4, DOI [10.2196/11770, DOI 10.2196/11770]
   Colavita F, 2017, EMERG INFECT DIS, V23, P1035, DOI 10.3201/eid2306.161682
   Crocker-Buque T, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4473-7
   Dolan SB, 2019, VACCINE, V37, P1859, DOI 10.1016/j.vaccine.2019.02.017
   EOC Sindh, 2020, POSTPONEMENT FIPV CA
   EPI Sindh, 2020, TECHN WORKSH FEBR 3
   Every Child's Birth Right, 2013, IN TRENDS BIRTH REG
   GAVI, 2020, 8 GAVI
   Gibson DG, 2015, VACCINE, V33, P6778, DOI 10.1016/j.vaccine.2015.10.021
   GPEI, 2020, POL ER PROGR CONT PL
   GPEI, 2020, PAK AFF WILD POL TYP
   GPEI, 2020, 1 CALL POL ER STAFF
   Haque SMR, 2013, INT J PSYCHOL BEHAV, V3, P11
   Hirabayashi DK, 2020, IMPACT COVID 19 ROUT
   Hoffman J., 2020, NEWYORK TIMES
   Hungerford D, 2020, EUROSURVEILLANCE, V25, P34, DOI 10.2807/1560-7917.ES.2020.25.18.2000756
   IRD/EPI-Sindh, 2020, ZIND MEHF EL I UNPUB
   Khawar H., 2020, DAWN NEWS
   Lau JTF, 2005, EMERG INFECT DIS, V11, P417
   Locke PRT, 2020, MEDSCAPE NEWS UK
   Maina LC, 2013, PAN AFR MED J, V14, DOI 10.11604/pamj.2013.14.3.2181
   Mangrio Nawab Khan, 2008, J Pak Med Assoc, V58, P64
   Mbengue Mouhamed Abdou Salam, 2017, Pan Afr Med J, V27, P8, DOI 10.11604/pamj.supp.2017.27.3.11534
   National Information Technology Board Government of Pakistan, 2020, COVID 19 DASHB
   National Institute of Population Studies (NIPS) [Pakistan] and ICF, 2019, PAK DEM HLTH SURV 20
   Noh JW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206766
   Office of the Project Director, 2020, 26662737 PDEPISK OFF
   Parashar S, 1982, SOC SCI MED, V2005, P989
   Parpia AS, 2016, EMERG INFECT DIS, V22, P433, DOI 10.3201/eid2203.150977
   Qureshi Z, 2020, GULF NEWS
   Ranscombe P, 2020, LANCET INFECT DIS, V20, P545, DOI 10.1016/S1473-3099(20)30301-7
   Roberts L, 2015, SCIENCE, V347, P1189, DOI 10.1126/science.347.6227.1189
   SAMRA S, 2015, J FINANCE EC, V3, P51, DOI DOI 10.12691/JFE-3-3-1.2015
   Santoli JM, 2020, EFFECTS COVID 19 PAN
   Schoeps A, 2013, VACCINE, V32, P96, DOI 10.1016/j.vaccine.2013.10.063
   Sindh H., 2020, IMP COVID 19 EPI VAC
   Staff writer, 2020, UN NEWS
   Truelove SA, 2015, EXPERT REV ANTI-INFE, V13, P1299, DOI 10.1586/14787210.2015.1085305
   Unicef, 2020, IMP COVID 19 VACC SU
   WHO, 2020, PROT LIF IMM SERV CO
   WHO, 2001, WHOEPITRAM980111
   WHO, 2019, REV LESS LEARNT
   WHO and Unicef, 2020, IMM CONT COVID 19 PA
   World Health Organization, 2020, GUID ROUT IMM SERV C
   World Health Organization, 2019, EM PREP RESP MEASL G
   World Health Organization, 2019, COR DIS COVID 19 PAN
   World Health Organization, 2018, AN US HLTH FAC DAT G
   World Health Organization, 2020, COVID 19 SIGN IMP HL
   World Health Organization, 2020, GUID PRINC IMM ACT C
NR 58
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 21
PY 2020
VL 38
IS 45
BP 7146
EP 7155
DI 10.1016/j.vaccine.2020.08.019
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OD4DW
UT WOS:000579804000026
PM 32943265
OA Green Published
DA 2021-01-01
ER

PT J
AU Kragholm, K
   Gerds, TA
   Fosbol, E
   Andersen, MP
   Phelps, M
   Butt, JH
   Ostergaard, L
   Bang, CN
   Pallisgaard, J
   Gislason, G
   Schou, M
   Kober, L
   Torp-Pedersen, C
AF Kragholm, Kristian
   Gerds, Thomas A.
   Fosbol, Emil
   Andersen, Mikkel Porsborg
   Phelps, Matthew
   Butt, Jawad H.
   ostergaard, Lauge
   Bang, Casper N.
   Pallisgaard, Jannik
   Gislason, Gunnar
   Schou, Morten
   Kober, Lars
   Torp-Pedersen, Christian
TI Association Between Prescribed Ibuprofen and Severe COVID-19 Infection:
   A Nationwide Register-Based Cohort Study
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
AB Recommendations regarding ibuprofen use in relation to coronavirus disease 2019 (COVID-19) have been conflicting. We examined the risk of severe COVID-19 between ibuprofen-prescribed and non-ibuprofen patients with COVID-19 in a nationwide register-based study of patients with COVID-19 in Denmark between the end of February 2020 and May 16, 2020. Patients with heart failure (n = 208), < 30 years (n = 575), and prescribed other nonsteroidal anti-inflammatory drugs (n = 57) were excluded. Patients with ibuprofen prescription claims between January 1, 2020, and before COVID-19 diagnosis or April 30, 2020 (last available prescription) were compared with patients without ibuprofen prescription claims. Outcome was a 30-day composite of severe COVID-19 diagnosis with acute respiratory syndrome, intensive care unit admission, or death. Absolute risks and average risk ratios comparing outcome for ibuprofen vs. non-ibuprofen patients standardized to the age, sex, and comorbidity distribution of all patients were derived from multivariable Cox regression. Among 4,002 patients, 264 (6.6%) had ibuprofen prescription claims before COVID-19. Age, sex, and comorbidities were comparable between the two study groups. Standardized absolute risks of the composite outcome for ibuprofen-prescribed vs. non-ibuprofen patients were 16.3% (95% confidence interval (CI) 12.1-20.6) vs. 17.0% (95% CI 16.0-18.1),P = 0.74. The standardized average risk ratio for ibuprofen-prescribed vs. non-ibuprofen patients was 0.96 (95% CI 0.72-1.23). Standardized absolute risks of the composite outcome for patients with ibuprofen prescription claims > 14 days before COVID-19 vs. <= 14 days of COVID-19 were 17.1% (95% CI 12.3-22.0) vs. 14.3% (95% CI 7.1-23.1). In conclusion, in this nationwide study, there was no significant association between ibuprofen prescription claims and severe COVID-19.
C1 [Kragholm, Kristian] Aalborg Univ Hosp, Unit Clin Biostat & Epidemiol, Aalborg, Denmark.
   [Kragholm, Kristian] North Denmark Reg Hosp, Dept Cardiol, Aalborg, Denmark.
   [Kragholm, Kristian] Aalborg Univ Hosp, Aalborg, Denmark.
   [Gerds, Thomas A.] Univ Copenhagen, Dept Biostat, Copenhagen, Denmark.
   [Fosbol, Emil; Butt, Jawad H.; ostergaard, Lauge; Kober, Lars] Rigshospitalet, Dept Cardiol, Copenhagen, Denmark.
   [Andersen, Mikkel Porsborg; Bang, Casper N.; Torp-Pedersen, Christian] Nordsjaellands Hosp, Dept Clin Res, Hillerod, Denmark.
   [Phelps, Matthew; Bang, Casper N.; Gislason, Gunnar] Danish Heart Fdn, Copenhagen, Denmark.
   [Pallisgaard, Jannik; Gislason, Gunnar; Schou, Morten] Herlev Gentofte Hosp, Dept Cardiol, Copenhagen, Denmark.
RP Kragholm, K (corresponding author), Aalborg Univ Hosp, Unit Clin Biostat & Epidemiol, Aalborg, Denmark.; Kragholm, K (corresponding author), North Denmark Reg Hosp, Dept Cardiol, Aalborg, Denmark.; Kragholm, K (corresponding author), Aalborg Univ Hosp, Aalborg, Denmark.
EM kdks@rn.dk
OI Butt, Jawad Haider/0000-0002-7380-4144; Gerds, Thomas
   Alexander/0000-0002-5955-816X; Kober, Lars/0000-0002-6635-1466; Phelps,
   Matthew David/0000-0003-0344-2026
CR Boccia S, 2020, JAMA INTERN MED, V180, P927, DOI 10.1001/jamainternmed.2020.1447
   Capuano A, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104849
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1086
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Grant RL, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.f7450
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Kinross P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.11.2000285
   Krogager ML, 2017, EUR HEART J, V38, P104, DOI 10.1093/eurheartj/ehw129
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Moore N, 2020, DRUG SAFETY, V43, P611, DOI 10.1007/s40264-020-00953-0
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   R Core Team, 2017, R LANG ENV STAT COMP
   Rinott E, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.06.003
   Rubino S, 2020, J INFECT DEV COUNTR, V14, P265, DOI 10.3855/jidc.12734
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   The Danish Health Data Authority, MAN COVID 19 HEALTHC
   Vaja R, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14514
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 19
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
PD NOV
PY 2020
VL 13
IS 6
BP 1103
EP 1107
DI 10.1111/cts.12904
EA OCT 2020
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PA7WR
UT WOS:000579840800001
PM 32970921
OA DOAJ Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Andina, D
   Colmenero, I
   Santonja, C
   de Leon, IM
   Noguera-Morel, L
   Hernandez-Martin, A
   Torrelo, A
AF Andina, David
   Colmenero, Isabel
   Santonja, Carlos
   Munoz de Leon, Irene
   Noguera-Morel, Lucero
   Hernandez-Martin, Angela
   Torrelo, Antonio
TI Suspected COVID-19-related reticulated purpura of the soles in an infant
SO PEDIATRIC DERMATOLOGY
LA English
DT Article; Early Access
DE acro-ischemic lesions; chilblain; COVID-19; exanthem;
   immunohistochemistry; pernio; SARS-CoV-2; skin; viral diseases
AB A growing number of skin lesions during the COVID-19 pandemic are being recognized. Acral ischemic lesions identical to chilblains are most typical in children and young adults. We report an infant girl, aged 1 month and 29 days, with a peculiar reticulated purpuric eruption on her soles, with positive immunohistochemistry for SARS-CoV-2 in the endothelia of dermal blood vessels. The patient had an excellent outcome without specific therapy.
C1 [Andina, David; Munoz de Leon, Irene] Hosp Infantil Univ Nino Jesus, Emergency Dept, Madrid, Spain.
   [Colmenero, Isabel] Hosp Infantil Univ Nino Jesus, Dept Pathol, Madrid, Spain.
   [Santonja, Carlos] Hosp Univ Fdn Jimenez Diaz, Dept Pathol, Madrid, Spain.
   [Noguera-Morel, Lucero; Hernandez-Martin, Angela; Torrelo, Antonio] Hosp Infantil Univ Nino Jesus, Dept Dermatol, Menendez Pelayo 65, Madrid 28009, Spain.
RP Torrelo, A (corresponding author), Hosp Infantil Univ Nino Jesus, Dept Dermatol, Menendez Pelayo 65, Madrid 28009, Spain.
EM atorrelo@aedv.es
OI Noguera-Morel, Lucero/0000-0001-5694-8536
CR Andina D, 2020, PEDIATR DERMATOL, V37, P406, DOI 10.1111/pde.14215
   Bosch-Amate X, 2020, J EUR ACAD DERMATOL, V34, pE548, DOI 10.1111/jdv.16689
   Colmenero I, 2020, BRIT J DERMATOL, V183, P729, DOI 10.1111/bjd.19327
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Manalo IF, 2020, J AM ACAD DERMATOL, V83, pE157, DOI [10.1016/j.jaad.2020.04.018, 10.1016/j.jaad.2020.05.001]
   Torrelo A, 2020, PEDIATR DERMATOL, V37, P442, DOI 10.1111/pde.14246
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
NR 7
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-8046
EI 1525-1470
J9 PEDIATR DERMATOL
JI Pediatr. Dermatol.
DI 10.1111/pde.14409
EA OCT 2020
PG 3
WC Dermatology; Pediatrics
SC Dermatology; Pediatrics
GA OD5OS
UT WOS:000579903800001
PM 33085141
OA Bronze
DA 2021-01-01
ER

PT J
AU Gupta, S
   Wang, W
   Hayek, SS
   Chan, LL
   Mathews, KS
   Melamed, ML
   Brenner, SK
   Leonberg-Yoo, A
   Schenck, EJ
   Radbel, J
   Reiser, J
   Bansal, A
   Srivastava, A
   Zhou, Y
   Finkel, D
   Green, A
   Mallappallil, M
   Faugno, AJ
   Zhang, JJ
   Velez, JCQ
   Shaefi, S
   Parikh, CR
   Charytan, DM
   Athavale, AM
   Friedman, AN
   Redfern, RE
   Short, SAP
   Correa, S
   Pokharel, KK
   Admon, AJ
   Donnelly, JP
   Gershengorn, HB
   Douin, DJ
   Semler, MW
   Hernan, MA
   Leaf, DE
AF Gupta, Shruti
   Wang, Wei
   Hayek, Salim S.
   Chan, Lili
   Mathews, Kusum S.
   Melamed, Michal L.
   Brenner, Samantha K.
   Leonberg-Yoo, Amanda
   Schenck, Edward J.
   Radbel, Jared
   Reiser, Jochen
   Bansal, Anip
   Srivastava, Anand
   Zhou, Yan
   Finkel, Diana
   Green, Adam
   Mallappallil, Mary
   Faugno, Anthony J.
   Zhang, Jingjing
   Velez, Juan Carlos Q.
   Shaefi, Shahzad
   Parikh, Chirag R.
   Charytan, David M.
   Athavale, Ambarish M.
   Friedman, Allon N.
   Redfern, Roberta E.
   Short, Samuel A. P.
   Correa, Simon
   Pokharel, Kapil K.
   Admon, Andrew J.
   Donnelly, John P.
   Gershengorn, Hayley B.
   Douin, David J.
   Semler, Matthew W.
   Hernan, Miguel A.
   Leaf, David E.
CA STOP-COVID Investigators
TI Association Between Early Treatment With Tocilizumab and Mortality Among
   Critically Ill Patients With COVID-19
SO JAMA INTERNAL MEDICINE
LA English
DT Article; Early Access
ID OFF-LABEL USE; SOFA SCORE
AB Importance Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract the inflammatory cytokine release syndrome in patients with severe COVID-19 illness. Objective To test whether tocilizumab decreases mortality in this population. Design, Setting, and Participants The data for this study were derived from a multicenter cohort study of 4485 adults with COVID-19 admitted to participating intensive care units (ICUs) at 68 hospitals across the US from March 4 to May 10, 2020. Critically ill adults with COVID-19 were categorized according to whether they received or did not receive tocilizumab in the first 2 days of admission to the ICU. Data were collected retrospectively until June 12, 2020. A Cox regression model with inverse probability weighting was used to adjust for confounding. Exposures Treatment with tocilizumab in the first 2 days of ICU admission. Main Outcomes and Measures Time to death, compared via hazard ratios (HRs), and 30-day mortality, compared via risk differences. Results Among the 3924 patients included in the analysis (2464 male [62.8%]; median age, 62 [interquartile range {IQR}, 52-71] years), 433 (11.0%) received tocilizumab in the first 2 days of ICU admission. Patients treated with tocilizumab were younger (median age, 58 [IQR, 48-65] vs 63 [IQR, 52-72] years) and had a higher prevalence of hypoxemia on ICU admission (205 of 433 [47.3%] vs 1322 of 3491 [37.9%] with mechanical ventilation and a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen of <200 mm Hg) than patients not treated with tocilizumab. After applying inverse probability weighting, baseline and severity-of-illness characteristics were well balanced between groups. A total of 1544 patients (39.3%) died, including 125 (28.9%) treated with tocilizumab and 1419 (40.6%) not treated with tocilizumab. In the primary analysis, during a median follow-up of 27 (IQR, 14-37) days, patients treated with tocilizumab had a lower risk of death compared with those not treated with tocilizumab (HR, 0.71; 95% CI, 0.56-0.92). The estimated 30-day mortality was 27.5% (95% CI, 21.2%-33.8%) in the tocilizumab-treated patients and 37.1% (95% CI, 35.5%-38.7%) in the non-tocilizumab-treated patients (risk difference, 9.6%; 95% CI, 3.1%-16.0%). Conclusions and Relevance Among critically ill patients with COVID-19 in this cohort study, the risk of in-hospital mortality in this study was lower in patients treated with tocilizumab in the first 2 days of ICU admission compared with patients whose treatment did not include early use of tocilizumab. However, the findings may be susceptible to unmeasured confounding, and further research from randomized clinical trials is needed.
   Question Is early treatment with tocilizumab associated with a lower mortality rate among critically ill patients with coronavirus disease 2019 (COVID-19)? Findings In this multicenter cohort study that included 3924 patients, the risk of in-hospital death was estimated to be lower with tocilizumab treatment in the first 2 days of intensive care unit admission compared with no early use of tocilizumab. Meaning These findings suggest that among critically ill patients with COVID-19, early treatment with tocilizumab may reduce mortality, although the findings may be susceptible to unmeasured confounding, and further research from randomized clinical trials is needed.
   This cohort study assesses mortality rates among patients with COVID-19 admitted to intensive care who were treated with tocilizumab.
C1 [Gupta, Shruti; Correa, Simon; Pokharel, Kapil K.; Leaf, David E.] Brigham & Womens Hosp, Div Renal Med, 75 Francis St, Boston, MA 02115 USA.
   [Wang, Wei] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.
   [Wang, Wei] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.
   [Hayek, Salim S.] Univ Michigan, Dept Med, Div Cardiol, Ann Arbor, MI 48109 USA.
   [Chan, Lili] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA.
   [Mathews, Kusum S.] Icahn Sch Med Mt Sinai, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA.
   [Mathews, Kusum S.] Icahn Sch Med Mt Sinai, Dept Emergency Med, New York, NY 10029 USA.
   [Melamed, Michal L.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
   [Brenner, Samantha K.] Hackensack Meridian Sch Med Seton Hall, Dept Internal Med, Nutley, NJ USA.
   [Brenner, Samantha K.] Hackensack Univ, Med Ctr, Hackensack Meridian Hlth, Dept Internal Med, Hackensack, NJ USA.
   [Leonberg-Yoo, Amanda] Univ Penn, Perelman Sch Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA.
   [Schenck, Edward J.] Weill Cornell Med Ctr, Dept Med, Div Pulm & Crit Care Med, New York, NY USA.
   [Radbel, Jared] Rutgers Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ USA.
   [Reiser, Jochen] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA.
   [Bansal, Anip] Univ Colorado, Div Renal Dis & Hypertens, Anschutz Med Campus Aurora, Aurora, CO USA.
   [Srivastava, Anand] Northwestern Univ, Div Nephrol & Hypertens, Inst Publ Hlth & Med, Feinberg Sch Med,Ctr Translat Metab & Hlth, Chicago, IL 60611 USA.
   [Zhou, Yan] Med Coll Wisconsin, Dept Med, Div Pulm Crit Care & Sleep Med, Milwaukee, WI 53226 USA.
   [Finkel, Diana] Rutgers State Univ, New Jersey Med Sch, Dept Med, Div Infect Dis, Newark, NJ USA.
   [Green, Adam] Cooper Univ Hlth Care, Div Crit Care, Camden, NJ USA.
   [Mallappallil, Mary] New York City Hlth & Hosp Corp, Kings Cty Hosp Ctr, Div Nephrol, Brooklyn, NY USA.
   [Faugno, Anthony J.] Tufts Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02111 USA.
   [Zhang, Jingjing] Thomas Jefferson Univ Hosp, Div Nephrol, Philadelphia, PA 19107 USA.
   [Velez, Juan Carlos Q.] Ochsner Hlth Syst, Dept Nephrol, New Orleans, LA USA.
   [Velez, Juan Carlos Q.] Univ Queensland, Ochsner Clin Sch, Brisbane, Qld, Australia.
   [Shaefi, Shahzad] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA.
   [Parikh, Chirag R.] Johns Hopkins Sch Med, Div Nephrol, Baltimore, MD USA.
   [Charytan, David M.] NYU, Dept Med, Div Nephrol, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA.
   [Athavale, Ambarish M.] Cook Cty Hlth, Div Nephrol, Chicago, IL USA.
   [Friedman, Allon N.] Indiana Univ, Sch Med, Dept Med, Indiana Univ Hlth, Indianapolis, IN USA.
   [Redfern, Roberta E.] ProMed Toledo Hosp, ProMed Res, Toledo, OH USA.
   [Short, Samuel A. P.] Univ Vermont, Larner Coll Med, Burlington, VT USA.
   [Admon, Andrew J.] Univ Michigan, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.
   [Donnelly, John P.] Univ Michigan, Sch Med, Dept Learning Hlth Sci, Ann Arbor, MI USA.
   [Donnelly, John P.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.
   [Gershengorn, Hayley B.] Univ Miami, Miller Sch Med, Div Pulm Crit Care & Sleep Med, Miami, FL 33136 USA.
   [Gershengorn, Hayley B.] Albert Einstein Coll Med, Div Crit Care Med, Bronx, NY 10467 USA.
   [Douin, David J.] Univ Colorado, Sch Med, Dept Anesthesiol, Aurora, CO USA.
   [Semler, Matthew W.] Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN USA.
   [Hernan, Miguel A.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol & Biostat, Boston, MA USA.
   [Hernan, Miguel A.] Harvard MIT, Program Hlth Sci & Technol, Boston, MA USA.
RP Leaf, DE (corresponding author), Brigham & Womens Hosp, Div Renal Med, 75 Francis St, Boston, MA 02115 USA.
EM deleaf@bwh.harvard.edu
OI Radbel, Jared/0000-0002-3013-6270; charytan, david/0000-0002-7695-3583;
   Wen, Yumeng/0000-0002-1392-6369; Redfern, Roberta/0000-0001-9883-2910;
   Azam, Tariq/0000-0002-1506-5099
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [F32HL149337, K23DK120811, R01HL085757,
   R01HL144566, R01DK125786, K12HL138039, K23HL130648, R37AI102634,
   F32DC017342, K08GM134220, R03AG060179, K23HL143053, R01HL153384];
   Frankel Cardiovascular Center COVID-19: Impact Research Ignitor [U-M
   G024231]
FX The writing committee was supported by grants F32HL149337 (Dr Admon),
   K23DK120811 (Dr Srivastava), R01HL085757 (Dr Parikh), R01HL144566 and
   R01DK125786 (Dr Leaf), K12HL138039 (Dr Donnelly), K23HL130648 (Dr
   Mathews), R37AI102634 (Dr Hernan), F32DC017342 (Dr Gupta), K08GM134220
   and R03AG060179 (Dr Shaefi), K23HL143053 (Dr Semler), and R01HL153384
   (Dr Hayek) from the NIH and grant U-M G024231 from the Frankel
   Cardiovascular Center COVID-19: Impact Research Ignitor (Dr Hayek).
CR Aakre C, 2017, INT J MED INFORM, V103, P1, DOI 10.1016/j.ijmedinf.2017.04.001
   Admon AJ, 2019, ANN AM THORAC SOC, V16, P998, DOI 10.1513/AnnalsATS.201903-241OC
   [Anonymous], CORIMUNO 19 TOC TRIA
   [Anonymous], RAND EV COVID 19 THE
   [Anonymous], TOC TREATM COR IND D
   [Anonymous], STUD EV SAF EFF TOC
   [Anonymous], EFF TOC PAT COVID 19
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Capra R, 2020, EUR J INTERN MED, V76, P31, DOI 10.1016/j.ejim.2020.05.009
   Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662
   Dickerman BA, 2019, NAT MED, V25, P1601, DOI 10.1038/s41591-019-0597-x
   Emberson JR, 2020, NEW ENGL J MED, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Emilsson L, 2018, JAMA ONCOL, V4, P63, DOI 10.1001/jamaoncol.2017.2752
   Frigault MJ, 2020, BLOOD, V136, P137, DOI 10.1182/blood.2020006216
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Gupta Shruti, 2020, JAMA Intern Med, DOI 10.1001/jamainternmed.2020.3596
   Hernan MA, 2016, J CLIN EPIDEMIOL, V79, P70, DOI 10.1016/j.jclinepi.2016.04.014
   Hernan MA, 2016, AM J EPIDEMIOL, V183, P758, DOI 10.1093/aje/kwv254
   Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008
   Jaber S, 2018, LANCET, V392, P31, DOI 10.1016/S0140-6736(18)31080-8
   Jentzer JC, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008169
   Landry A, 2017, CAN FAM PHYSICIAN, V63, pE316
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meng Y, 2016, ONCOTARGETS THER, V9, P1689, DOI 10.2147/OTT.S97993
   Moore C, 2013, JCR-J CLIN RHEUMATOL, V19, P324, DOI 10.1097/RHU.0b013e31829ce01f
   Morena V, 2020, EUR J INTERN MED, V76, P36, DOI 10.1016/j.ejim.2020.05.011
   Petito LC, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0452
   Price CC, 2020, CHEST, V158, P1397, DOI 10.1016/j.chest.2020.06.006
   Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686
   Raith EP, 2017, JAMA-J AM MED ASSOC, V317, P290, DOI 10.1001/jama.2016.20328
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529
   Subramaniam B, 2019, JAMA-J AM MED ASSOC, V321, P686, DOI 10.1001/jama.2019.0234
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   van Walraven C, 2011, J CLIN EPIDEMIOL, V64, P1054, DOI 10.1016/j.jclinepi.2011.01.001
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Xu S, 2010, VALUE HEALTH, V13, P273, DOI 10.1111/j.1524-4733.2009.00671.x
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 44
TC 3
Z9 3
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
DI 10.1001/jamainternmed.2020.6252
EA OCT 2020
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA OO6IW
UT WOS:000587482200004
PM 33080002
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hermine, O
   Mariette, X
   Tharaux, PL
   Resche-Rigon, M
   Porcher, R
   Ravaud, P
AF Hermine, Olivier
   Mariette, Xavier
   Tharaux, Pierre-Louis
   Resche-Rigon, Matthieu
   Porcher, Raphael
   Ravaud, Philippe
CA CORIMUNO-19 Collaborative Grp
TI Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19
   and Moderate or Severe Pneumonia A Randomized Clinical Trial
SO JAMA INTERNAL MEDICINE
LA English
DT Article; Early Access
AB IMPORTANCE Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus disease 2019 (COVID-19).
   OBJECTIVE To determine whether tocilizumab (TCZ) improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia.
   DESIGN, SETTING, AND PARTICPANTS This cohort-embedded, investigator-initiated, multicenter, open-label, bayesian randomized clinical trial investigating patients with COVID-19 and moderate or severe pneumonia requiring at least 3 L/min of oxygen but without ventilation or admission to the intensive care unit was conducted between March 31, 2020, to April 18, 2020, with follow-up through 28 days. Patients were recruited from 9 university hospitals in France. Analyses were performed on an intention-to-treat basis with no correction for multiplicity for secondary outcomes.
   INTERVENTIONS Patients were randomly assigned to receive TCZ, 8 mg/kg, intravenously plus usual care on day 1 and on day 3 if clinically indicated (TCZ group) or to receive usual care alone (UC group). Usual care included antibiotic agents, antiviral agents, corticosteroids, vasopressor support, and anticoagulants.
   MAIN OUTCOMES AND MEASURES Primary outcomes were scores higher than 5 on the World Health Organization 10-point Clinical Progression Scale (WHO-CPS) on day 4 and survival without need of ventilation (including noninvasive ventilation) at day 14. Secondary outcomes were clinical status assessed with the WHO-CPS scores at day 7 and day 14, overall survival, time to discharge, time to oxygen supply independency, biological factors such as C-reactive protein level, and adverse events.
   RESULTS Of 131 patients, 64 patients were randomly assigned to the TCZ group and 67 to UC group; 1 patient in the TCZ group withdrew consent and was not included in the analysis. Of the 130 patients, 42 were women (32%), and median (interquartile range) age was 64 (57.1-74.3) years. In the TCZ group, 12 patients had a WHO-CPS score greater than 5 at day 4 vs 19 in the UC group (median posterior absolute risk difference [ARD] -9.0%; 90% credible interval [CrI], -21.0 to 3.1), with a posterior probability of negative ARD of 89.0% not achieving the 95% predefined efficacy threshold. At day 14, 12% (95% CI -28% to 4%) fewer patients needed noninvasive ventilation (NIV) or mechanical ventilation (MV) or died in the TCZ group than in the UC group (24% vs 36%, median posterior hazard ratio [HR] 0.58; 90% CrI, 0.33-1.00), with a posterior probability of HR less than 1 of 95.0%, achieving the predefined efficacy threshold. The HR for MV or death was 0.58 (90% CrI, 0.30 to 1.09). At day 28, 7 patients had died in the TCZ group and 8 in the UC group (adjusted HR, 0.92; 95% CI 0.33-2.53). Serious adverse events occurred in 20 (32%) patients in the TCZ group and 29 (43%) in the UC group (P = .21).
   CONCLUSIONS AND RELEVANCE In this randomized clinical trial of patients with COVID-19 and pneumonia requiring oxygen support but not admitted to the intensive care unit, TCZ did not reduce WHO-CPS scores lower than 5 at day 4 but might have reduced the risk of NIV, MV, or death by day 14. No difference on day 28 mortality was found. Further studies are necessary for confirming these preliminary results.
C1 [Hermine, Olivier] Hop Necker Enfants Malad, AP HP, Dept Hematol, Paris, France.
   [Hermine, Olivier] Univ Paris, INSERM, Inst Imagine, UMR1183, Paris, France.
   [Mariette, Xavier] Hop Bicetre, AP HP, Dept Rheumatol, Paris, France.
   [Mariette, Xavier] Univ Paris Saclay, INSERM, UMR1184, Le Kremlin Bicetre, France.
   [Tharaux, Pierre-Louis] Univ Paris, INSERM, Paris Cardiovasc Ctr PARCC, F-75015 Paris, France.
   [Resche-Rigon, Matthieu] Univ Paris, INSERM, ECSTRRA Team, CRESS,UMR 1153, F-75010 Paris, France.
   [Resche-Rigon, Matthieu] Hop St Louis, AP HP, URC St Louis, F-75010 Paris, France.
   [Porcher, Raphael; Ravaud, Philippe] Univ Paris, Ctr Res Epidemiol & Stat CRESS, INSERM, U1153, Paris, France.
   [Ravaud, Philippe] Hop Hotel Dieu, AP HP, Ctr Epidemiol Clin, Paris, France.
RP Hermine, O (corresponding author), Univ Paris, Hop Necker, AP HP, INSERM,Imagine Inst, 149-161 Rue Sevres, F-75743 Paris, France.
EM ohermine@gmail.com
RI Tharaux, Pierre-Louis/A-9155-2009
OI Tharaux, Pierre-Louis/0000-0002-6062-5905
FU Ministry of Health, Programme Hospitalier de Recherche Clinique [PHRC
   COVID-19-20-0143, PHRC COVID-19-20-0029]; Foundation for Medical
   Research (FRM)Fondation pour la Recherche Medicale; AP-HP Foundation;
   Reacting program
FX This trial was publicly funded (Ministry of Health, Programme
   Hospitalier de Recherche Clinique [PHRC COVID-19-20-0143, PHRC
   COVID-19-20-0029], Foundation for Medical Research (FRM), AP-HP
   Foundation and the Reacting program).
CR Angus DC, 2020, JAMA-J AM MED ASSOC, V323, P1895, DOI 10.1001/jama.2020.4984
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cook DJ, 2020, JAMA-J AM MED ASSOC, V323, P1559, DOI 10.1001/jama.2020.5775
   Dechartres A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2304
   Del Valle DM, 2020, NAT MED, V26, P1636, DOI 10.1038/s41591-020-1051-9
   Grifoni E, 2020, J INFECTION, V81, P466, DOI 10.1016/j.jinf.2020.06.008
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Horby P., 2020, N ENGL J MED
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Roumier M, 2020, INTERLEUKIN 6 BLOCKA, DOI [10.1101/2020.04.20.20061861, 10.1101/2020.04.20.20061861., DOI 10.1101/2020.04.20.20061861]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu J, 2020, CLIN INFECT DIS, V71, P706, DOI 10.1093/cid/ciaa199
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhu JY, 2020, J MED VIROL, DOI 10.1002/jmv.26085
NR 22
TC 5
Z9 5
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
DI 10.1001/jamainternmed.2020.6820
EA OCT 2020
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA OO6IW
UT WOS:000587482200001
PM 33080017
OA Bronze
DA 2021-01-01
ER

PT J
AU Salvarani, C
   Dolci, G
   Massari, M
   Merlo, DF
   Cavuto, S
   Savoldi, L
   Bruzzi, P
   Boni, F
   Braglia, L
   Turra, C
   Ballerini, PF
   Sciascia, R
   Zammarchi, L
   Para, O
   Scotton, PG
   Inojosa, WO
   Ravagnani, V
   Salerno, ND
   Sainaghi, PP
   Brignone, A
   Codeluppi, M
   Teopompi, E
   Milesi, M
   Bertomoro, P
   Claudio, N
   Salio, M
   Falcone, M
   Cenderello, G
   Donghi, L
   Del Bono, V
   Colombelli, PL
   Angheben, A
   Passaro, A
   Secondo, G
   Pascale, R
   Piazza, I
   Facciolongo, N
   Costantini, M
AF Salvarani, Carlo
   Dolci, Giovanni
   Massari, Marco
   Merlo, Domenico Franco
   Cavuto, Silvio
   Savoldi, Luisa
   Bruzzi, Paolo
   Boni, Fabrizio
   Braglia, Luca
   Turra, Caterina
   Ballerini, Pier Ferruccio
   Sciascia, Roberto
   Zammarchi, Lorenzo
   Para, Ombretta
   Scotton, Pier Giorgio
   Inojosa, Walter Omar
   Ravagnani, Viviana
   Salerno, Nicola Duccio
   Sainaghi, Pier Paolo
   Brignone, Alessandro
   Codeluppi, Mauro
   Teopompi, Elisabetta
   Milesi, Maurizio
   Bertomoro, Perla
   Claudio, Norbiato
   Salio, Mario
   Falcone, Marco
   Cenderello, Giovanni
   Donghi, Lorenzo
   Del Bono, Valerio
   Colombelli, Paolo Luigi
   Angheben, Andrea
   Passaro, Angelina
   Secondo, Giovanni
   Pascale, Renato
   Piazza, Ilaria
   Facciolongo, Nicola
   Costantini, Massimo
CA RCT TCZ COVID 19 Study Grp
TI Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients
   Hospitalized With COVID-19 Pneumonia A Randomized Clinical Trial
SO JAMA INTERNAL MEDICINE
LA English
DT Article; Early Access
AB IMPORTANCE The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people worldwide. Tocilizumab has shown promising results in retrospective studies in patients with COVID-19 pneumonia with a good safety profile.
   OBJECTIVE To evaluate the effect of early tocilizumab administration vs standard therapy in preventing clinical worsening in patients hospitalized with COVID-19 pneumonia.
   DESIGN, SETTING, AND PARTICIPANTS Prospective, open-label, randomized clinical trial that randomized patients hospitalized between March 31 and June 11, 2020, with COVID-19 pneumonia to receive tocilizumab or standard of care in 24 hospitals in Italy. Cases of COVID-19 were confirmed by polymerase chain reaction method with nasopharyngeal swab. Eligibility criteria included COVID-19 pneumonia documented by radiologic imaging, partial pressure of arterial oxygen to fraction of inspired oxygen (Pao(2)/Fio(2)) ratio between 200 and 300 mm Hg, and an inflammatory phenotype defined by fever and elevated C-reactive protein.
   INTERVENTIONS Patients in the experimental arm received intravenous tocilizumab within 8 hours from randomization (8 mg/kg up to a maximum of 800 mg), followed by a second dose after 12 hours. Patients in the control arm received supportive care following the protocols of each clinical center until clinical worsening and then could receive tocilizumab as a rescue therapy.
   MAIN OUTCOME AND MEASURES The primary composite outcome was defined as entry into the intensive care unit with invasive mechanical ventilation, death from all causes, or clinical aggravation documented by the finding of a Pao(2)/Fio(2) ratio less than 150 mm Hg, whichever came first.
   RESULTS A total of 126 patients were randomized (60 to the tocilizumab group; 66 to the control group). The median (interquartile range) age was 60.0 (53.0-72.0) years, and the majority of patients were male (77 of 126, 61.1%). Three patients withdrew from the study, leaving 123 patients available for the intention-to-treat analyses. Seventeen patients of 60 (28.3%) in the tocilizumab arm and 17 of 63 (27.0%) in the standard care group showed clinical worsening within 14 days since randomization (rate ratio, 1.05; 95% CI, 0.59-1.86). Two patients in the experimental group and 1 in the control group died before 30 days from randomization, and 6 and 5 patients were intubated in the 2 groups, respectively. The trial was prematurely interrupted after an interim analysis for futility.
   CONCLUSIONS AND RELEVANCE In this randomized clinical trial of hospitalized adult patients with COVID-19 pneumonia and Pao(2)/Fio(2) ratio between 200 and 300 mm Hg who received tocilizumab, no benefit on disease progression was observed compared with standard care. Further blinded, placebo-controlled randomized clinical trials are needed to confirm the results and to evaluate possible applications of tocilizumab in different stages of the disease.
C1 [Salvarani, Carlo] Azienda USL IRCCS Reggio Emilia, SOC Reumatol, Reggio Emilia, Italy.
   [Salvarani, Carlo] Univ Modena & Reggio Emilia, Unita Reumatol, Reggio Emilia, Italy.
   [Dolci, Giovanni] Univ Modena & Reggio Emilia, Unita Malattie Infett, Reggio Emilia, Italy.
   [Massari, Marco] Azienda USL IRCCS Reggio Emilia, SOC Malattie Infett, Reggio Emilia, Italy.
   [Merlo, Domenico Franco; Cavuto, Silvio; Savoldi, Luisa; Braglia, Luca] Azienda USL IRCCS Reggio Emilia, SC Infrastruttura Ric & Stat, Reggio Emilia, Italy.
   [Bruzzi, Paolo] IRCCS Osped Policlin San Martino, SC Epidemiol Clin, Genoa, Italy.
   [Boni, Fabrizio; Teopompi, Elisabetta] Azienda USL IRCCS Reggio Emilia, SOC Internist Multidisciplinare, Reggio Emilia, Italy.
   [Turra, Caterina] Azienda USL IRCCS Reggio Emilia, SOC Farm, Reggio Emilia, Italy.
   [Ballerini, Pier Ferruccio; Sciascia, Roberto] UOC Med Gen Osped Vittorio Veneto, Treviso, Italy.
   [Zammarchi, Lorenzo] Univ Firenze, AOU Careggi, SOD Malattie Infett & Trop, Dipartimento Med Sperimentale & Clin, Florence, Italy.
   [Para, Ombretta] AOU Careggi, Dipartimento Emergenza Accettaz, Med Interna 1, Florence, Italy.
   [Scotton, Pier Giorgio; Inojosa, Walter Omar] Osped Reg Ca Foncello Treviso, UO Malattie Infett, Treviso, Italy.
   [Ravagnani, Viviana] ASST Mantova, SSD Ctr DH Allergol & Immunol Clin, Mantva, Italy.
   [Salerno, Nicola Duccio] AOUI Verona, UOC Malattie Infett & Trop, Verona, Italy.
   [Sainaghi, Pier Paolo] Univ Piemonte Orientale, DIMET, SS Reumatol, SC Med Interna, Vercelli, Italy.
   [Sainaghi, Pier Paolo] AOU Maggiore Carita Novara, Novara, Italy.
   [Brignone, Alessandro] Osped S Andrea, Reumatol Med Interna, La Spezia, Italy.
   [Codeluppi, Mauro] AUSL Piacenza, UOC Malattie Infett, Piacenza, Italy.
   [Milesi, Maurizio] ASST Cremona, Unita Malattie Infett, Cremona, Italy.
   [Bertomoro, Perla] ULSS6 Euganea Osped Riuniti Padova Sud, UOC Med Generale, Padua, Italy.
   [Claudio, Norbiato] AO Ordine Mauriziano, SC Med Interna, Turin, Italy.
   [Salio, Mario] AO SS Antonio & Biagio & C Arrigo, SC Malattie Apparato Resp, Alessandria, Italy.
   [Falcone, Marco] Univ Pisa, Unita Malattie Infett, Dipartimento Med Clin & Sperimentale, Pisa, Italy.
   [Cenderello, Giovanni] ASL1 Imperia, Malattie Infett, Imperia, Italy.
   [Donghi, Lorenzo] AOU Parma, UO Malattie Infett & Epatol, Parma, Italy.
   [Del Bono, Valerio] AOS Croce & Carle, Malattie Infett & Trop, Cuneo, Italy.
   [Colombelli, Paolo Luigi] ASST Bergamo Ovest, Osped Treviglio, UO Med, Bergamo, Italy.
   [Angheben, Andrea] IRCCS Osped Sacro Cuore Don Calabria, Dipartimento Malattie Infett Trop & Microbiol, Verona, Italy.
   [Passaro, Angelina] Med Interna Univ, AOU Ferrara, Ferrara, Italy.
   [Secondo, Giovanni] Osped Evangelico, Med Interna, Genoa, Italy.
   [Pascale, Renato] Univ Bologna, UO Malattie Infett, Dipartimento Sci Med & Chirurg, Bologna, Italy.
   [Piazza, Ilaria] AUSSS3 Serenissima, UOC Med Interna, Venice, Italy.
   [Facciolongo, Nicola] Azienda USL IRCCS Reggio Emilia, SOC Pneumol, Reggio Emilia, Italy.
   [Costantini, Massimo] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy.
RP Salvarani, C (corresponding author), Azienda USL IRCCS Reggio Emilia, Unita Operat Reumatol, Viale Risorgimento 80, I-42100 Reggio Emilia, Italy.
EM carlo.salvarani@ausl.re.it
RI Merlo, Domenico Franco/ABI-1345-2020
OI Merlo, Domenico Franco/0000-0002-1832-4754
FU Italian Ministry of Health "Fondi Ricerca Corrente - Linea 1, progetto
   4"
FX The coordinator center and participating centers used local resources to
   conduct the trial. The work at the IRCCS Sacro Cuore Don Calabria
   Hospital was partly funded by the Italian Ministry of Health "Fondi
   Ricerca Corrente - Linea 1, progetto 4". Roche provided the drug and its
   distribution to the centers.
CR Berlin David A, 2020, N Engl J Med, V383, P2451, DOI 10.1056/NEJMcp2009575
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Manfredi A, 2020, INTERN MED J, V50, P1085, DOI 10.1111/imj.14670
   McCarthy C, 2020, RESPIROLOGY, V25, P1090, DOI 10.1111/resp.13912
   Price CC, 2020, CHEST, V158, P1397, DOI 10.1016/j.chest.2020.06.006
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Schirmer M, 2018, EXPERT REV CLIN IMMU, V14, P339, DOI 10.1080/1744666X.2018.1468251
   Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529
   Stone JH, 2017, NEW ENGL J MED, V377, P317, DOI 10.1056/NEJMoa1613849
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zeng FR, 2020, INT J INFECT DIS, V96, P467, DOI 10.1016/j.ijid.2020.05.055
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 4
Z9 4
U1 4
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
DI 10.1001/jamainternmed.2020.6615
EA OCT 2020
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA OO6IW
UT WOS:000587482200002
PM 33080005
OA Bronze
DA 2021-01-01
ER

PT J
AU Jee, J
   Foote, MB
   Lumish, M
   Stonestrom, AJ
   Wills, B
   Narendra, V
   Avutu, V
   Murciano-Goroff, YR
   Chan, JE
   Derkach, A
   Philip, J
   Belenkaya, R
   Kerpelev, M
   Maloy, M
   Watson, A
   Fong, C
   Janjigian, Y
   Diaz, LA
   Bolton, KL
   Pessin, MS
AF Jee, Justin
   Foote, Michael B.
   Lumish, Melissa
   Stonestrom, Aaron J.
   Wills, Beatriz
   Narendra, Varun
   Avutu, Viswatej
   Murciano-Goroff, Yonina R.
   Chan, Jason E.
   Derkach, Andriy
   Philip, John
   Belenkaya, Rimma
   Kerpelev, Marina
   Maloy, Molly
   Watson, Adam
   Fong, Chris
   Janjigian, Yelena
   Diaz, Luis A.
   Bolton, Kelly L.
   Pessin, Melissa S.
TI Chemotherapy and COVID-19 Outcomes in Patients With Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID MORTALITY
AB PURPOSECoronavirus-2019 (COVID-19) mortality is higher in patients with cancer than in the general population, yet the cancer-associated risk factors for COVID-19 adverse outcomes are not fully characterized.PATIENTS AND METHODSWe reviewed clinical characteristics and outcomes from patients with cancer and concurrent COVID-19 at Memorial Sloan Kettering Cancer Center until March 31, 2020 (n = 309), and observed clinical end points until April 13, 2020. We hypothesized that cytotoxic chemotherapy administered within 35 days of a COVID-19 diagnosis is associated with an increased hazard ratio (HR) of severe or critical COVID-19. In secondary analyses, we estimated associations between specific clinical and laboratory variables and the incidence of a severe or critical COVID-19 event.RESULTSCytotoxic chemotherapy administration was not significantly associated with a severe or critical COVID-19 event (HR, 1.10; 95% CI, 0.73 to 1.60). Hematologic malignancy was associated with increased COVID-19 severity (HR, 1.90; 95% CI, 1.30 to 2.80). Patients with lung cancer also demonstrated higher rates of severe or critical COVID-19 events (HR, 2.0; 95% CI, 1.20 to 3.30). Lymphopenia at COVID-19 diagnosis was associated with higher rates of severe or critical illness (HR, 2.10; 95% CI, 1.50 to 3.10). Patients with baseline neutropenia 14-90 days before COVID-19 diagnosis had worse outcomes (HR, 4.20; 95% CI, 1.70 to 11.00). Findings from these analyses remained consistent in a multivariable model and in multiple sensitivity analyses. The rate of adverse events was lower in a time-matched population of patients with cancer without COVID-19.CONCLUSIONRecent cytotoxic chemotherapy treatment was not associated with adverse COVID-19 outcomes. Patients with active hematologic or lung malignancies, peri-COVID-19 lymphopenia, or baseline neutropenia had worse COVID-19 outcomes. Interactions among antineoplastic therapy, cancer type, and COVID-19 are complex and warrant further investigation.
C1 [Jee, Justin; Foote, Michael B.; Lumish, Melissa; Stonestrom, Aaron J.; Wills, Beatriz; Narendra, Varun; Avutu, Viswatej; Murciano-Goroff, Yonina R.; Chan, Jason E.; Janjigian, Yelena; Diaz, Luis A.; Bolton, Kelly L.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.
   [Derkach, Andriy; Fong, Chris] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
   [Philip, John; Belenkaya, Rimma; Maloy, Molly; Watson, Adam] Mem Sloan Kettering Canc Ctr, Dept Hlth Informat, 1275 York Ave, New York, NY 10021 USA.
   [Kerpelev, Marina] Mem Sloan Kettering Canc Ctr, Dept Informat Syst, 1275 York Ave, New York, NY 10021 USA.
   [Pessin, Melissa S.] Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10065 USA.
RP Pessin, MS (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10065 USA.
EM pessinm@mskcc.org
OI Stonestrom, Aaron/0000-0002-0602-1158; Avutu,
   Viswatej/0000-0002-2591-7187; Watson, Adam/0000-0002-9823-4838; Chan,
   Jason/0000-0003-0552-8544; Murciano-Goroff, Yonina/0000-0001-9027-2891
FU National Institutes Health K30 grant CTSA [UL1TR00457]; National Cancer
   Institute Cancer CenterUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30 CA008748]
FX Support for V.A. and Y.R.M.-G. training through the National Institutes
   Health K30 grant CTSA UL1TR00457. This research was funded in part
   through National Cancer Institute Cancer Center support grant P30
   CA008748.
CR Cannistra SA, 2020, J CLIN ONCOL, V38, P2206, DOI 10.1200/JCO.20.00858
   Centers for Disease Control and Prevention, CORONAVIRUS DIS 2019
   Cooksley CD, 2005, CANCER-AM CANCER SOC, V104, P618, DOI 10.1002/cncr.21203
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Henry BM, 2020, CLIN CHEM LAB MED, V58, P1021, DOI 10.1515/cclm-2020-0369
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yang KY, 2020, LANCET ONCOL, V21, P904, DOI 10.1016/S1470-2045(20)30310-7
   Zhang HY, 2020, CANCER-AM CANCER SOC, V126, P4023, DOI 10.1002/cncr.33042
NR 17
TC 6
Z9 6
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 20
PY 2020
VL 38
IS 30
BP 3538
EP +
DI 10.1200/JCO.20.01307
PG 10
WC Oncology
SC Oncology
GA OE5FF
UT WOS:000580555400008
PM 32795225
OA Green Published
DA 2021-01-01
ER

PT J
AU Berghoff, AS
   Gansterer, M
   Bathke, AC
   Trutschnig, W
   Hungerlander, P
   Berger, JM
   Kreminger, J
   Starzer, AM
   Strassl, R
   Schmidt, R
   Willschke, H
   Lamm, W
   Raderer, M
   Gottlieb, AD
   Mauser, NJ
   Preusser, M
AF Berghoff, Anna S.
   Gansterer, Margaretha
   Bathke, Arne C.
   Trutschnig, Wolfgang
   Hungerlaender, Philipp
   Berger, Julia M.
   Kreminger, Judith
   Starzer, Angelika M.
   Strassl, Robert
   Schmidt, Ralf
   Willschke, Harald
   Lamm, Wolfgang
   Raderer, Markus
   Gottlieb, Alex D.
   Mauser, Norbert J.
   Preusser, Matthias
TI SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care
   Hospital During the COVID-19 Pandemic
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
AB PURPOSETo analyze the prevalence of SARS-CoV-2 infection in patients with cancer in hospital care after implementation of institutional and governmental safety measurements.METHODSPatients with cancer routinely tested for SARS-CoV-2 RNA by nasal swab and real-time polymerase chain reaction between March 21 and May 4, 2020, were included. The results of this cancer cohort were statistically compared with the SARS-CoV-2 prevalence in the Austrian population as determined by a representative nationwide random sample study (control cohort 1) and a cohort of patients without cancer presenting to our hospital (control cohort 2).RESULTSA total of 1,688 SARS-CoV-2 tests in 1,016 consecutive patients with cancer were performed. A total of 270 of 1,016 (26.6%) of the patients were undergoing active anticancer treatment in a neoadjuvant/adjuvant and 560 of 1,016 (55.1%) in a palliative setting. A total of 53 of 1,016 (5.2%) patients self-reported symptoms potentially associated with COVID-19. In 4 of 1,016 (0.4%) patients, SARS-CoV-2 was detected. At the time of testing at our department, all four SARS-CoV-2-positive patients were asymptomatic, and two of them had recovered from symptomatic COVID-19. Viral clearance was achieved in three of the four patients 14-56 days after testing positive. The estimated odds ratio of SARS-CoV-2 prevalence between the cancer cohort and control cohort 1 was 1.013 (95% CI, 0.209 to 4.272; P = 1), and between control cohort 2 and the cancer cohort it was 18.333 (95% CI, 6.056 to 74.157).CONCLUSIONOur data indicate that continuation of active anticancer therapy and follow-up visits in a large tertiary care hospital are feasible and safe after implementation of strict population-wide and institutional safety measures during the current COVID-19 pandemic. Routine SARS-CoV-2 testing of patients with cancer seems advisable to detect asymptomatic virus carriers and avoid uncontrolled viral spread.
C1 [Berghoff, Anna S.; Berger, Julia M.; Kreminger, Judith; Starzer, Angelika M.; Lamm, Wolfgang; Raderer, Markus; Preusser, Matthias] Med Univ Vienna, Dept Med 1, Div Oncol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Gansterer, Margaretha] Univ Klagenfurt, Fac Management & Econ, Klagenfurt, Austria.
   [Bathke, Arne C.; Trutschnig, Wolfgang] Univ Salzburg, Fac Nat Sci, Salzburg, Austria.
   [Bathke, Arne C.; Trutschnig, Wolfgang] Univ Salzburg, Intelligent Data Analyt Lab Salzburg, Salzburg, Austria.
   [Hungerlaender, Philipp] Univ Klagenfurt, Fac Tech Sci, Klagenfurt, Austria.
   [Strassl, Robert; Schmidt, Ralf] Med Univ Vienna, Dept Lab Med, Vienna, Austria.
   [Willschke, Harald] Med Univ Vienna, Dept Anaesthesia & Gen Intens Care, Vienna, Austria.
   [Gottlieb, Alex D.; Mauser, Norbert J.] Univ Vienna, Wolfgang Pauli Inst, Fac Math, Vienna, Austria.
RP Preusser, M (corresponding author), Med Univ Vienna, Dept Med 1, Div Oncol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM matthias.preusser@meduniwien.ac.at
OI Starzer, Angelika/0000-0001-5867-8461; Bathke, Arne/0000-0002-6260-3726;
   Berghoff, Anna Sophie/0000-0001-9379-6797
FU Future Operations Clearing Board; Institute for Social Research and
   Consulting (SORA); Austrian Social Science Data Archive (AUSSDA)
FX Supported by Future Operations Clearing Board (Antonella Mei-Pochtler,
   Stephan Rihs, Thomas Starlinger), Institute for Social Research and
   Consulting (SORA) (Gunther Ogris, Florian Oberhuber), and The Austrian
   Social Science Data Archive (AUSSDA) (Lars Kaczmirek).
CR Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469
   Australian Social Science Data Archive, SPREAD COVID 19 AUST, DOI [10.11587/X2MIHW, DOI 10.11587/X2MIHW]
   Brunner E, 2018, RANK PSEUDO RANK PRO, P15
   Cannistra SA, 2020, J CLIN ONCOL, V38, P2206, DOI 10.1200/JCO.20.00858
   Dongarwar Deepa, 2020, Int J MCH AIDS, V9, P213, DOI 10.21106/ijma.389
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Giacomelli A, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104931
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Lai AG, 2020, ESTIMATING EXCESS MO, DOI [10.1101/2020.05.27.20083287, DOI 10.1101/2020.05.27.20083287]
   Long CQ, 2020, EUR J RADIOL, V126, DOI 10.1016/j.ejrad.2020.108961
   Madariaga A, CLIN CANC RES
   Nikpouraghdam M, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104378
   Patel R, 2020, MBIO, V11, DOI 10.1128/mBio.00722-20
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Posch M, ANAL DEATH RATE COVI
   Rabenau HF, 2007, J CLIN VIROL, V40, P93, DOI 10.1016/j.jcv.2007.07.009
   Tian JB, 2020, LANCET ONCOL, V21, P893, DOI 10.1016/S1470-2045(20)30309-0
   World Health Organization, 2020, WHO ANNOUNCES COVID
   World Health Organization, POPULATION BASED AGE
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Xing YY, 2020, EUROSURVEILLANCE, V25, P12, DOI 10.2807/1560-7917.ES.2020.25.10.2000191
   Xu TM, 2020, J MED VIROL, V92, P1884, DOI 10.1002/jmv.25944
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
NR 24
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 20
PY 2020
VL 38
IS 30
BP 3547
EP +
DI 10.1200/JCO.20.01442
PG 12
WC Oncology
SC Oncology
GA OE5FF
UT WOS:000580555400009
PM 32795227
OA Green Published
DA 2021-01-01
ER

PT J
AU Kreps, S
   Prasad, S
   Brownstein, JS
   Hswen, Y
   Garibaldi, BT
   Zhang, BB
   Kriner, DL
AF Kreps, Sarah
   Prasad, Sandip
   Brownstein, John S.
   Hswen, Yulin
   Garibaldi, Brian T.
   Zhang, Baobao
   Kriner, Douglas L.
TI Factors Associated With US Adults' Likelihood of Accepting COVID-19
   Vaccination
SO JAMA NETWORK OPEN
LA English
DT Article
ID DISCRETE-CHOICE EXPERIMENTS; SAMPLE-SIZE; PREFERENCES; INFLUENZA;
   CHILDREN; RISK
AB Importance The development of a coronavirus disease 2019 (COVID-19) vaccine has progressed at unprecedented speed. Widespread public uptake of the vaccine is crucial to stem the pandemic. Objective To examine the factors associated with survey participants' self-reported likelihood of selecting and receiving a hypothetical COVID-19 vaccine. Design, Setting, and Participants A survey study of a nonprobability convenience sample of 2000 recruited participants including a choice-based conjoint analysis was conducted to estimate respondents' probability of choosing a vaccine and willingness to receive vaccination. Participants were asked to evaluate their willingness to receive each hypothetical vaccine individually. The survey presented respondents with 5 choice tasks. In each, participants evaluated 2 hypothetical COVID-19 vaccines and were asked whether they would choose vaccine A, vaccine B, or neither vaccine. Vaccine attributes included efficacy, protection duration, major adverse effects, minor adverse effects, US Food and Drug Administration (FDA) approval process, national origin of vaccine, and endorsement. Levels of each attribute for each vaccine were randomly assigned, and attribute order was randomized across participants. Survey data were collected on July 9, 2020. Main Outcomes and Measures Average marginal component effect sizes and marginal means were calculated to estimate the relationship between each vaccine attribute level and the probability of the respondent choosing a vaccine and self-reported willingness to receive vaccination. Results A total of 1971 US adults responded to the survey (median age, 43 [interquartile range, 30-58] years); 999 (51%) were women, 1432 (73%) White, 277 (14%) were Black, and 190 (10%) were Latinx. An increase in efficacy from 50% to 70% was associated with a higher probability of choosing a vaccine (coefficient, 0.07; 95% CI, 0.06-0.09), and an increase from 50% to 90% was associated with a higher probability of choosing a vaccine (coefficient, 0.16; 95% CI, 0.15-0.18). An increase in protection duration from 1 to 5 years was associated with a higher probability of choosing a vaccine (coefficient, 0.05 95% CI, 0.04-0.07). A decrease in the incidence of major adverse effects from 1 in 10000 to 1 in 1000000 was associated with a higher probability of choosing a vaccine (coefficient, 0.07; 95% CI, 0.05-0.08). An FDA emergency use authorization was associated with a lower probability of choosing a vaccine (coefficient, -0.03; 95% CI, -0.04 to -0.01) compared with full FDA approval. A vaccine that originated from a non-US country was associated with a lower probability of choosing a vaccine (China: -0.13 [95% CI, -0.15 to -0.11]; UK: -0.04 [95% CI, -0.06 to -0.02]). Endorsements from the US Centers for Disease Control and Prevention (coefficient, 0.09; 95% CI, 0.07-0.11) and the World Health Organization (coefficient, 0.06; 95% CI, 0.04-0.08), compared with an endorsement from President Trump were associated with higher probabilities of choosing a vaccine. Analyses of participants' willingness to receive each vaccine when assessed individually yielded similar results. An increase in efficacy from 50% to 90% was associated with a 10% higher marginal mean willingness to receive a vaccine (from 0.51 to 0.61). A reduction in the incidence of major side effects was associated with a 4% higher marginal mean willingness to receive a vaccine (from 0.54 to 0.58).
   A vaccine originating in China was associated with a 10% lower willingness to receive a vaccine vs one developed in the US (from 0.60 to 0.50) Endorsements from the Centers for Disease Control and Prevention and World Health Organization were associated with increases in willingness to receive a vaccine (7% and 6%, respectively) from a baseline endorsement by President Trump (from 0.52 to 0.59 and from 0.52 to 0.58, respectively). Conclusions and Relevance In this survey study of US adults, vaccine-related attributes and political characteristics were associated with self-reported preferences for choosing a hypothetical COVID-19 vaccine and self-reported willingness to receive vaccination. These results may help inform public health campaigns to address vaccine hesitancy when a COVID-19 vaccine becomes available.
   This survey study evaluates the factors associated with US adults' choice of and willingness to accept a hypothetical COVID-19 vaccine.
   Question What factors are associated with US adults' choice of and willingness to accept a hypothetical COVID-19 vaccine? Findings In this survey study of a national sample of 1971 US adults, vaccine-related attributes (eg, vaccine efficacy, adverse effects, and protection duration) and political factors (eg, US Food and Drug Administration approval process, national origin of vaccine, and endorsements) were associated with preferences for choosing a hypothetical COVID-19 vaccine. Health care attitudes and practices, political partisanship, and demographic characteristics, including age, sex, and race/ethnicity, were also associated with willingness to receive a vaccination. Meaning The results of this survey study may help inform public health campaigns to address vaccine hesitancy.
C1 [Kreps, Sarah; Zhang, Baobao; Kriner, Douglas L.] Cornell Univ, Dept Govt, 209 White Hall, New York, NY 14850 USA.
   [Prasad, Sandip] Morristown Med Ctr, Atlantic Med Grp, Morris Township, NJ USA.
   [Brownstein, John S.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.
   [Brownstein, John S.; Hswen, Yulin] Boston Childrens Hosp, Computat Epidemiol Lab, Boston, MA USA.
   [Garibaldi, Brian T.] Johns Hopkins Univ, Sch Med, Johns Hopkins Biocontainment Unit, Baltimore, MD USA.
RP Kriner, DL (corresponding author), Cornell Univ, Dept Govt, 209 White Hall, New York, NY 14850 USA.
EM kriner@cornell.edu
FU Cornell Atkinson Center for Sustainability
FX Drs Kreps and Kriner would like to thank the Cornell Atkinson Center for
   Sustainability for financial support.
CR Baker R, 2013, J SUVERY STATE METHO, V1, P90, DOI [https:/doi.org/10.1093/jssam/smt008, DOI 10.1093/JSSAM/SMT008]
   Branswell H, 2020, STAT NEWS
   CATTIN P, 1982, J MARKETING, V46, P44, DOI 10.2307/1251701
   Chodosh S, 2020, POPULAR SCI
   Coppock A, 2019, RES POLITICS, V6, DOI 10.1177/2053168018822174
   Dayrit MM, 2020, J PUBLIC HEALTH POL, V41, P252, DOI 10.1057/s41271-020-00232-3
   de Bekker-Grob EW, 2018, VACCINE, V36, P1467, DOI 10.1016/j.vaccine.2018.01.054
   de Bekker-Grob EW, 2015, PATIENT, V8, P373, DOI 10.1007/s40271-015-0118-z
   de Bekker-Grob EW, 2010, VACCINE, V28, P6692, DOI 10.1016/j.vaccine.2010.08.001
   Determann D, 2016, EUROSURVEILLANCE, V21, P20, DOI 10.2807/1560-7917.ES.2016.21.22.30247
   Determann D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102505
   DSouza G., 2020, WHAT IS HERD IMMUNIT
   Goldstein A, 2020, WASHINGTON POST
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Guo N, 2017, VACCINE, V35, P2848, DOI 10.1016/j.vaccine.2017.04.006
   Hainmueller J, 2014, POLIT ANAL, V22, P1, DOI 10.1093/pan/mpt024
   Kelley K, 2003, PSYCHOL METHODS, V8, P305, DOI 10.1037/1082-989X.8.3.305
   Klein SL, 2014, J INFECT DIS, V209, pS114, DOI 10.1093/infdis/jiu066
   Kreps S, 2020, DETERMINANTS COVID 1
   Lambooij MS, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0010-5
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Ledent E, 2019, HUM VACC IMMUNOTHER, V15, P1080, DOI 10.1080/21645515.2019.1571890
   Leeper TJ, 2020, POLIT ANAL, V28, P207, DOI 10.1017/pan.2019.30
   MAHASE E, 2020, BMJ-BRIT MED J, V369, P95763, DOI DOI 10.1136/BMJ.M1502
   MAHASE E, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2126
   Nichol KL, 2001, ARCH INTERN MED, V161, P2702, DOI 10.1001/archinte.161.22.2702
   Paek HJ, 2008, HEALTH PROMOT PRACT, V9, p60S, DOI 10.1177/1524839908322114
   Quaife M, 2018, EUR J HEALTH ECON, V19, P1053, DOI 10.1007/s10198-018-0954-6
   Quinn SC, 2009, BIOSECUR BIOTERROR, V7, P275, DOI 10.1089/bsp.2009.0041
   Raude J, 2016, EXPERT REV VACCINES, V15, P937, DOI 10.1080/14760584.2016.1184092
   Reg B., 2010, PUBLIC OPIN QUART, V74, P711, DOI DOI 10.1093/POQ/NFQ048
   Shetty P, 2010, LANCET, V375, P970, DOI 10.1016/S0140-6736(10)60421-7
   Shono A, 2014, VACCINE, V32, P5071, DOI 10.1016/j.vaccine.2014.07.002
   Simpson CR, 2012, LANCET INFECT DIS, V12, P696, DOI 10.1016/S1473-3099(12)70133-0
   Trapero-Bertran M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219905
   Veldwijk J, 2014, VACCINE, V32, P6277, DOI 10.1016/j.vaccine.2014.09.004
   Wichmann O, 2010, EUROSURVEILLANCE, V15, P2
NR 37
TC 1
Z9 1
U1 3
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD OCT 20
PY 2020
VL 3
IS 10
DI 10.1001/jamanetworkopen.2020.25594
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA ON0VY
UT WOS:000586431300007
PM 33079199
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dong, JB
   Huang, B
   Wang, B
   Titong, A
   Kankanamalage, SG
   Jia, ZJ
   Wright, M
   Parthasarathy, P
   Liu, Y
AF Dong, Jianbo
   Huang, Betty
   Wang, Bo
   Titong, Allison
   Kankanamalage, Sachith Gallolu
   Jia, Zhejun
   Wright, Meredith
   Parthasarathy, Pannaga
   Liu, Yue
TI Development of humanized tri-specific nanobodies with potent
   neutralization for SARS-CoV-2
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FUNCTIONAL RECEPTOR; SARS CORONAVIRUS; ANTIBODIES
AB SARS-CoV-2 is a newly emergent coronavirus, which has adversely impacted human health and has led to the COVID-19 pandemic. There is an unmet need to develop therapies against SARS-CoV-2 due to its severity and lack of treatment options. A promising approach to combat COVID-19 is through the neutralization of SARS-CoV-2 by therapeutic antibodies. Previously, we described a strategy to rapidly identify and generate llama nanobodies (VHH) from naive and synthetic humanized VHH phage libraries that specifically bind the S1 SARS-CoV-2 spike protein, and block the interaction with the human ACE2 receptor. In this study we used computer-aided design to construct multi-specific VHH antibodies fused to human IgG1 Fc domains based on the epitope predictions for leading VHHs. The resulting tri-specific VHH-Fc antibodies show more potent S1 binding, S1/ACE2 blocking, and SARS-CoV-2 pseudovirus neutralization than the bi-specific VHH-Fcs or combination of individual monoclonal VHH-Fcs. Furthermore, protein stability analysis of the VHH-Fcs shows favorable developability features, which enable them to be quickly and successfully developed into therapeutics against COVID-19.
C1 [Dong, Jianbo; Huang, Betty; Wang, Bo; Titong, Allison; Kankanamalage, Sachith Gallolu; Jia, Zhejun; Wright, Meredith; Parthasarathy, Pannaga; Liu, Yue] Ab Studio Inc, Hayward, CA 94545 USA.
   [Liu, Yue] Ab Therapeut Inc, Hayward, CA USA.
RP Dong, JB (corresponding author), Ab Studio Inc, Hayward, CA 94545 USA.
EM jianbo.dong@antibodystudio.com
CR Bacac M, 2018, CLIN CANCER RES, V24, P4785, DOI 10.1158/1078-0432.CCR-18-0455
   Beard H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082849
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Beniac DR, 2006, NAT STRUCT MOL BIOL, V13, P751, DOI 10.1038/nsmb1123
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Chuang GY, 2008, BIOPHYS J, V95, P4217, DOI 10.1529/biophysj.108.135814
   De Vlieger D, 2018, ANTIBODIES, V8, DOI 10.3390/antib8010001
   Dong JB, 2020, EMERG MICROBES INFEC, V9, P1034, DOI 10.1080/22221751.2020.1768806
   Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602
   Fernandez-Recio J, 2010, PROTEINS, V78, P3065, DOI 10.1002/prot.22801
   HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255
   Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI 10.1038/s41594-020-0469-6
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jarasch A, 2015, J PHARM SCI-US, V104, P1885, DOI 10.1002/jps.24430
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Klasse PJ, 2014, ADV BIOL, V2014, P1, DOI DOI 10.1155/2014/157895
   Kozakov D, 2006, PROTEINS, V65, P392, DOI 10.1002/prot.21117
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lo Nigro C, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.01.42
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Padte NN, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0439-9
   Peck KM, 2018, J VIROL, V92, DOI 10.1128/JVI.01031-17
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ren W, 2008, J VIROL, V82, P1899, DOI 10.1128/JVI.01085-07
   Rogers LM, 2014, IMMUNOL RES, V59, P203, DOI 10.1007/s12026-014-8542-z
   Salam NK, 2014, PROTEIN ENG DES SEL, V27, P365, DOI 10.1093/protein/gzu017
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Shin D, 2020, NATURE, DOI 10.1038/s41586-020-2601-5
   Tay MZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00332
   van Erp EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00548
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xu YD, 2019, MABS-AUSTIN, V11, DOI 10.1080/19420862.2018.1553476
   Zellweger RM, 2010, CELL HOST MICROBE, V7, P128, DOI 10.1016/j.chom.2010.01.004
   Zeng X, 2020, ANTIB THER, DOI [10.1093/abt/tbaa008, DOI 10.1093/ABT/TBAA008]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu K, 2014, PROTEINS, V82, P1646, DOI 10.1002/prot.24551
NR 43
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 20
PY 2020
VL 10
IS 1
AR 17806
DI 10.1038/s41598-020-74761-y
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OL3JG
UT WOS:000585236900065
PM 33082473
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lyngbakken, MN
   Berdal, JE
   Eskesen, A
   Kvale, D
   Olsen, IC
   Rueegg, CS
   Rangberg, A
   Jonassen, CM
   Omland, T
   Rosjo, H
   Dalgard, O
AF Lyngbakken, Magnus Nakrem
   Berdal, Jan-Erik
   Eskesen, Arne
   Kvale, Dag
   Olsen, Inge Christoffer
   Rueegg, Corina Silvia
   Rangberg, Anbjorg
   Jonassen, Christine Monceyron
   Omland, Torbjorn
   Rosjo, Helge
   Dalgard, Olav
TI A pragmatic randomized controlled trial reports lack of efficacy of
   hydroxychloroquine on coronavirus disease 2019 viral kinetics
SO NATURE COMMUNICATIONS
LA English
DT Article
AB Here, we randomized 53 patients hospitalized with coronavirus disease 2019 (COVID-19) to hydroxychloroquine therapy (at a dose of 400mg twice daily for seven days) in addition to standard care or standard care alone (ClinicalTrials.gov Identifier, NCT04316377). All severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients 18 years of age or older were eligible for study inclusion if they had moderately severe COVID-19 at admission. Treatment with hydroxychloroquine did not result in a significantly greater rate of decline in SARS-CoV-2 oropharyngeal viral load compared to standard care alone during the first five days. Our results suggest no important antiviral effect of hydroxychloroquine in humans infected with SARS-CoV-2. The use of hydroxychloroquine therapy for the treatment of Covid-19 is controversial. In this study, Lyngbakken and colleagues present a randomized controlled trial and show that the drug has no antiviral effects in humans infected with SARS-CoV-2.
C1 [Lyngbakken, Magnus Nakrem; Omland, Torbjorn] Akershus Univ Hosp, Div Med, Lorenskog, Norway.
   [Lyngbakken, Magnus Nakrem; Berdal, Jan-Erik; Kvale, Dag; Omland, Torbjorn; Rosjo, Helge; Dalgard, Olav] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway.
   [Berdal, Jan-Erik; Eskesen, Arne; Dalgard, Olav] Akershus Univ Hosp, Div Med, Dept Infect Dis, Lorenskog, Norway.
   [Kvale, Dag] Oslo Univ Hosp, Dept Infect Dis, Oslo, Norway.
   [Olsen, Inge Christoffer; Rueegg, Corina Silvia] Oslo Univ Hosp, Dept Res Support Clin Trials, Oslo, Norway.
   [Rueegg, Corina Silvia] Oslo Univ Hosp, Oslo Ctr Biostat & Epidemiol, Oslo, Norway.
   [Rangberg, Anbjorg; Jonassen, Christine Monceyron] Ostfold Hosp Trust, Ctr Lab Med, Gralum, Norway.
   [Rosjo, Helge] Akershus Univ Hosp, Div Res & Innovat, Lorenskog, Norway.
RP Rosjo, H (corresponding author), Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway.; Rosjo, H (corresponding author), Akershus Univ Hosp, Div Res & Innovat, Lorenskog, Norway.
EM helge.rosjo@medisin.uio.no
OI Rueegg, Corina Silvia/0000-0003-3720-4659
FU European Virus Archive Global (EVA-GLOBAL) project from the European
   Union's Horizon 2020 research and innovation programme [871029]
FX We thank Shuo-Wang Qiao (Institute of Clinical Medicine, Faculty of
   Medicine, University of Oslo, Oslo, Norway) and Jan Haug Anonsen (NORCE
   Norwegian Research Centre AS, Bergen, Norway) for providing virus
   transport medium, and the Unit of Molecular Biology, Department of
   Multidisciplinary Laboratory Medicine and Medical Biochemistry, Division
   for Diagnostics and Technology, Akershus University Hospital, LOrenskog,
   Norway, for pre-study optimization of viral measurements. The
   publication was supported by the European Virus Archive Global
   (EVA-GLOBAL) project that has received funding from the European Union's
   Horizon 2020 research and innovation programme under grant agreement No
   871029. We thank Haldor Husby and the Unit of Data Analysis at the
   Division of Research and Innovation, Akershus University Hospital,
   LOrenskog, Norway, for valuable help with clinical data acquisition from
   the data warehouse at Akershus University Hospital, LOrenskog, Norway.
   We thank Randi Kristoffersen and Lisbeth Johnsen (Clinical Trial Unit,
   Akershus University Hospital, LOrenskog, Norway) for help with trial
   planning, management and regulatory approvals. We thank Jannicke Dokken,
   Merete Moen Tollefsen, Jessica Andreassen and Ingunn Melkeraaen
   (Department of Infectious Diseases, Division of Medicine, Akershus
   University Hospital, LOrenskog, Norway) for patient inclusion and
   follow-up. We thank all collaborators at the Clinical Trial Unit, Oslo
   University Hospital, Oslo, Norway, for valuable help with trial
   management, data handling and monitoring, and preparation of the
   electronic case report form. We thank all participating physicians at
   the Akershus University Hospital, LOrenskog, Norway, for help with
   patient screening and inclusion. Most importantly, we thank all the
   patients who participated in the trial.
CR Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Beigel J. H., 2020, N ENGL J MED
   Bhandari M, 2002, ARCH ORTHOP TRAUM SU, V122, P96, DOI 10.1007/s004020100347
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centers for Disease Control and Prevention, INT CLIN GUID MAN PA
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Ison MG, 2010, J INFECT DIS, V201, P1654, DOI 10.1086/652498
   Lyngbakken MN, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04420-0
   Magagnoli J, 2020, MED
   Marovich M, 2020, JAMA-J AM MED ASSOC, V324, P131, DOI 10.1001/jama.2020.10245
   Recovery Collaborative Group, 2020, N ENGL J MED
   Royal College of Physicians, 2017, NAT EARL WARN SCOR N
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
NR 18
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 20
PY 2020
VL 11
IS 1
AR 5284
DI 10.1038/s41467-020-19056-6
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OM3OG
UT WOS:000585935000001
PM 33082342
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Panda, PK
   Bandyopadhyay, A
   Singh, BC
   Moirangthem, B
   Chikara, G
   Saha, S
   Bahurupi, YA
AF Panda, Prasan Kumar
   Bandyopadhyay, Arkapal
   Singh, Budha Charan
   Moirangthem, Bikram
   Chikara, Gaurav
   Saha, Sarama
   Bahurupi, Yogesh Arvind
TI Safety and efficacy of antiviral combination therapy in symptomatic
   patients of Covid-19 infection-a randomised controlled trial (SEV-COVID
   Trial): A structured summary of a study protocol for a randomized
   controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Hydroxychloroquine; Lopinavir; Ritonavir combination;
   Protocol; Randomised controlled trial; Ribavirin
AB Objectives: 1. To compare the safety and efficacy of Hydroxychloroquine with Ribavirin and standard treatment in patients with non-severe COVID-19 infection 2. To compare the safety and efficacy of standard treatment, Lopinavir-ritonavir with Ribavarin, and Hydroxychloroquine with Ribavirin in patients with severe COVID-19 infection
   Trial design: The study is an Open label, Parallel arm design, stratified randomised controlled trial. Patients will be categorised as non-severe or severe based on predefined criteria. Those who satisfy all inclusion criteria and no exclusion criteria in the respective categories, will be randomly assigned to one of the three treatment groups in a ratio of 1:1 in the non-severe category and 1:1:1 in the severe category.
   Participants: The trial will be undertaken in a tertiary care center of the country where both Covid and non-Covid patients are getting treated. All patients who are confirmed positive and admitted will be screened for the eligibility criteria and will be enrolled in the study after a written informed consent. Patients will be categorised as non-severe or severe based on predefined criteria.
   Inclusion Criteria (all required): 1. Age >= 18 years at time of participation in the study
   2. Laboratory (RT-PCR) confirmed infection with SARS-CoV-2
   3. Symptomatic (severe or non-severe) Covid-19 disease
   4. Willingness of study participant to accept randomization to any assigned treatment arm
   Exclusion Criteria: 1. Use of medications that are contraindicated with Lopinavir/Ritonavir, Hydroxychloroquine/Chloroquine, or Ribavirin and that cannot be replaced or stopped
   2. Patient already on antiretroviral therapy with Lopinavir-Ritonavir based regimen or on Hydroxychloroquine/Chloroquine or on Ribavirin
   3. Any known contraindication to test drugs such as retinopathy and QT prolongation
   4. Known allergic reaction or inability to take orally of Lopinavir-ritonavir, Hydroxychloroquine/ Chloroquine, Ribavarin
   5. Pregnant or breastfeeding females
   6. Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or trial related) within 30 days prior to participation in the present study or want to participate after enrolment
   Intervention and comparator: Two therapeutic interventions for non-severe category and three for severe category as described below
   Non-severe Treatment arms (NS-group):
   [GRAPHICS]
   Standard Treatment for non-severe cases (STNS):Strict Isolation, Standard Precautions (Hand hygiene, Cough Etiquette, Wear surgical mask), Hydration, Proper Nutrition, Supportive Pharmacotherapy (Antipyretic, Antiallergic, Cough Suppressant), Treatment of Comorbid Diseases, Oseltamivir (75 mg BD) for patients who are tested positive for H1N1.
   Severe group Treatment arms (S-group)
   [GRAPHICS]
   Standard Treatment for severe patients (STs):Strict Isolation, Standard Precautions (Hand hygiene, Cough Etiquette, Wear surgical mask), Fluid Therapy, Supportive Pharmacotherapy (Antipyretic, Antiallergic, Cough Suppressant), Oxygen supplementation (As required), Invasive ventilation (As required), Antibiotic agents for other associated infections (according to 2019 ATS/IDSA guidelines for non-ICU and ICU patients), Vasopressor support, Renal-replacement therapy, Treatment of Comorbid Diseases, Oseltamivir (75 mg BD) for patients who are tested positive for H1N1.
   Main Outcomes: Primary endpoints:(1) Time to Clinical recovery (TTCR) defined as the time (in hours) from initiation of study treatment (active or placebo) until normalisation of fever, respiratory rate, oxygen saturation, and alleviation of cough, sustained for at least 72 hours. (2) Time to SARS-CoV-2 RT-PCR negative in upper respiratory tract specimen, time to laboratory recovery of each organ involvement.
   Secondary Endpoints: All causes mortality, Frequency of respiratory progression (defined as SPO2 <= 94% on room air or PaO2/FiO2 <300mmHg and requirement for supplemental oxygen or more advanced ventilator support), time to defervescence (in those with fever at enrolment), frequency of requirement for supplemental oxygen or non-invasive ventilation, frequency of requirement for mechanical ventilation, frequency of serious adverse events as per DAIDS table grade of severity. Outcomes are monitored for 28 days from the time of enrolment into the study OR until the patient is discharged or death whichever is longer.
   Randomization: The randomization will be done using a secured central computer-based randomization using a secure website using a central, computer-based randomisation program in a ratio of 1:1 in the non-severe category and 1:1:1 in the severe category.
   Blinding (masking): This is an open labelled study i.e. Study assigned treatment will be known to the research team, the investigators and participants.
   Numbers to be randomised (sample size): Since it is an exploratory trial as COVID-19 being a new disease, all patients who came under the purview of the inclusion criteria within the study period (5 months duration of the recruitment period of the total 6 months duration of the study i.e. from the month of June, 2020 to October 2020) and who have consented for the study will be included.
   Trial Status: Protocol version:1.0
   Recruitment start: June 3(rd), 2020 (Ongoing)
   Recruitment finish (expected): October 31(st), 2020
   Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
C1 [Panda, Prasan Kumar] AIIMS Rishikesh, Gen Med, Rishikesh, India.
   [Bandyopadhyay, Arkapal; Chikara, Gaurav] AIIMS Rishikesh, Dept Pharmacol, Rishikesh, India.
   [Singh, Budha Charan; Moirangthem, Bikram] AIIMS Rishikesh, Dept Med, Rishikesh, India.
   [Saha, Sarama] AIIMS Rishikesh, Biochem, Rishikesh, India.
   [Bahurupi, Yogesh Arvind] AIIMS Rishikesh, Community & Family Med, Rishikesh, India.
RP Panda, PK (corresponding author), AIIMS Rishikesh, Gen Med, Rishikesh, India.
EM prasan.med@aiimsrishikesh.edu.in
NR 0
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 20
PY 2020
VL 21
IS 1
AR 866
DI 10.1186/s13063-020-04774-5
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OK4WP
UT WOS:000584653000002
PM 33081849
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sivapalan, P
   Ulrik, CS
   Lappere, TS
   Eklof, JV
   Shaker, SB
   Bodtger, UCS
   Browatzki, A
   Meyer, CN
   Weinreich, UM
   Laursen, CB
   Biering-Sorensen, T
   Knop, FK
   Lundgren, JD
   Jensen, JUS
AF Sivapalan, Pradeesh
   Ulrik, Charlotte Suppli
   Lappere, Therese Sophie
   Eklof, Josefin Viktoria
   Shaker, Saher Burhan
   Bodtger, Uffe Christian Steinholtz
   Browatzki, Andrea
   Meyer, Christian Niels
   Weinreich, Ulla Moller
   Laursen, Christian B.
   Biering-Sorensen, Tor
   Knop, Filip Krag
   Lundgren, Jens D.
   Jensen, Jens-Ulrik Stohr
TI Proactive prophylaxis with azithromycin and hydroxychloroquine in
   hospitalized patients with COVID-19 (ProPAC-COVID): a statistical
   analysis plan
SO TRIALS
LA English
DT Article
DE Detailed statistical analysis plan; Randomized controlled trial;
   Infectious diseases; Safety; Hydroxychloroquine; Azithromycin;
   Intervention
AB Background: There is an urgent need for treatments that can shorten hospitalization and lower the risk of secondary infection and death in patients with corona disease. The ProPac-COVID trial evaluates whether combination therapy with macrolide azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy, and pre-emptive treatment of supra-infections can shorten hospitalization duration and reduce the risk of non-invasive ventilation, treatment in the intensive care unit, and death in patients with acute hospital admission and a positive test for 2019-nCoV and symptoms of COVID-19 disease.
   Methods: The ProPAC-COVID is a multi-center, randomized, placebo-controlled, double-blinded clinical trial. The primary outcome is number of days spent alive and out of hospital within 14 days from randomization. Randomization will be in blocks of unknown size, and the final allocation will be stratified for age, site of recruitment, and whether the patient has any chronic lung diseases. Data is analyzed using intention-to-treat (ITT) principles, and main analyses will also be subject to modified ITT analysis and per protocol analysis.
   Discussion: This paper describes the detailed statistical analysis plan for the evaluation of primary and secondary endpoints of the ProPAC-COVID study. Enrolment of patients to the ProPAC-COVID study is still ongoing. The purpose of this paper is to provide primary publication of study results to prevent selective reporting of outcomes, data-driven analysis, and to increase transparency.
C1 [Sivapalan, Pradeesh; Eklof, Josefin Viktoria; Shaker, Saher Burhan; Biering-Sorensen, Tor; Knop, Filip Krag; Jensen, Jens-Ulrik Stohr] Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen, Denmark.
   [Ulrik, Charlotte Suppli] Univ Copenhagen, Amager & Hvidovre Hosp, Copenhagen, Denmark.
   [Lappere, Therese Sophie] Univ Copenhagen, Bispebjerg & Frederiksberg Hosp, Copenhagen, Denmark.
   [Bodtger, Uffe Christian Steinholtz] Univ Southern Denmark, Naestved Slagelse & Ringsted Hosp, Odense, Denmark.
   [Browatzki, Andrea] Univ Copenhagen, Nordsjaellands Hosp Hillerod, Hillerod, Denmark.
   [Meyer, Christian Niels] Zeeland Univ Hosp, Roskilde, Denmark.
   [Weinreich, Ulla Moller] Aalborg Univ, Aalborg Univ Hosp, Aalborg, Denmark.
   [Laursen, Christian B.] Univ Southern Denmark, Odense Univ Hosp, Odense, Denmark.
   [Lundgren, Jens D.] Univ Copenhagen, Rigshosp, Copenhagen, Denmark.
RP Sivapalan, P (corresponding author), Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen, Denmark.
EM Pradeesh.s@dadlnet.dk
OI Bodtger, Uffe/0000-0002-1231-9209; Weinreich, Ulla
   Moller/0000-0003-1975-3654; Laursen, Christian B./0000-0001-6382-9906;
   Biering-Sorensen, Tor/0000-0003-4209-2778
FU Novo Nordisk FoundationNovo Nordisk Foundation [NNF20SA0062834]; Herlev
   and Gentofte Hospital, University of Copenhagen
FX The trial was funded by The Novo Nordisk Foundation (Grant number:
   NNF20SA0062834) with DKK 2,200,000. The research salary of PS was
   sponsored by Herlev and Gentofte Hospital, University of Copenhagen. The
   trial is not supported in any way by the pharmaceutical industry. The
   funding sources have not had or will have any influence on trial design,
   data collection, analysis, or reporting.
CR Arabi YM, 2017, CRIT CARE MED, V45, P1683, DOI 10.1097/CCM.0000000000002621
   Ariti CA, 2011, AM HEART J, V162, DOI 10.1016/j.ahj.2011.08.003
   Mo P, 2020, CLIN INFECT DIS
   Moher D, 2012, INT J SURG, V10, P28, DOI 10.1016/j.ijsu.2011.10.001
   Murthy S, 2020, JAMA
   Sivapalan P, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04409-9
   Sivapalan P, 2019, LANCET RESP MED, V7, P699, DOI 10.1016/S2213-2600(19)30176-6
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 9
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 20
PY 2020
VL 21
IS 1
AR 867
DI 10.1186/s13063-020-04795-0
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OK4WP
UT WOS:000584653000001
PM 33081817
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tincati, C
   Cannizzo, ES
   Giacomelli, M
   Badolato, R
   Monforte, AD
   Marchetti, G
AF Tincati, Camilla
   Cannizzo, E. Stefania
   Giacomelli, Mauro
   Badolato, Raffaele
   D'Arminio Monforte, Antonella
   Marchetti, Giulia
TI Heightened Circulating Interferon-Inducible Chemokines, and Activated
   Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the
   Second Week of Illness
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE Covid-19; SARS-CoV-2; immunity; S; M; N protein-reactive T-cells;
   immunopathology
ID T-CELL RESPONSES; IMMUNE ACTIVATION; SARS CORONAVIRUS; INFECTION; INNATE
AB Covid-19 features a delayed onset of critical illness occurring approximately one week from the beginning of symptoms, which corresponds to the bridging of innate and adaptive immunity. We reasoned that the immune events occurring at the turning point of disease might mark the direction toward pathogenic versus protective inflammatory responses. Subjects with either severe (s; PaO2/FiO2 ratio <200) or mild (m; PaO2/FiO2 ratio>300) Covid-19 were enrolled. A range of chemokines and cytokines as well as reactive oxygen species (ROS) were measured in plasma. Dendritic and NK cell frequency, monocyte and B-/T-cell phenotype and SARS-CoV-2-specific T-cell responses were assessed in PBMC. Twenty mCovid-19 and 20 sCovid-19 individuals were studied. sCovid-19 patients displayed higher non-classical monocytes, plasma chemokines (CXCL8, CXCL9, CXCL10), cytokines (IL-6, IL-10), and ROS versus mCovid-19. sCovid-19 also showed significantly increased activated CD38+HLA-DR+ T-lymphocyte, and granzyme-B+/perforin+ pro-cytolytic T-cells. All Covid-19 patients showed SARS-CoV-2 specific-T-cell response with a predominance of Th1 bi- or trifunctional IFN-gamma/IL-2/TNF-alpha-expressing CD4+, while no difference according to disease severity was observed. Severe Covid-19 features heightened circulating IFN-inducible chemokines and activated pro-cytolytic Th1 cell phenotype in the second week of illness, yet SARS-CoV-2-specific responses are similar to that of mild illness. Altogether, our observations suggest Th1 polarization coupled to higher cytolytic profile in sCovid-19 as correlate of disease pathogenesis and as potential targets to be investigated in the roadmap to therapy and vaccine development.
C1 [Tincati, Camilla; Cannizzo, E. Stefania; D'Arminio Monforte, Antonella; Marchetti, Giulia] Univ Milan, Dept Hlth Sci, Clin Infect Dis, ASST Santi Paolo & Carlo, Milan, Italy.
   [Giacomelli, Mauro; Badolato, Raffaele] Univ Brescia, Dipartimento Sci Clin & Sperimentali, ASST Spedali Civili, Spedali Civili, Brescia, Italy.
   [Giacomelli, Mauro; Badolato, Raffaele] Univ Brescia, A Nocivelli Inst Mol Med, Spedali Civili, Brescia, Italy.
RP Marchetti, G (corresponding author), Univ Milan, Dept Hlth Sci, Clin Infect Dis, ASST Santi Paolo & Carlo, Milan, Italy.
EM giulia.marchetti@unimi.it
FU Fondazione CariploFondazione Cariplo; Regione LombardiaRegione
   Lombardia; Fondazione Umberto VeronesiFondazione Umberto Veronesi
   [2020-1355, 2020-1376]
FX This work was supported by grants from Fondazione Cariplo in
   collaboration with Regione Lombardia and Fondazione Umberto Veronesi
   (Rif. 2020-1355 and 2020-1376). This work has been presented in part at
   the COVID-19 Virtual Conference (https://covid19.aids2020.org/9); oral
   poster "C-AIDS2020-10970"), 1011 July 2020.
CR [Anonymous], 2020, STRATEG COMMENTS, V26, pX, DOI [10.1080/13567888.2020.1762348, DOI 10.1038/s41591-020-0877-5]
   Appay V, 2008, J PATHOL, V214, P231, DOI 10.1002/path.2276
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Cameron MJ, 2007, J VIROL, V81, P8692, DOI 10.1128/JVI.00527-07
   Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   De Biasi S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17292-4
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Galluccio F, 2020, CLIN RHEUMATOL, V39, P2077, DOI 10.1007/s10067-020-05179-0
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harari A, 2006, IMMUNOL REV, V211, P236, DOI 10.1111/j.0105-2896.2006.00395.x
   Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim ES, 2016, J KOREAN MED SCI, V31, P1717, DOI 10.3346/jkms.2016.31.11.1717
   Kim KD, 2007, NAT MED, V13, P1248, DOI 10.1038/nm1633
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Moratto D, 2020, EUR J IMMUNOL, V50, P1412, DOI 10.1002/eji.202048724
   Oh HLJ, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.26
   Palm NW, 2007, NAT MED, V13, P1142, DOI 10.1038/nm1007-1142b
   Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Salute M.d., 2020, M D SAL
   Shin HS, 2019, CLIN INFECT DIS, V68, P984, DOI 10.1093/cid/ciy595
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tokunaga R, 2018, CANCER TREAT REV, V63, P40, DOI 10.1016/j.ctrv.2017.11.007
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhao JC, 2011, J CLIN INVEST, V121, P4921, DOI 10.1172/JCI59777
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhao JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000636
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 42
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 20
PY 2020
VL 11
AR 580987
DI 10.3389/fimmu.2020.580987
PG 12
WC Immunology
SC Immunology
GA OJ2QD
UT WOS:000583810500001
PM 33193384
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chu, HK
   Bai, T
   Chen, LY
   Hu, LL
   Xiao, L
   Yao, L
   Zhu, R
   Niu, XH
   Li, ZL
   Zhang, L
   Han, CQ
   Song, SN
   He, Q
   Zhao, Y
   Zhu, QJ
   Chen, H
   Schnabl, B
   Yang, L
   Hou, XH
AF Chu, Huikuan
   Bai, Tao
   Chen, Liuying
   Hu, Lilin
   Xiao, Li
   Yao, Lin
   Zhu, Rui
   Niu, Xiaohui
   Li, Zhonglin
   Zhang, Lei
   Han, Chaoqun
   Song, Shuangning
   He, Qi
   Zhao, Ying
   Zhu, Qingjing
   Chen, Hua
   Schnabl, Bernd
   Yang, Ling
   Hou, Xiaohua
TI Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE liver impairment; hepatocellular pattern; cholestatic pattern; mixed
   pattern; prognosis
ID PNEUMONIA
AB Background and Aim: Liver test abnormalities are common in COVID-19 patients. The aim of our study was to determine risk factors for different liver injury patterns and to evaluate the relationship between liver injury patterns and prognosis in patients with COVID-19.
   Methods: We retrospectively analyzed patients admitted between January 1st to March 10th, with laboratory-confirmed COVID-19 and followed them up to April 20th, 2020. Information of clinical features of patients was collected for analysis.
   Results: As a result, a total of 838 hospitalized patients with confirmed COVID-19, including 48.8% (409/838) patients with normal liver function and 51.2% (429/838) patients with liver injury were analyzed. Abnormal liver function tests are associated with organ injuries, hypoxia, inflammation, and the use of antiviral drugs. Hepatocellular injury pattern was associated with hypoxia. The mortality of the hepatocellular injury pattern, cholestatic pattern and mixed pattern were 25, 28.2, and 22.3%, respectively, while the death rate was only 6.1% in the patients without liver injury. Multivariate analyses showed that liver injury with cholestatic pattern and mixed pattern were associated with increased mortality risk.
   Conclusions: Our study confirmed that hepatocellular injury pattern that may be induced by hypoxia was not risk factor for mortality in SARS-COV-2 infection, while liver injury with mixed pattern and cholestatic pattern that might be induced by SARS-CoV-2 directly might be potential risk factors for increased mortality in COVID-19 patients.
C1 [Chu, Huikuan; Bai, Tao; Chen, Liuying; Hu, Lilin; Xiao, Li; Yao, Lin; Li, Zhonglin; Zhang, Lei; Han, Chaoqun; Song, Shuangning; He, Qi; Yang, Ling; Hou, Xiaohua] Huazhong Univ Sci & Technol, Union Hosp, Div Gastroenterol, Tongji Med Coll, Wuhan, Peoples R China.
   [Zhu, Rui] Huazhong Univ Sci & Technol, Union Hosp, Dept Integrated Chinese & Western Med, Tongji Med Coll, Wuhan, Peoples R China.
   [Niu, Xiaohui] Huazhong Agr Univ, Coll Informat, Wuhan, Peoples R China.
   [Zhao, Ying; Zhu, Qingjing] Wuhan Jinyintan Hosp, Liver & Infect Dis Dept, Wuhan, Peoples R China.
   [Chen, Hua] Wuhan Jinyintan Hosp, TB & Resp Dept, Wuhan, Peoples R China.
   [Schnabl, Bernd] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
RP Yang, L; Hou, XH (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Div Gastroenterol, Tongji Med Coll, Wuhan, Peoples R China.
EM hepayang@163.com; houxh@hust.edu.cn
FU Hubei Province Novel Pneumonia Emergency Research [2020FCA014];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P30 DK120515]
FX This study was supported by Hubei Province Novel Pneumonia Emergency
   Research (No. 2020FCA014 to XH) and the NIH funded San Diego Digestive
   Diseases Research Center (P30 DK120515 to BS).
CR Cai QX, 2020, J HEPATOL, V73, P566, DOI 10.1016/j.jhep.2020.04.006
   Cui YX, 2020, J INFECT DIS, V221, P1775, DOI 10.1093/infdis/jiaa113
   DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6
   Fan ZY, 2020, CLIN GASTROENTEROL H, V18, P1561, DOI 10.1016/j.cgh.2020.04.002
   Feng G, 2020, J CLIN TRANSL HEPATO, V8, P18, DOI 10.14218/JCTH.2020.00018
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ji D, 2020, J HEPATOL, V73, P451, DOI 10.1016/j.jhep.2020.03.044
   Kang Y, 2020, ALLERGY ASTHMA IMMUN, V12, P430, DOI 10.4168/aair.2020.12.3.430
   Kellum JA, 2013, CRIT CARE, V17, DOI 10.1186/cc11454
   Lei F, 2020, HEPATOLOGY, V72, P389, DOI 10.1002/hep.31301
   Li X, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02911-9
   Liu W, COVID 19 ATTACKS 1 B
   Marty FM, 2017, LANCET RESP MED, V5, P135, DOI 10.1016/S2213-2600(16)30435-0
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Wang CF, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102833
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YJ, 2020, J HEPATOL, V73, P807, DOI 10.1016/j.jhep.2020.05.002
   World Health Organization, 209 WHO
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yancheva N, 2019, INT J STD AIDS, V30, P620, DOI 10.1177/0956462419826723
   Yang L, 2019, HEPATOLOGY, V69, P294, DOI 10.1002/hep.30203
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang BC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235458
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang YF, 2020, LIVER INT, V40, P2095, DOI 10.1111/liv.14455
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 33
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD OCT 20
PY 2020
VL 7
AR 584342
DI 10.3389/fmed.2020.584342
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA OJ3AS
UT WOS:000583838200001
PM 33195339
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Skipper, CP
   Pastick, KA
   Engen, NW
   Bangdiwala, AS
   Abassi, M
   Lofgren, SM
   Williams, DA
   Okafor, EC
   Pullen, MF
   Nicol, MR
   Nascene, AA
   Hullsiek, KH
   Cheng, MP
   Luke, D
   Lother, SA
   MacKenzie, LJ
   Drobot, G
   Kelly, LE
   Schwartz, IS
   Zarychanski, R
   McDonald, EG
   Lee, TC
   Rajasingham, R
   Boulware, DR
AF Skipper, Caleb P.
   Pastick, Katelyn A.
   Engen, Nicole W.
   Bangdiwala, Ananta S.
   Abassi, Mahsa
   Lofgren, Sarah M.
   Williams, Darlisha A.
   Okafor, Elizabeth C.
   Pullen, Matthew F.
   Nicol, Melanie R.
   Nascene, Alanna A.
   Hullsiek, Kathy H.
   Cheng, Matthew P.
   Luke, Darlette
   Lother, Sylvain A.
   MacKenzie, Lauren J.
   Drobot, Glen
   Kelly, Lauren E.
   Schwartz, Ilan S.
   Zarychanski, Ryan
   McDonald, Emily G.
   Lee, Todd C.
   Rajasingham, Radha
   Boulware, David R.
TI Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 A
   Randomized Trial
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID ACUTE INFLUENZA; OSELTAMIVIR; EFFICACY; SAFETY
AB Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
   Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.
   Design: Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials .gov: NCT04308668)
   Setting: Internet-based trial across the United States and Canada (40 states and 3 provinces).
   Participants: Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.
   Intervention: Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo.
   Measurements: Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days.
   Results: Of 491 patients randomly assigned to a group, 423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 point [95% CI, -0.61 to 0.07 point]; P = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P =0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P < 0.001). With placebo, 10 hospitalizations occurred (2 non-COVID-19 -related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29).
   Limitation: Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages.
   Conclusion: Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.
   Primary Funding Source: Private donors.
C1 [Skipper, Caleb P.; Pastick, Katelyn A.; Engen, Nicole W.; Bangdiwala, Ananta S.; Abassi, Mahsa; Lofgren, Sarah M.; Williams, Darlisha A.; Okafor, Elizabeth C.; Pullen, Matthew F.; Nicol, Melanie R.; Nascene, Alanna A.; Hullsiek, Kathy H.; Rajasingham, Radha; Boulware, David R.] Univ Minnesota, Minneapolis, MN USA.
   [Cheng, Matthew P.; McDonald, Emily G.; Lee, Todd C.] McGill Univ, Res Inst, Hlth Ctr, Montreal, PQ, Canada.
   [Cheng, Matthew P.; McDonald, Emily G.; Lee, Todd C.] McGill Univ, Montreal, PQ, Canada.
   [Luke, Darlette] M Hlth Fairview Invest Drug Serv Pharm, Minneapolis, MN USA.
   [Lother, Sylvain A.; MacKenzie, Lauren J.; Drobot, Glen; Zarychanski, Ryan] Univ Manitoba, Winnipeg, MB, Canada.
   [Kelly, Lauren E.] George & Fay Yee Ctr Healthcare Innovat, Winnipeg, MB, Canada.
   [Schwartz, Ilan S.] Univ Alberta, Edmonton, AB, Canada.
RP Boulware, DR (corresponding author), 689 23rd Ave, Minneapolis, MN 55455 USA.
EM faq.covid19@gmail.com
RI Schwartz, Ilan S./J-5666-2019
OI Schwartz, Ilan S./0000-0002-7522-0281; Lofgren, Sarah
   M/0000-0001-6717-2614; Nicol, Melanie R/0000-0001-5513-5509; Engen,
   Nicole/0000-0003-1118-4194; Boulware, David/0000-0002-4715-0060; Pullen,
   Matthew/0000-0002-4644-7487; Skipper, Caleb/0000-0002-0000-8876; Okafor,
   Elizabeth/0000-0003-1495-4596
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [K08A1134262, K23A1138851, T32A1055433]; National Institute of Mental
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [K23MH121220]; Fogarty International Center/National Institute of
   Neurological Disorders and Stroke grant [D43TVV009345]; Doris Duke
   Charitable FoundationDoris Duke Charitable Foundation (DDCF); National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [RO1A1118511,
   U01A1125003]; Clinical Practice Assessment Unit of the McGill University
   Health Centre; McGill Interdisciplinary Initiative in Infection and
   Immunity's Emergency COVID-19 Research Funding; Manitoba Medical Service
   Foundation; Research Manitoba
FX By Steve Kirsch, Jan and David Baszucki, the Minnesota Chinese Chamber
   of Commerce, the Alliance of Minnesota Chinese Organizations, and the
   University of Minnesota Foundation. Drs. Nicol, Rajasingham, and Pullen
   are supported by the National Institute of Allergy and Infectious
   Diseases (K08A1134262, K23A1138851, and T32A1055433). Dr. Lofgren is
   supported by the National Institute of Mental Health (K23MH121220). Dr.
   Skipper is supported by a combined Fogarty International Center/National
   Institute of Neurological Disorders and Stroke grant (D43TVV009345). Ms.
   Pastick and Ms. Oka for are Doris Duke International Clinical Research
   Fellows supported through the Doris Duke Charitable Foundation. Drs.
   Boulware, Hullsiek, Engen, and Bangdiwala are supported by grants
   RO1A1118511 and U01A1125003 from the National Institutes of Health, with
   an emergency supplement request made. Drs. Lee and McDonald receive
   salary support from the Fonds de recherche du Quebec -Sante. Canadian
   funding was received from various sources. In Quebec, funds were
   received from the Clinical Practice Assessment Unit of the McGill
   University Health Centre and the McGill Interdisciplinary Initiative in
   Infection and Immunity's Emergency COVID-19 Research Funding. In
   Manitoba, research support was received from the Manitoba Medical
   Service Foundation and Research Manitoba. Purolator Canada provided in
   -kind courier support for the participating Canadian sites. Apotex
   Canada and Rising Pharmaceuticals in the United States provided a
   donation of some of the hydroxychloroquine tablets used.
CR Al-Kofahi M, 2020, CLIN PHARMACOL THER, V108, P766, DOI 10.1002/cpt.1874
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Burke RM, 2020, MMWR-MORBID MORTAL W, V69, P245, DOI 10.15585/mmwr.mm6909e1
   Cheng MP, 2020, ANN INTERN MED, V172, P726, DOI 10.7326/M20-1301
   Council of State and Territorial Epidemiologists, INT 20 ID 01 STAND S
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Horby P, 2020, EFFECT HYDROXYCHLORO, DOI [10.1101/2020.07.15.20151852, DOI 10.1101/2020.07.15.20151852]
   Kaptein SJ, 2020, BIORXIV, DOI [10.1101/2020.06.19.159053., DOI 10.1101/2020.06.19.159053]
   Kucirka LM, 2020, ANN INTERN MED, V173, P262, DOI 10.7326/M20-1495
   Lother SA, 2020, CAN J ANESTH, V67, P1201, DOI 10.1007/s12630-020-01684-7
   Maisonnasse P., 2020, HYDROXYCHLOROQUINE T, DOI [10.21203/RS.3.RS-27223/V1, DOI 10.21203/RS.3.RS-27223/V1, 10.21203/rs.3.rs-27223/v1]
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   Nicholson KG, 2000, LANCET, V355, P1845, DOI 10.1016/S0140-6736(00)02288-1
   Park SJ, 2020, MBIO, V11, DOI 10.1128/mBio.01114-20
   Pastick KA, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa130
   Ross SB, 2020, J AM GERIATR SOC, V68, P1636, DOI 10.1111/jgs.16623
   Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2020, REP WHO CHIN JOINT M
   World Health Organization, 2020, GLOB SURV HUM INF CO
   World Health Organization, 2020, Q A HYDR COVID 19
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 25
TC 33
Z9 35
U1 3
U2 3
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD OCT 20
PY 2020
VL 173
IS 8
BP 623
EP +
DI 10.7326/M20-4207
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OH7WZ
UT WOS:000582805500016
PM 32673060
OA Green Published
DA 2021-01-01
ER

PT J
AU Bosco-Lauth, AM
   Hartwig, AE
   Porter, SM
   Gordy, PW
   Nehring, M
   Byas, AD
   VandeWoude, S
   Ragan, IK
   Maison, RM
   Bowen, RA
AF Bosco-Lauth, Angela M.
   Hartwig, Airn E.
   Porter, Stephanie M.
   Gordy, Paul W.
   Nehring, Mary
   Byas, Alex D.
   VandeWoude, Sue
   Ragan, Izabela K.
   Maison, Rachel M.
   Bowen, Richard A.
TI Experimental infection of domestic dogs and cats with SARS-CoV-2:
   Pathogenesis, transmission, and response to reexposure in cats
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE cats; SARS-CoV-2; experimental infection; transmission
ID CORONAVIRUS
AB The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached nearly every country in the world with extraordinary person-to-person transmission. The most likely original source of the virus was spillover from an animal reservoir and subsequent adaptation to humans sometime during the winter of 2019 in Wuhan Province, China. Because of its genetic similarity to SARS-CoV-1, it is probable that this novel virus has a similar host range and receptor specificity. Due to concern for human-pet transmission, we investigated the susceptibility of domestic cats and dogs to infection and potential for infected cats to transmit to naive cats. We report that cats are highly susceptible to infection, with a prolonged period of oral and nasal viral shedding that is not accompanied by clinical signs, and are capable of direct contact transmission to other cats. These studies confirm that cats are susceptible to productive SARS-CoV-2 infection, but are unlikely to develop clinical disease. Further, we document that cats developed a robust neutralizing antibody response that prevented reinfection following a second viral challenge. Conversely, we found that dogs do not shed virus following infection but do seroconvert and mount an antiviral neutralizing antibody response. There is currently no evidence that cats or dogs play a significant role in human infection; however, reverse zoonosis is possible if infected owners expose their domestic pets to the virus during acute infection. Resistance to reinfection holds promise that a vaccine strategy may protect cats and, by extension, humans.
C1 [Bosco-Lauth, Angela M.; Hartwig, Airn E.; Porter, Stephanie M.; Gordy, Paul W.; Nehring, Mary; Byas, Alex D.; VandeWoude, Sue; Ragan, Izabela K.; Maison, Rachel M.; Bowen, Richard A.] Colorado State Univ, Coll Vet Med & Biomed Sci, Ft Collins, CO 80523 USA.
RP Bosco-Lauth, AM (corresponding author), Colorado State Univ, Coll Vet Med & Biomed Sci, Ft Collins, CO 80523 USA.
EM angela.bosco-lauth@colostate.edu
OI Byas, Alexandria/0000-0002-0762-7389
FU Animal Models Core, Colorado State University
FX We thank Todd Bass and the histology laboratory at Colorado State
   University for preparation of tissue cassettes and slides for
   histopathology and Dr. Brian Geiss for providing the SARS-CoV-2
   nucleocapsid protein. This work was funded by the Animal Models Core,
   Colorado State University. SARS-Related Coronavirus 2, Isolate
   USA-WA1/2020 (NR52281) was deposited by the Centers for Disease Control
   and Prevention and obtained through BEI Resources, National Institute of
   Allergy and Infectious Diseases (NIAID), NIH. The following reagents
   were produced under HHSN272201400008C and obtained through BEI
   Resources, NIAID, NIH: Spike Glycoprotein RBD from SARS-Related
   Coronavirus 2, Wuhan-Hu-1, Recombinant from HEK293 cells, NR-52306, and
   Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2,
   Wuhan-Hu-1, Recombinant from Baculovirus, NR-52396.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa008
   Carver S, 2016, ECOL APPL, V26, P367, DOI [10.1890/15-0445.1, 10.1890/15-0445]
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chini M., 2020, BRUSSELS TIMES  0401
   Chini M., 2020, BRUSSELS TIMES  0327
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Davidson M., 2020, COVID 19 UPDATE 124
   Deng JH, 2020, TRANSBOUND EMERG DIS, V67, P1745, DOI 10.1111/tbed.13577
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Halfmann PJ, 2020, NEW ENGL J MED, V383, P592, DOI 10.1056/NEJMc2013400
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Kropinski Andrew M., 2009, V501, P69, DOI 10.1007/978-1-60327-164-6_7
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   Matthews S., 2020, COVID 19 UPDATE 334
   Molenaar RJ, 2020, VET PATHOL, V57, P653, DOI 10.1177/0300985820943535
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Nikolich-Zugich J, 2020, GEROSCIENCE, V42, P505, DOI 10.1007/s11357-020-00186-0
   Noh JY, 2020, J INFECTION, V81, P816, DOI 10.1016/j.jinf.2020.05.035
   Olival KJ, 2017, NATURE, V546, P646, DOI 10.1038/nature22975
   Perera RAPM, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.16.2000421
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sit THC, 2020, NATURE, DOI 10.1038/s41586-020-2334-5
   Sprague WS, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040210
   Temmam S, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100164
   Van den Brand JMA, 2008, VET PATHOL, V45, P551, DOI 10.1354/vp.45-4-551
   Vlasov N., 2020, COVID 19 UPDATE 212
   Volz A, 2020, COVID 19 UPDATE 181
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang LF, 2007, CURR TOP MICROBIOL, V315, P325
   Zhang Q., 2020, SARS COV 2 NEUTRALIZ, DOI [10.1101/2020.04.01.021196, DOI 10.1101/2020.04.01.021196]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 35
TC 1
Z9 1
U1 3
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 20
PY 2020
VL 117
IS 42
BP 26382
EP 26388
DI 10.1073/pnas.2013102117
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OE5VG
UT WOS:000580597300058
PM 32994343
OA Bronze
DA 2021-01-01
ER

PT J
AU Wood, HJ
   Gannon, JM
   Chengappa, KNR
   Sarpal, DK
AF Wood, Helen J.
   Gannon, Jessica M.
   Chengappa, K. N. Roy
   Sarpal, Deepak K.
TI Group teletherapy for first-episode psychosis: Piloting its integration
   with coordinated specialty care during the COVID-19 pandemic
SO PSYCHOLOGY AND PSYCHOTHERAPY-THEORY RESEARCH AND PRACTICE
LA English
DT Article; Early Access
DE coordinated specialty care; COVID&#8208; 19; first&#8208; episode
   psychosis; groups; teletherapy
ID COMMITMENT THERAPY; INTERVENTION; FEASIBILITY; ACCEPTANCE; PEOPLE
AB Digital health has emerged in recent years as a tool to optimize care delivery and promote treatment adherence among individuals with first-episode psychosis (FEP). Recent mandates for social distancing and sheltering in place due to the COVID-19 pandemic have catapulted efforts to provide ongoing coordinated specialty care (CSC) on virtual platforms. While prior evidence provides support for the general implementation of virtual individual therapy, there is limited guidance and evidence for the adoption of group teletherapy. Here we describe our efforts to implement group teletherapy for two small cohorts of individuals with FEP receiving care in a coordinated specialty care clinic using methods adopted from Acceptance and Commitment Therapy. We observed high adherence with group visits as well as client satisfaction across groups. Based on our results, we have taken efforts to implement virtual group therapy more permanently in our clinic. Our experience provides guidance and a model for integration of virtual group therapy within CSC.
   Practitioner points
   In-person group therapy can be adapted as an online treatment modality for individuals with first-episode psychosis (FEP).
   Group teletherapy is both accessible and satisfactory to individuals with FEP.
   Group teletherapy has potential as a more standard and widespread treatment modality within coordinated specialty care for FEP.
C1 [Wood, Helen J.; Gannon, Jessica M.; Chengappa, K. N. Roy; Sarpal, Deepak K.] UPMC Western Psychiat Hosp, Comprehens Recovery Serv, Pittsburgh, PA USA.
   [Gannon, Jessica M.; Chengappa, K. N. Roy; Sarpal, Deepak K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA.
RP Wood, HJ (corresponding author), 3501 Forbes Ave, Pittsburgh, PA 15213 USA.
EM drhelenjanewood@gmail.com
CR Bartholomeusz CF, 2013, EARLY INTERV PSYCHIA, V7, P421, DOI 10.1111/eip.12036
   Ben-Zeev D, 2019, NPJ SCHIZOPHR, V5, DOI 10.1038/s41537-019-0083-y
   Birnbaum ML, 2018, PSYCHIAT SERV, V69, P1259, DOI 10.1176/appi.ps.201800180
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]
   Bucci S, 2018, JMIR MENT HEALTH, V5, DOI 10.2196/10091
   Burlingame GM, 2020, PSYCHOTHERAPY, V57, P219, DOI 10.1037/pst0000293
   Ennis L, 2012, J MENT HEALTH, V21, P395, DOI 10.3109/09638237.2012.689437
   Fanning F, 2012, EARLY INTERV PSYCHIA, V6, P432, DOI 10.1111/j.1751-7893.2011.00333.x
   Firth J, 2016, SCHIZOPHRENIA BULL, V42, P448, DOI 10.1093/schbul/sbv132
   GOLDMAN HH, 1992, AM J PSYCHIAT, V149, P1148
   Harris R., 2020, FACE COVID RESPOND E
   Hoffman L, 2020, J PSYCHIATR PRACT, V26, P80, DOI 10.1097/PRA.0000000000000450
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Johns LC, 2016, J BEHAV THER EXP PSY, V50, P257, DOI 10.1016/j.jbtep.2015.10.001
   Kane JM, 2016, AM J PSYCHIAT, V173, P362, DOI 10.1176/appi.ajp.2015.15050632
   Lal S, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00117
   Larsen D L, 1979, Eval Program Plann, V2, P197, DOI 10.1016/0149-7189(79)90094-6
   O'Donoghue E. K., 2018, ACT PSYCHOSIS RECOVE
   Rus-Calafell Mar, 2020, Mhealth, V6, P3, DOI 10.21037/mhealth.2019.09.14
   Suler J, 2004, CYBERPSYCHOL BEHAV, V7, P321, DOI 10.1089/1094931041291295
   Weinberg H., 2020, THEORY PRACTICE ONLI
   White R, 2011, BEHAV RES THER, V49, P901, DOI 10.1016/j.brat.2011.09.003
NR 22
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1476-0835
EI 2044-8341
J9 PSYCHOL PSYCHOTHER-T
JI Psychol. Psychother.-Theory Res. Pract.
DI 10.1111/papt.12310
EA OCT 2020
PG 8
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA OG1LF
UT WOS:000581653900001
PM 33078496
DA 2021-01-01
ER

PT J
AU Lebek, S
   Tafelmeier, M
   Messmann, R
   Provaznik, Z
   Schmid, C
   Maier, LS
   Birner, C
   Arzt, M
   Wagner, S
AF Lebek, Simon
   Tafelmeier, Maria
   Messmann, Rebecca
   Provaznik, Zdenek
   Schmid, Christof
   Maier, Lars S.
   Birner, Christoph
   Arzt, Michael
   Wagner, Stefan
TI Angiotensin-converting enzyme inhibitor/angiotensinIIreceptor blocker
   treatment and haemodynamic factors are associated with increased
   cardiacmRNAexpression of angiotensin-converting enzyme2in patients with
   cardiovascular disease
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article; Early Access
DE COVID-19 pandemic; SARS-CoV-2; ACE2; ACE inhibitor; Heart failure; Left
   ventricular assist device
ID ACE2; EXPRESSION
AB Aims Coronavirus disease 2019 (COVID-19) is a widespread pandemic with an increased morbidity and mortality, especially for patients with cardiovascular diseases. Angiotensin-converting enzyme 2 (ACE2) has been identified as necessary cell entry point for SARS-CoV-2. Previous animal studies have demonstrated an increased ACE2 expression following treatment with either angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) that have led to a massive precariousness regarding the optimal cardiovascular therapy during this pandemic. Methods and results We have measured ACE2 mRNA expression using real-time quantitative polymerase chain reaction in atrial biopsies of 81 patients undergoing coronary artery bypass grafting and we compared 62 patients that received ACEi/ARB vs. 19 patients that were not ACEi/ARB-treated. We found atrial ACE2 mRNA expression to be significantly increased in patients treated with an ACEi or an ARB, independent of potential confounding comorbidities. Interestingly, the cardiac ACE2 mRNA expression correlated significantly with the expression in white blood cells of 22 patients encouraging further evaluation if the latter may be used as a surrogate for the former. Similarly, analysis of 18 ventricular biopsies revealed a significant and independent increase in ACE2 mRNA expression in patients with end-stage heart failure that were treated with ACEi/ARB. On the other hand, cardiac unloading with a left ventricular assist device significantly reduced ventricular ACE2 mRNA expression. Conclusion Treatment with ACEi/ARB is independently associated with an increased myocardial ACE2 mRNA expression in patients with coronary artery disease and in patients with end-stage heart failure. Further trials are needed to test whether this association is deleterious for patients with COVID-19, or possibly protective. Nevertheless, haemodynamic factors seem to be equally important for regulation of cardiac ACE2 mRNA expression.
C1 [Lebek, Simon; Tafelmeier, Maria; Messmann, Rebecca; Maier, Lars S.; Arzt, Michael; Wagner, Stefan] Univ Hosp Regensburg, Dept Internal Med 2, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
   [Provaznik, Zdenek; Schmid, Christof] Univ Hosp Regensburg, Dept Cardiothorac Surg, Regensburg, Germany.
   [Birner, Christoph] Klinikum St Marien, Dept Internal Med 1, Amberg, Germany.
RP Wagner, S (corresponding author), Univ Hosp Regensburg, Dept Internal Med 2, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
EM stefan.wagner@ukr.de
OI Wagner, Stefan/0000-0002-9471-1166
FU DFGGerman Research Foundation (DFG) [SFB 1350, 387509280, WA 2539/4-1,
   WA 2539/5-1, WA 2539/7-1, WA 2539/8-1, MA 1982/5-1, MA 1982/7-1]; ReForM
   C program of the faculty; DZHK (Deutsches Zentrum fur
   Herz-Kreislauf-Forschung); German Centre for Cardiovascular Research;
   Philips Respironics
FX S.W. is funded by DFG grants WA 2539/4-1, 5-1, 7-1, and 8-1. L.S.M. is
   funded by DFG grants MA 1982/5-1 and 7-1. S.W. and L.S.M. are also
   supported by the DFG SFB 1350 grant (project no. 387509280, TPA6), are
   funded by the ReForM C program of the faculty and by the DZHK (Deutsches
   Zentrum fur Herz-Kreislauf-Forschung; German Centre for Cardiovascular
   Research). Philips Respironics.
CR Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Bean DM, 2020, EUR J HEART FAIL, V22, P967, DOI 10.1002/ejhf.1924
   Burchill LJ, 2012, CLIN SCI, V123, P649, DOI 10.1042/CS20120162
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Furuhashi M, 2015, AM J HYPERTENS, V28, P15, DOI 10.1093/ajh/hpu086
   Gao C, 2020, EUR HEART J, V41, P2058, DOI 10.1093/eurheartj/ehaa433
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Goulter AB, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-19
   Gu HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19840
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Igase M, 2005, AM J PHYSIOL-HEART C, V289, pH1013, DOI 10.1152/ajpheart.00068.2005
   Klotz S, 2007, J AM COLL CARDIOL, V49, P1166, DOI 10.1016/j.jacc.2006.10.071
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624
   McKinney CA, 2014, CLIN SCI, V126, P815, DOI 10.1042/CS20130436
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Nicin L, 2020, EUR HEART J, V41, P1804, DOI 10.1093/eurheartj/ehaa311
   Patel VB, 2014, J MOL CELL CARDIOL, V66, P167, DOI 10.1016/j.yjmcc.2013.11.017
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sama IE, 2020, EUR HEART J, V41, P1810, DOI 10.1093/eurheartj/ehaa373
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Soler MJ, 2009, AM J PHYSIOL-RENAL, V296, pF398, DOI 10.1152/ajprenal.90488.2008
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 30
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
DI 10.1002/ejhf.2020
EA OCT 2020
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OD0VI
UT WOS:000579571500001
PM 33017071
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mosquera-Yuqui, F
   Lopez-Guerra, N
   Moncayo-Palacio, EA
AF Mosquera-Yuqui, Francisco
   Lopez-Guerra, Nicolas
   Moncayo-Palacio, Eduardo A.
TI Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from
   medicinal plants of the Andean Region: molecular docking and molecular
   dynamics simulations
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; molecular docking; molecular dynamics; MM-PBSA; ADMET
ID GENERAL FORCE-FIELD; CORONAVIRUS; PROTEASE; FLAVONOIDS; GROMACS;
   BIOAVAILABILITY; LUPINIFOLIN; INHIBITION; AUTOMATION; FLAVANONES
AB Given the highly contagious nature of SARS-CoV-2, it has resulted in an unprecedented number of COVID-19 infected and dead people worldwide. Since there is currently no vaccine available in the market, the identification of potential drugs is urgently needed to control the pandemic. In this study, 92 phytochemicals from medicinal plants growing in the Andean region were screened against SARS-CoV-2 3 C-like protease (3CLpro) and RNA-dependent RNA polymerase (RdRp) in their active sites through molecular docking. The cutoff values were set from the lowest docking scores of the FDA-approved drugs that are being used to treat COVID-19 patients (remdesivir, lopinavir, and ritonavir). Compounds with docking scores that were lower than cutoff values were validated by molecular dynamics simulation with GROMACS, using root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), and intermolecular hydrogen bonds (H-bonds). Furthermore, binding free energies were estimated using the MM-PBSA method, and ADMET profiles of potential inhibitors were assessed. Computational analyses revealed that the interaction with hesperidin (theoretical binding energies, Delta G(bind)= -15.18 kcal/mol to 3CLpro and Delta G(bind)= -9.46 kcal/mol to RdRp) remained stable in both enzymes, unveiling its remarkable potential as a possible multitarget antiviral agent to treat COVID-19. Importantly, lupinifolin with an estimated binding affinity to 3CLpro higher than hesperidin (Delta G(bind)= -20.93 kcal/mol) is also a potential inhibitor of the 3CLpro. These two compounds displayed suitable pharmacological and structural properties to be drug candidates, demonstrating to be worthy of further research. Communicated by Ramaswamy H. Sarma
C1 [Mosquera-Yuqui, Francisco] Univ Fuerzas Armadas ESPE, Dept Ciencias Vida & Agr, Sangolqui, Ecuador.
   [Mosquera-Yuqui, Francisco; Lopez-Guerra, Nicolas; Moncayo-Palacio, Eduardo A.] Grp Invest & Desarrollo Biotecnol BioSin Biocienc, Quito, Ecuador.
   [Lopez-Guerra, Nicolas] Oklahoma State Univ, Stillwater, OK 74078 USA.
   [Moncayo-Palacio, Eduardo A.] Univ Tecn Particular Loja, Dept Quim & Ciencias Exactas, Loja, Ecuador.
RP Lopez-Guerra, N (corresponding author), Oklahoma State Univ, Stillwater, OK 74078 USA.
EM nicolas.lopez@okstate.edu
OI Mosquera-Yuqui, Francisco/0000-0001-8459-2653
CR AHMED SF, 2020, VIRUSES BASEL, V12, DOI DOI HTTPS://DOI.ORG/10.3390/V12030254
   Anand A. Zanwar, 2014, POLYPHENOLS HUMAN HL, P989, DOI [10.1016/B978-0-12-398456-2.00076-1, DOI 10.1016/B978-0-12-398456-2.00076-1]
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], 2016, DISC STUD VIS
   Anthelme F, 2014, ARCT ANTARCT ALP RES, V46, P811, DOI 10.1657/1938-4246-46.4.811
   Benet LZ, 2016, ADV DRUG DELIVER REV, V101, P89, DOI 10.1016/j.addr.2016.05.007
   Berellini G, 2012, J CHEM INF MODEL, V52, P2069, DOI 10.1021/ci300155y
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bjelkmar P, 2010, J CHEM THEORY COMPUT, V6, P459, DOI 10.1021/ct900549r
   Boyle SP, 2000, EUR J CLIN NUTR, V54, P774, DOI 10.1038/sj.ejcn.1601090
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Ganapaty S., 2006, Journal of Natural Remedies, V6, P73
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gonzales GB, 2017, P NUTR SOC, V76, P175, DOI 10.1017/S0029665116002858
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Jacome R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66440-9
   JAYARAJ JM, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1775122
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Joycharat N, 2016, PHARM BIOL, V54, P62, DOI 10.3109/13880209.2015.1014920
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   KIRCHDOERFER RN, 2019, NAT COMMUN, V10, DOI DOI https://doi.org/10.1038/s41467-019-10280-3
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   LALANI S, 2020, VIRUSES BASEL, V12, DOI DOI https://doi.org/10.3390/v12020184
   Lee GR, 2012, B KOREAN CHEM SOC, V33, P770, DOI 10.5012/bkcs.2012.33.3.770
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   LIN YL, 1991, CHEM PHARM BULL, V39, P3132, DOI 10.1248/cpb.39.3132
   Liu K, 2017, J COMPUT AID MOL DES, V31, P201, DOI 10.1007/s10822-016-0005-2
   Liu XW, 2018, EXPERT OPIN DRUG DIS, V13, P23, DOI 10.1080/17460441.2018.1403419
   Lobanov MY, 2008, MOL BIOL+, V42, P623, DOI 10.1134/S0026893308040195
   Mahidol C, 1997, PHYTOCHEMISTRY, V45, P825, DOI 10.1016/S0031-9422(97)00001-0
   Man MQ, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/2676307
   Mangar P., 2020, COMP ANAL BASED SPIK, DOI [https://doi.org/10.20944/preprints202004.0154.v1, 10.20944/preprints202004.0154.v1, DOI 10.20944/PREPRINTS202004.0154.V1]
   Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   McIntosh K., 1974, Current Topics in Microbiology and Immunology, V63, P85
   Menendez CA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165767
   MUTKE J, 2014, FRONT GENET, V5, DOI DOI https://doi.org/10.3389/fgene.2014.00351
   Nectoux AM, 2019, J AGR FOOD CHEM, V67, P9812, DOI 10.1021/acs.jafc.9b03594
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Paduch R, 2014, MINI-REV ORG CHEM, V11, P262, DOI 10.2174/1570193X1103140915105240
   Pennington RT, 2010, P NATL ACAD SCI USA, V107, P13783, DOI 10.1073/pnas.1001317107
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Prachayasittikul V, 2016, EXCLI J, V15, P113, DOI 10.17179/excli2015-768
   Rastelli G, 2009, CHEM BIOL DRUG DES, V73, P283, DOI 10.1111/j.1747-0285.2009.00780.x
   Ravindranathan K, 2011, J CHEM THEORY COMPUT, V7, P3859, DOI 10.1021/ct200565u
   Safarzadeh E, 2014, ADV PHARM BULL, V4, P421, DOI 10.5681/apb.2014.062
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   Savarino A, 2004, JAIDS-J ACQ IMM DEF, V35, P223, DOI 10.1097/00126334-200403010-00002
   Sianglum W, 2019, MICROB DRUG RESIST, V25, P1391, DOI 10.1089/mdr.2018.0391
   SMALBERG.TM, 1974, TETRAHEDRON, V30, P3927, DOI 10.1016/S0040-4020(01)97085-1
   Soonthornchareonnon N., 2004, THAI J PHYTOPHARM, V11, P19
   Sutthivaiyakit S, 2009, J NAT PROD, V72, P1092, DOI 10.1021/np900021h
   Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129
   Terao J, 2014, ARCH BIOCHEM BIOPHYS, V559, P12, DOI 10.1016/j.abb.2014.04.002
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Vanommeslaeghe K, 2012, J CHEM INF MODEL, V52, P3155, DOI 10.1021/ci3003649
   Vanommeslaeghe K, 2012, J CHEM INF MODEL, V52, P3144, DOI 10.1021/ci300363c
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang EC, 2019, PHYS CHEM CHEM PHYS, V21, P18958, DOI 10.1039/c9cp04096j
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Yusook K, 2017, J NAT MED-TOKYO, V71, P357, DOI 10.1007/s11418-016-1065-2
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 78
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1835716
EA OCT 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OE6BB
UT WOS:000580612500001
PM 33084512
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Pundir, H
   Joshi, T
   Joshi, T
   Sharma, P
   Mathpal, S
   Chandra, S
   Tamta, S
AF Pundir, Hemlata
   Joshi, Tanuja
   Joshi, Tushar
   Sharma, Priyanka
   Mathpal, Shalini
   Chandra, Subhash
   Tamta, Sushma
TI Using Chou's 5-steps rule to study pharmacophore-based virtual screening
   of SARS-CoV-2 Mpro inhibitors
SO MOLECULAR DIVERSITY
LA English
DT Article; Early Access
DE COVID-19; Pharmacophore modeling; Molecular docking; Main protease
   (MPro); PubChem compounds
ID HIGH-THROUGHPUT; DOCKING
AB Recently emerged SARS-CoV-2 is the cause of the ongoing outbreak of COVID-19. It is responsible for the deaths of millions of people and has caused global economic and social disruption. The numbers of COVID-19 cases are increasing exponentially across the world. Control of this pandemic disease is challenging because there is no effective drug or vaccine available against this virus and this situation demands an urgent need for the development of anti-SARS-CoV-2 potential medicines. In this regard, the main protease (Mpro) has emerged as an essential drug target as it plays a vital role in virus replication and transcription. In this research, we have identified two novel potent inhibitors of the Mpro (PubChem3408741 and PubChem4167619) from PubChem database by pharmacophore-based high-throughput virtual screening. The molecular docking, toxicity, and pharmacophore analysis indicate that these compounds may act as potential anti-viral candidates. The molecular dynamic simulation along with the binding free energy calculation by MMPBSA showed that these compounds bind to Mpro enzyme with high stability over 50 ns. Our results showed that two compounds: PubChem3408741 and PubChem4167619 had the binding free energy of - 94.02 kJ mol(-1)and - 122.75 kJ mol(-1), respectively, as compared to reference X77 (- 76.48 kJ mol(-1)). Based on our work's findings, we propose that these compounds can be considered as lead molecules for targeting Mpro enzyme and they can be potential SARS-CoV-2 inhibitors. These inhibitors could be tested in vitro and explored for effective drug development against COVID-19. Graphic abstract
C1 [Pundir, Hemlata; Sharma, Priyanka; Tamta, Sushma] Kumaun Univ, Dept Bot, DSB Campus, Naini Tal 263002, Uttarakhand, India.
   [Joshi, Tanuja; Chandra, Subhash] Soban Singh Jeena Univ, Dept Bot, Computat Biol & Biotechnol Lab, Almora, Uttarakhand, India.
   [Joshi, Tushar; Mathpal, Shalini] Kumaun Univ, Dept Biotechnol, Bhimtal Campus, Bhimtal 263136, Uttarakhand, India.
   [Chandra, Subhash] Kumaun Univ, Dept Bot, SSJ Campus, Almora, Uttarakhand, India.
RP Chandra, S (corresponding author), Soban Singh Jeena Univ, Dept Bot, Computat Biol & Biotechnol Lab, Almora, Uttarakhand, India.; Chandra, S (corresponding author), Kumaun Univ, Dept Bot, SSJ Campus, Almora, Uttarakhand, India.
EM scjnu@yahoo.co.in
RI Joshi, Tushar/AAJ-9626-2020; Chandra, Subhash/AAN-6789-2020
OI Chandra, Subhash/0000-0002-8978-5427
CR Ali SS, 2018, RHEUMATOLOGY ADV S1, V2, prky033, DOI [10.1093/rap/rky033.014., DOI 10.1093/RAP/RKY033.014, 10.1093/rap/rky033.014]
   Alves VM, 2020, MOL INFORM, DOI 10.1002/minf.202000113
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Chou KC, 2011, J THEOR BIOL, V273, P236, DOI 10.1016/j.jtbi.2010.12.024
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Du XQ, 2019, J PROTEOME RES, V18, P3119, DOI 10.1021/acs.jproteome.9b00226
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ghasemi F, 2016, J MOL GRAPH MODEL, V68, P39, DOI 10.1016/j.jmgm.2016.05.011
   Gonzalez J, 2018, MOJ PROTEOMICS BIOIN, V7, P12, DOI [10.15406/mojpb.2018.07.00207, DOI 10.15406/MOJPB.2018.07.00207]
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kabir M, 2020, GENOMICS, V112, P276, DOI 10.1016/j.ygeno.2019.02.006
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Kraemer MUG, 2015, ELIFE, V4, DOI 10.7554/eLife.08347
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Kuzmanic A, 2010, BIOPHYS J, V98, P861, DOI 10.1016/j.bpj.2009.11.011
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Lobanov MY, 2008, MOL BIOL+, V42, P623, DOI 10.1134/S0026893308040195
   Marsh JA, 2011, STRUCTURE, V19, P859, DOI 10.1016/j.str.2011.03.010
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Pant R, 2020, J MOL GRAPH MODEL, V98, DOI 10.1016/j.jmgm.2020.107584
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Srikumar PS, 2014, PROTEIN J, V33, P289, DOI 10.1007/s10930-014-9561-2
   Sunseri J, 2016, NUCLEIC ACIDS RES, V44, pW442, DOI 10.1093/nar/gkw287
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Wondafrash DZ, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/5214751
NR 33
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1381-1991
EI 1573-501X
J9 MOL DIVERS
JI Mol. Divers.
DI 10.1007/s11030-020-10148-5
EA OCT 2020
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Applied; Chemistry,
   Medicinal; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA OE3JW
UT WOS:000580432000001
PM 33079314
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Fernandes, MS
   da Silva, FS
   Freitas, ACSG
   de Melo, EB
   Trossini, GHG
   Paula, FR
AF Fernandes, Mariana S.
   da Silva, Francielly S.
   Freitas, Ana Carolina S. G.
   de Melo, Eduardo B.
   Trossini, Gustavo H. G.
   Paula, Favero R.
TI Insights on 3D Structures of Potential Drug-Targeting Proteins of
   SARS-CoV-2: Application of Cavity Search and Molecular Docking
SO MOLECULAR INFORMATICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID19; 3D Structures; Cavity Search; Molecular Docking
ID CORONAVIRUS; VIRUS; SARS; EPIDEMIOLOGY
AB The emergence of the COVID-19 has caused public health problems worldwide and there is no effective pharmacological treatment for this disease. Research on 3D models of proteins and the search for active molecular sites are important tools to assist in the discovery of effective antiviral drugs to combat COVID-19. To address this problem, the 3D protein structures of SARS-CoV 2 were analyzed and submitted to cavities research, evaluation of their druggabillity and liganbility, and applied to molecular docking studies with potential ligand candidates actually assayed against COVID-19. Eight druggable potential cavity sites were determined in model structures' PDB code, 6W4B, 6VWW, 6W01, 6M3M, and 6VYO, and these are the good alternatives to be characterized as targets for antiviral compounds. The good cavity model of the protease 3D structure was used in molecular docking, and this allowed verifying the theoric interactions of this protein and lopinavir and ritonavir antiviral drugs. These results may assist in the use of 3D protein models in drug design studies aiming to develop drugs against the COVID-19 pandemic.
C1 [Fernandes, Mariana S.; da Silva, Francielly S.; Freitas, Ana Carolina S. G.; Paula, Favero R.] Fed Univ Pampa UNIPAMPA, Course Pharm, BR 472,Km 592,POB 118, BR-97500970 Uruguaiana, RS, Brazil.
   [de Melo, Eduardo B.] State Univ West Parana UNIOESTE, Dept Pharm, Univ St 2069, BR-85819110 Cascavel, PR, Brazil.
   [Trossini, Gustavo H. G.] Univ Sao Paulo, Dept Pharm, Lineu Prestes Ave 580, BR-05508900 Sao Paulo, SP, Brazil.
RP Paula, FR (corresponding author), Fed Univ Pampa UNIPAMPA, Course Pharm, BR 472,Km 592,POB 118, BR-97500970 Uruguaiana, RS, Brazil.
EM faveropaula@unipampa.edu.br
RI Paula, Favero/I-6163-2017
OI Paula, Favero/0000-0002-6221-8318
FU CAPESCAPES; FAPERGSFoundation for Research Support of the State of Rio
   Grande do Sul (FAPERGS) [19/2551-0001784-7]; PDA-UNIPAMPA
FX The authors thanks to CAPES (DS), FAPERGS (Number 19/2551-0001784-7),
   and PDA-UNIPAMPA for financial support.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Arabi YM, 2020, TRIALS, V21, DOI 10.1186/s13063-019-3846-x
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chang C., 2020, RCSB PROTEIN DATA BA, DOI [10.2210/pdb6VYO/pdb, DOI 10.2210/PDB6VY0/PDB]
   Cheng AC, 2007, NAT BIOTECHNOL, V25, P71, DOI 10.1038/nbt1273
   Chong YP, 2015, INFECT CHEMOTHER, V47, P212, DOI 10.3947/ic.2015.47.3.212
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Eisfeld AJ, 2015, NAT REV MICROBIOL, V13, P28, DOI 10.1038/nrmicro3367
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Muri EMF, 2014, QUIM NOVA, V37, P308, DOI 10.5935/0100-4042.20140052
   Furuta Y, 2009, ANTIVIR RES, V82, P95, DOI 10.1016/j.antiviral.2009.02.198
   Gao GF, 2018, CELL, V172, P1157, DOI 10.1016/j.cell.2018.02.025
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Izquierdo L, 2014, PHARMACOGEN PERS MED, V7, P241, DOI 10.2147/PGPM.S52715
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Leonis G, 2013, J CHEM INF MODEL, V53, P2141, DOI 10.1021/ci4002102
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lin S., 2020, BIORXIV, DOI [10.1101/2020.01.31.929695, DOI 10.1101/2020.01.31.929695]
   Macchiagodena M, 2020, CHEM PHYS LETT, V750, DOI 10.1016/j.cplett.2020.137489
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Normile D., 2020, SCIENCE, V367, P6485, DOI [10.1126/science.aba7672, DOI 10.1126/SCIENCE.ABA7672]
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Teslova E., 2020, RUSSIA RECOMMENDS LO
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   Wu F, 2020, APPL MATH COMPUT, V380, DOI 10.1016/j.amc.2020.125278
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xu YJ, 2018, NUCLEIC ACIDS RES, V46, pW374, DOI 10.1093/nar/gky380
   Yang JM, 2004, PROTEINS, V55, P288, DOI 10.1002/prot.20035
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 42
TC 1
Z9 1
U1 4
U2 4
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1868-1743
EI 1868-1751
J9 MOL INFORM
JI Mol. Inf.
DI 10.1002/minf.202000096
EA OCT 2020
PG 13
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications;
   Mathematical & Computational Biology
SC Pharmacology & Pharmacy; Computer Science; Mathematical & Computational
   Biology
GA OD0JF
UT WOS:000579540000001
PM 32750187
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Naeimi, R
   Ghasemi-Kasman, M
AF Naeimi, Reza
   Ghasemi-Kasman, Maryam
TI Update on cerebrovascular manifestations of COVID-19
SO NEUROLOGICAL SCIENCES
LA English
DT Article
DE Coronavirus; SARS-CoV-2; COVID-19; Coagulation; Stroke; Anticoagulative
   therapies
ID PROPHYLAXIS; INFECTION; SEPSIS
AB The novel member of coronaviruses family, severe acute respiratory coronavirus-2 (SARS-CoV-2), with high structural homology to SARS-CoV and Middle East respiratory syndrome-related coronavirus (MERS) has spread rapidly with about 20 million cases infection and over 700,000 deaths. SARS-CoV-2 has been emerged as a worldwide disaster due to non-specific few respiratory and gastrointestinal manifestations at the onset of disease as well as long incubation period. Surprisingly, not only respiratory failure but also the underlying coagulation disorder and neurovascular involvement worsen the clinical outcome of infected patients. In this review article, we describe the probable mechanisms of SARS-CoV-2 infection and stroke occurrence. We will also discuss the cerebrovascular events following SARS-CoV-2 infection, the recommended therapies, and future prospects to better manage these patients in coronavirus disease 2019 (COVID-19) outbreak.
C1 [Naeimi, Reza] Babol Univ Med Sci, Student Res Comm, Babol, Iran.
   [Ghasemi-Kasman, Maryam] Babol Univ Med Sci, Hlth Res Inst, Cellular & Mol Biol Res Ctr, Babol, Iran.
   [Ghasemi-Kasman, Maryam] Babol Univ Med Sci, Hlth Res Inst, Neurosci Res Ctr, POB 4136747176, Babol, Iran.
RP Ghasemi-Kasman, M (corresponding author), Babol Univ Med Sci, Hlth Res Inst, Cellular & Mol Biol Res Ctr, Babol, Iran.; Ghasemi-Kasman, M (corresponding author), Babol Univ Med Sci, Hlth Res Inst, Neurosci Res Ctr, POB 4136747176, Babol, Iran.
EM m.ghasemi@mubabol.ac.ir
CR Aggarwal G, 2020, INT J STROKE, V15, P385, DOI 10.1177/1747493020921664
   Al Saiegh F., 2020, J NEUROLOGY NEUROSUR
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Avula A, 2020, COVID 19 PRESENTING
   Baracchini C, 2020, NEUROL SCI, P1
   Belani P, 2020, AM J NEURORADIOL, V41, P1361, DOI 10.3174/ajnr.A6650
   Beyrouti R., 2020, J NEUROLOGY NEUROSUR
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Ciavarella A, 2020, THROMB RES, V191, P29, DOI 10.1016/j.thromres.2020.04.023
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Dalan R, 2020, HORM METAB RES, V52, P257, DOI 10.1055/a-1155-0501
   Dogra S, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104984
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Gonzalez-Pinto T, 2020, EUR J NEUROL, V27, pE35, DOI 10.1111/ene.14286
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Harzallah I, 2020, J THROMB HAEMOST, V18, P2064, DOI 10.1111/jth.14867
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hughes C, 2020, EUR J CASE REP INTER, V7
   Immovilli P, 2020, INT J STROKE, V15, P701, DOI 10.1177/1747493020938294
   Inciardi R.M., 2020, JAMA CARDIOLOGY
   Jin H, 2020, STROKE VASC NEUROL
   Juusela Alexander, 2020, Am J Obstet Gynecol MFM, V2, P100113, DOI 10.1016/j.ajogmf.2020.100113
   Klok FA, 2020, THROMB RES
   Lee M, 2020, J NEUROL SCI, V414, DOI 10.1016/j.jns.2020.116883
   Leslie-Mazwi TM, 2020, AM J NEURORADIOL, V41, P1136, DOI 10.3174/ajnr.A6606
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Lippi G, 2020, CLIN CHIM ACTA
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1131, DOI 10.1515/cclm-2020-0198
   Lyons PG, 2018, CRIT CARE MED, V46, P736, DOI [10.1097/ccm.0000000000002997, 10.1097/CCM.0000000000002997]
   Machado C, 2020, BRAINSTEM DYSFUNCTIO
   Mansoor S.R, J MED VIROLOGY
   Manuel A., 2020, LANCET RESP MED
   Mao L, 2020, NEUROLOGICAL MANIFES
   Markus HS, 2020, INT J STROKE, V15, P361, DOI 10.1177/1747493020923472
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Montalvan V, 2020, CLIN NEUROL NEUROSUR, V194, DOI 10.1016/j.clineuro.2020.105921
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Qin C, 2020, CLIN INFECT DIS
   Shankar-Hari M, 2016, JAMA-J AM MED ASSOC, V315, P775, DOI 10.1001/jama.2016.0289
   Shi JC, 2020, FRONT PHYS-BEIJING, V15, DOI 10.1007/s11467-019-0930-3
   Siegler JE, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104953
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Viguier A, 2020, J NEURORADIOLOG
   Wang AR, 2020, J NEUROINTERV SURG, V12, P648, DOI [10.1136/neurintsurg-2020-016220, 10.1136/neurintsurg-2019-015702]
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   Yavarpour-Bali H, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118063
   Yeboah K, 2020, NEUROLOGY CLIN PRACT
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 53
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1590-1874
EI 1590-3478
J9 NEUROL SCI
JI Neurol. Sci.
PD DEC
PY 2020
VL 41
IS 12
BP 3423
EP 3435
DI 10.1007/s10072-020-04837-0
EA OCT 2020
PG 13
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OP9VA
UT WOS:000581062500002
PM 33083934
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Singh, M
   Pawar, M
   Tiwari, A
   Bothra, A
   Maheswari, A
   Adhikari, P
AF Singh, Mehak
   Pawar, Manoj
   Tiwari, Apoorv
   Bothra, Atul
   Maheswari, Anshu
   Adhikari, Pankaj
TI SARS-CoV-2 and Trojan horse phenomenon-caveat in vaccine quest?
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Letter
C1 [Singh, Mehak] JK Med Coll, Dept Dermatol, E7-691 B, Bhopal 462016, Madhya Pradesh, India.
   [Singh, Mehak] LN Hosp, E7-691 B, Bhopal 462016, Madhya Pradesh, India.
   [Pawar, Manoj] MVPs Dr VP Med Coll & Hosp & Res Ctr, Dept Dermatol, Nasik, India.
   [Tiwari, Apoorv] All India Inst Med Sci AIIMS, Dept Med, Bhopal, India.
   [Bothra, Atul; Adhikari, Pankaj] Gauhati Med Coll & Hosp, Dept Dermatol, Gauhati, India.
RP Singh, M (corresponding author), JK Med Coll, Dept Dermatol, E7-691 B, Bhopal 462016, Madhya Pradesh, India.; Singh, M (corresponding author), LN Hosp, E7-691 B, Bhopal 462016, Madhya Pradesh, India.
EM med.mehak@gmail.com
RI Tiwari, Apoorv/ABD-9532-2020
OI , ATUL/0000-0002-7331-273X; Singh, Mehak/0000-0001-9180-7931
CR Aquino-Jarquin G, 2019, NANOMED-NANOTECHNOL, V18, P428, DOI 10.1016/j.nano.2019.03.006
   PELUSO R, 1985, VIROLOGY, V147, P231, DOI 10.1016/0042-6822(85)90246-6
   Singh M, 2019, ACTA DERMATOVEN ALP, V28, P189, DOI 10.15570/actaapa.2019.46
   Smatti MK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02991
   Tahamtan A, 2020, EXPERT REV MOL DIAGN, V20, P453, DOI [10.1080/14737159.2020.1757437, 10.1080/07435800.2020.1713802]
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD DEC
PY 2020
VL 92
IS 6
AR e12969
DI 10.1111/sji.12969
EA OCT 2020
PG 3
WC Immunology
SC Immunology
GA PA6TY
UT WOS:000580538000001
PM 32875611
OA Bronze
DA 2021-01-01
ER

PT J
AU Park, HH
   Park, W
   Lee, YY
   Kim, H
   Seo, HS
   Choi, DW
   Kwon, HK
   Na, DH
   Kim, TH
   Choy, YB
   Ahn, JH
   Lee, W
   Park, CG
AF Park, Hee Ho
   Park, Wooram
   Lee, Yun Young
   Kim, Hyelim
   Seo, Hee Seung
   Choi, Dong Wook
   Kwon, Ho-Keun
   Na, Dong Hee
   Kim, Tae-Hyung
   Choy, Young Bin
   Ahn, June Hong
   Lee, Wonhwa
   Park, Chun Gwon
TI Bioinspired DNase-I-Coated Melanin-Like Nanospheres for Modulation of
   Infection-Associated NETosis Dysregulation
SO ADVANCED SCIENCE
LA English
DT Article
DE Bioinspiration; COVID-19; DNase-I; Nanospheres; NETosis
ID NEUTROPHIL EXTRACELLULAR TRAPS; SEPSIS; SURVIVAL
AB The current outbreak of the beta-coronavirus (beta-Cov) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in December 2019. No specific antiviral treatments or vaccines are currently available. A recent study has reported that coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2 infection, is associated with neutrophil-specific plasma membrane rupture, and release excessive neutrophil extracellular traps (NETs) and extracellular DNAs (eDNAs). This mechanism involves the activation of NETosis, a neutrophil-specific programmed cell death, which is believed to play a crucial role in COVID-19 pathogenesis. Further progression of the disease can cause uncontrolled inflammation, leading to the initiation of cytokine storms, acute respiratory distress syndrome (ARDS), and sepsis. Herein, it is reported that DNase-I-coated melanin-like nanospheres (DNase-I pMNSs) mitigate sepsis-associated NETosis dysregulation, thereby preventing further progression of the disease. Recombinant DNase-I and poly(ethylene glycol) (PEG) are used as coatings to promote the lengthy circulation and dissolution of NET structure. The data indicate that the application of bioinspired DNase-I pMNSs reduce neutrophil counts and NETosis-related factors in the plasma of SARS-CoV-2 sepsis patients, alleviates systemic inflammation, and attenuates mortality in a septic mouse model. Altogether, the findings suggest that these nanoparticles have potential applications in the treatment of SARS-CoV-2-related illnesses and other beta-CoV-related diseases.
C1 [Park, Hee Ho] Kangwon Natl Univ, Dept Biotechnol & Bioengn, Chunchon 24341, Gangwon Do, South Korea.
   [Park, Wooram] Catholic Univ Korea, Dept Biomed Chem Engn, Bucheon 14662, South Korea.
   [Lee, Yun Young; Choy, Young Bin] Seoul Natl Univ, Coll Med, Dept Biomed Engn, Seoul 03080, South Korea.
   [Kim, Hyelim] Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea.
   [Seo, Hee Seung] Sungkyunkwan Univ SKKU, SKKU Inst Convergence, Dept Biomed Engn, Suwon 16419, South Korea.
   [Choi, Dong Wook] Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
   [Kwon, Ho-Keun] Yonsei Univ, Coll Med, Dept Microbiol & Immunol, Seoul 03722, South Korea.
   [Na, Dong Hee] Chung Ang Univ, Coll Pharm, Seoul 06974, South Korea.
   [Kim, Tae-Hyung] Chung Ang Univ, Sch Integrat Engn, Seoul 06974, South Korea.
   [Ahn, June Hong] Yeungnam Univ, Coll Med, Dept Internal Med, Div Pulmonol & Allergy, Daegu 42415, South Korea.
   [Ahn, June Hong] Yeungnam Univ, Coll Med, Reg Ctr Resp Dis, Daegu 42415, South Korea.
   [Lee, Wonhwa] Korea Res Inst Biosci & Biotechnol KRIBB, Aging Res Ctr, Daejeon 34141, South Korea.
   [Park, Chun Gwon] Sungkyunkwan Univ SKKU, SKKU Inst Convergence, Dept Biomed Engn, Suwon, South Korea.
   [Park, Chun Gwon] Sungkyunkwan Univ, Biomed Inst Convergence SKKU BICS, 2066 Seobu Ro, Suwon 16419, South Korea.
   [Park, Chun Gwon] Inst Basic Sci IBS, Ctr Neurosci Imaging Res, Suwon 16419, South Korea.
   [Park, Chun Gwon] Sungkyunkwan Univ SKKU, SKKU Inst Convergence, Dept Intelligent Precis Healthcare Convergence, Suwon 16419, South Korea.
RP Ahn, JH (corresponding author), Yeungnam Univ, Coll Med, Dept Internal Med, Div Pulmonol & Allergy, Daegu 42415, South Korea.; Ahn, JH (corresponding author), Yeungnam Univ, Coll Med, Reg Ctr Resp Dis, Daegu 42415, South Korea.; Lee, W (corresponding author), Korea Res Inst Biosci & Biotechnol KRIBB, Aging Res Ctr, Daejeon 34141, South Korea.; Park, CG (corresponding author), Sungkyunkwan Univ SKKU, SKKU Inst Convergence, Dept Biomed Engn, Suwon, South Korea.; Park, CG (corresponding author), Sungkyunkwan Univ, Biomed Inst Convergence SKKU BICS, 2066 Seobu Ro, Suwon 16419, South Korea.; Park, CG (corresponding author), Inst Basic Sci IBS, Ctr Neurosci Imaging Res, Suwon 16419, South Korea.; Park, CG (corresponding author), Sungkyunkwan Univ SKKU, SKKU Inst Convergence, Dept Intelligent Precis Healthcare Convergence, Suwon 16419, South Korea.
EM fireajh@yu.ac.kr; wonhwalee@kribb.kr; chunpark@skku.edu
FU National Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2019R1C1C1006300, 2019R1A4A1028700, 2018R1C1B6001120, 2020R1A4A3078645,
   2020R1A4A4079817]; Basic Science Research Program through the National
   Research Foundation of Korea (NRF) - Ministry of Education
   [2019M3C9A6091949]; National Research Foundation of Korea (NRF) -
   Ministry of Science and ICT [2018M3A7B4071204]; BK21 FOUR Project
FX H.H.P., W.P and Y.Y.L contributed equally to this work. This work was
   supported by the following grants: the National Research Foundation of
   Korea (NRF) grant funded by the Korea government (MSIT)
   (2019R1C1C1006300, 2019R1A4A1028700, 2018R1C1B6001120, 2020R1A4A3078645,
   and 2020R1A4A4079817). This research was supported by Basic Science
   Research Program through the National Research Foundation of Korea (NRF)
   funded by the Ministry of Education (2019M3C9A6091949). This work was
   supported by the National Research Foundation of Korea (NRF) grant
   funded by the Ministry of Science and ICT (2018M3A7B4071204) This work
   was also supported by the BK21 FOUR Project.
CR Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227
   Bangash MN, 2020, LANCET GASTROENTEROL, V5, P529, DOI 10.1016/S2468-1253(20)30084-4
   Barclay TG, 2017, ADV MATER INTERFACES, V4, DOI 10.1002/admi.201601192
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Colon DF, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2407-8
   Czaikoski PG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148142
   Douda DN, 2014, BLOOD, V123, P597, DOI 10.1182/blood-2013-09-526707
   Han J, 2016, ACS APPL MATER INTER, V8, P7739, DOI 10.1021/acsami.6b01664
   Hazeldine J, 2014, AGING CELL, V13, P690, DOI 10.1111/acel.12222
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jorch SK, 2017, NAT MED, V23, P279, DOI 10.1038/nm.4294
   Ju KY, 2011, BIOMACROMOLECULES, V12, P625, DOI 10.1021/bm101281b
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kim KS, 2019, BIOMATERIALS, V221, DOI 10.1016/j.biomaterials.2019.119418
   Lee H, 2009, ADV MATER, V21, P431, DOI 10.1002/adma.200801222
   Lefrancais E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98178
   Liu H, 2020, ADV SCI, V7, DOI 10.1002/advs.201903129
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   Ma AC, 2008, J THROMB HAEMOST, V6, P415, DOI 10.1111/j.1538-7836.2007.02865.x
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meng W, 2012, CRIT CARE, V16, DOI 10.1186/cc11442
   Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105
   Papayannopoulos V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028526
   Park J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1711
   Paunel-Gorgulu A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17561-1
   Prince WS, 1998, CLIN EXP IMMUNOL, V113, P289
   Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214
   Ryu JH, 2018, ACS APPL MATER INTER, V10, P7523, DOI 10.1021/acsami.7b19865
   Sapey E, 2014, BLOOD, V123, P239, DOI 10.1182/blood-2013-08-519520
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Strnad P, 2017, NAT REV GASTRO HEPAT, V14, P55, DOI 10.1038/nrgastro.2016.168
   Thomas GM, 2012, BLOOD, V119, P6335, DOI 10.1182/blood-2012-01-405183
   Timsit JF, 2016, JAMA-J AM MED ASSOC, V316, P1555, DOI 10.1001/jama.2016.14655
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xiao M, 2015, ACS NANO, V9, P5454, DOI 10.1021/acsnano.5b01298
   Xu JJ, 2014, J MOL MED, V92, P77, DOI 10.1007/s00109-013-1081-6
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Yoshida Y, 2020, PEDIATR RES, V87, P998, DOI 10.1038/s41390-019-0710-3
   Yoshikawa N, 2013, MOL MED REP, V7, P1091, DOI 10.3892/mmr.2013.1318
   Zhang B., 2020, MEDRXIV
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou Yong, 2018, Oncotarget, V9, P13276, DOI 10.18632/oncotarget.24022
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 46
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2198-3844
J9 ADV SCI
JI Adv. Sci.
PD DEC
PY 2020
VL 7
IS 23
AR 2001940
DI 10.1002/advs.202001940
EA OCT 2020
PG 10
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA PB5PW
UT WOS:000579391400001
PM 33173718
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lazarus, JV
   Ratzan, SC
   Palayew, A
   Gostin, LO
   Larson, HJ
   Rabin, K
   Kimball, S
   El-Mohandes, A
AF Lazarus, Jeffrey V.
   Ratzan, Scott C.
   Palayew, Adam
   Gostin, Lawrence O.
   Larson, Heidi J.
   Rabin, Kenneth
   Kimball, Spencer
   El-Mohandes, Ayman
TI A global survey of potential acceptance of a COVID-19 vaccine
SO NATURE MEDICINE
LA English
DT Article; Early Access
ID TRUST; COMMUNICATION; HESITANCY
AB Survey data from across 19 countries reveal heterogeneity in attitudes toward acceptance of a COVID-19 vaccine and suggest that trust in government is associated with vaccine confidence.
   Several coronavirus disease 2019 (COVID-19) vaccines are currently in human trials. In June 2020, we surveyed 13,426 people in 19 countries to determine potential acceptance rates and factors influencing acceptance of a COVID-19 vaccine. Of these, 71.5% of participants reported that they would be very or somewhat likely to take a COVID-19 vaccine, and 61.4% reported that they would accept their employer's recommendation to do so. Differences in acceptance rates ranged from almost 90% (in China) to less than 55% (in Russia). Respondents reporting higher levels of trust in information from government sources were more likely to accept a vaccine and take their employer's advice to do so.
C1 [Lazarus, Jeffrey V.; Palayew, Adam] Univ Barcelona, Barcelona Inst Global Hlth ISGlobal, Hosp Clin, Barcelona, Spain.
   [Ratzan, Scott C.; Rabin, Kenneth; El-Mohandes, Ayman] CUNY, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10021 USA.
   [Gostin, Lawrence O.] Georgetown Univ, Washington, DC USA.
   [Larson, Heidi J.] London Sch Hyg & Trop Med, London, England.
   [Kimball, Spencer] Emerson Coll, Boston, MA 02116 USA.
RP Lazarus, JV (corresponding author), Univ Barcelona, Barcelona Inst Global Hlth ISGlobal, Hosp Clin, Barcelona, Spain.
EM jeffrey.lazarus@isglobal.org
RI Lazarus, Jeffrey/R-6248-2018
OI Lazarus, Jeffrey/0000-0001-9618-2299
FU City University of New York Graduate School of Public Health and Health
   Policy Foundation; United States Council for International Business
   Foundation; Spanish Ministry of Science, Innovation and Universities
   through the 'Centro de Excelencia Severo Ochoa 2019-2023' Programme
   [CEX2018-000806-S]; Government of Catalonia through the CERCA Programme;
   Bocconi University
FX Funding was provided by the City University of New York Graduate School
   of Public Health and Health Policy Foundation, Bocconi University, J.
   Fielding, the United States Council for International Business
   Foundation and K. Rabin. Consensus Strategies was the funding recipient.
   J.V.L. acknowledges support to ISGlobal from the Spanish Ministry of
   Science, Innovation and Universities through the 'Centro de Excelencia
   Severo Ochoa 2019-2023' Programme (CEX2018-000806-S) and from the
   Government of Catalonia through the CERCA Programme.
CR Biasio LR, 2017, HUM VACC IMMUNOTHER, V13, P701, DOI 10.1080/21645515.2016.1243633
   Burki TK, 2020, LANCET RESP MED, V8, pE85, DOI 10.1016/S2213-2600(20)30402-1
   Cornwall W, 2020, SCIENCE, V369, P14, DOI 10.1126/science.369.6499.14
   Enserink M., 2020, SCIENCE
   European Centre for Disease Prevention and Control, 2017, CAT INT ADDR VACC HE
   Fadda M, 2020, INT J PUBLIC HEALTH, V65, P711, DOI 10.1007/s00038-020-01404-4
   Hovland CI, 1951, PUBLIC OPIN QUART, V15, P635, DOI 10.1086/266350
   Johns Hopkins Coronavirus Resource Center, 2020, COVID 19 DASHB
   Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061
   Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063
   Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lazarus JV, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240011
   Lugo NR, 2007, AM J INFECT CONTROL, V35, P1, DOI 10.1016/j.ajic.2006.10.004
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   MAHASE E, 2020, BMJ-BRIT MED J, V370, P73898, DOI DOI 10.1136/bmj.m3525
   Munoz DC, 2015, INT J PUBLIC HEALTH, V60, P767, DOI 10.1007/s00038-015-0715-6
   Quinn SC, 2013, BIOSECUR BIOTERROR, V11, P96, DOI 10.1089/bsp.2012.0048
   Shore DA, 2003, J HEALTH COMMUN, V8, P13, DOI 10.1080/10810730390224839
   Siegrist M, 2014, EUR PSYCHOL, V19, P23, DOI 10.1027/1016-9040/a000169
   Thomson A, 2018, VACCINE, V36, P6457, DOI 10.1016/j.vaccine.2018.08.031
NR 21
TC 2
Z9 2
U1 11
U2 11
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
DI 10.1038/s41591-020-1124-9
EA OCT 2020
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA OE3ZR
UT WOS:000580473100001
PM 33082575
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Thompson, KM
   Kalkowska, DA
   Badizadegan, K
AF Thompson, Kimberly M.
   Kalkowska, Dominika A.
   Badizadegan, Kamran
TI A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent
   COVID-19 in the United States
SO RISK ANALYSIS
LA English
DT Article; Early Access
DE COVID-19; health economics; oral poliovirus vaccine; polio
ID COST-EFFECTIVENESS; POLIOMYELITIS; EPIDEMIOLOGY; ERADICATION; MORTALITY;
   OUTBREAK; IMMUNITY; INFANTS; DISEASE; OPTIONS
AB COVID-19 led to a recent high-profile proposal to reintroduce oral poliovirus vaccine (OPV) in the United States (U.S.), initially in clinical trials, but potentially for widespread and repeated use. We explore logistical challenges related to U.S. OPV administration in 2020, review the literature related to nonspecific effects of OPV to induce innate immunity, and model the health and economic implications of the proposal. The costs of reintroducing a single OPV dose to 331 million Americans would exceed $4.4 billion. Giving a dose of bivalent OPV to the entire U.S. population would lead to an expected 40 identifiable cases of vaccine-associated paralytic polio, with young Americans at the highest risk. Reintroducing any OPV use in the U.S. poses a risk of restarting transmission of OPV-related viruses and could lead to new infections in immunocompromised individuals with B-cell related primary immunodeficiencies that could lead to later cases of paralysis. Due to the lack of a currently licensed OPV in the U.S., the decision to administer OPV to Americans for nonspecific immunological effects would require purchasing limited global OPV supplies that could impact polio eradication efforts. Health economic modeling suggests no role for reintroducing OPV into the U.S. with respect to responding to COVID-19. Countries that currently use OPV experience fundamentally different risks, costs, and benefits than the U.S. Successful global polio eradication will depend on sufficient OPV supplies, achieving and maintaining high OPV coverage in OPV-using countries, and effective global OPV cessation and containment in all countries, including the U.S.
C1 [Thompson, Kimberly M.; Kalkowska, Dominika A.; Badizadegan, Kamran] Kid Risk Inc, 7512 Dr Phillips Blvd,50-523, Orlando, FL 32819 USA.
RP Thompson, KM (corresponding author), Kid Risk Inc, 7512 Dr Phillips Blvd,50-523, Orlando, FL 32819 USA.
EM kimt@kidrisk.org
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [INV-009333]
FX The authors thank the Bill and Melinda Gates Foundation for supporting
   the completion of this work [INV-009333] and thank John Modlin and Mark
   Pallansch for helpful discussions.
CR Aaby P, 2005, VACCINE, V23, P1746, DOI 10.1016/j.vaccine.2004.02.054
   Aaby P, 2004, VACCINE, V22, P3014, DOI 10.1016/j.vaccine.2004.02.009
   Andersen A, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00013
   Anis E, 2013, EUROSURVEILLANCE, V18, P2, DOI 10.2807/1560-7917.ES2013.18.38.20586
   [Anonymous], 2015, Public Health Rep, V130, P573
   [Anonymous], 2000, MMWR Recomm Rep, V49, P1
   Badizadegan K, 2020, EXPERT REV VACCINES, V19, P175, DOI 10.1080/14760584.2020.1732215
   Centers for Disease Control and Prevention, 1982, MMWR-MORBID MORTAL W, V31, P32
   Centers for Disease Control and Prevention, 2020, US NAT AUTH CONT POL
   Chumakov K, 2020, SCIENCE, V368, P1187, DOI 10.1126/science.abc4262
   Chumakov MP, 1992, J MICROBIOL EPIDEMIO, V11-12, P37
   Cohn M., 2020, OLD POLIO VACCINE CO
   Dreazen JR, 1999, AM FAM PHYSICIAN, V60, P1929
   Duintjer Tebbens RJ, 2015, BMC INFECT DIS, V15, P1
   Edens C, 2015, VACCINE, V33, P4683, DOI 10.1016/j.vaccine.2015.01.089
   Farrell M, 2017, J INFECT DIS, V216, pS193, DOI 10.1093/infdis/jiw558
   Fidel PL, 2020, MBIO, V11, DOI 10.1128/mBio.00907-20
   Gallo R., 2020, OLD VACCINE MAY HELP
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   Jenkins PC, 2006, PEDIATRICS, V118, P611, DOI 10.1542/peds.2005-2358
   Kalkowska D A, 2019, Epidemiol Infect, V147, pe295, DOI 10.1017/S095026881900181X
   Kalkowska DA, 2020, RISK ANAL, DOI 10.1111/risa.13555
   Kalkowska DA, 2020, RISK ANAL, DOI 10.1111/risa.13447
   Kalkowska DA, 2015, J INFECT DIS, V211, P1800, DOI 10.1093/infdis/jiu674
   Kandasamy R, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5225
   Kew O, 2002, SCIENCE, V296, P356, DOI 10.1126/science.1068284
   Lund N, 2015, CLIN INFECT DIS, V61, P1504, DOI 10.1093/cid/civ617
   Maldonado YA, 1997, J INFECT DIS, V175, P545, DOI 10.1093/infdis/175.3.545
   Miller MA, 1996, JAMA-J AM MED ASSOC, V276, P967, DOI 10.1001/jama.276.12.967
   Modell V, 2018, IMMUNOL RES, V66, P367, DOI 10.1007/s12026-018-8996-5
   Mogensen SW, 2017, EBIOMEDICINE, V17, P192, DOI 10.1016/j.ebiom.2017.01.041
   Muller DA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13011-0
   Mychaleckyj JC, 2016, VACCINE, V34, P358, DOI 10.1016/j.vaccine.2015.11.046
   Nathanson N, 2010, AM J EPIDEMIOL, V172, P1213, DOI 10.1093/aje/kwq320
   Offit PA, 2005, NEW ENGL J MED, V352, P1411, DOI 10.1056/NEJMp048180
   Oshinsky D, 2005, POLIO AM STORY
   Platt LR, 2014, J INFECT DIS, V210, pS380, DOI 10.1093/infdis/jiu184
   Schudel M., 2018, D SALAMONE WHO CONTR
   Seppala E, 2011, VACCINE, V29, P8615, DOI 10.1016/j.vaccine.2011.09.015
   SHINDAROV LM, 1979, J HYG EPID MICROB IM, V23, P284
   Sorup S, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofv204
   Stabell C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004056
   Sullivan K, 2020, NBC NEWS
   Tebbens RJD, 2006, RISK ANAL, V26, P1471, DOI 10.1111/j.1539-6924.2006.00827.x
   Tebbens RJD, 2013, RISK ANAL, V33, P703, DOI 10.1111/risa.12044
   Thompson KM, 2006, RISK ANAL, V26, P1423, DOI 10.1111/j.1539-6924.2006.00831.x
   Thompson KM, 2020, EXPERT REV VACCINES, V19, P661, DOI 10.1080/14760584.2020.1791093
   Thompson KM, 2020, RISK ANAL, DOI 10.1111/risa.13557
   Thompson KM, 2020, RISK ANAL, DOI 10.1111/risa.13484
   Thompson KM, 2020, VACCINE, V38, P2136, DOI 10.1016/j.vaccine.2020.01.042
   Thompson KM, 2019, LANCET, V394, P99, DOI 10.1016/S0140-6736(19)31294-2
   Thompson KM, 2015, LANCET INFECT DIS, V15, P1120, DOI 10.1016/S1473-3099(15)00099-7
   Thompson KM, 2015, VACCINE, V33, P1568, DOI 10.1016/j.vaccine.2015.02.013
   Thompson KM, 2012, EXPERT REV VACCINES, V11, P449, DOI [10.1586/erv.11.195, 10.1586/ERV.11.195]
   Thompson KM, 2012, PUBLIC HEALTH REP, V127, P23, DOI 10.1177/003335491212700104
   Thompson Kimberly M, 2008, Medscape J Med, V10, P190
   UNICEF, 2019, UNICEF SUPPL LOG VAC
   Upfill-Brown A, 2017, CLIN INFECT DIS, V65, P414, DOI 10.1093/cid/cix354
   Van Damme P, 2019, LANCET, V394, P148, DOI 10.1016/S0140-6736(19)31279-6
   VOROSHILOVA MK, 1989, PROG MED VIROL, V36, P191
   Wallace GS, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3386-1
   World Health Assembly, 2018, POL CONT POL RES 71
   World Health Assembly, 2008, POL MECH MAN POT RIS
   World Health Organization, 2015, 14 M GLOB COMM CERT
   World Health Organization, 2019, 20 M GLOB COMM CERT
   World Health Organization and UNICEF, 2018, 17 WHO UNICEF CONS O
   World Health Organization Global Polio Eradication Initiative, 2020, US BIV OR POL VACC S
NR 67
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4332
EI 1539-6924
J9 RISK ANAL
JI Risk Anal.
DI 10.1111/risa.13614
EA OCT 2020
PG 11
WC Public, Environmental & Occupational Health; Mathematics,
   Interdisciplinary Applications; Social Sciences, Mathematical Methods
SC Public, Environmental & Occupational Health; Mathematics; Mathematical
   Methods In Social Sciences
GA OD2ZD
UT WOS:000579720200001
PM 33084153
OA Other Gold
DA 2021-01-01
ER

PT J
AU Basu, A
   Sarkar, A
   Maulik, U
AF Basu, Anamika
   Sarkar, Anasua
   Maulik, Ujjwal
TI Molecular docking study of potential phytochemicals and their effects on
   the complex of SARS-CoV2 spike protein and human ACE2
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SWISS-MODEL; CORONAVIRUS; EMODIN; MOLPROBITY; PNEUMONIA; RECEPTOR
AB Angiotensin converting enzyme 2 (ACE2) (EC:3.4.17.23) is a transmembrane protein which is considered as a receptor for spike protein binding of novel coronavirus (SARS-CoV2). Since no specific medication is available to treat COVID-19, designing of new drug is important and essential. In this regard, in silico method plays an important role, as it is rapid and cost effective compared to the trial and error methods using experimental studies. Natural products are safe and easily available to treat coronavirus affected patients, in the present alarming situation. In this paper five phytochemicals, which belong to flavonoid and anthraquinone subclass, have been selected as small molecules in molecular docking study of spike protein of SARS-CoV2 with its human receptor ACE2 molecule. Their molecular binding sites on spike protein bound structure with its receptor have been analyzed. From this analysis, hesperidin, emodin and chrysin are selected as competent natural products from both Indian and Chinese medicinal plants, to treat COVID-19. Among them, the phytochemical hesperidin can bind with ACE2 protein and bound structure of ACE2 protein and spike protein of SARS-CoV2 noncompetitively. The binding sites of ACE2 protein for spike protein and hesperidin, are located in different parts of ACE2 protein. Ligand spike protein causes conformational change in three-dimensional structure of protein ACE2, which is confirmed by molecular docking and molecular dynamics studies. This compound modulates the binding energy of bound structure of ACE2 and spike protein. This result indicates that due to presence of hesperidin, the bound structure of ACE2 and spike protein fragment becomes unstable. As a result, this natural product can impart antiviral activity in SARS CoV2 infection. The antiviral activity of these five natural compounds are further experimentally validated with QSAR study.
C1 [Basu, Anamika] Gurudas Coll, Dept Biochem, Kolkata, W Bengal, India.
   [Sarkar, Anasua; Maulik, Ujjwal] Jadavpur Univ, Comp Sci & Engn Dept, Kolkata, W Bengal, India.
RP Sarkar, A (corresponding author), Jadavpur Univ, Comp Sci & Engn Dept, Kolkata, W Bengal, India.
EM anasua.sarkar@jadavpuruniversity.in
CR Anand A. Zanwar, 2014, POLYPHENOLS HUMAN HL, P989, DOI [10.1016/B978-0-12-398456-2.00076-1, DOI 10.1016/B978-0-12-398456-2.00076-1]
   Betts M.J., 2003, BIOINFORMATICS GENET, V317, P289, DOI [10.1002/0470867302.ch14, DOI 10.1002/0470867302.CH14]
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Dai JP, 2017, MOLECULES, V22, DOI 10.3390/molecules22101754
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Grosdidier A, 2011, J COMPUT CHEM, V32, P2149, DOI 10.1002/jcc.21797
   Guex N, 2009, ELECTROPHORESIS, V30, pS162, DOI 10.1002/elps.200900140
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Ho TY, 2007, ANTIVIR RES, V74, P92, DOI 10.1016/j.antiviral.2006.04.014
   Izhaki I, 2002, NEW PHYTOL, V155, P205, DOI 10.1046/j.1469-8137.2002.00459.x
   Kannan D, 2018, INT J MED RES HEALTH, V7, P1
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kozakov D, 2013, PROTEINS, V81, P2159, DOI 10.1002/prot.24403
   Kozma D, 2013, NUCLEIC ACIDS RES, V41, pD524, DOI 10.1093/nar/gks1169
   Laskowski R., 2001, INT TABLES CRYSTALLO, P722, DOI DOI 10.1107/97809553602060000882
   Laskowski RA, 2009, NUCLEIC ACIDS RES, V37, pD355, DOI 10.1093/nar/gkn860
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lovell SC, 2002, PROTEIN-STRUCT FUNCT, V50, P437, DOI DOI 10.1002/PR0T.10286
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Remmert M, 2012, NAT METHODS, V9, P173, DOI [10.1038/NMETH.1818, 10.1038/nmeth.1818]
   Santos KB, 2020, J CHEM INF MODEL, V60, P667, DOI 10.1021/acs.jcim.9b00905
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Sharma R., 2014, POLYPHENOLS HUMAN HL, P757, DOI [DOI 10.1016/C2011-1-09286-X, 10.1016/B978-0-12-398456-2.00059-1]
   Song JH, 2015, BIOMOL THER, V23, P465, DOI 10.4062/biomolther.2015.095
   Studer G, 2020, BIOINFORMATICS, V36, P1765, DOI 10.1093/bioinformatics/btz828
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Utomo R. Y., 2020, REVEALING POTENCY CI, DOI [10.20944/preprints202003.0214.v1, DOI 10.20944/PREPRINTS202003.0214.V1, 10.20944/preprints202003.0214.v1.]
   Vangone A, 2015, ELIFE, V4, DOI 10.7554/eLife.07454
   Varshney K. K., MOL MODELING ISOLATE
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089668
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514
   Yin X, 2018, NANO-MICRO LETT, V10, DOI 10.1007/s40820-017-0156-2
   Zargar BA, 2011, FOOD CHEM, V128, P585, DOI 10.1016/j.foodchem.2011.03.083
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zoete V, 2010, J MOL RECOGNIT, V23, P457, DOI 10.1002/jmr.1012
NR 46
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 19
PY 2020
VL 10
IS 1
AR 17699
DI 10.1038/s41598-020-74715-4
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OL2UQ
UT WOS:000585197800029
PM 33077836
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Keretsu, S
   Bhujbal, SP
   Cho, SJ
AF Keretsu, Seketoulie
   Bhujbal, Swapnil P.
   Cho, Seung Joo
TI Rational approach toward COVID-19 main protease inhibitors via molecular
   docking, molecular dynamics simulation and free energy calculation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CORONAVIRUS; CHLOROQUINE; SARS
AB In the rapidly evolving coronavirus disease (COVID-19) pandemic, repurposing existing drugs and evaluating commercially available inhibitors against druggable targets of the virus could be an effective strategy to accelerate the drug discovery process. The 3C-Like proteinase (3CL(pro)) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as an important drug target due to its role in viral replication. The lack of a potent 3CL(pro) inhibitor and the availability of the X-ray crystal structure of 3CL(pro) (PDB-ID 6LU7) motivated us to perform computational studies to identify commercially available potential inhibitors. A combination of modeling studies was performed to identify potential 3CL(pro) inhibitors from the protease inhibitor database MEROPS (https://www.ebi.ac.uk/merops/index.shtml). Binding energy evaluation identified key residues for inhibitor design. We found 15 potential 3CL(pro) inhibitors with higher binding affinity than that of an alpha -ketoamide inhibitor determined via X-ray structure. Among them, saquinavir and three other investigational drugs aclarubicin, TMC-310911, and faldaprevir could be suggested as potential 3CL(pro) inhibitors. We recommend further experimental investigation of these compounds.
C1 [Keretsu, Seketoulie; Bhujbal, Swapnil P.; Cho, Seung Joo] Chosun Univ, Coll Med, Dept Biomed Sci, Gwangju 501759, South Korea.
   [Cho, Seung Joo] Chosun Univ, Coll Med, Dept Cellular Mol Med, 375 Seosuk Dong, Gwangju 501759, South Korea.
RP Cho, SJ (corresponding author), Chosun Univ, Coll Med, Dept Biomed Sci, Gwangju 501759, South Korea.; Cho, SJ (corresponding author), Chosun Univ, Coll Med, Dept Cellular Mol Med, 375 Seosuk Dong, Gwangju 501759, South Korea.
EM chosj@chosun.ac.kr
FU National Research Foundation of Korea (MRC) [2015-009070]
FX This work was supported by Grants from the National Research Foundation
   of Korea (MRC, 2015-009070).
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Byrd JC, 2020, BLOOD, V135, P1204, DOI 10.1182/blood.2018884940
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   Carr A.C., 2020, CRIT CARE, V24, P1, DOI DOI 10.1186/s13054-019-2683-3
   Cava C, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040404
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Chakraborty Chiranjib, 2020, Arch Med Res, V51, P728, DOI 10.1016/j.arcmed.2020.05.021
   Chakraborty C, 2020, J MED VIROL, V92, P2314, DOI 10.1002/jmv.25997
   Chang MW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011955
   Chen Y, 2020, LANCET INFECT DIS, V20, P515, DOI 10.1016/S1473-3099(20)30235-8
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   D'Acquarica I, 2020, DRUG DISCOV TODAY, V25, P1121, DOI 10.1016/j.drudis.2020.04.021
   Dierynck I, 2011, ANTIMICROB AGENTS CH, V55, P5723, DOI 10.1128/AAC.00748-11
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI [10.1186/1756-0500-5-185, 10.1186/1756-0500-5-367]
   GALPIN IJ, 1984, INT J PEPT PROT RES, V23, P477
   Geronikaki A., 2016, TOPICS MED CHEM, V29, P37
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Howser GB, 2020, COMPUTER NETWORKS IN, P321
   Huey R, 2008, USING AUTODOCK 4 AUT, P54
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Jacome R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66440-9
   Jaffe S, 2020, LANCET, V395, P1179, DOI 10.1016/S0140-6736(20)30817-5
   Jagasia M, 2020, BLOOD, V135, P1739, DOI 10.1182/blood.2020004823
   Javorac D, 2020, FOOD CHEM TOXICOL, V144, DOI 10.1016/j.fct.2020.111639
   JENSEN PB, 1991, CANCER RES, V51, P5093
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Keretsu S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1714483
   Keretsu S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48949-w
   KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Levy RM, 2003, J AM CHEM SOC, V125, P9523, DOI 10.1021/ja029833a
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Liang JL, 2020, COMPUT BIOL CHEM, V87, DOI 10.1016/j.compbiolchem.2020.107292
   MAHASE E, 2020, BMJ-BRIT MED J, V368, P48071, DOI DOI 10.1136/BMJ.M641
   Mimoto T, 1999, PEPTIDE SCIENCE - PRESENT AND FUTURE, P652
   Noble S, 1996, DRUGS, V52, P93, DOI 10.2165/00003495-199652010-00007
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Pearlman RS, 1987, CHEM DES AUTO NEWS, V2, P1
   Perez-Moreiras JV, 2018, AM J OPHTHALMOL, V195, P181, DOI 10.1016/j.ajo.2018.07.038
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Rawlings ND, 2010, NUCLEIC ACIDS RES, V38, pD227, DOI 10.1093/nar/gkp971
   Saha A, 2020, ARCH MED RES, V51, P595, DOI 10.1016/j.arcmed.2020.05.009
   Saha A, 2020, ARCH MED RES, V51, P585, DOI 10.1016/j.arcmed.2020.05.001
   Sliwoski G, 2014, PHARMACOL REV, V66, P334, DOI 10.1124/pr.112.007336
   Spitzer R, 2012, J COMPUT AID MOL DES, V26, P687, DOI 10.1007/s10822-011-9533-y
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tong L, 2002, CHEM REV, V102, P4609, DOI 10.1021/cr010184f
   Touret F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70143-6
   Trezza A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70863-9
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yilmaz NK, 2016, TRENDS MICROBIOL, V24, P547, DOI 10.1016/j.tim.2016.03.010
   Zeuzem S, 2013, NEW ENGL J MED, V369, P630, DOI 10.1056/NEJMoa1213557
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 69
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 19
PY 2020
VL 10
IS 1
AR 17716
DI 10.1038/s41598-020-74468-0
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OL2UQ
UT WOS:000585197800046
PM 33077821
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rattanapisit, K
   Shanmugaraj, B
   Manopwisedjaroen, S
   Purwono, PB
   Siriwattananon, K
   Khorattanakulchai, N
   Hanittinan, O
   Boonyayothin, W
   Thitithanyanont, A
   Smith, DR
   Phoolcharoen, W
AF Rattanapisit, Kaewta
   Shanmugaraj, Balamurugan
   Manopwisedjaroen, Suwimon
   Purwono, Priyo Budi
   Siriwattananon, Konlavat
   Khorattanakulchai, Narach
   Hanittinan, Oranicha
   Boonyayothin, Wanuttha
   Thitithanyanont, Arunee
   Smith, Duncan R.
   Phoolcharoen, Waranyoo
TI Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike
   specific monoclonal antibody CR3022 in Nicotiana benthamiana
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TRANSIENT EXPRESSION; VIRUS; INFECTION; POTENT; BIOPHARMACEUTICALS;
   VECTORS; VACCINE; PROTEIN; PLANTS; CHAIN
AB Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the ongoing global outbreak of coronavirus disease (COVID-19) which is a significant threat to global public health. The rapid spread of COVID-19 necessitates the development of cost-effective technology platforms for the production of vaccines, drugs, and protein reagents for appropriate disease diagnosis and treatment. In this study, we explored the possibility of producing the receptor binding domain (RBD) of SARS-CoV-2 and an anti-SARS-CoV monoclonal antibody (mAb) CR3022 in Nicotiana benthamiana. Both RBD and mAb CR3022 were transiently produced with the highest expression level of 8 mu g/g and 130 mu g/g leaf fresh weight respectively at 3 days post-infiltration. The plant-produced RBD exhibited specific binding to the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2). Furthermore, the plant-produced mAb CR3022 binds to SARS-CoV-2, but fails to neutralize the virus in vitro. This is the first report showing the production of anti-SARS-CoV-2 RBD and mAb CR3022 in plants. Overall these findings provide a proof-of-concept for using plants as an expression system for the production of SARS-CoV-2 antigens and antibodies or similar other diagnostic reagents against SARS-CoV-2 rapidly, especially during epidemic or pandemic situation.
C1 [Rattanapisit, Kaewta; Shanmugaraj, Balamurugan; Phoolcharoen, Waranyoo] Chulalongkorn Univ, Res Unit Plant Produced Pharmaceut, Bangkok, Thailand.
   [Rattanapisit, Kaewta; Shanmugaraj, Balamurugan; Siriwattananon, Konlavat; Khorattanakulchai, Narach; Hanittinan, Oranicha; Boonyayothin, Wanuttha; Phoolcharoen, Waranyoo] Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Pharmacognosy & Pharmaceut Bot, Bangkok, Thailand.
   [Manopwisedjaroen, Suwimon; Purwono, Priyo Budi; Thitithanyanont, Arunee] Mahidol Univ, Fac Sci, Dept Microbiol, Bangkok, Thailand.
   [Purwono, Priyo Budi] Univ Airlangga, Fac Med, Dept Microbiol, Surabaya, Indonesia.
   [Smith, Duncan R.] Mahidol Univ, Inst Mol Biosci, Salaya, Nakhon Pathom, Thailand.
RP Phoolcharoen, W (corresponding author), Chulalongkorn Univ, Res Unit Plant Produced Pharmaceut, Bangkok, Thailand.; Phoolcharoen, W (corresponding author), Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Pharmacognosy & Pharmaceut Bot, Bangkok, Thailand.
EM Waranyoo.P@chula.ac.th
OI Thitithanyanont, Arunee/0000-0002-9756-4763
FU Thailand Research FundThailand Research Fund (TRF) [RSA6280006];
   Graduate School, Ratchadaphisek Somphot Fund; Second Century Fund (C2F),
   Chulalongkorn University
FX This study was supported by the Thailand Research Fund grant No.
   RSA6280006. We would like to thank Department of Disease Control,
   Ministry of Public Health Thailand for providing clinical specimens for
   the viral isolate and sera from a COVID-19 survivor. We also thank
   Professor Hugh Mason (Arizona State University) for providing
   geminiviral vectors. The authors would like to thank Graduate School,
   Ratchadaphisek Somphot Fund (KR), and The Second Century Fund (C2F) (BS,
   NK), Chulalongkorn University for providing the financial support.
CR Ahmad AR, 2019, PLANTS-BASEL, V8, DOI 10.3390/plants8120566
   Bloom DE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00549
   BOERE WAM, 1983, J GEN VIROL, V64, P1405, DOI 10.1099/0022-1317-64-6-1405
   Bootz A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006601
   Chan HT, 2016, PLANT BIOTECHNOL J, V14, P2190, DOI 10.1111/pbi.12575
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang Hui, 2013, Bing Du Xue Bao, V29, P106
   Chen Q, 2011, HUM VACCINES, V7, P331, DOI 10.4161/hv.7.3.14262
   Dent M, 2016, J GEN VIROL, V97, P3280, DOI 10.1099/jgv.0.000635
   Diamos AG, 2019, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01974
   Dreyfus C, 2012, SCIENCE, V337, P1343, DOI 10.1126/science.1222908
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Fischer R, 2020, BIOTECHNOL ADV, V40, DOI 10.1016/j.biotechadv.2020.107519
   Greenough TC, 2005, J INFECT DIS, V191, P507, DOI 10.1086/427242
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang Z, 2010, BIOTECHNOL BIOENG, V106, P9, DOI 10.1002/bit.22652
   Hurtado J, 2020, PLANT BIOTECHNOL J, V18, P266, DOI 10.1111/pbi.13194
   Kelley B, 2009, MABS-AUSTIN, V1, P443, DOI 10.4161/mabs.1.5.9448
   Komarova TV, 2010, EXPERT REV VACCINES, V9, P859, DOI [10.1586/erv.10.85, 10.1586/ERV.10.85]
   Lai HF, 2014, PLANT BIOTECHNOL J, V12, P1098, DOI 10.1111/pbi.12217
   Lai HF, 2012, PLANT BIOTECHNOL J, V10, P95, DOI 10.1111/j.1467-7652.2011.00649.x
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lip KM, 2006, J VIROL, V80, P941, DOI 10.1128/JVI.80.2.941-950.2006
   Lomonossoff GP, 2016, SCIENCE, V353, P1237, DOI 10.1126/science.aaf6638
   Maharjan PM, 2019, CLIN EXP VACCINE RES, V8, P124, DOI 10.7774/cevr.2019.8.2.124
   Malla A, 2020, J PURE APPL MICROBIO, V14, P931, DOI 10.22207/JPAM.14.SPL1.30
   Marsian J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00090-w
   Peyret H, 2019, PLANT METHODS, V15, DOI 10.1186/s13007-019-0494-9
   Phoolcharoen W, 2011, PLANT BIOTECHNOL J, V9, P807, DOI 10.1111/j.1467-7652.2011.00593.x
   Rattanapisit K, 2019, PLANTS-BASEL, V8, DOI 10.3390/plants8120560
   Rattanapisit K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51656-1
   Rattanapisit K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17666-7
   Rosales-Mendoza S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00252
   Sainsbury F, 2014, CURR OPIN PLANT BIOL, V19, P1, DOI 10.1016/j.pbi.2014.02.003
   Schillberg S, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00720
   SCHMALJOHN AL, 1982, NATURE, V297, P70, DOI 10.1038/297070a0
   Shanmugaraj B, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9070842
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Shanmugaraj B, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020148
   Streatfield SJ, 2015, PLANT BIOTECHNOL J, V13, P1136, DOI 10.1111/pbi.12475
   Teh AYH, 2014, PLANT BIOTECHNOL J, V12, P300, DOI 10.1111/pbi.12137
   ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   van den Brink EN, 2005, J VIROL, V79, P1635, DOI 10.1128/JVI.79.3.1635-1644.2005
   van Dolleweerd CJ, 2014, J INFECT DIS, V210, P200, DOI 10.1093/infdis/jiu085
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   WHO, NOV COR CHIN
   World Health Organization, 2005, 2 M INT HLTH REG EM
   Yee Jane, 2020, J Am Coll Emerg Physicians Open, DOI 10.1002/emp2.12034
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang B, 2017, CURR OPIN CHEM BIOL, V38, P17, DOI 10.1016/j.cbpa.2017.02.007
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 55
TC 1
Z9 1
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 19
PY 2020
VL 10
IS 1
AR 17698
DI 10.1038/s41598-020-74904-1
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OL2UQ
UT WOS:000585197800028
PM 33077899
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ahmed, N
   Chakrabarty, A
   Guengerich, FP
   Chowdhury, G
AF Ahmed, Nabeel
   Chakrabarty, Anindita
   Guengerich, F. Peter
   Chowdhury, Goutam
TI Protective Role of Glutathione against Peroxynitrite-Mediated DNA Damage
   During Acute Inflammation
SO CHEMICAL RESEARCH IN TOXICOLOGY
LA English
DT Article
ID N-ACETYLCYSTEINE; NITRIC-OXIDE; DOUBLE-BLIND; CROSS-LINKS; IN-VIVO;
   8-NITROGUANINE
AB Inflammation is an immune response to protect against various types of infections. When unchecked, acute inflammation can be life-threatening, as seen with the current coronavirus pandemic. Strong oxidants, such as peroxynitrite produced by immune cells, are major mediators of the inflammation-associated pathogenesis. Cellular thiols play important roles in mitigating inflammation-associated macromolecular damage including DNA. Herein, we have demonstrated a role of glutathione (GSH) and other thiols in neutralizing the effect of peroxynitrite-mediated DNA damage through stable GSH-DNA adduct formation. Our observation supports the use of thiol supplements as a potential therapeutic strategy against severe COVID-19 cases and a Phase II (NCT04374461) open-label clinical trial launched in early May 2020 by the Memorial Sloan Kettering Cancer Center.
C1 [Ahmed, Nabeel; Chakrabarty, Anindita] Shiv Nadar Univ, Dept Life Sci, Greater Noida 201314, Uttar Pradesh, India.
   [Guengerich, F. Peter] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA.
   [Chowdhury, Goutam] Shiv Nadar Univ, Dept Chem, Greater Noida 201314, Uttar Pradesh, India.
RP Chowdhury, G (corresponding author), Shiv Nadar Univ, Dept Chem, Greater Noida 201314, Uttar Pradesh, India.
EM goutam.chowdhury@outlook.com
OI Chowdhury, Goutam/0000-0003-1397-8684
FU DBTDepartment of Biotechnology (DBT) India [BT/RLF/RE-ENTRY/18/2013,
   BT/RLF/RE-ENTRY/35/2012]; SERBDepartment of Science & Technology
   (India)Science Engineering Research Board (SERB), India
   [ECR/2015/000197, ECR/2015/000198]; National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [R01 ES010546]
FX This work was supported in part by grants from DBT
   [BT/RLF/RE-ENTRY/18/2013: G.C. and BT/RLF/RE-ENTRY/35/2012: A.C.] and
   SERB [ECR/2015/000197: G.C. and ECR/2015/000198: A.C.] and the National
   Institutes of Health (R01 ES010546 (F.P.G.)). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health. We also thank Shiv
   Nadar University, T. Wani, S. Siddiqui, and A. Jana.
CR Alexander KJ, 2018, CHEM-EUR J, V24, P3013, DOI 10.1002/chem.201705541
   Augusto O, 2019, FREE RADICAL BIO MED, V135, P210, DOI 10.1016/j.freeradbiomed.2019.02.026
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Bhamra I, 2012, NUCLEIC ACIDS RES, V40, P11126, DOI 10.1093/nar/gks799
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Cho SH, 2013, CHEM RES TOXICOL, V26, P1765, DOI 10.1021/tx4003534
   Chowdhury G, 2013, ANGEW CHEM INT EDIT, V52, P12879, DOI 10.1002/anie.201307580
   Chowdhury G, 2010, CHEM RES TOXICOL, V23, P1018, DOI 10.1021/tx900367p
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Domenighetti G, 1997, J CRIT CARE, V12, P177, DOI 10.1016/S0883-9441(97)90029-0
   Fujiwara Nagatoshi, 2005, Current Drug Targets - Inflammation and Allergy, V4, P281, DOI 10.2174/1568010054022024
   Gan JP, 2005, CHEM RES TOXICOL, V18, P896, DOI 10.1021/tx0496791
   Hu CW, 2018, MOLECULES, V23, DOI 10.3390/molecules23030605
   Hu CW, 2016, FREE RADICAL BIO MED, V101, P348, DOI 10.1016/j.freeradbiomed.2016.10.505
   KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017
   LI XY, 1994, AM J RESP CRIT CARE, V149, P1518, DOI 10.1164/ajrccm.149.6.8004308
   Lin X, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8010013
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006
   Murata M, 2018, ENVIRON HEALTH PREV, V23, DOI 10.1186/s12199-018-0740-1
   Parohan M, 2020, HEPATOL RES, V50, P924, DOI 10.1111/hepr.13510
   Perrone LA, 2013, J INFECT DIS, V207, P1576, DOI 10.1093/infdis/jit062
   Polonikov A, 2020, ACS INFECT DIS, V6, P1558, DOI 10.1021/acsinfecdis.0c00288
   Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x
   Robinson KM, 2005, METHOD ENZYMOL, V396, P207, DOI 10.1016/S0076-6879(05)96019-9
   Sawa T, 2007, NAT CHEM BIOL, V3, P727, DOI 10.1038/nchembio.2007.33
   Sedgeman CA, 2017, CHEM RES TOXICOL, V30, P1188, DOI 10.1021/acs.chemrestox.7b00022
   SUTER PM, 1994, CHEST, V105, P190, DOI 10.1378/chest.105.1.190
   Wani TH, 2018, CHEM RES TOXICOL, V31, P612, DOI 10.1021/acs.chemrestox.8b00094
   Wani TH, 2017, CHEM RES TOXICOL, V30, P1622, DOI 10.1021/acs.chemrestox.7b00127
   Weiss U, 2008, NATURE, V454, P427, DOI 10.1038/454427a
   Winterbourn CC, 2016, ARCH BIOCHEM BIOPHYS, V595, P68, DOI 10.1016/j.abb.2015.11.028
   Yun BH, 2011, CHEM RES TOXICOL, V24, P1144, DOI 10.1021/tx200139c
NR 33
TC 0
Z9 0
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0893-228X
EI 1520-5010
J9 CHEM RES TOXICOL
JI Chem. Res. Toxicol.
PD OCT 19
PY 2020
VL 33
IS 10
BP 2668
EP 2674
DI 10.1021/acs.chemrestox.0c00299
PG 7
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology
SC Pharmacology & Pharmacy; Chemistry; Toxicology
GA OK0OY
UT WOS:000584353400017
PM 32894672
DA 2021-01-01
ER

PT J
AU Forman, L
   Kohler, JC
AF Forman, Lisa
   Kohler, Jillian Clare
TI Global health and human rights in the time of COVID-19: Response,
   restrictions, and legitimacy
SO JOURNAL OF HUMAN RIGHTS
LA English
DT Article
AB Policy responses to the COVID-19 pandemic have impacted a range of human rights, with the pandemic being used to justify police violence, authoritarian power grabs, and corruption. Health systems in high- and low-income countries have struggled to provide adequate COVID-19 testing, tracing, and treatment, with non-COVID-19 healthcare-restricted, vulnerable populations at high risk of infection and negative health and social impacts, and lockdowns exacerbating poverty, domestic violence, and mental health problems. If underresourced health systems are overwhelmed by COVID-19, and individuals are forced to bear testing and treatment costs, there is a stronger likelihood of health system failures, for higher mortality from a range of causes, and for people to be pushed further into poverty and insecurity. COVID-19 thus underscores the urgent need for clearer rules about legitimate restrictions of the right to health in responding to the pandemic, and for safeguarding global health policy initiatives in its aftermath. This article focuses on key right-to-health challenges, including realization of universal health coverage, and potential challenges in access to future COVID-19 therapies and vaccines. We conclude with reflections on what the pandemic may mean for the evolution of human rights, and the right to health in particular.
C1 [Forman, Lisa] Univ Toronto, Human Rights & Global Hlth Equ, Toronto, ON, Canada.
   [Forman, Lisa; Kohler, Jillian Clare] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Kohler, Jillian Clare] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.
   [Kohler, Jillian Clare] Univ Toronto, Munk Sch Global Affairs, Toronto, ON, Canada.
   [Kohler, Jillian Clare] Univ Toronto, WHO Collaborating Ctr Governance Transparency & A, Pharmaceut Sect, Toronto, ON, Canada.
   [Kohler, Jillian Clare] Univ Toronto, Toronto, ON, Canada.
RP Forman, L (corresponding author), Dalla Lana Sch Publ Hlth, 155 Coll St, Toronto, ON M5T 3M7, Canada.
EM lisa.forman@utoronto.ca
CR Adepoju P, 2020, LANCET HIV, V7, pE319, DOI 10.1016/S2352-3018(20)30109-0
   ALINDOGAN Jamela., 2020, HRW COVID 19 LOCKDOW
   allAfrica, 2020, ALLAFRICA
   ALONSO-ZALDIVAR Rocardo., 2020, US FACES TRULY DAUNT
   AUDIT SERVICE OF SIERRA LEONE, 2014, REP AUD MAN EB FUNDS
   CENTER FOR HEALTH HUMAN RIGHTS AND DEVELOPMENT, 2020, SEX REPR HLTH COVID
   COHEN Jon., 2020, UNVEILING WARP SPEED
   COUNCIL OF EUROPE FOR HUMAN RIGHTS, 2020, LEARN PAND BETT FULF
   COUSINS Ben., 2020, LACK RESOURCES LED L
   CUMMINS Isabel Ortiz Matthew., 2013, ISABEL INITIATIVE PO
   Durojaye E, 2012, ESR REV, V13, P3
   EUROPEAN MEDICINES AGENCY (EMA), 2020, COVID 19 BEW FALS ME
   FORANI Jonathan., 2020, HALF CANADIANS REPOR
   Forman L, 2016, HEALTH HUM RIGHTS, V18, P23
   Forman L, 2015, INT J HEALTH POLICY, V4, P799, DOI 10.15171/ijhpm.2015.171
   FORMAN Lisa, 2012, ACCESS MEDICINES HUM
   Freedom in the World 2019: Democracy in retreat, 2019, FREED WORLD 2019 DEM
   Goodman JL, 2020, JAMA-J AM MED ASSOC, V323, P1899, DOI 10.1001/jama.2020.6434
   HUMAN RIGHTS WATCH-INDIA, 2020, COVID 19 LOCKD PUTS
   KYRILI Katerina, 2010, IMPACT GLOBAL EC CRI
   LUI Angus., 2020, FAIR PRICE GILEADS C
   MANN Jonathan, 1999, HLTH HUMAN RIGHTS RE
   MCCONAGHIE Andrew., 2020, COVID 19 VACCINE COU
   MEDECINS SANS FRONTIERES (MSF), 2020, MSF ANY FUT COVID 19
   MEDICINES PATENT POOL, 2020, COVID 19
   MEIER Benjamin Mason, 2020, INFECT DIS NEW MILLE
   MORALES Mark, 2020, BLACKS LATINOS ARE O
   Newton PN, 2020, LANCET GLOB HEALTH, V8, pE754, DOI 10.1016/S2214-109X(20)30136-4
   Nolan A, 2014, ECONOMIC AND SOCIAL RIGHTS AFTER THE GLOBAL FINANCIAL CRISIS, P1, DOI 10.1017/CBO9781107337954
   Norheim OF, 2015, INT J HEALTH POLICY, V4, P711, DOI 10.15171/ijhpm.2015.184
   ODHIAMBO Agnes., 2020, TACKLING KENYAS DOME
   OOMS G, 2014, BMC INT HEALTH HUM R, V14, P1
   ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT (OECD), 2020, POL MEAS AV CORR BRI
   PUBLIC HEALTH ONTARIO, 2020, SYN COVID 19 WHAT WE
   RADIO CANADA INTERNATIONAL, 2020, COVID 19 CO CHARG PR
   REYNOLDS Christopher., 2020, CORONAVIRUS CANADA L
   RTL NEWS, 2020, RTL NEWS
   SHALAL Andrea., 2020, 80 COUNTRIES ARE HOA
   Shannon D, 2014, THEORY ACTION, V7, P1, DOI 10.3798/tia.1937-0237.14024
   TOEBES Brigit., 2009, GLOBAL HLTH HUMAN RI
   TRANSPARENCY INTERNATIONAL, 2020, WHAT IS CORR
   TRIPATHI Salil., 2020, WORLD NEEDS CHANGE I
   UN General Assembly, 2015, TRANSF OUR WORLD 203
   UN OFFICE OF THE HIGH COMMISSION FOR HUMAN RIGHTS, 2020, UN HUM RIGHTS TREAT
   UN OFFICE OF THE HIGH COMMISSION FOR HUMAN RIGHTS, 170 COUNTR HAV RAT I
   UN OFFICE ON DRUGS AND CRIME, 2020, COVID 19 REL TRAFF M
   UNITED NATIONS, 1993, WORLD C HUM RIGHTS 2
   WEINTRAUB Rebecca, 2020, DANGER VACCINE NATL
   WORLD BANK, 2019, HIGH PERF HLTH FIN U
   World Health Organization, 2020, ADDR HUM RIGHTS KEY
   WORLD HEALTH ORGANIZATION (WHO), 2020, WHO FAIR PRIC FOR 20
   World Health Organization (WHO), 2019, PRIM HLTH CAR ROAD U
   WORLD HEALTH ORGANIZATION (WHO), 2020, MED PROD AL 3 2020
   WORLD HEALTH ORGANIZATION (WHO), 2020, COVID 19 RESP QUICKL
   WORLD HEALTH ORGANIZATION (WHO), 2020, MOR 150 COUNTR ENG C
   WORLD HEALTH ORGANIZATION (WHO), 2012, POS HLTH POST 2015 D
   2013, WORLD MAL REP 2013, P1
NR 57
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1475-4835
EI 1475-4843
J9 J HUM RIGHTS
JI J. Hum. Rights
PD OCT 19
PY 2020
VL 19
IS 5
BP 547
EP 556
DI 10.1080/14754835.2020.1818556
PG 10
WC International Relations; Political Science
SC International Relations; Government & Law
GA OQ0BX
UT WOS:000588459000005
OA Bronze
DA 2021-01-01
ER

PT J
AU Santoro, M
   Shanklin, R
AF Santoro, Michael
   Shanklin, Robert
TI Human rights obligations of drug companies
SO JOURNAL OF HUMAN RIGHTS
LA English
DT Article
ID BUSINESS; ETHICS; ACCESS
AB This article addresses the human rights obligations of pharmaceutical companies regarding access to vaccines and other drugs developed to prevent and treat COVID-19, and more broadly regarding access to essential medicines. We examine two United Nations guidelines-the Guiding Principles on Business and Human Rights and the Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines-which assert that pharmaceutical companies have human rights responsibilities to make essential medicines available to patients in the global South, and that member-states are responsible for enforcing these obligations. We develop a moral theory that justifies such human rights duties based on the idea of a "social contract" that more broadly underpins the idea of corporate social responsibility. We conclude by offering practical advice enabling pharmaceutical companies to balance their human rights duties to the global South with their responsibilities to shareholders and the need to sustainably incentivize drug discovery.
C1 [Santoro, Michael] Santa Clara Univ, Management & Entrepreneurship, Leavey Sch Business, Santa Clara, CA 95053 USA.
   [Shanklin, Robert] Santa Clara Univ, Dept Philosophy, Santa Clara, CA 95053 USA.
   [Shanklin, Robert] Santa Clara Univ, Eth & Chinese Philosophy, Santa Clara, CA 95053 USA.
RP Santoro, M (corresponding author), 500 El Camino Real,Lucas Hall 321K, Santa Clara, CA 95053 USA.
EM masantoro@scu.edu
CR Bjornsson Gunnar, 2014, Deontic Logic and Normative Systems. 12th International Conference, DEON 2014. Proceedings: LNCS 8554, P33, DOI 10.1007/978-3-319-08615-6_4
   CHAPMAN Audrey R, 2016, GLOBAL HLTH HUMAN RI
   D'AGOSTINO Fred, 2019, CONT APPROACHES SOCI
   DIFLUCAN PARTNERSHIP PROGRAM, 2012, DIFL PARTN PROGR FAC
   Donaldson T., 1989, ETHICS INT BUSINESS
   FRENCH PA, 1979, AM PHILOS QUART, V16, P207
   Friedman Milton, 1970, NY TIMES
   Gauri V, 2008, COURTING SOCIAL JUSTICE: JUDICIAL ENFORCEMENT OF SOCIAL AND ECONOMIC RIGHTS IN THE DEVELOPING WORLD, P1, DOI 10.1017/CBO9780511511240
   GAVI THE VACCINE ALLIANCE, 2020, NEW PRIV SECT COMM F
   Gruskin S, 2006, AM J PUBLIC HEALTH, V96, P1903, DOI 10.2105/AJPH.2006.099606
   HASSOUN Nicole, 2020, ENDING PANDEMIC WILL
   Hsieh NH, 2015, J HUM RIGHTS, V14, P218, DOI 10.1080/14754835.2015.1007223
   Hunt P, 2016, HEALTH HUM RIGHTS, V18, P109
   Hunt P, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000330
   IP Greg, 2020, WALL STREET J, pA2
   Joseph S, 2003, HUM RIGHTS QUART, V25, P425, DOI 10.1353/hrq.2003.0018
   KING Jr. Martin Luther., 1963, EBONY            AUG, P23
   LAPIDOR Eden, 2020, OUT SPOTLIGHT COVID
   Leisinger KM, 2005, BUS ETHICS Q, V15, P577, DOI 10.5840/beq200515440
   McMullan P, 2018, GLOBAL HEALTH ACTION, V11, DOI 10.1080/16549716.2018.1434935
   MOON Suerie, 2003, RESPECTING RIGHT ACC
   NEBEHAY Stephanie, 2020, WORLD LEADERS LAUNCH
   OBI Evaristus, 2017, POSTTRIAL ACCESS DRU
   PAINE Lynn Sharp, 2003, POWER SHIFT WHY COMP
   Parker-Lue S, 2015, ANNU REV PHARMACOL, V55, P191, DOI 10.1146/annurev-pharmtox-010814-124649
   POGGE Thomas, 2016, INCENTIVES GLOBAL HL
   POGGE Thomas, 2010, INCENTIVES GLOBAL PU
   REINHARDT Uwe, 2019, PRICED OUT EC ETHICA
   Ritchie H, 2020, CORONAVIRUS PANDEMIC
   RODRiGUEZ-GARAVITO Cesar, 2017, BUSINESS HUMAN RIGHT
   ROSER Max, 2019, HIV AIDS
   Santoro MA, 2010, BUS ETHICS Q, V20, P285, DOI 10.5840/beq201020221
   SANTORO Michael A, 2009, CHINA 2020 W BUSINES
   SANTORO MichaelA, 2006, N CAROLINA J INT LAW, V31, P923
   UNITED NATIONS, 2008, HUM RIGHTS GUID PHAR
   United Nations, 2011, GUID PRINC BUS HUM R
   UNITED NATIONS, 2000, CESCR GEN COMM 14 RI
   United Nations (UN), 1966, INT COV EC SOC CULT
   WETTSTEIN Florian, 2009, MULTINATIONAL CORPOR
   Wolitz RE, 2019, INDIANA LAW J, V94, P1163
   WORLD HEALTH ORGANIZATION, 2020, ESS MED HKLTH PROD
   WORLD HEALTH ORGANIZATION, 2001, WTMIN01DECW2 WHO
   WORLD HEALTH ORGANIZATION, 2020, NUMB DEATHS DUE HIV
   WORLD TRADE ORGANIZATION, 1994, TRIPS AGR TRAD ASP I
   YAMIN Alicia Ely, 2017, POWER SUFFERING STRU
   YAMIN Alicia Ely, 2020, MISFORTUNE BECOMES I
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1475-4835
EI 1475-4843
J9 J HUM RIGHTS
JI J. Hum. Rights
PD OCT 19
PY 2020
VL 19
IS 5
BP 557
EP 567
DI 10.1080/14754835.2020.1820315
PG 11
WC International Relations; Political Science
SC International Relations; Government & Law
GA OQ0BX
UT WOS:000588459000006
OA Bronze
DA 2021-01-01
ER

PT J
AU Aronson, ID
   Bennett, AS
   Freeman, R
AF Aronson, Ian David
   Bennett, Alex S.
   Freeman, Robert
TI Toward a human-centered use of technology: a stakeholder analysis of
   harm reduction and CBO staff
SO HARM REDUCTION JOURNAL
LA English
DT Article
DE Technology; Harm reduction; Stakeholder; PWUD; COVID-19
AB Background Technology can enable syringe service programs (SSPs) and other community-based organizations (CBOs) operating under a harm reduction framework to work with an increased number of clients and can also enable organizations to offer services more effectively (e.g., offering HIV testing in ways participants may be more likely to accept). In the current time of COVID-19 social distancing, technology can also help organizations more safely provide services to people with compromised immune systems and to clients who might otherwise not be reached. However, technology projects implemented in harm reduction settings are frequently conceptualized and developed by researchers or technology specialists rather than by SSP staff or clients. Methods To more effectively meet the needs of SSPs and other CBOs across the USA, our team conducted qualitative interviews with 16 individuals who have extensive backgrounds working in the field of harm reduction. Interviews were digitally recorded and professionally transcribed, and the transcripts were checked for accuracy by the interviewers. The resulting transcripts were coded and analyzed to determine emerging themes. Results Interviewees mentioned the ability of technology to deliver consistent quality messaging to multiple clients at the same time and the potential to customize or tailor technology-based messaging to specific client populations as positive benefits. Clear barriers to technology use also emerged, in particular regarding privacy, data security, and the need to maintain client trust when discussing sensitive issues (e.g., illicit drug use). Conclusions Technology offers the potential to deliver consistently high-quality health communication and maintain contact with clients who may have no other access to care. If designed and managed effectively, technology can also address issues related to providing services during times when physical contact is limited due to COVID-19 social distancing measures.
C1 [Aronson, Ian David; Bennett, Alex S.] Digital Hlth Empowerment, Brooklyn, NY 11215 USA.
   [Aronson, Ian David; Bennett, Alex S.; Freeman, Robert] NYU, Sch Global Publ Hlth, New York, NY USA.
RP Aronson, ID (corresponding author), Digital Hlth Empowerment, Brooklyn, NY 11215 USA.
EM ian@dhempowerment.com
OI Aronson, Ian/0000-0002-2238-3810
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   DevelopmentUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [NICHD R42
   HD088325, NICHD R42 HD088325-02A1S1]; National Institute on Drug
   AbuseUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA) [P30 DA029926, P30 DA011041]
FX Funding was provided by Eunice Kennedy Shriver National Institute of
   Child Health and Human Development (Grant Nos. NICHD R42 HD088325, NICHD
   R42 HD088325-02A1S1). National Institute on Drug Abuse (Grant Nos. P30
   DA029926, P30 DA011041).
CR Aarons GA, 2009, AM J PUBLIC HEALTH, V99, P2087, DOI 10.2105/AJPH.2009.161711
   [Anonymous], 2020, BAD DATE LIST INCIDE
   Aronson ID, 2020, AIDS BEHAV, V24, P475, DOI 10.1007/s10461-019-02517-5
   Aronson ID, 2020, CUREUS, V12, DOI 10.7759/cureus.7209
   Aronson ID, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00217
   Aronson ID, 2013, TRANSL BEHAV MED, V3, P234, DOI 10.1007/s13142-012-0137-4
   Aronson ID, 2020, COLL PROBLEMS DRUG D
   Baernholdt M, 2018, J NURS CARE QUAL, V33, P149, DOI 10.1097/NCQ.0000000000000292
   Bandura A., 1986, SOCIAL FDN THOUGHT A
   Bandura A, 1994, PREVENTING AIDS THEO, P173
   Bennett AS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179054
   Bennett AS, 2020, SMS REPORTING SUBSTA
   Brugha R, 2000, HEALTH POLICY PLANN, V15, P239, DOI 10.1093/heapol/15.3.239
   Dallery J, 2017, ADDICTION, V112, P875, DOI 10.1111/add.13715
   Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50
   Drucker E, 2016, J BIOETHIC INQ, V13, P239, DOI 10.1007/s11673-016-9720-6
   Dunlop A, 2020, HARM REDUCT J, V17, DOI 10.1186/s12954-020-00370-7
   FISHER JD, 1992, PSYCHOL BULL, V111, P455, DOI 10.1037/0033-2909.111.3.455
   Gagne R.M., 2005, PRINCIPLES INSTRUCTI
   Garland AF, 2004, PSYCHIAT SERV, V55, P671, DOI 10.1176/appi.ps.55.6.671
   Glick SN, 2020, AIDS BEHAV, V24, P2466, DOI 10.1007/s10461-020-02886-2
   Golub SA, 2019, INT J ADOLESC MED HL
   Greenhalgh T, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.8775
   Hedegaard H, 2020, DRUG OVERDOSE DEATHS
   Holtyn AF, 2019, CONT CLIN TRIAL COMM, V15, DOI 10.1016/j.conctc.2019.100392
   Hosseinichimeh N, 2019, SYST RES BEHAV SCI, V36, P476, DOI 10.1002/sres.2563
   Mackenzie SLC, 2007, J ADOLESCENT HEALTH, V40, P572
   Marlatt GA, 1996, ADDICT BEHAV, V21, P779, DOI 10.1016/0306-4603(96)00042-1
   Marsch LA, 2006, J CHILD ADOLES SUBST, V16, P69, DOI 10.1300/J029v16n02_04
   May C, 2009, SOCIOLOGY, V43, P535, DOI 10.1177/0038038509103208
   Mayer R. E., 2005, CAMBRIDGE HDB MULTIM
   Mayer RE, 2003, EDUC PSYCHOL-US, V38, P43, DOI 10.1207/S15326985EP3801_6
   Moore Sarah K, 2019, JMIR Form Res, V3, pe12389, DOI 10.2196/12389
   Suffoletto B, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/mhealth.8530
   Thingiverse, 2020, AB
   Torian LV, 2018, AM J PUBLIC HEALTH, V108, P652, DOI 10.2105/AJPH.2018.304321
NR 36
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7517
J9 HARM REDUCT J
JI Harm Reduct. J.
PD OCT 19
PY 2020
VL 17
IS 1
AR 77
DI 10.1186/s12954-020-00422-y
PG 11
WC Substance Abuse
SC Substance Abuse
GA OM0ZB
UT WOS:000585757900001
PM 33076911
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lucchetta, M
   Pellegrini, M
AF Lucchetta, Marta
   Pellegrini, Marco
TI Finding disease modules for cancer and COVID-19 in gene co-expression
   networks with the Core&Peel method
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENRICHMENT ANALYSIS; MOLECULAR NETWORKS; EBOLA-VIRUS; WEB SERVER;
   MERS-COV; CORONAVIRUS; IDENTIFICATION; CHLOROQUINE; INFECTION;
   INHIBITION
AB Genes are organized in functional modules (or pathways), thus their action and their dysregulation in diseases may be better understood by the identification of the modules most affected by the disease (aka disease modules, or active subnetworks). We describe how an algorithm based on the Core&Peel method is used to detect disease modules in co-expression networks of genes. We first validate Core&Peel for the general task of functional module detection by comparison with 42 methods participating in the Disease Module Identification DREAM challenge. Next, we use four specific disease test cases (colorectal cancer, prostate cancer, asthma, and rheumatoid arthritis), four state-of-the-art algorithms (ModuleDiscoverer, Degas, KeyPathwayMiner, and ClustEx), and several pathway databases to validate the proposed algorithm. Core&Peel is the only method able to find significant associations of the predicted disease module with known validated relevant pathways for all four diseases. Moreover, for the two cancer datasets, Core&Peel detects further eight relevant pathways not discovered by the other methods used in the comparative analysis. Finally, we apply Core&Peel and other methods to explore the transcriptional response of human cells to SARS-CoV-2 infection, finding supporting evidence for drug repositioning efforts at a pre-clinical level.
C1 [Lucchetta, Marta; Pellegrini, Marco] CNR, Inst Informat & Telemat IIT, I-56124 Pisa, Italy.
   [Lucchetta, Marta] Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy.
RP Lucchetta, M; Pellegrini, M (corresponding author), CNR, Inst Informat & Telemat IIT, I-56124 Pisa, Italy.
EM marco.pellegrini@iit.cnr.it
CR Alcaraz N, 2011, INTERNET MATH, V7, P299, DOI 10.1080/15427951.2011.604548
   Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272
   Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   Barrett T, 2011, NUCLEIC ACIDS RES, V39, pD1005, DOI 10.1093/nar/gkq1184
   Bautista DM, 2013, ANNU REV PHYSIOL, V75, P181, DOI 10.1146/annurev-physiol-030212-183811
   Bertin S, 2014, NAT IMMUNOL, V15, P1055, DOI 10.1038/ni.3009
   Blanco-Melo D., 2020, BIORXIV
   Bryson-Cahn C, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz028
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carnevale V, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9030052
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chen T., 2020, POSITIVE EPSTEIN BAR
   Choobdar S., 2018, BIORXIV, DOI [10.1101/265553, DOI 10.1101/265553]
   Choobdar S, 2019, NAT METHODS, V16, P843, DOI 10.1038/s41592-019-0509-5
   Chowdhury HA, 2020, IEEE ACM T COMPUT BI, V17, P1154, DOI 10.1109/TCBB.2019.2893170
   Chuang HY, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100180
   Chuang HY, 2012, BLOOD, V120, P2639, DOI 10.1182/blood-2012-03-416461
   Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507
   Csermely P, 2013, PHARMACOL THERAPEUT, V138, P333, DOI 10.1016/j.pharmthera.2013.01.016
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Eastman R. T, 2020, ACS CENTRAL SCI
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Gaire R.K, 2013, BMC BIOINFORMATICS, V14, P1
   Girvan M, 2002, P NATL ACAD SCI USA, V99, P7821, DOI 10.1073/pnas.122653799
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gov E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05298-w
   Gu J, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-47
   Hamosh A, 2002, NUCLEIC ACIDS RES, V30, P52, DOI 10.1093/nar/30.1.52
   Harapan H., 2020, J INFECT PUBLIC HLTH
   Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036
   He H, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1567-2
   Hoffmann M, 2020, NATURE, V585, P588, DOI 10.1038/s41586-020-2575-3
   Huang JK, 2018, CELL SYST, V6, P484, DOI 10.1016/j.cels.2018.03.001
   Huczynski A, 2011, J ANTIBIOT, V64, P249, DOI 10.1038/ja.2010.167
   Nguyen H, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00155
   Iannone R, 2018, R PACKAGE VERSION 1
   Ideker T., 2012, MOL SYST BIOL, V8
   Ideker T, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005771
   Ideker Trey, 2002, Bioinformatics, V18 Suppl 1, pS233
   Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941
   Jazzi A. S., 2020, PREPRINT
   Jockusch S, 2020, BIORXIV
   Jockusch S, 2020, ANTIVIR RES, V180, DOI 10.1016/j.antiviral.2020.104857
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   KAYE MG, 1990, CHEST, V97, P788, DOI 10.1378/chest.97.4.788
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Kohler S, 2017, NUCLEIC ACIDS RES, V45, pD865, DOI 10.1093/nar/gkw1039
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Kumar N., 2020, BIORXIV, DOI [10.1101/2020.04.09.033910, DOI 10.1101/2020.04.09.033910]
   Kunowska N, 2015, NUCLEIC ACIDS RES, V43, P1418, DOI 10.1093/nar/gku1350
   Lamparter D, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004714
   Levi H., 2020, BIORXIV
   LIANG YF, 1990, FEBS LETT, V275, P143, DOI 10.1016/0014-5793(90)81459-2
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Mendes RE, 2014, ANTIMICROB AGENTS CH, V58, P2921, DOI 10.1128/AAC.02482-13
   Mitra K, 2013, NAT REV GENET, V14, P719, DOI 10.1038/nrg3552
   Moran MM, 2011, NAT REV DRUG DISCOV, V10, P601, DOI 10.1038/nrd3456
   Morselli Gysi D., 2020, ARXIV200407229
   Mounir M, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006701
   Ofstead CL, 2020, INFECT CONT HOSP EP, V41, P862, DOI 10.1017/ice.2020.102
   Pardo J., 2020, DRUGS CONTEXT, V9
   Pastick KA, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa130
   Pellegrini M., 2020, NETWORK BIOSCIENCE
   Pellegrini M, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1191-6
   Pico AR, 2008, PLOS BIOL, V6, P1403, DOI 10.1371/journal.pbio.0060184
   Pinero J., 2019, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Pletscher-Frankild S, 2015, METHODS, V74, P83, DOI 10.1016/j.ymeth.2014.11.020
   R Core Team, 2019, R LANG ENV STAT COMP
   Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Silva T. C, 2016, F1000RESEARCH, V5
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   Taylor IW, 2009, NAT BIOTECHNOL, V27, P199, DOI 10.1038/nbt.1522
   Tripathi B, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00164
   Tsai CY, 2018, INFECT DRUG RESIST, V11, P1205, DOI 10.2147/IDR.S171236
   Ulitsky I., 2010, PLOS ONE, V5
   Ulitsky I, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-8
   van Dam S, 2018, BRIEF BIOINFORM, V19, P575, DOI 10.1093/bib/bbw139
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Vlaic S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18370-2
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wickham H., 2016, GGPLOT2 ELEGANT GRAP
   Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Yao X, 2020, CLIN INFECT DIS
   Yu GC, 2016, MOL BIOSYST, V12, P477, DOI 10.1039/c5mb00663e
   Zhang K, 2017, DESTECH TRANS ECON, P1
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zitnik M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04948-5
   Zsembery a, 2020, BICARBONATE ANCIENT
NR 97
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 19
PY 2020
VL 10
IS 1
AR 17628
DI 10.1038/s41598-020-74705-6
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OL2RT
UT WOS:000585190100026
PM 33077837
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Brochot, E
   Demey, B
   Touze, A
   Belouzard, S
   Dubuisson, J
   Schmit, JL
   Duverlie, G
   Francois, C
   Castelain, S
   Helle, F
AF Brochot, Etienne
   Demey, Baptiste
   Touze, Antoine
   Belouzard, Sandrine
   Dubuisson, Jean
   Schmit, Jean-Luc
   Duverlie, Gilles
   Francois, Catherine
   Castelain, Sandrine
   Helle, Francois
TI Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2
   Inpatients and Asymptomatic Individuals
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; spike; nucleocapsid; neutralizing antibodies;
   vaccine; convalescent plasma therapy
AB A better understanding of the anti-SARS-CoV-2 immune response is necessary to finely evaluate commercial serological assays but also to predict protection against reinfection and to help the development of vaccines. For this reason, we monitored the anti-SARS-CoV-2 antibody response in infected patients. In order to assess the time of seroconversion, we used 151 samples from 30 COVID-19 inpatients and monitored the detection kinetics of anti-S1, anti-S2, anti-RBD and anti-N antibodies with in-house ELISAs. We observed that specific antibodies were detectable in all inpatients 2 weeks post-symptom onset and that the detection of the SARS-CoV-2 Nucleocapsid and RBD was more sensitive than the detection of the S1 or S2 subunits. Using retroviral particles pseudotyped with the spike of the SARS-CoV-2, we also monitored the presence of neutralizing antibodies in these samples as well as 25 samples from asymptomatic individuals that were shown SARS-CoV-2 seropositive using commercial serological tests. Neutralizing antibodies reached a plateau 2 weeks post-symptom onset and then declined in the majority of inpatients but they were undetectable in 56% of asymptomatic patients. Our results indicate that the SARS-CoV-2 does not induce a prolonged neutralizing antibody response. They also suggest that induction of neutralizing antibodies is not the only strategy to adopt for the development of a vaccine. Finally, they imply that anti-SARS-CoV-2 neutralizing antibodies should be titrated to optimize convalescent plasma therapy.
C1 [Brochot, Etienne; Demey, Baptiste; Schmit, Jean-Luc; Duverlie, Gilles; Francois, Catherine; Castelain, Sandrine] Amiens Univ, Med Ctr, Dept Virol, Amiens, France.
   [Brochot, Etienne; Demey, Baptiste; Schmit, Jean-Luc; Duverlie, Gilles; Francois, Catherine; Castelain, Sandrine; Helle, Francois] Jules Verne Univ Picardie, AGIR Res Unit, UR UPJV 4294, Amiens, France.
   [Touze, Antoine] Univ Tours, INRA, ISP1282, Tours, France.
   [Belouzard, Sandrine; Dubuisson, Jean] Univ Lille, CNRS, CIIL Ctr Infect & Immunity Lille, INSERM,CHU Lille,Inst Pasteur Lille,UMR 8204,U101, Lille, France.
RP Helle, F (corresponding author), Jules Verne Univ Picardie, AGIR Res Unit, UR UPJV 4294, Amiens, France.
EM francois.helle@u-picardie.fr
RI BROCHOT, ETIENNE/I-5318-2012; HELLE, Francois/G-7427-2011
OI BROCHOT, ETIENNE/0000-0002-8677-6349; HELLE,
   Francois/0000-0001-6884-2456
FU Amiens University Hospital; French "Agence Nationale de la
   Recherche"French National Research Agency (ANR)
FX This work was supported by the Flash Covid-19 funds from the Amiens
   University Hospital and the French "Agence Nationale de la Recherche".
CR Brochot E., 2020, ANTISPIKE ANTINUCLEO, DOI [10.1101/2020.05.12.20098236, DOI 10.1101/2020.05.12.20098236]
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cox RJ, 2020, NAT REV IMMUNOL, V20, P581, DOI 10.1038/s41577-020-00436-4
   Demey B, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.033
   Fafi-Kremer S, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102915
   Kirkcaldy RD, 2020, JAMA-J AM MED ASSOC, V323, P2245, DOI 10.1001/jama.2020.7869
   Ko JH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072268
   Kruttgen A, 2020, J CLIN VIROL, V128
   Liu L, 2020, EMERG MICROBES INFEC, V9, P1664, DOI 10.1080/22221751.2020.1791738
   Lowe DA, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.4153
   Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018
   Millet Jean Kaoru, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.2035
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Ota Miyo, 2020, Nat Rev Immunol, V20, P351, DOI 10.1038/s41577-020-0316-3
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Schmidt F, 2020, J EXP MED, V217, DOI 10.1084/jem.20201181
   Sekine T, 2020, CELL
   Seow G., 2020, LONGITUDINAL EVALUAT, DOI [10.1101/2020.07.09.20148429., 10.1101/2020.07.09.20148429, DOI 10.1101/2020.07.09.20148429]
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   WANG KX, 2020, PROC SPIE, V1437, DOI DOI 10.1093/CID/CIAA1143
   Wang X, 2020, NEUTRALIZING ANTIBOD, DOI [10. 1101/2020.04.15.20065623, DOI 10.1101/2020.04.15.20065623]
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 27
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD OCT 19
PY 2020
VL 11
AR 584251
DI 10.3389/fmicb.2020.584251
PG 8
WC Microbiology
SC Microbiology
GA OI4RI
UT WOS:000583267400001
PM 33193227
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xu, YH
   Xu, ZH
   Liu, XS
   Cai, LH
   Zheng, HC
   Huang, YB
   Zhou, LX
   Huang, LX
   Ling, Y
   Deng, LH
   Li, JW
   Chen, SB
   Liu, DD
   Lin, ZM
   Zhou, L
   He, WQ
   Zhong, NS
   Liu, XQ
   Li, YM
AF Xu, Yonghao
   Xu, Zhiheng
   Liu, Xuesong
   Cai, Lihua
   Zheng, Haichong
   Huang, Yongbo
   Zhou, Lixin
   Huang, Linxi
   Ling, Yun
   Deng, Liehua
   Li, Jianwei
   Chen, Sibei
   Liu, Dongdong
   Lin, Zhimin
   Zhou, Liang
   He, Weiqun
   Zhong, Nanshan
   Liu, Xiaoqing
   Li, Yimin
TI Clinical Findings of COVID-19 Patients Admitted to Intensive Care Units
   in Guangdong Province, China: A Multicenter, Retrospective,
   Observational Study
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE intensive care unit; COVID-19; SARS-CoV-2; critically ill; mortality
ID PNEUMONIA; MORTALITY; WUHAN; H1N1; RISK
AB Background: Information about critically ill patients with coronavirus disease 2019 (COVID-19) in China but outside of Wuhan is scarce. We aimed to describe the clinical features, treatment, and outcomes of patients with COVID-19 admitted to the intensive care unit (ICU) in Guangdong Province.
   Methods: In this multicenter, retrospective, observational study, we enrolled consecutive patients with COVID-19 who were admitted to seven ICUs in Guangdong Province. Demographic data, symptoms, laboratory findings, comorbidities, treatment, and outcomes were collected. Data were compared between patients with and without intubation.
   Results: A total of 45 COVID-19 patients required ICU admission in the study hospitals [mean age 56.7 +/- 15.4 years, 29 males (64.4%)]. The most common symptoms at onset were fever and cough. Most patients presented with lymphopenia and elevated lactate dehydrogenase. Treatment with antiviral drugs was initiated in all patients. Thirty-six patients (80%) developed acute respiratory distress syndrome at ICU admission, and 15 (33.3%) septic shock. Twenty patients (44.4%) were intubated, and 10 (22.2%) received extracorporeal membrane oxygenation. The 60-day mortality was 4.4% (2 of 45).
   Conclusion: COVID-19 patients admitted to ICU were characterized by fever, lymphopenia, acute respiratory failure, and multiple organ dysfunction. The mortality of ICU patients in Guangdong Province was relatively low with a small sample size.
C1 [Xu, Yonghao; Xu, Zhiheng; Liu, Xuesong; Zheng, Haichong; Huang, Yongbo; Chen, Sibei; Liu, Dongdong; Lin, Zhimin; Zhou, Liang; He, Weiqun; Zhong, Nanshan; Liu, Xiaoqing; Li, Yimin] Guangzhou Med Univ, State Key Lab Resp Dis, Dept Crit Care Med, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Cai, Lihua] Dongguan Peoples Hosp, Dept Crit Care Med, Dongguan, Peoples R China.
   [Zhou, Lixin] Foshan First Peoples Hosp, Dept Crit Care Med, Foshan, Peoples R China.
   [Huang, Linxi] Shantou Univ, Dept Crit Care Med, Affiliated Hosp 1, Coll Med, Shantou, Peoples R China.
   [Ling, Yun] Huizhou Municipal Cent Hosp, Dept Crit Care Med, Huizhou, Peoples R China.
   [Deng, Liehua] Guangdong Med Univ, Dept Crit Care Med, Affiliated Hosp, Zhanjiang, Peoples R China.
   [Li, Jianwei] Zhongshan City Peoples Hosp, Dept Crit Care Med, Zhongshan, Peoples R China.
RP Liu, XQ; Li, YM (corresponding author), Guangzhou Med Univ, State Key Lab Resp Dis, Dept Crit Care Med, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, Guangzhou, Peoples R China.
EM lxq1118@126.com; dryiminli@vip.163.com
FU National Science and Technology Major Project [2017ZX10204401]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81970071, 81870069, 81700080]; National Key Research
   and Development Program of China [2020YFC0841300, 2020YFC0845100,
   2018YFC1200100]; Special Project of Guangdong Science and Technology
   Department [2020B111105001]; Science and Technology Program of
   Guangzhou, China [202008040003]
FX This study was funded by the National Science and Technology Major
   Project (Grant no. 2017ZX10204401), National Natural Science Foundation
   of China (Grant nos. 81970071, 81870069, and 81700080), National Key
   Research and Development Program of China (Grant nos. 2020YFC0841300,
   2020YFC0845100, and 2018YFC1200100), the Special Project of Guangdong
   Science and Technology Department (Grant no. 2020B111105001), and the
   Science and Technology Program of Guangzhou, China (Grant no.
   202008040003).
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Eaaswarkhanth M, 2020, INT J INFECT DIS, V96, P459, DOI 10.1016/j.ijid.2020.05.071
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Ito T, 2018, INTERNAL MED, V57, P1819, DOI 10.2169/internalmedicine.0316-17
   Kellum JA, 2013, CRIT CARE, V17, DOI 10.1186/cc11454
   Ko JH, 2016, J INFECTION, V73, P468, DOI 10.1016/j.jinf.2016.08.005
   Korber B, 2020, SPIKE MUTATION PIPEL, V12, P122, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   National Health Commission of the People's Republic of China, 2020, CHINESE MANAGEMENT G
   O'Donnell R, 2003, BRIT MED J, V327, P620, DOI 10.1136/bmj.327.7415.620-b
   Qiu HB, 2020, INTENS CARE MED, V46, P576, DOI 10.1007/s00134-020-05966-y
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   SCHUSTER DP, 1984, AM J MED, V76, P623, DOI 10.1016/0002-9343(84)90286-9
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Toyoshima Y, 2020, J HUM GENET, V65, P1075, DOI 10.1038/s10038-020-0808-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang JJ, 2017, BRAZ J INFECT DIS, V21, P12, DOI 10.1016/j.bjid.2016.10.005
   Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC
   Xie JF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.5619
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 35
TC 1
Z9 1
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD OCT 19
PY 2020
VL 7
AR 576457
DI 10.3389/fmed.2020.576457
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA OI4NE
UT WOS:000583256600001
PM 33195325
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Negri, EM
   Piloto, BM
   Morinaga, LK
   Jardim, CVP
   Lamy, SAE
   Ferreira, MA
   D'Amico, EA
   Deheinzelin, D
AF Negri, Elnara Marcia
   Piloto, Bruna Mamprim
   Morinaga, Luciana Kato
   Jardim, Carlos Viana Poyares
   Lamy, Shari Anne El-Dash
   Ferreira, Marcelo Alves
   D'Amico, Elbio Antonio
   Deheinzelin, Daniel
TI Heparin Therapy Improving Hypoxia in COVID-19 Patients - A Case Series
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE COVID-19; respiratory failure; thrombosis; perfusion mismatch; heparin
AB Introduction Elevated D-dimer is a predictor of severity and mortality in COVID-19 patients, and heparin use during in-hospital stay has been associated with decreased mortality. COVID-19 patient autopsies have revealed thrombi in the microvasculature, suggesting that hypercoagulability is a prominent feature of organ failure in these patients. Interestingly, in COVID-19, pulmonary compliance is preserved despite severe hypoxemia corroborating the hypothesis that perfusion mismatch may play a significant role in the development of respiratory failure. Methods We describe a series of 27 consecutive COVID-19 patients admitted to Sirio-Libanes Hospital in Sao Paulo-Brazil and treated with heparin in therapeutic doses tailored to clinical severity. Results PaO2/FiO2 ratio increased significantly over the 72 h following the start of anticoagulation, from 254(+/- 90) to 325(+/- 80), p = 0.013, and 92% of the patients were discharged home within a median time of 11 days. There were no bleeding complications or fatal events. Discussion Even though this uncontrolled case series does not offer absolute proof that micro thrombosis in the pulmonary circulation is the underlying mechanism of respiratory failure in COVID-19, patient's positive response to heparinization contributes to the understanding of the pathophysiological mechanism of the disease and provides valuable information for the treatment of these patients while we await the results of further prospective controlled studies.
C1 [Negri, Elnara Marcia; Piloto, Bruna Mamprim; Morinaga, Luciana Kato; Jardim, Carlos Viana Poyares; Deheinzelin, Daniel] Sirio Libanes Hosp, Sao Paulo, Brazil.
   [Negri, Elnara Marcia; Ferreira, Marcelo Alves] Univ Sao Paulo, Hosp Clin, Cell Biol Lab LIM 59, Sch Med, Sao Paulo, Brazil.
   [Piloto, Bruna Mamprim; Morinaga, Luciana Kato; Jardim, Carlos Viana Poyares] Univ Sao Paulo, Dept Pulm, Inst Heart, Sch Med, Sao Paulo, Brazil.
   [Lamy, Shari Anne El-Dash] AC Camargo Canc Ctr, CriticalCare Unit, Sao Paulo, Brazil.
   [D'Amico, Elbio Antonio] Univ Sao Paulo, Dept Hematol & Hemotherapy, Sch Med, Sao Paulo, Brazil.
RP Negri, EM (corresponding author), Sirio Libanes Hosp, Sao Paulo, Brazil.; Negri, EM (corresponding author), Univ Sao Paulo, Hosp Clin, Cell Biol Lab LIM 59, Sch Med, Sao Paulo, Brazil.
EM emnegri@yahoo.com.br
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Ayerbe L, 2020, J THROMB THROMBOLYS, V50, P298, DOI 10.1007/s11239-020-02162-z
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Burzynski LC, 2019, IMMUNITY, V50, P1033, DOI 10.1016/j.immuni.2019.03.003
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cramer CL, 2017, POSTGRAD MED, V129, P493, DOI 10.1080/00325481.2017.1285677
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   Gai ZT, 2012, J INFECT DIS, V206, P1095, DOI 10.1093/infdis/jis472
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Iba T, 2020, J THROMB HAEMOST, V18, P2103, DOI 10.1111/jth.14975
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lins M, 2020, ACAD RADIOL, V27, P1449, DOI 10.1016/j.acra.2020.07.019
   Lobete C, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2012.12.006
   Mauri T, 2020, CRIT CARE MED, V48, P1129, DOI 10.1097/CCM.0000000000004386
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Middleton EA, 2020, BLOOD, V136, P1169, DOI 10.1182/blood.2020007008
   Negri EM, 2020, HEPARIN THERAPY IMPR
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Rauch A, 2020, J THROMB HAEMOST, V18, P2942, DOI 10.1111/jth.15067
   Subramaniam S, 2018, FRONT BIOSCI-LANDMRK, V23, P1060, DOI 10.2741/4633
   Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   van Dam LF, 2020, THROMB RES, V193, P86, DOI 10.1016/j.thromres.2020.06.010
   Wada H, 2014, CLIN CHIM ACTA, V436, P130, DOI 10.1016/j.cca.2014.04.020
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Wilson AJ, 2016, CLIN INFECT DIS, V62, P610, DOI 10.1093/cid/civ977
   World Health Organization, 2020, COR DIS COVID 2019 R
   Wright FL, 2020, J AM COLL SURGEONS, V231, P193, DOI 10.1016/j.jamcollsurg.2020.05.007
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Ye Z, 2020, EUR RADIOL, V30, P4381, DOI 10.1007/s00330-020-06801-0
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 42
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD OCT 19
PY 2020
VL 11
AR 573044
DI 10.3389/fphys.2020.573044
PG 7
WC Physiology
SC Physiology
GA OI4PX
UT WOS:000583263700001
PM 33192569
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Taylor, S
   Landry, CA
   Paluszek, MM
   Groenewoud, R
   Rachor, GS
   Asmundson, GJG
AF Taylor, Steven
   Landry, Caeleigh A.
   Paluszek, Michelle M.
   Groenewoud, Rosalind
   Rachor, Geoffrey S.
   Asmundson, Gordon J. G.
TI A Proactive Approach for Managing COVID-19: The Importance of
   Understanding the Motivational Roots of Vaccination Hesitancy for
   SARS-CoV2
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE COVID-19; SARSCoV2; pandemic; coronavirus; vaccination; vaccination
   hesitancy; vaccination attitudes
AB Importance Vaccination hesitancy-the reluctance or refusal to be vaccinated-is a leading global health threat (World Health Organization, 2019). It is imperative to identify the prevalence of vaccination hesitancy for SARS-CoV2 in order to understand the scope of the problem and to identify its motivational roots in order to proactively prepare to address the problem when a vaccine eventually becomes available. Objective To identify (1) the prevalence of vaccination hesitancy for a SARS-CoV2 vaccine, (2) the motivational roots of this hesitancy, and (3) the most promising incentives for improving the likelihood of vaccination uptake when a vaccine does become available. Design, Setting, and Participants A cross-sectional sample of 3,674 American and Canadian adults assessed during the COVID-19 pandemic in May 2020. Main Outcomes Measures of vaccination intention (i.e., "If a vaccine for COVID-19 was available, would you get vaccinated?"), attitudes toward vaccines in general and specific to SARS-CoV2 using the Vaccination Attitudes Examination Scale, and incentives for getting vaccinated for those who reported they would not get vaccinated. Results Many American (25%) and Canadian (20%) respondents said that they would not get vaccinated against SARS-CoV2 if a vaccine was available. Non-adherence rates of this magnitude would make it difficult or impossible to achieve herd immunity. Vaccine rejection was most strongly correlated with mistrust of vaccine benefit, and also correlated with worry about unforeseen future effects, concerns about commercial profiteering from pharmaceutical companies, and preferences for natural immunity. When asked about incentives for getting vaccinated, respondents were most likely to report that evidence for rigorous testing and safety of the vaccine were of greatest importance. Conclusions and Relevance Vaccination hesitancy is a major looming problem for COVID-19. To improve vaccine uptake, it is imperative that the vaccine is demonstrated to the public to be rigorously tested and not perceived as rushed or premature in its dissemination.
C1 [Taylor, Steven; Groenewoud, Rosalind] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada.
   [Landry, Caeleigh A.; Paluszek, Michelle M.; Rachor, Geoffrey S.; Asmundson, Gordon J. G.] Univ Regina, Dept Psychol, Regina, SK, Canada.
RP Taylor, S (corresponding author), Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada.
EM steven.taylor@ubc.ca
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [439751]; University of Regina
FX This research was supported by funding from the Canadian Institutes of
   Health Research (grant no. 439751) and the University of Regina.
CR Angus Reid Institute, 2020, COVID 19 THREE FIVE
   Bangerter A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049806
   Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z
   Bracken M., 2020, TREND WORRIES HLTH E
   Cohen J., 1988, STAT POWER ANAL BEHA
   Dodd Rachael H, 2020, Lancet Infect Dis, DOI 10.1016/S1473-3099(20)30559-4
   Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007
   Fisher Kimberly A, 2020, Ann Intern Med, V173, P964, DOI 10.7326/M20-3569
   Gallup P., 2020, ONE THREE AMERICANS
   Hornsey MJ, 2018, HEALTH PSYCHOL, V37, P307, DOI 10.1037/hea0000586
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Maltezou HC, 2019, EXPERT REV VACCINES, V18, P5, DOI 10.1080/14760584.2019.1552141
   Martin LR, 2017, ANN BEHAV MED, V51, P652, DOI 10.1007/s12160-017-9888-y
   McKie R., 2020, COVID 19 ONLY HALF B
   Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6
   Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8
   Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6
   Taylor S, 2020, FEM PSYCHOL, V30, P63, DOI 10.1177/0959353519864390
   U.S. Census Bureau, 2020, AGE SEX COMPOSITION
   U.S. Food & Drug Administration, 2020, FDA CAUTIONS USE HYD
   World Health Organization, 2019, TEN THREATS GLOBAL H
   World Health Organization, 2020, GUIDE TAILORING IMMU
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
NR 23
TC 0
Z9 0
U1 8
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD OCT 19
PY 2020
VL 11
AR 575950
DI 10.3389/fpsyg.2020.575950
PG 5
WC Psychology, Multidisciplinary
SC Psychology
GA OI4MT
UT WOS:000583255500001
PM 33192883
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chen, ZL
   Zhong, M
   Jiang, L
   Chen, NS
   Tu, SJ
   Wei, Y
   Sang, L
   Zheng, X
   Zhang, CY
   Tao, JL
   Deng, LH
   Song, YL
AF Chen, Zhenglong
   Zhong, Ming
   Jiang, Li
   Chen, Nanshan
   Tu, Shengjin
   Wei, Yuan
   Sang, Ling
   Zheng, Xia
   Zhang, Chunyuan
   Tao, Jiale
   Deng, Linhong
   Song, Yuanlin
TI Effects of the Lower Airway Secretions on Airway Opening Pressures and
   Suction Pressures in Critically Ill COVID-19 Patients: A Computational
   Simulation
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE Coronavirus disease 2019; Airway mucus; Airway opening pressure;
   Endotracheal suctioning; Respiratory mechanics
ID CLOSURE; MODEL
AB In patients with critically ill COVID-19 pneumonia, lower airways are filled with plenty of highly viscous exudates or mucus, leading to airway occlusion. The estimation of airway opening pressures and effective mucus clearance are therefore two issues that clinicians are most concerned about during mechanical ventilation. In this study we retrospectively analyzed respiratory data from 24 critically ill patients with COVID-19 who received invasive mechanical ventilation and recruitment maneuver at Jinyintan Hospital in Wuhan, China. Among 24 patients, the mean inspiratory plateau pressure was 52.4 +/- 4.4 cmH(2)O (mean +/- [SD]). Particularly, the capnograms presented an upward slope during the expiratory plateau, indicting the existence of airway obstruction. A computational model of airway opening was subsequently introduced to investigate possible fluid dynamic mechanisms for the extraordinarily high inspiratory plateau pressures among these patients. Our simulation results showed that the predicted airway opening pressures could be as high as 40-50 cmH(2)O and the suction pressure could exceed 20 kPa as the surface tension and viscosity of secretion simulants markedly increased, likely causing the closures of the distal airways. We concluded that, in some critically ill patients with COVID-19, limiting plateau pressure to 30 cmH(2)O may not guarantee the opening of airways due to the presence of highly viscous lower airway secretions, not to mention spontaneous inspiratory efforts. Active airway humidification and effective expectorant drugs are therefore strongly recommended during airway management.
C1 [Chen, Zhenglong] Shanghai Univ Med & Hlth Sci, Sch Med Instrumentat, 257 Tianxiong Rd, Shanghai 201318, Peoples R China.
   [Zhong, Ming; Tao, Jiale] Fudan Univ, Zhongshan Hosp, Dept Intens Care Med, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
   [Jiang, Li] Capital Med Univ, Xuanwu Hosp, Dept Crit Care Med, 45 Changchun St, Beijing 100053, Peoples R China.
   [Chen, Nanshan; Tu, Shengjin; Wei, Yuan] Wuhan Jinyintan Hosp, Dept Resp & Crit Care Med, 1 Yintan Rd, Wuhan 430023, Peoples R China.
   [Sang, Ling] Guangzhou Med Univ, Affiliated Hosp 1, GuangZhou Inst Resp Hlth, Dept Crit Care Med, 151 Yanjiangxi Rd, Guangzhou 510120, Peoples R China.
   [Zheng, Xia] Zhejiang Univ, Affiliated Hosp 1, Dept Crit Care Med, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhang, Chunyuan] NMPA Key Lab Resp & Anaesthet Equipment, 1 Jinyinhua Rd, Shanghai 201321, Peoples R China.
   [Deng, Linhong] Changzhou Univ, Changzhou Key Lab Resp Med Engn, Inst Biomed Engn & Hlth Sci, Changzhou 213164, Jiangsu, Peoples R China.
   [Song, Yuanlin] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
RP Zhong, M (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Intens Care Med, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM zhong_ming@fudan.edu.cn
OI Chen, Zhenglong/0000-0002-4075-251X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81971807, 11532003, 31670950]; Special
   Project of the National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [82041003]
FX This work was supported by the National Natural Science Foundation of
   China (81971807, 11532003 and 31670950) and Special Project of the
   National Natural Science Foundation of China (82041003). We would like
   to express our gratitude to the patients who participated in this
   research and to all health-care workers involved in the diagnosis and
   treatment of patients in Wuhan.
CR Albaiceta GM, 2005, INTENS CARE MED, V31, P1370, DOI 10.1007/s00134-005-2746-6
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen ZL, 2015, J APPL PHYSIOL, V119, P190, DOI 10.1152/japplphysiol.00112.2015
   Chen ZL, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1229-1
   Crotti S, 2001, AM J RESP CRIT CARE, V164, P131, DOI 10.1164/ajrccm.164.1.2007011
   Fahy JV, 2010, NEW ENGL J MED, V363, P2233, DOI 10.1056/NEJMra0910061
   GAVER DP, 1990, J APPL PHYSIOL, V69, P74
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han SW, 2020, CANCER MED-US, V9, P6667, DOI 10.1002/cam4.3289
   HORSFIEL.K, 1971, J APPL PHYSIOL, V31, P207
   HORSFIELD K, 1982, J APPL PHYSIOL, V52, P21
   Hsu SH, 1996, J APPL PHYSIOL, V80, P1649
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   HUGHES JMB, 1970, J APPL PHYSIOL, V29, P340
   Kacmarek RM, 2016, CRIT CARE MED, V44, P32, DOI 10.1097/CCM.0000000000001383
   Krauss B, 2005, ANESTH ANALG, V100, P884, DOI 10.1213/01.ANE.0000146520.90393.91
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P86, DOI 10.1016/j.addr.2008.09.012
   Lindgren S, 2004, INTENS CARE MED, V30, P1630, DOI 10.1007/s00134-003-2153-9
   Low HT, 1997, J BIOMECH ENG-T ASME, V119, P298, DOI 10.1115/1.2796094
   Lowe DA, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.4153
   Lumb A, 2010, NUNNS APPL RESP PHYS
   MACKLEM PT, 1970, RESP PHYSIOL, V8, P191, DOI 10.1016/0034-5687(70)90015-0
   MCEWAN AD, 1966, J FLUID MECH, V26, P1, DOI 10.1017/S0022112066001058
   OTIS DR, 1993, J APPL PHYSIOL, V75, P1323
   Poston J.T, 2020, JAMA
   Siobal MS, 2016, RESP CARE, V61, P1397, DOI 10.4187/respcare.04919
   SUKI B, 1994, NATURE, V368, P615, DOI 10.1038/368615a0
   Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Xu Z, 2020, LANCET RESP MED
   YAP DYK, 1994, J APPL PHYSIOL, V76, P2095
   刘茜, 2020, [法医学杂志, Journal of Forensic Medicine], V36, P21
NR 33
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0090-6964
EI 1573-9686
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD DEC
PY 2020
VL 48
IS 12
BP 3003
EP 3013
DI 10.1007/s10439-020-02648-0
EA OCT 2020
PG 11
WC Engineering, Biomedical
SC Engineering
GA PD4VU
UT WOS:000579677200001
PM 33078367
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wang, JH
   Li, X
   Wang, A
   Zhao, FXN
   Wu, Q
   Li, L
   Yu, HZ
   Wu, JP
   Chen, HY
AF Wang, Jianhai
   Li, Xue
   Wang, An
   Zhao, Fuxiaonan
   Wu, Qi
   Li, Li
   Yu, Hongzhi
   Wu, Junping
   Chen, Huaiyong
TI Organoid technology demonstrates effects of potential drugs for COVID-19
   on the lung regeneration
SO CELL PROLIFERATION
LA English
DT Letter
C1 [Wang, Jianhai; Li, Xue; Chen, Huaiyong] Tianjin Univ, Haihe Hosp, Dept Basic Med, Tianjin, Peoples R China.
   [Wang, Jianhai; Li, Xue; Wang, An; Zhao, Fuxiaonan; Chen, Huaiyong] Tianjin Med Univ, Haihe Clin Coll, Dept Basic Med, Tianjin, Peoples R China.
   [Wu, Qi; Wu, Junping] Tianjin Univ, Haihe Hosp, Dept TB, 890 Jingu Rd, Tianjin 300350, Peoples R China.
   [Li, Li; Yu, Hongzhi] Tianjin Univ, Haihe Hosp, Dept Resp Med, 890 Jingu Rd, Tianjin 300350, Peoples R China.
   [Yu, Hongzhi; Chen, Huaiyong] Tianjin Inst Resp Dis, Key Res Lab Infect Dis Prevent, State Adm Tradit Chinese Med, Tianjin, Peoples R China.
   [Chen, Huaiyong] Tianjin Key Lab Lung Regenerat Med, Tianjin, Peoples R China.
RP Wu, JP (corresponding author), Tianjin Univ, Haihe Hosp, Dept TB, 890 Jingu Rd, Tianjin 300350, Peoples R China.; Yu, HZ (corresponding author), Tianjin Univ, Haihe Hosp, Dept Resp Med, 890 Jingu Rd, Tianjin 300350, Peoples R China.; Chen, HY (corresponding author), Tianjin Univ, Haihe Hosp, Tianjin Key Lab Lung Regenerat Med, 890 Jingu Rd, Tianjin 300350, Peoples R China.
EM 13512205663@163.com; wujp0618@126.com; huaiyong.chen@foxmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81773394, 81970001, 82070001]; Natural
   Science Foundation of TianjinNatural Science Foundation of Tianjin
   [18ZXDBSY00150, 19JCZDJC33600]
FX We are grateful to Dr Zichuan Liu at Tianjin University for critical
   review and constructive advice. This study was supported by the National
   Natural Science Foundation of China (81773394, 81970001 and 82070001)
   and the Natural Science Foundation of Tianjin (18ZXDBSY00150 and
   19JCZDJC33600).
CR Basil MC, 2020, CELL STEM CELL, V26, P482, DOI 10.1016/j.stem.2020.03.009
   Chen HY, 2012, STEM CELLS, V30, P1948, DOI 10.1002/stem.1150
   George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3
   Lou Y, 2020, CLIN OUTCOMES PLASMA, DOI [10.1101/2020.04.29.20085761, DOI 10.1101/2020.04.29.20085761]
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Rackley CR, 2012, J CLIN INVEST, V122, P2724, DOI 10.1172/JCI60519
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Tang DL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008536
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yamamoto N., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.06.026476, 10.1101/ 2020.04.06.026476]
NR 10
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7722
EI 1365-2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD DEC
PY 2020
VL 53
IS 12
SI SI
AR e12928
DI 10.1111/cpr.12928
EA OCT 2020
PG 4
WC Cell Biology
SC Cell Biology
GA PB0MV
UT WOS:000581085600001
PM 33078494
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Garcia, P
   Revet, A
   Yrondi, A
   Rousseau, V
   Degboe, Y
   Montastruc, F
AF Garcia, Philippe
   Revet, Alexis
   Yrondi, Antoine
   Rousseau, Vanessa
   Degboe, Yannick
   Montastruc, Francois
TI Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease
   2019 (COVID-19): A VigiBase Study
SO DRUG SAFETY
LA English
DT Article
ID DATABASE
AB Introduction In the stressful context of the coronavirus disease 2019 (COVID-19) pandemic, some reports have raised concerns regarding psychiatric disorders with the use of hydroxychloroquine. In this study, we reviewed all psychiatric adverse effects with hydroxychloroquine in COVID-19 patients, as well as in other indications, reported in VigiBase, the World Health Organization's (WHO) global database of individual case safety reports. Methods First, we analyzed all psychiatric adverse effects, including suicide, of hydroxychloroquine in COVID-19 patients reported to 16 June 2020. We also performed disproportionality analysis to investigate the risk of reporting psychiatric disorders with hydroxychloroquine compared with remdesivir, tocilizumab, or lopinavir/ritonavir prescribed in COVID-19 patients. We used reporting odds ratios (RORs) and their 95% confidence intervals (CIs) to calculate disproportionality. Second, we sought to examine the psychiatric safety profile of hydroxychloroquine in other indications (before 2020). Results Among the 1754 reports with hydroxychloroquine in COVID-19 patients, we found 56 psychiatric adverse effects. Half of these adverse effects were serious, including four completed suicides, three cases of intentional self-injury, and 12 cases of psychotic disorders with hallucinations. Compared with remdesivir, tocilizumab, or lopinavir/ritonavir, the use of hydroxychloroquine was associated with an increased risk of reporting psychiatric disorders (ROR 6.27, 95% CI 2.74-14.35). Before 2020, suicide was the main cause of death among all adverse drug reactions reported with hydroxychloroquine, followed by cardiac adverse effects (cardiomyopathy) and respiratory failure. Conclusions This pharmacovigilance analysis suggests that COVID-19 patients exposed to hydroxychloroquine experienced serious psychiatric disorders, and, among these patients, some committed suicide. Further real-world studies are needed to quantify the psychiatric risk associated with hydroxychloroquine during the COVID-19 pandemic.
C1 [Garcia, Philippe; Rousseau, Vanessa; Montastruc, Francois] Toulouse Univ Hosp CHU, Dept Med & Clin Pharmacol, Ctr PharmacoVigilance & Pharmacoepidemiol, Fac Med, 37 Allees Jules Guesde, F-31000 Toulouse, France.
   [Revet, Alexis] Toulouse Univ Hosp CHU, Dept Child & Adolescent Psychiat, Fac Med, Toulouse, France.
   [Revet, Alexis; Rousseau, Vanessa; Montastruc, Francois] Univ Paul Sabatier Toulouse, UMR 1027 Pharmacoepidemiol Assessment Drug Utiliz, INSERM, CIC 1426, Toulouse, France.
   [Yrondi, Antoine] Univ Paul Sabatier Toulouse, Dept Psychiat Med,INSERM, Toulouse Univ Hosp CHU,ToNIC Toulouse NeuroImagin, Fac Med,Treatment Resistant Depress Expert Ctr,Fo, Toulouse, France.
   [Degboe, Yannick] Toulouse Univ Hosp CHU, Dept Rheumatol, Fac Med, Toulouse, France.
RP Montastruc, F (corresponding author), Toulouse Univ Hosp CHU, Dept Med & Clin Pharmacol, Ctr PharmacoVigilance & Pharmacoepidemiol, Fac Med, 37 Allees Jules Guesde, F-31000 Toulouse, France.; Montastruc, F (corresponding author), Univ Paul Sabatier Toulouse, UMR 1027 Pharmacoepidemiol Assessment Drug Utiliz, INSERM, CIC 1426, Toulouse, France.
EM francois.montastruc@univ-tlse3.fr
RI Montastruc, Francois/ABE-9903-2020
OI Montastruc, Francois/0000-0001-7056-8126; Garcia,
   Philippe/0000-0002-4999-7628
CR [Anonymous], 2020, CLOR HIDR PREC VIG P
   Aronson JK, 2017, THERAPIE, V72, P555, DOI 10.1016/j.therap.2017.02.005
   Aronson JK, 2014, CASE REPORTS EVIDENC, P121
   Brown EG, 1999, DRUG SAFETY, V20, P109, DOI 10.2165/00002018-199920020-00002
   Center for Drug Evaluation & Research, 2020, FDA CAUT US HYDR CHL
   Das P, 2014, PSYCHOSOMATICS, V55, P409, DOI 10.1016/j.psym.2013.06.017
   de Boissieu P, 2014, PHARMACOEPIDEM DR S, V23, P989, DOI 10.1002/pds.3622
   Ribeiro NPD, 2013, COMPR PSYCHIAT, V54, P1185, DOI 10.1016/j.comppsych.2013.05.010
   Drew J., 1962, MED J AUSTRALIA, P618
   Faillie JL, 2019, THERAPIE, V74, P225, DOI 10.1016/j.therap.2019.01.006
   Ferraro V, 2004, ANN DERMATOL VENER, V131, P471, DOI 10.1016/S0151-9638(04)93642-3
   Fiolet T, 2020, CLIN MICROBIOL INFEC, DOI [10.1016/j.cmi.2020.08.02, DOI 10.1016/J.CMI.2020.08.02]
   Gerard A, 2020, THERAPIE, V75, P371, DOI 10.1016/j.therap.2020.05.002
   Gonzalez-Nieto JA, 2015, LUPUS, V24, P339, DOI 10.1177/0961203314558863
   GOOD MI, 1977, AM J PSYCHIAT, V134, P798
   Gunnell D, 2020, LANCET PSYCHIAT, V7, P468, DOI 10.1016/S2215-0366(20)30171-1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kawohl W, 2020, LANCET PSYCHIAT, V7, P389, DOI 10.1016/S2215-0366(20)30141-3
   Lindquist M, 2008, DRUG INF J, V42, P409, DOI 10.1177/009286150804200501
   Manzo Ciro, 2017, Drug Saf Case Rep, V4, P6, DOI 10.1007/s40800-017-0048-x
   Mascolo A, 2018, INFLAMMOPHARMACOLOGY, V26, P1141, DOI 10.1007/s10787-018-0498-5
   Pariente A, 2007, DRUG SAFETY, V30, P891, DOI 10.2165/00002018-200730100-00007
   Reger MA, 2020, JAMA PSYCHIAT, V77, P1093, DOI 10.1001/jamapsychiatry.2020.1060
   Rothman KJ, 2004, PHARMACOEPIDEM DR S, V13, P519, DOI 10.1002/pds.1001
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD DEC
PY 2020
VL 43
IS 12
BP 1315
EP 1322
DI 10.1007/s40264-020-01013-3
EA OCT 2020
PG 8
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA OW1DX
UT WOS:000579710600001
PM 33078372
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Emirik, M
AF Emirik, Mustafa
TI Potential therapeutic effect of turmeric contents against SARS-CoV-2
   compared with experimental COVID-19 therapies: in silico study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19 drug; turmeric; spike glycoprotein; RNA polymerase;
   main protease; molecular docking; MMGBSA; ADME; molecular dynamic
ID CURCUMA-LONGA; VIRUS-INFECTION; REPLICATION; CURCUMINOIDS; CORONAVIRUS;
   DERIVATIVES; CELLS; TRIAL; SPIKE
AB Inspired by the 'There is no scientific evidence that turmeric prevents COVID-19' statement made by WHO, the protective or therapeutic potential of the compounds in turmeric contents was investigated against COVID-19 with in silico methodology. The drugs used for experimental COVID-19 therapies were included in this study using the same method for comparison with turmeric components. The 30 turmeric compounds and nine drugs were performed in the docking procedure for vital proteins of COVID-19. With evaluations based on docking scores, the Prime MMGBSA binding free energy and protein-ligand interactions were identified in detail. The 100 ns MD simulations were also performed to assess the stability of the ligands at the binding site of the target proteins. The Root Mean Square Deviation (RMSD) is used to obtain the average displacement for a particular frame concerning a reference frame. The results of this study are suggesting that turmeric spice have a potential to inhibit the SARS-CoV-2 vital proteins and can be use a therapeutic or protective agent against SARS-CoV-2 via inhibiting key protein of the SARS-CoV-2 virus. The compound 4, 23 and 6 are the most prominent inhibitor for the main protease, the spike glycoprotein and RNA polymerase of virus, respectively. The MD simulation validated the stability of ligand-protein interactions. The compactness of the complexes was shown using a radius of gyration. ADME properties of featured compounds are in range of 95% drug molecules. It is hoped that the outputs of this study will contribute to the struggle of humanity with COVID-19.
C1 [Emirik, Mustafa] Recep Tayyip Erdogan Univ, Dept Chem, TR-53100 Rize, Turkey.
RP Emirik, M (corresponding author), Recep Tayyip Erdogan Univ, Dept Chem, TR-53100 Rize, Turkey.
EM mustafa.emirik@erdogan.edu.tr
RI emirik, mustafa/D-4291-2015
OI emirik, mustafa/0000-0001-9489-9093
CR [Anonymous], 2018, SCHROD REL 2018 1
   [Anonymous], 2018, SCHROD REL 2018 4
   [Anonymous], 2020, WHO DIRECTOR GENERAL
   Barik A., 2020, MOL DOCKING BINDING
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Bowers E., 2006, ACM IEEE C SUP TAMP, DOI [10.1109/SC.2006.54, DOI 10.1109/SC.2006.54]
   CHEN A, 2001, ANTICANCER RES, V21
   Chen DY, 2010, FOOD CHEM, V119, P1346, DOI 10.1016/j.foodchem.2009.09.011
   Chen JJ, 2010, FOOD CHEM, V119, P974, DOI 10.1016/j.foodchem.2009.07.060
   Chen MH, 2012, INT J MOL MED, V30, P1021, DOI 10.3892/ijmm.2012.1096
   Chen TY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062482
   Cikrikci S, 2008, REC NAT PROD, V2, P19
   Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024
   Ekins S, 2020, DRUG DISCOV TODAY, V25, P928, DOI 10.1016/j.drudis.2020.03.019
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Frisch G. W. T. M. J., 2009, GAUSSIAN 09 REVISION
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gupta AP, 1999, J LIQ CHROMATOGR R T, V22, P1561, DOI 10.1081/JLC-100101751
   Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248-012-9432-8
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hewlings SJ, 2017, FOODS, V6, DOI 10.3390/foods6100092
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kalirajan Rajagopal, 2019, Curr Drug Res Rev, V11, P118, DOI 10.2174/2589977511666190912154817
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Lal B, 1999, PHYTOTHER RES, V13, P318, DOI 10.1002/(SICI)1099-1573(199906)13:4&lt;318::AID-PTR445&gt;3.0.CO;2-7
   Li H, 2019, ANTIVIR RES, V167, P98, DOI 10.1016/j.antiviral.2019.04.011
   Li S, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-S1-S10
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lung JH, 2020, J MED VIROL, V92, P693, DOI 10.1002/jmv.25761
   Mathew D, 2018, J FUNCT FOODS, V40, P692, DOI 10.1016/j.jff.2017.12.017
   Mentese E, 2019, BIOORG CHEM, V83, P289, DOI 10.1016/j.bioorg.2018.10.031
   Mermer A, 2019, J MOL STRUCT, V1189, P279, DOI 10.1016/j.molstruc.2019.04.039
   Moghadamtousi SZ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/186864
   Mounce BC, 2017, ANTIVIR RES, V142, P148, DOI 10.1016/j.antiviral.2017.03.014
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Narayanan A, 2012, J BIOL CHEM, V287, P33198, DOI 10.1074/jbc.M112.356535
   NTIEKANG F, 2013, SPRINGERPLUS, V2, DOI DOI https://doi.org/10.1186/2193-1801-2-353
   Ozil M, 2020, LETT ORG CHEM, V17, P309, DOI 10.2174/1570178616666190828200207
   Pant R, 2020, J MOL GRAPH MODEL, V98, DOI 10.1016/j.jmgm.2020.107584
   Park BS, 2005, J AGR FOOD CHEM, V53, P9005, DOI 10.1021/jf051765z
   Park SY, 2002, J NAT PROD, V65, P1227, DOI 10.1021/np010039x
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Prasad S, 2015, FOOD FUNCT, V6, P3412, DOI [10.1039/c5fo00485c, 10.1039/C5FO00485C]
   RISMANBAF A, 2020, ARCH ACAD EMERG MED, V8
   Roth GN, 1998, J NAT PROD, V61, P542, DOI 10.1021/np970459f
   SAKUI N, 1992, PHYTOCHEMISTRY, V31, P143, DOI 10.1016/0031-9422(91)83023-E
   Samant L. R., 2020, COMP DOCKING ANAL RA, Vx
   SATOSKAR RR, 1986, INT J CLIN PHARM TH, V24, P651
   Schlagenhauf P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101658
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Shan YB, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1839571
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744
   Sherman W, 2006, J MED CHEM, V49, P534, DOI 10.1021/jm050540c
   Si XN, 2007, J VIROL, V81, P3142, DOI 10.1128/JVI.02028-06
   Takano Y, 2005, J CHEM THEORY COMPUT, V1, P70, DOI 10.1021/ct049977a
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   TON AT, 2020, MOL INFORM 0323, DOI DOI https://doi.org/10.1002/minf.202000028
   University of Liverpool, DET REC INT EXP COVI
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wang LY, 2008, BIOCHEM SYST ECOL, V36, P476, DOI 10.1016/j.bse.2007.12.005
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Ziebuhr J, 2003, J VIROL, V77, P1415, DOI 10.1128/JVI.77.2.1415-1426.2003
NR 69
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1835719
EA OCT 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OD2UB
UT WOS:000579707000001
PM 33078675
OA Bronze
DA 2021-01-01
ER

PT J
AU Yang, SM
   Dong, D
   Gu, HF
   Gale, RP
   Ma, J
   Huang, XJ
AF Yang, Shenmiao
   Dong, Dong
   Gu, Hongfei
   Gale, Robert Peter
   Ma, Jun
   Huang, Xiaojun
TI Impact of stopping therapy during the SARS-CoV-2 pandemic in persons
   with lymphoma
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article; Early Access
DE Anxiety; Health relatedquality-of-life; Lymphoma; SARS-CoV-2 pandemic;
   COVID-19
ID QUALITY-OF-LIFE; CANCER; ANXIETY; DEPRESSION; INSTRUMENT; CAREGIVERS;
   DELAYS; CARE; UK
AB Introduction The severe acute respiratory syndrome-2 (SARS-CoV-2) pandemic disrupted medical care for persons with cancer including those with lymphoma. Many professional societies recommend postponing, decreasing, or stopping anti-cancer therapy in selected persons during the pandemic. Although seemingly sensible, these recommendations are not evidence-based and their impact on anxiety and health-relatedquality-of-life(HRQoL) is unknown. Methods We surveyed 2532 subjects including 1060 persons with lymphoma, 948 caregivers, and 524 normals using a purposed-designed questionnaire on a patient organization website. Respondents also completed the Zung Self-Rating Anxiety and patient respondents, the EORTC QLQ-C30 instruments to quantify anxiety, and HRQoL. We also evaluated caregiver support and an online education programme of the Chinese Society of Clinical Oncology (CSCO). Data of HRQoL from a 2019 pre-pandemic online survey of 1106 persons with lymphoma were a control. Results 33% (95% confidence interval [CI] 30, 36%) of lymphoma patients and 31% (28, 34%) of caregivers but only 21% (17, 24%) of normals had any level of anxiety (both pair-wiseP < 0.001). Among lymphoma respondents, physical exercise and better caregiver support were associated with less anxiety, whereas female sex, receiving therapy, and reduced therapy intensity were associated with more anxiety. Paradoxically, lymphoma respondents during the pandemic had better HRQoL than pre-pandemic controls. Reduced therapy intensity was associated with worse HRQoL, whereas respondents who scored caregiver support and the online patient education programme high had better HRQoL. Conclusion During the SARS-CoV-2 pandemic, lymphoma patients and their caregivers had significantly higher incidences of anxiety compared with normals. Lymphoma respondents reported better HRQoL compared with pre-pandemic controls. Reduced therapy intensity in persons with cancer may have unanticipated adverse effects on anxiety and HRQoL. Regular and intense support by caregivers and online education programmes alleviate anxiety and improve HRQoL.
C1 [Yang, Shenmiao; Huang, Xiaojun] Peking Univ, Peoples Hosp, Natl Clin Res Ctr Hematol Dis, Inst Hematol, 11 Xizhimen Nan St, Beijing 100044, Peoples R China.
   [Dong, Dong] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China.
   [Gu, Hongfei] Chinese Lymphoma Patients Org, House086, Beijing, Peoples R China.
   [Gale, Robert Peter] Imperial Coll London, Dept Immunol & Inflammat, Haematol Res Ctr, London, England.
   [Ma, Jun] Harbin Inst Hematol & Oncol, Harbin, Peoples R China.
RP Huang, XJ (corresponding author), Peking Univ, Peoples Hosp, Natl Clin Res Ctr Hematol Dis, Inst Hematol, 11 Xizhimen Nan St, Beijing 100044, Peoples R China.
EM huangxiaojun@bjmu.edu.cn
OI Gale, Robert Peter/0000-0002-9156-1676
FU National Institute of Health Research (NIHR) Biomedical Research Centre
   funding schemeNational Institute for Health Research (NIHR)
FX Yinan Sun MS, Director of Student Wellness (Yungu School; China)
   reviewed the questionnaire. Prof. Norbert Schmitz (University Hospital,
   Munster, Germany) kindly reviewed the typescript. RPG acknowledges
   support from the National Institute of Health Research (NIHR) Biomedical
   Research Centre funding scheme.
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   Cao C, 2018, ANN DIAGN PATHOL, V34, P60, DOI 10.1016/j.anndiagpath.2017.05.005
   Castillo EG, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1017-0
   Chen-See S, 2020, LANCET ONCOL, V21, pE374, DOI 10.1016/S1470-2045(20)30397-1
   Di Ciaccio P, 2020, INTERN MED J, V50, P667, DOI 10.1111/imj.14859
   ESMO, 2020, ESMO GUID CANC PAT M
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Ismael J, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1044
   Li QP, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-1051-3
   Liao ML, 2020, J AFFECT DISORDERS, V264, P115, DOI 10.1016/j.jad.2019.11.148
   Liu XC, 1997, SOC PSYCH PSYCH EPID, V32, P63, DOI 10.1007/BF00788922
   Maringe C, 2020, LANCET ONCOL, V21, P1023, DOI 10.1016/S1470-2045(20)30388-0
   Nipp RD, 2016, ANN ONCOL, V27, P1607, DOI 10.1093/annonc/mdw205
   Romito F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01270
   Shah MA, 2020, CA-CANCER J CLIN, V70, P349, DOI 10.3322/caac.21627
   Shao Ruyue, 2020, BMC Psychol, V8, P38, DOI 10.1186/s40359-020-00402-8
   Sklenarova H, 2015, CANCER-AM CANCER SOC, V121, P1513, DOI 10.1002/cncr.29223
   Stewart WC, 2016, J RELIG HEALTH, V55, P1326, DOI 10.1007/s10943-015-0076-8
   Sud A, 2020, LANCET ONCOL, V21, P1035, DOI 10.1016/S1470-2045(20)30392-2
   Sun J, 2012, AM J CLIN PATHOL, V138, P429, DOI 10.1309/AJCP7YLTQPUSDQ5C
   TRIGGLE N., 2020, BBC NEWS
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang ZY, 1984, J SHANGHAI PSYCHIAT, V2, P73
   Yang QP, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-77
   Zhao H, 2000, QUAL LIFE RES, V9, P129, DOI 10.1023/A:1008981520920
   ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371
NR 28
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
DI 10.1007/s00432-020-03426-0
EA OCT 2020
PG 11
WC Oncology
SC Oncology
GA OD2UW
UT WOS:000579709100001
PM 33078214
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lee, SY
   Song, KJ
   Lim, CS
   Kim, BG
   Chai, YJ
   Lee, JK
   Kim, SH
   Lim, HJ
AF Lee, Sun Young
   Song, Kyoung Jun
   Lim, Chun Soo
   Kim, Byeong Gwan
   Chai, Young Jun
   Lee, Jung-Kyu
   Kim, Su Hwan
   Lim, Hyouk Jae
TI Operation and Management of Seoul Metropolitan City Community Treatment
   Center for Mild Condition COVID-19 Patients
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE COVID-19; Community Treatment Center; Surge Capacity; Disaster
ID HOSPITAL SURGE CAPACITY; CORONAVIRUS DISEASE; SYMPTOMATIC PATIENTS;
   OUTBREAK
AB Background: In response to the disaster of coronavirus disease 2019 (COVID-19) pandemic, Seoul Metropolitan Government (SMG) established a patient facility for mild condition patients other than hospital. This study was conducted to investigate the operation and necessary resources of a community treatment center (CTC) operated in Seoul, a metropolitan city with a population of 10 million.
   Methods: To respond COVID-19 epidemic, the SMG designated 5 municipal hospitals as dedicated COVID-19 hospitals and implemented one CTC cooperated with the Boramae Municipal Hospital for COVID-19 patients in Seoul. As a retrospective cross-sectional observational study, retrospective medical records review was conducted for patients admitted to the Seoul CTC. The admission and discharge route of CTC patients were investigated. The patient characteristics were compared according to route of discharge whether the patient was discharged to home or transferred to hospital. To report the operation of CTC, the daily mean number of tests (reverse transcription polymerase chain reaction and chest X-ray) and consultations by medical staffs were calculated per week. The list of frequent used medications and who used medication most frequently were investigated.
   Results: Until May 27 when the Seoul CTC was closed, 26.5% (n = 213) of total 803 COVID-19 patients in Seoul were admitted to the CTC. It was 35.7% (n = 213) of 597 newly diagnosed patients in Seoul during the 11 weeks of operation. The median length of stay was 21 days (interquartile range, 12-29 days). A total of 191 patients (89.7%) were discharged to home after virologic remission and 22 (10.3%) were transferred to hospital for further treatment. Fifty percent of transferred patients were within a week since CTC admission. Daily 2.5-3.6 consultations by doctors or nurses and 0.4-0.9 tests were provided to one patient. The most frequently prescribed medication was symptomatic medication for COVID-19 (cough/sputum and rhinorrhea). The next ranking was psychiatric medication for sleep problem and depression/anxiety, which was prescribed more than digestive drug.
   Conclusion: In the time of an infectious disease disaster, a metropolitan city can operate a temporary patient facility such as CTC to make a surge capacity and appropriately allocate scarce medical resource.
C1 [Lee, Sun Young] Seoul Natl Univ Hosp, Publ Healthcare Ctr, Seoul, South Korea.
   [Lee, Sun Young; Song, Kyoung Jun; Lim, Hyouk Jae] Seoul Natl Univ Hosp, Lab Emergency Med Serv, Biomed Res Inst, Seoul, South Korea.
   [Song, Kyoung Jun] Seoul Natl Univ, Dept Emergency Med, Boramae Med Ctr, Seoul Metropolitan Govt, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.
   [Lim, Chun Soo] Seoul Natl Univ, Coll Med, Boramae Med Ctr, Seoul Metropolitan Govt,Div Nephrol,Dept Internal, Seoul, South Korea.
   [Kim, Byeong Gwan; Kim, Su Hwan] Seoul Natl Univ, Coll Med, Div Gastroenterol, Seoul Metropolitan Govt,Dept Internal,Boramae Med, Seoul, South Korea.
   [Chai, Young Jun] Seoul Natl Univ, Dept Surg, Seoul Metropolitan Govt, Boramae Med Ctr, Seoul, South Korea.
   [Lee, Jung-Kyu] Seoul Natl Univ, Div Pulm & Crit Care Med, Seoul Metropolitan Govt, Boramae Med Ctr,Dept Internal Med, Seoul, South Korea.
   [Lim, Hyouk Jae] Seoul Natl Univ Hosp, Dept Emergency Med, Seoul, South Korea.
RP Song, KJ (corresponding author), Seoul Natl Univ, Dept Emergency Med, Boramae Med Ctr, Seoul Metropolitan Govt, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.
EM skciva@gmail.com
OI Lim, Chun Soo/0000-0001-9123-6542; Lee, Sun Young/0000-0002-1626-2721;
   Song, Kyoung Jun/0000-0002-0027-6352
CR Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449
   Biddison ELD, 2019, CHEST, V155, P848, DOI 10.1016/j.chest.2018.09.025
   Choi WS, 2020, EMERG INFECT DIS, V26, P2338, DOI 10.3201/eid2610.201539
   Disaster medical services, 2018, ANN EMERG MED, V72, pe39
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Fagbuyi DB, 2011, ANN EMERG MED, V57, P52, DOI 10.1016/j.annemergmed.2010.08.026
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Hick JL, 2014, CHEST, V146, pE1S, DOI 10.1378/chest.14-0733
   Hick JL, 2012, ANN EMERG MED, V59, P177, DOI 10.1016/j.annemergmed.2011.06.012
   Hui EKW, 2006, MICROBES INFECT, V8, P905, DOI 10.1016/j.micinf.2005.06.032
   Ji YP, 2020, LANCET GLOB HEALTH, V8, pE480, DOI 10.1016/S2214-109X(20)30068-1
   Kang CR, 2020, EMERG INFECT DIS, V26, P2499, DOI 10.3201/eid2610.202573
   Kang E, 2020, EMERG INFECT DIS, V26, P2329, DOI 10.3201/eid2610.201460
   Kelen GD, 2006, LANCET, V368, P1984, DOI 10.1016/S0140-6736(06)69808-5
   Korea Disease Control and Prevention Agency, COR DIS 19 MAIN WEBS
   Landman A, 2015, ANN EMERG MED, V66, P51, DOI 10.1016/j.annemergmed.2014.06.009
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lee YH, 2020, EMERG INFECT DIS, V26, P2346, DOI 10.3201/eid2610.201620
   Morton MJ, 2015, ACAD EMERG MED, V22, P1235, DOI 10.1111/acem.12815
   Nacoti M, 2020, NEJM CATAL INNOV CAR
   Noji EK, 1997, DISASTERS, V21, P366, DOI 10.1111/1467-7717.00068
   Olson DR, 2020, MMWR-MORBID MORTAL W, V69, P603, DOI 10.15585/mmwr.mm6919e5
   Park SY, 2020, EMERG INFECT DIS, V26, P1666, DOI 10.3201/eid2608.201274
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Seoul Metropolitan Government, SEOUL COVID 19 INF W
   Sung HK, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e280
   Tang B, 2020, INT J INFECT DIS, V95, P288, DOI 10.1016/j.ijid.2020.03.018
   Tanne JH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1090
   Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689
   Wang TY, 2020, ANN EMERG MED, V76, P374, DOI 10.1016/j.annemergmed.2020.05.001
   Westgard BC, 2020, ANN EMERG MED, V76, P595, DOI 10.1016/j.annemergmed.2020.06.019
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Wurmb T, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03104-0
   Xu SQ, 2020, LANCET, V395, P1321, DOI 10.1016/S0140-6736(20)30845-X
NR 36
TC 0
Z9 0
U1 3
U2 3
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD OCT 19
PY 2020
VL 35
IS 40
AR e367
DI 10.3346/jkms.2020.35.e367
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA OD5LL
UT WOS:000579895100007
PM 33075858
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lai, THT
   Lee, M
   Au, AKH
   Tang, HHY
   Tang, EWH
   Li, KKW
AF Lai, Tracy H. T.
   Lee, Monica
   Au, Alvin K. H.
   Tang, Heather H. Y.
   Tang, Emily W. H.
   Li, Kenneth K. W.
TI The use of short message service (SMS) to reduce outpatient attendance
   in ophthalmic clinics during the coronavirus pandemic
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article; Early Access
DE COVID-19; SMS; Flow-control; Ophthalmology; Outpatient attendance; Drug
   refill
AB Purpose In order to minimize the risk of transmission of coronavirus disease 2019 (COVID-19), many clinic appointments were postponed to lower patient attendance. Actively calling patients to postpone appointments is a labour-intensive process. We were the first ophthalmic clinics in Hong Kong to use short message service (SMS) to dispatch messages simultaneously to a large number of patients to offer postponement of appointments. The aim of this study is to evaluate whether SMS is an effective method to reduce outpatient attendance during the COVID-19 pandemic. Methods This is an observational study reviewing data on SMS messages sent to all patients attending ophthalmology clinics of a tertiary eye centre in Hong Kong. All SMS were sent at least 5 days before the scheduled appointments. The text message included an enquiry hotline for postponement of appointments and offered drug refill. The study included data from February to April 2020. Two hundred patients were invited to take part in a questionnaire on satisfaction level and reason(s) for appointment rescheduling. Results During the study period, a total of 17,028 SMS were sent. The overall response rate was 23.6%. 14.3% postponed their appointments. This led to an overall 13.9% reduction of clinic attendance. The overall satisfaction was high (96%). The main reason for postponing appointment was worries about infection risk (93.1%). Conclusion SMS was an efficient and cost-effective flow-control method which was well accepted by patients and can reduce outpatient attendance. The time saved can potentially allow healthcare workers to conduct other infection control measures during the COVID-19 pandemic.
C1 [Lai, Tracy H. T.; Lee, Monica; Au, Alvin K. H.; Tang, Heather H. Y.; Tang, Emily W. H.; Li, Kenneth K. W.] United Christian Hosp, Dept Ophthalmol, Kwun Tong, Kowloon, 130 Hip Wo St, Hong Kong, Peoples R China.
   [Lai, Tracy H. T.; Lee, Monica; Au, Alvin K. H.; Tang, Heather H. Y.; Tang, Emily W. H.; Li, Kenneth K. W.] Tseung Kwan O Hosp, Dept Ophthalmol, Tseung Kwan O, 2 Po Ning Path, Hong Kong, Peoples R China.
RP Li, KKW (corresponding author), United Christian Hosp, Dept Ophthalmol, Kwun Tong, Kowloon, 130 Hip Wo St, Hong Kong, Peoples R China.
EM kennethkwli56@gmail.com
RI ; Li, Kenneth/M-4140-2017
OI Tang, Emily W.H./0000-0002-6885-7882; Lai, Tracy/0000-0002-0420-9456;
   Li, Kenneth/0000-0001-9440-8063
CR [Anonymous], 2020, COVID 19 CORONAVIRUS
   [Anonymous], 2020, KECC00120
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Brannan SO, 2011, SCOT MED J, V56, P148, DOI 10.1258/smj.2011.011112
   Chen TT, 2018, AM J OPHTHALMOL, V194, P54, DOI 10.1016/j.ajo.2018.07.006
   Koshy E, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-9
   Lai THT, 2020, GRAEF ARCH CLIN EXP, V258, P1341, DOI 10.1007/s00417-020-04663-2
   Lai THT, 2020, GRAEF ARCH CLIN EXP, V258, P1135, DOI 10.1007/s00417-020-04653-4
   Lai THT, 2020, GRAEF ARCH CLIN EXP, V258, P1049, DOI 10.1007/s00417-020-04641-8
   Lin HT, 2012, OPHTHALMOLOGY, V119, P2463, DOI 10.1016/j.ophtha.2012.06.046
   Wang YH, 2020, INT J OPHTHALMOL-CHI, V13, P1161, DOI 10.18240/ijo.2020.07.22
   Wong DHT, 2020, GRAEF ARCH CLIN EXP, V258, P1571, DOI 10.1007/s00417-020-04683-y
NR 12
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
DI 10.1007/s10792-020-01616-w
EA OCT 2020
PG 8
WC Ophthalmology
SC Ophthalmology
GA OD2SM
UT WOS:000579702900003
PM 33078227
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gil-Moles, M
   Basu, U
   Bssing, R
   Hoffmeister, H
   Trck, S
   Varchmin, A
   Ott, I
AF Gil-Moles, Maria
   Basu, Uttara
   Bussing, Rolf
   Hoffmeister, Henrik
   Turck, Sebastian
   Varchmin, Agnieszka
   Ott, Ingo
TI Gold Metallodrugs to Target Coronavirus Proteins: Inhibitory Effects on
   the Spike-ACE2 Interaction and on PLpro Protease Activity by Auranofin
   and Gold Organometallics
SO CHEMISTRY-A EUROPEAN JOURNAL
LA English
DT Article
DE Auranofin; coronavirus; gold complexes; metallodrugs; SARS-CoV-2
ID COMPLEXES; REPLICATION; OUTBREAK
AB Gold complexes have a long tradition in medicine and for many examples antirheumatic, anticancer or anti-infective effects have been confirmed. Herein, we evaluated the lead compound Auranofin and five selected gold organometallics as inhibitors of two relevant drug targets of severe acute respiratory syndrome coronaviruses (SARS-CoV). The gold metallodrugs were effective inhibitors of the interaction of the SARS-CoV-2 spike protein with the angiotensin converting enzyme 2 (ACE2) host receptor and might thus interfere with the viral entry process. The gold metallodrugs were also efficient inhibitors of the papain-like protease (PLpro) of SARS-CoV-1 and SARS-CoV-2, which is a key enzyme in the viral replication. Regarding PLpro from SARS-CoV-2, the here reported inhibitors are among the very first experimentally confirmed examples with activity against this target enzyme. Importantly, the activity of the complexes against both PLpro enzymes correlated with the ability of the inhibitors to remove zinc ions from the labile zinc center of the enzyme. Taken together, the results of this pilot study suggest further evaluation of gold complexes as SARS-CoV antiviral drugs.
C1 [Gil-Moles, Maria; Basu, Uttara; Bussing, Rolf; Hoffmeister, Henrik; Turck, Sebastian; Varchmin, Agnieszka; Ott, Ingo] Tech Univ Carolo Wilhelmina Braunschweig, Inst Med & Pharmaceut Chem, Beethovenstr 55, D-38106 Braunschweig, Germany.
RP Ott, I (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Med & Pharmaceut Chem, Beethovenstr 55, D-38106 Braunschweig, Germany.
EM ingo.ott@tu-bs.de
OI Ott, Ingo/0000-0002-8087-4618
FU Projekt DEAL
FX Open access funding enabled and organized by Projekt DEAL.
CR Abbehausen C, 2019, METALLOMICS, V11, P15, DOI 10.1039/c8mt00262b
   Andermark V, 2016, J INORG BIOCHEM, V160, P140, DOI 10.1016/j.jinorgbio.2015.12.020
   Casini A., METALLO DRUGS DEV AC, P199
   Cerrada E., ADV ORGANOMETALLIC C
   Cheng X., 2020, COMMUN BIOL, V3, P519
   Chiou JYZ, 2009, EUR J INORG CHEM, P1950, DOI 10.1002/ejic.200801186
   Clasman JR, 2017, SCI REP-UK, V7, DOI 10.1038/srep40292
   Fonteh PN, 2010, BIOMETALS, V23, P185, DOI 10.1007/s10534-010-9293-5
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Ghosh AK, 2009, J MED CHEM, V52, P5228, DOI 10.1021/jm900611t
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Maiti Biplab K, 2020, ACS Pharmacol Transl Sci, V3, P1017, DOI 10.1021/acsptsci.0c00093
   Marzo T, 2020, ACS MED CHEM LETT, V11, P1067, DOI 10.1021/acsmedchemlett.0c00190
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Mora M, 2019, CHEM SOC REV, V48, P447, DOI 10.1039/c8cs00570b
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   OKADA T, 1993, VIROLOGY, V192, P631, DOI 10.1006/viro.1993.1079
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Rothan HA, 2020, VIROLOGY, V547, P7, DOI 10.1016/j.virol.2020.05.002
   Rubbiani R, 2011, J MED CHEM, V54, P8646, DOI 10.1021/jm201220n
   Rubbiani R, 2010, J MED CHEM, V53, P8608, DOI 10.1021/jm100801e
   Rut Wioletta, 2020, bioRxiv, DOI 10.1101/2020.04.29.068890
   Sargsyan K, 2020, CHEM SCI, V11, P9904, DOI 10.1039/d0sc02646h
   Sivararn H, 2012, ORGANOMETALLICS, V31, P5875, DOI 10.1021/om300444c
   Sun RWY, 2004, CHEMBIOCHEM, V5, P1293, DOI 10.1002/cbic.200300773
   Traber KE, 1999, INT IMMUNOL, V11, P143, DOI 10.1093/intimm/11.2.143
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 33
TC 1
Z9 1
U1 1
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0947-6539
EI 1521-3765
J9 CHEM-EUR J
JI Chem.-Eur. J.
PD NOV 26
PY 2020
VL 26
IS 66
BP 15140
EP 15144
DI 10.1002/chem.202004112
EA OCT 2020
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA OV5KG
UT WOS:000579111100001
PM 32915473
OA Other Gold
DA 2021-01-01
ER

PT J
AU Gao, YC
   Liu, T
   Zhong, WJ
   Liu, R
   Zhou, HH
   Huang, WH
   Zhang, W
AF Gao, Yongchao
   Liu, Tao
   Zhong, Weijun
   Liu, Rong
   Zhou, Honghao
   Huang, Weihua
   Zhang, Wei
TI Risk of Metformin in Patients With Type 2 Diabetes With COVID-19: A
   Preliminary Retrospective Report
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
ID CORONAVIRUS
AB The current outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread across the world. No specific antiviral agents have been adequately evidenced for the treatment of coronavirus disease 2019 (COVID-19). Although metformin has been recommended as a host-directed therapy for COVID-19, there are some opposite views. The effects of metformin on the disease severity of patients with COVID-19 with diabetes during hospitalization remains unclear. This study aimed to determine the effect of metformin on disease severity. We enrolled 110 hospitalized patients with COVID-19 with diabetes prescribed either metformin or non-metformin hypoglycemic treatment for a case-control study. The primary outcome was the occurrence of life-threatening complications. There were no differences between the two groups in age, sex, comorbidities, and clinical severity at admission. Blood glucose and lactate dehydrogenase levels of the metformin group were higher than those of the non-metformin group at admission. Other laboratory parameters at admission and treatments after admission were not different between the two groups. Strikingly, the percentage of patients who experienced life-threatening complications was significantly higher in the metformin group (28.6% (16/56) vs. 7.4% (4/54),P = 0.004). Antidiabetic therapy with metformin was associated with a higher risk of disease progression in patients with COVID-19 with diabetes during hospitalization (adjusted odds ratio = 3.964, 95% confidence interval 1.034-15.194,P = 0.045). This retrospective analysis suggested a potential safety signal for metformin, the use of which was associated with a higher risk of severe COVID-19. We propose that metformin withdrawal in patients with COVID-19 be considered to prevent disease progression.
C1 [Gao, Yongchao; Zhong, Weijun; Liu, Rong; Zhou, Honghao; Huang, Weihua; Zhang, Wei] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Peoples R China.
   [Gao, Yongchao; Zhong, Weijun; Liu, Rong; Zhou, Honghao; Huang, Weihua; Zhang, Wei] Cent South Univ, Hunan Key Lab Pharmacogenet, Inst Clin Pharmacol, Changsha, Peoples R China.
   [Gao, Yongchao; Zhong, Weijun; Liu, Rong; Zhou, Honghao; Huang, Weihua; Zhang, Wei] Minist Educ, Engn Res Ctr Appl Technol Pharmacogen, Changsha, Peoples R China.
   [Gao, Yongchao; Zhong, Weijun; Liu, Rong; Zhou, Honghao; Huang, Weihua; Zhang, Wei] Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China.
   [Liu, Tao] Shenzhen Ctr Chron Dis Control, Shenzhen, Peoples R China.
RP Huang, WH; Zhang, W (corresponding author), Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Peoples R China.; Huang, WH; Zhang, W (corresponding author), Cent South Univ, Hunan Key Lab Pharmacogenet, Inst Clin Pharmacol, Changsha, Peoples R China.; Huang, WH; Zhang, W (corresponding author), Minist Educ, Engn Res Ctr Appl Technol Pharmacogen, Changsha, Peoples R China.; Huang, WH; Zhang, W (corresponding author), Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China.
EM csuzhangwei@csu.edu.cn; endeavor34852@aliyun.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81874329, 81573511, 81472802]; Emergency
   Project of Prevention and Control for COVID-19 of Central South
   University
FX This study was supported by the National Natural Science Foundation of
   China (No. 81874329, 81573511 and 81472802) and the Emergency Project of
   Prevention and Control for COVID-19 of Central South University.
CR Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Chen YC, 2020, DIABETES CARE, V43, P1399, DOI 10.2337/dc20-0660
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Katulanda P, 2020, DIABETOLOGIA, V63, P1440, DOI 10.1007/s00125-020-05164-x
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   Roncon L, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104354
   Shi Q, 2020, DIABETES CARE, V43, P1382, DOI 10.2337/dc20-0598
   Wang QM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz7086
   World Health Organization (WHO), 2020, 117 WHO
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang J, 2018, AM J RESP CRIT CARE, V198, P509, DOI 10.1164/rccm.201712-2570OC
   Zhao XX, 2020, EUR J CLIN MICROBIOL, V39, P1209, DOI 10.1007/s10096-020-03897-6
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 20
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
PD NOV
PY 2020
VL 13
IS 6
BP 1055
EP 1059
DI 10.1111/cts.12897
EA OCT 2020
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PA7WR
UT WOS:000579187500001
PM 32955785
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sainsbury, C
   Wang, JY
   Gokhale, K
   Acosta-Mena, D
   Dhalla, S
   Byne, N
   Chandan, JS
   Anand, A
   Cooper, J
   Okoth, K
   Subramanian, A
   Bangash, MN
   Taverner, T
   Hanif, W
   Ghosh, S
   Narendran, P
   Cheng, KK
   Marshall, T
   Gkoutos, G
   Toulis, K
   Thomas, N
   Tahrani, A
   Adderley, NJ
   Haroon, S
   Nirantharakumar, K
AF Sainsbury, Christopher
   Wang, Jingya
   Gokhale, Krishna
   Acosta-Mena, Dionisio
   Dhalla, Samir
   Byne, Nathan
   Chandan, Joht Singh
   Anand, Astha
   Cooper, Jennifer
   Okoth, Kelvin
   Subramanian, Anuradhaa
   Bangash, Mansoor N.
   Taverner, Thomas
   Hanif, Wasim
   Ghosh, Sandip
   Narendran, Parth
   Cheng, Kar K.
   Marshall, Tom
   Gkoutos, Georgios
   Toulis, Konstantinos
   Thomas, Neil
   Tahrani, Abd
   Adderley, Nicola J.
   Haroon, Shamil
   Nirantharakumar, Krishnarajah
TI Sodium-glucose co-transporter-2 inhibitors and susceptibility
   toCOVID-19: A population-based retrospective cohort study
SO DIABETES OBESITY & METABOLISM
LA English
DT Article
DE antidiabetic drug; DPP-4 inhibitor; pharmaco-epidemiology; SGLT2
   inhibitor; type 2 diabetes
ID MORTALITY
AB Sodium-glucose co-transporter-2 (SGLT2) inhibitors are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2 inhibitor prescription is associated with COVID-19, when compared with an active comparator. We performed a propensity-score-matched cohort study with active comparators and a negative control outcome in a large UK-based primary care dataset. Participants prescribed SGLT2 inhibitors (n = 9948) and a comparator group prescribed dipeptidyl peptidase-4 (DPP-4) inhibitors (n = 14 917) were followed up from January 30 to July 27, 2020. The primary outcome was confirmed or clinically suspected COVID-19. The incidence rate of COVID-19 was 19.7/1000 person-years among users of SGLT2 inhibitors and 24.7/1000 person-years among propensity-score-matched users of DPP-4 inhibitors. The adjusted hazard ratio was 0.92 (95% confidence interval 0.66 to 1.29), and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVID-19 in primary care amongst those prescribed SGLT2 inhibitors compared to DPP-4 inhibitors, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVID-19 pandemic.
C1 [Sainsbury, Christopher; Wang, Jingya; Gokhale, Krishna; Chandan, Joht Singh; Anand, Astha; Cooper, Jennifer; Okoth, Kelvin; Subramanian, Anuradhaa; Taverner, Thomas; Cheng, Kar K.; Marshall, Tom; Toulis, Konstantinos; Thomas, Neil; Adderley, Nicola J.; Haroon, Shamil; Nirantharakumar, Krishnarajah] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England.
   [Sainsbury, Christopher] NHS Greater Glasgow & Clyde, Dept Diabet, Gartnavel Gen Hosp, Glasgow, Lanark, Scotland.
   [Acosta-Mena, Dionisio; Byne, Nathan] Ceged Rx, Ceged Hlth Data, London, England.
   [Dhalla, Samir] Hlth Improvement Network Thin, London, England.
   [Bangash, Mansoor N.] Univ Birmingham, Inst Clin Sci, Birmingham, W Midlands, England.
   [Bangash, Mansoor N.] Univ Hosp Birmingham NHS Fdn Trust, Dept Crit Care, Birmingham, W Midlands, England.
   [Hanif, Wasim; Ghosh, Sandip; Narendran, Parth; Tahrani, Abd] Univ Birmingham, Inst Metab & Syst Res, Birmingham, W Midlands, England.
   [Narendran, Parth; Gkoutos, Georgios; Tahrani, Abd] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England.
   [Tahrani, Abd; Nirantharakumar, Krishnarajah] Univ Hosp Birmingham NHS Fdn Trust, Dept Diabet & Endocrinol, Birmingham, W Midlands, England.
   [Nirantharakumar, Krishnarajah] Midlands Hlth Data Res UK, Birmingham, W Midlands, England.
RP Adderley, NJ (corresponding author), Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England.
EM N.J.Adderley@bham.ac.uk
RI Bangash, Mansoor/AAR-6546-2020; Tahrani, Abd/C-6939-2014; Chandan,
   Joht/D-6361-2015
OI Bangash, Mansoor/0000-0001-5039-5184; Tahrani, Abd/0000-0001-9037-1937;
   Chandan, Joht/0000-0002-9561-5141; Haroon, Shamil/0000-0002-0096-1413;
   Gkoutos, Georgios/0000-0002-2061-091X; Adderley,
   Nicola/0000-0003-0543-3254; Marshall, Tom/0000-0001-9277-5214;
   Narendran, Parth/0000-0002-4583-8793
CR Aronson JK, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1313
   Barron E, 2020, LANCET DIABETES ENDO, V8, P813, DOI 10.1016/S2213-8587(20)30272-2
   Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Bossi AC, 2020, DIABETES THER, V11, P1605, DOI 10.1007/s13300-020-00844-8
   Ceriello A, 2020, DIABETES CARE, V43, P1427, DOI 10.2337/dc20-0941
   Chen YC, 2020, DIABETES CARE, V43, P1399, DOI 10.2337/dc20-0660
   Dalan R, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108216
   Holman N, 2020, LANCET DIABETES ENDO, V8, P823, DOI 10.1016/S2213-8587(20)30271-0
   Kramer CK, 2019, ANNU REV MED, V70, P323, DOI 10.1146/annurev-med-042017-094221
   Maguire A, 2009, PHARMACOEPIDEM DR S, V18, P76, DOI 10.1002/pds.1688
   National Institute for Health and Care Excellence, 2019, TYP 2 DIAB AD MAN NI, P2019
   Sanderson E, 2018, INT J EPIDEMIOL, V47, P587, DOI 10.1093/ije/dyx213
   Shi Q, 2020, DIABETES CARE, V43, P1382, DOI 10.2337/dc20-0598
   The OpenSAFELY Collaborative, 2020, OPENSAFELY FACT ASS
   Verma S, 2018, DIABETOLOGIA, V61, P2108, DOI 10.1007/s00125-018-4670-7
NR 15
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8902
EI 1463-1326
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD JAN
PY 2021
VL 23
IS 1
BP 263
EP 269
DI 10.1111/dom.14203
EA OCT 2020
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA PE1FJ
UT WOS:000579187800001
PM 32991065
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Saibeni, S
   Scucchi, L
   Dragoni, G
   Bezzio, C
   Miranda, A
   Ribaldone, DG
   Bertani, A
   Bossa, F
   Allocca, M
   Buda, A
   Mocci, G
   Soriano, A
   Mazzuoli, S
   Bertani, L
   Baccini, F
   Loddo, E
   Privitera, AC
   Sartini, A
   Viscido, A
   Grossi, L
   Casini, V
   Gerardi, V
   Ascolani, M
   Di Ruscio, M
   Casella, G
   Savarino, E
   Stradella, D
   Pumpo, R
   Cortelezzi, CC
   Daperno, M
   Ciardo, V
   Nardone, OM
   Caprioli, F
   Vitale, G
   Cappello, M
   Comberlato, M
   Alvisi, P
   Festa, S
   Campigotto, M
   Bodini, G
   Balestrieri, P
   Viola, A
   Pugliese, D
   Armuzzi, A
   Fantini, MC
   Fiorino, G
AF Saibeni, Simone
   Scucchi, Ludovica
   Dragoni, Gabriele
   Bezzio, Cristina
   Miranda, Agnese
   Ribaldone, Davide Giuseppe
   Bertani, Angela
   Bossa, Fabrizio
   Allocca, Mariangela
   Buda, Andrea
   Mocci, Gianmarco
   Soriano, Alessandra
   Mazzuoli, Silvia
   Bertani, Lorenzo
   Baccini, Flavia
   Loddo, Erika
   Privitera, Antonino Carlo
   Sartini, Alessandro
   Viscido, Angelo
   Grossi, Laurino
   Casini, Valentina
   Gerardi, Viviana
   Ascolani, Marta
   Di Ruscio, Mirko
   Casella, Giovanni
   Savarino, Edoardo
   Stradella, Davide
   Pumpo, Rossella
   Cortelezzi, Claudio Camillo
   Daperno, Marco
   Ciardo, Valeria
   Nardone, Olga Maria
   Caprioli, Flavio
   Vitale, Giovanna
   Cappello, Maria
   Comberlato, Michele
   Alvisi, Patrizia
   Festa, Stefano
   Campigotto, Michele
   Bodini, Giorgia
   Balestrieri, Paola
   Viola, Anna
   Pugliese, Daniela
   Armuzzi, Alessandro
   Fantini, Massimo C.
   Fiorino, Gionata
CA IG-IBD Italian Grp Study Inflamma
TI Activities related to inflammatory bowel disease management during and
   after the coronavirus disease 2019 lockdown in Italy: How to maintain
   standards of care
SO UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
LA English
DT Article
DE Inflammatory bowel disease; COVID-19; standards of care; Crohn&#8217; s
   disease; ulcerative colitis; therapy
ID COVID-19; IBD
AB Background and aims
   Restructuring activities have been necessary during the lockdown phase of the coronavirus disease 2019 (COVID-19) pandemic. Few data are available on the post-lockdown phase in terms of health-care procedures in inflammatory bowel disease (IBD) care, and no data are available specifically from IBD units. We aimed to investigate how IBD management was restructured during the lockdown phase, the impact of the restructuring on standards of care and how Italian IBD units have managed post-lockdown activities.
   Methods
   A web-based online survey was conducted in two phases (April and June 2020) among the Italian Group for IBD affiliated units within the entire country. We investigated preventive measures, the possibility of continuing scheduled visits/procedures/therapies because of COVID-19 and how units resumed activities in the post-lockdown phase.
   Results
   Forty-two referral centres participated from all over Italy. During the COVID-19 lockdown, 36% of first visits and 7% of follow-up visits were regularly done, while >70% of follow-up scheduled visits and 5% of first visits were done virtually. About 25% of scheduled endoscopies and bowel ultrasound scans were done. More than 80% of biological therapies were done as scheduled. Compared to the pre-lockdown situation, 95% of centres modified management of outpatient activity, 93% of endoscopies, 59% of gastrointestinal ultrasounds and 33% of biological therapies. Resumption of activities after the lockdown phase may take three to six months to normalize. Virtual clinics, implementation of IBD pathways and facilities seem to be the main factors to improve care in the future.
   Conclusion
   Italian IBD unit restructuring allowed quality standards of care during the COVID-19 pandemic to be maintained. A return to normal appears to be feasible and achievable relatively quickly. Some approaches, such as virtual clinics and identified IBD pathways, represent a valid starting point to improve IBD care in the post-COVID-19 era.
C1 [Saibeni, Simone; Bezzio, Cristina] ASST Rhodense, Gastroenterol Unit, Rho Hosp, Milan, Italy.
   [Scucchi, Ludovica] Univ Tor Vergata, Dept Syst Med, GI Unit, Policlin Tor Vergata, Rome, Italy.
   [Dragoni, Gabriele] Careggi Univ Hosp Florence, Gastroenterol Unit, Florence, Italy.
   [Miranda, Agnese] Univ Campania L Vanvitelli, Gastroenterol & Endoscopy Unit, Naples, Italy.
   [Ribaldone, Davide Giuseppe] Univ Turin, Dept Med Sci, Turin, Italy.
   [Bertani, Angela] Policlin Hosp, Dept Gastroenterol, IBD Unit, Modena, Italy.
   [Bossa, Fabrizio] IRCCS Casa Sollievo Sofferenza, Div Gastroenterol, San Giovanni Rotondo, Italy.
   [Allocca, Mariangela; Fiorino, Gionata] IBD Ctr, Humanitas Clin & Res Ctr, Gastroenterol, IRCCS, Milan, Italy.
   [Allocca, Mariangela; Fiorino, Gionata] Humanitas Univ, Dept Biomed Sci, Milan, Italy.
   [Buda, Andrea] S Maria Prato Hosp, Dept Gastrointestinal Oncol Surg, Gastroenterol & Endoscopy Unit, Feltre, Italy.
   [Mocci, Gianmarco] Brotzu Hosp, Gastroenterol Unit, Cagliari, Italy.
   [Soriano, Alessandra] Azienda USL Arcispedale S Maria Nuova, Gastroenterol Div, IRCCS Reggio Emilia, Reggio Emilia, Italy.
   [Mazzuoli, Silvia] Monsignor R Dimiccoli Hosp, Gastroenterol & Artificial Nutr Unit, ASL BT, Barletta, Italy.
   [Bertani, Lorenzo] Apuane Hosp Tuscany NorthWest ASL, Gastroenterol & Digest Endoscopy Dept, Massa, Italy.
   [Baccini, Flavia] St Andrea Univ Hosp, Digest Dis Unit, Rome, Italy.
   [Loddo, Erika; Fantini, Massimo C.] AOU Cagliari, Gastroenterol Unit, AOU Cagliari, Cagliari, Italy.
   [Loddo, Erika; Fantini, Massimo C.] Univ Cagliari, Dept Med Sci & Publ Hlth, Cagliari, Italy.
   [Privitera, Antonino Carlo] Cannizzaro Hosp, IBD Unit, Catania, Italy.
   [Sartini, Alessandro] AUSL Romagna, Gastroenterol & Digest Endoscopy Unit, Rimini, Italy.
   [Viscido, Angelo] Univ Aquila, Dept Life Hlth & Environm Sci, Gastroenterol Unit, Laquila, Italy.
   [Grossi, Laurino] DAnnunzio Univ, Osped Spirito Santo, Digest Physiopathol, Rimini, Italy.
   [Casini, Valentina] Seriate Hosp, Gastroenterol Unit, ASST Bergamo EST, Bergamo, Italy.
   [Gerardi, Viviana] Poliambulanza Fdn, Dept Med, Gastroenterol & Endoscopy, Brescia, Italy.
   [Ascolani, Marta] Santa Maria Ca Foncello Hosp, Gastroenterol Unit, Treviso, Italy.
   [Di Ruscio, Mirko] IRCCS Sacro Cuore Don Calabria, IBD Unit, Negrar, Italy.
   [Casella, Giovanni] ATS Brianza, Monza Brianza, Limbiate, Italy.
   [Savarino, Edoardo] Univ Padua, Gastroenterol Unit, Dept Surg Oncol & Gastroenterol, Padua, Italy.
   [Stradella, Davide] AOU Maggiore Carita, Gastroenterol Unit, Novara, Italy.
   [Pumpo, Rossella] ASLNA1, Endoscopy Unit PO SG Bosco, Naples, Italy.
   [Cortelezzi, Claudio Camillo] ASST Sette Laghi, Gastroenterol & Endoscopy Unit, Varese, Italy.
   [Daperno, Marco] Mauriziano Hosp, Gastroenterol Unit, Turin, Italy.
   [Ciardo, Valeria] Antonio Hosp, Gastroenterol Unit, San Daniele Del Friuli, Italy.
   [Nardone, Olga Maria] Univ Naples Federico II, Dept Clin Med & Surg, Gastroenterol, Naples, Italy.
   [Caprioli, Flavio] Univ Milan, IRCCS Ca Granda Osped Maggiore Milano Policlin, Dept Pathophysiol & Transplantat, Gastroenterol & Endoscopy Unit, Milan, Italy.
   [Vitale, Giovanna] San Carlo Hosp, Gastroenterol & Endoscopy Unit, Potenza, Italy.
   [Cappello, Maria] Univ Palermo, IBD Clin, Gastroenterol Sect, Promise, Palermo, Italy.
   [Comberlato, Michele] IBD Unit, Dept Gastroenterol, Bolzano, Italy.
   [Alvisi, Patrizia] Maggiore Hosp, Paediat Gastroenterol Unit, Bologna, Italy.
   [Festa, Stefano] S Filippo Neri Hosp, IBD Unit, Rome, Italy.
   [Campigotto, Michele] Trieste Univ, Acad Surg & Hlth Sci Dept, Trieste, Italy.
   [Bodini, Giorgia] Genoa Univ, Internal Med Dept, Gastroenterol Chair, Genoa, Italy.
   [Balestrieri, Paola] Univ Rome, Unit Digest Dis Campus Bio Med, Rome, Italy.
   [Viola, Anna] Policlin Messina, IBD Unit, Messina, Italy.
   [Pugliese, Daniela; Armuzzi, Alessandro] Acad Policlin Fdn A Gemelli IRCCS, CEMAD IBD Unit, Internal & Gastroenterol Unit, Rome, Italy.
RP Saibeni, S (corresponding author), ASST Rhodense, Rho Hosp, Gastroenterol Unit, Corso Europa 250, I-20017 Rho, MI, Italy.
EM saibo@tiscali.it
RI Caprioli, Flavio/AAB-5176-2019; Ribaldone, Davide Giuseppe/H-3478-2019;
   Saibeni, Simone/AAA-3663-2019; Viscido, Angelo/AAB-7536-2020
OI Caprioli, Flavio/0000-0002-8077-8175; Ribaldone, Davide
   Giuseppe/0000-0002-9421-3087; Saibeni, Simone/0000-0001-5677-2534;
   Viscido, Angelo/0000-0001-8513-3758; Buda, Andrea/0000-0002-3099-8612;
   Dragoni, Gabriele/0000-0001-5752-5113; Sartini,
   Alessandro/0000-0003-1573-6451
CR Allocca M, 2020, CLIN GASTROENTEROL H, V18, P1882, DOI 10.1016/j.cgh.2020.04.028
   Beddok Arnaud, 2020, Radiother Oncol, V150, P12, DOI 10.1016/j.radonc.2020.05.043
   Bilato C, 2020, G ITAL CARDIOL, V21, P408, DOI 10.1714/3359.33322
   Danese S, 2020, NAT REV GASTRO HEPAT, V17, P253, DOI 10.1038/s41575-020-0294-8
   Fiorino G, 2020, J CROHNS COLITIS, V14, pS102
   Fiorino G, 2020, LANCET GASTROENTEROL, V5, P639, DOI 10.1016/S2468-1253(20)30152-7
   Fiorino G, 2020, J CROHNS COLITIS, V14, P1330, DOI 10.1093/ecco-jcc/jjaa058
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   John Hopkins University Coronavirus Resource Center, 2020, COR COVID 19 GLOB CA
   Arranz EM, 2020, INFLAMM BOWEL DIS, V26, P1149, DOI 10.1093/ibd/izaa142
   Occhipinti Vincenzo, 2020, Gastroenterology, DOI 10.1053/j.gastro.2020.05.027
   Occhipinti V, 2020, INFLAMM BOWEL DIS, V26, P793, DOI 10.1093/ibd/izaa084
   Pugliese D, 2020, DIGEST LIVER DIS, V52, P1238, DOI 10.1016/j.dld.2020.05.053
   Scaldaferri F, 2020, UNITED EUR GASTROENT, V8, P775, DOI 10.1177/2050640620929133
NR 14
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2050-6406
EI 2050-6414
J9 UNITED EUR GASTROENT
JI United European Gastroenterol. J.
PD DEC
PY 2020
VL 8
IS 10
BP 1228
EP 1235
AR 2050640620964132
DI 10.1177/2050640620964132
EA OCT 2020
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA PA6RF
UT WOS:000583889700001
PM 33070758
OA Bronze, Green Accepted
DA 2021-01-01
ER

PT J
AU Zizzo, J
AF Zizzo, John
TI The Missing Link in the Covid-19 Vaccine Race
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE Covid-19; vaccine; vaccine marketing; immunization campaign; vaccine
   hesitancy
AB Operation Warp Speed and global vaccine research efforts have succeeded in rapidly launching three vaccine candidates for coronavirus disease 2019 (COVID-19) into Phase III clinical trials. A recent letter from Centers for Disease Control and Prevention (CDC) Director Redfield underscored the possibility of "large-scale" distribution of a coronavirus vaccine as early as November 1, 2020. However, recent polling reveals that the majority of Americans remain skeptical of both the safety and efficacy of a potential Covid-19 vaccine. Even more troublesome is the fact that a comprehensive, collaborative vaccine marketing campaign has not been initiated to educate the U.S. public on and encourage widespread Covid-19 vaccination. Accordingly, this article lays out a plan of action, utilizing proven immunization marketing strategies and novel approaches, that could be used to combat vaccine hesitancy toward Covid-19. A vaccine may indeed be our ticket out of this pandemic, but targeted marketing is needed to increase public optimism toward that fact.
C1 [Zizzo, John] Univ Miami, Miller Sch Med, 1600 NW 10th Ave 1140, Miami, FL 33136 USA.
RP Zizzo, J (corresponding author), Univ Miami, Miller Sch Med, 1600 NW 10th Ave 1140, Miami, FL 33136 USA.
EM Jjz41@med.miami.edu
OI Zizzo, John/0000-0001-9512-0715
CR [Anonymous], 2020, DEP HLTH HUM SERV HH
   Centers for Disease Control and Prevention, 2020, COVIDVIEW WEEKL SURV
   Nowak GJ, 2015, VACCINE, V33, P4204, DOI 10.1016/j.vaccine.2015.04.039
   Tai Don Bambino Geno, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa815
NR 4
TC 0
Z9 0
U1 5
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1831859
EA OCT 2020
PG 3
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA OG2OW
UT WOS:000581731000001
PM 33079612
DA 2021-01-01
ER

PT J
AU Lu, Y
   Wang, YJ
   Zhang, Z
   Huang, JL
   Yao, MC
   Huang, GB
   Ge, YY
   Zhang, PC
   Huang, HX
   Wang, Y
   Li, HL
   Wang, W
AF Lu, Yan
   Wang, Yajun
   Zhang, Zhen
   Huang, Jingliang
   Yao, Meicun
   Huang, Guobin
   Ge, Yuanyuan
   Zhang, Peichun
   Huang, Huaxin
   Wang, Yong
   Li, Huiliang
   Wang, Wen
TI Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope
   Mapping
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID ANTIBODIES; CORONAVIRUS; INFECTION; OUTBREAK; COVID-19; CLEAVAGE;
   THERAPY
AB This new decade has started with a global pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), precipitating a worldwide health crisis and economic downturn. Scientists and clinicians have been racing against time to find therapies for COVID-19. Repurposing approved drugs, developing vaccines and employing passive immunization are three major therapeutic approaches to fighting COVID-19. Chicken immunoglobulin Y (IgY) has the potential to be used as neutralizing antibody against respiratory infections, and its advantages include high avidity, low risk of adverse immune responses, and easy local delivery by intranasal administration. In this study, we raised antibody against the spike (S) protein of SARS-CoV-2 in chickens and extracted IgY (called IgY-S) from egg yolk. IgY-S exhibited high immunoreactivity against SARS-CoV-2 S, and by epitope mapping, we found five linear epitopes of IgY-S in SARS-CoV-2 S, two of which are cross-reactive with SARS-CoV S. Notably, epitope SIIAYTMSL, one of the identified epitopes, partially overlaps the S1/S2 cleavage region in SARS-CoV-2 S and is located on the surface of S trimer in 3D structure, close to the S1/S2 cleavage site. Thus, antibody binding at this location could physically block the access of proteolytic enzymes to S1/S2 cleavage site and thereby impede S1/S2 proteolytic cleavage, which is crucial to subsequent virus-cell membrane fusion and viral cell entry. Therefore, the feasibility of using IgY-S or epitope SIIAYTMS-specific IgY as neutralizing antibody for preventing or treating SARS-CoV-2 infection is worth exploring.
C1 [Lu, Yan; Zhang, Peichun; Huang, Huaxin; Wang, Wen] Huamin Med Co Ltd, Zhuhai, Peoples R China.
   [Wang, Yajun; Li, Huiliang] UCL, Wolfson Inst Biomed Res, London, England.
   [Zhang, Zhen] Tsinghua Univ, Sch Life Sci, Joint Ctr Life Sci, Beijing, Peoples R China.
   [Huang, Jingliang] Sun Yat Sen Univ, Sch Chem Engn & Technol, Zhuhai, Peoples R China.
   [Yao, Meicun] Sun Yat Sen Univ, Sch Pharmaceut Sci, Shenzhen, Peoples R China.
   [Huang, Guobin; Ge, Yuanyuan] Levi Regenerat Med Technol, Zhuhai, Peoples R China.
   [Wang, Yong] Guangzhou Hongxiang Biol Med Technol Co Ltd, Guangzhou, Peoples R China.
RP Wang, W (corresponding author), Huamin Med Co Ltd, Zhuhai, Peoples R China.; Li, HL (corresponding author), UCL, Wolfson Inst Biomed Res, London, England.
EM yluyanlu@gmail.com; yajun.wang@ucl.ac.uk;
   zhenzhang@mail.tsinghua.edu.cn; starfarming09@163.com;
   lssymc@mail.sysu.edu.cn; bine2013@126.com; 1549127718@qq.com;
   1329379326@qq.com; 970932399@qq.com; 57304210@qq.com;
   huiliang.li@ucl.ac.uk; wangwen0001@126.com
FU BBSRCBiotechnology and Biological Sciences Research Council (BBSRC)
   [BB/S000844/1, BB/S008934/1]; Shenzhen Sanming Project of Medicine
   [SZSM201911003]
FX We thank Dr. Ling Zhang and Dr. Cheng Yang for their kind help and
   discussion. Li's Lab is supported by BBSRC (BB/S000844/1 and
   BB/S008934/1) and Shenzhen Sanming Project of Medicine (SZSM201911003);
   Yajun Wang is a Newton International Fellow (NIF003/1003).
CR Abbas AT, 2019, HUM VACC IMMUNOTHER, V15, P264, DOI 10.1080/21645515.2018.1514224
   [Anonymous], 2020, LANCET INFECT DIS, V20, P511, DOI 10.1016/S1473-3099(20)30298-X
   Arnold C, 2020, NEW SCI, V245, P6, DOI 10.1016/S0262-4079(20)30831-9
   Barnes CO, 2020, CELL, V182, P828, DOI 10.1016/j.cell.2020.06.025
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076
   Constantin C, 2020, EXP THER MED, V20, P151, DOI 10.3892/etm.2020.8704
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Duffy S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000003
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Green MS, 2020, LANCET, V395, P1034, DOI 10.1016/S0140-6736(20)30630-9
   Hammarstrom L, 2020, J ALLERGY CLIN IMMUN, V146, P58, DOI 10.1016/j.jaci.2020.04.043
   Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827
   Hayden EC, 2018, NATURE, V557, P475, DOI 10.1038/d41586-018-05205-x
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kovacs-Nolan J, 2012, ANNU REV FOOD SCI T, V3, P163, DOI 10.1146/annurev-food-022811-101137
   Lee YC, 2007, VET IMMUNOL IMMUNOP, V117, P75, DOI 10.1016/j.vetimm.2007.02.001
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Pauly D, 2011, JOVE-J VIS EXP, DOI 10.3791/3084
   de la Lastra JMP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030486
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Somasundaram R, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106654
   Sykes KF, 2013, TRENDS BIOTECHNOL, V31, P45, DOI 10.1016/j.tibtech.2012.10.012
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tsukamoto M, 2011, MOL MED REP, V4, P209, DOI 10.3892/mmr.2011.410
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Wallach MG, 2011, CLIN VACCINE IMMUNOL, V18, P1083, DOI 10.1128/CVI.05075-11
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wen JL, 2012, ANTIVIR RES, V93, P154, DOI 10.1016/j.antiviral.2011.11.005
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xie Min-qiang, 2004, Zhonghua Er Bi Yan Hou Ke Za Zhi, V39, P112
   Yang YE, 2014, J VIROL METHODS, V206, P19, DOI 10.1016/j.jviromet.2014.05.016
   Yi ZG, 2020, EMERG MICROBES INFEC, V9, P1988, DOI 10.1080/22221751.2020.1815591
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhou DRN, 2020, NAT STRUCT MOL BIOL, V27, P950, DOI 10.1038/s41594-020-0480-y
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 57
TC 0
Z9 0
U1 2
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PD OCT 17
PY 2020
VL 2020
AR 9465398
DI 10.1155/2020/9465398
PG 8
WC Immunology
SC Immunology
GA OP8GM
UT WOS:000588328100001
PM 33134398
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Abd Elkodous, M
   El-Sayyad, GS
   Abdel-Daim, MM
AF Abd Elkodous, Mohamed
   El-Sayyad, Gharieb S.
   Abdel-Daim, Mohamed M.
TI Engineered nanomaterials as fighters against SARS-CoV-2: The way to
   control and treat pandemics
SO ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
LA English
DT Article; Early Access
DE Corona viruses; Nanomaterials; COVID-19; Nano-vaccines; Nanodrugs
ID VIRUS-LIKE PARTICLES; GAMMA-RAYS; CORONAVIRUS; NANOPARTICLES;
   PATHOGENESIS; DELIVERY; CELLS; DRUG
AB In this editorial trend, we aim to collect and present recently available data about the characteristics of SARS-CoV-2 virus, severity, infection, replication, diagnosis, and current medications. In addition, we propose the role of nanomaterials in controlling and treating COVID-19 through their antiviral and antibacterial potential with suggested action mechanisms indicating the capability of interaction between these nanomaterials and SARS-CoV-2. These nanomaterials might be among the possible and most effective cures against coronavirus.
C1 [Abd Elkodous, Mohamed] Toyohashi Univ Technol, Dept Elect & Elect Informat Engn, Toyohashi, Aichi 4418580, Japan.
   [Abd Elkodous, Mohamed] Nile Univ, Sch Engn & Appl Sci, Ctr Nanotechnol CNT, Giza 16453, Egypt.
   [El-Sayyad, Gharieb S.] Egyptian Atom Energy Author EAEA, Natl Ctr Radiat Res & Technol NCRRT, Drug Radiat Res Dept, Cairo, Egypt.
   [El-Sayyad, Gharieb S.] Egyptian Armed Forces, Mil Tech Coll MTC, Dept Chem Engn, Cairo, Egypt.
   [Abdel-Daim, Mohamed M.] King Saud Univ, Coll Sci, Dept Zool, POB 2455, Riyadh 11451, Saudi Arabia.
   [Abdel-Daim, Mohamed M.] Suez Canal Univ, Fac Vet Med, Dept Pharmacol, Ismailia 41522, Egypt.
RP Abd Elkodous, M (corresponding author), Toyohashi Univ Technol, Dept Elect & Elect Informat Engn, Toyohashi, Aichi 4418580, Japan.; Abd Elkodous, M (corresponding author), Nile Univ, Sch Engn & Appl Sci, Ctr Nanotechnol CNT, Giza 16453, Egypt.; El-Sayyad, GS (corresponding author), Egyptian Atom Energy Author EAEA, Natl Ctr Radiat Res & Technol NCRRT, Drug Radiat Res Dept, Cairo, Egypt.; El-Sayyad, GS (corresponding author), Egyptian Armed Forces, Mil Tech Coll MTC, Dept Chem Engn, Cairo, Egypt.; Abdel-Daim, MM (corresponding author), King Saud Univ, Coll Sci, Dept Zool, POB 2455, Riyadh 11451, Saudi Arabia.; Abdel-Daim, MM (corresponding author), Suez Canal Univ, Fac Vet Med, Dept Pharmacol, Ismailia 41522, Egypt.
EM mohamed.hamada.abdlekodous.xi@tut.jp; Gharieb.Elsayyad@eaea.org.eg;
   abdeldaim.m@vet.suez.edu.eg
RI Abdel-Daim, Mohamed M./B-2545-2013; Elkodous, Mohamed Abd/S-4020-2019;
   El-Sayyad/ABH-9053-2020
OI Abdel-Daim, Mohamed M./0000-0002-4341-2713; Elkodous, Mohamed
   Abd/0000-0002-9408-9178; El-Sayyad/0000-0001-5410-7936
CR Abd Elkodous M, 2020, BIOL TRACE ELEM RES, V196, P297, DOI 10.1007/s12011-019-01894-1
   Abd Elkodous M, 2019, J CLUST SCI, V30, P531, DOI 10.1007/s10876-019-01533-8
   Abd Elkodous M, 2019, COLLOID SURFACE B, V180, P411, DOI 10.1016/j.colsurfb.2019.05.008
   Abd Ellah NH, 2020, NANOMEDICINE-UK, V15, P2085, DOI 10.2217/nnm-2020-0247
   Abdel Maksoud MIA, 2020, J HAZARD MATER, V399
   Aina DA, 2019, KARBALA INT J MOD SC, V5, P2, DOI [10.33640/2405-609X.1018, DOI 10.33640/2405-609X.1018]
   Akinola PO, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04610
   Angel-Korman Avital, 2020, Harefuah, V159, P231
   Buzon MJ, 2011, J VIROL, V85, P9646, DOI 10.1128/JVI.05327-11
   Cascella M, 2020, FEATURES EVALUATION
   Chafekar A, 2012, PRODUCTION CYTOKINES
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen L, 2020, MAT SCI ENG C-MATER, V112, DOI 10.1016/j.msec.2020.110924
   Chen Y, 2011, COCHRANE DATABASE SY
   Choi J, 2017, EXPERT OPIN THER PAT, V27, P721, DOI 10.1080/13543776.2017.1281248
   Coleman CM, 2014, VACCINE, V32, P3169, DOI 10.1016/j.vaccine.2014.04.016
   Control CfD Prevention, 2014, INFL ANT MED SUMM CL
   Curley GF, 2015, J THORAC DIS, V7, P1092, DOI 10.3978/j.issn.2072-1439.2015.07.18
   Dhakal S, 2019, VET RES, V50, DOI 10.1186/s13567-019-0712-5
   El-Batal AI, 2020, RSC ADV, V10, P9274, DOI 10.1039/c9ra10765g
   El-Batal AI, 2018, J CLUST SCI, V29, P1003, DOI 10.1007/s10876-018-1411-5
   El-Sayyad GS, 2020, RSC ADV, V10, P5241, DOI 10.1039/c9ra10505k
   Elegbede JA, 2020, WASTE BIOMASS VALORI, V11, P781, DOI 10.1007/s12649-018-0540-2
   Elegbede JA, 2019, BIOTECHNOL PROGR, V35, DOI 10.1002/btpr.2829
   Fan Y, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030210
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Frieman M, 2008, MICROBIOL MOL BIOL R, V72, P672, DOI 10.1128/MMBR.00015-08
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Huo CY, 2020, INT J NANOMED, V15, P661, DOI 10.2147/IJN.S221667
   Jacobi A, 2020, CLIN IMAG, V64, P35, DOI 10.1016/j.clinimag.2020.04.001
   Jansen RR, 2011, J CLIN MICROBIOL, V49, P2631, DOI 10.1128/JCM.02094-10
   Kabir MT, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00616
   Kell AM, 2015, VIROLOGY, V479, P110, DOI 10.1016/j.virol.2015.02.017
   Kheirollahpour Mehdi, 2020, Pharmaceutical Nanotechnology, V8, P6, DOI 10.2174/2211738507666191024162042
   Kim Juhyun, 2020, Journal of Water and Environment Technology, V18, P1, DOI 10.2965/jwet.19-046
   Lateef A, 2016, J CLUST SCI, V27, P1561, DOI 10.1007/s10876-016-1019-6
   Lippi G, 2020, LAB ABNORMALITIES PA
   Liu YV, 2011, VACCINE, V29, P6606, DOI 10.1016/j.vaccine.2011.06.111
   Lopez LA, 2007, CORONAVIRUS ENVELOPE
   Ma X, 2020, BMC INFECT DIS, V20, DOI [10.1186/s12866-020-01842-3, 10.1186/s12879-020-05135-y]
   McCulloh RJ, 2013, VIRULENCE, V4, P1, DOI 10.4161/viru.22788
   Mitsdoerffer M, 2010, P NATL ACAD SCI USA, V107, P14292, DOI 10.1073/pnas.1009234107
   Mohamed HEA, 2020, NANOMEDICINE-UK, V15, P467, DOI 10.2217/nnm-2019-0368
   Nikitina E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092821
   Ojo SA, 2016, IEEE T NANOBIOSCI, V15, P433, DOI 10.1109/TNB.2016.2559161
   Panda PK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb8097
   Park H-J, 2017, AM ASS IMMNOL
   Perez-Casares A, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00079
   Poeck H, 2010, NAT IMMUNOL, V11, P63, DOI 10.1038/ni.1824
   Rai PK, 2020, CURR RES GREEN SUSTA, V3, P100011, DOI 10.1016/j.crgsc.2020.100011
   Scheerlinck JPY, 2008, DRUG DISCOV TODAY, V13, P882, DOI 10.1016/j.drudis.2008.06.016
   Schneider-Ohrum K, 2012, CURR TOP MICROBIOL, V354, P53, DOI 10.1007/82_2011_135
   Sekhon B. S., 2011, INT J PHARM FRONT RE, V1, P101
   Sivakumar B, 2020, STUDIES INDIAN PLACE, V40, P228
   Sportelli MC, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10040802
   Storch GA, 2000, CLIN INFECT DIS, V31, P739, DOI 10.1086/314015
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Takeuchi O, 2008, CURR OPIN IMMUNOL, V20, P17, DOI 10.1016/j.coi.2008.01.002
   Thompson R, 2020, LANCET INFECT DIS, V20, P280, DOI 10.1016/S1473-3099(20)30068-2
   Tran DN, 2020, MAT RES EXPRESS
   Verma A, 2008, NAT MATER, V7, P588, DOI 10.1038/nmat2202
   VK Venugopal, 2020, SYSTEMATIC METAANALY
   Vos LM, 2019, CLIN INFECT DIS, V69, P1243, DOI 10.1093/cid/ciz056
   Wong CW, 2020, J CLUST SCI, V31, P367, DOI 10.1007/s10876-019-01651-3
   World Heath Organization, 2020, 72 WHO
   Wu J, 2020, INVEST RADIOL, V55, P257, DOI 10.1097/RLI.0000000000000670
   Xu C, 2020, PROCEEDINGS OF THE ASME INTERNAL COMBUSTION ENGINE FALL TECHNICAL CONFERENCE, 2019
   Yang PH, 2020, CELL MOL IMMUNOL, V17, P555, DOI 10.1038/s41423-020-0407-x
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 72
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0944-1344
EI 1614-7499
J9 ENVIRON SCI POLLUT R
JI Environ. Sci. Pollut. Res.
DI 10.1007/s11356-020-11032-3
EA OCT 2020
PG 7
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA OC9CI
UT WOS:000579452100009
PM 33068246
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gomez-Fernandez, C
   Lopez-Sundh, AE
   Gonzalez-Vela, C
   Ocejo-Vinyals, JG
   Mayor-Ibarguren, A
   Salas-Venero, CA
   Gutierrez-Larranaga, M
   Tejerina-Puente, A
   Farinas, MC
   Cabero-Perez, MJ
   Lopez-Hoyos, M
   Gonzalez-Lopez, MA
AF Gomez-Fernandez, Cristina
   Lopez-Sundh, Ana E.
   Gonzalez-Vela, Carmen
   Ocejo-Vinyals, Javier Gonzalo
   Mayor-Ibarguren, Ander
   Salas-Venero, Carlos A.
   Gutierrez-Larranaga, Maria
   Tejerina-Puente, Ana
   Farinas, Maria Carmen
   Cabero-Perez, Maria Jesus
   Lopez-Hoyos, Marcos
   Gonzalez-Lopez, Marcos A.
TI High prevalence of cryofibrinogenemia in patients with chilblains during
   the COVID-19 outbreak
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Article
ID INFECTION; PERNIOSIS; SKIN
AB Background Many cutaneous manifestations have been described in possible association with the COVID-19 pandemic, including acral lesions resembling chilblains. The underlying pathomechanisms of COVID-19 chilblains are not fully understood. The aim of this study was to describe the clinical, pathological, and laboratory findings of a series of patients who developed chilblains during the COVID-19 outbreak and to investigate the possible factors that could be involved in the pathogenesis of these lesions. Methods We conducted a prospective cohort study that included 54 patients who presented with chilblains during the highest peak in the incidence of COVID-19 in Cantabria (northern Spain). Skin biopsies were performed on 10 of these patients who presented with recent lesions. Laboratory investigations, including immunological analysis, serological studies, and the assessment of cryoproteins, were also performed. Results Most patients presented erythematous plaques located on the toes and/or purpuric macules located on the feet. Histopathological findings were compatible with those of idiopathic chilblains. Immunohistochemical evaluation showed C3d and C4d deposits in the vessel walls in seven cases. The autoimmunity panel was negative in most of our series. Cryoprotein testing showed positive cryofibrinogen in two-thirds (66.7%) of the patients assessed. On follow-up, most patients presented almost complete resolution, although six patients required prednisone and antiaggregant drug treatment. Conclusions This study shows, for the first time to our knowledge, a high prevalence of cryofibrinogenemia in patients with chilblains during the COVID-19 pandemic. Cryofibrinogenemia could be implicated in the pathogenesis of chilblains related to COVID-19.
C1 [Gomez-Fernandez, Cristina; Lopez-Sundh, Ana E.; Gonzalez-Lopez, Marcos A.] Univ Cantabria, IDIVAL, Div Dermatol, Hosp Univ Marques de Valdecilla, Santander, Spain.
   [Gonzalez-Vela, Carmen] Univ Cantabria, Div Pathol, Hosp Univ Marques de Valdecilla, IDIVAL, Santander, Spain.
   [Ocejo-Vinyals, Javier Gonzalo; Gutierrez-Larranaga, Maria; Lopez-Hoyos, Marcos] Univ Cantabria, IDIVAL, Hosp Univ Marques de Valdecilla, Div Immunol, Santander, Spain.
   [Mayor-Ibarguren, Ander] Hosp Univ La Paz Hosp, Div Dermatol, Madrid, Spain.
   [Salas-Venero, Carlos A.] Univ Cantabria, Hosp Univ Marques de Valdecilla, IDIVAL, Div Microbiol, Santander, Spain.
   [Tejerina-Puente, Ana] Cantabrian Hlth Serv, Pediat Unit, Hlth Ctr Marina Santander, Santander, Spain.
   [Farinas, Maria Carmen] Univ Cantabria, Infect Dis Unit, Hosp Univ Marques de Valdecilla, IDIVAL, Santander, Spain.
   [Cabero-Perez, Maria Jesus] Univ Cantabria, IDIVAL, Hosp Univ Marques de Valdecilla, Div Pediat, Santander, Spain.
RP Gonzalez-Lopez, MA (corresponding author), Hosp Univ Marques de Valdecilla, Serv Dermatol, Avda Valdecilla S-N, Santander 39008, Cantabria, Spain.
EM marcosg@aedv.es
OI Lopez-Sundh, Ana Elisabet/0000-0002-2660-2347
CR Abdel-Wahab N, 2018, LUPUS, V27, P572, DOI 10.1177/0961203317731532
   Agencia Estatal de Metereologia (AEMET), B CLIM MARZ 2020 CAN
   Andina D, 2020, PEDIATR DERMATOL, V37, P406, DOI 10.1111/pde.14215
   Belizna CC, 2008, RHEUMATOLOGY, V47, P205, DOI 10.1093/rheumatology/kem341
   Blain H, 2000, CLIN EXP IMMUNOL, V120, P253, DOI 10.1046/j.1365-2249.2000.01210.x
   Caimi G, 2017, EUR J INTERN MED, V42, P24, DOI 10.1016/j.ejim.2017.04.001
   Chou HF, 2018, PEDIATR RHEUMATOL, V16, DOI 10.1186/s12969-018-0249-6
   St Clair NE, 2006, PEDIATR DERMATOL, V23, P451
   Colmenero I, 2020, BRIT J DERMATOL, V183, P729, DOI 10.1111/bjd.19327
   Cordoro KM, 2020, PEDIATR DERMATOL, V37, P419, DOI 10.1111/pde.14227
   Cribier B, 2001, J AM ACAD DERMATOL, V45, P924, DOI 10.1067/mjd.2001.117861
   Crowson AN, 1997, HUM PATHOL, V28, P478, DOI 10.1016/S0046-8177(97)90038-1
   de Masson A, 2020, J AM ACAD DERMATOL, V83, P667, DOI 10.1016/j.jaad.2020.04.161
   Delluc A, 2008, AM J MED, V121, P624, DOI 10.1016/j.amjmed.2008.03.011
   Dhochak N, 2020, INDIAN J PEDIATR, V87, P537, DOI 10.1007/s12098-020-03322-y
   Fernandez-Nieto D, 2020, J AM ACAD DERMATOL, V83, pE61, DOI 10.1016/j.jaad.2020.04.093
   FURIOLI J, 1985, ARCH FR PEDIATR, V42, P313
   Casas CG, 2020, BRIT J DERMATOL, V183, P71, DOI 10.1111/bjd.19163
   Garcia-Lara G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13516
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   IRELAND TA, 1984, J PEDIATR-US, V105, P67, DOI 10.1016/S0022-3476(84)80363-7
   Kim H, 2016, J MOL MED, V94, P1111, DOI 10.1007/s00109-016-1465-5
   Landa N, 2020, INT J DERMATOL, V59, P739, DOI 10.1111/ijd.14937
   Larkins N, 2013, J PAEDIATR CHILD H, V49, P144, DOI 10.1111/jpc.12094
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Mallapaty S, 2020, NATURE, V580, P571, DOI 10.1038/d41586-020-01115-z
   Mazzotta F, 2020, EUR J PEDIAT DERMATO, V30, P71, DOI DOI 10.26326/2281-9649.30.2.2102
   Michaud M, 2013, JCR-J CLIN RHEUMATOL, V19, P142, DOI 10.1097/RHU.0b013e318289e06e
   Nash JW, 2003, AM J CLIN PATHOL, V119, P114, DOI 10.1309/KB5ARGWVL1R2BPBN
   Paradis C, 2019, J CLIN IMMUNOL, V39, P118, DOI 10.1007/s10875-018-0584-x
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   ROBINSON MG, 1966, J PEDIATR-US, V69, P35, DOI 10.1016/S0022-3476(66)80358-X
   Saadoun D, 2009, AM J MED, V122, P1128, DOI 10.1016/j.amjmed.2009.03.040
   Schultz K, 2020, J HAND SURG-AM, V45, P518, DOI 10.1016/j.jhsa.2020.04.024
   Simon T, 2015, PEDIATRICS, V116, pe472
   van Geest AJ, 1999, J EUR ACAD DERMATOL, V12, P47, DOI 10.1016/S0926-9959(98)00111-1
   Weston WL, 2000, PEDIATR DERMATOL, V17, P97, DOI 10.1046/j.1525-1470.2000.01722.x
NR 38
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0011-9059
EI 1365-4632
J9 INT J DERMATOL
JI Int. J. Dermatol.
PD DEC
PY 2020
VL 59
IS 12
BP 1475
EP 1484
DI 10.1111/ijd.15234
EA OCT 2020
PG 10
WC Dermatology
SC Dermatology
GA OR5JG
UT WOS:000578562000001
PM 33070314
OA Bronze
DA 2021-01-01
ER

PT J
AU Maurya, VK
   Kumar, S
   Bhatt, MLB
   Saxena, SK
AF Maurya, Vimal K.
   Kumar, Swatantra
   Bhatt, Madan L. B.
   Saxena, Shailendra K.
TI Antiviral activity of traditional medicinal plants from Ayurveda against
   SARS-CoV-2 infection
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; structure-based drug design; attachment inhibitor;
   gene network analysis; target prediction; pharmacokinetics; Ayurveda
ID VIRUS-INFECTION; MECHANISMS; COVID-19; CELLS
AB SARS-CoV-2 is the etiological agent of COVID-19 and responsible for more than 6 million cases globally, for which no vaccine or antiviral is available. Therefore, this study was planned to investigate the antiviral role of the active constituents against spike glycoprotein of SARS-CoV-2 as well as its host ACE2 receptor. Structure-based drug design approach has been used to elucidate the antiviral activity of active constituents present in traditional medicinal plants from Ayurveda. Further, parameters like drug-likeness, pharmacokinetics, and toxicity were determined to ensure the safety and efficacy of active constituents. Gene network analysis was performed to investigate the pathways altered during COVID-19. The prediction of drug-target interactions was performed to discover novel targets for active constituents. The results suggested that amarogentin, eufoliatorin, alpha-amyrin, caesalpinins, kutkin, beta-sitosterol, and belladonnine are the top-ranked molecules have the highest affinity towards both the spike glycoprotein and ACE2. Most active constituents have passed the criteria of drug-likeness and demonstrated good pharmacokinetic profile with minimum predicted toxicity level. Gene network analysis confirmed that G-protein coupled receptor, protein kinase B signaling, protein secretion, peptidyl-serine phosphorylation, nuclear transport, apoptotic pathway, tumor necrosis factor, regulation of angiotensin level, positive regulation of ion transport, and membrane protein proteolysis were altered during COVID-19. The target prediction analysis revealed that most active constituents target the same pathways which are found to be altered during COVID-19. Collectively, our data encourages the use of active constituents as a potential therapy for COVID-19. However, further studies are ongoing to confirm its efficacy against disease.
C1 [Maurya, Vimal K.; Kumar, Swatantra; Bhatt, Madan L. B.; Saxena, Shailendra K.] King Georges Med Univ KGMU, Dept Ctr Adv Res CFAR, Fac Med, Lucknow, Uttar Pradesh, India.
RP Saxena, SK (corresponding author), King Georges Med Univ KGMU, Dept Ctr Adv Res, Fac Med, Lucknow 226003, Uttar Pradesh, India.
EM shailen@kgmcindia.edu
OI Saxena, Shailendra K/0000-0003-2856-4185
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Carod-Artal FJ, 2020, REV NEUROLOGIA, V70, P311, DOI 10.33588/rn.7009.2020179
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen X, 2020, CHINA PERSPECT-SER, P1
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   El-Tantawy WH, 2015, J CLIN BIOCHEM NUTR, V57, P33, DOI 10.3164/jcbn.14-141
   Food and drug administration, FDA CAUT US HYDR CHL
   Franz M, 2018, NUCLEIC ACIDS RES, V46, pW60, DOI 10.1093/nar/gky311
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   GUZZI PH, 2020, J CLIN MED, V9, DOI DOI https://doi.org/10.3390/jcm9040982
   Hosseini A, 2014, IRAN J BASIC MED SCI, V17, P993
   Keating JA, 2012, REV MED VIROL, V22, P166, DOI 10.1002/rmv.722
   Khemka NM, 2020, ROU RES ASIA DEVELOP, P200
   KONG Q, 2020, MOL CANCER, V19, DOI DOI https://doi.org/10.1186/s12943-020-01209-2
   Kumar Swatantra, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00571-5
   Kumar V, 2016, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00308
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li MM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230295
   LI MY, 2020, INFECT DIS POVERTY, V9, DOI DOI https://doi.org/10.1186/s40249-020-00662-x
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Londino JD, 2017, AM J PHYSIOL-LUNG C, V313, pL845, DOI 10.1152/ajplung.00244.2017
   Mages J, 2008, J CELL MOL MED, V12, P1974, DOI 10.1111/j.1582-4934.2008.00235.x
   Maurya V. K., 2020, NAT PUBLIC HLTH EMER, DOI [10.1007/978-981-15-4814-7_10, DOI 10.1007/978-981-15-4814-7_10]
   Maurya Vimal K., 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00598-8
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   MEINEKE R, 2019, VIRUSES BASEL, V11, DOI DOI https://doi.org/10.3390/v11020171
   Naderer T, 2018, J LEUKOCYTE BIOL, V103, P275, DOI 10.1189/JLB.4MR0717-286R
   Newman DJ, 2020, J NAT PROD, V83, P770, DOI 10.1021/acs.jnatprod.9b01285
   Owais F, 2014, PAK J PHARM SCI, V27, P2183
   Paludan SR, 2001, J VIROL, V75, P10170, DOI 10.1128/JVI.75.21.10170-10178.2001
   Pandey MM, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/376327
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Ravi SK, 2018, ENVIRON TOXICOL PHAR, V58, P202, DOI 10.1016/j.etap.2018.01.008
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Thomsen R, 2006, J MED CHEM, V49, P3315, DOI 10.1021/jm051197e
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   VAISERMAN A, 2020, FRONT BIOENG BIOTECH, V7, DOI DOI https://doi.org/10.3389/fbioe.2019.00447
   Verma PC, 2009, CURR PHARM BIOTECHNO, V10, P641, DOI 10.2174/138920109789069314
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ZP, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040920
   WHO, COR DIS COVID 19 PAN
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Ye J, 2013, BBA-BIOMEMBRANES, V1828, P2926, DOI 10.1016/j.bbamem.2013.05.005
   Zhang JJ, 2016, BIOCHEM PHARMACOL, V114, P69, DOI 10.1016/j.bcp.2016.03.021
   Zhao JJ, 2019, INT J PHARMACEUT, V570, DOI 10.1016/j.ijpharm.2019.118642
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
NR 53
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1832577
EA OCT 2020
PG 17
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OD2IL
UT WOS:000579676800001
PM 33073699
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tian, R
   Wu, W
   Wang, CY
   Pang, HY
   Zhang, ZY
   Xu, HP
   Luo, QF
   Gao, P
   Shi, JH
   Li, WB
   Qian, H
   Guo, F
   Li, TS
   Liu, ZY
   Wang, JL
   Zhou, X
   Qin, Y
   Yan, XW
   Zhang, SY
AF Tian, Ran
   Wu, Wei
   Wang, Chunyao
   Pang, Haiyu
   Zhang, Zhiyu
   Xu, Haopeng
   Luo, Qingfeng
   Gao, Peng
   Shi, Jihua
   Li, Wenbin
   Qian, Hao
   Guo, Fan
   Li, Taisheng
   Liu, Zhengyin
   Wang, Jinglan
   Zhou, Xiang
   Qin, Yan
   Yan, Xiaowei
   Zhang, Shuyang
TI Clinical characteristics and survival analysis in critical and
   non-critical patients with COVID-19 in Wuhan, China: a single-center
   retrospective case control study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CRITERIA
AB Since the outbreak of COVID-19 in China at the end of 2019, the world has experienced a large-scale epidemic caused by the SARS-CoV-2. The epidemiological and clinical course of COVID-19 patients has been reported, but there have been few analyses about the characteristics, predictive risk factors, and outcomes of critical patients. In this single-center retrospective case-control study, 90 adult inpatients hospitalized at Tongji Hospital (Wuhan, China) were included. Demographic, clinical, laboratory tests, and treatment data were obtained and compared between critical and non-critical patients. We found that compared with non-critical patients, the critical patients had higher SOFA score and qSOFA scores. Critical patients had lower lymphocyte and platelet count, elevated D-dimer, decreased fibrinogen, and elevated high-sensitivity C-reactive protein (hsCRP), and interleukin-6(IL-6). More critical patients received treatment including antibiotics, anticoagulation, corticosteroid, and oxygen therapy than non-critical ones. Multivariable regression showed higher qSOFA score and elevation of IL-6 were related to critical patients. Antibiotic usage and anticoagulation were associated with decreased in-hospital mortality. And critical grouping contributed greatly to in-hospital death. Critical COVID-19 patients have a more severe clinical course. qSOFA score and elevation of IL-6 are risk factors for critical condition. Non-critical grouping, positive antibiotic application, and anticoagulation may be beneficial for patient survival.
C1 [Tian, Ran; Wu, Wei; Gao, Peng; Qian, Hao; Guo, Fan; Yan, Xiaowei; Zhang, Shuyang] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Cardiol, Beijing, Peoples R China.
   [Tian, Ran; Wu, Wei; Wang, Chunyao; Pang, Haiyu; Zhang, Zhiyu; Xu, Haopeng; Gao, Peng; Qian, Hao; Guo, Fan; Li, Taisheng; Liu, Zhengyin; Wang, Jinglan; Zhou, Xiang; Qin, Yan; Yan, Xiaowei; Zhang, Shuyang] Peking Union Med Coll, Beijing, Peoples R China.
   [Wang, Chunyao] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Med Intens Care Med, Beijing, Peoples R China.
   [Pang, Haiyu] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Med Res Ctr, Beijing, Peoples R China.
   [Zhang, Zhiyu; Xu, Haopeng] Chinese Acad Med Sci, Beijing, Peoples R China.
   [Luo, Qingfeng; Shi, Jihua; Li, Wenbin] Chinese Acad Med Sci, Beijing Hosp, Natl Ctr Gerontol, Inst Geriatr Med,Dept Gastroenterol, Beijing, Peoples R China.
   [Li, Taisheng; Liu, Zhengyin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Infect Dis, Beijing, Peoples R China.
   [Wang, Jinglan] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pulm & Crit Care Med, Beijing, Peoples R China.
   [Zhou, Xiang] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Intens Care Med, Beijing, Peoples R China.
   [Qin, Yan] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Nephrol, Beijing, Peoples R China.
RP Zhang, SY (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Cardiol, Beijing, Peoples R China.; Zhang, SY (corresponding author), Peking Union Med Coll, Beijing, Peoples R China.
EM shuyangzhang103@nrdrs.org
FU CAMS Innovation Fund for Medical Sciences (CIFMS) [2020-I2M-CoV19-001];
   National key research and development plan [2020YFC0861000]
FX This work was supported by the CAMS Innovation Fund for Medical Sciences
   (CIFMS) (No. 2020-I2M-CoV19-001) and National key research and
   development plan (No. 2020YFC0861000).
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Nation Health Commission of China, 2020, UPD COVID 19
   National Health Commission of China, 2020, GUID DIAGN TREATM CO
   Raith EP, 2017, JAMA-J AM MED ASSOC, V317, P290, DOI 10.1001/jama.2016.20328
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, WHO COR DIS COVID 19
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 18
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 16
PY 2020
VL 10
IS 1
AR 17524
DI 10.1038/s41598-020-74465-3
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OM2FA
UT WOS:000585841900005
PM 33067568
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vieira, T
   Stevens, AC
   Chtchemelinine, A
   Gao, DT
   Badalov, P
   Heumann, L
AF Vieira, Tiago
   Stevens, Andrew C.
   Chtchemelinine, Andrei
   Gao, Detian
   Badalov, Pavel
   Heumann, Lars
TI Development of a Large-Scale Cyanation Process Using Continuous Flow
   Chemistry En Route to the Synthesis of Remdesivir
SO ORGANIC PROCESS RESEARCH & DEVELOPMENT
LA English
DT Article
DE continuous flow chemistry; cyanation; remdesivir; COVID-19
ID GS-5734; EBOLA
AB The implementation of cyanation chemistry at manufacturing scales using batch equipment can be challenging because of the hazardous nature of the reagents employed and the tight control of reaction parameters, including cryogenic temperatures, that help to afford acceptable selectivity and conversion for the desired reaction. Application of continuous flow chemistry offers a means to mitigate the risk associated with handling large amounts of hazardous reagents and to better control the reaction parameters. A case study describing the cyanation of a glycoside using continuous flow chemistry toward the synthesis of the drug candidate remdesivir is presented.
C1 [Chtchemelinine, Andrei; Heumann, Lars] Gilead Sci Inc, Foster City, CA 94404 USA.
   [Vieira, Tiago; Stevens, Andrew C.; Gao, Detian; Badalov, Pavel] Gilead Alberta ULC, Edmonton, AB T6S 1A1, Canada.
RP Vieira, T; Stevens, AC (corresponding author), Gilead Alberta ULC, Edmonton, AB T6S 1A1, Canada.
EM tiago.vieira@gilead.com; andrew.stevens@gilead.com
CR Baumann M, 2020, ORG PROCESS RES DEV, V24, P1802, DOI 10.1021/acs.oprd.9b00524
   Brahma A, 2016, SYNLETT, V27, P262, DOI 10.1055/s-0035-1560644
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gutmann B, 2015, ANGEW CHEM INT EDIT, V54, P6688, DOI 10.1002/anie.201409318
   Hartman RL, 2011, ANGEW CHEM INT EDIT, V50, P7502, DOI 10.1002/anie.201004637
   Hessel V, 2009, CHEM ENG TECHNOL, V32, P1655, DOI 10.1002/ceat.200900474
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Monteiro JL, 2016, SYNLETT, V27, P83, DOI 10.1055/s-0035-1560317
   MUKAIYAMA T, 1987, CARBOHYD RES, V171, P81, DOI 10.1016/S0008-6215(00)90880-2
   Plutschack MB, 2017, CHEM REV, V117, P11796, DOI 10.1021/acs.chemrev.7b00183
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Xolin A, 2014, ORG CHEM FRONT, V1, P992, DOI 10.1039/c4qo00183d
NR 15
TC 6
Z9 6
U1 2
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1083-6160
EI 1520-586X
J9 ORG PROCESS RES DEV
JI Org. Process Res. Dev.
PD OCT 16
PY 2020
VL 24
IS 10
BP 2113
EP 2121
DI 10.1021/acs.oprd.0c00172
PG 9
WC Chemistry, Applied; Chemistry, Organic
SC Chemistry
GA OH4YM
UT WOS:000582583300032
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Reche, PA
AF Reche, Pedro A.
TI Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human
   Pathogens and Vaccines
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE coronavirus disease 19 (COVID-19); severe acute respiratory syndrome
   coronavirus 2 (SARS-CoV-2); epitope; cross-reactive immunity; DTP
   vaccine
ID HETEROLOGOUS IMMUNITY; WHOLE-CELL; PERTUSSIS
AB The recently emerged SARS-CoV-2 causing the ongoing COVID-19 pandemic is particularly virulent in the elderly while children are largely spared. Here, we explored the potential role of cross-reactive immunity acquired from pediatric vaccinations and exposure to common human pathogens in the protection and pathology of COVID-19. To that end, we sought for peptide matches to SARS-CoV-2 (identity >= 80%, in at least eight residues) in the proteomes of 25 human pathogens and in vaccine antigens, and subsequently predicted their T and B cell reactivity to identify potential cross-reactive epitopes. We found that viruses subject to pediatric vaccinations do not contain cross-reactive epitopes with SARS-CoV-2, precluding that they can provide any general protection against COVID-19. Likewise, common viruses including rhinovirus, respiratory syncytial virus, influenza virus, and several herpesviruses are also poor or null sources of cross-reactive immunity to SARS-CoV-2, discarding that immunological memory against these viruses can have any general protective or pathological role in COVID-19. In contrast, we found combination vaccines for treating diphtheria, tetanus, and pertussis infectious diseases (DTP vaccine) to be significant sources of potential cross-reactive immunity to SARS-CoV-2. DTP cross-reactive epitopes with SARS-CoV-2 include numerous CD8 and CD4 T cell epitopes with broad population protection coverage and potentially neutralizing B cell epitopes in SARS-CoV-2 Spike protein. Worldwide, children receive several DTP vaccinations, including three-four doses the first year of life and one at 4-6 years of age. Moreover, a low antigenic Tdap dose is also given at ages 9-14. Thereby, children may well be protected from SARS-CoV-2 through cross-reactive immunity elicited by DTP vaccinations, supporting testing in the general population to prevent COVID-19.
C1 [Reche, Pedro A.] Univ Complutense Madrid, Dept Immunol & O2, Fac Med, Madrid, Spain.
RP Reche, PA (corresponding author), Univ Complutense Madrid, Dept Immunol & O2, Fac Med, Madrid, Spain.
EM parecheg@med.ucm.es
FU Complutense University [AE21/20-23164]
FX The author wishes to thank the editor for handling the manuscript with
   care and professionalism. The author also wishes to thank the reviewers
   for their positive assessment and their thoughtful and insightful
   comments, which helped to improve the manuscript. The author also thanks
   Dr. Esther M. Lafuente for comments and motivation and the Complutense
   University for special grant action B AE21/20-23164 to PAR to cover
   potential publication costs. A preprint version of this manuscript is
   available at https://osf.io/sbgy3 (DOI: 10.31219/osf.io/sbgy3).
CR Agrawal B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02631
   Ahmad H, 1999, INFECT DIS CLIN N AM, V13, P113, DOI 10.1016/S0891-5520(05)70046-5
   Alonso-Padilla J, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/9363750
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Moro-Garcia MA, 2012, CURR GENOMICS, V13, P589, DOI 10.2174/138920212803759749
   Arts RJW, 2016, CELL REP, V17, P2562, DOI 10.1016/j.celrep.2016.11.011
   Azcarate IG, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66384-0
   Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Che JW, 2015, VIROLOGY, V482, P89, DOI 10.1016/j.virol.2015.03.002
   Choe YJ, 2020, INT J INFECT DIS, V92, P261, DOI 10.1016/j.ijid.2019.12.021
   Cohn AC, 2013, MMWR RECOMM REP, V62, P1
   Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4
   Daniels Calvin C, 2016, J Pediatr Pharmacol Ther, V21, P27, DOI 10.5863/1551-6776-21.1.27
   Egorov ES, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01618
   Embgenbroich M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01643
   Franklin R., 2020, HOMOLOGOUS PROTEIN D, DOI [10.1101/2020.04.10.20053207, DOI 10.1101/2020.04.10.20053207]
   Fulton Ross B, 2009, Aging health, V5, P775, DOI 10.2217/ahe.09.69
   GE H, 2020, EUR J CLIN MICR 0414, V39, DOI DOI 10.1007/s10096-10020-03874-z
   Goldblatt D, 2000, CLIN EXP IMMUNOL, V119, P1, DOI 10.1046/j.1365-2249.2000.01109.x
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Gu XX, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00034-17
   Guiso N, 2020, VACCINE, V38, P1271, DOI 10.1016/j.vaccine.2019.11.022
   Habel JR, 2020, P NATL ACAD SCI USA, V10, P2015486117, DOI 10.1101/2020.08.17.20176370
   Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hubbard SJ, 1993, NACCESS COMPUTER PRO
   India State Level Disease Burden Initiative Road Injury Collaborators, 2020, LANCET PUBLIC HEALTH, V5, pe86, DOI DOI 10.1038/s41564-41020-40695-z
   Ju B, 2020, NATURE, V26, P20, DOI [10.1101/2020.03.21.990770, DOI 10.1101/2020.03.21.990770]
   KUHDARI P, 2016, PATHOG GLOB HEALTH, V110, DOI DOI 10.1080/20477724.20472016.21195072
   LAN J, 2020, NATURE 0330, V581, DOI DOI 10.1038/s41586-41020-42180-41585
   Li RQ, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104363
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790
   Mathurin KS, 2009, J VIROL, V83, P3528, DOI 10.1128/JVI.02393-08
   Miller A, 2020, CORRELATION UNIVERSA, DOI [DOI 10.1101/2020.03.24.20042937, 10.1101/2020.03.24.20042937]
   Moller J, 2019, VACCINE, V37, P3061, DOI 10.1016/j.vaccine.2019.04.059
   Moller J, 2019, PROTEOMES, V7, DOI 10.3390/proteomes7020015
   Molero-Abraham M, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/601943
   Moller Jens, 2019, BMC Res Notes, V12, P329, DOI 10.1186/s13104-019-4373-2
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Mosca A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00455
   Nikolich-Zugich J, 2005, J EXP MED, V201, P837, DOI 10.1084/jem.20050341
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Pandhi Deepika, 2011, Indian J Sex Transm Dis AIDS, V32, P75, DOI 10.4103/0253-7184.85409
   Quinzo MJ, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3052-6
   Rodrigues Charlene M C, 2018, Wellcome Open Res, V3, P151, DOI 10.12688/wellcomeopenres.14859.2
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   ROUGHAN G, 1990, ARCH BIOCHEM BIOPHYS, V276, P38, DOI 10.1016/0003-9861(90)90007-L
   Sanchez-Ramon S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02936
   Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   She J, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169-020-00271-z
   Sheridan SL, 2015, VACCINE, V33, P5027, DOI 10.1016/j.vaccine.2015.08.021
   Soler-Garcia Aleix, 2020, J Pediatric Infect Dis Soc, V9, P454, DOI 10.1093/jpids/piz071
   Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882
   Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244
   van der Lee S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00051
   Welsh RM, 2007, NAT REV MICROBIOL, V5, P555, DOI 10.1038/nrmicro1709
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
   Zinkernagel RM, 2018, IMMUNOL REV, V283, P238, DOI 10.1111/imr.12648
NR 61
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 16
PY 2020
VL 11
AR 586984
DI 10.3389/fimmu.2020.586984
PG 13
WC Immunology
SC Immunology
GA OL8VI
UT WOS:000585609700001
PM 33178220
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rath, SL
   Kumar, K
AF Rath, Soumya Lipsa
   Kumar, Kishant
TI Investigation of the Effect of Temperature on the Structure of
   SARS-CoV-2 Spike Protein by Molecular Dynamics Simulations
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Article
DE structural protein; receptor binding motif; N-terminal domain; closed
   conformation; temperature-sensitive
ID NEUTRALIZING ANTIBODIES; SARS; HUMIDITY; OUTBREAK; VACCINE; DOMAIN;
   VIRUS
AB Statistical and epidemiological data imply temperature sensitivity of the SARS-CoV-2 coronavirus. However, the molecular level understanding of the virus structure at different temperature is still not clear. Spike protein is the outermost structural protein of the SARS-CoV-2 virus which interacts with the Angiotensin Converting Enzyme 2 (ACE2), a human receptor, and enters the respiratory system. In this study, we performed an all atom molecular dynamics simulation to study the effect of temperature on the structure of the Spike protein. After 200 ns of simulation at different temperatures, we came across some interesting phenomena exhibited by the protein. We found that the solvent exposed domain of Spike protein, namely S1, is more mobile than the transmembrane domain, S2. Structural studies implied the presence of several charged residues on the surface of N-terminal Domain of S1 which are optimally oriented at 10-30 degrees C. Bioinformatics analyses indicated that it is capable of binding to other human receptors and should not be disregarded. Additionally, we found that receptor binding motif (RBM), present on the receptor binding domain (RBD) of S1, begins to close around temperature of 40 degrees C and attains a completely closed conformation at 50 degrees C. We also found that the presence of glycan moieties did not influence the observed protein dynamics. Nevertheless, the closed conformation disables its ability to bind to ACE2, due to the burying of its receptor binding residues. Our results clearly show that there are active and inactive states of the protein at different temperatures. This would not only prove beneficial for understanding the fundamental nature of the virus, but would be also useful in the development of vaccines and therapeutics.
C1 [Rath, Soumya Lipsa] Natl Inst Technol Warangal, Dept Biotechnol, Warangal, Andhra Pradesh, India.
   [Kumar, Kishant] Natl Inst Technol Warangal, Dept Chem Engn, Warangal, Andhra Pradesh, India.
RP Rath, SL (corresponding author), Natl Inst Technol Warangal, Dept Biotechnol, Warangal, Andhra Pradesh, India.
EM slrath@nitw.ac.in
OI Rath, Soumya/0000-0003-0767-3016
FU Ernest Orlando Lawrence Berkeley National Laboratory, a DOE Office of
   Science User Facility; Office of Science of the U.S. Department of
   EnergyUnited States Department of Energy (DOE) [DE-AC02-05CH11231]
FX This research used resources of the National Energy Research Scientific
   Computing Center of the Ernest Orlando Lawrence Berkeley National
   Laboratory, a DOE Office of Science User Facility supported by the
   Office of Science of the U.S. Department of Energy under Contract No.
   DE-AC02-05CH11231 and used the Extreme Science and Engineering Discovery
   Environment (XSEDE). We are thankful to the Covid19 HPC Consortium for
   providing resources and helping researchers work for a noble cause. We
   are also thankful to Drs. Suchetana Gupta, Debakanta Tripathy, and
   Chockalingam S. for critically proofreading the manuscript. We are also
   grateful to National Institute of Technology Warangal for providing
   facilities. This manuscript has been released as a pre-print at BioRxiv
   (Rath and Kumar, 2020).
CR [Anonymous], 2020, WHO CORONAVIRUS DIS
   [Anonymous], 2019, PYMOL MOL GRAPH SYST
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Berendsen HJC, 2000, CURR OPIN STRUC BIOL, V10, P165, DOI 10.1016/S0959-440X(00)00061-0
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bukhari Q., 2020, SSRN ELECT J
   Cai QC, 2007, PUBLIC HEALTH, V121, P258, DOI 10.1016/j.puhe.2006.09.023
   Casanova LM, 2010, APPL ENVIRON MICROB, V76, P2712, DOI 10.1128/AEM.02291-09
   Chan K, 2011, ADV OPTOELECTRON, V2011, DOI [10.1155/2011/734690, 10.1155/2011/196707]
   Chin AWH, 2020, LANCET MICROBE, V1, pe10, DOI [DOI 10.1101/2020.03.15.20036673, heresAdoi. moll 0.10161 S2666-5247(20130003-3, 10.1016/S2666-5247(20)130003-3]
   Coleman CM, 2014, VACCINE, V32, P3169, DOI 10.1016/j.vaccine.2014.04.016
   Dong YW, 2018, P NATL ACAD SCI USA, V115, P1274, DOI 10.1073/pnas.1718910115
   Edwards Robert J, 2020, bioRxiv, DOI 10.1101/2020.07.12.199588
   Foxman EF, 2015, P NATL ACAD SCI USA, V112, P827, DOI 10.1073/pnas.1411030112
   Gao HN, 2016, FRONT MED-PRC, V10, P377, DOI 10.1007/s11684-016-0466-7
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   GROMACS, 2020, GROMACS DOCUMENTATIO
   Guillen J, 2005, J VIROL, V79, P1743, DOI 10.1128/JVI.79.3.1743-1752.2005
   He JH, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040428
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Ishida Y, 2002, INTERVIROLOGY, V45, P125, DOI 10.1159/000065865
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Plana LJ, 2019, J CHEM INF MODEL, V59, P441, DOI 10.1021/acs.jcim.8b00840
   Lan JM, 2017, VACCINE, V35, P10, DOI 10.1016/j.vaccine.2016.11.064
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li J, 2013, VIRAL IMMUNOL, V26, P126, DOI 10.1089/vim.2012.0076
   Lindorff-Larsen K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032131
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Lowen AC, 2014, J VIROL, V88, P7692, DOI 10.1128/JVI.03544-13
   Mackenzie JS, 2020, MICROBIOL AUST, V41, P45, DOI 10.1071/MA20013
   Meyer T, 2006, J CHEM THEORY COMPUT, V2, P251, DOI 10.1021/ct050285b
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pelletier I, 2011, EUROSURVEILLANCE, V16, P12
   Rath S. L., 2020, BIORXIV PREPRINT, DOI [10.1101/2020.06.10.145086, DOI 10.1101/2020.06.10.145086]
   Sayers EW, 2009, NUCLEIC ACIDS RES, V37, pD5, DOI [10.1093/nar/gkn741, 10.1093/nar/gkp967]
   Shang J, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008392
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tan JG, 2005, J EPIDEMIOL COMMUN H, V59, P186, DOI 10.1136/jech.2004.020180
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Woo H, 2020, J PHYS CHEM B, V124, P7128, DOI 10.1021/acs.jpcb.0c04553
   Wu Y, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.139051
   Xiong XL, 2020, NAT STRUCT MOL BIOL, DOI 10.1038/s41594-020-0478-5
   Xu JR, 2010, BIOINFORMATICS, V26, P889, DOI 10.1093/bioinformatics/btq066
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zaim S, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100618
NR 54
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD OCT 16
PY 2020
VL 7
AR 583523
DI 10.3389/fmolb.2020.583523
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OL9BR
UT WOS:000585626200001
PM 33195427
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pasion, R
   Paiva, TO
   Fernandes, C
   Barbosa, F
AF Pasion, Rita
   Paiva, Tiago O.
   Fernandes, Carina
   Barbosa, Fernando
TI The AGE Effect on Protective Behaviors During the COVID-19 Outbreak:
   Sociodemographic, Perceptions and Psychological Accounts
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE pandemic (COVID-19); aging; risk; protective behaviors; anxiety; fear;
   social isolation; optimism
ID ACUTE RESPIRATORY SYNDROME; SOCIAL-ISOLATION; RISK PERCEPTION;
   HONG-KONG; ANXIETY; SATISFACTION; LONELINESS; COMMUNITY; OPTIMISM;
   HEALTH
AB COVID-19 outbreak is a sudden and devastating global pandemic in which the control of the spread is highly dependent on individual reactions, until the development of a vaccine and adequate treatments. Considering that older adults are at high risk for COVID-related medical complications and mortality, the present study focuses on the age-related differences on the adoption of protective behaviors during the initial stages of this outbreak, while accounting for the role of sociodemographic, COVID-related, perceived risk, and psychosocial variables (i.e., anxiety, optimism, fear of death, and social isolation) in this relation. The study sample included 1696 participants, aged between 18 and 85 years old, who completed an online survey during the initial stages of the first COVID-19 outbreak in Portugal. Overall, results reveal that the engagement in protective behaviors declines with advancing age and that older adults show a pattern toward lower perceived risk compared with middle-aged adults. Multicategorical mediation analyses show that anxiety, optimism, fear of death, and social isolation significantly mediate age effects on protective behaviors. Specifically, both anxiety and fear of death increase protective behaviors via higher perceived risk in the middle-aged and in the younger groups, respectively. Optimism directly predicts protective behaviors in the middle-aged groups, while social isolation reduces protective behaviors in the younger and older-aged groups. Results are discussed in terms of its implications for public health policies.
C1 [Pasion, Rita; Paiva, Tiago O.; Fernandes, Carina; Barbosa, Fernando] Univ Porto, Fac Psychol & Educ Sci, Lab Neuropsychophysiol, Porto, Portugal.
RP Pasion, R (corresponding author), Univ Porto, Fac Psychol & Educ Sci, Lab Neuropsychophysiol, Porto, Portugal.
EM ritapasion@gmail.com
FU Foundation for Science and Technology [SFRH/BD/117130/2016,
   PTDC/PSIGER/29435/2017]
FX This work was supported by the Foundation for Science and Technology
   under Grants SFRH/BD/117130/2016, PTDC/PSIGER/29435/2017, and PTDC/PSI
   GER/28076/2017.
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   Bish A, 2010, BRIT J HEALTH PSYCH, V15, P797, DOI 10.1348/135910710X485826
   Bonem EM, 2015, J BEHAV DECIS MAKING, V28, P317, DOI 10.1002/bdm.1848
   Brug J, 2004, EMERG INFECT DIS, V10, P1486, DOI 10.3201/eid1008.040283
   Cacioppo JT, 2014, SOC PERSONAL PSYCHOL, V8, P58, DOI 10.1111/spc3.12087
   Cacioppo JT, 2003, PERSPECT BIOL MED, V46, pS39, DOI 10.1353/pbm.2003.0049
   Chapin J, 2001, N AM J PSYCHOL, V3, P253
   Charles ST, 2010, ANNU REV PSYCHOL, V61, P383, DOI 10.1146/annurev.psych.093008.100448
   Chowdhury R, 2014, PSYCHOL MED, V44, P2003, DOI 10.1017/S0033291713002602
   Cicirelli VG, 2002, J GERONTOL B-PSYCHOL, V57, pP358, DOI 10.1093/geronb/57.4.P358
   European Centre for Disease Prevention and Control, 2020, COR DIS 2019 COVID 1
   Eurostat, 2019, AG EUR LOOK LIV OLD
   Eurostat, 2010, SOC PART SOC IS
   Fernandes C, 2018, NEUROBIOL AGING, V65, P51, DOI 10.1016/j.neurobiolaging.2018.01.003
   Fielding R, 2005, EMERG INFECT DIS, V11, P677, DOI 10.3201/eid1105.041225
   Flint AJ, 2010, AM J GERIAT PSYCHIAT, V18, P404, DOI 10.1097/JGP.0b013e3181c294ac
   Fortner B. V., 2000, DEATH ATTITUDES OLDE, P95, DOI 10.4324/9781315784489-6
   Gesser G., 1988, OMEGA, V18, P113, DOI DOI 10.2190/0DQB-7Q1E-2BER-H6YC
   Hammig O, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219663
   Hawkley LC, 2010, ANN BEHAV MED, V40, P218, DOI 10.1007/s12160-010-9210-8
   Hayes A.F., 2018, INTRO MEDIATION MODE
   Hayes A.F., 2012, CISC VIS NETW IND GL
   Holt-Lunstad J, 2015, PERSPECT PSYCHOL SCI, V10, P227, DOI 10.1177/1745691614568352
   Johnson C. L., 1997, LIFE 85 YEARS
   Jones X. R., 2020, PREPRINT
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593
   Kim ES, 2019, AM J EPIDEMIOL, V188, P1084, DOI 10.1093/aje/kwz056
   Lachman ME, 2008, PSYCHOL SCI, V19, P889, DOI 10.1111/j.1467-9280.2008.02173.x
   Laranjeira CA, 2008, UNIV PSYCHOL, V7, P469
   Lau JTF, 2003, J EPIDEMIOL COMMUN H, V57, P864, DOI 10.1136/jech.57.11.864
   Lauder William, 2006, Psychol Health Med, V11, P233, DOI 10.1080/13548500500266607
   Lee LO, 2019, P NATL ACAD SCI USA, V116, P18357, DOI 10.1073/pnas.1900712116
   Lennings CJ, 2000, INT J AGING HUM DEV, V51, P167, DOI 10.2190/06GK-WHER-37XC-BTRY
   Leung GM, 2003, J EPIDEMIOL COMMUN H, V57, P857, DOI 10.1136/jech.57.11.857
   Mather M, 2016, ANNU REV PSYCHOL, V67, P213, DOI 10.1146/annurev-psych-122414-033540
   Mok Esther, 2005, Int J Nurs Pract, V11, P150, DOI 10.1111/j.1440-172X.2005.00520.x
   Novotney A., 2019, MONITOR PSYCHOL, V50
   Pachur T, 2012, J EXP PSYCHOL-APPL, V18, P314, DOI 10.1037/a0028279
   Pais-Ribeiro J, 2007, Psychol Health Med, V12, P225, DOI 10.1080/13548500500524088
   Pasion R, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01785
   Pocinho M., 2010, INTERACOES, V18, P65
   Population Reference and Bureau, 2020, PERC POP AG 65 OLD
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Rubin GJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2651
   Russac RJ, 2007, DEATH STUD, V31, P549, DOI 10.1080/07481180701356936
   Russell DW, 1996, J PERS ASSESS, V66, P20, DOI 10.1207/s15327752jpa6601_2
   SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063
   Serra S., 2012, THESIS
   Sharot T, 2011, CURR BIOL, V21, pR941, DOI 10.1016/j.cub.2011.10.030
   Spinella M, 2007, INT J NEUROSCI, V117, P359, DOI 10.1080/00207450600588881
   Sze YH, 2004, ASIA PAC J SOC WORK, V14, P33, DOI 10.1080/21650993.2004.9755941
   Tang CSK, 2005, J AGING HEALTH, V17, P490, DOI 10.1177/0898264305277966
   Thorson J. A., 2000, DEATH ATTITUDES OLDE, P123, DOI [10.4324/9781315784489-8, DOI 10.1108/09534810210449550]
   Van Bortel T, 2016, B WORLD HEALTH ORGAN, V94, P210, DOI 10.2471/BLT.15.158543
   Vijaya K, 2005, INT J HEALTH PROMOT, V43, P17, DOI 10.1080/14635240.2005.10708030
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Webster RK, 2020, PUBLIC HEALTH, V182, P163, DOI 10.1016/j.puhe.2020.03.007
   WEINSTEIN ND, 1984, HEALTH PSYCHOL, V3, P431, DOI 10.1037/0278-6133.3.5.431
   Welte J, 2001, J STUD ALCOHOL, V62, P706, DOI 10.15288/jsa.2001.62.706
   WHO, 2020, NOV COR COVID 19 SIT
   Wise T., 2020, PREPRINT
   Wong CY, 2005, J ADOLESCENT HEALTH, V36, P193, DOI 10.1016/j.jadohealth.2004.02.024
   World Health Organization, 2020, ROLL UPD COR DIS COV
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 64
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD OCT 16
PY 2020
VL 11
AR 561785
DI 10.3389/fpsyg.2020.561785
PG 14
WC Psychology, Multidisciplinary
SC Psychology
GA OL8ZO
UT WOS:000585620700001
PM 33178069
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fragoso-Saavedra, S
   Iruegas-Nunez, DA
   Quintero-Villegas, A
   Garcia-Gonzalez, HB
   Nunez, I
   Carbajal-Morelos, SL
   Audelo-Cruz, BM
   Arias-Martinez, S
   Caro-Vega, Y
   Calva, JJ
   Luqueno-Martinez, V
   Gonzalez-Duarte, A
   Crabtree-Ramirez, B
   Crispin, JC
   Sierra-Madero, J
   Belaunzaran-Zamudio, PF
   Valdes-Ferrer, SI
AF Fragoso-Saavedra, Sergio
   Iruegas-Nunez, David A.
   Quintero-Villegas, Alejandro
   Garcia-Gonzalez, H. Benjamin
   Nunez, Isaac
   Carbajal-Morelos, Sergio L.
   Audelo-Cruz, Belem M.
   Arias-Martinez, Sarahi
   Caro-Vega, Yanink
   Calva, Juan Jose
   Luqueno-Martinez, Veronica
   Gonzalez-Duarte, Alejandra
   Crabtree-Ramirez, Brenda
   Crispin, Jose C.
   Sierra-Madero, Juan
   Belaunzaran-Zamudio, Pablo F.
   Valdes-Ferrer, Sergio I.
TI A parallel-group, multicenter randomized, double-blinded,
   placebo-controlled, phase 2/3, clinical trial to test the efficacy of
   pyridostigmine bromide at low doses to reduce mortality or invasive
   mechanical ventilation in adults with severe SARS-CoV-2 infection: the
   Pyridostigmine In Severe COvid-19 (PISCO) trial protocol
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; SARS-Cov-2; Mortality; Invasive mechanical ventilation;
   Immunomodulation; Pyridostigmine; ACh; Inflammatory reflex;
   Placebo-controlled trial
AB BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative agent of coronavirus disease 2019 (COVID-19), may lead to severe systemic inflammatory response, pulmonary damage, and even acute respiratory distress syndrome (ARDS). This in turn may result in respiratory failure and in death. Experimentally, acetylcholine (ACh) modulates the acute inflammatory response, a neuro-immune mechanism known as the inflammatory reflex. Recent clinical evidence suggest that electrical and chemical stimulation of the inflammatory reflex may reduce the burden of inflammation in chronic inflammatory diseases. Pyridostigmine (PDG), an ACh-esterase inhibitor (i-ACh-e), increases the half-life of endogenous ACh, therefore mimicking the inflammatory reflex. This clinical trial is aimed at evaluating if add-on of PDG leads to a decrease of invasive mechanical ventilation and death among patients with severe COVID-19.MethodsA parallel-group, multicenter, randomized, double-blinded, placebo-controlled, phase 2/3 clinical trial to test the efficacy of pyridostigmine bromide 60mg/day P.O. to reduce the need for invasive mechanical ventilation and mortality in hospitalized patients with severe COVID-19.DiscussionThis study will provide preliminary evidence of whether or not -by decreasing systemic inflammation- add-on PDG can improve clinical outcomes in patients with severe COVID-19.Trial registrationClinicalTrials.gov NCT04343963 (registered on April 14, 2020).
C1 [Fragoso-Saavedra, Sergio] Univ Nacl Autonoma Mexico, MD PhD Program, Programa Estudios Combinados Med, Mexico City, DF, Mexico.
   [Fragoso-Saavedra, Sergio; Iruegas-Nunez, David A.; Audelo-Cruz, Belem M.; Arias-Martinez, Sarahi; Gonzalez-Duarte, Alejandra; Valdes-Ferrer, Sergio I.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Neurol, Mexico City, DF, Mexico.
   [Iruegas-Nunez, David A.] Inst Tecnol & Destudios Super Monterrey, Escuela Nacl Med & Ciencias Salud, Monterrey, Mexico.
   [Quintero-Villegas, Alejandro; Garcia-Gonzalez, H. Benjamin; Nunez, Isaac; Carbajal-Morelos, Sergio L.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Internal Med Residency Training Program, Mexico City, DF, Mexico.
   [Caro-Vega, Yanink; Calva, Juan Jose; Luqueno-Martinez, Veronica; Crabtree-Ramirez, Brenda; Sierra-Madero, Juan; Belaunzaran-Zamudio, Pablo F.; Valdes-Ferrer, Sergio I.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Mexico City, DF, Mexico.
   [Crispin, Jose C.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Inmunol & Reumatol, Mexico City, DF, Mexico.
   [Belaunzaran-Zamudio, Pablo F.] NIAID, Div AIDS, NIH, Rockville, MD USA.
   [Valdes-Ferrer, Sergio I.] Feinstein Inst Med Res, Ctr Biomed Sci, Manhasset, NY USA.
RP Valdes-Ferrer, SI (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Neurol, Mexico City, DF, Mexico.; Valdes-Ferrer, SI (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Mexico City, DF, Mexico.
EM sergio.valdesf@incmnsz.mx
FU Consejo Nacional de Ciencia y Tecnologia (CONACyT)Consejo Nacional de
   Ciencia y Tecnologia (CONACyT) [289788, 311783]
FX This study is funded by peer-reviewed, competitive grants from Consejo
   Nacional de Ciencia y Tecnologia (CONACyT): Grants 289788 and 311783,
   both to SIVF.
CR ALMOG S, 1991, ISRAEL J MED SCI, V27, P659
   Borovikova LV, 2000, NATURE, V405, P458
   Chavan SS, 2017, J IMMUNOL, V198, P3389, DOI 10.4049/jimmunol.1601613
   Cocks K, 2013, J CLIN EPIDEMIOL, V66, P197, DOI 10.1016/j.jclinepi.2012.09.002
   Gilhus NE, 2015, LANCET NEUROL, V14, P1023, DOI 10.1016/S1474-4422(15)00145-3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Valdes-Ferrer SI, 2009, AIDS RES HUM RETROV, V25, P749, DOI 10.1089/aid.2008.0257
   KEELER JR, 1991, JAMA-J AM MED ASSOC, V266, P693, DOI 10.1001/jama.266.5.693
   Koopman FA, 2016, P NATL ACAD SCI USA, V113, P8284, DOI 10.1073/pnas.1605635113
   Lehner KR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00585
   Mayeux R, 2010, NEW ENGL J MED, V362, P2194, DOI 10.1056/NEJMcp0910236
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   O'Brien JT, 2015, LANCET, V386, P1698, DOI 10.1016/S0140-6736(15)00463-8
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Robinson-Papp J, 2019, J NEUROVIROL, V25, P551, DOI 10.1007/s13365-019-00756-9
   Rosas-Ballina M, 2015, BRAIN BEHAV IMMUN, V44, P19, DOI 10.1016/j.bbi.2014.07.010
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Satapathy SK, 2011, MOL MED, V17, P599, DOI 10.2119/molmed.2011.00083
   Singer W, 2006, ARCH NEUROL-CHICAGO, V63, P513, DOI 10.1001/archneur.63.4.noc50340
   Valdes-Ferrer SI, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01301
   Valdes-Ferrer SI, 2014, REV INVEST CLIN, V66, P439
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yeboah MM, 2008, KIDNEY INT, V74, P62, DOI 10.1038/ki.2008.94
   Zaghloul N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01673
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 25
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD OCT 16
PY 2020
VL 20
IS 1
AR 765
DI 10.1186/s12879-020-05485-7
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA OH7AG
UT WOS:000582746200005
PM 33066761
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mortaz, E
   Malkmohammad, M
   Jamaati, H
   Naghan, PA
   Hashemian, SM
   Tabarsi, P
   Varahram, M
   Zaheri, H
   Chousein, EGU
   Folkerts, G
   Adcock, IM
AF Mortaz, Esmaeil
   Malkmohammad, Majid
   Jamaati, Hamidreza
   Naghan, Parisa Adimi
   Hashemian, Seyed MohamadReza
   Tabarsi, Payam
   Varahram, Maohammad
   Zaheri, Hamidreza
   Chousein, Efsun Gonca Ugur
   Folkerts, Gert
   Adcock, Ian M.
TI Silent hypoxia: higher NO in red blood cells of COVID-19 patients
SO BMC PULMONARY MEDICINE
LA English
DT Article
DE COVID-19; NO; Hypoxia
ID TNF RECEPTOR
AB Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has spread to almost 100 countries, infected over 31 M patients and resulted in 961 K deaths worldwide as of 21st September 2020. The major clinical feature of severe COVID-19 requiring ventilation is acute respiratory distress syndrome (ARDS) with multi-functional failure as a result of a cytokine storm with increased serum levels of cytokines. The pathogenesis of the respiratory failure in COVID-19 is yet unknown, but diffuse alveolar damage with interstitial thickening leading to compromised gas exchange is a plausible mechanism. Hypoxia is seen in the COVID-19 patients, however, patients present with a distinct phenotype. Intracellular levels of nitric oxide (NO) play an important role in the vasodilation of small vessels. To elucidate the intracellular levels of NO inside of RBCs in COVID-19 patients compared with that of healthy control subjects. Methods We recruited 14 COVID-19 infected cases who had pulmonary involvement of their disease, 4 non-COVID-19 healthy controls (without pulmonary involvement and were not hypoxic) and 2 hypoxic non-COVID-19 patients subjects who presented at the Masih Daneshvari Hospital of Tehran, Iran between March-May 2020. Whole blood samples were harvested from patients and intracellular NO levels in 1 x 10(6)red blood cells (RBC) was measured by DAF staining using flow cytometry (FACS Calibour, BD, CA, USA). Results The Mean florescent of intensity for NO was significantly enhanced in COVID-19 patients compared with healthy control subjects (P <= 0.05). As a further control for whether hypoxia induced this higher intracellular NO, we evaluated the levels of NO inside RBC of hypoxic patients. No significant differences in NO levels were seen between the hypoxic and non-hypoxic control group. Conclusions This pilot study demonstrates increased levels of intracellular NO in RBCs from COVID-19 patients. Future multi-centre studies should examine whether this is seen in a larger number of COVID-19 patients and whether NO therapy may be of use in these severe COVID-19 patients.
C1 [Mortaz, Esmaeil; Tabarsi, Payam; Varahram, Maohammad] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis NRITLD, Masih Daneshvari Hosp, Mycobacteriol Res Ctr, Tehran, Iran.
   [Malkmohammad, Majid] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis NRITLD, Tracheal Dis Res Ctr, Tehran, Iran.
   [Jamaati, Hamidreza; Naghan, Parisa Adimi; Hashemian, Seyed MohamadReza; Zaheri, Hamidreza] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis NRITLD, Chron Resp Dis Res Ctr, Tehran, Iran.
   [Chousein, Efsun Gonca Ugur] Univ Hlth Sci Turkey, Yedikule Chest Dis & Thorac Surg Educ & Res Hosp, Dept Pulmonol, Istanbul, Turkey.
   [Folkerts, Gert] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacol, Fac Sci, Utrecht, Netherlands.
   [Adcock, Ian M.] Imperial Coll London, Natl Heart & Lung Inst, Airways Dis Sect, Cell & Mol Biol Grp,Fac Med, London, England.
   [Adcock, Ian M.] Univ Newcastle, Hunter Med Res Inst, Prior Res Ctr Asthma & Resp Dis, Newcastle, NSW, Australia.
RP Malkmohammad, M (corresponding author), Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis NRITLD, Tracheal Dis Res Ctr, Tehran, Iran.
EM mmalekmohammad@yahoo.com
CR Allali G, 2020, J MED VIROL, V92, P2272, DOI 10.1002/jmv.26172
   Cameron MJ, 2008, VIRUS RES, V133, P13, DOI 10.1016/j.virusres.2007.02.014
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Couzin-Frankel J, 2020, SCIENCE, V368, P455, DOI 10.1126/science.368.6490.455
   Doctor A, 2005, P NATL ACAD SCI USA, V102, P5709, DOI 10.1073/pnas.0407490102
   Ellsworth ML, 2009, PHYSIOLOGY, V24, P107, DOI 10.1152/physiol.00038.2008
   Grivennikov SI, 2005, IMMUNITY, V22, P93, DOI 10.1016/j.immuni.2004.11.016
   Han H, 2020, EMERG MICROBES INFEC, V9, P1123, DOI 10.1080/22221751.2020.1770129
   Helms CC, 2013, J THROMB HAEMOST, V11, P2148, DOI 10.1111/jth.12422
   Horiuchi T, 2010, RHEUMATOLOGY, V49, P1215, DOI 10.1093/rheumatology/keq031
   Lazarian G, 2020, BRIT J HAEMATOL, V190, P29, DOI 10.1111/bjh.16794
   Lopez C, 2020, BRIT J HAEMATOL, V190, P31, DOI 10.1111/bjh.16786
   Magro G., 2020, SARS COV 2 COVID 19, V2
   Nile SH, 2020, CYTOKINE GROWTH F R, V53, P66, DOI 10.1016/j.cytogfr.2020.05.002
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1
   REIMERS RC, 1984, BLOOD, V64, P1200
   Singel DJ, 2005, ANNU REV PHYSIOL, V67, P99, DOI 10.1146/annurev.physiol.67.060603.090918
   Soy M, 2020, CLIN RHEUMATOL, V39, P2085, DOI 10.1007/s10067-020-05190-5
   Sprague RS, 1996, AM J PHYSIOL-HEART C, V271, pH2717
   Tay MZ, 2020, TRINITY COVID 19 IMM, P363
   Tobin MJ, 2020, AM J RESP CRIT CARE
   Ulker P, 2013, CLIN HEMORHEOL MICRO, V54, P357, DOI 10.3233/CH-2012-1618
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WARE CF, 1991, J IMMUNOL, V147, P4229
   Wilkerson RG, 2020, AM J EMERG MED
   Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427
   Zhang YG, 2020, CELL MOL IMMUNOL, V17, P878, DOI 10.1038/s41423-020-0484-x
NR 28
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2466
J9 BMC PULM MED
JI BMC Pulm. Med.
PD OCT 16
PY 2020
VL 20
IS 1
AR 269
DI 10.1186/s12890-020-01310-8
PG 6
WC Respiratory System
SC Respiratory System
GA OG9ZU
UT WOS:000582233800001
PM 33066765
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Saravanan, KM
   Zhang, HP
   Senthil, R
   Vijayakumar, KK
   Sounderrajan, V
   Wei, YJ
   Shakila, H
AF Saravanan, Konda Mani
   Zhang, Haiping
   Senthil, Renganathan
   Vijayakumar, Kevin Kumar
   Sounderrajan, Vignesh
   Wei, Yanjie
   Shakila, Harshavardhan
TI Structural basis for the inhibition of SARS-CoV2 main protease by Indian
   medicinal plant-derived antiviral compounds
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV2; main protease; medicinal plants; molecular docking and
   dynamics; drug design
ID COVID-19; SARS
AB A novel coronavirus (SARS-CoV2) has caused a major outbreak in humans around the globe, and it became a severe threat to human healthcare than all other infectious diseases. Researchers were urged to discover and test various approaches to control and prevent such a deadly disease. Considering the emergency and necessity, we screened reported antiviral compounds present in the traditional Indian medicinal plants for the inhibition of SARS-CoV2 main protease. In this study, we used molecular docking to screen 41 reported antiviral compounds that exist in Indian medicinal plants and shown amentoflavone from the plantTorreyanuciferawith a higher docking score. Furthermore, we performed a 40 ns atomic molecular dynamics simulation and free binding energy calculations to explore the stability of the top five protein-ligand complexes. Through the article, we insist that the amentoflavone, hypericin and Torvoside H from the traditional Indian medicinal plants may be used as a potential inhibitor of SARS-CoV2 main protease and further biochemical experiments could shed light on understanding the mechanism of inhibition by these plant-derived antiviral compounds. Communicated by Ramaswamy H. Sarma
C1 [Saravanan, Konda Mani; Zhang, Haiping; Wei, Yanjie] Chinese Acad Sci, Shenzhen Inst Adv Technol, Joint Engn Res Ctr Hlth Big Data Intelligent Anal, Ctr High Performance Comp, Shenzhen 518055, Guangdong, Peoples R China.
   [Senthil, Renganathan] Marudupandiyar Coll & Lysine Biotech Pvt Ltd, Dept Bioinformat, Thanjavur, Tamil Nadu, India.
   [Vijayakumar, Kevin Kumar; Shakila, Harshavardhan] Madurai Kamaraj Univ, Sch Biotechnol, Dept Mol Microbiol, Madurai 625021, Tamil Nadu, India.
   [Sounderrajan, Vignesh] GTN Arts Coll, Dept Zool, Dindigul, Tamil Nadu, India.
RP Wei, YJ (corresponding author), Chinese Acad Sci, Shenzhen Inst Adv Technol, Joint Engn Res Ctr Hlth Big Data Intelligent Anal, Ctr High Performance Comp, Shenzhen 518055, Guangdong, Peoples R China.; Shakila, H (corresponding author), Madurai Kamaraj Univ, Sch Biotechnol, Dept Mol Microbiol, Madurai 625021, Tamil Nadu, India.
EM yj.wei@siat.ac.cn; mohanshakila@yahoo.com
RI KM, Saravanan K/G-3121-2014; Saravanan, Konda Mani/AAH-3960-2019
OI KM, Saravanan K/0000-0002-5541-234X; Saravanan, Konda
   Mani/0000-0002-5541-234X; Renganathan, Senthil/0000-0002-8451-9832
CR Adhikari P. P., 2018, ASIAN J PHARM CLIN R, V11, DOI https://doi.org/10.22159/ajpcr.2018.v11i1.21893
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Berman H. M., 2000, NUCL ACIDS RES, V28, pD235, DOI DOI HTTPS://DOI.ORG/10.1093/NAR/28.1.235
   BHARADWAJ S, 2019, SCI REP UK, V9, DOI DOI https://doi.org/10.1038/s41598-019-55723-5
   Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang YC, 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2., 10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Dhawan BN, 2012, P NATL A SCI INDIA B, V82, P209, DOI 10.1007/s40011-011-0016-7
   DWIVEDI VD, 2020, J BIOMOL STRUCT 0306, DOI DOI https://doi.org/10.1080/07391102.2020.1734485
   Fabricant DS, 2001, ENV HLTH PERSPECT, V109, P69, DOI DOI https://doi.org/10.1289/ehp.01109s169
   Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI [10.1186/1756-0500-5-185, 10.1186/1756-0500-5-367]
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Huang HY, 2020, ACS NANO, V14, P3747, DOI 10.1021/acsnano.0c02618
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Killerby ME, 2018, J CLIN VIROL, V101, P52, DOI 10.1016/j.jcv.2018.01.019
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   LI F, 2019, VIRUSES BASEL, V11, DOI DOI https://doi.org/10.3390/v11050466
   Li-Weber M, 2009, CANCER TREAT REV, V35, P57, DOI 10.1016/j.ctrv.2008.09.005
   Liao Jiayu, 2020, Med Drug Discov, V5, P100037, DOI 10.1016/j.medidd.2020.100037
   Malik YS, 2020, VET QUART, V40, P68, DOI 10.1080/01652176.2020.1727993
   Mishra A., 2020, RES SQ, DOI [10.21203/rs.3.rs-22839/v1, DOI 10.21203/RS.3.RS-22839/V1]
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nikhat S, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138859
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   SONG ZQ, 2019, VIRUSES BASEL, V11, DOI DOI https://doi.org/10.3390/v11010059
   Tabuti JRS, 2003, J ETHNOPHARMACOL, V88, P19, DOI 10.1016/S0378-8741(03)00161-2
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Ullrich S, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2020.127377
   Wang CH, 2018, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00087
   World Health Organization, 2020, COR COVID 19 EV THEY
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhang HP, 2020, INTERDISCIP SCI, V12, P368, DOI 10.1007/s12539-020-00376-6
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
NR 46
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1834457
EA OCT 2020
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OE4PF
UT WOS:000580513700001
PM 33073712
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Naci, H
   Kesselheim, AS
   Rottingen, JA
   Salanti, G
   Vandvik, PO
   Cipriani, A
AF Naci, Huseyin
   Kesselheim, Aaron S.
   Rottingen, John-Arne
   Salanti, Georgia
   Vandvik, Per O.
   Cipriani, Andrea
TI Producing and using timely comparative evidence on drugs: lessons from
   clinical trials for covid-19
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
ID GENERATING COMPARATIVE EVIDENCE; INCREASING VALUE; REDUCING WASTE;
   DEVICES
C1 [Naci, Huseyin] London Sch Econ & Polit Sci, Dept Hlth Policy, London, England.
   [Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, 75 Francis St, Boston, MA 02115 USA.
   [Kesselheim, Aaron S.] Harvard Med Sch, Boston, MA 02115 USA.
   [Rottingen, John-Arne] Res Council Norway, Oslo, Norway.
   [Rottingen, John-Arne] Univ Oxford, Blavatnik Sch Govt, Oxford, England.
   [Salanti, Georgia] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland.
   [Vandvik, Per O.] Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, Norway.
   [Cipriani, Andrea] Univ Oxford, Dept Psychiat, Oxford, England.
   [Cipriani, Andrea] Oxford Hlth NHS Fdn Trust, Wameford Hosp, Oxford, England.
RP Naci, H (corresponding author), London Sch Econ & Polit Sci, Dept Hlth Policy, London, England.
EM h.naci@lse.ac.uk
FU National Institute for Health Research (NIHR) Research Professorship
   [RP-2017-08-ST2-006]; NIHR Oxford cognitive health Clinical Research
   Facility; NIHR Oxford and Thames Valley Applied Research Collaboration;
   NIHR Oxford Health Biomedical Research Centre [BRC-1215-20005]; Arnold
   Ventures; Harvard-MIT Center for Regulatory Science; Swiss National
   Science FoundationSwiss National Science Foundation (SNSF)
   [320030_179158]
FX AC is supported by the National Institute for Health Research (NIHR)
   Research Professorship (grant RP-2017-08-ST2-006), by the NIHR Oxford
   cognitive health Clinical Research Facility, by the NIHR Oxford and
   Thames Valley Applied Research Collaboration, and by the NIHR Oxford
   Health Biomedical Research Centre (grant BRC-1215-20005). ASK's research
   is supported by Arnold Ventures and the Harvard-MIT Center for
   Regulatory Science. GS's research is supported by the Swiss National
   Science Foundation (Grant No 320030_179158). The views expressed are
   those of the authors and not necessarily those of the UK National Health
   Service, the NIHR, or the UK Department of Health.
CR [Anonymous], 2020, LIVING MAPPING LIVIN
   Chalmers I, 2009, LANCET, V374, P86, DOI 10.1016/S0140-6736(09)60329-9
   Cipriani A, 2020, LANCET, V395, P998, DOI 10.1016/S0140-6736(19)33177-0
   Core Outcome Measures in Effectiveness Trials, 2020, COR OUTC SET COV 19
   Dean NE, 2020, NEW ENGL J MED, V382, P1366, DOI 10.1056/NEJMsb1905390
   Debray TPA, 2018, STAT METHODS MED RES, V27, P1351, DOI 10.1177/0962280216660741
   Dechartres A, 2014, JAMA-J AM MED ASSOC, V312, P623, DOI 10.1001/jama.2014.8166
   Desai Aakash, 2020, EClinicalMedicine, V23, P100403, DOI 10.1016/j.eclinm.2020.100403
   European Medicines Agency, 2020, EMEAHC0056220000 EUR
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Glasziou P, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4645
   Glasziou PP, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1847
   Graham R, 2011, CLIN PRACTICE GUIDEL, DOI [10.17226/13058, DOI 10.17226/13058]
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Herper M., 2020, STAT
   Ioannidis JPA, 2014, LANCET, V383, P166, DOI 10.1016/S0140-6736(13)62227-8
   Janke K, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2288
   Jin Xinyao, 2020, Engineering (Beijing), V6, P1147, DOI 10.1016/j.eng.2020.03.002
   Kieny MP, 2016, LANCET, V388, P460, DOI 10.1016/S0140-6736(16)31152-7
   Kouzy R, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.15100
   Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379
   London AJ, 2020, SCIENCE, V368, P476, DOI 10.1126/science.abc1731
   Mahase Elisabeth, 2020, BMJ, V370, pm2815, DOI 10.1136/bmj.m2815
   Marshall JC, 2020, LANCET INFECT DIS
   Matthiessen L, 2016, LANCET, V387, P2197, DOI 10.1016/S0140-6736(16)30604-3
   Miller Jennifer, 2019, BMJ, V366, pl4217, DOI 10.1136/bmj.l4217
   MOYNIHAN R, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2456
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Mullard A, 2020, LANCET, V395, P1245, DOI 10.1016/S0140-6736(20)30894-1
   Naci H, 2020, LANCET, V395, P986, DOI 10.1016/S0140-6736(19)33178-2
   Naci H, 2013, J CLIN EPIDEMIOL, V66, P812, DOI 10.1016/j.jclinepi.2013.04.002
   National Covid-19 Clinical Evidence Taskforce, 2020, CAR PEOPL COVID 19
   Nevitt SJ, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1390
   Nikolakopoulou A, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k585
   Pundi K, 2020, JAMA INTERN MED, V180, P1398, DOI 10.1001/jamainternmed.2020.2904
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rice DB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2081
   Rochwerg B, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2924
   Rome BN, 2020, NEW ENGL J MED, V382, P2282, DOI 10.1056/NEJMp2009457
   Salanti G, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2740-2
   Salman RA, 2014, LANCET, V383, P176, DOI 10.1016/S0140-6736(13)62297-7
   Sarpatwari A, 2020, JAMA-J AM MED ASSOC, V324, P331, DOI 10.1001/jama.2020.11932
   Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980
   Singh I, 2020, LANCET, V395, P926, DOI 10.1016/S0140-6736(20)30413-X
   Vandvik PO, 2020, J CLIN EPIDEMIOL, V123, P166, DOI 10.1016/j.jclinepi.2020.02.008
   von Cube M, 2020, HARMONIZING HETEROGE
   Wang CY, 2020, BRAIN BEHAV IMMUN, V87, P40, DOI 10.1016/j.bbi.2020.04.028
   Wellcome Trust, 2020, SHAR RES DAT IMPR PU
   Wise J, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2670
   World Health Oganization, 2020, ACC COVID 19 TOOLS A
NR 50
TC 1
Z9 1
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD OCT 16
PY 2020
VL 371
AR m3869
DI 10.1136/bmj.m3869
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA OD1ZH
UT WOS:000579653000002
PM 33067179
OA Bronze
DA 2021-01-01
ER

PT J
AU Khan, ATA
   Khalid, Z
   Zahid, H
   Yousaf, MA
   Shakoori, AR
AF Khan, Abeedha Tu-Allah
   Khalid, Zumama
   Zahid, Hafsa
   Yousaf, Muhammad Abrar
   Shakoori, Abdul Rauf
TI A computational and bioinformatic analysis of ACE2: an elucidation of
   its dual role in COVID-19 pathology and finding its associated partners
   as potential therapeutic targets
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Angiotensin-converting enzyme-2; Acute respiratory distress syndrome
   Predicted ACE2 structure; miRNA-1246; FOXO4; FOS; MiR-212-5p
ID CORONAVIRUS SPIKE PROTEIN; SARS RECEPTOR; PREDICTION; DATABASE;
   EXPRESSION; ACTIVATION; VARIANTS; TOPOLOGY; OUTBREAK; CLEAVAGE
AB Despite the continued global spread of the current COVID-19 pandemic, the nonavailability of a vaccine or targeted drug against this disease is still prevailing. The most established mechanism of viral entry into the body is considered to be via angiotensin-converting enzyme 2 (ACE2) acting as a receptor for viral spike protein thereby facilitating its entry in the cell. However, ACE2 is also involved in providing the protection from severe pathological changes. This article provides a computational and bioinformatics-based analysis of ACE2 with an objective of providing further insight into the earnest efforts to determine its true position in COVID-19 pathology. The results of this study show that ACE2 has strikingly low expression in healthy human lung tissue and was absent from the list of differentially expressed genes. However, when transcription factors were analyzed, we found a significant upregulation of FOS and downregulation of FOXO4 and FOXP2. Moreover, the miRNA prediction analysis revealed that miR-1246, whose upregulation has been experimentally established to be a cause of acute respiratory distress syndrome (ARDS), was found to be targeting the coding DNA sequence (CDS) of ACE2. This study presents a wide range of potentially important transcription factors as well as miRNA targets associated with ACE2 which can be potentially used for drug designing amid this challenging pandemic situation. Communicated by Ramaswamy H. Sarma
C1 [Khan, Abeedha Tu-Allah; Khalid, Zumama; Zahid, Hafsa; Shakoori, Abdul Rauf] Univ Punjab, Sch Biol Sci, Quaid I Azam Campus, Lahore, Pakistan.
   [Yousaf, Muhammad Abrar] Univ Punjab, Dept Zool, Lahore, Pakistan.
RP Shakoori, AR (corresponding author), Univ Punjab, Sch Biol Sci, Quaid I Azam Campus, Lahore, Pakistan.
EM arshaksbs@yahoo.com
OI Yousaf, Muhammad Abrar/0000-0001-8018-3895
CR Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Blanco-Melo D., 2020, SARS COV 2 LAUNCHES
   Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771
   Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757
   Cheng H, 2020, J MED VIROL, V92, P726, DOI [10.1002/jmv.25785, 10.2112/JCR-SI112-001.1]
   Choi Y, 2015, BIOINFORMATICS, V31, P2745, DOI 10.1093/bioinformatics/btv195
   Dingerdissen HM, 2018, NUCLEIC ACIDS RES, V46, pD1128, DOI 10.1093/nar/gkx907
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Duckert P, 2004, PROTEIN ENG DES SEL, V17, P107, DOI 10.1093/protein/gzh013
   Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131
   Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600
   Fang Y, 2017, AM J TRANSL RES, V9, P1287
   Ferrario CM, 2005, AM J PHYSIOL-HEART C, V289, pH2281, DOI 10.1152/ajpheart.00618.2005
   Gao GF, 2018, CELL, V172, P1157, DOI 10.1016/j.cell.2018.02.025
   Garg VK, 2016, BIOINFORMATION, V12, P74, DOI 10.6026/97320630012074
   GeneCards T. H. G. D., 2020, ACE2 GENE
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   GUPTA R, 2004, INT J CANCER, V46, P203
   GURUPRASAD K, 1990, PROTEIN ENG, V4, P155, DOI 10.1093/protein/4.2.155
   Hamming I, 2007, J PATHOL, V212, P1, DOI 10.1002/path.2162
   He XM, 2008, NUCLEIC ACIDS RES, V36, pD836, DOI 10.1093/nar/gkm730
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   IKAI A, 1980, J BIOCHEM-TOKYO, V88, P1895
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jia Q, 2018, DISCOV MED, V26, P173
   Johansen MB, 2006, GLYCOBIOLOGY, V16, P844, DOI 10.1093/glycob/cwl009
   Julenius K, 2007, GLYCOBIOLOGY, V17, P868, DOI 10.1093/glycob/cwm050
   Kiemer L, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-72
   Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuba K, 2006, J MOL MED, V84, P814, DOI 10.1007/s00109-006-0094-9
   Kuba K, 2010, PHARMACOL THERAPEUT, V128, P119, DOI 10.1016/j.pharmthera.2010.06.003
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Lai M.M.C., 2007, FIELDS VIROLOGY, V1, P1305
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   LIU Q, 2017, CELL DISCOV, V3, DOI DOI https://doi.org/10.1038/celldisc.2017.21
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lu GW, 2012, PROTEIN CELL, V3, P803, DOI 10.1007/s13238-012-2811-1
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lv ZD, 2017, CELL PHYSIOL BIOCHEM, V44, P1785, DOI 10.1159/000485785
   McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042
   McWilliam H, 2013, NUCLEIC ACIDS RES, V41, pW597, DOI 10.1093/nar/gkt376
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   NCBI Gene, 2020, ACE2 ANG I CONV ENZ
   NCBI Gene, 2020, FOS FOS PROR ONC AP
   NCBI Gene, 2020, FOXO4 FORKH BOX O4
   NCBI Gene, 2020, FOXP2 FORKH BOX P2
   Patel S, 2017, BIOMED PHARMACOTHER, V94, P317, DOI 10.1016/j.biopha.2017.07.091
   R Development Core Team, 2010, R LANG ENV STAT COMP
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Sim NL, 2012, NUCLEIC ACIDS RES, V40, pW452, DOI 10.1093/nar/gks539
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Simmons G, 2013, ANTIVIR RES, V100, P605, DOI 10.1016/j.antiviral.2013.09.028
   Slenter DN, 2018, NUCLEIC ACIDS RES, V46, pD661, DOI 10.1093/nar/gkx1064
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Steentoft C, 2013, EMBO J, V32, P1478, DOI 10.1038/emboj.2013.79
   Sticht C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206239
   Su S, 2017, BIOINFORMATICS, V33, P2050, DOI 10.1093/bioinformatics/btx094
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tang HM, 2016, BIOINFORMATICS, V32, P2230, DOI 10.1093/bioinformatics/btw222
   Thomas PD, 2003, NUCLEIC ACIDS RES, V31, P334, DOI 10.1093/nar/gkg115
   Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Warnes G., 2005, GPLOTS VARIOUS R PRO
   Wilkins MR, 1999, METH MOL B, V112, P531
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   XIAO L, 2020, VIRUSES BASEL, V12, DOI DOI https://doi.org/10.3390/v12050491
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yan J, 2020, MOL HUM REPROD, V26, P367, DOI 10.1093/molehr/gaaa030
   Yan TT, 2020, FASEB J, V34, P6017, DOI 10.1096/fj.202000782
   Yang X., 2020, ANGIOTENSIN CONVERTI
   Yu CS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099368
   Zhao Y., 2020, BIORXIV
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 82
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1833760
EA OCT 2020
PG 17
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OD2KZ
UT WOS:000579683400001
PM 33073716
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ferraro, F
   Patella, F
   Costa, JR
   Ketteler, R
   Kriston-Vizi, J
   Cutler, DF
AF Ferraro, Francesco
   Patella, Francesca
   Costa, Joana R.
   Ketteler, Robin
   Kriston-Vizi, Janos
   Cutler, Daniel F.
TI Modulation of endothelial organelle size as an antithrombotic strategy
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE COVID-19; drug repurposing; thrombosis; von Willebrand factor;
   Weibel-Palade bodies
ID VON-WILLEBRAND-FACTOR; PROTEIN PHOSPHATASE 2B; KRUPPEL-LIKE FACTOR-2;
   CYCLOSPORINE-A; CARDIAC-GLYCOSIDES; KLF2; INHIBITION; SECRETION;
   ADHESION; TRANSCRIPTION
AB Background It is long established that von Willebrand factor (VWF) is central to hemostasis and thrombosis. Endothelial VWF is stored in cell-specific secretory granules, Weibel-Palade bodies (WPBs), organelles generated in a wide range of lengths (0.5-5.0 mu m). WPB size responds to physiological cues and pharmacological treatment, and VWF secretion from shortened WPBs dramatically reduces platelet and plasma VWF adhesion to an endothelial surface. Objective We hypothesized that WPB-shortening represented a novel target for antithrombotic therapy. Our objective was to determine whether compounds exhibiting this activity do exist. Methods Using a microscopy approach coupled to automated image analysis, we measured the size of WPB bodies in primary human endothelial cells treated with licensed compounds for 24 hours. Results and Conclusions A novel approach to identification of antithrombotic compounds generated a significant number of candidates with the ability to shorten WPBs. In vitro assays of two selected compounds confirm that they inhibit the pro-hemostatic activity of secreted VWF. This set of compounds acting at a very early stage of the hemostatic process could well prove to be a useful adjunct to current antithrombotic therapeutics. Further, in the current SARS-CoV-2 pandemic, with a considerable fraction of critically ill COVID-19 patients affected by hypercoagulability, these WPB size-reducing drugs might also provide welcome therapeutic leads for frontline clinicians and researchers.
C1 UCL, Endothelial Cell Biol Grp, MRC Lab Mol Cell Biol, London, England.
   UCL, Cell Signalling & Autophagy Grp, MRC Lab Mol Cell Biol, London, England.
   UCL, MRC Lab Mol Cell Biol, Bioinformat Image Core BIONIC, London, England.
   [Ferraro, Francesco] Stn Zool Anton Dohrn, Dept Biol & Evolut Marine Organisms BEOM, I-80121 Naples, Italy.
   [Costa, Joana R.] UCL, Canc Inst, Dept Haematol, Leukaemia Biol Res Grp, London, England.
RP Cutler, DF (corresponding author), UCL, MRC Lab Mol Cell Biol, Gower St, London WC1E 6BT, England.; Ferraro, F (corresponding author), Stn Zool Anton Dohrn, Dept Biol & Evolut Marine Organisms BEOM, I-80121 Naples, Italy.
EM francesco.ferraro@szn.it; d.cutler@ucl.ac.uk
RI ; Ferraro, Francesco/R-3660-2018; Kriston-Vizi, Janos/L-6021-2013
OI Ketteler, Robin/0000-0002-2786-7291; Patella,
   Francesca/0000-0001-8687-2480; Ferraro, Francesco/0000-0002-6199-637X;
   Kriston-Vizi, Janos/0000-0002-0149-145X; Cutler,
   Daniel/0000-0002-4288-7530
FU Medical Research CouncilMedical Research Council UK (MRC) [MC_U12266B,
   MC_UU_12018/2]
FX Medical Research Council, Grant/Award Number: MC_U12266B and
   MC_UU_12018/2
CR Andersson K-E, 1981, CARDIAC GLYCOSIDES P
   Apostolova MH, 2018, CLIN APPL THROMB-HEM, V24, P93, DOI 10.1177/1076029616670258
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arya M, 2002, BLOOD, V99, P3971, DOI 10.1182/blood-2001-11-0060
   Bauer AT, 2015, BLOOD, V125, P3153, DOI 10.1182/blood-2014-08-595686
   Boutros M, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r66
   Chang JC, 2019, THROMB J, V17, DOI 10.1186/s12959-019-0198-4
   Cole SPC, 2014, J BIOL CHEM, V289, P30880, DOI 10.1074/jbc.R114.609248
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Da Q, 2017, J THROMB HAEMOST, V15, P1032, DOI 10.1111/jth.13671
   Dekker RJ, 2006, BLOOD, V107, P4354, DOI 10.1182/blood-2005-08-3465
   Escher R, 2020, THROMB RES, V190, P62, DOI 10.1016/j.thromres.2020.04.014
   Farber-Katz SE, 2014, CELL, V156, P413, DOI 10.1016/j.cell.2013.12.023
   Ferraro F, 2016, SCI REP-UK, V6, DOI 10.1038/srep32473
   Ferraro F, 2014, DEV CELL, V29, P292, DOI 10.1016/j.devcel.2014.03.021
   Fledderus JO, 2007, BLOOD, V109, P4249, DOI 10.1182/blood-2006-07-036020
   Gendarme M, 2017, MOL BIOL CELL, V28, P3756, DOI 10.1091/mbc.E17-03-0176
   Goshua G, 2020, LANCET HAEMATOL, V7, pE575, DOI 10.1016/S2352-3026(20)30216-7
   Greenwood J, 2007, TRENDS IMMUNOL, V28, P88, DOI 10.1016/j.it.2006.12.003
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Hewlett L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027314
   Hundeshagen P, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-38
   Jorgensen KA, 2003, SCAND J IMMUNOL, V57, P93, DOI 10.1046/j.1365-3083.2003.01221.x
   Kanaji S, 2012, J THROMB HAEMOST, V10, P1646, DOI 10.1111/j.1538-7836.2012.04797.x
   Kanji S, 2012, CRIT CARE CLIN, V28, P527, DOI 10.1016/j.ccc.2012.07.005
   Ketteler R, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.22
   Kumar A, 2005, MOL CELL BIOL, V25, P5893, DOI 10.1128/MCB.25.14.5893-5903.2005
   Lee CR, 2012, BIOCHEM PHARMACOL, V84, P425, DOI 10.1016/j.bcp.2012.05.009
   LEGG B, 1988, EUR J CLIN PHARMACOL, V34, P451, DOI 10.1007/BF01046701
   Leoncini M, 2013, J THORAC DIS, V5, P335, DOI 10.3978/j.issn.2072-1439.2013.05.09
   Lillicrap D, 2020, J THROMB HAEMOST, V18, P786, DOI 10.1111/jth.14781
   Lin ZY, 2005, CIRC RES, V96, pE48, DOI 10.1161/01.RES.0000159707.05637.a1
   Lopes-da-Silva M, 2019, DEV CELL, V49, P786, DOI 10.1016/j.devcel.2019.04.006
   Marietta M, 2020, BLOOD TRANSFUS-ITALY, V18, P167, DOI 10.2450/2020.0083-20
   Marshall WF, 2012, BIOESSAYS, V34, P721, DOI 10.1002/bies.201200043
   McCormack JJ, 2020, J THROMB HAEMOST, V18, P243, DOI 10.1111/jth.14634
   McCormack JJ, 2017, J CELL SCI, V130, P3611, DOI 10.1242/jcs.208033
   Michaux G, 2006, DEV CELL, V10, P223, DOI 10.1016/j.devcel.2005.12.012
   Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8
   NICHOLS TC, 1995, P NATL ACAD SCI USA, V92, P2455, DOI 10.1073/pnas.92.7.2455
   Nicolay JP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28961-2
   Nolasco LH, 2009, J THROMB HAEMOST, V7, P1009, DOI 10.1111/j.1538-7836.2009.03355.x
   Pappelbaum KI, 2013, CIRCULATION, V128, P50, DOI 10.1161/CIRCULATIONAHA.113.002008
   Park HG, 2011, PROG NEURO-PSYCHOPH, V35, P1933, DOI 10.1016/j.pnpbp.2011.09.008
   Parmar KM, 2005, J BIOL CHEM, V280, P26714, DOI 10.1074/jbc.C500144200
   Perne A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008292
   Ruggeri ZM, 2015, HAMOSTASEOLOGIE, V35, P211, DOI 10.5482/HAMO-14-12-0081
   Ruggeri ZM, 2007, THROMB RES, V120, pS5, DOI 10.1016/j.thromres.2007.03.011
   Rybaltowski M, 2011, PFLUG ARCH EUR J PHY, V461, P623, DOI 10.1007/s00424-011-0958-x
   Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395
   Sen-Banerjee S, 2005, CIRCULATION, V112, P720, DOI 10.1161/CIRCULATIONAHA.104.525774
   Stevenson NL, 2014, J THROMB HAEMOST, V12, P261, DOI 10.1111/jth.12470
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   THYBERG J, 1985, EXP CELL RES, V159, P1, DOI 10.1016/S0014-4827(85)80032-X
   Torisu T, 2013, NAT MED, V19, P1281, DOI 10.1038/nm.3288
   Triana-Martinez F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12888-x
   Tsai HM, 2010, INT J HEMATOL, V91, P1, DOI 10.1007/s12185-009-0476-1
   van Agtmaal EL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038399
   Varga-Szabo D, 2008, ARTERIOSCL THROM VAS, V28, P403, DOI 10.1161/ATVBAHA.107.150474
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Wang Y, 2012, INT J BIOCHEM CELL B, V44, P1813, DOI 10.1016/j.biocel.2012.06.028
   Westein E, 2017, CLIN SCI, V131, P1245, DOI 10.1042/CS20160391
   Zhang XH, 2009, SCIENCE, V324, P1330, DOI 10.1126/science.1170905
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 64
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD DEC
PY 2020
VL 18
IS 12
BP 3296
EP 3308
DI 10.1111/jth.15084
EA OCT 2020
PG 13
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA OZ9HC
UT WOS:000579317100001
PM 32881285
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gasparini, M
   Khan, S
   Patel, JM
   Parekh, D
   Bangash, MN
   Stumpfle, R
   Shah, A
   Baharlo, B
   Soni, S
AF Gasparini, M.
   Khan, S.
   Patel, J. M.
   Parekh, D.
   Bangash, M. N.
   Stumpfle, R.
   Shah, A.
   Baharlo, B.
   Soni, S.
TI Renal impairment and its impact on clinical outcomes in patients who are
   critically ill with COVID-19: a multicentre observational study
SO ANAESTHESIA
LA English
DT Article; Early Access
DE acute kidney disease; chronic kidney disease; COVID-19; critical illness
ID COMORBIDITIES
AB Renal impairment is common in patients who are critically ill with coronavirus disease-19 (COVID-19). We examined the association between acute and chronic kidney disease with clinical outcomes in 372 patients with coronavirus disease-19 admitted to four regional intensive care units between 10 March 2020 and 31 July 2020. A total of 216 (58%) patients presented with COVID-19 and renal impairment. Acute kidney injury and/or chronic kidney disease was associated with greater in-hospital mortality compared with patients with preserved renal function (107/216 patients (50%) (95%CI 44-57) vs. 32/156 (21%) (95%CI 15-28), respectively; p < 0.001, relative risk 2.4 (95%CI 1.7-3.4)). Mortality was greatest in patients with renal transplants (6/7 patients (86%) (95%CI 47-100)). Mortality rates increased in patients with worsening renal injury according to the Kidney Disease: Improving Global Outcomes classification: stage 0 mortality 33/157 patients (21%) (95%CI 15-28) vs. stages 1-3 mortality 91/186 patients (49%) (95%CI 42-56); p < 0.001, relative risk 2.3 (95%CI 1.7-3.3). Survivors were less likely to require renal replacement therapy compared with non-survivors (57/233 patients (24%) vs. 64/139 patients (46%), respectively; p < 0.001, relative risk 1.9 (95%CI 1.4-2.5)). One-fifth of survivors who required renal replacement therapy acutely in intensive care continued to require renal support following discharge. Our data demonstrate that renal impairment in patients admitted to intensive care with COVID-19 is common and is associated with a high mortality and requirement for on-going renal support after discharge from critical care. Our findings have important implications for future pandemic planning in this patient cohort.
C1 [Gasparini, M.] Imperial Coll Healthcare NHS Trust, Canc & Cardiovasc Div, Surg, London, England.
   [Khan, S.] Imperial Coll Healthcare NHS Trust, Med & Integrated Care Div, London, England.
   [Stumpfle, R.; Baharlo, B.] Imperial Coll Healthcare NHS Trust, Ctr Perioperat Med & Crit Care Res, London, England.
   [Patel, J. M.; Parekh, D.; Bangash, M. N.] Univ Hosp Birmingham, Dept Crit Care Med, Birmingham, W Midlands, England.
   [Shah, A.] Univ Oxford, Oxford, England.
   [Soni, S.] Imperial Coll London, Div Anaesthet Pain Med & Intens Care, London, England.
RP Soni, S (corresponding author), Imperial Coll London, Div Anaesthet Pain Med & Intens Care, London, England.
EM s.soni@imperial.ac.uk
RI Bangash, Mansoor/AAR-6546-2020
OI Bangash, Mansoor/0000-0001-5039-5184; Soni, Sanooj/0000-0001-8126-8313;
   Shah, Akshay/0000-0002-1869-2231
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Armstrong RA, 2020, ANAESTHESIA, V75, P1340, DOI 10.1111/anae.15201
   Auld SC, 2020, CRIT CARE MED, V48, pE799, DOI 10.1097/CCM.0000000000004457
   Bagshaw SM, 2020, NEW ENGL J MED, V383, P240, DOI 10.1056/NEJMoa2000741
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Chaibi K, 2020, AM J RESP CRIT CARE, V202, P1299, DOI 10.1164/rccm.202005-1524LE
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Cunningham PN, 2002, J IMMUNOL, V168, P5817, DOI 10.4049/jimmunol.168.11.5817
   Darmon M, 2014, CLIN J AM SOC NEPHRO, V9, P1347, DOI 10.2215/CJN.08300813
   Fidalgo P, 2014, MANAGING CHRONIC KID, P417
   Forte JC, 2019, LANCET DIGIT HEALTH, V1, pE48, DOI 10.1016/S2589-7500(19)30030-5
   Gabarre P, 2020, INTENS CARE MED, V46, P1339, DOI 10.1007/s00134-020-06153-9
   Gallagher M, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001601
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3
   Hu L., 2020, CLIN INFECT DIS, V52, DOI [10.1093/cid/ciaa539, DOI 10.1093/CID/CIAA539]
   ICNARC, 2020, ICNARC REP COVID 19
   Kotwal S, 2016, NEPHROLOGY, V21, P930, DOI 10.1111/nep.12694
   Lee CCM, 2020, ANAESTHESIA, V75, P861, DOI 10.1111/anae.15074
   Miller SE, 2020, KIDNEY INT, V98, P231, DOI 10.1016/j.kint.2020.05.004
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Soni S, 2019, FASEB J, V33, P6442, DOI 10.1096/fj.201802386R
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   von Elm E, 2007, B WORLD HEALTH ORGAN, V85, P867, DOI 10.2471/BLT.07.045120
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Wright SE, 2003, ANAESTHESIA, V58, P1063, DOI 10.1046/j.1365-2044.2003.03449.x
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang WJ, 2020, J INFECTION, V80, P388, DOI 10.1016/j.jinf.2020.02.016
   Yang XH, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03065-4
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 33
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
DI 10.1111/anae.15293
EA OCT 2020
PG 7
WC Anesthesiology
SC Anesthesiology
GA OA4DF
UT WOS:000577737400001
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Zheng, WJ
   Yan, Q
   Ni, YS
   Zhan, SF
   Yang, LL
   Zhuang, HF
   Liu, XH
   Jiang, Y
AF Zheng, Wen-jiang
   Yan, Qian
   Ni, Yong-shi
   Zhan, Shao-feng
   Yang, Liu-liu
   Zhuang, Hong-fa
   Liu, Xiao-hong
   Jiang, Yong
TI Examining the effector mechanisms of Xuebijing injection on COVID-19
   based on network pharmacology
SO BIODATA MINING
LA English
DT Article
DE Active ingredient; Coronavirus disease 2019; Effector mechanism;
   Molecular docking; Network pharmacology; Xuebijing
ID NF-KAPPA-B; RESPIRATORY SYNDROME CORONAVIRUS; CLINICAL CHARACTERISTICS;
   GENE ONTOLOGY; LUNG INJURY; CELL ENTRY; PATHWAY; EXPRESSION; PNEUMONIA;
   OUTBREAK
AB Background Chinese medicine Xuebijing (XBJ) has proven to be effective in the treatment of mild coronavirus disease 2019 (COVID-19) cases. But the bioactive compounds and potential mechanisms of XBJ for COVID-19 prevention and treatment are unclear. This study aimed to examine the potential effector mechanisms of XBJ on COVID-19 based on network pharmacology. Methods We searched Chinese and international papers to obtain the active ingredients of XBJ. Then, we compiled COVID-19 disease targets from the GeneCards gene database and via literature searches. Next, we used the SwissTargetPrediction database to predict XBJ's effector targets and map them to the abovementioned COVID-19 disease targets in order to obtain potential therapeutic targets of XBJ. Cytoscape software version 3.7.0 was used to construct a "XBJ active-compound-potential-effector target" network and protein-protein interaction (PPI) network, and then to carry out network topology analysis of potential targets. We used the ClueGO and CluePedia plugins in Cytoscape to conduct gene ontology (GO) biological process (BP) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis of XBJ's effector targets. We used AutoDock vina and PyMOL software for molecular docking. Results We obtained 144 potential COVID-19 effector targets of XBJ. Fourteen of these targets-glyceraldehyde 3-phosphate dehydrogenase (GAPDH), albumin (ALB), tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), mitogen-activated protein kinase 1 (MAPK1), Caspase-3 (CASP3), signal transducer and activator of transcription 3 (STAT3),MAPK8, prostaglandin-endoperoxide synthase 2 (PTGS2),JUN, interleukin-2 (IL-2), estrogen receptor 1 (ESR1), andMAPK14had degree values > 40 and therefore could be considered key targets. They participated in extracellular signal-regulated kinase 1 and 2 (ERK1,ERK2) cascade, the T-cell receptor signaling pathway, activation ofMAPKactivity, cellular response to lipopolysaccharide, and other inflammation- and immune-related BPs. XBJ exerted its therapeutic effects through the renin-angiotensin system (RAS), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B),MAPK, phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)-protein kinase B (Akt)-vascular endothelial growth factor (VEGF), toll-like receptor (TLR), TNF, and inflammatory-mediator regulation of transient receptor potential (TRP) signaling pathways to ultimately construct a "drug-ingredient-target-pathway" effector network. The molecular docking results showed that the core 18 effective ingredients had a docking score of less than - 4.0 with those top 10 targets. Conclusion The active ingredients of XBJ regulated different genes, acted on different pathways, and synergistically produced anti-inflammatory and immune-regulatory effects, which fully demonstrated the synergistic effects of different components on multiple targets and pathways. Our study demonstrated that key ingredients and their targets have potential binding activity, the existing studies on the pharmacological mechanisms of XBJ in the treatment of sepsis and severe pneumonia, could explain the effector mechanism of XBJ in COVID-19 treatment, and those provided a preliminary examination of the potential effector mechanism in this disease.
C1 [Zheng, Wen-jiang; Yan, Qian] Guangzhou Univ Chinese Med, Clin Med Sch 1, Guangzhou, Peoples R China.
   [Ni, Yong-shi] Guangzhou Univ Chinese Med, Clin Med Sch 2, Guangzhou, Peoples R China.
   [Zhan, Shao-feng; Yang, Liu-liu; Zhuang, Hong-fa; Liu, Xiao-hong] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Jiang, Yong] Shenzhen Hosp Integrated Tradit Chinese & Western, Shenzhen, Peoples R China.
RP Liu, XH (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.; Jiang, Y (corresponding author), Shenzhen Hosp Integrated Tradit Chinese & Western, Shenzhen, Peoples R China.
EM drlxh@foxmail.com; jiangyongszzxy@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81973814]; Liu Xiaohong Famous Traditional
   Chinese Medicine Inheritance Studio from the Traditional Chinese
   Medicine Bureau of Guangdong Province [201805]; Construction Project of
   the National Clinical Medical Research Center (respiratory department)
   [2110200309]; Student Learning Team Incubation Project of Innovation
   Academy from The First Affiliated Hospital of Guangzhou University of
   Chinese Medicine [2018XXTD003]; Guangdong Provincial Science and
   Technology Plan Project (South China Traditional Chinese Medicine
   Collaborative Innovation Center) [2014b0902002]; Construction Project of
   High Level Hospital on Modified Weijing Granules [211010010603]; 2018
   Guangzhou University of Chinese Medicine National University Student
   Innovation and Entrepreneurship Training Project [201810572038]; 2020
   National College Student Innovation and Entrepreneurship Training
   Project of Guangzhou University of Chinese Medicine [202010572001]
FX This research was funded by grants from the National Natural Science
   Foundation of China (No.81973814), the Liu Xiaohong Famous Traditional
   Chinese Medicine Inheritance Studio from the Traditional Chinese
   Medicine Bureau of Guangdong Province (No.201805), the Construction
   Project of the National Clinical Medical Research Center (respiratory
   department, No.2110200309), the Construction Project of High Level
   Hospital on Modified Weijing Granules (No.211010010603), and the Student
   Learning Team Incubation Project of Innovation Academy from The First
   Affiliated Hospital of Guangzhou University of Chinese Medicine
   (No.2018XXTD003), and the Guangdong Provincial Science and Technology
   Plan Project (South China Traditional Chinese Medicine Collaborative
   Innovation Center, No.2014b0902002), 2018 Guangzhou University of
   Chinese Medicine National University Student Innovation and
   Entrepreneurship Training Project (No.201810572038), and 2020 National
   College Student Innovation and Entrepreneurship Training Project of
   Guangzhou University of Chinese Medicine (No. 202010572001).
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bindea G, 2013, BIOINFORMATICS, V29, P661, DOI 10.1093/bioinformatics/btt019
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Canton J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006838
   Chen J, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110281
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen X, 2018, J ETHNOPHARMACOL, V211, P358, DOI 10.1016/j.jep.2017.10.001
   Chen Y, 2017, EXP THER MED, V13, P3408, DOI 10.3892/etm.2017.4444
   Cheng C, 2016, ACTA PHARMACOL SIN, V37, P530, DOI 10.1038/aps.2015.103
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Deng LY, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080409
   Dunn EF, 2012, PROG MOL BIOL TRANSL, V106, P223, DOI 10.1016/B978-0-12-396456-4.00002-X
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   He F, 2018, BIOMED PHARMACOTHER, V106, P1404, DOI 10.1016/j.biopha.2018.07.111
   He XD, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/804940
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang M, 2013, J ETHNOPHARMACOL, V147, P426, DOI 10.1016/j.jep.2013.03.032
   Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063
   Kong Q, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110316
   Li CY, 2018, J ETHNOPHARMACOL, V224, P512, DOI 10.1016/j.jep.2018.05.043
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875-5364(13)60037-0]
   Li TT, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00104
   Liu MW, 2016, INT J MOL MED, V38, P1419, DOI 10.3892/ijmm.2016.2749
   Liu Ming-wei, 2014, BMC Complement Altern Med, V14, P498, DOI 10.1186/1472-6882-14-498
   Liu MW, 2014, INT J MOL MED, V34, P1492, DOI 10.3892/ijmm.2014.1943
   Liu YQ, 2014, J PHARMACOL SCI, V126, P107, DOI 10.1254/jphs.14055FP
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379
   Messina F, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02405-w
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Pleschka S, 2008, BIOL CHEM, V389, P1273, DOI 10.1515/BC.2008.145
   Rappaport N, 2017, BIOMED ENG ONLINE, V16, DOI 10.1186/s12938-017-0359-2
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Sauter JL, 2020, HISTOPATHOLOGY, V77, P915, DOI 10.1111/his.14201
   Song YL, 2019, CRIT CARE MED, V47, pE735, DOI 10.1097/CCM.0000000000003842
   Sparks MA, 2020, CLIN J AM SOC NEPHRO, V15, P714, DOI 10.2215/CJN.03530320
   Su Gang, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi0813s47
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang J, 2020, ACE2 EXPRESSION COLO, DOI [10.1101/2020.02.05.20020545, DOI 10.1101/2020.02.05.20020545]
   Wang Q, 2015, EURASIP J WIREL COMM, DOI 10.1186/s13638-015-0358-6
   Wang YP, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/2720369
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang RC, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104820
   Yin Q, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/949254
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang QF, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.07.78
   Zhang YL, 2020, TRADIT MED RES, V5, P201, DOI 10.12032/TMR20200507178
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
   Zuo LH, 2017, J PHARMACEUT BIOMED, V137, P220, DOI 10.1016/j.jpba.2017.01.024
NR 64
TC 0
Z9 0
U1 11
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-0381
J9 BIODATA MIN
JI BioData Min.
PD OCT 16
PY 2020
VL 13
IS 1
AR 17
DI 10.1186/s13040-020-00227-6
PG 23
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA OA9FI
UT WOS:000578084900001
PM 33082858
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ehsani, S
AF Ehsani, Sepehr
TI COVID-19 and iron dysregulation: distant sequence similarity between
   hepcidin and the novel coronavirus spike glycoprotein
SO BIOLOGY DIRECT
LA English
DT Article
DE Coronavirus; COVID-19; Cysteine; Ferroportin; Hepcidin; IL-6;
   Inflammation; Iron; Pufferfish; Sequence similarity; Spike protein
ID HUMAN HEPATOCYTES; PEPTIDE HEPCIDIN; BINDING-SITE; SARS-COV; PROTEIN;
   FUSION; VIRUS; PALMITOYLATION; DISCOVERY; ANEMIA
AB The spike glycoprotein of the SARS-CoV-2 virus, which causes COVID-19, has attracted attention for its vaccine potential and binding capacity to host cell surface receptors. Much of this research focus has centered on the ectodomain of the spike protein. The ectodomain is anchored to a transmembrane region, followed by a cytoplasmic tail. Here we report a distant sequence similarity between the cysteine-rich cytoplasmic tail of the coronavirus spike protein and the hepcidin protein that is found in humans and other vertebrates. Hepcidin is thought to be the key regulator of iron metabolism in humans through its inhibition of the iron-exporting protein ferroportin. An implication of this preliminary observation is to suggest a potential route of investigation in the coronavirus research field making use of an already-established literature on the interplay of local and systemic iron regulation, cytokine-mediated inflammatory processes, respiratory infections and the hepcidin protein. The question of possible homology and an evolutionary connection between the viral spike protein and hepcidin is not assessed in this report, but some scenarios for its study are discussed.
C1 [Ehsani, Sepehr] UCL, Dept Philosophy, Theoret & Philosoph Biol, London WC1E 6BT, England.
   [Ehsani, Sepehr] Ronin Inst Independent Scholarship, Montclair, NJ 07043 USA.
RP Ehsani, S (corresponding author), UCL, Dept Philosophy, Theoret & Philosoph Biol, London WC1E 6BT, England.; Ehsani, S (corresponding author), Ronin Inst Independent Scholarship, Montclair, NJ 07043 USA.
EM ehsani@uclmail.net
RI Ehsani, Sepehr/E-9257-2010
OI Ehsani, Sepehr/0000-0002-9613-6898
FU University College London Overseas Research Scholarship
FX The author is supported by a University College London Overseas Research
   Scholarship.
CR Abobaker A, 2020, EUR J CLIN PHARMACOL, DOI 10.1007/s00228-020-02988-9
   ALEXANDER D, 1992, MOL PLANT MICROBE IN, V5, P513, DOI 10.1094/MPMI-5-513
   Ali MK, 2020, J PATHOL, V251, P49, DOI 10.1002/path.5401
   Almeida JD, 1968, NATURE, V220, P650
   Anand P, 2020, ELIFE, V9, DOI 10.7554/eLife.58603
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Andrews NC, 2008, BLOOD, V112, P219, DOI 10.1182/blood-2007-12-077388
   [Anonymous], 2020, COR COVID 19 GLOB CA
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Archer SL, 2020, CIRCULATION, V142, P101, DOI 10.1161/CIRCULATIONAHA.120.047915
   Arias-Reyes C, 2020, RESP PHYSIOL NEUROBI, V277, DOI 10.1016/j.resp.2020.103443
   Armitage AE, 2014, P NATL ACAD SCI USA, V111, P12187, DOI 10.1073/pnas.1402351111
   Armitage AE, 2011, BLOOD, V118, P4129, DOI 10.1182/blood-2011-04-351957
   Aschemeyer S, 2018, BLOOD, V131, P899, DOI 10.1182/blood-2017-05-786590
   Bar-On YM, 2020, ELIFE, V9, DOI 10.7554/eLife.57309
   Baron DM, 2020, ANAESTHESIA, V75, P1105, DOI 10.1111/anae.15095
   Basnyat B, 2020, BMJ
   Beliveau F, 2019, CELL CHEM BIOL, V26, P1559, DOI 10.1016/j.chembiol.2019.09.004
   Beniac DR, 2006, NAT STRUCT MOL BIOL, V13, P751, DOI 10.1038/nsmb1123
   Billesbolle CB, 2020, NATURE, DOI 10.1038/s41586-020-2668-z
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Brissot P, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.16
   Camaschella C, 2015, NEW ENGL J MED, V372, P1832, DOI 10.1056/NEJMra1401038
   Chang KW, 2000, VIROLOGY, V269, P212, DOI 10.1006/viro.2000.0219
   Chen J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2603-0
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Choque-Quispe BM, 2020, ANN NY ACAD SCI, V1473, P35, DOI 10.1111/nyas.14356
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Crielaard BJ, 2017, NAT REV DRUG DISCOV, V16, P400, DOI 10.1038/nrd.2016.248
   De Domenico I, 2008, NAT REV MOL CELL BIO, V9, P72, DOI 10.1038/nrm2295
   Dhont S, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01462-5
   Di Paola L, 2020, J PROTEOME RES, V19, P4576, DOI 10.1021/acs.jproteome.0c00273
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Drakesmith H, 2012, SCIENCE, V338, P768, DOI 10.1126/science.1224577
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Du X, 2008, SCIENCE, V320, P1088, DOI 10.1126/science.1157121
   Dufort EM, 2020, NEW ENGL J MED, V383, P347, DOI 10.1056/NEJMoa2021756
   Ebihara T, 2005, J INFECT DIS, V192, P351, DOI 10.1086/430797
   Edeas M, 2020, INT J INFECT DIS, V97, P303, DOI 10.1016/j.ijid.2020.05.110
   Ehsani S, 2015, 150503196V1 ARXIV
   Ehsani S., 2013, 13012397V2 ARXIV
   Ehsani S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026800
   Esper F, 2005, J INFECT DIS, V191, P499, DOI 10.1086/428291
   Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680
   FERNANDEZ H, 1980, NEW ENGL J MED, V302, P865
   Finn RD, 2008, NUCLEIC ACIDS RES, V36, pD281, DOI 10.1093/nar/gkm960
   Gadalla MR, 2020, EXPERT OPIN DRUG DIS, V15, P159, DOI 10.1080/17460441.2020.1696306
   Galesloot TE, 2011, BLOOD, V117, pE218, DOI 10.1182/blood-2011-02-337907
   Ganz T, 2006, AM J PHYSIOL-GASTR L, V290, pG199, DOI 10.1152/ajpgi.00412.2005
   Ganz T, 2019, NEW ENGL J MED, V381, P1148, DOI 10.1056/NEJMra1804281
   Ganz T, 2017, EBIOMEDICINE, V20, P13, DOI 10.1016/j.ebiom.2017.05.023
   Garrick MD, 2020, EUR J CLIN PHARMACOL, DOI 10.1007/s00228-020-02987-w
   Garvin MR, 2020, ELIFE, V9, DOI 10.7554/eLife.59177
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Go HJ, 2019, FISH SHELLFISH IMMUN, V93, P683, DOI 10.1016/j.fsi.2019.08.017
   Gomez-Pastora J, 2020, CLIN CHIM ACTA, V509, P249, DOI 10.1016/j.cca.2020.06.033
   Grover N., 2019, ENDPOINTS NEWS
   Gussow AB, 2020, P NATL ACAD SCI USA, V117, P15193, DOI 10.1073/pnas.2008176117
   Hennigar SR, 2020, HIGH ALT MED BIOL, V21, P232, DOI 10.1089/ham.2019.0109
   Hippchen T, 2020, HYPOFERREMIA PREDICT, DOI [10.1101/2020.06.26.20140525, DOI 10.1101/2020.06.26.20140525]
   Huang YH, 2018, J MOL CELL CARDIOL, V117, P82, DOI 10.1016/j.yjmcc.2018.02.017
   Hulswit RJG, 2019, P NATL ACAD SCI USA, V116, P2681, DOI 10.1073/pnas.1809667116
   Hunter HN, 2002, J BIOL CHEM, V277, P37597, DOI 10.1074/jbc.M205305200
   Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020-0123
   Jordan JB, 2009, J BIOL CHEM, V284, P24155, DOI 10.1074/jbc.M109.017764
   Kielian M, 2014, ANNU REV VIROL, V1, P171, DOI 10.1146/annurev-virology-031413-085521
   Kim CH, 2019, FISH SHELLFISH IMMUN, V88, P117, DOI 10.1016/j.fsi.2019.02.045
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7
   Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6
   Lakhal-Littleton S, 2019, P NATL ACAD SCI USA, V116, P13122, DOI 10.1073/pnas.1822010116
   Lauth X, 2005, J BIOL CHEM, V280, P9272, DOI 10.1074/jbc.M411154200
   Lee P, 2008, BLOOD CELL MOL DIS, V40, P139, DOI 10.1016/j.bcmd.2007.07.010
   Lefkowitch JH, 2005, CURR OPIN GASTROEN, V21, P260, DOI 10.1097/01.mog.0000159820.78532.68
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lidgard S, 2018, BIOSCIENCE, V68, P760, DOI 10.1093/biosci/biy084
   Linder ME, 2007, NAT REV MOL CELL BIO, V8, P74, DOI 10.1038/nrm2084
   Liu B, 2020, FISH SHELLFISH IMMUN, V104, P419, DOI 10.1016/j.fsi.2020.06.029
   Liu W, 2020, CURR CLIN MICROBIOL, V7, P13, DOI [10.1080/15384101.2020.1731644, 10.1007/s40588-020-00140-w]
   McBride CE, 2007, J VIROL, V81, P2418, DOI 10.1128/JVI.02146-06
   McBride CE, 2010, VIROLOGY, V405, P139, DOI 10.1016/j.virol.2010.05.031
   McIntosh K, 2004, J INFECT DIS, V190, P1033, DOI 10.1086/422851
   McLaughlin KM, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10080539
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Michels K, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004998
   Moccia F, 2020, GEROSCIENCE, V42, P1021, DOI 10.1007/s11357-020-00198-w
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Muriuki JM, 2019, SCI ADV, V5, DOI [10.112, 10.1126/sciadv.aaw0109]
   Nemeth E, 2009, ACTA HAEMATOL-BASEL, V122, P78, DOI 10.1159/000243791
   Neves J, 2017, EBIOMEDICINE, V20, P230, DOI 10.1016/j.ebiom.2017.04.036
   Neves JV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14933-5
   Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686
   NOBUSAWA E, 1991, VIROLOGY, V182, P475, DOI 10.1016/0042-6822(91)90588-3
   Noguchi-Sasaki M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2305-2
   Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620
   Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200
   Peng GQ, 2011, P NATL ACAD SCI USA, V108, P10696, DOI 10.1073/pnas.1104306108
   Perez E, 2020, J IMMUNOL, V205, P2489, DOI 10.4049/jimmunol.1901284
   Perricone C, 2020, IMMUNOL RES, V68, P213, DOI 10.1007/s12026-020-09145-5
   Petit CM, 2007, VIROLOGY, V360, P264, DOI 10.1016/j.virol.2006.10.034
   Petit CM, 2005, VIROLOGY, V341, P215, DOI 10.1016/j.virol.2005.06.046
   Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200
   Poli M, 2019, J BIOL CHEM, V294, P13292, DOI 10.1074/jbc.RA118.007213
   Poli M, 2011, BLOOD, V117, P997, DOI 10.1182/blood-2010-06-289082
   Prentice AM, 2017, ANN NUTR METAB, V71, P40, DOI 10.1159/000480743
   Preza GC, 2011, J CLIN INVEST, V121, P4880, DOI 10.1172/JCI57693
   Ramakrishnan L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31095-0
   Ren Z, 2020, STRUCTURE MECH PRIMA, DOI [10.1101/2020.03.04.975748, DOI 10.1101/2020.03.04.975748]
   Rishi G, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20191499
   Roche JA, 2020, FASEB J, V34, P7265, DOI 10.1096/fj.202000967
   Schmitt-Ulms G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007208
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Seah I, 2020, EYE, V34, P1155, DOI 10.1038/s41433-020-0790-7
   Shah A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03051-w
   Shang J, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008392
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shulla A, 2009, J BIOL CHEM, V284, P32725, DOI 10.1074/jbc.M109.043547
   Sobocinska J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2017.02003
   South AM, 2020, NAT REV NEPHROL, V16, P305, DOI 10.1038/s41581-020-0279-4
   Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   Tang XP, 2020, CELL RES, V30, P119, DOI 10.1038/s41422-019-0260-6
   Tardiff DF, 2014, MOVEMENT DISORD, V29, P1231, DOI 10.1002/mds.25989
   Valore EV, 2008, BLOOD CELL MOL DIS, V40, P132, DOI 10.1016/j.bcmd.2007.07.009
   Van de Peer Y, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-250
   van Swelm RPL, 2020, NAT REV NEPHROL, V16, P77, DOI 10.1038/s41581-019-0197-5
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wagner R, 2005, J VIROL, V79, P6449, DOI 10.1128/JVI.79.10.6449-6458.2005
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wrapp D, 2019, J VIROL, V93, DOI 10.1128/JVI.00923-19
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Qingfa, 2003, Genomics Proteomics & Bioinformatics, V1, P131
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xu QH, 2008, MOL BIOL EVOL, V25, P1099, DOI 10.1093/molbev/msn056
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yen FT, 1999, J BIOL CHEM, V274, P13390, DOI 10.1074/jbc.274.19.13390
   Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhao Kang, 2020, Open Forum Infect Dis, V7, pofaa250, DOI 10.1093/ofid/ofaa250
   Zhou CX, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.926178
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zimmermann L, 2018, J MOL BIOL, V430, P2237, DOI 10.1016/j.jmb.2017.12.007
NR 145
TC 1
Z9 1
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6150
J9 BIOL DIRECT
JI Biol. Direct
PD OCT 16
PY 2020
VL 15
IS 1
AR 19
DI 10.1186/s13062-020-00275-2
PG 13
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA OA9GS
UT WOS:000578088500001
PM 33066821
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Raparelli, V
   Palmieri, L
   Canevelli, M
   Pricci, F
   Unim, B
   Lo Noce, C
   Villani, ER
   Rochon, PA
   Pilote, L
   Vanacore, N
   Onder, G
AF Raparelli, Valeria
   Palmieri, Luigi
   Canevelli, Marco
   Pricci, Flavia
   Unim, Brigid
   Lo Noce, Cinzia
   Villani, Emanuele R.
   Rochon, Paula A.
   Pilote, Louise
   Vanacore, Nicola
   Onder, Graziano
CA Italian Natl Inst
   Hlth COVID-19 Mortality Grp
TI Sex differences in clinical phenotype and transitions of care among
   individuals dying of COVID-19 in Italy
SO BIOLOGY OF SEX DIFFERENCES
LA English
DT Article
DE Sex; COVID-19; Transition of care; Comorbidities; In-hospital
   complications
ID RESPIRATORY SYNDROME CORONAVIRUS; ACUTE KIDNEY INJURY; FRAILTY; WOMEN;
   MEN
AB Background Among the unknowns posed by the coronavirus disease 2019 (COVID-19) outbreak, the role of biological sex to explain disease susceptibility and progression is still a matter of debate, with limited sex-disaggregated data available. Methods A retrospective analysis was performed to assess if sex differences exist in the clinical manifestations and transitions of care among hospitalized individuals dying with laboratory-confirmed SARS-CoV-2 infection in Italy (February 27-June 11, 2020). Clinical characteristics and the times from symptoms' onset to admission, nasopharyngeal swab, and death were compared between sexes. Adjusted multivariate analysis was performed to identify the clinical features associated with male sex. Results Of the 32,938 COVID-19-related deaths that occurred in Italy, 3517 hospitalized and deceased individuals with COVID-19 (mean 78 +/- 12 years, 33% women) were analyzed. At admission, men had a higher prevalence of ischemic heart disease (adj-OR = 1.76, 95% CI 1.39-2.23), chronic obstructive pulmonary disease (adj-OR = 1.7, 95% CI 1.29-2.27), and chronic kidney disease (adj-OR = 1.48, 95% CI 1.13-1.96), while women were older and more likely to have dementia (adj-OR = 0.73, 95% CI 0.55-0.95) and autoimmune diseases (adj-OR = 0.40, 95% CI 0.25-0.63), yet both sexes had a high level of multimorbidity. The times from symptoms' onset to admission and nasopharyngeal swab were slightly longer in men despite a typical acute respiratory illness with more frequent fever at the onset. Men received more often experimental therapy (adj-OR = 2.89, 95% CI 1.45-5.74) and experienced more likely acute kidney injury (adj-OR = 1.47, 95% CI 1.13-1.90). Conclusions Men and women dying with COVID-19 had different clinical manifestations and transitions of care. Identifying sex-specific features in individuals with COVID-19 and fatal outcome might inform preventive strategies.
C1 [Raparelli, Valeria] Sapienza Univ Rome, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy.
   [Palmieri, Luigi; Pricci, Flavia; Unim, Brigid; Lo Noce, Cinzia; Onder, Graziano] Ist Super Sanita, Dept Cardiovasc Endocrine Metab Dis & Aging, Via Giano Bella 34, I-00161 Rome, Italy.
   [Canevelli, Marco; Vanacore, Nicola] Ist Super Sanita, Natl Ctr Dis Prevent & Hlth Promot, Via Giano Bella 34, I-00161 Rome, Italy.
   [Canevelli, Marco] Sapienza Univ Rome, Dept Human Neurosci, Rome, Italy.
   [Villani, Emanuele R.] Catholic Univ, Sacred Heart, Largo Francesco Vito 1, I-00168 Rome, Italy.
   [Rochon, Paula A.] Univ Toronto, Womens Coll Hosp, Womens Coll Res Inst, 76 Grenville St, Toronto, ON M5G 1N8, Canada.
   [Pilote, Louise] McGill Univ, Hlth Ctr Res Inst, Ctr Outcomes Res & Evaluat, 1001 Boul Decarie, Montreal, PQ H4A 3J1, Canada.
RP Raparelli, V (corresponding author), Sapienza Univ Rome, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy.
EM valeria.raparelli@uniroma1.it
RI Punzo, Ornella/AAK-7517-2020; Vichi, Monica/M-7398-2017
OI Punzo, Ornella/0000-0003-3077-8174; Raparelli,
   Valeria/0000-0002-2100-5682
FU GOING-FWD Consortium within the GENDER-NET Plus ERA-NET Initiative
   [GNP-78]
FX VR acknowledges the Scientific Independence of Young Researcher Program
   of the Italian Ministry of University, Education, and Research
   (RBSI14HNVT) and the GOING-FWD Consortium within the GENDER-NET Plus
   ERA-NET Initiative (Project ref. number GNP-78) for supporting her
   research activity. Group authorship-Italian National Institute of Health
   COVID-19 Mortality Group:; Luigi Palmieri, Elvira Agazio, Xanthi
   Andrianou, Pierfrancesco Barbariol, Antonino Bella, Stefania Bellino,
   Eva Benelli, Luigi Bertinato, Stefano Boros, Gianfranco Brambilla,
   Giovanni Calcagnini, Marco Canevelli, Maria Rita Castrucci, Federica
   Censi, Alessandra Ciervo, Elisa Colaizzo, Fortunato D'Ancona, Martina
   Del Manso, Chiara Donfrancesco, Massimo Fabiani, Francesco Facchiano,
   Antonietta Filia, Marco Floridia, Fabio Galati, Marina Giuliano, Tiziana
   Grisetti, Yllka Kodra, Martin Langer, Ilaria Lega, Cinzia Lo Noce,
   Pietro Maiozzi, Fiorella Malchiodi Albedi, Valerio Manno, Margherita
   Martini, Alberto Mateo Urdiales, Eugenio Mattei, Claudia Meduri, Paola
   Meli, Giada Minelli, Manuela Nebuloni, Lorenza Nistic, Marino Nonis,
   Graziano Onder, Lucia Palmisano, Nicola Petrosillo, Patrizio Pezzotti,
   Flavia Pricci, Ornella Punzo, Vincenzo Puro, Valeria Raparelli, Giovanni
   Rezza, Flavia Riccardo, Maria Cristina Rota, Paolo Salerno, Debora
   Serra, Andrea Siddu, Paola Stefanelli, Manuela Tamburo De Bella, Dorina
   Tiple, Brigid Unim, Luana Vaianella, Nicola Vanacore, Monica Vichi,
   Emanuele Rocco Villani, Amerigo Zona, Silvio Brusaferro.
CR Alghamdi IG, 2014, INT J GEN MED, V7, P417, DOI 10.2147/IJGM.S67061
   Ali H, 2020, RENAL FAILURE, V42, P393, DOI 10.1080/0886022X.2020.1756323
   [Anonymous], 2016, LANCET, V387, P506, DOI 10.1016/S0140-6736(16)00267-1
   [Anonymous], 2018, LANCET, V392, P1859, DOI [DOI 10.1016/S0140-6736(18)32335-3, 10.1016/S0140-6736(18)32335-3]
   [Anonymous], COVID 19 SURV REP
   Argenzian MG, 2020, BMJ-BRIT MED J, V369
   Batlle D, 2020, J AM SOC NEPHROL, V31, P1380, DOI 10.1681/ASN.2020040419
   Bischof E, 2020, J CLIN INVEST, V130, P3350, DOI 10.1172/JCI139306
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Evans SS, 2015, NAT REV IMMUNOL, V15, P335, DOI 10.1038/nri3843
   Gebhard C, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00304-9
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Gordon EH, 2019, MECH AGEING DEV, V179, P44, DOI 10.1016/j.mad.2019.02.004
   Gordon EH, 2017, EXP GERONTOL, V89, P30, DOI 10.1016/j.exger.2016.12.021
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hubbard RE, 2011, MATURITAS, V69, P203, DOI 10.1016/j.maturitas.2011.04.006
   Iaccarino G, 2020, HYPERTENSION, V76, P366, DOI 10.1161/HYPERTENSIONAHA.120.15324
   Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Kragholm Kristian, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa924
   Leong HN, 2006, ANN ACAD MED SINGAP, V35, P326
   Nichols E, 2019, LANCET NEUROL, V18, P88, DOI 10.1016/S1474-4422(18)30403-4
   Oksuzyan A, 2008, AGING CLIN EXP RES, V20, P91
   Oksuzyan A, 2009, ANN EPIDEMIOL, V19, P504, DOI 10.1016/j.annepidem.2009.03.014
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Palmieri L, 2020, J GERONTOL A-BIOL, V75, P1796, DOI 10.1093/gerona/glaa146
   Regitz-Zagrosek V, 2012, EMBO REP, V13, P596, DOI 10.1038/embor.2012.87
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rochon PA, 2020, J AM GERIATR SOC, V68, P1671, DOI 10.1111/jgs.16646
   Rochon PA, 2020, LANCET, V395, P1530, DOI 10.1016/S0140-6736(20)30849-7
   Scully EP, 2020, NAT REV IMMUNOL, V20, P442, DOI 10.1038/s41577-020-0348-8
   Spagnolo PA, 2020, ANN INTERN MED, V173, P385, DOI 10.7326/M20-1941
   Tadiri CP, 2020, CAN MED ASSOC J, V192, pE1041, DOI 10.1503/cmaj.200971
   Tannenbaum C, 2017, PHARMACOL RES, V121, P83, DOI 10.1016/j.phrs.2017.04.027
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wenham C, 2020, LANCET, V395, P846, DOI 10.1016/S0140-6736(20)30526-2
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   Yang F, 2020, J MED VIROL, V92, P2511, DOI 10.1002/jmv.25891
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
NR 42
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2042-6410
J9 BIOL SEX DIFFER
JI Biol. Sex Differ.
PD OCT 16
PY 2020
VL 11
IS 1
AR 57
DI 10.1186/s13293-020-00334-3
PG 9
WC Endocrinology & Metabolism; Genetics & Heredity
SC Endocrinology & Metabolism; Genetics & Heredity
GA OA8ZE
UT WOS:000578068800001
PM 33066823
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Welker, A
   Kersten, C
   Muller, C
   Madhugiri, R
   Zimmer, C
   Muller, P
   Zimmermann, R
   Hammerschmidt, S
   Maus, H
   Ziebuhr, J
   Sotriffer, C
   Schirmeister, T
AF Welker, Armin
   Kersten, Christian
   Mueller, Christin
   Madhugiri, Ramakanth
   Zimmer, Collin
   Mueller, Patrick
   Zimmermann, Robert
   Hammerschmidt, Stefan
   Maus, Hannah
   Ziebuhr, John
   Sotriffer, Christoph
   Schirmeister, Tanja
TI Deal;Structure-Activity Relationships of Benzamides and Isoindolines
   Designed as SARS-CoV Protease Inhibitors Effective against SARS-CoV-2
SO CHEMMEDCHEM
LA English
DT Article; Early Access
DE Antiviral agents; Computational chemistry; Drug design; Protease
   inhibitors; Structure-activity relationships
ID CORONAVIRUS PAPAIN-LIKE; RESPIRATORY SYNDROME CORONAVIRUS; PNEUMONIA
AB Inhibition of coronavirus (CoV)-encoded papain-like cysteine proteases (PLpro) represents an attractive strategy to treat infections by these important human pathogens. Herein we report on structure-activity relationships (SAR) of the noncovalent active-site directed inhibitor (R)-5-amino-2-methyl-N-(1-(naphthalen-1-yl)ethyl) benzamide (2 b), which is known to bind into the S3 and S4 pockets of the SARS-CoV PLpro. Moreover, we report the discovery of isoindolines as a new class of potent PL(pro)inhibitors. The studies also provide a deeper understanding of the binding modes of this inhibitor class. Importantly, the inhibitors were also confirmed to inhibit SARS-CoV-2 replication in cell culture suggesting that, due to the high structural similarities of the target proteases, inhibitors identified against SARS-CoV PL(pro)are valuable starting points for the development of new pan-coronaviral inhibitors.
C1 [Welker, Armin; Sotriffer, Christoph] Justus Maximilians Univ Wurzburg, Inst Pharm & Food Chem, D-97074 Wurzburg, Germany.
   [Kersten, Christian; Zimmer, Collin; Mueller, Patrick; Zimmermann, Robert; Hammerschmidt, Stefan; Maus, Hannah; Schirmeister, Tanja] Johannes Gutenberg Univ Mainz, Inst Pharmaceut & Biomed Sci, Staudingerweg 5, D-55128 Mainz, Germany.
   [Mueller, Christin; Madhugiri, Ramakanth; Ziebuhr, John] Justus Liebig Univ Giessen, Inst Med Virol, Schubertstr 81, D-35392 Giessen, Germany.
RP Schirmeister, T (corresponding author), Johannes Gutenberg Univ Mainz, Inst Pharmaceut & Biomed Sci, Staudingerweg 5, D-55128 Mainz, Germany.
EM schirmei@uni-mainz.de
OI Zimmermann, Robert Alexander/0000-0002-5330-9234
FU Projekt DEAL
FX We thank the research group of Prof. Dr. Caroline Kisker (Justus
   Maximilians University Wurzburg) for kindly providing us with the
   plasmid coding for the SARS CoV PL<SUP>pro</SUP> and protocols for
   expression and purification. We also thank Moritz Hering (Johannes
   Gutenberg University Mainz) for his experimental support during the
   expression and purification of the SARS CoV-2 PL<SUP>pro</SUP>. Open
   access funding enabled and organized by Projekt DEAL.
CR [Anonymous], 2017, LEADIT VERS 2 3 2
   [Anonymous], 2020, SEESAR VERS 10 0
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Chemical Computing Group Inc, 2010, MOL OP ENV MOE
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Freitas BT, 2020, ACS INFECT DIS, V6, P2099, DOI 10.1021/acsinfecdis.0c00168
   Ghosh AK, 2010, J MED CHEM, V53, P4968, DOI 10.1021/jm1004489
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:6<490::AID-JCC1>3.3.CO;2-V
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Memish ZA, 2020, LANCET, V395, P1063, DOI 10.1016/S0140-6736(19)33221-0
   Muller C, 2018, ANTIVIR RES, V150, P123, DOI 10.1016/j.antiviral.2017.12.010
   Mysinger MM, 2012, J MED CHEM, V55, P6582, DOI 10.1021/jm300687e
   O'Keefe LC, 2016, WORKPLACE HEALTH SAF, V64, P184, DOI 10.1177/2165079915607497
   Osipiuk A., 2020, RCSB PDB 6WRH CRYSTA
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Schrodinger, PYMOL MOL GRAPHICS S
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 29
TC 0
Z9 0
U1 3
U2 3
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
DI 10.1002/cmdc.202000548
EA OCT 2020
PG 16
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OA0MX
UT WOS:000577492100001
PM 32930481
OA Other Gold
DA 2021-01-01
ER

PT J
AU Buetti, N
   Wicky, PH
   Le Hingrat, Q
   Ruckly, S
   Mazzuchelli, T
   Loiodice, A
   Trimboli, P
   Ogna, VF
   de Montmollin, E
   Bernasconi, E
   Visseaux, B
   Timsit, JF
AF Buetti, Niccolo
   Wicky, Paul-Henri
   Le Hingrat, Quentin
   Ruckly, Stephane
   Mazzuchelli, Timothy
   Loiodice, Ambre
   Trimboli, Pierpaolo
   Forni Ogna, Valentina
   de Montmollin, Etienne
   Bernasconi, Enos
   Visseaux, Benoit
   Timsit, Jean-Francois
TI SARS-CoV-2 detection in the lower respiratory tract of invasively
   ventilated ARDS patients
SO CRITICAL CARE
LA English
DT Article
DE SARS-CoV-2; COVID-19; Viral shedding; Viral load; Lower respiratory
   tract; ICU; Mortality
AB Background Data on SARS-CoV-2 load in lower respiratory tract (LRT) are scarce. Our objectives were to describe the viral shedding and the viral load in LRT and to determine their association with mortality in critically ill COVID-19 patients. Methods We conducted a binational study merging prospectively collected data from two COVID-19 reference centers in France and Switzerland. First, we described the viral shedding duration (i.e., time to negativity) in LRT samples. Second, we analyzed viral load in LRT samples. Third, we assessed the association between viral presence in LRT and mortality using mixed-effect logistic models for clustered data adjusting for the time between symptoms' onset and date of sampling. Results From March to May 2020, 267 LRT samples were performed in 90 patients from both centers. The median time to negativity was 29 (IQR 23; 34) days. Prolonged viral shedding was not associated with age, gender, cardiac comorbidities, diabetes, immunosuppression, corticosteroids use, or antiviral therapy. The LRT viral load tended to be higher in non-survivors. This difference was statistically significant after adjusting for the time interval between onset of symptoms and date of sampling (OR 3.78, 95% CI 1.13-12.64,p = 0.03). Conclusions The viral shedding in LRT lasted almost 30 days in median in critically ill patients, and the viral load in the LRT was associated with the 6-week mortality.
C1 [Buetti, Niccolo; Le Hingrat, Quentin; Ruckly, Stephane; Loiodice, Ambre; de Montmollin, Etienne; Visseaux, Benoit; Timsit, Jean-Francois] Univ Paris, INSERM, IAME, F-75006 Paris, France.
   [Buetti, Niccolo; Mazzuchelli, Timothy; Forni Ogna, Valentina] Locarno Community Hosp, Ente Osped Cantonale, Locarno, Switzerland.
   [Buetti, Niccolo] Univ Geneva Hosp, Infect Control Program, Geneva, Switzerland.
   [Buetti, Niccolo] Univ Geneva Hosp, WHO Collaborating Ctr Patient Safety, Geneva, Switzerland.
   [Buetti, Niccolo] Fac Med, Geneva, Switzerland.
   [Wicky, Paul-Henri; de Montmollin, Etienne; Timsit, Jean-Francois] Bichat Claude Bernard Hosp, AP HP, Med & Infect Dis ICU MI2, F-75018 Paris, France.
   [Le Hingrat, Quentin; Visseaux, Benoit] Hop Bichat Claude Bernard, AP HP, Lab Virol, F-75018 Paris, France.
   [Trimboli, Pierpaolo] Univ Svizzera Italiana USI, Fac Biomed Sci, Lugano, Switzerland.
   [Trimboli, Pierpaolo] Ente Osped Cantonale, Lugano & Mendrisio Reg Hosp, Clin Endocrinol & Diabetol, Lugano, Switzerland.
   [Bernasconi, Enos] Reg Hosp Lugano, Ente Osped Cantonale, Div Infect Dis, Lugano, Switzerland.
RP Buetti, N (corresponding author), Univ Paris, INSERM, IAME, F-75006 Paris, France.; Buetti, N (corresponding author), Locarno Community Hosp, Ente Osped Cantonale, Locarno, Switzerland.
EM niccolo.buetti@gmail.com
OI WICKY, Paul-Henri/0000-0002-1105-4667; Buetti,
   Niccolo/0000-0002-8096-1834
FU Swiss National Science FoundationSwiss National Science Foundation
   (SNSF) [P400PM_183865]; Bangerter-Rhyner Foundation
FX NB is currently receiving a mobility grant from the Swiss National
   Science Foundation (Grant Number: P400PM_183865) and a grant from the
   Bangerter-Rhyner Foundation. These grants support his fellowship in
   France. The French center (Bichat University Hospital) was part of the
   overall French COVID-19 cohort assessing patients with COVID-19 and
   registered in clinicaltrials.gov (NCT04262921).
CR Buetti N, 2020, ENDOCRINE, V70, P454, DOI 10.1007/s12020-020-02465-4
   ECDC, 2020, GUID DISCH END IS CO
   Fang ZX, 2020, J INFECTION, V81, P172, DOI 10.1016/j.jinf.2020.03.013
   Faust JS, 2020, JAMA INTERN MED, V180, P1045, DOI 10.1001/jamainternmed.2020.2306
   Fu Y, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01190-2020
   Huang YB, 2020, AM J RESP CRIT CARE, V201, P1435, DOI 10.1164/rccm.202003-0572LE
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Pujadas E, 2020, LANCET RESP MED, V8, pE70, DOI 10.1016/S2213-2600(20)30354-4
   Qi L, 2020, INT J INFECT DIS, V96, P531, DOI 10.1016/j.ijid.2020.05.045
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   von Elm E, 2007, BMJ-BRIT MED J, V335, P806
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xiao Ai Tang, 2020, Clin Infect Dis, V71, P2249, DOI 10.1093/cid/ciaa460
   Xu KJ, 2020, CLIN INFECT DIS, V71, P799, DOI 10.1093/cid/ciaa351
   Yan D, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00799-2020
   Yu FT, 2020, CLIN INFECT DIS, V71, P793, DOI 10.1093/cid/ciaa345
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
NR 19
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD OCT 16
PY 2020
VL 24
IS 1
AR 610
DI 10.1186/s13054-020-03323-5
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA OA9AM
UT WOS:000578072200001
PM 33066801
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Unni, S
   Aouti, S
   Thiyagarajan, S
   Padmanabhan, B
AF Unni, Sruthi
   Aouti, Snehal
   Thiyagarajan, Saravanamuthu
   Padmanabhan, Balasundaram
TI Identification of a repurposed drug as an inhibitor of Spike protein of
   human coronavirus SARS-CoV-2 by computational methods
SO JOURNAL OF BIOSCIENCES
LA English
DT Article
DE Bisoxatin; docking; DrugBank; MD simulations; PubChem; SARS-CoV-2; Spike
   protein
ID RECEPTOR; DOCKING; GLYCOPROTEIN; MEFLOQUINE; GENERATION; RIOCIGUAT;
   BISACODYL
AB Severe acute respiratory syndrome coronavirus (SARS-CoV-2) is an emerging new viral pathogen that causes severe respiratory disease. SARS-CoV-2 is responsible for the outbreak of COVID-19 pandemic worldwide. As there are no confirmed antiviral drugs or vaccines currently available for the treatment of COVID-19, discovering potent inhibitors or vaccines are urgently required for the benefit of humanity. The glycosylated Spike protein (S-protein) directly interacts with human angiotensin-converting enzyme 2 (ACE2) receptor through the receptor-binding domain (RBD) of S-protein. As the S-protein is exposed to the surface and is essential for entry into the host, the S-protein can be considered as a first-line therapeutic target for antiviral therapy and vaccine development.In silicoscreening, docking, and molecular dynamics simulation studies were performed to identify repurposing drugs using DrugBank and PubChem library against the RBD of S-protein. The study identified a laxative drug, Bisoxatin (DB09219), which is used for the treatment of constipation and preparation of the colon for surgical procedures. It binds nicely at the S-protein-ACE2 interface by making substantial pi-pi interactions with Tyr505 in the 'Site 1' hook region of RBD and hydrophilic interactions with Glu406, Ser494, and Thr500. Bisoxatin consistently binds to the protein throughout the 100 ns simulation. Taken together, we propose that the discovered molecule, Bisoxatin may be a promising repurposable drug molecule to develop new chemical libraries for inhibiting SARS-CoV-2 entry into the host.
C1 [Unni, Sruthi; Aouti, Snehal; Padmanabhan, Balasundaram] Natl Inst Mental Hlth & Neuro Sci NIMHANS, Dept Biophys, Hosur Main Rd, Bengaluru 560029, India.
   [Thiyagarajan, Saravanamuthu] Inst Bioinformat & Appl Biotechnol IBAB, Biotech Pk,Elect City Phase 1, Bengaluru 560100, India.
RP Padmanabhan, B (corresponding author), Natl Inst Mental Hlth & Neuro Sci NIMHANS, Dept Biophys, Hosur Main Rd, Bengaluru 560029, India.
EM balapaddy@gmail.com
FU DSTDepartment of Science & Technology (India) [DST-FIST:
   SR/FST/LS-I/2017(C)]; SERBDepartment of Science & Technology
   (India)Science Engineering Research Board (SERB), India
   [CRG/2019/002603]; DBT, IndiaDepartment of Biotechnology (DBT) India
   [BT/PR32378/BRB/10/1784/2019]; ICMR, IndiaIndian Council of Medical
   Research (ICMR) [ISRM/12(04)/2019]; Council of Scientific and Industrial
   Research (CSIR), IndiaCouncil of Scientific & Industrial Research (CSIR)
   - India [09/490(0103)/2019]; Department of IT, BT, Science and
   Technology, the Karnataka; DST-FISTDepartment of Science & Technology
   (India) [SR/FST/LSI-536/2012]
FX We thank Dr. V. Ravi and Dr. V. Manjunatha, Department of Neurovirology,
   for scientific discussion. BP is grateful to the DST (DST-FIST:
   SR/FST/LS-I/2017(C)), SERB (CRG/2019/002603), DBT, India
   (BT/PR32378/BRB/10/1784/2019), and to the ICMR, India
   (ISRM/12(04)/2019), for the financial support. SU is grateful to the
   Council of Scientific and Industrial Research (CSIR), India, for SRF
   fellowship (09/490(0103)/2019). ST acknowledges the institutional grant
   to IBAB from the Department of IT, BT, Science and Technology, the
   Karnataka. IBAB is also supported by DST-FIST vide sanction no.
   SR/FST/LSI-536/2012.
CR Beura S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772111
   Bolton EE, 2010, ANN REP COMP CHEM, V4, P217, DOI 10.1016/S1574-1400(08)00012-1
   Bowers K., 2006, P 2006 ACM IEEE C SU
   Colombier MA, 2018, CURR OPIN HIV AIDS, V13, P308, DOI 10.1097/COH.0000000000000471
   Coogan PF, 2000, J NATL CANCER I, V92, P1943, DOI 10.1093/jnci/92.23.1943
   de Oliveira OV, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772885
   Delorme D, 1996, J MED CHEM, V39, P3951, DOI 10.1021/jm960301c
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du J, 2011, J COMPUT CHEM, V32, P2800, DOI 10.1002/jcc.21859
   GAGINELLA TS, 1994, J PHARMACOL EXP THER, V270, P1239
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Ghofrani HA, 2013, NEW ENGL J MED, V369, P319, DOI 10.1056/NEJMoa1209657
   Goto Y, 2002, EUR J PHARMACOL, V438, P189, DOI 10.1016/S0014-2999(02)01340-7
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   HARDCASTLE GA, 1966, J ORG CHEM, V31, P897, DOI 10.1021/jo01341a060
   Harishma KM, 2020, ECOL PROCESS, V9, DOI 10.1186/s13717-020-00227-8
   Hoy SM, 2018, DRUGS, V78, P1939, DOI 10.1007/s40265-018-1026-z
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Lyne PD, 2006, J MED CHEM, V49, P4805, DOI 10.1021/jm060522a
   Malik A, 2020, BIORXIV
   Massova I, 2000, PERSPECT DRUG DISCOV, V18, P113, DOI 10.1023/A:1008763014207
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   MUID RE, 1991, FEBS LETT, V293, P169, DOI 10.1016/0014-5793(91)81178-B
   Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   PALMER KJ, 1993, DRUGS, V45, P430, DOI 10.2165/00003495-199345030-00009
   RIDER JA, 1971, CURR THER RES CLIN E, V13, P386
   Rino R, 2004, SEVERE ACUTE RESP SY
   Roos K, 2019, J CHEM THEORY COMPUT, V15, P1863, DOI 10.1021/acs.jctc.8b01026
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sardana V, 2017, MUSCULOSKELET CARE, V15, P114, DOI 10.1002/msc.1163
   Sardar R, 2020, COMP ANAL SAR COV2 G, DOI [10.1101/2020.03.21.001586, DOI 10.1101/2020.03.21.001586]
   Schrodinger L. L. C., 2017, PYMOL MOL GRAPHICS S
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Smid P, 2005, J MED CHEM, V48, P6855, DOI 10.1021/jm050148z
   SMITH JT, 1970, CHEMOTHERAPY, V15, P366, DOI 10.1159/000220703
   Soleimani V, 2019, PHYTOTHER RES, V33, P1627, DOI 10.1002/ptr.6361
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   Xie Y, 2019, MOLECULES, V24, DOI 10.3390/molecules24203693
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
NR 58
TC 0
Z9 0
U1 0
U2 0
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0250-5991
EI 0973-7138
J9 J BIOSCIENCES
JI J. Biosci.
PD OCT 16
PY 2020
VL 45
IS 1
AR 130
DI 10.1007/s12038-020-00102-w
PG 20
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA OA9AW
UT WOS:000578073200001
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Booth, AL
   Abels, E
   McCaffrey, P
AF Booth, Adam L.
   Abels, Elizabeth
   McCaffrey, Peter
TI Development of a prognostic model for mortality in COVID-19 infection
   using machine learning
SO MODERN PATHOLOGY
LA English
DT Article; Early Access
ID BIOPSIES; DISEASE
AB Coronavirus disease 2019 (COVID-19) is a novel disease resulting from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has quickly risen since the beginning of 2020 to become a global pandemic. As a result of the rapid growth of COVID-19, hospitals are tasked with managing an increasing volume of these cases with neither a known effective therapy, an existing vaccine, nor well-established guidelines for clinical management. The need for actionable knowledge amidst the COVID-19 pandemic is dire and yet, given the urgency of this illness and the speed with which the healthcare workforce must devise useful policies for its management, there is insufficient time to await the conclusions of detailed, controlled, prospective clinical research. Thus, we present a retrospective study evaluating laboratory data and mortality from patients with positive RT-PCR assay results for SARS-CoV-2. The objective of this study is to identify prognostic serum biomarkers in patients at greatest risk of mortality. To this end, we develop a machine learning model using five serum chemistry laboratory parameters (c-reactive protein, blood urea nitrogen, serum calcium, serum albumin, and lactic acid) from 398 patients (43 expired and 355 non-expired) for the prediction of death up to 48 h prior to patient expiration. The resulting support vector machine model achieved 91% sensitivity and 91% specificity (AUC 0.93) for predicting patient expiration status on held-out testing data. Finally, we examine the impact of each feature and feature combination in light of different model predictions, highlighting important patterns of laboratory values that impact outcomes in SARS-CoV-2 infection.
C1 [Booth, Adam L.; Abels, Elizabeth; McCaffrey, Peter] Univ Texas Med Branch, Galveston, TX 77555 USA.
RP McCaffrey, P (corresponding author), Univ Texas Med Branch, Galveston, TX 77555 USA.
EM pemccaff@UTMB.EDU
OI Mccaffrey, Peter/0000-0002-4450-8143
CR Campanella G, 2019, NAT MED, V25, P1301, DOI 10.1038/s41591-019-0508-1
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
   Colombo Jacopo, 2017, Int J Crit Illn Inj Sci, V7, P12, DOI 10.4103/2229-5151.201959
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Enders CK, 2010, APPL MISSING DATA AN
   Gong P, 2020, CLIN CHARACTERISTICS
   Graham JW, 2009, ANNU REV PSYCHOL, V60, P549, DOI 10.1146/annurev.psych.58.110405.085530
   Grandvalet Y, 2006, PROBABILISTIC INTERP
   Huang L, 2018, THEOR BIOL MED MODEL, V15, DOI 10.1186/s12976-018-0093-x
   Ko J, 2018, LAB CHIP, V18, P395, DOI 10.1039/c7lc00955k
   Korbar Bruno, 2017, J Pathol Inform, V8, P30, DOI 10.4103/jpi.jpi_34_17
   Kumar D, 2020, EARTH SCI INFORM, V13, P1237, DOI 10.1007/s12145-020-00508-y
   Kumar V., 2015, ROBBINS COTRAN PATHO
   Li Z, 2020, CAUTION KIDNEY DYSFU, V2020
   Lichtenauer M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091893
   Lundberg SM, 2017, ADV NEURAL INFORM PR
   Luo Y, 2016, AM J CLIN PATHOL, V145, P778, DOI [10.1093/AJCP/AQW064, 10.1093/ajcp/aqw064]
   McCaffrey P, 2020, INTRO HEALTHCARE INF
   Peng Y D, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P450, DOI 10.3760/cma.j.cn112148-20200220-00105
   Pillay TS, 2020, J CLIN PATHOL, V73, P366, DOI 10.1136/jclinpath-2020-206658
   Prasad N, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00327
   Shankland SJ, 2006, KIDNEY INT, V69, P2131, DOI 10.1038/sj.ki.5000410
   Shoenfeld Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102538
   Strom P, 2020, LANCET ONCOL, V21, P222, DOI 10.1016/S1470-2045(19)30738-7
   Su H, 2020, KIDNEY INT
   Tan CC, 2020, J MED VIROL, V92, P856, DOI 10.1002/jmv.25871
   Tang JJ, 2020, SURG INFECT, V21, P895, DOI 10.1089/sur.2020.042
   Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x
   Wiedermann Christian J, 2017, World J Nephrol, V6, P176, DOI 10.5527/wjn.v6.i4.176
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
   Yadaw AS, 2020, LANCET DIGIT HEALTH, V2, pE516, DOI 10.1016/S2589-7500(20)30217-X
   Zhang L, 2020, CALCIUM CHANNEL BLOC
   Zhao ZR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236618
   Zhou B, 2020, UTILITY FERRITIN PRO
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou XJ, 2020, CRIT CARE MED, V48, pE657, DOI 10.1097/CCM.0000000000004411
NR 37
TC 0
Z9 0
U1 6
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
DI 10.1038/s41379-020-00700-x
EA OCT 2020
PG 10
WC Pathology
SC Pathology
GA OB3CA
UT WOS:000578348900001
PM 33067522
OA Green Published
DA 2021-01-01
ER

PT J
AU Asrani, P
   Hassan, MI
AF Asrani, Purva
   Hassan, Md Imtaiyaz
TI SARS-CoV-2 mediated lung inflammatory responses in host: targeting the
   cytokine storm for therapeutic interventions
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; Lung inflammation; Cytokine storm; Therapeutic
   strategies; And antibody-dependent enhancement
ID ACUTE-RESPIRATORY-SYNDROME; SARS-COV; RHEUMATOID-ARTHRITIS; CONVERTING
   ENZYME; SPIKE PROTEIN; CORONAVIRUS; RECEPTOR; INFECTION; VIRUS;
   ANGIOTENSIN-CONVERTING-ENZYME-2
AB The recent exposure of novel coronavirus strain, severe acute respiratory syndrome (SARS-CoV-2) has spread to different countries at an alarming rate. Faster transmission rate and genetic modifications have provoked scientists to search for an immediate solution. With an increasing death rate, it becomes important to throw some light on the life cycle of the virus and its associated pathogenesis in the form of lung inflammation through cytokine storm (CS) production. This paper highlights the different stages of viral-mediated inflammatory responses in the host respiratory system. Previously, known anti-inflammatory drugs and therapeutic strategies that might show potential in controlling the CS of Coronavirus disease-2019 (COVID-19) is also mentioned in this study. Our critical analysis provides insights into the inflammation cycle induced in the lungs by early virus replication, downregulation and shedding of angiotensin-converting enzyme 2 (ACE2), and in the CS production. Identification of suitable targets within the inflammatory pathways for devising the therapeutic strategies useful in controlling the prognosis of COVID-19 finds a special mention in this article. However, antibody-dependent enhancement is the key aspect to consider before testing any drug/compound for therapeutic purposes. Our in-depth analysis would provide similarities and differences between the inflammatory responses induced by SARS-CoV and SARS-CoV-2, providing an excellent avenue to further look at how earlier outbreaks of coronaviruses were controlled and where new steps are required?
C1 [Asrani, Purva] Indian Agr Res Inst, Div Biochem, New Delhi 110012, India.
   [Hassan, Md Imtaiyaz] Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi 110025, India.
RP Hassan, MI (corresponding author), Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi 110025, India.
EM mihassan@jmi.ac.in
RI HASSAN, Imtaiyaz/G-7072-2017; Hassan, Imtaiyaz/ABF-6485-2020
OI HASSAN, Imtaiyaz/0000-0002-3663-4940; Hassan,
   Imtaiyaz/0000-0002-3663-4940; Asrani, Purva/0000-0002-4747-4567
FU Indian Council of Medical ResearchIndian Council of Medical Research
   (ICMR) [BIC/12(01)/2015]
FX MIH thanks the Indian Council of Medical Research for funding the study
   (Grant No. BIC/12(01)/2015).
CR Aggarwal NR, 2014, AM J PHYSIOL-LUNG C, V306, pL709, DOI 10.1152/ajplung.00341.2013
   Al-Salama ZT, 2019, DRUGS, V79, P99, DOI 10.1007/s40265-018-1046-8
   Amlani A, 2020, ONCOLOGIST, V25, pE1120, DOI 10.1634/theoncologist.2020-0194
   Aoki Y, 2009, RESPIRATION, V77, P311, DOI 10.1159/000168676
   Aouba A, 2020, ANN RHEUM DIS, V79, P1381, DOI 10.1136/annrheumdis-2020-217706
   Asrani P, 2020, OMICS, V24, P634, DOI 10.1089/omi.2020.0131
   Asrani P, 2020, EXPERT REV RESP MED, DOI 10.1080/17476348.2021.1823833
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Balestri R, 2020, J EUR ACAD DERMATOL, V34, pE435, DOI 10.1111/jdv.16578
   Barzegar M, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000753
   Braumuller H, 2013, NATURE, V494, P361, DOI 10.1038/nature11824
   Bright JJ, 1999, J IMMUNOL, V162, P6255
   Carboni E, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109776
   Chand K, 2020, ARAB J CHEM, V13, P8248, DOI [10.1142/S0192415X20500378, 10.1016/j.arabjc.2020.01.009]
   Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Chen HL, 2016, EXP THER MED, V11, P1865, DOI 10.3892/etm.2016.3141
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Durkin A, 2020, J IMMUNOL, V204, P788, DOI 10.4049/jimmunol.1900531
   Fabbi M, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/3958069
   Fatima U, 2020, J INTERF CYTOK RES, V40, P469, DOI 10.1089/jir.2020.0105
   Faure E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088716
   Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8
   Glowacka I, 2010, J VIROL, V84, P1198, DOI 10.1128/JVI.01248-09
   GOLDBLUM R, 1993, CLIN EXP RHEUMATOL, V11, pS117
   Guan W-J, 2020, CLINICAL CHARACTERIS
   Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105
   Haslwanter D, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006643
   Hassan AV, 2013, CLIN KIDNEY J, V6, P384, DOI 10.1093/ckj/sft071
   Horiuchi T, 2016, INFLAMM REGEN, V36, DOI 10.1186/s41232-016-0013-6
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Imai Y, 2008, EXP PHYSIOL, V93, P543, DOI 10.1113/expphysiol.2007.040048
   Jarvis B, 1999, DRUGS, V57, P945, DOI 10.2165/00003495-199957060-00014
   Jia HP, 2009, AM J PHYSIOL-LUNG C, V297, pL84, DOI 10.1152/ajplung.00071.2009
   Josset L, 2013, MBIO, V4, DOI 10.1128/mBio.00165-13
   Kristensen LE, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2084
   Kuba K, 2006, CURR OPIN PHARMACOL, V6, P271, DOI 10.1016/j.coph.2006.03.001
   Kumari P, 2020, CLIN CHIM ACTA, V510, P488, DOI [10.1016/j.cca.2020.08.013, 10.1016/j.caa.2020.08.013]
   KURLANDER RJ, 1986, J CLIN INVEST, V77, P2010, DOI 10.1172/JCI112530
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lambert DW, 2005, J BIOL CHEM, V280, P30113, DOI 10.1074/jbc.M505111200
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Leong HN, 2006, ANN ACAD MED SINGAP, V35, P332
   Li LL, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aas9332
   LIU H, 2018, RESP RES, V19, P1, DOI DOI 10.1186/s12931-017-0698-3
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Locatelli F, 2020, NEW ENGL J MED, V382, P1811, DOI 10.1056/NEJMoa1911326
   Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811
   Markham A, 2000, DRUGS, V59, P1341, DOI 10.2165/00003495-200059060-00010
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Mohammad T, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198102
   Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878
   Nikolich-Zugich J, 2020, GEROSCIENCE, V42, P505, DOI 10.1007/s11357-020-00186-0
   Nimmerjahn F, 2008, ANNU REV IMMUNOL, V26, P513, DOI 10.1146/annurev.immunol.26.021607.090232
   Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206
   Nimmerjahn Falk, 2008, V415, P151, DOI 10.1007/978-1-59745-570-1_9
   OCHIAI H, 1992, J MED VIROL, V36, P217, DOI 10.1002/jmv.1890360312
   Oldstone MBA, 2014, CURR TOP MICROBIOL, V378, P129, DOI 10.1007/978-3-319-05879-5_6
   Oldstone MBA, 2013, VIROLOGY, V435, P92, DOI 10.1016/j.virol.2012.09.039
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Poduri R, 2020, CELL SIGNAL, V74, DOI 10.1016/j.cellsig.2020.109721
   Ramirez J, 2018, EXPERT OPIN DRUG SAF, V17, P727, DOI 10.1080/14740338.2018.1486819
   Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200
   Scala S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01201
   Shamsi Anas, 2020, Biosci Rep, V40, DOI 10.1042/BSR20201256
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   So A, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2143
   Stoecklin SB, 2020, EUROSURVEILLANCE, V25, P20, DOI 10.2807/1560-7917.ES.2020.25.6.2000094
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Takada A, 2003, REV MED VIROL, V13, P387, DOI 10.1002/rmv.405
   Tian X, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0315-x
   To KKW, 2016, J GEN VIROL, V97, P1807, DOI 10.1099/jgv.0.000512
   Tse GMK, 2004, J CLIN PATHOL, V57, P260, DOI 10.1136/jcp.2003.013276
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   van Mirre E, 2004, BLOOD, V103, P1973, DOI 10.1182/blood-2003-11-3933
   Veri MC, 2007, IMMUNOLOGY, V121, P392, DOI 10.1111/j.1365-2567.2007.02588.x
   Wang C, 2020, AVEOLAR MACROPHAGE A
   Wang S, 2008, VIRUS RES, V136, P8, DOI 10.1016/j.virusres.2008.03.004
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   Wu D, 2020, J MICROBIOL IMMUNOL
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yam LYC, 2007, J INFECTION, V54, P28, DOI 10.1016/j.jinf.2006.01.005
   Yang ML, 2020, CONTEMP NURSE, V56, P90, DOI [10.1080/10376178.2020.1742178, 10.1080/02713683.2020.1857781]
   Zenewicz Lauren A, 2018, Immunohorizons, V2, P198, DOI 10.4049/immunohorizons.1800006
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 96
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
DI 10.1007/s11010-020-03935-z
EA OCT 2020
PG 13
WC Cell Biology
SC Cell Biology
GA OB4KJ
UT WOS:000578439700002
PM 33064288
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kurup, D
   Wirblich, C
   Ramage, H
   Schnell, MJ
AF Kurup, Drishya
   Wirblich, Christoph
   Ramage, Holly
   Schnell, Matthias J.
TI Rabies virus-based COVID-19 vaccine CORAVAX (TM) induces high levels of
   neutralizing antibodies against SARS-CoV-2
SO NPJ VACCINES
LA English
DT Article
ID SPIKE PROTEIN; CORONAVIRUS
AB The recently emerged coronavirus SARS-CoV-2, the causative agent of COVID-19, is rapidly spreading in the world. The exponentially expanding threat of SARS-CoV-2 to global health highlights the urgent need for a vaccine. Herein we show the rapid development of a novel, highly efficient, and safe COVID-19 vaccine using a rabies virus-based vector that has proven to be an efficient vaccine against several emerging infectious diseases. This study reports that both a live and an inactivated rabies virus containing the SARS-CoV-2 spike S1 protein induces potent virus-neutralizing antibodies at much higher levels than seen in the sera of convalescent patients. In summary, the results provided here warrant further development of this safe and established vaccine platform against COVID-19.
C1 [Kurup, Drishya; Wirblich, Christoph; Ramage, Holly; Schnell, Matthias J.] Thomas Jefferson Univ, Dept Microbiol & Immunol, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.
   [Ramage, Holly; Schnell, Matthias J.] Thomas Jefferson Univ, Jefferson Vaccine Ctr, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.
RP Schnell, MJ (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.; Schnell, MJ (corresponding author), Thomas Jefferson Univ, Jefferson Vaccine Ctr, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.
EM Matthias.Schnell@jefferson.edu
OI Kurup, Drishya/0000-0002-3959-7700
FU Jefferson Vaccine Center, Thomas Jefferson University
FX We thank Jennifer Wilson (Thomas Jefferson University, Philadelphia, PA)
   for critical reading and editing the manuscript. The Jefferson Vaccine
   Center, Thomas Jefferson University provide some funding for this
   study).
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Blaney JE, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003389
   CONZELMANN KK, 1990, VIROLOGY, V175, P485, DOI 10.1016/0042-6822(90)90433-R
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Gorse GJ, 2010, CLIN VACCINE IMMUNOL, V17, P1875, DOI 10.1128/CVI.00278-10
   Ho Mitchell, 2020, Antib Ther, V3, P109, DOI 10.1093/abt/tbaa009
   Jaimes JA, 2020, J MOL BIOL, V432, P3309, DOI 10.1016/j.jmb.2020.04.009
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P545, DOI 10.1016/j.it.2020.04.008
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Johnson RF, 2016, J INFECT DIS, V214, pS342, DOI 10.1093/infdis/jiw231
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Juan-Giner A, 2019, VACCINE, V37, P7171, DOI 10.1016/j.vaccine.2018.09.009
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   McGettigan JP, 2003, J VIROL, V77, P237, DOI 10.1128/JVI.77.1.237-244.2003
   Milne S, 2020, LANCET RESP MED, V8, pE50, DOI 10.1016/S2213-2600(20)30224-1
   Mullard A, 2020, LANCET, V395, P1245, DOI 10.1016/S0140-6736(20)30894-1
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Perera RAPM, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.16.2000421
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Robbiani DF, 2017, CELL, V169, P597, DOI 10.1016/j.cell.2017.04.024
   Seydoux Emilie, 2020, bioRxiv, DOI 10.1101/2020.05.12.091298
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Stanley DA, 2014, NAT MED, V20, P1126, DOI 10.1038/nm.3702
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Thomas S, 2006, EXPERT REV VACCINES, V5, P409, DOI 10.1586/14760584.5.4.409
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Willet M, 2015, J INFECT DIS, V212, pS414, DOI 10.1093/infdis/jiv251
   Wirblich C, 2017, J VIROL, V91, DOI 10.1128/JVI.02040-16
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 38
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2059-0105
J9 NPJ VACCINES
JI npj Vaccines
PD OCT 16
PY 2020
VL 5
IS 1
AR 98
DI 10.1038/s41541-020-00248-6
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OA9AF
UT WOS:000578071500001
PM 33088593
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Novir, SB
   Aram, MR
AF Novir, Samaneh Bagheri
   Aram, Mohammad Reza
TI Quantum mechanical simulation of Chloroquine drug interaction with C60
   fullerene for treatment of COVID-19
SO CHEMICAL PHYSICS LETTERS
LA English
DT Article
DE Chloroquine; COVID-19; DFT; Drug delivery; Fullerene
ID ELECTRONIC-PROPERTIES; DELIVERY; ENERGIES; DFT; ADSORPTION; NANOTUBES;
   MOLECULES; PRISTINE; CR; NI
AB Chloroquine (CQ) has been reported as an effective drug in the control of COVID-19 infection. Since C60 fullerene has been considered as a drug delivery system, the interaction between pristine fullerene and chloroquine drug and also the interaction between B, Al, Si doped fullerene and chloroquine drug have been investigated based on the density functional theory calculations. The results of this study show that the doped fullerene, especially Al and Si doped fullerene could be the better drug delivery vehicles for chloroquine drug because of their relatively better energetic and electronic properties with chloroquine.
C1 [Novir, Samaneh Bagheri; Aram, Mohammad Reza] Iranian Ctr Quantum Technol ICQTs, Tehran, Iran.
   [Aram, Mohammad Reza] Nucl Sci & Technol Res Inst NSTRI, Tehran, Iran.
RP Novir, SB (corresponding author), Iranian Ctr Quantum Technol ICQTs, Tehran, Iran.
EM sa_bagheri@chem.iust.ac.ir
FU Development and Application of New Technologies Company (TAKFAN)
FX The present study was carried out in - Iranian Center for Quantum
   Technologies (ICQTs). We would like to thank Development and Application
   of New Technologies Company (TAKFAN) for their support.
CR Bakry R, 2007, INT J NANOMED, V2, P639
   Barone V, 1998, J PHYS CHEM A, V102, P1995, DOI 10.1021/jp9716997
   Bashiri S, 2017, VACUUM, V136, P156, DOI 10.1016/j.vacuum.2016.12.003
   BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561
   Ordaz JC, 2017, NEW J CHEM, V41, P8045, DOI 10.1039/c7nj01133d
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Anota EC, 2013, J MOL MODEL, V19, P4991, DOI 10.1007/s00894-013-1999-1
   Anota EC, 2014, PHYSICA E, V56, P134, DOI 10.1016/j.physe.2013.08.033
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cossi M, 2003, J COMPUT CHEM, V24, P669, DOI 10.1002/jcc.10189
   Cossi M, 1996, CHEM PHYS LETT, V255, P327, DOI 10.1016/0009-2614(96)00349-1
   de Leon A, 2008, CHEM PHYS LETT, V452, P306, DOI 10.1016/j.cplett.2007.12.065
   Dubacheva GV, 2012, COORDIN CHEM REV, V256, P2628, DOI 10.1016/j.ccr.2012.04.007
   Fanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis-2019-215089
   Farmanzadeh D, 2019, THEOR CHEM ACC, V138, DOI 10.1007/s00214-018-2400-3
   Feng W, 2012, NANOSCALE, V4, P6118, DOI 10.1039/c2nr31505j
   Frisch MJ, 2003, GAUSSIAN 03
   Gallo M, 2007, CHEM PHYS LETT, V447, P105, DOI 10.1016/j.cplett.2007.08.098
   Hazrati MK, 2016, PHYS LETT A, V380, P937, DOI 10.1016/j.physleta.2016.01.020
   Jeon S, 2013, SCI REP-UK, V3, DOI 10.1038/srep03269
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Krishna V, 2010, NAT NANOTECHNOL, V5, P330, DOI [10.1038/NNANO.2010.35, 10.1038/nnano.2010.35]
   Larki S, 2019, CHEM PHYS, V526, DOI 10.1016/j.chemphys.2019.110424
   Lecuit M, 2020, MED MALADIES INFECT, V50, P229, DOI 10.1016/j.medmal.2020.03.004
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Moradi M, 2017, PHYSICA E, V87, P186, DOI 10.1016/j.physe.2016.11.027
   Narayan Samanta P., 2017, J MOL GRAPH MODEL, V72, P187
   Padmanabhan J, 2007, J PHYS CHEM A, V111, P1358, DOI 10.1021/jp0649549
   Park S, 2009, NAT NANOTECHNOL, V4, P217, DOI [10.1038/NNANO.2009.58, 10.1038/nnano.2009.58]
   Parlak C, 2017, CHEM PHYS LETT, V678, P85, DOI 10.1016/j.cplett.2017.04.025
   Rad A. Shokuhi, 2017, APPL ORGANOMET CHEM, V32, P1
   Rad AS, 2018, MATER RES BULL, V97, P399, DOI 10.1016/j.materresbull.2017.09.036
   Rad AS, 2017, DIAM RELAT MATER, V77, P116, DOI 10.1016/j.diamond.2017.06.013
   Gonzalez VR, 2019, APPL NANOSCI, V9, P317, DOI 10.1007/s13204-018-0901-y
   Sazonova V, 2004, NATURE, V431, P284, DOI 10.1038/nature02905
   Shah A, 2020, MAYO CLIN PROC, V95, P646, DOI 10.1016/j.mayocp.2020.02.003
   Shariatinia Z, 2014, J MOL GRAPH MODEL, V52, P71, DOI 10.1016/j.jmgm.2014.06.001
   Shi JJ, 2013, BIOMATERIALS, V34, P251, DOI 10.1016/j.biomaterials.2012.09.039
   Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c
   ShokuhiRad A., 2017, COM THEOR CHEM, V1121, P68
   Singh R, 2009, EXP MOL PATHOL, V86, P215, DOI 10.1016/j.yexmp.2008.12.004
   Smolen JS, 2014, ANN RHEUM DIS, V73, P492, DOI 10.1136/annrheumdis-2013-204573
   Tektonidou MG, 2019, ANN RHEUM DIS, V78, P1296, DOI 10.1136/annrheumdis-2019-215213
   Vivino FB, 2016, RHEUM DIS CLIN N AM, V42, P531, DOI 10.1016/j.rdc.2016.03.010
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697
   Yuna Y.H., 2006, P SOC PHOTO-OPT INS, V6172
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 49
TC 1
Z9 1
U1 13
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0009-2614
EI 1873-4448
J9 CHEM PHYS LETT
JI Chem. Phys. Lett.
PD OCT 16
PY 2020
VL 757
AR 137869
DI 10.1016/j.cplett.2020.137869
PG 10
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA NR9OW
UT WOS:000571892900012
PM 32834063
OA Green Published
DA 2021-01-01
ER

PT J
AU Kang, QL
   Wang, YY
   Cui, QH
   Gong, LL
   Yang, Y
   Jiang, HQ
   Rong, LJ
   Rong, R
   Du, RK
AF Kang, Qianli
   Wang, Yanyan
   Cui, Qinghua
   Gong, Lili
   Yang, Yong
   Jiang, Haiqiang
   Rong, Lijun
   Rong, Rong
   Du, Ruikun
TI Screening for Anti-Influenza Actives of Prefractionated Traditional
   Chinese Medicines
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID NATURAL-PRODUCTS; IN-VITRO; VIRUS; RESISTANCE; DRUGS
AB Traditional Chinese medicines (TCMs) have proven to possess advantages in counteracting virus infections according to clinical practices. It's therefore of great value to discover novel antivirals from TCMs. In this paper, One hundred medicinal plants which have been included in TCM prescriptions for antiviral treatment were selected and prefractionated into 5 fractions each by sequentially using cyclohexane, dichloromethane, ethyl acetate, n-butanol, and water. 500 TCM-simplified extracts were then subjected to a phenotypic screening using a recombinant IAV expressing Gaussia luciferase. Ten TCM fractions were identified to possess antiviral activities against influenza virus. The IC50's of the hit fractions range from 1.08 to 6.45 mu g/mL, while the SIs, from 7.52 to 98.40. Furthermore, all the ten hit fractions inhibited the propagation of progeny influenza virus significantly at 20 mu g/mL. The hit TCM fractions deserve further isolation for responsible constituents leading towards anti-influenza drugs. Moreover, a library consisting of 500 simplified TCM extracts was established, facilitating antiviral screening in quick response to emerging and re-emerging viruses such as Ebola virus and current SARS-CoV-2 pandemic.
C1 [Kang, Qianli; Wang, Yanyan; Cui, Qinghua; Gong, Lili; Jiang, Haiqiang; Rong, Rong] Shandong Univ Tradit Chinese Med, Coll Pharm, Jinan 250355, Shandong, Peoples R China.
   [Cui, Qinghua; Gong, Lili; Yang, Yong; Rong, Rong] Shandong Prov Collaborat Innovat Ctr Antiviral Tr, Jinan 250355, Shandong, Peoples R China.
   [Cui, Qinghua; Du, Ruikun] Shandong Univ Tradit Chinese Med, Qingdao Acad Chinese Med Sci, Qingdao 266122, Shandong, Peoples R China.
   [Gong, Lili; Yang, Yong; Jiang, Haiqiang; Du, Ruikun] Shandong Univ Tradit Chinese Med, Expt Ctr, Jinan 250355, Shandong, Peoples R China.
   [Rong, Lijun] Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA.
RP Rong, R (corresponding author), Shandong Univ Tradit Chinese Med, Coll Pharm, Jinan 250355, Shandong, Peoples R China.; Rong, R (corresponding author), Shandong Prov Collaborat Innovat Ctr Antiviral Tr, Jinan 250355, Shandong, Peoples R China.; Du, RK (corresponding author), Shandong Univ Tradit Chinese Med, Qingdao Acad Chinese Med Sci, Qingdao 266122, Shandong, Peoples R China.; Du, RK (corresponding author), Shandong Univ Tradit Chinese Med, Expt Ctr, Jinan 250355, Shandong, Peoples R China.
EM 17862953566@163.com; yyw0196@163.com; cuiqinghua1122@163.com;
   gonglily@163.com; yy7204@163.com; jhq12723@163.com; lijun@uic.edu;
   rosierong@163.com; duzi857@163.com
OI Du, Ruikun/0000-0002-9172-7824
FU National Science and Technology Major Project [2018ZX09711001-003-004];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81873220]; KeyResearch and Development
   Program in Shandong Province [2017CXGC1309]
FX The research was financially supported by the National Science and
   Technology Major Project (no. 2018ZX09711001-003-004), National Natural
   Science Foundation of China (no. 81774167), National Natural Science
   Foundation of China (no. 81873220), KeyResearch and Development Program
   in Shandong Province (no. 2018CXGC1307), and KeyResearch and Development
   Program in Shandong Province (no. 2017CXGC1309).
CR Appleton B. A. D., 2015, CHIMIA, V61, P327
   Baz M, 2009, NEW ENGL J MED, V361, P2296, DOI 10.1056/NEJMc0910060
   Bright RA, 2005, LANCET, V366, P1175, DOI 10.1016/S0140-6736(05)67338-2
   Chao-Man H. E., 2009, CHINA J CHINESE MAT, V29, P452
   Chen W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028093
   Fatima M, 2016, J MICROBIOL BIOTECHN, V26, P151, DOI 10.4014/jmb.1508.08024
   Feher M, 2003, J CHEM INF COMP SCI, V43, P218, DOI 10.1021/ci0200467
   Fu YF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09340-9
   Fukao K A. Y., 2016, PLOS ONE, V14
   Gao Q, 2014, ACTA PHARM SIN B, V4, P301, DOI 10.1016/j.apsb.2014.06.005
   Gao SY, 2015, MOLECULES, V20, P4290, DOI 10.3390/molecules20034290
   Harvey AL, 2015, NAT REV DRUG DISCOV, V14, P111, DOI 10.1038/nrd4510
   Henkel T., 2019, ANGEW CHEM INT EDIT, V30, P643
   Ho PL, 2009, INFLUENZA OTHER RESP, V3, P261, DOI 10.1111/j.1750-2659.2009.00105.x
   Li P, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10060325
   Lin C., 2009, PLOS ONE, V10
   Lin TJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep27768
   Liu J., 2015, BMC COMPLEM ALTERN M, V18, P102
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Qi FH, 2013, DRUG DISCOV THER, V7, P212, DOI 10.5582/ddt.2013.v7.6.212
   Qin S., 2016, ZHONGGUO ZHONG YAO Z, V43, P2216
   Samson M, 2013, ANTIVIR RES, V98, P174, DOI 10.1016/j.antiviral.2013.03.014
   Song W, 2014, J NAT PROD, V77, P1632, DOI 10.1021/np500253m
   Tian J., 2019, RES APPL ANTIVIRAL C
   Tian L, 2011, J ETHNOPHARMACOL, V137, P534, DOI 10.1016/j.jep.2011.06.002
   Tu Y, 2010, J NAT PROD, V73, P751, DOI 10.1021/np9007359
   Wagenaar MM, 2008, MOLECULES, V13, P1406, DOI 10.3390/molecules13061406
   Wang J, 2014, J BIOMOL SCREEN, V19, P100, DOI 10.1177/1087057113494405
   WHO, 2018, INFLUENZA
   Wu XN, 2011, J ETHNOPHARMACOL, V134, P191, DOI 10.1016/j.jep.2010.11.074
   Zhao XJ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090826
   Zhao XJ, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120679
   Zhu HY, 2018, J ETHNOPHARMACOL, V218, P90, DOI 10.1016/j.jep.2018.02.016
NR 33
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD OCT 15
PY 2020
VL 2020
AR 4979850
DI 10.1155/2020/4979850
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA OP7RG
UT WOS:000588283700002
PM 33123207
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cherrak, SA
   Merzouk, H
   Mokhtari-Soulimane, N
AF Cherrak, Sabri Ahmed
   Merzouk, Hafida
   Mokhtari-Soulimane, Nassima
TI Potential bioactive glycosylated flavonoids as SARS-CoV-2 main protease
   inhibitors: A molecular docking and simulation studies
SO PLOS ONE
LA English
DT Article
ID IN-VITRO; GLYCOSIDES; RUTIN; VIVO
AB A novel coronavirus responsible of acute respiratory infection closely related to SARS-CoV has recently emerged. So far there is no consensus for drug treatment to stop the spread of the virus. Discovery of a drug that would limit the virus expansion is one of the biggest challenges faced by the humanity in the last decades. In this perspective, to test existing drugs as inhibitors of SARS-CoV-2 main protease is a good approach. Among natural phenolic compounds found in plants, fruit, and vegetables; flavonoids are the most abundant. Flavonoids, especially in their glycosylated forms, display a number of physiological activities, which makes them interesting to investigate as antiviral molecules. The flavonoids chemical structures were downloaded from PubChem and protease structure 6LU7 was from the Protein Data Bank site. Molecular docking study was performed using AutoDock Vina. Among the tested moleculesshowed the highest binding affinity (-9,7 kcal/mol). Docking studies showed that glycosylated flavonoids are good inhibitors for the SARS-CoV-2 protease and could be further investigated by in vitro and in vivo experiments for further validation. MD simulations were further performed to evaluate the dynamic behavior and stability of the protein in complex with the three best hits of docking experiments. Our results indicate that the rutin is a potential drug to inhibit the function of Chymotrypsin-like protease (3CL pro) of Coronavirus.
C1 [Cherrak, Sabri Ahmed; Merzouk, Hafida; Mokhtari-Soulimane, Nassima] Univ Tlemcen, Fac Nat & Life Sci, Lab Physiol Physiopathol & Biochem Nutr, Dept Biol,Earth & Univere, Tilimsen, Algeria.
RP Cherrak, SA (corresponding author), Univ Tlemcen, Fac Nat & Life Sci, Lab Physiol Physiopathol & Biochem Nutr, Dept Biol,Earth & Univere, Tilimsen, Algeria.
EM cherraksabri@gmail.com
RI Cherrak, Sabri Ahmed/ABD-6356-2020
CR Abraham LCN, 2008, FOOD CHEM, V109, P415, DOI 10.1016/j.foodchem.2007.12.069
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Ahmad S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1775129
   Amaretti A, 2015, NUTRIENTS, V7, P2788, DOI 10.3390/nu7042788
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], 2018, AM J TRANSPLANT S1, V18, P10, DOI DOI 10.1109/JSEN.2018.2870228
   Benson NC, 2012, J PHYS CHEM B, V116, P8722, DOI 10.1021/jp302103t
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Bobone S, 2017, J VIROL, V91, DOI 10.1128/JVI.00267-17
   de Oliveira OV, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772885
   Dou J, 2011, ARCH VIROL, V156, P793, DOI 10.1007/s00705-011-0917-z
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Ferreyra MLF, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00222
   Feng Z., 2020, EARLY PREDICTION DIS
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gupta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1776157
   Hemida MG, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100127
   Hofer CT, 2019, BBA-BIOMEMBRANES, V1861, P1123, DOI 10.1016/j.bbamem.2019.03.013
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Khalil H, 2019, J MED VIROL, V91, P45, DOI 10.1002/jmv.25295
   Khan A, 2020, INTERDISCIP SCI, V12, P335, DOI 10.1007/s12539-020-00381-9
   Khan A, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1779128, 10.1080/01634372.2020.1787575]
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kumar A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1726816
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779131
   Kumar M, 2010, FITOTERAPIA, V81, P234, DOI 10.1016/j.fitote.2009.09.003
   Kumar S, 2020, CURR TOP MED CHEM, V20, P599, DOI 10.2174/1568026620999200305144319
   Kumar V, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1775704, 10.1080/07391102.2020.1772108]
   Kutzner C, 2019, J COMPUT CHEM, V40, P2418, DOI 10.1002/jcc.26011
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li HZ, 2013, TOXICOL APPL PHARM, V272, P180, DOI 10.1016/j.taap.2013.05.011
   Li SG, 2010, CANCER LETT, V298, P222, DOI 10.1016/j.canlet.2010.07.009
   Liu W., 2020, CHEMBIOCHEM
   Liu ZM, 2005, J CHEM INF MODEL, V45, P10, DOI 10.1021/ci049809b
   Mahanta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768902
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Nyakas M, 2019, CLIN EXP IMMUNOL, V197, P74, DOI 10.1111/cei.13283
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Powers CN, 2016, COMB CHEM HIGH T SCR, V19, P516, DOI 10.2174/1386207319666160506123715
   Reutrakul V, 2007, PLANTA MED, V73, P683, DOI 10.1055/s-2007-981538
   Sati Priyanka, 2019, J Tradit Complement Med, V9, P15, DOI 10.1016/j.jtcme.2017.10.003
   Serseg T, 2020, CURR COMPUT-AID DRUG
   Sk MF, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768149
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tao J, 2007, ANTIVIR RES, V75, P227, DOI 10.1016/j.antiviral.2007.03.008
   Tasdemir D, 2006, ANTIMICROB AGENTS CH, V50, P1352, DOI 10.1128/AAC.50.4.1352-1364.2006
   Thi THN, 2012, BIOTECHNOL LETT, V34, P831, DOI 10.1007/s10529-011-0845-8
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Valentova K, 2014, FOOD CHEM TOXICOL, V68, P267, DOI 10.1016/j.fct.2014.03.018
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wen LR, 2017, FREE RADICAL BIO MED, V110, P92, DOI 10.1016/j.freeradbiomed.2017.05.027
   Wu WJ, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8010006
   Xiao JB, 2017, CRIT REV FOOD SCI, V57, P1874, DOI 10.1080/10408398.2015.1032400
   Xiao JB, 2016, CRIT REV FOOD SCI, V56, pS29, DOI 10.1080/10408398.2015.1067595
   Xu G, 2010, BIOL PHARM BULL, V33, P238, DOI 10.1248/bpb.33.238
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhu LL, 2011, ANTIVIR RES, V92, P204, DOI 10.1016/j.antiviral.2011.08.001
NR 60
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2020
VL 15
IS 10
AR e0240653
DI 10.1371/journal.pone.0240653
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OG3UY
UT WOS:000581814700021
PM 33057452
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Khairkhah, N
   Aghasadeghi, MR
   Namvar, A
   Bolhassani, A
AF Khairkhah, Niloofar
   Aghasadeghi, Mohammad Reza
   Namvar, Ali
   Bolhassani, Azam
TI Design of novel multiepitope constructs-based peptide vaccine against
   the structural S, N and M proteins of human COVID-19 using
   immunoinformatics analysis
SO PLOS ONE
LA English
DT Article
ID SARS-CORONAVIRUS; SPIKE PROTEIN; IMMUNE-RESPONSES; RECEPTOR; BINDING;
   DETERMINANTS; PREDICTION
AB The causative agent of severe acute respiratory syndrome (SARS) reported by the Chinese Center for Disease Control (China CDC) has been identified as a novelBetacoronavirus(SARS-CoV-2). A computational approach was adopted to identify multiepitope vaccine candidates against SARS-CoV-2 based on S, N and M proteins being able to elicit both humoral and cellular immune responses. In this study, the sequence of the virus was obtained from NCBI database and analyzed within silicotools such as NetMHCpan, IEDB, BepiPred, NetCTL, Tap transport/proteasomal cleavage, (PaP)-P-3, GalexyPepDock, I-TASSER, Ellipro and ClusPro. To identify the most immunodominant regions, after analysis of population coverage and epitope conservancy, we proposed three different constructs based on linear B-cell, CTL and HTL epitopes. The 3D structure of constructs was assessed to find discontinuous B-cell epitopes. Among CTL predicted epitopes, S257-265, S(603-611)and S360-368, and among HTL predicted epitopes, N167-181, S(313-330)and S(1110-1126)had better MHC binding rank. We found one putative CTL epitope, S(360-368)related to receptor-binding domain (RBD) region for S protein. The predicted epitopes were non-allergen and showed a high quality of proteasomal cleavage and Tap transport efficiency and 100% conservancy within four different clades of SARS-CoV-2. For CTL and HTL epitopes, the highest population coverage of the world's population was calculated for S(27-37)with 86.27% and for S196-231, S303-323, S313-330, S(1009-1030)and N(328-349)with 90.33%, respectively. We identified overall 10 discontinuous B-cell epitopes for three multiepitope constructs. All three constructs showed strong interactions with TLRs 2, 3 and 4 supporting the hypothesis of SARS-CoV-2 susceptibility to TLRs 2, 3 and 4 like other Coronaviridae families. These data demonstrated that the novel designed multiepitope constructs can contribute to develop SARS-CoV-2 peptide vaccine candidates. Thein vivostudies are underway using several vaccination strategies.
C1 [Khairkhah, Niloofar; Aghasadeghi, Mohammad Reza; Bolhassani, Azam] Pasteur Inst Iran, Dept Hepatitis AIDS & Blood Borne Dis, Tehran, Iran.
   [Khairkhah, Niloofar; Namvar, Ali] Iranian Comprehens Hemophilia Care Ctr, Tehran, Iran.
RP Bolhassani, A (corresponding author), Pasteur Inst Iran, Dept Hepatitis AIDS & Blood Borne Dis, Tehran, Iran.; Namvar, A (corresponding author), Iranian Comprehens Hemophilia Care Ctr, Tehran, Iran.
EM azam.bolhassani@yahoo.com; A_bolhasani@pasteur.ac.ir
CR Abdelmageed MI, 2020, BIORXIV
   [Anonymous], 2018, J CANC RES THER, V14, pS622
   [Anonymous], 2015, NUCLEIC ACIDS RES, V43, pD204
   [Anonymous], 2019, CIRCULATION, V2019
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Chrysostomou C, 2014, 2014 36 ANN INT C IE, V2014, P2014
   Derebail VK, 2020, NEW ENGL J MED, V382, P671, DOI 10.1056/NEJMe1917490
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Durai P, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.76
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Gupta S, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-27
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   He Y, 2011, BIOMED RES INT, V2010, P2011
   Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Keith P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2836-4
   Khairkhah N, 2018, PROTEINS, V86, P1284, DOI 10.1002/prot.25609
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Lapelosa M, 2009, J MOL BIOL, V385, P675, DOI 10.1016/j.jmb.2008.10.089
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ma CQ, 2014, VACCINE, V32, P2100, DOI 10.1016/j.vaccine.2014.02.004
   Malherbe L, 2009, ANN ALLERG ASTHMA IM, V103, P76, DOI 10.1016/S1081-1206(10)60147-0
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Nagpal G, 2017, SCI REP-UK, V7, DOI 10.1038/srep42851
   Namvar A, 2020, BIOTECHNOL LETT, V42, P403, DOI 10.1007/s10529-020-02792-6
   Namvar A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51679-8
   Oany AR, 2014, DRUG DES DEV THER, V8, P1139, DOI [10.2147/DDDT.567861, 10.2147/DDDT.S67861]
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Reynisson B, 2020, J PROTEOME RES, V19, P2304, DOI 10.1021/acs.jproteome.9b00874
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Sanjuan R, 2016, CELL MOL LIFE SCI, V73, P4433, DOI 10.1007/s00018-016-2299-6
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h
   SS V et al. on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, 2020, CIRCULATION, V2020, pe1
   Teimouri H, 2019, SILICO IMMUNOMODELLI
   Thanh LT, 2020, NAT REV DRUG DISCOV, P1
   The Gene Ontology Consortium, 2019, NUCLEIC ACIDS RES, V47, pD330
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 50
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2020
VL 15
IS 10
AR e0240577
DI 10.1371/journal.pone.0240577
PG 28
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OG3UY
UT WOS:000581814700078
PM 33057358
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rodriguez-Molinero, A
   Galvez-Barron, C
   Minarro, A
   Macho, O
   Lopez, GF
   Robles, MT
   Dapena, MD
   Martinez, S
   Rafols, NM
   Monaco, EE
   Garcia, AH
AF Rodriguez-Molinero, Alejandro
   Galvez-Barron, Cesar
   Minarro, Antonio
   Macho, Oscar
   Lopez, Gabriela F.
   Robles, Maria Teresa
   Dapena, Maria Dolores
   Martinez, Sergi
   Mila Rafols, Nuria
   Monaco, Ernesto E.
   Hidalgo Garcia, Antonio
CA COVID-19 Res Grp CSAPG
TI Association between COVID-19 prognosis and disease presentation,
   comorbidities and chronic treatment of hospitalized patients
SO PLOS ONE
LA English
DT Article
AB Importance
   The rapid pandemic expansion of the disease caused by the new SARS-CoV-2 virus has compromised health systems worldwide. Knowledge of prognostic factors in affected patients can help optimize care.
   Objective
   The objective of this study was to analyze the relationship between the prognosis of COVID-19 and the form of presentation of the disease, the previous pathologies of patients and their chronic treatments.
   Design, participants and locations
   This was an observational study on a cohort of 418 patients admitted to three regional hospitals in Catalonia (Spain). As primary outcomes, severe disease (need for oxygen therapy via nonrebreather mask or mechanical ventilation) and death were studied. Multivariate binary logistic regression models were performed to study the association between the different factors and the results.
   Results
   Advanced age, male sex and obesity were independent markers of poor prognosis. The most frequent presenting symptom was fever, while dyspnea was associated with severe disease and the presence of cough with greater survival. Low oxygen saturation in the emergency room, elevated CRP in the emergency room and initial radiological involvement were all related to worse prognosis. The presence of eosinophilia (% of eosinophils) was an independent marker of less severe disease.
   Conclusions
   This study identified the most robust markers of poor prognosis for COVID-19. These results can help to correctly stratify patients at the beginning of hospitalization based on the risk of developing severe disease.
C1 [Rodriguez-Molinero, Alejandro; Galvez-Barron, Cesar; Macho, Oscar; Lopez, Gabriela F.; Robles, Maria Teresa; Dapena, Maria Dolores; Martinez, Sergi; Mila Rafols, Nuria; Monaco, Ernesto E.; Hidalgo Garcia, Antonio] Consorci Sanitari Alt Penedes & Garraf CSAPG, Res Area, Barcelona, Spain.
   [Minarro, Antonio] Univ Barcelona, Sch Biol, Dept Genet Microbiol & Stat, Barcelona, Spain.
RP Rodriguez-Molinero, A (corresponding author), Consorci Sanitari Alt Penedes & Garraf CSAPG, Res Area, Barcelona, Spain.
EM rodriguez.molinero@gmail.com
RI ; Minarro, Antonio/G-1740-2015
OI Galvez-Barron, Cesar/0000-0001-5333-3317; Minarro,
   Antonio/0000-0001-7747-5299; Rodriguez-Molinero,
   Alejandro/0000-0002-9678-2654
CR a R-M, 2020, J CLIN MED, V9
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Ciceri F, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108509
   Dormann CF, 2013, ECOGRAPHY, V36, P27, DOI 10.1111/j.1600-0587.2012.07348.x
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Sanchez-Alvarez JE, 2020, NEFROLOGIA, V40, P272, DOI 10.1016/j.nefro.2020.04.002
   Felice C, 2020, AM J HYPERTENS
   FosbOl EL, 2020, JAMA
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Giacomelli A, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104931
   Goicoechea M, 2020, KIDNEY INT, V98, P27, DOI 10.1016/j.kint.2020.04.031
   Ibanez-Samaniego L, 2020, J INFECT DIS
   Jain V, 2020, INT J PUBLIC HEALTH, V65, P533, DOI 10.1007/s00038-020-01390-7
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Martins PR, 2020, EUR J INTERN MED, V76, P97, DOI 10.1016/j.ejim.2020.04.043
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Pirola CJ, 2020, J INFECT
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rodriguez-Cola Miguel, 2020, Spinal Cord Ser Cases, V6, P39, DOI 10.1038/s41394-020-0288-3
   Sattar N, 2020, CIRCULATION
   Tian WJ, 2020, J MED VIROL, V92, P1875, DOI 10.1002/jmv.26050
   Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   WHO, COR DIS COVID 19 SIT
   World Health Organization, 2011, GLOB STAT REP NONC D
   Yu W, 2020, INFECT DIS THER, V9, P927, DOI 10.1007/s40121-020-00342-1
   Zheng Z., 2020, J INFECT
   Zhou YW, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233328
NR 27
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2020
VL 15
IS 10
AR e0239571
DI 10.1371/journal.pone.0239571
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OG3UY
UT WOS:000581814700009
PM 33057443
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Biasio, LR
   Bonaccorsi, G
   Lorini, C
   Pecorelli, S
AF Biasio, Luigi Roberto
   Bonaccorsi, Guglielmo
   Lorini, Chiara
   Pecorelli, Sergio
TI Assessing COVID-19 vaccine literacy: a preliminary online survey
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE Vaccine Literacy; Vaccination Beliefs; COVID-19; Online Surveys
ID HEALTH LITERACY; COMMUNICATION
AB The COVID-19 infodemic can be countered by scientific evidence, clear and consistent communication, and improved health literacy of both individuals in need of information and those providing it. A rapid online survey was carried out to evaluate vaccine literacy (VL) skills in the general population and perceptions about COVID-19 vaccine candidates, along with behavior and beliefs about current vaccinations. Observed VL levels were consistent with previous observations - where comparable self-reported tools were administered face-to-face and by paper-and-pencil - the mean functional score being = 2.92, while the interactive-critical score was = 3.27, out of a maximum of 4. Perceptions regarding future COVID-19 vaccines, along with beliefs about vaccination, were mostly positive and significantly associated with functional and interactive-critical VL scales. Despite limitations, the study confirms that surveys via the web are a suitable method to evaluate and track attitudes during infectious disease outbreaks and assess health literacy skills about vaccination, which can be useful to adapt medical communication strategies, for a better understanding of the value of immunization.
C1 [Biasio, Luigi Roberto; Pecorelli, Sergio] Giovanni Lorenzini Fdn, Viale Piave 35, I-20129 Milan, Italy.
   [Bonaccorsi, Guglielmo; Lorini, Chiara] Univ Florence, Dept Hlth Sci, Florence, Italy.
RP Biasio, LR (corresponding author), Giovanni Lorenzini Fdn, Viale Piave 35, I-20129 Milan, Italy.
EM lrbiasio@gmail.com
RI ; Biasio, Luigi Roberto/AAH-7726-2019
OI bonaccorsi, guglielmo/0000-0002-5171-4308; Biasio, Luigi
   Roberto/0000-0001-8932-0411; Lorini, Chiara/0000-0003-3170-1857
CR Aharon AA, 2016, PATIENT EDUC COUNS, DOI [10.1016/j.pec.2016.11.0, DOI 10.1016/J.PEC.2016.11.0]
   [Anonymous], 2014, 5 03 ADD 1995 2014
   [Anonymous], 2014, ALZHEIMERS DEMENT J, V10, pe47, DOI DOI 10.4161/HV.29603
   Arokiaraj MC, CORRELATION INFLUENZ
   Belongia EA, 2020, SCIENCE, V368, P1163, DOI 10.1126/science.abd2220
   Betsch C, 2015, POLICY INSIGHTS BEHA, V2, P61, DOI DOI 10.1177/2372732215600716
   Biasio L R, 2020, Ann Ig, V32, P205, DOI 10.7416/ai.2020.2344
   Biasio LR, 2018, HUM VACC IMMUNOTHER, V14, P1515, DOI 10.1080/21645515.2018.1434382
   Brach C, 2014, J GEN INTERN MED, V29, P273, DOI 10.1007/s11606-013-2619-6
   Censis, MED COSTR ID 16 RAPP
   Del Giudice P, 2018, MISURARE ALFABETIZZA
   EngageMinds Hub, 2020, OR IT VERS POSS VACC
   Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34
   Geldsetzer P, 2020, J MED INTERNET RES, V22, DOI 10.2196/18790
   Health Literacy about Vaccination of adults ITalian (HLVa-IT), DOWNL HLTH LIT TOOL
   Hua JL, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072309
   Ishikawa H, 2008, DIABETES CARE, V31, P874, DOI 10.2337/dc07-1932
   ISTAT, 2019, CITT ICT ANN
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   MedCalc Software bvba, 2015, OST BELG
   Nutbeam D, 2000, HEALTH PROMOT INT, V15, P259, DOI 10.1093/heapro/15.3.259
   Paakkari L, 2020, LANCET PUBLIC HEALTH, V5, pE249, DOI 10.1016/S2468-2667(20)30086-4
   Ratzan SC, 2011, J HEALTH COMMUN, V16, P227, DOI 10.1080/10810730.2011.561726
   Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2
   Signorelli Carlo, 2020, Acta Biomed, V91, P175, DOI 10.23750/abm.v91i3-S.9511
   Sorensen K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-80
   Zarocostas J, 2020, LANCET, V395, P676, DOI 10.1016/S0140-6736(20)30461-X
NR 27
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1829315
EA OCT 2020
PG 9
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA OM5OT
UT WOS:000586074600001
PM 33118868
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Beretta, A
   Cranage, M
   Zipeto, D
AF Beretta, Alberto
   Cranage, Martin
   Zipeto, Donato
TI Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; antibody-dependent enhancement;
   immunopathogenesis; cross-reactivity; human coronaviruses
ID RESPIRATORY SYNDROME CORONAVIRUS; ANTIBODY-DEPENDENT ENHANCEMENT;
   PERITONITIS VIRUS-INFECTION; SARS CORONAVIRUS; PROTECTIVE IMMUNITY;
   RESPONSES; MACROPHAGES; DISEASE; NEUTRALIZATION; IMMUNIZATION
AB The serological responses to both SARS-CoV-1 and SARS-CoV-2 virus have some unique characteristics that suggest cross-reactive priming by other human coronaviruses (hCoVs). The early kinetics and magnitude of these responses are, in some cases, associated with worse clinical outcomes in SARS and COVID-19. Cross-reactive hCoV antibody responses have been detected in both SARS and COVID-19 patients. There is also evidence that pre-existing T cell immunity to common cold coronaviruses can prime the response to SARS-CoV-2. Studies in non-human primates show that SARS-CoV-1 S-protein vaccine-induced antibodies are associated with acute lung injury in macaques challenged with SARS-CoV-1. Here we discuss the potential of cross-reactive immunity to drive the immunopathogenesis of COVID-19 and its implications for current efforts to develop immune-based therapies and vaccines.
C1 [Beretta, Alberto] Solongev Res, Milan, Italy.
   [Cranage, Martin] St Georges Univ London, Inst Infect & Immun, London, England.
   [Zipeto, Donato] Univ Verona, Dept Neurosci Biomed & Movement Sci, Lab Mol Biol & Virol, Verona, Italy.
RP Beretta, A (corresponding author), Solongev Res, Milan, Italy.
EM alberto.beretta@solongevity.com
FU FUR 2019, Department of Neuroscience, Biomedicine and Movement Sciences,
   University of Verona; Department of Excellence [2018/2022]; MIUR,
   ItalyMinistry of Education, Universities and Research (MIUR); Brain
   Research Foundation Verona (BRFV)
FX This work was supported by FUR 2019, Department of Neuroscience,
   Biomedicine and Movement Sciences, University of Verona, by Department
   of Excellence 2018/2022, MIUR, Italy, and by the Brain Research
   Foundation Verona (BRFV).
CR Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   Arakawa S, 2019, CLIN EXP IMMUNOL, V195, P287, DOI 10.1111/cei.13253
   Atyeo C, 2020, IMMUNITY, V53, P524, DOI 10.1016/j.immuni.2020.07.020
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Borchering RK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13628-x
   Brodin P, 2020, ACTA PAEDIATR, V109, P1082, DOI 10.1111/apa.15271
   Burton DR, 2020, CELL HOST MICROBE, V27, P695, DOI 10.1016/j.chom.2020.04.022
   Cao Q, 2020, J FORMOS MED ASSOC, V119, P670, DOI 10.1016/j.jfma.2020.02.009
   Carsetti R, 2020, LANCET CHILD ADOLESC, V4, P414, DOI 10.1016/S2352-4642(20)30135-8
   Cervia C, 2020, BIORXIV, DOI [10.1101/2020.05.21.108308, DOI 10.1101/2020.05.21.108308]
   Chan KH, 2005, CLIN DIAGN LAB IMMUN, V12, P1317, DOI 10.1128/CDLI.12.11.1317-1321.2005
   Chen ZW, 2005, J VIROL, V79, P2678, DOI 10.1128/JVI.79.5.2678-2688.2005
   Monsalvo AC, 2011, NAT MED, V17, P195, DOI 10.1038/nm.2262
   Clay C, 2012, J VIROL, V86, P4234, DOI 10.1128/JVI.06791-11
   CRANAGE MP, 1981, CLIN EXP IMMUNOL, V43, P28
   Cristiani L, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00749-2020
   Du LY, 2008, VACCINE, V26, P1644, DOI 10.1016/j.vaccine.2008.01.025
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Fett C, 2013, J VIROL, V87, P6551, DOI 10.1128/JVI.00087-13
   Gauttier V, 2020, BIORXIV, DOI [10.1101/2020.08.14.240093, DOI 10.1101/2020.08.14.240093]
   Gorse GJ, 2020, J MED VIROL, V92, P512, DOI 10.1002/jmv.25715
   Gorse GJ, 2010, CLIN VACCINE IMMUNOL, V17, P1875, DOI 10.1128/CVI.00278-10
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   He DH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11013
   Ho MS, 2005, EMERG INFECT DIS, V11, P1730, DOI 10.3201/eid1111.040659
   HOHDATSU T, 1991, ARCH VIROL, V120, P207, DOI 10.1007/BF01310476
   Hohdatsu T, 1998, J VET MED SCI, V60, P49, DOI 10.1292/jvms.60.49
   Holodick NE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00872
   Huang Angkana T, 2020, medRxiv, DOI 10.1101/2020.04.14.20065771
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Kaneko N, 2020, CELL, V183, P143, DOI 10.1016/j.cell.2020.08.025
   Khan Saahir, 2020, bioRxiv, DOI 10.1101/2020.03.24.006544
   Ko JH, 2017, DIAGN MICR INFEC DIS, V89, P106, DOI 10.1016/j.diagmicrobio.2017.07.006
   Korber B, 2020, SPIKE MUTATION PIPEL, V12, P122, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Liu L, 2016, MUCOSAL IMMUNOL, V9, P1089, DOI 10.1038/mi.2015.127
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lv Huibin, 2020, bioRxiv, DOI 10.1101/2020.03.15.993097
   Ma H, 2020, CELL MOL IMMUNOL, V17, P773, DOI 10.1038/s41423-020-0474-z
   Moore JP, 2020, J VIROL, V94, DOI 10.1128/JVI.01083-20
   MORTON HC, 1995, J BIOL CHEM, V270, P29781
   Ng K., 2020, PREEXISTING NOVO HUM, V15, DOI [10.1101/2020.05.14.095414, DOI 10.1101/2020.05.14.095414]
   Nielsen SCA, 2020, CELL HOST MICROBE, V28, P516, DOI 10.1016/j.chom.2020.09.002
   Okba NMA, 2019, EMERG INFECT DIS, V25, P1868, DOI [10.3201/eid2509.190051, 10.3201/eid2510.190051]
   Olas K, 2005, CLIN EXP IMMUNOL, V140, P478, DOI 10.1111/j.1365-2249.2005.02779.x
   Oortwijn BD, 2007, MOL IMMUNOL, V44, P966, DOI 10.1016/j.molimm.2006.03.014
   Openshaw PJM, 2005, CLIN MICROBIOL REV, V18, P541, DOI 10.1128/CMR.18.3.541-555.2005
   Pan YB, 2020, J INFECTION, V81, pE28, DOI 10.1016/j.jinf.2020.03.051
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Nguyen-Contant P, 2020, MBIO, V11, DOI 10.1128/mBio.01991-20
   Randad Pranay R, 2020, medRxiv, DOI 10.1101/2020.05.24.20112300
   Schulien I, 2020, BIORXIV, DOI [10.1101/2020.08.13.249433, DOI 10.1101/2020.08.13.249433]
   Severance EG, 2008, CLIN VACCINE IMMUNOL, V15, P1805, DOI 10.1128/CVI.00124-08
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Sun BQ, 2020, EMERG MICROBES INFEC, V9, P940, DOI 10.1080/22221751.2020.1762515
   Suthar Mehul S, 2020, medRxiv, DOI 10.1101/2020.05.03.20084442
   Takano T, 2019, J VET MED SCI, V81, P911, DOI 10.1292/jvms.18-0702
   Tan W, 2020, VIRAL KINETICS ANTIB, DOI [10.1101/2020.03.24.20042382, DOI 10.1101/2020.03.24.20042382]
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wang Xiaoli, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa721
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Yonker LM, 2020, J PEDIATR-US, V227, P45, DOI 10.1016/j.jpeds.2020.08.037
   Yu HQ, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01526-2020
   Zhang LQ, 2006, J MED VIROL, V78, P1, DOI 10.1002/jmv.20499
   Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006
   Zhou WM, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-433
NR 74
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 15
PY 2020
VL 11
AR 567710
DI 10.3389/fimmu.2020.567710
PG 9
WC Immunology
SC Immunology
GA OK7XX
UT WOS:000584859500001
PM 33178193
OA DOAJ Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Perazzo, P
   Giorgino, R
   Briguglio, M
   Zuffada, M
   Accetta, R
   Mangiavini, L
   Peretti, GM
AF Perazzo, Paolo
   Giorgino, Riccardo
   Briguglio, Matteo
   Zuffada, Martina
   Accetta, Riccardo
   Mangiavini, Laura
   Peretti, Giuseppe M.
TI From Standard to Escalated Anticoagulant Prophylaxis in Fractured Older
   Adults With SARS-CoV-2 Undergoing Accelerated Orthopedic Surgery
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE femoral fractures; anticoagulants; low-molecular-weight heparin;
   COVID-19 drug treatment; SARS-CoV-2
AB Proximal femoral fractures in older adults are not uncommon and represent a great challenge for orthopedic surgeons because of the high risks of complications. In the COVID-19 panorama, fractures occurring in infected older adults become an even more intricate task because of concomitant metabolic derangements due to SARS-CoV-2. Multidisciplinary protocols are mandatory and pharmacological treatment in infected patients should be tailored. Regrettably, the spread of the virus in northern Italy, has been faster than scientific progress in characterizing the disease and many hospitals have had to manage the symptoms on a daily clinical bases. Our Italian hospital in the region of Lombardy, which has been the epicenter of the Italian pandemic, has admitted sixteen patients with fractured femurs in March and April 2020. The first seven patients were treated with the antithrombotic prophylaxis of a single daily dose of low-molecular-weight heparin, but we observed the highest prevalence of deaths from cardiovascular complications (four deaths). By doubling the daily dose of anticoagulants in the subsequent patients, we observed a reduction in the incidence of death (one death out of nine). Controversies exist about the surgical treatment of fractures in older adults during this pandemic. However, we have observed an increased survival after fall trauma in infected older adults if treated with high doses of anticoagulant. Although not being statistically significant, our results are in line with the current knowledge of the pathophysiology of SARS-CoV-2 infection, but more studies should be shared about the efficacy and dosage of anticoagulants in traumatic injuries of the elderly.
C1 [Perazzo, Paolo] IRCCS Orthoped Inst Galeazzi, Intens Care Unit, Milan, Italy.
   [Giorgino, Riccardo; Zuffada, Martina] Univ Milan, Orthoped & Traumatol, Milan, Italy.
   [Briguglio, Matteo] IRCCS Orthoped Inst Galeazzi, Milan, Italy.
   [Accetta, Riccardo] IRCCS Orthoped Inst Galeazzi, Traumatol Unit, Milan, Italy.
   [Mangiavini, Laura; Peretti, Giuseppe M.] IRCCS Orthoped Inst Galeazzi, Regenerat & Reconstruct Unit, Milan, Italy.
   [Mangiavini, Laura; Peretti, Giuseppe M.] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy.
RP Briguglio, M (corresponding author), IRCCS Orthoped Inst Galeazzi, Milan, Italy.
EM matteo.briguglio@grupposandonato.it
RI Briguglio, Matteo/J-4957-2018
OI Briguglio, Matteo/0000-0003-0801-2359
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Borges FK, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-033150
   Briguglio M, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00671
   Briguglio M, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00146
   Catellani F, 2020, J BONE JOINT SURG AM, V102, DOI 10.2106/JBJS.20.00617
   Chang JC, 2019, THROMB J, V17, DOI 10.1186/s12959-019-0198-4
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Elia M, 2003, DEV USE MALNUTRITION
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Hill J, 2010, HEART, V96, P879, DOI 10.1136/hrt.2010.198275
   Iyengar Karthikeyan, 2020, J Clin Orthop Trauma, V11, P718, DOI 10.1016/j.jcot.2020.05.010
   Julius Mary, 2017, Fed Pract, V34, P27
   Leung C, 2020, MECH AGEING DEV, V188, DOI 10.1016/j.mad.2020.111255
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Lillicrap D, 2020, J THROMB HAEMOST, V18, P786, DOI 10.1111/jth.14781
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Maniscalco Pietro, 2020, Acta Biomed, V91, P97, DOI 10.23750/abm.v91i2.9635
   Mi BB, 2020, J BONE JOINT SURG AM, V102, P750, DOI 10.2106/JBJS.20.00390
   Vives JMM, 2020, J BONE JOINT SURG AM, V102, DOI 10.2106/JBJS.20.00686
   Panel CTG, 2020, ANT THER PAT COVID 1
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Service Benjamin C, 2020, J Bone Joint Surg Am, V102, pe76, DOI 10.2106/JBJS.20.00599
   Spyropoulos AC, 2020, LANCET, V395, pE75, DOI 10.1016/S0140-6736(20)30926-0
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Yang Y, 2016, CELL MOL IMMUNOL, V13, P432, DOI 10.1038/cmi.2016.1
   Zagra L, 2020, INT ORTHOP, V44, P1591, DOI 10.1007/s00264-020-04590-1
NR 27
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD OCT 15
PY 2020
VL 7
AR 566770
DI 10.3389/fmed.2020.566770
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA OK7VY
UT WOS:000584854400001
PM 33178713
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Waqas, M
   Haider, A
   Sufyan, M
   Siraj, S
   Sehgal, SA
AF Waqas, Muhammad
   Haider, Ali
   Sufyan, Muhammad
   Siraj, Sami
   Sehgal, Sheikh Arslan
TI Determine the Potential Epitope Based Peptide Vaccine Against Novel
   SARS-CoV-2 Targeting Structural Proteins Using Immunoinformatics
   Approaches
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Article
DE immunoinformatics; SARS-CoV-2; SARS-CoV; peptide vaccines; corona virus
   disease 2019
ID FAST INTERACTION REFINEMENT; COMPUTATIONAL DESIGN; WEB SERVER;
   PREDICTION; SARS; CORONAVIRUS; FIREDOCK; ANTIBODY; LIGANDS; GENOME
AB Coronaviruses (CoVs) belong to the Coronaviridae-family. The genus Beta-coronaviruses, are enveloped positive strand RNA viruses with club-like spikes at the surface with a unique replication process and a large RNA genome (similar to 25 kb). CoVs are known as one of the major pathogenic viruses causing a variety of diseases in birds and mammals including humans (lethal respiratory dysfunctions). Recently, a new strain of coronavirus has been identified and named as SARS-CoV-2. A large number of COVID-19 (disease caused by SARS-CoV-2) cases are being diagnosed all over the World especially in China (Wuhan). COVID-19 showed high mortality rate exponentially, however, not even a single effective cure is being introduced yet against COVID-19. In the current study, immunoinformatics approaches were employed to predict the antigenic epitopes against COVID-19 for the development of a coronavirus peptide vaccine. Cytotoxic T-lymphocyte (CTL) and B-cell epitopes were predicted for SARS-CoV-2 coronavirus structural proteins (Spikes, Membrane, Envelope, and Nucleocapsid). The docking complexes of the top 10 epitopes having antigenic sites were analyzed led by binding affinity and binding interactional analyses of top ranked predicted peptides with the MHC-I HLA molecule. The predicted peptides may have potential to be used as peptide vaccine against COVID-19.
C1 [Waqas, Muhammad; Haider, Ali; Sufyan, Muhammad; Sehgal, Sheikh Arslan] Govt Coll Univ Faisalabad, Dept Bioinformat & Biotechnol, Faisalabad, Pakistan.
   [Siraj, Sami] Khyber Med Univ, Inst Basic Med Sci, Peshawar, Pakistan.
   [Sehgal, Sheikh Arslan] Univ Okara, Dept Bioinformat, Okara, Pakistan.
RP Sehgal, SA (corresponding author), Govt Coll Univ Faisalabad, Dept Bioinformat & Biotechnol, Faisalabad, Pakistan.; Sehgal, SA (corresponding author), Univ Okara, Dept Bioinformat, Okara, Pakistan.
EM arslansehgal@yahoo.com
CR Abdelmageed MI, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2683286
   Ahmad B, 2019, MICROB PATHOGENESIS, V132, P243, DOI 10.1016/j.micpath.2019.05.010
   Al-amri SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep44875
   Alam A, 2016, IMMUNOLOGY, V149, P386, DOI 10.1111/imm.12656
   Alexander Nathan, 2011, IEEE Int Conf Comput Adv Bio Med Sci, V2011, P13, DOI 10.1109/ICCABS.2011.5729867
   Andrusier N, 2007, PROTEINS, V69, P139, DOI 10.1002/prot.21495
   [Anonymous], 2020, BEIJING NEWS
   Ashfaq UA, 2016, VIRAL IMMUNOL, V29, P436, DOI 10.1089/vim.2016.0033
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Cascella M, 2020, FEATURES EVALUATION
   Chang CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065045
   Chew MF, 2017, INT J MED SCI, V14, P1342, DOI 10.7150/ijms.21875
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Davies MN, 2007, DRUG DISCOV TODAY, V12, P389, DOI 10.1016/j.drudis.2007.03.010
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619
   Douglas MG, 2018, VIROLOGY, V517, P98, DOI 10.1016/j.virol.2017.12.006
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   Geer LY, 2010, NUCLEIC ACIDS RES, V38, pD492, DOI 10.1093/nar/gkp858
   Guy JS, 2000, J CLIN MICROBIOL, V38, P4523, DOI 10.1128/JCM.38.12.4523-4526.2000
   Heurich M, 2013, TOXINS, V5, P1202, DOI 10.3390/toxins5061202
   Huang PT, 2010, ACTA CRYSTALLOGR A, V66, pS233, DOI 10.1107/S0108767310094699
   Imai N., 2020, ESTIMATING POTENTIAL
   Ip PP, 2015, VACCINES-BASEL, V3, P203, DOI 10.3390/vaccines3020203
   KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768
   Kingsford CL, 2005, BIOINFORMATICS, V21, P1028, DOI 10.1093/bioinformatics/bti144
   Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329
   Lazarski CA, 2005, IMMUNITY, V23, P29, DOI 10.1016/j.immuni.2005.05.009
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   Mashiach E, 2008, NUCLEIC ACIDS RES, V36, pW229, DOI 10.1093/nar/gkn186
   Maupetit J, 2007, PROTEINS, V69, P394, DOI 10.1002/prot.21505
   MCCLAIN CS, 1995, PERSPECT BIOL MED, V38, P624
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nain Z, 2020, J BIOMOL STRUCT DYN, V38, P4850, DOI 10.1080/07391102.2019.1692072
   Nair DT, 2002, J IMMUNOL, V168, P2371, DOI 10.4049/jimmunol.168.5.2371
   Palatnik-de-Sousa CB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00826
   PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Sayers EW, 2020, NUCLEIC ACIDS RES, V48, pD84, DOI 10.1093/nar/gkz956
   Sayers EW, 2019, NUCLEIC ACIDS RES, V47, pD94, DOI 10.1093/nar/gky989
   Seema M. T., 2019, CELL EPITOPE BASED V, DOI [10.26434/chemrxiv.12029523.v2, DOI 10.26434/CHEMRXIV.12029523.V2]
   Sehgal SA, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5925714
   Sehgal SA, 2013, THEOR BIOL MED MODEL, V10, DOI 10.1186/1742-4682-10-3
   Sieker F, 2009, CURR PROTEIN PEPT SC, V10, P286, DOI 10.2174/138920309788452191
   SIEVERS F, 2014, CURR PROTOC BIOINFOR, V48, P3, DOI DOI 10.1002/0471250953.BI0313S48
   Sievers F, 2018, PROTEIN SCI, V27, P135, DOI 10.1002/pro.3290
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Tahir RA, 2018, J THEOR BIOL, V459, P162, DOI 10.1016/j.jtbi.2018.10.005
   ul Qamar M.T., 2020, DESIGNING NEXT GENER, DOI [10.1101/2020.02.28.970343, DOI 10.1101/2020.02.28.970343]
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   Usman Mirza M., 2017, SCI REP, V6
   Vanhee P, 2011, TRENDS BIOTECHNOL, V29, P231, DOI 10.1016/j.tibtech.2011.01.004
   Rodrigues TCV, 2019, ROY SOC OPEN SCI, V6, DOI 10.1098/rsos.190907
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wilkins MR, 1999, METH MOL B, V112, P531
   World Health Organization, 2020, WHO STAT REG CLUST P
   Xiao Y., 2020, BIORXIV PREPRINT, DOI [10.1101/2020.07.06.189860, DOI 10.1101/2020.07.06.189860]
   Xu DR, 2017, COMPUT BIOL CHEM, V69, P120, DOI 10.1016/j.compbiolchem.2017.06.001
   Yu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106012
NR 64
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD OCT 15
PY 2020
VL 7
AR 227
DI 10.3389/fmolb.2020.00227
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OK6XY
UT WOS:000584792000001
PM 33195402
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yang, FX
   Yue, RM
   Luo, XX
   Liu, RG
   Huang, XB
AF Yang, Fuxun
   Yue, Ruiming
   Luo, Xiaoxiu
   Liu, Rongan
   Huang, Xiaobo
TI Hydrogen: A Potential New Adjuvant Therapy for COVID-19 Patients
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Hydrogen; COVID-19; therapy; cytokine storm; mucus
ID CYTOKINE STORM; LUNG INJURY; INFLAMMATION; INHALATION; ANTIOXIDANT;
   SEVERITY; DISEASE; GAMMA; GAS
AB Hydrogen has been shown to have antioxidant, anti-inflammatory, hormone-regulating, and apoptosis-resistance properties, among others. Based on a review of the research, the use of hydrogen might reduce the destructive cytokine storm and lung injury caused by SARS-CoV-2 during COVID-19 (Corona Virus Disease 2019) in the early stage, stimulating ropy sputum drainage, and ultimately reducing the incidence of severe disease. Molecular hydrogen treatment has the potential to become a new adjuvant therapy for COVID-19, but its efficacy and safety require large clinical trials and further confirmation.
C1 [Yang, Fuxun; Yue, Ruiming; Luo, Xiaoxiu; Liu, Rongan; Huang, Xiaobo] Sichuan Prov Peoples Hosp, Dept Crit Care Med, Chengdu, Peoples R China.
RP Liu, RG; Huang, XB (corresponding author), Sichuan Prov Peoples Hosp, Dept Crit Care Med, Chengdu, Peoples R China.
EM frog007_119@qq.com; 659492700@qq.com
FU Sichuan Province Science and Technology Support Program [2017SZ0138];
   Chengdu Science and Technology Support Program [2020-YF05-00104-SN]
FX This study was supported by the Sichuan Province Science and Technology
   Support Program (numbers: 2017SZ0138)and Chengdu Science and Technology
   Support Program (numbers: 2020-YF05-00104-SN).
CR Botek M, 2019, INT J SPORTS MED, V40, P879, DOI [10.1055/a-0991-0268, 10.1055/s-00000028]
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen X, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/106836
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   FERRARA JLM, 1993, TRANSPLANT P, V25, P1216
   Gong Z J, 2016, Zhonghua Jie He He Hu Xi Za Zhi, V39, P916, DOI 10.3760/cma.j.issn.1001-0939.2016.12.003
   Guan WJ, 2020, J THORAC DIS, V12, P3448, DOI 10.21037/jtd-2020-057
   Gwarzo Muhammad Yalwa, 2010, Int J Biomed Sci, V6, P294
   Hayashida K, 2014, CIRCULATION, V130, P2173, DOI 10.1161/CIRCULATIONAHA.114.011848
   Hayashida K, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.003459
   Hillman NH, 2007, AM J RESP CRIT CARE, V176, P575, DOI 10.1164/rccm.200701-051OC
   Hoetzel A, 2008, AM J RESP CRIT CARE, V177, P1223, DOI 10.1164/rccm.200708-1265OC
   Homma K, 2014, NEPHRON EXP NEPHROL, V128, P116, DOI 10.1159/000369068
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang CS, 2010, CRIT CARE, V14, DOI 10.1186/cc9389
   Huang CS, 2010, FREE RADICAL RES, V44, P971, DOI 10.3109/10715762.2010.500328
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Igarashi T, 2019, AM J OPHTHALMOL, V207, P10, DOI 10.1016/j.ajo.2019.04.014
   Kalil AC, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2539-x
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Laveda R, 2005, WORLD J GASTROENTERO, V11, P5309, DOI 10.3748/wjg.v11.i34.5309
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   Ma LB, 2015, J THORAC DIS, V7, P1732, DOI 10.3978/j.issn.2072-1439.2015.10.18
   Nakao A, 2010, J CLIN BIOCHEM NUTR, V46, P140, DOI 10.3164/jcbn.09-100
   Ning YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083429
   Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577
   Perez-Vilar J, 2006, J BIOL CHEM, V281, P4844, DOI 10.1074/jbc.M510520200
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Rutherford AI, 2018, ANN RHEUM DIS, V77, P905, DOI 10.1136/annrheumdis-2017-212825
   Selvaraj Vijairam, 2020, R I Med J (2013), V103, P39
   Shi Hai-mei, 2013, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V25, P347, DOI 10.3760/cma.j.issn.2095-4352.2013.06.008
   Shimizu T, 2001, AM J RESP CRIT CARE, V164, P1077, DOI 10.1164/ajrccm.164.6.2012058
   Tamura T, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2246-3
   Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142
   Voynow JA, 2006, AM J RESP CELL MOL, V34, P661, DOI 10.1165/rcmb.2006-0035SF
   WANG S, 2020, OPTIK, V217, DOI DOI 10.1093/QJMED/HCAA164
   Xie KL, 2012, SHOCK, V37, P548, DOI 10.1097/SHK.0b013e31824ddc81
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang H, 2016, NEWS WRITING, V5, P28
   Zhou ZQ, 2019, RESPIRATION, V97, P42, DOI 10.1159/000492031
   刘茜, 2020, [法医学杂志, Journal of Forensic Medicine], V36, P21
NR 43
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 15
PY 2020
VL 11
AR 543718
DI 10.3389/fphar.2020.543718
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OK5ZJ
UT WOS:000584728100001
PM 33178011
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Candeloro, E
   Carimati, F
   Damavandi, PT
   Cariddi, LP
   Banfi, P
   Clemenzi, A
   Gallazzi, M
   Mauri, M
   Rebecchi, V
   Baruzzi, F
   Giorgianni, A
   Tozzi, M
   Bianchi, M
   Ageno, W
   Versino, M
AF Candeloro, Elisa
   Carimati, Federico
   Tabaee Damavandi, Payam
   Princiotta Cariddi, Lucia
   Banfi, Paola
   Clemenzi, Alessandro
   Gallazzi, Marco
   Mauri, Marco
   Rebecchi, Valentina
   Baruzzi, Fabio
   Giorgianni, Andrea
   Tozzi, Matteo
   Bianchi, Massimo
   Ageno, Walter
   Versino, Maurizio
TI An Example of a Stroke Unit Reshaping in the Context of a Regional Hub
   and Spoke System in the COVID-19 Era
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE stroke unit; reshaping; hub and spoke system; COVID-19 pandemic; timing
ID ACUTE ISCHEMIC-STROKE; HEALTH-CARE PROFESSIONALS; EARLY MANAGEMENT; 2018
   GUIDELINES
AB During the COVID-19 outbreak, the Neurology and Stroke Unit (SU) of the hospital of Varese had to serve as a cerebrovascular hub, meaning that the referral area for the unit doubled. The number of beds in the SU was increased from 4 to 8. We took advantage of the temporary suspension of the out-patient clinic and reshaped our activity to guarantee the 24/7 availability of recombinant tissue Plasminogen Activator (rtPA) intravenous therapy (IVT) in the SU, and to ensure we were able to admit patients to the SU as soon as they completed endovascular treatment (EVT). In 42 days, 46 stroke patients were admitted to our hospital, and 34.7% of them underwent IVT and/or EVT, which means that we treated 0.38 patients per day; in the baseline period from 2016 to 2018, these same figures had been 23.5% and 0.23, respectively. The mean values of the door-to-first CT/MRI and the door-to-groin puncture, but not of the onset-to-door and the door-to-needle periods were slightly but significantly longer than those observed in the baseline period in 276 patients. On an individual basis, only one patient exceeded the door-to-groin puncture time limit computed from the baseline period by about 10 min. None of the patients had a major complication following the procedures. None of the patients was or became SARS-CoV2 positive. In conclusion, we were able to manage the new hub-and-spoke system safely and without significant delays. The reshaping of the SU was made possible by the significant reduction of out-patient activity. The consequences of this reduction are still unknown but eventually, this emergency will suggest ways to reconsider the management and the allocation of health system resources.
C1 [Candeloro, Elisa; Carimati, Federico; Tabaee Damavandi, Payam; Princiotta Cariddi, Lucia; Banfi, Paola; Clemenzi, Alessandro; Gallazzi, Marco; Mauri, Marco; Rebecchi, Valentina; Versino, Maurizio] Osped Circolo Varese, Neurol & Stroke Units, ASST Settelaghi, Varese, Italy.
   [Tabaee Damavandi, Payam] Bicocca Univ, Dept Med & Surg, Milan, Italy.
   [Princiotta Cariddi, Lucia; Mauri, Marco; Tozzi, Matteo; Ageno, Walter; Versino, Maurizio] Insubria Univ, Dept Med & Surg, Varese, Italy.
   [Baruzzi, Fabio; Giorgianni, Andrea] Osped Circolo Varese, Neuroradiol Unit, ASST Settelaghi, Varese, Italy.
   [Tozzi, Matteo] Osped Circolo Varese, Vasc Surg Unit, ASST Settelaghi, Varese, Italy.
   [Bianchi, Massimo; Ageno, Walter] Osped Circolo Varese, Emergency Dept, ASST Settelaghi, Varese, Italy.
RP Versino, M (corresponding author), Osped Circolo Varese, Neurol & Stroke Units, ASST Settelaghi, Varese, Italy.; Versino, M (corresponding author), Insubria Univ, Dept Med & Surg, Varese, Italy.
EM maurizio.versino@asst-settelaghi.it
RI Carimati, Federico/ABG-2232-2020
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Agosti E, 2020, WORLD NEUROSURG, V138, P548, DOI 10.1016/j.wneu.2020.04.141
   Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Avula A, 2020, BRAIN BEHAV IMMUN, V87, P115, DOI 10.1016/j.bbi.2020.04.077
   Baracchini C, 2020, NEUROL SCI, V41, P1003, DOI 10.1007/s10072-020-04375-9
   Bersano A, 2020, EUR J NEUROL, V27, P1794, DOI 10.1111/ene.14375
   Cariddi LP, 2020, J NEUROL, V267, P3157, DOI 10.1007/s00415-020-10001-7
   Carod-Artal FJ, 2020, REV NEUROLOGIA, V70, P311, DOI 10.33588/rn.7009.2020179
   Diegoli H, 2020, STROKE, V51, P2315, DOI 10.1161/STROKEAHA.120.030481
   Hess DC, 2020, TRANSL STROKE RES, V11, P322, DOI 10.1007/s12975-020-00818-9
   Lg S, 2017, SPREAD STROKE PREVEN
   Nalleballe K, 2020, BRAIN BEHAV IMMUN, V88, P71, DOI 10.1016/j.bbi.2020.06.020
   Natoli S, 2020, EUR J NEUROL, V27, P1764, DOI 10.1111/ene.14277
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2
   Sardu C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051417
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
NR 20
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD OCT 15
PY 2020
VL 11
AR 1029
DI 10.3389/fneur.2020.01029
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OK5XQ
UT WOS:000584723600001
PM 33178094
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tan, WYT
   Young, BE
   Lye, DC
   Chew, DEK
   Dalan, R
AF Tan, Wilnard Y. T.
   Young, Barnaby E.
   Lye, David Chien
   Chew, Daniel E. K.
   Dalan, Rinkoo
TI Statin use is associated with lower disease severity in COVID-19
   infection
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COENZYME-A REDUCTASE; CYTOKINE PRODUCTION; DOUBLE-BLIND; MORTALITY;
   ATORVASTATIN; PRAVASTATIN; INHIBITORS; THERAPY; PROTEIN; TRIAL
AB We aim to study the association of hyperlipidemia and statin use with COVID-19 severity. We analysed a retrospective cohort of 717 patients admitted to a tertiary centre in Singapore for COVID-19 infection. Clinical outcomes of interest were oxygen saturation <= 94% requiring supplemental oxygen, intensive-care unit (ICU) admission, invasive mechanical-ventilation and death. Patients on long term dyslipidaemia medications (statins, fibrates or ezetimibe) were considered to have dyslipidaemia. Logistic regression models were used to study the association between dyslipidaemia and clinical outcomes adjusted for age, gender and ethnicity. Statin treatment effect was determined, in a nested case-control design, through logistic treatment models with 1:3 propensity matching for age, gender and ethnicity. All statistical tests were two-sided, and statistical significance was taken as p<0.05. One hundred fifty-six (21.8%) patients had dyslipidaemia and 97% of these were on statins. Logistic treatment models showed a lower chance of ICU admission for statin users when compared to non-statin users (ATET: Coeff (risk difference):-0.12 (-0.23,-0.01); p=0.028). There were no other significant differences in other outcomes. Statin use was independently associated with lower ICU admission. This supports current practice to continue prescription of statins in COVID-19 patients.
C1 [Tan, Wilnard Y. T.; Young, Barnaby E.; Lye, David Chien] Tan Tock Seng Hosp, Yong Loo Lin Sch Med, Lee Kong Chian Sch Med, Natl Ctr Infect Dis, 16 Jalan Tan Tock Seng, Singapore 308442, Singapore.
   [Chew, Daniel E. K.; Dalan, Rinkoo] Tan Tock Seng Hosp, Lee Kong Chian Sch Med, Dept Endocrinol, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
RP Dalan, R (corresponding author), Tan Tock Seng Hosp, Lee Kong Chian Sch Med, Dept Endocrinol, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM Rinkoo_dalan@ttsh.com.sg
FU NMRC COVID-19 research fund [COVID19RF-001]; Ministry of Health,
   Clinician Scientist Award [MOH-000014]; National Medical Research
   Council Centre Grant [NMRC/CG/017/2013]
FX The study is funded through NMRC COVID-19 research fund (COVID19RF-001).
   RD is supported in part by Ministry of Health, Clinician Scientist Award
   [MOH-000014]; and National Medical Research Council Centre Grant
   [NMRC/CG/017/2013].
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64
   [Anonymous], 2020, SITUATION REPORTS
   Artifoni M, 2020, J THROMB THROMBOLYS, V50, P211, DOI 10.1007/s11239-020-02146-z
   Bifulco M, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104803
   Castiglione V, 2020, EUR HEART J-CARD PHA, V6, P258, DOI 10.1093/ehjcvp/pvaa042
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Chen X, 2019, INFECT DIS CLIN, DOI [10.1093/cid/ciaa449, DOI 10.1093/CID/CIAA449]
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Crunkhorn Sarah, 2020, Nat Rev Drug Discov, V19, P588, DOI 10.1038/d41573-020-00137-6
   Dalan Rinkoo, 2020, Eur Heart J Cardiovasc Pharmacother, DOI 10.1093/ehjcvp/pvaa098
   Dashti-Khavidaki S, 2020, PHARMACOTHERAPY, V40, P484, DOI 10.1002/phar.2397
   De Spiegeleer A, 2020, J AM MED DIR ASSOC, V21, P909, DOI 10.1016/j.jamda.2020.06.018
   Duan HY, 2015, GENET MOL RES, V14, P15739, DOI 10.4238/2015.December.1.25
   Erkan D, 2014, ANN RHEUM DIS, V73, P1176, DOI 10.1136/annrheumdis-2013-203622
   Evans Paul C, 2020, Cardiovasc Res, V116, P2177, DOI 10.1093/cvr/cvaa230
   Fang CH, 2005, MED HYPOTHESES, V64, P192, DOI 10.1016/j.mehy.2004.06.018
   Glende J, 2008, VIROLOGY, V381, P215, DOI 10.1016/j.virol.2008.08.026
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iwata A, 2012, CLIN EXP IMMUNOL, V168, P234, DOI 10.1111/j.1365-2249.2012.04564.x
   Konig MF, 2020, J CLIN INVEST, V130, P3345, DOI 10.1172/JCI139642
   Li GL, 2020, CARDIOL J, V27, P616, DOI 10.5603/CJ.a2020.0101
   Liappis AP, 2001, CLIN INFECT DIS, V33, P1352, DOI 10.1086/323334
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Ma Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051548
   MABUCHI H, 1981, NEW ENGL J MED, V305, P478, DOI 10.1056/NEJM198108273050902
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140-6736(04)16449-0
   Mortensen EM, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-82
   Ng YX, 2020, MMWR-MORBID MORTAL W, V69, P307, DOI 10.15585/mmwr.mm6911e1
   Novack V, 2009, INTENS CARE MED, V35, P1255, DOI 10.1007/s00134-009-1429-0
   Peretz A, 2019, QJM-INT J MED, V112, P749, DOI 10.1093/qjmed/hcy305
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Rodrigues-Diez RR, 2020, BRIT J PHARMACOL, V177, P4873, DOI 10.1111/bph.15166
   Rodriguez-Nava G, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03154-4
   Schonbeck U, 2004, CIRCULATION, V109, P18, DOI 10.1161/01.CIR.0000129505.34151.23
   Scicali R, 2020, NUTR METAB CARDIOVAS, V30, P1068, DOI 10.1016/j.numecd.2020.05.003
   Shams A, 2020, IDCases, V21, DOI 10.1016/j.idcr.2020.e00923
   Soto-Acosta R, 2013, VIROLOGY, V442, P132, DOI 10.1016/j.virol.2013.04.003
   Tedeschi D, 2020, CATHETER CARDIO INTE, DOI 10.1002/ccd.29179
   van der Meij E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053882
   Vandermeer ML, 2012, J INFECT DIS, V205, P13, DOI 10.1093/infdis/jir695
   Vuorio A, 2020, J INTERN MED, V287, P746, DOI 10.1111/joim.13070
   Wang H, 2020, CLIN TRANSL GASTROEN, V11
   Wassmann S, 2003, CIRC RES, V93, pE98, DOI 10.1161/01.RES.0000099503.13312.7B
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zeiser R, 2018, IMMUNOLOGY, V154, P69, DOI 10.1111/imm.12902
   Zhang J, 2013, CYTOKINE, V61, P540, DOI 10.1016/j.cyto.2012.12.006
   Zhang XJ, 2020, CELL METAB, V32, P176, DOI 10.1016/j.cmet.2020.06.015
NR 53
TC 1
Z9 1
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 15
PY 2020
VL 10
IS 1
AR 17458
DI 10.1038/s41598-020-74492-0
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OH6ML
UT WOS:000582705900072
PM 33060704
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sotgia, F
   Lisanti, MP
AF Sotgia, Federica
   Lisanti, Michael P.
TI Using the common cold virus as a naturally occurring vaccine to prevent
   COVID-19: Lessons from Edward Jenner
SO AGING-US
LA English
DT Article
DE coronavirus; viral spike glycoprotein; vaccine; common cold; COVID-19
ID CLINICAL-FEATURES
AB Three recent papers published in Nature, Science and Cell, all present clear evidence that there is cross-reactive T-cell immunity between human coronaviruses (229E, NL63, OC43, and HKU1), linked with the common cold, and SARS-CoV-2, the causative agent of COVID-19. Can we use this information to design and build a new vaccine based on the less pathogenic, common cold coronaviruses, for the prevention of COVID-19? If we look at the history of medicine and vaccine development, from the point of view of Edward Jenner, the answer just might be yes.
C1 [Sotgia, Federica; Lisanti, Michael P.] Univ Salford, Sch Sci Engn & Environm SEE, Translat Med, Manchester, England.
RP Sotgia, F; Lisanti, MP (corresponding author), Univ Salford, Sch Sci Engn & Environm SEE, Translat Med, Manchester, England.
EM f.sotgia@salford.ac.uk; m.p.lisanti@salford.ac.uk
FU Lunella Biotech, Inc.
FX This work was supported by research grant funding, provided by Lunella
   Biotech, Inc. We are grateful to Rumana Rafiq, for her kind and
   dedicated assistance, in keeping the Translational Medicine Laboratory
   at Salford running smoothly. We would like to thank the Foxpoint
   Foundation (Canada) and the Healthy Life Foundation (UK) for their
   philanthropic donations towards new equipment and infrastructure, in the
   Translational Medicine Laboratory at the University of Salford.
CR Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hicks Jennifer, 2020, medRxiv, DOI 10.1101/2020.06.22.20137695
   Komabayashi Kenichi, 2020, Jpn J Infect Dis, V73, P394, DOI 10.7883/yoken.JJID.2020.525
   Li SW, 2013, BIOMEDICINE-TAIWAN, V3, P43, DOI 10.1016/j.biomed.2012.12.007
   Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871
   Ogimi C, 2020, J PEDIAT INF DIS SOC, V9, P210, DOI 10.1093/jpids/piaa037
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
NR 8
TC 0
Z9 0
U1 0
U2 0
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD OCT 15
PY 2020
VL 12
IS 19
BP 18797
EP 18803
DI 10.18632/aging.104166
PG 7
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA OF3EF
UT WOS:000581094800004
PM 33049711
OA Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Guo, HY
   Zhang, ZG
   Zhang, YY
   Liu, Y
   Wang, JF
   Qian, ZP
   Zou, Y
   Lu, HZ
AF Guo, Hongying
   Zhang, Zhengguo
   Zhang, Yuyi
   Liu, Yu
   Wang, Jiefei
   Qian, Zhiping
   Zou, Ying
   Lu, Hongzhou
TI Analysis of liver injury factors in 332 patients with COVID-19 in
   Shanghai, China
SO AGING-US
LA English
DT Article
DE coronavirus disease 2019; COVID-19; SARS-CoV-2; liver injury; medication
ID CORONAVIRUS
AB Objective: We analyzed clinical parameters and risk factors for coronavirus disease 2019 (COVID-19)-related liver damage.
   Results: Of the 332 COVID-19 patients, 306 and 26 were included in the non-critical and critical groups, respectively. The median time from onset to admission was 4.0 (2.0-8.0) days. Of the 332 COVID-19 patients, 98 (29.5%) were admitted with liver injury. The rates of aspartate transaminase, gamma-glutamyl transpeptidase, and total bilirubin abnormalities were higher in the critical group than in the non-critical group. The patient's sex, COVID-19 severity, and a low liver CT density strongly correlated with liver injury (ORs: 2.936, 6.543, and 3.387, respectively). Statistical analysis on drug administration after admission showed that the usage rates of lopinavir/ritonavir, glucocorticoids, and thymopeptides were significantly higher in the abnormal group than the normal groups (p<0.05).
   Conclusions: Though not severe, the liver injury among COVID-19 patients was pervasive. Being male, COVID-19 severity, low CT density, and medications may be risk factors for liver damage. Following recovery, liver function gradually returns to normal.
   Methods: This retrospective study screened 332 confirmed COVID-19 patients from January 20 to March 13, 2020. Liver indicators were evaluated on admission. The risk factors, medications, and the dynamic change of liver functions were analyzed.
C1 [Guo, Hongying; Zhang, Zhengguo; Zhang, Yuyi; Liu, Yu; Wang, Jiefei; Qian, Zhiping; Zou, Ying] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Severe Hepatopathy, Shanghai, Peoples R China.
   [Lu, Hongzhou] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect Dis & Immunol, Shanghai, Peoples R China.
RP Guo, HY (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Severe Hepatopathy, Shanghai, Peoples R China.
EM luhongzhou@fudan.edu.cn; zouying@shphc.org.cn
FU Fudan University [IDF162005]; Shanghai Public Health Clinical Center
   [2020YJKY01]; hospital-level project by Shanghai Public Health Clinical
   Center [KY-GW-201818]; National Science and Technology Major Project of
   China [2018ZX10302206]
FX This study was supported by Fudan University (IDF162005); Shanghai
   Public Health Clinical Center (2020YJKY01), and a hospital-level project
   by Shanghai Public Health Clinical Center (KY-GW-201818) and the
   National Science and Technology Major Project of China (2018ZX10302206).
CR Bajema KL, 2020, MMWR-MORBID MORTAL W, V69, P166, DOI 10.15585/mmwr.mm6906e1
   Chai X, 2020, SPECIFIC ACE2 EXPRES
   Chen J, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.004
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Fan Z, 2020, CLIN FEATURES COVID
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M., 2020, NOVEL CORONAVIRUS 20
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang Y GZ, 2003, J CLIN HEPATOL, V2003, P2
   Kupferschmidt K, 2013, SCIENCE, V341, P702, DOI 10.1126/science.341.6147.702
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Liu Z GJ, 2003, J CLIN HEPATOL, V2003, P3
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Y, 2020, J HEPATOL
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu L, 2020, LIVER INT, V40, P998, DOI 10.1111/liv.14435
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang Zhang, 2005, Hepatobiliary Pancreat Dis Int, V4, P60
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 21
TC 0
Z9 0
U1 7
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD OCT 15
PY 2020
VL 12
IS 19
BP 18844
EP 18852
DI 10.18632/aging.103860
PG 9
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA OF3EF
UT WOS:000581094800008
PM 33001040
OA Green Published
DA 2021-01-01
ER

PT J
AU Zheng, KL
   Xu, Y
   Guo, YF
   Diao, L
   Kong, XY
   Wan, XJ
   Zhao, F
   Ning, FZ
   Wang, LB
   Qiao, F
   Zhao, JM
   Zhou, JH
   Zhong, YQ
   Wu, SX
   Chen, Y
   Jin, G
   Dong, YC
AF Zheng, Kai-Lian
   Xu, Ying
   Guo, Yu-Feng
   Diao, Le
   Kong, Xiang-Yu
   Wan, Xiao-Jian
   Zhao, Feng
   Ning, Fang-Zheng
   Wang, Li-Bing
   Qiao, Fan
   Zhao, Jiang-Man
   Zhou, Jia-Huan
   Zhong, Yue-Qian
   Wu, Shou-Xin
   Chen, Yi
   Jin, Gang
   Dong, Yu-Chao
TI Efficacy and safety of tocilizumab in COVID-19 patients
SO AGING-US
LA English
DT Article
DE COVID-19; SARS-CoV-2; tocilizumab; interleukin-6; C-reactive protein
ID RESPIRATORY SYNDROME CORONAVIRUS; C-REACTIVE PROTEIN;
   RHEUMATOID-ARTHRITIS; RECEPTOR ANTIBODY; DOUBLE-BLIND; CYTOKINES;
   INTERLEUKIN-6; PATHOGENESIS; IL-6
AB In this retrospective study we assessed the efficacy and safety of tocilizumab in patients with critical or severe coronavirus disease 2019 (COVID-19). We enrolled 181 patients admitted to Huoshenshan Hospital (Wuhan, China) with confirmed COVID-19 between January 2020 and February 2020. Ninety-two patients were treated with tocilizumab, and 89 patients were treated conventionally. We analyzed the clinical manifestations, changes in CT scan images, and laboratory tests before and after tocilizumab treatment, and compared these results with the conventionally treated group. A significant reduction in the level of C-reactive protein was observed 1 week after tocilizumab administration. In some cases this meant the end of the IL-6-related cytokine storm. In addition, tocilizumab relieved fever, cough, and shortness of breath with no reported adverse drug reactions. These findings suggest tocilizumab improves clinical outcomes and is effective for treatment of patients with critical or severe COVID-19. However, future clinical trials are needed to better understand the impact of tocilizumab interference with IL-6 and provide a therapeutic strategy for treatment of COVID-19.
C1 [Zheng, Kai-Lian; Ning, Fang-Zheng; Jin, Gang] Naval Med Univ, Changhai Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.
   [Zheng, Kai-Lian; Guo, Yu-Feng; Kong, Xiang-Yu; Wan, Xiao-Jian; Zhao, Feng; Wang, Li-Bing; Qiao, Fan; Chen, Yi; Dong, Yu-Chao] Huoshenshan Hosp, Wuhan 430100, Hubei, Peoples R China.
   [Xu, Ying] Hankou Hosp, Dept Gastroenterol, Wuhan 430000, Hubei, Peoples R China.
   [Guo, Yu-Feng] Naval Med Univ, Off Med Educ, Shanghai 200433, Peoples R China.
   [Diao, Le; Zhao, Jiang-Man; Zhou, Jia-Huan; Zhong, Yue-Qian; Wu, Shou-Xin] Shanghai Biotecan Pharmaceut Co Ltd, Shanghai Zhangjiang Inst Med Innovat, Shanghai 201204, Peoples R China.
   [Kong, Xiang-Yu] Naval Med Univ, Changhai Hosp, Dept Gastroenterol, Shanghai 200433, Peoples R China.
   [Wan, Xiao-Jian] Naval Med Univ, Changhai Hosp, Fac Anesthesiol, Shanghai 200433, Peoples R China.
   [Zhao, Feng] Naval Med Univ, Changhai Hosp, Dept Cardiovasc Med, Shanghai 200433, Peoples R China.
   [Wang, Li-Bing] Naval Med Univ, Changhai Hosp, Dept Hematol, Shanghai 200433, Peoples R China.
   [Qiao, Fan] Naval Med Univ, Changhai Hosp, Dept Cardiac Surg, Shanghai 200433, Peoples R China.
   [Chen, Yi] Naval Med Univ, Changhai Hosp, Dept Infect Dis, Shanghai 200433, Peoples R China.
   [Dong, Yu-Chao] Naval Med Univ, Changhai Hosp, Resp & Crit Care Med Dept, Shanghai 200433, Peoples R China.
RP Jin, G (corresponding author), Naval Med Univ, Changhai Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.; Chen, Y; Dong, YC (corresponding author), Huoshenshan Hosp, Wuhan 430100, Hubei, Peoples R China.; Chen, Y (corresponding author), Naval Med Univ, Changhai Hosp, Dept Infect Dis, Shanghai 200433, Peoples R China.; Dong, YC (corresponding author), Naval Med Univ, Changhai Hosp, Resp & Crit Care Med Dept, Shanghai 200433, Peoples R China.
EM cheny7805@163.com; jingang@sohu.com; dongyuchao2020@163.com
FU Shanghai Natural Science FoundationNatural Science Foundation of
   Shanghai [19ZR1455800]
FX This work was supported by Shanghai Natural Science Foundation [Grant
   No.19ZR1455800].
CR Ansar W, 2013, IMMUNOL RES, V56, P131, DOI 10.1007/s12026-013-8384-0
   Bennardo F, 2020, ORAL ONCOL, V106, DOI 10.1016/j.oraloncology.2020.104659
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Gabay C, 2013, LANCET, V381, P1541, DOI 10.1016/S0140-6736(13)60250-0
   Gu YN, 2019, VIRAL IMMUNOL, V32, P244, DOI 10.1089/vim.2019.0032
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Hahn WH, 2018, J MATERN-FETAL NEO M, V31, P822, DOI 10.1080/14767058.2017.1297410
   Han H, 2020, EMERG MICROBES INFEC, V9, P1123, DOI 10.1080/22221751.2020.1770129
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kaly L, 2012, BEST PRACT RES CL RH, V26, P157, DOI 10.1016/j.berh.2012.01.001
   Korniluk A, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/9213074
   Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0
   Li Y, 2013, MICROBES INFECT, V15, P88, DOI 10.1016/j.micinf.2012.10.008
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Liu F, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104370
   Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Mooiweer E, 2011, J INFECTION, V62, P314, DOI 10.1016/j.jinf.2011.01.012
   NHC, 2020, CHIN MAN GUID COVID
   Nishimoto N, 2000, ANN RHEUM DIS, V59, P21, DOI 10.1136/ard.59.suppl_1.i21
   Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Scheller J, 2006, MED MICROBIOL IMMUN, V195, P173, DOI 10.1007/s00430-006-0019-9
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tamer F, 2019, ACTA DERMATOVEN ALP, V28, P65, DOI 10.15570/actaapa.2019.17
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang XE, 2015, PLATELETS, V26, P67, DOI 10.3109/09537104.2013.875137
   WHO, REP WHO CHIN JOINT M
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yokota S, 2008, LANCET, V371, P998, DOI 10.1016/S0140-6736(08)60454-7
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 39
TC 0
Z9 0
U1 4
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD OCT 15
PY 2020
VL 12
IS 19
BP 18878
EP 18888
DI 10.18632/aging.103988
PG 11
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA OF3EF
UT WOS:000581094800011
PM 33031060
OA Green Published
DA 2021-01-01
ER

PT J
AU Peng, Y
   Du, N
   Lei, YQ
   Dorje, S
   Qi, JX
   Luo, TR
   Gao, GF
   Song, H
AF Peng, Ya
   Du, Ning
   Lei, Yuqing
   Dorje, Sonam
   Qi, Jianxun
   Luo, Tingrong
   Gao, George F.
   Song, Hao
TI Structures of theSARS-CoV-2 nucleocapsid and their perspectives for drug
   design
SO EMBO JOURNAL
LA English
DT Article
DE 2019-nCoV; antivirals; dimerization; nucleocapsid; RNAbinding
ID RESPIRATORY SYNDROME-CORONAVIRUS; N-TERMINAL DOMAIN; CRYSTAL-STRUCTURE;
   PROTEIN; IDENTIFICATION; DIFFRACTION; ANTIBODIES; OUTBREAK; MODEL
AB COVID-19, caused bySARS-CoV-2, has resulted in severe and unprecedented economic and social disruptions in the world. Nucleocapsid (N) protein, which is the major structural component of the virion and is involved in viral replication, assembly and immune regulation, plays key roles in the viral life cycle. Here, we solved the crystal structures of the N- and C-terminal domains (N-NTDand N-CTD) ofSARS-CoV-2 N protein, at 1.8 and 1.5 angstrom resolution, respectively. Both structures show conserved features from other CoV N proteins. The binding sites targeted by small molecules againstHCoV-OC43 andMERS-CoV, which inhibit viral infection by blocking theRNA-binding activity or normal oligomerization of N protein, are relatively conserved in our structure, indicating N protein is a promising drug target. In addition, certain areas of N-NTDand N-CTDdisplay distinct charge distribution patterns inSARS-CoV-2, which may alter theRNA-binding modes. The specific antigenic characteristics are critical for developing specific immune-based rapid diagnostic tests. Our structural information can aid in the discovery and development of antiviral inhibitors againstSARS-CoV-2 in the future.
C1 [Peng, Ya; Luo, Tingrong] Guangxi Univ, Coll Anim Sci & Vet Med, Lab Anim Infect Dis, Nanning, Peoples R China.
   [Peng, Ya; Lei, Yuqing; Dorje, Sonam; Qi, Jianxun; Gao, George F.] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.
   [Du, Ning; Gao, George F.; Song, Hao] Chinese Acad Sci, Beijing Inst Life Sci, Res Network Immun & Hlth RNIH, Beijing, Peoples R China.
   [Lei, Yuqing; Dorje, Sonam; Qi, Jianxun; Gao, George F.] Univ Chinese Acad Sci, Beijing, Peoples R China.
RP Gao, GF (corresponding author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.; Gao, GF; Song, H (corresponding author), Chinese Acad Sci, Beijing Inst Life Sci, Res Network Immun & Hlth RNIH, Beijing, Peoples R China.; Gao, GF (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.
EM gaof@im.ac.cn; songhao@im.ac.cn
OI Dorje, Sonam/0000-0002-1885-3007; Reis, AlessanRSS/0000-0001-8486-7469
FU Ministry of Science and Technology of the People's Republic of
   ChinaMinistry of Science and Technology, China [2020YFC0845900];
   National Science and Technology Major Project [2018ZX10733403]; National
   Natural Science Foundation of China (NSFC)National Natural Science
   Foundation of China (NSFC) [81702015]; Youth Innovation Promotion
   Association CAS [2017117]; COVID-19 Emergency Project of CAS; External
   Cooperation Program of CAS [153211KYSB20160001]
FX We thank the staff of BL19U1 beamlines at Shanghai Synchrotron Radiation
   Facility. We thank Qian Wang (Institute of Microbiology CAS) for help
   with analytical ultracentrifugation experiment. This work was supported
   by the Ministry of Science and Technology of the People's Republic of
   China (2020YFC0845900), the National Science and Technology Major
   Project (2018ZX10733403), and the National Natural Science Foundation of
   China (NSFC) (81702015). H.S. is supported by the Youth Innovation
   Promotion Association CAS (2017117). G.F.G. is supported partly by the
   COVID-19 Emergency Project of CAS and the External Cooperation Program
   of CAS (153211KYSB20160001).
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408
   Barcena M, 2009, P NATL ACAD SCI USA, V106, P582, DOI 10.1073/pnas.0805270106
   Beigel J. H., 2020, N ENGL J MED
   Burbelo PD, 2020, J INFECT DIS, V222, P206, DOI 10.1093/infdis/jiaa273
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cavalcanti AB, 2020, N ENGL J MED
   Chang CK, 2016, MOL BIOSYST, V12, P59, DOI 10.1039/c5mb00582e
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Che XY, 2004, J CLIN MICROBIOL, V42, P2629, DOI 10.1128/JCM.42.6.2629-2635.2004
   Chen CY, 2007, J MOL BIOL, V368, P1075, DOI 10.1016/j.jmb.2007.02.069
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   Cong YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06062-w
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gui M, 2017, PROTEIN CELL, V8, P219, DOI 10.1007/s13238-016-0352-8
   Hoffmann M, 2020, NATURE, V585, P588, DOI 10.1038/s41586-020-2575-3
   Horber S, 2020, CLIN CHEM LAB MED, DOI 10.1515/cclm-2020-0975
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Klein S, 2020, BIORXIV, DOI 10.1101/2020.06.23.167064
   Li CY, 2019, MBIO, V10, DOI 10.1128/mBio.02483-19
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lin SM, 2020, J MED CHEM, V63, P3131, DOI 10.1021/acs.jmedchem.9b01913
   Lin SY, 2014, J MED CHEM, V57, P2247, DOI 10.1021/jm500089r
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lu XL, 2011, VIRUS GENES, V42, P37, DOI 10.1007/s11262-010-0544-x
   Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4
   Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949
   Mu JF, 2020, SCI CHINA LIFE SCI, DOI 10.1007/s11427-020-1692-1
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   Neuman BW, 2006, J VIROL, V80, P7918, DOI 10.1128/JVI.00645-06
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Papageorgiou N, 2016, ACTA CRYSTALLOGR D, V72, P192, DOI 10.1107/S2059798315024328
   Peng TY, 2008, FEBS J, V275, P4152, DOI 10.1111/j.1742-4658.2008.06564.x
   Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471
   Saikatendu KS, 2007, J VIROL, V81, P3913, DOI 10.1128/JVI.02236-06
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Surjit M, 2006, J BIOL CHEM, V281, P10669, DOI 10.1074/jbc.M509233200
   Surjit M, 2004, BIOCHEM J, V383, P13, DOI 10.1042/BJ20040984
   Szelazek B, 2017, J VIROL, V91, DOI 10.1128/JVI.02503-16
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Nguyen THV, 2019, ACTA CRYSTALLOGR D, V75, P8, DOI 10.1107/S2059798318014948
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang HY, 2017, SCI CHINA LIFE SCI, V60, P1403, DOI 10.1007/s11427-017-9238-8
   Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Wu YL, 2020, CELL HOST MICROBE, V27, P891, DOI 10.1016/j.chom.2020.04.023
   Xiang F, 2020, CLIN INFECT DIS, DOI 10.1093/cid/ciaa461
   Ye QZ, 2020, PROTEIN SCI, V29, P1890, DOI 10.1002/pro.3909
   Yu IM, 2006, J BIOL CHEM, V281, P17134, DOI 10.1074/jbc.M602107200
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang XN, 2020, NATURE, V583, P437, DOI 10.1038/s41586-020-2355-0
   Zhou H, 2020, CURR BIOL, V30, P2196, DOI 10.1016/j.cub.2020.05.023
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zuniga S, 2010, J VIROL, V84, P2169, DOI 10.1128/JVI.02011-09
NR 60
TC 0
Z9 0
U1 15
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD OCT 15
PY 2020
VL 39
IS 20
AR e105938
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA OH3OI
UT WOS:000582478100012
PM 32914439
DA 2021-01-01
ER

PT J
AU Xie, XP
   Muruato, AE
   Zhang, XW
   Lokugamage, KG
   Fontes-Garfias, CR
   Zou, J
   Liu, JY
   Ren, P
   Balakrishnan, M
   Cihlar, T
   Tseng, CTK
   Makino, S
   Menachery, VD
   Bilello, JP
   Shi, PY
AF Xie, Xuping
   Muruato, Antonio E.
   Zhang, Xianwen
   Lokugamage, Kumari G.
   Fontes-Garfias, Camila R.
   Zou, Jing
   Liu, Jianying
   Ren, Ping
   Balakrishnan, Mini
   Cihlar, Tomas
   Tseng, Chien-Te K.
   Makino, Shinji
   Menachery, Vineet D.
   Bilello, John P.
   Shi, Pei-Yong
TI A nanoluciferase SARS-CoV-2 for rapid neutralization testing and
   screening of anti-infective drugs for COVID-19
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ANTIVIRAL ACTIVITY; NONNUCLEOSIDE INHIBITOR; PHOSPHORAMIDATE PRODRUG;
   TENOFOVIR ALAFENAMIDE; 10-DAY MONOTHERAPY; INFECTIOUS CDNA; NAIVE
   PATIENTS; DOUBLE-BLIND; IN-VITRO; VIRUS
AB A high-throughput platform would greatly facilitate coronavirus disease 2019 (COVID-19) serological testing and antiviral screening. Here we present a high-throughput nanoluciferase severe respiratory syndrome coronavirus 2 (SARS-CoV-2-Nluc) that is genetically stable and replicates similarly to the wild-type virus in cell culture. SARS-CoV-2-Nluc can be used to measure neutralizing antibody activity in patient sera within 5hours, and it produces results in concordance with a plaque reduction neutralization test (PRNT). Additionally, using SARS-CoV-2-Nluc infection of A549 cells expressing human ACE2 receptor (A549-hACE2), we show that the assay can be used for antiviral screening. Using the optimized SARS-CoV-2-Nluc assay, we evaluate a panel of antivirals and other anti-infective drugs, and we identify nelfinavir, rupintrivir, and cobicistat as the most selective inhibitors of SARS-CoV-2-Nluc (EC50 0.77 to 2.74 mu M). In contrast, most of the clinically approved antivirals, including tenofovir alafenamide, emtricitabine, sofosbuvir, ledipasvir, and velpatasvir were inactive at concentrations up to 10 mu M. Collectively, this high-throughput platform represents a reliable tool for rapid neutralization testing and antiviral screening for SARS-CoV-2.
C1 [Xie, Xuping; Muruato, Antonio E.; Zhang, Xianwen; Fontes-Garfias, Camila R.; Zou, Jing; Shi, Pei-Yong] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
   [Muruato, Antonio E.; Lokugamage, Kumari G.; Liu, Jianying; Tseng, Chien-Te K.; Makino, Shinji; Menachery, Vineet D.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
   [Ren, Ping; Menachery, Vineet D.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Balakrishnan, Mini; Cihlar, Tomas; Bilello, John P.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA.
   [Menachery, Vineet D.; Shi, Pei-Yong] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.
   [Shi, Pei-Yong] Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX 77555 USA.
   [Shi, Pei-Yong] Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA.
RP Xie, XP; Shi, PY (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.; Bilello, JP (corresponding author), Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX 77555 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA.
EM xuxie@UTMB.edu; john.bilello@gilead.com; peshi@UTMB.edu
FU Clinical and Translational Science Award NRSA (TL1) Training Core from
   NIH [TL1TR001440]; McLaughlin Fellowship Endowment at UTMB; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [AI114657, AI146081, U19AI100625, R00AG049092,
   R24AI120942, AI142759, AI134907, AI145617, UL1TR001439]; STARs Award
   from the University of Texas System; Sealy & Smith Foundation; Kleberg
   Foundation; John S. Dunn Foundation; Amon G. Carter Foundation; Gilson
   Longenbaugh Foundation; Summerfield Robert Foundation
FX We also thank colleagues at UTMB for support and discussions. A.E.M. is
   supported by a Clinical and Translational Science Award NRSA (TL1)
   Training Core (TL1TR001440) from NIH. C.R.F.-G. is supported by the
   predoctoral fellowship from the McLaughlin Fellowship Endowment at UTMB.
   S.M. was supported by NIH grants AI114657 and AI146081. V.D.M. was
   supported by NIH grants U19AI100625, R00AG049092, R24AI120942, and STARs
   Award from the University of Texas System. P.-Y.S. was supported by NIH
   grants AI142759, AI134907, AI145617, and UL1TR001439, and awards from
   the Sealy & Smith Foundation, Kleberg Foundation, John S. Dunn
   Foundation, Amon G. Carter Foundation, Gilson Longenbaugh Foundation,
   and Summerfield Robert Foundation.
CR Adkins JC, 1998, DRUGS, V56, P1055, DOI 10.2165/00003495-199856060-00014
   Almazan F, 2014, VIRUS RES, V189, P262, DOI 10.1016/j.virusres.2014.05.026
   Amanat Fatima, 2020, Curr Protoc Microbiol, V58, pe108, DOI 10.1002/cpmc.108
   Anderson PL, 2000, AIDS, V14, P2293, DOI 10.1097/00002030-200010200-00010
   Bardsley-Elliot A, 2000, DRUGS, V59, P581, DOI 10.2165/00003495-200059030-00014
   Bond DA, 2019, CURR HEMATOL MALIG R, V14, P197, DOI 10.1007/s11899-019-00512-0
   Carroll SS, 2009, ANTIMICROB AGENTS CH, V53, P926, DOI 10.1128/AAC.01032-08
   Chien Minchen, 2020, bioRxiv, DOI 10.1101/2020.03.18.997585
   Cho A, 2014, J MED CHEM, V57, P1812, DOI 10.1021/jm400201a
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Copertino D.C., 2020, ANTIRETROVIRAL DRUG, DOI [10.26434/chemrxiv.12250199.v1, DOI 10.26434/CHEMRXIV.12250199.V1]
   Custodio JM, 2016, ANTIMICROB AGENTS CH, V60, P5135, DOI 10.1128/AAC.00005-16
   De Clercq E, 2003, CLIN MICROBIOL REV, V16, P569, DOI 10.1128/CMR.16.4.569-596.2003
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Deval J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004995
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Eron JJ, 2004, J INFECT DIS, V189, P265, DOI 10.1086/380799
   Gallant JE, 2017, JAIDS-J ACQ IMM DEF, V75, P61, DOI [10.1097/QAI.0000000000001306, 10.1097/qai.0000000000001306]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Gillenwater S, 2020, NEW ENGL J MED, V383, P992, DOI 10.1056/NEJMc2022236
   Goebel F, 2006, AIDS, V20, P1721, DOI 10.1097/01.aids.0000242818.65215.bd
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Hayden FG, 2003, ANTIMICROB AGENTS CH, V47, P3907, DOI 10.1128/AAC.47.12.3907-3916.2003
   HOU YJ, 2020, CELL, V182, P1
   Izzi A, 2020, Eur Rev Med Pharmacol Sci, V24, P5193, DOI 10.26355/eurrev_202005_21297
   Jacome R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66440-9
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Kawatkar SP, 2016, BIOORG MED CHEM LETT, V26, P3248, DOI 10.1016/j.bmcl.2016.05.066
   Langley DR, 2007, J VIROL, V81, P3992, DOI 10.1128/JVI.02395-06
   Lazerwith SE, 2014, J MED CHEM, V57, P1893, DOI 10.1021/jm401420j
   Lea AP, 1996, DRUGS, V52, P541, DOI 10.2165/00003495-199652040-00007
   Link JO, 2019, BIOORG MED CHEM LETT, V29, P2415, DOI 10.1016/j.bmcl.2019.04.027
   Link JO, 2014, J MED CHEM, V57, P2033, DOI 10.1021/jm401499g
   Liu J, 2012, NUCLEOS NUCLEOT NUCL, V31, P277, DOI 10.1080/15257770.2012.658131
   MacGregor TR, 2004, HIV CLIN TRIALS, V5, P371, DOI 10.1310/RRX7-49ME-27V7-MWWV
   Marty Francisco M, 2019, Clin Infect Dis, DOI 10.1093/cid/ciz1167
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Molla A, 1998, VIROLOGY, V250, P255, DOI 10.1006/viro.1998.9383
   Mossel EC, 2005, J VIROL, V79, P3846, DOI 10.1128/JVI.79.6.3846-3850.2005
   Muruato AE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17892-0
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Noshi T, 2018, ANTIVIR RES, V160, P109, DOI 10.1016/j.antiviral.2018.10.008
   Patick AK, 1999, ANTIMICROB AGENTS CH, V43, P2444, DOI 10.1128/AAC.43.10.2444
   Perron M, 2016, ANTIMICROB AGENTS CH, V60, P1264, DOI 10.1128/AAC.01497-15
   Pruijssers AJ, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107940
   Puig-Basagoiti F, 2005, ANTIMICROB AGENTS CH, V49, P4980, DOI 10.1128/AAC.49.12.4980-4988.2005
   Ratziu V, 2012, HEPATOLOGY, V55, P419, DOI 10.1002/hep.24747
   Ray AS, 2008, ANTIMICROB AGENTS CH, V52, P648, DOI 10.1128/AAC.01209-07
   Roberts RS, 2006, ADV EXP MED BIOL, V581, P597
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Ruane PJ, 2013, JAIDS-J ACQ IMM DEF, V63, P449, DOI 10.1097/QAI.0b013e3182965d45
   Saag MS, 2004, JAMA-J AM MED ASSOC, V292, P180, DOI 10.1001/jama.292.2.180
   Sadler BM, 2002, ANN PHARMACOTHER, V36, P102
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Shan C, 2016, CELL HOST MICROBE, V19, P891, DOI 10.1016/j.chom.2016.05.004
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Sheng XC, 2012, BIOORG MED CHEM LETT, V22, P1394, DOI 10.1016/j.bmcl.2011.12.038
   Shih IH, 2011, ANTIMICROB AGENTS CH, V55, P4196, DOI 10.1128/AAC.00307-11
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Singh K, 2008, CLIN PHARMACOL THER, V83, P867, DOI 10.1038/sj.clpt.6100375
   Sofia Michael J., 2011, Antiviral Chemistry & Chemotherapy, V22, P23, DOI 10.3851/IMP1797
   Stein DS, 1996, AIDS, V10, P485, DOI 10.1097/00002030-199605000-00006
   Surleraux DLNG, 2005, J MED CHEM, V48, P1813, DOI 10.1021/jm049560p
   Takahashi Kazumi, 2003, Antiviral Chemistry & Chemotherapy, V14, P235
   Takano T, 2013, ANTIVIR RES, V99, P100, DOI 10.1016/j.antiviral.2013.04.016
   Taylor JG, 2019, BIOORG MED CHEM LETT, V29, P2428, DOI 10.1016/j.bmcl.2019.03.037
   Vanderlinden E, 2016, ANTIMICROB AGENTS CH, V60, P6679, DOI 10.1128/AAC.01156-16
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
   Xu LH, 2010, ACS MED CHEM LETT, V1, P209, DOI 10.1021/ml1000257
   Yang HL, 2014, ANTIMICROB AGENTS CH, V58, P647, DOI 10.1128/AAC.00487-13
   Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu L, 2012, J ANTIMICROB CHEMOTH, V67, P465, DOI 10.1093/jac/dkr490
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou G, 2011, ANTIVIR RES, V91, P11, DOI 10.1016/j.antiviral.2011.05.001
NR 81
TC 1
Z9 1
U1 2
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 15
PY 2020
VL 11
IS 1
AR 5214
DI 10.1038/s41467-020-19055-7
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OH6EH
UT WOS:000582681400026
PM 33060595
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gaeckle, NT
   Lee, J
   Park, Y
   Kreykes, G
   Evans, MD
   Hogan, CJ
AF Gaeckle, Nathaniel T.
   Lee, Jihyeon
   Park, Yensil
   Kreykes, Gean
   Evans, Michael D.
   Hogan, Christopher J., Jr.
TI Aerosol Generation from the Respiratory Tract with Various Modes of
   Oxygen Delivery
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE SARS-CoV-2; droplet; particle
ID SIZE DISTRIBUTION; PARTICLES; QUANTITY
AB Rationale: Aerosol generation with modes of oxygen therapy such as high-flow nasal cannula and noninvasive positive-pressure ventilation is a concern for healthcare workers during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The amount of aerosol generation from the respiratory tract with these various oxygen modalities is unknown.
   Objectives: To measure the size and number concentration of particles and droplets generated from the respiratory tract of humans exposed to various oxygen delivery modalities.
   Methods: Ten healthy participants with no active pulmonary disease were enrolled. Oxygen modalities tested included nonhumidified nasal cannula, face mask, heated and humidified high-flow nasal cannula, and noninvasive positive-pressure ventilation. Aerosol generation was measured with each oxygen mode while participants performed maneuvers of normal breathing, talking, deep breathing, and coughing. Testing was conducted in a negative-pressure room. Particles with a diameter between 0.37 and 20 mu m were measured using an aerodynamic particle spectrometer.
   Measurements and Main Results: Median particle concentration ranged from 0.041 to 0.168 particles/cm(3). Median diameter ranged from 1.01 to 1.53 mu m. Cough significantly increased the number of particles measured. Measured aerosol concentration did not significantly increase with the use of either humidified high-flow nasal cannula or noninvasive positive-pressure ventilation. This was the case during normal breathing, talking, deep breathing, and coughing.
   Conclusions: Oxygen delivery modalities of humidified high-flow nasal cannula and noninvasive positive-pressure ventilation do not increase aerosol generation from the respiratory tract in healthy human participants with no active pulmonary disease measured in a negative-pressure room.
C1 [Gaeckle, Nathaniel T.] Univ Minnesota, Dept Med, Div Pulm Allergy Crit Care & Sleep, Box 736 UMHC, Minneapolis, MN 55455 USA.
   [Lee, Jihyeon; Park, Yensil; Hogan, Christopher J., Jr.] Univ Minnesota, Dept Mech Engn, 111 Church St SE, Minneapolis, MN 55455 USA.
   [Evans, Michael D.] Univ Minnesota, Clin & Translat Sci Inst, Minneapolis, MN USA.
   [Kreykes, Gean] M Hlth Fairview, Dept Resp Care, Minneapolis, MN USA.
RP Gaeckle, NT (corresponding author), Dept Med, Div Pulm Allergy Crit Care & Sleep, 350 Variety Club Res Ctr,MMC 276, Minneapolis, MN 55455 USA.
EM gaeckle@umn.edu
RI ; Hogan, Christopher/E-6509-2010
OI Evans, Michael/0000-0001-7449-3993; Gaeckle,
   Nathaniel/0000-0002-4200-8110; Hogan, Christopher/0000-0001-7655-4980
FU Office of Academic and Clinical Affairs at the University of Minnesota;
   NIH's National Center for Advancing Translational Sciences [UL1TR002494]
FX Supported by a rapid COVID grant from the Office of Academic and
   Clinical Affairs at the University of Minnesota (N.T.G.) and by the
   NIH's National Center for Advancing Translational Sciences, grant
   UL1TR002494 (M.D.E.). The content is solely the responsibility of the
   author and does not necessarily represent the official views of the
   NIH's National Center for Advancing Translational Sciences.
CR Asadi S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227699
   Asadi S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38808-z
   Dhand R, 2020, AM J RESP CRIT CARE, V202, P651, DOI 10.1164/rccm.202004-1263PP
   Feng Y, 2020, J AEROSOL SCI, V147, DOI 10.1016/j.jaerosci.2020.105585
   Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108
   Hersen G, 2008, CLEAN-SOIL AIR WATER, V36, P572, DOI 10.1002/clen.200700189
   Hui D S C, 2014, Hong Kong Med J, V20 Suppl 4, P9
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Johnson GR, 2011, J AEROSOL SCI, V42, P839, DOI 10.1016/j.jaerosci.2011.07.009
   Johnson GR, 2009, J AEROSOL MED PULM D, V22, P229, DOI 10.1089/jamp.2008.0720
   Kainu A, 2018, SCAND J CLIN LAB INV, V78, P245, DOI 10.1080/00365513.2018.1439185
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Kotoda M, 2020, J HOSP INFECT, V104, P534, DOI 10.1016/j.jhin.2019.11.010
   Lee J, 2019, AEROSOL AIR QUAL RES, V19, P840, DOI 10.4209/aaqr.2018.01.0031
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Li J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00892-2020
   Lindsley WG, 2012, J OCCUP ENVIRON HYG, V9, P443, DOI 10.1080/15459624.2012.684582
   Liu Y, 2020, NATURE, V582, P557, DOI 10.1038/s41586-020-2271-3
   Loh NHW, 2020, CAN J ANESTH, V67, P893, DOI 10.1007/s12630-020-01634-3
   Morawska L, 1998, INDOOR AIR, V8, P285, DOI 10.1111/j.1600-0668.1998.00009.x
   Morawska L, 2009, J AEROSOL SCI, V40, P256, DOI 10.1016/j.jaerosci.2008.11.002
   Papineni RS, 1996, J AEROSOL MED, V10, P105, DOI 10.1089/jam.1997.10.105
   Schwarz K, 2010, J AEROSOL MED PULM D, V23, P371, DOI 10.1089/jamp.2009.0809
   Volckens J, 2005, J AEROSOL SCI, V36, P1400, DOI 10.1016/j.jaerosci.2005.03.009
   Wilson NM, 2020, ANAESTHESIA, V75, P1086, DOI 10.1111/anae.15093
   Wurie Fatima, 2013, F1000Res, V2, P14, DOI 10.12688/f1000research.2-14.v1
   Yang SH, 2007, J AEROSOL MED, V20, P484, DOI 10.1089/jam.2007.0610
   Yu IT, 2007, CLIN INFECT DIS, V44, P1017, DOI 10.1086/512819
NR 28
TC 3
Z9 3
U1 2
U2 2
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD OCT 15
PY 2020
VL 202
IS 8
BP 1115
EP 1124
DI 10.1164/rccm.202006-2309OC
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA OH1TT
UT WOS:000582354600013
PM 32822208
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gamberini, L
   Tonetti, T
   Spadaro, S
   Zani, G
   Mazzoli, CA
   Capozzi, C
   Giampalma, E
   Reggiani, MLB
   Bertellini, E
   Castelli, A
   Cavalli, I
   Colombo, D
   Crimaldi, F
   Damiani, F
   Fogagnolo, A
   Fusari, M
   Gamberini, E
   Gordini, G
   Laici, C
   Lanza, MC
   Leo, M
   Marudi, A
   Nardi, G
   Ottaviani, I
   Papa, R
   Potalivo, A
   Russo, E
   Taddei, S
   Volta, CA
   Ranieri, VM
AF Gamberini, Lorenzo
   Tonetti, Tommaso
   Spadaro, Savino
   Zani, Gianluca
   Mazzoli, Carlo Alberto
   Capozzi, Chiara
   Giampalma, Emanuela
   Bacchi Reggiani, Maria Letizia
   Bertellini, Elisabetta
   Castelli, Andrea
   Cavalli, Irene
   Colombo, Davide
   Crimaldi, Federico
   Damiani, Federica
   Fogagnolo, Alberto
   Fusari, Maurizio
   Gamberini, Emiliano
   Gordini, Giovanni
   Laici, Cristiana
   Lanza, Maria Concetta
   Leo, Mirco
   Marudi, Andrea
   Nardi, Giuseppe
   Ottaviani, Irene
   Papa, Raffaella
   Potalivo, Antonella
   Russo, Emanuele
   Taddei, Stefania
   Volta, Carlo Alberto
   Ranieri, V. Marco
CA ICU-RER COVID-19 Collaboration
TI Factors influencing liberation from mechanical ventilation in
   coronavirus disease 2019: multicenter observational study in fifteen
   Italian ICUs
SO JOURNAL OF INTENSIVE CARE
LA English
DT Article
DE Coronavirus disease 2019; Intensive care; Mechanical ventilation;
   Outcomes; mortality; Respiration; artificial; ARDS
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE KIDNEY INJURY; COVID-19;
   EPIDEMIOLOGY; CARE; PREVENTION; MORTALITY
AB Background: A large proportion of patients with coronavirus disease 2019 (COVID-19) develop severe respiratory failure requiring admission to the intensive care unit (ICU) and about 80% of them need mechanical ventilation (MV). These patients show great complexity due to multiple organ involvement and a dynamic evolution over time; moreover, few information is available about the risk factors that may contribute to increase the time course of mechanical ventilation.
   The primary objective of this study is to investigate the risk factors associated with the inability to liberate COVID-19 patients from mechanical ventilation. Due to the complex evolution of the disease, we analyzed both pulmonary variables and occurrence of non-pulmonary complications during mechanical ventilation. The secondary objective of this study was the evaluation of risk factors for ICU mortality.
   Methods: This multicenter prospective observational study enrolled 391 patients from fifteen COVID-19 dedicated Italian ICUs which underwent invasive mechanical ventilation for COVID-19 pneumonia. Clinical and laboratory data, ventilator parameters, occurrence of organ dysfunction, and outcome were recorded. The primary outcome measure was 28 days ventilator-free days and the liberation from MV at 28 days was studied by performing a competing risks regression model on data, according to the method of Fine and Gray; the event death was considered as a competing risk.
   Results: Liberation from mechanical ventilation was achieved in 53.2% of the patients (208/391). Competing risks analysis, considering death as a competing event, demonstrated a decreased sub-hazard ratio for liberation from mechanical ventilation (MV) with increasing age and SOFA score at ICU admission, low values of PaO2/FiO(2)ratio during the first 5 days of MV, respiratory system compliance (C-RS) lower than 40 mL/cmH(2)O during the first 5 days of MV, need for renal replacement therapy (RRT), late-onset ventilator-associated pneumonia (VAP), and cardiovascular complications.
   ICU mortality during the observation period was 36.1% (141/391). Similar results were obtained by the multivariate logistic regression analysis using mortality as a dependent variable.
   Conclusions: Age, SOFA score at ICU admission, C-RS, PaO2/FiO(2), renal and cardiovascular complications, and late-onset VAP were all independent risk factors for prolonged mechanical ventilation in patients with COVID-19.
C1 [Gamberini, Lorenzo; Mazzoli, Carlo Alberto; Gordini, Giovanni] Osped Maggiore Carlo Alberto Pizzardi, Dept Anaesthesia Intens Care & Prehosp Emergency, Bologna, Italy.
   [Tonetti, Tommaso; Cavalli, Irene; Ranieri, V. Marco] Univ Bologna, Alma Mater Studiorum, Dipartimento Sci Med & Chirurg Anesthesia & Inten, Policlin St Orsola, Bologna, Italy.
   [Spadaro, Savino; Fogagnolo, Alberto; Ottaviani, Irene; Volta, Carlo Alberto] Univ Ferrara, Azienda Osped Univ S Anna, Dept Morphol Surg & Expt Med, Sect Anaesthesia & Intens Care, Via Aldo Moro,8, I-44121 Ferrara, Cona, Italy.
   [Zani, Gianluca; Fusari, Maurizio] Santa Maria Croci Hosp, Dept Anesthesia & Intens Care, Ravenna, Italy.
   [Capozzi, Chiara; Castelli, Andrea] Univ Bologna, S Orsola Hosp, Cardioanesthesiol Unit, Cardiothorac Vasc Dept, Bologna, Italy.
   [Giampalma, Emanuela] Osped Gen Provinciale M Bufalini, Radiol Dept, Cesena, Italy.
   [Bacchi Reggiani, Maria Letizia] Alma Mater Univ, Stat Serv, S Orsola Malpighi Hosp Bologna, Dept Clin Integrated & Expt Med DIMES, Bologna, Italy.
   [Bertellini, Elisabetta; Marudi, Andrea] Univ Hosp Modena, Dept Anaesthesiol, Via Pozzo 71, I-41100 Modena, Italy.
   [Colombo, Davide] ASL, SS Trinita Hosp, Anaesthesia & Intens Care Dept, Novara, Italy.
   [Colombo, Davide] Eastern Piedmont Univ, Translat Med Dept, Novara, Italy.
   [Crimaldi, Federico] Eastern Piedmont Univ, Anaesthesia & Intens Care Residency Program, Translat Med Dept, Novara, Italy.
   [Damiani, Federica] Imola Hosp, Dept Anaesthesia Intens Care & Pain Therapy, Imola, Italy.
   [Gamberini, Emiliano; Russo, Emanuele] Osped Gen Provinciale M Bufalini, Anaesthesia & Intens Care Unit, Cesena, Italy.
   [Laici, Cristiana] Alma Mater Studiorum Univ Bologna, Hosp S Orsola Malpighi, Div Anesthesiol, Bologna, Italy.
   [Lanza, Maria Concetta] GB Morgagni Pierantoni Hosp, Dept Anesthesia & Intens Care, Forli, Italy.
   [Leo, Mirco] Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Dept Anaesthesia & Intens Care, Alessandria, Italy.
   [Nardi, Giuseppe; Potalivo, Antonella] Infermi Hosp, Dept Anaesthesia & Intens Care, Rimini, Italy.
   [Papa, Raffaella] Santa Maria Annunziata Hosp, Anaesthesia & Intens Care Unit, Florence, Italy.
   [Taddei, Stefania] Bentivoglio Hosp, Anaesthesia & Intens Care Unit, Bentivoglio, Italy.
RP Tonetti, T (corresponding author), Univ Bologna, Alma Mater Studiorum, Dipartimento Sci Med & Chirurg Anesthesia & Inten, Policlin St Orsola, Bologna, Italy.
EM tommaso.tonetti@unibo.it
RI Tonetti, Tommaso/AAF-1606-2019; Russo, Emanuele/AAP-5645-2020;
   Gamberini, Lorenzo/S-5476-2017
OI Russo, Emanuele/0000-0002-6531-5527; Tonetti,
   Tommaso/0000-0001-9676-3595; Gamberini, Lorenzo/0000-0002-4364-9163
CR Auld SC, 2020, CRIT CARE MED, V48, pE799, DOI 10.1097/CCM.0000000000004457
   Balzer F, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0272-4
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Chao CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050675
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Fan E, 2020, LANCET RESP MED, V8, P816, DOI 10.1016/S2213-2600(20)30304-0
   Ferrando C, 2020, INTENS CARE MED, V46, P2200, DOI 10.1007/s00134-020-06192-2
   Forel JM, 2012, CRIT CARE, V16, DOI 10.1186/cc11312
   Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Grasselli Giacomo, 2020, Lancet Respir Med, V8, P1201, DOI 10.1016/S2213-2600(20)30370-2
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Grasso S, 2020, CRIT CARE MED, V48, pE1332, DOI 10.1097/CCM.0000000000004640
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3
   Hoste E, 2015, INTENS CARE MED, V41, P1411, DOI 10.1007/s00134-015-3934-7
   Joannidis M, 2017, INTENS CARE MED, V43, P730, DOI 10.1007/s00134-017-4832-y
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Luo L, 2017, CHEST, V151, P755, DOI 10.1016/j.chest.2016.09.004
   Mai F, 2020, J CARDIOL, V76, P453, DOI 10.1016/j.jjcc.2020.07.013
   Mathew Divij, 2020, bioRxiv, DOI 10.1101/2020.05.20.106401
   McGrath BA, 2020, LANCET RESP MED, V8, P717, DOI 10.1016/S2213-2600(20)30230-7
   Ochiai R, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-015-0091-6
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Quah P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03006-1
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Schenck EJ, 2020, ANN AM THORAC SOC, V17, P1158, DOI 10.1513/AnnalsATS.202005-427RL
   Sellares J, 2011, INTENS CARE MED, V37, P775, DOI 10.1007/s00134-011-2179-3
   Spadaro S, 2019, J INFLAMM-LOND, V16, DOI 10.1186/s12950-018-0202-y
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Sugerman HJ, 1997, J TRAUMA, V43, P741, DOI 10.1097/00005373-199711000-00002
   Terragni PP, 2010, JAMA-J AM MED ASSOC, V303, P1483, DOI 10.1001/jama.2010.447
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Y, 2020, AM J RESP CRIT CARE, V201, P1430, DOI 10.1164/rccm.202003-0736LE
   Wendel Garcia Pedro David, 2020, EClinicalMedicine, V25, P100449, DOI 10.1016/j.eclinm.2020.100449
   World Health Organization, 2020, CLIN MAN COVID 19 IN
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yehya N, 2019, AM J RESP CRIT CARE, V200, P828, DOI 10.1164/rccm.201810-2050CP
   Zhang L, 2015, J CRIT CARE, V30, DOI 10.1016/j.jcrc.2015.03.025
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Ziehr DR, 2020, AM J RESP CRIT CARE, V201, P1560, DOI 10.1164/rccm.202004-1163LE
   Zubair AS, 2020, JAMA NEUROL, V77, P1018, DOI 10.1001/jamaneurol.2020.2065
NR 49
TC 1
Z9 1
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2052-0492
J9 J INTENSIVE CARE
JI J. Intensive Care
PD OCT 15
PY 2020
VL 8
IS 1
AR 80
DI 10.1186/s40560-020-00499-4
PG 12
WC Critical Care Medicine
SC General & Internal Medicine
GA OG8EO
UT WOS:000582110500001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chitalia, VC
   Munawar, AH
AF Chitalia, Vipul C.
   Munawar, Ali H.
TI A painful lesson from the COVID-19 pandemic: the need for
   broad-spectrum, host-directed antivirals
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE COVID-19; Broad-spectrum antivirals; Mechanism of action (MOA);
   Pandemics; Drug discovery and development; SARS-CoV-2; Host-directed
   antivirals; Antiviral drug design; Coronavirus (CoV); Drug design
   strategies; Prophylactic antiviral therapy
ID SIGMA-1 RECEPTOR; CORONAVIRUS; RIBAVIRIN; REPLICATION; INNOVATION;
   TARGET
AB While the COVID-19 pandemic has spurred intense research and collaborative discovery worldwide, the development of a safe, effective, and targeted antiviral from the ground up is time intensive. Therefore, most antiviral discovery efforts are focused on the re-purposing of clinical stage or approved drugs. While emerging data on drugs undergoing COVID-19 repurpose are intriguing, there is an undeniable need to develop broad-spectrum antivirals to prevent future viral pandemics of unknown origin. The ideal drug to curtail rapid viral spread would be a broad-acting agent with activity against a wide range of viruses. Such a drug would work by modulating host-proteins that are often shared by multiple virus families thereby enabling preemptive drug development and therefore rapid deployment at the onset of an outbreak. Targeting host-pathways and cellular proteins that are hijacked by viruses can potentially offer broad-spectrum targets for the development of future antiviral drugs. Such host-directed antivirals are also likely to offer a higher barrier to the development and selection of drug resistant mutations. Given that most approved antivirals do not target host-proteins, we reinforce the need for the development of such antivirals that can be used in pre- and post-exposure populations.
C1 [Chitalia, Vipul C.] Boston Univ, Med Ctr, 625 Albany St, Boston, MA USA.
   [Chitalia, Vipul C.] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Munawar, Ali H.] Bisect Therapeutics Inc, 45 Dan Rd, Canton, MA 02021 USA.
RP Munawar, AH (corresponding author), Bisect Therapeutics Inc, 45 Dan Rd, Canton, MA 02021 USA.
EM amunawar@bisect-tx.com
CR Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Braun E, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1073
   Chaudhuri S, 2018, ANTIVIR RES, V155, P76, DOI 10.1016/j.antiviral.2018.05.005
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Crotty S, 2000, NAT MED, V6, P1375
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   de Wilde AH, 2015, J VIROL, V89, P8318, DOI 10.1128/JVI.01029-15
   DiMasi JA, 2016, J HEALTH ECON, V47, P20, DOI 10.1016/j.jhealeco.2016.01.012
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Friesland M, 2013, J VIROL, V87, P6377, DOI 10.1128/JVI.03557-12
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hayashi T, 2015, J PHARMACOL SCI, V127, P2, DOI 10.1016/j.jphs.2014.07.001
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Kim TS, 2006, MOL CELL BIOL, V26, P965, DOI 10.1128/MCB.26.3.965-975.2006
   Laporte M, 2017, CURR OPIN VIROL, V24, P16, DOI 10.1016/j.coviro.2017.03.018
   Lesch M, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007601
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Markland W, 2000, ANTIMICROB AGENTS CH, V44, P859, DOI 10.1128/AAC.44.4.859-866.2000
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Nehme Z, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0654-9
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang SG, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav7999
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 28
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD OCT 15
PY 2020
VL 18
IS 1
AR 390
DI 10.1186/s12967-020-02476-9
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OG1HC
UT WOS:000581643200002
PM 33059719
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Palacios, R
   Patino, EG
   Piorelli, RD
   Conde, MTRP
   Batista, AP
   Zeng, G
   Xin, QQ
   Kallas, EG
   Flores, J
   Ockenhouse, CF
   Gast, C
AF Palacios, Ricardo
   Patino, Elizabeth Gonzalez
   de Oliveira Piorelli, Roberta
   Conde, Monica Tilli Reis Pessoa
   Batista, Ana Paula
   Zeng, Gang
   Xin, Qianqian
   Kallas, Esper G.
   Flores, Jorge
   Ockenhouse, Christian F.
   Gast, Christopher
TI Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to
   Evaluate the Efficacy and Safety of treating Healthcare Professionals
   with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac
   - PROFISCOV: A structured summary of a study protocol for a randomised
   controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; Inactivated Vaccines;
   Phase III Clinical Trial; COVID-19 Vaccine; Brazil
AB Objectives: To evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological confirmation of COVID-19, two weeks after the completion of the two-dose vaccination regimen, aged 18 years or older who work as health professionals providing care to patients with possible or confirmed COVID-19.To describe the occurrence of adverse reactions associated with the administration of each of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac up to one week after vaccination in Adults (18-59 years of age) and Elderly (60 years of age or more).
   Trial design: This is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac.The adsorbed vaccine COVID-19 (inactivated) produced by Sinovac (product under investigation) will be compared to placebo. Voluntary participants will be randomized to receive two intramuscular doses of the investigational product or the placebo, in a 1: 1 ratio, stratified by age group (18 to 59 years and 60 years or more) and will be monitored for one year by active surveillance of COVID-19. Two databases will be established according to the age groups: one for adults (18-59 years) and one for the elderly (60 years of age or older).
   The threshold to consider the vaccine efficacious will be to reach a protection level of at least 50%, as proposed by the World Health Organization and the FDA. Success in this criterion will be defined by sequential monitoring with adjustment of the lower limit of the 95% confidence interval above 30% for the primary efficacy endpoint.
   Participants: Healthy participants and / or participants with clinically controlled disease, of both genders, 18 years of age or older, working as health professionals performing care in units specialized in direct contact with people with possible or confirmed cases of COVID-19. Participation of pregnant women and those who are breastfeeding, as well as those intending to become pregnant within three months after vaccination will not be allowed. Participants will only be included after signing the voluntary Informed Consent Form and ensuring they undergo screening evaluation and conform to all the inclusion and exclusion criteria. All the clinical sites are located in Brazil.
   Intervention and comparator: Experimental intervention: The vaccine was manufactured by Sinovac Life Sciences (Beijing, China) and contains 3 mu g/0.5 mL (equivalent to 600 SU per dose) of inactivated SARS-CoV-2 virus, and aluminium hydroxide as adjuvant.Control comparator: The placebo contains aluminium hydroxide in a 0.5 mL solutionThe schedule of both, experimental intervention and placebo is two 0.5 mL doses IM (deltoid) with a two week interval.
   Main outcomes: The primary efficacy endpoint is the incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second vaccination. The virological diagnosis will be confirmed by detection of SARS-CoV-2 nucleic acid in a clinical sample.The primary safety endpoint is the frequency of solicited and unsolicited local and systemic adverse reactions during the period of one week after vaccination according to age group in adult (18-59 years old) and elder (60 years of age or older) subjects. Adverse reactions are defined as adverse events that have a reasonable causal relationship to vaccination.
   Randomisation: There will be two randomization lists, one for each age group, based on the investigational products to be administered, i.e., vaccine or placebo at a 1: 1 ratio. Each randomization list will be made to include up to 11,800 (18-59 year-old) adults, and 1,260 elderly (60 y-o and older) participants, the maximum number of participants needed per age group. An electronic central randomization system will be used to designate the investigational product that each participant must receive.
   Blinding (masking): This trial is designed as a double-blind study to avoid introducing bias in the evaluation of efficacy, safety and immunogenicity. The clinical care team, the professionals responsible for the vaccination and the participants will not know which investigational product will be administered. Only pharmacists or nurses in the study who are responsible for the randomization, separation and blinding of the investigational product will have access to unblinded information. The sponsor's operational team will also remain blind.
   Numbers to be randomised (sample size): The total number of participants needed to evaluate efficacy, 13,060 participants, satisfies the needed sample size calculated to evaluate safety. Therefore, the total number obtained for efficacy will be the number retained for the study. Up to 13,060 participants are expected to enter the study, with up to 11,800 participants aged 18 to 59 years and 1,260 elderly participants aged 60 and over. Half of the participants of each group will receive the experimental vaccine and half of them will receive the placebo. The recruitment of participants may be modified as recommended by the Data Safety Monitoring Committee at time of the interim unblinded analysis or blind assessment of the COVID-19 attack rate during the study.
   Trial Status: Protocol version 2.0 - 24-Aug-2020. Recruitment started on July 21(st), 2020. The recruitment is expected to conclude in October 2020.
   Trial registration: ClinicalTrials.gov Identifier: NCT0445659. Registry on 2 July 2020
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Palacios, Ricardo; Patino, Elizabeth Gonzalez; de Oliveira Piorelli, Roberta; Conde, Monica Tilli Reis Pessoa; Batista, Ana Paula] Inst Butantan, Ctr Clin Trials & Pharmacovigilance, Sao Paulo, Brazil.
   [Zeng, Gang; Xin, Qianqian] Sinovac Life Sci, Beijing, Peoples R China.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Flores, Jorge; Ockenhouse, Christian F.] PATH US, Washington, DC USA.
   [Gast, Christopher] PATH, Seattle, WA USA.
RP Palacios, R (corresponding author), Inst Butantan, Ctr Clin Trials & Pharmacovigilance, Sao Paulo, Brazil.
EM ricardo.palacios@butantan.gov.br
RI Palacios, Ricardo/B-7248-2018
OI Palacios, Ricardo/0000-0002-1410-8579
FU Fundacao Butantan; Sao Paulo Research Foundation - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2020/10127-1]
FX This study is financed by Fundacao Butantan and The Sao Paulo Research
   Foundation - FAPESP (Grant 2020/10127-1).; Fundacao Butantan supports
   the activities of Instituto Butantan as trial sponsor. Instituto
   Butantan is leading the design, analysis, interpretation of data and
   manuscript writing.
NR 0
TC 1
Z9 1
U1 7
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 15
PY 2020
VL 21
IS 1
AR 853
DI 10.1186/s13063-020-04775-4
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OG1KB
UT WOS:000581650900001
PM 33059771
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sharma, K
   Morla, S
   Goyal, A
   Kumar, S
AF Sharma, Kedar
   Morla, Sudhir
   Goyal, Arun
   Kumar, Sachin
TI Computational guided drug repurposing for targeting 2 '-O-ribose
   methyltransferase of SARS-CoV-2
SO LIFE SCIENCES
LA English
DT Article
DE SARS-CoV-2; 2-O-methyltransferase; FDA approved drugs; Repurposing;
   Virtual screening
AB Aims: The recent outbreak of pandemic severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led the world towards a global health emergency. Currently, no proper medicine or effective treatment strategies are available; therefore, repurposing of FDA approved drugs may play an important role in overcoming the situation.
   Materials and methods: The SARS-CoV-2 genome encodes for 2-O-methyltransferase (2'OMTase), which plays a key role in methylation of viral RNA for evading host immune system. In the present study, the protein sequence of 2'OMTase of SARS-CoV-2 was analyzed, and its structure was modeled by a comparative modeling approach and validated. The library of 3000 drugs was screened against the active site of 2'OMTase followed by re-docking analysis. The apo and ligand-bound 2'OMTase were further validated and analyzed by using molecular dynamics simulation.
   Key findings: The modeled structure displayed the conserved characteristic fold of class I MTase family. The quality assessment analysis by SAVES server reveals that the modeled structure follows protein folding rules and of excellent quality. The docking analysis displayed that the active site of 2'OMTase accommodates an array of drugs, which includes alkaloids, antivirals, cardiac glycosides, anticancer, steroids, and other drugs. The redocking and MD simulation analysis of the best 5 FDA approved drugs reveals that these drugs form a stable conformation with the 2'OMTase.
   Significance: The results suggested that these drugs may be used as potential inhibitors for 2'OMTase for combating the SARS-CoV-2 infection.
C1 [Sharma, Kedar; Morla, Sudhir; Goyal, Arun; Kumar, Sachin] Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Gauhati 781039, Assam, India.
RP Kumar, S (corresponding author), Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Gauhati 781039, Assam, India.
EM sachinku@iitg.ac.in
FU Department of Biotechnology, Government of IndiaDepartment of
   Biotechnology (DBT) India [BT/562/NE/U-Excel/2016,
   BT/PR24308/NER/95/644/2017]
FX The virus research in our lab is currently supported by the Department
   of Biotechnology, Government of India (BT/562/NE/U-Excel/2016, and
   BT/PR24308/NER/95/644/2017).
CR Bouvet M, 2012, M S-MED SCI, V28, P423, DOI 10.1051/medsci/2012284021
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Kuroda Y, 2019, J ANTIBIOT, V72, P981, DOI 10.1038/s41429-019-0234-4
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Mitja O, 2020, LANCET GLOB HEALTH, V8, pE639, DOI 10.1016/S2214-109X(20)30114-5
   Mukhopadhyay R, 2018, J VIROL, V92, DOI 10.1128/JVI.01861-17
   RICHTER A, 1987, NUCLEIC ACIDS RES, V15, P3455, DOI 10.1093/nar/15.8.3455
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Tfelt-Hansen PC, 2008, CEPHALALGIA, V28, P877, DOI 10.1111/j.1468-2982.2008.01578.x
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Zeng C, 2016, J VIROL, V90, P6675, DOI 10.1128/JVI.00658-16
NR 20
TC 1
Z9 1
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD OCT 15
PY 2020
VL 259
AR 118169
DI 10.1016/j.lfs.2020.118169
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OC9PD
UT WOS:000579486200001
PM 32738360
OA Green Published
DA 2021-01-01
ER

PT J
AU Xu, H
   Martin, A
   Singh, A
   Narasimhan, M
   Lau, J
   Weinberg, M
   Jauhar, R
   Rao, G
AF Xu, Hai
   Martin, Angel
   Singh, Avneet
   Narasimhan, Mangala
   Lau, Joe
   Weinberg, Mitchell
   Jauhar, Rajiv
   Rao, Gaurav
TI Pulmonary Embolism in Patients Hospitalized With COVID-19 (From a New
   York Health System)
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
AB Pulmonary embolisms (PEs) in coronavirus disease 2019 (COVID-19) have increasingly been reported in observational studies. However, limited information describing their clinical characteristics and outcomes exists. Our study aims to describe clinical features and risk stratification strategies of hospitalized COVID-19 patients with PE. We retrospectively analyzed 101 hospitalized patients with COVID-19 infection and acute PE. Clinical outcomes measured were intensive care unit admission, mechanical ventilation, bleeding and transfusion events, acute kidney injury (AKI) and mortality. Pulmonary severity index (PESI) scores were used for risk stratification. The most common comorbidities were hypertension (50%), obesity (27%) and hyperlipidemia (32%) among this cohort. Baseline D-dimer abnormalities (4,647.0 +/- 8,281.8) were noted on admission with a 3-fold increase at the time of PE diagnosis (13,288.4 +/- 14,917.9; p 0.05). Five (5%) patients required systemic thrombolysis and 12 (12%) patients experienced moderate to severe bleeding. Thirty-one (31%) patients developed AKI and 1 (1%) patient required renal replacement therapy. Twenty-three (23%) patients were admitted to intensive care unit, of which 20 (20%) patients received mechanical ventilation. The mortality rate was 20%. Most patients (65%) had Intermediate to high risk PESI scores (>85), which portended a worse prognosis with higher mortality rate and length of stay. In conclusion, this study provides characteristics and early outcomes for hospitalized patients with COVID19 and acute pulmonary embolism. PESI scores were utilized for risk stratifying clinical outcomes. Our results should serve to alert the medical community to heighted vigilance of this VTE complication associated with COVID-19 infection. (c) 2020 Elsevier Inc. All rights reserved.
C1 [Xu, Hai; Martin, Angel; Singh, Avneet; Narasimhan, Mangala; Lau, Joe; Weinberg, Mitchell; Jauhar, Rajiv; Rao, Gaurav] Donald & Barbara Zucker Sch Med Hofstra Northwell, Hempstead, NY 11549 USA.
RP Rao, G (corresponding author), Donald & Barbara Zucker Sch Med Hofstra Northwell, Hempstead, NY 11549 USA.
EM Gaurav.j.rao@gmail.com
OI narasimhan, mangala/0000-0001-5834-5675; Xu, Hai/0000-0001-8924-1289
FU Northwell COVID19 Research Consortium
FX We would like to acknowledge the Northwell COVID19 Research Consortium
   for their support and resources.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Atri Deepak, 2020, JACC Basic Transl Sci, V5, P518, DOI 10.1016/j.jacbts.2020.04.002
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Erkens PMG, 2012, THROMB RES, V129, P710, DOI 10.1016/j.thromres.2011.08.025
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jaff MR, 2011, CIRCULATION, V123, P1788, DOI 10.1161/CIR.0b013e318214914f
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Li YX, 2020, NEUROIMAGE-CLIN, V27, DOI 10.1016/j.nicl.2020.102355
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Long B, 2020, AM J EMERG MED, V38, P1504, DOI 10.1016/j.ajem.2020.04.048
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   PETRUZZELLI S, 1986, RESPIRATION, V50, P233
   Poissy J, 2020, CIRCULATION, V120
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Shi S, 2020, J ETHNOPHARMACOL, V256, DOI 10.1016/j.jep.2020.112780
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 26
TC 0
Z9 0
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD OCT 15
PY 2020
VL 133
BP 148
EP 153
DI 10.1016/j.amjcard.2020.07.036
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OA7JB
UT WOS:000577955800020
PM 32800295
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Giamarellos-Bourboulis, EJ
   Tsilika, M
   Moorlag, S
   Antonakos, N
   Kotsaki, A
   Dominguez-Andres, J
   Kyriazopoulou, E
   Gkavogianni, T
   Adami, ME
   Damoraki, G
   Koufargyris, P
   Karageorgos, A
   Bolanou, A
   Koenen, H
   van Crevel, R
   Droggiti, DI
   Renieris, G
   Papadopoulos, A
   Netea, MG
AF Giamarellos-Bourboulis, Evangelos J.
   Tsilika, Maria
   Moorlag, Simone
   Antonakos, Nikolaos
   Kotsaki, Antigone
   Dominguez-Andres, Jorge
   Kyriazopoulou, Evdoxia
   Gkavogianni, Theologia
   Adami, Maria-Evangelia
   Damoraki, Georgia
   Koufargyris, Panagiotis
   Karageorgos, Athanassios
   Bolanou, Amalia
   Koenen, Hans
   van Crevel, Reinout
   Droggiti, Dionyssia-Irene
   Renieris, George
   Papadopoulos, Antonios
   Netea, Mihai G.
TI Activate: Randomized Clinical Trial of BCG Vaccination against Infection
   in the Elderly
SO CELL
LA English
DT Article
ID ANTIBIOTIC-THERAPY; DEFINITIONS; PNEUMONIA; IMMUNITY; SEPSIS; VIRUS
AB BCG vaccination in children protects against heterologous infections and improves survival independently of tuberculosis prevention. The phase III ACTIVATE trial assessed whether BCG has similar effects in the elderly. In this double-blind, randomized trial, elderly patients (n = 198) received BCG or placebo vaccine at hospital discharge and were followed for 12 months for new infections. At interim analysis, BCG vaccination significantly increased the time to first infection (median 16 weeks compared to 11 weeks after placebo). The incidence of new infections was 42.3% (95% CIs 31.9%-53.4%) after placebo vaccination and 25.0% (95% CIs 16.4%-36.1%) after BCG vaccination; most of the protection was against respiratory tract infections of probable viral origin (hazard ratio 0.21, p = 0.013). No difference in the frequency of adverse effects was found. Data show that BCG vaccination is safe and can protect the elderly against infections. Larger studies are needed to assess protection against respiratory infections, including COVID-19.
C1 [Giamarellos-Bourboulis, Evangelos J.; Tsilika, Maria; Antonakos, Nikolaos; Kotsaki, Antigone; Kyriazopoulou, Evdoxia; Gkavogianni, Theologia; Adami, Maria-Evangelia; Damoraki, Georgia; Koufargyris, Panagiotis; Karageorgos, Athanassios; Bolanou, Amalia; Droggiti, Dionyssia-Irene; Renieris, George; Papadopoulos, Antonios] Natl & Kapodistrian Univ Athens, Med Sch, Dept Internal Med 4, Athens 12462, Greece.
   [Moorlag, Simone; Dominguez-Andres, Jorge; van Crevel, Reinout; Netea, Mihai G.] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, NL-6500 Nijmegen, Netherlands.
   [Moorlag, Simone; Dominguez-Andres, Jorge; van Crevel, Reinout; Netea, Mihai G.] Radboud Univ Nijmegen, Radboud Ctr Infect Dis, Med Ctr, NL-6500 Nijmegen, Netherlands.
   [Koenen, Hans] Radboud Univ Nijmegen, Dept Lab Med, Med Ctr, NL-6500 Nijmegen, Netherlands.
   [Netea, Mihai G.] Univ Bonn, Life & Med Sci Inst, Dept Immunol & Metab, D-53115 Bonn, Germany.
RP Giamarellos-Bourboulis, EJ (corresponding author), Natl & Kapodistrian Univ Athens, Med Sch, Dept Internal Med 4, Athens 12462, Greece.
EM egiamarel@med.uoa.gr
OI Kyriazopoulou, Evdoxia/0000-0002-9585-517X
FU Horizon 2020 grant ImmunoSep [847422]; Hellenic Institute for the Study
   of Sepsis
FX The study was funded in part by the Horizon 2020 grant ImmunoSep
   (#847422) and in part by the Hellenic Institute for the Study of Sepsis.
   The authors wish to acknowledge the contribution of Prof. Jos W.M. van
   der Meer, of Prof. Christine Stabell Benn, and of Miltiades Kyprianou
   for the interim analysis.
CR Antonopoulou A, 2012, INT J INFECT DIS, V16, pE204, DOI 10.1016/j.ijid.2011.11.012
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192
   Bender BS, 2003, IMMUNOL ALLERGY CLIN, V23, P57, DOI 10.1016/S0889-8561(02)00078-4
   Calandra T, 2005, CRIT CARE MED, V33, P1538, DOI 10.1097/01.CCM.0000168253.91200.83
   Christ-Crain M, 2006, AM J RESP CRIT CARE, V174, P84, DOI 10.1164/rccm.200512-1922OC
   DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308
   Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kalil AC, 2016, CLIN INFECT DIS, V63, pE61, DOI 10.1093/cid/ciw353
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Leentjens J, 2015, J INFECT DIS, V212, P1930, DOI 10.1093/infdis/jiv332
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]
   Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   Ohrui Takashi, 2005, Nihon Ronen Igakkai Zasshi, V42, P34
   Pinson AG, 1997, AM J EMERG MED, V15, P148, DOI 10.1016/S0735-6757(97)90087-5
   R Core Team, 2013, R LANG ENV STAT COMP
   Russo A, 2016, CLIN MICROBIOL INFEC, V22, pS27, DOI 10.1016/S1198-743X(16)30095-7
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Stensballe LG, 2005, VACCINE, V23, P1251, DOI 10.1016/j.vaccine.2004.09.006
   Walk J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08659-3
   Wardhana, 2011, Acta Med Indones, V43, P185
   Welsh RM, 2010, IMMUNOL REV, V235, P244, DOI 10.1111/j.0105-2896.2010.00897.x
   Xue XN, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-88
NR 27
TC 7
Z9 7
U1 7
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD OCT 15
PY 2020
VL 183
IS 2
BP 315
EP +
DI 10.1016/j.cell.2020.08.051
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA OB6UR
UT WOS:000578604900008
PM 32941801
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Li, XL
   Lin, HW
   Wang, Q
   Cui, L
   Luo, H
   Luo, LX
AF Li, Xiaoling
   Lin, Haowen
   Wang, Qu
   Cui, Liao
   Luo, Hui
   Luo, Lianxiang
TI Chemical composition and pharmacological mechanism of shenfu decoction
   in the treatment of novel coronaviruspneumonia(COVID-19)
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article; Early Access
DE Novel coronavirus Pneumonia; network pharmacology; Shenfu Decoction;
   mechanism of action; molecular docking
ID MEDICINE
AB Purpose Shenfu decoction has outstanding curative effects in the treatment of COVID-19. This study aimed to explore the material basis and molecular mechanism of Shenfu Decoction through network pharmacology and molecular mechanisms, to provide a research basis for clinical medication and clues for subsequent research. Methods The active components and targets of Shenfu decoction were searched in the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), and the COVID-19-associated genes were collected using the Gene Cards platform. The target protein-protein interaction network map was constructed by mapping two genes, and the 'drug-active ingredient-target' network was constructed using Cytoscape software. The Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment of the mapping targets were analyzed. Result Based on Traditional Chinese medicine, Shenfu Decoction can take effect in the lung, spleen, kidney and heart. Considering oral bioavailability (OB) >= 30% and drug-like (DL) >= 0.18 as the standard, 43 active compounds were screened and 114 Shenfu decoction action targets were collected. The key targets were CASP3, MAPK8, PTGS2, IL1B, PPARG, ICAM1, IFNG, RELA, NOS2, NOS3, HMOX1, CASP8, STAT1, and TGFB1. According to the standard ofp < .05, GO function was enriched in 108 biological processes, 16 cell processes and 27 molecular processes. Sixty-three signaling pathways were enriched by KEGG, which can be divided into four types: viral infection pathways, signal pathways, biological process pathways and different disease pathways. The comparison of negative and positive prescriptions further reflects the positive effect of Shenfu decoction against COVID-19. Finally, the effective ingredients with the high degree were molecular docked with Mpro, Rdrp and Spro proteins to further confirm the intervention effect of Shenfu Decoction on COVID-19. Conclusion Shenfu decoction played an important role in regulating the anti-virus process, regulating immunity, inhibiting inflammation and regulating apoptosis through the interrelated regulation mechanism of multi-components and multi-targets, to treat patients with severe COVID-19.
C1 [Li, Xiaoling] Guangdong Med Univ, Anim Expt Ctr, Zhanjiang, Peoples R China.
   [Lin, Haowen; Wang, Qu] Guangdong Med Univ, Clin Coll 1, Zhanjiang, Peoples R China.
   [Cui, Liao] Guangdong Med Univ, Guangdong Key Lab Res & Dev Nat Drugs, Zhanjiang, Peoples R China.
   [Luo, Hui; Luo, Lianxiang] Guangdong Med Univ, Marine Biomed Res Inst, Zhanjiang 524023, Peoples R China.
   [Luo, Lianxiang] Marine Biomed Res Inst Guangdong Zhanjiang, Zhanjiang, Peoples R China.
   [Luo, Lianxiang] Southern Marine Sci & Engn Guangdong Lab, Zhanjiang, Peoples R China.
RP Luo, LX (corresponding author), Guangdong Med Univ, Marine Biomed Res Inst, Zhanjiang 524023, Peoples R China.
EM luolianxiang321@163.com
FU Guangdong Medical University [B2019016]; Administration of Traditional
   Chinese Medicine of Guangdong Province [20201180]; Science and
   Technology Special Project of Zhanjiang [2019A01009]; Basic and Applied
   Basic Research Program of Guangdong Province [2019A1515110201]; Key
   Program of Marine Economy Development(Six Marine Industries) Special
   Foundation of Department of Natural Resources of Guangdong Province
   [GDNRC[2020]038]; Educational Commission of Guangdong Province
   [4SG20138G]; Science and technology program of Guangdong Province
   [2019B090905011]; Fund of Southern Marine Science and Engineering
   GuangdongLaboratory (Zhanjiang) [ZJW-2019-007]
FX This project was supported by the PhD Startup Fund of Guangdong Medical
   University [B2019016]; Administration of Traditional Chinese Medicine of
   Guangdong Province [20201180]; Science and Technology Special Project of
   Zhanjiang [2019A01009]; Basic and Applied Basic Research Program of
   Guangdong Province [2019A1515110201]; Key Program of Marine Economy
   Development(Six Marine Industries) Special Foundation of Department of
   Natural Resources of Guangdong Province [GDNRC[2020]038]; Educational
   Commission of Guangdong Province (4SG20138G); Science and technology
   program of Guangdong Province [2019B090905011]; Fund of Southern Marine
   Science and Engineering GuangdongLaboratory (Zhanjiang) [ZJW-2019-007].
CR Alam MB, 2019, FOOD CHEM TOXICOL, V131, DOI 10.1016/j.fct.2019.110583
   Antwi AO, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3984068
   Calderon-Montano JM, 2011, MINI-REV MED CHEM, V11, P298, DOI 10.2174/138955711795305335
   Chen G, 2020, THEORETICAL STUDY AN
   Fishilevich S, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw030
   Gong J, 2020, PNEUMONIA, DOI [10.1101/2020.02.25.20025643v1, DOI 10.1101/2020.02.25.20025643V1]
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guo Fei-Fei, 2020, Zhongguo Zhong Yao Za Zhi, V45, P2257, DOI 10.19540/j.cnki.cjcmm.20200312.401
   Huang C, 2019, LANCET, V2020, P395
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Khalilzadeh B, 2018, MICROCHIM ACTA, V185, DOI 10.1007/s00604-018-2980-6
   Li S, 2014, J NAT MED, V11
   [李雪 Li Xue], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P2379
   Lin FX, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/2679409
   Liu XM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004882.pub3
   [刘毅 Liu Yi], 2017, [中草药, Chinese Traditional and Herbal Drugs], V48, P2925
   Lucas AJ, 2019, EXPERT OPIN DRUG DIS, V14, P1313, DOI 10.1080/17460441.2019.1660642
   Luo Y, 2019, AM J CHINESE MED, V47, P1223, DOI 10.1142/S0192415X19500629
   Mahase E., 2020, BMJ, V368
   Pang Wen-Tai, 2020, Zhongguo Zhong Yao Za Zhi, V45, P1242, DOI 10.19540/j.cnki.cjcmm.20200218.502
   Patel S, 2017, BIOMED PHARMACOTHER, V85, P120, DOI 10.1016/j.biopha.2016.11.112
   Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Russell B., 2020, ECANCERMEDICALSCIENC, V14, ped98, DOI 10.3332/ecancer.2020.ed98
   Sherman BT, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-426
   Szklarczyk D., 2015, NUC ACIDS RES, V43, pD447, DOI 10.1093/nar/ gkul003'
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tian B, 2018, J BIOL CHEM, V293, P16528, DOI 10.1074/jbc.RA118.003662
   Wan S., 2020, CHARACTERISTICS LYMP
   Wang C, 2020, J TRADIT CHIN MED, V40, P1
   Wang J, 2017, CLIN J TRADIT CHIN M
   Wang YX, 2020, EUR REV MED PHARMACO, V24, P3360, DOI 10.26355/eurrev_202003_20704
   Wei SYLHDGCDLYZ., 2020, ASIA PACIFIC TRADIT, V16
   Xi1 2 HZZXYXQXH, 2020, CHIN J ARTERIOSCLER, V28
   Xu Hai-Yu, 2020, Zhongguo Zhong Yao Za Zhi, V45, P1488, DOI 10.19540/j.cnki.cjcmm.20200229.401
   Xue CC, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-164
   Yan X, 2018, J ETHNOPHARMACOL, V227, P105, DOI 10.1016/j.jep.2018.05.006
   Zhang Y, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-00372-0
NR 38
TC 0
Z9 0
U1 4
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0363-9045
EI 1520-5762
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
DI 10.1080/03639045.2020.1826510
EA OCT 2020
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OC5NH
UT WOS:000579202400001
PM 33054436
OA Bronze
DA 2021-01-01
ER

PT J
AU Nadim, MK
   Forni, LC
   Mehta, RL
   Connor, MJ
   Liu, KD
   Ostermann, M
   Rimmele, T
   Zarbock, A
   Bell, S
   Bihorac, A
   Cantaluppi, V
   Hoste, E
   Husain-Syed, F
   Germain, MJ
   Goldstein, SL
   Gupta, S
   Joannidis, M
   Kashani, K
   Koyner, JL
   Legrand, M
   Lumlertgul, N
   Mohan, S
   Pannu, N
   Peng, ZY
   Perez-Fernandez, XL
   Pickkers, P
   Prowle, J
   Reis, T
   Srisawat, N
   Tolwani, A
   Vijayan, A
   Villa, G
   Yang, L
   Ronco, C
   Kellum, JA
AF Nadim, Mitra K.
   Forni, Lui C.
   Mehta, Ravindra L.
   Connor, Michael J., Jr.
   Liu, Kathleen D.
   Ostermann, Marlies
   Rimmele, Thomas
   Zarbock, Alexander
   Bell, Samira
   Bihorac, Azra
   Cantaluppi, Vincenzo
   Hoste, Eric
   Husain-Syed, Faeq
   Germain, Michael J.
   Goldstein, Stuart L.
   Gupta, Shruti
   Joannidis, Michael
   Kashani, Kianoush
   Koyner, Jay L.
   Legrand, Matthieu
   Lumlertgul, Nuttha
   Mohan, Sumit
   Pannu, Neesh
   Peng, Zhiyong
   Perez-Fernandez, Xose L.
   Pickkers, Peter
   Prowle, John
   Reis, Thiago
   Srisawat, Nattachai
   Tolwani, Ashita
   Vijayan, Anitha
   Villa, Gianluca
   Yang, Li
   Ronco, Claudio
   Kellum, John A.
TI COVID-19-associated acute kidney injury: consensus report of the 25th
   Acute Disease Quality Initiative (ADQI) Workgroup
SO NATURE REVIEWS NEPHROLOGY
LA English
DT Article
ID RENAL-REPLACEMENT THERAPY; CRITICALLY-ILL PATIENTS; POLYMYXIN-B
   HEMOPERFUSION; SEPTIC SHOCK; BALANCED CRYSTALLOIDS; PERITONEAL-DIALYSIS;
   COVID-19; CORONAVIRUS; SARS-COV-2; INFECTION
AB Kidney involvement in patients with coronavirus disease 2019 (COVID-19) is common, and can range from the presence of proteinuria and haematuria to acute kidney injury (AKI) requiring renal replacement therapy (RRT; also known as kidney replacement therapy). COVID-19-associated AKI (COVID-19 AKI) is associated with high mortality and serves as an independent risk factor for all-cause in-hospital death in patients with COVID-19. The pathophysiology and mechanisms of AKI in patients with COVID-19 have not been fully elucidated and seem to be multifactorial, in keeping with the pathophysiology of AKI in other patients who are critically ill. Little is known about the prevention and management of COVID-19 AKI. The emergence of regional 'surges' in COVID-19 cases can limit hospital resources, including dialysis availability and supplies; thus, careful daily assessment of available resources is needed. In this Consensus Statement, the Acute Disease Quality Initiative provides recommendations for the diagnosis, prevention and management of COVID-19 AKI based on current literature. We also make recommendations for areas of future research, which are aimed at improving understanding of the underlying processes and improving outcomes for patients with COVID-19 AKI.
C1 [Nadim, Mitra K.] Univ Southern Calif, Keck Sch Med, Dept Med, Div Nephrol & Hypertens, Los Angeles, CA 90007 USA.
   [Forni, Lui C.] Univ Surrey, Fac Hlth Sci, Dept Clin & Expt Med, Guildford, Surrey, England.
   [Forni, Lui C.] Royal Surrey Cty Hosp NHS Fdn Trust, Intens Care Unit, Guildford, Surrey, England.
   [Mehta, Ravindra L.] Univ Calif San Diego, Dept Med, Div Nephrol, San Diego, CA 92103 USA.
   [Connor, Michael J., Jr.] Emory Univ, Sch Med, Dept Med, Div Renal Med,Div Pulm, Atlanta, GA USA.
   [Connor, Michael J., Jr.] Emory Univ, Sch Med, Dept Med, Div Renal Med,Div Allergy, Atlanta, GA USA.
   [Connor, Michael J., Jr.] Emory Univ, Sch Med, Dept Med, Div Renal Med,Div Crit Care, Atlanta, GA USA.
   [Connor, Michael J., Jr.] Emory Univ, Sch Med, Dept Med, Div Renal Med,Div Sleep Med, Atlanta, GA USA.
   [Liu, Kathleen D.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA.
   [Liu, Kathleen D.] Univ Calif San Francisco, Dept Med, Div Crit Care Med, San Francisco, CA 94143 USA.
   [Liu, Kathleen D.] Univ Calif San Francisco, Dept Anesthesia, Div Nephrol, San Francisco, CA USA.
   [Liu, Kathleen D.] Univ Calif San Francisco, Dept Anesthesia, Div Crit Care Med, San Francisco, CA USA.
   [Ostermann, Marlies; Lumlertgul, Nuttha] Guys & St Thomas NHS Fdn Hosp, Dept Intens Care, London, England.
   [Rimmele, Thomas] Hosp Civils Lyon, Edouard Herriot Hosp, Dept Anesthesiol & Intens Care Med, Lyon, France.
   [Zarbock, Alexander] Univ Hosp Munster, Dept Anesthesiol Intens Care & Pain Med, Munster, Germany.
   [Bell, Samira] Univ Dundee, Sch Med, Div Populat Hlth & Genom, Dundee, Scotland.
   [Bihorac, Azra] Univ Florida, Dept Med, Gainesville, FL USA.
   [Cantaluppi, Vincenzo] Univ Piemonte Orientate, Dept Translat Med, Nephrol & Kidney Transplantat Unit, Novara, Italy.
   [Hoste, Eric] Univ Ghent, Ghent Univ Hosp, Intens Care Unit, Ghent, Belgium.
   [Husain-Syed, Faeq] Univ Hosp Giessen & Marburg, Dept Med 2, Div Nephrol Pulmonol & Crit Care Med, Giessen, Germany.
   [Germain, Michael J.] Baystate Med Ctr U Mass Med Sch, Renal Transplant Associates New England, Div Nephrol, Springfield, MA USA.
   [Goldstein, Stuart L.] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA.
   [Gupta, Shruti] Brigham & Womens Hosp, Div Renal Med, 75 Francis St, Boston, MA 02115 USA.
   [Joannidis, Michael] Med Univ Innsbruck, Dept Med, Div Intens Care & Emergency Med, Innsbruck, Austria.
   [Kashani, Kianoush] Mayo Clin, Dept Med, Div Pulm & Crit Care Med, Div Nephrol & Hypertens, Rochester, MN USA.
   [Koyner, Jay L.] Univ Chicago, Dept Med, Div Nephrol, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Legrand, Matthieu] Univ Calif San Francisco, Dept Anesthesiol & Perioperat Care, San Francisco, CA 94143 USA.
   [Lumlertgul, Nuttha; Srisawat, Nattachai] Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Crit Care Nephrol Res Unit, Div Nephrol,Excellence Ctr Crit Care Nephrol, Bangkok, Thailand.
   [Mohan, Sumit] Columbia Univ Coll Phys & Surg, Dept Med, Div Nephrol, New York, NY USA.
   [Mohan, Sumit] New York Presbyterian Hosp, New York, NY USA.
   [Mohan, Sumit] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   [Pannu, Neesh] Univ Alberta, Fac Med & Dent, Div Crit Care Med, Edmonton, AB, Canada.
   [Peng, Zhiyong] Wuhan Univ, Zhongnan Hosp, Div Crit Care Med, Wuhan, Peoples R China.
   [Perez-Fernandez, Xose L.] Hosp Univ Bellvitge, Serv Med Intens, Barcelona, Spain.
   [Pickkers, Peter] Radboudumc, Dept Intens Care Med, Nijmegen, Netherlands.
   [Prowle, John] Queen Mary Univ London, William Harvey Res Inst, Crit Care & Pert Operat Med Res Grp, London, England.
   [Reis, Thiago; Ronco, Claudio] San Bortolo Hosp, Int Renal Res Inst Vicenza, Dept Nephrol Dialysis & Transplantat, Vicenza, Italy.
   [Reis, Thiago] Clin Doencas Renais Brasilia, Dept Nephrol, Brasilia, DF, Brazil.
   [Srisawat, Nattachai] Royal Soc Thailand, Acad Sci, Bangkok, Thailand.
   [Tolwani, Ashita] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA.
   [Vijayan, Anitha] Washington Univ, Sch Med, Div Nephrol, St Louis, MO USA.
   [Villa, Gianluca] Univ Florence, Dept Hlth Sci, Sect Anaesthesiol & Intens Care, Florence, Italy.
   [Yang, Li] Peking Univ First Hosp, Renal Div, Beijing, Peoples R China.
   [Ronco, Claudio] Univ Padua, Dept Med, Padua, Italy.
   [Kellum, John A.] Univ Pittsburgh, Ctr Crit Care Nephrol, Dept Crit Care Med, Pittsburgh, PA 15260 USA.
RP Kellum, JA (corresponding author), Univ Pittsburgh, Ctr Crit Care Nephrol, Dept Crit Care Med, Pittsburgh, PA 15260 USA.
EM kellumja@upmc.edu
RI Mohan, Sumit/I-5625-2019; Hoste, Eric/A-6353-2008; Bihorac,
   Azra/Q-6500-2016; Ostermann, Marlies/B-8777-2015
OI Mohan, Sumit/0000-0002-5305-9685; Hoste, Eric/0000-0001-9301-8055; Reis,
   Thiago/0000-0002-7071-117X; Forni, Lui/0000-0002-0617-5309; Bihorac,
   Azra/0000-0002-5745-2863; Ostermann, Marlies/0000-0001-9500-9080; Bell,
   Samira/0000-0001-9100-1575; Connor, Michael/0000-0001-7613-5583
FU Baxter; CytoSorbents; BioMerieux; Jafron; NxStage; MedtronicMedtronic
FX The authors wish to acknowledge Faye Cotton, University of Pittsburgh,
   PA, USA, for her help in organizing this virtual ADQI meeting. This
   conference was supported by Unrestricted Educational Grants from Baxter,
   CytoSorbents, BioMerieux, Jafron, NxStage and Medtronic.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Adapa Sreedhar, 2020, J Clin Med Res, V12, P276, DOI 10.14740/jocmr4160
   Al-Jaghbeer M, 2018, J AM SOC NEPHROL, V29, P654, DOI 10.1681/ASN.2017070765
   Alfano G, 2020, CLIN KIDNEY J, V13, P265, DOI 10.1093/ckj/sfaa093
   Ankawi G, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2181-z
   Antequera Martin AM, 2019, COCHRANE DB SYST REV, V7, pCd012247
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Argenziano Michael G, 2020, medRxiv, DOI 10.1101/2020.04.20.20072116
   Argenziano MG, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1996
   Arkin N, 2020, CLIN NUTR, V39, P2327, DOI 10.1016/j.clnu.2020.05.007
   Armutcu F, 2019, INFLAMM RES, V68, P825, DOI 10.1007/s00011-019-01271-7
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Barazzoni R, 2020, CLIN NUTR, V39, P1631, DOI 10.1016/j.clnu.2020.03.022
   Barbar SD, 2018, NEW ENGL J MED, V379, P1431, DOI 10.1056/NEJMoa1803213
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413
   Braun F, 2020, LANCET, V396, P597, DOI 10.1016/S0140-6736(20)31759-1
   Broman ME, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220444
   Brown RM, 2019, AM J RESP CRIT CARE, V200, P1487, DOI 10.1164/rccm.201903-0557OC
   Burgner A, 2020, CLIN J AM SOC NEPHRO, V15, P720, DOI 10.2215/CJN.03750320
   Busund R, 2002, INTENS CARE MED, V28, P1434, DOI 10.1007/s00134-002-1410-7
   Cao JL, 2020, CLIN INFECT DIS, V71, P748, DOI 10.1093/cid/ciaa243
   Chang JH, 2019, AM J KIDNEY DIS, V73, P134, DOI 10.1053/j.ajkd.2018.05.008
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Chien JY, 2006, RESPIROLOGY, V11, P715, DOI 10.1111/j.1440-1843.2006.00942.x
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Chua HR, 2020, AM J KIDNEY DIS, V76, P392, DOI 10.1053/j.ajkd.2020.05.008
   Claure-Del Gramdo R, 2011, CLIN J AM SOC NEPHRO, V6, P467, DOI 10.2215/CJN.02500310
   Cruz DN, 2009, JAMA-J AM MED ASSOC, V301, P2445, DOI 10.1001/jama.2009.856
   Cuadrado-Payan E, 2020, LANCET, V395, pE84, DOI 10.1016/S0140-6736(20)31052-7
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Dambha-Miller Hajira, 2020, BJGP Open, V4, DOI 10.3399/bjgpopen20X101115
   Delanghe JR, 2020, CLIN CHIM ACTA, V505, P192, DOI 10.1016/j.cca.2020.03.031
   Dellinger RP, 2018, JAMA-J AM MED ASSOC, V320, P1455, DOI 10.1001/jama.2018.14618
   Douglas IS, 2020, CHEST, V158, P1431, DOI 10.1016/j.chest.2020.04.025
   Dudoignon E, 2020, ANAESTH CRIT CARE PA, V39, P453, DOI 10.1016/j.accpm.2020.06.006
   Durvasula R, 2020, AM J KIDNEY DIS, V76, P4, DOI 10.1053/j.ajkd.2020.04.001
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   El Shamy Osama, 2020, Kidney Med, V2, P377, DOI 10.1016/j.xkme.2020.04.001
   Farkash EA, 2020, J AM SOC NEPHROL, V31, P1683, DOI 10.1681/ASN.2020040432
   Fosbol EL, 2020, JAMA-J AM MED ASSOC, V324, P168, DOI 10.1001/jama.2020.11301
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gaudry S, 2020, LANCET, V395, P1506, DOI 10.1016/S0140-6736(20)30531-6
   Gaudry S, 2016, NEW ENGL J MED, V375, P122, DOI 10.1056/NEJMoa1603017
   Genovese G, 2010, SCIENCE, V329, P841, DOI 10.1126/science.1193032
   Goldstein SL, 2020, KIDNEY INT, V97, P580, DOI 10.1016/j.kint.2019.10.015
   Goldstein SL, 2016, KIDNEY INT, V90, P212, DOI 10.1016/j.kint.2016.03.031
   Goldstein SL, 2013, PEDIATRICS, V132, pE756, DOI 10.1542/peds.2013-0794
   Griffin KM, 2020, AM J RESP CRIT CARE, V201, P1337, DOI 10.1164/rccm.202004-1037CP
   Gruda MC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191676
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta Shruti, 2020, JAMA Intern Med, DOI 10.1001/jamainternmed.2020.3596
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Hering R, 2001, ANESTH ANALG, V92, P1226, DOI 10.1097/00000539-200105000-00027
   Hernandez-Arroyo C.F., 2020, KIDNEY, DOI [10.34067/KID.0003352020, DOI 10.34067/KID.0003352020]
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Honore PM, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0530-y
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Husain-Syed F, 2020, NEPHROL DIAL TRANSPL, V35, P1271, DOI 10.1093/ndt/gfaa162
   Iba T, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03077-0
   Iba T, 2020, CRIT CARE MED, V48, P1358, DOI 10.1097/CCM.0000000000004458
   Intensive Care National Audit and Research Centre, 2020, ICNARC REP COVID 19
   Jaber S, 2018, LANCET, V392, P31, DOI 10.1016/S0140-6736(18)31080-8
   Jin M, 2020, EMERG INFECT DIS, V26, P1618, DOI 10.3201/eid2607.200445
   Joannidis M, 2007, CRIT CARE, V11, DOI 10.1186/cc5937
   Joannidis M, 2020, INTENS CARE MED, V46, P654, DOI 10.1007/s00134-019-05869-7
   Joly BS, 2020, INTENS CARE MED, V46, P1603, DOI 10.1007/s00134-020-06088-1
   Kacar CK, 2020, BLOOD PURIFICAT, V49, P448, DOI 10.1159/000505565
   Kashani K, 2019, CLIN J AM SOC NEPHRO, V14, P941, DOI 10.2215/CJN.01250119
   Keith P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2836-4
   Kellum JA, 2008, INT J ARTIF ORGANS, V31, P90
   Kissling S, 2020, KIDNEY INT, V98, P228, DOI 10.1016/j.kint.2020.04.006
   Klein DJ, 2018, INTENS CARE MED, V44, P2205, DOI 10.1007/s00134-018-5463-7
   Knaup H, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2220-9
   Koch B, 2018, BLOOD PURIFICAT, V46, P126, DOI 10.1159/000487224
   Koyner JL, 2008, CLIN J AM SOC NEPHRO, V3, P562, DOI 10.2215/CJN.03090707
   Larsen CP, 2020, KIDNEY INT REP, V5, P935, DOI 10.1016/j.ekir.2020.04.002
   Lempert KD, 2019, DISASTER MED PUBLIC, V13, P782, DOI 10.1017/dmp.2018.142
   Li T, 2020, EUR J CLIN NUTR, V74, P871, DOI 10.1038/s41430-020-0642-3
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Liu LF, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011457.pub2
   Magrone T, 2020, ENDOCR METAB IMMUNE, V20, P807, DOI 10.2174/1871530320666200427112902
   Malbrain MLNG, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00679-3
   Marik PE, 2012, CRIT CARE MED, V40, P2479, DOI 10.1097/CCM.0b013e318255d9bc
   Martindale R, 2020, JPEN-PARENTER ENTER, V44, P1174, DOI 10.1002/jpen.1930
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   Mohamed MM, 2020, KIDNEY, V360, DOI [10.34067/KID.0002652020, DOI 10.34067/KID.0002652020]
   Murugan R, 2010, KIDNEY INT, V77, P527, DOI 10.1038/ki.2009.502
   Nagatomo M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03024-z
   Nahum J, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10478
   Nasr SH, 2020, KIDNEY INT REP, V5, P759, DOI 10.1016/j.ekir.2020.04.030
   Noris M, 2020, KIDNEY INT, V98, P314, DOI 10.1016/j.kint.2020.05.013
   Oliver MJ, 2002, INT J ARTIF ORGANS, V25, P40
   Ostermann M, 2019, INTENS CARE MED, V45, P1006, DOI 10.1007/s00134-019-05615-z
   Ostermann M, 2019, CHEST, V156, P594, DOI 10.1016/j.chest.2019.04.004
   Ostermann M, 2018, BRIT J CLIN PHARMACO, V84, P396, DOI 10.1111/bcp.13449
   Ostermann M, 2016, BLOOD PURIFICAT, V42, P224, DOI 10.1159/000448506
   Othman H, 2020, BIOCHEM BIOPH RES CO, V527, P702, DOI 10.1016/j.bbrc.2020.05.028
   Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639
   Parienti JJ, 2008, JAMA-J AM MED ASSOC, V299, P2413, DOI 10.1001/jama.299.20.2413
   Peacock WF, 2020, ACAD EMERG MED, DOI 10.1111/acem.13954
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Peleg Y, 2020, KIDNEY INT REP, V5, P940, DOI 10.1016/j.ekir.2020.04.017
   Ponce D, 2020, CLIN KIDNEY J, V13, P269, DOI 10.1093/ckj/sfaa102
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Rossi GM, 2020, KIDNEY INT REP, V5, P1100, DOI 10.1016/j.ekir.2020.05.005
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Santoriello D, 2020, J AM SOC NEPHROL, V31, P2158, DOI 10.1681/ASN.2020050744
   Sargiacomo C, 2020, AGING-US, V12, P6511, DOI 10.18632/aging.103001
   Schaller T, 2020, JAMA-J AM MED ASSOC, V323, P2518, DOI 10.1001/jama.2020.8907
   Self WH, 2018, NEW ENGL J MED, V378, P819, DOI 10.1056/NEJMoa1711586
   Semler MW, 2018, NEW ENGL J MED, V378, P829, DOI 10.1056/NEJMoa1711584
   Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037
   Sourial MY, 2020, AM J KIDNEY DIS, V76, P401, DOI 10.1053/j.ajkd.2020.06.001
   Spagnolo P, 2020, LANCET RESP MED, V8, P750, DOI 10.1016/S2213-2600(20)30222-8
   Spittler A, 2000, CLIN INFECT DIS, V31, P1338, DOI 10.1086/317499
   Srivatana V, 2020, KIDNEY360, V1, P410, DOI DOI 10.34067/KID.0002152020
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Velez JCQ, 2020, NAT REV NEPHROL, V16, P565, DOI 10.1038/s41581-020-0332-3
   Verma B, 2016, CRIT CARE RESUSC, V18, P205
   Vesconi S, 2009, CRIT CARE, V13, DOI 10.1186/cc7784
   Villa G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172039
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471
   Welch HK, 2018, PHARMACOTHERAPY, V38, P785, DOI 10.1002/phar.2152
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu J, 2020, CLIN INFECT DIS, V71, P706, DOI 10.1093/cid/ciaa199
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zarbock A, 2016, JAMA-J AM MED ASSOC, V315, P2190, DOI 10.1001/jama.2016.5828
   Zayed YZM, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0320-x
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zwager CL, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2658-4
NR 145
TC 4
Z9 4
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1759-5061
EI 1759-507X
J9 NAT REV NEPHROL
JI Nat. Rev. Nephrol.
PD DEC
PY 2020
VL 16
IS 12
BP 747
EP 764
DI 10.1038/s41581-020-00356-5
EA OCT 2020
PG 18
WC Urology & Nephrology
SC Urology & Nephrology
GA OQ9BR
UT WOS:000578834000002
PM 33060844
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Corbett, KS
   Flynn, B
   Foulds, KE
   Francica, JR
   Boyoglu-Barnum, S
   Werner, AP
   Flach, B
   O'Connell, S
   Bock, KW
   Minai, M
   Nagata, BM
   Andersen, H
   Martinez, DR
   Noe, AT
   Douek, N
   Donaldson, MM
   Nji, NN
   Alvarado, GS
   Edwards, DK
   Flebbe, DR
   Lamb, E
   Doria-Rose, NA
   Lin, BC
   Louder, MK
   O'Dell, S
   Schmidt, SD
   Phung, E
   Chang, LA
   Yap, C
   Todd, JPM
   Pessaint, L
   Van Ry, A
   Browne, S
   Greenhouse, J
   Putman-Taylor, T
   Strasbaugh, A
   Campbell, TA
   Cook, A
   Dodson, A
   Steingrebe, K
   Shi, W
   Zhang, Y
   Abiona, OM
   Wang, LS
   Pegu, A
   Yang, ES
   Leung, K
   Zhou, T
   Teng, IT
   Widge, A
   Gordon, I
   Novik, L
   Gillespie, RA
   Loomis, RJ
   Moliva, JI
   Stewart-Jones, G
   Himansu, S
   Kong, WP
   Nason, MC
   Morabito, KM
   Ruckwardt, TJ
   Ledgerwood, JE
   Gaudinski, MR
   Kwong, PD
   Mascola, JR
   Carfi, A
   Lewis, MG
   Baric, RS
   McDermott, A
   Moore, IN
   Sullivan, NJ
   Roederer, M
   Seder, RA
   Graham, BS
AF Corbett, Kizzmekia S.
   Flynn, Barbara
   Foulds, Kathryn E.
   Francica, Joseph R.
   Boyoglu-Barnum, Seyhan
   Werner, Anne P.
   Flach, Britta
   O'Connell, Sarah
   Bock, Kevin W.
   Minai, Mahnaz
   Nagata, Bianca M.
   Andersen, Hanne
   Martinez, David R.
   Noe, Amy T.
   Douek, Naomi
   Donaldson, Mitzi M.
   Nji, Nadesh N.
   Alvarado, Gabriela S.
   Edwards, Darin K.
   Flebbe, Dillon R.
   Lamb, Evan
   Doria-Rose, Nicole A.
   Lin, Bob C.
   Louder, Mark K.
   O'Dell, Sijy
   Schmidt, Stephen D.
   Phung, Emily
   Chang, Lauren A.
   Yap, Christina
   Todd, John-Paul M.
   Pessaint, Laurent
   Van Ry, Alex
   Browne, Shanai
   Greenhouse, Jack
   Putman-Taylor, Tammy
   Strasbaugh, Amanda
   Campbell, Tracey-Ann
   Cook, Anthony
   Dodson, Alan
   Steingrebe, Katelyn
   Shi, Wei
   Zhang, Yi
   Abiona, Olubukola M.
   Wang, Lingshu
   Pegu, Amarendra
   Yang, Eun Sung
   Leung, Kwanyee
   Zhou, Tongqing
   Teng, I-Ting
   Widge, Alicia
   Gordon, Ingelise
   Novik, Laura
   Gillespie, Rebecca A.
   Loomis, Rebecca J.
   Moliva, Juan I.
   Stewart-Jones, Guillaume
   Himansu, Sunny
   Kong, Wing-Pui
   Nason, Martha C.
   Morabito, Kaitlyn M.
   Ruckwardt, Tracy J.
   Ledgerwood, Julie E.
   Gaudinski, Martin R.
   Kwong, Peter D.
   Mascola, John R.
   Carfi, Andrea
   Lewis, Mark G.
   Baric, Ralph S.
   McDermott, Adrian
   Moore, Ian N.
   Sullivan, Nancy J.
   Roederer, Mario
   Seder, Robert A.
   Graham, Barney S.
TI Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman
   Primates
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID LENGTH INFECTIOUS CDNA; REVERSE GENETICS; SPIKE; MERS; IMMUNOGENICITY
AB BackgroundVaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important to evaluate in nonhuman primates.
   MethodsNonhuman primates received 10 or 100 mu g of mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein of SARS-CoV-2, or no vaccine. Antibody and T-cell responses were assessed before upper- and lower-airway challenge with SARS-CoV-2. Active viral replication and viral genomes in bronchoalveolar-lavage (BAL) fluid and nasal swab specimens were assessed by polymerase chain reaction, and histopathological analysis and viral quantification were performed on lung-tissue specimens.
   ResultsThe mRNA-1273 vaccine candidate induced antibody levels exceeding those in human convalescent-phase serum, with live-virus reciprocal 50% inhibitory dilution (ID50) geometric mean titers of 501 in the 10-mu g dose group and 3481 in the 100-mu g dose group. Vaccination induced type 1 helper T-cell (Th1)-biased CD4 T-cell responses and low or undetectable Th2 or CD8 T-cell responses. Viral replication was not detectable in BAL fluid by day 2 after challenge in seven of eight animals in both vaccinated groups. No viral replication was detectable in the nose of any of the eight animals in the 100-mu g dose group by day 2 after challenge, and limited inflammation or detectable viral genome or antigen was noted in lungs of animals in either vaccine group.
   ConclusionsVaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung. (Funded by the National Institutes of Health and others.)
   Two injections of an mRNA-based vaccine encoding the SARS-CoV-2 spike protein elicited high levels of neutralizing antibody and Th1 CD4 T-cell responses in rhesus macaques. Two days after challenge of vaccinated animals with intranasal and intratracheal virus, viral replication was undetectable in bronchoalveolar-lavage fluid and nasal secretions.
C1 [Corbett, Kizzmekia S.; Flynn, Barbara; Foulds, Kathryn E.; Francica, Joseph R.; Boyoglu-Barnum, Seyhan; Werner, Anne P.; Flach, Britta; O'Connell, Sarah; Noe, Amy T.; Douek, Naomi; Donaldson, Mitzi M.; Nji, Nadesh N.; Alvarado, Gabriela S.; Flebbe, Dillon R.; Lamb, Evan; Doria-Rose, Nicole A.; Lin, Bob C.; Louder, Mark K.; O'Dell, Sijy; Schmidt, Stephen D.; Phung, Emily; Chang, Lauren A.; Yap, Christina; Todd, John-Paul M.; Shi, Wei; Zhang, Yi; Abiona, Olubukola M.; Wang, Lingshu; Pegu, Amarendra; Yang, Eun Sung; Leung, Kwanyee; Zhou, Tongqing; Teng, I-Ting; Widge, Alicia; Gordon, Ingelise; Novik, Laura; Gillespie, Rebecca A.; Loomis, Rebecca J.; Moliva, Juan I.; Kong, Wing-Pui; Morabito, Kaitlyn M.; Ruckwardt, Tracy J.; Ledgerwood, Julie E.; Gaudinski, Martin R.; Kwong, Peter D.; Mascola, John R.; McDermott, Adrian; Sullivan, Nancy J.; Roederer, Mario; Seder, Robert A.; Graham, Barney S.] NIAID, Vaccine Res Ctr, NIH, 40 Convent Dr, Bethesda, MD 20892 USA.
   [Bock, Kevin W.; Minai, Mahnaz; Nagata, Bianca M.; Lewis, Mark G.] NIAID, Infect Dis Pathogenesis Sect, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Nason, Martha C.] NIAID, Biostat Res Branch, Div Clin Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Andersen, Hanne; Pessaint, Laurent; Van Ry, Alex; Browne, Shanai; Greenhouse, Jack; Putman-Taylor, Tammy; Strasbaugh, Amanda; Campbell, Tracey-Ann; Cook, Anthony; Dodson, Alan; Steingrebe, Katelyn; Moore, Ian N.] Bioqual, Rockville, MD USA.
   [Gaudinski, Martin R.] Public Hlth Serv Commissioned Corps, Rockville, MD USA.
   [Martinez, David R.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.
   [Edwards, Darin K.; Stewart-Jones, Guillaume; Himansu, Sunny; Carfi, Andrea] Moderna, Cambridge, MA USA.
   [Phung, Emily] George Washington Univ, Inst Biomed Sci, Washington, DC USA.
RP Graham, BS (corresponding author), NIAID, Vaccine Res Ctr, NIH, 40 Convent Dr, Bethesda, MD 20892 USA.
EM rseder@mail.nih.gov
RI McDermott, Adrian B/E-7306-2011
OI Chang, Lauren/0000-0002-3287-3987
FU Intramural Research Program of the Vaccine Research Center (VRC),
   National Institute of Allergy and Infectious Diseases (NIAID), National
   Institutes of Health (NIH); Office of the Assistant Secretary for
   Preparedness and Response, Biomedical Advanced Research and Development
   Authority, Department of Health and Human Services [75A50120C00034];
   Undergraduate Scholarship Program, Office of Intramural Training and
   Education, Office of the Director, NIH; NIAIDUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [T32-AI007151, F32 AI152296]; Burroughs Wellcome Fund Postdoctoral
   Enrichment Program AwardBurroughs Wellcome Fund
FX Supported by the Intramural Research Program of the Vaccine Research
   Center (VRC), National Institute of Allergy and Infectious Diseases
   (NIAID), National Institutes of Health (NIH); and the Office of the
   Assistant Secretary for Preparedness and Response, Biomedical Advanced
   Research and Development Authority, Department of Health and Human
   Services (contract 75A50120C00034). Dr. Corbett is the recipient of a
   research fellowship that was partially funded by the Undergraduate
   Scholarship Program, Office of Intramural Training and Education, Office
   of the Director, NIH. Dr. Martinez was funded by grants from the NIAID
   (T32-AI007151 and F32 AI152296) and a Burroughs Wellcome Fund
   Postdoctoral Enrichment Program Award.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   [Anonymous], 2016, CLIN DIABETOL SA, V5, pA20
   Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035
   Callaway E, 2020, NATURE, V579, P482, DOI 10.1038/d41586-020-00758-2
   Chandrashekar A, 2020, SCIENCE
   Chen WH, 2020, CURR TROP MED REP
   CHEN Y, 2017, WORLD CONSTRUCTION, V5, P6
   Chuang GY, 2017, J VIROL, V91, DOI 10.1128/JVI.02268-16
   Corbett KS, 2020, PREPRINT, DOI [10.1101/2020.06.11.145920v1, DOI 10.1101/2020.06.11.145920V1]
   Crank MC, 2019, SCIENCE, V365, P505, DOI 10.1126/science.aav9033
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Donaldson MM, 2019, CYTOM PART A, V95A, P261, DOI 10.1002/cyto.a.23670
   Edridge AWD, 2020, PREPRINT, DOI [10.1101/2020.05.11.20086439v2, DOI 10.1101/2020.05.11.20086439V2]
   Finak G, 2014, BIOSTATISTICS, V15, P87, DOI 10.1093/biostatistics/kxt024
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Graham BS, 2019, ANNU REV MED, V70, P91, DOI 10.1146/annurev-med-121217-094234
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hou YJ, 2020, CELL, V182
   India State Level Disease Burden Initiative Road Injury Collaborators, 2020, LANCET PUBLIC HEALTH, V5, pe86
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200
   Killikelly AM, 2016, SCI REP-UK, V6, DOI 10.1038/srep34108
   Long QQ, 2020, REPROD BIOL ENDOCRIN, V18, DOI 10.1186/s12958-020-00600-4
   Loomis RJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00842
   Meckiff BJ, 2020, PREPRINT, DOI [10.1101/2020.06.12.148916v1, DOI 10.1101/2020.06.12.148916V1]
   Mulligan MJ, 2020, PREPRINT, DOI [10.1101/2020.06.30.20142570v1, DOI 10.1101/2020.06.30.20142570V1]
   Munster VJ, 2020, PREPRINT, DOI [10.1101/2020.03.21.001628v1, DOI 10.1101/2020.03.21.001628V1]
   Neidleman J, 2020, PREPRINT, DOI [10.1101/2020.06.08.138826v1, DOI 10.1101/2020.06.08.138826V1]
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450
   Peng Y, 2020, PREPRINT, DOI [DOI 10.1101/2020.06.05.134551V1, 10.1101/2020.06.05.134551v1]
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Rogers TF, 2020, SCIENCE
   Sanders RW, 2002, J VIROL, V76, P8875, DOI 10.1128/JVI.76.17.8875-8889.2002
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Sekine T, 2020, ROBUST T CELL IMMUNI, DOI [10.1101/2020.06.29.174888v1, DOI 10.1101/2020.06.29.174888V1]
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Stewart-Jones GBE, 2018, P NATL ACAD SCI USA, V115, P12265, DOI 10.1073/pnas.1811980115
   van Doremalen N, 2020, CHADOX1 NCOV 19 VACC, DOI [10.1101/2020.05.13.093195v1, DOI 10.1101/2020.05.13.093195V1]
   Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002
   Wang H, 2020, CELL
   Wang L, 2018, J VIROL, V92, pe02002
   Wang N, 2019, CELL REP, V28
   Widjaja I, 2019, EMERG MICROBES INFEC, V8, P516, DOI 10.1080/22221751.2019.1597644
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Yu J, 2020, SCIENCE
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 54
TC 31
Z9 30
U1 18
U2 18
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 15
PY 2020
VL 383
IS 16
BP 1544
EP 1555
DI 10.1056/NEJMoa2024671
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA OE4ES
UT WOS:000580486200011
PM 32722908
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU El-Baba, TJ
   Lutomski, CA
   Kantsadi, AL
   Malla, TR
   John, T
   Mikhailov, V
   Bolla, JR
   Schofield, CJ
   Zitzmann, N
   Vakonakis, I
   Robinson, CV
AF El-Baba, Tarick J.
   Lutomski, Corinne A.
   Kantsadi, Anastassia L.
   Malla, Tika R.
   John, Tobias
   Mikhailov, Victor
   Bolla, Jani R.
   Schofield, Christopher J.
   Zitzmann, Nicole
   Vakonakis, Ioannis
   Robinson, Carol V.
TI Allosteric Inhibition of the SARS-CoV-2 Main Protease: Insights from
   Mass Spectrometry Based Assays
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE allosteric inhibitors; drug development; proteases; native mass
   spectrometry; SARS-CoV-2
ID RESPIRATORY SYNDROME CORONAVIRUS; DIMER
AB The SARS-CoV-2 main protease (M-pro) cleaves along the two viral polypeptides to release non-structural proteins required for viral replication. M-Pro is an attractive target for antiviral therapies to combat the coronavirus-2019 disease. Here, we used native mass spectrometry to characterize the functional unit of M-pro. Analysis of the monomer/dimer equilibria reveals a dissociation constant of K-d=0.14 +/- 0.03 mu M, indicating M-Pro has a strong preference to dimerize in solution. We characterized substrate turnover rates by following temporal changes in the enzyme-substrate complexes, and screened small molecules, that bind distant from the active site, for their ability to modulate activity. These compounds, including one proposed to disrupt the dimer, slow the rate of substrate processing by approximate to 35 %. This information, together with analysis of thex-ray crystal structures, provides a starting point for the development of more potent molecules that allosterically regulate M-Pro activity.
C1 [El-Baba, Tarick J.; Lutomski, Corinne A.; Bolla, Jani R.; Robinson, Carol V.] Univ Oxford, Phys & Theoret Chem Lab, South Parks Rd, Oxford OX1 3QZ, England.
   [Kantsadi, Anastassia L.; Zitzmann, Nicole; Vakonakis, Ioannis] Univ Oxford, Dept Biochem, South Parks Rd, Oxford OX1 3QU, England.
   [Malla, Tika R.; John, Tobias; Mikhailov, Victor; Schofield, Christopher J.] Univ Oxford, Chem Res Lab, 12 Mansfield Rd, Oxford OX1 3TA, England.
RP Robinson, CV (corresponding author), Univ Oxford, Phys & Theoret Chem Lab, South Parks Rd, Oxford OX1 3QZ, England.
EM carol.robinson@chem.ox.ac.uk
RI Bolla, Jani Reddy/AAT-1370-2020
OI Bolla, Jani Reddy/0000-0003-4346-182X; John, Tobias/0000-0002-6123-595X
FU Medical Research Council (MRC)Medical Research Council UK (MRC)
   [MR/N020413/1]; European Research Council Advanced Grant ENABLE
   [695511]; Wellcome Trust Investigator AwardWellcome Trust
   [104633/Z/14/Z]; Royal SocietyRoyal Society of London; European
   CommissionEuropean CommissionEuropean Commission Joint Research Centre;
   Oxford Glycobiology Institute Endowment; Biotechnology and Biological
   Sciences Research CouncilBiotechnology and Biological Sciences Research
   Council (BBSRC) [BB/M011224/1]; Oxford-GSK-Crick Doctoral Program in
   Chemical Biology, EPSRC [EP/R512060/1]; GlaxoSmithKlineGlaxoSmithKline;
   Wellcome TrustWellcome Trust; Medical Research CouncilMedical Research
   Council UK (MRC); University of Oxford COVID-19 Research Response fund
   [BRD00230]
FX We are grateful to Claire Strain-Damerell, Petra Lukacik, David Owen and
   Martin A. Walsh for providing the MPro expression construct and advice
   on protein production, and to the Diamond Light Source XChem facility,
   led by Frank von Delft, for providing small molecule ligands. Work in
   the C.V.R. laboratory is supported by a Medical Research Council (MRC)
   program grant (MR/N020413/1), a European Research Council Advanced Grant
   ENABLE (695511), and a Wellcome Trust Investigator Award
   (104633/Z/14/Z). T.J.E. is supported by the Royal Society as a Royal
   Society Newton International Fellow. C.A.L. is supported by the European
   Commission as a Marie Sklodowska Curie Postdoctoral Fellow. A.L.K. was
   supported by the Oxford Glycobiology Institute Endowment. T.R.M. thanks
   Biotechnology and Biological Sciences Research Council (BB/M011224/1).
   T.J. was supported by the Oxford-GSK-Crick Doctoral Program in Chemical
   Biology, EPSRC (EP/R512060/1) and GlaxoSmithKline. C.J.S. thanks the
   Wellcome Trust and the Medical Research Council for support. We are
   grateful for generous support provided by the University of Oxford
   COVID-19 Research Response fund and its donors (BRD00230). Carol
   Robinson is also a part of the COVID-19 mass spectrometry
   consortium.<SUP>[12]</SUP>
CR Chen S, 2008, J BIOCHEM, V143, P525, DOI 10.1093/jb/mvm246
   Douangamath A., 2020, BIORXIV, DOI [10.1101/2020.05.27.118117., DOI 10.1101/2020.05.27.118117, 10.1101/2020.05.27.118117 .]
   Fuller DR, 2018, J AM CHEM SOC, V140, P9357, DOI 10.1021/jacs.8b04751
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Graziano V, 2006, BIOCHEMISTRY-US, V45, P14632, DOI 10.1021/bi061746y
   Gupta K, 2017, NATURE, V541, P421, DOI 10.1038/nature20820
   Hsu WC, 2005, J BIOL CHEM, V280, P22741, DOI 10.1074/jbc.M502556200
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kantsadi A.L., 2020, BIORXIV, DOI [10.1101/2020.06.17.156679, DOI 10.1101/2020.06.17.156679]
   Struwe W, 2020, LANCET, V395, P1761, DOI 10.1016/S0140-6736(20)31211-3
   Wang FH, 2016, J VIROL, V90, P1910, DOI 10.1128/JVI.02685-15
   Xia B, 2011, PROTEIN CELL, V2, P282, DOI 10.1007/s13238-011-1034-1
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang S, 2015, CHEM BIOL DRUG DES, V86, P1411, DOI 10.1111/cbdd.12606
   Zhong N, 2008, J VIROL, V82, P4227, DOI 10.1128/JVI.02612-07
NR 16
TC 0
Z9 0
U1 1
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PD DEC 21
PY 2020
VL 59
IS 52
BP 23544
EP 23548
DI 10.1002/anie.202010316
EA OCT 2020
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA PE3BW
UT WOS:000577668300001
PM 32841477
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Shi, C
   Wang, C
   Wang, HX
   Yang, C
   Cai, F
   Zeng, F
   Cheng, F
   Liu, YH
   Zhou, TT
   Deng, B
   Vlodavsky, I
   Li, JP
   Zhang, Y
AF Shi, Chen
   Wang, Cong
   Wang, Hanxiang
   Yang, Chao
   Cai, Fei
   Zeng, Fang
   Cheng, Fang
   Liu, Yihui
   Zhou, Taotao
   Deng, Bin
   Vlodavsky, Israel
   Li, Jin-Ping
   Zhang, Yu
TI The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm
   in Severe COVID-19 Patients: A Retrospective Cohort Study
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
ID D-DIMER LEVELS; HEPARANASE; IL-6; RELEASE; SULFATE; BINDING; HEALTH
AB On March 11, 2020, the World Health Organization declared its assessment of coronavirus disease 2019 (COVID-19) as a global pandemic. However, specific anti-severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) drugs are still under development, and patients are managed by multiple complementary treatments. We performed a retrospective analysis to compare and evaluate the effect of low molecular weight heparin (LMWH) treatment on disease progression. For this purpose, the clinical records and laboratory indicators were extracted from electronic medical records of 42 patients with COVID-19 (21 of whom were treated with LMWH, and 21 without LMWH) hospitalized (Union Hospital of Huazhong University of Science and Technology) from February 1 to March 15, 2020. Changes in the percentage of lymphocytes before and after LMWH treatment were significantly different from those in the control group (P = 0.011). Likewise, changes in the levels of D-dimer and fibrinogen degradation products in the LMWH group before and after treatment were significantly different from those in the control group (P = 0.035). Remarkably, IL-6 levels were significantly reduced after LMWH treatment (P = 0.006), indicating that, besides other beneficial properties, LMWH may exert an anti-inflammatory effect and attenuate in part the "cytokine storm" induced by the virus. Our results support the use of LMWH as a potential therapeutic drug for the treatment of COVID-19, paving the way for a subsequent well-controlled clinical study.
C1 [Shi, Chen; Wang, Cong; Wang, Hanxiang; Zeng, Fang; Cheng, Fang; Liu, Yihui; Zhou, Taotao; Deng, Bin; Zhang, Yu] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pharm, Wuhan, Peoples R China.
   [Shi, Chen; Zhang, Yu] Hubei Prov Clin Res Ctr Precis Med Crit Illness, Wuhan, Peoples R China.
   [Yang, Chao; Cai, Fei] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Vasc Surg, Wuhan, Peoples R China.
   [Vlodavsky, Israel] Technion, Rappaport Fac Med, Technion Integrated Canc Ctr, Haifa, Israel.
   [Li, Jin-Ping] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden.
RP Zhang, Y (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pharm, Wuhan, Peoples R China.; Zhang, Y (corresponding author), Hubei Prov Clin Res Ctr Precis Med Crit Illness, Wuhan, Peoples R China.
EM whxhzy@163.com
FU National Key Research and Development Plan of China [2017YFC0909900];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81603037]
FX This study was funed by the National Key Research and Development Plan
   of China (2017YFC0909900) National Natural Science Foundation of China
   (No. 81603037 to S.C.).
CR Agelidis AM, 2017, CELL REP, V20, P439, DOI 10.1016/j.celrep.2017.06.041
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729
   Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Derhaschnig U, 2003, CRIT CARE MED, V31, P1108, DOI 10.1097/01.CCM.0000059441.70680.DC
   Duarte JC, 2015, REV PORT PNEUMOL, V21, P218, DOI 10.1016/j.rppnen.2015.02.007
   Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI13530
   Glasner DR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006673
   Guo YN, 2008, NEPHROLOGY, V13, P545, DOI 10.1111/j.1440-1797.2008.01012.x
   Hadigal SR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7985
   Hippensteel JA, 2020, AM J PHYSIOL-LUNG C, V319, pL211, DOI 10.1152/ajplung.00199.2020
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Khanna M, 2019, VIROLOGY, V529, P1, DOI 10.1016/j.virol.2019.01.001
   Li XN, 2016, JIANGXI U TRAD CHINE, V28, P117, DOI DOI 10.3760/cma.j.issn.2095-4352.2016.02.007
   Li X, 2020, INT J INFECT DIS, V94, P128, DOI 10.1016/j.ijid.2020.03.053
   Liao YC, 2002, J IMMUNOL, V169, P4288, DOI 10.4049/jimmunol.169.8.4288
   Milewska A, 2018, J VIROL, V92, DOI 10.1128/JVI.01933-17
   Mummery RS, 2000, J IMMUNOL, V165, P5671, DOI 10.4049/jimmunol.165.10.5671
   Mycroft-West D. S., 2020, PREPRINT, DOI [10.1101/2020.02.29.971093, DOI 10.1101/2020.02.29.971093]
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Qian YB, 2014, COPD, V11, P171, DOI 10.3109/15412555.2013.831062
   Querol-Ribelles JM, 2004, CHEST, V126, P1087, DOI 10.1378/chest.126.4.1087
   Rao D., 2014, MED INFORM, V27, P480, DOI 10.3969/
   Sarrazin S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004952
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799
   Snijders D, 2012, EUR J INTERN MED, V23, P436, DOI 10.1016/j.ejim.2011.10.019
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   Thachil J, 2020, J THROMB HAEMOST, V18, P2424, DOI 10.1111/jth.14933
   Vlodavsky I, 2007, CURR PHARM DESIGN, V13, P2057
   Wan S.X., 2020, PREPRINT, DOI [10.1101/2020.02.10.20021832, DOI 10.1101/2020.02.10.20021832]
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Zhang QC, 2019, INT GEOL REV, V61, P175, DOI 10.1080/00206814.2017.1419444
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
NR 39
TC 4
Z9 4
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
PD NOV
PY 2020
VL 13
IS 6
BP 1087
EP 1095
DI 10.1111/cts.12880
EA OCT 2020
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PA7WR
UT WOS:000578338400001
PM 32881340
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, JC
   Ma, XL
   Guo, S
   Hou, CY
   Shi, LP
   Zhang, HC
   Zheng, B
   Liao, CC
   Yang, L
   Ye, L
   He, XD
AF Li, Jiacheng
   Ma, Xiaoliang
   Guo, Shuai
   Hou, Chengyu
   Shi, Liping
   Zhang, Hongchi
   Zheng, Bing
   Liao, Chenchen
   Yang, Lin
   Ye, Lin
   He, Xiaodong
TI A Hydrophobic-Interaction-Based Mechanism Triggers Docking between the
   SARS-CoV-2 Spike and Angiotensin-Converting Enzyme 2
SO GLOBAL CHALLENGES
LA English
DT Article
DE angiotensin-converting enzyme 2; coronavirus; COVID-19; docking;
   hydrophobic interactions; SARS-CoV-2
ID MOLECULAR-DYNAMICS; SCORING FUNCTIONS; BINDING; COMPENSATION
AB A recent experimental study found that the binding affinity between the cellular receptor human angiotensin-converting enzyme 2 (ACE2) and receptor-binding domain (RBD) in the spike (S) protein of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is more than tenfold higher than that of the original severe acute respiratory syndrome coronavirus (SARS-CoV). However, main chain structures of the SARS-CoV-2 RBD are almost the same with that of the SARS-CoV RBD. Understanding the physical mechanism responsible for the outstanding affinity between the SARS-CoV-2 S and ACE2 is an "urgent challenge" for developing blockers, vaccines, and therapeutic antibodies against the coronavirus disease 2019 (COVID-19) pandemic. Taking into account the mechanisms of hydrophobic interaction, hydration shell, surface tension, and the shielding effect of water molecules, this study reveals a hydrophobic-interaction-based mechanism by means of which SARS-CoV-2 S and ACE2 bind together in an aqueous environment. The hydrophobic interaction between the SARS-CoV-2 S and ACE2 protein is found to be significantly greater than that between SARS-CoV S and ACE2. At the docking site, the hydrophobic portions of the hydrophilic side chains of SARS-CoV-2 S are found to be involved in the hydrophobic interaction between SARS-CoV-2 S and ACE2.
C1 [Li, Jiacheng; Ma, Xiaoliang; Guo, Shuai; Shi, Liping; Zhang, Hongchi; Yang, Lin; He, Xiaodong] Harbin Inst Technol, Ctr Composite Mat & Struct, Natl Key Lab Sci & Technol Adv Composites Special, Harbin 150080, Peoples R China.
   [Hou, Chengyu; Liao, Chenchen] Harbin Inst Technol, Sch Elect & Informat Engn, Harbin 150080, Peoples R China.
   [Zheng, Bing] Heilongjiang Univ, Minist Educ, Sch Chem & Mat Sci, Key Lab Funct Inorgan Mat Chem, Harbin 150001, Peoples R China.
   [Yang, Lin; Ye, Lin] Univ Sydney, Sch Aerosp Mech & Mechatron Engn, Sydney, NSW 2006, Australia.
   [He, Xiaodong] Shenzhen STRONG Adv Mat Res Inst Co Ltd, Shenzhen 518035, Peoples R China.
RP Yang, L (corresponding author), Harbin Inst Technol, Ctr Composite Mat & Struct, Natl Key Lab Sci & Technol Adv Composites Special, Harbin 150080, Peoples R China.; Yang, L (corresponding author), Univ Sydney, Sch Aerosp Mech & Mechatron Engn, Sydney, NSW 2006, Australia.
EM linyang@hit.edu.cn
FU Fundamental Research Funds for the Central Universities of
   ChinaFundamental Research Funds for the Central Universities; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [21601054]; Shenzhen Science and Technology Program
   [KQTD2016112814303055]; Science Foundation of the National Key
   Laboratory of Science and Technology on Advanced Composites in Special
   Environments; University Nursing Program for Young Scholars with
   Creative Talents in Heilongjiang Province of China [UNPYSCT-2017126]
FX J.L., X.M., S.G., and C.H. contributed equally to this work. The authors
   acknowledge financial support from the Fundamental Research Funds for
   the Central Universities of China. L.Y. is indebted to Daniel Wagner
   from the Weizmann Institute of Science and Liyong Tong from the
   University of Sydney for their support and guidance. L.Y. is grateful
   for his research experience in the Weizmann Institute of Science for
   inspiration. The authors acknowledge the financial support from the
   National Natural Science Foundation of China (grant 21601054), Shenzhen
   Science and Technology Program (grant KQTD2016112814303055), Science
   Foundation of the National Key Laboratory of Science and Technology on
   Advanced Composites in Special Environments, and the University Nursing
   Program for Young Scholars with Creative Talents in Heilongjiang
   Province of China (grant UNPYSCT-2017126). The authors thank Joan
   Rosenthal for editing this article.
CR [Anonymous], 2005, SCIENCE, V309, P78
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Chen DL, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501240
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Chodera JD, 2013, ANNU REV BIOPHYS, V42, P121, DOI 10.1146/annurev-biophys-083012-130318
   CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0
   Du X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020144
   Henderson R, 2020, NAT STRUCT MOL BIOL, V27, P925, DOI 10.1038/s41594-020-0479-4
   Khan F., 2016, BIOTECHNOLOGY FUNDAM
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Leigh DA, 2003, CHEM BIOL, V10, P1143, DOI 10.1016/j.chembiol.2003.12.006
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Li Y, 2014, J CHEM INF MODEL, V54, P1717, DOI 10.1021/ci500081m
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   McPherson A, 2014, ACTA CRYSTALLOGR F, V70, P2, DOI 10.1107/S2053230X13033141
   Olsson TSG, 2011, PROTEIN SCI, V20, P1607, DOI 10.1002/pro.692
   Pace CN, 1996, FASEB J, V10, P75
   Patil R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012029
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Qiao BF, 2019, P NATL ACAD SCI USA, V116, P19274, DOI 10.1073/pnas.1910225116
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Soares CM, 2003, BIOPHYS J, V84, P1628, DOI 10.1016/S0006-3495(03)74972-8
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang RX, 2002, J COMPUT AID MOL DES, V16, P11, DOI 10.1023/A:1016357811882
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang L, 2003, BIOPHYS J, V84, P509, DOI 10.1016/S0006-3495(03)74870-X
   Yang L., 2019, PROG BIOCHEM BIOPHYS, V46, P8
   Yang L, 2017, PHYS CHEM CHEM PHYS, V19, P24478, DOI 10.1039/c7cp04838f
   Zhang LY, 2007, P NATL ACAD SCI USA, V104, P18461, DOI 10.1073/pnas.0707647104
NR 36
TC 0
Z9 0
U1 3
U2 3
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
EI 2056-6646
J9 GLOB CHALL
JI Glob. Chall.
PD DEC
PY 2020
VL 4
IS 12
AR 2000067
DI 10.1002/gch2.202000067
EA OCT 2020
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PB4BE
UT WOS:000577697000001
PM 33173592
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pannu, J
AF Pannu, Jaspreet
TI Inclusive Biomedical Innovation during the COVID-19 Pandemic
SO GLOBAL POLICY
LA English
DT Article
AB CEPI represents the first step towards Joseph Stiglitz's vision, cited by Gubby, of a fund which provides large rewards for cures to common diseases such as malaria, and smaller rewards for rarer diseases or less innovative 'me-too' drugs (Stiglitz,BMJ, 333, 2006, pp. 1279-1280). As a fledgling organization facing a Goliath, it deserves international support in its dual goals of incentivizing innovation and ensuring equitable access to biomedical advances.
C1 [Pannu, Jaspreet] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
RP Pannu, J (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.
EM jassi@stanford.edu
CR Bollyky TJ, 2020, TRAGEDY VACCINE NATL
   Cowen T., 2018, MODERN PRINCIPLES MA
   Gubby H, 2020, GLOB POLICY, V11, P46, DOI 10.1111/1758-5899.12730
   Hachett R., 2020, COVAX ENSURING FAIR
   Huneycutt B, 2020, VACCINE, V38, P2144, DOI 10.1016/j.vaccine.2019.12.055
   Kremer M, 1998, Q J ECON, V113, P1137, DOI 10.1162/003355398555865
   Kremer M., 2020, NATL BUREAU EC RES W
   Kremer Michael, 2004, STRONG MED CREATING
   Sedyaningsih ER, 2008, ANN ACAD MED SINGAP, V37, P482
   Stiglitz JE, 2006, BMJ-BRIT MED J, V333, P1279, DOI 10.1136/bmj.39048.428380.80
   Tabarrok A., 2011, LAUNCHING INNOVATION
NR 11
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1758-5880
EI 1758-5899
J9 GLOB POLICY
JI Glob. Policy
PD NOV
PY 2020
VL 11
IS 5
BP 647
EP 649
DI 10.1111/1758-5899.12876
EA OCT 2020
PG 3
WC International Relations; Political Science
SC International Relations; Government & Law
GA OY1FI
UT WOS:000577666900001
PM 33230401
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kannan, R
   Przekwas, A
AF Kannan, Ravishekar
   Przekwas, Andrzej
TI A multiscale absorption and transit model for oral delivery of
   hydroxychloroquine: Pharmacokinetic modeling and intestinal
   concentration prediction to assess toxicity and drug-induced damage in
   healthy subjects
SO INTERNATIONAL JOURNAL FOR NUMERICAL METHODS IN BIOMEDICAL ENGINEERING
LA English
DT Article
DE CC50; COVID-19; cytotoxicity; gastrointestinal tract; GIT; HCQ; MAT;
   multiscale; multiscale absorption and transit; quasi-3D (Q3D)
ID COMPUTATIONAL MODEL; TISSUE DISTRIBUTION; METABOLIC ENZYMES;
   TRANSPORTERS; DEPOSITION
AB Hydroxychloroquine (HCQ) is commonly used in the treatment of malaria and rheumatic diseases. Recently it has also been identified as possible therapeutic option in combating COVID-19. However, the use of HCQ is known to induce cytotoxicity. In 2020, we developed a multiscale absorption and transit (MAT) toolkit to simulate the dissolution, transport, absorption, distribution, metabolism, and elimination of orally administered drugs in the human GIT at multiple levels. MAT was constructed by integrating the spatially accurate first-principles driven high-fidelity drug transport, dissolution, and absorption model in the human stomach and GIT using the recently published Quasi-3D framework. The computational results showed that MAT was able to match the experimental concentration results better than the traditional compartmental models. In this study, we adapted MAT, to predict the pharmacokinetics of orally delivered HCQ in healthy subjects. The computational results matched the experimental concentration results. The simulated stomach and intestinal fluid and enterocyte concentrations were compared with the in vitro CC50 values. While the peak enterocyte concentrations were several orders lower than the in vitro CC50 values, the peak stomach and the intestinal fluid concentrations were only one order smaller than the in vitro CC50 values. In particular, the peak stomach and the duodenum fluid concentrations were just 3x smaller than the in vitro CC50 values. This implies that the lumen walls are much more susceptible to cytotoxicity-based damage than the enterocyte layers. We envision that MAT can be used to optimize the dosing regimen of HCQ by maximizing its bioavailability, while simultaneously minimizing the cytotoxic damage.
C1 [Kannan, Ravishekar; Przekwas, Andrzej] CFD Res Corp, 701 McMillian Way NW,Suite D, Huntsville, AL 35806 USA.
RP Kannan, R (corresponding author), CFD Res Corp, 701 McMillian Way NW,Suite D, Huntsville, AL 35806 USA.
EM ravi.kannan@cfdrc.com
OI Kannan, Ravishekar/0000-0001-8046-673X
FU National Institute of General Medical SciencesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R43GM133232]
FX National Institute of General Medical Sciences, Grant/Award Number:
   R43GM133232
CR Abu-Zahra TN, 2000, DRUG METAB DISPOS, V28, P807
   Agoram B, 2001, ADV DRUG DELIVER REV, V50, pS41, DOI 10.1016/S0169-409X(01)00179-X
   Au OKC, 2008, ACM T GRAPHIC, V27, DOI 10.1145/1360612.1360643
   Bahloul E, 2017, LUPUS, V26, P1304, DOI 10.1177/0961203317700486
   Cabal A, 2016, DRUG DELIVERY LUNGS
   Carmichael SJ, 2003, THER DRUG MONIT, V25, P671, DOI 10.1097/00007691-200312000-00005
   Chen ZJ, 2010, J COMPUT PHYS, V229, P9150, DOI 10.1016/j.jcp.2010.08.029
   Chiorean L, 2014, MED ULTRASON, V16, P319
   Collins KP, 2018, J PHARMACOL EXP THER, V365, P447, DOI 10.1124/jpet.117.245639
   Doherty MM, 2000, PHARMACEUT RES, V17, P291, DOI 10.1023/A:1007548905772
   Ezra N, 2012, CLIN EXP DERMATOL, V37, P327, DOI 10.1111/j.1365-2230.2011.04266.x
   Furst DE, 1996, LUPUS, V5, pS11, DOI 10.1177/096120339600500104
   Helander HF, 2014, SCAND J GASTROENTERO, V49, P681, DOI 10.3109/00365521.2014.898326
   Huang WL, 2009, AAPS J, V11, P217, DOI 10.1208/s12248-009-9098-z
   Kannan R, 2012, INT J NUMER METH BIO, V28, P1093, DOI 10.1002/cnm.2480
   Kannan R, 2011, INT J NUMER METH BIO, V27, P13, DOI 10.1002/cnm.1406
   Kannan R, 2017, INT J NUMER METH BIO, V33, DOI 10.1002/cnm.2838
   Kannan R, 2016, INT J NUMER METH BIO, V32, DOI 10.1002/cnm.2746
   Kannan R, 2018, INT J NUMER METH BIO, V34, DOI 10.1002/cnm.2955
   Kannan R, 2017, MED ENG PHYS, V42, P35, DOI 10.1016/j.medengphy.2016.11.007
   Kolanjiyil AV, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025332
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Nylund K, 2012, Ultraschall Med, V33, pE225, DOI 10.1055/s-0031-1299329
   OLANSKY AJ, 1982, J AM ACAD DERMATOL, V6, P19, DOI 10.1016/S0190-9622(82)70002-7
   Pang KS, 2003, DRUG METAB DISPOS, V31, P1507, DOI 10.1124/dmd.31.12.1507
   Pavurala N, 2013, COMPUT CHEM ENG, V57, P196, DOI 10.1016/j.compchemeng.2013.06.002
   Ravishekar K, 2020, INT J NUMER METH BIO, V36, P17
   Rodgers T, 2005, J PHARM SCI-US, V94, P1259, DOI 10.1002/jps.20322
   Rodgers T, 2006, J PHARM SCI-US, V95, P1238, DOI 10.1002/jps.20502
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Susmallian S, 2017, IMAJ, V19, P12
   Tam D, 2003, DRUG METAB DISPOS, V31, P373, DOI 10.1124/dmd.31.4.373
   TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x
   Tian G, 2015, PHARM RES-DORDR, V32, P3170, DOI 10.1007/s11095-015-1695-1
   Yang J, BIORXIV, DOI [10.1101/2020.04.22.056762, DOI 10.1101/2020.04.22.056762]
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 37
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2040-7939
EI 2040-7947
J9 INT J NUMER METH BIO
JI Int. J. Numer. Meth. Biomed.
PD DEC
PY 2020
VL 36
IS 12
AR e3403
DI 10.1002/cnm.3403
EA OCT 2020
PG 16
WC Engineering, Biomedical; Mathematical & Computational Biology;
   Mathematics, Interdisciplinary Applications
SC Engineering; Mathematical & Computational Biology; Mathematics
GA PD9BS
UT WOS:000577699300001
PM 33029911
DA 2021-01-01
ER

PT J
AU Garrido, PF
   Calvelo, M
   Blanco-Gonzalez, A
   Veleiro, U
   Suarez, F
   Conde, D
   Cabezon, A
   Pineiro, A
   Garcia-Fandino, R
AF Garrido, Pablo F.
   Calvelo, Martin
   Blanco-Gonzalez, Alexandre
   Veleiro, Uxia
   Suarez, Fabian
   Conde, Daniel
   Cabezon, Alfonso
   Pineiro, Angel
   Garcia-Fandino, Rebeca
TI The Lord of the NanoRings: Cyclodextrins and the battle against
   SARS-CoV-2
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Cyclodextrins; Coronavirus; SARS-CoV-2; COVID-19; Rings
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NEWCASTLE-DISEASE VIRUS; OF-THE-ART;
   BETA-CYCLODEXTRIN; ANTIVIRAL ACTIVITY; LIPID RAFTS; IN-VITRO;
   CHOLESTEROL DEPLETION; MEMBRANE CHOLESTEROL; ALPHA-CYCLODEXTRINS
AB A handful of singular structures and laws can be observed in nature. They are not always evident but, once discovered, it seems obvious how to take advantage of them. In chemistry, the discovery of reproducible patterns stimulates the imagination to develop new functional materials and technological or medical applications. Two clear examples are helical structures at different levels in biological polymers as well as ring and spherical structures of different size and composition. Rings are intuitively observed as holes able to thread elongated structures. A large number of real and fictional stories have rings as inanimate protagonists. The design, development or just discovering of a special ring has often been taken as a symbol of power or success. Several examples are the Piscatory Ring wore by the Pope of the Catholic Church, the NBA Championship ring and the One Ring created by the Dark Lord Sauron in the epic story The Lord of the Rings. In this work, we reveal the power of another extremely powerful kind of rings to fight against the pandemic which is currently affecting the whole world. These rings are as small as similar to 1 nm of diameter and so versatile that they are able to participate in the attack of viruses, and specifically SARS-CoV-2, in a large range of different ways. This includes the encapsulation and transport of specific drugs, as adjuvants to stabilize proteins, vaccines or other molecules involved in the infection, as cholesterol trappers to destabilize the virus envelope, as carriers for RNA therapies, as direct antiviral drugs and even to rescue blood coagulation upon heparin treatment.
   "One ring to rule them all. One ring to find them. One ring to bring them all and in the darkness bind them." J. R. R. Tolkien.
C1 [Garrido, Pablo F.; Veleiro, Uxia; Suarez, Fabian; Pineiro, Angel] Univ Santiago de Compostela, Fac Fis, Dept Fis Aplicada, E-15782 Santiago De Compostela, Spain.
   [Calvelo, Martin; Blanco-Gonzalez, Alexandre; Conde, Daniel; Cabezon, Alfonso; Garcia-Fandino, Rebeca] Univ Santiago de Compostela, Ctr Res Biol Chem & Mol Mat, Dept Quim Organ, Campus Vida S-N, E-15782 Santiago De Compostela, Spain.
RP Pineiro, A (corresponding author), Univ Santiago de Compostela, Fac Fis, Dept Fis Aplicada, E-15782 Santiago De Compostela, Spain.; Garcia-Fandino, R (corresponding author), Univ Santiago de Compostela, Ctr Res Biol Chem & Mol Mat, Dept Quim Organ, Campus Vida S-N, E-15782 Santiago De Compostela, Spain.
EM Angel.Pineiro@usc.es; rebeca.garcia.fandino@usc.es
RI Blanco-Gonzalez, Alexandre/ABE-1140-2020; Garcia Fandino,
   Rebeca/M-1880-2014
OI Blanco-Gonzalez, Alexandre/0000-0001-8593-5881; Garcia Fandino,
   Rebeca/0000-0002-5274-3928
FU Spanish Agencia Estatal de Investigacion (AEI); ERDFEuropean Union (EU)
   [CTQ2016-78423-R, RTI2018098795-A-I00, ED431G 2019/03]; Xunta de
   GaliciaXunta de Galicia; ERDF (Centro singular de investigacion de
   Galicia accreditation 2016-2019)European Union (EU) [RYC-201620335];
   Xunta de GaliciaXunta de Galicia [ED481A-2017/068]; Spanish Ministry of
   Economy and Competitiveness; European Social FundEuropean Social Fund
   (ESF) [BES-2016-076761]
FX This work was supported by the Spanish Agencia Estatal de Investigacion
   (AEI) and the ERDF (CTQ2016-78423-R and RTI2018098795-A-I00), and by the
   Xunta de Galicia and the ERDF (ED431G 2019/03 and Centro singular de
   investigacion de Galicia accreditation 2016-2019, ED431G/09). R.G.-F.
   thanks to Ministerio de Ciencia, Innovacion y Universidades for a "Ramon
   y Cajal" contract (RYC-201620335). M.C. thanks to Xunta de Galicia for a
   predoctoral fellowship (ED481A-2017/068). P. F. G. thanks the Spanish
   Ministry of Economy and Competitiveness and the European Social Fund for
   his predoctoral research grant, reference BES-2016-076761.
CR Abdou S, 1997, ARCH VIROL, V142, P1585, DOI 10.1007/s007050050182
   Adeoye O, 2020, CARBOHYD POLYM, V227, DOI 10.1016/j.carbpol.2019.115287
   Adeoye O, 2017, INT J PHARMACEUT, V531, P521, DOI 10.1016/j.ijpharm.2017.04.050
   Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6
   Ain S., 2015, INT J PHARM CHEM BIO, V5
   Anderson A, 2020, REDOX BIOL, V29, DOI 10.1016/j.redox.2019.101380
   [Anonymous], 2018, CYCLODEXTRIN NEWS
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arima H, 2009, SENSORS-BASEL, V9, P6346, DOI 10.3390/s90806346
   Arnold J, 2002, J PHARM SCI-US, V91, P1707, DOI 10.1002/jps.10171
   ASDERA, 2020, ASDERA ALPH CYCL COR
   ASHP, 2020, ASS EV COVID 19 REL
   Atger VM, 1997, J CLIN INVEST, V99, P773, DOI 10.1172/JCI119223
   Baglivo Mirko, 2020, Acta Biomed, V91, P161, DOI 10.23750/abm.v91i1.9402
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Bajracharya R, 2019, COMPUT STRUCT BIOTEC, V17, P1290, DOI 10.1016/j.csbj.2019.09.004
   Barman S, 2007, J VIROL, V81, P12169, DOI 10.1128/JVI.00835-07
   Bencini M, 2008, J CONTROL RELEASE, V126, P17, DOI 10.1016/j.jconrel.2007.11.004
   Bloomberg, 2020, VIR BIOT CEO FIND CO
   Bodier-Montagutelli E, 2018, EXPERT OPIN DRUG DEL, V15, P729, DOI 10.1080/17425247.2018.1503251
   Braga SS, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120801
   Cantin C, 2007, J GEN VIROL, V88, P559, DOI 10.1099/vir.0.82150-0
   Carrouel F, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041126
   Carrouel F, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10010140
   Castellanos IJ, 2006, J PHARM SCI-US, V95, P849, DOI 10.1002/jps.20512
   Cavalli R, 2009, J CONTROL RELEASE, V137, P116, DOI 10.1016/j.jconrel.2009.04.004
   Chacornac I., 2016, Patent No. [WO2016012385A1, 2016012385]
   Chan JFW, 2013, TRENDS MICROBIOL, V21, P544, DOI 10.1016/j.tim.2013.05.005
   Chang Z, 2006, GENE THER, V13, P871
   CHANGEUX jean-pierre, 2020, QEIOS
   Chaturvedi K, 2011, EXPERT OPIN DRUG DEL, V8, P1455, DOI 10.1517/17425247.2011.610790
   Chen SH, 2019, J MED VIROL, V91, P949, DOI 10.1002/jmv.25414
   Choi KS, 2005, J VIROL, V79, P9862, DOI 10.1128/JVI.79.15.9862-9871.2005
   Christian AE, 1997, J LIPID RES, V38, P2264
   Christian AE, 1999, J LIPID RES, V40, P1475
   Coelho Paraguassu E., 2020, BRAZ J IMPLANTOL HLT, V2, P96, DOI [10.36557/2674-8169.2020v2n3p96-109., DOI 10.36557/2674-8169.2020V2N3P96-109]
   Conceicao J, 2018, DRUG DISCOV TODAY, V23, P1274, DOI 10.1016/j.drudis.2018.04.009
   Crini G, 2014, CHEM REV, V114, P10940, DOI 10.1021/cr500081p
   Crooke S.T., 2008, Patent No. [WO2005023083A2, 2005023083]
   Cryan SA, 2004, J DRUG DELIV SCI TEC, V14, P57, DOI 10.1016/S1773-2247(04)50006-0
   Cyclolab, CYCL APIS
   Davis ME, 2009, MOL PHARMACEUT, V6, P659, DOI 10.1021/mp900015y
   Davis ME, 2004, NAT REV DRUG DISCOV, V3, P1023, DOI 10.1038/nrd1576
   De Andrea Marco, 2002, Eur J Paediatr Neurol, V6 Suppl A, pA41, DOI 10.1053/ejpn.2002.0573
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Del Curto M.D., 2010, Patent No. [WO2005058346A1, 2005058346]
   Domanska MK, 2013, BIOPHYS J, V105, P1383, DOI 10.1016/j.bpj.2013.08.003
   Erb-Zohar K, 2017, CTS-CLIN TRANSL SCI, V10, P487, DOI 10.1111/cts.12483
   Evenou P, 2018, ANGEW CHEM INT EDIT, V57, P7753, DOI 10.1002/anie.201802550
   Fernandez M, 2004, ENZYME MICROB TECH, V34, P78, DOI 10.1016/j.enzmictec.2003.09.003
   FRENCH D, 1957, ADV CARBOHYD CHEM, V12, P189
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Glende JH, 2008, FASEB J, V22
   Goyal G, 2012, J INCL PHENOM MACRO, V73, P75, DOI 10.1007/s10847-011-0022-7
   Graham DRM, 2003, J VIROL, V77, P8237, DOI 10.1128/JVI.77.15.8237-8248.2003
   Grancher N, 2004, ANTIVIR RES, V62, P135, DOI 10.1016/j.antiviral.2004.01.003
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo JF, 2010, MOL BIOSYST, V6, P1143, DOI 10.1039/c001050m
   Guyader M, 2002, J VIROL, V76, P10356, DOI 10.1128/JVI.76.20.10356-10364.2002
   Hambleton S, 2007, J VIROL, V81, P7548, DOI 10.1128/JVI.00486-07
   Higashi T, 2019, CHEM PHARM BULL, V67, P289, DOI 10.1248/cpb.c18-00735
   Higashi T, 2019, YAKUGAKU ZASSHI, V139, P175, DOI 10.1248/yakushi.18-00168-4
   Higashi T, 2015, AAPS PHARMSCITECH, V16, P1290, DOI 10.1208/s12249-015-0309-x
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   HU W, 2017, PLOS ONE, V12
   Hu X, 2020, LOW SERUM CHOLESTERO, DOI [10.2139/ssrn.3544826, DOI 10.2139/SSRN.3544826]
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Iannazzo D, 2014, COLLOID SURFACE B, V123, P264, DOI 10.1016/j.colsurfb.2014.09.025
   Jeulin H, 2009, ANTIVIR RES, V81, P261, DOI 10.1016/j.antiviral.2008.12.006
   Jones ST, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax9318
   Kane Colleen, 2013, Inflammation & Allergy Drug Targets, V12, P81
   Khan N. A., 2013, INT J BIOASSAYS, V2, P858
   KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250
   Kim SK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00435
   Kozbial M, 2013, J SOLUTION CHEM, V42, P866, DOI 10.1007/s10953-013-9995-8
   Krause MR, 2014, ACCOUNTS CHEM RES, V47, P3512, DOI 10.1021/ar500260t
   Kurkov SV, 2013, INT J PHARMACEUT, V453, P167, DOI 10.1016/j.ijpharm.2012.06.055
   Kusakabe T, 2016, VACCINE, V34, P3191, DOI 10.1016/j.vaccine.2016.04.001
   Kwon S, 2009, J MOL STRUCT, V938, P192, DOI 10.1016/j.molstruc.2009.09.025
   Lakkakula JR, 2014, NANOMEDICINE-UK, V9, P877, DOI [10.2217/NNM.14.41, 10.2217/nnm.14.41]
   Larson N., 2019, Patent No. [US20190083525A1, 20190083525]
   Lauder SN, 2013, EUR J IMMUNOL, V43, P2613, DOI 10.1002/eji.201243018
   Leclercq L, 2016, BEILSTEIN J ORG CHEM, V12, P2644, DOI 10.3762/bjoc.12.261
   Lembo D, 2013, INT J PHARMACEUT, V443, P262, DOI 10.1016/j.ijpharm.2012.12.031
   Li GM, 2007, MICROBES INFECT, V9, P96, DOI 10.1016/j.micinf.2006.10.015
   Li J, 2006, ADV MATER, V18, P2969, DOI 10.1002/adma.200600812
   Li PY, 2019, CHEM COMMUN, V55, P11790, DOI 10.1039/c9cc06545h
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Liang SB, 2019, EUR J MED CHEM, V166, P328, DOI 10.1016/j.ejmech.2019.01.074
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Loftsson T, 1996, J PHARM SCI, V85, P1017, DOI 10.1021/js950534b
   Loftsson T, 2002, J INCL PHENOM MACRO, V44, P63, DOI 10.1023/A:1023088423667
   Lopez CA, 2013, SCI REP-UK, V3, DOI 10.1038/srep02071
   Lopez CA, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002020
   Lorizate M, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004820
   Lu RM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0592-z
   Lu YN, 2008, BIOCHEM BIOPH RES CO, V369, P344, DOI 10.1016/j.bbrc.2008.02.023
   Mahammad S, 2015, METHODS MOL BIOL, V1232, P91, DOI 10.1007/978-1-4939-1752-5_8
   Marichal-Gallardo PA, 2012, BIOTECHNOL PROGR, V28, P899, DOI 10.1002/btpr.1567
   Martin J., 2018, CYCLODEXTRIN VERSATI, DOI [10.5772/intechopen.72736., DOI 10.5772/INTECHOPEN.72736]
   Martin JJ, 2012, BBA-BIOMEMBRANES, V1818, P753, DOI 10.1016/j.bbamem.2011.12.004
   Marty FM, 2017, NEW ENGL J MED, V377, P2433, DOI 10.1056/NEJMoa1706640
   Mazzaglia A, 2018, COLLOID SURFACE B, V163, P55, DOI 10.1016/j.colsurfb.2017.12.028
   Mazzon M, 2014, CELL MICROBIOL, V16, P1493, DOI 10.1111/cmi.12340
   Meher G, 2019, J PHYS CHEM B, V123, P10654, DOI 10.1021/acs.jpcb.9b08455
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meijers J.C.M., 2019, Patent No. [WO2017188820A1, 2017188820]
   Miertus S, 1999, MACROMOL SYMP, V138, P41, DOI 10.1002/masy.19991380106
   Morra ME, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1977
   Nair AB, 2014, DRUG DELIV, V21, P540, DOI 10.3109/10717544.2013.853213
   Nayak DP, 2004, SUB CELL BIOCHEM, V37, P443
   Nemeth K, 2011, J PHARMACEUT BIOMED, V54, P475, DOI 10.1016/j.jpba.2010.09.020
   Nicolazzi C, 2001, BIOORGAN MED CHEM, V9, P275, DOI 10.1016/S0968-0896(00)00247-9
   Nicolazzi C, 2002, ANTIVIR RES, V54, P121, DOI 10.1016/S0166-3542(01)00218-2
   Nishijo J, 2003, CHEM PHARM BULL, V51, P1253, DOI 10.1248/cpb.51.1253
   Notario-Perez F, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12040321
   NUSSBAUM O, 1992, J GEN VIROL, V73, P2831, DOI 10.1099/0022-1317-73-11-2831
   O'Mahony AM, 2013, PHARM NANOTECHNOL, V1, P6
   OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x
   Ohvo H, 1996, BIOCHEMISTRY-US, V35, P8018, DOI 10.1021/bi9528816
   Onishi M, 2015, J IMMUNOL, V194, P2673, DOI 10.4049/jimmunol.1402027
   Ono A, 2005, ADV VIRUS RES, V64, P311, DOI 10.1016/S0065-3527(05)64010-9
   Mellet CO, 2011, CHEM SOC REV, V40, P1586, DOI 10.1039/c0cs00019a
   Padmanabhan S., 2020, PREPRINT, DOI [10.13140/RG.2.2.28124.74882, DOI 10.13140/RG.2.2.28124.74882]
   Pan YF, 2015, MACROMOL CHEM PHYS, V216, P511, DOI 10.1002/macp.201400525
   Parkin J, 2001, LANCET, V357, P1777, DOI 10.1016/S0140-6736(00)04904-7
   Pharma Advancement, 2020, WUXI BIOL ENABLES DE
   Ping Y, 2011, BIOMATERIALS, V32, P8328, DOI 10.1016/j.biomaterials.2011.07.038
   Radi AE, 2014, MONATSH CHEM, V145, P421, DOI 10.1007/s00706-013-1109-1
   Ramezani V, 2017, DRUG DEV IND PHARM, V43, P1103, DOI 10.1080/03639045.2017.1293679
   Rane S., 2017, Patent No. [WO2012135561A1, 2012135561]
   Rao MRP, 2018, AAPS PHARMSCITECH, V19, P2358, DOI 10.1208/s12249-018-1064-6
   Roy A, 2020, J INCL PHENOM MACRO, V97, P65, DOI 10.1007/s10847-020-00984-1
   Sagan SM, 2006, BIOCHEM CELL BIOL, V84, P67, DOI 10.1139/O05-149
   Sallas F, 2008, EUR J ORG CHEM, V2008, P957, DOI 10.1002/ejoc.200700933
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sanofi, 2020, SAN REG BEG GLOB KEV
   Saokham P, 2017, INT J PHARMACEUT, V516, P278, DOI 10.1016/j.ijpharm.2016.10.062
   Schmitt AP, 2005, ADV VIRUS RES, V64, P383, DOI 10.1016/S0065-3527(05)64012-2
   Schule S, 2008, EUR J PHARM BIOPHARM, V69, P793, DOI 10.1016/j.ejpb.2008.02.010
   Serno T, 2011, ADV DRUG DELIVER REV, V63, P1086, DOI 10.1016/j.addr.2011.08.003
   Serno T, 2010, J PHARM SCI-US, V99, P1193, DOI 10.1002/jps.21931
   Sevukarajan M., 2010, J PHARM SCI RES, V2, P583
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shi Y, 2005, CELL RES, V15, P193, DOI 10.1038/sj.cr.7290286
   Shulmann RI, 2000, PHARMACOL THERAPEUT, V87, P1, DOI 10.1016/S0163-7258(00)00060-7
   Song JC, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00247-7
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Sun PF, 2020, J MED VIROL, V92, P1721, DOI 10.1002/jmv.25804
   Sun XJ, 2003, J VIROL, V77, P12543, DOI 10.1128/JVI.77.23.12543-12551.2003
   Szente L, 2016, J PHARMACEUT BIOMED, V130, P347, DOI 10.1016/j.jpba.2016.05.009
   Tan L, 2020, DRUG DELIV TRANSL RE, V10, P678, DOI 10.1007/s13346-020-00725-4
   Tang QP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11050438
   Tang YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048013
   Tavornvipas S, 2004, PHARM RES-DORDR, V21, P2369, DOI 10.1007/s11095-004-7691-5
   Taylor DR, 2007, SEMIN CELL DEV BIOL, V18, P638, DOI 10.1016/j.semcdb.2007.07.008
   Thuja Capital, 2019, ALV PHARM CLOS SER R
   Tian ZY, 2017, EUR J MED CHEM, V134, P133, DOI 10.1016/j.ejmech.2017.03.087
   Totura AL, 2019, EXPERT OPIN DRUG DIS, V14, P397, DOI 10.1080/17460441.2019.1581171
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Tsamaloukas A, 2005, BIOPHYS J, V89, P1109, DOI 10.1529/biophysj.105.061846
   Uekama K, 2004, CHEM PHARM BULL, V52, P900, DOI 10.1248/cpb.52.900
   Verma DK, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110650
   Villiers A., 1891, CR HEBD ACAD SCI, V112, P536
   Vinetz JM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2018
   Wang Hao, 2020, bioRxiv, DOI 10.1101/2020.05.09.086249
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang Z, 2004, J VIROL, V78, P7523, DOI 10.1128/JVI.78.14.7523-7527.2004
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wudiri GA, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02383
   Wudiri GA, 2017, J VIROL, V91, DOI 10.1128/JVI.00445-17
   Xiao SL, 2016, BIOMATERIALS, V78, P74, DOI 10.1016/j.biomaterials.2015.11.034
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang CA, 2009, POLYMER, V50, P1378, DOI 10.1016/j.polymer.2009.01.010
   Yang ST, 2016, CHEM PHYS LIPIDS, V199, P136, DOI 10.1016/j.chemphyslip.2016.05.003
   Yang TZ, 2004, PHARM RES-DORDR, V21, P1127, DOI 10.1023/B:PHAM.0000032998.84488.7a
   Zawada KE, 2016, SCI REP-UK, V6, DOI 10.1038/srep29842
   Zhang JX, 2013, ADV DRUG DELIVER REV, V65, P1215, DOI 10.1016/j.addr.2013.05.001
   Zhang YJ, 2004, FEBS LETT, V560, P141, DOI 10.1016/S0014-5793(04)00087-0
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu XL, 2018, EUR J MED CHEM, V146, P194, DOI 10.1016/j.ejmech.2018.01.040
   Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamem.2007.03.026
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 186
TC 2
Z9 2
U1 12
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD OCT 15
PY 2020
VL 588
AR 119689
DI 10.1016/j.ijpharm.2020.119689
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OA1MC
UT WOS:000577557700007
PM 32717282
OA Green Published
DA 2021-01-01
ER

PT J
AU Glynn, JR
   Moss, PAH
AF Glynn, Judith R.
   Moss, Paul A. H.
TI Systematic analysis of infectious disease outcomes by age shows lowest
   severity in school-age children
SO SCIENTIFIC DATA
LA English
DT Article; Data Paper
ID ACUTE RESPIRATORY SYNDROME; EBOLA-AFFECTED HOUSEHOLDS;
   ZOSTER-VIRUS-INFECTION; ST-LOUIS ENCEPHALITIS; HEPATITIS-B-VIRUS;
   IMMUNE-RESPONSES; VARICELLA-ZOSTER; 1918 INFLUENZA;
   CYTOMEGALOVIRUS-INFECTION; SALMONELLA INFECTIONS
AB The COVID-19 pandemic has ignited interest in age-specific manifestations of infection but surprisingly little is known about relative severity of infectious disease between the extremes of age. In a systematic analysis we identified 142 datasets with information on severity of disease by age for 32 different infectious diseases, 19 viral and 13 bacterial. For almost all infections, school-age children have the least severe disease, and severity starts to rise long before old age. Indeed, for many infections even young adults have more severe disease than children, and dengue was the only infection that was most severe in school-age children. Together with data on vaccine response in children and young adults, the findings suggest peak immune function is reached around 5-14 years of age. Relative immune senescence may begin much earlier than assumed, before accelerating in older age groups. This has major implications for understanding resilience to infection, optimal vaccine scheduling, and appropriate health protection policies across the life course.
C1 [Glynn, Judith R.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Moss, Paul A. H.] Univ Birmingham, Coll Med & Dent Sci, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England.
RP Glynn, JR (corresponding author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
EM Judith.glynn@lshtm.ac.uk
FU Higher Education Funding Council of England via the London School of
   Hygiene & Tropical Medicine; University of Birmingham
FX With thanks to Hilary Bower, Judy Breuer, Oona Campbell, Michel Carael,
   Hazel Dockrell, Paul Fine, Helen Fletcher, Nigel Klein, Andrew Prentice,
   Milica Vukmanovic-Stejic for helpful discussions at various stages of
   this work. No specific funding was received for this work. JRG is funded
   largely by the Higher Education Funding Council of England via the
   London School of Hygiene & Tropical Medicine and PAHM is funded by the
   University of Birmingham.
CR AABY P, 1988, REV INFECT DIS, V10, P478
   Acland H. W, 1856, MEMOIR CHOLERA OXFOR
   Agua-Agum J, 2016, NEW ENGL J MED, V374, P96, DOI 10.1056/NEJMc1510305
   Ahmed R, 2007, NAT IMMUNOL, V8, P1188, DOI 10.1038/ni1530
   Aiello AE, 2017, GEROSCIENCE, V39, P261, DOI 10.1007/s11357-017-9983-9
   Alipio M. M., 2020, EPIDEMIOLOGICAL CHAR, DOI 10.1101/2020.04.12.20053926v1
   Anon, 1849, REPORT CHOLERA PARIS
   Anon, 1897, REPORT MED SUPERINTE
   Anon, 1895, PUBLIC HLTH, P333
   Anon, 1903, PLAGUE CASES TREATED
   [Anonymous], 1955, WHO MONOGR SER, V26
   [Anonymous], 2020, ACT 103 ENF COR COVI
   Babiker A, 2000, LANCET, V355, P1131
   Barry D, 1889, REPORT EPIDEMIC SMAL
   Barton ES, 2007, NATURE, V447, P326, DOI 10.1038/nature05762
   Ben-Smith A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-139
   Benedict C, 1992, THESIS
   Bignami-Van Assche S., 2020, ESTIMATES COVID 19 C, DOI [10.1101/2020.04.16.20067751v1, DOI 10.1101/2020.04.16.20067751V1]
   BILLE B, 1964, ACTA MED SCAND, V175, P557
   Boelle PY, 2002, EPIDEMIOL INFECT, V129, P599, DOI 10.1017/S0950268802007720
   Bouman A, 2005, HUM REPROD UPDATE, V11, P411, DOI 10.1093/humupd/dmi008
   Bower H, 2016, EMERG INFECT DIS, V22, P1403, DOI 10.3201/eid2208.160163
   Bower H, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2403
   Boyd E, 1936, AM J DIS CHILD, V51, P313
   BRADSHAW MJ, 1980, POSTGRAD MED J, V56, P80, DOI 10.1136/pgmj.56.652.80
   Brisson M, 2001, EPIDEMIOL INFECT, V127, P305, DOI 10.1017/S0950268801005921
   Burattini MN, 2016, CLINICS, V71, P455, DOI 10.6061/clinics/2016(08)08
   Burnet Ham B, 1907, REPORT PLAGUE QUEENS
   Byrne L, 2015, EPIDEMIOL INFECT, V143, P3475, DOI 10.1017/S0950268815000746
   Cao WC, 2011, INFECT DIS REP, V3, P3, DOI 10.4081/idr.2011.e2
   Carr EJ, 2016, NAT IMMUNOL, V17, P461, DOI 10.1038/ni.3371
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Chen PL, 2012, EPIDEMIOL INFECT, V140, P2256, DOI 10.1017/S0950268812000088
   Choksy N. H, 1903, TREATMENT PLAGUE PRO
   Chowell G, 2011, VACCINE, V29, pB21, DOI 10.1016/j.vaccine.2011.02.048
   Chowell G, 2014, EMERG INFECT DIS, V20, P1803, DOI 10.3201/eid2011.130632
   Chowell G, 2012, EMERG INFECT DIS, V18, P48, DOI 10.3201/eid1801.101969
   Clark S. J., 2011, CONT MODEL LIFE TABL
   Cohen DI, 2006, INFECTION, V34, P208, DOI 10.1007/s15010-006-6604-4
   Collins SD, 1931, PUBLIC HEALTH REP, V46, P1909, DOI 10.2307/4580139
   COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593
   Cox S. M, 1908, REPORT OUTBREAK ASIA
   Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9
   Davies S, 1896, PUBLIC HLTH, V8, P119
   Davis MM, 2018, ANNU REV IMMUNOL, V36, P843, DOI 10.1146/annurev-immunol-042617-053206
   Debono J. E, 1939, BRUCEL LOSIS MAN ANI
   Department of Health for Scotland, 1950, POL SURV OUTBR SCOTL
   Dickie D, 1930, PUBLIC HLTH B, V194
   Dingle CV, 1898, PUBLIC HLTH, V11, P173, DOI [10.1016/S0033-3506(05)81047-9, DOI 10.1016/S0033-3506(05)81047-9]
   DIZON JJ, 1965, B WORLD HEALTH ORGAN, V33, P627
   Donovan CR, 1942, CAN MED ASSOC J, V46, P525
   Donovan CR, 1942, CANADIAN PUBLIC HLTH, V33, P241
   DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203
   EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197, DOI 10.1098/rspb.1993.0102
   FEREBEE SH, 1962, AM REV RESPIR DIS, V85, P490
   Finger D, 1851, CHOLERA EPIDEMICA NA
   Fisker N, 2003, CLIN INFECT DIS, V37, pE47, DOI 10.1086/375897
   FORBES A, 1988, J ROY COLL PHYS LOND, V22, P237
   Frost WH, 1919, PUBLIC HLTH REPORTS, V34, P491, DOI [10.2307/4575056, DOI 10.2307/4575056]
   Furman D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa2293
   Ghosh S, 2017, J IMMUNOL, V198, P1782, DOI 10.4049/jimmunol.1601166
   Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326
   Prieto RG, 2009, J INFECTION, V58, P175, DOI 10.1016/j.jinf.2009.01.002
   Glynn J.R., 2020, SYSTEMATIC ANAL INFE, DOI [10.17037/DATA.00001787, DOI 10.17037/DATA.00001787GLYNN]
   GLYNN JR, 1995, EPIDEMIOL INFECT, V115, P23, DOI 10.1017/S0950268800058088
   GLYNN JR, 1992, AM J EPIDEMIOL, V136, P1369, DOI 10.1093/oxfordjournals.aje.a116449
   GLYNN JR, 1992, EPIDEMIOL INFECT, V109, P371, DOI 10.1017/S0950268800050366
   Glynn JR, 2017, LANCET INFECT DIS, V17, P645, DOI 10.1016/S1473-3099(17)30111-1
   Godfrey ES, 1928, AM J PUBLIC HEALTH N, V18, P616, DOI 10.2105/AJPH.18.5.616
   Gould LH, 2009, CLIN INFECT DIS, V49, P1480, DOI 10.1086/644621
   GUESS HA, 1986, PEDIATRICS, V78, P723
   Guest Gornall J, 1900, PUBLIC HLTH, V12, P841, DOI [10.1016/S0033-3506(00)80339-X, DOI 10.1016/S0033-3506(00)80339-X]
   Gull W. W, 1854, REPORTS PI DEMIC CHO
   Guzman Maria G., 2002, International Journal of Infectious Diseases, V6, P118, DOI 10.1016/S1201-9712(02)90072-X
   Hayden T., 1867, REPORT CHOLERA EPIDE
   Heiman H., 1913, MENINGOCOCCUS MENING
   HENKE CE, 1973, AM J EPIDEMIOL, V98, P483, DOI 10.1093/oxfordjournals.aje.a121577
   Hill A, 1896, PUBLIC HLTH, V8, P413, DOI [10.1016/S0033-3506(05)82673-3, DOI 10.1016/S0033-3506(05)82673-3]
   Hill E, 1904, REPORT PLAGUE NATAL
   HOLDEN O. M., 1939, Public Health, V52, P135, DOI 10.1016/S0033-3506(38)80123-2
   HOPKINS CC, 1975, AM J EPIDEMIOL, V102, P1
   Ilori E. A, 2019, EMERG INFECT DIS, V25
   Joachim RB, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20177998
   Kaczorowski KJ, 2017, P NATL ACAD SCI USA, V114, pE6097, DOI 10.1073/pnas.1705065114
   Kang GD, 2016, HUM VACC IMMUNOTHER, V12, P2312, DOI 10.1080/21645515.2016.1172757
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Killinck Mallard C, 1904, PUBLIC HLTH, V16, P607, DOI [10.1016/S0033-3506(03)80120-8, DOI 10.1016/S0033-3506(03)80120-8]
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   KONO R, 1969, B WORLD HEALTH ORGAN, V40, P263
   Laing JS, 1902, PUBLIC HLTH, V14, P584, DOI [10.1016/S0033-3506(01)80186-4, DOI 10.1016/S0033-3506(01)80186-4]
   Lau EHY, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-50
   Launders N, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009933
   Lavinder C. H., 1918, PUBLIC HLTH B, V91, P1
   LEBACQ F, 1994, EUR J EPIDEMIOL, V10, P367, DOI 10.1007/BF01719658
   LEDNAR WM, 1985, AM J EPIDEMIOL, V122, P226, DOI 10.1093/oxfordjournals.aje.a114093
   Lessler J, 2016, AM J EPIDEMIOL, V183, P657, DOI 10.1093/aje/kwv452
   Lindhardt M, 1939, STAT PULMONARY TUBER
   LOGAN W P, 1952, Mon Bull Minist Health Public Health Lab Serv, V11, P147
   LUBY JP, 1967, AM J EPIDEMIOL, V86, P584
   Lumsden L. L, 1936, EPIDEMIOLOGICAL STUD
   Macchiavello A, 1941, CONTRIBUCIONES ESTUD
   MacGregor ASM, 1924, PUBLIC HLTH, V27, P269, DOI [10.1016/S0033-3506(14)80027-9, DOI 10.1016/S0033-3506(14)80027-9]
   Mahoney O. B, 1853, PATHOLOGICAL PRACTIA
   Mamelund SE, 2011, EPIDEMICS-NETH, V3, P46, DOI 10.1016/j.epidem.2011.02.001
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P278
   Marson J. F, 1857, PAPERS RELATING HIST
   MCCORMICK JB, 1987, J INFECT DIS, V155, P437, DOI 10.1093/infdis/155.3.437
   MCCORMICK JB, 1987, J INFECT DIS, V155, P445, DOI 10.1093/infdis/155.3.445
   McCulloch T., 1907, REPORTS COMMISSION A
   McDade TW, 2016, EVOL MED PUBLIC HLTH, P1, DOI 10.1093/emph/eov033
   MCGOWAN JE, 1973, AM J EPIDEMIOL, V97, P199, DOI 10.1093/oxfordjournals.aje.a121500
   MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599
   McMorrow ML, 2015, J INFECT DIS, V212, P853, DOI 10.1093/infdis/jiv100
   Merrillees C. R, 1943, REPORT TYPHOID FEVER
   Miles DJC, 2008, IMMUNOLOGY, V124, P388, DOI 10.1111/j.1365-2567.2007.02787.x
   Miller E, 1997, BIOLOGICALS, V25, P137, DOI 10.1006/biol.1997.0072
   Muckenfuss R S, 1934, Bull N Y Acad Med, V10, P444
   Murchison C, 1858, Med Chir Trans, V41, P219
   Muscat M, 2016, EUROSURVEILLANCE, V21, P19, DOI 10.2807/1560-7917.ES.2016.21.9.30152
   Nagelkerke N. J. D, 2012, COURTESANS CONSUMPTI
   Nathanson N, 2010, AM J EPIDEMIOL, V172, P1213, DOI 10.1093/aje/kwq320
   Nichols GL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001179
   Nikolich-Zugich J, 2017, CURR OPIN IMMUNOL, V48, P23, DOI 10.1016/j.coi.2017.07.011
   Niven J, 1893, PUBLIC HLTH, V64, P324
   Okokhere P, 2018, LANCET INFECT DIS, V18, P684, DOI 10.1016/S1473-3099(18)30121-X
   Olin G, 1952, 2 INT POL C, P367
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Ostergaard L, 2017, NEW ENGL J MED, V377, P2349, DOI 10.1056/NEJMoa1614474
   Ottochian M, 2009, INJURY, V40, P354, DOI 10.1016/j.injury.2008.10.015
   Page AL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003605
   Pant DK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180591
   Panum P. L, 1940, OBSERVATIONS MADE EP
   Parkin J, 1852, STAT REPORT EPIDEMIC
   PEARCE N, 1988, NEW ZEAL MED J, V101, P788
   Pera A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088538
   Petersen LK, 2017, PAPILLOMAVIRUS RES, V3, P105, DOI 10.1016/j.pvr.2017.03.002
   PICKEN R. M. F., 1940, Public Health, V54, P42, DOI 10.1016/S0033-3506(40)80039-5
   Picken RMF, 1915, PUBLIC HLTH, V29, P2, DOI [10.1016/S0033-3506(15)80471-5, DOI 10.1016/S0033-3506(15)80471-5]
   Porter C, 1893, PUBLIC HLTH, V68, P80
   PORTER IA, 1980, J HYG-CAMBRIDGE, V84, P415, DOI 10.1017/S0022172400026942
   Preston S. H, 1976, MORTALITY PATTERNS N
   Procter J. R, 1879, NOTES YELLOW FEVER E
   Ramsay M, 1994, COMMUNICAB DIS REP, V4, P141
   Ramsey Smith W, 1923, OFFICIAL YB COMMONWE, V16
   Read M, 1900, PUBLIC HLTH, V12, P346, DOI [10.1016/S0033-3506(00)80222-X, DOI 10.1016/S0033-3506(00)80222-X]
   Redeker A, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01953
   Reincke, 1894, REPORTS PAPERS CHOLE
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rogers L, 1911, CHOLERA ITS TREATMEN
   ROSS AH, 1962, NEW ENGL J MED, V267, P369, DOI 10.1056/NEJM196208232670801
   Roved J, 2017, HORM BEHAV, V88, P95, DOI 10.1016/j.yhbeh.2016.11.017
   Ruzante JM, 2011, EPIDEMIOL INFECT, V139, P937, DOI 10.1017/S0950268810001883
   Savva GM, 2013, AGING CELL, V12, P381, DOI 10.1111/acel.12059
   Shaffer JG, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002748
   Shanley DP, 2009, TRENDS IMMUNOL, V30, P374, DOI 10.1016/j.it.2009.05.001
   Shattuck-Heidorn H, 2017, EVOL MED PUBLIC HLTH, P27, DOI 10.1093/emph/eow034
   Shim JJ, 2012, EPIDEMIOL INFECT, V140, P2182, DOI 10.1017/S095026881200012X
   Sibley S. W, 1855, REPORT CHOLERA PATIE
   Simanek AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016103
   Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085
   Solis P., 2020, COVID 19 FATALITY CO, DOI [10.1101/2020.04.21.20074591v1, DOI 10.1101/2020.04.21.20074591V1]
   Stallybrass C. O, 1931, PRINCIPLES EPIDEMIOL
   STEINMANN GG, 1985, SCAND J IMMUNOL, V22, P563, DOI 10.1111/j.1365-3083.1985.tb01916.x
   Sternberg G. M, 1890, REPORT ETIOLOGY PREV
   Sticker G, 1910, ABHANDLUNGEN SEUCHEN
   Sticker G, 1912, ABHANDLUNGEN SEUCHEN
   Stockdale L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192086
   Stockman LJ, 2007, PEDIATR INFECT DIS J, V26, P68, DOI 10.1097/01.inf.0000247136.28950.41
   Tahden M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164508
   Tang YX, 2015, CLIN INFECT DIS, V61, pS531, DOI 10.1093/cid/civ601
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   The Government of the Republic of Korea, 2020, TACKL COVID 19 HLTH
   The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P1, DOI DOI 10.5194/GCHRON-2-1-2020
   Thomson G. S., 1901, TREATISE PLAGUE COND
   Townsend S. C, 1878, REPORT EPIDEMIC CHOL
   Turner JE, 2014, AGE, V36, P287, DOI 10.1007/s11357-013-9557-4
   UMOH JU, 1983, J HYG-CAMBRIDGE, V91, P101, DOI 10.1017/S0022172400060083
   US Treasury Department Public Health Service, 1935, PUBLIC HLTH B, V214
   Van Damme P, 2016, VACCINE, V34, P4205, DOI 10.1016/j.vaccine.2016.06.056
   van Lier A, 2013, VACCINE, V31, P5127, DOI 10.1016/j.vaccine.2013.08.029
   Viner R. M, 2020, SUSCEPTIBILITY SARS, DOI [10.1101/2020.05.20.20108126v2, DOI 10.1101/2020.05.20.20108126V2]
   Virlogeux V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148506
   Virlogeux V, 2016, EMERG INFECT DIS, V22, P526, DOI 10.3201/eid2203.151437
   Virlogeux V, 2015, EPIDEMIOLOGY, V26, P666, DOI 10.1097/EDE.0000000000000339
   Williamson G. A, 1909, REPORT OUTBREAK EPID
   Wilson GN, 1905, PUBLIC HLTH LONDON, V18, P65, DOI [10.1016/S0033-3506(05)82698-8, DOI 10.1016/S0033-3506(05)82698-8]
   Wilson HL, 2018, INTERN MED J, V48, P316, DOI 10.1111/imj.13625
   Woods HM, 1933, MEDICAL RES COUNCIL, V180
   World Health Organization, 2018, MERS COV DIS OUTBR N
   Woudenberg T, 2017, EUROSURVEILLANCE, V22, P11, DOI 10.2807/1560-7917.ES.2017.22.3.30443
   Wu L. T, 1926, TREATISE PNEUMONIC P
   Yoshida K, 2017, EXP GERONTOL, V96, P29, DOI 10.1016/j.exger.2017.05.015
NR 192
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2052-4463
J9 SCI DATA
JI Sci. Data
PD OCT 15
PY 2020
VL 7
IS 1
AR 329
DI 10.1038/s41597-020-00668-y
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OA9EO
UT WOS:000578082900001
PM 33057040
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cappellari, M
   Zini, A
   Sangalli, D
   Cavallini, A
   Reggiani, M
   Sepe, FN
   Rifino, N
   Giussani, G
   Guidetti, D
   Zedde, M
   Marcheselli, S
   Longoni, M
   Beretta, S
   Sidoti, V
   Papurello, DM
   Giossi, A
   Nencini, P
   Plocco, M
   Balestrino, M
   Rota, E
   Toni, D
AF Cappellari, M.
   Zini, A.
   Sangalli, D.
   Cavallini, A.
   Reggiani, M.
   Sepe, F. N.
   Rifino, N.
   Giussani, G.
   Guidetti, D.
   Zedde, M.
   Marcheselli, S.
   Longoni, M.
   Beretta, S.
   Sidoti, V.
   Papurello, D. M.
   Giossi, A.
   Nencini, P.
   Plocco, M.
   Balestrino, M.
   Rota, E.
   Toni, D.
TI Thrombolysis and bridging therapy in patients with acute ischaemic
   stroke and Covid-19
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE bridging therapy; Covid-19; outcome; stroke; thrombolysis
ID SYMPTOMATIC INTRACEREBRAL HEMORRHAGE; SICH NOMOGRAM
AB Background and purpose Comorbidity of acute ischaemic stroke with Covid-19 is a challenging condition, potentially influencing the decision of whether to administer intravenous thrombolysis (IVT). We aimed to assess the 1-month outcome in ischaemic stroke patients with Covid-19 infection who received IVT alone or before thrombectomy (bridging therapy). Methods As a collaboration initiative promoted by the Italian Stroke Organization, all Italian stroke units (n = 190) were contacted and invited to participate in data collection on stroke patients with Covid-19 who received IVT. Results Seventy-five invited centers agreed to participate. Thirty patients received IVT alone and 17 received bridging therapy between 21 February 2020 and 30 April 2020 in 20 centers (n = 18, Northern Italy;n = 2, Central Italy). At 1 month, 14 (30.4%) patients died and 20 (62.5%) survivors had a modified Rankin Scale (mRS) score of 3 to 5. At 24 to 36 hours, asymptomatic intracerebral hemorrhage (ICH) was reported in eight (17.4%) patients and symptomatic ICH (sICH) in two (4.3%) patients. Causes of death were severe ischaemic stroke (n = 8), a new ischaemic stroke (n = 2), acute respiratory failure (n = 1), acute renal failure (n = 1), acute myocardial infarction (n = 1), and endocarditis (n = 1). In survivors with a 1-month mRS score of 3 to 5, baseline glucose level was higher, whereas endovascular procedure time in cases of bridging therapy was longer. Baseline National Institutes of Health Stroke Scale glucose and creatinine levels were higher in patients who died. Conclusions Intravenous thrombolysis for patients with stroke and Covid-19 was not a rare event in the most affected areas by pandemic, and rates of 1-month unfavorable outcomes were high compared to previous data from the pre-Covid-19 literature. However, risk of sICH was not increased.
C1 [Cappellari, M.] Azienda Osped Univ Integrata, Dept Neurosci, Stroke Unit, Verona, Italy.
   [Zini, A.] Maggiore Hosp, IRCCS, Dept Neurol, Ist Sci Neurol Bologna, Bologna, Italy.
   [Zini, A.] Maggiore Hosp, Stroke Ctr, Bologna, Italy.
   [Sangalli, D.] Osped Alessandro Manzoni ASST, UO Neurol Stroke Unit, Lecce, Italy.
   [Cavallini, A.] IRCCS Fdn Mondino, UC Malattie Cerebrovasc Stroke Unit, Pavia, Italy.
   [Reggiani, M.] ASLTO3, Neurol, Rivoli, Italy.
   [Sepe, F. N.] Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Stroke Unit, Alessandria, Italy.
   [Rifino, N.] Osped Papa Giovanni XXIII, Stroke Unit, Bergamo, Italy.
   [Giussani, G.] ASST Grande Osped Metropolitano Niguarda, Neurol Stroke Unit, Milan, Italy.
   [Guidetti, D.] Osped Guglielmo da Saliceto, UOC Neurol, Piacenza, Italy.
   [Zedde, M.] Arcispedale Santa Maria Nuova, Patol Cerebrovasc Stroke Unit, Reggio Emilia, Italy.
   [Marcheselli, S.] Humanitas Res Hosp, Sez Autonoma Neurol Urgenza, Rozzano, Italy.
   [Marcheselli, S.] Humanitas Res Hosp, Stroke Unit, Rozzano, Italy.
   [Longoni, M.] Osped M Bufalini AUSL Romagna, Neurol Stroke Unit, Cesana, Italy.
   [Beretta, S.] ASST Monza, San Gerardo Hosp, Dept Neurol, Monza, Italy.
   [Beretta, S.] ASST Monza, San Gerardo Hosp, Stroke Unit, Monza, Italy.
   [Sidoti, V.] ASST Franciacorta, UOS Stroke Unit, Chiari, Italy.
   [Papurello, D. M.] ASLTO4, Neurol, Cirie, Italy.
   [Giossi, A.] ASST Cremona, UO Neurol, Cremona, Italy.
   [Nencini, P.] AOU Careggi, Dipartimento DEA, SOD Stroke Unit, Florence, Italy.
   [Plocco, M.] F Spaziani, Stroke Unit, Frosinone, Italy.
   [Balestrino, M.] Osped Policlin San Martino, Ctr Ictus, Genoa, Italy.
   [Rota, E.] Osped S Giacomo, Neurol, Novi Ligure, Italy.
   [Toni, D.] Sapienza Univ, Dept Human Neurosci, Rome, Italy.
RP Cappellari, M (corresponding author), Azienda Osped Univ Integrata, Stroke Unit, DAI Neurosci, Piazzale A Stefani 1, I-37126 Verona, Italy.
EM manuel_cappellari@libero.it
RI Zini, Andrea/K-1136-2014; Toni, Danilo/K-3151-2016
OI Zini, Andrea/0000-0003-1486-4507; Reis, AlessanRSS/0000-0001-8486-7469;
   Toni, Danilo/0000-0003-2735-8427
CR Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Beyrouti R, 2020, J NEUROL NEUROSUR PS, V91, P889, DOI 10.1136/jnnp-2020-323586
   Cappellari M, 2019, STROKE, V50, P909, DOI 10.1161/STROKEAHA.118.023316
   Cappellari M, 2020, INT J STROKE, V15, P412, DOI 10.1177/1747493019837756
   Cappellari M, 2018, INT J STROKE, V13, P700, DOI 10.1177/1747493018765490
   Cappellari M, 2018, STROKE, V49, P397, DOI 10.1161/STROKEAHA.117.018427
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Escalard S, 2020, STROKE, V51, P2540, DOI 10.1161/STROKEAHA.120.030574
   Kansagra AP, 2020, NEW ENGL J MED, V383, P400, DOI 10.1056/NEJMc2014816
   Kerleroux B, 2020, STROKE, V51, P2012, DOI 10.1161/STROKEAHA.120.030373
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Ovbiagele B, 2010, NEUROLOGY, V75, P688, DOI 10.1212/WNL.0b013e3181eee426
   Yaghi S, 2020, STROKE, V51, P2002, DOI 10.1161/STROKEAHA.120.030335
   Zhao J, 2020, STROKE, V51, P1996, DOI 10.1161/STROKEAHA.120.030225
NR 14
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD DEC
PY 2020
VL 27
IS 12
BP 2641
EP 2645
DI 10.1111/ene.14511
EA OCT 2020
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OO3VR
UT WOS:000577661600001
PM 32905639
OA Bronze
DA 2021-01-01
ER

PT J
AU von Oertzen, TJ
   Macerollo, A
   Leone, MA
   Beghi, E
   Crean, M
   Oztuk, S
   Bassetti, C
   Twardzik, A
   Bereczki, D
   Di Liberto, G
   Helbok, R
   Guevara, CO
   Pisani, A
   Sauerbier, A
   Sellner, J
   Soffietti, R
   Zedde, M
   Bianchi, E
   Bodini, B
   Cavallieri, F
   Campiglio, L
   Maia, LF
   Priori, A
   Rakusa, M
   Taba, P
   Moro, E
   Jenkins, TM
AF von Oertzen, T. J.
   Macerollo, A.
   Leone, M. A.
   Beghi, E.
   Crean, M.
   Oztuk, S.
   Bassetti, C.
   Twardzik, A.
   Bereczki, D.
   Di Liberto, G.
   Helbok, R.
   Oreja- Guevara, C.
   Pisani, A.
   Sauerbier, A.
   Sellner, J.
   Soffietti, R.
   Zedde, M.
   Bianchi, E.
   Bodini, B.
   Cavallieri, F.
   Campiglio, L.
   Maia, L. F.
   Priori, A.
   Rakusa, M.
   Taba, P.
   Moro, E.
   Jenkins, T. M.
CA EANcore COVID-19 Task Force
TI EAN consensus statement for management of patients with neurological
   diseases during the COVID-19 pandemic
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article; Early Access
DE chronic disease; COVID-19; human; neurology; practice guideline
ID CARE; ANESTHESIOLOGY; NEUROSCIENCE; SOCIETY
AB Background and purpose The recent SARS-CoV-2 pandemic has posed multiple challenges to the practice of clinical neurology including recognition of emerging neurological complications and management of coexistent neurological diseases. In a fast-evolving pandemic, evidence-based studies are lacking in many areas. This paper presents European Academy of Neurology (EAN) expert consensus statements to guide neurologists caring for patients with COVID-19. Methods A refined Delphi methodology was applied. In round 1, statements were provided by EAN scientific panels (SPs). In round 2, these statements were circulated to SP members not involved in writing them, asking for agreement/disagreement. Items with agreement >70% were retained for round 3, in which SP co-chairs rated importance on a five-point Likert scale. Results were graded by importance and reported as consensus statements. Results In round one, 70 statements were provided by 23 SPs. In round two, 259/1061 SP member responses were received. Fifty-nine statements obtained >70% agreement and were retained. In round three, responses were received from 55 co-chairs of 29 SPs. Whilst general recommendations related to prevention of COVID-19 transmission had high levels of agreement and importance, opinion was more varied concerning statements related to therapy. Conclusion This is the first structured consensus statement on good clinical practice in patients with neurological disease during the COVID-19 pandemic that provides immediate guidance for neurologists. In this fast-evolving pandemic, a rapid response using refined Delphi methodology is possible, but guidance may be subject to change as further evidence emerges.
C1 [von Oertzen, T. J.] Johannes Kepler Univ Linz, Fac Med, Linz, Austria.
   [von Oertzen, T. J.] Kepler Univ Klinikum, Dept Neurol 1, Linz, Austria.
   [Macerollo, A.] Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England.
   [Macerollo, A.] Univ Liverpool, Fac Hlth & Life Sci, Liverpool, Merseyside, England.
   [Leone, M. A.] Fdn IRCCS Casa Sollievo Sofferenza, UO Neurol, San Giovanni Rotondo, Italy.
   [Beghi, E.] Ist Ric Farmacol Mario Negri IRCCS, Dept Neurosci, Milan, Italy.
   [Crean, M.; Twardzik, A.] European Acad Neurol, Head Off, Vienna, Austria.
   [Oztuk, S.] Selcuk Univ, Dept Neurol, Fac Med, Konya, Turkey.
   [Bassetti, C.] Univ Bern, Inselspital, Dept Neurol, Bern, Switzerland.
   [Bereczki, D.] Semmelweis Univ, Dept Neurol, Budapest, Hungary.
   [Di Liberto, G.] Geneva Fac Med, Dept Pathol & Immunol, Geneva, Switzerland.
   [Helbok, R.] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria.
   [Oreja- Guevara, C.] Hosp Clin San Carlos, Dept Neurol, Madrid, Spain.
   [Oreja- Guevara, C.] Univ Complutense Madrid UCM, Fac Med, Dept Med, Madrid, Spain.
   [Oreja- Guevara, C.] IdISSC, Madrid, Spain.
   [Pisani, A.] Univ Roma Tor Vergata, Dept Syst Med, Neurol, Rome, Italy.
   [Sauerbier, A.] Univ Hosp Cologne, Dept Neurol, Cologne, Germany.
   [Sellner, J.] Landesklinikum Mistelbach Ganserndorf, Dept Neurol, Mistelbach, Austria.
   [Sellner, J.] Paracelsus Med Univ, Christian Doppler Med Ctr, Dept Neurol, Salzburg, Austria.
   [Sellner, J.] Tech Univ Munich, Dept Neurol, Klinikum Rechts Isar, Munich, Germany.
   [Soffietti, R.] Univ Turin, Dept Neurosci, Div Neurooncol, Turin, Italy.
   [Zedde, M.; Cavallieri, F.] Azienda USL IRCCS Reggio Emilia, Neuromotor & Rehabil Dept, Neurol Unit, Reggio Emilia, Italy.
   [Bianchi, E.] Ist Ric Farmacol Mario Negri IRCCS, Dept Neurosci, Milan, Italy.
   [Bodini, B.] Sorbonne Univ, St Antoine Hosp, AP HP, Dept Neurol, Paris, France.
   [Cavallieri, F.] Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Reggio Emilia, Italy.
   [Campiglio, L.; Priori, A.] Univ Milan, Aldo Ravelli Res Ctr, Dept Neurol, Div Neurol, Milan, Italy.
   [Campiglio, L.; Priori, A.] ASST Santi Paolo & Carlo, Milan, Italy.
   [Maia, L. F.] Ctr Hosp Univ Porto, Dept Neurol, Porto, Portugal.
   [Rakusa, M.] Univ Med Ctr Maribor, Dept Neurol, Maribor, Slovenia.
   [Taba, P.] Univ Tartu, Inst Clin Med, Dept Neurol & Neurosurg, Tartu, Estonia.
   [Moro, E.] Univ Grenoble Alpes, CHU Grenoble, Grenoble Inst Neurosci, Div Neurol, Grenoble, France.
   [Jenkins, T. M.] Univ Sheffield, Sheffield Inst Translat Neurosci, Sheffield, S Yorkshire, England.
   [Jenkins, T. M.] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England.
RP von Oertzen, TJ (corresponding author), Johannes Kepler Univ Linz, Altenberger Str 69, A-4040 Linz, Austria.
EM Tim.von_oertzen@jku.at
RI von Oertzen, Tim J/B-6295-2013; Bianchi, Elisa/ABF-8173-2020; Leone,
   Maurizio/J-4130-2016
OI von Oertzen, Tim J/0000-0003-2164-7842; Bianchi,
   Elisa/0000-0002-0279-0128; Bereczki, Daniel/0000-0002-8374-0500; Beghi,
   Ettore/0000-0003-2542-0469; Leone, Maurizio/0000-0002-6339-5738
CR Aggour M, 2020, J NEUROINTERV SURG, V12, P542, DOI 10.1136/neurintsurg-2020-016137
   Baker D, 2020, MULT SCLER RELAT DIS, V43, DOI 10.1016/j.msard.2020.102174
   Berger JR, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000761
   Bernhardt D, 2020, NEURO-ONCOLOGY, V22, P928, DOI 10.1093/neuonc/noaa113
   Dubbioso R, 2020, NEUROL SCI, V41, P1345, DOI 10.1007/s10072-020-04448-9
   Flexman AM, 2020, J NEUROSURG ANESTH, V32, P202, DOI 10.1097/ANA.0000000000000691
   Hartung HP, 2020, NAT REV NEUROL, V16, P347, DOI 10.1038/s41582-020-0368-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jacob S, 2020, J NEUROL SCI, V412, DOI 10.1016/j.jns.2020.116803
   Jin HJ, 2020, STROKE VASC NEUROL, V5, P146, DOI [10.1136/svn-2020-000382, 10.1136/svn-2020-000482]
   Lyden P, 2020, STROKE, V51, P1910, DOI 10.1161/STROKEAHA.120.030023
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Miocinovic S, 2020, J PARKINSON DIS, V10, P903, DOI 10.3233/JPD-202072
   Moro E, 2020, EUR J NEUROL, V27, P1727, DOI 10.1111/ene.14407
   Moro E, 2020, LANCET NEUROL, V19, P482, DOI 10.1016/S1474-4422(20)30151-4
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rubin MA, 2020, NEUROLOGY, V95, P167, DOI 10.1212/WNL.0000000000009744
   Sellner J, 2020, EUR J NEUROL, V27, pE31, DOI 10.1111/ene.14257
   Sharma D, 2020, J NEUROSURG ANESTH, V32, P193, DOI 10.1097/ANA.0000000000000688
   Sole G, 2020, REV NEUROL-FRANCE, V176, P507, DOI 10.1016/j.neurol.2020.04.004
   von Oertzen TJ, 2020, EUR J NEUROL, V27, P1710, DOI 10.1111/ene.14365
   Vonck K, 2020, EUR J NEUROL, V27, P1578, DOI 10.1111/ene.14329
   WHO, 2020, DIR GEN OP REM MED B
   Zolk O, 2020, N-S ARCH PHARMACOL, V393, P1131, DOI 10.1007/s00210-020-01890-6
NR 24
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
DI 10.1111/ene.14521
EA OCT 2020
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OA3NM
UT WOS:000577696500001
PM 33058321
OA Green Published, Other Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Madadlou, A
AF Madadlou, Ashkan
TI Food proteins are a potential resource for mining cathepsin L inhibitory
   drugs to combat SARS-CoV-2
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE COVID-19; Infection; Virus; Food; Protein; Lactoferrin
ID ORYZACYSTATIN; PEPTIDES; ENTRY; MILK; VI
AB The entry of SARS-CoV-2 into host cells proceeds by a proteolysis process, which involves the lysosomal peptidase cathepsin L. Inhibition of cathepsin L is therefore considered an effective method to decrease the virus internalization. Analysis from the perspective of structure-functionality elucidates that cathepsin L inhibitory proteins/peptides found in food share specific features: multiple disulfide crosslinks (buried in protein core), lack or low contents of (small) alpha-helices, and high surface hydrophobicity.
   Lactoferrin can inhibit cathepsin L, but not cathepsins B and H. This selective inhibition might be useful in fine targeting of cathepsin L. Molecular docking indicated that only the carboxyl-terminal lobe of lactoferrin interacts with cathepsin L and that the active site cleft of cathepsin L is heavily superposed by lactoferrin. A controlled proteolysis process might yield lactoferrin-derived peptides that strongly inhibit cathepsin L.
C1 [Madadlou, Ashkan] Wageningen Univ & Res, Dept Agrotechnol & Food Sci, Wageningen, Netherlands.
RP Madadlou, A (corresponding author), Wageningen Univ & Res, Dept Agrotechnol & Food Sci, Wageningen, Netherlands.
EM Ashkan.madadlou@wur.nl
CR ABE K, 1988, J BIOL CHEM, V263, P7655
   Adedeji AO, 2013, J VIROL, V87, P8017, DOI 10.1128/JVI.00998-13
   BONNER AB, 1995, ALCOHOL, V12, P505, DOI 10.1016/0741-8329(95)00035-6
   Fujishima A, 1997, FEBS LETT, V407, P47, DOI 10.1016/S0014-5793(97)00216-0
   Goudarzi M, 2020, J HYPERTENS, V38, P1614, DOI 10.1097/HJH.0000000000002534
   HATANO K, 1995, EUR J BIOCHEM, V232, P335, DOI 10.1111/j.1432-1033.1995.335zz.x
   Hatano K, 1996, BIOCHEMISTRY-US, V35, P5379, DOI 10.1021/bi952754+
   Hellinger R, 2019, DRUG DISCOV TODAY, V24, P1877, DOI 10.1016/j.drudis.2019.05.026
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   KUMOSINSKI TF, 1993, J DAIRY SCI, V76, P931, DOI 10.3168/jds.S0022-0302(93)77420-2
   Lankelma JM, 2010, LIFE SCI, V86, P225, DOI 10.1016/j.lfs.2009.11.016
   Lee HS, 2000, PEPTIDES, V21, P807, DOI 10.1016/S0196-9781(00)00212-6
   Moore SA, 1997, J MOL BIOL, V274, P222, DOI 10.1006/jmbi.1997.1386
   Nagata K, 2000, BIOCHEMISTRY-US, V39, P14753, DOI 10.1021/bi0006971
   Ogawa N, 2009, J NUTR SCI VITAMINOL, V55, P264, DOI 10.3177/jnsv.55.264
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Polya G.M., 2003, PROTEIN NONPROTEIN P, P567, DOI [10.1016/S1572-5995(03)80015-7, DOI 10.1016/S1572-5995(03)80015-7]
   Sano E, 2005, FOOD RES INT, V38, P427, DOI 10.1016/j.foodres.2004.10.011
   Sreedhara A, 2010, INT DAIRY J, V20, P487, DOI 10.1016/j.idairyj.2010.02.003
   Tiemann JKS, 2017, NAT METHODS, V14, P1123, DOI 10.1038/nmeth.4497
   Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002
   Wang B, 2019, CRIT REV FOOD SCI, V59, P580, DOI 10.1080/10408398.2017.1381583
NR 22
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD OCT 15
PY 2020
VL 885
AR 173499
DI 10.1016/j.ejphar.2020.173499
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NY8ZR
UT WOS:000576673700002
PM 32841639
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Nunnari, G
   Sanfilippo, C
   Castrogiovanni, P
   Imbesi, R
   Li Volti, G
   Barbagallo, I
   Musumeci, G
   Di Rosa, M
AF Nunnari, Giuseppe
   Sanfilippo, Cristina
   Castrogiovanni, Paola
   Imbesi, Rosa
   Li Volti, Giovanni
   Barbagallo, Ignazio
   Musumeci, Giuseppe
   Di Rosa, Michelino
TI Network perturbation analysis in human bronchial epithelial cells
   following SARS-CoV2 infection
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Innate immunity; COVID-19; SARS-CoV2; Bioinformatics; CEACAM7; CSF3;
   DNAH7; c8orf4; Respiratory cilia
ID GENE-EXPRESSION; DISEASE; METAANALYSIS; FLUNISOLIDE; APOPTOSIS;
   COVID-19; DATABASE; PLATFORM; ENTRY
AB Background: SARS-CoV2, the agent responsible for the current pandemic, is also causing respiratory distress syndrome (RDS), hyperinflammation and high mortality. It is critical to dissect the pathogenetic mechanisms in order to reach a targeted therapeutic approach.
   Methods: In the present investigation, we evaluated the effects of SARS-CoV2 on human bronchial epithelial cells (HBEC). We used RNA-seq datasets available online for identifying SARS-CoV2 potential genes target on human bronchial epithelial cells. RNA expression levels and potential cellular gene pathways have been analyzed. In order to identify possible common strategies among the main pandemic viruses, such as SARS-CoV2, SARS-CoV1, MERS-CoV, and H1N1, we carried out a hypergeometric test of the main genes transcribed in the cells of the respiratory tract exposed to these viruses.
   Results: The analysis showed that two mechanisms are highly regulated in HBEC: the innate immunity recruitment and the disassembly of cilia and cytoskeletal structure. The granulocyte colony-stimulating factor (CSF3) and dynein heavy chain 7, axonemal (DNAH7) represented respectively the most upregulated and downregulated genes belonging to the two mechanisms highlighted above. Furthermore, the carcinoembryonic antigen-related cell adhesion molecule 7 (CEACAM7) that codifies for a surface protein is highly specific of SARS-CoV2 and not for SARS-CoV1, MERS-CoV, and H1N1, suggesting a potential role in viral entry. In order to identify potential new drugs, using a machine learning approach, we highlighted Flunisolide, Thalidomide, Lenalidomide, Desoximetasone, xylazine, and salmeterol as potential drugs against SARS-CoV2 infection.
   Conclusions: Overall, lung involvement and RDS could be generated by the activation and down regulation of diverse gene pathway involving respiratory cilia and muscle contraction, apoptotic phenomena, matrix destructuration, collagen deposition, neutrophil and macrophages recruitment.
C1 [Nunnari, Giuseppe] Univ Messina, Dept Clin & Expt Med, Unit Infect Dis, Messina, Italy.
   [Sanfilippo, Cristina] IRCCS, Ctr Neurolesi Bonino Pulejo, Str Statale 113, I-98124 Messina, Italy.
   [Castrogiovanni, Paola; Imbesi, Rosa; Musumeci, Giuseppe; Di Rosa, Michelino] Univ Catania, Sch Med, Dept Biomed & Biotechnol Sci, Human Anat & Histol Sect, Catania, Italy.
   [Li Volti, Giovanni] Univ Catania, Dept Biomed & Biotechnol Sci, Via S Sofia 97, I-95125 Catania, Italy.
   [Barbagallo, Ignazio] Univ Catania, Dept Drug Sci, Viale Andrea Doria 6, I-95125 Catania, Italy.
RP Di Rosa, M (corresponding author), Univ Catania, Sch Med, Dept Biomed & Biotechnol Sci, Human Anat & Histol Sect, Catania, Italy.
EM gnunnari@unime.it; cristina.sanfilippo@irccsme.it; pacastro@unict.it;
   livolti@unict.it; ignazio.barbagallo@unict.it; g.musumeci@unict.it;
   mdirosa@unict.it
RI Castrogiovanni, Paola/E-3152-2013
OI Castrogiovanni, Paola/0000-0001-5873-2456
CR BEWIG B, 1993, EUR J CLIN PHARMACOL, V44, P541, DOI 10.1007/BF02440855
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bogoch II A., 2020, J TRAV MED, V27
   Box GE, 1992, BAYESIAN INFERENCE S, DOI 10.1002/9781118033197
   Cao KAL, 2014, GENOMICS, V103, P239, DOI 10.1016/j.ygeno.2014.03.001
   Care MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055895
   Castrogiovanni P, 2018, MOL NEUROBIOL, V55, P6881, DOI 10.1007/s12035-018-0891-5
   Chan CM, 2016, J VIROL, V90, P9114, DOI 10.1128/JVI.01133-16
   Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483
   Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2
   Cheadle Chris, 2003, Appl Bioinformatics, V2, P209
   Chen QR, 2008, GENOMICS, V92, P195, DOI 10.1016/j.ygeno.2008.05.014
   Clough E, 2016, METHODS MOL BIOL, V1418, P93, DOI 10.1007/978-1-4939-3578-9_5
   Czepczynska-Krezel H, 2012, POSTEP HIG MED DOSW, V66, P521, DOI 10.5604/17322693.1004113
   Feng CJ, 2018, ONCOL LETT, V15, P6925, DOI 10.3892/ol.2018.8198
   Han K, 2014, CELL BIOL INT, V38, P1394, DOI 10.1002/cbin.10351
   Hauber HP, 2003, J ALLERGY CLIN IMMUN, V112, P58, DOI 10.1067/mai.2003.1612
   Hodos RA, 2016, WIRES SYST BIOL MED, V8, P186, DOI 10.1002/wsbm.1337
   Horani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059436
   Ivanov AI, 2010, AM J PATHOL, V177, P512, DOI 10.2353/ajpath.2010.100168
   Jin GX, 2014, DRUG DISCOV TODAY, V19, P637, DOI 10.1016/j.drudis.2013.11.005
   Jones RT, 2015, MODERN PATHOL, V28, P596, DOI 10.1038/modpathol.2014.150
   Kang CZ, 2019, J THEOR BIOL, V463, P77, DOI 10.1016/j.jtbi.2018.12.010
   Karpov PA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-S1-S14
   Kim J, 2009, J IMMUNOL, V183, P3996, DOI 10.4049/jimmunol.0900956
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Kuo MW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029000
   Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1733, DOI 10.1002/jmv.25819
   Lee C, 2016, BIOINFORMATICS, V32, P1100, DOI 10.1093/bioinformatics/btv694
   Li K, 2017, P NATL ACAD SCI USA, V114, pE3119, DOI 10.1073/pnas.1619109114
   Liu TP, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.181321
   Liu ZC, 2013, DRUG DISCOV TODAY, V18, P110, DOI 10.1016/j.drudis.2012.08.005
   Lu T, 2020, J THORAC IMAG, V35, pW90, DOI 10.1097/RTI.0000000000000508
   Ma J, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108408
   Mehmood R, 2017, SCI REP-UK, V7, DOI 10.1038/srep45602
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Mitchell HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069374
   Miyatake K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7666
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Reddy TBK, 2009, NUCLEIC ACIDS RES, V37, pD499, DOI 10.1093/nar/gkn652
   Ruiz-Colon K, 2014, FORENSIC SCI INT, V240, P1, DOI 10.1016/j.forsciint.2014.03.015
   Rybak MJ, 2020, PHARMACOTHERAPY, V40, P363, DOI 10.1002/phar.2376
   Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126
   Sanfilippo C, 2019, BRAIN RES, V1720, DOI 10.1016/j.brainres.2019.146305
   Sanfilippo C, 2019, NEUROSCIENCE, V406, P333, DOI 10.1016/j.neuroscience.2019.03.008
   Scarpino M, 2013, EUR REV MED PHARMACO, V17, P2660
   Siergiejko Z, 1998, Pneumonol Alergol Pol, V66, P440
   Smith CM, 2014, EUR RESPIR J, V43, P485, DOI 10.1183/09031936.00205312
   Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tao XR, 2013, J VIROL, V87, P9953, DOI 10.1128/JVI.01562-13
   To KF, 2004, J PATHOL, V203, P740, DOI 10.1002/path.1597
   Touzelet O, 2020, MOL CELL PROTEOMICS, V19, P793, DOI 10.1074/mcp.RA119.001546
   Wang J, 2004, BIOINFORMATICS, V20, P3166, DOI 10.1093/bioinformatics/bth381
   Wang ZC, 2018, BIOINFORMATICS, V34, P2150, DOI 10.1093/bioinformatics/bty060
   Xiao J, 2017, BIOINFORMATICS, V33, P2873, DOI 10.1093/bioinformatics/btx311
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Yasrebi H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007431
   Yuen KM, 2011, INFLUENZA OTHER RESP, V5, P437
   Zetterberg H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226697
   Zuberi K, 2013, NUCLEIC ACIDS RES, V41, pW115, DOI 10.1093/nar/gkt533
NR 62
TC 2
Z9 2
U1 4
U2 4
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD OCT 15
PY 2020
VL 395
IS 2
AR 112204
DI 10.1016/j.yexcr.2020.112204
PG 12
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA NY6BA
UT WOS:000576471200012
PM 32735892
OA Green Published
DA 2021-01-01
ER

PT J
AU Li, L
   Sun, T
   He, YF
   Li, WD
   Fan, YB
   Zhang, J
AF Li, Lin
   Sun, Ting
   He, Yufei
   Li, Wendong
   Fan, Yubo
   Zhang, Jing
TI Epitope-based peptide vaccines predicted against novel coronavirus
   disease caused by SARS-CoV-2
SO VIRUS RESEARCH
LA English
DT Article
DE SARS-CoV-2; Spike protein; T-cell epitope; B-cell epitope;
   Immune-informatics; Vaccine design
ID SPIKE PROTEIN; RESPONSES; SARS; CONFORMATION; BINDING; SERVER
AB The outbreak of the 2019 novel coronavirus (SARS-CoV-2) has infected millions of people with a large number of deaths across the globe. The existing therapies are limited in dealing with SARS-CoV-2 due to the sudden appearance of the virus. Therefore, vaccines and antiviral medicines are in desperate need. We took immuneinformatics approaches to identify B- and T-cell epitopes for surface glycoprotein (S), membrane glycoprotein (M) and nucleocapsid protein (N) of SARS-CoV-2, followed by estimating their antigenicity and interactions with the human leukocyte antigen (HLA) alleles. Allergenicity, toxicity, physiochemical properties analysis and stability were examined to confirm the specificity and selectivity of the epitope candidates. We identified a total of five B cell epitopes in RBD of S protein, seven MHC class-I, and 18 MHC class-II binding T-cell epitopes from S, M and N protein which showed non-allergenic, non-toxic and highly antigenic features and non-mutated in 55,179 SARS-CoV-2 virus strains until June 25, 2020. The epitopes identified here can be a potentially good candidate repertoire for vaccine development.
C1 [Li, Lin; Sun, Ting; Li, Wendong; Fan, Yubo; Zhang, Jing] Beihang Univ, Beijing Adv Innovat Ctr Biomed Engn, Beijing, Peoples R China.
   [Li, Lin; Sun, Ting; He, Yufei; Li, Wendong; Fan, Yubo] Beihang Univ, Sch Biol Sci & Med Engn, Beijing, Peoples R China.
RP Zhang, J (corresponding author), Beihang Univ, Beijing Adv Innovat Ctr Biomed Engn, Beijing, Peoples R China.; Fan, YB (corresponding author), Beihang Univ, Beijing Adv Innovat Ctr Biomed Engn, Sch Biol Sci & Med Engn, Beijing, Peoples R China.
EM yubofan@buaa.edu.cn; jz2716@buaa.edu.cn
OI Zhang, Jing/0000-0001-8549-3286
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [11421202, 11827803]; Youth Thousand
   Scholar Program of China; Beijing Advanced Innovation Center for
   Biomedical Engineering, BUAA
FX This work was supported by grants from the National Natural Science
   Foundation of China (NSFC No. 11421202, and 11827803 to YBF), the Youth
   Thousand Scholar Program of China (J.Z.) and Beijing Advanced Innovation
   Center for Biomedical Engineering, BUAA (J.Z.)
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ashkenazy H, 2010, NUCLEIC ACIDS RES, V38, pW529, DOI 10.1093/nar/gkq399
   Azmi F, 2014, HUM VACC IMMUNOTHER, V10, P778, DOI 10.4161/hv.27332
   BAKHSHESH M, 2018, BIOMED BIOTECHNOL RE, V2, P208, DOI DOI 10.4103/BBRJ.BBRJ_71_18
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Buchan DWA, 2013, NUCLEIC ACIDS RES, V41, pW349, DOI 10.1093/nar/gkt381
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen A, 2020, STRESS RESILIENCE: MOLECULAR AND BEHAVIORAL ASPECTS, P1, DOI 10.1016/C2016-0-03233-3
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   de Vries SJ, 2017, NUCLEIC ACIDS RES, V45, pW361, DOI 10.1093/nar/gkx335
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Fast E.C., 2020, BIORXIV
   Ferre F, 2006, NUCLEIC ACIDS RES, V34, pW182, DOI 10.1093/nar/gkl189
   FIESER TM, 1987, P NATL ACAD SCI USA, V84, P8568, DOI 10.1073/pnas.84.23.8568
   Fu XH, 2020, RES ASTRON ASTROPHYS, V20, DOI 10.1088/1674-4527/20/1/8
   Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   Grifoni A, 2020, CELL HOST MICROBE
   Hai P, 2004, J GEN VIROL, V85, P3109, DOI 10.1099/vir.0.80111-0
   Huang J, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-50
   Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lindenbach BD, 2003, ADV VIRUS RES, V59, P23, DOI 10.1016/S0065-3527(03)59002-9
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maenaka K, 2000, J IMMUNOL, V165, P3260, DOI 10.4049/jimmunol.165.6.3260
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Menssen R, 1999, J MOL BIOL, V285, P645, DOI 10.1006/jmbi.1998.2363
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Peters B, 2005, PLOS BIOL, V3, P379, DOI 10.1371/journal.pbio.0030091
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Qiu Y, 2020, MICROBES INFECT
   Saha S., 2004, BCEPRED PREDICTION C
   Schindewolf C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010074
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shi JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144475
   Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6
   Song Z, 2019, VIRUSES, V11, P1
   Srivastava S, 2020, GENES-BASEL, V11, DOI 10.3390/genes11050551
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Trabuco LG, 2012, NUCLEIC ACIDS RES, V40, pW423, DOI 10.1093/nar/gks398
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   ul Qamar MT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1672-7
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wrapp D., 2020, SCIENCE
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang T, 2020, J MT SCI-ENGL, V17, P2108, DOI 10.1007/s11629-019-5772-5
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 54
TC 2
Z9 2
U1 12
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD OCT 15
PY 2020
VL 288
AR 198082
DI 10.1016/j.virusres.2020.198082
PG 9
WC Virology
SC Virology
GA NW3JE
UT WOS:000574904700008
PM 32621841
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Mohammad, T
   Shamsi, A
   Anwar, S
   Umair, M
   Hussain, A
   Rehman, MT
   AlAjmi, MF
   Islam, A
   Hassan, MI
AF Mohammad, Taj
   Shamsi, Anas
   Anwar, Saleha
   Umair, Mohd
   Hussain, Afzal
   Rehman, Md Tabish
   AlAjmi, Mohamed F.
   Islam, Asimul
   Hassan, Md Imtaiyaz
TI Identification of high-affinity inhibitors of SARS-CoV-2 main protease:
   Towards the development of effective COVID-19 therapy
SO VIRUS RESEARCH
LA English
DT Article
DE Coronavirus disease 2019; SARS-CoV-2; Main protease; Virtual screening;
   Molecular dynamics simulations; Drug discovery
ID SARS-COV; SPIKE
AB Coronavirus disease 2019 (COVID-19) is an infectious disease, caused by a newly emerged highly pathogenic virus called novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Targeting the main protease (M-pro, 3CL(pro)) of SARS-CoV-2 is an appealing approach for drug development because this enzyme plays a significant role in the viral replication and transcription. The available crystal structures of SARS-CoV-2 M-pro determined in the presence of different ligands and inhibitor-like compounds provide a platform for the quick development of selective inhibitors of SARS-CoV-2 M-pro. In this study, we utilized the structural information of co-crystallized SARS-CoV-2 M-pro for the structure-guided drug discovery of high-affinity inhibitors from the PubChem database. The screened compounds were selected on the basis of their physicochemical properties, drug-likeliness, and strength of affinity to the SARS-CoV-2 M-pro. Finally, we have identified 6-Deaminosinefungin (PubChem ID: 10428963) and UNII-O9H5KY11SV (PubChem ID: 71481120) as potential inhibitors of SARS-CoV-2 M-pro which may be further exploited in drug development to address SARS-CoV-2 pathogenesis. Both compounds are structural analogs of known antivirals, having considerable protease inhibitory potential with improved pharmacological properties. All-atom molecular dynamics simulations suggested SARS-CoV-2 M-pro in complex with these compounds is stable during the simulation period with minimal structural changes. This work provides enough evidence for further implementation of the identified compounds in the development of effective therapeutics of COVID-19.
C1 [Mohammad, Taj; Shamsi, Anas; Anwar, Saleha; Islam, Asimul; Hassan, Md Imtaiyaz] Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi 110025, India.
   [Umair, Mohd] Jamia Millia Islamia, Dept Comp Sci, New Delhi 110025, India.
   [Hussain, Afzal; Rehman, Md Tabish; AlAjmi, Mohamed F.] King Saud Univ, Coll Pharm, Dept Pharmacognosy, Riyadh 11451, Saudi Arabia.
RP Hassan, MI (corresponding author), Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi 110025, India.
EM mihassan@jmi.ac.in
RI HASSAN, Imtaiyaz/G-7072-2017
OI HASSAN, Imtaiyaz/0000-0002-3663-4940
FU Indian Council of Medical ResearchIndian Council of Medical Research
   (ICMR)
FX This work is funded by the Indian Council of Medical Research.
CR Altis A, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2945165
   AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ausaf AS, 2014, CURR PROTEIN PEPT SC, V15, P456, DOI [10.2174/1389203715666140327114232, DOI 10.2174/1389203715666140327114232]
   Biovia D.S., 2015, DISCOVERY STUDIO MOD
   Chary MA, 2020, J MED TOXICOL, V16, P109, DOI 10.1007/s13181-020-00760-0
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Guan WJ, 2020, N ENGL J MED
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Hopkins AL, 2004, DRUG DISCOV TODAY, V9, P430, DOI 10.1016/S1359-6446(04)03069-7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hubbard R.E., 2001, HYDROGEN BONDS PROTE, V164, P2399
   Jacob RB, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002499
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Khan P, 2019, J NAT PROD, V82, P2252, DOI 10.1021/acs.jnatprod.9b00372
   Lagunin A, 2000, BIOINFORMATICS, V16, P747, DOI 10.1093/bioinformatics/16.8.747
   Liu H, 2020, P I MECH ENG A-J POW, DOI 10.1177/0957650920943000
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lu R., 2015, GENOME ANNOUNCEMENTS, V3
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Minakshi R, 2014, VIRUS RES, V191, P180, DOI 10.1016/j.virusres.2014.08.001
   Mohammad T, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1711810
   Mohammad T, 2019, J BIOMOL STRUCT DYN, V37, P1813, DOI 10.1080/07391102.2018.1468282
   Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878
   Naqvi AA, 2020, J BIOMOL STRUCT DYN, V38, P3892, DOI 10.1080/07391102.2019.1666745
   Naqvi AA, 2018, CURR TOP MED CHEM, V18, P1755, DOI 10.2174/1568026618666181025114157
   Naz F, 2018, INT J BIOL MACROMOL, V107, P2580, DOI 10.1016/j.ijbiomac.2017.10.143
   Naz H, 2017, INT J BIOL MACROMOL, V96, P161, DOI 10.1016/j.ijbiomac.2016.12.024
   Papaleo E, 2009, J MOL GRAPH MODEL, V27, P889, DOI 10.1016/j.jmgm.2009.01.006
   PETERLIROTH P, 1994, J ORG CHEM, V59, P4186, DOI 10.1021/jo00094a033
   Rodier F, 2005, PROTEINS, V60, P36, DOI 10.1002/prot.20478
   Shamsi A., 2020, BIOSCI REP, V40
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang QH, 2016, ANTIVIR RES, V133, P165, DOI 10.1016/j.antiviral.2016.07.015
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 40
TC 5
Z9 5
U1 21
U2 21
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD OCT 15
PY 2020
VL 288
AR 198102
DI 10.1016/j.virusres.2020.198102
PG 9
WC Virology
SC Virology
GA NW3JE
UT WOS:000574904700001
PM 32717346
OA Green Published
DA 2021-01-01
ER

PT J
AU Kalinina, TS
   Zlenko, DV
   Kiselev, AV
   Litvin, AA
   Stovbun, SV
AF Kalinina, Tatiana S.
   Zlenko, Dmitry, V
   Kiselev, Aleksei, V
   Litvin, Alexander A.
   Stovbun, Sergey, V
TI Antiviral activity of the high-molecular-weight plant polysaccharides
   (Panavir (R))
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Antiviral activity; Immune modulator; COVID-19
AB This short report is dedicated to the description of the wide antiviral and antibacterial activity of the immune modulating agent Panavir (R). Panavir (R) is a high-molecular-weight fraction of the polysaccharides extracted from the shoots of the Solanum tuberosum. It demonstrates activity against many types of viruses, including animal coronavirus and also against bacterial infections. These properties look very promising considering the COVID-19 epidemy and allow propose that Panavir (R) would be effective in the therapy of the SARS-CoV-2 infection. (c) 2020 Elsevier B.V. All rights reserved.
C1 [Kalinina, Tatiana S.] RAMS, VV Zakusov Inst Pharmacol, Moscow, Russia.
   [Zlenko, Dmitry, V] Moscow MV Lomonosov State Univ, Moscow, Russia.
   [Litvin, Alexander A.] Fed Res & Clin Ctr Phys Chem Med FMBA, Moscow, Russia.
   [Zlenko, Dmitry, V; Kiselev, Aleksei, V; Stovbun, Sergey, V] Russian Acad Sci, NN Semenov Fed Res Ctr Chem Phys, Moscow, Russia.
RP Zlenko, DV (corresponding author), Moscow MV Lomonosov State Univ, Moscow, Russia.; Zlenko, DV (corresponding author), Russian Acad Sci, NN Semenov Fed Res Ctr Chem Phys, Moscow, Russia.
EM dvzlenko@gmail.com
RI Zlenko, Dmitry V/S-1658-2016
OI Zlenko, Dmitry V/0000-0002-4126-3080
CR Cha AE, 2020, WASHINGTON POST
   Chen L, 2018, INT J BIOL MACROMOL, V115, P77, DOI 10.1016/j.ijbiomac.2018.04.056
   Gautier JF, 2020, OBESITY, V28, P848, DOI 10.1002/oby.22809
   Gribencha S. V., 2009, Antibiotiki i Khimioterapiya, V54, P31
   Kalinina TS, 2005, B EXP BIOL MED+, V140, P55, DOI 10.1007/s10517-005-0410-3
   Kolbukhina L., 2009, TSYTOKINY VOSPALENIY, V8, P49
   Kovchur P., 2011, B MSRU, V1, P24
   [Лепехин А.В. Lepekhin A.V.], 2007, [Инфекционные болезни, Infektsionnye bolezni], V5, P41
   Litvin A., 2012, CYTOKINES INFLAMMATI, V11, P123
   Martinez MJA, 2005, STUD NAT PROD CHEM, V30, P393
   [Мельникова С.Е. Melnikova S.E.], 2017, [Российский вестник акушера-гинеколога, Rossiiskii vestnik akushera-ginekologa], V17, P97, DOI 10.17116/rosakush201717397-101
   [Перламутров Ю.Н. Perlamutrov Iu.N.], 2014, [Российский вестник акушера-гинеколога, Rossiiskii vestnik akushera-ginekologa], V14, P90
   Prokudina E. N., 2006, Antibiotiki i Khimioterapiya, V51, P7
   Rakhmanina N., 2015, RUSSIAN VET J, V2, P38
   Stovbun S., 2011, B MSRU, V2, P94
   Stovbun S., 2011, B MSRU, V3, P82
   Stovbun SV, 2012, NANOTECHNOL RUSS, V7, P539, DOI 10.1134/S1995078012050138
   Stovbun SV, 2014, MOSC U PHYS B+, V69, P542, DOI 10.3103/S0027134914060150
   Wang W, 2012, MAR DRUGS, V10, P2795, DOI 10.3390/md10122795
NR 19
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD OCT 15
PY 2020
VL 161
BP 936
EP 938
DI 10.1016/j.ijbiomac.2020.06.031
PG 3
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA NR6LI
UT WOS:000571673600015
PM 32534094
OA Green Published
DA 2021-01-01
ER

PT J
AU Rein, N
   Haham, N
   Orenbuch-Harroch, E
   Romain, M
   Argov, Z
   Vaknin-Dembinsky, A
   Gotkine, M
AF Rein, Netaniel
   Haham, Nitzan
   Orenbuch-Harroch, Efrat
   Romain, Marc
   Argov, Zohar
   Vaknin-Dembinsky, Adi
   Gotkine, Marc
TI Description of 3 patients with myasthenia gravis and COVID-19
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Neuromuscular; Neuroimmunology; COVID-19; Myasthenia
AB Background: The COVID-19 pandemic presents two main concerns for patients with myasthenia gravis (MG); chronic immunosuppression may put them at greater risk, and some proposed treatments for COVID-19 could cause MG exacerbation.
   Case description: We present three patients with generalized seropositive MG who developed COVID-19. All patients had a favorable outcome, with only one patient experiencing exacerbation. In this case, exacerbation began before COVID-19; she required ICU admission, non-invasive ventilatory support, and received hydroxy-chloroquine, lopinavir and ritonavir which were well tolerated. One patient received IVIG in place of scheduled plasma exchange.
   Conclusion: Outcome was favorable in all cases despite immunosuppressive therapy, use of experimental COVID-19 medication and switching of plasma exchange for IVIG.
C1 [Rein, Netaniel; Haham, Nitzan; Argov, Zohar; Vaknin-Dembinsky, Adi; Gotkine, Marc] Hadassah Hebrew Univ, Agnes Ginges Ctr Neurogenet Jerusalem, Dept Neurol, Med Ctr, Jerusalem, Israel.
   [Orenbuch-Harroch, Efrat; Romain, Marc] Hadassah Hebrew Univ, Med Intens Care Unit, Med Ctr, Jerusalem, Israel.
RP Rein, N (corresponding author), Hadassah Hebrew Univ, Agnes Ginges Ctr Neurogenet Jerusalem, Dept Neurol, Med Ctr, Jerusalem, Israel.
EM Netaniel.rein@mail.huji.ac.il; Nitan.haham@mail.huji.ac.il;
   Marcro@hadassah.org.il; zohara@ekmd.huji.ac.il; marc@gotkine.com
CR Argov Z., 2010, DISORDERS VOLUNTARY, P471
   Guidon AC, 2020, NEUROLOGY, V94, P959, DOI 10.1212/WNL.0000000000009566
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273v1, DOI 10.1101/2020.06.22.20137273V1]
   Jacob S, 2020, J NEUROL SCI, V412, DOI 10.1016/j.jns.2020.116803
   Ji D, 2020, CLIN INFECT DIS, V71, P1393, DOI 10.1093/cid/ciaa414
   Perricone C, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102468
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Varan O, 2015, REUMATISMO, V67, P125
NR 8
TC 2
Z9 2
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD OCT 15
PY 2020
VL 417
AR 117053
DI 10.1016/j.jns.2020.117053
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NP6HG
UT WOS:000570274600023
PM 32731059
OA Bronze
DA 2021-01-01
ER

PT J
AU Iqbal, MM
   Abid, I
   Hussain, S
   Shahzad, N
   Waqas, MS
   Iqbal, MJ
AF Iqbal, Muhammad Mazhar
   Abid, Irfan
   Hussain, Saddam
   Shahzad, Naeem
   Waqas, Muhammad Sohail
   Iqbal, Muhammad Jawed
TI The effects of regional climatic condition on the spread of COVID-19 at
   global scale
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Article
DE COVID-19; Regional climate; Average high temperature; Average low
   temperature; Daylight hours
ID RESPIRATORY SYNCYTIAL VIRUS; DISEASE 2019 COVID-19; INFLUENZA-VIRUS;
   ZIKA VIRUS; CORONAVIRUS; TRANSMISSION; MERS; TEMPERATE; SCENARIOS;
   EVOLUTION
AB The pandemic outbreak of the novel coronavirus epidemic disease (COVID-19) is spreading like a diffusion-reaction in the world and almost 208 countries and territories are being affected around the globe. It became a sever health and socio-economic problem, while the world has no vaccine to combat this virus. This research aims to analyze the connection between the fast spread of COVID-19 and regional climate parameters over a global scale. In this research, we collected the data of COVID-19 cases from the time of 1st reported case to the 5th June 2020 in different affected countries and regional climatic parameters data from January 2020 to 5th June 2020. It was found that most of the countries located in the relatively lower temperature region show a rapid increase in the COVID-19 cases than the countries locating in the warmer climatic regions despite their better socio-economic conditions. A correlation between metrological parameters and COVID-19 cases was observed. Average daylight hours are correlated to total the COVID-19 cases with a coefficient of determination of 0.42, while average high-temperature shows a correlation of 0.59 and 0.42 with total COVID-19 cases and death cases respectively. The finding of the study will help international health organizations and local administrations to combat and well manage the spread of COVID-19. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Iqbal, Muhammad Mazhar; Abid, Irfan; Shahzad, Naeem; Iqbal, Muhammad Jawed] Natl Univ Sci & Technol NUST, Islamabad, Pakistan.
   [Hussain, Saddam] Univ Agr Faisalabad, Dept Irrigat & Drainage, Faisalabad, Pakistan.
   [Waqas, Muhammad Sohail] Govt Punjab, Soil Conservat Grp, Agr Dept Field Wing, Lahore, Pakistan.
RP Iqbal, MM (corresponding author), Natl Univ Sci & Technol NUST, Islamabad, Pakistan.
EM maziqbal@mce.nust.edu.pk
RI Hussain, Saddam/AAP-6745-2020
OI Hussain, Saddam/0000-0001-7706-6778; Iqbal,
   Muhammad/0000-0003-1988-4590; Waqas, Muhammad/0000-0002-3690-5966
FU National University of Science and Technology
FX This research work was supported by the National University of Science
   and Technology. The authors are grateful to Mr. Asif Ali, School of
   Civil Engineering, National University of Science and Technology,
   Islamabad, for helping in GIS based heat mapping the COVID case.
   Furthermore, authors also thankful for providing free data sources by
   worldometer and different climatic data portals of NASA, JAXA, and ESA.
CR Abduljalil JM, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100672
   Ahmadi M, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.138705
   Akkina R, 2019, ANTIVIR RES, V172, DOI 10.1016/j.antiviral.2019.104645
   Altamimi A, 2020, J INFECT PUBLIC HEAL, V13, P704, DOI 10.1016/j.jiph.2019.11.011
   Armitage R, 2020, LANCET PLANET HEALTH, V4, pE175, DOI 10.1016/S2542-5196(20)30084-X
   Artika IM, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104215
   Auler AC, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.139090
   Beeler JA, 2013, MICROB PATHOGENESIS, V55, P9, DOI 10.1016/j.micpath.2012.11.013
   Bhandari D, 2020, ACTA TROP, V204, DOI 10.1016/j.actatropica.2020.105337
   Bhowmick S, 2020, J THEOR BIOL, V488, DOI 10.1016/j.jtbi.2019.110117
   Brugger K, 2009, PREV VET MED, V88, P24, DOI 10.1016/j.prevetmed.2008.06.023
   Burki T, 2020, LANCET INFECT DIS, V20, P292, DOI 10.1016/S1473-3099(20)30076-1
   Casanova LM, 2010, APPL ENVIRON MICROB, V76, P2712, DOI 10.1128/AEM.02291-09
   Chan K, 2011, ADV OPTOELECTRON, V2011, DOI [10.1155/2011/734690, 10.1155/2011/196707]
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Chow Ken Yan Ching, 2003, Genomics Proteomics & Bioinformatics, V1, P247
   CLARK MA, 1993, BRIT VET J, V149, P51, DOI 10.1016/S0007-1935(05)80210-6
   Corman V., 2012, EUROSURVEILLANCE, V17
   Coverstone AM, 2019, IMMUNOL ALLERGY CLIN, V39, P391, DOI 10.1016/j.iac.2019.03.007
   Crisci E, 2013, MOL IMMUNOL, V55, P200, DOI 10.1016/j.molimm.2013.02.008
   Darniot M, 2018, J CLIN VIROL, V104, P77, DOI 10.1016/j.jcv.2018.05.002
   Davis JK, 2018, ACTA TROP, V185, P242, DOI 10.1016/j.actatropica.2018.04.028
   de Sousa R, 2014, J CLIN VIROL, V59, P4, DOI 10.1016/j.jcv.2013.10.030
   Decaro N, 2020, VET MICROBIOL, V244, DOI 10.1016/j.vetmic.2020.108693
   Djalante R, 2020, PROGR DISASTER SCI, V6, DOI [10.1016/j.pdisas.2020.100091, DOI 10.1016/J.PDISAS.2020.100091]
   Feng Y, 2020, J AEROSOL SCI, V147, DOI 10.1016/j.jaerosci.2020.105585
   Gould E, 2009, CLIN MICROBIOL INFEC, V15, P503, DOI 10.1111/j.1469-0691.2009.02845.x
   Hansen LJJ, 2015, VACCINE, V33, P5507, DOI 10.1016/j.vaccine.2015.08.085
   Hoogeveen MJ, 2020, SCI TOTAL ENVIRON, V727, DOI 10.1016/j.scitotenv.2020.138543
   Hussain S., 2020, BIG DATA WATER RESOU, V1, P22
   Iqbal MM, 2019, J COASTAL RES, P231, DOI 10.2112/SI91-047.1
   Iqbal MM, 2018, WATER-SUI, V10, DOI 10.3390/w10081068
   Iqbal MM, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15102258
   Ji YP, 2020, LANCET GLOB HEALTH, V8, pE480, DOI 10.1016/S2214-109X(20)30068-1
   Jones RAC, 2016, ADV VIRUS RES, V95, P87, DOI 10.1016/bs.aivir.2016.02.004
   Kandel N, 2020, LANCET, V395, P1047, DOI 10.1016/S0140-6736(20)30553-5
   Keilman LJ, 2019, NURS CLIN N AM, V54, P227, DOI 10.1016/j.cnur.2019.02.009
   Kone N., 2017, Annals of Agricultural Science (Cairo), V62, P227, DOI 10.1016/j.aoas.2017.12.005
   Lai C.-C., 2020, INT J ANTIMICROB AGE, V55
   Lee N, 2013, CRIT CARE CLIN, V29, P1045, DOI 10.1016/j.ccc.2013.07.003
   Lee S, 2017, J THEOR BIOL, V412, P36, DOI 10.1016/j.jtbi.2016.09.023
   Li CL, 2018, SCI TOTAL ENVIRON, V622, P493, DOI 10.1016/j.scitotenv.2017.11.326
   Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015
   Liu HX, 2020, ENVIRON RES, V183, DOI [10.1016/j.envres.2020.109189, 10.1016/j.euvres.2020.109189]
   Liu JT, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138513
   Liu KK, 2020, ENVIRON RES, V183, DOI 10.1016/j.envres.2020.109190
   Liu Y, 2020, ENVIRON RES, V182, DOI 10.1016/j.envres.2020.109114
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Lyth A, 2015, CLIM RISK MANAG, V10, P77, DOI 10.1016/j.crm.2015.06.004
   Ma YL, 2020, SCI TOTAL ENVIRON, V724, DOI 10.1016/j.scitotenv.2020.138226
   Malik S., 2020, BIG DATA WATER RESOU, V1, P4
   Mas-Coma S, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100132
   Mendez-Arriaga F, 2020, SCI TOTAL ENVIRON, V735, DOI 10.1016/j.scitotenv.2020.139560
   Merle H, 2018, J FR OPHTALMOL, V41, pE235, DOI 10.1016/j.jfo.2018.05.002
   Millan-Onate J, 2020, INFECTIO, V24
   Molineri A, 2017, PREV VET MED, V140, P106, DOI 10.1016/j.prevetmed.2017.02.019
   Morin CW, 2018, ENVIRON INT, V119, P241, DOI 10.1016/j.envint.2018.06.018
   Nicholson EG, 2018, CLIN THER, V40, P1268, DOI 10.1016/j.clinthera.2018.06.014
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   O'Reilly KM, 2020, LANCET PLANET HEALTH, V4, pE172, DOI 10.1016/S2542-5196(20)30106-6
   Otter JA, 2016, J HOSP INFECT, V92, P235, DOI 10.1016/j.jhin.2015.08.027
   Pattison N, 2020, INTENS CRIT CARE NUR, V58, DOI 10.1016/j.iccn.2020.102862
   Paz S, 2016, LANCET, V387, P745, DOI 10.1016/S0140-6736(16)00256-7
   Qi HC, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138778
   Robert MA, 2019, EPIDEMICS-NETH, V28, DOI 10.1016/j.epidem.2019.05.003
   Salam M., 2020, BIG DATA WATER RESOU, V1, P13
   Salchuddin AR, 2017, ASIAN PAC J TROP MED, V10, P201, DOI 10.1016/j.apjtm.2017.03.002
   Schwartz SA, 2020, EXPLORE-NY, V16, P141, DOI [10.1016.j.explore.2020.02.022, 10.1016/j.explore.2020.02.022]
   Segars J, 2020, FERTIL STERIL, V113, P1140, DOI 10.1016/j.fertnstert.2020.04.025
   Shahkarami M, 2015, EMERG INFECT DIS, V21, P1664, DOI 10.3201/eid2109.150476
   Sirisena PDNN, 2014, INT J INFECT DIS, V19, P6, DOI 10.1016/j.ijid.2013.10.012
   Smith E, 2019, JNP-J NURSE PRACT, V15, P405, DOI 10.1016/j.nurpra.2019.02.023
   Sprygin A, 2019, VIRUS RES, V269, DOI 10.1016/j.virusres.2019.05.015
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Tobias A, 2020, ENVIRON RES, V186, DOI 10.1016/j.envres.2020.109553
   Turnage NL, 2017, J VIROL METHODS, V248, P31, DOI 10.1016/j.jviromet.2017.06.008
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang PF, 2020, RESOUR CONSERV RECY, V158, DOI 10.1016/j.resconrec.2020.104814
   World Health Organization, 2020, COR DIS 2019 COVID 1, V51
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yang Y Tony, 2016, Prev Med Rep, V4, P444, DOI 10.1016/j.pmedr.2016.07.011
   Yezli S, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101692
   Yokomatsu M, 2020, INT J DISAST RISK RE, V43, DOI 10.1016/j.ijdrr.2019.101368
   Zambrano-Monserrate MA, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138813
   Zhang YZ, 2020, SCI TOTAL ENVIRON, V701, DOI 10.1016/j.scitotenv.2019.134607
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 86
TC 8
Z9 8
U1 26
U2 27
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0048-9697
EI 1879-1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD OCT 15
PY 2020
VL 739
AR 140101
DI 10.1016/j.scitotenv.2020.140101
PG 9
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA NE9XG
UT WOS:000562956600004
PM 32531684
OA Green Published
DA 2021-01-01
ER

PT J
AU Gomides, A
   Ferreira, G
   Kakehasi, A
   Lacerda, M
   Marques, C
   Mota, L
   Paiva, E
   Pileggi, G
   Provenza, J
   Reis-Neto, E
   Sampaio, V
   Xavier, R
   Pinheiro, M
AF Gomides, Ana
   Ferreira, Gilda
   Kakehasi, Adriana
   Lacerda, Marcus
   Marques, Claudia
   Mota, Licia
   Paiva, Eduardo
   Pileggi, Gecilmara
   Provenza, Jose
   Reis-Neto, Edgard
   Sampaio, Vanderson
   Xavier, Ricardo
   Pinheiro, Marcelo
TI Impact of Chronic Use of Antimalarials on SARS-CoV-2 Infection in
   Patients With Immune-Mediated Rheumatic Diseases: Protocol for a
   Multicentric Observational Cohort Study
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE COVID-19; SARS-CoV-2; coronavirus; antimalarial; rheumatic diseases;
   mortality; immune system; immunology; protocol; observational;
   pharmacological; drug
ID CLASSIFICATION CRITERIA; AMERICAN-COLLEGE; RHEUMATOLOGY/EUROPEAN LEAGUE;
   COVID-19; HYDROXYCHLOROQUINE; MANIFESTATIONS; EFFICACY
AB Background: COVID-19, caused by the virus SARS-CoV-2, has brought extensive challenges to the scientific community in recent months. Several studies have been undertaken in an attempt to minimize the impact of the disease worldwide. Although new knowledge has been quickly disseminated, including viral mechanisms, pathophysiology, and clinical findings, there is a lack of information on the effective pharmacological management of this disease. In vitro studies have shown some benefits related to the use of antimalarials (chloroquine and hydroxychloroquine) for inhibiting SARS-CoV-2. However, the data from open clinical trials on COVID-19 patients are controversial.
   Objective: We present the protocol for a research project that compares the potential protective effect of antimalarials in preventing moderate-to-severe forms of COVID-19 in two groups: (1) patients treated chronically with antimalarials for rheumatic diseases and (2) other members of the patients' household who have not been diagnosed with rheumatic diseases and are not taking antimalarials.
   Methods: This is a 24-week, prospective, observational cohort study comprising patients from public and private health services across Brazil, who chronically use antimalarials for the treatment of immune-mediated rheumatic diseases, osteoarthritis, or chikungunya-related arthropathy. A total of six sequential phone interviews were scheduled during the COVID-19 outbreak in five different regions of Brazil. Information regarding social, epidemiological, and demographic data, as well as details about rheumatic diseases, antimalarials, comorbidities, and concomitant medication, is being recorded using a specific online form in the REDCap database. Symptoms suggestive of COVID-19, including fever, cough, dyspnea, anosmia, and dysgeusia, are being self-reported and collected via phone interviews. Our main outcomes are hospitalization, need of intensive care unit, and death.
   Results: Recruitment began at the end of March 2020, and the inclusion was done during an 8-week period (from March 29 to May 17) with a total of 10,443 individuals enrolled at baseline, 5166 of whom have rheumatic diseases, from 23 tertiary rheumatology centers across 97 Brazilian cities. Data analysis is scheduled to begin after all inclusion data have been collected.
   Conclusions: This study, which includes a large sample of chronic antimalarial users, will allow us to explore whether SARS-CoV-2 infection may be associated with immune-mediated rheumatic diseases and long-term antimalarial usage.
C1 [Gomides, Ana] Univ Ctr Brasilia, Brasilia, DF, Brazil.
   [Ferreira, Gilda; Kakehasi, Adriana] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Lacerda, Marcus; Sampaio, Vanderson] Univ Estado Amazonas, Manaus, Amazonas, Brazil.
   [Marques, Claudia] Univ Fed Pernambuco, Recife, PE, Brazil.
   [Mota, Licia] Univ Brasilia, Brasilia, DF, Brazil.
   [Paiva, Eduardo] Univ Fed Parana, Curitiba, Parana, Brazil.
   [Pileggi, Gecilmara] Fac Ciencias Saude Barretos, Barretos, Brazil.
   [Provenza, Jose] Soc Brasileira Reumatol, Sao Paulo, Brazil.
   [Reis-Neto, Edgard; Pinheiro, Marcelo] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Xavier, Ricardo] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil.
RP Pinheiro, M (corresponding author), Univ Fed Sao Paulo, Hosp Sao Paulo, Sao Paulo, Brazil.
EM mpinheiro@uol.com.br
FU Abbvie; Boehringer IngelheimBoehringer Ingelheim; GSKGlaxoSmithKline;
   JanssenJohnson & Johnson USAJanssen Biotech Inc; Libbs; LillyEli Lilly;
   NovartisNovartis; PfizerPfizer; RocheRoche Holding; SandozNovartis;
   UCBUCB Pharma SA
FX LM has received personal or institutional support from Abbvie, Janssen,
   Pfizer and Roche, and has delivered speeches at events related to this
   work and sponsored by Abbvie, Boehringer Ingelheim, GSK, Janssen, Libbs,
   Lilly, Novartis, Pfizer, Roche, Sandoz, and UCB. AG has received
   personal or institutional support from Pfizer and Abbvie.
CR Al-Bari Abdul Alim, 2020, Curr Drug Targets, V21, P1703, DOI 10.2174/1389450121666200617133142
   Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI 10.1136/ard.2010.138461
   ALTMAN R, 1990, ARTHRITIS RHEUM, V33, P1601, DOI 10.1002/art.1780331101
   [Anonymous], 2020, ESP COVID 19 DAD MUN
   Aringer M, 2019, ARTHRITIS RHEUMATOL, V71, P1400, DOI 10.1002/art.40930
   Asfahan S, 2020, MONALDI ARCH CHEST D, V90, P313, DOI 10.4081/monaldi.2020.1325
   Bonini S, 2020, ALLERGY, V75, P2542, DOI 10.1111/all.14409
   Candido DS, 2020, SCIENCE, V369, P1255, DOI 10.1126/science.abd2161
   Chang D, 2020, J ALLER CL IMM-PRACT, V8, P2585, DOI 10.1016/j.jaip.2020.06.015
   Cleary S, 2020, BRIT J PHARMACOL, DOI [10.22541/au.158861365.54417186, DOI 10.22541/AU.158861365.54417186]
   Neto ETD, 2020, ADV RHEUMATOL, V60, DOI 10.1186/s42358-020-00134-8
   Felten R, 2020, JOINT BONE SPINE, V87, P279, DOI 10.1016/j.jbspin.2020.04.006
   Fidahic M, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-01047-2
   Graef ER, 2020, ANN RHEUM DIS, V79, P734, DOI 10.1136/annrheumdis-2020-217480
   Gulati A, 2020, AM J MED SCI, V360, P5, DOI 10.1016/j.amjms.2020.05.006
   Hassan SA, 2020, CUREUS, V12, DOI 10.7759/cureus.7355
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Ji W, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e237
   Juul S, 2020, SYST REV-LONDON, V9, DOI 10.1186/s13643-020-01371-0
   Kasukawa R, 1999, INTERNAL MED, V38, P386, DOI 10.2169/internalmedicine.38.386
   Khatami A, 2020, J PAEDIATR CHILD H, V56, P1172, DOI 10.1111/jpc.15026
   Li XG, 2020, J MED VIROL, V92, P501, DOI 10.1002/jmv.25701
   Liu W, 2020, CAN MED ASSOC J, V192, pE734, DOI 10.1503/cmaj.200647
   Lundberg IE, 2017, ARTHRITIS RHEUMATOL, V69, P2271, DOI 10.1002/art.40320
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P4539, DOI 10.26355/eurrev_202004_21038
   Michaud Kaleb, 2020, ACR Open Rheumatol, V2, P335, DOI 10.1002/acr2.11148
   Ministry of Health (BR), 2020, COR DIS 2019 EXP SUR
   Misra DP, 2020, CLIN RHEUMATOL, V39, P2055, DOI 10.1007/s10067-020-05073-9
   Park JH, 2020, CLIN EXP OTORHINOLAR, V13, P95, DOI 10.21053/ceo.2020.00570
   Pastick KA, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa130
   Polak SB, 2020, MODERN PATHOL, V33, P2128, DOI 10.1038/s41379-020-0603-3
   Rabby MII, 2020, J PHARM PHARM SCI, V23, P58, DOI 10.18433/jpps31002
   Salata C, 2019, PATHOG DIS, V77, DOI 10.1093/femspd/ftaa006
   Saqrane S, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100680
   Sarma P, 2020, J MED VIROL, V92, P776, DOI 10.1002/jmv.25898
   Shiboski CH, 2017, ANN RHEUM DIS, V76, P9, DOI 10.1136/annrheumdis-2016-210571
   Shukla Ashutosh M, 2020, Drugs Context, V9, DOI 10.7573/dic.2020-4-5
   Singh AK, 2020, DIABETES OBES METAB, V22, P1915, DOI 10.1111/dom.14124
   Sun JK, 2020, POSTGRAD MED, V132, P604, DOI 10.1080/00325481.2020.1778982
   Teymoori-Rad M, 2020, EXPERT REV RESP MED, V14, P881, DOI 10.1080/17476348.2020.1782197
   Tu HL, 2020, J INFECTION, V81, P1, DOI 10.1016/j.jinf.2020.04.011
   van den Hoogen F, 2013, ARTHRITIS RHEUM-US, V65, P2737, DOI 10.1002/art.38098
   Venkatasubbaiah Meda, 2020, Curr Med Res Pract, V10, P100, DOI 10.1016/j.cmrp.2020.05.013
   World Health Organization, 2020, 51 WHO
   Xu XN, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00251-x
   Yang RR, 2020, EXPERT REV RESP MED, V14, P835, DOI 10.1080/17476348.2020.1761791
   Ye CY, 2020, J MED VIROL, V92, P2821, DOI 10.1002/jmv.26183
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 51
TC 0
Z9 0
U1 0
U2 0
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD OCT 14
PY 2020
VL 22
IS 10
AR e23532
DI 10.2196/23532
PG 10
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA OL0WZ
UT WOS:000585064700017
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sardar, R
   Satish, D
   Gupta, D
AF Sardar, Rahila
   Satish, Deepshikha
   Gupta, Dinesh
TI Identification of Novel SARS-CoV-2 Drug Targets by Host MicroRNAs and
   Transcription Factors Co-regulatory Interaction Network Analysis
SO FRONTIERS IN GENETICS
LA English
DT Article
DE regulatory network; miRNA; SARS-CoV-2; hub genes; TFS
ID VIRUS; EXPRESSION; INFECTION; MODULATION; RESOURCE; DATABASE; ALTERS
AB Understanding the host regulatory mechanisms opposing virus infection and virulence can provide actionable insights to identify novel therapeutics against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We have used a network biology approach to elucidate the crucial factors involved in host responses involving host-microRNA (miRNA) interactions with host and virus genes using recently published experimentally verified protein-protein interaction data. We were able to identify 311 host genes to be potentially targetable by 2,197 human miRNAs. These miRNAs are known to be involved in various biological processes, such as T-cell differentiation and activation, virus replication, and immune system. Among these, the anti-viral activity of 38 miRNAs to target 148 host genes is experimentally validated. Six anti-viral miRNAs, namely, hsa-miR-1-3p, hsa-miR-17-5p, hsa-miR-199a-3p, hsa-miR-429, hsa-miR-15a-5p, and hsa-miR-20a-5p, are previously reported to be anti-viral in respiratory diseases and were found to be downregulated. The interaction network of the 2,197 human miRNAs and interacting transcription factors (TFs) enabled the identification of 51 miRNAs to interact with 77 TFs inducing activation or repression and affecting gene expression of linked genes. Further, from the gene regulatory network analysis, the top five hub genes HMOX1, DNMT1, PLAT, GDF1, and ITGB1 are found to be involved in interferon (IFN)-alpha 2b induction, epigenetic modification, and modulation of anti-viral activity. The comparative miRNAs target identification analysis in other respiratory viruses revealed the presence of 98 unique host miRNAs targeting SARS-CoV-2 genome. Our findings identify prioritized key regulatory interactions that include miRNAs and TFs that provide opportunities for the identification of novel drug targets and development of anti-viral drugs.
C1 [Sardar, Rahila; Satish, Deepshikha; Gupta, Dinesh] Int Ctr Genet Engn & Biotechnol ICGEB, Translat Bioinformat Grp, New Delhi, India.
   [Sardar, Rahila] Jamia Hamdard, Dept Biochem, New Delhi, India.
RP Gupta, D (corresponding author), Int Ctr Genet Engn & Biotechnol ICGEB, Translat Bioinformat Grp, New Delhi, India.
EM dinesh@icgeb.res.in
OI Satish, Deepshikha/0000-0002-1313-5495
FU Department of Biotechnology (DBT), Government of IndiaDepartment of
   Biotechnology (DBT) India [BT/BI/25/066/2012]; Indian Council of Medical
   Research (ICMR), IndiaIndian Council of Medical Research (ICMR)
   [20195850]; Council of Scientific and Industrial Research [CSIR,
   India]Council of Scientific & Industrial Research (CSIR) - India
   [09/0512(0207)/2016/EMR-1]
FX This work was financially supported by the Department of Biotechnology
   (DBT), Government of India, grant BT/BI/25/066/2012, awarded to DG.
   Financial support provided by the Indian Council of Medical Research
   (ICMR), India to RS as Senior Research Fellowship is duly acknowledged
   (20195850). DS received a fellowship from the Council of Scientific and
   Industrial Research [CSIR, India, 09/0512(0207)/2016/EMR-1].
CR Ahmed SSSJ, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00802
   Bernier A, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080440
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Blanco-Melo D., 2020, BIORXIV, DOI [10.1101/2020.03.24.004655, DOI 10.1101/2020.03.24.004655]
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Cameron JE, 2008, VIROLOGY, V382, P257, DOI 10.1016/j.virol.2008.09.018
   Chen CY, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S1-S41
   Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990
   Chen L., 2020, LUNG ADENOCARCINOMA, V2020
   Chen LJ, 2015, INT J HYPERTENS, V2015, DOI 10.1155/2015/896861
   Chiang HS, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03086
   Danesh A, 2011, VIROLOGY, V409, P102, DOI 10.1016/j.virol.2010.10.002
   Demirci MDS, 2020, PEERJ, V8, DOI 10.7717/peerj.9369
   Enright AJ, 2004, GENOME BIOL, V5
   Espinoza JA, 2017, AM J PATHOL, V187, P487, DOI 10.1016/j.ajpath.2016.11.011
   Fan YN, 2016, NUCLEIC ACIDS RES, V44, pW135, DOI 10.1093/nar/gkw288
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gassen NC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13659-4
   Girardit E, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00439
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013
   Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329
   Kaufmann SHE, 2018, NAT REV DRUG DISCOV, V17, P35, DOI 10.1038/nrd.2017.162
   Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682
   Khan MAA, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00765
   Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784
   Leon-Icaza S.A., 2019, EXRNA, V1, P1, DOI [10.1186/s41544-018-0004-7, DOI 10.1186/S41544-018-0004-7]
   Li ZP, 2013, BIOINFORMATICS, V29, P2375, DOI 10.1093/bioinformatics/btt391
   Lou WY, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-018-1761-7
   Ludwig N, 2016, NUCLEIC ACIDS RES, V44, P3865, DOI 10.1093/nar/gkw116
   Mohamed RH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41978-5
   Nakhaei P, 2009, SEMIN IMMUNOL, V21, P215, DOI 10.1016/j.smim.2009.05.001
   Pickett BE, 2012, NUCLEIC ACIDS RES, V40, pD593, DOI 10.1093/nar/gkr859
   Potenza N, 2011, NUCLEIC ACIDS RES, V39, P5157, DOI 10.1093/nar/gkr067
   Qiu CX, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-90
   Schafer A, 2017, PATHOGENS, V6, DOI 10.3390/pathogens6010008
   Shu X, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7080100
   Song LP, 2010, J VIROL, V84, P8849, DOI 10.1128/JVI.00456-10
   Tong Z, 2019, NUCLEIC ACIDS RES, V47, pD253, DOI 10.1093/nar/gky1023
   Triboulet R, 2007, SCIENCE, V315, P1579, DOI 10.1126/science.1136319
   Tsang J, 2007, MOL CELL, V26, P753, DOI 10.1016/j.molcel.2007.05.018
   Wang FZ, 2008, J VIROL, V82, P9065, DOI 10.1128/JVI.00961-08
   Wang HH, 2020, EUR J CLIN MICROBIOL, V39, P1629, DOI 10.1007/s10096-020-03899-4
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Yoshikawa T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008729
   Zhang HM, 2015, BRIEF BIOINFORM, V16, P45, DOI 10.1093/bib/bbt085
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zheng SQ, 2011, ANTIVIR RES, V89, P219, DOI 10.1016/j.antiviral.2011.01.008
   Zhu Z, 2014, VIRUSES-BASEL, V6, P1525, DOI 10.3390/v6041525
NR 52
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD OCT 14
PY 2020
VL 11
AR 571274
DI 10.3389/fgene.2020.571274
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA OR9FF
UT WOS:000589770600001
PM 33173539
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Borgen, I
   Romney, MC
   Redwood, N
   Delgado, B
   Alea, P
   George, BH
   Puzziferro, J
   Shihabuddin, L
AF Borgen, Irene
   Romney, Martha C.
   Redwood, Nicole
   Delgado, Belynda
   Alea, Patricia
   George, Brian H.
   Puzziferro, Jennifer
   Shihabuddin, Lina
TI From Hospital to Home: An Intensive Transitional Care Management
   Intervention for Patients with COVID-19
SO POPULATION HEALTH MANAGEMENT
LA English
DT Article; Early Access
DE intensive transitional care management; home health services; home
   oxygen concentrators; home monitoring; telemedicine; tele-management;
   COVID-19
AB Implementing emergency department (ED) and hospital patient throughput management coupled with at-home medical and tele-management upon discharge may increase surge capacity during national emergencies and pandemics. This novel intensive transitional care management (ITCM) intervention presents the opportunity to optimize hospital bed capacity through prevention of inpatient admissions for patients who could be discharged home safely with appropriate in-home medical support and tele-management. This observational cohort intervention was conducted between April 7, 2020 and April 30, 2020, at the 4 largest inpatient facilities of RWJBarnabas Health System in New Jersey. The intervention group included a convenience sample of 192 patients who were evaluated in the ED, monitored in the observation unit, or admitted to the hospital with a diagnosis of mild-to-moderate COVID-19 infection. Their outcomes were compared to a matched comparison group of 593 patients who were admitted with the same COVID-19-related diagnosis and severity. The primary outcome was the reduction in inpatient days as a result of the intervention that included provision of at-home oxygen supplementation therapy, expanded home care services, and tele-management sessions. Secondary outcomes were re-encounters with the health system in the ED, observation unit, or inpatient readmissions. A total of 481.6 hospital patient days were avoided for 78 patients who had been discharged from the ED or observation unit stays. Secondary analysis included hospital readmission rates. The ITCM intervention demonstrated a feasible strategy for improving throughput of patients with COVID-19, resulting in increased hospital bed capacity.
C1 [Borgen, Irene] Jersey City Med Ctr, Ambulatory Serv, 355 Grand St, Jersey City, NJ 07302 USA.
   [Borgen, Irene; George, Brian H.] RWJBarnabas Hlth RWJBH Syst, W Orange, NJ USA.
   [Romney, Martha C.] Thomas Jefferson Univ, Coll Populat Hlth, Philadelphia, PA 19107 USA.
   [Redwood, Nicole; Delgado, Belynda] RWJBarnabas Hlth RWJBH Syst, Cent Access, W Orange, NJ USA.
   [Alea, Patricia] RWJBarnabas Hlth RWJBH Syst, Populat Hlth, W Orange, NJ USA.
   [Puzziferro, Jennifer] RWJBarnabas Hlth RWJBH Syst, Case Management, W Orange, NJ USA.
   [Shihabuddin, Lina] RWJBarnabas Hlth RWJBH Syst, RWJBH Rutgers Med Grp, W Orange, NJ USA.
RP Borgen, I (corresponding author), Jersey City Med Ctr, Ambulatory Serv, 355 Grand St, Jersey City, NJ 07302 USA.
EM irene.borgen@rwjbh.org
CR Al-Hazmi A, 2016, SAUDI J BIOL SCI, V23, P507, DOI 10.1016/j.sjbs.2016.02.019
   Ali Inayat, 2020, Disaster Med Public Health Prep, V14, pe16, DOI 10.1017/dmp.2020.149
   [Anonymous], 2020, GUARDIAN
   [Anonymous], 2020, CNBC
   [Anonymous], 2020, NEW JERS COVID 19 DA
   Blavin F, 2020, HOSP READINESS COVID
   Centers for Disease Control and Prevention, 2020, INT INF PREV CONTR R
   Centers for Disease Control and Prevention, 2020, HEALTHC FAC MAN OP C
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Dentzer S, 2020, MODERN HEALTHCARE
   Hunter CL, 2020, COVID 19 EC IMPACTS
   Keesara S, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005835
   Miller R, 2020, CLEV CLIN J MED, DOI [10.3949/ccjm.87a, DOI 10.3949/CCJM.87A]
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Sheikhbardsiri H, 2017, DISASTER MED PUBLIC, V11, P612, DOI 10.1017/dmp.2016.178
   Sokouti M, 2020, ARCH MED RES, V51, P458, DOI 10.1016/j.arcmed.2020.04.005
   U.S. News & World Report, 2020, US NEWS WORLD REPORT
   United States Department of Health and Human Services, 2020, OEI062000300 US DEP
   Whittle Jessica S, 2020, J Am Coll Emerg Physicians Open, DOI 10.1002/emp2.12071
   WHO, 2020, CLIN MAN SEV AC RESP
   Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427
NR 21
TC 0
Z9 0
U1 5
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1942-7891
EI 1942-7905
J9 POPUL HEALTH MANAG
JI Popul. Health Manag.
DI 10.1089/pop.2020.0178
EA OCT 2020
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA OM9TW
UT WOS:000586358300001
PM 33054603
OA Bronze
DA 2021-01-01
ER

PT J
AU Surti, M
   Patel, M
   Adnan, M
   Moin, A
   Ashraf, SA
   Siddiqui, AJ
   Snoussi, M
   Deshpande, S
   Reddy, MN
AF Surti, Malvi
   Patel, Mitesh
   Adnan, Mohd
   Moin, Afrasim
   Ashraf, Syed Amir
   Siddiqui, Arif Jamal
   Snoussi, Mejdi
   Deshpande, Sumukh
   Reddy, Mandadi Narsimha
TI Ilimaquinone (marine sponge metabolite) as a novel inhibitor of
   SARS-CoV-2 key target proteins in comparison with suggested COVID-19
   drugs: designing, docking and molecular dynamics simulation study
SO RSC ADVANCES
LA English
DT Article
ID ILLIMAQUINONE
AB The outbreak of novel coronavirus, SARS-CoV-2, has infected more than 36 million people and caused approximately 1 million deaths around the globe as of 9 October 2020. The escalating outspread of the virus and rapid rise in the number of cases require the instantaneous development of effectual drugs and vaccines. Presently, there are no approved drugs or vaccine available to treat the infection. In such scenario, one of the propitious therapeutic approaches against viral infection is to explore enzyme inhibitors amidst natural compounds, utilizing computational approaches aiming to get products with negligible side effects. In the present study, the inhibitory prospects of ilimaquinone (marine sponge metabolite) were assessed in comparison with hydroxychloroquine, azithromycin, favipiravir, ivermectin and remdesivir at the active binding pockets of nine different vital SARS-CoV-2 target proteins (spike receptor binding domain, RNA-dependent RNA polymerase, Nsp10, Nsp13, Nsp14, Nsp15, Nsp16, main protease, and papain-like-protease), employing an in silico molecular interaction based approach. In addition, molecular dynamics (MD) simulations of the SARS-CoV-2 papain-like protease (PLpro)-ilimaquinone complex were also carried out to calculate various structural parameters including root mean square fluctuation (RMSF), root mean square deviation (RMSD), radius of gyration (R-g) and hydrogen bond interactions. PLpro is a promising drug target, due to its imperative role in viral replication and additional function of stripping ubiquitin and interferon-stimulated gene 15 (ISG15) from host-cell proteins. In light of the possible inhibition of all vital SARS-CoV-2 target proteins, our study has emphasized the importance to study in depth ilimaquinone actions in vivo.
C1 [Surti, Malvi; Patel, Mitesh; Reddy, Mandadi Narsimha] Veer Narmad South Gujarat Univ, Dept Biosci, Bapalal Vaidya Bot Res Ctr, Surat 395007, Gujarat, India.
   [Adnan, Mohd; Siddiqui, Arif Jamal; Snoussi, Mejdi] Univ Hail, Coll Sci, Dept Biol, POB 2440, Hail, Saudi Arabia.
   [Moin, Afrasim] Univ Hail, Coll Pharm, Dept Pharmaceut, POB 2440, Hail, Saudi Arabia.
   [Ashraf, Syed Amir] Univ Hail, Coll Appl Med Sci, Dept Clin Nutr, POB 2440, Hail, Saudi Arabia.
   [Deshpande, Sumukh] Cardiff Univ, Coll Biomed & Life Sci, Cent Biotechnol Serv, Cardiff CF14 4XN, Wales.
   [Snoussi, Mejdi] Univ Monastir, Higher Inst Biotechnol Monastir, Lab Genet Biodivers & Valorizat Bioresources LR11, Ave Tahar Haddad,BP74, Monastir 5000, Tunisia.
RP Reddy, MN (corresponding author), Veer Narmad South Gujarat Univ, Dept Biosci, Bapalal Vaidya Bot Res Ctr, Surat 395007, Gujarat, India.; Deshpande, S (corresponding author), Cardiff Univ, Coll Biomed & Life Sci, Cent Biotechnol Serv, Cardiff CF14 4XN, Wales.
EM deshpandes1@cardiff.ac.uk; nrutya_reddy@yahoo.com
RI Siddiqui, Arif Jamal/Z-5214-2019; moin, afrasim/A-9254-2012; Adnan,
   Mohd/N-9207-2015
OI Siddiqui, Arif Jamal/0000-0002-6236-0920; moin,
   afrasim/0000-0002-3902-1162; Adnan, Mohd/0000-0002-7080-6822; Patel,
   Mitesh/0000-0002-9283-2124
FU SHODH-Scheme of Developing High Quality Research from Education
   Department, Gujarat state, India [635]
FX Malvi Surti is supported by a SHODH-Scheme of Developing High Quality
   Research (No. 635) from Education Department, Gujarat state, India.
CR Adnan M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20237-z
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   BEKKER H, 1993, PHYSICS COMPUTING '92, P252
   Biovia D.S., 2015, DISCOVERY STUDIO MOD
   BOURGUETKONDRACKI ML, 1991, INT J IMMUNOPHARMACO, V13, P393, DOI 10.1016/0192-0561(91)90009-V
   Cleveland W.S., 1992, LOCAL REGRESSION MOD
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Le Guilloux V, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-168
   LOYA SS, 1993, J BIOL CHEM, V268, P9323
   Lu PH, 2007, EUR J PHARMACOL, V556, P45, DOI 10.1016/j.ejphar.2006.10.061
   LUIBRAND RT, 1979, TETRAHEDRON, V35, P609, DOI 10.1016/0040-4020(79)87004-0
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Owis AI, 2020, RSC ADV, V10, P19570, DOI 10.1039/d0ra03582c
   Patel M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10060920
   Popov A.M., 1999, PHARM CHEM J, V33, P71, DOI DOI 10.1007/BF02508109
   Rangel HR, 1997, CELL BIOL INT, V21, P337, DOI 10.1006/cbir.1997.0143
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Tziveleka LA, 2003, CURR TOP MED CHEM, V3, P1512, DOI 10.2174/1568026033451790
   WATOWICH SJ, 1988, J COMPUT CHEM, V9, P650, DOI 10.1002/jcc.540090611
NR 25
TC 0
Z9 0
U1 2
U2 2
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD OCT 14
PY 2020
VL 10
IS 62
BP 37707
EP 37720
DI 10.1039/d0ra06379g
PG 14
WC Chemistry, Multidisciplinary
SC Chemistry
GA OI8LO
UT WOS:000583523300012
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Ebada, SS
   Al-Jawabri, NA
   Youssef, FS
   El-Kashef, DH
   Knedel, TO
   Albohy, A
   Korinek, M
   Hwang, TL
   Chen, BH
   Lin, GH
   Lin, CY
   Aldalaien, SM
   Disi, AM
   Janiak, C
   Proksch, P
AF Ebada, Sherif S.
   Al-Jawabri, Nariman A.
   Youssef, Fadia S.
   El-Kashef, Dina H.
   Knedel, Tim-Oliver
   Albohy, Amgad
   Korinek, Michal
   Hwang, Tsong-Long
   Chen, Bing-Hung
   Lin, Guan-Hua
   Lin, Chia-Yi
   Aldalaien, Sa'ed M.
   Disi, Ahmad M.
   Janiak, Christoph
   Proksch, Peter
TI Anti-inflammatory, antiallergic and COVID-19 protease inhibitory
   activities of phytochemicals from the Jordanian hawksbeard:
   identification, structure-activity relationships, molecular modeling and
   impact on its folk medicinal uses
SO RSC ADVANCES
LA English
DT Article
ID EUDESMANE SESQUITERPENES; AERIAL PARTS; LUNG INJURY; NEUTROPHIL;
   FLAVONOIDS; BIFLAVONOIDS; DERIVATIVES; DYNAMICS; ACID
AB On Wednesday 11(th) March, 2020, the world health organization (WHO) announced novel coronavirus (COVID-19, also called SARS-CoV-2) as a pandemic. Due to time shortage and lack of either a vaccine and/or an effective treatment, many trials focused on testing natural products to find out potential lead candidates. In this field, an edible and folk medicinal Jordanian plant Crepis sancta (Asteraceae) was selected for this study. Phytochemical investigation of its enriched polyphenolic extract afforded four eudesmane sesquiterpenes (1-4) together with (6S,9R)-roseoside (5) and five different methylated flavonols (6-10). Structure elucidation of isolated compounds was unambiguously determined based on HRESIMS, X-ray crystallography, and exhaustive 1D and 2D NMR experiments. All isolated compounds were assessed for their in vitro anti-inflammatory, antiallergic and in silico COVID-19 main protease (M-pro) inhibitory activities. Among the tested compounds, compounds 5-10 revealed potent anti-inflammatory, antiallergic and COVID-19 protease inhibitory activities. Chrysosplenetin (10) is considered as a promising anti-inflammatory and antiallergic lead structure adding to the phytotherapeutic pipeline. Moreover, its inhibitory activity against SARS-CoV-2 M-pro, supported by docking and molecular dynamic studies, strengthens its potential as a lead structure paving the way toward finding out a natural remedy to treat and/or to control the current COVID-19 pandemic.
C1 [Ebada, Sherif S.; Youssef, Fadia S.; El-Kashef, Dina H.; Proksch, Peter] Heinrich Heine Univ, Inst Pharmaceut Biol & Biotechnol, D-40225 Dusseldorf, Germany.
   [Ebada, Sherif S.; Al-Jawabri, Nariman A.; Aldalaien, Sa'ed M.] Mutah Univ, Dept Pharmaceut Chem, Fac Pharm, Al Karak 61710, Jordan.
   [Ebada, Sherif S.; Youssef, Fadia S.] Ain Shams Univ, Dept Pharmacognosy, Fac Pharm, Cairo 11566, Egypt.
   [Knedel, Tim-Oliver] Menia Univ, Dept Pharmacognosy, Fac Pharm, Al Minya 61519, Egypt.
   [Knedel, Tim-Oliver] Heinrich Heine Univ, Inst Anorgan Chem & Strukturchem, D-40204 Dusseldorf, Germany.
   [Albohy, Amgad] British Univ Egypt BUE, Dept Pharmaceut Chem, Fac Pharm, Cairo Suez Desert Rd, Al Sherouk City 11837, Egypt.
   [Korinek, Michal; Chen, Bing-Hung] Kaohsiung Med Univ, Grad Inst Nat Prod, Coll Pharm, Kaohsiung, Taiwan.
   [Korinek, Michal; Hwang, Tsong-Long] Kaohsiung Med Univ, Coll Life Sci, Dept Biotechnol, Kaohsiung, Taiwan.
   [Korinek, Michal; Hwang, Tsong-Long] Chang Gung Univ, Grad Inst Nat Prod, Coll Med, Taoyuan, Taiwan.
   [Hwang, Tsong-Long] Chang Gung Univ Sci & Technol, Grad Inst Hlth Ind Technol, Res Ctr Food & Cosmet Safety, Res Ctr Chinese Herbal Med,Coll Human Ecol, Taoyuan, Taiwan.
   [Chen, Bing-Hung] Chang Gung Mem Hosp, Dept Anesthesiol, Taoyuan, Taiwan.
   [Chen, Bing-Hung] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan.
   [Lin, Guan-Hua; Lin, Chia-Yi] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan.
   [Disi, Ahmad M.] Al Isra Univ, Dept Basic Pharmaceut Sci, Fac Pharm, Amman 11622, Jordan.
RP Ebada, SS; Proksch, P (corresponding author), Heinrich Heine Univ, Inst Pharmaceut Biol & Biotechnol, D-40225 Dusseldorf, Germany.
EM ss_ebada@mutah.edu.jo; Peter.Proksch@hhu.de
OI Hwang, Tsong-Long/0000-0002-5780-3977; Youssef,
   Fadia/0000-0002-5871-2639
FU International Research Center (JUNO) at Heinrich-Heine University
   (Dusseldorf, Germany); Manchot Foundation; Ministry of Science and
   Technology [MOST 106-2320-B-255-003-MY3, MOST 108-2320-B-255-003-MY3,
   MOST108-2320-B-037-004]; Ministry of Education [EMRPD1G0231,
   EMRPD1H0381]; Kaohsiung Medical University [KMU-DK109002-3]; Chang Gung
   University of Science and Technology [ZRRPF3H0101, ZRRPF3H0111]; Chang
   Gung Memorial HospitalChang Gung Memorial Hospital [CMRPF1F0011similar
   to3, CMRPF1F0061similar to3, CMRPF1G0241similar to3, CMRPF1J0051similar
   to3, BMRP450]
FX S. S. E. acknowledges the Junior Scientist and International Research
   Center (JUNO) at Heinrich-Heine University (Dusseldorf, Germany) for
   financial support. P. P. wants to thank Manchot Foundation for their
   support. The research was supported by the grants from the Ministry of
   Science and Technology (MOST 106-2320-B-255-003-MY3, MOST
   108-2320-B-255-003-MY3, and MOST108-2320-B-037-004), Ministry of
   Education (EMRPD1G0231 and EMRPD1H0381), Kaohsiung Medical University
   (KMU-DK109002-3), Chang Gung University of Science and Technology
   (ZRRPF3H0101 and ZRRPF3H0111), and Chang Gung Memorial Hospital
   (CMRPF1F0011 similar to 3, CMRPF1F0061 similar to 3, CMRPF1G0241 similar
   to 3, CMRPF1J0051 similar to 3, and BMRP450), Taiwan. The funders had no
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Ali HA, 2008, PHYTOTHER RES, V22, P1684, DOI 10.1002/ptr.2539
   Ayoub IM, 2018, J NAT PROD, V81, P243, DOI 10.1021/acs.jnatprod.7b00476
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Chen R, 2018, PHYTOMEDICINE, V40, P10, DOI 10.1016/j.phymed.2017.12.035
   Crocetti L, 2013, J MED CHEM, V56, P6259, DOI 10.1021/jm400742j
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Ebada SS, 2019, PHYTOCHEM LETT, V33, P46, DOI 10.1016/j.phytol.2019.07.007
   Ebada SS, 2020, INFLAMMOPHARMACOLOGY, V28, P321, DOI 10.1007/s10787-019-00637-x
   El-Kashef DH, 2020, MAR DRUGS, V18, DOI 10.3390/md18040204
   Fattorusso E, 2004, J NAT PROD, V67, P37, DOI 10.1021/np030222l
   Flamini G, 2001, PHYTOCHEMISTRY, V57, P559, DOI 10.1016/S0031-9422(01)00066-8
   Garcez FR, 2010, QUIM NOVA, V33, P1739, DOI 10.1590/S0100-40422010000800022
   Hagiwara S, 2008, INFLAMMATION, V31, P227, DOI 10.1007/s10753-008-9069-z
   Hegazy MEF, 2017, BIOORG MED CHEM LETT, V27, P3825, DOI 10.1016/j.bmcl.2017.06.057
   Hegazy MEF, 2014, PHYTOCHEMISTRY, V103, P154, DOI 10.1016/j.phytochem.2014.03.027
   Henriksen PA, 2014, CURR OPIN HEMATOL, V21, P23, DOI 10.1097/MOH.0000000000000001
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hirose E, 2009, INFLAMMATION, V32, P99, DOI 10.1007/s10753-009-9108-4
   Hoenderdos K, 2013, AM J RESP CELL MOL, V48, P531, DOI 10.1165/rcmb.2012-0492TR
   Hsieh CF, 2020, EMERG MICROBES INFEC, V9, P1194, DOI 10.1080/22221751.2020.1767512
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Korinek M, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00356
   Korinek M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030398
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w
   Michalsk K, 2016, MAGN RESON CHEM, V54, P175, DOI 10.1002/mrc.4358
   Moraes TJ, 2003, CRIT CARE MED, V31, pS189, DOI 10.1097/01.CCM.0000057842.90746.1E
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Prasanth DSNBK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779129
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Sajjadi SE, 2017, IRAN J PHARM RES, V16, P58
   Sansanelli S, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-69
   Sayed AM, 2020, RSC ADV, V10, P19790, DOI 10.1039/d0ra04199h
   Somerville VS, 2016, ADV NUTR, V7, P488, DOI 10.3945/an.115.010538
   Stallberg B, 2014, PRIM CARE RESP J, V23, P38, DOI 10.4104/pcrj.2013.00106
   Tsai YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep08347
   Uddin Z, 2017, TETRAHEDRON LETT, V58, P2507, DOI 10.1016/j.tetlet.2017.05.059
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang GC, 2013, PHYTOCHEMISTRY, V96, P201, DOI 10.1016/j.phytochem.2013.07.014
   Woo JH, 2017, J AGR FOOD CHEM, V65, P7893, DOI 10.1021/acs.jafc.7b01543
   Xie XY, 2014, CHEM NAT COMPD+, V50, P910, DOI 10.1007/s10600-014-1114-6
   Yang SC, 2013, J IMMUNOL, V190, P6511, DOI 10.4049/jimmunol.1202215
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
NR 49
TC 0
Z9 0
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD OCT 14
PY 2020
VL 10
IS 62
BP 38128
EP 38141
DI 10.1039/d0ra04876c
PG 14
WC Chemistry, Multidisciplinary
SC Chemistry
GA OI8LO
UT WOS:000583523300065
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Roozenbeek, J
   Schneider, CR
   Dryhurst, S
   Kerr, J
   Freeman, ALJ
   Recchia, G
   van der Bles, AM
   van der Linden, S
AF Roozenbeek, Jon
   Schneider, Claudia R.
   Dryhurst, Sarah
   Kerr, John
   Freeman, Alexandra L. J.
   Recchia, Gabriel
   van der Bles, Anne Marthe
   van der Linden, Sander
TI Susceptibility to misinformation about COVID-19 around the world
SO ROYAL SOCIETY OPEN SCIENCE
LA English
DT Article
DE COVID-19; misinformation; fake news; vaccine hesitancy
ID MEASUREMENT INVARIANCE; FAKE NEWS; NUMERACY; IMPACT; BELIEF; LITERACY;
   MESSAGES; SCIENCE; MEDIA
AB Misinformation about COVID-19 is a major threat to public health. Using five national samples from the UK (n= 1050 and n= 1150), Ireland (n = 700), the USA (n = 700), Spain (n= 700) and Mexico (n= 700), we examine predictors of belief in the most common statements about the virus that contain misinformation. We also investigate the prevalence of belief in COVID-19 misinformation across different countries and the role of belief in such misinformation in predicting relevant health behaviours. We find that while public belief in misinformation about COVID-19 is not particularly common, a substantial proportion views this type of misinformation as highly reliable in each country surveyed. In addition, a small group of participants find common factual information about the virus highly unreliable. We also find that increased susceptibility to misinformation negatively affects people's self-reported compliance with public health guidance about COVID-19, as well as people's willingness to get vaccinated against the virus and to recommend the vaccine to vulnerable friends and family. Across all countries surveyed, we find that higher trust in scientists and having higher numeracy skills were associated with lower susceptibility to coronavirus-related misinformation. Taken together, these results demonstrate a clear link between susceptibility to misinformation and both vaccine hesitancy and a reduced likelihood to comply with health guidance measures, and suggest that interventions which aim to improve critical thinking and trust in science may be a promising avenue for future research.
C1 [Roozenbeek, Jon; Schneider, Claudia R.; Kerr, John; van der Bles, Anne Marthe; van der Linden, Sander] Univ Cambridge, Dept Psychol, Downing St, Cambridge CB2 3EB, England.
   [Roozenbeek, Jon] Univ Cambridge, Sect Slavon Studies, Sidgwick Ave, Cambridge CB3 9DA, England.
   [Schneider, Claudia R.; Dryhurst, Sarah; Kerr, John; Freeman, Alexandra L. J.; Recchia, Gabriel; van der Bles, Anne Marthe; van der Linden, Sander] Univ Cambridge, Winton Ctr Risk & Evidence Commun, Wilberforce Rd, Cambridge CB3 0WA, England.
   [van der Bles, Anne Marthe] Univ Groningen, Dept Psychol, Grote Kruisstr 2-1, NL-9712 TS Groningen, Netherlands.
RP van der Linden, S (corresponding author), Univ Cambridge, Dept Psychol, Downing St, Cambridge CB2 3EB, England.; van der Linden, S (corresponding author), Univ Cambridge, Winton Ctr Risk & Evidence Commun, Wilberforce Rd, Cambridge CB3 0WA, England.
EM sander.vanderlinden@psychol.cam.ac.uk
RI van der Linden, Sander/ABE-6441-2020
OI van der Linden, Sander/0000-0002-0269-1744; Recchia,
   Gabriel/0000-0002-0210-8635; Kerr, John/0000-0002-6606-5507; Schneider,
   Claudia R/0000-0002-6612-5186
FU Winton Centre for Risk & Evidence Communication; Science Foundation
   IrelandScience Foundation Ireland
FX h The Spanish translation of the survey was conducted by Maria del
   Carmen Climent-Palmer. We thank all participants for their time and
   input. The surveys in the UK, the USA, Mexico and Spain were funded by
   the Winton Centre for Risk & Evidence Communication, which is supported
   by a donation from the David & Claudia Harding Foundation. The survey in
   Ireland was funded by Science Foundation Ireland.
CR Allcott H, 2017, J ECON PERSPECT, V31, P211, DOI 10.1257/jep.31.2.211
   Allen J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay3539
   Allington D., 2020, RELATIONSHIP CONSPIR
   Allington Daniel, 2020, Psychol Med, P1, DOI 10.1017/S003329172000224X
   [Anonymous], 2020, IB AD INCL NUR
   [Anonymous], 2020, BBC NEWS
   Bago B, 2020, J EXP PSYCHOL GEN, V149, P1608, DOI 10.1037/xge0000729
   Banas JA, 2013, HUM COMMUN RES, V39, P184, DOI 10.1111/hcre.12000
   Basol Melisa, 2020, J Cogn, V3, P2, DOI 10.5334/joc.91
   Bertin P, 2020, PSYARXIV PREPR, DOI DOI 10.31234/OSF.IO/RZ78K
   Bleich S, 2007, OBESITY, V15, P2145, DOI 10.1038/oby.2007.255
   Bro P, 2014, DIGIT JOURNAL, V2, P446, DOI 10.1080/21670811.2014.895507
   Bronstein MV, 2019, J APPL RES MEM COGN, V8, P108, DOI 10.1016/j.jarmac.2018.09.005
   Cheung GW, 2002, STRUCT EQU MODELING, V9, P233, DOI 10.1207/S15328007SEM0902_5
   Cokely ET, 2012, JUDGM DECIS MAK, V7, P25
   De Keersmaecker J, 2017, INTELLIGENCE, V65, P107, DOI 10.1016/j.intell.2017.10.005
   Dryhurst S, 2020, J RISK RES, V23, P994, DOI 10.1080/13669877.2020.1758193
   Duffy B, 2020, COVID CONSPIRACIES C
   Einstein K, 2015, POLIT BEHAV, V37, P679, DOI 10.1007/s11109-014-9287-z
   Georgiou N, 2020, PERS INDIV DIFFER, V166, DOI 10.1016/j.paid.2020.110201
   GOERTZEL T, 1994, POLIT PSYCHOL, V15, P731, DOI 10.2307/3791630
   Grinberg N, 2019, SCIENCE, V363, P374, DOI 10.1126/science.aau2706
   Guess A, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau4586
   Imhoff R, 2020, SOC PSYCHOL PERS SCI, V11, P1110, DOI 10.1177/1948550620934692
   Iyengar S, 2019, P NATL ACAD SCI USA, V116, P7656, DOI 10.1073/pnas.1805868115
   Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1
   Jolley D, 2020, BRIT J SOC PSYCHOL, V59, P628, DOI 10.1111/bjso.12394
   Jolley D, 2017, J APPL SOC PSYCHOL, V47, P459, DOI 10.1111/jasp.12453
   Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177
   Jost JT, 2018, CURR OPIN PSYCHOL, V23, P77, DOI 10.1016/j.copsyc.2018.01.003
   Kahan DM, 2012, NAT CLIM CHANGE, V2, P732, DOI 10.1038/NCLIMATE1547
   Keller FB, 2020, POLIT COMMUN, V37, P256, DOI 10.1080/10584609.2019.1661888
   Kim M, 2016, INT J COMMUN-US, V10, P3808
   Krause NM, 2020, J RISK RES, V23, P1052, DOI 10.1080/13669877.2020.1756385
   Lazer DMJ, 2018, SCIENCE, V359, P1094, DOI 10.1126/science.aao2998
   Lewandowsky S, 2017, J APPL RES MEM COGN, V6, P353
   Lewandowsky S, 2016, CURR DIR PSYCHOL SCI, V25, P217, DOI 10.1177/0963721416654436
   Lewandowsky S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075637
   Lewandowsky S, 2012, PSYCHOL SCI PUBL INT, V13, P106, DOI 10.1177/1529100612451018
   Li HOY, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002604
   Lutzke L, 2019, GLOBAL ENVIRON CHANG, V58, DOI 10.1016/j.gloenvcha.2019.101964
   McManus Sally, 2020, Psychol Med, P1, DOI 10.1017/S0033291720002184
   Men J, 2020, ROUT STUD COMP ASI P, P3
   Milfont TL, 2010, INT J PSYCHOL RES, V3, P111
   Miller JM, 2020, CAN J POLIT SCI, V53, P319, DOI 10.1017/S0008423920000517
   Motta M, 2020, CAN J POLIT SCI, V53, P335, DOI 10.1017/S0008423920000396
   Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365
   Ofcom, 2020, HALF UK AD EXP FALS
   Pennycook G, 2018, J EXP PSYCHOL GEN, V147, P1865, DOI 10.1037/xge0000465
   Pennycook G, 2019, COGNITION, V188, P39, DOI 10.1016/j.cognition.2018.06.011
   Peters E, 2006, PSYCHOL SCI, V17, P407, DOI 10.1111/j.1467-9280.2006.01720.x
   Plohl N, 2020, PSYCHOL HEALTH MED, DOI 10.1080/13548506.2020.1772988
   Poland GA, 2010, VACCINE, V28, P2361, DOI 10.1016/j.vaccine.2010.02.052
   Putnick DL, 2016, DEV REV, V41, P71, DOI 10.1016/j.dr.2016.06.004
   Rogers de Waal Joel, 2018, BREXIT TRUMP VOTERS
   Roozenbeek J., 2020, HARVARD KENNEDY SCH, V1, P1
   Roozenbeek J, 2019, CONVERSATION
   ROOZENBEEK J, 2019, PALGR COMMUN, V5, DOI DOI 10.1057/S41599-019-0279-9
   Roozenbeek J, 2020, EDUC PSYCHOL MEAS, DOI 10.1177/0013164420940378
   Roser M., 2020, CORONAVIRUS PANDEMIC
   Rothgerber H, 2020, POLITICIZING COVID 1, DOI [10.31234/osf.io/k23cv, DOI 10.31234/OSF.IO/K23CV]
   Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003
   Stanley ML, 2020, THINK REASONING, DOI 10.1080/13546783.2020.1813806
   Swami V, 2014, COGNITION, V133, P572, DOI 10.1016/j.cognition.2014.08.006
   Swami V, 2011, BRIT J PSYCHOL, V102, P443, DOI 10.1111/j.2044-8295.2010.02004.x
   Uscinski J. E., 2020, WHY DO PEOPLE BELIEV, V1, P1
   Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z
   van der Bles AM, 2019, ROY SOC OPEN SCI, V6, DOI 10.1098/rsos.181870
   van der Linden S, 2020, POLIT PSYCHOL, DOI 10.1111/pops.12681
   van der Linden S, 2020, MEDIA CULT SOC, V42, P460, DOI 10.1177/0163443720906992
   van Prooijen JW, 2018, APPL COGNITIVE PSYCH, V32, P661, DOI 10.1002/acp.3442
   van Prooijen JW, 2017, APPL COGNITIVE PSYCH, V31, P50, DOI 10.1002/acp.3301
   van Prooijen JW, 2015, SOC PSYCHOL PERS SCI, V6, P570, DOI 10.1177/1948550614567356
   World. 2020-World Health Organization, 2020, 13 WHO
   World Health Organization, 2020, COR DIS COVID 19 ADV
   Wright AJ, 2009, BRIT J HEALTH PSYCH, V14, P107, DOI 10.1348/135910708X304432
   Zarocostas J, 2020, LANCET, V395, P676, DOI 10.1016/S0140-6736(20)30461-X
NR 77
TC 5
Z9 5
U1 13
U2 13
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 2054-5703
J9 ROY SOC OPEN SCI
JI R. Soc. Open Sci.
PD OCT 14
PY 2020
VL 7
IS 10
AR 201199
DI 10.1098/rsos.201199
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OH0CJ
UT WOS:000582240600001
PM 33204475
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Popov, GT
   Baymakova, M
   Vaseva, V
   Kundurzhiev, T
   Mutafchiyski, V
AF Popov, Georgi T.
   Baymakova, Magdalena
   Vaseva, Virsavia
   Kundurzhiev, Todor
   Mutafchiyski, Ventsislav
TI Clinical Characteristics of Hospitalized Patients with COVID-19 in
   Sofia, Bulgaria
SO VECTOR-BORNE AND ZOONOTIC DISEASES
LA English
DT Article
DE clinical outcome; clinical signs; COVID-19; imaging procedures;
   laboratory results; therapy
ID CORONAVIRUS; INFECTION
AB Introduction:SARS-CoV-2 infection is spreading around the world, including countries from Southeastern Europe. The purpose of the study was to present the clinical manifestations of COVID-19 patients admitted to the Military Medical Academy, Sofia, Bulgaria. Materials and Methods:A retrospective study was conducted for a period of 3 months from March 2020 to June 2020 on this infection in our hospital. All participants were laboratory confirmed cases of COVID-19. RT-PCR was performed for etiological diagnosis. The hospitalized patients were divided into two groups on admission, that is, nonsevere and severe. Results:One hundred thirty-eight COVID-19 patients were hospitalized and analyzed during the study period. The mean age was 52.9 years. Male was the dominant sex (sex ratio: male/female = 1/0.6). The leading clinical signs were fever, fatigue, cough, and headache. On comparative analysis of both groups (nonsevere and severe) was measured significant elevation of white blood cells (odds ratio [OR] = 1.238;pvalue = 0.006), C-reactive protein (OR = 1.021;p < 0.001), creatinine (OR = 1.037;p < 0.001), aspartate aminotransferase (OR = 1.014;p = 0.040), lactate dehydrogenase (OR = 1.004;p < 0.001), ferritin (OR = 1.002;p < 0.001), fibrinogen (OR = 2.028;p < 0.001), and d-dimer (OR = 2.162;p = 0.002) in severe group than in nonsevere group. Interleukin 6 was tested in 17.4% of patients and high value was found-38.6 pg/mL (95% confidence interval: 16.5-60.7). Conclusion:The first Bulgarian retrospective study of COVID-19 hospitalized patients was presented. Older age, male sex, comorbidity, and signs of dyspnea and nausea were estimated as higher risk factors for severe form. Abnormality in inflammatory markers was associated with poor progression of the illness.
C1 [Popov, Georgi T.; Baymakova, Magdalena] Mil Med Acad, Dept Infect Dis, Sofia 1606, Bulgaria.
   [Vaseva, Virsavia] Mil Med Acad, Dept Teaching & Sci Act, Sofia, Bulgaria.
   [Kundurzhiev, Todor] Med Univ, Fac Publ Hlth, Dept Occupat Med, Sofia, Bulgaria.
   [Mutafchiyski, Ventsislav] Mil Med Acad, Dept Surg, Sofia, Bulgaria.
RP Baymakova, M (corresponding author), Mil Med Acad, Dept Infect Dis, Sofia 1606, Bulgaria.
EM dr.baymakova@gmail.com
CR Colaneri M, 2020, EUROSURVEILLANCE, V25, P8, DOI 10.2807/1560-7917.ES.2020.25.16.2000460
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Information Services Jsc (ISJ) Sofia Bulgaria, COVID 19 UN INF PORT
   Kim ES, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e142
   Lechien JR, 2020, J INTERN MED, V288, P335, DOI 10.1111/joim.13089
   Li RQ, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104363
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang RR, 2020, INT J INFECT DIS, V95, P421, DOI 10.1016/j.ijid.2020.03.070
   World Health Organization (WHO), WHO HLTH TOP
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhang GM, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01338-8
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zheng F, 2020, EUR REV MED PHARMACO, V24, P3404, DOI 10.26355/eurrev_202003_20711
   Zheng YL, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104366
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 24
TC 2
Z9 2
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-3667
EI 1557-7759
J9 VECTOR-BORNE ZOONOT
JI Vector-Borne Zoonotic Dis.
PD DEC 1
PY 2020
VL 20
IS 12
BP 910
EP 915
DI 10.1089/vbz.2020.2679
EA OCT 2020
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA OZ0LX
UT WOS:000581230300001
PM 33054699
OA Bronze
DA 2021-01-01
ER

PT J
AU Jaffe, E
   Lyerly, AD
   Goldfarb, IT
AF Jaffe, Elana
   Lyerly, Anne Drapkin
   Goldfarb, Ilona Telefus
TI Pregnant women's perceptions of risks and benefits when considering
   participation in vaccine trials
SO VACCINE
LA English
DT Article
DE Pregnancy; Vaccine research; Zika vaccines; Decision-making
ID MATERNAL IMMUNIZATION; CLINICAL-TRIALS; ADVERSE EVENTS; KNOWLEDGE;
   ATTITUDES; HEALTH
AB Introduction: Despite historical exclusion, there has been recent recognition of the need to address the health of pregnant women in research on vaccines against emerging pathogens. However, pregnant women's views and decision-making processes about vaccine research participation during infectious disease outbreaks remain underexplored. This study aims to examine women's decision-making processes around vaccine research participation during infectious disease outbreaks.
   Methods: We conducted qualitative semi-structured in-depth interviews with pregnant and recently pregnant women (n = 13), eliciting their views on four hypothetical Zika Virus vaccine research scenarios and probing their decision-making processes around participation. After recorded interviews were transcribed, thematic analysis was conducted based on a priori and emergent themes.
   Results: Most women interviewed were accepting of vaccine research scenarios. Three broad themes-evidence, risk, and trust-characterized women's decision-making processes. Women varied in how different types and levels of evidence impacted their considerations, which risks were most salient to their decision-making processes, and from whom they trusted recommendations about vaccine research participation. Exemplary quotes from each theme are presented, and lessons for vaccine development during the current COVID-19 pandemic and future outbreaks are discussed.
   Conclusion: Some pregnant women are accepting of participation in vaccine research during infectious disease outbreaks. Incorporating their priorities into trial design may facilitate their participation and generation of evidence for this important population. (c) 2020 Elsevier Ltd. All rights reserved.
C1 [Jaffe, Elana; Lyerly, Anne Drapkin] Univ N Carolina, Ctr Bioeth, Chapel Hill, NC 27515 USA.
   [Jaffe, Elana; Lyerly, Anne Drapkin] Univ N Carolina, Dept Social Med, Chapel Hill, NC 27515 USA.
   [Jaffe, Elana] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Maternal Child & Family Hlth, Chapel Hill, NC 27515 USA.
   [Lyerly, Anne Drapkin] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC 27515 USA.
   [Goldfarb, Ilona Telefus] Massachusetts Gen Hosp, Dept Obstet & Gynecol, 55 Fruit St, Boston, MA 02114 USA.
RP Goldfarb, IT (corresponding author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, 55 Fruit St, Boston, MA 02114 USA.
EM IGOLDFARB@mgh.harvard.edu
OI Jaffe, Elana/0000-0003-1917-2278
FU National Institute of Allergy and Infectious Diseases of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI108368]
FX This work was supported in part by the National Institute of Allergy and
   Infectious Diseases of the National Institutes of Health under award
   number R01AI108368 (PI, Lyerly). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Alholm Z, 2017, OPEN FORUM INFECT DI, V4, DOI [10.1093/ofid/ofx163.1167, DOI 10.1093/OFID/OFX163.1167]
   Andersen MD, 2018, ANIMAL MODEL FETAL M, DOI [10.5772/intechopen.74038, DOI 10.5772/INTECHOPEN.74038]
   [Anonymous], PREGN LACT LAB DRUGS
   [Anonymous], 2018, HLTH HUM SERV SECR C
   Baylis F, 2016, RES ETHICS FORUM, V3, P1, DOI 10.1007/978-3-319-26512-4
   Bond L, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-943
   Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y
   Faucette AN, 2015, HUM REPROD UPDATE, V21, P119, DOI 10.1093/humupd/dmu041
   Fraiz LD, 2018, VACCINE, V36, P165, DOI 10.1016/j.vaccine.2017.11.021
   Fulton TR, 2015, VACCINE, V33, P6453, DOI 10.1016/j.vaccine.2015.08.043
   Goldfarb IT, 2018, VACCINE, V36, P6711, DOI 10.1016/j.vaccine.2018.09.042
   Gruber MF, 2015, VACCINE, V33, P6499, DOI 10.1016/j.vaccine.2015.05.107
   Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903
   Healy CM, 2015, VACCINE, V33, P5445, DOI 10.1016/j.vaccine.2015.08.028
   Henninger M, 2013, OBSTET GYNECOL, V121, P741, DOI 10.1097/AOG.0b013e3182878a5a
   Kazma JM, 2020, J PHARMACOKINET PHAR, V47, P271, DOI 10.1007/s10928-020-09677-1
   Keller-Stanislawski B, 2014, VACCINE, V32, P7057, DOI 10.1016/j.vaccine.2014.09.052
   Kilich E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234827
   Koren G, 2002, AM J OBSTET GYNECOL, V186, pS248, DOI 10.1067/mob.2002.122601
   Krubiner Carleigh B, 2021, Vaccine, V39, P85, DOI 10.1016/j.vaccine.2019.01.011
   Laris-Gonzalez A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010124
   Lutz CS, 2018, VACCINE, V36, P7445, DOI 10.1016/j.vaccine.2018.10.046
   Lyerly AD, 2012, IRB ETHICS HUM RES, P34
   Lyerly AD, 2017, JAMA PEDIATR, V171, P719, DOI 10.1001/jamapediatrics.2017.1496
   Lyerly AD, 2009, HASTINGS CENT REP, V39, P34
   Lynch MM, 2012, MATERN CHILD HLTH J, V16, P1657, DOI 10.1007/s10995-011-0865-y
   McQuaid F, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010790
   Moniz MH, 2014, HUM VACC IMMUNOTHER, V10, P2562, DOI 10.4161/21645515.2014.970901
   Mountifield RE, 2010, J CROHNS COLITIS, V4, P176, DOI 10.1016/j.crohns.2009.10.001
   Nganga SW, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4537-8
   Palmer S, 2016, J OBSTET GYNAECOL CA, V38, P945, DOI 10.1016/j.jogc.2016.04.100
   Pariente G, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002160
   Pellegrini C, 2015, VACCINE, V33, P6501, DOI 10.1016/j.vaccine.2015.06.118
   Roberts JN, 2015, VACCINE, V33, P966, DOI 10.1016/j.vaccine.2014.12.068
   Rodger MA, 2003, AM J PERINAT, V20, P69, DOI 10.1055/s-2003-38318
   Shavell VI, 2012, AM J OBSTET GYNECOL, V207, pS67, DOI 10.1016/j.ajog.2012.06.077
   Spier RE, 2001, VACCINE, V20, pS78, DOI 10.1016/S0264-410X(01)00306-1
   Swamy GK, 2015, VACCINE, V33, P6436, DOI 10.1016/j.vaccine.2015.08.035
   Widnes SF, 2017, AM J OBSTET GYNECOL, V216, P375, DOI 10.1016/j.ajog.2016.12.007
   Wilcox CR, 2019, PEDIATR INFECT DIS J, V38, P625, DOI 10.1097/INF.0000000000002242
   Wong LP, 2017, VACCINE, V35, P5912, DOI 10.1016/j.vaccine.2017.08.074
   Wood ME, 2019, CLIN THER, V41, P2467, DOI 10.1016/j.clinthera.2019.08.016
NR 42
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 14
PY 2020
VL 38
IS 44
BP 6922
EP 6929
DI 10.1016/j.vaccine.2020.08.059
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OA7SQ
UT WOS:000577981500010
PM 32893036
OA Green Published
DA 2021-01-01
ER

PT J
AU Finsterer, J
   Scorza, FA
   Fiorini, AC
AF Finsterer, J.
   Scorza, F. A.
   Fiorini, A. C.
TI SARS-CoV-2-associated Guillain-Barre syndrome in 62 patients
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Letter; Early Access
DE cardiotoxicity; drugs; epilepsy; hippocampus; sudden death; takotsubo
C1 [Finsterer, J.] Krankenanstalt Rudolfstiftung Wien, Messerli Inst, Postfach 20, A-1180 Vienna, Austria.
   [Scorza, F. A.] Univ Fed Sao Paulo, Disciplina Neurociencia, Escola Paulista Med, UNIFESP EPM, Sao Paulo, Brazil.
   [Fiorini, A. C.] Pontificia Univ Catolica Sao Paulo PUC SP, Programa Estudos Posgrad Fonoaudiol, Sao Paulo, Brazil.
   [Fiorini, A. C.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Fonoaudiol, EPM UNIFESP, Sao Paulo, Brazil.
RP Finsterer, J (corresponding author), Krankenanstalt Rudolfstiftung Wien, Messerli Inst, Postfach 20, A-1180 Vienna, Austria.
EM fipaps@yahoo.de
OI finsterer, josef/0000-0003-2839-7305
CR Barbi L, 2018, BRAZ J INFECT DIS, V22, P137, DOI 10.1016/j.bjid.2018.02.005
   De Sanctis P, 2020, EUR J NEUROL, V27, P2361, DOI 10.1111/ene.14462
   Finsterer J, 2020, J MED VIROL
   Manganotti P, 2020, J MED VIROL, DOI 10.1002/jmv.26289
   Tanasa IA, 2020, EXP THER MED, V20, P2344, DOI 10.3892/etm.2020.8808
NR 5
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
DI 10.1111/ene.14544
EA OCT 2020
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OA2WO
UT WOS:000577652500001
PM 32978857
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Dhont, S
   Callens, R
   Stevens, D
   Bauters, F
   De Bleecker, JL
   Derom, E
   Van Braeckel, E
AF Dhont, Sebastiaan
   Callens, Rutger
   Stevens, Dieter
   Bauters, Fre
   De Bleecker, Jan L.
   Derom, Eric
   Van Braeckel, Eva
TI Myotonic dystrophy type 1 as a major risk factor for severe COVID-19?
SO ACTA NEUROLOGICA BELGICA
LA English
DT Article; Early Access
DE Steinert's disease; Myotonic dystrophy; Neuromuscular disorders;
   COVID-19; SARS-CoV-2
ID FLOW
AB The coronavirus disease 2019 (COVID-19) pandemic is challenging health care systems worldwide. People with myotonic dystrophy type 1 (DM1) represent a high-risk population during infectious disease outbreaks, little is known about the potential impact of COVID-19 on patients with DM1. We studied the clinical course of COVID-19 in three hospitalized patients with myotonic dystrophy type 1 or Steinert's disease, between April 1, 2020-April 30-2020. All three had advanced Steinert's disease receiving non-invasive nocturnal home ventilatory support. Two of them lived in a residential care centre. Two patients had a limited respiratory capacity, whereas one patient had a rather preserved functional capacity but more comorbidities. Two out of three patients were obese, none of them had diabetes mellitus. Two patients received hydroxychloroquine. Despite maximal supportive care with oxygen therapy, antibiotics, intensive respiratory physiotherapy and non-invasive positive pressure ventilation, all three patients eventually died due to COVID-19. Our case series of three patients with DM1 admitted for COVID-19 confirms that they are at high risk for severe disease and poor outcome. Clinical trials are needed to define best practices and determinants of outcomes in this unique population.
C1 [Dhont, Sebastiaan; Callens, Rutger] Ghent Univ Hosp, Dept Internal Med & Paediat, Corneel Heymanslaan 10, B-9000 Ghent, Belgium.
   [Stevens, Dieter; Bauters, Fre; Derom, Eric; Van Braeckel, Eva] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium.
   [De Bleecker, Jan L.] Ghent Univ Hosp, Neuromuscular Reference Ctr, Ghent, Belgium.
RP Dhont, S (corresponding author), Ghent Univ Hosp, Dept Internal Med & Paediat, Corneel Heymanslaan 10, B-9000 Ghent, Belgium.
EM sebastiaan.dhont@ugent.be
CR [Anonymous], 2020, MODES TRANSMISSION V, DOI [10.3201/eid2606.200239, DOI 10.3201/EID2606.200239]
   Bargiela A, 2019, P NATL ACAD SCI USA, V116, P25203, DOI 10.1073/pnas.1820297116
   Berlin David A, 2020, N Engl J Med, V383, P2451, DOI 10.1056/NEJMcp2009575
   BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0
   Curtis JR, 2020, JAMA-J AM MED ASSOC, V323, P1771, DOI 10.1001/jama.2020.4894
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   GREGG I, 1973, BMJ-BRIT MED J, V3, P282, DOI 10.1136/bmj.3.5874.282
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   LEINER GC, 1963, AM REV RESPIR DIS, V88, P644
   Lindquist S, 2011, NEUROPSYCH DIS TREAT, V7, P341, DOI 10.2147/NDT.S10464
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mellies Uwe, 2014, Ann Am Thorac Soc, V11, P1560, DOI 10.1513/AnnalsATS.201406-264OC
   MIERJEDRZEJOWICZ A, 1988, AM REV RESPIR DIS, V138, P5
   Olejniczak M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/873860
   Peric S, 2019, NEUROL SCI, V40, P1035, DOI 10.1007/s10072-019-03763-0
   Poponick JM, 1997, AM J RESP CRIT CARE, V156, P659, DOI 10.1164/ajrccm.156.2.9611029
   Prokop M, 2020, RADIOLOGY, V296, pE97, DOI 10.1148/radiol.2020201473
   REARDON W, 1993, ARCH DIS CHILD, V68, P177, DOI 10.1136/adc.68.2.177
   Rhodes JD, 2012, HUM MOL GENET, V21, P852, DOI 10.1093/hmg/ddr515
   Varan O, 2015, REUMATISMO, V67, P125
   Vujnic Milorad, 2018, Acta Myol, V37, P252
   Wasay M, 1998, NEUROLOGY, V51, P1226, DOI 10.1212/WNL.51.4.1226
   Wenninger S, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00303
NR 23
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-9009
EI 2240-2993
J9 ACTA NEUROL BELG
JI Acta Neurol. Belg.
DI 10.1007/s13760-020-01514-z
EA OCT 2020
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NZ6QG
UT WOS:000577229800003
PM 33052531
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Yue, L
   Cao, H
   Xie, TH
   Long, RX
   Li, H
   Yang, T
   Yan, M
   Xie, ZP
AF Yue, Lei
   Cao, Han
   Xie, Tianhong
   Long, Runxiang
   Li, Hua
   Yang, Ting
   Yan, Min
   Xie, Zhongping
TI N-terminally truncated nucleocapsid protein of SARS-CoV-2 as a better
   serological marker than whole nucleocapsid protein in evaluating the
   immunogenicity of inactivated SARS-CoV-2
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE N-terminally truncated NP; protein expression and purification;
   SARS-CoV-2; sensitivity
AB The coronavirus disease 2019 pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) had led to a serious public health crisis, and no specific treatments or vaccines are available yet. A nucleocapsid protein (NP)-based enzyme-linked immunosorbent assay (ELISA) detection method is not only important in disease diagnosis, but is required for the evaluation of vaccine efficacy during the development of an inactivated SARS-CoV-2 vaccine. In this study, we expressed both the NP and N-terminally truncated NP (Delta N-NP) of SARS-CoV-2 in anEscherichia coliexpression system and described the purification of the soluble recombinant NP and Delta N-NP in details. The identities of the NP and Delta N-NP were confirmed with mass spectrometry. We then used immunoglobulin G detection ELISAs to compare the sensitivity of NP and Delta N-NP in detecting anti-SARS-CoV-2 antibodies. Delta N-NP showed greater sensitivity than NP in the analysis of serially diluted sera from mice and rabbits vaccinated with inactive SARS-CoV-2 and in human sera diluted 1:400. Delta N-NP showed a positive detection rate similar to that of the SARS-CoV-2 S protein in human sera. We conclude that Delta N-NP is a better serological marker than NP for evaluating the immunogenicity of inactivated SARS-CoV-2.
C1 [Yue, Lei; Cao, Han; Xie, Tianhong; Long, Runxiang; Li, Hua; Yang, Ting; Xie, Zhongping] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, 935 Jiaoling Rd, Kunming 650118, Yunnan, Peoples R China.
   [Yan, Min] Kunming Med Univ, Dept Microbiol & Immunol, Kunming, Yunnan, Peoples R China.
RP Xie, ZP (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, 935 Jiaoling Rd, Kunming 650118, Yunnan, Peoples R China.
EM xzp218@126.com
FU Kunming Science and Technology Project [2020-1-H-021]; Foundation for
   High-level Talents in Health & Health Technical of Yunnan [H-2018061];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81800012]; Applied Basic Research Foundation
   of Yunnan Province [2016FB037, 2017FB019]; CAMS Innovation Fund for
   Medical Sciences [2016-I2M-1-019, 2020-I2M-CoV19-012]
FX Kunming Science and Technology Project, Grant/Award Number:
   2020-1-H-021; Foundation for High-level Talents in Health & Health
   Technical of Yunnan, Grant/Award Number: H-2018061; National Natural
   Science Foundation of China, Grant/Award Number: 81800012; Applied Basic
   Research Foundation of Yunnan Province, Grant/Award Numbers: 2016FB037,
   2017FB019; CAMS Innovation Fund for Medical Sciences, Grant/Award
   Numbers: 2016-I2M-1-019, 2020-I2M-CoV19-012
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Burbelo PD, 2020, J INFECT DIS, V222, P206, DOI 10.1093/infdis/jiaa273
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Kouznetsov VV, 2020, EUR J MED CHEM, V203, DOI 10.1016/j.ejmech.2020.112647
   Liu W, 2020, J CLIN MICROBIOL, V58
   Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543
   Yamaoka Yutaro, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa637
   Yu FX, 2007, CLIN VACCINE IMMUNOL, V14, P146, DOI 10.1128/CVI.00360-06
   Yu FX, 2005, CLIN DIAGN LAB IMMUN, V12, P848, DOI 10.1128/CDLI.12.7.848-854.2005
   Zeng WH, 2020, BIOCHEM BIOPH RES CO, V527, P618, DOI 10.1016/j.bbrc.2020.04.136
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 13
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26541
EA OCT 2020
PG 7
WC Virology
SC Virology
GA OA2UU
UT WOS:000577647900001
PM 32965677
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Barrett, R
   Catangui, E
   Scott, R
AF Barrett, Ravina
   Catangui, Eugene
   Scott, Railton
TI Acute oxygen therapy: a cross-sectional study of prescribing practices
   at an English hospital immediately before COVID-19 pandemic
SO EXPERT REVIEW OF RESPIRATORY MEDICINE
LA English
DT Article; Early Access
DE Oxygen; hypercapnia; inpatients; oxygen inhalation therapy; oximetry;
   hypoxia; pulmonary disease; chronic obstructive; dyspnea; iatrogenic
   disease
ID AUDIT
AB Background Approximately 14% of UK hospital in-patients receive supplemental oxygen therapy, only 57% have valid prescriptions. Oxygen must be optimally prescribed to ensure maximal therapeutic response whilst minimizing adverse outcomes (including fatality). This study investigates prescription compliance. Methods All adults admitted to medical wards (18 February to 3 March 2020) were included. Analyses present proportions, descriptive statistics, and hypothesis testing. Ethical approval was unnecessary for this audit. Results Of the 636 patients admitted, 66 (10%) were receiving oxygen therapy. Ages ranged from 34 to 100 years with 36 (54.5%) males and 30 (45.5%) females. The prescription was not documented in the oxygen section of the drug chart (n = 37, 56.1%, p = 0.389), nor did it have the physicians signature (n = 40, 60.6%, p = 0.110) nor date (n = 46, 69.7%, p = 0.002). Thirteen chronic obstructive pulmonary disease (COPD) patients (19.7%) were at risk of hypercapnic failure (p = 1.582x10(-6)). Target oxygen saturation (SpO2) range had been documented for 30 (45.5%) patients. A target SpO2 range of 88-92% was documented for 9 patients (13.6%), a 94-98% range documented for 11 patients (16.7%). All patients had an invalid prescription. Conclusion We present real-world practice in naturalistic settings, immediately before pandemic-lockdown. Enhanced compliance is advocated to reduce risks of harm and mortality.
C1 [Barrett, Ravina; Catangui, Eugene; Scott, Railton] Univ Brighton, Sch Pharm & Biomol Sci, Cockcroft Bldg,Moulsecoomb Campus,Lewes Rd, Brighton BN2 4GJ, E Sussex, England.
RP Barrett, R (corresponding author), Univ Brighton, Sch Pharm & Biomol Sci, Cockcroft Bldg,Moulsecoomb Campus,Lewes Rd, Brighton BN2 4GJ, E Sussex, England.
EM R.Barrett2@Brighton.ac.uk
OI Barrett, Ravina/0000-0003-0004-2131
FU University of Brighton
FX Funding for this study was provided by the University of Brighton.
CR Abdo WF, 2012, CRIT CARE, V16, DOI 10.1186/cc11475
   Abernethy AP, 2010, LANCET LOND ENGL, V376
   Al-Otaibi HM, 2019, J TAIBAH U MED SCI, V14
   [Anonymous], 2018, CHRON OBSTR PULM DIS
   Austin M.A, 2010, BMJ, V341, pc5462
   Brill SE, 2014, INT J CHRON OBSTRUCT, V9
   Choudhury A, 2018, BMJ OPEN QUAL, V7
   Chu DK, 2018, LANCET LOND ENGL, V391
   Corfield AR, 2014, EMERG MED J, V31, P482, DOI 10.1136/emermed-2012-202186
   Curry JP, 2014, PATIENT SAF SURG, V8, DOI 10.1186/1754-9493-8-29
   Echevarria C, 2019, THORAX, V74, pA39, DOI 10.1136/thorax-2019-BTSabstracts2019.64
   Franke TM, 2012, AM J EVAL, V33, P448, DOI 10.1177/1098214011426594
   Helliar Sebastian, 2016, BMJ Qual Improv Rep, V5, DOI 10.1136/bmjquality.u209520.w4033
   Holbourn A, 2014, INTERN MED J, V44, P1231, DOI 10.1111/imj.12602
   IBM Corp, 2014, IBM SPSS STAT WIND V
   Kamran A, 2018, INTERN MED J, V48, P151, DOI 10.1111/imj.13612
   Kelly CA, 2018, CLIN RESPIR J, V12, P616, DOI 10.1111/crj.12571
   Kelly CA, 2015, CHRON RESP DIS, V12, P11, DOI 10.1177/1479972314562408
   Kraemer HC, 2016, MANY SUBJECTS STAT P
   Li W-F, 2018, CORON ARTERY DIS, V29
   LILLIEFORS HW, 1967, J AM STAT ASSOC, V62, P399, DOI 10.2307/2283970
   Martin J, 2020, RESP CARE, V65, P1202, DOI 10.4187/respcare.07310
   Munshi L, 2020, JAMA, V323
   Myers H, 2015, RESPIROL CARLTON VIC, V20
   National Patient Safety Agency, 2009, NPSA2009RRR006
   Neves JT, 2012, REV PORT PNEUMOL, V18, P80, DOI 10.1016/j.rppneu.2012.01.001
   O'Driscoll BR, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2016-209729
   O'Driscoll BR, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2015-000102
   Okubadejo AA, 1996, EUR RESPIR J, V9, P2335, DOI 10.1183/09031936.96.09112335
   Rudge James, 2014, BMJ Qual Improv Rep, V3, DOI 10.1136/bmjquality.u204031.w1815
   Sanderson S, 2016, NZ MED J, V129
   Sjoberg F, 2013, J INTERN MED, V274, P505, DOI 10.1111/joim.12139
   Stolmeijer R, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7841295
   Takeuchi Y, 2020, MOLECULES, V25, DOI 10.3390/molecules25143197
   The National Institute for Health and Care Excellence, OX OV
   Thomson L, 2014, PAEDIATR RESPIR REV, V15, P120, DOI 10.1016/j.prrv.2014.03.003
   Uronis HE, 2008, BR J CANC, V98
   Veale D, 1998, EUR RESPIR J, V12, P780, DOI 10.1183/09031936.98.12040780
   von Elm E, 2014, INT J SURG, V12
   Williams B., 2019, CLIN MED LOND ENGL, V19
   World Medical Association (WMA), 2018, WMA DECL HELS ETH PR
NR 41
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1747-6348
EI 1747-6356
J9 EXPERT REV RESP MED
JI Expert Rev. Respir. Med.
DI 10.1080/17476348.2021.1826316
EA OCT 2020
PG 8
WC Respiratory System
SC Respiratory System
GA NZ7WR
UT WOS:000577314600001
PM 32945710
OA Bronze
DA 2021-01-01
ER

PT J
AU Kara, M
   Ekiz, T
   Ricci, V
   Kara, O
   Chang, KV
   Ozcakar, L
AF Kara, Murat
   Ekiz, Timur
   Ricci, Vincenzo
   Kara, Ozgur
   Chang, Ke-Vin
   Ozcakar, Levent
TI 'Scientific Strabismus' or two related pandemics: coronavirus disease
   and vitamin D deficiency
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Coronavirus; Death; Insufficiency; Europe; Acute respiratory syndrome
ID SERUM 25-HYDROXYVITAMIN D; STANDARDIZATION PROGRAM PROTOCOLS; D
   INSUFFICIENCY; COMMUNITY; HEALTH; POPULATION; PREVALENCE; NUTRITION;
   PEOPLE; AGE
AB The WHO has announced the novel coronavirus disease (COVID-19) outbreak to be a global pandemic. The distribution of community outbreaks shows seasonal patterns along certain latitude, temperature and humidity, that is, similar to the behaviour of seasonal viral respiratory tract infections. COVID-19 displays significant spread in northern mid-latitude countries with an average temperature of 5-11 degrees C and low humidity. Vitamin D deficiency has also been described as pandemic, especially in Europe. Regardless of age, ethnicity and latitude, recent data showed that 40 % of Europeans are vitamin D deficient (25-hydroxyvitamin D (25(OH)D) levels <50 nmol/l), and 13 % are severely deficient (25(OH)D < 30 nmol/l). A quadratic relationship was found between the prevalences of vitamin D deficiency in most commonly affected countries by COVID-19 and the latitudes. Vitamin D deficiency is more common in the subtropical and mid-latitude countries than the tropical and high-latitude countries. The most commonly affected countries with severe vitamin D deficiency are from the subtropical (Saudi Arabia 46 %; Qatar 46 %; Iran 33.4 %; Chile 26.4 %) and mid-latitude (France 27.3 %; Portugal 21.2 %; Austria 19.3 %) regions. Severe vitamin D deficiency was found to be nearly 0 % in some high-latitude countries (e.g. Norway, Finland, Sweden, Denmark and Netherlands). Accordingly, we would like to call attention to the possible association between severe vitamin D deficiency and mortality pertaining to COVID-19. Given its rare side effects and relatively wide safety, prophylactic vitamin D supplementation and/or food fortification might reasonably serve as a very convenient adjuvant therapy for these two worldwide public health problems alike.
C1 [Kara, Murat; Ozcakar, Levent] Hacettepe Univ, Med Sch, Dept Phys Med & Rehabil, Ankara, Turkey.
   [Ekiz, Timur] Turkmenbasi Med Ctr, Dept Phys Med & Rehabil, Adana, Turkey.
   [Ricci, Vincenzo] IRCCS Rizzoli Orthopaed Inst, Phys & Rehabil Med Unit, Dept Biomed & Neuromotor Sci, Bologna, Italy.
   [Kara, Ozgur] Yildirim Beyazit Univ, Yenimahalle Training & Res Hosp, Geriatr Unit, Ankara, Turkey.
   [Chang, Ke-Vin] Natl Taiwan Univ Hosp, Bei Hu Branch, Dept Phys Med & Rehabil, Taipei, Taiwan.
RP Ekiz, T (corresponding author), Turkmenbasi Med Ctr, Dept Phys Med & Rehabil, Adana, Turkey.
EM timurekiz@gmail.com
RI DINCEL, Gungor Cagdas/H-7026-2018
OI DINCEL, Gungor Cagdas/0000-0002-6985-3197; Ricci,
   Vincenzo/0000-0003-2576-2039; Ekiz, Timur/0000-0002-9249-8162
CR Alfawaz H, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-159
   Alipio M., 2020, VITAMIN D SUPPLEMENT
   [Anonymous], 2015, BMJ, V2015, ph1887
   Aspell N, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061253
   Beard JA, 2011, J CLIN VIROL, V50, P194, DOI 10.1016/j.jcv.2010.12.006
   Buchebner D, 2014, OSTEOPOROSIS INT, V25, P2767, DOI 10.1007/s00198-014-2823-1
   Cashman KD, 2016, AM J CLIN NUTR, V103, P1033, DOI 10.3945/ajcn.115.120873
   Cashman KD, 2015, SCAND J CLIN LAB INV, V75, P549, DOI 10.3109/00365513.2015.1057898
   Cashman KD, 2013, AM J CLIN NUTR, V97, P1235, DOI 10.3945/ajcn.112.057182
   Chin KY, 2014, NUTRIENTS, V6, P5419, DOI 10.3390/nu6125419
   Clark P, 2015, ARCH OSTEOPOROS, V10, DOI 10.1007/s11657-015-0225-4
   Cougnard-Greoire A, 2015, J NUTR, V145, P1865, DOI 10.3945/jn.115.214387
   Duarte C, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657-020-0695-x
   El-Menyar A, 2012, OPEN CARDIOVASC MED, V6, P76, DOI 10.2174/1874192401206010076
   Elmadfa I, 2017, AUSTIN J NUTR METAB, V4, P1050
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Eymundsdottir H, 2020, AGING CLIN EXP RES, V32, P2649, DOI 10.1007/s40520-020-01531-1
   Feldman D, 2017, VITAMIN D
   Formiga F, 2014, GERONTOLOGY, V60, P10, DOI 10.1159/000351024
   Gill TK, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1001
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Hoge A, 2015, NUTR RES, V35, P716, DOI 10.1016/j.nutres.2015.06.005
   Karonova T, 2016, J STEROID BIOCHEM, V164, P230, DOI 10.1016/j.jsbmb.2016.03.026
   Kassi Eva N, 2015, Hormones (Athens), V14, P245, DOI 10.14310/horm.2002.1521
   Khosravi-Boroujeni H, 2017, J NUTR SCI VITAMINOL, V63, P284, DOI 10.3177/jnsv.63.284
   Laktasic-Zerjavic N, 2010, CLIN RHEUMATOL, V29, P861, DOI 10.1007/s10067-010-1409-3
   Lips P, 2019, EUR J ENDOCRINOL, V180, pP23, DOI 10.1530/EJE-18-0736
   Lopes JB, 2014, MATURITAS, V78, P335, DOI 10.1016/j.maturitas.2014.05.023
   Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583
   Mechenro J, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6244-5
   Mehboobali N, 2015, J PAK MED ASSOC, V65, P946
   Mendes MM, 2018, NUTR BULL, V43, P428, DOI 10.1111/nbu.12349
   Mostafa WZ, 2015, J ADV RES, V6, P793, DOI 10.1016/j.jare.2014.01.011
   Nakamura K, 2015, BONE, V74, P10, DOI 10.1016/j.bone.2014.12.064
   Niculescu DA, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657-017-0407-3
   Ozturk ZA, 2017, WIEN KLIN WOCHENSCHR, V129, P854, DOI 10.1007/s00508-017-1241-8
   Pludowski P, 2016, POL ARCH MED WEWN, V126, P530, DOI 10.20452/pamw.3479
   Robien K, 2013, BRIT J NUTR, V109, P493, DOI 10.1017/S0007114512001675
   Sajadi M.M., 2020, TEMPERATURE HUMIDITY, DOI 10.2139/ssrn.3550308
   Sakem B, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-176
   Saliba W, 2012, OSTEOPOROSIS INT, V23, P687, DOI 10.1007/s00198-011-1597-y
   Sarafin K, 2015, AM J CLIN NUTR, V102, P1044, DOI 10.3945/ajcn.114.103689
   Schleicher RL, 2016, J NUTR, V146, P1051, DOI 10.3945/jn.115.227728
   Shin JH, 2015, J WOMENS HEALTH, V24, P1021, DOI 10.1089/jwh.2015.5358
   Solis-Urra P, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020300
   ten Haaf DSM, 2019, EUR J NUTR, V58, P3121, DOI 10.1007/s00394-018-1856-1
   Urrunaga-Pastor D, 2019, DIABETES METAB SYND, V13, P258, DOI 10.1016/j.dsx.2018.09.008
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Veronese N, 2014, J CLIN ENDOCR METAB, V99, P2351, DOI 10.1210/jc.2013-3883
   Vetter VM, 2020, J GERONTOL A-BIOL, V75, P2056, DOI 10.1093/gerona/glaa101
   Wei J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56297-y
   Welch D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21058-w
   World Health Organization, 2020, COR DIS COVID 2019 S
   Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 55
TC 9
Z9 9
U1 21
U2 21
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD OCT 14
PY 2020
VL 124
IS 7
BP 736
EP 741
DI 10.1017/S0007114520001749
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA NG9MG
UT WOS:000564305000010
PM 32393401
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Kousar, K
   Majeed, A
   Yasmin, F
   Hussain, W
   Rasool, N
AF Kousar, Kafila
   Majeed, Arshia
   Yasmin, Farkhanda
   Hussain, Waqar
   Rasool, Nouman
TI Phytochemicals from Selective Plants Have Promising Potential against
   SARS-CoV-2: Investigation and Corroboration through Molecular Docking,
   MD Simulations, and Quantum Computations
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID CORONAVIRUS; INHIBITORS; RNA; ANTIBODIES; HELICASE; DATABASE; 229E;
   SARS; QSAR; DNA
AB Coronaviruses have been reported previously due to their association with the severe acute respiratory syndrome (SARS). After SARS, these viruses were known to be causing Middle East respiratory syndrome (MERS) and caused 35% evanescence amid victims pursuing remedial care. Nowadays, beta coronaviruses, members of Coronaviridae, family order Nidovirales, have become subjects of great importance due to their latest pandemic originating from Wuhan, China. The virus named as human-SARS-like coronavirus-2 contains four structural as well as sixteen nonstructural proteins encoded by single-stranded ribonucleic acid of positive polarity. As there is no vaccine available to treat the infection caused by these viruses, there is a dire need for taking necessary steps against this virus. Herein, we have targeted two nonstructural proteins of SARS-CoV-2, namely, methyltransferase (nsp16) and helicase (nsp13), respectively, due to their substantial activity in viral pathogenesis. A total of 2035 compounds were analyzed for their pharmacokinetics and pharmacological properties. The screened 108 compounds were docked against both targeted proteins and were compared with previously reported known compounds. Compounds with high binding affinity were analyzed for their reactivity through DFT analysis, and binding was analyzed using molecular dynamics simulations. Through the analyses performed in this study, it is concluded that EryvarinM, Silydianin, Osajin, and Raddeanine can be considered potential inhibitors for MTase, while TomentodiplaconeB, Osajin, Sesquiterpene Glycoside, Rhamnetin, and Silydianin for helicase after these compounds are validated thoroughly using in vitro and in vivo protocols.
C1 [Kousar, Kafila] Natl Univ Sci & Technol Islamabad, Atta ur Rahman Sch Appl Biosci, Dept Healthcare Biotechnol, Islamabad, Pakistan.
   [Majeed, Arshia] Medicare Hlth Serv, Lahore, Pakistan.
   [Yasmin, Farkhanda] Khawaja Fareed Univ Sci & Technol, Dept Biotechnol, Rahim Yar Khan, Pakistan.
   [Hussain, Waqar] Univ Punjab, Natl Ctr Artificial Intelligence, Coll Informat Technol, Lahore, Pakistan.
   [Hussain, Waqar; Rasool, Nouman] Ctr Profess & Appl Studies, Lahore, Pakistan.
RP Rasool, N (corresponding author), Ctr Profess & Appl Studies, Lahore, Pakistan.
EM kafilaibrahim87@gmail.com; drarshiamajeed@gmail.com;
   farkhandayasmin3535@gmail.com; waqar.hussain@pucit.edu.pk;
   noumanrasool@gmail.com
OI Rasool, Nouman/0000-0003-0210-5845
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Adedeji AO, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00235-16
   Adedeji AO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036521
   Akhtar A, 2019, U SCI, V24, P441, DOI [10.11144/Javeriana.SC24-3.artf, DOI 10.11144/Javeriana.SC24-3.artf]
   Akhtar A, 2019, CURR COMPUT-AID DRUG, V15, P401, DOI 10.2174/1573409915666190130164923
   Arif N., 2019, CURRENT DRUG DISCOVE, V17
   Ashfaq UA, 2013, BIOINFORMATION, V9, P993, DOI 10.6026/97320630009993
   Balboni A, 2011, EPIDEMIOL INFECT, V139, P216, DOI 10.1017/S0950268810001147
   Cascella M, 2020, STATPEARLS
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   CHEATHAM TE, 1995, J AM CHEM SOC, V117, P4193, DOI 10.1021/ja00119a045
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Cruz JV, 2018, J MOL MODEL, V24, DOI 10.1007/s00894-018-3756-y
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dillard CJ, 2000, J SCI FOOD AGR, V80, P1744, DOI [10.1002/1097-0010(20000915)80:12<1744::AID-JSFA725>3.0.CO;2-W, 10.1002/1097-0010(20000915)80:12&lt;1744::AID-JSFA725&gt;3.0.CO;2-W]
   Drexler JF, 2014, ANTIVIR RES, V101, P45, DOI 10.1016/j.antiviral.2013.10.013
   Durrant JD, 2014, J CHEM THEORY COMPUT, V10, P5047, DOI 10.1021/ct500381c
   Eroglu E, 2007, J MOL GRAPH MODEL, V26, P701, DOI 10.1016/j.jmgm.2007.03.015
   Fairman-Williams ME, 2010, CURR OPIN STRUC BIOL, V20, P313, DOI 10.1016/j.sbi.2010.03.011
   Gorbalenya A., 2020, NATURE MICROBIOLOGY, V2020, P3
   Gordon D.E., 2020, NATURE NATURE, V583, P1
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hussain W., 2018, J ANTIVIRALS ANTIRET, V10
   Hussain W, 2018, VIRUSDIS, V29, P1
   Hussain W, 2020, STRUCT CHEM, V31, P1363, DOI 10.1007/s11224-020-01507-x
   Jarvis B, 1998, DRUGS, V56, P147, DOI 10.2165/00003495-199856010-00013
   Jia WH, 2020, CARDIOVASC DRUG THER, V34, P525, DOI 10.1007/s10557-020-06965-3
   Koebel MR, 2016, J CHEMINFORMATICS, V8, DOI 10.1186/s13321-016-0139-1
   Krafcikova P., 2020, STRUCTURAL ANAL SARS, V11, P1
   Ma XH, 2010, PHARM RES-DORDR, V27, P739, DOI 10.1007/s11095-010-0065-2
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mukhtar M, 2008, VIRUS RES, V131, P111, DOI 10.1016/j.virusres.2007.09.008
   Mumtaz A, 2017, NAT PROD RES, V31, P1228, DOI 10.1080/14786419.2016.1233409
   Neese F, 2012, WIRES COMPUT MOL SCI, V2, P73, DOI 10.1002/wcms.81
   Prisant M., 2003, PROTEINS, V50, article 437450
   Qaddir I, 2017, J VECTOR DIS, V54, P255
   Rasool N, 2017, J PROTEOM BIOINFORM, V10, P324, DOI [10.4172/jpb.1000458, DOI 10.4172/JPB.1000458]
   Rasool N, 2020, STRUCT CHEM, V31, P1777, DOI 10.1007/s11224-020-01536-6
   Rasool Nouman, 2020, Curr Drug Discov Technol, DOI 10.2174/1570163817666200312102659
   Rasool N, 2019, TURK J BIOCHEM, V44, P261, DOI 10.1515/tjb-2018-0002
   Rasool N, 2019, COMPUT BIOL CHEM, V83, DOI 10.1016/j.compbiolchem.2019.107108
   Rasool N, 2018, BRAZ ARCH BIOL TECHN, V61, DOI 10.1590/1678-4324-2018180004
   Rasool N, 2018, J MOL GRAPH MODEL, V80, P126, DOI 10.1016/j.jmgm.2017.12.011
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Seybert A, 2000, J VIROL, V74, P9586, DOI 10.1128/JVI.74.20.9586-9593.2000
   Seybert A, 2000, RNA, V6, P1056, DOI 10.1017/S1355838200000728
   Shen EM, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43027
   Sinopoli A, 2019, CURR OPIN SOLID ST M, V23, DOI 10.1016/j.cossms.2019.06.004
   Sizun J, 1998, J VIROL METHODS, V72, P145, DOI 10.1016/S0166-0934(98)00013-5
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Song Z, 2019, VIRUSES, V11, P1
   Studio D., 2009, STUDIO D VERSION 2 5
   Tanner JA, 2003, J BIOL CHEM, V278, P39578, DOI 10.1074/jbc.C300328200
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Turner P., 2005, XMGRACE VERSION 5 1
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang Y, 2015, J VIROL, V89, P8416, DOI 10.1128/JVI.00948-15
   Webb B, 2014, METHODS MOL BIOL, V1137, P1, DOI 10.1007/978-1-4939-0366-5_1
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xu Z., 2020, NELFINAVIR WAS PREDI
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 65
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD OCT 13
PY 2020
VL 2020
AR 6237160
DI 10.1155/2020/6237160
PG 15
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA OP8EO
UT WOS:000588322800006
PM 33102585
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Duvignaud, A
   Lhomme, E
   Pistone, T
   Onaisi, R
   Sitta, R
   Journot, V
   Nguyen, D
   Peiffer-Smadja, N
   Cremer, A
   Bouchet, S
   Darnaud, T
   Poitrenaud, D
   Piroth, L
   Binquet, C
   Michel, JF
   Lefevre, B
   Lebeaux, D
   Lebel, J
   Dupouy, J
   Roussillon, C
   Gimbert, A
   Wittkop, L
   Thiebaut, R
   Orne-Gliemann, J
   Joseph, JP
   Richert, L
   Anglaret, X
   Malvy, D
AF Duvignaud, Alexandre
   Lhomme, Edouard
   Pistone, Thierry
   Onaisi, Racha
   Sitta, Remi
   Journot, Valerie
   Duc Nguyen
   Peiffer-Smadja, Nathan
   Cremer, Antoine
   Bouchet, Stephane
   Darnaud, Thomas
   Poitrenaud, Delphine
   Piroth, Lionel
   Binquet, Christine
   Michel, Jean-Francois
   Lefevre, Benjamin
   Lebeaux, David
   Lebel, Josselin
   Dupouy, Julie
   Roussillon, Caroline
   Gimbert, Anne
   Wittkop, Linda
   Thiebaut, Rodolphe
   Orne-Gliemann, Joanna
   Joseph, Jean-Philippe
   Richert, Laura
   Anglaret, Xavier
   Malvy, Denis
CA COVERAGE Study Grp
TI Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection
   (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm
   Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and
   Tolerability of Several Experimental Treatments to Reduce the Risk of
   Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE
   trial)
SO TRIALS
LA English
DT Letter
AB Objectives: To assess the efficacy of several repurposed drugs to prevent hospitalisation or death in patients aged 65 or more with recent symptomatic SARS-CoV-2 infection (COVID-19) and no criteria for hospitalisation.
   Trial design: Phase III, multi-arm (5) and multi-stage (MAMS), randomized, open-label controlled superiority trial.Participants will be randomly allocated 1:1:1:1:1 to the following strategies:
   Arm 1: Control arm
   Arms 2 to 5: Experimental treatment arms
   Planned interim analyses will be conducted at regular intervals. Their results will be reviewed by an Independent Data and Safety Monitoring Board. Experimental arms may be terminated for futility, efficacy or toxicity before the end of the trial. New experimental arms may be added if new evidence suggests that other treatments should be tested.A feasibility and acceptability substudy as well as an immunological substudy will be conducted alongside the trial.
   Participants: Inclusion criteria are: 65-year-old or more; Positive test for SARS-CoV-2 on a nasopharyngeal swab; Symptoms onset within 3 days before diagnosis; No hospitalisation criteria; Signed informed consent; Health insurance.Exclusion criteria are: Inability to make an informed decision to participate (e.g.: dementia, guardianship); Rockwood Clinical Frailty Scale >= 7; Long QT syndrome; QTc interval > 500 ms; Heart rate <50/min; Kalaemia >5.5 mmol/L or <3.5 mmol/L; Ongoing treatment with piperaquine, halofantrine, dasatinib, nilotinib, hydroxyzine, domperidone, citalopram, escitalopram, potent inhibitors or inducers of cytochrome P450 CYP3A4 isoenzyme, repaglinide, azathioprine, 6-mercaptopurine, theophylline, pyrazinamide, warfarin; Known hypersensitivity to any of the trial drugs or to chloroquine and other 4-aminoquinolines, amodiaquine, mefloquine, glafenine, floctafenine, antrafenine, ARB; Hepatic porphyria; Liver failure (Child-Pugh stage >= B); Stage 4 or 5 chronic kidney disease (GFR <30 mL/min/1.73 m(2)); Dialysis; Hypersentivity to lactose; Lactase deficiency; Abnormalities in galactose metabolism; Malabsorption syndrome; Glucose-6-phosphate dehydrogenase deficiency; Symptomatic hyperuricemia; Ileus; Colitis; Enterocolitis; Chronic hepatitis B virus disease.The trial is being conducted in France in the Bordeaux, Corse, Dijon, Nancy, Paris and Toulouse areas as well as in the Grand Duchy of Luxembourg. Participants are recruited either at home, nursing homes, general practices, primary care centres or hospital outpatient consultations.
   Intervention and comparator: The four experimental treatments planned in protocol version 1.2 (April 8(th), 2020) are: (1) Hydroxychloroquine 200 mg, 2 tablets BID on day 0, 2 tablets QD from day 1 to 9; (2) Imatinib 400 mg, 1 tablet QD from day 0 to 9; (3) Favipiravir 200 mg, 12 tablets BID on day 0, 6 tablets BID from day 1 to 9; (4) Telmisartan 20 mg, 1 tablet QD from day 0 to 9.The comparator is a complex of vitamins and trace elements (AZINC Forme et Vitalite (R)), 1 capsule BID for 10 days, for which there is no reason to believe that they are active on the virus.In protocol version 1.2 (April 8th, 2020): People in the control arm will receive a combination of vitamins and trace elements; people in the experimental arms will receive hydroxychloroquine, or favipiravir, or imatinib, or telmisartan.
   Main outcome: The primary outcome is the proportion of participants with an incidence of hospitalisation and/or death between inclusion and day 14 in each arm.
   Randomisation: Participants are randomized in a 1:1:1:1:1 ratio to each arm using a web-based randomisation tool. Participants not treated with an ARB or ACEI prior to enrolment are randomized to receive the comparator or one of the four experimental drugs. Participants already treated with an ARB or ACEI are randomized to receive the comparator or one of the experimental drugs except telmisartan (i.e.: hydroxychloroquine, imatinib, or favipiravir). Randomisation is stratified on ACEI or ARBs treatment at inclusion and on the type of residence (personal home vs. nursing home).
   Blinding (masking): This is an open-label trial. Participants, caregivers, investigators and statisticians are not blinded to group assignment.
   Numbers to be randomised (sample size): A total of 1057 participants will be enrolled if all arms are maintained until the final analysis and no additional arm is added.
   Three successive futility interim analyses are planned, when the number of participants reaches 30, 60 and 102 in the control arm. Two efficacy analyses (interim n degrees 3 and final) will be performed successively.
   Trial Status: This describes the Version 1.2 (April 8(th), 2020) of the COVERAGE protocol that was approved by the French regulatory authority and ethics committee. The trial was opened for enrolment on April 15(th), 2020 in the Nouvelle Aquitaine region (South-West France). Given the current decline of the COVID-19 pandemic in France and its unforeseeable dynamic in the coming months, new trial sites in 5 other French regions and in Luxembourg are currently being opened. A revised version of the protocol was submitted to the regulatory authority and ethics committee on June 15(th), 2020. It contains the following amendments: (i) Inclusion criteria: age >= 65 replaced by age >= 60; time since first symptoms <3 days replaced by time since first symptoms <5 days; (ii) Withdrawal of the hydroxychloroquine arm (due to external data); (iii) increase in the number of trial sites.
   Trial registration: The trial was registered on Clinical Trials.gov on April 22(nd), 2020 (Identifier: NCT04356495): and on EudraCT on April 10(th), 2020 (Identifier: 2020-001435-27).
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
C1 [Duvignaud, Alexandre; Pistone, Thierry; Duc Nguyen; Malvy, Denis] CHU Bordeaux, Dept Infect Dis & Trop Med, Div Trop Med & Clin Int Hlth, F-33000 Bordeaux, France.
   [Duvignaud, Alexandre; Pistone, Thierry; Journot, Valerie; Duc Nguyen; Orne-Gliemann, Joanna; Anglaret, Xavier; Malvy, Denis] Univ Bordeaux, INSERM, U1219, IRD, F-33000 Bordeaux, France.
   [Lhomme, Edouard; Sitta, Remi; Thiebaut, Rodolphe; Richert, Laura] Univ Bordeaux, INSERM, CHU Bordeaux, CIC 1401,EUCLID F CRIN Clin Trials Platform, F-33000 Bordeaux, France.
   [Lhomme, Edouard; Thiebaut, Rodolphe; Richert, Laura] Univ Bordeaux, Dept Publ Hlth, INSERM, Bordeaux Populat Hlth Res Ctr,Inria,SISTM, F-33000 Bordeaux, France.
   [Lhomme, Edouard; Sitta, Remi; Wittkop, Linda; Thiebaut, Rodolphe; Richert, Laura] CHU Bordeaux, Pole Sante Publ, F-33000 Bordeaux, France.
   [Onaisi, Racha] Univ Bordeaux, Dept Gen Practice, F-33000 Bordeaux, France.
   [Peiffer-Smadja, Nathan] AP HP, CHU Bichat Claude Bernard, Dept Infect Dis & Trop Med, F-75000 Paris, France.
   [Peiffer-Smadja, Nathan] Univ Paris, INSERM, IAME, F-75018 Paris, France.
   [Peiffer-Smadja, Nathan] Imperial Coll London, Natl Inst Hlth Res Hlth Protect Res Unit Healthca, London, England.
   [Cremer, Antoine] CHU Bordeaux, Dept Cardiol Hypertens, F-33000 Bordeaux, France.
   [Cremer, Antoine; Bouchet, Stephane] Univ Bordeaux, INSERM, U1219, F-33000 Bordeaux, France.
   [Bouchet, Stephane] CHU Bordeaux, Dept Pharmacol & Toxicol, F-33000 Bordeaux, France.
   [Darnaud, Thomas] Ctr Hosp Bastia, Serv Chirurg Specialisee, F-20200 Bastia, France.
   [Darnaud, Thomas] Unite Rech Clin, F-20200 Bastia, France.
   [Poitrenaud, Delphine] Ctr Hosp Ajaccio, Dept Infect Dis & Trop Med, F-20090 Ajaccio, France.
   [Piroth, Lionel] CHU Dijon, Dept Infect Dis & Trop Med, F-21079 Dijon, France.
   [Piroth, Lionel] Univ Bourgogne, INSERM, U1432, F-21000 Dijon, France.
   [Binquet, Christine] CHU Dijon, INSERM, CIC EC 1432, F-21000 Dijon, France.
   [Michel, Jean-Francois] Ctr Med Steinsel, Steinsel, Luxembourg.
   [Michel, Jean-Francois] Univ Luxembourg, Format Specialisee Med Gen FSMG, Luxembourg, Luxembourg.
   [Lefevre, Benjamin] CHU Nancy, Dept Infect Dis & Trop Med, F-54000 Nancy, France.
   [Lebeaux, David] Hop Europeen Georges Pompidou, AP HP, Dept Infect Dis & Trop Med, F-75000 Paris, France.
   [Lebel, Josselin] Univ Paris, Dept Gen Practice, F-75018 Paris, France.
   [Lebel, Josselin] INSERM, IAME, UMR 1137, F-75018 Paris, France.
   [Dupouy, Julie] MSPU Pins Justaret, F-31860 Pins Justaret, France.
   [Dupouy, Julie] Univ Paul Sabatier, Dept Gen Practice, F-31000 Toulouse, France.
   [Dupouy, Julie] Univ Paul Sabatier, INSERM, UMR 1027, F-31000 Toulouse, France.
   [Dupouy, Julie] CHU Toulouse, CIC, F-31000 Toulouse, France.
   [Roussillon, Caroline] CHU Bordeaux, Safety & vigilance, Clin Res & Innovat Dept, F-33000 Bordeaux, France.
   [Gimbert, Anne] CHU Bordeaux, Clin Res & Innovat Dept, F-33000 Bordeaux, France.
   [Wittkop, Linda] Univ Bordeaux, Dept Publ Hlth, INSERM, Bordeaux Populat Hlth Res Ctr,MORPH3EUS, F-33000 Bordeaux, France.
   [Joseph, Jean-Philippe] Univ Bordeaux, CIC 1401, Dept Gen Practice, F-33000 Bordeaux, France.
RP Duvignaud, A (corresponding author), CHU Bordeaux, Dept Infect Dis & Trop Med, Div Trop Med & Clin Int Hlth, F-33000 Bordeaux, France.; Duvignaud, A (corresponding author), Univ Bordeaux, INSERM, U1219, IRD, F-33000 Bordeaux, France.
EM alexandre.duvignaud@chu-bordeaux.fr
RI Michel, Jean-Francois/I-5335-2019; Duvignaud, Alexandre/I-1544-2013
OI Michel, Jean-Francois/0000-0002-1282-3835; Duvignaud,
   Alexandre/0000-0001-7139-2687
FU University of Bordeaux, Research and Action Targeting Emerging
   Infectious Diseases (REACTing)/Institut de la Sante et de la Recherche
   Medicale (INSERM); Agence Nationale de la Recherche (ANR)French National
   Research Agency (ANR); French Ministry of Health (DGOS); EIT HEALTH
FX The COVERAGE trial received funding from the following sources:
   University of Bordeaux, Research and Action Targeting Emerging
   Infectious Diseases (REACTing)/Institut de la Sante et de la Recherche
   Medicale (INSERM), Agence Nationale de la Recherche (ANR) and the French
   Ministry of Health (DGOS). The immunological substudy received funding
   from EIT HEALTH. The funding sources had a role neither in the design of
   the study nor in the collection, analysis, and interpretation of data
   and in writing the manuscript.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 13
PY 2020
VL 21
IS 1
AR 846
DI 10.1186/s13063-020-04619-1
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OI4SK
UT WOS:000583270200002
PM 33050924
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Quirke, S
   Quinn, L
   Hegarty, D
   Loy, A
   Lyons, F
   Mulcahy, F
   Devitt, E
AF Quirke, Siobhan
   Quinn, Laura
   Hegarty, Deborah
   Loy, Aisling
   Lyons, Fiona
   Mulcahy, Fiona
   Devitt, Emma
TI Virtual HIV pre-exposure prophylaxis outpatient service in the era of
   COVID-19
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article; Early Access
DE Human immunodeficiency virus; prevention; antiretroviral therapy
AB In the midst of the COVID-19 pandemic, health care providers have had to rapidly change how they deliver care to patients. We discuss how we are delivering a virtual HIV pre-exposure prophylaxis (PrEP) service during this time; challenges faced; challenges expected and goals for the coming months.
C1 [Quirke, Siobhan; Quinn, Laura; Hegarty, Deborah; Loy, Aisling; Lyons, Fiona; Mulcahy, Fiona; Devitt, Emma] St James Hosp, Dept Genitourinary Med & Infect Dis GUIDe, Dublin, Ireland.
RP Quirke, S (corresponding author), St James Hosp, Dept Genitourinary Med & Infect Dis GUIDe, Dublin, Ireland.
EM quirkesm@tcd.ie
CR [Anonymous], 2019, NAT STAND DEL MAN PR
   [Anonymous], GUIDE CLIN
   Brawley S, 2020, 23 INT AIDS C AIDS 2
   Clinical management guidance for individuals taking HIV, 2019, CLIN MAN GUID IND TA
   Hammoud M, 2020, 23 INT AIDS C AIDS 2
   Junejo M, 2020, LANCET HIV, V7, pE460, DOI [10.1016/S2357-3018(20)30146-6, 10.1016/S2352-3018(20)30146-6]
   Mehrota A, 2020, RAPIDLY CONVERTING V
NR 7
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
AR 0956462420961951
DI 10.1177/0956462420961951
EA OCT 2020
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA OH5TV
UT WOS:000582648300001
PM 33050787
OA Other Gold
DA 2021-01-01
ER

PT J
AU Emson, C
   Diver, S
   Chachi, L
   Megally, A
   Small, C
   Downie, J
   Parnes, JR
   Bowen, K
   Colice, G
   Brightling, CE
AF Emson, Claire
   Diver, Sarah
   Chachi, Latifa
   Megally, Ayman
   Small, Cherrie
   Downie, John
   Parnes, Jane R.
   Bowen, Karin
   Colice, Gene
   Brightling, Chris E.
TI CASCADE: a phase 2, randomized, double-blind, placebo-controlled,
   parallel-group trial to evaluate the effect of tezepelumab on airway
   inflammation in patients with uncontrolled asthma
SO RESPIRATORY RESEARCH
LA English
DT Article
DE Asthma; Tezepelumab; T2 inflammation; TSLP
ID THYMIC STROMAL LYMPHOPOIETIN; BASEMENT-MEMBRANE THICKNESS; HUMAN
   EPITHELIAL-CELLS; BRONCHIAL-MUCOSA; ALLERGIC-ASTHMA; TSLP; OMALIZUMAB;
   EOSINOPHILS; MEPOLIZUMAB; PHENOTYPE
AB Background: Patients with severe, uncontrolled asthma, particularly those with a non-eosinophilic phenotype, have a great unmet need for new treatments that act on a broad range of inflammatory pathways in the airway. Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin, an epithelial cytokine. In the PATHWAY phase 2b study (NCT02054130), tezepelumab reduced exacerbations by up to 71% in adults with severe, uncontrolled asthma, irrespective of baseline eosinophilic inflammatory status. This article reports the design and objectives of the phase 2 CASCADE study.
   Methods: CASCADE is an ongoing exploratory, phase 2, randomized, double-blind, placebo-controlled, parallel-group study aiming to assess the anti-inflammatory effects of tezepelumab 210 mg administered subcutaneously every 4 weeks for 28 weeks in adults aged 18-75 years with uncontrolled, moderate-to-severe asthma. The primary endpoint is the change from baseline to week 28 in airway submucosal inflammatory cells (eosinophils, neutrophils, T cells and mast cells) from bronchoscopic biopsies. Epithelial molecular phenotyping, comprising the three-gene-mean technique, will be used to assess participants' type 2 (T2) status to enable evaluation of the anti-inflammatory effect of tezepelumab across the continuum of T2 activation. Other exploratory analyses include assessments of the impact of tezepelumab on airway remodelling, including reticular basement membrane thickening and airway epithelial integrity. At the onset of the COVID-19 pandemic, the protocol was amended to address the possibility that site visits would be limited. The amendment allowed for: at-home dosing of study drug by a healthcare professional, extension of the treatment period by up to 6 months so patients are able to attend an onsite visit to undergo the end-of-treatment bronchoscopy, and replacement of final follow-up visits with a virtual or telephone visit.
   Discussion: CASCADE aims to determine the mechanisms by which tezepelumab improves clinical asthma outcomes by evaluating the effect of tezepelumab on airway inflammatory cells and remodelling in patients with moderate-to-severe, uncontrolled asthma. An important aspect of this study is the evaluation of the anti-inflammatory effect of tezepelumab across patients with differing levels of eosinophilic and T2 inflammation.
C1 [Emson, Claire] AstraZeneca, BioPharmaceut R&D, Translat Sci & Expt Med, Res & Early Dev,Resp & Immunol, Gaithersburg, MD 20878 USA.
   [Diver, Sarah; Chachi, Latifa; Brightling, Chris E.] Univ Leicester, Leicester, Leics, England.
   [Megally, Ayman; Colice, Gene] AstraZeneca, BioPharmaceut R&D, Resp & Immunol, Gaithersburg, MD USA.
   [Small, Cherrie] AstraZeneca, BioPharmaceut R&D, Mississauga, ON, Canada.
   [Downie, John; Parnes, Jane R.] Amgen Inc, Thousand Oaks, CA USA.
   [Bowen, Karin] AstraZeneca, BioPharmaceut R&D, Biometr Resp & Immunol, Gaithersburg, MD USA.
RP Emson, C (corresponding author), AstraZeneca, BioPharmaceut R&D, Translat Sci & Expt Med, Res & Early Dev,Resp & Immunol, Gaithersburg, MD 20878 USA.
EM Claire.emson@astrazeneca.com
FU AstraZenecaAstraZeneca; Amgen Inc.Amgen
FX This study was funded by AstraZeneca and Amgen Inc.
CR Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211
   Bergeron C, 2010, CAN RESPIR J, V17, pE85, DOI 10.1155/2010/318029
   Bhakta Nirav R, 2013, Clin Transl Allergy, V3, P24, DOI 10.1186/2045-7022-3-24
   Brightling C., 2015, Clinical Investigation, V5, P713, DOI 10.4155/cli.15.36
   Busse WW, 2019, LANCET RESP MED, V7, P46, DOI 10.1016/S2213-2600(18)30406-5
   Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092
   Chastek Benjamin, 2016, J Manag Care Spec Pharm, V22, P848, DOI 10.18553/jmcp.2016.22.7.848
   Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142
   Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568
   Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013
   Cook Ellen B, 2012, Clin Mol Allergy, V10, P8, DOI 10.1186/1476-7961-10-8
   Corren J, 2019, J ALLERGY CLIN IMMUN, V199, pA2621
   Corren J, 2019, NAT IMMUNOL, V20, P1603, DOI 10.1038/s41590-019-0524-9
   Corren J, 2017, NEW ENGL J MED, V377, P936, DOI 10.1056/NEJMoa1704064
   Costa JJ, 1997, JAMA-J AM MED ASSOC, V278, P1815, DOI 10.1001/jama.278.22.1815
   Datta A, 2013, J IMMUNOL, V191, P4867, DOI 10.4049/jimmunol.1300588
   Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC
   Farne HA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010834.pub3
   Fleming TR, 2020, JAMA-J AM MED ASSOC, V324, P33, DOI 10.1001/jama.2020.9286
   Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974
   Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC
   Gauvreau GM, 2020, EXPERT OPIN THER TAR, V24, P777, DOI 10.1080/14728222.2020.1783242
   Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895
   Greer AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099084
   Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991
   Hanabuchi S, 2012, ALLERGOL INT, V61, P19, DOI 10.2332/allergolint.11-RAI-0394
   Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC
   James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069
   Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170
   Kelly EA, 2017, AM J RESP CRIT CARE, V196, P1385, DOI 10.1164/rccm.201611-2234OC
   Kitajima M, 2011, EUR J IMMUNOL, V41, P1862, DOI 10.1002/eji.201041195
   LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697
   Laviolette M, 2013, J ALLERGY CLIN IMMUN, V132, P1086, DOI 10.1016/j.jaci.2013.05.020
   Li Y, 2018, J IMMUNOL, V200, P2253, DOI 10.4049/jimmunol.1701455
   Ly N, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.congress-2018.PA1688
   Mauri P, 2014, IMMUNOL LETT, V162, P2, DOI 10.1016/j.imlet.2014.08.010
   Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382
   NAYLOR BERNARD, 1962, THORAX, V17, P69, DOI 10.1136/thx.17.1.69
   Normansell R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub4
   Redhu NS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02301
   Riccio AM, 2012, INT J IMMUNOPATH PH, V25, P475, DOI 10.1177/039463201202500217
   Riccio AM, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0143-1
   Rochman I, 2007, J IMMUNOL, V178, P6720, DOI 10.4049/jimmunol.178.11.6720
   Russell RJ, 2018, LANCET RESP MED, V6, P499, DOI 10.1016/S2213-2600(18)30201-7
   Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805
   Swedin L, 2017, PHARMACOL THERAPEUT, V169, P13, DOI 10.1016/j.pharmthera.2016.06.016
   Tanaka J, 2009, CLIN EXP ALLERGY, V39, P89, DOI 10.1111/j.1365-2222.2008.03151.x
   Torii Y, 2008, J IMMUNOL, V181, P5340, DOI 10.4049/jimmunol.181.8.5340
   Rensen ELJ, 2009, ALLERGY, V64, P72, DOI 10.1111/j.1398-9995.2008.01881.x
   Wong CK, 2010, AM J RESP CELL MOL, V43, P305, DOI 10.1165/rcmb.2009-0168OC
   Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC
   Xiong XF, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1065-3
   Zayed Yazan, 2019, J Asthma, V56, P1110, DOI 10.1080/02770903.2018.1520865
   Zeiger RS, 2015, J ALLER CL IMM-PRACT, V3, P986, DOI 10.1016/j.jaip.2015.06.016
   Zhang YL, 2012, IMMUNOL RES, V52, P211, DOI 10.1007/s12026-012-8264-z
   Ziegler SF, 2013, ADV PHARMACOL, V66, P129, DOI 10.1016/B978-0-12-404717-4.00004-4
   Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852
NR 57
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1465-993X
J9 RESP RES
JI Respir. Res.
PD OCT 13
PY 2020
VL 21
IS 1
AR 265
DI 10.1186/s12931-020-01513-x
PG 9
WC Respiratory System
SC Respiratory System
GA OH6ZC
UT WOS:000582743200002
PM 33050900
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chaccour, C
   Abizanda, G
   Irigoyen-Barrio, A
   Casellas, A
   Aldaz, A
   Martinez-Galan, F
   Hammann, F
   Gil, AG
AF Chaccour, Carlos
   Abizanda, Gloria
   Irigoyen-Barrio, Angel
   Casellas, Aina
   Aldaz, Azucena
   Martinez-Galan, Fernando
   Hammann, Felix
   Gil, Ana Gloria
TI Nebulized ivermectin for COVID-19 and other respiratory diseases, a
   proof of concept, dose-ranging study in rats
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DRUG IVERMECTIN; IN-VIVO; REPLICATION; PENTAMIDINE; ANESTHESIA;
   INHIBITOR; THERAPY; TISSUES
AB Ivermectin is a widely used antiparasitic drug with known efficacy against several single-strain RNA viruses. Recent data shows significant reduction of SARS-CoV-2 replication in vitro by ivermectin concentrations not achievable with safe doses orally. Inhaled therapy has been used with success for other antiparasitics. An ethanol-based ivermectin formulation was administered once to 14 rats using a nebulizer capable of delivering particles with alveolar deposition. Rats were randomly assigned into three target dosing groups, lower dose (80-90 mg/kg), higher dose (110-140 mg/kg) or ethanol vehicle only. A toxicology profile including behavioral and weight monitoring, full blood count, biochemistry, necropsy and histological examination of the lungs was conducted. The pharmacokinetic profile of ivermectin in plasma and lungs was determined in all animals. There were no relevant changes in behavior or body weight. There was a delayed elevation in muscle enzymes compatible with rhabdomyolysis, that was also seen in the control group and has been attributed to the ethanol dose which was up to 11 g/kg in some animals. There were no histological anomalies in the lungs of any rat. Male animals received a higher ivermectin dose adjusted by adipose weight and reached higher plasma concentrations than females in the same dosing group (mean C-max 86.2 ng/ml vs. 26.2 ng/ml in the lower dose group and 152 ng/ml vs. 51.8 ng/ml in the higher dose group). All subjects had detectable ivermectin concentrations in the lungs at seven days post intervention, up to 524.3 ng/g for high-dose male and 27.3 ng/g for low-dose females. nebulized ivermectin can reach pharmacodynamic concentrations in the lung tissue of rats, additional experiments are required to assess the safety of this formulation in larger animals.
C1 [Chaccour, Carlos; Casellas, Aina] Hosp Clin Univ Barcelona, ISGlobal, Rosello 132,5a 2a, Barcelona 08036, Spain.
   [Chaccour, Carlos] Ifakara Hlth Inst, Ifakara 67501, Tanzania.
   [Chaccour, Carlos] Univ Navarra, Fac Med, Pamplona 31008, Spain.
   [Abizanda, Gloria] Ctr Invest Med Aplicada, Pamplona 31008, Spain.
   [Abizanda, Gloria; Aldaz, Azucena] Clin Univ Navarra, Pamplona 31008, Spain.
   [Irigoyen-Barrio, Angel; Aldaz, Azucena; Martinez-Galan, Fernando; Gil, Ana Gloria] Univ Navarra, Fac Farm & Nutr, Pamplona 31008, Spain.
   [Irigoyen-Barrio, Angel; Gil, Ana Gloria] Univ Navarra, Drug Dev Unit, Pamplona 31008, Spain.
   [Casellas, Aina] Univ Barcelona, Fac Med, Dept Fonaments Clin, Barcelona, Spain.
   [Hammann, Felix] Univ Hosp, Inselspital, Dept Gen Internal Med Clin Pharmacol & Toxicol, CH-3010 Bern, Switzerland.
RP Chaccour, C (corresponding author), Hosp Clin Univ Barcelona, ISGlobal, Rosello 132,5a 2a, Barcelona 08036, Spain.; Chaccour, C (corresponding author), Ifakara Hlth Inst, Ifakara 67501, Tanzania.; Chaccour, C (corresponding author), Univ Navarra, Fac Med, Pamplona 31008, Spain.
EM carlos.chaccour@isglobal.org
RI Casellas, Aina/Q-1247-2016; Gil, Ana G./ABG-7426-2020
OI Casellas, Aina/0000-0003-4939-8411; 
FU University of Navarra; Spanish Ministry of Science and Innovation
   through the "Centro de Excelencia Severo Ochoa 2019-2023" Program
   [CEX2018-000806-S]; Generalitat de Catalunya through the CERCA Program
FX This study was supported by the University of Navarra with a generous
   donation from Jeffery and Heart Deal. CCh received salary support from
   Unitaid through the BOHEMIA Grant to ISGlobal. ISGlobal acknowledges
   support from the Spanish Ministry of Science and Innovation through the
   "Centro de Excelencia Severo Ochoa 2019-2023" Program
   (CEX2018-000806-S), and support from the Generalitat de Catalunya
   through the CERCA Program.
CR Baraka OZ, 1996, EUR J CLIN PHARMACOL, V50, P407, DOI 10.1007/s002280050131
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chaccour C, 2020, AM J TROP MED HYG, V102, P1156, DOI 10.4269/ajtmh.20-0271
   Changeux JP, 2020, CR BIOL, V343, P33, DOI 10.5802/crbiol.8
   Ci XX, 2009, FUND CLIN PHARMACOL, V23, P449, DOI 10.1111/j.1472-8206.2009.00684.x
   ELKHATIB E, 1989, INT J RADIAT ONCOL, V16, P745, DOI 10.1016/0360-3016(89)90494-X
   Eraslan G, 2010, FOOD CHEM TOXICOL, V48, P2181, DOI 10.1016/j.fct.2010.05.043
   FDA. Center for drug evaluation and research, APPR PACK MECT
   FERRELL CL, 1986, J NUTR, V116, P2525
   Gil AG, 2004, CONTEMP TOP LAB ANIM, V43, P25
   Homeida MM, 2013, ACTA TROP, V127, P97, DOI 10.1016/j.actatropica.2013.03.019
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Ji L., 2016, CHINESE J COMPARAT M, V26, P70
   Krause RM, 1998, MOL PHARMACOL, V53, P283
   Lifschitz A, 2000, VET PARASITOL, V87, P327, DOI 10.1016/S0304-4017(99)00175-2
   MacLean RR, 2017, ALCOHOL CLIN EXP RES, V41, P238, DOI 10.1111/acer.13291
   Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147
   Mathiasen Joanne R, 2018, Curr Protoc Pharmacol, V83, pe43, DOI 10.1002/cpph.43
   McIvor RA, 1996, CHEST, V110, P141, DOI 10.1378/chest.110.1.141
   Melotti A, 2014, EMBO MOL MED, V6, P1263, DOI 10.15252/emmm.201404084
   MONTGOMERY AB, 1987, LANCET, V2, P480
   Nishiyama T, 1998, CAN J ANAESTH, V45, P753, DOI 10.1007/BF03012146
   Ouedraogo AL, 2015, CLIN INFECT DIS, V60, P357, DOI 10.1093/cid/ciu797
   Pacanowski J, 2005, AM J TROP MED HYG, V73, P122, DOI 10.4269/ajtmh.2005.73.122
   Papadatos SS, 2015, CLIN CASE REP, V3, P769, DOI 10.1002/ccr3.326
   Russo P, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01116-2020
   Salluh JIF, 2005, INTENS CARE MED, V31, P1292, DOI 10.1007/s00134-005-2725-y
   Schwartz C, 2018, TRENDS PARASITOL, V34, P388, DOI 10.1016/j.pt.2017.12.007
   Sutherland IA, 2011, TRENDS PARASITOL, V27, P176, DOI 10.1016/j.pt.2010.11.008
   Tokuda Y, 2012, NEW ENGL J MED, V367, P1670, DOI 10.1056/NEJMc1210168
   Vanapalli SR, 2003, CLIN PHARMACOL THER, V73, pP94, DOI 10.1016/S0009-9236(03)90702-8
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   WIBERG GS, 1970, TOXICOL APPL PHARM, V16, P718, DOI 10.1016/0041-008X(70)90077-3
   Yang P, 2020, ANN INTERN MED, V172, pJC63, DOI 10.7326/ACPJ202006160-063
   Yang SNY, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104760
   Zhang X, 2008, INFLAMM RES, V57, P524, DOI 10.1007/s00011-008-8007-8
   Zhang XZ, 2011, FUND CLIN PHARMACOL, V25, P700, DOI 10.1111/j.1472-8206.2010.00896.x
NR 41
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 13
PY 2020
VL 10
IS 1
AR 17073
DI 10.1038/s41598-020-74084-y
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OH6GJ
UT WOS:000582687300012
PM 33051517
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Holt, GE
   Batra, M
   Murthi, M
   Kambali, S
   Santos, K
   Bastidas, MVP
   Asif, H
   Haddadi, S
   Arias, S
   Mirsaeidi, M
AF Holt, Gregory E.
   Batra, Mayank
   Murthi, Mukunthan
   Kambali, Shweta
   Santos, Kayo
   Bastidas, Maria Virginia Perez
   Asif, Huda
   Haddadi, Sara
   Arias, Sixto
   Mirsaeidi, Mehdi
TI Lack of tocilizumab effect on mortality in COVID19 patients
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CYTOKINE RELEASE SYNDROME; BIOMARKERS
AB Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn't imply causality however lack of improvement by tocilizumab requires further clinical trial alterations.
C1 [Holt, Gregory E.; Batra, Mayank; Murthi, Mukunthan; Kambali, Shweta; Santos, Kayo; Bastidas, Maria Virginia Perez; Asif, Huda; Haddadi, Sara; Arias, Sixto; Mirsaeidi, Mehdi] Univ Miami, Div Pulm & Crit Care, Miami, FL 33146 USA.
RP Mirsaeidi, M (corresponding author), Univ Miami, Div Pulm & Crit Care, Miami, FL 33146 USA.
EM msm249@med.miami.edu
OI Mirsaeidi, Mehdi/0000-0001-5298-8442
CR [Anonymous], 2016, N Engl J Med, V374, P998, DOI 10.1056/NEJMx160005
   Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Canziani LM, 2020, J AUTOIMMUN, V114, DOI 10.1016/j.jaut.2020.102511
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   Cortegiani A, 2021, Pulmonology, V27, P52, DOI 10.1016/j.pulmoe.2020.07.003
   De Rossi Nicola, 2020, EClinicalMedicine, V25, P100459, DOI 10.1016/j.eclinm.2020.100459
   Grifoni E, 2020, J INFECTION, V81, P466, DOI 10.1016/j.jinf.2020.06.008
   Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134
   Hay KA, 2017, BLOOD, V130, P2295, DOI 10.1182/blood-2017-06-793141
   Kewan Tariq, 2020, EClinicalMedicine, V24, P100418, DOI 10.1016/j.eclinm.2020.100418
   Langer-Gould A, 2020, INT J INFECT DIS, V99, P291, DOI 10.1016/j.ijid.2020.07.081
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Maude SL, 2014, CANCER J, V20, P119, DOI 10.1097/PPO.0000000000000035
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   Velazquez-Salinas L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01057
   Wu W, 2015, SCI REP-UK, V5, DOI 10.1038/srep10501
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 18
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 13
PY 2020
VL 10
IS 1
AR 17100
DI 10.1038/s41598-020-74328-x
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OH6GU
UT WOS:000582688400014
PM 33051534
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tateno, M
   Stone, BJ
   Srodulski, SJ
   Reedy, S
   Gawriluk, TR
   Chambers, TM
   Woodward, J
   Chappell, J
   Kempinski, CF
AF Tateno, Mizuki
   Stone, Barbara J.
   Srodulski, Sarah J.
   Reedy, Stephanie
   Gawriluk, Thomas R.
   Chambers, Thomas M.
   Woodward, Jerold
   Chappell, Joe
   Kempinski, Chase F.
TI Synthetic Biology-derived triterpenes as efficacious immunomodulating
   adjuvants
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SEASONAL INFLUENZA VACCINES; IMMUNE-RESPONSES; EMULSION; ANTIBODIES;
   SQUALENE; MF59; FORMULATION; IDENTIFICATION; BIOSYNTHESIS; VACCINATION
AB The triterpene oil squalene is an essential component of nanoemulsion vaccine adjuvants. It is most notably in the MF59 adjuvant, a component in some seasonal influenza vaccines, in stockpiled, emulsion-based adjuvanted pandemic influenza vaccines, and with demonstrated efficacy for vaccines to other pandemic viruses, such as SARS-CoV-2. Squalene has historically been harvested from shark liver oil, which is undesirable for a variety of reasons. In this study, we have demonstrated the use of a Synthetic Biology (yeast) production platform to generate squalene and novel triterpene oils, all of which are equally as efficacious as vaccine adjuvants based on physiochemical properties and immunomodulating activities in a mouse model. These Synthetic Biology adjuvants also elicited similar IgG1, IgG2a, and total IgG levels compared to marine and commercial controls when formulated with common quadrivalent influenza antigens. Injection site morphology and serum cytokine levels did not suggest any reactogenic effects of the yeast-derived squalene or novel triterpenes, suggesting their safety in adjuvant formulations. These results support the advantages of yeast produced triterpene oils to include completely controlled growth conditions, just-in-time and scalable production, and the capacity to produce novel triterpenes beyond squalene.
C1 [Tateno, Mizuki; Chappell, Joe; Kempinski, Chase F.] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Stone, Barbara J.; Srodulski, Sarah J.] ParaTechs Corp, Lexington, KY 40505 USA.
   [Reedy, Stephanie; Chambers, Thomas M.] Univ Kentucky, Gluck Equine Res Ctr, Lexington, KY 40546 USA.
   [Gawriluk, Thomas R.; Chappell, Joe; Kempinski, Chase F.] Enepret Inc, Lexington, KY 40506 USA.
   [Woodward, Jerold] Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA.
RP Kempinski, CF (corresponding author), Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.; Kempinski, CF (corresponding author), Enepret Inc, Lexington, KY 40506 USA.
EM chase.kempinski@enepret.com
FU Kentucky Agricultural Experiment Station [KY014053]
FX We are thankful to Dr. Xun Zhuang for generation of the initial yeast
   platform and purification of some of the yeast-derived triterpenes used
   in this study. TMC and SR were supported in part by a project of the
   Kentucky Agricultural Experiment Station (KY014053).
CR Akutsu K, 2006, FOOD ADDIT CONTAM A, V23, P1323, DOI 10.1080/02652030600892966
   ALLISON AC, 1986, J IMMUNOL METHODS, V95, P157, DOI 10.1016/0022-1759(86)90402-3
   Barackman JD, 1999, INFECT IMMUN, V67, P4276, DOI 10.1128/IAI.67.8.4276-4279.1999
   Bell SA, 2014, BIOCHEMISTRY-US, V53, P7570, DOI 10.1021/bi501264s
   Brito LA, 2011, VACCINE, V29, P6262, DOI 10.1016/j.vaccine.2011.06.067
   Buglione-Corbett R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074820
   Calabro S, 2013, VACCINE, V31, P3363, DOI 10.1016/j.vaccine.2013.05.007
   Chambers TM, 2014, METHODS MOL BIOL, V1161, P411, DOI 10.1007/978-1-4939-0758-8_36
   Cruz-Valdez A, 2018, HUM VACC IMMUNOTHER, V14, P386, DOI 10.1080/21645515.2017.1373227
   ELLOUZ F, 1974, BIOCHEM BIOPH RES CO, V59, P1317, DOI 10.1016/0006-291X(74)90458-6
   Fineberg HV, 2014, NEW ENGL J MED, V370, P1335, DOI 10.1056/NEJMra1208802
   Fox CB, 2008, COLLOID SURFACE B, V65, P98, DOI 10.1016/j.colsurfb.2008.03.003
   Fox CB, 2009, MOLECULES, V14, P3286, DOI 10.3390/molecules14093286
   Furuhashi K, 2016, ALGAL RES, V16, P160, DOI 10.1016/j.algal.2016.02.021
   Galli G, 2009, P NATL ACAD SCI USA, V106, P7962, DOI 10.1073/pnas.0903181106
   Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105
   Gross C P, 1998, Int J Infect Dis, V3, P54
   Huber VC, 2006, CLIN VACCINE IMMUNOL, V13, P981, DOI 10.1128/CVI.00156-06
   Keitel W, 2010, VACCINE, V28, P840, DOI 10.1016/j.vaccine.2009.10.019
   Khatri W, 2014, BIOTECHNOL BIOENG, V111, P493, DOI 10.1002/bit.25126
   Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167
   Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9
   Knudsen NPH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19570
   Leenaars PPAM, 1998, LAB ANIM-UK, V32, P387, DOI 10.1258/002367798780599884
   MASIHI KN, 1986, INT J IMMUNOPHARMACO, V8, P339
   Matyas GR, 2002, J IMMUNOL METHODS, V267, P119, DOI 10.1016/S0022-1759(02)00180-1
   METZGER P, 1988, PHYTOCHEMISTRY, V27, P1383, DOI 10.1016/0031-9422(88)80199-7
   Nakaya HI, 2016, P NATL ACAD SCI USA, V113, P1853, DOI 10.1073/pnas.1519690113
   National Research Council of the National Academies, 2011, GUIDE CARE USE LAB A
   Naziri E., 2011, Lipid Technology, V23, P270, DOI 10.1002/lite.201100157
   Niehaus TD, 2012, J BIOL CHEM, V287, P8163, DOI 10.1074/jbc.M111.316059
   Niehaus TD, 2011, P NATL ACAD SCI USA, V108, P12260, DOI 10.1073/pnas.1106222108
   O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061
   Oh DY, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00080
   OTT G, 1995, VACCINE, V13, P1557, DOI 10.1016/0264-410X(95)00089-J
   Petrova VN, 2018, NAT REV MICROBIOL, V16, P47, DOI 10.1038/nrmicro.2017.118
   Popa O, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/367202
   Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409
   Schwartz AM, 2017, METHODS MOL BIOL, V1494, P273, DOI 10.1007/978-1-4939-6445-1_20
   Shah RR, 2019, SCI REP, V9, P1, DOI [10.1038/s41598-018-37186-2, DOI 10.1038/S41598-018-37186-2]
   SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127
   Stephenson I, 2005, J INFECT DIS, V191, P1210, DOI 10.1086/428948
   Tsujimoto M., 1916, J IND ENG CHEM, V8, P889, DOI 10.1021/i500010a005
   US Food & Drug Administration, 2018, MICR MICR DER INGR U, DOI [10.1002/jcu.20152, DOI 10.1002/JCU.20152]
   VALENSI JPM, 1994, J IMMUNOL, V153, P4029
   Vickers CE, 2017, CURR OPIN CHEM BIOL, V40, P47, DOI 10.1016/j.cbpa.2017.05.017
   Wilkins AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01760
   World Health Organization, 2019, INFL SEAS
   Zedda L, 2015, PEDIATR INFECT DIS J, V34, P73, DOI 10.1097/INF.0000000000000465
   Zhuang X, 2015, BIOTECHNOL BIOENG, V112, P1854, DOI 10.1002/bit.25588
NR 50
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 13
PY 2020
VL 10
IS 1
AR 17090
DI 10.1038/s41598-020-73868-6
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OH6GU
UT WOS:000582688400004
PM 33051497
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Laczko, D
   Hogan, MJ
   Toulmin, SA
   Hicks, P
   Lederer, K
   Gaudette, BT
   Castano, D
   Amanat, F
   Muramatsu, H
   Oguin, TH
   Ojha, A
   Zhang, LZ
   Mu, ZK
   Parks, R
   Manzoni, TB
   Roper, B
   Strohmeier, S
   Tombacz, I
   Arwood, L
   Nachbagauer, R
   Kariko, K
   Greenhouse, J
   Pessaint, L
   Porto, M
   Putman-Taylor, T
   Strasbaugh, A
   Campbell, TA
   Lin, PJC
   Tam, YK
   Sempowski, GD
   Farzan, M
   Choe, H
   Saunders, KO
   Haynes, BF
   Andersen, H
   Eisenlohr, LC
   Weissman, D
   Krammer, F
   Bates, P
   Allman, D
   Locci, M
   Pardi, N
AF Laczko, Dorottya
   Hogan, Michael J.
   Toulmin, Sushila A.
   Hicks, Philip
   Lederer, Katlyn
   Gaudette, Brian T.
   Castano, Diana
   Amanat, Fatima
   Muramatsu, Hiromi
   Oguin, Thomas H., III
   Ojha, Amrita
   Zhang, Lizhou
   Mu, Zekun
   Parks, Robert
   Manzoni, Tomaz B.
   Roper, Brianne
   Strohmeier, Shirin
   Tombacz, Istvan
   Arwood, Leslee
   Nachbagauer, Raffael
   Kariko, Katalin
   Greenhouse, Jack
   Pessaint, Laurent
   Porto, Maciel
   Putman-Taylor, Tammy
   Strasbaugh, Amanda
   Campbell, Tracey-Ann
   Lin, Paulo J. C.
   Tam, Ying K.
   Sempowski, Gregory D.
   Farzan, Michael
   Choe, Hyeryun
   Saunders, Kevin O.
   Haynes, Barton F.
   Andersen, Hanne
   Eisenlohr, Laurence C.
   Weissman, Drew
   Krammer, Florian
   Bates, Paul
   Allman, David
   Locci, Michela
   Pardi, Norbert
TI A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits
   Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
SO IMMUNITY
LA English
DT Article
ID LIPID NANOPARTICLES; CELLS; PROTECTION; INFECTION; MEMORY
AB SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high transmissibility of the virus and the high rate of morbidity and mortality associated with COVID-19, developing effective and safe vaccines is a top research priority. Here, we provide a detailed evaluation of the immunogenicity of lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccines encoding the full-length SARS-CoV-2 spike protein or the spike receptor binding domain in mice. We demonstrate that a single dose of these vaccines induces strong type 1 CD4(+) and CD8(+) T cell responses, as well as long-lived plasma and memory B cell responses. Additionally, we detect robust and sustained neutralizing antibody responses and the antibodies elicited by nucleoside-modified mRNA vaccines do not show antibody-dependent enhancement of infection in vitro. Our findings suggest that the nucleoside-modified mRNA-LNP vaccine platform can induce robust immune responses and is a promising candidate to combat COVID-19.
C1 [Laczko, Dorottya; Muramatsu, Hiromi; Tombacz, Istvan; Kariko, Katalin; Weissman, Drew; Pardi, Norbert] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
   [Hogan, Michael J.; Toulmin, Sushila A.; Eisenlohr, Laurence C.] Univ Penn, Childrens Hosp, Div Protect Immun, Philadelphia, PA 19104 USA.
   [Hicks, Philip; Lederer, Katlyn; Castano, Diana; Manzoni, Tomaz B.; Roper, Brianne; Bates, Paul; Locci, Michela] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Hicks, Philip] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA.
   [Gaudette, Brian T.; Eisenlohr, Laurence C.; Allman, David] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA.
   [Castano, Diana] Univ Antioquia, Fac Med, Inst Invest Med, Grp Inmunol Celular & Inmunogenet, Medellin, Colombia.
   [Amanat, Fatima; Strohmeier, Shirin; Nachbagauer, Raffael; Krammer, Florian] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
   [Amanat, Fatima] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA.
   [Oguin, Thomas H., III; Mu, Zekun; Parks, Robert; Arwood, Leslee; Sempowski, Gregory D.; Saunders, Kevin O.; Haynes, Barton F.] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC USA.
   [Ojha, Amrita; Zhang, Lizhou; Farzan, Michael; Choe, Hyeryun] Scripps Res Inst, Dept Immunol & Microbiol, Jupiter, FL USA.
   [Kariko, Katalin] BioNTech RNA Pharmaceut, Mainz, Germany.
   [Greenhouse, Jack; Pessaint, Laurent; Porto, Maciel; Putman-Taylor, Tammy; Strasbaugh, Amanda; Campbell, Tracey-Ann; Andersen, Hanne] BIOQUAL Inc, Rockville, MD USA.
   [Lin, Paulo J. C.; Tam, Ying K.] Acuitas Therapeut, Vancouver, BC, Canada.
   [Sempowski, Gregory D.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
RP Pardi, N (corresponding author), Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
EM pnorbert@pennmedicine.upenn.edu
RI Krammer, Florian/H-3237-2019
OI Krammer, Florian/0000-0003-4121-776X; Roper,
   Brianne/0000-0003-0034-173X; Castano, Diana/0000-0002-5697-5603;
   Nachbagauer, Raffael/0000-0001-5568-5420; Hogan,
   Michael/0000-0002-6244-2993
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [1R01AI146101, R01AI123738]; National Institute of Allergy and
   Infectious Diseases Collaborative Influenza Vaccine Innovation Centers
   (CIVIC) [75N93019C00051]; NIAID Centers of Excellence for Influenza
   Research and Surveillance (CEIRS) [HHSN272201400008C]; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [T32AI055400, R21AI129531, R21AI142638]; Peer Reviewed Medical
   Research Program [PR182551]; NIAIDUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI142596, AI124429];
   State of North Carolina from the CARES Act Funds; Cancer Research
   Institute; National Heart, Lung, And Blood InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [F30HL145907];
   BioNTech;  [NIH R01 AI129868]
FX We thank Lisa Mistretta and Dalia Benetiene for helping with animal
   procedures (Bioqual). We thank Florin Tuluc and Jennifer Murray of the
   CHOP Flow Cytometry core facility for technical assistance. We thank
   Alec W. Freyn, Allen Zheng, Katarzyna Janowska, and Priyamvada Acharya
   for providing SARSCoV-2 reagents used in the study. The graphical
   abstract was created with BioRender. N.P. was supported by the National
   Institute of Allergy and Infectious Diseases (1R01AI146101). M.L. was
   supported by the National Institute of Allergy and Infectious Diseases
   (R01AI123738). Work in the Krammer laboratory was supported by the
   National Institute of Allergy and Infectious Diseases Collaborative
   Influenza Vaccine Innovation Centers (CIVIC; 75N93019C00051), the NIAID
   Centers of Excellence for Influenza Research and Surveillance (CEIRS;
   HHSN272201400008C), institutional funding, and philanthropic donations.
   M.F. and H.C. were supported by an administrative supplement to NIH R01
   AI129868 for coronavirus research. P.H. and T.B.M were supported by NIH
   (T32AI055400 and R21AI129531, respectively). P.B. was supported by a
   Peer Reviewed Medical Research Program (PR182551) and grants from the
   NIH (R21AI129531 and R21AI142638). B.F.H. was supported by NIAID
   (AI142596) and by a contract from the State of North Carolina from the
   CARES Act Funds. D.W. was supported by grants from the NIAID (AI142596
   and AI124429) and BioNTech. M.J. H. is a Cancer Research Institute
   Irvington Fellow supported by the Cancer Research Institute. S.A.T was
   supported by the National Heart, Lung, And Blood Institute
   (F30HL145907).
CR Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074
   Alameh Mohamad-Gabriel, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_202
   Amanat Fatima, 2020, medRxiv, DOI 10.1101/2020.03.17.20037713
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Awasthi S, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw7083
   Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035
   Baiersdorfer M, 2019, MOL THER-NUCL ACIDS, V15, P26, DOI 10.1016/j.omtn.2019.02.018
   Bao L., 2020, NATURE, V2020, P7
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Dowd KA, 2011, VIROLOGY, V411, P306, DOI 10.1016/j.virol.2010.12.020
   Espeseth AS, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0163-z
   Freyn AW, 2020, MOL THER, V28, P1569, DOI 10.1016/j.ymthe.2020.04.018
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008
   Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Lindgren G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01539
   Maier MA, 2013, MOL THER, V21, P1570, DOI 10.1038/mt.2013.124
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Meyer M, 2018, J INFECT DIS, V217, P451, DOI 10.1093/infdis/jix592
   Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004
   Mulligan M.J., 2020, PHASE 1 2 STUDY DESC, DOI [10.1101/2020.06.30, DOI 10.1101/2020.06.30]
   Pardi N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05482-0
   Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450
   Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243
   Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428
   Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007
   Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017
   Roth C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01424
   Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008
   Shim BS, 2019, MBIO, V10, DOI 10.1128/mBio.00758-19
   Smatti MK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02991
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Weissman Drew, 2013, Methods Mol Biol, V969, P43, DOI 10.1007/978-1-62703-260-5_3
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhang LZ, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120700
   Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006
NR 42
TC 6
Z9 5
U1 12
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD OCT 13
PY 2020
VL 53
IS 4
BP 724
EP +
DI 10.1016/j.immuni.2020.07.019
PG 16
WC Immunology
SC Immunology
GA OF2RX
UT WOS:000581062800007
PM 32783919
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhou, RH
   To, KKW
   Wong, YC
   Liu, L
   Zhou, B
   Li, X
   Huang, HD
   Mo, YF
   Luk, TY
   Lau, TTK
   Yeung, P
   Chan, WM
   Wu, AKL
   Lung, KC
   Tsang, OTY
   Leung, WS
   Hung, IFN
   Yuen, KY
   Chen, ZW
AF Zhou, Runhong
   To, Kelvin Kai-Wang
   Wong, Yik-Chun
   Liu, Li
   Zhou, Biao
   Li, Xin
   Huang, Haode
   Mo, Yufei
   Luk, Tsz-Yat
   Lau, Thomas Tsz-Kan
   Yeung, Pauline
   Chan, Wai-Ming
   Wu, Alan Ka-Lun
   Lung, Kwok-Cheung
   Tsang, Owen Tak-Yin
   Leung, Wai-Shing
   Hung, Ivan Fan-Ngai
   Yuen, Kwok-Yung
   Chen, Zhiwei
TI Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses
SO IMMUNITY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; NEUTRALIZING ANTIBODY-RESPONSE;
   SARS-CORONAVIRUS; PNEUMONIA; GLYCOPROTEIN; PROTECTION; COVID-19; DISEASE
AB The SARS-CoV-2 pandemic has resulted in millions of infections, yet the role of host immune responses in early COVID-19 pathogenesis remains unclear, By investigating 17 acute and 24 convalescent patients, we found that acute SARS-CoV-2 infection resulted in broad immune cell reduction including T, natural killer, monocyte, and dendritic cells (DCs). DCs were significantly reduced with functional impairment, and ratios of conventional DCs to plasmacytoid DCs were increased among acute severe patients. Besides lymphocytopenia, although neutralizing antibodies were rapidly and abundantly generated in patients, there were delayed receptor binding domain (RBD)- and nucleocapsid protein (NP)-specific T cell responses during the first 3 weeks after symptoms onset. Moreover, acute RBD- and NP-specific T cell responses included relatively more CD4 T cells than CD8 T cells. Our findings provided evidence that impaired DCs, together with timely inverted strong antibody but weak CD8 T cell responses, could contribute to acute COVID-19 pathogenesis and have implications for vaccine development.
C1 [Zhou, Runhong; Wong, Yik-Chun; Liu, Li; Zhou, Biao; Li, Xin; Huang, Haode; Mo, Yufei; Luk, Tsz-Yat; Lau, Thomas Tsz-Kan; Chen, Zhiwei] Univ Hong Kong, Li Ka Shing Fac Med, AIDS Inst, Hong Kong, Peoples R China.
   [Zhou, Runhong; To, Kelvin Kai-Wang; Wong, Yik-Chun; Liu, Li; Zhou, Biao; Mo, Yufei; Yuen, Kwok-Yung; Chen, Zhiwei] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Dept Microbiol, Hong Kong, Peoples R China.
   [Yeung, Pauline] Univ Hong Kong, Queen Mary Hosp, Dept Intens Care, Hong Kong, Peoples R China.
   [Chan, Wai-Ming] Queen Mary Hosp, Dept Adult Intens Care, Hong Kong, Peoples R China.
   [Wu, Alan Ka-Lun] Pamela Youde Nethersole Eastern Hosp, Dept Microbiol, Hong Kong, Peoples R China.
   [Lung, Kwok-Cheung] Pamela Youde Nethersole Eastern Hosp, Dept Med, Hong Kong, Peoples R China.
   [Tsang, Owen Tak-Yin; Leung, Wai-Shing] Princess Margaret Hosp, Dept Med, Hong Kong, Peoples R China.
   [Hung, Ivan Fan-Ngai] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Peoples R China.
RP Chen, ZW (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, AIDS Inst, Hong Kong, Peoples R China.; Yuen, KY; Chen, ZW (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Dept Microbiol, Hong Kong, Peoples R China.
EM kyyuen@hku.hk; zchenai@hku.hk
RI Liu, Li/C-4348-2009
OI Liu, Li/0000-0003-2566-7357; To, Kelvin/0000-0002-1921-5824; Mo,
   Yufei/0000-0002-5580-698X
FU Hong Kong Research Grants Council, University Development FundHong Kong
   Research Grants Council [T11706/18-N]; Li Ka Shing Faculty of Medicine
   Matching Fund from HKU; Health and Medical Research Fund [COVID190123];
   Food and Health Bureau, The Government of the Hong Kong Special
   Administrative Region; National Program on Key Research Project of China
   [2020YFA0707500, 2020YFA0707504]; Consultancy Service for Enhancing
   Laboratory Surveillance of Emerging Infectious Diseases and Research
   Capability on Antimicrobial Resistance for Department of Health of the
   Hong Kong Special Administrative Region Government; Research Grants
   Council, Hong Kong Special Administrative RegionHong Kong Research
   Grants Council [T11/707/15]; Sanming Project of Medicine in Shenzhen,
   China [SZSM201911014]; Health Commission of Guangdong Province, China
FX This work was partly supported by Theme-Based Research Scheme
   (T11706/18-N to Z.C.) of the Hong Kong Research Grants Council,
   University Development Fund, and Li Ka Shing Faculty of Medicine
   Matching Fund from HKU to AIDS Institute. We thank Dr. Xu Aiming for
   providing purified NP protein. We also thank Serena J. Chen and Lok-Yan
   Yim for editorial work. Funding supports to K.Y. include the donations
   of the Shaw Foundation Hong Kong, Richard Yu and Carol Yu, May Tam Mak
   Mei Yin, Michael Seak-Kan Tong, Respiratory Viral Research Foundation
   Limited, Hui Ming, Hui Hoy and Chow Sin Lan Charity Fund Limited, Chan
   Yin Chuen Memorial Charitable Foundation, Marina Man-Wai Lee, the Hong
   Kong Hainan Commercial Association South China Microbiology Research
   Fund, the Jessie & George Ho Charitable Foundation, Perfect Shape
   Medical Limited, and Kai Chong Tong; funding from the Health and Medical
   Research Fund (grant no. COVID190123), the Food and Health Bureau, The
   Government of the Hong Kong Special Administrative Region; the National
   Program on Key Research Project of China (grant no. 2020YFA0707500 and
   2020YFA0707504); the Consultancy Service for Enhancing Laboratory
   Surveillance of Emerging Infectious Diseases and Research Capability on
   Antimicrobial Resistance for Department of Health of the Hong Kong
   Special Administrative Region Government; the Theme-Based Research
   Scheme (T11/707/15) of the Research Grants Council, Hong Kong Special
   Administrative Region; Sanming Project of Medicine in Shenzhen, China
   (No. SZSM201911014); and the High Level-Hospital Program, Health
   Commission of Guangdong Province, China. The funding sources had no role
   in study design, data collection, analysis, interpretation, or writing
   of the report. The corresponding author had full access to all the data
   in the study and had final responsibility for the decision to submit for
   publication.
CR Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Chaplin DD, 2010, J ALLERGY CLIN IMMUN, V125, pS3, DOI 10.1016/j.jaci.2009.12.980
   Chen HB, 2005, J IMMUNOL, V175, P591, DOI 10.4049/jimmunol.175.1.591
   Chen J, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.004
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chiappelli F, 2020, BIOINFORMATION, V16, P219, DOI [10.6026/97320630016222, 10.6026/97320630016219]
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Fitzgerald-Bocarsly P, 2008, CYTOKINE GROWTH F R, V19, P3, DOI 10.1016/j.cytogfr.2007.10.006
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Gutzmer R, 2004, J IMMUNOL, V173, P1023, DOI 10.4049/jimmunol.173.2.1023
   Ho MS, 2005, EMERG INFECT DIS, V11, P1730, DOI 10.3201/eid1111.040659
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jiang HW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17488-8
   Jongbloed SL, 2010, J EXP MED, V207, P1247, DOI 10.1084/jem.20092140
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Law HKW, 2005, BLOOD, V106, P2366, DOI 10.1182/blood-2004-10-4166
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Liu L, 2016, MUCOSAL IMMUNOL, V9, P1089, DOI 10.1038/mi.2015.127
   Liu L, 2020, EMERG MICROBES INFEC, V9, P1664, DOI 10.1080/22221751.2020.1791738
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lv YB, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-61
   Mitchison NA, 2004, NAT REV IMMUNOL, V4, P308, DOI 10.1038/nri1334
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Schuler-Thurner B, 2002, J EXP MED, V195, P1279, DOI 10.1084/jem.20012100
   Shin HS, 2019, CLIN INFECT DIS, V68, P984, DOI 10.1093/cid/ciy595
   Tan W, 2020, VIRAL KINETICS ANTIB, P2020
   Temperton NJ, 2005, EMERG INFECT DIS, V11, P411, DOI 10.3201/eid1103.040906
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tseng CTK, 2005, J IMMUNOL, V174, P7977, DOI 10.4049/jimmunol.174.12.7977
   Waldrop SL, 1998, J IMMUNOL, V161, P5284
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang P., 2020, BIORXIV
   Wang YD, 2004, J VIROL, V78, P5612, DOI 10.1128/JVI.78.11.5612-5618.2004
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu XL, 2018, J CLIN INVEST, V128, P2239, DOI 10.1172/JCI96764
   XU B, 2020, J INFECTION, V81, pE51, DOI 10.1016/j.jinf.2020.04.012
   Xu XJ, 2004, CELL MOL IMMUNOL, V1, P119
   Yi CE, 2005, J VIROL, V79, P11638, DOI 10.1128/JVI.79.18.11638-11646.2005
   Zhang LQ, 2006, J MED VIROL, V78, P1, DOI 10.1002/jmv.20499
   Zhang Zheng, 2004, Zhonghua Yi Xue Za Zhi, V84, P22
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zheng YL, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104366
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 54
TC 10
Z9 10
U1 3
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD OCT 13
PY 2020
VL 53
IS 4
BP 864
EP +
DI 10.1016/j.immuni.2020.07.026
PG 19
WC Immunology
SC Immunology
GA OF2RX
UT WOS:000581062800017
PM 32791036
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lauriola, M
   Pani, A
   Ippoliti, G
   Mortara, A
   Milighetti, S
   Mazen, M
   Perseghin, G
   Pastori, D
   Grosso, P
   Scaglione, F
AF Lauriola, Marinella
   Pani, Arianna
   Ippoliti, Giovanbattista
   Mortara, Andrea
   Milighetti, Stefano
   Mazen, Marjieh
   Perseghin, Gianluca
   Pastori, Daniele
   Grosso, Paolo
   Scaglione, Francesco
TI Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on
   Mortality in Patients With COVID-19
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
ID EXPRESSION
AB Conflicting evidence regarding the use of hydroxychloroquine (HCQ) and azithromycin for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection do exist. We performed a retrospective single-center cohort study including 377 consecutive patients admitted for pneumonia related to coronavirus disease 2019 (COVID-19). Of these, 297 were in combination treatment, 17 were on HCQ alone, and 63 did not receive either of these 2 drugs because of contraindications. The primary end point was in-hospital death. Mean age was 71.8 +/- 13.4 years and 34.2% were women. We recorded 146 deaths: 35 in no treatment, 7 in HCQ treatment group, and 102 in HCQ + azithromycin treatment group (log rank test for Kaplan-Meier curveP < 0.001). At multivariable Cox proportional hazard regression analysis, age (hazard ratio (HR) 1.057, 95% confidence interval (CI) 1.035-1.079,P < 0.001), mechanical ventilation/continuous positive airway pressure (HR 2.726, 95% CI 1.823-4.074,P < 0.001), and C reactive protein above the median (HR 2.191, 95% CI 1.479-3.246,P < 0.001) were directly associated with death, whereas use of HCQ + azithromycin (vs. no treatment; HR 0.265, 95% CI 0.171-0.412,P < 0.001) was inversely associated. In this study, we found a reduced in-hospital mortality in patients treated with a combination of HCQ and azithromycin after adjustment for comorbidities. A large randomized trial is necessary to confirm these findings.
C1 [Lauriola, Marinella] Policlin Monza, Infect Dis Dept, Monza, Italy.
   [Pani, Arianna; Scaglione, Francesco] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy.
   [Ippoliti, Giovanbattista; Milighetti, Stefano; Mazen, Marjieh; Perseghin, Gianluca] Policlin Monza, Internal Med Dept, Monza, Italy.
   [Mortara, Andrea] Policlin Monza, Cardiol Dept, Monza, Italy.
   [Perseghin, Gianluca] Univ Milano Bicocca, Dept Med & Surg, Milan, Italy.
   [Pastori, Daniele] Sapienza Univ Rome, Dept Clin Internal Anesthesiol & Cardiovasc Sci, Rome, Italy.
   [Grosso, Paolo] Policlin Monza, Intens Care Unit, Monza, Italy.
RP Pastori, D (corresponding author), Sapienza Univ Rome, Dept Clin Internal Anesthesiol & Cardiovasc Sci, Rome, Italy.
EM daniele.pastori@uniroma1.it
RI MONDAL, DEBA BRATA/ABH-5517-2020
OI MONDAL, DEBA BRATA/0000-0002-0228-0099
CR Al-Kofahi M, 2020, CLIN PHARMACOL THER, V108, P766, DOI 10.1002/cpt.1874
   Arnold SLM, 2020, CTS-CLIN TRANSL SCI, V13, P642, DOI 10.1111/cts.12797
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bessiere F, 2020, JAMA CARDIOL, V5, P1067, DOI 10.1001/jamacardio.2020.1787
   Bonow RO, 2020, JAMA CARDIOL, V5, P986, DOI 10.1001/jamacardio.2020.1782
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chang D, 2020, J AM COLL CARDIOL, V75, P2992, DOI 10.1016/j.jacc.2020.04.032
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Cory TJ, 2014, J CYST FIBROS, V13, P164, DOI 10.1016/j.jcf.2013.08.007
   Fantini J, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106020
   Gao XG, 2008, BASIC CLIN PHARMACOL, V103, P255, DOI 10.1111/j.1742-7843.2008.00255.x
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Humeniuk R, 2020, CTS-CLIN TRANSL SCI, V13, P896, DOI 10.1111/cts.12840
   Kawamura K, 2018, INT J ANTIMICROB AG, V51, P918, DOI 10.1016/j.ijantimicag.2018.02.009
   Kawamura K, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2866-1
   Lippi G, 2020, ANN CLIN BIOCHEM, V57, P262, DOI 10.1177/0004563220922255
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Naksuk N, 2020, EUR HEART J-ACUTE CA, V9, P215, DOI 10.1177/2048872620922784
   Pani A, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106053
   Perinel Sophie, 2020, Clin Infect Dis, V71, P2227, DOI 10.1093/cid/ciaa394
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yeo KR, 2020, CLIN PHARMACOL THER, V108, P976, DOI 10.1002/cpt.1955
   Zimmermann P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00302
NR 28
TC 1
Z9 1
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
PD NOV
PY 2020
VL 13
IS 6
BP 1071
EP 1076
DI 10.1111/cts.12860
EA OCT 2020
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PA7WR
UT WOS:000579056600001
PM 32926573
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kennedy, PGE
AF Kennedy, Peter G. E.
TI An overview of viral infections of the nervous system in the
   immunosuppressed
SO JOURNAL OF NEUROLOGY
LA English
DT Article; Early Access
DE Virus; Nervous system; Immunosuppression; Infection; PCR;
   Immunodeficiency
ID PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ZOSTER SINE HERPETE;
   INBORN-ERRORS; ENCEPHALITIS; SIMPLEX; GUIDELINES; COMPLICATIONS;
   DIAGNOSIS; DNA
AB Several viruses have the capacity to cause serious infections of the nervous system in patients who are immunosuppressed. Individuals may be immunosuppressed because of primary inherited immunodeficiency, secondary immunodeficiency due to particular diseases such as malignancy, administration of immunosuppressant drugs or organ or bone marrow transplantation. The viruses capable of such opportunistic infection of the nervous system include herpes simplex virus (HSV), Varicella-Zoster virus (VZV), Cytomegalovirus (CMV), Epstein -Barr virus (EBV), Human Herpes virus type 6 (HHV-6), JC virus (JCV), enterovirus, measles virus and Covid-19. In most cases it seems likely that immunological defence mechanisms in the immunosuppressed are deficient which creates a suitable environment for certain viruses to become opportunistic in the nervous and other systems. Further research is required both to understand these opportunistic mechanisms in more detail and also to determine how many virus infections are modified by specific inborn errors of immunological responses.
C1 [Kennedy, Peter G. E.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun & Inflammat, Glasgow G61 1QH, Lanark, Scotland.
RP Kennedy, PGE (corresponding author), Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun & Inflammat, Glasgow G61 1QH, Lanark, Scotland.
EM Peter.Kennedy@glasgow.ac.uk
CR Ahmed MU, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00518
   AICARDI J, 1977, PEDIATRICS, V59, P232
   Berger JR, 2020, J NEUROVIROL, V26, P143, DOI 10.1007/s13365-020-00840-5
   Brainin M, 2004, EUR J NEUROL, V11, P577, DOI 10.1111/j.1468-1331.2004.00867.x
   Carter-Timofte ME, 2018, TRENDS MOL MED, V24, P904, DOI 10.1016/j.molmed.2018.07.009
   Carter-Timofte ME, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01606
   CINQUE P, 1993, LANCET, V342, P398, DOI 10.1016/0140-6736(93)92814-A
   Denes E, 2004, EMERG INFECT DIS, V10, P729, DOI 10.3201/eid1004.030587
   Fisher DL, 2014, QJM, V108, P177, DOI DOI 10.1093/QJMED/HCU113
   Fodor PA, 1998, NEUROLOGY, V51, P554, DOI 10.1212/WNL.51.2.554
   FORMAN SJ, 1999, BLUE BOOK PRACT NEUR, V21, P45
   Gershon AA, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.16
   Gheuens S, 2013, ANNU REV PATHOL-MECH, V8, P189, DOI 10.1146/annurev-pathol-020712-164018
   GILDEN DH, 1994, ANN NEUROL, V35, P530, DOI 10.1002/ana.410350505
   Gilden DH, 2005, PERIPHERAL NEUROPATH, P2117
   Gofshteyn J, 2016, PEDIATR NEUROL, V64, P94, DOI 10.1016/j.pediatrneurol.2016.06.014
   Helleberg M, 2020, J INFECT DIS, V222, P1103, DOI 10.1093/infdis/jiaa446
   Jouanguy E, 2020, CURR OPIN IMMUNOL, V62, P106, DOI 10.1016/j.coi.2020.01.004
   Kennedy PGE, 2020, J NEUROVIROL, V26, P482, DOI 10.1007/s13365-020-00857-w
   Kennedy PGE, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110609
   Kennedy PGE, 2016, NEUROTHERAPEUTICS, V13, P509, DOI 10.1007/s13311-016-0430-x
   Kennedy PGE, 2015, J GEN VIROL, V96, P1581, DOI 10.1099/vir.0.000128
   Kennedy PGE, 2011, NEUROLOGY, V76, P416, DOI 10.1212/WNL.0b013e31820a0d5d
   Kennedy PGE, 2004, J NEUROL NEUROSUR PS, V75, pI10, DOI 10.1136/jnnp.2003.034280
   Langer-Gould A, 2005, NEW ENGL J MED, V353, P375, DOI 10.1056/NEJMoa051847
   Lim HK, 2014, NEUROLOGY, V83, P1888, DOI 10.1212/WNL.0000000000000999
   Nagel MA, 2007, NEUROLOGY, V68, P1069, DOI 10.1212/01.wnl.0000258549.13334.16
   Nagel MA, 2013, CURR TREAT OPTION NE, V15, P439, DOI 10.1007/s11940-013-0246-5
   Ogunjimi B, 2017, J CLIN INVEST, V127, P3543, DOI [10.1172/JCI92280, 10.1172/jci92280]
   Said-Conti V, 2013, PEDIATR NEPHROL, V28, P2053, DOI 10.1007/s00467-013-2499-3
   Steiner I, 2005, EUR J NEUROL, V12, P331, DOI 10.1111/j.1468-1331.2005.01126.x
   Steiner I, 2012, EUR J NEUROL, V19, P1278, DOI 10.1111/j.1468-1331.2012.03808.x
   Steiner I, 2007, LANCET NEUROL, V6, P1015, DOI 10.1016/S1474-4422(07)70267-3
   TOLKOFFRUBIN NE, 1999, BLUE BOOK PRACT NEUR, V21, P141
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WIJDICKS EFM, 1999, BLUE BOOK PRACT NEUR, V21, P57
   Yousry TA, 2006, NEW ENGL J MED, V354, P924, DOI 10.1056/NEJMoa054693
NR 37
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
DI 10.1007/s00415-020-10265-z
EA OCT 2020
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA OA1GQ
UT WOS:000577543500002
PM 33048220
OA Other Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Rothan, HA
   Byrareddy, SN
AF Rothan, Hussin A.
   Byrareddy, Siddappa N.
TI The potential threat of multisystem inflammatory syndrome in children
   during the COVID-19 pandemic
SO PEDIATRIC ALLERGY AND IMMUNOLOGY
LA English
DT Article; Early Access
DE antibody-dependent enhancement; COVID-19; Kawasaki syndrome; multisystem
   inflammatory syndrome; SARS-CoV-2
ID SARS; ANTIBODIES; CHALLENGE; INFECTION; CELLS
AB Multisystem inflammatory syndrome in children (MIS-C) during the COVID-19 pandemic raised a global alert from the Centers for Disease Control and Prevention's Health Alert Network. The main manifestations of MIS-C (also known as pediatric MIS (PMIS)) in the setting of a severe inflammatory state include fever, diarrhea, shock, and variable presence of rash, conjunctivitis, extremity edema, and mucous membrane changes. In some cases, these symptoms progressed to multi-organ failure. The low percentage of children with asymptomatic cases compared with mild illness and moderate illness could be correlated with the rare cases of MIS-C. One potential explanation for the progression to severe MIS-C disease despite the presence of readily detectable anti-SARS-CoV-2 antibodies could be due to the potential role of antibody-dependent enhancement (ADE). We reason that the incidence of the ADE phenomenon whereby the pathogen-specific antibodies can promote pathology should be considered in vaccine development against SARS-CoV-2.
C1 [Rothan, Hussin A.] Georgia State Univ, Dept Biol, Coll Arts & Sci, POB 4010, Atlanta, GA 30302 USA.
   [Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE USA.
   [Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA.
RP Rothan, HA (corresponding author), Georgia State Univ, Dept Biol, Coll Arts & Sci, POB 4010, Atlanta, GA 30302 USA.; Byrareddy, SN (corresponding author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
EM hrothan@gsu.edu; sid.byrareddy@unmc.edu
OI ROTHAN, HUSSIN/0000-0002-7300-6388
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI129745]
FX National Institute of Allergy and Infectious Diseases, Grant/Award
   Number: AI129745
CR Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   American College of Rheumatology, 2020, CLIN GUID PED PAT MU
   Belhadjer Z, 2020, CIRCULATION, V142, P429, DOI 10.1161/CIRCULATIONAHA.120.048360
   Chiotos K, 2020, J PEDIAT INFECT DIS, V69, P1074
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Denison Mark R, 2004, Pediatr Infect Dis J, V23, pS207, DOI 10.1097/01.inf.0000144666.95284.05
   Dolinger Michael T, 2020, J Pediatr Gastroenterol Nutr, V71, P153, DOI 10.1097/MPG.0000000000002809
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680
   Garber K, 2020, NAT BIOTECHNOL, V38, P773, DOI 10.1038/d41587-020-00016-w
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Godfred-Cato S, 2020, MMWR-MORBID MORTAL W, V69, P1074, DOI 10.15585/mmwr.mm6932e2
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Hennon TR, 2020, PROG PEDIATR CARDIOL, V57, DOI 10.1016/j.ppedcard.2020.101232
   Ho MS, 2005, EMERG INFECT DIS, V11, P1730, DOI 10.3201/eid1111.040659
   Jacquinet E, 2000, FEBS LETT, V468, P93, DOI 10.1016/S0014-5793(00)01196-0
   Jaimes JA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010083
   Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011
   Levin M, 2020, NEW ENGL J MED, V383, P393, DOI 10.1056/NEJMe2023158
   Li LJ, 2003, J CLIN VIROL, V28, P239, DOI 10.1016/S1386-6532(03)00195-1
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Park Matthew D, 2020, Nat Rev Immunol, V20, P351, DOI 10.1038/s41577-020-0317-2
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Rothan HA, 2018, J AUTOIMMUN, V89, P11, DOI 10.1016/j.jaut.2018.01.002
   Rowley AH, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00374
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Schouten LR, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0529-4
   She JT, 2020, J MED VIROL, V92, P747, DOI 10.1002/jmv.25807
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wu H, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10895
   Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018
NR 36
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-6157
EI 1399-3038
J9 PEDIAT ALLERG IMM-UK
JI Pediatr. Allergy Immunol.
DI 10.1111/pai.13361
EA OCT 2020
PG 6
WC Allergy; Immunology; Pediatrics
SC Allergy; Immunology; Pediatrics
GA OB8IS
UT WOS:000578709300001
PM 32897642
OA Bronze
DA 2021-01-01
ER

PT J
AU Wang, Y
   Yao, L
   Zhang, JP
   Tang, PJ
   Ye, ZJ
   Shen, XH
   Xu, JC
   Wu, MY
   Yu, X
AF Wang, Yi
   Yao, Lin
   Zhang, Jian-Ping
   Tang, Pei-Jun
   Ye, Zhi-Jian
   Shen, Xing-Hua
   Xu, Jun-Chi
   Wu, Mei-Ying
   Yu, Xin
TI Clinical characteristics and laboratory indicator analysis of 67
   COVID-19 pneumonia patients in Suzhou, China
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE OVID-19; SARS-CoV-2; FIB; Treatment; Hormone
ID WUHAN
AB Background Sudden exacerbations and respiratory failure are major causes of death in patients with severe coronavirus disease 2019(COVID-19) pneumonia, but indicators for the prediction and treatment of severe patients are still lacking. Methods A retrospective analysis of 67 collected cases was conducted and included approximately 67 patients with COVID-19 pneumonia who were admitted to the Suzhou Fifth People's Hospital from January 1, 2020 to February 8, 2020. The epidemiological, clinical and imaging characteristics as well as laboratory data of the 67 patients were analyzed. Results The study found that fibrinogen (FIB) was increased in 45 (65.2%) patients, and when FIB reached a critical value of 4.805 g/L, the sensitivity and specificity,DA, helping to distinguish general and severe cases, were 100 and 14%,92.9%, respectively, which were significantly better than those for lymphocyte count and myoglobin. Chest CT images indicated that the cumulative number of lung lobes with lesions in severe patients was significantly higher than that in general patients (P < 0.05), and the cumulative number of lung lobes with lesions was negatively correlated with lymphocyte count and positively correlated with myoglobin and FIB. Our study also found that there was no obvious effect of hormone therapy in patients with severe COVID-19. Conclusions Based on the retrospective analysis, FIB was found to be increased in severe patients and was better than lymphocyte count and myoglobin in distinguishing general and severe patients. The study also suggested that hormone treatment has no significant effect on COVID-19.
C1 [Wang, Yi; Yao, Lin; Zhang, Jian-Ping; Tang, Pei-Jun; Ye, Zhi-Jian; Shen, Xing-Hua; Xu, Jun-Chi; Wu, Mei-Ying; Yu, Xin] Soochow Univ, Affiliated Infect Hosp, 10 Guangqian Rd, Suzhou 215000, Jiangsu, Peoples R China.
   [Wang, Yi; Yao, Lin; Zhang, Jian-Ping; Tang, Pei-Jun; Ye, Zhi-Jian; Shen, Xing-Hua; Xu, Jun-Chi; Wu, Mei-Ying; Yu, Xin] Fifth Peoples Hosp Suzhou, Suzhou, Peoples R China.
RP Xu, JC; Wu, MY; Yu, X (corresponding author), Soochow Univ, Affiliated Infect Hosp, 10 Guangqian Rd, Suzhou 215000, Jiangsu, Peoples R China.
EM xujunchi19850504@126.com; wu_my@126.com; xinxin810104@126.com
FU Science and Technology Plan of Suzhou, China [SS2019010]; Social
   Development Project of Jiangsu Provincial Department of Science and
   Technology [BE2019673]; High-level Health Talents in Jiangsu Province
   [LGY2019014]
FX This study was supported by grants from the Science and Technology Plan
   of Suzhou, China [No.SYS201778.SS201880.SYS2018096 and SS2019010](XY,
   ZJY and MYW, design of the study, analysis, interpretation of data and
   writing the manuscript);Social Development Project of Jiangsu Provincial
   Department of Science and Technology [No. BE2019673](PJT, writing the
   manuscript); High-level Health Talents in Jiangsu Province
   [LGY2019014](PJT, writing the manuscript);
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Feng K, 2020, Zhonghua Er Ke Za Zhi, V58, pE007, DOI [10.3760/cma.j.cn112140-20200210-00071, 10.3760/cma.j.issn.0578-1310.2020.0007]
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Rabaan Ali A, 2020, Infez Med, V28, P174
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Thompson RN, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020498
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang G, 2020, J MED VIROL, V92, P468, DOI 10.1002/jmv.25705
   Wassenaar TM, 2020, LETT APPL MICROBIOL, V70, P342, DOI 10.1111/lam.13285
   Xu X, 2020, EUR J NUCL MED MOL I, V47, P1275, DOI 10.1007/s00259-020-04735-9
   Yang Y, 2016, CELL MOL IMMUNOL, V13, P432, DOI 10.1038/cmi.2016.1
NR 13
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD OCT 12
PY 2020
VL 20
IS 1
AR 747
DI 10.1186/s12879-020-05468-8
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA OH6ZS
UT WOS:000582744800003
PM 33046047
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Villa, G
   Romagnoli, S
   De Rosa, S
   Greco, M
   Resta, M
   Montin, DP
   Prato, F
   Patera, F
   Ferrari, F
   Rotondo, G
   Ronco, C
AF Villa, Gianluca
   Romagnoli, Stefano
   De Rosa, Silvia
   Greco, Massimiliano
   Resta, Marco
   Montin, Diego Pomare
   Prato, Federico
   Patera, Francesco
   Ferrari, Fiorenza
   Rotondo, Giuseppe
   Ronco, Claudio
TI Blood purification therapy with a hemodiafilter featuring enhanced
   adsorptive properties for cytokine removal in patients presenting
   COVID-19: a pilot study
SO CRITICAL CARE
LA English
DT Article
DE Acute renal injury; IL-6; Multiorgan dysfunction; SOFA score
ID TOCILIZUMAB
AB Background Systemic inflammation in COVID-19 often leads to multiple organ failure, including acute kidney injury (AKI). Renal replacement therapy (RRT) in combination with sequential extracorporeal blood purification therapies (EBP) might support renal function, attenuate systemic inflammation, and prevent or mitigate multiple organ dysfunctions in COVID-19. Aim Describe overtime variations of clinical and biochemical features of critically ill patients with COVID-19 treated with EBP with a hemodiafilter characterized by enhanced cytokine adsorption properties. Methods An observational prospective study assessing the outcome of patients with COVID-19 admitted to the ICU (February to April 2020) treated with EBP according to local practice. Main endpoints included overtime variation of IL-6 and multiorgan function-scores, mortality, and occurrence of technical complications or adverse events. Results The study evaluated 37 patients. Median baseline IL-6 was 1230 pg/ml (IQR 895) and decreased overtime (p < 0.001 Kruskal-Wallis test) during the first 72 h of the treatment, with the most significant decrease in the first 24 h (p = 0.001). The reduction in serum IL-6 concentrations correlated with the improvement in organ function, as measured in the decrease of SOFA score (rho = 0.48,p = 0.0003). Median baseline SOFA was 13 (IQR 6) and decreased significantly overtime (p < 0.001 at Kruskal-Wallis test) during the first 72 h of the treatment, with the most significant decrease in the first 48 h (median 8 IQR 5,p = 0.001). Compared to the expected mortality rates, as calculated by APACHE IV, the mean observed rates were 8.3% lower after treatment. The best improvement in mortality rate was observed in patients receiving EBP early on during the ICU stay. Premature clotting (running < 24 h) occurred in patients (18.9% of total) which featured higher effluent dose (median 33.6 ml/kg/h, IQR 9) and higher filtration fraction (median 31%, IQR 7.4). No electrolyte disorders, catheter displacement, circuit disconnection, unexpected bleeding, air, or thromboembolisms due to venous cannulation of EBP were recorded during the treatment. In one case, infection of vascular access occurred during RRT, requiring replacement. Conclusions EBP with heparin-coated hemodiafilter featuring cytokine adsorption properties administered to patients with COVID-19 showed to be feasible and with no adverse events. During the treatment, patients experienced serum IL-6 level reduction, attenuation of systemic inflammation, multiorgan dysfunction improvement, and reduction in expected ICU mortality rate.
C1 [Villa, Gianluca; Romagnoli, Stefano; Montin, Diego Pomare] Univ Florence, Sect Anaesthesiol Intens Care & Pain Med, Dept Hlth Sci, Viale Pieraccini 6, I-50139 Florence, Italy.
   [Villa, Gianluca; Romagnoli, Stefano] Azienda Osped Univ Careggi, Dept Anaesthesia & Intens Care, Florence, Italy.
   [De Rosa, Silvia] St Bortolo Hosp, Dept Anesthesia, Vicenza, Italy.
   [De Rosa, Silvia] St Bortolo Hosp, Intens Care Unit, Vicenza, Italy.
   [De Rosa, Silvia; Montin, Diego Pomare; Ferrari, Fiorenza; Ronco, Claudio] Int Renal Res Inst Vicenza IRRIV, Vicenza, Italy.
   [Greco, Massimiliano] Humanitas Clin & Res Ctr IRCCS, Dept Anesthesiol & Intens Care, Milan, Italy.
   [Greco, Massimiliano] Humanitas Univ, Dept Biomed Sci, Milan, Italy.
   [Resta, Marco] IRCCS Policlin San Donato, Dept Gen Anesthesia & Intens Care, Milan, Italy.
   [Prato, Federico] Osped Infermi, Anesthesia & Intens Care, Ponderano, Biella, Italy.
   [Patera, Francesco] Osped S Maria Misericordia, Dept Nephrol Dialysis & Transplantat, Perugia, Italy.
   [Ferrari, Fiorenza] IRCCS San Matteo Hosp, Dept Anaesthesia, Pavia, Italy.
   [Ferrari, Fiorenza] IRCCS San Matteo Hosp, Intens Care Unit, Pavia, Italy.
   [Ferrari, Fiorenza] Univ Pavia, Pavia, Italy.
   [Rotondo, Giuseppe] Maria Vittoria Hosp, Turin, Italy.
   [Ronco, Claudio] Univ Padua, Dept Med, Padua, Italy.
   [Ronco, Claudio] San Bortolo Hosp, Dept Nephrol Dialysis & Kidney Transplant, Vicenza, Italy.
RP Villa, G (corresponding author), Univ Florence, Sect Anaesthesiol Intens Care & Pain Med, Dept Hlth Sci, Viale Pieraccini 6, I-50139 Florence, Italy.; Villa, G (corresponding author), Azienda Osped Univ Careggi, Dept Anaesthesia & Intens Care, Florence, Italy.
EM gianluca.villa@unifi.it
OI Villa, Gianluca/0000-0003-4274-3593; Resta, marco
   Vittorio/0000-0001-6705-0561
FU Baxter, Italy
FX Costs for statistical analyses and writing support to authors in the
   preparation of the manuscript have been covered thanks to the
   unconditional support (investigator-initiated research grant) of Baxter,
   Italy.
CR Aldo P, 2016, AM J REPROD IMMUNOL, V75, P678, DOI 10.1111/aji.12512
   Bellomo R, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0260-y
   Broman ME, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220444
   Brzezinski M, 2012, STATA J, V12, P368, DOI 10.1177/1536867X1201200302
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Honore PM, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0530-y
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Husain-Syed F, 2016, AM J RESP CRIT CARE, V194, P402, DOI 10.1164/rccm.201602-0420CP
   Ko M, 2018, ACUTE CRIT CARE, V33, P216, DOI 10.4266/acc.2018.00178
   Lowe DA, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.4153
   Monard C, 2019, BLOOD PURIFICAT, V47, P2, DOI 10.1159/000499520
   Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846
   Papazian L, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0540-9
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Ronco C, 2020, BLOOD PURIFICAT, V49, P255, DOI [10.1159/000507039, 10.1159/000508125]
   Sheppard M, 2017, HUM VACC IMMUNOTHER, V13, P1972, DOI 10.1080/21645515.2017.1316909
   Sise ME, 2020, NEW ENGL J MED, V382, P2147, DOI 10.1056/NEJMcpc2002418
   Tetta C, 2003, ARTIF ORGANS, V27, P202, DOI 10.1046/j.1525-1594.2003.00963.x
   Turani F, 2019, BLOOD PURIFICAT, V47, P54, DOI 10.1159/000499589
   Villa G, 2019, BLOOD PURIFICAT, V47, P16, DOI 10.1159/000499356
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang L, 2019, BLOOD PURIFICAT, V47, P45, DOI 10.1159/000499357
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 30
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1364-8535
EI 1466-609X
J9 CRIT CARE
JI Crit. Care
PD OCT 12
PY 2020
VL 24
IS 1
AR 605
DI 10.1186/s13054-020-03322-6
PG 13
WC Critical Care Medicine
SC General & Internal Medicine
GA OH6YT
UT WOS:000582742300002
PM 33046113
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Komatsu, TS
   Okimoto, N
   Koyama, YM
   Hirano, Y
   Morimoto, G
   Ohno, Y
   Taiji, M
AF Komatsu, Teruhisa S.
   Okimoto, Noriaki
   Koyama, Yohei M.
   Hirano, Yoshinori
   Morimoto, Gentaro
   Ohno, Yousuke
   Taiji, Makoto
TI Drug binding dynamics of the dimeric SARS-CoV-2 main protease,
   determined by molecular dynamics simulation
SO SCIENTIFIC REPORTS
LA English
DT Article
AB We performed molecular dynamics simulation of the dimeric SARS-CoV-2 (severe acute respiratory syndrome corona virus 2) main protease (M-pro) to examine the binding dynamics of small molecular ligands. Seven HIV inhibitors, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir, were used as the potential lead drugs to investigate access to the drug binding sites in M-pro. The frequently accessed sites on M-pro were classified based on contacts between the ligands and the protein, and the differences in site distributions of the encounter complex were observed among the ligands. All seven ligands showed binding to the active site at least twice in 28 simulations of 200 ns each. We further investigated the variations in the complex structure of the active site with the ligands, using microsecond order simulations. Results revealed a wide variation in the shapes of the binding sites and binding poses of the ligands. Additionally, the C-terminal region of the other chain often interacted with the ligands and the active site. Collectively, these findings indicate the importance of dynamic sampling of protein-ligand complexes and suggest the possibilities of further drug optimisations.
C1 [Komatsu, Teruhisa S.; Okimoto, Noriaki; Koyama, Yohei M.; Hirano, Yoshinori; Morimoto, Gentaro; Ohno, Yousuke; Taiji, Makoto] RIKEN Ctr Biosyst Dynam Res BDR, Lab Computat Mol Design, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.
   [Okimoto, Noriaki; Hirano, Yoshinori; Morimoto, Gentaro; Taiji, Makoto] RIKEN Ctr Biosyst Dynam Res BDR, Drug Discovery Mol Simulat Platform Unit, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.
RP Komatsu, TS; Taiji, M (corresponding author), RIKEN Ctr Biosyst Dynam Res BDR, Lab Computat Mol Design, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.; Taiji, M (corresponding author), RIKEN Ctr Biosyst Dynam Res BDR, Drug Discovery Mol Simulat Platform Unit, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.
EM teruhisa.komatsu@riken.jp; taiji@riken.jp
RI Okimoto, Noriaki/AAI-4656-2020
OI Okimoto, Noriaki/0000-0002-2956-1317
FU Leading-edge Research Infrastructure Program of Japan Society of the
   Promotion of Science (JSPS); Development of a Drug Discovery Informatics
   System of Japan Agency for Medical Research and Development (AMED);
   Taisho pharmaceutical Co. Ltd.; RIKEN Program for Drug Discovery and
   Medical Technology Platforms (DMP); RIKEN Pioneering Research Project on
   Dynamic Structural Biology; RIKEN President's Discretionary Fund
FX The calculations were performed in part on the HOKUSAI Big Waterfall
   system and Sailing Ship system at RIKEN ISC. We would like sincerely to
   acknowledge their immediate support for our urgent requests, especially
   to thank Dr. Hiroo Kenzaki and Dr. Motoyoshi Kurokawa. The MDGRAPE-4A
   project was partially supported by Leading-edge Research Infrastructure
   Program of Japan Society of the Promotion of Science (JSPS), Development
   of a Drug Discovery Informatics System of Japan Agency for Medical
   Research and Development (AMED), Taisho pharmaceutical Co. Ltd., RIKEN
   Program for Drug Discovery and Medical Technology Platforms (DMP), RIKEN
   Pioneering Research Project on Dynamic Structural Biology, and RIKEN
   President's Discretionary Fund. We also thank Dr. Hao Zhang, Dr. Itta
   Ohmura, Dr. Hiroshi Koyama, and Mr. Keigo Nishida of RIKEN for their
   contribution to the MDGRAPE-4A development.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Amaro RE, 2020, J CHEM INF MODEL, V60, P2653, DOI 10.1021/acs.jcim.0c00319
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], 2018, MOL OP ENV MOE 2013, DOI [10.1038/ja.2010.129, DOI 10.1038/JA.2010.129]
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen X, 2020, CHINA PERSPECT-SER, P1
   Contini A, 2020, VIRTUAL SCREENING FD, DOI [10.26434/chemrxiv.11847381, DOI 10.26434/CHEMRXIV.11847381]
   Cornell W. D, 1995, J AM CHEM SOC
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Farag A, 2020, IDENTIFICATION FDA A, DOI [10.26434/chemrxiv.12003930.v3, DOI 10.26434/CHEMRXIV.12003930.V3]
   Frisch M.J., 2016, GAUSSIAN16 REVISION
   Gohlke H, 2004, J COMPUT CHEM, V25, P238, DOI 10.1022/jcc.10379
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kneller DW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16954-7
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Komatsu T. S, Japanese published unexamined patent application, Patent No. [2020-64560(JP202064560A, 202064560]
   Kumar Sumit, 2020, J Chem Inf Model, DOI 10.1021/acs.jcim.0c00326
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Muramatsu T, 2013, FEBS J, V280, P2002, DOI 10.1111/febs.12222
   Ngo Son Tung, 2020, J Chem Inf Model, DOI 10.1021/acs.jcim.0c00491
   Ohashi H., 2020, BIORXIV, DOI [10.1101/2020.04.14.039925., DOI 10.1101/2020.04.14.039925, 10.1101/ 2020.04.14.039925.]
   Ohmura I, 2014, PHILOS T R SOC A, V372, DOI 10.1098/rsta.2013.0387
   Sang P, 2020, RSC ADV, V10, P15775, DOI 10.1039/d0ra01899f
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yamamoto N., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.06.026476, 10.1101/ 2020.04.06.026476]
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
NR 35
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 12
PY 2020
VL 10
IS 1
AR 16986
DI 10.1038/s41598-020-74099-5
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OH6FU
UT WOS:000582685800012
PM 33046764
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Elbadawi, A
   Mahtta, D
   Elgendy, IY
   Saad, M
   Krittanawong, C
   Hira, RS
   Omer, M
   Ogunbayo, GO
   Garratt, K
   Rao, SV
   Jneid, H
AF Elbadawi, Ayman
   Mahtta, Dhruv
   Elgendy, Islam Y.
   Saad, Marwan
   Krittanawong, Chayakrit
   Hira, Ravi S.
   Omer, Mohamed
   Ogunbayo, Gbolahan O.
   Garratt, Kirk
   Rao, Sunil V.
   Jneid, Hani
TI Trends and Outcomes of Fibrinolytic Therapy for STEMI Insights and
   Reflections in the COVID-19 Era
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Letter
C1 [Elbadawi, Ayman; Mahtta, Dhruv; Elgendy, Islam Y.; Saad, Marwan; Krittanawong, Chayakrit; Hira, Ravi S.; Omer, Mohamed; Ogunbayo, Gbolahan O.; Garratt, Kirk; Rao, Sunil V.; Jneid, Hani] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Div Cardiol, Houston, TX 77030 USA.
RP Jneid, H (corresponding author), Baylor Coll Med, Michael E DeBakey VA Med Ctr, Div Cardiol, Houston, TX 77030 USA.
EM Jneid@bcm.edu
CR Jneid H, 2017, J AM COLL CARDIOL, V70, P2048, DOI 10.1016/j.jacc.2017.06.032
   Welt FGP, 2020, J AM COLL CARDIOL, V75, P2372, DOI 10.1016/j.jacc.2020.03.021
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1936-8798
EI 1876-7605
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD OCT 12
PY 2020
VL 13
IS 19
BP 2312
EP 2314
DI 10.1016/j.jcin.2020.07.004
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NZ9VS
UT WOS:000577447400027
PM 33032721
OA Green Published
DA 2021-01-01
ER

PT J
AU Paul, AS
   Islam, R
   Parves, MR
   Al Mamun, A
   Shahriar, I
   Hossain, MI
   Hossain, MN
   Ali, MA
   Halim, MA
AF Paul, Archi Sundar
   Islam, Rajib
   Parves, Md Rimon
   Al Mamun, Abdulla
   Shahriar, Imrul
   Hossain, Md Imran
   Hossain, Md Nayeem
   Ali, Md Ackas
   Halim, Mohammad A.
TI Cysteine focused covalent inhibitors against the main protease of
   SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Cysteine focused inhibitors; Covid-19; main protease; molecular docking;
   molecular dynamics
ID MOLECULAR DOCKING; GENERATION; PREDICTION
AB In viral replication and transcription, the main protease (Mpro) of SARS-CoV-2 plays an important role and appears to be a vital target for drug design. In Mpro, there is a Cys-His catalytic dyad, and ligands that interact with the Cys145 assumed to be an effective approach to inhibit the Mpro. In this study, approximately 1400 cysteine-focused ligands were screened to identify the best candidates that can act as potent inhibitors against Mpro. Our results show that the selected ligands strongly interact with the key Cys145 and His41 residues. Covalent docking was performed for the selected candidates containing the acrylonitrile group, which can form a covalent bond with Cys145. All atoms molecular dynamics (MD) simulation was performed on the selected four inhibitors including L1, L2, L3 and L4 to validate the docking interactions. Our results were also compared with a control ligand, alpha-ketoamide (11r). Principal component analysis on structural and energy data obtained from the MD trajectories shows that L1, L3, L4 and alpha-ketoamide (11r) have structural similarity with the apo-form of the Mpro. Quantitative structure-activity relationship method was employed for pattern recognition of the best ligands, which discloses that ligands containing acrylonitrile and amide warheads can show better performance. ADMET analysis displays that our selected candidates appear to be safer inhibitors. Our combined studies suggest that the best cysteine focused ligands can help to design an effective lead drug for COVID-19 treatment. Communicated by Ramaswamy H. Sarma
C1 [Paul, Archi Sundar; Islam, Rajib; Parves, Md Rimon; Hossain, Md Imran; Hossain, Md Nayeem; Ali, Md Ackas; Halim, Mohammad A.] BICCB, Red Green Res Ctr, Div Infect Dis, Dhaka, Bangladesh.
   [Paul, Archi Sundar; Islam, Rajib; Parves, Md Rimon; Hossain, Md Imran; Hossain, Md Nayeem; Ali, Md Ackas; Halim, Mohammad A.] BICCB, Red Green Res Ctr, Div Comp Aided Drug Design, Dhaka, Bangladesh.
   [Al Mamun, Abdulla] Nanjing Univ Sci & Technol, Sch Chem Engn, Key Lab Soft Chem & Funct Mat MOE, Nanjing, Peoples R China.
   [Shahriar, Imrul] Purdue Univ, Dept Chem, W Lafayette, IN USA.
   [Halim, Mohammad A.] Univ Arkansas, Dept Phys Sci, Ft Smith, AR 72904 USA.
RP Halim, MA (corresponding author), Univ Arkansas, Dept Phys Sci, Ft Smith, AR 72904 USA.
EM mohammad.halim@uafs.edu
RI Islam, Rajib/AAP-7503-2020; parves/AAF-8816-2020; Ali,
   Ackas/AAP-7500-2020
OI Islam, Rajib/0000-0001-8499-5516; parves/0000-0003-1379-7410; Ali,
   Ackas/0000-0002-8235-3517; Halim, Mohammad/0000-0002-1698-7044
CR Adinsoft S., 2010, XLSTAT SOFTWARE VERS
   AHMED S, 2020, J BIOMOL STRUCT 0727, DOI DOI https://doi.org/10.1080/07391102.2020.1796804
   AHMED S, 2020, J BIOMOL STRUCT 0121, DOI DOI https://doi.org/10.1080/07391102.2020.1714482
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Barrientos A., 1990, COMMINUTION, V819, DOI [10.1007/978-1-61779-465-0, DOI 10.1007/978-1-61779-465-0]
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   De Jong S., 1990, J CHEMOMETR, V4, DOI 10.1002/cem.1180040607
   Dickson CJ, 2014, J CHEM THEORY COMPUT, V10, P865, DOI 10.1021/ct4010307
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   ISLAM MJ, 2019, SCI REP UK, V9, DOI DOI https://doi.org/10.1038/s41598-019-52308-0
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Johnson DS, 2010, FUTURE MED CHEM, V2, P949, DOI 10.4155/FMC.10.21
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Junaid M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211935
   Kasmi Y, 2020, EMERGING AND REEMERGING VIRAL PATHOGENS, VOL 1: FUNDAMENTAL AND BASIC VIROLOGY ASPECTS OF HUMAN, ANIMAL AND PLANT PATHOGENS, P127, DOI 10.1016/B978-0-12-819400-3.00007-7
   Kassambara A., 2017, R PACKAGE VERSION
   Khan AM, 2017, J MOL GRAPH MODEL, V77, P386, DOI 10.1016/j.jmgm.2017.09.010
   Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041
   Krieger E, 2006, J MOL GRAPH MODEL, V25, P481, DOI 10.1016/j.jmgm.2006.02.009
   Krieger E, 2015, J COMPUT CHEM, V36, P996, DOI 10.1002/jcc.23899
   Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Lyne PD, 2006, J MED CHEM, V49, P4805, DOI 10.1021/jm060522a
   Mah R, 2014, BIOORG MED CHEM LETT, V24, P33, DOI 10.1016/j.bmcl.2013.10.003
   Morris Garrett M., 2008, V443, P365, DOI 10.1007/978-1-59745-177-2_19
   Motohashi H, 2013, AAPS J, V15, P581, DOI 10.1208/s12248-013-9465-7
   Mukhametov A, 2017, J MOL GRAPH MODEL, V71, P227, DOI 10.1016/j.jmgm.2016.12.008
   Osman EEA, 2020, ACS INFECT DIS, V6, P1548, DOI 10.1021/acsinfecdis.0c00224
   R Core Team, 2014, R LANG ENV STAT COMP
   RAHMAN MM, 2020, J BIOMOL STRUCT 0718, DOI DOI https://doi.org/10.1080/07391102.2020.1794974
   RStudio Team, 2015, RSTUDIO INT DEV R
   Santos MMM, 2007, MINI-REV MED CHEM, V7, P1040, DOI 10.2174/138955707782110105
   Scarpino A, 2018, J CHEM INF MODEL, V58, P1441, DOI 10.1021/acs.jcim.8b00228
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   VERMA S, 2016, FRONT PHARMACOL, V7, DOI DOI https://doi.org/10.3389/fphar.2016.00107
   Wang F. H., 2016, SCI REP UK, V6, DOI DOI https://doi.org/10.1038/srep22677
   Watts KS, 2010, J CHEM INF MODEL, V50, P534, DOI 10.1021/ci100015j
   WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   ZHENG Y, 2020, NAT REV CARDIOL 0305, V17, DOI DOI https://doi.org/10.1038/s41569-020-0360-5
   Zhu K, 2014, J CHEM INF MODEL, V54, P1932, DOI 10.1021/ci500118s
NR 48
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1831610
EA OCT 2020
PG 20
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OB8OH
UT WOS:000578723800001
PM 33047658
OA Bronze
DA 2021-01-01
ER

PT J
AU Priyambada, L
   Wolfsdorf, JI
   Brink, SJ
   Fritsch, M
   Codner, E
   Donaghue, KC
   Craig, ME
AF Priyambada, Leena
   Wolfsdorf, Joseph, I
   Brink, Stuart J.
   Fritsch, Maria
   Codner, Ethel
   Donaghue, Kim C.
   Craig, Maria E.
TI ISPAD Clinical Practice Consensus Guideline: Diabetic ketoacidosis in
   the time ofCOVID-19 and resource-limited settings-role of subcutaneous
   insulin
SO PEDIATRIC DIABETES
LA English
DT Article
DE COVID-19; diabetic ketoacidosis; resource-limited settings; subcutaneous
   insulin
ID INTRAVENOUS REGULAR INSULIN; LISPRO; THERAPY; CRISES
AB The International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guideline 2018 for management of diabetic ketoacidosis (DKA) and the hyperglycemic hyperosmolar state provide comprehensive guidance for management of DKA in young people. Intravenous (IV) infusion of insulin remains the treatment of choice for treating DKA; however, the policy of many hospitals around the world requires admission to an intensive care unit (ICU) for IV insulin infusion. During the coronavirus 2019 (COVID-19) pandemic or other settings where intensive care resources are limited, ICU services may need to be prioritized or may not be appropriate due to risk of transmission of infection to young people with type 1 or type 2 diabetes. The aim of this guideline, which should be used in conjunction with the ISPAD 2018 guidelines, is to ensure that young individuals with DKA receive management according to best evidence in the context of limited ICU resources. Specifically, this guideline summarizes evidence for the role of subcutaneous insulin in treatment of uncomplicated mild to moderate DKA in young people and may be implemented if administration of IV insulin is not an option.
C1 [Priyambada, Leena] Rainbow Childrens Hosp, Div Pediat Endocrinol, Hyderabad, India.
   [Wolfsdorf, Joseph, I] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA.
   [Brink, Stuart J.] New England Diabet & Endocrinol Ctr, Waltham, MA USA.
   [Fritsch, Maria] Med Univ Graz, Dept Pediat & Adolescent Med, Graz, Austria.
   [Codner, Ethel] Univ Chile, Sch Med, Inst Maternal & Child Res, Santiago, Chile.
   [Donaghue, Kim C.; Craig, Maria E.] Sydney Childrens Hosp Network, Sydney, NSW, Australia.
   [Donaghue, Kim C.; Craig, Maria E.] Univ Sydney, Discipline Child & Adolescent Hlth, Sydney, NSW, Australia.
   [Craig, Maria E.] Univ New South Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia.
RP Craig, ME (corresponding author), Sydney Childrens Hosp Network, Sydney, NSW, Australia.
EM m.craig@unsw.edu.au
OI Codner, Ethel/0000-0002-2899-2705; Wolfsdorf,
   Joseph/0000-0001-6220-6758; Craig, Maria E/0000-0001-6004-576X;
   Donaghue, Kim/0000-0002-4210-7872
CR Andrade-Castellanos CA, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011281.pub2
   [Anonymous], 2017, DIABETES CARE, V40, pS1, DOI 10.2337/dc17-S001
   Basetty Sudhakar, 2017, J Family Med Prim Care, V6, P25, DOI 10.4103/2249-4863.214992
   Bode Bruce, 2020, J Diabetes Sci Technol, V14, P813, DOI 10.1177/1932296820924469
   Brink S, 2011, DIABETES CHILDREN AD
   Brink SJ, 2014, PRACT DIABETES, V31, P342, DOI 10.1002/pdi.1899
   Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467
   Cherubini V, 2020, J PEDIATR-US, V223, P197, DOI 10.1016/j.jpeds.2020.05.004
   Codner E, 2018, PEDIATR DIABETES, V19, P328, DOI 10.1111/pedi.12767
   Cohen M, 2017, PEDIATR DIABETES, V18, P290, DOI 10.1111/pedi.12380
   Cohn BG, 2015, J EMERG MED, V49, P530, DOI 10.1016/j.jemermed.2015.05.016
   Della Manna T, 2005, DIABETES CARE, V28, P1856, DOI 10.2337/diacare.28.8.1856
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Ersoz HO, 2006, INT J CLIN PRACT, V60, P429, DOI 10.1111/j.1368-5031.2006.00786.x
   FISHER JN, 1977, NEW ENGL J MED, V297, P238, DOI 10.1056/NEJM197708042970502
   Homko C, 2003, DIABETES CARE, V26, P2027, DOI 10.2337/diacare.26.7.2027
   Karoli R, 2011, INDIAN J PHARMACOL, V43, P398, DOI 10.4103/0253-7613.83109
   Kitabchi AE, 2009, DIABETES CARE, V32, P1335, DOI 10.2337/dc09-9032
   Kuppermann N, 2018, NEW ENGL J MED, V379, P1183, DOI 10.1056/NEJMc1810064
   Laffel LM, 2018, PEDIATR DIABETES, V19, P193, DOI 10.1111/pedi.12741
   LFaC IDF ISPAD, 2017, POCKETBOOK MANAGEMEN
   MOSELEY J, 1975, BRIT MED J, V1, P59, DOI 10.1136/bmj.1.5949.59
   Ogimi C, 2019, J PEDIAT INF DIS SOC, V8, P21, DOI 10.1093/jpids/pix093
   Peters AL, 2020, DIABETES TECHNOL THE, V22, P449, DOI 10.1089/dia.2020.0187
   Rave K, 1998, DIABETIC MED, V15, P747, DOI 10.1002/(SICI)1096-9136(199809)15:9<747::AID-DIA664>3.0.CO;2-V
   Razavi Z, 2018, ENDOCRINE, V61, P267, DOI 10.1007/s12020-018-1635-z
   Rubino F, 2020, NEW ENGL J MED, V383, P789, DOI [10.1056/NEJMc2018688, 10.1056/NEJMc2021832]
   Steiner MJ, 2004, JAMA-J AM MED ASSOC, V291, P2746, DOI 10.1001/jama.291.22.2746
   Swan KL, 2008, DIABETES CARE, V31, P44, DOI 10.2337/dc07-0737
   Umpierrez GE, 2004, DIABETES CARE, V27, P1873, DOI 10.2337/diacare.27.8.1873
   Umpierrez GE, 2004, AM J MED, V117, P291, DOI 10.1016/j.amjmed.2004.05.010
   Vincent M, 2013, DIABETES METAB, V39, P299, DOI 10.1016/j.diabet.2012.12.003
   Wolfsdorf JI, 2018, PEDIATR DIABETES, V19, P155, DOI 10.1111/pedi.12701
NR 33
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1399-543X
EI 1399-5448
J9 PEDIATR DIABETES
JI Pediatr. Diabetes
PD DEC
PY 2020
VL 21
IS 8
BP 1394
EP 1402
DI 10.1111/pedi.13118
EA OCT 2020
PG 9
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA OM9SJ
UT WOS:000578613400001
PM 32935435
OA Bronze
DA 2021-01-01
ER

PT J
AU Tarquinio, C
   Brennstuhl, MJ
   Rydberg, JA
   Bassan, F
   Peter, L
   Tarquinio, CL
   Auxemery, Y
   Rotonda, C
   Tarquinio, P
AF Tarquinio, Cyril
   Brennstuhl, Marie-Jo
   Rydberg, Jenny Ann
   Bassan, Fanny
   Peter, Lydia
   Tarquinio, Camille Louise
   Auxemery, Yann
   Rotonda, Christine
   Tarquinio, Pascale
TI EMDR in Telemental Health Counseling for Healthcare Workers Caring for
   COVID-19 Patients: A Pilot Study
SO ISSUES IN MENTAL HEALTH NURSING
LA English
DT Article; Early Access
ID POSTTRAUMATIC-STRESS-DISORDER; EYE-MOVEMENT DESENSITIZATION;
   PSYCHOLOGICAL IMPACT; PSYCHOTHERAPY; METAANALYSIS; DEPRESSION; EFFICACY;
   THERAPY; DISASTER; VIOLENCE
AB Background The COVID-19 pandemic is putting a strain on health systems around the world. Healthcare workers, on the front lines of the epidemic, are facing major and potentially traumatic stressful events, overwhelming their ability to cope and their resources. Objective The objective of this article will be to show how the use of the URG-EMDR protocol in a telemental health setting has proven to be feasible and effective in the treatment of a group of healthcare professionals working in nursing homes or hospital services that were highly mobilized during the acute phase of COVID-19. Method 17 participants, registered nurses (N = 7) and licensed practical nurses (N = 10), were remotely treated using the URG-EMDR protocol in a single session. The assessment focused on anxiety and depressive symptoms (HAD scale) and the level of perceived disturbance (SUD). An additional evaluation of the satisfaction with the remote psychotherapy intervention was conducted. Results As the URG-EMDR protocol has already proven itself during emergency interventions, it is interesting to note that its remote use in the treatment of healthcare providers caring for COVID-19 patients allows for an improvement in the emotional state and a decrease in perceived disturbance, in a single session. This result is maintained 1 week after the intervention, despite the continued professional activities of the participants and the continuity of the event. Moreover, the remote therapy setting was judged satisfactory by the patients, even if it required adjustments and certain recommendations for practice. Discussion The remote use of the URG-EMDR protocol opens up innovative perspectives for early interventions and the prevention of the development of psychological disorders in the long term following a situation of acute stress.
C1 [Tarquinio, Cyril; Brennstuhl, Marie-Jo; Rydberg, Jenny Ann; Bassan, Fanny; Peter, Lydia; Tarquinio, Camille Louise; Auxemery, Yann; Rotonda, Christine; Tarquinio, Pascale] Ctr Pierre Janet, APEMAC EPSAM EA 4360, Metz, France.
   [Tarquinio, Cyril; Brennstuhl, Marie-Jo; Rydberg, Jenny Ann; Bassan, Fanny; Tarquinio, Camille Louise; Auxemery, Yann; Rotonda, Christine; Tarquinio, Pascale] Univ Lorraine, UFR Sci Humaines & Sociales, EPSAM APEMAC, BP 30309, F-57045 Metz 1, France.
   [Peter, Lydia] Univ Lorraine, UFR Sci Humaines & Sociales Ile Saulcy, Metz, France.
RP Tarquinio, CL (corresponding author), Univ Lorraine, UFR Sci Humaines & Sociales, EPSAM APEMAC, BP 30309, F-57045 Metz 1, France.
EM camilletarquinio@gmail.com
OI Rydberg, Jenny Ann/0000-0002-1260-7104; , Christine/0000-0002-8854-0591
CR American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Artigas L., 2010, EYE MOVEMENT DESENSI, P5
   Backhaus A, 2012, PSYCHOL SERV, V9, P111, DOI 10.1037/a0027924
   Barak A, 2008, J TECHNOL HUMAN SERV, V26, P109, DOI 10.1080/15228830802094429
   Bisson J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003388.pub3
   Bradley R, 2005, AM J PSYCHIAT, V162, P214, DOI 10.1176/appi.ajp.162.2.214
   Cabello I. R., 2020, IMPACT VIRAL EPIDEMI, DOI [10.1101/2020.04.02.20048892, DOI 10.1101/2020.04.02.20048892]
   Centers for Disease Control and Prevention, 2017, QUAR IS
   Chen YR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103676
   Cooper SE, 2019, COUNS PSYCHOL, V47, P1074, DOI 10.1177/0011000019895276
   Cuijpers P, 2020, COGN BEHAV THERAPY, V49, P165, DOI 10.1080/16506073.2019.1703801
   Fluckiger C, 2018, PSYCHOTHERAPY, V55, P316, DOI 10.1037/pst0000172
   Gardner PJ, 2015, CAN PSYCHOL, V56, P123, DOI 10.1037/a0037973
   Ghosh G J, 1997, J Telemed Telecare, V3 Suppl 1, P33, DOI 10.1258/1357633971930283
   Harms L, 2015, BRIT J SOC WORK, V45, P170, DOI 10.1093/bjsw/bcv122
   Hilty DM, 2013, TELEMED E-HEALTH, V19, P444, DOI 10.1089/tmj.2013.0075
   Jarero I., 2018, IBEROAMERICAN J PSYC, V10
   Kang LJ, 2020, BRAIN BEHAV IMMUN, V87, P11, DOI 10.1016/j.bbi.2020.03.028
   Kiropoulos LA, 2008, J ANXIETY DISORD, V22, P1273, DOI 10.1016/j.janxdis.2008.01.008
   Kramer GM, 2012, TELEMED E-HEALTH, V18, P309, DOI 10.1089/tmj.2011.0149
   Kutz I, 2008, J EMDR PRACT RES, V2, P190, DOI 10.1891/1933-3196.2.3.190
   Langarizadeh Mostafa, 2017, Acta Inform Med, V25, P240, DOI 10.5455/aim.2017.25.240-246
   Lee CW, 2013, J BEHAV THER EXP PSY, V44, P231, DOI 10.1016/j.jbtep.2012.11.001
   Liu XH, 2012, COMPR PSYCHIAT, V53, P15, DOI 10.1016/j.comppsych.2011.02.003
   Luxton D., 2016, PRACTITIONERS GUIDE
   Maxfield L, 2002, J CLIN PSYCHOL, V58, P23, DOI 10.1002/jclp.1127
   McFarlane AC, 2015, AUST NZ J PSYCHIAT, V49, P313, DOI 10.1177/0004867415576393
   Norris FH, 2002, PSYCHIATRY, V65, P207, DOI 10.1521/psyc.65.3.207.20173
   Ogden P., 2000, TRAUMATOLOGY, V6, P3, DOI DOI 10.1177/153476560000600302
   Pappa S, 2020, BRAIN BEHAV IMMUN, V88, P901, DOI 10.1016/j.bbi.2020.05.026
   Perlini C, 2020, J AFFECT DISORDERS, V269, P1, DOI 10.1016/j.jad.2020.03.001
   Quinn G., 2009, EYE MOVEMENT DESENSI
   Razavi D., 1989, REV PSYCHOL APPL, V39
   Reynolds DL, 2008, EPIDEMIOL INFECT, V136, P997, DOI 10.1017/S0950268807009156
   Sante publique France, 2020, COVID 19 POINT EP HE
   Seidler GH, 2006, PSYCHOL MED, V36, P1515, DOI 10.1017/S0033291706007963
   Shapiro E, 2008, J EMDR PRACT RES, V2, P79, DOI 10.1891/1933-3196.2.2.79
   SHAPIRO F, 1994, J BEHAV THER EXP PSY, V25, P89, DOI 10.1016/0005-7916(94)90071-X
   Shapiro F., 1995, EYE MOVEMENT DESENSI
   Shapiro F., 2015, EVIDENCE BASED TREAT
   Shapiro F., 2018, EYE MOVEMENT DESENSI, V3rd
   Shapiro F., 2001, EYE MOVEMENT DESENSI
   Shapiro F., 1991, EMDR NETWORK NEWSLET, V1
   Shapiro F, 2007, J EMDR PRACT RES, V1, P68, DOI 10.1891/1933-3196.1.2.68
   Shepherd L, 2006, J PAIN SYMPTOM MANAG, V32, P453, DOI 10.1016/j.jpainsymman.2006.05.018
   Shore JH, 2018, TELEMED E-HEALTH, V24, P827, DOI 10.1089/tmj.2018.0237
   Siegel DJ, 1999, DEV MIND NEUROBIOLOG
   Spek V, 2007, PSYCHOL MED, V37, P319, DOI 10.1017/S0033291706008944
   Spence Jay, 2013, F1000Res, V2, P79, DOI 10.12688/f1000research.2-79.v1
   Suler J, 2001, CYBERPSYCHOL BEHAV, V4, P675, DOI 10.1089/109493101753376614
   Tan BYQ, 2020, ANN INTERN MED, V173, P317, DOI 10.7326/M20-1083
   Tarquinio C., 2012, SEXOLOGIES, V21, DOI [https://doi.org/10.1016/j.sexol.2011.11.013, DOI 10.1016/J.SEXOL.2011.11.013]
   Tarquinio C, 2016, ISSUES MENT HEALTH N, V37, P787, DOI 10.1080/01612840.2016.1224282
   Tarquinio C, 2012, EVOL PSYCHIATR, V77, P97, DOI 10.1016/j.evopsy.2011.11.002
   Thepaut M, 2020, ENCEPHALE, V46, pS124, DOI 10.1016/j.encep.2020.04.002
   Todder D, 2007, TELEMED J E-HEALTH, V13, P461, DOI 10.1089/tmj.2006.0058
   Turvey C, 2013, TELEMED E-HEALTH, V19, P722, DOI 10.1089/tmj.2013.9989
   Valiente-Gomez A, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01668
   Van Daele T., 2020, J PSYCHOTHERAPY INTE, V30
   Van Etten ML, 1998, CLIN PSYCHOL PSYCHOT, V5, P126, DOI 10.1002/(SICI)1099-0879(199809)5:3<126::AID-CPP153>3.3.CO;2-8
   Virtual Training and Therapy Task Group, 2020, GUID VIRT EMDR THER
   Wilbarger P., 1997, SENSORY DEFENSIVENES
   WOLPE J, 1991, J BEHAV THER EXP PSY, V22, P39, DOI 10.1016/0005-7916(91)90032-Z
   Wolpe J, 1990, PRACTICE BEHAV THERA
   World Health Organization, 2018, INT CLASS DIS
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 66
TC 0
Z9 0
U1 5
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0161-2840
EI 1096-4673
J9 ISSUES MENT HEALTH N
JI Issues Ment. Health Nurs.
DI 10.1080/01612840.2020.1818014
EA OCT 2020
PG 12
WC Nursing; Psychiatry
SC Nursing; Psychiatry
GA NZ7SC
UT WOS:000577302700001
PM 33052727
OA Bronze
DA 2021-01-01
ER

PT J
AU Schneede, P
   Schneede, JB
AF Schneede, P.
   Schneede, J. B.
TI The urologist as a vaccinator
SO UROLOGE
LA German
DT Article
DE Human papillomavirus; Vaccination recommendations; Informed consent;
   Vaccination status; Immunization; secondary
ID HUMAN-PAPILLOMAVIRUS
AB Vaccines are one of the most effective weapons of humankind in the fight against various infectious diseases. Therefore, physicians from all specialties should not only regularly confirm their knowledge regarding vaccinations but also actively offer them in their daily routine. Urologists can use various vaccination offers to help protect their patients' future health. In addition to human papillomavirus (HPV) vaccinations for children and adolescents, this article shows how urologists who provide vaccines can fulfill their responsibility to implement the state vaccination recommendations to patients over the age of 60. Among others, HPV vaccination can have the effect of finally eradicating an evolutionary burden of humanity. In addition to standard vaccinations against tetanus, diphtheria and pertussis, special vaccinations also protect individuals over the age of 60 against pneumococci, influenza and herpes zoster. Moreover, urologists may in the future also save patients from COVID-19-the disease that actually made people aware of vaccinations again.
C1 [Schneede, P.] LMU Munchen, Lehrkrankenhaus, Klinikum Memmingen, Munich, Germany.
   [Schneede, J. B.] Julius Maximilians Univ, Wurzburg, Germany.
   [Schneede, P.] Klinikum Memmingen, Urol Klin, Bismarckstr 23, D-87700 Memmingen, Germany.
RP Schneede, P (corresponding author), Klinikum Memmingen, Urol Klin, Bismarckstr 23, D-87700 Memmingen, Germany.
EM Peter.Schneede@klinikum-memmingen.de
CR [Anonymous], 2020, EPID B, V34, P313
   [Anonymous], 2005, EMERGENCY COMMITTEE
   Be, 2002, DTSCH ARZTEBL, V99, pA2504
   BETSCH C, 2019, DTSCH ARZTEBL, V116, pB427
   Buhmann W, 2018, UROLOGE, V57, P1499, DOI 10.1007/s00120-018-0807-z
   Butikofer J, 1998, DTSCH ARZTEBL, V95, pA7
   Dempsey AF, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2018.0016
   Klug SJ, 2018, DTSCH ARZTEBL, V115, pA1382
   Klug SJ, 2018, UROLOGE, V57, P1346, DOI 10.1007/s00120-018-0793-1
   Nachtigall N, 2020, COMMUNICATION   0529
   Rand CM, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-0498
   Reuschenbach M, 2019, VORG EUROGIN K 04 BI
   Rieser S, 2007, DTSCH ARZTEBL, V104, pA2379
   Schneede P, 2006, UROLOGE, V45, P1514, DOI 10.1007/s00120-006-1232-2
   Schneede P, 2018, UROLOGE, V57, P1452, DOI 10.1007/s00120-018-0770-8
   Schneede P, 2018, UROLOGE, V57, P413, DOI 10.1007/s00120-018-0597-3
   Schneede P, 2017, UROLOGE, V56, P728, DOI 10.1007/s00120-017-0394-4
   Schneede P, 2019, UROLOGE, V58, P1353, DOI 10.1007/s00120-019-01055-1
   Smith MA, 2015, J INFECT DIS, V211, P91, DOI 10.1093/infdis/jiu370
   STIKO (Standige Impfkommission am Robert Koch-Institut), 2018, EPIDEMIOL B, V26, P233, DOI DOI 10.17886/EPIBULL-2018-032
   Willemsen A, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0303
NR 21
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-2592
EI 1433-0563
J9 UROLOGE
JI Urologe
PD DEC
PY 2020
VL 59
IS 12
SI SI
BP 1492
EP 1497
DI 10.1007/s00120-020-01358-8
EA OCT 2020
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA PB8BD
UT WOS:000577049700002
PM 33044633
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rodriguez-Tajes, S
   Miralpeix, A
   Costa, J
   Lopez-Sune, E
   Laguno, M
   Pocurull, A
   Lens, S
   Marino, Z
   Forns, X
AF Rodriguez-Tajes, Sergio
   Miralpeix, Anna
   Costa, Josep
   Lopez-Sune, Ester
   Laguno, Montserrat
   Pocurull, Anna
   Lens, Sabela
   Marino, Zoe
   Forns, Xavier
TI Low risk of hepatitis B reactivation in patients with severe COVID-19
   who receive immunosuppressive therapy
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Article
ID MANAGEMENT; INFECTION
AB A significant proportion of patients infected with SARS-CoV-2 develop severe respiratory symptoms due to an excessive immune response. Treatment of this condition may include immunosuppressive therapies, such as IL-6 receptor antagonists and corticosteroids, which pose a risk for patients with active or past hepatitis B virus (HBV) infection. In this prospective cohort study, we analysed the risk of HBV reactivation in patients with severe COVID-19 and resolved HBV infection undergoing immunosuppressive therapy. From 15th March to 30th April 2020, 600 patients with severe COVID-19 were admitted to our hospital and treated with immune modulators. Data regarding HBV infection were available in 484, of whom 69 (14%) were HBsAg negative/anti-HBc positive. For these patients, HBV reactivation prophylaxis with entecavir was strongly recommended. Complete follow-up was available in 61 patients: 72% were male, median age was 67 years, and anti-HBs was >10 IU/mL in 72%. The immunosuppressive drug most used was tocilizumab (72%). Despite HBV prophylaxis recommendation, 38 (62%) patients received entecavir and 23 (38%) did not. Baseline features of both groups were similar. At follow-up, we found no cases of HBsAg seroreversion and only 2 (3%) patients (no prophylaxis group) had detectable serum HBV-DNA (<15 IU/mL). Both were anti-HBs negative and had normal aminotransferase levels. Our data show that the risk of HBV reactivation in patients with severe COVID-19 and resolved HBV infection undergoing immunosuppressive treatment is low. However, if a systematic follow-up after hospital discharge is unfeasible in patients without anti-HBs, a short course of antiviral prophylaxis may be a safe option.
C1 [Rodriguez-Tajes, Sergio; Miralpeix, Anna; Pocurull, Anna; Lens, Sabela; Marino, Zoe; Forns, Xavier] Univ Barcelona, IDIBAPS, Hosp Clin, Liver Unit, Barcelona, Spain.
   [Rodriguez-Tajes, Sergio; Miralpeix, Anna; Costa, Josep; Lens, Sabela; Marino, Zoe; Forns, Xavier] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
   [Costa, Josep] Univ Barcelona, Hosp Clin, Microbiol Dept, Barcelona, Spain.
   [Lopez-Sune, Ester] Univ Barcelona, IDIBAPS, Div Med, Pharm Serv,Hosp Clin, Barcelona, Spain.
   [Laguno, Montserrat] Univ Barcelona, Hosp Clin, IDIBAPS, Infectious Dis Serv, Barcelona, Spain.
RP Forns, X (corresponding author), Univ Barcelona, IDIBAPS, Hosp Clin, CIBERehd,Liver Unit, Barcelona, Spain.
EM xforns@clinic.cat
OI Lens, Sabela/0000-0003-4900-411X; Rodriguez-Tajes,
   Sergio/0000-0002-3189-7557; Forns, Xavier/0000-0002-8188-1764
FU Instituto de Salud Carlos III (ISCIII) through the Plan Estatal de
   Investigacion Cientifica y Tecnica y de Innovacion [PI18/00079];
   European Regional Development Fund (ERDF)European Union (EU); Secretaria
   d'Universitats i Recerca del Departament d'Economia i Coneixement
   [2017_SGR_1753]; CERCA Programme/Generalitat de Catalunya; Rio Hortega
   programme of the ISCIII [CM17/00015]
FX This study was sponsored by the Instituto de Salud Carlos III (ISCIII)
   through the Plan Estatal de Investigacion Cientifica y Tecnica y de
   Innovacion grant PI18/00079 (FRF), co-funded by the European Regional
   Development Fund (ERDF). XF also received support by Secretaria
   d'Universitats i Recerca del Departament d'Economia i Coneixement (grant
   2017_SGR_1753) and CERCA Programme/Generalitat de Catalunya. SRT was
   funded by the Rio Hortega programme (fellowship CM17/00015) of the
   ISCIII.
CR Ahn SS, 2018, YONSEI MED J, V59, P452, DOI 10.3349/ymj.2018.59.3.452
   Cai QX, 2020, J HEPATOL, V73, P566, DOI 10.1016/j.jhep.2020.04.006
   Dominguez A, 2001, J MED VIROL, V65, P688, DOI 10.1002/jmv.2091
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Lei F, 2020, HEPATOLOGY, V72, P389, DOI 10.1002/hep.31301
   Loomba R, 2017, GASTROENTEROLOGY, V152, P1297, DOI 10.1053/j.gastro.2017.02.009
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Perrillo RP, 2015, GASTROENTEROLOGY, V148, P221, DOI 10.1053/j.gastro.2014.10.038
   Raimondo G, 2019, J HEPATOL, V71, P397, DOI 10.1016/j.jhep.2019.03.034
   Richardson S, 2020, JAMA-J AM MED ASSOC, V10022, pE1
   Sonneveld MJ, 2019, ACG CASE REP J, V6, DOI 10.14309/crj.0000000000000243
   Terrault NA, 2018, HEPATOLOGY, V67, P1560, DOI 10.1002/hep.29800
   Watanabe T, 2019, INT J RHEUM DIS, V22, P574, DOI 10.1111/1756-185X.13401
   Wong GLH, 2020, J HEPATOL, V72, P57, DOI 10.1016/j.jhep.2019.08.023
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
NR 15
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JAN
PY 2021
VL 28
IS 1
BP 89
EP 94
DI 10.1111/jvh.13410
EA OCT 2020
PG 6
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA PF6EV
UT WOS:000578660400001
PM 32969557
OA Green Published
DA 2021-01-01
ER

PT J
AU Shaban, WM
   Rabie, AH
   Saleh, AI
   Abo-Elsoud, MA
AF Shaban, Warda M.
   Rabie, Asmaa H.
   Saleh, Ahmed, I
   Abo-Elsoud, M. A.
TI A new COVID-19 Patients Detection Strategy (CPDS) based on hybrid
   feature selection and enhanced KNN classifier
SO KNOWLEDGE-BASED SYSTEMS
LA English
DT Article
DE COVID-19; Classification; KNN; Feature selection
ID ALGORITHM
AB COVID-19 infection is growing in a rapid rate. Due to unavailability of specific drugs, early detection of (COVID-19) patients is essential for disease cure and control. There is a vital need to detect the disease at early stage and instantly quarantine the infected people. Many research have been going on, however, none of them introduces satisfactory results yet. In spite of its simplicity, K-Nearest Neighbor (KNN) classifier has proven high flexibility in complex classification problems. However, it can be easily trapped. In this paper, a new COVID-19 diagnose strategy is introduced, which is called COVID-19 Patients Detection Strategy (CPDS). The novelty of CPDS is concentrated in two contributions. The first is a new hybrid feature selection Methodology (HFSM), which elects the most informative features from those extracted from chest Computed Tomography (CT) images for COVID-19 patients and non COVID-19 peoples. HFSM is a hybrid methodology as it combines evidence from both wrapper and filter feature selection methods. It consists of two stages, namely; Fast Selection Stage (FS2) and Accurate Selection Stage (AS(2)). FS2 relies on filter, while AS(2) uses Genetic Algorithm (GA) as a wrapper method. As a hybrid methodology, HFSM elects the significant features for the next detection phase. The second contribution is an enhanced K-Nearest Neighbor (EKNN) classifier, which avoids the trapping problem of the traditional KNN by adding solid heuristics in choosing the neighbors of the tested item. EKNN depends on measuring the degree of both closeness and strength of each neighbor of the tested item, then elects only the qualified neighbors for classification. Accordingly, EKNN can accurately detect infected patients with the minimum time penalty based on those significant features selected by HFSM technique. Extensive experiments have been done considering the proposed detection strategy as well as recent competitive techniques on the chest CT images. Experimental results have shown that the proposed detection strategy outperforms recent techniques as it introduces the maximum accuracy rate. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Shaban, Warda M.] Nile Higher Inst Engn & Technol, Mansoura, Egypt.
   [Rabie, Asmaa H.; Saleh, Ahmed, I] Mansoura Univ, Comp & Control Dept Fac Engn, Mansoura, Egypt.
   [Abo-Elsoud, M. A.] Mansoura Univ, Elect & Commun Dept, Fac Engn, Mansoura, Egypt.
RP Shaban, WM (corresponding author), Nile Higher Inst Engn & Technol, Mansoura, Egypt.
EM warda.mohammed2010@yahoo.com
CR Abualigah L., 2019, STUDIES COMPUTATIONA, P1
   Abualigah LM, 2017, J SUPERCOMPUT, V73, P4773, DOI 10.1007/s11227-017-2046-2
   ALLAM M, 2017, INT J COMPUTER SCI E, V9, P75
   Alyam R., 2017, P 2017 INT C INF HLT
   Ayyad SM, 2019, INT J BIOMATH, V12, DOI 10.1142/S1793524519500396
   Ayyad SM, 2019, BIOSYSTEMS, V176, P41, DOI 10.1016/j.biosystems.2018.12.009
   Barstugan M., ARXIV200309424
   Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]
   Conghy T., 2020, DOES HOSP CAPACITY G
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   De Felice F, 2020, RADIOTHER ONCOL, V147, P84, DOI 10.1016/j.radonc.2020.03.020
   Djellali H, 2016, LECT NOTE NETW SYST, P281, DOI 10.1007/978-3-319-33410-3_20
   Farid A., 2020, INT J SCI ENG RES, P1
   Gayathri G., SMART INTELLIGENT CO, P751
   Gu SK, 2018, SOFT COMPUT, V22, P811, DOI 10.1007/s00500-016-2385-6
   Gupta N, 2019, MEASUREMENT, V140, P590, DOI 10.1016/j.measurement.2019.02.042
   Hemdan E.E.-D., 2020, ARXIV2020200311055
   Jain D., 2019, INT J COMPUT APPL, P1, DOI [10.1080/1206212X.2019.1577534., DOI 10.1080/1206212X.2019.1577534]
   Kanagaraj G, 2020, J SCI IND RES INDIA, V79, P132
   Khare P., 2016, INT J COMPUT SCI INF, V7, P194
   Kong W., 2020, RADIOLOGY, V2, P1
   Li YH, 2017, J INTERDISCIP MATH, V20, P153, DOI 10.1080/09720502.2016.1259769
   Lingayat N. S., 2013, INT J BIOSCIENCE BIO, P624, DOI DOI 10.7763/IJBBB.2013.V3.289
   Mohan G, 2018, BIOMED SIGNAL PROCES, V39, P139, DOI 10.1016/j.bspc.2017.07.007
   Narin A, 2020, ARXIV200310849
   Rabie AH, 2015, INT J MODERN TRENDS, V2, P332
   Raj RJS, 2020, IEEE ACCESS, V8, P58006, DOI 10.1109/ACCESS.2020.2981337
   Rajab KD, 2017, SECUR COMMUN NETW, P1, DOI 10.1155/2017/9838169
   Saleh AI, 2016, ADV ENG INFORM, V30, P422, DOI 10.1016/j.aei.2016.05.005
   Sethy P., 2020, DETECTION CORONAVIRU, P1
   Shah S., 2020, INT J SCI ENG RES, V11, P469
   Shanthi S, 2020, NEURAL PROCESS LETT, DOI 10.1007/s11063-020-10192-0
   Shariaty F., 2019, J PHYS C SER IOP C, P1
   Thamilselvana Sathiaseelan P., 2015, I J ED MANAGEMENT EN, P1, DOI DOI 10.5815/IJEME.2015.02.0
   Thomson MC, 2019, ROU ST ENVIRON HEAL, P1
   Vinutha HP, 2018, ADV INTELL SYST, V672, P442, DOI 10.1007/978-981-10-7512-4_44
   Wang L, 2020, PROCEEDINGS OF THE 18TH USENIX CONFERENCE ON FILE AND STORAGE TECHNOLOGIES, P1
   Zhao J., 2020, ARXIV200313865V1
   Zotin A, 2019, PROCEDIA COMPUT SCI, V159, P1439, DOI 10.1016/j.procs.2019.09.314
NR 39
TC 3
Z9 3
U1 12
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0950-7051
EI 1872-7409
J9 KNOWL-BASED SYST
JI Knowledge-Based Syst.
PD OCT 12
PY 2020
VL 205
AR 106270
DI 10.1016/j.knosys.2020.106270
PG 18
WC Computer Science, Artificial Intelligence
SC Computer Science
GA NK4RT
UT WOS:000566719900009
PM 32834553
OA Green Published
DA 2021-01-01
ER

PT J
AU Dey, KK
   Ghosh, M
AF Dey, Krishna Kishor
   Ghosh, Manasi
TI Understanding the structure and dynamics of anti-inflammatory
   corticosteroid dexamethasone by solid state NMR spectroscopy
SO RSC ADVANCES
LA English
DT Article
ID CHEMICAL-SHIFT-ANISOTROPY; INTERNAL STRUCTURE; CANCER-CHEMOTHERAPY; PLUS
   DEXAMETHASONE; RELAXATION; NAUSEA; EXPRESSION; PREVENTION; SEPARATION;
   SPECTRA
AB For decades corticosteroid dexamethasone has been applied as an anti-inflammatory, immunosuppressant, and decongestant, in the prevention of postoperative nausea and vomiting (PONV), and for auto-immune diseases, allergic reactions, total hip arthroplasty (THA), and cancer. Recentlyin vitrostudies suggested that it may be beneficial to deal with the COVID-19 pandemic. This important drug molecule was investigated by solid state NMR measurements to provide more complete features of its structure and dynamics at atomic scale resolution. The spin-lattice relaxation time at twenty-two different carbon sites of dexamethasone was determined by the Torchia CP method. The principle components of the chemical shift anisotropy tensor were determined by(13)C two-dimensional phase adjusted spinning sideband (2DPASS) cross-polarization magic angle spinning (CP-MAS) solid state NMR experiments. The molecular correlation time at twenty-two crystallographically different carbon sites of dexamethasone was calculated by considering that the spin-lattice relaxation mechanism of the(13)C nucleus is mainly governed by the chemical shift anisotropy interaction and the heteronuclear dipole-dipole coupling. The spin-lattice relaxation time of carbon nuclei resides on 'A', 'B', 'C', and 'D' rings and the side-chain of dexamethasone is quite large, which implies the close-packed arrangement of the molecule. The difference in molecular correlation time at various regions of the molecule demonstrates the existence of different degrees of freedom within the molecule. This may be the reason for the various biological activities exhibited by the molecule. These types of detailed features of the structure and dynamics of such an important drug with multiple biological activities are necessary to develop the advanced medicine and it will also help to understand the structure-activity relationships of corticosteroid.
C1 [Dey, Krishna Kishor] Dr Harisingh Gour Cent Univ, Dept Phys, Sagar 470003, Madhya Pradesh, India.
   [Ghosh, Manasi] Banaras Hindu Univ, MMV, Phys Sect, Varanasi 221005, Uttar Pradesh, India.
RP Ghosh, M (corresponding author), Banaras Hindu Univ, MMV, Phys Sect, Varanasi 221005, Uttar Pradesh, India.
EM manasi.ghosh@bhu.ac.in
RI Ghosh, Manasi/ABH-7221-2020
OI Ghosh, Manasi/0000-0002-8472-0288; Dey, Krishna
   Kishor/0000-0002-8056-9357
FU Science and Engineering Research Board (SERB), Department of Science and
   Technology (DST), government of India [EMR/2016/000249]; UGC-BSR
   [30-12/2014(BSR)]
FX The authors are indebted to Science and Engineering Research Board
   (SERB), Department of Science and Technology (DST), government of India
   (File no. EMR/2016/000249), and UGC-BSR (File no. 30-12/2014(BSR)) for
   financial support. We are also grateful to Sophisticated Instrumentation
   Centre (SIC) of Dr Hari Singh Gour Central University for providing high
   resolution solid state NMR facility.
CR ANTZUTKIN ON, 1995, J MAGN RESON SER A, V115, P7, DOI 10.1006/jmra.1995.1142
   BAX A, 1983, J MAGN RESON, V52, P147, DOI 10.1016/0022-2364(83)90267-6
   BAX A, 1983, J MAGN RESON, V55, P494, DOI 10.1016/0022-2364(83)90134-8
   BAX A, 1983, J MAGN RESON, V51, P400, DOI 10.1016/0022-2364(83)90292-5
   BETTINI V, 1978, Bollettino Societa Italiana Biologia Sperimentale, V54, P2191
   Bordag N, 2015, SCI REP-UK, V5, DOI 10.1038/srep15954
   Chan JCC, 2003, J CHEM PHYS, V118, P8378, DOI 10.1063/1.1565109
   Clark JA, 2008, MOL PSYCHIATR, V13, P498, DOI 10.1038/sj.mp.4002041
   Dais P, 1995, PROG NUCL MAG RES SP, V27, P555, DOI 10.1016/0079-6565(95)01014-9
   Dey KK, 2020, RSC ADV, V10, P4310, DOI 10.1039/c9ra09866f
   Dey KK, 2020, CHEM PHYS LETT, V738, DOI 10.1016/j.cplett.2019.136782
   Dey KK, 2019, ACS OMEGA, V4, P21627, DOI 10.1021/acsomega.9b03558
   DIXON WT, 1982, J CHEM PHYS, V77, P1800, DOI 10.1063/1.444076
   Duax W L, 1976, Recent Prog Horm Res, V32, P81
   Fayon F, 1999, J MAGN RESON, V137, P116, DOI 10.1006/jmre.1998.1641
   FREDRIKSON M, 1992, BRIT J CANCER, V65, P779, DOI 10.1038/bjc.1992.165
   GAN ZH, 1992, J AM CHEM SOC, V114, P8307, DOI 10.1021/ja00047a062
   Geer EB, 2014, ENDOCRIN METAB CLIN, V43, P75, DOI 10.1016/j.ecl.2013.10.005
   Ghosh M, 2020, RSC ADV, V10, P24973, DOI 10.1039/d0ra03772a
   Ghosh M, 2019, J BIOMOL NMR, V73, P601, DOI 10.1007/s10858-019-00272-2
   Ghosh M, 2019, SOLID STATE NUCL MAG, V101, P1, DOI 10.1016/j.ssnmr.2019.04.007
   Ghosh M, 2019, SOLID STATE NUCL MAG, V97, P7, DOI 10.1016/j.ssnmr.2018.11.001
   Glatz K, 2003, J NEUROCHEM, V86, P1072, DOI 10.1046/j.1471-4159.2003.01944.x
   Goldstein A., 1971, PRINCIPLES DRUG ACTI, P206
   Halpin DMG, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01009-2020
   HARRIS AL, 1982, LANCET, V1, P714
   Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038
   HERZFELD J, 1980, J CHEM PHYS, V73, P6021, DOI 10.1063/1.440136
   Hou GJ, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4754149
   KRIS MG, 1989, J CLIN ONCOL, V7, P108, DOI 10.1200/JCO.1989.7.1.108
   Liu SF, 2002, J MAGN RESON, V155, P15, DOI 10.1006/jmre.2002.2503
   MCCONNELL HM, 1957, J CHEM PHYS, V27, P226, DOI 10.1063/1.1743676
   Ni Chonghaile T, 2006, APOPTOSIS, V11, P1247, DOI 10.1007/s10495-006-7233-1
   Nicholas MP, 2010, PROG NUCL MAG RES SP, V57, P111, DOI 10.1016/j.pnmrs.2010.04.003
   Orendt AM, 2007, ANNU REP NMR SPECTRO, V62, P115, DOI 10.1016/S0066-4103(07)62003-1
   PARVEZ H, 1972, EXPERIENTIA, V28, P1330, DOI 10.1007/BF01965327
   Perez EA, 1998, CANCER J SCI AM, V4, P72
   RICH WM, 1980, GYNECOL ONCOL, V9, P193, DOI 10.1016/0090-8258(80)90027-X
   SAGAR SM, 1991, CANCER TREAT REV, V18, P95, DOI 10.1016/0305-7372(91)90009-O
   Simpson JH, 2017, NMR CASE STUDIES: DATA ANALYSIS OF COMPLICATED MOLECULES, P1
   SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4
   TERZIS A, 1976, J PHARM SCI, V65, P1092, DOI 10.1002/jps.2600650740
   Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m
   TORCHIA DA, 1978, J MAGN RESON, V30, P613, DOI 10.1016/0022-2364(78)90288-3
   TYCKO R, 1989, J MAGN RESON, V85, P265, DOI 10.1016/0022-2364(89)90142-X
   Uen YH, 2008, INT J ONCOL, V33, P1263, DOI 10.3892/ijo_00000117
   Valente EJ, 1997, J CHEM CRYSTALLOGR, V27, P219, DOI 10.1007/BF02575958
   Walder BJ, 2013, J CHEM PHYS, V138, DOI 10.1063/1.4803142
   WEEKS CM, 1973, J AM CHEM SOC, V95, P2865, DOI 10.1021/ja00790a021
   Weller M, 1997, NEUROLOGY, V48, P1704, DOI 10.1212/WNL.48.6.1704
   YOUDIM MBH, 1989, FASEB J, V3, P1753
   YOUNG SN, 1981, BRIT J PHARMACOL, V74, P695, DOI 10.1111/j.1476-5381.1981.tb10480.x
   Zheng-rui F., 2018, SYSTEMATIC REV META, V97, P1
NR 53
TC 0
Z9 0
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD OCT 11
PY 2020
VL 10
IS 61
BP 37564
EP 37575
DI 10.1039/d0ra05474g
PG 12
WC Chemistry, Multidisciplinary
SC Chemistry
GA OB8PT
UT WOS:000578727600063
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Benkeser, D
   Diaz, I
   Luedtke, A
   Segal, J
   Scharfstein, D
   Rosenblum, M
AF Benkeser, David
   Diaz, Ivan
   Luedtke, Alex
   Segal, Jodi
   Scharfstein, Daniel
   Rosenblum, Michael
TI Improving precision and power in randomized trials for COVID-19
   treatments using covariate adjustment, for binary, ordinal, and
   time-to-event outcomes
SO BIOMETRICS
LA English
DT Article; Early Access
DE covariate adjustment; COVID-19; ordinal outcomes; randomized trial;
   survival analysis
ID CLINICAL-TRIALS; EFFICIENCY; REGRESSION; DIFFERENCE; SURVIVAL
AB Time is of the essence in evaluating potential drugs and biologics for the treatment and prevention of COVID-19. There are currently 876 randomized clinical trials (phase 2 and 3) of treatments for COVID-19 registered on clinicaltrials.gov. Covariate adjustment is a statistical analysis method with potential to improve precision and reduce the required sample size for a substantial number of these trials. Though covariate adjustment is recommended by the U.S. Food and Drug Administration and the European Medicines Agency, it is underutilized, especially for the types of outcomes (binary, ordinal, and time-to-event) that are common in COVID-19 trials. To demonstrate the potential value added by covariate adjustment in this context, we simulated two-arm, randomized trials comparing a hypothetical COVID-19 treatment versus standard of care, where the primary outcome is binary, ordinal, or time-to-event. Our simulated distributions are derived from two sources: longitudinal data on over 500 patients hospitalized at Weill Cornell Medicine New York Presbyterian Hospital and a Centers for Disease Control and Prevention preliminary description of 2449 cases. In simulated trials with sample sizes ranging from 100 to 1000 participants, we found substantial precision gains from using covariate adjustment-equivalent to 4-18% reductions in the required sample size to achieve a desired power. This was the case for a variety of estimands (targets of inference). From these simulations, we conclude that covariate adjustment is a low-risk, high-reward approach to streamlining COVID-19 treatment trials. We provide anRpackage and practical recommendations for implementation.
C1 [Benkeser, David] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA.
   [Diaz, Ivan] Weill Cornell Med, Div Biostat, Dept Populat Hlth Sci, New York, NY USA.
   [Luedtke, Alex] Univ Washington, Dept Stat, Seattle, WA 98195 USA.
   [Luedtke, Alex] Univ Washington, Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98195 USA.
   [Segal, Jodi] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Scharfstein, Daniel] Univ Utah, Sch Med, Dept Populat Hlth Sci, Div Biostat, Salt Lake City, UT USA.
   [Rosenblum, Michael] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA.
RP Rosenblum, M (corresponding author), Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA.
EM mrosen@jhu.edu
OI Benkeser, David/0000-0002-1019-8343
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [DP2-LM013340]; U.S.
   Food and Drug Administration [U01FD005942]
FX National Institutes of Health, Grant/Award Number: DP2-LM013340; U.S.
   Food and Drug Administration, Grant/Award Number: U01FD005942
CR Austin PC, 2010, J CLIN EPIDEMIOL, V63, P142, DOI 10.1016/j.jclinepi.2009.06.002
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Benkeser D., 2020, IMPROVING PRECISION, DOI DOI 10.1101/2020.04.19.20069922V1?VERSI0NED=TRUE
   Benkeser D, 2019, J AM STAT ASSOC, V114, P1038, DOI 10.1080/01621459.2018.1529594
   Benkeser D, 2018, STAT MED, V37, P280, DOI 10.1002/sim.7337
   Bloniarz A, 2016, P NATL ACAD SCI USA, V113, P7383, DOI 10.1073/pnas.1510506113
   Brooks JC, 2013, J CAUSAL INFERENCE, V1, P235, DOI 10.1515/jci-2013-0001
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chaisinanunkul N, 2015, STROKE, V46, P2238, DOI 10.1161/STROKEAHA.114.008547
   Chen PY, 2001, BIOMETRICS, V57, P1030, DOI 10.1111/j.0006-341X.2001.01030.x
   Diaz I, 2019, LIFETIME DATA ANAL, V25, P439, DOI 10.1007/s10985-018-9428-5
   Diaz I, 2016, BIOMETRICS, V72, P422, DOI 10.1111/biom.12450
   Efron B., 1994, INTRO BOOTSTRAP
   European Medicines Agency (EMA), 2015, EMACHMP2950502013
   Fang R, 2019, ORG PREP PROCED INT, V51, P381, DOI 10.1080/00304948.2019.1615362
   FDA, 2019, ADJ COV RAND CLIN TR
   FDA and EMA, 1998, CPMPICH36396 FDA EMA
   Food and Drug Administration (FDA), 2020, COVID 19 DEV DRUGS B
   Ge MM, 2011, DRUG INF J, V45, P481, DOI 10.1177/009286151104500409
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Jennison C, 1997, J AM STAT ASSOC, V92, P1330
   Jennison C., 1999, GROUP SEQUENTIAL MET
   Jiang F, 2019, J AM STAT ASSOC, V114, P1854, DOI 10.1080/01621459.2018.1527226
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Lu XM, 2011, LIFETIME DATA ANAL, V17, P566, DOI 10.1007/s10985-011-9199-8
   MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109
   Moore KL, 2009, J BIOPHARM STAT, V19, P1099, DOI 10.1080/10543400903243017
   Moore KL, 2009, STAT MED, V28, P39, DOI 10.1002/sim.3445
   Moore KL, 2011, STAT MED, V30, P2389, DOI 10.1002/sim.4301
   National Research Council, 2010, PREV TREATM MISS DAT
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Parast L, 2014, J AM STAT ASSOC, V109, P384, DOI 10.1080/01621459.2013.842488
   Qian T., 2016, J HOPKINS U DEP BIOS
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Royston P, 2011, STAT MED, V30, P2409, DOI 10.1002/sim.4274
   Rubin D., 2008, UC BERKELEY DIVISION
   Rubin Daniel B., 2008, INT J BIOSTAT, V4, P5, DOI [10.2202/1557-4679.1084, DOI 10.2202/1557-4679.1084]
   Scharfstein DO, 1997, J AM STAT ASSOC, V92, P1342, DOI 10.2307/2965404
   Scharfstein DO, 1999, J AM STAT ASSOC, V94, P1096, DOI 10.2307/2669923
   Stitelman OM, 2012, INT J BIOSTAT, V8, DOI 10.1515/1557-4679.1334
   Tian L, 2019, STAT MED, V38, P917, DOI 10.1002/sim.8015
   Tsiatis AA, 2008, STAT MED, V27, P4658, DOI 10.1002/sim.3113
   van der Vaart A.W., 1998, CAMBRIDGE SERIES STA, DOI DOI 10.1017/CBO9780511802256
   Vermeulen K, 2015, STAT MED, V34, P1012, DOI 10.1002/sim.6386
   Wager S, 2016, P NATL ACAD SCI USA, V113, P12673, DOI 10.1073/pnas.1614732113
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Yang L, 2001, AM STAT, V55, P314, DOI 10.1198/000313001753272466
   Zhang M, 2010, STAT COMMUNICATIONS, V2, P1, DOI [DOI 10.2202/1948-4690.1002, 10.2202/1948-4690.1002]
   Zhang M, 2008, BIOMETRICS, V64, P707, DOI 10.1111/j.1541-0420.2007.00976.x
   Zhang YY, 2014, J ATHEROSCLER THROMB, V21, P119, DOI 10.5551/jat.19174
NR 50
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-341X
EI 1541-0420
J9 BIOMETRICS
JI Biometrics
DI 10.1111/biom.13377
EA OCT 2020
PG 15
WC Biology; Mathematical & Computational Biology; Statistics & Probability
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology; Mathematics
GA NY7WN
UT WOS:000576594700001
PM 32978962
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Aranda-Abreu, GE
   Aranda-Martinez, JD
   Araujo, R
   Hernandez-Aguilar, ME
   Herrera-Covarrubias, D
   Rojas-Duran, F
AF Aranda-Abreu, Gonzalo Emiliano
   Aranda-Martinez, Jose D.
   Araujo, Ramiro
   Hernandez-Aguilar, Maria Elena
   Herrera-Covarrubias, Deissy
   Rojas-Duran, Fausto
TI Observational study of people infected with SARS-Cov-2, treated with
   amantadine
SO PHARMACOLOGICAL REPORTS
LA English
DT Article
DE Amantadine; SARS-cov-2; Celecoxib; Azithromycin
AB Background We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine. Methodology In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infection, which were treated on an ambulatory basis with 100 mg of amantadine for a period of 14 days. Results This drug demonstrated its effectiveness, as patients recovered successfully with this treatment without the necessity of attending a hospital to use mechanical ventilation. All patients developed IgG antibodies to SARS-Cov-2. Conclusion Amantadine can be used as a viable and cost-effective alternative for treating people with severe acute respiratory syndrome (SARS-Cov-2) on an ambulatory basis, while the vaccine is not available.
C1 [Aranda-Abreu, Gonzalo Emiliano; Hernandez-Aguilar, Maria Elena; Herrera-Covarrubias, Deissy; Rojas-Duran, Fausto] Univ Veracruzana, Ctr Invest Cerebrales, Xalapa, Veracruz, Mexico.
   [Aranda-Martinez, Jose D.] Ctr Med Cordobes, Cordoba, Veracruz, Mexico.
   [Araujo, Ramiro] Hosp Da Lapa, Porto, Portugal.
RP Aranda-Abreu, GE (corresponding author), Univ Veracruzana, Ctr Invest Cerebrales, Xalapa, Veracruz, Mexico.
EM garanda@uv.mx; g_aranda@hotmail.com; ramirogeraldesaraujo@hotmail.com;
   elenahernandez@uv.mx; dherrera@uv.mx; frojas@uv.mx
RI Herrera-Covarrubias, Deissy/K-1418-2017
OI Herrera-Covarrubias, Deissy/0000-0001-5752-4700
CR Al-Rashed F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24548-z
   Abreu GEA, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109755
   Aranda-Abreu GE, 2020, J MED VIROL, DOI 10.1002/jmv.26179
   Araujo Ramiro, 2020, Arch Med Res, V51, P739, DOI 10.1016/j.arcmed.2020.06.009
   Barth RF, 2020, DIAGN PATHOL, V15, DOI 10.1186/s13000-020-00999-9
   Borra AC, 2020, NEUROL NEUROCHIR POL, V54, P284, DOI 10.5603/PJNNS.a2020.0041
   Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005
   Duwe S, 2017, GMS INFECT DIS, V5
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Marik PE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143252
   McKimm-Breschkin JL, 2016, ANTIVIR RES, V129, P21, DOI 10.1016/j.antiviral.2016.01.012
   Meyer M, 2009, AM J RESP CELL MOL, V41, P590, DOI 10.1165/rcmb.2008-0155OC
   NISAR T, 2019, LANCET NEUROL, V18, P1080
   Rascol O, 2020, DRUG AGING, V37, P215, DOI 10.1007/s40266-019-00740-2
   Rejdak K, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102163
   Roser M, 2020, CORONAVIRUS DIS COVI
   Schmith VD, 2020, CLIN PHARMACOL THER, V108, P762, DOI 10.1002/cpt.1889
   US Food and Drug Administration, 2020, COR COVID 19 UPD FDA
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008
   Welte T, 2019, AM J RESP CRIT CARE, V200, P269, DOI 10.1164/rccm.201903-0706ED
   Wolkove N, 2002, CHEST, V121, P702, DOI 10.1378/chest.121.3.702
NR 21
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1734-1140
EI 2299-5684
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD DEC
PY 2020
VL 72
IS 6
SI SI
BP 1538
EP 1541
DI 10.1007/s43440-020-00168-1
EA OCT 2020
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ3OU
UT WOS:000581965600001
PM 33040252
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Smith, E
   Davis-Gardner, ME
   Garcia-Ordonez, RD
   Nguyen, TT
   Hull, M
   Chen, E
   Baillargeon, P
   Scampavia, L
   Strutzenberg, T
   Griffin, PR
   Farzan, M
   Spicer, TP
AF Smith, Emery
   Davis-Gardner, Meredith E.
   Garcia-Ordonez, Ruben D.
   Nguyen, Tu-Trinh
   Hull, Mitchell
   Chen, Emily
   Baillargeon, Pierre
   Scampavia, Louis
   Strutzenberg, Timothy
   Griffin, Patrick R.
   Farzan, Michael
   Spicer, Timothy P.
TI High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in
   SARS-CoV-2
SO SLAS DISCOVERY
LA English
DT Article
DE COVID-19; HTS; PLpro; cell-based
AB The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 has triggered an ongoing global pandemic whereby infection may result in a lethal severe pneumonia-like disease designated as coronavirus disease 2019 (COVID-19). To date, millions of confirmed cases and hundreds of thousands of deaths have been reported worldwide, and there are currently no medical countermeasures available to prevent or treat the disease. The purported development of a vaccine could require at least 1-4 years, while the typical timeline from hit finding to drug registration of an antiviral is >10 years. Thus, repositioning of known drugs can significantly accelerate the development and deployment of therapies for COVID-19. To identify therapeutics that can be repurposed as SARS-CoV-2 antivirals, we developed and initiated a high-throughput cell-based screen that incorporates the essential viral papain-like protease (PLpro) and its peptide cleavage site into a luciferase complementation assay to evaluate the efficacy of known drugs encompassing approximately 15,000 clinical-stage or US Food and Drug Administration (FDA)-approved small molecules. Confirmed inhibitors were also tested to determine their cytotoxic properties. Here, we report the identification of four clinically relevant drugs that exhibit selective inhibition of the SARS-CoV-2 viral PLpro.
C1 [Smith, Emery; Garcia-Ordonez, Ruben D.; Baillargeon, Pierre; Scampavia, Louis; Strutzenberg, Timothy; Griffin, Patrick R.; Spicer, Timothy P.] Scripps Florida, Scripps Res Inst, Dept Mol Med, 130 Scripps Way, Jupiter, FL 33458 USA.
   [Davis-Gardner, Meredith E.; Farzan, Michael] Scripps Florida, Scripps Res Inst, Immunol & Microbiol, Jupiter, FL USA.
   [Nguyen, Tu-Trinh; Hull, Mitchell; Chen, Emily] Calibr Scripps Res, La Jolla, CA USA.
RP Spicer, TP (corresponding author), Scripps Florida, Scripps Res Inst, Dept Mol Med, 130 Scripps Way, Jupiter, FL 33458 USA.
EM spicert@scripps.edu
RI Baillargeon, Pierre/C-3000-2018
OI Baillargeon, Pierre/0000-0003-4431-1372; Davis Gardner,
   Meredith/0000-0002-6133-3613; Hull, Mitchell/0000-0002-9364-1901
CR Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Beigel J. H., 2020, N ENGL J MED
   Deng Y, 2020, J VIROL, V94, DOI 10.1128/JVI.02161-19
   Freitas BT, 2020, ACS INFECT DIS, V6, P2099, DOI 10.1021/acsinfecdis.0c00168
   Fu Z., STRUCTURAL BASIS INH, DOI [10.1101/2020.07.17.208959, DOI 10.1101/2020.07.17.208959]
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Janes J, 2018, P NATL ACAD SCI USA, V115, P10750, DOI 10.1073/pnas.1810137115
   Klemm T., MECH INHIBITION SARS, DOI [10.1101/2020.06.18.160614, DOI 10.1101/2020.06.18.160614]
   Mielech AM, 2014, VIRUS RES, V194, P184, DOI 10.1016/j.virusres.2014.01.025
   Moustaqil M. Ollivier E. Chiu H.-P., SARS COV 2 PROTEASES, DOI [10.1101/2020.06.05.135699, DOI 10.1101/2020.06.05.135699]
   Pruijssers AJ, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107940
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Shin MD, 2020, NAT NANOTECHNOL, V15, P646, DOI 10.1038/s41565-020-0737-y
   Steger K, 2015, J BIOMOL SCREEN, V20, P545, DOI 10.1177/1087057114563494
   Swaim Caleb D, 2020, bioRxiv, DOI 10.1101/2020.07.01.183020
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zhou JW, 2019, FASEB J, V33, P14575, DOI 10.1096/fj.201901624RR
   Zhou JW, 2017, BIOCHEM BIOPH RES CO, V488, P621, DOI 10.1016/j.bbrc.2017.05.063
NR 23
TC 0
Z9 0
U1 4
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2472-5552
EI 2472-5560
J9 SLAS DISCOV
JI SLAS Discov.
PD DEC
PY 2020
VL 25
IS 10
SI SI
BP 1152
EP 1161
AR 2472555220963667
DI 10.1177/2472555220963667
EA OCT 2020
PG 10
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry
GA OT8JK
UT WOS:000581794100001
PM 33043784
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Azar, M
   Shin, JJ
   Kang, I
   Landry, M
AF Azar, Marwan
   Shin, Junghee J.
   Kang, Insoo
   Landry, Marie
TI Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release
   syndrome
SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
LA English
DT Article
DE SARS-CoV-2; cytokine-release syndrome; COVID-19; cytokines; diagnosis;
   RNA; sensitivity
ID MONOCLONAL-ANTIBODY; CELLS; STORM; IDENTIFICATION; INVOLVEMENT;
   BIOMARKERS; CHEMOKINES; COVID-19; THERAPY; IMMUNE
AB Introduction Coronavirus disease (COVID-19) can trigger a cytokine response storm (CRS) that is associated with high mortality but for which the underlying pathophysiology and diagnostics are not yet well characterized. This review provides an overview of the underlying immune profile of COVID-19-related CRS as well as laboratory markers for acute diagnosis and chronic follow-up of patients with SARS-CoV-2 and CRS. Areas covered Innate and acquired immune profiles in COVID-19-CRS, RNA-detection methods for SARS-CoV-2 in the setting of CRS including factors that affect assay performance, serology for SARS-CoV-2 in the setting of CRS, and other biomarkers for COVID-19 will be discussed. Expert opinion Studies support the implication of CRS in the pathogenesis, clinical severity and outcome of COVID-19 through the production of multiple inflammatory cytokines and chemokines from activated innate and adaptive immune cells. Although these inflammatory molecules, including IL-6, IL-2 R, IL-10, IP-10 and MCP-1, often correlate with disease severity as possible biomarkers, the pathogenic contributions of individual molecules and the therapeutic benefits of targeting them are yet to be demonstrated. Detection of SARS-CoV-2 RNA is the gold standard method for diagnosis of COVID-19 in the context of CRS but assay performance varies and is susceptible to false-negative results even as patients clinically deteriorate due to decreased viral shedding in the setting of CRS. Biomarkers including CRP, ferritin, D-dimer and procalcitonin may provide early clues about progression to CRS and help identify thrombotic and infectious complications of COVID-19.
C1 [Azar, Marwan; Landry, Marie] Yale Sch Med, Dept Internal Med, Sect Infect Dis, New Haven, CT 06510 USA.
   [Shin, Junghee J.; Kang, Insoo] Yale Sch Med, Dept Internal Med, Sect Rheumatol Allergy & Immunol, New Haven, CT 06510 USA.
   [Landry, Marie] Yale Sch Med, Dept Lab Med, New Haven, CT 06510 USA.
RP Azar, M (corresponding author), Yale Sch Med, Dept Internal Med, Sect Infect Dis, New Haven, CT 06510 USA.
EM marwan.azar@yale.edu
CR Alexandra N, 2020, IL 13 PREDICTS NEED
   Artesi M, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01598-20
   Aue G, 2009, HAEMATOL-HEMATOL J, V94, P1266, DOI 10.3324/haematol.2009.005835
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Behrens EM, 2017, ARTHRITIS RHEUMATOL, V69, P6, DOI 10.1002/art.39934
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bullard Jared, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa638
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   CHATENOUD L, 1989, NEW ENGL J MED, V320, P1420
   Chau AS, 2020, ARTHRITIS RHEUMATOL, DOI 10.1002/art.41526
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen X, 2020, CLIN INFECT DIS, DOI 10.1093/cid/ciaa449
   Cho C, 2016, BONE MARROW TRANSPL, V51, P1620, DOI 10.1038/bmt.2016.229
   Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   de Vos S, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-44
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680
   Freeman CL, 2015, BLOOD, V126, P2646, DOI 10.1182/blood-2015-09-670802
   Fry TJ, 2005, J IMMUNOL, V174, P6571, DOI 10.4049/jimmunol.174.11.6571
   Ge HP, 2020, EUR J CLIN MICROBIOL, V39, P1011, DOI 10.1007/s10096-020-03874-z
   Goetz L, 2020, J APPL LAB MED, V5, P1401, DOI 10.1093/jalm/jfaa137
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Han H, 2020, EMERG MICROBES INFEC, V9, P1123, DOI 10.1080/22221751.2020.1770129
   Hanson Kimberly E, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1343
   Hashimoto S, 2001, J ALLERGY CLIN IMMUN, V107, P1001, DOI 10.1067/mai.2001.114702
   Hay KA, 2017, BLOOD, V130, P2295, DOI 10.1182/blood-2017-06-793141
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hou W, 2020, INFECT DIS-NOR, V52, P498, DOI 10.1080/23744235.2020.1759817
   Huang C., 2020, LANCET, V15, P395
   Jamal Alainna J, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa848
   Ji D, 2020, CLIN INFECT DIS, V71, P1393, DOI 10.1093/cid/ciaa414
   Kim KD, 2007, NAT MED, V13, P1248, DOI 10.1038/nm1633
   Kimmig LM, 2020, IL6 INHIBITION CRITI
   Kishimoto T, 2010, INT IMMUNOL, V22, P347, DOI 10.1093/intimm/dxq030
   KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0
   La Scola B, 2020, EUR J CLIN MICROBIOL, V39, P1059, DOI 10.1007/s10096-020-03913-9
   Lang VR, 2012, RHEUMATOLOGY, V51, P852, DOI 10.1093/rheumatology/ker223
   Lee N, 2012, J GERONTOL A-BIOL, V67, P254, DOI 10.1093/gerona/glr237
   Lee Seungjae, 2020, JAMA Intern Med, DOI 10.1001/jamainternmed.2020.3862
   Lee WW, 2010, BLOOD, V115, P530, DOI 10.1182/blood-2009-08-236521
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Lippi G, 2020, CLIN CHIM ACTA, V505, P190, DOI 10.1016/j.cca.2020.03.004
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1070, DOI 10.1515/cclm-2020-0285
   Lippi G, 2018, CLIN CHEM LAB MED, V56, P1660, DOI 10.1515/cclm-2017-0277
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511
   MATTHYS P, 1993, EUR J IMMUNOL, V23, P2209, DOI 10.1002/eji.1830230924
   McCulloch DJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.16382
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Murthy H, 2019, IMMUNOTARGETS THER, V8, P43, DOI 10.2147/ITT.S202015
   Palm NW, 2007, NAT MED, V13, P1142, DOI 10.1038/nm1007-1142b
   Pasomsub E, 2020, CLIN MICROBIOL INFEC
   Pawar A, 2019, ANN RHEUM DIS, V78, P456, DOI 10.1136/annrheumdis-2018-214367
   Pfister R, 2014, CRIT CARE, V18, DOI 10.1186/cc13760
   Pihusch R, 2002, BONE MARROW TRANSPL, V30, P347, DOI 10.1038/sj.bmt.1703640
   Price CC, 2020, CHEST, V158, P1397, DOI 10.1016/j.chest.2020.06.006
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ragab D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01446
   Rojas JM, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/6104054
   Rotz SJ, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26642
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529
   Sethi G, 2008, FRONT BIOSCI-LANDMRK, V13, P5094, DOI 10.2741/3066
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842
   Tan CC, 2020, J MED VIROL, V92, P856, DOI 10.1002/jmv.25871
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tu YP, 2020, NEW ENGL J MED, V383, P494, DOI 10.1056/NEJMc2016321
   Vogels CBF, 2020, NAT MICROBIOL, V5, P1299, DOI 10.1038/s41564-020-0761-6
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wei LL, 2020, J MED VIROL, V92, P2768, DOI 10.1002/jmv.26181
   Wing MG, 1996, J CLIN INVEST, V98, P2819, DOI 10.1172/JCI119110
   Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224
   Winthrop KL, 2020, ARTHRITIS RHEUMATOL, V72, P874, DOI 10.1002/art.41260
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Xiao AT, 2020, J INFECTION, V81, P174, DOI 10.1016/j.jinf.2020.03.012
   XIAO AT, 2020, J MED VIROL 0711, DOI DOI 10.1093/cid/ciaa460
   Yang Y, 2020, J ALLERGY CLIN IMMUN, V146, P119, DOI 10.1016/j.jaci.2020.04.027
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang LD, 2020, IRAN J BIOTECHNOL, V18, P6, DOI 10.30498/IJB.2020.127412.2244
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zheng S, 2020, BMJ-BRIT MED J, V2020, P369
   Zhou YD, 2020, MAR BIODIVERS, V50, DOI 10.1007/s12526-019-01034-x
   Zhou YJ, 2016, RSC ADV, V6, P40010, DOI 10.1039/c6ra04150g
   Zhu L, 2020, EUR UROL, V77, P748, DOI 10.1016/j.eururo.2020.03.039
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou L, 2020, N ENGL J MED, V382, pXXX
NR 96
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 1473-7159
EI 1744-8352
J9 EXPERT REV MOL DIAGN
JI Expert Rev. Mol. Diagn.
PD NOV 1
PY 2020
VL 20
IS 11
BP 1087
EP 1097
DI 10.1080/14737159.2020.1830760
EA OCT 2020
PG 11
WC Pathology
SC Pathology
GA PB6KD
UT WOS:000579145500001
PM 32990479
OA Bronze
DA 2021-01-01
ER

PT J
AU Fedele, P
   Ferro, A
   Sanna, V
   La Verde, N
   Paris, I
   Chiari, R
AF Fedele, Palma
   Ferro, Antonella
   Sanna, Valeria
   La Verde, Nicla
   Paris, Ida
   Chiari, Rita
TI Exploring metastatic breast cancer treatment changes during COVID-19
   pandemic
SO JOURNAL OF CHEMOTHERAPY
LA English
DT Article; Early Access
DE Metastatic breast cancer; COVID-19 pandemic; endocrine therapy;
   chemotherapy; antiHer2 agents; elderly patients
AB The emergency caused by COVID-19 pandemic has imposed a sudden reorganization of the healthcare structures and has created consequences in cancer patients management. General clinical recommendations for cancer patients were released, even if limited clinical cancer-specific data were available. A number of critical issues have come out during COVID-19 pandemic in the management of patients with metastatic breast cancer (MBC). To explore the changes in the treatment of patients with MBC during COVID-19 pandemic, we promoted a survey to the oncologists operating in the Italian breast units. The results of this survey show that Italian oncologists have tried to ensure continuity of care for patients with MBC. De-escalation of cancer treatments, especially monotherapy administration, and greater use of oral anticancer drugs are the main changes that emerge from this survey. Some subgroups of patients, especially the elderly and endocrine-responsive patients, have been undertreated during the COVID-19 pandemic.
C1 [Fedele, Palma] D Camberlingo Hosp, UOC Oncol, Francavilla Fontana, Brindisi, Italy.
   [Ferro, Antonella] Santa Chiara Hosp, Breast Ctr, Trento, Italy.
   [Sanna, Valeria] Hosp Sassari, Med Oncol, Sassari, Italy.
   [La Verde, Nicla] ASST Fatebenefratelli Sacco, Luigi Sacco Hosp, Dept Oncol, Milan, Italy.
   [Paris, Ida] Fdn Policlin Univ A Gemelli IRCCS, Dept Woman & Child Hlth & Publ Hlth, Div Gynecol Oncol, Rome, Italy.
   [Chiari, Rita] AULSS6 Euganea, Ospedali Riuniti Padova Sud, UOC Oncol, Padua, Italy.
RP Fedele, P (corresponding author), Med Oncol D Camberlingo Hosp, Francavilla Fontana, Brindisi, Italy.
EM minafedele@hotmail.com
RI la verde, nicla/AAW-9398-2020; Ferro, Antonella/AAA-8241-2020
OI la verde, nicla/0000-0002-2884-1632; Ferro,
   Antonella/0000-0003-4109-6769
CR Carrick S, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003372.pub2
   Curigliano G, 2020, BREAST, V52, P8, DOI 10.1016/j.breast.2020.04.006
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Luo XJ, 2016, DIABETES-METAB RES, V32, P11
   Mestres JA, 2017, CLIN TRANSL ONCOL, V19, P149, DOI 10.1007/s12094-016-1520-2
   Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615
   Slamon DJ, 2020, NEW ENGL J MED, V382, P514, DOI 10.1056/NEJMoa1911149
   Sledge GW, 2020, JAMA ONCOL, V6, P116, DOI 10.1001/jamaoncol.2019.4782
   Thill M, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918793326
   Vuagnat P, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01293-8
   Wang ZJ, 2020, JAMA ONCOL, V6, P631, DOI 10.1001/jamaoncol.2020.1198
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 12
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1120-009X
EI 1973-9478
J9 J CHEMOTHERAPY
JI J. Chemother.
DI 10.1080/1120009X.2020.1829328
EA OCT 2020
PG 6
WC Oncology; Infectious Diseases; Pathology; Pharmacology & Pharmacy
SC Oncology; Infectious Diseases; Pathology; Pharmacology & Pharmacy
GA OB7VW
UT WOS:000578675900001
PM 33047649
OA Bronze
DA 2021-01-01
ER

PT J
AU Li, T
   Sun, LF
   Zhang, WW
   Zheng, CF
   Jiang, CC
   Chen, MJ
   Chen, D
   Dai, ZJ
   Bao, SH
   Shen, X
AF Li, Ting
   Sun, Laifang
   Zhang, Wenwu
   Zheng, Chanfan
   Jiang, Chenchen
   Chen, Mingjing
   Chen, Di
   Dai, Zhijuan
   Bao, Shihui
   Shen, Xian
TI Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19:
   An Open-Label Randomized Controlled Pilot Study
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
ID TMPRSS2; SARS-COV-2; ACE2; H7N9
AB This open-label randomized controlled pilot study aimed to test the study feasibility of bromhexine hydrochloride (BRH) tablets for the treatment of mild or moderate coronavirus disease 2019 (COVID-19) and to explore its clinical efficacy and safety. Patients with mild or moderate COVID-19 were randomly divided into the BRH group or the control group at a 2:1 ratio. Routine treatment according to China's Novel Coronavirus Pneumonia Diagnosis and Treatment Plan was performed in both groups, whereas patients in the BRH group were additionally given oral BRH (32 mg t.i.d.) for 14 consecutive days. The efficacy and safety of BRH were evaluated. A total of 18 patients with moderate COVID-19 were randomized into the BRH group (n = 12) or the control group (n = 6). There were suggestions of BRH advantage over placebo in improved chest computed tomography, need for oxygen therapy, and discharge rate within 20 days. However, none of these findings were statistically significant. BRH tablets may potentially have a beneficial effect in patients with COVID-19, especially for those with lung or hepatic injury. A further definitive large-scale clinical trial is feasible and necessary.
C1 [Li, Ting] Wenzhou Med Univ, Affiliated Hosp 2, Dept Anesthesia & Crit Care, Wenzhou, Zhejiang, Peoples R China.
   [Li, Ting; Sun, Laifang; Zhang, Wenwu; Zheng, Chanfan; Jiang, Chenchen; Chen, Mingjing; Chen, Di; Dai, Zhijuan; Bao, Shihui; Shen, Xian] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China.
   [Li, Ting; Zheng, Chanfan; Jiang, Chenchen; Chen, Mingjing; Chen, Di] Wenzhou Med Univ, Affiliated Hosp 2, Clin Res Unit, Wenzhou, Zhejiang, Peoples R China.
   [Sun, Laifang] Wenzhou Med Univ, Affiliated Hosp 2, Dept Emergency, Wenzhou, Zhejiang, Peoples R China.
   [Zhang, Wenwu] Wenzhou Med Univ, Affiliated Hosp 2, Dept Crit Med, Wenzhou, Zhejiang, Peoples R China.
   [Dai, Zhijuan] Wenzhou Med Univ, Affiliated Hosp 2, Dept Endocrinol, Wenzhou, Zhejiang, Peoples R China.
   [Bao, Shihui] Wenzhou Med Univ, Affiliated Hosp 2, Dept Pharm, Wenzhou, Zhejiang, Peoples R China.
   [Shen, Xian] Wenzhou Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Wenzhou, Zhejiang, Peoples R China.
RP Shen, X (corresponding author), Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China.; Shen, X (corresponding author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Wenzhou, Zhejiang, Peoples R China.
EM 1396888872@126.com
OI Zheng, Chanfan/0000-0002-0054-4580
FU Special Project for Significant New Drug Research and Development in the
   Major National Science and Technology Projects of China [2020ZX09201002]
FX This study was funded by the Special Project for Significant New Drug
   Research and Development in the Major National Science and Technology
   Projects of China (No. 2020ZX09201002).
CR cBisolvon Oral Solution, 2016, 2173773 CRN
   Chau T.N., 2004, HEPATOLOGY BALTIMORE, V39, P20111
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Depfenhart M., 2020, AM J BIOMED SCI RES, V8, P248
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hatesuer B, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003774
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lee JY, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2576-5
   Limburg H, 2019, J VIROL, V93, DOI 10.1128/JVI.00649-19
   Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Sakai K, 2014, J VIROL, V88, P5608, DOI 10.1128/JVI.03677-13
   Tarnow C, 2014, J VIROL, V88, P4744, DOI 10.1128/JVI.03799-13
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang L L, 2000, Se Pu, V18, P543
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
NR 23
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
PD NOV
PY 2020
VL 13
IS 6
BP 1096
EP 1102
DI 10.1111/cts.12881
EA OCT 2020
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PA7WR
UT WOS:000578442400001
PM 32881359
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Coma, E
   Mora, N
   Mendez, L
   Benitez, M
   Hermosilla, E
   Fabregas, M
   Fina, F
   Mercade, A
   Flayeh, S
   Guiriguet, C
   Ballo, E
   Leon, NM
   Mas, A
   Cordomi, S
   Lejardi, Y
   Medina, M
AF Coma, Ermengol
   Mora, Nuria
   Mendez, Leonardo
   Benitez, Mencia
   Hermosilla, Eduardo
   Fabregas, Mireia
   Fina, Francesc
   Mercade, Albert
   Flayeh, Souhel
   Guiriguet, Carolina
   Ballo, Elisabet
   Leon, Nuria Martinez
   Mas, Ariadna
   Cordomi, Silvia
   Lejardi, Yolanda
   Medina, Manuel
TI Primary care in the time of COVID-19: monitoring the effect of the
   pandemic and the lockdown measures on 34 quality of care indicators
   calculated for 288 primary care practices covering about 6 million
   people in Catalonia
SO BMC FAMILY PRACTICE
LA English
DT Article
DE Quality Indicators; Health Care; COVID-19 [Supplementary Concept];
   Chronic disease; Quaternary Prevention; Quality Assurance; Health Care;
   Primary health care
AB Background: To analyse the impact of the COVID-19 epidemic and the lockdown measures on the follow-up and control of chronic diseases in primary care.
   Methods: Retrospective study in 288 primary care practices (PCP) of the Catalan Institute of Health. We analysed the results of 34 indicators of the Healthcare quality standard (EQA), comprising different types: treatment (4), follow-up (5), control (10), screening (7), vaccinations (4) and quaternary prevention (4). For each PCP, we calculated each indicator's percentage of change in February, March and April 2020 respective to the results of the previous month; and used the T-Student test for paired data to compare them with the percentage of change in the same month of the previous year. We defined indicators with a negative effect those with a greater negative change or a lesser positive change in 2020 in comparison to 2019; and indicators with a positive effect those with a greater positive change or a lesser negative change.
   Results: We observed a negative effect on 85% of the EQA indicators in March and 68% in April. 90% of the control indicators had a negative effect, highlighting the control of LDL cholesterol with a reduction of - 2.69% (95%CI - 3.17% to - 2.23%) in March and - 3.41% (95%CI - 3.82% to - 3.01%) in April; and the control of blood pressure with a reduction of - 2.13% (95%CI - 2.34% to - 1.9%) and - 2.59% (95%CI - 2.8% to - 2.37%). The indicators with the greatest negative effect were those of screening, such as the indicator of diabetic foot screening with a negative effect of - 2.86% (95%CI - 3.33% to - 2.39%) and - 4.13% (95%CI - 4.55% to - 3.71%) in March and April, respectively. Only one vaccination indicator, adult Measles-Mumps-Rubella vaccine, had a negative effect in both months. Finally, among the indicators of quaternary prevention, we observed negative effects in March and April although in that case a lower inadequacy that means better clinical outcome.
   Conclusions: The COVID-19 epidemic and the lockdown measures have significantly reduced the results of the follow-up, control, screening and vaccination indicators for patients in primary care. On the other hand, the indicators for quaternary prevention have been strengthened and their results have improved.
C1 [Coma, Ermengol; Mora, Nuria; Mendez, Leonardo; Benitez, Mencia; Hermosilla, Eduardo; Fabregas, Mireia; Fina, Francesc; Mercade, Albert; Flayeh, Souhel; Guiriguet, Carolina; Ballo, Elisabet; Medina, Manuel] Inst Catala Salut ICS, Sistemes Informacio Serves Atencio Primaria SISAP, Gran Via Corts Catalanes 587, Barcelona 08007, Spain.
   [Mora, Nuria; Hermosilla, Eduardo] Fundacio Inst Univ Recerca Atencio Primaria Salut, Barcelona, Spain.
   [Benitez, Mencia; Guiriguet, Carolina] Inst Catala Salut, Equip Atencio Primaria Got, Barcelona, Spain.
   [Flayeh, Souhel] Inst Catala Salut, Equip Atencio Primaria Gran Sol, Badalona, Spain.
   [Ballo, Elisabet] Inst Catala Salut, Equip Atencio Primaria Salt, Girona, Spain.
   [Leon, Nuria Martinez; Mas, Ariadna; Cordomi, Silvia; Lejardi, Yolanda] Inst Catala Salut, Direccio Assistencial Atencio Primaria, Barcelona, Spain.
RP Coma, E (corresponding author), Inst Catala Salut ICS, Sistemes Informacio Serves Atencio Primaria SISAP, Gran Via Corts Catalanes 587, Barcelona 08007, Spain.
EM ecomaredon@gencat.cat
OI Guiriguet, Carolina/0000-0003-1201-6248; Coma Redon,
   Ermengol/0000-0001-8000-3321
CR Andreas Moser D, 2020, YEARS LIFE LOST DUE, V04, P20069716, DOI 10.1101/2020.04.17.20069716
   Beato-Vibora PI, 2020, DIABETES TECHNOL THE, V22, P643, DOI 10.1089/dia.2020.0184.retract
   Bolibar B, 2012, MED CLIN-BARCELONA, V138, P617, DOI 10.1016/j.medcli.2012.01.020
   Cuixart CB, 2018, ATEN PRIM, V50, P4
   Coma E, 2019, BMC MED INFORM DECIS, V19, DOI 10.1186/s12911-019-0976-8
   Coma E, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-51
   Ferguson N.M., 2020, PREPRINT, P16, DOI [DOI 10.25561/77482, 10.25561/77482]
   Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011
   Garcia-Gil M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109706
   Ghosal S, 2020, DIABETES METAB SYND, V14, P319, DOI 10.1016/j.dsx.2020.03.014
   Issaka BR, 2020, JAMA
   M&eacute;ndez Boo L, 2010, AMF, V6, P473
   McColl A, 1998, BMJ-BRIT MED J, V317, P1354, DOI 10.1136/bmj.317.7169.1354
   Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI 10.1093/eurheartj/ehw106
   PRIETOALHAMBRA D, 2020, HOSPITALIZATION 30 D, DOI DOI 10.1101/2020.05.04.20090050
   R Core Team, 2018, R SOFTW VERS 3 5 1, DOI 10.1007/978-3-540-74686-7
   Range G, 2020, EUR HEART J-QUAL CAR, DOI 10.1093/ehjqcco/qcaa034.
   Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2
   Stoecklin SB, 2020, EUROSURVEILLANCE, V25, P20, DOI 10.2807/1560-7917.ES.2020.25.6.2000094
   Vigliar E, 2020, J CLIN PATHOLOGY
   White R. G., 2020, IMPACT COVID19 PANDE, DOI 10.1101/2020.04.24.20078550
NR 21
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2296
J9 BMC FAM PRACT
JI BMC Fam. Pract.
PD OCT 10
PY 2020
VL 21
IS 1
AR 208
DI 10.1186/s12875-020-01278-8
PG 9
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA NY7LW
UT WOS:000576567000001
PM 33038926
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Germain, M
   Caputo, F
   Metcalfe, S
   Tosi, G
   Spring, K
   Aslund, AKO
   Pottier, A
   Schiffelers, R
   Ceccaldi, A
   Schmid, R
AF Germain, Matthieu
   Caputo, Fanny
   Metcalfe, Su
   Tosi, Giovanni
   Spring, Kathleen
   Aslund, Andreas K. O.
   Pottier, Agnes
   Schiffelers, Raymond
   Ceccaldi, Alexandre
   Schmid, Ruth
TI Delivering the power of nanomedicine to patients today
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Nanomedicine; Clinical translation; Nanotechnology; Healthtech;
   Regulatory; Standardization
ID DISEASE; THERAPY
AB The situation of the COVID-19 pandemic reminds us that we permanently need high-value flexible solutions to urgent clinical needs including simplified diagnostic technologies suitable for use in the field and for delivering targeted therapeutics. From our perspective nanotechnology is revealed as a vital resource for this, as a generic platform of technical solutions to tackle complex medical challenges. It is towards this perspective and focusing on nanomedicine that we take issue with Prof Parks recent editorial published in the Journal of Controlled Release. Prof. Park argued that in the last 15 years nanomedicine failed to deliver the promised innovative clinical solutions to the patients (Park, K. The beginning of the end of the nanomedicine hype. Journal of Controlled Release, 2019; 305, 221-222 [1]. We, the ETPN (European Technology Platform on Nanomedicine) [2], respectfully disagree. In fact, the more than 50 formulations currently in the market, and the recent approval of 3 key nanomedicine products (e. g. Onpattro, Hensify and Vyxeos), have demonstrated that the nanomedicine field is concretely able to design products that overcome critical barriers in conventional medicine in a unique manner, but also to deliver within the cells new drug-free therapeutic effects by using pure physical modes of action, and therefore make a difference in patients lives. Furthermore, the > 400 nanomedicine formulations currently in clinical trials are expecting to bring novel clinical solutions (e.g. platforms for nucleic acid delivery), alone or in combination with other key enabling technologies to the market, including biotechnologies, microfluidics, advanced materials, biomaterials, smart systems, photonics, robotics, textiles, Big Data and ICT (information & communication technologies) more generally. However, we agree with Prof. Park that " it is time to examine the sources of difficulty in clinical translation of nanomedicine and move forward ". But for reaching this goal, the investments to support clinical translation of promising nanomedicine formulations should increase, not decrease. As recently encouraged by EMA in its roadmap to 2025, we should create more unity through a common knowledge hub linking academia, industry, healthcare providers and hopefully policy makers to reduce the current fragmentation of the standardization and regulatory body landscape. We should also promote a strategy of cross-technology innovation, support nanomedicine development as a high value and low-cost solution to answer unmet medical needs and help the most promising innovative projects of the field to get better and faster to the clinic. This global vision is the one that the ETPN chose to encourage for the last fifteen years. All actions should be taken with a clear clinical view in mind, " without any fanfare", to focus "on what matters in real life", which is the patient and his/her quality of life.
   This ETPN overview of achievements in nanomedicine serves to reinforce our drive towards further expanding and growing the maturity of nanomedicine for global healthcare, accelerating the pace of transformation of its great potential into tangible medical breakthroughs.
C1 [Germain, Matthieu] Curadigm SAS, 60 Rue Wattignies, F-75012 Paris, France.
   [Caputo, Fanny; Aslund, Andreas K. O.; Schmid, Ruth] SINTEF Ind, Dept Biotechnol & Nanomed, N-7465 Trondheim, Norway.
   [Metcalfe, Su] Univ Cambridge, Clin Sch, LIFNano Therapeut, 10 Fendon Rd, Cambridge CB1 7RT, England.
   [Tosi, Giovanni] Univ Modena & Reggio Emilia, Dept Life Sci, Nanotech Lab, Te Far TI, Via Campi 103, I-41124 Modena, Italy.
   [Spring, Kathleen] Gesell Bioanalyt Muenster eV, Mendelstr 17, D-48151 Munster, Germany.
   [Pottier, Agnes; Ceccaldi, Alexandre] ETPN Assoc, 64-66 Rue Arch, F-75003 Paris, France.
   [Schiffelers, Raymond] Univ Med Ctr Utrecht, Dept Clin Chem & Haematol, NL-3584 CX Utrecht, Netherlands.
RP Germain, M (corresponding author), Curadigm SAS, 60 Rue Wattignies, F-75012 Paris, France.
EM matthieu.germain@curadigm.com
RI Schiffelers, Raymond/E-8786-2011; Tosi, Giovanni/D-4547-2011
OI Schiffelers, Raymond/0000-0002-1012-9815; Tosi,
   Giovanni/0000-0001-8318-667X
CR Adams D, 2018, NEW ENGL J MED, V379, P11, DOI 10.1056/NEJMoa1716153
   [Anonymous], 2019, NAT NANOTECHNOL, V14, P1083, DOI 10.1038/s41565-019-0597-5
   Anselmo AC, 2019, BIOENG TRANSL MED, V4, DOI 10.1002/btm2.10143
   Bonvalot S, 2019, LANCET ONCOL, V20, P1148, DOI 10.1016/S1470-2045(19)30326-2
   Box H., 2019, REFINE WHITE PAPER A
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   Bulbake U, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9020012
   Douek M, 2014, ANN SURG ONCOL, V21, P1237, DOI 10.1245/s10434-013-3379-6
   Duskey JT, 2017, INT REV NEUROBIOL, V137, P1, DOI 10.1016/bs.irn.2017.08.006
   FDA, 2017, DRUG PROD INCL BIOL
   Germain M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23140-9
   Gioria S, 2019, NANOMEDICINE-UK, V14, P1787, DOI 10.2217/nnm-2019-0173
   Givens BE, 2018, AAPS J, V20, DOI 10.1208/s12248-018-0267-9
   Grodzinski P, 2019, J CONTROL RELEASE, V309, P341, DOI 10.1016/j.jconrel.2019.08.016
   He HL, 2019, ACCOUNTS CHEM RES, V52, P2445, DOI 10.1021/acs.accounts.9b00228
   Hoffmann SB, 2018, J INTERDISCIPLINARY, V3, P4, DOI DOI 10.1002/JIN2.34
   Jena L, 2020, DRUG DELIV TRANSL RE, V10, P304, DOI 10.1007/s13346-019-00679-2
   Krauss AC, 2019, CLIN CANCER RES, V25, P2685, DOI 10.1158/1078-0432.CCR-18-2990
   Marques MRC, 2019, ADV DRUG DELIVER REV, V151, P23, DOI 10.1016/j.addr.2019.06.003
   Martins JP, 2020, DRUG DELIV TRANSL RE, V10, P726, DOI 10.1007/s13346-020-00743-2
   McNeil S. E., 2016, NAT REV MATER, V1, P16073, DOI DOI 10.1038/NATREVMATS.2016.73
   Meng T, 2019, DRUG DISCOV TODAY, V24, P1524, DOI 10.1016/j.drudis.2019.05.006
   Metcalfe SM, 2017, CURR PHARM DESIGN, V23, P776, DOI [10.2174/1381612822666161206, 10.2174/1381612822666161206141744]
   Mizrahy S, 2019, J DRUG TARGET, V27, P542, DOI 10.1080/1061186X.2018.1533556
   Munawar A, 2019, RSC ADV, V9, P6793, DOI 10.1039/c8ra10144b
   Park K, 2019, J CONTROL RELEASE, V305, P221, DOI 10.1016/j.jconrel.2019.05.044
   Paviolo C, 2017, NANOMATERIALS-BASEL, V7, DOI 10.3390/nano7040092
   Richardson JJ, 2020, NANO LETT, V20, P1481, DOI 10.1021/acs.nanolett.0c00620
   Rigon L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20082014
   Salvalaio M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156452
   Suh N.P., 1990, PRINCIPLES OF DESIGN
   Swenson CE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139752
   Tiwari S, 2019, INT J NANOMED, V14, P5541, DOI 10.2147/IJN.S200490
   Tyner KM, 2015, WIRES NANOMED NANOBI, V7, P640, DOI 10.1002/wnan.1338
   U. Food D. Administration Global Summit on Regulatory Science (GSRS16), 2016, GLOB SUMM REG SCI 1, P7
   Valenza M, 2015, EMBO MOL MED, V7, P1547, DOI 10.15252/emmm.201505413
   Ventola C Lee, 2017, P T, V42, P742
   Vilella A, 2018, J TRACE ELEM MED BIO, V49, P210, DOI 10.1016/j.jtemb.2017.12.006
   Weissig V, 2014, INT J NANOMED, V9, P4357, DOI 10.2147/IJN.S46900
   Wilhelm S, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.14
   Wong CH, 2019, BIOSTATISTICS, V20, P273, DOI 10.1093/biostatistics/kxx069
NR 41
TC 3
Z9 3
U1 20
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD OCT 10
PY 2020
VL 326
BP 164
EP 171
DI 10.1016/j.jconrel.2020.07.007
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA NS2GO
UT WOS:000572083700006
PM 32681950
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Turonova, B
   Sikora, M
   Schurmann, C
   Hagen, WJH
   Welsch, S
   Blanc, FEC
   von Bulow, S
   Gecht, M
   Bagola, K
   Horner, C
   van Zandbergen, G
   Landry, J
   de Azevedo, NTD
   Mosalaganti, S
   Schwarz, A
   Covino, R
   Muhlebach, MD
   Hummer, G
   Locker, JK
   Beck, M
AF Turonova, Beata
   Sikora, Mateusz
   Schuermann, Christoph
   Hagen, Wim J. H.
   Welsch, Sonja
   Blanc, Florian E. C.
   von Buelow, Soeren
   Gecht, Michael
   Bagola, Katrin
   Hoerner, Cindy
   van Zandbergen, Ger
   Landry, Jonathan
   de Azevedo, Nayara Trevisan Doimo
   Mosalaganti, Shyamal
   Schwarz, Andre
   Covino, Roberto
   Muehlebach, Michael D.
   Hummer, Gerhard
   Locker, Jacomine Krijnse
   Beck, Martin
TI In situ structural analysis of SARS-CoV-2 spike reveals flexibility
   mediated by three hinges
SO SCIENCE
LA English
DT Article
ID MOLECULAR-DYNAMICS; CELL ENTRY; PROTEIN; VISUALIZATION; PREDICTION;
   RESOLUTION
AB The spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is required for cell entry and is the primary focus for vaccine development. In this study, we combined cryo-electron tomography, subtomogram averaging, and molecular dynamics simulations to structurally analyze S in situ. Compared with the recombinant S, the viral S was more heavily glycosylated and occurred mostly in the closed prefusion conformation. We show that the stalk domain of S contains three hinges, giving the head unexpected orientational freedom. We propose that the hinges allow S to scan the host cell surface, shielded from antibodies by an extensive glycan coat. The structure of native S contributes to our understanding of SARS-CoV-2 infection and potentially to the development of safe vaccines.
C1 [Turonova, Beata; Hagen, Wim J. H.; Schwarz, Andre; Beck, Martin] European Mol Biol Lab, Struct & Computat Biol Unit, Meyerhofstr 1, D-69117 Heidelberg, Germany.
   [Turonova, Beata; Mosalaganti, Shyamal; Beck, Martin] Max Planck Inst Biophys, Dept Mol Sociol, Max von Laue Str 3, D-60438 Frankfurt, Germany.
   [Sikora, Mateusz; Blanc, Florian E. C.; von Buelow, Soeren; Gecht, Michael; Covino, Roberto; Hummer, Gerhard] Max Planck Inst Biophys, Dept Theoret Biophys, Max von Laue Str 3, D-60438 Frankfurt, Germany.
   [Schuermann, Christoph; Hoerner, Cindy; Muehlebach, Michael D.] Paul Ehrlich Inst, Div Vet Med, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
   [Welsch, Sonja] Max Planck Inst Biophys, Cent Electron Microscopy Facil, Max von Laue Str 3, D-60438 Frankfurt, Germany.
   [Bagola, Katrin; van Zandbergen, Ger] Paul Ehrlich Inst, Div Immunol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
   [Hoerner, Cindy; Muehlebach, Michael D.] German Ctr Infect Res, Giessen Marburg Langen, Germany.
   [van Zandbergen, Ger] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Immunol, Mainz, Germany.
   [van Zandbergen, Ger] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immunotherapy FZI, Mainz, Germany.
   [Landry, Jonathan; de Azevedo, Nayara Trevisan Doimo] EMBL, Genom Core Facil, Meyerhofstr 1, D-69117 Heidelberg, Germany.
   [Covino, Roberto] Frankfurt Inst Adv Studies, Ruth Moufang Str 1, D-60438 Frankfurt, Germany.
   [Hummer, Gerhard] Goethe Univ Frankfurt, Inst Biophys, D-60438 Frankfurt, Germany.
   [Locker, Jacomine Krijnse] Paul Ehrlich Inst, Electron Microscopy Pathogens Unit, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
RP Beck, M (corresponding author), European Mol Biol Lab, Struct & Computat Biol Unit, Meyerhofstr 1, D-69117 Heidelberg, Germany.; Beck, M (corresponding author), Max Planck Inst Biophys, Dept Mol Sociol, Max von Laue Str 3, D-60438 Frankfurt, Germany.; Hummer, G (corresponding author), Max Planck Inst Biophys, Dept Theoret Biophys, Max von Laue Str 3, D-60438 Frankfurt, Germany.; Hummer, G (corresponding author), Goethe Univ Frankfurt, Inst Biophys, D-60438 Frankfurt, Germany.; Locker, JK (corresponding author), Paul Ehrlich Inst, Electron Microscopy Pathogens Unit, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
EM gerhard.hummer@biophys.mpg.de; jacomina.krijnselocker@pei.de;
   martin.beck@biophys.mpg.de
RI ; Hummer, Gerhard/A-2546-2013; Beck, Martin/B-5589-2011
OI Muehlebach, Michael/0000-0002-7069-5018; Mosalaganti,
   Shyamal/0000-0002-5934-687X; Gecht, Michael/0000-0002-4643-6593; Hagen,
   Wim/0000-0001-6229-2692; von Bulow, Soren/0000-0001-7125-5973; Landry,
   Jonathan/0000-0003-2262-9099; Horner, Cindy/0000-0002-9653-1249; Hummer,
   Gerhard/0000-0001-7768-746X; Beck, Martin/0000-0002-7397-1321;
   Schurmann, Christoph/0000-0003-1530-1378
FU Leibniz Supercomputing Centre; Human Frontier Science ProgramHuman
   Frontier Science Program [RGP0026/2017]; German Ministry of Health;
   German Center for Infection Research; Loewe Center DRUID from the Justus
   Liebig University Giessen; Austrian Science Fund FWF (Schrodinger
   Fellowship)Austrian Science Fund (FWF) [J4332-B28]
FX We acknowledge a generous SuperMUC-NG computing allocation at the
   Leibniz Supercomputing Centre (M.S., S.v.B., M.G., F.E.C.B., R.C., and
   G.H.), the Human Frontier Science Program (RGP0026/2017; S.v.B. and
   G.H.), the German Ministry of Health (C.S.), the German Center for
   Infection Research (C.H. and M.D.M.), and the Loewe Center DRUID from
   the Justus Liebig University Giessen (J.K.L.) for funding. M.S.
   acknowledges support from the Austrian Science Fund FWF (Schrodinger
   Fellowship, J4332-B28).
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Benton DJ, 2018, P NATL ACAD SCI USA, V115, P10112, DOI 10.1073/pnas.1810927115
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Briones R, 2019, BIOPHYS J, V116, P4, DOI 10.1016/j.bpj.2018.11.3126
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Davidson AD, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00763-0
   de Haan CAM, 2005, ADV VIRUS RES, V64, P165, DOI 10.1016/S0065-3527(05)64006-7
   Duquerroy S, 2005, VIROLOGY, V335, P276, DOI 10.1016/j.virol.2005.02.022
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Forster F, 2005, P NATL ACAD SCI USA, V102, P4729, DOI 10.1073/pnas.0409178102
   Funke S, 2008, MOL THER, V16, P1427, DOI 10.1038/mt.2008.128
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Grant T, 2015, ELIFE, V4, DOI 10.7554/eLife.06980
   Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462
   Harrison SC, 2015, VIROLOGY, V479, P498, DOI 10.1016/j.virol.2015.03.043
   Henderson R, 2020, NAT STRUCT MOL BIOL, V27, P925, DOI 10.1038/s41594-020-0479-4
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hubert J., 1984, BIOASSAY, P65
   Hulswit RJG, 2016, ADV VIRUS RES, V96, P29, DOI 10.1016/bs.aivir.2016.08.004
   Igaev M, 2019, ELIFE, V8, DOI 10.7554/eLife.43542
   Jacquemyn J, 2017, EMBO REP, V18, P1905, DOI 10.15252/embr.201643426
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Ke ZL, 2020, NATURE, DOI 10.1038/s41586-020-2665-2
   Klein S., 2020, SARS COV 2 STRUCTURE, DOI [10.1101/2020.06.23.167064., DOI 10.1101/2020.06.23.167064]
   Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013
   Lau SY, 2020, EMERG MICROBES INFEC, V9, P837, DOI 10.1080/22221751.2020.1756700
   Lee J, 2016, J CHEM THEORY COMPUT, V12, P405, DOI 10.1021/acs.jctc.5b00935
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Luo Y, 2010, J PHYS CHEM LETT, V1, P183, DOI 10.1021/jz900079w
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   Ogando NS, 2020, J GEN VIROL, V101, P925, DOI 10.1099/jgv.0.001453
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Park SJ, 2019, GLYCOBIOLOGY, V29, P320, DOI 10.1093/glycob/cwz003
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Shajahan Asif, 2020, Glycobiology, V30, P981, DOI 10.1093/glycob/cwaa042
   Turonova B., 2020, TURONOVA NOVASTA NOV, DOI 10.5281/zenodo.3973623
   Turonova B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14535-2
   Turonova B, 2017, J STRUCT BIOL, V199, P187, DOI 10.1016/j.jsb.2017.07.007
   Vincent TL, 2013, BIOINFORMATICS, V29, P69, DOI 10.1093/bioinformatics/bts648
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Wan W., 2020, WILLIAMNWAN STOPGAP, DOI 10.5281/zenodo.3973664.
   Wan W, 2017, NATURE, V551, P394, DOI 10.1038/nature24490
   Wan YN, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0060-y
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wood CW, 2018, PROTEIN SCI, V27, P103, DOI 10.1002/pro.3279
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiong XL, 2020, NAT STRUCT MOL BIOL, DOI 10.1038/s41594-020-0478-5
   Yao HP, 2020, CELL, V183, P730, DOI 10.1016/j.cell.2020.09.018
   Zhang L., 2020, BIORXIV148726
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
NR 58
TC 10
Z9 10
U1 7
U2 7
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD OCT 9
PY 2020
VL 370
IS 6513
BP 203
EP +
DI 10.1126/science.abd5223
PG 32
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OC5CH
UT WOS:000579173800043
PM 32817270
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Wang, H
   Tu, L
   Li, Y
   Bai, T
   Zou, KF
   Xiao, F
   Li, J
   Chen, M
   Zhang, H
   Li, GQ
   Lu, YY
   Wang, K
   Jin, S
   Yang, YP
   Zhu, LR
   Hou, XH
AF Wang, Huan
   Tu, Lei
   Li, Ying
   Bai, Tao
   Zou, Kaifang
   Xiao, Fang
   Li, Jin
   Chen, Min
   Zhang, Heng
   Li, Gangqin
   Lu, Yueyue
   Wang, Kai
   Jin, Shu
   Yang, Yuanping
   Zhu, Liangru
   Hou, Xiaohua
TI The Symptoms and Medications of Patients with Inflammatory Bowel Disease
   in Hubei Province after COVID-19 Epidemic
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID STRESS
AB Objectives. The COVID-19 epidemic triggered by coronavirus SARS-CoV-2 is rapidly spreading around the globe. This study is aimed at finding out the suspected or confirmed SARS-CoV-2 infection in patients with inflammatory bowel disease (IBD) in Hubei province, China. We also investigated symptoms, medications, life quality, and psychological issues of IBD patients under the ongoing pandemic.Methods. We conducted a self-reported questionnaire survey via an online survey platform. SARS-CoV-2 infection-related data was collected from IBD patients. The status quo of medications and symptoms of the subjects were investigated. Life quality, depression, and anxiety were measured by clinical questionnaires and rated on scoring systems.Results. A total of 204 IBD patients from Hubei province were included in this study. No suspected or confirmed SARS-CoV-2 infection case was found in this study. As a result of city shutdown, two-thirds of the patients (138/204) in our series reported difficulty in accessing medicines and nearly half of them (73/138) had to discontinue medications. Apart from gastrointestinal symptoms, systemic symptoms were common while respiratory symptoms were rare in the cohort. Though their quality of life was not significantly lowered, depression and anxiety were problems that seriously affected them during the COVID-19 epidemic.Conclusions. Inaccessibility to medications is a serious problem for IBD patients after city shutdown. Efforts have to be made to address the problems of drug withdrawal and psychological issues that IBD patients suffer from during the COVID-19 outbreak.
C1 [Wang, Huan; Tu, Lei; Li, Ying; Bai, Tao; Zou, Kaifang; Zhu, Liangru; Hou, Xiaohua] Huazhong Univ Sci & Technol, Union Hosp, Div Gastroenterol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Xiao, Fang] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Gastroenterol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Li, Jin; Chen, Min] Wuhan Univ, Zhongnan Hosp, Dept Gastroenterol, Wuhan, Hubei, Peoples R China.
   [Zhang, Heng] Cent Hosp Wuhan, Dept Gastroenterol, Wuhan, Hubei, Peoples R China.
   [Li, Gangqin] Eighth Hosp Wuhan, Dept Gastroenterol, Wuhan, Hubei, Peoples R China.
   [Lu, Yueyue] Changjiang Univ, Dept Gastroenterol, Affiliated Hosp 1, Jingzhou, Hubei, Peoples R China.
   [Wang, Kai] Huazhong Univ Sci & Technol, Jingzhou Hosp, Dept Gastroenterol, Tongji Med Coll, Jingzhou, Hubei, Peoples R China.
   [Jin, Shu] Huei Univ Med, Taihe Hosp, Dept Gastroenterol, Shiyan, Hubei, Peoples R China.
   [Yang, Yuanping] Yichang Cent Hosp, Dept Gastroenterol, Yichang, Hubei, Peoples R China.
RP Zhu, LR; Hou, XH (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Div Gastroenterol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
EM wanghuan508524@163.com; tulei_1985@126.com; 13147104569@163.com;
   drbaitao@126.com; zoukaifanghu@qq.com; christina_fx@126.com;
   15071178164@163.com; 10941482@qq.com; 653262549@qq.com;
   piano1972@163.com; 453369050@qq.com; wk19821005@163.com;
   jinshu76@sohu.com; 357965530@qq.com; zhuliangru@hust.edu.cn;
   houxh@medmail.com.cn
FU National Natural Foundation Project of ChinaNational Natural Science
   Foundation of China (NSFC) [81873558, 81700490, 81500415]; National Key
   Research and Development Program of China [2018YFC0114604]
FX This work is supported by the National Natural Foundation Project of
   China (No. 81873558, 81700490, and 81500415) and the National Key
   Research and Development Program of China (No. 2018YFC0114604). We thank
   Troy Gharibani at the University of Maryland, USA, for editing and
   providing feedback on this article.
CR Bernstein CN, 2018, INFLAMM BOWEL DIS, V24, P1867, DOI 10.1093/ibd/izy068
   Byrne G, 2017, CAN J GASTROENTEROL, V2017, DOI 10.1155/2017/6496727
   Chinse Society of IBD, 2020, CHIN J DIG, V40
   Danese S, 2020, NAT REV GASTRO HEPAT, V17, P253, DOI 10.1038/s41575-020-0294-8
   Fiorino G, 2020, J CROHNS COLITIS, V14, P1330, DOI 10.1093/ecco-jcc/jjaa058
   Goodhand JR, 2012, INFLAMM BOWEL DIS, V18, P2301, DOI 10.1002/ibd.22916
   Gu JY, 2020, GASTROENTEROLOGY, V158, P1518, DOI 10.1053/j.gastro.2020.02.054
   Han CQ, 2020, AM J GASTROENTEROL, V115, P916, DOI 10.14309/ajg.0000000000000664
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209
   Kirchgesner J, 2018, GASTROENTEROLOGY, V155, P337, DOI 10.1053/j.gastro.2018.04.012
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006
   Leong RWL, 2003, ALIMENT PHARM THER, V17, P711, DOI 10.1046/j.1365-2036.2003.01489.x
   Marinelli C, 2019, GASTROENT RES PRACT, V2019, DOI 10.1155/2019/5354320
   Maunder RG, 2008, CURR MOL MED, V8, P247, DOI 10.2174/156652408784533832
   Monteleone G, 2020, J CROHNS COLITIS, V14, P1334, DOI 10.1093/ecco-jcc/jjaa061
   National Health Commission, DIAGN TREATM COVID 1
   Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661
   Tian Y, 2020, ALIMENT PHARM THER, V51, P843, DOI 10.1111/apt.15731
   Wisniewski A, 2020, UNITED EUR GASTROENT, V8, P303, DOI 10.1177/2050640619889763
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
NR 22
TC 0
Z9 0
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PD OCT 9
PY 2020
VL 2020
AR 2847316
DI 10.1155/2020/2847316
PG 7
WC Immunology
SC Immunology
GA OI2VH
UT WOS:000583142300001
PM 33062719
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kerkhoff, AD
   Sachdev, D
   Mizany, S
   Rojas, S
   Gandhi, M
   Peng, J
   Black, D
   Jones, D
   Rojas, S
   Jacobo, J
   Tulier-Laiwa, V
   Petersen, M
   Martinez, J
   Chamie, G
   Havlir, DV
   Marquez, C
AF Kerkhoff, Andrew D.
   Sachdev, Darpun
   Mizany, Sara
   Rojas, Susy
   Gandhi, Monica
   Peng, James
   Black, Douglas
   Jones, Diane
   Rojas, Susana
   Jacobo, Jon
   Tulier-Laiwa, Valerie
   Petersen, Maya
   Martinez, Jackie
   Chamie, Gabriel
   Havlir, Diane V.
   Marquez, Carina
TI Evaluation of a novel community-based COVID-19 'Test-to-Care' model for
   low-income populations
SO PLOS ONE
LA English
DT Article
ID HEALTH WORKER INTERVENTIONS; ANTIRETROVIRAL THERAPY; COUNTRIES; PROGRAM;
   SUPPORT; PEOPLE; MIDDLE
AB Background After a COVID-19 diagnosis, vulnerable populations face considerable logistical and financial challenges to isolate and quarantine. We developed and evaluated a novel, community-based approach ('Test-to-Care' Model) designed to address these barriers for socioeconomically vulnerable Latinx individuals with newly diagnosed COVID-19 and their households. Methods This three-week demonstration project was nested within an epidemiologic surveillance study in a primarily Latinx neighborhood in the Mission district of San Francisco, California. The Test-to-Care model was developed with input from community members and public health leaders. Key components included: (1) provision of COVID-19-related education and information about available community resources, (2) home deliveries of material goods to facilitate safe isolation and quarantine (groceries, personal protective equipment and cleaning supplies), and (3) longitudinal clinical and social support. Newly SARS-CoV-2 PCR-positive participants were eligible to participate. Components of the model were delivered by the Test-to-Care team, which was comprised of healthcare providers and community health workers (CHWs) who provided longitudinal clinic- and community-based support for the duration of the isolation period to augment existing services from the Department of Public Health (DPH). We evaluated the Test-to-Care Model using the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) Framework and drew upon multiple data sources including: programmatic data, informal interviews with participants and providers/CHWs and structured surveys among providers/CHWs. Results Overall, 83 participants in the surveillance study were diagnosed with COVID-19, of whom 95% (79/83) were Latinx and 88% (65/74) had an annual household income <$50,000. Ninety-six percent (80/83) of participants were reached for results disclosure, needs assessment and DPH linkage for contact tracing. Among those who underwent an initial needs assessment, 45% (36/80) were uninsured and 55% (44/80) were not connected to primary care. Sixty-seven percent (56/83) of participants requested community-based CHW support to safely isolate at their current address and 65% (54/83) of all COVID-19 participants received ongoing community support via CHWs for the entire self-isolation period. Participants reported that the intervention was highly acceptable and that their trust increased over time-this resulted in 9 individuals who disclosed a larger number of household members than first reported, and 6 persons who requested temporary relocation to a hotel room for isolation despite initially declining this service; no unintended harms were identified. The Test-to-Care Model was found to be both acceptable and feasible to providers and CHWs. Challenges identified included a low proportion of participants linked to primary care despite support (approximately 10% after one month), and insufficient access to financial support for wage replacement. Conclusions The Test-to-Care Model is a feasible and acceptable intervention for supporting self-isolation and quarantine among newly diagnosed COVID-19 patients and their households by directly addressing key barriers faced by socioeconomically vulnerable populations.
C1 [Kerkhoff, Andrew D.; Gandhi, Monica; Peng, James; Black, Douglas; Jones, Diane; Martinez, Jackie; Chamie, Gabriel; Havlir, Diane V.; Marquez, Carina] Univ Calif San Francisco, Dept Med, Div HIV Infect Dis & Global Med, San Francisco, CA 94143 USA.
   [Sachdev, Darpun] San Francisco Dept Publ Hlth, San Francisco, CA USA.
   [Mizany, Sara; Rojas, Susy; Rojas, Susana; Jacobo, Jon; Tulier-Laiwa, Valerie] San Francisco Latino Task Force COVID 19, San Francisco, CA USA.
   [Petersen, Maya] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol & Biostat, Berkeley, CA 94720 USA.
RP Kerkhoff, AD (corresponding author), Univ Calif San Francisco, Dept Med, Div HIV Infect Dis & Global Med, San Francisco, CA 94143 USA.
EM andrew.kerkhoff@ucsf.edu
OI Mizany, Sara/0000-0003-3147-253X
FU Chan Zuckerberg Biohub; UCSF; Program for Breakthrough Biomedical
   Research award
FX The study was supported by the Chan Zuckerberg Biohub, UCSF, and a
   Program for Breakthrough Biomedical Research award. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR [Anonymous], 2020, SAN FRANCISCO LATINO
   [Anonymous], 2018, OBSTET GYNECOL, V13, pe49
   Association of State and Territorial Health Officials, 2020, COMM HLTH WORK EV TH
   Atkins L, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0605-9
   Azar KMJ, 2020, HLTH AFFAIR, DOI [10.1377/ hlthaff, 10.1377/hlthaff.2020.00598]
   Bowen DJ, 2009, AM J PREV MED, V36, P452, DOI 10.1016/j.amepre.2009.02.002
   Brownstein JN, 2007, AM J PREV MED, V32, P435, DOI 10.1016/j.amepre.2007.01.011
   Calo WA, 2020, PREV CHRONIC DIS, V17, DOI 10.5888/pcd17.200165
   Centers for Disease Control and Prevention, 2014, POL EV ASS REP COMM
   Chamie G, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1234, DOI 10.1093/CID/CIAA123432821935]
   Christopoulos KA, 2011, AIDS PATIENT CARE ST, V25, P439, DOI 10.1089/apc.2011.0041
   Coffey S, 2019, AIDS, V33, P825, DOI 10.1097/QAD.0000000000002124
   Drahota A, 2016, MILBANK Q, V94, P163, DOI 10.1111/1468-0009.12184
   Gil RM, 2020, J INFECT DIS, DOI [10.1093/infdis/jiaa474, DOI 10.1093/INFDIS/JIAA47432729903]
   Haines A, 2020, LANCET, V395, P1173, DOI 10.1016/S0140-6736(20)30735-2
   Havlir DV, 2019, NEW ENGL J MED, V381, P219, DOI 10.1056/NEJMoa1809866
   Kangovi S., 2020, WANT HELP BATTLE COV
   Kangovi S, 2017, AM J PUBLIC HEALTH, V107, P1660, DOI [10.2105/AJPH.2017.303985, 10.2105/ajph.2017.303985]
   Kenya S, 2011, HIV MED, V12, P525, DOI 10.1111/j.1468-1293.2011.00921.x
   Kim K, 2016, AM J PUBLIC HEALTH, V106, pE3, DOI 10.2105/AJPH.2015.302987
   Kucharski AJ, 2020, LANCET INFECT DIS, DOI [10.1016/s1473-3099(20)30457-6, DOI 10.1016/S1473-3099(20)30457-632559451]
   Landers S, 2016, AM J PUBLIC HEALTH, V106, P591, DOI 10.2105/AJPH.2016.303099
   Michie S. F., 2014, BEHAV CHANGE WHEEL G
   Palmas W, 2015, J GEN INTERN MED, V30, P1004, DOI 10.1007/s11606-015-3247-0
   Parekh TM, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0878-7
   Penn Center for Community Health Workers, 2020, CALL ACT
   Perry HB, 2014, ANNU REV PUBL HEALTH, V35, P399, DOI 10.1146/annurev-publhealth-032013-182354
   POWER TJ, 1995, J DEV BEHAV PEDIATR, V16, P238
   Rajan S, 2020, J ROY SOC MED, V113, P245, DOI 10.1177/0141076820939395
   San Francisco Chronicle, 2020, SAN FRANCISCO CHRONI
   San Francisco Department of Public Health, 2020, POP CHAR COVID 19 CA
   Siegler AJ, 2020, WILLINGNESS SEEK LAB, V2020, DOI [10.1101/2020.05.06.20093005., DOI 10.1101/2020.05.06.20093005]
   Smith DO, 2020, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20200504.336184/full/, DOI 10.1377/HBL0G20200504.336184/FULL/]
   Smith DO, WHAT YOU NEED KNOW C
   Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2
   Trump LJ, 2017, FAM SYST HEALTH, V35, P320, DOI 10.1037/fsh0000283
   U.S. Citezenship and Immigration Services, 2020, PUBL CHARG
   Urban Displacement Project, 2018, RIS HOUS COSTS RE SE
   Weaver A, 2018, J HEALTH CARE POOR U, V29, P159, DOI 10.1353/hpu.2018.0011
   Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598
   Weiner BJ, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0635-3
NR 41
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 9
PY 2020
VL 15
IS 10
AR e0239400
DI 10.1371/journal.pone.0239400
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OG3WA
UT WOS:000581817500011
PM 33035216
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Scholer, L
   Le-Trilling, VTK
   Eilbrecht, M
   Mennerich, D
   Anastasiou, OE
   Krawczyk, A
   Herrmann, A
   Dittmer, U
   Trilling, M
AF Schoeler, Lara
   Le-Trilling, Vu Thuy Khanh
   Eilbrecht, Mareike
   Mennerich, Denise
   Anastasiou, Olympia E.
   Krawczyk, Adalbert
   Herrmann, Anke
   Dittmer, Ulf
   Trilling, Mirko
TI A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of
   SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; neutralizing; antibodies; vaccine; interferon
ID COVID-19
AB The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the most pressing medical and socioeconomic challenge. Constituting important correlates of protection, the determination of virus-neutralizing antibodies (NAbs) is indispensable for convalescent plasma selection, vaccine candidate evaluation, and immunity certificates. In contrast to standard serological ELISAs, plaque reduction neutralization tests (PRNTs) are laborious, time-consuming, expensive, and restricted to specialized laboratories. To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in-cell ELISA (icELISA) approach. After optimization of various parameters such as virus-specific antibodies, cell lines, virus doses, and duration of infection, SARS-CoV-2-infected cells became amenable as direct antigen source for quantitative icELISA. Antiviral agents such as human sera containing NAbs or antiviral interferons dose dependently reduced the SARS-CoV-2-specific signal. Applying increased infectious doses, the icELISA-based neutralization test (icNT) was superior to PRNT in discriminating convalescent sera with high from those with intermediate neutralizing capacities. In addition, the icNT was found to be specific, discriminating between SARS-CoV-2-specific NAbs and those raised against other coronaviruses. Altogether, the SARS-CoV-2 icELISA test allows rapid (<48 h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs and antiviral drugs using reagents and equipment present in most routine diagnostics departments.
C1 [Schoeler, Lara; Le-Trilling, Vu Thuy Khanh; Eilbrecht, Mareike; Mennerich, Denise; Anastasiou, Olympia E.; Krawczyk, Adalbert; Herrmann, Anke; Dittmer, Ulf; Trilling, Mirko] Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, Essen, Germany.
   [Krawczyk, Adalbert] Univ Duisburg Essen, Univ Hosp Essen, West German Ctr Infect Dis, Dept Infect Dis, Essen, Germany.
RP Trilling, M (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, Essen, Germany.
EM Mirko.Trilling@uk-essen.de
FU Stiftung Universitatsmedizin Essen, Kulturstiftung Essen; Else-Kroner
   Promotionskolleg ELAN; Deutsche Forschungsgemeinschaft (DFG)German
   Research Foundation (DFG) [RTG 1949/2, TR1208/1-1, TR1208/2-1]
FX The authors received support by the Stiftung Universitatsmedizin Essen,
   Kulturstiftung Essen, the Else-Kroner Promotionskolleg ELAN, and the
   Deutsche Forschungsgemeinschaft (DFG) through grants RTG 1949/2,
   TR1208/1-1, and TR1208/2-1. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anderson DE, 2020, EMERG MICROBES INFEC, V9, P900, DOI 10.1080/22221751.2020.1761267
   Bar-On YM, 2020, ELIFE, V9, DOI 10.7554/eLife.57309
   Bezstarosti K., 2020, TARGETED PROTEOMICS, DOI [10.1101/2020.04.23.057810, DOI 10.1101/2020.04.23.057810]
   Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Corrales-Aguilar E, 2016, MED MICROBIOL IMMUN, V205, P409, DOI 10.1007/s00430-016-0457-y
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Finkel Y, 2020, NATURE, DOI 10.1038/s41586-020-2739-1
   Gao T, 2020, HIGHLY PATHOGENIC CO, DOI [10.1101/2020.03.29.20041962, DOI 10.1101/2020.03.29.20041962]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang Angkana T, 2020, medRxiv, DOI 10.1101/2020.04.14.20065771
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Ke ZL, 2020, NATURE, DOI 10.1038/s41586-020-2665-2
   Klein S., 2020, SARS COV 2 STRUCTURE, DOI [10.1101/2020.06.23.167064., DOI 10.1101/2020.06.23.167064]
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Manenti A, 2020, J MED VIROL, V92, P2096, DOI 10.1002/jmv.25986
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   Muruato AE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17892-0
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Ogando NS, 2020, J GEN VIROL, V101, P925, DOI 10.1099/jgv.0.001453
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Perera Ranawaka Apm, 2020, Euro Surveill, V25, DOI 10.2807/1560-7917.ES.2020.25.16.2000421
   Phelan AL, 2020, LANCET, V395, P1595, DOI 10.1016/S0140-6736(20)31034-5
   Reinhard H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014532
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Scholer L, 2020, BIORXIV, DOI [10.1101/2020.06.05.135806, DOI 10.1101/2020.06.05.135806]
   Schwaiger Julia, 2020, J Infect Dis, V222, P1960, DOI 10.1093/infdis/jiaa593
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z
   Trilling M, 2009, J VIROL, V83, P3684, DOI 10.1128/JVI.02042-08
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Whiteman MC, 2018, AM J TROP MED HYG, V99, P1430, DOI 10.4269/ajtmh.17-0948
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhao R, 2020, CLIN INFECT DIS
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 42
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 9
PY 2020
VL 11
AR 573526
DI 10.3389/fimmu.2020.573526
PG 11
WC Immunology
SC Immunology
GA OH0WM
UT WOS:000582293200001
PM 33162987
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Polverino, F
   Stern, DA
   Ruocco, G
   Balestro, E
   Bassetti, M
   Candelli, M
   Cirillo, B
   Contoli, M
   Corsico, A
   D'Amico, F
   D'Elia, E
   Falco, G
   Gasparini, S
   Guerra, S
   Harari, S
   Kraft, M
   Mennella, L
   Papi, A
   Parrella, R
   Pelosi, P
   Poletti, V
   Polverino, M
   Tana, C
   Terribile, R
   Woods, JC
   Di Marco, F
   Martinez, FD
AF Polverino, Francesca
   Stern, Debra A.
   Ruocco, Gaetano
   Balestro, Elisabetta
   Bassetti, Matteo
   Candelli, Marcello
   Cirillo, Bruno
   Contoli, Marco
   Corsico, Angelo
   D'Amico, Filippo
   D'Elia, Emilia
   Falco, Giuseppe
   Gasparini, Stefano
   Guerra, Stefano
   Harari, Sergio
   Kraft, Monica
   Mennella, Luigi
   Papi, Alberto
   Parrella, Roberto
   Pelosi, Paolo
   Poletti, Venerino
   Polverino, Mario
   Tana, Claudio
   Terribile, Roberta
   Woods, Jason C.
   Di Marco, Fabiano
   Martinez, Fernando D.
CA ItaliCO Study Grp
TI Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A
   Nationwide, Italian Observational Study (ItaliCO)
SO FRONTIERS IN CARDIOVASCULAR MEDICINE
LA English
DT Article
DE COVID-19; comorbidities; ACE inhibitors; mortality; cohort study
ID ACE2
AB Background: Italy has one of the world's oldest populations, and suffered one the highest death tolls from Coronavirus disease 2019 (COVID-19) worldwide. Older people with cardiovascular diseases (CVDs), and in particular hypertension, are at higher risk of hospitalization and death for COVID-19. Whether hypertension medications may increase the risk for death in older COVID 19 inpatients at the highest risk for the disease is currently unknown.
   Methods: Data from 5,625 COVID-19 inpatients were manually extracted from medical charts from 61 hospitals across Italy. From the initial 5,625 patients, 3,179 were included in the study as they were either discharged or deceased at the time of the data analysis. Primary outcome was inpatient death or recovery. Mixed effects logistic regression models were adjusted for sex, age, and number of comorbidities, with a random effect for site.
   Results: A large proportion of participating inpatients were >= 65 years old (58%), male (68%), non-smokers (93%) with comorbidities (66%). Each additional comorbidity increased the risk of death by 35% [adjOR = 1.35 (1.2, 1.5) p < 0.001]. Use of ACE inhibitors, ARBs, beta-blockers or Ca-antagonists was not associated with significantly increased risk of death. There was a marginal negative association between ARB use and death, and a marginal positive association between diuretic use and death.
   Conclusions: This Italian nationwide observational study of COVID-19 inpatients, the majority of which >= 65 years old, indicates that there is a linear direct relationship between the number of comorbidities and the risk of death. Among CVDs, hypertension and pre-existing cardiomyopathy were significantly associated with risk of death. The use of hypertension medications reported to be safe in younger cohorts, do not contribute significantly to increased COVID-19 related deaths in an older population that suffered one of the highest death tolls worldwide.
C1 [Polverino, Francesca; Stern, Debra A.; Gasparini, Stefano; Harari, Sergio; Martinez, Fernando D.] Univ Arizona, Tucson, AZ 85721 USA.
   [Polverino, Francesca] Lovelace Resp Res Inst, Albuquerque, NM 87108 USA.
   [Ruocco, Gaetano] Regina Montis Regalis Hosp, Mondovi, Italy.
   [Balestro, Elisabetta] Univ Hosp Padua, Padua, Italy.
   [Bassetti, Matteo; Pelosi, Paolo] San Martino Hosp, Ist Ricovero & Cura Carattere Sci, Genoa, Italy.
   [Candelli, Marcello] Univ Cattolica Sacro Cuore, Agostino Gemelli Univ Polyclin, Rome, Italy.
   [Cirillo, Bruno] Sapienza Univ Rome, Rome, Italy.
   [Contoli, Marco; Papi, Alberto] Univ Ferrara, Ferrara, Italy.
   [Corsico, Angelo] Univ Pavia, Pavia, Italy.
   [D'Amico, Filippo] Azienda Socio Sanit Terr Bergamo EST, Seriate, Italy.
   [D'Elia, Emilia] Osped Papa Giovanni XXIII, Bergamo, Italy.
   [Falco, Giuseppe] Ist Ricovero & Cura Carattere Sci Reggio Emilia, Azienda Unita Sanit Locale, Reggio Emilia, Italy.
   [Gasparini, Stefano] Marche Polytech Univ, Ancona, Italy.
   [Harari, Sergio] San Giuseppe Hosp MultiMed IRCCS, Dept Med Sci, Milan, Italy.
   [Harari, Sergio] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Mennella, Luigi] San Luca Hosp, Vallo Della Lucania, Italy.
   [Parrella, Roberto] Colli Hosp, Dept Infect Dis, Naples, Italy.
   [Poletti, Venerino] L Pierantoni GB Morganis Hosp, Forli, Italy.
   [Polverino, Mario] Mauro Scarlato Hosp, Azienda Sanit Locale Salerno, Scafati, Italy.
   [Tana, Claudio] ASL Lanciano Vasto Chieti, Chieti, Italy.
   [Terribile, Roberta] Univ Hosp Major Charity Novara, Novara, Italy.
   [Woods, Jason C.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
   [Di Marco, Fabiano] Univ Milan, Milan, Italy.
RP Polverino, F (corresponding author), Univ Arizona, Tucson, AZ 85721 USA.; Polverino, F (corresponding author), Lovelace Resp Res Inst, Albuquerque, NM 87108 USA.
EM fpolverino@copdnet.org
RI Candelli, Marcello/W-2375-2019
OI Candelli, Marcello/0000-0001-8443-7880; Stirpe,
   Emanuele/0000-0001-5062-4733
FU FAMRI; Asthma and Airway Disease Research Center, University of Arizona
   research funds
FX This work was funded by the FAMRI and the Asthma and Airway Disease
   Research Center, University of Arizona research funds.
CR Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fosbol EL, 2020, JAMA-J AM MED ASSOC, V324, P168, DOI 10.1001/jama.2020.11301
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01227-2020
   Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Inciardi RM, 2020, EUR HEART J, V41, P1821, DOI 10.1093/eurheartj/ehaa388
   International Institute for Applied Systems Analysis (IIASA), 2018, AG DEM DAT SHEET
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Odone A, 2020, LANCET PUBLIC HEALTH, V5, pE310, DOI 10.1016/S2468-2667(20)30099-2
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Paquissi FC, 2016, THER CLIN RISK MANAG, V12, P851, DOI 10.2147/TCRM.S107635
   Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sama IE, 2020, EUR HEART J, V41, P1810, DOI 10.1093/eurheartj/ehaa373
   Tomasoni D, 2020, EUR J HEART FAIL, V22, P957, DOI 10.1002/ejhf.1871
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Zhang P, 2020, CIRC RES, V126, pE142, DOI 10.1161/CIRCRESAHA.120.317242
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 23
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2297-055X
J9 FRONT CARDIOVASC MED
JI Front. Cardiovasc. Med.
PD OCT 9
PY 2020
VL 7
AR 585866
DI 10.3389/fcvm.2020.585866
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OG4SU
UT WOS:000581876700001
PM 33195473
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Al-Motawa, MS
   Abbas, H
   Wijten, P
   de la Fuente, A
   Xue, MZ
   Rabbani, N
   Thornalley, PJ
AF Al-Motawa, Maryam S.
   Abbas, Hafsa
   Wijten, Patrick
   de la Fuente, Alberto
   Xue, Mingzhan
   Rabbani, Naila
   Thornalley, Paul J.
TI Vulnerabilities of the SARS-CoV-2 Virus to Proteotoxicity-Opportunity
   for Repurposed Chemotherapy of COVID-19 Infection
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE COVID-19; coronavirus; methylglyoxal; glyoxalase; doxorubicin;
   paclitaxel; proteomics; bioinformatics
ID BROMOBENZYLGLUTATHIONE CYCLOPENTYL DIESTER; GLYOXALASE I; ANTIVIRAL
   ACTIVITY; DICARBONYL STRESS; HUMAN SERUM; METHYLGLYOXAL; REPLICATION;
   INHIBITION; CANCER; VITRO
AB The global pandemic of COVID-19 disease caused by infection with the SARS-CoV-2 coronavirus, has produced an urgent requirement and search for improved treatments while effective vaccines are developed. A strategy for improved drug therapy is to increase levels of endogenous reactive metabolites for selective toxicity to SARS-CoV-2 by preferential damage to the viral proteome. Key reactive metabolites producing major quantitative damage to the proteome in physiological systems are: reactive oxygen species (ROS) and the reactive glycating agent methylglyoxal (MG); cysteine residues and arginine residues are their most susceptible targets, respectively. From sequenced-based prediction of the SARS-CoV-2 proteome, we found 0.8-fold enrichment or depletion of cysteine residues in functional domains of the viral proteome; whereas there was a 4.6-fold enrichment of arginine residues, suggesting SARS-CoV-2 is resistant to oxidative agents and sensitive to MG. For arginine residues of the SARS-CoV-2 coronavirus predicted to be in functional domains, we examined which are activated toward modification by MG - residues with predicted or expected low pK(a)by neighboring group in interactions. We found 25 such arginine residues, including 2 in the spike protein and 10 in the nucleoprotein. These sites were partially conserved in relatedcoronaviridae: SARS-CoV and MERS. Finally, we identified drugs which increase cellular MG concentration to virucidal levels: antitumor drugs with historical antiviral activity, doxorubicin and paclitaxel. Our findings provide evidence of potential vulnerability of SARS-CoV-2 to inactivation by MG and a scientific rationale for repurposing of doxorubicin and paclitaxel for treatment of COVID-19 disease, providing efficacy and adequate therapeutic index may be established.
C1 [Al-Motawa, Maryam S.; Thornalley, Paul J.] Hamad Bin Khalifa Univ, Qatar Fdn, Coll Hlth & Life Sci, Doha, Qatar.
   [Al-Motawa, Maryam S.; Wijten, Patrick; de la Fuente, Alberto; Xue, Mingzhan; Thornalley, Paul J.] Hamad Bin Khalifa Univ, Qatar Fdn, Diabet Res Ctr, Qatar Biomed Res Inst, Doha, Qatar.
   [Abbas, Hafsa; Xue, Mingzhan; Thornalley, Paul J.] Univ Warwick, Univ Hosp, Warwick Med Sch, Clin Sci Res Labs, Coventry, W Midlands, England.
   [Rabbani, Naila] Qatar Univ, Coll Med, Dept Basic Med Sci, QU Hlth, Doha, Qatar.
RP Thornalley, PJ (corresponding author), Hamad Bin Khalifa Univ, Qatar Fdn, Coll Hlth & Life Sci, Doha, Qatar.; Thornalley, PJ (corresponding author), Hamad Bin Khalifa Univ, Qatar Fdn, Diabet Res Ctr, Qatar Biomed Res Inst, Doha, Qatar.; Thornalley, PJ (corresponding author), Univ Warwick, Univ Hosp, Warwick Med Sch, Clin Sci Res Labs, Coventry, W Midlands, England.; Rabbani, N (corresponding author), Qatar Univ, Coll Med, Dept Basic Med Sci, QU Hlth, Doha, Qatar.
EM n.rabbani@qu.edu.qa; pthornalley@hbku.edu.qa
FU Qatar Foundation [QB-14]; Qatar University [QU ERGCMED-2020-1]
FX MA-M thanks the Qatar Foundation for a PhD studentship. PJT thanks the
   Qatar Foundation for funding his research program (project code QB-14).
   NR thanks Qatar University for funding her COVID-19 research (project
   code QU ERGCMED-2020-1).
CR Ahmed N, 2005, J BIOL CHEM, V280, P5724, DOI 10.1074/jbc.M410973200
   Ahmed U, 2008, ANN NY ACAD SCI, V1126, P262, DOI 10.1196/annals.1433.035
   Al-Motawa M., 2020, VULNERABILITIES SARS, DOI [10.2139/ssrn.3582068, DOI 10.2139/SSRN.3582068]
   ALLEN RE, 1993, J PROTEIN CHEM, V12, P111, DOI 10.1007/BF01026032
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Arai Makoto, 2014, Biochem Soc Trans, V42, P491, DOI 10.1042/BST20140010
   ASH RJ, 1987, ANTIVIR RES, V8, P71, DOI 10.1016/0166-3542(87)90078-7
   Barrett-Lee PJ, 2009, ANN ONCOL, V20, P816, DOI 10.1093/annonc/mdn728
   BERGAMINI A, 1992, AIDS RES HUM RETROV, V8, P1239, DOI 10.1089/aid.1992.8.1239
   Borowski P, 2002, ANTIVIR RES, V55, P397, DOI 10.1016/S0166-3542(02)00096-7
   Briguglio I, 2011, INT J MED CHEM, V2011, DOI 10.1155/2011/213135
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Charyasriwong S, 2016, DRUG DISCOV THER, V10, P201, DOI 10.5582/ddt.2016.01045
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Chien HC, 2016, DRUG METAB DISPOS, V44, P356, DOI 10.1124/dmd.115.066647
   de Haan CAM, 2005, ADV VIRUS RES, V64, P165, DOI 10.1016/S0065-3527(05)64006-7
   DEBOCK CA, 1957, NATURE, V179, P706, DOI 10.1038/179706a0
   Demel HR, 2015, AM J CANCER RES, V5, P1649
   Fitch CA, 2015, PROTEIN SCI, V24, P752, DOI 10.1002/pro.2647
   Gallet X, 2000, J MOL BIOL, V302, P917, DOI 10.1006/jmbi.2000.4092
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Herrera-Rodriguez J, 2019, VACCINE, V37, P1630, DOI 10.1016/j.vaccine.2019.01.086
   Irshad Z, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44358-1
   Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6
   Kavarana MJ, 1999, J MED CHEM, V42, P221, DOI 10.1021/jm9708036
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Lottes RG, 2014, AM J PHYSIOL-LUNG C, V306, pL947, DOI 10.1152/ajplung.00298.2013
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Maldonado EN, 2010, CANCER RES, V70, P10192, DOI 10.1158/0008-5472.CAN-10-2429
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Meng T, 2020, INSERT SEQUENCE SARS, DOI [10.1101/2020.02.08.926006, DOI 10.1101/2020.02.08.926006]
   Mirzapolazova T, 2007, EUR RESPIR J, V30, P429, DOI 10.1183/09031936.00154206
   Murphy MP, 2011, CELL METAB, V13, P361, DOI 10.1016/j.cmet.2011.03.010
   Neuman BW, 2008, J VIROL, V82, P5279, DOI 10.1128/JVI.02631-07
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pezzulo AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016166
   Rabbani N, 2019, TRENDS ENDOCRIN MET, V30, P419, DOI 10.1016/j.tem.2019.04.011
   Rabbani N, 2018, SEMIN CANCER BIOL, V49, P83, DOI 10.1016/j.semcancer.2017.05.006
   Rabbani N, 2016, CLIN SCI, V130, P1677, DOI 10.1042/CS20160025
   Rabbani N, 2016, GLYCOCONJUGATE J, V33, P553, DOI 10.1007/s10719-016-9709-8
   Rabbani N, 2015, BIOCHEM BIOPH RES CO, V458, P221, DOI 10.1016/j.bbrc.2015.01.140
   Rabbani N, 2014, NAT PROTOC, V9, P1969, DOI 10.1038/nprot.2014.129
   Rabbani N, 2012, AMINO ACIDS, V42, P1133, DOI 10.1007/s00726-010-0783-0
   Rowinsky EK, 1997, ANNU REV MED, V48, P353
   Sakamoto H, 2001, CLIN CANCER RES, V7, P2513
   SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282
   TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249
   Thornalley P.J., 1994, BIOCHEM PHARMACOL, V268, P14189
   Thornalley PJ, 1996, BIOCHEM PHARMACOL, V51, P1365, DOI 10.1016/0006-2952(96)00059-7
   Tylor S, 2009, CAN J MICROBIOL, V55, P254, DOI [10.1139/w08-139, 10.1139/W08-139]
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   Wang L, 2016, BIOINFORMATICS, V32, P614, DOI 10.1093/bioinformatics/btv607
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Winterbourn CC, 2008, NAT CHEM BIOL, V4, P278, DOI 10.1038/nchembio.85
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xue MZ, 2016, DIABETES, V65, P2282, DOI 10.2337/db16-0153
   Xue Mingzhan, 2014, Biochem Soc Trans, V42, P495, DOI 10.1042/BST20140026
NR 63
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 9
PY 2020
VL 11
AR 585408
DI 10.3389/fphar.2020.585408
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OF3HB
UT WOS:000581102200001
PM 33162891
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Brandariz-Nunez, D
   Correas-Sanahuja, M
   Guarc, E
   Picon, R
   Garcia, B
   Gil, R
AF Brandariz-Nunez, David
   Correas-Sanahuja, Marcelo
   Guarc, Eva
   Picon, Rafael
   Garcia, Barbara
   Gil, Rocio
TI Potential drug-drug interactions in COVID 19 patients in treatment with
   lopinavir/ritonavir
SO MEDICINA CLINICA
LA Spanish
DT Article
DE Potential drug-drug interactions; Lopinavir/ritonavir; COVID 19;
   SARS-CoV-2; Protease inhibitor
ID HIV; STATINS; RISK
AB Objectives: To determine the prevalence of potential interactions in COVID-19 patients receiving lopinavir/ritonavir (LPV/r). The secondary objective was to develop recommendations and identify the risk factors associated with presenting potential interactions with LPV/r.
   Subjects and methods: Cross-sectional and multicenter study with the participation of 2 hospitals. COVID-19 patients over 18 years of age, admitted to hospital and under treatment with LPV/r were included. A screening of potential interactions related to LPV/r and home and hospital medication was carried out. Lexicomp (R) (Uptodate), HIV-drug interactions and COVID-drug interactions were used as the query database.
   Results: 361 patients with a mean age of 62.77 +/- 14.64 years were included, where 59.6% (n = 215) were men. 62.3% (n = 225) had 1 or more potential interactions and 26, 87% (n = 97) 2 or more. The independent variables associated with presenting >= 1 potential interactions were age (> 65) (OR 1.95; 95% CI 1.06-3.59, P =.033), ICU admission (OR 9.22; CI 95% 1.98-42.93; P =.005), previous respiratory pathology (OR 2.90; 95% CI 1.15-7.36; P =.024), psychiatric (OR 4.14; 95 CI % 1.36-12.61; P =.013), dyslipidemia (OR 3.21; 95% CI 1.63-6.35; P =.001) and the number of drugs prescribed (OR 4.33; 95% CI 2.40-7.81; P =.000).
   Conclusion: The prevalence of potential interactions in COVD-19 patient undergoing treatment with LPV/r is high, with age (> 65), ICU admission, previous respiratory and psychiatric pathology, dyslipidemia and the number of prescribed drugs acting as risk factors. (C) 2020 Elsevier Espana, S.L.U. All rights reserved.
C1 [Brandariz-Nunez, David; Guarc, Eva; Picon, Rafael; Garcia, Barbara; Gil, Rocio] Hosp Quironsalud, Serv Farm, Barcelona, Spain.
   [Correas-Sanahuja, Marcelo] Hosp CIMA, Serv Farm, Barcelona, Spain.
RP Brandariz-Nunez, D (corresponding author), Hosp Quironsalud, Serv Farm, Barcelona, Spain.
EM vrandariz@gmail.com
CR [Anonymous], HERR ONL INT MED U L
   [Anonymous], HERR ONL INT MED U L
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Bucsa C, 2013, EUR J INTERN MED, V24, P27, DOI 10.1016/j.ejim.2012.09.011
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chauvin B, 2013, CLIN PHARMACOKINET, V52, P815, DOI 10.1007/s40262-013-0075-4
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004
   Documento del Ministerio de Sanidad, 2020, ENF COR COVID 19
   ELANJIAN S, 1993, AM J HOSP PHARM, V50, P2546, DOI 10.1093/ajhp/50.12.2546
   Evans-Jones JG, 2010, CLIN INFECT DIS, V50, P1419, DOI 10.1086/652149
   Goodlet KI, 2019, CNS SPECTRUMS, V24, P287, DOI 10.1017/S109285291800113X
   Hernandez M, 2018, BIOMEDICA, V38, P407, DOI 10.7705/biomedica.v38i4.3884
   Marzolini C, 2010, ANTIVIR THER, V15, P413, DOI 10.3851/IMP1540
   Pedros Cholvi C, 2008, REV ESP GERIATR GERO, V43, P261, DOI DOI 10.1016/S0211-139X(08)1-07119
   Tisdale JE, 2016, CAN PHARM J, V149, P139, DOI 10.1177/1715163516641136
   Tseng A, 2012, CURR INFECT DIS REP, V14, P67, DOI 10.1007/s11908-011-0229-1
   Vandermeer ML, 2012, J INFECT DIS, V205, P13, DOI 10.1093/infdis/jir695
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Yuan S, 2015, MBIO, V6, DOI 10.1128/mBio.01120-15
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 21
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER ESPANA SLU
PI BARCELONA
PA AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN
SN 0025-7753
EI 1578-8989
J9 MED CLIN-BARCELONA
JI Med. Clin.
PD OCT 9
PY 2020
VL 155
IS 7
BP 281
EP 287
DI 10.1016/j.medcli.2020.06.026
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC7QV
UT WOS:000579353000001
PM 32718719
OA Green Published
DA 2021-01-01
ER

PT J
AU Huang, SL
   Wang, SY
   Li, GQ
   Wang, MM
   Yu, WJ
   Shao, GL
   Zhang, J
   Yang, DH
AF Huang, Shaolei
   Wang, Suyao
   Li, Guoqiang
   Wang, Mengmeng
   Yu, Wenjie
   Shao, Guoliang
   Zhang, Jian
   Yang, Dianhui
TI Efficacy and safety of acupuncture therapy for asymptomatic infection of
   COVID-19 A protocol for systematic review and meta-analysis
SO MEDICINE
LA English
DT Article
DE acupuncture; asymptomatic infection of COVID-19; protocol; systematic
ID DISEASE
AB Background: The study aims to evaluate the effectiveness and safety of acupuncture therapy for asymptomatic infection of COVID-19. Methods: The following electronic databases will be searched from December 2019 to December 2020: MEDLINE, PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure (CNKI), Wan-fang database, Chinese Scientific Journal Database (VIP), Chinese Biomedical Literature Databases (CBM), and other databases. All published randomized controlled trials (RCTs) about this topic will be included. Two independent researchers will operate article retrieval, duplication removing, screening, quality evaluation, and data analyses by Review Manager (V.5.3.5). Meta-analyses, subgroup analysis, and/or descriptive analysis will be performed based on the included data conditions. Results: High-quality synthesis and/or descriptive analysis of current evidence will be provided from the time of negative nucleic acid detection for 2 consecutive times (not on the same day), cure rate, converting to clinical diagnosis rate, and side effects of acupuncture. Conclusion: This study will provide the evidence of whether acupuncture is an effective and safe intervention for asymptomatic infection of COVID-19. PROSPERO registration number: CRD 42020179729.
C1 [Huang, Shaolei; Wang, Mengmeng; Shao, Guoliang; Yang, Dianhui] Shandong Univ Tradit Chinese Med, Jinan, Shandong, Peoples R China.
   [Wang, Suyao; Zhang, Jian] Peoples Hosp Lixia Dist, Jinan 250014, Shandong, Peoples R China.
   [Li, Guoqiang] Shandong First Med Univ, Affiliated Hosp 1, Jinan, Shandong, Peoples R China.
   [Yu, Wenjie] Weifang Hosp Tradit Chinese Med, Weifang, Peoples R China.
   [Yang, Dianhui] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Jinan, Shandong, Peoples R China.
RP Zhang, J (corresponding author), Peoples Hosp Lixia Dist, Jinan 250014, Shandong, Peoples R China.
EM 282545101@qq.com
FU Shandong province Science and technology development program of
   Traditional Chinese Medicine
FX This paper is funded by Shandong province Science and technology
   development program of Traditional Chinese Medicine (NO.2019-1059).
CR China Association of Acupuncture-Moxibustion, 2020, CHINESE ACUPUNCT MOX, V40, P462
   Gao W J, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P990, DOI 10.3760/cma.j.cn112338-20200404-00514
   Hosoki K, 2020, J ALLERGY CLIN IMMUN, V146, P285, DOI 10.1016/j.jaci.2020.05.033
   Hsieh PC, 2019, COMPLEMENT THER CLIN, V35, P208, DOI 10.1016/j.ctcp.2019.02.016
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kwon S, 2014, ACUPUNCT MED, V32, P509, DOI 10.1136/acupmed-2014-010629
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Liu M, 2020, CHINESE ACUPUNCT MOX, V40, P471
   Liu Mai-Lan, 2020, Zhongguo Zhen Jiu, V40, P457, DOI 10.13703/j.0255-2930.20200224-k0004
   Liu YL, 2018, INFLAMMATION, V41, P741, DOI 10.1007/s10753-017-0726-y
   Ma Y, 2020, MICROBES INFECT, V22, P212, DOI 10.1016/j.micinf.2020.04.011
   Meng H, 2020, J INFECTION, V81, pE33, DOI 10.1016/j.jinf.2020.04.004
   Miyamae Y, 2020, INT J INFECT DIS, V97, P293, DOI 10.1016/j.ijid.2020.06.020
   Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Qiu ZG, 2020, NEUROCHEM RES, V45, P345, DOI 10.1007/s11064-019-02922-1
   Romagnoli S, 2020, PHYSIOL REV, V100, P1455, DOI 10.1152/physrev.00020.2020
   Wang SH, 2020, BIOENERG RES, V13, P167, DOI 10.1007/s12155-019-10084-9
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 22
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 9
PY 2020
VL 99
IS 41
DI 10.1097/MD.0000000000022697
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC6DZ
UT WOS:000579245800088
PM 33031341
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, Y
   Xie, HY
   Gao, H
   Xie, CG
AF Liu, Yan
   Xie, Hongyan
   Gao, Hong
   Xie, Chunguang
TI Efficacy and safety of DPP-4 inhibitor in the treatment of patients with
   COVID-19 combined with diabetes mellitus A protocol for systematic
   review and meta-analysis
SO MEDICINE
LA English
DT Article
DE COVID-19; diabetes mellitus; DPP-4 inhibitors; meta-analysis; protocol;
   systematic review
ID BIAS
AB Background: DM is a common chronic metabolic disease. COVID-19 is a large-scale infectious disease. Some studies have shown that DM is an independent risk factor that increases COVID-19 mortality or other adverse outcomes. There is currently no specific and effective drug treatment. More and more people realize that DPP-4 inhibitors may play a huge role in fighting COVID-19 combined with diabetes. However, there is no evidence-based medicine to confirm the effectiveness and safety of DPP-4 inhibitors in the treatment of COVID-19 patients with diabetes. Therefore, we will conduct a systematic review and meta-analysis to synthesize the existing clinical evidence. Methods and analysis: Electronic databases include CNKI, Wanfang, VIP, CBM database, Cochrane Library, PubMed, Web of Science, EMBASE, etc. We will retrieve each database from December 2019 to September 2020. At the same time, we will look for clinical trial registration and gray literature. This study only included clinical randomized controlled trials. The reviewers independently conduct literature selection, data analysis, quality analysis, and evaluation. The primary outcomes include mortality rate, morbidity, interleukin-6, tumor necrosis factor-alpha, clinical improvement, symptoms improvement, fasting blood glucose, 2-hour postprandial blood glucose, glycosylated hemoglobin, fasting insulin, adverse reactions, etc. Finally, we will conducted a meta-analysis through Review Manager Software version 5.3. Results: The results will be published in peer-reviewed journals and presented at a relevant conference. Conclusion: This study will explore the effectiveness and safety of DPP-4 inhibitors in the treatment of COVID-19 patients with diabetes. It will provide evidence-based medical evidence for DPP-4 inhibitors in the treatment of diabetes with COVID-19. Registration number: INPLASY202090015.
C1 [Liu, Yan; Xie, Hongyan; Gao, Hong; Xie, Chunguang] Univ Tradit Chinese Med, Hosp Chengdu, Add 39,Shi Er Qiao Rd, Chengdu 610072, Sichuan, Peoples R China.
   [Liu, Yan] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China.
RP Gao, H; Xie, CG (corresponding author), Univ Tradit Chinese Med, Hosp Chengdu, Add 39,Shi Er Qiao Rd, Chengdu 610072, Sichuan, Peoples R China.
EM cdgh76@163.com; xiecg@cdutcm.edu.cn
FU first batch of science and technology emergency projects of Sichuan
   Provincial Science and technology department in 2020 [2020YFS0012,
   2020YFS0013]
FX This project is funded by the first batch of science and technology
   emergency projects of Sichuan Provincial Science and technology
   department in 2020. (2020YFS0012, 2020YFS0013). The sponsors are not
   involved in design, execution, or writing the study.
CR Bouhanick B, 2020, THERAPIE, V75, P327, DOI 10.1016/j.therap.2020.05.006
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dalan R, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108216
   Du HZ, 2020, J CELL MOL MED, V24, P10274, DOI 10.1111/jcmm.15674
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fadini GP, 2020, DIABETES OBES METAB, V22, P1946, DOI 10.1111/dom.14097
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Furlan AD, 2009, SPINE, V34, P1929, DOI 10.1097/BRS.0b013e3181b1c99f
   Higgins J.P., 2019, COCHRANE HDB SYSTEMA
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kumar A, 2020, DIABETES METAB SYND, V14, P535, DOI 10.1016/j.dsx.2020.04.044
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Moher D, 2016, REV ESP NUTR HUM DIE, V20, P148, DOI [10.1186/2046-4053-4-1, 10.14306/renhyd.20.2.223]
   Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010
   Riddle MC, 2019, DIABETES CARE S1, V42, pS34, DOI [10.2337/dc19-S004, DOI 10.2337/DC19-S004]
   Solerte SB, 2020, ACTA DIABETOL, V57, P779, DOI 10.1007/s00592-020-01539-z
   Tao ZQ, 2015, CELL BIOCHEM BIOPHYS, V73, P181, DOI 10.1007/s12013-015-0598-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu ZH, 2020, ACTA DIABETOL, DOI 10.1007/s00592-020-01546-0
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
NR 20
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 9
PY 2020
VL 99
IS 41
DI 10.1097/MD.0000000000022592
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC6DZ
UT WOS:000579245800058
PM 33031311
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Klug, B
   Schnierle, B
   Trebesch, I
AF Klug, Bettina
   Schnierle, Barbara
   Trebesch, Isabel
TI Monoclonal antibodies for anti-infective therapy
SO BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ
LA German
DT Article
DE Immunetherapy; Anti-viral monoclonal antibodies; Anti-bacterial
   monoclonal antibodie; Symptomatic treatment; SARS-CoV-2
ID CORONAVIRUS; SARILUMAB
AB Sera of animal origin and hyperimmunoglobulins have dominated serum therapy for a century. Although numerous monoclonal antibodies (MABs) have been developed since the end of the 1980s, particularly for the treatment of immunological and oncological diseases, it will take 20 years before the first anti-infective MAB is approved in the European Union. Interestingly, to combat the COVID-19 pandemic, numerous MABs, which are approved in particular for immunological indications, are currently being used to treat the consequences of SARS-CoV-2 infection, such as pneumonia or hyperimmune reactions. The approved monoclonal antibodies for the treatment of infectious diseases are presented here. In addition, an overview of the current developments, in particular in the treatment of SARS-CoV-2 infection, is provided.
C1 [Klug, Bettina; Schnierle, Barbara] Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
   [Trebesch, Isabel] Robert Koch Inst, Berlin, Germany.
RP Klug, B (corresponding author), Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
EM Bettina.Klug@pei.de
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR [Anonymous], 2013, Arthritis Rheum, V65, pS1, DOI 10.1002/art.38216
   Behring, 1965, Dtsch Med Wochenschr, V90, P2183
   Berry JD, 2011, NEW BIOTECHNOL, V28, P489, DOI 10.1016/j.nbt.2011.03.018
   Bosmann M, 2014, EXPERT OPIN THER TAR, V18, P703, DOI 10.1517/14728222.2014.902938
   Chien JY, 2006, RESPIROLOGY, V11, P715, DOI 10.1111/j.1440-1843.2006.00942.x
   Chow SK, 2012, TOXINS, V4, P430, DOI 10.3390/toxins4060430
   Crotti C, 2019, DRUGS, V79, P1741, DOI 10.1007/s40265-019-01192-z
   Dhimolea E, 2010, MABS-AUSTIN, V2, P3, DOI 10.4161/mabs.2.1.10328
   European Medicines Agency, 2019, COMM MED PROD HUM US
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Gomez-Rial J, 2020, CLIN IMMUNOL, V216, DOI 10.1016/j.clim.2020.108442
   Graham BS, 2015, CURR OPIN HIV AIDS, V10, P129, DOI 10.1097/COH.0000000000000154
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   GRUNDBACHER FJ, 1992, IMMUNOL TODAY, V13, P188, DOI 10.1016/0167-5699(92)90125-Q
   Hashimoto K, 2017, FUKUSHIMA J MED SCI, V63, P127, DOI 10.5387/fms.2017-09
   Igarashi T, 1999, NAT MED, V5, P211, DOI 10.1038/5576
   Kim ES, 2016, J KOREAN MED SCI, V31, P1717, DOI 10.3346/jkms.2016.31.11.1717
   Kim GW, 2015, ARCH PHARM RES, V38, P575, DOI 10.1007/s12272-015-0569-8
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   KUNG PC, 1979, SCIENCE, V206, P347, DOI 10.1126/science.314668
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lamb YN, 2018, DRUGS, V78, P929, DOI 10.1007/s40265-018-0929-z
   Leneva IA, 2019, J MED VIROL, V91, P588, DOI 10.1002/jmv.25358
   McKeage K, 2019, DRUGS, V79, P347, DOI 10.1007/s40265-019-01068-2
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Morrison AR, 2020, J MED VIROL, V92, P1791, DOI 10.1002/jmv.25907
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   NORMAN DJ, 1987, NEPHRON, V46, P41, DOI 10.1159/000184433
   Pelfrene E, 2019, CLIN MICROBIOL INFEC, V25, P60, DOI 10.1016/j.cmi.2018.04.024
   Prabakaran M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005672
   Raimondo MG, 2017, DRUG DES DEV THER, V11, P1593, DOI 10.2147/DDDT.S100302
   Salazar G, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0019-3
   Saylor C, 2009, VACCINE, V27, pG38, DOI 10.1016/j.vaccine.2009.09.105
   Shun XWL, 2018, ANTIBODIES, V7, DOI 10.3390/antib7010005
   Sitenga J, 2018, PATIENT-RELAT OUTCOM, V9, P35, DOI 10.2147/PROM.S140011
   Soares MM, 2008, NAT MED, V14, P1357, DOI 10.1038/nm.1885
   Sparrow E, 2017, B WORLD HEALTH ORGAN, V95, P235, DOI [10.2471/blt.16.178061, 10.2471/BLT.16.178061]
   Stern RM, 2019, THER ADV HEMATOL, V10, DOI 10.1177/2040620719874728
   Sun SH, 2015, CLIN INFECT DIS, V60, P586, DOI 10.1093/cid/ciu887
   Taylor PC, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1879-x
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Uciechowski P, 2020, ONCOLOGY-BASEL, V98, P131, DOI 10.1159/000505099
   Vallurupalli M, 2019, BLOOD, V134, P1783, DOI 10.1182/blood.2019002289
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang RX, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.28
   Widjaja I, 2019, EMERG MICROBES INFEC, V8, P516, DOI 10.1080/22221751.2019.1597644
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 48
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1436-9990
EI 1437-1588
J9 BUNDESGESUNDHEITSBLA
JI Bundesgesundheitsblatt-Gesund.
PD NOV
PY 2020
VL 63
IS 11
SI SI
BP 1396
EP 1402
DI 10.1007/s00103-020-03229-1
EA OCT 2020
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OO1BD
UT WOS:000579302300001
PM 33034695
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jiang, YP
   Zhao, XX
   Lv, HQ
   Wen, CP
AF Jiang, Yue-Peng
   Zhao, Xiao-Xuan
   Lv, Hui-Qing
   Wen, Cheng-Ping
TI Drug screening and development from the affinity of S protein of new
   coronavirus with ACE2
SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; ACE2; Spike protein; Drug
ID ANGIOTENSIN-CONVERTING ENZYME; HUMAN MONOCLONAL-ANTIBODY; SARS-COV
   ENTRY; SPIKE PROTEIN; POTENT INHIBITORS; BAT CORONAVIRUSES; LIPID RAFTS;
   PEPTIDES; RECEPTOR; REGIONS
AB Recently, various studies have shown that angiotensin-converting enzyme 2 (ACE2) acts as the "doorknob" that can be bound by the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which conduces to its entrance to the host cells, and plays an important role in corona virus disease 2019 (COVID-19). This paper aims to collect and sorts out the existing drugs, which exert the ability to block the binding of S protein and ACE2 so as to provide directions for the later drug development. By reviewing the existing literature, we expound the pathogenesis of SARS-CoV-2 from the perspective of S protein and ACE2 binding, and summarize the drugs and compounds that can interfere with the interaction of spike protein and ACE2 receptor from different ways. We summarized five kinds of substances, including peptide P6, griffithsin, hr2p analogs, EK1, vaccine, monoclonal antibody, cholesterol-depleting agents, and extracts from traditional Chinese medicine. They can fight SARS-CoV-2 by specifically binding to ACE2 receptor, S protein, or blocking membrane fusion between the host and virus. ACE2 is the key point for SARS-CoV-2 to enter the cells, and it is also the focus of drug intervention. Our drug summary on this pathomechanism is expected to provide ideas for the drug research on SARS-CoV-2 and help to develop anti-coronavirus drugs of broad spectrum for future epidemics.
C1 [Jiang, Yue-Peng; Wen, Cheng-Ping] Zhejiang Chinese Med Univ, Coll Basic Med Sci, Hangzhou 310058, Peoples R China.
   [Zhao, Xiao-Xuan] Heilongjiang Univ Chinese Med, Dept Gynecol, Harbin 150040, Peoples R China.
   [Lv, Hui-Qing] Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 310053, Peoples R China.
RP Wen, CP (corresponding author), Zhejiang Chinese Med Univ, Coll Basic Med Sci, Hangzhou 310058, Peoples R China.; Lv, HQ (corresponding author), Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 310053, Peoples R China.
EM hzlhq@126.com; wengcp@163.com
CR Acharya KR, 2003, NAT REV DRUG DISCOV, V2, P891, DOI 10.1038/nrd1227
   Arunachalam R, 2020, BIORXIV
   Bian YJ, 2020, NATURE, DOI 10.1038/s41586-020-2682-1
   Bosch BJ, 2004, P NATL ACAD SCI USA, V101, P8455, DOI 10.1073/pnas.0400576101
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Fischer DD, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00172-17
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Glende J, 2008, VIROLOGY, V381, P215, DOI 10.1016/j.virol.2008.08.026
   Han DP, 2006, VIROLOGY, V350, P15, DOI 10.1016/j.virol.2006.01.029
   He X, 2020, INTEGRATIVE BIOINFOR
   Ho TY, 2007, ANTIVIR RES, V74, P92, DOI 10.1016/j.antiviral.2006.04.014
   Hoffmann M., 2020, NOVEL CORONAVIRUS 20
   Jiang S, 2012, EMERG MICROBES INFEC
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Ksiazek TG, 2003, NEW ENGL J MED
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lancet G, 2020, LANCET
   Larbi A, 2004, EXP GERONTOL, V39, P551, DOI 10.1016/j.exger.2003.10.031
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li GM, 2007, MICROBES INFECT, V9, P96, DOI 10.1016/j.micinf.2006.10.015
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   Liu W., 2020, CHEMBIOCHEM
   Lu H., 2020, BIOSCI TRENDS
   Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067
   Lu R, 2020, LANCET
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Miao XN, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2020.1804241
   Ming N, 2020, RAPID SCREENING MODE
   O'Keefe BR, 2010, J VIROL, V84, P2511, DOI 10.1128/JVI.02322-09
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Phan T, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104211
   Turner AJ, 2002, TRENDS PHARMACOL SCI, V23, P177, DOI 10.1016/S0165-6147(00)01994-5
   Wang C, 2019, IEEE IND ELEC, P2020, DOI 10.1109/IECON.2019.8927477
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Wrapp D., 2020, BIORXIV
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xin L, 2020, BIORXIV
   Xu Z., 2020, BIORXIV
   Yan L, 2020, BIORXIV
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yuan KH, 2004, BIOCHEM BIOPH RES CO, V319, P746, DOI 10.1016/j.bbrc.2004.05.046
   Zheng BJ, 2005, ANTIVIR THER, V10, P393
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
   Zisman LS, 2003, CIRCULATION, V108, P1707, DOI 10.1161/01.CIR.0000094734.67990.99
NR 55
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0934-9723
EI 1435-4373
J9 EUR J CLIN MICROBIOL
JI Eur. J. Clin. Microbiol. Infect. Dis.
DI 10.1007/s10096-020-04048-7
EA OCT 2020
PG 9
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA OC6MM
UT WOS:000579270100002
PM 33034780
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Boomhower, J
   Noland, HE
   Frakes, MA
   Seethala, RR
   Cohen, JE
   Wilcox, SR
AF Boomhower, James
   Noland, Heidi E.
   Frakes, Michael A.
   Seethala, Raghu R.
   Cohen, Jason E.
   Wilcox, Susan R.
TI Transport of a Nonintubated Prone Patient with Severe Hypoxemic
   Respiratory Failure Due to COVID-19
SO PREHOSPITAL EMERGENCY CARE
LA English
DT Article; Early Access
DE prone; ARDS; hypoxemia; transport; patient safety
AB With the COVID-19 pandemic, healthcare systems have been facing an unprecedented, large-scale respiratory disaster. Prone positioning improves mortality in severe hypoxemic respiratory failure, including COVID-19. While this is effective for intubated patients with moderate-to-severe ARDS, it has also been shown to be beneficial for non-intubated patients. Critical care transport (CCT) has become an essential component of combating COVID-19, frequently transporting patients to receive advanced respiratory therapies and distribute patients in concert with available resources. With increasing awake proning, CCT teams may encounter patients supported in the prone position. Historically, transporting in the prone position has not been embraced due to substantial risks of desaturation during transport. In this case report, we describe the first known report of transporting a non-intubated, critically ill COVID-19 patient in the prone position.
C1 [Boomhower, James; Noland, Heidi E.; Frakes, Michael A.] Boston MedFlight, Boston, MA USA.
   [Seethala, Raghu R.] Brigham & Womens Hosp, Dept Emergency Med, Div Emergency Crit Care Med, 75 Francis St, Boston, MA 02115 USA.
   [Cohen, Jason E.] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.
   [Wilcox, Susan R.] Massachusetts Gen Hosp, Dept Emergency Med, Bedford, MA USA.
   [Wilcox, Susan R.] Massachusetts Gen Hosp, Heart Ctr ICU, Bedford, MA USA.
RP Wilcox, SR (corresponding author), Massachusetts Gen Hosp, Dept Emergency Med, Heart Ctr ICU, 55 Fruit St, Boston, MA 02114 USA.
EM swilcox1@partners.org
CR Bergman LM, 2017, CRIT CARE MED, V45, pE1043, DOI 10.1097/CCM.0000000000002653
   Caputo ND, 2020, ACAD EMERG MED, V27, P375, DOI 10.1111/acem.13994
   CDC, 2020, COR DIS 2019 COVID 1
   Coppo A, 2020, LANCET RESP MED, V8, P765, DOI 10.1016/S2213-2600(20)30268-X
   DellaVolpe JD, 2016, PREHOSP EMERG CARE, V20, P643, DOI 10.3109/10903127.2016.1162888
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Hersey David, 2018, Air Med J, V37, P206, DOI 10.1016/j.amj.2018.02.003
   Lyphout C, 2018, INT EMERG NURS, V36, P22, DOI 10.1016/j.ienj.2017.07.008
   Parmentier-Decrucq E, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-10
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Swickard Scott, 2018, Air Med J, V37, P253, DOI 10.1016/j.amj.2018.02.009
   Taccone P, 2009, JAMA-J AM MED ASSOC, V302, P1977, DOI 10.1001/jama.2009.1614
   Thompson Alison E, 2020, JAMA Intern Med, DOI 10.1001/jamainternmed.2020.3030
   Wilcox SR, 2017, J INTENSIVE CARE MED, V32, P163, DOI 10.1177/0885066616668484
   Wilcox Susan R, 2015, Air Med J, V34, P369, DOI 10.1016/j.amj.2015.07.006
NR 15
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1090-3127
EI 1545-0066
J9 PREHOSP EMERG CARE
JI Prehosp. Emerg. Care
DI 10.1080/10903127.2020.1819492
EA OCT 2020
PG 4
WC Emergency Medicine; Public, Environmental & Occupational Health
SC Emergency Medicine; Public, Environmental & Occupational Health
GA OC8AA
UT WOS:000579377600001
PM 32886569
DA 2021-01-01
ER

PT J
AU Safa, O
   Hassaniazad, M
   Farashahinejad, M
   Davoodian, P
   Dadvand, H
   Hassanipour, S
   Fathalipour, M
AF Safa, Omid
   Hassaniazad, Mehdi
   Farashahinejad, Mehdi
   Davoodian, Parivash
   Dadvand, Habib
   Hassanipour, Soheil
   Fathalipour, Mohammad
TI Effects of Ginger on clinical manifestations and paraclinical features
   of patients with Severe Acute Respiratory Syndrome due to COVID-19: A
   structured summary of a study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomized controlled trial; Protocol; Ginger; GI symptoms;
   C-reactive protein
AB Objectives: We investigate the effects of Ginger, compared to the usual therapeutic regimen on clinical manifestations and paraclinical features in patients with confirmed COVID-19 that are moderately ill.
   Trial design: This is a single center, randomized, double-blind, placebo-controlled clinical trial with parallel group design.
   Participants: Inclusion criteria:
   1. Patients admitted to Severe Acute Respiratory Syndrome (SARS) Departments at Shahid Mohammadi Hospital, Bandar Abbas, Iran
   2. Age >= 18 years (weight >= 35 kg)
   3. Hospitalized <= 48 hours
   4. Confirmed SARS-CoV-2 diagnosis (Positive polymerase chain reaction (PCR))
   5. Moderate pneumonia and lung involvement in imaging
   6. Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm
   Exclusion criteria:
   1. Underlying diseases, including heart disease, chronic hypertension, severe renal failure, severe liver failure, and thyroid disorders
   2. Use of warfarin, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), diuretics, corticosteroids, and antiarrhythmic drugs
   3. Severe and critical pneumonia
   4. History of known allergy to Ginger
   5. Pregnancy and breastfeeding
   Intervention and comparator: Intervention group: The standard treatment regimen for COVID-19 along with Ginger-based herbal tablets (Vomigone (R), Dineh Pharmaceutical Company, Iran) at a dose of 1000 mg three times a day for a period of seven days.
   Control group: The standard treatment for COVID-19 based on the Iranian Ministry of Health and Medical Education's protocol, along with Vomigone-like placebo tablets (Dineh Pharmaceutical Company, Iran) at a dose of two tablets three times a day for a period of seven days.
   Main outcomes: The primary outcome is recovery rate of clinical symptoms, including fever, dry cough, tiredness, and GI symptoms as well as paraclinical features, including thrombocytopenia, lymphocytopenia, and C-reactive protein within seven days of randomization.
   Time to improvement of clinical and paraclinical features along with the incidence of serious adverse events are the secondary outcomes within seven days of randomization.
   Randomization: An interactive web-based system will be used to allocate eligible participants, based on the inclusion and exclusion criteria, to one of the two study arms (in a 1:1 ratio) using block randomization.
   Blinding (masking): All study participants, research coordinators, clinicians, nurses, and investigators will be blinded to the group assignment.
   Numbers to be randomized (sample size): A total of 84 participants will be randomized into two groups of 42 patients.
   Trial Status: The protocol is Version 1.0, May 23, 2020. Recruitment began July 21, 2020, and is anticipated to be completed by October 30, 2020.
   Trial registration: This clinical trial has been registered in the Iranian Registry of Clinical Trials (IRCT). The registration number is "IRCT20200506047323N1". Registration date is 23 May 2020.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Safa, Omid] Hormozgan Univ Med Sci, Dept Clin Pharm, Fac Pharm, Bandar Abbas, Iran.
   [Hassaniazad, Mehdi; Farashahinejad, Mehdi; Davoodian, Parivash; Dadvand, Habib] Hormozgan Univ Med Sci, Hormozgan Hlth Inst, Infect & Trop Dis Res Ctr, Bandar Abbas, Iran.
   [Hassanipour, Soheil] Guilan Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Rasht, Iran.
   [Fathalipour, Mohammad] Hormozgan Univ Med Sci, Dept Pharmacol & Toxicol, Fac Pharm, Bandar Abbas, Iran.
   [Fathalipour, Mohammad] Hormozgan Univ Med Sci, Endocrinol & Metab Res Ctr, Bandar Abbas, Iran.
RP Fathalipour, M (corresponding author), Hormozgan Univ Med Sci, Dept Pharmacol & Toxicol, Fac Pharm, Bandar Abbas, Iran.; Fathalipour, M (corresponding author), Hormozgan Univ Med Sci, Endocrinol & Metab Res Ctr, Bandar Abbas, Iran.
EM M.fathalipour@hums.ac.ir
RI Hassanipour, Soheil/Y-7903-2019; Fathalipour, Mohammad/L-9204-2016
OI Fathalipour, Mohammad/0000-0002-4568-7024
FU Hormozgan University of Medical Sciences, Bandar Abbas, Iran [990089]
FX This trial has been supported by Hormozgan University of Medical
   Sciences, Bandar Abbas, Iran (grant no. 990089). The funders did not
   have a role in the design of the trial, the intervention procedures,
   collection, evaluation, and analysis of data.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 9
PY 2020
VL 21
IS 1
AR 841
DI 10.1186/s13063-020-04765-6
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OB6OH
UT WOS:000578587800001
PM 33036662
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hu, FY
   Chen, FJ
   Ou, ZH
   Fan, QH
   Tan, XH
   Wang, YP
   Pan, YJ
   Ke, BX
   Li, LH
   Guan, YJ
   Mo, XN
   Wang, J
   Wang, JL
   Luo, C
   Wen, XL
   Li, M
   Ren, PD
   Ke, CW
   Li, JH
   Lei, CL
   Tang, XP
   Li, F
AF Hu, Fengyu
   Chen, Fengjuan
   Ou, Zhihua
   Fan, Qinghong
   Tan, Xinghua
   Wang, Yaping
   Pan, Yuejun
   Ke, Bixia
   Li, Linghua
   Guan, Yujuan
   Mo, Xiaoneng
   Wang, Jian
   Wang, Jinlin
   Luo, Chun
   Wen, Xueliang
   Li, Min
   Ren, Peidi
   Ke, Changwen
   Li, Junhua
   Lei, Chunliang
   Tang, Xiaoping
   Li, Feng
TI A compromised specific humoral immune response against the SARS-CoV-2
   receptor-binding domain is related to viral persistence and periodic
   shedding in the gastrointestinal tract
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article
DE SARS-CoV-2; protective antibody; gastrointestinal infection; virus
   recurrence
ID COVID-19; RNA
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been redetected after discharge in some coronavirus disease 2019 (COVID-19) patients. The reason for the recurrent positivity of the test and the potential public health concern due to this occurrence are still unknown. Here, we analyzed the viral data and clinical manifestations of 289 domestic Chinese COVID-19 patients and found that 21 individuals (7.3%) were readmitted for hospitalization after detection of SARS-CoV-2 after discharge. First, we experimentally confirmed that the virus was involved in the initial infection and was not a secondary infection. In positive retests, the virus was usually found in anal samples (15 of 21, 71.4%). Through analysis of the intracellular viral subgenomic messenger RNA (sgmRNA), we verified that positive retest patients had active viral replication in their gastrointestinal tracts (3 of 16 patients, 18.7%) but not in their respiratory tracts. Then, we found that viral persistence was not associated with high viral titers, delayed viral clearance, old age, or more severe clinical symptoms during the first hospitalization. In contrast, viral rebound was associated with significantly lower levels of and slower generation of viral receptor-binding domain (RBD)-specific IgA and IgG antibodies. Our study demonstrated that the positive retest patients failed to create a robust protective humoral immune response, which might result in SARS-CoV-2 persistence in the gastrointestinal tract and possibly in active viral shedding. Further exploration of the mechanism underlying the rebound in SARS-CoV-2 in this population will be crucial for preventing virus spread and developing effective vaccines.
C1 [Hu, Fengyu; Chen, Fengjuan; Fan, Qinghong; Tan, Xinghua; Wang, Yaping; Pan, Yuejun; Li, Linghua; Guan, Yujuan; Mo, Xiaoneng; Wang, Jian; Wang, Jinlin; Luo, Chun; Wen, Xueliang; Lei, Chunliang; Tang, Xiaoping; Li, Feng] Guangzhou Eighth Peoples Hosp, Guangzhou 510440, Peoples R China.
   [Ou, Zhihua; Li, Min; Ren, Peidi; Li, Junhua] BGI Shenzhen, Shenzhen Key Lab Unknown Pathogen Identificat, Shenzhen 518083, Peoples R China.
   [Ke, Bixia; Ke, Changwen] Guangdong Prov Ctr Dis Control & Prevent, Guangzhou 511430, Peoples R China.
   [Li, Min] Univ Chinese Acad Sci, BGI Educ Ctr, Shenzhen 518083, Peoples R China.
   [Li, Junhua] South China Univ Technol, Sch Biol & Biol Engn, Guangzhou 510006, Peoples R China.
RP Lei, CL; Tang, XP; Li, F (corresponding author), Guangzhou Eighth Peoples Hosp, Guangzhou 510440, Peoples R China.
EM gz8hlcl@126.com; tangxiaopinggz@163.com; gz8h_lifeng@126.com
OI Ou, Zhihua/0000-0002-1479-9007; Li, Junhua/0000-0001-6784-1873
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81670536, 81770593]; National Grand Program
   on Key Infectious Disease Control [2017ZX10202203-004-002,
   2018ZX10301404-003-002]
FX We thank all the physicians and nurses who cared for these patients and
   collected the samples in the isolation ward. We also thank all the
   laboratory technicians who handled the samples and performed the
   measurements in Guangzhou Eighth People's Hospital. We thank Dr. Daxi
   Wang and Miss Wanying Sun for their assistance with constructing the
   sgmRNA detection pipeline and Mr. Jiandong Li for his experimental
   assistance. We thank the China National GeneBank for providing
   sequencing services. We also acknowledge all the authors who contributed
   SARSCoV-2 genomes to the GISAID platform. This work was supported by the
   National Natural Science Foundation of China (Nos. 81670536 and
   81770593) and the National Grand Program on Key Infectious Disease
   Control (2017ZX10202203-004-002 and 2018ZX10301404-003-002).
CR Bradley BT, 2020, LANCET, V396, P320, DOI 10.1016/S0140-6736(20)31305-2
   Chen DB, 2020, INT J INFECT DIS, V93, P297, DOI 10.1016/j.ijid.2020.03.003
   Derespina KR, 2020, J PEDIATR-US, V226, P55, DOI 10.1016/j.jpeds.2020.07.039
   Feng Y.Y, 2018, REGTOOLS INTEGRATED, DOI [10.1101/436634, DOI 10.1101/436634]
   Hao XJ, 2020, NATURE, DOI 10.1038/s41586-020-2554-8
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Huang J, 2020, RECURRENCE SARS COV, DOI [10.1101/2020.05.06.20089573, DOI 10.1101/2020.05.06.20089573]
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kang YJ, 2020, DISASTER MED PUBLIC, V14, P384, DOI [10.1017/dmp.2020.60, 10.1017/dmp.2020.141]
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/nmeth.3317, 10.1038/NMETH.3317]
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Ma H, 2020, CELL MOL IMMUNOL, V17, P773, DOI 10.1038/s41423-020-0474-z
   Mei Q, 2020, LANCET INFECT DIS, V20, P1004, DOI 10.1016/S1473-3099(20)30433-3
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Pyrc K, 2004, VIROL J, V1, DOI 10.1186/1743-422X-1-7
   Sola I, 2015, ANNU REV VIROL, V2, P265, DOI 10.1146/annurev-virology-100114-055218
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang XR, 2020, INT J INFECT DIS, V95, P433, DOI 10.1016/j.ijid.2020.04.063
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wong J, 2020, PROBABLE CAUSES RISK, DOI [10.1101/2020.04.30.20086082, DOI 10.1101/2020.04.30.20086082]
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiao MF, 2020, BIORXIV, DOI [10.1101/2020.03.16.993584, DOI 10.1101/2020.03.16.993584]
   Xu X, 2020, NAT MED, V26, P1193, DOI 10.1038/s41591-020-0949-6
   Yao XH, 2020, CELL RES, V30, P541, DOI 10.1038/s41422-020-0318-5
   Yu Guangchuang, 2020, Curr Protoc Bioinformatics, V69, pe96, DOI 10.1002/cpbi.96
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 31
TC 0
Z9 0
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1672-7681
EI 2042-0226
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
PD NOV
PY 2020
VL 17
IS 11
BP 1119
EP 1125
DI 10.1038/s41423-020-00550-2
EA OCT 2020
PG 7
WC Immunology
SC Immunology
GA OJ1AF
UT WOS:000578521700002
PM 33037400
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kallingal, A
   Kundil, VT
   Ayyolath, A
   Karlapudi, AP
   Joseph, TM
   Variyar, EJ
AF Kallingal, Anoop
   Kundil, Varun Thachan
   Ayyolath, Aravind
   Karlapudi, Abraham Peele
   Joseph, Tomy Muringayil
   Variyar, Jayadevi E.
TI Molecular modeling study of tectoquinone and acteoside fromTectona
   grandislinn: a new SARS-CoV-2 main protease inhibitor against COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Tectoquinone; Acteoside; SARS-CoV-2; Mpro inhibitor; COVID-19; molecular
   modeling
AB Coronavirus disease 2019 (COVID-19), a highly contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has drastically changed the lifestyle of people around the globe. Due to the lack of specific and effective antiviral drugs, transmission of the disease increases exponentially and makes it more serious and harder to control. Drugs that were assumed to be effective against COVID-19 have failed in various stages of clinical trials and this made the scientific community more disappointed. But, the race of researchers for developing new and effective antiviral to stop the disease progression still continues and our work is one among them. This study is an attempt to analyze the action of Tectoquinone and Acteoside; an important phytocompound, on SARS-CoV2 viral protease via in silico approach. The compounds were selected on the basis of their molecular docking values and they were subjected to molecular dynamics simulations about 50 ns to determine the stability and the thermodynamic feasibility between the target and the ligands. Binding energies like hydrogen bonding, hydrophobic and electrostatic interactions of the complexes were determined after MD simulations. The Pharmacokinetics and drug likeness evaluation of the compounds provide a strong evidence for the use of these compounds in developing drugs for clinical trials. Thus, the current study reveals the potential phytoconstituents present inTectona grandisLinn to inhibit COVID-19 viral protease and thereby act as a lead therapeutic agent. Communicated by Ramaswamy H. Sarma
C1 [Kallingal, Anoop; Kundil, Varun Thachan; Ayyolath, Aravind; Variyar, Jayadevi E.] Kannur Univ, Sch Lifesci, Dept Biotechnol & Microbiol, Kannur 670661, Kerala, India.
   [Karlapudi, Abraham Peele] Vignans Fdn Sci Technol & Res, Dept Biotechnol, Guntur, Andhra Pradesh, India.
   [Joseph, Tomy Muringayil] Gdansk Univ Technol, Chem Fac, Polymers Technol Dept, Gdansk, Poland.
RP Variyar, EJ (corresponding author), Kannur Univ, Sch Lifesci, Dept Biotechnol & Microbiol, Kannur 670661, Kerala, India.
EM ejayadevi@gmail.com
OI T K, Varun/0000-0003-4797-8850; Ayyolath, Aravind/0000-0002-2858-1703;
   Kallingal, Anoop/0000-0002-9613-3259
CR Amin SA, 2020, EUR J MED CHEM, V201, DOI 10.1016/j.ejmech.2020.112559
   Amudha M., 2016, ASIAN J PHARM CLIN R, V9
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anoop K., 2020, SCREENING POTENTIAL, DOI [https://doi.org/10.21203/rs.3.rs-21617/v1, 10.21203/rs.3.rs-21617/v1, DOI 10.21203/RS.3.RS-21617/V1]
   Awoniyi O., 2020, PETRIDISH EFFECT DIS, DOI [https://doi.org/10.1017/dmp.2020.67, 10.1017/dmp.2020.67, DOI 10.1017/DMP.2020.67]
   Cascella M, 2020, FEATURES EVALUATION
   CHOWDHURY P, 2020, J BIOMOL STRUCT 0806, DOI DOI https://doi.org/10.1080/07391102.2020.1803968
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Gopal Samy B., 2015, INT J ADV RES COMPUT, V5, P75
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   GUPTA MK, 2020, J BIOMOL STRUCT 0413, DOI DOI https://doi.org/10.1080/07391102.2020.1751300
   Ji YP, 2020, LANCET GLOB HEALTH, V8, pE480, DOI 10.1016/S2214-109X(20)30068-1
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Kumar D.V, 2017, J BACTERIOL MYCOL, V5, P363, DOI [10.15406/jbmoa.2017.05.00147, DOI 10.15406/JBMOA.2017.05.00147]
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   MUCHTARIDI M, 2020, MOLECULES, V25, DOI DOI https://doi.org/10.3390/molecules25173980
   Ng WL, 2020, J MACROECON, V65, DOI 10.1016/j.jmacro.2020.103230
   Panahi L, 2020, ARCH ACAD EMERG MED, V8
   Parasuraman P., 2014, INT J PHARM PHARM SC, V2
   Patel SK, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101831
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Qamar MTU, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38450-1
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Schrodinger L, 2015, MESQUITE MODULAR SYS, V1, P8
   TRIPATHI MK, 2020, J BIOMOL STRUCT 0706, DOI DOI https://doi.org/10.1080/07391102.2020.1790425
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 31
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1832580
EA OCT 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA OB2XI
UT WOS:000578336500001
PM 33036548
OA Bronze
DA 2021-01-01
ER

PT J
AU Sarfaraz, S
   Muneer, I
   Liu, HY
AF Sarfaraz, Sara
   Muneer, Iqra
   Liu, Haiyan
TI Combining fragment docking with graph theory to improve ligand docking
   for homology model structures
SO JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
LA English
DT Article
DE Fragment docking; Homology modeling; Graph theory; Maximum clique;
   Cytochrome P450-substrate complex
ID SECONDARY STRUCTURE MOTIFS; MOLECULAR DOCKING; PROTEIN FLEXIBILITY;
   SCORING FUNCTION; DRUG DESIGN; PREDICTION; ACCURACY; ALGORITHMS;
   PROGRAM; IMPACT
AB Computational protein-ligand docking is well-known to be prone to inaccuracies in input receptor structures, and it is challenging to obtain good docking results with computationally predicted receptor structures (e.g. through homology modeling). Here we introduce a fragment-based docking method and test if it reduces requirements on the accuracy of an input receptor structures relative to non-fragment docking approaches. In this method, small rigid fragments are docked first using AutoDock Vina to generate a large number of favorably docked poses spanning the receptor binding pocket. Then a graph theory maximum clique algorithm is applied to find combined sets of docked poses of different fragment types onto which the complete ligand can be properly aligned. On the basis of these alignments, possible binding poses of complete ligand are determined. This docking method is first tested for bound docking on a series of Cytochrome P450 (CYP450) enzyme-substrate complexes, in which experimentally determined receptor structures are used. For all complexes tested, ligand poses of less than 1 angstrom root mean square deviations (RMSD) from the actual binding positions can be recovered. Then the method is tested for unbound docking with modeled receptor structures for a number of protein-ligand complexes from different families including the very recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease. For all complexes, poses with RMSD less than 3 angstrom from actual binding positions can be recovered. Our results suggest that for docking with approximately modeled receptor structures, fragment-based methods can be more effective than common complete ligand docking approaches.
C1 [Sarfaraz, Sara; Muneer, Iqra; Liu, Haiyan] Univ Sci & Technol China, Sch Iife Sci, Hefei 230026, Anhui, Peoples R China.
RP Liu, HY (corresponding author), Univ Sci & Technol China, Sch Iife Sci, Hefei 230026, Anhui, Peoples R China.
EM sara20@mail.ustc.edu.cn; iqra@mail.ustc.edu.cn; hyliu@ustc.edu.cn
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [21773220]
FX This work has been supported by the Natural Science Foundation of China
   (Grant number 21773220).
CR Amaro RE, 2018, BIOPHYS J, V114, P2271, DOI 10.1016/j.bpj.2018.02.038
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2019, ORIGINPRO VERSION
   Bholowalia P., 2014, INT J COMPUT APPL, V105, P17, DOI DOI 10.5120/18405-9674
   BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/BF00124387
   Bordogna A, 2011, J COMPUT CHEM, V32, P81, DOI 10.1002/jcc.21601
   BRON C, 1973, COMMUN ACM, V16, P575, DOI 10.1145/362342.362367
   Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503
   Cao Y, 2014, BIOINFORMATICS, V30, P1674, DOI 10.1093/bioinformatics/btu104
   Chen HJ, 2015, DRUG DISCOV TODAY, V20, P105, DOI 10.1016/j.drudis.2014.09.015
   Chen Y, 2009, NAT CHEM BIOL, V5, P358, DOI 10.1038/nchembio.155
   Csizmadia P, 1999, P ECSOC 3 THIRD INT, p[1, 67]
   Davis IW, 2009, J MOL BIOL, V385, P381, DOI 10.1016/j.jmb.2008.11.010
   Degen J, 2008, CHEMMEDCHEM, V3, P1503, DOI 10.1002/cmdc.200800178
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Deng H, 2006, PROTEINS, V64, P34, DOI 10.1002/prot.20973
   Erlanson DA, 2004, J MED CHEM, V47, P3463, DOI 10.1021/jm040031v
   Erlanson DA, 2016, NAT REV DRUG DISCOV, V15, P605, DOI 10.1038/nrd.2016.109
   Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450
   Falcon WE, 2019, J PHYS CHEM B, V123, P5189, DOI 10.1021/acs.jpcb.8b11491
   Ferguson CS, 2011, TRENDS PHARMACOL SCI, V32, P708, DOI 10.1016/j.tips.2011.08.005
   Ferreira LG, 2015, MOLECULES, V20, P13384, DOI 10.3390/molecules200713384
   Fujisawa T, 2017, NAT REV MOL CELL BIO, V18, P246, DOI 10.1038/nrm.2016.143
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hao GF, 2016, NUCLEIC ACIDS RES, V44, pW550, DOI 10.1093/nar/gkw393
   Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317
   Insel PA, 2007, BBA-BIOMEMBRANES, V1768, P994, DOI 10.1016/j.bbamem.2006.09.029
   Jacobs DJ, 2001, PROTEINS, V44, P150, DOI 10.1002/prot.1081
   Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h
   Jain AK, 2010, PATTERN RECOGN LETT, V31, P651, DOI 10.1016/j.patrec.2009.09.011
   Ji YM, 2004, BIOINFORMATICS, V20, P1591, DOI 10.1093/bioinformatics/bth131
   Joseph-McCarthy D, 2014, J CHEM INF MODEL, V54, P693, DOI 10.1021/ci400731w
   Ko E, 2017, 2017 THIRD IEEE INTERNATIONAL CONFERENCE ON BIG DATA COMPUTING SERVICE AND APPLICATIONS (IEEE BIGDATASERVICE 2017), P277, DOI 10.1109/BigDataService.2017.39
   Kolb P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049910
   Kramer B, 1999, PROTEINS, V37, P228, DOI 10.1002/(SICI)1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO;2-8
   Landrum G., 2013, RELEASE, V1, P1
   Lopez-Vallejo F, 2011, COMB CHEM HIGH T SCR, V14, P475, DOI 10.2174/138620711795767866
   Majeux N, 1999, PROTEINS, V37, P88, DOI 10.1002/(SICI)1097-0134(19991001)37:1<88::AID-PROT9>3.0.CO;2-O
   Makino K, 2004, LECT NOTES COMPUT SC, V3111, P260
   Mallek S, 2015, ADV INTELL SYST, V323, P629, DOI 10.1007/978-3-319-11310-4_54
   McGovern SL, 2003, J MED CHEM, V46, P2895, DOI 10.1021/jm0300330
   McNae IW, 2005, CRYSTALLOGR REV, V11, P61
   Meng XY, 2011, CURR COMPUT-AID DRUG, V7, P146
   MITCHELL EM, 1990, J MOL BIOL, V212, P151, DOI 10.1016/0022-2836(90)90312-A
   Montellano Paul R Ortiz de, 2005, CYTOCHROME P450 STRU
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Neudert G, 2011, J CHEM INF MODEL, V51, P2731, DOI 10.1021/ci200274q
   Nissink JWM, 2002, PROTEINS, V49, P457, DOI 10.1002/prot.10232
   ORLIN J, 1977, P K NED AKAD A MATH, V80, P406
   Pavlopoulos GA, 2011, BIODATA MIN, V4, DOI 10.1186/1756-0381-4-10
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Raymond JW, 2002, J COMPUT AID MOL DES, V16, P521, DOI 10.1023/A:1021271615909
   Rees DC, 2004, NAT REV DRUG DISCOV, V3, P660, DOI 10.1038/nrd1467
   Reinharz V, 2018, NUCLEIC ACIDS RES, V46, P3841, DOI 10.1093/nar/gky197
   Riniker S, 2015, J CHEM INF MODEL, V55, P2562, DOI 10.1021/acs.jcim.5b00654
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Salazar NC, 2007, BBA-BIOMEMBRANES, V1768, P1006, DOI 10.1016/j.bbamem.2007.02.010
   Salon JA, 2011, PHARMACOL REV, V63, P901, DOI 10.1124/pr.110.003350
   Senior AW, 2020, NATURE, V577, P706, DOI 10.1038/s41586-019-1923-7
   Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606
   Studio Discovery, 2008, STUDIO DISCOVERY
   Sutherland JJ, 2007, J CHEM INF MODEL, V47, P2293, DOI 10.1021/ci700253h
   Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129
   Thomsen R, 2006, J MED CHEM, V49, P3315, DOI 10.1021/jm051197e
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465
   Wang RX, 2000, J MOL MODEL, V6, P498, DOI 10.1007/s0089400060498
   Webb B., 2014, CURR PROTOC BIOINF, V47, DOI [10.1002/0471250953.bi0506s47, DOI 10.1088/1751-8113/47/31/315202]
   Xiang ZX, 2006, CURR PROTEIN PEPT SC, V7, P217, DOI 10.2174/138920306777452312
   Yamaotsu N, 2018, J COMPUT AID MOL DES, V32, P1229, DOI 10.1007/s10822-018-0160-8
   Yang J, 2019, J COMPUT CHEM, V40, P2739, DOI 10.1002/jcc.26050
NR 71
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-654X
EI 1573-4951
J9 J COMPUT AID MOL DES
JI J. Comput.-Aided Mol. Des.
PD DEC
PY 2020
VL 34
IS 12
BP 1237
EP 1259
DI 10.1007/s10822-020-00345-7
EA OCT 2020
PG 23
WC Biochemistry & Molecular Biology; Biophysics; Computer Science,
   Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Computer Science
GA OH8UK
UT WOS:000577932000002
PM 33034007
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Masana, M
   Martinez, LI
   Gil, M
   Bueno, G
   Llagostera, S
AF Masana, Marc
   Martinez, Lucia I.
   Gil, Miquel
   Bueno, Gonzalo
   Llagostera, Secundino
TI Thoracic Aortic Mural Thrombus, Right Ventricular Clot and Pulmonary
   Embolism in a Patient With COVID-19 Pneumonia
SO VASCULAR AND ENDOVASCULAR SURGERY
LA English
DT Article; Early Access
DE coronavirus disease 2019; coagulopathy; pulmonary embolism; aortic mural
   thrombus; ventricular clot and low-molecular-weight heparin
ID HEPARIN
AB Since the outbreak of the COVID-19 pandemic, increasing evidence suggests that infected patients present a high incidence of thrombotic complications. We report a 67-year-old-woman admitted for severe acute respiratory syndrome coronavirus 2 infection. Chest CT images showed bilateral ground glass opacities, bilateral pulmonary embolism, right ventricular clot in transit and 2 thoracic aortic mural thrombus. Therapy was initiated with subcutaneous low-molecular-weight heparin, and the patient was discharged at 20 days asymptomatic. Complete resolution of the aortic thrombus was observed in a 1-month surveillance CT angiogram. Our case illustrates vascular complications in a COVID-19 patient and its effective treatment with anticoagulation.
C1 [Masana, Marc; Martinez, Lucia I.; Gil, Miquel; Bueno, Gonzalo; Llagostera, Secundino] Germans Trias & Pujol Hosp, Vasc Surg Dept, Ctra Canyet S-N,CP 08916, Badalona 08916, Spain.
RP Martinez, LI (corresponding author), Germans Trias & Pujol Hosp, Vasc Surg Dept, Ctra Canyet S-N,CP 08916, Badalona 08916, Spain.
EM luciaimartinez@hotmail.com
OI Gil Olaria, Miquel/0000-0001-9628-6071
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Bowdish ME, 2002, J VASC SURG, V36, P713, DOI 10.1067/mva.2002.127968
   Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Gomez-Arbelaez D, 2020, ANN VASC SURG, V67, P10, DOI 10.1016/j.avsg.2020.05.031
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Kashi M, 2020, THROMB RES, V192, P75, DOI 10.1016/j.thromres.2020.05.025
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lau LS, 1997, ANN VASC SURG, V11, P348, DOI 10.1007/s100169900059
   Le Berre A, 2020, DIAGN INTERV IMAG, V101, P321, DOI 10.1016/j.diii.2020.04.003
   Li JL, 2018, INT J CLIN EXP MED, V11, P414
   Li JP, 2009, THROMB HAEMOSTASIS, V102, P823, DOI 10.1160/TH09-02-0091
   Ma JQ, 2015, INT J CLIN EXP MED, V8, P5547
   Meyermann K, 2017, J VASC SURG, V66, P931, DOI 10.1016/j.jvs.2017.05.109
   Pagni S, 2011, ANN THORAC SURG, V91, P1875, DOI 10.1016/j.athoracsur.2011.02.011
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Sethi Sanjum S, 2020, JACC Case Rep, V2, P1391, DOI 10.1016/j.jaccas.2020.05.034
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Woehl Bastien, 2020, JACC Case Rep, V2, P1397, DOI 10.1016/j.jaccas.2020.06.003
   Young E, 2008, THROMB RES, V122, P743, DOI 10.1016/j.thromres.2006.10.026
NR 25
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1538-5744
EI 1938-9116
J9 VASC ENDOVASC SURG
JI Vasc. Endovasc. Surg.
AR 1538574420966106
DI 10.1177/1538574420966106
EA OCT 2020
PG 4
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA OA1IE
UT WOS:000577547500001
PM 33034240
DA 2021-01-01
ER

PT J
AU Jain, R
   Gupta, M
   Taneja, S
   Hemanth, DJ
AF Jain, Rachna
   Gupta, Meenu
   Taneja, Soham
   Hemanth, D. Jude
TI Deep learning based detection and analysis of COVID-19 on chest X-ray
   images
SO APPLIED INTELLIGENCE
LA English
DT Article; Early Access
DE Covid-19; XCeption; Inception net 3; Deep-learning; ResNeXt; Chest X-ray
   images; CNN
ID ACUTE RESPIRATORY SYNDROME; CT; INFECTION; PNEUMONIA; CHINA
AB Covid-19 is a rapidly spreading viral disease that infects not only humans, but animals are also infected because of this disease. The daily life of human beings, their health, and the economy of a country are affected due to this deadly viral disease. Covid-19 is a common spreading disease, and till now, not a single country can prepare a vaccine for COVID-19. A clinical study of COVID-19 infected patients has shown that these types of patients are mostly infected from a lung infection after coming in contact with this disease. Chest x-ray (i.e., radiography) and chest CT are a more effective imaging technique for diagnosing lunge related problems. Still, a substantial chest x-ray is a lower cost process in comparison to chest CT. Deep learning is the most successful technique of machine learning, which provides useful analysis to study a large amount of chest x-ray images that can critically impact on screening of Covid-19. In this work, we have taken the PA view of chest x-ray scans for covid-19 affected patients as well as healthy patients. After cleaning up the images and applying data augmentation, we have used deep learning-based CNN models and compared their performance. We have compared Inception V3, Xception, and ResNeXt models and examined their accuracy. To analyze the model performance, 6432 chest x-ray scans samples have been collected from the Kaggle repository, out of which 5467 were used for training and 965 for validation. In result analysis, the Xception model gives the highest accuracy (i.e., 97.97%) for detecting Chest X-rays images as compared to other models. This work only focuses on possible methods of classifying covid-19 infected patients and does not claim any medical accuracy.
C1 [Jain, Rachna; Taneja, Soham] Bharati Vidyapeeths Coll Engn, Dept CSE, Delhi, India.
   [Gupta, Meenu] Chandigarh Univ, Dept CSE, Mohali, Punjab, India.
   [Hemanth, D. Jude] Karunya Inst Technol & Sci, Dept ECE, Coimbatore, Tamil Nadu, India.
RP Hemanth, DJ (corresponding author), Karunya Inst Technol & Sci, Dept ECE, Coimbatore, Tamil Nadu, India.
EM judehemanth@karunya.edu
CR Afshar P., 2020, ARXIV200402696
   Ajlan AM, 2014, AM J ROENTGENOL, V203, P782, DOI 10.2214/AJR.14.13021
   Alqudah AM, 2020, AUTOMATED SYSTEMS DE
   Apostolopoulos I.D., 2020, PHYS ENG SCI MED, P1
   Ayan E., 2019, P 2019 SCI M EL EL B, V7, P1
   Basile C, 2020, NEPHROL DIAL TRANSPL, V35, P737, DOI 10.1093/ndt/gfaa069
   Cai C, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-01945-z
   Chan YH, 2018, J HEALTHC ENG, V2018, DOI 10.1155/2018/2908517
   Choi WJ, 2016, KOREAN J RADIOL, V17, P166, DOI 10.3348/kjr.2016.17.1.166
   Chollet F, 2017, PROC CVPR IEEE, P1800, DOI 10.1109/CVPR.2017.195
   Chowdhury M. E. H., 2020, ARXIV200313145
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Cohen JP, 2020, ARXIV200311597
   Dadario AMV, 2020, RADIOLOGY, V296, pE192, DOI 10.1148/radiol.2020201178
   Diao B, 2020, HUMAN KIDNEY IS TARG
   Durrani M, 2020, PAK J MED SCI, V36, pS22, DOI 10.12669/pjms.36.COVID19-S4.2778
   Fu S, 2020, VIROLOGIC CLIN CHARA
   Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712
   Hassani RTJ, 2020, J FR OPHTALMOL, V43, P291, DOI 10.1016/j.jfo.2020.02.001
   Hassanien AE, 2020, AUTOMATIC XRAY COVID
   Hemdan E.E.-D., 2020, ARXIV2020200311055
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ilyas M, 2020, ARXIV200405436
   Jacobi A, 2020, CLIN IMAG, V64, P35, DOI 10.1016/j.clinimag.2020.04.001
   Kanne J. P., 2020, CHEST CT FINDINGS 20
   Koo HJ, 2018, RADIOGRAPHICS, V38, P719, DOI 10.1148/rg.2018170048
   Li L., 2020, RADIOLOGY, DOI [10.1148/radiol.2020200905 ., DOI 10.1148/RADI0L.2020200905]
   Maghdid HS, 2020, ARXIV200400038
   Narin A, 2020, ARXIV200310849
   Ooi GC, 2004, RADIOLOGY, V230, P836, DOI 10.1148/radiol.2303030853
   Ozkaya U, 2020, ARXIV200403698
   Ozturk T, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103792
   Parikh R, 2008, INDIAN J OPHTHALMOL, V56, P45, DOI 10.4103/0301-4738.37595
   Patel Prashant, CHEST XRAY COVID 19
   Roosa K, 2020, INFECT DIS MODEL, V5, P256, DOI 10.1016/j.idm.2020.02.002
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Sokolova M, 2006, LECT NOTES COMPUT SC, V4304, P1015
   Stoecklin SB, 2020, EUROSURVEILLANCE, V25, P20, DOI 10.2807/1560-7917.ES.2020.25.6.2000094
   Szegedy C, 2016, PROC CVPR IEEE, P2818, DOI 10.1109/CVPR.2016.308
   Thejeshwar SS, PRECISE PREDICTION C
   Wang S., 2020, DEEP LEARNING ALGORI, DOI 10.1101/2020.02.14.20023028
   Wang Y, 2020, ARXIV200205534
   Watts A, 2020, J TRAVEL MED
   Wong KT, 2003, RADIOLOGY, V228, P401, DOI 10.1148/radiol.2282030593
   Xie SN, 2017, PROC CVPR IEEE, P5987, DOI 10.1109/CVPR.2017.634
   Xie XY, 2006, LECT NOTES ARTIF INT, V3755, P282
   Xu B, DEEP LEARNING ALGORI
   Yadav S. K., 2019, Journal of AgriSearch, V6, P1, DOI 10.12921/jas.v6i1.14911
   Yan L, 2020, PREDICTION CRITICALI
   Zhang J., 2020, ARXIV200312338
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
NR 51
TC 0
Z9 0
U1 8
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0924-669X
EI 1573-7497
J9 APPL INTELL
JI Appl. Intell.
DI 10.1007/s10489-020-01902-1
EA OCT 2020
PG 11
WC Computer Science, Artificial Intelligence
SC Computer Science
GA OB3VK
UT WOS:000578400200001
OA Bronze
DA 2021-01-01
ER

PT J
AU Aschendorff, A
   Arndt, S
   Kroger, S
   Wesarg, T
   Ketterer, MC
   Kirchem, P
   Pixner, S
   Hassepass, F
   Beck, R
AF Aschendorff, A.
   Arndt, S.
   Kroeger, S.
   Wesarg, T.
   Ketterer, M. C.
   Kirchem, P.
   Pixner, S.
   Hassepass, F.
   Beck, R.
TI Quality of cochlear implant rehabilitation under COVID-19 conditions
SO HNO
LA English
DT Article; Early Access
DE Speech therapy; Aftercare; Severe acute respiratory syndrome coronavirus
   2; Quality assurance; Standard of care
AB Background The rehabilitation process following cochlear implant (CI) surgery is carried out in a multimodal therapy according to German national guidelines and includes technical and medical aftercare. In times of the corona pandemic surgery and rehabilitation appointments were cancelled or delayed leading to a more difficult access to auditory rehabilitation. Newly implemented hygiene modalities due to the SARS-CoV-2 pandemic have changed medical aftercare and the rehabilitation process. The aim of this study was to evaluate the quality of rehabilitation under corona conditions. Material and methods An anonymous survey of adult cochlear implant patients was carried out by a non-standardized questionnaire. Demographics were analyzed and the quality of medical aftercare, speech therapy, technical aftercare, psychological support and the hygiene modalities were compared to previous rehabilitation stays. Results In total 109 patients completed the questionnaire. The quality of rehabilitation and individual therapy were rated as qualitatively similar or improved. The threat of the pandemic and fear of corona were rated unexpectedly high with 68% and 50%, respectively. The hygiene measures during the rehabilitation stay eased subjective fears at the same time. The majority of patients were annoyed by wearing face masks but visors, protection shields and social distancing were more tolerated. Conclusion The implementation of the new hygiene modalities within the therapeutic rehabilitation setting was well-accepted by patients allowing access to auditory rehabilitation. A successful rehabilitation should ensure a fear-free environment by adhering to the necessary hygiene modalities.
C1 [Aschendorff, A.; Arndt, S.; Kroeger, S.; Wesarg, T.; Ketterer, M. C.; Kirchem, P.; Pixner, S.; Hassepass, F.; Beck, R.] Univ Klinikum Freiburg, Dept Otorhinolaryngol, Killianstr 5, D-79106 Freiburg, Germany.
RP Aschendorff, A (corresponding author), Univ Klinikum Freiburg, Dept Otorhinolaryngol, Killianstr 5, D-79106 Freiburg, Germany.
EM antje.aschendorff@uniklinik-freiburg.de
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR Baungaard LH, 2019, DAN MED J, V66
   Bhangu A, 2020, BRIT J SURG, DOI [10.1002/bjs.11746, DOI 10.1002/BJS.11746]
   Blom A., 2020, MANNHEIMER CORONA ST
   Carlson ML, 2020, NEW ENGL J MED, V382, P1531, DOI 10.1056/NEJMra1904407
   Fu Qian-Jie, 2004, Cochlear Implants Int, V5 Suppl 1, P84, DOI 10.1179/cim.2004.5.Supplement-1.84
   Green T, 2019, TRENDS HEAR, V23, DOI 10.1177/2331216519843878
   Illg A, 2017, HNO, V65, P552, DOI 10.1007/s00106-016-0311-y
   Korzilius H, 2020, DTSCH ARZTEBL, V117, pA
   Luryi AL, 2020, OTOL NEUROTOL, V41, pE330, DOI 10.1097/MAO.0000000000002551
   Naumann E, 2020, MANNHEIMER CORONA ST
   Reis M, 2019, EAR HEARING, V40, P1445, DOI 10.1097/AUD.0000000000000724
   Zeh R, 2015, HNO, V63, P557, DOI 10.1007/s00106-015-0037-2
NR 12
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0017-6192
EI 1433-0458
J9 HNO
JI HNO
DI 10.1007/s00106-020-00923-z
EA OCT 2020
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA NY7IC
UT WOS:000576557200001
PM 33034674
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Hambleton, A
   Le Grange, D
   Miskovic-Wheatley, J
   Touyz, S
   Cunich, M
   Maguire, S
AF Hambleton, A.
   Le Grange, D.
   Miskovic-Wheatley, J.
   Touyz, S.
   Cunich, M.
   Maguire, S.
TI Translating evidence-based treatment for digital health delivery: a
   protocol for family-based treatment for anorexia nervosa using
   telemedicine
SO JOURNAL OF EATING DISORDERS
LA English
DT Article
DE Anorexia nervosa; Cost-consequence analysis; Inequalities; Eating
   disorder; Covid-19; Young people; Telemedicine; Telemedicine;
   Family-based treatment; Rural health
ID COGNITIVE-BEHAVIORAL THERAPY; EATING-DISORDER EXAMINATION; RANDOMIZED
   CLINICAL-TRIAL; BULIMIA-NERVOSA; ADOLESCENTS; TELEHEALTH; RECOVERY;
   EFFICACY; REMISSION; INTERVIEW
AB Background Family-based treatment (FBT) is an efficacious outpatient intervention for young people diagnosed with Anorexia Nervosa (AN). To date, treatment to protocol has relied on standard face-to-face delivery. Face-to-face therapy is subject to geographic, temporal and human factors, rendering it particularly susceptible to inequities and disruption. This has resulted in poorer service provision for rural and regional families, and recently a significant challenge to providing face-to-face services during the COVID-19 global pandemic. The present study examines whether FBT for AN can be successfully translated to a digital delivery platform to address these access issues. Method Forty young people aged 12 to 18 years who meet DSM-5 diagnostic criteria for AN, and live in a rural or regional setting, will along with their family be recruited to the study. Trained therapists will provide 18 sessions of FBT over 9 months via telemedicine to the home of the young person and their family. The analysis will examine treatment effectiveness, feasibility, acceptability, and cost-effectiveness. Discussion The study addresses the treatment needs of families not able to attend face-to-face clinical services for evidence-based treatment for eating disorders. This might be due to several barriers, including a lack of local services or long travel distances to services. There has been a recent and unprecedented demand for telemedicine to facilitate the continuity of care during COVID-19 despite geographical circumstances. If delivering treatment in this modality is clinically and economically effective and feasible, it will facilitate access to potentially lifesaving, evidence-based treatments for families formerly unable to access such care and provide evidence for the continuity of services when and where face-to-face treatment is not feasible.
C1 [Hambleton, A.; Miskovic-Wheatley, J.; Touyz, S.; Maguire, S.] Univ Sydney, InsideOut Inst Eating Disorders, Boden Collaborat Obes Nutr Exercise & Eating Diso, Sydney, NSW, Australia.
   [Le Grange, D.] Univ Calif San Francisco, Sch Med, UCSF Weill Inst Neurosci, San Francisco, CA USA.
   [Touyz, S.] Univ Sydney, Sch Psychol, Fac Sci, Sydney, NSW, Australia.
   [Cunich, M.] Univ Sydney, Fac Med & Hlth, Cent Clin Sch, Boden Collaborat Obes Nutr & Eating Disorders, Sydney, NSW, Australia.
   [Cunich, M.] Sydney Local Hlth Dist, Sydney Hlth Econ Collaborat, Camperdown, NSW, Australia.
   [Maguire, S.] NSW Hlth, Sydney Local Hlth Dist, St Leonards, NSW, Australia.
RP Hambleton, A (corresponding author), Univ Sydney, InsideOut Inst Eating Disorders, Boden Collaborat Obes Nutr Exercise & Eating Diso, Sydney, NSW, Australia.
EM ashlea.hambleton@sydney.edu.au
FU Charles Warman Foundation Pty Ltd.; University of SydneyUniversity of
   Sydney
FX The study is funded by philanthropic funds donated by the Charles Warman
   Foundation Pty Ltd. Funding is being managed by Dr. Sarah Maguire
   (coauthor) who is appointed within the University of Sydney.
CR Agras WS, 2014, JAMA PSYCHIAT, V71, P1279, DOI 10.1001/jamapsychiatry.2014.1025
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   ANDERSON K, 2015, J EAT DISORD, V3, P1, DOI DOI 10.1186/s40337-015-0037-3
   Anderson KE, 2017, INT J EAT DISORDER, V50, P1235, DOI 10.1002/eat.22759
   [Anonymous], 2000, 2 20 YEARS GIRLS BOD
   [Anonymous], 2017, NICE GUID
   [Anonymous], 2014, GUID ADM CHILDR YOUN
   Astrachan-Fletcher E, 2018, J EAT DISORD, V6, DOI 10.1186/s40337-018-0228-9
   Blumenstyk G, 2020, THE CHRONICLE
   Bohn K, 2008, BEHAV RES THER, V46, P1105, DOI 10.1016/j.brat.2008.06.012
   Chorpita B, 1998, REVISED CHILDRENS AN
   Chorpita BF, 2015, REVISED CHILDRENS AN
   COOPER Z, 1987, INT J EAT DISORDER, V6, P1, DOI 10.1002/1098-108X(198701)6:1<1::AID-EAT2260060102>3.0.CO;2-9
   Couturier J, 2013, INT J EAT DISORDER, V46, P3, DOI 10.1002/eat.22042
   Crow SJ, 2009, BEHAV RES THER, V47, P451, DOI 10.1016/j.brat.2009.02.006
   Eddy KT, 2017, J CLIN PSYCHIAT, V78, P184, DOI 10.4088/JCP.15m10393
   Eisler I, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1129-6
   Ellison R, 2012, INT J EAT DISORDER, V45, P609, DOI 10.1002/eat.22000
   EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x
   FAIRBURN CG, 1994, INT J EAT DISORDER, V16, P363
   Fernandez-Aranda F., 2020, J EATING DISORDERS A, V28, P239, DOI [10.1002/erv.2738, DOI 10.1002/erv.2738]
   Fisk M, 2020, J MED INTERNET RES, V22, DOI 10.2196/19264
   Griffiths L, 2006, J TELEMED TELECARE, V12, P136, DOI 10.1258/135763306776738567
   Harris M, 2006, J PSYCHOSOC NURS MEN, V44, P21, DOI 10.3928/02793695-20060401-06
   Hay P, 2014, AUST NZ J PSYCHIAT, V48, P977, DOI 10.1177/0004867414555814
   Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687
   Jang-Jaccard J, 2014, TELEMED E-HEALTH, V20, P496, DOI 10.1089/tmj.2013.0189
   Karpowicz E, 2009, INT J MENT HEALTH NU, V18, P318, DOI 10.1111/j.1447-0349.2009.00621.x
   Katzman DK, 2005, INT J EAT DISORDER, V37, pS52, DOI 10.1002/eat.20118
   Keel PK, 2003, ARCH GEN PSYCHIAT, V60, P179, DOI 10.1001/archpsyc.60.2.179
   Khalsa SS, 2017, J EAT DISORD, V5, DOI 10.1186/s40337-017-0145-3
   Le Grange D, 2019, INT J EAT DISORDER, V52, P996, DOI 10.1002/eat.23138
   Le Grange D, 2016, J AM ACAD CHILD PSY, V55, P683, DOI 10.1016/j.jaac.2016.05.007
   Levesque JF, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-18
   Lock J, 2005, INT J EAT DISORDER, V37, pS64, DOI 10.1002/eat.20122
   Lock J, 2005, J AM ACAD CHILD PSY, V44, P632, DOI 10.1097/01.chi.0000161647.82775.0a
   Lock J, 2012, TREATMENT MANUAL ANO
   Lock J. D., 2009, BMJ CLIN EVIDENCE, V2009, P1011
   Lock J, 2019, INT J EAT DISORDER, V52, P481, DOI 10.1002/eat.22980
   Lock J, 2010, ARCH GEN PSYCHIAT, V67, P1025, DOI 10.1001/archgenpsychiatry.2010.128
   Loeb KL, 2008, EATING DISORDER EXAM
   Loucas CE, 2014, BEHAV RES THER, V63, P122, DOI 10.1016/j.brat.2014.09.011
   Madden S, 2015, PSYCHOL MED, V45, P415, DOI 10.1017/S0033291714001573
   Madden S, 2015, INT J EAT DISORDER, V48, P919, DOI 10.1002/eat.22414
   Madden S, 2009, MED J AUSTRALIA, V190, P410, DOI 10.5694/j.1326-5377.2009.tb02487.x
   McCormack J, 2013, AUST J RURAL HEALTH, V21, P8, DOI 10.1111/ajr.12007
   Medway M, 2016, ADV EAT DISORD, V4, P189, DOI DOI 10.1080/21662630.2016.1164609
   Mehler PS, 2015, J EAT DISORD, V3, P6
   Mitchell JE, 2008, BEHAV RES THER, V46, P581, DOI 10.1016/j.brat.2008.02.004
   Mond JM, 2006, BEHAV RES THER, V44, P53, DOI 10.1016/j.brat.2004.12.003
   Myers K, 2015, J AM ACAD CHILD PSY, V54, P263, DOI 10.1016/j.jaac.2015.01.009
   Ravens-Sieberer U, 2010, QUAL LIFE RES, V19, P1487, DOI 10.1007/s11136-010-9706-5
   Rhodes P, 2005, EUR EAT DISORD REV, V13, P399, DOI 10.1002/erv.661
   Rienecke RD, 2017, ADOLESC HEALTH MED T, V8, P69, DOI 10.2147/AHMT.S115775
   Rosenberg M., 1965, ROSENBERG SELF ESTEE
   SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228
   Sheridan T, 2013, AUST J RURAL HEALTH, V21, P232, DOI 10.1111/ajr.12042
   Singer JD, 2003, MODELING CHANGE EVEN
   Steinhausen HC, 2002, AM J PSYCHIAT, V159, P1284, DOI 10.1176/appi.ajp.159.8.1284
   Taranis L, 2011, EUR EAT DISORD REV, V19
   Thevarajan I, 2020, MED J AUSTRALIA, V213, P134, DOI 10.5694/mja2.50698
   Touyz S, 2020, J EAT DISORD, V8, DOI 10.1186/s40337-020-00295-3
   Tuerk PW, 2010, J TRAUMA STRESS, V23, P116, DOI 10.1002/jts.20494
   Van Langenberg T, 2018, EAT DISORD, V26, P373, DOI 10.1080/10640266.2018.1453632
   Wallis A, 2017, J EAT DISORD, V5, DOI 10.1186/s40337-017-0184-9
   Weber M, 2012, AUST J RURAL HEALTH, V20, P208, DOI 10.1111/j.1440-1584.2012.01280.x
   Wille N, 2010, QUAL LIFE RES, V19, P875, DOI 10.1007/s11136-010-9648-y
   Williams JS, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-25
   Withington T, 2019, 17 ANN C AUSTR NZ AC
   Zhou XY, 2020, TELEMED E-HEALTH, V26, P377, DOI 10.1089/tmj.2020.0068
NR 70
TC 0
Z9 0
U1 8
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2050-2974
J9 J EAT DISORD
JI J. Eat. Disord.
PD OCT 9
PY 2020
VL 8
IS 1
AR 50
DI 10.1186/s40337-020-00328-x
PG 12
WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry
SC Psychology; Nutrition & Dietetics; Psychiatry
GA NY1QC
UT WOS:000576171900001
PM 33052259
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ali, SH
   Foreman, J
   Tozan, Y
   Capasso, A
   Jones, AM
   DiClemente, RJ
AF Ali, Shahmir H.
   Foreman, Joshua
   Tozan, Yesim
   Capasso, Ariadna
   Jones, Abbey M.
   DiClemente, Ralph J.
TI Trends and Predictors of COVID-19 Information Sources and Their
   Relationship With Knowledge and Beliefs Related to the Pandemic:
   Nationwide Cross-Sectional Study
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE COVID-19; coronavirus; pandemic; outbreak; infectious disease; social
   media; information seeking behaviors; surveillance
ID GENERAL-POPULATION; AVIAN INFLUENZA; OUTBREAK; BEHAVIOR; VACCINE; NEEDS;
   SARS
AB Background: During the COVID-19 pandemic, there is a heightened need to understand health information seeking behaviors to address disparities in knowledge and beliefs about the crisis.
   Objective: This study assessed sociodemographic predictors of the use and trust of different COVID-19 information sources, as well as the association between information sources and knowledge and beliefs about the pandemic.
   Methods: An online survey was conducted among US adults in two rounds during March and April 2020 using advertisement-based recruitment on social media. Participants were asked about their use of 11 different COVID-19 information sources as well as their most trusted source of information. The selection of COVID-related knowledge and belief questions was based on past empirical literature and salient concerns at the time of survey implementation.
   Results: The sample consisted of 11,242 participants. When combined, traditional media sources (television, radio, podcasts, or newspapers) were the largest sources of COVID-19 information (91.2%). Among those using mainstream media sources for COVID-19 information (n=7811, 69.5%), popular outlets included CNN (24.0%), Fox News (19.3%), and other local or national networks (35.2%). The largest individual information source was government websites (87.6%). They were also the most trusted source of information (43.3%), although the odds of trusting government websites were lower among males (adjusted odds ratio [AOR] 0.58, 95% CI 0.53-0.63) and those aged 40-59 years and >= 60 years compared to those aged 18-39 years (AOR 0.83, 95% CI 0.74-0.92; AOR 0.62, 95% CI 0.54-0.71). Participants used an average of 6.1 sources (SD 2.3). Participants who were male, aged 40-59 years or >= 60 years; not working, unemployed, or retired; or Republican were likely to use fewer sources while those with children and higher educational attainment were likely to use more sources. Participants surveyed in April were markedly less likely to use (AOR 0.41, 95% CI 0.35-0.46) and trust (AOR 0.51, 95% CI 0.47-0.56) government sources. The association between information source and COVID-19 knowledge was mixed, while many COVID-19 beliefs were significantly predicted by information source; similar trends were observed with reliance on different types of mainstream media outlets.
   Conclusions: COVID-19 information source was significantly determined by participant sociodemographic characteristics and was also associated with both knowledge and beliefs about the pandemic. Study findings can help inform COVID-19 health communication campaigns and highlight the impact of using a variety of different and trusted information sources.
C1 [Ali, Shahmir H.; Foreman, Joshua; Capasso, Ariadna; DiClemente, Ralph J.] NYU, Sch Global Publ Hlth, Dept Social & Behav Sci, 715 Broadway, New York, NY 10003 USA.
   [Foreman, Joshua] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
   [Tozan, Yesim] NYU, Sch Global Publ Hlth, Global Hlth Program, New York, NY USA.
   [Jones, Abbey M.] NYU, Sch Global Publ Hlth, Dept Epidemiol, New York, NY USA.
RP DiClemente, RJ (corresponding author), NYU, Sch Global Publ Hlth, Dept Social & Behav Sci, 715 Broadway, New York, NY 10003 USA.
EM rjd438@nyu.edu
OI Tozan, Yesim/0000-0001-8997-8897; Jones, Abbey/0000-0002-4958-4612;
   DiClemente, Ralph/0000-0002-4374-4611; Ali, Shahmir/0000-0002-0360-3507;
   Capasso, Ariadna/0000-0001-5462-7800
CR Agency for Healthcare Research and Quality, 2018, AHRQ PUBLICATION, V18-0033-EF
   Al-Rabiaah A, 2020, J INFECT PUBLIC HEAL, V13, P687, DOI 10.1016/j.jiph.2020.01.005
   Ali SH, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-01011-0
   American Association for Public Opinion Research, 2016, STAND DEF FIN DISP C
   [Anonymous], 2019, PUBLIC OPINION STRAT
   Bish A, 2010, BRIT J HEALTH PSYCH, V15, P797, DOI 10.1348/135910710X485826
   Boyl J, 2020, AM TRUST COVID 19 IN
   Brug J, 2004, EMERG INFECT DIS, V10, P1486, DOI 10.3201/eid1008.040283
   Centers for Disease Control and Prevention, 2020, HLTH EQ CONS RAC ETH
   Clark Cory, 2020, Glob Transit, V2, P76, DOI 10.1016/j.glt.2020.06.003
   Clements John M, 2020, JMIR Public Health Surveill, V6, pe19161, DOI 10.2196/19161
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Fisher JH, 2016, AM J RESP CRIT CARE, V194, P218, DOI 10.1164/rccm.201512-2393OC
   Frenkel S., 2020, NY TIMES
   Gargano LM, 2015, HUM VACC IMMUNOTHER, V11, P1641, DOI 10.1080/21645515.2015.1038445
   Hasan F, 2018, CUREUS, V10, DOI 10.7759/cureus.2048
   Henrich N, 2011, HEALTH PROMOT PRACT, V12, P610, DOI 10.1177/1524839910363536
   Hosseini SH, 2011, INT J PREVENTIVE MED, V2, P32
   Ingraham C., 2020, WASHINGTON POST
   Jalloh MF, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000471
   Kouzy R, 2020, CUREUS, V12, DOI 10.7759/cureus.7255
   La Torre G, 2012, SCAND J PUBLIC HEALT, V40, P69, DOI 10.1177/1403494811424612
   Lau JTF, 2007, AM J INFECT CONTROL, V35, P38, DOI 10.1016/j.ajic.2006.07.010
   Mian A, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01556-3
   Painter JE, 2018, HUM VACC IMMUNOTHER, V14, P1665, DOI 10.1080/21645515.2018.1423928
   Painter JE, 2017, VACCINE, V35, P508, DOI 10.1016/j.vaccine.2016.11.093
   Painter M., 2020, 3569098 SSRN, DOI [10.2139/ssrn.3569098, DOI 10.2139/SSRN.3569098]
   Panchal N, 2020, IMPLICATIONS COVID 1
   Parolin Z., 2020, FORECASTING ESTIMATE
   Pennycook G, 2020, PSYCHOL SCI, V31, P770, DOI 10.1177/0956797620939054
   Perrin A, 2019, SHARE US ADULTS USIN
   Pickles K, 2020, COVID 19 BELIEFS MIS, DOI [10.1101/2020.08.04.20168583, DOI 10.1101/2020.08.04.20168583]
   Rolison Jonathan J, 2015, Prev Med Rep, V2, P262, DOI 10.1016/j.pmedr.2015.04.005
   Romm Tony, 2020, WASHINGTON POST
   Sadique MZ, 2007, EMERG INFECT DIS, V13, P1307, DOI 10.3201/eid1309.070372
   Somera LP, 2016, J HEALTH COMMUN, V21, P469, DOI 10.1080/10810730.2015.1095822
   Voeten HACM, 2009, INT J BEHAV MED, V16, P49, DOI 10.1007/s12529-008-9006-4
   Walter D, 2012, EURO SURVEILL, V17
   Whitaker C, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7071
   WHO, 2020, SURV TOOL GUID RAP S, P38
   Wong LP, 2010, J COMMUN HEALTH, V35, P676, DOI 10.1007/s10900-010-9271-4
   Wortham JM, 2020, MMWR-MORBID MORTAL W, V69, P923, DOI 10.15585/mmwr.mm6928e1
NR 42
TC 0
Z9 0
U1 2
U2 2
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD OCT 8
PY 2020
VL 22
IS 10
AR e21071
DI 10.2196/21071
PG 15
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA OL0TK
UT WOS:000585055200009
PM 32936775
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pan, YH
   Xin, MQ
   Zhang, CH
   Dong, W
   Fang, Y
   Wu, WH
   Li, MZ
   Pang, J
   Zheng, ZL
   Wang, ZX
   Yuan, JQ
   He, YL
AF Pan, Yihang
   Xin, Meiqi
   Zhang, Changhua
   Dong, Willa
   Fang, Yuan
   Wu, Wenhui
   Li, Mingzhe
   Pang, Jun
   Zheng, Zilong
   Wang, Zixin
   Yuan, Jinqiu
   He, Yulong
TI Associations of Mental Health and Personal Preventive Measure Compliance
   With Exposure to COVID-19 Information During Work Resumption Following
   the COVID-19 Outbreak in China: Cross-Sectional Survey Study
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE COVID-19; information exposure; risk; communication; mental health;
   personal preventive measures; China; cross-sectional; public health;
   prevention
ID MEDIATING ROLE; SLEEP QUALITY; MERS OUTBREAK; RISK; CRISIS;
   COMMUNICATION; RESIDENTS; BEHAVIORS; KNOWLEDGE; IMPACT
AB Background: Risk and crisis communication plays an essential role in public health emergency responses. The COVID-19 pandemic has triggered spontaneous and intensive media attention, which has affected people's adoption of personal preventive measures and their mental health.
   Objective: The aim of this study was to investigate the associations between exposure to COVID-19-specific information and mental health (depression and sleep quality) and self-reported compliance with personal preventive measures (face mask wearing and hand sanitizing). We also tested whether these associations were moderated by thoughtful consideration of the veracity of the information to which people were exposed.
   Methods: A cross-sectional, closed web-based survey was conducted among a sample of 3035 factory workers at the beginning of work resumption following the COVID-19 outbreak in Shenzhen, China. A stratified two-stage cluster sampling design was used for recruitment. Multivariate linear and logistic regression models were used for the analyses.
   Results: The prevalence of probable moderate-to-severe depression was 170/3035 (5.6%), while that of good or excellent sleep quality was 2110/3035 (69.5%). The prevalence of self-reported consistent face mask wearing in public places was 2903/3035 (95.7%), while that of sanitizing hands every time after returning from public spaces or touching public installations was 2151/3035 (70.9%). Of the 3035 respondents, 1013 to 1638 (33.3% to 54.0%) reported >1 hour of daily exposure to COVID-19-specific information through web-based media and television. After controlling for significant background variables, higher information exposure via television and via newspapers and magazines was associated with better sleep quality and higher compliance with hand sanitizing. Higher exposure via unofficial web-based media was associated with higher compliance with hand sanitizing but was also associated with higher depressive symptoms. In contrast, higher exposure through face-to-face communication was associated with higher depressive symptoms, worse sleep quality, and lower compliance with hand sanitizing. Exposure to information about positive outcomes for patients with COVID-19, development of vaccines and effective treatments, and heroic stories about frontline health care workers were associated with both better mental health and higher compliance with preventive measures. Higher overall information exposure was associated with higher depressive symptoms among participants who were less likely to carefully consider the veracity of the information to which they were exposed; it was also associated with better sleep quality among people who reported more thoughtful consideration of information veracity.
   Conclusions: This study provides empirical evidence of how the amount, sources, and contents of information to which people were exposed influenced their mental health and compliance with personal preventive measures at the initial phase of work resumption in China. Thoughtful consideration of information quality was found to play an important moderating role. Our findings may inform strategic risk communication by government and public health authorities during the COVID-19 pandemic.
C1 [Pan, Yihang; Yuan, Jinqiu] Sun Yat Sen Univ, Affiliated Hosp 7, Precis Med Ctr, Ctr Sci Res, Shenzhen, Peoples R China.
   [Pan, Yihang; Zheng, Zilong; Yuan, Jinqiu] Sun Yat Sen Univ, Affiliated Hosp 7, Big Data Ctr, Shenzhen, Peoples R China.
   [Xin, Meiqi; Wang, Zixin] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China.
   [Zhang, Changhua; Wu, Wenhui; Li, Mingzhe; He, Yulong] Sun Yat Sen Univ, Affiliated Hosp 7, Ctr Digest Dis, Shenzhen, Peoples R China.
   [Dong, Willa] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Hlth Behav, Chapel Hill, NC USA.
   [Fang, Yuan] Educ Univ Hong Kong, Dept Early Childhood Educ, Hong Kong, Peoples R China.
   [Pang, Jun] Sun Yat Sen Univ, Affiliated Hosp 7, Ctr Urol, Shenzhen, Peoples R China.
   [Yuan, Jinqiu] Sun Yat Sen Univ, Affiliated Hosp 7, Clin Res Ctr, Shenzhen, Peoples R China.
RP Wang, ZX (corresponding author), Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Sch Publ Hlth, Prince Wales Hosp,Shatin, Room 508, Hong Kong 666888, Peoples R China.
EM wangzx@cuhk.edu.hk
OI Pang, Jun/0000-0003-0024-9415; Fang, Yuan/0000-0003-1154-5076; XIN,
   Meiqi/0000-0002-8636-4918
FU Startup Fund for the 100 Top Talents Program, Sun Yat-sen University
   [392012]; National Key Research and Development Program [2018YFA0902801]
FX This study was funded by the Startup Fund for the 100 Top Talents
   Program, Sun Yat-sen University (grant number 392012), and the National
   Key Research and Development Program (grant number 2018YFA0902801).
CR Ahmad AR, 2020, J MED INTERNET RES, V22, DOI 10.2196/19556
   [Anonymous], 2020, 2020 1 QUART GDP
   [Anonymous], 2019, SHENZH STAT YB
   [Anonymous], 2017, RISK COMMUNICATION
   Bao HY, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/20156
   Brennen JS, 2020, TYPES SOURCES CLAIMS
   Briscese G, 2020, NBER WORKING PAPERS
   Chen Y, 2017, PSYCHOL MED, V47, P958, DOI 10.1017/S0033291716002889
   Choi DH, 2017, COMPUT HUM BEHAV, V72, P422, DOI 10.1016/j.chb.2017.03.004
   Chong YY, 2020, INT J NURS STUD, V108, DOI 10.1016/j.ijnurstu.2020.103644
   Chuang YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122970
   Clarifications, CLAR
   Covello VT, 2003, J HEALTH COMMUN, V8, P5, DOI 10.1080/10810730390224802
   Esposito S, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01260-2020
   Gammage KL, 2011, AM J HEALTH BEHAV, V35, P371
   Garfin DR, 2020, HEALTH PSYCHOL, V39, P355, DOI 10.1037/hea0000875
   Ho CSH, 2020, ANN ACAD MED SINGAP, V49, P155
   Hua JL, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072309
   Kreps GL, 2005, GLOBAL PUBLIC HLTH C, P349
   Kwok KO, 2020, EMERG INFECT DIS, V26, P1575, DOI 10.3201/eid2607.200500
   Lee Dong-Hun, 2016, [Korean Journal of Psychology: General, 한국심리학회지:일반], V35, P355, DOI 10.22257/kjp.2016.06.35.2.355
   Liao QY, 2020, J MED INTERNET RES, V22, DOI 10.2196/18796
   Liao W, 2015, ARCH SEX BEHAV, V44, P791, DOI 10.1007/s10508-014-0317-z
   Ludolph R, 2018, J HEALTH COMMUN, V23, P1, DOI 10.1080/10810730.2017.1388455
   Moriarty AS, 2015, GEN HOSP PSYCHIAT, V37, P567, DOI 10.1016/j.genhosppsych.2015.06.012
   Paakkari L, 2020, LANCET PUBLIC HEALTH, V5, pE249, DOI 10.1016/S2468-2667(20)30086-4
   Posid JM, 2005, J PUBLIC HEALTH MAN, V11, P208
   Qian M, 2020, PSYCHOL RESPONSES BE, DOI [10.1101/2020.02.18.20024448, DOI 10.1101/2020.02.18.20024448]
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   RENN O, 1992, J SOC ISSUES, V48, P137, DOI 10.1111/j.1540-4560.1992.tb01949.x
   Reynolds B, 2005, J HEALTH COMMUN, V10, P43, DOI 10.1080/10810730590904571
   Sanchez TH, 2020, AIDS BEHAV, V24, P2024, DOI 10.1007/s10461-020-02894-2
   Seng J.J.B., 2020, PANDEMIC RELATED HLT, DOI [10.1101/2020.05.07.20094227, DOI 10.1101/2020.05.07.20094227]
   Sentell T, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093010
   Seo M, 2019, J MASS COMMUN Q, DOI 10.1177/1077699019857693
   Sibley CG, 2020, AM PSYCHOL, V75, P618, DOI 10.1037/amp0000662
   Snyder E, 2018, J CLIN SLEEP MED, V14, P1849, DOI 10.5664/jcsm.7478
   Tai ZX, 2007, NEW MEDIA SOC, V9, P987, DOI 10.1177/1461444807082691
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wipatayotin A., 2020, BANGKOK POST
   WITTE K, 1992, COMMUN MONOGR, V59, P329, DOI 10.1080/03637759209376276
   World Health Organization, 2020, REC MEMB STAT IMPR H
   World Health Organization, 2020, COUNT MIS COVID 19
   Yang Y, 2020, SLEEP MED, V73, P47, DOI 10.1016/j.sleep.2020.06.034
   YONG KIM, 2016, [Health Communication, the Official Journal of Korean Academy on Communication in Healthcare, 의료커뮤니케이션], V11, P39, DOI 10.15715/kjhcom.2016.11.1.39
   Yuen KF, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103513
   Zarocostas J, 2020, LANCET, V395, P676, DOI 10.1016/S0140-6736(20)30461-X
   Zhang L, 2020, WHAT IS REQUIRED PRE, DOI [10.1101/2020.03.24.20042374, DOI 10.1101/2020.03.24.20042374]
   Zhang Ll, 2015, ATL J COMMUN, V23, P67, DOI 10.1080/15456870.2015.1013101
   Zhao YX, 2020, J MED INTERNET RES, V22, DOI 10.2196/18825
   Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221
NR 51
TC 0
Z9 0
U1 2
U2 2
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD OCT 8
PY 2020
VL 22
IS 10
AR e22596
DI 10.2196/22596
PG 17
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA OL0TK
UT WOS:000585055200013
PM 32936776
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Niles, JK
   Gudin, J
   Radcliff, J
   Kaufman, HW
AF Niles, Justin K.
   Gudin, Jeffrey
   Radcliff, Jeff
   Kaufman, Harvey W.
TI The Opioid Epidemic Within the COVID-19 Pandemic: Drug Testing in 2020
SO POPULATION HEALTH MANAGEMENT
LA English
DT Article; Early Access
DE clinical drug testing; substance use disorder; COVID-19; SARS-CoV-2;
   opioid; fentanyl
ID INVOLVED OVERDOSE DEATHS; STRESS; STATES
AB The convergence of the opioid epidemic and the coronavirus disease 2019 (COVID-19) pandemic has created new health care challenges. The authors analyzed changes in clinical drug testing patterns and results at a national clinical laboratory, comparing data obtained before and during the pandemic. Testing for prescription and illicit drugs declined rapidly during the pandemic, with weekly test volumes falling by approximately 70% from the baseline period to the trough (the week beginning March 29) before rising in subsequent weeks. Among individuals tested, positivity increased by 35% for non-prescribed fentanyl and 44% for heroin during the pandemic. Positivity for non-prescribed fentanyl increased significantly among patients positive for other drugs: by 89% for specimens positive for amphetamines; 48% for benzodiazepines; 34% for cocaine; and 39% for opiates (P < 0.01 for all comparisons). These findings suggest significant increases in dangerous drug combinations. Positivity for non-prescribed use of many other drugs remained consistent or declined for some drugs, relative to pre-pandemic patterns. Models adjusting for potential confounding variables, including medication-assisted treatment and treatment at a substance use disorder facility indicated that the risk for non-prescribed fentanyl positivity rose by more than 50% during the pandemic. In summary, these findings demonstrate decreased drug testing overall, with increased positivity for high-risk drugs and dangerous drug combinations. The convergence of the drug abuse epidemic and COVID-19 pandemic has led to an increased need for health care and public health resources dedicated to supporting vulnerable patients and addressing the underlying causes of these disturbing trends.
C1 [Niles, Justin K.; Gudin, Jeffrey; Radcliff, Jeff; Kaufman, Harvey W.] Quest Diagnost, 500 Plaza Dr, Secaucus, NJ 07094 USA.
RP Kaufman, HW (corresponding author), Quest Diagnost, 500 Plaza Dr, Secaucus, NJ 07094 USA.
EM harvey.w.kaufman@questdiagnostics.com
CR [Anonymous], 2020, COP COLL PUBL HLTH C
   [Anonymous], 2020, LOS ANGELES TIMES
   [Anonymous], 2020, WASHINGTON POST
   Centers for Disease Control and Prevention, 2020, OP OV FENT
   Centers for Disease Control and Prevention, 2020, FRAM HEALTHC SYST PR
   Centers for Disease Control and Prevention, 2020, OP OV
   Centers for Disease Control and Prevention. National Center for Health Statistics, VIT STAT RAP REL PRO
   Centers for Disease Control and Prevention. National Center for Health Statistics, OV DEATH US 1999 201
   Gladden RM, 2019, MMWR-MORBID MORTAL W, V68, P737, DOI 10.15585/mmwr.mm6834a2
   Johns Hopkins University and Medicine, 2020, COVID19 DASHB CTR SY
   Overdose Detection Mapping Application Program, 2020, CONS COVID 19 OV EP
   Petterson S., 2020, PROJECTED DEATHS DES
   Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI 10.1007/s002130100917
   Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030
   Wilson N, 2020, MMWR-MORBID MORTAL W, V69, P290, DOI 10.15585/mmwr.mm6911a4
NR 15
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1942-7891
EI 1942-7905
J9 POPUL HEALTH MANAG
JI Popul. Health Manag.
DI 10.1089/pop.2020.0230
EA OCT 2020
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA OM9ED
UT WOS:000586317400001
PM 33031013
OA Bronze
DA 2021-01-01
ER

PT J
AU Naik, PA
   Yavuz, M
   Qureshi, S
   Zu, J
   Townley, S
AF Naik, Parvaiz Ahmad
   Yavuz, Mehmet
   Qureshi, Sania
   Zu, Jian
   Townley, Stuart
TI Modeling and analysis of COVID-19 epidemics with treatment in fractional
   derivatives using real data from Pakistan
SO EUROPEAN PHYSICAL JOURNAL PLUS
LA English
DT Article
ID DIFFERENTIAL-EQUATIONS; NUMERICAL-SIMULATION; LYAPUNOV FUNCTIONS;
   STABILITY; DYNAMICS
AB Coronaviruses are a large family of viruses that cause different symptoms, from mild cold to severe respiratory distress, and they can be seen in different types of animals such as camels, cattle, cats and bats. Novel coronavirus called COVID-19 is a newly emerged virus that appeared in many countries of the world, but the actual source of the virus is not yet known. The outbreak has caused pandemic with 26,622,706 confirmed infections and 874,708 reported deaths worldwide till August 31, 2020, with 17,717,911 recovered cases. Currently, there exist no vaccines officially approved for the prevention or management of the disease, but alternative drugs meant for HIV, HBV, malaria and some other flus are used to treat this virus. In the present paper, a fractional-order epidemic model with two different operators called the classical Caputo operator and the Atangana-Baleanu-Caputo operator for the transmission of COVID-19 epidemic is proposed and analyzed. The reproduction number R-0 is obtained for the prediction and persistence of the disease. The dynamic behavior of the equilibria is studied by using fractional Routh-Hurwitz stability criterion and fractional La Salle invariant principle. Special attention is given to the global dynamics of the equilibria. Moreover, the fitting of parameters through least squares curve fitting technique is performed, and the average absolute relative error between COVID-19 actual cases and the model's solution for the infectious class is tried to be reduced and the best fitted values of the relevant parameters are achieved. The numerical solution of the proposed COVID-19 fractional-order model under the Caputo operator is obtained by using generalized AdamsBashforth-Moulton method, whereas for the Atangana-Baleanu-Caputo operator, we have used a new numerical scheme. Also, the treatment compartment is included in the population which determines the impact of alternative drugs applied for treating the infected individuals. Furthermore, numerical simulations of the model and their graphical presentations are performed to visualize the effectiveness of our theoretical results and to monitor the effect of arbitrary-order derivative.
C1 [Naik, Parvaiz Ahmad; Zu, Jian] Xi An Jiao Tong Univ, Sch Math & Stat, Xian 710049, Shaanxi, Peoples R China.
   [Yavuz, Mehmet] Necmettin Erbakan Univ, Fac Sci, Dept Math & Comp Sci, TR-42090 Konya, Turkey.
   [Yavuz, Mehmet; Townley, Stuart] Univ Exeter, Coll Engn Math & Phys Sci, Dept Math, Penryn TR10, Cornwall, England.
   [Qureshi, Sania] Mehran Univ Engn & Technol, Dept Basic Sci & Related Studies, Jamshoro 76062, Pakistan.
RP Zu, J (corresponding author), Xi An Jiao Tong Univ, Sch Math & Stat, Xian 710049, Shaanxi, Peoples R China.
EM naik.parvaiz@xjtu.edu.cn; mehmetyavuz@erbakan.edu.tr;
   sania.qureshi@faculty.muet.edu.pk; jianzu@xjtu.edu.cn;
   S.B.Townley@exeter.ac.uk
RI Yavuz, Mehmet/G-9422-2018
OI Yavuz, Mehmet/0000-0002-3966-6518
FU China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2019M663653, 2014M560755]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [11971375, 11571272, 11201368, 11631012]; National Science and
   Technology Major Project of China [2018ZX10721202]; Natural Science
   Foundation of Shaanxi ProvinceNatural Science Foundation of Shaanxi
   Province [2019JM-273]; TUBITAK (The Scientific and Technological
   Research Council of Turkey)Turkiye Bilimsel ve Teknolojik Arastirma
   Kurumu (TUBITAK)
FX The authors would like to thank the reviewers and editors of this paper
   for their careful attention to detail and constructive feedback that
   improved the presentation of the paper greatly. The study was supported
   by grants from the China Postdoctoral Science Foundation (Grant Nos.
   2019M663653 and 2014M560755), the National Natural Science Foundation of
   China (Grant Nos. 11971375, 11571272, 11201368 and 11631012), the
   National Science and Technology Major Project of China (Grant No.
   2018ZX10721202) and the Natural Science Foundation of Shaanxi Province
   (Grant No. 2019JM-273). The funding body did not play any roles in the
   design of the study and in writing the manuscript. M. Yavuz was
   supported by TUBITAK (The Scientific and Technological Research Council
   of Turkey).
CR Abdeljawad T, 2018, ADV DIFFER EQU-NY, DOI 10.1186/s13662-018-1914-2
   Aguila-Camacho N, 2014, COMMUN NONLINEAR SCI, V19, P2951, DOI 10.1016/j.cnsns.2014.01.022
   Ahmed A, 2020, AIMS BIOENG, V7, P130, DOI 10.3934/bioeng.2020013
   Ahmed E, 2007, PHYSICA A, V379, P607, DOI 10.1016/j.physa.2007.01.010
   Atangana A, 2020, CHAOS SOLITON FRACT, V136, DOI 10.1016/j.chaos.2020.109860
   Atangana A, 2020, ALEX ENG J, V59, P1117, DOI 10.1016/j.aej.2020.01.005
   Atangana A, 2020, ALEX ENG J, V59, P1971, DOI 10.1016/j.aej.2019.12.028
   Atangana A, 2016, THERM SCI, V20, P763, DOI 10.2298/TSCI160111018A
   Avci D, 2019, HEAT CONDUCTION, P95
   BALEANU D, 2020, MATHEMATICS-BASEL, V8, DOI DOI 10.3390/MATH8030360
   CAPUTO M, 2015, PROGR FRACT DIFFER A, V1, P1, DOI DOI 10.12785/PFDA/010201
   Castillo-Chavez C, 2002, IMA VOL MATH APPL, V125, P229
   Chen T., 2020, BIORXIV, DOI [10.1101/2020.01.19.911669v1, DOI 10.1101/2020.01.19.911669V1]
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Diekmann O, 2010, J R SOC INTERFACE, V7, P873, DOI 10.1098/rsif.2009.0386
   Diethelm K, 2004, NUMER ALGORITHMS, V36, P31, DOI 10.1023/B:NUMA.0000027736.85078.be
   Diethelm K., 1999, FORSCH WISSENSCHAFTL, V1998, P57
   Diethelm K., 1997, ELECTRON T NUMER ANA, V5, P1
   Du Toit A, 2020, NAT REV MICROBIOL, V18, P1, DOI [10.1038/s41579-019-0302-6, DOI 10.1038/S41579-019-0302-6]
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Jarad F, 2018, CHAOS SOLITON FRACT, V117, P16, DOI 10.1016/j.chaos.2018.10.006
   Jha BK, 2018, INTERDISCIP SCI, V10, P674, DOI 10.1007/s12539-016-0202-7
   Joshi H, 2018, INT J BIOMATH, V11, DOI 10.1142/S1793524518501036
   Katugampola UN, 2011, APPL MATH COMPUT, V218, P860, DOI 10.1016/j.amc.2011.03.062
   Khan A, 2020, ALEX ENG J, V59, P49, DOI 10.1016/j.aej.2019.12.007
   Kheiri H, 2019, J COMPUT APPL MATH, V346, P323, DOI 10.1016/j.cam.2018.06.055
   Kucharski AJ, 2020, CMMID NCOV WORKING G, DOI [10.1101/2020.01.31.20019901, DOI 10.1101/2020.01.31.20019901]
   LaSalle J, 1976, CBMS NSF REGIONAL C
   Li CP, 2009, COMPUT MATH APPL, V58, P1573, DOI 10.1016/j.camwa.2009.07.050
   Lin W, 2007, J MATH ANAL APPL, V332, P709, DOI 10.1016/j.jmaa.2006.10.040
   Mekkaoui T, 2019, METHODS MATH MODELLI, P51
   Ming W., 2020, BREAKING HEALTHCARE, DOI [10.1101/2020.01.27.922443, DOI 10.1101/2020.01.27.922443]
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Nadim S. S., 2020, ARXIV200308150
   Naik P. A., 2020, CHAOS SOLITON FRACT, V140, P10272
   Naik PA, 2020, J APPL ANAL COMPUT, V10, P1482, DOI 10.11948/20190239
   Naik PA, 2020, ALEX ENG J, V59, P2513, DOI 10.1016/j.aej.2020.04.016
   Naik PA, 2020, CHAOS SOLITON FRACT, V138, DOI 10.1016/j.chaos.2020.109826
   Naik PA, 2020, PHYSICA A, V545, DOI 10.1016/j.physa.2019.123816
   Naik PA, 2020, CHAOS SOLITON FRACT, V131, DOI 10.1016/j.chaos.2019.109500
   Odibat ZM, 2007, APPL MATH COMPUT, V186, P286, DOI 10.1016/j.amc.2006.07.102
   Owolabi KM, 2019, SPRINGER SERIES COMP
   Owolabi KM, 2020, ALEX ENG J, V59, P2477, DOI 10.1016/j.aej.2020.03.022
   Owolabi KM, 2019, PHYSICA A, V525, P849, DOI 10.1016/j.physa.2019.04.024
   Owolabi KM, 2019, CHAOS, V29, DOI 10.1063/1.5085490
   Peng L, 2020, EPIDEMIC ANAL COVID, DOI [10.1101/2020.02.16.20023465, DOI 10.1101/2020.02.16.20023465]
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Podlubny I., 1999, FRACTIONAL DIFFERENT
   Podlubny I., 1998, FRACTIONAL DIFFERENT, V198
   Qureshi S, 2020, CHAOS SOLITON FRACT, V136, DOI 10.1016/j.chaos.2020.109812
   Qureshi S, 2020, CHAOS, V30, DOI 10.1063/1.5121845
   Qureshi S, 2020, EUR PHYS J PLUS, V135, DOI 10.1140/epjp/s13360-020-00133-0
   Qureshi S, 2019, PHYSICA A, V535, DOI 10.1016/j.physa.2019.122496
   Qureshi S, 2019, PHYSICA A, V526, DOI 10.1016/j.physa.2019.121127
   Qureshi S, 2019, CHAOS, V29, DOI 10.1063/1.5082907
   Saeedian M, 2017, PHYS REV E, V95, DOI 10.1103/PhysRevE.95.022409
   SAMKO S. G., 1993, FRACTIONAL INTEGRALS
   Shen M, 2020, MODELLING EPIDEMIC T, DOI [10.1101/2020.01.23.916726, DOI 10.1101/2020.01.23.916726, 10.1101/2020.01.23.916726.]
   Shuai ZS, 2013, SIAM J APPL MATH, V73, P1513, DOI 10.1137/120876642
   Singh J, 2018, APPL MATH COMPUT, V316, P504, DOI 10.1016/j.amc.2017.08.048
   Sookaromdee P, 2020, ASIAN PAC J TROP MED, V13, P139, DOI 10.4103/1995-7645.277516
   Tang B, 2020, INT J INFECT DIS, V96, P636, DOI 10.1016/j.ijid.2020.05.113
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Toufik M, 2017, EUR PHYS J PLUS, V132, DOI 10.1140/epjp/i2017-11717-0
   Ucar S, 2019, CHAOS SOLITON FRACT, V118, P300, DOI 10.1016/j.chaos.2018.12.003
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   Vargas-De-Leon C, 2015, COMMUN NONLINEAR SCI, V24, P75, DOI 10.1016/j.cnsns.2014.12.013
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Yavuz M, 2018, MATH MODEL NAT PHENO, V13, DOI 10.1051/mmnp/2018009
   Yavuz M., 2020, MATH SCI APPL E NOTE, V8, P1
   Yavuz M, 2020, FRACTAL FRACT, V4, DOI 10.3390/fractalfract4030035
   Yavuz M, 2020, ADV DIFFER EQU-NY, V2020, DOI 10.1186/s13662-020-02828-1
   Yavuz M, 2020, NUMER METH PART D E, V36, P1348, DOI 10.1002/num.22476
   Yavuz M, 2019, PHYSICA A, V525, P373, DOI 10.1016/j.physa.2019.03.069
   Yavuz M, 2019, MATH MODEL NAT PHENO, V14, DOI 10.1051/mmnp/2018070
   Yavuz M, 2018, FRACTAL FRACT, V2, DOI 10.3390/fractalfract2010003
   Zhou Tao, 2020, J Evid Based Med, V13, P3, DOI 10.1111/jebm.12376
   Zu J, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00709-z
NR 79
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-5444
J9 EUR PHYS J PLUS
JI Eur. Phys. J. Plus
PD OCT 8
PY 2020
VL 135
IS 10
AR 795
DI 10.1140/epjp/s13360-020-00819-5
PG 42
WC Physics, Multidisciplinary
SC Physics
GA OH9MR
UT WOS:000582914000001
PM 33145145
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ai, ZZ
   Zhou, SS
   Li, WN
   Wang, MF
   Wang, LQ
   Hu, GM
   Tao, R
   Wang, XQ
   Shen, YF
   Xie, LH
   Ba, YM
   Wu, HZ
   Yang, YF
AF Ai, Zhongzhu
   Zhou, Shanshan
   Li, Weinan
   Wang, Mengfan
   Wang, Linqun
   Hu, Gangming
   Tao, Ran
   Wang, Xiaoqin
   Shen, Yinfeng
   Xie, Lihan
   Ba, Yuanming
   Wu, Hezhen
   Yang, YanFang
TI "Fei Yan No. 1" as a Combined Treatment for COVID-19: An Efficacy and
   Potential Mechanistic Study
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Fei Yan NO1; COVID-19; SARS-CoV-2; clinical efficacy; network
   pharmacology
ID TRADITIONAL CHINESE MEDICINE; CORONAVIRUS PNEUMONIA; CYTOKINE STORM;
   RECEPTOR; IL-6; SARS-COV-2; VIRUS
AB There has been a large global outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), representing a major public health issue. In China, combination therapy, including traditional Chinese medicine (TCM) as a treatment for COVID-19 has been used widely. "Fei Yan No. 1" (QFDYG) is a formula recommended by the Hubei Government to treat COVID-19. A retrospective study of 84 COVID-19 patients from Hubei Provincial Hospital of TCM and Renmin Hospital of Hanchuan was conducted to explore the clinical efficacy of QFDYG combination therapy. TCMSP and YaTCM databases were used to determine the components of all Chinese herbs in QFDYG. Oral bioavailability (OB) >= 30% and drug-like (DL) quality >= 0.18 were selected as criteria for screening the active compounds identified within the TCMSP database. The targets of active components in QFDYG were determined using the Swiss TargetPrediction (SIB) and Targetnet databases. The STRING database and the Network Analyzer plugin in Cytoscape were used to obtain protein-protein interaction (PPI) network topology parameters and to identify hub targets. Gene Ontology (GO) enrichment was conducted using FunRich version 3.1.3, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment using ClueGO version 2.5.6 software. PPI and compound-pathway (C-T) networks were constructed using Cytoscape 3.6.0. Compared with the control group, combined treatment with QFDYG resulted in a significantly higher rate of patients recovering from symptoms and shorter the time. After 14 days of treatment, QFDYG combined treatment increased the proportion of patients testing negative for SARS-CoV-2 nucleic acid by RT-PCR. Compared with the control group, promoting focal absorption and inflammation as viewed on CT images. GO and KEGG pathway enrichment indicated that QFDYG principally regulated biological processes, such as inflammation, an immune response, and apoptosis. The present study revealed that QFDYG combination therapy offered particular therapeutic advantages, indicating that the theoretical basis for the treatment of COVID-19 by QFDYG may play an antiviral and immune response regulation through multiple components, targets, and pathways, providing reference for the clinical treatment of COVID-19.
C1 [Ai, Zhongzhu; Wang, Mengfan; Wu, Hezhen; Yang, YanFang] Hubei Univ Chinese Med, Fac Pharm, Wuhan, Peoples R China.
   [Zhou, Shanshan; Wang, Linqun; Shen, Yinfeng] Hubei Univ Chinese Med, Clin Coll 1, Wuhan, Peoples R China.
   [Li, Weinan; Wang, Xiaoqin; Ba, Yuanming] Hubei Prov Hosp TCM, Nephrol Dept, Hanchuan, Peoples R China.
   [Li, Weinan; Wang, Xiaoqin; Ba, Yuanming] Hubei Prov Tradit Chinese Med Res Inst, Nephrol Dept, Wuhan, Peoples R China.
   [Hu, Gangming] Renmin Hosp Hanchuan, TCM Dept, Hanchuan, Peoples R China.
   [Tao, Ran] Hubei Prov Hosp TCM, Surg Dept, Wuhan, Peoples R China.
   [Tao, Ran] Hubei Prov Tradit Chinese Med Res Inst, Surg Dept, Wuhan, Peoples R China.
   [Xie, Lihan] Cent Hosp Wuhan, Nephrol Dept, Wuhan, Peoples R China.
RP Wu, HZ; Yang, YF (corresponding author), Hubei Univ Chinese Med, Fac Pharm, Wuhan, Peoples R China.; Ba, YM (corresponding author), Hubei Prov Hosp TCM, Nephrol Dept, Hanchuan, Peoples R China.; Ba, YM (corresponding author), Hubei Prov Tradit Chinese Med Res Inst, Nephrol Dept, Wuhan, Peoples R China.
EM bayuanming@126.com; hezh_wu@163.com; yyf0204@hbtcm.edu.cn
FU Hubei Provincial Department of Science and Technology [2020FCA007];
   Novel Coronavirus Pneumonia Emergency Science and Technology Project of
   Hubei University of Chinese Medicine [6]; Academic Experience
   Inheritance of the Sixth National Group of Old Chinese Medicine Experts
   of the State Administration of Traditional Chinese Medicine [2017 [29]]
FX This study was supported by Hubei Provincial Department of Science and
   Technology about New Pneumonia Emergency Project (No. 2020FCA007), Novel
   Coronavirus Pneumonia Emergency Science and Technology Project of Hubei
   University of Chinese Medicine (2020[NO.6]), and Academic Experience
   Inheritance of the Sixth National Group of Old Chinese Medicine Experts
   of the State Administration of Traditional Chinese Medicine (No. 2017
   [29]).
CR Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101608
   Almeida CR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00101
   Ba YM, 2020, SHI JIE ZHONG YI YAO, V15, P1962, DOI DOI 10.3969/j.issn.1673-7202.2020.13.021
   Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen WH, 2020, HUM VACC IMMUNOTHER, V16, P1239, DOI 10.1080/21645515.2020.1740560
   Columbus Cristie, 2020, Proc (Bayl Univ Med Cent), V33, P209, DOI 10.1080/08998280.2020.1731272
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003
   Dai JP, 2017, MOLECULES, V22, DOI 10.3390/molecules22101754
   Du HZ, 2020, CHIN J NAT MEDICINES, V18, P206, DOI [10.3724/SP.J.1009.2019.000000, 10.1016/S1875-5364(20)30022-4]
   Fiore C, 2008, PHYTOTHER RES, V22, P141, DOI 10.1002/ptr.2295
   General Office Of The National Health And Health Commission, 2020, PROT DIAGN TREATM CO
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hanley B, 2020, J CLIN PATHOL, V73, P239, DOI 10.1136/jclinpath-2020-206522
   Hasoksuz M, 2020, TURK J MED SCI, V50, P549, DOI 10.3906/sag-2004-127
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Jawhara S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072272
   Khanra R, 2017, BIOMED PHARMACOTHER, V88, P918, DOI 10.1016/j.biopha.2017.01.132
   Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391
   Kong WH, 2020, NAT MICROBIOL, V5, P675, DOI 10.1038/s41564-020-0713-1
   Kong XL, 2019, INFLAMMOPHARMACOLOGY, V27, P773, DOI 10.1007/s10787-018-0537-2
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875-5364(13)60037-0]
   Li SF, 2020, J PHARM PHARMACOL, V72, P1092, DOI 10.1111/jphp.13279
   Li XQ, 2018, J ASIAN NAT PROD RES, V20, P399, DOI 10.1080/10286020.2018.1465937
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Liu F, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104370
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pearson M, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100906
   Pirozyan MR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00372
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Rotondi M, 2007, ENDOCR REV, V28, P492, DOI 10.1210/er.2006-0044
   Scheller J, 2006, MED MICROBIOL IMMUN, V195, P173, DOI 10.1007/s00430-006-0019-9
   Shang XF, 2010, J ETHNOPHARMACOL, V128, P279, DOI 10.1016/j.jep.2010.01.006
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779132
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Soraya GV, 2020, MED CLIN-BARCELONA, V155, P143, DOI 10.1016/j.medcli.2020.05.017
   Su ZZ, 2012, CHIN J NAT MEDICINES, V10, P415, DOI [10.3724/SP.J.1009.2012.00415, 10.1016/S1875-5364(12)60081-8]
   Sun ZG, 2019, MINI-REV MED CHEM, V19, P826, DOI 10.2174/1389557519666190119111125
   Tahamtan A, 2020, EXPERT REV MOL DIAGN, V20, P453, DOI [10.1080/14737159.2020.1757437, 10.1080/07435800.2020.1713802]
   Vinayagam A, 2016, P NATL ACAD SCI USA, V113, P4976, DOI 10.1073/pnas.1603992113
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang L, 2020, MED MALADIES INFECT, V50, P332, DOI 10.1016/j.medmal.2020.03.007
   Wei XM, 2020, NATL SCI REV, V7, P239, DOI 10.1093/nsr/nwaa009
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Xue ZZ, 2016, NAT PROD COMMUN, V11, P1861
   Yang HF, 2017, J VET RES, V61, P405, DOI 10.1515/jvetres-2017-0062
   Yang WJ, 2020, RADIOLOGY, V295, pE3, DOI 10.1148/radiol.2020200702
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Yang Y, 2020, MOLECULES, V25, DOI 10.3390/molecules25010189
   Yusuf S, 2019, IRAN J MICROBIOL, V11, P412
   Zambello R, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030768
   Zemans RL, 2009, AM J RESP CELL MOL, V40, P519, DOI 10.1165/rcmb.2008-0348TR
   Zhang Xi-ping, 2007, Journal of Zhejiang University-Science B, V8, P147, DOI 10.1631/jzus.2007.B0147
   Zhou SS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00425
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 63
TC 0
Z9 0
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 8
PY 2020
VL 11
AR 581277
DI 10.3389/fphar.2020.581277
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OH0XT
UT WOS:000582296500001
PM 33132913
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Russo, V
   Carbone, A
   Mottola, FF
   Mocerino, R
   Verde, R
   Attena, E
   Verde, N
   Di Micco, P
   Nunziata, L
   Santelli, F
   Nigro, G
   Severino, S
AF Russo, Vincenzo
   Carbone, Andreina
   Mottola, Filiberto Fausto
   Mocerino, Rosa
   Verde, Raffaele
   Attena, Emilio
   Verde, Nicoletta
   Di Micco, Pierpaolo
   Nunziata, Luigi
   Santelli, Francesco
   Nigro, Gerardo
   Severino, Sergio
TI Effect of Triple Combination Therapy With Lopinavir-Ritonavir,
   Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk
   in Hospitalized COVID-19 Patients
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE coronavirus disease 2019; arrhythmias; QTc prolongation; SARS-CoV2;
   lopinavir; ritonavir; torsades des pointes
ID PROLONGATION
AB Introduction
   No data are provided about the effect of triple combination therapy with Lopinavir/Ritonavir (LPN/RTN), hydroxychloroquine (HQ) and azithromycin (AZT) on corrected QT (QTc) interval and arrhythmic risk, in COVID-19 patients. This study aims to describe the incidence of extreme QTc interval prolongation among COVID-19 patients on this experimental treatment and to identify the clinical features associated with extreme QTc prolongation.
   Materials and Methods
   Data of 87 COVID-19 patients, treated with triple combination including LPN/RTN, HQ and AZT, were analyzed. QT interval was obtained by the tangent method and corrected for heart rate using Bazett's formula. Extreme QTc interval prolongation was considered an absolute QTc interval >= 500 ms or an increase in QTc intervals of 60 ms or greater (Delta QTc >= 60 ms) compared with baseline.
   Results
   Hypertension (66.7%) and diabetes (25.3%) were the most prevalent cardiovascular comorbidities. Twenty patients (23%) showed extreme QTc interval prolongation; no clinical, electrocardiographic or pharmacological characteristics have been associated to extreme QTc prolongation, except the history of ischemic stroke (P= 0,007). One torsade de pointes (TdP) in patient with QTc extreme prolongation (QTc: 560 ms) after 5 days of therapy was recorded.
   Conclusions
   We observed a high incidence of extreme QTc interval prolongation among COVID-19 patients on triple combination therapy. Since the incidence of malignant arrhythmias seems to be not negligible, a careful electrocardiographic monitoring would be advisable.
C1 [Russo, Vincenzo; Carbone, Andreina; Mottola, Filiberto Fausto; Verde, Nicoletta; Nigro, Gerardo] Univ Campania Luigi Vanvitelli, Monaldi Hosp, Dept Translat Med Sci, Chair Cardiol, Naples, Italy.
   [Mocerino, Rosa; Verde, Raffaele; Severino, Sergio] Cotugno Hosp, Cardiol Unit, Naples, Italy.
   [Attena, Emilio] San Giuliano Hosp, Italy Med Unit, Div Cardiol, Naples, Italy.
   [Di Micco, Pierpaolo] Fatebenefratelli Hosp Naples, Dept Cardiol, Naples, Italy.
   [Nunziata, Luigi] Boscotrecase Hosp, Cardiol Unit, Naples, Italy.
   [Santelli, Francesco] Univ Naples Federico II, Dept Polit Sci, Naples, Italy.
RP Russo, V (corresponding author), Univ Campania Luigi Vanvitelli, Monaldi Hosp, Dept Translat Med Sci, Chair Cardiol, Naples, Italy.
EM v.p.russo@libero.it
RI Santelli, Francesco/ABI-4537-2020; Russo, Vincenzo/ABH-1766-2020
OI Santelli, Francesco/0000-0003-3853-4246; 
CR Anson BD, 2005, LANCET, V365, P682, DOI 10.1016/S0140-6736(05)70936-3
   Bessiere F, 2020, JAMA CARDIOL, V5, P1067, DOI 10.1001/jamacardio.2020.1787
   Bun SS, 2020, CLIN PHARMACOL THER, V108, P1090, DOI 10.1002/cpt.1968
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Cipriani A, 2020, INT J CARDIOL, V316, P280, DOI 10.1016/j.ijcard.2020.05.036
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Drew BJ, 2010, CIRCULATION, V121, P1047, DOI 10.1161/CIRCULATIONAHA.109.192704
   Hor CP, 2020, J INFECTION, V81, pE117, DOI 10.1016/j.jinf.2020.05.058
   Khan Q, 2017, EUR J CLIN PHARMACOL, V73, P1511, DOI 10.1007/s00228-017-2321-4
   Li Yang, 2020, Journal of Hymenoptera Research, P39, DOI 10.3897/jhr.76.50794
   Marafioti V, 2014, INT J CARDIOL, V176, P1203, DOI 10.1016/j.ijcard.2014.07.226
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Oppenheimer S, 2006, CLIN AUTON RES, V16, P6, DOI 10.1007/s10286-006-0276-0
   OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727
   Postema PG, 2008, HEART RHYTHM, V5, P1015, DOI 10.1016/j.hrthm.2008.03.037
   Ramireddy A, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017144
   Russo V, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061944
   Russo V, 2020, J CARDIOVASC PHARM, V76, P138, DOI 10.1097/FJC.0000000000000854
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   Wang L, 2009, CELL PHYSIOL BIOCHEM, V23, P305, DOI 10.1159/000218177
NR 20
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 8
PY 2020
VL 11
AR 582348
DI 10.3389/fphar.2020.582348
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OG3MY
UT WOS:000581793900001
PM 33132915
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU McAuley, AJ
   Kuiper, MJ
   Durr, PA
   Bruce, MP
   Barr, J
   Todd, S
   Au, GG
   Blasdell, K
   Tachedjian, M
   Lowther, S
   Marsh, GA
   Edwards, S
   Poole, T
   Layton, R
   Riddell, SJ
   Drew, TW
   Druce, JD
   Smith, TRF
   Broderick, KE
   Vasan, SS
AF McAuley, Alexander J.
   Kuiper, Michael J.
   Durr, Peter A.
   Bruce, Matthew P.
   Barr, Jennifer
   Todd, Shawn
   Au, Gough G.
   Blasdell, Kim
   Tachedjian, Mary
   Lowther, Sue
   Marsh, Glenn A.
   Edwards, Sarah
   Poole, Timothy
   Layton, Rachel
   Riddell, Sarah-Jane
   Drew, Trevor W.
   Druce, Julian D.
   Smith, Trevor R. F.
   Broderick, Kate E.
   Vasan, S. S.
TI Experimental and in silico evidence suggests vaccines are unlikely to be
   affected by D614G mutation in SARS-CoV-2 spike protein
SO NPJ VACCINES
LA English
DT Article
AB The 'D614G' mutation (Aspartate-to-Glycine change at position 614) of the SARS-CoV-2 spike protein has been speculated to adversely affect the efficacy of most vaccines and countermeasures that target this glycoprotein, necessitating frequent vaccine matching. Virus neutralisation assays were performed using sera from ferrets which received two doses of the INO-4800 COVID-19 vaccine, and Australian virus isolates (VIC01, SA01 and VIC31) which either possess or lack this mutation but are otherwise comparable. Through this approach, supported by biomolecular modelling of this mutation and the commonly-associated P314L mutation in the RNA-dependent RNA polymerase, we have shown that there is no experimental evidence to support this speculation. We additionally demonstrate that the putative elastase cleavage site introduced by the D614G mutation is unlikely to be accessible to proteases.
C1 [McAuley, Alexander J.; Durr, Peter A.; Bruce, Matthew P.; Barr, Jennifer; Todd, Shawn; Au, Gough G.; Blasdell, Kim; Tachedjian, Mary; Lowther, Sue; Marsh, Glenn A.; Edwards, Sarah; Poole, Timothy; Layton, Rachel; Riddell, Sarah-Jane; Drew, Trevor W.; Vasan, S. S.] Commonwealth Sci & Ind Res Org, Australian Ctr Dis Preparedness, Geelong, Vic 3219, Australia.
   [Kuiper, Michael J.] Commonwealth Sci & Ind Res Org, Data61, Docklands, Vic 3008, Australia.
   [Druce, Julian D.] Royal Melbourne Hosp, Peter Doherty Inst Infect & Immun, Victorian Infect Dis Reference Lab, Melbourne, Vic 3000, Australia.
   [Smith, Trevor R. F.; Broderick, Kate E.] Inovio Pharmaceut, 10480 Wateridge Circle, San Diego, CA 92121 USA.
   [Vasan, S. S.] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.
RP Vasan, SS (corresponding author), Commonwealth Sci & Ind Res Org, Australian Ctr Dis Preparedness, Geelong, Vic 3219, Australia.; Vasan, SS (corresponding author), Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.
EM vasan.vasan@csiro.au
RI ; Durr, Peter/O-2948-2014
OI Barr, Jennifer/0000-0001-5266-9142; Durr, Peter/0000-0003-0851-5300; Au,
   Gough/0000-0001-6923-8875
FU Coalition for Epidemic Preparedness Innovations (CEPI)
FX We are grateful for support from our colleagues at the Australian Centre
   for Disease Preparedness (https://www.grid.ac/institutes/grid.413322.5);
   South Australia Pathology (especially Dr. Lex Leong), and the Victorian
   Infectious Diseases Reference Laboratory (especially Dr. Mike Catton).
   Biomolecular modelling was enabled by the Australian National Computing
   Infrastructure and CSIRO High Performance Computing infrastructure. We
   thank Inovio Pharmaceuticals for the INO-4800 vaccine; Dr. Elisa Fadda
   (Manooth University, Ireland) for glycosylation modelling insights; and
   Professor Changchun Tu (Changchun University of Agriculture and Animal
   Sciences, China) for the hyperimmune horse anti-SARS-CoV serum sample
   used in this study. This work was conducted with funding to the CSIRO
   from the Coalition for Epidemic Preparedness Innovations (CEPI).
CR Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525
   Bhattacharyya C., 2020, GLOBAL SPREAD SARS C, DOI [10.1101/2020.05.04.075911v1, DOI 10.1101/2020.05.04.075911V1]
   Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Daniloski Z., 2020, D614G MUTATION SARS, DOI [10.1101/2020.06.14.151357v2, DOI 10.1101/2020.06.14.151357V2]
   Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8
   Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042
   Huang J, 2017, NAT METHODS, V14, P71, DOI [10.1038/NMETH.4067, 10.1038/nmeth.4067]
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Korber B., 2020, SPIKE MUTATION PIPEL, DOI [10.1101/2020.04.29.069054v2, DOI 10.1101/2020.04.29.069054V2]
   McCloskey S., 2020, NANOME CREATING POWE
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Tang L., 2020, SARS COV 2 SPIKE PRO
   Thao TTN, 2020, NATURE, V582, P561, DOI 10.1038/s41586-020-2294-9
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Woo H, 2020, J PHYS CHEM B, V124, P7128, DOI 10.1021/acs.jpcb.0c04553
   Woods AS, 2005, J PROTEOME RES, V4, P1397, DOI 10.1021/pr050077s
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Zhang L, 2020, D614G MUTATION SARS
NR 25
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2059-0105
J9 NPJ VACCINES
JI npj Vaccines
PD OCT 8
PY 2020
VL 5
IS 1
AR 96
DI 10.1038/s41541-020-00246-8
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OG1RP
UT WOS:000581670500001
PM 33083031
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mason, SE
   Scott, AJ
   Markar, SR
   Clarke, JM
   Martin, G
   Beatty, JW
   Sounderajah, V
   Yalamanchili, S
   Denning, M
   Arulampalam, T
   Kinross, JM
AF Mason, Sam E.
   Scott, Alasdair J.
   Markar, Sheraz R.
   Clarke, Jonathan M.
   Martin, Guy
   Winter Beatty, Jasmine
   Sounderajah, Viknesh
   Yalamanchili, Seema
   Denning, Max
   Arulampalam, Thanjakumar
   Kinross, James M.
CA PanSurg Collaborative
TI Insights from a global snapshot of the change in elective colorectal
   practice due to the COVID-19 pandemic
SO PLOS ONE
LA English
DT Article
ID CANCER; DELAY; RISK
AB Background There is a need to understand the impact of COVID-19 on colorectal cancer care globally and determine drivers of variation. Objective To evaluate COVID-19 impact on colorectal cancer services globally and identify predictors for behaviour change. Design An online survey of colorectal cancer service change globally in May and June 2020. Participants Attending or consultant surgeons involved in the care of patients with colorectal cancer. Main outcome measures Changes in the delivery of diagnostics (diagnostic endoscopy), imaging for staging, therapeutics and surgical technique in the management of colorectal cancer. Predictors of change included increased hospital bed stress, critical care bed stress, mortality and world region. Results 191 responses were included from surgeons in 159 centers across 46 countries, demonstrating widespread service reduction with global variation. Diagnostic endoscopy was reduced in 93% of responses, even with low hospital stress and mortality; whilst rising critical care bed stress triggered complete cessation (p= 0.02). Availability of CT and MRI fell by 40-41%, with MRI significantly reduced with high hospital stress. Neoadjuvant therapy use in rectal cancer changed in 48% of responses, where centers which had ceased surgery increased its use (62vs30%,p= 0.04) as did those with extended delays to surgery (p<0.001). High hospital and critical care bed stresses were associated with surgeons forming more stomas (p<0.04), using more experienced operators (p<0.003) and decreased laparoscopy use (critical care bed stress only,p<0.001). Patients were also more actively prioritized for resection, with increased importance of co-morbidities and ICU need. Conclusions The COVID-19 pandemic was associated with severe restrictions in the availability of colorectal cancer services on a global scale, with significant variation in behaviours which cannot be fully accounted for by hospital burden or mortality.
C1 [Mason, Sam E.; Scott, Alasdair J.; Markar, Sheraz R.; Martin, Guy; Winter Beatty, Jasmine; Sounderajah, Viknesh; Yalamanchili, Seema; Denning, Max; Kinross, James M.] Imperial Coll London, Dept Surg & Canc, London, England.
   [Clarke, Jonathan M.] Imperial Coll London, Ctr Math Precis Healthcare, London, England.
   [Arulampalam, Thanjakumar] Anglia Ruskin Univ, Dept Allied Hlth & Med, Cambridge, England.
RP Mason, SE (corresponding author), Imperial Coll London, Dept Surg & Canc, London, England.
EM sam.mason@imperial.ac.uk
OI Clarke, Jonathan/0000-0003-1495-7746; Denning, Max/0000-0001-6215-6885
CR [Anonymous], END ACT COVID 19 BSG
   [Anonymous], LOC RES EL SURG GUID
   Association of Coloproctology of Great Britain and Ireland, CONS MULT MAN PAT CO
   Bilimoria KY, 2013, J AM COLL SURGEONS, V217, P833, DOI 10.1016/j.jamcollsurg.2013.07.385
   Burki TK, LANCET ONCOL
   Cancer Research UK, COR IS IMP CANC SERV
   Coccolini F, ANN SURG
   Emanuel EJ, N ENGL J MED
   European Association for Endoscopic Surgery, RES SMOK GAS EV OP L
   European Society of Coloproctology, ESCP REC REG COVID 1
   Fang Y, RADIOLOGY
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   International Agency for Research on Cancer, GLOB CANC OBS 2018
   Korsgaard M, 2006, CANCER DETECT PREV, V30, P341, DOI 10.1016/j.cdp.2006.07.001
   Kutikov A, ANN INTERN MED
   Kwak HD, 2016, OCCUP ENVIRON MED, V73, P857, DOI 10.1136/oemed-2016-103724
   Lai AG, 2020, ESTIMATING EXCESS MO, DOI DOI 10.1101/2020.05.27.20083287V1
   Lefevre JH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-417
   National Health Service, CLIN GUID MAN PAT RE
   New South Wales Government, COVID 19 INT GUID EL
   Petrelli F, 2016, ANN SURG, V263, P458, DOI 10.1097/SLA.0000000000000368
   Pruitt SL, 2013, CANCER CAUSE CONTROL, V24, P961, DOI 10.1007/s10552-013-0172-6
   Royal College of Radiologists and others, GUID PREOP CHEST CT
   Royal College of Surgeons and others, URG INT GEN SURV GUI
   RStudio Team, RSTUDIO INT DEV R
   Seymour MT, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3504
   Shin DW, 2013, ANN SURG ONCOL, V20, P2468, DOI 10.1245/s10434-013-2957-y
   Society of American Gastrointestinal and Endoscopic Surgeons, SAG EAES REC REG SUR
   Wickham H., 2019, J OPEN SOURCE SOFTWA, V4, P1686, DOI [10.21105/joss.01686, DOI 10.21105/joss.01686]
NR 29
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 8
PY 2020
VL 15
IS 10
AR e0240397
DI 10.1371/journal.pone.0240397
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OG3TB
UT WOS:000581809800004
PM 33031464
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Garcia-Suarez, J
   de la Cruz, J
   Cedillo, A
   Llamas, P
   Duarte, R
   Jimenez-Yuste, V
   Hernandez-Rivas, JA
   Gil-Manso, R
   Kwon, M
   Sanchez-Godoy, P
   Martinez-Barranco, P
   Colas-Lahuerta, B
   Herrera, P
   Benito-Parra, L
   Alegre, A
   Velasco, A
   Matilla, A
   Alaez-Uson, MC
   Martos-Martinez, R
   Martinez-Chamorro, C
   Susana-Quiroz, K
   Del Campo, JF
   de la Fuente, A
   Herraez, R
   Pascual, A
   Gomez, E
   Perez-Oteyza, J
   Ruiz, E
   Alonso, A
   Gonzalez-Medina, J
   Martin-Buitrago, LN
   Canales, M
   Gonzalez-Gascon, I
   Vicente-Ayuso, MC
   Valenciano, S
   Roa, MG
   Monteliu, PE
   Lopez-Jimenez, J
   Escobar, CE
   Ortiz-Martin, J
   Diez-Martin, JL
   Martinez-Lopez, J
AF Garcia-Suarez, Julio
   de la Cruz, Javier
   Cedillo, Angel
   Llamas, Pilar
   Duarte, Rafael
   Jimenez-Yuste, Victor
   Hernandez-Rivas, Jose Angel
   Gil-Manso, Rodrigo
   Kwon, Mi
   Sanchez-Godoy, Pedro
   Martinez-Barranco, Pilar
   Colas-Lahuerta, Blanca
   Herrera, Pilar
   Benito-Parra, Laurentino
   Alegre, Adrian
   Velasco, Alberto
   Matilla, Arturo
   Alaez-Uson, Maria Concepcion
   Martos-Martinez, Rafael
   Martinez-Chamorro, Carmen
   Susana-Quiroz, Keina
   Del Campo, Juan Francisco
   de la Fuente, Adolfo
   Herraez, Regina
   Pascual, Adriana
   Gomez, Elvira
   Perez-Oteyza, Jaime
   Ruiz, Elena
   Alonso, Arancha
   Gonzalez-Medina, Jose
   Martin-Buitrago, Lucia Nunez
   Canales, Miguel
   Gonzalez-Gascon, Isabel
   Vicente-Ayuso, Maria Carmen
   Valenciano, Susana
   Roa, Maria Garcia
   Monteliu, Pablo Estival
   Lopez-Jimenez, Javier
   Escobar, Cristian Escolano
   Ortiz-Martin, Javier
   Diez-Martin, Jose Luis
   Martinez-Lopez, Joaquin
CA Assoc Madrilena Hematologia Hemo
TI Impact of hematologic malignancy and type of cancer therapy on COVID-19
   severity and mortality: lessons from a large population-based registry
   study
SO JOURNAL OF HEMATOLOGY & ONCOLOGY
LA English
DT Article
DE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); COVID-19;
   Hematologic neoplasms
AB BackgroundPatients with cancer have been shown to have a higher risk of clinical severity and mortality compared to non-cancer patients with COVID-19. Patients with hematologic malignancies typically are known to have higher levels of immunosuppression and may develop more severe respiratory viral infections than patients with solid tumors. Data on COVID-19 in patients with hematologic malignancies are limited. Here we characterize disease severity and mortality and evaluate potential prognostic factors for mortality.MethodsIn this population-based registry study, we collected de-identified data on clinical characteristics, treatment and outcomes in adult patients with hematologic malignancies and confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection within the Madrid region of Spain. Our case series included all patients admitted to 22 regional health service hospitals and 5 private healthcare centers between February 28 and May 25, 2020. The primary study outcome was all-cause mortality. We assessed the association between mortality and potential prognostic factors using Cox regression analyses adjusted for age, sex, comorbidities, hematologic malignancy and recent active cancer therapy.ResultsOf 833 patients reported, 697 were included in the analyses. Median age was 72 years (IQR 60-79), 413 (60%) patients were male and 479 (69%) and 218 (31%) had lymphoid and myeloid malignancies, respectively. Clinical severity of COVID-19 was severe/critical in 429 (62%) patients. At data cutoff, 230 (33%) patients had died. Age >= 60 years (hazard ratios 3.17-10.1 vs<50 years),>2 comorbidities (1.41 vs <= 2), acute myeloid leukemia (2.22 vs non-Hodgkin lymphoma) and active antineoplastic treatment with monoclonal antibodies (2.02) were associated with increased mortality; conventional chemotherapy showed borderline significance (1.50 vs no active therapy). Conversely, Ph-negative myeloproliferative neoplasms (0.33) and active treatment with hypomethylating agents (0.47) were associated with lower mortality. Overall, 574 (82%) patients received antiviral therapy. Mortality with severe/critical COVID-19 was higher with no therapy vs any antiviral combination therapy (2.20).ConclusionsIn this series of patients with hematologic malignancies and COVID-19, mortality was associated with higher age, more comorbidities, type of hematological malignancy and type of antineoplastic therapy. Further studies and long-term follow-up are required to validate these criteria for risk stratification.
C1 [Garcia-Suarez, Julio; Valenciano, Susana] Univ Hosp Principe Asturias, Hematol Dept, Madrid, Spain.
   [de la Cruz, Javier] Univ Hosp, Res Inst Imas12, SAMID ISCIII, Madrid, Spain.
   [Cedillo, Angel] Asociac Madrilena Hematol & Hemoterapia AMHH, Madrid, Spain.
   [Llamas, Pilar; Gonzalez-Medina, Jose] Univ Hosp Fdn Jimenez Diaz, Hematol Dept, Madrid, Spain.
   [Duarte, Rafael; Martin-Buitrago, Lucia Nunez] Univ Hosp Puerta Hierro Majadahonda, Hematol Dept, Madrid, Spain.
   [Jimenez-Yuste, Victor; Canales, Miguel] Univ Hosp La Paz, Hematol Dept, Madrid, Spain.
   [Hernandez-Rivas, Jose Angel; Gonzalez-Gascon, Isabel] Univ Hosp Infanta Leonor, Hematol Dept, Madrid, Spain.
   [Gil-Manso, Rodrigo; Martinez-Lopez, Joaquin] Univ Complutense Madrid, Hosp Octubre 12, CIBERONC, Hematol Dept,CNIO ISCIII,Imas 12, Madrid, Spain.
   [Kwon, Mi; Diez-Martin, Jose Luis] Univ Gen Hosp Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Hematol Dept, Madrid, Spain.
   [Kwon, Mi; Diez-Martin, Jose Luis] Univ Complutense Madrid, Dept Med, Madrid, Spain.
   [Sanchez-Godoy, Pedro; Vicente-Ayuso, Maria Carmen] Univ Hosp Severo Ochoa, Hematol Dept, Madrid, Spain.
   [Martinez-Barranco, Pilar; Roa, Maria Garcia] Univ Hosp Fdn Alcorcon, Hematol Dept, Madrid, Spain.
   [Colas-Lahuerta, Blanca; Monteliu, Pablo Estival] Univ Hosp Clin San Carlos, Hematol Dept, Madrid, Spain.
   [Herrera, Pilar; Lopez-Jimenez, Javier] Univ Hosp Ramon Y Cajal, Hematol Dept, Madrid, Spain.
   [Benito-Parra, Laurentino; Escobar, Cristian Escolano] Univ Hosp Getafe, Hematol Dept, Madrid, Spain.
   [Alegre, Adrian; Ortiz-Martin, Javier] Univ Hosp La Princesa, Hematol Dept, Madrid, Spain.
   [Velasco, Alberto] Univ Hosp Rey Juan Carlos, Hematol Dept, Madrid, Spain.
   [Matilla, Arturo] Univ Hosp Cent Def Gomez Ulla, Hematol Dept, Madrid, Spain.
   [Alaez-Uson, Maria Concepcion] Univ Hosp HLA Moncloa, Hematol Dept, Madrid, Spain.
   [Martos-Martinez, Rafael] Univ Hosp Villalba, Hematol Dept, Madrid, Spain.
   [Martinez-Chamorro, Carmen] Univ Hosp Quironsalud, Hematol Dept, Madrid, Spain.
   [Susana-Quiroz, Keina] Univ Hosp Mostoles, Hematol Dept, Madrid, Spain.
   [Del Campo, Juan Francisco] Univ Hosp Henares, Hematol Dept, Madrid, Spain.
   [de la Fuente, Adolfo] MD Anderson Canc Ctr Madrid, Hematol Dept, Madrid, Spain.
   [Herraez, Regina] Univ Hosp Infanta Sofia, Hematol Dept, Madrid, Spain.
   [Pascual, Adriana] Univ Hosp Infanta Elena, Hematol Dept, Madrid, Spain.
   [Gomez, Elvira] Univ Hosp Sureste, Hematol Dept, Madrid, Spain.
   [Perez-Oteyza, Jaime] Univ Hosp HM Sanchinarro, Hematol Dept, Madrid, Spain.
   [Ruiz, Elena] Univ Hosp Tajo, Hematol Dept, Madrid, Spain.
   [Alonso, Arancha] Hosp Ruber, Hematol Dept, Madrid, Spain.
   [Martinez-Lopez, Joaquin] Univ Complutense, Hosp Octubre 12, Serv Hematol, I 12,CNIO ISCIII,Ctr Actividades Ambulatorias, Planta Tercera Bloque D,Avd Cordoba S-N, Madrid 28041, Spain.
RP Martinez-Lopez, J (corresponding author), Univ Complutense Madrid, Hosp Octubre 12, CIBERONC, Hematol Dept,CNIO ISCIII,Imas 12, Madrid, Spain.; Martinez-Lopez, J (corresponding author), Univ Complutense, Hosp Octubre 12, Serv Hematol, I 12,CNIO ISCIII,Ctr Actividades Ambulatorias, Planta Tercera Bloque D,Avd Cordoba S-N, Madrid 28041, Spain.
OI Kwon, Mi/0000-0002-3855-7774; Martinez-Lopez,
   Joaquin/0000-0001-7908-0063; Hernandez-Rivas,
   Jose-Angel/0000-0003-4550-757X; Canales Albendea, Miguel
   Angel/0000-0002-6550-2621
FU Fundacion Madrilena de Hematologia y Hemoterapia; Fundacion Leucemia y
   Linfoma
FX Fundacion Madrilena de Hematologia y Hemoterapia. This project was
   partly performed with a grant "Marcos Fernandez-Vistare" from the
   Fundacion Leucemia y Linfoma. The funder had no role in study design,
   data collection, data analysis, data interpretation, or writing of the
   report. JG-S, JdlC, JLD-M and JM-L had full access to all the data in
   the study and had final responsibility for the decision to submit for
   publication.
CR American Society of Clinical Oncology (ASCO), 2020, ASCO COR RESOURCES20
   Cancer Patient Management During the COVID-19, 2020, CANC PAT MAN COVID 1
   Chemaly RF, 2006, MEDICINE, V85, P278, DOI 10.1097/01.md.0000232560.22098.4e
   Comunidad de Madrid-Consejeria de Sanidad, 2020, DATOS COVID 19 COMUN
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   EBMT, 2020, COVID 19 BMT
   European Center for Disease Prevention and Control, 2020, COVID 19 SIT UPD WOR
   Fontana L, 2019, INFECT DIS CLIN N AM, V33, P523, DOI 10.1016/j.idc.2019.02.004
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Instituto de Salud Carlos III-Centro Nacional de Epidemiologia, 2020, INF SIT COVID 19
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Li WM, 2020, LEUKEMIA, V34, P1799, DOI 10.1038/s41375-020-0853-6
   Malard F, 2020, BONE MARROW TRANSPL, V55, P2180, DOI 10.1038/s41409-020-0931-4
   Martinez-Lopez J, 2020, GUIA MULTIPLE MYELOM, DOI [10.1101/2020.06.29.20142455v1, DOI 10.1101/2020.06.29.20142455V1]
   Meng YF, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00907-0
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rodriguez-Abreu D, 2007, ANN ONCOL, V18, pI3, DOI 10.1093/annonc/mdl443
   Shah V, 2020, BRIT J HAEMATOL, V190, pE279, DOI 10.1111/bjh.16935
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Sisk JM, 2018, J GEN VIROL, V99, P619, DOI 10.1099/jgv.0.001047
   Szer J, 2020, BONE MARROW TRANSPL, V55, P2043, DOI 10.1038/s41409-020-0873-x
   Tang YW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00512-20
   Wang B, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00934-x
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, WHO CHIN JOINT MISS
   World Health Organization, 2020, TIM WHOS RESP COVID
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 32
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-8722
J9 J HEMATOL ONCOL
JI J. Hematol. Oncol.
PD OCT 8
PY 2020
VL 13
IS 1
AR 133
DI 10.1186/s13045-020-00970-7
PG 12
WC Oncology; Hematology
SC Oncology; Hematology
GA OB6TJ
UT WOS:000578601300002
PM 33032660
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Maggiolo, F
   Zoboli, F
   Arosio, M
   Valenti, D
   Guarneri, D
   Sangiorgio, L
   Ripamonti, D
   Callegaro, A
AF Maggiolo, Franco
   Zoboli, Fabio
   Arosio, Marco
   Valenti, Daniela
   Guarneri, Davide
   Sangiorgio, Lorena
   Ripamonti, Diego
   Callegaro, Annapaola
TI SARS-CoV-2 infection in persons living with HIV: A single center
   prospective cohort
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE asymptomatic; CD4; CNS; cohort; co-morbidities; COVID-19; HIV;
   mortality; risk factors; SARS-CoV-2; symptoms
AB Information about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in HIV-infected individuals is scarce. In this prospective study, we included HIV (human immunodefeciency virus)-infected individuals (people living with HIV [PLWHIV]) with confirmed SARS-CoV-2 infection and compared them with PLWHIV negative for SARS-CoV-2. We compared 55 cases of SARS-CoV-2 infection with 69 asymptomatic PLWHIV negative for SARS-CoV-2 reverse transcription-polymerase chain reaction and/or serology. There was no significant difference between SARS-CoV-2 positive or negative patients for age distribution, gender, time with HIV infection, nadir CD4-cell counts, type and number of co-morbidities, current CD4 and CD8 counts and type of anti-HIV therapy. Positive patients presented with a median of three symptoms (interquartile range, 1-3). Most common symptoms were fever (76%), dyspnea (35%), anosmia (29%) non-productive cough (27%), fatigue 22%), and ageusia (20%). Ten patients (18%) were completely asymptomatic. Four (7.2%) subjects died of coronavirus disease 2019. Factors significantly (P < .05) associated with death included age and number of co-morbidities, while time from HIV infection and lower current CD4 counts were significant only in univariate analysis. HIV-infected individuals are not protected from SARS-CoV-2 infection or have a lower risk of severe disease. Indeed, those with low CD4 cell counts might have worse outcomes. Infection is asymptomatic in a large proportion of subjects and this is relevant for epidemiological studies.
C1 [Maggiolo, Franco; Zoboli, Fabio; Ripamonti, Diego] ASST Papa Giovanni XXIII, Div Infect Dis, Dept Med, Bergamo, Italy.
   [Maggiolo, Franco; Valenti, Daniela] ASST Papa Giovanni XXIII, Dept Med, Unit HIV Related Dis & Expt Therapies, Bergamo, Italy.
   [Arosio, Marco; Guarneri, Davide; Sangiorgio, Lorena; Callegaro, Annapaola] ASST Papa Giovanni XXIII, Dept Lab, Biobanking Unit, Bergamo, Italy.
   [Arosio, Marco; Guarneri, Davide; Sangiorgio, Lorena] ASST Papa Giovanni XXIII, Dept Lab, Microbiol & Virol Lab, Bergamo, Italy.
   [Valenti, Daniela] ASST Papa Giovanni XXIII, FROM Fdn, Bergamo, Italy.
RP Maggiolo, F (corresponding author), ASST Papa Giovanni XXII, I-28127 Bergamo, Italy.
EM franco31556@hotmail.com
FU Jannsen; GileadGilead Sciences; ViiV
FX FM received research grants from Gilead, ViiV, Jannsen and acted as
   member of advisory board for Gilead, ViiV, Jannsen and Merck.
CR Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Chou R, 2020, ANN INTERN MED, V173, P120, DOI 10.7326/M20-1632
   Gervasoni Cristina, 2020, Clin Infect Dis, V71, P2276, DOI 10.1093/cid/ciaa579
   Hileman CO, 2017, CURR HIV-AIDS REP, V14, P93, DOI 10.1007/s11904-017-0356-x
   Italian Ministry of Health (Ministero della Salute), NOV COR
   Jockusch S, 2020, BIORXIV, DOI [10.1101/2020.04.03.022939, DOI 10.1101/2020.04.03.022939]
   Marimuthu J, 2020, J MED VIROL, DOI 10.1002/jmv.26271
   Masukume G, 2020, J MED VIROL, DOI 10.1002/jmv.26270
   Patel RH, 2020, J MED VIROL, DOI 10.1002/jmv.26177
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Ridgway JP, 2020, AIDS PATIENT CARE ST, V34, P331, DOI 10.1089/apc.2020.0103
   Ruan LG, 2020, J MED VIROL, DOI 10.1002/jmv.26223
   Vizcarra P, 2020, LANCET HIV, V7, pE554, DOI 10.1016/S2352-3018(20)30164-8
   Zhao Juanjuan, 2020, Clin Infect Dis, V71, P2233, DOI 10.1093/cid/ciaa408
   Zhu F, 2020, J MED VIROL, V92, P1417, DOI 10.1002/jmv.25838
   Zhu F, 2020, J MED VIROL, V92, P529, DOI 10.1002/jmv.25732
NR 16
TC 3
Z9 3
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26352
EA OCT 2020
PG 5
WC Virology
SC Virology
GA OA1BS
UT WOS:000577530700001
PM 32706409
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kant, S
   Morris, A
   Ravi, S
   Floyd, L
   Gapud, E
   Antichos, B
   Dhaygude, A
   Seo, P
   Geetha, D
AF Kant, Sam
   Morris, Adam
   Ravi, Srekar
   Floyd, Lauren
   Gapud, Eric
   Antichos, Brendan
   Dhaygude, Ajay
   Seo, Phil
   Geetha, Duvuru
TI The impact of COVID-19 pandemic on patients with ANCA associated
   vasculitis
SO JOURNAL OF NEPHROLOGY
LA English
DT Article; Early Access
ID CORTICOSTEROID TREATMENT
AB Introduction The coronavirus 2019 (COVID-19) pandemic has brought on challenges not only to acute care, but also chronic care of patients. Individuals maintained on immunosuppression appear to be especially susceptible to COVID-19 infection. Patients with ANCA-associated vasculitis (AAV) frequently require immunosuppression and may be at increased risk for developing COVID-19. The incidence and impact of COVID-19 on patients with AAV is currently not known. We aimed to investigate this impact via a telephone questionnaire-based patient survey and chart review. Methods A cross-sectional study of AAV patients followed at two centers was conducted. Data regarding demographics, disease characteristics and therapy were confirmed by chart review. A telephone survey was conducted to ascertain symptoms and contact exposure related to COVID-19, as well as changes in health care delivery during the pandemic period between January and July, 2020. Results Of the 206 patients surveyed, the median age was 64 years, 51% were female and mean (SD) disease duration was 7 (5) years. The majority had kidney (n = 160) and lung (n = 108) involvement. Seventy-five percent (n = 155) were receiving immunosuppression, with 77 patients (50%) receiving rituximab during the pandemic period. Of the 10 patients tested for severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) by PCR, three were positive. Patients had a significant disruption in care; none had an in-person visit and 69% had a telemedicine consultation. Rituximab maintenance was postponed in 21 patients. Twelve patients experienced disease relapse. Conclusion The incidence of COVID-19 in patients with AAV appears to be similar to that of the general population. For a patient population that requires active clinical surveillance, there is significant disruption in care as a result of the pandemic. Reduction of immunosuppression may not be indicated, and the risk of relapse likely far outweighs the risk of COVID-19.
C1 [Kant, Sam; Geetha, Duvuru] Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA.
   [Morris, Adam; Floyd, Lauren; Dhaygude, Ajay] Royal Preston Hosp, Fulwood, Lancs, England.
   [Ravi, Srekar] Florida Atlantic Univ, Boca Raton, FL 33431 USA.
   [Gapud, Eric; Antichos, Brendan; Seo, Phil; Geetha, Duvuru] Johns Hopkins Univ, Sch Med, Dept Med, Div Rheumatol, Baltimore, MD 21205 USA.
RP Geetha, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA.; Geetha, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Rheumatol, Baltimore, MD 21205 USA.
EM gduvura@jhmi.edu
OI GEETHA, DUVURU/0000-0001-8353-5542
CR Angeletti A, 2020, CLIN J AM SOC NEPHRO, V15, P1494, DOI 10.2215/CJN.06400420
   Boomsma MM, 2000, ARTHRITIS RHEUM-US, V43, P2025, DOI 10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O
   CDC, 2020, COVID 19 SURVEILLANC
   CDC, 2020, PEOPLE ANY AGE UNDER
   Emmi G, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102575
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guilpain Philippe, 2021, Ann Rheum Dis, V80, pe10, DOI 10.1136/annrheumdis-2020-217549
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Meca-Lallana Virginia, 2020, Mult Scler Relat Disord, V44, P102306, DOI 10.1016/j.msard.2020.102306
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Nataraja A, 2007, BEST PRACT RES CL RH, V21, P713, DOI 10.1016/j.berh.2007.01.004
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sanchez-Piedra C, 2020, ANN RHEUM DIS, V79, DOI 10.1136/annrheumdis-2020-217948
   Schulze-Koops Hendrik, 2020, Ann Rheum Dis, DOI 10.1136/annrheumdis-2020-218075
   Shahidi-Dadras M, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1789041
NR 19
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1121-8428
EI 1724-6059
J9 J NEPHROL
JI J. Nephrol.
DI 10.1007/s40620-020-00881-3
EA OCT 2020
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA OA7ZT
UT WOS:000578000100001
PM 33034038
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Dresler, T
   Guth, AL
   Lupke, J
   Kropp, P
AF Dresler, T.
   Guth, A. -L.
   Luepke, J.
   Kropp, P.
TI Psychological treatment of headache in times of COVID-19
SO SCHMERZ
LA German
DT Article
DE Headache; COVID-19; Cognitive behavioral therapy; Digitalization; Stress
   management
ID MIGRAINE; INTERVENTIONS; METAANALYSIS; BIOFEEDBACK; EFFICACY
AB Background The coronavirus disease 2019 (COVID-19) pandemic has substantially changed life worldwide in 2020. This also influences the psychological treatment options of patients with headache. Aim The present article intends to illustrate the different psychological forms of treatment for headache patients and their implementation during the COVID-19 pandemic. Material and methods Literature review and case reports. Results Even during the COVID-19 pandemic, psychological treatment enables the increased stress level in headache patients to be counteracted by using cognitive behavioral therapy and relaxation techniques. The changed living conditions are often unfavorable but sometimes also favorable in the course of disease. It can be shown that even during the pandemic, such favorable changes can be used to support patients to cope with their headache. Conclusion The digital implementation of psychological approaches makes a major contribution to maintaining psychological treatment of headache patients, so that the individually changed needs can be addressed. With respect to content, stress regulation techniques and increased acceptance gain in importance. Regarding biofeedback there are limitations, which may be overcome by improved technical devices.
C1 [Dresler, T.] Univ Tubingen, Klin Psychiat & Psychotherapie, Calwerstr 14, D-72076 Tubingen, Germany.
   [Dresler, T.] Univ Tubingen, Graduiertenschule & Forsch Netzwerk LEAD, Tubingen, Germany.
   [Guth, A. -L.] Migrane & Kopfschmerzklin Konigstein, Konigstein, Germany.
   [Luepke, J.; Kropp, P.] Univ Med Rostock, Inst Med Psychol & Med Soziol, Rostock, Germany.
RP Dresler, T (corresponding author), Univ Tubingen, Klin Psychiat & Psychotherapie, Calwerstr 14, D-72076 Tubingen, Germany.
EM thomas.dresler@med.uni-tuebingen.de
CR Beerheide R, 2020, DTSCH ARZTEBL INT, V19, P247
   Bellido A, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-0955-0
   Blume C, 2020, CURR BIOL, V30, pR795, DOI 10.1016/j.cub.2020.06.021
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Christmann CA, 2017, JMIR MHEALTH UHEALTH, V5, DOI 10.2196/mhealth.6471
   Devan H, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/13080
   Diener H-C, 2018, LEITLINIEN DIAGNOSTI
   Dresler T, 2019, NERVENHEILKUNDE, V38, P745, DOI [10.1055/a-0989-6551, DOI 10.1055/A-0989-6551]
   Eichenberg C, 2020, DTSCH ARZTEBL INT, V19, P255
   Fatke B, 2020, DEUT MED WOCHENSCHR, V145, P675, DOI 10.1055/a-1147-2889
   Gaul C, 2016, CEPHALALGIA, V36, P1181, DOI 10.1177/0333102415617413
   Klan T, 2020, KOGNITIV VERHALTENST
   Klan T, 2019, HEADACHE, V59, P741, DOI 10.1111/head.13532
   Krampen G, 2013, ENTSPANNUNGSVERFAHRE
   Kropp P, 2017, SCHMERZ, V31, P433, DOI 10.1007/s00482-017-0214-1
   Kropp P, 1992, EXPT UNTERSUCHUNGEN
   Kropp P, 2015, J NEURAL TRANSM, V122, P877, DOI 10.1007/s00702-014-1345-5
   Manzoni GM, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-41
   Mikolasek M, 2018, INT J BEHAV MED, V25, P1, DOI 10.1007/s12529-017-9679-7
   Nahman-Averbuch H, 2020, HEADACHE, V60, P1165, DOI 10.1111/head.13814
   Neeb L, 2020, SCHMERZ, V34, P495, DOI 10.1007/s00482-020-00508-3
   Nestoriuc Y, 2008, J CONSULT CLIN PSYCH, V76, P379, DOI 10.1037/0022-006X.76.3.379
   Nestoriuc Y, 2007, PAIN, V128, P111, DOI 10.1016/j.pain.2006.09.007
   Parodi IC, 2020, NEUROL SCI, V41, P2025, DOI 10.1007/s10072-020-04543-x
   Siniatchkin M, 2000, APPL PSYCHOPHYS BIOF, V25, P167, DOI 10.1023/A:1009502808906
   Spijkerman MPJ, 2016, CLIN PSYCHOL REV, V45, P102, DOI 10.1016/j.cpr.2016.03.009
   Szperka CL, 2020, HEADACHE, V60, P833, DOI 10.1111/head.13810
   Teufel M, 2020, J PUBLIC HEALTH-UK, V42, P644, DOI 10.1093/pubmed/fdaa060
   Tracey I, 2002, J NEUROSCI, V22, P2748, DOI 10.1523/JNEUROSCI.22-07-02748.2002
   Wallasch TM, 2012, J HEADACHE PAIN, V13, P521, DOI 10.1007/s10194-012-0469-y
   Wallasch TM, 2012, HEADACHE, V52, P1094, DOI 10.1111/j.1526-4610.2012.02189.x
NR 31
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-433X
EI 1432-2129
J9 SCHMERZ
JI Schmerz
PD DEC
PY 2020
VL 34
IS 6
SI SI
BP 503
EP 510
DI 10.1007/s00482-020-00507-4
EA OCT 2020
PG 8
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA OV0VJ
UT WOS:000578381500001
PM 33030591
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Guillen, L
   Padilla, S
   Fernandez, M
   Agullo, V
   Garcia, JA
   Telenti, G
   Garcia-Abellan, J
   Botella, A
   Gutierrez, F
   Masia, M
AF Guillen, Lucia
   Padilla, Sergio
   Fernandez, Marta
   Agullo, Vanesa
   Garcia, Jose Alberto
   Telenti, Guillermo
   Garcia-Abellan, Javier
   Botella, Angela
   Gutierrez, Felix
   Masia, Mar
TI Preemptive interleukin-6 blockade in patients with COVID-19
SO SCIENTIFIC REPORTS
LA English
DT Article
ID IL-6; VIRUS; THROMBOSIS
AB Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial in severely ill patients, but no data are available on earlier stages of disease. An anticipated blockade of interleukin-6 might hypothetically prevent the catastrophic consequences of the overt cytokine storm. We evaluated early-given tocilizumab in patients hospitalized with COVID-19, and identified outcome predictors. Consecutive patients with initial Sequential-Organ-Failure-Assessment (SOFA) score<3 fulfilling pre-defined criteria were treated with tocilizumab. Serial plasma biomarkers and nasopharyngeal swabs were collected. Of 193 patients admitted with COVID-19, 64 met the inclusion criteria. After tocilizumab, 49 (76.6%) had an early favorable response. Adjusted predictors of response were gender, SOFA score, neutrophil/lymphocyte ratio, Charlson comorbidity index and systolic blood pressure. At week-4, 56.1% of responders and 30% of non-responders had cleared the SARS-CoV-2 from nasopharynx. Temporal profiles of interleukin-6, C-reactive protein, neutrophil/lymphocyte ratio, NT-ProBNP, D-dimer, and cardiac-troponin-I differed according to tocilizumab response and discriminated final in-hospital outcome. No deaths or disease recurrences were observed. Preemptive therapy with tocilizumab was safe and associated with favorable outcomes in most patients. Biological and clinical markers predicted outcomes.
C1 [Guillen, Lucia; Padilla, Sergio; Fernandez, Marta; Agullo, Vanesa; Garcia, Jose Alberto; Telenti, Guillermo; Garcia-Abellan, Javier; Botella, Angela] Hosp Gen Univ Elche, Infect Dis Unit, Cami Almazara S-N, Alicante 03203, Spain.
   [Gutierrez, Felix; Masia, Mar] Univ Miguel Hernandez, Clin Med Dept, Ctra Valencia N-322,Km 87, Alacant 03550, Spain.
   [Gutierrez, Felix; Masia, Mar] Univ Miguel Hernandez, Avda Univ S-N, Alicante 03202, Spain.
RP Gutierrez, F; Masia, M (corresponding author), Univ Miguel Hernandez, Clin Med Dept, Ctra Valencia N-322,Km 87, Alacant 03550, Spain.; Gutierrez, F; Masia, M (corresponding author), Univ Miguel Hernandez, Avda Univ S-N, Alicante 03202, Spain.
EM gutierrez_fel@gva.es; mmasia@umh.es
OI GARCIA GOMEZ, JOSE ALBERTO/0000-0002-1203-7260
FU Plan Nacional Research + Development + Innovation (R + D + I)
   [RD16/0025/0038]; Instituto de Salud Carlos III-Subdireccion General de
   Evaluacion y Fondo Europeo de Desarrollo Regional; Instituto de Salud
   Carlos III (Fondo de Investigaciones Sanitarias)Instituto de Salud
   Carlos III [PI16/01740, PI18/01861, CM 19/00160 COV20-00005]
FX This work was supported by the RD16/0025/0038 project as a part of the
   Plan Nacional Research + Development + Innovation (R + D + I) and
   cofinanced by Instituto de Salud Carlos III-Subdireccion General de
   Evaluacion y Fondo Europeo de Desarrollo Regional; Instituto de Salud
   Carlos III (Fondo de Investigaciones Sanitarias [Grant number
   PI16/01740; PI18/01861; CM 19/00160 COV20-00005]).
CR Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Gaborit BJ, 2020, LANCET INFECT DIS, VS1473-3099, P30312
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Harker JA, 2011, SCIENCE, V334, P825, DOI 10.1126/science.1208421
   Hou WQ, 2014, J VIROL, V88, P8479, DOI 10.1128/JVI.00724-14
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0
   Liu YW, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.002
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Nosaka M, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03150
   Pathan N, 2004, LANCET, V363, P203, DOI 10.1016/S0140-6736(03)15326-3
   Rogez-Kreuz C, 2005, INT IMMUNOL, V17, P1047, DOI 10.1093/intimm/dxh285
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Velazquez-Salinas L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01057
   Velazquez-Salinas L, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01891
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wattrang E, 2003, VIRAL IMMUNOL, V16, P57, DOI 10.1089/088282403763635456
   Wickham H., 2016, GGPLOT2 ELEGANT GRAP
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu W, 2015, SCI REP-UK, V5, DOI 10.1038/srep10501
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang ML, 2017, SCI REP-UK, V7, DOI 10.1038/srep43829
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang YH, 2020, ARTERIOSCL THROM VAS, V40, P323, DOI 10.1161/ATVBAHA.119.313137
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
NR 36
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 8
PY 2020
VL 10
IS 1
AR 16826
DI 10.1038/s41598-020-74001-3
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OA0GJ
UT WOS:000577475100050
PM 33033405
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lim, H
   Baek, A
   Kim, J
   Kim, MS
   Liu, J
   Nam, KY
   Yoon, J
   No, KT
AF Lim, Hocheol
   Baek, Ayoung
   Kim, Jongwan
   Kim, Min Sung
   Liu, Jiaxin
   Nam, Ky-Youb
   Yoon, JeongHyeok
   No, Kyoung Tai
TI Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein
   interaction obtained by density functional tight binding fragment
   molecular orbital method
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CORONAVIRUS SPIKE PROTEIN; HEMAGGLUTININ; ADAPTATION; PREDICTION;
   ANTIBODY
AB The prevalence of a novel beta-coronavirus (SARS-CoV-2) was declared as a public health emergency of international concern on 30 January 2020 and a global pandemic on 11 March 2020 by WHO. The spike glycoprotein of SARS-CoV-2 is regarded as a key target for the development of vaccines and therapeutic antibodies. In order to develop anti-viral therapeutics for SARS-CoV-2, it is crucial to find amino acid pairs that strongly attract each other at the interface of the spike glycoprotein and the human angiotensin-converting enzyme 2 (hACE2) complex. In order to find hot spot residues, the strongly attracting amino acid pairs at the protein-protein interaction (PPI) interface, we introduce a reliable inter-residue interaction energy calculation method, FMO-DFTB3/D/PCM/3D-SPIEs. In addition to the SARS-CoV-2 spike glycoprotein/hACE2 complex, the hot spot residues of SARS-CoV-1 spike glycoprotein/hACE2 complex, SARS-CoV-1 spike glycoprotein/antibody complex, and HCoV-NL63 spike glycoprotein/hACE2 complex were obtained using the same FMO method. Following this, a 3D-SPIEs-based interaction map was constructed with hot spot residues for the hACE2/SARS-CoV-1 spike glycoprotein, hACE2/HCoV-NL63 spike glycoprotein, and hACE2/SARS-CoV-2 spike glycoprotein complexes. Finally, the three 3D-SPIEs-based interaction maps were combined and analyzed to find the consensus hot spots among the three complexes. As a result of the analysis, two hot spots were identified between hACE2 and the three spike proteins. In particular, E37, K353, G354, and D355 of the hACE2 receptor strongly interact with the spike proteins of coronaviruses. The 3D-SPIEs-based map would provide valuable information to develop anti-viral therapeutics that inhibit PPIs between the spike protein of SARS-CoV-2 and hACE2.
C1 [Lim, Hocheol; Kim, Jongwan; Kim, Min Sung; Liu, Jiaxin; No, Kyoung Tai] Yonsei Univ, Dept Biotechnol, Seoul, South Korea.
   [Lim, Hocheol; No, Kyoung Tai] Yonsei Univ, Interdisciplinary Grad Program Integrat Biotechno, Incheon, South Korea.
   [Lim, Hocheol; Baek, Ayoung; Kim, Jongwan; Kim, Min Sung; No, Kyoung Tai] Bioinformat & Mol Design Res Ctr BMDRC, Incheon, South Korea.
   [Nam, Ky-Youb; Yoon, JeongHyeok] Pharos I&BT Co Ltd, Anyang Si, Gyeonggi Do, South Korea.
RP No, KT (corresponding author), Yonsei Univ, Dept Biotechnol, Seoul, South Korea.; No, KT (corresponding author), Yonsei Univ, Interdisciplinary Grad Program Integrat Biotechno, Incheon, South Korea.; No, KT (corresponding author), Bioinformat & Mol Design Res Ctr BMDRC, Incheon, South Korea.
EM ktno@yonsei.ac.kr
FU Brain Korea 21 (BK21) PLUS program; National Research Foundation of
   Korea (NRF) - Korean Government [NRF-2017M3A9G2074773]; Grant of the
   Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HI17C2314]
FX This work was supported by the Brain Korea 21 (BK21) PLUS program and
   the National Research Foundation of Korea (NRF) Grant funded by the
   Korean Government (NRF-2017M3A9G2074773). This research was supported by
   a Grant of the Korea Health Technology R&D Project through the Korea
   Health Industry Development Institute (KHIDI), funded by the Ministry of
   Health & Welfare, Republic of Korea (Grant Number: HI17C2314).
CR Alexeev Y, 2012, CURR TOP MED CHEM, V12, P2013, DOI 10.2174/156802612804910269
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Fedorov DG, 2012, PHYS CHEM CHEM PHYS, V14, P7562, DOI 10.1039/c2cp23784a
   Gaus M, 2014, J CHEM THEORY COMPUT, V10, P1518, DOI 10.1021/ct401002w
   Gaus M, 2013, J CHEM THEORY COMPUT, V9, P338, DOI 10.1021/ct300849w
   Gaus M, 2011, J CHEM THEORY COMPUT, V7, P931, DOI 10.1021/ct100684s
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Heifetz A, 2016, J CHEM INF MODEL, V56, P159, DOI 10.1021/acs.jcim.5b00644
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Jacobson MP, 2002, J MOL BIOL, V320, P597, DOI 10.1016/S0022-2836(02)00470-9
   Kitaura K, 1999, CHEM PHYS LETT, V313, P701, DOI 10.1016/S0009-2614(99)00874-X
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lim H, 2019, SCI REP, V9, P1, DOI [10.1038/s41598-018-37186-2, DOI 10.1038/S41598-018-37186-2]
   Nakano T, 2000, CHEM PHYS LETT, V318, P614, DOI 10.1016/S0009-2614(00)00070-1
   Nakano T, 2002, CHEM PHYS LETT, V351, P475, DOI 10.1016/S0009-2614(01)01416-6
   Nishimoto Y, 2016, PHYS CHEM CHEM PHYS, V18, P22047, DOI 10.1039/c6cp02186g
   Olsson MHM, 2011, J CHEM THEORY COMPUT, V7, P525, DOI 10.1021/ct100578z
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Qu XX, 2005, J BIOL CHEM, V280, P29588, DOI 10.1074/jbc.M500662200
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   Takematsu K, 2009, J PHYS CHEM B, V113, P4991, DOI 10.1021/jp810997c
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu KL, 2012, J BIOL CHEM, V287, P8904, DOI 10.1074/jbc.M111.325803
   Wu KL, 2011, J VIROL, V85, P5331, DOI 10.1128/JVI.02274-10
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   Yoshioka A, 2011, J MOL GRAPH MODEL, V30, P110, DOI 10.1016/j.jmgm.2011.06.011
   Zhechkov L, 2005, J CHEM THEORY COMPUT, V1, P841, DOI 10.1021/ct050065y
NR 30
TC 0
Z9 0
U1 2
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 8
PY 2020
VL 10
IS 1
AR 16862
DI 10.1038/s41598-020-73820-8
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OA0GJ
UT WOS:000577475100086
PM 33033344
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Panoskaltsis, N
   McCarthy, NE
   Stagg, AJ
   Mummery, CJ
   Husni, M
   Arebi, N
   Greenstein, D
   Price, CL
   Al-Hassi, HO
   Koutinas, M
   Mantalaris, A
   Knight, SC
AF Panoskaltsis, Nicki
   McCarthy, Neil E.
   Stagg, Andrew J.
   Mummery, Catherine J.
   Husni, Mariwan
   Arebi, Naila
   Greenstein, David
   Price, Claire L.
   Al-Hassi, Hafid O.
   Koutinas, Michalis
   Mantalaris, Athanasios
   Knight, Stella C.
TI Immune reconstitution and clinical recovery following anti-CD28 antibody
   (TGN1412)-induced cytokine storm
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Article; Early Access
DE Cytokine storm; Cytokine release syndrome; TGN1412; Immunotherapy;
   Immune monitoring; Immune-related adverse events (irAEs)
ID T-CELL THERAPY; CANCER IMMUNOTHERAPIES; RELEASE SYNDROME; NEUROTOXICITY;
   DISRUPTION; BIOMARKERS; BLOCKADE; EFFECTOR; SUBSET; CD8(+)
AB Cytokine storm can result from cancer immunotherapy or certain infections, including COVID-19. Though short-term immune-related adverse events are routinely described, longer-term immune consequences and sequential immune monitoring are not as well defined. In 2006, six healthy volunteers received TGN1412, a CD28 superagonist antibody, in a first-in-man clinical trial and suffered from cytokine storm. After the initial cytokine release, antibody effect-specific immune monitoring started on Day + 10 and consisted mainly of evaluation of dendritic cell and T-cell subsets and 15 serum cytokines at 21 time-points over 2 years. All patients developed problems with concentration and memory; three patients were diagnosed with mild-to-moderate depression. Mild neutropenia and autoantibody production was observed intermittently. One patient suffered from peripheral dry gangrene, required amputations, and had persistent Raynaud's phenomenon. Gastrointestinal irritability was noted in three patients and coincided with elevated gamma delta T-cells. One had pruritus associated with elevated IgE levels, also found in three other asymptomatic patients. Dendritic cells, initially undetectable, rose to normal within a month. Naive CD8(+)T-cells were maintained at high levels, whereas naive CD4(+)and memory CD4(+)and CD8(+)T-cells started high but declined over 2 years. T-regulatory cells cycled circannually and were normal in number. Cytokine dysregulation was especially noted in one patient with systemic symptoms. Over a 2-year follow-up, cognitive deficits were observed in all patients following TGN1412 infusion. Some also had signs or symptoms of psychological, mucosal or immune dysregulation. These observations may discern immunopathology, treatment targets, and long-term monitoring strategies for other patients undergoing immunotherapy or with cytokine storm.
C1 [Panoskaltsis, Nicki] Imperial Coll London, Dept Haematol, Northwick Pk & St Marks Campus, London, England.
   [Panoskaltsis, Nicki; McCarthy, Neil E.; Stagg, Andrew J.; Price, Claire L.; Al-Hassi, Hafid O.; Knight, Stella C.] Imperial Coll London, Antigen Presentat Res Grp, Northwick Pk & St Marks Campus, London, England.
   [Panoskaltsis, Nicki; Koutinas, Michalis; Mantalaris, Athanasios] Imperial Coll London, Dept Chem Engn, Ctr Proc Syst Engn, Biol Syst Engn Lab, London, England.
   [Mummery, Catherine J.] Northwick Pk Hosp & Clin Res Ctr, Dementia Res Ctr, Natl Hosp Neurol & Neurosurg, Dept Neurol, Queen Sq, London, England.
   [Husni, Mariwan] Cent & North West London Mental Hlth NHS Fdn Trus, Northwick Pk Hosp, London, England.
   [Arebi, Naila] St Marks Hosp, Dept Gastroenterol & Intestinal Physiol, London, England.
   [Greenstein, David] North West London Hosp NHS Trust, Dept Vasc Surg, Northwick Pk & St Marks Hosp Site, London, England.
   [Panoskaltsis, Nicki] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA.
   [McCarthy, Neil E.; Stagg, Andrew J.] Queen Mary Univ London, Ctr Immunobiol, Blizard Inst, Barts & London Sch Med & Dent, London, England.
   [Mummery, Catherine J.] UCL, Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, London, England.
   [Husni, Mariwan] Arabian Gulf Univ, Dept Psychiat, Manama, Bahrain.
   [Arebi, Naila] St Marks Hosp, Inflammatory Bowel Dis Clin Serv, London, England.
   [Greenstein, David] Northwick Pk Hosp & Clin Res Ctr, Dept Vasc Surg, London, England.
   [Greenstein, David] Imperial Coll London, London, England.
   [Price, Claire L.] Lucid Grp Commun, High Wycombe, Bucks, England.
   [Al-Hassi, Hafid O.] Univ Wolverhampton, Res Inst Healthcare Sci, Fac Sci & Engn, Wolverhampton, England.
   [Koutinas, Michalis] Cyprus Univ Technol, Dept Chem Engn, Limassol, Cyprus.
   [Panoskaltsis, Nicki; Mantalaris, Athanasios] Georgia Inst Technol, BioMed Syst Engn Lab, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.
RP Panoskaltsis, N (corresponding author), Imperial Coll London, Dept Haematol, Northwick Pk & St Marks Campus, London, England.; Panoskaltsis, N (corresponding author), Imperial Coll London, Antigen Presentat Res Grp, Northwick Pk & St Marks Campus, London, England.; Panoskaltsis, N (corresponding author), Imperial Coll London, Dept Chem Engn, Ctr Proc Syst Engn, Biol Syst Engn Lab, London, England.; Panoskaltsis, N (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA.; Panoskaltsis, N (corresponding author), Georgia Inst Technol, BioMed Syst Engn Lab, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.
EM nicki.panoskaltsis@emory.edu
FU North West London Hospitals NHS Trust; Cancer Research UKCancer Research
   UK; Northwick Park Hospital Leukemia Research Trust Fund
FX The North West London Hospitals NHS Trust; Cancer Research UK; The
   Northwick Park Hospital Leukemia Research Trust Fund.
CR Agarwal S, 2020, CANCER DISCOV, V10, P775, DOI 10.1158/2159-8290.CD-20-0473
   [Anonymous], TGN1412 INV BROCH
   Beck KE, 2006, J CLIN ONCOL, V24, P2283, DOI 10.1200/JCO.2005.04.5716
   Beyersdorf N, 2005, J EXP MED, V202, P445, DOI 10.1084/jem.20051060
   Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4
   Cousin S, 2016, CLIN CANCER RES, V22, P4550, DOI 10.1158/1078-0432.CCR-15-2569
   Cuzzubbo S, 2017, EUR J CANCER, V73, P1, DOI [10.1016/j.ejca.2016.12:001, 10.1016/j.ejca.2016.12.001]
   Faint JM, 2001, J IMMUNOL, V167, P212, DOI 10.4049/jimmunol.167.1.212
   Giavridis T, 2018, NAT MED, V24, P731, DOI 10.1038/s41591-018-0041-7
   Gust J, 2017, CANCER DISCOV, V7, P1404, DOI 10.1158/2159-8290.CD-17-0698
   Hartmann FJ, 2019, CELL REP, V28, P819, DOI 10.1016/j.celrep.2019.06.049
   Hay KA, 2017, BLOOD, V130, P2295, DOI 10.1182/blood-2017-06-793141
   Hegde PS, 2016, CLIN CANCER RES, V22, P1865, DOI 10.1158/1078-0432.CCR-15-1507
   Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950
   June CH, 2017, NAT MED, V23, P540, DOI 10.1038/nm.4321
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Kanjanapan Y, 2019, EUR J CANCER, V107, P1, DOI 10.1016/j.ejca.2018.10.017
   Kipnis J, 2004, P NATL ACAD SCI USA, V101, P8180, DOI 10.1073/pnas.0402268101
   Kipnis J, 2008, TRENDS IMMUNOL, V29, P455, DOI 10.1016/j.it.2008.07.007
   Kuri-Cervantes L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd7114
   Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729
   LEVI F, 1991, ANN NY ACAD SCI, V618, P312, DOI 10.1111/j.1749-6632.1991.tb27251.x
   LEVI FA, 1988, J CLIN INVEST, V81, P407, DOI 10.1172/JCI113333
   Lim SY, 2019, CLIN CANCER RES, V25, P1557, DOI 10.1158/1078-0432.CCR-18-2795
   Liu YY, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aax7969
   MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303
   Mackall CL, 1997, BLOOD, V89, P3700, DOI 10.1182/blood.V89.10.3700.3700_3700_3707
   Maxwell S. E., 2003, DESIGNING EXPT ANAL
   Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010
   Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4
   Oh DY, 2017, CANCER RES, V77, P1322, DOI 10.1158/0008-5472.CAN-16-2324
   Panoskaltsis N, 2003, LEUKEMIA, V17, P716, DOI 10.1038/sj.leu.2402835
   Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI 10.1056/NEJMra1703481
   Rowshanravan B, 2018, BLOOD, V131, P58, DOI 10.1182/blood-2017-06-741033
   Santomasso BD, 2018, CANCER DISCOV, V8, P958, DOI 10.1158/2159-8290.CD-17-1319
   Shang Y, 2009, J SURG RES, V155, P104, DOI 10.1016/j.jss.2008.10.003
   Staedtke V, 2018, NATURE, V564, P273, DOI 10.1038/s41586-018-0774-y
   Stummvoll GH, 2008, J IMMUNOL, V181, P1908, DOI 10.4049/jimmunol.181.3.1908
   Subudhi SK, 2016, P NATL ACAD SCI USA, V113, P11919, DOI 10.1073/pnas.1611421113
   Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613
   Weide B, 2015, SEMIN ONCOL, V42, P448, DOI 10.1053/j.seminoncol.2015.02.016
   Wick W, 2016, LANCET ONCOL, V17, pE529, DOI 10.1016/S1470-2045(16)30571-X
   Yuan RR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001924
NR 45
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340-7004
EI 1432-0851
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
DI 10.1007/s00262-020-02725-2
EA OCT 2020
PG 16
WC Oncology; Immunology
SC Oncology; Immunology
GA NZ1RL
UT WOS:000576868400001
PM 33033851
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Muccioli, L
   Pensato, U
   Bernabe, G
   Ferri, L
   Tappata, M
   Volpi, L
   Cani, I
   Henry, OJ
   Ceccaroni, F
   Cevoli, S
   Stofella, G
   Pasini, E
   Fornaro, G
   Tonon, C
   Vidale, S
   Liguori, R
   Tinuper, P
   Michelucci, R
   Cortelli, P
   Bisulli, F
AF Muccioli, Lorenzo
   Pensato, Umberto
   Bernabe, Giorgia
   Ferri, Lorenzo
   Tappata, Maria
   Volpi, Lilia
   Cani, Ilaria
   Henry, Olivia J.
   Ceccaroni, Francesca
   Cevoli, Sabina
   Stofella, Gloria
   Pasini, Elena
   Fornaro, Giacomo
   Tonon, Caterina
   Vidale, Simone
   Liguori, Rocco
   Tinuper, Paolo
   Michelucci, Roberto
   Cortelli, Pietro
   Bisulli, Francesca
TI Intravenous immunoglobulin therapy in COVID-19-related encephalopathy
SO JOURNAL OF NEUROLOGY
LA English
DT Article; Early Access
AB Objective To report on efficacy and safety of intravenous immunoglobulin (IVIg) therapy in a case series of patients with COVID-19-related encephalopathy.
   Methods We retrospectively collected data on all patients with COVID-19 hospitalized at two Italian hospitals who developed encephalopathy during disease course and were treated with IVIg.
   Results Five patients (two females, mean age 66.8 years) developed encephalopathy after a mean of 12.6 days, since the onset of respiratory/constitutional symptoms related to COVID-19. Four patients suffered severe respiratory distress, three of which required invasive mechanical ventilation. Neurological manifestations included impaired consciousness, agitation, delirium, pyramidal and extrapyramidal signs. EEG demonstrated diffuse slowing in all patients. Brain MRI showed non-specific findings. CSF analysis revealed normal cell count and protein levels. In all subjects, RT-PCR for SARS-CoV-2 in CSF tested negative. IVIg at 0.4 g/kg/die was commenced 29.8 days (mean, range: 19-55 days) after encephalopathy onset, leading to complete electroclinical recovery in all patients, with an initial improvement of neuropsychiatric symptoms observed in 3.4 days (mean, range: 1-10 days). No adverse events related to IVIg were observed.
   Conclusions Our preliminary findings suggest that IVIg may represent a safe and effective treatment for COVID-19-associated encephalopathy. Clinical efficacy may be driven by the anti-inflammatory action of IVIg, associated with its anti-cytokine qualities.
C1 [Muccioli, Lorenzo; Pensato, Umberto; Ferri, Lorenzo; Cani, Ilaria; Tonon, Caterina; Liguori, Rocco; Tinuper, Paolo; Cortelli, Pietro; Bisulli, Francesca] Univ Bologna, Bellaria Hosp, Dept Biomed & Neuromotor Sci, Via Altura 3, I-40139 Bologna, Italy.
   [Bernabe, Giorgia; Ceccaroni, Francesca; Vidale, Simone] AUSL Romagna, Infermi Hosp, Rimini, Italy.
   [Tappata, Maria; Volpi, Lilia; Cevoli, Sabina; Stofella, Gloria; Pasini, Elena; Tonon, Caterina; Liguori, Rocco; Tinuper, Paolo; Michelucci, Roberto; Cortelli, Pietro; Bisulli, Francesca] IRCCS Ist Sci Neurol Bologna, Bologna, Italy.
   [Henry, Olivia J.] Karolinska Inst, Stockholm, Sweden.
   [Fornaro, Giacomo] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy.
RP Bisulli, F (corresponding author), Univ Bologna, Bellaria Hosp, Dept Biomed & Neuromotor Sci, Via Altura 3, I-40139 Bologna, Italy.; Bisulli, F (corresponding author), IRCCS Ist Sci Neurol Bologna, Bologna, Italy.
EM francesca.bisulli@unibo.it
RI Muccioli, Lorenzo/AAX-3927-2020; Pensato, Umberto/AAT-3058-2020
OI Muccioli, Lorenzo/0000-0001-6827-0099; Pensato,
   Umberto/0000-0002-4042-4735; Ferri, Lorenzo/0000-0003-0148-9795
FU Alma Mater Studiorum - Universita di Bologna within the CRUI-CARE
   Agreement
FX Open access funding provided by Alma Mater Studiorum - Universita di
   Bologna within the CRUI-CARE Agreement.
CR ABE Y, 1994, IMMUNOL REV, V139, P5, DOI 10.1111/j.1600-065X.1994.tb00854.x
   Al-Ani F, 2020, THROMB RES, V192, P152, DOI 10.1016/j.thromres.2020.05.039
   Beach SR, 2020, GEN HOSP PSYCHIAT, V65, P47, DOI 10.1016/j.genhosppsych.2020.05.008
   Benameur K, 2020, EMERG INFECT DIS, V26, P2016, DOI 10.3201/eid2609.202122
   Cani I, 2020, J NEUROL, DOI 10.1007/s00415-020-10057-5
   Cao W, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa102
   Chaumont H, 2020, J NEUROL, V267, P3121, DOI 10.1007/s00415-020-09986-y
   Dogan L, 2020, BRAIN BEHAV IMMUN, V87, P155, DOI 10.1016/j.bbi.2020.05.022
   Farhadian S, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01812-2
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Koralnik IJ, 2020, ANN NEUROL, V88, P1, DOI 10.1002/ana.25807
   Le Guennec L, 2020, EPILEPSIA, V61, pE90, DOI 10.1111/epi.16612
   Liu XS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01660
   Lunemann JD, 2015, NAT REV NEUROL, V11, P80, DOI 10.1038/nrneurol.2014.253
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Muccioli L, 2020, ANN NEUROL, V88, P860, DOI 10.1002/ana.25855
   Pilotto A, 2020, ANN NEUROL, V88, P423, DOI 10.1002/ana.25783
   Pugin D, 2020, NEUROLOGY, V95, P543, DOI 10.1212/WNL.0000000000010354
   Santomasso BD, 2018, CANCER DISCOV, V8, P958, DOI 10.1158/2159-8290.CD-17-1319
   Sharief MK, 1999, NEUROLOGY, V52, P1833, DOI 10.1212/WNL.52.9.1833
   St-Amour I, 2013, J CEREBR BLOOD F MET, V33, P1983, DOI 10.1038/jcbfm.2013.160
NR 21
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
DI 10.1007/s00415-020-10248-0
EA OCT 2020
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA NY7AR
UT WOS:000576537900001
PM 33030607
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, M
   Zhang, L
   Huo, XH
   Zhang, ZF
   Yuan, QJ
   Li, PP
   Chen, JZ
   Zou, YS
   Wu, ZX
   Zhang, WB
AF Wang, Mo
   Zhang, Lu
   Huo, Xiaohong
   Zhang, Zhenfeng
   Yuan, Qianjia
   Li, Panpan
   Chen, Jianzhong
   Zou, Yashi
   Wu, Zhengxing
   Zhang, Wanbin
TI Catalytic Asymmetric Synthesis of the anti-COVID-19 Drug Remdesivir
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE asymmetric catalysis; drug design; organocatalysis; phosphoramidates;
   synthetic methods
ID ENANTIOSELECTIVE C-ACYLATION; KINETIC RESOLUTION; ACID; PHOSPHATE;
   GS-5734; DESIGN; EBOLA
AB The catalytic asymmetric synthesis of the anti-COVID-19 drug Remdesivir has been realized by the coupling of theP-racemic phosphoryl chloride with protected nucleoside GS441524. The chiral bicyclic imidazole catalyst used is crucial for the dynamic kinetic asymmetric transformation (DyKAT) to proceed smoothly with high reactivity and excellent stereoselectivity (96 % conv., 22:1S(P):R-P). Mechanistic studies showed that this DyKAT is a first-order visual kinetic reaction dependent on the catalyst concentration. The unique chiral bicyclic imidazole skeleton and carbamate substituent of the catalyst are both required for the racemization process, involving the phosphoryl chloride, and subsequent stereodiscriminating step. A 10 gram scale reaction was also conducted with comparably excellent results, showing its potential for industrial application.
C1 [Wang, Mo; Huo, Xiaohong; Yuan, Qianjia; Li, Panpan; Chen, Jianzhong; Zou, Yashi; Wu, Zhengxing; Zhang, Wanbin] Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Shanghai Key Lab Mol Engn Chiral Drugs, Frontiers Sci Ctr Transformat Mol, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
   [Wang, Mo; Zhang, Lu; Zhang, Zhenfeng; Zhang, Wanbin] Shanghai Jiao Tong Univ, Sch Pharm, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
RP Zhang, WB (corresponding author), Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Shanghai Key Lab Mol Engn Chiral Drugs, Frontiers Sci Ctr Transformat Mol, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.; Zhang, WB (corresponding author), Shanghai Jiao Tong Univ, Sch Pharm, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
EM wanbin@sjtu.edu.cn
RI Zhang, Wanbin/I-1208-2013
OI zhang, wanbin/0000-0002-4788-4195
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [91856106, 21991112]; National Key R&D
   Program of China [2018YFE0126800]; Medical-Engineering Cross Research
   Foundation of SJTU [YG2020YQ13]; Shanghai Municipal Education
   CommissionShanghai Municipal Education Commission (SHMEC)
   [201701070002E00030]; Science and Technology Commission of Shanghai
   MunicipalityScience & Technology Commission of Shanghai Municipality
   (STCSM) [19JC1430100]
FX This work was supported by National Natural Science Foundation of China
   (Nos. 91856106 and 21991112), National Key R&D Program of China (No.
   2018YFE0126800), Medical-Engineering Cross Research Foundation of SJTU
   (YG2020YQ13), Shanghai Municipal Education Commission (No.
   201701070002E00030), and Science and Technology Commission of Shanghai
   Municipality (19JC1430100).
CR Akiyama T, 2007, CHEM REV, V107, P5744, DOI 10.1021/cr068374j
   [Anonymous], 2020, GILEAD SCI UPDATE VE
   Bhat V, 2017, CHEM REV, V117, P4528, DOI 10.1021/acs.chemrev.6b00731
   Demmer CS, 2011, CHEM REV, V111, P7981, DOI 10.1021/cr2002646
   DiRocco DA, 2017, SCIENCE, V356, P426, DOI 10.1126/science.aam7936
   Glazier DA, 2019, ADV SYNTH CATAL, V361, P3729, DOI 10.1002/adsc.201900382
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Jacobsen E. N., 2003, COMPREHENSIVE ASYMME
   Liu S, 2012, TETRAHEDRON-ASYMMETR, V23, P329, DOI 10.1016/j.tetasy.2012.02.018
   Oka N, 2011, CHEM SOC REV, V40, P5829, DOI 10.1039/c1cs15102a
   Parmar D, 2014, CHEM REV, V114, P9047, DOI 10.1021/cr5001496
   Pradere U, 2014, CHEM REV, V114, P9154, DOI 10.1021/cr5002035
   Quasdorf KW, 2014, NATURE, V516, P181, DOI 10.1038/nature14007
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Terada M, 2010, SYNTHESIS-STUTTGART, P1929, DOI 10.1055/s-0029-1218801
   TROST BM, 1991, SCIENCE, V254, P1471, DOI 10.1126/science.1962206
   US Food and Drug Administration, 2020, REMD EUA LETT AUTH
   Wang ML, 2014, CHEM COMMUN, V50, P1227, DOI 10.1039/c3cc47455k
   Wang M, 2020, CHEM SCI, V11, P4801, DOI 10.1039/d0sc00808g
   Wang M, 2017, CHEM COMMUN, V53, P1381, DOI 10.1039/c6cc09451a
   Wang M, 2014, CHEM COMMUN, V50, P3163, DOI 10.1039/c3cc49107b
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Young IS, 2009, NAT CHEM, V1, P193, DOI [10.1038/nchem.216, 10.1038/NCHEM.216]
   Zhang L, 2019, ASIAN J ORG CHEM, V8, P1024, DOI 10.1002/ajoc.201900294
   Zhang ZF, 2014, ADV SYNTH CATAL, V356, P3164, DOI 10.1002/adsc.201400415
   Zhang ZF, 2010, J AM CHEM SOC, V132, P15939, DOI 10.1021/ja109069k
   Zhou MX, 2019, ORG CHEM FRONT, V6, P3969, DOI 10.1039/c9qo01025d
   Zhu RY, 2020, ACTA CHIM SINICA, V78, P193, DOI 10.6023/A20010002
NR 28
TC 1
Z9 1
U1 15
U2 15
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PD NOV 16
PY 2020
VL 59
IS 47
BP 20814
EP 20819
DI 10.1002/anie.202011527
EA OCT 2020
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA OS5XB
UT WOS:000576149400001
PM 32870563
OA Bronze
DA 2021-01-01
ER

PT J
AU Ielpo, B
   Podda, M
   Pellino, G
   Pata, E
   Caruso, R
   Gravante, G
   Di Saverio, S
AF Ielpo, B.
   Podda, M.
   Pellino, G.
   Pata, E.
   Caruso, R.
   Gravante, G.
   Di Saverio, S.
CA ACIE Appy Study Collaborative
TI Global attitudes in the management of acute appendicitis duringCOVID-19
   pandemic:ACIEAppy Study
SO BRITISH JOURNAL OF SURGERY
LA English
DT Article; Early Access
ID ANTIBIOTIC-THERAPY; COMPLICATED APPENDICITIS; CONSERVATIVE TREATMENT;
   OPEN APPENDECTOMY; ABSCESS; METAANALYSIS; ADULTS
AB Background Surgical strategies are being adapted to face the COVID-19 pandemic. Recommendations on the management of acute appendicitis have been based on expert opinion, but very little evidence is available. This study addressed that dearth with a snapshot of worldwide approaches to appendicitis. Methods The Association of Italian Surgeons in Europe designed an online survey to assess the current attitude of surgeons globally regarding the management of patients with acute appendicitis during the pandemic. Questions were divided into baseline information, hospital organization and screening, personal protective equipment, management and surgical approach, and patient presentation beforeversusduring the pandemic. Results Of 744 answers, 709 (from 66 countries) were complete and were included in the analysis. Most hospitals were treating both patients with and those without COVID. There was variation in screening indications and modality used, with chest X-ray plus molecular testing (PCR) being the commonest (19 center dot 8 per cent). Conservative management of complicated and uncomplicated appendicitis was used by 6 center dot 6 and 2 center dot 4 per cent respectively before, but 23 center dot 7 and 5 center dot 3 per cent, during the pandemic (bothP < 0 center dot 001). One-third changed their approach from laparoscopic to open surgery owing to the popular (but evidence-lacking) advice from expert groups during the initial phase of the pandemic. No agreement on how to filter surgical smoke plume during laparoscopy was identified. There was an overall reduction in the number of patients admitted with appendicitis and one-third felt that patients who did present had more severe appendicitis than they usually observe. Conclusion Conservative management of mild appendicitis has been possible during the pandemic. The fact that some surgeons switched to open appendicectomy may reflect the poor guidelines that emanated in the early phase of SARS-CoV-2.
C1 [Ielpo, B.] Univ Hosp Leon, Dept Surg, Hepatopancreatobiliary Unit, Leon, Spain.
   [Pellino, G.] Vall Hebron Univ Hosp, Colorectal Surg, Barcelona, Spain.
   [Caruso, R.] Hosp Univ HM Sanchinarro, Madrid, Spain.
   [Podda, M.] Cagliari Univ Hosp, Dept Gen & Emergency Surg, Azienda Ospedaliero Univ, Cagliari, Italy.
   [Pellino, G.] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, Naples, Italy.
   [Pata, E.] Nicola Giannettasio Hosp, Gen Surg Unit, Corigliano Rossano, Italy.
   [Pata, E.] Univ Roma La Sapienza, Dept Gen Surg, Rome, Italy.
   [Gravante, G.] Osped Francesco Ferrari, Dept Gen Surg, Casarano, Italy.
   [Di Saverio, S.] Univ Insubria, Dept Gen Surg, Univ Hosp Varese, ASST Sette Laghi, Milan, Italy.
RP Ielpo, B (corresponding author), Univ Hosp Leon, Dept Surg, Hepatopancreatobiliary Unit, Leon, Spain.
EM ielpo.b@gmail.com
RI Alconchel, Felipe/Q-8398-2019; Bellato, Vittoria/AAQ-5526-2020;
   Francone, Elisa/AAC-6725-2019; Awad, Selmy/ABC-2273-2020; Syn,
   Nicholas/AAK-3858-2020; Ferrario, Luca/ABF-2519-2020; Martin,
   Beatriz/AAU-1267-2020; Di Marzo, Francesco/ABD-9236-2020; Bellini, Maria
   Irene/O-2971-2013; Baili, Efstratia/AAE-3367-2019; Perra,
   Teresa/AAW-8098-2020; Koh, Peng Soon/B-9637-2011; Smith-Singares,
   Eduardo/I-3518-2018; Bouhuwaish, Ahmad/AAX-8333-2020; Dudi-Venkata,
   Nagendra Naidu/AAR-9204-2020; Machairas, Nikolaos/AAA-2982-2020;
   Brisinda, Giuseppe/G-6436-2010; Mitul, Ashrarur Rahman/X-1178-2018;
   Ferrara, Francesco/A-4559-2014; Gallo, Gaetano/I-6917-2019; Elhadi,
   Muhammed/AAU-5641-2020; Gica, Nicolae/W-1142-2018; Boddy,
   Alex/B-6098-2014; Rutegard, Martin/H-6716-2019; Vigorita,
   Vincenzo/B-1871-2014
OI Alconchel, Felipe/0000-0002-5483-0312; Bellato,
   Vittoria/0000-0003-0123-1700; Francone, Elisa/0000-0001-6393-6859; Awad,
   Selmy/0000-0002-2724-5599; Syn, Nicholas/0000-0002-6343-176X; Ferrario,
   Luca/0000-0002-3652-3255; Martin, Beatriz/0000-0002-1207-6622; Di Marzo,
   Francesco/0000-0001-6435-5693; Bellini, Maria Irene/0000-0003-0730-4923;
   Baili, Efstratia/0000-0001-8745-2269; Perra, Teresa/0000-0001-7032-1289;
   Koh, Peng Soon/0000-0001-9726-6566; Smith-Singares,
   Eduardo/0000-0002-0169-2788; Bouhuwaish, Ahmad/0000-0001-7182-1277;
   Dudi-Venkata, Nagendra Naidu/0000-0002-9775-3599; Machairas,
   Nikolaos/0000-0003-3239-3905; Brisinda, Giuseppe/0000-0001-8820-9471;
   Mitul, Ashrarur Rahman/0000-0002-7100-7723; Ferrara,
   Francesco/0000-0002-8208-1945; Gallo, Gaetano/0000-0003-1066-4671;
   Elhadi, Muhammed/0000-0001-6406-4212; Gica, Nicolae/0000-0002-8425-6307;
   Di Martino, Marcello/0000-0001-6510-7210; Boddy,
   Alex/0000-0001-7243-0155; Tallon Aguilar, Luis/0000-0002-7549-619X;
   Blanco-Antona, Francisco/0000-0001-5946-9944; Charalabopoulos,
   Alexandros/0000-0003-1835-4723; Rutegard, Martin/0000-0002-0974-6373;
   Calini, Giacomo/0000-0002-7460-9578; Agastra, Ervis/0000-0003-0819-675X;
   Porcu, Alberto/0000-0001-6307-8938; Delogu, Daniele/0000-0002-7538-1229;
   Alselaim, Nahar/0000-0003-2503-0030; Vigorita,
   Vincenzo/0000-0003-2142-4737
CR American College of Radiology, 2020, ACR REC US CHEST RAD
   American College of Surgeon, COVID 19 CONS OPT SU
   An YB, 2020, BRIT J SURG, V107, pE543, DOI 10.1002/bjs.11833
   Andersson RE, 2007, ANN SURG, V246, P741, DOI 10.1097/SLA.0b013e31811f3f9f
   [Anonymous], 2020, COVID 19 GUID TRIAG
   [Anonymous], 2020, UPD INT GEN SURG GUI
   Asociacion Espanola de Coloproctologia, 2020, AS ESP COL AECP REC
   Athanasiou C, 2017, WORLD J SURG, V41, P3083, DOI 10.1007/s00268-017-4123-3
   Balibrea JM, 2020, CIR ESPAN, V98, P251, DOI 10.1016/j.ciresp.2020.03.001
   Cash CL, 2012, AM SURGEON, V78, P213
   Chang DC, 2011, J AM COLL SURGEONS, V212, P12, DOI 10.1016/j.jamcollsurg.2010.09.014
   Coccolini F, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00307-2
   Di Saverio S, 2020, J TRAUMA ACUTE CARE, V88, P715, DOI 10.1097/TA.0000000000002727
   Feng GZ, 2020, CASE STUD THERM ENG, V21, DOI 10.1016/j.csite.2020.100685
   Ferris M, 2017, ANN SURG, V266, P237, DOI 10.1097/SLA.0000000000002188
   Hansson J, 2009, BRIT J SURG, V96, P473, DOI 10.1002/bjs.6482
   Hansson J, 2014, J GASTROINTEST SURG, V18, P961, DOI 10.1007/s11605-013-2413-0
   Helling TS, 2017, AM J SURG, V214, P1195, DOI 10.1016/j.amjsurg.2017.07.039
   Jaschinski T, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001546.pub4
   Khalil M, 2016, J TRAUMA ACUTE CARE, V80, P923, DOI 10.1097/TA.0000000000001030
   Kwak HD, 2016, OCCUP ENVIRON MED, V73, P857, DOI 10.1136/oemed-2016-103724
   Liu Y, 2020, DIAGNOSTIC INDEXES R
   Melmer PD, 2019, AM SURGEON, V85, P761
   Mentula P, 2015, ANN SURG, V262, P237, DOI 10.1097/SLA.0000000000001200
   Mintz Y, 2020, ANN SURG, V272, pE7, DOI 10.1097/SLA.0000000000003965
   MIS Filtration Grp, 2020, COLORECTAL DIS, V22, P644, DOI 10.1111/codi.15086
   Nepogodiev D, 2020, BRIT J SURG, V107, P73, DOI 10.1002/bjs.11440
   Podda M, 2019, ANN SURG, V270, P1028, DOI 10.1097/SLA.0000000000003225
   Salminen P, 2015, JAMA-J AM MED ASSOC, V313, P2340, DOI 10.1001/jama.2015.6154
   Sartelli M, 2018, WORLD J EMERG SURG, V13, DOI 10.1186/s13017-018-0179-0
   Simillis C, 2010, SURGERY, V147, P818, DOI 10.1016/j.surg.2009.11.013
   Societa Italiana di Chirurgia Oncologica, 2020, SOC IT CHIR ONC SIC
   Society of American Gastrointestinal and Endoscopic Surgeons and European Association of Endoscopic Surgeons, 2020, SAGES EAES REC REG S
   Spinelli A, 2020, BRIT J SURG, V107, P785, DOI 10.1002/bjs.11627
   Talan DA, 2017, ANN EMERG MED, V70, P1, DOI 10.1016/j.annemergmed.2016.08.446
   Vanni G, 2020, IN VIVO, V34, P1651, DOI 10.21873/invivo.11957
   Vons C, 2011, LANCET, V377, P1573, DOI 10.1016/S0140-6736(11)60410-8
   World Health Organization, 2020, WHO COR DIS COVID 19
   Zhao J, 2020, ANTIBODY RESPONSES S, V2019
NR 39
TC 1
Z9 1
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1323
EI 1365-2168
J9 BRIT J SURG
JI Br. J. Surg.
DI 10.1002/bjs.11999
EA OCT 2020
PG 13
WC Surgery
SC Surgery
GA NX9LI
UT WOS:000576022800001
PM 33030744
DA 2021-01-01
ER

PT J
AU Lampasona, V
   Secchi, M
   Scavini, M
   Bazzigaluppi, E
   Brigatti, C
   Marzinotto, I
   Davalli, A
   Caretto, A
   Laurenzi, A
   Martinenghi, S
   Molinari, C
   Vitali, G
   Di Filippo, L
   Mercalli, A
   Melzi, R
   Tresoldi, C
   Rovere-Querini, P
   Landoni, G
   Ciceri, F
   Bosi, E
   Piemonti, L
AF Lampasona, Vito
   Secchi, Massimiliano
   Scavini, Marina
   Bazzigaluppi, Elena
   Brigatti, Cristina
   Marzinotto, Ilaria
   Davalli, Alberto
   Caretto, Amelia
   Laurenzi, Andrea
   Martinenghi, Sabina
   Molinari, Chiara
   Vitali, Giordano
   Di Filippo, Luigi
   Mercalli, Alessia
   Melzi, Raffaella
   Tresoldi, Cristina
   Rovere-Querini, Patrizia
   Landoni, Giovanni
   Ciceri, Fabio
   Bosi, Emanuele
   Piemonti, Lorenzo
TI Antibody response to multiple antigens of SARS-CoV-2 in patients with
   diabetes: an observational cohort study
SO DIABETOLOGIA
LA English
DT Article
DE Antibodies; COVID-19; Diabetes; Human; Humoral response;
   Receptor-binding domain; SARS-CoV-2; Survival rate
ID ACE2; COVID-19; RECEPTOR; ACTIVATION; EXPRESSION; MORTALITY; SEVERITY
AB Aims/hypothesis The aim of the study was to characterise the humoral response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with diabetes. Demonstrating the ability to mount an appropriate antibody response in the presence of hyperglycaemia is relevant for the comprehension of mechanisms related to the observed worse clinical outcome of coronavirus disease 2019 (COVID-19) pneumonia in patients with diabetes and for the development of any future vaccination campaign to prevent SARS-CoV-2 infection.
   Methods Using a highly specific and sensitive measurement of antibodies by fluid-phase luciferase immunoprecipitation assays, we characterised the IgG, IgM and IgA response against multiple antigens of SARS-CoV-2 in a cohort of 509 patients with documented diagnosis of COVID-19, prospectively followed at our institution. We analysed clinical outcomes and antibody titres according to the presence of hyperglycaemia, i.e., either diagnosed or undiagnosed diabetes, at the time of, or during, hospitalisation.
   Results Among patients with confirmed COVID-19, 139 (27.3%) had diabetes: 90 (17.7%) had diabetes diagnosed prior to the hospital admission (comorbid diabetes) while 49 (9.6%) had diabetes diagnosed at the time of admission (newly diagnosed). Diabetes was associated with increased levels of inflammatory biomarkers and hypercoagulopathy, as well as leucocytosis and neutrophilia. Diabetes was independently associated with risk of death (HR 2.32 [95% CI 1.44, 3.75],p = 0.001), even after adjustment for age, sex and other relevant comorbidities. Moreover, a strong association between higher glucose levels and risk of death was documented irrespective of diabetes diagnosis (HR 1.14 x 1.1 mmol/l [95% CI 1.08, 1.21],p < 0.001). The humoral response against SARS-CoV-2 in patients with diabetes was present and superimposable, as for timing and antibody titres, to that of non-diabetic patients, with marginal differences, and was not influenced by glucose levels. Of the measured antibody responses, positivity for IgG against the SARS-CoV-2 spike receptor-binding domain (RBD) was predictive of survival rate, both in the presence or absence of diabetes.
   Conclusions/interpretation The observed increased severity and mortality risk of COVID-19 pneumonia in patients with hyperglycaemia was not the result of an impaired humoral response against SARS-CoV-2. RBD IgG positivity was associated with a remarkable protective effect, allowing for a cautious optimism about the efficacy of future vaccines against SARs-COV-2 in people with diabetes.
C1 [Lampasona, Vito; Secchi, Massimiliano; Scavini, Marina; Bazzigaluppi, Elena; Brigatti, Cristina; Marzinotto, Ilaria; Davalli, Alberto; Caretto, Amelia; Laurenzi, Andrea; Martinenghi, Sabina; Molinari, Chiara; Vitali, Giordano; Di Filippo, Luigi; Mercalli, Alessia; Melzi, Raffaella; Bosi, Emanuele; Piemonti, Lorenzo] IRCCS Osped San Raffaele, San Raffaele Diabet Res Inst, Milan, Italy.
   [Tresoldi, Cristina] IRCCS Osped San Raffaele, Mol Hematol Unit, Milan, Italy.
   [Rovere-Querini, Patrizia] IRCCS Osped San Raffaele, Dept Immunol Transplantat & Infect Dis, Milan, Italy.
   [Rovere-Querini, Patrizia; Landoni, Giovanni; Ciceri, Fabio; Bosi, Emanuele; Piemonti, Lorenzo] Univ Vita Salute San Raffaele, Sch Med & Surg, Milan, Italy.
   [Landoni, Giovanni] IRCCS Osped San Raffaele, Dept Anesthesia & Intens Care, Milan, Italy.
   [Ciceri, Fabio] IRCCS Osped San Raffaele, Hematol & Bone Marrow Transplantat Unit, Milan, Italy.
RP Piemonti, L (corresponding author), IRCCS Osped San Raffaele, San Raffaele Diabet Res Inst, Milan, Italy.; Piemonti, L (corresponding author), Univ Vita Salute San Raffaele, Sch Med & Surg, Milan, Italy.
EM piemonti.lorenzo@hsr.it
RI Piemonti, Lorenzo/P-7605-2017; Caretto, Amelia/AAG-8695-2020
OI Piemonti, Lorenzo/0000-0002-2172-2198; Caretto,
   Amelia/0000-0003-1153-6700; Scavini, Marina/0000-0002-7983-6905;
   Marzinotto, Ilaria/0000-0002-4765-4509; LANDONI,
   Giovanni/0000-0002-8594-5980; Lampasona, Vito/0000-0001-5162-8445
CR Abdi A, 2020, DIABETES RES CLIN PR, V166, DOI 10.1016/j.diabres.2020.108347
   Apicella M, 2020, LANCET DIABETES ENDO, V8, P782, DOI 10.1016/S2213-8587(20)30238-2
   Banik GR, 2016, VIROL SIN, V31, P81, DOI 10.1007/s12250-015-3679-z
   Chen X, 2020, HYPERTENSION DIABETE, DOI [10.1101/2020.03.22.20040774, DOI 10.1101/2020.03.22.20040774]
   Ciceri F, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108509
   Daryabor G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01582
   DeFuria J, 2013, P NATL ACAD SCI USA, V110, P5133, DOI 10.1073/pnas.1215840110
   Dos Santos G, 2018, HUM VACC IMMUNOTHER, V14, P1853, DOI 10.1080/21645515.2018.1446719
   Fernandez C, 2018, J INTERN MED, V284, P377, DOI 10.1111/joim.12783
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Geerlings SE, 1999, FEMS IMMUNOL MED MIC, V26, P259, DOI 10.1016/S0928-8244(99)00142-X
   Gianchandani R, 2020, DIABETES, V69, P2048, DOI 10.2337/dbi20-0022
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Holman N, 2020, LANCET DIABETES ENDO, V8, P823, DOI 10.1016/S2213-8587(20)30271-0
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ji HL, 2020, PHYSIOL REV, V100, P1065, DOI 10.1152/physrev.00013.2020
   Kulcsar KA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131774
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Mantovani A, 2020, NUTR METAB CARDIOVAS, V30, P1236, DOI 10.1016/j.numecd.2020.05.014
   Rao ST, 2020, DIABETES CARE, V43, P1416, DOI 10.2337/dc20-0643
   Rego GNA, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030474
   Romani-Perez M, 2015, ENDOCRINOLOGY, V156, P3559, DOI 10.1210/en.2014-1685
   Rubino F, 2020, NEW ENGL J MED, V383, P789, DOI [10.1056/NEJMc2018688, 10.1056/NEJMc2021832]
   Schillie SF, 2012, DIABETES CARE, V35, P2690, DOI 10.2337/dc12-0312
   Secchi Massimiliano, 2020, J Clin Invest, V130, P6366, DOI 10.1172/JCI142804
   Tikoo K, 2015, BIOCHEM PHARMACOL, V93, P343, DOI 10.1016/j.bcp.2014.11.013
   Verstraeten Thomas, 2020, Expert Rev Vaccines, V19, P445, DOI 10.1080/14760584.2020.1760098
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Q, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00375-20
   Wang QM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz7086
   Wang SF, 2020, DIABETOLOGIA, V63, P2102, DOI 10.1007/s00125-020-05209-1
   Whitman Jeffrey D, 2020, medRxiv, DOI 10.1101/2020.04.25.20074856
   Williams AJK, 2006, J IMMUNOL METHODS, V314, P170, DOI 10.1016/j.jim.2006.06.003
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wysocki J, 2006, DIABETES, V55, P2132, DOI 10.2337/db06-0033
   Xu LZ, 2020, AGING-US, V12, P12410, DOI 10.18632/aging.103383
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Zangrillo Alberto, 2020, Crit Care Resusc, V22, P91
   Zhai X, 2016, CELL PHYSIOL BIOCHEM, V38, P1257, DOI 10.1159/000443073
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 42
TC 3
Z9 3
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD DEC
PY 2020
VL 63
IS 12
BP 2548
EP 2558
DI 10.1007/s00125-020-05284-4
EA OCT 2020
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OM2SQ
UT WOS:000576095700002
PM 33029657
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Badua, CLDC
   Baldo, KAT
   Medina, PMB
AF Badua, Christian Luke D. C.
   Baldo, Karol Ann T.
   Medina, Paul Mark B.
TI Genomic and proteomic mutation landscapes of SARS-CoV-2
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE coldspot; coronavirus; genetic variability; mutation; mutation hotspot;
   SARS-CoV-2; virus bioinformatics
ID SEQUENCE ALIGNMENT; CORONAVIRUS
AB The ongoing pandemic caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), affects thousands of people every day worldwide. Hence, drugs and vaccines effective against all variants of SARS-CoV-2 are crucial today. Viral genome mutations exist commonly which may impact the encoded proteins, possibly resulting to varied effectivity of detection tools and disease treatment. Thus, this study surveyed the SARS-CoV-2 genome and proteome and evaluated its mutation characteristics. Phylogenetic analyses of SARS-CoV-2 genes and proteins show three major clades and one minor clade (P6810S; ORF1ab). The overall frequency and densities of mutations in the genes and proteins of SARS-CoV-2 were observed. Nucleocapsid exhibited the highest mutation density among the structural proteins while the spike D614G was the most common, occurring mostly in genomes outside China and United States. ORF8 protein had the highest mutation density across all geographical areas. Moreover, mutation hotspots neighboring and at the catalytic site of RNA-dependent RNA polymerase were found that might challenge the binding and effectivity of remdesivir. Mutation coldspots may present as conserved diagnostic and therapeutic targets were found in ORF7b, ORF9b, and ORF14. These findings suggest that the virion's genotype and phenotype in a specific population should be considered in developing diagnostic tools and treatment options.
C1 [Badua, Christian Luke D. C.; Baldo, Karol Ann T.; Medina, Paul Mark B.] Univ Philippines Manila, Dept Biochem & Mol Biol, Biol Models Lab, Manila, Philippines.
RP Medina, PMB (corresponding author), Univ Philippines Manila, Dept Biochem & Mol Biol, Biol Models Lab, Coll Med, Pedro Gil St, Malate 1000, Metro Manila, Philippines.
EM pmbmedina@post.upm.edu.ph
OI Baldo, Karol Ann/0000-0001-7854-7004; Medina, Paul
   Mark/0000-0001-6116-1818
CR Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Cotten M, 2014, MBIO, V5, DOI 10.1128/mBio.01062-13
   Hoang DT, 2018, MOL BIOL EVOL, V35, P518, DOI 10.1093/molbev/msx281
   Enjuanes L, 2005, CORONAVIRUS REPLICAT
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Huang C, 2006, J VIROL, V80, P210, DOI 10.1128/JVI.80.1.210-217.2006
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Kalyaanamoorthy S, 2017, NAT METHODS, V14, P587, DOI [10.1038/NMETH.4285, 10.1038/nmeth.4285]
   Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108
   Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682
   Kim Jun-Sub, 2020, Osong Public Health Res Perspect, V11, P101, DOI 10.24171/j.phrp.2020.11.3.05
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Kuraku S, 2013, NUCLEIC ACIDS RES, V41, pW22, DOI 10.1093/nar/gkt389
   Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300
   Lin S., 2020, BIORXIV, DOI [10.1101/2020.01.31.929695, DOI 10.1101/2020.01.31.929695]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maitra A, 2020, J BIOSCIENCES, V45, DOI 10.1007/s12038-020-00046-1
   Minakshi R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008342
   Moosa MM, 2020, J MED VIROL, V92, P2891, DOI 10.1002/jmv.26195
   National Center for Biotechnology Information, 2020, PUBCHEM DAT
   Ou J, 2020, BIORXIV, DOI [10.1101/2020.03.15.991844, DOI 10.1101/2020.03.15.991844]
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Peck KM, 2018, J VIROL, V92, DOI 10.1128/JVI.01031-17
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tiwari M, 2020, J CLIN VIROL, V128
   Tseng YT, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-34
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zeng WH, 2020, BIOCHEM BIOPH RES CO, V527, P618, DOI 10.1016/j.bbrc.2020.04.136
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
   Zhao Z, 2002, GENOME RES, V12, P1679, DOI 10.1101/gr.287302
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 33
TC 0
Z9 0
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26548
EA OCT 2020
PG 20
WC Virology
SC Virology
GA NX9UN
UT WOS:000576046700001
PM 32970329
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Liu, XL
   Liu, Y
   Wang, LM
   Hu, LH
   Liu, D
   Li, J
AF Liu, Xiulan
   Liu, Yi
   Wang, Liuming
   Hu, Luhong
   Liu, Dong
   Li, Juan
TI Analysis of the prophylactic effect of thymosin drugs on COVID-19 for
   435 medical staff: A hospital-based retrospective study
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE ADR; COVID-19; prophylactic; SARS-CoV-2; thymosin drugs
ID ALPHA-1
AB To explore the role of thymosin drugs in the prevention of novel coronavirus disease (COVID-19), we analyzed the preventive effects of different medication timings on health medical staff, and then provided recommendations for pharmaceutical monitoring of thymus drugs. The hospital-based retrospective study analyzed 435 medical staffers, treated with or without thymosin drugs as preventive medicines in our hospital of Wuhan City, from January 25 to March 25, 2020. For the prophylactics, the medical staff was prevented from pre-exposure prophylaxis (risk prevention of exposure to COVID-19 patients before using thymosin drugs) and postexposure prophylaxis (risk prevention of exposure to COVID-19 patients after using thymosin drugs). The effectiveness and safety of thymosin drugs were studied in the prevention and control of COVID-19 application, in real-world data research for the application of the drug for COVID- 19. In a similar exposure environment, compared to medical staffers who did not take preventive medicine, the use of thymosin drugs, before exposure and after exposure had an insignificant effect, and the adverse drug reaction (ADR) was increased, especially when thymosin drugs were used together with alpha-interferon.
C1 [Liu, Xiulan; Liu, Yi; Liu, Dong; Li, Juan] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pharm, Wuhan 430030, Hubei, Peoples R China.
   [Wang, Liuming] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Nursing Dept, Wuhan, Hubei, Peoples R China.
   [Hu, Luhong] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Med Off, Wuhan, Hubei, Peoples R China.
RP Liu, D; Li, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pharm, Wuhan 430030, Hubei, Peoples R China.
EM ld2069@outlook.com; 947281063@qq.com
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Ciancio A, 2012, J VIRAL HEPATITIS, V19, P52, DOI 10.1111/j.1365-2893.2011.01524.x
   Crisi GM, 1998, MECH AGEING DEV, V103, P235, DOI 10.1016/S0047-6374(98)00030-X
   Goldstein AL, 2004, EXPERT OPIN BIOL TH, V4, P559, DOI 10.1517/eobt.4.4.559.29474
   Han Q, 2020, J INFECT
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li CL, 2002, INT IMMUNOPHARMACOL, V2, P39, DOI 10.1016/S1567-5769(01)00136-9
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li S, 2006, AM J CHINESE MED, V34, P937, DOI 10.1142/S0192415X06004417
   Lu Y, 2004, J CHIN CLIN MED, V5, P109
   Matteucci C, 2017, FUTURE MICROBIOL, V12, P141, DOI 10.2217/fmb-2016-0125
   Naylor PH, 2018, J VIRAL HEPATITIS, V25, P4, DOI 10.1111/jvh.12807
   WHO, 2020, CLIN MAN SEV AC RESP
   Wolf E, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003993.pub3
   朱兆恩, 2005, [中国医院药学杂志, Chinese Journal of Hospital Pharmacy], V25, P482
NR 15
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26492
EA OCT 2020
PG 8
WC Virology
SC Virology
GA NX9UQ
UT WOS:000576047000001
PM 32897543
OA Bronze
DA 2021-01-01
ER

PT J
AU Mondi, A
   Cimini, E
   Colavita, F
   Cicalini, S
   Pinnetti, C
   Matusali, G
   Casetti, R
   Maeurer, M
   Vergori, A
   Mazzotta, V
   Gagliardini, R
   De Zottis, F
   Schinina, V
   Girardi, E
   Puro, V
   Ippolito, G
   Vaia, F
   Capobianchi, MR
   Castilletti, C
   Agrati, C
   Antinori, A
AF Mondi, Annalisa
   Cimini, Eleonora
   Colavita, Francesca
   Cicalini, Stefania
   Pinnetti, Carmela
   Matusali, Giulia
   Casetti, Rita
   Maeurer, Markus
   Vergori, Alessandra
   Mazzotta, Valentina
   Gagliardini, Roberta
   De Zottis, Federico
   Schinina, Vincenzo
   Girardi, Enrico
   Puro, Vincenzo
   Ippolito, Giuseppe
   Vaia, Francesco
   Capobianchi, Maria Rosaria
   Castilletti, Concetta
   Agrati, Chiara
   Antinori, Andrea
TI COVID-19 in people living with HIV: Clinical implications of dynamics of
   the immune response to SARS-CoV-2
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE COVID-19; HIV infection; immune response; SARS-CoV-2
ID PNEUMONIA
AB Little evidence on coronavirus disease 2019 (COVID-19) in people living with HIV (PLWH) is currently available. We reported clinical and viroimmunological data of all HIV-positive patients admitted to our center with COVID-19 from March 1 to May 12, 2020. Overall, five patients were included: all were virologically-suppressed on antiretroviral therapy and CD4+ count was greater than 350 cell/mm(3)in all but two patients. Although all patients had evidence of pneumonia on admission, only one developed respiratory failure. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was never detected from nasopharyngeal swabs in two patients, whereas in the others, viral clearance occurred within a maximum of 43 days. Immunoglobulin G production was elicited in all patients and neutralizing antibodies in all but one patient. Specific-T-cell response developed in all patients but was stronger in those with the more severe presentations. Similarly, the highest level of proinflammatory cytokines was found in the only patient experiencing respiratory failure. Despite a mild presentation, patients with more pronounced immunosuppression showed high degrees of both cytokines production and immune activation. Our study did not find an increased risk and severity of COVID-19 in PLWH. Adaptative cellular immune response to SARS-CoV-2 appeared to correlate to disease severity. The mild clinical picture showed in advanced HIV patients, despite a significant T-cell activation and inflammatory profile, suggests a potential role of HIV-driven immunological dysregulation in avoiding immune-pathogenetic processes. However, other possible explanations, as a protective role of certain antiretroviral drugs, should be considered. Further larger studies are needed to better clarify the impact of HIV infection on COVID-19.
C1 [Mondi, Annalisa; Cicalini, Stefania; Pinnetti, Carmela; Vergori, Alessandra; Mazzotta, Valentina; Gagliardini, Roberta; De Zottis, Federico; Antinori, Andrea] Lazzaro Spallanzani IRCCS, HIV AIDS Unit, Natl Inst Infect Dis, Via Portuense 292, I-00149 Rome, Italy.
   [Cimini, Eleonora; Casetti, Rita; Agrati, Chiara] Lazzaro Spallanzani IRCCS, Lab Cellular Immunol & Pharmacol, Natl Inst Infect Dis, Rome, Italy.
   [Colavita, Francesca; Matusali, Giulia; Capobianchi, Maria Rosaria; Castilletti, Concetta] Lazzaro Spallanzani IRCCS, Lab Virol, Natl Inst Infect Dis, Rome, Italy.
   [Maeurer, Markus] Champalimaud Ctr Unknown, Immunotherapy Programme, Lisbon, Portugal.
   [Maeurer, Markus] Johannes Gutenberg Univ Mainz, Med Clin 1, Mainz, Germany.
   [Schinina, Vincenzo] Lazzaro Spallanzani IRCCS, Radiol Unit, Natl Inst Infect Dis, Rome, Italy.
   [Girardi, Enrico] IRCCS, Clin Epidemiol Unit, Natl Inst Infect Dis Lazzaro Spallanzani, Rome, Italy.
   [Puro, Vincenzo] IRCCS, Natl Inst Infect Dis Lazzaro Spallanzani, AIDS Reference Ctr, Rome, Italy.
   [Ippolito, Giuseppe] IRCCS, Natl Inst Infect Dis Lazzaro Spallanzani, Sci Direct, Rome, Italy.
   [Vaia, Francesco] IRCCS, Natl Inst Infect Dis Lazzaro Spallanzani, Hlth Direct, Rome, Italy.
RP Mondi, A (corresponding author), Lazzaro Spallanzani IRCCS, HIV AIDS Unit, Natl Inst Infect Dis, Via Portuense 292, I-00149 Rome, Italy.
EM annalisa.mondi@inmi.it
OI Vergori, Alessandra/0000-0001-6944-0686
CR Antonioli L, 2020, CELL MOL IMMUNOL, V17, P672, DOI 10.1038/s41423-020-0450-7
   Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Capeau J, 2011, CLIN INFECT DIS, V53, P1127, DOI 10.1093/cid/cir628
   Childs K, 2020, CLIN INFECT DIS, V71, P2021, DOI 10.1093/cid/ciaa657
   COLAVITA F, 2019, VIRUSES-BASEL, V11, DOI DOI 10.3390/V11040373
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   del Amo J, 2020, ANN INTERN MED, V173, P536, DOI 10.7326/M20-3689
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Ford N, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25489
   Gervasoni Cristina, 2020, Clin Infect Dis, V71, P2276, DOI 10.1093/cid/ciaa579
   Guo W., 2020, LANCET
   Hadi Yousaf B, 2020, AIDS, V34, pF3, DOI 10.1097/QAD.0000000000002666
   Karmen-Tuohy S, 2020, JAIDS-J ACQ IMM DEF, V85, P6, DOI 10.1097/QAI.0000000000002423
   Maggiolo F, 2020, J MED VIROL, DOI 10.1002/jmv.26352
   Mascolo S, 2020, J MED VIROL, V92, P1777, DOI 10.1002/jmv.25881
   Patel RH, 2020, J MED VIROL, DOI 10.1002/jmv.26416
   Patel RH, 2020, J MED VIROL, DOI 10.1002/jmv.26177
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ridgway JP, 2020, AIDS PATIENT CARE ST, V34, P331, DOI 10.1089/apc.2020.0103
   Ruan LG, 2020, J MED VIROL, DOI 10.1002/jmv.26223
   Shalhoub S, 2015, J CLIN VIROL, V62, P69, DOI 10.1016/j.jcv.2014.11.030
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Vietzen H, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-34505/v1, DOI 10.21203/RS.3.RS-34505/V1]
   Vizcarra P, 2020, LANCET HIV, V7, pE554, DOI 10.1016/S2352-3018(20)30164-8
   Wong ATY, 2004, AIDS, V18, P829, DOI 10.1097/00002030-200403260-00021
   World Health Organisation, CLIN MAN COVID 19
   Xu KJ, 2020, CLIN INFECT DIS, V71, P799, DOI 10.1093/cid/ciaa351
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
NR 29
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26556
EA OCT 2020
PG 9
WC Virology
SC Virology
GA NX9VF
UT WOS:000576048500001
PM 32975842
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Pereson, MJ
   Mojsiejczuk, L
   Martinez, AP
   Flichman, DM
   Garcia, GH
   Di Lello, FA
AF Pereson, Matias J.
   Mojsiejczuk, Laura
   Martinez, Alfredo P.
   Flichman, Diego M.
   Garcia, Gabriel H.
   Di Lello, Federico A.
TI Phylogenetic analysis of SARS-CoV-2 in the first few months since its
   emergence
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE evolution; evolutionary rate; phylogeny; SARS-CoV-2
ID CORONAVIRUS; MODELS
AB During the first few months of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution in a new host, contrasting hypotheses have been proposed about the way the virus has evolved and diversified worldwide. The aim of this study was to perform a comprehensive evolutionary analysis to describe the human outbreak and the evolutionary rate of different genomic regions of SARS-CoV-2. The molecular evolution in nine genomic regions of SARS-CoV-2 was analyzed using three different approaches: phylogenetic signal assessment, emergence of amino acid substitutions, and Bayesian evolutionary rate estimation in eight successive fortnights since the virus emergence. All observed phylogenetic signals were very low and tree topologies were in agreement with those signals. However, after 4 months of evolution, it was possible to identify regions revealing an incipient viral lineage formation, despite the low phylogenetic signal since fortnight 3. Finally, the SARS-CoV-2 evolutionary rate for regions nsp3 and S, the ones presenting greater variability, was estimated as 1.37 x 10(-3)and 2.19 x 10(-3)substitution/site/year, respectively. In conclusion, results from this study about the variable diversity of crucial viral regions and determination of the evolutionary rate are consequently decisive to understand essential features of viral emergence. In turn, findings may allow the first-time characterization of the evolutionary rate of S protein, crucial for vaccine development.
C1 [Pereson, Matias J.; Mojsiejczuk, Laura; Garcia, Gabriel H.; Di Lello, Federico A.] Univ Buenos Aires, Fac Farm & Bioquim, Inst Invest Bacteriol & Virol Mol IBaViM, Junin 956,4 Piso, RA-1113 Buenos Aires, DF, Argentina.
   [Pereson, Matias J.; Mojsiejczuk, Laura; Flichman, Diego M.; Di Lello, Federico A.] Consejo Nacl Invest Cient & Tecn CONICET, Buenos Aires, Argentina.
   [Martinez, Alfredo P.] Ctr Educ Med & Invest Clin Norberto Quirno CEMIC, Virol Sect, Buenos Aires, DF, Argentina.
   [Flichman, Diego M.] Univ Buenos Aires, Inst Invest Biomed Retrovirus & Sindrome Inmunode, Consejo Nacl Invest Cient & Tecn CONICET, Buenos Aires, DF, Argentina.
RP Di Lello, FA (corresponding author), Univ Buenos Aires, Fac Farm & Bioquim, Inst Invest Bacteriol & Virol Mol IBaViM, Junin 956,4 Piso, RA-1113 Buenos Aires, DF, Argentina.
EM fadilello@ffyb.uba.ar
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Barnes Christopher O, 2020, bioRxiv, DOI 10.1101/2020.08.30.273920
   Benvenuto D, 2020, PATHOG GLOB HEALTH, V114, P64, DOI 10.1080/20477724.2020.1725339
   Cagliani R, 2020, J VIROL, V94, DOI 10.1128/JVI.00411-20
   Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y
   Cavanagh D, 2007, VET RES, V38, P281, DOI 10.1051/vetres:2006055
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Duchene S, 2020, BIORXIV, DOI [DOI 10.1101/2020.05.04.077735, 10.1101/2020.05.04.077735]
   Giovanetti M, 2020, J MED VIROL, V92, P518, DOI 10.1002/jmv.25699
   Grassly NC, 2008, NAT REV MICROBIOL, V6, P477, DOI 10.1038/nrmicro1845
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Issa E, 2020, MSYSTEMS, V5, DOI 10.1128/mSystems.00266-20
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Koyama T, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050324
   Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li XG, 2020, J MED VIROL, V92, P501, DOI 10.1002/jmv.25701
   Liu LH, 2020, NATURE, DOI 10.1038/s41586-020-2571-7
   Luk HKH, 2019, INFECT GENET EVOL, V71, P21, DOI 10.1016/j.meegid.2019.03.001
   Mavian C, 2020, JMIR PUBLIC HLTH SUR, V6, DOI DOI 10.2196/19170
   Miller M.A., 2010, GAT COMP ENV WORKSH, P1, DOI [10.1109/GCE.2010.5676129, DOI 10.1109/GCE.2010.5676129]
   Rambaut Andrew, 2020, Nat Microbiol, V5, P1403, DOI 10.1038/s41564-020-0770-5
   Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032
   Rieux A, 2017, MOL ECOL RESOUR, V17, P608, DOI 10.1111/1755-0998.12603
   Ronquist F, 2012, SYST BIOL, V61, P539, DOI 10.1093/sysbio/sys029
   Sanchez-Pacheco SJ, 2020, P NATL ACAD SCI USA, V117, P12518, DOI 10.1073/pnas.2007062117
   Sanjuan R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002685
   Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502
   Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Suchard MA, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey016
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   To Kelvin Kai-Wang, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1275
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351
   Vega VB, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-32
   Weisblum Yiska, 2020, bioRxiv, DOI 10.1101/2020.07.21.214759
   World Health Organization, 2020, 118 WHO
   Yin CC, 2020, GENOMICS, V112, P3588, DOI 10.1016/j.ygeno.2020.04.016
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhao ZM, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-21
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 46
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26545
EA OCT 2020
PG 10
WC Virology
SC Virology
GA NX9UO
UT WOS:000576046800001
PM 32966646
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ipe, TS
   Le, T
   Quinn, B
   Kellar, S
   Clark, M
   Carlisle, S
   Rassmann, A
   Hennigan, S
   Ridenour, T
   Roberts, A
   Avery, D
   Ryan, S
   Pearson, S
   Kothari, A
   Patil, N
AF Ipe, Tina S.
   Le, Tuan
   Quinn, Brian
   Kellar, Stan
   Clark, Melisa
   Carlisle, Suzanna
   Rassmann, Anja
   Hennigan, Steve
   Ridenour, Terry
   Roberts, Anthony
   Avery, David
   Ryan, Stefanie
   Pearson, Shanna
   Kothari, Atul
   Patil, Naveen
TI Provision ofCOVID-19 Convalescent Plasma in aResource-ConstrainedState
SO TRANSFUSION
LA English
DT Article
DE donors; FFP transfusion; transfusion service operations
AB Background Arkansas is a rural state of 3 million people. It is ranked fifth for poverty nationally. The first case of coronavirus disease 2019 (COVID-19) in Arkansas occurred on 11 March 2020. Since then, approximately 8% of all Arkansans have tested positive. Given the resource limitations of Arkansas, COVID-19 convalescent plasma (CCP) was explored as a potentially lifesaving, therapeutic option. Therefore, the Arkansas Initiative for Convalescent Plasma was developed to ensure that every Arkansan has access to this therapy. Study Design and Method This brief report describes the statewide collaborative response from hospitals, blood collectors, and the Arkansas Department of Health (ADH) to ensure that CCP was available in a resource-limited state. Results Early contact tracing by ADH identified individuals who had come into contact with "patient zero" in early March. Within the first week, 32 patients tested positive for COVID-19. The first set of CCP collections occurred on 9 April 2020. Donors had to be triaged carefully in the initial period, as many had recently resolved their symptoms. From our first collections, with appropriate resource and inventory management, we collected sufficient CCP to provide the requested number of units for every patient treated with CCP in Arkansas. Conclusions The Arkansas Initiative, a statewide effort to ensure CCP for every patient in a resource-limited state, required careful coordination among key players. Collaboration and resource management was crucial to meet the demand of CCP products and potentially save lives.
C1 [Ipe, Tina S.] Univ Arkansas Med Sci, Dept Pathol & Lab Med, 4301 W Markham St,Slot 503, Little Rock, AR 72205 USA.
   [Le, Tuan; Ridenour, Terry] Oklahoma Texas & Arkansas Blood Inst, Oklahoma City, OK USA.
   [Quinn, Brian] Baptist Hlth, Dept Pathol, Little Rock, AR USA.
   [Kellar, Stan] Baptist Hlth, Dept Med, Little Rock, AR USA.
   [Clark, Melisa; Carlisle, Suzanna] Univ Arkansas Med Sci, Off Res Regulatory Affairs ORRA, Little Rock, AR 72205 USA.
   [Rassmann, Anja; Avery, David] Univ Arkansas Med Sci, Clin Trials Innovat Unit CTIU, Translat Res Inst TRI, Little Rock, AR 72205 USA.
   [Hennigan, Steve] Washington Reg Med Ctr, Fayetteville, AR USA.
   [Roberts, Anthony] Community Blood Ctr Ozarks, Springfield, MO USA.
   [Ryan, Stefanie; Pearson, Shanna; Kothari, Atul; Patil, Naveen] Arkansas Dept Hlth, Little Rock, AR 72205 USA.
RP Ipe, TS (corresponding author), Univ Arkansas Med Sci, Dept Pathol & Lab Med, 4301 W Markham St,Slot 503, Little Rock, AR 72205 USA.
EM tipe@uams.edu
CR American Heart Association, 2017, ARK STAT FACT SHEET
   [Anonymous], 2020, REC INV COVID 19 CON
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Miller W, 2019, RURAL PROFILE ARKANS
   Robert Wood Johnson Foundation, 2017, NEW REP FIND PROGR P
   US Census Bureau, 2020, QUICK FACTS ARK
   Washington State Department of Health, 2020, NOV COR OUTBR 2020
   Wikipedia, 2020, ARK METR AR
NR 10
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD DEC
PY 2020
VL 60
IS 12
BP 2828
EP 2833
DI 10.1111/trf.16118
EA OCT 2020
PG 6
WC Hematology
SC Hematology
GA PB1EO
UT WOS:000576040900001
PM 32989778
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Brzezinski, D
   Kowiel, M
   Cooper, DR
   Cymborowski, M
   Grabowski, M
   Wlodawer, A
   Dauter, Z
   Shabalin, IG
   Gilski, M
   Rupp, B
   Jaskolski, M
   Minor, W
AF Brzezinski, Dariusz
   Kowiel, Marcin
   Cooper, David R.
   Cymborowski, Marcin
   Grabowski, Marek
   Wlodawer, Alexander
   Dauter, Zbigniew
   Shabalin, Ivan G.
   Gilski, Miroslaw
   Rupp, Bernhard
   Jaskolski, Mariusz
   Minor, Wladek
TI Covid-19.bioreproducibility.org: A web resource forSARS-CoV-2-related
   structural models
SO PROTEIN SCIENCE
LA English
DT Article
DE coronavirus; COVID-19; ligand assessment; PDB; reproducibility;
   SARS-CoV-2; structure validation; structure-guided drug discovery
ID CONFORMATION-DEPENDENT RESTRAINTS; DIFFRACTION DATA; POLYNUCLEOTIDES;
   VALIDATION; PLACEMENT
AB The COVID-19 pandemic has triggered numerous scientific activities aimed at understanding the SARS-CoV-2 virus and ultimately developing treatments. Structural biologists have already determined hundreds of experimental X-ray, cryo-EM, and NMR structures of proteins and nucleic acids related to this coronavirus, and this number is still growing. To help biomedical researchers, who may not necessarily be experts in structural biology, navigate through the flood of structural models, we have created an online resource,covid19.bioreproducibility.org, that aggregates expert-verified information about SARS-CoV-2-related macromolecular models. In this article, we describe this web resource along with the suite of tools and methodologies used for assessing the structures presented therein.
C1 [Brzezinski, Dariusz; Cooper, David R.; Cymborowski, Marcin; Grabowski, Marek; Shabalin, Ivan G.; Minor, Wladek] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA.
   [Brzezinski, Dariusz; Kowiel, Marcin; Gilski, Miroslaw; Jaskolski, Mariusz] Polish Acad Sci, Ctr Biocrystallog Res, Inst Bioorgan Chem, Poznan, Poland.
   [Brzezinski, Dariusz] Poznan Univ Tech, Inst Comp Sci, Poznan, Poland.
   [Wlodawer, Alexander; Dauter, Zbigniew] NCI, Macromol Crystallog Lab, Frederick, MD USA.
   [Gilski, Miroslaw; Jaskolski, Mariusz] Adam Mickiewicz Univ, Fac Chem, Dept Crystallog, Poznan, Poland.
   [Rupp, Bernhard] KK Hofkristallamt, San Diego, CA USA.
   [Rupp, Bernhard] Med Univ Innsbruck, Inst Genet Epidemiol, Schopfstr 41, A-6020 Innsbruck, Austria.
RP Minor, W (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA.
EM wladek@iwonka.med.virginia.edu
RI Brzezinski, Dariusz/F-7789-2014; Cooper, David/R-6071-2016
OI Brzezinski, Dariusz/0000-0001-9723-525X; Jaskolski,
   Mariusz/0000-0003-1587-6489; Cooper, David/0000-0001-5240-9789; Rupp,
   Bernhard/0000-0002-3300-6965
FU Austrian Science FundAustrian Science Fund (FWF) [P32821]; Intramural
   Research Program of the NIH, National Cancer Institute, Center for
   Cancer ResearchUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); Narodowe Centrum NaukiNational Science Center,
   PolandNational Science Centre, Poland [2020/01/0/NZ1/00134]; National
   Institute of General Medical SciencesUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [R01-GM132595]; Polish
   National Agency for Academic Exchange [PPN/BEK/2018/00058/U/00001]
FX Austrian Science Fund, Grant/Award Number: P32821; Intramural Research
   Program of the NIH, National Cancer Institute, Center for Cancer
   Research; Narodowe Centrum Nauki, Grant/Award Number:
   2020/01/0/NZ1/00134; National Institute of General Medical Sciences,
   Grant/Award Number: R01-GM132595; Polish National Agency for Academic
   Exchange, Grant/Award Number: PPN/BEK/2018/00058/U/00001
CR Borek D, 2010, ACTA CRYSTALLOGR D, V66, P426, DOI 10.1107/S0907444909040177
   Brzezinski D, 2020, FEBS J, V287, P2685, DOI 10.1111/febs.15314
   Casanal A, 2020, PROTEIN SCI, V29, P1069, DOI 10.1002/pro.3791
   Czub MP, 2020, J MED CHEM, V63, P6847, DOI 10.1021/acs.jmedchem.0c00225
   Dauter Z, 2013, ACTA CRYSTALLOGR D, V69, P872, DOI 10.1107/S0907444913002722
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071
   Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Gilski M, 2019, ACTA CRYSTALLOGR B, V75, DOI 10.1107/S2052520619002002
   Grabowski M, 2016, ACTA CRYSTALLOGR D, V72, P1181, DOI 10.1107/S2059798316014716
   HAMILTON WC, 1965, ACTA CRYSTALLOGR, V18, P502, DOI 10.1107/S0365110X65001081
   Handing KB, 2018, NAT PROTOC, V13, P1062, DOI 10.1038/nprot.2018.018
   Helliwell JR, 2019, ACTA CRYSTALLOGR D, V75, P455, DOI 10.1107/S2059798319004844
   Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.1218231, 10.1126/science.121823]
   Kinjo AR, 2010, PDBJ MINE DESIGN IMP
   Kovalevskiy O, 2018, ACTA CRYSTALLOGR D, V74, P215, DOI 10.1107/S2059798318000979
   Kowiel M, 2020, NUCLEIC ACIDS RES, V48, P962, DOI 10.1093/nar/gkz1122
   Kowiel M, 2019, BIOINFORMATICS, V35, P452, DOI 10.1093/bioinformatics/bty626
   Kowiel M, 2016, NUCLEIC ACIDS RES, V44, P8479, DOI 10.1093/nar/gkw717
   Kowiel M, 2014, ACTA CRYSTALLOGR D, V70, P3290, DOI 10.1107/S1399004714024572
   Kutner J, 2018, BIOCHEMISTRY-US, V57, P963, DOI 10.1021/acs.biochem.7b01137
   Luo ZP, 2014, ACTA CRYSTALLOGR D, V70, P253, DOI 10.1107/S1399004713026680
   Majorek K. A., 2020, STRUCTURAL BIOL DRUG, P253
   McKinney W, 2010, P 9 PYTH SCI C, V9, P51, DOI DOI 10.1016/S0168-0102(02)00204-3
   Minor W, 2020, MOL BRAIN, V13, P24, DOI [10.3410/f.737405003.793574963, DOI 10.3410/F.737405003.793574963]
   Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949
   Miyakawa T, 2020, MOL BRAIN, V13, DOI 10.1186/s13041-020-0552-2
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987
   Pearce NM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15123
   Porebski PJ, 2020, PROTEIN SCI, V29, P120, DOI 10.1002/pro.3747
   Raczynska JE, 2018, DRUG RESIST UPDATE, V40, P1, DOI 10.1016/j.drup.2018.08.001
   Rawlinson C, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l2301
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Ruffell D, 2020, FEBS LETT, V594, P1127, DOI 10.1002/1873-3468.13784
   Rupp B, 2010, BIOMOLECULAR CRYSTALLOGRAPHY: PRINCIPLES, PRACTICE, AND APPLICATION TO STRUCTURAL BIOLOGY, P1
   Sever R, 2019, BIORXIV, DOI [10.1101/833400, DOI 10.1101/833400]
   Shabalin IG, 2018, CRYSTALLOGR REV, V24, P236, DOI 10.1080/0889311X.2018.1521805
   Smart O, 2011, GRADE WEB SERVER
   Villadangos AF, 2011, MOL MICROBIOL, V82, P998, DOI 10.1111/j.1365-2958.2011.07882.x
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wlodawer A, 2020, FEBS J, V287, P3703, DOI 10.1111/febs.15366
   Wlodawer A, 2018, FEBS J, V285, P444, DOI 10.1111/febs.14320
   Zheng H, 2017, ACTA CRYSTALLOGR D, V73, P223, DOI 10.1107/S2059798317001061
   Zheng HP, 2015, NUCLEIC ACIDS RES, V43, P3789, DOI 10.1093/nar/gkv225
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
NR 48
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0961-8368
EI 1469-896X
J9 PROTEIN SCI
JI Protein Sci.
PD JAN
PY 2021
VL 30
IS 1
SI SI
BP 115
EP 124
DI 10.1002/pro.3959
EA OCT 2020
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA PE9FV
UT WOS:000575956600001
PM 32981130
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Coroiu, A
   Moran, C
   Campbell, T
   Geller, AC
AF Coroiu, Adina
   Moran, Chelsea
   Campbell, Tavis
   Geller, Alan C.
TI Barriers and facilitators of adherence to social distancing
   recommendations during COVID-19 among a large international sample of
   adults
SO PLOS ONE
LA English
DT Article
AB Background
   Social distancing measures (e.g., avoiding travel, limiting physical contact with people outside of one's household, and maintaining a 1 or 2-metre distance between self and others when in public, depending on the country) are the primary strategies used to prevent transmission of the SARS-Cov-2 virus that causes COVID-19. Given that there is no effective treatment or vaccine for COVID-19, it is important to identify barriers and facilitators to adherence to social distancing to inform ongoing and future public health campaigns.
   Method
   This cross-sectional study was conducted online with a convenience sample of English-speaking adults. The survey was administered over the course of three weeks (March 30 -April 16, 2020) when social distancing measures were well-enforced in North America and Europe. Participants were asked to complete measures assessing socio-demographic characteristics, psychological constructs, including motivations to engage in social distancing, prosocial attitudes, distress, and social distancing behaviors. Descriptive (mean, standard deviation, percentage) and inferential statistics (logistic regression) were used to describes endorsement rates for various motivations, rates of adherence to social distancing recommendations, and predictors of adherence.
   Results
   Data were collected from 2013 adults living primarily in North America and Europe. Most frequently endorsed motivations to engage in social distancing (or facilitators) included "I want to protect others" (86%), "I want to protect myself" (84%), and I feel a sense of responsibility to protect our community" (84%). Most frequently endorsed motivations against social distancing (or barriers) included "There are many people walking on the streets in my area" (31%), "I have friends or family who need me to run errands for them" (25%), "I don't trust the messages my government provides about the pandemic" (13%), and "I feel stressed when I am alone or in isolation" (13%). Adherence to social distancing recommendations ranged from 45% for "working from home or remotely" to 90% for "avoiding crowded places/non-essential travel", with men and younger individuals (18-24 years) showing lower adherence compared to women and older individuals.
   Conclusion
   This study found that adherence to social distancing recommendations vary depending on the behaviour, with none of the surveyed behaviours showing perfect adherence. Strongest facilitators included wanting to protect the self, feeling a responsibility to protect the community, and being able to work/study remotely; strongest barriers included having friends or family who needed help with running errands and socializing in order to avoid feeling lonely. Future interventions to improve adherence to social distancing measures should couple individual-level strategies targeting key barriers to social distancing identified herein, with effective institutional measures and public health interventions. Public health campaigns should continue to highlight compassionate attitudes towards social distancing.
C1 [Coroiu, Adina; Geller, Alan C.] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA.
   [Moran, Chelsea; Campbell, Tavis] Univ Calgary, Dept Psychol, Calgary, AB, Canada.
RP Coroiu, A (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA.
EM acoroiu@hsph.harvard.edu
FU Canadian Institutes of Health Research (CIHR)Canadian Institutes of
   Health Research (CIHR); Fonds de Recherche du Quebec - Sante (FRQS)Fonds
   de la Recherche en Sante du Quebec; Vanier Canada Graduate Scholarship;
   University of Calgary Training in Research and Clinical Trials in
   Integrative Oncology (TRACTION) fellowship
FX AC is supported by post-doctoral research fellowships from the Canadian
   Institutes of Health Research (CIHR) and Fonds de Recherche du Quebec -
   Sante (FRQS). CM is supported by a Vanier Canada Graduate Scholarship
   and a University of Calgary Training in Research and Clinical Trials in
   Integrative Oncology (TRACTION) fellowship.
CR Adler NE, 2000, HEALTH PSYCHOL, V19, P586, DOI 10.1037/0278-6133.19.6.586
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], 2016, SPECIAL EDGE, V29, P1
   [Anonymous], 2020, COVID 19 ICARE STUD
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   BAUMEISTER RF, 1995, PSYCHOL BULL, V117, P497, DOI 10.1037/0033-2909.117.3.497
   Baumsteiger R, 2019, J PERS ASSESS, V101, P305, DOI 10.1080/00223891.2017.1411918
   Bavel Jay J Van, 2020, Nat Hum Behav, V4, P460, DOI 10.1038/s41562-020-0884-z
   Bonell C, 2020, J EPIDEMIOL COMMUN H, V74, P617, DOI 10.1136/jech-2020-214290
   CDC, 2020, SOC DIST COR DIS 201
   CDC, 2020, COR DIS 2019 COVID 1
   CDC, 2020, SOC DIST QUAR IS
   Cialdini RB, 2004, ANNU REV PSYCHOL, V55, P591, DOI 10.1146/annurev.psych.55.090902.142015
   Clark Cory, 2020, Glob Transit, V2, P76, DOI 10.1016/j.glt.2020.06.003
   Davies N, 2020, CMMID REPOS     0401
   Ek S, 2015, HEALTH PROMOT INT, V30, P736, DOI 10.1093/heapro/dat063
   Giatti L, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1096
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harris CR, 2006, GENDER DIFFERENCES R
   Heffner J, 2020, PSYARXIV
   Iaccarino G, 2020, HYPERTENSION, V76, P366, DOI 10.1161/HYPERTENSIONAHA.120.15324
   Inglesby TV., 2020, JAMA
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Jordan J, 2020, PSYARXIV
   Kissler SM, 2020, SCIENCE
   Kissler SM, 2020, SOCIAL DISTANCING ST, DOI [10.1101/2020.03.22.20041079v1, DOI 10.1101/2020.03.22.20041079V1]
   Kroenke K, 2009, PSYCHOSOMATICS, V50, P613, DOI 10.1176/appi.psy.50.6.613
   Lab GenderSCI, US GEND SEX COVID 19
   Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0
   Lowe B, 2010, J AFFECT DISORDERS, V122, P86, DOI 10.1016/j.jad.2009.06.019
   Lunn P, 2020, MOTIVATING SOCIAL DI
   MCLEROY KR, 1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401
   Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10
   MILLER WR, 1983, BEHAV PSYCHOTHER, V11, P147, DOI 10.1017/S0141347300006583
   Pan A, 2020, JAMA
   Patel JA, 2020, PUBLIC HEALTH, V183, P110, DOI 10.1016/j.puhe.2020.05.006
   Perkins A, 2020, OPTIMAL CONTROL COVI, DOI [10.1101/2020.04.22.20076018v1, DOI 10.1101/2020.04.22.20076018V1]
   Pfattheicher S, 2020, PSYARXIV
   Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686
   Public Health Agency of Canada, 2020, VULN POP COVID 19
   Qualls N, 2017, MMWR RECOMM REP, P66
   Roche B, 2020, OPTIMAL STRATEGIES Q
   Rollnick S, 1995, BEHAV COGN PSYCHOTH, V23, P325, DOI DOI 10.1017/S135246580001643X
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68
   Sharma Garima, 2020, JACC Case Rep, V2, P1407, DOI 10.1016/j.jaccas.2020.04.027
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
   WHO, 2020, PNEUM UNKN CAUS CHIN
   WHO CC for IDM MRC Centre for Global Infectious Disease Analysis Abdul Latif Jameel Institute for Disease and Emergency Analytics Imperial College London  UK, 2020, 9 WHO CC IDM MRC CTR
   World Health Organization, COR DIS COVID 19 ADV
NR 50
TC 1
Z9 1
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 7
PY 2020
VL 15
IS 10
AR e0239795
DI 10.1371/journal.pone.0239795
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OG3SJ
UT WOS:000581808000053
PM 33027281
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sestili, P
   Fimognari, C
AF Sestili, Piero
   Fimognari, Carmela
TI Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe
   COVID-19 Illness?
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE COVID-19; paracetamol; non-steroidal anti-inflammatory drugs;
   inflammation; oxidative damage; glutathione; antioxidant; risk factors
ID N-ACETYLCYSTEINE; INTRACELLULAR GLUTATHIONE; OXIDATIVE STRESS;
   ACETAMINOPHEN; REPLICATION; IMPROVEMENT; DEFICIENCY; RESISTANCE; ASTHMA;
   GSTT1
AB COVID-19 pandemic is posing an unprecedented sanitary threat: antiviral and host-directed medications to treat the disease are urgently needed. A great effort has been paid to find drugs and treatments for hospitalized, severely ill patients. However, medications used for the domiciliary management of early symptoms, notwithstanding their importance, have not been and are not presently regarded with the same attention and seriousness. In analogy with other airways viral infections, COVID-19 patients in the early phase require specific antivirals (still lacking) and non-etiotropic drugs to lower pain, fever, and control inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol (PAC) are widely used as non-etiotropic agents in common airways viral infections and hence are both theoretically repurposable for COVID-19. However, a warning from some research reports and National Authorities raised NSAIDs safety concerns because of the supposed induction of angiotensin-converting enzyme 2 (ACE2) levels (the receptor used by SARS-CoV2 to enter host airways cells), the increased risk of bacterial superinfections and masking of disease symptoms. As a consequence, the use of NSAIDs was, and is still, discouraged while the alternative adoption of paracetamol is still preferred. On the basis of novel data and hypothesis on the possible role of scarce glutathione (GSH) levels in the exacerbation of COVID-19 and of the GSH depleting activity of PAC, this commentary raises the question of whether PAC may be the better choice.
C1 [Sestili, Piero] Univ Urbino Carlo Bo, Dept Biomol Sci DISB, Urbino, Italy.
   [Fimognari, Carmela] Univ Bologna, Dipartimento Sci Qual Vita, Rimini, Italy.
RP Sestili, P (corresponding author), Univ Urbino Carlo Bo, Dept Biomol Sci DISB, Urbino, Italy.
EM piero.sestili@uniurb.it
CR Aktas B, 2020, TURK J BIOL, V44, P265, DOI 10.3906/biy-2005-102
   Ali N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00458
   Aydemir D, 2020, PATHOG GLOB HEALTH, V114, P109, DOI 10.1080/20477724.2020.1751388
   Bolt HM, 2006, CURR DRUG METAB, V7, P613, DOI 10.2174/138920006778017786
   Bruce E, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082586
   Brune K, 2015, EUR J PAIN, V19, P953, DOI 10.1002/ejp.621
   BURGUNDER JM, 1989, EUR J CLIN PHARMACOL, V36, P127, DOI 10.1007/BF00609183
   CANTIN AM, 1991, LUNG, V169, P123, DOI 10.1007/BF02714149
   Cantoni O, 1996, BIOCHEM PHARMACOL, V51, P1021, DOI 10.1016/0006-2952(95)02436-0
   Capuano A, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104849
   Crpv De Tours CRPV de Marseille, 2019, RAPP EXP INF BACT GR
   Cure MC, 2020, THERAPIE, V75, P387, DOI 10.1016/j.therap.2020.06.012
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1086
   De Flora S, 2020, FASEB J, V34, P13185, DOI 10.1096/fj.202001807
   DeFlora S, 1997, EUR RESPIR J, V10, P1535, DOI 10.1183/09031936.97.10071535
   Dimova S, 2005, INT J BIOCHEM CELL B, V37, P1727, DOI 10.1016/j.biocel.2005.03.005
   Driver B, 2020, RES PRACT THROMB HAE, V4, P36, DOI 10.1002/rth2.12283
   Estevez Francisco, 1994, Acta Physiologica Pharmacologica et Therapeutica Latinoamericana, V44, P48
   Farouk SS, 2020, J NEPHROL, V33, P1213, DOI 10.1007/s40620-020-00789-y
   FitzGerald GA, 2020, SCIENCE, V367, P1434, DOI 10.1126/science.abb8034
   Giardini V, 2020, AM J HEMATOL, V95, pE188, DOI 10.1002/ajh.25882
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Hati S, 2020, ACS OMEGA, V5, P16292, DOI 10.1021/acsomega.0c02125
   Homma T, 2015, CURR DRUG METAB, V16, P560, DOI 10.2174/1389200216666151015114515
   Horowitz RI, 2020, RESPIR MED CASE REP, V30, DOI 10.1016/j.rmcr.2020.101063
   Ibrahim HA, 2004, MED SCI MONITOR, V10, pCR85
   Ibrahim H, 2020, CLIN IMMUNOL, V219, DOI 10.1016/j.clim.2020.108544
   Jain SK, 2014, EUR J CLIN NUTR, V68, P1148, DOI 10.1038/ejcn.2014.114
   Jain SK, 2020, J AM COLL NUTR, V39, P694, DOI 10.1080/07315724.2020.1789518
   Jothimani D, 2020, J HEPATOL, V73, P1231, DOI 10.1016/j.jhep.2020.06.006
   Kaufmann SHE, 2018, NAT REV DRUG DISCOV, V17, P35, DOI 10.1038/nrd.2017.162
   Khomich OA, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080392
   Klopcic I, 2015, CHEM-BIOL INTERACT, V242, P407, DOI 10.1016/j.cbi.2015.11.002
   Kowalewski M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02925-3
   Lee C, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/6208067
   Martins PR, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13576
   Mast C, 2018, NUTR RES REV, V31, P179, DOI [10.1017/S0954422418000021, 10.1017/s0954422418000021]
   McBride JT, 2011, PEDIATRICS, V128, P1181, DOI 10.1542/peds.2011-1106
   Meltzer DO, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.19722
   Messika J, 2014, J CRIT CARE, V29, P733, DOI 10.1016/j.jcrc.2014.05.021
   Micallef J, 2020, THERAPIE, V75, P515, DOI 10.1016/j.therap.2020.07.008
   Micallef J, 2020, THERAPIE, V75, P355, DOI 10.1016/j.therap.2020.05.003
   Moore N, 2020, DRUG SAFETY, V43, P611, DOI 10.1007/s40264-020-00953-0
   Mukhtar I, 2019, PAK J PHARM SCI, V32, P751
   Nencioni L, 2003, FASEB J, V17, P758, DOI 10.1096/fj.02-0508fje
   Nuttall SL, 2003, J CLIN PHARM THER, V28, P289, DOI 10.1046/j.1365-2710.2003.00493.x
   Nydlova E, 2014, J APPL TOXICOL, V34, P968, DOI 10.1002/jat.2914
   PACHT ER, 1991, CHEST, V100, P1397, DOI 10.1378/chest.100.5.1397
   Palamara AT, 1996, AIDS RES HUM RETROV, V12, P1537, DOI 10.1089/aid.1996.12.1537
   Poggiali Erika, 2020, Eur J Case Rep Intern Med, V7, P001646, DOI 10.12890/2020_001646
   Polonikov A, 2020, ACS INFECT DIS, V6, P1558, DOI 10.1021/acsinfecdis.0c00288
   Pujos-Guillot E, 2012, AGE, V34, P181, DOI 10.1007/s11357-011-9218-4
   Roberts E, 2016, ANN RHEUM DIS, V75, P552, DOI 10.1136/annrheumdis-2014-206914
   Rothuizen Laura E, 2020, Rev Med Suisse, V16, P852
   Saadat M, 2020, CLIN CHIM ACTA, V508, P213, DOI 10.1016/j.cca.2020.05.041
   Sansgiry SS, 2017, INTEGR PHARM RES PRA, V6, P1, DOI 10.2147/IPRP.S103494
   Schoenrich Gunther, 2020, Advances in Biological Regulation, V77, P100741, DOI 10.1016/j.jbior.2020.100741
   Sestili P, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00854
   Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Smart L, 2020, INFLAMMOPHARMACOLOGY, V28, P1141, DOI 10.1007/s10787-020-00745-z
   Soeiro T, 2020, BRIT J CLIN PHARMACO, V86, P1192
   Soltan-Sharifi MS, 2007, HUM EXP TOXICOL, V26, P697, DOI 10.1177/0960327107083452
   Sridharan GK, 2020, AM J THER, V27, pE400, DOI 10.1097/MJT.0000000000001196
   Stahl Simone H, 2015, Drug Discov Today Technol, V15, P9, DOI 10.1016/j.ddtec.2015.06.003
   Sun LP, 2020, J CLIN VIROL, V128
   Tomera K., 2020, HOSPITALIZED COVID 1, DOI [10.2139/ssrn.3646583, DOI 10.2139/SSRN.3646583]
   Vaja R, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14514
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Veronese N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00170
   Violi F, 2017, ANTIOXID REDOX SIGN, V27, P1083, DOI 10.1089/ars.2016.6963
   Zolk O, 2020, N-S ARCH PHARMACOL, V393, P1131, DOI 10.1007/s00210-020-01890-6
NR 73
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 7
PY 2020
VL 11
AR 579944
DI 10.3389/fphar.2020.579944
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OE1IL
UT WOS:000580293100001
PM 33117175
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Weil, T
   Gross, R
   Rocker, A
   Bravo-Rodriguez, K
   Heid, C
   Sowislok, A
   Le, MH
   Erwin, N
   Dwivedi, M
   Bart, SM
   Bates, P
   Wettstein, L
   Muller, JA
   Harms, M
   Sparrer, K
   Ruiz-Blanco, YB
   Sturzel, CM
   von Einem, J
   Lippold, S
   Read, C
   Walther, P
   Hebel, M
   Kreppel, F
   Klarner, FG
   Bitan, G
   Ehrmann, M
   Weil, T
   Winter, R
   Schrader, T
   Shorter, J
   Sanchez-Garcia, E
   Munch, J
AF Weil, Tatjana
   Gross, Rudiger
   Rocker, Annika
   Bravo-Rodriguez, Kenny
   Heid, Christian
   Sowislok, Andrea
   Le, My-Hue
   Erwin, Nelli
   Dwivedi, Mridula
   Bart, Stephen M.
   Bates, Paul
   Wettstein, Lukas
   Muller, Janis A.
   Harms, Mirja
   Sparrer, Konstantin
   Ruiz-Blanco, Yasser B.
   Sturzel, Christina M.
   von Einem, Jens
   Lippold, Sina
   Read, Clarissa
   Walther, Paul
   Hebel, Marco
   Kreppel, Florian
   Klarner, Frank-Gerrit
   Bitan, Gal
   Ehrmann, Michael
   Weil, Tanja
   Winter, Roland
   Schrader, Thomas
   Shorter, James
   Sanchez-Garcia, Elsa
   Muench, Jan
TI Supramolecular Mechanism of Viral Envelope Disruption by Molecular
   Tweezers
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INHIBITORS; PROTEIN; HIV; MEMBRANE;
   AMYLOIDS; TOXICITY; LYSINE; EBOLA; CLR01
AB Broad-spectrum antivirals are powerful weapons against dangerous viruses where no specific therapy exists, as in the case of the ongoing SARS-CoV-2 pandemic. We discovered that a lysine- and arginine-specific supramolecular ligand (CLR01) destroys enveloped viruses, including HIV, Ebola, and Zika virus, and remodels amyloid fibrils in semen that promote viral infection. Yet, it is unknown how CLR01 exerts these two distinct therapeutic activities. Here, we delineate a novel mechanism of antiviral activity by studying the activity of tweezer variants: the "phosphate tweezer" CLR01, a "carboxylate tweezer" CLR05, and a "phosphate clip" PC. Lysine complexation inside the tweezer cavity is needed to antagonize amyloidogenesis and is only achieved by CLR01. Importantly, CLR01 and CLR05 but not PC form closed inclusion complexes with lipid head groups of viral membranes, thereby altering lipid orientation and increasing surface tension. This process disrupts viral envelopes and diminishes infectivity but leaves cellular membranes intact. Consequently, CLR01 and CLR05 display broad antiviral activity against all enveloped viruses tested, including herpesviruses, Measles virus, influenza, and SARS-CoV-2. Based on our mechanistic insights, we potentiated the antiviral, membrane-disrupting activity of CLR01 by introducing aliphatic ester arms into each phosphate group to act as lipid anchors that promote membrane targeting. The most potent ester modifications harbored unbranched C4 units, which engendered tweezers that were approximately one order of magnitude more effective than CLR01 and nontoxic. Thus, we establish the mechanistic basis of viral envelope disruption by specific tweezers and establish a new class of potential broad-spectrum antivirals with enhanced activity.
C1 [Weil, Tatjana; Gross, Rudiger; Rocker, Annika; Wettstein, Lukas; Muller, Janis A.; Harms, Mirja; Sparrer, Konstantin; Sturzel, Christina M.; Muench, Jan] Ulm Univ, Inst Mol Virol, Med Ctr, D-89081 Ulm, Germany.
   [Bravo-Rodriguez, Kenny; Ruiz-Blanco, Yasser B.; Sanchez-Garcia, Elsa] Univ Duisburg Essen, Ctr Med Biotechnol, Computat Biochem, D-45117 Essen, Germany.
   [Heid, Christian; Sowislok, Andrea; Le, My-Hue; Klarner, Frank-Gerrit; Schrader, Thomas] Univ Duisburg Essen, Fac Chem, D-45117 Essen, Germany.
   [Erwin, Nelli; Dwivedi, Mridula; Winter, Roland] TU Dortmund Univ, Fac Chem & Chem Biol, Phys Chem Biophys Chem 1, D-44227 Dortmund, Germany.
   [Bart, Stephen M.; Bates, Paul] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
   [Bart, Stephen M.; Bates, Paul; Shorter, James] Univ Penn, Perelman Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA.
   [von Einem, Jens; Lippold, Sina; Read, Clarissa] Ulm Univ, Inst Virol, Med Ctr, D-89081 Ulm, Germany.
   [Read, Clarissa; Walther, Paul] Ulm Univ, Cent Facil Electron Microscopy, D-89081 Ulm, Germany.
   [Hebel, Marco; Weil, Tanja] Max Planck Inst Polymer Res, D-55128 Mainz, Germany.
   [Hebel, Marco; Weil, Tanja] Ulm Univ, Inst Inorgan Chem 1, D-89081 Ulm, Germany.
   [Kreppel, Florian] Univ Witten Herdecke, Ctr Biomed Educ & Res, D-58453 Witten, Germany.
   [Bitan, Gal] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Dept Neurol, Los Angeles, CA 90095 USA.
   [Bitan, Gal] Univ Calif Los Angeles, David Geffen Sch Med, Mol Biol Inst, Los Angeles, CA 90095 USA.
   [Ehrmann, Michael] Univ Duisburg Essen, Ctr Med Biotechnol, Microbiol 2, D-45117 Essen, Germany.
   [Shorter, James] Perelman Sch Med Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.
RP Munch, J (corresponding author), Ulm Univ, Inst Mol Virol, Med Ctr, D-89081 Ulm, Germany.; Sanchez-Garcia, E (corresponding author), Univ Duisburg Essen, Ctr Med Biotechnol, Computat Biochem, D-45117 Essen, Germany.; Schrader, T (corresponding author), Univ Duisburg Essen, Fac Chem, D-45117 Essen, Germany.; Shorter, J (corresponding author), Univ Penn, Perelman Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA.; Shorter, J (corresponding author), Perelman Sch Med Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.
EM thomas.schrader@uni-due.de; jshorter@pennmedicine.upenn.edu;
   elsa.sanchez-garcia@uni-due.de; jan.muench@uni-ulm.de
RI Ehrmann, Michael/A-7307-2012; Bitan, Gal/U-2204-2019; Shorter,
   James/ABE-7307-2020
OI Ehrmann, Michael/0000-0002-1927-260X; Bitan, Gal/0000-0001-7046-3754;
   Shorter, James/0000-0001-5269-8533; Read, Clarissa/0000-0002-4632-2684
FU International Graduate School in Molecular Medicine Ulm; DFGGerman
   Research Foundation (DFG) [CRC1279, CRC 1093]; Bill and Melinda Gates
   Foundation Grand Challenges Explorations Award; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [R21HD074510]; Volkswagen FoundationVolkswagen; EU's Horizon 2020
   research and innovation programme (Fight-nCoV) [101003555]; Medical
   Faculty of Ulm University; BadenWurttemberg Stiftung; Deutsche
   Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's
   Federal and State Excellence Strategy EXC2033German Research Foundation
   (DFG) [390677874]; Boehringer Ingelheim Foundation (Plus-3
   grant)Boehringer Ingelheim; NIH/NIAUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Aging (NIA) [R01AG050721]
FX Graduate School in Molecular Medicine Ulm. R.G. was funded by a
   scholarship from the International Graduate School in Molecular Medicine
   Ulm. P.W., J.M., and E.S.-G. acknowledge funding by the DFG CRC1279.
   J.S. was supported by a Bill and Melinda Gates Foundation Grand
   Challenges Explorations Award and NIH grant R21HD074510. J.M.
   acknowledges funding by the Volkswagen Foundation and the EU's Horizon
   2020 research and innovation programme (Fight-nCoV, 101003555). J.A.M.
   is funded by a grant from the Medical Faculty of Ulm University and
   indebted to the BadenWurttemberg Stiftung for the financial support of
   this research project by the Eliteprogramme for Postdocs. A.S, C.H., and
   T.S. as well as K.B.R. and E.S-G. gratefully acknowledge funding by the
   DFG CRC 1093 "Supramolecular Chemistry on Proteins" (A3 and A8). E.S-G.
   and R.W. acknowledge the Deutsche Forschungsgemeinschaft (DFG, German
   Research Foundation) under Germany's Federal and State Excellence
   Strategy EXC2033 Projektnummer 390677874. E.S-G. also acknowledges the
   Boehringer Ingelheim Foundation (Plus-3 grant) and the computational
   time provided by the Computing and Data Facility of the Max Planck
   Society and the supercomputer magnitUDE of the University of
   Duisburg-Essen. G.B. acknowledges support from NIH/NIA grant
   R01AG050721. We thank Stefan Pohlmann for providing the SARS-CoV-2 spike
   expression plasmid.
CR Acharya S, 2014, J BIOL CHEM, V289, P10727, DOI 10.1074/jbc.M113.524520
   Arnold F, 2012, J VIROL, V86, P1244, DOI 10.1128/JVI.06121-11
   Attar A, 2014, CURR PHARM DESIGN, V20, P2469, DOI 10.2174/13816128113199990496
   Attar A, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-23
   Attar A, 2012, BRAIN, V135, P3735, DOI 10.1093/brain/aws289
   Badani H, 2014, BBA-BIOMEMBRANES, V1838, P2180, DOI 10.1016/j.bbamem.2014.04.015
   Bart SM, 2018, P NATL ACAD SCI USA, V115, P7410, DOI 10.1073/pnas.1721646115
   Bavari S, 2002, J EXP MED, V195, P593, DOI 10.1084/jem.20011500
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   Castellano Laura M, 2012, Biology (Basel), V1, P58, DOI 10.3390/biology1010058
   Chan R, 2008, J VIROL, V82, P11228, DOI 10.1128/JVI.00981-08
   Diwaker D, 2013, ACTA VIROL, V57, P293, DOI 10.4149/av_2013_03_293
   Dutt S, 2013, J ORG CHEM, V78, P6721, DOI 10.1021/jo4009673
   Ferreira N, 2014, NEUROTHERAPEUTICS, V11, P450, DOI 10.1007/s13311-013-0256-8
   Fogerson SM, 2016, EXP NEUROL, V278, P105, DOI 10.1016/j.expneurol.2016.02.004
   French KC, 2012, BIOCHEMISTRY-US, V51, P10127, DOI 10.1021/bi301406d
   Hadrovic I, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00657
   Hollmann A, 2014, BIOCHEM J, V459, P161, DOI 10.1042/BJ20131058
   Jackman JA, 2019, ACS INFECT DIS, V5, P4, DOI 10.1021/acsinfecdis.8b00286
   Jasper C, 2002, ANGEW CHEM INT EDIT, V41, P1355, DOI 10.1002/1521-3773(20020415)41:8<1355::AID-ANIE1355>3.0.CO;2-6
   Kim KA, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-55
   Koehler JW, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002430
   Liao MF, 2005, J CELL BIOL, V171, P111, DOI 10.1083/jcb.200507075
   Lorizate M, 2013, CELL MICROBIOL, V15, P292, DOI 10.1111/cmi.12101
   Lulla A, 2016, ENVIRON HEALTH PERSP, V124, P1766, DOI 10.1289/EHP141
   Lump E, 2015, ELIFE, V4, DOI 10.7554/eLife.05397
   Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014
   Polkowska J, 2009, J PHYS ORG CHEM, V22, P779, DOI 10.1002/poc.1519
   Pollock S, 2010, P NATL ACAD SCI USA, V107, P17176, DOI 10.1073/pnas.1009445107
   Prabhudesai S, 2012, NEUROTHERAPEUTICS, V9, P464, DOI 10.1007/s13311-012-0105-1
   Roan NR, 2011, CELL HOST MICROBE, V10, P541, DOI 10.1016/j.chom.2011.10.010
   Roan NR, 2009, J VIROL, V83, P73, DOI 10.1128/JVI.01366-08
   Rocker AE, 2018, ANTIVIR RES, V152, P26, DOI 10.1016/j.antiviral.2018.02.003
   Schrader T, 2005, J ORG CHEM, V70, P10227, DOI 10.1021/jo0511896
   Schrader T, 2016, CHEM COMMUN, V52, P11318, DOI 10.1039/c6cc04640a
   Sinha S, 2012, ACS CHEM NEUROSCI, V3, P451, DOI 10.1021/cn200133x
   Sinha S, 2011, J AM CHEM SOC, V133, P16958, DOI 10.1021/ja206279b
   St Vincent MR, 2010, P NATL ACAD SCI USA, V107, P17339, DOI 10.1073/pnas.1010026107
   Suzuki T., 2011, BIOCH RES INT, V2011, P1
   Talbiersky P, 2008, J AM CHEM SOC, V130, P9824, DOI 10.1021/ja801441j
   Thaa B, 2014, FEBS LETT, V588, P1031, DOI 10.1016/j.febslet.2014.02.014
   Torres L, 2015, VIRUSES-BASEL, V7, P2057, DOI 10.3390/v7042057
   Usmani SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4508
   VAN GENDEREN IL, 1994, VIROLOGY, V200, P831, DOI 10.1006/viro.1994.1252
   Vigant F, 2015, NAT REV MICROBIOL, V13, P426, DOI 10.1038/nrmicro3475
   Zheng XY, 2015, J PHYS CHEM B, V119, P4831, DOI 10.1021/acs.jpcb.5b00692
NR 46
TC 0
Z9 0
U1 10
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
EI 1520-5126
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD OCT 7
PY 2020
VL 142
IS 40
BP 17024
EP 17038
DI 10.1021/jacs.0c06400
PG 15
WC Chemistry, Multidisciplinary
SC Chemistry
GA OC3VV
UT WOS:000579087600017
PM 32926779
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Motolese, F
   Magliozzi, A
   Puttini, F
   Rossi, M
   Capone, F
   Karlinski, K
   Stark-Inbar, A
   Yekutieli, Z
   Di Lazzaro, V
   Marano, M
AF Motolese, Francesco
   Magliozzi, Alessandro
   Puttini, Fiorella
   Rossi, Mariagrazia
   Capone, Fioravante
   Karlinski, Keren
   Stark-Inbar, Alit
   Yekutieli, Ziv
   Di Lazzaro, Vincenzo
   Marano, Massimo
TI Parkinson's Disease Remote Patient Monitoring During the COVID-19
   Lockdown
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE Parkinson's disease (PD); remote patient monitoring (RPM); telemedicine;
   smartphone; COVID
AB Objective:To evaluate the feasibility of a smartphone remote patient monitoring approach in a real-life Parkinson's disease (PD) cohort during the Italian COVID-19 lockdown. Methods:Fifty-four non-demented PD patients who were supposed to attend the outpatient March clinic were recruited for a prospective study. All patients had a known UPDRS-III and a modified Hoehn and Yahr (H&Y) score and were provided with a smartphone application capable of providing indicators of gait, tapping, tremor, memory and executive functions. Different questionnaires exploring non-motor symptoms and quality of life were administered through phone-calls. Patients were asked to run the app at least twice per week (i.e., full compliance). Subjects were phone-checked weekly throughout a 3-week period for compliance and final satisfaction questionnaires. Results:Forty-five patients (83.3%) ran the app at least once; Twenty-nine (53.7%) subjects were half-compliant, while 16 (29.6%) were fully compliant. Adherence was hindered by technical issues or digital illiteracy (38.7%), demotivation (24%) and health-related issues (7.4%). Ten patients (18.5%) underwent PD therapy changes. The main factors related to lack of compliance included loss of interest, sadness, anxiety, the absence of a caregiver, the presence of falls and higher H&Y. Gait, tapping, tremor and cognitive application outcomes were correlated to disease duration, UPDRS-III and H&Y. Discussion:The majority of patients were compliant and satisfied by the provided monitoring program. Some of the application outcomes were statistically correlated to clinical parameters, but further validation is required. Our pilot study suggested that the available technologies could be readily implemented even with the current population's technical and intellectual resources.
C1 [Motolese, Francesco; Magliozzi, Alessandro; Puttini, Fiorella; Rossi, Mariagrazia; Capone, Fioravante; Di Lazzaro, Vincenzo; Marano, Massimo] Univ Campus Biomed Rome, Dept Med, Neurol Neurophysiol & Neurobiol Unit, Rome, Italy.
   [Karlinski, Keren; Stark-Inbar, Alit; Yekutieli, Ziv] Montfort Brain Monitor, Binyamina, Israel.
RP Marano, M (corresponding author), Univ Campus Biomed Rome, Dept Med, Neurol Neurophysiol & Neurobiol Unit, Rome, Italy.
EM m.marano@unicampus.it
RI Motolese, Francesco/AAW-1368-2020
OI Motolese, Francesco/0000-0003-1542-3738
CR Arora S, 2015, PARKINSONISM RELAT D, V21, P650, DOI 10.1016/j.parkreldis.2015.02.026
   Assenza G, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00737
   Di Stasio E, 2020, APPL NURS RES, V51, DOI 10.1016/j.apnr.2019.151186
   Duffy S, 2018, NEW ENGL J MED, V378, P104, DOI 10.1056/NEJMp1710735
   Erb MK, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-019-0214-x
   Espay AJ, 2019, MOVEMENT DISORD, V34, P657, DOI 10.1002/mds.27671
   Fahn S, 1987, RECENT DEV PARKINSON, V2, P293
   Fasano A, 2020, LANCET NEUROL, V19, P378, DOI 10.1016/S1474-4422(20)30033-8
   Horin Adam P, 2019, Neurodegener Dis Manag, V9, P97, DOI 10.2217/nmt-2018-0036
   Lee W, 2018, NEURODEGENER DIS, V18, P133, DOI 10.1159/000488593
   Lee W, 2016, J PARKINSON DIS, V6, P371, DOI 10.3233/JPD-150708
   Martinez-Martin P, 2014, GUIDE ASSESSMENT SCA, DOI [10.1007/978-1-907673-88-7_6, DOI 10.1007/978-1-907673-88-7_6]
   OECD, 2019, OECD SKILLS OUTL 201
   Sensi M, 2017, PARKINSONISM RELAT D, V38, P90, DOI 10.1016/j.parkreldis.2017.02.020
   Sim I, 2019, NEW ENGL J MED, V381, P956, DOI 10.1056/NEJMra1806949
   Tchelet K, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19235179
   Tessitore A, 2018, J NEUROL, V265, P1124, DOI 10.1007/s00415-018-8816-9
   Yahalom G, 2020, ISR MED ASSOC J, V22, P37
   Yahalom H, 2020, CLIN NEUROPHARMACOL, V43, P1, DOI 10.1097/WNF.0000000000000371
   Zhan AD, 2018, JAMA NEUROL, V75, P876, DOI 10.1001/jamaneurol.2018.0809
NR 20
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD OCT 7
PY 2020
VL 11
AR 567413
DI 10.3389/fneur.2020.567413
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OD4KP
UT WOS:000579821600001
PM 33117262
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zinsstag, J
   Utzinger, J
   Probst-Hensch, N
   Shan, L
   Zhou, XN
AF Zinsstag, Jakob
   Utzinger, Jurg
   Probst-Hensch, Nicole
   Shan, Lv
   Zhou, Xiao-Nong
TI Towards integrated surveillance-response systems for the prevention of
   future pandemics
SO INFECTIOUS DISEASES OF POVERTY
LA English
DT Article
DE Integrated surveillance-response; One health; Pandemics;
   Transdisciplinarity; Zoonoses
ID ONE HEALTH; RABIES CONTROL; TRANSMISSION; BRUCELLOSIS; ELIMINATION;
   DYNAMICS
AB Most human pathogens originate from non-human hosts and certain pathogens persist in animal reservoirs. The transmission of such pathogens to humans may lead to self-sustaining chains of transmission. These pathogens represent the highest risk for future pandemics. For their prevention, the transmission over the species barrier - although rare - should, by all means, be avoided. In the current COVID-19 pandemic, surprisingly though, most of the current research concentrates on the control by drugs and vaccines, while comparatively little scientific inquiry focuses on future prevention. Already in 2012, the World Bank recommended to engage in a systemic One Health approach for zoonoses control, considering integrated surveillance-response and control of human and animal diseases for primarily economic reasons. First examples, like integrated West Nile virus surveillance in mosquitos, wild birds, horses and humans in Italy show evidence of financial savings from a closer cooperation of human and animal health sectors. Provided a zoonotic origin can be ascertained for the COVID-19 pandemic, integrated wildlife, domestic animal and humans disease surveillance-response may contribute to prevent future outbreaks. In conclusion, the earlier a zoonotic pathogen can be detected in the environment, in wildlife or in domestic animals; and the better human, animal and environmental surveillance communicate with each other to prevent an outbreak, the lower are the cumulative costs.
C1 [Zinsstag, Jakob; Utzinger, Jurg; Probst-Hensch, Nicole] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
   [Zinsstag, Jakob; Utzinger, Jurg; Probst-Hensch, Nicole] Univ Basel, Basel, Switzerland.
   [Shan, Lv; Zhou, Xiao-Nong] Chinese Ctr Dis Control & Prevent, Natl Inst Parasit Dis, Shanghai, Peoples R China.
   [Shan, Lv; Zhou, Xiao-Nong] Chinese Ctr Trop Dis Res, WHO Collaborating Ctr Trop Dis, Shanghai, Peoples R China.
   [Shan, Lv; Zhou, Xiao-Nong] Shanghai Jiao Tong Univ, Sch Med, Chinese Ctr Trop Dis Res, Sch Global Hlth, Shanghai, Peoples R China.
RP Zinsstag, J (corresponding author), Swiss Trop & Publ Hlth Inst, Basel, Switzerland.; Zinsstag, J (corresponding author), Univ Basel, Basel, Switzerland.
EM jakob.zinsstag@swisstph.ch
FU National Key Research and Development Programme of China
   [2016YFC1202000]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81973108]
FX This work was supported by the National Key Research and Development
   Programme of China (grant No. 2016YFC1202000), and the National Natural
   Science Foundation of China (grant No. 81973108).
CR [Anonymous], 2012, 69145GLB50 WORLD BAN, V2, P1
   [Anonymous], 2020, AN ADDR SOC CHALL US, V88, P1
   Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4
   Bordier M, 2018, PREV VET MED, DOI [10.1016/j.prevvetmed.2018.10.005, DOI 10.1016/J.PREVVETMED.2018.10.005]
   Bordier M, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00109
   Bordier M, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6022-4
   Butler CD, 2012, INFECT DIS POVERTY, V1, DOI 10.1186/2049-9957-1-5
   Cleaveland S, 2014, VET REC, V175, P188, DOI 10.1136/vr.g4996
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dong Y, 2018, INFECT DIS POVERTY, V7, DOI 10.1186/s40249-018-0511-7
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Karimuribo Esron Daniel, 2017, JMIR Public Health Surveill, V3, pe94, DOI 10.2196/publichealth.7373
   Lloyd-Smith JO, 2009, SCIENCE, V326, P1362, DOI 10.1126/science.1177345
   Monday Busuulwa, 2011, Pan Afr Med J, V10 Supp 1, P13
   Ostrom E, 2007, P NATL ACAD SCI USA, V104, P15181, DOI 10.1073/pnas.0702288104
   Paternoster G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188156
   Roth F, 2003, B WORLD HEALTH ORGAN, V81, P867
   Rweyemamu M, 2013, CURR TOP MICROBIOL, V366, P73, DOI 10.1007/82_2012_244
   Shi ZL, 2008, VIRUS RES, V133, P74, DOI 10.1016/j.virusres.2007.03.012
   Wang LD, 2008, LANCET, V372, P1793, DOI 10.1016/S0140-6736(08)61358-6
   Wolfe ND, 2007, NATURE, V447, P279, DOI 10.1038/nature05775
   Woods A, 2018, ANIMALS SHAPING MODE
   Wurapa Frederick, 2011, Pan Afr Med J, V10 Supp 1, P6
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou X, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0144-7
   Zhou XN, 2012, INFECT DIS POVERTY, V1, DOI 10.1186/2049-9957-1-1
   Zinsstag J, 2005, LANCET, V366, P2142, DOI 10.1016/S0140-6736(05)67731-8
   Zinsstag J, 2005, PREV VET MED, V69, P77, DOI 10.1016/j.prevetmed.2005.01.017
   Zinsstag J, 2011, PREV VET MED, V101, P148, DOI 10.1016/j.prevetmed.2010.07.003
   Zinsstag J, 2009, P NATL ACAD SCI USA, V106, P14996, DOI 10.1073/pnas.0904740106
   Zinsstag J, 2018, FEMS MICROBIOL LETT, V365, DOI 10.1093/femsle/fny085
   2015, 1 HLTH THEOR PRACT, P1
NR 32
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-5162
EI 2049-9957
J9 INFECT DIS POVERTY
JI Infect. Dis. Poverty
PD OCT 7
PY 2020
VL 9
IS 1
AR 140
DI 10.1186/s40249-020-00757-5
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA OB6LW
UT WOS:000578581400003
PM 33028426
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alzaid, F
   Julla, JB
   Diedisheim, M
   Potier, C
   Potier, L
   Velho, G
   Gaborit, B
   Manivet, P
   Germain, S
   Vidal-Trecan, T
   Roussel, R
   Riveline, JP
   Dalmas, E
   Venteclef, N
   Gautier, JF
AF Alzaid, Fawaz
   Julla, Jean-Baptiste
   Diedisheim, Marc
   Potier, Charline
   Potier, Louis
   Velho, Gilberto
   Gaborit, Benedicte
   Manivet, Philippe
   Germain, Stephane
   Vidal-Trecan, Tiphaine
   Roussel, Ronan
   Riveline, Jean-Pierre
   Dalmas, Elise
   Venteclef, Nicolas
   Gautier, Jean-Francois
TI Monocytopenia, monocyte morphological anomalies and hyperinflammation
   characterise severeCOVID-19 in type 2 diabetes
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE COVID-19; inflammation; monocyte; SARS-CoV-2; type 2 diabetes
ID SUBSETS; IRF5; COVID-19
AB Early in theCOVID-19 pandemic, type 2 diabetes (T2D) was marked as a risk factor for severe disease and mortality. Inflammation is central to the aetiology of both conditions where variations in immune responses can mitigate or aggravate disease course. Identifying at-risk groups based on immunoinflammatory signatures is valuable in directing personalised care and developing potential targets for precision therapy. This observational study characterised immunophenotypic variation associated withCOVID-19 severity in T2D. Broad-spectrum immunophenotyping quantified 15 leucocyte populations in peripheral circulation from a cohort of 45 hospitalisedCOVID-19 patients with and without T2D. Lymphocytopenia and specific loss of cytotoxicCD8(+)lymphocytes were associated with severeCOVID-19 and requirement for intensive care in both non-diabetic and T2D patients. A morphological anomaly of increased monocyte size and monocytopenia restricted to classicalCD14(Hi)CD16(-)monocytes was specifically associated with severeCOVID-19 in patients with T2D requiring intensive care. Increased expression of inflammatory markers reminiscent of the type 1 interferon pathway (IL6,IL8,CCL2,INFB1) underlaid the immunophenotype associated with T2D. These immunophenotypic and hyperinflammatory changes may contribute to increased voracity ofCOVID-19 in T2D. These findings allow precise identification of T2D patients with severeCOVID-19 as well as provide evidence that the type 1 interferon pathway may be an actionable therapeutic target for future studies.
C1 [Alzaid, Fawaz; Julla, Jean-Baptiste; Diedisheim, Marc; Potier, Charline; Potier, Louis; Velho, Gilberto; Roussel, Ronan; Riveline, Jean-Pierre; Dalmas, Elise; Venteclef, Nicolas; Gautier, Jean-Francois] Univ Paris, Sorbonne Univ, Cordeliers Res Ctr, INSERM,IMMEDIAB Lab, Paris, France.
   [Julla, Jean-Baptiste; Vidal-Trecan, Tiphaine; Riveline, Jean-Pierre; Gautier, Jean-Francois] Lariboisiere Hosp, AP HP, Dept Diabet, Clin Invest Ctr CIC 9504, Paris, France.
   [Diedisheim, Marc] Univ Paris, Dept Diabetol, Cochin Hosp, AP HP, Paris, France.
   [Potier, Louis; Roussel, Ronan] Hop Xavier Bichat, AP HP, Dept Diabetol Endocrinol & Nutr, Paris, France.
   [Gaborit, Benedicte] Aix Marseille Univ, C2VN, INRA, INSERM, Marseille, France.
   [Gaborit, Benedicte] Assistance Publ Hopitaux Marseille, Endocrinol Metab Dis & Nutr Dept, Marseille, France.
   [Manivet, Philippe] Univ Paris, Hop Lariboisiere, AP HP, Paris Diderot,Ctr Ressources Biol Biobank Lariboi, Paris, France.
   [Germain, Stephane] Paris Sci & Lettres PSL Res Univ, Coll France, Ctr Interdisciplinary Res Biol CIRB, CNRS,INSERM, Paris, France.
RP Alzaid, F; Gautier, JF (corresponding author), Univ Paris, Sorbonne Univ, Cordeliers Res Ctr, INSERM,IMMEDIAB Lab, Paris, France.; Gautier, JF (corresponding author), Lariboisiere Hosp, AP HP, Dept Diabet, Clin Invest Ctr CIC 9504, Paris, France.
EM fawaz.alzaid@gmail.com; jean-francois.gautier@aphp.fr
RI GABORIT, Benedicte/AAK-3842-2020
OI GABORIT, Benedicte/0000-0002-4180-158X
FU French National Agency of Research (ANR)French National Research Agency
   (ANR) [ANR-19-CE14-0005]; European Foundation for the Study of Diabetes
   (EFSD)/Lilly grant (Characterisation of monocyte metabolism and
   bioenergetic responses in type-2 diabetes and risk of cardiovascular
   disease); French National Agency of Research (GLUTADIAB); European
   Foundation for Diabetes (EFSD); European UnionEuropean Union (EU)
   [ERC-EpiFAT 725790]; Assistance Publique des Hopitaux de Paris (ANR-DGOS
   Project AngioSafe T2D); French National Agency of Research (ANGIOSAFE);
   ASSERADT (a non-profit patient association); French and European
   Foundation for Diabetes (SFD); French and European Foundation for
   Diabetes (EFSD)
FX F.A. was supported by grants from the French National Agency of Research
   (ANR) for ANR MitoFLAME (ANR-19-CE14-0005) and the European Foundation
   for the Study of Diabetes (EFSD)/Lilly grant (Characterisation of
   monocyte metabolism and bioenergetic responses in type-2 diabetes and
   risk of cardiovascular disease). N.V. was supported by grants from the
   French National Agency of Research (GLUTADIAB and ANGIOSAFE), the
   European Foundation for Diabetes (EFSD) and the European Union H2020
   Framework (ERC-EpiFAT 725790). The human study was performed at the
   Clinical Investigation Centre (Groupe Hospitalier
   Saint-Louis/Lariboisiere, Paris) and was supported by Assistance
   Publique des Hopitaux de Paris (ANR-DGOS Project AngioSafe T2D; J.-F.G.,
   principal investigator) and ASSERADT (a non-profit patient association).
   E.D was supported by grants from the French and European Foundation for
   Diabetes (SFD and EFSD). The authors would like to thank Helene
   Fohrer-Ting of the Centre for Cytometry, Histology and Cellular Imaging
   (CHIC) core facility of the Cordeliers Research Centre (CRC), for her
   guidance, patience and support. The authors thank the Unite de Recherche
   Clinique of Lariboisiere/Fernand Widal (Pr Eric Vicaut & Dr Veronique
   Jouis); the Delegation a la Recherche Clinique de Paris-Ile de France;
   and the Direction de la Recherche Sante de Marseille for their
   administrative support. The authors also thank Nassima Haddadi, Djamila
   Bellili and Hanane Mersel for their technical support, and nurses and
   patients who accepted to be involved in these studies. The authors also
   thank Jagadeesh Bayry and Anupama Karnam for their generous gift of the
   IL-8 ELISA Kit.
CR Alzaid F, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88689
   Autissier P, 2010, J IMMUNOL METHODS, V360, P119, DOI 10.1016/j.jim.2010.06.017
   Coates BM, 2018, J IMMUNOL, V200, P2391, DOI 10.4049/jimmunol.1701543
   Codo AC, 2020, CELL METAB, V32, P437, DOI 10.1016/j.cmet.2020.07.007
   Corbin AL, 2019, BIORXIV, DOI [10.1101/601963, DOI 10.1101/601963]
   Dalmas E, 2015, NAT MED, V21, P610, DOI 10.1038/nm.3829
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Forbester JL, 2020, J VIROL, V94, DOI 10.1128/JVI.00121-20
   Friedrich K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01874
   Gruber C, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0335-0
   Hadjadj J., 2020, IMPAIRED TYPE 1 INTE, DOI [10.1101/2020.04.19.20068015, DOI 10.1101/2020.04.19.20068015]
   Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091
   Hijdra D, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00339
   Hoeve MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029443
   Jardine L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09913-4
   Julla Jean-Baptiste, 2019, Methods Mol Biol, V1951, P33, DOI 10.1007/978-1-4939-9130-3_3
   Kim D, 2017, CELL REP, V20, P832, DOI 10.1016/j.celrep.2017.06.088
   Koressaar T, 2007, BIOINFORMATICS, V23, P1289, DOI 10.1093/bioinformatics/btm091
   Koutsakos M, 2019, NAT IMMUNOL, V20, P613, DOI 10.1038/s41590-019-0320-6
   Laviada-Molina HA, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00514
   Melzer S, 2015, CYTOM PART B-CLIN CY, V88, P270, DOI 10.1002/cyto.b.21234
   Menart-Houtermans B, 2014, DIABETES CARE, V37, P2326, DOI 10.2337/dc14-0316
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Park Matthew D, 2020, Nat Rev Immunol, V20, P351, DOI 10.1038/s41577-020-0317-2
   R Core Team, 2013, R LANG ENV STAT COMP
   Rogacev KS, 2012, J AM COLL CARDIOL, V60, P1512, DOI 10.1016/j.jacc.2012.07.019
   Sanchez-Torres C, 2001, INT IMMUNOL, V13, P1571, DOI 10.1093/intimm/13.12.1571
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   van der Maaten L, 2008, J MACH LEARN RES, V9, P2579
   Vangeti S, 2019, J IMMUNOL, V202, P2069, DOI 10.4049/jimmunol.1801191
   Wang QM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz7086
   Wang ZZ, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108214
   Weiss M, 2015, P NATL ACAD SCI USA, V112, P11001, DOI 10.1073/pnas.1506254112
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang LS, 2012, J IMMUNOL, V189, P3741, DOI 10.4049/jimmunol.1201162
   Yu YRA, 2020, J IMMUNOL, V204, P1474, DOI 10.4049/jimmunol.1900239
   Zhang D., 2020, COVID 19 INFECT INDU, DOI [10.1101/2020.03.24, DOI 10.1101/2020.03.24.20042655, 10.1101/2020.03.24.20042655]
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 41
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD OCT 7
PY 2020
VL 12
IS 10
AR e13038
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OB3PU
UT WOS:000578385400008
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Hazariwala, V
   Hadid, H
   Kirsch, D
   Big, C
AF Hazariwala, Vikisha
   Hadid, Hind
   Kirsch, Denise
   Big, Cecilia
TI Spontaneous pneumomediastinum, pneumopericardium, pneumothorax and
   subcutaneous emphysema in patients with COVID-19 pneumonia, a case
   report
SO JOURNAL OF CARDIOTHORACIC SURGERY
LA English
DT Article
DE COVID-19 pneumonia; Spontaneous pneumomediastinum; Spontaneous
   pneumopericardium; Acute respiratory distress syndrome; Severe acute
   respiratory syndrome
ID CARDIOVASCULAR COMPLICATIONS; DISEASE; OBESITY
AB BackgroundSpontaneous pneumomediastinum unrelated to mechanical ventilation is a newly described complication of COVID-19 pneumonia. The objective of this case presentation is to highlight an important complication and to explore potential predisposing risk factors and possible underlying pathophysiology of this phenomenon.Case presentationWe present two patients with COVID-19 pneumonia complicated by spontaneous pneumomediastinum, pneumopericardium, pneumothorax and subcutaneous emphysema without positive pressure ventilation. Both patients had multiple comorbidities, received a combination of antibiotics, steroids and supportive oxygen therapy, and underwent routine laboratory workup. Both patients then developed spontaneous pneumomediastinum and ultimately required intubation and mechanical ventilation, which proved to be challenging to manage.ConclusionsSpontaneous pneumomediastinum is a serious complication of COVID-19 pneumonia, of which clinicians should be aware. Further studies are needed to determine risk factors and laboratory data predictive of development of spontaneous pneumomediastinum in COVID-19 pneumonia.
C1 [Hazariwala, Vikisha; Hadid, Hind; Kirsch, Denise; Big, Cecilia] Beaumont Hosp, Dearborn, MI 48124 USA.
RP Hazariwala, V (corresponding author), Beaumont Hosp, Dearborn, MI 48124 USA.
EM Vikisha.hazariwala@beaumont.org
CR Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Baudin F, 2016, RESP CARE, V61, P1305, DOI 10.4187/respcare.04452
   Carsana L, 2020, PULMONARY POSTMORTEM, V2020, P1
   Chauhan Z, 2019, CHEST, V156, p1875A, DOI 10.1016/j.chest.2019.08.1619
   Chu CM, 2004, EUR RESPIR J, V23, P802, DOI 10.1183/09031936.04.00096404
   Gross O, 2020, LANCET, V395, pE87, DOI 10.1016/S0140-6736(20)31041-2
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Haque AK, 2008, ARCH PATHOL LAB MED, V132, P1397, DOI 10.1043/1543-2165(2008)132[1397:PACCOO]2.0.CO;2
   Iyer VN, 2009, MAYO CLIN PROC, V84, P417, DOI 10.1016/S0025-6196(11)60560-0
   Kass DA, 2020, LANCET, V395, P1544, DOI 10.1016/S0140-6736(20)31024-2
   Korkmaz C, 2001, RHEUMATOLOGY, V40, P476, DOI 10.1093/rheumatology/40.4.476
   Liew MF, 2020, CRIT CARE, V24, DOI [10.1186/s13054-020-2814-x, 10.1186/s13054-020-2828-4]
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Sachdeva R, 2015, MED J DY PATIL U, V8, P344, DOI [10.4103/0975-2870.157082, DOI 10.4103/0975-2870.157082]
   SHENNIB HF, 1988, CHEST, V93, P1301, DOI 10.1378/chest.93.6.1301
   Vanzo V, 2013, J ATHL TRAINING, V48, P277, DOI 10.4085/1062-6050-48.1.11
   Wang J, 2020, KOREAN J RADIOL, V21, P627, DOI 10.3348/kjr.2020.0281
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhou CY, 2020, LANCET INFECT DIS, V20, P510, DOI 10.1016/S1473-3099(20)30156-0
   Zhu H, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01292-3
NR 20
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1749-8090
J9 J CARDIOTHORAC SURG
JI J. Cardiothorac. Surg.
PD OCT 7
PY 2020
VL 15
IS 1
AR 301
DI 10.1186/s13019-020-01308-7
PG 5
WC Cardiac & Cardiovascular Systems; Surgery
SC Cardiovascular System & Cardiology; Surgery
GA OB6BK
UT WOS:000578554000001
PM 33028398
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Douangamath, A
   Fearon, D
   Gehrtz, P
   Krojer, T
   Lukacik, P
   Owen, CD
   Resnick, E
   Strain-Damerell, C
   Aimon, A
   Abranyi-Balogh, P
   Brandao-Neto, J
   Carbery, A
   Davison, G
   Dias, A
   Downes, TD
   Dunnett, L
   Fairhead, M
   Firth, JD
   Jones, SP
   Keeley, A
   Keseru, GM
   Klein, HF
   Martin, MP
   Noble, MEM
   O'Brien, P
   Powell, A
   Reddi, RN
   Skyner, R
   Snee, M
   Waring, MJ
   Wild, C
   London, N
   von Delft, F
   Walsh, MA
AF Douangamath, Alice
   Fearon, Daren
   Gehrtz, Paul
   Krojer, Tobias
   Lukacik, Petra
   Owen, C. David
   Resnick, Efrat
   Strain-Damerell, Claire
   Aimon, Anthony
   Abranyi-Balogh, Peter
   Brandao-Neto, Jose
   Carbery, Anna
   Davison, Gemma
   Dias, Alexandre
   Downes, Thomas D.
   Dunnett, Louise
   Fairhead, Michael
   Firth, James D.
   Jones, S. Paul
   Keeley, Aaron
   Keserue, Gyoergy M.
   Klein, Hanna F.
   Martin, Mathew P.
   Noble, Martin E. M.
   O'Brien, Peter
   Powell, Ailsa
   Reddi, Rambabu N.
   Skyner, Rachael
   Snee, Matthew
   Waring, Michael J.
   Wild, Conor
   London, Nir
   von Delft, Frank
   Walsh, Martin A.
TI Crystallographic and electrophilic fragment screening of the SARS-CoV-2
   main protease
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CORONAVIRUS 3C-LIKE PROTEASE; INTERFERENCE COMPOUNDS PAINS; COVALENT
   INHIBITORS; DIMER INTERFACE; SARS-COV; DESIGN; DISCOVERY; INTEGRATION;
   PROTEINASE; LIBRARIES
AB COVID-19, caused by SARS-CoV-2, lacks effective therapeutics. Additionally, no antiviral drugs or vaccines were developed against the closely related coronavirus, SARS-CoV-1 or MERS-CoV, despite previous zoonotic outbreaks. To identify starting points for such therapeutics, we performed a large-scale screen of electrophile and non-covalent fragments through a combined mass spectrometry and X-ray approach against the SARS-CoV-2 main protease, one of two cysteine viral proteases essential for viral replication. Our crystallographic screen identified 71 hits that span the entire active site, as well as 3 hits at the dimer interface. These structures reveal routes to rapidly develop more potent inhibitors through merging of covalent and non-covalent fragment hits; one series of low-reactivity, tractable covalent fragments were progressed to discover improved binders. These combined hits offer unprecedented structural and reactivity information for on-going structure-based drug design against SARS-CoV-2 main protease.
C1 [Douangamath, Alice; Fearon, Daren; Lukacik, Petra; Owen, C. David; Strain-Damerell, Claire; Aimon, Anthony; Brandao-Neto, Jose; Carbery, Anna; Dias, Alexandre; Dunnett, Louise; Powell, Ailsa; Skyner, Rachael; Snee, Matthew; Wild, Conor; von Delft, Frank; Walsh, Martin A.] Diamond Light Source Ltd, Harwell Sci & Innovat Campus, Didcot OX11 0QX, Oxon, England.
   [Douangamath, Alice; Lukacik, Petra; Owen, C. David; Strain-Damerell, Claire; Aimon, Anthony; Brandao-Neto, Jose; Skyner, Rachael; von Delft, Frank; Walsh, Martin A.] Res Complex Harwell, Harwell Sci & Innovat Campus, Didcot OX11 0FA, Oxon, England.
   [Gehrtz, Paul; Resnick, Efrat; Reddi, Rambabu N.; London, Nir] Weizmann Inst Sci, Dept Organ Chem, IL-7610001 Rehovot, Israel.
   [Krojer, Tobias; Fairhead, Michael; von Delft, Frank] Univ Oxford, Struct Genom Consortium, Old Rd Campus, Headington OX3 7DQ, England.
   [Abranyi-Balogh, Peter] Res Ctr Nat Sci, Med Chem Res Grp, Magyar Tudosok Krt 2, H-1117 Budapest, Hungary.
   [Carbery, Anna] Univ Oxford, Dept Stat, Oxford OX1 3LB, England.
   [Davison, Gemma] Newcastle Univ, Canc Res UK Drug Discovery Unit, Newcastle Univ Ctr Canc, Chem,Sch Nat & Environm Sci, Bedson Bldg, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Downes, Thomas D.; Firth, James D.; Jones, S. Paul; Klein, Hanna F.; O'Brien, Peter] Univ York, Dept Chem, York YO10 5DD, N Yorkshire, England.
   [Martin, Mathew P.; Noble, Martin E. M.] Newcastle Univ, Canc Res UK Drug Discovery Unit, Ctr Canc, Sch Med, Paul OGorman Bldg,Framlington Pl, Newcastle Upon Tyne, Tyne & Wear, England.
   [von Delft, Frank] Univ Johannesburg, Dept Biochem, ZA-2006 Auckland Pk, South Africa.
RP von Delft, F; Walsh, MA (corresponding author), Diamond Light Source Ltd, Harwell Sci & Innovat Campus, Didcot OX11 0QX, Oxon, England.; von Delft, F; Walsh, MA (corresponding author), Res Complex Harwell, Harwell Sci & Innovat Campus, Didcot OX11 0FA, Oxon, England.; London, N (corresponding author), Weizmann Inst Sci, Dept Organ Chem, IL-7610001 Rehovot, Israel.; von Delft, F (corresponding author), Univ Oxford, Struct Genom Consortium, Old Rd Campus, Headington OX3 7DQ, England.; von Delft, F (corresponding author), Univ Johannesburg, Dept Biochem, ZA-2006 Auckland Pk, South Africa.
EM nir.london@weizmann.ac.il; frank.von-delft@diamond.ac.uk;
   martin.walsh@diamond.ac.uk
RI ; Abranyi-Balogh, Peter/B-9474-2013
OI Keeley, Aaron/0000-0002-3384-5945; Aimon, Anthony/0000-0002-9135-129X;
   Abranyi-Balogh, Peter/0000-0002-9284-5160; Fearon,
   Daren/0000-0003-3529-7863
FU Diamond MX group; AstraZenecaAstraZeneca; Astex Pharmaceuticals;
   LillyEli Lilly; PfizerPfizer; Vernalis; University of York; EU (Horizon
   2020 program, Marie Skodowska-Curie grant) [675899]; AbbVie [1097737];
   Bayer Pharma AG [1097737]; Boehringer IngelheimBoehringer Ingelheim
   [1097737]; Canada Foundation for InnovationCanada Foundation for
   InnovationCGIAR [1097737]; Eshelman Institute for Innovation [1097737];
   Genome CanadaGenome Canada [1097737]; Innovative Medicines Initiative
   (EU/EFPIA) [ULTRA-DD grant] [1097737, 115766]; JanssenJohnson & Johnson
   USAJanssen Biotech Inc [1097737]; Merck KGaA Darmstadt Germany
   [1097737]; MSD [1097737]; Novartis Pharma AG [1097737]; Ontario Ministry
   of Economic Development and Innovation [1097737]; PfizerPfizer
   [1097737]; Sao Paulo Research Foundation-FAPESPFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [1097737]; TakedaTakeda
   Pharmaceutical Company Ltd [1097737]; Wellcome [1097737, 106169/ZZ14/Z];
   Israel Science FoundationIsrael Science Foundation [2462/19]; Israel
   Cancer Research Fund; Israeli Ministry of Science Technology [3-14763];
   Moross Integrated Cancer Center; Barry Sherman institute for Medicinal
   Chemistry; Helen and Martin Kimmel Center for Molecular Design; Joel and
   Mady Dukler Fund for Cancer Research; Estate of Emile Mimran and Virgin
   JustGiving; George Schwartzman Fund; Foreign Commonwealth and
   Development Office (UK); Hungarian Science FoundationOrszagos Tudomanyos
   Kutatasi Alapprogramok (OTKA) [PD124598]
FX We thank all the staff of Diamond Light Source for providing support and
   encouragement which allowed us to carry out this work during the
   COVID-19 lockdown. We also thank the Diamond MX group for their support
   and expertise, in particular David AragAo, Ralf Flaig, Dave Hall,
   Katherine McAuley and Mark Williams. We thank Clemens Vonrhein of
   GlobalPhasing for independent validation of the initially deposited
   models. We are grateful to AstraZeneca, Astex Pharmaceuticals, Lilly,
   Pfizer and Vernalis, University of York (T.D.D. and S.P.J.) and the EU
   (Horizon 2020 program, Marie Skodowska-Curie grant agreement No. 675899,
   FRAGNET) (AK and HFK) for support. The SGC is a registered charity
   (number 1097737) that receives funds from AbbVie, Bayer Pharma AG,
   Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman
   Institute for Innovation, Genome Canada, Innovative Medicines Initiative
   (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA Darmstadt
   Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic
   Development and Innovation, Pfizer, Sao Paulo Research
   Foundation-FAPESP, Takeda, and Wellcome [106169/ZZ14/Z]. N.L. is the
   incumbent of the Alan and Laraine Fischer Career Development Chair. N.L.
   would like to acknowledge funding from the Israel Science Foundation
   (grant no. 2462/19), The Israel Cancer Research Fund, the Israeli
   Ministry of Science Technology (grant no. 3-14763), the Moross
   Integrated Cancer Center and the Barry Sherman institute for Medicinal
   Chemistry. This research was supported by Nelson P. Sirotsky. N.L. is
   also supported by the Helen and Martin Kimmel Center for Molecular
   Design, Joel and Mady Dukler Fund for Cancer Research, the Estate of
   Emile Mimran and Virgin JustGiving, and the George Schwartzman Fund. FvD
   and GMK are grateful for the support of the Foreign Commonwealth and
   Development Office (UK). ABP received a Postdoctoral Fellowship from the
   Hungarian Science Foundation (PD124598).
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Arrowsmith CH, 2015, NAT CHEM BIOL, V11, P536, DOI 10.1038/nchembio.1867
   Backus KM, 2016, NATURE, V534, P570, DOI 10.1038/nature18002
   Baell JB, 2018, ACS CHEM BIOL, V13, P36, DOI 10.1021/acschembio.7b00903
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Baillie TA, 2016, ANGEW CHEM INT EDIT, V55, P13408, DOI 10.1002/anie.201601091
   Barrila J, 2006, BIOCHEMISTRY-US, V45, P14908, DOI 10.1021/bi0616302
   Bauer RA, 2015, DRUG DISCOV TODAY, V20, P1061, DOI 10.1016/j.drudis.2015.05.005
   Bauman JD, 2016, IUCRJ, V3, P51, DOI 10.1107/S2052252515021259
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   BREDENBEEK PJ, 1990, NUCLEIC ACIDS RES, V18, P1825, DOI 10.1093/nar/18.7.1825
   Chen S, 2008, J BIOCHEM, V143, P525, DOI 10.1093/jb/mvm246
   Chou CY, 2004, BIOCHEMISTRY-US, V43, P14958, DOI 10.1021/bi0490237
   Collins PM, 2017, ACTA CRYSTALLOGR D, V73, P246, DOI 10.1107/S205979831700331X
   Cox OB, 2016, CHEM SCI, V7, P2322, DOI 10.1039/c5sc03115j
   De Cesco S, 2017, EUR J MED CHEM, V138, P96, DOI 10.1016/j.ejmech.2017.06.019
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Downes TD, 2020, CHEM-EUR J, V26, P8969, DOI 10.1002/chem.202001123
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Erlanson DA, 2016, NAT REV DRUG DISCOV, V15, P605, DOI 10.1038/nrd.2016.109
   Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061
   Ferla MP, 2020, BIOINFORMATICS, V36, P3268, DOI 10.1093/bioinformatics/btaa104
   Fuller N, 2016, DRUG DISCOV TODAY, V21, P1272, DOI 10.1016/j.drudis.2016.04.023
   Ghosh AK, 2007, BIOORG MED CHEM LETT, V17, P5876, DOI 10.1016/j.bmcl.2007.08.031
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Helliwell JR, 2015, IUCRJ, V2, P283, DOI 10.1107/S205225251402795X
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hsu WC, 2005, J BIOL CHEM, V280, P22741, DOI 10.1074/jbc.M502556200
   Hu TC, 2009, VIROLOGY, V388, P324, DOI 10.1016/j.virol.2009.03.034
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Johansson H, 2019, J AM CHEM SOC, V141, P2703, DOI 10.1021/jacs.8b13193
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P133, DOI 10.1107/S0907444909047374
   Kathman SG, 2015, J AM CHEM SOC, V137, P12442, DOI 10.1021/jacs.5b06839
   Kathman SG, 2014, J MED CHEM, V57, P4969, DOI 10.1021/jm500345q
   Keegan R, 2015, ACTA CRYSTALLOGR A, V71, pS18, DOI 10.1107/S2053273315099702
   Keeley A, 2019, MEDCHEMCOMM, V10, P263, DOI 10.1039/c8md00327k
   Keeley A, 2018, ARCH PHARM, V351, DOI 10.1002/ardp.201800184
   Krojer T, 2017, ACTA CRYSTALLOGR D, V73, P267, DOI 10.1107/S2059798316020234
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, pE79, DOI 10.1016/S1473-3099(20)30251-6
   Kuhn B, 2019, J MED CHEM, V62, P10441, DOI 10.1021/acs.jmedchem.9b01545
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lee WH, 2011, J INHERIT METAB DIS, V34, P565, DOI 10.1007/s10545-011-9334-4
   Long F, 2017, ACTA CRYSTALLOGR D, V73, P112, DOI 10.1107/S2059798317000067
   Mons E, 2019, J AM CHEM SOC, V141, P3507, DOI 10.1021/jacs.8b11027
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Nonoo RH, 2012, CHEMMEDCHEM, V7, P2082, DOI 10.1002/cmdc.201200404
   O'Reilly M, 2019, DRUG DISCOV TODAY, V24, P1081, DOI 10.1016/j.drudis.2019.03.009
   Pearce NM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15123
   Pearce NM, 2017, ACTA CRYSTALLOGR D, V73, P256, DOI 10.1107/S2059798317003412
   Resnick E, 2019, J AM CHEM SOC, V141, P8951, DOI 10.1021/jacs.9b02822
   Severson WE, 2007, J BIOMOL SCREEN, V12, P33, DOI 10.1177/1087057106296688
   Shi JH, 2006, FEBS J, V273, P1035, DOI 10.1111/j.1742-4658.2006.05130.x
   Singh J, 2011, NAT REV DRUG DISCOV, V10, P307, DOI 10.1038/nrd3410
   Sirois S, 2005, COMPUT BIOL CHEM, V29, P55, DOI 10.1016/j.compbiolchem.2004.11.003
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Thomas SE, 2019, PHILOS T R SOC A, V377, DOI 10.1098/rsta.2018.0422
   Verschueren KHG, 2008, CHEM BIOL, V15, P597, DOI 10.1016/j.chembiol.2008.04.011
   Vonrhein C, 2011, ACTA CRYSTALLOGR D, V67, P293, DOI 10.1107/S0907444911007773
   Winter G, 2019, ACTA CRYSTALLOGR D, V75, P242, DOI 10.1107/S2059798319003528
   Winter G, 2018, ACTA CRYSTALLOGR D, V74, P85, DOI 10.1107/S2059798317017235
   Winter G, 2013, ACTA CRYSTALLOGR D, V69, P1260, DOI 10.1107/S0907444913015308
   Winter G, 2011, METHODS, V55, P81, DOI 10.1016/j.ymeth.2011.06.010
   Wood DJ, 2019, J MED CHEM, V62, P3741, DOI 10.1021/acs.jmedchem.9b00304
   Wright N. D., 2019, LOW COST SEMIAUTOMAT, DOI [10.1101/2019.12.20.875674v1, DOI 10.1101/2019.12.20.875674V1]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhang TH, 2019, CELL CHEM BIOL, V26, P1486, DOI 10.1016/j.chembiol.2019.09.012
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 74
TC 4
Z9 4
U1 5
U2 5
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 7
PY 2020
VL 11
IS 1
AR 5047
DI 10.1038/s41467-020-18709-w
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NZ6VY
UT WOS:000577244600013
PM 33028810
OA DOAJ Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Agrawal, H
   Das, N
   Nathani, S
   Saha, S
   Saini, S
   Kakar, SS
   Roy, P
AF Agrawal, Himanshu
   Das, Neeladrisingha
   Nathani, Sandip
   Saha, Sarama
   Saini, Surendra
   Kakar, Sham S.
   Roy, Partha
TI An Assessment on Impact of COVID-19 Infection in a Gender Specific
   Manner
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article; Early Access
DE Severe acute respiratory syndrome (SARS); Coronavirus-2; Spike protein;
   COVID-19; Transmembrane protease serine-2; Gender; Mesenchymal stem
   cells
ID RESPIRATORY SYNDROME CORONAVIRUS; ACUTE LUNG INJURY; SEX-DIFFERENCES;
   IMMUNE-RESPONSE; B-CELL; EPIDEMIOLOGIC ANALYSIS; CONVALESCENT PLASMA;
   ESTROGEN-RECEPTORS; GENE-EXPRESSION; INFLUENZA-VIRUS
AB Coronavirus disease 2019 (COVID-19) is caused by novel coronavirus Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first time reported in December 2019 in Wuhan, China and thereafter quickly spread across the globe. Till September 19, 2020, COVID-19 has spread to 216 countries and territories. Severe infection of SARS-CoV-2 cause extreme increase in inflammatory chemokines and cytokines that may lead to multi-organ damage and respiratory failure. Currently, no specific treatment and authorized vaccines are available for its treatment. Renin angiotensin system holds a promising role in human physiological system specifically in regulation of blood pressure and electrolyte and fluid balance. SARS-CoV-2 interacts with Renin angiotensin system by utilizing angiotensin-converting enzyme 2 (ACE2) as a receptor for its cellular entry. This interaction hampers the protective action of ACE2 in the cells and causes injuries to organs due to persistent angiotensin II (Ang-II) level. Patients with certain comorbidities like hypertension, diabetes, and cardiovascular disease are under the high risk of COVID-19 infection and mortality. Moreover, evidence obtained from several reports also suggests higher susceptibility of male patients for COVID-19 mortality and other acute viral infections compared to females. Analysis of severe acute respiratory syndrome coronavirus (SARS) and Middle East respiratory syndrome coronavirus (MERS) epidemiological data also indicate a gender-based preference in disease consequences. The current review addresses the possible mechanisms responsible for higher COVID-19 mortality among male patients. The major underlying aspects that was looked into includes smoking, genetic factors, and the impact of reproductive hormones on immune systems and inflammatory responses. Detailed investigations of this gender disparity could provide insight into the development of patient tailored therapeutic approach which would be helpful in improving the poor outcomes of COVID-19.
   Graphical abstract
C1 [Agrawal, Himanshu; Das, Neeladrisingha; Nathani, Sandip; Saini, Surendra; Roy, Partha] Indian Inst Technol Roorkee, Mol Endocrinol Lab, Dept Biotechnol, Roorkee 247667, Uttarakhand, India.
   [Saha, Sarama] All India Inst Med Sci, Dept Biochem, Rishikesh, India.
   [Kakar, Sham S.] Univ Louisville, James Graham Brown Canc Ctr, Dept Physiol, Louisville, KY 40292 USA.
RP Roy, P (corresponding author), Indian Inst Technol Roorkee, Mol Endocrinol Lab, Dept Biotechnol, Roorkee 247667, Uttarakhand, India.
EM himanshu.bt@sric.iitr.ac.in; ndas@bt.iitr.ac.in; snathani@bt.iitr.ac.in;
   sarama.bchem@aiimsrishikesh.edu.in; sursaini123@gmail.com;
   sham.kakar@louisville.edu; partha.roy@bt.iitr.ac.in
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [T32HL134644]
FX Part of this research was funded by NIH T32HL134644 (SSK).
CR Alghamdi IG, 2014, INT J GEN MED, V7, P417, DOI 10.2147/IJGM.S67061
   [Anonymous], 2020, REPORT WHO CHINA JOI
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Atal S, 2020, PHARM MED, V34, P223, DOI 10.1007/s40290-020-00342-z
   Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364
   Bale TL, 2015, NAT NEUROSCI, V18, P1413, DOI 10.1038/nn.4112
   Barakat TS, 2012, DEVELOPMENT, V139, P2085, DOI 10.1242/dev.069328
   Barel E, 2018, J NEUROSCI RES, V96, P1388, DOI 10.1002/jnr.24259
   Bereshchenko O, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01332
   Bhasin S, 2018, J CLIN ENDOCR METAB, V103, P1715, DOI 10.1210/jc.2018-00229
   Bianchi VE, 2019, J ENDOCR SOC, V3, P91, DOI 10.1210/js.2018-00186
   Bleibtreu A, 2020, MED MALADIES INFECT, V50, P243, DOI 10.1016/j.medmal.2019.10.004
   Bornstein SR, 2019, MOL PSYCHIATR, V24, P2, DOI 10.1038/s41380-018-0244-9
   Bose Subhasish, 2020, J Clin Med Res, V12, P329, DOI 10.14740/jocmr4201
   Bouman A, 2004, AM J REPROD IMMUNOL, V52, P19, DOI 10.1111/j.1600-0897.2004.00177.x
   Bouman A, 2005, HUM REPROD UPDATE, V11, P411, DOI 10.1093/humupd/dmi008
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479
   Chan MCW, 2016, P NATL ACAD SCI USA, V113, P3621, DOI 10.1073/pnas.1601911113
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Choi WS, 2016, INFECT CHEMOTHER, V48, P118, DOI 10.3947/ic.2016.48.2.118
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Cortuk M, 2017, EXP THER MED, V13, P1431, DOI 10.3892/etm.2017.4153
   Cunningham M, 2011, CLIN REV ALLERG IMMU, V40, P66, DOI 10.1007/s12016-010-8203-5
   Cutolo M, 2006, ANN NY ACAD SCI, V1089, P538, DOI 10.1196/annals.1386.043
   D'Ardes D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21083003
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dijkman R, 2012, J GEN VIROL, V93, P1924, DOI 10.1099/vir.0.043919-0
   Ecochard R, 2017, FERTIL STERIL, V108, P175, DOI 10.1016/j.fertnstert.2017.05.012
   Eggan K, 2000, SCIENCE, V290, P1578, DOI 10.1126/science.290.5496.1578
   Elgendy I. Y., 2020, INT J CARDIOLOGY
   Faas M, 2000, FERTIL STERIL, V74, P1008, DOI 10.1016/S0015-0282(00)01553-3
   FOLSTAD I, 1992, AM NAT, V139, P603, DOI 10.1086/285346
   Foo YZ, 2017, BIOL REV, V92, P551, DOI 10.1111/brv.12243
   Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111
   Gagliardi MC, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0276-1
   Gao KY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04552-5
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gheblawi M., 2020, CIRC RES, V126, P1456
   Gheblawi M., 2020, NAT MED, V11, P875
   Ghosh S, 2017, J IMMUNOL, V198, P1782, DOI 10.4049/jimmunol.1601166
   Giltay EJ, 2000, J CLIN ENDOCR METAB, V85, P1648, DOI 10.1210/jc.85.4.1648
   Global health 50/50, 2020, COVID 19 SEX DISAGGR
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Gold SM, 2009, PROG BRAIN RES, V175, P239, DOI 10.1016/S0079-6123(09)17516-7
   Goren A, 2020, J COSMET DERMATOL-US, V19, P1545, DOI 10.1111/jocd.13443
   Grabek A, 2019, CELL STEM CELL, V25, P290, DOI 10.1016/j.stem.2019.04.012
   Grimaldi CM, 2006, J IMMUNOL, V176, P2703, DOI 10.4049/jimmunol.176.5.2703
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Halim NSS, 2019, STEM CELL REV REP, V15, P112, DOI 10.1007/s12015-018-9844-7
   Hammadi A, 2008, NITRIC OXIDE-BIOL CH, V19, P138, DOI 10.1016/j.niox.2008.04.017
   Hannah R, 2013, SMOKING
   Hepworth MR, 2010, EUR J IMMUNOL, V40, P406, DOI 10.1002/eji.200939589
   Hermankova B, 2019, STEM CELL REV REP, V15, P880, DOI 10.1007/s12015-019-09908-0
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hudspeth K, 2012, BLOOD, V119, P4013, DOI 10.1182/blood-2011-11-390153
   Ito T, 2005, SPRINGER SEMIN IMMUN, V26, P221, DOI 10.1007/s00281-004-0180-4
   Jiang C, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/123845
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Kadkhoda K, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00344-20
   Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056
   Karpuzoglu E, 2007, MOL IMMUNOL, V44, P1808, DOI 10.1016/j.molimm.2006.08.005
   Kaufman JM, 2005, ENDOCR REV, V26, P833, DOI 10.1210/er.2004-0013
   Kelly DM, 2013, ENDOCR RES, V38, P125, DOI 10.3109/07435800.2012.735307
   Khatri M, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0774-8
   Kissick HT, 2014, P NATL ACAD SCI USA, V111, P9887, DOI 10.1073/pnas.1402468111
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Klein SL, 2000, NEUROSCI BIOBEHAV R, V24, P627, DOI 10.1016/S0149-7634(00)00027-0
   Koh YT, 2009, PROSTATE, V69, P571, DOI 10.1002/pros.20906
   Kovats S, 2015, CELL IMMUNOL, V294, P63, DOI 10.1016/j.cellimm.2015.01.018
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kvetnansky R, 1995, ANN NY ACAD SCI, V771, P131, DOI 10.1111/j.1749-6632.1995.tb44676.x
   Kwaa AKR, 2019, J VIROL, V93, DOI 10.1128/JVI.01541-18
   Lau EHY, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-50
   Lawrence H, 2019, J INFECTION, V79, P401, DOI 10.1016/j.jinf.2019.08.014
   Lee JS, 2010, INFECT CHEMOTHER, V42, P391, DOI 10.3947/ic.2010.42.6.391
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   Li Y, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0395-z
   Liang B, 2020, CLIN REMISSION CRITI, V2, pv1
   Libert C, 2010, NAT REV IMMUNOL, V10, P594, DOI 10.1038/nri2815
   Lin BY, 1999, CANCER RES, V59, P4180
   Ling LM, 2010, CLIN INFECT DIS, V50, P963, DOI 10.1086/651083
   Liu Meng-Yuan, 2020, Chronic Dis Transl Med, V6, P98, DOI 10.1016/j.cdtm.2020.05.003
   Liu P, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008421
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Maggio M, 2005, J Endocrinol Invest, V28, P116
   Malha L, 2020, KIDNEY INT REP, V5, P563, DOI 10.1016/j.ekir.2020.03.024
   Mallick B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007837
   Mariniello K, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00772
   Markle JG, 2014, TRENDS IMMUNOL, V35, P97, DOI 10.1016/j.it.2013.10.006
   Mattioli Anna Vittoria, 2020, Future Cardiol, V16, P539, DOI 10.2217/fca-2020-0055
   Mauvais-Jarvis F, 2020, ENDOCRINOLOGY, V161, DOI 10.1210/endocr/bqaa127
   McMurray RW, 2001, PATHOBIOLOGY, V69, P44, DOI 10.1159/000048757
   Mendes D, 2019, STEM CELL REV REP, V15, P463, DOI 10.1007/s12015-019-09897-0
   Mikkonen L, 2010, MOL CELL ENDOCRINOL, V317, P14, DOI 10.1016/j.mce.2009.12.022
   Mizgerd JP, 2006, PLOS MED, V3, P155, DOI 10.1371/journal.pmed.0030076
   Mo R, 2005, J IMMUNOL, V174, P6023, DOI 10.4049/jimmunol.174.10.6023
   Mohamad NV, 2019, AGING MALE, V22, P129, DOI 10.1080/13685538.2018.1482487
   Nguyen LT, 2003, J NEUROL SCI, V209, P93, DOI 10.1016/S0022-510X(03)00004-2
   Nicola W G, 1997, Boll Chim Farm, V136, P39
   Oyola MG, 2017, STRESS, V20, P476, DOI 10.1080/10253890.2017.1369523
   Panchanathan R, 2013, INT IMMUNOL, V25, P521, DOI 10.1093/intimm/dxt015
   Panchanathan R, 2009, J IMMUNOL, V183, P7031, DOI 10.4049/jimmunol.0802665
   Park JK, 2018, KOREAN J FAM MED, V39, P90, DOI 10.4082/kjfm.2018.39.2.90
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Qiu FF, 2017, ONCOTARGET, V8, P268, DOI 10.18632/oncotarget.13613
   Quakkelaar ED, 2012, ADV IMMUNOL, V114, P77, DOI 10.1016/B978-0-12-396548-6.00004-4
   Rahimi Z, 2014, J RES MED SCI, V19, P1090
   Rossi GP, 2020, ELIFE, V9, DOI 10.7554/eLife.57278
   Roved J, 2017, HORM BEHAV, V88, P95, DOI 10.1016/j.yhbeh.2016.11.017
   Ruhle A, 2019, STEM CELL REV REP, V15, P356, DOI 10.1007/s12015-019-09886-3
   Sabo-Attwood T, 2004, MOL CELL ENDOCRINOL, V218, P107, DOI 10.1016/j.mce.2003.12.007
   Sanders J. M., 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.6019, DOI 10.1001/JAMA.2020.6019.ADVANCE]
   Schlenker EH, 2006, BRAIN RES, V1123, P89, DOI 10.1016/j.brainres.2006.09.035
   Schroeder M., 2020, MAJORITY MALE PATIEN
   Schurz H, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-018-0185-z
   Seki M, 2010, J IMMUNOL, V184, P1410, DOI 10.4049/jimmunol.0901709
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shen H, 2010, J MOL CELL BIOL, V2, P284, DOI 10.1093/jmcb/mjq023
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Smith JC, 2020, DEV CELL, V53, P514, DOI 10.1016/j.devcel.2020.05.012
   Snyder PJ, 2016, NEW ENGL J MED, V374, P611, DOI 10.1056/NEJMoa1506119
   Sodhi CP, 2018, AM J PHYSIOL-LUNG C, V314, pL17, DOI 10.1152/ajplung.00498.2016
   Souyris M, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8855
   Steenblock C, 2020, MOL PSYCHIATR, V25, P1611, DOI 10.1038/s41380-020-0758-9
   Steenblock C, 2018, P NATL ACAD SCI USA, V115, P12997, DOI 10.1073/pnas.1814072115
   Taneja V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01931
   Tang YJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01708
   Tornwall J, 1999, J Gend Specif Med, V2, P33
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Wambier CG, 2020, J AM ACAD DERMATOL, V83, P308, DOI 10.1016/j.jaad.2020.04.032
   Wang C, 2014, CLIN INFECT DIS, V58, P1095, DOI 10.1093/cid/ciu053
   Wang C, 2011, DIABETES CARE, V34, P1669, DOI 10.2337/dc10-2339
   Wei X., 2020, ARXIV200313547
   Wichmann MW, 1996, ARCH SURG-CHICAGO, V131, P1186
   Wu FCW, 2008, J CLIN ENDOCR METAB, V93, P2737, DOI 10.1210/jc.2007-1972
   Zeng FF, 2020, J MED VIROL, V92, P2050, DOI 10.1002/jmv.25989
   Zhang JC, 2020, BRAIN BEHAV IMMUN, V87, P59, DOI 10.1016/j.bbi.2020.04.046
   Zhou G, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5203-5
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 150
TC 1
Z9 1
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
DI 10.1007/s12015-020-10048-z
EA OCT 2020
PG 19
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA NZ8MP
UT WOS:000577356000001
PM 33029768
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Woodruff, MC
   Ramonell, RP
   Nguyen, DC
   Cashman, KS
   Saini, AS
   Haddad, NS
   Ley, AM
   Kyu, S
   Howell, JC
   Ozturk, T
   Lee, SY
   Suryadevara, N
   Case, JB
   Bugrovsky, R
   Chen, WR
   Estrada, J
   Morrison-Porter, A
   Derrico, A
   Anam, FA
   Sharma, M
   Wu, HM
   Le, SN
   Jenks, SA
   Tipton, CM
   Staitieh, B
   Daiss, JL
   Ghosn, E
   Diamond, MS
   Carnahan, RH
   Crowe, JE
   Hu, WT
   Lee, FEH
   Sanz, I
AF Woodruff, Matthew C.
   Ramonell, Richard P.
   Nguyen, Doan C.
   Cashman, Kevin S.
   Saini, Ankur Singh
   Haddad, Natalie S.
   Ley, Ariel M.
   Kyu, Shuya
   Howell, J. Christina
   Ozturk, Tugba
   Lee, Saeyun
   Suryadevara, Naveenchandra
   Case, James Brett
   Bugrovsky, Regina
   Chen, Weirong
   Estrada, Jacob
   Morrison-Porter, Andrea
   Derrico, Andrew
   Anam, Fabliha A.
   Sharma, Monika
   Wu, Henry M.
   Le, Sang N.
   Jenks, Scott A.
   Tipton, Christopher M.
   Staitieh, Bashar
   Daiss, John L.
   Ghosn, Eliver
   Diamond, Michael S.
   Carnahan, Robert H.
   Crowe, James E., Jr.
   Hu, William T.
   Lee, F. Eun-Hyung
   Sanz, Ignacio
TI Extrafollicular B cell responses correlate with neutralizing antibodies
   and morbidity in COVID-19
SO NATURE IMMUNOLOGY
LA English
DT Article
ID DENGUE VIRUS-INFECTION; SOMATIC HYPERMUTATION; EFFECTOR; POPULATION;
   ACTIVATION
AB A wide spectrum of clinical manifestations has become a hallmark of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 pandemic, although the immunological underpinnings of diverse disease outcomes remain to be defined. We performed detailed characterization of B cell responses through high-dimensional flow cytometry to reveal substantial heterogeneity in both effector and immature populations. More notably, critically ill patients displayed hallmarks of extrafollicular B cell activation and shared B cell repertoire features previously described in autoimmune settings. Extrafollicular activation correlated strongly with large antibody-secreting cell expansion and early production of high concentrations of SARS-CoV-2-specific neutralizing antibodies. Yet, these patients had severe disease with elevated inflammatory biomarkers, multiorgan failure and death. Overall, these findings strongly suggest a pathogenic role for immune activation in subsets of patients with COVID-19. Our study provides further evidence that targeted immunomodulatory therapy may be beneficial in specific patient subpopulations and can be informed by careful immune profiling.
   Sanz and colleagues examine B cell subsets in a cohort of patients with COVID-19. Severely ill patients have higher frequencies of activated extrafollicular T-bet(+)B cells that form antibody-secreting cells, the majority of which express germline sequences and are reminiscent of antibody responses observed in patients with systemic lupus erythematosus during flares.
C1 [Woodruff, Matthew C.; Cashman, Kevin S.; Saini, Ankur Singh; Lee, Saeyun; Bugrovsky, Regina; Chen, Weirong; Estrada, Jacob; Anam, Fabliha A.; Sharma, Monika; Le, Sang N.; Jenks, Scott A.; Tipton, Christopher M.; Ghosn, Eliver; Sanz, Ignacio] Emory Univ, Dept Med, Div Rheumatol, Lowance Ctr Human Immunol, Atlanta, GA 30322 USA.
   [Woodruff, Matthew C.; Jenks, Scott A.; Tipton, Christopher M.; Sanz, Ignacio] Emory Univ, Emory Autoimmun Ctr Excellence, Atlanta, GA 30322 USA.
   [Ramonell, Richard P.; Nguyen, Doan C.; Haddad, Natalie S.; Ley, Ariel M.; Kyu, Shuya; Lee, Saeyun; Morrison-Porter, Andrea; Derrico, Andrew; Le, Sang N.; Staitieh, Bashar; Lee, F. Eun-Hyung] Emory Univ, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA 30322 USA.
   [Haddad, Natalie S.; Daiss, John L.] MicroB Plex, Atlanta, GA USA.
   [Howell, J. Christina; Ozturk, Tugba; Hu, William T.] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA.
   [Suryadevara, Naveenchandra; Carnahan, Robert H.; Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Nashville, TN USA.
   [Case, James Brett; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Wu, Henry M.] Emory Univ, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA.
   [Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
   [Diamond, Michael S.] Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO USA.
   [Carnahan, Robert H.; Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
RP Sanz, I (corresponding author), Emory Univ, Dept Med, Div Rheumatol, Lowance Ctr Human Immunol, Atlanta, GA 30322 USA.; Sanz, I (corresponding author), Emory Univ, Emory Autoimmun Ctr Excellence, Atlanta, GA 30322 USA.; Lee, FEH (corresponding author), Emory Univ, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA 30322 USA.
EM f.e.lee@emory.edu; ignacio.sanz@emory.edu
RI Saini, Ankur/AAF-8507-2019
OI Saini, Ankur/0000-0003-3963-6586; Woodruff, Matthew/0000-0002-5252-7539;
   Cashman, Kevin/0000-0002-2907-9264; Nguyen, Doan/0000-0002-5389-6731;
   Ramonell, Richard/0000-0002-2385-0636
FU National Institutes of Health grantsUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [UL TR000424,
   R01-AG054991, U19-AI110483, P01-AI125180-01, R37-AI049660, 1R01AI121252,
   1U01AI141993, R01 AI127828, T32-HL116271-07]; HHS/NIAID/NIH contract
   [75N93019C00074]; Defense Advanced Research Project AgencyUnited States
   Department of DefenseDefense Advanced Research Projects Agency (DARPA)
   [HR001117S0019]; Dolly Parton COVID-19 Research Fund at Vanderbilt; Fast
   Grants Award
FX We thank all of the healthy individuals, patients and their families for
   their selfless participation in this study. We also thank the nurses,
   staff and providers in the 71 ICU in Emory University Hospital Midtown
   and the 2E ICU in Emory Saint Joseph's Hospital without whom our work
   would not have been possible. We acknowledge the contributions of D.
   Murphy, W. Bender, C. Swenson, C. Coleman, M. Horwath, D. Alter, V.
   Engineer, M. Hernandez and J. Varghese and their time and expertise.
   Extensive efforts by the Pediatric/Winship Flow Cytometry Core and the
   Flow Cytometry Core at the Emory Vaccine Center made this work possible.
   This work was supported by National Institutes of Health grants UL
   TR000424 (Emory Library IT), R01-AG054991 (to W.T.H.), U19-AI110483
   Emory Autoimmunity Center of Excellence (to I.S.), P01-AI125180-01 (to
   I.S. and F.E.-H.L.), R37-AI049660 (to I.S.), 1R01AI121252 (to
   F.E.-H.L.), 1U01AI141993 (to F.E.-H.L.), R01 AI127828 (to J.E.C. and
   M.S.D.) and T32-HL116271-07 (to R.P.R.); HHS/NIAID/NIH contract
   75N93019C00074 (to J.E.C.); Defense Advanced Research Project Agency
   grant HR001117S0019 (to J.E.C.); the Dolly Parton COVID-19 Research Fund
   at Vanderbilt; and a Fast Grants Award (to J.E.C.)
CR Allman D, 2019, IMMUNOL REV, V288, P128, DOI 10.1111/imr.12754
   Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314
   Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603
   Chan OTM, 1999, J EXP MED, V189, P1639, DOI 10.1084/jem.189.10.1639
   Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   COVID-19 Treatment Guidelines, 2020, COVID 19 TREATM GUID
   Di Niro R, 2015, IMMUNITY, V43, P120, DOI 10.1016/j.immuni.2015.06.013
   Fang YT, 2010, MOL IMMUNOL, V47, P1000, DOI 10.1016/j.molimm.2009.11.019
   Gaya M, 2018, CELL, V172, P517, DOI 10.1016/j.cell.2017.11.036
   Gustave CA, 2018, J IMMUNOL, V200, P2418, DOI 10.4049/jimmunol.1700929
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harrison C, 2020, NAT BIOTECHNOL, V38, P905, DOI 10.1038/s41587-020-0634-9
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Hoepel W., 2020, ANTI SARS COV 2 IGG, DOI [DOI 10.1101/2020.07.13.190140, 10.1101/2020.07.13.190140]
   Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2021436, DOI 10.1056/NEJM0A2021436]
   Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179
   Ingraham NE, 2020, LANCET RESP MED, V8, P544, DOI 10.1016/S2213-2600(20)30226-5
   Jenks SA, 2019, IMMUNOL REV, V288, P136, DOI 10.1111/imr.12741
   Jenks SA, 2018, IMMUNITY, V49, P725, DOI 10.1016/j.immuni.2018.08.015
   Kaneko N, 2020, CELL, V183, P143, DOI 10.1016/j.cell.2020.08.025
   Kiprov D, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102856
   Kwissa M, 2014, CELL HOST MICROBE, V16, P115, DOI 10.1016/j.chom.2014.06.001
   Lam JH, 2020, VIRAL IMMUNOL, V33, P294, DOI 10.1089/vim.2019.0207
   Lee FEH, 2011, J IMMUNOL, V186, P5514, DOI 10.4049/jimmunol.1002932
   Leon Beatriz, 2012, Infectious Disorders - Drug Targets, V12, P213
   Liu LH, 2020, NATURE, DOI 10.1038/s41586-020-2571-7
   Liu Y, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1438-2
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Lucas C, 2020, NATURE, DOI 10.1038/s41586-020-2588-y
   Lund FE, 2010, NAT REV IMMUNOL, V10, P236, DOI 10.1038/nri2729
   Manni M, 2018, NAT IMMUNOL, V19, P407, DOI 10.1038/s41590-018-0056-8
   Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Menard LC, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87310
   Pioli PD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02768
   Reed JH, 2016, J EXP MED, V213, P1255, DOI 10.1084/jem.20151978
   Rodriguez-Bayona B, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3042
   Rubtsov AV, 2015, J IMMUNOL, V195, P71, DOI 10.4049/jimmunol.1500055
   Rubtsova K, 2017, J CLIN INVEST, V127, P1392, DOI 10.1172/JCI91250
   Rubtsova K, 2015, J IMMUNOL, V195, P1933, DOI 10.4049/jimmunol.1501209
   Sanz I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02458
   Scharer CD, 2019, NAT IMMUNOL, V20, P1071, DOI 10.1038/s41590-019-0419-9
   Sellam J, 2011, ARTHRITIS RHEUM-US, V63, P3692, DOI 10.1002/art.30599
   Stone SL, 2019, IMMUNITY, V50, P1172, DOI 10.1016/j.immuni.2019.04.004
   Sun BQ, 2020, EMERG MICROBES INFEC, V9, P940, DOI 10.1080/22221751.2020.1762515
   Suthar Mehul S, 2020, Cell Rep Med, V1, P100040, DOI 10.1016/j.xcrm.2020.100040
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tang YJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01708
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tipton CM, 2018, IMMUNOL REV, V284, P120, DOI 10.1111/imr.12660
   Tipton CM, 2015, NAT IMMUNOL, V16, P755, DOI 10.1038/ni.3175
   Dang VD, 2014, CURR OPIN IMMUNOL, V28, P77, DOI 10.1016/j.coi.2014.02.009
   Wang S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03750-7
   Wec AZ, 2020, P NATL ACAD SCI USA, V117, P6675, DOI 10.1073/pnas.1921388117
   William J, 2002, SCIENCE, V297, P2066, DOI 10.1126/science.1073924
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
   Xiao M, 2020, ARTHRITIS RHEUMATOL, V72, P1998, DOI 10.1002/art.41425
   Yang J, 2019, NEUROINFORMATICS, V17, P185, DOI 10.1007/s12021-018-9392-y
   Yang XY, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-020-06936-w
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zeng Q, 2014, J CLIN INVEST, V124, P1052, DOI 10.1172/JCI70084
   Zhang WQ, 2019, P NATL ACAD SCI USA, V116, P18550, DOI 10.1073/pnas.1901340116
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zost SJ, 2020, NATURE, DOI 10.1038/s41586-020-2548-6
   Zumaquero E, 2019, ELIFE, V8, DOI 10.7554/eLife.41641
NR 65
TC 5
Z9 5
U1 7
U2 7
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1529-2908
EI 1529-2916
J9 NAT IMMUNOL
JI Nat. Immunol.
PD DEC
PY 2020
VL 21
IS 12
BP 1506
EP +
DI 10.1038/s41590-020-00814-z
EA OCT 2020
PG 17
WC Immunology
SC Immunology
GA OT0EL
UT WOS:000576667200001
PM 33028979
OA Green Accepted, Bronze
DA 2021-01-01
ER

PT J
AU Bagheri, M
   Niavarani, A
AF Bagheri, Milad
   Niavarani, Ahmadreza
TI Molecular dynamics analysis predicts ritonavir and naloxegol strongly
   block the SARS-CoV-2 spike protein-hACE2 binding
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; spike protein; ACE2; ritonavir; naloxegol
ID RECEPTOR; GROMACS
AB The rapid emergence of COVID-19 pandemics has posed humans particularly vulnerable to the novel SARS-CoV-2 virus. Sincede novodrug discovery is both expensive and time-consuming, drug repurposing approaches are believed to be of particular help. The SARS-CoV-2 spike (S) protein is known to attach human angiotensin-converting enzyme-2 (hACE2) through its receptor-binding domain (RBD). We screened 1930 FDA-approved ligands for the selection of optimal ones blocking this interaction. Virtual screening predicted top 25 ligands docking to any of the reported binding sites. After exclusion of those ligands which were unsuitable for systemic use, the remaining 69 RBD-ligand complexes were screened based on the masking capacity of the amino acid residues engaged in RBD-hACE2 interaction, excluding 47 RBD-ligand complexes. A short molecular dynamics (MD) simulation analysis identified 11 globally stable complexes with the lowest RMSD (root-mean-square deviation). Next, a moderately long MD analysis revealed those six RBD-ligand complexes with the lowest RMSD variation, as a measure of global stability. Finally, a long MD analysis revealed two select candidate ligands, including ritonavir and naloxegol, highly stabilizing those key residues engaged in RBD-hACE2 interaction. A similar MD analysis of a few antiviral drugs which are under clinical trials or approved for COVID-19 treatment showed them inferior to both select ligands in terms of stabilizing the RBD globally and locally at binding sites. Because of the crucial role of the S protein in virus virulence, our results highly propose ritonavir and naloxegol as the potentially helpful therapeutics against COVID-19, mandating appropriate clinical trials. Communicated by Ramaswamy H. Sarma
C1 [Bagheri, Milad; Niavarani, Ahmadreza] Univ Tehran Med Sci, Digest Oncol Res Ctr DORC, Digest Dis Res Inst DDRI, Tehran, Iran.
RP Niavarani, A (corresponding author), Univ Tehran Med Sci, Digest Oncol Res Ctr DORC, Digest Dis Res Inst DDRI, Tehran, Iran.
EM Niavarani@tums.ac.ir
RI ; Niavarani, Ahmadreza/B-9946-2017
OI bagheri, milad/0000-0002-4117-4192; Niavarani,
   Ahmadreza/0000-0001-7773-6778
FU Digestive Disease Research Institute (DDRI), Tehran University of
   Medical Sciences (TUMS)
FX This study was funded by a grant from Digestive Disease Research
   Institute (DDRI), Tehran University of Medical Sciences (TUMS).
CR Beigel JH, 2020, NEW ENGLAND J MED
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Dodda LS, 2017, NUCLEIC ACIDS RES, V45, pW331, DOI 10.1093/nar/gkx312
   Douguet D., 2010, NUCL ACIDS RES S2, V38, pW615
   Douguet D, 2018, ACS MED CHEM LETT, V9, P204, DOI 10.1021/acsmedchemlett.7b00462
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P116, DOI 10.1021/ct700200b
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Sayad B, 2020, ARCH MED RES, V51, P577, DOI 10.1016/j.arcmed.2020.04.018
   Schoergenhofer C, 2020, ANN INTERN MED, V173, P670, DOI 10.7326/M20-1550
   Shelton MJ, 2003, ANTIMICROB AGENTS CH, V47, P1694, DOI 10.1128/AAC.47.5.1694-1699.2003
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wrapp D, 2020, CELL, V181, P1436, DOI 10.1016/j.cell.2020.05.047
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 35
TC 0
Z9 0
U1 7
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1830854
EA OCT 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NY2NG
UT WOS:000576232200001
PM 33030105
OA Bronze
DA 2021-01-01
ER

PT J
AU Motiwale, M
   Yadav, NS
   Kumar, S
   Kushwaha, T
   Choudhir, G
   Sharma, S
   Singour, PK
AF Motiwale, Mohit
   Yadav, Neetu Singh
   Kumar, Sushil
   Kushwaha, Tushar
   Choudhir, Gourav
   Sharma, Supriya
   Singour, Pradeep Kumar
TI Finding potent inhibitors for COVID-19 main protease (M-pro): an in
   silico approach using SARS-CoV-3CL protease inhibitors for combating
   CORONA
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Coronavirus; SARS-CoV-2; COVID-19; main protease (M-pro); molecular
   modeling; virtual screening; molecular dynamics simulation
ID LINEAR CONSTRAINT SOLVER; MOLECULAR-DYNAMICS; DOCKING; GROMACS;
   OPTIMIZATION; DESIGN; LINCS; TOOL
AB SARS-CoV-2 is liable for the worldwide coronavirus disease (COVID-19) exigency. This pandemic created the need for all viable treatment strategies available in the market. In this scenario, computer-aided drug design techniques can be efficiently applied for the quick identification of promising drug repurposing candidates. In the current study, we applied the molecular docking approach in conjugation with molecular dynamics (MD) simulations to find out potential inhibitors against M(pro)of SARS-CoV-2 from previously reported SARS-3CL protease inhibitors. Our results showed thatN-substituted isatin derivatives and pyrazolone compounds could be used as a potent inhibitor and may possess an anti-viral activity against SARS-CoV-2. However, further experimental investigation and validation of the selected hits are required to find out their suitability for clinical trials.
C1 [Motiwale, Mohit; Sharma, Supriya; Singour, Pradeep Kumar] VNS Grp Inst, Dept Pharmaceut Chem, Computat & Synthet Chem Lab, Fac Pharm, Bhopal 462044, India.
   [Yadav, Neetu Singh] Indian Inst Technol, Dept Biochem Engn & Biotechnol, New Delhi, India.
   [Kumar, Sushil] Shaheed Mangal Pandey Govt PG Coll, Dept Bot, Meerut, Uttar Pradesh, India.
   [Kushwaha, Tushar] All India Inst Med Sci, Dept Biophys, New Delhi, India.
   [Choudhir, Gourav] CCS Univ, Dept Bot, Meerut, Uttar Pradesh, India.
RP Singour, PK (corresponding author), VNS Grp Inst, Dept Pharmaceut Chem, Computat & Synthet Chem Lab, Fac Pharm, Bhopal 462044, India.
EM psingour@gmail.com
RI Motiwale, Mohit/ABD-2142-2020
OI Motiwale, Mohit/0000-0001-6608-1374
CR Abraham MJ, 2011, J COMPUT CHEM, V32, P2031, DOI 10.1002/jcc.21773
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Brooijmans N, 2003, ANNU REV BIOPH BIOM, V32, P335, DOI 10.1146/annurev.biophys.32.110601.142532
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chakraborty I, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138882
   Chen L, 2005, HERPETOL J, V15, p23l, DOI DOI https://doi.org/10.1016/j.bmcl.2005.04.027
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chien MC, 2020, J PROTEOME RES, V19, P4690, DOI 10.1021/acs.jproteome.0c00392
   Contini A, 2020, VIRTUAL SCREENING FD, DOI [10.26434/chemrxiv.11847381, DOI 10.26434/CHEMRXIV.11847381]
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   David CC, 2014, METHODS MOL BIOL, V1084, P193, DOI 10.1007/978-1-62703-658-0_11
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   GUPTA MK, 2020, J BIOMOL STRUCT 0413, DOI DOI https://doi.org/10.1080/07391102.2020.1751300
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   Halperin I, 2002, PROTEINS, V47, P409, DOI 10.1002/prot.10115
   Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P116, DOI 10.1021/ct700200b
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hussain S, 2005, J VIROL, V79, P5288, DOI 10.1128/JVI.79.9.5288-5295.2005
   Jimenez-Alberto A, 2020, COMPUT BIOL CHEM, V88, DOI 10.1016/j.compbiolchem.2020.107325
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Konno H, 2017, BIOORG MED CHEM LETT, V27, P2746, DOI 10.1016/j.bmcl.2017.04.056
   KUMAR A, 2020, J BIOMOL STRUCT 0602, DOI DOI https://doi.org/10.1080/07391102.2020.1772112
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   LONDHE AM, 2019, MOLECULES, V24, DOI DOI https://doi.org/10.3390/molecules24224085
   Macchiagodena M, 2020, CHEM PHYS LETT, V750, DOI 10.1016/j.cplett.2020.137489
   Maestro, 2020, SCHROD REL 2020 2 MA
   Marinho EM, 2020, MICROB PATHOGENESIS, V148, DOI 10.1016/j.micpath.2020.104365
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Ohnishi K, 2019, BIOORGAN MED CHEM, V27, P425, DOI 10.1016/j.bmc.2018.12.019
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Ramajayam R, 2010, BIOORGAN MED CHEM, V18, P7849, DOI 10.1016/j.bmc.2010.09.050
   Ramajayam R, 2010, BIOORG MED CHEM LETT, V20, P3569, DOI 10.1016/j.bmcl.2010.04.118
   Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Singh Sweta, 2020, F1000Res, V9, P502, DOI 10.12688/f1000research.24218.1
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Sisay M, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104779
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   YUKI K, 2020, CLIN IMMUNOL, V215, DOI DOI https://doi.org/10.1016/j.clim.2020.108427
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 59
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1829501
EA OCT 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NY2KR
UT WOS:000576225500001
PM 33030102
OA Bronze
DA 2021-01-01
ER

PT J
AU Endres, P
   Rosovsky, R
   Zhao, S
   Krinsky, S
   Percy, S
   Kamal, O
   Roberts, RJ
   Lopez, N
   Sise, ME
   Steele, DJR
   Lundquist, AL
   Rhee, EP
   Hibbert, KA
   Hardin, CC
   Mc Causland, FR
   Czarnecki, PG
   Mutter, W
   Tolkoff-Rubin, N
   Allegretti, AS
AF Endres, Paul
   Rosovsky, Rachel
   Zhao, Sophia
   Krinsky, Scott
   Percy, Shananssa
   Kamal, Omer
   Roberts, Russel J.
   Lopez, Natasha
   Sise, Meghan E.
   Steele, David J. R.
   Lundquist, Andrew L.
   Rhee, Eugene P.
   Hibbert, Kathryn A.
   Hardin, C. Corey
   Mc Causland, Finnian R.
   Czarnecki, Peter G.
   Mutter, Walter
   Tolkoff-Rubin, Nina
   Allegretti, Andrew S.
TI Filter clotting with continuous renal replacement therapy in COVID-19
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article; Early Access
DE Continuous venovenous hemofiltration; CRRT; CVVH; Acute kidney injury;
   End stage renal disease; Hemodialysis; Hemofiltration; Coronavirus;
   SARS; SARS-CoV2; Hypercoagulability; Thrombosis
ID TIME
AB Coronavirus disease 2019 (COVID-19) appears to be associated with increased arterial and venous thromboembolic disease. These presumed abnormalities in hemostasis have been associated with filter clotting during continuous renal replacement therapy (CRRT). We aimed to characterize the burden of CRRT filter clotting in COVID-19 infection and to describe a CRRT anticoagulation protocol that used anti-factor Xa levels for systemic heparin dosing. Multi-center study of consecutive patients with COVID-19 receiving CRRT. Primary outcome was CRRT filter loss. Sixty-five patients were analyzed, including 17 using an anti-factor Xa protocol to guide systemic heparin dosing. Fifty-four out of 65 patients (83%) lost at least one filter. Median first filter survival time was 6.5 [2.5, 33.5] h. There was no difference in first or second filter loss between the anti-Xa protocol and standard of care anticoagulation groups, however fewer patients lost their third filter in the protocolized group (55% vs. 93%) resulting in a longer median third filter survival time (24 [15.1, 54.2] vs. 17.3 [9.5, 35.1] h, p = 0.04). The rate of CRRT filter loss is high in COVID-19 infection. An anticoagulation protocol using systemic unfractionated heparin, dosed by anti-factor Xa levels is reasonable approach to anticoagulation in this population.
C1 [Endres, Paul; Zhao, Sophia; Krinsky, Scott; Percy, Shananssa; Sise, Meghan E.; Steele, David J. R.; Lundquist, Andrew L.; Rhee, Eugene P.; Tolkoff-Rubin, Nina; Allegretti, Andrew S.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, 55 Fruit St,GRB 1008, Boston, MA 02114 USA.
   [Rosovsky, Rachel] Massachusetts Gen Hosp, Dept Med, Div Hematol, Boston, MA 02114 USA.
   [Kamal, Omer; Mc Causland, Finnian R.; Czarnecki, Peter G.] Brigham & Womens Hosp, Dept Med, Div Renal Med, 75 Francis St, Boston, MA 02115 USA.
   [Roberts, Russel J.; Lopez, Natasha] Massachusetts Gen Hosp, Dept Pharm, Boston, MA 02114 USA.
   [Hibbert, Kathryn A.; Hardin, C. Corey] Massachusetts Gen Hosp, Dept Med, Div Pulm & Crit Care, Boston, MA 02114 USA.
   [Mutter, Walter] Newton Wellesley Hosp, Dept Med, Div Nephrol, Newton, MA USA.
RP Allegretti, AS (corresponding author), Massachusetts Gen Hosp, Dept Med, Div Nephrol, 55 Fruit St,GRB 1008, Boston, MA 02114 USA.
EM aallegretti@mgh.harvard.edu
OI Endres, Paul/0000-0002-8574-1312
FU American Heart AssociationAmerican Heart Association [18CDA34110131];
   National Heart, Lung and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [RO1-AI138999-01,
   UO1-HL123022-06]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [K23DK102511,
   R03DK122240, U01DK096189]; Astra-ZenecaAstraZeneca; BMSBristol-Myers
   Squibb; JanssenJohnson & Johnson USAJanssen Biotech Inc; National
   Institute of Diabetes and Digestive and Kidney DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [K08DK123400]
FX ASA is supported by American Heart Association Award 18CDA34110131. KAH
   is supported by the National Heart, Lung and Blood Institute
   (RO1-AI138999-01, UO1-HL123022-06). FRM is supported by NIH grants
   K23DK102511, R03DK122240, and U01DK096189. CH reports research funding
   from Astra-Zeneca. RR reports institutional research funding from BMS,
   Janssen. PGC is supported by the National Institute of Diabetes and
   Digestive and Kidney Diseases (K08DK123400). ASA reports advisory board
   fees from Mallinckrodt Pharmaceuticals. DJRS reports consulting fees
   from HealthReveal and Blackstone Life Sciences. RR reports institutional
   research support from BMS, Janssen and advisory/consulting fees from
   BMS, Janssen, Portola, and Dova. PGC reports advisory/consulting fees
   from Reata and Alexion.
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bai M, 2015, INTENS CARE MED, V41, P2098, DOI 10.1007/s00134-015-4099-0
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Div Nephrology, 2020, J AM SOC NEPHROL, V31, P1371, DOI 10.1681/ASN.2020040520
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Klok FA, 2020, THROMB RES, V191, P154
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Richardson S, 2020, JAMA-J AM MED ASSOC, DOI [10.1016/S0140-6736(20)30566-3, DOI 10.1016/S0140-6736(20)30566-3]
   Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x
   Tolwani A, 2012, NEW ENGL J MED, V367, P2505, DOI 10.1056/NEJMct1206045
   Uchino S, 2003, INTENS CARE MED, V29, P575, DOI 10.1007/s00134-003-1672-8
   Vandiver JW, 2012, PHARMACOTHERAPY, V32, P546, DOI 10.1002/j.1875-9114.2011.01049.x
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang ZH, 2012, ASAIO J, V58, P46, DOI 10.1097/MAT.0b013e31823fdf20
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 17
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
DI 10.1007/s11239-020-02301-6
EA OCT 2020
PG 5
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA NY2HF
UT WOS:000576216500001
PM 33026569
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kumar, P
   Sah, AK
   Tripathi, G
   Kashyap, A
   Tripathi, A
   Rao, RS
   Mishra, PC
   Mallick, K
   Husain, A
   Kashyap, MK
AF Kumar, Pravindra
   Sah, Ashok Kumar
   Tripathi, Greesham
   Kashyap, Anjali
   Tripathi, Avantika
   Rao, Rashmi
   Mishra, Prabhu C.
   Mallick, Koustav
   Husain, Amjad
   Kashyap, Manoj Kumar
TI Role of ACE2 receptor and the landscape of treatment options from
   convalescent plasma therapy to the drug repurposing in COVID-19
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article; Early Access
DE Cytokine storm syndrome; ARDS; Rheumatoid arthritis; Herd immunity;
   Vertical transmission; Vaccine nationalism
ID DIPEPTIDYL PEPTIDASE IV; MESENCHYMAL STEM-CELLS; VIRUS-INFECTION;
   CHLOROQUINE; CORONAVIRUS; INHIBITOR; FAVIPIRAVIR; COMBINATION;
   BARICITINIB; REMDESIVIR
AB Since the first case reports in Wuhan, China, the SARS-CoV-2 has caused a pandemic and took lives of > 8,35,000 people globally. This single-stranded RNA virus uses Angiotensin-converting enzyme 2 (ACE2) as a receptor for entry into the host cell. Overexpression of ACE2 is mainly observed in hypertensive, diabetic and heart patients that make them prone to SARS-CoV-2 infection. Mitigations strategies were opted globally by the governments to minimize transmission of SARS-CoV-2 via the implementation of social distancing norms, wearing the facemasks, and spreading awareness using digital platforms. The lack of an approved drug treatment regimen, and non-availability of a vaccine, collectively posed a challenge for mankind to fight against the SARS-CoV-2 pandemic. In this scenario, repurposing of existing drugs and old treatment options like convalescent plasma therapy can be one of the potential alternatives to treat the disease. The drug repurposing provides a selection of drugs based on the scientific rationale and with a shorter cycle of clinical trials, while plasma isolated from COVID-19 recovered patients can be a good source of neutralizing antibody to provide passive immunity. In this review, we provide in-depth analysis on these two approaches currently opted all around the world to treat COVID-19 patients. For this, we used "Boolean Operators" such as AND, OR & NOT to search relevant research articles/reviews from the PUBMED for the repurposed drugs and the convalescent plasma in the COVID-19 treatment. The repurposed drugs like Chloroquine and Hydroxychloroquine, Tenofovir, Remdesivir, Ribavirin, Darunavir, Oseltamivir, Arbidol (Umifenovir), Favipiravir, Anakinra, and Baricitinib are already being used in clinical trials to treat the COVID-19 patients. These drugs have been approved for a different indication and belong to a diverse category such as anti-malarial/anti-parasitic, anti-retroviral/anti-viral, anti-cancer, or against rheumatoid arthritis. Although, the vaccine would be an ideal option for providing active immunity against the SARS-CoV-2, but considering the current situation, drug repurposing and convalescent plasma therapy and repurposed drugs are the most viable option against SARS-CoV-2.
C1 [Kumar, Pravindra; Rao, Rashmi] Glocal Univ, Sch Life & Allied Hlth Sci, Saharanpur, UP, India.
   [Sah, Ashok Kumar] Amity Univ Haryana, Dept Med Lab Technol, Amity Med Sch, Gurugram, Haryana, India.
   [Tripathi, Greesham; Tripathi, Avantika; Mishra, Prabhu C.; Kashyap, Manoj Kumar] Amity Univ Haryana, Amity Stem Cell Inst, Amity Med Sch, Gurugram 122413, Haryana, India.
   [Kashyap, Anjali] Thapar Inst Engn & Technol, Dept Biotechnol, Patiala, Punjab, India.
   [Mallick, Koustav] Inst Liver & Biliary Sci, Natl Liver Dis Biobank, New Delhi, India.
   [Husain, Amjad] Indian Inst Sci Educ & Res, Ctr Sci & Soc, Bhopal, India.
   [Husain, Amjad] Indian Inst Sci Educ & Res, Innovat & Incubat Ctr Entrepreneurship IICE, Bhopal, India.
RP Kashyap, MK (corresponding author), Amity Univ Haryana, Amity Stem Cell Inst, Amity Med Sch, Gurugram 122413, Haryana, India.
EM mkkashyap@ggn.amity.edu
OI Kashyap, Manoj/0000-0002-3064-8452
FU Science and Engineering Research Board (SERB), Department of Science and
   Technology, Government of IndiaDepartment of Science & Technology
   (India)Science Engineering Research Board (SERB), India
   [TAR/2018/001054]
FX MKK is the recipient of the TARE fellowship (Grant #TAR/2018/001054)
   from the Science and Engineering Research Board (SERB), Department of
   Science and Technology, Government of India.
CR Adachi J, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r80
   Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Andersen PI, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100964
   Angelini J, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10071002
   Berardi A, 2020, INT J PHARMACEUT, V584, DOI 10.1016/j.ijpharm.2020.119431
   Best JH, 2020, RHEUMATOL THER, V7, P345, DOI 10.1007/s40744-020-00201-y
   Biot C, 2006, J MED CHEM, V49, P2845, DOI 10.1021/jm0601856
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   Cao JZ, 2015, ANTIVIR RES, V114, P1, DOI 10.1016/j.antiviral.2014.11.010
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen IS, 2018, J PHYSIOL-LONDON, V596, P1833, DOI 10.1113/JP275236
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Collado-Borrell R, 2020, J MED INTERNET RES, V22, DOI 10.2196/20334
   Coomes EA, 2020, J ANTIMICROB CHEMOTH, V75, P2013, DOI 10.1093/jac/dkaa171
   Coote K, 2009, J PHARMACOL EXP THER, V329, P764, DOI 10.1124/jpet.108.148155
   Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   Dalan R, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108216
   Dazzi F, 2007, CURR OPIN ONCOL, V19, P650, DOI 10.1097/CCO.0b013e3282f0e116
   De Clercq E, 2002, BBA-MOL BASIS DIS, V1587, P258, DOI 10.1016/S0925-4439(02)00089-3
   de Oliveira JT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121590
   de Souza GA, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-r72
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Elli EM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01186
   Emori T, 2020, EUR J PHARMACOL, V882, DOI 10.1016/j.ejphar.2020.173238
   Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600
   FDA, APPR DRUG PROD KAL L
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Fridman JS, 2010, J IMMUNOL, V184, P5298, DOI 10.4049/jimmunol.0902819
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Fu CZ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01671-5
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gibson PG, 2020, MED J AUSTRALIA, V213, P54, DOI 10.5694/mja2.50674
   Giwa Al, 2020, Emerg Med Pract, V22, P1
   Golchin A, 2019, CURR STEM CELL RES T, V14, P22, DOI 10.2174/1574888X13666180913123424
   Graves PR, 2002, MOL PHARMACOL, V62, P1364, DOI 10.1124/mol.62.6.1364
   Gray KA, 2013, NUCLEIC ACIDS RES, V41, pD545, DOI 10.1093/nar/gks1066
   Guo XC, 2019, CHEM RES TOXICOL, V32, P1791, DOI 10.1021/acs.chemrestox.9b00141
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Iwaki-Egawa S, 1998, J BIOCHEM, V124, P428, DOI 10.1093/oxfordjournals.jbchem.a022130
   Kahn Jeffrey S, 2005, Pediatr Infect Dis J, V24, pS223, DOI 10.1097/01.inf.0000188166.17324.60
   Kashyap MK, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0435-x
   Khalili JS, 2020, J MED VIROL, V92, P740, DOI 10.1002/jmv.25798
   Khan A, 2006, J PROTEOME RES, V5, P2824, DOI 10.1021/pr060305y
   Kulkarni P, 2020, INFLUENZA OTHER RESP, V14, P601, DOI 10.1111/irv.12746
   Kulkarni R, 2020, INFECTION, DOI 10.1007/s15010-020-01493-6
   Kumar V, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1775704, 10.1080/07391102.2020.1772108]
   Kuriya B, 2017, THER ADV MUSCULOSKEL, V9, P37, DOI 10.1177/1759720X16687481
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li D, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2122-y
   Liang B, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021429
   Liu J, 2020, J ALLERGY CLIN IMMUN, V146, P325, DOI 10.1016/j.jaci.2020.05.021
   Liu Z, 2020, INFECT DIS MODEL, V5, P323, DOI 10.1016/j.idm.2020.03.003
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   MacIntyre CR, 2020, LANCET, V395, P1950, DOI 10.1016/S0140-6736(20)31183-1
   Mariano VJ, 2018, CARDIOL REV, V26, P321, DOI 10.1097/CRD.0000000000000204
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   Marson P, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102847
   McDermott CV, 2020, J HOSP INFECT, V105, P397, DOI 10.1016/j.jhin.2020.04.024
   McEvoy GK, 2003, AHFS DRUG INFORM 200
   Mesa RA, 2010, IDRUGS, V13, P394
   Ming LC, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/19796
   Moreira A, 2017, J MOL ENDOCRINOL, V59, pR109, DOI 10.1530/JME-17-0117
   Muller O, 2020, DEUT MED WOCHENSCHR, V145, P670, DOI 10.1055/a-1162-1987
   Ng Kimberly E, 2019, P T, V44, P9
   O'Hanlon R, 2019, ACS INFECT DIS, V5, P1779, DOI 10.1021/acsinfecdis.9b00230
   Oestereich L, 2014, ANTIVIR RES, V105, P17, DOI 10.1016/j.antiviral.2014.02.014
   Ono H, 2019, YAKUGAKU ZASSHI, V139, P767, DOI 10.1248/yakushi.18-00191
   Oscanoa TJ, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106078
   Ozma Mahdi Asghari, 2020, Infez Med, V28, P153
   Pardanani A, 2015, JAMA ONCOL, V1, P643, DOI 10.1001/jamaoncol.2015.1590
   Paskas S, 2019, INVEST NEW DRUG, V37, P1014, DOI 10.1007/s10637-019-00733-3
   Perotti Cesare, 2020, Haematologica, DOI 10.3324/haematol.2020.261784
   Pilch B, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-r40
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   RAJ K, 2020, VIRUSDISEASE 0420, V151, P424, DOI DOI 10.1007/s13337-020-00580-4
   Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012
   Rao R, 2019, PROTEOM CLIN APPL, V13, DOI 10.1002/prca.201900006
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Santos C, 2017, MMWR-MORBID MORTAL W, V66, P23, DOI 10.15585/mmwr.mm6608a5
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Sedo A, 2003, PHYSIOL RES, V52, P367
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Teixeira da Silva Jaime A, 2020, Med J Armed Forces India, V76, P236, DOI 10.1016/j.mjafi.2020.04.006
   Tirupathi Raghavendra, 2020, Infez Med, V28, P57
   Torres T, 2020, AM J CLIN DERMATOL, V21, P307, DOI 10.1007/s40257-020-00514-2
   Tungekar A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30579-3
   Uno Y, 2020, INTERN EMERG MED, V15, P1577, DOI 10.1007/s11739-020-02345-9
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   West R, 2020, NAT HUM BEHAV, DOI 10.1038/s41562-020-0887-9
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Yamauchi J, 2001, PANCREATOLOGY, V1, P662, DOI 10.1159/000055878
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yang H Y, 2020, Zhonghua Yu Fang Yi Xue Za Zhi, V54, P608, DOI 10.3760/cma.j.cn112150-20200227-00196
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Yehudai D, 2019, HAEMATOLOGICA, V104, P963, DOI 10.3324/haematol.2018.195172
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhang JN, 2020, CURR MED SCI, V40, P480, DOI 10.1007/s11596-020-2203-3
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 121
TC 1
Z9 1
U1 11
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
DI 10.1007/s11010-020-03924-2
EA OCT 2020
PG 22
WC Cell Biology
SC Cell Biology
GA NY0OE
UT WOS:000576098500001
PM 33029696
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yuan, SF
   Wang, RM
   Chan, JFW
   Zhang, AJX
   Cheng, TF
   Chik, KKH
   Ye, ZW
   Wang, SY
   Lee, ACY
   Jin, LJ
   Li, HY
   Jin, DY
   Yuen, KY
   Sun, HZ
AF Yuan, Shuofeng
   Wang, Runming
   Chan, Jasper Fuk-Woo
   Zhang, Anna Jinxia
   Cheng, Tianfan
   Chik, Kenn Ka-Heng
   Ye, Zi-Wei
   Wang, Suyu
   Lee, Andrew Chak-Yiu
   Jin, Lijian
   Li, Hongyan
   Jin, Dong-Yan
   Yuen, Kwok-Yung
   Sun, Hongzhe
TI Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication
   and relieves virus-associated pneumonia in Syrian hamsters
SO NATURE MICROBIOLOGY
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS; INHIBITOR; HELICASE; BINDING
AB Drug used to treatHelicobacter pyloriinfection reduces SARS-CoV-2 viral loads in lungs and alleviates virus-associated pneumonia in a golden Syrian hamster model.
   SARS-CoV-2 is causing a pandemic of COVID-19, with high infectivity and significant mortality(1). Currently, therapeutic options for COVID-19 are limited. Historically, metal compounds have found use as antimicrobial agents, but their antiviral activities have rarely been explored. Here, we test a set of metallodrugs and related compounds, and identify ranitidine bismuth citrate, a commonly used drug for the treatment ofHelicobacter pyloriinfection, as a potent anti-SARS-CoV-2 agent, both in vitro and in vivo. Ranitidine bismuth citrate exhibited low cytotoxicity and protected SARS-CoV-2-infected cells with a high selectivity index of 975. Importantly, ranitidine bismuth citrate suppressed SARS-CoV-2 replication, leading to decreased viral loads in both upper and lower respiratory tracts, and relieved virus-associated pneumonia in a golden Syrian hamster model. In vitro studies showed that ranitidine bismuth citrate and its related compounds exhibited inhibition towards both the ATPase (IC50 = 0.69 mu M) and DNA-unwinding (IC50 = 0.70 mu M) activities of the SARS-CoV-2 helicase via an irreversible displacement of zinc(ii) ions from the enzyme by bismuth(iii) ions. Our findings highlight viral helicase as a druggable target and the clinical potential of bismuth(iii) drugs or other metallodrugs for the treatment of SARS-CoV-2 infection.
C1 [Yuan, Shuofeng; Chan, Jasper Fuk-Woo; Zhang, Anna Jinxia; Chik, Kenn Ka-Heng; Ye, Zi-Wei; Lee, Andrew Chak-Yiu; Yuen, Kwok-Yung] Univ Hong Kong, State Key Lab Emerging Infect Dis, Carol Yu Ctr Infect, Dept Microbiol,Li Ka Shing Fac Med,Pokfulam, Hong Kong, Peoples R China.
   [Wang, Runming; Wang, Suyu; Li, Hongyan; Sun, Hongzhe] Univ Hong Kong, State Key Lab Synthet Chem, CAS HKU Joint Lab Metall Hlth & Environm, Dept Chem,Pokfulam, Hong Kong, Peoples R China.
   [Chan, Jasper Fuk-Woo; Yuen, Kwok-Yung] Univ Hong Kong, Shenzhen Hosp, Dept Clin Microbiol & Infect Control, Shenzhen, Guangdong, Peoples R China.
   [Chan, Jasper Fuk-Woo; Cheng, Tianfan; Jin, Lijian] Univ Hong Kong, Fac Dent, Pokfulam, Hong Kong, Peoples R China.
   [Jin, Dong-Yan] Univ Hong Kong, Li Ka Shing Fac Med, Sch Biomed Sci, Pokfulam, Hong Kong, Peoples R China.
RP Yuen, KY (corresponding author), Univ Hong Kong, State Key Lab Emerging Infect Dis, Carol Yu Ctr Infect, Dept Microbiol,Li Ka Shing Fac Med,Pokfulam, Hong Kong, Peoples R China.; Sun, HZ (corresponding author), Univ Hong Kong, State Key Lab Synthet Chem, CAS HKU Joint Lab Metall Hlth & Environm, Dept Chem,Pokfulam, Hong Kong, Peoples R China.; Yuen, KY (corresponding author), Univ Hong Kong, Shenzhen Hosp, Dept Clin Microbiol & Infect Control, Shenzhen, Guangdong, Peoples R China.
EM kyyuen@hku.hk; hsun@hku.hk
OI Wang, Runming/0000-0001-8525-5659
FU Research Grants Council (RGC)Hong Kong Research Grants Council
   [R707018]; HKSAR of China [2020YFA0707500, 2020YFA0707504]; National Key
   R&D Programmes of China [2020YFA0707500, 2020YFA0707504]; University of
   Hong Kong (HKU) Seed Fund for Basic Research [201909185060]
FX This study was partly supported by funding from the Research Impact Fund
   (R707018) of the Research Grants Council (RGC), HKSAR of China and the
   National Key R&D Programmes of China (grant nos. 2020YFA0707500 and
   2020YFA0707504), the University of Hong Kong (HKU) Seed Fund for Basic
   Research (no. 201909185060) and donations from the Lo Ying Shek Chi Wai
   Foundation, Richard Yu and Carol Yu, the Shaw Foundation of Hong Kong,
   Michael Seak-Kan Tong, May Tam Mak Mei Yin, Hong Kong Sanatorium &
   Hospital, Hui Ming, Hui Hoy and Chow Sin Lan Charity Fund Limited, Chan
   Yin Chuen Memorial Charitable Foundation, Marina Man-Wai Lee, the Hong
   Kong Hainan Commercial Association South China Microbiology Research
   Fund, the Jessie & George Ho Charitable Foundation, Perfect Shape
   Medical Limited, Kai Chong Tong, Foo Oi Foundation Limited, Tse Kam Ming
   Laurence, and Norman & Cecilia Yip Foundation. The funding sources had
   no role in the study design, data collection, analysis, interpretation
   or writing of the paper.
CR Adedeji AO, 2012, ANTIMICROB AGENTS CH, V56, P4718, DOI 10.1128/AAC.00957-12
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bardhan KD, 1997, GUT, V41, P181, DOI 10.1136/gut.41.2.181
   Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan JFW, 2018, ANTIVIR RES, V160, P38, DOI 10.1016/j.antiviral.2018.10.007
   Cheng TF, 2019, METALLOMICS, V11, P1207, DOI 10.1039/c9mt00085b
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Cun SJ, 2010, P NATL ACAD SCI USA, V107, P4943, DOI 10.1073/pnas.0913970107
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Keum YS, 2012, BIOCHEM PHARMACOL, V84, P1351, DOI 10.1016/j.bcp.2012.08.012
   Koch KM, 1996, BRIT J CLIN PHARMACO, V42, P201, DOI 10.1046/j.1365-2125.1996.03929.x
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li HY, 2012, CURR OPIN CHEM BIOL, V16, P74, DOI 10.1016/j.cbpa.2012.01.006
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   Mirza MU, 2020, J PHARM ANAL, V10, P320, DOI 10.1016/j.jpha.2020.04.008
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Patel SS, 2006, J BIOL CHEM, V281, P18265, DOI 10.1074/jbc.R600008200
   Pipkin Graham A., 1996, Pharmacoepidemiology and Drug Safety, V5, P399
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Roberts M., 2020, BMJ OPINION
   SADLER PJ, 1995, J CHEM SOC DALTON, P1395, DOI 10.1039/dt9950001395
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Serafin MB, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105969
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Tanner JA, 2003, J BIOL CHEM, V278, P39578, DOI 10.1074/jbc.C300328200
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang RM, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101054
   Wang RM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02828-6
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2002, 157 WHO
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang N, 2007, ANGEW CHEM INT EDIT, V46, P6464, DOI 10.1002/anie.200701021
   Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x
   Yuan SF, 2016, J ANTIMICROB CHEMOTH, V71, P2489, DOI 10.1093/jac/dkw194
   Yuan SF, 2015, ANTIMICROB AGENTS CH, V59, P4082, DOI 10.1128/AAC.00306-15
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 50
TC 1
Z9 1
U1 5
U2 5
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2058-5276
J9 NAT MICROBIOL
JI NAT. MICROBIOL
PD NOV
PY 2020
VL 5
IS 11
BP 1439
EP +
DI 10.1038/s41564-020-00802-x
EA OCT 2020
PG 17
WC Microbiology
SC Microbiology
GA OE5YT
UT WOS:000576097800001
PM 33028965
OA Bronze
DA 2021-01-01
ER

PT J
AU Dhamad, AE
   Rhida, MAA
AF Dhamad, Ahmed E.
   Rhida, Muna A. Abdal
TI COVID-19: molecular and serological detection methods
SO PEERJ
LA English
DT Article
DE COVID-19; SARS-CoV-2; rRT-PCR; ID NOW COVID-19; Isothermal
   amplification; CRISPR-Cas12; LFA; ELISA
ID LATERAL FLOW ASSAY; RAPID DETECTION; CORONAVIRUS; SARS-COV-2; ELISA;
   3,3',5,5'-TETRAMETHYLBENZIDINE; IMMUNOASSAY; OUTBREAK; ANTIBODY; PROTEIN
AB Since COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared as a pandemic disease by the World Health Organization in early 2020, many countries, organizations and companies have tried to find the best way to diagnose the virus and contain its spreading. SARS-CoV-2 is a positive-sense single RNA (+ssRNA) coronavirus and mainly spreads through droplets, respiratory secretions, and direct contact. The early detection of the virus plays a central role in lowering COVID19 incidents and mortality rates. Thus, finding a simple, accurate, cheap and quick detection approach for SARS-CoV-2 at early stage of the viral infection is urgent and at high demand all around the world. The Food and Drug Administration and other health agencies have declared Emergency Use Authorization to develop diagnostic methods for COVID-19 and fulfill the demand. However, not all developed methods are appropriate and selecting a suitable method is challenging. Among all detection methods, rRT-PCR is the gold standard method. Unlike molecular methods, serological methods lack the ability of early detection with low accuracy. In this review, we summarized the current knowledge about COVID-19 detection methods aiming to highlight the advantages and disadvantages of molecular and serological methods.
C1 [Dhamad, Ahmed E.; Rhida, Muna A. Abdal] Univ Arkansas, Cell & Mol Biol, Fayetteville, AR 72701 USA.
   [Dhamad, Ahmed E.; Rhida, Muna A. Abdal] Wasit Univ, Dept Biol Sci, Kut, Wasit, Iraq.
RP Dhamad, AE (corresponding author), Univ Arkansas, Cell & Mol Biol, Fayetteville, AR 72701 USA.; Dhamad, AE (corresponding author), Wasit Univ, Dept Biol Sci, Kut, Wasit, Iraq.
EM adhamad@uark.edu
RI Dhamad, Ahmed E./H-2336-2018
OI Dhamad, Ahmed E./0000-0002-1846-5768
CR Abbott, 2020, ID NOW COVID 19
   Amer HM, 2013, J VIROL METHODS, V193, P337, DOI 10.1016/j.jviromet.2013.06.027
   Amrane S, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101632
   Bisoffi Z, 2020, DIAGNOSTICS, V10, pE669
   Boisen ML, 2015, J INFECT DIS, V212, pS359, DOI 10.1093/infdis/jiv353
   Broughton James P, 2020, medRxiv, DOI 10.1101/2020.03.06.20032334
   Capobianchi MR, 2020, CLIN MICROBIOL INFEC, V26, P954, DOI 10.1016/j.cmi.2020.03.025
   Carrio A, 2015, SENSORS-BASEL, V15, P29569, DOI 10.3390/s151129569
   Carter LJ, 2020, ACS CENTRAL SCI, V6, P591, DOI 10.1021/acscentsci.0c00501
   Cascella M, 2020, FEATURES EVALUATION
   Centers of Disease Control and Prevention (CDC), 2020, RES LAB WORK COR COV
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   COVID 19 Investigation, 2020, NAT MED, V26, P861, DOI 10.1038/s41591-020-0877-5
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9
   Moreno MD, 2017, GUT, V66, P250, DOI 10.1136/gutjnl-2015-310148
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Drew DA, 2020, SCIENCE, V368, P1362, DOI 10.1126/science.abc0473
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gao X, 2015, J INFECTION, V71, P599, DOI 10.1016/j.jinf.2015.07.002
   Gauger Phillip C, 2020, Methods Mol Biol, V2123, P321, DOI 10.1007/978-1-0716-0346-8_23
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Harrington A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00798-20
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussain A, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108142
   Infantino M, 2020, J MED VIROL, V92, P1671, DOI 10.1002/jmv.25932
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Koczula KM, 2016, ESSAYS BIOCHEM, V60, P111, DOI 10.1042/EBC20150012
   Kooraki S, 2020, J AM COLL RADIOL, V17, P447, DOI 10.1016/j.jacr.2020.02.008
   Kreutz R, 2020, CARDIOVASC RES, V116, P1688, DOI 10.1093/cvr/cvaa097
   Kubina R, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10060434
   La Marca A, 2020, REPROD BIOMED ONLINE, V41, P483, DOI 10.1016/j.rbmo.2020.06.001
   Lamb LE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234682
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   LEE M, 1990, AM J TROP MED HYG, V42, P314, DOI 10.4269/ajtmh.1990.42.314
   Li DY, 2013, MICROCHIM ACTA, V180, P711, DOI 10.1007/s00604-013-0974-y
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lippi G, 2020, RESP MED, V167, DOI 10.1016/j.rmed.2020.105941
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MADERSBACHER S, 1991, J IMMUNOL METHODS, V138, P121, DOI 10.1016/0022-1759(91)90071-M
   Magambo KA, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19040
   Maxim LD, 2014, INHAL TOXICOL, V26, P811, DOI 10.3109/08958378.2014.955932
   Menni C, 2020, NAT MED, V26, P1037, DOI 10.1038/s41591-020-0916-2
   Muniyappa R, 2020, AM J PHYSIOL-ENDOC M, V318, pE736, DOI 10.1152/ajpendo.00124.2020
   Muruato Antonio E, 2020, bioRxiv, DOI 10.1101/2020.05.21.109546
   Nao N, 2020, DETECTION 2 CASE 201
   Nielsen K, 2008, J IMMUNOASS IMMUNOCH, V29, P10, DOI 10.1080/15321810701734693
   Notomi T, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e63
   Pan YB, 2020, J INFECTION, V81, pE28, DOI 10.1016/j.jinf.2020.03.051
   Parolo C, 2013, BIOSENS BIOELECTRON, V40, P412, DOI 10.1016/j.bios.2012.06.049
   Peihua Niu RL, 2020, CHINA CDC WEEKLY, V2, P453, DOI [10.46234/ccdcw2020.116., DOI 10.46234/CCDCW2020.116]
   Pujadas E, 2020, LANCET RESP MED, V8, pE70, DOI 10.1016/S2213-2600(20)30354-4
   Rohrman BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045611
   Schiffrin EL, 2020, AM J HYPERTENS, V33, P373, DOI 10.1093/ajh/hpaa057
   Schramm EC, 2015, ANAL BIOCHEM, V477, P78, DOI 10.1016/j.ab.2015.01.024
   Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Thai HTC, 2004, J CLIN MICROBIOL, V42, P1956, DOI 10.1128/JCM.42.5.1956-1961.2004
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   U.S. Food & Drug Administration, 2020, IMP INF US SER ANT T
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang DG, 2020, J VIROL METHODS, V276, DOI 10.1016/j.jviromet.2019.113775
   Wei YQ, 2020, J MED VIROL, V92, P2758, DOI 10.1002/jmv.26175
   Wong HYF, 2020, RADIOLOGY, V296, pE72, DOI 10.1148/radiol.2020201160
   World Health Organization, 2020, COVID 19 SYMPT
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia JH, 2020, J MED VIROL, V92, P589, DOI 10.1002/jmv.25725
   Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461
   Xiang J, 2020, EVALUATION ENZYME LI, DOI [10.1101/2020.02.27.20028787, DOI 10.1101/2020.02.27.20028787, 10.1101/2020.02.27. 20028787]
   Yang Jianyi, 2015, Curr Protoc Bioinformatics, V52, DOI 10.1002/0471250953.bi0508s52
   Yang PH, 2020, CELL MOL IMMUNOL, V17, P555, DOI 10.1038/s41423-020-0407-x
   Yang WJ, 2020, EUR RADIOL, V30, P4874, DOI 10.1007/s00330-020-06827-4
   Yu L, 2020, CLIN CHEM, V66, P975, DOI 10.1093/clinchem/hvaa102
   Zhang Lab, 2020, GENOME WIDE STRUCTUR
   Zhang P, 2020, EVALUATION RECOMBINA, DOI [10.1101/2020.03.17.20036954, DOI 10.1101/2020.03.17.20036954]
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhang YG, 2014, J VIROL METHODS, V206, P55, DOI 10.1016/j.jviromet.2014.05.008
   Zhang ZY, 2015, ACS APPL MATER INTER, V7, P27639, DOI 10.1021/acsami.5b07344
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 92
TC 0
Z9 0
U1 11
U2 11
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD OCT 7
PY 2020
VL 8
AR e10180
DI 10.7717/peerj.10180
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NX4MQ
UT WOS:000575687200006
PM 33083156
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bazmjoo, A
   Bagherzadeh, MA
   Farahmandpoor, F
   Raoofi, R
   Abdoli, A
AF Bazmjoo, Ahmadreza
   Bagherzadeh, Mohammad Aref
   Farahmandpoor, Farida
   Raoofi, Rahim
   Abdoli, Amir
TI SARS-CoV-2 infection in an advanced rheumatoid arthritis patient
SO APMIS
LA English
DT Letter
DE SARS-CoV-2; COVID-19; rheumatoid arthritis; immunosuppressive therapy
C1 [Bazmjoo, Ahmadreza; Bagherzadeh, Mohammad Aref] Jahrom Univ Med Sci, Student Res Comm, Jahrom, Iran.
   [Farahmandpoor, Farida] Fasa Univ Med Sci, Control Dis Dept, Dept Hlth, Fasa, Iran.
   [Raoofi, Rahim] Dept Infect Dis, Jahrom, Jahrom, Iran.
   [Abdoli, Amir] Jahrom Univ Med Sci, Zoonoses Res Ctr, Jahrom, Iran.
   [Abdoli, Amir] Jahrom Univ Med Sci, Dept Parasitol & Mycol, Jahrom, Iran.
RP Abdoli, A (corresponding author), Jahrom Univ Med Sci, Zoonoses Res Ctr, Jahrom, Iran.; Abdoli, A (corresponding author), Jahrom Univ Med Sci, Dept Parasitol & Mycol, Jahrom, Iran.
EM a.abdoli25@gmail.com
OI Abdoli, Amir/0000-0003-4326-4586
CR Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lopez-Gonzalez Maria-Del-Carmen, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217914, 10.1136/annrheumdis-2020-218368]
   Mendel Arielle, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217835, 10.1136/annrheumdis-2020-218164]
   Moiseev Sergey, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217676, 10.1136/annrheumdis-2020-217570, 10.1136/annrheumdis-2020-219265]
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
NR 8
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0903-4641
EI 1600-0463
J9 APMIS
JI APMIS
PD DEC
PY 2020
VL 128
IS 12
BP 654
EP 656
DI 10.1111/apm.13080
EA OCT 2020
PG 3
WC Immunology; Microbiology; Pathology
SC Immunology; Microbiology; Pathology
GA OK4FC
UT WOS:000575786100001
PM 32945021
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ahluwalia, M
   Givertz, MM
   Mehra, MR
AF Ahluwalia, Monica
   Givertz, Michael M.
   Mehra, Mandeep R.
TI A proposed strategy for management of immunosuppression in heart
   transplant patients with COVID-19
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE COVID-19; heart transplantation; immunosuppression
AB There is limited experience in management of orthotopic heart transplant (OHT) patients with COVID-19. In this study, we present our initial experience using a standardized management algorithm. Data collection was performed on OHT patients with COVID-19 after March 10, 2020 (declaration of state of emergency in Massachusetts). Among the 358 OHT patients currently followed at our program, 5 patients (1.4%) tested positive for COVID-19 (median age 50 years [IQR, 49-58], duration post-OHT 21 years [IQR, 6-25], and 4 of 5 [80%] were men). Among the 5 OHT patients, 2 of 5 (20%) had mild disease and had no change in baseline immunosuppression therapy. Two of 5 (20%) had moderate disease and received remdesivir as part of a clinical trial and reduced immunosuppression therapy. One patient (20%) died prior to presenting to the hospital, consistent with 20% case fatality rate. Four patients (80%) are doing well 4 weeks post-discharge. In this small cohort of OHT patients with COVID-19, we report a 1.4% COVID-19 infection rate and 20% case fatality rate. All OHT patients managed under our clinical management algorithm had good short-term outcomes. Further study to estimate the true risk profile of OHT patients and validate the proposed management strategy is warranted.
C1 Brigham & Womens Hosp, Ctr Adv Heart Dis, Boston, MA 02115 USA.
   Harvard Med Sch, Boston, MA 02115 USA.
RP Ahluwalia, M (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
EM mahluwalia@bwh.harvard.edu
CR Al Ghamdi M, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1492-4
   Aslam S, 2020, GUIDANCE INT SOC HEA
   Aslam S, 2020, J HEART LUNG TRANSPL, V39, P408, DOI 10.1016/j.healun.2020.03.007
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Kates OS, 2020, AM J TRANSPLANT, V20, P1885, DOI 10.1111/ajt.15944
   Latif F, 2020, JAMA CARDIOL, V5, P1165, DOI 10.1001/jamacardio.2020.2159
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Mathies D, 2020, AM J TRANSPLANT, V20, P1925, DOI 10.1111/ajt.15932
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Ren ZL, 2020, J HEART LUNG TRANSPL, V39, P412, DOI 10.1016/j.healun.2020.03.008
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
NR 14
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
EI 1399-0012
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD NOV
PY 2020
VL 34
IS 11
AR e14032
DI 10.1111/ctr.14032
EA OCT 2020
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OZ9QZ
UT WOS:000575653300001
PM 32621523
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rey, JR
   Caro-Codon, J
   Rosillo, SO
   Iniesta, AM
   Castrejon-Castrejon, S
   Marco-Clement, I
   Martin-Polo, L
   Merino-Argos, C
   Rodriguez-Sotelo, L
   Garcia-Veas, JM
   Martinez-Marin, LA
   Martinez-Cossiani, M
   Buno, A
   Gonzalez-Valle, L
   Herrero, A
   Lopez-Sendon, JL
   Merino, JL
AF Rey, Juan R.
   Caro-Codon, Juan
   Rosillo, Sandra O.
   Iniesta, Angel M.
   Castrejon-Castrejon, Sergio
   Marco-Clement, Irene
   Martin-Polo, Lorena
   Merino-Argos, Carlos
   Rodriguez-Sotelo, Laura
   Garcia-Veas, Jose M.
   Martinez-Marin, Luis A.
   Martinez-Cossiani, Marcel
   Buno, Antonio
   Gonzalez-Valle, Luis
   Herrero, Alicia
   Lopez-Sendon, Jose L.
   Merino, Jose L.
CA CARD-COVID Investigators
TI Heart failure in COVID-19 patients: prevalence, incidence and prognostic
   implications
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article; Early Access
DE COVID-19; Heart failure; NT-proBNP; Drug withdrawal; Mortality;
   Morbidity
ID NATRIURETIC PEPTIDES; CLINICAL-TRIALS; ASSOCIATION; SOCIETY
AB Aims Data on the impact of COVID-19 in chronic heart failure (CHF) patients and its potential to trigger acute heart failure (AHF) are lacking. The aim of this work was to study characteristics, cardiovascular outcomes and mortality in patients with confirmed COVID-19 infection and a prior diagnosis of heart failure (HF). Further aims included the identification of predictors and prognostic implications for AHF decompensation during hospital admission and the determination of a potential correlation between the withdrawal of HF guideline-directed medical therapy (GDMT) and worse outcomes during hospitalization. Methods and results Data for a total of 3080 consecutive patients with confirmed COVID-19 infection and follow-up of at least 30 days were analysed. Patients with a previous history of CHF (n= 152, 4.9%) were more prone to the development of AHF (11.2% vs. 2.1%;P < 0.001) and had higher levels of N-terminal pro brain natriuretic peptide. In addition, patients with previous CHF had higher mortality rates (48.7% vs. 19.0%;P < 0.001). In contrast, 77 patients (2.5%) were diagnosed with AHF, which in the vast majority of cases (77.9%) developed in patients without a history of HF. Arrhythmias during hospital admission and CHF were the main predictors of AHF. Patients developing AHF had significantly higher mortality (46.8% vs. 19.7%;P < 0.001). Finally, the withdrawal of beta-blockers, mineralocorticoid receptor antagonists and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was associated with a significant increase in in-hospital mortality. Conclusions Patients with COVID-19 have a significant incidence of AHF, which is associated with very high mortality rates. Moreover, patients with a history of CHF are prone to developing acute decompensation after a COVID-19 diagnosis. The withdrawal of GDMT was associated with higher mortality.
C1 [Rey, Juan R.; Caro-Codon, Juan; Rosillo, Sandra O.; Iniesta, Angel M.; Castrejon-Castrejon, Sergio; Marco-Clement, Irene; Martin-Polo, Lorena; Merino-Argos, Carlos; Rodriguez-Sotelo, Laura; Garcia-Veas, Jose M.; Martinez-Marin, Luis A.; Martinez-Cossiani, Marcel; Lopez-Sendon, Jose L.; Merino, Jose L.] Hosp Univ La Paz, Cardiol Dept, Paseo Castellana 261, Madrid 28046, Spain.
   [Buno, Antonio] Hosp Univ La Paz, Clin Analyt, Madrid, Spain.
   [Gonzalez-Valle, Luis; Herrero, Alicia] Hosp Univ La Paz, Pharm Dept, Madrid, Spain.
RP Rey, JR (corresponding author), Hosp Univ La Paz, Cardiol Dept, Paseo Castellana 261, Madrid 28046, Spain.
EM cardcovid@arritmias.net
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Bromage DI, 2020, EUR J HEART FAIL, V22, P978, DOI 10.1002/ejhf.1925
   Corrales-Medina VF, 2013, LANCET, V381, P496, DOI 10.1016/S0140-6736(12)61266-5
   Corrales-Medina VF, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001048
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   European Society of Cardiology, 2020, ESC GUID DIAGN MAN C
   Fauvel C, 2020, EUR HEART J, V41, P3058, DOI 10.1093/eurheartj/ehaa500
   Fox SE, 2020, CIRCULATION, V142, P1123, DOI 10.1161/CIRCULATIONAHA.120.049465
   Gao C, 2020, EUR HEART J, V41, P2058, DOI 10.1093/eurheartj/ehaa433
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Halliday BP, 2019, LANCET, V393, P61, DOI 10.1016/S0140-6736(18)32484-X
   Ibrahim NE, 2020, JACC-HEART FAIL, V8, P347, DOI 10.1016/j.jchf.2019.12.010
   Inciardi RM, 2020, EUR HEART J, V41, P1821, DOI 10.1093/eurheartj/ehaa388
   Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014
   Lopes RD, 2020, AM HEART J, V226, P49, DOI 10.1016/j.ahj.2020.05.002
   Maggioni AP, 2013, EUR J HEART FAIL, V15, P808, DOI 10.1093/eurjhf/hft050
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Mehran R, 2011, CIRCULATION, V123, P2736, DOI 10.1161/CIRCULATIONAHA.110.009449
   Mueller C, 2019, EUR J HEART FAIL, V21, P715, DOI 10.1002/ejhf.1494
   Myhre PL, 2018, JAMA CARDIOL, V3, P1000, DOI 10.1001/jamacardio.2018.2568
   Panhwar MS, 2019, JACC-HEART FAIL, V7, P112, DOI 10.1016/j.jchf.2018.10.011
   Puntmann Valentina O, 2020, JAMA Cardiol, V5, P1265, DOI 10.1001/jamacardio.2020.3557
   Rey Juan R, 2020, Rev Esp Cardiol (Engl Ed), V73, P769, DOI 10.1016/j.rec.2020.05.008
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Santhanakrishnan R, 2016, CIRCULATION, V133, pe962
   Skulstad H, 2020, EUR HEART J-CARD IMG, V21, P592, DOI 10.1093/ehjci/jeaa072
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhang YH, 2020, EUR J HEART FAIL, V22, P941, DOI 10.1002/ejhf.1915
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 30
TC 5
Z9 5
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
DI 10.1002/ejhf.1990
EA OCT 2020
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NX5XI
UT WOS:000575783400001
PM 32833283
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ibrahim, OM
   Ibrahim, RM
   Abdel-Qader, DH
   Al Meslamani, AZ
   Al Mazrouei, N
AF Mohamed Ibrahim, Osama
   Ibrahim, Rana M.
   Abdel-Qader, Derar H.
   Al Meslamani, Ahmad Z.
   Al Mazrouei, Nadia
TI Evaluation of Telepharmacy Services in Light of COVID-19
SO TELEMEDICINE AND E-HEALTH
LA English
DT Article; Early Access
DE telehealth; telemedicine; pharmacy; telecommunications; telepharmacy
ID REMOTE; PHARMACY; PATIENT; ACCESS; IMPACT; CARE
AB Background:Telepharmacy services are expected to have an important role in increasing access of patients to pharmaceutical care and reducing potential dispensing errors in community pharmacies. Objective:To assess the predictors for effective telepharmacy services on increasing access of patients to care and reducing dispensing errors in community pharmacies. Method:This is a prospective study carried out for 4 months in 52 community pharmacies across the United Arab Emirates (UAE) using disguised direct observation. Multivariable logistic regression was used as a tool to predict factors associated with effective telepharmacy services in improving dispensing safety and increasing access of patients to pharmaceutical care. Data were entered and analyzed using the Statistical Package for Social Science (SPSS) software version 26. Results:Pharmacist recommendations related to COVID-19 at pharmacies with telepharmacy (n = 63,714) versus those without remote services (n = 15,539) were significantly more likely to be (1) contact the nearest testing center (adjusted odds ratio [AOR] = 7.93), (2) maintain home quarantine (AOR = 5.64), and (3) take paracetamol for fever (AOR = 3.53), all were significant results (p< 0.05). Rates of medication dispensing errors (MDEs) and its subcategories, prescription-related errors, and pharmacist counseling errors across pharmacies with telepharmacy versus those without remote services were (15.81% vs. 19.43%,p< 0.05), (5.38% vs. 10.08%,p< 0.05), and (10.42% vs. 9.35%,p> 0.05), respectively. However, pharmacies with telepharmacy were more likely to include wrong patient errors (AOR = 5.38,p< 0.05). Conclusions:Telepharmacy can be used as a tool to reduce the burden on the health care system and improve drug dispensing safety in community pharmacies.
C1 [Mohamed Ibrahim, Osama; Ibrahim, Rana M.; Al Mazrouei, Nadia] Univ Sharjah, Coll Pharm, Dept Pharm Practice & Pharmacotherapeut, Sharjah 27272, U Arab Emirates.
   [Mohamed Ibrahim, Osama] Cairo Univ, Fac Pharm, Dept Clin Pharm, Cairo, Egypt.
   [Abdel-Qader, Derar H.] Univ Petra, Fac Pharm & Med Sci, Amman, Jordan.
   [Al Meslamani, Ahmad Z.] Al Ain Univ Sci & Technol, Coll Pharm, Abu Dhabi, U Arab Emirates.
RP Ibrahim, OM (corresponding author), Univ Sharjah, Coll Pharm, Dept Pharm Practice & Pharmacotherapeut, Sharjah 27272, U Arab Emirates.
EM oibrahim@sharjah.ac.ae
CR Abdel-Qader DH, 2020, INT J CLIN PHARM-NET, DOI 10.1007/s11096-020-01126-w
   Abdel-Qader DH, 2020, J PHARM HEALTH SERV, V11, P375, DOI 10.1111/jphs.12376
   Abdel-Qader DH, 2020, HOSP PHARM, DOI 10.1177/0018578720942231
   Adunlin G, 2020, J RURAL HEALTH, DOI 10.1111/jrh.12439
   AlFaar AS, 2012, TELEMED E-HEALTH, V18, P470, DOI 10.1089/tmj.2011.0182
   Ameri A, 2020, HEALTH POLICY TECHN, V9, P281, DOI 10.1016/j.hlpt.2020.06.005
   Ameri A, 2020, J PHARM TECHNOL, V36, P171, DOI 10.1177/8755122520931442
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Bell R, 2007, G POWER STAT POWER A
   Boon AD, 2007, AM J HEALTH-SYST PH, V64, P242, DOI 10.2146/ajhp060392
   Brown W, 2017, J ASTHMA, V54, P961, DOI 10.1080/02770903.2017.1281292
   Cadogan Cathal A, 2021, Res Social Adm Pharm, V17, P2032, DOI 10.1016/j.sapharm.2020.03.015
   Casey MM, 2010, AM J HEALTH-SYST PH, V67, P1085, DOI 10.2146/ajhp090531
   Collins JC, 2019, ENCY PHARM PRACT CLI, P282
   Department of Health Abu Dhabi, 2020, REM HEALTHC PLATF
   European Centre for Disease Prevention and Control. Case definition for coronavirus disease, 2020, CAS DEF COR DIS 2019
   Friesner DL, 2011, J AM PHARM ASSOC, V51, P580, DOI 10.1331/JAPhA.2011.10115
   General Pharmaceutical Council, 2020, UPD NEW LEG REL CONT
   Gross AE, 2020, J AM COLL CLIN PHARM, V3, P564
   Ho Inger, 2015, Int J Pharm Pract, V23, P61, DOI 10.1111/ijpp.12109
   Kimber Michael B., 2006, Journal of Pharmacy Practice and Research, V36, P128
   Le T, 2020, J PHARM PRACT, V33, P176, DOI 10.1177/0897190018791060
   Li Huibo, 2021, Res Social Adm Pharm, V17, P1813, DOI 10.1016/j.sapharm.2020.04.003
   Margolis A, 2013, AM J HEALTH-SYST PH, V70, P1875, DOI 10.2146/ajhp120241
   Margusino-Framinan L, 2020, FARM HOSP, V44, P61, DOI 10.7399/fh.11498
   Margusino-Framin L, 2019, TELEMED E-HEALTH, V25, P399, DOI 10.1089/tmj.2018.0041
   McFarland R, 2017, J TELEMED TELECARE, V23, P861, DOI 10.1177/1357633X17732367
   Merks Piotr, 2021, Res Social Adm Pharm, V17, P1807, DOI 10.1016/j.sapharm.2020.05.033
   Nadeem Muhammad Faisal, 2021, Res Social Adm Pharm, V17, P2046, DOI 10.1016/j.sapharm.2020.05.021
   Ohannessian R, 2020, JMIR PUBLIC HLTH SUR, V6, P121, DOI 10.2196/18810
   Omboni S, 2020, TELEMED E-HEALTH, V26, P973, DOI 10.1089/tmj.2020.0106
   Poudel A, 2016, INTEGR PHARM RES PRA, V5, P75, DOI 10.2147/IPRP.S101685
   Poulson LK, 2010, J TELEMED TELECARE, V16, P95, DOI 10.1258/jtt.2009.090716
   Sankaranarayanan J, 2014, TELEMED E-HEALTH, V20, P893, DOI 10.1089/tmj.2013.0362
   Schneider PJ, 2013, AM J HEALTH-SYST PH, V70, P2130, DOI 10.2146/ajhp130138
   Scott DM, 2012, J AM PHARM ASSOC, V52, pE97, DOI 10.1331/JAPhA.2012.11119
   Smith AC, 2020, J TELEMED TELECARE, V26, P309, DOI 10.1177/1357633X20916567
   The Centers for Disease Control and Prevention, 2019, COR DIS 2019 COVID 1
   Wakefield DS, 2010, AM J HEALTH-SYST PH, V67, P2052, DOI 10.2146/ajhp090643
   Woodall Sandra C, 2004, Jt Comm J Qual Saf, V30, P442
   Young HN, 2012, TELEMED E-HEALTH, V18, P427, DOI 10.1089/tmj.2011.0194
   Zheng Si-Qian, 2021, Res Social Adm Pharm, V17, P1819, DOI 10.1016/j.sapharm.2020.03.012
NR 42
TC 0
Z9 0
U1 4
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
EI 1556-3669
J9 TELEMED E-HEALTH
JI Telemed. e-Health
DI 10.1089/tmj.2020.0283
EA OCT 2020
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA NZ3WE
UT WOS:000577026400001
PM 33030986
OA Bronze
DA 2021-01-01
ER

PT J
AU Gupta, AK
   Quinlan, EM
AF Gupta, Aditya K.
   Quinlan, Emma M.
TI Changing trends in surgical hair restoration: Use of Google Trends and
   the ISHRS practice census survey
SO JOURNAL OF COSMETIC DERMATOLOGY
LA English
DT Article
DE FUE; FUT; Google; hair transplant; ISHRS
AB Background Hair loss affects most people at some point in their lifetime, causing anxiety and decreased self-esteem. There are multiple surgical and nonsurgical treatments available, with the surgical options having greater and longer-lasting effects. Such treatments have evolved over time with advances in technology and research, with numerous patients researching these treatments on Google. Many surgeons who provide these treatments belong to the International Society of Hair Restoration Surgeons (ISHRS). Aims To investigate trends in surgical hair restoration treatment from both the surgeon and patient perspectives. Methods Patient epidemiological and surgical data from the ISHRS were combined with search trend data from Google to analyze changing trends in surgical hair restoration treatment. Results Worldwide Internet searches for "hair transplant" have increased from 2004 to the present. Follicular unit excision (FUE) has supplanted follicular unit transplant (FUT) as the most popular hair transplant performed. Since 2004, there has been an increase in both nonsurgical and surgical female patients. Beard and eyebrow transplants have increased in popularity. Google searches follow this trend. Nonsurgical treatments such as platelet-rich plasma (PRP) are being searched more frequently. Hair restoration clinics and Google searches were affected adversely by the COVID-19 pandemic. Conclusion Technological advances in available therapies, improvement in delivery systems, changes in hair fashion, and global events have direct impact on hair restoration treatments offered by physicians and researched by patients. It is in the best interest of all hair restoration providers to keep abreast of changing technologies and treatment trends to stay at the forefront of their profession.
C1 [Gupta, Aditya K.; Quinlan, Emma M.] Mediprobe Res Inc, 645 Windermere Rd, London, ON N5X 2P1, Canada.
   [Gupta, Aditya K.] Univ Toronto, Fac Med, Dept Dermatol, Toronto, ON, Canada.
RP Gupta, AK (corresponding author), Mediprobe Res Inc, 645 Windermere Rd, London, ON N5X 2P1, Canada.
EM agupta@execulink.com
OI Quinlan, Emma/0000-0002-1806-5561; Gupta, Aditya/0000-0002-8664-7723
FU Mediprobe Research Inc
FX Mediprobe Research Inc is an independent research site; no outside
   funding supported this study.
CR [Anonymous], 2011, BBC NEWS
   Epstein JS, 2020, HAIR TRANSPL FORUM I, V30, P91
   Google, GOOGLE TRENDS
   Gupta AK, 2020, J COSMET DERMATOL-US, DOI 10.1111/jocd.13681
   Gupta AK, 2020, J COSMET DERMATOL-US, V19, P1883, DOI 10.1111/jocd.13506
   Gupta AK, 2019, DERMATOL SURG, V45, P1262, DOI 10.1097/DSS.0000000000001894
   Gupta Aditya K, 2014, Skin Therapy Lett, V19, P5
   Gupta Aditya K, 2014, Skinmed, V12, P213
   Hairmax, 2020, FDA CLEAR
   ISHRS, 2017, AB
   ISHRS, 2017, STAT RES
   Newman AA, 2015, NY TIMES
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   O'Neill N., 2014, NEW YORK POST
   Pathomvanich D, 2015, HAIR TRANSPL FORUM I, V25, P177
   Preston H., 2019, NEWSWEEK
   Rassman William R, 2015, J Clin Aesthet Dermatol, V8, P35
   Relevant Research Inc, 2020, INT SOC HAIR REST SU
   Russo PM, 2019, J EUR ACAD DERMATOL, V33, P608, DOI 10.1111/jdv.15327
   World Health Organization, 2020, TIM WHOS RESP COVID
   York K, 2020, EXPERT OPIN PHARMACO, V21, P603, DOI 10.1080/14656566.2020.1721463
   Zhitny VP, 2020, J SKIN STEM CELL, V6
NR 22
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1473-2130
EI 1473-2165
J9 J COSMET DERMATOL-US
JI J. Cosmet. Dermatol.
PD NOV
PY 2020
VL 19
IS 11
BP 2974
EP 2981
DI 10.1111/jocd.13723
EA OCT 2020
PG 8
WC Dermatology
SC Dermatology
GA ON9CE
UT WOS:000575580600001
PM 32945026
DA 2021-01-01
ER

PT J
AU Dequin, PF
   Heming, N
   Meziani, F
   Plantefeve, G
   Voiriot, G
   Badie, J
   Francois, B
   Aubron, C
   Ricard, JD
   Ehrmann, S
   Jouan, Y
   Guillon, A
   Leclerc, M
   Coffre, C
   Bourgoin, H
   Lengelle, C
   Caille-Fenerol, C
   Tavernier, E
   Zohar, S
   Giraudeau, B
   Annane, D
   Le Gouge, A
AF Dequin, Pierre-Francois
   Heming, Nicholas
   Meziani, Ferhat
   Plantefeve, Gaetan
   Voiriot, Guillaume
   Badie, Julio
   Francois, Bruno
   Aubron, Cecile
   Ricard, Jean-Damien
   Ehrmann, Stephan
   Jouan, Youenn
   Guillon, Antoine
   Leclerc, Marie
   Coffre, Carine
   Bourgoin, Helene
   Lengelle, Celine
   Caille-Fenerol, Caroline
   Tavernier, Elsa
   Zohar, Sarah
   Giraudeau, Bruno
   Annane, Djillali
   Le Gouge, Amelie
CA CAPE COVID Trial Grp
   CRICS-TriGGERSep Network
TI Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support
   Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; CORTICOSTEROID TREATMENT; THERAPY;
   FAILURE; SCORE
AB IMPORTANCE Coronavirus disease 2019 (COVID-19) is associated with severe lung damage. Corticosteroids are a possible therapeutic option. OBJECTIVE To determine the effect of hydrocortisone on treatment failure on day 21 in critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute respiratory failure.
   DESIGN, SETTING, AND PARTICIPANTS Multicenter randomized double-blind sequential trial conducted in France, with interim analyses planned every 50 patients. Patients admitted to the intensive care unit (ICU) for COVID-19-related acute respiratory failure were enrolled from March 7 to June 1, 2020, with last follow-up on June 29, 2020. The study intended to enroll 290 patients but was stopped early following the recommendation of the data and safety monitoring board.
   INTERVENTIONS Patients were randomized to receive low-dose hydrocortisone (n = 76) or placebo (n = 73).
   MAIN OUTCOMES AND MEASURES The primary outcome, treatment failure on day 21, was defined as death or persistent dependency on mechanical ventilation or high-flow oxygen therapy. Prespecified secondary outcomes included the need for tracheal intubation (among patients not intubated at baseline); cumulative incidences (until day 21) of prone position sessions, extracorporeal membrane oxygenation, and inhaled nitric oxide; PaO2:FIO2 ratio measured daily from day 1 to day 7, then on days 14 and 21; and the proportion of patients with secondary infections during their ICU stay.
   RESULTS The study was stopped after 149 patients (mean age, 62.2 years; 30.2% women; 81.2% mechanically ventilated) were enrolled. One hundred forty-eight patients (99.3%) completed the study, and there were 69 treatment failure events, including 11 deaths in the hydrocortisone group and 20 deaths in the placebo group. The primary outcome, treatment failure on day 21, occurred in 32 of 76 patients (42.1%) in the hydrocortisone group compared with 37 of 73 (50.7%) in the placebo group (difference of proportions, -8.6%[95.48% CI, -24.9% to 7.7%]; P = .29). Of the 4 prespecified secondary outcomes, none showed a significant difference. No serious adverse events were related to the study treatment.
   CONCLUSIONS AND RELEVANCE In this study of critically ill patients with COVID-19 and acute respiratory failure, low-dose hydrocortisone, compared with placebo, did not significantly reduce treatment failure (defined as death or persistent respiratory support) at day 21. However, the study was stopped early and likely was underpowered to find a statistically and clinically important difference in the primary outcome.
C1 [Dequin, Pierre-Francois; Ehrmann, Stephan; Jouan, Youenn; Guillon, Antoine] CHU Tours, Med Intens Reanimat, Tours, France.
   [Dequin, Pierre-Francois; Ehrmann, Stephan; Jouan, Youenn; Guillon, Antoine] Univ Tours, Ctr Etud Pathol Resp, INSERM, U1100, Tours, France.
   [Dequin, Pierre-Francois; Ehrmann, Stephan; Jouan, Youenn; Guillon, Antoine; Tavernier, Elsa; Giraudeau, Bruno; Le Gouge, Amelie] CHU Tours, INSERM, CIC1415, Tours, France.
   [Heming, Nicholas; Annane, Djillali] Univ Paris Saclay, Med Intens Reanimat, Hop Raymond Poincare, GHU APHP, Garches, France.
   [Heming, Nicholas; Annane, Djillali] RHU RECORDS, Garches, France.
   [Heming, Nicholas; Annane, Djillali] FHU SEPSIS, Garches, France.
   [Heming, Nicholas; Annane, Djillali] Univ Versailles SQY Univ Paris Saclay, U1173, INSERM, Garches, France.
   [Meziani, Ferhat] Hop Univ Strasbourg, Nouvel Hop Civil, Med Intens Reanimat, Strasbourg, France.
   [Meziani, Ferhat] Univ Strasbourg, INSERM, UMR 1260, Strasbourg, France.
   [Plantefeve, Gaetan] CH Victor Dupouy, Reanimat Polyvalente, Argenteuil, France.
   [Voiriot, Guillaume] Hop Tenon, AP HP, Med Intens Reanimat, Paris, France.
   [Voiriot, Guillaume] Sorbonne Univ, Paris, France.
   [Badie, Julio] Hop Nord Franche Comte, Reanimat Polyvalente, Trevenans, France.
   [Francois, Bruno] CHU Limoges, Reanimat Polyvalente, Limoges, France.
   [Francois, Bruno] Univ Limoges, INSERM, UMR 1092, Limoges, France.
   [Francois, Bruno; Caille-Fenerol, Caroline] CHU Limoges, INSERM, CIC 1435, Limoges, France.
   [Aubron, Cecile] CHRU Brest, Med Intens Reanimat, Brest, France.
   [Aubron, Cecile] Univ Bretagne Occidentale, Brest, France.
   [Ricard, Jean-Damien] Univ Paris, Hop Louis Mourier, AP HP, IAME U1137,Med Intens Reanimat,DMU ESPRIT, Colombe, France.
   [Leclerc, Marie; Coffre, Carine] CHU Tours, Delegat Rech Clin & lInnovat, Tours, France.
   [Bourgoin, Helene] CHU Tours, Pharm Usage Interne, Tours, France.
   [Lengelle, Celine] CHU Tours, Serv Pharmacosurveillance, Ctr Reg Pharmacovigilance & Informat Medicament, Tours, France.
   [Zohar, Sarah] Univ Paris, Sorbonne Univ, Ctr Rech Cordeliers, INSERM, Paris, France.
   [Giraudeau, Bruno] Univ Tours, Univ Nantes, SPHERE U1246, INSERM, Tours, France.
RP Dequin, PF (corresponding author), Hop Bretonneau, Serv Med Intens Reanimat, F-37044 Tours 09, France.
EM dequin@univ-tours.fr
RI GIRAUDEAU, Bruno/L-9003-2015
OI GIRAUDEAU, Bruno/0000-0003-3031-8258
FU French Ministry of Health, Programme Hospitalier de Recherche Clinique
   (PHRC)
FX This study was funded by the French Ministry of Health, Programme
   Hospitalier de Recherche Clinique (PHRC) (2014 [CAPE COD parent trial],
   2020 [CAPE COVID subtrial]).
CR [Anonymous], COVID 19 DASHB
   Arabi YM, 2020, INTENS CARE MED, V46, P315, DOI 10.1007/s00134-020-05943-5
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Blum CA, 2015, LANCET, V385, P1511, DOI 10.1016/S0140-6736(14)62447-8
   Dequin PF, 2020, STAT BIOPHARM RES, V12, P478, DOI 10.1080/19466315.2020.1800509
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guillon A, 2020, INTENS CARE MED, V46, P1897, DOI 10.1007/s00134-020-06170-8
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jouan Y, J EXP MED, DOI DOI 10.1101/2020.05.03.20089300V1.FULL.PDF
   LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Moreno G, 2018, INTENS CARE MED, V44, P1470, DOI 10.1007/s00134-018-5332-4
   Papazian L, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0540-9
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715
   Sinha P, 2020, JAMA INTERN MED, V180, P1152, DOI 10.1001/jamainternmed.2020.3313
   Sterne JAC, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04641-3
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Torres A, 2015, JAMA-J AM MED ASSOC, V313, P677, DOI 10.1001/jama.2015.88
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
NR 30
TC 12
Z9 12
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 6
PY 2020
VL 324
IS 13
BP 1298
EP 1306
DI 10.1001/jama.2020.16761
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA OS4SZ
UT WOS:000590156000014
PM 32876689
OA Bronze
DA 2021-01-01
ER

PT J
AU Tomazini, BM
   Maia, IS
   Cavalcanti, AB
   Berwanger, O
   Rosa, RG
   Veiga, VC
   Avezum, A
   Lopes, RD
   Bueno, FR
   Silva, MVAO
   Baldassare, FP
   Costa, ELV
   Moura, RAB
   Honorato, MO
   Costa, AN
   Damiani, LP
   Lisboa, T
   Kawano-Dourado, L
   Zampieri, FG
   Olivato, GB
   Righy, C
   Amendola, CP
   Roepke, RML
   Freitas, DHM
   Forte, DN
   Freitas, FGR
   Fernandes, CCF
   Melro, LMG
   Junior, GFS
   Morais, DC
   Zung, S
   Machado, FR
   Azevedo, LCP
AF Tomazini, Bruno M.
   Maia, Israel S.
   Cavalcanti, Alexandre B.
   Berwanger, Otavio
   Rosa, Regis G.
   Veiga, Viviane C.
   Avezum, Alvaro
   Lopes, Renato D.
   Bueno, Flavia R.
   Silva, Maria Vitoria A. O.
   Baldassare, Franca P.
   Costa, Eduardo L., V
   Moura, Ricardo A. B.
   Honorato, Michele O.
   Costa, Andre N.
   Damiani, Lucas P.
   Lisboa, Thiago
   Kawano-Dourado, Leticia
   Zampieri, Fernando G.
   Olivato, Guilherme B.
   Righy, Cassia
   Amendola, Cristina P.
   Roepke, Roberta M. L.
   Freitas, Daniela H. M.
   Forte, Daniel N.
   Freitas, Flavio G. R.
   Fernandes, Caio C. F.
   Melro, Livia M. G.
   Junior, Gedealvares F. S.
   Morais, Douglas Costa
   Zung, Stevin
   Machado, Flavia R.
   Azevedo, Luciano C. P.
CA COALITION COVID-19 Brazil III Inve
TI Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients
   With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19
   The CoDEX Randomized Clinical Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID INTENSIVE-CARE-UNIT; MULTICENTER; SAPS-3
AB IMPORTANCE Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) is associated with substantial mortality and use of health care resources. Dexamethasone use might attenuate lung injury in these patients.
   OBJECTIVE To determine whether intravenous dexamethasone increases the number of ventilator-free days among patients with COVID-19-associated ARDS.
   DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized, open-label, clinical trial conducted in 41 intensive care units (ICUs) in Brazil. Patients with COVID-19 and moderate to severe ARDS, according to the Berlin definition, were enrolled from April 17 to June 23, 2020. Final follow-up was completed on July 21, 2020. The trial was stopped early following publication of a related study before reaching the planned sample size of 350 patients.
   INTERVENTIONS Twenty mg of dexamethasone intravenously daily for 5 days, 10 mg of dexamethasone daily for 5 days or until ICU discharge, plus standard care (n = 151) or standard care alone (n = 148).
   MAIN OUTCOMES AND MEASURES The primary outcome was ventilator-free days during the first 28 days, defined as being alive and free from mechanical ventilation. Secondary outcomes were all-cause mortality at 28 days, clinical status of patients at day 15 using a 6-point ordinal scale (ranging from 1, not hospitalized to 6, death), ICU-free days during the first 28 days, mechanical ventilation duration at 28 days, and Sequential Organ Failure Assessment (SOFA) scores (range, 0-24, with higher scores indicating greater organ dysfunction) at 48 hours, 72 hours, and 7 days.
   RESULTS A total of 299 patients (mean [SD] age, 61 [14] years; 37% women) were enrolled and all completed follow-up. Patients randomized to the dexamethasone group had a mean 6.6 ventilator-free days (95% CI, 5.0-8.2) during the first 28 days vs 4.0 ventilator-free days (95% CI, 2.9-5.4) in the standard care group (difference, 2.26; 95% CI, 0.2-4.38; P =.04). At 7 days, patients in the dexamethasone group had a mean SOFA score of 6.1 (95% CI, 5.5-6.7) vs 7.5 (95% CI, 6.9-8.1) in the standard care group (difference, -1.16; 95% CI, -1.94 to -0.38; P = .004). There was no significant difference in the prespecified secondary outcomes of all-cause mortality at 28 days, ICU-free days during the first 28 days, mechanical ventilation duration at 28 days, or the 6-point ordinal scale at 15 days. Thirty-three patients (21.9%) in the dexamethasone group vs 43 (29.1%) in the standard care group experienced secondary infections, 47 (31.1%) vs 42 (28.3%) needed insulin for glucose control, and 5 (3.3%) vs 9 (6.1%) experienced other serious adverse events.
   CONCLUSIONS AND RELEVANCE Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over 28 days.
C1 [Tomazini, Bruno M.; Bueno, Flavia R.; Silva, Maria Vitoria A. O.; Baldassare, Franca P.; Costa, Eduardo L., V; Moura, Ricardo A. B.; Honorato, Michele O.; Costa, Andre N.; Forte, Daniel N.; Azevedo, Luciano C. P.] Hosp Sirio Libanes, Rua Prof Daher Cutait 69, BR-01308060 Sao Paulo, Brazil.
   [Tomazini, Bruno M.; Roepke, Roberta M. L.] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Dept Cirurgia, Sao Paulo, Brazil.
   [Maia, Israel S.; Cavalcanti, Alexandre B.; Damiani, Lucas P.; Lisboa, Thiago; Kawano-Dourado, Leticia; Zampieri, Fernando G.] HCor Res Inst, Sao Paulo, Brazil.
   [Maia, Israel S.; Cavalcanti, Alexandre B.; Rosa, Regis G.; Veiga, Viviane C.; Lisboa, Thiago; Zampieri, Fernando G.; Freitas, Flavio G. R.; Machado, Flavia R.; Azevedo, Luciano C. P.] Brazilian Res Intens Care Network BRICNet, Sao Paulo, Brazil.
   [Berwanger, Otavio; Olivato, Guilherme B.] Hosp Israelita Albert Einstein, Acad Res Org, Sao Paulo, Brazil.
   [Rosa, Regis G.] Hosp Moinhos Vento, Porto Alegre, RS, Brazil.
   [Veiga, Viviane C.] BP Beneficencia Portuguesa Sao Paulo, Sao Paulo, Brazil.
   [Avezum, Alvaro] Hosp Alemao Oswaldo Cruz, Int Res Ctr, Sao Paulo, Brazil.
   [Lopes, Renato D.] Brazilian Clin Res Inst, Sao Paulo, Brazil.
   [Lopes, Renato D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
   [Costa, Eduardo L., V; Freitas, Daniela H. M.] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, UTI Resp,Inst Coracao Incor, Sao Paulo, Brazil.
   [Costa, Andre N.] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Dept Cardiopneumol,Inst Coracao Incor, Sao Paulo, Brazil.
   [Lisboa, Thiago] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
   [Olivato, Guilherme B.] Hosp Vila Santa Catarina, Sao Paulo, Brazil.
   [Righy, Cassia] Inst Estadual Cerebro Paulo Niemeyer, Rio De Janeiro, Brazil.
   [Righy, Cassia] Fundacao Oswaldo Cruz, Lab Med Intens, Inst Nacl Infectol, Rio De Janeiro, Brazil.
   [Amendola, Cristina P.] Barretos Canc Hosp, Barretos, Brazil.
   [Roepke, Roberta M. L.] AC Camargo Canc Ctr, Intens Care Unit, Sao Paulo, Brazil.
   [Forte, Daniel N.] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, UTI 09DN, Sao Paulo, Brazil.
   [Freitas, Flavio G. R.; Machado, Flavia R.] Univ Fed Sao Paulo, Anesthesiol Pain & Intens Care Dept, Sao Paulo, Brazil.
   [Fernandes, Caio C. F.] Hosp Mario Covas, FMABC, Santo Andre, SP, Brazil.
   [Melro, Livia M. G.] Hosp Samaritano Paulista, Sao Paulo, Brazil.
   [Junior, Gedealvares F. S.] Hosp Evangel Vila Velha, Vila Velha, Brazil.
   [Morais, Douglas Costa; Zung, Stevin] Ache Labs Farmaceut, Sao Paulo, Brazil.
   [Azevedo, Luciano C. P.] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Disciplina Emergencias Clin, Sao Paulo, Brazil.
RP Azevedo, LCP (corresponding author), Hosp Sirio Libanes, Rua Prof Daher Cutait 69, BR-01308060 Sao Paulo, Brazil.
EM luciano.azevedo@hsl.org.br
RI Roepke, Roberta/AAN-6414-2020; Lisboa, Thiago/W-2973-2019; Tomazini,
   Bruno/AAZ-6149-2020; Rosa, Regis Goulart/P-6422-2019; de Carvalho,
   Carlos Roberto Ribeiro/N-9827-2018
OI Lisboa, Thiago/0000-0003-4306-2212; de Carvalho, Carlos Roberto
   Ribeiro/0000-0002-1618-8509; Reis, AlessanRSS/0000-0001-8486-7469;
   Roepke, Roberta Muriel Longo/0000-0003-2214-5166
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, US SUPP UN PRINC DES
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Becluneau G, 2017, AM J RESP CRIT CARE, V195, P772, DOI [10.1164/1-ccin.201602-032006, DOI 10.1164/1-CCIN.201602-032006]
   Beduneau G, 2017, AM J RESP CRIT CARE, V195, P772, DOI 10.1164/rccm.201602-0320OC
   Cao B, 2016, CRIT CARE MED, V44, pE318, DOI 10.1097/CCM.0000000000001616
   Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Grasselli G, 2020, JAMA INTERN MED, V180, P1345, DOI 10.1001/jamainternmed.2020.3539
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Lehmann EL, 1975, NONPARAMETRICS STAT
   Metnitz PGH, 2005, INTENS CARE MED, V31, P1336, DOI 10.1007/s00134-005-2762-6
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Neto AS, 2016, LANCET RESP MED, V4, P882, DOI 10.1016/S2213-2600(16)30305-8
   Steinberg KP, 2006, NEW ENGL J MED, V354, P1671
   Tomazini BM, 2020, REV BRAS TER INTENSI
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Wang Y, 2020, AM J RESP CRIT CARE, V201, P1430, DOI 10.1164/rccm.202003-0736LE
   World Health Organization, 2020, COVID 19 THER TRIAL
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 30
TC 27
Z9 27
U1 2
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 6
PY 2020
VL 324
IS 13
BP 1307
EP 1316
DI 10.1001/jama.2020.17021
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OS4SZ
UT WOS:000590156000015
PM 32876695
OA Bronze
DA 2021-01-01
ER

PT J
AU Angus, DC
   Derde, L
   Al-Beidh, F
   Annane, D
   Arabi, Y
   Beane, A
   Van Bentum-Puijk, W
   Berry, L
   Bhimani, Z
   Bonten, M
   Bradbury, C
   Brunkhorst, F
   Buxton, M
   Buzgau, A
   Cheng, AC
   de Jong, M
   Detry, M
   Estcourt, L
   Fitzgerald, M
   Goossens, H
   Green, C
   Haniffa, R
   Higgins, AM
   Horvat, C
   Hullegie, SJ
   Kruger, P
   Lamontagne, F
   Lawler, PR
   Linstrum, K
   Litton, E
   Lorenzi, E
   Marshall, J
   McAuley, D
   McGlothin, A
   McGuinness, S
   McVerry, B
   Montgomery, S
   Mouncey, P
   Murthy, S
   Nichol, A
   Parke, R
   Parker, J
   Rowan, K
   Sanil, A
   Santos, M
   Saunders, C
   Seymour, C
   Turner, A
   van de Veerdonk, F
   Venkatesh, B
   Zarychanski, R
   Berry, S
   Lewis, RJ
   McArthur, C
   Webb, SA
   Gordon, AC
AF Angus, Derek C.
   Derde, Lennie
   Al-Beidh, Farah
   Annane, Djillali
   Arabi, Yaseen
   Beane, Abigail
   Van Bentum-Puijk, Wilma
   Berry, Lindsay
   Bhimani, Zahra
   Bonten, Marc
   Bradbury, Charlotte
   Brunkhorst, Frank
   Buxton, Meredith
   Buzgau, Adrian
   Cheng, Allen C.
   de Jong, Menno
   Detry, Michelle
   Estcourt, Lise
   Fitzgerald, Mark
   Goossens, Herman
   Green, Cameron
   Haniffa, Rashan
   Higgins, Alisa M.
   Horvat, Christopher
   Hullegie, Sebastiaan J.
   Kruger, Peter
   Lamontagne, Francois
   Lawler, Patrick R.
   Linstrum, Kelsey
   Litton, Edward
   Lorenzi, Elizabeth
   Marshall, John
   McAuley, Daniel
   McGlothin, Anna
   McGuinness, Shay
   McVerry, Bryan
   Montgomery, Stephanie
   Mouncey, Paul
   Murthy, Srinivas
   Nichol, Alistair
   Parke, Rachael
   Parker, Jane
   Rowan, Kathryn
   Sanil, Ashish
   Santos, Marlene
   Saunders, Christina
   Seymour, Christopher
   Turner, Anne
   van de Veerdonk, Frank
   Venkatesh, Balasubramanian
   Zarychanski, Ryan
   Berry, Scott
   Lewis, Roger J.
   McArthur, Colin
   Webb, Steven A.
   Gordon, Anthony C.
TI Effect of Hydrocortisone on Mortality and Organ Support in Patients With
   Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized
   Clinical Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
AB IMPORTANCE Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited.
   OBJECTIVE To determine whether hydrocortisone improves outcome for patients with severe COVID-19.
   DESIGN, SETTING, AND PARTICIPANTS An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020.
   INTERVENTIONS The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108).
   MAIN OUTCOMES AND MEASURES The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%).
   RESULTS After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0(IQR, -1 to 15), 0(IQR, -1 to 13), and 0(-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively.
   CONCLUSIONS AND RELEVANCE Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions.
C1 [Angus, Derek C.; Horvat, Christopher; Linstrum, Kelsey; Montgomery, Stephanie; Seymour, Christopher] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness CRI, Dept Crit Care Med, Sch Med, Pittsburgh, PA 15261 USA.
   [Angus, Derek C.; Horvat, Christopher; Montgomery, Stephanie; Seymour, Christopher] UPMC Hlth Syst Off Healthcare Innovat, Pittsburgh, PA USA.
   [Derde, Lennie; Van Bentum-Puijk, Wilma; Bonten, Marc; Hullegie, Sebastiaan J.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Derde, Lennie] Univ Med Ctr Utrecht, Intens Care Ctr, Utrecht, Netherlands.
   [Al-Beidh, Farah; Gordon, Anthony C.] Imperial Coll London, Dept Surg & Canc, Div Anaesthet Pain Med & Intens Care Med, London, England.
   [Al-Beidh, Farah; Gordon, Anthony C.] Imperial Coll Healthcare NHS Trust, London, England.
   [Annane, Djillali] Hop Raymond Poincare, AP HP, Intens Care Unit, Paris, France.
   [Annane, Djillali] Univ Versailles, Simone Veil Sch Med, Versailles, France.
   [Annane, Djillali] Univ Paris Saclay, Garches, France.
   [Arabi, Yaseen] King Saud Bin Abdulaziz Univ Hlth Sci, Coll Med, King Abdullah Int Med Res Ctr, Intens Care Dept,King Abdulaziz Med City, Riyadh, Saudi Arabia.
   [Beane, Abigail] Univ Oxford, Nuffield Dept Clin Med, Oxford, England.
   [Berry, Lindsay; Detry, Michelle; Fitzgerald, Mark; Lorenzi, Elizabeth; McGlothin, Anna; Sanil, Ashish; Saunders, Christina; Berry, Scott; Lewis, Roger J.] Berry Consultants LLC, Austin, TX USA.
   [Bhimani, Zahra; Marshall, John; Santos, Marlene] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [Bonten, Marc] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands.
   [Bradbury, Charlotte] Bristol Royal Informatory, Bristol, Avon, England.
   [Bradbury, Charlotte] Univ Bristol, Bristol, Avon, England.
   [Brunkhorst, Frank] Jena Univ Hosp, Ctr Clin Studies & Ctr Sepsis Control & Care CSCC, Dept Anesthesiol & Intens Care Med, Jena, Germany.
   [Buxton, Meredith] Global Coalit Adapt Res, San Francisco, CA USA.
   [Buzgau, Adrian] Monash Univ, Helix, Melbourne, Vic, Australia.
   [Cheng, Allen C.] Alfred Hlth, Infect Prevent & Healthcare Epidemiol Unit, Melbourne, Vic, Australia.
   [Cheng, Allen C.; Green, Cameron; Higgins, Alisa M.; McGuinness, Shay; Nichol, Alistair; Parker, Jane; Webb, Steven A.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Epidemiol & Prevent Med, Melbourne, Vic, Australia.
   [de Jong, Menno] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Med Microbiol, Amsterdam, Netherlands.
   [Goossens, Herman] Antwerp Univ Hosp, Dept Microbiol, Antwerp, Belgium.
   [Estcourt, Lise] NHS Blood & Transplant, Bristol, Avon, England.
   [Estcourt, Lise] Univ Oxford, Med Sci Div, Transfus Med, Oxford, England.
   [Haniffa, Rashan] Network Improving Crit Care Syst & Training, Colombo, Sri Lanka.
   [Haniffa, Rashan] Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand.
   [Kruger, Peter] Princess Alexandra Hosp, Intens Care Unit, Brisbane, Qld, Australia.
   [Lamontagne, Francois] Univ Sherbrooke, Sherbrooke, PQ, Canada.
   [Lawler, Patrick R.] Univ Toronto, Univ Hlth Network, Peter Munk Cardiac Ctr, Interdept Div Crit Care Med,Cardiac Intens Care U, Toronto, ON, Canada.
   [Litton, Edward; Webb, Steven A.] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia.
   [Marshall, John] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada.
   [McAuley, Daniel] Queens Univ Belfast, Ctr Expt Med, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
   [McGuinness, Shay; Parke, Rachael] Auckland City Hosp, Cardiothorac & Vasc Intens Care Unit, Auckland, New Zealand.
   [McGuinness, Shay; Parke, Rachael] Hlth Res Council New Zealand, Wellington, New Zealand.
   [McGuinness, Shay; Parke, Rachael; Turner, Anne; McArthur, Colin] Med Res Inst New Zealand, Wellington, New Zealand.
   [McVerry, Bryan] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
   [Mouncey, Paul; Rowan, Kathryn] Intens Care Natl Audit & Res Ctr ICNARC, Clin Trials Unit, London, England.
   [Murthy, Srinivas] Univ British Columbia, Sch Med, Vancouver, BC, Canada.
   [Nichol, Alistair] St Vincents Univ Hosp, Dept Anesthesia & Intens Care, Dublin, Ireland.
   [Nichol, Alistair] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland.
   [Nichol, Alistair] Alfred Hlth, Dept Intens Care, Melbourne, Vic, Australia.
   [Parke, Rachael] Univ Auckland, Sch Nursing, Auckland, New Zealand.
   [van de Veerdonk, Frank] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Med Ctr, Nijmegen, Netherlands.
   [Venkatesh, Balasubramanian] Princess Alexandra Hosp, Southside Clin Unit, Brisbane, Qld, Australia.
   [Venkatesh, Balasubramanian] George Inst Global Hlth, Sydney, NSW, Australia.
   [Zarychanski, Ryan] Univ Manitoba, Dept Med Crit Care & Hematol Med Oncol, Winnipeg, MB, Canada.
   [Lewis, Roger J.] Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA.
   [Lewis, Roger J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Emergency Med, Los Angeles, CA 90095 USA.
   [McArthur, Colin] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand.
   [Webb, Steven A.] St John God Hosp, Subiaco, WA, Australia.
RP Angus, DC (corresponding author), Univ Pittsburgh, Dept Crit Care Med, 3550 Terrace St,614 Scaife Hall, Pittsburgh, PA 15261 USA.
EM angusdc@upmc.edu
OI Carrier, Francois Martin/0000-0003-0310-0616; Nichol,
   Alistair/0000-0002-4689-1238; Dark, Paul/0000-0003-3309-0164; Puxty,
   Kathryn/0000-0002-5742-6171; Haniffa, Rashan/0000-0002-8288-449X; Duffy,
   Eamon/0000-0002-4515-5116; Hagel, Stefan/0000-0003-2999-6131; Laffan,
   Michael/0000-0002-8268-3268; Hills, Thomas/0000-0003-0322-5822;
   Dushianthan, Ahilanandan/0000-0002-0165-3359; Derde,
   Lennie/0000-0002-3577-5629
FU Platform for European Preparedness Against (Re-) emerging Epidemics
   (PREPARE) consortium by the European Union, FP7-HEALTH-2013-INNOVATION-1
   [602525]; Australian National Health and Medical Research
   CouncilNational Health and Medical Research Council of Australia
   [APP1101719]; New Zealand Health Research CouncilHealth Research Council
   of New Zealand [161 631]; Canadian Institute of Health Research Strategy
   for Patient -Oriented Research Innovative Clinical Trials
   ProgramCanadian Institutes of Health Research (CIHR) [158584]; UK
   National Institute for Health Research (NIHR)National Institute for
   Health Research (NIHR); NIHR Imperial Biomedical Research Centre; Health
   Research Board of Ireland [CTN 2014-012]; Breast Cancer Research
   Foundation; French Ministry of Health [PHRC-20-0147]; Minderoo
   Foundation; UPMC Learning While Doing Program
FX This study was supported by the Platform for European Preparedness
   Against (Re-) emerging Epidemics (PREPARE) consortium by the European
   Union, FP7-HEALTH-2013-INNOVATION-1 (grant 602525), the Australian
   National Health and Medical Research Council (grant APP1101719), the New
   Zealand Health Research Council (grant 161 631), the Canadian Institute
   of Health Research Strategy for Patient -Oriented Research Innovative
   Clinical Trials Program (grant 158584), the UK National Institute for
   Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre,
   the Health Research Board of Ireland (grant CTN 2014-012), the UPMC
   Learning While Doing Program, the Breast Cancer Research Foundation, the
   French Ministry of Health (grant PHRC-20-0147), and the Minderoo
   Foundation.
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Angus DC, 2020, ANN AM THORAC SOC, V17, P879, DOI 10.1513/AnnalsATS.202003-192SD
   Angus DC, 2015, JAMA-J AM MED ASSOC, V314, P767, DOI 10.1001/jama.2015.7762
   Annane D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002243.pub3
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bittl JA, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.117.003563
   Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032
   China National Health Commission, CHIN CLIN GUID COVID
   Chopra Amit, 2020, Crit Care Explor, V2, pe0143, DOI 10.1097/CCE.0000000000000143
   Ewald H, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006150.pub2
   Fadel Raef, 2020, Clin Infect Dis, V71, P2114, DOI 10.1093/cid/ciaa601
   Johns Hopkins University of Medicine Coronavirus Resource Center, COVID 19 US
   Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093
   Laterre PF, 2019, JAMA-J AM MED ASSOC, V322, P1476, DOI 10.1001/jama.2019.14607
   Li H, 2020, LEUKEMIA, V34, P1503, DOI 10.1038/s41375-020-0848-3
   Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7
   Quintana M, 2017, JAMA-J AM MED ASSOC, V318, P1605, DOI 10.1001/jama.2017.15574
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980
   Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023
   World Health Organization, WHO CLIN MAN COVID 1
   Ye ZK, 2020, CAN MED ASSOC J, V192, pE756, DOI 10.1503/cmaj.200645
NR 23
TC 17
Z9 17
U1 4
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 6
PY 2020
VL 324
IS 13
BP 1317
EP 1329
DI 10.1001/jama.2020.17022
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA OS4SZ
UT WOS:000590156000016
PM 32876697
OA Bronze
DA 2021-01-01
ER

PT J
AU Sterne, JAC
   Murthy, S
   Diaz, JV
   Slutsky, AS
   Villar, J
   Angus, DC
   Annane, D
   Azevedo, LCP
   Berwanger, O
   Cavalcanti, AB
   Dequin, PF
   Du, B
   Emberson, J
   Fisher, D
   Giraudeau, B
   Gordon, AC
   Granholm, A
   Green, C
   Haynes, R
   Heming, N
   Higgins, JPT
   Horby, P
   Juni, P
   Landray, MJ
   Le Gouge, A
   Leclerc, M
   Lim, WS
   Machado, FR
   McArthur, C
   Meziani, F
   Moller, MH
   Perner, A
   Petersen, MW
   Savovic, J
   Tomazini, B
   Veiga, VC
   Webb, S
   Marshall, JC
AF Sterne, Jonathan A. C.
   Murthy, Srinivas
   Diaz, Janet, V
   Slutsky, Arthur S.
   Villar, Jesus
   Angus, Derek C.
   Annane, Djillali
   Pontes Azevedo, Luciano Cesar
   Berwanger, Otavio
   Cavalcanti, Alexandre B.
   Dequin, Pierre-Francois
   Du, Bin
   Emberson, Jonathan
   Fisher, David
   Giraudeau, Bruno
   Gordon, Anthony C.
   Granholm, Anders
   Green, Cameron
   Haynes, Richard
   Heming, Nicholas
   Higgins, Julian P. T.
   Horby, Peter
   Juni, Peter
   Landray, Martin J.
   Le Gouge, Amelie
   Leclerc, Marie
   Lim, Wei Shen
   Machado, Flavia R.
   McArthur, Colin
   Meziani, Ferhat
   Moller, Morten Hylander
   Perner, Anders
   Petersen, Marie Warrer
   Savovic, Jelena
   Tomazini, Bruno
   Veiga, Viviane C.
   Webb, Steve
   Marshall, John C.
CA WHO Rapid Evidence Appraisal COVID
TI Association Between Administration of Systemic Corticosteroids and
   Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID CONSENSUS
AB IMPORTANCE Effective therapies for patients with coronavirus disease 2019 (COVID-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support.
   OBJECTIVE To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality.
   DESIGN, SETTING, AND PARTICIPANTS Prospective meta-analysis that pooled data from 7 randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19. The trials were conducted in 12 countries from February 26, 2020, to June 9, 2020, and the date of final follow-up was July 6, 2020. Pooled data were aggregated from the individual trials, overall, and in predefined subgroups. Risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I-2 statistic. The primary analysis was an inverse variance-weighted fixed-effect meta-analysis of overall mortality, with the association between the intervention and mortality quantified using odds ratios (ORs). Random-effects meta-analyses also were conducted (with the Paule-Mandel estimate of heterogeneity and the Hartung-Knapp adjustment) and an inverse variance-weighted fixed-effect analysis using risk ratios.
   EXPOSURES Patients had been randomized to receive systemic dexamethasone, hydrocortisone, or methylprednisolone (678 patients) or to receive usual care or placebo (1025 patients).
   MAIN OUTCOMES AND MEASURES The primary outcome measure was all-cause mortality at 28 days after randomization. A secondary outcome was investigator-defined serious adverse events.
   RESULTS A total of 1703 patients (median age, 60 years [interquartile range, 52-68 years]; 488 [29%] women) were included in the analysis. Risk of bias was assessed as "low" for 6 of the 7 mortality results and as "some concerns" in 1 trial because of the randomization method. Five trials reported mortality at 28 days, 1 trial at 21 days, and 1 trial at 30 days. There were 222 deaths among the 678 patients randomized to corticosteroids and 425 deaths among the 1025 patients randomized to usual care or placebo (summary OR, 0.66 [95% CI, 0.53-0.82]; P < .001 based on a fixed-effect meta-analysis). There was little inconsistency between the trial results (I-2 = 15.6%; P = .31 for heterogeneity) and the summary OR was 0.70 (95% CI, 0.48-1.01; P = .053) based on the random-effects meta-analysis. The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths). Among the 6 trials that reported serious adverse events, 64 events occurred among 354 patients randomized to corticosteroids and 80 events occurred among 342 patients randomized to usual care or placebo.
   CONCLUSIONS AND RELEVANCE In this prospective meta-analysis of clinical trials of critically ill patients with COVID-19, administration of systemic corticosteroids, compared with usual care or placebo, was associated with lower 28-day all-cause mortality.
C1 [Sterne, Jonathan A. C.; Higgins, Julian P. T.; Savovic, Jelena] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England.
   [Sterne, Jonathan A. C.; Higgins, Julian P. T.] NIHR Bristol Biomed Res Ctr, Bristol, Avon, England.
   [Murthy, Srinivas] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada.
   [Diaz, Janet, V] WHO, Clin Unit, Hlth Emergencies Programme, Geneva, Switzerland.
   [Slutsky, Arthur S.; Juni, Peter] Univ Toronto, Appl Hlth Res Ctr, Dept Med, Li Ka Shing Knowledge Inst,St Michaels Hosp, Toronto, ON, Canada.
   [Villar, Jesus] Hosp Univ Dr Negrin, Res Unit, Las Palmas Gran Canaria, Spain.
   [Villar, Jesus] Inst Salud Carlos III, CIBER Enfermedades Respiratorias, Madrid, Spain.
   [Angus, Derek C.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA.
   [Annane, Djillali; Heming, Nicholas] Univ Paris Saclay UVSQ, Raymond Poincare Hosp, AP HP, Dept Intens Care,Sch Med Simone Veil, Paris, France.
   [Pontes Azevedo, Luciano Cesar; Tomazini, Bruno] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Pontes Azevedo, Luciano Cesar] Univ Sao Paulo, Emergency Med Dept, Sch Med, Sao Paulo, Brazil.
   [Berwanger, Otavio] Hosp Israelita Albert Einstein, Acad Res Org, Sao Paulo, Brazil.
   [Cavalcanti, Alexandre B.] HCor Res Insitute, Sao Paulo, Brazil.
   [Dequin, Pierre-Francois] CHRU Tours, INSERM, Med Intens Reanimat, CIC1415, Tours, France.
   [Dequin, Pierre-Francois] Univ Tours, Ctr Etud Pathol Respiratoires, CRICS TriGGERSep Network, Tours, France.
   [Du, Bin] Peking Union Med Coll Hosp, Beijing, Peoples R China.
   [Emberson, Jonathan; Haynes, Richard; Landray, Martin J.] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England.
   [Emberson, Jonathan; Haynes, Richard; Landray, Martin J.] Univ Oxford, MRC, Populat Hlth Res Unit, Oxford, England.
   [Fisher, David] UCL, Fac Populat Hlth Sci, Inst Clin Trials & Methodol, MRC,Clin Trials Unit, London, England.
   [Giraudeau, Bruno; Le Gouge, Amelie; Leclerc, Marie] CHRU Tours, CIC INSERM 1415, Tours, Indre & Loire, France.
   [Gordon, Anthony C.] Imperial Coll London, Div Anaesthet Pain Med & Intens Care, London, England.
   [Granholm, Anders; Moller, Morten Hylander; Perner, Anders; Petersen, Marie Warrer] Univ Copenhagen, Rigshosp, Dept Intens Care, Copenhagen, Denmark.
   [Green, Cameron; McArthur, Colin; Webb, Steve] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Epidemiol & Prevent Med, Melbourne, Vic, Australia.
   [Higgins, Julian P. T.; Savovic, Jelena] Univ Hosp Bristol & Weston NHS Fdn Trust, NIHR Appl Res Collaborat West, Bristol, Avon, England.
   [Horby, Peter] Univ Oxford, Nuffield Dept Med, Oxford, England.
   [Landray, Martin J.] Oxford Univ Hosp NHS Fdn Trust, NIHR Oxford Biomed Res Ctr, Oxford, England.
   [Lim, Wei Shen] Nottingham Univ Hosp NHS Trust, Resp Med Dept, Nottingham, England.
   [Machado, Flavia R.] Univ Fed Sao Paulo, Anesthesiol Pain & Intens Care Dept, Sao Paulo, Brazil.
   [McArthur, Colin] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand.
   [Meziani, Ferhat] Hop Univ Strasbourg, Serv Med Intens Reanimat, Nouvel Hop Civil, Strasbourg, France.
   [Meziani, Ferhat] FMTS, Regenerat Nanomed, UMR 1260, Strasbourg, France.
   [Tomazini, Bruno] Univ Sao Paulo, Sch Med, Dept Surg, Sao Paulo, Brazil.
   [Veiga, Viviane C.] BP A Beneficencia Portuguesa Sao Paulo, Sao Paulo, Brazil.
   [Webb, Steve] St John God Healthcare, Subiaco, WA, Australia.
   [Marshall, John C.] Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON, Canada.
RP Sterne, JAC (corresponding author), Univ Bristol, Bristol Med Sch, Dept Populat Hlth Sci, Oakfield House, Bristol BS8 2BN, England.
EM jonathan.sterne@bristol.ac.uk
RI Villar, Jesus/R-4526-2019; Tomazini, Bruno/AAZ-6149-2020; Savovic,
   Jelena/O-4107-2019; GIRAUDEAU, Bruno/L-9003-2015; Higgins,
   Julian/H-4008-2011
OI Villar, Jesus/0000-0001-5687-3562; Savovic, Jelena/0000-0002-2861-0578;
   Sterne, Jonathan/0000-0001-8496-6053; GIRAUDEAU,
   Bruno/0000-0003-3031-8258; Higgins, Julian/0000-0002-8323-2514; Badenes,
   Rafael/0000-0001-7017-0150; Granholm, Anders/0000-0001-5799-7655
FU World Health OrganizationWorld Health Organization
FX Funding for administrative and communications support was provided by
   the World Health Organization.
CR Abate SM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235653
   Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022
   Angus DC, 2020, ANN AM THORAC SOC, V17, P879, DOI 10.1513/AnnalsATS.202003-192SD
   Annane D, 2019, COCHRANE DB SYST REV, V12
   Annane D, 2017, INTENS CARE MED, V43, P1751, DOI 10.1007/s00134-017-4919-5
   Annane D, 2009, JAMA-J AM MED ASSOC, V301, P2362, DOI 10.1001/jama.2009.815
   DALE DC, 1973, MED CLIN N AM, V57, P1277, DOI 10.1016/S0025-7125(16)32228-3
   Dequin PF, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.16 761, DOI 10.1001/JAMA.2020.16]
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Fisher DJ, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j573
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Hartung J, 2001, STAT MED, V20, P3875, DOI 10.1002/sim.1009
   International Severe Acute Respiratory and Emerging Infections Consortium, 2020, COVID 19 REP
   IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25
   Jeronimo Christiane Maria Prado, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1177
   Js V, 2020, CRIT CARE EXPLOR, V2, pe0111
   Langan D, 2017, RES SYNTH METHODS, V8, P181, DOI 10.1002/jrsm.1198
   Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093
   PAULE RC, 1982, J RES NAT BUR STAND, V87, P377, DOI 10.6028/jres.087.022
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sterne JAC, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04641-3
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898
   Thomas J, PROSPECTIVE APPROACH, DOI 10.1002/9781119536604.ch22
   Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021
NR 26
TC 53
Z9 53
U1 4
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 6
PY 2020
VL 324
IS 13
BP 1330
EP 1341
DI 10.1001/jama.2020.17023
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA OS4SZ
UT WOS:000590156000017
PM 32876694
OA Bronze
DA 2021-01-01
ER

PT J
AU Zhou, Y
   Cen, LS
AF Zhou, Yuan
   Cen, Lu-Sha
TI Managing acute appendicitis during the COVID-19 pandemic in Jiaxing,
   China
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE COVID-19; Acute appendicitis; Perioperative management; Postoperative
   management; Perforated appendicitis; Pandemic
ID APPENDECTOMY
AB BACKGROUND
   Coronavirus disease 19 (COVID-19) is a global pandemic and has had a profound impact on our routine surgical activities. Acute appendicitis is the most common abdominal emergency worldwide. Therefore, it is highly essential to assess the influence the pandemic has on acute appendicitis.
   AIM
   To assess the efficacy of the management of acute appendicitis during the COVID-19 pandemic.
   METHODS
   We retrospectively analyzed 90 patients who presented with acute appendicitis during the outbreak of COVID-19 in Jiaxing, China. Clinical data regarding appendectomies patients were also collected for the corresponding time frame from 2019. Preoperative management, intraoperative protective measures, and postoperative management were conducted.
   RESULTS
   After screening, six patients were identified as unqualified due to fever and were then referred to the COVID-19 expert group. The results of the nucleic acid test were negative. Of the 76 patients enrolled in the simple group, nine patients received medication therapy, and all others underwent surgery. From this same group, 66 patients were diagnosed with suppurative appendicitis, and one patient was diagnosed with perforated appendicitis after surgery. There were 14 patients in the complex group, for which the postoperative diagnosis indicated perforated appendicitis. The proportion of men with perforated appendicitis was higher than that in 2019 (P < 0.05). The chief complaint duration for perforated appendicitis patients in 2020 was longer than that in 2019 (P < 0.05). The routine blood test showed that white blood cell counts and neutrophil ratios were higher in perforated appendicitis patients in 2020 than in 2019 (P < 0.05). The ratio of open appendectomies to the amount of mean blood loss during surgery was greater in 2020 than in 2019 (P < 0.05). Online consultation after discharge was selected in 59 cases (65.6%). No perioperative infection with COVID-19 or long-term postoperative complications were found.
   CONCLUSION
   The management of acute appendicitis from Jiaxing effectively reduced the influence of the pandemic and minimized the risk of nosocomial infection.
C1 [Zhou, Yuan] Jiaxing Univ, Affiliated Hosp, Hosp Jiaxing 1, Dept Gastrointestinal Surg, Jiaxing 31400, Zhejiang, Peoples R China.
   [Cen, Lu-Sha] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
RP Cen, LS (corresponding author), Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
EM Cenlusa2@sina.com
FU Jiaxing Key Discipline of Medicine-Oncology (Supporting Subject)
   [2019-zc11]
FX Supported by Jiaxing Key Discipline of Medicine-Oncology (Supporting
   Subject), No. 2019-zc11.
CR Bhangu A, 2015, LANCET, V386, P1278, DOI 10.1016/S0140-6736(15)00275-5
   Cheeyandira A, 2020, J SURG CASE REP, DOI 10.1093/jscr/rjaa109
   Cholankeril G, 2020, GASTROENTEROLOGY, V159, P775, DOI 10.1053/j.gastro.2020.04.008
   Collard M, 2020, J VISC SURG, V157, pS33, DOI 10.1016/j.jviscsurg.2020.04.014
   Giorgi PD, 2020, BONE JOINT J, V102B, P671, DOI 10.1302/0301-620X.102B6.BJJ-2020-0537
   Jaschinski T, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001546.pub4
   Jindal V, 2020, MED ONCOL, V37, DOI 10.1007/s12032-020-01382-w
   Kelly ME, 2020, COLORECTAL DIS, V22, P648, DOI 10.1111/codi.15141
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   Marudanayagam R, 2006, J GASTROENTEROL, V41, P745, DOI 10.1007/s00535-006-1855-5
   Sahu KK, 2020, BONE MARROW TRANSPL, V55, P2193, DOI 10.1038/s41409-020-0913-6
   Shen Q, 2020, PEDIATR NEPHROL, V35, P1351, DOI 10.1007/s00467-020-04555-x
   Slim K, 2020, J VISC SURG, V157, pS5, DOI 10.1016/j.jviscsurg.2020.04.001
   Snapiri O, 2020, ACTA PAEDIATR, V109, P1672, DOI 10.1111/apa.15376
   Tankel J, 2020, WORLD J SURG, V44, P2458, DOI 10.1007/s00268-020-05599-8
   Vigneswaran Y, 2020, J GASTROINTEST SURG, V24, P1686, DOI 10.1007/s11605-020-04592-9
   Wang C, 2020, INT J ENV RES PUBLIC, V17
   Wang DY, 2019, BMC SURG, V19, DOI 10.1186/s12893-019-0515-7
   Westfall KM, 2019, AM SURGEON, V85, P1209
   Xiang BQ, 2020, AM J INFECT CONTROL, V48, P915, DOI 10.1016/j.ajic.2020.05.020
NR 20
TC 0
Z9 0
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD OCT 6
PY 2020
VL 8
IS 19
BP 4349
EP 4359
DI 10.12998/wjcc.v8.i19.4349
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA OS5TR
UT WOS:000590226600008
PM 33083394
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Cheng, X
   Liu, YO
   Li, HM
   Zhang, X
   Lei, F
   Qin, JJ
   Chen, Z
   Deng, KQ
   Lin, LJ
   Chen, MM
   Song, XH
   Xia, M
   Huang, XW
   Liu, WF
   Cai, JJ
   Zhang, XJ
   Zhou, F
   Zhang, P
   Wang, YB
   Ma, XL
   Xu, QB
   Yang, J
   Ye, P
   Mao, WM
   Huang, XD
   Xia, JH
   Zhang, BH
   Guo, J
   Zhu, LH
   Lu, ZB
   Yuan, YF
   Wei, X
   She, ZG
   Ji, YX
   Li, HL
AF Cheng, Xu
   Liu, Ye-O
   Li, Haomiao
   Zhang, Xin
   Lei, Fang
   Qin, Juan-Juan
   Chen, Ze
   Deng, Ke-Qiong
   Lin, Lijin
   Chen, Ming-Ming
   Song, Xiaohui
   Xia, Meng
   Huang, Xuewei
   Liu, Weifang
   Cai, Jingjing
   Zhang, Xiao-Jing
   Zhou, Feng
   Zhang, Peng
   Wang, Yibin
   Ma, Xinliang
   Xu, Qingbo
   Yang, Juan
   Ye, Ping
   Mao, Weiming
   Huang, Xiaodong
   Xia, Jiahong
   Zhang, Bing-Hong
   Guo, Jiao
   Zhu, Lihua
   Lu, Zhibing
   Yuan, Yufeng
   Wei, Xiang
   She, Zhi-Gang
   Ji, Yan-Xiao
   Li, Hongliang
TI Metformin Is Associated with Higher Incidence of Acidosis, but Not
   Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes
SO CELL METABOLISM
LA English
DT Article
ID LACTIC-ACIDOSIS; MECHANISMS; DIAGNOSIS; PROTECTS; LACTATE; SEPSIS; DRUG
AB The safety and efficacy of anti-diabetic drugs are critical for maximizing the beneficial impacts of well-controlled blood glucose on the prognosis of individuals with COVID-19 and pre-existing type 2 diabetes (T2D). Metformin is the most commonly prescribed first-line medication for T2D, but its impact on the outcomes of individuals with COVID-19 and T2D remains to be clarified. Our current retrospective study in a cohort of 1,213 hospitalized individuals with COVID-19 and pre-existing T2D indicated that metformin use was significantly associated with a higher incidence of acidosis, particularly in cases with severe COVID-19, but not with 28-day COVID-19-related mortality. Furthermore, metformin use was significantly associated with reduced heart failure and inflammation. Our findings provide clinical evidence in support of continuing metformin treatment in individuals with COVID-19 and pre-existing T2D, but acidosis and kidney function should be carefully monitored in individuals with severe COVID-19.
C1 [Cheng, Xu; Lei, Fang; Deng, Ke-Qiong; Liu, Weifang; Lu, Zhibing; Li, Hongliang] Wuhan Univ, Zhongnan Hosp, Sch Basic Med Sci, Dept Cardiol, Wuhan, Peoples R China.
   [Cheng, Xu; Liu, Ye-O; Li, Haomiao; Zhang, Xin; Lei, Fang; Qin, Juan-Juan; Chen, Ze; Lin, Lijin; Chen, Ming-Ming; Song, Xiaohui; Xia, Meng; Huang, Xuewei; Liu, Weifang; Zhang, Xiao-Jing; Zhou, Feng; Zhang, Peng; Yang, Juan; Zhu, Lihua; She, Zhi-Gang; Ji, Yan-Xiao; Li, Hongliang] Wuhan Univ, Inst Model Anim, Wuhan, Peoples R China.
   [Liu, Ye-O; Li, Haomiao; Qin, Juan-Juan; Chen, Ze; Lin, Lijin; Chen, Ming-Ming; Song, Xiaohui; Huang, Xuewei; Zhang, Xiao-Jing; Yang, Juan; Zhu, Lihua; She, Zhi-Gang; Li, Hongliang] Wuhan Univ, Dept Cardiol, Renmin Hosp, Wuhan, Peoples R China.
   [Cai, Jingjing] Cent South Univ, Xiangya Hosp 3, Dept Cardiol, Changsha 410000, Peoples R China.
   [Zhou, Feng; Zhang, Peng; Ji, Yan-Xiao; Li, Hongliang] Wuhan Univ, Med Sci Res Ctr, Zhongnan Hosp, Wuhan, Peoples R China.
   [Wang, Yibin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol, Cardiovasc Res Labs, Los Angeles, CA 90095 USA.
   [Wang, Yibin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Cardiovasc Res Labs, Los Angeles, CA 90095 USA.
   [Wang, Yibin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Cardiovasc Res Labs, Los Angeles, CA 90095 USA.
   [Ma, Xinliang] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19004 USA.
   [Xu, Qingbo] Queen Mary Univ London, Ctr Clin Pharmacol, William Harvey Res Inst, London, England.
   [Ye, Ping] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Cardiol, Wuhan, Peoples R China.
   [Mao, Weiming] Huanggang Cent Hosp, Dept Gen Surg, Huanggang, Peoples R China.
   [Huang, Xiaodong] Wuhan Univ, Dept Gastroenterol, Wuhan Hosp 3, Wuhan, Peoples R China.
   [Huang, Xiaodong] Wuhan Univ, Tongren Hosp, Wuhan, Peoples R China.
   [Xia, Jiahong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiovasc Surg, Wuhan, Peoples R China.
   [Zhang, Bing-Hong] Wuhan Univ, Dept Neonatol, Renmin Hosp, Wuhan, Peoples R China.
   [Guo, Jiao] Guangdong Pharmaceut Univ, Guangdong Metab Dis Res Ctr Integrated Chinese &, Guangdong TCM Key Lab Metab Dis, Guangzhou 510006, Peoples R China.
   [Guo, Jiao] Guangdong Pharmaceut Univ, Key Lab Glucolipid Metab Disorder, Minist Educ China, Guangdong TCM Key Lab Metab Dis, Guangzhou 510006, Peoples R China.
   [Guo, Jiao] Guangdong Pharmaceut Univ, Inst Chinese Med, Guangdong TCM Key Lab Metab Dis, Guangzhou 510006, Peoples R China.
   [Yuan, Yufeng] Wuhan Univ, Dept Hepatobiliary & Pancreat Surg, Zhongnan Hosp, Wuhan, Peoples R China.
   [Wei, Xiang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Div Cardiothorac & Vasc Surg, Wuhan, Peoples R China.
RP Li, HL (corresponding author), Wuhan Univ, Zhongnan Hosp, Sch Basic Med Sci, Dept Cardiol, Wuhan, Peoples R China.; She, ZG; Ji, YX; Li, HL (corresponding author), Wuhan Univ, Inst Model Anim, Wuhan, Peoples R China.; She, ZG; Li, HL (corresponding author), Wuhan Univ, Dept Cardiol, Renmin Hosp, Wuhan, Peoples R China.; Ji, YX; Li, HL (corresponding author), Wuhan Univ, Med Sci Res Ctr, Zhongnan Hosp, Wuhan, Peoples R China.; Yuan, YF (corresponding author), Wuhan Univ, Dept Hepatobiliary & Pancreat Surg, Zhongnan Hosp, Wuhan, Peoples R China.; Wei, X (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Div Cardiothorac & Vasc Surg, Wuhan, Peoples R China.
EM yuanyf1971@whu.edu.cn; xiangwei@tjh.tjmu.edu.cn; zgshe@whu.edu.cn;
   jiyanxiao@whu.edu.cn; lihl@whu.edu.cn
OI Lei, Fang/0000-0003-0103-9348
FU National Key R&D Program of China [2016YFF0101504, 2019YFC2004700];
   Special Foundation for Emergency Research on Prevention and Control of
   COVID-19 of Guangdong Province [2020B1111330003]; National Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81630011, 81970364, 81970070, 81970011, 81870171]; Major Research Plan
   of the National Natural Science Foundation of ChinaNational Natural
   Science Foundation of China (NSFC) [91639304]; Hubei Science and
   Technology Support Project [2019BFC582, 2018BEC473, 2017BEC001]; Medical
   Flight Plan of Wuhan University
FX This work was supported by grants from the National Key R&D Program of
   China (2016YFF0101504 to Z.-G.S. and 2019YFC2004700 to L.Z.), the
   Special Foundation for Emergency Research on Prevention and Control of
   COVID-19 of Guangdong Province (2020B1111330003), the National Science
   Foundation of China (81630011 to Hongliang Li, 81970364 to Z.-G.S.,
   81970070 to X.-J.Z., 81970011 to P.Z., and 81870171 to J.C.), the Major
   Research Plan of the National Natural Science Foundation of China
   (91639304 to Hongliang Li), the Hubei Science and Technology Support
   Project (2019BFC582, 2018BEC473, and 2017BEC001 to Hongliang Li), and
   Medical Flight Plan of Wuhan University.
CR American Diabetes Association, 2019, CARE, V42, pS90, DOI DOI 10.2337/DC19-S005
   Amin S, 2019, BRIT J CLIN PHARMACO, V85, P37, DOI 10.1111/bcp.13780
   Bailey CJ, 2017, DIABETOLOGIA, V60, P1566, DOI 10.1007/s00125-017-4318-z
   BAKKER J, 1991, CHEST, V99, P956, DOI 10.1378/chest.99.4.956
   Bodmer M, 2008, DIABETES CARE, V31, P2086, DOI 10.2337/dc08-1171
   Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Bowker SL, 2010, DIABETOLOGIA, V53, P1631, DOI 10.1007/s00125-010-1750-8
   Cameron AR, 2016, CIRC RES, V119, P652, DOI 10.1161/CIRCRESAHA.116.308445
   Chinese Diabetes Society, 2018, ZHONGGUO SHIYONG NEI, V38, P53
   Doenyas-Barak K, 2016, CRIT CARE, V20, DOI 10.1186/s13054-015-1180-6
   Dziubak A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102869
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018
   Gando S, 2013, J THROMB HAEMOST, V11, P826, DOI 10.1111/jth.12190
   Haneuse S, 2019, JAMA-J AM MED ASSOC, V321, P602, DOI 10.1001/jama.2018.21554
   HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Inzucchi SE, 2014, JAMA-J AM MED ASSOC, V312, P2668, DOI 10.1001/jama.2014.15298
   Kraut JA, 2010, NAT REV NEPHROL, V6, P274, DOI 10.1038/nrneph.2010.33
   Lalau JD, 2010, DRUG SAFETY, V33, P727, DOI 10.2165/11536790-000000000-00000
   Lexis CPH, 2014, JAMA-J AM MED ASSOC, V311, P1526, DOI 10.1001/jama.2014.3315
   Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0
   Luo P, 2020, AM J TROP MED HYG, V103, P69, DOI 10.4269/ajtmh.20-0375
   Mathur MB, 2018, EPIDEMIOLOGY, V29, pE45, DOI 10.1097/EDE.0000000000000864
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mikkelsen ME, 2009, CRIT CARE MED, V37, P1670, DOI 10.1097/CCM.0b013e31819fcf68
   Misbin RI, 1998, NEW ENGL J MED, V338, P265, DOI 10.1056/NEJM199801223380415
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   National Health Commission of China, 2020, NEW COR PNEUM PREV C
   Oh TK, 2020, ANN PALLIAT MED, V9, P903, DOI 10.21037/apm.2020.04.25
   Overbeek JA, 2017, CLIN THER, V39, P759, DOI 10.1016/j.clinthera.2017.02.008
   Pollak M, 2017, DIABETOLOGIA, V60, P1662, DOI 10.1007/s00125-017-4352-x
   Rena G, 2017, DIABETOLOGIA, V60, P1577, DOI 10.1007/s00125-017-4342-z
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Shirani A, 2012, JAMA-J AM MED ASSOC, V308, P247, DOI 10.1001/jama.2012.7625
   Stricker BHC, 2010, EUR J EPIDEMIOL, V25, P245, DOI 10.1007/s10654-010-9451-7
   Suetrong B, 2016, CHEST, V149, P252, DOI 10.1378/chest.15-1703
   Tomczynska M, 2016, CURR TOP MED CHEM, V16, P2223, DOI 10.2174/1568026616666160216152324
   Tsai WL, 2017, ONCOTARGET, V8, P91928, DOI 10.18632/oncotarget.20248
   Tzanavari T, 2016, METABOLISM, V65, P1447, DOI 10.1016/j.metabol.2016.06.012
   Ursini F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01236
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607
   Waljee AK, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002847
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Yancy CW, 2017, CIRCULATION, V136, pE137, DOI 10.1161/CIR.0000000000000509
   Zhang J, 2018, AM J RESP CRIT CARE, V198, P509, DOI 10.1164/rccm.201712-2570OC
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhang ZH, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.02.12
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 51
TC 1
Z9 1
U1 3
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD OCT 6
PY 2020
VL 32
IS 4
BP 537
EP +
DI 10.1016/j.cmet.2020.08.013
PG 14
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA OH1IK
UT WOS:000582325100007
PM 32861268
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zeng, H
   Wang, DF
   Nie, JM
   Liang, HY
   Gu, J
   Zhao, AN
   Xu, LX
   Lang, CH
   Cui, XP
   Guo, XL
   Zhou, CL
   Li, HB
   Guo, B
   Zhang, JY
   Wang, Q
   Fang, L
   Liu, W
   Huang, YS
   Mao, W
   Chen, YK
   Zou, QM
AF Zeng, Hao
   Wang, Dongfang
   Nie, Jingmin
   Liang, Haoyu
   Gu, Jiang
   Zhao, Anne
   Xu, Lixin
   Lang, Chunhui
   Cui, Xiaoping
   Guo, Xiaolan
   Zhou, Changlong
   Li, Haibo
   Guo, Bin
   Zhang, Jinyong
   Wang, Qiang
   Fang, Li
   Liu, Wen
   Huang, Yishan
   Mao, Wei
   Chen, Yaokai
   Zou, Quanming
TI The efficacy assessment of convalescent plasma therapy for COVID-19
   patients: a multi-center case series
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Article
ID VIRUS; DISEASE
AB Convalescent plasma (CP) transfusion has been indicated as a promising therapy in the treatment for other emerging viral infections. However, the quality control of CP and individual variation in patients in different studies make it rather difficult to evaluate the efficacy and risk of CP therapy for coronavirus disease 2019 (COVID-19). We aimed to explore the potential efficacy of CP therapy, and to assess the possible factors associated with its efficacy. We enrolled eight critical or severe COVID-19 patients from four centers. Each patient was transfused with 200-400 mL of CP from seven recovered donors. The primary indicators for clinical efficacy assessment were the changes of clinical symptoms, laboratory parameters, and radiological image after CP transfusion. CP donors had a wide range of antibody levels measured by serology tests which were to some degree correlated with the neutralizing antibody (NAb) level. No adverse events were observed during and after CP transfusion. Following CP transfusion, six out of eight patients showed improved oxygen support status; chest CT indicated varying degrees of absorption of pulmonary lesions in six patients within 8 days; the viral load was decreased to a negative level in five patients who had the previous viremia; other laboratory parameters also tended to improve, including increased lymphocyte counts, decreased C-reactive protein, procalcitonin, and indicators for liver function. The clinical efficacy might be associated with CP transfusion time, transfused dose, and the NAb levels of CP. This study indicated that CP might be a potential therapy for severe patients with COVID-19.
C1 [Zeng, Hao; Gu, Jiang; Zhao, Anne; Li, Haibo; Zhang, Jinyong; Zou, Quanming] Third Mil Med Univ, Coll Pharm & Lab Med, Dept Microbiol & Biochem Pharm, Natl Engn Res Ctr Immunol, Chongqing, Peoples R China.
   [Zeng, Hao] Third Mil Med Univ, State Key Lab Trauma Burn & Combined Injury, Chongqing, Peoples R China.
   [Wang, Dongfang; Mao, Wei] Chongqing Blood Ctr, Inst Blood Transfus, Chongqing, Peoples R China.
   [Nie, Jingmin; Chen, Yaokai] Chongqing Publ Hlth Med Cent, Chongqing, Peoples R China.
   [Liang, Haoyu] Natl Inst Food & Drug Control, Inst Biol Prod Control, Div HIV AIDS & Sex Transmitted Virus Vaccines, Beijing, Peoples R China.
   [Xu, Lixin; Lang, Chunhui; Cui, Xiaoping] Chongqing Univ, Three Gorges Hosp, Chongqing, Peoples R China.
   [Xu, Lixin; Lang, Chunhui; Cui, Xiaoping] Chongqing Three Gorges Cent Hosp, Chongqing, Peoples R China.
   [Guo, Xiaolan; Guo, Bin; Wang, Qiang; Fang, Li; Liu, Wen; Huang, Yishan] North Sichuan Med Coll, Affiliated Hosp, Nanchong, Peoples R China.
   [Zhou, Changlong] Chongqing Med Univ, Yongchuan Hosp, Chongqing, Peoples R China.
RP Zou, QM (corresponding author), Third Mil Med Univ, Coll Pharm & Lab Med, Dept Microbiol & Biochem Pharm, Natl Engn Res Ctr Immunol, Chongqing, Peoples R China.; Mao, W (corresponding author), Chongqing Blood Ctr, Inst Blood Transfus, Chongqing, Peoples R China.; Chen, YK (corresponding author), Chongqing Publ Hlth Med Cent, Chongqing, Peoples R China.
EM maoweicqbc@163.com; yaokaichen@hotmail.com; qmzou2007@163.com
FU Emergency Project from the Science & Technology Commission of Chongqing
   [cstc2020jscx-fyzx0078]; Health Committee of Chongqing [2020NCPZX11]
FX This work was supported by the Emergency Project from the Science &
   Technology Commission of Chongqing (cstc2020jscx-fyzx0078) and Health
   Committee of Chongqing (2020NCPZX11). We thank all patients and donors
   involved in this study.
CR Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Barlow A, 2020, PHARMACOTHERAPY, V40, P416, DOI 10.1002/phar.2398
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   China NHCo, 2020, GUID DIAGN TREATM NO
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   FDA, FDA ISS EM US AUTH C
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Luchsinger Larry L, 2020, medRxiv, DOI 10.1101/2020.06.08.20124792
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Rajendran K, 2020, J MED VIROL, V92, P1475, DOI 10.1002/jmv.25961
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shen CG, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam5752
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tiberghien P, 2020, VOX SANG, V115, P488, DOI 10.1111/vox.12926
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   WHO, 2020, NOV COR COVID 19 SIT
   World Health Organization, CLIN MAN SEV AC RESP
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Yu HJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002985
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
NR 34
TC 2
Z9 2
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD OCT 6
PY 2020
VL 5
IS 1
AR 219
DI 10.1038/s41392-020-00329-x
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA OF9VG
UT WOS:000581544800002
PM 33024082
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cross, TJ
   Takahashi, GR
   Diessner, EM
   Crosby, MG
   Farahmand, V
   Zhuang, S
   Butts, CT
   Martin, RW
AF Cross, Thomas J.
   Takahashi, Gemma R.
   Diessner, Elizabeth M.
   Crosby, Marquise G.
   Farahmand, Vesta
   Zhuang, Shannon
   Butts, Carter T.
   Martin, Rachel W.
TI Sequence Characterization and Molecular Modeling of Clinically Relevant
   Variants of the SARS-CoV-2 Main Protease
SO BIOCHEMISTRY
LA English
DT Article
ID RESPIRATORY-SYNDROME CORONAVIRUS; AMINO-ACID-COMPOSITION; CATION-PI
   INTERACTIONS; SARS-CORONAVIRUS; 3C-LIKE PROTEASE; DYNAMICS; DIMER;
   DIMERIZATION; DISSOCIATION; CATALYSIS
AB The SARS-CoV-2 main protease (M-pro) is essential to viral replication and cleaves highly specific substrate sequences, making it an obvious target for inhibitor design. However, as for any virus, SARS-CoV-2 is subject to constant neutral drift and selection pressure, with new Mpro mutations arising over time. Identification and structural characterization of Mpro variants is thus critical for robust inhibitor design. Here we report sequence analysis, structure predictions, and molecular modeling for seventy-nine Mpro variants, constituting all clinically observed mutations in this protein as of April 29, 2020. Residue substitution is widely distributed, with some tendency toward larger and more hydrophobic residues. Modeling and protein structure network analysis suggest differences in cohesion and active site flexibility, revealing patterns in viral evolution that have relevance for drug discovery.
C1 [Cross, Thomas J.; Diessner, Elizabeth M.; Farahmand, Vesta; Zhuang, Shannon; Martin, Rachel W.] Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA.
   [Takahashi, Gemma R.; Crosby, Marquise G.; Martin, Rachel W.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.
   [Diessner, Elizabeth M.; Butts, Carter T.] Univ Calif Irvine, Calif Inst Telecommun & Informat Technol, Irvine, CA 92697 USA.
   [Butts, Carter T.] Univ Calif Irvine, Dept Sociol, Irvine, CA 92697 USA.
   [Butts, Carter T.] Univ Calif Irvine, Dept Stat, Irvine, CA 92697 USA.
   [Butts, Carter T.] Univ Calif Irvine, Dept Comp Sci, Irvine, CA 92697 USA.
   [Butts, Carter T.] Univ Calif Irvine, Dept Elect Engn & Comp Sci, Irvine, CA 92697 USA.
RP Martin, RW (corresponding author), Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA.; Martin, RW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.; Butts, CT (corresponding author), Univ Calif Irvine, Calif Inst Telecommun & Informat Technol, Irvine, CA 92697 USA.; Butts, CT (corresponding author), Univ Calif Irvine, Dept Sociol, Irvine, CA 92697 USA.; Butts, CT (corresponding author), Univ Calif Irvine, Dept Stat, Irvine, CA 92697 USA.; Butts, CT (corresponding author), Univ Calif Irvine, Dept Comp Sci, Irvine, CA 92697 USA.; Butts, CT (corresponding author), Univ Calif Irvine, Dept Elect Engn & Comp Sci, Irvine, CA 92697 USA.
EM buttsc@uci.edu; rwmartin@uci.edu
FU NSFNational Science Foundation (NSF) [DMS-1361425]; NASANational
   Aeronautics & Space Administration (NASA) [80NSSC20K0620]; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [2R01EY021514]; CIFAR Molecular Architecture of Life
   program; UC Irvine School of Physical Sciences Dean's Excellence Fund
FX This research was supported by the NSF award DMS-1361425 to C.T.B. and
   R.W.M., NASA Award 80NSSC20K0620 to R.W.M. and C.T.B., NIH 2R01EY021514
   to R.W.M., the CIFAR Molecular Architecture of Life program, and the UC
   Irvine School of Physical Sciences Dean's Excellence Fund. R.W.M. is a
   CIFAR Fellow.
CR Alvarez S, 2013, DALTON T, V42, P8617, DOI 10.1039/c3dt50599e
   Amamuddy O. S., 2020, BIORXIV, DOI [10.1101/2020.05.29.123190., DOI 10.1101/2020.05.29.123190.]
   Amamuddy OS, 2020, J CHEM INF MODEL, V60, P5080, DOI 10.1021/acs.jcim.0c00634
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   ASZODI A, 1993, COMPUT APPL BIOSCI, V9, P523
   Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525
   Benson NC, 2012, J BIOINF COMPUT BIOL, V10, DOI 10.1142/S0219720012500084
   Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x
   Bhakat S, 2014, MOL BIOSYST, V10, P2215, DOI 10.1039/c4mb00253a
   Bhattacharyya C, 2020, GLOBAL SPREAD SARS C, DOI [10.1101/2020.05.04.075911, DOI 10.1101/2020.05.04.075911]
   Bogatyreva Natalya S., 2006, Journal of Bioinformatics and Computational Biology, V4, P597, DOI 10.1142/S0219720006002016
   Brown DK, 2017, GLOB HEART, V12, P151, DOI 10.1016/j.gheart.2017.01.009
   Brune Daniel, 2018, BMC Res Notes, V11, P117, DOI 10.1186/s13104-018-3221-0
   Butts CT, 2008, J STAT SOFTW, V24, P36, DOI DOI 10.18637/JSS.V024.I02
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chandwani Ashish, 2008, Ther Clin Risk Manag, V4, P1023
   Chen H, 2006, J BIOL CHEM, V281, P13894, DOI 10.1074/jbc.M510745200
   Chen S, 2005, J BIOL CHEM, V280, P164, DOI 10.1074/jbc.M408211200
   Chen S, 2008, J BIOL CHEM, V283, P554, DOI 10.1074/jbc.M705240200
   Chou CY, 2004, BIOCHEMISTRY-US, V43, P14958, DOI 10.1021/bi0490237
   CORNISHBOWDEN A, 1985, NUCLEIC ACIDS RES, V13, P3021, DOI 10.1093/nar/13.9.3021
   Cross Thomas J, 2020, bioRxiv, DOI 10.1101/2020.05.15.097493
   Crowley PB, 2005, PROTEINS, V59, P231, DOI 10.1002/prot.20417
   Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145
   Duong VT, 2018, INTEGR BIOL-UK, V10, P768, DOI 10.1039/c8ib00140e
   Echols N, 2002, NUCLEIC ACIDS RES, V30, P2515, DOI 10.1093/nar/30.11.2515
   Eddelbuettel D, 2017, PEERJ PREPRINTS, V5, P3188, DOI DOI 10.7287/PEERJ.PREPRINTS.3188V1
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Efron B., 1993, INTRO BOOTSTRAP
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459
   Grant BJ, 2006, BIOINFORMATICS, V22, P2695, DOI 10.1093/bioinformatics/btl461
   Grazioli G, 2019, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00042
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Handcock Mark S, 2008, J Stat Softw, V24, P1548
   Hsu MF, 2005, J BIOL CHEM, V280, P31257, DOI 10.1074/jbc.M502577200
   Ide<prime> J., 2017, RPDB READ WRITE VISU
   James KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113488
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Jungreis Irwin, 2020, bioRxiv, DOI 10.1101/2020.06.02.130955
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kowalczyk A, 2001, ADV NEURAL INFORM PR, V14, P439
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Kwok J. T., 2003, P 20 INT C MACH LEAR
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Li X., 2020, SCI ADV, V6
   Lin PY, 2008, ARCH BIOCHEM BIOPHYS, V472, P34, DOI 10.1016/j.abb.2008.01.023
   Liu P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11110979
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   MENARD R, 1992, BIOL CHEM H-S, V373, P393, DOI 10.1515/bchm3.1992.373.2.393
   Olsson MHM, 2011, J CHEM THEORY COMPUT, V7, P525, DOI 10.1021/ct100578z
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Portelli S., 2020, BIORXIV, DOI [10.1101/2020.05.29.124610, DOI 10.1101/2020.05.29.124610]
   R_Core_Team, 2020, R LANG ENV STAT COMP
   Roser M, 2020, CORONAVIRUS DIS COVI
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   Scholkopf B., 2001, LEARNING KERNELS SUP
   SEIDMAN SB, 1983, SOC NETWORKS, V5, P269, DOI 10.1016/0378-8733(83)90028-X
   Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218, DOI 10.1128/AAC.42.12.3218
   Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200
   Shi JH, 2008, J VIROL, V82, P4620, DOI 10.1128/JVI.02680-07
   SHIMONI L, 1995, PROTEIN SCI, V4, P65
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Unhelkar MH, 2017, BBA-GEN SUBJECTS, V1861, P636, DOI 10.1016/j.bbagen.2016.12.007
   Van Rossum G., 1995, PYTHON TUTORIAL, V620
   Vondrasek J, 2009, J PHYS CHEM B, V113, P9041, DOI 10.1021/jp902377q
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wasserman S., 1994, SOCIAL NETWORK ANAL, V8
   Wright E. S., 2020, BIORXIV
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao KP, 2020, NATURE, V583, P286, DOI 10.1038/s41586-020-2313-x
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhong N, 2008, J VIROL, V82, P4227, DOI 10.1128/JVI.02612-07
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 81
TC 0
Z9 0
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD OCT 6
PY 2020
VL 59
IS 39
BP 3741
EP 3756
DI 10.1021/acs.biochem.0c00462
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OE3HG
UT WOS:000580425200009
PM 32931703
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Payne, N
AF Payne, Nick
TI Covid-19 elimination: consider population level effects of vaccine
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Letter
C1 [Payne, Nick] Univ Sheffield, Sch Hlth & Related Res, Publ Hlth, Sheffield S1 4DA, S Yorkshire, England.
RP Payne, N (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Publ Hlth, Sheffield S1 4DA, S Yorkshire, England.
EM n.payne@sheffield.ac.uk
CR Lee A, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3410
   McKee M., 2020, BMJ
NR 2
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD OCT 6
PY 2020
VL 371
AR m3889
DI 10.1136/bmj.m3889
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC8YM
UT WOS:000579442100010
PM 33023934
DA 2021-01-01
ER

PT J
AU Stolfi, P
   Manni, L
   Soligo, M
   Vergni, D
   Tieri, P
AF Stolfi, Paola
   Manni, Luigi
   Soligo, Marzia
   Vergni, Davide
   Tieri, Paolo
TI Designing a Network Proximity-Based Drug Repurposing Strategy for
   COVID-19
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE COVID-19; network medicine; drug repurposing; network-based;
   pharmacologic (drug) therapy
ID PATHWAYS; STATES
AB The ongoing COVID-19 pandemic still requires fast and effective efforts from all fronts, including epidemiology, clinical practice, molecular medicine, and pharmacology. A comprehensive molecular framework of the disease is needed to better understand its pathological mechanisms, and to design successful treatments able to slow down and stop the impressive pace of the outbreak and harsh clinical symptomatology, possibly via the use of readily available, off-the-shelf drugs. This work engages in providing a wider picture of the human molecular landscape of the SARS-CoV-2 infection via a network medicine approach as the ground for a drug repurposing strategy. Grounding on prior knowledge such as experimentally validated host proteins known to be viral interactors, tissue-specific gene expression data, and using network analysis techniques such as network propagation and connectivity significance, the host molecular reaction network to the viral invasion is explored and exploited to infer and prioritize candidate target genes, and finally to propose drugs to be repurposed for the treatment of COVID-19. Ranks of potential target genes have been obtained for coherent groups of tissues/organs, potential and distinct sites of interaction between the virus and the organism. The normalization and the aggregation of the different scores allowed to define a preliminary, restricted list of genes candidates as pharmacological targets for drug repurposing, with the aim of contrasting different phases of the virus infection and viral replication cycle.
C1 [Stolfi, Paola; Vergni, Davide; Tieri, Paolo] Natl Res Council CNR, Inst Appl Comp IAC, Rome, Italy.
   [Manni, Luigi; Soligo, Marzia] Natl Res Council CNR, Inst Translat Pharmacol IFT, Rome, Italy.
RP Tieri, P (corresponding author), Natl Res Council CNR, Inst Appl Comp IAC, Rome, Italy.
EM paolo.tieri@cnr.it
FU Horizon 2020 H2020-ICT-2018-2 project iPC - individualized Paediatric
   Cure [826121]
FX This research was partially supported by the Horizon 2020
   H2020-ICT-2018-2 project iPC - individualized Paediatric Cure (grant no.
   826121) to PT. We wish to thank the CNR-IAC Digital Biology Unit
   (https://www.iac.cnr.it/similar to dbu/), CNR-IAC colleagues, and Dr. R.
   Mazzucco, MD (AUSL Ferrara) for useful comments, discussions, and
   encouragement during the lockdown months.
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Ahmad I, 2020, J CLIN NEUROSCI, V77, P8, DOI 10.1016/j.jocn.2020.05.017
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Bal A, 2020, INDIAN J PATHOL MICR, V63, P358, DOI 10.4103/IJPM.IJPM_779_20
   Bauer-Mehren A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020284
   Carlin DE, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005598
   Cheng Feixiong, 2020, Cleve Clin J Med, DOI 10.3949/ccjm.87a.ccc037
   Cong YY, 2014, REV MED VIROL, V24, P308, DOI 10.1002/rmv.1792
   Cowen L, 2017, NAT REV GENET, V18, P551, DOI 10.1038/nrg.2017.38
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Ghiassian SD, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004120
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gustafsson M, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0082-6
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Kovacs IA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09177-y
   Lahiri D, 2020, CUREUS, V12, DOI 10.7759/cureus.7889
   Lin S., 2010, RANK AGGREGATION MET
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Milanetti E., 2020, IN SILICO EVIDENCE 2
   Mosca E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113660
   Oughtred R, 2019, NUCLEIC ACIDS RES, V47, pD529, DOI 10.1093/nar/gky1079
   Paull EO, 2013, BIOINFORMATICS, V29, P2757, DOI 10.1093/bioinformatics/btt471
   Qualls N, 2017, MMWR RECOMM REP, V66, P1, DOI 10.15585/mmwr.rr6601a1
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Silverman E. K., 2017, NET MED, V2017, P1, DOI [10.4159/9780674545533-002, DOI 10.4159/9780674545533-002]
   Silverman EK, 2020, WIRES SYST BIOL MED, V12, DOI 10.1002/wsbm.1489
   Stelzer G, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2722-2
   Sumathipala M, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00888
   Taylor IW, 2009, NAT BIOTECHNOL, V27, P199, DOI 10.1038/nbt.1522
   Tieri P, 2019, ENCY BIOINFORMA COMP, V2, P805, DOI DOI 10.1016/b978-0-12-809633-8.20290-2
   Tsivgoulis G, 2020, THER ADV NEUROL DISO, V13, DOI 10.1177/1756286420932036
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   Vandin F, 2011, J COMPUT BIOL, V18, P507, DOI 10.1089/cmb.2010.0265
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu T, 2020, AGING DIS, V11, P874, DOI 10.14336/AD.2020.0520
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 40
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD OCT 6
PY 2020
VL 8
AR 545089
DI 10.3389/fcell.2020.545089
PG 21
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA OC9HW
UT WOS:000579466800001
PM 33123533
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU De Stefano, L
   Bobbio-Pallavicini, F
   Manzo, A
   Montecucco, C
   Bugatti, S
AF De Stefano, Ludovico
   Bobbio-Pallavicini, Francesca
   Manzo, Antonio
   Montecucco, Carlomaurizio
   Bugatti, Serena
TI A "Window of Therapeutic Opportunity" for Anti-Cytokine Therapy in
   Patients With Coronavirus Disease 2019
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE cytokine storm; coronavirus; tocilizumab (IL-6 inhibitor); T cell;
   immune activation; innate and adaptive immune response
ID RESPIRATORY-DISTRESS-SYNDROME; VIRAL-RNA; COVID-19; TOCILIZUMAB;
   INTERFERON; RECEPTOR; STORM; BLOOD
AB The effects of cytokine inhibition in the different phases of the severe coronavirus disease 2019 (COVID-19) are currently at the center of intense debate, and preliminary results from observational studies and case reports offer conflicting results thus far. The identification of the correct timing of administration of anti-cytokine therapies and other immunosuppressants in COVID-19 should take into account the intricate relationship between the viral burden, the hyperactivation of the innate immune system and the adaptive immune dysfunction. The main challenge for effective administration of anti-cytokine therapy in COVID-19 will be therefore to better define a precise "window of therapeutic opportunity." Only considering a more specific set of criteria able to integrate information on direct viral damage, the cytokine burden, and the patient's immune vulnerability, it will be possible to decide, carefully balancing both benefits and risks, the appropriateness of using immunosuppressive drugs even in patients affected primarily by an infectious disease.
C1 [De Stefano, Ludovico; Bobbio-Pallavicini, Francesca; Manzo, Antonio; Montecucco, Carlomaurizio; Bugatti, Serena] IRCCS Policlin San Matteo Fdn, Div Rheumatol, Pavia, Italy.
   [De Stefano, Ludovico; Manzo, Antonio; Montecucco, Carlomaurizio; Bugatti, Serena] Univ Pavia, Dept Internal Med & Therapeut, Pavia, Italy.
RP Bugatti, S (corresponding author), IRCCS Policlin San Matteo Fdn, Div Rheumatol, Pavia, Italy.; Bugatti, S (corresponding author), Univ Pavia, Dept Internal Med & Therapeut, Pavia, Italy.
EM serena.bugatti@unipv.it
FU IRCCS Policlinico San Matteo Foundation, Pavia, Italy
FX This article was supported in part by fundings from the IRCCS
   Policlinico San Matteo Foundation, Pavia, Italy.
CR Al-Samkari H, 2018, ANNU REV PATHOL-MECH, V13, P27, DOI 10.1146/annurev-pathol-020117-043625
   Alijotas-Reig J, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102569
   Antinori S, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102564
   Behrens EM, 2017, ARTHRITIS RHEUMATOL, V69, P1135, DOI 10.1002/art.40071
   Biran N, 2020, LANCET RHEUMATOL, V2, pE603, DOI 10.1016/S2665-9913(20)30277-0
   Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Cantini F, 2020, J INFECTION, V81, P673, DOI 10.1016/j.jinf.2020.06.052
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen WL, 2020, EMERG MICROBES INFEC, V9, P469, DOI 10.1080/22221751.2020.1732837
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   De Rossi Nicola, 2020, EClinicalMedicine, V25, P100459, DOI 10.1016/j.eclinm.2020.100459
   Del Valle DM, 2020, NAT MED, V26, P1636, DOI 10.1038/s41591-020-1051-9
   Della-Torre E, 2020, ANN RHEUM DIS, V79, P1277, DOI [10.1136/annrheumdis-2020-218122, 10.1136/annrheumdis-2020-218759, 10.1136/annrheumdis-2020-218724]
   Fadel Raef, 2020, Clin Infect Dis, V71, P2114, DOI 10.1093/cid/ciaa601
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hanley Brian, 2020, Lancet Microbe, V1, pe245, DOI 10.1016/S2666-5247(20)30115-4
   Hogner K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003188
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Ip WKE, 2005, J INFECT DIS, V191, P1697, DOI 10.1086/429631
   Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567
   Joynt GM, 2020, LANCET INFECT DIS, V20, P635, DOI 10.1016/S1473-3099(20)30237-1
   Keller MJ, 2020, J HOSP MED, V15, P489, DOI 10.12788/jhm.3497
   Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6
   Li Q, 2020, INFECT DIS THER, V9, P823, DOI 10.1007/s40121-020-00332-3
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Lucas C, 2020, NATURE, DOI 10.1038/s41586-020-2588-y
   Manson JJ, 2020, LANCET RHEUMATOL, V2, pE594, DOI 10.1016/S2665-9913(20)30275-7
   Martinez-Urbistondo Diego, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa910
   Maude S, 2016, BRIT J HAEMATOL, V172, P11, DOI 10.1111/bjh.13792
   Maude SL, 2014, CANCER J, V20, P119, DOI 10.1097/PPO.0000000000000035
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   McKechnie JL, 2020, CELL HOST MICROBE, V27, P863, DOI 10.1016/j.chom.2020.05.009
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Ovsyannikova IG, 2020, IMMUNOL REV, V296, P205, DOI 10.1111/imr.12897
   Price CC, 2020, CHEST, V158, P1397, DOI 10.1016/j.chest.2020.06.006
   Quartuccio L, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104444
   Ravelli A, 2015, HEMATOL ONCOL CLIN N, V29, P927, DOI 10.1016/j.hoc.2015.06.010
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rivellese F, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102536
   Rossotti R, 2020, J INFECTION, V81, pE11, DOI 10.1016/j.jinf.2020.07.008
   Ruscitti P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102562
   Ruscitti P, 2020, ANN RHEUM DIS, V79, P1515, DOI [10.1136/annrheumdis-2020-217618, 10.1136/annrheumdis-2020-218048, 10.1136/annrheumdis-2020-218868, 10.1136/annrheumdis-2020-218909, 10.1136/annrheumdis-2020-218032]
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529
   Sinha Pratik, 2020, Lancet Respir Med, V8, P1209, DOI 10.1016/S2213-2600(20)30366-0
   Sinha P, 2019, CURR OPIN CRIT CARE, V25, P12, DOI 10.1097/MCC.0000000000000571
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Velazquez-Salinas L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01057
   Wang XL, 2020, CELL MOL IMMUNOL, DOI 10.1038/s41423-020-0424-9
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Yap JKY, 2020, J IMMUNOL, V205, P307, DOI 10.4049/jimmunol.2000513
   Zhang XN, 2020, NATURE, V583, P437, DOI 10.1038/s41586-020-2355-0
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
NR 69
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 6
PY 2020
VL 11
AR 572635
DI 10.3389/fimmu.2020.572635
PG 10
WC Immunology
SC Immunology
GA OC9JO
UT WOS:000579471200001
PM 33123149
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hajjo, R
   Tropsha, A
AF Hajjo, Rima
   Tropsha, Alexander
TI A Systems Biology Workflow for Drug and Vaccine Repurposing: Identifying
   Small-Molecule BCG Mimics to Reduce or Prevent COVID-19 Mortality
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE BCG vaccine; COVID-19; innate immunity; SARS-CoV-2; systems biology
ID CALMETTE-GUERIN; INNATE IMMUNITY; PROTECTION; DATABASE
AB PurposeCoronavirus disease 2019 (COVID-19) is expected to continue to cause worldwide fatalities until the World population develops 'herd immunity', or until a vaccine is developed and used as a prevention. Meanwhile, there is an urgent need to identify alternative means of antiviral defense. Bacillus Calmette-Guerin (BCG) vaccine that has been recognized for its off-target beneficial effects on the immune system can be exploited to boast immunity and protect from emerging novel viruses.MethodsWe developed and employed a systems biology workflow capable of identifying small-molecule antiviral drugs and vaccines that can boast immunity and affect a wide variety of viral disease pathways to protect from the fatal consequences of emerging viruses.ResultsOur analysis demonstrates that BCG vaccine affects the production and maturation of naive T cells resulting in enhanced, long-lasting trained innate immune responses that can provide protection against novel viruses. We have identified small-molecule BCG mimics, including antiviral drugs such as raltegravir and lopinavir as high confidence hits. Strikingly, our top hits emetine and lopinavir were independently validated by recent experimental findings that these compounds inhibit the growth of SARS-CoV-2 in vitro.ConclusionsOur results provide systems biology support for using BCG and small-molecule BCG mimics as putative vaccine and drug candidates against emergent viruses including SARS-CoV-2.
C1 [Hajjo, Rima] Al Zaytoonah Univ Jordan, Dept Pharm Computat Chem Biol, Fac Pharm, POB 130, Amman 11733, Jordan.
   [Tropsha, Alexander] Univ N Carolina, UNC Eshelman Sch Pharm, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
RP Hajjo, R (corresponding author), Al Zaytoonah Univ Jordan, Dept Pharm Computat Chem Biol, Fac Pharm, POB 130, Amman 11733, Jordan.
EM rhajjo@gmail.com
OI Hajjo, Rima/0000-0002-7090-5425; Tropsha, Alexander/0000-0003-3802-8896
FU Al-Zaytoonah University of Jordan [2020-2019/17/03]; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [OT2TR003441]
FX RH acknowledges support from the Deanship of Scientific Research at
   Al-Zaytoonah University of Jordan grant 2020-2019/17/03. AT acknowledges
   partial support from NIH grant OT2TR003441. We thank Clarivate Analytics
   for providing access to MetaCore, a specialized pathway and functional
   genomics analysis product. Reference to commercial products or services
   does not constitute their endorsement.
CR Albert R, 2007, PLANT CELL, V19, P3327, DOI 10.1105/tpc.107.054700
   [Anonymous], 2017, BCG VACCINES 1 REPOR
   Aronson NE, 2004, JAMA-J AM MED ASSOC, V291, P2086, DOI 10.1001/jama.291.17.2086
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Ayoub BM, 2020, PHARMAZIE, V75, P159, DOI 10.1691/ph.2020.0444
   Bader GD, BIND BIOMOLECULAR IN
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Basta S, 2001, IMMUNOLOGY, V103, P488, DOI 10.1046/j.1365-2567.2001.01266.x
   Belizario JE, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9523628
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Breitkreutz BJ, 2008, NUCLEIC ACIDS RES, V36, pD637, DOI 10.1093/nar/gkm1001
   Buffen K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004485
   Bull NC, 2019, MUCOSAL IMMUNOL, V12, P555, DOI 10.1038/s41385-018-0109-1
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   CHATRARYAMONTRI A, 2007, NUCLEIC ACIDS RES, V35, pD57, DOI DOI 10.1093/NAR/GKL950
   Chindelevitch L, 2012, BIOINFORMATICS, V28, P1114, DOI 10.1093/bioinformatics/bts090
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Consortium GO, GENE ONTOLOGY GO DAT
   Covian C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02806
   Dar TB, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03077
   Demaria O, 2019, NATURE, V574, P45, DOI 10.1038/s41586-019-1593-5
   DOBRIN R, 2004, NAT REV GENET, V5
   Dong HJ, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110601
   Dyall J, 2017, DRUGS, P1935
   Ellmeier W, 2018, NAT REV IMMUNOL, V18, P617, DOI 10.1038/s41577-018-0037-z
   Escobar LE, 2020, P NATL ACAD SCI USA, V117, P17720, DOI 10.1073/pnas.2008410117
   Farias Kleber Juvenal Silva, 2019, Access Microbiol, V1, pe000041, DOI 10.1099/acmi.0.000041
   Faustman DL, 2020, J INTERN MED, V288, P641, DOI 10.1111/joim.13050
   GABRIELSEN B, 1992, J NAT PROD, V55, P1569, DOI 10.1021/np50089a003
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gordon DE, 2020, BIORXIV, DOI [10.1101/2020.03.22.002386v1.full, DOI 10.1101/2020.03.22.002386V1]
   Gui JG, 2012, AGING DIS, V3, P280
   Gursel M, 2020, ALLERGY, V75, P1815, DOI 10.1111/all.14345
   Guzzi PH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040982
   Hajjo R, 2012, J MED CHEM, V55, P5704, DOI 10.1021/jm2011657
   Hanney SR, 2020, HLTH RES POLICY SYST
   Harris SJ, 2016, CANCER BIOL MED, V13, P171, DOI 10.20892/j.issn.2095-3941.2016.0015
   Hezareh M, 2005, DRUG NEWS PERSPECT, V18, P496, DOI 10.1358/dnp.2005.18.8.944543
   Hollander M, 1999, NONPARAMETRIC STAT M, P178
   Huang ZQ, 2018, MOL MED REP, V17, P2673, DOI 10.3892/mmr.2017.8189
   Ianevski A, 2018, ANTIVIR RES, V154, P174, DOI 10.1016/j.antiviral.2018.04.016
   Kagina BMN, 2009, VACCINE, V27, P5488, DOI 10.1016/j.vaccine.2009.06.103
   Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882
   Keseler IM, 2005, NUCLEIC ACIDS RES, V33, pD334, DOI 10.1093/nar/gki108
   Khatri P, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002375
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Kruger S, 2019, J EXPT CLIN CANC RES
   Krupa S, 2007, NAT PRECED, V1, P1
   Kwaa AK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174516
   Lamb J, 2006, SCIENCE NEW YORK
   Leentjens J, 2015, J INFECT DIS, V212, P1930, DOI 10.1093/infdis/jiv332
   Liao FH, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-25
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Maleki F, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00654
   Mangtani P, 2017, DURATION PROTECTION
   Marzolini C, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01177-20
   Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871
   Matsumiya M, 2014, GENE EXPRESSION CYTO
   Matsumiya M, 2015, J INFECT DIS, V211, P1499, DOI 10.1093/infdis/jiu615
   McGovern ME, 2015, AM J EPIDEMIOL, V182, P791, DOI 10.1093/aje/kwv125
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Netea MG, 2014, SEMIN IMMUNOL, V26, P512, DOI 10.1016/j.smim.2014.09.006
   Nguipdop-Djomo P, 2016, LANCET INFECT DIS, V16, P219, DOI 10.1016/S1473-3099(15)00400-4
   Nikolsky Y, 2009, METHODS MOL BIOL, V563, P177, DOI 10.1007/978-1-60761-175-2_10
   Ota MOC, 2002, J IMMUNOL, V168, P919, DOI 10.4049/jimmunol.168.2.919
   Ozdemir C, 2020, ALLERGY, V75, P1824, DOI 10.1111/all.14344
   Pattabhi S, 2016, J VIROL, V90, P2372, DOI 10.1128/JVI.02202-15
   Pavlidis P, 2004, NEUROCHEM RES, V29, P1213, DOI 10.1023/B:NERE.0000023608.29741.45
   Peri S, 2004, NUCLEIC ACIDS RES, V32, pD497, DOI 10.1093/nar/gkh070
   Pollard Jack Jr, 2005, Diabetes Technol Ther, V7, P323, DOI 10.1089/dia.2005.7.323
   Pradhan P, 2018, VIRUS RES, V249, P93, DOI 10.1016/j.virusres.2018.03.015
   Qi Q, 2014, EXP GERONTOL, V54, P71, DOI 10.1016/j.exger.2014.01.005
   Quevedo M, 2019, NATURE COMMUNICATION, V10, P1
   Raghab Mohapatra P, 2020, INDIAN J TUBERCULOSI
   Redelman-Sidi G, 2014, NAT REV UROL, V11, P153, DOI 10.1038/nrurol.2014.15
   Ritz N, 2013, VACCINE, V31, P3098, DOI 10.1016/j.vaccine.2013.03.059
   Scheid A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00029
   Schoergenhofer C, 2020, ANN INTERNAL MED, DOI 10.7326/M20-1550
   Sekine T, 2020, CELL
   Seth RB, 2006, CELL RES, V16, P141, DOI 10.1038/sj.cr.7310019
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sharma P, 2011, NAT REV CANCER, V11, P805, DOI 10.1038/nrc3153
   Shehadeh N, 1997, REPEATED BCG VACCINA
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Sung TL, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-66
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   TAMURA G, 1968, J ANTIBIOT, V21, P160, DOI 10.7164/antibiotics.21.160
   Tizard IR, 2020, VACCINE, V38, P5123, DOI 10.1016/j.vaccine.2020.06.026
   Uthayakumar D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02869
   White MR, 2008, EXPERT REV CLIN IMMU, V4, P497, DOI 10.1586/1744666X.4.4.497
   Wisskirchen K, 2014, TRENDS PHARMACOL SCI, V35, P470, DOI 10.1016/j.tips.2014.06.004
   Xenarios I, 2000, NUCL ACIDS RES
   Yang S, 2018, CELL DISCOVERY NATUR, V4, P1
   Zhan ZZ, 2015, J IMMUNOL, V195, P3849, DOI 10.4049/jimmunol.1403083
   Zhang YY, 2020, CELL MOL IMMUNOL, V17, P807, DOI 10.1038/s41423-020-0488-6
NR 95
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD OCT 6
PY 2020
VL 37
IS 11
AR 212
DI 10.1007/s11095-020-02930-9
PG 15
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA OB3XM
UT WOS:000578405800001
PM 33025261
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Coelho, C
   Gallo, G
   Campos, CB
   Hardy, L
   Wurtele, M
AF Coelho, Camila
   Gallo, Gloria
   Campos, Claudia B.
   Hardy, Leon
   Wurtele, Martin
TI Biochemical screening for SARS-CoV-2 main protease inhibitors
SO PLOS ONE
LA English
DT Article
ID SMALL-MOLECULE INHIBITORS; CORONAVIRUS 3CL PROTEASE; IDENTIFIES
   INHIBITORS; SARS; CYSTEINE; AGENTS; ACID
AB The Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) pandemic represents a global challenge. SARS-CoV-2's ability to replicate in host cells relies on the action of its non-structural proteins, like its main protease (M-pro). This cysteine protease acts by processing the viruses' precursor polyproteins. As proteases, together with polymerases, are main targets of antiviral drug design, we here have performed biochemical high throughput screening (HTS) with recombinantly expressed SARS-CoV-2 M-pro. A fluorescent assay was used to identify inhibitors in a compound library containing known drugs, bioactive molecules and natural products. These screens led to the identification of 13 inhibitors with IC(50)values ranging from 0.2 mu M to 23 mu M. The screens confirmed several known SARS-CoV M(pro)inhibitors as inhibitors of SARS-CoV-2 M-pro, such as the organo-mercuric compounds thimerosal and phenylmercuric acetate. Benzophenone derivatives could also be identified among the most potent screening hits. Additionally, Evans blue, a sulfonic acid-containing dye, could be identified as an M(pro)inhibitor. The obtained compounds could be of interest as lead compounds for the development of future SARS-CoV-2 drugs.
C1 [Coelho, Camila; Gallo, Gloria; Campos, Claudia B.; Wurtele, Martin] Univ Fed Sao Paulo, Dept Sci & Technol, Sao Jose Dos Campos, SP, Brazil.
   [Hardy, Leon] Univ S Florida, Dept Phys, Tampa, FL 33620 USA.
RP Wurtele, M (corresponding author), Univ Fed Sao Paulo, Dept Sci & Technol, Sao Jose Dos Campos, SP, Brazil.
EM martin.wurtele@unifeso.br
OI Coelho, Camila/0000-0002-6904-8681; Wurtele, Martin/0000-0001-8571-419X
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [11/50963-4]; FINEPCiencia Tecnologia e Inovacao (FINEP) [04.16.0054.02]
FX This project obtained funding from FAPESP grant 11/50963-4 (MW) and
   FINEP grant 04.16.0054.02 (institutional/MW). The funders had no role in
   the study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Allison RR, 2010, PHOTODIAGN PHOTODYN, V7, P61, DOI 10.1016/j.pdpdt.2010.02.001
   [Anonymous], 2015, J RUSSIAN CARDIOLOGY, V2, P118
   [Anonymous], 1996, ANAL BIOCHEM, V237, P260
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Baghai TC, 2007, INT J NEUROPSYCHOPH, V10, pS1, DOI 10.1017/S1461145707008255
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   BUETTNER GR, 1984, FEBS LETT, V177, P295, DOI 10.1016/0014-5793(84)81303-4
   Chen CN, 2005, EVID-BASED COMPL ALT, V2, P209, DOI 10.1093/ecam/neh081
   CLANTON DJ, 1992, J ACQ IMMUN DEF SYND, V5, P771
   Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI DOI 10.1128/CMR.00102-15
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   de Almeida L, 2015, BIOMED PHARMACOTHER, V75, P93, DOI 10.1016/j.biopha.2015.08.030
   Fintelman-Rodrigues N., 2020, BIORXIV, DOI [10.1101/2020.04.04.020925, DOI 10.1101/2020.04.04.020925]
   Geier DA, 2007, J TOXICOL ENV HEAL B, V10, P575, DOI 10.1080/10937400701389875
   Hamill P, 2006, BIOL CHEM, V387, P1063, DOI 10.1515/BC.2006.131
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hsu JTA, 2004, FEBS LETT, V574, P116, DOI 10.1016/j.febslet.2004.08.015
   Huang LQ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36730-4
   Ji M, 2009, METHOD ENZYMOL, DOI DOI 10.1016/S0076-6879(08)03811-1
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kao RY, 2004, FEBS LETT, V576, P325, DOI 10.1016/j.febslet.2004.09.026
   Kao RY, 2004, CHEM BIOL, V11, P1293, DOI 10.1016/j.chembiol.2004.07.013
   Liu YC, 2005, BIOCHEM BIOPH RES CO, V333, P194, DOI 10.1016/j.bbrc.2005.05.095
   Liu YY, 1999, ANAL BIOCHEM, V267, P331, DOI 10.1006/abio.1998.3014
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Machado PD, 2019, LIFE SCI, V219, P163, DOI 10.1016/j.lfs.2019.01.015
   Mamber SW, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00288-20
   MOLE S, 1987, PHYTOCHEMISTRY, V26, P99
   OBRIEN PJ, 1991, CHEM-BIOL INTERACT, V80, P1, DOI 10.1016/0009-2797(91)90029-7
   SHEPHERD JA, 1988, ANTIMICROB AGENTS CH, V32, P1693, DOI 10.1128/AAC.32.11.1693
   STRETTON RJ, 1973, J APPL BACTERIOL, V36, P61, DOI 10.1111/j.1365-2672.1973.tb04073.x
   Sun G, 2013, TEXT RES J, V83, P532, DOI 10.1177/0040517512454202
   To-Figueras J, 2019, MOL GENET METAB, V128, P282, DOI 10.1016/j.ymgme.2019.05.003
   TONOMURA K, 1968, NATURE, V217, P644, DOI 10.1038/217644b0
   Tropea Joseph E., 2009, V498, P297, DOI 10.1007/978-1-59745-196-3_19
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao Y, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02638
   Yang S, 2006, J MED CHEM, V49, P4971, DOI 10.1021/jm0603926
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 44
TC 0
Z9 0
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 6
PY 2020
VL 15
IS 10
AR e0240079
DI 10.1371/journal.pone.0240079
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OB4WW
UT WOS:000578473000004
PM 33022015
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gianola, S
   Jesus, TS
   Bargeri, S
   Castellini, G
AF Gianola, Silvia
   Jesus, Tiago S.
   Bargeri, Silvia
   Castellini, Greta
TI Characteristics of academic publications, preprints, and registered
   clinical trials on the COVID-19 pandemic
SO PLOS ONE
LA English
DT Article
ID SYSTEMATIC REVIEWS; CHLOROQUINE
AB The COVID-19 pandemic has unleashed a deluge of publications. For this cross-sectional study we compared the amount and reporting characteristics of COVID-19-related academic articles and preprints and the number of ongoing clinical trials and systematic reviews. To do this, we searched the PubMed database of citations and abstracts for published life science journals by using appropriate combinations of medical subject headings (MeSH terms), and the COVID-19 section of the MedRxiv and BioRxiv archives up to 20 May 2020 (21 weeks). In addition, we searched Clinicaltrial.gov, Chinese Clinical Trial Registry, EU Clinical Trials Register, and 15 other trial registers, as well as PROSPERO, the international prospective register of systematic reviews. The characteristics of each publication were extracted. Regression analyses and Z tests were used to detect publication trends and their relative proportions. A total of 3635 academic publications and 3805 preprints were retrieved. Only 8.6% (n = 329) of the preprints were already published in indexed journals. The number of academic and preprint publications increased significantly over time (p<0.001). Case reports (6% academic vs 0.9% preprints;p<0.001) and letters (17.4% academic vs 0.5% preprints;p<0.001) accounted for a greater share of academic compared to preprint publications. Differently, randomized controlled trials (0.22% vs 0.63%;p<0.001) and systematic reviews (0.08% vs 5%) made up a greater share of the preprints. The relative proportion of clinical studies registered at Clinicaltrials.gov, Chinese Clinical Trial Registry, and EU Clinical Trials Register was 57.9%, 49.5%, and 98.9%, respectively, most of which were still "recruiting". PROSPERO listed 962 systematic review protocols. Preprints were slightly more prevalent than academic articles but both were increasing in number. The void left by the lack of primary studies was filled by an outpour of immediate opinions (i.e., letters to the editor) published in PubMed-indexed journals. Summarizing, preprints have gained traction as a publishing response to the demand for prompt access to empirical, albeit not peer-reviewed, findings during the present pandemic.
C1 [Gianola, Silvia; Bargeri, Silvia; Castellini, Greta] IRCCS Ist Ortoped Galeazzi, Unit Clin Epidemiol, Milan, Italy.
   [Jesus, Tiago S.] NOVA Univ Lisbon, WHO Collaborating Ctr Hlth Workforce Policy & Pla, Global Hlth & Trop Med GHTM, Inst Hyg & Trop Med, Lisbon, Portugal.
RP Castellini, G (corresponding author), IRCCS Ist Ortoped Galeazzi, Unit Clin Epidemiol, Milan, Italy.
EM greta.castellini@grupposandonato.it
FU Italian Ministry of Health "Epidemiologia degli studi clinici: qualita
   delle evidenze e caratteristiche di reporting" [L2060]
FX SG and GC were supported by the Italian Ministry of Health
   "Epidemiologia degli studi clinici: qualita delle evidenze e
   caratteristiche di reporting" (L2060). The funder had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alexander PE, 2020, J CLIN EPIDEMIOLOGY
   [Anonymous], 2020, BMJ-BRIT MED J, V369, pm2170, DOI 10.1136/bmj.m2170
   [Anonymous], 2018, CANC DISCOV, V8, pOF6
   Bauchner H, 2020, JAMA
   Booth A, 2011, LANCET, V377, P108, DOI 10.1016/S0140-6736(10)60903-8
   Chalmers I, 2009, OBSTET GYNECOL, V114, P1341, DOI 10.1097/AOG.0b013e3181c3020d
   Charles P, 2020, SCIENCE
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Cowling BJ, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.6.2000110
   Diana K, 2020, NATURE, V581, P130, DOI [10.1038/d41586-020-01394-6, DOI 10.1038/D41586-020-01394-6]
   Ebuenyi ID, 2018, GLOBAL HEALTH ACTION, V11, DOI 10.1080/16549716.2018.1463658
   Ektorp E, 2020, LANCET INFECT DIS, V20, P661, DOI 10.1016/S1473-3099(20)30383-2
   Expert Panel on Women's I, 2018, J AM COLL RADIOL, V15, pS365
   f1000research.com. search.bio, PREPR DISC TOOL CUTT
   Falagas ME, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-56
   Fidahic M, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-01047-2
   Fu DY, 2019, ELIFE, V8, DOI 10.7554/eLife.54646
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gianola S, 2013, PHYS THER, V93, P1456, DOI 10.2522/ptj.20120382
   Glasziou P, 2017, COMMENT CAN IT REALL
   Gori D, 2020, EARLY SCI LIT RESPON
   Graham T, 2019, NATURE, V574
   Grant C, 2018, INT J EPIDEMIOL, V47, P938, DOI 10.1093/ije/dyy109
   Gutierrez J, 2020, J RURAL HEALTH, DOI 10.1111/jrh.12443
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Haghani M, 2020, SAFETY SCI, V2020, P104806
   Halladay CW, 2015, J CLIN EPIDEMIOL, V68, P1076, DOI 10.1016/j.jclinepi.2014.12.017
   Hodgson J, 2020, NAT BIOTECHNOL, V38, P523, DOI 10.1038/d41587-020-00005-z
   Hossain MM, 2020, CURRENT STATUS GLOBA
   Iwema Carrie L, 2016, F1000Res, V5, P1396, DOI 10.12688/f1000research.8798.1
   Kambhampati SBS, 2020, J CLIN ORTHOPAEDICS
   Bonilla-Aldana DK, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101566
   Kelly Jacalyn, 2014, EJIFCC, V25, P227
   Khachfe H, 2020, J CLIN EPIDEMIOLOGY
   Kwon D, 2020, NATURE, V581
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lariviere V, 2020, ARXIV E PRINTS J REC
   Ligthelm RJ, 2007, CLIN THER, V29, P1284, DOI 10.1016/j.clinthera.2007.07.004
   Lv MH, 2020, CELL MOL BIOL LETT, V25, DOI 10.1186/s11658-020-00235-8
   Moher D, 2015, SYST REV, V4, DOI 10.1186/s13643-015-0087-2
   MUTHUVEL T, 2016, INT J QUAL STUD HEAL, V11, DOI DOI 10.3402/GHA.V9.32962
   Nowakowska J, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110451
   Odone Anna, 2020, Acta Biomed, V91, P34, DOI 10.23750/abm.v91i9-S.10121
   Page MJ, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002028
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Rzymski P, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106711
   Vabret N, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0319-0
   Yang Z, APPEALING EFFICIENT, DOI [10.21037/atm-20-2429, DOI 10.21037/ATM-20-2429]
   Zyoud SH, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1600-5
NR 49
TC 0
Z9 0
U1 4
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 6
PY 2020
VL 15
IS 10
AR e0240123
DI 10.1371/journal.pone.0240123
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OB4WW
UT WOS:000578473000020
PM 33022014
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Holter, JC
   Pischke, SE
   de Boer, E
   Lind, A
   Jenum, S
   Holten, AR
   Tonby, K
   Barratt-Due, A
   Sokolova, M
   Schjalm, C
   Chaban, V
   Kolderup, A
   Trand, T
   Gjolberg, TT
   Skeie, LG
   Hesstvedt, L
   Ormasen, V
   Fevang, B
   Austad, C
   Muller, KE
   Fladeby, C
   Holberg-Petersen, M
   Halvorsen, B
   Muller, F
   Aukrust, P
   Dudman, S
   Ueland, T
   Andersen, JT
   Lund-Johansen, F
   Heggelund, L
   Dyrhol-Riise, AM
   Mollnes, TE
AF Holter, Jan C.
   Pischke, Soeren E.
   de Boer, Eline
   Lind, Andreas
   Jenum, Synne
   Holten, Aleksander R.
   Tonby, Kristian
   Barratt-Due, Andreas
   Sokolova, Marina
   Schjalm, Camilla
   Chaban, Viktoriia
   Kolderup, Anette
   Trand, Trung
   Gjolberg, Torleif Tollefsrud
   Skeie, Linda G.
   Hesstvedt, Liv
   Ormasen, Vidar
   Fevang, Borre
   Austad, Cathrine
   Muller, Karl Erik
   Fladeby, Cathrine
   Holberg-Petersen, Mona
   Halvorsen, Bente
   Muller, Fredrik
   Aukrust, Pal
   Dudman, Susanne
   Ueland, Thor
   Andersen, Jan Terje
   Lund-Johansen, Fridtjof
   Heggelund, Lars
   Dyrhol-Riise, Anne M.
   Mollnes, Tom E.
TI Systemic complement activation is associated with respiratory failure in
   COVID-19 hospitalized patients
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE complement system; COVID-19; SARS-CoV-2; sC5b-9; respiratory failure
ID MANNOSE-BINDING LECTIN; COAGULATION; INFECTION
AB Respiratory failure in the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is hypothesized to be driven by an overreacting innate immune response, where the complement system is a key player. In this prospective cohort study of 39 hospitalized coronavirus disease COVID-19 patients, we describe systemic complement activation and its association with development of respiratory failure. Clinical data and biological samples were obtained at admission, days 3 to 5, and days 7 to 10. Respiratory failure was defined as PO2/FiO(2) ratio of <= 40 kPa. Complement activation products covering the classical/lectin (C4d), alternative (C3bBbP) and common pathway (C3bc, C5a, and sC5b-9), the lectin pathway recognition molecule MBL, and antibody serology were analyzed by enzyme-immunoassays; viral load by PCR. Controls comprised healthy blood donors. Consistently increased systemic complement activation was observed in the majority of COVID-19 patients during hospital stay. At admission, sC5b-9 and C4d were significantly higher in patients with than without respiratory failure (P = 0.008 and P = 0.034). Logistic regression showed increasing odds of respiratory failure with sC5b-9 (odds ratio 31.9, 95% CI 1.4 to 746, P = 0.03) and need for oxygen therapy with C4d (11.7, 1.1 to 130, P = 0.045). Admission sC5b-9 and C4d correlated significantly to ferritin (r = 0.64, P < 0.001; r = 0.69, P < 0.001). C4d, sC5b-9, and C5a correlated with antiviral antibodies, but not with viral load. Systemic complement activation is associated with respiratory failure in COVID-19 patients and provides a rationale for investigating complement inhibitors in future clinical trials.
C1 [Holter, Jan C.; Lind, Andreas; Fladeby, Cathrine; Holberg-Petersen, Mona; Muller, Fredrik; Dudman, Susanne] Oslo Univ Hosp, Dept Microbiol, N-0424 Oslo, Norway.
   [Holter, Jan C.; Pischke, Soeren E.; de Boer, Eline; Holten, Aleksander R.; Tonby, Kristian; Barratt-Due, Andreas; Sokolova, Marina; Schjalm, Camilla; Chaban, Viktoriia; Kolderup, Anette; Gjolberg, Torleif Tollefsrud; Ormasen, Vidar; Halvorsen, Bente; Muller, Fredrik; Aukrust, Pal; Dudman, Susanne; Dyrhol-Riise, Anne M.; Mollnes, Tom E.] Univ Oslo, Inst Clin Med, N-0315 Oslo, Norway.
   [Pischke, Soeren E.] Oslo Univ Hosp, Div Emergencies & Crit Care, N-0424 Oslo, Norway.
   [Pischke, Soeren E.; de Boer, Eline; Barratt-Due, Andreas; Sokolova, Marina; Schjalm, Camilla; Chaban, Viktoriia; Trand, Trung; Gjolberg, Torleif Tollefsrud; Andersen, Jan Terje; Lund-Johansen, Fridtjof; Mollnes, Tom E.] Oslo Univ Hosp, Dept Immunol, N-0424 Oslo, Norway.
   [Jenum, Synne; Tonby, Kristian; Skeie, Linda G.; Hesstvedt, Liv; Ormasen, Vidar; Dyrhol-Riise, Anne M.] Oslo Univ Hosp, Dept Infect Dis, N-0424 Oslo, Norway.
   [Holten, Aleksander R.] Oslo Univ Hosp, Dept Acute Med, N-0424 Oslo, Norway.
   [Kolderup, Anette; Gjolberg, Torleif Tollefsrud] Univ Oslo, Dept Pharmacol, N-0315 Oslo, Norway.
   [Gjolberg, Torleif Tollefsrud] Oslo Univ Hosp, Dept Ophthalmol, N-0424 Oslo, Norway.
   [Fevang, Borre; Halvorsen, Bente; Aukrust, Pal; Ueland, Thor] Oslo Univ Hosp, Res Inst Internal Med, N-0424 Oslo, Norway.
   [Fevang, Borre; Aukrust, Pal] Oslo Univ Hosp, Sect Clin Immunol & Infect Dis, N-0424 Oslo, Norway.
   [Austad, Cathrine; Muller, Karl Erik; Heggelund, Lars] Vestre Viken Hosp Trust, Dept Internal Med, N-3004 Drammen, Norway.
   [Muller, Karl Erik] Univ Bergen, Dept Clin Sci, Fac Med, N-5007 Bergen, Norway.
   [Aukrust, Pal; Ueland, Thor; Mollnes, Tom E.] Univ Tromso, KG Jebsen Thrombosis Res & Expertise Ctr, Fac Hlth Sci, N-9037 Tromso, Norway.
   [Lund-Johansen, Fridtjof] Univ Oslo, ImmunoLingo Convergence Ctr, N-0315 Oslo, Norway.
   [Mollnes, Tom E.] Nordland Hosp Bodo, Res Lab, N-8092 Bodo, Norway.
   [Mollnes, Tom E.] Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res, N-7491 Trondheim, Norway.
RP Pischke, SE (corresponding author), Univ Oslo, Inst Clin Med, N-0315 Oslo, Norway.; Pischke, SE (corresponding author), Oslo Univ Hosp, Div Emergencies & Crit Care, N-0424 Oslo, Norway.; Pischke, SE (corresponding author), Oslo Univ Hosp, Dept Immunol, N-0424 Oslo, Norway.
EM s.e.pischke@medisin.uio.no
RI Mollnes, Tom/ABI-5183-2020; Dudman, Susanne/ABC-5434-2020
OI Dudman, Susanne/0000-0001-5047-4982; Barratt-Due,
   Andreas/0000-0001-5408-7162; Lind, Andreas/0000-0002-8289-8410; Holter,
   Jan Cato/0000-0003-1618-5022; Holten, Aleksander/0000-0001-7916-0717
FU Research Council of NorwayResearch Council of Norway [274352, 312780];
   Simon Fougner Hartman Family Foundation [SHFF-2019]; Oslo University
   Hospital; South-Eastern Norway Regional Health Authority [10357]; Odd
   Fellow Foundation, Norway
FX We thank the staff at the laboratory and clinical wards of Infectious
   Diseases at Oslo University Hospital, Ulleval, and Drammen Hospital for
   support, including the patients, blood sampling, and processing of
   biobank. We also thank Karine Flem Karlsen, Siri Sakya, and Heidrun
   Elisabeth Lode at Oslo University Hospital for vector and protein
   production followed by purification and functional validation of the
   viral proteins. We thank Dr. Florian Krammer (Icahn School for Medicine
   Mount Sinai) for providing the vector encoding RBD. This study received
   the following funding: Research Council of Norway (Grant 274352 to
   S.E.P., E.d.B., M.S.; Grant 312780 to J.C.H., S.D.), Simon Fougner
   Hartman Family Foundation (Grant SHFF-2019 to S.E.P.), Oslo University
   Hospital (A.M.D.-R.), private donation from Vivaldi Invest A/S owned by
   Jon Stephenson von Tetzchner (J.C.H.), and South-Eastern Norway Regional
   Health Authority (Grant 10357 to F.L.-J., J.T.A., and A.K.). Odd Fellow
   Foundation, Norway, funded part of the study (T.E.M.).
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Barratt-Due A, 2017, J LEUKOCYTE BIOL, V101, P193, DOI 10.1189/jlb.3VMR0316-132R
   Barratt-Due A, 2016, RHEUMATOLOGY, V55, P1337, DOI 10.1093/rheumatology/kew040
   Bergseth G, 2013, MOL IMMUNOL, V56, P232, DOI 10.1016/j.molimm.2013.05.221
   Brown SM, 2017, CRIT CARE MED, V45, P1317, DOI 10.1097/CCM.0000000000002514
   Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419
   Carvelli J, 2020, NATURE, V588, P146, DOI 10.1038/s41586-020-2600-6
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cugno M, 2020, J ALLERGY CLIN IMMUN, V146, P215, DOI 10.1016/j.jaci.2020.05.006
   Diao B, 2020, HUMAN KIDNEY IS TARG, DOI [10.1101/2020.03.04.20031120, DOI 10.1101/2020.03.04.20031120]
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Ekdahl KN, 2016, IMMUNOL REV, V274, P245, DOI 10.1111/imr.12471
   Escher R, 2020, THROMB RES, V190, P62, DOI 10.1016/j.thromres.2020.04.014
   Gao T, 2020, HIGHLY PATHOGENIC CO, DOI [10.1101/2020.03.29.20041962, DOI 10.1101/2020.03.29.20041962]
   Garred P, 2003, MOL IMMUNOL, V40, P73, DOI 10.1016/S0161-5890(03)00104-4
   Garred P, 2016, IMMUNOL REV, V274, P74, DOI 10.1111/imr.12468
   Gavriilaki E, 2020, BRIT J HAEMATOL, V189, pE227, DOI 10.1111/bjh.16783
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Huber-Lang M, 2018, NAT IMMUNOL, V19, P327, DOI 10.1038/s41590-018-0064-8
   Ip WKE, 2005, J INFECT DIS, V191, P1697, DOI 10.1086/429631
   Ji SR, 2006, ARTERIOSCL THROM VAS, V26, P935, DOI 10.1161/01.ATV.0000206211.21895.73
   Jiang YT, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0063-8
   LANGLOIS PF, 1988, AM REV RESPIR DIS, V138, P368, DOI 10.1164/ajrccm/138.2.368
   Laurence J, 2020, CLIN IMMUNOL, V219, DOI 10.1016/j.clim.2020.108555
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lucas C, 2020, NATURE, DOI 10.1038/s41586-020-2588-y
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Markiewski MM, 2007, TRENDS IMMUNOL, V28, P184, DOI 10.1016/j.it.2007.02.006
   Mastaglio S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108450
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pischke S. E., 2020, DATA SYSTEMIC COMPLE, DOI 10.18712/NSD-NSD2880-V2
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Remy KE, 2020, LANCET RESP MED, V8, P946, DOI 10.1016/S2213-2600(20)30217-4
   Ricklin D, 2017, MOL IMMUNOL, V89, P10, DOI 10.1016/j.molimm.2017.05.013
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Risitano AM, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0320-7
   Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288
   Sikorski K, 2018, NAT METHODS, V15, P909, DOI 10.1038/s41592-018-0179-8
   Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754
   Volokhina EB, 2015, BLOOD, V126, P278, DOI 10.1182/blood-2015-03-637645
   Wang RX, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.28
   Wu WW, 2009, MOL CELL PROTEOMICS, V8, P245, DOI 10.1074/mcp.M800171-MCP200
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 46
TC 1
Z9 1
U1 2
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 6
PY 2020
VL 117
IS 40
BP 25018
EP 25025
DI 10.1073/pnas.2010540117
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OC3GA
UT WOS:000579045200007
PM 32943538
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jockusch, S
   Tao, CJ
   Li, XX
   Chien, MC
   Kumar, S
   Morozova, I
   Kalachikov, S
   Russo, JJ
   Ju, JY
AF Jockusch, Steffen
   Tao, Chuanjuan
   Li, Xiaoxu
   Chien, Minchen
   Kumar, Shiv
   Morozova, Irina
   Kalachikov, Sergey
   Russo, James J.
   Ju, Jingyue
TI Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader
   than RNA terminated by Remdesivir
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INHIBITORS; HCV; POLYMERASE; DISCOVERY; INFECTION; RIBAVIRIN; EXCISION;
   DRUG
AB SARS-CoV-2 is responsible for COVID-19, resulting in the largest pandemic in over a hundred years. After examining the molecular structures and activities of hepatitis C viral inhibitors and comparing hepatitis C virus and coronavirus replication, we previously postulated that the FDA-approved hepatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) might inhibit SARS-CoV-2. We subsequently demonstrated that Sofosbuvir triphosphate is incorporated by the relatively low fidelity SARS-CoV and SARS-CoV-2 RNA-dependent RNA polymerases (RdRps), serving as an immediate polymerase reaction terminator, but not by a host-like high fidelity DNA polymerase. Other investigators have since demonstrated the ability of Sofosbuvir to inhibit SARS-CoV-2 replication in lung and brain cells; additionally, COVID-19 clinical trials with EPCLUSA and with Sofosbuvir plus Daclatasvir have been initiated in several countries. SARS-CoV-2 has an exonuclease-based proofreader to maintain the viral genome integrity. Any effective antiviral targeting the SARS-CoV-2 RdRp must display a certain level of resistance to this proofreading activity. We report here that Sofosbuvir terminated RNA resists removal by the exonuclease to a substantially higher extent than RNA terminated by Remdesivir, another drug being used as a COVID-19 therapeutic. These results offer a molecular basis supporting the current use of Sofosbuvir in combination with other drugs in COVID-19 clinical trials.
C1 [Jockusch, Steffen; Tao, Chuanjuan; Li, Xiaoxu; Chien, Minchen; Kumar, Shiv; Morozova, Irina; Kalachikov, Sergey; Russo, James J.; Ju, Jingyue] Columbia Univ, Ctr Genome Technol & Biomol Engn, New York, NY 10027 USA.
   [Tao, Chuanjuan; Li, Xiaoxu; Chien, Minchen; Kumar, Shiv; Morozova, Irina; Kalachikov, Sergey; Russo, James J.; Ju, Jingyue] Columbia Univ, Dept Chem Engn, New York, NY 10027 USA.
   [Ju, Jingyue] Columbia Univ, Dept Mol Pharmacol & Therapeut, New York, NY 10032 USA.
   [Jockusch, Steffen] Columbia Univ, Dept Chem, New York, NY 10032 USA.
RP Ju, JY (corresponding author), Columbia Univ, Ctr Genome Technol & Biomol Engn, New York, NY 10027 USA.; Ju, JY (corresponding author), Columbia Univ, Dept Chem Engn, New York, NY 10027 USA.; Ju, JY (corresponding author), Columbia Univ, Dept Mol Pharmacol & Therapeut, New York, NY 10032 USA.
EM dj222@columbia.edu
FU Columbia University; Jack Ma Foundation
FX This research is supported by Columbia University, a grant from the Jack
   Ma Foundation, a generous gift from the Columbia Engineering Member of
   the Board of Visitors Dr. Bing Zhao, and Fast Grants to J.J. We thank
   Dr. Robert Kirchdoerfer for providing the RdRp (nsp12, nsp7 and nsp8).
CR Afdhal N, 2014, NEW ENGL J MED, V370, P1889, DOI 10.1056/NEJMoa1402454
   Alanazi AS, 2019, ACS MED CHEM LETT, V10, P2, DOI 10.1021/acsmedchemlett.8b00586
   Bouvet M, 2012, P NATL ACAD SCI USA, V109, P9372, DOI 10.1073/pnas.1201130109
   Buonaguro L, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02355-3
   Chien MC, 2020, J PROTEOME RES, V19, P4690, DOI 10.1021/acs.jproteome.0c00392
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   Dustin LB, 2016, CLIN MICROBIOL INFEC, V22, P826, DOI 10.1016/j.cmi.2016.08.025
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Eltahla AA, 2015, VIRUSES-BASEL, V7, P5206, DOI 10.3390/v7102868
   Feld JJ, 2014, NEW ENGL J MED, V370, P1594, DOI 10.1056/NEJMoa1315722
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   German P, 2016, CLIN PHARMACOKINET, V55, P1337, DOI 10.1007/s40262-016-0397-0
   Gitto S, 2017, J VIRAL HEPATITIS, V24, P180, DOI 10.1111/jvh.12657
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8
   Izzi A, 2020, Eur Rev Med Pharmacol Sci, V24, P5193, DOI 10.26355/eurrev_202005_21297
   Jacome R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66440-9
   Jockusch S, 2020, ANTIVIR RES, V180, DOI 10.1016/j.antiviral.2020.104857
   Ju J., 2020, NUCLEOTIDE ANALOGUES, DOI [10.1101/2020.03.12.989186, DOI 10.1101/2020.03.12.989186]
   Ju J., 2020, BIORXIV, DOI [10.1101/2020.01.30.927574, DOI 10.1101/2020.01.30.927574, 10.1101/2020.01.30.927574.]
   Ju JY, 2006, P NATL ACAD SCI USA, V103, P19635, DOI 10.1073/pnas.0609513103
   Kayali Z, 2014, PHARMACOGEN PERS MED, V7, P387, DOI 10.2147/PGPM.S52629
   Lawitz E, 2015, LANCET, V385, P1075, DOI 10.1016/S0140-6736(14)61795-5
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   MCKENNA CE, 1989, ACS SYM SER, V401, P1
   Mesci P, 2020, BIORXIV, DOI [10.1101/2020.05.30.125856, DOI 10.1101/2020.05.30.125856]
   Ng TI, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.02558-16, 10.1128/AAC.02558-16]
   Oberg B, 2006, ANTIVIR RES, V71, P90, DOI 10.1016/j.antiviral.2006.05.012
   Quezada Elizabeth M, 2009, Open Biochem J, V3, P39, DOI 10.2174/1874091X00903010039
   Sacramento C. Q., 2020, BIORXIV, DOI [10.1101/2020.06.15.153411, DOI 10.1101/2020.06.15.153411]
   Sadeghi A, 2020, J ANTIMICROB CHEMOTH, V75, P3379, DOI 10.1093/jac/dkaa334
   Sayad B, 2020, ARCH MED RES, V51, P577, DOI 10.1016/j.arcmed.2020.04.018
   Selisko B, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020059
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Smith MA, 2016, ANN PHARMACOTHER, V50, P39, DOI 10.1177/1060028015610342
   Sofia MJ, 2010, J MED CHEM, V53, P7202, DOI 10.1021/jm100863x
   te Velthuis AJW, 2014, CELL MOL LIFE SCI, V71, P4403, DOI 10.1007/s00018-014-1695-z
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 41
TC 1
Z9 1
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 6
PY 2020
VL 10
IS 1
AR 16577
DI 10.1038/s41598-020-73641-9
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OB4XT
UT WOS:000578475300045
PM 33024223
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Janssen, M
   Schakel, U
   Fokou, CD
   Krisam, J
   Stermann, J
   Kriegsmann, K
   Haberbosch, I
   Novotny, JP
   Weber, S
   Vehreschild, M
   Bornhauser, M
   Bullinger, L
   Schmitt, M
   Liebregts, T
   Dreger, P
   Lorenz, HM
   Plaszczyca, A
   Bartenschlager, R
   Muller, B
   Krausslich, HG
   Halama, N
   Jager, D
   Schlenk, RF
   Leo, A
   Meuer, S
   Weigand, MA
   Motsch, J
   Merle, U
   Denkinger, CM
   Muller-Tidow, C
AF Janssen, Maike
   Schaekel, Ulrike
   Djuka Fokou, Carine
   Krisam, Johannes
   Stermann, Jacek
   Kriegsmann, Katharina
   Haberbosch, Isabella
   Novotny, Jan Philipp
   Weber, Stefan
   Vehreschild, Maria
   Bornhaeuser, Martin
   Bullinger, Lars
   Schmitt, Michael
   Liebregts, Tobias
   Dreger, Peter
   Lorenz, Hanns-Martin
   Plaszczyca, Anna
   Bartenschlager, Ralf
   Mueller, Barbara
   Kraeusslich, Hans-Georg
   Halama, Niels
   Jaeger, Dirk
   Schlenk, Richard F.
   Leo, Albrecht
   Meuer, Stefan
   Weigand, Markus A.
   Motsch, Johann
   Merle, Uta
   Denkinger, Claudia M.
   Mueller-Tidow, Carsten
TI A Randomized Open label Phase-II Clinical Trial with or without Infusion
   of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in
   High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A
   structured summary of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; convalescent plasma;
   early application; high-risk patients with severe disease
AB Objectives: Primary objectives
   center dot To assess the time from randomisation until an improvement within 84 days defined as two points on a seven point ordinal scale or live discharge from the hospital in high-risk patients (group 1 to group 4) with SARS-CoV-2 infection requiring hospital admission by infusion of plasma from subjects after convalescence of SARS-CoV-2 infection or standard of care. Secondary objectives
   center dot To assess overall survival, and the overall survival rate at 28 56 and 84 days. center dot To assess SARS-CoV-2 viral clearance and load as well as antibody titres.
   center dot To assess the percentage of patients that required mechanical ventilation.
   center dot To assess time from randomisation until discharge.
   Trial design: Randomised, open-label, multicenter phase II trial, designed to assess the clinical outcome of SARS-CoV-2 disease in high-risk patients (group 1 to group 4) following treatment with anti-SARS-CoV-2 convalescent plasma or standard of care.
   Participants: High-risk patients >18 years of age hospitalized with SARS-CoV-2 infection in 10-15 university medical centres will be included. High-risk is defined as SARS-CoV-2 positive infection with Oxygen saturation at <= 94% at ambient air with additional risk features as categorised in 4 groups:
   center dot Group 1, pre-existing or concurrent hematological malignancy and/or active cancer therapy (incl. chemotherapy, radiotherapy, surgery) within the last 24 months or less.
   center dot Group 2, chronic immunosuppression not meeting the criteria of group 1.
   center dot Group 3, age >= 50 - 75 years meeting neither the criteria of group 1 nor group 2 and at least one of these criteria:
   Lymphopenia < 0.8 x G/l
   and/or
   D-dimer > 1 mu g/mL.
   center dot Group 4, age >= 75 years meeting neither the criteria of group 1 nor group 2.
   Observation time for all patients is expected to be at least 3 months after entry into the study. Patients receive convalescent plasma for two days (day 1 and day 2) or standard of care. For patients in the standard arm, cross over is allowed from day 10 in case of not improving or worsening clinical condition. Nose/throat swabs for determination of viral load are collected at day 0 and day 1 (before first CP administration) and subsequently at day 2, 3, 5, 7, 10, 14, 28 or until discharge. Serum for SARS-Cov-2 diagnostic is collected at baseline and subsequently at day 3, 7, 14 and once during the follow-up period (between day 35 and day 84).
   There is a regularfollow-upof 3 months. All discharged patients are followed by regular phone calls. All visits, time points and study assessments are summarized in the Trial Schedule (see full protocol Table1).
   All participating trial sites will be supplied with study specific visit worksheets that list all assessments and procedures to be completed at each visit. All findings including clinical and laboratory data are documented by the investigator or an authorized member of the study team in the patient's medical record and in the electronic case report forms (eCRFs).
   Intervention and comparator: This trial will analyze the effects of convalescent plasma from recovered subjects with SARS-CoV-2 antibodies in high-risk patients with SARS-CoV-2 infection. Patients at high risk for a poor outcome due to underlying disease, age or condition as listed above are eligible for enrollment. In addition, eligible patients have a confirmed SARS-CoV-2 infection and O-2 saturation <= 94% while breathing ambient air. Patients are randomised to receive (experimental arm) or not receive (standard arm) convalescent plasma in two bags (238 - 337 ml plasma each) from different donors (day 1, day 2). A cross over from the standard arm into the experimental arm is possible after day 10 in case of not improving or worsening clinical condition.
   Main outcomes Primary endpoints: The main purpose of the study is to assess the time from randomisation until an improvement within 84 days defined as two points on a seven-point ordinal scale or live discharge from the hospital in high-risk patients (group 1 to group 4) with SARS-CoV-2 infection requiring hospital admission by infusion of plasma from subjects after convalescence of a SARS-CoV-2 infection or standard of care.
   Secondary endpoints:
   center dot Overall survival, defined as the time from randomisation until death from any cause 28-day, 56-day and 84-day overall survival rates.
   center dot SARS-CoV-2 viral clearance and load as well as antibody titres.
   center dot Requirement mechanical ventilation at any time during hospital stay (yes/no).
   center dot Time until discharge from randomisation.
   center dot Viral load, changes in antibody titers and cytokine profiles are analysed in an exploratory manner using paired non-parametric tests (before - after treatment).
   Randomisation: Upon confirmation of eligibility (patients must meet all inclusion criteria and must not meet exclusion criteria described in section 5.3 and 5.4 of the full protocol), the clinical site must contact a centralized internet randomization system (https://randomizer.at/). Patients are randomized using block randomisation to one of the two arms, experimental arm or standard arm, in a 1:1 ratio considering a stratification according to the 4 risk groups (see Participants).
   Blinding (masking): The study is open-label, no blinding will be performed.
   Numbers to be randomised (sample size): A total number of 174 patients is required for the entire trial, n=87 per group.
   Trial Status: Protocol version 1.2 dated 09/07/2020.
   A recruitment period of approximately 9 months and an overall study duration of approximately 12 months is anticipated. Recruitment of patients starts in the third quarter of 2020. The study duration of an individual patient is planned to be 3 months.
   After finishing all study-relevant procedures, therapy, and follow-up period, the patient is followed in terms of routine care and treated if necessary.
   [GRAPHICS]
   .
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
   The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file2). The eCRF is attached (Additional file3).
C1 [Janssen, Maike; Schaekel, Ulrike; Kriegsmann, Katharina; Haberbosch, Isabella; Novotny, Jan Philipp; Schmitt, Michael; Liebregts, Tobias; Dreger, Peter; Lorenz, Hanns-Martin; Schlenk, Richard F.; Mueller-Tidow, Carsten] Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany.
   [Djuka Fokou, Carine; Schlenk, Richard F.] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, NCT Trial Ctr, Heidelberg, Germany.
   [Djuka Fokou, Carine; Schlenk, Richard F.] German Canc Res Ctr, Heidelberg, Germany.
   [Krisam, Johannes; Stermann, Jacek] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany.
   [Weber, Stefan; Vehreschild, Maria; Denkinger, Claudia M.] Heidelberg Univ Hosp, Dept Infect Dis, Div Trop Med, Heidelberg, Germany.
   [Vehreschild, Maria] Univ Hosp Frankfurt, Div Infect Dis, Frankfurt, Germany.
   [Bornhaeuser, Martin] Univ Hosp Dresden, Dresden, Germany.
   [Bullinger, Lars] Charite, Berlin, Germany.
   [Plaszczyca, Anna; Bartenschlager, Ralf] Heidelberg Univ Hosp, Dept Infect Dis, Mol Virol, Heidelberg, Germany.
   [Mueller, Barbara; Kraeusslich, Hans-Georg] Heidelberg Univ Hosp, Dept Infect Dis, Virol, Heidelberg, Germany.
   [Halama, Niels; Jaeger, Dirk; Schlenk, Richard F.] Natl Ctr Tumor Dis NCT, Med Oncol, Heidelberg, Germany.
   [Leo, Albrecht; Meuer, Stefan] Inst Clin Transfus Med & Cell Therapy Heidelberg, Heidelberg, Germany.
   [Weigand, Markus A.; Motsch, Johann] Heidelberg Univ Hosp, Dept Anaesthesiol, Heidelberg, Germany.
   [Merle, Uta] Heidelberg Univ Hosp, Dept Internal Med 4, Heidelberg, Germany.
RP Janssen, M (corresponding author), Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany.
EM maike.janssen@med.uni-heidelberg.de
FU BMBF programFederal Ministry of Education & Research (BMBF); Heidelberg
   University Hospital
FX The trial is co-financed by the BMBF program on emergency research
   funding for COVID-19 and the funds of Heidelberg University Hospital.
   The legal sponsor of the trial is the Ruprecht-Karls-University
   Heidelberg, Medical Faculty, represented in law by Heidelberg University
   Hospital, Germany, and its commercial director Katrin Erk. The trial is
   investigator-initiated, therefore, the main investigator has obtained
   all rights and duties from the legal sponsor except contract management.
   The legal sponsor itself does not have a role in collection, management,
   analysis, and interpretation of data; writing of the report; and the
   decision to submit the report for publication.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 6
PY 2020
VL 21
IS 1
AR 828
DI 10.1186/s13063-020-04735-y
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OB2GU
UT WOS:000578292600001
PM 33023671
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ferrando, C
   Mellado-Artigas, R
   Gea, A
   Arruti, E
   Aldecoa, C
   Adalia, R
   Ramasco, F
   Monedero, P
   Maseda, E
   Tamayo, G
   Hernandez-Sanz, ML
   Mercadal, J
   Martin-Grande, A
   Kacmarek, RM
   Villar, J
   Suarez-Sipmann, F
AF Ferrando, Carlos
   Mellado-Artigas, Ricard
   Gea, Alfredo
   Arruti, Egoitz
   Aldecoa, Cesar
   Adalia, Ramon
   Ramasco, Fernando
   Monedero, Pablo
   Maseda, Emilio
   Tamayo, Gonzalo
   Hernandez-Sanz, Maria L.
   Mercadal, Jordi
   Martin-Grande, Ascension
   Kacmarek, Robert M.
   Villar, Jesus
   Suarez-Sipmann, Fernando
CA COVID-19 Spanish ICU Network
TI Awake prone positioning does not reduce the risk of intubation in
   COVID-19 treated with high-flow nasal oxygen therapy: a multicenter,
   adjusted cohort study
SO CRITICAL CARE
LA English
DT Article
DE Acute respiratory failure; COVID-19; High-flow nasal oxygen therapy;
   Prone positioning; Mechanical ventilation; Critical care
ID LUNG INJURY; FAILURE
AB BackgroundAwake prone positioning (awake-PP) in non-intubated coronavirus disease 2019 (COVID-19) patients could avoid endotracheal intubation, reduce the use of critical care resources, and improve survival. We aimed to examine whether the combination of high-flow nasal oxygen therapy (HFNO) with awake-PP prevents the need for intubation when compared to HFNO alone.MethodsProspective, multicenter, adjusted observational cohort study in consecutive COVID-19 patients with acute respiratory failure (ARF) receiving respiratory support with HFNO from 12 March to 9 June 2020. Patients were classified as HFNO with or without awake-PP. Logistic models were fitted to predict treatment at baseline using the following variables: age, sex, obesity, non-respiratory Sequential Organ Failure Assessment score, APACHE-II, C-reactive protein, days from symptoms onset to HFNO initiation, respiratory rate, and peripheral oxyhemoglobin saturation. We compared data on demographics, vital signs, laboratory markers, need for invasive mechanical ventilation, days to intubation, ICU length of stay, and ICU mortality between HFNO patients with and without awake-PP.ResultsA total of 1076 patients with COVID-19 ARF were admitted, of which 199 patients received HFNO and were analyzed. Fifty-five (27.6%) were pronated during HFNO; 60 (41%) and 22 (40%) patients from the HFNO and HFNO + awake-PP groups were intubated. The use of awake-PP as an adjunctive therapy to HFNO did not reduce the risk of intubation [RR 0.87 (95% CI 0.53-1.43), p=0.60]. Patients treated with HFNO + awake-PP showed a trend for delay in intubation compared to HFNO alone [median 1 (interquartile range, IQR 1.0-2.5) vs 2 IQR 1.0-3.0] days (p=0.055), but awake-PP did not affect 28-day mortality [RR 1.04 (95% CI 0.40-2.72), p=0.92].ConclusionIn patients with COVID-19 ARF treated with HFNO, the use of awake-PP did not reduce the need for intubation or affect mortality.
C1 [Ferrando, Carlos; Mellado-Artigas, Ricard; Mercadal, Jordi] Hosp Clin Barcelona, Inst Invest August Pi & Sunyer, Dept Anesthesiol & Crit Care, Barcelona 08036, Spain.
   [Ferrando, Carlos; Villar, Jesus; Suarez-Sipmann, Fernando] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.
   [Gea, Alfredo] Univ Navarra, Dept Prevent Med & Publ Hlth, Pamplona, Spain.
   [Arruti, Egoitz] Ubikare Technol, Vizcaya, Spain.
   [Aldecoa, Cesar] Hosp Univ Rio Hortega, Dept Anesthesiol & Crit Care, Valladolid, Spain.
   [Adalia, Ramon] Hosp del Mar, Dept Anesthesiol & Crit Care, Barcelona, Spain.
   [Ramasco, Fernando] Hosp Univ La Princesa, Dept Anesthesiol & Crit Care, Madrid, Spain.
   [Monedero, Pablo] Clin Univ Navarra, Dept Anesthesiol & Intens Care, Pamplona, Spain.
   [Maseda, Emilio] Hosp Univ La Paz, Dept Anesthesiol & Crit Care, Madrid, Spain.
   [Tamayo, Gonzalo; Hernandez-Sanz, Maria L.] Hosp Univ Cruces, Dept Anesthesiol & Crit Care, Baracaldo, Vizcaya, Spain.
   [Martin-Grande, Ascension] Hosp Univ Ramon Y Cajal, Dept Anesthesiol & Crit Care, Madrid, Spain.
   [Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA.
   [Villar, Jesus] Hosp Univ Dr Negrin, Multidisciplinary Organ Dysfunct Evaluat Res Netw, Res Unit, Las Palmas Gran Canaria, Spain.
   [Suarez-Sipmann, Fernando] Hosp Univ La Princesa, Intens Care Unit, Madrid, Spain.
RP Ferrando, C (corresponding author), Hosp Clin Barcelona, Inst Invest August Pi & Sunyer, Dept Anesthesiol & Crit Care, Barcelona 08036, Spain.; Ferrando, C (corresponding author), Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.
EM cafeoranestesia@gmail.com
RI Villar, Jesus/R-4526-2019
OI Villar, Jesus/0000-0001-5687-3562; Almuedo Riera,
   Alex/0000-0003-4643-4456; , Eva/0000-0002-5816-998X; Castro Rebollo,
   Pedro/0000-0002-6118-8970; Gil, Diego/0000-0002-2695-2224; Perez Ferrer,
   Antonio/0000-0003-0913-4446; Carreras Castaner, Anna/0000-0002-7231-2236
FU Instituto de Salud Carlos III, Madrid, SpainInstituto de Salud Carlos
   III [CB06/06/1088, PI16/00049, PI18/01611, PI19/00141]
FX Instituto de Salud Carlos III, Madrid, Spain (#CB06/06/1088;
   #PI16/00049; #PI18/01611; #PI19/00141).
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   [Anonymous], 2020, JAMA-J AM MED ASSOC, V323, P1574
   Broccard AF, 1997, CRIT CARE MED, V25, P16, DOI 10.1097/00003246-199701000-00007
   Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP
   Cinesi C, 2020, REV ESP ANESTESIOL R, V67, P245, DOI [10.1016/j.redar.2020.03.004, DOI 10.1016/J.REDAR.2020.03.004]
   Coppo A, 2020, LANCET RESP MED, V8, P765, DOI 10.1016/S2213-2600(20)30268-X
   Ding L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2738-5
   Elharrar X, 2020, JAMA-J AM MED ASSOC, V323, P2336, DOI 10.1001/jama.2020.8255
   Ferrando C, 2020, REV ESP ANESTESIOL R, DOI 10.1016/j.redare.2020.07.001
   Ferrando C, 2020, INTENS CARE MED, V46, P2200, DOI 10.1007/s00134-020-06192-2
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43
   Hopkins SR, 2007, J APPL PHYSIOL, V103, P240, DOI 10.1152/japplphysiol.01289.2006
   Kang BJ, 2015, INTENS CARE MED, V41, P623, DOI 10.1007/s00134-015-3693-5
   Ng Z, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01198-2020
   Rochwerg B, 2019, INTENS CARE MED, V45, P1171, DOI 10.1007/s00134-019-05658-2
   Sartini C, 2020, JAMA-J AM MED ASSOC, V323, P2338, DOI 10.1001/jama.2020.7861
   Telias I, 2020, JAMA-J AM MED ASSOC, V323, P2265, DOI 10.1001/jama.2020.8539
   Thompson A.E, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.3030
   von Elm E, 2007, BMJ-BRIT MED J, V335, P806
   Xu QH, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02991-7
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 23
TC 2
Z9 2
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD OCT 6
PY 2020
VL 24
IS 1
AR 597
DI 10.1186/s13054-020-03314-6
PG 11
WC Critical Care Medicine
SC General & Internal Medicine
GA OB4CI
UT WOS:000578418700004
PM 33023669
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Grimaldi, D
   Aissaoui, N
   Blonz, G
   Carbutti, G
   Courcelle, R
   Gaudry, S
   Gaultier, A
   D'hondt, A
   Higny, J
   Horlait, G
   Hraiech, S
   Lefebvre, L
   Lejeune, F
   Ly, A
   Piagnerelli, M
   Sauneuf, B
   Serck, N
   Soumagne, T
   Szychowiak, P
   Textoris, J
   Vandenbunder, B
   Vinsonneau, C
   Lascarrou, JB
AF Grimaldi, David
   Aissaoui, Nadia
   Blonz, Gauthier
   Carbutti, Giuseppe
   Courcelle, Romain
   Gaudry, Stephane
   Gaultier, Aurelie
   D'hondt, Alain
   Higny, Julien
   Horlait, Geoffrey
   Hraiech, Sami
   Lefebvre, Laurent
   Lejeune, Francois
   Ly, Andre
   Piagnerelli, Michael
   Sauneuf, Bertrand
   Serck, Nicolas
   Soumagne, Thibaud
   Szychowiak, Piotr
   Textoris, Julien
   Vandenbunder, Benoit
   Vinsonneau, Christophe
   Lascarrou, Jean-Baptiste
CA COVADIS Study Grp
TI Characteristics and outcomes of acute respiratory distress syndrome
   related to COVID-19 in Belgian and French intensive care units according
   to antiviral strategies: the COVADIS multicentre observational study
SO ANNALS OF INTENSIVE CARE
LA English
DT Article
DE Renal replacement therapy; Remdesivir; Lopinavir; Ritonavir; Acute
   kidney injury; Hydroxychloroquine
ID EPIDEMIOLOGY
AB Background Limited data are available regarding antiviral therapy efficacy in most severe patients under mechanical ventilation for Covid-19-related acute respiratory distress syndrome (ARDS). Methods Comparison of antiviral strategies (none, hydroxychloroquine (OHQ), lopinavir/ritonavir (L/R), others (combination or remdesivir) in an observational multicentre cohort of patients with moderate-to-severe Covid-19 ARDS. The primary endpoint was the number of day 28 ventilator-free days (VFD). Patients who died before d28 were considered as having 0 VFD. The variable was dichotomized into "patients still ventilated or dead at day 28" versus "patients weaned and alive at day 28". Results We analyzed 415 patients (85 treated with standard of care (SOC), 57 with L/R, 220 with OHQ, and 53 others). The median number of d28-VFD was 0 (IQR 0-13) and differed between groups (P = 0.03), SOC patients having the highest d28-VFD. After adjustment for age, sex, Charlson Comorbidity Index, PaO2/FiO(2)ratio and plateau pressure and accounting for center effect with a generalized linear mixed model, none of the antiviral strategies increased the chance of being alive and weaned from MV at day 28 compared to the SOC strategy (OR 0.48 CI95% (0.18-1.25); OR 0.96 (0.47-2.02) and OR 1.43 (0.53-4.04) for L/R, OHQ and other treatments, respectively). Acute kidney injury during ICU stay was frequent (55%); its incidence was higher in patients receiving lopinavir (66 vs 53%,P = 0.03). After adjustment for age, sex, BMI, chronic hypertension and chronic renal disease, the use of L/R was associated with an increased risk of renal replacement therapy (RRT). (OR 2.52 CI95% 1.16-5.59). Conclusion In this multicentre observational study of moderate-to-severe Covid-19 ARDS patients, we did not observe any benefit among patients treated with OHQ or L/R compared with SOC. The use of L/R treatment was associated with an increased need for RRT. Take home messageNeither hydroxychloroquine nor lopinavir/ritonavir as COVID-19 antiviral treatment is associated with higher ventilator-free days at day 28 when compared with standard of care (no antiviral treatment) in ICU patients under invasive mechanical ventilation. Lopinavir/ritonavir is associated with an increased risk of renal replacement therapy requirement. TweetCOVID-19: Insights from ARDS cohort: no signal of efficacy of any antiviral drugs. Lopinavir/ritonavir may be associated with need for RRT
C1 [Grimaldi, David] ULB, Soins IntensifsHop Erasme, Route Lenn 808, B-1070 Brussels, Belgium.
   [Aissaoui, Nadia] PARCC, Hop Europeen Georges Pompidou, Med Intens Reanimat, Paris Ctr U 970, Paris, France.
   [Blonz, Gauthier] Med Intens Reanimat, Dist Hosp Ctr, Blvd Stephane Moreau, F-85000 La Roche Sur Yon, France.
   [Carbutti, Giuseppe] CHR Mons Hainaut, Unite Soins Intensifs, Mons, Belgium.
   [Courcelle, Romain] Ctr Hosp Jolimont, Unite Soins Intensifs, La Louviere, Belgium.
   [Gaudry, Stephane] Univ Sorbonne Paris Nord, Reanimat Med Chirurgicale CHU Avicennes, Bobigny, France.
   [Gaultier, Aurelie] CHU Nantes, Plateforme Methodol & Biostat, 1 Pl Alexis Ricordeau, F-44093 Nantes, France.
   [D'hondt, Alain] CHU Ambroise Pare, Unite Soins Intensifs, Mons, Belgium.
   [Higny, Julien] CHU Dinant Godinne, Unite Soins Intensifs, Site Dinant, Dinant, Belgium.
   [Horlait, Geoffrey] CHU Dinant Godinne, Unite Soins Intensifs, Site Dinant, Godinne, Belgium.
   [Hraiech, Sami] Hop Nord Marseille, Assistance Publ Hop Marseille, Med Intens Reanimat, F-13015 Marseille, France.
   [Hraiech, Sami] Marseille Univ, Aix Fac Med, Ctr Etud & Rech Serv Sante & Qualite Vie EA 3279, F-13005 Marseille, France.
   [Lefebvre, Laurent] Hosp Pays DAix, Reanimat Polyvalente Ctr, Aix En Provence, France.
   [Lejeune, Francois] Clin Notre Dame Grace, Unite Soins Intensifs, Gosselies, Belgium.
   [Ly, Andre] Hop Univ Henri Mondor, Serv Anesthesie Reanimat Chirurgicale Unite, Reanimat Chirurgicale Polyvalente, Creteil, France.
   [Piagnerelli, Michael] Univ Libre Bruxelles, CHU Charleroi, Intens Care CHU Charleroi, 140 Chaussee Bruxelles, B-6042 Charleroi, Belgium.
   [Sauneuf, Bertrand] Ctr Hosp Publ Cotentin, Reanimat Med Intens, BP208, F-50102 Cherbourg En Cotentin, France.
   [Serck, Nicolas] Clin St Pierre, Unite Soins Intensifs, Ottignies, Belgium.
   [Soumagne, Thibaud] CHU Besancon, Med Intens Reanimat, Blvd FLEMING, F-25030 Besancon, France.
   [Szychowiak, Piotr] CHRU Tours, Med Intens Reanimat, Tours, France.
   [Szychowiak, Piotr] CHRU Tours, INSERM CIC 1415, Tours, France.
   [Szychowiak, Piotr; Lascarrou, Jean-Baptiste] CRICS TriggerSEP Res Network, Tours, France.
   [Textoris, Julien] Hosp Civils Lyon, Serv Reanimat, 5 Pl DArsonval, Lyon, France.
   [Textoris, Julien] Univ Lyon 1, Lab Commun Rech BioMerieux, Hosp Civils Lyon, EA7426 Pl3, Lyon, France.
   [Vandenbunder, Benoit] Hop Prive dAntony, Grp Anesthesistes Reanimateurs, Antony, France.
   [Vinsonneau, Christophe] Hosp BETHUNE, Serv Med, Intens Reanimat Unite, Sevrage Ventilatoire & Rehabil Ctr, 27 Rue Delbecque, F-62660 Beuvry, France.
   [Lascarrou, Jean-Baptiste] CHU Nantes, Med Intens Reanimat, 30 Blvd Jean Monnet, F-44093 Nantes 9, France.
RP Grimaldi, D (corresponding author), ULB, Soins IntensifsHop Erasme, Route Lenn 808, B-1070 Brussels, Belgium.; Lascarrou, JB (corresponding author), CRICS TriggerSEP Res Network, Tours, France.; Lascarrou, JB (corresponding author), CHU Nantes, Med Intens Reanimat, 30 Blvd Jean Monnet, F-44093 Nantes 9, France.
EM david.grimaldi@erasme.ulb.ac.be
OI Grimaldi, David/0000-0001-8428-065X; Serck, Nicolas/0000-0001-5486-7812
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Bodet-Contentin L, 2018, CRIT CARE MED, V46, P425, DOI 10.1097/CCM.0000000000002890
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Christensen Steffen, 2011, Clin Epidemiol, V3, P203, DOI 10.2147/CLEP.S20247
   Courcelle R, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03164-2
   Ferrando C, 2020, INTENS CARE MED, V46, P2200, DOI 10.1007/s00134-020-06192-2
   Gregoire M, 2020, J ANTIMICROB CHEMOTH, V75, P2702, DOI 10.1093/jac/dkaa195
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Karagiannidis C, 2020, LANCET RESP MED, V8, P853, DOI 10.1016/S2213-2600(20)30316-7
   Le MP, 2020, J ANTIMICROB CHEMOTH, V75, P2657, DOI 10.1093/jac/dkaa261
   Levey AS, 2013, AM J KIDNEY DIS, V61, P686, DOI 10.1053/j.ajkd.2013.03.003
   McNicholas BA, 2019, CRIT CARE MED, V47, P1216, DOI 10.1097/CCM.0000000000003832
   Mocroft A, 2016, LANCET HIV, V3, pE23, DOI 10.1016/S2352-3018(15)00211-8
   Pan XW, 2020, INTENS CARE MED, V46, P1114, DOI 10.1007/s00134-020-06026-1
   Papazian L, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0540-9
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016
   Shafi T, 2011, CLIN NEPHROL, V75, pS60, DOI 10.5414/CN106469
   Shelton JD, 2000, JAMA-J AM MED ASSOC, V284, P2687, DOI 10.1001/jama.284.21.2687
   Soumagne Thibaud, 2020, Crit Care Explor, V2, pe0166, DOI 10.1097/CCE.0000000000000166
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Taccone FS, 2020, LANCET RESP MED, V8, P539, DOI 10.1016/S2213-2600(20)30172-7
   The A.D.T.F, JAMA, V307, P2526
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Ziehr DR, 2020, AM J RESP CRIT CARE, V201, P1560, DOI 10.1164/rccm.202004-1163LE
NR 37
TC 3
Z9 3
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2110-5820
J9 ANN INTENSIVE CARE
JI Ann. Intensive Care
PD OCT 6
PY 2020
VL 10
IS 1
AR 131
DI 10.1186/s13613-020-00751-y
PG 11
WC Critical Care Medicine
SC General & Internal Medicine
GA NX0OW
UT WOS:000575419800001
PM 33025225
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rehman, S
   Mahmood, T
   Aziz, E
   Batool, R
AF Rehman, Shazia
   Mahmood, Tariq
   Aziz, Ejaz
   Batool, Riffat
TI Identification of novel mutations in SARS-COV-2 isolates from Turkey
SO ARCHIVES OF VIROLOGY
LA English
DT Article
AB SARS-CoV-2 was first detected in the city of Wuhan, Hubei Province, China. In this study, we identified 11 unique mutations in viral SARS-COV-2 isolates from Turkey. Nine of them cause structural alterations in the S protein, nsp2, nsp3, nsp4 and nsp12 regions. The mutations identified here might have significant functional implications that need to be addressed in future studies in the context of vaccine engineering and therapeutic interventions. Moreover, transmission and phylogenetic analysis revealed multiple independent sources of introductions of SARS-CoV-2 into Turkey and a close relationship to the isolates from Saudi Arabia.
C1 [Rehman, Shazia] Rawalpindi Women Univ, Dept Bot, Rawalpindi, Pakistan.
   [Rehman, Shazia] Govt Gordon Coll Rawalpindi, Dept Bot, Rawalpindi, Pakistan.
   [Mahmood, Tariq] Quaid I Azam Univ, Dept Plant Sci, Islamabad 45320, Pakistan.
   [Aziz, Ejaz] GDC Khanpur, Dept Bot, Haripur, Pakistan.
   [Batool, Riffat] PMAS UAAR, Univ Inst Biochem & Biotechnol, Rawalpindi, Pakistan.
RP Rehman, S (corresponding author), Rawalpindi Women Univ, Dept Bot, Rawalpindi, Pakistan.; Rehman, S (corresponding author), Govt Gordon Coll Rawalpindi, Dept Bot, Rawalpindi, Pakistan.
EM shaziarehman7@gmail.com
OI Rehman, Shazia/0000-0003-1435-6166
CR Ayub MI, 2020, REPORTING 2 SARS COV, DOI [10.20944/preprints202004.0337.v1, DOI 10.20944/PREPRINTS202004.0337.V1]
   Banerjee S, 2020, MUTATIONAL SPECTRA S
   Benvenuto D, 2020, J INFECTION, V81, pE24, DOI 10.1016/j.jinf.2020.03.058
   Chand GB, 2020, IDENTIFICATION NOVEL
   Eden JS, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa027
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Joshi A, 2020, PHYLOGENETIC ANAL NO, DOI [10.1101/2020.04.14.041301, DOI 10.1101/2020.04.14.041301]
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Kumar T.A., 2013, WIDE SPECTRUM, V1, P15, DOI DOI 10.5281/ZENODO.50733
   Kurosaki Y, 2018, J GEN VIROL, V99, P181, DOI 10.1099/jgv.0.000999
   Maitra A, 2020, J BIOSCIENCES, V45, DOI 10.1007/s12038-020-00046-1
   Marquez-Jurado S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100547
   Mercatelli D, 2020, GEOGRAPHIC GENOMIC D, V338, P2020040529, DOI [10.20944/preprints202004.0529.v1, DOI 10.20944/PREPRINTS202004.0529.V1]
   Ministry of Health of Turkey, 2020, CURR STAT TURK
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Rouchka EC, 2020, PHYLOGENETIC VARIANT, DOI [10.20944/preprints202005.0396.v1, DOI 10.20944/PREPRINTS202005.0396.V1]
   Sakai Y, 2017, VIROLOGY, V510, P165, DOI 10.1016/j.virol.2017.07.019
   Samyuktha V, 2020, EMERGENCE RBD D614G, DOI [10.20944/preprints202006.0032.v1, DOI 10.20944/PREPRINTS202006.0032.V1]
   Ueda MT, 2017, GENES CELLS, V22, P148, DOI 10.1111/gtc.12463
   WHO, 2020, TRANSM SARS COV 2 IM
   World Health Organization, 95 WHO
   Wu C, 2020, ACTA PHARM SINICA B
NR 22
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
EI 1432-8798
J9 ARCH VIROL
JI Arch. Virol.
PD DEC
PY 2020
VL 165
IS 12
BP 2937
EP 2944
DI 10.1007/s00705-020-04830-0
EA OCT 2020
PG 8
WC Virology
SC Virology
GA OK2LU
UT WOS:000575707900004
PM 33025199
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zyoud, SH
   Zyoud, AH
AF Zyoud, Shaher H.
   Zyoud, Ahed H.
TI Coronavirus disease-19 in environmental fields: a bibliometric and
   visualization mapping analysis
SO ENVIRONMENT DEVELOPMENT AND SUSTAINABILITY
LA English
DT Article; Early Access
DE Air quality; Content analysis; Ecosystems; Green recovery; Pandemic;
   Sustainability
ID SCIENTIFIC-RESEARCH; GOOGLE-SCHOLAR; ARAB-WORLD; COVID-19; SCOPUS; WEB;
   SCIENCE; INDEX
AB A coronavirus disease-19 (COVID-19) caused by a novel coronavirus has appeared in China by the end of 2019 and later recognized as a global pandemic. This pandemic has evolved as a global public health menace. It has affected every aspect of human life. In line with these concerns, governments and the scientific community react promptly to the outbreak of this pandemic. These efforts are devoted to develop vaccine and curative medicines. Further efforts are dedicated to assessing the impacts of the pandemic in relation to socioeconomic, psychological, and environmental dimensions. In this regard, it is important to follow up developments and research activities on this global issue. The present work intended to tracking the current hotspots and research trends on COVID-19 in environmental fields. Bibliometric analysis and visualization mapping were utilized with the objective of revealing and evaluating the developments in knowledge on COVID-2019 and its impacts based on a collection of environmental sources. A sum of 729 documents were collected from Scopus database limiting to environmental sources only. Of all these publications, 563 (77.2%) were articles, 56 (7.7%) were reviews, and 110 (15.0%) were others. China has the highest share of publications (163; 22.4%). It is followed by the USA (139; 19.15), and Italy (110; 15.1%). Most publications on COVID-19 were in prestigious journals. The most productive institution at global level wasChinese Academy of Sciences, China (24 documents; 3.3%). The most prevalent topics are in relation to impacts of the pandemic on air quality, mental health, psychological, and economic aspects. The development of these topics is based on cross-sectional studies, evidence-based tools, remote sensing, satellite mapping, geographic information systems, market analysis and sampling. The progress of environmental research on COVID-19 will guide the development of global environmental strategies to control future global environmental risks.
C1 [Zyoud, Shaher H.] Palestine Tech Univ Kadoorie, Dept Bldg Engn & Environm, Tulkarem, Palestine.
   [Zyoud, Ahed H.] An Najah Natl Univ, Coll Sci, Dept Chem, Nablus, Palestine.
RP Zyoud, SH (corresponding author), Palestine Tech Univ Kadoorie, Dept Bldg Engn & Environm, Tulkarem, Palestine.
EM shaher.zyoud@ptuk.edu.ps; ahedzyoud@najah.edu
OI Zyoud, Shaher/0000-0002-2832-1047
CR Ahmed W, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138764
   Aleixandre-Benavent R, 2017, J CLEAN PROD, V147, P406, DOI 10.1016/j.jclepro.2017.01.112
   Arora AS, 2020, ENVIRON DEV SUSTAIN, DOI 10.1007/s10668-020-00883-y
   Bogler A, 2020, NAT SUSTAIN, V3, P981, DOI 10.1038/s41893-020-00605-2
   Bornmann L, 2016, SCIENTOMETRICS, V107, P1041, DOI 10.1007/s11192-016-1925-2
   Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Changotra R, 2020, ENVIRON DEV SUSTAIN, DOI 10.1007/s10668-020-00963-z
   Chen CM, 2004, P NATL ACAD SCI USA, V101, P5303, DOI 10.1073/pnas.0307513100
   Chen JL, 2020, MICROBES INFECT, V22, P69, DOI 10.1016/j.micinf.2020.01.004
   Conticini E, 2020, ENVIRON POLLUT, V261, DOI 10.1016/j.envpol.2020.114465
   Du HB, 2014, RENEW ENERG, V66, P696, DOI 10.1016/j.renene.2014.01.018
   Dutheil F, 2020, ENVIRON POLLUT, V263, DOI 10.1016/j.envpol.2020.114466
   Environemntal Protection Ageny (EPA), 2020, RES COVID 19 ENV
   Falagas ME, 2008, FASEB J, V22, P338, DOI 10.1096/fj.07-9492LSF
   Fan JC, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00477
   Gallegos M, 2020, ELECTRON J GEN MED, V17, DOI 10.29333/ejgm/8460
   Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921
   Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019
   Havemann Frank, 2006, J Biomed Discov Collab, V1, P6, DOI 10.1186/1747-5333-1-6
   He GJ, 2020, NAT SUSTAIN, V3, DOI 10.1038/s41893-020-0581-y
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   Hirsch JE, 2005, P NATL ACAD SCI USA, V102, P16569, DOI 10.1073/pnas.0507655102
   Iyer M, 2020, BMB REP, V53, P191, DOI 10.5483/BMBRep.2020.53.4.080
   Kambhampati Srinivas B S, 2020, J Clin Orthop Trauma, V11, pS304, DOI 10.1016/j.jcot.2020.04.030
   Kampf G, 2020, J HOSP INFECT, V105, P587, DOI 10.1016/j.jhin.2020.01.022.
   Li SJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062032
   Liu JT, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138513
   Lou J, 2020, EUR REV MED PHARMACO, V24, P3411, DOI 10.26355/eurrev_202003_20712
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ma YL, 2020, SCI TOTAL ENVIRON, V724, DOI 10.1016/j.scitotenv.2020.138226
   Mao XJ, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020137
   Martin-Martin A, 2018, J INFORMETR, V12, P1160, DOI 10.1016/j.joi.2018.09.002
   Meho LI, 2008, J AM SOC INF SCI TEC, V59, P1711, DOI 10.1002/asi.20874
   Merigo JM, 2017, INT J INTELL SYST, V32, P526, DOI 10.1002/int.21859
   Mohadab ME, 2020, SOLITONS FRACTALS, V139, P110052, DOI [10.1016/j.chaos.2020.110052, DOI 10.1016/J.CHAOS.2020.110052]
   Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730
   Muhammad S, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138820
   NVIVO, 2020, UNL INS YOUR DAT POW
   Ogen Y, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138605
   Oh J, 2020, SCI ED, V7, P118, DOI 10.6087/kcse.205
   Rajput H, 2020, ENVIRON DEV SUSTAIN, DOI 10.1007/s10668-020-00934-4
   Raju NV, 2020, DIABETES METAB SYND, V14, P1171, DOI 10.1016/j.dsx.2020.07.007
   Romero L, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00564
   Setti L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082932
   Sharma S, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138878
   Song PP, 2020, BIOSCI TRENDS, V14, P1, DOI 10.5582/bst.2020.01056
   Tobias A, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138540
   Tosepu R, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138436
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   Venugopal Anila, 2020, Curr Opin Environ Sci Health, V17, P8, DOI 10.1016/j.coesh.2020.05.003
   Verma S, 2020, J BUS RES, V118, P253, DOI 10.1016/j.jbusres.2020.06.057
   Wallin JA, 2005, BASIC CLIN PHARMACOL, V97, P261, DOI 10.1111/j.1742-7843.2005.pto_139.x
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang LY, 2017, RENEW SUST ENERG REV, V68, P57, DOI 10.1016/j.rser.2016.08.021
   World Health Organization W, 2020, COR DIS COVID 19 PAN
   Wu YT, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30557-2
   Xie JG, 2020, SCI TOTAL ENVIRON, V724, DOI 10.1016/j.scitotenv.2020.138201
   Yataganbaba A, 2016, RENEW SUST ENERG REV, V59, P206, DOI 10.1016/j.rser.2015.12.357
   Zambrano-Monserrate MA, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138813
   Zhai F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17113766
   Zhang HY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103370
   ZHANG Y, 2020, J HAZARD MATER, V400
   Zhang YF, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072381
   Zheng TL, 2018, APPL MICROBIOL BIOT, V102, P3453, DOI 10.1007/s00253-018-8844-5
   Zheng TL, 2017, ENVIRON SCI POLLUT R, V24, P27613, DOI 10.1007/s11356-017-0696-5
   Zhu YJ, 2020, SCI TOTAL ENVIRON, V727, DOI 10.1016/j.scitotenv.2020.138704
   Zyoud SH, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05293-z
   Zyoud SH, 2015, IDA J DESALINATION W, V7, P3
   Zyoud SH, 2020, ENVIRON SCI POLLUT R, V27, P3523, DOI 10.1007/s11356-019-07100-y
   Zyoud SH, 2017, APPL WATER SCI, V7, P1255, DOI [10.1007/s13201-016-0520-2, 10.100]
NR 71
TC 1
Z9 1
U1 7
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1387-585X
EI 1573-2975
J9 ENVIRON DEV SUSTAIN
JI Environ. Dev. Sustain.
DI 10.1007/s10668-020-01004-5
EA OCT 2020
PG 29
WC Green & Sustainable Science & Technology; Environmental Sciences
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA NX5MW
UT WOS:000575756000007
PM 33041643
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Russo, E
   Esposito, P
   Taramasso, L
   Magnasco, L
   Saio, M
   Briano, F
   Russo, C
   Dettori, S
   Vena, A
   Di Biagio, A
   Garibotto, G
   Bassetti, M
   Viazzi, F
AF Russo, Elisa
   Esposito, Pasquale
   Taramasso, Lucia
   Magnasco, Laura
   Saio, Michela
   Briano, Federica
   Russo, Chiara
   Dettori, Silvia
   Vena, Antonio
   Di Biagio, Antonio
   Garibotto, Giacomo
   Bassetti, Matteo
   Viazzi, Francesca
CA GECOVID Working Grp
TI Kidney disease and all-cause mortality in patients with COVID-19
   hospitalized in Genoa, Northern Italy
SO JOURNAL OF NEPHROLOGY
LA English
DT Article; Early Access
DE Acute kidney injury; Chronic kidney disease; COVID-19; Mortality;
   Proteinuria
ID CRITICALLY-ILL PATIENTS; INJURY; INVOLVEMENT
AB Background The prevalence of kidney involvement during SARS-CoV-2 infection has been reported to be high. Nevertheless, data are lacking about the determinants of acute kidney injury (AKI) and the combined effect of chronic kidney disease (CKD) and AKI in COVID-19 patients. Methods We collected data on patient demographics, comorbidities, chronic medications, vital signs, baseline laboratory test results and in-hospital treatment in patients with COVID-19 consecutively admitted to our Institution. Chronic kidney disease was defined as eGFR < 60 mL/min per 1.73 m(2)or proteinuria at urinalysis within 180 days prior to hospital admission. AKI was defined according to KDIGO criteria. The primary and secondary outcomes were the development of AKI and death. Results Of 777 patients eligible for the study, acute kidney injury developed in 176 (22.6%). Of these, 79 (45%) showed an acute worsening of a preexisting CKD, and 21 (12%) required kidney replacement therapy. Independent associates of AKI were chronic kidney disease, C-reactive protein (CRP) and ventilation support.Among patients with acute kidney injury, 111 died (63%) and its occurrence increased the risk of death by 60% (HR 1.60 [95% IC 1.21-2.49] p = 0.002) independently of potential confounding factors including hypertension, preexisting kidney damage, and comorbidities. Patients with AKI showed a significantly higher rate of deaths attributed to bleeding compared to CKD and the whole population (7.5 vs 1.5 vs 3.5%, respectively). Conclusion Awareness of kidney function, both preexisting CKD and development of acute kidney injury, may help to identify those patients at increased risk of death.
C1 [Russo, Elisa; Esposito, Pasquale; Saio, Michela; Garibotto, Giacomo; Viazzi, Francesca] Univ Genoa, Hosp Policlin San Martino, Dept Internal Med, Clin Nefrol Dialisi & Trapianto,IRCCS, Viale Benedetto XV, I-16132 Genoa, Italy.
   [Taramasso, Lucia; Magnasco, Laura; Briano, Federica; Russo, Chiara; Dettori, Silvia; Vena, Antonio; Di Biagio, Antonio; Bassetti, Matteo] Univ Genoa, Hosp Policlin San Martino IRCCS, Dept Hlth Sci, Infect Dis Clin, Genoa, Italy.
RP Viazzi, F (corresponding author), Univ Genoa, Hosp Policlin San Martino, Dept Internal Med, Clin Nefrol Dialisi & Trapianto,IRCCS, Viale Benedetto XV, I-16132 Genoa, Italy.
EM francesca.viazzi@unige.it
RI garibotto, giacomo/AAB-1190-2019
OI garibotto, giacomo/0000-0001-6432-2429
FU Universita degli Studi di Genova within the CRUI-CARE Agreement
FX Open access funding provided by Universita degli Studi di Genova within
   the CRUI-CARE Agreement. This research did not receive any specific
   grant from funding agencies in the public, commercial, or not-for-profit
   sectors.
CR Martinez-Rojas MA, 2020, AM J PHYSIOL-RENAL, V318, pF1454, DOI 10.1152/ajprenal.00160.2020
   Bartoletti M, 2020, CLIN MICROBIOL INFEC, V26, P1545, DOI 10.1016/j.cmi.2020.08.003
   Batlle D, 2020, J AM SOC NEPHROL, V31, P1380, DOI 10.1681/ASN.2020040419
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chawla LS, 2014, NEW ENGL J MED, V371, P58, DOI 10.1056/NEJMra1214243
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003
   Das S, 2020, CLIN DRUG INVEST, V40, P591, DOI 10.1007/s40261-020-00927-1
   Diao B, 2020, HUMAN KIDNEY IS TARG, DOI [10.1101/2020.03.04.20031120, DOI 10.1101/2020.03.04.20031120]
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Edelstein CL, 2020, KIDNEY INT, V98, P234, DOI 10.1016/j.kint.2020.05.001
   Giannini B, 2018, AIDS RES HUM RETROV, V34, P239, DOI 10.1089/aid.2017.0064
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guzzi F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194941
   Han H, 2020, EMERG MICROBES INFEC, V9, P1123, DOI 10.1080/22221751.2020.1770129
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Joannidis M, 2020, INTENS CARE MED, V46, P654, DOI 10.1007/s00134-019-05869-7
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Malberti F, 2020, J NEPHROL, V33, P625, DOI 10.1007/s40620-020-00743-y
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Potere N, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03022-1
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   Rabb H, 2016, J AM SOC NEPHROL, V27, P371, DOI 10.1681/ASN.2015030261
   Rico-Mesa JS, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01291-4
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Shang Yufeng, 2020, EClinicalMedicine, V24, P100426, DOI 10.1016/j.eclinm.2020.100426
   Stevens LA, 2010, AM J KIDNEY DIS, V55, pS23, DOI 10.1053/j.ajkd.2009.09.035
   Tang TT, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0378-3
   Uribarri A, 2020, J NEPHROL, V33, P737, DOI 10.1007/s40620-020-00790-5
   Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xiao G, 2020, ACUTE KIDNEY INJURY, DOI [10.1101/2020.04.06.20055194, DOI 10.1101/2020.04.06.20055194]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhao ZR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236618
NR 37
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1121-8428
EI 1724-6059
J9 J NEPHROL
JI J. Nephrol.
DI 10.1007/s40620-020-00875-1
EA OCT 2020
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA NX6AH
UT WOS:000575791100001
PM 33025516
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hempel, L
   Piehler, A
   Pfaffl, MW
   Molnar, J
   Kirchner, B
   Robert, S
   Veloso, J
   Gandorfer, B
   Trepotec, Z
   Mederle, S
   Keim, S
   Milani, V
   Ebner, F
   Schweneker, K
   Fleischmann, B
   Kleespies, A
   Scheiber, J
   Hempel, D
   Zehn, D
AF Hempel, Louisa
   Piehler, Armin
   Pfaffl, Michael W.
   Molnar, Jakob
   Kirchner, Benedikt
   Robert, Sebastian
   Veloso, Julia
   Gandorfer, Beate
   Trepotec, Zeljka
   Mederle, Stefanie
   Keim, Sabine
   Milani, Valeria
   Ebner, Florian
   Schweneker, Katrin
   Fleischmann, Bastian
   Kleespies, Axel
   Scheiber, Josef
   Hempel, Dirk
   Zehn, Dietmar
TI SARS-CoV-2 infections in cancer outpatients-Most infected patients are
   asymptomatic carriers without impact on chemotherapy
SO CANCER MEDICINE
LA English
DT Article
ID F-18-FDG PET/CT
AB Oncologic patients are regarded as the population most at risk of developing a severe course of COVID-19 due to the fact that malignant diseases and chemotherapy often weaken the immune system. In the face of the ongoing SARS-CoV-2 pandemic, how particular patients deal with this infection remains an important question. In the period between the 15 and 26 April 2020, a total of 1227 patients were tested in one of seven oncologic outpatient clinics for SARS-CoV-2, regardless of symptoms, employing RT-qPCR. Of 1227 patients, 78 (6.4%) were tested positive of SARS-CoV-2. Only one of the patients who tested positive developed a severe form of COVID-19 with pneumonia (CURB-65 score of 2), and two patients showed mild symptoms. Fourteen of 75 asymptomatic but positively tested patients received chemotherapy or chemo-immunotherapy according to their regular therapy algorithm (+/- 4 weeks of SARS-CoV-2 test), and 48 of 78 (61.5%) positive-tested patients received glucocorticoids as co-medication. None of the asymptomatic infected patients showed unexpected complications due to the SARS-CoV-2 infection during the cancer treatment. These data clearly contrast the view that patients with an oncologic disease are particularly vulnerable to SARS-CoV-2 and suggest that compromising therapies could be continued or started despite the ongoing pandemic. Moreover the relatively low appearance of symptoms due to COVID-19 among patients on chemotherapy and other immunosuppressive co-medication like glucocorticoids indicate that suppressing the response capacity of the immune system reduces disease severity.
C1 [Hempel, Louisa] Sigmund Freud Univ Vienna, Vienna, Austria.
   [Piehler, Armin; Gandorfer, Beate; Trepotec, Zeljka; Mederle, Stefanie] MVZ Freising Lab, Freising Weihenstephan, Germany.
   [Pfaffl, Michael W.; Kirchner, Benedikt; Zehn, Dietmar] Tech Univ Munich, Sch Life Sci Weihenstephan, Div Anim Physiol & Immunol, Munich, Germany.
   [Molnar, Jakob; Ebner, Florian; Schweneker, Katrin; Kleespies, Axel] Canc Ctr Dachau, Dachau, Germany.
   [Robert, Sebastian; Veloso, Julia] Fraunhofer Inst Optron Syst Technol & Image Explo, Karlsruhe, Germany.
   [Keim, Sabine] Helios Clin Pasing, Dept Obstet, Munich, Germany.
   [Milani, Valeria] Oncol Ctr Furstenfeldbruck, Dachau, Germany.
   [Fleischmann, Bastian] Oncol Ctr Donauwoerth, Donauwoerth, Germany.
   [Scheiber, Josef] BioVariance GmbH, Waldsassen, Germany.
   [Hempel, Dirk] Steinbeis Hsch Berlin, Berlin, Germany.
RP Hempel, D (corresponding author), Steinbeis Hsch Berlin, Oncol Ctr, Neudegger Allee 10, D-86609 Donauworth, Germany.; Zehn, D (corresponding author), Tech Univ Munich, Sch Life Sci Weihenstephan, Div Anim Physiol & Immunol, D-85354 Freising Weihenstephan, Germany.
EM dirk.hempel@gmail.com; Dietmar.zehn@tum.de
RI Pfaffl, Michael W./G-6622-2013
OI Pfaffl, Michael W./0000-0002-3192-1019
FU ProjektDEAL
FX There are no acknowledgments. No authors received funding for this
   article. Open access funding enabled and organized by ProjektDEAL.
CR Acosta PL, 2016, CLIN VACCINE IMMUNOL, V23, P189, DOI 10.1128/CVI.00609-15
   Albano D, 2020, CLIN NUCL MED, V45, pE378, DOI 10.1097/RLU.0000000000003150
   Albano D, 2020, J NUCL MED, V61, P632, DOI 10.2967/jnumed.120.246256
   Barclay W, 2018, LANCET RESP MED, V6, P588, DOI 10.1016/S2213-2600(18)30272-8
   Besteman SB, 2019, AM J RESP CRIT CARE, V200, P410, DOI 10.1164/rccm.201901-0233ED
   Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   Dalgleish A, 2009, LANCET, V373, P805, DOI 10.1016/S0140-6736(09)60470-0
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Dourakis SP, 2006, AGE AGEING, V35, P196, DOI 10.1093/ageing/afj021
   Ha SY, 2004, J KOREAN MED SCI, V19, P453, DOI 10.3346/jkms.2004.19.3.453
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang HL, 2020, EUR J NUCL MED MOL I, V47, P2048, DOI 10.1007/s00259-020-04848-1
   Jones TC, 2020, ANAL SARS COV 2 VIRA
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu Y, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01112-2020
   Mattoli MV, 2020, CLIN NUCL MED, V45, pE383, DOI 10.1097/RLU.0000000000003175
   Office C Building RD Campus OR Drive R, 2020, EFF DEX HOSP PAT COV
   Ooi EE, 2011, TROPICAL INFECT DIS, V11, P504, DOI [10.1016/B978-0-7020-3935-5.00075-6, DOI 10.1016/B978-0-7020-3935-5.00075-6]
   RKI, 2010, BUNDESGESUNDHEITSBLA, V53, P357, DOI 10.1007/s00103-010-1028-9
   Smatti MK, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00211
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 23
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD NOV
PY 2020
VL 9
IS 21
BP 8020
EP 8028
DI 10.1002/cam4.3435
EA OCT 2020
PG 9
WC Oncology
SC Oncology
GA OL7GY
UT WOS:000575308400001
PM 33022856
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dong, D
   Xu, RH
   Wong, ELY
   Hung, CT
   Feng, D
   Feng, ZC
   Yeoh, EK
   Wong, SYS
AF Dong, Dong
   Xu, Richard Huan
   Wong, Eliza Lai-yi
   Hung, Chi-Tim
   Feng, Da
   Feng, Zhanchun
   Yeoh, Eng-kiong
   Wong, Samuel Yeung-shan
TI Public preference for COVID-19 vaccines in China: A discrete choice
   experiment
SO HEALTH EXPECTATIONS
LA English
DT Article; Early Access
DE Chinese public; COVID-19 pandemic; discrete choice experiment; vaccine;
   willingness to pay
ID SEASONAL INFLUENZA VACCINE; UNITED-STATES; VALIDITY; TRENDS; IMPACT;
   ONLINE
AB Background As the coronavirus disease 2019 (COVID-19) pandemic is sweeping across the globe, there is an urgent need to develop effective vaccines as the most powerful strategy to end the pandemic. This study aimed to examine how factors related to vaccine characteristics, their social normative influence and convenience of vaccination can affect the public's preference for the uptake of the COVID-19 vaccine in China. Methods An online discrete choice experiment (DCE) survey was administered to a sample of China's general population. Participants were asked to make a series of hypothetical choices and estimate their preference for different attributes of the vaccine. A mixed logit regression model was used to analyse the DCE data. Willingness to pay for each attribute was also calculated. Results Data of 1236 participants who provided valid responses were included in the analysis. There was strong public preference for high effectiveness of the vaccine, followed by long protective duration, very few adverse events and being manufactured overseas. Price was the least important attribute affecting the public preference in selecting the COVID-19 vaccine. Conclusions The strong public preferences detected in this study should be considered when developing COVID-19 vaccination programme in China. The results provide useful information for policymakers to identify the individual and social values for a good vaccination strategy. Patient or Public Contribution The design of the experimental choices was fully based on interviews and focus group discussions participated by 26 Chinese people with diverse socio-economic backgrounds. Without their participation, the study would not be possible.
C1 [Dong, Dong; Xu, Richard Huan; Wong, Eliza Lai-yi; Hung, Chi-Tim; Yeoh, Eng-kiong; Wong, Samuel Yeung-shan] Chinese Univ Hong Kong, Fac Med, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China.
   [Dong, Dong; Xu, Richard Huan; Wong, Eliza Lai-yi; Hung, Chi-Tim; Yeoh, Eng-kiong] Chinese Univ Hong Kong, Ctr Hlth Syst & Policy Res, Hong Kong, Peoples R China.
   [Feng, Da] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan, Peoples R China.
   [Feng, Zhanchun] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Med & Hlth Management, Wuhan, Peoples R China.
RP Dong, D; Xu, RH (corresponding author), Prince Wales Hosp, Sch Publ Hlth, Shatin, 4-F, Hong Kong, Peoples R China.
EM dongdong@cuhk.edu.hk; richardhxu@cuhk.edu.hk
RI Wong, Eliza Lai-Yi/ABI-2092-2020; Wong, Samuel Yeung-shan/D-7311-2013
OI Dong, Dong/0000-0001-9784-6472; Xu, Richard Huan/0000-0002-4720-5172;
   Hung, Chi-tim/0000-0003-2103-8377; Wong, Samuel
   Yeung-shan/0000-0003-0934-6385
FU Centre for Health Systems and Policy Research of the Chinese University
   of Hong Kong; Tung Foundation [6905422]
FX This research was funded by the Centre for Health Systems and Policy
   Research of the Chinese University of Hong Kong. The Centre was
   supported by the Tung Foundation (Project code: 6905422).
CR Anywaine Z, 2019, J INFECT DIS, V220, P46, DOI 10.1093/infdis/jiz070
   Barnett S, 2002, J EPIDEMIOL COMMUN H, V56, P754, DOI 10.1136/jech.56.10.754
   Butler AM, 2019, MED CARE, V57, P73, DOI 10.1097/MLR.0000000000001018
   Callegaro M, 2014, WILEY SER SURV METH, P1
   Cheung E., 2020, S CHINA MORNING POST
   Connell J, 2018, QUAL LIFE RES, V27, P1893, DOI 10.1007/s11136-018-1847-y
   de Bekker-Grob EW, 2018, VACCINE, V36, P1467, DOI 10.1016/j.vaccine.2018.01.054
   Determann D, 2017, VALUE HEALTH, V20, P953, DOI 10.1016/j.jval.2017.02.007
   Eilers R, 2014, PREV MED, V69, P224, DOI 10.1016/j.ypmed.2014.10.017
   European Centre for Disease Prevention and Control, 2020, RES REP CAS COVID 19
   Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Fung ICH, 2016, AM J INFECT CONTROL, V44, P1194, DOI 10.1016/j.ajic.2016.04.248
   Galarce EM, 2011, VACCINE, V29, P5284, DOI 10.1016/j.vaccine.2011.05.014
   Garcia LY, 2020, VACCINE, V38, P5424, DOI 10.1016/j.vaccine.2020.06.068
   Gold MS, 2020, VACCINE, V38, P3025, DOI 10.1016/j.vaccine.2020.02.046
   Green C, 2009, HEALTH ECON, V18, P951, DOI 10.1002/hec.1414
   Guo N, 2017, VACCINE, V35, P2848, DOI 10.1016/j.vaccine.2017.04.006
   Hanley N, 2001, J ECON SURV, V15, P435, DOI 10.1111/1467-6419.00145
   Hoyos D, 2010, ECOL ECON, V69, P1595, DOI 10.1016/j.ecolecon.2010.04.011
   Hu Y, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16224575
   Huang ZY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197437
   Jackson ML, 2017, NEW ENGL J MED, V377, P534, DOI [10.1056/NEJMoa1700153, 10.1056/nejmoa1700153]
   Jimenez-Garcia R, 2010, VACCINE, V28, P6169, DOI 10.1016/j.vaccine.2010.07.029
   Johnson FR, 2019, VALUE HEALTH, V22, P157, DOI 10.1016/j.jval.2018.07.876
   Johnson FR, 2013, VALUE HEALTH, V16, P3, DOI 10.1016/j.jval.2012.08.2223
   Joinson A. N., 2007, OXFORD HDB INTERNET
   Kabir KMA, 2019, CHAOS SOLITON FRACT, V120, P41, DOI 10.1016/j.chaos.2019.01.013
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C
   Kudo R, 2019, J INFECT DIS, V219, P382, DOI 10.1093/infdis/jiy516
   Li RC, 2018, VACCINE, V36, P3315, DOI 10.1016/j.vaccine.2018.04.060
   Liao QY, 2020, VACCINE, V38, P4557, DOI 10.1016/j.vaccine.2020.05.012
   Liao QY, 2019, VACCINE, V37, P4124, DOI 10.1016/j.vaccine.2019.05.072
   Liu SM, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012358
   Loharikar A, 2018, VACCINE, V36, P299, DOI 10.1016/j.vaccine.2017.11.017
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Mahieu P-A, 2015, IS CHOICE EXPT BECOM
   McGregor G, 2020, FORTUNE
   Murphy F, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3244
   Nagata JM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-388
   Norman R, 2020, VALUE HEALTH, V23, P495, DOI 10.1016/j.jval.2019.11.006
   Pohar SL, 2007, CLIN THER, V29, P1316, DOI 10.1016/j.clinthera.2007.07.001
   Rosenthal E, 2020, NY TIMES
   Ryan M, 2008, ECON NON-MARK GOOD, V11, P1, DOI 10.1007/978-1-4020-5753-3
   Shono A, 2014, VACCINE, V32, P5071, DOI 10.1016/j.vaccine.2014.07.002
   Sun J, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2875-6
   Ultsch B, 2016, PHARMACOECONOMICS, V34, P227, DOI 10.1007/s40273-015-0335-2
   Wang YH, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8388-3
   WHO, COR DIS COVID 19
   Wu J, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0334-8
   WU YH, 2020, P ROY SOC B-BIOL SCI, V287
   Yu M, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16162813
   Zhang XY, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0802-4
   Zhou M, 2019, VACCINE, V37, P3419, DOI 10.1016/j.vaccine.2019.05.020
   Zimmerman RK, 2016, CLIN INFECT DIS, V63, P1564, DOI 10.1093/cid/ciw635
NR 56
TC 0
Z9 0
U1 7
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1369-6513
EI 1369-7625
J9 HEALTH EXPECT
JI Health Expect.
DI 10.1111/hex.13140
EA OCT 2020
PG 36
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA NW8ZT
UT WOS:000575305500001
PM 33022806
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Thakur, A
   Tan, SPF
   Chan, JCY
AF Thakur, Aarzoo
   Tan, Shawn Pei Feng
   Chan, James Chun Yip
TI Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical
   Efficacy of the Coadministration of Lopinavir and Ritonavir against
   SARS-CoV-2
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article; Early Access
ID DRUG INTERACTIONS; IN-VITRO; LOPINAVIR/RITONAVIR; INHIBITORS;
   TRANSPORTERS; METABOLISM; COMBINATION; INDUCTION; EXPOSURE; ABT-378
AB Lopinavir/ritonavir, originally developed for treating HIV, is currently undergoing clinical studies for treating the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although recent reports suggest that lopinavir exhibitsin vitroefficacy against SARS-CoV-2, it is a highly protein-bound drug and it remains unknown if it reaches adequatein vivounbound (free) concentrations in lung tissue. We built a physiologically-based pharmacokinetic model of lopinavir/ritonavir in white and Chinese populations. Our aim was to perform pharmacokinetic/pharmacodynamic correlations by comparing simulated free plasma and lung concentration values achieved using different dosing regimens of lopinavir/ritonavir with unbound half-maximal effective concentration (EC50,unbound) and unbound effective concentration 90% values of lopinavir against SARS-CoV-2. The model was validated against multiple observed clinical datasets for single and repeated dosing of lopinavir/ritonavir. Predicted pharmacokinetic parameters, such as the maximum plasma concentration, area under the plasma concentration-time profile, oral clearance, half-life, and minimum plasma concentration at steady-state were within two-fold of clinical values for both populations. Using the current lopinavir/ritonavir regimen of 400/100 mg twice daily, lopinavir does not achieve sufficient free lung concentrations for efficacy against SARS-CoV-2. Although the Chinese population reaches greater plasma and lung concentrations as compared with whites, our simulations suggest that a significant dose increase from the current clinically used dosing regimen is necessary to reach the EC(50,unbound)value for both populations. Based on safety data, higher doses would likely lead to QT prolongation and gastrointestinal disorders (nausea, vomiting, and diarrhea), thus, any dose adjustment must be carefully weighed alongside these safety concerns.
C1 [Thakur, Aarzoo; Tan, Shawn Pei Feng; Chan, James Chun Yip] Agcy Sci Technol & Res, Innovat Food & Chem Safety, Singapore, Singapore.
   [Thakur, Aarzoo; Tan, Shawn Pei Feng; Chan, James Chun Yip] Agcy Sci Technol & Res, Skin Res Inst Singapore, Singapore, Singapore.
   [Chan, James Chun Yip] Agcy Sci Technol & Res, Singapore Inst Food & Biotechnol Innovat, Singapore, Singapore.
RP Chan, JCY (corresponding author), Agcy Sci Technol & Res, Innovat Food & Chem Safety, Singapore, Singapore.; Chan, JCY (corresponding author), Agcy Sci Technol & Res, Skin Res Inst Singapore, Singapore, Singapore.; Chan, JCY (corresponding author), Agcy Sci Technol & Res, Singapore Inst Food & Biotechnol Innovat, Singapore, Singapore.
EM james_chan@sifbi.a-star.edu.sg
OI Tan, Shawn Pei Feng/0000-0003-4195-9886
FU Agency for Science, Technology and Research (A*STAR) under its Industry
   Alignment Fund -Pre-Positioning Programme (IAF-PP) as part of the A*STAR
   Innovations in Food and Chemical Safety (IFCS) Programme
   [H18/01/a0/J14]; A*STAR Graduate AcademyAgency for Science Technology &
   Research (ASTAR)
FX This research was supported by the Agency for Science, Technology and
   Research (A*STAR) under its Industry Alignment Fund -Pre-Positioning
   Programme (IAF-PP) grant number H18/01/a0/J14 as part of the A*STAR
   Innovations in Food and Chemical Safety (IFCS) Programme (to J.C.Y.C.).
   S.P.F.T is supported by the A*STAR Graduate Academy.
CR Atzori C, 2003, AIDS, V17, P1710, DOI 10.1097/00002030-200307250-00022
   Barter ZE, 2013, CLIN PHARMACOKINET, V52, P1085, DOI 10.1007/s40262-013-0089-y
   Bierman WFW, 2010, J ANTIMICROB CHEMOTH, V65, P1672, DOI 10.1093/jac/dkq209
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centre for Drug Evaluation and Research, 2000, CLIN PHARM BIOPH REV
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Chu X, 2013, CLIN PHARMACOL THER, V94, P126, DOI 10.1038/clpt.2013.78
   de Kanter CTMM, 2010, J ANTIMICROB CHEMOTH, V65, P538, DOI 10.1093/jac/dkp472
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Du XL, 2019, PHARMACOTHERAPY, V39, P1179, DOI 10.1002/phar.2333
   Eron JJ, 2004, J INFECT DIS, V189, P265, DOI 10.1086/380799
   Fukushima K, 2013, J PHARM SCI-US, V102, P2044, DOI 10.1002/jps.23545
   Hickman D, 2004, ANTIMICROB AGENTS CH, V48, P2911, DOI 10.1128/AAC.48.8.2911-2917.2004
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang SM, 2010, CLIN PHARMACOL THER, V87, P497, DOI 10.1038/clpt.2009.308
   Jackson A, 2011, J ANTIMICROB CHEMOTH, V66, P635, DOI 10.1093/jac/dkq468
   Jeon S., 2020, IDENTIFICATION ANTIV, DOI [10.1101/ 2020.03.20.999730., DOI 10.1101/2020.03.20.999730, 10.1101/2020.03.20.999730.]
   Kaspera R, 2014, BIOCHEM PHARMACOL, V91, P109, DOI 10.1016/j.bcp.2014.06.020
   Kirby BJ, 2011, DRUG METAB DISPOS, V39, P2329, DOI 10.1124/dmd.111.038646
   Kumar GN, 2004, PHARM RES-DORDR, V21, P1622, DOI 10.1023/B:PHAM.0000041457.64638.8d
   Kumar GN, 1996, J PHARMACOL EXP THER, V277, P423
   la Porte CJL, 2004, ANTIMICROB AGENTS CH, V48, P1553, DOI 10.1128/AAC.48.5.1553-1560.2004
   Liu L, 2013, BIOPHARM DRUG DISPOS, V34, P155, DOI 10.1002/bdd.1832
   Aspiroz EL, 2011, THER DRUG MONIT, V33, P573, DOI 10.1097/FTD.0b013e31822d578b
   Maisch B, 2020, HERZ, V45, P321, DOI 10.1007/s00059-020-04925-z
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Ohashi H., MULTIDRUG TREATMENT, DOI [10.1101/2020.04.14.03992, DOI 10.1101/2020.04.14.03992]
   Penzak SR, 2010, PHARMACOTHERAPY, V30, P797, DOI 10.1592/phco.30.8.797
   Podzamczer D, 2007, HIV CLIN TRIALS, V8, P193, DOI 10.1310/hct0804-193
   Ryu S, 2020, J PHARM SCI-US, V109, P1178, DOI 10.1016/j.xphs.2019.10.060
   Scholler-Gyure M, 2013, J CLIN PHARMACOL, V53, P202, DOI 10.1177/0091270012445205
   Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218, DOI 10.1128/AAC.42.12.3218
   Smith DA, 2010, NAT REV DRUG DISCOV, V9, P929, DOI 10.1038/nrd3287
   Smith PF, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14314
   Twigg Homer L. III, 2010, HIV Therapy, V4, P247, DOI [10.2217/hiv.10.5, 10.2217/HIV.10.5]
   Vicente J, 2019, CLIN PHARMACOL THER, V105, P943, DOI 10.1002/cpt.1303
   Wagner C, 2017, J CLIN PHARMACOL, V57, P1295, DOI 10.1002/jcph.936
   WHO, 2020, WHO DISC HYDR LOP RI
   WHO, 2020, INT CLIN TRIALS REG
   World Health Organization, 2020, SOL CLIN TRIAL COVID
   World Health Organization, 2020, 167 WHO
   Yamamoto N., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.06.026476, 10.1101/ 2020.04.06.026476]
   Yang WQ, 2017, XENOBIOTICA, V47, P133, DOI 10.3109/00498254.2016.1166532
NR 44
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
DI 10.1002/cpt.2014
EA OCT 2020
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NW8QX
UT WOS:000575282500001
PM 32767755
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU del Amo, J
   Polo, R
   Moreno, S
   Diaz, A
   Martinez, E
   Arribas, JR
   Jarrin, I
   Hernan, MA
AF del Amo, Julia
   Polo, Rosa
   Moreno, Santiago
   Diaz, Asuncion
   Martinez, Esteban
   Ramon Arribas, Jose
   Jarrin, Inma
   Hernan, Miguel A.
CA Spanish HIV COVID-19 Collaboration
TI Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving
   Antiretroviral Therapy A Cohort Study
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID INFECTION; AGE
AB Background: The incidence and severity of coronavirus disease 2019 (COVID-19) among HIV-positive persons receiving anti-retroviral therapy (ART) have not been characterized in large populations.
   Objective: To describe the incidence and severity of COVID-19 by nucleos(t)ide reverse transcriptase inhibitor (NRTI) use among HIV-positive persons receiving ART.
   Design: Cohort study. Setting: HIV clinics in 60 Spanish hospitals between 1 February and 15 April 2020.
   Participants: 77 590 HIV-positive persons receiving ART.
   Measurements: Estimated risks (cumulative incidences) per 10 000 persons and 95% CIs for polymerase chain reaction-confirmed COVID-19 diagnosis, hospitalization, intensive care unit (ICU) admission, and death. Risk and 95% CIs for COVID-19 diagnosis and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafen-amide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and others were estimated through Poisson regression models.
   Results: Of 77 590 HIV-positive persons receiving ART, 236 were diagnosed with COVID-19, 151 were hospitalized, 15 were admitted to the ICU, and 20 died. The risks for COVID-19 diag-nosis and hospitalization were greater in men and persons older than 70 years. The risk for COVID-19 hospitalization was 20.3 (95% CI, 15.2 to 26.7) among patients receiving TAF/FTC, 10.5 (CI, 5.6 to 17.9) among those receiving TDF/FTC, 23.4 (CI, 17.2 to 31.1) among those receiving ABC/3TC, and 20.0 (CI, 14.2 to 27.3) for those receiving other regimens. The corresponding risks for COVID-19 diagnosis were 39.1 (CI, 31.8 to 47.6), 16.9 (CI, 10.5 to 25.9), 28.3 (CI, 21.5 to 36.7), and 29.7 (CI, 22.6 to 38.4), respectively. No patient receiving TDF/FTC was admitted to the ICU or died.
   Limitation: Residual confounding by comorbid conditions cannot be completely excluded.
   Conclusion: HIV-positive patients receiving TDF/FTC have a lower risk for COVID-19 and related hospitalization than those receiving other therapies. These findings warrant further investigation in HIV preexposure prophylaxis studies and randomized trials in persons without HIV.
C1 [del Amo, Julia; Polo, Rosa] Minist Hlth, Natl Plan AIDS, Paseo Prado 19, Madrid 28004, Spain.
   [Moreno, Santiago] Univ Hosp Ramon Y Cajal, M-607,Km 9,100, Madrid 28034, Spain.
   [Diaz, Asuncion; Jarrin, Inma] Inst Hlth Carlos III, Natl Ctr Epidemiol, Av Monforte de Lemos 5, Madrid 28029, Spain.
   [Martinez, Esteban] Univ Hosp Clin, Carrer Villarroel 170, Barcelona 08036, Spain.
   [Ramon Arribas, Jose] Univ Hosp La Paz, IdiPAZ, Paseo Castellana 261, Madrid 28046, Spain.
   [Hernan, Miguel A.] Harvard TH Chan Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA.
   [Hernan, Miguel A.] Harvard Mit Div Hlth Sci & Technol, 677 Huntington Ave, Boston, MA 02115 USA.
RP del Amo, J (corresponding author), Minist Hlth, Natl Plan AIDS, Paseo Prado 19, Madrid 28004, Spain.
EM jamo@mscbs.es; ijarrin@isciii.es
RI Rull, Anna/A-9438-2017; Diaz, Asuncion/Q-6016-2017; Perez, Maria Angeles
   Munoz/ABH-4734-2020; Gomez, Javier/AAX-6677-2020
OI Rull, Anna/0000-0002-8907-7754; Diaz, Asuncion/0000-0002-8309-4270;
   Martinez Sanchez, Elena Vanessa/0000-0003-1620-7113; Diaz-Brito,
   Vicens/0000-0002-9734-9334; Perez-Molina, Jose
   Antonio/0000-0001-8735-4124
FU Instituto de Salud Carlos IIIInstituto de Salud Carlos III [COV20/01112,
   RD16/0002]; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [R37
   AI102634]
FX By grants COV20/01112 and RD16/0002 from Instituto de Salud Carlos III
   and grant R37 AI102634 from the National Institutes of Health.
CR Alejos B, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221598
   Alejos B, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004727
   Alvarez S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230339
   Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Borobia AM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061733
   Chen XP, 2004, CLIN INFECT DIS, V38, P1030, DOI 10.1086/386340
   Chien Minchen, 2020, bioRxiv, DOI 10.1101/2020.03.18.997585
   Cottrell ML, 2017, J ANTIMICROB CHEMOTH, V72, P1731, DOI 10.1093/jac/dkx064
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   Desai Seema, 2010, Curr HIV/AIDS Rep, V7, P4, DOI 10.1007/s11904-009-0038-4
   Di Mascio M, 2009, ANTIMICROB AGENTS CH, V53, P4086, DOI 10.1128/AAC.00419-09
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   European Centre for Disease Prevention and Control, HIV AIDS SURVEILLANC
   European Medicines Agency Committee for Medicinal Products for Human Use, 2020, ASSESSMENT REPORT VE
   Government of Spain Ministry of Health, 2020, HOSPITAL SURVEY OF P
   Government of Spain Ministry of Health, 2020, COVID 19 SITUATION I
   Government of Spain Ministry of Health Alerts and Emergencies Coordination Center, 2019, SCIENTIFIC AND TECHN
   Government of Spain National Center of Epidemiology-Institute of Health Carlos III/National AIDS Plan-Subdirectorate General Directorate of Public Health Quality and Innovation, 2016, ESTIMATES FOR HIV CO
   Gross AM, 2016, MOL CELL, V62, P157, DOI 10.1016/j.molcel.2016.03.019
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo W, 2020, SURVEY COVID 19 HIV, DOI [10.2139/ssrn.3550029, DOI 10.2139/SSRN.3550029]
   Haerter G, COVID 19 PEOPLE LIVI, DOI [10.1101/2020.04.28.20073767, DOI 10.1101/2020.04.28.20073767]
   Horvath S, 2015, J INFECT DIS, V212, P1563, DOI 10.1093/infdis/jiv277
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jockusch S, 2020, BIORXIV, DOI [10.1101/2020.04.03.022939, DOI 10.1101/2020.04.03.022939]
   Ju J., 2020, BIORXIV, DOI [10.1101/2020.01.30.927574, DOI 10.1101/2020.01.30.927574, 10.1101/2020.01.30.927574.]
   Kostecka P, 2012, INT IMMUNOPHARMACOL, V12, P342, DOI 10.1016/j.intimp.2011.12.005
   Lipsitch M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003846
   Melchjorsen J, 2011, JAIDS-J ACQ IMM DEF, V57, P265, DOI 10.1097/QAI.0b013e3182185276
   Park D, 2020, MBIO, V11, DOI 10.1128/mBio.03328-19
   Patterson KB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003174
   Peters HL, 2015, CURR MED CHEM, V22, P3910, DOI 10.2174/0929867322666150818103624
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sanchez-Conde M, 2019, EPIGENOMICS-UK, V11, P501, DOI 10.2217/epi-2018-0130
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Twigg Homer L. III, 2010, HIV Therapy, V4, P247, DOI [10.2217/hiv.10.5, 10.2217/HIV.10.5]
   Wang WJ, 2020, CELL MOL IMMUNOL, V17, P650, DOI 10.1038/s41423-020-0447-2
   World Health Organization, 2020, CORONAVIRUS DISEASE
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang J, INT J INFECT DIS
   Zidek Z, 2003, EUR J PHARMACOL, V475, P149, DOI 10.1016/S0014-2999(03)02110-1
   Zidek Z, 2001, ANTIMICROB AGENTS CH, V45, P3381, DOI 10.1128/AAC.45.12.3381-3386.2001
NR 43
TC 16
Z9 16
U1 2
U2 2
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD OCT 6
PY 2020
VL 173
IS 7
BP 536
EP +
DI 10.7326/M20-3689
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA NX4GS
UT WOS:000575671400009
PM 32589451
OA Green Published
DA 2021-01-01
ER

PT J
AU Pinto, D
   Cirnes, L
   Pinto, R
   Pina, MJ
   Troncone, G
   Schmitt, F
AF Pinto, Daniel
   Cirnes, Luis
   Pinto, Regina
   Pina, Maria Joao
   Troncone, Giancarlo
   Schmitt, Fernando
TI How the COVID-19 Pandemic Impacted Oncological Molecular Diagnosis: A
   Picture from a National Reference Center for Molecular Pathology
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
AB Introduction. The Portuguese healthcare system had to adapt at short notice to the COVID-19 pandemic. We implemented workflow changes to our molecular pathology laboratory, a national reference center, to maximize safety and productivity. We assess the impact this situation had on our caseload and what conclusions can be drawn about the wider impact of the pandemic in oncological therapy in Portugal.Material and Methods. We reviewed our database for all oncological molecular tests requested between March and April of 2019 and 2020. For each case, we recorded age, sex, region of the country, requesting institution, sample type, testing method, and turnaround time (TAT). A comparison between years was made.Results. The total number of tests decreased from 421 in 2019 to 319 in 2020 (p=0.0027). The greatest reduction was in clinical trial-related cases. Routine cases were similar between years (267 vs. 256). TAT was higher in 2019 (mean 15 days vs. 12.3 days;p=0.0003). Medium- to large-sized public hospitals in the north of the country were mostly responsible for the reduction in cases (p=0.0153).Conclusions. Case reduction was observed at hospitals that have mostly been involved in the treatment of COVID-19 and in the north of the country, the region worst-hit by the pandemic. Similar to other studies, our TAT decreased, even with a similar number of routine cases. Thus, we conclude that it is possible to successfully adapt the workflow of a molecular pathology laboratory to new safety standards without losing efficiency.
C1 [Pinto, Daniel] EPE, Serv Anat Patol, Ctr Hosp Lisboa Ocident, Lisbon, Portugal.
   [Pinto, Daniel] NOVA Med Sch, Lisbon, Portugal.
   [Cirnes, Luis; Pinto, Regina; Pina, Maria Joao; Schmitt, Fernando] Univ Porto, IPATIMUP Inst Patol & Imunol Mol, Inst Invest & Inovacao Saude, I3S, Porto, Portugal.
   [Cirnes, Luis] Inst Politecn Porto, Escola Super Saude, Porto, Portugal.
   [Troncone, Giancarlo] Univ Naples Federico II, Dept Publ Hlth, Naples, Italy.
   [Schmitt, Fernando] Univ Porto, Fac Med, Porto, Portugal.
RP Schmitt, F (corresponding author), Univ Porto, IPATIMUP Inst Patol & Imunol Mol, Inst Invest & Inovacao Saude, I3S, Porto, Portugal.; Schmitt, F (corresponding author), Univ Porto, Fac Med, Porto, Portugal.
EM fernando.schmitt@ipatimup.pt
OI Schmitt, Fernando/0000-0003-1006-6946
CR [Anonymous], 2020, COV 19 CIR PRIOR SNS
   [Anonymous], 2020, EU COV STATS
   [Anonymous], 2020, COVID 19 REC LAB WOR
   Barel F, 2018, ACTA DERM-VENEREOL, V98, P44, DOI 10.2340/00015555-2738
   Colling R, 2019, VIRCHOWS ARCH, V474, P187, DOI 10.1007/s00428-018-2486-y
   Costa JL, 2019, ACTA CYTOL, V63, P448, DOI 10.1159/000501355
   Deans ZC, 2017, VIRCHOWS ARCH, V470, P5, DOI 10.1007/s00428-016-2025-7
   DGS, 2020, REL SIT COVID 19
   Fernandes MG, 2019, CANCERS, V11, DOI 10.3390/cancers11091229
   Freitas G., 2020, CASOS INFECAO NOVO C
   Iwen PC, 2020, AM J CLIN PATHOL, V153, P567, DOI 10.1093/ajcp/aqaa047
   Malapelle Umberto, 2020, J Clin Pathol, DOI 10.1136/jclinpath-2020-206957
   Pinto D, 2020, DIAGN CYTOPATHOL, V48, P840, DOI 10.1002/dc.24410
   Pisapia P, 2019, CANCER CYTOPATHOL, V127, P285, DOI 10.1002/cncy.22134
   Solassol J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163444
   Vigliar Elena, 2020, J Clin Pathol, DOI 10.1136/jclinpath-2020-206614
   World Health Organization, 2020, LAB BIOS GUID REL NO
NR 17
TC 1
Z9 1
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD OCT 5
PY 2020
VL 2020
AR 8397053
DI 10.1155/2020/8397053
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA OK4QO
UT WOS:000584637300006
PM 33029526
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mast, FD
   Navare, AT
   van der Sloot, AM
   Coulombe-Huntington, J
   Rout, MP
   Baliga, NS
   Kaushansky, A
   Chait, BT
   Aderem, A
   Rice, CM
   Sali, A
   Tyers, M
   Aitchison, JD
AF Mast, Fred D.
   Navare, Arti T.
   van der Sloot, Almer M.
   Coulombe-Huntington, Jasmin
   Rout, Michael P.
   Baliga, Nitin S.
   Kaushansky, Alexis
   Chait, Brian T.
   Aderem, Alan
   Rice, Charles M.
   Sali, Andrej
   Tyers, Mike
   Aitchison, John D.
TI Crippling life support for SARS-CoV-2 and other viruses through
   synthetic lethality
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID WIDE CRISPR SCREEN; HEPATITIS-B; ZIKA VIRUS; SARS-CORONAVIRUS;
   STRUCTURAL BASIS; HOST FACTORS; DENGUE; REPLICATION; GENES; ANTIBODIES
AB With the rapid global spread of SARS-CoV-2, we have become acutely aware of the inadequacies of our ability to respond to viral epidemics. Although disrupting the viral life cycle is critical for limiting viral spread and disease, it has proven challenging to develop targeted and selective therapeutics. Synthetic lethality offers a promising but largely unexploited strategy against infectious viral disease; as viruses infect cells, they abnormally alter the cell state, unwittingly exposing new vulnerabilities in the infected cell. Therefore, we propose that effective therapies can be developed to selectively target the virally reconfigured host cell networks that accompany altered cellular states to cripple the host cell that has been converted into a virus factory, thus disrupting the viral life cycle.
C1 [Mast, Fred D.; Navare, Arti T.; Kaushansky, Alexis; Aderem, Alan; Aitchison, John D.] Seattle Childrens Res Inst, Ctr Global Infect Dis Res, Seattle, WA 98101 USA.
   [van der Sloot, Almer M.; Coulombe-Huntington, Jasmin; Tyers, Mike] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ, Canada.
   [Rout, Michael P.] Rockefeller Univ, Lab Cellular & Struct Biol, 1230 York Ave, New York, NY 10021 USA.
   [Baliga, Nitin S.] Inst Syst Biol, Seattle, WA USA.
   [Kaushansky, Alexis; Aderem, Alan; Aitchison, John D.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
   [Chait, Brian T.] Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, 1230 York Ave, New York, NY 10021 USA.
   [Rice, Charles M.] Rockefeller Univ, Lab Virol & Infect Dis, 1230 York Ave, New York, NY 10021 USA.
   [Sali, Andrej] Univ Calif San Francisco, Dept Pharmaceut Chem, Dept Bioengn & Therapeut Sci, San Francisco, CA USA.
   [Sali, Andrej] Univ Calif San Francisco, Calif Inst Quantitat Biosci, San Francisco, CA 94143 USA.
   [Aitchison, John D.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
RP Aitchison, JD (corresponding author), Seattle Childrens Res Inst, Ctr Global Infect Dis Res, Seattle, WA 98101 USA.; Aitchison, JD (corresponding author), Univ Washington, Dept Pediat, Seattle, WA 98195 USA.; Aitchison, JD (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
EM John.Aitchison@seattlechildrens.org
RI ; Mast, Fred/A-6507-2011; van der Sloot, Almer/M-7083-2015
OI Reis, AlessanRSS/0000-0001-8486-7469; Kaushansky,
   Alexis/0000-0001-5721-258X; Mast, Fred/0000-0002-2177-6647; van der
   Sloot, Almer/0000-0003-0049-2044
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U19 AI100627, R01
   AI032972, U19 AI135976, U19 AI111276, P41 GM109824, R01 GM112108, R01
   AI141953, R01 AI128215, 109824, R01 CA228351, U19AI135990, R01GM083960,
   P01 AI138398-S1, U19 AI111825, R21 AI151344, R01 GM101183, R01
   AI091707]; Canadian Institutes for Health ResearchCanadian Institutes of
   Health Research (CIHR) [FDN-167277]; G. Harold and Leila Y. Mathers
   Charitable Foundation; George Mason University
FX The authors gratefully acknowledge support from the National Institutes
   of Health: U19 AI100627 (A. Aderem), R01 AI032972 (A. Aderem), U19
   AI135976 (A. Aderem, J.D. Aitchison, N.S. Baliga), U19 AI111276 (J.D.
   Aitchison), P41 GM109824 (J.D. Aitchison, M.P. Rout, A. Sali, B.T.
   Chait), R01 GM112108 (J.D. Aitchison, M.P. Rout), R01 AI141953 (N.S.
   Baliga, J.D. Aitchison), R01 AI128215 (N.S. Baliga), GM 109824 (B.T.
   Chait), R01 CA228351 (M.P. Rout), U19AI135990 (A. Sali), R01GM083960 (A.
   Sali), P01 AI138398-S1 (C.M. Rice), U19 AI111825 (C.M. Rice), R01
   AI091707 (C.M. Rice), R21 AI151344 (A. Kaushansky), and R01 GM101183 (A.
   Kaushansky); the Canadian Institutes for Health Research: FDN-167277 (M.
   Tyers); The G. Harold and Leila Y. Mathers Charitable Foundation (J.D.
   Aitchison, M.P. Rout, B.T. Chait, C.M. Rice); and a George Mason
   University Fast Grant (C.M. Rice).
CR Agbowuro AA, 2018, MED RES REV, V38, P1295, DOI 10.1002/med.21475
   Alshukairi AN, 2016, EMERG INFECT DIS, V22, P1113, DOI 10.3201/eid2206.160010
   Andrusiak K, 2012, BIOORGAN MED CHEM, V20, P1952, DOI 10.1016/j.bmc.2011.12.023
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Ashworth A, 2011, CELL, V145, P30, DOI 10.1016/j.cell.2011.03.020
   Bader GD, 2003, TRENDS CELL BIOL, V13, P344, DOI 10.1016/S0962-8924(03)00127-2
   Badorff C, 2000, J BIOL CHEM, V275, P11191, DOI 10.1074/jbc.275.15.11191
   Banerjee A, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117842
   Barrows NJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45910-9
   Basler CF, 2019, ANTIVIR RES, V162, P90, DOI 10.1016/j.antiviral.2018.12.006
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bell SM, 2019, ELIFE, V8, DOI 10.7554/eLife.42496
   Benstead-Hume G, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006888
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4
   Bouhaddou M, 2020, CELL, V182, P685, DOI 10.1016/j.cell.2020.06.034
   Calhoun S, 2018, ELIFE, V7, DOI 10.7554/eLife.31097
   Carpp LN, 2014, MOL CELL PROTEOMICS, V13, P2836, DOI 10.1074/mcp.M114.038984
   Carrasco-Hernandez R, 2017, ILAR J, V58, P343, DOI 10.1093/ilar/ilx026
   Casadevall A, 2020, JAMA-J AM MED ASSOC, V324, P455, DOI 10.1001/jama.2020.10218
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Castro LA, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007683
   Chaudhuri S, 2018, ANTIVIR RES, V155, P76, DOI 10.1016/j.antiviral.2018.05.005
   Chung HY, 2014, J VIROL, V88, P11022, DOI 10.1128/JVI.01582-14
   Cokol M, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006677
   Cokol M, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.71
   Comalada M, 2010, J LEUKOCYTE BIOL, V88, P1063, DOI 10.1189/jlb.0710401
   Costanzo M, 2019, CELL, V177, P85, DOI 10.1016/j.cell.2019.01.033
   Costanzo M, 2016, SCIENCE, V353, DOI 10.1126/science.aaf1420
   Coyaud E, 2018, MOL CELL PROTEOMICS, V17, P2242, DOI 10.1074/mcp.TIR118.000800
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Davey NE, 2011, TRENDS BIOCHEM SCI, V36, P159, DOI 10.1016/j.tibs.2010.10.002
   de Chassey B, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0115-1
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   Denison MR, 2011, RNA BIOL, V8, P270, DOI 10.4161/rna.8.2.15013
   Dewe JM, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00214-17
   Diep J, 2019, NAT MICROBIOL, V4, P2523, DOI 10.1038/s41564-019-0551-1
   Dominguez-Bello MG, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.97, 10.1038/nmicrobiol.2016.97]
   Durham ND, 2019, ELIFE, V8, DOI 10.7554/eLife.52384
   Eckhardt M, 2020, NAT REV GENET, V21, P339, DOI 10.1038/s41576-020-0212-5
   Eroshenko N, 2020, NAT BIOTECHNOL, V38, P789, DOI 10.1038/s41587-020-0577-1
   Fabre E, 1997, ANNU REV GENET, V31, P277, DOI 10.1146/annurev.genet.31.1.277
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1610
   Ferreira AR, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030790
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Flint M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08135-4
   Freitas BT, 2020, ACS INFECT DIS, V6, P2099, DOI 10.1021/acsinfecdis.0c00168
   Fridy PC, 2014, NAT METHODS, V11, P1253, DOI [10.1038/NMETH.3170, 10.1038/nmeth.3170]
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gordon DE, 2020, MOL CELL, V78, P197, DOI 10.1016/j.molcel.2020.02.004
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Guise AJ, 2013, VIRUSES-BASEL, V5, P1607, DOI 10.3390/v5071607
   Gulbahce N, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002531
   Haga K, 2016, P NATL ACAD SCI USA, V113, pE6248, DOI 10.1073/pnas.1605575113
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   HAMRE D, 1972, AM J EPIDEMIOL, V96, P94, DOI 10.1093/oxfordjournals.aje.a121445
   Han J, 2018, CELL REP, V23, P596, DOI 10.1016/j.celrep.2018.03.045
   Harada Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236074
   Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015
   Hart T, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145216
   Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064
   Hayden FG, 2018, NEW ENGL J MED, V379, P913, DOI 10.1056/NEJMoa1716197
   Heaton SM, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1067
   Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8
   Ho MR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07023-z
   Hofmann Wolf Peter, 2009, V189, P321, DOI 10.1007/978-3-540-79086-0_12
   Hoofnagle J.H., 2018, LIVERTOX CLIN RES IN
   Huang A, 2020, NAT REV DRUG DISCOV, V19, P23, DOI 10.1038/s41573-019-0046-z
   Huang HC, 2019, NUCLEIC ACIDS RES, V47, P7333, DOI 10.1093/nar/gkz493
   Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI 10.1038/s41594-020-0469-6
   Hyrina A, 2019, CELL REP, V29, P2970, DOI 10.1016/j.celrep.2019.10.113
   ISAACS D, 1983, ARCH DIS CHILD, V58, P500, DOI 10.1136/adc.58.7.500
   Isaacson MK, 2009, CELL HOST MICROBE, V5, P559, DOI 10.1016/j.chom.2009.05.012
   Ison MG, 2020, LANCET INFECT DIS, V20, P1204, DOI [10.1016/51473-3099(20)30004-9, 10.1016/S1473-3099(20)30004-9]
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Jefferson T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2545
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jonikas MC, 2009, SCIENCE, V323, P1693, DOI 10.1126/science.1167983
   Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691
   Kaufmann SHE, 2018, NAT REV DRUG DISCOV, V17, P35, DOI 10.1038/nrd.2017.162
   Kim SJ, 2018, NATURE, V555, P475, DOI 10.1038/nature26003
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Krishnan MN, 2008, NATURE, V455, P242, DOI 10.1038/nature07207
   Krogan NJ, 2015, MOL CELL, V58, P690, DOI 10.1016/j.molcel.2015.05.008
   Kulsuptrakul J, 2020, BIORXIV, DOI [10.1101/2019.12.15.877100, DOI 10.1101/2019.12.15.877100]
   Laitinen OH, 2016, REV MED VIROL, V26, P251, DOI 10.1002/rmv.1883
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13965-x
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li PL, 2016, NAT MED, V22, P807, DOI 10.1038/nm.4124
   Li Y, 2019, P NATL ACAD SCI USA, V116, P9527, DOI 10.1073/pnas.1900867116
   Lin DL, 2017, MBIO, V8, DOI [10.1128/mBio.00939-17, 10.1128/mbio.00939-17]
   Liu DD, 2015, ANTIMICROB AGENTS CH, V59, P3482, DOI 10.1128/AAC.00223-15
   Liu LH, 2020, NATURE, DOI 10.1038/s41586-020-2571-7
   Liu P, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008421
   Liu YY, 2011, NATURE, V473, P167, DOI 10.1038/nature10011
   Lloyd RE, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8040093
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344
   Lum KK, 2016, EXPERT REV PROTEOMIC, V13, P325, DOI 10.1586/14789450.2016.1147353
   Luo Y, 2016, NAT MICROBIOL, V1, DOI 10.1038/NMICROBIOL.2016.68
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Ma HM, 2015, CELL REP, V12, P673, DOI 10.1016/j.celrep.2015.06.049
   Ma S, 2019, MBIO, V10, DOI 10.1128/mBio.02627-19
   Ma YJ, 2017, CELL HOST MICROBE, V21, P580, DOI 10.1016/j.chom.2017.04.005
   Mair B, 2019, CURR OPIN GENET DEV, V54, P64, DOI 10.1016/j.gde.2019.03.002
   Marceau CD, 2016, NATURE, V535, P159, DOI 10.1038/nature18631
   Mast FD, 2014, J CELL BIOL, V206, P695, DOI 10.1083/jcb.201405027
   Menachery VD, 2017, CURR OPIN VIROL, V23, P1, DOI 10.1016/j.coviro.2017.01.002
   Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041
   Messina JP, 2019, NAT MICROBIOL, V4, P1508, DOI 10.1038/s41564-019-0476-8
   Meyniel-Schicklin L, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014738
   Mo HY, 2006, RESPIROLOGY, V11, P49, DOI 10.1111/j.1440-1843.2006.00783.x
   Mohr S, 2010, ANNU REV BIOCHEM, V79, P37, DOI 10.1146/annurev-biochem-060408-092949
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Mueller H, 2019, HEPATOLOGY, V69, P1398, DOI 10.1002/hep.30329
   Mueller H, 2018, J HEPATOL, V68, P412, DOI 10.1016/j.jhep.2017.10.014
   Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042
   Ngo AM, 2019, ELIFE, V8, DOI 10.7554/eLife.48469
   Niepel M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01383-w
   Orchard RC, 2016, SCIENCE, V353, P933, DOI 10.1126/science.aaf1220
   Osterhaus A, 2001, PHILOS T ROY SOC B, V356, P791, DOI 10.1098/rstb.2001.0856
   Park RJ, 2017, NAT GENET, V49, P193, DOI 10.1038/ng.3741
   PEIRIS JSM, 1979, NATURE, V282, P509, DOI 10.1038/282509a0
   Perreira JM, 2015, CELL REP, V12, P850, DOI 10.1016/j.celrep.2015.06.076
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Pierson TC, 2020, NAT MICROBIOL, V5, P796, DOI 10.1038/s41564-020-0714-0
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Plaisier CL, 2016, CELL SYST, V3, P172, DOI 10.1016/j.cels.2016.06.006
   Pontremoli C, 2016, MOL BIOL EVOL, V33, P2836, DOI 10.1093/molbev/msw158
   Puschnik AS, 2017, NAT REV MICROBIOL, V15, P351, DOI 10.1038/nrmicro.2017.29
   Ravindran V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38224-9
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Richardson RB, 2018, NAT MICROBIOL, V3, P1214, DOI 10.1038/s41564-018-0244-1
   Riva L, 2020, NATURE, V586, P113, DOI 10.1038/s41586-020-2577-1
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rodriguez-Barraquer I, 2019, SCIENCE, V363, P607, DOI 10.1126/science.aav6618
   Roger T, 2011, BLOOD, V117, P1205, DOI 10.1182/blood-2010-05-284711
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Rout MP, 2019, CELL, V177, P1384, DOI 10.1016/j.cell.2019.05.016
   Rut Wioletta, 2020, bioRxiv, DOI 10.1101/2020.04.29.068890
   Sauder DN, 2003, BRIT J DERMATOL, V149, P5, DOI 10.1046/j.0366-077X.2003.05628.x
   Savidis G, 2016, CELL REP, V16, P232, DOI 10.1016/j.celrep.2016.06.028
   Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072
   Seydoux E, 2020, IMMUNITY, V53, P98, DOI 10.1016/j.immuni.2020.06.001
   Shah PS, 2018, CELL, V175, P1931, DOI 10.1016/j.cell.2018.11.028
   Tabata K, 2016, CELL REP, V16, P2339, DOI 10.1016/j.celrep.2016.07.068
   Tse LV, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00658
   Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61
   Tyers M, 2019, NAT REV MICROBIOL, V17, P141, DOI 10.1038/s41579-018-0141-x
   Van Poelvoorde LA, 2020, TRENDS BIOTECHNOL, V38, P360, DOI 10.1016/j.tibtech.2019.09.009
   Viswanathan T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17496-8
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wang Q, 2020, CELL, V182, P417, DOI 10.1016/j.cell.2020.05.034
   Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041
   Wei Jin, 2020, bioRxiv, DOI 10.1101/2020.06.16.155101
   Whitehead SS, 2019, NATURE, V567, P467, DOI 10.1038/d41586-019-00868-6
   Wiltshire TD, 2010, J BIOL CHEM, V285, P14565, DOI 10.1074/jbc.M110.104745
   Woolhouse MEJ, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.17
   World Health Organization (WHO), 2020, INFL SEAS
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wu YL, 2020, CELL HOST MICROBE, V27, P891, DOI 10.1016/j.chom.2020.04.023
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang R, 2016, NATURE, V535, P164, DOI 10.1038/nature18625
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 177
TC 0
Z9 0
U1 7
U2 7
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD OCT 5
PY 2020
VL 219
IS 10
AR e202006159
DI 10.1083/jcb.202006159
PG 15
WC Cell Biology
SC Cell Biology
GA OC3QW
UT WOS:000579074200007
PM 32785687
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wang, SB
   Li, WY
   Hui, H
   Tiwari, SK
   Zhang, Q
   Croker, B
   Rawlings, S
   Smith, D
   Carlin, AF
   Rana, TM
AF Wang, Shaobo
   Li, Wanyu
   Hui, Hui
   Tiwari, Shashi Kant
   Zhang, Qiong
   Croker, Ben A.
   Rawlings, Stephen
   Smith, Davey
   Carlin, Aaron F.
   Rana, Tariq M.
TI Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses
   by depleting membrane cholesterol
SO EMBO JOURNAL
LA English
DT Article; Early Access
DE cholesterol 25-hydroxylase; COVID-19 treatment; innate immunity;
   restriction factor of coronaviruses; viral fusion
ID SPIKE PROTEIN; ENTRY; INTERFERONS; CLEAVAGE; ACE2
AB Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2 and has spread across the globe. SARS-CoV-2 is a highly infectious virus with no vaccine or antiviral therapy available to control the pandemic; therefore, it is crucial to understand the mechanisms of viral pathogenesis and the host immune responses to SARS-CoV-2. SARS-CoV-2 is a new member of the betacoronavirus genus like other closely related viruses including SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Both SARS-CoV and MERS-CoV have caused serious outbreaks and epidemics in the past eighteen years. Here, we report that one of the interferon-stimulated genes (ISGs), cholesterol 25-hydroxylase (CH25H), is induced by SARS-CoV-2 infection in vitro and in COVID-19-infected patients. CH25H converts cholesterol to 25-hydrocholesterol (25HC) and 25HC shows broad anti-coronavirus activity by blocking membrane fusion. Furthermore, 25HC inhibits USA-WA1/2020 SARS-CoV-2 infection in lung epithelial cells and viral entry in human lung organoids. Mechanistically, 25HC inhibits viral membrane fusion by activating the ER-localized acyl-CoA:cholesterol acyltransferase (ACAT) which leads to the depletion of accessible cholesterol from the plasma membrane. Altogether, our results shed light on a potentially broad antiviral mechanism by 25HC through depleting accessible cholesterol on the plasma membrane to suppress virus-cell fusion. Since 25HC is a natural product with no known toxicity at effective concentrations, it provides a potential therapeutic candidate for COVID-19 and emerging viral diseases in the future.
C1 [Wang, Shaobo; Li, Wanyu; Hui, Hui; Tiwari, Shashi Kant; Zhang, Qiong; Rana, Tariq M.] Univ Calif San Diego, Program Immunol, Inst Genom Med, Div Genet,Dept Pediat, La Jolla, CA 92093 USA.
   [Li, Wanyu; Hui, Hui] Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.
   [Hui, Hui] Univ Calif San Diego, Bioinformat Program, La Jolla, CA 92093 USA.
   [Croker, Ben A.] Univ Calif San Diego, Dept Pediat, Div Allergy Immunol & Rheumatol, La Jolla, CA 92093 USA.
   [Rawlings, Stephen; Smith, Davey; Carlin, Aaron F.] Univ Calif San Diego, Dept Med, Div Infect Dis & Global Publ Hlth, La Jolla, CA 92093 USA.
RP Rana, TM (corresponding author), Univ Calif San Diego, Program Immunol, Inst Genom Med, Div Genet,Dept Pediat, La Jolla, CA 92093 USA.
EM trana@ucsd.edu
FU Burroughs Wellcome FundBurroughs Wellcome Fund; John and Mary Tu
   Foundation; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [CA177322, DA039562, DA049524, AI125103]
FX We thank Arun Radhakrishnan and Kristen Johnson from UT Southwestern
   Medical Center for their advice on ALOD4 purification. We thank members
   of the Rana laboratory for helpful discussions and advice. The following
   reagent was deposited by the Centers for Disease Control and Prevention
   and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus
   2, Isolate USA-WA1/2020, NR-52281. This work was supported by a Career
   Award for Medical Scientists from the Burroughs Wellcome Fund to AFC,
   John and Mary Tu Foundation, and in part by grants from the National
   Institutes of Health (CA177322, DA039562, DA049524, and AI125103).
CR Abrams ME, 2020, NAT MICROBIOL, V5, P929, DOI 10.1038/s41564-020-0701-5
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Castiglione V, 2020, EUR HEART J-CARD PHA, V6, P258, DOI 10.1093/ehjcvp/pvaa042
   Chazal N, 2003, MICROBIOL MOL BIOL R, V67, P226, DOI 10.1128/MMBR.67.2.226-237.2003
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Daamen AR, 2020, PREPRINT, DOI [10.1101/2020.05.28.121889, DOI 10.1101/2020.05.28.121889]
   Das A, 2014, ELIFE, V3, DOI 10.7554/eLife.02882
   Dashti-Khavidaki S, 2020, PHARMACOTHERAPY, V40, P484, DOI 10.1002/phar.2397
   de Weerd NA, 2012, IMMUNOL CELL BIOL, V90, P483, DOI 10.1038/icb.2012.9
   Dong DS, 2020, LIGHT-SCI APPL, V9, DOI 10.1038/s41377-020-0249-4
   Du XM, 2004, J BIOL CHEM, V279, P47010, DOI 10.1074/jbc.M408690200
   Endapally Shreya, 2019, Methods Mol Biol, V1949, P153, DOI 10.1007/978-1-4939-9136-5_12
   Osuna-Ramos JF, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00388
   Fukushi S, 2005, J GEN VIROL, V86, P2269, DOI 10.1099/vir.0.80955-0
   Gay A, 2015, BIOPHYS J, V108, P1459, DOI 10.1016/j.bpj.2015.02.008
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Leibel SL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49696-8
   Li CF, 2017, IMMUNITY, V46, P446, DOI 10.1016/j.immuni.2017.02.012
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Liu SY, 2013, IMMUNITY, V38, P92, DOI 10.1016/j.immuni.2012.11.005
   Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316
   Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811
   Meng Z., 2020, EXPT TRIAL RECOMBINA, DOI [10.1101/2020.04.11.20061473., DOI 10.1101/2020.04.11.20061473, 10.1101/2020.04.11.20061473]
   Miller AJ, 2019, NAT PROTOC, V14, P518, DOI 10.1038/s41596-018-0104-8
   Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008
   Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231
   Shin YH, 2017, HEART VESSELS, V32, P618, DOI 10.1007/s00380-016-0936-5
   Spann NJ, 2013, NAT IMMUNOL, V14, P893, DOI 10.1038/ni.2681
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   Tikoo K, 2015, BIOCHEM PHARMACOL, V93, P343, DOI 10.1016/j.bcp.2014.11.013
   Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006
   Yang ST, 2016, CHEM PHYS LIPIDS, V199, P136, DOI 10.1016/j.chemphyslip.2016.05.003
   Yang ST, 2015, NAT CHEM BIOL, V11, P424, DOI [10.1038/NCHEMBIO.1800, 10.1038/nchembio.1800]
   Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582
   Zhang XJ, 2020, CELL METAB, V32, P176, DOI 10.1016/j.cmet.2020.06.015
   Zhou Q, 2020, INTERFERON A2B TREAT, DOI [10.1101/2020.04.06.20042580, DOI 10.1101/2020.04.06.20042580]
NR 38
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
AR e106057
DI 10.15252/embj.2020106057
EA OCT 2020
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NW4XW
UT WOS:000575012600001
PM 32944968
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Assaf, AM
   Haddadin, RN
   Akour, AA
AF Assaf, Areej M.
   Haddadin, Randa N.
   Akour, Amal A.
TI COVID-19: Between Past and Present
SO VIRAL IMMUNOLOGY
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV2; immunopathology; therapy; cytokine storm;
   coronavirus
ID ACUTE RESPIRATORY SYNDROME; IN-VITRO; CORONAVIRUS; SARS; OUTBREAK;
   REPLICATION; INHIBITION; ANTIBODIES; PNEUMONIA; EFFECTOR
AB Since the WHO declared coronavirus disease 2019 (COVID-19) as a pandemic, huge efforts were made to understand the disease, its pathogenesis, and treatment. COVID-19 is caused by severe acute respiratory syndrome (SARS) coronavirus-2 (SARS-CoV2), which is closely related to SARS-associated coronavirus (SARS-CoV). This article attempts to provide a timely and comprehensive review of the coronaviruses over the years, and the epidemics they caused in this century with a focus on the current pandemic COVID-19. It also covers the basics about the disease immunopathogenesis, diagnosis, prognosis, and treatment options. Although almost every single week new clinical findings are published, which change our understanding of COVID-19, this review explores and explains the disease and the treatment options available so far. In summary, many therapeutic options are being investigated to treat and/or ameliorate the symptoms of COVID-19, but none is registered and no sufficient data to support immune-based therapy beyond the context of clinical trials. For that, strengthening our immune system is the best defense at this time.
C1 [Assaf, Areej M.; Haddadin, Randa N.; Akour, Amal A.] Univ Jordan, Sch Pharm, Dept Biopharmaceut & Clin Pharm, Amman 11942, Jordan.
RP Assaf, AM (corresponding author), Univ Jordan, Sch Pharm, Dept Biopharmaceut & Clin Pharm, Amman 11942, Jordan.
EM areej_assaf@ju.edu.jo
CR Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2020, RECOVERY TRIAL REPOR
   [Anonymous], 2020, NOV COR STRUCT REV T
   Barnard Dale L., 2006, Antiviral Chemistry & Chemotherapy, V17, P275
   Ben Addi A, 2008, EUR J IMMUNOL, V38, P1610, DOI 10.1002/eji.200737781
   Birra D, 2020, IMMUNOL RES, V68, P161, DOI 10.1007/s12026-020-09137-5
   Blanco-Melo D., 2020, BIORXIV, DOI [10.1101/2020.03.24.004655, DOI 10.1101/2020.03.24.004655]
   Bleibtreu A, 2020, MED MALADIES INFECT, V50, P243, DOI 10.1016/j.medmal.2019.10.004
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   Cai G., 2020, TOBACCO USE DISPARIT, DOI [10.20944/preprints202002.0051.v1, DOI 10.20944/PREPRINTS202002.0051.V1]
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cameron MJ, 2008, VIRUS RES, V133, P13, DOI 10.1016/j.virusres.2007.02.014
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   CDC, 2019, MIDDL E RESP SYNDR M
   CDC, COR DIS 2019 COVID 1
   CDC, 2017, SEV AC RESP SYNDR SA
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen C, 2020, FAVIPIRAVIR VERSUS A
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, ASIANS OTHER RACES E, DOI [10.20944/preprints202002.0258.v1, DOI 10.20944/PREPRINTS202002.0258.V1]
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Chu DKW, 2018, P NATL ACAD SCI USA, V115, P3144, DOI 10.1073/pnas.1718769115
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Couture F, 2015, EXPERT OPIN THER PAT, V25, P379, DOI 10.1517/13543776.2014.1000303
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Diao B., 2020, REDUCTION FUNCTIONAL, DOI [10.1101/2020.02.18.20024364, DOI 10.1101/2020.02.18.20024364]
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Dyer O, 2003, BRIT MED J, V326, P999, DOI 10.1136/bmj.326.7397.999
   ECDC, 2020, Q A COVID 19
   EU Clinical Trials Register, MULT AD RAND TRIAL S
   Eurosurveillance Editorial T., 2020, EURO SURVEILL, V25, P2002131
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fenwick C, 2019, IMMUNOL REV, V292, P149, DOI 10.1111/imr.12823
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Fraser C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/pnas.0307506101
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Horby P, EFFECT DEXAMETHASONE, DOI 10.1101/2020.06.22.20137273
   Hu B, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0422-1
   Hui DS, 2014, CURR OPIN PULM MED, V20, P233, DOI 10.1097/MCP.0000000000000046
   International Committee on Taxonomy of Viruses (ICTV, 2020, TAX
   Kellam P, 2020, J GEN VIROL, V101, P791, DOI 10.1099/jgv.0.001439
   KENDALL EJC, 1962, BRIT MED J, P82
   Killerby ME, 2018, J CLIN VIROL, V101, P52, DOI 10.1016/j.jcv.2018.01.019
   Kuwajima K, 2019, J INTENSIVE CARE, V7, DOI 10.1186/s40560-019-0365-5
   Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0
   LeDuc J.W., 2004, EMERG INFECT DIS, V10, pe26, DOI [10.3201/eid1011.040797_02, DOI 10.3201/EID1011.040797_02]
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li G, 2003, NEW ENGL J MED, V349, P508, DOI 10.1056/NEJM200307313490520
   Li TS, 2004, J INFECT DIS, V189, P648, DOI 10.1086/381535
   Li Y, 2020, EXPLORATORY RANDOMIZ
   Liu C, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0771-3
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu XL, 2011, VIRUS GENES, V42, P37, DOI 10.1007/s11262-010-0544-x
   Luo Y, 2019, HYPERTENS RES, V42, P681, DOI 10.1038/s41440-018-0166-6
   Mantlo Emily, 2020, bioRxiv, DOI 10.1101/2020.04.02.022764
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   Meftahi GH, 2020, INFLAMM RES, V69, P825, DOI 10.1007/s00011-020-01372-8
   Mescher MF, 2006, IMMUNOL REV, V211, P81, DOI 10.1111/j.0105-2896.2006.00382.x
   Monchatre-Leroy E, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120364
   Morawska Lidia, 2020, Clin Infect Dis, V71, P2311, DOI 10.1093/cid/ciaa939
   Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730
   National Health Commission of the People's Republic of China (NHC), 2020, DIAGN TREATM GUID CO
   Ng CT, 2013, CELL HOST MICROBE, V13, P652, DOI 10.1016/j.chom.2013.05.014
   Parry J, 2004, BRIT MED J, V328, P123, DOI 10.1136/bmj.328.7432.123-a
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Phan MVT, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey035
   Piechotta V, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600.pub2
   Pruijssers AJ, 2019, CURR OPIN VIROL, V35, P57, DOI 10.1016/j.coviro.2019.04.002
   Ruan SG, 2020, LANCET INFECT DIS, V20, P630, DOI 10.1016/S1473-3099(20)30257-7
   Seow G., 2020, LONGITUDINAL EVALUAT, DOI [10.1101/2020.07.09.20148429., 10.1101/2020.07.09.20148429, DOI 10.1101/2020.07.09.20148429]
   Sette A, 2020, NAT REV IMMUNOL, V20, P457, DOI 10.1038/s41577-020-0389-z
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shiraki K, 2020, PHARMACOL THERAPEUT, V209, DOI 10.1016/j.pharmthera.2020.107512
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Turner AJ, 2004, HDB PROTEOLYTIC ENZY, P349, DOI DOI 10.1016/B978-0-12-079611-3.50092-6
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wadman M, 2020, SCI AAAS
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wei WE, 2020, MMWR-MORBID MORTAL W, V69, P411, DOI 10.15585/mmwr.mm6914e1
   Wen C Y, 2020, Zhonghua Nei Ke Za Zhi, V59, pE012, DOI 10.3760/cma.j.cn112138-20200227-00147
   WHO, 2020, WHO MIDDL E RESP SYN
   WHO, 2003, SEV AC RESP SYNDR SA
   WHO, 2020, WHO MERS COV SUMM LI
   WHO, 2020, COR COVID 19 EV AS T
   WHO, 2020, Q A IS COVID 19 TRAN
   World Health Organization, 2020, SARS SEV AC RESP SYN
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang PH, 2020, CELL MOL IMMUNOL, V17, P555, DOI 10.1038/s41423-020-0407-x
   Zhang H, 2020, DIGESTIVE SYSTEM IS, DOI [10.1101/2020.01.30.927806, DOI 10.1101/2020.01.30.927806]
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhao JX, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan5393
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 122
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0882-8245
EI 1557-8976
J9 VIRAL IMMUNOL
JI Viral Immunol.
DI 10.1089/vim.2020.0102
EA OCT 2020
PG 13
WC Immunology; Virology
SC Immunology; Virology
GA NZ3GN
UT WOS:000576985700001
PM 33017280
OA Bronze
DA 2021-01-01
ER

PT J
AU Hakmi, M
   Bouricha, ELM
   Akachar, J
   Lmimouni, B
   El Harti, J
   Belyamani, L
   Ibrahimi, A
AF Hakmi, Mohammed
   Bouricha, E. L. Mehdi
   Akachar, Jihane
   Lmimouni, Badreddine
   El Harti, Jaouad
   Belyamani, Lahcen
   Ibrahimi, Azeddine
TI In silico exploration of small-molecule alpha-helix mimetics as
   inhibitors of SARS-COV-2 attachment to ACE2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Coronavirus; SARS-COV-2; COVID-19; treatment; alpha-helix mimetics;
   ACE2; spike; virtual screening; MD simulation
ID SCREENING LIBRARIES; PROTEIN; CORONAVIRUS; BINDING; IDENTIFICATION;
   DISCOVERY; SEQUENCE; LESSONS; ENERGY; PRODY
AB The novel coronavirus, SARS-CoV-2, has infected more than 10 million people and caused more than 502,539 deaths worldwide as of June 2020. The explosive spread of the virus and the rapid increase in the number of cases require the immediate development of effective therapies and vaccines as well as accurate diagnosis tools. The pathogenesis of the disease is triggered by the entry of SARS-CoV-2 via its spike protein into ACE2-bearing host cells, particularly pneumocytes, resulting in overactivation of the immune system, which attacks the infected cells and damages the lung tissue. The interaction of the SARS-CoV-2 receptor binding domain (RBD) with host cells is primarily mediated by the N-terminal helix of ACE2; thus, inhibition of the spike-ACE2 interaction may be a promising therapeutic strategy for blocking the virus entry into host cells. In this paper, we used an in-silico approach to explore small-molecule alpha-helix mimetics as inhibitors that may disrupt the attachment of SARS-CoV-2 to ACE2. First, the RBD-ACE2 interface in the 6M0J structure was studied by the MM-GBSA decomposition module of the HawkDock server, which led to the identification of two critical target regions in the RBD. Next, two virtual screening experiments of 7236 alpha-helix mimetics from ASINEX were conducted on the above regions using the iDock tool, which resulted in 10 candidates with favorable binding affinities. Finally, the stability of RBD complexes with the top-two ranked compounds was further validated by 100 ns of molecular dynamics simulations.
C1 [Hakmi, Mohammed; Bouricha, E. L. Mehdi; Akachar, Jihane; Ibrahimi, Azeddine] Mohammed Vth Univ Rabat, Bioinova Res Ctr, Rabat Med & Pharm Sch, Med Biotechnol Lab MedBiotech, Rabat, Morocco.
   [Lmimouni, Badreddine] Mohammed Vth Univ Rabat, Lab Med Parasitol & Mycol, Mil Hosp Mohammed V, Rabat Med & Pharm Sch,Bioinova Res Ctr, Rabat, Morocco.
   [El Harti, Jaouad] Mohammed Vth Univ Rabat, Rabat Med & Pharm Sch, Therapeut Chem Lab, Med Biotechnol Lab MedBiotech, Rabat, Morocco.
   [Belyamani, Lahcen] Mohammed Vth Univ Rabat, Mil Hosp Mohammed V, Bioinova Res Ctr, Rabat Med & Pharm Sch,Emergency Dept, Rabat, Morocco.
RP Ibrahimi, A (corresponding author), Mohammed Vth Univ Rabat, Rabat Med & Pharm Sch, Med Biotechnol Lab MedBiotech, Rabat 10500, Morocco.
EM a.ibrahimi@um5s.net.ma
FU Moroccan Ministry of Higher Education and Scientific Research; Institute
   of Cancer Research; PPR-1 program
FX We sincerely thank the authors and laboratories around the world who
   have sequenced and shared the full genome data for SARS-CoV-2 in the
   GISAID database. All data authors can be contacted directly via
   www.gisaid.org. This work was carried out under National Funding from
   the Moroccan Ministry of Higher Education and Scientific Research
   (Covid-19 Program) to AI. This work was also supported by a grant from
   Institute of Cancer Research and the PPR-1 program to AI.
CR AMIN M, 2020, J BIOMOL STRUCT 0703, DOI DOI https://doi.org/10.1080/07391102.2020.1775703
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Arkin MR, 2009, CURR OPIN CHEM BIOL, V13, P284, DOI 10.1016/j.cbpa.2009.05.125
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bakan A, 2014, BIOINFORMATICS, V30, P2681, DOI 10.1093/bioinformatics/btu336
   Bakan A, 2011, BIOINFORMATICS, V27, P1575, DOI 10.1093/bioinformatics/btr168
   BANERJEE A, 2019, VIRUSES BASEL, V11, DOI DOI https://doi.org/10.3390/v11010041
   BORKOTOKY S, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1774419
   Brenk R, 2008, CHEMMEDCHEM, V3, P435, DOI 10.1002/cmdc.200700139
   Buchwald P, 2010, IUBMB LIFE, V62, P724, DOI 10.1002/iub.383
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Craik DJ, 2013, CHEM BIOL DRUG DES, V81, P136, DOI 10.1111/cbdd.12055
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   de Freitas RF, 2017, MEDCHEMCOMM, V8, P1970, DOI 10.1039/c7md00381a
   Deng X, 2014, J VIROL, V88, P11886, DOI 10.1128/JVI.01528-14
   DEOLIVEIRA OV, 2020, J BIOMOL STRUCT 0601, DOI DOI https://doi.org/10.1080/07391102.2020.1772885
   Doveston RG, 2015, ORG BIOMOL CHEM, V13, P859, DOI 10.1039/c4ob02287d
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Grant BJ, 2006, BIOINFORMATICS, V22, P2695, DOI 10.1093/bioinformatics/btl461
   GUPTA S, 2020, J BIOMOL STRUCT 0609, DOI DOI https://doi.org/10.1080/07391102.2020.1776157
   Hakmi M, 2020, BIOINFORMATION, V16, P301, DOI 10.6026/97320630016301
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   He F, 2020, J MED VIROL, V92, P719, DOI [10.1002/jmv.25766, 10.3171/2020.3.JNS193202]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hongjian Li, 2012, 2012 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB), P77, DOI 10.1109/CIBCB.2012.6217214
   Hulswit RJG, 2016, ADV VIRUS RES, V96, P29, DOI 10.1016/bs.aivir.2016.08.004
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Institute of Electrical and Electronics Engineers, 2006, ACM IEEE SC C IEEE A
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   King AMQ, 2012, 9 INT COMM TAX VIR, P806, DOI [10.1016/B978-0-12-384684-6.00068-9, DOI 10.1016/B978-0-12-384684-6.00068-9, 10.1016/B978-0-12-384684-6.00068-9.3.]
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   KUMAR A, 2020, J BIOMOL STRUCT 0602, DOI DOI https://doi.org/10.1080/07391102.2020.1772112
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lee Y, 2019, CHEM COMMUN, V55, P13311, DOI 10.1039/c9cc03627j
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Malmstrom RD, 2011, J CHEM INF MODEL, V51, P1648, DOI 10.1021/ci200126v
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   Moon H, 2015, CURR OPIN CHEM BIOL, V24, P38, DOI 10.1016/j.cbpa.2014.10.023
   Morelli X, 2011, CURR OPIN CHEM BIOL, V15, P475, DOI 10.1016/j.cbpa.2011.05.024
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Patel S, 2008, EXPERT OPIN INV DRUG, V17, P1865, DOI [10.1517/13543780802493366, 10.1517/13543780802493366 ]
   Peele K Abraham, 2020, Inform Med Unlocked, V19, P100345, DOI 10.1016/j.imu.2020.100345
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Taylor RD, 2014, J MED CHEM, V57, P5845, DOI 10.1021/jm4017625
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Vogler M, 2009, CELL DEATH DIFFER, V16, P360, DOI 10.1038/cdd.2008.137
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weng GQ, 2019, NUCLEIC ACIDS RES, V47, pW322, DOI 10.1093/nar/gkz397
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025
   Yang PH, 2020, CELL MOL IMMUNOL, V17, P555, DOI 10.1038/s41423-020-0407-x
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 60
TC 0
Z9 0
U1 6
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1830175
EA OCT 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NX3FM
UT WOS:000575598200001
PM 33023417
OA Bronze
DA 2021-01-01
ER

PT J
AU Tan, Y
   Liu, F
   Xu, XG
   Ling, Y
   Huang, WJ
   Zhu, ZQ
   Guo, MQ
   Lin, YX
   Fu, ZY
   Liang, DG
   Zhang, TF
   Fan, J
   Xu, M
   Lu, HZ
   Chen, SJ
AF Tan, Yun
   Liu, Feng
   Xu, Xiaoguang
   Ling, Yun
   Huang, Weijin
   Zhu, Zhaoqin
   Guo, Mingquan
   Lin, Yixiao
   Fu, Ziyu
   Liang, Dongguo
   Zhang, Tengfei
   Fan, Jian
   Xu, Miao
   Lu, Hongzhou
   Chen, Saijuan
TI Durability of neutralizing antibodies and T-cell response post
   SARS-CoV-2 infection
SO FRONTIERS OF MEDICINE
LA English
DT Article; Early Access
DE SARS-CoV-2; neutralizing antibodies; T-cell response
AB The ongoing pandemic of Coronavirus disease 19 (COVID-19) is caused by a newly discovered beta Coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). How long the adaptive immunity triggered by SARS-CoV-2 can last is of critical clinical relevance in assessing the probability of second infection and efficacy of vaccination. Here we examined, using ELISA, the IgG antibodies in serum specimens collected from 17 COVID-19 patients at 6-7 months after diagnosis and the results were compared to those from cases investigated 2 weeks to 2 months post-infection. All samples were positive for IgGs against the S- and N-proteins of SARS-CoV-2. Notably, 14 samples available at 6-7 months post-infection all showed significant neutralizing activities in a pseudovirus assay, with no difference in blocking the cell-entry of the 614D and 614G variants of SARS-CoV-2. Furthermore, in 10 blood samples from cases at 6-7 months post-infection used for memory T-cell tests, we found that interferon gamma-producing CD4(+)and CD8(+)cells were increased upon SARS-CoV-2 antigen stimulation. Together, these results indicate that durable anti-SARS-CoV-2 immunity is common in convalescent population, and vaccines developed from 614D variant may offer protection from the currently predominant 614D variant of SARS-CoV-2.
C1 [Tan, Yun; Liu, Feng; Xu, Xiaoguang; Fu, Ziyu; Liang, Dongguo; Chen, Saijuan] Shanghai Jiao Tong Univ, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom, Shanghai Inst Hematol,Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China.
   [Ling, Yun; Zhu, Zhaoqin; Guo, Mingquan; Lin, Yixiao; Zhang, Tengfei; Fan, Jian; Lu, Hongzhou] Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China.
   [Huang, Weijin; Xu, Miao] Natl Inst Food & Drug Control NIFDC, Beijing 102629, Peoples R China.
RP Chen, SJ (corresponding author), Shanghai Jiao Tong Univ, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom, Shanghai Inst Hematol,Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China.; Lu, HZ (corresponding author), Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China.
EM luhongzhou@shphc.org.cn; sjchen@stn.sh.cn
OI Huang, Weijin/0000-0002-4246-8889
FU Double First-Class Project from the Ministry of Education [WF510162602];
   State Key Laboratory of Medical Genomics; Overseas Expertise
   Introduction Project for Discipline Innovation (111 Project) [B17029];
   National Key R&D Program of China, the Shanghai Guangci Translational
   Medical Research Development Foundation [2019YFA0905902]
FX This work was supported by grant from Double First-Class Project (No.
   WF510162602) from the Ministry of Education, State Key Laboratory of
   Medical Genomics, Overseas Expertise Introduction Project for Discipline
   Innovation (111 Project, No. B17029) and National Key R&D Program of
   China (No. 2019YFA0905902), the Shanghai Guangci Translational Medical
   Research Development Foundation.
CR Alter G, 2020, NEW ENGL J MED, V383, P1782, DOI 10.1056/NEJMe2028079
   Goudot C, 2017, IMMUNITY, V47, P582, DOI 10.1016/j.immuni.2017.08.016
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116
   Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Peng H, 2006, MICROBES INFECT, V8, P2424, DOI 10.1016/j.micinf.2006.05.008
   Peng H, 2006, VIROLOGY, V351, P466, DOI 10.1016/j.virol.2006.03.036
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Shi H, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1258-4
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Yang LT, 2007, J GEN VIROL, V88, P2740, DOI 10.1099/vir.0.82839-0
   Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024
   Zhang XN, 2020, NATURE, V583, P437, DOI 10.1038/s41586-020-2355-0
   Zhou GB, 2020, FRONT MED-PRC, V14, P117, DOI 10.1007/s11684-020-0773-x
   Zhou GB, 2020, FRONT MED-PRC, V14, P113, DOI 10.1007/s11684-020-0758-9
   Zhou M, 2020, FRONT MED-PRC, V14, P126, DOI 10.1007/s11684-020-0767-8
NR 21
TC 2
Z9 2
U1 9
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2095-0217
EI 2095-0225
J9 FRONT MED-PRC
JI Front. Med.
DI 10.1007/s11684-020-0822-5
EA OCT 2020
PG 6
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA NW9LJ
UT WOS:000575337800001
PM 33017040
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Vanassche, T
   Orlando, C
   Vandenbosch, K
   Gadisseur, A
   Hermans, C
   Jochmans, K
   Minon, JM
   Motte, S
   Peperstraete, H
   Peters, P
   Sprynger, M
   Lancellotti, P
   Dehaene, I
   Emonts, P
   Vandenbriele, C
   Verhamme, P
   Oury, C
AF Vanassche, Thomas
   Orlando, Christelle
   Vandenbosch, Kristel
   Gadisseur, Alain
   Hermans, Cedric
   Jochmans, Kristin
   Minon, Jean-Marc
   Motte, Serge
   Peperstraete, Harlinde
   Peters, Pierre
   Sprynger, Muriel
   Lancellotti, Patrizio
   Dehaene, Isabelle
   Emonts, Patrick
   Vandenbriele, Christophe
   Verhamme, Peter
   Oury, Cecile
TI Belgian clinical guidance on anticoagulation management in hospitalised
   and ambulatory patients with COVID-19
SO ACTA CLINICA BELGICA
LA English
DT Article; Early Access
DE Practice guideline; primary health care; COVID-19
AB Objectives COVID-19 predisposes patients to thrombotic disease. The aim of this guidance document is to provide Belgian health-care workers with recommendations on anticoagulation management in COVID-19 positive patients. Methods These recommendations were based on current knowledge and a limited level of evidence. Results We formulated recommendations for the prophylaxis and treatment of COVID-related venous thromboembolism in ambulatory and hospitalised patients, as well as recommendations for the use of antithrombotic drugs in patients with prior indication for anticoagulation who develop COVID-19. Conclusions These recommendations represent an easy-to-use practical guidance that can be implemented in every Belgian hospital and be used by primary care physicians and gynaecologists. Of note, they are likely to evolve with increased knowledge of the disease and availability of data from ongoing clinical trials.
C1 [Vanassche, Thomas; Vandenbriele, Christophe; Verhamme, Peter] Univ Leuven, Dept Cardiovasc Sci, Leuven, Belgium.
   [Orlando, Christelle; Jochmans, Kristin] Univ Ziekenhuis Brussel, Vrije Univ Brussel VUB, Dept Haematol, Brussels, Belgium.
   [Vandenbosch, Kristel; Peters, Pierre] CHU Univ Hosp Liege, Dept Lab Haematol, Liege, Belgium.
   [Gadisseur, Alain] Antwerp Univ Hosp, Dept Haematol, Antwerp, Belgium.
   [Hermans, Cedric] Clin Univ St Luc, Dept Haematol, Brussels, Belgium.
   [Minon, Jean-Marc] CHR Citadelle, Thrombosis Haemostasis & Transfus Unit, Dept Lab Med, Liege, Belgium.
   [Motte, Serge] Univ Libre Bruxelles, Erasme Univ Hosp, Dept Vasc Dis, Brussels, Belgium.
   [Peperstraete, Harlinde] Ghent Univ Hosp, Dept Cardiac Intens Care, Ghent, Belgium.
   [Sprynger, Muriel; Lancellotti, Patrizio] CHU Univ Hosp Liege, Dept Cardiol, Liege, Belgium.
   [Dehaene, Isabelle] Univ Ziekenhuis Gent, Vlaamse Vereniging Obstet Gynaecol, Ghent, Belgium.
   [Emonts, Patrick] CHU Univ Hosp Liege, Grp Gynecologues Obstetriciens Langue Francaise B, Liege, Belgium.
   [Oury, Cecile] Univ Liege, GIGA Inst, Lab Cardiol, Liege, Belgium.
RP Oury, C (corresponding author), Univ Liege, GIGA Cardiovasc Sci, Lab Cardiol, B-4000 Liege, Belgium.; Vanassche, T (corresponding author), Ctr Mol Vasc Biol, UZ Herestr 49, B-3000 Leuven, Belgium.
EM thomas.vanassche@kuleuven.be; cecile.oury@uliege.be
RI sprynger, muriel/ABB-2766-2020
OI Orlando, Christelle/0000-0003-2163-8778
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Atallah B, 2020, EUR HEART J-CARD PHA, V6, P260, DOI 10.1093/ehjcvp/pvaa036
   Barnes GD, 2020, J THROMB THROMBOLYS, V50, P72, DOI 10.1007/s11239-020-02138-z
   Bikdeli B, 2020, THROMB HAEMOSTASIS, V120, P1004, DOI 10.1055/s-0040-1713152
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Giusti B, 2020, THROMB HAEMOSTASIS, V120, P1233, DOI 10.1055/s-0040-1712918
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Helms J, 2020, INTENS CARE MED 0504, DOI [DOI 10.1007/S00134-020-06062-X, 10.1007/s00134-020-06062-x]
   Huang C, 2019, LANCET, V2020, P395
   Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Konstantinides SV, 2020, EUR HEART J, V41, P543, DOI 10.1093/eurheartj/ehz405
   Leonard-Lorant I, 2020, RADIOLOGY, V296, pE189, DOI 10.1148/radiol.2020201561
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pe437, DOI 10.1016/S2665-9913(20)30121-1
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Sebaaly J, 2018, ANN PHARMACOTHER, V52, P898, DOI 10.1177/1060028018768449
   Shang Y, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00689-1
   Spyropoulos AC, 2020, J THROMB HAEMOST, V18, P1859, DOI 10.1111/jth.14929
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Testa S, 2020, J THROMB HAEMOST, V18, P1320, DOI 10.1111/jth.14871
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Wada Kai, 2013, J Circadian Rhythms, V11, P4, DOI 10.1186/1740-3391-11-4
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wiegers HMG, 2020, THER ADV RESPIR DIS, V14, DOI 10.1177/1753466620914222
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yu  BL, 2020, J THROMB THROMBOLYS, V50, P548, DOI 10.1007/s11239-020-02171-y
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 36
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1784-3286
EI 2295-3337
J9 ACTA CLIN BELG
JI Acta Clin. Belg.
DI 10.1080/17843286.2020.1829252
EA OCT 2020
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA NW4LE
UT WOS:000574979100001
PM 33012274
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yan, HD
   Valdes, AM
   Vijay, A
   Wang, SB
   Liang, LL
   Yang, SQ
   Wang, HX
   Tan, XY
   Du, JY
   Jin, SS
   Huang, KC
   Jiang, FR
   Zhang, S
   Zheng, NH
   Hu, YR
   Cai, T
   Aithal, GP
AF Yan, Huadong
   Valdes, Ana M.
   Vijay, Amrita
   Wang, Shanbo
   Liang, Lili
   Yang, Shiqing
   Wang, Hongxia
   Tan, Xiaoyan
   Du, Jingyuan
   Jin, Susu
   Huang, Kecheng
   Jiang, Fanrong
   Zhang, Shun
   Zheng, Nanhong
   Hu, Yaoren
   Cai, Ting
   Aithal, Guruprasad P.
TI Role of Drugs Used for Chronic Disease Management on Susceptibility and
   Severity of COVID-19: A Large Case-Control Study
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article; Early Access
ID SARS-CORONAVIRUS; RECEPTOR; ACE2; HYPERTENSION; PROTEIN
AB This study aimed to investigate whether specific medications used in the treatment chronic diseases affected either the development and/ or severity of coronavirus disease 2019 (COVID-19) in a cohort of 610 COVID-19 cases and 48,667 population-based controls from Zhejiang, China. Using a cohort of 578 COVID-19 cases and 48,667 population-based controls from Zhejiang, China, we tested the role of usage of cardiovascular, antidiabetic, and other medications on risk and severity of COVID-19. Analyses were adjusted for age, sex, and body mass index and for presence of relevant comorbidities. Individuals with hypertension taking calcium channel blockers had significantly increased risk (odds ratio (OR) = 1.73, 95% confidence interval (CI) 1.2-2.3) of manifesting symptoms of COVID-19, whereas those taking angiotensin receptor blockers and diuretics had significantly lower disease risk (OR = 0.22, 95% CI 0.15-0.30 and OR = 0.30, 95% CI 0.19-0.58, respectively). Among those with type 2 diabetes, dipeptidyl peptidase-4 inhibitors (OR = 6.02, 95% CI 2.3-15.5) and insulin (OR = 2.71, 95% CI 1.6-5.5) were more and glucosidase inhibitors were less prevalent (OR = 0.11, 95% CI 0.1-0.3) among with patients with COVID-19. Drugs used in the treatment of hypertension and diabetes influence the risk of development of COVID-19, but, not its severity.
C1 [Yan, Huadong; Liang, Lili; Yang, Shiqing; Wang, Hongxia; Du, Jingyuan; Jin, Susu; Zheng, Nanhong; Hu, Yaoren; Cai, Ting] Univ Chinese Acad Sci, Ningbo No 2 Hosp, Hwamei Hosp, Dept Infect Dis, Ningbo, Peoples R China.
   [Yan, Huadong; Zhang, Shun; Cai, Ting] Univ Chinese Acad Sci, Key Lab Diag & Treatment Digest Syst Tumors Zheji, Hwamei Hosp, Dept New Med Sci,Ningbo No 2 Hosp, Ningbo, Peoples R China.
   [Valdes, Ana M.] Nottingham Univ Hosp NHS Trust, NIHR Nottingham Biomed Res Ctr, Nottingham, England.
   [Valdes, Ana M.; Vijay, Amrita; Aithal, Guruprasad P.] Univ Nottingham, Nottingham, England.
   [Valdes, Ana M.; Vijay, Amrita; Aithal, Guruprasad P.] Univ Nottingham, Sch Med, Div Rheumatol Orthopaed & Dermatol, Nottingham, England.
   [Vijay, Amrita] Univ Nottingham, Sch Med, Nottingham Digest Dis Ctr, Nottingham, England.
   [Wang, Shanbo; Tan, Xiaoyan] Gulin Township Hlth Ctr, Dept Gen Practice, Ningbo, Peoples R China.
   [Wang, Hongxia] Ninghai No 1 Hosp, Dept Infect Dis, Ningbo, Peoples R China.
   [Jiang, Fanrong] Univ Chinese Acad Sci, Ningbo No 2 Hosp, Hwamei Hosp, Dept Pharmacol, Ningbo, Peoples R China.
RP Cai, T (corresponding author), Univ Chinese Acad Sci, Ningbo No 2 Hosp, Hwamei Hosp, Dept Infect Dis, Ningbo, Peoples R China.; Cai, T (corresponding author), Univ Chinese Acad Sci, Key Lab Diag & Treatment Digest Syst Tumors Zheji, Hwamei Hosp, Dept New Med Sci,Ningbo No 2 Hosp, Ningbo, Peoples R China.; Vijay, A; Aithal, GP (corresponding author), Univ Nottingham, Nottingham, England.; Vijay, A; Aithal, GP (corresponding author), Univ Nottingham, Sch Med, Div Rheumatol Orthopaed & Dermatol, Nottingham, England.; Vijay, A (corresponding author), Univ Nottingham, Sch Med, Nottingham Digest Dis Ctr, Nottingham, England.
EM Amrita.vijay@nottingham.ac.uk; caiting@ucas.ac.cn;
   Guru.Aithal@nottingham.ac.uk
OI Reis, AlessanRSS/0000-0001-8486-7469; Vijay, Amrita/0000-0002-9595-5680
FU Social Development Major Projects of Ningbo City [2016C51005]; Medical
   Health Science and Technology Project of Zhejiang Provincial Health
   Commission [2018ZD039]; Zhejiang Provincial Natural Science
   FoundationNatural Science Foundation of Zhejiang Province
   [LGF20H030006]; NIHR Nottingham Biomedical Research Centre
   [BRC-1215-20003]
FX This study was supported by the Social Development Major Projects of
   Ningbo City (2016C51005), Medical Health Science and Technology Project
   of Zhejiang Provincial Health Commission (2018ZD039), Zhejiang
   Provincial Natural Science Foundation (LGF20H030006), and by the NIHR
   Nottingham Biomedical Research Centre (Reference no: BRC-1215-20003).
CR Aronson JK, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1313
   Bornstein SR, 2020, NAT REV ENDOCRINOL, V16, P297, DOI 10.1038/s41574-020-0353-9
   Bozkurt B., AM HEART ASS PR 0319
   Caldeira D, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4260
   Czopek A, 2019, EUR HEART J, V40, P768, DOI 10.1093/eurheartj/ehy881
   Dijkman R, 2012, J GEN VIROL, V93, P1924, DOI 10.1099/vir.0.043919-0
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Filardi T, 2020, J ENDOCRINOL INVEST, P1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Head BM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226347
   Henry Christopher, 2018, Proc (Bayl Univ Med Cent), V31, P419, DOI 10.1080/08998280.2018.1499293
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li G, 2020, HYPERTENS RES, V43, P588, DOI 10.1038/s41440-020-0433-1
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lin HB, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019698
   Lu JP, 2017, LANCET, V390, P2549, DOI [10.1016/S0140-6736(17)32478-9, 10.1016/s0140-6736(17)32478-9]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mahmoudpour SH, 2018, BRIT J CLIN PHARMACO, V84, P2365, DOI 10.1111/bcp.13692
   Mancia G, 2013, J HYPERTENS, V31, DOI 10.1097/HJH.0000000000000006
   National Health Commission of the people's Republic of China, GUID DIAGN TREATM NE
   Phadke M.A., 2020, BMJ-BRIT MED J, V368, pm406, DOI [10.1136/bmj.m406, DOI 10.1136/BMJ.M406]
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Rice GI, 2004, BIOCHEM J, V383, P45, DOI 10.1042/BJ20040634
   Shi Q., LANCET, DOI [10.2139/ssrn.3551369, DOI 10.2139/SSRN.3551369]
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Singanayagam A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04574-1
   Steiner G. S., 2018, AM HEART ASS SCI C 2
   Thomas BJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep07176
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ZW, 2018, CIRCULATION, V137, P2344, DOI 10.1161/CIRCULATIONAHA.117.032380
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   World Health Organization (WHO), 90 WHO
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhao XS, 2015, ANTIMICROB AGENTS CH, V59, P206, DOI 10.1128/AAC.03999-14
NR 43
TC 0
Z9 0
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
DI 10.1002/cpt.2047
EA OCT 2020
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NW4OC
UT WOS:000574986800001
PM 32910830
OA Other Gold
DA 2021-01-01
ER

PT J
AU Omrani, AS
   Zaqout, A
   Baiou, A
   Daghfal, J
   Elkum, N
   Alattar, RA
   Bakdach, D
   Abusriwil, H
   Mostafa, AM
   Alhariri, B
   Ambra, N
   Khatib, M
   Eldeeb, AM
   Merenkov, Z
   Fawzi, Z
   Hmissi, SM
   Hssain, AA
   Coyle, PV
   Alsoub, H
   Almaslamani, MA
   Alkhal, A
AF Omrani, Ali S.
   Zaqout, Ahmed
   Baiou, Anas
   Daghfal, Joanne
   Elkum, Naser
   Alattar, Rand A.
   Bakdach, Dana
   Abusriwil, Hatem
   Mostafa, Abdalrahman M.
   Alhariri, Bassem
   Ambra, Naseem
   Khatib, Mohamed
   Eldeeb, Ali M.
   Merenkov, Zeyd
   Fawzi, Zeinab
   Hmissi, Saloua M.
   Hssain, Ali A.
   Coyle, Peter V.
   Alsoub, Hussam
   Almaslamani, Muna A.
   Alkhal, Abdullatif
TI Convalescent plasma for the treatment of patients with severe
   coronavirus disease 2019: A preliminary report
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE convalescent plasma; coronavirus; COVID-19; passive immunotherapy;
   SARS-CoV-2
AB Background The role of convalescent plasma therapy for patients with coronavirus disease 2019 (COVID-19) is unclear. Methods We retrospectively compared outcomes in a cohort of critical COVID-19 patients who received standard care (SC Group) and those who, in addition, received convalescent plasma (CP Group). Results In total, 40 patients were included in each group. The median patient age was 53.5 years (interquartile range [IQR] 42-60.5), and the majority of patients required invasive ventilation (69, 86.2%). Plasma was harvested from donors after a median of 37 days (IQR 31-46) from the first positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) result and 26 days (IQR 21-32) after documented viral clearance; it was administered after a median of 10 days (IQR 9-10) from the onset of symptoms and 2.5 days (IQR 2-4) from admission to intensive care unit. The primary endpoint of improvement in respiratory support status within 28 days was achieved in 26 patients (65%) in the SC Group and 31 patients (77.5%) in the CP Group (p = .32). The 28-day all-cause mortality (12.5% vs. 2.5%;p = .22) and viral clearance (65% vs. 55%;p = .49) were not significantly different between the two groups. Convalescent plasma was not significantly associated with the primary endpoint (adjusted hazard ratio 0.87; 95% confidence interval 0.51-1.49;p = .62). Adverse events were balanced between the two study groups. Conclusion In severe COVID-19, convalescent plasma therapy was not associated with clinical benefits. Randomized trials are required to confirm our findings.
C1 [Omrani, Ali S.; Zaqout, Ahmed; Alsoub, Hussam; Almaslamani, Muna A.; Alkhal, Abdullatif] Hamad Med Corp, Div Infect Dis, Dept Med, Doha, Qatar.
   [Omrani, Ali S.; Zaqout, Ahmed; Daghfal, Joanne; Alattar, Rand A.; Alsoub, Hussam; Almaslamani, Muna A.; Alkhal, Abdullatif] Hamad Med Corp, Communicable Dis Ctr, POB 3050, Doha, Qatar.
   [Baiou, Anas] Hamad Med Corp, Div Crit Care, Dept Med, Doha, Qatar.
   [Elkum, Naser] Sidra Med, Res Dept, Doha, Qatar.
   [Bakdach, Dana; Hssain, Ali A.] Hamad Med Corp, Med Intens Care Unit, Doha, Qatar.
   [Abusriwil, Hatem; Mostafa, Abdalrahman M.; Alhariri, Bassem; Ambra, Naseem] Hamad Med Corp, Hazm Mebaireek Gen Hosp, Dept Internal Med, Doha, Qatar.
   [Khatib, Mohamed] Hamad Med Corp, Hazm Mebaireek Gen Hosp, Crit Care & Pulm Med, Doha, Qatar.
   [Eldeeb, Ali M.] Hamad Med Corp, Dept Clin Imaging, Doha, Qatar.
   [Merenkov, Zeyd; Fawzi, Zeinab; Hmissi, Saloua M.] Hamad Med Corp, Dept Pathol & Lab Med, Transfus Med, Doha, Qatar.
   [Coyle, Peter V.] Hamad Med Corp, Dept Pathol & Lab Med, Div Virol, Doha, Qatar.
RP Omrani, AS (corresponding author), Hamad Med Corp, Communicable Dis Ctr, POB 3050, Doha, Qatar.
EM aomrani@hamad.qa
RI Elkum, Naser/AAU-5555-2020
OI Elkum, Naser/0000-0002-0457-0444; AIT HSSAIN, Ali/0000-0002-7764-5793;
   Reis, AlessanRSS/0000-0001-8486-7469; Alattar, Rand/0000-0002-5161-4155;
   Omrani, Ali/0000-0001-5309-6358
FU Qatar National Library
FX Open access publication of this article was funded by Qatar National
   Library. No other funding was required.
CR Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Busch MP, 2019, BLOOD, V133, P1854, DOI 10.1182/blood-2018-11-833996
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Crowe JE, 2001, J IMMUNOL, V167, P3910, DOI 10.4049/jimmunol.167.7.3910
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2021436, DOI 10.1056/NEJM0A2021436]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   MAHASE E, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/bmj.m2422
   Rajendran K, 2020, J MED VIROL, V92, P1475, DOI 10.1002/jmv.25961
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   World Health Organization, 2020, 165 WHO
   World Health Organization, 2020, CLIN MAN COVID 19 IN
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
NR 31
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26537
EA OCT 2020
PG 9
WC Virology
SC Virology
GA NW3XN
UT WOS:000574943600001
PM 32965715
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Franco-Moreno, A
   Herrera-Morueco, M
   Mestre-Gomez, B
   Munoz-Rivas, N
   Abad-Motos, A
   Salazar-Chiriboga, D
   Duffort-Falco, M
   Medrano-Izquierdo, P
   Bustamante-Fermosel, A
   Pardo-Guimera, V
   Ulla-Anes, M
   Torres-Macho, J
AF Franco-Moreno, Anabel
   Herrera-Morueco, Maria
   Mestre-Gomez, Beatriz
   Munoz-Rivas, Nuria
   Abad-Motos, Ane
   Salazar-Chiriboga, Danilo
   Duffort-Falco, Mercedes
   Medrano-Izquierdo, Pilar
   Bustamante-Fermosel, Ana
   Pardo-Guimera, Virginia
   Ulla-Anes, Mariano
   Torres-Macho, Juan
CA Infanta Leonor Thrombosis Res Grp
TI Incidence of Deep Venous Thrombosis in Patients WithCOVID-19 and
   Pulmonary Embolism Compression Ultrasound COVID Study
SO JOURNAL OF ULTRASOUND IN MEDICINE
LA English
DT Article; Early Access
DE compression ultrasound; coronavirus disease 2019; COVID-19; deep venous
   thrombosis; pulmonary embolism; thromboinflammatory syndrome
ID VEIN THROMBOSIS
AB Objectives Several reports had observed a high risk of pulmonary embolism (PE) in patients with coronavirus disease 2019 (COVID-19), most of them in the intensive care unit. Reported findings indicate that a direct viral-mediated hyperinflammatory response leads to local thromboinflammation. According to those findings, the incidence of deep venous thrombosis (DVT) in patients with COVID-19 and PE should be low. The objective of this study was to evaluate the incidence of DVT in patients with COVID-19 who developed PE. Methods In this prospective observational study, consecutive patients hospitalized in the internal medicine ward with a diagnosis of COVID-19 who developed PE were screened for DVT in the lower extremities with complete compression ultrasound. Results The study comprised 26 patients. Fifteen patients (57.7%) were male. The median age was 60 years (interquartile range, 54-73 years). Compression ultrasound findings were positive for DVT in 2 patients (7.7%; 95% confidence interval, 3.6%-11.7%). Patients with DVT had central and bilateral PE. In both, venous thromboembolism was diagnosed in the emergency department, so they did not receive previous prophylactic therapy with low-molecular-weight heparin. Patients without DVT had higher mediand-dimer levels: 25,688 mu g/dL (interquartile range, 80,000-1210 mu g/dL) versus 5310 mu g/dL (P < .05). Conclusions Our study showed a low incidence of DVT in a cohort of patients with COVID-19 and PE. This observation suggests that PE in these patients could be produced mainly by a local thromboinflammatory syndrome induced by severe acute respiratory syndrome coronavirus 2 infection and not by a thromboembolic event.
C1 [Franco-Moreno, Anabel; Herrera-Morueco, Maria; Mestre-Gomez, Beatriz; Munoz-Rivas, Nuria; Abad-Motos, Ane; Medrano-Izquierdo, Pilar; Bustamante-Fermosel, Ana; Pardo-Guimera, Virginia; Ulla-Anes, Mariano; Torres-Macho, Juan] Infanta Leonor Univ Hosp, Dept Internal Med, Gran Via Este Ave 80, Madrid 28031, Spain.
   [Abad-Motos, Ane] Infanta Leonor Univ Hosp, Anesthesiol, Madrid, Spain.
   [Salazar-Chiriboga, Danilo] Infanta Leonor Univ Hosp, Radiol, Madrid, Spain.
RP Franco-Moreno, A (corresponding author), Infanta Leonor Univ Hosp, Dept Internal Med, Gran Via Este Ave 80, Madrid 28031, Spain.
EM anaisabel.franco@salud.madrid.org
OI Abad-Motos, Ane/0000-0002-9644-2887
CR Abou-Ismail MY, 2020, THROMB RES, V194, P101, DOI 10.1016/j.thromres.2020.06.029
   Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Belen-Apak FB, 2020, J THROMB THROMBOLYS, V50, P278, DOI 10.1007/s11239-020-02129-0
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Cattaneo M, 2020, THROMB HAEMOSTASIS, V120, P1230, DOI 10.1055/s-0040-1712097
   Chong PY, 2004, ARCH PATHOL LAB MED, V128, P195
   Ciceri Fabio, 2020, Crit Care Resusc, V22, P95
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Demelo-Rodriguez P, 2020, THROMB RES, V192, P23, DOI 10.1016/j.thromres.2020.05.018
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Lee Jun Sung, 2016, Vasc Specialist Int, V32, P166, DOI 10.5758/vsi.2016.32.4.166
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Ren B, 2020, CIRCULATION, V142, P181, DOI 10.1161/CIRCULATIONAHA.120.047407
   ROSE SC, 1994, J ULTRAS MED, V13, P243, DOI 10.7863/jum.1994.13.4.243
   Van Rossum AB, 1998, BRIT J RADIOL, V71, P1260, DOI 10.1259/bjr.71.852.10318998
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Zuker-Herman R, 2018, J THROMB THROMBOLYS, V45, P99, DOI 10.1007/s11239-017-1595-9
NR 27
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0278-4297
EI 1550-9613
J9 J ULTRAS MED
JI J. Ultrasound Med.
DI 10.1002/jum.15524
EA OCT 2020
PG 7
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA NW4WE
UT WOS:000575008200001
PM 33017480
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kubo, A
   Kurtovich, E
   McGinnis, M
   Aghaee, S
   Altschuler, A
   Quesenberry, C
   Kolevska, T
   Liu, R
   Greyz-Yusupov, N
   Avins, A
AF Kubo, Ai
   Kurtovich, Elaine
   McGinnis, MegAnn
   Aghaee, Sara
   Altschuler, Andrea
   Quesenberry, Charles, Jr.
   Kolevska, Tatjana
   Liu, Raymond
   Greyz-Yusupov, Natalya
   Avins, Andrew
TI Pilot pragmatic randomized trial of mHealth mindfulness-based
   intervention for advanced cancer patients and their informal caregivers
SO PSYCHO-ONCOLOGY
LA English
DT Article; Early Access
DE cancer; caregivers; chemotherapy; clinical trial; distress;
   intervention; mindfulness; oncology; psycho-oncology; quality of life
ID BREAST-CANCER; DEPRESSION; DISTRESS; VALIDITY; ANXIETY; SCALE; WOMEN
AB Objective Assess the feasibility of conducting a cluster randomized controlled trial (RCT) comparing technology-delivered mindfulness-based intervention (MBI) programs against a waitlist control arm targeting advanced cancer patients and their informal caregivers. Methods Two-arm cluster RCT within Kaiser Permanente Northern California. We recruited patients with metastatic solid malignancies or hematological cancers and their informal caregivers. Intervention-group participants chose to use either a commercially available mindfulness app (10-20 min/day) or a webinar-based mindfulness course for 6 weeks. The waitlist control group received usual care. We assessed feasibility measures and obtained participant-reported data on quality of life (QoL; primary outcome) and distress outcomes (secondary) pre- and postintervention. Results A hundred and three patients (median age 67 years; 70% female; 81% White) and 39 caregivers (median age 66 years; 79% female; 69% White) were enrolled. Nearly all participants chose the mindfulness app over the webinar-based program. Among the participants in the intervention arm who chose the mobile-app program and completed the postintervention (6-week) survey, 21 (68%) patients and 7 (47%) caregivers practiced mindfulness at least 50% of the days during the 6-week study period. Seventy-four percent of intervention participants were "very" or "extremely" satisfied with the mindfulness program. We observed improvements in anxiety, QoL, and mindfulness among patients in the intervention arm compared to those in the control group. Conclusions We demonstrated the feasibility of conducting a cluster RCT of mHealth MBI for advanced cancer patients and their caregivers. Such remote interventions can be helpful particularly during the COVID-19 pandemic.
C1 [Kubo, Ai; Kurtovich, Elaine; McGinnis, MegAnn; Aghaee, Sara; Altschuler, Andrea; Quesenberry, Charles, Jr.; Liu, Raymond; Avins, Andrew] Kaiser Permanente Div Res, 2000 Broadway, Oakland, CA 94612 USA.
   [Kolevska, Tatjana] Kaiser Permanente Napa, Solano Med Ctr, Vallejo, CA USA.
   [Liu, Raymond] Kaiser Permanente San Francisco Med Ctr, San Francisco, CA USA.
   [Greyz-Yusupov, Natalya] Kaiser Permanente San Rafael Med Ctr, San Rafael, CA USA.
   [Avins, Andrew] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
RP Kubo, A (corresponding author), Kaiser Permanente Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM ai.kubo@kp.org
OI Aghaee, Sara/0000-0003-4912-5069
FU Permanente Medical Group (TPMG) Delivery Science Research Program
FX The Permanente Medical Group (TPMG) Delivery Science Research Program
CR [Anonymous], SHAR AD US WHO OWN S
   Avins AL, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-44
   Baer RA, 2006, ASSESSMENT, V13, P27, DOI 10.1177/1073191105283504
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   Carlson L. E., 2010, MINDFULNESS BASED CA
   Compen F, 2018, J CLIN ONCOL, V36, P2413, DOI 10.1200/JCO.2017.76.5669
   Eyles C, 2015, INTEGR CANCER THER, V14, P42, DOI 10.1177/1534735414546567
   Giese-Davis J, 2011, J CLIN ONCOL, V29, P413, DOI 10.1200/JCO.2010.28.4455
   Gordon N., 2015, SIMILARITY ADULT KAI
   Haller H, 2017, ACTA ONCOL, V56, P1665, DOI 10.1080/0284186X.2017.1342862
   Holland JC, 2013, J NATL COMPR CANC NE, V11, P190, DOI 10.6004/jnccn.2013.0027
   Kabat-Zinn J., 1990, FULL CATASTROPHE LIV
   Kinser PA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/140467
   Kubo A, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419850634
   Kubo A, 2018, MINDFULNESS, V9, P1885, DOI 10.1007/s12671-018-0931-2
   Lengacher CA, 2012, J HOLIST NURS, V30, P170, DOI 10.1177/0898010111435949
   Li LM, 2020, PSYCHIAT SERV, V71, P624, DOI 10.1176/appi.ps.202000166
   Lindsay EK, 2017, CLIN PSYCHOL REV, V51, P48, DOI 10.1016/j.cpr.2016.10.011
   Litzelman K, 2016, J CLIN ONCOL, V34, P3554, DOI 10.1200/JCO.2016.67.3434
   Lyons KD, 2009, J PAIN SYMPTOM MANAG, V37, P23, DOI 10.1016/j.jpainsymman.2007.12.015
   Oehrli M, 2017, NO CALIFORNIA CANC R
   Panchal N, 2020, IMPLICATIONS COVID 1
   Pirl WF, 2014, CANCER-AM CANCER SOC, V120, P2946, DOI 10.1002/cncr.28750
   Pitceathly C, 2003, EUR J CANCER, V39, P1517, DOI 10.1016/S0959-8049(03)00309-5
   Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215
   Stenberg U, 2010, PSYCHO-ONCOLOGY, V19, P1013, DOI 10.1002/pon.1670
   Wahbeh H, 2016, JMIR MENT HEALTH, V3, DOI 10.2196/mental.5900
   Wahbeh H, 2014, MINDFULNESS, V5, P88, DOI 10.1007/s12671-012-0155-9
   Weitzner MA, 1999, QUAL LIFE RES, V8, P55, DOI 10.1023/A:1026407010614
   Zabora J, 2001, PSYCHO-ONCOL, V10, P19, DOI 10.1002/1099-1611(200101/02)10:1<19::AID-PON501>3.3.CO;2-Y
   Zernicke KA, 2014, PSYCHOSOM MED, V76, P257, DOI 10.1097/PSY.0000000000000053
NR 31
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
DI 10.1002/pon.5557
EA OCT 2020
PG 11
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
   Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA NW4DJ
UT WOS:000574958800001
PM 32979294
DA 2021-01-01
ER

PT J
AU Okoh, AK
   Bishburg, E
   Grinberg, S
   Nagarakanti, S
AF Okoh, Alexis K.
   Bishburg, Eliahu
   Grinberg, Sagy
   Nagarakanti, Sandhya
TI Tocilizumab use in COVID-19-associated pneumonia
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE coronavirus; disease control; epidemiology; pandemics; virus
   classification
ID CYTOKINE; IL-6
AB Background We sought to evaluate the effect of tocilizumab (TCB), a recombinant humanized monoclonal antibody against soluble interleukin-6 receptors, in patients hospitalized for coronavirus disease 2019 (COVID-19). Methods We included all patients with laboratory-confirmed COVID-19 who had completed hospitalization between March 10, 2020 and April 10, 2020 with follow-up through April 20, 2020. Patients who received TCB in addition to standard of care within 48 h of admission were matched in a 1:2 fashion to a similar cohort who received standard of care alone. Clinical outcomes were compared between matched groups. The primary outcome was de-escalation in oxygen therapy. Secondary outcomes were in-hospital death, septic shock, and acute kidney injury (AKI) requiring hemodialysis. Results Out of 77 patients who received TCB in addition to standard of care, 34% (n = 26) received TCB within 48 h of admission. One-to-two propensity matching identified 20 versus 40 patients in the TCB and no-TCB treatment arms. In the TCB group, an improvement in oxygenation was observed in 80% (n = 16) of the patients by 7 days post TCB administration. After matching, there was no difference in clinical outcomes between TCB and no-TCB patients. In-hospital death: 10% versus 8%;p = .823, septic shock: 10% versus 11%,p = .912, AKI requiring hemodialysis (10% vs. 13%;p = .734). Conclusions Early treatment with TCB in patients admitted for COVID-19 led to an improvement in their oxygen status during hospitalization. This change however did not translate into improved survival when compared to a matched cohort with a similar clinical profile.
C1 [Okoh, Alexis K.; Bishburg, Eliahu; Grinberg, Sagy; Nagarakanti, Sandhya] Newark Beth Israel Med Ctr, Dept Med, Div Infect Dis, 201 Lyons Ave,Suite G3, Newark, NJ 07112 USA.
RP Nagarakanti, S (corresponding author), Newark Beth Israel Med Ctr, Dept Med, Div Infect Dis, 201 Lyons Ave,Suite G3, Newark, NJ 07112 USA.
EM sandhya.nagarakanti@rwjbh.org
CR Andrianopoulos I, 2020, J MED VIROL, DOI 10.1002/jmv.26209
   Antony SJ, 2020, J MED VIROL, DOI 10.1002/jmv.26288
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Knorr JP, 2020, J MED VIROL, V92, P2813, DOI 10.1002/jmv.26191
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Quartuccio L, 2020, J MED VIROL, V92, P2852, DOI 10.1002/jmv.26149
   Scheller J, 2006, MED MICROBIOL IMMUN, V195, P173, DOI 10.1007/s00430-006-0019-9
   Somers EC, 2020, CLIN INFECT DIS
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Teijaro JR, 2017, SEMIN IMMUNOPATHOL, V39, P501, DOI 10.1007/s00281-017-0640-2
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 14
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26471
EA OCT 2020
PG 6
WC Virology
SC Virology
GA NW3XC
UT WOS:000574942500001
PM 32860432
OA Bronze
DA 2021-01-01
ER

PT J
AU Wang, YF
   Wang, LC
   Cao, H
   Liu, CB
AF Wang, Yunfei
   Wang, Lichun
   Cao, Han
   Liu, Cunbao
TI SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine
   antigen
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE antibody-dependent enhancement; COVID-19; receptor-binding domain; S1;
   SARS-CoV-2 subunit vaccine; spike protein
ID RECEPTOR-BINDING DOMAIN; SPIKE PROTEIN; SARS CORONAVIRUS; MERS-COV;
   EOSINOPHILIC INFILTRATION; PROTECTIVE IMMUNITY; ANTIBODIES; INFECTION;
   MICE; TARGET
AB Since its emergence in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed into a global pandemic within a matter of months. While subunit vaccines are one of the prominent options for combating coronavirus disease 2019 (COVID-19), the immunogenicity of spike protein-based antigens remains unknown. When immunized in mice, the S1 domain induced much higher IgG and IgA antibody levels than the receptor-binding domain (RBD) and more efficiently neutralized SARS-CoV-2 when adjuvanted with alum. It is inferred that a large proportion of these neutralization epitopes are located in the S1 domain but outside the RBD and that some of these are spatial epitopes. This finding indicates that expression systems with posttranslational modification abilities are important to maintain the natural configurations of recombinant spike protein antigens and are critical for effective COVID-19 vaccines. Further, adjuvants prone to a Th1 response should be considered for S1-based subunit COVID-19 vaccines to reduce the potential risk of antibody-dependent enhancement of infection.
C1 [Wang, Yunfei; Wang, Lichun; Cao, Han; Liu, Cunbao] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming, Yunnan, Peoples R China.
RP Liu, CB (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, 935 Jiaoling Rd, Kunming 650118, Yunnan, Peoples R China.
EM cunbao_liu@imbcams.com.cn
FU CAMS Initiative for Innovative Medicine [2017-I2M-3-022]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81503117]
FX This work was financially supported by the CAMS Initiative for
   Innovative Medicine (grant number 2017-I2M-3-022) and the National
   Natural Science Foundation of China (grant number 81503117).
CR Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Du LY, 2014, J VIROL, V88, P7045, DOI 10.1128/JVI.00433-14
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Enjuanes L, 2016, ADV VIRUS RES, V96, P245, DOI 10.1016/bs.aivir.2016.08.003
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Ghaebi M, 2020, J CELL PHYSIOL, V235, P9098, DOI 10.1002/jcp.29771
   He YX, 2006, J VIROL, V80, P5757, DOI 10.1128/JVI.00083-06
   Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14
   Iwata-Yoshikawa N, 2014, J VIROL, V88, P8597, DOI 10.1128/JVI.00983-14
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Lan JM, 2015, EBIOMEDICINE, V2, P1438, DOI 10.1016/j.ebiom.2015.08.031
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5
   Lefeber DJ, 2003, INFECT IMMUN, V71, P6915, DOI 10.1128/IAI.71.12.6915-6920.2003
   Liao Y, 2020, J MED VIROL, V92, P2830, DOI 10.1002/jmv.26200
   Liu CB, 2015, J MICROBIOL BIOTECHN, V25, P936, DOI 10.4014/jmb.1412.12027
   Liu CB, 2014, BIOTECHNOL LETT, V36, P937, DOI 10.1007/s10529-014-1455-z
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MOUNTFORD AP, 1994, PARASITE IMMUNOL, V16, P521, DOI 10.1111/j.1365-3024.1994.tb00306.x
   Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Sekimukai H, 2020, MICROBIOL IMMUNOL, V64, P33, DOI 10.1111/1348-0421.12754
   Shajahan Asif, 2020, Glycobiology, V30, P981, DOI 10.1093/glycob/cwaa042
   Sharpe HR, 2020, IMMUNOLOGY, V160, P223, DOI 10.1111/imm.13222
   Smatti MK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02991
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tai WB, 2016, VIROLOGY, V499, P375, DOI 10.1016/j.virol.2016.10.005
   Tan M, 2011, J VIROL, V85, P753, DOI 10.1128/JVI.01835-10
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Tsunetsugu-Yokota Y, 2006, REV MED VIROL, V16, P117, DOI 10.1002/rmv.492
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang C, 2017, ANTIVIR RES, V140, P55, DOI 10.1016/j.antiviral.2016.12.019
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wang YX, 2017, HUM VACC IMMUNOTHER, V13, P153, DOI 10.1080/21645515.2016.1225637
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia M, 2019, VACCINE, V37, P4103, DOI 10.1016/j.vaccine.2019.05.075
   Xia M, 2018, ACS NANO, V12, P10665, DOI 10.1021/acsnano.8b02776
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YS, 2018, EXPERT REV VACCINES, V17, P677, DOI 10.1080/14760584.2018.1506702
   Zhu MS, 2004, CELL MOL IMMUNOL, V1, P193
NR 49
TC 0
Z9 0
U1 8
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26320
EA OCT 2020
PG 7
WC Virology
SC Virology
GA NW3WA
UT WOS:000574939700001
PM 32691875
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Awasthi, A
   Vishwas, S
   Corrie, L
   Kumar, R
   Khursheed, R
   Kaur, J
   Kumar, R
   Arya, KR
   Gulati, M
   Kumar, B
   Singh, SK
   Pandey, NK
   Wadhwa, S
   Kumar, P
   Kapoor, B
   Gupta, RK
   Kumar, A
AF Awasthi, Ankit
   Vishwas, Sukriti
   Corrie, Leander
   Kumar, Rajesh
   Khursheed, Rubiya
   Kaur, Jaskiran
   Kumar, Rajan
   Arya, K. R.
   Gulati, Monica
   Kumar, Bimlesh
   Singh, Sachin Kumar
   Pandey, Narendra Kumar
   Wadhwa, Sheetu
   Kumar, Pardeep
   Kapoor, Bhupinder
   Gupta, Rajneesh Kumar
   Kumar, Ankit
TI OUTBREAK of novel corona virus disease (COVID-19): Antecedence and
   aftermath
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE COVID-19; Diagnostic kits; Plasma therapy; Hydroxychloroquine; Antiviral
   drugs
ID RESPIRATORY SYNDROME CORONAVIRUS; IN-VITRO; MERS-COV; SARS; HIV;
   CHLOROQUINE; PNEUMONIA; IDENTIFICATION; REPLICATION; PROGRESSION
AB Outbreak of Coronavirus disease 2019 (COVID-19) started in mid of December 2019 and spread very rapidly across the globe within a month of its outbreak. Researchers all across the globe started working to find out its possible treatments. However, most of initiatives taken were based on various hypotheses and till date no successful treatments have been achieved. Some strategies adopted by China where existing antiviral therapy was initially used to treat COVID-19 have not given very successful results. Researchers from Thailand explored the use of combination of anti-influenza drugs such as Oseltamivir, Lopinavir and Ritonavir to treat it. In some cases, combination therapy of antiviral drugs with chloroquine showed better action against COVID-19. Some of the clinical studies showed very good effect of chloroquine and hydroxychloroquine against COVID-19, however, they were not recommended due to serious clinical toxicity. In some cases, use of rho kinase inhibitor, fasudil was found very effective. In some of the countries, antibody-based therapies have proved fairly successful. The use of BCG vaccines came in light; however, they were not found successful due to lack of full-proof mechanistic studies. In Israel as well as in other developed countries, pluristems allogeneic placental expanded cell therapy has been found successful. Some phytochemicals and nutraceuticals have also been explored to treat it. In a recent report, the use of dexamethasone was found very effective in patients suffering from COVID-19. Its effect was most striking among patients on ventilator. The research for vaccines that can prevent the disease is still going on. In light of the dynamic trends, present review focuses on etiopathogenesis, factors associated with spreading of the virus, and possible strategies to treat this deadly infection. In addition, it attempts to compile the recent updates on development of drugs and vaccines for the dreaded disease.
C1 [Awasthi, Ankit; Vishwas, Sukriti; Corrie, Leander; Kumar, Rajesh; Khursheed, Rubiya; Kaur, Jaskiran; Kumar, Rajan; Arya, K. R.; Gulati, Monica; Kumar, Bimlesh; Singh, Sachin Kumar; Pandey, Narendra Kumar; Wadhwa, Sheetu; Kumar, Pardeep; Kapoor, Bhupinder; Gupta, Rajneesh Kumar; Kumar, Ankit] Lovely Profess Univ, Sch Pharmaceut Sci, Phagwara 144411, Punjab, India.
RP Singh, SK (corresponding author), Lovely Profess Univ, Sch Pharmaceut Sci, Phagwara 144411, Punjab, India.
EM singhsachin23@gmail.com
RI Sharma, Pardeep Kumar/AAV-3250-2020; Kumar, Bimlesh/B-9781-2018
OI Sharma, Pardeep Kumar/0000-0001-9191-2731; Vishwas,
   Sukriti/0000-0002-3956-1898; Kumar, Rajesh/0000-0002-1489-8144; Kumar,
   Bimlesh/0000-0001-8072-5172; Corrie, Leander/0000-0002-1626-3513
CR Abedi F, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104808
   Acree W.M., 1986, CANINE CORONA VIRUS
   Aeri Vidhu, 2020, P241, DOI 10.1016/B978-0-12-818092-1.00048-8
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   An P, 2020, BALK MED J, V37, P163, DOI 10.4274/balkanmedj.galenos.2020.2020.2.15
   Armstrong-James D, 2010, ANTIVIR RES, V86, P224, DOI 10.1016/j.antiviral.2010.02.324
   Baras B., 2012, Vaccine, Patent No. [CA2704283A1, 2704283A1]
   Basu A., 2020, BIORXIV, DOI [10.1101/2020.02.27.967422., DOI 10.1101/2020.02.27.967422]
   Beniac DR, 2006, NAT STRUCT MOL BIOL, V13, P751, DOI 10.1038/nsmb1123
   Bleibtreu A, 2020, MED MALADIES INFECT, V50, P243, DOI 10.1016/j.medmal.2019.10.004
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Cameron CE, 2001, CURR OPIN INFECT DIS, V14, P757, DOI 10.1097/00001432-200112000-00015
   Carneiro VC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004116
   Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9
   Chen CY, 2005, BIOCHEM BIOPH RES CO, V335, P874, DOI 10.1016/j.bbrc.2005.07.155
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Ciaramella G., 2017, [No title captured], Patent No. [WO2017070626A2, 2017070626]
   CINATL J, 1994, ANTIVIR RES, V25, P73, DOI 10.1016/0166-3542(94)90095-7
   DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06
   DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Ding Defang, 2020, Am J Med, V133, P1291, DOI 10.1016/j.amjmed.2020.02.023
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Fedson DS, 2020, MBIO, V11, DOI 10.1128/mBio.00398-20
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gao Y., 2017, IONICS, V7, P1, DOI DOI 10.1016/J.GENE.2017.03.021
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Hurst KR, 2009, J VIROL, V83, P7221, DOI 10.1128/JVI.00440-09
   Jawerth N., 2020, IS COVID 19 VIRUS DE
   Jiang HY, 2014, INT J INFECT DIS, V25, P130, DOI 10.1016/j.ijid.2014.04.020
   Justice AC, 2004, J CLIN EPIDEMIOL, V57, P89, DOI 10.1016/S0895-4356(03)00245-2
   KE H, 2020, AM J RESP CRIT CARE, V201
   Kosiboro M., 2020, DAPAGLIFLOZIN RESP F
   Kumar S., 2020, DRUG VACCINE DESIGN, DOI [10.20944/preprints202002.0071.v1., DOI 10.20944/PREPRINTS202002.0071.V1]
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5
   Lee J, 2015, J KOREAN MED SCI, V30, P835, DOI 10.3346/jkms.2015.30.7.835
   Li CF, 2017, EBIOMEDICINE, V24, P189, DOI 10.1016/j.ebiom.2017.09.034
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Millan-Onate J, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-00358-y
   Miller SC, 2006, INT J EXP PATHOL, V87, P81, DOI 10.1111/j.0959-9673.2006.00474.x
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Nal B, 2005, J GEN VIROL, V86, P1423, DOI 10.1099/vir.0.80671-0
   Nassar MS, 2018, EUR REV MED PHARMACO, V22, P4956, DOI 10.26355/eurrev_201808_15635
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Ni L, 2020, FRONT MED-PRC, V14, P210, DOI 10.1007/s11684-020-0757-x
   Oh MD, 2016, INFECT CHEMOTHER, V48, P145, DOI 10.3947/ic.2016.48.2.145
   Okada M, 2007, VACCINE, V25, P3038, DOI 10.1016/j.vaccine.2007.01.032
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Peng Z, 2020, VITAMIN C INFUSION T
   Perrone F., 2020, TOCILIZUMAB COVID 19
   Reiter RJ, 2020, MELATONIN RES, V3, P43, DOI [10.32794/mr11250047, DOI 10.32794/MR11250047]
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Richardson PJ, 2020, LANCET INFECT DIS, V20, P1013, DOI 10.1016/S1473-3099(20)30270-X
   Roberts M., 2020, CORONAVIRUS US VOLUN, DOI [10.1016/S1473-3099(20)30270-X., DOI 10.1016/S1473-3099(20)30270-X]
   Rojas M, 2020, J AUTOIMMUN, V106, DOI 10.1016/j.jaut.2019.102375
   Salathe M., 2020, STUDY OPEN LABEL LOS
   Sharquie I., 2020, ELECT J GEN MED, V17, P2516
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Smego RA, 2003, INT J TUBERC LUNG D, V7, P208
   Smith G., 2015, Patent No. [WO2015042373A1, 2015042373A1]
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Taramasso L, 2015, BIOMED PHARMACOTHER, V69, P233, DOI 10.1016/j.biopha.2014.12.006
   Teixeira da Silva Jaime A, 2020, Med J Armed Forces India, V76, P236, DOI 10.1016/j.mjafi.2020.04.006
   Tyrrell D.A., 1996, CORONAVIRUSES MED MI, P10
   Uyeki TM, 2020, NEW ENGL J MED, V382
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wnuk A, 2008, HIV AIDS REV, V7, P10, DOI 10.1016/S1730-1270(10)60060-4
   Wu T.-C.U., 2005, Patent No. [WO/2005/081716, 2005/081716]
   Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
NR 84
TC 0
Z9 0
U1 20
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD OCT 5
PY 2020
VL 884
AR 173381
DI 10.1016/j.ejphar.2020.173381
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NR9AZ
UT WOS:000571856400006
PM 32721449
OA Green Published
DA 2021-01-01
ER

PT J
AU Das, CM
   Guo, Y
   Yang, G
   Kang, LX
   Xu, GX
   Ho, HP
   Yong, KT
AF Das, Chandreyee Manas
   Guo, Yan
   Yang, Guang
   Kang, Lixing
   Xu, Gaixia
   Ho, Ho-Pui
   Yong, Ken-Tye
TI Gold Nanorod Assisted Enhanced Plasmonic Detection Scheme of COVID-19
   SARS-CoV-2 Spike Protein
SO ADVANCED THEORY AND SIMULATIONS
LA English
DT Article
DE COVID-19; gold nanorods; kretschmann layouts; plasmonic immunosensors
ID RAPID DETECTION; PHOTOTHERMAL THERAPY; RESONANCE BIOSENSOR; SIGNAL;
   NANOPARTICLES; SENSOR; NRS
AB The beautiful interplay between light and matter can give rise to many striking physical phenomena, surface plasmon resonance (SPR) being one of them. Plasmonic immunosensors monitor refractive index changes that occur as a result of specific ligand-analyte or antibody-antigen interactions taking place on the sensor surface. The coronavirus disease (COVID-19) pandemic has jeopardized the entire world and has resulted in economic slowdown of most countries. In this work, a model of a sandwich plasmonic biosensor that utilizes gold nanorods (Au NRs) for the detection of COVID-19 SARS-CoV-2 spike protein is presented. Simulation results for different prismatic configurations for the basic Kretschmann layout are presented. It is found that a BK7 glass prism-based SPR sensor has an incremental sensitivity of 111.11 deg RIU-1. Additionally, using Comsol Multiphysics the electric field enhancement observed for various aspect ratios and layouts of Au NRs are discussed in depth.
C1 [Das, Chandreyee Manas; Kang, Lixing; Yong, Ken-Tye] Nanyang Technol Univ, THALES, CNRS, CINTRA,UMI 3288, Res Techno Plaza,50 Nanyang Dr,Border X Block, Singapore 637553, Singapore.
   [Das, Chandreyee Manas; Yang, Guang; Kang, Lixing; Yong, Ken-Tye] Nanyang Technol Univ, Sch Elect & Elect Engn, 50 Nanyang Ave, Singapore 639798, Singapore.
   [Guo, Yan] Hangzhou Dianzi Univ, Sch Automat, Hangzhou 310018, Zhejiang, Peoples R China.
   [Xu, Gaixia] Shenzhen Univ, Sch Med, Dept Biomed Engn, Guangdong Key Lab Biomed Measurements & Ultrasoun, Shenzhen 518060, Peoples R China.
   [Ho, Ho-Pui] Chinese Univ Hong Kong, Dept Biomed Engn, Hong Kong 999077, Peoples R China.
RP Yong, KT (corresponding author), Nanyang Technol Univ, THALES, CNRS, CINTRA,UMI 3288, Res Techno Plaza,50 Nanyang Dr,Border X Block, Singapore 637553, Singapore.; Yong, KT (corresponding author), Nanyang Technol Univ, Sch Elect & Elect Engn, 50 Nanyang Ave, Singapore 639798, Singapore.
EM ktyong@ntu.edu.sg
FU National Research Foundation (NRF) SingaporeSingapore National Research
   Foundation [NRF2017-ANR002 2DPS]; French National Research Agency
   (ANR)French National Research Agency (ANR) [NRF2017-ANR002 2DPS];
   Provost's Chair in Electrical and Electronic Engineering Award
   [002354-00001]
FX C.M.D. and Y.G. contributed equally to this work. This work was
   supported by the National Research Foundation (NRF) Singapore and French
   National Research Agency (ANR), Grant No. (NRF2017-ANR002 2DPS) and
   Provost's Chair in Electrical and Electronic Engineering Award
   (002354-00001).
CR Ambrosino I, 2020, MONALDI ARCH CHEST D, V90, P318, DOI 10.4081/monaldi.2020.1389
   Bergquist R., 2020, GEOSPAT HLTH, V15
   Borade RM, 2020, MATER RES EXPRESS, V7, DOI 10.1088/2053-1591/ab6c9c
   Bulut C, 2020, TURK J MED SCI, V50, P563, DOI 10.3906/sag-2004-172
   Cao J, 2014, SENSOR ACTUAT B-CHEM, V195, P332, DOI 10.1016/j.snb.2014.01.056
   Cao J, 2012, SENSOR ACTUAT B-CHEM, V169, P360, DOI 10.1016/j.snb.2012.05.019
   Castellana ET, 2010, LANGMUIR, V26, P6066, DOI 10.1021/la904467b
   Chinowsky TM, 2007, BIOSENS BIOELECTRON, V22, P2268, DOI 10.1016/j.bios.2006.11.026
   Das G, 2020, ACS CHEM NEUROSCI, V11, P1206, DOI 10.1021/acschemneuro.0c00201
   de Assis Rafael R, 2020, bioRxiv, DOI 10.1101/2020.04.15.043364
   Dowd JB, 2020, P NATL ACAD SCI USA, V117, P9696, DOI 10.1073/pnas.2004911117
   Gormley AJ, 2011, INT J PHARMACEUT, V415, P315, DOI 10.1016/j.ijpharm.2011.05.068
   Gupta N, 2020, MONALDI ARCH CHEST D, V90, DOI 10.4081/monaldi.2020.1290
   He L, 2000, J AM CHEM SOC, V122, P9071, DOI 10.1021/ja001215b
   Huang X, 2009, TALANTA, V78, P1036, DOI 10.1016/j.talanta.2009.01.018
   Huang XH, 2009, ADV MATER, V21, P4880, DOI 10.1002/adma.200802789
   Jasti M, 2020, J NEUROL, DOI 10.1007/s00415-020-09950-w
   Jeon J, 2018, SENSOR ACTUAT B-CHEM, V266, P710, DOI 10.1016/j.snb.2018.03.167
   Jindal V, 2020, MED ONCOL, V37, DOI 10.1007/s12032-020-01382-w
   Joshi PP, 2013, BIOCONJUGATE CHEM, V24, P878, DOI 10.1021/bc3004815
   Kadkhoda K, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00344-20
   Kaushik S, 2019, BIOSENS BIOELECTRON, V126, P501, DOI 10.1016/j.bios.2018.11.006
   Kebede Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233744
   Lau H, 2020, J MICROBIOL IMMUNOL, V53, P454, DOI 10.1016/j.jmii.2020.03.013
   Law WC, 2011, ACS NANO, V5, P4858, DOI 10.1021/nn2009485
   Lee B, 2018, BIOSENS BIOELECTRON, V102, P504, DOI 10.1016/j.bios.2017.11.062
   Lee T, 2019, COLLOID SURFACE B, V182, DOI 10.1016/j.colsurfb.2019.06.070
   Lepinay S, 2014, BIOSENS BIOELECTRON, V52, P337, DOI 10.1016/j.bios.2013.08.058
   Li M, 2015, ANALYST, V140, P386, DOI 10.1039/c4an01079e
   Liu YS, 2015, J COLLOID INTERF SCI, V439, P7, DOI 10.1016/j.jcis.2014.10.023
   Ma XY, 2018, PART PART SYST CHAR, V35, DOI 10.1002/ppsc.201700326
   Mackey MA, 2014, J PHYS CHEM B, V118, P1319, DOI 10.1021/jp409298f
   Mahari S., 2020, BIORXIV, P1, DOI [10.1101/2020.04.24.059204, DOI 10.1101/2020.04.24.059204]
   Nasrin F, 2018, BIOSENS BIOELECTRON, V122, P16, DOI 10.1016/j.bios.2018.09.024
   Nguyen T, 2020, MICROMACHINES-BASEL, V11, DOI 10.3390/mi11030306
   Nikoobakht B, 2003, CHEM MATER, V15, P1957, DOI [10.1021/cm020732l, 10.1021/cm0207321]
   Petherick A, 2020, LANCET, V395, P1101, DOI 10.1016/S0140-6736(20)30788-1
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Qiu GG, 2020, ACS NANO, V14, P5268, DOI 10.1021/acsnano.0c02439
   Seo G, 2020, ACS NANO, V14, P5135, DOI 10.1021/acsnano.0c02823
   Shankaran DR, 2007, J PHYS D APPL PHYS, V40, P7187, DOI 10.1088/0022-3727/40/23/S02
   Sharma AK, 2007, J APPL PHYS, V101, DOI 10.1063/1.2721779
   Smith ML, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01341
   Soelberg SD, 2009, ANAL CHEM, V81, P2357, DOI 10.1021/ac900007c
   Soelberg SD, 2005, J IND MICROBIOL BIOT, V32, P669, DOI 10.1007/s10295-005-0044-5
   Spangler BD, 2001, ANAL CHIM ACTA, V444, P149, DOI 10.1016/S0003-2670(01)01156-4
   Tahamtan A, 2020, EXPERT REV MOL DIAGN, V20, P453, DOI [10.1080/14737159.2020.1757437, 10.1080/07435800.2020.1713802]
   Te L. T., 2015, MATER CHEM PHYS, V149-150, P324
   Tezer H, 2020, TURK J MED SCI, V50, P592, DOI 10.3906/sag-2004-174
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   van Kasteren PB, 2020, J CLIN VIROL, V128
   Wu Q, 2015, BIOSENS BIOELECTRON, V74, P16, DOI 10.1016/j.bios.2015.06.010
   Wu Y, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.139051
   Xue TY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07947-8
   Yadav SR, 2020, MONALDI ARCH CHEST D, V90, P367, DOI 10.4081/monaldi.2020.1364
   Yang T, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10030165
   Yao X, 2006, ANAL BIOCHEM, V354, P220, DOI 10.1016/j.ab.2006.04.011
   Yi J., 2020, ARXIV200405759
   Yin F, 2015, THERANOSTICS, V5, P818, DOI 10.7150/thno.11335
   Yong KT, 2008, TOP CATAL, V47, P49, DOI 10.1007/s11244-007-9030-7
   Zhan PF, 2017, ACS NANO, V11, P1172, DOI 10.1021/acsnano.6b06861
   Zhang J, 2013, BIOSENS BIOELECTRON, V45, P230, DOI 10.1016/j.bios.2013.02.008
   Zhang X., 2020, ARXIV200312529
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 64
TC 0
Z9 0
U1 9
U2 9
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
EI 2513-0390
J9 ADV THEOR SIMUL
JI Adv. Theory Simul.
PD NOV
PY 2020
VL 3
IS 11
AR 2000185
DI 10.1002/adts.202000185
EA OCT 2020
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OR7RZ
UT WOS:000576370100001
PM 33173847
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Quiros-Roldan, E
   Magro, P
   Carriero, C
   Chiesa, A
   El Hamad, I
   Tratta, E
   Fazio, R
   Formenti, B
   Castelli, F
AF Quiros-Roldan, Eugenia
   Magro, Paola
   Carriero, Canio
   Chiesa, Annacarla
   El Hamad, Issa
   Tratta, Elena
   Fazio, Raffaella
   Formenti, Beatrice
   Castelli, Francesco
TI Consequences of the COVID-19 pandemic on the continuum of care in a
   cohort of people living with HIV followed in a single center of Northern
   Italy
SO AIDS RESEARCH AND THERAPY
LA English
DT Article
DE HIV continuum of care; COVID-19; Public health; SARS-CoV-2; Follow-up;
   Adherence
AB Introduction During the COVID-19 pandemic, hospitals faced increasing pressure, where people living with HIV risked to either acquire SARS-CoV-2 and to interrupt the HIV continuum of care. Methods This is a retrospective, observational study. We compared the numbers of medical visits performed, antiretroviral drugs dispensed and the number of new HIV diagnosis and of hospitalizations in a cohort of people living with HIV (PLWH) followed by the Spedali Civili of Brescia between the bimester of the COVID-19 pandemic peak and the bimester of October-November 2019. Data were retrieved from administrative files and from paper and electronic clinical charts. Categorical variables were described using frequencies and percentages, while continuous variables were described using mean, median, and interquartile range (IQR) values. Means for continuous variables were compared using Student's t-tests and the Mann-Whitney test. Proportions for categorical variables were compared using the chi(2)test. Results As of December 31st, 2019, a total of 3875 PLWH were followed in our clinic. Mean age was 51.4 +/- 13 years old, where 28% were females and 18.8% non-Italian. Overall, 98.9% were on ART (n = 3834), 93% were viro-suppressed. A total of 1217 and 1162 patients had their visit scheduled at our out-patient HIV clinic during the two bimesters of 2019 and 2020, respectively. Comparing the two periods, we observed a raise of missed visits from 5 to 8% (p < 0.01), a reduction in the number of new HIV diagnosis from 6.4 in 2019 to 2.5 per month in 2020 (p = 0.01), a drop in ART dispensation and an increase of hospitalized HIV patients due to COVID-19.ART regimens including protease inhibitors (PIs) had a smaller average drop than ART not including PIs (16.6 vs 21.6%,p < 0.05). Whether this may be due to the perception of a possible efficacy of PIs on COVID19 is not known. Conclusions Our experience highlights the importance of a resilient healthcare system and the need to implement new strategies in order to guarantee the continuum of HIV care even in the context of emergency.
C1 [Quiros-Roldan, Eugenia; Magro, Paola; Carriero, Canio; Chiesa, Annacarla; Castelli, Francesco] Univ Brescia, Dept Infect Dis, Brescia, Italy.
   [Quiros-Roldan, Eugenia; Magro, Paola; Carriero, Canio; Chiesa, Annacarla; El Hamad, Issa; Formenti, Beatrice; Castelli, Francesco] ASST Spedali Civili, Div Infect Dis, Brescia, Italy.
   [Tratta, Elena; Fazio, Raffaella] ASST Spedali Civili, Cent Pharm, Brescia, Italy.
RP Magro, P (corresponding author), Univ Brescia, Dept Infect Dis, Brescia, Italy.; Magro, P (corresponding author), ASST Spedali Civili, Div Infect Dis, Brescia, Italy.
EM magropao@gmail.com
CR [Anonymous], 2020, COVID 19 SITUAZIONE
   [Anonymous], 2020, WHO ANNOUNCES COVID
   [Anonymous], 2020, COVID 19 RIPARTIZION
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Comelli A, 2019, HIV RES CLIN PRACT, V20, P1, DOI 10.1080/15284336.2019.1595887
   Gervasoni Cristina, 2020, Clin Infect Dis, V71, P2276, DOI 10.1093/cid/ciaa579
   Hargreaves J, 2020, LANCET HIV, V7, pE309, DOI 10.1016/S2352-3018(20)30110-7
   Istituto Superiore di Sanita, 2019, AGG NUOV DIAGN INF H
   Jiang H, LANCET HIV
   Jones R, 2020, LANCET HIV, V7, pE383, DOI 10.1016/S2352-3018(20)30139-9
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Lu H, EFFICACY SAFETY DARU
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Pinto RM, 2020, AIDS BEHAV, V24, P2486, DOI 10.1007/s10461-020-02893-3
   Regione Lombardia Direzione Generale Welfare, 2019, PERC DIAGN TER ASS P
   Ridgway JP, 2020, AIDS BEHAV, V24, P2770, DOI 10.1007/s10461-020-02905-2
   Riva A, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104826
   UN Joint Programme on HIV/AIDS (UNAIDS), 2014, 909090 UNAIDS
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
NR 21
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-6405
J9 AIDS RES THER
JI Aids Res. Ther.
PD OCT 4
PY 2020
VL 17
IS 1
AR 59
DI 10.1186/s12981-020-00314-y
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA NZ3KM
UT WOS:000576996000001
PM 33012282
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Abdallah, I
   Eltahir, A
   Fernyhough, L
   El-Bardissy, A
   Ahmed, R
   Abdulgelil, M
   Elgaily, D
   Mohammed, A
   Jassim, A
   Barakat, L
   Al-Ansari, M
   Javed, M
   Alkhawaja, R
   Elzouki, AN
AF Abdallah, Ibtihal
   Eltahir, Asma
   Fernyhough, Liam
   El-Bardissy, Ahmed
   Ahmed, Rana
   Abdulgelil, Mohammed
   Elgaily, Dina
   Mohammed, AbdulMoqeeth
   Jassim, Ameena
   Barakat, Loluwa
   Al-Ansari, Mazen
   Javed, Mehak
   Alkhawaja, Raja
   Elzouki, Abdel-nasser
TI The experience of Hamad General Hospital collaborative anticoagulation
   clinic in Qatar during the COVID-19 pandemic
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article; Early Access
DE Anticoagulation; Clinical pharmacy; Collaborative practice; COVID-19;
   Social distancing; Warfarin
AB Hamad General Hospital Anticoagulation Clinic is one of the largest collaborative-practice clinics of its type in Qatar. The patients being followed at this clinic are typically complex and vulnerable. During the coronavirus disease 2019 pandemic, measures were implemented at the clinic to minimize the exposure of patients and healthcare providers to the acute respiratory syndrome coronavirus-2 and to promote social distancing. These measures included extending INR-recall period, transitioning to direct oral anticoagulant drugs whenever feasible, home visits to elderly and immunocompromised patients for INR testing, establishing an anticoagulation hotline, and relocation of warfarin dispensing from the main pharmacy to the anticoagulation clinic. In addition, the clinic shifted its multidisciplinary team meetings onto an online platform using Microsoft Teams. Telehealth consultations were extensively utilized to closely follow up with the patients and ensure that anticoagulation efficacy and safety remained optimal. The aim of this paper is to share our experience and describe the measures adopted by the clinic as part of the Hamad Medical Corporation response to the emerging situation.
C1 [Abdallah, Ibtihal; Eltahir, Asma; El-Bardissy, Ahmed; Ahmed, Rana; Abdulgelil, Mohammed; Elgaily, Dina; Barakat, Loluwa; Javed, Mehak; Alkhawaja, Raja] Hamad Med Corp, Hamad Gen Hosp, Dept Clin Pharm, Doha, Qatar.
   [Fernyhough, Liam] Hamad Med Corp, Natl Ctr Canc Care & Res, Dept Hematol, Doha, Qatar.
   [Fernyhough, Liam; Elzouki, Abdel-nasser] Weill Cornell Med, Doha, Qatar.
   [Mohammed, AbdulMoqeeth; Jassim, Ameena; Al-Ansari, Mazen; Elzouki, Abdel-nasser] Hamad Med Corp, Hamad Gen Hosp, Internal Med, Doha, Qatar.
RP Eltahir, A (corresponding author), Hamad Med Corp, Hamad Gen Hosp, Dept Clin Pharm, Doha, Qatar.
EM aabdulrahman@hamad.qa
FU Qatar National Library
FX Open Access funding provided by the Qatar National Library.
CR Allen A, 2020, MANAGING ANTICOAGULA
   Amaraneni A, 2020, STATPEARLS
   Anticoagulation Toolkit, ANT DESKT REF VERS 2
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 WHO IS
   Erkens PMG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042269
   Holbrook A, 2012, CHEST, V141, pE152S, DOI 10.1378/chest.11-2295
   Hou Kelu, 2017, J Pharm Pharm Sci, V20, P378, DOI 10.18433/J3SQ0B
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   University of Washington, WARF FREQ MON
   World Health Organization, 2020, ROLL UPD COR DIS COV
   Young S, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-88
NR 11
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
DI 10.1007/s11239-020-02276-4
EA OCT 2020
PG 7
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA NW5FO
UT WOS:000575037500002
PM 33015725
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kuerban, A
   Al-Malki, AL
   Kumosani, TA
   Sheikh, RA
   Al-Abbasi, FAM
   Alshubaily, FA
   Abulnaja, KO
   Moselhy, SS
AF Kuerban, Abudukadeer
   Al-Malki, Abdulrahman L.
   Kumosani, Taha A.
   Sheikh, Ryan A.
   Al-Abbasi, Fahad Ahmed M.
   Alshubaily, Fawzia A.
   Omar Abulnaja, Khalid
   Salama Moselhy, Said
TI Identification, protein antiglycation, antioxidant, antiproliferative,
   and molecular docking of novel bioactive peptides produced from
   hydrolysis ofLens culinaris
SO JOURNAL OF FOOD BIOCHEMISTRY
LA English
DT Article; Early Access
DE antiglycation; antioxidant; antiproliferative; bioactive peptides; Lens
   culinaris
ID GLYCATION END-PRODUCTS; FRACTIONATION; EXTRACTION; ASSAY
AB Bioactive peptides produced from natural sources are considered as strategic target for drug discovery. Hyperglycemia caused protein glycation alters the structure of many tissues that impairs their functions and lead complications diseases in human body. This study investigated the bioactive peptides produced from red and brownLens culinaristhat might inhibit protein glycation to prevent diabetic complications. In this study, red and brownLens culinarisprotein hydrolysates were prepared by tryptic digestion, using an enzyme/substrate ratio of 1:20 (g/g), at 37 degrees C, 12 hr then peptide fractions <3 kDa were filtered by using ultrafiltration membranes. Protective ability against protein glycation, DPPH radical scavenging, and anti-proliferative activities (on HepG2, MCF-7, and PC3 cell lines) of peptide fractions were assayed in vitro. Results showed that glycation was inhibited by peptides from 28.1% to 68.3% in different test model. PC3 cell line was more sensitive to the peptides which showed strong anticancer activity with lower IC50 (0.96 mg/ml). Peptide fractions were sequenced by HPLC-MS-MS. Twenty eight novel peptides sequences was identified. In silico study, two peptides could be developed as a potential bioactive peptides exhibited antiglycation, antioxidant, and antiproliferative activities. Practical applications Peptides are becoming an emerging source of medications with the development of new technologies. We have selectedLens Culinarisas one of the rich sources of proteins to explore novel bioactive peptides encapsulated in its seeds. Peptides fractions demonstrated protective ability against protein glycation, strong antioxidant potential, and promising antiproliferative activity. We have identified 28 novel peptides and molecular docking study revealed that some peptides showed strong binding potential to insulin receptor and ACE. Thus, these peptides might be used to manage diabetes complication as well as COVID-19 disease due to their interaction with ACE. However, those peptides needs to be further studied as a potential new drug.
C1 [Kuerban, Abudukadeer; Al-Malki, Abdulrahman L.; Kumosani, Taha A.; Sheikh, Ryan A.; Al-Abbasi, Fahad Ahmed M.; Alshubaily, Fawzia A.; Omar Abulnaja, Khalid; Salama Moselhy, Said] King Abdulaziz Univ KAU, Dept Biochem, Fac Sci, Jeddah, Saudi Arabia.
   [Al-Malki, Abdulrahman L.; Omar Abulnaja, Khalid; Salama Moselhy, Said] King Abdulaziz Univ KAU, Bioact Nat Prod Res Grp, Jeddah, Saudi Arabia.
   [Al-Malki, Abdulrahman L.; Kumosani, Taha A.; Salama Moselhy, Said] King Abdulaziz Univ KAU, Expt Biochem Unit, King Fahd Med Res Ctr, Jeddah, Saudi Arabia.
   [Kumosani, Taha A.; Omar Abulnaja, Khalid] King Abdulaziz Univ KAU, Prod Bioprod Ind Applicat Res Grp, Jeddah, Saudi Arabia.
   [Salama Moselhy, Said] Ain Shams Univ, Dept Biochem, Fac Sci, Cairo, Egypt.
RP Moselhy, SS (corresponding author), Ain Shams Univ, Dept Biochem, Fac Sci, Cairo, Egypt.
EM moselhy6@hotmail.com
RI Sheikh, Ryan Adnan/C-4363-2015; Alshubaily, Fawzia/O-6301-2019; moselhy,
   said/I-1446-2012
OI Sheikh, Ryan Adnan/0000-0003-3275-0861; Alshubaily,
   Fawzia/0000-0001-6875-7411; moselhy, said/0000-0002-2384-3700
FU King Abdulaziz University [RG-87-130-38]
FX King Abdulaziz University, Grant/Award Number: RG-87-130-38
CR Ashraf JM, 2015, INT J BIOL MACROMOL, V77, P188, DOI 10.1016/j.ijbiomac.2015.03.021
   Barbana C, 2011, FOOD RES INT, V44, P174, DOI 10.1016/j.foodres.2010.10.045
   Cheung KS, 2020, HYPERTENSION, V76, P968, DOI 10.1161/HYPERTENSIONAHA.120.15317
   CHURCH FC, 1985, ANAL BIOCHEM, V146, P343, DOI 10.1016/0003-2697(85)90549-4
   Dullius A, 2018, J FUNCT FOODS, V42, P58, DOI 10.1016/j.jff.2017.12.063
   Garcia-Mora P, 2015, FOOD CHEM, V171, P224, DOI 10.1016/j.foodchem.2014.08.116
   Garcia-Mora P, 2017, FOOD CHEM, V221, P464, DOI 10.1016/j.foodchem.2016.10.087
   Gkogkolou P, 2012, DERM-ENDOCRINOL, V4, DOI 10.4161/derm.22028
   Hwang SH, 2017, FOOD CHEM, V214, P726, DOI 10.1016/j.foodchem.2016.07.118
   Karatas SC, 2017, FOOD CHEM, V230, P182, DOI 10.1016/j.foodchem.2017.03.037
   Koo YC, 2016, TOXICOL IN VITRO, V34, P8, DOI 10.1016/j.tiv.2016.03.013
   Lau JL, 2018, BIOORGAN MED CHEM, V26, P2700, DOI 10.1016/j.bmc.2017.06.052
   Lee HC, 2007, FOOD CHEM, V102, P1199, DOI 10.1016/j.foodchem.2006.07.008
   Luna-Vital D, 2018, CURR OPIN FOOD SCI, V20, P13, DOI 10.1016/j.cofs.2018.02.012
   Matsui R, 2018, FOOD CHEM, V245, P750, DOI 10.1016/j.foodchem.2017.11.119
   MCPHERSON JD, 1988, BIOCHEMISTRY-US, V27, P1901, DOI 10.1021/bi00406a016
   MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030
   Phongthai S, 2018, FOOD CHEM, V240, P156, DOI 10.1016/j.foodchem.2017.07.080
   Pompella A, 2003, BIOCHEM PHARMACOL, V66, P1499, DOI 10.1016/S0006-2952(03)00504-5
   Ruiqi L., 2014, INT J RES MED HLTH S, V4, P13
   Shahidi F, 2008, J AOAC INT, V91, P914
   Sharma OP, 2009, FOOD CHEM, V113, P1202, DOI 10.1016/j.foodchem.2008.08.008
   SWANSON BG, 1990, J AM OIL CHEM SOC, V67, P276, DOI 10.1007/BF02539676
   Torres-Fuentes C, 2015, FOOD CHEM, V180, P194, DOI 10.1016/j.foodchem.2015.02.046
   Van Heijst JWJ, 2005, ANN NY ACAD SCI, V1043, P725, DOI 10.1196/annals.1333.084
   WAGNER I, 1983, ANGEW CHEM INT EDIT, V22, P816, DOI 10.1002/anie.198308161
   Wang ZB, 2016, J TAIWAN INST CHEM E, V67, P54, DOI 10.1016/j.jtice.2016.07.029
   Weiss M., 2000, ENDOTEXT
   Zhang B, 2018, FOOD CHEM, V239, P520, DOI 10.1016/j.foodchem.2017.06.153
NR 29
TC 0
Z9 0
U1 7
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-8884
EI 1745-4514
J9 J FOOD BIOCHEM
JI J. Food Biochem.
AR e13494
DI 10.1111/jfbc.13494
EA OCT 2020
PG 9
WC Biochemistry & Molecular Biology; Food Science & Technology
SC Biochemistry & Molecular Biology; Food Science & Technology
GA NW2BY
UT WOS:000574816400001
PM 33015836
DA 2021-01-01
ER

PT J
AU Kitano, T
   Aoki, H
AF Kitano, Taito
   Aoki, Hirosato
TI The estimated impact of decreased childhood vaccination due to COVID-19
   using a dynamic transmission model of mumps in Japan
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE COVID-19; coronavirus; vaccine-preventable diseases; mumps; impact;
   quality-adjusted life years; cost; mathematical model
AB The exact impact of the decline in childhood vaccination coverage during COVID-19 outbreak has not been estimated for any vaccine-preventable diseases. Our objective was to evaluate the impact of decreased mumps vaccination due to COVID-19 on the disease burden of mumps in Japan. Using a previously validated dynamic transmission model of mumps infection in Japan, the incidence rate of mumps over the next 30 y since July 2020 was estimated. The estimated average incidences were 269.1, 302.0, and 455.4/100,000 person-years in rapid recovery, slow recovery, and permanent decline scenarios. Compared with the rapid recovery scenario, the incremental number of mumps cases, total costs, and QALYs loss over the next 30 y were 6.53 million cases, 2.63 billion USD, and 49,246 for the permanent decline scenario, respectively. In conclusion, the persistent decline of mumps vaccination rate as an impact of COVID-19 causes a significant incremental disease burden of mumps, which is consistent irrespective of the possible decline of transmission rate of mumps infection, unless the rapid recovery of coverage rate is achieved. The immediate measures to advocate the vaccination program is essential to mitigate the incremental disease burden in the COVID-19 period.
C1 [Kitano, Taito] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Infect Dis, Toronto, ON M5G 1X8, Canada.
   [Aoki, Hirosato] Kanagawa Childrens Med Ctr, Dept Neonatol, Yokohama, Kanagawa, Japan.
RP Kitano, T (corresponding author), Univ Toronto, Hosp Sick Children, Dept Pediat, Div Infect Dis, Toronto, ON M5G 1X8, Canada.
EM taito.kitano@sickkids.ca
CR Ambikapathy Bakiya, 2020, JMIR Public Health Surveill, V6, pe19368, DOI 10.2196/19368
   Bramer CA, 2020, MMWR-MORBID MORTAL W, V69, P630, DOI 10.15585/mmwr.mm6920e1
   Cabinet Office Government of Japan, 2017, STAT POP AG 2017
   Kitano T, 2020, HUM VACC IMMUNOTHER, DOI 10.1080/21645515.2020.1765619
   Kitano T, 2020, J INFECT CHEMOTHER, V26, P225, DOI 10.1016/j.jiac.2019.09.005
   Kitano T, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268818003230
   Kitano T, 2018, PEDIATR INT, V60, P362, DOI 10.1111/ped.13502
   Kitano T, 2017, CLIN EXP VACCINE RES, V6, P120, DOI 10.7774/cevr.2017.6.2.120
   Know VPD! Protect Our Children, 2020, REL DECR CHILDH VACC
   Millward G, 2019, VACCINATING BRITAIN
   Ministry of Health Labour and Welfare, 2019, ADV REACT REP MUMPS
   Ministry of Health Labour and Welfare of Japan, BAS POL NOV COR DIS
   Morikawa Y, 2019, PEDIATR INT, V61, P882, DOI 10.1111/ped.13916
   National Institute of Infectious Diseases, 2020, INF DIS SURV ANN REP
   Ozaki T, 2019, JPN J INFECT DIS, V72, P106, DOI 10.7883/yoken.JJID.2018.276
   Statistics Bureau Ministry of internal affairs and communications, 2020, STAT JAP STAT YB 202
   Usami S, 2017, ACTA OTO-LARYNGOL, V137, pS2, DOI 10.1080/00016489.2017.1300321
NR 17
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1826799
EA OCT 2020
PG 4
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA OM6ZZ
UT WOS:000586171400001
PM 33121326
DA 2021-01-01
ER

PT J
AU Furtado, RHM
   Berwanger, O
   Fonseca, HA
   Correa, TD
   Ferraz, LR
   Lapa, MG
   Zampieri, FG
   Veiga, VC
   Azevedo, LCP
   Rosa, RG
   Lopes, RD
   Avezum, A
   Manoel, ALO
   Piza, FMT
   Martins, PA
   Lisboa, TC
   Pereira, AJ
   Olivato, GB
   Dantas, VCS
   Milan, EP
   Gebara, OCE
   Amazonas, RB
   Oliveira, MB
   Soares, RVP
   Moia, DDF
   Piano, LPA
   Castilho, K
   Momesso, RGRAP
   Schettino, GPP
   Rizzo, LV
   Neto, AS
   Machado, FR
   Cavalcanti, AB
AF Furtado, Remo H. M.
   Berwanger, Otavio
   Fonseca, Henrique A.
   Correa, Thiago D.
   Ferraz, Leonardo R.
   Lapa, Maura G.
   Zampieri, Fernando G.
   Veiga, Viviane C.
   Azevedo, Luciano C. P.
   Rosa, Regis G.
   Lopes, Renato D.
   Avezum, Alvaro
   Manoel, Airton L. O.
   Piza, Felipe M. T.
   Martins, Priscilla A.
   Lisboa, Thiago C.
   Pereira, Adriano J.
   Olivato, Guilherme B.
   Dantas, Vicente C. S.
   Milan, Eveline P.
   Gebara, Otavio C. E.
   Amazonas, Roberto B.
   Oliveira, Monalisa B.
   Soares, Ronaldo V. P.
   Moia, Diogo D. F.
   Piano, Luciana P. A.
   Castilho, Kleber
   Momesso, Roberta G. R. A. P.
   Schettino, Guilherme P. P.
   Rizzo, Luiz Vicente
   Neto, Ary Serpa
   Machado, Flavia R.
   Cavalcanti, Alexandre B.
CA COALITION COVID-19 Brazil II
TI Azithromycin in addition to standard of care versus standard of care
   alone in the treatment of patients admitted to the hospital with severe
   COVID-19 in Brazil (COALITION II): a randomised clinical trial
SO LANCET
LA English
DT Article
ID OPEN-LABEL; COMBINATION
AB Background The efficacy and safety of azithromycin in the treatment of COVID-19 remain uncertain. We assessed whether adding azithromycin to standard of care, which included hydroxychloroquine, would improve clinical outcomes of patients admitted to the hospital with severe COVID-19.
   Methods We did an open-label, randomised clinical trial at 57 centres in Brazil. We enrolled patients admitted to hospital with suspected or confirmed COVID-19 and at least one additional severity criteria as follows: use of oxygen supplementation of more than 4 L/min flow; use of high-flow nasal cannula; use of non-invasive mechanical ventilation; or use of invasive mechanical ventilation. Patients were randomly assigned (1:1) to azithromycin (500 mg via oral, nasogastric, or intravenous administration once daily for 10 days) plus standard of care or to standard of care without macrolides. All patients received hydroxychloroquine (400 mg twice daily for 10 days) because that was part of standard of care treatment in Brazil for patients with severe COVID-19. The primary outcome, assessed by an independent adjudication committee masked to treatment allocation, was clinical status at day 15 after randomisation, assessed by a six-point ordinal scale, with levels ranging from 1 to 6 and higher scores indicating a worse condition (with odds ratio [OR] greater than 1.00 favouring the control group). The primary outcome was assessed in all patients in the intention-to-treat (ITT) population who had severe acute respiratory syndrome coronavirus 2 infection confirmed by molecular or serological testing before randomisation (ie, modified ITT [mITT] population). Safety was assessed in all patients according to which treatment they received, regardless of original group assignment. This trial was registered at ClinicalTrials.gov, NCT04321278.
   Findings 447 patients were enrolled from March 28 to May 19, 2020. COVID-19 was confirmed in 397 patients who constituted the mITT population, of whom 214 were assigned to the azithromycin group and 183 to the control group. In the mITT population, the primary endpoint was not significantly different between the azithromycin and control groups (OR 1.36 [95% CI 0.94-1.97], p=0.11). Rates of adverse events, including clinically relevant ventricular arrhythmias, resuscitated cardiac arrest, acute kidney failure, and corrected QT interval prolongation, were not significantly different between groups.
   Interpretation In patients with severe COVID-19, adding azithromycin to standard of care treatment (which included hydroxychloroquine) did not improve clinical outcomes. Our findings do not support the routine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Furtado, Remo H. M.; Berwanger, Otavio; Fonseca, Henrique A.; Correa, Thiago D.; Ferraz, Leonardo R.; Lapa, Maura G.; Pereira, Adriano J.; Olivato, Guilherme B.; Soares, Ronaldo V. P.; Moia, Diogo D. F.; Piano, Luciana P. A.; Castilho, Kleber; Momesso, Roberta G. R. A. P.; Schettino, Guilherme P. P.; Rizzo, Luiz Vicente; Neto, Ary Serpa] Hosp Israelita Albert Einstein, BR-05652900 Sao Paulo, Brazil.
   [Furtado, Remo H. M.] Univ Sao Paulo, Fac Med, Hosp Clin, Inst Coracao, Sao Paulo, Brazil.
   [Correa, Thiago D.; Zampieri, Fernando G.; Veiga, Viviane C.; Azevedo, Luciano C. P.; Rosa, Regis G.; Neto, Ary Serpa; Machado, Flavia R.; Cavalcanti, Alexandre B.] Brazilian Res Intens Care Network, Sao Paulo, Brazil.
   [Zampieri, Fernando G.; Cavalcanti, Alexandre B.] HCor Res Inst, Sao Paulo, Brazil.
   [Veiga, Viviane C.] BP A Beneficencia Portuguesa Sao Paulo, Sao Paulo, Brazil.
   [Azevedo, Luciano C. P.] Hosp Sirio Libanes Res & Educ Inst, Sao Paulo, Brazil.
   [Rosa, Regis G.] Hosp Moinhos de Vento, Porto Alegre, RS, Brazil.
   [Lopes, Renato D.] Brazilian Clin Res Inst, Sao Paulo, Brazil.
   [Lopes, Renato D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
   [Avezum, Alvaro] Hosp Alemao Oswaldo Cruz, Int Res Ctr, Sao Paulo, Brazil.
   [Manoel, Airton L. O.; Piza, Felipe M. T.] Hosp Moyses Deustche MBoi Mirim, Sao Paulo, Brazil.
   [Martins, Priscilla A.] Hosp Estadual Jayme dos Santos Neves, Serra, Brazil.
   [Lisboa, Thiago C.] Hosp Clin, Porto Alegre, RS, Brazil.
   [Pereira, Adriano J.; Olivato, Guilherme B.] Hosp Vila Santa Catarina, Sao Paulo, Brazil.
   [Dantas, Vicente C. S.] Hosp Naval Marcilio Dias, Rio De Janeiro, Brazil.
   [Milan, Eveline P.] Hosp Giselda Trigueiro, Natal, RN, Brazil.
   [Gebara, Otavio C. E.] Hosp Santa Paula, Sao Paulo, Brazil.
   [Amazonas, Roberto B.; Oliveira, Monalisa B.] EMS Pharma, Hortolandia, Brazil.
   [Neto, Ary Serpa] Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia.
   [Machado, Flavia R.] Univ Fed Sao Paulo, Dept Anesthesiol Pain & Intens Care Med, Sao Paulo, Brazil.
RP Berwanger, O (corresponding author), Hosp Israelita Albert Einstein, BR-05652900 Sao Paulo, Brazil.
EM otavio.berwanger@einstein.br
RI Lisboa, Thiago/W-2973-2019; Rosa, Regis Goulart/P-6422-2019; Neto, Ary
   Serpa/D-1927-2012
OI Lisboa, Thiago/0000-0003-4306-2212; Neto, Ary Serpa/0000-0003-1520-9387;
   Reis, AlessanRSS/0000-0001-8486-7469
FU COALITION COVID-19 Brazil
FX COALITION COVID-19 Brazil and EMS.; The authors are indebted to all site
   staff who helped to enrol participants and to all health-care
   professionals who took care of the patients during this study. This
   trial was funded by the members of the COALITION COVID-19 Brazil. EMS
   provided partial funding, the study drugs, and coordinated logistics for
   the trial, but was not involved in the study conduct, analysis, or
   decision to publish these results. The authors vouch for the integrity
   and completeness of the data and the fidelity of the trial to the
   protocol.
CR Angus DC, 2020, JAMA-J AM MED ASSOC, V323, P1895, DOI 10.1001/jama.2020.4984
   Arabi YM, 2019, INT J INFECT DIS, V81, P184, DOI 10.1016/j.ijid.2019.01.041
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Beigelman A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-90
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Cheng YJ, 2015, J AM COLL CARDIOL, V66, P2173, DOI 10.1016/j.jacc.2015.09.029
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hraiech S, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00678-4
   Hung IFN, 2017, CHEST, V151, P1069, DOI 10.1016/j.chest.2016.11.012
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Kawamura K, 2018, INT J ANTIMICROB AG, V51, P918, DOI 10.1016/j.ijantimicag.2018.02.009
   Martin-Loeches I, 2013, INTENS CARE MED, V39, P693, DOI 10.1007/s00134-013-2829-8
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Nguyen LS, 2020, CIRCULATION, V142, P303, DOI 10.1161/CIRCULATIONAHA.120.048238
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Sermo, 2020, LARG STAT SIGN STUD
   Tsai WC, 2004, AM J RESP CRIT CARE, V170, P1331, DOI 10.1164/rccm.200402-200OC
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, 2020, 165 WHO
   Yamamoto K, 2016, PHARMACOL RES, V111, P804, DOI 10.1016/j.phrs.2016.07.033
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zimmermann P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00302
NR 30
TC 4
Z9 4
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD OCT 3
PY 2020
VL 396
IS 10256
BP 959
EP 967
DI 10.1016/S0140-6736(20)31862-6
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC4RU
UT WOS:000579146300029
PM 32896292
OA Bronze
DA 2021-01-01
ER

PT J
AU Bucci, E
   Andreev, K
   Bjorkman, A
   Calogero, RA
   Carafoli, E
   Carninci, P
   Castagnoli, P
   Cossarizza, A
   Mussini, C
   Guerin, P
   Lipworth, B
   Sbardella, G
   Stocki, T
   Tuosto, L
   van Tulleken, C
   Viola, A
AF Bucci, Enrico
   Andreev, Konstantin
   Bjorkman, Anders
   Calogero, Raffaele Adolfo
   Carafoli, Ernesto
   Carninci, Piero
   Castagnoli, Paola
   Cossarizza, Andrea
   Mussini, Cristina
   Guerin, Philippe
   Lipworth, Brian
   Sbardella, Gianluca
   Stocki, Teresa
   Tuosto, Loretta
   van Tulleken, Christoffer
   Viola, Antonella
TI Safety and efficacy of the Russian COVID-19 vaccine: more information
   needed
SO LANCET
LA English
DT Letter
C1 [Bucci, Enrico] Temple Univ, Sbarro Hlth Res Org, Philadelphia, PA 19122 USA.
   [Bucci, Enrico] Resis Srl, I-10010 Samone, Italy.
   [Andreev, Konstantin] Northwestern Univ, Evanston, IL USA.
   [Andreev, Konstantin] Howard Hughes Med Inst, Chevy Chase, MD USA.
   [Bjorkman, Anders] Karolinska Inst, Stockholm, Sweden.
   [Calogero, Raffaele Adolfo] Univ Turin, Turin, Italy.
   [Carafoli, Ernesto] Acad Nazl Lincei, Rome, Italy.
   [Carninci, Piero] RIKEN Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan.
   [Castagnoli, Paola] Toscana Life Sci Fdn, Siena, Italy.
   [Cossarizza, Andrea; Mussini, Cristina] Univ Modena & Reggio Emilia, Modena, Italy.
   [Guerin, Philippe] Univ Oxford, Oxford, England.
   [Lipworth, Brian] Univ Dundee, Dundee, Scotland.
   [Sbardella, Gianluca] Univ Salerno, Fisciano, Italy.
   [Stocki, Teresa] Leeds Teaching Hosp Natl Hlth Serv Trust, Leeds, W Yorkshire, England.
   [Tuosto, Loretta] Sapienza Univ Rome, Rome, Italy.
   [van Tulleken, Christoffer] UCL, London, England.
   [Viola, Antonella] Univ Padua, Padua, Italy.
RP Bucci, E (corresponding author), Temple Univ, Sbarro Hlth Res Org, Philadelphia, PA 19122 USA.; Bucci, E (corresponding author), Resis Srl, I-10010 Samone, Italy.
EM enrico.bucci@resis-srl.com
RI Andreev, Konstantin/L-9852-2018; Sbardella, Gianluca/E-2823-2010;
   Tuosto, Loretta/F-7017-2011
OI Andreev, Konstantin/0000-0002-1757-4532; Sbardella,
   Gianluca/0000-0003-0748-1145; Tuosto, Loretta/0000-0001-9056-4077
CR Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3
NR 1
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD OCT 3
PY 2020
VL 396
IS 10256
BP E53
EP E53
DI 10.1016/S0140-6736(20)31960-7
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC4RU
UT WOS:000579146300001
PM 32971041
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Logunov, DY
   Dolzhikova, IV
   Tukhvatullin, AI
   Shcheblyakov, DV
AF Logunov, Denis Y.
   Dolzhikova, Inna V.
   Tukhvatullin, Amir I.
   Shcheblyakov, Dmitry V.
TI Safety and efficacy of the Russian COVID-19 vaccine: more information
   needed
SO LANCET
LA English
DT Letter
C1 [Logunov, Denis Y.; Dolzhikova, Inna V.; Tukhvatullin, Amir I.; Shcheblyakov, Dmitry V.] NF Gamaleya Natl Res Ctr Epidemiol & Microbiol, Moscow 123098, Russia.
RP Logunov, DY (corresponding author), NF Gamaleya Natl Res Ctr Epidemiol & Microbiol, Moscow 123098, Russia.
EM ldenisy@gmail.com
RI Logunov, Denis/E-8300-2014
OI Logunov, Denis/0000-0003-4035-6581
FU Ministry of Health of the Russian Federation
FX We receive funding from the Ministry of Health of the Russian Federation
   and have a patent pending for the use of vector constructs for the
   induction of immunity to severe acute respiratory syndrome coronavirus 2
   pending.
CR Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3
NR 1
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD OCT 3
PY 2020
VL 396
IS 10256
BP E54
EP E55
DI 10.1016/S0140-6736(20)31970-X
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC4RU
UT WOS:000579146300002
PM 32971043
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Henderson, LA
   Canna, SW
   Friedman, KG
   Gorelik, M
   Lapidus, SK
   Bassiri, H
   Behrens, EM
   Ferris, A
   Kernan, KF
   Schulert, GS
   Seo, P
   Son, MBF
   Tremoulet, AH
   Yeung, RSM
   Mudano, AS
   Turner, AS
   Karp, DR
   Mehta, JJ
AF Henderson, Lauren A.
   Canna, Scott W.
   Friedman, Kevin G.
   Gorelik, Mark
   Lapidus, Sivia K.
   Bassiri, Hamid
   Behrens, Edward M.
   Ferris, Anne
   Kernan, Kate F.
   Schulert, Grant S.
   Seo, Philip
   F. Son, Mary Beth
   Tremoulet, Adriana H.
   Yeung, Rae S. M.
   Mudano, Amy S.
   Turner, Amy S.
   Karp, David R.
   Mehta, Jay J.
TI American College of Rheumatology Clinical Guidance for Multisystem
   Inflammatory Syndrome in Children Associated With SARS-CoV-2 and
   Hyperinflammation in Pediatric COVID-19: Version 1
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID INTRAVENOUS IMMUNOGLOBULIN THERAPY; RESPIRATORY-DISTRESS-SYNDROME;
   RECEPTOR ANTAGONIST ANAKINRA; REFRACTORY KAWASAKI-DISEASE; CONGENITAL
   HEART-DISEASE; LONG-TERM MANAGEMENT; SCIENTIFIC STATEMENT;
   HEALTH-PROFESSIONALS; RANDOMIZED-TRIAL; MULTICENTER
AB Objective To provide guidance on the management of multisystem inflammatory syndrome in children (MIS-C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and to provide recommendations for children with hyperinflammation during coronavirus disease 2019 (COVID-19), the acute, infectious phase of SARS-CoV-2 infection. Methods A multidisciplinary task force was convened by the American College of Rheumatology (ACR) to provide guidance on the management of MIS-C associated with SARS-CoV-2 and hyperinflammation in COVID-19. The task force was composed of 9 pediatric rheumatologists, 2 adult rheumatologists, 2 pediatric cardiologists, 2 pediatric infectious disease specialists, and 1 pediatric critical care physician. Preliminary statements addressing clinical questions related to MIS-C and hyperinflammation in COVID-19 were developed based on evidence reports. Consensus was built through a modified Delphi process that involved 2 rounds of anonymous voting and 2 webinars. A 9-point scale was used to determine the appropriateness of each statement (median scores of 1-3 for inappropriate, 4-6 for uncertain, and 7-9 for appropriate), and consensus was rated as low, moderate, or high based on dispersion of the votes along the numeric scale. Approved guidance statements were those that were classified as appropriate with moderate or high levels of consensus, as prespecified prior to voting. Results The ACR task force approved a total of 128 guidance statements addressing the management of MIS-C and hyperinflammation in pediatric COVID-19. These statements were refined into 40 final clinical guidance statements, accompanied by a flow diagram depicting the diagnostic pathway for MIS-C. Conclusion Our understanding of SARS-CoV-2-related syndromes in the pediatric population continues to evolve. The guidance provided in this "living document" reflects currently available evidence, coupled with expert opinion, and will be revised as further evidence becomes available.
C1 [Henderson, Lauren A.; Friedman, Kevin G.; F. Son, Mary Beth] Boston Childrens Hosp, Boston, MA USA.
   [Henderson, Lauren A.; Friedman, Kevin G.; F. Son, Mary Beth] Harvard Med Sch, Boston, MA 02115 USA.
   [Canna, Scott W.] UPMC Childrens Hosp Pittsburgh, Pittsburgh, PA USA.
   [Canna, Scott W.] Univ Pittsburgh, Pittsburgh, PA USA.
   [Gorelik, Mark] Morgan Stanley Childrens Hosp, New York, NY USA.
   [Gorelik, Mark] Columbia Univ, New York, NY USA.
   [Lapidus, Sivia K.] Hackensack Univ, Joseph M Sanzari Childrens Hosp, Med Ctr, Hackensack, NJ USA.
   [Lapidus, Sivia K.] Hackensack Meridian Sch Med, Hackensack, NJ USA.
   [Bassiri, Hamid; Behrens, Edward M.; Mehta, Jay J.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   [Bassiri, Hamid; Behrens, Edward M.; Mehta, Jay J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Ferris, Anne] Columbia Univ, Irving Med Ctr, New York, NY USA.
   [Kernan, Kate F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
   [Schulert, Grant S.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
   [Schulert, Grant S.] Univ Cincinnati, Coll Med, Cincinnati, OH USA.
   [Seo, Philip] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Tremoulet, Adriana H.] Univ Calif San Diego, La Jolla, CA 92093 USA.
   [Tremoulet, Adriana H.] Rady Childrens Hosp San Diego, San Diego, CA USA.
   [Yeung, Rae S. M.] Hosp Sick Children, Toronto, ON, Canada.
   [Yeung, Rae S. M.] Univ Toronto, Toronto, ON, Canada.
   [Mudano, Amy S.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Turner, Amy S.] Amer Coll Rheumatol, 60 Execut Pk S,Suite 150, Atlanta, GA 30329 USA.
   [Karp, David R.] Univ Texas Southwestern Med Ctr, Dallas, TX USA.
RP Henderson, LA (corresponding author), Karp Family Res Bldg,10th Floor,1 Blackfan Circle, Boston, MA 02115 USA.
EM Lauren.Henderson@childrens.harvard.edu
RI Bassiri, Hamid/B-9840-2014
OI Bassiri, Hamid/0000-0001-6532-8478
FU American College of Rheumatology
FX Supported by the American College of Rheumatology.
CR American College of Rheumatology, 2020, CLIN GUID PED PAT MU
   Aouba A, 2020, ANN RHEUM DIS, DOI 10.1136/
   Banka P, 2015, J CARDIOVASC MAGN R, V17, DOI 10.1186/s12968-015-0201-6
   Belhadjer Z, 2020, CIRCULATION, V142, P429, DOI 10.1161/CIRCULATIONAHA.120.048360
   Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032
   Brook R, 1994, CLIN PRACTICE GUIDEL, P59
   Cao B, 2016, CRIT CARE MED, V44, pE318, DOI 10.1097/CCM.0000000000001616
   Capone C A, 2020, J PEDIAT
   Capra R, 2020, EUR J INTERN MED, V76, P31, DOI 10.1016/j.ejim.2020.05.009
   Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Centers for Disease Control and Prevention, 2020, EM PREP RESP HLTH AL
   Chao JY, 2020, J PEDIATR-US, V223, P14, DOI 10.1016/j.jpeds.2020.05.006
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen K, 2013, BLOOD COAGUL FIBRIN, V24, P221, DOI 10.1097/MBC.0b013e32835bfd85
   Cheung EW, 2020, JAMA-J AM MED ASSOC, V324, P294, DOI 10.1001/jama.2020.10374
   Children's Hospital of Philadelphia, 2020, EM DEP ICU INP CLIN
   Chiotos K, 2020, J PEDIAT INF DIS SOC, V9, P393, DOI 10.1093/jpids/piaa069
   Colan SD, 2013, J AM SOC ECHOCARDIOG, V26, P38, DOI 10.1016/j.echo.2012.11.005
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   Dallan C, 2020, LANCET CHILD ADOLESC, V4, pE21, DOI 10.1016/S2352-4642(20)30164-4
   DeBiasi RL, 2020, J PEDIATR-US, V223, P199, DOI 10.1016/j.jpeds.2020.05.007
   Dennert R, 2010, ANTIVIR THER, V15, P193, DOI 10.3851/IMP1516
   Dimopoulos G, 2020, CELL HOST MICROBE, V28, P117, DOI 10.1016/j.chom.2020.05.007
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Dufort EM, 2020, NEW ENGL J MED, V383, P347, DOI 10.1056/NEJMoa2021756
   Eloseily EM, 2020, ARTHRITIS RHEUMATOL, V72, P326, DOI 10.1002/art.41103
   Fadel R, 2020, CLIN INFECT DIS
   Fang XW, 2020, J INFECTION, V81, P147, DOI 10.1016/j.jinf.2020.03.039
   Feldstein LR, 2020, NEW ENGL J MED, V50, P229
   Filocamo G, 2020, INT J INFECT DIS, V96, P607, DOI 10.1016/j.ijid.2020.05.026
   FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836
   Franzetti M, 2020, INT J INFECT DIS, V97, P215, DOI 10.1016/j.ijid.2020.05.050
   Friedman KG, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003289
   FURUSHO K, 1984, LANCET, V2, P1055
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Giglia TM, 2013, CIRCULATION, V128, P2622, DOI [10.1161/01.cir.0000441866.35288.9d, 10.1161/01.cir.0000436140.77832.7a]
   Goland S, 2008, CAN J CARDIOL, V24, P571, DOI 10.1016/S0828-282X(08)70638-X
   Guillaume MP, 2018, CARDIOL YOUNG, V28, P739, DOI 10.1017/S1047951117002864
   Hennon TR, 2020, PROG PEDIATR CARDIOL, V57, DOI 10.1016/j.ppedcard.2020.101232
   Holman RC, 2003, PEDIATRICS, V112, P495, DOI 10.1542/peds.112.3.495
   Horby P, 2020, N ENGL J MED
   Hu H, 2020, EUR HEART J
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Inoue Y, 2006, J PEDIATR-US, V149, P336, DOI 10.1016/j.jpeds.2006.05.025
   Kanegaye JT, 2009, PEDIATRICS, V123, pE783, DOI 10.1542/peds.2008-1871
   KAWASAKI T, 1974, PEDIATRICS, V54, P271
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kobayashi T, 2012, LANCET, V379, P1613, DOI 10.1016/S0140-6736(11)61930-2
   Kociol RD, 2020, CIRCULATION, V141, pE69, DOI 10.1161/CIR.0000000000000745
   Kone-Paut I, 2018, AUTOIMMUN REV, V17, P768, DOI 10.1016/j.autrev.2018.01.024
   Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Leon MPD, 2020, J PEDIAT INF DIS SOC, V9, P407, DOI 10.1093/jpids/piaa061
   Licciardi F, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-1711
   Lind-Holst Marie, 2019, BMJ Case Rep, V12, DOI 10.1136/bcr-2019-229708
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Lopez L, 2010, J AM SOC ECHOCARDIOG, V23, P465, DOI 10.1016/j.echo.2010.03.019
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Makino N, 2019, PEDIATR INT, V61, P397, DOI 10.1111/ped.13809
   Marlais M, 2020, LANCET CHILD ADOLESC, V4, pE17, DOI 10.1016/S2352-4642(20)30145-0
   McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484
   Melendez E, 2019, PEDIATR CRIT CARE ME, V20, pE55, DOI 10.1097/PCC.0000000000001777
   Michelena X, 2020, SEMIN ARTHRITIS RHEU, V50, P564, DOI 10.1016/j.semarthrit.2020.05.001
   Morena V, 2020, EUR J INTERN MED, V76, P36, DOI 10.1016/j.ejim.2020.05.011
   Newburger JW, 2007, NEW ENGL J MED, V356, P663, DOI 10.1056/NEJMoa061235
   Newburger JW, 2004, PEDIATRICS, V114, P1708, DOI 10.1542/peds.2004-2182
   NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Ogata S, 2012, PEDIATRICS, V129, pE17, DOI 10.1542/peds.2011-0148
   Parri N, 2020, NEW ENGL J MED, V383, P187, DOI 10.1056/NEJMc2007617
   Pontali E, 2020, J ALLERGY CLIN IMMUN, V146, P213, DOI 10.1016/j.jaci.2020.05.002
   Quartier P, 2011, ANN RHEUM DIS, V70, P747, DOI 10.1136/ard.2010.134254
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Royal College of Paediatrics and Child Health, 2020, GUID PAED MULT INFL
   Seam N, 2012, CRIT CARE MED, V40, P495, DOI 10.1097/CCM.0b013e318232da5e
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Shekerdemian LS, 2020, JAMA PEDIATR, V174, P868, DOI 10.1001/jamapediatrics.2020.1948
   Son MBF, 2009, PEDIATRICS, V124, P1, DOI 10.1542/peds.2008-0730
   Tagarro A, 2020, JAMA PEDIAT
   ter Haar NM, 2019, ARTHRITIS RHEUMATOL, V71, P1163, DOI 10.1002/art.40865
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094
   Tsuda E, 2018, J PEDIATR-US, V194, P165, DOI 10.1016/j.jpeds.2017.09.077
   Turner D, 2020, J PEDIATR GASTR NUTR, V70, P727, DOI 10.1097/MPG.0000000000002729
   University of Oxford, 2020, NEWS EV LOW COST DEX
   Venkatesh B, 2018, NEW ENGL J MED, V378, P797, DOI 10.1056/NEJMoa1705835
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Wardle AJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011188.pub2
   Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369
   WHO, 2020, MULT INFL SYNDR CHIL
   World Federation of Pediatric Intensive and Critical Care Societies, 2020, STAT MED FOLL 2 MAY
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang T, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2111-0
   Yehya N, 2015, INTENS CARE MED, V41, P1658, DOI 10.1007/s00134-015-3953-4
   Yen CY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46888-0
   Yetkin O, 2008, INT J CLIN PRACT, V62, P488, DOI 10.1111/j.1742-1241.2007.01305.x
   Zhou B, 2020, J THROMB THROMBOLYS, V50, P229, DOI 10.1007/s11239-020-02084-w
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 104
TC 7
Z9 7
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD NOV
PY 2020
VL 72
IS 11
BP 1791
EP 1805
DI 10.1002/art.41454
EA OCT 2020
PG 15
WC Rheumatology
SC Rheumatology
GA OM4BA
UT WOS:000574703500001
PM 32705809
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Golchin, A
AF Golchin, Ali
TI Cell-Based Therapy for Severe COVID-19 Patients: Clinical Trials and
   Cost-Utility
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article; Early Access
DE COVID-19; Cell-based therapy; Stem cell; Clinical trials; Cost
AB The race among countries and companies to develop efficacious vaccines and therapeutics for the COVID-19 is ongoing fast, with many trials underway. Among this, cell-based therapy is focused on moderate to severe phases of COVID-19, and there have been promising outcomes. Mesenchymal stem cells (MSCs) due to their pro/anti-inflammatory and immune-modulatory behavior, Natural Killer (NK) cells thanks to their capacity of lysing virus-infected cells and regulate the resulting immune response, Dendritic cells thanks to immunotherapy and cell-based vaccine engineering, SARS-CoV2-specific T cells due to stimulate and promote the immune system and MSC-derived exosomes because of cell-free therapy and beneficial manufacturing aspects, hold great promises for cell-based therapy applications for treating COVID-19 and similar viral infections. Moreover, recently, an innovative approach to COVID-19 based on engineered human MSC has been introduced, which is continuously evacuated and degraded by the body's immune system during the antigen recognition process. However, the economic situation of governments and nations, and the cost of therapeutics influence the clinical approaches to manage and exit from this pandemic. This summary describes cell-based clinical trials and the cost-utility aspects of cell therapy. In this regard, limited clinical studies have been reported; while, several clinical trials have been approved for starting phases 2 and 3 of their trials for treating COVID-19 patients with acute respiratory distress syndrome. Regarding the cost of cell therapy, many believe that the high cost of cell-based therapy will decrease substantially. Hence, there are hopes that cellular therapy can be approved soon for the treatment of viral diseases such as COVID-19.
C1 [Golchin, Ali] Urmia Univ Med Sci, Fac Med, Dept Clin Biochem & Appl Cell Sci, Orumiyeh, Iran.
   [Golchin, Ali] Univ Sci Educ & Res Network USERN, Regenerat Med Grp REMED, Orumiyeh, Iran.
RP Golchin, A (corresponding author), Urmia Univ Med Sci, Fac Med, Dept Clin Biochem & Appl Cell Sci, Orumiyeh, Iran.; Golchin, A (corresponding author), Univ Sci Educ & Res Network USERN, Regenerat Med Grp REMED, Orumiyeh, Iran.
EM agolchin.vet10@yahoo.com
RI Golchin, Ali/V-9682-2019
OI Golchin, Ali/0000-0001-8661-5046
CR Adriana G.Lopes, 2018, BIOPROCESS INT, V16, P1
   [Anonymous], 2020, SARS COV 2 VACCINE A
   [Anonymous], 2020, PHASE IB 2 TRIAL DEN
   Bellingan G., 2019, AM THOR SOC INT C M, pA7353, DOI [10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7353, DOI 10.1164/AJRCCM-CONFERENCE.2019.199.1_MEETINGABSTRACTS.A7353]
   Cancio M, 2020, CYTOTHERAPY, V22, P474, DOI 10.1016/j.jcyt.2020.04.100
   Cona L. A, 2020, COST STEM CELL THERA
   Freitag J., 2020, FUTURE SCI OA, DOI 10.2144/fsoa-2020-0048
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Golchin A, 2019, STEM CELL REV REP, V15, P166, DOI 10.1007/s12015-018-9866-1
   Hill A, 2020, J VIRUS ERAD, V6, P61
   Lalu M. M., 2010, AM THOR SOC INT C M, pA6043, DOI [10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a6043, DOI 10.1164/AJRCCM-CONFERENCE.2010.181.1_MEETINGABSTRACTS.A6043]
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Liang B, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021429
   Liu J., 2020, BIORXIV, DOI [10.1101/2020.06.20.163030, DOI 10.1101/2020.06.20.163030]
   Market M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01512
   Nagpal A, 2019, VALUE HEALTH, V22, P254, DOI 10.1016/j.jval.2018.07.878
   Sanchez-Guijo Fermin, 2020, EClinicalMedicine, V25, P100454, DOI 10.1016/j.eclinm.2020.100454
   Sengupta V, 2020, STEM CELLS DEV, V29, P747, DOI 10.1089/scd.2020.0080
   Shu L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01875-5
   Tang LL, 2020, FRONT MED-PRC, V14, P664, DOI 10.1007/s11684-020-0810-9
   The Science Advisory Board staff writers, 2020, NOV COVID 19 CELL TH
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
NR 23
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
DI 10.1007/s12015-020-10046-1
EA OCT 2020
PG 7
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA NW1OV
UT WOS:000574782300002
PM 33009982
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Haase, N
   Plovsing, R
   Christensen, S
   Poulsen, LM
   Brochner, AC
   Rasmussen, BS
   Helleberg, M
   Jensen, JUS
   Andersen, LPK
   Siegel, H
   Ibsen, M
   Jorgensen, V
   Winding, R
   Iversen, S
   Pedersen, HP
   Madsen, J
   Solling, C
   Garcia, RS
   Michelsen, J
   Mohr, T
   Mannering, A
   Espelund, US
   Bundgaard, H
   Kirkegaard, L
   Smitt, M
   Buck, DL
   Ribergaard, NE
   Pedersen, HS
   Christensen, BV
   Perner, A
AF Haase, Nicolai
   Plovsing, Ronni
   Christensen, Steffen
   Poulsen, Lone Musaeus
   Brochner, Anne Craveiro
   Rasmussen, Bodil Steen
   Helleberg, Marie
   Jensen, Jens Ulrik Staehr
   Andersen, Lars Peter Kloster
   Siegel, Hanna
   Ibsen, Michael
   Jorgensen, Vibeke
   Winding, Robert
   Iversen, Susanne
   Pedersen, Henrik Planck
   Madsen, Jacob
   Solling, Christoffer
   Garcia, Ricardo Sanchez
   Michelsen, Jens
   Mohr, Thomas
   Mannering, Anne
   Espelund, Ulrick Skipper
   Bundgaard, Helle
   Kirkegaard, Lynge
   Smitt, Margit
   Buck, David Levarett
   Ribergaard, Niels-Erik
   Pedersen, Helle Scharling
   Christensen, Birgitte Viebaek
   Perner, Anders
TI Characteristics, interventions, and longer term outcomes of COVID-19 ICU
   patients in Denmark-A nationwide, observational study
SO ACTA ANAESTHESIOLOGICA SCANDINAVICA
LA English
DT Article
DE comorbidities; COVID-19; intensive care; mortality; SARS-CoV-2
ID EXPOSURE
AB Background Most data on intensive care unit (ICU) patients with COVID-19 originate in selected populations from stressed healthcare systems with shorter term follow-up. We present characteristics, interventions and longer term outcomes of the entire, unselected cohort of all ICU patients with COVID-19 in Denmark where the ICU capacity was not exceeded. Methods We identified all patients with SARS-CoV-2 admitted to any Danish ICU from 10 March to 19 May 2020 and registered demographics, chronic comorbidities, use of organ support, length of stay, and vital status from patient files. Risk factors for death were analyzed using adjusted Cox regression analysis. Results There were 323 ICU patients with confirmed COVID-19. Median age was 68 years, 74% were men, 50% had hypertension, 21% diabetes, and 20% chronic pulmonary disease; 29% had no chronic comorbidity. Invasive mechanical ventilation was used in 82%, vasopressors in 83%, renal replacement therapy in 26%, and extra corporeal membrane oxygenation in 8%. ICU stay was median 13 days (IQR 6-22) and hospital stay 19 days (11-30). Median follow-up was 79 days. At end of follow-up, 118 had died (37%), 15 (4%) were still in hospital hereof 4 in ICU as of 16 June 2020. Risk factors for mortality included male gender, age, chronic pulmonary disease, active cancer, and number of co-morbidities. Conclusions In this nationwide, population-based cohort of ICU patients with COVID-19, longer term survival was high despite high age and substantial use of organ support. Male gender, age, and chronic co-morbidities, in particular chronic pulmonary disease, were associated with increased risk of death.
C1 [Haase, Nicolai; Perner, Anders] Rigshosp, Dept Intens Care, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
   [Plovsing, Ronni] Hvidovre Univ Hosp, Dept Anesthesiol & Intens Care, Copenhagen, Denmark.
   [Christensen, Steffen] Arhus Univ Hosp, Dept Anesthesiol & Intens Care, Aarhus, Denmark.
   [Poulsen, Lone Musaeus] Zealand Univ Hosp, Dept Anesthesiol & Intens Care, Koge, Denmark.
   [Brochner, Anne Craveiro] Kolding Cty Hosp, Dept Anesthesiol & Intens Care, Kolding, Denmark.
   [Rasmussen, Bodil Steen; Madsen, Jacob] Alborg Univ Hosp, Dept Anesthesiol & Intens Care, Aalborg, Denmark.
   [Helleberg, Marie] Rigshosp, Dept Infect Dis, Copenhagen, Denmark.
   [Jensen, Jens Ulrik Staehr] Herlev Gentofte Hosp, Dept Resp Med, Copenhagen, Denmark.
   [Andersen, Lars Peter Kloster] Bispebjerg Hosp, Dept Anesthesiol & Intens Care, Copenhagen, Denmark.
   [Siegel, Hanna; Mohr, Thomas] Herlev Gentofte Hosp, Dept Anesthesiol & Intens Care, Copenhagen, Denmark.
   [Ibsen, Michael] North Zealand Hosp, Dept Anesthesiol & Intens Care, Hillerod, Denmark.
   [Jorgensen, Vibeke] Rigshosp, Dept Cardiothorac Anesthesiol, Copenhagen, Denmark.
   [Winding, Robert] Herning Hosp, Dept Anesthesiol & Intens Care, Herning, Denmark.
   [Iversen, Susanne] Slagelse Hosp, Dept Anesthesiol & Intens Care, Slagelse, Denmark.
   [Pedersen, Henrik Planck] Zealand Univ Hosp, Dept Anesthesiol & Intens Care, Roskilde, Denmark.
   [Solling, Christoffer] Viborg Hosp, Dept Anesthesiol & Intens Care, Viborg, Denmark.
   [Garcia, Ricardo Sanchez] Esbjerg Cent Hosp, Dept Anesthesiol & Intens Care, Esbjerg, Denmark.
   [Michelsen, Jens] Odense Univ Hosp, Dept Anesthesiol & Intens Care, Odense, Denmark.
   [Mannering, Anne] Svendborg Hosp, Dept Anesthesiol & Intens Care, Svendborg, Denmark.
   [Espelund, Ulrick Skipper] Horsens Hosp, Dept Anesthesiol & Intens Care, Horsens, Denmark.
   [Bundgaard, Helle] Randers Cent Hosp, Dept Anesthesiol & Intens Care, Randers, Denmark.
   [Kirkegaard, Lynge] Abenra Hosp, Dept Anesthesiol & Intens Care, Abenra, Denmark.
   [Smitt, Margit] Rigshosp, Dept Neuroanesthesiol, Copenhagen, Denmark.
   [Buck, David Levarett] Holbaek Cent Hosp, Dept Anesthesiol & Intens Care, Holbaek, Denmark.
   [Ribergaard, Niels-Erik] Hjorring Hosp, Dept Anesthesiol & Intens Care, Hjorring, Denmark.
   [Pedersen, Helle Scharling] Nykobing Falster Hosp, Dept Anesthesiol & Intens Care, Nykobing, Denmark.
   [Christensen, Birgitte Viebaek] Glostrup Cty Hosp, Dept Anesthesiol & Intens Care, Copenhagen, Denmark.
RP Haase, N (corresponding author), Rigshosp, Dept Intens Care, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM nicolai.rosenkrantz.segelcke.haase@regionh.dk
RI Helleberg, Marie/ABC-8199-2020
OI Helleberg, Marie/0000-0002-2370-1657; Poulsen, Lone
   Musaeus/0000-0002-7030-3395; Rasmussen, Bodil Steen/0000-0003-2190-145X
FU Novo Nordisk FoundationNovo Nordisk Foundation [NCT04348305];
   PfizerPfizer
FX The study was partly done within the framework of the COVID STEROID
   trial (Clini calTrials. gov Identifier NCT04348305), which is funded by
   the Novo Nordisk Foundation and supported by Pfizer. None of the authors
   declared any other conflicts of interest.
CR AABY P, 1988, REV INFECT DIS, V10, P452
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Atramont A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.3215
   Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Jeannet R, 2020, INTENS CARE MED, V46, P1769, DOI 10.1007/s00134-020-06127-x
   Nielsen NM, 2001, SCAND J INFECT DIS, V33, P301, DOI 10.1080/003655401300077360
   Peigne V, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0107-y
   Poulsen A, 2002, J INFECTION, V45, P237, DOI 10.1053/jinf.2002.1049
   Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   The ARDS Network Authors for the ARDS Network, 2020, JAMA-J AM MED ASSOC, V283, P1995
   Wang Y, 2020, AM J RESP CRIT CARE, V201, P1430, DOI 10.1164/rccm.202003-0736LE
   Wunsch H, 2008, CRIT CARE MED, V36, P2787, DOI 10.1097/CCM.0b013e318186aec8
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 18
TC 1
Z9 1
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-5172
EI 1399-6576
J9 ACTA ANAESTH SCAND
JI Acta Anaesthesiol. Scand.
PD JAN
PY 2021
VL 65
IS 1
BP 68
EP 75
DI 10.1111/aas.13701
EA OCT 2020
PG 8
WC Anesthesiology
SC Anesthesiology
GA PD7IT
UT WOS:000574646300001
PM 32929715
OA Bronze
DA 2021-01-01
ER

PT J
AU Nasri, E
   Shoaei, P
   Vakili, B
   Mirhendi, H
   Sadeghi, S
   Hajiahmadi, S
   Sadeghi, A
   Vaezi, A
   Badali, H
   Fakhim, H
AF Nasri, Elahe
   Shoaei, Parisa
   Vakili, Bahareh
   Mirhendi, Hossein
   Sadeghi, Somayeh
   Hajiahmadi, Somayeh
   Sadeghi, Alireza
   Vaezi, Afsane
   Badali, Hamid
   Fakhim, Hamed
TI Fatal Invasive Pulmonary Aspergillosis in COVID-19 Patient with Acute
   Myeloid Leukemia in Iran
SO MYCOPATHOLOGIA
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; Aspergillosis; Acute myeloid leukemia
AB Although patients with severe immunodeficiency and hematological malignancies has been considered at highest risk for invasive fungal infection, patients with severe pneumonia due to influenza, and severe acute respiratory syndrome coronavirus (SARS-CoV) are also at a higher risk of developing invasive pulmonary aspergillosis (IPA). Recently, reports of IPA have also emerged among SARS-CoV-2 infected patients admitted to intensive care units (ICUs). Here, we report a fatal case of probable IPA in an acute myeloid leukemia patient co-infected with SARS-CoV-2 and complicated by acute respiratory distress syndrome (ARDS). Probable IPA is supported by multiple pulmonary nodules with ground glass opacities which indicate halo sign and positive serum galactomannan results. Screening studies are needed to evaluate the prevalence of IPA in immunocompromised patients infected with SARS-CoV-2. Consequently, testing for the presence ofAspergillusin lower respiratory secretions and galactomannan in consecutive serum samples of COVID-19 patients with timely and targeted antifungal therapy based on early clinical suspicion of IPA are highly recommended.
C1 [Nasri, Elahe; Vakili, Bahareh; Sadeghi, Somayeh; Fakhim, Hamed] Isfahan Univ Med Sci, Infect Dis & Trop Med Res Ctr, Esfahan, Iran.
   [Shoaei, Parisa] Isfahan Univ Med Sci, Nosocomial Infect Res Ctr, Esfahan, Iran.
   [Mirhendi, Hossein] Isfahan Univ Med Sci, Res Core Facil Lab, Esfahan, Iran.
   [Sadeghi, Somayeh; Sadeghi, Alireza] Isfahan Univ Med Sci, Sch Med, Dept Internal Med, Esfahan, Iran.
   [Hajiahmadi, Somayeh] Isfahan Univ Med Sci, Sch Med, Dept Radiol, Esfahan, Iran.
   [Vaezi, Afsane; Badali, Hamid] Mazandaran Univ Med Sci, Communicable Dis Inst, Invas Fungi Res Ctr, Sari, Iran.
   [Badali, Hamid] Univ Texas Hlth Sci Ctr San Antonio, Fungus Testing Lab, Dept Pathol & Lab Med, San Antonio, TX 78229 USA.
RP Fakhim, H (corresponding author), Isfahan Univ Med Sci, Infect Dis & Trop Med Res Ctr, Esfahan, Iran.
EM Fakhiim.hamed@gmail.com
FU Emergency special program for COVID-19 of Isfahan University of Medical
   Sciences, Isfahan, Iran project [198338]
FX This study was supported by grants from the Emergency special program
   for COVID-19 of Isfahan University of Medical Sciences, Isfahan, Iran
   project (No. 198338).
CR Al-Hatmi AMS, 2020, J INFECT, V7
   Alanio A, 2020, LANCET RESP MED, V8, pE48, DOI 10.1016/S2213-2600(20)30237-X
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Donnelly JP, 2019, CLIN INFECT DIS
   Duarte RF, 2014, CLIN INFECT DIS, V59, P1696, DOI 10.1093/cid/ciu673
   JL Jameson, 2018, HARRISONS PRINCIPLES, P499
   Koehler P, 2020, MYCOSES, V63, P528, DOI 10.1111/myc.13096
   Lahmer T, 2020, CLIN MICROBIOL INFEC, V2
   Leeang MM, 2008, COCHRANE DB SYST REV, V8, pCD007394
   Maertens J, 2004, BRIT J HAEMATOL, V126, P852, DOI 10.1111/j.1365-2141.2004.05140.x
   Marr KA, 2004, J INFECT DIS, V190, P641, DOI 10.1086/422009
   Meijer EFJ, 2020, J FUNGI, V6, DOI 10.3390/jof6020079
   Prattes Juergen, 2020, Med Mycol Case Rep, DOI 10.1016/j.mmcr.2020.05.001
   Rutsaert L, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00686-4
   Salehi M, 2020, MYCOPATHOLOGIA, V185, P607, DOI 10.1007/s11046-020-00472-7
   Song G, 2020, MYCOPATHOLOGIA, V185, P599, DOI 10.1007/s11046-020-00462-9
   Verweij Paul E, 2020, Lancet Microbe, V1, pe53, DOI 10.1016/S2666-5247(20)30027-6
   Wang HJ, 2003, NEW ENGL J MED, V349, P507, DOI 10.1056/NEJM200307313490519
NR 18
TC 1
Z9 1
U1 4
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-486X
EI 1573-0832
J9 MYCOPATHOLOGIA
JI Mycopathologia
DI 10.1007/s11046-020-00493-2
EA OCT 2020
PG 8
WC Mycology
SC Mycology
GA NW1QD
UT WOS:000574785700001
PM 33009966
DA 2021-01-01
ER

PT J
AU Sarantis, P
   Koustas, E
   Papavassiliou, AG
   Karamouzis, MV
AF Sarantis, Panagiotis
   Koustas, Evangelos
   Papavassiliou, Athanasios G.
   Karamouzis, Michalis V.
TI Are cystic fibrosis mutation carriers a potentially highly vulnerable
   group to COVID-19?
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE ACE-2; COVID-19; CTFR; cystic fibrosis; SARS-CoV-2
ID NF-KAPPA-B; EXPRESSION; DISEASE; GENE
AB Undoubtedly, the new SARS-CoV-2 virus poses a grave health threat, plaguing the health and socio-economic sectors. COVID-19 disease must be treated quickly and effectively as soon as possible. The main axes in this direction are establishing vaccines, drugs, diagnostic tests, as well as identifying the most vulnerable groups. Probably, there is a correlation between COVID-19 and cystic fibrosis. Our interest is focused on cystic fibrosis carriers that, due to limited tests, remain undetectable. There is an activation of the inflammatory response in the carriers, as well as in cystic fibrosis patients. First of all, a striking similarity lies between the inflammatory response in COVID-19 and cystic fibrosis carriers. Notably, ACE-2 plays the same role in both cases and a similar geographical distribution is observed in both diseases. In conclusion, we suggest that cystic fibrosis mutation carriers are potential members of a certain vulnerable group and the detection of such mutations in the population might be vital for the prevention of SARS-CoV-2 virus, and more specifically to limit its serious complications.
C1 [Sarantis, Panagiotis; Koustas, Evangelos; Papavassiliou, Athanasios G.; Karamouzis, Michalis V.] Natl & Kapodistrian Univ Athens, Mol Oncol Unit, Dept Biol Chem, Sch Med, Athens, Greece.
RP Papavassiliou, AG; Karamouzis, MV (corresponding author), Natl & Kapodistrian Univ Athens, Sch Med, Dept Biol Chem, 75 M Asias St, Athens 11527, Greece.
EM papavas@med.uoa.gr; mkaramouz@med.uoa.gr
RI Karamouzis, Michalis/AAD-2860-2020; Koustas, Evangelos/ABE-9336-2020
OI Karamouzis, Michalis/0000-0003-1369-8201
CR Bell SC, 2020, LANCET RESP MED, V8, P65, DOI 10.1016/S2213-2600(19)30337-6
   Bodas M, 2010, DISCOV MED, V9, P346
   Bombieri C, 2011, J CYST FIBROS, V10, pS86, DOI 10.1016/S1569-1993(11)60014-3
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kelly C, 2013, EUR RESPIR J, V41, P1315, DOI 10.1183/09031936.00032412
   Kelly C, 2013, AM J PHYSIOL-LUNG C, V304, pL371, DOI 10.1152/ajplung.00372.2011
   KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460
   Lao O, 2003, EUR J HUM GENET, V11, P385, DOI 10.1038/sj.ejhg.5200970
   Li XP, 2008, AM J PHYSIOL-LUNG C, V295, pL178, DOI 10.1152/ajplung.00009.2008
   Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07
   Polgreen PM, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy219
   Ruocco G, 2020, INT J INFECT DIS, V95, P373, DOI 10.1016/j.ijid.2020.04.058
   Shah VS, 2016, P NATL ACAD SCI USA, V113, P5382, DOI 10.1073/pnas.1604905113
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Wang H, 2016, CELL PHYSIOL BIOCHEM, V40, P1063, DOI 10.1159/000453162
NR 15
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD NOV
PY 2020
VL 24
IS 22
BP 13542
EP 13545
DI 10.1111/jcmm.15941
EA OCT 2020
PG 4
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA OY0OR
UT WOS:000574530600001
PM 33009727
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Abe, KT
   Li, ZJ
   Samson, R
   Samavarchi-Tehrani, P
   Valcourt, EJ
   Wood, H
   Budylowski, P
   Dupuis, AP
   Girardin, RC
   Rathod, B
   Wang, JH
   Barrios-Rodiles, M
   Colwill, K
   McGeer, AJ
   Mubareka, S
   Gommerman, JL
   Durocher, Y
   Ostrowski, M
   McDonough, KA
   Drebot, MA
   Drews, SJ
   Rini, JM
   Gingras, AC
AF Abe, Kento T.
   Li, Zhijie
   Samson, Reuben
   Samavarchi-Tehrani, Payman
   Valcourt, Emelissa J.
   Wood, Heidi
   Budylowski, Patrick
   Dupuis, Alan P.
   Girardin, Roxie C.
   Rathod, Bhavisha
   Wang, Jenny H.
   Barrios-Rodiles, Miriam
   Colwill, Karen
   McGeer, Allison J.
   Mubareka, Samira
   Gommerman, Jennifer L.
   Durocher, Yves
   Ostrowski, Mario
   McDonough, Kathleen A.
   Drebot, Michael A.
   Drews, Steven J.
   Rini, James M.
   Gingras, Anne-Claude
TI A simple protein-based surrogate neutralization assay for SARS-CoV-2
SO JCI INSIGHT
LA English
DT Article
ID CORONAVIRUS; PIGGYBAC
AB Most of the patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mount a humoral immune response to the virus within a few weeks of infection, but the duration of this response and how it correlates with clinical outcomes has not been completely characterized. Of particular importance is the identification of immune correlates of infection that would support public health decision-making on treatment approaches, vaccination strategies, and convalescent plasma therapy. While ELISA-based assays to detect and quantitate antibodies to SARS-CoV-2 in patient samples have been developed, the detection of neutralizing antibodies typically requires more demanding cell-based viral assays. Here, we present a safe and efficient protein-based assay for the detection of serum and plasma antibodies that block the interaction of the SARS-CoV-2 spike protein receptor binding domain (RBD) with its receptor, angiotensin-converting enzyme 2 (ACE2). The assay serves as a surrogate neutralization assay and is performed on the same platform and in parallel with an ELISA for the detection of antibodies against the RBD, enabling a direct comparison. The results obtained with our assay correlate with those of 2 viral-based assays, a plaque reduction neutralization test (PRNT) that uses live SARS-CoV-2 virus and a spike pseudotyped viral vector-based assay.
C1 [Abe, Kento T.; Li, Zhijie; Samson, Reuben; Rini, James M.; Gingras, Anne-Claude] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
   [Abe, Kento T.; Samson, Reuben; Samavarchi-Tehrani, Payman; Rathod, Bhavisha; Wang, Jenny H.; Barrios-Rodiles, Miriam; Colwill, Karen; McGeer, Allison J.; Gingras, Anne-Claude] Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Toronto, ON, Canada.
   [Valcourt, Emelissa J.; Wood, Heidi; Drebot, Michael A.] Publ Hlth Agcy Canada, Natl Microbiol Lab NML, Zoonot Dis & Special Pathogens, Winnipeg, MB, Canada.
   [Budylowski, Patrick; Gommerman, Jennifer L.; Ostrowski, Mario] Univ Toronto, Dept Immunol, Toronto, ON, Canada.
   [Budylowski, Patrick] Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
   [Dupuis, Alan P.; Girardin, Roxie C.; McDonough, Kathleen A.] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA.
   [McGeer, Allison J.] Univ Hlth Network, Dept Microbiol, Toronto, ON, Canada.
   [McGeer, Allison J.] Sinai Hlth Syst, Toronto, ON, Canada.
   [McGeer, Allison J.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [McGeer, Allison J.; Mubareka, Samira] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   [Mubareka, Samira] Sunnybrook Hlth Sci Ctr, Dept Lab Med & Mol Diagnost, Div Microbiol, Toronto, ON, Canada.
   [Mubareka, Samira] Sunnybrook Res Inst, Biol Sci, Toronto, ON, Canada.
   [Mubareka, Samira] Sunnybrook Hlth Sci Ctr, Div Infect Dis, Toronto, ON, Canada.
   [Durocher, Yves] Natl Res Council Canada, Mammalian Cell Express Human Hlth Therapeut Res C, Montreal, PQ, Canada.
   [Ostrowski, Mario] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Ostrowski, Mario] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [McDonough, Kathleen A.] SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY USA.
   [Drebot, Michael A.] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada.
   [Drews, Steven J.] Canadian Blood Serv, Edmonton, AB, Canada.
   [Drews, Steven J.] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada.
   [Rini, James M.] Univ Toronto, Dept Biochem, Toronto, ON, Canada.
RP Rini, JM (corresponding author), MaRS Ctr, West Tower,Room 1614,661 Univ Ave, Toronto, ON M5G 1M1, Canada.; Gingras, AC (corresponding author), Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, 600 Univ Ave,Room 992, Toronto, ON M5G 1X5, Canada.
EM james.rini@utoronto.ca; gingras@lunenfeld.ca
OI Girardin, Roxie/0000-0001-8277-7822
FU Royal Bank of Canada (RBC); QuestCap; Krembil Foundation; Government of
   Ontario; Canada Foundation for InnovationCanada Foundation for
   InnovationCGIAR; Ontarian Government; Genome CanadaGenome Canada;
   Ontario Genomics [OGI-139]; New York State Department of Health;
   Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [CIHR 439999, FRN 162305, FDN 143301]; Canada Research
   Chair, Tier 1, in Functional Proteomics; Ontario Graduate
   ScholarshipOntario Graduate Scholarship
FX We thank Janet McManus at Canadian Blood Services for her technical and
   logistical expertise and the Wadsworth Center Media and Tissue Culture
   Core. We thank Joan Wither for the lupus patient samples, and Jesse
   Bloom and Katharine Crawford for sharing protocols and reagents for the
   lentiviral S pseudotyping assay. The following reagent was produced by
   Florian Krammer's group under HHSN272201400008C and obtained through BEI
   Resources, NIAID, NIH: Spike Glycoprotein RBD from SARS-Related
   Coronavirus 2, WuhanHu-1, Recombinant from HEK293 Cells, NR-52306. We
   thank Matthew Stuible and Alex Pelletier (National Research Council;
   NRC) for VHH72hFc1X7 expression and purification, Joe Schrag (NRC) for
   SEC-UPLC/MALS analysis, and members of our laboratories and the Network
   Biology Collaborative Centre for advice and technical help. Funding for
   the development of the assays in the Gingras lab was provided through
   generous donations from the Royal Bank of Canada (RBC), QuestCap, and
   the Krembil Foundation to the Sinai Health System Foundation. We also
   acknowledge an "Ontario Together" team grant from the Government of
   Ontario to JG, JMR, ACG, MO, and AM to develop serology and saliva
   assays. The equipment used is housed in the Network Biology
   Collaborative Centre at the Lunenfeld-Tanenbaum Research Institute, a
   facility supported by Canada Foundation for Innovation funding, by the
   Ontarian Government, and by Genome Canada and Ontario Genomics
   (OGI-139). We also acknowledge funding support from New York State
   Department of Health (to KAM). AJM, JMR, JLG, and ACG are supported by
   the Canadian Institutes of Health Research (CIHR 439999, FRN 162305, and
   FDN 143301, respectively). ACG is also supported by a Canada Research
   Chair, Tier 1, in Functional Proteomics. KTA is a recipient of an
   Ontario Graduate Scholarship.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Corti D, 2013, ANNU REV IMMUNOL, V31, P705, DOI 10.1146/annurev-immunol-032712-095916
   Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513
   Crawford KH, 2020, DYNAMICS NEUTRALIZIN, DOI [10.1101/2020.08.06.20169367, DOI 10.1101/2020.08.06.20169367]
   Darnell MER, 2006, TRANSFUSION, V46, P1770, DOI 10.1111/j.1537-2995.2006.00976.x
   Fairhead Michael, 2015, Methods Mol Biol, V1266, P171, DOI 10.1007/978-1-4939-2272-7_12
   Ferrara F., 2018, METHODS PROTOC, V1, P8
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hulswit RJG, 2016, ADV VIRUS RES, V96, P29, DOI 10.1016/bs.aivir.2016.08.004
   Isho B, 2020, EVIDENCE SUSTAINED M, DOI [10.1101/2020.08.01.20166553, DOI 10.1101/2020.08.01.20166553]
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Li ZJ, 2013, P NATL ACAD SCI USA, V110, P5004, DOI 10.1073/pnas.1218620110
   LINDSEY HS, 1976, J CLIN MICROBIOL, V4, P503
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Mendoza EJ, 2020, CURR PROTOC MICROBIO, V57, DOI [10.1002/cmpc.105, DOI 10.1002/CMPC.105]
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Poulain A, 2017, J BIOTECHNOL, V255, P16, DOI 10.1016/j.jbiotec.2017.06.009
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   RUSSELL PK, 1967, J IMMUNOL, V99, P285
   Seow G., 2020, LONGITUDINAL EVALUAT, DOI [10.1101/2020.07.09.20148429., 10.1101/2020.07.09.20148429, DOI 10.1101/2020.07.09.20148429]
   Shi CH, 2005, BIOCHEMISTRY-US, V44, P15705, DOI 10.1021/bi051292p
   Stuible M, 2018, J BIOTECHNOL, V281, P39, DOI 10.1016/j.jbiotec.2018.06.307
   Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z
   Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Wajnberg A, 2020, SARS COV 2 INFECT IN, DOI [10.1101/2020.07.14.20151126, DOI 10.1101/2020.07.14.20151126]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan J, 2020, BIORXIV
   Wan JK, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107918
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang SX, 2005, J IMMUNOL METHODS, V301, P21, DOI 10.1016/j.jim.2005.03.008
   Wang W, 2008, P NATL ACAD SCI USA, V105, P9290, DOI 10.1073/pnas.0801017105
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Yao XY, 2020, NEUTRALIZING BINDING, DOI [10.1101/2020.07.18.20156810, DOI 10.1101/2020.07.18.20156810]
NR 39
TC 1
Z9 1
U1 2
U2 2
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD OCT 2
PY 2020
VL 5
IS 19
AR e142362
DI 10.1172/jci.insight.142362
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OC4MM
UT WOS:000579132200001
PM 32870820
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kasahun, GG
   Kahsay, GM
   Asayehegn, AT
   Demoz, GT
   Desta, DM
   Gebretekle, GB
AF Kasahun, Gebremicheal Gebreslassie
   Kahsay, Gebremichael Mulu
   Asayehegn, Amha Teklu
   Demoz, Gebre Teklemariam
   Desta, Desilu Mahari
   Gebretekle, Gebremedhin Beedemariam
TI Pharmacy preparedness and response for the prevention and control of
   coronavirus disease (COVID-19) in Aksum, Ethiopia; a qualitative
   exploration
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
DE Pharmacy service; Community pharmacy; Hospital pharmacy; COVID-19;
   SARS-CoV-2
AB Background Novel Coronavirus is a global pandemic affecting all walks of life and it significantly changed the health system practices. Pharmacists are at the front line and have long been involved in combating this public health emergency. Therefore, the study was aimed to explore pharmacy preparedness and response to prevent and control coronavirus disease 2019 (COVID-19). Methods A qualitative study was conducted in six pharmacies in Aksum, Ethiopia in May, 2020. We conducted six in-depth interviews with purposively selected key informants. Direct observation measures were made to assess the activities made in the medicine retail outlets for the prevention and control of the pandemic. Interview data were audio-recorded, translated and transcribed verbatim. Thematic analysis was employed to analyze the data and OpenCode version 4.02 software was used to facilitate the data analysis. Results The thematic analysis has resulted in seven major themes. Good preparedness measures were undertaken to control and prevent COVID-19. Study informants had good knowledge about the pandemic disease and reported they had used different resource materials to update themselves. Preparing of alcohol-based hand-rub, availing finished sanitizers and alcohol, and advising clients to maintain physical distancing were the major counseling information being delivered to prevent the disease. Some tendencies of irrational drug use and false claims of COVID-19 were observed at the beginning of the pandemic. Interview informants had reported they were working with relevant stakeholders and appropriate patient education and support were given to combat the pandemic. Conclusion The study revealed necessary pharmacy services has been rendered to all clients. However, availability of drugs and medical supplies were scarce which negatively affected the optimal delivery of pharmacy services. The government and other responsible bodies should work together to solve such problems and contain the pandemic.
C1 [Kasahun, Gebremicheal Gebreslassie; Kahsay, Gebremichael Mulu; Asayehegn, Amha Teklu; Demoz, Gebre Teklemariam] Aksum Univ, Coll Hlth Sci, Dept Pharm, Aksum, Tigray, Ethiopia.
   [Desta, Desilu Mahari] Mekelle Univ, Coll Hlth Sci, Sch Pharm, Mekelle, Tigray, Ethiopia.
   [Gebretekle, Gebremedhin Beedemariam] Addis Ababa Univ, Coll Hlth Sci, Sch Pharm, Addis Ababa, Ethiopia.
RP Kasahun, GG (corresponding author), Aksum Univ, Coll Hlth Sci, Dept Pharm, Aksum, Tigray, Ethiopia.
EM gebremicheal.kassahun@gmail.com
RI Gebretekle, Gebremedhin/ABE-4212-2020; Gebretekle, Gebremedhin
   B/ABD-2827-2020; Demoz, Gebre Teklemariam/K-6986-2019; Kasahun,
   Gebremicheal Gebreslassie/AAI-9900-2020
OI Demoz, Gebre Teklemariam/0000-0002-2534-821X; Kasahun, Gebremicheal
   Gebreslassie/0000-0002-8981-1832; Gebretekle, Gebremedhin
   B./0000-0002-2485-505X
CR Alemu S, 2020, PANDEMIC SARS COV 2C
   [Anonymous], 2019, HELATH FACILITY ALCO
   [Anonymous], 2020, 2019 NOVEL CORONAVIR
   [Anonymous], 2020, COVID 19 GUIDELINES
   [Anonymous], 2020, MED PRODUCT ALERT N
   [Anonymous], 2020, COVID 19 COMMUNITY P
   [Anonymous], 2020, INFECT PREVENTION CO
   [Anonymous], 2020, COVID 19 SUMMARY GUI
   [Anonymous], 2020, PHARM READINESS CORO
   Dahab MV-ZK, 2020, CONFL HEALTH, V14, P1, DOI [10.1186/s13031-019-0247-4, DOI 10.1186/S13031-019-0247-4]
   Erick Hedima MA, 2020, COMMUNITY PHARM FRON
   Erku BA, 2020, RES SOC ADM PHARM
   James Sanders MM, 2020, PHARM TREATMENTS COR
   Jamison GH, 2017, DIS CONTROL PRIORITI, V9, P9
   Meghana H-AT, 2020, PHARM EMERGENCY PREP
   Mukhtar S, 2020, PREPAREDNESS PROACTI
   Nadia Bukhari HR, 2020, PHARM FRONTLINE BEAT
   Osama M., 2020, SARS COV 2 OUTBREAK
   Pedro Amariles ML-M, 2020, LINK PATIENTS SUSPIC
   Pramath Kakodkar NK, 2020, COMPREHENSIVE LIT RE
   Raina Merchant NL, 2020, SOCIAL MEDIA EMERGEN
   Sasmita Adhikari SM, 2020, EPIDEMIOLOGY CAUSES
   Shadi Doroudgar FH, 2020, MULTICULTURAL PROJEC
   Si-qian Zheng LY, 2020, R S RECOMMENDATIONS
   Ung L, 2020, COMMUNITY PHARM PUBL
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wang Ying YQ, 2020, DRUGS SUPPLY PHARM C
   Zaiwei Song YH, 2020, HOSP PHARM PHARM CAR
NR 28
TC 0
Z9 0
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD OCT 2
PY 2020
VL 20
IS 1
AR 913
DI 10.1186/s12913-020-05763-9
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA NZ3EK
UT WOS:000576980200002
PM 33008384
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yi, ZM
   Hu, Y
   Wang, GR
   Zhao, RS
AF Yi, Zhan-Miao
   Hu, Yang
   Wang, Guan-Ru
   Zhao, Rong-Sheng
TI Mapping Evidence of Pharmacy Services for COVID-19 in China
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE COVID-19; pharmacy service; guideline development; emergency supply;
   service model innovation; treatment regimens
ID PHARMACEUTICAL CARE; RATIONAL USE; CONTROL STRATEGY; ANTIVIRAL DRUGS;
   PREVENTION; MANAGEMENT; RECOMMENDATIONS; OUTPATIENT; MEDICATION;
   MEDICINES
AB Objective To explore the role of pharmacists and innovation of pharmacy interventions for COVID-19 patients in China. Methods We comprehensively searched PubMed and Chinese databases Sinomed, China National Knowledge Infrastructure to identify articles reporting pharmacist interventions and pharmacy services for COVID-19 patients using a predefined search strategy. The search period was from inception to April 7(th)2020. We also manually searched the reference list of included articles and websites of important journals with special issues for COVID-19. Results A total of 156 articles were identified by applying the search criteria. After screening, 91 articles, with the majority are literature reviews (n = 77, 84.62%) published in Chinese (n = 83, 91.2%), were included. Pharmacist interventions for COVID-19 patients most commonly related to guidelines or consensus development for the treatment of disease and practice procedure to prevent the spread of COVID-19 (n = 10, 10.98%), the supply of medicines to treat patients with severe respiratory or systematic symptoms related to COVID-19 (n = 10, 10.98%), formulating infections prevention and control strategies related to COVID-19 for pharmaceutical personnel/pharmacy staff (n = 14, 15.39%), new way of delivery pharmacy services and the implementation of new pharmacy services for COVID-19 outbreak (n = 14, 15.39%), routine pharmacy services under the restrict limit of COVID-19 outbreak (n = 39, 42.86%), and case series analysis of treatment regimens using existing, routinely collected data (n = 4, 4.40%). Conclusion Pharmacy services have a role in the COVID-19 pandemic control, and there were many rapid changes in response to the pandemic.
C1 [Yi, Zhan-Miao; Hu, Yang; Wang, Guan-Ru; Zhao, Rong-Sheng] Peking Univ Third Hosp, Dept Pharm, Beijing, Peoples R China.
   [Yi, Zhan-Miao; Hu, Yang; Wang, Guan-Ru; Zhao, Rong-Sheng] Peking Univ, Inst Drug Evaluat, Hlth Sci Ctr, Beijing, Peoples R China.
   [Yi, Zhan-Miao; Hu, Yang; Wang, Guan-Ru; Zhao, Rong-Sheng] Peking Univ, Therapeut Drug Monitoring & Clin Toxicol Ctr, Beijing, Peoples R China.
   [Hu, Yang; Wang, Guan-Ru] Peking Univ, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, Beijing, Peoples R China.
RP Zhao, RS (corresponding author), Peking Univ Third Hosp, Dept Pharm, Beijing, Peoples R China.; Zhao, RS (corresponding author), Peking Univ, Inst Drug Evaluat, Hlth Sci Ctr, Beijing, Peoples R China.; Zhao, RS (corresponding author), Peking Univ, Therapeut Drug Monitoring & Clin Toxicol Ctr, Beijing, Peoples R China.
EM zhaorongsheng@bjmu.edu.cn
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   AGREE Next Steps Consortium, 2017, AGREE 2 INSTR EL VER
   ALQUTEIMAT O, 2020, J ONCOL PHARM P 0611, DOI DOI 10.1016/j.sapharm.2020.03.018
   Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]
   BIAN Y, 2020, HER MED, V39, P338, DOI DOI 10.3870/j.issn.1004-0781.2020.03.016
   [边原 Bian Yuan], 2020, [中国新药与临床杂志, Chinese Journal of New Drugs and Clinical Remedies], V39, P212
   Cao J., 2020, J JIANGSU U MED, V30, P109, DOI [10.13312/j.issn.1671-7783.y200080, DOI 10.13312/J.ISSN.1671-7783.Y200080]
   Carico Ronald Ron Jr, 2021, Res Social Adm Pharm, V17, P1984, DOI 10.1016/j.sapharm.2020.03.017
   [车坷科 Che Keke], 2020, [西南大学学报. 自然科学版, Journal of Southwest University. Natural Science Edition], V42, P1
   Chen J. Z., 2020, CHIN PHARM, V31, P536, DOI [10.6039/j.issn.1001-0408.2020.05.06, DOI 10.6039/J.ISSN.1001-0408.2020.05.06]
   Chen L., 2020, CHINA J CHIN MAT MED, V45, P2232, DOI [10.19540/j.cnki.cjcmm.20200322.505, DOI 10.19540/J.CNKI.CJCMM.20200322.505]
   Chen L. F., 2020, CHINA PHARM, V29, P18, DOI [10.3969/j.issn.1006-4931.2020.05.004, DOI 10.3969/J.ISSN.1006-4931.2020.05.004]
   [陈灵 Chen Ling], 2020, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V26, P35
   [陈丽坪 Chen Liping], 2020, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V37, P549
   CHEN M, 2020, HER MED, V39, P483, DOI DOI 10.3870/j.issn.1004-0781.2020.04.010
   Chen ND, 2020, CURR TOP NUTRACEUT R, V18, P21
   CHEN YW, 2020, CHIN J HOSP PHARM, V40, P632, DOI DOI 10.13286/j.1001-5213.2020.06.07
   CHENG F, 2020, CHIN J HOSP PHARM, V40, P1189, DOI DOI 10.13286/j.1001-5213.2020.11.03
   Dong S. J., 2020, CHIN PHARM, V31, P513, DOI [10.6039/j.issn.1001-0408.2020.05.01, DOI 10.6039/J.ISSN.1001-0408.2020.05.01]
   Duan H. F., 2020, MODERN TRADIT CHIN M, V3, P597, DOI [10.11842/wst.20200224009, DOI 10.11842/WST.20200224009]
   GAO YY, 2020, CHIN J HOSP PHARM, V40, P606, DOI DOI 10.13286/j.1001-5213.2020.06.02
   GONG WJ, 2020, CHIN J HOSP PHARM, V40, P876, DOI DOI 10.13286/j.1001-5213.2020.08.08
   GONG WJ, 2020, HER MED, V39, P650, DOI DOI 10.3870/j.issn.1004-0781.2020.05.014
   Gu M., 2020, CHINA PHARMACIST, V23, P702
   Guo W., 2020, ADVERSE DRUG REACT J, V3, P176, DOI [10.3760/cma.j.cn114015-20200222-00146, DOI 10.3760/CMA.J.CN114015-20200222-00146]
   Han L. Z., 2020, CENT S PHARM, V18, P591
   [何璐璐 He Lulu], 2020, [华西药学杂志, West China Journal of Pharmaceutical Sciences], V35, P225
   He S. Z., 2020, PHARM TODAY, V335, P313
   Hu C. J., 2020, W CHIN J PHARM SCI, V33, P100, DOI [10.3969/j.issn.1674-0904.2020.02.004, DOI 10.3969/J.ISSN.1674-0904.2020.02.004]
   Hu Z. Q., 2020, J CANC CONT TREAT, V33, P100
   Huang L. J., 2020, CENT S PHARM, V18, P739
   Huang L. J., 2020, CHINESE PHARMACOL B, V36, P30
   [黄凌斐 Huang Lingfei], 2020, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V37, P555
   International Pharmaceutical Federation, 2020, CHIN PHARM J, V55, P249, DOI [10.11669/cpj.2020.04.001, DOI 10.11669/CPJ.2020.04.001]
   Jin Y., 2020, CHIN J HOSP PHARM
   Leading Group of the Central Committee on Response to COVID-19, 2020, GUID OP CENTR LEAD G
   Li G. H., 2020, ADVERSE DRUG REACT J, V22, P139, DOI [10.3760/cma.j.issn.1008-5734.2020.0004, DOI 10.3760/CMA.J.ISSN.1008-5734.2020.0004]
   Li Huibo, 2021, Res Social Adm Pharm, V17, P1813, DOI 10.1016/j.sapharm.2020.04.003
   Lin Zhi-Jian, 2020, Zhongguo Zhong Yao Za Zhi, V45, P1259, DOI 10.19540/j.cnki.cjcmm.20200211.501
   Liu Q. Y., 2020, ADVERSE DRUG REACT J, DOI [10.3760/cma.j.cn114015-20200224-00158, DOI 10.3760/CMA.J.CN114015-20200224-00158]
   LIU S, 2020, CHIN J HOSP PHARM, V40, P243, DOI DOI 10.13286/j.1001-5213.2020.03.01
   Liu S, 2020, INT J CLIN PHARM-NET, V42, P299, DOI 10.1007/s11096-020-01017-0
   Liu X. L., 2020, CHIN J HOSP ADM, V4, P324, DOI [10.3760/cma.j.cn112225-20200302-00440, DOI 10.3760/CMA.J.CN112225-20200302-00440]
   LIU XX, 2020, HER MED, V39, P451, DOI DOI 10.3870/j.issn.1004-0781.2020.04.006
   LIU Y, 2020, HER MED, V39, P522, DOI DOI 10.3870/j.issn.1004-0781.2020.04.017
   Liu Y, 2020, FUND CLIN PHARMACOL, DOI 10.1111/fcp.12574
   Martin P, 2018, JAMA-J AM MED ASSOC, V320, P1889, DOI 10.1001/jama.2018.16131
   Medical Research Council, 2019, DEV EV COMPL INT FOL
   Meng L, 2020, INT J CLIN PHARM-NET, V42, P305, DOI 10.1007/s11096-020-01020-5
   Moola S, 2020, JBI MANUAL EVIDENCE, DOI [10.46658/JBIMES-20-08, DOI 10.46658/JBIMES-20-08]
   National Health Commission of People's Republic of China, 2020, PRESS C JOINT DEF JO
   National Institute for Health and Care Excellence, 2020, COVID 19 RAP GUID CR
   Omer SB, 2020, JAMA-J AM MED ASSOC, V323, P1767, DOI 10.1001/jama.2020.5788
   [彭玲玲 Peng Lingling], 2020, [中国临床药理学杂志, The Chinese Journal of Clinical Pharmacology], V36, P926
   RAO YF, 2020, CHIN J HOSP PHARM, V40, P726, DOI DOI 10.13286/j.1001-5213.2020.07.02
   Shao M. M., 2020, CHIN J HOSP PHARM, V40, P753, DOI [10.13286/j.1001-5213.2020.07.08, DOI 10.13286/j.1001-5213.2020.07.08]
   SHEN AZ, 2020, CHIN J HOSP PHARM, V40, P1603, DOI DOI 10.13286/j.1001-5213.2020.15.01
   SONG B, 2020, CHIN J HOSP PHARM, V40, P748, DOI DOI 10.13286/j.1001-5213.2020.07.07
   Song Zaiwei, 2021, Res Social Adm Pharm, V17, P2027, DOI 10.1016/j.sapharm.2020.03.027
   Tan S. L., 2020, CENT S PHARM, V18, P335, DOI [10.7539/j.issn.1672-2981.2020.02.038, DOI 10.7539/J.ISSN.1672-2981.2020.02.038]
   The State Council of the People's Republic of China, 2020, NOT ISS GUID PREV CO
   Therapeutic Drug Monitoring Pharmacists Branch of Chinese Pharmacists Association Hospital Pharmacy Branch of China Association of Chinese Medicine Emergency Medicine Branch of Chinese Geriatrics Society Cardiovascular Medicine Branch of Chinese Society of Cardiothoracic and Vascular Anesthesiology Clinical Toxicology Professional Committee of Chinese Society of Toxicology Drug induced Diseases Professional Committee of Chinese Pharmacological Society, 2020, ADVERSE DRUG REACT J, V3, P121, DOI [10.3760/cma.j.cn114015-20200304-00211, DOI 10.3760/CMA.J.CN114015-20200304-00211]
   Ung COL, 2020, RES SOC ADMIN PHARM, V16, P583, DOI 10.1016/j.sapharm.2020.02.003
   Wang N. N., 2020, CHINA PHARM, V29, P15, DOI [10.3969/j.issn.1006-4931.2020.05.003, DOI 10.3969/J.ISSN.1006-4931.2020.05.003]
   WANG RR, 2020, CHIN J HOSP PHARM, V40, P612, DOI DOI 10.13286/j.1001-5213.2020.06.03
   WANG XY, 2020, CHIN J HOSP PHARM, V40, P847, DOI DOI 10.13286/j.1001-5213.2020.08.02
   Wang Y., 2020, CHIN J HOSP PHARM, DOI [10.13286/j. 1001-5213.2020.06.01, DOI 10.13286/J.1001-5213.2020.06.01]
   Wei L., 2020, PHARM TODAY
   WHO, 2020, COR DIS COVID 19 SIT
   World Health Organization, 2020, ROLL UPD COR DIS COV
   Xie Y. L., 2020, EMERGENCY PLAN HOSP, V18, P1
   Xiong Y., 2020, W CHINA J PHARM SCI
   XIONG Y, 2020, CHIN J HOSP PHARM, V40, P857, DOI DOI 10.13286/j.1001-5213.2020.08.04
   [徐晓涵 Xu Xiaohan], 2020, [中国药学杂志, Chinese Pharmaceutical Journal], V55, P700
   Xu Y. X., 2020, CHIN J CLIN PHARM, V36, P922, DOI [10.13699/j.cnki.1001-6821.2020.07.054, DOI 10.13699/J.CNKI.1001-6821.2020.07.054]
   Xu Y, 2020, J CLIN PHARM THER, V45, P1363, DOI 10.1111/jcpt.13228
   Yan J. L., 2020, CHINA PHARM, V29, P16, DOI [10.3969/j.issn.1006-4931.2020.06.004, DOI 10.3969/J.ISSN.1006-4931.2020.06.004]
   Yan Y. Y., 2020, CHINA PHARM, V31, P523, DOI [10.6039/j.issn.1001-0408.2020.05.03, DOI 10.6039/J.ISSN.1001-0408.2020.05.03]
   [闫盈盈 Yan Yingying], 2012, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V12, P92
   Yang C. X., 2020, HERALD MED
   [杨晨 Yang Chen], 2020, [暨南大学学报. 自然科学与医学版, Journal of Jinan University. Natural Science & Medicine Edition], V41, P137
   YANG CX, 2020, CHIN J HOSP PHARM, V40, P1071, DOI DOI 10.13286/j.1001-5213.2020.10.01
   Yang L., 2020, CHINA PHARM, V29, P46, DOI [10.3969/j.issn.1006-4931.2020.05.010, DOI 10.3969/J.ISSN.1006-4931.2020.05.010]
   Yang L., 2020, CHIN PHARM, V31, P517, DOI [10.6039/j.issn.1001-0408.2020.05.02, DOI 10.6039/J.ISSN.1001-0408.2020.05.02]
   YANG MY, 2020, CHIN J HOSP PHARM, V40, P617, DOI DOI 10.13286/j.1001-5213.2020.06.04
   YANG Y, 2020, HER MED, V39, P518, DOI DOI 10.3870/j.issn.1004-0781.2020.04.016
   Yang Y. H., 2020, CLIN MED J, V18, P1, DOI [10.3969/j.issn.1672-3384.2020.02.001, DOI 10.3969/J.ISSN.1672-3384.2020.02.001]
   YANG YY, 2020, CHIN J HOSP PHARM, V40, P864, DOI DOI 10.13286/j.1001-5213.2020.08.05
   Yi Z. M., 2020, CHIN PHARM, V31, P527, DOI [10.6039/j.issn.1001-0408.2020.05.04, DOI 10.6039/J.ISSN.1001-0408.2020.05.04]
   Yin Y. Q., 2020, CHIN PHARM, V31, P532, DOI [10.6039/j.issn.1001-0408.2020.05.05, DOI 10.6039/J.ISSN.1001-0408.2020.05.05]
   Ying Wang, 2021, Res Social Adm Pharm, V17, P1978, DOI 10.1016/j.sapharm.2020.04.001
   YUAN DD, 2020, CHIN J HOSP PHARM, V40, P869, DOI DOI 10.13286/j.1001-5213.2020.08.06
   Zeng D. Y., 2020, ADVERSE DRUG REACT J, DOI [10.3760/cma.j.issn.1008-5734.2020.0010, DOI 10.3760/CMA.J.ISSN.1008-5734.2020.0010]
   Zhang Dan, 2020, Zhongguo Zhong Yao Za Zhi, V45, P2275, DOI 10.19540/j.cnki.cjcmm.20200322.503
   [章晓茜 Zhang Xiaoqian], 2020, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V37, P536
   Zhang Y. L., 2020, CHINA PHARM, V29, P27, DOI [10.3969/j.issn.1006-4931.2020.05.006, DOI 10.3969/J.ISSN.1006-4931.2020.05.006]
   Zhang Z. H., 2020, CHIN J HOSP PHARM
   ZHANG ZH, 2020, CHIN J HOSP PHARM, V40, P721, DOI DOI 10.13286/j.1001-5213.2020.07.01
   Zhao R. S., 2020, CHIN PHARM, V31, P385, DOI [10.6039/j.issn.1001-0408.2020.04.01, DOI 10.6039/J.ISSN.1001-0408.2020.04.01]
   Zhao RS, 2020, ZHONGGUO YAO XUE ZA, V55, P268
   Zheng Si-Qian, 2021, Res Social Adm Pharm, V17, P1819, DOI 10.1016/j.sapharm.2020.03.012
   ZHOU H, 2020, HER MED, V39, P330, DOI DOI 10.3870/j.issn.1004-0781.2020.03.014
   Zhou P. X., 2020, CLIN MED J, V18, P34, DOI [10.3969/j.issn.1672-3384.2020.02.007, DOI 10.3969/J.ISSN.1672-3384.2020.02.007]
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
   [朱素燕 Zhu Suyan], 2020, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V37, P560
   Zhu Y. G., 2020, DRUG INFORM COMPILAT
   杜姗, 2020, [药物不良反应杂志, Adverse Drug Reactions Journal], V22, P147
   王婧雯, 2020, [中国药学杂志, Chinese Pharmaceutical Journal], V55, P278
NR 108
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 2
PY 2020
VL 11
AR 555753
DI 10.3389/fphar.2020.555753
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OA3IW
UT WOS:000577684500001
PM 33117160
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Artigas, L
   Coma, M
   Matos-Filipe, P
   Aguirre-Plans, J
   Farres, J
   Valls, R
   Fernandez-Fuentes, N
   de la Haba-Rodriguez, J
   Olvera, A
   Barbera, J
   Morales, R
   Oliva, B
   Mas, JM
AF Artigas, Laura
   Coma, Mireia
   Matos-Filipe, Pedro
   Aguirre-Plans, Joaquim
   Farres, Judith
   Valls, Raquel
   Fernandez-Fuentes, Narcis
   de la Haba-Rodriguez, Juan
   Olvera, Alex
   Barbera, Jose
   Morales, Rafael
   Oliva, Baldo
   Mas, Jose Manuel
TI In-silico drug repurposing study predicts the combination of pirfenidone
   and melatonin as a promising candidate therapy to reduce SARS-CoV-2
   infection progression and respiratory distress caused by cytokine storm
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; GAMMA-LINOLENIC ACID; EICOSAPENTAENOIC ACID;
   NLRP3 INFLAMMASOME; ANTIOXIDANT STATUS; FURIN; PRECURSOR; PROTEIN;
   EXPRESSION; PHENOTYPE
AB From January 2020, COVID-19 is spreading around the world producing serious respiratory symptoms in infected patients that in some cases can be complicated by the severe acute respiratory syndrome, sepsis and septic shock, multiorgan failure, including acute kidney injury and cardiac injury. Cost and time efficient approaches to reduce the burthen of the disease are needed. To find potential COVID-19 treatments among the whole arsenal of existing drugs, we combined system biology and artificial intelligence-based approaches. The drug combination of pirfenidone and melatonin has been identified as a candidate treatment that may contribute to reduce the virus infection. Starting from different drug targets the effect of the drugs converges on human proteins with a known role in SARS-CoV-2 infection cycle. Simultaneously, GUILDify v2.0 web server has been used as an alternative method to corroborate the effect of pirfenidone and melatonin against the infection of SARS-CoV-2. We have also predicted a potential therapeutic effect of the drug combination over the respiratory associated pathology, thus tackling at the same time two important issues in COVID-19. These evidences, together with the fact that from a medical point of view both drugs are considered safe and can be combined with the current standard of care treatments for COVID-19 makes this combination very attractive for treating patients at stage II, non-severe symptomatic patients with the presence of virus and those patients who are at risk of developing severe pulmonary complications.
C1 [Artigas, Laura; Coma, Mireia; Matos-Filipe, Pedro; Farres, Judith; Valls, Raquel; Mas, Jose Manuel] Anax Biotech, Barcelona, Spain.
   [Matos-Filipe, Pedro; Aguirre-Plans, Joaquim; Oliva, Baldo] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Res Programme Biomed Informat, Struct Bioinformat Grp, Barcelona, Catalonia, Spain.
   [Fernandez-Fuentes, Narcis] Univ Cent Catalunya, Univ Vic, U Sci Tech, Dept Biosci, Vic, Catalonia, Spain.
   [de la Haba-Rodriguez, Juan] Univ Cordoba, Reina Sofia Hosp, Maimonides Biomed Res Inst, Cordoba, Spain.
   [Olvera, Alex] Hosp Univ Germans Trias i Pujol, Inst Recerca Sida IrsiCaixa, Badalona, Barcelona, Spain.
   [Barbera, Jose; Morales, Rafael] La Mancha Ctr Hosp, Serv Med Interna, Unidad Infecciosas, Alcazar De San Juan, Spain.
RP Coma, M (corresponding author), Anax Biotech, Barcelona, Spain.; Oliva, B (corresponding author), Univ Pompeu Fabra, Dept Expt & Hlth Sci, Res Programme Biomed Informat, Struct Bioinformat Grp, Barcelona, Catalonia, Spain.
EM mcoma@anaxomics.com; baldo.oliva@upf.edu
RI Aguirre-Plans, Joaquim/K-4089-2017
OI Aguirre-Plans, Joaquim/0000-0002-1971-1350
FU Spanish Ministry of Economy (MINECO) [BIO2017-85329-R, RYC2015-17519];
   Unidad de Excelencia Maria de Maeztu - Spanish Ministry of Economy
   [MDM-2014-0370]; European Union's Horizon 2020 research and innovation
   programme under the Marie Sklodowska-Curie grantEuropean Union (EU)
   [765912]
FX LA, MC, PMF, JF, RV and JMM have commercial affiliation to Anaxomics
   Biotech SL. The funders provided support in the form of salaries for
   authors JAP, NFF and PMF, but did not have any additional role in the
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. The specific roles of these authors are
   articulated in the `author contributions' section. JAP, NFF and BO
   acknowledge support from the Spanish Ministry of Economy (MINECO)
   [BIO2017-85329-R] [RYC2015-17519]; Unidad de Excelencia Maria de
   Maeztu", funded by the Spanish Ministry of Economy [ref:
   MDM-2014-0370].PMF has received funding from the European Union's
   Horizon 2020 research and innovation programme under the Marie
   Sklodowska-Curie grant agreement No 765912.
CR Acellera, 2020, MEL POT COMP SARS CO
   Aguirre-Plans J, 2019, J MOL BIOL, V431, P2477, DOI 10.1016/j.jmb.2019.02.027
   Aguirre-Plans J, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11030061
   Alvarez-Garcia V, 2013, J PINEAL RES, V54, P373, DOI 10.1111/jpi.12007
   Barrett T, 2011, NUCLEIC ACIDS RES, V39, pD1005, DOI 10.1093/nar/gkq1184
   Blanco-Melo D., 2020, BIORXIV, DOI [10.1101/2020.03.24.004655, DOI 10.1101/2020.03.24.004655]
   Braun E, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1073
   Brown KV, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r95
   Burnham EL, 2014, EUR RESPIR J, V43, P276, DOI 10.1183/09031936.00196412
   Centers for Disease Control and Prevention (CDC), 2020, SYMPT COR DIS 2019 C
   Chen J, 2007, ANNU REV IMMUNOL, V25, P443, DOI 10.1146/annurev.immunol.25.022106.141706
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Cheng J, 2019, INT J MOL MED, V43, P945, DOI 10.3892/ijmm.2018.4021
   Constam DB, 2014, SEMIN CELL DEV BIOL, V32, P85, DOI 10.1016/j.semcdb.2014.01.008
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Dai M, 2008, J PINEAL RES, V44, P121, DOI 10.1111/j.1600-079X.2007.00498.x
   Dubois CM, 2001, AM J PATHOL, V158, P305, DOI 10.1016/S0002-9440(10)63970-3
   DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618
   Eric, 2020, MATLAB CENTRAL FILE
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fois AG, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/2639081
   Gadek JE, 1999, CRIT CARE MED, V27, P1409, DOI 10.1097/00003246-199908000-00001
   George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3
   Gomez-Florit M, 2016, SCI REP-UK, V6, DOI 10.1038/srep22444
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guney E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043557
   Gysi DM, 2020, NETWORK MED FRAMEWOR
   He X, 2013, EUR RESPIR J, P42, DOI [10.1183/09031936.00058912, DOI 10.1183/09031936.00058912]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang SH, 2019, J FUNCT FOODS, V58, P189, DOI 10.1016/j.jff.2019.04.062
   Huang XF, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/1264913
   Iborra-Egea Oriol, 2019, JACC Basic Transl Sci, V4, P831, DOI 10.1016/j.jacbts.2019.07.010
   Iborra-Egea O, 2017, NPJ SYST BIOL APPL, V3, DOI 10.1038/s41540-017-0013-4
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Iyer SN, 2000, INFLAMMATION, V24, P477, DOI 10.1023/A:1007068313370
   Jassal B, 2020, NUCLEIC ACIDS RES, V48, pD498, DOI 10.1093/nar/gkz1031
   Jorba G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228926
   Juss JK, 2016, AM J RESP CRIT CARE, V194, P961, DOI 10.1164/rccm.201509-1818OC
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Kiefer T, 2002, BREAST CANCER RES TR, V71, P37, DOI 10.1023/A:1013301408464
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   Klenk H D, 1988, Adv Virus Res, V34, P247, DOI 10.1016/S0065-3527(08)60520-5
   Kuchipudi SV, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/272359
   Lau WWI, 2012, J PINEAL RES, V52, P477, DOI 10.1111/j.1600-079X.2011.00965.x
   Lesur I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011485
   Li QS, 2006, ADV EXP MED BIOL, V581, P121
   Li Y, 2018, MOL IMMUNOL, V99, P134, DOI 10.1016/j.molimm.2018.05.003
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   Liu X., 2020, POTENTIAL INHIBITORS, DOI [10.1101/2020.01.29.924100, DOI 10.1101/2020.01.29.924100]
   Liu ZJ, 2019, CNS NEUROSCI THER, V25, P1353, DOI 10.1111/cns.13261
   Loren V, 2019, J CROHNS COLITIS, V13, P351, DOI 10.1093/ecco-jcc/jjy171
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   Mateos-Toledo H, 2020, ARCH BRONCONEUMOL, V56, P163, DOI 10.1016/j.arbres.2019.08.019
   Metnitz PGH, 1999, INTENS CARE MED, V25, P180, DOI 10.1007/s001340050813
   Morrell ED, 2018, AM J RESP CRIT CARE, V197, P528, DOI 10.1164/rccm.201703-0614LE
   Mueller MD, 2000, P NATL ACAD SCI USA, V97, P10972, DOI 10.1073/pnas.200377097
   Nagai Y, 1989, Prog Vet Microbiol Immunol, V5, P16
   Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625
   NCBI Resource Coordinators, 2018, NUCLEIC ACIDS RES, V46, pD8
   Orchard S, 2014, NUCLEIC ACIDS RES, V42, pD358, DOI 10.1093/nar/gkt1115
   Oughtred R, 2019, NUCLEIC ACIDS RES, V47, pD529, DOI 10.1093/nar/gky1079
   Pacht ER, 2003, CRIT CARE MED, V31, P491, DOI 10.1097/01.CCM.0000049952.96496.3E
   Peng ZY, 2018, INT IMMUNOPHARMACOL, V62, P23, DOI 10.1016/j.intimp.2018.06.033
   Perera S., 2014, NUTRAfoods, V13, P61
   Perfetto L, 2020, bioRxiv, DOI 10.1101/2020.06.16.153817
   Pesu M, 2006, BLOOD, V108, P983, DOI 10.1182/blood-2005-09-3824
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Pujol A, 2010, TRENDS PHARMACOL SCI, V31, P115, DOI 10.1016/j.tips.2009.11.006
   Reiter RJ, 2003, ACTA BIOCHIM POL, V50, P1129
   Reiter RJ, 2016, J PINEAL RES, V61, P253, DOI 10.1111/jpi.12360
   Rizzo P, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0791-5
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rodella LF, 2010, J PINEAL RES, V48, P126, DOI 10.1111/j.1600-079X.2009.00735.x
   Romeo-Guitart D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19767-3
   Salazar-Montes A, 2008, EUR J PHARMACOL, V595, P69, DOI 10.1016/j.ejphar.2008.06.110
   Schaefer CJ, 2011, EUR RESPIR REV, V20, P85, DOI 10.1183/09059180.00001111
   Schmidt R, 2004, EUR RESPIR J, V24, P994, DOI 10.1183/09031936.04.00120703
   Shen S, 2020, REUTERS
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shin NR, 2017, ONCOTARGET, V8, P95692
   Silvestri M, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-61
   SK AZ, 2016, DIABETOLOGIE STOFFWE, V11, pS01
   Tarocco A, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1556-7
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Villalba A, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00258
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang K, 2020, SARS COV 2 INVADES H, V3, P14, DOI DOI 10.1101/2020.03.14.988345
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Yakala GK, 2019, ARTERIOSCL THROM VAS, V39, P387, DOI 10.1161/ATVBAHA.118.311903
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Ying SB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075695
   Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   2020, WRIT APP ANTH, P1, DOI DOI 10.1038/D41586-020-01295-8
   2016, CANC DISCOV, V6
NR 97
TC 0
Z9 0
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 2
PY 2020
VL 15
IS 10
AR e0240149
DI 10.1371/journal.pone.0240149
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NZ4YX
UT WOS:000577103500069
PM 33006999
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Klimczak, LJ
   Randall, TA
   Saini, N
   Li, JL
   Gordenin, DA
AF Klimczak, Leszek J.
   Randall, Thomas A.
   Saini, Natalie
   Li, Jian-Liang
   Gordenin, Dmitry A.
TI Similarity between mutation spectra in hypermutated genomes of rubella
   virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic
SO PLOS ONE
LA English
DT Article
ID REPLICATION; DEAMINATION; MUTAGENESIS
AB Genomes of tens of thousands of SARS-CoV2 isolates have been sequenced across the world and the total number of changes (predominantly single base substitutions) in these isolates exceeds ten thousand. We compared the mutational spectrum in the new SARS-CoV-2 mutation dataset with the previously published mutation spectrum in hypermutated genomes of rubella-another positive single stranded (ss) RNA virus. Each of the rubella virus isolates arose by accumulation of hundreds of mutations during propagation in a single subject, while SARS-CoV-2 mutation spectrum represents a collection events in multiple virus isolates from individuals across the world. We found a clear similarity between the spectra of single base substitutions in rubella and in SARS-CoV-2, with C to U as well as A to G and U to C being the most prominent in plus strand genomic RNA of each virus. Of those, U to C changes universally showed preference for loops versus stems in predicted RNA secondary structure. Similarly, to what was previously reported for rubella virus, C to U changes showed enrichment in the uCn motif, which suggested a subclass of APOBEC cytidine deaminase being a source of these substitutions. We also found enrichment of several other trinucleotide-centered mutation motifs only in SARS-CoV-2-likely indicative of a mutation process characteristic to this virus. Altogether, the results of this analysis suggest that the mutation mechanisms that lead to hypermutation of the rubella vaccine virus in a rare pathological condition may also operate in the background of the SARS-CoV-2 viruses currently propagating in the human population.
C1 [Klimczak, Leszek J.; Randall, Thomas A.; Li, Jian-Liang] NIEHS, Integrat Bioinformat Support Grp, NIH, Durham, NC USA.
   [Saini, Natalie; Gordenin, Dmitry A.] NIEHS, Mech Genome Dynam Grp, NIH, Durham, NC 27709 USA.
RP Gordenin, DA (corresponding author), NIEHS, Mech Genome Dynam Grp, NIH, Durham, NC 27709 USA.
EM gordenin@niehs.nih.gov
RI ; Gordenin, Dmitry/C-3907-2018
OI Li, Jian-Liang/0000-0002-6487-081X; Randall, Thomas/0000-0002-4605-7606;
   Gordenin, Dmitry/0000-0002-8399-1836
FU US National Institute of Health Intramural Research ProgramUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [Z1AES103266]
FX This work was supported by the US National Institute of Health
   Intramural Research Program Project Z1AES103266 to D.A.G.
CR Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3
   Alsoe L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07314-5
   [Anonymous], 2004, ITAL HEART J S3, V5, p49S
   Barbieri I, 2020, NAT REV CANCER, V20, P303, DOI 10.1038/s41568-020-0253-2
   Behringer MG, 2016, G3-GENES GENOM GENET, V6, P149, DOI 10.1534/g3.115.022129
   Blango MG, 2016, GENOME RES, V26, P852, DOI 10.1101/gr.203992.116
   Boo SH, 2020, EXP MOL MED, V52, P400, DOI 10.1038/s12276-020-0407-z
   Buisson R, 2019, SCIENCE, V364, P1251, DOI 10.1126/science.aaw2872
   Chan K, 2015, ANNU REV GENET, V49, P243, DOI 10.1146/annurev-genet-112414-054714
   Chan K, 2015, NAT GENET, V47, P1067, DOI 10.1038/ng.3378
   Chan K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003149
   Chiara M, 2020, COMP GENOMICS SUGGES, DOI [10.1101/2020.03.30.016790, DOI 10.1101/2020.03.30.016790]
   Conticello SG, 2012, ANN NY ACAD SCI, V1267, P79, DOI 10.1111/j.1749-6632.2012.06614.x
   Costello M, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1443
   Degtyareva NP, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000263
   Degtyareva NP, 2013, NUCLEIC ACIDS RES, V41, P8995, DOI 10.1093/nar/gkt671
   Denison MR, 2011, RNA BIOL, V8, P270, DOI 10.4161/rna.8.2.15013
   Di Giorgio S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb5813
   Domingo E, 2020, VIRUS AS POPULATIONS: COMPOSITION, COMPLEXITY, QUASISPECIES, DYNAMICS, AND BIOLOGICAL IMPLICATIONS, 2ND EDITION, P35, DOI 10.1016/B978-0-12-816331-3.00002-7
   Domingo E, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008271
   Eggington JM, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1324
   Grigoriev A, 2004, TRENDS GENET, V20, P131, DOI 10.1016/j.tig.2004.01.009
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Harris RS, 2015, VIROLOGY, V479, P131, DOI 10.1016/j.virol.2015.03.012
   Jalili P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16802-8
   Lee JY, 2000, CLIN MICROBIOL REV, V13, P571, DOI 10.1128/CMR.13.4.571-587.2000
   LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0
   LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035
   Lorenz R, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-26
   Marcais G, 2011, BIOINFORMATICS, V27, P764, DOI 10.1093/bioinformatics/btr011
   Matyasek R, 2020, GENES-BASEL, V11, DOI 10.3390/genes11070761
   Niavarani A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120089
   Nik-Zainal S, 2015, MUTAGENESIS, V30, P763, DOI 10.1093/mutage/gev073
   Paul David, 2013, World J Virol, V2, P32, DOI 10.5501/wjv.v2.i2.32
   Perelygina L, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008080
   PLOTKIN SA, 1969, AM J DIS CHILD, V118, P178, DOI 10.1001/archpedi.1969.02100040180004
   Posthuma CC, 2017, VIRUS RES, V234, P58, DOI 10.1016/j.virusres.2017.01.023
   Roberts SA, 2014, NAT REV CANCER, V14, P786, DOI 10.1038/nrc3816
   Saini N, 2020, NUCLEIC ACIDS RES, V48, P3692, DOI 10.1093/nar/gkaa150
   Saini N, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006385
   Samuel CE, 2019, J BIOL CHEM, V294, P1710, DOI 10.1074/jbc.TM118.004166
   Sanjuan R, 2010, J VIROL, V84, P9733, DOI 10.1128/JVI.00694-10
   Saraconi G, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0417-z
   Sharma S, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1651-1
   Sharma S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7881
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Simmonds P, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00408-20.
   Smith HC, 2012, SEMIN CELL DEV BIOL, V23, P258, DOI 10.1016/j.semcdb.2011.10.004
   Takakura M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13525-3
   Tulloch F, 2014, ELIFE, V3, DOI 10.7554/eLife.04531
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Wen SP, 2019, IEEE T SYST MAN CY-S, V49, P1787, DOI 10.1109/TSMC.2018.2825021
   Woo PCY, 2007, VIROLOGY, V369, P431, DOI 10.1016/j.virol.2007.08.010
   Xia XH, 2020, MOL BIOL EVOL, V37, P2699, DOI 10.1093/molbev/msaa094
NR 54
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 2
PY 2020
VL 15
IS 10
AR e0237689
DI 10.1371/journal.pone.0237689
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NZ4YX
UT WOS:000577103500061
PM 33006981
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, B
   Li, DD
   Liu, T
   Wang, HH
   Luo, FM
   Liu, YB
AF Wang, Bo
   Li, Diandian
   Liu, Tao
   Wang, Haohua
   Luo, Fengming
   Liu, Yanbin
TI Subcutaneous injection of IFN alpha-2b for COVID-19: an observational
   study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Interferon alpha-2b; Subcutaneous injection; Viral clearance; COVID-19
ID RESPIRATORY SYNDROME; RIBAVIRIN
AB BackgroundThe global pandemic of coronavirus disease 2019 (COVID-19) infection is ongoing and associated with high mortality. The aim of this study was to investigate the efficacy and safety of subcutaneous injection of interferon alpha-2b (IFN alpha-2b) combined with lopinavir/ritonavir (LPV/r) in the treatment of COVID-19 infection, compared with that of using LPV/r alone.MethodsPatients diagnosed with laboratory-confirmed COVID-19 infection in Wuhan Red Cross hospital during the period from January 23, 2020 to March 19, 2020 were included. The length of stay, the time to viral clearance and adverse reactions during hospitalization were compared between patients using oral LPV/r and combined therapy of LPV/r and subcutaneous injection of IFN alpha-2b.ResultsA total of 22 patients were treated with LPV/r alone and 19 with combined therapy with subcutaneous injection of IFN alpha-2b. The average length of hospitalization in the combination group was shorter than that of LPV/r group (169.7 vs 23 +/- 10.5days; P=0.028). Moreover, the days of hospitalization in early intervention group decreased from 25 +/- 8.5days to 10 +/- 2.9days compared with delayed intervention group (P=0.001). Combined therapy with IFN alpha-2b also significantly reduced the duration of detectable virus in the upper respiratory tract. No patient in each group was transferred to intensive care unit (ICU) or died during the treatment. There was no significant difference in the adverse effect composition between two groups.Conclusions Subcutaneous injection of IFN alpha-2b combined with LPV/r shortened the length of hospitalization and accelerated viral clearance in COVID-19 patients, which deserves further investigation in clinical practice.
C1 [Wang, Bo; Li, Diandian; Luo, Fengming] Sichuan Univ, West China Hosp, Dept Resp & Crit Care Med, Chengdu 610041, Sichuan, Peoples R China.
   [Liu, Tao] Eleventh Hosp Wuhan City, Red Cross Hosp Wuhan, Wuhan 430015, Hubei, Peoples R China.
   [Wang, Haohua] Sichuan Univ, West China Sch Med, Chengdu 610041, Peoples R China.
   [Liu, Yanbin] Sichuan Univ, West China Hosp, Ctr Infect Dis, Chengdu 610041, Sichuan, Peoples R China.
RP Liu, YB (corresponding author), Sichuan Univ, West China Hosp, Ctr Infect Dis, Chengdu 610041, Sichuan, Peoples R China.
EM dr_liuyanbin@foxmail.com
CR Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Kumari G, 2020, BIORXIV, DOI [10.1101/2020.03.07.982264, DOI 10.1101/2020.03.07.982264]
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Morra ME, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1977
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   WHO, 2020, CLIN MAN SEV AC RESP
   Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061
NR 15
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD OCT 2
PY 2020
VL 20
IS 1
AR 723
DI 10.1186/s12879-020-05425-5
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA NZ2NY
UT WOS:000576934000002
PM 33008327
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lancman, G
   Mascarenhas, J
   Bar-Natan, M
AF Lancman, Guido
   Mascarenhas, John
   Bar-Natan, Michal
TI Severe COVID-19 virus reactivation following treatment for B cell acute
   lymphoblastic leukemia
SO JOURNAL OF HEMATOLOGY & ONCOLOGY
LA English
DT Letter
DE COVID-19; SARS-CoV-2; Reactivation; Rituximab; Cytarabine
AB SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation. Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib. She was initially hospitalized with COVID-19 in April and developed a high antibody titer with two negative nasal polymerase chain reaction (PCR) swabs for SARS-CoV-2 on discharge. After recovery, she resumed treatment in June for her leukemia, which included rituximab, cytarabine, and dasatinib. She promptly lost her COVID-19 antibodies, and her nasal PCR turned positive in June. She developed a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic bilateral ground-glass opacities on chest CT, requiring high-flow nasal cannula and transfer to the intensive care unit. She received steroids, anticoagulation, and convalescent plasma, and within 48 h she was off oxygen. She was discharged home in stable condition several days later. Given the short time frame from leukemia treatment to PCR positivity and the low case rate in mid-June in New York City, reinfection appears to have been unlikely and SARS-CoV-2 reactivation is a possible explanation. This case illustrates the risks of treating recently recovered COVID-19 patients with immunosuppressive therapy, particularly lymphocyte- and antibody-depleting therapy, and raises new questions about the potential of SARS-CoV-2 reactivation.
C1 [Lancman, Guido; Mascarenhas, John; Bar-Natan, Michal] Icahn Sch Med Mt Sinai, Tisch Canc Inst, 1 Gustave Levy Pl, New York, NY 10029 USA.
RP Bar-Natan, M (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, 1 Gustave Levy Pl, New York, NY 10029 USA.
EM Michal.Bar-Natan@mssm.edu
CR Bakhtawar N, 2020, CUREUS, V12, DOI 10.7759/cureus.9535
   Huang I, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00453-4
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Ravioli S, 2020, J INFECTION, VS0163-4453, P30279
   Rousselot P, 2016, BLOOD, V128, P774, DOI 10.1182/blood-2016-02-700153
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xiao AT, 2020, J MED VIROL, V92, P1755, DOI 10.1002/jmv.25855
   Ye GM, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.001
   Yuan Jing, 2020, Clin Infect Dis, V71, P2230, DOI 10.1093/cid/ciaa398
NR 9
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-8722
J9 J HEMATOL ONCOL
JI J. Hematol. Oncol.
PD OCT 2
PY 2020
VL 13
IS 1
AR 131
DI 10.1186/s13045-020-00968-1
PG 3
WC Oncology; Hematology
SC Oncology; Hematology
GA NZ2GH
UT WOS:000576913200002
PM 33008453
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Takayama, S
   Namiki, T
   Ito, T
   Arita, R
   Nakae, H
   Kobayashi, S
   Yoshino, T
   Ishigami, T
   Tanaka, K
   Kainuma, M
   Nochioka, K
   Takagi, A
   Mimura, M
   Yamaguchi, T
   Ishii, T
AF Takayama, Shin
   Namiki, Takao
   Ito, Takashi
   Arita, Ryutaro
   Nakae, Hajime
   Kobayashi, Seiichi
   Yoshino, Tetsuhiro
   Ishigami, Tomoaki
   Tanaka, Koichiro
   Kainuma, Mosaburo
   Nochioka, Kotaro
   Takagi, Airi
   Mimura, Masaru
   Yamaguchi, Takuhiro
   Ishii, Tadashi
TI A multi-center, randomized controlled trial by the Integrative
   Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use
   of Kampo medicine, kakkonto with shosaikotokakikyosekko, in
   mild-to-moderate COVID-19 patients for symptomatic relief and prevention
   of severe stage: a structured summary of a study protocol for a
   randomized controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomized controlled trial; Protocol; Kampo medicines;
   Symptom relief; Prevention for severe stage
AB Objectives: We aimed to test our hypothesis that additional administration of traditional Japanese (Kampo) medicine, kakkonto (kakkon-to: KT) and shosaikotokakikyosekko (sho-saiko-to-ka-kikyo-sekko: SSKKS), is more effective in relieving symptoms and preventing the onset of severe infection in mild-to-moderate COVID-19 patients compared to those treated only with conventional treatment.
   Trial design: The study is designed as a multi-center, interventional, parallel-group, randomized (1:1 ratio), investigator-sponsored, two-arm study.
   Participants: Patients and inpatients will be recruited from 8 Japanese academic and non-academic hospitals. The inclusion and exclusion criteria are as follows:
   Inclusion criteria:
   1. Diagnosed as positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
   2. Clinical stages of mild-to-moderate COVID-19
   3. Symptomatic
   4. >= 20 years of age
   5. Male or female
   6. Ability to communicate in Japanese
   7. Outpatients and inpatients
   8. Provided informed consent
   Exclusion criteria:
   1.Difficulty in providing informed consent due to dementia, psychosis, or psychiatric symptoms
   2. Allergic to Kampo or Western medicines used in this study
   3. Pregnant and lactating
   4. Unable to follow up
   5. Participating in another clinical trial or interventional study
   6. Hypokalemic or taking oral furosemide or steroids
   7. Determined unsuitable for this study by the physician
   Intervention and comparator: Patients in the control group will receive conventional treatment with antipyretics, painkillers, or antitussives for symptoms that occurred after they contracted the SARS-CoV-2 infection.
   Patients in the Kampo group will receive 2.5 g of KT (TJ-1@TSUMURA and Co.) and 2.5 g of SSKKS (TJ-109@TSUMURA and Co.) 3 times a day, orally, for 14 days in addition to the conventional treatment as mentioned above.
   Main outcomes: The number of days till at least one of the symptoms (fever, cough, sputum, malaise, shortness of breath) improves in the first 14 days of treatment. To assess the cough, sputum, malaise, and shortness of breath, a numeric rating scale will be used to define improvement in terms of a 2-point decrease in the number of days from the start of treatment for at least 2 days. Fever will be defined as an improvement when the temperature is less than 37 degrees C.
   Randomization: Patients are randomized (1:1 ratio) to each group using the minimization method, with balancing of the arms with severity of disease stage and patient age (< 65, 65 to < 75, or >= 75 years). Computer-generated random numbers will be used for the minimization method.
   Blinding (masking): Open-label with no blinding
   Numbers to be randomized (sample size): The main research hypothesis of this study is that the combination of Kampo medicine and conventional treatment will significantly improve the patients' symptoms (fever, fatigue, cough, sputum, and shortness of breath) during the first 14 days of treatment as compared with conventional treatment alone. Concerning the analysis of the primary endpoint, the duration of time before improvement of at least one of the common cold-like symptoms (fever, malaise, cough, sputum, and shortness of breath) will be estimated using the Kaplan-Meier method, and the survival curves will be compared between groups using the log-rank test. Assuming this method of analysis and based on previous studies reporting the efficacy of Kampo medicine for COVID-19 and H1N1 influenza patients, the median survival time in the Kampo medicine group is estimated as 3 days; this time will be 1.5 times longer in the control group.
   Assuming a one-sided significance level of 5%, a power of 70%, and an allocation ratio of 1:1, the required sample size is calculated as 126 cases. To compensate for a loss in follow-up, we plan to include 150 cases in both groups (Kampo group = 75, control group = 75).
   Trial status: Protocol version 1.2 as of August 20, 2020
   Recruitment start (expected): October 1, 2020
   Recruitment finish (expected): October 31, 2023
   Full protocol: The full protocol is attached as an additional file and is accessible from theTrialswebsite (Additional file1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Takayama, Shin; Arita, Ryutaro; Ishii, Tadashi] Tohoku Univ Hosp, Dept Kampo Med, Aoba Ku, 1-1 Seiryomachi, Sendai, Miyagi 9808574, Japan.
   [Takayama, Shin; Arita, Ryutaro; Ishii, Tadashi] Tohoku Univ Hosp, Dept Educ & Support Reg Med, Aoba Ku, 1-1 Seiryomachi, Sendai, Miyagi 9808574, Japan.
   [Takayama, Shin; Ishii, Tadashi] Tohoku Univ, Grad Sch Med, Dept Kampo & Integrat Med, 1-2 Seiryomachi, Sendai, Miyagi 9808575, Japan.
   [Namiki, Takao] Chiba Univ, Grad Sch Med, Dept Japanese Oriental Kampo Med, 1-8-1 Inohana, Chiba 2608670, Japan.
   [Ito, Takashi] Akashi Clin Kanda, Chiyoda Ku, 3-8 Kandaogawa Machi, Tokyo 1010052, Japan.
   [Nakae, Hajime] Akita Univ, Grad Sch Med, Dept Emergency & Crit Care Med, 1-1-1 Hondo, Akita 0108543, Japan.
   [Kobayashi, Seiichi] Japanese Red Cross Ishinomaki Hosp, Dept Resp Med, Nishimichishita 71, Ishinomaki 9868522, Japan.
   [Yoshino, Tetsuhiro] Keio Univ, Sch Med, Ctr Kampo Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
   [Ishigami, Tomoaki] Yokohama City Univ Med, Dept Cardiol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.
   [Tanaka, Koichiro] Toho Univ, Fac Med, Dept Tradit Med, Ota Ku, 6-11-1 Omori Nishi, Tokyo 1438541, Japan.
   [Kainuma, Mosaburo] Kyushu Univ, Grad Sch Med Sci, Commun Med Educ Unit, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
   [Nochioka, Kotaro] Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.
   [Takagi, Airi] Tohoku Univ Hosp, Clin Res Data Ctr, Aoba Ku, 1-1 Seiryomachi, Sendai, Miyagi 9808574, Japan.
   [Mimura, Masaru] Keio Univ, Sch Med, Dept Neuropsychiat, 35 Shinanomachi, Tokyo 1608582, Japan.
   [Yamaguchi, Takuhiro] Tohoku Univ, Grad Sch Med, Div Biostat, 1-1 Seiryomachi, Sendai, Miyagi 9808574, Japan.
RP Takayama, S (corresponding author), Tohoku Univ Hosp, Dept Kampo Med, Aoba Ku, 1-1 Seiryomachi, Sendai, Miyagi 9808574, Japan.; Takayama, S (corresponding author), Tohoku Univ Hosp, Dept Educ & Support Reg Med, Aoba Ku, 1-1 Seiryomachi, Sendai, Miyagi 9808574, Japan.
EM takayama@med.tohoku.ac.jp
OI Takayama, Shin/0000-0002-6388-4566
FU TSUMURA and Co., Tokyo, Japan
FX This study was supported by a research grant from TSUMURA and Co.,
   Tokyo, Japan. The funding body had no role in the design of the study
   and collection, analysis, and interpretation of data and in writing the
   manuscript.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 2
PY 2020
VL 21
IS 1
AR 827
DI 10.1186/s13063-020-04746-9
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NZ2NS
UT WOS:000576933400003
PM 33008479
OA DOAJ Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Hosangadi, D
   Shearer, MP
   Warmbrod, KL
   Kan, L
   Cantu, M
   Nuzzo, J
AF Hosangadi, Divya
   Shearer, Matthew P.
   Warmbrod, Kelsey Lane
   Kan, Lilly
   Cantu, Michelle
   Nuzzo, Jennifer
TI Current State of Mass Vaccination Preparedness and Operational
   Challenges in the United States,2018-2019
SO HEALTH SECURITY
LA English
DT Article
DE Vaccines; Pandemic influenza; COVID-19; Public health preparedness;
   response; Epidemic management; response; PHEP
ID MEDICAL COUNTERMEASURES; READINESS; PROGRAM; HEALTH
AB Mass vaccination is a crucial public health intervention during outbreaks or pandemics for which vaccines are available. The US government has sponsored the development of medical countermeasures, including vaccines, for public health emergencies; however, federally supported programs, including the Public Health and Emergency Preparedness program and Cities Readiness Initiative, have historically emphasized antibiotic pill dispensing over mass vaccination. While mass vaccination and pill dispensing programs share similarities, they also have fundamental differences that require dedicated preparedness efforts to address. To date, only a limited number of public assessments of local mass vaccination operational capabilities have been conducted. To fill this gap, we interviewed 37 public health and preparedness officials representing 33 jurisdictions across the United States. We aimed to characterize their existing mass vaccination operational capacities and identify challenges and lessons learned in order to support the efforts of other jurisdictions to improve mass vaccination preparedness. We found that most jurisdictions were not capable of or had not planned for rapidly vaccinating their populations within a short period of time (eg, 1 to 2 weeks). Many also noted that their focus on pill dispensing was driven largely by federal funding requirements and that preparedness efforts for mass vaccination were often self-motivated. Barriers to implementing rapid mass vaccination operations included insufficient personnel qualified to administer vaccinations, increased patient load compared to pill-dispensing modalities, logistical challenges to maintaining cold chain, and operational challenges addressing high-risk populations, including children, pregnant women, and non-English-speaking populations. Considering the expected availability of a severe acute respiratory syndrome coronavirus 2 vaccine for distribution and dispensing to the public, our findings highlight critical considerations for planning possible future mass vaccination events, including during the novel coronavirus disease 2019 pandemic.
C1 [Hosangadi, Divya; Shearer, Matthew P.; Warmbrod, Kelsey Lane; Nuzzo, Jennifer] Johns Hopkins Ctr Hlth Secur, 621 East Pratt St,Suite 210, Baltimore, MD 21202 USA.
   [Hosangadi, Divya; Shearer, Matthew P.; Warmbrod, Kelsey Lane; Nuzzo, Jennifer] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth & Engn, Baltimore, MD USA.
   [Kan, Lilly] Natl Assoc Cty & City Hlth Officials, Infect Dis & Informat, Washington, DC USA.
   [Cantu, Michelle] Natl Assoc Cty & City Hlth Officials, Infect Dis & Immunizat, Washington, DC USA.
RP Hosangadi, D (corresponding author), Johns Hopkins Ctr Hlth Secur, 621 East Pratt St,Suite 210, Baltimore, MD 21202 USA.
EM dhosang1@jhu.edu
OI Warmbrod, Lane/0000-0003-4326-7541
FU Open Philanthropy Project
FX We would like to acknowledge the funder for this study, the Open
   Philanthropy Project, and the jurisdictions that volunteered their time
   to provide insight and share their experiences. The authors declare no
   conflicts of interest.
CR Adams LM, 2019, J AM COLL HEALTH, V67, P88, DOI 10.1080/07448481.2018.1463228
   [Anonymous], CDCRFATP191901 GRANT
   Caum J, 2013, BIOSECUR BIOTERROR, V11, P262, DOI 10.1089/bsp.2013.0064
   Centers for Disease Control and Prevention (CDC) Office of Public Health Preparedness and Response, 2019, 2019 2024 PUBL HLTH
   Farberman RK, 2020, READY NOT PROTECTING
   Jarrett E., 2018, PANDEMIC INFLUENZA V
   Jones JR, 2012, DISASTER MED PUBLIC, V6, P357, DOI 10.1001/dmp.2012.68
   Lawrenz Joshua, 2013, Am J Disaster Med, V8, P287, DOI 10.5055/ajdm.2013.0136
   Nelson CD, 2010, HEALTH AFFAIR, V29, P2286, DOI 10.1377/hlthaff.2010.0189
   Palinkas LA, 2015, ADM POLICY MENT HLTH, V42, P533, DOI 10.1007/s10488-013-0528-y
   Porter D, 2011, J PUBLIC HEALTH MAN, V17, P530, DOI 10.1097/PHH.0b013e31822146eb
   Public Health Emergency, STOCKP RESP
   Rambhia KJ, 2010, BIOSECUR BIOTERROR, V8, P321, DOI 10.1089/bsp.2010.0043
   Rebmann T, 2017, HEALTH SECUR, V15, P539, DOI 10.1089/hs.2016.0125
   Rebmann T, 2015, HEALTH SECUR, V13, P96, DOI 10.1089/hs.2014.0080
   Renard PG, 2017, AM J PUBLIC HEALTH, V107, pS200, DOI 10.2105/AJPH.2017.304037
   Savitz S, 2007, MIL MED, V172, P353, DOI 10.7205/MILMED.172.4.353
   Seib K, 2014, HUM VACC IMMUNOTHER, V10, P2915, DOI 10.4161/21645515.2014.972798
   Sunshine G, 2019, HEALTH SECUR, V17, P156, DOI 10.1089/hs.2018.0126
   Taylor JL, 2005, BIOSECUR BIOTERROR, V3, P61, DOI 10.1089/bsp.2005.3.61
   US Centers for Disease Control and Prevention (CDC), 2020, INT UPD PLANN GUID A
   US Centers for Disease Control and Prevention (CDC), 2020, QUEST ANSW VACC PURC
   US Centers for Disease Control and Prevention (CDC) Office of Public Health Preparedness and Response, 2020, 2015 2016 NAT REP ME
   US Centers for Disease Control and Prevention Center for Preparedness and Response, 2020, PUBL HLTH EM PREP PH
   US Centers for Disease Control and Prevention Office of Public Health Preparedness and Response, CDCRFATP121201 US CT
   US Centers for Disease Control and Prevention Public Health Preparedness and Response for Bioterrorism, 2004, CONT GUID COOP AGR P
   US Department of Health and Human Services, 2017, PAND INFL PLAN
   US Department of Health and Human Services, HOSP PREP PROGR PUBL
   US Department of Health and Human Services US, 2020, EXPL OP WARP SPEED
NR 29
TC 0
Z9 0
U1 4
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2326-5094
EI 2326-5108
J9 HEALTH SECUR
JI Health Secur.
PD DEC 1
PY 2020
VL 18
IS 6
BP 473
EP 482
DI 10.1089/hs.2019.0146
EA OCT 2020
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA PF6BW
UT WOS:000576377600001
PM 33017195
OA Bronze
DA 2021-01-01
ER

PT J
AU Ahmed, Z
AF Ahmed, Zeeshan
TI Practicing precision medicine with intelligently integrative clinical
   and multi-omics data analysis
SO HUMAN GENOMICS
LA English
DT Article
DE Precision medicine; Clinics; Genomics; Metabolomics; Integrative
   analysis; Artificial intelligence; Machine learning
ID ARTIFICIAL-INTELLIGENCE; BIG DATA; HEALTH; SEQUENCE; RARE
AB Precision medicine aims to empower clinicians to predict the most appropriate course of action for patients with complex diseases like cancer, diabetes, cardiomyopathy, and COVID-19. With a progressive interpretation of the clinical, molecular, and genomic factors at play in diseases, more effective and personalized medical treatments are anticipated for many disorders. Understanding patient's metabolomics and genetic make-up in conjunction with clinical data will significantly lead to determining predisposition, diagnostic, prognostic, and predictive biomarkers and paths ultimately providing optimal and personalized care for diverse, and targeted chronic and acute diseases. In clinical settings, we need to timely model clinical and multi-omits data to find statistical patterns across millions of features to identify underlying biologic pathways, modifiable risk factors, and actionable information that support early detection and prevention of complex disorders, and development of new therapies for better patient care. It is important to calculate quantitative phenotype measurements, evaluate variants in unique genes and interpret using ACMG guidelines, find frequency of pathogenic and likely pathogenic variants without disease indicators, and observe autosomal recessive carriers with a phenotype manifestation in metabolome. Next, ensuring security to reconcile noise, we need to build and train machine-learning prognostic models to meaningfully process multisource heterogeneous data to identify high-risk rare variants and make medically relevant predictions. The goal, today, is to facilitate implementation of mainstream precision medicine to improve the traditional symptom-driven practice of medicine, and allow earlier interventions using predictive diagnostics and tailoring better-personalized treatments. We strongly recommend automated implementation of cutting-edge technologies, utilizing machine learning (ML) and artificial intelligence (AI) approaches for the multimodal data aggregation, multifactor examination, development of knowledgebase of clinical predictors for decision support, and best strategies for dealing with relevant ethical issues.
C1 [Ahmed, Zeeshan] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, 112 Paterson St, New Brunswick, NJ 08903 USA.
   [Ahmed, Zeeshan] Rutgers Biomed & Hlth Sci, Robert Wood Johnson Med Sch, Dept Med, 125 Paterson St, New Brunswick, NJ 08903 USA.
RP Ahmed, Z (corresponding author), Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, 112 Paterson St, New Brunswick, NJ 08903 USA.; Ahmed, Z (corresponding author), Rutgers Biomed & Hlth Sci, Robert Wood Johnson Med Sch, Dept Med, 125 Paterson St, New Brunswick, NJ 08903 USA.
EM zahmed@ifh.rutgers.edu
OI Ahmed, Zeeshan/0000-0002-7065-1699
FU Institute for Health, Health Care Policy and Aging Research; Robert Wood
   Johnson Medical School, at Rutgers, The State University of New Jersey
FX This work was supported by the Institute for Health, Health Care Policy
   and Aging Research, and Robert Wood Johnson Medical School, at Rutgers,
   The State University of New Jersey.
CR Ahmed Z, 2020, CLIN TRANSL MED, V2020, P1
   Ahmed Z, 2020, BMJ INNOV, DOI [10.1136/bmjinnov-2020-000444, DOI 10.1136/BMJINNOV-2020-000444]
   Ahmed Z, 2020, DATABASE-OXFORD, DOI 10.1093/database/baaa010
   Ahmed Zeeshan, 2019, JAMIA Open, V2, P23, DOI 10.1093/jamiaopen/ooy052
   Ahmed Z, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0243-8
   Ahmed Zeeshan, 2014, Database (Oxford), V2014, DOI 10.1093/database/bau077
   Ahmed Z, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-218
   Alipanahi B, 2015, NAT BIOTECHNOL, V33, P831, DOI 10.1038/nbt.3300
   Bakris G, 2018, NEW ENGL J MED, V378, P497, DOI 10.1056/NEJMp1716193
   Bali J, 2019, INDIAN J OPHTHALMOL, V67, P3, DOI 10.4103/ijo.IJO_1292_18
   Beltran H, 2015, JAMA ONCOL, V1, P466, DOI 10.1001/jamaoncol.2015.1313
   Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038
   Bradford W, 2014, J AM MED INFORM ASSN, V21, P185, DOI 10.1136/amiajnl-2013-001769
   Buch VH, 2018, BRIT J GEN PRACT, V68, P143, DOI 10.3399/bjgp18X695213
   Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523
   Dandekar T, 2014, BRIEF BIOINFORM, V15, P91, DOI 10.1093/bib/bbs065
   Esteva A, 2019, NAT MED, V25, P24, DOI 10.1038/s41591-018-0316-z
   Feero WG, 2014, JAMA-J AM MED ASSOC, V311, P1017, DOI 10.1001/jama.2014.1718
   Guo LN, 2015, P NATL ACAD SCI USA, V112, pE4901, DOI 10.1073/pnas.1508425112
   Hou YCC, 2020, P NATL ACAD SCI USA, V117, P3053, DOI 10.1073/pnas.1909378117
   Karczewski KJ, 2018, NAT REV GENET, V19, P299, DOI 10.1038/nrg.2018.4
   Katsanis N, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1107-9
   Kelly CJ, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1426-2
   Khoury MJ, 2016, AM J PREV MED, V50, P398, DOI 10.1016/j.amepre.2015.08.031
   Khoury MJ, 2014, SCIENCE, V346, P1054, DOI 10.1126/science.aaa2709
   Lazaridis KN, 2014, AM J MED GENET C, V166, P15, DOI 10.1002/ajmg.c.31387
   Lee SI, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02465-5
   Long T, 2017, NAT GENET, V49, P568, DOI 10.1038/ng.3809
   Luo Y, 2017, J CARDIOVASC TRANSL, V10, P305, DOI 10.1007/s12265-016-9727-8
   Manrai AK, 2016, JAMA-J AM MED ASSOC, V315, P1233, DOI 10.1001/jama.2016.1519
   Marouli E, 2017, NATURE, V542, P186, DOI 10.1038/nature21039
   Norgeot B, 2019, NAT MED, V25, P14, DOI 10.1038/s41591-018-0320-3
   Perkins BA, 2018, P NATL ACAD SCI USA, V115, P3686, DOI 10.1073/pnas.1706096114
   Rajkomar A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0029-1
   Sboner A, 2016, BRIEF BIOINFORM, V17, P145, DOI 10.1093/bib/bbv032
   Schussler-Fiorenza R. S. M., 2019, NAT MED, V25, P792
   Shah P, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0148-3
   Shieh Y, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw290
   Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136
   Tonn MK, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0347-0
   van Panhuis WG, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1144
   Venter JC, 2015, CLIN CHEM, V61, P1207, DOI 10.1373/clinchem.2014.237016
   Zeeshan S, 2020, BRIEF BIOINFORM, V21, P885, DOI 10.1093/bib/bbz038
NR 43
TC 0
Z9 0
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1473-9542
EI 1479-7364
J9 HUM GENOMICS
JI Hum. Genomics
PD OCT 2
PY 2020
VL 14
IS 1
AR 35
DI 10.1186/s40246-020-00287-z
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA NZ2HJ
UT WOS:000576916100001
PM 33008459
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kipshidze, N
   Yeo, NI
   Kipshidze, N
AF Kipshidze, Nicholas
   Yeo, Nicholas
   Kipshidze, Nodar
TI Photodynamic therapy for COVID-19
SO NATURE PHOTONICS
LA English
DT Letter
C1 [Kipshidze, Nicholas; Yeo, Nicholas] NY Cardiovasc Res LLC, New York, NY 10019 USA.
   [Yeo, Nicholas] Veryan Med Ltd, Horsham, W Sussex, England.
   [Kipshidze, Nodar] NYU Langone Hlth, New York, NY USA.
RP Kipshidze, N (corresponding author), NY Cardiovasc Res LLC, New York, NY 10019 USA.
EM nicholas02@msn.com
OI Kipshidze, Nodar/0000-0003-1748-6679
CR Caputo ND, 2020, ACAD EMERG MED, V27, P375, DOI 10.1111/acem.13994
   Dondorp AM, 2020, AM J TROP MED HYG, V102, P1191, DOI 10.4269/ajtmh.20-0283
   Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2021436, DOI 10.1056/NEJM0A2021436]
   Kharkwal GB, 2011, LASER SURG MED, V43, P755, DOI 10.1002/lsm.21080
   Majiya H, 2018, J PHOTOCH PHOTOBIO B, V189, P87, DOI 10.1016/j.jphotobiol.2018.10.009
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x
   Read R. J, 2020, PREPRINT, DOI [10.26434/chemrxiv.12120912.v1, DOI 10.26434/CHEMRXIV.12120912.V1]
   Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wenzhong L, 2019, PREPRINT, DOI [10.26434/chemrxiv.11938173.v9, DOI 10.26434/CHEMRXIV.11938173.V9]
   Wiehe A, 2019, PHOTOCH PHOTOBIO SCI, V18, P2565, DOI 10.1039/c9pp00211a
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
NR 13
TC 0
Z9 0
U1 8
U2 8
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1749-4885
EI 1749-4893
J9 NAT PHOTONICS
JI Nat. Photonics
PD NOV
PY 2020
VL 14
IS 11
BP 651
EP 652
DI 10.1038/s41566-020-00703-9
EA OCT 2020
PG 2
WC Optics; Physics, Applied
SC Optics; Physics
GA OH5TA
UT WOS:000574744700001
OA Bronze
DA 2021-01-01
ER

PT J
AU Ece, I
   Kocoglu, M
   Kavurt, AV
   Bagrul, D
   Gul, AEK
   Koca, S
   Cetin, II
   Parlakay, ANO
   Aksoy, S
AF Ece, Ibrahim
   Kocoglu, Mucahit
   Kavurt, Ahmet Vedat
   Bagrul, Denizhan
   Gul, A. Esin Kibar
   Koca, Serhat
   cetin, Ibrahim Ilker
   Parlakay, A. Nur ozkaya
   Aksoy, Sevcan
TI Assessment of Cardiac Arrhythmic Risk in Children With Covid-19
   Infection
SO PEDIATRIC CARDIOLOGY
LA English
DT Article; Early Access
DE COVID-19; Myocardial damage; Arrhythmia; Cardiovascular system
ID QT; DISPERSION; ELECTROCARDIOGRAM; CHLOROQUINE; INTERVAL; ECG
AB Coronavirus disease of 2019 (COVID-19) is a cause of significant morbidity and mortality worldwide. Although COVID-19 clinical manifestations are mainly respiratory, major cardiac complications are being reported. The mechanism of cardiac injury and arrhythmias is unclear. Also, drugs currently used to treat the COVID-19 may prolong the QT interval and may have a proarrhythmic propensity. The study aims to investigate the effects of COVID-19 infection with asymptomatic and mild symptoms on trans-myocardial repolarization parameters in children without treatment. A total of 105 COVID-19 patients were compared with 40 healthy children. The patient and control group data were compared by calculating the QT interval, corrected QT (QTc), QT dispersion (QTd), QTc dispersion (QTcd), Tp-e, Tp-e dispersion, Tp-e/QT ratio, and Tp-e/QTc ratio on the 12-lead surface electrocardiogram. The mean age was determined as 11.2 +/- 0.3 years in the patient group, and 10.8 +/- 2.1 years in the control group. In the COVID-19 group, QTd, QTcd, Tp-e, Tp-e dispersion, Tp-e/QT ratio and Tp-e/QTc ratio were statistically higher than the control group. The ventricular repolarization was impaired even in asymptomatic children with COVID-19 infection. These results suggest the need to further assess the long terms risks of prolonged QT dispersion in the setting of COVID-19 infection.
C1 [Ece, Ibrahim; Kocoglu, Mucahit; Kavurt, Ahmet Vedat; Bagrul, Denizhan; Gul, A. Esin Kibar; Koca, Serhat] Univ Hlth Sci, Ankara City Hosp, Dept Pediat Cardiol, Fac Med, Ankara, Turkey.
   [cetin, Ibrahim Ilker] Univ Yildirim Beyazit, Ankara City Hosp, Dept Pediat Cardiol, Fac Med, Ankara, Turkey.
   [Parlakay, A. Nur ozkaya] Univ Yildirim Beyazit, Ankara City Hosp, Dept Pediat Infect, Fac Med, Ankara, Turkey.
   [Aksoy, Sevcan] Univ Hlth Sci, Ankara City Hosp, Dept Pediat, Fac Med, Ankara, Turkey.
RP Ece, I (corresponding author), Univ Hlth Sci, Ankara City Hosp, Dept Pediat Cardiol, Fac Med, Ankara, Turkey.
EM dribrahimece@gmail.com
CR Akin A, 2018, PACE, V41, P372, DOI 10.1111/pace.13286
   Bazett HC, 1920, J PHYSIOL-LONDON, V53, P320, DOI 10.1113/jphysiol.1920.sp001881
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   FAUCHIER JP, 1993, ARCH MAL COEUR VAISS, V86, P757
   GOLDNER B, 1995, AM J CARDIOL, V76, P1192, DOI 10.1016/S0002-9149(99)80337-3
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Gupta P, 2008, J ELECTROCARDIOL, V41, P567, DOI 10.1016/j.jelectrocard.2008.07.016
   Hevia JC, 2006, J AM COLL CARDIOL, V47, P1828, DOI 10.1016/j.jacc.2005.12.049
   Hlaing T, 2005, J ELECTROCARDIOL, V38, P154, DOI 10.1016/j.jelectrocard.2005.06.028
   Hu Hongde, 2020, Eur Heart J, DOI 10.1093/eurheartj/ehaa190
   Hui H, 2020, CLIN RADIOGRAPHIC FE, DOI [10.1101/2020.02.24.20027052, DOI 10.1101/2020.02.24.20027052]
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   MACFARLANE PW, 1994, J ELECTROCARDIOL, V27, P14, DOI 10.1016/S0022-0736(94)80039-1
   Macfarlane PW, 1998, CIRCULATION, V98, P2160, DOI 10.1161/01.CIR.98.20.2160
   Malik M, 2000, J AM COLL CARDIOL, V36, P1749, DOI 10.1016/S0735-1097(00)00962-1
   Ozyurt A, 2017, CARDIOVASC TOXICOL, V17, P326, DOI 10.1007/s12012-016-9389-4
   SESHADRI MS, 1979, MED J AUSTRALIA, V1, P406, DOI 10.5694/j.1326-5377.1979.tb127000.x
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Siqueira-Batista R, 1998, E AFR MED J, V75, P117
   Tutar HE, 1998, HEART, V80, P77, DOI 10.1136/hrt.80.1.77
   VANDELOO A, 1994, AM J CARDIOL, V74, P1113, DOI 10.1016/0002-9149(94)90462-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu Z, 2020, AM J MED QUAL, DOI 10.1177/1062860620956623
   Zheng Y-Y, 2020, NAT REV CARDIOL
   Zhu H, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01292-3
NR 26
TC 1
Z9 1
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0172-0643
EI 1432-1971
J9 PEDIATR CARDIOL
JI Pediatr. Cardiol.
DI 10.1007/s00246-020-02474-0
EA OCT 2020
PG 5
WC Cardiac & Cardiovascular Systems; Pediatrics
SC Cardiovascular System & Cardiology; Pediatrics
GA NW0YT
UT WOS:000574735600002
PM 33006644
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Desideri, I
   Francolini, G
   Ciccone, LP
   Stocchi, G
   Salvestrini, V
   Aquilano, M
   Greto, D
   Bonomo, P
   Meattini, I
   Scotti, V
   Scoccianti, S
   Simontacchi, G
   Livi, L
AF Desideri, Isacco
   Francolini, G.
   Ciccone, L. P.
   Stocchi, G.
   Salvestrini, V
   Aquilano, M.
   Greto, D.
   Bonomo, P.
   Meattini, I
   Scotti, V
   Scoccianti, S.
   Simontacchi, G.
   Livi, L.
TI Impact of COVID-19 on patient-doctor interaction in a complex radiation
   therapy facility
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article; Early Access
DE COVID-19; Radiotherapy; QoL; Patient satisfaction
ID SATISFACTION
AB Purpose In the last months, Italy faced a COVID-19 emergency and implemented preventive measures in order to protect patients and healthcare providers from a disease outbreak. The pandemic control strategies impacted patient experience directly. Questionnaires evaluating patients reported measures (PREMs) may assess critical issues and represent a helpful tool to measure the patient perception of healthcare service. Our aim was to prospectively assess patient satisfaction about doctor-patient interaction in a high-volume radiation therapy and oncology center during the COVID-19 pandemic. Methods Cancer patients receiving either systemic and/or radiation treatment underwent a survey. Two validated questionnaires (EORTC QLQ-C30, FACIT-TS-G version 1) and 14 specific questions evaluating patients' perception of COVID-19 measures were administered. Results One hundred twenty-five patients admitted to our department from 1-30 April 2020 completed the questionnaires. The majority (66.4%) of patients were women and the most common disease was breast cancer (40%). The average Global Health Status (GHS) of EORTC QLQ-C30 was 61.67. Emotional functioning, social, and cognitive domains obtained scores of 75.48, 80.13, and 84.67, respectively. FACIT-TS-G results revealed 120 patients rated the treatments effective and 108 patients thought the side effects were the same as expected or better. Most (89.6%) rated their treatment good, very good, or excellent. Concerning COVID-19-related questions, patients reported overall very good level of information. Conclusions Despite the introduction of strict COVID-19 control measures, there was a high level of cancer outpatient satisfaction. The satisfaction levels may influence compliance, continuity of treatments, and patient-doctor communication, impacting the quality of clinical care in the next phases of the pandemic.
C1 [Desideri, Isacco; Ciccone, L. P.; Stocchi, G.; Salvestrini, V; Aquilano, M.; Meattini, I; Livi, L.] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serie, Viale Morgagni 85, I-50134 Florence, Italy.
   [Francolini, G.] Univ Florence, Radiat Oncol Unit, Florence, Italy.
   [Francolini, G.] Ist Fiorentino Cura & Assistenza, CyberKnife Ctr, Florence, Italy.
   [Francolini, G.; Greto, D.; Bonomo, P.; Meattini, I; Scotti, V; Scoccianti, S.; Simontacchi, G.] Azienda Osped Univ Careggi, Radiat Oncol Unit, Florence, Italy.
RP Desideri, I (corresponding author), Univ Florence, Dept Biomed Expt & Clin Sci Mario Serie, Viale Morgagni 85, I-50134 Florence, Italy.
EM isacco.desideri@unifi.it
RI Desideri, Isacco/K-4415-2018
OI Desideri, Isacco/0000-0002-9880-8387
FU Universita degli Studi di Firenze within the CRUI-CARE Agreement
FX Open access funding provided by Universita degli Studi di Firenze within
   the CRUI-CARE Agreement.
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Aharony L, 1993, Med Care Rev, V50, P49, DOI 10.1177/002570879305000104
   Crispo A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01571
   Francolini, IMPACT COVID 19 PATI
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Imran M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219093
   Koehler W F, 1992, Med Care Rev, V49, P455, DOI 10.1177/002570879204900404
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Peipert JD, 2014, QUAL LIFE RES, V23, P815, DOI 10.1007/s11136-013-0520-8
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P1873, DOI 10.1056/NEJMp2005492
   RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835
   Shakespeare T. P., 2007, SMJ Singapore Medical Journal, V48, P246
   Tang J I, 2005, Australas Radiol, V49, P304, DOI 10.1111/j.1440-1673.2005.01467.x
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Ware J E Jr, 1983, Eval Program Plann, V6, P291, DOI 10.1016/0149-7189(83)90009-5
   Webster Kimberly, 2003, Health Qual Life Outcomes, V1, P79, DOI 10.1186/1477-7525-1-79
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
DI 10.1007/s00520-020-05793-3
EA OCT 2020
PG 7
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA NW0ZV
UT WOS:000574738400001
PM 33006676
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Hartzell, S
   Bin, S
   Benedetti, C
   Haverly, M
   Gallon, L
   Zaza, G
   Riella, LV
   Menon, MC
   Florman, S
   Rahman, AH
   Leech, JM
   Heeger, PS
   Cravedi, P
AF Hartzell, Susan
   Bin, Sofia
   Benedetti, Claudia
   Haverly, Meredith
   Gallon, Lorenzo
   Zaza, Gianluigi
   Riella, Leonardo V.
   Menon, Madhav C.
   Florman, Sander
   Rahman, Adeeb H.
   Leech, John M.
   Heeger, Peter S.
   Cravedi, Paolo
TI Evidence of potent humoral immune activity in COVID-19-infected kidney
   transplant recipients
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE immune regulation; immunobiology; immunosuppressant - other;
   immunosuppression; immune modulation; infection and infectious agents -
   viral; kidney transplantation; nephrology; translational research;
   science
ID T-CELLS; INFECTION; SUBSETS; BLOOD
AB Whether kidney transplant recipients are capable of mounting an effective anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adaptive immune response despite chronic immunosuppression is unknown and has important implications for therapy. Herein, we analyzed peripheral blood cell surface and intracellular cytokine phenotyping by flow cytometry along with serum antibody testing in 18 kidney transplant recipients with active coronavirus disease 2019 (COVID-19) infection and 36 matched, transplanted controls without COVID-19. We observed significantly fewer total lymphocytes and fewer circulating memory CD4(+)and CD8(+)T cells in the COVID-19 subjects. We also showed fewer anergic and senescent CD8(+)T cells in COVID-19 individuals, but no differences in exhausted CD8(+)T cells, nor in any of these CD4(+)T cell subsets between groups. We also observed greater frequencies of activated B cells in the COVID-19 patients. Sixteen of 18 COVID-19 subjects tested for anti-SARS-CoV-2 serum antibodies showed positive immunoglobulin M or immunoglobulin G titers. Additional analyses showed no significant correlation among immune phenotypes and degrees of COVID-19 disease severity. Our findings indicate that immunosuppressed kidney transplant recipients admitted to the hospital with acute COVID-19 infection can mount SARS-CoV-2-reactive adaptive immune responses. The findings raise the possibility that empiric reductions in immunosuppressive therapy for all kidney transplant recipients with active COVID-19 may not be required.
C1 [Hartzell, Susan; Bin, Sofia; Benedetti, Claudia; Haverly, Meredith; Menon, Madhav C.; Heeger, Peter S.; Cravedi, Paolo] Icahn Sch Med Mt Sinai, Translat Transplant Res Ctr, Dept Med, New York, NY 10029 USA.
   [Gallon, Lorenzo] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Nephrol, Chicago, IL 60611 USA.
   [Zaza, Gianluigi] Univ Hosp Verona, Dept Med, Renal Unit, Verona, Italy.
   [Riella, Leonardo V.] Harvard Med Sch, Brigham & Womens Hosp, Transplantat Res Ctr, Renal Div, Boston, MA 02115 USA.
   [Florman, Sander] Mt Sinai Hosp, Recanati Miller Transplantat Inst, New York, NY 10029 USA.
   [Rahman, Adeeb H.; Leech, John M.] Icahn Sch Med Mt Sinai, Human Immune Monitoring Core, New York, NY 10029 USA.
RP Cravedi, P (corresponding author), Icahn Sch Med Mt Sinai, Translat Transplant Res Ctr, Dept Med, New York, NY 10029 USA.
EM paolo.cravedi@mssm.edu
OI Menon, Madhav/0000-0002-9567-4299
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01 AI132949-02]
FX National Institute of Allergy and Infectious Diseases, Grant/Award
   Number: R01 AI132949-02
CR Akiyama M, 2018, RHEUMATOLOGY, V57, P236, DOI 10.1093/rheumatology/kex171
   Baiyegunhi O, 2018, J VIROL, V92, DOI 10.1128/JVI.00659-18
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen X., 2020, RESTORATION LEUKOMON, DOI [10.1101/2020.03.03.20030437, DOI 10.1101/2020.03.03.20030437]
   Cravedi P, 2020, AM J TRANSPLANT, V20, P3140, DOI 10.1111/ajt.16185
   Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400
   Duhen T, 2012, BLOOD, V119, P4430, DOI 10.1182/blood-2011-11-392324
   Ellebedy AH, 2016, NAT IMMUNOL, V17, P1226, DOI 10.1038/ni.3533
   Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7
   Fribourg M, 2019, KIDNEY INT, V96, P436, DOI 10.1016/j.kint.2019.01.040
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Klotz U, 2007, CLIN PHARMACOKINET, V46, P645, DOI 10.2165/00003088-200746080-00002
   Li XY, 2012, BIOCHEM BIOPH RES CO, V422, P238, DOI 10.1016/j.bbrc.2012.04.133
   Liu YW, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.002
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   McElroy AK, 2015, P NATL ACAD SCI USA, V112, P4719, DOI 10.1073/pnas.1502619112
   Omrani Hamidreza, 2019, Open Access Maced J Med Sci, V7, P174, DOI 10.3889/oamjms.2018.369
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Savage HP, 2015, ANN NY ACAD SCI, V1362, P132, DOI 10.1111/nyas.12799
   Spitzer MH, 2016, CELL, V165, P780, DOI 10.1016/j.cell.2016.04.019
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Tschopp J, 2020, AM J TRANSPLANT, V20, P2876, DOI 10.1111/ajt.16062
   Wang WJ, 2020, CELL MOL IMMUNOL, V17, P650, DOI 10.1038/s41423-020-0447-2
   Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Zeiser R, 2006, BLOOD, V108, P390, DOI 10.1182/blood-2006-01-0329
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 30
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD NOV
PY 2020
VL 20
IS 11
BP 3149
EP 3161
DI 10.1111/ajt.16261
EA OCT 2020
PG 13
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OH7XN
UT WOS:000574215400001
PM 32786152
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Norman, P
   Wilding, S
   Conner, M
AF Norman, Paul
   Wilding, Sarah
   Conner, Mark
TI Reasoned action approach and compliance with recommended behaviours to
   prevent the transmission of the SARS-CoV-2 virus in the UK
SO BRITISH JOURNAL OF HEALTH PSYCHOLOGY
LA English
DT Article
DE behaviour; compliance; coronavirus; COVID-19; prevention; reasoned
   action approach; theory of planned behaviour
ID ACUTE RESPIRATORY SYNDROME; HEALTH IMPACT; PREVALENCE; INTENTIONS;
   OUTBREAK; VACCINE
AB Objectives To examine associations between demographics, people's beliefs, and compliance with behaviours recommended by the UK government to prevent the transmission of the SARS-CoV-2 virus that causes COVID-19. Design A two-wave online survey conducted one week apart during the national lockdown (April, 2020). Measures A sample of 477 UK residents completed baseline measures from the reasoned action approach (experiential attitudes, instrumental attitudes, injunctive norms, descriptive norms, capacity, autonomy, and intention) and perceived susceptibility for each of the following recommended behaviours: limiting leaving home, keeping at least 2 m away from other people when outside and when inside shops, not visiting or meeting friends or other family members, and washing hands when returning home. Self-reported compliance with each of the recommended behaviours was assessed one week later. Results Rates of full compliance with the recommended behaviours ranged from 31% (keeping at least 2 m away from other people when inside shops) to 68% (not visiting or meeting friends or other family members). Capacity was a significant predictor of compliance with each of the five recommended behaviours. Increasing age and intentions were also predictive of compliance with three of the behaviours. Conclusions Interventions to increase compliance with the recommended behaviours to prevent the transmission of the SARS-CoV-2 virus, especially those relating to social distancing, need to bolster people's intentions and perceptions of capacity. This may be achieved through media-based information campaigns as well as environmental changes to make compliance with such measures easier. Such interventions should particularly target younger adults.
C1 [Norman, Paul] Univ Sheffield, Dept Psychol, Sheffield S1 2LT, S Yorkshire, England.
   [Wilding, Sarah; Conner, Mark] Univ Leeds, Sch Psychol, Leeds, W Yorkshire, England.
RP Norman, P (corresponding author), Univ Sheffield, Dept Psychol, Sheffield S1 2LT, S Yorkshire, England.
EM p.norman@sheffield.ac.uk
OI Conner, Mark/0000-0002-6229-8143; Norman, Paul/0000-0002-5892-0470
FU University of Sheffield; University of Leeds
FX The authors acknowledge financial support from the University of
   Sheffield and the University of Leeds for participant payments.
CR Agarwal V, 2014, J AM COLL HEALTH, V62, P416, DOI 10.1080/07448481.2014.917650
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Cheng C, 2006, J APPL SOC PSYCHOL, V36, P222, DOI 10.1111/j.0021-9029.2006.00059.x
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   Conner M, 2015, PREDICTING CHANGING
   Fishbein M., 2010, PREDICTING CHANGING
   Miller JG, 2020, BRIT J HEALTH PSYCH, V25, P856, DOI 10.1111/bjhp.12426
   GOV.UK, 2020, POT IMP BEH SOC INT
   GOV.UK, 2020, COR COVID 19
   Lee M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17092977
   Leung GM, 2003, J EPIDEMIOL COMMUN H, V57, P857, DOI 10.1136/jech.57.11.857
   Liao QY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017713
   McEachan R, 2016, ANN BEHAV MED, V50, P592, DOI 10.1007/s12160-016-9798-4
   Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10
   Milne S, 2000, J APPL SOC PSYCHOL, V30, P106, DOI 10.1111/j.1559-1816.2000.tb02308.x
   Office of National Statistics, 2020, DEATHS REG WEEKL ENG
   Orbell S, 2017, HEALTH PSYCHOL, V36, P1161, DOI 10.1037/hea0000525
   Rhodes RE, 2017, PSYCHOL HEALTH, V32, P942, DOI 10.1080/08870446.2017.1325486
   Sarma EA, 2019, PSYCHOL HEALTH, V34, P1036, DOI 10.1080/08870446.2019.1584673
   Schwarzer R, 2015, PREDICTING HLTH BEHA, P252
   Tang CSK, 2003, AM J PUBLIC HEALTH, V93, P1887, DOI 10.2105/AJPH.93.11.1887
   West R, 2017, PSYCHOL HEALTH, V32, P1018, DOI 10.1080/08870446.2017.1325890
   WHO, 2020, COR DIS COVID 19 SIT
   Yang ZJ, 2015, J HEALTH COMMUN, V20, P69, DOI 10.1080/10810730.2014.904023
   Zhang XJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010197
NR 25
TC 1
Z9 1
U1 9
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1359-107X
EI 2044-8287
J9 BRIT J HEALTH PSYCH
JI Br. J. Health Psychol.
PD NOV
PY 2020
VL 25
IS 4
BP 1006
EP 1019
DI 10.1111/bjhp.12474
EA OCT 2020
PG 14
WC Psychology, Clinical
SC Psychology
GA OJ3NA
UT WOS:000574219600001
PM 33007143
OA Green Accepted, Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Worley, CB
   LoSavio, ST
   Aajmain, S
   Rosen, C
   Stirman, SW
   Sloan, DM
AF Worley, Courtney B.
   LoSavio, Stefanie T.
   Aajmain, Syed
   Rosen, Craig
   Stirman, Shannon Wiltsey
   Sloan, Denise M.
TI Training During a Pandemic: Successes, Challenges, and Practical
   Guidance From a Virtual Facilitated Learning Collaborative Training
   Program for Written Exposure Therapy
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID EVIDENCE-BASED-PSYCHOTHERAPIES; IMPLEMENTATION; HEALTH; DISSEMINATION;
   SETTINGS; MODEL; PTSD
AB In response to COVID-19, continued workforce training is essential to ensure that evidence-based treatments are available on the frontline to meet communities' ongoing and emerging mental health needs. However, training during a pandemic imposes many new challenges. This paper describes a multisite training and implementation pilot program, facets of which allowed for continued training despite the onset of the COVID-19 pandemic and subsequent social distancing guidelines. This virtual facilitated learning collaborative in Written Exposure Therapy, an evidence-based treatment for posttraumatic stress disorder, included virtual workshop training, phone-based clinical consultation, implementation-focused video calls for program leadership, and program evaluation. Data are presented about program enrollees and patient impact following the onset of COVID-19-related social distancing restrictions. Challenges, successes, and practical guidance are discussed to inform the field regarding training strategies likely to be durable in an uncertain, dynamic healthcare landscape.
C1 [Worley, Courtney B.; LoSavio, Stefanie T.; Aajmain, Syed; Rosen, Craig; Stirman, Shannon Wiltsey] Natl Ctr PTSD, Disseminat & Training Div, Palo Alto, CA USA.
   [Worley, Courtney B.] Cent Alabama Vet Hlth Care Syst, Montgomery, AL USA.
   [Worley, Courtney B.] Alabama Res Inst Aging, Tuscaloosa, AL USA.
   [LoSavio, Stefanie T.] Duke Univ, Med Ctr, Durham, NC USA.
   [Aajmain, Syed; Rosen, Craig; Stirman, Shannon Wiltsey] Stanford Univ, Stanford, CA 94305 USA.
   [Sloan, Denise M.] Natl Ctr PTSD, Behav Sci Div, VA Boston Healthcare Syst, Palo Alto, CA USA.
   [Sloan, Denise M.] Boston Univ, Sch Med, Boston, MA 02215 USA.
RP Worley, CB (corresponding author), CAVHCS, 215 Perry Hill Rd, Montgomery, AL 36109 USA.
EM cbworley@crimson.ua.edu
RI Worley, Courtney/J-2911-2019
CR Bauer Mark S, 2015, BMC Psychol, V3, P32, DOI 10.1186/s40359-015-0089-9
   Beidas RS, 2010, CLIN PSYCHOL-SCI PR, V17, P1, DOI 10.1111/j.1468-2850.2009.01187.x
   Brown CH, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0134-8
   Chen JA, 2017, CURR OPIN PSYCHOL, V14, P61, DOI 10.1016/j.copsyc.2016.11.007
   Creed TA, 2016, J CONSULT CLIN PSYCH, V84, P1116, DOI 10.1037/ccp0000105
   Department of Veterans Affairs/Department of Defense, 2017, VA DOD CLIN PRACT GU
   Foa EB, 2007, PROLONGED EXPOSURE T
   Godley SH, 2011, CLIN PSYCHOL-SCI PR, V18, P67, DOI 10.1111/j.1468-2850.2011.01236.x
   Hale AC, 2019, PSYCHIAT SERV, V70, P367, DOI 10.1176/appi.ps.201800361
   Hanson RF, 2019, PSYCHOL SERV, V16, P170, DOI 10.1037/ser0000319
   Harvey G, 2002, J ADV NURS, V37, P577, DOI 10.1046/j.1365-2648.2002.02126.x
   Helseth SA, 2020, ADM POLICY MENT HLTH, V47, P569, DOI 10.1007/s10488-020-01024-3
   Hepner K. A., 2018, TRAINING CLIN DELIVE
   Herschell AD, 2010, CLIN PSYCHOL REV, V30, P448, DOI 10.1016/j.cpr.2010.02.005
   Hoffman J. E., 2011, PTSD COACH
   Karlin BE, 2014, AM PSYCHOL, V69, P19, DOI 10.1037/a0033888
   LoSavio ST, 2019, BEHAV THER, V50, P36, DOI 10.1016/j.beth.2018.03.007
   McHugh RK, 2010, AM PSYCHOL, V65, P73, DOI 10.1037/a0018121
   McLean CP, 2013, J ANXIETY DISORD, V27, P788, DOI 10.1016/j.janxdis.2013.03.004
   Monon CM, 2018, BEHAV RES THER, V110, P31, DOI 10.1016/j.brat.2018.08.007
   Morland LA, 2017, CURR OPIN PSYCHOL, V14, P102, DOI 10.1016/j.copsyc.2016.12.003
   Nadeem E, 2013, MILBANK Q, V91, P354, DOI 10.1111/milq.12016
   Powell BJ, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0209-1
   Resick P.A., 2017, COGNITIVE PROCESSING
   Ritchie M. J., 2017, VETERANS HLTH ADM QU
   Rosen CS, 2016, ADM POLICY MENT HLTH, V43, P957, DOI 10.1007/s10488-016-0755-0
   Rosen CS, 2020, J PSYCHOTHER INTEGR, V30, P174, DOI 10.1037/int0000221
   Sloan D. M., 2019, WRITTEN EXPOSURE THE
   Sloan DM, 2018, JAMA PSYCHIAT, V75, P233, DOI 10.1001/jamapsychiatry.2017.4249
   Sloan DM, 2013, J TRAUMA STRESS, V26, P776, DOI 10.1002/jts.21858
   Sloan DM, 2012, BEHAV RES THER, V50, P627, DOI 10.1016/j.brat.2012.07.001
   Stetler CB, 2006, IMPLEMENT SCI, V1, DOI 10.1186/1748-5908-1-23
   Stirman SW, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0544-5
   Stirman SW, 2016, BEHAV THER, V47, P920, DOI 10.1016/j.beth.2015.12.001
   Stirman SW, 2010, PROF PSYCHOL-RES PR, V41, P48, DOI 10.1037/a0018099
   Torous J, 2015, JMIR MENT HEALTH, V2, DOI 10.2196/mental.3889
NR 36
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD OCT
PY 2020
VL 33
IS 5
BP 634
EP 642
DI 10.1002/jts.22589
EA OCT 2020
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA OA2DV
UT WOS:000574221600001
PM 33007149
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Senoo, Y
   Suzuki, Y
   Takahashi, K
   Tsuda, K
   Tanimoto, T
AF Senoo, Y.
   Suzuki, Y.
   Takahashi, K.
   Tsuda, K.
   Tanimoto, T.
TI Prioritizing infants in a time of Bacille Calmette-Guerin vaccine
   shortage caused by premature expectations against COVID-19
SO QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Senoo, Y.] Comenius Univ, Fac Med, Spitalska 24, Bratislava 81372, Slovakia.
   [Suzuki, Y.] Tone Chuo Hosp, Dept Obstet & Gynecol, 910-1 Numasu Machi, Numata, Gunma 3780012, Japan.
   [Takahashi, K.] Kenwork LLC, Saiwai Ku, Kawasaki, Kanagawa 2120013, Japan.
   [Tsuda, K.] Teikyo Univ, Grad Sch Publ Hlth, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.
   [Tanimoto, T.] Med Governance Res Inst, Minato Ku, 2-12-13 Takanawa, Tokyo 1080074, Japan.
RP Takahashi, K (corresponding author), Med Governance Res Inst, Minato Ku, 2-12-13 Takanawa, Tokyo 1080074, Japan.
EM ken-zo.takahashi.chgh@med.teikyo-u.ac.jp
CR [Anonymous], 2020, JAPAN TIMES
   de Vrieze J., 2020, SCIENCE
   Japan BCG Laboratory, 2020, REQ BCG VACC ADM
   Laguipo ABB, 2020, NEWS MED
   Mainichi Japan, 2020, TUB VACC DRAW ATT FI
   Newton PN, 2020, LANCET GLOB HEALTH, V8, pE754, DOI 10.1016/S2214-109X(20)30136-4
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3
NR 7
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1460-2725
EI 1460-2393
J9 QJM-INT J MED
JI QJM-An Int. J. Med.
PD OCT
PY 2020
VL 113
IS 10
BP 773
EP 774
DI 10.1093/qjmed/hcaa179
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA PA2UC
UT WOS:000595487800028
PM 32442278
OA Green Published, Bronze, Green Accepted
DA 2021-01-01
ER

PT J
AU Abolghasemi, H
   Eshghi, P
   Cheraghali, AM
   Fooladi, AAI
   Moghaddam, FB
   Imanizadeh, S
   Maleki, MM
   Ranjkesh, M
   Rezapour, M
   Bahramifar, A
   Einollahi, B
   Hosseini, MJ
   Jafari, NJ
   Nikpouraghdam, M
   Sadri, N
   Tazik, M
   Sali, S
   Okati, S
   Askari, E
   Tabarsi, P
   Aslani, J
   Sharifipour, E
   Jarahzadeh, MH
   Khodakarim, N
   Salesi, M
   Jafari, R
   Shahverdi, S
AF Abolghasemi, Hassan
   Eshghi, Peyman
   Cheraghali, Abdol Majid
   Fooladi, Abbas Ali Imani
   Moghaddam, Farzaneh Bolouki
   Imanizadeh, Sina
   Maleki, Matin Moeini
   Ranjkesh, Mohammad
   Rezapour, Mohammad
   Bahramifar, Ali
   Einollahi, Behzad
   Hosseini, Mohammad Javad
   Jafari, Nematollah Joneidi
   Nikpouraghdam, Mohamad
   Sadri, Nariman
   Tazik, Mokhtar
   Sali, Shanaz
   Okati, Shamsi
   Askari, Elham
   Tabarsi, Payam
   Aslani, Jafar
   Sharifipour, Ehsan
   Jarahzadeh, Mohammad Hossein
   Khodakarim, Nastaran
   Salesi, Mahmood
   Jafari, Ramezan
   Shahverdi, Samira
TI Clinical efficacy of convalescent plasma for treatment of COVID-19
   infections: Results of a multicenter clinical study
SO TRANSFUSION AND APHERESIS SCIENCE
LA English
DT Article
DE COVID-19; Convalescent plasma; Clinical trial; Hospital stay; Mortality
   rate
AB Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients' need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy.
C1 [Abolghasemi, Hassan; Cheraghali, Abdol Majid] Baqiyatallah Univ Med Sci, Syst Biol & Poisonings Inst, Appl Microbiol Res Ctr, Tehran, Iran.
   [Eshghi, Peyman] Shahid Beheshti Univ Med Sci, Pediat Congenital Hematol Disorders Res Ctr, Tehran, Iran.
   [Eshghi, Peyman] Iran Blood Transfus Org, Tehran, Iran.
   [Cheraghali, Abdol Majid] Baqiyatallah Univ Med Sci, Sch Pharm, Tehran, Iran.
   [Cheraghali, Abdol Majid] Baqiyatallah Univ Med Sci, Chem Injuries Res Ctr, Tehran, Iran.
   [Moghaddam, Farzaneh Bolouki; Imanizadeh, Sina; Maleki, Matin Moeini; Ranjkesh, Mohammad; Rezapour, Mohammad] Baqiyatallah Univ Med Sci, Student Res Comm, Tehran, Iran.
   [Bahramifar, Ali] Baqiyatallah Univ Med Sci, Trauma Res Ctr, Tehran, Iran.
   [Einollahi, Behzad] Baqiyatallah Univ Med Sci, Nephrol & Urol Res Ctr, Tehran, Iran.
   [Hosseini, Mohammad Javad] Baqiyatallah Univ Med Sci, Syst Biol & Poisonings Inst Baqiyatallah, Mol Biol Res Ctr, Tehran, Iran.
   [Jafari, Nematollah Joneidi] Baqiyatallah Univ Med Sci, Life Style Inst, Hlth Res Ctr, Tehran, Iran.
   [Nikpouraghdam, Mohamad] Baqiyatallah Univ Med Sci, Nephrol & Urol Res Ctr, Tehran, Iran.
   [Sadri, Nariman; Tazik, Mokhtar] Darman Ara PJS Co, Tehran, Iran.
   [Sali, Shanaz] Shahid Behesti Univ Med Sci, Infect Dis & Trop Med Res Ctr, Tehran, Iran.
   [Okati, Shamsi] High Inst Res & Educ Transfu Med, Tehran, Iran.
   [Askari, Elham; Tabarsi, Payam] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis, Tehran, Iran.
   [Aslani, Jafar; Salesi, Mahmood; Jafari, Ramezan] Baqiyatallah Univ Med Sci, Chem Injuries Res Ctr, Tehran, Iran.
   [Sharifipour, Ehsan] Qom Univ Med Sci, Neurosci Res Ctr, Qom, Iran.
   [Jarahzadeh, Mohammad Hossein] Shahid Sadoughi Univ Med Sci, Dept Anesthesiol, Yazd, Iran.
   [Khodakarim, Nastaran] Iran Univ Med Sci, Dept Med Oncol & Hematol, Tehran, Iran.
   [Shahverdi, Samira] Baqiyatallah Univ Med Sci, Dept Radiol, Tehran, Iran.
RP Cheraghali, AM (corresponding author), Baqiyatallah Univ Med Sci, Sch Pharm, Tehran, Iran.; Cheraghali, AM (corresponding author), Baqiyatallah Univ Med Sci, Chem Injuries Res Ctr, Tehran, Iran.
EM majidcheraghali@gmail.com
OI askari, elham/0000-0002-8854-5341
FU Baqiyatallah Medical Science University, Tehran; Iran Blood Transfusion
   Organization, Tehran, Iran; Darman Ara Company, Tehran, Iran
FX This study was sponsored by Baqiyatallah Medical Science University,
   Tehran, Iran Blood Transfusion Organization, Tehran, Iran and Darman Ara
   Company, Tehran, Iran. Sponsors did not have any role in study design,
   data collection, data analysis, data interpretation or writing of the
   report. The principle investigators had fully authorization to access to
   database in the study and had final responsibility for submission of the
   data for publication.
CR Abdi M, 2020, INFECT CONT HOSP EP, V41, P754, DOI 10.1017/ice.2020.86
   Ahn JY, 2020, J KOREAN MED SCI, V35, pe149, DOI [10.3346/jkms. 2020.35.e149, DOI 10.3346/JKMS.2020.35.E149.E149.2020.]
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bloch EM, 2020, J CLIN INVEST, V7
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Cheraghali AM, 2020, IRAN J ALLERGY ASTHM
   Duan K, 2020, P NATL ACAD SCI US
   Fleming AB, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104388
   Joyner JM, 2020, EARLY SAFETY INDICAT
   Langhi DM, 2020, HEMATOL TRANSF CELL, V42, P113, DOI 10.1016/j.htct.2020.04.003
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Nikpouraghdam M, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104378
   Pan F, 2020, RADIOLOGY, DOI [10.1172/JCI138745, DOI 10.1172/JCI138745.200370.]
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Sullivan HC, 2020, TRANSFUS MED REV, V34, P145, DOI 10.1016/j.tmrv.2020.04.001
   Tiberghien P, 2020, VOX SANG, V115, P488, DOI 10.1111/vox.12926
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zhao J, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa344.ciaa344., DOI 10.1093/CID/CIAA344.CIAA344.]
NR 23
TC 6
Z9 6
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1473-0502
J9 TRANSFUS APHER SCI
JI Transfus. Apher. Sci.
PD OCT
PY 2020
VL 59
IS 5
AR 102875
DI 10.1016/j.transci.2020.102875
PG 5
WC Hematology
SC Hematology
GA OY3XZ
UT WOS:000594183900016
PM 32694043
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Cinar, OE
   Sayinalp, B
   Karakulak, EA
   Karatas, AA
   Velet, M
   Inkaya, AC
   Ortac, NEE
   Ocal, S
   Aksu, S
   Haznedaro, IC
   Sayinalp, N
   Ozcebe, OI
AF Cinar, Olgu Erkin
   Sayinalp, Basak
   Karakulak, Elifcan Aladag
   Karatas, Ayse Avsar
   Velet, Mustafa
   Inkaya, Ahmet Cagkan
   Ortac, Nazmiye Ebru Ersoy
   Ocal, Serpil
   Aksu, Salih
   Haznedaro, Ibrahim Celalettin
   Sayinalp, Nilgun
   Ozcebe, Osman Ilhami
TI Convalescent (immune) plasma treatment in a myelodysplastic COVID-19
   patient with disseminated tuberculosis
SO TRANSFUSION AND APHERESIS SCIENCE
LA English
DT Article
DE COVID-19; Convalescent; Plasmapheresis; Myelodysplastic; Tuberculosis
AB During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with associated comorbidities. Convalescent immune plasma therapy is a promising option as a sort of 'rescue' treatment in COVID-19 immune syndrome, where miraculous antiviral drugs are not available yet. In this report, we aim to convey our experience of multi-task treatment approach with convalescent immune plasma and anti-cytokine drug combination in a COVID-19 patient with extremely challenging comorbidities including active myeloid malignancy, disseminated tuberculosis and kidney failure.
C1 [Cinar, Olgu Erkin; Karakulak, Elifcan Aladag; Karatas, Ayse Avsar; Velet, Mustafa; Aksu, Salih; Haznedaro, Ibrahim Celalettin; Sayinalp, Nilgun; Ozcebe, Osman Ilhami] Hacettepe Univ, Dept Internal Med, Hematol Unit, Fac Med, Ankara, Turkey.
   [Sayinalp, Basak] Hacettepe Univ, Fac Med, Dept Internal Med, Ankara, Turkey.
   [Inkaya, Ahmet Cagkan] Hacettepe Univ, Fac Med, Dept Infect Dis, Ankara, Turkey.
   [Ortac, Nazmiye Ebru Ersoy; Ocal, Serpil] Hacettepe Univ, Fac Med, Dept Internal Med, Intens Care Unit, Ankara, Turkey.
RP Cinar, OE (corresponding author), Hacettepe Univ, Dept Internal Med, Hematol Unit, Fac Med, Ankara, Turkey.
EM drerkincinar@gmail.com
OI Cinar, Olgu Erkin/0000-0003-1226-5797; Karatas, Ayse/0000-0002-3990-9719
CR Asadi-Pooya AA, 2020, J NEUROL SCI, V413, DOI 10.1016/j.jns.2020.116832
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34
   Ronco C, 2020, NAT REV NEPHROL, P1
   Scott LJ, 2017, DRUGS, V77, P1029, DOI 10.1007/s40265-017-0752-y
   Simsek Yavuz S, 2020, TURK J MED SCI, V50, P611, DOI 10.3906/sag-2004-145
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zini G., AM J HEMATOLOGY
NR 12
TC 4
Z9 4
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1473-0502
J9 TRANSFUS APHER SCI
JI Transfus. Apher. Sci.
PD OCT
PY 2020
VL 59
IS 5
AR 102821
DI 10.1016/j.transci.2020.102821
PG 4
WC Hematology
SC Hematology
GA OY3YQ
UT WOS:000594185700006
PM 32487513
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Erkurt, MA
   Sarici, A
   Berber, I
   Kuku, I
   Kaya, E
   Ozgul, M
AF Erkurt, Mehmet Ali
   Sarici, Ahmet
   Berber, Ilhami
   Kuku, Irfan
   Kaya, Emin
   Ozgul, Mustafa
TI Life-saving effect of convalescent plasma treatment in covid-19 disease:
   Clinical trial from eastern Anatolia
SO TRANSFUSION AND APHERESIS SCIENCE
LA English
DT Article
DE Convalescent plasma; Sars-Cov-2 infection; Covid-19; Coronavirus; Immun
   plasma
AB Aim: Convalescent Plasma (CP) therapy is of interest as no vaccine or specific treatment is available for emerging viruses such as severe acute respiratory syndrome coronavirus 2 causing Covid-19. It was aimed to report the results of our patients who underwent CP in the treatment of Covid-19.
   Methods: CP treatment was applied to 26 Covid-19 patients in intensive care unit who had quantitative reverse transcriptase-polymerase chain reaction positive Sars-Cov-2 infection. Plasma was collected at least 14 days after complete recovery from patients who had mild or moderate infection with Sars-Cov-2 infection. The collected CP (200cc) were applied to severe Covid-19 patients. Laboratory values of patients just before CP and after 7 days were compared.
   Results: There were no statistically significant differences in leukocyte, neutrophil, lymphocyte, platelet, CRP, ferritin, LDH, ALT, AST, sO(2) and total bilirubin values just before and after 1 week of CP. A statistically significant difference was found between age and lymphocyte values of living and dying patients. The patients who died were determined to have older age (74,6 vs 61,85, p-0,018) and more severe lymphopenia (0,47 vs 1,18, p = 0,001).
   Conclusion: CP therapy has the potential to provide immediate and promising treatment options before specific vaccines and treatments are developed. In early stage Covid-19 patients who do not need mechanical ventilation, CP treatment may be a curative treatment option.
C1 [Erkurt, Mehmet Ali; Sarici, Ahmet; Berber, Ilhami; Kuku, Irfan; Kaya, Emin; Ozgul, Mustafa] Inonu Univ, Turgut Ozal Med Ctr, Adult Hematol Dept, Malatya, Turkey.
RP Erkurt, MA (corresponding author), Inonu Univ, Turgut Ozal Med Ctr, Adult Hematol Dept, Malatya, Turkey.
EM erkurtali@hotmail.com; ahmetsarici@inonu.edu.tr;
   ilhami.berber@inonu.edu.tr
OI SARICI, AHMET/0000-0002-5916-0119
CR Ahn JY, 2020, J KOREAN MED SCI, V35
   Brown BL, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102790
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   FDA, 2020, INV COVID 19 CONV PL
   Food U., INV COVID 19 CONV PL
   Francis F, 1920, MIL SURG, V47, P177
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Li L, 2020, JAMA
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   World Health Organization, 2020, WHO COR DIS COVID 19
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
   Zhang B, 2020, J CHEM RES, V44, P571, DOI 10.1177/1747519820912675
NR 18
TC 2
Z9 2
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1473-0502
J9 TRANSFUS APHER SCI
JI Transfus. Apher. Sci.
PD OCT
PY 2020
VL 59
IS 5
AR 102867
DI 10.1016/j.transci.2020.102867
PG 3
WC Hematology
SC Hematology
GA OY3XZ
UT WOS:000594183900027
PM 32620409
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Figlerowicz, M
   Mania, A
   Lubarski, K
   Lewandowska, Z
   Sluzewski, W
   Derwich, K
   Wachowiak, J
   Mazur-Melewska, K
AF Figlerowicz, Magdalena
   Mania, Anna
   Lubarski, Karol
   Lewandowska, Zuzanna
   Sluzewski, Wojciech
   Derwich, Katarzyna
   Wachowiak, Jacek
   Mazur-Melewska, Katarzyna
TI First case of convalescent plasma transfusion in a child with
   COVID-19-associated severe aplastic anemia
SO TRANSFUSION AND APHERESIS SCIENCE
LA English
DT Article
DE Transfusion; Convalescent plasma; SARS-CoV-2; Children; Pancytopenia
ID EPIDEMIOLOGY; COVID-19
AB We present the case of a six-year-old girl with severe COVID-19, in whom SARS-CoV-2 was successfully eliminated after convalescent plasma transfusion. Children show a variable clinical course of COVID-19, from asymptomatic to critical. In our patient, we diagnosed COVID-19-associated aplastic anemia with severe pancytopenia. The correlation between SARS-CoV-2 infection with aplastic anemia remains unclear. At the beginning of the disease, we used antiviral drugs and immune modulators as therapy but without any positive results. After providing a transfusion of convalescent plasma, the elimination of SARS-CoV-2 was observed. We did not observe any adverse events of this treatment. The girl still has a diagnosis of aplastic anemia and requires specialist therapy.
C1 [Figlerowicz, Magdalena; Mania, Anna; Lubarski, Karol; Lewandowska, Zuzanna; Sluzewski, Wojciech; Mazur-Melewska, Katarzyna] Poznan Univ Med Sci, Dept Infect Dis & Child Neurol, Szpitalna 27-33, PL-60572 Poznan, Poland.
   [Derwich, Katarzyna; Wachowiak, Jacek] Poznan Univ Med Sci, Dept Pediat Oncol Hematol & Transplantol, Szpitalna 27-33, PL-60572 Poznan, Poland.
RP Figlerowicz, M (corresponding author), Poznan Univ Med Sci, Dept Infect Dis & Child Neurol, Szpitalna 27-33, PL-60572 Poznan, Poland.
EM mfiglerowicz@gmail.com
CR Bomhof G, 2020, BRIT J HAEMATOL, V190, pE61, DOI 10.1111/bjh.16850
   Chiotos K, 2020, J PEDIAT INF DIS SOC, V9, P393, DOI 10.1093/jpids/piaa069
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Ye ZK, 2020, CAN MED ASSOC J, V192, pE536, DOI 10.1503/cmaj.200648
   Young NS, 2008, HAEMATOLOGICA, V93, P489, DOI 10.3324/haematol.12855
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
NR 10
TC 3
Z9 3
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1473-0502
J9 TRANSFUS APHER SCI
JI Transfus. Apher. Sci.
PD OCT
PY 2020
VL 59
IS 5
AR 102866
DI 10.1016/j.transci.2020.102866
PG 3
WC Hematology
SC Hematology
GA OY3XZ
UT WOS:000594183900004
PM 32636116
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kong, YJ
   Cai, C
   Ling, L
   Zeng, L
   Wu, MH
   Wu, YY
   Zhang, W
   Liu, Z
AF Kong, Yujie
   Cai, Chen
   Ling, Li
   Zeng, Li
   Wu, Meihong
   Wu, Yanyun
   Zhang, Wei
   Liu, Zhong
TI Successful treatment of a centenarian with coronavirus disease 2019
   (COVID-19) using convalescent plasma
SO TRANSFUSION AND APHERESIS SCIENCE
LA English
DT Article
DE Coronavirus Disease 2019; convalescent plasma; transfusion
AB Background: Because treatment options for coronavirus disease 2019 (COVID-19) are very limited, the use of convalescent plasma has bee explored.
   Case presentation and treatment: A male centenarian with cough and dyspnea for 2 months was diagnosed with COVID-19. Without effective treatments and with the increased risks of antiviral therapy for the elderly, this patient was given convalescent plasma. The viral load, complete blood count, inflammatory indicators, vital signs, and clinical symptoms were observed before and after COVID-19 convalescent plasma transfusion.
   Results: After convalescent plasma transfusion, significant improvement was observed on laboratory indicators and clinical symptoms of the patient. Concurrently, SARS-CoV-2 viral load decreased sharply after the first transfusion (from 2.55 x 104 to 1.39 x 103 copies/mL) and became undetectable after the second transfusion.
   Conclusions: With the substantial increase of COVID-19 in recent months,treatment for elderly patients has become restricted in some countries. The successful treatment of this 100-year-old patient using convalescent plasma suggests that we should consider adding convalescent plasma in th management of the elderly.
C1 [Kong, Yujie; Ling, Li; Liu, Zhong] Chinese Acad Med Sci & Peking Union Med Coll, Inst Blood Transfus, Clin Transfus Res Ctr, Chengdu 610052, Sichuan, Peoples R China.
   [Kong, Yujie; Ling, Li; Liu, Zhong] CAMS, Key Lab Transfus Adverse React, Chengdu 610052, Sichuan, Peoples R China.
   [Cai, Chen] Second Mil Med Univ, Affiliated Hosp 1, Dept Special Clin, Shanghai 200433, Peoples R China.
   [Cai, Chen; Zeng, Li; Wu, Meihong; Zhang, Wei] Maternal & Child Hlth Hosp Hubei Prov, Wuhan 430070, Hubei, Peoples R China.
   [Zeng, Li] Second Mil Med Univ, Affiliated Hosp 1, Dept Organ Transplantat, Shanghai 200433, Peoples R China.
   [Wu, Meihong] Second Mil Med Univ, Affiliated Hosp 1, Dept Oncol, Shanghai 200433, Peoples R China.
   [Wu, Yanyun] Univ Miami, Miami, FL USA.
   [Zhang, Wei] Second Mil Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Shanghai 200433, Peoples R China.
RP Liu, Z (corresponding author), 26 Huacai Rd,Longtan Ind Zone, Chengdu, Sichuan, Peoples R China.; Zhang, W (corresponding author), 168 Changhai Rd, Shanghai, Peoples R China.
EM zhangweismmu@126.com; liuz@ibt.pumc.edu.cn
OI Zhang, Wei/0000-0001-5292-7308
FU CAMS Innovation Fund for Medical Sciences (CIFMS) [2020-I2M-CoV19-006,
   2016-I2M-3024]; Non-profit Central Research Institute Fund of Chinese
   Academy of Medical Sciences [2018PT32016]
FX This work was supported by the CAMS Innovation Fund for Medical Sciences
   (CIFMS) (Grant Nos. 2020-I2M-CoV19-006 and 2016-I2M-3024) and Non-profit
   Central Research Institute Fund of Chinese Academy of Medical Sciences
   (Grant Nos. 2018PT32016).
CR CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Choi S, 2018, AM J TROP MED HYG, V99, P1466, DOI 10.4269/ajtmh.17-0766
   Garraud O, 2017, TRANSFUS APHER SCI, V56, P31, DOI 10.1016/j.transci.2016.12.014
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2013, ANTIVIR RES, V98, P410, DOI 10.1016/j.antiviral.2013.03.019
   Lisa Rosenbaum MD, 2020, NEW ENGL J MED, DOI [10.1056/NEJMp2005492., DOI 10.1056/NEJMP2005492]
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   van Griensven J, 2016, NEW ENGL J MED, V374, P2500, DOI 10.1056/NEJMc1602284
NR 10
TC 8
Z9 8
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1473-0502
J9 TRANSFUS APHER SCI
JI Transfus. Apher. Sci.
PD OCT
PY 2020
VL 59
IS 5
AR 102820
DI 10.1016/j.transci.2020.102820
PG 3
WC Hematology
SC Hematology
GA OY3YQ
UT WOS:000594185700022
PM 32467007
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lanza, F
   Seghatchian, J
AF Lanza, Francesco
   Seghatchian, Jerard
TI Trends and targets of various types of stem cell derived transfusable
   RBC substitution therapy: Obstacles that need to be converted to
   opportunity
SO TRANSFUSION AND APHERESIS SCIENCE
LA English
DT Article
DE Transfusable RBC bioproducts; Stem cells; Induced pluripotent stem cell;
   Expansion media; GMP regulatory processes; Bioreactors; Artificial
   intelligence
ID RED-BLOOD-CELLS; EX-VIVO; GENERATION; VITRO
AB A shortage of blood during the pandemic outbreak of COVID-19 is a typical example in which the maintenance of a safe and adequate blood supply becomes difficult and highly demanding. So far, human RBCs have been produced in vitro using diverse sources: hematopoietic stem cells (SCs), embryonic SCs and induced pluripotent SCs. The existing, even safest core of conventional cellular bioproducts destined for transfusion have some shortcoming in respects to: donor-dependency variability in terms of hematological /immunological and process/ storage period issues. SCs-derived transfusable RBC bioproducts, as one blood group type for all, were highly complex to work out. Moreover, the strategies for their successful production are often dependent upon the right selection of starting source materials and the composition and the stability of the right expansion media and the strict compliance to GMP regulatory processes. In this mini-review we highlight some model studies, which showed that the efficiency and the functionality of RBCs that could be produced by the various types of SCs, in relation to the in-vitro culture procedures are such that they may, potentially, be used at an industrial level. However, all cultured products do not have an unlimited life due to the critical metabolic pathways or the metabolites produced. New bioreactors are needed to remove these shortcomings and the development of a new mouse model is required. Modern clinical trials based on the employment of regenerative medicine approaches in combination with novel large-scale bioengineering tools, could overcome the current obstacles in artificial RBC substitution, possibly allowing an efficient RBC industrial production.
C1 [Lanza, Francesco] Ravenna Hosp, Hematol Unit, Romagna Transplant Network, Via Randi 5, Ravenna, Italy.
   [Lanza, Francesco] Univ Ferrara Italy, Via Randi 5, Ravenna, Italy.
   [Seghatchian, Jerard] Int Consultancy Strateg Safety, Qual Innovat Blood Derived Bioprod & Qual Audit I, London, England.
RP Seghatchian, J (corresponding author), Int Consultancy Strateg Safety, Qual Innovat Blood Derived Bioprod & Qual Audit I, London, England.
EM francesco.lanza@auslromagna.it; jsegnatchian@btopenworld.com
CR Bessos H, 2008, TRANSFUS APHER SCI, V38, P77, DOI 10.1016/j.transci.2007.12.011
   Bonsi L, 2020, STEM CELLS
   Campioni D, 2009, CYTOM PART B-CLIN CY, V76B, P225, DOI 10.1002/cyto.b.20461
   Douay L, 2018, REGEN MED, V13, P627, DOI 10.2217/rme-2018-0025
   Giarratana MC, 2011, BLOOD, V118, P5071, DOI 10.1182/blood-2011-06-362038
   Jin H., 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/435215
   Kurita R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059890
   Lanza F, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102753
   Lanza F, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102785
   Lanza F, 2001, J BIOL REG HOMEOS AG, V15, P1
   Lanza F, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102940
   Lapillonne H, 2010, HAEMATOL-HEMATOL J, V95, P1651, DOI 10.3324/haematol.2010.023556
   Lee E, 2018, BIOTECHNOL J, V13, DOI 10.1002/biot.201700567
   Migliaccio AR, 2012, BLOOD REV, V26, P81, DOI 10.1016/j.blre.2011.11.002
   Migliaccio AR, 2009, CURR OPIN HEMATOL, V16, P259, DOI 10.1097/MOH.0b013e32832bcaa2
   Nazareth EJP, 2016, STEM CELL REP, V6, P679, DOI 10.1016/j.stemcr.2016.04.003
   Neildez-Nguyen TMA, 2002, NAT BIOTECHNOL, V20, P467, DOI 10.1038/nbt0502-467
   Rousseau GF, 2014, BIOTECHNOL J, V9, P28, DOI 10.1002/biot.201200368
   Seo Y, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9281329
   Shah SN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166657
   Sniecinski I, 2018, TRANSFUS APHER SCI, V57, P422, DOI 10.1016/j.transci.2018.05.004
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Timmins NE, 2011, TISSUE ENG PART C-ME, V17, P1131, DOI [10.1089/ten.tec.2011.0207, 10.1089/ten.TEC.2011.0207]
   Trakarnsanga K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14750
   Tzounakas VL, 2018, TRANSFUS APHER SCI, V57, P347, DOI 10.1016/j.transci.2018.05.018
   Zhang YN, 2017, 2017 IEEE 3RD INFORMATION TECHNOLOGY AND MECHATRONICS ENGINEERING CONFERENCE (ITOEC), P6, DOI 10.1109/ITOEC.2017.8122388
NR 26
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1473-0502
J9 TRANSFUS APHER SCI
JI Transfus. Apher. Sci.
PD OCT
PY 2020
VL 59
IS 5
AR 102941
DI 10.1016/j.transci.2020.102941
PG 4
WC Hematology
SC Hematology
GA OY3XZ
UT WOS:000594183900028
PM 32958397
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lung, T
   Kazatchkine, MD
   Risch, L
   Risch, M
   Nydegger, UE
AF Lung, Thomas
   Kazatchkine, Michel D.
   Risch, Lorenz
   Risch, Martin
   Nydegger, Urs E.
TI A consideration of convalescent plasma and plasma derivatives in the
   care of Severely-ill patients with COVID-19
SO TRANSFUSION AND APHERESIS SCIENCE
LA English
DT Article
DE IVIG; Convalescent plasma; Plasma exchange; COVID-19
ID DISSEMINATED INTRAVASCULAR COAGULATION; CORONAVIRUS; SARS-COV-2;
   ANTIBODIES; LUNG; INFLAMMATION; INFECTION; IMMUNITY; MICE; ACE2
AB The pathogenesis and immunopathological damage of severe forms of COVID-19 resemble acute autoimmune disease sparked by SARS-CoV-2, including an early systemic overproduction of proinflammatory cytokines. Such immunopathological features provide a rationale for the use of passive immunotherapy with convalescent plasma as a source of neutralizing anti-viral antibodies and of anti-inflammatory plasma components. While convalescent plasma therapy is now being evaluated in prospective clinical trials, we further consider the therapeutic potential of human hyper immune globulins, and of heterologous, engineered and monoclonal neutralizing antibodies as anti-viral agents to treat COVID-19. Good medical practice procedures are still needed and is why we also discuss the potential use of polyclonal polyspecific immunoglobulins (IVIG), a therapeutic plasma derivative, with potent anti-inflammatory activity, in severe forms of Covid-19.
C1 [Lung, Thomas; Risch, Lorenz; Risch, Martin; Nydegger, Urs E.] Lab Med Zentrum Dr Risch, Vaduz, Liechtenstein.
   [Kazatchkine, Michel D.] Grad Inst Int Affairs & Dev, Geneva, Switzerland.
RP Nydegger, UE (corresponding author), Lab Med Zentrum Dr Risch, Vaduz, Liechtenstein.
EM urs.nydegger@risch.ch
RI Risch, Lorenz/D-4629-2011
OI Risch, Lorenz/0000-0003-2692-6699
CR Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228
   Antinori S, 2020, TRAVEL MED INFECT DI
   Arbaeen AF, 2017, TRANSFUSION, V57, P1208, DOI 10.1111/trf.14043
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Beigel JH, 2019, LANCET RESP MED, V7, P941, DOI 10.1016/S2213-2600(19)30199-7
   Beigel JH, 2018, LANCET INFECT DIS, V18, P410, DOI 10.1016/S1473-3099(18)30002-1
   Bonam Srinivasa Reddy, 2020, Cell Rep Med, V1, P100016, DOI 10.1016/j.xcrm.2020.100016
   Bruggemann M, 2015, ARCH IMMUNOL THER EX, V63, P101, DOI 10.1007/s00005-014-0322-x
   Cao W, 2020, OPEN FORUM INFECT DI, P1
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Cho WK, 2019, YONSEI MED J, V60, P407, DOI 10.3349/ymj.2019.60.5.407
   Collins RA, 2015, AM J CLIN PATHOL, V143, P329, DOI 10.1309/AJCP42WMHSSTPHXI
   Crayne CB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00119
   Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9
   Crowe JE, 2001, J IMMUNOL, V167, P3910, DOI 10.4049/jimmunol.167.7.3910
   Davies DH, 2005, P NATL ACAD SCI USA, V102, P547, DOI 10.1073/pnas.0408782102
   De Assis RR, 2020, BIORXIV, P17
   DEVOS M, 1974, ACTA HAEMATOL-BASEL, V52, P120
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Duan K Bc, 2020, P NATL ACAD SCI USA, P1
   Escobar PM, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14209
   Evert J, 2003, J GERONTOL A-BIOL, V58, P232
   Fan BE, 2020, AM J HEMATOL, V95, pE158, DOI 10.1002/ajh.25823
   Fanelli V, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02872-z
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Feng ZH, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00116
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Fujihashi K, 2009, TRENDS IMMUNOL, V30, P334, DOI 10.1016/j.it.2009.04.004
   Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960
   Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0
   Garraud O, 2019, TRANSFUS APHER SCI, V58, P358, DOI 10.1016/j.transci.2019.06.004
   Goronzy JJ, 2017, IMMUNITY, V46, P364, DOI 10.1016/j.immuni.2017.03.010
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01227-2020
   Haass KA, 2019, TRANSFUS MED REV, V33, P84, DOI 10.1016/j.tmrv.2019.01.001
   Hall BM, 2016, AGING-US, V8, P1294, DOI 10.18632/aging.100991
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hotchkiss RS, 2020, NEW ENGL J MED, V382, P1270, DOI 10.1056/NEJMcibr1917242
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Jin JM, 2020, FRONT IMMUNOL
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Joyner Michael, 2020, medRxiv, DOI 10.1101/2020.05.12.20099879
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kesici S, 2020, P NATL ACAD SCI USA, V117, P12526, DOI 10.1073/pnas.2006691117
   Khokha R, 2013, NAT REV IMMUNOL, V13, P649, DOI 10.1038/nri3499
   Klein HG, 2019, TRANSFUSION, V59, P3046, DOI 10.1111/trf.15500
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kumpel BM, 2001, TRENDS IMMUNOL, V22, P26, DOI 10.1016/S1471-4906(00)01801-9
   Ledford H, 2020, NATURE, V580, P573, DOI 10.1038/d41586-020-01165-3
   Lee YL, 2020, J INFECTION, V81, pE55, DOI 10.1016/j.jinf.2020.04.019
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li X, 2020, J PHARM ANAL
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Marovich M, 2020, JAMA-J AM MED ASSOC, V324, P131, DOI 10.1001/jama.2020.10245
   MAUR CAD, 1993, TRANSFUSION, V33, P915, DOI 10.1046/j.1537-2995.1993.331194082382.x
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Monneret Guillaume, 2019, Aging Clin Exp Res, DOI 10.1007/s40520-019-01350-z
   Moriwaki T, 2020, EXP CELL RES, V390, DOI 10.1016/j.yexcr.2020.111914
   NAKAMURA S, 1990, ACTA PATHOL JAPON, V40, P476
   Navarro S, 2017, GERONTOLOGY, V63, P270, DOI 10.1159/000451081
   Negro F, 2020, SWISS MED WEEKLY, V150
   Nguyen AA, 2020, CLIN IMMUNOL, V216, DOI 10.1016/j.clim.2020.108459
   Nickel CH, 2020, SWISS MED WEEKLY, V150
   Nydegger U, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/4121837
   Passerini CG, 2020, AM J HEMATOL
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Phelan J, 2020, BIORXIV
   Quinlan BD, 2020, SARS COV 2 RECEPTOR, DOI 10.036418
   Radmanesh F, 2020, J CLIN NEUROSCI, V76, P236, DOI 10.1016/j.jocn.2020.04.054
   Risch M, 2018, J LAB MED, V42, P109, DOI 10.1515/labmed-2018-0034
   Risch M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005726
   Rivellese F, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102536
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Robbiani DF, 2020, CONVERGENT ANTIBODY
   Roth JA, 2020, SWISS MED WKLY, V150, DOI [10.44147/SMW.2020.20299, 10.4414/smw.2020.20299]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sethuraman N, 2020, JAMA
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shi H, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105974
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Tissot JD, 2015, TRANSFUS APHER SCI, V52, P261, DOI 10.1016/j.transci.2015.04.004
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Toubina J, 2020, OUTBREAK KAWASAKI DI, DOI [10.1101/2020.05.10.20097394., DOI 10.1101/2020.05.10.20097394, 10.1101/2020.05.10.20097394]
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vlaar APJ, 2019, TRANSFUS APHER SCI, V58, P632, DOI 10.1016/j.transci.2019.07.011
   Wang XY, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-018-0095-z
   Ward PA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00086
   Wardemann H, 2017, TRENDS IMMUNOL, V38, P471, DOI 10.1016/j.it.2017.05.003
   Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Yan L, 2020, NAT MACH INTELL, V2, P283, DOI 10.1038/s42256-020-0180-7
   Zhang L, 2005, J MED VIROL
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004
   Zhao C, 2020, SWISS MED WEEKLY, V150
NR 100
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1473-0502
J9 TRANSFUS APHER SCI
JI Transfus. Apher. Sci.
PD OCT
PY 2020
VL 59
IS 5
AR 102936
DI 10.1016/j.transci.2020.102936
PG 8
WC Hematology
SC Hematology
GA OY3XZ
UT WOS:000594183900032
PM 32919880
OA Bronze
DA 2021-01-01
ER

PT J
AU Putter, JS
   Seghatchian, J
AF Putter, Jeffrey S.
   Seghatchian, Jerard
TI An update on COVID-19 infection control measures, plasma-based
   therapeutics, corticosteroid pharmacotherapy and vaccine research
SO TRANSFUSION AND APHERESIS SCIENCE
LA English
DT Article
DE COVID-19 convalescent plasma; Corticosteroids; Vaccine; Hyperimmune NAb
   for passive immunization; Therapeutic plasma exchange
AB This communication provides a compilation on aspects of COVID-19 infection control measures, describes the potential role of therapeutic plasma exchange to reduce fatality rates, addresses precautions concerning dexamethasone pharmacotherapy and updates the current status on the availability of vaccines. As part of passive immunotherapy, it focuses on various blood derivatives. These include coronavirus neutralising antibodies extracted from different sources to be administered as a pure hyper concentrate intramuscularly or for upgrading and standardising the specific potency of high affinity antibodies. These processes are intended to compose standardised pooled bioproducts of corona convalescent plasma/cryosupernatant that are pathogen inactivated for additional safety by well-established UV technologies. For the best practice of optimising plasma exchange, hyper concentrate NAb should be added to the cryosupernatant, which contains some of the active principles of corona convalescent plasma. The cryosupernatant apart from the high molecular weight viscous part of cold insoluble proteins that are removed, is equivalent to CCP, but makes it safer for general application. Such a bioproduct is often used routinely for substitution therapy of thrombotic thrombocytopaenic purpura. Alternative resources of large-scale specific coronavirus antibodies warrant further exploration such as cadaveric donations. The early uses of therapeutic plasma exchange and low molecular weight heparin, for any clinical trial in development is warranted, in order to interdict the intense inflammatory/kinin driven cascade. Because coronavirus positive patients are highly prone to thrombosis, thromboprophylaxis is necessary, even some time after recovery guided by the laboratory data.
C1 [Putter, Jeffrey S.] Med Biomech Inc, 100 E San Marcos Blvd,400,San Marcos, San Marcos, CA 92069 USA.
   [Seghatchian, Jerard] Strateg Safety Qual Improvements Blood Derived Bi, London, England.
RP Putter, JS (corresponding author), Med Biomech Inc, 100 E San Marcos Blvd,400,San Marcos, San Marcos, CA 92069 USA.
EM Jputter@LTSP.com; jseghatchian@btopenworld.com
CR Amiral J, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102804
   [Anonymous], 2020, LOW COST DEXAMETHASO
   Brown BL, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102790
   Brun-Buisson C, 2011, AM J RESP CRIT CARE, V183, P1200, DOI 10.1164/rccm.201101-0135OC
   Burnouf T, 2014, TRANSFUS APHER SCI, V51, P120, DOI 10.1016/j.transci.2014.10.003
   Byambasuren O, 2020, ESTIMATING EXTENT AS, DOI [10.1101/2020.05.10.20097543, DOI 10.1101/2020.05.10.20097543]
   Folegatti PM, 2020, SAFETY IMMUNOGENICIT, DOI [10.1016/S0140-6736(20)31604-4, DOI 10.1016/S0140-6736(20)31604-4]
   Seghatchian J, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102794
   Theoharides TC, 2020, J BIOL REGUL HOMEOST, DOI DOI 10.23812/20.EDITORIAL
   WHO, 2020, US CONV WHOL BLOOD P
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
NR 11
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1473-0502
J9 TRANSFUS APHER SCI
JI Transfus. Apher. Sci.
PD OCT
PY 2020
VL 59
IS 5
AR 102934
DI 10.1016/j.transci.2020.102934
PG 5
WC Hematology
SC Hematology
GA OY3XZ
UT WOS:000594183900017
PM 32948465
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Seghatchian, J
   Acker, JP
   Putter, JS
AF Seghatchian, Jerard
   Acker, Jason P.
   Putter, Jeffery S.
TI Update on newer approaches to prevent or treat COVID-19 infection: What
   we all need the most right now!!
SO TRANSFUSION AND APHERESIS SCIENCE
LA English
DT Article
DE SARS-CoV-2; Convalescent plasma; COVID-19; Neutralizing antibodies
AB COVID-19 convalescent plasma (CCP) therapy involves the use of circulating antibodies administration from recovered COVID 19 patients as a practical strategy to provide immediate passive immunity in susceptible recipients in need. Global concern over the potential for "second" or "third" waves of infection to occur before effective vaccines or drug therapies are available has many looking at other biological sources for large-scale production of neutralizing SARS-CoV-2 antibodies. This report summarizes some of the novel strategies for developing alternative safe sources of therapeutic autologous antibodies from COVID-19 infected patients, and provides some original thoughts on how to rapidly implement a safe passive immunity in those COVID-19 patients who are most in need of intervention. COVID-19 antibodies can be isolated or delivered using a number of other techniques including: plasmapheresis, plasma cryoprecipitate reduced (cryosupernatant), antibody hyperconcentrates and advanced cell-based delivery systems. While these proposed technological options may, in some cases, be theoretical, the growing concern over the rapid spread of the SARS-CoV-2 virus has prompted many to pursue innovative and creative solutions to reduce the mortality and morbidity resulting from the current global pandemic. A comparative analysis of various strategies currently in use deserved exploring and this highlighted separately as the essential part of this concise theme.
C1 [Seghatchian, Jerard] Int Consultancy Strateg Safety Qual Innovat Blood, London, England.
   [Acker, Jason P.] Canadian Blood Serv, Ctr Innovat, 8249-114 St, Edmonton, AB T6G 2R8, Canada.
   [Acker, Jason P.] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada.
   [Putter, Jeffery S.] Med Biomech Inc, San Marcos, CA USA.
RP Acker, JP (corresponding author), Canadian Blood Serv, Ctr Innovat, 8249-114 St, Edmonton, AB T6G 2R8, Canada.
EM jason.acker@blood.ca
CR Amiral J, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102804
   Brown BL, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102790
   Burnouf T, 2014, TRANSFUS APHER SCI, V51, P120, DOI 10.1016/j.transci.2014.10.003
   Dholaria B, 2020, BRIT J HAEMATOL, V189, P239, DOI 10.1111/bjh.16597
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Lanza F, 2020, BRIT J HAEMATOL, V190, pE27, DOI 10.1111/bjh.16814
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   POOL JG, 1964, NATURE, V203, P312, DOI 10.1038/203312a0
   Rossi L, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01070
   Seghatchian J, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102794
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Villa CH, 2016, TRANSFUS APHER SCI, V55, P275, DOI 10.1016/j.transci.2016.10.017
   WHO, 2014, US CONV WHOL BLOOD P
NR 14
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1473-0502
J9 TRANSFUS APHER SCI
JI Transfus. Apher. Sci.
PD OCT
PY 2020
VL 59
IS 5
AR 102933
DI 10.1016/j.transci.2020.102933
PG 3
WC Hematology
SC Hematology
GA OY3XZ
UT WOS:000594183900033
PM 32919879
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Yilmaz, S
   Oruc, E
   Ozcebe, OI
   Azap, A
   Cetin, AT
   Yenicesu, I
   Ozturk, A
   Gunduz, M
   Tekin, A
AF Yilmaz, Soner
   Oruc, Nigar Ertugrul
   Ozcebe, Osman Ilhami
   Azap, Alpay
   Cetin, Ahmet Turker
   Yenicesu, Idil
   Ozturk, Abdullah
   Gunduz, Mehmet
   Tekin, Ahmet
TI Regulatory consideration on preparation and clinical use of COVID-19
   convalescent plasma
SO TRANSFUSION AND APHERESIS SCIENCE
LA English
DT Article
DE COVID-19; Convalescent plasma; Plasma donation; Pandemic
AB Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), spreading from Wuhan to worldwide has been emerged since December 2019. Although scientists and researchers have been racing to develop specific therapeutic agents or vaccines against SARS-CoV-2 since the identification of the agent, either a drug or a vaccine has not been approved to treat or to prevent COVID-19 up to date. On the base of historical experiences, Convalescent Plasma (CP), a passive antibody therapy, has been evaluated as a hopeful and potential therapeutic option since the beginning of the COVID-19 outbreak. Immune plasma had been used previously for the treatment of H1N1 influenza virus, SARS-CoV-1 and MERS-CoV epidemics successfully. In this scope competent authorities are responsible to set up certain principles and criteria for the collection and clinical use of COVID-19 Convalescent Plasma (CCP). This document has been prepared to aid both for the convalescent plasma suppliers and the clinicians. The first part encompasses the supply of CCP and the second part lead the clinical use of CCP for the treatment of patients with severe COVID-19 infection.
   Turkish Ministry of Health developed a guide on collection and clinical use of CCP and created a web-based monitoring system to follow-up the patients treated with convalescent plasma in universal. This follow-up process is thought to be crucial for the creation and development of current and future treatment modalities. This guide would be a pathfinder for clinicians and/or institutions those eager to conduct CCP treatment more effectively.
C1 [Yilmaz, Soner] Univ Hlth Sci, Gulhane Training & Res Hosp, Reg Blood Ctr, Ankara, Turkey.
   [Oruc, Nigar Ertugrul] Hlth Sci Univ, Diskapi Yildirim Beyazit Training & Res Hosp, Dept Transfus Serv, Ankara, Turkey.
   [Ozcebe, Osman Ilhami] Hacettepe Univ, Sch Med, Dept Haematol, Ankara, Turkey.
   [Azap, Alpay] Ankara Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Ankara, Turkey.
   [Cetin, Ahmet Turker] Mem Hosp, Clin Haematol, Ankara, Turkey.
   [Yenicesu, Idil] EPOS Hlth Management GmbH, Ankara, Turkey.
   [Ozturk, Abdullah; Gunduz, Mehmet; Tekin, Ahmet] Minist Hlth, Gen Directorate Hlth Serv, Ankara, Turkey.
RP Yilmaz, S (corresponding author), Univ Hlth Sci, Gulhane Training & Res Hosp, Reg Blood Ctr, Ankara, Turkey.
EM soner.yilmaz3@saglik.gov.tr; nigarertugrul@gmail.com; oozcebe@gmail.com;
   alpayazap@yahoo.com; tcetin1@gmail.com; iyenicesu@gmail.com;
   abdullah.ozturk@saglik.gov.tr; mehmet.gunduz52@saglik.gov.tr;
   ahmet.tekin42@saglik.gov.tr
CR [Anonymous], 2020, COVID 19 CONVALESCEN
   [Anonymous], 2020, COVID 19 BLOOD SUPPL
   Cascella M, 2020, EVALUATION TREATMENT
   Council of Europe, 19 ED GUID PREP US Q
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Epstein J, 2020, VOX SANG, V115, P485, DOI 10.1111/vox.12939
   FDA, 2020, INV COVID 19 CONV PL
   Fleming AB, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104388
   National Guide on Preperation, 2020, US QUAL ASS BLOOD BL
   She J, 2020, CLIN TRANSL MED, V20, P9, DOI DOI 10.1186/S40169-020-00271-Z]
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Statement on the second meeting of the International Health Regulations, 2005, EM COMM REG OUTBR NO
   WHO Blood Regulators Network, 2017, POS PAP US CONV PLAS
   WHO Blood Regulators Network, 2014, POS PAP COLL US CONV
   WHO Blood Regulators Network (BRN), 2020, INT POS PAP BLOOD RE
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
NR 16
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1473-0502
J9 TRANSFUS APHER SCI
JI Transfus. Apher. Sci.
PD OCT
PY 2020
VL 59
IS 5
AR 102846
DI 10.1016/j.transci.2020.102846
PG 7
WC Hematology
SC Hematology
GA OY3YQ
UT WOS:000594185700011
PM 32593519
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU McCaw, ZR
   Tian, L
   Sheth, KN
   Hsu, WT
   Kimberly, WT
   Wei, LJ
AF McCaw, Zachary R.
   Tian, Lu
   Sheth, Kevin N.
   Hsu, Wan-Ting
   Kimberly, W. Taylor
   Wei, Lee-Jen
TI Selecting appropriate endpoints for assessing treatment effects in
   comparative clinical studies for COVID-19
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
AB To evaluate the efficacy and safety of a new treatment for COVID-19 vs. standard care, certain key endpoints are related to the duration of a specific event, such as hospitalization, ICU stay, or receipt of supplemental oxygen. However, since patients may die in the hospital during study follow-up, using, for example, the duration of hospitalization to assess treatment efficacy can be misleading. If the treatment tends to prolong patients' survival compared with standard care, patients in the new treatment group may spend more time in hospital. This can lead to a "survival bias" issue, where a treatment that is effective for preventing death appears to prolong an undesirable outcome. On the other hand, by using hospital-free survival time as the endpoint, we can circumvent the survival bias issue. In this article, we use reconstructed data from a recent, large clinical trial for COVID-19 to illustrate the advantages of this approach. For the analysis of ICU stay or oxygen usage, where the initiating event is potentially an outcome of treatment, standard survival analysis techniques may not be appropriate. We also discuss issues with analyzing the durations of such events.
C1 [McCaw, Zachary R.] Google, Mountain View, CA 94043 USA.
   [Tian, Lu] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.
   [Sheth, Kevin N.] Yale Sch Med, Div Neurocrit Care & Emergency Neurol, New Haven, CT USA.
   [Hsu, Wan-Ting] Med Wizdom LLC, Brookline, MA USA.
   [Kimberly, W. Taylor] Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care, Boston, MA 02114 USA.
   [Wei, Lee-Jen] Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
RP Wei, LJ (corresponding author), Harvard Univ, Dept Biostat, 655 Huntington Ave, Boston, MA 02115 USA.
EM wei@hsph.harvard.edu
OI McCaw, Zachary/0000-0002-2006-9828; Hsu, Wan-Ting/0000-0002-6677-0951
CR Austin PC, 2016, CIRCULATION, V133, P601, DOI 10.1161/CIRCULATIONAHA.115.017719
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Guyot P, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-9
   Huang B, 2020, ANN INTERN MED, V173, P368, DOI 10.7326/M20-0104
   Kim DH, 2017, JAMA CARDIOL, V2, P1179, DOI 10.1001/jamacardio.2017.2922
   Lau B, 2009, AM J EPIDEMIOL, V170, P244, DOI 10.1093/aje/kwp107
   Mccaw ZR, 2020, ANN INTERN MED, V173, P632, DOI 10.7326/M20-4044
   McCaw ZR, 2019, AM J MED, V132, P13, DOI 10.1016/j.amjmed.2018.07.026
   Pak K, 2017, JAMA ONCOL, V3, P1692, DOI 10.1001/jamaoncol.2017.2797
   Uno H, 2014, J CLIN ONCOL, V32, P2380, DOI 10.1200/JCO.2014.55.2208
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Zhao LH, 2018, JAMA CARDIOL, V3, P357, DOI 10.1001/jamacardio.2018.0127
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD OCT
PY 2020
VL 97
AR 106145
DI 10.1016/j.cct.2020.106145
PG 4
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OY1BO
UT WOS:000593988600009
PM 32927092
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Cala-Garcia, JD
   Sierra-Breton, JD
   Cavelier-Baiz, JE
   Faccini-Martinez, AA
   Perez-Diaz, CE
AF Cala-Garcia, Juan David
   Sierra-Breton, Juan David
   Cavelier-Baiz, Jorge Eduardo
   Faccini-Martinez, Alvaro A.
   Perez-Diaz, Carlos Eduardo
TI Recovery of COVID-19 acute respiratory distress syndrome with
   tocilizumab: successful outcome in two critically ill patients
SO IMMUNOTHERAPY
LA English
DT Article
DE ARDS; C-reactive protein; COVID-19; cytokine storm syndrome;
   hyperinflammation; IL-6; immunotherapy; monoclonal antibodies;
   SARS-CoV-2; severe pneumonia; tocilizumab
ID CYTOKINE STORM; SARS-COV-2; PNEUMONIA
AB Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivation of the immune system, better known as cytokine storm syndrome. Tocilizumab has been proposed to treat COVID-19 severe cases associated to ARDS. Results & methodology: Here we present two successful cases of tocilizumab administration in two COVID-19 patients with prior administration of antiviral therapy (hydroxychloroquine, azithromycin, lopinavir and ritonavir) with adequate response and resolution of ARDS, septic shock and severe pneumonia within the first 72 h. Discussion & conclusion: This case supports the usage of tocilizumab as an effective therapy in COVID-19 associated cytokine storm syndrome. Further studies should be done in order to assess its effectiveness and security.
C1 [Cala-Garcia, Juan David; Sierra-Breton, Juan David; Cavelier-Baiz, Jorge Eduardo; Perez-Diaz, Carlos Eduardo] Clin Marly, Infect Dis, Bogota 110231, Colombia.
   [Faccini-Martinez, Alvaro A.] Assoc Colombiana Infectol, Bogota 110111, Colombia.
   [Perez-Diaz, Carlos Eduardo] Hosp Samaritana, Infect Dis, Bogota 110321, Colombia.
RP Cala-Garcia, JD (corresponding author), Clin Marly, Infect Dis, Bogota 110231, Colombia.
EM juancala97@hotmail.com
OI Faccini-Martinez, Alvaro A./0000-0002-1127-0132; perez,
   carlos/0000-0002-5103-5938; Cala-Garcia, Juan/0000-0002-2571-1373
CR Alzghari SK, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104380
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Cellina M, 2020, DIAGN INTERV IMAG, V101, P323, DOI 10.1016/j.diii.2020.03.010
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Chakraborty C, 2020, J MED VIROL, V92, P2260, DOI 10.1002/jmv.26078
   Chakraborty C, 2020, J MED VIROL, V92, P2314, DOI 10.1002/jmv.25997
   Chinese clinical trial register, CHIN CLIN TRIAL REG
   Colombian Ministry of Health, COR COV 19
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Radbel J, 2020, CHEST, V158, pE15, DOI 10.1016/j.chest.2020.04.024
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Saha A, 2020, ARCH MED RES, V51, P595, DOI 10.1016/j.arcmed.2020.05.009
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Wang HL, 2008, AM J EMERG MED, V26, P711, DOI 10.1016/j.ajem.2007.10.031
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 20
TC 6
Z9 5
U1 0
U2 0
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-743X
EI 1750-7448
J9 IMMUNOTHERAPY-UK
JI Immunotherapy
PD OCT
PY 2020
VL 12
IS 15
BP 1127
EP 1132
DI 10.2217/imt-2020-0154
PG 6
WC Immunology
SC Immunology
GA PE7VI
UT WOS:000598570700001
PM 32664810
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Quinn, L
   Macpherson, C
   Long, K
   Shah, H
AF Quinn, Lori
   Macpherson, Chelsea
   Long, Katrina
   Shah, Hiral
TI Promoting Physical Activity via Telehealth in People With Parkinson
   Disease: The Path Forward After the COVID-19 Pandemic?
SO PHYSICAL THERAPY
LA English
DT Article
ID EXERCISE; PROGRAM; INTERVENTION
AB Objective. There is mounting evidence in support of exercise and physical activity as a first-line approach to managing symptoms and potentially altering disease progression in people with Parkinson disease (PD). For many patients, a critical gap is the need for expert guidance to overcome barriers, set realistic goals, and provide personalized advice to optimize exercise uptake and adherence. The purpose of this case report is to describe a physical activity coaching program (Engage-PD) for individuals newly diagnosed with PD and to highlight rapid modifications made to this program in response to the COVID-19 pandemic.
   Methods (Case Description). Engage-PD is a single cohort implementation study of a coaching intervention grounded in self-determination theory being conducted at Columbia University Parkinson's Foundation Center of Excellence in New York City, NY (USA), the early epicenter of the COVID-19 pandemic in the United States. The project was uniquely positioned to be adapted to telehealth delivery and to address an immediate need for support and guidance in the home environment, including people with early-mid-stage PD. Participants completed baseline and follow-up (3 months) assessments and participated in up to 4 coaching sessions, all delivered via a telehealth platform. The intervention incorporated 1:1 coaching, goal-setting, physical activity monitoring, and use of a disease-specific workbook to promote and support safe exercise uptake.
   Results. While the program is ongoing, 52 referrals were received and 27 individuals with PD enrolled in the first 2 months of the pandemic for a recruitment rate of 52%. Although direct comparisons with pre-coronavirus recruitment are difficult due to the recency of the Engage-PD implementation study, this recruitment rate was larger than expected, which may have been due to several factors (eg, most patients had limited, if any, access to inperson programs and therapy services during this time, so the Engage program filled an immediate need to provide exercise and activity guidance). There was a wide range of scores for both baseline physical activity and self-efficacy measures.
   Conclusion. Remotely delivered interventions may serve as a sustainable platform for physical activity coaching programs for people with PD as well as other neurodegenerative diseases.
   Impact. With the uncertainty brought about by the current pandemic, this case report highlights the opportunity to shift the current model of care for individuals with neurodegenerative diseases such as PD.
C1 [Quinn, Lori; Macpherson, Chelsea; Long, Katrina] Columbia Univ, Teachers Coll, Dept Biobehav Sci, 525 W 120th St,Box 199, New York, NY 10027 USA.
   [Quinn, Lori] Columbia Univ, Dept Rehabil & Regenerat Med Phys Therapy, Irving Med Ctr, 525 W 120th St,Box 199, New York, NY 10027 USA.
   [Shah, Hiral] Columbia Univ, Dept Neurol, Irving Med Ctr, New York, NY 10027 USA.
RP Quinn, L (corresponding author), Columbia Univ, Teachers Coll, Dept Biobehav Sci, 525 W 120th St,Box 199, New York, NY 10027 USA.; Quinn, L (corresponding author), Columbia Univ, Dept Rehabil & Regenerat Med Phys Therapy, Irving Med Ctr, 525 W 120th St,Box 199, New York, NY 10027 USA.
EM lq2165@tc.columbia.edu
OI Macpherson, Chelsea/0000-0002-9152-2917
FU Parkinson's Foundation; Teachers College, Columbia University; Health
   and Care Research Wales; Parkinson's Disease Foundation
FX This program was funded in part by a community grant from the
   Parkinson's Foundation. Support for this program and earlier pilot
   studies was provided by Teachers College, Columbia University. Support
   for development of the Engage-HD intervention was funded by Health and
   Care Research Wales. C. Macpherson's role as a clinical evaluator was
   supported by the Parkinson's Disease Foundation. The funders played no
   role in the design, conduct, and reporting of this case report.
CR Ahlskog JE, 2011, NEUROLOGY, V77, P288, DOI 10.1212/WNL.0b013e318225ab66
   APTA, TELEHEALTH PRACTICE
   Bryant MS, 2018, NEUROLOGY, V90, P812, DOI 10.1212/WNL.0000000000005368
   Campos C, 2016, EXPERT REV NEUROTHER, V16, P723, DOI 10.1080/14737175.2016.1179582
   Chatto CA, 2018, J NEUROL PHYS THER, V42, P22, DOI 10.1097/NPT.0000000000000209
   Colon-Semenza C, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/mhealth.8074
   Dobkin BH, 2016, CURR OPIN NEUROL, V29, P693, DOI 10.1097/WCO.0000000000000380
   Ellis T, 2013, J NEUROL PHYS THER, V37, P85, DOI 10.1097/NPT.0b013e31829157c0
   Ellis T, 2013, PHYS THER, V93, P628, DOI 10.2522/ptj.20120279
   Ellis TD, 2019, PHYS THER, V99, P203, DOI 10.1093/ptj/pzy131
   Elsworth C, 2011, CLIN REHABIL, V25, P588, DOI 10.1177/0269215510392076
   Fullard ME, 2017, NEUROLOGY, V89, P1162, DOI 10.1212/WNL.0000000000004355
   Gallo PM, 2011, ACSMS HEALTH FIT J, V15, P8, DOI 10.1249/FIT.0b013e31821eca84
   Jette AM, 2019, PHYS THER, V99, P125, DOI 10.1093/ptj/pzy138
   Jones TM, 2016, PHYS THER, V96, P1982, DOI 10.2522/ptj.20160028
   Kim Y, 2019, AM J PHYS MED REHAB, V98, P613, DOI 10.1097/PHM.0000000000001174
   Kruse CS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016242
   Long KM, 2020, PROQUEST PUBL, P1
   Marras C, 2018, NPJ PARKINSON DIS, V4, DOI 10.1038/s41531-018-0058-0
   Norman GJ, 2004, PSYCHOL HEALTH, V19, P561, DOI 10.1080/08870440410001722930
   O'Brien C, 2015, DISABIL REHABIL, V8288, P1
   Paillard T, 2015, J CLIN NEUROL, V11, P212, DOI 10.3988/jcn.2015.11.3.212
   Quinn L, 2017, J NEUROL PHYS THER, V41, pS46, DOI 10.1097/NPT.0000000000000166
   Quinn L, 2016, J NEUROL PHYS THER, V40, P71, DOI 10.1097/NPT.0000000000000119
   Rafferty MR, 2019, PHYS THER, V99, P1644, DOI 10.1093/ptj/pzz129
   Speelman AD, 2014, PHYSIOTHERAPY, V100, P134, DOI 10.1016/j.physio.2013.05.003
   Speelman AD, 2011, NAT REV NEUROL, V7, P528, DOI 10.1038/nrneurol.2011.107
   Teixeira PJ, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-78
   THOMAS S, 1992, CAN J SPORT SCI, V17, P338
   Totten A, 2016, REPORT 16 EHC034 EF
   van der Eijk M, 2013, PARKINSONISM RELAT D, V19, P923, DOI 10.1016/j.parkreldis.2013.04.022
   van Nimwegen M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f576
   van Weert E, 2008, PATIENT EDUC COUNS, V71, P169, DOI 10.1016/j.pec.2007.11.027
   Vencato MM, 2017, PSYCHOL SPORT EXERC, V33, P24, DOI 10.1016/j.psychsport.2017.07.003
NR 34
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0031-9023
EI 1538-6724
J9 PHYS THER
JI Phys. Ther.
PD OCT
PY 2020
VL 100
IS 10
BP 1730
EP 1736
DI 10.1093/ptj/pzaa128
PG 7
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA OW8QU
UT WOS:000593145200003
PM 32734298
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ng, JA
   Miccile, LA
   Iracheta, C
   Berndt, C
   Detwiller, M
   Yuse, C
   Tolland, J
AF Ng, Jillian A.
   Miccile, Lauren A.
   Iracheta, Christine
   Berndt, Carolyn
   Detwiller, Meredith
   Yuse, Carolyn
   Tolland, Joseph
TI Prone Positioning of Patients With Acute Respiratory Distress Syndrome
   Related to COVID-19: A Rehabilitation-Based Prone Team
SO PHYSICAL THERAPY
LA English
DT Article
AB Objective. Prone positioning is an effective intervention for acute respiratory distress syndrome (ARDS). An increasing number of patients with ARDS related to coronavirus disease 2019 require prone positioning, which poses a challenge to the intensive care unit staff at Brigham and Women's Hospital.
   Methods. A prone team service of physical therapists and occupational therapists with critical care experience was established to assist with increasing demands for prone positioning of patients who were mechanically ventilated. The goals of the rehabilitation-based prone team were to provide support to nursing and respiratory therapy; create a consistent, efficient process; and ensure patient and staff safety.
   Results. The service evolved over 7 weeks, expanding to 24-hour coverage and adding responsibilities to support the staff as patient volume grew. The volume of requests to the rehabilitation-based prone team generally increased to week 4 and has, since then, declined. Key points for successful implementation included identification of rehabilitation therapists with intensive care unit experience and leadership qualities, multidisciplinary collaboration, availability of needed positioning devices and supplies to protect the integument, and well-defined roles of all disciplines participating in position change process.
   Conclusion. The description of the development, operations, evolution, and utilization of a rehabilitation therapist prone team acts as a guide for future development and implementation.
   Impact. This case report is one of the first reports of a rehabilitation-based prone team established to assist with positioning patients in prone as an intervention for ARDS related to coronavirus disease 2019 and will help guide other institutions.
C1 [Ng, Jillian A.; Miccile, Lauren A.; Iracheta, Christine; Berndt, Carolyn; Detwiller, Meredith; Yuse, Carolyn; Tolland, Joseph] Brigham & Womens Hosp, Dept Rehabil Serv, 75 Francis St, Boston, MA 20115 USA.
RP Ng, JA (corresponding author), Brigham & Womens Hosp, Dept Rehabil Serv, 75 Francis St, Boston, MA 20115 USA.
EM jng3@bwh.harvard.edu
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Bailek S, 2020, MMWR-MORBID MORTAL W, V69, P343
   Diaz JV, 2020, CLIN MANAGEMENT SEVE
   Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Kallet RH, 2015, RESP CARE, V60, P1660, DOI 10.4187/respcare.04271
   Massachusetts Department of Public Health, ARCH COVID 19 CAS MA
   Mitchell DA, 2018, AACN ADV CRIT CARE, V29, P415, DOI 10.4037/aacnacc2018161
   PIEHL MA, 1976, CRIT CARE MED, V4, P13, DOI 10.1097/00003246-197601000-00003
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Thomas P, 2020, J PHYSIOTHER, V66, P73, DOI 10.1016/j.jphys.2020.03.011
NR 12
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0031-9023
EI 1538-6724
J9 PHYS THER
JI Phys. Ther.
PD OCT
PY 2020
VL 100
IS 10
BP 1737
EP 1745
DI 10.1093/ptj/pzaa124
PG 9
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA OW8QU
UT WOS:000593145200004
PM 32691056
OA Bronze, Green Accepted
DA 2021-01-01
ER

PT J
AU Bury, TJ
   Stokes, EK
AF Bury, Tracy J.
   Stokes, Emma K.
TI On "Musculoskeletal Physical Therapy During the COVID-19 Pandemic: Is
   Telerehabilitation the Answer?" Turolla A, Rossettini G, Viceconti A,
   Palese A, Geri T. Phys Ther. 2020;100:1260-1264
SO PHYSICAL THERAPY
LA English
DT Letter
DE COVID-19; Rehabilitation; Telemedicine
C1 [Bury, Tracy J.] Victoria Char Ctr, World Physiotherapy, 11 Belgrave Rd London, London SW1V 1RB, England.
   [Stokes, Emma K.] Qatar Univ, Dept Physiotherapy & Rehabil Sci, Doha, Qatar.
   [Stokes, Emma K.] World Physiotherapy, London, England.
RP Bury, TJ (corresponding author), Victoria Char Ctr, World Physiotherapy, 11 Belgrave Rd London, London SW1V 1RB, England.
EM tbury@wcpt.org; president@wcpt.org
CR Turolla A, 2020, PHYS THER, V100, P1260, DOI 10.1093/ptj/pzaa093
   World Confederation for Physical Therapy (WCPT), COVID 19 INF HUB
   World Confederation for Physical Therapy (WCPT) International Network of Physiotherapy Regulatory Authorities, 2020, INT NETW PHYS REG AU
NR 3
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0031-9023
EI 1538-6724
J9 PHYS THER
JI Phys. Ther.
PD OCT
PY 2020
VL 100
IS 10
BP 1883
EP 1883
DI 10.1093/ptj/pzaa131
PG 1
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA OW8QU
UT WOS:000593145200017
PM 32976592
OA Green Published
DA 2021-01-01
ER

PT J
AU Turolla, A
   Rossettini, G
   Viceconti, A
   Palese, A
   Geri, T
AF Turolla, Andrea
   Rossettini, Giacomo
   Viceconti, Antonello
   Palese, Alvisa
   Geri, Tommaso
TI On "Musculoskeletal Physical Therapy During the COVID-19 Pandemic: Is
   Telerehabilitation the Answer?" Turolla A, Rossettini G, Viceconti A,
   Palese A, Geri T. Phys Ther. 2020;100:1260-1264 Response
SO PHYSICAL THERAPY
LA English
DT Letter
C1 [Turolla, Andrea] IRCCS San Camillo Hosp, Lab Rehabil Technol, Venice, Italy.
   [Rossettini, Giacomo] Univ Genoa, Dept Neurosci Rehabil Ophtalmol Genet Maternal &, Genoa, Liguria, Italy.
   [Viceconti, Antonello; Geri, Tommaso] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Campus Savona,Via Magliotto 2, I-17100 Savona, Savona, Italy.
   [Palese, Alvisa] Univ Udine, Sch Nursing, Dept Med Sci, Udine, Italy.
RP Turolla, A (corresponding author), IRCCS San Camillo Hosp, Lab Rehabil Technol, Venice, Italy.
EM andrea.turolla@ospedalesancamillo.net; giacomo.rossettini@gmail.com;
   antonello.viceconti@gmail.com; alvisa.palese@uniud.it;
   tommaso.geri@gmail.com
CR Associazione Italiana Fisioterapisti Commissioni di Albo dei Fisioterapisti (Rome), 2020, AGG NOT RIM INT FIS
   Turolla A, 2020, PHYS THER, V100, P1260, DOI 10.1093/ptj/pzaa093
NR 2
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0031-9023
EI 1538-6724
J9 PHYS THER
JI Phys. Ther.
PD OCT
PY 2020
VL 100
IS 10
BP 1884
EP 1884
DI 10.1093/ptj/pzaa132
PG 1
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA OW8QU
UT WOS:000593145200018
PM 32976584
DA 2021-01-01
ER

PT J
AU Han, J
   Wang, XQ
   Shen, X
   Hu, J
   Zhang, X
   Tang, X
   Wang, H
   Luo, QL
   Jiang, Y
   Jiang, Z
   Yang, L
   Zhang, Q
   Bai, YW
   Wu, XB
AF Han, Jia
   Wang, Xueqiang
   Shen, Xia
   Hu, Jia
   Zhang, Xin
   Tang, Xin
   Wang, Hong
   Luo, Qinglu
   Jiang, Ying
   Jiang, Zheng
   Yang, Lin
   Zhang, Qi
   Bai, Yiwen
   Wu, Xubo
TI On "Translating COVID-19 Evidence to Maximize Physical Therapists'
   Impact and Public Health Response." Dean E, Jones A, Yu HP-M, Gosselink
   R, Skinner M. Phys Ther. 2020:100;1458-1464
SO PHYSICAL THERAPY
LA English
DT Letter
DE Physical therapy education; Clinical Competence; Public Health
C1 [Han, Jia; Wang, Xueqiang] Shanghai Univ Sport, Dept Physiotherapy & Sports Rehabil, Sch Kinesiol, Shanghai 200438, Peoples R China.
   [Han, Jia] Swinburne Univ Technol, Fac Hlth Arts & Design, Hawthorn, Vic, Australia.
   [Han, Jia] Univ Canberra, Res Inst Sport & Exercise, Canberra, ACT, Australia.
   [Shen, Xia; Zhang, Xin] Tongji Univ, Dept Rehabil Sci, Sch Med, Shanghai, Peoples R China.
   [Shen, Xia; Hu, Jia] Tongji Univ, Shanghai Yangzhi Affiliated Rehabil Hosp, Shanghai, Peoples R China.
   [Zhang, Xin] Shanghai First Rehabil Hosp, Shanghai, Peoples R China.
   [Tang, Xin] Kunming Med Univ, Dept Physiotherapy, Rehabil Sch, Kunming, Yunnan, Peoples R China.
   [Wang, Hong] Shanghai Univ Med & Hlth Sci, Coll Rehabil Sci, Shanghai, Peoples R China.
   [Luo, Qinglu] Guangzhou Med Univ, Dept Rehabil, Affiliated Hosp 5, Guangzhou, Guangdong, Peoples R China.
   [Luo, Qinglu] Guangzhou Med Univ, Community Hlth Serv Ctr, Affiliated Hosp 5, Guangzhou, Guangdong, Peoples R China.
   [Jiang, Zheng] Binzhou Med Univ, Sch Rehabil Med, Yantai, Peoples R China.
   [Jiang, Zheng] Fujian Univ Tradit Chinese Med, Coll Rehabil Med, Fuzhou, Fujian, Peoples R China.
   [Yang, Lin] Sichuan Univ, Dept Rehabil Med, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Zhang, Qi] Capital Med Univ, Sch Rehabil Med, Dept Pediat Phys Therapy, Beijing, Peoples R China.
   [Zhang, Qi] Boai Hosp, China Rehabil Res Ctr, Beijing, Peoples R China.
   [Bai, Yiwen; Wu, Xubo] Shanghai Univ Tradit Chinese Med, Dept Phys Therapy, Shanghai, Peoples R China.
RP Han, J (corresponding author), Shanghai Univ Sport, Dept Physiotherapy & Sports Rehabil, Sch Kinesiol, Shanghai 200438, Peoples R China.; Han, J (corresponding author), Swinburne Univ Technol, Fac Hlth Arts & Design, Hawthorn, Vic, Australia.; Han, J (corresponding author), Univ Canberra, Res Inst Sport & Exercise, Canberra, ACT, Australia.
EM jia.han@canberra.edu.au; qiang897@163.com; shxia18003@tongji.edu.cn;
   reginahjj@163.com; xin.zhang@tongji.edu.cn; tangxin@kmmu.edu.cn;
   wanghongplus@163.com; 164475222@qq.com; 949273304@qq.com;
   13501320729@163.com; baiyiwen0507@163.com; wuxubo320@163.com
CR Chen PJ, 2020, J SPORT HEALTH SCI, V9, P103, DOI 10.1016/j.jshs.2020.02.001
   Dean E, 2020, PHYS THER, V100, P1458, DOI 10.1093/ptj/pzaa115
   Dunleavy K, 2018, DISABIL REHABIL, V40, P1600, DOI 10.1080/09638288.2017.1300692
   Haines KJ, 2020, J PHYSIOTHER, V66, P67, DOI 10.1016/j.jphys.2020.03.012
NR 4
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0031-9023
EI 1538-6724
J9 PHYS THER
JI Phys. Ther.
PD OCT
PY 2020
VL 100
IS 10
BP 1885
EP 1886
DI 10.1093/ptj/pzaa133
PG 2
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA OW8QU
UT WOS:000593145200019
PM 32737974
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Nagendrappa, S
   Shoib, S
   Rehman, S
   Grigo, O
   Ransing, R
AF Nagendrappa, Sachin
   Shoib, Sheikh
   Rehman, Sajjadur
   Grigo, Omityah
   Ransing, Ramdas
TI Recognizing the role of animal-assisted therapies in addressing mental
   health needs during the COVID-19 pandemic
SO ASIAN JOURNAL OF PSYCHIATRY
LA English
DT Letter
C1 [Nagendrappa, Sachin] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Psychiat, Bengaluru 29, India.
   [Shoib, Sheikh] Jawahar Lal Nehru Mem Hosp JLNMH, Dept Psychiat, Srinagar 190003, Jammu & Kashmir, India.
   [Rehman, Sajjadur] Lady Hardinge Med Coll & Hosp, Dept Psychiat, New Delhi 110001, India.
   [Grigo, Omityah] MMU Med Coll, Dept Psychiat, Solan 173229, Himachal Prades, India.
   [Ransing, Ramdas] BKL Walawalkar Rural Med Coll, Dept Psychiat, Ratnagiri 415606, Maharashtra, India.
RP Ransing, R (corresponding author), BKL Walawalkar Rural Med Coll, Dept Psychiat, Ratnagiri 415606, Maharashtra, India.
EM nsachin40@gmail.com; sheikhshoib22@gmail.com; sajjadur25@gmail.com;
   dromityah@gmail.com; ramdas_ransing123@yahoo.co.in
RI RANSING, RAMDAS Sarjerao/H-4776-2014
OI RANSING, RAMDAS Sarjerao/0000-0002-5040-5570; Shoib,
   Sheikh/0000-0002-3739-706X
CR Andrade BB, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00121
   Brooks H, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1111-3
   Maujean A, 2015, ANTHROZOOS, V28, P23, DOI 10.2752/089279315X14129350721812
   Parry N.M.A., 2020, FORENSIC SCI INT REP, V2, DOI [10.1016/j.fsir.2020.100090, DOI 10.1016/J.FSIR.2020.100090]
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Ransing R, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102085
   Rew L, 2000, J Child Adolesc Psychiatr Nurs, V13, P125, DOI 10.1111/j.1744-6171.2000.tb00089.x
   Shoib Sheikh, 2020, Asian J Psychiatr, V53, P102223, DOI 10.1016/j.ajp.2020.102223
   Tandon R, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102256
   Tandon R, 2020, ASIAN J PSYCHIATR, V50, DOI 10.1016/j.ajp.2020.102100
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1876-2018
EI 1876-2026
J9 ASIAN J PSYCHIATR
JI Asian J. Psychiatr.
PD OCT
PY 2020
VL 53
AR 102390
DI 10.1016/j.ajp.2020.102390
PG 2
WC Psychiatry
SC Psychiatry
GA PB9IS
UT WOS:000596626500006
PM 32882672
OA Green Published
DA 2021-01-01
ER

PT J
AU Chen, SL
   Xu, H
   Feng, HY
   Sun, JF
   Li, X
   Zhou, L
   Song, WL
   Huang, SS
   He, JL
   Deng, YY
   Wang, RJ
   Fang, M
AF Chen, Sheng-Long
   Xu, Hui
   Feng, Hui-Ying
   Sun, Jiu-Feng
   Li, Xin
   Zhou, Lin
   Song, Wen-Liang
   Huang, Shan-Shan
   He, Jun-Lei
   Deng, Yi-Yu
   Wang, Rui-Jie
   Fang, Ming
TI Epidemiological and Clinical Findings of Short-Term Recurrence of Severe
   Acute Respiratory Syndrome Coronavirus 2 Ribonucleic Acid Polymerase
   Chain Reaction Positivity in 1282 Discharged Coronavirus Disease 2019
   Cases: A Multicenter, Retrospective, Observational Study
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE communicable; COVID-19; recurrence; relapse; retrospective
ID COVID-19
AB Background. Short-term recurrence of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ribonucleic acid (RNA) polymerase chain reaction (PCR) in discharged coronavirus disease 2019 (COVID-19) patients attracts the public's concern. This study aimed to determine the clinical and epidemiological results of such patients.
   Methods. This retrospective study was conducted on 32 designated hospitals for COVID-19 patients discharged from January 14 to March 10, 2020. After 28-day followed-up, patients who tested positive again for SARS-CoV-2 RNA and confirmed by reverse-transcriptase polymerase chain reaction were re-admitted to hospital for further treatments. All of the close contacts of patients who tested positive again were asked to self-segregate for 14 days. Data of epidemiology, symptoms, laboratory tests, and treatments were analyzed in those patients, and their close contacts were investigated.
   Results. Of 1282 discharged patients, 189 (14.74%) tested positive again for SARS-CoV-2 RNA during 28-day follow-up. The median time from discharge to the next positive test was 8 days (interquartile range [IQR], 5-13). Patients in the group that tested positive again were younger (34 vs 45 years, P < .001) with a higher proportion of moderate symptoms (95.77% vs 84.35%, P < .001) in the first hospitalization than in the negative group. During the second hospitalization, all patients who tested positive again showed normal peripheral white blood cells and lymphocytes and no new symptoms of COVID-19; 78.31% further improved on chest computed tomography scan compared with the first discharge, yet 25.93% accepted antiviral therapy. The median time of re-positive to negative test was 8 days (IQR, 4-15). None of the close contacts developed COVID-19.
   Conclusions. Our data suggest that the short-term recurrence of positive SARS-CoV-2 RNA in discharged patients is not a relapse of COVID-19, and the risk of onward transmission is very low. This provides important information for managing COVID-19 patients.
C1 [Chen, Sheng-Long; Xu, Hui; Li, Xin; Song, Wen-Liang; Deng, Yi-Yu; Wang, Rui-Jie; Fang, Ming] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China.
   [Xu, Hui] Shantou Univ, Med Coll, Shantou, Peoples R China.
   [Feng, Hui-Ying; Zhou, Lin; Huang, Shan-Shan; He, Jun-Lei] Ctr TB Control Guangdong Prov, Guangzhou, Peoples R China.
   [Sun, Jiu-Feng] Guangdong Prov Ctr Dis Control & Prevent, Guangdong Prov Inst Publ Hlth, Guangzhou, Peoples R China.
   [Song, Wen-Liang; Fang, Ming] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China.
   [Wang, Rui-Jie; Fang, Ming] South China Univ Technol, Sch Med, Guangzhou, Peoples R China.
RP Fang, M (corresponding author), 106 Zhongshan Er Rd, Guangzhou 510080, Peoples R China.
EM drfangming@163.com
FU Health Commission of Guangdong Province; Department of Science and
   Technology of Guangdong Province; Special Project on Emergency Response
   to Control of Novel Coronavirus Infection of Guangdong Province; Special
   Project on Emergency Response to Control of COVID-19 Infection of
   Guangdong Province [2020B1111330003]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81701875]
FX This study is supported by the Health Commission of Guangdong Province
   and the Department of Science and Technology of Guangdong Province. This
   study is also supported by Special Project on Emergency Response to
   Control of Novel Coronavirus Infection of Guangdong Province. This work
   was funded by the Special Project on Emergency Response to Control of
   COVID-19 Infection of Guangdong Province (No. 2020B1111330003) and the
   National Natural Science Foundation of China (No. 81701875).
CR Aquino-Jarquin G, 2019, NANOMED-NANOTECHNOL, V18, P428, DOI 10.1016/j.nano.2019.03.006
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Chen DB, 2020, INT J INFECT DIS, V93, P297, DOI 10.1016/j.ijid.2020.03.003
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Ding J, 2020, J PUBLIC HEALTH MAN, V26, P345, DOI 10.1097/PHH.0000000000001189
   GREISMAN S E, 1961, Trans Am Clin Climatol Assoc, V73, P146
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   National Health Commission National Administration of Traditional Chinese Medicine, 2020, INFECT MICROBE DIS, V2, P48
   Qu YM, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101619
   Sun JF, 2020, EMERG INFECT DIS, V26, P1834, DOI 10.3201/eid2608.201097
   Tan L, 2020, SPECIAL CASE COVID 1, DOI [10.1101/2020.03.22.20040071, DOI 10.1101/2020.03.22.20040071]
   To Kelvin Kai-Wang, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1275
   Waddington CS, 2014, J INFECTION, V68, P405, DOI 10.1016/j.jinf.2014.01.006
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, COR DIS COVID 19 PAN
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yuan J, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa398, DOI 10.1093/CID/CIAA398]
   Zhang B, 2020, J INFECTION, V81, pE49, DOI 10.1016/j.jinf.2020.04.023
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 28
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD OCT
PY 2020
VL 7
IS 10
AR ofaa432
DI 10.1093/ofid/ofaa432
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OW8JN
UT WOS:000593126300052
PM 33123610
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kalligeros, M
   Tashima, KT
   Mylona, EK
   Rybak, N
   Flanigan, TP
   Farmakiotis, D
   Beckwith, CG
   Sanchez, M
   Neill, M
   Johnson, JE
   Garland, JM
   Aung, S
   Byrd, KM
   O'Brien, T
   Pandita, A
   Aridi, J
   Gil, RM
   Larkin, J
   Shehadeh, F
   Mylonakis, E
AF Kalligeros, Markos
   Tashima, Karen T.
   Mylona, Evangelia K.
   Rybak, Natasha
   Flanigan, Timothy P.
   Farmakiotis, Dimitrios
   Beckwith, Curt G.
   Sanchez, Martha
   Neill, Marguerite
   Johnson, Jennie E.
   Garland, Joseph M.
   Aung, Su
   Byrd, Katrina M.
   O'Brien, Thomas
   Pandita, Aakriti
   Aridi, Jad
   Gil, Raul Macias
   Larkin, Jerome
   Shehadeh, Fadi
   Mylonakis, Eleftherios
TI Remdesivir Use Compared With Supportive Care in Hospitalized Patients
   With Severe COVID-19: A Single-Center Experience
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; efficacy; remdesivir; safety; SARS-CoV-2
AB Background. The US Food and Drug Administration issued an Emergency Use Authorization for remdesivir use in patients with severe COVID-19.
   Methods. We utilized data from 2 quaternary acute care hospitals. The outcomes of interest were the impact of remdesivir on in-hospital death by day 28 and time to recovery, clinical improvement, and discharge. We utilized Cox proportional hazards models and stratified log-rank tests.
   Results. Two hundred twenty-four patients were included in the study. The median age was 59 years; 67.0% were male; 17/125 patients (13.6%) who received supportive care and 7/99 patients (7.1%) who received remdesivir died. The unadjusted risk for 28-day in-hospital death was lower for patients who received remdesivir compared with patients who received supportive care (hazard ratio [HR], 0.42; 95% CI, 0.16-1.08). Although this trend remained the same after adjusting for age, sex, race, and oxygen requirements on admission (adjusted HR [aHR], 0.49; 95% CI, 0.19-1.28), as well as chronic comorbidities and use of corticosteroids (aHR, 0.44; 95% CI, 0.16-1.23), it did not reach statistical significance. The use of remdesivir was not associated with an increased risk of acute kidney injury (AKI) or liver test abnormalities. Although not statistically significant, the rate ratios for time to recovery, clinical improvement, and discharge were higher in women and black or African American patients.
   Conclusions. Patients on remdesivir had lower, albeit not significant, all-cause in-hospital mortality, and the use of remdesivir did not increase the risk for AKI. Promising signals from this study need to be confirmed by future placebo-controlled randomized clinical trials.
C1 [Kalligeros, Markos; Tashima, Karen T.; Mylona, Evangelia K.; Rybak, Natasha; Flanigan, Timothy P.; Farmakiotis, Dimitrios; Beckwith, Curt G.; Sanchez, Martha; Neill, Marguerite; Johnson, Jennie E.; Garland, Joseph M.; Aung, Su; Byrd, Katrina M.; O'Brien, Thomas; Pandita, Aakriti; Aridi, Jad; Gil, Raul Macias; Larkin, Jerome; Shehadeh, Fadi; Mylonakis, Eleftherios] Brown Univ, Infect Dis Div, Warren Alpert Med Sch, Providence, RI 02912 USA.
RP Tashima, KT (corresponding author), Miriam Hosp, 180 Corliss St Suite F, Providence, RI 02904 USA.
EM KTashima@Lifespan.org; emylonakis@lifespan.org
FU Providence/Boston Center for AIDS Research [P30AI042853]; NIAID AIDS
   Clinical Trials Unit [UM1 A1069412]
FX This work was facilitated by the Providence/Boston Center for AIDS
   Research (P30AI042853) and the NIAID AIDS Clinical Trials Unit UM1
   A1069412.
CR Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Gilead Sciences Inc, GIL SCI STAT EXP GLO
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Kellum JA, 2013, CRIT CARE, V17, DOI 10.1186/cc11454
   Levesque LE, 2010, BMJ-BRIT MED J, V340, pb5087, DOI DOI 10.1136/BMJ.B5087
   Norrie JD, 2020, LANCET, V395, P1525, DOI 10.1016/S0140-6736(20)31023-0
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   US Food Drug and Administration, FACT SHEET HLTH CAR
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
NR 15
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD OCT
PY 2020
VL 7
IS 10
AR ofaa319
DI 10.1093/ofid/ofaa319
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OW8JN
UT WOS:000593126300003
PM 33117850
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Salton, F
   Confalonieri, P
   Meduri, GU
   Santus, P
   Harari, S
   Scala, R
   Lanini, S
   Vertui, V
   Oggionni, T
   Caminati, A
   Patruno, V
   Tamburrini, M
   Scartabellati, A
   Parati, M
   Villani, M
   Radovanovic, D
   Tomassetti, S
   Ravaglia, C
   Poletti, V
   Vianello, A
   Gaccione, AT
   Guidelli, L
   Raccanelli, R
   Lucernoni, P
   Lacedonia, D
   Barbaro, MPF
   Centanni, S
   Mondoni, M
   Davi, M
   Fantin, A
   Cao, XY
   Torelli, L
   Zucchetto, A
   Montico, M
   Casarin, A
   Romagnoli, M
   Gasparini, S
   Bonifazi, M
   D'Agaro, P
   Marcello, A
   Licastro, D
   Ruaro, B
   Volpe, MC
   Umberger, R
   Confalonieri, M
AF Salton, Francesco
   Confalonieri, Paola
   Meduri, G. Umberto
   Santus, Pierachille
   Harari, Sergio
   Scala, Raffaele
   Lanini, Simone
   Vertui, Valentina
   Oggionni, Tiberio
   Caminati, Antonella
   Patruno, Vincenzo
   Tamburrini, Mario
   Scartabellati, Alessandro
   Parati, Mara
   Villani, Massimiliano
   Radovanovic, Dejan
   Tomassetti, Sara
   Ravaglia, Claudia
   Poletti, Venerino
   Vianello, Andrea
   Gaccione, Anna Talia
   Guidelli, Luca
   Raccanelli, Rita
   Lucernoni, Paolo
   Lacedonia, Donato
   Barbaro, Maria Pia Foschino
   Centanni, Stefano
   Mondoni, Michele
   Davi, Matteo
   Fantin, Alberto
   Cao, Xueyuan
   Torelli, Lucio
   Zucchetto, Antonella
   Montico, Marcella
   Casarin, Annalisa
   Romagnoli, Micaela
   Gasparini, Stefano
   Bonifazi, Martina
   D'Agaro, Pierlanfranco
   Marcello, Alessandro
   Licastro, Danilo
   Ruaro, Barbara
   Volpe, Maria Concetta
   Umberger, Reba
   Confalonieri, Marco
TI Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19
   Pneumonia
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE ARDS; COVID-19; methylprednisolone; pneumonia; SARS-CoV-2
ID ACUTE RESPIRATORY SYNDROME; INTENSIVE-CARE UNITS;
   CORTICOSTEROID-THERAPY; TRIALS
AB Background. In hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia, progression to acute respiratory failure requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality. Severe dysregulated systemic inflammation is the putative mechanism. We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for intensive care unit (ICU) admission and mortality.
   Methods. We conducted a multicenter observational study to explore the association between exposure to prolonged, low-dose MP treatment and need for ICU referral, intubation, or death within 28 days (composite primary end point) in patients with severe COVID-19 pneumonia admitted to Italian respiratory high-dependency units. Secondary outcomes were invasive MV-free days and changes in C-reactive protein (CRP) levels.
   Results. Findings are reported as MP (n = 83) vs control (n = 90). The composite primary end point was met by 19 vs 40 (adjusted hazard ratio [aHR], 0.41; 95% CI, 0.24-0.72). Transfer to ICU and invasive MV were necessary in 15 vs 27 (P = .07) and 14 vs 26 (P = .10), respectively. By day 28, the MP group had fewer deaths (6 vs 21; aHR, 0.29; 95% CI, 0.12-0.73) and more days off invasive MV (24.0 +/- 9.0 vs 17.5 +/- 12.8; P = .001). Study treatment was associated with rapid improvement in PaO2:FiO(2) and CRP levels. The complication rate was similar for the 2 groups (P = .84).
   Conclusion. In patients with severe COVID-19 pneumonia, early administration of prolonged, low dose MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Treatment was safe and did not impact viral clearance. A large randomized controlled trial (RECOVERY trial) has been performed that validates these findings.
C1 [Salton, Francesco; Confalonieri, Paola; Ruaro, Barbara; Confalonieri, Marco] Univ Hosp Cattinara, Dept Pulmonol, Trieste, Italy.
   [Meduri, G. Umberto] Univ Tennessee, Ctr Hlth Sci, Memphis VA Med Ctr, Pulm Crit Care & Sleep Med Serv, Memphis, TN 38163 USA.
   [Meduri, G. Umberto] Univ Tennessee, Ctr Hlth Sci, Memphis VA Med Ctr, Res Serv, Memphis, TN 38163 USA.
   [Meduri, G. Umberto] Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA.
   [Santus, Pierachille; Radovanovic, Dejan] Univ Milan, L Sacco Univ Hosp, Dept Biomed & Clin Sci DIBIC, ASST Fatebenefratelli Sacco, Milan, Italy.
   [Harari, Sergio] Univ Milan, San Giuseppe Hosp MultiMed IRCCS, Dept Med Sci, Milan, Italy.
   [Harari, Sergio] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Scala, Raffaele; Guidelli, Luca] S Donato Hosp, Pulmonol & Resp Intens Care Unit, Arezzo, Italy.
   [Lanini, Simone] Natl Inst Infect Dis L Spallanzani, Rome, Italy.
   [Vertui, Valentina; Oggionni, Tiberio] Policlin San Matteo IRCCS, Pulmonol Unit, Pavia, Italy.
   [Caminati, Antonella; Raccanelli, Rita] San Giuseppe Hosp MultiMed IRCCS, Div Pulm & Crit Care Med, Milan, Italy.
   [Patruno, Vincenzo; Fantin, Alberto] S Maria della Misericordia Univ Hosp, Pulmonol Dept, Udine, Italy.
   [Tamburrini, Mario] Azienda Osped Friuli Occident, SC Pneumol, Pordenone, Italy.
   [Scartabellati, Alessandro; Parati, Mara; Villani, Massimiliano] Osped Maggiore Crema, Dept Pulmonol, Crema, Italy.
   [Scartabellati, Alessandro; Parati, Mara; Villani, Massimiliano] Osped Maggiore Crema, Resp High Dependency Unit, Crema, Italy.
   [Tomassetti, Sara] Careggi Univ Hosp, Dept Expt & Clin Med, Florence, Italy.
   [Ravaglia, Claudia; Poletti, Venerino] GB Morgagni L Pierantoni Hosp, Dept Resp & Thorax Dis, Forli, Italy.
   [Vianello, Andrea] Univ City Hosp, Div Resp Pathophysiol & Intens Care, Padua, Italy.
   [Gaccione, Anna Talia; Lucernoni, Paolo] Vittorio Veneto Hosp, Pulmonol Dept, Vittorio Veneto, Italy.
   [Lacedonia, Donato; Barbaro, Maria Pia Foschino] Univ Foggia, Policlin Riuniti, Dept Med & Surg Sci, Foggia, Italy.
   [Centanni, Stefano; Mondoni, Michele; Davi, Matteo] S Paolo Hosp, Pulmonol Dept, Milan, Italy.
   [Cao, Xueyuan; Umberger, Reba] Univ Tennessee, Ctr Hlth Sci, Coll Nursing, Dept Acute & Tertiary Care, Memphis, TN 38163 USA.
   [Torelli, Lucio] Univ Trieste, Dept Clin Surg & Hlth Sci, Trieste, Italy.
   [Zucchetto, Antonella; Montico, Marcella] Ctr Riferimento Oncol Aviano CRO IRCCS, Sci Directorate, Aviano, Italy.
   [Casarin, Annalisa] Univ Hertfordshire, Ctr Hlth Serv & Clin Res, Hatfield, Herts, England.
   [Romagnoli, Micaela] Treviso Hosp, Pulm Unit, Treviso, Italy.
   [Gasparini, Stefano; Bonifazi, Martina] Polytech Univ Marche Reg, Azienda Osped Riuniti, Dept Biomed Sci & Publ Hlth, Ancona, Italy.
   [D'Agaro, Pierlanfranco] Univ Trieste, Azienda Sanit Univ Integrata Giuliano Isontina AS, Lab Riferimento SARS CoV 2, Trieste, Italy.
   [Marcello, Alessandro] Int Ctr Genet Engn & Biotechnol ICGEB, Lab Mol Virol, Trieste, Italy.
   [Licastro, Danilo] ARGO Open Lab Platform Genome Sequencing, Area Sci Pk, Trieste, Italy.
   [Volpe, Maria Concetta; Confalonieri, Marco] Univ Trieste, Trieste, Italy.
RP Confalonieri, M (corresponding author), Osped Cattinara, ASUGI, Struttura Complessa Pneumol, Str Fiume 447, I-34149 Trieste, Italy.
EM rnconfalonieri@units.it
RI ; Montico, Marcella/B-5290-2013; Zucchetto, Antonella/ABC-8649-2020
OI Vianello, Andrea/0000-0002-8790-6029; Umberger,
   Reba/0000-0002-4722-4031; Montico, Marcella/0000-0003-0377-8232;
   Zucchetto, Antonella/0000-0003-2812-6345
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Confalonieri M, 2005, AM J RESP CRIT CARE, V171, P242, DOI 10.1164/rccm.200406-808OC
   Confalonieri M, 2001, THORAX, V56, P373, DOI 10.1136/thorax.56.5.373
   Czock D, 2005, CLIN PHARMACOKINET, V44, P61, DOI 10.2165/00003088-200544010-00003
   Draghici S, 2020, COVID 19 DIS PATHW G, DOI [10.21203/rs.3.rs-29392/v1, DOI 10.21203/RS.3.RS-29392/V1]
   Fang XW, 2020, J INFECTION, V81, P147, DOI 10.1016/j.jinf.2020.03.039
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Henry BM, 2020, CLIN CHEM LAB MED, V58, P1021, DOI 10.1515/cclm-2020-0369
   Jung J, 2020, J INFECTION, V81, pE79, DOI 10.1016/j.jinf.2020.05.004
   Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456
   Long Y, 2016, INT J CLIN EXP MED, V9, P8865
   Meduri GU, 2016, INTENS CARE MED, V42, P829, DOI 10.1007/s00134-015-4095-4
   Meduri GU, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00161
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Nicastri E, 2020, INFECT DIS REP, V12, P3, DOI 10.4081/idr.2020.8543
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016
   VICHYANOND P, 1989, J ALLERGY CLIN IMMUN, V84, P867, DOI 10.1016/0091-6749(89)90381-3
   Villar Jesus, 2020, Crit Care Explor, V2, pe0111, DOI 10.1097/CCE.0000000000000111
   Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016
   Vitacca M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00632-2020
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Yam LYC, 2007, J INFECTION, V54, P28, DOI 10.1016/j.jinf.2006.01.005
NR 28
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD OCT
PY 2020
VL 7
IS 10
AR ofaa421
DI 10.1093/ofid/ofaa421
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OW8JN
UT WOS:000593126300042
PM 33072814
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ulrich, RJ
   Troxel, AB
   Carmody, E
   Eapen, J
   Backer, M
   DeHovitz, JA
   Prasad, PJ
   Li, Y
   Delgado, C
   Jrada, M
   Robbins, GA
   Henderson, B
   Hrycko, A
   Delpachitra, D
   Raabe, V
   Austrian, JS
   Dubrovskaya, Y
   Mulligan, MJ
AF Ulrich, Robert J.
   Troxel, Andrea B.
   Carmody, Ellie
   Eapen, Jaishvi
   Backer, Martin
   DeHovitz, Jack A.
   Prasad, Prithiv J.
   Li, Yi
   Delgado, Camila
   Jrada, Morris
   Robbins, Gabriel A.
   Henderson, Brooklyn
   Hrycko, Alexander
   Delpachitra, Dinuli
   Raabe, Vanessa
   Austrian, Jonathan S.
   Dubrovskaya, Yanina
   Mulligan, Mark J.
TI Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter,
   Double-Blind Randomized Controlled Trial in Hospitalized Patients
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; hydroxychloroquine; randomized controlled trial; SARS-CoV-2
ID RHEUMATOID-ARTHRITIS; CHLOROQUINE
AB Background. Effective therapies to combat coronavirus 2019 (COVID-19) arc urgently needed. Hydroxychloroquine (HCQ) has in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the clinical benefit of HCQ in treating COVID-19 is unclear. Randomized controlled trials are needed to determine the safety and efficacy of HCQ for the treatment of hospitalized patients with COVID-19.
   Methods. We conducted a multicenter, double-blind randomized clinical trial of HCQ among patients hospitalized with laboratory-confirmed COVID-19. Subjects were randomized in a 1:1 ratio to HCQ or placebo for 5 days and followed for 30 days. The primary efficacy outcome was a severe disease progression composite end point (death, intensive care unit admission, mechanical ventilation, extracorporeal membrane oxygenation, and/or vasopressor use) at day 14.
   Results. A total of 128 patients were included in the intention-to-treat analysis. Baseline demographic, clinical, and laboratory characteristics were similar between the HCQ (n = 67) and placebo (n = 61) arms. At day 14, 11 (16.4%) subjects assigned to HCQ and 6 (9.8%) subjects assigned to placebo met the severe disease progression end point, but this did not achieve statistical significance (P = .350). There were no significant differences in COVID-19 clinical scores, number of oxygen-free days, SARS-CoV-2 clearance, or adverse events between HCQ and placebo. HCQ was associated with a slight increase in mean corrected QT interval, an increased D-dimer, and a trend toward an increased length of stay.
   Conclusions. In hospitalized patients with COVID-19, our data suggest that HCQ does not prevent severe outcomes or improve clinical scores. However, our conclusions are limited by a relatively small sample size, and larger randomized controlled trials or pooled analyses are needed.
C1 [Ulrich, Robert J.; Carmody, Ellie; Eapen, Jaishvi; Prasad, Prithiv J.; Jrada, Morris; Henderson, Brooklyn; Hrycko, Alexander; Raabe, Vanessa; Austrian, Jonathan S.; Dubrovskaya, Yanina; Mulligan, Mark J.] NYU, Dept Med, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Robbins, Gabriel A.; Raabe, Vanessa] NYU, Dept Pediat, Grossman Sch Med, New York, NY 10016 USA.
   [Troxel, Andrea B.; Li, Yi] NYU, Dept Populat Hlth, Grossman Sch Med, New York, NY USA.
   [Ulrich, Robert J.; Carmody, Ellie; Eapen, Jaishvi; Prasad, Prithiv J.; Henderson, Brooklyn; Hrycko, Alexander; Raabe, Vanessa; Dubrovskaya, Yanina; Mulligan, Mark J.] NYU, Div Infect Dis & Immunol, Grossman Sch Med, New York, NY USA.
   [Raabe, Vanessa] NYU, Div Pediat Infect Dis, Grossman Sch Med, New York, NY USA.
   [Robbins, Gabriel A.] NYU, Div Pediat Hematol Oncol, Grossman Sch Med, New York, NY USA.
   [Troxel, Andrea B.; Li, Yi] NYU, Div Biostat, Grossman Sch Med, New York, NY USA.
   [Delgado, Camila] NYU, Grossman Sch Med, New York, NY USA.
   [DeHovitz, Jack A.] State Univ New York Downstate Hlth Sci Univ, Dept Med, Div Infect Dis, Brooklyn, NY USA.
   [Backer, Martin; Delpachitra, Dinuli] NYU, Dept Med, Div Infect Dis, Long Isl Sch Med, Mineola, NY USA.
   [Dubrovskaya, Yanina] NYU Langone Hlth, Dept Pharm, New York, NY USA.
RP Ulrich, RJ (corresponding author), 551 First Ave, New York, NY 10016 USA.
OI li, yi/0000-0002-3875-3513; Carmody, Ellie/0000-0001-5297-4948; Troxel,
   Andrea/0000-0002-1393-3075; Robbins, Gabriel/0000-0002-4447-0667;
   Ulrich, Robert/0000-0002-3217-5062; Austrian,
   Jonathan/0000-0002-0016-4705; Raabe, Vanessa/0000-0003-2579-1104;
   Prasad, Prithiv/0000-0003-4142-067X
FU New York University Grossman School of Medicine; NYU CTSA grant from the
   National Center for Advancing Translational Sciences (NCATS) [UL1
   TR001445]; New York State Empire Clinical Research Investigator Program
   (ECRIP); National Institute of Allergy and Infectious Diseases (NIAID)
   at the National Institutes of Health (NIH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [UM1
   AI148574]; National Institutes of Health Fogarty grants [D43 TW010046,
   D43 TW010562, D43 TW011532]; NYU CTSA grant from the National Center for
   Advancing Translational Sciences, National Institutes of Health [UL1
   TR001445]
FX This work was supported by the New York University Grossman School of
   Medicine. R.J.U. is supported in part by the NYU CTSA grant (TL1
   TR001445) from the National Center for Advancing Translational Sciences
   (NCATS) and the New York State Empire Clinical Research Investigator
   Program (ECRIP). M.J.M. and V.R. are supported by the National Institute
   of Allergy and Infectious Diseases (NIAID) at the National Institutes of
   Health (NIH) grant (UM1 AI148574). J.A.D. is supported by National
   Institutes of Health Fogarty grants (D43 TW010046, D43 TW010562, and D43
   TW011532). This research was supported in part by an NYU CTSA grant (UL1
   TR001445) from the National Center for Advancing Translational Sciences,
   National Institutes of Health. The funders had no role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abarientos C, 2011, EXPERT OPIN DRUG SAF, V10, P705, DOI 10.1517/14740338.2011.566555
   Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Chen Z, 2020, 20040758 MEDRXIV, DOI [10.1101/2020.03.22.2004, DOI 10.1101/2020.03.22.2004]
   China National Health Commission, 2020, CHIN CLIN GUID COVID
   Dong EDH, INTERACTIVE WEB BASE
   Fanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis-2019-215089
   Furst DE, 1999, ARTHRITIS RHEUM, V42, P357, DOI 10.1002/1529-0131(199902)42:2<357::AID-ANR19>3.0.CO;2-J
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496
   Horby P, 2020, EFFECT HYDROXYCHLORO, DOI [10.1101/2020.07.15.20151852, DOI 10.1101/2020.07.15.20151852]
   Hunt CD, 2007, AM J CLIN NUTR, V86, P1054
   Lagier JC, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101791
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lopes JA, 2013, CLIN KIDNEY J, V6, P8, DOI 10.1093/ckj/sfs160
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   National Institue of Health, NAT CANC I COMM TERM
   New York City Health Department, COVID 19 DAT PAG
   NIH/NHLBI, NIH HALTS CLIN TRIAL
   Petkova E, 2020, JAMA-J AM MED ASSOC, V324, P543, DOI 10.1001/jama.2020.13042
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   US Food and Drug Administration, EM US AUTH US CHLOR
   US Food and Drug Administration, COR COVID 19 UPD FDA
   vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55
   Vannice KS, 2019, VACCINE, V37, P863, DOI 10.1016/j.vaccine.2018.12.040
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Whyte MB, 2020, THROMB RES, V195, P95, DOI 10.1016/j.thromres.2020.07.025
   Wilson KC, COVID 19 INTERIM GUI
   Wu SF, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1393-y
   YACHIDA S, 1986, RES VET SCI, V40, P1
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yu  BL, 2020, J THROMB THROMBOLYS, V50, P548, DOI 10.1007/s11239-020-02171-y
   Zeng FR, 2020, INT J INFECT DIS, V96, P467, DOI 10.1016/j.ijid.2020.05.055
NR 38
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD OCT
PY 2020
VL 7
IS 10
AR ofaa446
DI 10.1093/ofid/ofaa446
PG 12
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OW8JN
UT WOS:000593126300059
PM 33134417
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lano, G
   Braconnier, A
   Bataille, S
   Cavaille, G
   Moussi-Frances, J
   Gondouin, B
   Bindi, P
   Nakhla, M
   Mansour, J
   Halin, P
   Levy, B
   Canivet, E
   Gaha, K
   Kazes, I
   Noel, N
   Wynckel, A
   Debrumetz, A
   Jourde-Chiche, N
   Moal, V
   Vial, R
   Scarfogliere, V
   Bobot, M
   Gully, M
   Legris, T
   Pelletier, M
   Sallee, M
   Burtey, S
   Brunet, P
   Robert, T
   Rieu, P
AF Lano, Guillaume
   Braconnier, Antoine
   Bataille, Stanislas
   Cavaille, Guilhem
   Moussi-Frances, Julie
   Gondouin, Bertrand
   Bindi, Pascal
   Nakhla, Magued
   Mansour, Janette
   Halin, Pascale
   Levy, Benedicte
   Canivet, Eric
   Gaha, Khaled
   Kazes, Isabelle
   Noel, Natacha
   Wynckel, Alain
   Debrumetz, Alexandre
   Jourde-Chiche, Noemie
   Moal, Valerie
   Vial, Romain
   Scarfogliere, Violaine
   Bobot, Mickael
   Gully, Marion
   Legris, Tristan
   Pelletier, Marion
   Sallee, Marion
   Burtey, Stephane
   Brunet, Philippe
   Robert, Thomas
   Rieu, Philippe
TI Risk factors for severity of COVID-19 in chronic dialysis patients from
   a multicentre French cohort
SO CLINICAL KIDNEY JOURNAL
LA English
DT Article
DE angiotensin II receptor blockers; COVID-19; dialysis;
   hydroxychloroquine; lymphocytes
ID CORONAVIRUS DISEASE 2019; HEMODIALYSIS-PATIENTS; BLOCKADE; OUTBREAK;
   OUTCOMES
AB Background. Coronavirus disease 2019 (COVID-19) is an emerging infectious disease, related to severe acute respiratory syndrome coronavirus 2 infection. Few data are available in patients with end-stage renal disease (ESRD).
   Methods. We conducted an observational cohort study of COVID-19 patients at 11 dialysis centres in two distinct districts of France to examine the epidemiological and clinical characteristics of COVID-19 in this population, and to determine risk factors of disease severity (defined as a composite outcome including intensive care unit admission or death) and mortality.
   Results. Among the 2336 patients enrolled, 5.5% had confirmed COVID-19 diagnosis. Of the 122 patients with a follow-up superior to 28 days, 37% reached the composite outcome and 28% died. Multivariate analysis showed that oxygen therapy on diagnosis and a decrease in lymphocyte count were independent risk factors associated with disease severity and with mortality. Chronic use of angiotensin II receptor blockers (ARBs) (18% of patients) was associated with a protective effect on mortality. Treatment with azithromycin and hydroxychloroquine (AZT/HCQ) (46% of patients) were not associated with the composite outcome and with death in univariate and multivariate analyses.
   Conclusions. COVID-19 is a severe disease with poor prognosis in patients with ESRD. Usual treatment with ARBs seems to be protective of critical evolution and mortality. There is no evidence of clinical benefit with the combination of AZT/HCQ.
C1 [Lano, Guillaume; Gondouin, Bertrand; Jourde-Chiche, Noemie; Moal, Valerie; Vial, Romain; Scarfogliere, Violaine; Bobot, Mickael; Gully, Marion; Legris, Tristan; Pelletier, Marion; Sallee, Marion; Burtey, Stephane; Brunet, Philippe; Robert, Thomas] Concept Hosp, AP HM, Dept Nephrol & Renal Transplantat, Marseille, France.
   [Lano, Guillaume; Bataille, Stanislas; Jourde-Chiche, Noemie; Bobot, Mickael; Sallee, Marion; Burtey, Stephane; Brunet, Philippe] Aix Marseille Univ, C2VN, Inserm 1263, INRAe 1260, Marseille, France.
   [Braconnier, Antoine; Gaha, Khaled; Kazes, Isabelle; Noel, Natacha; Wynckel, Alain; Debrumetz, Alexandre; Rieu, Philippe] Univ Hosp Reims, Maison Blanche Hosp, Dept Nephrol & Renal Transplantat, Reims, France.
   [Bataille, Stanislas] Clin Bouchard, Elsan, Phocean Inst Nephrol, Marseille, France.
   [Cavaille, Guilhem; Moussi-Frances, Julie] St Joseph Hosp, DIAVERUM, Marseille, France.
   [Gondouin, Bertrand] Assoc Dialyses Provence & Corse ADPC, Marseille, France.
   [Bindi, Pascal] Verdun Hosp, Dept Nephrol, Verdun, France.
   [Nakhla, Magued] Laon Hosp, Dept Nephrol, Laon, France.
   [Mansour, Janette] Soissons Hosp, Dept Nephrol, Soissons, France.
   [Halin, Pascale] Charleville Mezieres Hosp, Dept Nephrol, Charleville Mezieres, France.
   [Levy, Benedicte] Troyes Hosp, Dept Nephrol, Troyes, France.
   [Canivet, Eric] Assoc Reg Promot Dialyse Domicile ARPDD, Reims, France.
   [Rieu, Philippe] UMR CNRS URCA 7369 Matrice Extracellulaire & Dyna, MEDyC, Lab Nephrol, Reims, France.
RP Lano, G (corresponding author), Concept Hosp, AP HM, Dept Nephrol & Renal Transplantat, Marseille, France.; Lano, G (corresponding author), Aix Marseille Univ, C2VN, Inserm 1263, INRAe 1260, Marseille, France.
EM guillaume.lano@ap-hm.fr
OI Bataille, Stanislas/0000-0001-8344-1300; Lano,
   Guillaume/0000-0003-1692-5799
CR Alberici F, 2020, KIDNEY INT, V98, P20, DOI 10.1016/j.kint.2020.04.030
   Alhenc-Gelas F, 2020, KIDNEY INT, V97, P1091, DOI 10.1016/j.kint.2020.04.009
   Arslan H, 2020, EXP CLIN TRANSPLANT, V18, P275, DOI 10.6002/ect.2020.0194
   Basile C, 2020, NEPHROL DIAL TRANSPL, V35, P737, DOI 10.1093/ndt/gfaa069
   Bataille S, 2020, KIDNEY INT, V98, P235, DOI 10.1016/j.kint.2020.04.017
   D'Marco L, 2020, CLIN KIDNEY J, V13, P297, DOI 10.1093/ckj/sfaa104
   da Cunha TS, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072264
   Fosbol EL, 2020, JAMA-J AM MED ASSOC, V324, P168, DOI 10.1001/jama.2020.11301
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Goicoechea M, 2020, KIDNEY INT, V98, P27, DOI 10.1016/j.kint.2020.04.031
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Henry BM, 2020, INT UROL NEPHROL, V52, P1193, DOI 10.1007/s11255-020-02451-9
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   La Milia V, 2020, KIDNEY INT REP, V5, P1095, DOI 10.1016/j.ekir.2020.05.019
   Mackey K, 2020, ANN INTERN MED, V173, P195, DOI 10.7326/M20-1515
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Michaud V, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072096
   Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517
   Sparks MA, 2020, CLIN J AM SOC NEPHRO, V15, P714, DOI 10.2215/CJN.03530320
   Wang R, 2020, CLIN KIDNEY J, V13, P328, DOI 10.1093/ckj/sfaa086
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xiong F, 2020, J AM SOC NEPHROL, V31, P1387, DOI 10.1681/ASN.2020030354
   Yau K, 2020, AM J KIDNEY DIS, V76, P690, DOI 10.1053/j.ajkd.2020.07.001
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhang X, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104927
   Zhao QW, 2020, INT J INFECT DIS, V96, P131, DOI 10.1016/j.ijid.2020.04.086
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
NR 30
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2048-8505
EI 2048-8513
J9 CLIN KIDNEY J
JI Clin. Kidney J.
PD OCT
PY 2020
VL 13
IS 5
BP 878
EP 888
DI 10.1093/ckj/sfaa199
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA OZ8FJ
UT WOS:000595155000022
PM 33354330
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Meizlish, ML
   Pine, AB
   Goshua, G
   Chang, CH
   Zhang, HM
   Bishai, J
   Bahel, P
   Patel, A
   Gbyli, R
   Kwan, J
   Price, C
   Dela Cruz, CS
   Halene, S
   van Dijk, D
   Hwa, J
   Lee, AI
   Chun, HJ
AF Meizlish, Matthew L.
   Pine, Alexander B.
   Goshua, George
   Chang, C-Hong
   Zhang, Hanming
   Bishai, Jason
   Bahel, Parveen
   Patel, Amisha
   Gbyli, Rana
   Kwan, Jennifer
   Price, Christina
   Dela Cruz, Charles S.
   Halene, Stephanie
   van Dijk, David
   Hwa, John
   Lee, Alfred, I
   Chun, Hyung J.
TI Circulating markers of angiogenesis and endotheliopathy in COVID-19
SO PULMONARY CIRCULATION
LA English
DT Article
DE COVID-19; endotheliopathy; angiogenesis
AB Increase in thrombotic and microvascular complications is emerging to be a key feature of patients with critical illness associated with COVID-19 infection. While endotheliopathy is thought to be a key factor of COVID-19-associated coagulopathy, markers indicative of this process that are prognostic of disease severity have not been well-established in this patient population. Using plasma profiling of patients with COVID-19, we identified circulating markers that segregated with disease severity: markers of angiogenesis (VEGF-A, PDGF-AA and PDGF-AB/BB) were elevated in hospitalized patients with non-critical COVID-19 infection, while markers of endothelial injury (angiopoietin-2, FLT-3L, PAI-1) were elevated in patients with critical COVID-19 infection. In survival analysis, elevated markers of endothelial injury (angiopoietin-2, follistatin, PAI-1) were strongly predictive of in-hospital mortality. Our findings demonstrate that non-critical and critical phases of COVID-19 disease may be driven by distinct mechanisms involving key aspects of endothelial cell function, and identify drivers of COVID-19 pathogenesis and potential targets for future therapies.
C1 [Meizlish, Matthew L.; Goshua, George; Lee, Alfred, I] Yale Sch Med, Sect Hematol, New Haven, CT 06520 USA.
   [Pine, Alexander B.; Patel, Amisha; Gbyli, Rana; Halene, Stephanie] Yale Sch Med, New Haven, CT 06520 USA.
   [Chang, C-Hong; Zhang, Hanming; Bishai, Jason; Kwan, Jennifer; van Dijk, David; Hwa, John; Chun, Hyung J.] Yale Sch Med, Sect Cardiovasc Med, Yale Cardiovasc Res Ctr, New Haven, CT 06520 USA.
   [Bahel, Parveen] Yale Sch Med, Dept Lab Med, New Haven, CT 06520 USA.
   [Dela Cruz, Charles S.] Yale Sch Med, Sect Pulm Crit Care & Sleep Med, New Haven, CT 06520 USA.
   [Price, Christina] Yale Sch Med, Sect Immunol, New Haven, CT 06520 USA.
RP Chun, HJ (corresponding author), Yale Sch Med, Sect Cardiovasc Med, Yale Cardiovasc Res Ctr, New Haven, CT 06520 USA.; Lee, AI (corresponding author), Yale Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06520 USA.
EM alfred.lee@yale.edu; hyung.chun@yale.edu
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL142818, HL139116]; NIGMSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [GM136651]; AHA
   (Transformational Project Award)
FX This work is supported in part by the NHLBI (HL142818 to HJC and
   HL139116 to MLM), NIGMS (GM136651 to MLM), AHA (Transformational Project
   Award to HJC), and gift donation from Jack Levin to the Benign
   Hematology Program at Yale.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Goshua G, 2020, LANCET HAEMATOL, V7, pE575, DOI 10.1016/S2352-3026(20)30216-7
   Hothorn T, 2003, COMPUT STAT DATA AN, V43, P121
   Patel BV, 2020, AM J RESP CRIT CARE, V202, P690, DOI 10.1164/rccm.202004-1412OC
   Richardson S., 2020, JAMA-J AM MED ASSOC, V323, DOI DOI 10.1001/jama.2020.7681
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 6
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD OCT
PY 2020
VL 10
IS 4
AR 2045894020966547
DI 10.1177/2045894020966547
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA PA7IY
UT WOS:000595805600001
PM 33282193
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Capoluongo, E
AF Capoluongo, Ettore
TI PARP-inhibitors in a non-oncological indication as COVID-19: Are we
   aware about its potential role as anti-thrombotic drugs? The discussion
   is open
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE COVID-19; PARP-inhibitors; PARP; COVi-2
ID BRCA
AB In the last three months, the whole scientific community has shifted its focus to the fight against the COVI-2 infection (COVID-19) trying to use different medications to save the patients' life. In some studies, the results were completely inconclusive, as in the case of chloroquine. However, the recent discovery on benefits deriving from use of such anticoagulants for Covid-19 patients, has increased the success of patients' treatment. Among lots of old and new drugs, PARP-inhibitors were not considered as possible option in the treatment of Covi-2 infection, being the latter able to induce the inflammatory and thrombotic cascades. Since PARP-inhibitors are able to reduce and block mechanisms leading to thrombosis and inflammation, they could be used as antithrombotic medications. Therefore, the present brief report is aimed to open the discussion on the potentials of PARP-inhibitors in non-oncological settings, like Covid-19.
C1 [Capoluongo, Ettore] Dept Mol Med & Med Biotechnol, Naples, Italy.
   [Capoluongo, Ettore] Azienda Osped Univ Federico II, Dept Lab & Transfus Med, Naples, Italy.
   [Capoluongo, Ettore] Univ Naples Federico II, Adv Biotechnol, CEINGE, Naples, Italy.
RP Capoluongo, E (corresponding author), Dept Mol Med & Med Biotechnol, Naples, Italy.; Capoluongo, E (corresponding author), Azienda Osped Univ Federico II, Dept Lab & Transfus Med, Naples, Italy.; Capoluongo, E (corresponding author), Univ Naples Federico II, Adv Biotechnol, CEINGE, Naples, Italy.
EM ettoredomenico.capoluongo@unina.it
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Berger NA, 2018, BRIT J PHARMACOL, V175, P192, DOI 10.1111/bph.13748
   Capoluongo E.D., 2020, CLIN CHEM LAB MED
   Capoluongo E, 2016, EUR J HUM GENET, V24, pS1, DOI 10.1038/ejhg.2016.92
   Chand K, 2020, ARAB J CHEM, V13, P8248, DOI [10.1142/S0192415X20500378, 10.1016/j.arabjc.2020.01.009]
   Curtin N, 2020, BRIT J PHARMACOL, V177, P3635, DOI 10.1111/bph.15137
   Di Gennaro F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082690
   Fogarty H., BR J HAEMATOL
   Ge Y., 2020, BIORXIV PREPRINT, DOI [10.1101/2020.03.11.9868362020, DOI 10.1101/2020.03.11.9868362020]
   Jin Y, 2020, VIRUSES, V12
   Kuk A, 2017, TARGET ONCOL, V12, P495, DOI 10.1007/s11523-017-0496-3
   Lorusso D, 2016, ANN ONCOL, V27, P487, DOI 10.1093/annonc/mdv608
   Marchetti C, 2018, ANN SURG ONCOL, V25, P3701, DOI 10.1245/s10434-018-6700-6
   Marietta M, 2020, BRIT J HAEMATOL, V189, P1059, DOI 10.1111/bjh.16772
   Mathews MT, 2008, ARTERIOSCL THROM VAS, V28, P711, DOI 10.1161/ATVBAHA.107.156406
   McCann KE, 2019, FUTURE ONCOL, V15, P1707, DOI 10.2217/fon-2018-0751
   Paris I, 2019, INT J HYPERTHER, V35, P370, DOI 10.1080/02656736.2018.1503346
   Poggiali Erika, 2020, Eur J Case Rep Intern Med, V7, P001646, DOI 10.12890/2020_001646
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sachdev E, 2019, TARGET ONCOL, V14, P657, DOI 10.1007/s11523-019-00680-2
   Thachil J., 2020, J THROMB HEMOST
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Xie HY, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110204
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2020
VL 130
AR 110536
DI 10.1016/j.biopha.2020.110536
PG 3
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OH6JX
UT WOS:000582697900042
PM 32688139
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Hu, Y
   Wang, TP
   Hu, ZM
   Wang, X
   Zhang, ZB
   Li, L
   Peng, P
AF Hu, Yan
   Wang, Tingping
   Hu, Zhimin
   Wang, Xuan
   Zhang, Zhengbin
   Li, Li
   Peng, Peng
TI Clinical efficacy of glucocorticoid on the treatment of patients with
   COVID-19 pneumonia: A single-center experience
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE COVID-19; Glucocorticoid therapy; Clinical course
ID ACUTE-RESPIRATORY-SYNDROME; GUANGZHOU; OUTBREAK; SARS
AB The aim of the present study was to identify the clinical efficacy of glucocorticoid therapy on the treatment of patients with Coronavirus Disease 2019 (COVID-19) pneumonia. Clinical and laboratory parameters were collected from 308 patients with COVID-19 pneumonia from the fever clinic of Wuhan Pulmonary Hospital (Wuhan City, Hubei Province, China) between January 14, 2020 and February 9, 2020, of which 216 patients received low-dose (equivalent of methylprednisolone 0.75-1.5 mg/kg/d) glucocorticoid treatment. The effect of glucocorticoid on imaging progress, adverse events, nucleic acid results and the outcomes were investigated. Lymphocyte count and C-reactive protein (CRP) significantly differed between the glucocorticoid therapy and non-glucocorticoid therapy groups. Compared with the non-glucocorticoid therapy group, glucocorticoid therapy did not significantly influence the clinical course of COVID-19 pneumonia, including imaging progress and the time duration for negative transformation of nucleic acid. Glucocorticoid therapy did not significantly influence the outcomes nor the adverse events of COVID-19 pneumonia. For the treatment of COVID-19 pneumonia, systemic and in-depth investigation is needed to determine the timing and dosage of glucocorticoids needed to inhibit overwhelming inflammatory response and not the protective immune response to COVID-19 pneumonia.
C1 [Hu, Yan; Wang, Tingping; Hu, Zhimin; Wang, Xuan; Zhang, Zhengbin; Li, Li; Peng, Peng] Wuhan Pulm Hosp, Wuhan Inst TB Control, Wuhan 430030, Hubei, Peoples R China.
RP Li, L; Peng, P (corresponding author), Wuhan Pulm Hosp, Wuhan Inst TB Control, Wuhan 430030, Hubei, Peoples R China.
EM ly_li@aliyun.com; pengpengwg@126.com
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Cruz-Topete D, 2015, NEUROIMMUNOMODULAT, V22, P20, DOI 10.1159/000362724
   Garfin DR, 2020, HEALTH PSYCHOL, V39, P355, DOI 10.1037/hea0000875
   Liu HJ, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016839
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Lupia T, 2020, J GLOB ANTIMICROB RE, V21, P22, DOI 10.1016/j.jgar.2020.02.021
   National Health Commission of the People's Republic of China, 2020, CHIN MAN GUID COVID
   Panahi L, 2020, ARCH ACAD EMERG MED, V8
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang X, 2020, J HOSP INFECT, V105, P399, DOI 10.1016/j.jhin.2020.04.019
   Xie JF, 2020, INTENS CARE MED, V46, P837, DOI 10.1007/s00134-020-05979-7
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang XM, 2020, JPN J RADIOL, V38, P407, DOI 10.1007/s11604-020-00945-1
   Zhao Z, 2003, J MED MICROBIOL, V52, P715, DOI 10.1099/jmm.0.05320-0
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu HB, 2020, GLOB HEALTH RES POL, V5, DOI 10.1186/s41256-020-00135-6
   Zhu Y, 2020, J INFECTION, V81, P154, DOI 10.1016/j.jinf.2020.03.033
NR 24
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2020
VL 130
AR 110529
DI 10.1016/j.biopha.2020.110529
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OH6JX
UT WOS:000582697900035
PM 32736237
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Norinder, U
   Tuck, A
   Norgren, K
   Kos, VM
AF Norinder, Ulf
   Tuck, Astrud
   Norgren, Kalle
   Kos, Vesna Munic
TI Existing highly accumulating lysosomotropic drugs with potential for
   repurposing to target COVID-19
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE COVID-19; Antiviral drugs; Drug repositioning; Lysosomotropism;
   Endosomal pathway; Broad spectrum antivirals
ID CLINICAL PHARMACOKINETICS; PHOSPHOLIPIDOSIS; CHLOROQUINE;
   CLARITHROMYCIN; AZITHROMYCIN; PROLONGATION; CLEMASTINE; DISCOVERY;
   VOLUME
AB Given the speed of viral infection spread, repurposing of existing drugs has been given the highest priority in combating the ongoing COVID-19 pandemic. Only drugs that are already registered or close to registration, and therefore have passed lengthy safety assessments, have a chance to be tested in clinical trials and reach patients quickly enough to help in the current disease outbreak.
   Here, we have reviewed available evidence and possible ways forward to identify already existing pharmaceuticals displaying modest broad-spectrum antiviral activity which is likely linked to their high accumulation in cells. Several well studied examples indicate that these drugs accumulate in lysosomes, endosomes and biological membranes in general, and thereby interfere with endosomal pathway and intracellular membrane trafficking crucial for viral infection. With the aim to identify other lysosomotropic drugs with possible inherent antiviral activity, we have applied a set of clear physicochemical, pharmacokinetic and molecular criteria on 530 existing drugs. In addition to publicly available data, we have also used our in silico model for the prediction of accumulation in lysosomes and endosomes. By this approach we have identified 36 compounds with possible antiviral effects, also against coronaviruses. For 14 of them evidence of broad-spectrum antiviral activity has already been reported, adding support to the value of this approach.
   Presented pros and cons, knowledge gaps and methods to identify lysosomotropic antivirals, can help in the evaluation of many drugs currently in clinical trials considered for repurposing to target COVID-19, as well as open doors to finding more potent and safer alternatives.
C1 [Norinder, Ulf] Stockholm Univ, Dept Comp & Syst Sci, Box 7003, SE-16407 Kista, Sweden.
   [Norinder, Ulf] Orebro Univ, MTM Res Ctr, Sch Sci & Technol, SE-70182 Orebro, Sweden.
   [Tuck, Astrud; Norgren, Kalle; Kos, Vesna Munic] Karolinska Inst, Dept Physiol & Pharmacol, Solnavagen 9, SE-17177 Stockholm, Sweden.
RP Kos, VM (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Solnavagen 9, SE-17177 Stockholm, Sweden.
EM vesna.munic.kos@ki.se
FU Karolinska Institutet, Stockholm, Sweden
FX This study has been funded by Karolinska Institutet, Stockholm, Sweden.
CR Administration, DRUGS FDA FDA APPR D
   Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Alsaadi EAJ, 2019, FUTURE VIROL, V14, P275, DOI 10.2217/fvl-2018-0144
   Andersen PI, 2020, INT J INFECT DIS, V93, P268, DOI 10.1016/j.ijid.2020.02.018
   [Anonymous], MEDICINE
   Ashoor R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082481
   BJORNEBOE M, 1967, ACTA MED SCAND, V182, P491
   Boriskin YS, 2008, CURR MED CHEM, V15, P997, DOI 10.2174/092986708784049658
   Cavalluzzi MM, 2020, DRUG DISCOV TODAY, V25, P344, DOI 10.1016/j.drudis.2019.11.005
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Crawford KW, 2010, JAIDS-J ACQ IMM DEF, V53, P598, DOI 10.1097/QAI.0b013e3181c9caac
   DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9
   Dragovic S, 2016, ARCH TOXICOL, V90, P2979, DOI 10.1007/s00204-016-1845-1
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Easwaranathan A, 2019, J PHARM SCI-US, V108, P652, DOI 10.1016/j.xphs.2018.11.001
   Ekins S, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01711-17
   Fda, FDA CAUT US HYDR CHL
   Fu D, 2014, NAT CHEM, V6, P615, DOI [10.1038/nchem.1961, 10.1038/NCHEM.1961]
   Funk RS, 2012, MOL PHARMACEUT, V9, P1384, DOI 10.1021/mp200641e
   Garcia DS, 2018, CHEM-BIOL INTERACT, V281, P1, DOI 10.1016/j.cbi.2017.12.021
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   GH MS, 2018, ACS MED CHEM LETT, V9, P569
   Goracci L, 2013, J CHEM INF MODEL, V53, P1436, DOI 10.1021/ci400113t
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grilo LS, 2010, FRONT PHARMACOL, V1, DOI 10.3389/fphar.2010.00137
   Hancox JC, 2013, THER ADV INFECT DIS, V1, P155, DOI 10.1177/2049936113501816
   Hanumegowda UM, 2010, CHEM RES TOXICOL, V23, P749, DOI 10.1021/tx9003825
   Kaneko T., 2007, COMPREHENSIV MED CHE, VII
   Kosol S, 2012, J MED CHEM, V55, P5632, DOI 10.1021/jm300647f
   Krishna S, 1996, CLIN PHARMACOKINET, V30, P263, DOI 10.2165/00003088-199630040-00002
   Lentini G, 2020, MOLECULES, V25, DOI 10.3390/molecules25081834
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu WB, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00461-20
   Logan R, 2012, EXPERT OPIN DRUG MET, V8, P943, DOI 10.1517/17425255.2012.691165
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Munic V, 2011, PHARMACOL RES, V64, P298, DOI 10.1016/j.phrs.2011.03.011
   Nadanaciva S, 2011, TOXICOL IN VITRO, V25, P715, DOI 10.1016/j.tiv.2010.12.010
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 2012, LIVERTOX CLIN RES IN
   Norinder U, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235938
   Nujic K, 2012, CELL IMMUNOL, V279, P78, DOI 10.1016/j.cellimm.2012.09.007
   O'Mara E, 2010, ANTIMICROB AGENTS CH, V54, P2448, DOI 10.1128/AAC.01447-09
   Orogo AM, 2012, MOL INFORM, V31, P725, DOI 10.1002/minf.201200048
   Ridley JM, 2006, J MOL CELL CARDIOL, V40, P107, DOI 10.1016/j.yjmcc.2005.09.017
   RORIG KJ, 1987, P SOC EXP BIOL MED, V184, P165
   Salata C, 2017, EXPERT REV ANTI-INFE, V15, P483, DOI 10.1080/14787210.2017.1305888
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schmitt MV, 2019, DRUG METAB DISPOS, V47, P49, DOI 10.1124/dmd.118.084541
   Schran HF, 1996, J CLIN PHARMACOL, V36, P911, DOI 10.1002/j.1552-4604.1996.tb04758.x
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shayman JA, 2013, BBA-MOL CELL BIOL L, V1831, P602, DOI 10.1016/j.bbalip.2012.08.013
   Shi J, 2005, CLIN PHARMACOKINET, V44, P915, DOI 10.2165/00003088-200544090-00003
   Sisk JM, 2018, J GEN VIROL, V99, P619, DOI 10.1099/jgv.0.001047
   Stanat SJC, 2003, MOL CELL BIOCHEM, V254, P1, DOI 10.1023/A:1027309703313
   Sun HM, 2013, BIOORG MED CHEM LETT, V23, P4587, DOI 10.1016/j.bmcl.2013.06.034
   TAYLOR G, 1983, BRIT J CLIN PHARMACO, V15, P287, DOI 10.1111/j.1365-2125.1983.tb01501.x
   Togami K, 2013, BIOL PHARM BULL, V36, P1494
   Traebert Martin, 2005, Expert Opin Drug Saf, V4, P421, DOI 10.1517/14740338.4.3.421
   van Haarst AD, 1998, CLIN PHARMACOL THER, V64, P542, DOI 10.1016/S0009-9236(98)90137-0
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Walker R.B., 1996, EUR J PHARM SCI
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
NR 62
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2020
VL 130
AR 110582
DI 10.1016/j.biopha.2020.110582
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OH6JX
UT WOS:000582697900081
PM 32763818
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yousefi, H
   Poursheikhani, A
   Bahmanpour, Z
   Vatanmakanian, M
   Taheri, M
   Mashouri, L
   Alahari, SK
AF Yousefi, Hassan
   Poursheikhani, Arash
   Bahmanpour, Zahra
   Vatanmakanian, Mousa
   Taheri, Mohammad
   Mashouri, Ladan
   Alahari, Suresh K.
TI SARS-CoV infection crosstalk with human host cell noncoding-RNA
   machinery: An in-silico approach
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE SARS-CoV; Covid-19; Noncoding RNA, miRNA, lncRNA; Bioinformatics
   analysis
AB Although 70 % of the genome is transcribed to RNA in humans, only similar to 2% of these transcripts are translated into proteins. The rest of the transcripts are defined as noncoding RNAs, including Long noncoding RNAs (LncRNAs) and MicroRNAs (miRNAs) that mostly function post-transcriptionally to regulate the gene expression. The outbreak of a novel coronavirus (SARS-CoV) has caused a major public health concern across the globe. The SARS-CoV is the seventh coronavirus that is known to cause human disease. There are currently no promising antiviral drugs with proven efficacy nor are there vaccines for its prevention. As of August 10, 2020, SARS-CoV has been infected more than 13 million cases in more than 213 countries, with an estimated mortality rate of similar to 3 %. Thus, it is of utmost important priority to develop novel therapies for COVID-19. It is not fully investigated whether noncoding RNAs regulate signaling pathways that SARS-CoV involved in. Hence, computational analysis of the noncoding RNA interactions and determining importance of key regulatory noncoding RNAs in antiviral defense mechanisms will likely be helpful in developing new drugs to attack SARS-CoV infection. To elucidate this, we utilized bioinformatic approaches to find the interaction network of SARS-CoV/human proteins, miRNAs, and lncRNAs. We found TGF-beta signaling pathway as one of the potential interactive pathways. Furthermore, potential miRNAs/lncRNAs networks that the virus might engage during infection in human host cells have been shown. Altogether, TGF-beta signaling pathway as well as hub miRNAs, and LncRNAs involve during SARS-CoV pathogenesis can be considered as potential therapeutic targets.
C1 [Yousefi, Hassan; Vatanmakanian, Mousa; Alahari, Suresh K.] LSUHSC, Dept Biochem & Mol Biol, Sch Med, New Orleans, LA 70112 USA.
   [Poursheikhani, Arash] Mashhad Univ Med Sci, Med Genet Res Ctr, Mashhad, Razavi Khorasan, Iran.
   [Bahmanpour, Zahra] Tabriz Univ Med Sci, Fac Med, Dept Med Genet, Tabriz, Iran.
   [Taheri, Mohammad] Shahid Beheshti Univ Med Sci, Urogenital Stem Cell Res Ctr, Tehran, Iran.
   [Mashouri, Ladan] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
RP Alahari, SK (corresponding author), LSUHSC, Dept Biochem & Mol Biol, Sch Med, New Orleans, LA 70112 USA.
EM salaha@lsuhsc.edu
OI Taheri, Mohammad/0000-0001-8381-0591
FU LSUHSC School of Medicine and Fred G. Brazda Foudation
FX The authors thank LSUHSC School of Medicine and Fred G. Brazda Foudation
   for financial support.
CR Chen WJ, 2020, INT J BIOL SCI, V16, P1954, DOI 10.7150/ijbs.46891
   Cook HV, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100519
   Damas N.D., 2019, RNA, V5
   Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Gillen J, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00425
   Girardit E, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00439
   Gulbahce N, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002531
   Henke JI, 2008, EMBO J, V27, P3300, DOI 10.1038/emboj.2008.244
   Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329
   Li QS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01954-x
   Li SS, 2016, INT J MOL MED, V38, P1703, DOI 10.3892/ijmm.2016.2796
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Omer S.B., 2020, JAMA
   Sadegh S., 2020, ARXIV PREPRINT ARXIV
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Treiber T, 2019, NAT REV MOL CELL BIO, V20, P5, DOI 10.1038/s41580-018-0059-1
   Yousefi H., 2019, ONCOGENE, P1
   Zuo W, 2010, MOLECULAR BIOLOGY OF THE SARS-CORONAVIRUS, P247, DOI 10.1007/978-3-642-03683-5_15
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2020
VL 130
AR 110548
DI 10.1016/j.biopha.2020.110548
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OH6JX
UT WOS:000582697900053
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Maharaj, AR
   Wu, HL
   Hornik, CP
   Balevic, SJ
   Hornik, CD
   Smith, PB
   Gonzalez, D
   Zimmerman, KO
   Jr, DKB
   Cohen-Wolkowiez, M
AF Maharaj, Anil R.
   Wu, Huali
   Hornik, Christoph P.
   Balevic, Stephen J.
   Hornik, Chi D.
   Smith, P. Brian
   Gonzalez, Daniel
   Zimmerman, Kanecia O.
   Jr, Daniel K. Benjamin
   Cohen-Wolkowiez, Michael
CA Best Pharmaceuticals Children
TI Simulated Assessment of Pharmacokinetically Guided Dosing for
   Investigational Treatments of Pediatric Patients With Coronavirus
   Disease 2019
SO JAMA PEDIATRICS
LA English
DT Article
ID HYDROXYCHLOROQUINE TABLETS; BIOAVAILABILITY; CHLOROQUINE;
   IDENTIFICATION; ANTIMALARIAL
AB Key PointsQuestionWhat are appropriate dosing strategies for hydroxychloroquine and remdesivir in children with coronavirus disease 2019? FindingsIn this simulation-based dose-ranging study, pediatric dosing strategies were devised that provided similar exposures between children within different developmental stages and adults. However, the analysis raised concerns regarding hydroxychloroquine use for coronavirus disease 2019 treatment because unbound plasma concentrations were less than those postulated to mediate an antiviral effect. MeaningTo confirm the appropriateness of the proposed dosing schemes, prospective pharmacokinetic, safety, and efficacy studies in children are required.
   ImportanceChildren of all ages appear susceptible to severe acute respiratory syndrome coronavirus 2 infection. To support pediatric clinical studies for investigational treatments of coronavirus disease 2019 (COVID-19), pediatric-specific dosing is required. ObjectiveTo define pediatric-specific dosing regimens for hydroxychloroquine and remdesivir for COVID-19 treatment. Design, Setting, and ParticipantsPharmacokinetic modeling and simulation were used to extrapolate investigated adult dosages toward children (March 2020-April 2020). Physiologically based pharmacokinetic modeling was used to inform pediatric dosing for hydroxychloroquine. For remdesivir, pediatric dosages were derived using allometric-scaling with age-dependent exponents. Dosing simulations were conducted using simulated pediatric and adult participants based on the demographics of a white US population. InterventionsSimulated drug exposures following a 5-day course of hydroxychloroquine (400 mg every 12 hours x 2 doses followed by 200 mg every 12 hours x 8 doses) and a single 200-mg intravenous dose of remdesivir were computed for simulated adult participants. A simulation-based dose-ranging study was conducted in simulated children exploring different absolute and weight-normalized dosing strategies. Main Outcomes and MeasuresThe primary outcome for hydroxychloroquine was average unbound plasma concentrations for 5 treatment days. Additionally, unbound interstitial lung concentrations were simulated. For remdesivir, the primary outcome was plasma exposure (area under the curve, 0 to infinity) following single-dose administration. ResultsFor hydroxychloroquine, the physiologically based pharmacokinetic model analysis included 500 and 600 simulated white adult and pediatric participants, respectively, and supported weight-normalized dosing for children weighing less than 50 kg. Geometric mean-simulated average unbound plasma concentration values among children within different developmental age groups (32-35 ng/mL) were congruent to adults (32 ng/mL). Simulated unbound hydroxychloroquine concentrations in lung interstitial fluid mirrored those in unbound plasma and were notably lower than in vitro concentrations needed to mediate antiviral activity. For remdesivir, the analysis included 1000 and 6000 simulated adult and pediatric participants, respectively. The proposed pediatric dosing strategy supported weight-normalized dosing for participants weighing less than 60 kg. Geometric mean-simulated plasma area under the time curve 0 to infinity values among children within different developmental age-groups (4315-5027 ngxh/mL) were similar to adults (4398 ngxh/mL). Conclusions and RelevanceThis analysis provides pediatric-specific dosing suggestions for hydroxychloroquine and remdesivir and raises concerns regarding hydroxychloroquine use for COVID-19 treatment because concentrations were less than those needed to mediate an antiviral effect.
   This pharmacokinetic simulation study estimates appropriate pediatric-specific dosing regimens for hydroxychloroquine and remdesivir in the treatment of pediatric patients with COVID-19.
C1 [Maharaj, Anil R.; Wu, Huali; Hornik, Christoph P.; Balevic, Stephen J.; Hornik, Chi D.; Smith, P. Brian; Zimmerman, Kanecia O.; Jr, Daniel K. Benjamin; Cohen-Wolkowiez, Michael] Duke Clin Res Inst, Durham, NC USA.
   [Hornik, Christoph P.; Balevic, Stephen J.; Hornik, Chi D.; Smith, P. Brian; Zimmerman, Kanecia O.; Jr, Daniel K. Benjamin; Cohen-Wolkowiez, Michael] Duke Univ, Dept Pediat, Sch Med, Durham, NC 27705 USA.
   [Hornik, Chi D.] Duke Univ, Dept Pharm, Med Ctr, Durham, NC 27705 USA.
   [Gonzalez, Daniel] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27515 USA.
RP Cohen-Wolkowiez, M (corresponding author), Duke Univ, Dept Pediat, Sch Med, Durham, NC 27705 USA.
EM michael.cohenwolkowiez@duke.edu
OI Gonzalez, Daniel/0000-0001-5522-5686
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [K24 AI143971] Funding Source: Medline
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Arnold SLM, 2020, CTS-CLIN TRANSL SCI, V13, P642, DOI 10.1111/cts.12797
   Balevic SJ, 2019, CLIN PHARMACOKINET, V58, P525, DOI 10.1007/s40262-018-0712-z
   Biot C, 2006, J MED CHEM, V49, P2845, DOI 10.1021/jm0601856
   BROCKS DR, 1994, J CLIN PHARMACOL, V34, P1088, DOI 10.1002/j.1552-4604.1994.tb01986.x
   Cheung KWK, 2019, CLIN PHARMACOL THER, V106, P1083, DOI 10.1002/cpt.1516
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Denney WS, 2015, J PHARMACOKINET PHAR, V42, pS65
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Dykstra K, 2015, J PHARMACOKINET PHAR, V42, P301, DOI 10.1007/s10928-015-9417-1
   European Medicines Agency (EMA), 2020, SUMM COMP US REMD GI
   Fan HW, 2015, RHEUMATOL THER, V2, P183, DOI 10.1007/s40744-015-0012-0
   Furst DE, 1996, LUPUS, V5, pS11, DOI 10.1177/096120339600500104
   Grimstein M, 2019, J PHARM SCI-US, V108, P21, DOI 10.1016/j.xphs.2018.10.033
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Kramer NI, 2012, CHEM RES TOXICOL, V25, P436, DOI 10.1021/tx200479k
   Lee JY, 2016, ARTHRITIS RHEUMATOL, V68, P184, DOI 10.1002/art.39402
   Leong R, 2012, CLIN PHARMACOL THER, V91, P926, DOI 10.1038/clpt.2012.19
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li XQ, 2003, EUR J CLIN PHARMACOL, V59, P429, DOI 10.1007/s00228-003-0636-9
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Maharaj AR, 2014, CPT-PHARMACOMET SYST, V3, DOI 10.1038/psp.2014.45
   Maharaj AR, 2013, AAPS J, V15, P455, DOI 10.1208/s12248-013-9451-0
   Mahmood I, 2019, J CLIN PHARMACOL, V59, P189, DOI 10.1002/jcph.1310
   MCLACHLAN AJ, 1993, BRIT J CLIN PHARMACO, V36, P405, DOI 10.1111/j.1365-2125.1993.tb00388.x
   MCLACHLAN AJ, 1993, EUR J CLIN PHARMACOL, V44, P481, DOI 10.1007/BF00315548
   MCLACHLAN AJ, 1994, BRIT J RHEUMATOL, V33, P235
   Michigan Medicine University of Michigan, INP GUID TREATM COVI
   Morita S, 2016, THER DRUG MONIT, V38, P259, DOI 10.1097/FTD.0000000000000261
   Muller F, 2011, ANTIMICROB AGENTS CH, V55, P3091, DOI 10.1128/AAC.01835-10
   Postnikova E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194880
   Projean D, 2003, DRUG METAB DISPOS, V31, P748, DOI 10.1124/dmd.31.6.748
   Raoult D, 1999, ARCH INTERN MED, V159, P167, DOI 10.1001/archinte.159.2.167
   Sciensano Epidemiology of Infectious Disease, 2020, INTERIM CLIN GUIDANC
   Tegenge MA, 2018, THER DRUG MONIT, V40, P635, DOI 10.1097/FTD.0000000000000543
   TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x
   TETT SE, 1992, J PHARM SCI, V81, P155, DOI 10.1002/jps.2600810211
   TETT SE, 1989, BRIT J CLIN PHARMACO, V27, P771, DOI 10.1111/j.1365-2125.1989.tb03439.x
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Wilke CO, COWPLOT STREAMLINED
   Willmann S, 2007, J PHARMACOKINET PHAR, V34, P401, DOI 10.1007/s10928-007-9053-5
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zeileis A, 2005, J STAT SOFTW, V14
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 51
TC 5
Z9 5
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6203
EI 2168-6211
J9 JAMA PEDIATR
JI JAMA Pediatr.
PD OCT
PY 2020
VL 174
IS 10
DI 10.1001/jamapediatrics.2020.2422
PG 9
WC Pediatrics
SC Pediatrics
GA OX8JS
UT WOS:000593804800020
PM 32501511
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tempestilli, M
   Caputi, P
   Avataneo, V
   Notari, S
   Forini, O
   Scorzolini, L
   Marchioni, L
   Bartoli, TA
   Castilletti, C
   Lalle, E
   Capobianchi, MR
   Nicastri, E
   D'Avolio, A
   Ippolito, G
   Agrati, C
AF Tempestilli, Massimo
   Caputi, Priscilla
   Avataneo, Valeria
   Notari, Stefanie
   Forini, Olinda
   Scorzolini, Laura
   Marchioni, Luisa
   Bartoli, Tommaso Ascoli
   Castilletti, Concetta
   Lalle, Eleanore
   Capobianchi, Maria R.
   Nicastri, Emanuele
   D'Avolio, Antonio
   Ippolito, Giuseppe
   Agrati, Chiara
CA Covid 19 INMI Study Grp
TI Pharmacokinetics of remdesivir and GS-441524 in two critically ill
   patients who recovered from COVID-19
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID GS-5734; EBOLA
AB Background: Remdesivir is a prodrug of the nucleoside analogue GS-441524 and is under evaluation for treatment of SARS-CoV-2-infected patients.
   Objectives: To evaluate the pharmacokinetics of remdesivir and GS-441524 in plasma, bronchoalveolar aspirate (BAS) and CSF in two critically ill COVID-19 patients.
   Methods: Remdesivir was administered at 200mg loading dose on the first day followed by 12days of 100mg in two critically ill patients. Blood samples were collected immediately after (C-0) and at 1 (C-1) and 24h (C-24) after intravenous administration on day 3 until day 9. BAS samples were collected on Days 4, 7 and 9 from both patients while one CSF on Day 7 was obtained in one patient. Remdesivir and GS-441524 concentrations were measured in these samples using a validated UHPLC-MS/MS method.
   Results: We observed higher concentrations of remdesivir at C-0 (6- to 7-fold higher than EC50 from in vitro studies) and a notable decay at C-1. GS-441524 plasma concentrations reached a peak at C-1 and persisted until the next administration. Higher concentrations of GS-441524 were observed in the patient with mild renal dysfunction. Mean BAS/plasma concentration ratios of GS-441524 were 2.3% and 6.4% in Patient 1 and Patient 2, respectively. The CSF concentration found in Patient 2 was 25.7% with respect to plasma. GS-441524 levels in lung and CNS suggest compartmental differences in drug exposure.
   Conclusions: We report the first pharmacokinetic evaluation of remdesivir and GS-441524 in recovered COVID-19 patients. Further study of the pharmacokinetic profile of remdesivir, GS-441524 and the intracellular triphosphate form are required.
C1 [Tempestilli, Massimo; Caputi, Priscilla; Notari, Stefanie; Forini, Olinda; Scorzolini, Laura; Marchioni, Luisa; Bartoli, Tommaso Ascoli; Castilletti, Concetta; Lalle, Eleanore; Capobianchi, Maria R.; Nicastri, Emanuele; Ippolito, Giuseppe; Agrati, Chiara] Natl Inst Infect Dis L Spallanzani IRCCS, Via Portuense 292, I-00149 Rome, Italy.
   [Avataneo, Valeria; D'Avolio, Antonio] Univ Turin, Amedeo di Savoia Hosp, Dept Med Sci, Lab Clin Pharmacol & Pharmacogenet, Cso Svizzera 164, I-10149 Turin, Italy.
RP Agrati, C (corresponding author), Natl Inst Infect Dis L Spallanzani IRCCS, Via Portuense 292, I-00149 Rome, Italy.
EM chiara.agrati@inmi.it
RI tempestilli, massimo/K-5952-2016; D'Abramo, Alessandra/AAA-3054-2019;
   Caputi, Priscilla/AAJ-4012-2020
OI tempestilli, massimo/0000-0003-3107-7441; D'Abramo,
   Alessandra/0000-0002-5160-9743; Caputi, Priscilla/0000-0002-0428-0658;
   Reis, AlessanRSS/0000-0001-8486-7469; Avataneo,
   Valeria/0000-0002-4102-5218
FU Italian Ministry of Health (Ricerca Corrente, Linea 1)
FX This study was supported by funds from the Italian Ministry of Health
   (Ricerca Corrente, Linea 1).
CR Albarello F, 2020, INT J INFECT DIS, V93, P192, DOI 10.1016/j.ijid.2020.02.043
   Avataneo V, 2020, J ANTIMICROB CHEMOTH, V75, P1772, DOI 10.1093/jac/dkaa152
   Borst P, 2013, J CLIN INVEST, V123, P4131, DOI 10.1172/JCI70430
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Ko WC, 2020, INT J ANTIMICROB AG, V5
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Rizk ML, 2017, CTS-CLIN TRANSL SCI, V10, P133, DOI 10.1111/cts.12448
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Taneva E, 2016, ANTIMICROB AGENTS CH, V60, P1667, DOI 10.1128/AAC.02793-15
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
NR 15
TC 4
Z9 4
U1 5
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD OCT
PY 2020
VL 75
IS 10
BP 2977
EP 2980
DI 10.1093/jac/dkaa239
PG 4
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA OK2SY
UT WOS:000584502800035
PM 32607555
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Stader, F
   Khoo, S
   Stoeckle, M
   Back, D
   Hirsch, HH
   Battegay, M
   Marzolini, C
AF Stader, Felix
   Khoo, Saye
   Stoeckle, Marcel
   Back, David
   Hirsch, Hans H.
   Battegay, Manuel
   Marzolini, Catia
TI Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug
   interacting effect
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Letter
ID ENZYMES; CYP1A2; CYP3A4
C1 [Stader, Felix; Stoeckle, Marcel; Hirsch, Hans H.; Battegay, Manuel; Marzolini, Catia] Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Dept Med, Basel, Switzerland.
   [Stader, Felix; Stoeckle, Marcel; Hirsch, Hans H.; Battegay, Manuel; Marzolini, Catia] Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Dept Clin Res, Basel, Switzerland.
   [Stader, Felix; Stoeckle, Marcel; Battegay, Manuel; Marzolini, Catia] Univ Basel, Basel, Switzerland.
   [Khoo, Saye; Back, David; Marzolini, Catia] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.
   [Hirsch, Hans H.] Univ Basel, Dept Biomed, Transplantat & Clin Virol, Basel, Switzerland.
RP Stader, F (corresponding author), Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Dept Med, Basel, Switzerland.; Stader, F (corresponding author), Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Dept Clin Res, Basel, Switzerland.; Stader, F (corresponding author), Univ Basel, Basel, Switzerland.
EM Felix.Stader@usb.ch
OI Hirsch, Hans H./0000-0003-0883-0423; Reis,
   AlessanRSS/0000-0001-8486-7469
FU Swiss National FoundationSwiss National Science Foundation (SNSF)
   [324730188504]; Adolf and Mary -Mil Foundation
FX F.S. was supported by a grant from the Swiss National Foundation (grant
   number: 324730188504). C.M. was supported by the Adolf and Mary -Mil
   Foundation. All other authors did the study as part of their routine
   work.
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Dickmann LJ, 2011, DRUG METAB DISPOS, V39, P1415, DOI 10.1124/dmd.111.038679
   Magnusson MO, 2008, CLIN PHARMACOL THER, V84, P52, DOI 10.1038/sj.clpt.6100431
   Stader F, 2020, CLIN PHARMACOKINET, V59, P383, DOI 10.1007/s40262-019-00822-9
   Stader F, 2019, CPT-PHARMACOMET SYST, V8, P444, DOI 10.1002/psp4.12399
   Stader F, 2019, CLIN PHARMACOKINET, V58, P483, DOI 10.1007/s40262-018-0709-7
   Yeh RF, 2006, JAIDS-J ACQ IMM DEF, V42, P52
   Yeo KR, 2011, EUR J PHARM SCI, V43, P160, DOI 10.1016/j.ejps.2011.04.008
   Yuan J, 2020, INFLAMM RES, V69, P599, DOI 10.1007/s00011-020-01342-0
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 10
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD OCT
PY 2020
VL 75
IS 10
BP 3084
EP 3086
DI 10.1093/jac/dkaa253
PG 3
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA OK2SY
UT WOS:000584502800057
PM 32556272
OA Green Published
DA 2021-01-01
ER

PT J
AU Singh, S
   Maurya, RP
   Singh, RK
AF Singh, Samer
   Maurya, Rajendra Prakash
   Singh, Rakesh K.
TI "Trained immunity" from Mycobacterium spp. exposure or BCG vaccination
   and COVID-19 outcomes
SO PLOS PATHOGENS
LA English
DT Article
ID TUBERCULIN; RESPONSES
AB Protective variables for Coronavirus Disease 2019 (COVID-19) are unknown. "Trained immunity" of the populace as a result of Bacille Calmette-Guerin (BCG) vaccination policy implementation and coverage had been suggested to be one of the factors responsible for the differential impact of COVID-19 on different countries. Several trials are underway to evaluate the potential protective role of BCG vaccination in COVID-19. However, the lack of clarity on the use of appropriate controls concerning the measures of "trained immunity" or the heterologous cell-mediated immunity conferred by BCG vaccination has been a cause of concern leading to more confusion as exemplified by a recently concluded trial in Israel that failed to find any protective correlation with regard to BCG vaccination. Whereas, when we analyze the COVID-19 epidemiological data of European countries without any regard for BCG vaccination policy but with similar age distribution, comparable confounding variables, and the stage of the pandemic, the prevalence of tuberculin immunoreactivity-a measure of cell-mediated immunity persistence as a result of Mycobacterium spp. (including BCG vaccine) exposure of the populations-is found consistently negatively correlated with COVID-19 infections and mortality. We seek to draw attention toward the inclusion of controls for underlying "trained immunity" and heterologous cell-mediated immunity prevalence that may be preexisting or resulting from the intervention (e.g., BCG vaccine) in such trials to arrive at more dependable conclusions concerning potential benefit from them.
C1 [Singh, Samer] Banaras Hindu Univ, Inst Med Sci, Ctr Expt Med & Surg, Varanasi, Uttar Pradesh, India.
   [Singh, Samer] Panjab Univ, Dept Microbial Biotechnol, Chandigarh, India.
   [Maurya, Rajendra Prakash] Banaras Hindu Univ, Reg Inst Ophthalmol, Inst Med Sci, Varanasi, Uttar Pradesh, India.
   [Singh, Rakesh K.] Banaras Hindu Univ, Inst Sci, Dept Biochem, Varanasi, Uttar Pradesh, India.
RP Singh, S (corresponding author), Banaras Hindu Univ, Inst Med Sci, Ctr Expt Med & Surg, Varanasi, Uttar Pradesh, India.; Singh, S (corresponding author), Panjab Univ, Dept Microbial Biotechnol, Chandigarh, India.
EM samer.singh10@bhu.ac.in
OI Singh, Samer/0000-0002-0921-1686
FU DBT, IndiaDepartment of Biotechnology (DBT) India
   [BT/RLF/Re-Entry/50/2011]
FX The current study did not receive any funding from any source. The
   general support by Banaras Hindu University to the laboratory of SS is
   acknowledged. SS is a Ramalingaswami Fellow, DBT, India
   (BT/RLF/Re-Entry/50/2011). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Behr MA, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l5770
   Berg MK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc1463
   COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593
   Diel R, 2006, EUR RESPIR J, V28, P16, DOI 10.1183/09031936.06.00107005
   Escobar LE, 2020, P NATL ACAD SCI USA, V117, P17720, DOI 10.1073/pnas.2008410117
   Getahun H, 2015, NEW ENGL J MED, V372, P2127, DOI 10.1056/NEJMra1405427
   Global Burden of Disease Collaborative Network, 2018, GLOB BURD DIS STUD 2
   Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189
   Hauer J, 2020, LEUKEMIA, V34, P2217, DOI 10.1038/s41375-020-0871-4
   Kleinnijenhuis J, 2015, T ROY SOC TROP MED H, V109, P29, DOI 10.1093/trstmh/tru168
   Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628
   Menzies D, 2000, CLIN INFECT DIS, V31, pS71, DOI 10.1086/314075
   Menzies D, 1999, AM J RESP CRIT CARE, V159, P15, DOI 10.1164/ajrccm.159.1.9801120
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Nakayama K, 2000, THORAX, V55, P867, DOI 10.1136/thorax.55.10.867
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Ohrui Takashi, 2005, Nihon Ronen Igakkai Zasshi, V42, P34
   Rakshit S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130540
   Singh S, 2020, BCG VACCINES MAY NOT, DOI [10.1101/2020.04.11.20062232, DOI 10.1101/2020.04.11.20062232]
   Singh S, 2020, J SCI RES, V64, P153, DOI [10.37398/JSR.2020.640222, DOI 10.37398/JSR.2020.640222]
   Singh S, 2020, AGING CLIN EXP RES, V32, P1609, DOI 10.1007/s40520-020-01619-8
   World Health Organization, 2018, LAT TUB INF UPD CONS
   Worldometer, COVID 19 COR PAND
   Zwerling A, 2017, WORLD ATLAS BCG POLI
NR 25
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD OCT
PY 2020
VL 16
IS 10
AR e1008969
DI 10.1371/journal.ppat.1008969
PG 8
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA PB8QW
UT WOS:000596580000002
PM 33119725
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Franco, V
   Bradley, EA
   Badagliacca, R
   Sabanayagam, A
   Rajpal, S
   Lastinger, LT
   Daniels, CJ
   Smith, JS
   Benza, RL
AF Franco, Veronica
   Bradley, Elisa A.
   Badagliacca, Roberto
   Sabanayagam, Aarthi
   Rajpal, Saurabh
   Lastinger, Lauren T.
   Daniels, Curt J.
   Smith, J. Shaun
   Benza, Raymond L.
TI Pulmonary vasodilators: beyond the bounds of pulmonary arterial
   hypertension therapy in COVID-19
SO PULMONARY CIRCULATION
LA English
DT Article
DE pulmonary hypertension; COVID-19; treatment; nitric oxide; prostacyclin
AB Pulmonary arterial hypertension (PAH) and novel coronavirus (SARS-CoV-2) disease COVID-19 are characterized by extensive endothelial dysfunction and inflammation leading to vascular remodeling and severe microthrombi and microvascular obliterative disease. It is hypothesized that those patients with underlying lung disease, like PAH, represent a high-risk cohort in this pandemic. However, reports of COVID-19 in this cohort of patient have been scaring and an observational survey showed that the disease was relatively well tolerated. We postulate that specific PAH vasodilator may offer some protection and/or advantage in the case of concomitant COVID-19. Here we review the literature describing mechanisms of action for each of the broad categories of PAH therapy, and offer potential hypothesis about why this therapy may impact outcomes in COVID-19.
C1 [Franco, Veronica; Bradley, Elisa A.; Rajpal, Saurabh; Lastinger, Lauren T.; Daniels, Curt J.; Benza, Raymond L.] Ohio State Univ, Wexner Med Ctr, Div Cardiovasc Dis, Columbus, OH 43210 USA.
   [Badagliacca, Roberto] Sapienza Univ Rome, Dept Cardiovasc & Resp Sci, Rome, Italy.
   [Smith, J. Shaun] Ohio State Univ, Wexner Med Ctr, Div Pulm Crit Care & Sleep Med, Columbus, OH 43210 USA.
   [Sabanayagam, Aarthi] Univ Calif San Francisco, Div Cardiovasc Dis, San Francisco, CA 94143 USA.
RP Franco, V (corresponding author), 473 W 12th St,Suite 200, Columbus, OH 43210 USA.
EM veronica.franco@osumc.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [K08HL148701]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by NIH K08HL148701 (EAB).
CR Abraham D, 2008, EUR RESPIR REV, V17, P145, DOI 10.1183/09059180.00010907
   Adhikari NKJ, 2007, BMJ-BRIT MED J, V334, P779, DOI 10.1136/bmj.39139.716794.55
   Adhikari NKJ, 2014, CRIT CARE MED, V42, P404, DOI 10.1097/CCM.0b013e3182a27909
   Afshari A, 2011, ANESTH ANALG, V112, P1411, DOI 10.1213/ANE.0b013e31820bd185
   Afshari A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007733.pub2
   Akerstrom S, 2005, J VIROL, V79, P1966, DOI 10.1128/JVI.79.3.1966-1969.2005
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Badagliacca R, 2020, J HEART LUNG TRANSPL, V39, P729, DOI 10.1016/j.healun.2020.04.007
   CHANG SW, 1994, J APPL PHYSIOL, V77, P2817
   Chen LN, 2004, CLIN INFECT DIS, V39, P1531, DOI 10.1086/425357
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   DeBacker D, 1996, CHEST, V110, P1361, DOI 10.1378/chest.110.5.1361
   Delgado M, 1999, J IMMUNOL, V162, P1200
   Feng L, 2020, CHIN MED J, V133, P1390
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Fuller BM, 2015, CHEST, V147, P1510, DOI 10.1378/chest.14-3161
   Galie N, 2015, EUR RESPIR J, V46, P903, DOI 10.1183/13993003.01032-2015
   Gallagher PE, 2008, AM J PHYSIOL-HEART C, V295, pH2373, DOI 10.1152/ajpheart.00426.2008
   Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z
   GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Gralinski LE, 2013, MBIO, V4, DOI 10.1128/mBio.00271-13
   Horn EM, 2020, PULM CIRC, V10, DOI 10.1177/2045894020922799
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hunt JL, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00074
   Inglessis I, 2004, J AM COLL CARDIOL, V44, P793, DOI 10.1016/j.jacc.2004.05.047
   Joshi MS, 2002, P NATL ACAD SCI USA, V99, P10341, DOI 10.1073/pnas.152149699
   Keyaerts E, 2004, INT J INFECT DIS, V8, P223, DOI 10.1016/j.ijid.2004.04.012
   Konstam MA, 2018, CIRCULATION, V137, pE578, DOI 10.1161/CIR.0000000000000560
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   KURIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P1435, DOI 10.1016/0006-291X(89)92270-5
   Leisman DE, 2020, INTENS CARE MED, V46, P1105, DOI 10.1007/s00134-020-06059-6
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Luo W, 2020, CLIN PATHOLOGY CRITI, DOI [10.13140/RG.2.2.22934.29762, DOI 10.13140/RG.2.2.22934.29762]
   MAEMURA K, 1992, GERONTOLOGY, V38, P29
   Mannick Joan B, 2006, Proc Am Thorac Soc, V3, P161, DOI 10.1513/pats.200505-048BG
   Mitchell JA, 2008, EXP PHYSIOL, V93, P141, DOI 10.1113/expphysiol.2007.038588
   MONCADA S, 1990, THROMB RES, P3
   Morrell NW, 2013, PULM CIRC, V3, P226, DOI 10.4103/2045-8932.109940
   Plum J, 2002, NEPHRON, V91, P391, DOI 10.1159/000064278
   Rabinovitch M, 2014, CIRC RES, V115, P165, DOI 10.1161/CIRCRESAHA.113.301141
   RADOMSKI MW, 1993, THROMB HAEMOSTASIS, V70, P36
   Raghu G, 2013, ANN INTERN MED, V158, P641, DOI 10.7326/0003-4819-158-9-201305070-00003
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Reiss CS, 1998, J VIROL, V72, P4547, DOI 10.1128/JVI.72.6.4547-4551.1998
   Rodriguez-Pascual F, 2014, LIFE SCI, V118, P156, DOI 10.1016/j.lfs.2013.12.024
   ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605
   ROSSAINT R, 1995, INTENS CARE MED, V21, P197, DOI 10.1007/BF01701472
   Sakamaki F, 2000, CIRCULATION, V102, P2720, DOI 10.1161/01.CIR.102.22.2720
   SAMAMA CM, 1995, ANESTHESIOLOGY, V83, P56, DOI 10.1097/00000542-199507000-00007
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   Spiekerkoetter E, 2019, ANNU REV MED, V70, P45, DOI 10.1146/annurev-med-041717-085955
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Tsai BM, 2004, AM J PHYSIOL-LUNG C, V287, pL1215, DOI 10.1152/ajplung.00179.2004
   Tsai BM, 2004, ANN THORAC SURG, V78, P360, DOI 10.1016/j.athoracsur.2003.11.035
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Venkataraman T, 2017, ANTIVIR RES, V143, P142, DOI 10.1016/j.antiviral.2017.03.022
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziesche R, 2000, HEART, V83, P406, DOI 10.1136/heart.83.4.406
NR 65
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD OCT
PY 2020
VL 10
IS 4
AR 2045894020970369
DI 10.1177/2045894020970369
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA OZ3RZ
UT WOS:000594848800001
PM 33282201
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Meyer-Almes, FJ
AF Meyer-Almes, Franz-Josef
TI Repurposing approved drugs as potential inhibitors of 3CL-protease of
   SARS-CoV-2: Virtual screening and structure based drug design
SO COMPUTATIONAL BIOLOGY AND CHEMISTRY
LA English
DT Article
DE COVID-19; Antiviral; Drug discovery; Docking; Pharmacophore;
   Therapeutic; C30 endopeptidase
ID DISCOVERY; PROTEASE; VISUALIZATION; OPTIMIZATION; DOCKING; PAINS
AB 3CL proteases (3CL(pro)) are only found in RNA viruses and have a central role in polyprotein processing during replication. Therefore, 3CL(pro) has emerged as promising drug target for therapeutic treatment of infections caused by Coronaviruses. In the light of the recent major outbreak of the SARS-CoV-2 virus and the continuously rising numbers of infections and casualties, there is an urgent need for quickly available drugs or vaccines to stop the current COVID-19 pandemic. Repurposing of approved drugs as 3CL(pro) inhibitors could dramatically shorten the period up to approval as therapeutic against SARS-CoV-2, since pharmacokinetics and toxicity is already known. Several known drugs, e.g. oxytetracycline, doxorubicin, kanamycin, cefpiramide, teniposide, proan-thocyanidin and salvianolic acid B, but also not-approved active compounds from the ZINC15 library were identified as new potential inhibitors of 3CL(pro) by using different complementary virtual screening and docking approaches. These compounds have the potential to be further optimized using structure based drug design as demonstrated for oxytetracycline.
C1 [Meyer-Almes, Franz-Josef] Univ Appl Sci Darmstadt, Dept Chem Engn & Biotechnol, Haardtring 100, D-64295 Darmstadt, Germany.
RP Meyer-Almes, FJ (corresponding author), Univ Appl Sci Darmstadt, Dept Chem Engn & Biotechnol, Haardtring 100, D-64295 Darmstadt, Germany.
EM franz-josef.meyer-almes@h-da.de
CR Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bajorath J, 2009, DRUG DISCOV TODAY, V14, P698, DOI 10.1016/j.drudis.2009.04.003
   Berry M, 2015, VIRUSES-BASEL, V7, P6642, DOI 10.3390/v7122963
   Capuzzi SJ, 2017, J CHEM INF MODEL, V57, P417, DOI 10.1021/acs.jcim.6b00465
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Cortegiani A, 2020, J CRIT CARE
   Dong E, 2020, LANCET INFECT DIS
   Douangamath A., 2020, BIORXIV2020052711811
   Du B, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE012, DOI 10.3760/cma.j.issn.1001-0939.2020.0012
   Fan H.H., 2020, CHIN MED
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hoffmann C, 2020, CELL RES, DOI 10.1038/s41422-020-00440-2
   Horby P., 2020, MEDRXIV2020062220137
   Jacobs J, 2013, J MED CHEM, V56, P534, DOI 10.1021/jm301580n
   Jin Z., 2020, RCSB PROTEIN DATA BA
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Liu W, 2014, BIOORGAN MED CHEM, V22, P292, DOI 10.1016/j.bmc.2013.11.028
   Mukherjee P, 2011, J CHEM INF MODEL, V51, P1376, DOI 10.1021/ci1004916
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsai KC, 2006, J MED CHEM, V49, P3485, DOI 10.1021/jm050852f
   Turlington M, 2013, BIOORG MED CHEM LETT, V23, P6172, DOI 10.1016/j.bmcl.2013.08.112
   Zhang L., 2020, SCIENCE
NR 27
TC 3
Z9 3
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1476-9271
EI 1476-928X
J9 COMPUT BIOL CHEM
JI Comput. Biol. Chem.
PD OCT
PY 2020
VL 88
AR 107351
DI 10.1016/j.compbiolchem.2020.107351
PG 10
WC Biology; Computer Science, Interdisciplinary Applications
SC Life Sciences & Biomedicine - Other Topics; Computer Science
GA OU0UA
UT WOS:000591250400006
PM 32769050
DA 2021-01-01
ER

PT J
AU Berman, M
   Eaton, LA
   Watson, RJ
   Andrepont, JL
   Kalichman, S
AF Berman, Marcie
   Eaton, Lisa A.
   Watson, Ryan J.
   Andrepont, J. L.
   Kalichman, Seth
TI Social Distancing to Mitigate COVID-19 Risks Is Associated With COVID-19
   Discriminatory Attitudes Among People Living with HIV
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Article
DE COVID-19; Discriminatory attitudes; Xenophobic attitudes; HIV
ID STIGMA; HIV/AIDS; INTERVENTION; CONTINUUM; WOMEN; AIDS; CARE; MEN; SEX
AB Background Severe acute respiratory syndrome coronavirus-2, the virus that causes COVID-19, is an emerging pandemic with heightened concerns for people with compromised immune systems, including people living with HIV.
   Purpose In the absence of a vaccine, public health messaging to mitigate risks for COVID-19 primarily focuses on social distancing. Because people living with HIV commonly experience mistreatment associated with HIV, their response to social distancing may be complicated by psychosocial attitudes associated with COVID-19.
   Methods To evaluate these relationships, we conducted a rapid-response, cross-sectional survey with people living with HIV (N = 149) to assess social distancing practices, COVID-19 discriminatory attitudes, COVID-19 xenophobic attitudes, HIV microaggressions, and concern over contracting COVID-19. Data were collected from participants enrolled in a larger ongoing study between March 30, 2020 and April 17, 2020.
   Results Results indicated that choosing to socially distance to reduce COVID-19 exposure was associated with COVID-19 discriminatory attitudes, concerns of contracting COVID-19, and identifying as transgender. Likewise, social distancing imposed by others (e.g., cancelations and restrictions) was associated with concerns of contracting COVID-19.
   onclusions Findings demonstrate that social distancing measures are related to concerns of contracting the virus and discriminatory attitudes toward those who are presumed to be living with COVID-19. These potentially negative psychosocial attitudes toward people perceived to have COVID-19 echo the discriminatory actions and attitudes that we continue to observe in HIV social sciences research.
C1 [Berman, Marcie; Eaton, Lisa A.; Watson, Ryan J.; Kalichman, Seth] Univ Connecticut, Inst Collaborat Hlth Intervent & Policy, 2006 Hillside Rd, Storrs, CT 06269 USA.
   [Andrepont, J. L.] Oregon State Univ, Sch Publ Policy, Bexell Hall,2251 SW Campus Way, Corvallis, OR 97331 USA.
RP Eaton, LA (corresponding author), Univ Connecticut, Inst Collaborat Hlth Intervent & Policy, 2006 Hillside Rd, Storrs, CT 06269 USA.
EM lisa.eaton@uconn.edu
OI Berman, Marcie/0000-0003-4071-3243
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [K01DA047918,
   R01DA043068, R01MH109409]
FX This work was supported by the National Institutes of Health
   (K01DA047918, R01DA043068, and R01MH109409).
CR Allcott H, 2020, 26946 NBER
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Bartos M, 2000, AIDS CARE, V12, P299, DOI 10.1080/09540120050042954
   Bogart LM, 2017, CULT HEALTH SEX, V19, P723, DOI 10.1080/13691058.2016.1258492
   Burke RM, 2020, MMWR-MORBID MORTAL W, V69, P245, DOI 10.15585/mmwr.mm6909e1
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chesney MA, 2003, AM J PUBLIC HEALTH, V93, P933, DOI 10.2105/AJPH.93.6.933
   Des Jarlais DC, 2006, AM J PUBLIC HEALTH, V96, P561, DOI 10.2105/AJPH.2004.054742
   Earnshaw VA, 2012, AIDS EDUC PREV, V24, P574, DOI 10.1521/aeap.2012.24.6.574
   Earnshaw VA, 2009, AIDS BEHAV, V13, P1160, DOI 10.1007/s10461-009-9593-3
   Eaton LA, 2020, J BEHAV MED, V43, P34, DOI 10.1007/s10865-019-00064-x
   Eaton LA, 2018, J BEHAV MED, V41, P458, DOI 10.1007/s10865-018-9922-y
   Eaton LA, 2013, AIDS CARE, V25, P805, DOI 10.1080/09540121.2012.748870
   Farboodi M, 2020, 08982937 NBER BECK F
   Fischer LS, 2019, DISASTER MED PUBLIC, V13, P989, DOI 10.1017/dmp.2018.157
   Genberg BL, 2009, SOC SCI MED, V68, P2279, DOI 10.1016/j.socscimed.2009.04.005
   Georgia Department of Public Health, 2020, COVID 19 DAIL STAT R
   Gostin LO, 2020, JAMA-J AM MED ASSOC, V323, P2137, DOI 10.1001/jama.2020.5460
   Greenberg AE, 2015, JAIDS-J ACQ IMM DEF, V69, pS1, DOI 10.1097/QAI.0000000000000569
   Halkitis P.N., 2012, PSYCHOL AIDS EXCHANG, V1, P4
   He J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082933
   HEREK GM, 1988, AM PSYCHOL, V43, P886, DOI 10.1037/0003-066X.43.11.886
   Jemmott JB, 2019, J ASSOC NURSE AIDS C, V30, P352, DOI 10.1097/JNC.0000000000000087
   Jiang HB, 2020, LANCET HIV, V7, pE308, DOI 10.1016/S2352-3018(20)30105-3
   Kalichman SC, 2005, AIDS BEHAV, V9, P135, DOI 10.1007/s10461-005-3895-x
   Kim HS, 2016, PSYCHOL SCI, V27, P935, DOI 10.1177/0956797616642596
   Lin C-Y, 2020, SOCIAL HLTH BEHAV, V3, P1, DOI [10.4103/SHB.SHB_11_20, DOI 10.4103/SHB.SHB_11_20]
   Logie CH, 2020, AIDS BEHAV, V24, P2003, DOI 10.1007/s10461-020-02856-8
   Logie CH, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001124
   Mak WWS, 2006, SOC SCI MED, V63, P1912, DOI 10.1016/j.socscimed.2006.04.016
   Malcolm A, 1998, CRITICAL PUBLIC HLTH, V8, P347, DOI DOI 10.1080/09581599808402920
   Meier BM, 2018, HEALTH HUM RIGHTS, V20, P85
   Ng E, 2020, AM J TROP MED HYG, V102, P1158, DOI 10.4269/ajtmh.20-0285
   Painter M, 2020, POLITICAL BELIEFS AF, DOI [10.2139/ssrn.3569098, DOI 10.2139/SSRN.3569098]
   Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620
   Petros G, 2006, CULT HEALTH SEX, V8, P67, DOI 10.1080/13691050500391489
   Pickles D, 2009, J ADV NURS, V65, P2262, DOI 10.1111/j.1365-2648.2009.05128.x
   Poteat T, 2014, CURR OPIN HIV AIDS, V9, P168, DOI 10.1097/COH.0000000000000030
   Prati G, 2016, RISK ANAL, V36, P2000, DOI 10.1111/risa.12537
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Shiau S, 2020, AIDS BEHAV, V24, P2244, DOI 10.1007/s10461-020-02871-9
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Suleman S, 2018, J PUBLIC HEALTH POL, V39, P407, DOI 10.1057/s41271-018-0140-1
   Tan RKJ, 2019, J HOMOSEXUAL, V66, P1082, DOI 10.1080/00918369.2018.1491249
   Turan B, 2019, AIDS, V33, P571, DOI 10.1097/QAD.0000000000002071
   van Dorn A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X
   Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598
NR 48
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD OCT
PY 2020
VL 54
IS 10
BP 728
EP 737
DI 10.1093/abm/kaaa074
PG 10
WC Psychology, Multidisciplinary
SC Psychology
GA OW2UW
UT WOS:000592749500002
PM 32940326
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gaudette, E
AF Gaudette, Etienne
TI COVID-19's Limited Impact on Drug Shortages in Canada
SO CANADIAN PUBLIC POLICY-ANALYSE DE POLITIQUES
LA English
DT Article
DE drug shortages; public health shocks; pharmaceutical supply chain;
   pharmaceutical demand
ID ESSENTIAL MEDICINES LIST
AB Using data from the Drug Shortages Canada website, we ask whether the first months of the coronavirus disease 2019 (COVID-19) pandemic were associated with a significant increase in drug shortages in Canada. We find an increase of 147 shortages (32 percent) reported by manufacturers during March and April 2020 relative to the same months in previous years. The upsurge was concentrated during the two-week period from 25 March to 7 April 2020, after which report counts returned to usual levels. Excess reports cite both supply-side and demand-side causes for shortages. Increases were noted in therapeutic classes associated with COVID-19 care.
C1 [Gaudette, Etienne] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
RP Gaudette, E (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
CR Bidstats, 2019, ESSENTIAL MEDICINES
   Canada, 2020, EXCEPTIONAL IMPORTAT
   Canada, 2018, TOWARDS IMPLEMENTATI
   Canada, 2020, INTERIM ORDER RESPEC
   Canadian Pharmacists Association, 2020, STATEMENT ON 30 DAY
   Davidson S., 2020, CTV NEWS
   Donelle J., 2018, ASSESSING CANADAS DR
   Drug Shortages Canada, DRUG SHORTAGES HOMEP
   Drug Shortages Task Force, 2019, DRUG SHORTAGES ROOT
   Eom G, 2016, CAN MED ASSOC J, V188, pE499, DOI 10.1503/cmaj.160134
   Health Canada, 2015, DRUG PRODUCT DATABAS
   Jarvis JD, 2019, CAN MED ASSOC J, V191, pE1093, DOI 10.1503/cmaj.190567
   Kennedy P., 2003, GUIDE ECONOMETRICS
   Multi-Stakeholder Steering Committee on Drug Shortages, 2017, PREVENTING DRUG SHOR
   Osman L., 2020, GLOBAL NEWS
   Rinaldi F, 2017, CAN J CARDIOL, V33, P283, DOI 10.1016/j.cjca.2016.08.010
   Slaughter Graham, 2020, CTV NEWS
   World Customs Organization, LIST OF NATIONAL LEG
   Young ND, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01208-5
NR 19
TC 0
Z9 0
U1 1
U2 1
PU UNIV TORONTO PRESS INC
PI TORONTO
PA JOURNALS DIVISION, 5201 DUFFERIN ST, DOWNSVIEW, TORONTO, ON M3H 5T8,
   CANADA
SN 0317-0861
EI 1911-9917
J9 CAN PUBLIC POL
JI Can. Public Policy-Anal. Polit.
PD OCT 1
PY 2020
VL 46
SU 3
SI SI
BP S307
EP S312
DI 10.3138/cpp.2020-107
PG 6
WC Economics; Public Administration
SC Business & Economics; Public Administration
GA OR7DV
UT WOS:000589629000008
DA 2021-01-01
ER

PT J
AU Imani-Saber, Z
   Vaseghi, H
   Mahdian, M
   Safari, F
   Ghadami, M
AF Imani-Saber, Zeinab
   Vaseghi, Hajar
   Mahdian, Mojdeh
   Safari, Fatemeh
   Ghadami, Mohsen
TI Variable Clinical Manifestations of COVID-19: Viral and Human Genomes
   Talk
SO IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY
LA English
DT Article
DE Angiotensin-converting enzyme 2; Coronavirus; FURIN protein;
   Personalized medicine; Severe acute respiratory syndrome coronavirus 2
ID ANGIOTENSIN-II; SPIKE PROTEIN; CORONAVIRUS; FURIN; RECEPTOR; SARS;
   HYDROXYCHLOROQUINE; POLYMORPHISM; CHLOROQUINE; ACTIVATION
AB The new coronavirus, known as "SARS-CoV-2"; is the cause of one of the most prevalent infectious viral diseases that was recently announced pandemic by the world health organization. Ongoing research in the fields of prevention, management, and therapy establishes a functional scaffold for clinics during the time of crisis. To obtain this goal, it is necessary that all pathophysiologic aspects of COVID-19 from infection to predisposing backgrounds of infection be identified, so that all the ambiguities of researchers regarding transmission mechanisms, variable clinical manifestation, and therapeutic response can be solved. Here, we firstly discuss about the homology screening between nCoV-2019 and beta-coronavirus family using phylogenetic analyses. Secondly, we analyzed the viral motifs to show that viral entry into the host cells requires a primary activation step performed by FURIN and FURIN-like-mediated enzymatic cleavage on the structural glycoprotein. The cleavage increases viral performance by 1000 folds. We then present a comprehensive view on host cells and the significance of gene variants affecting activation enzymes, supportive entry, and spread mechanisms in humans including renin-angiotensin-aldosterone system (RAAS) a pathway results in certain phenotypes or exacerbate infection-related phenotypes in different organs, hence causes variable clinical manifestations. This is followed by discussing about the importance of personalized medicine in nCoV-2019 exposure. Moreover, chemical drugs prescribed for individuals affected with COVID-19, as well as genes involved in drug transport and metabolisms are reviewed as a prelude to drug response. Finally, we suggest some therapeutic approaches developed based on new methods and technology such as anti-sense therapy and antibodies.
C1 [Imani-Saber, Zeinab; Vaseghi, Hajar; Mahdian, Mojdeh; Safari, Fatemeh; Ghadami, Mohsen] Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran, Iran.
   [Ghadami, Mohsen] Univ Tehran Med Sci, Cardiac Primary Prevent Res Ctr, Tehran Heart Ctr, Tehran, Iran.
RP Ghadami, M (corresponding author), Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran, Iran.
EM mghadami@tums.ac.ir
CR Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Bain LJ, 1997, ENVIRON HEALTH PERSP, V105, P812, DOI 10.2307/3433698
   Banerjee A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00026
   Bassi DE, 2003, AM J PATHOL, V162, P439, DOI 10.1016/S0002-9440(10)63838-2
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Bertram S, 2012, PLOS ONE, V7
   Boucher E, 2006, KIDNEY INT, V69, P1570, DOI 10.1038/sj.ki.5000316
   Cameron A, 2000, J BIOL CHEM, V275, P36741, DOI 10.1074/jbc.M003848200
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Champney WS, 2002, CURR MICROBIOL, V44, P418, DOI 10.1007/s00284-001-0016-6
   Control CfD, 2020, INT CLIN GUID MAN PA
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Deshotels MR, 2014, HYPERTENSION, V64, P1368, DOI 10.1161/HYPERTENSIONAHA.114.03743
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Fang L., 2020, LANCET RESP MED
   Fedson DS, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.11.03
   Fohner AE, 2017, PHARMACOGENET GENOM, V27, P164, DOI 10.1097/FPC.0000000000000270
   Fowler DM, 2006, PLOS BIOL, V4, P100, DOI 10.1371/journal.pbio.0040006
   Fukushima A, 2009, INTERVIROLOGY, V52, P92, DOI 10.1159/000215946
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736
   Gondzik V, 2012, AM J PHYSIOL-CELL PH, V303, pC936, DOI 10.1152/ajpcell.00395.2011
   He Q, 2013, PLOS ONE, V8
   He XJ, 2009, PHARMACOL REP, V61, P843, DOI 10.1016/S1734-1140(09)70140-9
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hilgenfeld R, 2013, ANTIVIR RES, V100, P286, DOI 10.1016/j.antiviral.2013.08.015
   Hoffmann C, 2020, CELL RES, DOI 10.1038/s41422-020-00440-2
   Karnik SS, 2015, PHARMACOL REV, V67, P754, DOI 10.1124/pr.114.010454
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Kim KA, 2003, ARCH PHARM RES, V26, P631, DOI 10.1007/BF02976712
   Knuckley B, 2008, BIOORGAN MED CHEM, V16, P739, DOI 10.1016/j.bmc.2007.10.021
   Kong Xiaoyuan, 2007, Genet Vaccines Ther, V5, P4, DOI 10.1186/1479-0556-5-4
   Kumar GV, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100682
   Lau SKP, 2013, J VIROL, V87, P8638, DOI 10.1128/JVI.01055-13
   Lee JY, 2016, ARTHRITIS RHEUMATOL, V68, P184, DOI 10.1002/art.39402
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Montgomery HE, 1997, CIRCULATION, V96, P741
   Moulard M, 2000, BBA-REV BIOMEMBRANES, V1469, P121, DOI 10.1016/S0304-4157(00)00014-9
   Neuman BW, 2006, ADV EXP MED BIOL, V581, P567
   Ornatowski W, 2007, J CLIN INVEST, V117, P3489, DOI 10.1172/JCI31499
   Pouya F, 2020, ARCH BONE JT SURG-AB, V8, P226, DOI 10.22038/abjs.2020.47828.2361
   Qu R, 2020, J MED VIROL, V92, P1533, DOI 10.1002/jmv.25767
   Saavedra JM, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104832
   Shanmuganathan R, 2015, J POSTGRAD MED, V61, P230, DOI 10.4103/0022-3859.166510
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Somer M, 2000, BRIT J CLIN PHARMACO, V49, P549, DOI 10.1046/j.1365-2125.2000.00197.x
   Sudevan S, 2019, FASEB J, V33, P9540, DOI 10.1096/fj.201802298R
   SUN ZD, 2020, NAT REV CARDIOL, P1, DOI DOI 10.1145/3377644.3377649
   Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev
   Tikka A, 2016, ENDOCRINE, V52, P187, DOI 10.1007/s12020-015-0838-9
   Tousoulis D, 2010, AM J HYPERTENS, V23, P237, DOI 10.1038/ajh.2009.233
   Tse Victor, 2013, J VIROL, P1673
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang P, 2008, SPORTS MED, V38, P1065, DOI 10.2165/00007256-200838120-00008
   Wondafrash DZ, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/5214751
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu MJ, 2018, J LIPID RES, V59, P2456, DOI 10.1194/jlr.D086793
   Xu CH, 2016, J PHARM SCI-US, V105, P884, DOI 10.1002/jps.24663
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Yakala GK, 2019, ARTERIOSCLER THROMB, V39
   Yamada Y, 2009, J VIROL, V83, P8744, DOI 10.1128/JVI.00613-09
   Yang HN, 2020, CLIN CARDIOL, V43, P450, DOI 10.1002/clc.23341
   Yang X, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.014333
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhang HG, 2020, IEEE T NEUR NET LEAR, V31, P4816, DOI 10.1109/TNNLS.2019.2958107
   Zhao Y., 2020, BIORXIV
   Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200
   Zhou F., 2020, LANCET
NR 74
TC 0
Z9 0
U1 1
U2 1
PU TEHRAN UNIV MEDICAL SCIENCES
PI TEHRAN
PA CTR ELECTR RES PROVISION & J IMPROVEMENT, #7, POURSINA AVE, QODS AVE, PO
   1417653911, TEHRAN, 11498, IRAN
SN 1735-1502
EI 1735-5249
J9 IRAN J ALLERGY ASTHM
JI Iran. J. Allergy Asthma Immunol.
PD OCT
PY 2020
VL 19
IS 5
BP 456
EP 470
DI 10.18502/ijaai.v19i5.4461
PG 15
WC Allergy; Immunology
SC Allergy; Immunology
GA ON5QK
UT WOS:000586755100001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Reinisch, W
   Danese, S
   Peyrin-Biroulet, L
   Loftus, EV
AF Reinisch, Walter
   Danese, Silvio
   Peyrin-Biroulet, Laurent
   Loftus, Edward V., Jr.
CA Int Org Study Inflammatory Bowel D
TI Clinical Trials for Inflammatory Bowel Disease: Global Guidance During
   the COVID-19 Pandemic
SO JOURNAL OF CROHNS & COLITIS
LA English
DT Article
DE Inflammatory bowel disease; Crohn's disease; ulcerative colitis;
   COVID-19; SARS-CoV2; clinical trials
AB The severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]-causing coronavirus disease [COVID]-19 pandemic poses major challenges for patients with inflammatory bowel disease [IBD] to be recruited and maintained in clinical trials. However, clinical trials offer patients who have failed multiple drugs access to study medications with alternative modes of action and the potential for relief from inflammation-mediated symptoms. Therefore, the continuation of clinical trials in IBD during the COVID-19 pandemic is important both for participants and for the community of IBD patients, due to the dire need for an expanded therapeutic armamentarium. As the safety of patients in clinical trials is the leading principle, we are providing ten specific rules to guide patients and principal investigators safely through the challenging time.
C1 [Reinisch, Walter] Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
   [Danese, Silvio] Humanitas Clin & Res Ctr IRCCS, IBD Ctr, Dept Gastroenterol, Via Manzoni 56, I-20089 Milan, Italy.
   [Danese, Silvio] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20090 Milan, Italy.
   [Peyrin-Biroulet, Laurent] Lorraine Univ, Nancy Univ Hosp, Inserm NGERE U1256, Nancy, France.
   [Peyrin-Biroulet, Laurent] Lorraine Univ, Nancy Univ Hosp, Dept Gastroenterol, Nancy, France.
   [Loftus, Edward V., Jr.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA.
RP Reinisch, W (corresponding author), Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM walter.reinisch@meduniwien.ac.at
RI Danese, Silvio/ABH-9571-2020
OI Danese, Silvio/0000-0001-7341-1351; peyrin-biroulet,
   laurent/0000-0003-2536-6618
FU ECCO; IOIBD
FX This paper was published as part of a supplement financially supported
   by ECCO and IOIBD.
CR Brenner EJ, 2020, GASTROENTEROLOGY
   Danese S, 2020, NAT REV GASTRO HEPAT, V17, P253, DOI 10.1038/s41575-020-0294-8
   European Medicines Agency, GUID MAN CLIN TRIALS
   Harris MS, 2019, GASTROENTEROLOGY, V157, P1457, DOI 10.1053/j.gastro.2019.08.020
   Kaiser UB, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa148
   Kennedy NA, 2020, GUT, V69, P984, DOI 10.1136/gutjnl-2020-321244
   Neurath MF, 2020, GUT, V69, P1335, DOI 10.1136/gutjnl-2020-321269
   Osterman MT, 2016, AM J GASTROENTEROL, V111, P1806, DOI 10.1038/ajg.2016.433
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P350, DOI 10.1053/j.gastro.2020.04.012
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
   Teijaro JR, 2014, VIROLOGY, V452, P152, DOI 10.1016/j.virol.2014.01.003
   U.S. Food & Drug Administration, ENF POL NON REM MON
   US Food and Drug Administration, FDA GUID COND CLIN T
NR 14
TC 1
Z9 1
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1873-9946
EI 1876-4479
J9 J CROHNS COLITIS
JI J. Crohns Colitis
PD OCT
PY 2020
VL 14
SU 3
BP S815
EP S819
DI 10.1093/ecco-jcc/jjaa119
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OW7TY
UT WOS:000593085400009
PM 32520311
OA Green Published
DA 2021-01-01
ER

PT J
AU Siegel, CA
   Christensen, B
   Kornbluth, A
   Rosh, JR
   Kappelman, MD
   Ungaro, RC
   Johnson, DF
   Chapman, S
   Wohl, DA
   Mantzaris, GJ
AF Siegel, Corey A.
   Christensen, Britt
   Kornbluth, Asher
   Rosh, Joel R.
   Kappelman, Michael D.
   Ungaro, Ryan C.
   Johnson, Douglas Forsyth
   Chapman, Scott
   Wohl, David A.
   Mantzaris, Gerassimos J.
CA Int Org Study Inflammatory Bowel D
TI Guidance for Restarting Inflammatory Bowe Disease Therapy in Patients
   Who Withheld Immunosuppressant Medications During COVID-19
SO JOURNAL OF CROHNS & COLITIS
LA English
DT Article
DE IBD; Crohn's; de-escalation; immunomodulator; biologic
ID IBD
AB Patients with inflammatory bowel diseases [IBD] are frequently treated with immunosuppressant medications. During the coronavirus disease 2019 [COVID-19] pandemic, recommendations for IBD management have included that patients should stay on their immunosuppressant medications if they are not infected with the severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], but to temporarily hold these medications if symptomatic with COVID-19 or asymptomatic but have tested positive for SARS-CoV-2. As more IBD patients are infected globally, it is important to also understand how to manage IBD medications during convalescence while an individual with IBD is recovering from COVID-19. In this review, we address the differences between a test-based versus a symptoms-based strategy as related to COVID-19, and offer recommendations on when it is appropriate to consider restarting IBD therapy in patients testing positive for SARS-CoV-2 or with clinical symptoms consistent with COVID-19. In general, we recommend a symptoms-based approach, due to the current lack of confidence in the accuracy of available testing and the clinical significance of prolonged detection of virus via molecular testing.
C1 [Siegel, Corey A.] Dartmouth Hitchcock IBD Ctr, Sect Gastroenterol & Hepatol, Lebanon, NH USA.
   [Christensen, Britt] Royal Melbourne Hosp, Gastroenterol Dept, Melbourne, Vic, Australia.
   [Kornbluth, Asher; Ungaro, Ryan C.] Icahn Sch Med Mt Sinai, Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA.
   [Rosh, Joel R.] Goryeb Childrens Hosp, Div Pediat Gastroenterol, Morristown, NJ USA.
   [Kappelman, Michael D.] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27515 USA.
   [Johnson, Douglas Forsyth] Royal Melbourne Hosp, Dept Infect Dis, Melbourne, Vic, Australia.
   [Johnson, Douglas Forsyth] Royal Melbourne Hosp, Dept Internal Med, Melbourne, Vic, Australia.
   [Chapman, Scott] St Vincents Hosp, Dept Infect Dis, Sydney, NSW, Australia.
   [Wohl, David A.] Univ N Carolina, Div Infect Dis, Chapel Hill, NC 27515 USA.
   [Mantzaris, Gerassimos J.] Evaggelismos Ophthalmiatre Athinon Polyklin GHA, Dept Gastroenterol, Athens, Greece.
RP Siegel, CA (corresponding author), Dartmouth Hitchcock Med Ctr, Inflammatory Bowel Dis Ctr, Sect Gastroenterol & Hepatol, Lebanon, NH 03756 USA.
EM corey.a.siegel@hitchcock.org
FU ECCO; IOIBD
FX This project did not receive any funding. CAS and GJM are active members
   of the International Organization for the Study of Inflammatory Bowel
   Diseases [IOIBD]. This paper was published as part of a supplement
   financially supported by ECCO and IOIBD.
CR Al-Ani AH, 2020, ALIMENT PHARM THER, V52, P54, DOI 10.1111/apt.15779
   Beaugerie L, 2020, CLIN GASTROENTEROL H, V18, P1324, DOI 10.1016/j.cgh.2020.02.009
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Brenner EJ, SECURE IBD DATABASE
   Danese S, 2020, NAT REV GASTRO HEPAT, V17, P253, DOI 10.1038/s41575-020-0294-8
   Eichenberger EM, 2019, BONE MARROW TRANSPL, V54, P1058, DOI 10.1038/s41409-018-0386-z
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Holmer A, 2019, EXPERT REV CLIN IMMU, V15, P969, DOI 10.1080/1744666X.2019.1646127
   Kennedy NA, 2020, GUT, V69, P984, DOI 10.1136/gutjnl-2020-321244
   Prescott J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00205
   Rubin DT, 2020, GASTROENTEROLOGY
   Turner D, 2020, J PEDIATR GASTR NUTR, V70, P727, DOI 10.1097/MPG.0000000000002729
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 13
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1873-9946
EI 1876-4479
J9 J CROHNS COLITIS
JI J. Crohns Colitis
PD OCT
PY 2020
VL 14
SU 3
BP S769
EP S773
DI 10.1093/ecco-jcc/jjaa135
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OW7TY
UT WOS:000593085400002
PM 33085972
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Felice, C
   Nardin, C
   Di Tanna, GL
   Grossi, U
   Bernardi, E
   Scaldaferri, L
   Romagnoli, M
   Tonon, L
   Cavasin, P
   Novello, S
   Scarpa, R
   Farnia, A
   De Menis, E
   Rigoli, R
   Cinetto, F
   Pauletto, P
   Agostini, C
   Rattazzi, M
AF Felice, Carla
   Nardin, Chiara
   Di Tanna, Gian Luca
   Grossi, Ugo
   Bernardi, Enrico
   Scaldaferri, Luca
   Romagnoli, Micaela
   Tonon, Luca
   Cavasin, Paola
   Novello, Simone
   Scarpa, Riccardo
   Farnia, Antonio
   De Menis, Ernesto
   Rigoli, Roberto
   Cinetto, Francesco
   Pauletto, Paolo
   Agostini, Carlo
   Rattazzi, Marcello
TI Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19:
   Results From an Italian Cohort of 133 Hypertensives
SO AMERICAN JOURNAL OF HYPERTENSION
LA English
DT Article
DE ACEIs/ARBs; blood pressure; COVID-19 infection; hypertension;
   hypertensive patients; mortality; SARS-COV-2
ID ACE2; CORONAVIRUS
AB BACKGROUND
   The effect of chronic use of renin-angiotensin-aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19-related outcomes in hypertensive patients.
   METHODS
   A single-center study was conducted on 133 consecutive hypertensive subjects presenting to the emergency department with acute respiratory symptoms and/or fever who were diagnosed with COVID-19 infection between 9 and 31 March 2020.
   RESULTS
   All patients were grouped according to their chronic antihypertensive medications (ACEIs, N = 40; ARBs, N = 42; not on RAAS inhibitors, N = 51). There was no statistical difference between ACEIs and ARBs groups in terms of hospital admission rate, oxygen therapy, and need for noninvasive ventilation. Patients chronically treated with RAAS inhibitors showed a significantly lower rate of admission to semi-intensive/intensive care units, when compared with the non-RAAS population (odds ratio (OR) 0.25, confidence interval (CI) 95% 0.09-0.66, P= 0.006). Similarly, the risk of mortality was lower in the former group, although not reaching statistical significance (OR 0.56, CI 95% 0.17-1.83, P= 0.341).
   CONCLUSIONS
   Our data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.
C1 [Felice, Carla; Bernardi, Enrico; Scaldaferri, Luca] Ca Foncello Hosp, Acute & Emergency Dept, Treviso, Italy.
   [Felice, Carla; Nardin, Chiara; Tonon, Luca; Cavasin, Paola; Scarpa, Riccardo; Cinetto, Francesco; Agostini, Carlo; Rattazzi, Marcello] Univ Padua, Ca Foncello Hosp, Dept Med DIMED, Med Gen 1, Padua, Italy.
   [Di Tanna, Gian Luca] Univ New South Wales, Fac Med, George Inst Global Hlth, Sydney, NSW, Australia.
   [Grossi, Ugo; Novello, Simone] Univ Padua, Ca Foncello Hosp, Dept Surg Oncol & Gastroenterol Sci DISCOG, Padua, Italy.
   [Romagnoli, Micaela] Ca Foncello Hosp, Dept Specialist & Lab Med, Pulmonol Unit, Treviso, Italy.
   [Farnia, Antonio] Ca Foncello Hosp, Dept Anesthesia & Intens Care, Treviso, Italy.
   [De Menis, Ernesto] Ca Foncello Hosp, Dept Med, Med Gen 2, Treviso, Italy.
   [Rigoli, Roberto] Ca Foncello Hosp, Dept Specialist & Lab Med, Microbiol Unit, Treviso, Italy.
   [Pauletto, Paolo] Osped Riabilitat Alta Specializzaz, ORAS SpA, Motta Di Livenza, Italy.
RP Rattazzi, M (corresponding author), Univ Padua, Ca Foncello Hosp, Dept Med DIMED, Med Gen 1, Padua, Italy.
EM marcello.rattazzi@unipd.it
RI ; Cinetto, Francesco/J-7386-2018; Felice, Carla/M-1914-2018
OI Novello, Simone/0000-0001-7375-3140; Cinetto,
   Francesco/0000-0001-8486-5850; SCARPA, Riccardo/0000-0002-1085-2333; Di
   Tanna, Gian Luca/0000-0002-5470-3567; Felice, Carla/0000-0001-6646-6231
FU Ministero della SaluteMinistry of Health, Italy [RF-2013-02358024]
FX This study was supported by the Ministero della Salute (RF-2013-02358024
   to M.R.).
CR Burrell LM, 2005, EUR HEART J, V26, P369, DOI 10.1093/eurheartj/ehi114
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iaccarino G, 2020, HIGH BLOOD PRESS CAR, V27, P105, DOI 10.1007/s40292-020-00380-3
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li J, 2020, JAMA CARDIOL
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta N, 2020, JAMA CARDIOL, V5, P1020, DOI 10.1001/jamacardio.2020.1855
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Tan WSD, 2018, CURR OPIN PHARMACOL, V40, P9, DOI 10.1016/j.coph.2017.12.002
   Walters TE, 2017, EUROPACE, V19, P1280, DOI 10.1093/europace/euw246
   World Health Organization (WHO), GUID COR DIS COVID 1
   Zhang P, 2020, CIRC RES, V126, pE142, DOI 10.1161/CIRCRESAHA.120.317242
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 19
TC 11
Z9 11
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0895-7061
EI 1941-7225
J9 AM J HYPERTENS
JI Am. J. Hypertens.
PD OCT
PY 2020
VL 33
IS 10
BP 944
EP 948
DI 10.1093/ajh/hpaa096
PG 5
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA OW2KG
UT WOS:000592721900007
PM 32511678
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Moreno-Montoya, J
AF Moreno-Montoya, Jose
TI Epidemiology of self-care beyond the individual and the sanitary spheres
SO BIOMEDICA
LA Spanish
DT Article
DE Coronavirus infections; severe acute respiratory sindrome; SARS virus;
   self-care; vaccines; epidemiology; public health
ID COVID-19
AB Amid the global pandemic crisis, international concern has centered on the control and prevention measures aimed at reducing the speed of the virus transmission while a more radical sanitary measure, such as vaccines, is achieved. Governmental and social efforts have had great impact on various sectors of society and their consequences have exceeded the sphere of health.
   This essay discusses the scope of specific measures in the sense of the appropriation of risk control measures and proposes the epidemiological method as an alternative that goes beyond the quantification of risks and the attribution of responsibilities. To conclude, the emphasis is placed on the need to promote information about socialization processes to better understand the consequences of individual acts favoring alternatives other than pandemic control based on the use of coercive measures.
C1 [Moreno-Montoya, Jose] Fdn Santa Fe Bogota, Subdirecc Estudios Clin, Bogota, DC, Colombia.
RP Moreno-Montoya, J (corresponding author), Fdn Santa Fe Bogota, Subdirecc Estudios Clin, Bogota, DC, Colombia.
EM josemorenomontoya@gmail.com
CR Al-Dmour H, 2020, J MED INTERNET RES, V22, DOI 10.2196/19996
   Angileri Salvatore Alessio, 2020, J Clin Imaging Sci, V10, P42, DOI 10.25259/JCIS_72_2020
   Arsalan M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155592
   Badgujar KC, 2020, DIABETES METAB SYND, V14, P1361, DOI 10.1016/j.dsx.2020.07.022
   Bispo JP, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311X00151620, 10.1590/0102-311x00151620]
   Caplan P, 2020, ANTHROPOL TODAY, V36, P8, DOI 10.1111/1467-8322.12573
   Chiang CH, 2020, INT J SURG, V79, P125, DOI 10.1016/j.ijsu.2020.05.058
   Gauthier G Robin, 2020, J Gerontol B Psychol Sci Soc Sci, DOI 10.1093/geronb/gbaa117
   Hsieh CC, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17134877
   Kwok M, 2020, J POPUL THER CLIN PH, V27, pE53, DOI 10.15586/jptcp.v27SP1.716
   Lange S, 2020, CAN J PUBLIC HEALTH, V111, P466, DOI 10.17269/s41997-020-00391-6
   Ong MM, 2020, J PRIM CARE COMMUNIT, V11, DOI 10.1177/2150132720946951
   Raveendran AV, 2020, DIABETES METAB SYND, V14, P1323, DOI 10.1016/j.dsx.2020.07.029
   Rhodes R, 2020, AM J BIOETHICS, V20, P163, DOI 10.1080/15265161.2020.1777354
   Schuch FB, 2020, PSYCHIAT RES, V292, DOI 10.1016/j.psychres.2020.113339
   Watson MF, 2020, FAM PROCESS, V59, P832, DOI 10.1111/famp.12572
NR 16
TC 0
Z9 0
U1 0
U2 0
PU INST NACIONAL SALUD
PI BOGOTA D C
PA AVENIDA CALLE 26 NO 51-60, APARTADO AEREO 80334 Y 80080, BOGOTA D C,
   00000, COLOMBIA
SN 0120-4157
EI 2590-7379
J9 BIOMEDICA
JI Biomedica
PD OCT
PY 2020
VL 40
SU 2
BP 73
EP 76
DI 10.7705/biomedica.5761
PG 4
WC Tropical Medicine
SC Tropical Medicine
GA OJ1XU
UT WOS:000583761500009
PM 33152190
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dey, L
   Chakraborty, S
   Mukhopadhyay, A
AF Dey, Lopamudra
   Chakraborty, Sanjay
   Mukhopadhyay, Anirban
TI Machine learning techniques for sequence-based prediction of viral-host
   interactions between SARS-CoV-2 and human proteins
SO BIOMEDICAL JOURNAL
LA English
DT Article
DE COVID-19; SARS-CoV-2; Protein-protein interaction; Supervised
   classification; Machine learning; Classifier ensemble
ID FEATURE-SELECTION; PATHWAY; MAP
AB Background: COVID-19 (Coronavirus Disease-19), a disease caused by the SARS-CoV-2 virus, has been declared as a pandemic by the World Health Organization on March 11, 2020. Over 15 million people have already been affected worldwide by COVID-19, resulting in more than 0.6 million deaths. Protein-protein interactions (PPIs) play a key role in the cellular process of SARS-CoV-2 virus infection in the human body. Recently a study has reported some SARS-CoV-2 proteins that interact with several human proteins while many potential interactions remain to be identified.
   Method: In this article, various machine learning models are built to predict the PPIs between the virus and human proteins that are further validated using biological experiments. The classification models are prepared based on different sequence-based features of human proteins like amino acid composition, pseudo amino acid composition, and conjoint triad.
   Result: We have built an ensemble voting classifier using SVMRadial, SVMPolynomial, and Random Forest technique that gives a greater accuracy, precision, specificity, recall, and F1 score compared to all other models used in the work. A total of 1326 potential human target proteins of SARS-CoV-2 have been predicted by the proposed ensemble model and validated using gene ontology and KEGG pathway enrichment analysis. Several repurposable drugs targeting the predicted interactions are also reported.
   Conclusion: This study may encourage the identification of potential targets for more effective anti-COVID drug discovery.
C1 [Mukhopadhyay, Anirban] Heritage Inst Technol, Dept Comp Sci & Engn, Kolkata, India.
   Techno Main, Dept Informat Technol, Kolkata, India.
   Univ Kalyani, Dept Comp Sci & Engn, Kalyani, W Bengal, India.
RP Mukhopadhyay, A (corresponding author), Univ Kalyani, Dept Comp Sci & Engn, Nadia 741235, W Bengal, India.
EM anirban@klyuniv.ac.in
OI Mukhopadhyay, Anirban/0000-0001-8128-3521
FU Department of Science & Technology and Biotechnology, Government of West
   Bengal, India [355(Sanc.)/ST/P/ST/6G-10/2018]
FX Anirban Mukhopadhyay acknowledges the support received from the research
   project grant (Memo No: 355(Sanc.)/ST/P/S&T/6G-10/2018 dt. 08/03/2019)
   of Department of Science & Technology and Biotechnology, Government of
   West Bengal, India.
CR Ako-Adjei D, 2015, NUCLEIC ACIDS RES, V43, pD566, DOI 10.1093/nar/gku1126
   Amid S, 2017, ENVIRON PROG SUSTAIN, V36, P577, DOI 10.1002/ep.12448
   Ardabili SF, 2020, COVID 19 OUTBREAK PR
   Bandyopadhyay S, 2015, BRIEF BIOINFORM, V16, P830, DOI 10.1093/bib/bbu041
   Barman RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112034
   Barstugan M., 2020, ARXIV200309424
   Basit AH, 2018, J BIOINF COMPUT BIOL, V16, DOI 10.1142/S0219720018500142
   Batra R, 2020, J PHYS CHEM LETT, V11, P7058, DOI 10.1021/acs.jpclett.0c02278
   Ben-Hur A, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S1-S2
   Bullock J, 2020, PREPRINT
   Chou KC, 2001, PROTEINS, V43, P246, DOI 10.1002/prot.1035
   DENNIS G, 2003, GENOME BIOL, V4
   Desautels T, 2020, BIORXIV
   Dey Lopamudra, 2016, International Journal of Information Engineering and Electronic Business, V8, P54, DOI 10.5815/ijieeb.2016.04.07
   Dey L, 2019, IEEE REGION 10 SYMP, P373, DOI 10.1109/TENSYMP46218.2019.8971382
   Dey L, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005879
   Galar M, 2012, IEEE T SYST MAN CY C, V42, P463, DOI 10.1109/TSMCC.2011.2161285
   Ge Y, 2020, BIORXIV
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gurumayum S, 2018, VIROLOGY, V514, P203, DOI 10.1016/j.virol.2017.11.007
   Gysi DM, 2020, PREPRINT
   Hastie T., 2009, ELEMENTS STAT LEARNI
   Heidari A.A., 2020, STUDIES COMPUTATIONA, P23, DOI [DOI 10.1007/978-3-030-12127-3_3, 10.1007/978-3-030-12127-3_3]
   Horry MJ, 2020, XRAY IMAGE BASED COV
   Hu YM, 2014, NEURAL COMPUT APPL, V24, P1431, DOI 10.1007/s00521-013-1366-2
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Kassani SH, 2020, ARXIV200410641
   Kumar R, 2020, 20063461 MEDRXIV
   Kwofie SK, 2011, INFECT GENET EVOL, V11, P1971, DOI 10.1016/j.meegid.2011.09.001
   Liu WJ, 2020, PREPRINT
   Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009.abs
   Ong E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01581
   Ozkaya U, 2020, PREPRINT
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Pregenzer M, 1996, NEUROCOMPUTING, V11, P19, DOI 10.1016/0925-2312(94)00071-9
   Qing EY, 2020, MBIO, V11, DOI 10.1128/mBio.02764-19
   Roy S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007813
   Sen Pratap Chandra, 2020, Emerging Technology in Modelling and Graphics. Proceedings of IEM Graph 2018. Advances in Intelligent Systems and Computing (937), P99, DOI 10.1007/978-981-13-7403-6_11
   Sen R, 2016, EUR J CLIN MICROBIOL, V35, P1581, DOI 10.1007/s10096-016-2716-7
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shapira SD, 2009, CELL, V139, P1255, DOI 10.1016/j.cell.2009.12.018
   Sun TL, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1700-2
   Tang Y, 2017, RES J LIFE SCI BIOIN, V3, P1
   Ucar F, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109761
   Wan SH, 2018, IEEE ACCESS, V6, P36825, DOI 10.1109/ACCESS.2018.2851382
   Wang HC, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0828-1
   Wang L. D., 2020, ARXIV200309871
   Wu GM, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r53
   Xiao N, 2015, BIOINFORMATICS, V31, P1857, DOI 10.1093/bioinformatics/btv042
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
   Zhou X, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4924-2
NR 51
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2319-4170
EI 2320-2890
J9 BIOMED J
JI Biomed. J.
PD OCT
PY 2020
VL 43
IS 5
BP 438
EP 450
DI 10.1016/j.bj.2020.08.003
PG 13
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA OV7DX
UT WOS:000592366800006
PM 33036956
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Huang, ACC
   Huang, CG
   Yang, CT
   Hu, HC
AF Huang, Allen Chung-Cheng
   Huang, Chung-Guei
   Yang, Cheng-Ta
   Hu, Han-Chung
TI Concomitant infection with COVID-19 and Mycoplasma pneumoniae
SO BIOMEDICAL JOURNAL
LA English
DT Article
ID FEATURES
AB In late 2019, cases of atypical pneumonia caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were first reported in Wuhan, China. The disease was officially called coronavirus disease 2019 (COVID-19) and has been declared a pandemic disease by the World Health Organization (WHO). The clinical symptoms may include fever, cough, fatigue, headache, and diarrhea. The radiographic features comprise various presentations, including ground-glass opacities, tiny nodules, and consolidation. However, some atypical pathogens related to community-acquired pneumonia (CAP) may share similar presentations. They may be difficult to distinguish according to the clinical presentation and radiographic findings. Recently, there have been several reports reminding physicians to heed the possibility of co-infection with other pathogens in patients diagnosed with COVID-19. We report a COVID-19 patient co-infected with Mycoplasma pneumoniae who recovered well after combination therapy. We propose that all COVID-19 patients should undergo a meticulous screening routine to ensure that they receive adequate treatments.
C1 [Huang, Allen Chung-Cheng; Yang, Cheng-Ta; Hu, Han-Chung] Chang Gung Mem Hosp Linkou, Dept Thorac Med, 5 Fusing St, Taoyuan 333, Taiwan.
   [Huang, Chung-Guei] Chang Gung Mem Hosp Linkou, Dept Lab Med, Taoyuan, Taiwan.
   [Yang, Cheng-Ta; Hu, Han-Chung] Chang Gung Mem Hosp Linkou, Dept Resp Therapy, Taoyuan, Taiwan.
   [Huang, Allen Chung-Cheng; Huang, Chung-Guei; Yang, Cheng-Ta; Hu, Han-Chung] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
RP Yang, CT; Hu, HC (corresponding author), Chang Gung Mem Hosp Linkou, Dept Thorac Med, 5 Fusing St, Taoyuan 333, Taiwan.
EM yang1946@cgmh.org.tw; h3226@cgmh.org.tw
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Fan BE, 2020, AM J HEMATOL, V95, P723, DOI 10.1002/ajh.25785
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ishiguro N, PLOS ONE
   Khaddour K, AM J TROP MED HYG
   Khoury T, 2016, CLIN MICROBIOL INFEC, V22, P711, DOI 10.1016/j.cmi.2016.05.028
   Miyashita N, 2007, J MED MICROBIOL, V56, P1625, DOI 10.1099/jmm.0.47119-0
   Miyashita Naoyuki, 2009, BMC Med Imaging, V9, P7, DOI 10.1186/1471-2342-9-7
   Reittner P, 2000, AM J ROENTGENOL, V174, P37, DOI 10.2214/ajr.174.1.1740037
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Wong HYF, 2020, RADIOLOGY, V296, pE72, DOI 10.1148/radiol.2020201160
   World Health Organization, COR DIS 2019 COVID 1
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
NR 16
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2319-4170
EI 2320-2890
J9 BIOMED J
JI Biomed. J.
PD OCT
PY 2020
VL 43
IS 5
BP 458
EP 461
DI 10.1016/j.bj.2020.07.002
PG 4
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA OV7DX
UT WOS:000592366800008
PM 32891590
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jimenez-Alberto, A
   Ribas-Aparicio, RM
   Aparicio-Ozores, G
   Castelan-Vega, JA
AF Jimenez-Alberto, Alicia
   Maria Ribas-Aparicio, Rosa
   Aparicio-Ozores, Gerardo
   Castelan-Vega, Juan A.
TI Virtual screening of approved drugs as potential SARS-CoV-2 main
   protease inhibitors
SO COMPUTATIONAL BIOLOGY AND CHEMISTRY
LA English
DT Article
DE Mpro; SARS-CoV-2; COVID-19; Docking; Molecular dynamics simulation
ID MOLECULAR-DYNAMICS; ANTIVIRAL ACTIVITY; CHARMM; SARS; GUI; SIMULATIONS;
   DISCOVERY
AB The global emergency caused by COVID-19 makes the discovery of drugs capable of inhibiting SARS-CoV-2 a priority, to reduce the mortality and morbidity of this disease. Repurposing approved drugs can provide ther-apeutic alternatives that promise rapid and ample coverage because they have a documented safety record, as well as infrastructure for large-scale production. The main protease of SARS-CoV-2 (Mpro) is an excellent therapeutic target because it is critical for viral replication; however, Mpro has a highly flexible active site that must be considered when performing computer-assisted drug discovery. In this work, potential inhibitors of the main protease (Mpro) of SARS-Cov-2 were identified through a docking-assisted virtual screening procedure. A total of 4384 drugs, all approved for human use, were screened against three conformers of Mpro. The ligands were further studied through molecular dynamics simulations and binding free energy analysis. A total of nine currently approved molecules are proposed as potential inhibitors of SARS-CoV-2. These molecules can be further tested to speed the development of therapeutics against COVID-19.
C1 [Jimenez-Alberto, Alicia; Maria Ribas-Aparicio, Rosa; Aparicio-Ozores, Gerardo; Castelan-Vega, Juan A.] Inst Politecn Nacl, Programa Posgrad Biomed & Biotecnol Mol, Escuela Nacl Ciencias Biol, Ciudad De Mexico, Mexico.
RP Castelan-Vega, JA (corresponding author), Inst Politecn Nacl, Programa Posgrad Biomed & Biotecnol Mol, Escuela Nacl Ciencias Biol, Ciudad De Mexico, Mexico.
EM pcbycbm@gmail.com; rribas233@yahoo.com; gaparici@hotmail.com;
   jcastelv@ipn.mx
FU Instituto Politecnico Nacional (IPN) through SIP [20201445, 20201245,
   20202136, 20201438]; Comision de Operacion y Fomento de Actividades
   Academicas (COFAA-IPN); JAC-V of the Programa de Estimulos al Desempeno
   de los Investigadores (EDI-IPN) grant; Programa de Estimulo al Desempeno
   Docente (EDD) fellowships; Instituto Politecnico Nacional; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [P41-GM103311]
FX This study received financial support from Instituto Politecnico
   Nacional (IPN) through SIP grants 20201445, 20201245, 20202136 y
   20201438. JAC-V, AJ-A, GA-O, and RMR-A are recipients of Comision de
   Operacion y Fomento de Actividades Academicas (COFAA-IPN) grants, and
   JAC-V of the Programa de Estimulos al Desempeno de los Investigadores
   (EDI-IPN) grant. RMR-A and GA-O are recipients of Programa de Estimulo
   al Desempeno Docente (EDD) fellowships, all of them granted by Instituto
   Politecnico Nacional. Molecular graphics and analyses were performed
   with UCSF Chimera, developed by the Resource for Biocomputing,
   Visualization, and Informatics at the University of California, San
   Francisco, with support from NIH P41-GM103311.
CR Abbad MM, 2009, INT J EMERG TECHNOL, V4, P4, DOI 10.3991/ijet.v4i4.928
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Abraham M. J., 2019, GROMACS USER MANUAL
   Amici C, 2006, ANTIVIR THER, V11, P1021
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Baker NC, 2018, DRUG DISCOV TODAY, V23, P661, DOI 10.1016/j.drudis.2018.01.018
   Bartlam M, 2005, CURR OPIN STRUC BIOL, V15, P664, DOI 10.1016/j.sbi.2005.10.004
   Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Cha Y, 2018, BRIT J PHARMACOL, V175, P168, DOI 10.1111/bph.13798
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.3.CO;2-D
   Dyall J, 2018, J INFECT DIS, V218, pS672, DOI 10.1093/infdis/jiy304
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ge H, 2013, J CHEM INF MODEL, V53, P2757, DOI 10.1021/ci400391s
   Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8
   Ho BL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144865
   Hoever G, 2005, J MED CHEM, V48, P1256, DOI 10.1021/jm0493008
   Hongjian Li, 2012, 2012 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB), P77, DOI 10.1109/CIBCB.2012.6217214
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Huang J, 2017, NAT METHODS, V14, P71, DOI [10.1038/NMETH.4067, 10.1038/nmeth.4067]
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jalava K, 2020, INT J HYG ENVIR HEAL, V226, DOI 10.1016/j.ijheh.2020.113490
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Jo SW, 2014, ADV PROTEIN CHEM STR, V96, P235, DOI 10.1016/bs.apcsb.2014.06.002
   Jurrus E, 2018, PROTEIN SCI, V27, P112, DOI 10.1002/pro.3280
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kumar A, 2019, J MOL STRUCT, V1189, P299, DOI 10.1016/j.molstruc.2019.04.023
   KUMAR N, 2019, J BIOMOL STRUCT 0824, DOI DOI 10.1080/07391102.2019
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lee J, 2016, J CHEM THEORY COMPUT, V12, P405, DOI 10.1021/acs.jctc.5b00935
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li YC, 2018, STRUCT DYNAM-US, V5, DOI 10.1063/1.5058172
   Liu H, 2016, BIOINFORMATICS, V32, P2216, DOI 10.1093/bioinformatics/btw215
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Okonechnikov K, 2012, BIOINFORMATICS, V28, P1166, DOI 10.1093/bioinformatics/bts091
   Pacios O, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9020065
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Phadke M, 2020, DRUG DEVELOP RES, V81, P541, DOI 10.1002/ddr.21666
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Piska K, 2017, INVEST NEW DRUG, V35, P375, DOI 10.1007/s10637-017-0443-2
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Razzaghi-Asl N, 2018, J MOL GRAPH MODEL, V83, P138, DOI 10.1016/j.jmgm.2018.05.010
   Sievers F, 2014, METHODS MOL BIOL, V1079, P105, DOI 10.1007/978-1-62703-646-7_6
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P16719, DOI 10.1039/c4cp01388c
   Tripp R., 2019, ROLES HOST GENE NONC
   Wang J., 2020, FAST IDENTIFICATION, DOI [10.26434/chemrxiv.11875446.v1, DOI 10.26434/CHEMRXIV.11875446.V1.]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang XY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103567
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Webb B., 2016, CURR PROTOC PROTEIN, V86, DOI [10.1002/cpps.20. 2.9.1-2.9.37., DOI 10.1002/CPPS.20.2.9.1-2.9.37.]
   World Health Organization, 2019, NOV COR 2019 NCOV SI
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
   Xia B, 2011, PROTEIN CELL, V2, P282, DOI 10.1007/s13238-011-1034-1
   Yang HT, 2006, CURR PHARM DESIGN, V12, P4573, DOI 10.2174/138161206779010369
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Zhang KY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00184
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   ZHAO SY, 2017, EURO SURVEILL B EUR, V22, DOI DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Zhu HB, 2020, GLOB HEALTH RES POL, V5, DOI 10.1186/s41256-020-00135-6
NR 65
TC 7
Z9 7
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1476-9271
EI 1476-928X
J9 COMPUT BIOL CHEM
JI Comput. Biol. Chem.
PD OCT
PY 2020
VL 88
AR 107325
DI 10.1016/j.compbiolchem.2020.107325
PG 7
WC Biology; Computer Science, Interdisciplinary Applications
SC Life Sciences & Biomedicine - Other Topics; Computer Science
GA OU0TT
UT WOS:000591249700008
PM 32623357
OA Green Published
DA 2021-01-01
ER

PT J
AU Zahid, U
   Ramachandran, P
   Spitalewitz, S
   Alasadi, L
   Chakraborti, A
   Azhar, M
   Mikhalina, G
   Sherazi, A
   Narh, JT
   Khattar, P
   Bedi, P
AF Zahid, Umar
   Ramachandran, Preethi
   Spitalewitz, Samuel
   Alasadi, Lutfi
   Chakraborti, Abhishek
   Azhar, Muhammad
   Mikhalina, Galina
   Sherazi, Andleeb
   Narh, Joshua Tetteh
   Khattar, Pallavi
   Bedi, Puneet
TI Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital
   Experience and Policy Implications
SO AMERICAN JOURNAL OF NEPHROLOGY
LA English
DT Article
DE Acute kidney injury; Acute respiratory distress syndrome; Coronavirus
   disease 19; In-hospital mortality
ID SARS CORONAVIRUS; ACE2; INFECTION; RECEPTOR; OUTCOMES
AB Background: Although diffuse alveolar damage and respiratory failure are the key features of coronavirus disease 2019 (COVID-19), the involvement of other organs such as the kidney has also been reported. The reports of the incidence of acute kidney injury (AKI) in COVID-19 patients vary widely. In this study, we report our unique experience with AKI in COVID-19 patients in a low socioeconomic and predominantly ethnic minority group and provide its incidence, risk factors, and prognosis to expand the current understanding of this complication. Methods: In this single-center, retrospective cohort study, we analyzed the data of 469 COVID-19 patients admitted to the Brookdale University Hospital in Brooklyn, NY, from March 18 through April 23, 2020. Information regarding demographics, comorbidities, medications, clinical and laboratory data, and outcomes was collected from the electronic medical records. Both univariate and multivariate analyses were performed to determine the association of AKI with in-hospital mortality. Results: The median age was 66 years (interquartile range [IQR] 25-75; range 19-101 years), and 268 (57.14%) patients were male. Estimated glomerular filtration rate (eGFR) as determined by the Modification of Diet in Renal Disease Study Equation was low (<60 mL/min/1.73 m(2)) in 207 (44.1%) patients. During hospitalization, 128 (27.3%) patients developed AKI, and the incidence was significantly higher in those patients presenting with a low eGFR (N = 81, 39.1%; p < 0.001). Male sex, hypertension, the use of angiotensin-converting enzyme inhibitors and non-steroidal anti-inflammatories, hemodynamic instability, mechanical ventilation, acute respiratory distress syndrome, and admission elevated ferritin, creatinine kinase, brain natriuretic peptide, and troponin 1 were identified as the risk factors for in-hospital AKI. Ninety-seven (28.45%) patients died in the non-AKI group versus 91 (71.1%) in the AKI group (p < 0.001). The Cox proportional hazard model after adjusting for age, gender, comorbidities, hemodynamic status, and PF ratio (arterial oxygen partial pressure [PaO2]/fractional inspired oxygen [FiO(2)]) determined that on admission, an elevated blood urea nitrogen (hazard ratio [HR]: 1.75; 95% confidence interval [CI] 1.23-2.48), a low eGFR (HR 1.43; CI 1.1-2.03), AKI stage 1 (HR 1.14; CI 0.64-2.03), AKI stage 2 (HR 1.86; CI 1.03-3.56), and AKI stage 3 (HR 2.1; CI 1.3-2.81) were independent risk factors for in-hospital mortality. Renal replacement therapy (RRT) did not improve survival in stage III AKI. Conclusion: AKI in our hospitalized COVID-19 patients was common and carried a high mortality, especially in patients with AKI stage 3. RRT did not improve survival. Policy changes and planning for this high incidence of AKI in COVID-19 patients and its associated high mortality are necessary at the local and national levels.
C1 [Zahid, Umar; Spitalewitz, Samuel; Alasadi, Lutfi; Azhar, Muhammad; Mikhalina, Galina; Sherazi, Andleeb; Bedi, Puneet] Brookdale Univ Hosp & Med Ctr, Div Nephrol, 1 Brookdale Plaza, Brooklyn, NY 11212 USA.
   [Ramachandran, Preethi] Brookdale Univ Hosp & Med Ctr, Div Hematol Oncol, Brooklyn, NY 11212 USA.
   [Chakraborti, Abhishek; Narh, Joshua Tetteh] Brookdale Univ Hosp & Med Ctr, Dept Internal Med, Brooklyn, NY 11212 USA.
   [Khattar, Pallavi] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA.
RP Bedi, P (corresponding author), Brookdale Univ Hosp & Med Ctr, Div Nephrol, 1 Brookdale Plaza, Brooklyn, NY 11212 USA.
EM pbedi@bhmcny.org
CR Batlle D, 2020, J AM SOC NEPHROL, V31, P1380, DOI 10.1681/ASN.2020040419
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Fanelli V, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02872-z
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Gu HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19840
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Hoffmann M., 2020, NOVEL CORONAVIRUS 20
   Hong KS, 2020, YONSEI MED J, V61, P431, DOI 10.3349/ymj.2020.61.5.431
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khadzhynov D, 2019, DTSCH ARZTEBL INT, V116, P397, DOI 10.3238/arztebl.2019.0397
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   King L, 2015, BROOKLYN COMMUNITY D, V40, P1
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   NYC Health, COVID 19 DAT
   Sawhney S, 2017, AM J KIDNEY DIS, V69, P18, DOI 10.1053/j.ajkd.2016.05.018
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Thebault R, 2020, WASHINGTON POST
   Vuille-Dit-Bille RN, 2015, AMINO ACIDS, V47, P693, DOI 10.1007/s00726-014-1889-6
   Wadhera RK, 2020, JAMA-J AM MED ASSOC, V323, P2192, DOI 10.1001/jama.2020.7197
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HE, 2012, AM J NEPHROL, V35, P349, DOI 10.1159/000337487
   Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Zhao Y, 2020, SINGLE CELL RNA EXPR
NR 25
TC 1
Z9 1
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-8095
EI 1421-9670
J9 AM J NEPHROL
JI Am. J. Nephrol.
PD OCT
PY 2020
VL 51
IS 10
BP 786
EP 796
DI 10.1159/000511160
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA OU2TQ
UT WOS:000591386600004
PM 33011717
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Annas, S
   Pratama, MI
   Rifandi, M
   Sanusi, W
   Side, S
AF Annas, Suwardi
   Pratama, Muh Isbar
   Rifandi, Muh
   Sanusi, Wahidah
   Side, Syafruddin
TI Stability analysis and numerical simulation of SEIR model for pandemic
   COVID-19 spread in Indonesia
SO CHAOS SOLITONS & FRACTALS
LA English
DT Article
DE SEIR model; COVID-19; Simulation model; Basic reproduction number;
   Lyapunov function
ID MATHEMATICAL-MODEL; TRANSMISSION; EPIDEMIC
AB The Aim of this research is construct the SEIR model for COVID-19, Stability Analysis and numerical simulation of the SEIR model on the spread of COVID-19. The method used to construct the model is the SEIR model by considering vaccination and isolation factors as model parameters, the analysis of the model uses the generation matrix method to obtain the basic reproduction numbers and the global stability of the COVID-19 distribution model. Numerical simulation models use secondary data on the number of COVID-19 cases in Indonesia. The results obtained are the SEIR model for COVID-19; model analysis yields global stability from the spread of COVID-19; The results of the analysis also provide information if no vaccine, Indonesia is endemic COVID-19. Then the simulation results provide a prediction picture of the number of COVID-19 in Indonesia in the following days, the simulation results also show that the vaccine can accelerate COVID-19 healing and maximum isolation can slow the spread of COVID-19. The results obtained can be used as a reference for early prevention of the spread of COVID-19 in Indonesia (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Annas, Suwardi] Univ Negeri Makassar, Fac Math & Nat Sci, Dept Stat, Parangtambung 90244, South Sulawesi, Indonesia.
   [Pratama, Muh Isbar; Rifandi, Muh; Sanusi, Wahidah; Side, Syafruddin] Univ Negeri Makassar, Fac Math & Nat Sci, Dept Math, Parangtambung 90244, South Sulawesi, Indonesia.
RP Side, S (corresponding author), Univ Negeri Makassar, Fac Math & Nat Sci, Dept Math, Parangtambung 90244, South Sulawesi, Indonesia.
EM suwardi_annas@unm.ac.id; isbarpratama@unm.ac.id;
   wahidah.sanusi@unm.ac.id; syafruddin@unm.ac.id
FU UNM 2020; Dikti
FX We would like thank to UNM 2020 for financial support, also thanks to
   Dikti for support this research.
CR [Anonymous], 2020, SIT KAS IND
   [Anonymous], 2020, DAFT NEG MEN PERT JU
   [Anonymous], 2020, PROYEKS JUML PEND IN
   [Anonymous], 2020, UNGK CAR PENYEB VIR
   Ashley T., 2010, MODELING SPREAD TUBE
   Briantika A., 2020, MENINGGAL, P48
   Demirci E, 2011, HACET J MATH STAT, V40, P287
   Diekmann O, 2010, J R SOC INTERFACE, V7, P873, DOI 10.1098/rsif.2009.0386
   Dontwi I. K, 2014, BRIT J MATH COMPUTER, V4, P402
   Egonmwan AO, 2019, J APPL MATH COMPUT, V59, P129, DOI 10.1007/s12190-018-1172-1
   Gao DZ, 2011, MATH BIOSCI, V232, P110, DOI 10.1016/j.mbs.2011.05.001
   Ofosuhene O., 2017, WORLD J MODEL SIMUL, V13, P183
   Rangkuti Y.M., 2014, J MATH FUND SCI, V46, P91, DOI DOI 10.5614/j.math.fund.sci.2014.46.1.8
   Rusliza A, 2012, INT J MATH COMPUT PH, V6, P151
   Side S., 2013, WORLD J MODEL SIMUL, V9, P96
   Side S, 2017, AIP CONF PROC, V1885, DOI 10.1063/1.5002379
   Side S, 2015, ADV SCI LETT, V21, P137, DOI 10.1166/asl.2015.5840
   Spencer JA, 2020, EPIDEMIOLOGICAL PARA
   Syafruddin S., 2013, International Journal of Simulation and Process Modelling, V8, P177
   Syafruddin S, 2017, AIP C P, V1830
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   THIEME HR, 1993, SIAM J MATH ANAL, V24, P407, DOI 10.1137/0524026
   Waziri A.S., 2012, APPL MATH, V2, P77, DOI DOI 10.5923/J.AM.20120203.06
   Yang CY, 2020, MATH BIOSCI ENG, V17, P2708, DOI 10.3934/mbe.2020148
NR 24
TC 1
Z9 1
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0779
EI 1873-2887
J9 CHAOS SOLITON FRACT
JI Chaos Solitons Fractals
PD OCT
PY 2020
VL 139
AR 110072
DI 10.1016/j.chaos.2020.110072
PG 7
WC Mathematics, Interdisciplinary Applications; Physics, Multidisciplinary;
   Physics, Mathematical
SC Mathematics; Physics
GA OP9TF
UT WOS:000588433800076
PM 32834616
OA Green Published
DA 2021-01-01
ER

PT J
AU Cakan, S
AF Cakan, Sumeyye
TI Dynamic analysis of a mathematical model with health care capacity for
   COVID-19 pandemic
SO CHAOS SOLITONS & FRACTALS
LA English
DT Article
DE New coronavirus; COVID-19; Health care capacity; Latent period; SEIR
   Model; Local and global stability analysis
AB The fact that no there exists yet an absolute treatment or vaccine for COVID-19, which was declared as a pandemic by the World Health Organization (WHO) in 2020, makes very important spread out over time of the epidemic in order to burden less on hospitals and prevent collapsing of the health care system. This case is a consequence of limited resources and is valid for all countries in the world facing with this serious threat. Slowing the speed of spread will probably make that the outbreak last longer, but it will cause lower total death count. In this study, a new SEIR epidemic model formed by taking into account the impact of health care capacity has been examined and local and global stability of the model has been analyzed. In addition, the model has been also supported by some numerical simulations. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Cakan, Sumeyye] Inonu Univ, Dept Math, TR-44280 Malatya, Turkey.
RP Cakan, S (corresponding author), Inonu Univ, Dept Math, TR-44280 Malatya, Turkey.
EM sumeyye.tay@inonu.edu.tr
RI CAKAN, Sumeyye/ABH-4275-2020
OI CAKAN, Sumeyye/0000-0001-8761-8564
CR DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Diekmann O., 2000, MATH EPIDEMIOLOGY IN
   Hale J. K., 1993, INTRO FUNCTIONAL DIF
   Ivorra B, 2020, COMMUN NONLINEAR SCI, V88, DOI 10.1016/j.cnsns.2020.105303
   Khan MA, 2020, ALEX ENG J, V59, P2379, DOI 10.1016/j.aej.2020.02.033
   Kuang Y., 1993, DELAY DIFFERENTIAL E
   La Salle J., 1961, STABILITY LIAPUNOVS
   Lakshmikantham S, 1989, STABILITY ANAL NONLI
   LaSalle J. P., 1976, NONLINEAR ANAL-THEOR, V1, P83, DOI [DOI 10.1016/0362-546X(76)90011-0, 10.1016/0362-546X(76)90011-0]
   LASALLE JP, 1968, J DIFFER EQUATIONS, V4, P57, DOI 10.1016/0022-0396(68)90048-X
   LYAPUNOV AM, 1992, GEN PROBLEM STABILIT
   Ndairoua F, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109846
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
NR 13
TC 3
Z9 3
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0779
EI 1873-2887
J9 CHAOS SOLITON FRACT
JI Chaos Solitons Fractals
PD OCT
PY 2020
VL 139
AR 110033
DI 10.1016/j.chaos.2020.110033
PG 8
WC Mathematics, Interdisciplinary Applications; Physics, Multidisciplinary;
   Physics, Mathematical
SC Mathematics; Physics
GA OP9TF
UT WOS:000588433800039
PM 32834594
OA Green Published
DA 2021-01-01
ER

PT J
AU Contreras, S
   Biron-Lattes, JP
   Villavicencio, HA
   Medina-Ortiz, D
   Llanovarced-Kawles, N
   Olivera-Nappa, A
AF Contreras, Sebastian
   Pablo Biron-Lattes, Juan
   Andres Villavicencio, H.
   Medina-Ortiz, David
   Llanovarced-Kawles, Nyna
   Olivera-Nappa, Alvaro
TI Statistically-based methodology for revealing real contagion trends and
   correcting delay-induced errors in the assessment of COVID-19 pandemic
SO CHAOS SOLITONS & FRACTALS
LA English
DT Article
DE COVID-19; SARS-CoV-2; Public health; Statistics; ARIMA Models; Data
   analysis
AB COVID-19 pandemic has reshaped our world in a timescale much shorter than what we can understand. Particularities of SARS-CoV-2, such as its persistence in surfaces and the lack of a curative treatment or vaccine against COVID-19, have pushed authorities to apply restrictive policies to control its spreading. As data drove most of the decisions made in this global contingency, their quality is a critical variable for decision-making actors, and therefore should be carefully curated. In this work, we analyze the sources of error in typically reported epidemiological variables and usual tests used for diagnosis, and their impact on our understanding of COVID-19 spreading dynamics. We address the existence of different delays in the report of new cases, induced by the incubation time of the virus and testing-diagnosis time gaps, and other error sources related to the sensitivity/specificity of the tests used to diagnose COVID-19. Using a statistically-based algorithm, we perform a temporal reclassification of cases to avoid delay-induced errors, building up new epidemiologic curves centered in the day where the contagion effectively occurred. We also statistically enhance the robustness behind the discharge/recovery clinical criteria in the absence of a direct test, which is typically the case of non-first world countries, where the limited testing capabilities are fully dedicated to the evaluation of new cases. Finally, we applied our methodology to assess the evolution of the pandemic in Chile through the Effective Reproduction Number R-t, identifying different moments in which data was misleading governmental actions. In doing so, we aim to raise public awareness of the need for proper data reporting and processing protocols for epidemiological modelling and predictions. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Contreras, Sebastian] Univ Chile, Lab Rheol & Fluid Dynam, Beauchef 850, Santiago 8370448, Chile.
   [Contreras, Sebastian; Pablo Biron-Lattes, Juan; Andres Villavicencio, H.; Medina-Ortiz, David; Llanovarced-Kawles, Nyna; Olivera-Nappa, Alvaro] Univ Chile, Ctr Biotechnol & Bioengn, Beauchef 851, Santiago 8370448, Chile.
   [Pablo Biron-Lattes, Juan; Llanovarced-Kawles, Nyna; Olivera-Nappa, Alvaro] Univ Chile, Dept Chem Engn Biotechnol & Mat, Beauchef 851, Santiago 8370448, Chile.
   [Medina-Ortiz, David] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.
   [Contreras, Sebastian] Max Planck Inst Dynam & Self Org, Fassberg 17, D-37077 Gottingen, Germany.
RP Contreras, S (corresponding author), Univ Chile, Lab Rheol & Fluid Dynam, Beauchef 850, Santiago 8370448, Chile.; Contreras, S; Olivera-Nappa, A (corresponding author), Univ Chile, Ctr Biotechnol & Bioengn, Beauchef 851, Santiago 8370448, Chile.; Olivera-Nappa, A (corresponding author), Univ Chile, Dept Chem Engn Biotechnol & Mat, Beauchef 851, Santiago 8370448, Chile.
EM sebastian.contreras@ds.mpg.de; aolivera@ing.uchile.cl
RI ; Olivera-Nappa, Alvaro/H-3769-2013
OI Contreras, Sebastian/0000-0001-8909-774X; Olivera-Nappa,
   Alvaro/0000-0001-6053-7019; Medina-Ortiz, David/0000-0002-8369-5746
FU Chilean National Agency for Research and development through ANID PIA
   Grant [AFB180004]; Centre for Biotechnology and Bioengineering - CeBiB
   (PIA project, Conicyt, Chile) [FB0001]; Conicyt, ChileComision Nacional
   de Investigacion Cientifica y Tecnologica (CONICYT) [21181435]
FX The authors gratefully acknowledge support from the Chilean National
   Agency for Research and development through ANID PIA Grant AFB180004,
   and the Centre for Biotechnology and Bioengineering - CeBiB (PIA project
   FB0001, Conicyt, Chile). DM-O gratefully acknowledges Conicyt, Chile,
   for PhD fellowship 21181435.
CR Aguilar J.B., 2020, INVESTIGATING IMPACT
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Allieta M A, 2020, COVID 19 OUTBREAK IT
   Backer J.A., 2020, INCUBATION PERIOD 20
   Benvenuto D, 2020, DATA BRIEF, V29, DOI 10.1016/j.dib.2020.105340
   Broughton JP, 2020, NAT BIOTECHNOL, V38, P870, DOI 10.1038/s41587-020-0513-4
   Castro M., 2020, PREDICTABILITY CAN T
   Chakraborty T, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109850
   Chowell G, 2007, J R SOC INTERFACE, V4, P155, DOI 10.1098/rsif.2006.0161
   Contreras S, 2020, REAL TIME ESTIMATION
   Contreras S, 2020, CHAOS SOLITON FRACT, V136, DOI 10.1016/j.chaos.2020.109925
   Ribeiro MHD, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109853
   Delamater PL, 2019, EMERG INFECT DIS, V25, P1, DOI 10.3201/eid2501.171901
   Dong E, 2020, LANCET INFECT DIS
   Fang Y., 2020, RADIOLOGY, DOI DOI 10.1148/RADI0L.2020200432
   Ganyani T, 2020, ESTIMATING GENERATIO
   Gevertz J, 2020, NOVEL COVID 19 EPIDE
   Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Heesterbeek JAP, 2002, ACTA BIOTHEOR, V50, P189, DOI 10.1023/A:1016599411804
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Lauer S.A., 2020, ANN INTERN MED
   Lauer SA, 2020, ANN INTERN MED, V3
   LeMieux J, 2020, GENET ENG BIOTECHNOL, V40, P21
   Li Q, 2020, N TOP N ENGL J MED
   Li X, 2020, J PHARM ANAL
   Li YC, 2020, J MED VIROL, V92, P707, DOI 10.1002/jmv.25824
   Li Z, 2020, J MED VIROL
   Liew MF, 2020, CRIT CARE, V24, DOI [10.1186/s13054-020-2814-x, 10.1186/s13054-020-2828-4]
   Lippi G, 2020, CLIN CHEM LAB MED CC, V1
   Long CQ, 2020, EUR J RADIOL, V126, DOI 10.1016/j.ejrad.2020.108961
   Ma JL, 2020, INFECT DIS MODEL, V5, P129, DOI 10.1016/j.idm.2019.12.009
   Medina-Ortiz D, 2020, FRONT PHYS
   Medina-Ortiz D, 2020, INFORM SYST, V93, DOI 10.1016/j.is.2020.101557
   MINSAL, 2020, TECH REP CRIT DISCH
   Nguyen T, 2019, MICROMACHINES, V2020, P11, DOI DOI 10.3390/MI11030306
   Nishiura H, 2007, EMERG THEMES EPIDEMI, V4, DOI 10.1186/1742-7622-4-2
   Pang W, 2020, ARXIV200406311
   Perasso Antoine, 2018, ESAIM: Proceedings and Surveys, V62, P123, DOI 10.1051/proc/201862123
   Seabold S., 2010, P 9 PYTH SCI C, P61
   Shi H, 2020, LANCET INFECT DIS
   Wang Y, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P476, DOI 10.3760/cma.j.cn112338-20200210-00086
   WHO, 2020, TECHNICAL REPORT
   Wilder B, 2020, ROLE AGE DISTRIBUTIO
   Woo PCY, 2004, CLIN DIAGN LAB IMMUN, V11, P665, DOI 10.1128/CDLI.11.4.665-668.2004
   Worldometers.info, 2020, OFF NUMB COR OUTBR C
   Xiao AT, 2020, J MED VIROL, V92, P1755, DOI 10.1002/jmv.25855
   Yang ZF, 2020, J THORAC DIS, V12, P165, DOI 10.21037/jtd.2020.02.64
   Zhou F., 2020, LANCET
NR 49
TC 2
Z9 2
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0779
EI 1873-2887
J9 CHAOS SOLITON FRACT
JI Chaos Solitons Fractals
PD OCT
PY 2020
VL 139
AR 110087
DI 10.1016/j.chaos.2020.110087
PG 7
WC Mathematics, Interdisciplinary Applications; Physics, Multidisciplinary;
   Physics, Mathematical
SC Mathematics; Physics
GA OP9TF
UT WOS:000588433800087
PM 32834623
OA Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Sardar, T
   Nadim, SS
   Rana, S
   Chattopadhyay, J
AF Sardar, Tridip
   Nadim, Sk Shahid
   Rana, Sourav
   Chattopadhyay, Joydev
TI Assessment of lockdown effect in some states and overall India: A
   predictive mathematical study on COVID-19 outbreak
SO CHAOS SOLITONS & FRACTALS
LA English
DT Article
DE COVID-19; Mathematical model; Lockdown effect; Outbreak containment
   policy
ID TRANSMISSION
AB In the absence of neither an effective treatment or vaccine and with an incomplete understanding of the epidemiological cycle, Govt. has implemented a nationwide lockdown to reduce COVID-19 transmission in India. To study the effect of social distancing measure, we considered a new mathematical model on COVID-19 that incorporates lockdown effect. By validating our model to the data on notified cases from five different states and overall India, we estimated several epidemiologically important parameters as well as the basic reproduction number (R-0). Combining the mechanistic mathematical model with different statistical forecast models, we projected notified cases in the six locations for the period May 17, 2020, till May 31, 2020. A global sensitivity analysis is carried out to determine the correlation of two epidemiologically measurable parameters on the lockdown effect and also on R-0. Our result suggests that lockdown will be effective in those locations where a higher percentage of symptomatic infection exists in the population. Furthermore, a large scale COVID-19 mass testing is required to reduce community infection. Ensemble model forecast suggested a high rise in the COVID-19 notified cases in most of the locations in the coming days. Furthermore, the trend of the effective reproduction number (R-t) during the projection period indicates if the lockdown measures are completely removed after May 17, 2020, a high spike in notified cases may be seen in those locations. Finally, combining our results, we provided an effective lockdown policy to reduce future COVID-19 transmission in India. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Sardar, Tridip] Dinabandhu Andrews Coll, Dept Math, Kolkata, India.
   [Nadim, Sk Shahid; Chattopadhyay, Joydev] Indian Stat Inst, Agr & Ecol Res Unit, Kolkata, India.
   [Rana, Sourav] Visva Bharati Univ, Dept Stat, Santini Ketan, W Bengal, India.
RP Sardar, T (corresponding author), Dinabandhu Andrews Coll, Dept Math, Kolkata, India.
EM tridipiitk@gmail.com
OI sardar, tridip/0000-0002-5172-2412
FU Science & Engineering Research Board (SERB), Government of
   IndiaDepartment of Science & Technology (India)Science Engineering
   Research Board (SERB), India [EEQ/2019/000008]; Council of Scientific &
   Industrial Research, Government of India, New DelhiCouncil of Scientific
   & Industrial Research (CSIR) - India [09/093(0172)/2016/EMR-I]
FX Dr. Tridip Sardar acknowledges the Science & Engineering Research Board
   (SERB) major project grant (File No: EEQ/2019/000008 dt. 4/11/2019),
   Government of India.; Sk Shahid Nadim receives funding as senior
   research fellowship from Council of Scientific & Industrial Research
   (Grant No: 09/093(0172)/2016/EMR-I), Government of India, New Delhi.
CR [Anonymous], 2020, COVID 19 LOCKDOWN RE
   [Anonymous], 2019, LIF EXP BIRTH
   [Anonymous], 2020, INDIA COVID 19 TRACK
   [Anonymous], 2020, CTR DIS CONTROL PREV
   [Anonymous], 2020, 334 CORONAVIRUS SUPE
   [Anonymous], 2020, CORONAVIRUS LOCKDOWN
   [Anonymous], 2020, 19 DOCTORS 38 NURSES
   [Anonymous], 2020, WORLDS BIGGEST LOCKD
   [Anonymous], 2020, CORONAVIRUS COVID 19
   [Anonymous], 2020, RED ORANGE GREEN ZON
   [Anonymous], 2020, WHAT CMS TOLD PM MOD
   [Anonymous], 2019, STATEWISE POPULATION
   [Anonymous], 2019, WUHAN WET MARKET CLO
   [Anonymous], 2020, CORONAVIRUS 5 INDIAN
   Chen T, 2020, MATH MODEL SIMULATIN
   Ferguson NM, REPORT 9 IMPACT NONP
   Gumel AB, 2004, P ROY SOC B-BIOL SCI, V271, P2223, DOI 10.1098/rspb.2004.2800
   Haario H, 2006, STAT COMPUT, V16, P339, DOI 10.1007/s11222-006-9438-0
   Kucharski AJ, 2020, LANCET INFECT DIS
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Mandal Sandip, 2020, Indian J Med Res, V151, P190, DOI 10.4103/ijmr.IJMR_504_20
   Marino S, 2008, J THEOR BIOL, V254, P178, DOI 10.1016/j.jtbi.2008.04.011
   Peng L, 2020, ARXIV200206563
   Quilty BJ, 2020, EUROSURVEILLANCE, V25, P4, DOI 10.2807/1560-7917.ES.2020.25.5.2000080
   Read J. M., 2020, NOVEL CORONAVIRUS 20
   Richman D.D., 2016, CLIN VIROLOGY
   Rothman KJ, 2008, MODERN EPIDEMIOLOGY
   Sardar T, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008065
   Sardar T, 2017, MATH BIOSCI, V288, P109, DOI 10.1016/j.mbs.2017.03.004
   Sardar T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081231
   Shaub D., 2020, FORECASTHYBRID CONVE
   Shen M., 2020, MODELLING EPIDEMIC T
   Singh R., 2020, ARXIV200312055
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
NR 38
TC 6
Z9 6
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0779
EI 1873-2887
J9 CHAOS SOLITON FRACT
JI Chaos Solitons Fractals
PD OCT
PY 2020
VL 139
AR 110078
DI 10.1016/j.chaos.2020.110078
PG 10
WC Mathematics, Interdisciplinary Applications; Physics, Multidisciplinary;
   Physics, Mathematical
SC Mathematics; Physics
GA OP9TF
UT WOS:000588433800081
PM 32834620
OA Green Published
DA 2021-01-01
ER

PT J
AU Sarkar, K
   Khajanchi, S
   Nieto, JJ
AF Sarkar, Kankan
   Khajanchi, Subhas
   Nieto, Juan J.
TI Modeling and forecasting the COVID-19 pandemic in India
SO CHAOS SOLITONS & FRACTALS
LA English
DT Article
DE COVID-19; Mathematical model; Basic reproduction number; Sensitivity
   analysis; Isolation; Model prediction
ID INFECTIOUS-DISEASES; VIRUS
AB In India, 100,340 confirmed cases and 3155 confirmed deaths due to COVID-19 were reported as of May 18, 2020. Due to absence of specific vaccine or therapy, non-pharmacological interventions including social distancing, contact tracing are essential to end the worldwide COVID-19. We propose a mathematical model that predicts the dynamics of COVID-19 in 17 provinces of India and the overall India. A complete scenario is given to demonstrate the estimated pandemic life cycle along with the real data or history to date, which in turn divulges the predicted inflection point and ending phase of SARS-CoV-2. The proposed model monitors the dynamics of six compartments, namely susceptible (S), asymptomatic (A), recovered (R), infected (I), isolated infected (I-q) and quarantined susceptible (S-q), collectively expressed SARII(q)S(q). A sensitivity analysis is conducted to determine the robustness of model predictions to parameter values and the sensitive parameters are estimated from the real data on the COVID-19 pandemic in India. Our results reveal that achieving a reduction in the contact rate between uninfected and infected individuals by quarantined the susceptible individuals, can effectively reduce the basic reproduction number. Our model simulations demonstrate that the elimination of ongoing SARS-CoV-2 pandemic is possible by combining the restrictive social distancing and contact tracing. Our predictions are based on real data with reasonable assumptions, whereas the accurate course of epidemic heavily depends on how and when quarantine, isolation and precautionary measures are enforced. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Sarkar, Kankan] Malda Coll, Dept Math, Malda 732101, W Bengal, India.
   [Khajanchi, Subhas] Presidency Univ, Dept Math, 86-1 Coll St, Kolkata 700073, W Bengal, India.
   [Nieto, Juan J.] Univ Santiago de Compostela, Inst Matemat, Santiago De Compostela, Spain.
RP Khajanchi, S (corresponding author), Presidency Univ, Dept Math, 86-1 Coll St, Kolkata 700073, W Bengal, India.
EM subhaskhajanchi@gmail.com
OI Nieto, Juan J./0000-0001-8202-6578; Khajanchi,
   Subhas/0000-0002-6533-1121; Sarkar, Kankan/0000-0002-2777-9611
FU Science and Engineering Research Board (SERB), Department of Science &
   Technology, Government of India [ECR/2017/000234]; Agencia Estatal de
   Investigacion (AEI) of Spain; Instituto de Salud Carlos IIIInstituto de
   Salud Carlos III [COV20/00617]; European Fund for Regional Development
   (FEDER)European Union (EU) [MTM2016-75140-P]
FX The authors are thankful to Dr. Sandip Banerjee, Department of
   Mathematics, IIT Roorkee for valuable suggestions, which helped in the
   better exposition of the manuscript. The work of Subhas Khajanchi is
   supported by Science and Engineering Research Board (SERB) (File No.
   ECR/2017/000234), Department of Science & Technology, Government of
   India. The work of J.J. Nieto has been partially supported by the
   Agencia Estatal de Investigacion (AEI) of Spain, co-financed by the
   European Fund for Regional Development (FEDER) corresponding to the
   2014--2020 multi year financial framework, project MTM2016-75140-P;
   Instituto de Salud Carlos III, grant COV20/00617.
CR ANDERSON R M, 1991
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], 2020, INDIAN EXPRESS
   [Anonymous], BBC NEWS
   [Anonymous], 2020, INDIA COVID 19 TRACK
   [Anonymous], 2020, LIVEMINT
   [Anonymous], 2020, INDIA TV NEWS
   [Anonymous], 2020, WHO SITUATION REPORT
   Banerjee S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123611
   Battegay M, 2020, SWISS MED WKLY, V150, DOI [10.4414/smw.w20203, 10.4414/smw.2020.20203]
   Chen TM, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00640-3
   Cohen J, 2020, SCIENCE, V367, P234, DOI 10.1126/science.367.6475.234
   Das DK, 2020, APPL MATH COMPUT, V366, DOI 10.1016/j.amc.2019.124732
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Diekmann O., 2000, MATH EPIDEMIOLOGY IN
   Eubank S, 2020, B MATH BIOL, V82, DOI 10.1007/s11538-020-00726-x
   Fanelli D, 2020, CHAOS SOLITON FRACT, V134, DOI 10.1016/j.chaos.2020.109761
   Gumel AB, 2004, P ROY SOC B-BIOL SCI, V271, P2223, DOI 10.1098/rspb.2004.2800
   Helen Regan, 2020, CNN
   Hethcote HW, 2000, SIAM REV, V42, P599, DOI 10.1137/S0036144500371907
   Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118
   Khajanchi S., 2020, ARXIV200506286
   Khajanchi S, 2018, PHYSICA A, V497, P52, DOI 10.1016/j.physa.2018.01.014
   Khan MA, 2019, NONLINEAR ANAL-REAL, V50, P144, DOI 10.1016/j.nonrwa.2019.04.006
   Khan MA, 2020, ALEX ENG J, V59, P2379, DOI 10.1016/j.aej.2020.02.033
   King AA, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2015.0347
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058
   Marino S, 2008, J THEOR BIOL, V254, P178, DOI 10.1016/j.jtbi.2008.04.011
   Ndairoua F, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109846
   NDTV NEWS, NDTV NEWS
   Subhas Khajanchi, 2020, ARXIV200614575
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Tang SY, 2012, J THEOR BIOL, V295, P47, DOI 10.1016/j.jtbi.2011.10.035
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Windarto, 2020, AIMS MATH, V5, P2758, DOI 10.3934/math.2020178
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 42
TC 9
Z9 9
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0779
EI 1873-2887
J9 CHAOS SOLITON FRACT
JI Chaos Solitons Fractals
PD OCT
PY 2020
VL 139
AR 110049
DI 10.1016/j.chaos.2020.110049
PG 16
WC Mathematics, Interdisciplinary Applications; Physics, Multidisciplinary;
   Physics, Mathematical
SC Mathematics; Physics
GA OP9TF
UT WOS:000588433800054
PM 32834603
OA Green Published
DA 2021-01-01
ER

PT J
AU Ullah, S
   Khan, MA
AF Ullah, Saif
   Khan, Muhammad Altaf
TI Modeling the impact of non-pharmaceutical interventions on the dynamics
   of novel coronavirus with optimal control analysis with a case study
SO CHAOS SOLITONS & FRACTALS
LA English
DT Article
DE Novel coronavirus; Quarantine; Hospitalization/self-isolation; Parameter
   estimation; Global sensitivity analysis; Optimal control theory;
   Numerical results
AB Coronavirus disease (COVID-19) is the biggest public health challenge the world is facing in recent days. Since there is no effective vaccine and treatment for this virus, therefore, the only way to mitigate this infection is the implementation of non-pharmaceutical interventions such as social-distancing, community lockdown, quarantine, hospitalization or self-isolation and contact-tracing. In this paper, we develop a mathematical model to explore the transmission dynamics and possible control of the COVID-19 pandemic in Pakistan, one of the Asian countries with a high burden of disease with more than 200,000 confirmed infected cases so far. Initially, a mathematical model without optimal control is formulated and some of the basic necessary analysis of the model, including stability results of the disease-free equilibrium is presented. It is found that the model is stable around the disease-free equilibrium both locally and globally when the basic reproduction number is less than unity. Despite the basic analysis of the model, we further consider the confirmed infected COVID-19 cases documented in Pakistan from March 1, till May 28, 2020 and estimate the model parameters using the least square fitting tools from statistics and probability theory. The results show that the model output is in good agreement with the reported COVID-19 infected cases. The approximate value of the basic reproductive number based on the estimated parameters is R-0 approximate to 1.87. The effect of low (or mild), moderate, and comparatively strict control interventions like social-distancing, quarantine rate, (or contact-tracing of suspected people) and hospitalization (or self-isolation) of testing positive COVID-19 cases are shown graphically. It is observed that the most effective strategy to minimize the disease burden is the implementation of maintaining a strict social-distancing and contact-tracing to quarantine the exposed people. Furthermore, we carried out the global sensitivity analysis of the most crucial parameter known as the basic reproduction number using the Latin Hypercube Sampling (LHS) and the partial rank correlation coefficient (PRCC) techniques. The proposed model is then reformulated by adding the time-dependent control variables u(1)(t) for quarantine and u(2)(t) for the hospitalization interventions and present the necessary optimality conditions using the optimal control theory and Pontryagin's maximum principle. Finally, the impact of constant and optimal control interventions on infected individuals is compared graphically. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Ullah, Saif] Univ Peshawar, Dept Math, Peshawar, Pakistan.
   [Khan, Muhammad Altaf] Ton Duc Thang Univ, Informetr Res Grp, Ho Chi Minh City, Vietnam.
   [Khan, Muhammad Altaf] Ton Duc Thang Univ, Fac Math & Stat, Ho Chi Minh City, Vietnam.
RP Khan, MA (corresponding author), Ton Duc Thang Univ, Informetr Res Grp, Ho Chi Minh City, Vietnam.; Khan, MA (corresponding author), Ton Duc Thang Univ, Fac Math & Stat, Ho Chi Minh City, Vietnam.
EM Saifullah.maths@uop.edu.pk; muhammad.altaf.khan@tdtu.edu.vn
CR Agusto FB, 2018, MATH BIOSCI, V305, P102, DOI 10.1016/j.mbs.2018.09.007
   Agusto FB, 2013, BIOSYSTEMS, V113, P155, DOI 10.1016/j.biosystems.2013.06.004
   Atangana A, 2020, CHAOS SOLITON FRACT, V136, DOI 10.1016/j.chaos.2020.109860
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Fanelli D, 2020, CHAOS SOLITON FRACT, V134, DOI 10.1016/j.chaos.2020.109761
   Khan MA, 2020, ALEXAND ENG J
   Khan MA, 2019, ADV MECH ENG, V11, DOI 10.1177/1687814019854835
   Khan MA, 2018, APPL MATH COMPUT, V331, P378, DOI 10.1016/j.amc.2018.03.029
   Kristensen MR, 2004, THESIS, P139
   LaSalle J. P., 1976, STABILITY DYNAMICAL
   Marino S, 2008, J THEOR BIOL, V254, P178, DOI 10.1016/j.jtbi.2008.04.011
   Ngonghala CN, 2020, MATH BIOSCI, V325, DOI 10.1016/j.mbs.2020.108364
   Pontryagin L. S., 1962, MATH THEORY OPTIMAL
   Torrealba-Rodriguez O, 2020, CHAOS SOLITON FRACT, V138, DOI 10.1016/j.chaos.2020.109946
   Ullah S, 2019, OPTIM CONTR APPL MET, V40, P529, DOI 10.1002/oca.2493
   Utkucan S, 2020, CHAOS SOLITON FRACT
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   Wu J H, 2020, J MATH IND, V10, DOI 10.1186/s13362-020-00083-3
NR 19
TC 10
Z9 10
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0779
EI 1873-2887
J9 CHAOS SOLITON FRACT
JI Chaos Solitons Fractals
PD OCT
PY 2020
VL 139
AR 110075
DI 10.1016/j.chaos.2020.110075
PG 15
WC Mathematics, Interdisciplinary Applications; Physics, Multidisciplinary;
   Physics, Mathematical
SC Mathematics; Physics
GA OP9TF
UT WOS:000588433800078
PM 32834618
OA Green Published
DA 2021-01-01
ER

PT J
AU Thomson, DJ
   Palma, D
   Guckenberger, M
   Balermpas, P
   Beitler, JJ
   Blanchard, P
   Brizel, D
   Budach, W
   Caudell, J
   Corry, J
   Corvo, R
   Evans, M
   Garden, AS
   Giralt, J
   Gregoire, V
   Harari, PM
   Harrington, K
   Hitchcock, YJ
   Johansen, J
   Kaanders, J
   Koyfman, S
   Langendijk, JA
   Le, QT
   Lee, N
   Margalit, D
   Mierzwa, M
   Porceddu, S
   Soong, YL
   Sun, Y
   Thariat, J
   Waldron, J
   Yom, SS
AF Thomson, David J.
   Palma, David
   Guckenberger, Matthias
   Balermpas, Panagiotis
   Beitler, Jonathan J.
   Blanchard, Pierre
   Brizel, David
   Budach, Wilfred
   Caudell, Jimmy
   Corry, June
   Corvo, Renzo
   Evans, Mererid
   Garden, Adam S.
   Giralt, Jordi
   Gregoire, Vincent
   Harari, Paul M.
   Harrington, Kevin
   Hitchcock, Ying J.
   Johansen, Jorgen
   Kaanders, Johannes
   Koyfman, Shlomo
   Langendijk, J. A.
   Le, Quynh-Thu
   Lee, Nancy
   Margalit, Danielle
   Mierzwa, Michelle
   Porceddu, Sandro
   Soong, Yoke Lim
   Sun, Ying
   Thariat, Juliette
   Waldron, John
   Yom, Sue S.
TI Practice recommendations for risk-adapted head and neck cancer
   radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus
   statement
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA
AB Purpose: Because of the unprecedented disruption of health care services caused by the COVID-19 pan-demic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncol-ogists treating head and neck cancer (HNC) in a time of limited resources and heightened risk for patients and staff.
   Methods and Materials: A panel of international experts from ASTRO, ESTRO, and select Asia-Pacific countries completed a modified rapid Delphi process. Topics and questions were presented to the group, and subsequent questions were developed from iterative feedback. Each survey was open online for 24 hours, and successive rounds started within 24 hours of the previous round. The chosen cutoffs for strong agreement (>80%) and agreement (>66%) were extrapolated from the RAND methodology. Two pandemic scenarios, early (risk mitigation) and late (severely reduced radiation therapy resources), were evaluated. The panel developed treatment recommendations for 5 HNC cases.
   Results: In total, 29 of 31 of those invited (94%) accepted, and after a replacement 30 of 30 completed all 3 surveys (100% response rate). There was agreement or strong agreement across a number of practice areas, including treatment prioritization, whether to delay initiation or interrupt radiation therapy for intercurrent SARS-CoV-2 infection, approaches to treatment (radiation dose-fractionation schedules and use of chemotherapy in each pandemic scenario), management of surgical cases in event of operating room closures, and recommended adjustments to outpatient clinic appointments and supportive care.
   Conclusions: This urgent practice recommendation was issued in the knowledge of the very difficult circumstances in which our patients find themselves at present, navigating strained health care systems functioning with limited resources and at heightened risk to their health during the COVID-19 pandemic. The aim of this consensus statement is to ensure high-quality HNC treatments continue, to save lives and for symptomatic benefit. (C) 2020 The Authors. Published by Elsevier B.V.
C1 [Thomson, David J.] Christie NHS Fdn Trust, Dept Clin Oncol, Manchester, Lancs, England.
   [Thomson, David J.] Univ Manchester, Div Canc Sci, Manchester, Lancs, England.
   [Palma, David] Western Univ, Div Radiat Oncol, London, ON, Canada.
   [Guckenberger, Matthias; Balermpas, Panagiotis] Univ Zurich, Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland.
   [Beitler, Jonathan J.] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   [Blanchard, Pierre] Gustave Roussy Canc Ctr, Dept Radiat Oncol, Villejuif, France.
   [Brizel, David] Duke Canc Inst, Dept Radiat Oncol, Durham, NC USA.
   [Budach, Wilfred] Univ Hosp Dusseldorf, Dept Radiat Oncol, Dusseldorf, Germany.
   [Caudell, Jimmy] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL USA.
   [Corry, June] St Vincents Hosp, Dept Radiat Oncol Genesiscare, Melbourne, Vic, Australia.
   [Corvo, Renzo] Osped Policlin San Martino & Univ, Dept Radiat Oncol, Genoa, Italy.
   [Evans, Mererid] Velindre Univ NHS Trust, Dept Clin Oncol, U, Cardiff, S Glam, Wales.
   [Garden, Adam S.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
   [Giralt, Jordi] Hosp Univ Vall dHebron, Dept Radiat Oncol, Barcelona, Spain.
   [Gregoire, Vincent] Ctr Leon Berard, Dept Radiat Oncol, Lyon, France.
   [Harari, Paul M.] Univ Wisconsin, Dept Human Oncol, Madison, WI USA.
   [Harrington, Kevin] Inst Canc Res, Div Radiotherapy & Imaging, London, England.
   [Hitchcock, Ying J.] Univ Utah, Huntsman Canc Hosp, Dept Radiat Oncol, Salt Lake City, UT USA.
   [Johansen, Jorgen] Odense Univ Hosp, Dept Oncol, Odense, Denmark.
   [Kaanders, Johannes] Radboudumc, Dept Radiat Oncol, Nijmegen, Netherlands.
   [Koyfman, Shlomo] Cleveland Clin, Dept Radiat Oncol, Cleveland, OH 44106 USA.
   [Langendijk, J. A.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands.
   [Le, Quynh-Thu] Stanford Univ, Dept Radiat Oncol, Palo Alto, CA 94304 USA.
   [Lee, Nancy] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA.
   [Margalit, Danielle] Harvard Med Sch, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA.
   [Mierzwa, Michelle] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.
   [Porceddu, Sandro] Univ Queensland, Princess Alexandra Hosp, Dept Radiat Oncol, Brisbane, Qld, Australia.
   [Soong, Yoke Lim] Natl Canc Ctr Singapore, Div Radiat Oncol, Singapore, Singapore.
   [Sun, Ying] Sun Yat Sen Univ, Dept Radiat Oncol, Canc Ctr, Guangzhou, Guangdong, Peoples R China.
   [Thariat, Juliette] Univ Normandy, Ctr Francois Baclesse, Dept Radiat Oncol, Caen, France.
   [Waldron, John] Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON, Canada.
   [Yom, Sue S.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
RP Yom, SS (corresponding author), Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
EM sue.yom@ucsf.ech
RI Guckenberger, Matthias/AAX-4994-2020; Johansen, Jorgen/I-6816-2013
OI Guckenberger, Matthias/0000-0002-7146-9071; Langendijk, Johannes
   A./0000-0003-1083-372X; Johansen, Jorgen/0000-0003-3911-3929; Balermpas,
   Panagiotis/0000-0001-5261-6446
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [UG1
   CA233277] Funding Source: Medline
CR Agger A, 2009, HEAD NECK-J SCI SPEC, V31, P1593, DOI 10.1002/hed.21132
   Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217
   Benghiat H, 2014, CANC CLIN ONCOL, V3
   Bourhis J, 2012, LANCET ONCOL, V13, P145, DOI 10.1016/S1470-2045(11)70346-1
   Cheah NLC, 2009, CLIN ONCOL-UK, V21, P494, DOI 10.1016/j.clon.2009.02.008
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chera BS, 2010, INT J RADIAT ONCOL, V78, P461, DOI 10.1016/j.ijrobp.2009.08.066
   Ermis E, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0505-6
   Fitch K, 2003, RAND UCLA APPROPRIAT
   Gowda RV, 2003, RADIOTHER ONCOL, V68, P105, DOI 10.1016/S0167-8140(03)00059-8
   Guckenberger M, 2020, RADIOTHER ONCOL, V146, P223, DOI 10.1016/j.radonc.2020.04.001
   Jacinto AA, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4893-5
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Meade S, 2017, CLIN ONCOL-UK, V30, P366
   Mehanna H, 2016, NEW ENGL J MED, V374, P1444, DOI 10.1056/NEJMoa1514493
   Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014
   Stavas MJ, 2014, J THROID RES, V2014, DOI 10.1155/2014/764281
   Thomson DJ, 2015, ACTA ONCOL, V54, P88, DOI 10.3109/0284186X.2014.958528
   Tobias JS, 2010, LANCET ONCOL, V11, P66, DOI 10.1016/S1470-2045(09)70306-7
   World Health Organization, COR DIS 2019 COVID 1
   2020, MMWR MORBID MORTAL W, V69, P343
NR 21
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-8140
EI 1879-0887
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD OCT
PY 2020
VL 151
BP 314
EP 321
DI 10.1016/j.radonc.2020.04.019
PG 8
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA OR9OF
UT WOS:000589794300049
PM 32730830
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Donadu, MG
   Pizzi, AR
   Zeppilli, P
AF Donadu, Matthew Gavino
   Pizzi, Angelo Renato
   Zeppilli, Paolo
TI COVID-19, indications for professional football teams and referees
   training resumption
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE COVID-19; infection; prevention; football; protocol; referees
AB These indications were drawn up by the Federal Medical-Scientific Commission (FIGC Commission), supplemented for the necessary time by some experts on the subject; currently they are intended to grant the highest achievable guarantee level to protect the health of players, referees and all professionals involved in case of resumption of collective training (Document dated 18 April 2020). They were designed to minimize the risk of contagion were thus based on the fact that during that phase of SARS-COV-2 virus pandemic (COVID-19) and in the absence of an effective vaccine, the zero-contagion risk did not exist and does not exist to date. Those guidelines have been updated on the basis of ongoing medical-scientific evidence, taking into account the indications given by the Technical-Scientific Committee and the opinion of the Italian Football Federation representatives, during a meeting that took place on May 7 and was transmitted to FIGC on May 11, 2020; these indications are to be considered stringent and binding for the purposes of sport training resumption.
C1 [Donadu, Matthew Gavino; Pizzi, Angelo Renato] Italian Football Federat, Italian Referees Assoc, Biomed Commiss, Referees Tech Sect, Rome, Italy.
   [Pizzi, Angelo Renato; Zeppilli, Paolo] Italian Football Federat, Sci Med Commiss, Rome, Italy.
   [Zeppilli, Paolo] Univ Cattolica Sacro Cuore, Sports Med Unit, Rome, Italy.
RP Donadu, MG (corresponding author), Univ Sassari, Dept Biomed Sci, Sect Expt & Clin Microbiol, Viale S Pietro 43-b, Sassari, Italy.
EM mdonadu@uniss.it
RI Donadu, Matthew Gavino/H-4618-2018
OI Donadu, Matthew Gavino/0000-0001-7681-6194
CR Kelvin DJ, 2020, J INFECT DEV COUNTR, V14, P1, DOI 10.3855/jidc.12496
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Piras A, 2020, AM J OTOLARYNG, V9, P41
   Piras A, 2020, OTOLARYNG HEAD NECK, V163, P459, DOI 10.1177/0194599820931793
   Prime Minister of Italy, 2020, METH CARR OUT TRAIN, P1
   Radulesco T, 2020, EUR ARCH OTO-RHINO-L, V7, P1
NR 6
TC 0
Z9 0
U1 2
U2 2
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD OCT
PY 2020
VL 14
IS 10
BP 1084
EP 1089
DI 10.3855/jidc.13436
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA OS6HJ
UT WOS:000590262200003
PM 33175700
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Tao, JX
   Nie, YJ
   Wu, H
   Cheng, L
   Qiu, YW
   Fu, JJ
   Jiang, XF
AF Tao, Jianxin
   Nie, Yunjuan
   Wu, Hui
   Cheng, Liang
   Qiu, Yuanwang
   Fu, Juanjuan
   Jiang, Xiufeng
TI Umbilical cord blood-derived mesenchymal stem cells in treating a
   critically ill COVID-19 patient
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE UCB-MSCs; COVID-19; ARDS; respiratory failure
ID STROMAL CELLS; ARDS
AB Introduction: The coronavirus disease 2019 (COVID-19) pandemic is spreading rapidly. Critically ill cases of COVID-19 can rapidly progress to acute respiratory distress syndrome and multiple organ failures. However, no effective drugs have been available till now, leading to more than 300,000 deaths up to 29 April 2020. Here, we present a critically ill case utilizing umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs).
   Case presentation: A 72-year-old man was admitted, with the diagnosis of COVID-19, ARDS, type-2 diabetes, diabetic nephropathy, renal insufficiency, and hypertension. His clinical condition continually developed to be life-threatening even receiving various treatment options including antiviral therapy and extracorporeal membrane oxygenation. Between 28 February and 8 March 2020, the patient was given 5-time intravenous infusions of UCB-MSCs. His hematological and biochemical indexes, including lymphocytes and renal function improved. Pulmonary static compliance increased significantly and PaO2/FiO(2) ratio maintained stable. On March 10, he received lung transplantation.
   Conclusions: Our current findings suggested that UCB-MSCs therapy may show some positive effect in treating critical COVID-19 to some extent, for its delaying deterioration of the disease and efficacy in respiratory and renal function, though limited.
C1 [Tao, Jianxin; Jiang, Xiufeng] Nanjing Med Univ, Wuxi Clin Coll, Wuxi, Jiangsu, Peoples R China.
   [Nie, Yunjuan] Jiangnan Univ, Wuxi Sch Med, Dept Basic Med, Wuxi, Jiangsu, Peoples R China.
   [Wu, Hui; Cheng, Liang; Qiu, Yuanwang; Fu, Juanjuan; Jiang, Xiufeng] Jiangnan Univ, Wuxi Peoples Hosp 5, Dept Resp & Crit Care Med, Wuxi, Jiangsu, Peoples R China.
RP Jiang, XF (corresponding author), Wuxi Fifth Peoples Hosp, Dept Resp & Crit Care Med, 1215 Guangrui Rd, Wuxi 214122, Jiangsu, Peoples R China.
EM jiangxiufeng69@163.com
FU Wuxi Municipal Health Commission Major Project [Z201811]; Wuxi Science
   and Technology Bureau guiding plan [201812]; Wuxi Science and Technology
   Bureau new pneumonia special [N2020X009, N2020X027]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81800065]; Jiangsu EyeCure Biomedical Technology Co., Ltd
FX This study was supported by Wuxi Municipal Health Commission Major
   Project Z201811, Wuxi Science and Technology Bureau guiding plan 201812,
   Wuxi Science and Technology Bureau new pneumonia special N2020X009 and
   N2020X027, National Natural Science Foundation of China 81800065.
   Mesenchymal stem cells were provided and supported by Jiangsu EyeCure
   Biomedical Technology Co., Ltd free of charge, and we would like to
   thank for its dedication to COVID-19. We would also like to thank the
   nursing staff involved in this patient's care, Infection Prevention and
   Control team members.
CR Bari E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040924
   Chang JW, 2011, CELL TRANSPLANT, V20, P245, DOI 10.3727/096368910X520056
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Gorman E, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04416-w
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hu CX, 2020, INT J BIOL SCI, V16, P893, DOI 10.7150/ijbs.39725
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kwon JH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194815
   Li N, 2017, CELL MOL LIFE SCI, V74, P2345, DOI 10.1007/s00018-017-2473-5
   Marchioni A, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2002-4
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   Matthay MA, 2017, STEM CELLS, V35, P316, DOI 10.1002/stem.2551
   Melief SM, 2013, HAEMATOLOGICA, V98, P888, DOI 10.3324/haematol.2012.078055
   National Health Commission of the People's Republic of China, 2020, GUID DIAGN TREATM CO
   Peired AJ, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4798639
   Qin H, 2020, PROTEIN CELL, V11, P707, DOI 10.1007/s13238-020-00738-2
   Shin TH, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.442
   Stiner R, 2019, CELL TISSUE RES, V378, P155, DOI 10.1007/s00441-019-03046-2
   Walter J, 2014, LANCET RESP MED, V2, P1016, DOI 10.1016/S2213-2600(14)70217-6
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zhang YX, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01725-4
NR 23
TC 0
Z9 0
U1 0
U2 0
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD OCT
PY 2020
VL 14
IS 10
BP 1138
EP 1145
DI 10.3855/jidc.13081
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA OS6HJ
UT WOS:000590262200012
PM 33175709
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Panda, PK
   Dawman, L
   Panda, P
   Sharawat, IK
AF Panda, Prateek Kumar
   Dawman, Lesa
   Panda, Pragnya
   Sharawat, Indar Kumar
TI Feasibility and effectiveness of teleconsultation in children with
   epilepsy amidst the ongoing COVID-19 pandemic in a resource-limited
   country
SO SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
LA English
DT Article
DE Teleconsultation; Epilepsy; COVID-19; Antiepileptic drugs; Child
   neurology
ID FOLLOW-UP; TELEMEDICINE
AB Introduction: The ongoing COVID-19 pandemic and the lockdown measures employed by the government have forced neurologists across the world to look upon telemedicine as the only feasible and practical option to continue providing health care towards children with epilepsy in home isolation. Children with epilepsy are challenging for teleconsultation as direct information from the patient is missing, regarding seizures and adverse effects, especially behavioral and psychological side effects.
   Methods: Clinical and epilepsy-related details of telephonic consultations for children 1 month-18 years, performed between 26th March and 17th May 2020 in a tertiary care teaching hospital in Uttarakhand (a state of India known for hilly terrains with low per capita income) were recorded. Suitable changes in the dose/commercial brand of antiepileptic drug (AED) regimen were performed, along with the addition of new AED and referral to local practitioners for immediate hospitalization, when urgent health care issues were detected. Voice call, text message, picture/video message, and all other possible measures were employed to accumulate maximum clinical information in real-time.
   Results: A total of 153 children(95 males [62 %], 9.45 +/- 3.24 years, 140 lower/middle socioeconomic status) were enrolled after screening 237 children with various neurological disorders, whose caregivers contacted for teleconsultation. A total of 278 telephone consultations performed for these 153 children (1-5 telephone calls per patient). Hundred-thirteen children were identified to have a total of 152 significant clinical events (breakthrough seizure/uncontrolled epilepsy (108), AED related (13), and unrelated systemic adverse effects (24), worsening of associated co-morbidities (7). In rest of the patients, the query of the caregiver included unavailability of AED/prescribed commercial brand in the locality, query related to the dose of drugs, proxy for a scheduled routine visit (no active issues), and concern regarding COVID-19 related symptoms and effect of COVID-19 and lockdown in children with epilepsy. Ninety-three (60 %) patients required hiking up of AED dose, whereas 29 (17 %) patients required the addition of a new AED/commercial brand. Five children were advised immediate admission to a nearby hospital. Overall, 147 (96 %) caregivers were satisfied with the quality of medical advice.
   Conclusion: Teleconsultation is one of the few feasible options with good effectiveness for providing medical advice to children with epilepsy during pandemic times.
C1 [Panda, Prateek Kumar; Sharawat, Indar Kumar] All India Inst Med Sci, Dept Pediat, Pediat Neurol Div, Rishikesh 249203, Uttarakhand, India.
   [Dawman, Lesa] Post Grad Inst Med Educ & Res, Dept Pediat, Chandigarh 160012, India.
   [Panda, Pragnya] SCB Med Coll, Dept Med, Cuttack, Odisha, India.
RP Sharawat, IK (corresponding author), All India Inst Med Sci, Dept Pediat, Pediat Neurol Div, Rishikesh 249203, Uttarakhand, India.
EM sherawatdrindar@gmail.com
CR Ahmed SN, 2008, EPILEPSIA, V49, P573, DOI 10.1111/j.1528-1167.2007.01464.x
   [Anonymous], 2020, COVID 19 DELIVERY CA
   [Anonymous], 2020, INT LEAGUE EPILEPSY
   [Anonymous], 2016, AM EPILEPSY SOC
   Bahrani K, 2017, SEIZURE-EUR J EPILEP, V53, P55, DOI 10.1016/j.seizure.2017.11.003
   Brigo F, 2020, EPILEPSY BEHAV, V110, DOI 10.1016/j.yebeh.2020.107164
   Caso V, 2020, NEUROL SCI, V41, P999, DOI 10.1007/s10072-020-04389-3
   Dheer Ajay, 2005, Med J Armed Forces India, V61, P51, DOI 10.1016/S0377-1237(05)80121-2
   Elger CE, 2000, EPILEPSIA, V41, pS9
   Gulati S, 2018, TELEPHONE BASED FOLL
   Haddad N, 2015, EPILEPSY BEHAV, V44, P1, DOI 10.1016/j.yebeh.2014.11.033
   Hatcher-Martin JM, 2020, NEUROLOGY, V94, P30, DOI 10.1212/WNL.0000000000008708
   Hernando-Requejo V, 2020, NEUROLOGIA, V35, P274, DOI 10.1016/j.nrl.2020.04.014
   Kappal R, 2014, CENT ASIAN J GLOB HE, V3, DOI 10.5195/cajgh.2014.116
   Kissani N, 2020, EPILEPSY BEHAV, V103, DOI 10.1016/j.yebeh.2019.106461
   Konanki R, 2018, EPILEPSY RES, V145, P110, DOI 10.1016/j.eplepsyres.2018.06.005
   Kuroda N, 2020, EPILEPSY BEHAV, V111, DOI 10.1016/j.yebeh.2020.107198
   Matias-Guiu J, 2020, NEUROL ENGL ED, DOI [10.1016/j.nrleng.2020.04.001., DOI 10.1016/J.NRLENG.2020.04.001]
   Panda PK, 2020, INDIAN J PEDIATR, V87, P556, DOI 10.1007/s12098-020-03326-8
   Patterson V, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00321
   Patterson V, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00120
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Rajbhandari H, 2019, SEIZURE-EUR J EPILEP, V64, P54, DOI 10.1016/j.seizure.2018.12.005
   Santos-Peyret A, 2020, REV NEUROLOGIA, V70, P323, DOI 10.33588/rn.7009.2020173
   Sethi NK, 2020, CLIN NEUROPHYSIOL, V131, P1462, DOI 10.1016/j.clinph.2020.04.007
NR 25
TC 1
Z9 1
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1059-1311
EI 1532-2688
J9 SEIZURE-EUR J EPILEP
JI Seizure
PD OCT
PY 2020
VL 81
BP 29
EP 35
DI 10.1016/j.seizure.2020.07.013
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OJ1EK
UT WOS:000583710200006
PM 32712376
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Dicker, D
   Lev, S
   Gottesman, T
   Kournos, T
   Dotan, M
   Ashorov, N
   Marcoviciu, D
   Golan, R
AF Dicker, Dror
   Lev, Shaul
   Gottesman, Tamar
   Kournos, Tatiana
   Dotan, Maya
   Ashorov, Nina
   Marcoviciu, Dana
   Golan, Rachel
TI A Time Frame for Testing Negative for SARS-COV2 in People with Obesity
SO OBESITY FACTS
LA English
DT Article
DE Obesity; Overweight; SARS-COV2
ID IMPACT
AB Objective: Obesity is a major risk factor for becoming seriously ill with the 2019 novel coronavirus (COVID-19). One difficulty faced by clinicians and by patients is the unknown time frame of hospitalization until discharge of symptomatic patients. Methods: We followed 34 patients with laboratory-confirmed COVID-19 infection who recovered fromthe infection. All diagnoses were given using semi-quantitative RT-PCR on nasopharyngeal swabs. Envelope protein gene (E), RNA-dependent RNA polymerase gene (RdRP), and nucleocapsid gene (N) were measured by RT-PCR. Weight was measured and height was self-reported. Results: Mean +/- SD age was 51.8 +/- 16.7 years. Mean +/- SD body mass index (BMI) was 27.4 +/- 4.7 kg/m(2). 26% (9/34) had obesity, with BMI above 30 kg/m(2). Fifteen patients had BMI between 25 and 29.9 kg/m(2). The mean length of hospital stay was longer for those with a BMI >25 kg/m(2) (n = 24) than for those with a normal BMI (19.2 vs. 16.0 days, p = 0.08). Comparing people with obesity (BMI >30 kg/m(2) or above) to those without obesity, the difference was larger (20.6 vs. 16.0 days, p = 0.06). A trend for correlation between body weight and the time to negative detection of RdRp gene was found (r = 0.33, p = 0.09). Conclusions: Our results highlight the need for priority of early detection and testing, and early therapy for people with obesity and COVID-19 infections.
C1 [Dicker, Dror; Kournos, Tatiana; Dotan, Maya; Ashorov, Nina; Marcoviciu, Dana] Rabin Med Ctr, Hasharon Hosp, Dept Internal Med D, 7 Keren Kayemet St, IL-49100 Petah Tiqwa, Israel.
   [Dicker, Dror] Tel Aviv Univ, Sackler Sch Med, Ramat Aviv, Israel.
   [Lev, Shaul] Rabin Med Ctr, Hasharon Hosp, Intens Care Unit, Petah Tiqwa, Israel.
   [Gottesman, Tamar] Rabin Med Ctr, Hasharon Hosp, Dept Infect Dis & Infect Control Serv, Petah Tiqwa, Israel.
   [Golan, Rachel] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Publ Hlth, Beer Sheva, Israel.
RP Dicker, D (corresponding author), Rabin Med Ctr, Hasharon Hosp, Dept Internal Med D, 7 Keren Kayemet St, IL-49100 Petah Tiqwa, Israel.
EM daniel3@013.net
CR Afshin A, 2017, NEW ENGL J MED, V377, P13, DOI 10.1056/NEJMoa1614362
   Andersen CJ, 2016, ADV NUTR, V7, P66, DOI 10.3945/an.115.010207
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dicker D, 2020, EUR J INTERN MED, V77, P144, DOI 10.1016/j.ejim.2020.04.063
   Dietz W, 2020, OBESITY, V28, P1005, DOI 10.1002/oby.22818
   Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Honce R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01071
   Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583
   Malavazos AE, 2020, OBESITY, V28, P1178, DOI 10.1002/oby.22844
   Ryan DH, 2020, OBESITY, V28, P847, DOI 10.1002/oby.22808
   Sattar N, 2020, CIRCULATION, V142, P4, DOI 10.1161/CIRCULATIONAHA.120.047659
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   World Health Organization (WHO), 2020, NOV COR CHIN
NR 17
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1662-4025
EI 1662-4033
J9 OBESITY FACTS
JI Obes. Facts
PD OCT
PY 2020
VL 13
IS 5
BP 528
EP 533
DI 10.1159/000511738
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA OM5MV
UT WOS:000586069600007
PM 32992323
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jaiswal, G
   Kumar, V
AF Jaiswal, Grijesh
   Kumar, Veerendra
TI In-silico design of a potential inhibitor of SARS-CoV-2 S protein
SO PLOS ONE
LA English
DT Article
ID CORONAVIRUS SPIKE PROTEIN; ANGIOTENSIN-CONVERTING ENZYME-2; SARS-COV;
   FUSION CORE; RECEPTOR; BINDING; DOMAIN; SIMULATIONS; MECHANISMS; GUI
AB The SARS-CoV-2 virus has caused a pandemic and is public health emergency of international concern. As of now, no registered therapies are available for treatment of coronavirus infection. The viral infection depends on the attachment of spike (S) glycoprotein to human cell receptor angiotensin-converting enzyme 2 (ACE2). We have designed a protein inhibitor (Delta ABP-D25Y) targeting S protein using computational approach. The inhibitor consists of two alpha helical peptides homologues to protease domain (PD) of ACE2. Docking studies and molecular dynamic simulation revealed that the inhibitor binds exclusively at the ACE2 binding site of S protein. The computed binding affinity of the inhibitor is higher than the ACE2 and thus will likely out compete ACE2 for binding to S protein. Hence, the proposed inhibitor Delta ABP-D25Y could be a potential blocker of S protein and receptor binding domain (RBD) attachment.
C1 [Jaiswal, Grijesh; Kumar, Veerendra] Amity Univ, Amity Inst Mol Med & Stem Cell Res AIMMSCR, Noida, Uttar Pradesh, India.
RP Kumar, V (corresponding author), Amity Univ, Amity Inst Mol Med & Stem Cell Res AIMMSCR, Noida, Uttar Pradesh, India.
EM vkumar34@amity.edu
OI Kumar, Veerendra/0000-0002-9241-1303
FU Department of Biotechnology, Govt of IndiaDepartment of Biotechnology
   (DBT) India [BT/RLF/Reentry/64/2017]
FX We would like to acknowledge the Ramalingaswami Fellowship
   (BT/RLF/Reentry/64/2017), Department of Biotechnology, Govt of India
   (VK). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bernardi RC, 2015, BBA-GEN SUBJECTS, V1850, P872, DOI 10.1016/j.bbagen.2014.10.019
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Chandel V, 2020, CHEM BIOL LETT
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   de Vries SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017695
   DeLano W.L., 2002, PYMOL MOL GRAPH SYST, DOI [10.1038/hr.2014.17, DOI 10.1038/HR.2014.17]
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Ferrario CM, 2011, CURR OPIN NEPHROL HY, V20, P1, DOI 10.1097/MNH.0b013e3283406f57
   Gao J, 2013, J VIROL, V87, P13134, DOI 10.1128/JVI.02433-13
   Han YX, 2020, ACS NANO, V14, P5143, DOI 10.1021/acsnano.0c02857
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Holm L, 2016, NUCLEIC ACIDS RES, V44, pW351, DOI 10.1093/nar/gkw357
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Imai Y, 2008, EXP PHYSIOL, V93, P543, DOI 10.1113/expphysiol.2007.040048
   Jimenez-Garcia B, 2013, BIOINFORMATICS, V29, P1698, DOI 10.1093/bioinformatics/btt262
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Ke M, 2012, VIRUS RES, V167, P322, DOI 10.1016/j.virusres.2012.05.017
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kumar Swatantra, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00571-5
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Laraia L, 2015, CHEM BIOL, V22, P689, DOI 10.1016/j.chembiol.2015.04.019
   Lee J, 2016, J CHEM THEORY COMPUT, V12, P405, DOI 10.1021/acs.jctc.5b00935
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li QL, 2011, PEPTIDES, V32, P1518, DOI 10.1016/j.peptides.2011.05.015
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Li WH, 2004, J VIROL, V78, P11429, DOI 10.1128/JVI.78.20.11429-11433.2004
   Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067
   MENEGUZZO F, 2020, PROCESSES, V8, DOI DOI 10.3390/PF18050549
   Meneguzzo F, 2020, PROCESSES, V8, DOI 10.3390/pr8050549
   Mirza M. U., 2020, STRUCTURAL ELUCIDATI, DOI [10.20944/preprints202003.0085.v1, DOI 10.20944/PREPRINTS202003.0085.V1]
   Park J, 2019, ELIFE, V8, DOI 10.7554/eLife.47839
   Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316
   Sainz B, 2006, VIRUS RES, V120, P146, DOI 10.1016/j.virusres.2006.03.001
   Sanchez-Garcia R, 2019, BIOINFORMATICS, V35, P470, DOI 10.1093/bioinformatics/bty647
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Waterhouse A, 2009, J BIOL CHEM, DOI [10.1097/MLR.0000000000000625, DOI 10.1097/MLR.0000000000000625]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang XH, 2007, COMP MED
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 67
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 1
PY 2020
VL 15
IS 10
AR e0240004
DI 10.1371/journal.pone.0240004
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OS6KJ
UT WOS:000590270000085
PM 33002032
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Demir, E
   Uyar, M
   Parmaksiz, E
   Sinangil, A
   Yelken, B
   Dirim, AB
   Merhametsiz, O
   Yadigar, S
   Ucar, ZA
   Ucar, AR
   Demir, ME
   Mese, M
   Akin, EB
   Garayeva, N
   Safak, S
   Oto, OA
   Yazici, H
   Turkmen, A
AF Demir, Erol
   Uyar, Murathan
   Parmaksiz, Ergun
   Sinangil, Ayse
   Yelken, Berna
   Dirim, Ahmet Burak
   Merhametsiz, Ozgur
   Yadigar, Serap
   Atan Ucar, Zuhal
   Ucar, Ali Riza
   Demir, Mehmet Emin
   Mese, Meral
   Akin, Emin Baris
   Garayeva, Nurana
   Safak, Seda
   Oto, Ozgur Akin
   Yazici, Halil
   Turkmen, Aydin
TI COVID-19 in kidney transplant recipients: A multicenter experience in
   Istanbul
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE acute kidney injury; antiviral agents; COVID&#8208; 19; cytokine release
   syndrome; cytokine&#8208; targeted therapy; kidney transplantation;
   respiratory distress syndrome; adult
AB Introduction Management of COVID-19 in kidney transplant recipients should include treatment of the infection, regulation of immunosuppression, and supportive therapy. However, there is no consensus on this issue yet. This study aimed to our experiences with kidney transplant recipients diagnosed with COVID-19.
   Material and Methods Kidney transplant recipients diagnosed with COVID-19 from five major transplant centers in Istanbul, Turkey, were included in this retrospective cohort study. Patients were classified as having moderate or severe pneumonia for the analysis. The primary endpoint was all-cause mortality. The secondary endpoints were acute kidney injury, the average length of hospital stay, admission to intensive care, and mechanical ventilation.
   Results Forty patients were reviewed retrospectively over a follow-up period of 32 days after being diagnosed with COVID-19. Cough, fever, and dyspnea were the most frequent symptoms in all patients. The frequency of previous induction and rejection therapy was significantly higher in the group with severe pneumonia compared to the moderate pneumonia group. None of the patients using cyclosporine A developed severe pneumonia. Five patients died during follow-up in the intensive care unit. None of the patients developed graft loss during follow-up.
   Discussion COVID-19 has been seen to more commonly cause moderate or severe pneumonia in kidney transplant recipients. Immunosuppression should be carefully reduced in these patients. Induction therapy with lymphocyte-depleting agents should be carefully avoided in kidney transplant recipients during the pandemic period.
C1 [Demir, Erol; Dirim, Ahmet Burak; Ucar, Ali Riza; Garayeva, Nurana; Safak, Seda; Oto, Ozgur Akin; Yazici, Halil; Turkmen, Aydin] Istanbul Univ, Istanbul Fac Med, Dept Internal Med, Div Nephrol, Istanbul, Turkey.
   [Uyar, Murathan; Merhametsiz, Ozgur; Demir, Mehmet Emin] Yeniyuzyil Univ, Gaziosmanpasa Hosp, Dept Internal Med, Div Nephrol, Istanbul, Turkey.
   [Parmaksiz, Ergun; Yadigar, Serap; Mese, Meral] Kartal Dr Lutfi Kirdar Training & Res Hosp, Dept Internal Med, Div Nephrol, Istanbul, Turkey.
   [Sinangil, Ayse; Atan Ucar, Zuhal; Akin, Emin Baris] Demiroglu Bilim Univ, Florence Nightingale Hosp, Dept Internal Med, Div Nephrol, Istanbul, Turkey.
   [Yelken, Berna; Turkmen, Aydin] Koc Univ, Koc Sch Med, Dept Internal Med, Div Nephrol, Istanbul, Turkey.
   [Akin, Emin Baris] Demiroglu Bilim Univ, Florence Nightingale Hosp, Dept Gen Surg, Unit Renal Transplantat, Istanbul, Turkey.
RP Demir, E (corresponding author), Istanbul Univ, Istanbul Fac Med, Dept Internal Med, Div Nephrol, Istanbul, Turkey.
EM eroldemir83@yahoo.com
RI demir, erol/B-9151-2018
OI demir, erol/0000-0003-0128-5645
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Alberici F, 2020, KIDNEY INT, V97, P1083, DOI 10.1016/j.kint.2020.04.002
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Cheng MP, 2020, ANN INTERN MED, V172, P726, DOI 10.7326/M20-1301
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   Johnson KM, 2020, PHARMACOTHERAPY, V40, P517, DOI 10.1002/phar.2410
   Lopez V, 2020, NEFROLOGIA, V40, P265, DOI 10.1016/j.nefro.2020.03.002
   Mohan S, 2020, J AM SOC NEPHROL, V31, P1150, DOI 10.1681/ASN.2020030375
   Montagud-Marrahi E, 2020, AM J TRANSPLANT, V20, P2958, DOI 10.1111/ajt.15970
   Ravelli A, 2002, CURR OPIN RHEUMATOL, V14, P548, DOI 10.1097/00002281-200209000-00012
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Willicombe M, 2020, J AM SOC NEPHROL, V31, P1145, DOI 10.1681/ASN.2020030348
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 14
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD OCT
PY 2020
VL 22
IS 5
AR e13371
DI 10.1111/tid.13371
PG 9
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA OR6XJ
UT WOS:000589611600017
PM 32657540
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Denning, DW
   Kilcoyne, A
   Ucer, C
AF Denning, David W.
   Kilcoyne, Anthony
   Ucer, Cemal
TI Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2
SO BRITISH DENTAL JOURNAL
LA English
DT Article
AB A key tenet of protection from infection for dentists is to know who is not infectious. The evidence base regarding protection from respiratory pathogens in dentistry is poor. Those with a positive SARS-CoV-2 IgG antibody are noninfectious (>99% certainty) and can be safely treated with good universal precautions, even for aerosol generating procedures. Viral infectivity with SARS-CoV-2 lasts eight days, unlike viral polymerase chain reaction (PCR) swab tests which can persist for as long as seven weeks. SARS-CoV-2 IgG antibody becomes detectable from 11 days after infection. SARS-CoV-2 IgG antibodies are usually neutralising against the virus and their direct antiviral activity was partially demonstrated in 33,000 patients with COVID-19 treated with convalescent plasma in the USA. So, a positive SARS-CoV-2 IgG antibody is a much more accurate determination of infectiousness than a repeat PCR which is only 70% sensitive. It remains to be seen whether SARS-Cov-2 vaccine responses include protective IgG titres and, once vaccines become widespread, can be used to assist decision-making on appropriate personal protective equipment (PPE) in dentistry.
C1 [Denning, David W.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Infect Immun & Resp Med, Manchester, Lancs, England.
   [Denning, David W.; Kilcoyne, Anthony] DenScreen Ltd, 86-90 Pail St, London EC2A 4NE, England.
   [Kilcoyne, Anthony] SmileSpecialist Ctr, 9-13 Stn Rd, Keighley BD22 8NL, W Yorkshire, England.
   [Ucer, Cemal] Univ Salford, Sch Hlth & Soc, Postgrad Dent Studies, Manchester, England.
   [Ucer, Cemal] ICE Postgrad Dent Inst & Hosp, Salford M50 3XZ, Lancs, England.
RP Denning, DW (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Infect Immun & Resp Med, Manchester, Lancs, England.; Denning, DW (corresponding author), DenScreen Ltd, 86-90 Pail St, London EC2A 4NE, England.
EM ddenning@manchester.ac.uk
FU NIHR Biomedical Research Centre in Manchester
FX DWD is partially supported by the NIHR Biomedical Research Centre in
   Manchester.
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Bullard Jared, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa638
   Carmo A, 2020, J MED VIROL, V92, P2227, DOI 10.1002/jmv.26103
   Cheng HY, 2020, JAMA INTERN MED, V180, P1156, DOI 10.1001/jamainternmed.2020.2020
   Danh K, 2020, DETECTION SARS COV 2, DOI DOI 10.1101/2020.05.28.20105692V1
   DAVIES KJ, 1994, BRIT DENT J, V176, P262, DOI 10.1038/sj.bdj.4808430
   Decker A, 2020, AM J TRANSPLANT, V20, P3239, DOI 10.1111/ajt.16133
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   Du Z, 2020, J MED VIROL, V92, P1735, DOI 10.1002/jmv.25820
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Jones T C, 2020, ANAL SARS COV 2 VIRA, DOI [10.1101/2020.06.08.20125484v1, DOI 10.1101/2020.06.08.20125484V1]
   Joyner M J, 2020, EFFECT CONVALESCENT, DOI DOI 10.1101/2020.08.12.20169359V1
   Kohmer N, 2020, J MED VIROL, V92, P2243, DOI 10.1002/jmv.26145
   La Scola B, 2020, EUR J CLIN MICROBIOL, V39, P1059, DOI 10.1007/s10096-020-03913-9
   Lassauniere R, 2020, EVALUATION 9 COMMERC, DOI DOI 10.1101/2020.04.09.20056325V1
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Markland E, 2020, SERUM IGG RESPONSES, DOI DOI 10.1101/2020.07.11.20151324V1
   Paltiel D A, 2020, SCREENING PREVENT SA, DOI DOI 10.1377/HBLOG20200909.430047/FULL/
   Peng Y, 2020, PREPRINT, DOI [DOI 10.1101/2020.06.05.134551V1, 10.1101/2020.06.05.134551v1]
   Porte L, 2020, INT J INFECT DIS, V99, P328, DOI 10.1016/j.ijid.2020.05.098
   Public Health Scotland, 2020, ENH SURV COVID 19 SC
   Qu Jiuxin, 2020, Clin Infect Dis, V71, P2255, DOI 10.1093/cid/ciaa489
   Rasheed Anwar M, 2020, Infez Med, V28, P357
   Seow J, 2020, PREPRINT, DOI [10.1101/2020.07.09.20148429v1, DOI 10.1101/2020.07.09.20148429V1]
   UK Biobank, 2020, UK BIOB COVID 19 ANT
   Van Elslande J, 2020, CLIN MICROBIOL INFEC, V26, P1082, DOI 10.1016/j.cmi.2020.05.023
   Ward H, 2020, ANTIBODY PREVALENCE, DOI [DOI 10.1101/2020.08.12.20173690V2, 10.1101/2020.08.12.20173690v2]
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
NR 29
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0007-0610
EI 1476-5373
J9 BRIT DENT J
JI Br. Dent. J.
PD OCT
PY 2020
VL 229
IS 8
BP 521
EP 524
DI 10.1038/s41415-020-2228-9
PG 4
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA OG4TN
UT WOS:000581878600026
PM 33097885
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lohse, A
   Klopfenstein, T
   Balblanc, JC
   Royer, PY
   Bossert, M
   Gendrin, V
   Charpentier, A
   Bozgan, AM
   Badie, J
   Bourgoin, C
   Contreras, R
   Mazurier, I
   Conrozier, T
   Zayet, S
AF Lohse, Anne
   Klopfenstein, Timothee
   Balblanc, Jean-Charles
   Royer, Pierre-Yves
   Bossert, Marie
   Gendrin, Vincent
   Charpentier, Aline
   Bozgan, Ana-Maria
   Badie, Julio
   Bourgoin, Charlotte
   Contreras, Remy
   Mazurier, Isabelle
   Conrozier, Thierry
   Zayet, Souheil
TI Predictive factors of mortality in patients treated with tocilizumab for
   acute respiratory distress syndrome related to coronavirus disease 2019
   (COVID-19)
SO MICROBES AND INFECTION
LA English
DT Article
DE SARS-CoV-2; COVID-19; Biomarkers; Tocilizumab; Acute respiratory
   distress syndrome; Predictive factors
AB COVID-19 patients (n = 34) suffering from ARDS were treated with tocilizumab (TCZ). Outcome was classified in two groups: "Death" and "Recovery". Predictive factors of mortality were studied. Mean age was 75.3, mean oxygen (O-2) requirements 10.4 l/min. At baseline, all patients had multiple biological abnormalities (lymphopenia, increased CRP, ferritin, fibrinogen, D-dimer and liver enzymes). 24 patients (70.5%) recovered after TCZ therapy and 10 died (29.5%). Deceased subjects differed from patients in whom treatment was effective with regard to more pronounced lymphopenia (0.6 vs 1.0 G/l; p = 0.037), lower platelet number (156 vs 314 G/l; p = 0.0001), lower fibrinogen serum level (0.6 vs 1.0 G/l; p = 0.03), higher aspartate-amino-transferase (108 vs 57 Ufil; p = 0.05) and greater O-2 requirements (11 vs 81/min; p = 0.003). (C) 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
C1 [Lohse, Anne; Balblanc, Jean-Charles; Bossert, Marie; Charpentier, Aline; Bozgan, Ana-Maria; Conrozier, Thierry] Nord Franche Comte Hosp, Dept Rheumatol, Belfort, France.
   [Klopfenstein, Timothee; Royer, Pierre-Yves; Gendrin, Vincent; Zayet, Souheil] Nord Franche Comte Hosp, Dept Infect Dis, Belfort, France.
   [Badie, Julio] Nord Franche Comte Hosp, Intens Care Unit, Belfort, France.
   [Badie, Julio; Bourgoin, Charlotte; Conrozier, Thierry] Nord Franche Comte Hosp, Clin Res Unit, Belfort, France.
   [Contreras, Remy] Nord Franche Comte Hosp, Dept Pharmacol, Belfort, France.
   [Mazurier, Isabelle] Nord Franche Comte Hosp, Dept Biol, Belfort, France.
RP Zayet, S (corresponding author), Hosp Nord Franche Comte, Serv Malad Infect, 100 Route MOVAL,CS 10499, F-90016 Trrvenans, Belfort, France.
EM souhail.zayet@gmail.com
CR Chen HL, 2019, FRONT MED-PRC, V13, P610, DOI 10.1007/s11684-019-0714-8
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Klopfenstein T, 2020, MED MALADIES INFECT, V50, P397, DOI 10.1016/j.medmal.2020.05.001
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Lowe DA, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.4153
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Pers YM, 2014, RHEUMATOLOGY, V53, P76, DOI 10.1093/rheumatology/ket301
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   SIMIT, VAD CUR PERS CON MAL
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Vivek S, 2020, MATERIA-BRAZIL, V25, DOI [10.1590/s1517-707620200003.1085, 10.1590/S1517-707620200003.1085]
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 24
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD OCT
PY 2020
VL 22
IS 9
BP 500
EP 503
DI 10.1016/j.micinf.2020.06.005
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA OJ2NW
UT WOS:000583804400019
PM 32574789
OA Green Published
DA 2021-01-01
ER

PT J
AU Zhou, M
   Xiong, XZ
AF Zhou, Mei
   Xiong, Xianzhi
TI COVID-19 Diagnosed by Serological Antibody Test: A Case Report
SO SIGNA VITAE
LA English
DT Article
DE COVID-19; Serological antibody test; Case report
AB The new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in Wuhan, China, is causing a pandemic. With an increased understanding of the disease, the diagnosis and treatment guidelines are being updated and improved. In addition to nucleic acid detection, antibody detection kits are also being developed and approved. A medical worker suspected of having COVID-19 in our hospital had fatigue and loss of appetite and pulmonary infection indicated by CT, but the nucleic acid test was negative three times. Finally, she was confirmed to have COVID-19 by a serological antibody test. After rest and oral antiviral treatment, she recovered and returned to work. This is a case report that focuses on suspected mild patients who tested negative for nucleic acids. Such a group of patients had to choose home isolation treatment during the outbreak. The majority of them did not make a definitive diagnosis or rule out COVID-19 by the time they recovered. The antibody test is of great significance to identify infected patients with multiple negative nucleic acid tests. It can complement nucleic acid testing to enhance diagnostic efficiency. We have reviewed the literature and realized that further validation and standardization of serological tests are needed for more mature application of antibody tests to clinical diagnosis and vaccine development.
C1 [Zhou, Mei; Xiong, Xianzhi] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Resp & Crit Care Med, Wuhan, Peoples R China.
RP Xiong, XZ (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Resp & Crit Care Med, Wuhan, Peoples R China.
EM xxz0508@hust.edu.cn
CR [Anonymous], 2020, CORONAVIRUS COVID 19
   [Anonymous], 2020, LIVE UPDATE NEW CORO
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018
   Ning Y, 2020, MED J PEKING UNION M, P1
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Touma M, 2020, J MOL MED, V98, P947, DOI 10.1007/s00109-020-01931-w
   Xiang F, 2020, CLIN INFECT DIS, DOI 10.1093/cid/ciaa461
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhang YC, 2020, EMERG MICROBES INFEC, V9, P833, DOI 10.1080/22221751.2020.1756699
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 14
TC 0
Z9 0
U1 1
U2 1
PU MRE PRESS
PI SINGAPORE
PA 14 ROBINSON RD #08-01A FAR EAST FINANCE, SINGAPORE, SINGAPORE
SN 1334-5605
EI 1845-206X
J9 SIGNA VITAE
JI Signa Vitae
PD OCT
PY 2020
VL 16
IS 2
BP 195
EP 198
DI 10.22514/sv.2020.16.0060
PG 4
WC Emergency Medicine
SC Emergency Medicine
GA OI5AY
UT WOS:000583292400028
DA 2021-01-01
ER

PT J
AU Kwiatek, A
   Adamczyk-Poplawska, M
AF Kwiatek, Agnieszka
   Adamczyk-Poplawska, Monika
TI SARS-COV-2 AND BETACORONAVIRUS: WHAT HAVE WE LEARNED IN 8 MONTHS?
SO ADVANCEMENTS OF MICROBIOLOGY
LA English
DT Article
DE SARS-CoV-2; betacoronavirus proteins; spike protein; furin-cleavage
   site; pathogenesis
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS-LIKE PARTICLES; SPIKE PROTEIN;
   FUSION PROTEIN; VIRUS; ENTRY; PATHOGENESIS; REPLICATION; RECOGNITION;
   EXPRESSION
AB In 2019, a new human pandemic coronavirus (SARS-CoV-2) emerged in Wuhan, China. We present the knowledge about SARS-CoV-2 compared to SARS-CoV and MERS-CoV. The SARS-CoV-2 is similar to other coronaviruses, nevertheless, differences were observed. Cell entry of SARS-CoV-2 is facilitated by cleavage of spike protein by furin. The receptor-binding motif of SARS-CoV-2 spike protein forms a larger binding interface and more contacts with host receptor ACE2 compared those of in SARS-CoV. Unlike other coronaviruses, the SARS-CoV-2 spike protein has a motif; known to bind integrins. Nucleocapsid protein and RNA-dependent RNA polymerase of SA RS-CoV-2 display some structural differences compared to those of SARS-CoV as well. These features may increase the efficiency of the spread of SARS-CoV-2 and indicate the putative targets for specific antiviral therapy.
C1 [Kwiatek, Agnieszka; Adamczyk-Poplawska, Monika] Univ Warsaw, Fac Biol, Inst Microbiol, Dept Mol Virol, Warsaw, Poland.
RP Kwiatek, A (corresponding author), Univ Warsaw, Inst Microbiol, Dept Mol Virol, Miecznikowa 1, PL-02096 Warsaw, Poland.
EM akwiat@biol.uw.edu.pl
OI Adamczyk-Poplawska, Monika/0000-0002-5885-9550
CR Alvarez E, 2010, VIROLOGY, V402, P281, DOI 10.1016/j.virol.2010.03.015
   Angelini MM, 2013, MBIO, V4, DOI 10.1128/mBio.00524-13
   Bhardwaj K, 2012, J VIROL, V86, P4294, DOI 10.1128/JVI.07012-11
   Bosch BJ, 2008, J VIROL, V82, P8887, DOI 10.1128/JVI.00415-08
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9
   Chatterjee A, 2009, J VIROL, V83, P1823, DOI 10.1128/JVI.01781-08
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Cornillez-Ty CT, 2009, J VIROL, V83, P10314, DOI 10.1128/JVI.00842-09
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   Dong X, 2020, ALLERGY, V75, P1699, DOI 10.1111/all.14289
   Egloff MP, 2006, J VIROL, V80, P8493, DOI 10.1128/JVI.00713-06
   Egloff MP, 2004, P NATL ACAD SCI USA, V101, P3792, DOI 10.1073/pnas.0307877101
   Escors D, 2001, J VIROL, V75, P1312, DOI 10.1128/JVI.75.3.1312-1324.2001
   Frieman M, 2009, J VIROL, V83, P6689, DOI 10.1128/JVI.02220-08
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Graham RL, 2005, J VIROL, V79, P13399, DOI 10.1128/JVI.79.21.13399-13411.2005
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002433
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   Kamitani W, 2006, P NATL ACAD SCI USA, V103, P12885, DOI 10.1073/pnas.0603144103
   Kamitani W, 2009, NAT STRUCT MOL BIOL, V16, P1134, DOI 10.1038/nsmb.1680
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x
   Li YW, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104833
   Lindner HA, 2007, ARCH BIOCHEM BIOPHYS, V466, P8, DOI 10.1016/j.abb.2007.07.006
   Luan JW, 2020, BIOCHEM BIOPH RES CO, V526, P165, DOI 10.1016/j.bbrc.2020.03.047
   Lundin A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004166
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Minakshi R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008342
   Mortola E, 2004, FEBS LETT, V576, P174, DOI 10.1016/j.febslet.2004.09.009
   Neuman BW, 2008, J VIROL, V82, P5279, DOI 10.1128/JVI.02631-07
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Nile SH, 2020, CYTOKINE GROWTH F R, V53, P66, DOI 10.1016/j.cytogfr.2020.05.002
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Oudshoorn D, 2017, MBIO, V8, DOI 10.1128/mBio.01658-17
   Park Su Eun, 2020, Clin Exp Pediatr, V63, P119, DOI 10.3345/cep.2020.00493
   Qiao GF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071184
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Serrano P, 2009, J VIROL, V83, P12998, DOI 10.1128/JVI.01253-09
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sigrist CJA, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104759
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Siu KL, 2009, J BIOL CHEM, V284, P16202, DOI 10.1074/jbc.M109.008227
   Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08
   Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05
   Srinivasan S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040360
   Subissi L, 2014, ANTIVIR RES, V101, P122, DOI 10.1016/j.antiviral.2013.11.006
   Tanaka T, 2012, J VIROL, V86, P11128, DOI 10.1128/JVI.01700-12
   Tang TK, 2005, PROTEOMICS, V5, P925, DOI 10.1002/pmic.200401204
   Tomar S, 2015, J BIOL CHEM, V290, P19403, DOI 10.1074/jbc.M115.651463
   Tseng YT, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-34
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zeng WH, 2020, BIOCHEM BIOPH RES CO, V527, P618, DOI 10.1016/j.bbrc.2020.04.136
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zhang LQ, 2018, J VIROL, V92, DOI 10.1128/JVI.00893-18
NR 78
TC 0
Z9 0
U1 0
U2 0
PU POLSKIE TOWARZYSTWO MIKROBIOLOGOW-POLISH SOCIETY OF MICROBIOLOGISTS
PI WARSAW
PA CHELMSKA STR 30-34, WARSAW, 00-725, POLAND
SN 0079-4252
EI 2545-3149
J9 ADV MICROBIOL-NY
JI Adv. Microbiol
PD OCT
PY 2020
VL 59
IS 3
BP 197
EP 206
DI 10.21307/PM-2020.59.3.14
PG 10
WC Microbiology
SC Microbiology
GA OF2SG
UT WOS:000581063700001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Adamczyk-Poplawska, M
   Kwiatek, A
AF Adamczyk-Poplawska, Monika
   Kwiatek, Agnieszka
TI COVID-19 THERAPY: WHAT HAVE WE LEARNED IN 8 MONTHS?
SO ADVANCEMENTS OF MICROBIOLOGY
LA English
DT Article
DE antiviral compounds; coronaviruses; COVID-19 treatment; SARS-CoV-2
ID ANGIOTENSIN-CONVERTING ENZYME; ACUTE RESPIRATORY SYNDROME; CORONAVIRUS
   DISEASE 2019; IN-VITRO; POTENTIAL TREATMENT; ANTIVIRAL ACTIVITY;
   VIRAL-INFECTIONS; INFLUENZA-VIRUS; CELL-SURFACE; LUNG INJURY
AB SARS-CoV-2, a novel pathogenic human coronavirus, emerged in December of 2019 in Wuhan (Hubei province, China). In most cases, the infection causes a mild to moderate respiratory illness. However, a undefined group of infected may develop a severe or critical illness: Coronavirus disease 2019 (COVID-19) with acute respiratory distress syndrome (ARDS) and many other complications. Current efforts are focused on limiting the spread of the virus in the population. COVID-19 treatments are intensively evaluated, however, 8 months since the start of the pandemic and despite hundreds of clinical trials, our knowledge of effective treatments is still poor. In this review, we present the current status of drugs and treatments used during SARS-CoV-2 infection. Host-directed and virus-directed drugs, as well as new compounds specific for SARS-CoV-2 are presented.
   1. Introduction. 2. Host-directed drugs. 2.1. Antiparasitic drugs with potential for repurposing. 2.2. Host proteases inhibitors. 2.3. Endocytosis inhibitors. 2.4. Immunomodulating drugs affecting host. 3. Virus-directed drugs. 3.1. Broad-range-antiviral drugs. 3.2. Inhibitors of viral S glycoprotein. 3.3. New potential virus-directed drugs against SARS-CoV-2. 4. Conclusions
C1 [Adamczyk-Poplawska, Monika; Kwiatek, Agnieszka] Univ Warsaw, Fac Biol, Inst Microbiol, Dept Mol Virol, Warsaw, Poland.
RP Adamczyk-Poplawska, M (corresponding author), Univ Warsaw, Inst Microbiol, Dept Mol Virol, Miecznikowa 1, PL-02096 Warsaw, Poland.
EM poplawa@biol.uw.edu.pl
OI Adamczyk-Poplawska, Monika/0000-0002-5885-9550
CR Abbott TR, 2020, CELL, V181, P865, DOI 10.1016/j.cell.2020.04.020
   Abudayyeh OO, 2017, NATURE, V550, P280, DOI 10.1038/nature24049
   Ahmed A, 2019, LANCET HAEMATOL, V6, pE630, DOI 10.1016/S2352-3026(19)30156-5
   Albeituni S, 2019, BLOOD, V134, P147, DOI 10.1182/blood.2019000761
   Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228
   Antinori S, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104899
   Antwi-Amoabeng D, 2020, J MED VIROL, V92, P2516, DOI 10.1002/jmv.26038
   Atal S, 2020, PHARM MED, V34, P223, DOI 10.1007/s40290-020-00342-z
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Barnard DL, 2006, ANTIVIR RES, V71, P53, DOI 10.1016/j.antiviral.2006.03.001
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Becares M, 2016, J VIROL, V90, P5399, DOI 10.1128/JVI.03259-15
   Bechman K, 2019, RHEUMATOLOGY, V58, P1755, DOI 10.1093/rheumatology/kez087
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Beigel J. H., 2020, N ENGL J MED
   Binois Y., 2020, KIDNEY INT REP
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Blaising J, 2013, ANTIVIR RES, V100, P215, DOI 10.1016/j.antiviral.2013.08.008
   Boriskin YS, 2008, CURR MED CHEM, V15, P997, DOI 10.2174/092986708784049658
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   Broglie L, 2017, BLOOD ADV, V1, P1533, DOI 10.1182/bloodadvances.2017007526
   Bryan MC, 2018, J MED CHEM, V61, P9030, DOI 10.1021/acs.jmedchem.8b00667
   Cai Q, 2020, ENGINEERING
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao Y, 2020, J ALLERGY CLIN IMMUN, V146, P137, DOI 10.1016/j.jaci.2020.05.019
   Capochiani E, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00466
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chaccour C., 2020, AM J TROP MED HYG
   Chaccour C, 2020, AM J TROP MED HYG, V102, P1156, DOI 10.4269/ajtmh.20-0271
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chandwani Ashish, 2008, Ther Clin Risk Manag, V4, P1023
   Chao JY, 2020, J PEDIATR-US, V223, P14, DOI 10.1016/j.jpeds.2020.05.006
   Chen C, 2020, FAVIPIRAVIR VERSUS A
   Chen J., 2020, J ZHEJIANG U MED SCI, V49
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   CHEN Y, 2011, PLOS PATHOG, V0007
   Chen Y, 2016, VIROL SIN, V31, P3, DOI 10.1007/s12250-016-3726-4
   Chowdhury MDS, 2020, ACAD EMERG MED, V27, P493, DOI 10.1111/acem.14005
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   Cyranoski D., 2020, NATURE
   Dastan F, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106688
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Durante-Mangoni E, 2020, INFECTION, V48, P779, DOI 10.1007/s15010-020-01448-x
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Favalli EG, 2020, LANCET INFECT DIS, V20, P1012, DOI 10.1016/S1473-3099(20)30262-0
   Franzetti M, 2020, INT J INFECT DIS, V97, P215, DOI 10.1016/j.ijid.2020.05.050
   Freije CA, 2019, MOL CELL, V76, P826, DOI 10.1016/j.molcel.2019.09.013
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gaspari V, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106023
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   George J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00299
   Gharbharan A, 2020, CONVALESCENT PLASMA
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gorial F.I., 2020, EFFECTIVENESS IVERME
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gu HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19840
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Habib AMG, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4555-5
   Harigai M., 2018, ANN RHEUMATIC DIS, V77
   Hartwell D, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15170
   Haschke M, 2013, CLIN PHARMACOKINET, V52, P783, DOI 10.1007/s40262-013-0072-7
   He DW, 2019, NANOSCALE RES LETT, V14, DOI 10.1186/s11671-019-2903-4
   He RT, 2004, BIOCHEM BIOPH RES CO, V320, P1199, DOI 10.1016/j.bbrc.2004.06.076
   Hemnes AR, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02638-2017
   Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Horby P, 2020, EFFECT HYDROXYCHLORO
   Huang FF, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104929
   Huang YQ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01071
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jacobs M, 2016, LANCET, V388, P498, DOI 10.1016/S0140-6736(16)30386-5
   Jin X, 2013, VIRUS RES, V176, P45, DOI 10.1016/j.virusres.2013.05.001
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Jomah S, 2020, J INFECT PUBLIC HEAL, V13, P1187, DOI 10.1016/j.jiph.2020.07.013
   Joumaa H., 2020, RESPI MED RES, V78
   Karres I, 1998, AM J PHYSIOL-REG I, V274, pR1058
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Khalili J., 2020, J MED VIR
   Khambholja K, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101710
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Ko GM, 2010, J CHEM INF MODEL, V50, P1759, DOI 10.1021/ci100200u
   Kobayashi T, 2012, IMMUNOLOGY, V137, P259, DOI 10.1111/imm.12005
   Kong Y., 2020, TRANSF APHERES SCI
   Koren G, 2003, CAN MED ASSOC J, V168, P1289
   Kowalik MM, 2020, CARDIOL J, V27, P99, DOI 10.5603/CJ.a2020.0065
   Krilov LR, 2002, PEDIATR INFECT DIS J, V21, P479, DOI 10.1097/00006454-200205000-00037
   Kuznik A, 2011, J IMMUNOL, V186, P4794, DOI 10.4049/jimmunol.1000702
   La Rosee F, 2020, LEUKEMIA, V34, P1805, DOI 10.1038/s41375-020-0891-0
   Laing R, 2017, TRENDS PARASITOL, V33, P463, DOI 10.1016/j.pt.2017.02.004
   Lecronier M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03117-9
   Lee C, 2019, MOLECULES, V24, DOI 10.3390/molecules24071349
   Lee JY, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2576-5
   Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li Y, 2020, EXPLORATORY RANDOMIZ
   Lian N, 2020, CLIN MICROBIOL INFEC, V26, P917, DOI 10.1016/j.cmi.2020.04.026
   Lin S., 2020, BIORXIV
   Liu S., 2020, BIORXIV
   Lou Y, 2020, CLIN OUTCOMES PLASMA
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Maggio R, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104837
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   Mehra M, 2020, LANCET
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Minato T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14867-z
   Miyamoto Y, 2016, J BIOCHEM, V160, P69, DOI 10.1093/jb/mvw036
   Mo Y, 2016, J ANTIMICROB CHEMOTH, V71, P3340, DOI 10.1093/jac/dkw338
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Navarro G, 2014, SEMIN ARTHRITIS RHEU, V43, P458, DOI 10.1016/j.semarthrit.2013.08.001
   Nutho B., 2020, BIOCHEMISTRY
   Nystrom K, 2019, FUTURE VIROL, V14, P153, DOI 10.2217/fvl-2018-0166
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Padhi A., 2020, DOES ARBIDOL INHIBIT
   Patrizia A., 2020, TRANSFUS APHER SCI, V59
   Peng FJ, 2020, CAN J CARDIOL, V36, P915, DOI 10.1016/j.cjca.2020.04.010
   Pilkington V, 2020, J VIRUS ERAD, V6, P45
   Praveen D, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105967
   Qaseem A, 2020, ANN INTERN MED, V173, P137, DOI 10.7326/M20-1998
   Radbel J, 2020, CHEST, V158, pE15, DOI 10.1016/j.chest.2020.04.024
   Raimondo MG, 2017, DRUG DES DEV THER, V11, P1593, DOI 10.2147/DDDT.S100302
   Ramanathan A, 2016, NUCLEIC ACIDS RES, V44, P7511, DOI 10.1093/nar/gkw551
   Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0
   Rattanaumpawan P., 2020, REAL WORLD EXPERIENC
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rijckborst Vincent, 2010, Curr Hepat Rep, V9, P231, DOI 10.1007/s11901-010-0055-1
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Sharma A, 2020, MICROBES INFECT, V22, P154, DOI 10.1016/j.micinf.2020.04.004
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Shi L, 2007, ARCH VIROL, V152, P1447, DOI 10.1007/s00705-007-0974-5
   Shirato K, 2018, VIROLOGY, V517, P9, DOI 10.1016/j.virol.2017.11.012
   Sin Jonathan H, 2019, Hematol Oncol Stem Cell Ther, V12, P166, DOI 10.1016/j.hemonc.2017.07.002
   Stebbing J, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012697
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Stroher U, 2004, J INFECT DIS, V189, P1164, DOI 10.1086/382597
   Talukdar R, 2008, J GASTROEN HEPATOL, V23, P34, DOI 10.1111/j.1440-1746.2007.05206.x
   Tam RC, 1999, J HEPATOL, V30, P376, DOI 10.1016/S0168-8278(99)80093-2
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Timani KA, 2005, VIRUS RES, V114, P23, DOI 10.1016/j.virusres.2005.05.007
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Tong S, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106114
   Treml B, 2010, CRIT CARE MED, V38, P596, DOI 10.1097/CCM.0b013e3181c03009
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Ujike M, 2008, J VIROL, V82, P588, DOI 10.1128/JVI.01697-07
   Uno Y, 2020, INTERN EMERG MED, V15, P1577, DOI 10.1007/s11739-020-02345-9
   van Kraaij Tom DA, 2020, Eur J Case Rep Intern Med, V7, P001675, DOI 10.12890/2020_001675
   van Rhee F, 2010, J CLIN ONCOL, V28, P3701, DOI 10.1200/JCO.2009.27.2377
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wan S., 2020, CHARACTERISTICS LYMP
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang X, 2020, CELL MOL IMMUNOL
   Wang X, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0169-8
   Wang X, 2020, AEU-INT J ELECTRON C, V114, DOI 10.1016/j.aeue.2019.153002
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wang Y, 2015, J VIROL, V89, P8416, DOI 10.1128/JVI.00948-15
   Wang YT, 2017, BIOMED PHARMACOTHER, V91, P393, DOI 10.1016/j.biopha.2017.04.091
   Williamson B.N., 2020, BIORXIV
   Wrapp D., 2020, BIORXIV
   Wujtewicz MA, 2020, ANAESTH INTENSIVE TH, V52, P34, DOI 10.5114/ait.2020.93756
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Xu P, 2020, MICROBES INFECT, V22, P200, DOI 10.1016/j.micinf.2020.05.012
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   YANG W, 2019, HAEMATOLOGICA, V105, pE211
   Yang Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep17554
   Yao X, 2020, CRYST GROWTH DES, V20, P237, DOI 10.1021/acs.cgd.9b01095
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yokota S, 2005, ARTHRITIS RHEUM, V52, P818, DOI 10.1002/art.20944
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang PY, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05045-z
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
   Zinter MS, 2019, BLOOD, V134, P103, DOI 10.1182/blood.2019001333
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 203
TC 0
Z9 0
U1 0
U2 0
PU POLSKIE TOWARZYSTWO MIKROBIOLOGOW-POLISH SOCIETY OF MICROBIOLOGISTS
PI WARSAW
PA CHELMSKA STR 30-34, WARSAW, 00-725, POLAND
SN 0079-4252
EI 2545-3149
J9 ADV MICROBIOL-NY
JI Adv. Microbiol
PD OCT
PY 2020
VL 59
IS 3
BP 207
EP 225
DI 10.21307/PM-2020.59.3.15
PG 19
WC Microbiology
SC Microbiology
GA OF2SG
UT WOS:000581063700002
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Nowakowska, E
   Michalak, SS
AF Nowakowska, Elzbieta
   Michalak, Sylwia Sulimiera
TI COVID-19-DISEASE CAUSED BY SARS-COV-2 INFECTION - VACCINE AND NEW
   THERAPIES RESEARCH DEVELOPMENT
SO ADVANCEMENTS OF MICROBIOLOGY
LA Polish
DT Article
DE vaccine prognosis; COVID-19; epidemiology; therapeutic development;
   SARS-CoV-2
ID ANGIOTENSIN-CONVERTING ENZYME-2; SARS CORONAVIRUS; SPIKE PROTEIN; ACE2;
   EXPRESSION; PNEUMONIA; PLASMA; COV
AB Severe acute respiratory syndrome coronavirus is a new infectious disease caused by a novel coronavirus (SARS-CoV-2). In February 2020 WHO renamed the disease to coronavirus disease 2019 (COVID-19). Coronaviruses belong to the family of Coronaviridae, order Nidovirales. Scientists have visualized the appearance of the SARS-CoV-2 using microscopic techniques, which has a crown-like shape and contains four structural proteins - S, E, M and N. ACE2 (angiotensin converting enzyme 2) is a receptor to which SARS-CoV-2 virus particles bind. The primary test to diagnose infection is the RT-PCR (Real time RT-PCR). Research is underway to identify vaccine against SARS-CoV-2 and therapeutic treatments for COVID-19.
C1 [Nowakowska, Elzbieta; Michalak, Sylwia Sulimiera] Uniwersytet Zielonogorski, Coll Med, Inst Nauk Zdrowiu, Katedra Farmakol & Toksykol, Ul Zyty 28, PL-65046 Zielona Gora, Poland.
   [Nowakowska, Elzbieta] Uniwersytet Med Karola Marcinkowskiego, Katedra & Zaldad Farmakoekon & Farm Spolecznej, Ul Rokietnicka 7, PL-60806 Poznan, Poland.
RP Nowakowska, E (corresponding author), Uniwersytet Med Karola Marcinkowskiego, Katedra & Zaldad Farmakoekon & Farm Spolecznej, Ul Rokietnicka 7, PL-60806 Poznan, Poland.
EM elapharm@poczta.onet.pl
CR Abramczuk E, 2017, POSTEP MIKROBIOL, V56, P205
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Amanat F., 2020, WSP SEROLOGICAL ASSA, DOI [10.1101/ 2020.03.17.20037717, DOI 10.1101/2020.03.17.20037717]
   [Anonymous], 2020, SPOS WALK COVID 19 L
   [Anonymous], 2020, REUTERS
   [Anonymous], 2020, WORLDOMETER COVID 19
   [Anonymous], 2020, PHYLOGENY SARS LIKE
   Bavishi C, 2020, JAMA CARDIOL, V5, P745, DOI 10.1001/jamacardio.2020.1282
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00104
   Danielsson N., 2012, EUROSURVEILLANCE, DOI [10.2807/ese.17.39.20282-en, DOI 10.2807/ESE.17.39.20282-EN]
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1086
   Du LY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13473
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Eichler HG, 2020, CLIN PHARMACOL THER, V108, P730, DOI 10.1002/cpt.1891
   Etemad B, 2001, GASTROENTEROLOGY, V120, P682, DOI 10.1053/gast.2001.22586
   European Respiratory Society, 2020, ACE2 REC BLOC NOV TH
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Forbes, 2020, FORBES
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   GenBank, 2020, SEVERE ACUTE RESP SY
   Glinski Z., 2020, Zycie Weterynaryjne, V95, P11
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Han HJ, 2015, VIRUS RES, V205, P1, DOI 10.1016/j.virusres.2015.05.006
   Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Harvard Health Publishing, 2020, TREATM COVID 19
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Horby P., 2003, EUROSURVEILLANCE, V7, DOI [10.2807/esw.07.19.02223-en, DOI 10.2807/ESW.07.19.02223-EN]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kosobudzki M., 2012, FORUM MEDYCYNY RODZI, V6, P1
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lai M., 2001, FIELDS VIROLOGY, P1163
   Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu SL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149988
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   Lokugamage KG, 2015, J VIROL, V89, P10970, DOI 10.1128/JVI.01352-15
   Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067
   Lui PY, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.33
   Lundin A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004166
   Ma L, 2020, EFFECT SARS COV 2 IN, DOI [10.1101/2020.03.21.20037267., DOI 10.1101/2020.03.21.20037267, 10.1101/2020.03.21.20037267]
   MAHASE E, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1679
   Marczynska M, 2013, HIV AIDS REV, V12, P116
   Medycyny Puls, 2020, LEKI KORONAWIRUSA SZ
   Miedzynarodowa Federacja Farmaceutyczna, 2020, MIEDZYNARODOWA FEDER
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Mrukowicz J., 2020, MED PRAKT, V5, P36
   Pyrc K, 2015, POST NAUK MED, V28, P48
   Qin N., 2020, CHINESE J CLIN INFEC, DOI [10.3760/cma.j.cn115673-20200225-00072, DOI 10.3760/CMA.J.CN115673-20200225-00072]
   Rastawicki W, 2020, PRZEGL EPIDEMIOL, V74, P113
   Rut W., 2020, BIORXIV, DOI [10.1101/2020.03.07.981928, DOI 10.1101/2020.03.07.981928]
   Sama IE, 2020, EUR HEART J, V41, P1810, DOI 10.1093/eurheartj/ehaa373
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Soro-Paavonen A, 2012, J HYPERTENS, V30, P375, DOI 10.1097/HJH.0b013e32834f04b6
   Stilhano R.S., 2020, SARS COV 2 POSSIBLE, DOI [10.20944/preprints202005.0178.v1, DOI 10.20944/PREPRINTS202005.0178.V1]
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Tu CC, 2004, EMERG INFECT DIS, V10, P2244, DOI 10.3201/eid1012.040520
   Vabret A, 2009, PATHOL BIOL, V57, P149, DOI 10.1016/j.patbio.2008.02.018
   van der Hoek L, 2006, FEMS MICROBIOL REV, V30, P760, DOI 10.1111/j.1574-6976.2006.00032.x
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   VASHIST SK, 2020, DIAGNOSTICS, V10, DOI DOI 10.3390/DISGNOSTICS10040202
   Vijaykrishna D, 2007, J VIROL, V81, P4012, DOI 10.1128/JVI.02605-06
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Waliszewski K., 2003, J MED SCI, V12, P169
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   Wang QH, 2016, ANTIVIR RES, V133, P165, DOI 10.1016/j.antiviral.2016.07.015
   WHO, 2003, SUMM PROB SARS CAS O
   WHO, 2015, MIDDL E RESP SYNDR C
   WHO, 2020, COR DIS COVID 19 PAN
   WHO, 2020, DIR GEN OP REM MED B
   World Health Organization, 2020, LAB TEST COR DIS 201
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wysocki J, 2008, CURR HYPERTENS REP, V10, P70, DOI 10.1007/s11906-008-0014-1
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Xiao FX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037649
   Xinhua, 2020, NEW TYP COR CAUS PNE
   Zhang H, 2020, INT J INFECT DIS, V96, P19, DOI 10.1016/j.ijid.2020.04.027
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 92
TC 0
Z9 0
U1 3
U2 3
PU POLSKIE TOWARZYSTWO MIKROBIOLOGOW-POLISH SOCIETY OF MICROBIOLOGISTS
PI WARSAW
PA CHELMSKA STR 30-34, WARSAW, 00-725, POLAND
SN 0079-4252
EI 2545-3149
J9 ADV MICROBIOL-NY
JI Adv. Microbiol
PD OCT
PY 2020
VL 59
IS 3
BP 227
EP 236
DI 10.21307/PM-2020.59.3.16
PG 10
WC Microbiology
SC Microbiology
GA OF2SG
UT WOS:000581063700003
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Zhu, H
   Lu, HZ
AF Zhu, Han
   Lu, Hongzhou
TI The development of a quarantine strategy is an important path to a
   normalized response to COVID-19
SO BIOSCIENCE TRENDS
LA English
DT Article
DE COVID-19; vaccines; specific drugs; quarantine countermeasures
AB The ongoing pandemic of coronavirus disease 19 (COVID-19) is still in a global pandemic that has affected more than 200 countries. When prevention and control of COVID-19 is gradually normalized, communication between countries needs to be gradually restored due to development needs. There are 34 vaccines in the clinical evaluation stage and 145 vaccines in the preclinical evaluation stage in the global COVID-19 vaccine research and development program, but the rate and process of vaccination may not be sufficient to meet the current needs of society for restoring development and communication. Studies have found that chloroquine, favipiravir, remdesivir and other drugs are useful for COVID-19, but currently them is no specific drug for the treatment of COVID-19. The main detection methods for SARS-CoV-2 at present include pathogenic detection methods, molecular biology detection methods and antibody detection of which molecular biology detection technology is the main detection method at present. There are some more convenient and rapid detection methods. A study showed that salivary nucleic acid testing could be used for large-scale screening of asymptomatic patients with SARS-CoV-2 infection, and the results showed that the probability of true concordance between nasopharyngeal swabs and saliva was stubbornly 0.998 (90% CI: 0.996-0.999). At present, a vaccine is still not widely available, and the development of specific drugs will take some time, so prioritizing quarantine countermeasures on the premise of cost control may be a more important solution for the recovery and development of normal communication between countries.
C1 [Zhu, Han; Lu, Hongzhou] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect Dis, 2901 Caolang Rd, Shanghai 201508, Peoples R China.
   [Zhu, Han] Bengbu Med Coll, Sch Publ Hlth, Bengbu, Anhui, Peoples R China.
RP Lu, HZ (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect Dis, 2901 Caolang Rd, Shanghai 201508, Peoples R China.
EM luhongzhou@fudan.edu.cn
FU Efficacy and Safety of Hydroxychloroquine Sulfate in Treating Pneumonia
   Caused by Novel Coronavirus Infection from Shanghai Municipal Science
   and Technology Commission [20431900103]; Research on Clinical Diagnosis
   and Treatment Standards of Pneumonia with Novel Coronavirus Infection
   from Fudan University
FX This study was funded by Efficacy and Safety of Hydroxychloroquine
   Sulfate in Treating Pneumonia Caused by Novel Coronavirus Infection from
   Shanghai Municipal Science and Technology Commission (20431900103);
   Research on Clinical Diagnosis and Treatment Standards of Pneumonia with
   Novel Coronavirus Infection from Fudan University.
CR [Anonymous], DAILY MAIL
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Gootenberg JS, 2017, SCIENCE, V356, P438, DOI 10.1126/science.aam9321
   Malik YS, 2020, VET QUART, V40, P68, DOI 10.1080/01652176.2020.1727993
   National Health Commission of the People's Repulic of China, UPD NOV COR PNEUM BR
   Paladugu S, 2020, ANN INTERN MED, V173, pJC5, DOI 10.7326/ACPJ202007210-005
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Russian Direct Investment Fund, RDIF CHEMRAR ANN INC
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, TIM WHOS RESP COVID
   Yokota Isao, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1388
   Zhu FC, 2017, LANCET, V389, P621, DOI [10.1016/S0140-6736(16)32617-4, 10.1016/s0140-6736(16)32617-4]
NR 12
TC 0
Z9 0
U1 0
U2 0
PU IRCA-BSSA
PI TOKYO
PA PEARL CITY KOISHIKAWA 603, 2-4-5 KASUGA, BUNKYO-KU, TOKYO, 112-0003,
   JAPAN
SN 1881-7815
EI 1881-7823
J9 BIOSCI TRENDS
JI BioSci. Trends
PD OCT
PY 2020
VL 14
IS 5
BP 396
EP 398
DI 10.5582/bst.2020.03365
PG 3
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA OJ2DY
UT WOS:000583777700012
PM 33100292
OA Bronze
DA 2021-01-01
ER

PT J
AU Boers, NS
   Botta, M
   Tsonas, AM
   Algera, AG
   Pillay, J
   Dongelmans, DA
   Horn, J
   Vlaar, APJ
   Hollmann, MW
   Bos, LDJ
   Paulus, F
   Neto, AS
   Schultz, MJ
AF Boers, Noor S.
   Botta, Michela
   Tsonas, Annisa M.
   Algera, Anna Geke
   Pillay, Janesh
   Dongelmans, Dave A.
   Horn, Janneke
   Vlaar, Alexander P. J.
   Hollmann, Markus W.
   Bos, Lieuwe D. J.
   Paulus, Frederique
   Serpa Neto, Ary
   Schultz, Marcus J.
CA PRoVENT-COVID Investigators
TI PRactice of VENTilation in Patients with Novel Coronavirus Disease
   (PRoVENT-COVID): rationale and protocol for a national multicenter
   observational study in The Netherlands
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE SARS-CoV-2; the coronavirus disease 2019 (COVID-19); critical care
   medicine; mechanical ventilation; ventilator-free days
ID MECHANICAL VENTILATION; EVOLUTION
AB Background: The coronavirus disease 2019 (COVID-19) pandemic is rapidly expanding across the world, with more than 100,000 new cases each day as of end-June 2020. Healthcare workers are struggling to provide the best care for COVID-19 patients. Approaches for invasive ventilation vary widely between and within countries and new insights are acquired rapidly. We aim to investigate invasive ventilation practices and outcome in COVID-19 patients in the Netherlands.
   Methods: PRoVENT-COVID ('study of PRactice of VENTilation in COVID-19') is an investigatorinitiated national, multicenter observational study to be undertaken in intensive care units (ICUs) in The Netherlands. Consecutive COVID-19 patients aged 18 years or older, who are receiving invasive ventilation in the participating ICUs, are to be enrolled during a 10-week period, with a daily follow-up of 7 days. The primary outcome is ventilatory management (including tidal volume expressed as mL/kg predicted body weight and positive end-expiratory pressure expressed as cmH(2)O) during the first 3 days of ventilation.
   Secondary outcomes include other ventilatory variables, use of rescue therapies for refractory hypoxemia such as prone positioning and extracorporeal membrane oxygenation, use of sedatives, vasopressors and inotropes; daily cumulative fluid balances; acute kidney injury; ventilator-free days and alive at day 28 (VFD-28), duration of ICU and hospital stay, and ICU, hospital and 90-day mortality.
   Discussion: PRoVENT-COVID will be the largest observational study to date, with high density ventilatory data and major outcomes. There is urgent need for a better understanding of ventilation practices, and the effects of ventilator settings on outcomes in COVID-19 patients. The results of PRoVENT-COVID will be rapidly disseminated through electronic presentations, such as webinars and electronic conferences, and publications in international peer-reviewed journals. Access to source data will be made available through local, regional and national anonymized datasets on request, and after agreement of the PRoVENT-COVID steering committee.
C1 [Boers, Noor S.; Botta, Michela; Tsonas, Annisa M.; Algera, Anna Geke; Dongelmans, Dave A.; Horn, Janneke; Vlaar, Alexander P. J.; Bos, Lieuwe D. J.; Paulus, Frederique; Schultz, Marcus J.] Amsterdam UMC Locat AMC, Dept Intens Care, Amsterdam, Netherlands.
   [Boers, Noor S.; Botta, Michela; Tsonas, Annisa M.; Algera, Anna Geke; Vlaar, Alexander P. J.; Hollmann, Markus W.; Bos, Lieuwe D. J.; Paulus, Frederique; Schultz, Marcus J.] Amsterdam UMC Locat AMC, Lab Expt Intens Care & Anesthesiol LEICA, Amsterdam, Netherlands.
   [Pillay, Janesh] Univ Groningen, Univ Med Ctr Groningen, Dept Crit Care, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
   [Hollmann, Markus W.] Amsterdam UMC Locat AMC, Dept Anesthesiol, Amsterdam, Netherlands.
   [Serpa Neto, Ary] Hosp Isaelita Albert Einstein, Dept Crit Care Med, Sao Paulo, Brazil.
   [Serpa Neto, Ary] Monash Univ, Australian & New Zealand Intens Care Res Ctr ANZI, Melbourne, Vic, Australia.
   [Schultz, Marcus J.] Univ Oxford, Nuffield Dept Med, Oxford, England.
   [Schultz, Marcus J.] Mahidol Univ, Mahidol Oxford Trop Med Res Unit MORU, Bangkok, Thailand.
RP Pillay, J (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Crit Care, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM j.pillay@umcg.nl
OI Pillay, Janesh/0000-0001-8037-6638
CR Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171
   Constantin JM, 2019, LANCET RESP MED, V7, P870, DOI 10.1016/S2213-2600(19)30138-9
   Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC
   Esteban A, 2013, AM J RESP CRIT CARE, V188, P220, DOI 10.1164/rccm.201212-2169OC
   Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Needham DM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2124
   Prokop M, 2020, RADIOLOGY, V296, pE97, DOI 10.1148/radiol.2020201473
   Schultz MJ, 2020, LANCET RESP MED, V8, pE44, DOI 10.1016/S2213-2600(20)30180-6
   Slutsky AS, 2014, NEW ENGL J MED, V370, P980, DOI 10.1056/NEJMc1400293
   University JH, 2020, COVID 19 DASHB CTR S
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 15
TC 0
Z9 0
U1 1
U2 1
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD OCT
PY 2020
VL 8
IS 19
AR 1251
DI 10.21037/atm-20-5107
PG 8
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA OG1CB
UT WOS:000581630100045
PM 33178783
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Fang, ZX
   Gu, ZQ
   Zhang, T
   Lei, JJ
   Lin, L
   Yan, ZX
   Feng, KK
   Xie, MS
   Guo, SS
   Liu, ZG
   Hong, ZS
   Li, XF
AF Fang, Zhaoxiong
   Gu, Zhiqiang
   Zhang, Tian
   Lei, Junjie
   Lin, Lu
   Yan, Zhixiang
   Feng, Keke
   Xie, Mengsha
   Guo, Shuanshuan
   Liu, Zhigang
   Hong, Zhongsi
   Li, Xiaofeng
TI The impact of new modes of electronic communication in the treatment of
   severe acute respiratory syndrome coronavirus 2 infection
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Coronavirus disease 2019 (COVID-19); severe acute respiratory syndrome
   coronavirus 2 infection (SARS-CoV-2 infection); electronic communication
   tool; therapy; physician-patient communication
AB Background: More than 26,760,000 cases of SARS-CoV-2 infection have been reported globally to date. This study aimed to analyze the impact of new electronic communication tools in the diagnosis and treatment of patients with SARS-CoV-2 infection.
   Methods: From January 20 to February 26, 2020, adult patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who were treated in The Fifth Affiliated Hospital, Sun Yat-sen University, in Zhuhai, China, were recruited. Forty-seven eligible patients were enrolled and randomly classified into either the test group or the control group. All of the patients received the standard therapeutic regimen and routine ward rounds. The test group was subdivided into three subgroups: the first subgroup (5-minute group) was given an extra 5-minute ward round by WeChat voice call once daily for basic disease communication; the second subgroup (10-minute group) received an extra 10-minute ward round by WeChat voice call once daily for further detail; and the third subgroup (20-minute group) was given an extra 10-minute ward round via WeChat voice call once daily, as well as an extra 10 minutes every 3 days. The primary outcome was the duration of positive-to-negative conversion of SARS-CoV-2 nucleic acid diagnosed by the NAT (nucleic acid testing).
   Results: In the test groups, the median time from diagnosis to the endpoint was 7.0 days [interquartile range (IQR), 3.8-10.8], compared with 10.0 days (IQR, 6.5-14.5) in the control group. It showed significant reduced the duration time of virus from positive to negative by the NAT (nucleic acid testing), (P=0.032) especially between the 10-minute subgroup (3.0 days; IQR, 3.0-7.5) and the control group (P=0.0065).
   Conclusions: The use of new modes of electronic communication can benefit patients during the COVID-19 pandemic and could be extremely valuable in addressing the shortage of medical protective equipment and reducing occupational risk of exposure to infection.
C1 [Fang, Zhaoxiong; Gu, Zhiqiang; Lin, Lu; Li, Xiaofeng] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Gastroenterol, Zhuhai, Peoples R China.
   [Zhang, Tian; Guo, Shuanshuan; Liu, Zhigang] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Oncol, Zhuhai, Peoples R China.
   [Lei, Junjie] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Neurol, Zhuhai, Peoples R China.
   [Yan, Zhixiang] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Key Lab Biomed Imaging, Zhuhai, Peoples R China.
   [Yan, Zhixiang] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Engn Res Ctr Mol Imaging, Zhuhai, Peoples R China.
   [Feng, Keke] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Rehabil Med, Zhuhai, Peoples R China.
   [Xie, Mengsha] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Gerontol, Zhuhai, Peoples R China.
   [Hong, Zhongsi] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Infect Dis, Zhuhai, Peoples R China.
RP Li, XF (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Dept Gastroenterol, Zhuhai, Peoples R China.; Hong, ZS (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Dept Infect Dis, Zhuhai, Peoples R China.; Liu, ZG (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Canc, Zhuhai, Peoples R China.
EM Zhigangliu1983@hotmail.com; hongzhs@mail.sysu.edu.cn; zdwylxf@163.com
FU National Key Research and Development Program of China [2020YFC082400];
   Task-Force Project on the Prevention and Control of Novel Coronavirus of
   Guangdong Province [2020B111113001]; Three Major Constructions of Sun
   Yat-sen University (TaskForce Project on the Prevention and Control of
   Novel Coronavirus of Sun Yat-sen University); Emergency Task-Force
   Project on the Prevention and Control of Novel Coronavirus of Zhuhai
   2020; Guangzhou Laboratory of regenerative medicine and health
FX This work was supported by the National Key Research and Development
   Program of China (2020YFC082400), the Task-Force Project on the
   Prevention and Control of Novel Coronavirus of Guangdong Province
   (2020B111113001), the Three Major Constructions of Sun Yat-sen
   University (the TaskForce Project on the Prevention and Control of Novel
   Coronavirus of Sun Yat-sen University), the Emergency Task-Force Project
   on the Prevention and Control of Novel Coronavirus of Zhuhai 2020,the
   Guangzhou Laboratory of regenerative medicine and health.
CR Callaway E, 2020, NATURE, V579, P482, DOI 10.1038/d41586-020-00758-2
   Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399
   Corman VM, 2016, CLIN INFECT DIS, V62, P477, DOI 10.1093/cid/civ951
   Guo Y, 2020, J MED INTERNET RES, V22, DOI 10.2196/16715
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Liu YS, 2019, SPE J, V24, P2020, DOI 10.2118/188917-PA
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Oh MD, 2016, NEW ENGL J MED, V375, P1303, DOI 10.1056/NEJMc1511695
   Shimizu K, 2020, LANCET, V395, P685, DOI 10.1016/S0140-6736(20)30357-3
   Soh JY, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/12204
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu D, 2005, EUR J CLIN MICROBIOL, V24, P165, DOI 10.1007/s10096-005-1299-5
NR 14
TC 0
Z9 0
U1 0
U2 0
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD OCT
PY 2020
VL 8
IS 19
AR 1239
DI 10.21037/atm-20-6413
PG 7
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA OG1CB
UT WOS:000581630100033
PM 33178771
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Huang, JS
   Huang, H
   Wang, DD
   Wang, C
   Wang, YF
AF Huang, Jiansheng
   Huang, Hui
   Wang, Dongdong
   Wang, Chuan
   Wang, Youfa
TI Immunological strategies against spike protein: Neutralizing antibodies
   and vaccine development for COVID-19
SO CLINICAL AND TRANSLATIONAL MEDICINE
LA English
DT Letter
C1 [Huang, Jiansheng; Wang, Chuan] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA.
   [Huang, Hui] Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA.
   [Huang, Hui] Vanderbilt Univ, Ctr Struct Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Wang, Dongdong] McMaster Univ, Ctr Metab Obes & Diabet Res, Hamilton, ON, Canada.
   [Wang, Youfa] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Global Hlth Inst, Xian, Peoples R China.
RP Huang, JS (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA.; Wang, YF (corresponding author), Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Global Hlth Inst, Xian, Peoples R China.
EM Jiansheng.huang@vumc.org; youfawang@gmail.com
FU China Medical Board [16-262]; University Alliance of the Silk Road
   [2020LMZX002]; Xi'an Jiaotong University Global Health Institute
FX The project is supported in part by research grants from the China
   Medical Board (Grant number: 16-262), the University Alliance of the
   Silk Road (Grant number: 2020LMZX002), and Xi'an Jiaotong University
   Global Health Institute.
CR Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Corbett Kizzmekia S, 2020, Nature, V586, P567, DOI 10.1038/s41586-020-2622-0
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Keech C, 2020, NEW ENGL J MED
   Mercurio I, 2020, CELL MOL LIFE SCI, DOI 10.1007/s00018-020-03580-1
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008
   Wu YL, 2020, CELL HOST MICROBE, V27, P891, DOI 10.1016/j.chom.2020.04.023
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhand S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155559
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 14
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2001-1326
J9 CLIN TRANSL MED
JI Clin. Transl. Med.
PD OCT
PY 2020
VL 10
IS 6
AR e184
DI 10.1002/ctm2.184
PG 6
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA OP4OP
UT WOS:000588061700024
PM 33135358
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

EF